FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Shoback, D
AF Shoback, Dolores
TI Update in osteoporosis and metabolic bone disorders
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID VITAMIN D SUPPLEMENTATION; MONTHLY ORAL IBANDRONATE; POSTMENOPAUSAL
   WOMEN; PARATHYROID HORMONE; BREAST CANCER; STRONTIUM RANELATE;
   RANDOMIZED TRIAL; FRACTURE RISK; ALENDRONATE; OSTEONECROSIS
AB Considerable progress has been made in the development and testing of agents to treat osteoporosis. Most impressive are reports on new antiresorptive agents both bisphosphonates ( ibandronate and zoledronic acid) and monoclonal antibodies (MAbs) (denosumab) directed against receptor activator of nuclear factor kappa B ligand, a key molecule in the control of commitment and activation of osteoclasts. Bisphosphonates promise convenience and potency at slowing bone loss, whereas denosumab offers powerful suppression of resorption and rapid offset of action. Attention is also shifting from the osteoclast as a target for new therapies to the osteoblast and the osteocyte, with its complex network within the depths of bone. Wnt signaling through the frizzled receptor and its coreceptor, the low density lipoprotein receptor related protein 5, appears from both molecular and in vivo evidence to be a pivotal pathway for modulating osteoblastic activity, bone formation, and bone strength. The recently identified product of the SOST gene or sclerostin has also been shown to block Wnt signaling. Sclerostin is produced by the osteocytes buried in the bone and is a new target to treat bone loss. Clinical trial reports indicate that the calcimimetic cinacalcet can effectively treat PTH hypersecretion due to primary and secondary hyperparathyroidism and parathyroid carcinoma. Lastly, it is now recognized that the matrix protein dentin matrix protein 1 enhances the release of the phosphate regulating factor fibroblast growth factor 23 and that mutations in dentin matrix protein 1 play a causative role in a form of hypophosphatemic rickets.
C1 San Francisco Dept Vet Affairs Med Ctr, Endocrine Res Unit, San Francisco, CA 94121 USA.
   Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA.
C3 University of California System; University of California San Francisco
RP Shoback, D (通讯作者)，San Francisco Dept Vet Affairs Med Ctr, Endocrine Res Unit, 111N,4150 Clement St, San Francisco, CA 94121 USA.
EM Dolores.Shoback@ucsf.edu
CR Barrett Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462
   Bilezikian JP, 2006, NEW ENGL J MED, V355, P2278, DOI 10.1056/NEJMp068157
   Bischoff Ferrari HA, 2005, JAMA J AM MED ASSOC, V293, P2257, DOI 10.1001/jama.293.18.2257
   Black DM, 2006, J BONE MINER RES, V21, pS16
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   Dawson Hughes B, 2005, OSTEOPOROSIS INT, V16, P713, DOI 10.1007/s00198 005 1867 7
   Delmas PD, 2006, ARTHRITIS RHEUM US, V54, P1838, DOI 10.1002/art.21918
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Finkelstein JS, 2006, J CLIN ENDOCR METAB, V91, P2882, DOI 10.1210/jc.2006 0190
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Holick MF, 2005, J CLIN ENDOCR METAB, V90, P3215, DOI 10.1210/jc.2004 2364
   Jackson RD, 2006, NEW ENGL J MED, V354, P669, DOI 10.1056/NEJMoa055218
   JANDEBEUR J, 2005, JAMA J AM MED ASSOC, V294, P1260
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200
   Larsson T, 2005, J CLIN ENDOCR METAB, V90, P2424, DOI 10.1210/jc.2004 2238
   Lorenz Depiereux B, 2006, NAT GENET, V38, P1248, DOI 10.1038/ng1868
   Martino S, 2004, J NATL CANCER I, V96, P1751, DOI 10.1093/jnci/djh319
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Miller PD, 2005, J BONE MINER RES, V20, P1315, DOI 10.1359/JBMR.050313
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Peacock M, 2006, J BONE MINER RES, V21, pS38
   Peacock M, 2005, J CLIN ENDOCR METAB, V90, P135, DOI 10.1210/jc.2004 0842
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Reginster JY, 2006, ANN RHEUM DIS, V65, P654, DOI 10.1136/ard.2005.044958
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Ringe JD, 2006, RHEUMATOL INT, V26, P427, DOI 10.1007/s00296 005 0004 4
   Ruggiero S, 2006, J ONCOL PRACT, V2, P7, DOI 10.1200/JOP.2.1.7
   Ruggiero SL, 2006, ORAL SURG ORAL MED O, V102, P433, DOI 10.1016/j.tripleo.2006.06.004
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Schiavi SC, 2006, NAT GENET, V38, P1230, DOI 10.1038/ng1106 1230
   Silverberg SJ, 2006, J BONE MINER RES, V21, pS440
   Topaz O, 2004, NAT GENET, V36, P579, DOI 10.1038/ng1358
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   Vogel VG, 2006, JAMA J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
NR 45
TC 72
Z9 80
U1 1
U2 11
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAR
PY 2007
VL 92
IS 3
BP 747
EP 753
DI 10.1210/jc.2007 0042
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 143LA
UT WOS:000244721900001
PM 17341572
DA 2025 08 17
ER

PT S
AU Martin, TJ
   Quinn, JMW
   Gillespie, MT
   Ng, KW
   Karsdal, MA
   Sims, NA
AF Martin, T. J.
   Quinn, J. M. W.
   Gillespie, M. T.
   Ng, K. W.
   Karsdal, M. A.
   Sims, N. A.
BE Zaidi, M
TI Mechanisms involved in skeletal anabolic therapies
SO SKELETAL DEVELOPMENT AND REMODELING IN HEALTH, DISEASE, AND AGING
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT Conference on Skeletal Development and Remodeling in Health, Disease and
   Aging
CY MAY 18 21, 2005
CL New York, NY
SP NY Acad Sci, Alliance Better Bone Hlth, Procter & Gamble Pharmaceut, Sanofi Aventis, Novartis Pharmaceut, Roche Pharmaceut, Merck & Co
DE osteoblast; osteoclast; parathyroid hormone; Wnt signaling
ID HORMONE RELATED PROTEIN; ENDOCHONDRAL BONE FORMATION; RECEPTOR RELATED
   PROTEIN 5; GROWTH FACTOR I; PARATHYROID HORMONE; OSTEOBLAST
   DIFFERENTIATION; TRABECULAR BONE; OSTEOCLASTIC RESORPTION; MOUSE BONE;
   YOUNG RATS
AB Since parathyroid hormone (PTH) is the only proven anabolic therapy for bone, it becomes the benchmark by which new treatments will be evaluated. The anabolic effect of PTH is dependent upon intermittent administration, but when an elevated PTH level is maintained even for a few hours it initiates processes leading to new osteoclast formation, and the consequent resorption overrides the effects of activating genes that direct bone formation. Identification of PTH related protein (PTHrP) production by cells early in the osteoblast lineage, and its action through the PTH1R upon more mature osteoblastic cells, together with the observation that PTHrP +/  mice are osteoporotic, all raise the possibility that PTHrP is a crucial paracrine regulator of bone formation. The finding that concurrent treatment with bisphosphonates impairs the anabolic response to PTH, adds to other clues that osteoclast activity is necessary to complement the direct effect that PTH has in promoting differentiation of committed osteoblast precursors. This might involve the generation of a coupling factor from osteoclasts that are transiently activated by receptor activator of nuclear factor kappa B ligand (RANKL) in response to PTH.
   New approaches to anabolic therapies may come from the discovery that an activating mutation in the LRP5 gene is responsible for an inherited high bone mass syndrome, and the fact that this can be recapitulated in transgenic mice, whereas inactivating mutations result in severe bone loss. This has focused attention on the Wnt/frizzled/beta catenin pathway as being important in bone formation, and proof of the concept has been obtained in experimental models.
C1 St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia.
   Univ Melbourne, Dept Med, Fitzroy, Vic 3063, Australia.
   Nord Biosci AS, DK 2730 Herlev, Denmark.
C3 St. Vincent's Institute of Medical Research; University of Melbourne;
   Nordic Bioscience
RP Martin, TJ (通讯作者)，St Vincents Inst Med Res, 9 Princess St, Fitzroy, Vic 3065, Australia.
EM jmartin@svi.edu.au
RI ; Sims, Natalie/A 7192 2012
OI Karsdal, Morten/0000 0001 5026 8740; Sims, Natalie/0000 0003 1421 8468;
   Gillespie, Matthew/0000 0001 6543 8909
CR Allan EH, 2003, J CELL BIOCHEM, V90, P158, DOI 10.1002/jcb.10614
   Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104
   AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611
   Bikle DD, 2002, J BONE MINER RES, V17, P1570, DOI 10.1359/jbmr.2002.17.9.1570
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   CANALIS E, 1989, ENDOCRIN METAB CLIN, V18, P903, DOI 10.1016/S0889 8529(18)30348 7
   CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885
   Chiusaroli R, 2004, MOL BIOL CELL, V15, P234, DOI 10.1091/mbc.e03 04 0207
   Cleiren E, 2001, HUM MOL GENET, V10, P2861, DOI 10.1093/hmg/10.25.2861
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   DELMAS PD, 1995, BONE, V16, P603, DOI 10.1016/8756 3282(95)00113 R
   Demiralp B, 2002, ENDOCRINOLOGY, V143, P4038, DOI 10.1210/en.2002 220221
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv 7 4 379
   EverhartCaye M, 1996, J CLIN ENDOCR METAB, V81, P199, DOI 10.1210/jc.81.1.199
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756 3282(03)00202 3
   Frost HM., 1964, Bone Biodyn, V6, P315
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   HARRIS WH, 1969, NEW ENGL J MED, V280, P193, DOI 10.1056/NEJM196901232800405
   Heymann D, 2000, CYTOKINE, V12, P1455, DOI 10.1006/cyto.2000.0747
   HOCK JM, 1989, ENDOCRINOLOGY, V125, P2022, DOI 10.1210/endo 125 4 2022
   HOLTROP ME, 1979, CALCIFIED TISSUE INT, V27, P129, DOI 10.1007/BF02441175
   Karaplis AC, 1996, VITAM HORM, V52, P177, DOI 10.1016/S0083 6729(08)60411 2
   Karsdal MA, 2005, AM J PATHOL, V166, P467, DOI 10.1016/S0002 9440(10)62269 9
   Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731
   Kartsogiannis V, 1997, BONE, V21, P385, DOI 10.1016/S8756 3282(97)00180 4
   Khosla S, 2003, NEW ENGL J MED, V349, P1277, DOI 10.1056/NEJMe038143
   Krishnan V, 2003, MOL ENDOCRINOL, V17, P423, DOI 10.1210/me.2002 0225
   Kulkarni NH, 2004, J BONE MINER RES, V19, pS57
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   LIPS P, 1978, CALC TISS RES, V26, P13, DOI 10.1007/BF02013227
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Martin TJ, 2004, TRENDS ENDOCRIN MET, V15, P49, DOI 10.1016/j.tem.2004.01.002
   Martin TJ., 2001, OSTEOPOROSIS, V1, P361
   Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756 3282(95)00332 2
   PARFITT AM, 1982, METAB BONE DIS RELAT, V4, P1, DOI 10.1016/0221 8747(82)90002 9
   Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581
   Rzeszutek K, 2003, J CRANIOFAC SURG, V14, P301, DOI 10.1097/00001665 200305000 00007
   Sims NA, 2004, J CLIN INVEST, V113, P379, DOI 10.1172/JCI200419872
   Suda N, 1996, J CELL PHYSIOL, V166, P94, DOI 10.1002/(SICI)1097 4652(199601)166:1<94::AID JCP11>3.0.CO;2 P
   WEIR EC, 1992, CALCIFIED TISSUE INT, V51, P30, DOI 10.1007/BF00296214
   WRONSKI TJ, 1993, ENDOCRINOLOGY, V132, P823, DOI 10.1210/en.132.2.823
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   YEE JA, 1993, J CELL PHYSIOL, V157, P528, DOI 10.1002/jcp.1041570312
NR 54
TC 47
Z9 56
U1 1
U2 3
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND
SN 0077 8923
BN 1 57331 583 4
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2006
VL 1068
BP 458
EP 470
DI 10.1196/annals.1346.043
PG 13
WC Multidisciplinary Sciences; Orthopedics
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Orthopedics
GA BFA92
UT WOS:000240548200044
PM 16831943
DA 2025 08 17
ER

PT J
AU Bedi, B
   Li, JY
   Tawfeek, H
   Baek, KH
   Adams, J
   Vangara, SS
   Chang, MK
   Kneissel, M
   Weitzmanna, MN
   Pacifici, R
AF Bedi, Brahmchetna
   Li, Jau Yi
   Tawfeek, Hesham
   Baek, Ki Hyun
   Adams, Jonathan
   Vangara, Sameera S.
   Chang, Ming Kang
   Kneissel, Michaela
   Weitzmanna, M. Neale
   Pacifici, Roberto
TI Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the
   bone anabolic activity of PTH
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE bone mass; T lymphocytes; bone cells
ID MESENCHYMAL STEM CELLS; BETA CATENIN; DIFFERENTIATED OSTEOBLASTS;
   TUBEROINFUNDIBULAR PEPTIDE; POSTMENOPAUSAL WOMEN; OSTEOCLAST FORMATION;
   GENE EXPRESSION; CD40 LIGAND; IN VIVO; WNT
AB Intermittent parathyroid hormone (iPTH) treatment stimulates T cell production of the osteogenic Wnt ligand Wnt10b, a factor required for iPTH to activate Wnt signaling in osteoblasts and stimulate bone formation. However, it is unknown whether iPTH induces Wnt10b production and bone anabolism through direct activation of the parathyroid hormone (PTH)/PTH related protein receptor (PPR) in T cells. Here, we show that conditional silencing of PPR in T cells blunts the capacity of iPTH to induce T cell production of Wnt10b; activate Wnt signaling in osteoblasts; expand the osteoblastic pool; and increase bone turnover, bone mineral density, and trabecular bone volume. These findings demonstrate that direct PPR signaling in T cells plays an important role in PTH induced bone anabolism by promoting T cell production of Wnt10b and suggest that T cells may provide pharmacological targets for bone anabolism.
C1 [Bedi, Brahmchetna; Li, Jau Yi; Tawfeek, Hesham; Baek, Ki Hyun; Adams, Jonathan; Vangara, Sameera S.; Weitzmanna, M. Neale; Pacifici, Roberto] Emory Univ, Dept Med, Div Endocrinol Metab & Lipids, Atlanta, GA 30322 USA.
   [Bedi, Brahmchetna; Weitzmanna, M. Neale] Atlanta Vet Affairs Med Ctr, Decatur, GA 30033 USA.
   [Chang, Ming Kang; Kneissel, Michaela] Novartis Inst Biomed Res, CH 4002 Basel, Switzerland.
   [Pacifici, Roberto] Emory Univ, Immunol & Mol Pathogenesis Program, Atlanta, GA 30322 USA.
C3 Emory University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Atlanta VA Health Care System; Novartis; Emory
   University
RP Pacifici, R (通讯作者)，Emory Univ, Dept Med, Div Endocrinol Metab & Lipids, Atlanta, GA 30322 USA.
EM roberto.pacifici@emory.edu
RI Tawfeek, Hesham/W 9530 2019; Kim, Hyungduk/CAH 5630 2022
OI Tawfeek, Hesham/0000 0002 6673 7393; 
FU National Institutes of Health [AR54625, AR49659]; Biomedical Laboratory
   Research and Development Service of the Veterans Affairs Office of
   Research and Development [5I01BX000105]; National Institute of Arthritis
   and Musculoskeletal and Skin Diseases [AR059364, AR056090, AR053607];
   National Institute on Aging [AG040013]; Georgia Research Alliance
FX This study was supported by the National Institutes of Health Grants
   AR54625 and AR49659. M.N.W. acknowledges financial support from the
   Biomedical Laboratory Research and Development Service of the Veterans
   Affairs Office of Research and Development through Grant 5I01BX000105;
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   through Grants AR059364, AR056090, and AR053607; National Institute on
   Aging Grant AG040013; and the Georgia Research Alliance.
CR Ahuja SS, 2003, ENDOCRINOLOGY, V144, P1761, DOI 10.1210/en.2002 221136
   Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bikle DD, 2002, J BONE MINER RES, V17, P1570, DOI 10.1359/jbmr.2002.17.9.1570
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Bodine PVN, 2005, J CELL BIOCHEM, V96, P1212, DOI 10.1002/jcb.20599
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   Divieti P, 2005, ENDOCRINOLOGY, V146, P1863, DOI 10.1210/en.2004 1262
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   Eichinger A, 2002, ENDOCRINOLOGY, V143, P3036, DOI 10.1210/en.143.8.3036
   Gao Y, 2008, CELL METAB, V8, P132, DOI 10.1016/j.cmet.2008.07.001
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   Hoare SRJ, 2000, J BIOL CHEM, V275, P27274
   Iida Klein A, 2002, J BONE MINER RES, V17, P808, DOI 10.1359/jbmr.2002.17.5.808
   Jackson A, 2005, BONE, V36, P585, DOI 10.1016/j.bone.2005.01.007
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Lanske B, 1999, J CLIN INVEST, V104, P399, DOI 10.1172/JCI6629
   Li JY, 2011, P NATL ACAD SCI USA, V108, P768, DOI 10.1073/pnas.1013492108
   Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200
   Lindsay R, 2006, J BONE MINER RES, V21, P366, DOI 10.1359/JBMR.051109
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   Meng XW, 1996, J BONE MINER RES, V11, P421
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   NISHIDA S, 1994, BONE, V15, P717, DOI 10.1016/8756 3282(94)90322 0
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pettway GJ, 2008, BONE, V42, P806, DOI 10.1016/j.bone.2007.11.017
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Sato K, 2007, BLOOD, V109, P228, DOI 10.1182/blood 2006 02 002246
   SCHMIDT IU, 1995, ENDOCRINOLOGY, V136, P5127, DOI 10.1210/en.136.11.5127
   Silvestrini G, 2007, J MOL HISTOL, V38, P261, DOI 10.1007/s10735 007 9096 3
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tawfeek H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012290
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Tobimatsu T, 2006, ENDOCRINOLOGY, V147, P2583, DOI 10.1210/en.2005 1627
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Usdin TB, 1999, NAT NEUROSCI, V2, P941, DOI 10.1038/14724
   Vaes BLT, 2005, BONE, V36, P803, DOI 10.1016/j.bone.2005.02.001
   Wan M, 2008, GENE DEV, V22, P2968, DOI 10.1101/gad.1702708
   Wu XW, 2010, CELL STEM CELL, V7, P571, DOI 10.1016/j.stem.2010.09.012
   Yamaguchi M, 2005, ENDOCRINOLOGY, V146, P2620, DOI 10.1210/en.2004 1511
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 58
TC 73
Z9 82
U1 1
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 20
PY 2012
VL 109
IS 12
BP E725
EP E733
DI 10.1073/pnas.1120735109
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 911JH
UT WOS:000301712600008
PM 22393015
OA Green Published
DA 2025 08 17
ER

PT J
AU Terauchi, M
   Li, JY
   Bedi, B
   Baek, KH
   Tawfeek, H
   Galley, S
   Gilbert, L
   Nanes, MS
   Zayzafoon, M
   Guldberg, R
   Lamar, DL
   Singer, MA
   Lane, TF
   Kronenberg, HM
   Weitzmann, MN
   Pacifici, R
AF Terauchi, Masakazu
   Li, Jau Yi
   Bedi, Brahmchetna
   Baek, Ki Hyun
   Tawfeek, Hesham
   Galley, Sarah
   Gilbert, Linda
   Nanes, Mark S.
   Zayzafoon, Majd
   Guldberg, Robert
   Lamar, David L.
   Singer, Meredith A.
   Lane, Timothy F.
   Kronenberg, Henry M.
   Weitzmann, M. Neale
   Pacifici, Roberto
TI T Lymphocytes Amplify the Anabolic Activity of Parathyroid Hormone
   through Wnt10b Signaling
SO CELL METABOLISM
LA English
DT Article
ID INCREASED BONE FORMATION; BETA CATENIN; DIFFERENTIATED OSTEOBLASTS;
   POSTMENOPAUSAL WOMEN; CELL PROLIFERATION; MICE DEFICIENT; STROMAL CELLS;
   IN VIVO; EXPRESSION; INCREASES
AB Intermittent administration of parathyroid hormone (iPTH) is used to treat osteoporosis because it improves bone architecture and strength, but the underlying cellular and molecular mechanisms are unclear. Here, we show that PTH increases the production of Wnt10b by bone marrow CD8+ T cells and induces these lymphocytes to activate canonical Wnt signaling in preosteoblasts. Accordingly, in responses to iPTH, T cell null mice display diminished Wnt signaling in preosteoblasts and blunted osteoblastic commitment, proliferation, differentiation, and life span, which result in decreased trabecular bone anabolism and no increase in strength. Demonstrating the specific role of lymphocytic Wntl Ob, PTH has no anabolic activity in mice lacking T cell produced Wntl Ob. Therefore, T cell mediated activation of Wnt signaling in osteoblastic cells plays a key permissive role in the mechanism by which iPTH increases bone strength, suggesting that T cell osteoblast crosstalk pathways may provide pharmacological targets for bone anabolism.
C1 [Terauchi, Masakazu; Li, Jau Yi; Bedi, Brahmchetna; Baek, Ki Hyun; Tawfeek, Hesham; Galley, Sarah; Nanes, Mark S.; Weitzmann, M. Neale; Pacifici, Roberto] Emory Univ, Dept Med, Div Endocrinol Metab & Lipids, Atlanta, GA 30332 USA.
   [Lamar, David L.] Emory Univ, Dept Med, Kathleen B & Mason I Lowance Ctr Human Immunol, Atlanta, GA 30332 USA.
   [Weitzmann, M. Neale] Emory Univ, Emory Winship Canc Inst, Atlanta, GA 30332 USA.
   [Pacifici, Roberto] Emory Univ, Immunol & Mol Pathogenesis Program, Atlanta, GA 30332 USA.
   [Gilbert, Linda; Nanes, Mark S.; Weitzmann, M. Neale] Atlanta VA Med Ctr, Decatur, GA 30033 USA.
   [Zayzafoon, Majd] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Guldberg, Robert] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA.
   [Singer, Meredith A.; Lane, Timothy F.] Univ Calif Los Angeles, Dept Obstet & Gynecol, Dept Biol Chem, Los Angeles, CA 90095 USA.
   [Singer, Meredith A.; Lane, Timothy F.] Univ Calif Los Angeles, Orthoped Hosp, Res Ctr, Los Angeles, CA 90095 USA.
   [Kronenberg, Henry M.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
C3 Emory University; Emory University; Emory University; Emory University;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Atlanta VA Medical Center; Atlanta VA Health Care System; University of
   Alabama System; University of Alabama Birmingham; University System of
   Georgia; Georgia Institute of Technology; University of California
   System; University of California Los Angeles; University of California
   System; University of California Los Angeles; Harvard University;
   Harvard University Medical Affiliates; Massachusetts General Hospital
RP Pacifici, R (通讯作者)，Emory Univ, Dept Med, Div Endocrinol Metab & Lipids, Atlanta, GA 30332 USA.
EM roberto.pacifici@emory.edu
RI Tawfeek, Hesham/W 9530 2019; Kim, Hyungduk/CAH 5630 2022; Terauchi,
   Masakazu/D 9831 2013; KRONENBERG, HENRY/MXK 0923 2025
OI Tawfeek, Hesham/0000 0002 6673 7393; Lane, Timothy
   F./0000 0002 0210 970X; Terauchi, Masakazu/0000 0001 5577 0094; 
FU National Institutes of Health [AR54625, AG28278]
FX This study was supported by grants from the National Institutes of
   Health (AR54625 and AG28278). We are grateful to Laurie McCauley
   (University of Michigan) for her review of the manuscript.
CR ALEXIEWICZ JM, 1990, J AM SOC NEPHROL, V1, P236
   Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Bodine PVN, 2005, J CELL BIOCHEM, V96, P1212, DOI 10.1002/jcb.20599
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   DIROSA F, 2008, CELL BIOL, V87, P20
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Gao Y, 2008, CELL METAB, V8, P132, DOI 10.1016/j.cmet.2008.07.001
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   GEFFNER ME, 1995, PEDIATR RES, V37, P507, DOI 10.1203/00006450 199504000 00021
   Gensure RC, 2005, BIOCHEM BIOPH RES CO, V328, P666, DOI 10.1016/j.bbrc.2004.11.069
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Grey AB, 1996, CLIN ENDOCRINOL, V44, P697
   Hardiman G, 1996, GENE, V172, P199, DOI 10.1016/0378 1119(96)00109 6
   Iida Klein A, 2002, J BONE MINER RES, V17, P808, DOI 10.1359/jbmr.2002.17.5.808
   Iwaniec UT, 2007, J BONE MINER RES, V22, P394, DOI 10.1359/JBMR.061118
   Jackson A, 2005, BONE, V36, P585, DOI 10.1016/j.bone.2005.01.007
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   NISHIDA S, 1994, BONE, V15, P717, DOI 10.1016/8756 3282(94)90322 0
   Ouji Y, 2006, BIOCHEM BIOPH RES CO, V342, P1063, DOI 10.1016/j.bbrc.2006.02.028
   Pettway GJ, 2005, BONE, V36, P959, DOI 10.1016/j.bone.2005.02.015
   Pettway GJ, 2008, BONE, V42, P806, DOI 10.1016/j.bone.2007.11.017
   Potts J, 1998, METABOLIC BONE DIS, P411
   Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Rifas L, 2003, J CELL BIOCHEM, V88, P650, DOI 10.1002/jcb.10436
   Robertson G, 2006, BONE, V39, P767, DOI 10.1016/j.bone.2006.04.006
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200
   SCHMIDT IU, 1995, ENDOCRINOLOGY, V136, P5127, DOI 10.1210/en.136.11.5127
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   STOJCEVATANEVA O, 1993, NEPHRON, V64, P592, DOI 10.1159/000187406
   Tobimatsu T, 2006, ENDOCRINOLOGY, V147, P2583, DOI 10.1210/en.2005 1627
   Vaes BLT, 2005, BONE, V36, P803, DOI 10.1016/j.bone.2005.02.001
   Wan M, 2008, GENE DEV, V22, P2968, DOI 10.1101/gad.1702708
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 53
TC 150
Z9 167
U1 1
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1550 4131
EI 1932 7420
J9 CELL METAB
JI Cell Metab.
PD SEP 2
PY 2009
VL 10
IS 3
BP 229
EP 240
DI 10.1016/j.cmet.2009.07.010
PG 12
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 491SX
UT WOS:000269600900010
PM 19723499
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Clément Demange, L
   Clézardin, P
AF Clement Demange, Lise
   Clezardin, Philippe
TI Emerging therapies in bone metastasis
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID RESISTANT PROSTATE CANCER; RADIUM 223 DICHLORIDE; PHASE II; ZOLEDRONIC
   ACID; DOUBLE BLIND; SURVIVAL; INHIBITION; EVEROLIMUS; EVENTS; AGENTS
AB Skeletal lesions contribute substantially to morbidity and mortality in patients with cancer. Emerging treatments for metastatic bone disease have arisen from our understanding of the biology of bone metastases. Tumour cells alter the functions of bone resorbing (osteoclasts) and bone forming (osteoblasts) cells, promoting skeletal destruction. Drugs that inhibit osteoclast mediated bone resorption (denosumab, bisphosphonates) are the standard of care for patients with skeletal metastases. In this review, we describe the progress and future directions of novel bone targeted therapies that not only focus on osteoclasts, but also on osteoblasts and the bone microenvironment.
C1 [Clement Demange, Lise; Clezardin, Philippe] INSERM, UMR 1033, F 69372 Lyon, France.
   [Clement Demange, Lise; Clezardin, Philippe] Univ Lyon 1, F 69622 Villeurbanne, France.
C3 Universite Claude Bernard Lyon 1; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite Claude Bernard Lyon 1
RP Clézardin, P (通讯作者)，INSERM, UMR 1033, F 69372 Lyon, France.
EM philippe.clezardin@inserm.fr
RI Clezardin, Philippe/M 8071 2014
OI Clezardin, Philippe/0000 0003 0149 4463
FU Ministere de l'Enseignement Superieur et de la Recherche; INSERM;
   University of Lyon; LabEX DEVweCAN [ANR 10 LABX 61]
FX L.C D is a recipient of a PhD fellowship from the Ministere de
   l'Enseignement Superieur et de la Recherche. PC is supported by INSERM,
   the University of Lyon and the LabEX DEVweCAN (ANR 10 LABX 61).
CR Abdulkadyrov KM, 2014, BRIT J HAEMATOL, V165, P814, DOI 10.1111/bjh.12835
   Araujo JC, 2013, LANCET ONCOL, V14, P1307, DOI 10.1016/S1470 2045(13)70479 0
   Bone HG, 2015, OSTEOPOROSIS INT, V26, P699, DOI 10.1007/s00198 014 2944 6
   Broom RJ, 2015, CLIN GENITOURIN CANC, V13, P50, DOI 10.1016/j.clgc.2014.07.002
   Campone M, 2012, ANN ONCOL, V23, P610, DOI 10.1093/annonc/mdr261
   Chu TQ, 2014, BIOCHEM BIOPH RES CO, V443, P962, DOI 10.1016/j.bbrc.2013.12.076
   Clézardin P, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2835
   Coleman R, 2014, BREAST CANCER RES TR, V145, P411, DOI 10.1007/s10549 014 2939 1
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Dienstmann R, 2014, MOL CANCER THER, V13, P1021, DOI 10.1158/1535 7163.MCT 13 0639
   Duong LT, 2014, MOL CANCER THER, V13, P2898, DOI 10.1158/1535 7163.MCT 14 0253
   Gartrell BA, 2014, NAT REV CLIN ONCOL, V11, P335, DOI 10.1038/nrclinonc.2014.70
   Gnant M, 2013, JNCI J NATL CANCER I, V105, P654, DOI 10.1093/jnci/djt026
   Hofbauer LC, 2014, LANCET DIABETES ENDO, V2
   Hussein O, 2012, CANCER LETT, V314, P176, DOI 10.1016/j.canlet.2011.09.026
   Lee RJ, 2013, CANCER J, V19, P90, DOI 10.1097/PPO.0b013e318281e280
   Lotinun S., 2012, CURR MOL PHARMACOL, V5, P195, DOI [10.2174/1874467211205020195, DOI 10.2174/1874467211205020195]
   Mantyh P, 2013, PAIN, V154, pS54, DOI 10.1016/j.pain.2013.07.044
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Michaelson MD, 2006, CANCER AM CANCER SOC, V107, P530, DOI 10.1002/cncr.22043
   Rosanò L, 2013, NAT REV CANCER, V13, P637, DOI 10.1038/nrc3546
   Sartor O, 2014, LANCET ONCOL, V15, P738, DOI 10.1016/S1470 2045(14)70183 4
   Suominen MI, 2013, JNCI J NATL CANCER I, V105, P908, DOI 10.1093/jnci/djt116
   Suvannasankha A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058 014 0484 9
   Terpos E, 2012, ANN ONCOL, V23, P2681, DOI 10.1093/annonc/mds068
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
NR 26
TC 22
Z9 24
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471 4892
EI 1471 4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD JUN
PY 2015
VL 22
BP 79
EP 86
DI 10.1016/j.coph.2015.04.004
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CL8MP
UT WOS:000357229100013
PM 25935860
DA 2025 08 17
ER

PT J
AU Nardone, V
   D'Asta, F
   Brandi, ML
AF Nardone, Valeria
   D'Asta, Federica
   Brandi, Maria Luisa
TI Pharmacological management of osteogenesis
SO CLINICS
LA English
DT Article
DE Antiresorptive Drugs; Bone Formation; Osteoblasts; Osteogenesis; RANKL
   Inhibitors
ID INCREASES BONE FORMATION; KAPPA B LIGAND; NITROGEN CONTAINING
   BISPHOSPHONATE; INTERMITTENT PARATHYROID HORMONE; ESTROGEN RECEPTOR
   MODULATORS; MARROW STROMAL CELLS; POSTMENOPAUSAL WOMEN; ZOLEDRONIC ACID;
   OSTEOBLAST DIFFERENTIATION; STRONTIUM RANELATE
AB Osteogenesis and bone remodeling are complex biological processes that are essential for the formation of new bone tissue and its correct functioning. When the balance between bone resorption and formation is disrupted, bone diseases and disorders such as Paget's disease, fibrous dysplasia, osteoporosis and fragility fractures may result. Recent advances in bone cell biology have revealed new specific targets for the treatment of bone loss that are based on the inhibition of bone resorption by osteoclasts or the stimulation of bone formation by osteoblasts. Bisphosphonates, antiresorptive agents that reduce bone resorption, are usually recommended as first line therapy in women with postmenopausal osteoporosis. Numerous studies have shown that bisphosphonates are able to significantly reduce the risk of femoral and vertebral fractures. Other antiresorptive agents indicated for the treatment of osteoporosis include selective estrogen receptor modulators, such as raloxifene. Denosumab, a human monoclonal antibody, is another antiresorptive agent that has been approved in Europe and the USA. This agent blocks the RANK/RANKL/OPG system, which is responsible for osteoclastic activation, thus reducing bone resorption. Other approved agents include bone anabolic agents, such as teriparatide, a recombinant parathyroid hormone that improves bone microarchitecture and strength, and strontium ranelate, considered to be a dual action drug that acts by both osteoclastic inhibition and osteoblastic stimulation. Currently, anti catabolic drugs that act through the Wnt beta catenin signaling pathway, serving as Dickkopf related protein 1 inhibitors and sclerostin antagonists, are also in development. This concise review provides an overview of the drugs most commonly used for the control of osteogenesis in bone diseases.
C1 [Nardone, Valeria; Brandi, Maria Luisa] Univ Florence, Dept Surg & Translat Med, Florence, Italy.
   [D'Asta, Federica] Univ Florence, Dept Neurosci Drug Area & Child Hlth, Florence, Italy.
C3 University of Florence; University of Florence
RP Brandi, ML (通讯作者)，Univ Florence, Dept Surg & Translat Med, Florence, Italy.
EM marialuisa.brandi@unifi.it
OI brandi, maria luisa/0000 0002 8741 0592; D'asta,
   Federica/0000 0001 8718 3476
CR Abe Y, 2000, J LAB CLIN MED, V136, P344, DOI 10.1067/mlc.2000.109757
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   Arlot M, 2005, J BONE MINER RES, V20, P1244, DOI 10.1359/JBMR.050309
   Baron R, 2002, EUR J PHARMACOL, V450, P11, DOI 10.1016/S0014 2999(02)02040 X
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Belavic Jennifer M, 2011, Nurse Pract, V36, P11, DOI 10.1097/01.NPR.0000391178.47878.73
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brennan TC, 2009, BRIT J PHARMACOL, V157, P1291, DOI 10.1111/j.1476 5381.2009.00305.x
   Briot K, 2012, J CLIN DENSITOM, V15, P176, DOI 10.1016/j.jocd.2011.11.006
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   Bukata Susan V, 2010, Curr Osteoporos Rep, V8, P28, DOI 10.1007/s11914 010 0006 3
   Cesareo R, 2010, INT J WOMENS HEALTH, V2, P1
   Chattopadhyay N, 2007, BIOCHEM PHARMACOL, V74, P438, DOI 10.1016/j.bcp.2007.04.020
   Cipriano Cara A, 2009, HSS J, V5, P149, DOI 10.1007/s11420 009 9109 8
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Collin Osdoby P, 2004, CIRC RES, V95, P1046, DOI 10.1161/01.RES.0000149165.99974.12
   Compston JE, 2007, BONE, V40, P1447, DOI 10.1016/j.bone.2006.09.008
   Cosman F, 1999, ENDOCR REV, V20, P418, DOI 10.1210/er.20.3.418
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   D'Aoust P, 2000, CELL TISSUE RES, V302, P353, DOI 10.1007/s004419900165
   EGGELMEIJER F, 1994, J RHEUMATOL, V21, P2016
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Enders GH, 2009, J CLIN INVEST, V119, P758, DOI 10.1172/JCI38973
   Evdokiou A, 2003, BONE, V33, P216, DOI 10.1016/S8756 3282(03)00223 0
   Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371
   Fonseca JE, 2008, RHEUMATOLOGY, V47, P17, DOI 10.1093/rheumatology/ken165
   GENNARI C, 1990, J CLIN ENDOCR METAB, V71, P1288, DOI 10.1210/jcem 71 5 1288
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Giuliani N, 1998, SCAND J RHEUMATOL, V27, P38
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   Hao YQ, 2012, J NANOSCI NANOTECHNO, V12, P207, DOI 10.1166/jnn.2012.5125
   Harper KD, 2007, J BONE MINER RES, V22, P334, DOI 10.1359/JBMR.061111
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Isaac J, 2011, EUR CELLS MATER, V21, P130, DOI 10.22203/eCM.v021a11
   Itoh F, 2003, EUR J PHARMACOL, V477, P9, DOI 10.1016/j.ejphar.2003.08.011
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   Kaback LA, 2008, J CELL BIOCHEM, V105, P219, DOI 10.1002/jcb.21816
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Kawamoto S, 2002, ARCH ORAL BIOL, V47, P67, DOI 10.1016/S0003 9969(01)00086 3
   Khajuria DK, 2011, REV BRAS REUMATOL, V51, P365
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim HKW, 2006, J BONE MINER RES, V21, P1946, DOI 10.1359/JBMR.060905
   Kim HK, 2009, CLIN ORTHOP RELAT R, V467, P3121, DOI 10.1007/s11999 008 0409 y
   Klein BY, 1998, J CELL BIOCHEM, V68, P186, DOI 10.1002/(SICI)1097 4644(19980201)68:2<186::AID JCB5>3.0.CO;2 R
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lala R, 2000, ACTA PAEDIATR, V89, P188, DOI 10.1080/080352500750028816
   Lane JM, 2001, CLIN ORTHOP RELAT R, P6
   Lewiecki EM, 2010, MATURITAS, V66, P182, DOI 10.1016/j.maturitas.2010.02.008
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lipton A, 2011, BONE, V48, P96, DOI 10.1016/j.bone.2010.10.161
   Liu F, 2011, J MATER SCI MATER M, V22, P683, DOI 10.1007/s10856 011 4247 1
   Losada BR, 2009, J CLIN DENSITOM, V12, P63, DOI 10.1016/j.jocd.2008.10.002
   Luvizuto ER, 2010, ARCH ORAL BIOL, V55, P52, DOI 10.1016/j.archoralbio.2009.11.001
   Manolagas SC, 2007, MOL ENDOCRINOL, V21, P2605, DOI 10.1210/me.2007 0259
   Marie PJ, 2007, BONE, V40, pS5, DOI 10.1016/j.bone.2007.02.003
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Marie PJ, 2005, OSTEOPOROSIS INT, V16, pS7, DOI 10.1007/s00198 004 1753 8
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   MCKANE WR, 1995, J CLIN ENDOCR METAB, V80, P3458, DOI 10.1210/jc.80.12.3458
   Mentaverri R., 2003, J BONE MINER RES, V18, pM237
   Michael H, 2007, BRIT J PHARMACOL, V151, P384, DOI 10.1038/sj.bjp.0707232
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Muchmore D B, 2000, Oncologist, V5, P388, DOI 10.1634/theoncologist.5 5 388
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nakazawa T, 2005, BONE, V37, P711, DOI 10.1016/j.bone.2005.06.013
   Nardone V, 2012, INT J BIOMATER, V2012, DOI 10.1155/2012/865291
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ni GX, 2011, J MATER SCI MATER M, V22, P961, DOI 10.1007/s10856 011 4264 0
   Nishikawa M, 1996, BONE, V18, P9, DOI 10.1016/8756 3282(95)00426 2
   Noda Seino H, 2013, J ENDOCRINOL INVEST, V36, P21, DOI 10.3275/8301
   Olivier S, 2005, BIOCHEM PHARMACOL, V69, P891, DOI 10.1016/j.bcp.2004.11.030
   Ominsky MS, 2007, OSTEOPOROSIS INT, V18, P1073, DOI 10.1007/s00198 007 0363 7
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Padagas J, 2006, CALCIFIED TISSUE INT, V78, P35, DOI 10.1007/s00223 005 0161 1
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Reinholz GG, 2002, BREAST CANCER RES TR, V71, P257, DOI 10.1023/A:1014418017382
   Rey JP, 2010, DEV DYNAM, V239, P102, DOI 10.1002/dvdy.22181
   Rizzoli R, 2011, OSTEOPOROSIS INT, V22, P373, DOI 10.1007/s00198 010 1453 5
   Rizzoli R, 2008, BONE, V42, P841, DOI 10.1016/j.bone.2008.01.003
   Rizzoli R, 2010, NAT REV DRUG DISCOV, V9, P591, DOI 10.1038/nrd3244
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Roux C, 2008, ANN RHEUM DIS, V67, P1736, DOI 10.1136/ard.2008.094516
   Ryder KM, 2010, J BONE MINER METAB, V28, P233, DOI 10.1007/s00774 009 0123 1
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Sila Asna Monnipha, 2007, Kobe J Med Sci, V53, P25
   Silvestrini G, 2005, J MOL HISTOL, V36, P59, DOI 10.1007/s10735 004 3839 1
   Still K, 2003, CALCIFIED TISSUE INT, V72, P143, DOI 10.1007/s00223 001 2066 y
   Stolina M, 2005, J BONE MINER RES, V20, P1756, DOI 10.1359/JBMR.050601
   Subbiah V, 2010, OSTEOPOROSIS INT, V21, P1041, DOI 10.1007/s00198 009 1004 0
   Sudhoff H, 2003, ANN OTO RHINOL LARYN, V112, P780, DOI 10.1177/000348940311200907
   Takahashi N, 2003, J BONE MINER RES, V18, P1082, DOI 10.1359/jbmr.2003.18.6.1082
   Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756 3282(01)00685 8
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Viereck V, 2003, J CLIN ENDOCR METAB, V88, P4206, DOI 10.1210/jc.2002 021877
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Wilker C, 2004, J BONE MINER RES  S1, V19, pSA435
   Xiong Y, 2009, J INT MED RES, V37, P407, DOI 10.1177/147323000903700216
   Zhang WB, 2011, ACTA BIOMATER, V7, P800, DOI 10.1016/j.actbio.2010.08.031
   Zhu LL, 2007, BIOCHEM BIOPH RES CO, V355, P307, DOI 10.1016/j.bbrc.2007.01.120
NR 139
TC 50
Z9 55
U1 0
U2 25
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807 5932
EI 1980 5322
J9 CLINICS
JI Clinics
PY 2014
VL 69
IS 6
BP 438
EP 446
DI 10.6061/clinics/2014(06)12
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA AK5CB
UT WOS:000338440500012
PM 24964310
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Mazziotti, G
   Bilezikian, J
   Canalis, E
   Cocchi, D
   Giustina, A
AF Mazziotti, G.
   Bilezikian, J.
   Canalis, E.
   Cocchi, D.
   Giustina, A.
TI New understanding and treatments for osteoporosis
SO ENDOCRINE
LA English
DT Article
DE Osteoporosis; Osteoblasts; Osteoclasts; PTH; RANKL; Cathepsin K;
   Sclerostin; Diabetes
ID BONE MINERAL DENSITY; FACTOR KAPPA B; GLUCOCORTICOID INDUCED
   OSTEOPOROSIS; RADIOLOGICAL SPINAL DEFORMITIES; CALCIUM SENSING RECEPTOR;
   PARATHYROID HORMONE 1 34; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES;
   INCREASED PREVALENCE; SCLEROSTIN ANTIBODY
AB To summarize promising areas of investigation in osteoporosis and to stimulate further research in this area, as discussed in a recent international conference. Over the recent years, there has been an improvement in the knowledge of molecular pathways involved in bone formation and resorption with the development of new drugs to treat osteoporosis. Intact parathyroid hormone, teriparatide, and anti sclerostin monoclonal antibody are anabolic drugs, whereas denosumab and odanacatib are anti resorptive drugs with more reversible effects as compared to bisphosphonates. Anabolic and anti resorptive agents have different effects on bone, and research in this area includes the efficacy of combination and sequential therapies with them. New insights in the molecular pathways of bone remodeling have clarified the mechanisms responsible for skeletal fragility in several forms of secondary osteoporosis, such as that occurring in type 2 diabetes, following drug exposure and systemic inflammatory diseases. Future research is needed to address the efficacy of anti osteoporotic drugs in these more recently recognized conditions of skeletal fragility. Osteoporosis continues to be an important field of biomedical research.
C1 [Mazziotti, G.] Azienda Osped Carlo Poma, Dept Med, Endocrine & Bone Unit, I 46100 Mantua, Italy.
   [Mazziotti, G.; Giustina, A.] Univ Brescia, Dept Med & Surg Sci, Brescia, Italy.
   [Bilezikian, J.] Columbia Univ, Dept Med, Coll Phys & Surg, New York, NY USA.
   [Canalis, E.] St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06105 USA.
   [Canalis, E.] Univ Connecticut, Sch Med, Farmington, CT USA.
   [Cocchi, D.] Univ Brescia, Dept Biomed Sci & Biotechnol, Brescia, Italy.
C3 Hospital Carlo Poma; University of Brescia; Columbia University; Saint
   Francis Hospital & Medical Center; University of Connecticut; University
   of Brescia
RP Mazziotti, G (通讯作者)，Azienda Osped Carlo Poma, Dept Med, Endocrine & Bone Unit, Via Lago Paiolo 10, I 46100 Mantua, Italy.
EM gherardo.mazziotti@aopoma.it
RI Mazziotti, Gherardo/AAC 1983 2019; Giustina, Andrea/AAN 5938 2020
OI Mazziotti, Gherardo/0000 0001 5458 701X; 
FU Eli Lilly; NPS Pharmaceuticals; Amgen
FX G.M. received lecture fee from Eli Lilly. J.B. is a consultant for
   Merck, Eli Lilly, Novartis, Amgen, Radius Pharmaceuticals, Johnson &
   Johnson; received research support from NPS Pharmaceuticals. E. C. is a
   consultant for Eli Lilly and received lecture fees from Eli Lilly and
   Amgen. D. C has nothing to declare. A. G. is a consultant for Eli Lilly
   and received lecture fees from Eli Lilly and Amgen.
CR Alikhani M, 2007, BONE, V40, P345, DOI 10.1016/j.bone.2006.09.011
   Almeida M, 2010, MOL ENDOCRINOL, V24, P2030, DOI 10.1210/me.2010 0189
   Almeida M, 2010, J BONE MINER RES, V25, P769, DOI 10.1359/jbmr.091017
   Ambrogini E, 2010, CELL METAB, V11, P136, DOI 10.1016/j.cmet.2009.12.009
   Ballen K, 2007, BONE MARROW TRANSPL, V39, P655, DOI 10.1038/sj.bmt.1705651
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bilezikian JP, 2011, J BONE MINER RES, V26, P2317, DOI 10.1002/jbmr.483
   Bilezikian John P, 2008, Curr Osteoporos Rep, V6, P24, DOI 10.1007/s11914 008 0005 9
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Bonadonna S, 2005, J BONE MINER RES, V20, P1837, DOI 10.1359/JBMR.050603
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Boonen S, 2011, J CLIN ENDOCR METAB, V96, P1727, DOI 10.1210/jc.2010 2784
   Boonen S, 2011, CURR MED RES OPIN, V27, P1149, DOI 10.1185/03007995.2011.573545
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Canalis E, 2000, J CLIN INVEST, V106, P177, DOI 10.1172/JCI10584
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chattopadhyay N, 2004, ENDOCRINOLOGY, V145, P3451, DOI 10.1210/en.2003 1127
   CHRISCHILLES EA, 1991, ARCH INTERN MED, V151, P2026, DOI 10.1001/archinte.151.10.2026
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Compston J., 2011, ENDOCRINE
   Compston JE, 2010, MATURITAS, V65, P3, DOI 10.1016/j.maturitas.2009.11.002
   Connor E. Barrett , 2011, OSTEOPOROS INT
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cosman F, 2009, J CLIN ENDOCR METAB, V94, P3772, DOI 10.1210/jc.2008 2719
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Cusano N.E., 2010, IBMS BoneKEy, V7, P84
   Cusano N.E., 2011, MED RES OPIN
   Deregowski V, 2006, J BIOL CHEM, V281, P6203, DOI 10.1074/jbc.M508370200
   Dormuth CR, 2009, ARCH INTERN MED, V169, P1395, DOI 10.1001/archinternmed.2009.214
   Douglas IJ, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000154
   Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Finkelstein JS, 2009, J CLIN ENDOCR METAB, V94, P2495, DOI 10.1210/jc.2009 0154
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fratzl Zelman N, 2004, J CLIN ENDOCR METAB, V89, P1538, DOI 10.1210/jc.2003 031055
   Gao Y, 2008, CELL METAB, V8, P132, DOI 10.1016/j.cmet.2008.07.001
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   Giles RH, 2003, BBA REV CANCER, V1653, P1, DOI 10.1016/S0304 419X(03)00005 2
   Giuliani N, 2002, BLOOD, V100, P4615, DOI 10.1182/blood 2002 04 1121
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Gopalakrishnan V, 2006, BIOCHEM CELL BIOL, V84, P93, DOI 10.1139/O05 163
   GOUGH AKS, 1994, LANCET, V344, P23, DOI 10.1016/S0140 6736(94)91049 9
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Grey A, 2008, OSTEOPOROSIS INT, V19, P129, DOI 10.1007/s00198 007 0477 y
   Hamada Y, 2010, ENDOCRINE, V38, P369, DOI 10.1007/s12020 010 9390 9
   Heider U, 2003, CLIN CANCER RES, V9, P1436
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Hofbauer L. C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P268
   Isidor B, 2011, NAT GENET, V43, P306, DOI 10.1038/ng.778
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kameda T, 1998, BIOCHEM BIOPH RES CO, V245, P419, DOI 10.1006/bbrc.1998.8448
   Kanazawa I, 2009, EUR J ENDOCRINOL, V160, P265, DOI 10.1530/EJE 08 0642
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Kayal RA, 2007, J BONE MINER RES, V22, P560, DOI 10.1359/JBMR.070115
   Khan AA, 2009, J RHEUMATOL, V36, P478, DOI 10.3899/jrheum.080759
   Khosla S, 2008, ENDOCR REV, V29, P441, DOI 10.1210/er.2008 0002
   Kostenuik PJ, 2001, ENDOCRINOLOGY, V142, P4295, DOI 10.1210/en.142.10.4295
   Lewiecki EM, 2011, DRUGS, V71, P791, DOI 10.2165/11585470 000000000 00000
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lo JC, 2010, J ORAL MAXIL SURG, V68, P243, DOI 10.1016/j.joms.2009.03.050
   Loke YK, 2009, CAN MED ASSOC J, V180, P32, DOI 10.1503/cmaj.080486
   Ma P, 2010, METABOLISM, V59, P359, DOI 10.1016/j.metabol.2009.08.003
   Mancini T, 2009, BONE, V45, P784, DOI 10.1016/j.bone.2009.06.006
   Manolagas SC, 2008, ENDOCRINOLOGY, V149, P3264, DOI 10.1210/en.2008 0402
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Marie PJ, 2010, BONE, V46, P571, DOI 10.1016/j.bone.2009.07.082
   Mazziotti G, 2006, J BONE MINER RES, V21, P520, DOI 10.1359/JBMR.060112
   Mazziotti G, 2008, J CLIN ENDOCR METAB, V93, P4649, DOI 10.1210/jc.2008 0791
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Mazziotti G, 2011, PITUITARY, V14, P299, DOI 10.1007/s11102 011 0293 4
   Mazziotti G, 2011, ENDOCRINE, V40, P102, DOI 10.1007/s12020 011 9486 x
   Mazziotti G, 2011, ENDOCRINE, V39, P288, DOI 10.1007/s12020 011 9462 5
   Mazziotti G, 2010, AM J MED, V123, P877, DOI 10.1016/j.amjmed.2010.02.028
   Nagase S., 2011, J CLIN PHARM
   Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nemeth K, 2011, J IMMUNOL, V186, P13, DOI 10.4049/jimmunol.1002483
   Nuche Berenguer B, 2010, J CELL PHYSIOL, V225, P585, DOI 10.1002/jcp.22243
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Pacifici R, 2010, BONE, V47, P461, DOI 10.1016/j.bone.2010.04.611
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Papapoulos SE, 2011, ANN RHEUM DIS, V70, pI119, DOI 10.1136/ard.2010.141150
   Pazianas M, 2010, J BONE MINER RES, V25, P2, DOI 10.1359/jbmr.091201
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Räkel A, 2008, DIABETES METAB, V34, P193, DOI 10.1016/j.diabet.2007.10.008
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002 9440(10)64417 3
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Roux S, 2002, BRIT J HAEMATOL, V117, P86, DOI 10.1046/j.1365 2141.2002.03417.x
   Rubin MR, 2010, ARQ BRAS ENDOCRINOL, V54, P220, DOI 10.1590/S0004 27302010000200019
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Sezer O, 2003, BLOOD, V101, P2094, DOI 10.1182/blood 2002 09 2684
   Sikjaer T, 2011, J BONE MINER RES, V26, P2358, DOI 10.1002/jbmr.470
   Molinuevo MS, 2010, J BONE MINER RES, V25, P211, DOI 10.1359/jbmr.090732
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Simpson MA, 2011, NAT GENET, V43, P303, DOI 10.1038/ng.779
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tao JN, 2011, CANCER CELL, V19, P159, DOI 10.1016/j.ccr.2011.01.043
   Tawfeek H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012290
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Vestergaard P, 2005, DIABETOLOGIA, V48, P1292, DOI 10.1007/s00125 005 1786 3
   Vestergaard P., 2011, CALCIF TISSUE INTERN
   Viégas M, 2011, J DIABETES COMPLICAT, V25, P216, DOI 10.1016/j.jdiacomp.2011.02.004
   von Keyserlingk C, 2011, SEMIN ARTHRITIS RHEU, V41, P178, DOI 10.1016/j.semarthrit.2011.03.005
   Wang WW, 2010, MOL CELL BIOCHEM, V338, P115, DOI 10.1007/s11010 009 0344 6
   Whyte MP, 2006, NEW ENGL J MED, V354, P860, DOI 10.1056/NEJMe068003
   Winer KK, 2010, J CLIN ENDOCR METAB, V95, P2680, DOI 10.1210/jc.2009 2464
   Zanotti S, 2008, ENDOCRINOLOGY, V149, P3890, DOI 10.1210/en.2008 0140
   Zanotti S, 2011, J BIOL CHEM, V286, P4576, DOI 10.1074/jbc.M110.161893
   Zanotti S, 2010, MOL CELL BIOL, V30, P886, DOI 10.1128/MCB.01285 09
NR 118
TC 133
Z9 138
U1 1
U2 47
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355 008X
EI 1559 0100
J9 ENDOCRINE
JI Endocrine
PD FEB
PY 2012
VL 41
IS 1
BP 58
EP 69
DI 10.1007/s12020 011 9570 2
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 874OU
UT WOS:000298968700007
PM 22180055
DA 2025 08 17
ER

PT J
AU Zhang, W
   Drake, MT
AF Zhang, Wei
   Drake, Matthew T.
TI Potential Role for Therapies Targeting DKK1, LRP5, and Serotonin in the
   Treatment of Osteoporosis
SO CURRENT OSTEOPOROSIS REPORTS
LA English
DT Article
DE Dickhopf1 (DKK1); Serotonin; Low density lipoprotein receptor related
   protein 5 (LRP5); Osteoporosis
AB Osteoporosis is a common disorder in which diminished bone mass leads to progressive microarchitectural skeletal deterioration and increased fracture risk. Our understanding of both normal and pathologic bone biology continues to evolve, and with it our grasp of the highly coordinated relationships between primary bone cells (osteoblasts, osteoclasts, and osteocytes) and the complex molecular signals bone cells use to integrate signals derived from other organ systems, including the immune, hematopoietic, gastrointestinal, and central nervous systems. It is nowclear that the Wnt signaling pathway is central to regulation of both skeletal modeling and remodeling. Herein, we discuss components of the Wnt signaling pathway (DKK1, an endogenous soluble inhibitor of Wnt signaling) and LRP5 (a plasma membrane localized Wnt co receptor) as potential future targets for osteoporosis therapy. Finally, we discuss the current controversial role for serotonin in skeletal metabolism, and the potential role of future therapies targeting serotonin for osteoporosis treatment.
C1 [Zhang, Wei; Drake, Matthew T.] Mayo Clin, Coll Med, Dept Med, Div Endocrinol, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Drake, MT (通讯作者)，Mayo Clin, Coll Med, Dept Med, Div Endocrinol, 200 First St SW, Rochester, MN 55905 USA.
EM drake.matthew@mayo.edu
CR Ai M, 2005, MOL CELL BIOL, V25, P4946, DOI 10.1128/MCB.25.12.4946 4955.2005
   Ai MR, 2005, AM J HUM GENET, V77, P741, DOI 10.1086/497706
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Butler JS, 2011, J ORTHOP RES, V29, P414, DOI 10.1002/jor.21260
   Butler JS, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 210
   Canalis E, 2010, J CLIN ENDOCR METAB, V95, P1496, DOI 10.1210/jc.2009 2677
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Ducy P, 2010, J CELL BIOL, V191, P7, DOI 10.1083/jcb.201006123
   Frost M, 2011, J BONE MINER RES, V26, P1721, DOI 10.1002/jbmr.376
   Frost M, 2010, J BONE MINER RES, V25, P673, DOI 10.1002/jbmr.44
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Gatti D, 2011, J CLIN ENDOCR METAB, V96, P1555, DOI 10.1210/jc.2010 2552
   Giles RH, 2003, BBA REV CANCER, V1653, P1, DOI 10.1016/S0304 419X(03)00005 2
   Glantschnig H, 2011, J PHARMACOL EXP THER, V338, P568, DOI 10.1124/jpet.111.181404
   Glantschnig H, 2010, J BIOL CHEM, V285, P40135, DOI 10.1074/jbc.M110.166892
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Goltzman D, 2011, J BONE MINER RES, V26, P1997, DOI 10.1002/jbmr.462
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Inose H, 2011, J BONE MINER RES, V26, P2002, DOI 10.1002/jbmr.439
   Kaiser M, 2008, EUR J HAEMATOL, V80, P490, DOI 10.1111/j.1600 0609.2008.01065.x
   Karsenty G, 2011, ANNU REV MED, V62, P323, DOI 10.1146/annurev med 090710 133426
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Kubota T, 2008, J BONE MINER RES, V23, P1661, DOI 10.1359/JBMR.080512
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Mödder UI, 2010, J BONE MINER RES, V25, P415, DOI 10.1359/jbmr.090721
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Ng AC, 2011, BLOOD, V118, P6529, DOI 10.1182/blood 2011 04 351437
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reppe S, 2010, BONE, V46, P604, DOI 10.1016/j.bone.2009.11.007
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Yadav VK, 2009, CELL, V138, P976, DOI 10.1016/j.cell.2009.06.051
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
NR 46
TC 29
Z9 37
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
EI 1544 2241
J9 CURR OSTEOPOROS REP
JI Curr. Osteoporos. Rep.
PD MAR
PY 2012
VL 10
IS 1
BP 93
EP 100
DI 10.1007/s11914 011 0086 8
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA V35YR
UT WOS:000209181500014
PM 22210558
DA 2025 08 17
ER

PT J
AU Migliaccio, S
   Fornari, R
   Greco, EA
   Di Luigi, L
   Lenzi, A
AF Migliaccio, Silvia
   Fornari, Rachele
   Greco, Emanuela A.
   Di Luigi, Luigi
   Lenzi, Andrea
TI New therapeutical horizons in the management of postmenopausal
   osteoporosis
SO AGING CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Osteoporosis; Therapies; Denosumab; Teriparatide; Sclerostin; Cathepsin
   K
ID BONE MINERAL DENSITY; PARATHYROID HORMONE; WOMEN; OSTEOPROTEGERIN;
   DIFFERENTIATION; ODANACATIB; FRACTURES; PATHWAYS; LIGAND
AB Osteoporosis is a bone metabolic disease characterized by a compromised skeletal fragility, leading to an increased risk of developing spontaneous and traumatic fractures. This disease is the consequence of an imbalance of the physiological process of bone turnover (or coupling), with the lost of the equilibrium between the activity of osteoblasts and osteoclasts. Therapy has been aimed mainly at the correction of the imbalance between bone resorption and bone formation, to protect skeletal integrity and reduce the risk of fractures. Thus, pharmacological treatments have been aimed at modulating the activity of bone cells.
C1 [Migliaccio, Silvia; Di Luigi, Luigi] Univ Foro Italico, Dept Movement Human & Hlth Sci, Endocrinol Unit, I 00135 Rome, Italy.
   [Fornari, Rachele; Greco, Emanuela A.; Lenzi, Andrea] Univ Roma La Sapienza, Sect Med Pathophysiol Endocrinol & Nutr, Dept Expt Med, I 00185 Rome, Italy.
C3 Foro Italico University of Rome; Sapienza University Rome
RP Migliaccio, S (通讯作者)，Univ Foro Italico, Dept Movement Human & Hlth Sci, Endocrinol Unit, Largo Bosis 14, I 00135 Rome, Italy.
EM migliacciosilvia@hotmail.it
RI Lenzi, Andrea/I 7711 2015
OI Lenzi, Andrea/0000 0002 7711 0465; Migliaccio,
   Silvia/0000 0002 4563 6630; Greco, Emanuela/0000 0003 0603 4079
CR Adami S, 2009, REUMATISMO, V61, P260, DOI 10.4081/reumatismo.2009.260
   Blick SKA, 2008, DRUGS, V68, P2709, DOI 10.2165/0003495 200868180 00012
   Brixen K, 2013, J CLIN ENDOCR METAB, V98, P571, DOI 10.1210/jc.2012 2972
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Cosman F, 2008, CURR OPIN ENDOCRINOL, V15, P495, DOI 10.1097/MED.0b013e32831a46d6
   Diez Perez A, 2002, MATURITAS, V43, pS19
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Gesty Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200
   Gold DT, 2001, RHEUM DIS CLIN N AM, V27, P255, DOI 10.1016/S0889 857X(05)70197 6
   Kostenuik PJ, 2001, CURR PHARM DESIGN, V7, P613, DOI 10.2174/1381612013397807
   Langdahl B, 2012, J BONE MINER RES, V27, P2251, DOI 10.1002/jbmr.1695
   MIGLIACCIO S, 2004, AGING CLIN EXP RES, V3, pS20
   Migliaccio S, 2007, CLIN INTERV AGING, V2, P55, DOI 10.2147/ciia.2007.2.1.55
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Pereira RC, 2002, BONE, V30, P685, DOI 10.1016/S8756 3282(02)00687 7
   Sabatini M, 1996, BONE, V18, P59, DOI 10.1016/8756 3282(95)00427 0
   Seeman E, 2003, OSTEOPOROSIS INT, V14, P3
   Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756 3282(01)00685 8
   Virk MS, 2013, J BONE JOINT SURG AM, V95A, P694, DOI 10.2106/JBJS.L.00285
   Wang BL, 2006, J ENDOCRINOL INVEST, V29, P101, DOI 10.1007/BF03344081
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 22
TC 5
Z9 5
U1 2
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1594 0667
EI 1720 8319
J9 AGING CLIN EXP RES
JI Aging Clin. Exp. Res.
PD OCT
PY 2013
VL 25
SU 1
BP S117
EP S119
DI 10.1007/s40520 013 0106 x
PG 3
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA 257MW
UT WOS:000327389800032
PM 24048905
DA 2025 08 17
ER

PT J
AU Madan, B
   McDonald, MJ
   Foxa, GE
   Diegel, CR
   Williams, BO
   Virshup, DM
AF Madan, Babita
   McDonald, Mitchell J.
   Foxa, Gabrielle E.
   Diegel, Cassandra R.
   Williams, Bart O.
   Virshup, David M.
TI Bone loss from Wnt inhibition mitigated by concurrent alendronate
   therapy
SO BONE RESEARCH
LA English
DT Article
ID MESENCHYMAL STEM CELLS; WNT/BETA CATENIN; TRANSMEMBRANE PROTEIN;
   SECRETION; OSTEOBLASTS; PORCUPINE; DIFFERENTIATION; ADIPOGENESIS;
   MUTATIONS; ACYLATION
AB Dysregulated Wnt signaling is associated with the pathogenesis of cancers, fibrosis, and vascular diseases. Inhibition of Wnt signaling has shown efficacy in various pre clinical models of these disorders. One of the key challenges in developing targeted anti cancer drugs is to balance efficacy with on target toxicity. Given the crucial role Wnts play in the differentiation of osteoblasts and osteoclasts, acute inhibition of Wnt signaling is likely to affect bone homeostasis. In this study, we evaluated the skeletal effect of small molecule inhibitor of an o acyl transferase porcupine (PORCN) that prevents Wnt signaling by blocking the secretion of all Wnts. Micro computed tomography and histomorphometric evaluation revealed that the bones of mice treated with two structurally distinct PORCN inhibitors LGK974 and ETC 1922159 (ETC 159) had loss of bone volume and density within 4 weeks of exposure. This decreased bone mass was associated with a significant increase in adipocytes within the bone marrow. Notably, simultaneous administration of a clinically approved anti resorptive, alendronate, a member of the bisphosphonate family, mitigated loss of bone mass seen upon ETC 159 treatment by regulating activity of osteoclasts and blocking accumulation of bone marrow adipocytes. Our results support the addition of bone protective agents when treating patients with PORCN inhibitors. Mitigation of bone toxicity can extend the therapeutic utility of Wnt pathway inhibitors.
C1 [Madan, Babita; Virshup, David M.] Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore.
   [McDonald, Mitchell J.; Foxa, Gabrielle E.; Diegel, Cassandra R.; Williams, Bart O.] Van Andel Res Inst, Ctr Canc & Cell Biol, Grand Rapids, MI 49503 USA.
   [McDonald, Mitchell J.; Foxa, Gabrielle E.; Diegel, Cassandra R.; Williams, Bart O.] Van Andel Res Inst, Program Skeletal Dis & Tumor Microenvironm, Grand Rapids, MI 49503 USA.
   [Virshup, David M.] Duke Univ, Dept Pediat, Durham, NC 27706 USA.
C3 National University of Singapore; Van Andel Institute; Van Andel
   Research Institute; Van Andel Institute; Van Andel Research Institute;
   Duke University
RP Virshup, DM (通讯作者)，Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore.; Williams, BO (通讯作者)，Van Andel Res Inst, Ctr Canc & Cell Biol, Grand Rapids, MI 49503 USA.; Williams, BO (通讯作者)，Van Andel Res Inst, Program Skeletal Dis & Tumor Microenvironm, Grand Rapids, MI 49503 USA.; Virshup, DM (通讯作者)，Duke Univ, Dept Pediat, Durham, NC 27706 USA.
EM bart.williams@vai.org; david.virshup@duke nus.edu.sg
RI ; Virshup, David/C 1449 2009; Williams, Bart/A 3539 2013
OI Virshup, David M/0000 0001 6976 850X; Williams,
   Bart/0000 0002 5261 5301; Diegel, Cassandra/0000 0002 6526 9372; 
FU NIH [R01AR053293]; Van Andel Research Institute; National Research
   Foundation Singapore
FX We acknowledge the technical assistance of Yunka Wang and other members
   of the Virshup lab, and the expert input of Zhendong Zhong. This work
   was supported by an NIH grant to BOW (R01AR053293) and by the Van Andel
   Research Institute, and supported in part by the National Research
   Foundation Singapore and administered by the Singapore Ministry of
   Health's National Medical Research Council under the STAR Award Program
   to DMV.
CR Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009
   Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200
   Blyszczuk P, 2017, EUR HEART J, V38, P1413, DOI 10.1093/eurheartj/ehw116
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chen YS, 2016, SCI REP UK, V6, DOI 10.1038/srep25283
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Coombs GS, 2010, J CELL SCI, V123, P3357, DOI 10.1242/jcs.072132
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Goodman RM, 2006, DEVELOPMENT, V133, P4901, DOI 10.1242/dev.02674
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879
   Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110
   Kolpakova E, 2005, DEV CELL, V8, P626, DOI 10.1016/j.devcel.2005.04.008
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110
   Madan B, 2016, ONCOGENE, V35, P2197, DOI 10.1038/onc.2015.280
   Madan B, 2016, KIDNEY INT, V89, P1062, DOI 10.1016/j.kint.2016.01.017
   Madan B, 2015, MOL CANCER THER, V14, P1087, DOI 10.1158/1535 7163.MCT 14 1038
   Proffitt KD, 2012, J BIOL CHEM, V287, P34167, DOI 10.1074/jbc.M112.381970
   Proffitt KD, 2013, CANCER RES, V73, P502, DOI 10.1158/0008 5472.CAN 12 2258
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460 2075.1993.tb06225.x
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Williams BO, 2017, BONE, V102, P26, DOI 10.1016/j.bone.2017.03.044
   Yu J, 2014, BIOSCIENCE REP, V34, P593, DOI 10.1042/BSR20140119
   Zhong ZD, 2014, WIRES DEV BIOL, V3, P489, DOI 10.1002/wdev.159
   Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109
NR 33
TC 82
Z9 95
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD MAY 25
PY 2018
VL 6
AR 17
DI 10.1038/s41413 018 0017 8
PG 10
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA GI6LP
UT WOS:000434482300001
PM 29844946
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Woo, JT
   Yonezawa, T
   Cha, BY
   Teruya, T
   Nagai, K
AF Woo, Je Tae
   Yonezawa, Takayuki
   Cha, Byung Yoon
   Teruya, Toshiaki
   Nagai, Kazuo
TI Antiresorptive microbial compounds that inhibit osteoclast
   differentiation, function, and survival
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article; Proceedings Paper
CT 80th Annual Meeting of the Japanese Pharmacological Society
CY MAR 14 16, 2007
CL Nagoya, JAPAN
SP Japanese Pharmacol Soc
DE microbial metabolite; antiresorptive agent; bone resorption; osteoclast;
   osteoporosis; bone metabolism
ID SUPPRESSES BONE RESORPTION; REVEROMYCIN A; IN VITRO;
   PARATHYROID HORMONE; CONCANAMYCIN B; H+ ATPASE; OSTEOPOROSIS;
   BISPHOSPHONATES; ALENDRONATE; ACTIVATION
AB The mass and function of bones depends on the maintenance of a complicated balance between osteoclast mediated bone resorption and osteoblast mediated bone formation. Osteoporosis typically reflects an imbalance in skeletal turnover, such that bone resorption exceeds bone formation. Osteoclasts are target cells for anti osteoporosis therapies. To discover new types of antiresorptive agents, we screened for natural compounds that regulate osteoclast differentiation, function, and survival. As a result, we identified reveromycin A, destruxins, mevastatin, FK506, cyclosporin A, prodigiosins, concanamycins, and symbiomine among microbial natural compounds. In this review, we discuss the mechanisms of action of these compounds on osteoclasts.
C1 [Woo, Je Tae; Yonezawa, Takayuki; Cha, Byung Yoon; Teruya, Toshiaki; Nagai, Kazuo] Chubu Univ, Dept Biol Chem, Kasugai, Aichi 4878501, Japan.
C3 Chubu University
RP Woo, JT (通讯作者)，Chubu Univ, Dept Biol Chem, Matsumoto 1200, Kasugai, Aichi 4878501, Japan.
EM jwoo@ise.chubu.ac.jp
RI ; YONEZAWA, Takayuki/O 3047 2019
OI YONEZAWA, Takayuki/0000 0001 8060 0839; 
CR Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chambers TJ, 2000, J PATHOL, V192, P4
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Huang CLH, 2006, CELL MOL BIOL, V52, P33
   Igarashi K, 2004, BONE, V35, P47, DOI 10.1016/j.bone.2004.02.009
   Jadhav SB, 2006, J PHARM PHARMACOL, V58, P3, DOI 10.1211/jpp.58.1.0002
   KATAOKA T, 1995, FEBS LETT, V359, P53, DOI 10.1016/0014 5793(94)01446 8
   Kita M, 2004, J AM CHEM SOC, V126, P4794, DOI 10.1021/ja049277f
   Milner RJ, 2004, J VET INTERN MED, V18, P597, DOI 10.1892/0891 6640(2004)18<597:BAC>2.0.CO;2
   Miyamoto Y, 2002, J BIOL CHEM, V277, P28810, DOI 10.1074/jbc.M203827200
   Muguruma H, 2005, CLIN CANCER RES, V11, P8822, DOI 10.1158/1078 0432.CCR 05 1335
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nakagawa H, 2003, BONE, V33, P443, DOI 10.1016/S8756 3282(03)00201 1
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Reszka Alfred A, 2003, Curr Rheumatol Rep, V5, P65, DOI 10.1007/s11926 003 0085 6
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Suzuki H, 1996, ENDOCRINOLOGY, V137, P4685, DOI 10.1210/en.137.11.4685
   Takahashi H, 1997, ONCOL RES, V9, P7
   Takahashi N, 2007, ODONTOLOGY, V95, P1, DOI 10.1007/s10266 007 0071 y
   TAKAHASHI S, 1995, J CLIN INVEST, V95, P167, DOI 10.1172/JCI117634
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   WOO JT, 1995, BIOSCI BIOTECH BIOCH, V59, P350, DOI 10.1271/bbb.59.350
   Woo JT, 2006, P NATL ACAD SCI USA, V103, P4729, DOI 10.1073/pnas.0505663103
   Woo JT, 2005, BIOCHEM PHARMACOL, V69, P87, DOI 10.1016/j.bcp.2004.08.036
   Woo JT, 2000, J BONE MINER RES, V15, P650, DOI 10.1359/jbmr.2000.15.4.650
   WOO JT, 1992, EUR J BIOCHEM, V207, P383, DOI 10.1111/j.1432 1033.1992.tb17061.x
   Woo JT, 1996, BIOL PHARM BULL, V19, P297
NR 34
TC 23
Z9 30
U1 0
U2 6
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD APR
PY 2008
VL 106
IS 4
BP 547
EP 554
DI 10.1254/jphs.FM0070288
PG 8
WC Pharmacology & Pharmacy
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 293AX
UT WOS:000255308300005
PM 18431038
OA Bronze
DA 2025 08 17
ER

PT J
AU Brommage, R
AF Brommage, Robert
TI Genetic Approaches To Identifying Novel Osteoporosis Drug Targets
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE OSTEOPOROSIS; DRUG DEVELOPMENT; SKELETOME; GENOMICS
ID BONE MINERAL DENSITY; PARATHYROID HORMONE; SKELETAL PHENOTYPES;
   POSTMENOPAUSAL WOMEN; EXPRESSION CHANGES; MUTATIONS; RECEPTOR; DISEASE;
   MICE; MOUSE
AB During the past two decades effective drugs for treating osteoporosis have been developed, including anti resorptives inhibiting bone resorption (estrogens, the SERM raloxifene, four bisphosphonates, RANKL inhibitor denosumab) and the anabolic bone forming daily injectable peptide teriparatide. Two potential drugs (odanacatib and romosozumab) are in late stage clinical development. The most pressing unmet need is for orally active anabolic drugs. This review describes the basic biological studies involved in developing these drugs, including the animal models employed for osteoporosis drug development. The genomics revolution continues to identify potential novel osteoporosis drug targets. Studies include human GWAS studies and identification of mutant genes in subjects having abnormal bone mass, mouse QTL and gene knockouts, and gene expression studies. Multiple lines of evidence indicate that Wnt signaling plays a major role in regulating bone formation and continued study of this complex pathway is likely to lead to key discoveries. In addition to the classic Wnt signaling targets DKK1 and sclerostin, LRP4, LRP5/LRP6, SFRP4, WNT16, and NOTUM can potentially be targeted to modulate Wnt signaling. Next generation whole genome and exome sequencing, RNA sequencing and CRISPR/CAS9 gene editing are new experimental techniques contributing to understanding the genome. The International Knockout Mouse Consortium efforts to knockout and phenotype all mouse genes are poised to accelerate. Accumulating knowledge will focus attention on readily accessible databases (Big Data). Efforts are underway by the International Bone and Mineral Society to develop an annotated Skeletome database providing information on all genes directly influencing bone mass, architecture, mineralization or strength. J. Cell. Biochem. 116: 2139 2145, 2015. (c) 2015 Wiley Periodicals, Inc.
C1 [Brommage, Robert] Lexicon Pharmaceut, The Woodlands, TX USA.
C3 Lexicon Pharmaceuticals
RP Brommage, R (通讯作者)，Helmholtz Ctr Munich, German Mouse Clin, Inst Expt Genet, D 85764 Neuherberg, Germany.
EM robert.brommage@helmholtz muenchen.de
RI Brommage, Robert/J 5670 2019
CR Aggarwal S, 2013, GENE, V528, P41, DOI 10.1016/j.gene.2013.04.069
   Augustine M, 2013, CURR OSTEOPOROS REP, V11, P400, DOI 10.1007/s11914 013 0171 2
   Ayturk UM, 2013, J BONE MINER RES, V28, P2081, DOI 10.1002/jbmr.1946
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brommage R., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P307
   Brommage R, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.34
   Brunham LR, 2013, HUM GENET, V132, P603, DOI 10.1007/s00439 013 1286 3
   Chang MK, 2014, P NATL ACAD SCI USA, V111, pE5187, DOI 10.1073/pnas.1413828111
   Chang MK, 2014, J BONE MINER RES, V29, P29, DOI 10.1002/jbmr.2059
   Davisson Muriel T, 2012, Curr Protoc Mouse Biol, V2, P103
   Farber CR, 2013, BONE RES, V1, P301, DOI 10.4248/BR201304001
   Ferrari S, 2014, BEST PRACT RES CL EN, V28, P859, DOI 10.1016/j.beem.2014.08.002
   Finan B, 2015, NAT MED, V21, P27, DOI 10.1038/nm.3761
   Gregson CL, 2012, OSTEOPOROSIS INT, V23, P643, DOI 10.1007/s00198 011 1603 4
   Hsu YH, 2012, J CLIN ENDOCR METAB, V97, pE1958, DOI 10.1210/jc.2012 1890
   Jerome CP, 2001, BONE, V29, P1, DOI 10.1016/S8756 3282(01)00477 X
   Jerome CP, 2001, BONE, V28, P150, DOI 10.1016/S8756 3282(00)00430 0
   Joeng KS, 2014, HUM MOL GENET, V23, P4035, DOI 10.1093/hmg/ddu117
   Kakugawa S, 2015, NATURE, V519, P187, DOI 10.1038/nature14259
   Kang KS, 2015, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00246
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370
   Maupin KA, 2013, BONE RES, V1, DOI 10.4248/BR201301004
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Miller MA, 2008, BONE, V42, P1175, DOI 10.1016/j.bone.2008.01.029
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Niziolek PJ, 2012, BONE, V51, P459, DOI 10.1016/j.bone.2012.05.023
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Ominsky MS, 2014, J BONE MINER RES, V29, P1424, DOI 10.1002/jbmr.2152
   Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199
   Pennypacker BL, 2011, J BONE MINER RES, V26, P252, DOI 10.1002/jbmr.223
   Powell WF, 2011, J ENDOCRINOL, V209, P21, DOI 10.1530/JOE 10 0308
   Rhee Y, 2011, J BONE MINER RES, V26, P1035, DOI 10.1002/jbmr.304
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Sakharkar Meena K, 2007, Curr Drug Discov Technol, V4, P48
   Smith SY, 2009, AM J PRIMATOL, V71, P752, DOI 10.1002/ajp.20715
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Spector R, 2006, PHARMACOLOGY, V77, P85, DOI 10.1159/000093166
   St John HC, 2015, BONE, V72, P81, DOI 10.1016/j.bone.2014.11.010
   Sule G, 2013, OSTEOPOROSIS INT, V24, P2253, DOI 10.1007/s00198 013 2290 0
   Swinney DC, 2009, CURR OPIN DRUG DISC, V12, P31
   Swinney DC, 2004, NAT REV DRUG DISCOV, V3, P801, DOI 10.1038/nrd1500
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Urano T, 2014, BIOCHEM BIOPH RES CO, V452, P287, DOI 10.1016/j.bbrc.2014.07.141
   Van Wesenbeeck L, 2005, CRIT REV EUKAR GENE, V15, P133, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.40
   Warman ML, 2011, AM J MED GENET A, V155A, P943, DOI 10.1002/ajmg.a.33909
   Wergedal JE, 2015, ENDOCRINOLOGY, V156, P1023, DOI 10.1210/en.2014 1702
   Whyte MP, 2012, NEW ENGL J MED, V366, P904, DOI 10.1056/NEJMoa1106173
   Wöhrle S, 2013, J BONE MINER RES, V28, P899, DOI 10.1002/jbmr.1810
   Yoon BH, 2014, J BONE MINER RES, V29, P1950, DOI 10.1002/jbmr.2238
   Zhang XJ, 2015, DEV CELL, V32, P719, DOI 10.1016/j.devcel.2015.02.014
   Zhao LM, 2013, BONE, V54, P35, DOI 10.1016/j.bone.2013.01.033
   Zhou FL, 2013, BLOOD REV, V27, P261, DOI 10.1016/j.blre.2013.08.002
NR 55
TC 27
Z9 32
U1 0
U2 59
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT
PY 2015
VL 116
IS 10
BP 2139
EP 2145
DI 10.1002/jcb.25179
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CP3UZ
UT WOS:000359809400003
PM 25833316
DA 2025 08 17
ER

PT J
AU Prommer, E
AF Prommer, Eric
TI Palliative Oncology: Denosumab
SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE
LA English
DT Article
DE pain; denosumab; bisphosphonates; RANK; osteoprotegerin; prostate cancer
ID METASTATIC BONE DISEASE; PHASE II TRIAL; PROSTATE CANCER; ZOLEDRONIC
   ACID; BREAST CANCER; INTRAVENOUS BISPHOSPHONATES; MECHANISMS; THERAPY
AB Bone metastases cause devastating clinical complications leading patients to have pain, poor quality of life, loss of mobility, and autonomy. Complications from osseous metastases cause a big economic burden reflected by repeated admissions for uncontrolled symptoms. Management of symptoms associated with bone metastasis includes systemic analgesics, glucocorticoids, radiation (external beam radiation and radiopharmaceuticals), ablative techniques (radiofrequency ablation and cryoablation), chemotherapeutic agents, hormonal therapies, interventional techniques (eg, kyphoplasty), and surgical approaches. Bisphosphonates have become a standard therapy for bony metastasis. They bind to bone eventually inhibiting osteoclast action. Bisphosphonates decrease fractures when given routinely. Adverse effects of bisphosphonates include osteonecrosis of the jaw and renal insufficiency. Late last year, the Food and Drug Administration approved denosumab to prevent skeletal related events (SREs) associated with metastatic solid tumors. This drug is a monoclonal antibody that inhibits the receptor activator of nuclear factor B (RANK) RANK ligand interaction. Clinical trials have shown superiority over bisphosphonates for the prevention of SREs. This article reviews the mechanism of action, pharmacology, adverse effects, and clinical trial evidence for this new drug.
C1 Mayo Clin, Coll Med, Mayo Clin Hosp, Div Hematol Oncol, Scottsdale, AZ 85054 USA.
C3 Mayo Clinic; Mayo Clinic Phoenix
RP Prommer, E (通讯作者)，Mayo Clin, Coll Med, Mayo Clin Hosp, Div Hematol Oncol, Mayo Clin Specialty Bldg,5777 E Mayo Blvd, Scottsdale, AZ 85054 USA.
EM prommer.eric@mayo.edu
CR Anandarajah AP, 2006, J CELL BIOCHEM, V97, P226, DOI 10.1002/jcb.20674
   [Anonymous], 2013, XGEV
   Antonarakis ES, 2011, NEW ENGL J MED, V364, P2055, DOI 10.1056/NEJMe1102758
   Arthur KK, 2012, BIOCHEMISTRY US, V51, P795, DOI 10.1021/bi2007806
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   CADA DJ, 2010, HOSP PHARM, V45, P785, DOI DOI 10.1310/hpj4510 785
   Denosumab Gehret C., 2010, PHARMACOTHERAPY UPDA, V8
   Diel IJ, 2004, EUR J CANCER, V40, P1704, DOI 10.1016/j.ejca.2004.03.025
   Fizazi K, 2013, J UROLOGY, V189, pS51, DOI 10.1016/j.juro.2012.11.022
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Freeman A, 2013, CLIN GENITOURIN CANC, V11, pE24, DOI 10.1016/j.clgc.2013.06.002
   Freemantle N, 2012, OSTEOPOROSIS INT, V23, P317, DOI 10.1007/s00198 011 1780 1
   Heino T, 2010, BONE GROWTH PLATE MI
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lewiecki EM, 2008, BIOL TARGETS THER, V2, P645
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Lobo ED, 2004, J PHARM SCI US, V93, P2645, DOI 10.1002/jps.20178
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Prommer EE, 2009, J PALLIAT MED, V12, P1061, DOI 10.1089/jpm.2009.9936
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Smith HS, 2011, PAIN PHYSICIAN, V14, pE373
   Smith MR, 2009, J UROLOGY, V182, P2670, DOI 10.1016/j.juro.2009.08.048
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tabrizi MA, 2006, DRUG DISCOV TODAY, V11, P81, DOI 10.1016/S1359 6446(05)03638 X
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Vadhan Raj S, 2012, ANN ONCOL, V23, P3045, DOI 10.1093/annonc/mds175
   Xie JP, 2011, J MANAGE CARE PHARM, V17, P621, DOI 10.18553/jmcp.2011.17.8.621
NR 29
TC 7
Z9 9
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049 9091
EI 1938 2715
J9 AM J HOSP PALLIAT ME
JI Am. J. Hosp. Palliat. Med.
PD AUG
PY 2015
VL 32
IS 5
BP 568
EP 572
DI 10.1177/1049909114539035
PG 5
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services
GA CM5QZ
UT WOS:000357745000014
PM 24928835
DA 2025 08 17
ER

PT J
AU Sharma, AR
   Nam, JS
AF Sharma, Ashish Ranjan
   Nam, Ju Suk
TI Kaempferol stimulates WNT/β catenin signaling pathway to induce
   differentiation of osteoblasts
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article
ID IN VITRO; BONE LOSS; RAT MODEL; MECHANISMS; QUERCETIN; PHYTOESTROGENS;
   OSTEOPOROSIS; FLAVONOIDS; MINERALIZATION; COMPONENTS
AB Flavonoids, a group of natural compounds found in a variety of vegetables and herbal medicines, have been intensively reported on stimulating bone mineral density and bone formation. Among them, kaempferol has been reported to assist bone formation in vitro and in vivo, but its precise mechanism of action for stimulating bone forming abilities of osteoblasts remained elusive. In SaOS 2 osteoblasts, treatment of kaempferol increased early and late osteogenic parameters significantly, including alkaline phosphatase (ALP) activity, collagen synthesis, and mRNA expression levels of Runx2, osterix, osteopontin and bone sialoprotein. Interestingly, kaempferol promoted osteoblastic differentiation via the activation of the WNT signaling pathway. The stimulation of SaOS 2 cells by kaempferol resulted in an increased activity of WNT signaling responsive reporter construct, Axin 2, and, subsequently, stabilization of WNT signaling mediated transcription factor beta catenin, probably leading to the activation of WNT targeted genes for osteogenesis. In corroboration, the kaempferol induced ALP activity was fully abolished by FH 535, an inhibitor of WNT signaling pathway. Kaempferol mediated activation of WNT signaling pathway through estrogen signaling pathway, as the application of ICI 182,780 (an inhibitor for estrogen receptors) markedly inhibited kaempferol induced WNT signaling activation and osteogenic marker like ALP activity in SaOS 2 cells. Immunohistochemical studies in drill hole defect model showed increased expression of Runx2 and beta catenin staining after kaempferol treatment. Thus, it may be concluded that kaempferol stimulates estrogen signaling followed by WNT signaling pathway activation to achieve its potential for bone sparing effects. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Sharma, Ashish Ranjan; Nam, Ju Suk] Hallym Univ, Chuncheon Sacred Heart Hosp, Inst Skeletal Aging & Orthoped Surg, Chuncheon Si 24252, Gangwon Do, South Korea.
C3 Hallym University
RP Nam, JS (通讯作者)，Hallym Univ Hosp, Coll Med, Inst Skeletal Aging & Orthoped Surg, Chuncheon Si 200704, Gangwon Do, South Korea.
EM jsnam88@hallym.ac.kr
RI Sharma, Ashish/W 4816 2019
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [NRF 2016R1D1A1 B03931318]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (NRF 2016R1D1A1 B03931318).
CR Alekel DL, 2000, AM J CLIN NUTR, V72, P844
   Arjmandi BH, 1996, J NUTR, V126, P161, DOI 10.1093/jn/126.1.161
   Bae SJ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 08190 9
   Blum JS, 2001, J CELL BIOCHEM, V80, P532, DOI 10.1002/1097 4644(20010315)80:4<532::AID JCB1007>3.0.CO;2 B
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Campbell TM, 2003, CALCIFIED TISSUE INT, V73, P49, DOI 10.1007/s00223 002 2120 4
   Capdevila J, 2001, ANNU REV CELL DEV BI, V17, P87, DOI 10.1146/annurev.cellbio.17.1.87
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Dang ZC, 2005, TRENDS ENDOCRIN MET, V16, P207, DOI 10.1016/j.tem.2005.05.001
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Glantschnig H, 2011, J PHARMACOL EXP THER, V338, P568, DOI 10.1124/jpet.111.181404
   Goldring SR, 2007, NAT MED, V13, P133, DOI 10.1038/nm0207 133
   Guo AJY, 2011, J BIOL CHEM, V286, P27882, DOI 10.1074/jbc.M111.236281
   Guo C, 2017, CELL PHYSIOL BIOCHEM, V43, P1547, DOI 10.1159/000481978
   He YX, 2011, BONE, V48, P1388, DOI 10.1016/j.bone.2011.03.720
   Hilal G, 1998, ARTHRITIS RHEUM, V41, P891, DOI 10.1002/1529 0131(199805)41:5<891::AID ART17>3.0.CO;2 X
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kugimiya F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000837
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Lim V, 2012, MATURITAS, V73, P269, DOI 10.1016/j.maturitas.2012.08.002
   Luyten FP, 2009, BONE, V44, P522, DOI 10.1016/j.bone.2008.12.006
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Milat F, 2009, MOL CELL ENDOCRINOL, V310, P52, DOI 10.1016/j.mce.2009.06.002
   Miyake M, 2003, BIOSCI BIOTECH BIOCH, V67, P1199, DOI 10.1271/bbb.67.1199
   Mödder UI, 2012, J CELL BIOCHEM, V113, P2248, DOI 10.1002/jcb.24095
   Mundy GR, 2006, AM J CLIN NUTR, V83, p427S
   Nash LA, 2015, MOL NUTR FOOD RES, V59, P443, DOI 10.1002/mnfr.201400592
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Pang JL, 2006, BIOCHEM PHARMACOL, V71, P818, DOI 10.1016/j.bcp.2005.12.023
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Reinhold MI, 2007, J BIOL CHEM, V282, P3653, DOI 10.1074/jbc.M608995200
   RiceEvans CA, 1996, BIOCHEM SOC T, V24, P790, DOI 10.1042/bst0240790
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Setchell KDR, 2003, AM J CLIN NUTR, V78, p593S, DOI 10.1093/ajcn/78.3.593S
   Sharan K, 2009, CURR MED CHEM, V16, P1138, DOI 10.2174/092986709787581806
   Solakidi S., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P240
   Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097
   Tang XL, 2008, ENDOCRINE, V34, P29, DOI 10.1007/s12020 008 9099 1
   Trivedi R, 2008, MOL CELL ENDOCRINOL, V289, P85, DOI 10.1016/j.mce.2008.02.027
   Uusitalo H, 2001, BONE, V28, P423, DOI 10.1016/S8756 3282(01)00406 9
   Wattel A, 2003, BIOCHEM PHARMACOL, V65, P35, DOI 10.1016/S0006 2952(02)01445 4
NR 44
TC 73
Z9 82
U1 1
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0955 2863
EI 1873 4847
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD DEC
PY 2019
VL 74
AR 108228
DI 10.1016/j.jnutbio.2019.108228
PG 9
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA JY4GN
UT WOS:000504375400006
PM 31678747
DA 2025 08 17
ER

PT J
AU Ferrari, S
AF Ferrari, Serge
TI Osteocytic targets in the treatment of osteoporosis
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Osteocytes; Bisphosphonates; Denosumab; Strontium; PTH; Cathepsin K
ID INCREASES BONE FORMATION; IN VIVO; SCLEROSTIN ANTIBODY; OSTEOBLASTS;
   MICE; MASS; BISPHOSPHONATES; OSTEOCLASTS; RISEDRONATE; STRENGTH
AB Osteoporosis drugs, which reduce the incidence of fragility fractures, are broadly categorized as those targeting osteoclasts, i.e. antiresorptives, and those targeting osteoblasts, i.e. anabolics. Although not primarily designed to target osteocytes, increasing evidence indicates that osteoporosis drugs may affect osteocytes life and/or functions as part of their therapeutic effects. In addition, ongoing therapeutic developments in osteoporosis, such as sclerostin neutralizing antibodies, purposely target osteocytic molecules. Here, we briefly review the implication of osteocytes in the mechanisms of action of osteoporosis drugs.
C1 [Ferrari, Serge] Univ Hosp Geneva, Div Bone Dis, Dept Internal Med Specialties, CH 1211 Geneva 14, Switzerland.
   [Ferrari, Serge] Fac Med, CH 1211 Geneva 14, Switzerland.
C3 University of Geneva; University of Geneva
RP Ferrari, S (通讯作者)，Univ Hosp Geneva, Div Bone Dis, Dept Internal Med Specialties, CH 1211 Geneva 14, Switzerland.
EM serge.ferrari@unige.ch
RI Ferrari, Serge/ABD 2730 2020
CR Atkins GJ, 2009, OSTEOPOROSIS INT, V20, P653, DOI 10.1007/s00198 008 0728 6
   Atkins G J., 2012, Osteoporos Int
   Bakker AD, 2013, BONE, V53, P112, DOI 10.1016/j.bone.2012.11.044
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bonnet N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058726
   Bonnet N, 2012, P NATL ACAD SCI USA, V109, P15048, DOI 10.1073/pnas.1203085109
   Cusick T, 2012, J BONE MINER RES, V27, P524, DOI 10.1002/jbmr.1477
   Duong LT, THERAPEUTIC INHIBITI, P1
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Kramer I, 2010, J BONE MINER RES, V25, P178, DOI 10.1359/jbmr.090730
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Pierroz DD, 2010, J BIOL CHEM, V285, P28164, DOI 10.1074/jbc.M110.101964
   Plotkin LI, 2008, J BONE MINER RES, V23, P1712, DOI [10.1359/jbmr.080617, 10.1359/JBMR.080617]
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Qing H, 2012, J BONE MINER RES, V27, P1018, DOI 10.1002/jbmr.1567
   Roelofs AJ, 2012, J BONE MINER RES, V27, P835, DOI 10.1002/jbmr.1543
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Rybchyn MS, 2011, J BIOL CHEM, V286, P23771, DOI 10.1074/jbc.M111.251116
   Sugiyama T, 2008, BONE, V43, P238, DOI 10.1016/j.bone.2008.04.012
   Sugiyama T, 2011, BONE, V49, P133, DOI 10.1016/j.bone.2011.03.775
NR 25
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JUN
PY 2014
VL 25
SU 3
BP S487
EP +
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CA1BD
UT WOS:000348646800009
DA 2025 08 17
ER

PT J
AU Qian, YN
   Chong, SM
   Chen, Q
   Yin, CL
   Cao, YJ
AF Qian, Yanan
   Chong, Siomui
   Chen, Qian
   Yin, Chengliang
   Cao, Yujing
TI Research Progress on Inhibition of Osteoclast Differentiation by
   Traditional Chinese Medicine
SO PHARMACOGNOSY MAGAZINE
LA English
DT Article
DE Traditional Chinese medicine; osteoclasts; osteoblasts; research
   progress; molecular mechanism
ID NF KAPPA B; BONE RESORBING ACTIVITY; SIGNALING PATHWAY;
   RHEUMATOID ARTHRITIS; IN VITRO; CELLS; RESORPTION; LIGAND; SUPPRESSION;
   ACTIVATION
AB Background: Bone tissue undergoes continuous remodeling to maintain a steady state of bone equilibrium. During this process, osteoblasts actively stimulate bone formation, while osteoclasts continuously engage in bone resorption. The dynamic equilibrium between bone formation and bone resorption is crucial for maintaining bone structure. In a healthy human skeletal structure, the two components are constantly in a state of benign dynamic equilibrium. However, due to factors such as aging, trauma, bone diseases, and other influences, the activity of osteoblasts decreases while the activity of osteoclasts increases. This disrupts the dynamic equilibrium, leading to a decrease in bone metabolism. As a result, bone resorption gradually surpasses bone production, making it challenging to maintain a normal amount of bone mass. The effectiveness of traditional Chinese medicine in treating bone related disorders is extraordinary, and its molecular biological mechanism has become a widely discussed subject.Objectives: This study aims to unravel the classical signaling pathways and potential targets involved in the effects of traditional Chinese medicine on osteoclast differentiation, and to provide evidence for its clinical efficacy.Methodology: The main keywords chosen for this study were "Traditional Chinese Medicine (TCM)", "osteoclast differentiation", "natural plant", and "medicinal plant". To gather relevant literature, we utilized multiple online search engines, including PubMed, Web of Science, and CNKI, as well as other publication resources.Results: The results indicated that Traditional Chinese Medicine (TCM) can modulate signaling pathways, including NF kappa B, MAPKs, STATs, and Wnt/beta catenin pathways., to influence osteoclast differentiation. This modulation involves maintaining the balance of inflammatory interactions, inhibiting oxidative stress.Conclusion: The impact of traditional Chinese medicine on osteoclast differentiation is reflected on multiple levels and through various pathways. Future research is envisioned to delve deeper from the perspective of precision targeted therapy, aiming to provide insights for identifying the core targets of traditional Chinese medicine in treating orthopedic diseases.
C1 [Qian, Yanan; Cao, Yujing] Henan Univ Chinese Med, Orthoped Trauma Fac, Dept Orthoped & Traumatol, Zhengzhou 450046, Henan, Peoples R China.
   [Chong, Siomui] Jinan Univ, Dept Dermatol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
   [Chong, Siomui] Jinan Univ, Inst Dermatol, Guangzhou, Guangdong, Peoples R China.
   [Chong, Siomui] Univ Macau, Inst Collaborat Innovat, Taipa, Macao, Peoples R China.
   [Chong, Siomui] Ctr Med Kong Wan Macau, Taipa, Macao, Peoples R China.
   [Chen, Qian] Henan Univ Tradit Chinese Med, Henan Prov Hosp Tradit Chinese Med, Affiliated Hosp 2, Dept Crit Care Med, Kaifeng, Henan, Peoples R China.
   [Yin, Chengliang] Macau Univ Sci & Technol, Fac Med, Taipa, Macao, Peoples R China.
C3 Henan University of Traditional Chinese Medicine; Jinan University;
   Jinan University; University of Macau; Henan University of Traditional
   Chinese Medicine; Macau University of Science & Technology
RP Cao, YJ (通讯作者)，Henan Univ Chinese Med, Orthoped Trauma Fac, Dept Orthoped & Traumatol, Zhengzhou 450046, Henan, Peoples R China.
EM bravecao@163.com
RI yin, chengliang/ADP 5778 2022
CR Bogado CE, 2011, CLIN MED INSIGHTS TH, V3, P395, DOI 10.4137/CMT.S6173
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Cao JQ, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024 018 0299 8
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Chen X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00647
   Cheng L, 2018, AM J TRANSL RES, V10, P1457
   Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939
   Du EX, 2017, J CELL BIOCHEM, V118, P914, DOI 10.1002/jcb.25772
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   FLEISCH H, 1993, OSTEOPOROSIS INT, V3, pS108, DOI 10.1007/BF01621880
   Fu LJ, 2017, IMMUNOBIOLOGY, V222, P597, DOI 10.1016/j.imbio.2016.11.009
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Gal M, 2022, PHYTOMEDICINE, V105, DOI 10.1016/j.phymed.2022.154378
   Hairul Islam MI, 2017, INT IMMUNOPHARMACOL, V53, P114, DOI 10.1016/j.intimp.2017.10.022
   Han JW, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.772944
   Hong YH, 2021, J ETHNOPHARMACOL, V268, DOI 10.1016/j.jep.2020.113602
   Huang L., 2019, RES ZHUANG MED LONGZ, DOI [10.27879/d.cnki.ggxzy.2019.000178, DOI 10.27879/D.CNKI.GGXZY.2019.000178]
   Jiang JH, 2008, INT J MOL MED, V21, P577
   Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320
   Jin XL, 2023, CALCIFIED TISSUE INT, V112, P704, DOI 10.1007/s00223 023 01080 5
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim YW, 2014, INT J MOL SCI, V15, P18840, DOI 10.3390/ijms151018840
   Kimira Y, 2015, PHYTOMEDICINE, V22, P1120, DOI 10.1016/j.phymed.2015.08.013
   Kushlinsky N. E., 2014, Voprosy Onkologii (St. Petersburg), V60, P413
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee HI, 2020, BMB REP, V53, P218, DOI 10.5483/BMBRep.2020.53.4.220
   Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552
   Lei L., 2010, CHINESE J OSTEOPOROS
   [李新 Li Xin], 2014, [吉林大学学报. 医学版, Journal of Jilin Univeristy. Medicine edition], V40, P1114
   Li Yan, 2014, Open Bone J, V6, P8
   Li ZN, 2019, BIOCHEM PHARMACOL, V163, P279, DOI 10.1016/j.bcp.2019.02.002
   Liang Z. H., 2020, THERAPEUTIC EFFECT M, DOI [10.27044/d.cnki.ggzzu.2020.000004, DOI 10.27044/D.CNKI.GGZZU.2020.000004]
   Liu MQ, 2021, J ETHNOPHARMACOL, V275, DOI 10.1016/j.jep.2021.114129
   Liu WF, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00228
   LORENZO JA, 1987, ENDOCRINOLOGY, V121, P1164, DOI 10.1210/endo 121 3 1164
   Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408
   MANN GN, 1994, ENDOCRINOLOGY, V135, P1077, DOI 10.1210/en.135.3.1077
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007
   Meng JH, 2020, BIOCHEM PHARMACOL, V171, DOI 10.1016/j.bcp.2019.113715
   Meng JJ, 2021, BIOORG CHEM, V112, DOI 10.1016/j.bioorg.2021.104976
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Pan ZR, 2021, PHARMACOL RES, V170, DOI 10.1016/j.phrs.2021.105742
   Park B, 2014, BIOCHIMIE, V105, P129, DOI 10.1016/j.biochi.2014.07.003
   Ramli ESM, 2013, J BONE MINER METAB, V31, P262, DOI 10.1007/s00774 012 0413 x
   SABATINI M, 1988, P NATL ACAD SCI USA, V85, P5235, DOI 10.1073/pnas.85.14.5235
   Schwendich E, 2022, CELLS BASEL, V11, DOI 10.3390/cells11101609
   SH Chen., 2019, CHINESE J OSTEOPOROS
   Sims NA, 2021, CYTOKINE, V146, DOI 10.1016/j.cyto.2021.155655
   Song X. C., 2020, INHIBITION COMPOUND, DOI [10.27764/d.cnki.ghbmz.2020.000122, DOI 10.27764/D.CNKI.GHBMZ.2020.000122]
   Sun YQ, 2019, J CELL PHYSIOL, V234, P11792, DOI 10.1002/jcp.27868
   TAKAHASHI N, 1986, J IMMUNOL, V137, P3544
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1857
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thummuri D, 2017, J MOL MED, V95, P1065, DOI 10.1007/s00109 017 1553 1
   Toraldo G, 2003, P NATL ACAD SCI USA, V100, P125, DOI 10.1073/pnas.0136772100
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wang J. Y., 2014, J FUJIAN U CHINESE M, V3, P11, DOI [10.13261/j.cnki.jfutcm.002930, DOI 10.13261/J.CNKI.JFUTCM.002930]
   Wang L. N., 2017, CHINA J MODERN MED
   Wang QR, 2019, INT IMMUNOPHARMACOL, V72, P292, DOI 10.1016/j.intimp.2019.04.027
   Wang T, 2015, INT J MOL SCI, V16, P27470, DOI 10.3390/ijms161126039
   Weitzmann MN, 2000, BLOOD, V96, P1873, DOI 10.1182/blood.V96.5.1873.h8001873_1873_1878
   Xiang K, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102866
   Xiao Ya Ping, 2018, Zhongguo Zhong Yao Za Zhi, V43, P21, DOI 10.19540/j.cnki.cjcmm.20171106.002
   Xu HY, 2018, IMMUNOLOGY, V154, P593, DOI 10.1111/imm.12907
   Yang ML, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2020.106202
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhang Chong Zhang Chong, 2016, Chinese Veterinary Science / Zhongguo Shouyi Kexue, V46, P532
   Zhang GY, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906 019 2691 5
   Zhang J. W., 2019, BASED KIDNEY MARROW, DOI [10.27282/d.cnki.gsdzu.2019.000130, DOI 10.27282/D.CNKI.GSDZU.2019.000130]
   Zhang M. G., 2020, CHINESE J EXPT FORMU, V12, P49, DOI [10.13422/j.cnki.syfjx.20201224, DOI 10.13422/J.CNKI.SYFJX.20201224]
   Zhang WY, 2020, J AGR FOOD CHEM, V68, P6604, DOI 10.1021/acs.jafc.0c01892
   Zhao FC, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm 21 2945
   Zhao X. Q., 2019, CLIN OBSERVATION TRE
   Zhu LX, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw6143
NR 79
TC 0
Z9 0
U1 1
U2 12
PU SAGE PUBLICATIONS INDIA  PVT LTD
PI NEW DELHI
PA B 1 I 1 MOHAN CO OPERATIVE INDUSTRIAL AREA, MATHURA RD, POST BAG NO 7,
   NEW DELHI 110 044, INDIA
SN 0973 1296
EI 0976 4062
J9 PHARMACOGN MAG
JI Pharmacogn. Mag.
PD DEC
PY 2024
VL 20
IS 4
BP 1179
EP 1190
DI 10.1177/09731296241228904
EA MAY 2024
PG 12
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA K6K1V
UT WOS:001217487600001
OA hybrid
DA 2025 08 17
ER

PT J
AU Gau, YC
   Yeh, TJ
   Hsu, CM
   Hsiao, SY
   Hsiao, HH
AF Gau, Yuh Ching
   Yeh, Tsung Jang
   Hsu, Chin Mu
   Hsiao, Samuel Yien
   Hsiao, Hui Hua
TI Pathogenesis and Treatment of Myeloma Related Bone Disease
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE myeloma; myeloma bone disease; osteoclastogenesis; bisphosphonates;
   denosumab; novel agents
ID REFRACTORY MULTIPLE MYELOMA; ACTIVATING FACTOR ANTIBODY; HUMAN
   MONOCLONAL ANTIBODY; KAPPA B LIGAND; ZOLEDRONIC ACID; ACTIVIN A;
   OSTEOCLAST DIFFERENTIATION; POSTMENOPAUSAL WOMEN; DOUBLE BLIND; SKELETAL
   COMPLICATIONS
AB Multiple myeloma is a hematologic malignancy of plasma cells that causes bone destructive lesions and associated skeletal related events (SREs). The pathogenesis of myeloma related bone disease (MBD) is the imbalance of the bone remodeling process, which results from osteoclast activation, osteoblast suppression, and the immunosuppressed bone marrow microenvironment. Many important signaling cascades, including the RANKL/RANK/OPG axis, Notch signaling, the Wnt/beta Catenin signaling pathways, and signaling molecules, such as DKK 1, sclerostin, osteopontin, activin A, chemokines, and interleukins are involved and play critical roles in MBD. Currently, bisphosphonate and denosumab are the gold standard for MBD prevention and treatment. As the molecular mechanisms of MBD become increasingly well understood, novel agents are being thoroughly explored in both preclinical and clinical settings. Herein, we will provide an updated overview of the pathogenesis of MBD, summarize the clinical management and guidelines, and discuss novel bone modifying therapies for further management of MBD.
C1 [Gau, Yuh Ching; Yeh, Tsung Jang; Hsu, Chin Mu; Hsiao, Hui Hua] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Kaohsiung 80756, Taiwan.
   [Gau, Yuh Ching; Yeh, Tsung Jang] Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, Kaohsiung 80708, Taiwan.
   [Hsiao, Samuel Yien] Univ Rutgers Camden, Dept Biol, Camden, NJ 08102 USA.
   [Hsiao, Hui Hua] Kaohsiung Med Univ Hosp, Canc Ctr, Kaohsiung 80756, Taiwan.
   [Hsiao, Hui Hua] Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung 80708, Taiwan.
   [Hsiao, Hui Hua] Kaohsiung Med Univ, Fac Med, Kaohsiung 80708, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University Hospital;
   Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University Hospital; Kaohsiung Medical University; Kaohsiung
   Medical University
RP Hsiao, HH (通讯作者)，Kaohsiung Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Kaohsiung 80756, Taiwan.; Hsiao, HH (通讯作者)，Kaohsiung Med Univ Hosp, Canc Ctr, Kaohsiung 80756, Taiwan.; Hsiao, HH (通讯作者)，Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung 80708, Taiwan.; Hsiao, HH (通讯作者)，Kaohsiung Med Univ, Fac Med, Kaohsiung 80708, Taiwan.
EM cheesecaketwin@gmail.com; aw7719@gmail.com; e12013@gmail.com;
   ucdsacnyu@gmail.com; huhuhs@kmu.edu.tw
OI Yeh, Tsung Jang/0000 0003 1634 2219; Gau, Yuh Ching/0000 0001 6753 112X
CR Abdulkadyrov KM, 2014, BRIT J HAEMATOL, V165, P814, DOI 10.1111/bjh.12835
   Accardi F, 2015, BIOMED RES INT UK, V2015, DOI 10.1155/2015/172458
   Anastasilakis AD, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010152
   Anderson K, 2018, J CLIN ONCOL, V36, P812, DOI 10.1200/JCO.2017.76.6402
   [Anonymous], NEWSWIRE P
   [Anonymous], 2021, INT J MOL SCI
   Bam R, 2013, AM J HEMATOL, V88, P463, DOI 10.1002/ajh.23433
   Bao HY, 2009, INT J HEMATOL, V90, P177, DOI 10.1007/s12185 009 0356 8
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Brunetti G, 2011, ANN NY ACAD SCI, V1237, P19, DOI 10.1111/j.1749 6632.2011.06196.x
   Brylka LJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02182
   Callander NS, 2022, J NATL COMPR CANC NE, V20, P9, DOI 10.6004/jnccn.2022.0002
   Cicci Jonathan D, 2014, Clin Lymphoma Myeloma Leuk, V14, pe207, DOI 10.1016/j.clml.2014.07.005
   Clarke BL, 2014, MATURITAS, V78, P199, DOI 10.1016/j.maturitas.2014.04.016
   Colombo M, 2013, LEUKEMIA, V27, P1009, DOI 10.1038/leu.2013.6
   Colombo M, 2015, ONCOTARGET, V6, P26826, DOI 10.18632/oncotarget.5025
   Colucci S, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.22
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   D'Souza S, 2012, BLOOD, V119, P1888, DOI 10.1182/blood 2011 11 393348
   Dalla Palma B, 2016, LEUKEMIA, V30, P409, DOI 10.1038/leu.2015.259
   Delgado Calle J, 2017, LEUKEMIA, V31, P2686, DOI 10.1038/leu.2017.152
   Delmas PD, 2008, J CLIN DENSITOM, V11, P325, DOI 10.1016/j.jocd.2008.02.002
   Dimopoulos MA, 2021, ANN ONCOL, V32, P309, DOI 10.1016/j.annonc.2020.11.014
   Eda H, 2016, J BONE MINER RES, V31, P1225, DOI 10.1002/jbmr.2789
   Fowler JA, 2012, CANCER RES, V72, P2183, DOI 10.1158/0008 5472.CAN 11 2067
   Fragioudaki M, 2012, LEUKEMIA RES, V36, P1004, DOI 10.1016/j.leukres.2012.03.012
   Fu R, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935 014 0132 6
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Fuller K, 2000, BIOCHEM BIOPH RES CO, V268, P2, DOI 10.1006/bbrc.2000.2075
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Giuliani N, 2012, LEUKEMIA, V26, P1391, DOI 10.1038/leu.2011.381
   Giuliani N, 2008, CANCER RES, V68, P6840, DOI 10.1158/0008 5472.CAN 08 0402
   Goldstein DA, 2018, HAEMATOLOGICA, V103, P753, DOI 10.3324/haematol.2017.185264
   Guenther A, 2010, INT J CANCER, V126, P239, DOI 10.1002/ijc.24758
   Gül G, 2016, CURR MED RES OPIN, V32, P133, DOI 10.1185/03007995.2015.1105795
   Gunn WG, 2006, STEM CELLS, V24, P986, DOI 10.1634/stemcells.2005 0220
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Harmer D, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00788
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Hemingway F, 2011, BONE, V48, P938, DOI 10.1016/j.bone.2010.12.023
   Hengeveld PJ, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.3
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Huang SY, 2020, ADV THER, V37, P3404, DOI 10.1007/s12325 020 01395 x
   Iida S, 2016, CANCER SCI, V107, P1281, DOI 10.1111/cas.13000
   Ito S, 2020, CANCERS, V12, DOI 10.3390/cancers12020265
   Iyer SP, 2014, BRIT J HAEMATOL, V167, P366, DOI 10.1111/bjh.13056
   Kaiser M, 2008, EUR J HAEMATOL, V80, P490, DOI 10.1111/j.1600 0609.2008.01065.x
   Kazandjian D, 2016, SEMIN ONCOL, V43, P676, DOI 10.1053/j.seminoncol.2016.11.004
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   King AE, 2008, PHARMACOTHERAPY, V28, P667, DOI 10.1592/phco.28.5.667
   Kyriakou C, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408 019 0187 7
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood 2003 06 1992
   Lewiecki EM, 2014, THER ADV MUSCULOSKEL, V6, P48, DOI 10.1177/1759720X13510479
   Luisi S, 2001, EUR J ENDOCRINOL, V145, P225, DOI 10.1530/eje.0.1450225
   Lund SA, 2009, J CELL COMMUN SIGNAL, V3, P311, DOI 10.1007/s12079 009 0068 0
   Manetta J, 2014, J INFLAMM RES, V7, P121, DOI 10.2147/JIR.S67751
   Masih Khan E, 2006, BLOOD, V108, P3465, DOI 10.1182/blood 2006 04 017087
   McDonald MM, 2017, BLOOD, V129, P3452, DOI 10.1182/blood 2017 03 773341
   Mikhael J, 2019, J CLIN ONCOL, V37, P1228, DOI 10.1200/JCO.18.02096
   Mirandola L, 2013, LEUKEMIA, V27, P1558, DOI 10.1038/leu.2013.27
   Morgan GJ, 2011, LANCET ONCOL, V12, P743, DOI 10.1016/S1470 2045(11)70157 7
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Munshi NC, 2012, BLOOD, V120, DOI 10.1182/blood.V120.21.331.331
   Neri P, 2007, CLIN CANCER RES, V13, P5903, DOI 10.1158/1078 0432.CCR 07 0753
   Nishida H, 2018, HEMATOL REP, V10, P11, DOI 10.4081/hr.2018.7401
   Noonan K, 2010, BLOOD, V116, P3554, DOI 10.1182/blood 2010 05 283895
   Oranger A, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/289458
   Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood 2002 12 3905
   Padmanabhan S, 2009, BLOOD, V114, P312
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   Panaroni C, 2017, CURR OSTEOPOROS REP, V15, P483, DOI 10.1007/s11914 017 0397 5
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Pennisi A, 2009, BLOOD, V114, P1803, DOI 10.1182/blood 2009 01 201954
   Pennisi A, 2009, AM J HEMATOL, V84, P6, DOI 10.1002/ajh.21310
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Pisklakova A, 2016, CANCER BIOL THER, V17, P477, DOI 10.1080/15384047.2016.1156261
   Pozzi S, 2011, ONCOLOGIST, V16, P651, DOI 10.1634/theoncologist.2010 0225
   Qian JF, 2012, BLOOD, V119, P161, DOI 10.1182/blood 2011 07 368472
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Qiang YW, 2012, SEMIN HEMATOL, V49, P243, DOI 10.1053/j.seminhematol.2012.04.011
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470 2045(18)30072 X
   Raje NS, 2017, BRIT J HAEMATOL, V176, P783, DOI 10.1111/bjh.14483
   Raje NS, 2016, CLIN CANCER RES, V22, P5688, DOI 10.1158/1078 0432.CCR 16 0201
   Rajkumar SV, 2016, AM J HEMATOL, V91, P90, DOI 10.1002/ajh.24236
   Rajkumar SV, 2016, MAYO CLIN PROC, V91, P101, DOI 10.1016/j.mayocp.2015.11.007
   Rasch S, 2020, CANCERS, V12, DOI 10.3390/cancers12082113
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Richardson PG, 2018, BRIT J HAEMATOL, V180, P821, DOI 10.1111/bjh.15058
   Robbiani DF, 2007, HEMATOL ONCOL, V25, P16, DOI 10.1002/hon.803
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Roodman GD, 2010, J CELL BIOCHEM, V109, P283, DOI 10.1002/jcb.22403
   Roodman GD, 2004, BLOOD CELL MOL DIS, V32, P290, DOI 10.1016/j.bcmd.2004.01.001
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Sabol HM, 2021, CANCER RES, V81, P5102, DOI 10.1158/0008 5472.CAN 21 0524
   Sanchez E, 2012, BRIT J HAEMATOL, V158, P727, DOI 10.1111/j.1365 2141.2012.09241.x
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747
   Schwarzer R, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.37
   Scullen T, 2013, LEUKEMIA, V27, P1715, DOI 10.1038/leu.2013.50
   Seckinger A, 2012, BLOOD, V120, P1087, DOI 10.1182/blood 2012 03 415588
   Sezer O, 2003, BLOOD, V101, P2094, DOI 10.1182/blood 2002 09 2684
   Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037
   Shipman CM, 2003, CANCER RES, V63, P912
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Silbermann R, 2013, J BONE ONCOL, V2, P59, DOI 10.1016/j.jbo.2013.04.001
   Silbermann R, 2011, BLOOD, V118, P1681, DOI 10.1182/blood.V118.21.3933.3933
   Singh SP, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0779 z
   Spaan I, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045 018 0615 3
   Standal T, 2004, HAEMATOLOGICA, V89, P174
   Standal T, 2002, BLOOD, V100, P3002, DOI 10.1182/blood 2002 04 1190
   Sugatani T, 2003, J CELL BIOCHEM, V90, P59, DOI 10.1002/jcb.10613
   Tai YT, 2012, BLOOD, V120, P1877, DOI 10.1182/blood 2011 12 396853
   Tanaka Y, 2007, CLIN CANCER RES, V13, P816, DOI 10.1158/1078 0432.CCR 06 2258
   Tang CH, 2018, CANCER EPIDEMIOL, V55, P136, DOI 10.1016/j.canep.2018.06.003
   Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078 0432.CCR 09 2329
   Terpos E, 2005, LEUKEMIA LYMPHOMA, V46, P1699, DOI 10.1080/10428190500175049
   Terpos E, 2012, ANN ONCOL, V23, P2681, DOI 10.1093/annonc/mds068
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Terpos E, 2010, LEUKEMIA, V24, P1043, DOI 10.1038/leu.2010.62
   Terpos E, 2009, ANN ONCOL, V20, P1303, DOI 10.1093/annonc/mdn796
   Terpos E, 2007, BLOOD, V110, P1098, DOI 10.1182/blood 2007 03 067710
   Terpos E, 2021, LANCET ONCOL, V22, pE119, DOI 10.1016/S1470 2045(20)30559 3
   Terpos E, 2021, BLOOD ADV, V5, P725, DOI 10.1182/bloodadvances.2020002378
   Terpos E, 2019, BLOOD, V133, P1534, DOI 10.1182/blood 2018 11 852459
   Terpos E, 2012, INT J CANCER, V131, P1466, DOI 10.1002/ijc.27342
   Toscani D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02467
   Trotter TN, 2015, BLOOD, V125, P3598, DOI 10.1182/blood 2014 12 613968
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Ullah TR, 2019, J BONE ONCOL, V17, DOI 10.1016/j.jbo.2019.100253
   Urade Masahiro, 2007, Clin Calcium, V17, P241
   VALENTINOPRAN A, 1982, BRIT J HAEMATOL, V52, P601, DOI 10.1111/j.1365 2141.1982.tb03936.x
   Valkovic T, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/513170
   Vallet S, 2011, LEUKEMIA, V25, P1174, DOI 10.1038/leu.2011.43
   Vallet S, 2007, BLOOD, V110, P3744, DOI 10.1182/blood 2007 05 093294
   Vallet S, 2009, CANCER RES, V69
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Vannala V, 2020, INT J PREVENTIVE MED, V11, DOI 10.4103/ijpvm.IJPVM_33_19
   Vij R, 2009, AM J HEMATOL, V84, P650, DOI 10.1002/ajh.21509
   Wang XT, 2014, LEUKEMIA RES, V38, P525, DOI 10.1016/j.leukres.2014.02.010
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Xu S, 2010, CELL MOL IMMUNOL, V7, P164, DOI 10.1038/cmi.2010.21
   Yee AJ, 2015, BLOOD, V126, P4241, DOI DOI 10.1182/BLOOD.V126.23.4241.4241
   Yen CH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186723
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zervas K, 2006, BRIT J HAEMATOL, V134, P620, DOI 10.1111/j.1365 2141.2006.06230.x
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhou FL, 2013, BLOOD REV, V27, P261, DOI 10.1016/j.blre.2013.08.002
NR 156
TC 31
Z9 35
U1 3
U2 12
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2022
VL 23
IS 6
AR 3112
DI 10.3390/ijms23063112
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 0C4HB
UT WOS:000775275200001
PM 35328533
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jörg, DJ
   Fuertinger, DH
   Cherif, A
   Bushinsky, DA
   Mermelstein, A
   Raimann, JG
   Kotanko, P
AF Jorg, David J.
   Fuertinger, Doris H.
   Cherif, Alhaji
   Bushinsky, David A.
   Mermelstein, Ariella
   Raimann, Jochen G.
   Kotanko, Peter
TI Modeling osteoporosis to design and optimize pharmacological therapies
   comprising multiple drug types
SO ELIFE
LA English
DT Article
DE osteoporosis; pharmacodynamics; mathematical model; combination therapy;
   Human
ID HUMAN MONOCLONAL ANTIBODY; INHIBITS BONE RESORPTION; POSTMENOPAUSAL
   WOMEN; MATHEMATICAL MODEL; COLLAGENASE 3; DENOSUMAB; SCLEROSTIN;
   ROMOSOZUMAB; OSTEOBLAST; APOPTOSIS
AB For the treatment of postmenopausal osteoporosis, several drug classes with different mechanisms of action are available. Since only a limited set of dosing regimens and drug combinations can be tested in clinical trials, it is currently unclear whether common medication strategies achieve optimal bone mineral density gains or are outperformed by alternative dosing schemes and combination therapies that have not been explored so far. Here, we develop a mathematical framework of drug interventions for postmenopausal osteoporosis that unifies fundamental mechanisms of bone remodeling and the mechanisms of action of four drug classes: bisphosphonates, parathyroid hormone analogs, sclerostin inhibitors, and receptor activator of NF kappa B ligand inhibitors. Using data from several clinical trials, we calibrate and validate the model, demonstrating its predictive capacity for complex medication scenarios, including sequential and parallel drug combinations. Via simulations, we reveal that there is a large potential to improve gains in bone mineral density by exploiting synergistic interactions between different drug classes, without increasing the total amount of drug administered.
C1 [Jorg, David J.; Fuertinger, Doris H.] Fresenius Med Care Germany, Biomed Modeling & Simulat Grp, Global Res & Dev, Bad Homburg, Germany.
   [Cherif, Alhaji; Mermelstein, Ariella; Raimann, Jochen G.; Kotanko, Peter] Renal Res Inst, New York, NY USA.
   [Bushinsky, David A.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14627 USA.
   [Kotanko, Peter] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
C3 Renal Research Institute; University of Rochester; Icahn School of
   Medicine at Mount Sinai
RP Jörg, DJ (通讯作者)，Fresenius Med Care Germany, Biomed Modeling & Simulat Grp, Global Res & Dev, Bad Homburg, Germany.
EM david.joerg@fmc ag.com
RI Jörg, David/I 3905 2012; Kotanko, Peter/AAE 5721 2019
OI Kotanko, Peter/0000 0003 4373 412X; Fuertinger,
   Doris/0000 0001 6321 2367; 
CR Atkins GJ, 2011, J BONE MINER RES, V26, P1425, DOI 10.1002/jbmr.345
   Austin M, 2012, J BONE MINER RES, V27, P687, DOI 10.1002/jbmr.1472
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Berger C, 2009, J BONE MINER RES, V24, P361, DOI 10.1359/JBMR.081004
   Berkhout J, 2015, CPT PHARMACOMET SYST, V4, P516, DOI 10.1002/psp4.12006
   Black DM, 2018, J BONE MINER RES, V33, P389, DOI 10.1002/jbmr.3194
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Boskey Adele L, 2013, Bonekey Rep, V2, P447, DOI 10.1038/bonekey.2013.181
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Buenzli PR, 2011, BONE, V48, P918, DOI 10.1016/j.bone.2010.12.009
   Buenzli PR, 2014, BIOMECH MODEL MECHAN, V13, P185, DOI 10.1007/s10237 013 0495 y
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Cooper C., 2017, IOF COMPENDIUM OSTEO
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   De Maré A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093199
   Delgado Calle J, 2017, BONE, V96, P29, DOI 10.1016/j.bone.2016.10.007
   Ensrud KE, 2022, J CLIN ENDOCR METAB, V107, pE3877, DOI 10.1210/clinem/dgac324
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Eudy RJ, 2015, CPT PHARMACOMET SYST, V4, P527, DOI 10.1002/psp4.12013
   FULLER K, 1995, J CELL SCI, V108, P2221
   Gazzerro E, 1999, ENDOCRINOLOGY, V140, P562, DOI 10.1210/en.140.2.562
   Graham JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063884
   Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148
   Hansen Nikolaus, 2023, Zenodo
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110
   Houde N, 2009, J BIOL CHEM, V284, P23397, DOI 10.1074/jbc.M109.019372
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Il Mödder U, 2011, J BONE MINER RES, V26, P27, DOI 10.1002/jbmr.128
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Kanis JA, 2001, OSTEOPOROSIS INT, V12, P989, DOI 10.1007/s001980170006
   Kanis JA, 2009, BONE, V44, P734, DOI 10.1016/j.bone.2009.01.373
   Keener J., 2009, MATH PHYSL CELLULAR, DOI [10.1007/978 0 387 75847 3, DOI 10.1007/978 0 387 75847 3]
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Komarova SV, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00051
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Krege John H, 2013, Bonekey Rep, V2, P404, DOI 10.1038/bonekey.2013.138
   Lavaill M, 2020, BIOMECH MODEL MECHAN, V19, P1765, DOI 10.1007/s10237 020 01307 6
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Leder BZ, 2014, J CLIN ENDOCR METAB, V99, P1694, DOI 10.1210/jc.2013 4440
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lemaire V, 2019, B MATH BIOL, V81, P3575, DOI 10.1007/s11538 018 0533 0
   Lewiecki EM, 2019, J BONE MINER RES, V34, P419, DOI 10.1002/jbmr.3622
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Lim SY, 2017, DRUG DES DEV THER, V11, P1221, DOI 10.2147/DDDT.S127568
   Lisberg A, 2017, CPT PHARMACOMET SYST, V6, P208, DOI 10.1002/psp4.12154
   Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Marathe A, 2008, J PHARMACOL EXP THER, V326, P555, DOI 10.1124/jpet.108.137703
   Marathe DD, 2011, BIOPHARM DRUG DISPOS, V32, P471, DOI 10.1002/bdd.770
   Martínez Reina J, 2019, BONE, V125, P87, DOI 10.1016/j.bone.2019.04.022
   McClung MR, 2017, OSTEOPOROSIS INT, V28, P1723, DOI 10.1007/s00198 017 3919 1
   McClung MR, 2018, J BONE MINER RES, V33, P1397, DOI 10.1002/jbmr.3452
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Mundy GR, 1999, CLIN CHEM, V45, P1347
   Odén A, 2013, CALCIFIED TISSUE INT, V92, P42, DOI 10.1007/s00223 012 9666 6
   Oliphant T. E., 2006, GUIDE NUMPY
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Painter Stephanie E, 2006, Endocr Pract, V12, P436
   Peterson MC, 2010, BONE, V46, P49, DOI 10.1016/j.bone.2009.08.053
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2013, ENG STRUCT, V47, P134, DOI 10.1016/j.engstruct.2012.09.006
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Recknor CP, 2015, J BONE MINER RES, V30, P1717, DOI 10.1002/jbmr.2489
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Ross DS, 2012, DISCRETE CONT DYN B, V17, P2185, DOI 10.3934/dcdsb.2012.17.2185
   Rydziel S, 1997, J CELL BIOCHEM, V67, P176, DOI 10.1002/(SICI)1097 4644(19971101)67:2<176::AID JCB3>3.3.CO;2 D
   Rydziel S, 1997, J CELL PHYSIOL, V170, P145, DOI 10.1002/(SICI)1097 4652(199702)170:2<145::AID JCP6>3.0.CO;2 O
   Ryser MD, 2009, J BONE MINER RES, V24, P860, DOI 10.1359/JBMR.081229
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Satterwhite J, 2010, CALCIFIED TISSUE INT, V87, P485, DOI 10.1007/s00223 010 9424 6
   Scheiner S, 2014, INT J NUMER METH BIO, V30, P1, DOI 10.1002/cnm.2584
   Scheiner S, 2013, COMPUT METHOD APPL M, V254, P181, DOI 10.1016/j.cma.2012.10.015
   Schmidt S, 2011, J PHARMACOKINET PHAR, V38, P873, DOI 10.1007/s10928 011 9224 2
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Solheim E, 1998, INT ORTHOP, V22, P410, DOI 10.1007/s002640050290
   Solling ASK, 2018, THER ADV MUSCULOSKEL, V10, P105, DOI 10.1177/1759720X18775936
   Sowers MR, 2008, J CLIN ENDOCR METAB, V93, P3847, DOI 10.1210/jc.2008 1056
   Streicher C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06614 0
   Suen PK, 2015, SCI REP UK, V5, DOI 10.1038/srep15632
   TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo 110 2 506
   Tanaka S, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.43
   Thouverey C, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.126
   Tu Kristie N, 2018, P T, V43, P92
   Virtanen P., [No title captured]
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200
   Zhang L, 2019, J PHARM SCI US, V108, P732, DOI 10.1016/j.xphs.2018.11.024
   Zumsande M, 2011, BONE, V48, P910, DOI 10.1016/j.bone.2010.12.010
NR 100
TC 7
Z9 9
U1 3
U2 14
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD AUG 9
PY 2022
VL 11
AR e76228
DI 10.7554/eLife.76228
PG 29
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA 3R9UT
UT WOS:000839250500001
PM 35942681
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Hanley, DA
   Adachi, JD
   Bell, A
   Brown, V
AF Hanley, D. A.
   Adachi, J. D.
   Bell, A.
   Brown, V.
TI Denosumab: mechanism of action and clinical outcomes
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Article
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; NONVERTEBRAL FRACTURES;
   PRACTICE GUIDELINES; HIP FRACTURE; OSTEOPOROSIS; ALENDRONATE; RISK;
   DIAGNOSIS; BISPHOSPHONATES
AB Aims: To describe the mechanisms of action of denosumab, a novel antiresorptive agent, contrasting it with other antiresorptive and anabolic osteoporosis treatments. Methods: Published papers related to the mechanism of action of approved osteoporosis treatments were sought through MEDLINE searches. Findings: Osteoporotic fractures carry a substantial burden of morbidity and mortality, but pharmacotherapy can prevent such fractures in high risk individuals. Antiresorptive drugs (e.g. bisphosphonates, oestrogen, denosumab) reduce bone turnover by distinct mechanisms. Denosumab, a recently approved therapy, is a fully human monoclonal antibody that binds the cytokine RANKL (receptor activator of NF?B ligand), an essential factor initiating bone turnover. RANKL inhibition blocks osteoclast maturation, function and survival, thus reducing bone resorption. In contrast, bisphosphonates bind bone mineral, where they are absorbed by mature osteoclasts, inducing osteoclast apoptosis and suppressing resorption. These differences in mechanism influence both the onset and reversibility of treatment. Discussion: Effective pharmacotherapy is necessary for patients at high risk of fracture. Among the treatment options for postmenopausal osteoporosis, there are significant differences in mechanism and dosing. Denosumab acts by a novel mechanism and is administered twice yearly by subcutaneous injection. Identified by Osteoporosis Canada Clinical Practice Guidelines as a first line agent for treatment of postmenopausal osteoporosis, denosumab represents an important addition to our treatment options.
C1 [Hanley, D. A.] Univ Calgary, Dept Med, Calgary, AB, Canada.
   [Hanley, D. A.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada.
   [Hanley, D. A.] Univ Calgary, Dept Oncol, Calgary, AB, Canada.
   [Adachi, J. D.] McMaster Univ, Dept Med, Michael G DeGroote Sch Med, St Josephs Healthcare, Hamilton, ON, Canada.
   [Bell, A.] Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada.
   [Brown, V.] McMaster Univ, Univ Toronto, Dept Family & Community Med, Hamilton, ON, Canada.
C3 University of Calgary; University of Calgary; University of Calgary;
   McMaster University; University of Toronto; University of Toronto;
   McMaster University
RP Hanley, DA (通讯作者)，Richmond Rd Diagnost & Treatment Ctr, Div Endocrinol & Metab, 1820 Richmond Rd SW, Calgary, AB T2T 5C7, Canada.
EM dahanley@ucalgary.ca
FU Alliance (Procter & Gamble, Aventis); Amgen; Eli Lilly; Merck; NPS
   Pharmaceuticals; Novartis; Sanofi Aventis; Amgen Canada
FX David Hanley: Research Support: Alliance (Procter & Gamble, Aventis),
   Amgen, Eli Lilly, Merck, NPS Pharmaceuticals, Novartis; Advisory Boards:
   Amgen, Eli Lilly, Novartis, Warner Chilcott; Speaker Honoraria: Amgen,
   Eli Lilly, Merck, Novartis, Warner Chilcott. Jonathan D. Adachi:
   Consultant/Speaker: Amgen, Eli Lilly, GSK, Merck, Novartis, Pfizer,
   Procter & Gamble, Roche, Sanofi Aventis, Warner Chilcott; Clinical
   trials: Amgen, Eli Lilly, Merck, Novartis, Pfizer, Procter & Gamble,
   Roche, Sanofi Aventis, Warner Chilcott. Alan Bell: Relevant to this
   paper, Dr Bell has received consultant and/or speaker fees from Amgen
   and Sanofi Aventis and research grants from Amgen. Vivien Brown:
   Relevant to this paper, Dr Brown has received consultant and/or speaker
   fees from Amgen.The opinions and analysis presented here are solely
   those of the authors. Writing assistance by John Ashkenas, PhD (SCRIPT,
   Toronto Ontario) was made possible by Amgen Canada, who supported this
   project from its inception.
CR Adachi JD, 2010, MAYO CLIN PROC, V85, P806, DOI 10.4065/mcp.2010.0082
   [Anonymous], 2011, PROL PROD MON
   [Anonymous], 2006, APO RAL PROD MON
   [Anonymous], 2010, FOS PROD MON
   [Anonymous], 2009, FORT PROD MON
   [Anonymous], 2011, ACT PROD MON
   [Anonymous], 2011, ACL PROD MON
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Belavic Jennifer M, 2011, Nurse Pract, V36, P11, DOI 10.1097/01.NPR.0000391178.47878.73
   Bessette L, 2008, OSTEOPOROSIS INT, V19, P79, DOI 10.1007/s00198 007 0426 9
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bolland MJ, 2010, J CLIN ENDOCR METAB, V95, P1174, DOI 10.1210/jc.2009 0852
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Brown JP, 2006, J OBSTET GYNAECOL CA, V28, pS95, DOI 10.1016/S1701 2163(16)32087 4
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Brown JP, 2002, CAN MED ASSOC J, V167, pS1
   Bush TL, 1996, JAMA J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389
   Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001 2002
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Dore RK, 2012, CURR OSTEOPOROS REP, V10, P16, DOI 10.1007/s11914 011 0082 z
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   File Elizabeth, 2009, Curr Rheumatol Rep, V11, P169
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Hanley DA, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1661
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hiligsmann M, 2010, HEALTH POLICY, V96, P170, DOI 10.1016/j.healthpol.2010.01.014
   Hussar DA, 2010, J AM PHARM ASSOC, V50, P658, DOI 10.1331/JAPhA.2010.10536
   Kanis JA, 2009, EUR J RADIOL, V71, P392, DOI 10.1016/j.ejrad.2008.04.061
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Leslie WD, 2010, OSTEOPOROSIS INT, V21, P1317, DOI 10.1007/s00198 009 1080 1
   Lewiecki EM, 2010, MATURITAS, V66, P182, DOI 10.1016/j.maturitas.2010.02.008
   Lipton A, 2011, BONE, V48, P96, DOI 10.1016/j.bone.2010.10.161
   MacLean C, 2008, ANN INTERN MED, V148, P197, DOI 10.7326/0003 4819 148 3 200802050 00198
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Moen MD, 2011, DRUG AGING, V28, P63, DOI 10.2165/11203300 000000000 00000
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Osteoporosis Society of Canada, 2005, OSTEOPOROS UPDATE, V9, P6
   Pallan S, 2011, CAN FAM PHYSICIAN, V57, P184
   Papaioannou A, 2005, OSTEOPOROSIS INT, V16, P568, DOI 10.1007/s00198 004 1735 x
   Papaioannou A, 2009, OSTEOPOROSIS INT, V20, P703, DOI 10.1007/s00198 008 0743 7
   Papaioannou A, CLIN PRACTICE GUIDEL
   Papaioannou A, 2010, CAN MED ASSOC J, V182, P1864, DOI 10.1503/cmaj.100771
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Pérez López FR, 2007, MATURITAS, V58, P117, DOI 10.1016/j.maturitas.2007.05.002
   Rizzoli R, 2010, NAT REV DRUG DISCOV, V9, P591, DOI 10.1038/nrd3244
   Rosen CJ, 2001, J CLIN ENDOCR METAB, V86, P957, DOI 10.1210/jc.86.3.957
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Seeman E, 2003, OSTEOPOROSIS INT, V14, pS2, DOI 10.1007/s00198 002 1340 9
   Seeman E, 2010, J BONE MINER RES, V25, P1886, DOI 10.1002/jbmr.81
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yan MZ, 2010, ENDOCRINE, V37, P55, DOI 10.1007/s12020 009 9267 y
NR 59
TC 239
Z9 267
U1 0
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1368 5031
EI 1742 1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
PD DEC
PY 2012
VL 66
IS 12
BP 1139
EP 1146
DI 10.1111/ijcp.12022
PG 8
WC Medicine, General & Internal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Pharmacology & Pharmacy
GA 041FD
UT WOS:000311382300004
PM 22967310
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ferrari, S
   Langdahl, B
AF Ferrari, Serge
   Langdahl, Bente
TI Mechanisms underlying the long term and withdrawal effects of denosumab
   therapy on bone
SO NATURE REVIEWS RHEUMATOLOGY
LA English
DT Article
ID VERTEBRAL FRACTURES; MINERAL DENSITY; DISCONTINUATION; OSTEOPOROSIS;
   TURNOVER; STRENGTH; RISK; LIGAND; RANKL
AB Denosumab, a human monoclonal antibody against receptor activator of nuclear factor kappa B ligand (RANKL), is a potent inhibitor of osteoclast differentiation and activity. As the first biologic drug used to treat osteoporosis, denosumab has shown potent anti resorptive properties and anti fracture efficacy. The effects of this drug are also unique compared with the effects of bisphosphonates: namely, long term treatment with this drug results in a continuous gain of bone mineral density, whereas withdrawal of the drug results in a transient overshoot in bone turnover and rapid bone loss. Although the mechanisms for these specific effects remain incompletely understood, emerging experimental and clinical data have started to highlight potential biological and pharmacological mechanisms by which denosumab might affect osteoclasts, as well as osteoblasts, and cause both sustained bone gain and bone loss upon treatment cessation. This Perspective discusses those potential mechanisms and the future studies and clinical implications that might ensue from these findings.
   Long term treatment with the anti resorptive drug denosumab results in a continuous gain in bone mineral density, whereas denosumab withdrawal results in a transient overshoot in bone turnover, with rapid bone loss. This Perspective explores the potential mechanisms underlying these effects.
C1 [Ferrari, Serge] Geneva Univ Hosp, Dept Med, Serv Bone Dis, Geneva, Switzerland.
   [Ferrari, Serge] Fac Med, Geneva, Switzerland.
   [Langdahl, Bente] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Aarhus, Denmark.
C3 University of Geneva; University of Geneva; Aarhus University
RP Ferrari, S (通讯作者)，Geneva Univ Hosp, Dept Med, Serv Bone Dis, Geneva, Switzerland.; Ferrari, S (通讯作者)，Fac Med, Geneva, Switzerland.
EM serge.ferrari@unige.ch
RI ; Ferrari, Serge/ABD 2730 2020
OI ferrari, serge/0000 0002 1372 4417; 
CR Adachi JD, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1520 6
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   Anastasilakis AD, 2017, EUR J ENDOCRINOL, V176, P677, DOI 10.1530/EJE 16 1027
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Black DM, 2020, LANCET DIABETES ENDO, V8, P672, DOI 10.1016/S2213 8587(20)30159 5
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bonnet N, 2023, J CLIN INVEST, V133, DOI 10.1172/JCI169317
   Bonnet N, 2021, J BONE MINER RES, V36, P1636, DOI 10.1002/jbmr.4307
   Bonnet N, 2017, J BONE MINER RES, V32, P1432, DOI 10.1002/jbmr.3136
   Bonnet N, 2016, MOL CELL ENDOCRINOL, V432, P85, DOI 10.1016/j.mce.2015.12.014
   Bonnet N, 2016, CALCIFIED TISSUE INT, V99, P99, DOI 10.1007/s00223 016 0124 8
   Boonen S, 2012, J BONE MINER RES, V27, P963, DOI 10.1002/jbmr.1570
   Brown JP, 2011, J BONE MINER RES, V26, P2737, DOI 10.1002/jbmr.448
   Burckhardt P, 2021, J BONE MINER RES, V36, P1717, DOI 10.1002/jbmr.4335
   Cawley KM, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108052
   Cosman F, 2022, J BONE MINER RES, V37, P2112, DOI 10.1002/jbmr.4705
   Cummings SR, 2018, J BONE MINER RES, V33, P190, DOI 10.1002/jbmr.3337
   Dempster DW, 2020, J BONE MINER RES, V35, P1282, DOI 10.1002/jbmr.4006
   Dempster DW, 2018, J CLIN ENDOCR METAB, V103, P2498, DOI 10.1210/jc.2017 02669
   Dennison EM, 2019, OSTEOPOROSIS INT, V30, P1733, DOI 10.1007/s00198 019 05002 w
   Eastell R, 2014, J BONE MINER RES, V29, P458, DOI 10.1002/jbmr.2047
   Eastell R, 2011, BONE, V49, P82, DOI 10.1016/j.bone.2011.02.011
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Everts Graber J, 2021, BONE, V144, DOI 10.1016/j.bone.2020.115830
   Farlay D, 2022, J BONE MINER RES, V37, P856, DOI 10.1002/jbmr.4538
   Ferrari S, 2019, J CLIN ENDOCR METAB, V104, P3450, DOI 10.1210/jc.2019 00271
   Fontalis A GF., 2020, BONE REP, V135, P39
   FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104
   Fu Q, 2022, J BONE MINER RES, V37, P338
   Fuller K, 2008, BONE, V42, P200, DOI 10.1016/j.bone.2007.09.044
   Gallagher JC, 2002, J CLIN ENDOCR METAB, V87, P4914, DOI 10.1210/jc.2002 020727
   Gerbaix M, 2015, BONE, V71, P94, DOI 10.1016/j.bone.2014.10.011
   Hart NH, 2017, J MUSCULOSKEL NEURON, V17, P114
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Jiang LH, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02554 8
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kendler DL, 2022, ADV THER, V39, P58, DOI 10.1007/s12325 021 01936 y
   Kim BJ, 2022, ANN GERIATR MED RES, V26, P63, DOI 10.4235/agmr.22.0054
   Kistler Fischbacher M, 2021, J BONE MINER RES, V36, P1680, DOI 10.1002/jbmr.4334
   Makras P, 2021, J CLIN ENDOCR METAB, V106, pE4155, DOI 10.1210/clinem/dgab321
   Martínez Reina J, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.635056
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Ominsky MS, 2015, J BONE MINER RES, V30, P1280, DOI 10.1002/jbmr.2480
   Omiya T, 2020, BONE REP, V13, DOI 10.1016/j.bonr.2020.100289
   Pennypacker BL, 2014, J BONE MINER RES, V29, P1847, DOI 10.1002/jbmr.2211
   Reid IR, 2017, CALCIFIED TISSUE INT, V101, P371, DOI 10.1007/s00223 017 0288 x
   Rinotas V, 2014, J BONE MINER RES, V29, P1158, DOI 10.1002/jbmr.2112
   Solling AS, 2021, J BONE MINER RES, V36, P1245, DOI 10.1002/jbmr.4305
   Solling AS, 2020, J BONE MINER RES, V35, P1858, DOI 10.1002/jbmr.4098
   Solling AS., 2022, BONE REP, V16, P12
   Tsourdi E, 2021, J CLIN ENDOCR METAB, V106, P264, DOI 10.1210/clinem/dgaa756
   Watanabe H, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10608
NR 54
TC 51
Z9 55
U1 2
U2 10
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1759 4790
EI 1759 4804
J9 NAT REV RHEUMATOL
JI Nat. Rev. Rheumatol.
PD MAY
PY 2023
VL 19
IS 5
BP 307
EP 317
DI 10.1038/s41584 023 00935 3
EA APR 2023
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA E3DE5
UT WOS:000963917900001
PM 37024711
DA 2025 08 17
ER

PT J
AU Smith, MR
AF Smith, Matthew R.
TI Osteoclast targeted therapy for prostate cancer: Bisphosphonates and
   beyond
SO UROLOGIC ONCOLOGY SEMINARS AND ORIGINAL INVESTIGATIONS
LA English
DT Article
DE prostate cancer; bone metastases; osteoclast; bisphosphonate; denosumab
ID ZOLEDRONIC ACID; MULTIPLE MYELOMA; BREAST CANCER; DOUBLE BLIND; SKELETAL
   COMPLICATIONS; POSTMENOPAUSAL WOMEN; AVASCULAR NECROSIS;
   AMERICAN SOCIETY; RANDOMIZED TRIAL; BONE METASTASES
AB Bone metastases are a major cause of morbidity for men with prostate cancer. Although typical bone metastases from prostate cancer appear osteoblastic by radiographic imaging, excess number and activity of both osteoblasts and osteoclasts characterize most "osteoblastic" bone metastases. Additionally, pathological osteoclast activation is associated with increased risk of skeletal complications, disease progression, and death. Zoledronic acid, a potent intravenous bisphosphonate, reduces markers of osteoclast activity and significantly decreases the risk of skeletal complications in men with androgen independent prostate cancer and bone metastases. Additional studies are needed to determine the optimal timing, schedule, and duration of bisphosphonate treatment in men with bone metastases as well as the potential role of bisphosphonates in other settings, including the prevention of bone metastases. Denosumab is a human monoclonal antibody that binds and neutralizes human receptor activator of NF kappa B ligand (RANKL), a critical mediator of osteoclast activation, differentiation, and survival. Three ongoing pivotal studies involving more than 4,500 subjects will evaluate the role of denosumab for prevention of treatment related fractures, bone metastases, and disease related skeletal complications in men with prostate cancer. (C) 2008 Elsevier Inc. All rights reserved.
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital
RP Smith, MR (通讯作者)，Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM smith.matthew@mgh.harvard.edu
FU NCI NIH HHS [1K24CA121990 01A1, K24 CA121990] Funding Source: Medline
CR Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Berenson JR, 2002, J CLIN ONCOL, V20, P3719, DOI 10.1200/JCO.2002.06.037
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   CLARKE NW, 1993, EUR UROL, V24, P286
   CLARKE NW, 1991, BRIT J UROL, V68, P74, DOI 10.1111/j.1464 410X.1991.tb15260.x
   Dearnaley DP, 2003, J NATL CANCER I, V95, P1300, DOI 10.1093/jnci/djg038
   Demers Laurence M., 2000, Cancer, V88, P2919, DOI 10.1002/1097 0142(20000615)88:12+<2919::AID CNCR7>3.0.CO;2 Z
   Diamond TH, 2004, CANCER AM CANCER SOC, V100, P892, DOI 10.1002/cncr.20056
   ERNST D, 2002, P ASCO, P177
   Garnero P, 2000, BRIT J CANCER, V82, P858, DOI 10.1054/bjoc.1999.1012
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mason M D., 2004, Proc Am Soc ClinO ncol, P4511
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2001, CANCER J, V7, P377
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   SMALL EJ, 2003, J CLIN ONCOL, V21
   Smith MR, 2005, J CLIN ONCOL, V23, P2918, DOI 10.1200/JCO.2005.01.529
   Tarassoff P, 2003, J ORAL MAXIL SURG, V61, P1238, DOI 10.1016/j.joms.2003.09.001
   Zojer N, 1999, DRUG SAFETY, V21, P389, DOI 10.2165/00002018 199921050 00004
   *ZOMETA, 2007, ZOL AC PRESCR INF NO
NR 27
TC 37
Z9 39
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1078 1439
J9 UROL ONCOL SEMIN ORI
JI Urol. Oncol. Semin. Orig. Investig.
PD JUL AUG
PY 2008
VL 26
IS 4
BP 420
EP 425
DI 10.1016/j.urolonc.2007.11.004
PG 6
WC Oncology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Urology & Nephrology
GA 326HP
UT WOS:000257649500017
PM 18593621
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Cui, PP
   Liu, HR
   Sun, J
   Amizuka, N
   Sun, QF
   Li, MQ
AF Cui, Pingping
   Liu, Hongrui
   Sun, Jing
   Amizuka, Norio
   Sun, Qinfeng
   Li, Minqi
TI Zoledronate promotes bone formation by blocking osteocyte osteoblast
   communication during bone defect healing
SO HISTOLOGY AND HISTOPATHOLOGY
LA English
DT Article
DE Zoledronate; Osteoblasts; Osteocytes; Connexin 43; Bone defect
ID DEFICIENT MICE; GAP JUNCTIONS; CORTICAL BONE; BISPHOSPHONATES;
   ALENDRONATE; CELLS; SCLEROSTIN; PROTEINS; PATHWAY; DIFFERENTIATION
AB Nitrogen containing bisphosphonates (N BPs) are potent antiresorptive drugs and their actions on osteoclasts have been studied extensively. Recent studies have suggested that N BPs also target bone forming cells. However, the precise mechanism of N BPs in osteoblasts is paradoxical, and the specific role of osteocytes is worthy of in depth study. Here, we investigated the cellular mechanisms of N BPs regulating bone defect healing by zoledronate (ZA). Bone histomorphometry confirmed an increase in new bone formation by systemic ZA administration. ZA induced more alkaline phosphatase positive osteoblasts and tartrate resistant acid phosphatase positive osteoclasts residing on the bone surface. Inexplicably, ZA increased SOST expression in osteocytes embedded in the bone matrix, which was not compatible with the intense osteoblast activity on the bone surface. ZA induced heterogeneous osteocytes and disturbed the distribution of the osteocytic canalicular system (OLCS). Furthermore, according to the degree of OLCS regularity, dentin matrix protein 1 reactivity had accumulated around osteocytes in the ZA group, but it was distributed evenly in the OLCS of the control group. The control group showed a dense array of the gap junction protein connexin 43. However, connexin 43 was extremely sparse after ZA administration. In summary, ZA treatment reduces gap junction connections and blocks cellular communication between osteocytes and osteoblasts. Retaining SOST expression in osteocytes leads to activation of the Wnt signaling pathway and subsequent bone formation.
C1 [Cui, Pingping; Liu, Hongrui; Sun, Jing; Sun, Qinfeng; Li, Minqi] Shandong Univ, Dept Bone Metab, Shandong Prov Key Lab Oral Tissue Regenerat, Sch Stomatol, Wenhua West Rd 44 1, Jinan 250012, Shandong, Peoples R China.
   [Amizuka, Norio] Hokkaido Univ, Grad Sch Dent Med, Dept Dev Biol Hard Tissue, Sapporo, Hokkaido, Japan.
C3 Shandong University; Hokkaido University
RP Li, MQ (通讯作者)，Shandong Univ, Dept Bone Metab, Shandong Prov Key Lab Oral Tissue Regenerat, Sch Stomatol, Wenhua West Rd 44 1, Jinan 250012, Shandong, Peoples R China.; Sun, QF (通讯作者)，Shandong Univ, Sch Stomatol, Shandong Prov Key Lab Oral Tissue Regenerat, Wenhua West Rd 44 1, Jinan 250012, Shandong, Peoples R China.
EM sunqinfeng@sdu.edu.cn; liminqi@sdu.edu.cn
RI Amizuka, Norio/G 1397 2012
FU National Nature Science Foundation of China [81271965, 81470719,
   81611140133]; Construction Engineering Special Fund of "Taishan
   Scholars" [Ts201511106]
FX This study was partially supported by the National Nature Science
   Foundation of China (Grant Nos. 81271965; 81470719; 81611140133) to Li M
   and the Construction Engineering Special Fund of "Taishan Scholars" (No.
   Ts201511106) to Xu X.
CR Giuliani N, 1998, Minerva Med, V89, P249
   Günes N, 2016, EXP THER MED, V12, P2417, DOI 10.3892/etm.2016.3685
   Hirose S, 2007, J BONE MINER METAB, V25, P374, DOI 10.1007/s00774 007 0764 x
   Itoh F, 2003, EUR J PHARMACOL, V477, P9, DOI 10.1016/j.ejphar.2003.08.011
   Iwata K, 2006, BONE, V39, P1053, DOI 10.1016/j.bone.2006.05.006
   John GR, 1999, P NATL ACAD SCI USA, V96, P11613, DOI 10.1073/pnas.96.20.11613
   Lezcano V, 2014, EXP CELL RES, V324, P30, DOI 10.1016/j.yexcr.2014.03.016
   Li MQ, 2013, HISTOL HISTOPATHOL, V28, P327, DOI 10.14670/HH 28.327
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Lindtner RA, 2014, OSTEOPOROSIS INT, V25, P1151, DOI 10.1007/s00198 013 2494 3
   Liu HR, 2015, J MOL HISTOL, V46, P313, DOI 10.1007/s10735 015 9620 9
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mardas N, 2017, CLIN ORAL IMPLAN RES, V28, P362, DOI 10.1111/clr.12810
   Masuki H, 2010, BIOMED RES TOKYO, V31, P307, DOI 10.2220/biomedres.31.307
   Oda K, 1999, J BIOCHEM, V126, P694, DOI 10.1093/oxfordjournals.jbchem.a022505
   Palokangas H, 1997, J CELL SCI, V110, P1767
   Phillips AM, 2005, INJURY, V36, P5, DOI 10.1016/j.injury.2005.07.027
   Plotkin LI, 2001, CELL COMMUN ADHES, V8, P377, DOI 10.3109/15419060109080757
   Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200
   Rabelo GD, 2015, ARCH ENDOCRIN METAB, V59, P507, DOI 10.1590/2359 3997000000097
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Rochefort GY, 2010, OSTEOPOROSIS INT, V21, P1457, DOI 10.1007/s00198 010 1194 5
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Sasaki M, 2013, BONE, V57, P206, DOI 10.1016/j.bone.2013.08.008
   Shapiro F, 1997, CALCIFIED TISSUE INT, V61, P285, DOI 10.1007/s002239900337
   Stains JP, 2014, CALCIFIED TISSUE INT, V94, P55, DOI 10.1007/s00223 013 9742 6
   Stains JP, 2005, BBA BIOMEMBRANES, V1719, P69, DOI 10.1016/j.bbamem.2005.10.012
   Tanaka T, 2010, J BIOMED MATER RES A, V93A, P469, DOI 10.1002/jbm.a.32560
   Tanzer M, 2005, CLIN ORTHOP RELAT R, P30, DOI 10.1097/01.blo.0000194728.62996.2d
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Toker H, 2012, ORAL SURG ORAL MED S, V114, P146
   Toyosawa S, 2001, J BONE MINER RES, V16, P2017, DOI 10.1359/jbmr.2001.16.11.2017
   Tsuboi K, 2016, HISTOCHEM CELL BIOL, V146, P337, DOI 10.1007/s00418 016 1450 7
   Ubaidus S, 2009, J ELECTRON MICROSC, V58, P381, DOI 10.1093/jmicro/dfp032
   WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021 9290(94)90010 8
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Yao W, 2008, ARTHRITIS RHEUM, V58, P3485, DOI 10.1002/art.23954
   Yu YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031771
NR 40
TC 10
Z9 10
U1 0
U2 20
PU F HERNANDEZ
PI MURCIA
PA PLAZA FUENSANTA 2 7 C, 30008 MURCIA, SPAIN
SN 0213 3911
EI 1699 5848
J9 HISTOL HISTOPATHOL
JI Histol. Histopath.
PD JAN
PY 2018
VL 33
IS 1
BP 89
EP 99
DI 10.14670/HH 11 893
PG 11
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Pathology
GA FO5OJ
UT WOS:000416909400009
PM 28345127
DA 2025 08 17
ER

PT J
AU Deal, C
AF Deal, Chad
TI Emerging Therapies for Osteoporosis
SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
LA English
DT Article
DE Cathepsin K; Sclerostin; Osteoporosis; Serotonin; Wnt signaling
ID HEALTHY POSTMENOPAUSAL WOMEN; PARATHYROID HORMONE 1 34; BONE MINERAL
   DENSITY; CATHEPSIN K; NITRIC OXIDE; RANDOMIZED TRIAL; RESORPTION;
   FRACTURES; SEROTONIN; GLP 2
AB This article reviews the conceptual framework for agents that are antiresorptive or anabolic, including pathways that affect bone formation and resorption, and the steps in those pathways that are targets for new therapeutic agents. This article discusses novel antiresorptive and anabolic agents in development. Recent developments that link bone remodeling with serotonin in the gastrointestinal system and the central nervous system via the sympathetic nervous system may change the paradigm for skeletal remodeling. Novel anabolic agents in development include antibodies that target molecules involved in Wnt signaling.
C1 [Deal, Chad] Ctr Osteoporosis & Metab Bone Dis, Orthoped & Rheumatol Inst, Dept Rheumatol, Cleveland, OH USA.
   [Deal, Chad] Case Western Reserve Univ, Clin Lerner Coll Med, Cleveland Clin, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation; University System of Ohio; Case Western
   Reserve University
RP Deal, C (通讯作者)，Ctr Osteoporosis & Metab Bone Dis, Orthoped & Rheumatol Inst, Dept Rheumatol, Cleveland, OH USA.
EM dealc@ccf.org
CR Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bauer DC, 2011, J BONE MINER RES, V26, P239, DOI 10.1002/jbmr.335
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Brown E. M., 2007, V45, P139
   Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104
   Del Fattore A, 2006, J MED GENET, V43, P315, DOI 10.1136/jmg.2005.036673
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Gardner JC, 2005, J CLIN ENDOCR METAB, V90, P6392, DOI 10.1210/jc.2005 1235
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Glass DA, 2007, ENDOCRINOLOGY, V148, P2630, DOI 10.1210/en.2006 1372
   Henriksen D, 2007, J BONE MINER RES, V22, pS37
   Henriksen DB, 2008, J BONE MINER RES, V23, pS474
   Henriksen DB, 2007, BONE, V40, P723, DOI 10.1016/j.bone.2006.09.025
   Horwitz MJ, 2010, J CLIN ENDOCR METAB, V95, P1279, DOI 10.1210/jc.2009 0233
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002 021122
   Jamal S, 2010, J BONE MINER RES, V25, pS77
   Jamal SA, 2004, J BONE MINER RES, V19, P1512, DOI 10.1359/JBMR.040716
   Jamal SA, 2011, JAMA J AM MED ASSOC, V305, P800, DOI 10.1001/jama.2011.176
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Kogianni Giolanta, 2007, Curr Osteoporos Rep, V5, P81
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Padhi D, 2007, J BONE MINER RES, V22, pS37
   Pouwels S, 2010, J CLIN ENDOCR METAB, V95, P1924, DOI 10.1210/jc.2009 2342
   Richards JB, 2007, ARCH INTERN MED, V167, P188, DOI 10.1001/archinte.167.2.188
   Rosen CJ, 2009, NAT REV RHEUMATOL, V5, P657, DOI 10.1038/nrrheum.2009.231
   Rosen CJ, 2009, NEW ENGL J MED, V360, P957, DOI 10.1056/NEJMp0810058
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Stoch SA, 2008, CLIN PHARMACOL THER, V83, P172, DOI 10.1038/sj.clpt.6100450
   Subbiah V, 2010, OSTEOPOROSIS INT, V21, P1041, DOI 10.1007/s00198 009 1004 0
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vasiljeva O, 2007, CURR PHARM DESIGN, V13, P387, DOI 10.2174/138161207780162962
   Williams BO, 2009, J BONE MINER RES, V24, P171, DOI [10.1359/JBMR.081235, 10.1359/jbmr.081235]
   Wimalawansa SJ, 2008, EXPERT OPIN PHARMACO, V9, P1935, DOI 10.1517/14656566.9.11.1935 
   Wimalawansa SJ, 2007, ANN NY ACAD SCI, V1117, P283, DOI 10.1196/annals.1402.066
   Wimalawansa SJ, 2010, ANN NY ACAD SCI, V1192, P391, DOI 10.1111/j.1749 6632.2009.05230.x
   Wimalawansa SJ, 2009, J CLIN ENDOCR METAB, V94, P3356, DOI 10.1210/jc.2008 2225
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
NR 42
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0889 857X
EI 1558 3163
J9 RHEUM DIS CLIN N AM
JI Rheum. Dis. Clin. North Am.
PD AUG
PY 2011
VL 37
IS 3
BP 337
EP +
DI 10.1016/j.rdc.2011.07.006
PG 15
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 853PU
UT WOS:000297439000003
PM 22023895
DA 2025 08 17
ER

PT J
AU Bishr, M
   Saad, F
AF Bishr, Mohamed
   Saad, Fred
TI Preventing bone complications in prostate cancer
SO CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE
LA English
DT Article
DE bisphosphonates; bone complications; denosumab; prostate cancer
ID ANDROGEN DEPRIVATION THERAPY; LONG TERM; ZOLEDRONIC ACID; MINERAL
   DENSITY; MEN; SURVIVAL; BISPHOSPHONATES; OSTEONECROSIS; OSTEOPOROSIS;
   GUIDELINES
AB Purpose of review
   Bone metastases alone or in combination with androgen deprivation therapy related bone loss places prostate cancer patients at greater risk for skeletal morbidities, including pain, pathologic fracture and spinal cord compression. These events significantly impair the patient's quality of life and place a significant burden on health care resources.
   Recent findings
   This review focuses on the management options for reducing skeletal morbidity in patients with prostate cancer, including life style modifications, food supplementation, osteoclast targeted therapy and selective estrogen receptor modulators.
   Summary
   The use of osteoclast targeted therapy (denosumab and zoledronic acid) is supported by the strongest evidence and has been US Food and Drug Administration approved for the treatment of patients with PCa at high risk of osteoporotic fractures and for the reduction of the risk of skeletal related events in patients with castration resistant prostate cancer. Ongoing trials are studying the potential role of osteoclast targeted therapy in other settings throughout the course of the disease.
C1 [Bishr, Mohamed; Saad, Fred] Ctr Hosp Univ Montreal, Ctr Rech, Montreal, PQ H2L 4M1, Canada.
   [Bishr, Mohamed; Saad, Fred] Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada.
   [Bishr, Mohamed] Theodor Bilharz Res Inst, Cairo, Egypt.
   [Saad, Fred] Univ Montreal, Dept Surg, CHUM, Montreal, PQ, Canada.
C3 Universite de Montreal; Universite de Montreal; Egyptian Knowledge Bank
   (EKB); Theodor Bilharz Research Institute (TBRI); Universite de Montreal
RP Saad, F (通讯作者)，Ctr Hosp Univ Montreal, Urol Oncol Dept Surg, 1560 Sherbrooke East, Montreal, PQ H2L 4M1, Canada.
EM fred.saad@umontreal.ca
RI Saad, Fred/ADN 9925 2022
FU Novartis; Amgen
FX Fred Saad serves as an advisor to Novartis, Amgen and Bayer and has
   received research funding from Novartis and Amgen.
CR Antonarakis ES, 2007, J CLIN ONCOL, V25, P4998, DOI 10.1200/JCO.2007.11.1559
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown JP, 2002, CAN MED ASSOC J, V167, pS1
   Conte P, 2004, ONCOLOGIST, V9, P28, DOI 10.1634/theoncologist.9 90004 28
   Dearnaley DP, 2009, LANCET ONCOL, V10, P872, DOI 10.1016/S1470 2045(09)70201 3
   Egerdie B, 2010, CUAJ CAN UROL ASSOC, V4, P129
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Gansler T, 2010, CA CANCER J CLIN, V60, P1, DOI [10.3322/caac.20049, 10.3322/caac.20073]
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Morote J, 2007, UROLOGY, V69, P500, DOI 10.1016/j.urology.2006.11.002
   Planas J, 2007, BJU INT, V99, P812, DOI 10.1111/j.1464 410X.2006.06695.x
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Ruggiero S, 2006, J ONCOL PRACT, V2, P7, DOI 10.1200/JOP.2.1.7
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Sharifi N, 2005, JAMA J AM MED ASSOC, V294, P238, DOI 10.1001/jama.294.2.238
   Smith MR, 2008, J UROLOGY, V179, P152, DOI 10.1016/j.juro.2007.08.137
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smith MR, 2010, J UROLOGY, V184, P1316, DOI 10.1016/j.juro.2010.06.022
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Smith MR, 2004, J CLIN ENDOCR METAB, V89, P3841, DOI 10.1210/jc.2003 032058
NR 24
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1751 4258
EI 1751 4266
J9 CURR OPIN SUPPORT PA
JI Curr. Opin Support Palliat. Car.
PD SEP
PY 2012
VL 6
IS 3
BP 299
EP 303
DI 10.1097/SPC.0b013e328356da87
PG 5
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services
GA V32OS
UT WOS:000208961100001
PM 22871982
DA 2025 08 17
ER

PT J
AU Delgado Calle, J
   McAndrews, K
   Wu, G
   Orr, AL
   Ferrari, A
   Tu, X
   Srinivasan, V
   Roodman, GD
   Ebetino, FH
   Boeckman, RK
   Bellido, T
AF Delgado Calle, Jesus
   McAndrews, Kevin
   Wu, Gerald
   Orr, Ashley L.
   Ferrari, Adam
   Tu, Xiaolin
   Srinivasan, Venkatesan
   Roodman, G. David
   Ebetino, Frank H.
   Boeckman, Robert K.
   Bellido, Teresita
TI The Notch pathway regulates the bone gain induced by PTH anabolic
   signaling
SO FASEB JOURNAL
LA English
DT Article
DE bone; Notch; osteoblasts; osteoclasts; osteocytes; PTH; resorption
ID PARATHYROID HORMONE; LIGAND JAGGED1; BETA CATENIN; OSTEOCYTES; RECEPTOR;
   GENE; OSTEOPOROSIS; OSTEOBLASTS; ACTIVATION; MECHANISMS
AB Parathyroid hormone (PTH) signaling downstream of the PTH 1 receptor (Pth1r) results in both bone anabolic and catabolic actions by mechanisms not yet fully understood. In this study, we show that Pth1r signaling upregulates the expression of several components of the Notch pathway and that Notch signals contribute to the catabolic actions of PTH in bone. We found that constitutive genetic activation of PTH receptor signaling in osteocytes (caPth1r(Ot)) or treatment with PTH daily increased the expression of several Notch ligands/receptors in bone. In contrast, sustained elevation of endogenous PTH did not change Notch components expression. Deletion of the PTH receptor or sclerostin overexpression in osteocytes abolished Notch increases by PTH. Further, deleting the canonical Notch transcription factor Rbpjk in osteocytes decreased bone mass and increased resorption and Rankl expression in caPth1r(Ot) mice. Moreover, pharmacological bone targeted Notch inhibition potentiated the bone mass gain induced by intermittent PTH by reducing bone resorption and preserving bone formation. Thus, Notch activation lies downstream of anabolic signaling driven by PTH actions in osteocytes, and Notch pharmacological inhibition maximizes the bone anabolic effects of PTH.
C1 [Delgado Calle, Jesus; Bellido, Teresita] Univ Arkansas Med Sci, Dept Physiol & Cell Biol, 4301 W Markham St, Little Rock, AR 72205 USA.
   [Delgado Calle, Jesus; Bellido, Teresita] Univ Arkansas Med Sci, Winthrop P Rockefeller Canc Inst, Little Rock, AR 72205 USA.
   [McAndrews, Kevin; Wu, Gerald; Tu, Xiaolin] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN USA.
   [Orr, Ashley L.; Ferrari, Adam; Roodman, G. David] Univ Rochester, Dept Med, Div Hematol Oncol, Rochester, NY USA.
   [Srinivasan, Venkatesan; Ebetino, Frank H.; Boeckman, Robert K.] Univ Rochester, Dept Chem, Rochester, NY USA.
   [Ebetino, Frank H.] Biovinc LLC, Pasadena, CA USA.
   [Bellido, Teresita] Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   Indiana University System; Indiana University Bloomington; University of
   Rochester; University of Rochester; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Central Arkansas Veterans
   Healthcare System
RP Delgado Calle, J; Bellido, T (通讯作者)，Univ Arkansas Med Sci, Dept Physiol & Cell Biol, 4301 W Markham St, Little Rock, AR 72205 USA.
EM jdelgadocalle@uams.edu; tmbellido@uams.edu
RI Tu, Xiaolin/JAC 9492 2023; Orr, Ashley/HZM 5309 2023; Delgado Calle,
   Jesus/AAG 1417 2020
OI Bellido, Teresita/0000 0002 8203 7004; Tu, Xiaolin/0000 0002 7923 2722
FU HHS \ National Institutes of Health (NIH) [R37 CA251763, R01 AR059357,
   P20GM125503]; U.S. Department of Veterans Affairs (VA) [I01 BX002104,
   IK6BX004596]; National Cancer Institute [R37CA251763] Funding Source:
   NIH RePORTER; National Institute of Arthritis and Musculoskeletal and
   Skin Diseases [R01AR059357] Funding Source: NIH RePORTER
FX HHS vertical bar National Institutes of Health (NIH), Grant/Award
   Number: R37  CA251763, R01  AR059357 and P20GM125503; U.S. Department of
   Veterans Affairs (VA), Grant/Award Number: I01 BX002104 and IK6BX004596
CR Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Bagheri L, 2018, J TISSUE ENG REGEN M, V12, P304, DOI 10.1002/term.2455
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Ben Awadh AN, 2014, ENDOCRINOLOGY, V155, P2797, DOI 10.1210/en.2014 1046
   Bivi N, 2012, CALCIFIED TISSUE INT, V91, P215, DOI 10.1007/s00223 012 9628 z
   Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Canalis E, 2018, OSTEOPOROSIS INT, V29, P2611, DOI 10.1007/s00198 018 4694 3
   Canalis E, 2016, J BIOL CHEM, V191, P1538, DOI 10.1074/jbc.M115.685453
   Canalis E, 2016, AM J PHYSIOL ENDOC M, V310, pE171, DOI 10.1152/ajpendo.00395.2015
   Chakravorty N, 2014, CLIN ORAL IMPLAN RES, V25, P475, DOI 10.1111/clr.12178
   Chen SX, 2015, J BONE MINER RES, V30, P1184, DOI 10.1002/jbmr.2453
   Cosman Felicia, 2005, Curr Osteoporos Rep, V3, P143, DOI 10.1007/s11914 996 0017 2
   Cosman F, 2017, J BONE MINER RES, V32, P198, DOI 10.1002/jbmr.3051
   Delgado Calle J, 2022, PHYSIOL REV, V102, DOI 10.1152/physrev.00043.2020
   Delgado Calle J, 2018, FASEB J, V32, P2878, DOI 10.1096/fj.201700919RRR
   Delgado Calle J, 2017, J BONE MINER RES, V32, P522, DOI 10.1002/jbmr.3011
   Eriksen EF, 2016, BONE, V86, P139, DOI 10.1016/j.bone.2016.02.009
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kode A, 2014, NATURE, V506, P240, DOI 10.1038/nature12883
   Lawal RA, 2017, J BONE MINER RES, V32, P1320, DOI 10.1002/jbmr.3106
   Leder BZ, 2016, BONE, V89, P73, DOI 10.1016/j.bone.2016.04.026
   Li JY, 2019, J BONE MINER RES, V34, P349, DOI 10.1002/jbmr.3600
   Liu P, 2016, P NATL ACAD SCI USA, V113, pE2152, DOI 10.1073/pnas.1603399113
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Manolagas SC, 2018, J BONE MINER RES, V33, P371, DOI 10.1002/jbmr.3400
   Martin TJ, 2021, ENDOCR REV, V42, P383, DOI 10.1210/endrev/bnab005
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Qiu T, 2015, J BONE MINER RES, V30, P309, DOI 10.1002/jbmr.2327
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Sabol HM, 2021, CANCER RES, V81, P5102, DOI 10.1158/0008 5472.CAN 21 0524
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   Weber JM, 2006, BONE, V39, P485, DOI 10.1016/j.bone.2006.03.002
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Yu J, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.101376
   Yu J, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115474
   Zanotti S, 2017, BONE, V103, P159, DOI 10.1016/j.bone.2017.06.027
NR 42
TC 9
Z9 11
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD MAR
PY 2022
VL 36
IS 3
AR e22196
DI 10.1096/fj.202101807R
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA ZH9LM
UT WOS:000761250800004
PM 35137455
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Delgado Calle, J
   Sato, AY
   Bellido, T
AF Delgado Calle, Jesus
   Sato, Amy Y.
   Bellido, Teresita
TI Role and mechanism of action of sclerostin in bone
SO BONE
LA English
DT Article
DE Wnt/beta catenin signaling; Bone formation; Bone resorption; Osteocytes;
   Anabolism; PTH; Glucocorticoids; Multiple myeloma
ID SOST DOWN REGULATION; VAN BUCHEM DISEASE; PARATHYROID HORMONE; SERUM
   SCLEROSTIN; POSTMENOPAUSAL WOMEN; VITAMIN D; CARDIOVASCULAR
   CALCIFICATION; ANTIBODY TREATMENT; TARGETED DELETION; MULTIPLE MYELOMA
AB After discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical studies demonstrated that sclerostin plays a critical role in bone homeostasis and that its deficiency or pharmacological neutralization increases bone formation. Dysregulation of sclerostin expression also underlies the pathophysiology of skeletal disorders characterized by loss of bone mass, as well as the damaging effects of some cancers in bone. Thus, sclerostin has quickly become a promising molecular target for the treatment of osteoporosis and other skeletal diseases, and beneficial skeletal outcomes are observed in animal studies and clinical trials using neutralizing antibodies against sclerostin. However, the anabolic effect of blocking sclerostin decreases with time, bone mass accrual is also accompanied by anti catabolic effects, and there is bone loss over time after therapy discontinuation. Further, the cellular source of sclerostin in the bone/bone marrow microenvironment under physiological and pathological conditions, the pathways that regulate sclerostin expression and the mechanisms by which sclerostin modulates the activity of osteocytes, osteoblasts, and osteoclasts remain unclear. In this review, we highlight the current knowledge on the regulation of Sost/sclerotin expression and its mechanism(s) of action, discuss novel observations regarding its role in signaling pathways activated by hormones and mechanical stimuli in bone, and propose future research needed to understand the full potential of therapeutic interventions that modulate Sost/sclerostin expression. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Delgado Calle, Jesus; Sato, Amy Y.; Bellido, Teresita] Dept Anat & Cell Biol, Indianapolis, IN USA.
   [Bellido, Teresita] Indiana Univ Sch Med, Dept Med, Div Endocrinol, Indianapolis, IN 46202 USA.
   [Delgado Calle, Jesus; Bellido, Teresita] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN USA.
C3 Indiana University System; Indiana University Bloomington; US Department
   of Veterans Affairs; Veterans Health Administration (VHA); Richard L.
   Roudebush VA Medical Center
RP Bellido, T (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, Dept Internal Med, Endocrinol, 635 Barnhill Dr,MS5045A, Indianapolis, IN 46202 USA.
EM jedelgad@iupui.edu; aysato@iupui.edu; tbellido@iupui.edu
RI Delgado Calle, Jesus/AAG 1417 2020
OI Sato, Amy/0000 0001 5061 1369; Bellido, Teresita/0000 0002 8203 7004
FU National Institutes of Health [R01 DK076007, R01 AR059357, S10 RR023710,
   T32  AR065971]; Veteran's Administration [BX002104 01]; American Society
   of Hematology Scholar Award
FX This work was supported by the National Institutes of Health (R01
   DK076007, R01 AR059357, and S10 RR023710 to TB; and T32  AR065971 to
   AYS), the Veteran's Administration (BX002104 01 to TB), and the American
   Society of Hematology Scholar Award (to JDC).
CR AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304
   Acibucu F., 2016, EXP CLIN ENDOCRINOL
   Amrein K, 2012, J CLIN ENDOCR METAB, V97, P148, DOI 10.1210/jc.2011 2152
   Appelman Dijkstra NM, 2016, CALCIFIED TISSUE INT, V98, P370, DOI 10.1007/s00223 016 0126 6
   Ardawi MSM, 2012, J BONE MINER RES, V27, P2592, DOI 10.1002/jbmr.1718
   Baertschi S, 2014, J BIOL CHEM, V289, P24995, DOI 10.1074/jbc.M114.564997
   Balemans W, 1999, AM J HUM GENET, V64, P1661, DOI 10.1086/302416
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bellido T, 2013, BONE, V54, P250, DOI 10.1016/j.bone.2012.09.016
   Ben Awadh AN, 2014, ENDOCRINOLOGY, V155, P2797, DOI 10.1210/en.2014 1046
   Bhat S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027475
   Bonnet N, 2009, J BIOL CHEM, V284, P35939, DOI 10.1074/jbc.M109.060335
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Brandenburg VM, 2013, BMC NEPHROL, V14, DOI 10.1186/1471 2369 14 219
   Brunetti G, 2011, ANN NY ACAD SCI, V1237, P19, DOI 10.1111/j.1749 6632.2011.06196.x
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Cain CJ, 2012, J BONE MINER RES, V27, P1451, DOI 10.1002/jbmr.1608
   Chang MK, 2014, P NATL ACAD SCI USA, V111, pE5187, DOI 10.1073/pnas.1413828111
   Choi HY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007930
   Cidem M, 2015, RHEUMATOL INT, V35, P1739, DOI 10.1007/s00296 015 3294 1
   Clarke Bart L, 2013, Bonekey Rep, V2, P361, DOI 10.1038/bonekey.2013.95
   Cohen Kfir E, 2011, ENDOCRINOLOGY, V152, P4514, DOI 10.1210/en.2011 1128
   Collette NM, 2012, P NATL ACAD SCI USA, V109, P14092, DOI 10.1073/pnas.1207188109
   Colucci S, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.22
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   Dawson Hughes B, 2014, EUR J ENDOCRINOL, V170, P645, DOI 10.1530/EJE 13 0862
   Delgado Calle J., 2016, J BONE MINER RES, V2016
   Delgado Calle J., 2016, J BONE MINER RES  S1, V1, pS30
   Delgado Calle J, 2016, CANCER RES, V76, P1089, DOI 10.1158/0008 5472.CAN 15 1703
   Delgado Calle Jesus, 2012, Biology (Basel), V1, P698, DOI 10.3390/biology1030698
   Delgado Calle J, 2014, CALCIFIED TISSUE INT, V94, P414, DOI 10.1007/s00223 013 9821 8
   Delgado Calle J, 2013, MOL CELL ENDOCRINOL, V369, P27, DOI 10.1016/j.mce.2013.02.002
   Delgado Calle J, 2012, J BONE MINER RES, V27, P926, DOI 10.1002/jbmr.1491
   Delgado Calle J, 2011, CALCIFIED TISSUE INT, V89, P327, DOI 10.1007/s00223 011 9522 0
   Devarajan Ketha H, 2012, BIOCHEM BIOPH RES CO, V417, P830, DOI 10.1016/j.bbrc.2011.12.048
   Di Nisio A, 2015, ENDOCRINOLOGY, V156, P4534, DOI 10.1210/en.2015 1244
   DIXON JM, 1982, J NEUROL NEUROSUR PS, V45, P913, DOI 10.1136/jnnp.45.10.913
   Eda H, 2016, J BONE MINER RES, V31, P1225, DOI 10.1002/jbmr.2789
   Fijalkowski I, 2016, J BONE MINER RES
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   FOGH J, 1975, HUMAN TUMOR CELLS IN, P115, DOI [DOI 10.1007/978 1 4757 1647 45, DOI 10.1007/978 1 4757 1647 4_5, 10.1007/978 1 4757 1647 45]
   FROST HM, 1987, BONE MINER, V2, P73
   Fujiwara M, 2016, BONE, V85, P91, DOI 10.1016/j.bone.2016.01.024
   Galea GL, 2011, FEBS LETT, V585, P2450, DOI 10.1016/j.febslet.2011.06.019
   García Fontana B, 2014, OSTEOPOROSIS INT, V25, P645, DOI 10.1007/s00198 013 2462 y
   Genetos D. C., 2010, J CELL BIOCHEM, V110, P87
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gori F, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.36
   Greenberg AJ, 2014, LEUKEMIA, V28, P398, DOI 10.1038/leu.2013.258
   Hassler N, 2014, J BONE MINER RES, V29, P2144, DOI 10.1002/jbmr.2259
   Hernandez P, 2014, BIOCHEM BIOPH RES CO, V446, P1108, DOI 10.1016/j.bbrc.2014.03.079
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Irie K, 2008, J HISTOCHEM CYTOCHEM, V56, P561, DOI 10.1369/jhc.2008.950527
   Jäger A, 2010, J PERIODONTAL RES, V45, P246, DOI 10.1111/j.1600 0765.2009.01227.x
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kato Y, 2001, J BONE MINER RES, V16, P1622, DOI 10.1359/jbmr.2001.16.9.1622
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kim RY, 2015, TISSUE ENG PT A, V21, P2076, DOI [10.1089/ten.tea.2014.0585, 10.1089/ten.TEA.2014.0585]
   Kim SJ, 2011, HUM GENET, V129, P497, DOI 10.1007/s00439 011 0947 3
   Klangjareonchai T, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/261545
   Koos R, 2013, J HEART VALVE DIS, V22, P317
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Kramer I, 2010, J BONE MINER RES, V25, P178, DOI 10.1359/jbmr.090730
   Kumar S, 2004, METH MOL B, V282, P19
   Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Loots GG, 2012, BONE, V50, P663, DOI 10.1016/j.bone.2011.11.016
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Marenzana M, 2011, ARTHRITIS RHEUM US, V63, P2385, DOI 10.1002/art.30385
   Maycas M., 2016, J BONE MINER RES
   McClung MR, 2015, ENDOCRINOL METAB, V30, P429, DOI 10.3803/EnM.2015.30.4.429
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Mendoza Villanueva D, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3048
   Moe SM, 2015, J BONE MINER RES, V30, P539, DOI 10.1002/jbmr.2372
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Niziolek PJ, 2015, J BONE MINER RES, V30, P1822, DOI 10.1002/jbmr.2514
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Ota K, 2013, J CELL BIOCHEM, V114, P1901, DOI 10.1002/jcb.24537
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Perez Campo F. M., 2016, J BONE MINER METAB
   Pirgon O, 2016, J PEDIATR ENDOCR MET, V29, P401, DOI 10.1515/jpem 2015 0222
   Plotkin LI, 2016, NAT REV ENDOCRINOL
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   RAO LG, 1994, ENDOCRINOLOGY, V134, P614, DOI 10.1210/en.134.2.614
   Reagan MR, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.119.119
   Recknor CP, 2015, J BONE MINER RES, V30, P1717, DOI 10.1002/jbmr.2489
   Rhee Y, 2013, J BIOL CHEM, V288, P29809, DOI 10.1074/jbc.M113.485938
   Rhee Y, 2011, J BONE MINER RES, V26, P1035, DOI 10.1002/jbmr.304
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Robling AG, 2011, ENDOCRINOLOGY, V152, P2963, DOI 10.1210/en.2011 0049
   Roforth MM, 2014, BONE, V59, P1, DOI 10.1016/j.bone.2013.10.019
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Roudier M, 2013, ARTHRITIS RHEUM US, V65, P721, DOI 10.1002/art.37802
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Sato A. Y., 2016, J BONE MINER RES
   Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140
   Spatz JM, 2015, J BIOL CHEM, V290, P16744, DOI 10.1074/jbc.M114.628313
   St John H. C., 2015, J STEROID BIOCHEM, P30063
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   Stolina M, 2014, BONE, V67, P305, DOI 10.1016/j.bone.2014.07.031
   Tanaka KI, 2015, BIOCHEM BIOPH RES CO, V461, P193, DOI 10.1016/j.bbrc.2015.02.091
   Terpos E, 2012, INT J CANCER, V131, P1466, DOI 10.1002/ijc.27342
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Ukita M, 2016, J CELL BIOCHEM, V117, P1419, DOI 10.1002/jcb.25432
   Urano T, 2012, J CLIN ENDOCR METAB, V97, pE1473, DOI 10.1210/jc.2012 1218
   van Bezooijen RL, 2009, J DENT RES, V88, P569, DOI 10.1177/0022034509338340
   van Lierop AHJM, 2010, J BONE MINER RES, V25, P2520, DOI 10.1002/jbmr.151
   Vincent C, 2009, J BONE MINER RES, V24, P1434, DOI [10.1359/JBMR.090305, 10.1359/jbmr.090305]
   Walker EC, 2010, J CLIN INVEST, V120, P582, DOI 10.1172/JCI40568
   WANG QR, 1990, EXP HEMATOL, V18, P355
   Warriner AH, 2013, CURR OPIN ENDOCRINOL, V20, P510, DOI 10.1097/01.med.0000436249.84273.7b
   Wehmeyer C, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aac4351
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Wijenayaka A. R., 2015, J STEROID BIOCHEM, P30152
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Yang F, 2010, BIOCHEM BIOPH RES CO, V400, P684, DOI 10.1016/j.bbrc.2010.08.128
   Yao W, 2016, OSTEOPOROSIS INT, V27, P283, DOI 10.1007/s00198 015 3308 6
   Zhang DD, 2016, BIOCHEM BIOPH RES CO, V472, P471, DOI 10.1016/j.bbrc.2016.01.178
NR 132
TC 323
Z9 361
U1 5
U2 106
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2017
VL 96
BP 29
EP 37
DI 10.1016/j.bone.2016.10.007
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EN2OR
UT WOS:000395850300006
PM 27742498
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Russell, RGG
   Espina, B
   Hulley, P
AF Russell, R. Graham G.
   Espina, Belen
   Hulley, Philippa
TI Bone biology and the pathogenesis of osteoporosis
SO CURRENT OPINION IN RHEUMATOLOGY
LA English
DT Article; Proceedings Paper
CT World Congress of the International Osteoporosis Foundation on
   Osteoporosis
CY JUN 02 06, 2006
CL Toronto, CANADA
SP Int Osteoporosis Fdn
DE ageing; bone; osteoblasts; osteoclasts; osteoporosis
ID PARATHYROID HORMONE; OSTEOCYTES; SCLEROSTIN; MUTATION; DENSITY; WOMEN
AB Much is now known about skeletal biology and the changes that take place during diseases. Skeletal development is programmed by the sequential activation of specific genetic pathways that culminate in the production of the adult skeleton, which is light but strong. Systemic hormones including parathyroid hormone, vitamin D metabolites, and calcitonin regulate blood calcium levels and contribute to the overall calcium economy of the body. Many other hormones have subtle but important effects on skeletal behaviour and its modelling and remodelling activity. At a local level, the integration of cellular differentiation and function within the microenvironment of bone is under the influence of a large number of cytokines and growth factors. Osteoporosis is a very common disorder and is a result of perturbation in these regulatory mechanisms. Much has been learnt in recent years about the many pathogenic processes that contribute to bone loss and fragility. Several drug treatments are now available to prevent bone loss and reduce the incidence of fractures, and there are prospects for the development of further novel pharmacological interventions that may modify some of the pathogenic processes themselves. Among the newer pathways for pharmacological intervention, the calcium sensing receptor and the receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system involved in osteoblast osteoclast interactions offer exciting opportunities.
C1 Botnar Res Ctr, Oxford OX3 7LD, England.
   Univ Oxford, Inst Musculoskeletal Sci, Nuffield Dept Orthopaed Surg, Nuffield Orthopaed Ctr, Oxford OX3 7LD, England.
C3 University of Oxford; Nuffield Orthopaedic Centre; University of Oxford
RP Russell, RGG (通讯作者)，Botnar Res Ctr, Oxford OX3 7LD, England.
EM graham.russell@ndos.ox.ac.uk
RI Russell, R/JEF 5877 2023; Russell, Robert Graham G/JEF 5877 2023;
   Hulley, Philippa/A 8538 2011
OI Russell, Robert Graham G/0000 0002 4136 1828; Hulley,
   Philippa/0000 0002 4994 2264
CR Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Boonen S, 2004, J AM GERIATR SOC, V52, P1832, DOI 10.1111/j.1532 5415.2004.52506.x
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cooper C, 2006, OSTEOPOROSIS INT, V17, P337, DOI 10.1007/s00198 005 2039 5
   Horton WA, 2006, AM J MED GENET A, V140A, P166, DOI 10.1002/ajmg.a.31029
   Kobayashi T, 2005, ENDOCRINOLOGY, V146, P1012, DOI 10.1210/en.2004 1343
   Kronenberg H. M., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P348
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Lazner F, 1999, HUM MOL GENET, V8, P1839, DOI 10.1093/hmg/8.10.1839
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Meunier PJ, 2002, J CLIN ENDOCR METAB, V87, P2060, DOI 10.1210/jc.87.5.2060
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Power J, 2001, CALCIFIED TISSUE INT, V69, P13, DOI 10.1007/s00223 001 0013 6
   Ralston SH, 2002, J CLIN ENDOCR METAB, V87, P2460, DOI 10.1210/jc.87.6.2460
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   RUSSELL RGG, 2006, IN PRESS ANN NY ACAD
   Russell RGG., 2003, Rheumatology, V3rd, P2075
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
NR 24
TC 33
Z9 39
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040 8711
EI 1531 6963
J9 CURR OPIN RHEUMATOL
JI Curr. Opin. Rheumatol.
PD JUN
PY 2006
VL 18
SU 1
BP S3
EP S10
DI 10.1097/01.bor.0000229521.95384.7d
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Rheumatology
GA 066KV
UT WOS:000239229200002
PM 16735843
DA 2025 08 17
ER

PT J
AU Coelho, RM
   Lemos, JM
   Alho, I
   Valério, D
   Ferreira, AR
   Costa, L
   Vinga, S
AF Coelho, Rui Moura
   Lemos, Joao Miranda
   Alho, Irina
   Valerio, Duarte
   Ferreira, Arlindo R.
   Costa, Luis
   Vinga, Susana
TI Dynamic modeling of bone metastasis, microenvironment and therapy
   Integrating parathyroid hormone (PTH) effect, anti resorptive and
   anti cancer therapy
SO JOURNAL OF THEORETICAL BIOLOGY
LA English
DT Article
DE Bone remodeling; Bone metastasis; Systems biomedicine
ID MATHEMATICAL MODEL; PROSTATE CANCER; BREAST CANCER; MECHANISMS;
   SKELETON; PREDICTS
AB Bone is a common site for the development of metastasis, as its microenvironment provides the necessary conditions for the growth and proliferation of cancer cells. Several mathematical models to describe the bone remodeling process and how osteoclasts and osteoblasts coupled action ensures bone homeostasis have been proposed and further extended to include the effect of cancer cells. The model proposed here includes the influence of the parathyroid hormone (PTH) as capable of triggering and regulating the bone remodeling cycle. It also considers the secretion of PTH related protein (PTHrP) by cancer cells, which stimulates the production of receptor activator of nuclear factor kappa B ligand (RANKL) by osteoblasts that activates osteoclasts, increasing bone resorption and the subsequent release of growth factors entrapped in the bone matrix, which induce tumor growth, giving rise to a self perpetuating cycle known as the vicious cycle of bone metastases. The model additionally describes how the presence of metastases contributes to the decoupling between bone resorption and formation. Moreover, the effects of anti cancer and anti resorptive treatments, through chemotherapy and the administration of bisphosphonates or denosumab, are also included, along with their corresponding pharmacokinetics (PK) and pharmacodynamics (PD). The simulated models, available at http://sels.tecnico.ulisboa.pt/software/, are able to describe bone remodeling cycles, the growth of bone metastases and how treatment can effectively reduce tumor burden on bone and prevent loss of bone strength. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Coelho, Rui Moura; Valerio, Duarte; Vinga, Susana] Univ Lisbon, Inst Super Tecn, IDMEC, Av Rovisco Pais 1, P 1049001 Lisbon, Portugal.
   [Lemos, Joao Miranda] Univ Lisbon, Inst Super Tecn, INESC ID, Rua Alves Redol 9, P 1000029 Lisbon, Portugal.
   [Alho, Irina; Ferreira, Arlindo R.; Costa, Luis] Univ Lisbon, Fac Med, Inst Med Mol, Av Prof Egos Moniz, P 1649028 Lisbon, Portugal.
   [Ferreira, Arlindo R.; Costa, Luis] Hosp Santa Maria, Av Prof Egas Moniz, P 1649035 Lisbon, Portugal.
C3 Universidade de Lisboa; Universidade de Lisboa; INESC ID; Universidade
   de Lisboa; Universidade de Lisboa; Hospital Santa Maria
RP Vinga, S (通讯作者)，Univ Lisbon, Inst Super Tecn, IDMEC, Av Rovisco Pais 1, P 1049001 Lisbon, Portugal.
EM rui.coelho@tecnico.ulisboa.pt; jlml@inesc id.pt;
   ialho@medicina.ulisboa.pt; duarte.valerio@tecnico.ulisboa.pt;
   ajrsferreira@gmail.com; luiscosta.oncology@gmail.com;
   susanavinga@tecnico.ulisboa.pt
RI Ferreira, Arlindo/AAD 6340 2020; Vinga, Susana/B 8450 2008; Alho Duarte,
   Irina/ISU 0382 2023; Lemos, J./B 2754 2008; Coelho, Rui/AAE 1255 2020;
   Costa, Luis/E 5117 2015; Valério, Duarte/C 9339 2012; Valerio,
   Duarte/C 9339 2012
OI Vinga, Susana/0000 0002 1954 5487; Costa, Luis/0000 0002 4782 7318;
   Moura Coelho, Rui/0000 0002 0301 8877; Ferreira,
   Arlindo/0000 0002 1567 9322; Valerio, Duarte/0000 0001 9388 4308
FU FCT, through IDMEC [UID/EMS/50022/2013, EXPL/EMS SIS/1954/2013,
   PTDC/EMS SIS/0642/2014, UID/CEC/5002/2013]; FCT   European Social Fund
   (ESF) through the Operational Program Human Potential (POPH)
   [IF/00653/2012]
FX This work was supported by FCT, through IDMEC, under LAETA projects
   UID/EMS/50022/2013, BoneSys, CancerSys (EXPL/EMS SIS/1954/2013),
   PERSEIDS (PTDC/EMS SIS/0642/2014), INESC ID UID/CEC/5002/2013 and
   COMPETE. SV acknowledges support by Program Investigador FCT
   (IF/00653/2012) from FCT, co funded by the European Social Fund (ESF)
   through the Operational Program Human Potential (POPH).
CR Araujo A, 2014, CANCER RES, V74, P2391, DOI 10.1158/0008 5472.CAN 13 2652
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   Boyce B. F., 2012, HDB CANC RELATED BON, P3
   Buenzli PR, 2011, BONE, V48, P918, DOI 10.1016/j.bone.2010.12.009
   Casimiro S, 2009, MOL CELL ENDOCRINOL, V310, P71, DOI 10.1016/j.mce.2009.07.004
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Dhillon S., 2006, CLIN PHARMACOKINET
   Gibiansky Leonid, 2012, Clin Pharmacokinet, V51, P247, DOI 10.2165/11598090 000000000 00000
   Haden ST, 2000, CLIN ENDOCRINOL, V52, P329, DOI 10.1046/j.1365 2265.2000.00912.x
   Hofbauer LC, 2014, LANCET DIABETES ENDO, V2, P500, DOI 10.1016/S2213 8587(13)70203 1
   Komarova SV, 2005, ENDOCRINOLOGY, V146, P3589, DOI 10.1210/en.2004 1642
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Makatsoris T, 2009, CANCER METAST BIOL T, V12, P287, DOI 10.1007/978 1 4020 9819 2_14
   Moulopoulos L.A., 2014, BONE MARROW MRI PATT, V17
   Mundy GR, 2008, J AM SOC NEPHROL, V19, P672, DOI 10.1681/ASN.2007090981
   Perez EA, 2001, J CLIN ONCOL, V19, P4216, DOI 10.1200/JCO.2001.19.22.4216
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Ryser MD, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002703
   Ryser MD, 2010, SIAM J APPL MATH, V70, P1899, DOI 10.1137/090746094
   Ryser MD, 2009, J BONE MINER RES, V24, P860, DOI 10.1359/JBMR.081229
   SAVAGEAU MA, 1988, MATH COMPUT MODEL, V11, P546, DOI 10.1016/0895 7177(88)90553 5
   Scheiner S, 2014, INT J NUMER METH BIO, V30, P1, DOI 10.1002/cnm.2584
   Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004 1211
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Voorzanger Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   Wang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027494
   Zumsande M, 2011, BONE, V48, P910, DOI 10.1016/j.bone.2010.12.010
NR 32
TC 18
Z9 19
U1 0
U2 19
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022 5193
EI 1095 8541
J9 J THEOR BIOL
JI J. Theor. Biol.
PD FEB
PY 2016
VL 391
BP 1
EP 12
DI 10.1016/j.jtbi.2015.11.024
PG 12
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Mathematical & Computational
   Biology
GA DY0IH
UT WOS:000384780000001
PM 26657065
OA Bronze
DA 2025 08 17
ER

PT J
AU John, AA
   Xie, J
   Yang, YS
   Kim, JM
   Lin, CJ
   Ma, H
   Gao, GP
   Shim, JH
AF John, Aijaz Ahmad
   Xie, Jun
   Yang, Yeon Suk
   Kim, Jung Min
   Lin, Chujiao
   Ma, Hong
   Gao, Guangping
   Shim, Jae Hyuck
TI AAV mediated delivery of osteoblast/osteoclast regulating miRNAs for
   osteoporosis therapy
SO MOLECULAR THERAPY NUCLEIC ACIDS
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; PARATHYROID HORMONE; BONE FORMATION;
   STEM CELLS; MIR 214; THERAPEUTICS; MICRORNA 34A; ANALOGS; LIGAND; DRUGS
AB Osteoporosis occurs due to a dysregulation in bone remodeling, a process requiring both bone forming osteoblasts and bone resorbing osteoclasts. Current leading osteoporosis therapies suppress osteoclast mediated bone resorption but show limited therapeutic effects because osteoblast mediated bone formation decreases concurrently. We developed a gene therapy strategy for osteoporosis that simultaneously promotes bone formation and suppresses bone resorption by targeting two microRNAs (miRNAs)???miR 214 3p and miR 34a 5p. We modulated the expression of these miRNAs using systemically delivered recombinant adeno associated viral (rAAV) vectors targeting the bone. rAAV mediated overexpression of miR 214 3p or inhibition of miR 34a 5p in the skeleton resulted in bone loss in adult mice, resembling osteoporotic bones. Conversely, rAAV mediated inhibition of miR 214 3p or overexpression of miR 34a 5p reversed bone loss in mouse models for postmenopausal and senile osteoporosis by increasing osteoblast mediated bone formation and decreasing osteoclast mediated bone resorption. Notably, these mice did not show any apparent pathological phenotypes in non skeletal tissues. Mechanistically, inhibiting miR 214 3p upregulated activating transcription factor 4 in osteoblasts and phatase and tensin homolog in osteoclasts, while overexpressing miR34a 5p downregulated Notch1 in osteoblasts and TGFb induced factor homeobox 2 in osteoclasts. In summary, bone targeting rAAV mediated regulation of miR 214 3p or miR 34a 5p is a promising new approach to treat osteoporosis, while limiting adverse effects in non skeletal tissues.
C1 [John, Aijaz Ahmad; Yang, Yeon Suk; Kim, Jung Min; Lin, Chujiao; Shim, Jae Hyuck] Univ Massachusetts, Dept Med, Div Rheumatol, Chan Med Sch, Worcester, MA 01655 USA.
   [Xie, Jun; Ma, Hong; Gao, Guangping; Shim, Jae Hyuck] Univ Massachusetts, Horae Gene Therapy Ctr, Chan Med Sch, Worcester, MA 01655 USA.
   [Xie, Jun; Ma, Hong; Gao, Guangping] Univ Massachusetts, Dept Microbiol & Physiol Syst, Chan Med Sch, Worcester, MA USA.
   [Xie, Jun; Ma, Hong; Gao, Guangping] Univ Massachusetts, Viral Vector Core, Chan Med Sch, Worcester, MA USA.
   [Gao, Guangping; Shim, Jae Hyuck] Univ Massachusetts, Li Weibo Inst Rare Dis Res, Chan Med Sch, Worcester, MA USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; UMass Chan Medical School; University of Massachusetts
   System; University of Massachusetts Worcester; UMass Chan Medical
   School; University of Massachusetts System; University of Massachusetts
   Worcester; UMass Chan Medical School; University of Massachusetts
   System; University of Massachusetts Worcester; UMass Chan Medical
   School; University of Massachusetts System; University of Massachusetts
   Worcester; UMass Chan Medical School
RP Shim, JH (通讯作者)，Univ Massachusetts, Dept Med, Div Rheumatol, Chan Med Sch, Worcester, MA 01655 USA.; Gao, GP (通讯作者)，Univ Massachusetts, Horae Gene Therapy Ctr, Chan Med Sch, Worcester, MA 01655 USA.
EM guangping.gao@umassmed.edu; jaehyuck.shim@umassmed.edu
RI Kim, Jung Min/JDW 1037 2023; lin, chujiao/GXH 8413 2022; Bhat,
   Aijaz/HOI 0728 2023
OI Bhat (Ph.D), Aijaz Ahmad John/0000 0002 8261 2742; Shim,
   Jae Hyuck/0000 0002 4947 3293; Kim, Jung Min/0000 0002 9072 4293
FU NIH NIAMS [R21AR077557, R01AR078230]; NIH [P01AI100263, R01NS076991,
   P01HD080642, R01AI12135]; AAVAA Therapeutics
FX We thank Zhihao Chen and Eunhye Son for their technical support. We also
   thank the many individuals who provided valuable reagents. This project
   was supported by NIH NIAMS (R21AR077557 and R01AR078230) and AAVAA
   Therapeutics. G.G. holds support from grants under the NIH (P01AI100263,
   R01NS076991, P01HD080642, R01AI12135).
CR Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092 8674(03)00428 8
   Amin MMJ, 2021, CELLS BASEL, V10, DOI 10.3390/cells10123274
   Augustine M, 2013, CURR OSTEOPOROS REP, V11, P400, DOI 10.1007/s11914 013 0171 2
   Bernardo BC, 2015, FUTURE MED CHEM, V7, P1771, DOI 10.4155/fmc.15.107
   Borumandi F, 2015, ANTI CANCER AGENT ME, V15, P736, DOI 10.2174/1871520615666150325232857
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   Chabot S, 2012, MOL THER, V20, P1590, DOI 10.1038/mt.2012.95
   Chakraborty C, 2017, MOL THER NUCL ACIDS, V8, P132, DOI 10.1016/j.omtn.2017.06.005
   Duan QL, 2015, J CELL PHYSIOL, V230, P1964, DOI 10.1002/jcp.24942
   Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079
   Fabre S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113439
   Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115
   Gebert LFR, 2019, NAT REV MOL CELL BIO, V20, P21, DOI 10.1038/s41580 018 0045 7
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hart M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425 019 0670 5
   Hart M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 018 1295 1
   Hong DVS, 2020, BRIT J CANCER, V122, P1630, DOI 10.1038/s41416 020 0802 1
   Ishida Masaharu, 2013, Curr Anesthesiol Rep, V1, P63
   Kaifer KA, 2019, HUM MOL GENET, V28, P3199, DOI 10.1093/hmg/ddz142
   Kang H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01312
   Kim JM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16038 6
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Krol J, 2010, CELL, V141, P618, DOI 10.1016/j.cell.2010.03.039
   Krützfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Krützfeldt J, 2007, NUCLEIC ACIDS RES, V35, P2885, DOI 10.1093/nar/gkm024
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li GW, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1403 x
   Li SS, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.717065
   Li Y, 2021, INT J BIOL SCI, V17, P3343, DOI 10.7150/ijbs.61274
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284
   Liu H, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1285 y
   Lopes HB, 2016, J BIOMAT SCI POLYM E, V27, P1369, DOI 10.1080/09205063.2016.1203217
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Peng WX, 2017, EXP BIOL MED, V242, P1234, DOI 10.1177/1535370217703975
   Pietschmann P, 2016, GERONTOLOGY, V62, P128, DOI 10.1159/000431091
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Sena Esteves Miguel, 2020, Cold Spring Harb Protoc, V2020, P095513, DOI 10.1101/pdb.top095513
   Sharma T, 2015, FUTURE ONCOL, V11, P349, DOI [10.2217/fon.14.193, 10.2217/FON.14.193]
   Sharma VK, 2015, FUTURE MED CHEM, V7, P2221, DOI 10.4155/fmc.15.144
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Smalley E, 2017, NAT BIOTECHNOL, V35, P998, DOI 10.1038/nbt1117 998
   Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15
   Swarts DC, 2014, NAT STRUCT MOL BIOL, V21, P743, DOI 10.1038/nsmb.2879
   Tang Y, 2017, SCI REP UK, V7, DOI 10.1038/srep38232
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Trouvin AP, 2010, CLIN INTERV AGING, V5, P345, DOI 10.2147/CIA.S10153
   Vandenberghe LH, 2009, GENE THER, V16, P311, DOI 10.1038/gt.2008.170
   Venditti CP, 2021, NAT BIOTECHNOL, V39, P24, DOI 10.1038/s41587 020 00756 9
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xie J, 2020, MOL THER, V28, P422, DOI 10.1016/j.ymthe.2019.11.018
   Xie J, 2012, NAT METHODS, V9, P403, DOI [10.1038/NMETH.1903, 10.1038/nmeth.1903]
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yang YS, 2020, MOL THER METH CLIN D, V17, P922, DOI 10.1016/j.omtm.2020.04.010
   Yang YS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10809 6
   Yin Y, 2014, CELL RES, V24, P1164, DOI 10.1038/cr.2014.121
   Zeng HB, 2020, ACTA HISTOCHEM, V122, DOI 10.1016/j.acthis.2020.151601
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
   Zhou YH, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0647 2
NR 65
TC 22
Z9 26
U1 0
U2 20
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162 2531
J9 MOL THER NUCL ACIDS
JI Mol. Ther. Nucl. Acids
PD SEP 13
PY 2022
VL 29
BP 296
EP 311
DI 10.1016/j.omtn.2022.07.008
EA JUL 2022
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 3Q4YE
UT WOS:000838237900008
PM 35950212
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Weivoda, MM
   Ruan, M
   Hachfeld, CM
   Pederson, L
   Howe, A
   Davey, RA
   Zajac, JD
   Kobayashi, Y
   Williams, BO
   Westendorf, JJ
   Khosla, S
   Oursler, MJ
AF Weivoda, Megan M.
   Ruan, Ming
   Hachfeld, Christine M.
   Pederson, Larry
   Howe, Alan
   Davey, Rachel A.
   Zajac, Jeffrey D.
   Kobayashi, Yasuhiro
   Williams, Bart O.
   Westendorf, Jennifer J.
   Khosla, Sundeep
   Oursler, Merry Jo
TI Wnt Signaling Inhibits Osteoclast Differentiation by Activating
   Canonical and Noncanonical cAMP/PKA Pathways
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOCLAST DIFFERENTIATION; WNT; beta CATENIN; PKA
ID GLYCOGEN SYNTHASE KINASE 3 BETA; HUMAN BREAST CANCER; PROTEIN KINASE;
   BETA CATENIN; SPHINGOSINE 1 PHOSPHATE; MULTIPLE MYELOMA;
   EPITHELIAL CELLS; TRANSGENIC MICE; EXPRESSION; RECEPTOR
AB Although there has been extensive characterization of the Wnt signaling pathway in the osteoblast lineage, the effects of Wnt proteins on the osteoclast lineage are less well studied. We found that osteoclast lineage cells express canonical Wnt receptors. Wnt3a reduced osteoclast formation when applied to early bone marrow macrophage (BMM) osteoclast differentiation cultures, whereas late addition did not suppress osteoclast formation. Early Wnt3a treatment inactivated the crucial transcription factor NFATc1 in osteoclast progenitors. Wnt3a led to the accumulation of nuclear beta catenin, confirming activation of canonical Wnt signaling. Reducing low density lipoprotein receptor related proteins (Lrp)5 and Lrp6 protein expression prevented Wnt3a induced inactivation of NFATc1; however, deletion of beta catenin did not block Wnt3a inactivation of NFATc1, suggesting that this effect was mediated by a noncanonical pathway. Wnt3a rapidly activated the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway and pharmacological stimulation of cAMP/PKA signaling suppressed osteoclast differentiation; Wnt3a induced NFATc1 phosphorylation was blocked by inhibiting interactions between PKA and A kinase anchoring proteins (AKAPs). These data indicate that Wnt3a directly suppresses osteoclast differentiation through both canonical (beta catenin) and noncanonical (cAMP/PKA) pathways in osteoclast precursors. In vivo reduction of Lrp5 and Lrp6 expressions in the early osteoclast lineage via Rank promoter Cre recombination reduced trabecular bone mass, whereas disruption of Lrp5/6 expression in late osteoclast precursors via cathepsin K (Ctsk) promoter Cre recombination did not alter the skeletal phenotype. Surprisingly, reduction of Lrp5/6 in the early osteoclast lineage decreased osteoclast numbers, as well as osteoblast numbers. Published studies have previously noted that b catenin signaling is required for osteoclast progenitor proliferation. Our in vivo data suggest that Rank promoter Cremediated deletion of Lrp5/6 may similarly impair osteoclast progenitor proliferation. (C) 2015 American Society for Bone and Mineral Research.
C1 [Weivoda, Megan M.; Ruan, Ming; Hachfeld, Christine M.; Pederson, Larry; Khosla, Sundeep; Oursler, Merry Jo] Mayo Clin, Endocrine Res Unit, Rochester, MN 55905 USA.
   [Weivoda, Megan M.; Ruan, Ming; Hachfeld, Christine M.; Pederson, Larry; Khosla, Sundeep; Oursler, Merry Jo] Mayo Clin, Kogod Ctr Aging, Rochester, MN 55905 USA.
   [Howe, Alan] Univ Vermont, Coll Med, Dept Pharmacol, Burlington, VT 05405 USA.
   [Davey, Rachel A.; Zajac, Jeffrey D.] Univ Melbourne, Austin Hlth, Dept Med, Heidelberg, Vic, Australia.
   [Kobayashi, Yasuhiro] Matsumoto Dent Univ, Inst Oral Sci, Shiojiri, Nagano, Japan.
   [Williams, Bart O.] Van Andel Inst, Ctr Canc & Cell Biol, Grand Rapids, MI USA.
   [Westendorf, Jennifer J.] Mayo Clin, Dept Orthoped Surg, Rochester, MN USA.
C3 Mayo Clinic; Mayo Clinic; University of Vermont; Austin Research
   Institute; University of Melbourne; Florey Institute of Neuroscience &
   Mental Health; Howard Florey Institute Affiliates; Matsumoto Dental
   University; Van Andel Institute; Mayo Clinic
RP Oursler, MJ (通讯作者)，Mayo Clin, Endocrine Res Unit, Guggenheim 7 11B,200 First St SW, Rochester, MN 55905 USA.
EM oursler.merryjo@mayo.edu
RI ; Khosla, Sundeep/AAE 6170 2020; Zajac, Jeffrey/ABC 3767 2021; Williams,
   Bart/A 3539 2013; KOBAYASHI, YASUHIRO/AAU 4931 2021
OI Williams, Bart/0000 0002 5261 5301; Zajac, Jeffrey/0000 0003 3933 5708;
   Khosla, Sundeep/0000 0002 2936 4372; Kobayashi,
   Yasuhiro/0000 0002 0903 3226; DAVEY, RACHEL A/0000 0001 5121 0209
FU NIH [F32 AR064679, T32 AR056950, R01 AR053293, P01 AG004875P3, P01
   AG004875P4, R01 GM097495, R01 DE020194]
FX This work was supported by NIH grants F32 AR064679, T32 AR056950, R01
   AR053293, P01 AG004875P3, P01 AG004875P4, R01 GM097495, and R01
   DE020194.
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103
   Bànkfalvi A, 1999, HISTOPATHOLOGY, V34, P25
   Benhaj K, 2006, ONCOL REP, V15, P701
   Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065
   Brault V, 2001, DEVELOPMENT, V128, P1253
   Chen AE, 2005, NATURE, V433, P317, DOI 10.1038/nature03126
   Chiu WSM, 2004, GENESIS, V39, P178, DOI 10.1002/gene.20041
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Doble BW, 2007, CELLS TISSUES ORGANS, V185, P73, DOI 10.1159/000101306
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Gingery A, 2008, EXP CELL RES, V314, P2725, DOI 10.1016/j.yexcr.2008.06.006
   Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047
   Jang HD, 2011, J BIOL CHEM, V286, P39043, DOI 10.1074/jbc.M111.256768
   Joeng KS, 2011, DEV BIOL, V359, P222, DOI 10.1016/j.ydbio.2011.08.020
   Jönsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959 8049(99)00276 2
   Karayiannakis AJ, 2001, EUR J SURG ONCOL, V27, P31, DOI 10.1053/ejso.1999.1017
   Kiechl S, 2013, NAT MED, V19, P358, DOI 10.1038/nm.3084
   Kim JH, 2010, J BIOL CHEM, V285, P5224, DOI 10.1074/jbc.M109.042812
   Koval A, 2011, BIOCHEM PHARMACOL, V82, P1311, DOI 10.1016/j.bcp.2011.06.005
   Koval A, 2011, BIOCHEM J, V433, P435, DOI 10.1042/BJ20101878
   Li AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113785
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273
   Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   McColm J, 2014, J BONE MINER RES, V29, P935, DOI 10.1002/jbmr.2092
   Modarresi R, 2009, AM J PATHOL, V174, P123, DOI 10.2353/ajpath.2009.080484
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Munshi NC, 2012, BLOOD, V120, DOI 10.1182/blood.V120.21.331.331
   Niehrs C, 2010, CELL MOL LIFE SCI, V67, P2551, DOI 10.1007/s00018 010 0329 3
   OLSON DJ, 1994, CELL GROWTH DIFFER, V5, P197
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Qiang YW, 2010, BRIT J HAEMATOL, V148, P726, DOI 10.1111/j.1365 2141.2009.08009.x
   Quint P, 2013, J BIOL CHEM, V288, P5398, DOI 10.1074/jbc.M112.413583
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Sanchez Fernandez MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003537
   Santiago F, 2012, BIOCHEM BIOPH RES CO, V417, P223, DOI 10.1016/j.bbrc.2011.11.089
   Sheridan CM, 2002, J BIOL CHEM, V277, P48664, DOI 10.1074/jbc.M207029200
   Skroblin P, 2010, INT REV CEL MOL BIO, V283, P235, DOI 10.1016/S1937 6448(10)83005 9
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Takeshita S, 2013, J CLIN INVEST, V123, P3914, DOI 10.1172/JCI69493
   Tanji C, 2002, J BIOL CHEM, V277, P36955, DOI 10.1074/jbc.M206210200
   Taylor SS, 2008, BBA PROTEINS PROTEOM, V1784, P16, DOI 10.1016/j.bbapap.2007.10.002
   Wang HY, 2006, CELL SIGNAL, V18, P934, DOI 10.1016/j.cellsig.2005.12.008
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Witze ES, 2008, SCIENCE, V320, P365, DOI 10.1126/science.1151250
   WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278
   Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Yoon SH, 2011, J BONE MINER RES, V26, P1217, DOI 10.1002/jbmr.310
   Yu H, 1996, BRIT J CANCER, V74, P1242, DOI 10.1038/bjc.1996.523
   Zardawi SJ, 2009, HISTOL HISTOPATHOL, V24, P385, DOI 10.14670/HH 24.385
   Zheng M, 2005, NAT GENET, V37, P300, DOI 10.1038/ng1512
NR 61
TC 119
Z9 130
U1 2
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2016
VL 31
IS 1
BP 65
EP 75
DI 10.1002/jbmr.2599
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DA3JP
UT WOS:000367693300006
PM 26189772
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Chirgwin, JM
   Guise, TA
AF Chirgwin, John M.
   Guise, Theresa A.
TI Skeletal metastases: Decreasing tumor burden by targeting the bone
   microenvironment
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE bone metastases; osteoblastic metastases; osteolytic metastases;
   transforming growth factor beta; endothelin 1; Wnt signaling;
   bisphosphonates; hypoxia
ID GROWTH FACTOR BETA; BREAST CANCER METASTASIS; PROSTATE CANCER; CELLS;
   MODEL; INHIBITION; MECHANISMS; STRATEGIES; RESORPTION; PATHWAYS
AB Several common cancers often metastasize to the skeleton in advanced disease. Bone metastases are incurable and cause protracted, severe symptoms. Growth of tumor in bone is driven by a vicious cycle: tumor secreted factors stimulate bone cells, which in turn release growth factors and cytokines. The bone derived factors fuel the vicious cycle by acting back on the tumor cells. The vicious cycle offers novel targets for the treatment of advanced cancers. Treatments can inhibit bone cells (osteoclasts and osteoblasts) that are stimulated by tumor secreted factors. Drugs can also inhibit tumor responses to factors enriched in the bone microenvironment, such as transforming growth factor P. Animal models show that these approaches, especially combination treatments, can reduce tumor burden. The results suggest a novel paradigm in which tumor growth can be effectively inhibited by drugs that target cells in the bone microenviroment and not the tumor cells themselves. J. Cell. Biochem. 102: 1333 1342, 2007. (c) 2007 Wiley Liss, Inc.
C1 Univ Virginia, Dept Med, Div Endocrinol, Aurbach Lab, Charlottesville, VA 22908 USA.
C3 University of Virginia
RP Chirgwin, JM (通讯作者)，Univ Virginia, Dept Med, Div Endocrinol, Aurbach Lab, POB 801401, Charlottesville, VA 22908 USA.
EM jc3qb@virginia.edu
OI Chirgwin, John/0009 0001 7638 0842
FU NCI NIH HHS [CA69158, CA40035] Funding Source: Medline; NIDDK NIH HHS
   [DK065837] Funding Source: Medline
CR Barnes GL, 2003, CANCER RES, V63, P2631
   Biswas S, 2006, CLIN CANCER RES, V12, P4142, DOI 10.1158/1078 0432.CCR 06 0952
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Boucharaba A, 2006, P NATL ACAD SCI USA, V103, P9643, DOI 10.1073/pnas.0600979103
   Boyce BF, 2006, CLIN CANCER RES, V12, p6291S, DOI 10.1158/1078 0432.CCR 06 0991
   Brown EM, 2007, NAT CLIN PRACT ENDOC, V3, P122, DOI 10.1038/ncpendmet0388
   Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168
   Carducci MA, 2006, CLIN CANCER RES, V12, p6296S, DOI 10.1158/1078 0432.CCR 06 0929
   Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006 0346
   Cohen MM, 2006, AM J MED GENET A, V140A, P2646, DOI 10.1002/ajmg.a.31368
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047
   Fidler IJ, 2007, J CELL BIOCHEM, V101, P927, DOI 10.1002/jcb.21148
   Fukumura D, 2007, J CELL BIOCHEM, V101, P937, DOI 10.1002/jcb.21187
   Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154 006 9000 6
   Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11 10 1121
   Hall CL, 2006, J CELL BIOCHEM, V97, P661, DOI 10.1002/jcb.20735
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Halvorson KG, 2006, CLIN J PAIN, V22, P587, DOI 10.1097/01.ajp.0000210902.67849.e6
   HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
   Hoebertz A, 2003, TRENDS PHARMACOL SCI, V24, P290, DOI 10.1016/S0165 6147(03)00123 8
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Käkönen SM, 2003, CANCER AM CANCER SOC, V97, P834, DOI 10.1002/cncr.11132
   Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kim SJ, 2005, CANCER RES, V65, P3707, DOI 10.1158/0008 5472.CAN 04 3601
   KINGSLEY LA, 2007, IN PRESS MOL CANC TH
   Koeneman KS, 1999, PROSTATE, V39, P246
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Mitsiades CS, 2007, J CELL BIOCHEM, V101, P950, DOI 10.1002/jcb.21213
   Morrissey C, 2007, J CELL BIOCHEM, V101, P873, DOI 10.1002/jcb.21214
   Powers MV, 2006, ENDOCR RELAT CANCER, V13, pS125, DOI 10.1677/erc.1.01324
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Price JT, 2005, CANCER RES, V65, P4929, DOI 10.1158/0008 5472.CAN 04 4458
   Roudier MP, 2003, HUM PATHOL, V34, P646, DOI 10.1016/S0046 8177(03)00190 4
   Rubin J, 2006, PROSTATE, V66, P789, DOI 10.1002/pros.20379
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Sánchez Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200
   Shoback D, 2007, J CLIN ENDOCR METAB, V92, P747, DOI 10.1210/jc.2007 0042
   Siclari VA, 2006, CANCER METAST REV, V25, P621, DOI 10.1007/s10555 006 9023 1
   Siclari Valerie A., 2007, V11, P241
   Titus B, 2005, CANCER RES, V65, P7320, DOI 10.1158/0008 5472.CAN 05 1403
   Vessella RL, 2006, CLIN CANCER RES, V12, p6285S, DOI 10.1158/1078 0432.CCR 06 0813
   White N, 2006, TRENDS PHARMACOL SCI, V27, P211, DOI 10.1016/j.tips.2006.02.004
   WORKMAN P, 2007, ANN N Y ACAD SCI
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   Zheng Y, 2007, BONE, V40, P471, DOI 10.1016/j.bone.2006.09.016
   Zhong H, 1999, CANCER RES, V59, P5830
NR 52
TC 28
Z9 33
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD DEC 15
PY 2007
VL 102
IS 6
BP 1333
EP 1342
DI 10.1002/jcb.21556
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 238FX
UT WOS:000251433900001
PM 17907152
DA 2025 08 17
ER

PT J
AU Lim, SY
   Bolster, MB
AF Lim, Sian Yik
   Bolster, Marcy B.
TI Profile of romosozumab and its potential in the management of
   osteoporosis
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE romosozumab; sclerostin; osteoporosis; bone mineral density
ID SCLEROSTIN ANTIBODY TREATMENT; INCREASES BONE FORMATION; POSTMENOPAUSAL
   WOMEN; OSTEOCYTE CONTROL; MINERAL DENSITY; MASS; WNT; DISEASE; PROTEIN;
   GENE
AB Increased understanding of bone biology has led to the discovery of several unique signaling pathways that regulate bone formation and resorption. The Wnt signaling pathway plays a significant role in skeletal development, adult skeletal homeostasis, and bone remodeling. Sclerostin is an inhibitor of the Wnt signaling pathway. Romosozumab, a humanized monoclonal antibody that binds to sclerostin, prevents sclerostin from exerting this inhibitory effect. Therefore, in the presence of romosozumab, the Wnt signaling pathway is activated leading to bone formation and bone mineral density gain. Clinical studies of romosozumab have shown that this agent is one of the most potent bone anabolic agents in development to date. Romosozumab does not act solely as an anabolic agent, but rather, it has effects on increasing bone formation as well as reducing bone resorption. In the clinical studies, patients tolerated romosozumab well with no major safety signals reported. In a Phase III study, romosozumab as compared to placebo has been shown to reduce vertebral fractures by 73% after 1 year of treatment. Sequential therapy with romosozumab for 1 year followed by denosumab in the second year reduced vertebral fractures by 75% as compared to the group that received placebo for 1 year and denosumab in the second year. Romosozumab holds significant potential, by a novel mechanism of action, to expand our ability to treat osteoporosis. More studies are needed to determine the ideal setting in which romosozumab may be used to optimize osteoporosis treatment.
C1 [Lim, Sian Yik] Straub Med Ctr, Straub Bone & Joint Ctr, 800 South King St, Honolulu, HI 96813 USA.
   [Bolster, Marcy B.] Harvard Med Sch, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard Medical School
RP Lim, SY (通讯作者)，Straub Med Ctr, Straub Bone & Joint Ctr, 800 South King St, Honolulu, HI 96813 USA.
EM limsianyik@gmail.com
RI Lim, Sian Yik/CAA 0989 2022; Bolster, Marcy/AAJ 9063 2020
OI Bolster, Marcy/0000 0002 5413 9345
FU National Institutes of Health [R01AR064850, 1U01AR068043, R01HL127118];
   Eli Lilly
FX MBB is currently receiving grants as a coinvestigator from the National
   Institutes of Health (# R01AR064850, 1U01AR068043, and R01HL127118) and
   Eli Lilly, outside the submitted work.
CR AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304
   Appelman Dijkstra NM, 2015, DRUGS, V75, P1049, DOI 10.1007/s40265 015 0417 7
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Deal C, 2009, NAT CLIN PRACT RHEUM, V5, P20, DOI 10.1038/ncprheum0977
   Evenepoel P, 2015, KIDNEY INT, V88, P235, DOI 10.1038/ki.2015.156
   Gardner JC, 2005, J CLIN ENDOCR METAB, V90, P6392, DOI 10.1210/jc.2005 1235
   Genant HK, 2017, J BONE MINER RES, V32, P181, DOI 10.1002/jbmr.2932
   GEUSENS P, 2015, RMD OPEN, V1, DOI DOI 10.1136/RMDOPEN 2015 000051265573744632141
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Keizer RJ, 2010, CLIN PHARMACOKINET, V49, P493, DOI 10.2165/11531280 000000000 00000
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Komiya Yuko, 2008, Organogenesis, V4, P68
   Krause C, 2010, J BIOL CHEM, V285, P41614, DOI 10.1074/jbc.M110.153890
   Langdahl B, 2016, ARTHRITIS RHEUMA S10, V68
   Leder BZ, 2014, J CLIN ENDOCR METAB, V99, P1694, DOI 10.1210/jc.2013 4440
   Lewiecki EM, 2013, J CLIN ENDOCR METAB, V98, P946, DOI 10.1210/jc.2012 3680
   Lewiecki EM, 2011, DISCOV MED, V12, P263
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   McClung MR, 2015, ANN RHEUM DIS, V74, P166, DOI 10.1136/annrheumdis 2015 eular.2291
   McClung MR, 2014, NEW ENGL J MED, V370, P1664, DOI 10.1056/NEJMc1402396
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Ominsky MS, 2017, BONE, V96, P63, DOI 10.1016/j.bone.2016.10.019
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Papapoulos SE, 2015, NAT REV ENDOCRINOL, V11, P69, DOI 10.1038/nrendo.2014.214
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Sapir Koren R, 2014, OSTEOPOROSIS INT, V25, P2685, DOI 10.1007/s00198 014 2808 0
   Shah AD, 2015, INT J WOMENS HEALTH, V7, P565, DOI 10.2147/IJWH.S73244
   Taylor S, 2016, BONE, V84, P148, DOI 10.1016/j.bone.2015.12.013
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   van Bezooijen RL, 2007, J BONE MINER RES, V22, P19, DOI 10.1359/JBMR.061002
   van Lierop AH, 2013, J BONE MINER RES, V28, P848, DOI 10.1002/jbmr.1794
   van Lierop AH, 2011, J BONE MINER RES, V26, P2804, DOI 10.1002/jbmr.474
   Wang W, 2008, CLIN PHARMACOL THER, V84, P548, DOI 10.1038/clpt.2008.170
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Xueling GE, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756 8722 3 33
NR 47
TC 69
Z9 82
U1 0
U2 8
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177 8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2017
VL 11
BP 1221
EP 1231
DI 10.2147/DDDT.S127568
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA ES1ND
UT WOS:000399293400002
PM 28458516
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Keizman, D
   Ish Shalom, M
   Maimon, N
   Gottfried, M
AF Keizman, Daniel
   Ish Shalom, Maya
   Maimon, Natalie
   Gottfried, Maya
TI Are bisphosphonates an indispensable tool in the era of targeted therapy
   for renal cell carcinoma and bone metastases?
SO WORLD JOURNAL OF UROLOGY
LA English
DT Article
DE Bisphosphonate; Bone metastases; Denosumab; Renal cell carcinoma;
   Targeted therapies
ID ZOLEDRONIC ACID; SOLID TUMORS; PHASE III; SKELETAL METASTASES;
   PROGRESSION FREE; CANCER PATIENTS; RISK FACTORS; DOUBLE BLIND;
   OSTEONECROSIS; SUNITINIB
AB One third of patients with metastatic renal cell carcinoma (RCC) suffer from bone metastases. Skeletal involvement in RCC is associated with the occurrence of skeletal related events, and may negatively impact on the outcome of patients treated with systemic therapies. In patients with RCC and bone metastases, therapies that inhibit osteoclasts, as bisphosphonates and denosumab, are used as adjunct to systemic targeted therapies to prevent skeletal related events. Data suggest that they may also improve the outcome of systemic targeted therapies. Herein we review the preclinical and clinical data on their use, as well as remaining open questions.
C1 [Keizman, Daniel; Ish Shalom, Maya; Maimon, Natalie; Gottfried, Maya] Tel Aviv Univ, Genitourinary Oncol Serv, Inst Oncol, Meir Med Ctr,Sackler Sch Med, IL 44281 Kefar Sava, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine
RP Keizman, D (通讯作者)，Tel Aviv Univ, Genitourinary Oncol Serv, Inst Oncol, Meir Med Ctr,Sackler Sch Med, Tchernichovsky 59, IL 44281 Kefar Sava, Israel.
EM danielkeizman@gmail.com
OI ish shalom, maya/0000 0002 3960 3066
CR [Anonymous], INT J CLIN ONCOL
   Aragon Ching JB, 2008, ONCOLOGIST, V13, P1314, DOI 10.1634/theoncologist.2008 0206
   Ayllon J, 2009, ANN ONCOL, V20, P600, DOI 10.1093/annonc/mdn788
   Beuselinck B, 2011, ANN ONCOL, V22, P794, DOI 10.1093/annonc/mdq554
   Beuselinck BL, 2011, J CLIN ONCOL S7, V29
   Brunello A, 2009, BONE, V44, P173, DOI 10.1016/j.bone.2008.08.132
   Chennuru S, 2008, INTERN MED J, V38, P635, DOI 10.1111/j.1445 5994.2007.01580.x
   Christodoulou C, 2009, ONCOLOGY BASEL, V76, P209, DOI 10.1159/000201931
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hoefert S, 2010, ORAL SURG ORAL MED O, V110, P463, DOI 10.1016/j.tripleo.2010.04.049
   Janzen NK, 2003, UROL CLIN N AM, V30, P843, DOI 10.1016/S0094 0143(03)00056 9
   Karaca H, 2010, MED ONCOL, V27, P1023, DOI 10.1007/s12032 009 9327 4
   Keizman D, 2012, EUR J CANCER, V48, P1031, DOI 10.1016/j.ejca.2012.02.050
   Khattak MA, 2012, EUR J CANC
   Kijima T, 2008, INT J UROL, V15, P546, DOI 10.1111/j.1442 2042.2008.02044.x
   Lam JS, 2005, WORLD J UROL, V23, P202, DOI 10.1007/s00345 004 0466 0
   Lipton A, 2003, CANCER, V98, P962, DOI 10.1002/cncr.11571
   Maita S, 2012, INT J CANCER, V130, P677, DOI 10.1002/ijc.26034
   Mikami S, 2009, J PATHOL, V218, P530, DOI 10.1002/path.2567
   Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207
   Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293
   Pandha H, 2006, J UROLOGY, V176, P2255, DOI 10.1016/j.juro.2006.07.053
   Parkin DM, 2005, CA CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Patil S, 2011, ANN ONCOL, V22, P295, DOI 10.1093/annonc/mdq342
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2010, SEMIN ONCOL, V37, pS38, DOI 10.1053/j.seminoncol.2010.06.001
   Soltau J, 2008, ANTICANCER RES, V28, P933
   Tan TH, 2010, ASIA PAC J CLIN ONCO, V6, P5, DOI 10.1111/j.1743 7563.2010.01277.x
   Ullén A, 2009, SCAND J UROL NEPHROL, V43, P98, DOI 10.1080/00365590802475904
   Wood SL, 2012, CANCER TREAT REV, V38, P284, DOI 10.1016/j.ctrv.2011.06.011
   Woodward E, 2011, BONE, V48, P160, DOI 10.1016/j.bone.2010.09.008
   Yuasa T, 2011, CLIN EXP METASTAS, V28, P405, DOI 10.1007/s10585 011 9379 7
   Zagoria RJ, 1997, SEMIN ULTRASOUND CT, V18, P91, DOI 10.1016/S0887 2171(97)90053 6
   Zekri J, 2001, INT J ONCOL, V19, P379
   Zhu XL, 2009, ACTA ONCOL, V48, P9, DOI 10.1080/02841860802314720
   Zolnierek J, 2010, J CANCER RES CLIN, V136, P371, DOI 10.1007/s00432 009 0664 7
NR 42
TC 5
Z9 8
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724 4983
EI 1433 8726
J9 WORLD J UROL
JI World J. Urol.
PD FEB
PY 2014
VL 32
IS 1
BP 39
EP 45
DI 10.1007/s00345 013 1059 6
PG 7
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA AA0EO
UT WOS:000330768300006
PM 23543006
DA 2025 08 17
ER

PT J
AU Minear, S
   Leucht, P
   Jiang, J
   Liu, B
   Zeng, A
   Fuerer, C
   Nusse, R
   Helms, JA
AF Minear, Steven
   Leucht, Philipp
   Jiang, Jie
   Liu, Bo
   Zeng, Arial
   Fuerer, Christophe
   Nusse, Roel
   Helms, Jill A.
TI Wnt Proteins Promote Bone Regeneration
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID STEM CELL ACTIVATION; BETA CATENIN; MORPHOGENETIC PROTEINS;
   ALKALINE PHOSPHATASE; MASS; IDENTIFICATION; PROLIFERATION;
   SPECIFICATION; OSTEOBLAST; INHIBITOR
AB The Wnt signaling pathway plays a central role in bone development and homeostasis. In most cases, Wnt ligands promote bone growth, which has led to speculation that Wnt factors could be used to stimulate bone healing. We gained insights into the mechanism by which Wnt signaling regulates adult bone repair through the use of the mouse strain Axin2(LacZ/LacZ) in which the cellular response to Wnt is increased. We found that bone healing after injury is accelerated in Axin2(LacZ/LacZ) mice, a consequence of more robust proliferation and earlier differentiation of skeletal stem and progenitor cells. In parallel, we devised a biochemical strategy to increase the duration and strength of Wnt signaling at the sites of skeletal injury. Purified Wnt3a was packaged in liposomal vesicles and delivered to skeletal defects, where it stimulated the proliferation of skeletal progenitor cells and accelerated their differentiation into osteoblasts, cells responsible for bone growth. The end result was faster bone regeneration. Because Wnt signaling is conserved in mammalian tissue repair, this protein based approach may have widespread applications in regenerative medicine.
C1 [Zeng, Arial; Fuerer, Christophe; Nusse, Roel] Stanford Sch Med, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA.
   [Minear, Steven; Leucht, Philipp; Jiang, Jie; Liu, Bo; Helms, Jill A.] Stanford Sch Med, Div Plast & Reconstruct Surg, Dept Surg, Stanford, CA 94305 USA.
   [Leucht, Philipp] Stanford Sch Med, Dept Orthopaed Surg, Stanford, CA 94305 USA.
C3 Howard Hughes Medical Institute; Stanford University; Stanford
   University; Stanford University
RP Nusse, R (通讯作者)，Stanford Sch Med, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA.
EM rnusse@stanford.edu; jhelms@stanford.edu
RI helms, jill/ISU 5419 2023; Leucht, Philipp/H 7238 2019
OI Jiang, Jie/0000 0001 6619 1936; Helms, Jill/0000 0002 0463 396X; Leucht,
   Philipp/0000 0002 8409 8513; Fuerer, Christophe/0000 0003 1717 6718
FU Howard Hughes Medical Institute Funding Source: Medline
CR Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Blum JS, 2001, J CELL BIOCHEM, V80, P532, DOI 10.1002/1097 4644(20010315)80:4<532::AID JCB1007>3.0.CO;2 B
   Blumenthal A, 2006, BLOOD, V108, P965, DOI 10.1182/blood 2005 12 5046
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   DasGupta R, 2002, J CELL BIOL, V158, P331, DOI 10.1083/jcb.200204134
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Fuentealba LC, 2007, CELL, V131, P980, DOI 10.1016/j.cell.2007.09.027
   Garrison KR, 2007, HEALTH TECHNOL ASSES, V11, P1
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gautschi OP, 2007, ANZ J SURG, V77, P626, DOI 10.1111/j.1445 2197.2007.04175.x
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gordon MD, 2005, NATURE, V437, P746, DOI 10.1038/nature04073
   Greco V, 2009, CELL STEM CELL, V4, P155, DOI 10.1016/j.stem.2008.12.009
   Heymann D, 2005, DRUG DISCOV TODAY, V10, P242, DOI 10.1016/S1359 6446(04)03265 9
   Hill TP, 2006, DEVELOPMENT, V133, P1219, DOI 10.1242/dev.02298
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Iatropoulos MJ, 1996, EXP TOXICOL PATHOL, V48, P175, DOI 10.1016/S0940 2993(96)80039 X
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Ito M, 2007, NATURE, V447, P316, DOI 10.1038/nature05766
   Jagasia R, 2006, TRENDS MOL MED, V12, P400, DOI 10.1016/j.molmed.2006.07.006
   Joseph V, 2007, SPINE, V32, P2885, DOI 10.1097/BRS.0b013e31815b7596
   Jugdutt BI, 2009, NEW ENGL J MED, V360, P1567, DOI 10.1056/NEJMcibr0810801
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Kim WY, 2009, NAT NEUROSCI, V12, P1390, DOI 10.1038/nn.2408
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Le Grand F, 2009, CELL STEM CELL, V4, P535, DOI 10.1016/j.stem.2009.03.013
   Leucht P, 2008, SEMIN CELL DEV BIOL, V19, P434, DOI 10.1016/j.semcdb.2008.09.002
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Liu J, 2005, ANGEW CHEM INT EDIT, V44, P1987, DOI 10.1002/anie.200462552
   Lobov IB, 2005, NATURE, V437, P417, DOI 10.1038/nature03928
   Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184 1193.2002
   Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006
   Minear S, 2010, J BONE MINER RES, V25, P1196, DOI 10.1002/jbmr.29
   Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542
   Morrell NT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002930
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Petersen CP, 2008, SCIENCE, V319, P327, DOI 10.1126/science.1149943
   Petersen CP, 2009, P NATL ACAD SCI USA, V106, P17061, DOI 10.1073/pnas.0906823106
   Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124
   Plikus MV, 2008, NATURE, V451, P340, DOI 10.1038/nature06457
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Shan JF, 2005, BIOCHEMISTRY US, V44, P15495, DOI 10.1021/bi0512602
   Takada R, 2006, DEV CELL, V11, P791, DOI 10.1016/j.devcel.2006.10.003
   Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117
   ten Berge D, 2008, DEVELOPMENT, V135, P3247, DOI 10.1242/dev.023176
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   van Noort M, 2002, EXP CELL RES, V276, P264, DOI 10.1006/excr.2002.5520
   Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960 9822(03)00240 9
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   WLODARSKI KH, 1986, CALCIFIED TISSUE INT, V39, P382, DOI 10.1007/BF02555175
   ZENG AY, 2010, CELL STEM CELL, DOI DOI 10.1016/J.STEM.2010.03.020
   Zhang QS, 2007, P NATL ACAD SCI USA, V104, P7444, DOI 10.1073/pnas.0702136104
NR 60
TC 227
Z9 268
U1 0
U2 36
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD APR 28
PY 2010
VL 2
IS 29
AR 29ra30
DI 10.1126/scitranslmed.3000231
PG 9
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 591ML
UT WOS:000277304700001
PM 20427820
DA 2025 08 17
ER

PT J
AU Tartaglione, L
   Pasquali, M
   Rotondi, S
   Muci, ML
   Covic, A
   Mazzaferro, S
AF Tartaglione, Lida
   Pasquali, Marzia
   Rotondi, Silverio
   Muci, Maria Luisa
   Covic, Adrian
   Mazzaferro, Sandro
TI Positioning novel biologicals in CKD mineral and bone disorders
SO JOURNAL OF NEPHROLOGY
LA English
DT Article; Proceedings Paper
CT Symposium on Bone in Chronic Kidney Disease (CKD)
CY SEP 23, 2016
CL Amsterdam, NETHERLANDS
DE Renal osteodystrophy; Osteoporosis; Mineral bone disorders; Bone mineral
   density; PTH 1 34; Teriparatide; Denosumab; Romosozumab
ID PARATHYROID HORMONE; POSTMENOPAUSAL WOMEN; CIRCULATING SCLEROSTIN;
   BIOCHEMICAL MARKERS; RENAL FAILURE; RAT MODEL; TERIPARATIDE;
   OSTEOPOROSIS; DENOSUMAB; DENSITY
AB Renal osteodystrophy (ROD), the histologic bone lesions of chronic kidney disease (CKD), is now included in a wider syndrome with laboratory abnormalities of mineral metabolism and extra skeletal calcifications or CKD mineral and bone disorders (CKD MBD), to highlight the increased burden of mortality. Aging people, frequently identified as early CKD, could suffer from either the classical age related osteoporosis (OP) or ROD. Distinguishing between these two bone diseases may not be easy without bone biopsy. In any case, besides classical therapies for ROD, nephrologists are now challenged by the possibility of using new drugs developed for OP. Importantly, while therapies for ROD mostly aim at controlling parathyroid secretion with bone effects regarded as indirect, new drugs for OP directly modulate bone cells activity. Thus, their action could be useful in specific types of ROD. Parathyroid hormone therapy, which is anabolic in OP, could be useful in renal patients with low turnover bone disease. Denosumab, the monoclonal antibody against receptor activator of NF kappa B ligand (RANK L) that inhibits osteoclast activity and proliferation, could be beneficial in cases with high turnover bone. Use of romosozumab, the monoclonal antibody against sclerostin, which both stimulates osteoblasts and inhibits osteoclasts, could allow both anabolic and anti resorptive effects. However, we should not forget the systemic role now attributed to CKD MBD. In fact, therapies targeting bone cells activity could also result in unpredicted extra bone effects and affect cardiovascular outcomes. In conclusion, the new biologicals established for OP could be useful in renal patients with either OP or ROD. In addition, their potential non bone effects warrant investigation.
C1 [Tartaglione, Lida; Rotondi, Silverio; Muci, Maria Luisa; Mazzaferro, Sandro] Sapienza Univ Rome, Dept Cardiovasc Resp Nephrol Anesthet & Geriatr S, Rome, Italy.
   [Pasquali, Marzia] Univ Hosp Co, Policlin Umberto 1, Dept Nephrol & Dialysis, Rome, Italy.
   [Covic, Adrian] Gr T Popa Univ Med & Pharm, Dept Nephrol, Iasi, Romania.
C3 Sapienza University Rome; Sapienza University Rome; University Hospital
   Sapienza Rome; Grigore T Popa University of Medicine & Pharmacy
RP Mazzaferro, S (通讯作者)，Sapienza Univ Rome, Dept Cardiovasc Resp Nephrol Anesthet & Geriatr S, Rome, Italy.
EM sandro.mazzaferro@uniroma1.it
RI Covic, Adrian/G 5017 2016; Rotondi, silverio/AAM 5845 2020; Tartaglione,
   Lida/AAA 9895 2019; Mazzaferro, Sandro/E 9321 2012
OI Tartaglione, Lida/0000 0003 4537 0876; Rotondi,
   Silverio/0000 0003 4553 1756; Mazzaferro, Sandro/0000 0003 3071 1893
FU Amgen
FX LT: no conflict of interests to declare; MP: no conflict of interests to
   declare; SR: no conflict of interests to declare; MML: no conflict of
   interests to declare; AC: consultant for FMC; SM: clinical investigation
   fundings from Amgen.
CR Barreto Fellype Carvalho, 2014, Braz. J. Nephrol., V36, P289, DOI 10.5935/0101 2800.20140042
   Bauer W, 1929, J EXP MED, V49, P145, DOI 10.1084/jem.49.1.145
   BEIGHTON P, 1984, CLIN GENET, V25, P175
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Brandenburg VM, 2013, BMC NEPHROL, V14, DOI 10.1186/1471 2369 14 219
   BROWN EM, 1983, J CLIN ENDOCR METAB, V56, P572, DOI 10.1210/jcem 56 3 572
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Chen CL, 2014, J CLIN ENDOCR METAB, V99, P2426, DOI 10.1210/jc.2014 1154
   Coen G, 1996, NEPHROL DIAL TRANSPL, V11, P813, DOI 10.1093/oxfordjournals.ndt.a027404
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cozzolino M, 2015, CLIN KIDNEY J, V8, P729, DOI 10.1093/ckj/sfv104
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dobnig H, 2005, J CLIN ENDOCR METAB, V90, P3970, DOI 10.1210/jc.2003 1703
   Drechsler C, 2015, NEPHROL DIAL TRANSPL, V30, P288, DOI 10.1093/ndt/gfu301
   Eckardt KU, 2009, KIDNEY INT, V76, pS1, DOI 10.1038/ki.2009.188
   Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122
   Festuccia F, 2017, J NEPHROL, V30, P271, DOI 10.1007/s40620 016 0334 1
   Gardella TJ, 2001, TRENDS ENDOCRIN MET, V12, P210, DOI 10.1016/S1043 2760(01)00409 X
   Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399 0004.2003.00036.x
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Imai H, 2014, INT J CLIN PHARM TH, V52, P166, DOI 10.5414/CP202001
   Jamal SA, 2011, J BONE MINER RES, V26, P1829, DOI 10.1002/jbmr.403
   Jerome CP, 2001, BONE, V28, P150, DOI 10.1016/S8756 3282(00)00430 0
   Kalantar Zadeh K, 2010, KIDNEY INT, V78, pS10, DOI 10.1038/ki.2010.189
   Kawakami R, 2016, INFLAMM REGEN, V36, DOI 10.1186/s41232 016 0016 3
   Kazama JJ, 2013, KIDNEY INT SUPPL, V3, P446, DOI 10.1038/kisup.2013.93
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lane NE, 2013, J BONE MINER RES, V28, P2325, DOI 10.1002/jbmr.1985
   Lavi Moshayoff V, 2010, AM J PHYSIOL RENAL, V299, pF882, DOI 10.1152/ajprenal.00360.2010
   Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2014, ENDOCRINOLOGY, V155, P4785, DOI 10.1210/en.2013 1905
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   LUND B, 1980, J CLIN ENDOCR METAB, V50, P480, DOI 10.1210/jcem 50 3 480
   Maierhofer WJ, 1984, KIDNEY INT, V26, P752
   Mazzaferro S, 2014, SEMIN NEPHROL, V34, P598, DOI 10.1016/j.semnephrol.2014.09.006
   Mazzaferro S, 2010, ARCH BIOCHEM BIOPHYS, V503, P95, DOI 10.1016/j.abb.2010.06.028
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Miller PD, 2007, OSTEOPOROSIS INT, V18, P59, DOI 10.1007/s00198 006 0189 8
   Miller PD, 2009, SEMIN NEPHROL, V29, P144, DOI 10.1016/j.semnephrol.2009.01.007
   Mochizuki S, 2002, J BONE MINER METAB, V20, P14, DOI 10.1007/s774 002 8441 x
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Moe S., 2009, KIDNEY INT, V76, P3, DOI [10.1038/ki.2009.193, DOI 10.1038/KI.2009.193]
   Morony S, 2001, J BONE MINER RES, V16, pS148
   Murray TM, 2005, ENDOCR REV, V26, P78, DOI 10.1210/er.2003 0024
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016
   Qureshi AR, 2015, KIDNEY INT, V88, P1356, DOI 10.1038/ki.2015.194
   Rotondi S, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/872193
   Rubin MR, 2002, OSTEOPOROSIS INT, V13, P267, DOI 10.1007/s001980200026
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sumida K, 2016, OSTEOPOROSIS INT, V27, P1441, DOI 10.1007/s00198 015 3377 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   West SL, 2015, J BONE MINER RES, V30, P913, DOI 10.1002/jbmr.2406
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Yenchek RH, 2012, CLIN J AM SOC NEPHRO, V7, P1130, DOI 10.2215/CJN.12871211
   Zanchetta JR, 2003, J BONE MINER RES, V18, P539, DOI 10.1359/jbmr.2003.18.3.539
NR 63
TC 10
Z9 11
U1 0
U2 12
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1121 8428
EI 1724 6059
J9 J NEPHROL
JI J. Nephrol.
PD OCT
PY 2017
VL 30
IS 5
SI SI
BP 689
EP 699
DI 10.1007/s40620 017 0410 1
PG 11
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Urology & Nephrology
GA FI9XX
UT WOS:000412364100010
PM 28540603
DA 2025 08 17
ER

PT J
AU Keinan, D
   Yang, SY
   Cohen, RE
   Yuan, X
   Liu, TJ
   Li, YP
AF Keinan, David
   Yang, Shuying
   Cohen, Robert E.
   Yuan, Xue
   Liu, Tongjun
   Li, Yi Ping
TI Role of regulator of G protein signaling proteins in bone
SO FRONTIERS IN BIOSCIENCE LANDMARK
LA English
DT Article
DE Osteoblasts; Osteoclasts; Bone; Heterotrimeric G protein; G protein
   coupled receptor; PTH; PTHrP; Calcium Sensing Receptor; Regulator of G
   Protein Signaling; RGS2; RGS5; RGS10; RGS12; RGS18; Wnt; bone
   remodeling; bone development
ID HORMONE RELATED PEPTIDE; CALCIUM SENSING RECEPTOR; PARATHYROID HORMONE;
   RGS PROTEINS; COUPLED RECEPTOR; GENE EXPRESSION; IN VIVO; TERMINAL
   DIFFERENTIATION; NEGATIVE REGULATOR; MOLECULAR CLONING
AB Regulators of G protein signaling (RGS) proteins are a family with more than 30 proteins that all contain an RGS domain. In the past decade, increasing evidence has indicated that RGS proteins play crucial roles in the regulation of G protein coupling receptors (GPCR), G proteins, and calcium signaling during cell proliferation, migration, and differentiation in a variety of tissues. In bone, those proteins modulate bone development and remodeling by influencing various signaling pathways such as GPCR G protein signaling, Wnt, calcium oscillations and PTH. This review summarizes the recent advances in the understanding of the regulation of RGS genes expression, as well as the functions and mechanisms of RGS proteins, especially in regulating GPCR G protein signaling, Wnt signaling, calcium oscillations signaling and PTH signaling during bone development and remodeling. This review also highlights the regulation of different RGS proteins in osteoblasts, chondrocytes and osteoclasts. The knowledge from the recent advances of RGS study summarized in the review would provide the insights into new therapies for bone diseases.
C1 [Keinan, David; Yang, Shuying; Yuan, Xue; Liu, Tongjun] SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14214 USA.
   [Keinan, David; Cohen, Robert E.] SUNY Buffalo, Sch Dent Med, Dept Periodont & Endodont, Buffalo, NY 14214 USA.
   [Yang, Shuying] SUNY Buffalo, New York State Ctr Excellence Bioinformat & Life, Dev Genom Grp, Buffalo, NY 14214 USA.
   [Liu, Tongjun] Shandong Univ, Jinan Cent Hosp, Dept Stomatol, Jinan 250013, Peoples R China.
   [Li, Yi Ping] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
C3 State University of New York (SUNY) System; University at Buffalo, SUNY;
   State University of New York (SUNY) System; University at Buffalo, SUNY;
   State University of New York (SUNY) System; University at Buffalo, SUNY;
   Shandong University; Shandong First Medical University & Shandong
   Academy of Medical Sciences; University of Alabama System; University of
   Alabama Birmingham
RP Yang, SY (通讯作者)，SUNY Buffalo, Sch Dent Med, Dept Oral Biol, B36 Foster Hall, Buffalo, NY 14214 USA.
EM sy47@buffalo.edu
RI Cohen, Robert/HRD 7869 2023; Yang, Shuying/G 4599 2011; Yuan,
   Xue/L 8066 2017; Li, Yi Ping/ABF 9245 2020
OI Yuan, Xue/0000 0002 8063 9431; 
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases,
   part of the National Institutes of Health [AR055678, AR061052]
FX Research reported in this publication was supported by the National
   Institute of Arthritis and Musculoskeletal and Skin Diseases, part of
   the National Institutes of Health, under Award Number AR055678 to S.Y.
   and AR061052 to S.Y. The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   Anantharam A, 2002, METHOD ENZYMOL, V345, P60
   Anger T, 2007, J BIOCHEM MOL BIOL, V40, P899
   Beadling C, 1999, J IMMUNOL, V162, P2677
   BEKKER PJ, 1990, J BONE MINER RES, V5, P557
   BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092 8674(92)90165 9
   Bowler Wayne B., 1998, Frontiers in Bioscience, V3, pD769
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Brown E M, 1993, Curr Opin Nephrol Hypertens, V2, P541, DOI 10.1097/00041552 199307000 00004
   BROWN EM, 1983, J CLIN ENDOCR METAB, V56, P572, DOI 10.1210/jcem 56 3 572
   Chang WH, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1159945
   Chattopadhyay N, 2007, BIOCHEM PHARMACOL, V74, P438, DOI 10.1016/j.bcp.2007.04.020
   Cho H, 2003, BIOCHEM J, V371, P973, DOI 10.1042/BJ20021769
   Cho H, 2012, MOL CELL BIOL, V32, P4561, DOI 10.1128/MCB.00651 12
   CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0
   Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092 8674(02)00699 2
   De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235
   DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365
   Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960
   Doupnik CA, 2001, BBA GENE STRUCT EXPR, V1522, P97, DOI 10.1016/S0167 4781(01)00342 6
   Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461
   Druey KM, 2009, IMMUNOL RES, V43, P62, DOI 10.1007/s12026 008 8050 0
   Dvorak MM, 2007, ENDOCRINOLOGY, V148, P3156, DOI 10.1210/en.2007 0147
   Eszlinger M, 2004, EUR J ENDOCRINOL, V151, P383, DOI 10.1530/eje.0.1510383
   Fields RD, 1997, J NEUROSCI, V17, P7252
   Gensure RC, 2005, BIOCHEM BIOPH RES CO, V328, P666, DOI 10.1016/j.bbrc.2004.11.069
   Giorelli M, 2002, CELL SIGNAL, V14, P673, DOI 10.1016/S0898 6568(02)00011 6
   Gold SJ, 1997, J NEUROSCI, V17, P8024
   GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0
   Guo J, 2002, DEV CELL, V3, P183, DOI 10.1016/S1534 5807(02)00218 6
   Gwak J, 2012, CELL RES, V22, P237, DOI 10.1038/cr.2011.127
   Haller C, 2002, GENE, V297, P39, DOI 10.1016/S0378 1119(02)00883 1
   Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669
   Haÿ E, 2009, MOL CELL BIOL, V29, P953, DOI 10.1128/MCB.00349 08
   Hömme M, 2009, CALCIFIED TISSUE INT, V84, P305, DOI 10.1007/s00223 009 9222 1
   Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527
   Hömme M, 2003, ENDOCRINOLOGY, V144, P2496, DOI 10.1210/en.2002 0160
   Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0
   Hurst JH, 2009, BIOCHEM PHARMACOL, V78, P1289, DOI 10.1016/j.bcp.2009.06.028
   Ishii M, 2005, BIOCHEM J, V385, P65, DOI 10.1042/BJ20040404
   Ishii M, 2003, LIFE SCI, V74, P163, DOI 10.1016/j.lfs.2003.09.004
   Iwai K, 2007, J BONE MINER RES, V22, P1612, DOI 10.1359/JBMR.070612
   James CG, 2005, MOL BIOL CELL, V16, P5316, DOI 10.1091/mbc.E05 01 0084
   Kach J, 2012, AM J PHYSIOL HEART C, V303, pH19, DOI 10.1152/ajpheart.00764.2011
   Kameda T, 1998, BIOCHEM BIOPH RES CO, V245, P419, DOI 10.1006/bbrc.1998.8448
   Kamenetsky M, 2006, J MOL BIOL, V362, P623, DOI 10.1016/j.jmb.2006.07.045
   Kimple AJ, 2011, PHARMACOL REV, V63, P728, DOI 10.1124/pr.110.003038
   Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a
   Kiselyov K, 2003, CELL SIGNAL, V15, P243, DOI 10.1016/S0898 6568(02)00074 8
   KLEIN RF, 1991, J PHARMACOL EXP THER, V258, P877
   Ko JK, 2001, BIOCHEM BIOPH RES CO, V287, P1025, DOI 10.1006/bbrc.2001.5692
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Koh J, 2011, MOL ENDOCRINOL, V25, P867, DOI 10.1210/me.2010 0277
   Lee HK, 2010, MOL PHARMACOL, V78, P478, DOI 10.1124/mol.110.064394
   LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453
   Lh Hong, 2005, Zhongguo Zhong Yao Za Zhi, V30, P1685
   Lione AM, 2000, J NEUROCHEM, V75, P934, DOI 10.1046/j.1471 4159.2000.0750934.x
   Luo X, 2001, MOL CELL, V7, P651, DOI 10.1016/S1097 2765(01)00211 8
   Luttrell LM, 2008, MOL BIOTECHNOL, V39, P239, DOI 10.1007/s12033 008 9031 1
   Machuca I, 1999, EXP CELL RES, V250, P364, DOI 10.1006/excr.1999.4526
   Martin McCaffrey L, 2005, DEV DYNAM, V234, P438, DOI 10.1002/dvdy.20555
   McCudden CR, 2005, CELL MOL LIFE SCI, V62, P551, DOI 10.1007/s00018 004 4462 3
   Miao DS, 2001, J BIOL CHEM, V276, P32204, DOI 10.1074/jbc.M101084200
   Miles RR, 2000, ENDOCRINOLOGY, V141, P28, DOI 10.1210/en.141.1.28
   Millard SM, 2011, J BONE MINER RES, V26, P822, DOI 10.1002/jbmr.273
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Moratz C, 2004, METHOD ENZYMOL, V389, P15
   Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373
   Muallem S, 1999, CELL CALCIUM, V26, P173, DOI 10.1054/ceca.1999.0077
   Nakagawa T, 2001, EUR J PHARMACOL, V433, P29, DOI 10.1016/S0014 2999(01)01485 6
   Oldham WM, 2008, NAT REV MOL CELL BIO, V9, P60, DOI 10.1038/nrm2299
   Oliveira dos Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397
   Parks IK, 2001, J BIOL CHEM, V276, P915, DOI 10.1074/jbc.M005947200
   Peng J, 2008, ENDOCRINOLOGY, V149, P1329, DOI 10.1210/en.2007 0235
   Pi M, 2005, J BIOL CHEM, V280, P40201, DOI 10.1074/jbc.M505186200
   Ponting CP, 1999, J MOL MED, V77, P695, DOI 10.1007/s001099900054
   Regard JB, 2011, P NATL ACAD SCI USA, V108, P20101, DOI 10.1073/pnas.1114656108
   Richman RW, 2005, J BIOL CHEM, V280, P1521, DOI 10.1074/jbc.M406607200
   Richman RW, 2004, METHOD ENZYMOL, V390, P224
   Riekenberg S, 2009, FEBS J, V276, P649, DOI 10.1111/j.1742 4658.2008.06813.x
   Roman Roman S, 2004, J BIOL CHEM, V279, P5725, DOI 10.1074/jbc.M309233200
   Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795
   Roy AA, 2003, MOL PHARMACOL, V64, P587, DOI 10.1124/mol.64.3.587
   Roy AA, 2006, J BIOL CHEM, V281, P32684, DOI 10.1074/jbc.M604416200
   Sakamoto A, 2005, J BIOL CHEM, V280, P21369, DOI 10.1074/jbc.M500346200
   Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   Schiff ML, 2000, NATURE, V408, P723, DOI 10.1038/35047093
   SEGRE GV, 1995, MINER ELECTROL METAB, V21, P129
   Shi GX, 2004, J IMMUNOL, V172, P5175, DOI 10.4049/jimmunol.172.9.5175
   SILVE CM, 1982, J CELL BIOL, V94, P379, DOI 10.1083/jcb.94.2.379
   Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537
   Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo 110 2 506
   Taylor CW, 2001, CURR BIOL, V11, pR352, DOI 10.1016/S0960 9822(01)00192 0
   Teplyuk NM, 2008, J BIOL CHEM, V283, P27585, DOI 10.1074/jbc.M802453200
   Terzi D, 2009, PROG MOL BIOL TRANSL, V86, P299, DOI 10.1016/S1877 1173(09)86010 9
   Thirunavukkarasu K, 2002, J CELL BIOCHEM, V85, P837, DOI 10.1002/jcb.10176
   Tran Tiffany, 2010, Int J Cell Biol, V2010, P529376, DOI 10.1155/2010/529376
   Traynor J, 2012, DRUG ALCOHOL DEPEN, V121, P173, DOI 10.1016/j.drugalcdep.2011.10.027
   Tsingotjidou A, 2002, BONE, V30, P677, DOI 10.1016/S8756 3282(02)00698 1
   Ueno Y, 2003, J CELL BIOCHEM, V90, P267, DOI 10.1002/jcb.10623
   UZAWA T, 1995, BONE, V16, P477
   Wang LM, 2009, MOL ENDOCRINOL, V23, P1455, DOI 10.1210/me.2009 0084
   Wang Q, 2011, J BIOL CHEM, V286, P7854, DOI 10.1074/jbc.M110.160911
   Wang XH, 2004, J BIOL CHEM, V279, P133, DOI 10.1074/jbc.M310040200
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Wieland T, 2007, CURR OPIN PHARMACOL, V7, P201, DOI 10.1016/j.coph.2006.11.007
   Willard FS, 2004, METHOD ENZYMOL, V389, P56
   Willard MD, 2007, EMBO J, V26, P2029, DOI 10.1038/sj.emboj.7601659
   Wu MR, 2010, FRONT BIOSCI LANDMRK, V15, P957, DOI 10.2741/3656
   Xie GX, 2007, J MOL BIOL, V366, P349, DOI 10.1016/j.jmb.2006.11.045
   Xie ZH, 2010, J MOL CELL BIOL, V2, P357, DOI 10.1093/jmcb/mjq031
   Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549
   Yamaguchi T, 1998, ENDOCRINOLOGY, V139, P3561, DOI 10.1210/en.139.8.3561
   Yan Y, 2009, J CELL SCI, V122, P3566, DOI 10.1242/jcs.051904
   Yang SY, 2007, J CELL SCI, V120, P3362, DOI 10.1242/jcs.008300
   Yang SY, 2007, GENE DEV, V21, P1803, DOI 10.1101/gad.1544107
   Yang SY, 2007, J BONE MINER RES, V22, P45, DOI 10.1359/JBMR.061007
   Yang Z, 2011, J BIOL CHEM, V286, P11444, DOI [10.1074/jbc.M110.212480, 10.1074/jbc.M111.229344]
   Yu HMI, 2005, DEVELOPMENT, V132, P1995, DOI 10.1242/dev.01786
   ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V163, P1461, DOI 10.1016/0006 291X(89)91143 1
   Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687
   Zhang P, 2011, CIRC RES, V109, P320, DOI 10.1161/CIRCRESAHA.110.231423
   Zhang P, 2011, AM J PHYSIOL HEART C, V301, pH147, DOI 10.1152/ajpheart.00026.2011
   Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968 0004(99)01474 7
   Zhong HL, 2003, J BIOL CHEM, V278, P7278, DOI 10.1074/jbc.M208819200
NR 128
TC 18
Z9 24
U1 0
U2 35
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093 9946
EI 1093 4715
J9 FRONT BIOSCI LANDMRK
JI Front. Biosci.
PD JAN 1
PY 2014
VL 19
BP 634
EP 648
DI 10.2741/4232
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 294FR
UT WOS:000330029200004
PM 24389209
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Marathe, A
   Peterson, MC
   Mager, DE
AF Marathe, Anshu
   Peterson, Mark C.
   Mager, Donald E.
TI Integrated cellular bone homeostasis model for denosumab
   pharmacodynamics in multiple myeloma patients
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article; Proceedings Paper
CT Experimental Biology Annual Meeting
CY APR 05 09, 2008
CL San Diego, CA
SP Amer Soc Pharmacol & Expt Therapeut, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Biochem & Mol Biol, Amer Assoc Immunologists, Amer Assoc Anatomists, Amer Physiol Soc
ID MEDIATED DRUG DISPOSITION; KAPPA B LIGAND; PHARMACOKINETIC MODEL;
   RECEPTOR ACTIVATOR; OSTEOCLAST; RESORPTION; RANKL; OSTEOPROTEGERIN;
   MARROW; CELLS
AB The purpose of this study is to couple a cellular bone homeostasis model with the pharmacokinetics (PK) and mechanism of action of denosumab, an inhibitor of receptor activator of nuclear factor kappa B ligand, to characterize the time course of serum N telopeptide (NTX), a bone resorption biomarker, following single escalating doses in multiple myeloma (MM) patients. Mean PK and median serum NTX temporal profiles were extracted from a previously conducted randomized, double blind, double dummy, active controlled, multicenter study including 25 MM patients receiving escalating denosumab doses. Nonlinear denosumab PK profiles were well described by a target mediated disposition model that includes rapid binding of drug to its pharmacological target. Fixed PK profiles were integrated into a previously reported theoretical cellular model of osteoblast osteoclast interactions, and the NTX concentrations were linked to a resorbing active osteoclast (AOC) pool by a nonlinear transfer function. Reasonable fits were obtained for the NTX profiles from maximal likelihood estimation using the final model. Transfer function parameters, including the basal NTX level and the AOC concentration producing 50% of maximal NTX production, were estimated with good precision as 5.55 nM and 1.88 X 10( 5) pM. An indirect response model for inhibition of NTX production by denosumab was also used to characterize the data. Although this model adequately characterized the pharmacodynamic data, simulations conducted with the full model reveal that a cellular model coupled with clinical data has the distinct advantage of not only quantitatively describing data but also providing new testable hypotheses on the role of cellular system variables on drug response.
C1 [Marathe, Anshu; Mager, Donald E.] SUNY Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14260 USA.
   [Peterson, Mark C.] Amgen Inc, Thousand Oaks, CA 91320 USA.
C3 State University of New York (SUNY) System; University at Buffalo, SUNY;
   Amgen
RP Mager, DE (通讯作者)，SUNY Buffalo, Dept Pharmaceut Sci, 543 Hochstetter Hall, Buffalo, NY 14260 USA.
EM dmager@buffalo.edu
FU NIGMS NIH HHS [R01 GM057980, GM57980] Funding Source: Medline
CR [Anonymous], 1997, BIOMEDICAL SIMULATIO
   Aubin JE, 2000, OSTEOPOROSIS INT, V11, P905, DOI 10.1007/s001980070028
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   DAYNEKA NL, 1993, J PHARMACOKINET BIOP, V21, P457, DOI 10.1007/BF01061691
   Filvaroff E, 1998, CURR BIOL, V8, pR679, DOI 10.1016/S0960 9822(98)70434 8
   Heider U, 2003, CLIN CANCER RES, V9, P1436
   Hideshima T, 2003, IMMUNOL REV, V194, P164, DOI 10.1034/j.1600 065X.2003.00053.x
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Iqbal J, 2006, P NATL ACAD SCI USA, V103, P14925, DOI 10.1073/pnas.0606805103
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lobo ED, 2004, J PHARM SCI US, V93, P2645, DOI 10.1002/jps.20178
   Mager DE, 2005, PHARM RES DORDR, V22, P1589, DOI 10.1007/s11095 005 6650 0
   Mager DE, 2001, J PHARMACOKINET PHAR, V28, P507, DOI 10.1023/A:1014414520282
   Martin MJ, 2004, BONE, V35, P918, DOI 10.1016/j.bone.2004.06.010
   Matsumoto T, 2006, ANN NY ACAD SCI, V1068, P319, DOI 10.1196/annals.1346.035
   PETERSON MC, 2007, PAGE POP APPR GROUP
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Schwarz EM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2171
   Schwarz EM, 2005, CURR OPIN ORTHOP, V16, P370
   Sezer O, 2002, J CLIN ONCOL, V20, P353, DOI 10.1200/JCO.2002.20.1.353
   Sharma A, 1998, BRIT J CLIN PHARMACO, V45, P229, DOI 10.1046/j.1365 2125.1998.00676.x
NR 27
TC 55
Z9 62
U1 1
U2 7
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0022 3565
EI 1521 0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD AUG
PY 2008
VL 326
IS 2
BP 555
EP 562
DI 10.1124/jpet.108.137703
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Pharmacology & Pharmacy
GA 327VC
UT WOS:000257755600021
PM 18460643
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Siewe, N
   Friedman, A
AF Siewe, Nourridine
   Friedman, Avner
TI Breast Cancer Exosomal microRNAs Facilitate Pre Metastatic Niche
   Formation in the Bone: A Mathematical Model
SO BULLETIN OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE Pre metastatic niche; RANKL OPG RANK signaling system; Bone forming by
   osteoblasts; Bone resorption by osteoclasts; Denosumab; Alendronate
ID PRECURSOR DIFFERENTIATION; CELLS; OSTEOCLASTOGENESIS; MICROENVIRONMENT;
   OSTEOBLASTS; BISPHOSPHONATES; ACTIVATION; MECHANISMS; DENOSUMAB; DENSITY
AB Pre metastatic niche is a location where cancer cells, separating from a primary tumor, find "fertile soil " for growth and proliferation, ensuring successful metastasis. Exosomal miRNAs of breast cancer are known to enter the bone and degrade it, which facilitates cancer cells invasion into the bone interior and ensures its successful colonization. In this paper, we use a mathematical model to first describe, in health, the continuous remodeling of the bone by bone forming osteoblasts, bone resorbing osteoclasts and the RANKL OPG RANK signaling system, which keeps the balance between bone formation and bone resorption. We next demonstrate how breast cancer exosomal miRNAs disrupt this balance, either by increasing or by decreasing the ratio of osteoclasts/osteoblasts, which results in abnormal high bone resorption or abnormal high bone forming, respectively, and in bone weakening in both cases. Finally we consider the case of abnormally high resorption and evaluate the effect of drugs, which may increase bone density to normal level, thus protecting the bone from invasion by cancer cells.
C1 [Siewe, Nourridine] Rochester Inst Technol, Coll Sci, Sch Math Sci, Rochester, NY 14623 USA.
   [Friedman, Avner] Ohio State Univ, Dept Math, Columbus, OH 43210 USA.
C3 Rochester Institute of Technology; University System of Ohio; Ohio State
   University
RP Siewe, N (通讯作者)，Rochester Inst Technol, Coll Sci, Sch Math Sci, Rochester, NY 14623 USA.
EM nourridine@aims.ac.za
OI Siewe, Nourridine/0000 0002 3005 8508
FU Faculty Evaluation And Development (FEAD);  [15096]
FX AcknowledgementsThis work was supported by the Faculty Evaluation And
   Development (FEAD) Grant #15096 at Rochester Institute of Technology.
CR Abdelmaksoud Dammak R, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695916
   Aghajanian P, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0021 z
   Al Bari AA, 2020, FASEB BIOADV, V2, P668, DOI 10.1096/fba.2020 00058
   Amgen Manufacturing Limited a subsidiary of Amgen Inc, 2010, US Patent, Patent No. [7,097,834, 7097834]
   Amgen Manufacturing Limited a subsidiary of Amgen Inc, 2010, US Patent, Patent No. [6,740,522, 6740522]
   Amgen Manufacturing Limited a subsidiary of Amgen Inc, 2010, US Patent, Patent No. [7,364,736, 7364736]
   Amgen Manufacturing Limited a subsidiary of Amgen Inc, 2010, US Patent, Patent No. [7,411,050, 7411050]
   Araujo A, 2014, CANCER RES, V74, P2391, DOI 10.1158/0008 5472.CAN 13 2652
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   Boyce BF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02263
   Brozovich A, 2021, ORTHOP J SPORTS MED, V9, DOI 10.1177/23259671211058459
   Buenzli PR, 2010, IOP CONF SER MAT SCI, V10, DOI 10.1088/1757 899X/10/1/012132
   Coelho RM, 2016, J THEOR BIOL, V391, P1, DOI 10.1016/j.jtbi.2015.11.024
   Cook CV, 2022, AICHE J, DOI 10.1002/aic.17809
   Crane JL, 2016, METHODS MOL BIOL, V1344, P287, DOI 10.1007/978 1 4939 2966 5_18
   Croset M, 2014, J BONE MINER RES, V29, P1886, DOI 10.1002/jbmr.2215
   Deep G, 2020, MOL CARCINOGEN, V59, P323, DOI 10.1002/mc.23157
   Dettori D, 2018, MOL THER, V26, P2008, DOI 10.1016/j.ymthe.2018.05.020
   Dillekås H, 2019, CANCER MED US, V8, P5574, DOI 10.1002/cam4.2474
   Dong Q, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.733627
   Eggenhofer E, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00297
   Furesi G, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031285
   Gardner CR, 2007, CELL BIOL INT, V31, P672, DOI 10.1016/j.cellbi.2006.12.008
   Graham JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063884
   Gu PF, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.657158
   Gu ZY, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.956167
   Guo YX, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 0995 1
   Hashimoto K, 2018, P NATL ACAD SCI USA, V115, P2204, DOI 10.1073/pnas.1717363115
   Hassan MQ, 2012, J BIOL CHEM, V287, P42084, DOI 10.1074/jbc.M112.377515
   He ZY, 2018, J IMMUNOL, V200, P4059, DOI 10.4049/jimmunol.1800207
   HEANEY RP, 1958, J CLIN ENDOCR METAB, V18, P1246, DOI 10.1210/jcem 18 11 1246
   Hoogduijn MJ, 2019, STEM CELL TRANSL MED, V8, P1126, DOI 10.1002/sctm.19 0073
   Huang JF, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.55
   Iseri K, 2019, J BONE MINER RES, V34, P1014, DOI 10.1002/jbmr.3676
   Iseri K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193846
   Javanmard SH, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935 020 01394 6
   Ji B, 2014, INT J NUMER METH BIO, V30, P1085, DOI 10.1002/cnm.2645
   Jiang WL, 2020, J ORTHOP SURG HONG K, V28, DOI 10.1177/2309499020915989
   Jinnah AH, 2018, CANCERS, V10, DOI 10.3390/cancers10060176
   Jolly JJ, 2018, IRAN J MED SCI, V43, P208
   Keshishi D, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 03214 x
   Kirschner D. E., 2007, Uncertainty and sensitivity functions and implementation
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Kylmäoja E, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00780
   Le Pape F, 2016, J BONE ONCOL, V5, P93, DOI 10.1016/j.jbo.2016.02.008
   Leder BZ, 2018, JBMR PLUS, V2, P62, DOI 10.1002/jbm4.10041
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Li FXZ, 2019, ONCOL LETT, V18, P3935, DOI 10.3892/ol.2019.10776
   Liu J, 2017, SCI REP UK, V7, DOI 10.1038/srep40487
   Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011
   Lösslein AK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22103 5
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Lou SH, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen 2016 012802
   Makler A, 2020, EXPERT REV MOL DIAGN, V20, P387, DOI 10.1080/14737159.2020.1731308
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marathe A, 2008, J PHARMACOL EXP THER, V326, P555, DOI 10.1124/jpet.108.137703
   Marino S, 2008, J THEOR BIOL, V254, P178, DOI 10.1016/j.jtbi.2008.04.011
   Martin TJ., 2000, Aust Prescriber, V23, P130
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   MEEMA HE, 1978, ACTA RADIOL ONCOL, V17, P342, DOI 10.3109/02841867809127938
   Mishra PJ, 2011, METHODS MOL BIOL, V717, P245, DOI 10.1007/978 1 61779 024 9_14
   Narayanan Prasad, 2013, South Asian J Cancer, V2, P272, DOI 10.4103/2278 330X.119895
   Niu X, 2021, TRANSL BREAST CANC R, V2, P1
   Ottewell P, 2019, BREAST CANCER BASIC, V13, DOI 10.1177/1178223419843501
   Oumghar IA, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.584198
   Padalecki SS, 2002, BREAST CANCER RES, V4, P35, DOI 10.1186/bcr415
   Paglia DN, 2016, ENDOCRINOLOGY, V157, P3058, DOI 10.1210/en.2015 2037
   Patel AA, 2017, J EXP MED, V214, P1913, DOI 10.1084/jem.20170355
   Perico ME, 2022, CELLS BASEL, V11, DOI 10.3390/cells11010001
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pratiwi ED, 2019, BIOMED PHARMACOL J, V12, P1, DOI DOI 10.13005/bpj/1614
   Preethi KA, 2022, MOL CANCER, V21, DOI 10.1186/s12943 022 01525 9
   Qayoom I, 2018, BONE JOINT RES, V7, P548, DOI 10.1302/2046 3758.710.BJR 2018 0015.R2
   Qin YH, 2014, POSTGRAD MED J, V90, P643, DOI 10.1136/postgradmedj 2013 132387
   Qiu ZY, 2019, WOODH PUBL SER BIOM, P1, DOI 10.1016/B978 0 08 102717 2.00001 1
   Rajani R, 2021, ORTHO INFO AM ACA OR, P1
   Rantalainen T, 2013, J CLIN ENDOCR METAB, V98, P2037, DOI 10.1210/jc.2012 3748
   Raue R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042210
   Razaq A, 2019, CUREUS J MED SCIENCE, V11, DOI 10.7759/cureus.6401
   Ryser MD, 2009, J BONE MINER RES, V24, P860, DOI 10.1359/JBMR.081229
   Sanmartin MC, 2021, CRIT REV ONCOL HEMAT, V164, DOI 10.1016/j.critrevonc.2021.103416
   Scheiner S, 2013, COMPUT METHOD APPL M, V254, P181, DOI 10.1016/j.cma.2012.10.015
   Sharp M, 1995, DOHME CORP SUBSIDIAR
   Siewe N, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252620
   Stafford MYC, 2022, BIOSCIENCE REP, V42, DOI 10.1042/BSR20211972
   Taipaleenmäki H, 2016, ONCOTARGET, V7, P79018, DOI 10.18632/oncotarget.12593
   Tat SK, 2006, BONE, V39, P706, DOI 10.1016/j.bone.2006.03.016
   Tetsunaga T, 2017, J ORTHOP SCI, V22, P230, DOI 10.1016/j.jos.2016.11.017
   Tiedemann K, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00054
   Tomoyasu A, 1998, BIOCHEM BIOPH RES CO, V245, P382, DOI 10.1006/bbrc.1998.8443
   VANFURTH R, 1968, J EXP MED, V128, P415, DOI 10.1084/jem.128.3.415
   Volk SW, 2014, CALCIFIED TISSUE INT, V94, P621, DOI 10.1007/s00223 014 9843 x
   Wang SL, 2020, MOL MED REP, V21, P1125, DOI 10.3892/mmr.2020.10938
   Wang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027494
   Warren JT, 2015, J CELL BIOCHEM, V116, P2476, DOI 10.1002/jcb.25191
   Wu J, 2020, CANCER MED US, V9, P6909, DOI 10.1002/cam4.3379
   Yang XY, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.703640
   Ye Y, 2017, ONCOTARGET, V8, P94834, DOI 10.18632/oncotarget.22014
   Yuan XX, 2021, THERANOSTICS, V11, P1429, DOI 10.7150/thno.45351
   Zhang CG, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.607017
   Zhang H, 2008, ACTA ORTHOP, V79, P281, DOI 10.1080/17453670710015166
   Zhang J, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.611054
   Zhang WJ, 2019, TRENDS CANCER, V5, P95, DOI 10.1016/j.trecan.2018.12.004
   Zouani OF, 2013, BIOL OPEN, V2, P872, DOI 10.1242/bio.20134986
NR 104
TC 4
Z9 5
U1 1
U2 17
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0092 8240
EI 1522 9602
J9 B MATH BIOL
JI Bull. Math. Biol.
PD JAN
PY 2023
VL 85
IS 2
AR 12
DI 10.1007/s11538 022 01117 0
PG 28
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Mathematical & Computational
   Biology
GA 7P6ZN
UT WOS:000908851100001
PM 36607440
DA 2025 08 17
ER

PT J
AU You, TM
   Lee, KH
   Lee, SH
   Park, W
AF You, Tae Min
   Lee, Kang Hee
   Lee, Soo Hyeon
   Park, Wonse
TI Denosumab related osteonecrosis of the jaw: a case report and management
   based on pharmacokinetics
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Article
ID BONE METASTASES; ZOLEDRONIC ACID; POSTMENOPAUSAL OSTEOPOROSIS;
   RISK FACTORS; CANCER; BISPHOSPHONATES; PATIENT; PHARMACOLOGY; TURNOVER;
   THERAPY
AB Denosumab, a monoclonal antibody against the receptor activator for nuclear factor kappa B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast formation by targeting preosteclasts, in contrast to the traditional antiresorptive bisphosphonates that target mature osteoclasts. Osteonecrosis of the jaw (ONJ) is a well known, if rare, side effect of bisphosphonate therapy; however, cases of ONJ have also been reported since 2010 in patients taking denosumab. We describe here a patient who developed ONJ while receiving denosumab; the pharmacokinetics of denosumab and bisphosphonates are discussed in the context of ONJ management.
C1 [You, Tae Min] Dankook Univ, Dent Hosp, Dept Adv Gen Dent, Cheonan, South Korea.
   [Lee, Kang Hee; Park, Wonse] Yonsei Univ, Dent Hosp, Dept Adv Gen Dent, Seoul 120752, South Korea.
   [Lee, Soo Hyeon] Yonsei Univ, Coll Med, Dept Oncol, Seoul 120752, South Korea.
C3 Dankook University; Yonsei University; Yonsei University; Yonsei
   University Health System
RP Park, W (通讯作者)，Yonsei Univ, Coll Dent, Dept Adv Gen Dent, Yonseiro 50 1, Seoul 120752, South Korea.
EM Wonse@yuhs.ac
OI Park, Wonse/0000 0002 2081 1156
FU Basic Science Research Program through the National Research Foundation
   of Korea   Ministry of Science, ICT, and Future Planning [NRF 2013 R1 A1
   A 1009513]
FX This research was supported by a Basic Science Research Program through
   the National Research Foundation of Korea, funded by the Ministry of
   Science, ICT, and Future Planning (NRF 2013 R1 A1 A 1009513).
CR Aghaloo TL, 2014, J ORAL MAXIL SURG, V72, P702, DOI 10.1016/j.joms.2013.09.008
   Aghaloo TL, 2010, J ORAL MAXIL SURG, V68, P959, DOI 10.1016/j.joms.2009.10.010
   Araújo MG, 2015, PERIODONTOL 2000, V68, P122, DOI 10.1111/prd.12082
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Cardaropoli G, 2003, J CLIN PERIODONTOL, V30, P809, DOI 10.1034/j.1600 051X.2003.00366.x
   Damm Douglas D., 2013, General Dentistry, V61, P33
   de Molon RS, J BONE MINER RES
   Diz P, 2012, J AM DENT ASSOC, V143, P981, DOI 10.14219/jada.archive.2012.0323
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Kane CM, 2015, BMJ BRIT MED J, V350, DOI 10.1136/bmj.h315
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Landesberg R, 2011, ANN NY ACAD SCI, V1218, P62, DOI 10.1111/j.1749 6632.2010.05835.x
   Lewiecki EM, 2010, EXPERT OPIN BIOL TH, V10, P467, DOI 10.1517/14712591003604708
   Malan J, 2012, OR SURG OR MED OR PA, V114, P671, DOI 10.1016/j.oooo.2012.08.439
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Neuprez A, 2014, OSTEOPOROSIS INT, V25, P393, DOI 10.1007/s00198 013 2437 z
   O'Halloran M, 2014, AUST DENT J, V59, P516, DOI 10.1111/adj.12217
   Ohga N, 2015, QUINTESSENCE INT, V46, P621, DOI 10.3290/j.qi.a33528
   Otto S, 2013, J CRANIO MAXILL SURG, V41, P694, DOI 10.1016/j.jcms.2013.05.038
   Papamerkouriou YM, 2015, EXPERT OPIN BIOL TH, V15, P213, DOI 10.1517/14712598.2015.978853
   Pichardo SEC, 2013, J CRANIO MAXILL SURG, V41, pE65, DOI 10.1016/j.jcms.2012.10.014
   Ristow O, 2014, BRIT J ORAL MAX SURG, V52, P308, DOI 10.1016/j.bjoms.2014.01.021
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Sigua Rodriguez EA, 2014, INT J DENT, V2014
   Silva I, 2012, ACTA REUMATOL PORT, V37, P302
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Taylor KH, 2010, BRIT J ORAL MAX SURG, V48, P221, DOI 10.1016/j.bjoms.2009.08.030
   Uyanne Jettie, 2014, Dent Clin North Am, V58, P369, DOI 10.1016/j.cden.2013.12.006
   Yamashita Junro, 2012, J Evid Based Dent Pract, V12, P233, DOI 10.1016/S1532 3382(12)70046 5
   Zwolak P, 2013, ANTICANCER RES, V33, P2981
NR 36
TC 24
Z9 24
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 2212 4403
EI 1528 395X
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD NOV
PY 2015
VL 120
IS 5
BP 548
EP 553
DI 10.1016/j.oooo.2015.07.017
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CW2OY
UT WOS:000364833200009
PM 26337218
DA 2025 08 17
ER

PT J
AU Terpos, E
   Christoulas, D
   Gavriatopoulou, M
AF Terpos, Evangelos
   Christoulas, Dimitrios
   Gavriatopoulou, Maria
TI Biology and treatment of myeloma related bone disease
SO METABOLISM CLINICAL AND EXPERIMENTAL
LA English
DT Article
DE Multiple myeloma; Bone disease; Receptor activator of nuclear factor kB
   ligand (RANKL); Wnt pathway
ID KAPPA B LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; ADVANCED
   MULTIPLE MYELOMA; SKELETAL RELATED EVENTS; NECROSIS FACTOR ALPHA;
   ZOLEDRONIC ACID; ACTIVIN A; RECEPTOR ACTIVATOR; DOUBLE BLIND;
   BREAST CANCER
AB Myeloma bone disease (MBD) is the most common complication of multiple myeloma (MM), resulting in skeleton related events (SREs) such as severe bone pain, pathologic fractures, vertebral collapse, hypercalcemia, and spinal cord compression that cause significant morbidity and mortality. It is due to an increased activity of osteoclasts coupled to the suppressed bone formation by osteoblasts. Novel molecules and pathways that are implicated in osteoclast activation and osteoblast inhibition have recently been described, including the receptor activator of nuclear factor kB ligand/osteoprotegerin pathway, activin A and the wingless type signaling inhibitors, dickkopf 1 (DKK 1) and sclerostin. These molecules interfere with tumor growth and survival, providing possible targets for the development of novel drugs for the management of lytic disease in myeloma but also for the treatment of MM itself. Currently, bisphosphonates are the mainstay of the treatment of myeloma bone disease although several novel agents such as denosumab and sotatercept appear promising. This review focuses on recent advances in MBD pathophysiology and treatment, in addition to the established therapeutic guidelines. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Terpos, Evangelos; Christoulas, Dimitrios; Gavriatopoulou, Maria] Univ Athens, Alexandra Gen Hosp, Dept Clin Therapeut, Sch Med, 80 Vas Sofias Ave, Athens 11528, Greece.
C3 Alexandra Hospital; National & Kapodistrian University of Athens
RP Terpos, E (通讯作者)，Univ Athens, Alexandra Gen Hosp, Dept Clin Therapeut, Sch Med, 80 Vas Sofias Ave, Athens 11528, Greece.
EM eterpos@med.uoa.gr
RI Terpos, Evangelos/AAD 3667 2019; Gavriatopoulou, Maria/AAD 3698 2019
OI Gavriatopoulou, Maria/0000 0002 6244 1229; Terpos,
   Evangelos/0000 0001 5133 1422
FU Amgen; Janssen
FX ET discloses research support from Amgen and Janssen; honoraria from
   Amgen, Janssen, Celgene and Novartis.
CR Abdulkadyrov KM, 2014, BRIT J HAEMATOL, V165, P814, DOI 10.1111/bjh.12835
   Abildgaard N, 2000, EUR J HAEMATOL, V64, P121, DOI 10.1034/j.1600 0609.2000.90074.x
   [Anonymous], EUR J CANC S
   Badros A, 2008, J CLIN ONCOL, V26, P5904, DOI 10.1200/JCO.2008.16.9300
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   BATAILLE R, 1991, J CLIN INVEST, V88, P62, DOI 10.1172/JCI115305
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bruce NJ, 1999, BRIT J HAEMATOL, V104, P358, DOI 10.1046/j.1365 2141.1999.01194.x
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chang ST, 2012, BONE, V51, P524, DOI 10.1016/j.bone.2012.05.010
   Chantry AD, 2010, J BONE MINER RES, V25, P2357, DOI 10.1002/jbmr.142
   Christoulas D, 2009, EXPERT REV HEMATOL, V2, P385, DOI 10.1586/ehm.09.36
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Colucci S, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.22
   Corso A, 2007, LEUKEMIA, V21, P1545, DOI 10.1038/sj.leu.2404682
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534
   Daragon A, 1993, Eur J Med, V2, P449
   Delgado Calle J, 2014, CURR OPIN SUPPORT PA, V8, P407, DOI 10.1097/SPC.0000000000000090
   Diamond T, 2011, AM J HEMATOL, V86, P617, DOI 10.1002/ajh.22030
   Dimopoulos MA, 2009, ANN ONCOL, V20, P117, DOI 10.1093/annonc/mdn554
   Dimopoulos MA, 2006, HAEMATOL HEMATOL J, V91, P968
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Eijken M, 2007, FASEB J, V21, P2949, DOI 10.1096/fj.07 8080com
   EVANS CE, 1992, CLIN EXP METASTAS, V10, P33, DOI 10.1007/BF00163574
   Fajardo RJ, 2010, BONE, V46, P64, DOI 10.1016/j.bone.2009.09.018
   Farrugia AN, 2003, CANCER RES, V63, P5438
   Favus MJ, 2010, NEW ENGL J MED, V363, P2027, DOI 10.1056/NEJMct1004903
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Fuller K, 2000, BIOCHEM BIOPH RES CO, V268, P2, DOI 10.1006/bbrc.2000.2075
   Gavriatopoulou M, 2009, EXPERT OPIN THER TAR, V13, P839, DOI 10.1517/14728220903025770
   George J, 2006, BIOTECHNOL BIOENG, V95, P404, DOI 10.1002/bit.20939
   Gimsing P, 2010, LANCET ONCOL, V11, P973, DOI 10.1016/S1470 2045(10)70198 4
   Giuliani N, 2001, BLOOD, V98, P3527, DOI 10.1182/blood.V98.13.3527
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Hedger MP, 2011, VITAM HORM, V85, P255, DOI 10.1016/B978 0 12 385961 7.00013 5
   Heider U, 2003, CLIN CANCER RES, V9, P1436
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Herrera L, 2015, OSTEOPOROSIS INT, V26, P1499, DOI 10.1007/s00198 014 3020 y
   Hill P A, 1998, Br J Orthod, V25, P101
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Hofbauer LC, 1998, EUR J ENDOCRINOL, V139, P152, DOI 10.1530/eje.0.1390152
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Iyer SP, 2014, BRIT J HAEMATOL, V167, P366, DOI 10.1111/bjh.13056
   Jakob C, 2009, CLIN LYMPHOMA MYELOM, V9, P430, DOI 10.3816/CLM.2009.n.085
   Janckila AJ, 2001, CLIN CHEM, V47, P74
   Kaiser M, 2008, EUR J HAEMATOL, V80, P490, DOI 10.1111/j.1600 0609.2008.01065.x
   Kawabata N, 2007, LIFE SCI, V81, P8, DOI 10.1016/j.lfs.2007.04.011
   Kogianni G, 2008, J BONE MINER RES, V23, P915, DOI 10.1359/JBMR.080207
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   LAHTINEN R, 1992, LANCET, V340, P1049, DOI 10.1016/0140 6736(92)93075 X
   Lewiecki EM, 2011, NAT REV RHEUMATOL, V7, P631, DOI 10.1038/nrrheum.2011.130
   Lloyd AA, 2017, P NATL ACAD SCI USA, V114, P8722, DOI 10.1073/pnas.1704460114
   Lotinun S, 2010, BONE, V46, P1082, DOI 10.1016/j.bone.2010.01.370
   Luisi S, 2001, EUR J ENDOCRINOL, V145, P225, DOI 10.1530/eje.0.1450225
   Mancino AT, 2001, J SURG RES, V100, P18, DOI 10.1006/jsre.2001.6204
   McCloskey EV, 2001, BRIT J HAEMATOL, V113, P1035, DOI 10.1046/j.1365 2141.2001.02851.x
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   MCSHEEHY PMJ, 1986, ENDOCRINOLOGY, V119, P1654, DOI 10.1210/endo 119 4 1654
   Melton LJ, 2005, J BONE MINER RES, V20, P487, DOI 10.1359/JBMR.041131
   Menssen HD, 2002, J CLIN ONCOL, V20, P2353, DOI 10.1200/JCO.2002.02.032
   Migliorati CA, 2005, J AM DENT ASSOC, V136, P1658, DOI 10.14219/jada.archive.2005.0108
   Mitsiades CS, 2006, EUR J CANCER, V42, P1564, DOI 10.1016/j.ejca.2005.12.025
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Montefusco V, 2008, LEUKEMIA LYMPHOMA, V49, P2156, DOI 10.1080/10428190802483778
   Morgan GJ, 2011, LANCET ONCOL, V12, P743, DOI 10.1016/S1470 2045(11)70157 7
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Moschen AR, 2005, GUT, V54, P479, DOI 10.1136/gut.2004.044370
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood 2002 12 3905
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Politou M, 2004, BRIT J HAEMATOL, V126, P686, DOI 10.1111/j.1365 2141.2004.05092.x
   Politou MC, 2006, INT J CANCER, V119, P1728, DOI 10.1002/ijc.22033
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Raje N, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2015.96
   Raje N, 2017, 16 INT MYEL WORKSH M
   Raje N, 2016, CLIN CANCER RES, V22, P1378, DOI 10.1158/1078 0432.CCR 15 1864
   Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756 3282(01)00682 2
   Roodman GD, 2004, BLOOD CELL MOL DIS, V32, P290, DOI 10.1016/j.bcmd.2004.01.001
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Ruckle J, 2009, J BONE MINER RES, V24, P744, DOI 10.1359/JBMR.081208
   Sati HIA, 1999, BRIT J HAEMATOL, V104, P350, DOI 10.1046/j.1365 2141.1999.01193.x
   Scullen T, 2013, LEUKEMIA, V27, P1715, DOI 10.1038/leu.2013.50
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Standal T, 2002, BLOOD, V100, P3002, DOI 10.1182/blood 2002 04 1190
   Steinman RM, 2005, ADV EXP MED BIOL, V560, P83
   Sugatani T, 2003, J CELL BIOCHEM, V90, P59, DOI 10.1002/jcb.10613
   TAUBE T, 1992, EUR J HAEMATOL, V49, P192
   Terpos E, 2017, HAEMATOLOGICA, V102, P318
   Terpos E, 2012, ANN ONCOL, V23, P2681, DOI 10.1093/annonc/mds068
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Terpos E, 2010, LEUKEMIA, V24, P1700, DOI 10.1038/leu.2010.173
   Terpos E, 2014, EXPERT REV HEMATOL, V7, P113, DOI 10.1586/17474086.2013.874943
   Terpos E, 2013, J CLIN ONCOL, V31, P2347, DOI 10.1200/JCO.2012.47.7901
   Terpos E, 2012, INT J CANCER, V131, P1466, DOI 10.1002/ijc.27342
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Tsukii K, 1998, BIOCHEM BIOPH RES CO, V246, P337, DOI 10.1006/bbrc.1998.8610
   VALENTINOPRAN A, 1982, BRIT J HAEMATOL, V52, P601, DOI 10.1111/j.1365 2141.1982.tb03936.x
   Vanderkerken K, 2003, CANCER RES, V63, P287
   Vij R, 2009, AM J HEMATOL, V84, P650, DOI 10.1002/ajh.21509
   Wang JC, 2016, INT J CARDIOL, V215, P232, DOI 10.1016/j.ijcard.2016.04.088
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yee AJ, 2012, CLIN INTERV AGING, V7, P331, DOI 10.2147/CIA.S14566
   Yonemori K, 2008, CANCER SCI, V99, P1237, DOI 10.1111/j.1349 7006.2008.00803.x
   Zervas K, 2006, BRIT J HAEMATOL, V134, P620, DOI 10.1111/j.1365 2141.2006.06230.x
NR 124
TC 46
Z9 54
U1 0
U2 7
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0026 0495
EI 1532 8600
J9 METABOLISM
JI Metab. Clin. Exp.
PD MAR
PY 2018
VL 80
BP 80
EP 90
DI 10.1016/j.metabol.2017.11.012
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FY0XE
UT WOS:000426535200009
PM 29175022
DA 2025 08 17
ER

PT J
AU Santiago, F
   Oguma, J
   Brown, AMC
   Laurence, J
AF Santiago, Francisco
   Oguma, Junya
   Brown, Anthony M. C.
   Laurence, Jeffrey
TI Noncanonical Wnt signaling promotes osteoclast differentiation and is
   facilitated by the human immunodeficiency virus protease inhibitor
   ritonavir
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE beta Catenin; Human immunodeficiency virus; Osteoclast; Pathogenesis;
   Protease inhibitor; Wnt signaling
ID BONE MINERAL DENSITY; BETA CATENIN; PATHWAY; CELLS; ADIPOGENESIS;
   OSTEOBLASTS; EXPRESSION
AB Wnt proteins that signal via the canonical Wnt/beta catenin pathway directly regulate osteoblast differentiation. In contrast, most studies of Wnt related effects on osteoclasts involve indirect changes. While investigating bone mineral density loss in the setting of human immunodeficiency virus (HIV) infection and its treatment with the protease inhibitor ritonavir (RTV), we observed that RN decreased nuclear localization of beta catenin, critical to canonical Wnt signaling, in primary human and murine osteoclast precursors. This occurred in parallel with upregulation of Wnt5a and Wnt5b transcripts. These Wnts typically stimulate noncanonical Wnt signaling, and this can antagonize the canonical Wnt pathway in many cell types, dependent upon Wnt receptor usage. We now document RN mediated upregulation of Wnt5a/b protein in osteoclast precursors. Recombinant Wnt5b and retrovirus mediated expression of Wnt5a enhanced osteoclast differentiation from human and murine monocytic precursors, processes facilitated by RN. In contrast, canonical Wnt signaling mediated by Wnt3a suppressed osteoclastogenesis. Both RN and Wnt5b inhibited canonical, beta catenin/T cell factor based Wnt reporter activation in osteoclast precursors. RTV and Wnt5 induced osteoclast differentiation were dependent upon the receptor like tyrosine kinase Ryk, suggesting that Ryk may act as a Wnt5a/b receptor in this context. This is the first demonstration of a direct role for Wnt signaling pathways and Ryk in regulation of osteoclast differentiation, and its modulation by a clinically important drug, ritonavir. These studies also reveal a potential role for noncanonical Wnt5a/b signaling in acceleration of bone mineral density loss in HIV infected individuals, and illuminate a potential means of influencing such processes in disease states that involve enhanced osteoclast activity. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Laurence, Jeffrey] Weill Cornell Med Coll, New York Blood Ctr, Lab AIDS Virus Res, Dept Med,Div Hematol Oncol, New York, NY 10065 USA.
   [Oguma, Junya; Brown, Anthony M. C.] Weill Cornell Med Coll, Dept Cell & Dev Biol, New York, NY 10065 USA.
C3 Cornell University; Weill Cornell Medicine; New York Blood Center;
   Cornell University; Weill Cornell Medicine
RP Laurence, J (通讯作者)，Weill Cornell Med Coll, New York Blood Ctr, Lab AIDS Virus Res, Dept Med,Div Hematol Oncol, 310 E 67th St, New York, NY 10065 USA.
EM jlaurenc@med.cornell.edu
RI Oguma, Junya/GPK 1859 2022
FU National Institutes of Health [DK65511, AI65200, CA123238]; Qatar
   National Research Fund [NPRP 08 632 3 132]; Angelo Donghia Fund
FX This work was supported by National Institutes of Health Grants DK65511
   and AI65200 (to J.L.) and CA123238 (to A.B.), Qatar National Research
   Fund Grant NPRP 08 632 3 132 (to A.B.), and the Angelo Donghia Fund (to
   J.L.). We are grateful to Kate McCarty for assistance with the siRNA
   experiments, Jordan Doyle for help with construction of beta catenin/TCF
   reporters, and Mariya A. Babayeva for help with flow cytometry. We thank
   the National Institutes of Health AIDS Research and Reference Reagent
   Program for providing the antiretroviral drugs and recombinant HIV
   proteins.
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bonjoch A, 2010, AIDS, V24, P2827, DOI 10.1097/QAD.0b013e328340a28d
   Duvivier C, 2009, AIDS, V23, P817, DOI 10.1097/QAD.0b013e328328f789
   Fakruddin JM, 2003, J BIOL CHEM, V278, P48251, DOI 10.1074/jbc.M304676200
   Fradkin LG, 2010, TRENDS NEUROSCI, V33, P84, DOI 10.1016/j.tins.2009.11.005
   Glass DA, 2006, ANN NY ACAD SCI, V1068, P117, DOI 10.1196/annals.1346.015
   Goldring SR, 2007, NAT MED, V13, P133, DOI 10.1038/nm0207 133
   Grigsby IF, 2010, BIOCHEM BIOPH RES CO, V394, P48, DOI 10.1016/j.bbrc.2010.02.080
   Kanazawa A, 2005, BIOCHEM BIOPH RES CO, V330, P505, DOI 10.1016/j.bbrc.2005.03.007
   Maeda K, 2009, BONE, V44, pS50, DOI 10.1016/j.bone.2009.01.129
   Malizia A.P., 2008, AIDS, V23, P243
   Masckauchan TNH, 2006, MOL BIOL CELL, V17, P5163, DOI 10.1091/mbc.E06 04 0320
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Mikels A, 2009, J BIOL CHEM, V284, P30167, DOI 10.1074/jbc.M109.041715
   Modarresi R, 2009, AM J PATHOL, V174, P123, DOI 10.2353/ajpath.2009.080484
   Monaghan H, 2001, HISTOPATHOLOGY, V39, P611, DOI 10.1046/j.1365 2559.2001.01287.x
   Saitoh T, 2002, INT J MOL MED, V10, P345
   Sato A, 2010, EMBO J, V29, P41, DOI 10.1038/emboj.2009.322
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Syed F, 2007, BIOMARKERS, V12, P414, DOI 10.1080/13547500701192652
   Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158
   van Amerongen R, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.135re9
   van Tienen FHJ, 2009, BIOCHEM BIOPH RES CO, V387, P207, DOI 10.1016/j.bbrc.2009.07.004
   Yin MT, 2011, OSTEOPOROSIS INT, V22, P1459, DOI 10.1007/s00198 010 1363 6
NR 26
TC 44
Z9 54
U1 1
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 6
PY 2012
VL 417
IS 1
BP 223
EP 230
DI 10.1016/j.bbrc.2011.11.089
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 881MU
UT WOS:000299491600039
PM 22142846
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Gan, DH
   Xu, XW
   Chen, DQ
   Feng, P
   Xu, ZW
AF Gan, Donghao
   Xu, Xiaowei
   Chen, Deqiang
   Feng, Peng
   Xu, Zhanwang
TI Network Pharmacology Based Pharmacological Mechanism of the Chinese
   Medicine Rhizoma drynariae Against Osteoporosis
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Medicine, Chinese Traditional; Molecular Mechanisms of Pharmacological
   Action; Osteoporosis; Protein Interaction Maps
ID SIGNALING PATHWAY; OXIDATIVE STRESS; BETA SITOSTEROL; WEB SERVER;
   KAPPA B; BONE; PREDICTION; MICE; CYTOSCAPE; NARINGIN
AB Rhizoma drynariae is the main traditional Chinese medicine used for the treatment of osteoporosis, but its anti osteoporotic targeting mechanism has not been fully elucidated due to the complexity of its active ingredients. In this study, the pharmacological mechanism of action of Rhizoma drynariae against osteoporosis was studied by integrating pharmacological concepts.
   The pharmacokinetic characteristics of selected major active constituents of Rhizoma drynariae and the SMILES structural similarity were used to predict related targets. A literature search was conducted to identify known osteoporosis treatment targets, which were then combined with the predicted targets to construct the direct or indirect target interaction network map of Rhizoma drynariae against osteoporosis. Finally, data on the key targets of the interactions, ranked according to relevant node parameters obtained through pathway enrichment analysis and screening of key targets and active ingredients of Rhizoma drynariae, were used to perform molecular docking simulation.
   We screened 16 active ingredients of Rhizoma drynariae, and 7 key targets with direct or indirect effects with a high frequency were obtained. These main pathways were found to play important roles in the PI3k akt signaling pathway, osteoclast differentiation, Wnt signaling pathway, and estrogen signaling pathway. Molecular docking showed that most active ingredients of Rhizoma drynariae had strong binding efficiency with key targets.
   Based on network pharmacology, we conclude that Rhizoma drynariae plays an anti osteoporotic role by directly or indirectly targeting multiple major signaling pathways and influencing the proliferation and differentiation of multiple types of cells.
C1 [Gan, Donghao; Xu, Xiaowei; Chen, Deqiang; Feng, Peng; Xu, Zhanwang] Shandong Univ Tradit Chinese Med, Coll Clin Med 1, Jinan, Shandong, Peoples R China.
   [Chen, Deqiang; Xu, Zhanwang] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Orthoped, Jinan, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University
   of Traditional Chinese Medicine
RP Xu, ZW (通讯作者)，Shandong Univ Tradit Chinese Med, Coll Clin Med 1, Jinan, Shandong, Peoples R China.; Xu, ZW (通讯作者)，Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Orthoped, Jinan, Shandong, Peoples R China.
EM xzw6001@163.com
RI feng, peng/JAX 4757 2023; Gan, Donghao/JYP 7839 2024; Xu,
   Xiaowei/I 6687 2018
OI FENG, PENG/0009 0002 3516 5414; 
FU National Natural Science Foundation of China [81473709]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (No. 81473709)
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Ambavade SD, 2014, ORIENTAL PHARM EXP M, V14, P193, DOI 10.1007/s13596 014 0151 9
   Amberger JS, 2017, CURR PROTOC BIOINFOR, V58
   Ambrogini E, 2010, CELL METAB, V11, P136, DOI 10.1016/j.cmet.2009.12.009
   Bone YA AJ, 2013, OSTEOPOROSIS INT, V24, P2377
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   BRITTO JM, 1994, ENDOCRINOLOGY, V134, P169, DOI 10.1210/en.134.1.169
   Choi SW, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/810563
   Chou CW, 2016, BBA CLIN, V5, P124, DOI 10.1016/j.bbacli.2016.03.001
   Cray JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069067
   Diao TY, 2014, J BONE MINER METAB, V32, P261, DOI 10.1007/s00774 013 0500 7
   Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293
   Gupta T, 2018, J DIET S
   He GQ, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00365
   Hsin KY, 2016, NUCLEIC ACIDS RES, V44, pW507, DOI 10.1093/nar/gkw335
   Hu ZB, 2015, SCI REP UK, V5, DOI 10.1038/srep18655
   Huang Y, 2014, BIOMED CHROMATOGR, V28, P878, DOI 10.1002/bmc.3194
   Jia M, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/364604
   Kim HK, 2013, MOLECULES, V18, P15474, DOI 10.3390/molecules181215474
   Kwok T, 2012, OSTEOPOROSIS INT, V23, P2159, DOI 10.1007/s00198 011 1831 7
   Leung VYL, 2017, CONNECT TISSUE RES, V58, P573, DOI 10.1080/03008207.2017.1282951
   Li GY, 2014, ARCH ORAL BIOL, V59, P513, DOI 10.1016/j.archoralbio.2014.02.015
   Li JS, 2015, SCI REP UK, V5, DOI 10.1038/srep15290
   Li LN, 2011, PHYTOMEDICINE, V18, P985, DOI 10.1016/j.phymed.2011.03.002
   Li S, 2007, IET SYST BIOL, V1, P51, DOI 10.1049/iet syb:20060032
   Lin Y, 2008, CURR CANCER DRUG TAR, V8, P634, DOI 10.2174/156800908786241050
   Liu H, 2013, J ETHNOPHARMACOL, V146, P773, DOI 10.1016/j.jep.2013.02.004
   Liu XY, 2012, J ETHNOPHARMACOL, V139, P311, DOI 10.1016/j.jep.2011.11.017
   Liu ZK, 2014, CAN J PHYSIOL PHARM, V92, P117, DOI 10.1139/cjpp 2013 0298
   Ma Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12709
   Manolagas SC, 2007, MOL ENDOCRINOL, V21, P2605, DOI 10.1210/me.2007 0259
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Neugebauer J, 2018, HUM MOL GENET, V27, P4249, DOI 10.1093/hmg/ddy318
   Nicolaidou V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039871
   Pang WY, 2010, BRIT J PHARMACOL, V159, P1693, DOI 10.1111/j.1476 5381.2010.00664.x
   Qin LJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150070
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tang Y, 2015, BIOSYSTEMS, V127, P67, DOI 10.1016/j.biosystems.2014.11.005
   Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a
   Valerio M, 2011, INT IMMUNOPHARMACOL, V11, P1012, DOI 10.1016/j.intimp.2011.02.018
   Vigneron A, 2010, AGING US, V2, P471, DOI 10.18632/aging.100189
   Wang SL, 2017, ONCOTARGET, V8, P14549, DOI 10.18632/oncotarget.14675
   Wang YL, 2017, NUCLEIC ACIDS RES, V45, pD955, DOI 10.1093/nar/gkw1118
   Wei M, 2007, AM J CHINESE MED, V35, P663, DOI 10.1142/S0192415X07005156
   Wu Q, 2015, MED SCI MONITOR, V21
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   Ye H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087864
   Yong W, 2012, EVID BASED COMPL ALT, V2012, P69853
   Zhang Wen, 2010, Chinese Medical Sciences Journal, V25, P1
   Zou W, 2013, MOL CELL BIOL, V33, P830, DOI 10.1128/MCB.00790 12
NR 54
TC 52
Z9 60
U1 1
U2 58
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643 3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD AUG 1
PY 2019
VL 25
BP 5700
EP 5716
DI 10.12659/MSM.915170
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA IO0UZ
UT WOS:000479097100002
PM 31368456
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Chitre, M
   Shechter, D
   Grauer, A
AF Chitre, Mona
   Shechter, David
   Grauer, Andreas
TI Denosumab for treatment of postmenopausal osteoporosis
SO AMERICAN JOURNAL OF HEALTH SYSTEM PHARMACY
LA English
DT Article
DE Alendronic acid; Antibodies; Bisphosphonates; Bone density; Denosumab;
   Fractures; Injections; Mechanism of action; Osteoporosis; Postmenopause;
   Toxicity
ID BONE MINERAL DENSITY; OSTEOCLAST DIFFERENTIATION; BISPHOSPHONATE
   THERAPY; OSTEOPROTEGERIN LIGAND; VERTEBRAL FRACTURE; WOMEN; TURNOVER;
   ALENDRONATE; PREVENTION; MANAGEMENT
AB Purpose. The pharmacologic properties, clinical efficacy, and safety profile of the injectable agent denosumab for the treatment of postmenopausal women with osteoporosis are reviewed.
   Summary. Denosumab, a human monoclonal antibody that targets a key protein mediator of bone resorption, was approved by the Food and Drug Administration in June 2010 for the treatment of postmenopausal women with osteoporosis who are at high risk for fracture, including "patients who have failed or are intolerant to other available osteoporosis therapy" Available in a 60 mg prefilled syringe, denosumab should be administered subcutaneously by a health care professional at six month intervals. In Phase III clinical efficacy trials involving nearly 10,000 postmenopausal women, the use of denosumab was associated with a number of significant benefits: reduced bone resorption, increased bone mass, and reduced rates of vertebral, nonvertebral, and hip fractures. Results of two comparison studies indicated that denosumab therapy increased bone mineral density (BMD) at various skeletal sites to a significantly greater extent than alendronate therapy. In the largest clinical trial of the drug to date, adverse effects occurring significantly more often with denosumab versus placebo included eczema related effects and cellulitis; long term safety evaluations are ongoing.
   Conclusion. Denosumab has been shown to decrease bone resorption; increase BMD at all skeletal sites measured; and significantly reduce rates of vertebral, nonvertebral, and hip fractures in postmenopausal women with osteoporosis. Denosumab appears to have a favorable risk:benefit profile and provides a new treatment option for many patients in this population.
C1 [Chitre, Mona] Excellus BlueCross BlueShield, Clin Serv Strategy & Policy, Rochester, NY 14647 USA.
   [Shechter, David; Grauer, Andreas] Amgen Inc, Global Dev, Thousand Oaks, CA 91320 USA.
C3 Amgen
RP Chitre, M (通讯作者)，Excellus BlueCross BlueShield, Clin Serv Strategy & Policy, 165 Court St, Rochester, NY 14647 USA.
EM mona.chitre@flrx.com
FU Amgen Inc.
FX Supported by funding from Amgen Inc.
CR [Anonymous], PROL DEN FULL PRESCR
   [Anonymous], BON INJ IB SOD FULL
   [Anonymous], 2002, Americas bone health: the state of osteoporosis and low bone mass in our nation
   [Anonymous], NAT KIDN FDN SPRING
   [Anonymous], STAT HLTH CAR QUAL R
   [Anonymous], XGEV DEN FULL PRESCR
   [Anonymous], BON HLTH OST REP SUR
   [Anonymous], MUSCULOSKELETAL COND
   [Anonymous], EFFECT DENOSUMAB INC
   [Anonymous], J BONE MINER RES S1
   [Anonymous], 2010, Clinical Guidelines: PMTCT (Prevention of Mother to Child Transmission), P1
   [Anonymous], AM COLL RHEUM ANN SC
   [Anonymous], 2003, WHO technical report series, V921, P1
   [Anonymous], RECL ZOL AC FULL PRE
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bock O, 2008, CLIN INTERV AGING, V3, P279, DOI 10.2147/CIA.S2134
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Boonen S, 2004, J AM GERIATR SOC, V52, P1832, DOI 10.1111/j.1532 5415.2004.52506.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   CHRISTIANSEN C, 1991, AM J MED, V90, P107
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Feldstein AC, 2009, BONE, V44, P153, DOI 10.1016/j.bone.2008.09.006
   Finkelstein JS, 2008, J CLIN ENDOCR METAB, V93, P861, DOI 10.1210/jc.2007 1876
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Hasserius R, 2005, CALCIFIED TISSUE INT, V76, P235, DOI 10.1007/s00223 004 2222 2
   Kendler DL, 2010, OSTEOPOROSIS INT, V21, P837, DOI 10.1007/s00198 009 1023 x
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lanham New SA, 2008, P NUTR SOC, V67, P163, DOI 10.1017/S0029665108007003
   Lindsay R, 2001, JAMA J AM MED ASSOC, V285, P320, DOI 10.1001/jama.285.3.320
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Miller PD, 2011, J CLIN ENDOCR METAB, V96, P394, DOI 10.1210/jc.2010 1805
   Owens G, 2007, AM J MANAG CARE, V13, pS290
   Seeman E, 2010, J BONE MINER RES, V25, P1886, DOI 10.1002/jbmr.81
   Shi NW, 2009, BONE, V45, P1084, DOI 10.1016/j.bone.2009.07.086
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Siris ES, 2009, AM J MED, V122, P3, DOI 10.1016/j.amjmed.2008.12.002
   Weycker D, 2006, OSTEOPOROSIS INT, V17, P1645, DOI 10.1007/s00198 006 0179 x
   World Health Organization Collaborating Centre for Metabolic Bone Diseases, FRAX WHO FRACT RISK
NR 47
TC 10
Z9 11
U1 0
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079 2082
EI 1535 2900
J9 AM J HEALTH SYST PH
JI Am. J. Health Syst. Pharm.
PD AUG 1
PY 2011
VL 68
IS 15
BP 1409
EP 1418
DI 10.2146/ajhp100493
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 858CO
UT WOS:000297773700017
PM 21785030
DA 2025 08 17
ER

PT J
AU Park, Y
   Sato, T
   Lee, JW
AF Park, Yongkuk
   Sato, Tadatoshi
   Lee, Jungwoo
TI Functional and analytical recapitulation of osteoclast biology on
   demineralized bone paper
SO NATURE COMMUNICATIONS
LA English
DT Article
ID POSTMENOPAUSAL WOMEN; IN VITRO; BISPHOSPHONATES; OSTEOBLAST; FRACTURES;
   MECHANOTRANSDUCTION; OSTEOPETROSIS; OSTEOMORPHS; DENOSUMAB; OSTEOCYTE
AB Osteoclasts are the primary target for osteoporosis drug development. Recent animal studies revealed the crucial roles of osteoblasts in regulating osteoclastogenesis and the longer lifespans of osteoclasts than previously thought with fission and recycling. However, existing culture platforms are limited to replicating these newly identified cellular processes. We report a demineralized bone paper (DBP) based osteoblast culture and osteoclast assay platform that replicates osteoclast fusion, fission, resorption, and apoptosis with high fidelity and analytical power. An osteoid inspired DBP supports rapid and structural mineral deposition by osteoblasts. Coculture osteoblasts and bone marrow monocytes under biochemical stimulation recapitulate osteoclast differentiation and function. The DBP based bone model allows longitudinal quantitative fluorescent monitoring of osteoclast responses to bisphosphonate drug, substantiating significantly reducing their number and lifespan. Finally, we demonstrate the feasibility of humanizing the bone model. The DBP based osteo assay platforms are expected to advance bone remodeling targeting drug development with improved prediction of clinical outcomes.
   Here, authors report demineralized bone paper based in vitro osteogenic culture and assay platforms that replicate essential bone tissue complexity, osteoclast processes, and drug responses with high fidelity and predictive power.
C1 [Park, Yongkuk; Lee, Jungwoo] Univ Massachusetts, Inst Appl Life Sci, Dept Chem Engn, Amherst, MA 01003 USA.
   [Sato, Tadatoshi] UMass Chan Med Sch, Dept Med, Worcester, MA 01605 USA.
   [Lee, Jungwoo] Univ Massachusetts, Dept Biomed Engn, Amherst, MA 01003 USA.
   [Lee, Jungwoo] Univ Massachusetts, Mol & Cellular Biol Grad Program, Amherst, MA 01003 USA.
C3 University of Massachusetts System; University of Massachusetts Amherst;
   University of Massachusetts System; UMass Chan Medical School;
   University of Massachusetts Worcester; University of Massachusetts
   System; University of Massachusetts Amherst; University of Massachusetts
   System; University of Massachusetts Amherst
RP Lee, JW (通讯作者)，Univ Massachusetts, Inst Appl Life Sci, Dept Chem Engn, Amherst, MA 01003 USA.; Lee, JW (通讯作者)，Univ Massachusetts, Dept Biomed Engn, Amherst, MA 01003 USA.; Lee, JW (通讯作者)，Univ Massachusetts, Mol & Cellular Biol Grad Program, Amherst, MA 01003 USA.
EM jungwoo@umass.edu
OI Lee, Jungwoo/0000 0003 2048 2142; Park, Yongkuk/0000 0003 4481 4287
FU U.S. Department of Health & Human Services | NIH | National Cancer
   Institute (NCI); University of Massachusetts Amherst Light Microscope
   Facility [R00CA163671, R01CA237171]; National Cancer Institute
   [1944188]; National Science Foundation [1545399]; NSF Research
   Traineeship
FX The authors thank and acknowledge the University of Massachusetts
   Amherst Light Microscope Facility. We thank Hyejin Yoon for helping with
   the fabrication of demineralized bone, Jun Goo Kwak for conducting
   radiographic imaging, and Ju Ho Lee for manufacturing cyclic pressure
   chambers. This work was supported by the National Cancer Institute
   (R00CA163671, R01CA237171) and the National Science Foundation
   (1944188). Y.P. was supported by an NSF Research Traineeship (1545399).
CR Anastasilakis AD, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010152
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   Andes FT, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115665
   Bellido T, 2014, CALCIFIED TISSUE INT, V94, P25, DOI 10.1007/s00223 013 9774 y
   Bennink LL, 2018, BIOMATERIALS, V183, P67, DOI 10.1016/j.biomaterials.2018.08.039
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Borciani G, 2020, ACTA BIOMATER, V108, P22, DOI 10.1016/j.actbio.2020.03.043
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Choi S, 2019, BIOMATERIALS, V198, P95, DOI 10.1016/j.biomaterials.2018.05.002
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Costa DO, 2013, BIOMATERIALS, V34, P7215, DOI 10.1016/j.biomaterials.2013.06.014
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Deepak V, 2017, MED CHEM RES, V26, P19, DOI 10.1007/s00044 016 1715 7
   Delaisse JM, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.644503
   DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070
   Duong L, 2000, MATRIX BIOL, V19, P97, DOI 10.1016/S0945 053X(00)00051 2
   Duong Le T., 1998, Frontiers in Bioscience, V3, pD757
   Elsayed R, 2018, BONE, V110, P141, DOI 10.1016/j.bone.2018.01.030
   Food and Drug Administration, 2017, Drug Safety Communication: safety update for osteoporosis drugs, bisphosphonates, and atypical fractures
   Furuya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02541 w
   Gedmintas L, 2013, J BONE MINER RES, V28, P1729, DOI 10.1002/jbmr.1893
   Gou WL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091317
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Jacquin C, 2006, J BONE MINER RES, V21, P67, DOI 10.1359/JBMR.051007
   Johnell O, 2004, OSTEOPOROSIS INT, V15, P38, DOI 10.1007/s00198 003 1490 4
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Kashemirov BA, 2008, BIOCONJUGATE CHEM, V19, P2308, DOI 10.1021/bc800369c
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Kim AS, 2022, CURR OSTEOPOROS REP, DOI 10.1007/s11914 022 00756 5
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Li CL, 2017, NAT CELL BIOL, V19, P106, DOI 10.1038/ncb3464
   Li DH, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19884 z
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Mabileau G, 2021, TRENDS ENDOCRIN MET, V32, P655, DOI 10.1016/j.tem.2021.04.004
   Matteini P, 2012, BIOPHYS J, V103, P1179, DOI 10.1016/j.bpj.2012.07.055
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Merrild DMH, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.32
   Morgan C, 2009, ACTA ONCOL, V48, P882, DOI 10.1080/02841860902874748
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Park Y, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd6495
   Peacock M, 2002, ENDOCR REV, V23, P303, DOI 10.1210/er.23.3.303
   RAINA V, 1972, J CLIN PATHOL, V25, P229, DOI 10.1136/jcp.25.3.229
   Ren XY, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw4991
   Reznikov N, 2018, SCIENCE, V360, P507, DOI 10.1126/science.aao2189
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04 06 0522
   Sarafrazi N., 2021, Osteoporosis or Low Bone Mass in Older Adults: United States, 2017 2018, DOI DOI 10.15620/CDC:103477
   Soysa NS, 2019, BONE REP, V11, DOI 10.1016/j.bonr.2019.100225
   Takito J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040984
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Uenaka M, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28673 2
   Wein MN, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031237
   Wojda SJ, 2018, J ORTHOP RES, V36, P2586, DOI 10.1002/jor.24075
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Youlten SE, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22517 1
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201 1148
   Zheng LZ, 2020, BIOMATERIALS, V238, DOI 10.1016/j.biomaterials.2020.119828
   Zhu ML, 2016, J BONE MINER RES, V31, P864, DOI 10.1002/jbmr.2733
   Zhu X, 2016, J BONE MINER RES, V31, P560, DOI 10.1002/jbmr.2710
   Zushin P. H., 2023, J. Clin. Invest., V133
NR 70
TC 12
Z9 12
U1 2
U2 22
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD DEC 7
PY 2023
VL 14
IS 1
AR 8092
DI 10.1038/s41467 023 44000 9
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AI0C2
UT WOS:001117708200016
PM 38062034
OA gold
DA 2025 08 17
ER

PT J
AU Masaike, Y
   Takagi, T
   Hirota, M
   Yamada, J
   Ishihara, S
   Yung, TMC
   Inoue, T
   Sawa, C
   Sagara, H
   Sakamoto, S
   Kabe, Y
   Takahashi, Y
   Yamaguchi, Y
   Handa, H
AF Masaike, Yuka
   Takagi, Takeshi
   Hirota, Masataka
   Yamada, Joe
   Ishihara, Satoru
   Yung, Tetsu M. C.
   Inoue, Takamasa
   Sawa, Chika
   Sagara, Hiroshi
   Sakamoto, Satoshi
   Kabe, Yasuaki
   Takahashi, Yasuyuki
   Yamaguchi, Yuki
   Handa, Hiroshi
TI Identification of Dynamin 2 Mediated Endocytosis as a New Target of
   Osteoporosis Drugs, Bisphosphonates
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID PERFORMANCE AFFINITY BEADS; PRENYLATION INHIBITOR; DYNAMIN; VIRUS;
   OSTEOCLAST; BONE; MECHANISMS; INFECTION; PATHWAY; KINASE
AB Nitrogen containing bisphosphonates are pyrophosphate analogs that have long been the preferred prescription for treating osteoporosis. Although these drugs are considered inhibitors of prenylation and are believed to exert their effects on bone resorption by disrupting the signaling pathways downstream of prenylated small GTPases, this explanation seems to be insufficient. Because other classes of prenylation inhibitors have recently emerged as potential antiviral therapeutic agents, we first investigated here the effects of bisphosphonates on simian virus 40 and adenovirus infections and, to our surprise, found that viral infections are suppressed by bisphosphonates through a prenylation independent pathway. By in house affinity capture techniques, dynamin 2 was identified as a new molecular target of bisphosphonates. We present evidence that certain bisphosphonates block endocytosis of adenovirus and a model substrate by inhibiting GTPase activity of dynamin 2. Hence, this study has uncovered a previously unknown mechanism of action of bisphosphonates and offers potential novel use for these drugs.
C1 [Masaike, Yuka; Ishihara, Satoru; Handa, Hiroshi] Tokyo Inst Technol, Integrated Res Inst, Yokohama, Kanagawa 2268503, Japan.
   [Takagi, Takeshi; Hirota, Masataka; Yamada, Joe; Yung, Tetsu M. C.; Inoue, Takamasa; Sakamoto, Satoshi; Kabe, Yasuaki; Yamaguchi, Yuki; Handa, Hiroshi] Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 2268503, Japan.
   [Sawa, Chika] St Marianna Univ, Sch Med, Inst Med Sci, Kawasaki, Kanagawa, Japan.
   [Sagara, Hiroshi] Univ Tokyo, Inst Med Sci, Tokyo, Japan.
   [Takahashi, Yasuyuki] Res Assoc Biotechnol, Yokohama, Kanagawa, Japan.
C3 Institute of Science Tokyo; Tokyo Institute of Technology; Institute of
   Science Tokyo; Tokyo Institute of Technology; Saint Marianna University;
   University of Tokyo
RP Handa, H (通讯作者)，Tokyo Inst Technol, Integrated Res Inst, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.
EM handa.h.aa@m.titech.ac.jp
RI ; Sakamoto, Satoshi/ABA 8705 2020; Yamaguchi, Yuki/B 9390 2015
OI Sakamoto, Satoshi/0000 0002 6165 1558; Yamaguchi,
   Yuki/0000 0002 0197 614X
FU Japan Science and Technology Agency [KH217001]; Ministry of Education,
   Culture, Sports, Science and Technology of Japan [A 04]
FX This study was supported by Special Coordination Funds for Promoting
   Science and Technology from the Japan Science and Technology Agency
   [Grant KH217001]; and a Grant from the Global COE Program from the
   Ministry of Education, Culture, Sports, Science and Technology of Japan
   [Grant A 04].
CR Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825
   Artalejo CR, 1997, EMBO J, V16, P1565, DOI 10.1093/emboj/16.7.1565
   Bordier BB, 2002, J VIROL, V76, P10465, DOI 10.1128/JVI.76.20.10465 10472.2002
   Bruzzaniti A, 2005, MOL BIOL CELL, V16, P3301, DOI 10.1091/mbc.E04 12 1117
   Catimel B, 2009, J PROTEOME RES, V8, P3712, DOI 10.1021/pr900320a
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915
   Damke H, 2001, METHOD ENZYMOL, V329, P447
   del Real G, 2004, J EXP MED, V200, P541, DOI 10.1084/jem.20040061
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Einav S, 2003, J ANTIMICROB CHEMOTH, V52, P883, DOI 10.1093/jac/dkg490
   Farassati F, 2001, NAT CELL BIOL, V3, P745, DOI 10.1038/35087061
   Frith JC, 2003, J BONE MINER RES, V18, P204, DOI 10.1359/jbmr.2003.18.2.204
   Glenn JS, 1998, J VIROL, V72, P9303, DOI 10.1128/JVI.72.11.9303 9306.1998
   Gower TL, 2001, ANTIMICROB AGENTS CH, V45, P1231, DOI 10.1128/AAC.45.4.1231 1237.2001
   Heymann D, 2004, TRENDS MOL MED, V10, P337, DOI 10.1016/j.molmed.2004.05.007
   Ishikawa C, 2007, BRIT J HAEMATOL, V136, P424, DOI 10.1111/j.1365 2141.2006.06445.x
   Lundmark R, 2003, J BIOL CHEM, V278, P46772, DOI 10.1074/jbc.M307334200
   Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645
   Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216
   Nakanishi A, 2008, VIROLOGY, V379, P110, DOI 10.1016/j.virol.2008.06.032
   Negredo E, 2005, AIDS, V19, P343
   Pizzato M, 2007, P NATL ACAD SCI USA, V104, P6812, DOI 10.1073/pnas.0607622104
   Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313
   Qaqish RB, 2004, PHARMACOTHERAPY, V24, P1331, DOI 10.1592/phco.24.14.1331.43150
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Sakamoto S, 2009, CHEM REC, V9, P66, DOI 10.1002/tcr.20170
   Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955 0674(98)80066 5
   Shimizu N, 2000, NAT BIOTECHNOL, V18, P877, DOI 10.1038/78496
   Soulet F, 2005, MOL BIOL CELL, V16, P2058, DOI 10.1091/mbc.E04 11 1016
   Stepensky D, 2003, CLIN PHARMACOKINET, V42, P863, DOI 10.2165/00003088 200342100 00001
   Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092 8674(00)81207 6
   TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   Wang KN, 1998, J VIROL, V72, P3455, DOI 10.1128/JVI.72.4.3455 3458.1998
   Ylitalo R, 1996, J LAB CLIN MED, V127, P200, DOI 10.1016/S0022 2143(96)90079 7
   Yun MH, 2006, J PHARMACEUT BIOMED, V40, P168, DOI 10.1016/j.jpba.2005.06.025
NR 40
TC 21
Z9 22
U1 0
U2 5
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0026 895X
EI 1521 0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD FEB
PY 2010
VL 77
IS 2
BP 262
EP 269
DI 10.1124/mol.109.059006
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 545IL
UT WOS:000273725600017
PM 19903825
DA 2025 08 17
ER

PT S
AU Frenkel, B
   White, W
   Tuckermann, J
AF Frenkel, Baruch
   White, Wendy
   Tuckermann, Jan
BE Wang, JC
   Harris, C
TI Glucocorticoid Induced Osteoporosis
SO GLUCOCORTICOID SIGNALING: FROM MOLECULES TO MICE TO MAN
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
DE GIO; Proliferation; Osteoblast; Wnt; Notch; ERK; Akt; MKP 1; FoxO; RUNX2
ID ACTIVATED PROTEIN KINASE; BONE MINERAL DENSITY; HEPATOCYTE
   GROWTH FACTOR; FACTOR BINDING PROTEIN 5; SIGNAL REGULATED KINASE;
   MESENCHYMAL STEM CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;
   CORTICOSTEROID INDUCED OSTEOPOROSIS; PROMOTES ADIPOCYTE DIFFERENTIATION;
   ALKALINE PHOSPHATASE ACTIVITY
AB Osteoporosis is among the most devastating side effects of glucocorticoid (GC) therapy for the management of inflammatory and auto immune diseases. Evidence from both humans and mice indicate deleterious skeletal effects within weeks of pharmacological GC administration, both related and unrelated to a decrease in bone mineral density (BMD). Osteoclast numbers and bone resorption are also rapidly increased, and together with osteoblast inactivation and decreased bone formation, these changes lead the fastest loss in BMD during the initial disease phase. Bone resorption then decreases to sub physiological levels, but persistent and severe inhibition of bone formation leads to further bone loss and progressively increased fracture risk, up to an order of magnitude higher than that observed in untreated individuals. Bone forming osteoblasts are thus considered the main culprits in GC induced osteoporosis (GIO). Accordingly, we focus this review primarily on deleterious effects on osteoblasts: inhibition of cell replication and function and acceleration of apoptosis. Mediating these adverse effects, GCs target pivotal regulatory mechanisms that govern osteoblast growth, differentiation and survival. Specifically, GCs inhibit growth factor pathways, including Insulin Growth Factors, Growth Hormone, Hepatocyte Growth/Scatter Factor and IL6 type cytokines. They also inhibit downstream kinases, including PI3 kinase and the MAP kinase ERK, the latter attributable in part to direct transcriptional stimulation of MAP kinase phosphatase 1. Most importantly, however, GCs inhibit the Wnt signaling pathway, which plays a pivotal role in osteoblast replication, function and survival. They transcriptionally stimulate expression of Wnt inhibitors of both the Dkk and Sfrp families, and they induce reactive oxygen species (ROS), which result in loss of beta catenin to ROS activated FoxO transcription factors. Identification of dissociated GCs, which would suppress the immune system without causing osteoporosis, is proving more challenging than initially thought, and GIO is currently managed by co treatment with bisphosphonates or PTH. These drugs, however, are not ideally suited for GIO. Future therapeutic approaches may aim at GC targets such as those mentioned above, or newly identified targets including the Notch pathway, the AP 1/Il11 axis and the osteoblast master regulator RUNX2.
C1 [Frenkel, Baruch] Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Orthopaed Surg, Los Angeles, CA 90033 USA.
   [Frenkel, Baruch] Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA.
   [White, Wendy] Eisenhower Med Ctr, Dept Diabet & Endocrinol, Rancho Mirage, CA 92270 USA.
   [Tuckermann, Jan] Univ Ulm, Inst Comparat Mol Endocrinol, D 89081 Ulm, Germany.
C3 University of Southern California; University of Southern California;
   Ulm University
RP Frenkel, B (通讯作者)，Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Orthopaed Surg, 2250 Alcazar St,CSC 240, Los Angeles, CA 90033 USA.
EM frenkel@usc.edu
FU NIDDK NIH HHS [R01 DK071122] Funding Source: Medline
CR AARON JE, 1989, CLIN ORTHOP RELAT R, P294
   Alesci S, 2005, NEUROIMMUNOMODULAT, V12, P1, DOI 10.1159/000082360
   Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   ANDRESS DL, 1992, J BIOL CHEM, V267, P22467
   Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017
   Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081
   Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097 4644(19970701)66:1<1::AID JCB1>3.0.CO;2 V
   Baniwal SK, 2009, MOL ENDOCRINOL, V23, P1203, DOI 10.1210/me.2008 0470
   Baschant U, 2012, NAT REV RHEUMATOL, V8, P645, DOI 10.1038/nrrheum.2012.166
   Belvisi MG, 2001, J IMMUNOL, V166, P1975, DOI 10.4049/jimmunol.166.3.1975
   Berendsen AD, 2014, CELL MOL LIFE SCI, V71, P493, DOI 10.1007/s00018 013 1440 z
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Bickle M, 2010, ANAL BIOANAL CHEM, V398, P219, DOI 10.1007/s00216 010 3788 3
   Biddie SC, 2011, MOL CELL, V43, P145, DOI 10.1016/j.molcel.2011.06.016
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Borchert KM, 2005, ASSAY DRUG DEV TECHN, V3, P133, DOI 10.1089/adt.2005.3.133
   Borgatti P, 2000, FEBS LETT, V477, P27, DOI 10.1016/S0014 5793(00)01758 0
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brunetti G, 2013, AM J PHYSIOL ENDOC M, V304, pE546, DOI 10.1152/ajpendo.00535.2012
   Butler JS, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 210
   Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   CANALIS E, 1983, ENDOCRINOLOGY, V112, P931, DOI 10.1210/endo 112 3 931
   Cárcamo Orive I, 2010, J BONE MINER RES, V25, P2115, DOI 10.1002/jbmr.120
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Chang DJ, 1998, J BIOL CHEM, V273, P4892, DOI 10.1074/jbc.273.9.4892
   Chang JK, 2009, TOXICOLOGY, V258, P148, DOI 10.1016/j.tox.2009.01.016
   Chaudhary LR, 1997, BIOCHEM BIOPH RES CO, V238, P134, DOI 10.1006/bbrc.1997.7256
   Chen TL, 1999, CALCIFIED TISSUE INT, V64, P304, DOI 10.1007/s002239900624
   CHEN TL, 1977, ENDOCRINOLOGY, V100, P619, DOI 10.1210/endo 100 3 619
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   Chevalley T, 1996, EUR J ENDOCRINOL, V134, P591, DOI 10.1530/eje.0.1340591
   Choi YH, 2014, FEBS J, V281, P3656, DOI 10.1111/febs.12887
   Clark AR, 2003, CURR OPIN PHARMACOL, V3, P404, DOI 10.1016/S1471 4892(03)00073 0
   Conradie MM, 2007, J ENDOCRINOL, V195, P229, DOI 10.1677/JOE 07 0217
   Conradie MM, 2011, CALCIFIED TISSUE INT, V89, P221, DOI 10.1007/s00223 011 9509 x
   COSMAN F, 1994, J BONE MINER RES, V9, P1097
   Cruciat CM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a015081
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002 0006
   De Bosscher K, 2014, CELL MOL LIFE SCI, V71, P143, DOI 10.1007/s00018 013 1367 4
   DELANY AM, 1995, J CELL BIOCHEM, V57, P488, DOI 10.1002/jcb.240570314
   DELANY AM, 1995, ENDOCRINOLOGY, V136, P4776, DOI 10.1210/en.136.11.4776
   Delany AM, 2001, MOL ENDOCRINOL, V15, P1781, DOI 10.1210/me.15.10.1781
   DELANY AM, 1995, J BIOL CHEM, V270, P26607, DOI 10.1074/jbc.270.44.26607
   Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097 4652(200009)184:3<341::AID JCP8>3.3.CO;2 Q
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   EKENSTAM E, 1988, METABOLISM, V37, P141
   Engelbrecht Y, 2003, ENDOCRINOLOGY, V144, P412, DOI 10.1210/en.2002 220769
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476
   Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917
   Fu LN, 2006, PROG BRAIN RES, V153, P177, DOI 10.1016/S0079 6123(06)53010 9
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Gabbitas B, 1996, J BIOL CHEM, V271, P9033, DOI 10.1074/jbc.271.15.9033
   Gabet Y, 2008, BONE, V42, pS50, DOI 10.1016/j.bone.2007.12.085
   Gabet Y, 2011, J CELL PHYSIOL, V226, P991, DOI 10.1002/jcp.22412
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gifre L, 2013, BONE, V57, P272, DOI 10.1016/j.bone.2013.08.016
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Glüer CC, 2013, J BONE MINER RES, V28, P1355, DOI 10.1002/jbmr.1870
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gonnelli S, 2010, CALCIFIED TISSUE INT, V87, P137, DOI 10.1007/s00223 010 9392 x
   Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Grontved L, 2013, EMBO J, V32, P1568, DOI 10.1038/emboj.2013.106
   Grossman JM, 2010, ARTHRIT CARE RES, V62, P1515, DOI 10.1002/acr.20295
   Gu G, 2005, APOPTOSIS, V10, P583, DOI 10.1007/s10495 005 1893 0
   Gu GL, 2005, BIOCHEM BIOPH RES CO, V335, P1095, DOI 10.1016/j.bbrc.2005.06.211
   Habib SJ, 2013, SCIENCE, V339, P1445, DOI 10.1126/science.1231077
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Harris C, 2013, AM J PHYSIOL ENDOC M, V304, pE282, DOI 10.1152/ajpendo.00154.2012
   Hayashi K, 2009, BIOCHEM BIOPH RES CO, V379, P261, DOI 10.1016/j.bbrc.2008.12.035
   HEINRICHS AAJ, 1993, BIOCHEMISTRY US, V32, P11436, DOI 10.1021/bi00093a022
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hoogeboom D, 2008, J BIOL CHEM, V283, P9224, DOI 10.1074/jbc.M706638200
   Horsch K, 2007, MOL ENDOCRINOL, V21, P2929, DOI 10.1210/me.2007 0153
   Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634
   Hulley PA, 1998, ENDOCRINOLOGY, V139, P2423, DOI 10.1210/en.139.5.2423
   Hulley PA, 2002, BONE, V31, P220, DOI 10.1016/S8756 3282(02)00807 4
   Hurson CJ, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 12
   Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822
   Iyer S, 2013, J CLIN INVEST, V123, P3409, DOI 10.1172/JCI68049
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Jia JJ, 2011, FASEB J, V25, P3366, DOI 10.1096/fj.11 182519
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Johansson Haque K, 2008, J MOL ENDOCRINOL, V41, P239, DOI 10.1677/JME 08 0015
   John S, 2011, NAT GENET, V43, P264, DOI 10.1038/ng.759
   JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092 8674(90)90395 U
   Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108
   Kassel O, 2007, MOL CELL ENDOCRINOL, V275, P13, DOI 10.1016/j.mce.2007.07.003
   Katoh M, 2004, INT J ONCOL, V25, P1495
   Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002
   Khalid O, 2008, ENDOCRINOLOGY, V149, P5984, DOI 10.1210/en.2008 0680
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Kim HJ, 2012, BONE, V51, P643, DOI 10.1016/j.bone.2012.07.015
   Ko JY, 2013, BONE, V57, P468, DOI 10.1016/j.bone.2013.09.019
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2011, J CELL BIOCHEM, V112, P750, DOI 10.1002/jcb.22994
   Koromila T, 2014, J CELL BIOCHEM, V115, P27, DOI 10.1002/jcb.24646
   Kuriwaka Kido R, 2013, ENDOCRINOLOGY, V154, P1156, DOI 10.1210/en.2013 1915
   LAAN RFJM, 1993, ANN INTERN MED, V119, P963, DOI 10.7326/0003 4819 119 10 199311150 00001
   LAAN RFJM, 1993, CALCIFIED TISSUE INT, V52, P5, DOI 10.1007/BF00675619
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Leclerc N, 2004, J MOL ENDOCRINOL, V33, P175, DOI 10.1677/jme.0.0330175
   Leclerc N, 2005, ARTHRITIS RHEUM US, V52, P929, DOI 10.1002/art.20872
   Levi G, 1996, DEVELOPMENT, V122, P113
   Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037030
   Li XD, 2010, BLOOD CELL MOL DIS, V45, P82, DOI 10.1016/j.bcmd.2010.03.002
   Li Y, 2010, J BONE MINER RES, V25, P154, DOI 10.1359/jbmr.090705
   Lian JB, 1997, ENDOCRINOLOGY, V138, P2117, DOI 10.1210/en.138.5.2117
   Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433
   Lim HW, 2015, GENOME RES      0508
   Little GH, 2014, CANCER RES, V74, P2857, DOI 10.1158/0008 5472.CAN 13 2003
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Liu Y, 2004, J BONE MINER RES, V19, P479, DOI 10.1359/JBMR.0301242
   Lützner N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042166
   Luppen CA, 2003, J BIOL CHEM, V278, P44995, DOI 10.1074/jbc.M306730200
   Luppen CA, 2003, J BONE MINER RES, V18, P1186, DOI 10.1359/jbmr.2003.18.7.1186
   Luppen CA, 2008, GROWTH FACTORS, V26, P226, DOI 10.1080/08977190802277880
   MacDonald BT, 2007, BONE, V41, P331, DOI 10.1016/j.bone.2007.05.009
   Maggi S, 2009, J CLIN DENSITOM, V12, P345, DOI 10.1016/j.jocd.2009.05.003
   Mak W, 2009, CALCIFIED TISSUE INT, V85, P538, DOI 10.1007/s00223 009 9303 1
   Marenzana M, 2011, ARTHRITIS RHEUM US, V63, P2385, DOI 10.1002/art.30385
   Matsumoto T, 2012, ENDOCR J, V59, P91, DOI 10.1507/endocrj.EJ11 0219
   McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398
   MCCARTHY TL, 1990, ENDOCRINOLOGY, V126, P1569, DOI 10.1210/endo 126 3 1569
   McKenzie R, 2000, J RHEUMATOL, V27, P2222
   METCALF D, 1990, BLOOD, V76, P50
   Meyer T, 1997, DNA CELL BIOL, V16, P919, DOI 10.1089/dna.1997.16.919
   Mikami Y, 2011, J CELL PHYSIOL, V226, P739, DOI 10.1002/jcp.22392
   MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491
   Miranda TB, 2013, MOL CELL ENDOCRINOL, V380, P16, DOI 10.1016/j.mce.2013.03.002
   Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   MORRISON N, 1993, J BONE MINER RES, V8, P969
   MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Moutsatsou P, 2012, TRENDS MOL MED, V18, P348, DOI 10.1016/j.molmed.2012.04.005
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Naito M, 2013, CELL TISSUE RES, V354, P761, DOI 10.1007/s00441 013 1696 5
   Naito M, 2012, HISTOCHEM CELL BIOL, V138, P833, DOI 10.1007/s00418 012 1007 3
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Ning YM, 1999, J BIOL CHEM, V274, P30624, DOI 10.1074/jbc.274.43.30624
   Nuttall ME, 1998, J BONE MINER RES, V13, P371, DOI 10.1359/jbmr.1998.13.3.371
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   Olkku A, 2009, BONE, V44, P555, DOI 10.1016/j.bone.2008.11.013
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Paredes R, 2004, MOL CELL BIOL, V24, P8847, DOI 10.1128/MCB.24.20.8847 8861.2004
   Patel MS, 2002, NEW ENGL J MED, V346, P1572, DOI 10.1056/NEJM200205163462011
   Pereira RC, 2002, BONE, V30, P685, DOI 10.1016/S8756 3282(02)00687 7
   Pereira RMR, 2002, J CELL BIOCHEM, V85, P252, DOI 10.1002/jcb.10125
   Plotkin LI, 2007, J BIOL CHEM, V282, P24120, DOI 10.1074/jbc.M611435200
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   Rao NAS, 2011, GENOME RES, V21, P1404, DOI 10.1101/gr.118042.110
   Rauch A, 2011, FASEB J, V25, P1323, DOI 10.1096/fj.10 173393
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Rauner M, 2013, ENDOCRINOLOGY, V154, P3719, DOI 10.1210/en.2012 2221
   Reber LL, 2012, J IMMUNOL, V188, P3478, DOI 10.4049/jimmunol.1004227
   Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092 8674(00)81183 6
   Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168
   Richman C, 1999, ENDOCRINOLOGY, V140, P4699, DOI 10.1210/en.140.10.4699
   Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181
   Roohk DJ, 2013, ENDOCRINOLOGY, V154, P1528, DOI 10.1210/en.2011 1047
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683
   Salih DAM, 2005, ENDOCRINOLOGY, V146, P931, DOI 10.1210/en.2004 0816
   Schäcke H, 2009, BRIT J PHARMACOL, V158, P1088, DOI 10.1111/j.1476 5381.2009.00238.x
   Schaecke H, 2007, MOL CELL ENDOCRINOL, V275, P109, DOI 10.1016/j.mce.2007.05.014
   Schiller BJ, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0418 y
   SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411
   Sher LB, 2004, ENDOCRINOLOGY, V145, P922, DOI 10.1210/en.2003 0655
   Shi XM, 2003, EMBO REP, V4, P374, DOI 10.1038/sj.embor.embor805
   Shipp LE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013754
   Siersbæk R, 2011, EMBO J, V30, P1459, DOI 10.1038/emboj.2011.65
   Sims NA, 2005, J BONE MINER RES, V20, P1093, DOI 10.1359/JBMR.050209
   Sims NA, 2010, BMB REP, V43, P513, DOI 10.5483/BMBRep.2010.43.8.513
   Skrtic S, 2000, CALCIFIED TISSUE INT, V66, P108, DOI 10.1007/PL00005831
   Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200
   Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200
   Smith E, 1997, J CELL BIOCHEM, V66, P141, DOI 10.1002/(SICI)1097 4644(19970801)66:2<141::AID JCB2>3.0.CO;2 Q
   SMITH E, 1995, CANCER RES, V55, P5019
   Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200
   Smith E, 2002, J BIOL CHEM, V277, P18191, DOI 10.1074/jbc.M109708200
   Soen Satoshi, 2005, Mod Rheumatol, V15, P163, DOI 10.1007/s10165 005 0391 0
   STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379
   SUBRAMANIAM M, 1992, J CELL BIOCHEM, V50, P411, DOI 10.1002/jcb.240500410
   Subramaniam N, 1997, DNA CELL BIOL, V16, P153, DOI 10.1089/dna.1997.16.153
   Takayama S, 2006, J BIOL CHEM, V281, P17856, DOI 10.1074/jbc.M602290200
   Thiele S, 2012, J BONE MINER RES, V27, P2242, DOI 10.1002/jbmr.1688
   Toh ML, 2004, ARTHRITIS RHEUM US, V50, P3118, DOI 10.1002/art.20580
   Tsunashima Y, 2011, BIOL PHARM BULL, V34, P700, DOI 10.1248/bpb.34.700
   Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365
   Uhlenhaut NH, 2013, MOL CELL, V49, P158, DOI 10.1016/j.molcel.2012.10.013
   van Loo G, 2010, MOL ENDOCRINOL, V24, P310, DOI 10.1210/me.2009 0236
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   van Staa TP, 2005, QJM INT J MED, V98, P191, DOI 10.1093/qjmed/hci029
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Wagner EF, 2002, ANN RHEUM DIS S, V61, pii40
   Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004 1050
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Weinstein RS, 2010, ENDOCRINOLOGY, V151, P2641, DOI 10.1210/en.2009 1488
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Weinstein RS, 2004, ENDOCRINOLOGY, V145, P1980, DOI 10.1210/en.2003 1133
   Whyte MP, 2012, NEW ENGL J MED, V366, P904, DOI 10.1056/NEJMoa1106173
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
   Wu XY, 2008, BONE, V42, P861, DOI 10.1016/j.bone.2007.12.226
   Wüst S, 2008, J IMMUNOL, V180, P8434, DOI 10.4049/jimmunol.180.12.8434
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yamamoto T, 2007, BONE, V40, P354, DOI 10.1016/j.bone.2006.09.002
   Yang MB, 2010, BONE, V47, P573, DOI 10.1016/j.bone.2010.06.002
   YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092 8674(90)90396 V
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   Zalavras C, 2003, CRIT REV EUKAR GENE, V13, P221, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.140
   Zanotti S, 2014, BONE, V62, P22, DOI 10.1016/j.bone.2014.01.023
NR 235
TC 117
Z9 131
U1 0
U2 25
PU SPRINGER VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D 14197 BERLIN, GERMANY
SN 0065 2598
EI 2214 8019
BN 978 1 4939 2895 8; 978 1 4939 2894 1
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2015
VL 872
BP 179
EP 215
DI 10.1007/978 1 4939 2895 8_8
D2 10.1007/978 1 4939 2895 8
PG 37
WC Biology; Medicine, Research & Experimental
WE Book Citation Index– Science (BKCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Research & Experimental
   Medicine
GA BD5ST
UT WOS:000361794000008
PM 26215995
DA 2025 08 17
ER

PT J
AU Uluçkan, Ö
   Jimenez, M
   Karbach, S
   Jeschke, A
   Graña, O
   Keller, J
   Busse, B
   Croxford, AL
   Finzel, S
   Koenders, M
   van den Berg, W
   Schinke, T
   Amling, M
   Waisman, A
   Schett, G
   Wagner, EF
AF Uluckan, Oezge
   Jimenez, Maria
   Karbach, Susanne
   Jeschke, Anke
   Grana, Osvaldo
   Keller, Johannes
   Busse, Bjoern
   Croxford, Andrew L.
   Finzel, Stephanie
   Koenders, Marije
   van den Berg, Wim
   Schinke, Thorsten
   Amling, Michael
   Waisman, Ari
   Schett, Georg
   Wagner, Erwin F.
TI Chronic skin inflammation leads to bone loss by IL 17 mediated
   inhibition of Wnt signaling in osteoblasts
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID DELTA T CELLS; PLAQUE PSORIASIS; MINERAL DENSITY; HUMAN GENOME; IN VIVO;
   MICE; DISEASE; ARTHRITIS; IL 17; JUNB
AB Inflammation has important roles in tissue regeneration, autoimmunity, and cancer. Different inflammatory stimuli can lead to bone loss by mechanisms that are not well understood. We show that skin inflammation induces bone loss in mice and humans. In psoriasis, one of the prototypic IL 17A mediated inflammatory human skin diseases, low bone formation and bone loss correlated with increased serum IL 17A levels. Similarly, in two mouse models with chronic IL 17A mediated skin inflammation, K14 IL17A(ind) and JunB(Delta ep), strong inhibition of bone formation was observed, different from classical inflammatory bone loss where osteoclast activation leads to bone degradation. We show that under inflammatory conditions, skin resident cells such as keratinocytes, gamma delta T cells, and innate lymphoid cells were able to express IL 17A, which acted systemically to inhibit osteoblast and osteocyte function by a mechanism involving Wnt signaling. IL 17A led to decreased Wnt signaling in vitro, and importantly, pharmacological blockade of IL 17A rescued Wnt target gene expression and bone formation in vivo. These data provide a mechanism where IL 17A affects bone formation by regulating Wnt signaling in osteoblasts and osteocytes. This study suggests that using IL 17A blocking agents in psoriasis could be beneficial against bone loss in these patients.
C1 [Uluckan, Oezge; Jimenez, Maria; Wagner, Erwin F.] Spanish Natl Canc Res Ctr CNIO, Canc Cell Biol Program, Madrid 28029, Spain.
   [Karbach, Susanne] Univ Med Ctr, Ctr Cardiol Cardiol 1, D 55131 Mainz, Germany.
   [Karbach, Susanne; Croxford, Andrew L.; Waisman, Ari] Johannes Gutenberg Univ Mainz, Inst Mol Med, D 55131 Mainz, Germany.
   [Jeschke, Anke; Keller, Johannes; Busse, Bjoern; Schinke, Thorsten; Amling, Michael] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, D 20246 Hamburg, Germany.
   [Grana, Osvaldo] Spanish Natl Canc Res Ctr CNIO, Bioinformat Unit, Dept Biotechnol, Madrid 28029, Spain.
   [Finzel, Stephanie; Schett, Georg] Univ Erlangen Nurnberg, Dept Internal Med 3, D 91054 Erlangen, Germany.
   [Koenders, Marije; van den Berg, Wim] Radboud Univ Nijmegen, Rheumatol Res & Adv Therapeut, Dept Rheumatol, Med Ctr, NL 6525 Nijmegen, Netherlands.
C3 Centro Nacional de Investigaciones Oncologicas (CNIO); Johannes
   Gutenberg University of Mainz; Johannes Gutenberg University of Mainz;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   Centro Nacional de Investigaciones Oncologicas (CNIO); University of
   Erlangen Nuremberg; Radboud University Nijmegen
RP Wagner, EF (通讯作者)，Spanish Natl Canc Res Ctr CNIO, Canc Cell Biol Program, Madrid 28029, Spain.
EM ewagner@cnio.es
RI ; Busse, Björn/AAC 4033 2020; Karbach, Susanne/X 8136 2019; Graña
   Castro, Osvaldo/F 8603 2016; JIMENEZ, MARIA/H 7117 2015; Grana Castro,
   Osvaldo/F 8603 2016; Koenders, Marije/A 1341 2012; Waisman,
   Ari/C 7383 2015; Finzel, Stephanie/T 8177 2019; Uluckan,
   Ozge/H 6912 2015
OI Wagner, Erwin F/0000 0001 7872 0196; Keller,
   Johannes/0000 0002 8925 7288; Busse, Bjorn/0000 0002 3099 8073; JIMENEZ,
   MARIA/0000 0003 2673 6369; Grana Castro, Osvaldo/0000 0003 1615 4242; 
FU European Molecular Biology Organization Long Term Fellowship
   [LT 1244 2009]; ECTS/AMGEN Bone Biology Fellowship; Ministry of Economy
   and Competitiveness [SAF2012 39670]; Margarete Waitz Stiftung; Stiftung
   Mainzer Herz; Banco Bilbao Vizcaya Argentaria (BBVA) Foundation;
   European Research Council [ERC FCK/2008/37]; Deutsche
   Forschungsgemeinschaft (DFG) [SPP1468 IMMUNOBONE]; Marie Curie project
   Osteoimmune; Innovative Medicines Initiative (IMI) project BTCure;
   Collaborative Research Centres [(SFB): TRR 128 TPA7]
FX O.U. was funded by the European Molecular Biology Organization Long Term
   Fellowship (LT 1244 2009), by the ECTS/AMGEN Bone Biology Fellowship,
   and by the Ministry of Economy and Competitiveness SAF2012 39670. S.K.
   was funded by Margarete Waitz Stiftung and supported by the Stiftung
   Mainzer Herz. A.W. is funded by Collaborative Research Centres (SFB):
   TRR 128 TPA7; E.F.W. by the Banco Bilbao Vizcaya Argentaria (BBVA)
   Foundation and a European Research Council advanced grant (ERC
   FCK/2008/37); G.S., M.A., T.S., and A.W. by Deutsche
   Forschungsgemeinschaft (DFG) (Project SPP1468 IMMUNOBONE); and G.S. by
   the Marie Curie project Osteoimmune and the Innovative Medicines
   Initiative (IMI) funded project BTCure.
CR Balato A, 2012, EXP DERMATOL, V21, P892, DOI 10.1111/exd.12027
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Becher B, 2012, NAT MED, V18, P1748, DOI 10.1038/nm.3016
   Buckland Jenny, 2015, Nat Rev Rheumatol, V11, P128, DOI 10.1038/nrrheum.2015.11
   Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001
   Castro CHM, 2004, J CELL SCI, V117, P2853, DOI 10.1242/jcs.01133
   Chien YH, 2013, TRENDS IMMUNOL, V34, P151, DOI 10.1016/j.it.2012.11.004
   Croxford AL, 2014, J INVEST DERMATOL, V134, P728, DOI 10.1038/jid.2013.404
   DeSelm CJ, 2012, J CELL BIOCHEM, V113, P2895, DOI 10.1002/jcb.24165
   El Malki K, 2013, J INVEST DERMATOL, V133, P441, DOI 10.1038/jid.2012.318
   Fang Y, 2006, DIABETES RES CLIN PR, V73, P95, DOI 10.1016/j.diabres.2005.11.010
   Foster AM, 2014, J IMMUNOL, V192, P6053, DOI 10.4049/jimmunol.1301481
   Hardy R, 2009, J ENDOCRINOL, V201, P309, DOI 10.1677/JOE 08 0568
   Kamata M, 2012, CLIN EXP DERMATOL, V37, P296, DOI 10.1111/j.1365 2230.2011.04265.x
   Keijsers RRMC, 2014, EXP DERMATOL, V23, P799, DOI 10.1111/exd.12487
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Khalid U, 2014, EUR J HEART FAIL, V16, P743, DOI 10.1002/ejhf.113
   Kocijan R, 2015, J BONE MINER RES, V30, P1775, DOI 10.1002/jbmr.2521
   Koehne T, 2014, BONE, V66, P31, DOI 10.1016/j.bone.2014.05.010
   Koenders MI, 2008, ARTHRITIS RHEUM US, V58, P3461, DOI 10.1002/art.23957
   Kurd SK, 2010, ARCH DERMATOL, V146, P891, DOI 10.1001/archdermatol.2010.186
   Laggner U, 2011, J IMMUNOL, V187, P2783, DOI 10.4049/jimmunol.1100804
   Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb 2009 10 3 r25
   Le Henaff C, 2015, J BIOL CHEM, V290, P18009, DOI 10.1074/jbc.M115.646208
   Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI [10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp698, 10.1093/bioinformatics/btp352]
   Li JY, 2015, CELL METAB, V22, P799, DOI 10.1016/j.cmet.2015.09.012
   Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123
   López Ferrer A, 2015, EXPERT REV CLIN IMMU, V11, P1177, DOI 10.1586/1744666X.2015.1095092
   Lowes MA, 2013, TRENDS IMMUNOL, V34, P174, DOI 10.1016/j.it.2012.11.005
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Meixner A, 2008, NAT CELL BIOL, V10, P1003, DOI 10.1038/ncb1761
   Milovanovic P, 2013, ACS NANO, V7, P7542, DOI 10.1021/nn401360u
   Nakajima K, 2012, J DERMATOL, V39, P219, DOI 10.1111/j.1346 8138.2011.01458.x
   Neimann AL, 2006, J AM ACAD DERMATOL, V55, P829, DOI 10.1016/j.jaad.2006.08.040
   Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365 2567.2009.03240.x
   Pantelyushin S, 2012, J CLIN INVEST, V122, P2252, DOI 10.1172/JCI61862
   Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pflegerl P, 2009, P NATL ACAD SCI USA, V106, P20423, DOI 10.1073/pnas.0910371106
   Schett G, 2013, NAT MED, V19, P822, DOI 10.1038/nm.3260
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Tawfeek H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012290
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   Uluçkan Ö, 2009, CANCER RES, V69, P3196, DOI 10.1158/0008 5472.CAN 08 3358
   van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999
   Wagner EF, 2010, NAT REV RHEUMATOL, V6, P704, DOI 10.1038/nrrheum.2010.157
   Waisman A, 2012, NEW ENGL J MED, V366, P1251, DOI 10.1056/NEJMe1201071
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Woo SM, 2011, J BONE MINER RES, V26, P2634, DOI 10.1002/jbmr.465
   Zhang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040797
   Zwerina K, 2012, EUR J IMMUNOL, V42, P413, DOI 10.1002/eji.201141871
NR 58
TC 143
Z9 161
U1 1
U2 30
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAR 16
PY 2016
VL 8
IS 330
AR 330ra37
DI 10.1126/scitranslmed.aad8996
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA DG4YS
UT WOS:000372079700005
PM 27089206
DA 2025 08 17
ER

PT J
AU China, SP
   Kalyanaraman, H
   Zhuang, SH
   Cabriales, JA
   Sah, RL
   Pilz, RB
AF China, Shyamsundar Pal
   Kalyanaraman, Hema
   Zhuang, Shunhui
   Cabriales, Justin A.
   Sah, Robert L.
   Pilz, Renate B.
TI Protein kinase G2 activation restores Wnt signaling and bone mass in
   glucocorticoid induced osteoporosis in mice
SO JCI INSIGHT
LA English
DT Article
ID OXIDATIVE STRESS; CYCLIC GMP; NITRIC OXIDE; IN VITRO; OSTEOCYTES;
   INHIBITION; EXPRESSION; EXCESS; NITROGLYCERIN; OSTEOBLASTS
AB Osteoporotic fractures are a major complication of long term glucocorticoid therapy. Glucocorticoids transiently increase bone resorption, but they predominantly inhibit bone formation and induce osteocyte apoptosis, leading to bone loss. Current treatments of glucocorticoid induced osteoporosis aim mainly at reducing bone resorption and are, therefore, inadequate. We previously showed that signaling via the NO/cGMP/protein kinase G pathway plays a key role in skeletal homeostasis. Here, we show that pharmacological PKG activation with the guanylyl cyclase 1 activator cinaciguat or expression of a constitutively active, mutant PKG2 R242Q restored proliferation, differentiation, and survival of primary mouse osteoblasts exposed to dexamethasone. Cinaciguat treatment of WT mice or osteoblast specific expression of PKG2 R242Q in transgenic mice prevented dexamethasone induced loss of cortical bone mass and strength. These effects of cinaciguat and PKG2 R242Q expression were due to preserved bone formation parameters and osteocyte survival. The basis for PKG2's effects appeared to be through recovery of Wnt/ beta catenin signaling, which was suppressed by glucocorticoids but critical for proliferation, differentiation, and survival of osteoblast lineage cells. Cinaciguat reduced dexamethasone activation of osteoclasts, but this did not occur in the PKG2 R242Q transgenic mice, suggesting a minor role in osteoprotection. We propose that existing PKG targeting drugs could represent a novel therapeutic approach to prevent glucocorticoid induced osteoporosis.
C1 [China, Shyamsundar Pal; Kalyanaraman, Hema; Zhuang, Shunhui; Cabriales, Justin A.; Pilz, Renate B.] UCSD, Dept Med, La Jolla, CA USA.
   [Sah, Robert L.] UCSD, Dept Bioengn, La Jolla, CA USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Pilz, RB (通讯作者)，Univ Calif San Diego, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM rpilz@ucsd.edu
RI Pal China, Shyamsundar/AAB 8041 2019
FU NIH [R01 AR068601, R01 AG070778, P30 NS047101]
FX Acknowledgments We are grateful to the staff of the UC San Diego
   Microscopy Core Facility for help with imaging. Artwork in the graphical
   abstract was adapted from Servier Medical Art (https://smart.servier.com
   ) . This work was supported by the NIH grants R01 AR068601 and
   R01 AG070778 (to RBP) and P30 NS047101 (UCSD Microscopy Shared Facility)
   .
CR Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   Arioka M, 2013, BIOCHEM BIOPH RES CO, V440, P677, DOI 10.1016/j.bbrc.2013.09.126
   Bakker A, 2003, METH MOLEC MED, V80, P19
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Buckley L, 2018, NEW ENGL J MED, V379, P2547, DOI 10.1056/NEJMcp1800214
   Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb 2006 7 10 r100
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Colditz J, 2019, J BONE MINER RES, V34, P1314, DOI 10.1002/jbmr.3702
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dong BZ, 2023, HORM METAB RES, V55, P236, DOI 10.1055/a 2015 1747
   Ersek A, 2016, SCI REP UK, V6, DOI 10.1038/srep36513
   Fumoto T, 2014, BIOCHEM BIOPH RES CO, V447, P407, DOI 10.1016/j.bbrc.2014.03.149
   Hildebrandt S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26300 z
   Holliday LS, 1997, AM J PHYSIOL RENAL, V272, pF283, DOI 10.1152/ajprenal.1997.272.3.F283
   Humphrey MB, 2023, ARTHRIT CARE RES, V75, P2405, DOI 10.1002/acr.25240
   Jamal SA, 2004, J BONE MINER RES, V19, P1512, DOI 10.1359/JBMR.040716
   Jamal SA, 1998, J BONE MINER RES, V13, P1755, DOI 10.1359/jbmr.1998.13.11.1755
   Joshua J, 2014, ENDOCRINOLOGY, V155, P4720, DOI 10.1210/en.2014 1343
   Kalyanaraman H, 2023, J BONE MINER RES, V38, P171, DOI 10.1002/jbmr.4746
   Kalyanaraman H, 2018, NITRIC OXIDE BIOL CH, V76, P62, DOI 10.1016/j.niox.2018.03.007
   Kalyanaraman H, 2018, DIABETES, V67, P607, DOI 10.2337/db17 0965
   Lane NE, 2019, CURR OSTEOPOROS REP, V17, P1, DOI 10.1007/s11914 019 00498 x
   Mak W, 2009, CALCIFIED TISSUE INT, V85, P538, DOI 10.1007/s00223 009 9303 1
   Marathe N, 2012, J BIOL CHEM, V287, P978, DOI 10.1074/jbc.M111.294959
   Maridas DE, 2018, JOVE J VIS EXP, DOI 10.3791/56750
   Noguchi T, 2017, OSTEOPOROSIS INT, V28, P1063, DOI 10.1007/s00198 016 3830 1
   Ohlsson C, 2018, AM J PHYSIOL ENDOC M, V314, pE597, DOI 10.1152/ajpendo.00292.2017
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Olkku A, 2009, BONE, V44, P555, DOI 10.1016/j.bone.2008.11.013
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Parker JD, 2004, J CLIN INVEST, V113, P352, DOI 10.1172/JCI200421003
   Piemontese M, 2016, AM J PHYSIOL ENDOC M, V311, pE587, DOI 10.1152/ajpendo.00219.2016
   Porter A, 2017, SCI REP UK, V7, DOI 10.1038/srep42505
   Ramdani G, 2018, J ENDOCRINOL, V238, P203, DOI 10.1530/JOE 18 0286
   Rangaswami H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001423
   Rejnmark L, 2006, J BONE MINER RES, V21, P1811, DOI 10.1359/JBMR.060804
   Robling AG, 2020, ANNU REV PHYSIOL, V82, P485, DOI 10.1146/annurev physiol 021119 034332
   Sato AY, 2019, ENDOCRINOLOGY, V160, P1659, DOI 10.1210/en.2019 00237
   Sato AY, 2018, CLIN REV BONE MINER, V16, P33, DOI 10.1007/s12018 018 9242 3
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Schepper JD, 2020, J BONE MINER RES, V35, P801, DOI 10.1002/jbmr.3947
   Steinbuch M, 2004, OSTEOPOROSIS INT, V15, P323, DOI 10.1007/s00198 003 1548 3
   Takahashi Naoyuki, 2007, V135, P285
   Takayama S, 2006, J BIOL CHEM, V281, P17856, DOI 10.1074/jbc.M602290200
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Triposkiadis F, 2022, HEART FAIL REV, V27, P1991, DOI 10.1007/s10741 022 10239 5
   Wang FS, 2009, LIFE SCI, V85, P685, DOI 10.1016/j.lfs.2009.09.009
   Weinstein RS, 2011, ENDOCRINOLOGY, V152, P3323, DOI 10.1210/en.2011 0170
   Weinstein RS, 2010, ENDOCRINOLOGY, V151, P2641, DOI 10.1210/en.2009 1488
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wergedal JE, 2005, BONE, V36, P111, DOI 10.1016/j.bone.2004.09.012
   Wimalawansa SJ, 1997, BONE, V21, P275, DOI 10.1016/S8756 3282(97)00125 7
   Wimalawansa SJ, 2009, J CLIN ENDOCR METAB, V94, P3356, DOI 10.1210/jc.2008 2225
   Wood CL, 2018, J ENDOCRINOL, V236, pR69, DOI 10.1530/JOE 17 0361
   Yao W, 2016, OSTEOPOROSIS INT, V27, P283, DOI 10.1007/s00198 015 3308 6
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   Yaroslavskiy BB, 2005, J CELL SCI, V118, P5479, DOI 10.1242/jcs.02655
   Yaroslavskiy BB, 2007, J CELL SCI, V120, P2884, DOI 10.1242/jcs.004184
   Yu CX, 2018, J BONE MINER METAB, V36, P560, DOI 10.1007/s00774 017 0873 0
   Zhao X, 2005, J BIOL CHEM, V280, P32683, DOI 10.1074/jbc.M505486200
NR 62
TC 7
Z9 7
U1 1
U2 2
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379 3708
J9 JCI INSIGHT
JI JCI Insight
PD JUL 22
PY 2024
VL 9
IS 14
AR e175089
DI 10.1172/jci.insight.175089
PG 21
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA ZF7X3
UT WOS:001273957100001
PM 38885330
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Baron, R
   Hesse, E
AF Baron, Roland
   Hesse, Eric
TI Update on Bone Anabolics in Osteoporosis Treatment: Rationale, Current
   Status, and Perspectives
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID PARATHYROID HORMONE 1 34; SENSING RECEPTOR ANTAGONIST; FRIZZLED RELATED
   PROTEIN 1; MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; OSTEOCLAST
   DIFFERENTIATION; SCLEROSTIN ANTIBODY; IN VIVO; OVARIECTOMIZED RATS;
   BETA CATENIN
AB Osteoporosis is defined as low bone mineral density associated with skeletal fractures secondary to minimal or no trauma, most often involving the spine, the hip, and the forearm. The decrease in bone mineral density is the consequence of an unbalanced bone remodeling process, with higher bone resorption than bone formation. Osteoporosis affects predominantly postmenopausal women, but also older men. This chronic disease represents a considerable medical and socioeconomic burden for modern societies. The therapeutic options for the treatment of osteoporosis have so far comprised mostly antiresorptive drugs, in particular bisphosphonates and more recently denosumab, but also calcitonin and, for women, estrogens or selective estrogen receptor modulators. These drugs have limitations, however, in particular the fact that they lead to a low turnover state where bone formation decreases with the decrease in bone remodeling activity. In this review, we discuss the alternative class of osteoporosis drugs, i.e. bone anabolics, their biology, and the perspectives they offer for our therapeutic armamentarium. We focus on the two main osteoanabolic pathways identified as of today: PTH, the only anabolic drug currently on the market; and activation of canonical Wnt signaling through inhibition of the endogenous inhibitors sclerostin and dickkopf1. Each approach is based on a different molecular mechanism, but most recent evidence suggests that these two pathways may actually converge, at least in part. Whereas recombinant human PTH treatment is being revisited with different formulations and attempts to regulate endogenous PTH secretion via the calcium sensing receptor, antibodies to sclerostin and dickkopf1 are currently in clinical trials and may prove to be even more efficient at increasing bone mass, possibly independent of bone turnover. Each of these anabolic approaches has its own limitations and safety issues, but the prospects of effective anabolic therapy for osteoporosis are indeed bright. (J Clin Endocrinol Metab 97: 311 325, 2012)
C1 Harvard Univ, Sch Med, Dept Med, Endocrine Unit,Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Harvard Univ, Dept Oral Med Infect & Immun, Sch Dent Med, Boston, MA 02115 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard Medical School; Harvard University; Harvard
   School of Dental Medicine
RP Baron, R (通讯作者)，Harvard Univ, Sch Med, 188 Longwood Ave,REB 310, Boston, MA 02115 USA.
EM roland_baron@hsdm.harvard.edu
FU National Institutes of Health (National Institute of Arthritis and
   Musculoskeletal and Skin Diseases and National Institute of Dental and
   Craniofacial Research)
FX Roland Baron acknowledges the support of National Institutes of Health
   (National Institute of Arthritis and Musculoskeletal and Skin Diseases
   and National Institute of Dental and Craniofacial Research).
CR Agholme F, 2010, J BONE MINER RES, V25, P2412, DOI 10.1002/jbmr.135
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Bolton JM, 2008, J CLIN PSYCHOPHARM, V28, P384, DOI 10.1097/JCP.0b013e31817d5943
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Cho HY, 2010, BONE, V47, P263, DOI 10.1016/j.bone.2010.05.010
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   COHN DV, 1995, J NUTR, V125, pS2015, DOI 10.1093/jn/125.suppl_7.2015S
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cosman F, 2010, J CLIN ENDOCR METAB, V95, P151, DOI 10.1210/jc.2009 0358
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   Di Comite G, 2011, J HYPERTENS, V29, P409, DOI 10.1097/HJH.0b013e328341a429
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Drake MT, 2011, BONE, V49, P349, DOI 10.1016/j.bone.2011.05.003
   Eastell R, 2011, J BONE MINER RES, V26, P1303, DOI 10.1002/jbmr.341
   Eijken M, 2007, FASEB J, V21, P2949, DOI 10.1096/fj.07 8080com
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Fitzpatrick LA, 2011, J CLIN ENDOCR METAB, V96, P2441, DOI 10.1210/jc.2010 2855
   Fukumoto Seiji, 2011, Clin Calcium, V21, P89, DOI CliCa11018993
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Gambardella A, 2011, J BONE MINER RES, V26, P811, DOI 10.1002/jbmr.266
   Gardner JC, 2005, J CLIN ENDOCR METAB, V90, P6392, DOI 10.1210/jc.2005 1235
   Gaur T, 2009, J CELL PHYSIOL, V220, P174, DOI 10.1002/jcp.21747
   Girotra M, 2006, REV ENDOCR METAB DIS, V7, P113, DOI 10.1007/s11154 006 9007 z
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gowen M, 2000, J CLIN INVEST, V105, P1595, DOI 10.1172/JCI9038
   Guo J, 2010, ENDOCRINOLOGY, V151, P3502, DOI 10.1210/en.2009 1494
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Heiland GR, 2010, ANN RHEUM DIS, V69, P2152, DOI 10.1136/ard.2010.132852
   Hollick Rosemary J, 2011, Menopause Int, V17, P66, DOI 10.1258/mi.2011.011014
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Horwitz MJ, 2010, J CLIN ENDOCR METAB, V95, P1279, DOI 10.1210/jc.2009 0233
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002 021122
   Jerome C, 2011, OSTEOPOROSIS INT, V22, P3001, DOI 10.1007/s00198 011 1529 x
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   John MR, 2011, BONE, V49, P233, DOI 10.1016/j.bone.2011.04.007
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Karsdal MA, 2007, J BONE MINER RES, V22, P487, DOI 10.1359/JBMR.070109
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Kumar S, 2010, BONE, V46, P534, DOI 10.1016/j.bone.2009.09.028
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Lotinun S, 2010, BONE, V46, P1082, DOI 10.1016/j.bone.2010.01.370
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Marie PJ, 2010, BONE, V46, P571, DOI 10.1016/j.bone.2009.07.082
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Nagase S, 2012, J CLIN PHARMACOL, V52, P306, DOI 10.1177/0091270011399080
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nemeth EF, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290015
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Pennypacker BL, 2011, J BONE MINER RES, V26, P252, DOI 10.1002/jbmr.223
   Raje N, 2010, CURR OPIN MOL THER, V12, P586
   Richards JB, 2008, LANCET, V371, P1505, DOI 10.1016/S0140 6736(08)60599 1
   Ruckle J, 2009, J BONE MINER RES, V24, P744, DOI 10.1359/JBMR.081208
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Saidak Z, 2009, MOL PHARMACOL, V76, P1131, DOI 10.1124/mol.109.058784
   Segovia Silvestre T, 2009, HUM GENET, V124, P561, DOI 10.1007/s00439 008 0583 8
   Shoyele SA, 2011, AAPS PHARMSCITECH, V12, P304, DOI 10.1208/s12249 011 9585 2
   Sims AM, 2008, J BONE MINER RES, V23, P499, DOI 10.1359/JBMR.071113
   Spiro AS, 2010, J TRAUMA, V69, P1473, DOI 10.1097/TA.0b013e3181dc59e4
   Stewart AF, 2000, J BONE MINER RES, V15, P1517, DOI 10.1359/jbmr.2000.15.8.1517
   Subbiah V, 2010, OSTEOPOROSIS INT, V21, P1041, DOI 10.1007/s00198 009 1004 0
   Sugatani T, 2003, J CELL BIOCHEM, V90, P59, DOI 10.1002/jcb.10613
   Suzuki A, 2008, J CELL BIOCHEM, V104, P304, DOI 10.1002/jcb.21626
   Tian XY, 2010, BONE, V47, P529, DOI 10.1016/j.bone.2010.05.032
   Tobimatsu T, 2006, ENDOCRINOLOGY, V147, P2583, DOI 10.1210/en.2005 1627
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   van Meurs JBJ, 2008, JAMA J AM MED ASSOC, V299, P1277, DOI 10.1001/jama.299.11.1277
   Vestergaard P, 2005, CALCIFIED TISSUE INT, V77, P1, DOI 10.1007/s00223 004 0258 y
   Wan M, 2008, GENE DEV, V22, P2968, DOI 10.1101/gad.1702708
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Wang FS, 2007, BONE, V40, P485, DOI 10.1016/j.bone.2006.09.004
   Wang FS, 2009, LIFE SCI, V85, P685, DOI 10.1016/j.lfs.2009.09.009
   Widler L, 2010, J MED CHEM, V53, P2250, DOI 10.1021/jm901811v
   Wilting I, 2007, BONE, V40, P1252, DOI 10.1016/j.bone.2006.12.055
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yakar S, 2009, J BONE MINER RES, V24, P1481, DOI [10.1359/JBMR.090226, 10.1359/jbmr.090226]
   Yao W, 2010, J BONE MINER RES, V25, P190, DOI 10.1359/jbmr.090719
   Zamani A, 2009, BONE, V44, P331, DOI 10.1016/j.bone.2008.10.001
NR 102
TC 252
Z9 293
U1 0
U2 65
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD FEB
PY 2012
VL 97
IS 2
BP 311
EP 325
DI 10.1210/jc.2011 2332
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 904VP
UT WOS:000301226800022
PM 22238383
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Stavre, Z
   Kim, JM
   Yang, YS
   Nündel, K
   Chaugule, S
   Sato, T
   Park, KH
   Gao, GP
   Gravallese, EM
   Shim, JH
AF Stavre, Zheni
   Kim, Jung Min
   Yang, Yeon Suk
   Nundel, Kerstin
   Chaugule, Sachin
   Sato, Tadatoshi
   Park, Kwang Hwan
   Gao, Guangping
   Gravallese, Ellen M.
   Shim, Jae Hyuck
TI Schnurri 3 inhibition suppresses bone and joint damage in models of
   rheumatoid arthritis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE rheumatoid arthritis; Schnurri 3; WNT signaling; osteoblast; osteoclast
ID AUTOIMMUNE ARTHRITIS; PARATHYROID HORMONE; OSTEOBLAST FUNCTION;
   TNF ALPHA; EROSION; MICE; THERAPIES; GENE; EXPRESSION; INTERACTS
AB Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to systemic and articular bone loss by activating bone resorption and suppressing bone formation. Despite current therapeutic agents, inflammation induced bone loss in RA continues to be a significant clinical problem due to joint deformity and lack of articular and systemic bone repair. Here, we identify the suppressor of bone formation, Schnurri 3 (SHN3), as a potential target to prevent bone loss in RA. SHN3 expression in osteoblast lineage cells is induced by proinflammatory cytokines. Germline deletion or conditional deletion of Shn3 in osteoblasts limits articular bone erosion and systemic bone loss in mouse models of RA. Similarly, silencing of SHN3 expression in these RA models using systemic delivery of a bone targeting recombinant adenoassociated virus protects against inflammation induced bone loss. In osteoblasts, TNF activates SHN3 via ERK MAPK mediated phosphorylation and, in turn, phosphorylated SHN3 inhibits WNT/(3 catenin signaling and up regulates RANKL expression. Accordingly, knock in of a mutation in Shn3 that fails to bind ERK MAPK promotes bone formation in mice overexpressing human TNF due to augmented WNT/(3 catenin signaling. Remarkably, Shn3 deficient osteoblasts are not only resistant to TNF induced suppression of osteogenesis, but also down regulate osteoclast development. Collectively, these findings demonstrate SHN3 inhibition as a promising approach to limit bone loss and promote bone repair in RA.
C1 [Stavre, Zheni; Kim, Jung Min; Yang, Yeon Suk; Nundel, Kerstin; Chaugule, Sachin; Sato, Tadatoshi; Shim, Jae Hyuck] Univ Massachusetts Chan Med Sch, Dept Med, Div Rheumatol, Worcester, MA 01605 USA.
   [Sato, Tadatoshi; Gao, Guangping; Shim, Jae Hyuck] Univ Massachusetts Chan Med Sch, Horae Gene Therapy Ctr, Worcester, MA 01605 USA.
   [Sato, Tadatoshi; Gao, Guangping; Shim, Jae Hyuck] Univ Massachusetts Chan Med Sch, Li Weibo Inst Rare Dis Res, Worcester, MA 01605 USA.
   [Sato, Tadatoshi] Harvard Med Sch, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Park, Kwang Hwan] Yonsei Univ, Coll Med, Dept Orthopaed Surg, Seoul 03722, South Korea.
   [Gao, Guangping] Univ Massachusetts Chan Med Sch, Dept Microbiol & Physiol Syst, Worcester, MA 01605 USA.
   [Gao, Guangping] Univ Massachusetts Chan Med Sch, Viral Vector Core, Worcester, MA 01605 USA.
   [Gravallese, Ellen M.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Rheumatol Inflammat & Immun, Boston, MA 02115 USA.
C3 University of Massachusetts System; UMass Chan Medical School;
   University of Massachusetts System; UMass Chan Medical School;
   University of Massachusetts System; UMass Chan Medical School; Harvard
   University; Harvard University Medical Affiliates; Massachusetts General
   Hospital; Harvard Medical School; Yonsei University; Yonsei University
   Health System; University of Massachusetts System; UMass Chan Medical
   School; University of Massachusetts System; UMass Chan Medical School;
   Harvard University; Harvard University Medical Affiliates; Brigham &
   Women's Hospital; Harvard Medical School
RP Shim, JH (通讯作者)，Univ Massachusetts Chan Med Sch, Dept Med, Div Rheumatol, Worcester, MA 01605 USA.; Shim, JH (通讯作者)，Univ Massachusetts Chan Med Sch, Horae Gene Therapy Ctr, Worcester, MA 01605 USA.; Shim, JH (通讯作者)，Univ Massachusetts Chan Med Sch, Li Weibo Inst Rare Dis Res, Worcester, MA 01605 USA.; Gravallese, EM (通讯作者)，Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Rheumatol Inflammat & Immun, Boston, MA 02115 USA.
EM egravallese@bwh.harvard.edu; jaehyuck.shim@umassmed.edu
RI ; chaugule, sachin/KLC 3969 2024; Kim, Jung Min/JDW 1037 2023
OI Park, Kwang Hwan/0000 0002 2110 0559; Kim, Jung Min/0000 0002 9072 4293;
   Shim, Jae Hyuck/0000 0002 4947 3293; chaugule,
   sachin/0000 0001 6323 2034; 
FU NIH NIAMS [R21AR077557, R01AR078230]; Rheumatology Research Foundation's
   Scientist Development Award; NIH [P01AI100263, R01NS076991, P01HD080642,
   R01AI12135]
FX We thank Drs. Laurie Glimcher, Matthew Greenblatt, Stanley Adoro, Shimon
   Sakaguchi, and George Kollias for providing Shn3KA/KA, SKG, and TNF tg
   mice, respectively.We also thank Matthew Finnegan, Cathy Manning,
   Priyanka Kushwaha, Zhihao Chen, and Eunhye Son for manuscript review or
   experimental support and the many individuals who provided valuable
   reagents. This project was supported by NIH NIAMS R21AR077557 and
   R01AR078230 to E.M.G. andJ. H.S. Additional funding for this project was
   provided by the Rheumatology Research Foundation's Scientist Development
   Award held by Z.S. G.G. holds support from grants under the NIH
   (P01AI100263, R01NS076991, P01HD080642, R01AI12135) .
CR Augustine M, 2013, CURR OSTEOPOROS REP, V11, P400, DOI 10.1007/s11914 013 0171 2
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Borumandi F, 2015, ANTI CANCER AGENT ME, V15, P736, DOI 10.2174/1871520615666150325232857
   Chang MH, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109902
   Christensen AD, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00213
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dimitroulas T, 2013, AUTOIMMUN REV, V12, P958, DOI 10.1016/j.autrev.2013.03.015
   Esbrit P, 2013, BIOCHEM PHARMACOL, V85, P1417, DOI 10.1016/j.bcp.2013.03.002
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791
   Harre U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7651
   Hata H, 2004, J CLIN INVEST, V114, P582, DOI 10.1172/JCI200421795
   Haugeberg G, 2000, ARTHRITIS RHEUM, V43, P522, DOI 10.1002/1529 0131(200003)43:3<522::AID ANR7>3.0.CO;2 Y
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Keller KK, 2013, RHEUMATOL INT, V33, P1127, DOI 10.1007/s00296 012 2500 7
   Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074 7613(00)80045 X
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Lavocat F, 2016, BONE, V87, P89, DOI 10.1016/j.bone.2016.04.008
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Matzelle MM, 2012, ARTHRITIS RHEUM US, V64, P1540, DOI 10.1002/art.33504
   McBride JL, 2008, P NATL ACAD SCI USA, V105, P5868, DOI 10.1073/pnas.0801775105
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   O'Brien W, 2016, ARTHRITIS RHEUMATOL, V68, P2889, DOI 10.1002/art.39837
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00425
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Oukka M, 2002, MOL CELL, V9, P121, DOI 10.1016/S1097 2765(01)00434 8
   Oukka M, 2004, J EXP MED, V199, P15, DOI 10.1084/jem.20030421
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Sabio G, 2014, SEMIN IMMUNOL, V26, P237, DOI 10.1016/j.smim.2014.02.009
   Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Shim JH, 2013, J CLIN INVEST, V123, P4010, DOI 10.1172/JCI69443
   Spatz JM, 2015, J BIOL CHEM, V290, P16744, DOI 10.1074/jbc.M114.628313
   Vandenberghe LH, 2009, GENE THER, V16, P311, DOI 10.1038/gt.2008.170
   Venditti CP, 2021, NAT BIOTECHNOL, V39, P24, DOI 10.1038/s41587 020 00756 9
   Walsh NC, 2009, J BONE MINER RES, V24, P1572, DOI [10.1359/JBMR.090320, 10.1359/jbmr.090320]
   Wehmeyer C, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aac4351
   Wein MN, 2012, P NATL ACAD SCI USA, V109, P8173, DOI 10.1073/pnas.1205848109
   Widdifield J, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen 2013 003888
   Wright NC, 2011, J RHEUMATOL, V38, P1680, DOI 10.3899/jrheum.101196
   Xie J, 2020, MOL THER, V28, P422, DOI 10.1016/j.ymthe.2019.11.018
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Yang YS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10809 6
   Yoshitomi H, 2005, J EXP MED, V201, P949, DOI 10.1084/jem.20041758
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhao JJ, 2016, BIOMED REP, V5, P171, DOI 10.3892/br.2016.708
NR 51
TC 20
Z9 21
U1 0
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 9
PY 2023
VL 120
IS 19
AR e2218019120
DI 10.1073/pnas.2218019120
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA L8NM3
UT WOS:001025776300008
PM 37141171
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Kansara, M
   Tsang, M
   Kodjabachian, L
   Sims, NA
   Trivett, MK
   Ehrich, M
   Dobrovic, A
   Slavin, J
   Choong, PFM
   Simmons, PJ
   Dawid, IB
   Thomas, DM
AF Kansara, Maya
   Tsang, Michael
   Kodjabachian, Laurent
   Sims, Natalie A.
   Trivett, Melanie K.
   Ehrich, Mathias
   Dobrovic, Alexander
   Slavin, John
   Choong, Peter F. M.
   Simmons, Paul J.
   Dawid, Igor B.
   Thomas, David M.
TI Wnt inhibitory factor 1 is epigenetically silenced in human
   osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in
   mice
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID TERMINAL OSTEOBLAST DIFFERENTIATION; FACTOR I; PARATHYROID HORMONE;
   BETA CATENIN; BONE FORMATION; GENE EXPRESSION; CPG METHYLATION;
   INACTIVATION; PATHWAY; PROTEIN
AB Wnt signaling increases bone mass by stimulating osteoblast lineage commitment and expansion and forms the basis for novel anabolic therapeutic strategies being developed for osteoporosis. These strategies include derepression of Wnt signaling by targeting secreted Wnt pathway antagonists, such as sclerostin. However, such therapies are associated with safety concerns regarding an increased risk of osteosarcoma, the most common primary malignancy of bone. Here, we analyzed 5 human osteosarcoma cell lines in a high throughput screen for epigenetically silenced tumor suppressor genes and identified Wnt inhibitory factor 1 (WIF1), which encodes an endogenous secreted Wnt pathway antagonist, as a candidate tumor suppressor gene. In vitro, WIF1 suppressed P catenin levels in human osteosarcoma cell lines, induced differentiation of human and mouse primary osteoblasts, and suppressed the growth of mouse and human osteosarcoma. cell Lines. Wif1 was highly expressed in the developing and mature mouse skeleton, and, although it was dispensable for normal development, targeted deletion of mouse Wif1 accelerated development of radiation induced osteosarcomas in vivo. In primary human osteosarcomas, silencing of WIF1 by promoter hypermethylation was associated with loss of differentiation, increased P catenin levels, and increased proliferation. These data lead us to suggest that derepression of Writ signaling by targeting secreted Wnt antagonists in osteoblasts may increase susceptibility to osteosarcoma.
C1 [Kansara, Maya; Trivett, Melanie K.; Dobrovic, Alexander; Simmons, Paul J.; Thomas, David M.] Peter MacCallum Canc Ctr, Ian Potter Fdn, Ctr Canc Genet & Preventat Med, Melbourne, Vic, Australia.
   [Kansara, Maya; Trivett, Melanie K.; Dobrovic, Alexander; Simmons, Paul J.; Thomas, David M.] Peter MacCallum Canc Ctr, Sir Donald & Lady Trescowthick Labs, Melbourne, Vic 3002, Australia.
   [Tsang, Michael; Kodjabachian, Laurent; Dawid, Igor B.] NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA.
   [Sims, Natalie A.; Slavin, John; Choong, Peter F. M.] St Vincents Hosp, Melbourne, Vic, Australia.
   [Ehrich, Mathias] SEQUENOM Inc, San Diego, CA USA.
C3 Peter Maccallum Cancer Center; Ian Potter Foundation; Peter Maccallum
   Cancer Center; National Institutes of Health (NIH)   USA; NIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD); St Vincent's Health; St Vincent's Hospital Melbourne; NSW
   Health; St Vincents Hospital Sydney; Sequenom
RP Thomas, DM (通讯作者)，Peter MacCallum Canc Ctr, Ian Potter Fdn, Ctr Canc Genom & Predict Med, St Andrews Pl, Melbourne, Vic 3002, Australia.
EM david.thomas@petermac.org
RI ; Thomas, David/AAD 2877 2019; Tsang, Michael/I 9305 2014; Choong,
   Peter/F 1109 2014; Tsang, Michael/AAG 9338 2020; Kodjabachian,
   Laurent/IXN 7521 2023; Sims, Natalie/A 7192 2012; Tsang,
   Michael/E 2758 2013
OI Thomas, David/0000 0002 2527 5428; Dobrovic,
   Alexander/0000 0003 3414 112X; Kansara, Maya/0000 0003 1908 3574; Tsang,
   Michael/0000 0001 7123 0063; Choong, Peter/0000 0002 3522 7374; Choong,
   Peter/0000 0001 7333 7665; Kodjabachian, Laurent/0000 0002 4000 612X;
   Sims, Natalie/0000 0003 1421 8468; Tsang, Michael/0000 0001 6384 2422;
   Ehrich, Mathias/0000 0001 8415 0310
FU National Health and Medical Research Council [350432, 508982]; Cancer
   Council Victoria; Sarcoma Foundation of America; NICHD, NIH
FX The authors would like to thank colleagues in the Bowtell and Thomas
   laboratories for helpful discussions and Alexander Grinberg, Andreas
   Tomac, Heiner Westphal, Martha Rebbert, and Paul Love for help in
   generating gene modified mice. We thank Carleen Cullinane and staff for
   PET scanning of the mice. This work was supported by grants 350432 and
   508982 from the National Health and Medical Research Council, by the
   Cancer Council Victoria, by the Sarcoma Foundation of America, by and
   the intramural Research Program of the NICHD, NIH. D.M. Thomas was
   supported by R.D. Wright Career Development Award 2003 7 and by
   Victorian Cancer Agency Clinician Researcher Fellowship 2008 10.
CR Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439
   Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Balemans W, 2007, ENDOCRINOLOGY, V148, P2622, DOI 10.1210/en.2006 1352
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168 9525(99)01971 X
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Besplug J, 2005, INT J RADIAT BIOL, V81, P157, DOI 10.1080/09553000500103512
   Bodine PVN, 2007, J CELL PHYSIOL, V210, P352, DOI 10.1002/jcp.20834
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0
   Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535 6108(02)00122 8
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008 5472.CAN 03 1346
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077
   Coussens AK, 2008, DIFFERENTIATION, V76, P531, DOI 10.1111/j.1432 0436.2007.00244.x
   Cullinane C, 2005, CANCER RES, V65, P9633, DOI 10.1158/0008 5472.CAN 05 2285
   Dahlin DC, 1957, BONE TUMORS
   DiNardo DNM, 2001, ONCOGENE, V20, P5331, DOI 10.1038/sj.onc.1204697
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Elston MS, 2008, ENDOCRINOLOGY, V149, P1235, DOI 10.1210/en.2007 0542
   FINKEL MIRIAM P., 1964, NAT CANCER INST MONOGR, V14, P243
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Gronthos S, 1999, J BONE MINER RES, V14, P47, DOI 10.1359/jbmr.1999.14.1.47
   Harper KD, 2007, J BONE MINER RES, V22, P334, DOI 10.1359/JBMR.061111
   Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719
   Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504
   Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899
   *INT AG RES CANC, 2002, PATH GEN TUM SOFT TI
   Iwaya K, 2003, CLIN EXP METASTAS, V20, P525, DOI 10.1023/A:1025821229013
   IWOA K, 1999, JPN J CANCER RES, V90, P205
   Jolette J, 2006, TOXICOL PATHOL, V34, P929, DOI 10.1080/01926230601072301
   Kahler RA, 2003, J BIOL CHEM, V278, P11937, DOI 10.1074/jbc.M211443200
   Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614
   Macsai CE, 2008, J CELL PHYSIOL, V215, P578, DOI 10.1002/jcp.21342
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008 5472.CAN 04 1389
   MILLER AD, 1989, BIOTECHNIQUES, V7, P980
   MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585
   Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008 5472.CAN 04 2463
   Morgan T, 2005, AM J PATHOL, V167, P117, DOI 10.1016/S0002 9440(10)62959 8
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Queimado L, 2007, GENE CHROMOSOME CANC, V46, P215, DOI 10.1002/gcc.20402
   Román Gómez J, 2007, BLOOD, V109, P3462, DOI 10.1182/blood 2006 09 047043
   Sadikovic B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002834
   SCHMIDT IU, 1995, ENDOCRINOLOGY, V136, P5127, DOI 10.1210/en.136.11.5127
   SCOTLANDI K, 1995, CANCER, V75, P806, DOI 10.1002/1097 0142(19950201)75:3<806::AID CNCR2820750310>3.0.CO;2 S
   Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95
   Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727
   SIMMONS PJ, 1991, BLOOD, V78, P55
   Sims NA, 2006, AM J PHYSIOL ENDOC M, V290, pE456, DOI 10.1152/ajpendo.00311.2005
   Sims NA, 2000, J CLIN INVEST, V106, P1095, DOI 10.1172/JCI10753
   Szabo PE, 1995, GENE DEV, V9, P3097, DOI 10.1101/gad.9.24.3097
   Taniguchi H, 2005, ONCOGENE, V24, P7946, DOI 10.1038/sj.onc.1208910
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Thomas D, 2006, J CELL BIOCHEM, V98, P757, DOI 10.1002/jcb.20850
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
   Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078 0432.CCR 05 1344
   Vaes BLT, 2002, J BONE MINER RES, V17, P2106, DOI 10.1359/jbmr.2002.17.12.2106
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Weiss DJ, 1997, HUM GENE THER, V8, P1545, DOI 10.1089/hum.1997.8.13 1545
   Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15
NR 69
TC 216
Z9 245
U1 1
U2 21
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD APR
PY 2009
VL 119
IS 4
BP 837
EP 851
DI 10.1172/JCI37175
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 428EF
UT WOS:000264830100022
PM 19307728
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Idolazzi, L
   Rossini, M
   Viapiana, O
   Braga, V
   Fassio, A
   Benini, C
   Kunnathully, V
   Adami, S
   Gatti, D
AF Idolazzi, L.
   Rossini, M.
   Viapiana, O.
   Braga, V.
   Fassio, A.
   Benini, C.
   Kunnathully, V.
   Adami, S.
   Gatti, D.
TI Teriparatide and denosumab combination therapy and skeletal metabolism
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Combined therapy; Denosumab; Postmenopausal osteoporosis; Teriparatide;
   Turnover arkers
ID POSTMENOPAUSAL WOMEN; PARATHYROID HORMONE; BONE FORMATION; OSTEOCLAST
   DIFFERENTIATION; OSTEOPOROSIS; ALENDRONATE; OSTEOBLASTS; SCLEROSTIN;
   PATHWAY; EXPRESSION
AB Several therapies are available for osteoporis. Understanding the bone turnover changes and their mutual realtionship gives an overall view and might lead to a target therapy
   Introduction The aim of this study is to compare the changes in bone turnover markers in patients treated with either denosumab alone, teriparatide (TPTD) alone, or in a third therapeutic scheme, when TPTD was added to patients previously treated with denosumab.
   Methods Fifty nine women over 65 years old with severe postmenopausal osteoporosis (evidence of at least two moderate severe vertebral fractures) were enrolled in the study. Serum samples were collected every 3 months. They were assayed for intact N propeptide of type I collagen (P1NP), C terminal telopeptide of type I collagen (CTX), intact parathyroid hormone (PTH), 25 hydroxy vitamin D (25 OHD), Sclerostin (SOST), and Dickkopf related protein 1 (DKK1). Bone mass density was assessed by dual energy Xray absorptiometry at the lumbar spine and at the total hip.
   Results In the groups treated only with TPTD or with denosumab, bone turnover markers increased and decreased, respectively. In TPTD group, a later significant increase in DKK1 was observed, while in denosumab group, a progressive increase in SOST was associated with a progressive significant decrease in DKK1. In the group treated first with denosumab and in which TPTD was added 3 months later, both CTX and P1NP increased 3 months after the beginning of TPTD. The strong effect of denosumab on bone turnover seems to be reversed by TPTD treatment.
   Conclusions In this study, we showed that TPTD is able to express its biological activity even when bone turnover is fully suppressed by denosumab treatment. The combination therapy is associated with significant increases in both DKK1 and SOST.
C1 [Idolazzi, L.; Rossini, M.; Viapiana, O.; Braga, V.; Fassio, A.; Benini, C.; Kunnathully, V.; Adami, S.; Gatti, D.] Univ Verona, Dept Med, Rheumatol Unit, Piazzale Stefani 1, I 37126 Verona, Italy.
C3 University of Verona
RP Idolazzi, L (通讯作者)，Univ Verona, Dept Med, Rheumatol Unit, Piazzale Stefani 1, I 37126 Verona, Italy.
EM luca.idolazzi@univr.it
RI rossini, maurizio/D 6610 2011; Fassio, Angelo/AAB 9767 2022; Idolazzi,
   Luca/X 4024 2019; Davide, Gatti/ABP 6506 2022
OI VIAPIANA, Ombretta/0000 0003 1917 5655; Rossini,
   Maurizio/0000 0001 9692 2293; Idolazzi, Luca/0000 0002 7254 4686;
   benini, camilla/0000 0002 8082 5023; gatti, davide/0000 0002 7471 3076;
   Kunnathully, Vidya Satheesh/0000 0003 4538 6165
FU Eli Lilly; UCB; Abbvie; Abiogen; Amgen; Eli Lilly; Neopharmed Gentili;
   Merck Sharp Dohme Corp.; Roche; Bristol Myers Squibb
FX Luca Idolazzi has received speaking fees from Eli Lilly, UCB, Abbvie
   Davide Gatti has received speaking fees from Abiogen, Amgen, Eli Lilly
   and Neopharmed Gentili. Maurizio Rossini has received speaking and
   consulting fees from Abiogen, Amgen, Eli Lilly and Merck Sharp & Dohme
   Corp. Silvano Adami has received consulting fees from Amgen, Merck Sharp
   & Dohme Corp., Eli Lilly, Roche and Bristol Myers Squibb. Ombretta
   Viapiana has received speaking fees from Abiogen, Amgen, Merck Sharp &
   Dohme Corp. Vania Braga, Angelo Fassio, Camilla Benini, and Vidya
   Kunnathully declare no conflict of interests.
CR Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Boonen S, 2008, J CLIN ENDOCR METAB, V93, P852, DOI 10.1210/jc.2007 0711
   Cosman F, 2008, OSTEOPOROSIS INT, V19, P529, DOI 10.1007/s00198 007 0475 0
   Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157
   Cosman F, 2016, J CLIN ENDOCR METAB, V101, P1498, DOI 10.1210/jc.2015 3698
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cosman F, 2009, J CLIN ENDOCR METAB, V94, P3772, DOI 10.1210/jc.2008 2719
   Dempster DW, 2016, J CLIN ENDOCR METAB, V101, P1353, DOI 10.1210/jc.2015 4181
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Garnero P, 2000, J BONE MINER RES, V15, P1526, DOI 10.1359/jbmr.2000.15.8.1526
   Gatti D, 2012, J BONE MINER RES, V27, P2259, DOI 10.1002/jbmr.1681
   Gatti D, 2012, BONE, V50, P739, DOI 10.1016/j.bone.2011.11.028
   Gatti D, 2011, J CLIN ENDOCR METAB, V96, P1555, DOI 10.1210/jc.2010 2552
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Glass DA, 2006, ANN NY ACAD SCI, V1068, P117, DOI 10.1196/annals.1346.015
   Ivaska KK, 2008, J CLIN ENDOCR METAB, V93, P2622, DOI 10.1210/jc.2007 1508
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198 012 2074 y
   Keaveny TM, 2007, J BONE MINER RES, V22, P149, DOI 10.1359/JBMR.061011
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Leder BZ, 2014, J CLIN ENDOCR METAB, V99, P1694, DOI 10.1210/jc.2013 4440
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   Miller PD, 2008, J CLIN ENDOCR METAB, V93, P3785, DOI 10.1210/jc.2008 0353
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P6741, DOI 10.1210/jc.2005 2370
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Zanchetta JR, 2003, J BONE MINER RES, V18, P539, DOI 10.1359/jbmr.2003.18.3.539
NR 33
TC 30
Z9 31
U1 1
U2 7
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD NOV
PY 2016
VL 27
IS 11
BP 3301
EP 3307
DI 10.1007/s00198 016 3647 y
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ED6GR
UT WOS:000388954600019
PM 27250971
DA 2025 08 17
ER

PT J
AU Park, YE
   Musson, DS
   Naot, D
   Cornish, J
AF Park, Young Eun
   Musson, David S.
   Naot, Dorit
   Cornish, Jillian
TI Cell cell communication in bone development and whole body homeostasis
   and pharmacological avenues for bone disorders
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID GROWTH FACTOR I; ANTIDIABETIC DRUG METFORMIN; POSTMENOPAUSAL WOMEN;
   MINERAL DENSITY; PARATHYROID HORMONE; CORTICAL BONE; OSTEOBLAST
   PROLIFERATION; PHYSICAL ACTIVITY; PROGENITOR CELLS; ADIPOSE TISSUE
AB Cell cell communication plays a crucial role in bone development and maintenance, in health and disease. Our knowledge of the signalling pathways that regulate the communication of osteoblasts, osteoclasts and osteocytes is improving with time, giving us a better understanding of the regulation of the bone remodelling process. Bone cell communication has wider significance than the local tissue environment, however, with bone derived factors playing a role in whole body homeostasis, including energy metabolism and kidney function. Similarly, there are a range of systemic conditions which affect the maintenance of bone mass. Understanding these complex interactions, the autocrine, paracrine and endocrine signalling involved in the regulation of bone health is paramount to a better understanding of bone disease, and ultimately developing targets for pharmaceutical intervention.
C1 [Park, Young Eun; Musson, David S.; Naot, Dorit; Cornish, Jillian] Univ Auckland, Bone & Joint Res Grp, Dept Med, Fac Med & Hlth Sci, Auckland, New Zealand.
C3 University of Auckland
RP Cornish, J (通讯作者)，Univ Auckland, Bone & Joint Res Grp, Dept Med, Fac Med & Hlth Sci, Auckland, New Zealand.
EM j.cornish@auckland.ac.nz
OI Musson, David/0000 0003 2109 8791; Park, Young Eun/0000 0001 9912 5513
FU Health Research Council of New Zealand
FX The authors wish to acknowledge Health Research Council of New Zealand
   for funding.
CR Abdallah BM, 2015, DIABETES, V64, P3069, DOI 10.2337/db14 1642
   Abdallah BM, 2004, J BONE MINER RES, V19, P841, DOI 10.1359/JBMR.040118
   Adams GR, 2002, CLIN ORTHOP RELAT R, pS188, DOI 10.1097/01.blo.0000031980.92980.48
   Agholme F, 2011, BONE, V48, P988, DOI 10.1016/j.bone.2011.02.008
   Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Amrein K, 2012, J CLIN ENDOCR METAB, V97, P148, DOI 10.1210/jc.2011 2152
   Amso Z, 2016, ORG BIOMOL CHEM, V14, P9225, DOI 10.1039/c6ob01455k
   Amso Z, 2016, MED RES REV, V36, P579, DOI 10.1002/med.21388
   Andrukhova O, 2016, MOL CELL ENDOCRINOL, V436, P224, DOI 10.1016/j.mce.2016.07.035
   Antoniucci DM, 2006, J CLIN ENDOCR METAB, V91, P3144, DOI 10.1210/jc.2006 0021
   Ardawi MSM, 2011, J BONE MINER RES, V26, P2812, DOI 10.1002/jbmr.479
   Arounleut P, 2013, EXP GERONTOL, V48, P898, DOI 10.1016/j.exger.2013.06.004
   Asamiya Y., 2016, Renal Replace. Ther, V2, P8, DOI [10.1186/s41100 016 0024 4, DOI 10.1186/S41100 016 0024 4]
   Baht GS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8131
   Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI200214588
   Baldock PA, 2007, J BIOL CHEM, V282, P19092, DOI 10.1074/jbc.M700644200
   Barbour KE, 2011, J BONE MINER RES, V26, P1568, DOI 10.1002/jbmr.361
   Bermeo S, 2014, CURR OSTEOPOROS REP, V12, P235, DOI 10.1007/s11914 014 0199 y
   Bialek P, 2014, BONE, V60, P162, DOI 10.1016/j.bone.2013.12.002
   Bielemann RM, 2014, OSTEOPOROSIS INT, V25, P2007, DOI 10.1007/s00198 014 2715 4
   Biver E, 2011, J CLIN ENDOCR METAB, V96, P2703, DOI 10.1210/jc.2011 0047
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Bonnet N, 2010, IBMS BONEKEY, V7, P235, DOI [DOI 10.1138/20100454, DOI 10.1138/20100453]
   Boot AM, 1997, J CLIN ENDOCR METAB, V82, P57, DOI 10.1210/jc.82.1.57
   Boström P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777
   Botolin S, 2007, ENDOCRINOLOGY, V148, P198, DOI 10.1210/en.2006 1006
   Bouaziz W, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0540 6
   Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090
   Bredella MA, 2011, OBESITY, V19, P49, DOI 10.1038/oby.2010.106
   Bredella MA, 2009, J CLIN ENDOCR METAB, V94, P2129, DOI 10.1210/jc.2008 2532
   Bredella MA, 2008, RADIOLOGY, V249, P938, DOI 10.1148/radiol.2492080173
   Burnett SAM, 2006, J BONE MINER RES, V21, P1187, DOI 10.1359/JBMR.060507
   Carrillo López N, 2016, KIDNEY INT, V90, P77, DOI 10.1016/j.kint.2016.01.024
   Cawthorn WP, 2014, CELL METAB, V20, P368, DOI 10.1016/j.cmet.2014.06.003
   Chaudhary N, 2017, WORLD NEUROSURG, V100, P551, DOI 10.1016/j.wneu.2016.11.135
   Chen SC, 2017, MOL CELL ENDOCRINOL, V440, P57, DOI 10.1016/j.mce.2016.11.011
   Cheung AM, 2012, CURR OPIN RHEUMATOL, V24, P561, DOI 10.1097/BOR.0b013e3283570238
   Colaianni G, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/902186
   Colaianni G, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.134
   Colaianni G, 2015, P NATL ACAD SCI USA, V112, P12157, DOI 10.1073/pnas.1516622112
   Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Cosman F, 2017, J BONE MINER RES, V32, P17, DOI 10.1002/jbmr.2991
   de Souza KSC, 2016, DIABETES METAB RES, V32, P589, DOI 10.1002/dmrr.2772
   Dankbar B, 2015, NAT MED, V21, P1085, DOI 10.1038/nm.3917
   De Toni L, 2016, ENDOCRINOLOGY, V157, P4473, DOI 10.1210/en.2016 1312
   Duque G, 2013, J BONE MINER RES, V28, P639, DOI 10.1002/jbmr.1782
   Elbaz A, 2010, J CELL MOL MED, V14, P982, DOI 10.1111/j.1582 4934.2009.00751.x
   Elkasrawy MN, 2010, J MUSCULOSKEL NEURON, V10, P56
   Engelke K, 2015, J BONE MINER RES, V30, P30, DOI 10.1002/jbmr.2292
   Fan X, 2004, ENDOCRINOLOGY, V145, P751, DOI 10.1210/en.2003 0726
   Fazeli PK, 2012, J BONE MINER RES, V27, P1864, DOI 10.1002/jbmr.1640
   Ferrari SL, 2005, J CLIN ENDOCR METAB, V90, P1519, DOI 10.1210/jc.2004 1039
   Ferron M, 2012, BONE, V50, P568, DOI 10.1016/j.bone.2011.04.017
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Föger Samwald U, 2014, EXP GERONTOL, V57, P114, DOI 10.1016/j.exger.2014.05.014
   Fulzele K, 2017, J BONE MINER RES, V32, P373, DOI 10.1002/jbmr.3001
   Galea GL, 2017, BONE, V96, P38, DOI 10.1016/j.bone.2016.10.008
   Gao Y, 2010, EUR J PHARMACOL, V635, P231, DOI 10.1016/j.ejphar.2010.02.051
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Gatti D, 2013, CALCIFIED TISSUE INT, V93, P448, DOI 10.1007/s00223 013 9770 2
   Gatti D, 2011, J CLIN ENDOCR METAB, V96, P1555, DOI 10.1210/jc.2010 2552
   Ghodsi M, 2016, J DIABETES METAB DIS, V15, DOI 10.1186/s40200 016 0275 1
   Glantschnig H, 2011, J PHARMACOL EXP THER, V338, P568, DOI 10.1124/jpet.111.181404
   Gregory SM, 2013, MED SCI SPORT EXER, V45, P420, DOI 10.1249/MSS.0b013e3182750bd4
   Gu QL, 2017, TOHOKU J EXP MED, V241, P13, DOI 10.1620/tjem.241.13
   Haam JH, 2016, J BONE MINER METAB
   Hannemann A, 2013, ANDROLOGY US, V1, P469, DOI 10.1111/j.2047 2927.2012.00044.x
   Hinton PS, 2017, BONE, V96, P85, DOI 10.1016/j.bone.2016.10.011
   Ichikawa S, 2007, J CLIN INVEST, V117, P2684, DOI 10.1172/JCI31330
   Idolazzi L, 2016, OSTEOPOROSIS INT, V27, P3301, DOI 10.1007/s00198 016 3647 y
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Iyer SP, 2014, BRIT J HAEMATOL, V167, P366, DOI 10.1111/bjh.13056
   Jang WG, 2011, BONE, V48, P885, DOI 10.1016/j.bone.2010.12.003
   Tolosa MJ, 2013, DIABETES RES CLIN PR, V101, P177, DOI 10.1016/j.diabres.2013.05.016
   Jou YC, 2014, UROLOGY, V83, P1006, DOI 10.1016/j.urology.2013.12.017
   Jürimäe J, 2009, EUR J ENDOCRINOL, V160, P381, DOI 10.1530/EJE 08 0673
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Kanazawa I, 2013, OSTEOPOROSIS INT, V24, P1115, DOI 10.1007/s00198 012 2017 7
   Kanazawa I, 2011, OSTEOPOROSIS INT, V22, P1191, DOI 10.1007/s00198 010 1310 6
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   KASTEN TP, 1994, P NATL ACAD SCI USA, V91, P3569, DOI 10.1073/pnas.91.9.3569
   Kawakubo Yasukochi T, 2016, OBESITY, V24, P895, DOI 10.1002/oby.21447
   Keats E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038752
   Keila S, 2001, J ENDOCRINOL, V168, P131, DOI 10.1677/joe.0.1680131
   Kim JY, 2015, BONE, V79, P242, DOI 10.1016/j.bone.2015.06.011
   Kim YS, 2015, CLIN ENDOCRINOL, V82, P686, DOI 10.1111/cen.12601
   Kirmani S, 2011, J BONE MINER RES, V26, P2212, DOI 10.1002/jbmr.421
   Larsson S, 2016, INJURY, V47, pS31, DOI 10.1016/S0020 1383(16)30008 0
   Lawson EA, 2010, BONE, V46, P458, DOI 10.1016/j.bone.2009.09.005
   LEAN JM, 1995, AM J PHYSIOL ENDOC M, V268, pE318, DOI 10.1152/ajpendo.1995.268.2.E318
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Leder BZ, 2014, J CLIN ENDOCR METAB, V99, P1694, DOI 10.1210/jc.2013 4440
   LEDGER GA, 1995, J CLIN ENDOCR METAB, V80, P3304, DOI 10.1210/jc.80.11.3304
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lee NJ, 2015, MOL METAB, V4, P164, DOI 10.1016/j.molmet.2014.12.010
   Levinger I, 2016, OSTEOPOROSIS INT, V27, P653, DOI 10.1007/s00198 015 3273 0
   Levinger I, 2014, J BONE MINER RES, V29, P2571, DOI 10.1002/jbmr.2285
   Li C, 2015, J DENT RES, V94, P455, DOI 10.1177/0022034514566431
   Li XD, 2011, J BONE MINER RES, V26, P2610, DOI 10.1002/jbmr.472
   Liao M, 2013, J CLIN ENDOCR METAB, V98, P3463, DOI 10.1210/jc.2013 1805
   Limonard EJ, 2015, CLIN ENDOCRINOL, V82, P753, DOI 10.1111/cen.12660
   Loke YK, 2009, CAN MED ASSOC J, V180, P32, DOI 10.1503/cmaj.080486
   Lombardi G, 2016, ENDOCRINE, V54, P284, DOI 10.1007/s12020 015 0834 0
   MacKenzie MG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068743
   Mana DL, 2017, OSTEOPOROSIS INT, V28, P1491, DOI 10.1007/s00198 016 3869 z
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Marciano DP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8443
   Martin TJ, 2015, REV ENDOCR METAB DIS, V16, P131, DOI 10.1007/s11154 014 9308 6
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Maurin AC, 2000, BONE, V26, P485, DOI 10.1016/S8756 3282(00)00252 0
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Melton LJ, 2008, J CLIN ENDOCR METAB, V93, P4804, DOI 10.1210/jc.2008 0639
   Mezil YA, 2015, MED SCI SPORT EXER, V47, P1495, DOI 10.1249/MSS.0000000000000555
   Michaud M, 2013, J AM MED DIR ASSOC, V14, P877, DOI 10.1016/j.jamda.2013.05.009
   Miller PD, 2016, J CLIN ENDOCR METAB, V101, P3163, DOI 10.1210/jc.2016 1801
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Milliken LA, 2003, CALCIFIED TISSUE INT, V72, P478, DOI 10.1007/s00223 001 1128 5
   Misra M, 2008, J CLIN ENDOCR METAB, V93, P3029, DOI 10.1210/jc.2008 0170
   Mizokami A, 2014, BONE, V69, P68, DOI 10.1016/j.bone.2014.09.006
   Moayyeri A, 2008, ANN EPIDEMIOL, V18, P827, DOI 10.1016/j.annepidem.2008.08.007
   Moreira CA, 2017, BONE, V97, P314, DOI 10.1016/j.bone.2016.11.004
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Naot D, 2016, ENDOCRINOLOGY, V157, P3550, DOI 10.1210/en.2016 1059
   Naot D, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00070
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Nguyen J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053813
   NICOLAS V, 1994, J CLIN ENDOCR METAB, V78, P1011, DOI 10.1210/jc.78.5.1011
   Nishikawa A, 2016, CLIN INTERV AGING, V11, P1653, DOI 10.2147/CIA.S120175
   Nuche Berenguer B, 2010, REGUL PEPTIDES, V159, P61, DOI 10.1016/j.regpep.2009.06.010
   Otani T, 2015, CELL SIGNAL, V27, P532, DOI 10.1016/j.cellsig.2014.12.018
   OURSLER MJ, 1994, J BONE MINER RES, V9, P443
   Oury F, 2013, J CLIN INVEST, V123, P2421, DOI 10.1172/JCI65952
   Oury F, 2011, CELL, V144, P796, DOI 10.1016/j.cell.2011.02.004
   Palermo A, 2015, CLIN ENDOCRINOL, V82, P615, DOI 10.1111/cen.12672
   Patti A, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/846480
   PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024
   Pi M, 2015, MOL ENDOCRINOL, V29, P1759, DOI 10.1210/me.2015 1161
   Prouteau S, 2006, EUR J ENDOCRINOL, V154, P389, DOI 10.1530/eje.1.02103
   Qi ZT, 2016, PROG BIOPHYS MOL BIO, V122, P131, DOI 10.1016/j.pbiomolbio.2016.05.010
   Quarles LD, 2008, J CLIN INVEST, V118, P3820, DOI 10.1172/JCI36479
   Rahman S, 2013, ENDOCRINOLOGY, V154, P2687, DOI 10.1210/en.2012 2162
   Rauner M, 2008, AGE, V30, P273, DOI 10.1007/s11357 008 9069 9
   Recker R, 2004, J BONE MINER RES, V19, P1628, DOI 10.1359/JBMR.040710
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Reid IR, 2010, ARCH BIOCHEM BIOPHYS, V503, P20, DOI 10.1016/j.abb.2010.06.027
   Reid IR, 2013, NUTR INFLUENCES BONE, P83
   Rocha Rodrigues S, 2016, LIFE SCI, V165, P100, DOI [10.1016/j.lfs.2016.09.023, 10.1016/j.lfs.2016.0]
   Rochefort GY, 2010, OSTEOPOROSIS INT, V21, P1457, DOI 10.1007/s00198 010 1194 5
   Roforth MM, 2014, BONE, V59, P1, DOI 10.1016/j.bone.2013.10.019
   Rubin MR, 2005, DRUGS, V65, P2481, DOI 10.2165/00003495 200565170 00005
   Ryan ZC, 2013, P NATL ACAD SCI USA, V110, P6199, DOI 10.1073/pnas.1221255110
   Sabek OM, 2015, ENDOCRINOLOGY, V156, P3137, DOI 10.1210/EN.2015 1143
   Saito H, 2005, J BIOL CHEM, V280, P2543, DOI 10.1074/jbc.M408903200
   Schwartz AV, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00040
   Shah K, 2011, J BONE MINER RES, V26, P2851, DOI 10.1002/jbmr.475
   Shi ZJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168691
   Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Sitara D, 2004, MATRIX BIOL, V23, P421, DOI 10.1016/j.matbio.2004.09.007
   Slemenda C, 1996, J CLIN INVEST, V97, P14, DOI 10.1172/JCI118382
   SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092 8674(93)90252 L
   Solomon DH, 2009, J CLIN ENDOCR METAB, V94, P2792, DOI 10.1210/jc.2008 2157
   Starup Linde J, 2014, OSTEOPOROSIS INT, V25, P1697, DOI 10.1007/s00198 014 2676 7
   Stechschulte LA, 2016, EBIOMEDICINE, V10, P174, DOI 10.1016/j.ebiom.2016.06.040
   Stunes AK, 2011, BMC ENDOCR DISORD, V11, DOI 10.1186/1472 6823 11 11
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Tang L, 2016, EXP BIOL MED, V241, P308, DOI 10.1177/1535370215606814
   Thompson ML, 2016, MOL PAIN, P12
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Tsuchiya Y, 2014, J MUSCULOSKEL NEURON, V14, P50
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   van Zoelen EJ, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0375 3
   VANDERSCHUEREN D, 1990, CALCIFIED TISSUE INT, V46, P179, DOI 10.1007/BF02555041
   Varela A, 2017, J BONE MINER RES, V32, P24, DOI 10.1002/jbmr.3003
   Vega SR, 2010, HORM METAB RES, V42, P982, DOI 10.1055/s 0030 1267950
   Verlinden L, 2016, MOL CELL ENDOCRINOL, V432, P76, DOI 10.1016/j.mce.2015.09.009
   Vestergaard P, 2005, DIABETOLOGIA, V48, P1292, DOI 10.1007/s00125 005 1786 3
   Wang C, 2012, J BONE MINER METAB, V30, P630, DOI 10.1007/s00774 012 0374 0
   Wang FS, 2016, OSTEOPOROSIS INT, V27, P2777, DOI 10.1007/s00198 016 3598 3
   Wang L, 2015, CELL DEATH DIFFER, V22, P1654, DOI 10.1038/cdd.2015.14
   Wehrli FW, 2000, RADIOLOGY, V217, P527, DOI 10.1148/radiology.217.2.r00nv20527
   Weivoda MM, 2016, J BONE MINER RES, V31, P76, DOI 10.1002/jbmr.2586
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Wu L, 2016, INT J MOL MED, V38, P1395, DOI 10.3892/ijmm.2016.2741
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Yang JH, 2010, CELL BIOCHEM FUNCT, V28, P334, DOI 10.1002/cbf.1668
   Yang KP, 2008, FASEB J, V22, P2452, DOI 10.1096/fj.07 100735
   Yao J, 2015, J CELL PHYSIOL, V230, P1235, DOI 10.1002/jcp.24858
   Yue R, 2016, CELL STEM CELL, V18, P782, DOI 10.1016/j.stem.2016.02.015
   Zhang W, 2012, CELL BIOCHEM FUNCT, V30, P297, DOI 10.1002/cbf.2801
   Zhang Y, 2016, AM J PHYSIOL ENDOC M, V311, pE530, DOI 10.1152/ajpendo.00094.2016
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhen DH, 2010, J DIABETES COMPLICAT, V24, P334, DOI 10.1016/j.jdiacomp.2009.05.002
   Zhu GX, 2016, J CARDIOVASC PHARM, V68, P67, DOI 10.1097/FJC.0000000000000386
   Zhu ZN, 2014, BONE, V68, P115, DOI 10.1016/j.bone.2014.08.010
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 199
TC 20
Z9 22
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471 4892
EI 1471 4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD JUN
PY 2017
VL 34
BP 21
EP 35
DI 10.1016/j.coph.2017.04.001
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FR9TT
UT WOS:000419416700006
PM 28472742
DA 2025 08 17
ER

PT J
AU Malan, J
   Ettinger, K
   Naumann, E
   Beirne, OR
AF Malan, John
   Ettinger, Kyle
   Naumann, Erich
   Beirne, O. Ross
TI The relationship of denosumab pharmacology and osteonecrosis of the jaws
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Article
ID BISPHOSPHONATE ASSOCIATED OSTEONECROSIS; REGULATES OSTEOCLAST
   DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; POSTMENOPAUSAL OSTEOPOROSIS;
   BONE RESORPTION; NECROSIS; CANCER; RANKL; PHARMACODYNAMICS; INHIBITION
AB Denosumab is a new bone antiresorptive agent that has received approval by the Food and Drug Administration for use in patients with osteoporosis and metastatic cancer to the bones. Like the bisphosponates that are used as antiresorptive medications, denosumab has been associated with osteonecrosis of the jaws (ONJ). However, because the pharmacodynamics and pharmacokinetics of denosumab differ from that of the bisphosphonates, ONJ related to denosumab may resolve more rapidly with a drug holiday than bisphosphonate related osteonecrosis of the jaws (BRONJ). This paper describes the management of a patient who developed ONJ while receiving denosumab, reviews the incidence of ONJ associated with denosumab, and compares the pharmacology of denosumab and the bisphosphonates. Because the effects of denosumab on bone turnover are more rapidly reversible than the effects of the bisphosphonates, ONJ related to denosumab may resolve more quickly with a drug holiday than BRONJ. (Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114:671 676)
C1 [Beirne, O. Ross] Univ Washington, Sch Dent, Dept Oral & Maxillofacial Surg, Seattle, WA 98195 USA.
   [Malan, John] USN, Okinawa, Japan.
   [Ettinger, Kyle] Mayo Clin, Rochester, MN USA.
C3 University of Washington; University of Washington Seattle; Mayo Clinic
RP Beirne, OR (通讯作者)，Univ Washington, Sch Dent, Dept Oral & Maxillofacial Surg, Box 357134, Seattle, WA 98195 USA.
EM slsb@uw.edu
CR Aghaloo TL, 2010, J ORAL MAXIL SURG, V68, P959, DOI 10.1016/j.joms.2009.10.010
   Badros A, 2008, J CLIN ONCOL, V26, P5904, DOI 10.1200/JCO.2008.16.9300
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Bridgeman MB, 2011, CLIN THER, V33, P1547, DOI 10.1016/j.clinthera.2011.10.008
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Fizazi K, 2009, J UROLOGY, V182, P509, DOI 10.1016/j.juro.2009.04.023
   Fleisch H, 2003, EUR SPINE J, V12, pS142, DOI 10.1007/s00586 003 0622 z
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Jin QM, 2007, J PERIODONTOL, V78, P1300, DOI 10.1902/jop.2007.070073
   Khan AA, 2008, J RHEUMATOL, V35, P1391
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Kyrgidis A, 2011, OSTEOPOROSIS INT, V22, P369, DOI 10.1007/s00198 010 1177 6
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Marathe DD, 2011, BIOPHARM DRUG DISPOS, V32, P471, DOI 10.1002/bdd.770
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mavrokokki T, 2007, J ORAL MAXIL SURG, V65, P415, DOI 10.1016/j.joms.2006.10.061
   Migliorati CA, 2005, J AM DENT ASSOC, V136, P1658, DOI 10.14219/jada.archive.2005.0108
   Migliorati CA, 2010, SUPPORT CARE CANCER, V18, P1099, DOI 10.1007/s00520 010 0882 1
   MOSEKILDE L, 1991, ENDOCRINOLOGY, V129, P421, DOI 10.1210/endo 129 1 421
   O'Brien EA, 2000, BIOCHEM BIOPH RES CO, V274, P281, DOI 10.1006/bbrc.2000.3129
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Silver David S, 2010, Curr Osteoporos Rep, V8, P1, DOI 10.1007/s11914 010 0001 8
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   Taylor KH, 2010, BRIT J ORAL MAX SURG, V48, P221, DOI 10.1016/j.bjoms.2009.08.030
   Van den Wyngaert T, 2011, SUPPORT CARE CANCER, V19, P2035, DOI 10.1007/s00520 010 1061 0
   Vidal NOA, 1998, J ENDOCRINOL, V159, P191, DOI 10.1677/joe.0.1590191
   Vij R, 2009, AM J HEMATOL, V84, P650, DOI 10.1002/ajh.21509
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Yonemori K, 2008, CANCER SCI, V99, P1237, DOI 10.1111/j.1349 7006.2008.00803.x
NR 37
TC 64
Z9 71
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2212 4403
EI 1528 395X
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD DEC
PY 2012
VL 114
IS 6
BP 671
EP 676
DI 10.1016/j.oooo.2012.08.439
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 041BA
UT WOS:000311370000013
PM 23159111
DA 2025 08 17
ER

PT J
AU Lin, CC
   Lin, RW
   Chang, CW
   Wang, GJ
   Lai, KA
AF Lin, Chih Chun
   Lin, Ru Wei
   Chang, Chih Wei
   Wang, Gwo Jaw
   Lai, Kuo An
TI Single Pulsed Electromagnetic Field Therapy Increases Osteogenic
   Differentiation Through Wnt Signaling Pathway and Sclerostin
   Downregulation
SO BIOELECTROMAGNETICS
LA English
DT Article
DE SPEMF; BMPs (bone morphogenetic proteins); Wnt pathway; PTHrP
   (parathyroid hormone related protein); sclerostin
ID BONE MORPHOGENETIC PROTEINS; OSTEOBLAST DIFFERENTIATION; BETA CATENIN;
   ELECTRICAL STIMULATION; TRANSCRIPTION FACTORS; OVARIECTOMIZED RATS;
   PARATHYROID HORMONE; MAGNETIC FIELDS; BMP ANTAGONIST; EXPRESSION
AB Pulsed electromagnetic field (PEMF) therapy has been used for more than three decades to treat bone diseases. The main complaint about using PEMF is that it is time consuming. Previously, we showed single pulsed electromagnetic field (SPEMF) applied for 3 min daily increased osteogenic differentiation of mesenchymal stem cells and accelerated bone growth in a long bone defect model. In the current study, we investigated the mechanism of SPEMF to increase osteogenic differentiation in osteoblastic cells. We found that both short term (SS) and long term (SL) SPEMF treatment increased mineralization, while alkaline phosphatase (ALP) activity increased during the first 5 days of SPEMF treatment. SS treatment increased gene expression of Wnt1, Wnt3a, Wnt10b, Fzd9, ALP, and Bmp2. Also, SPEMF inhibited sclerostin after 5 days of treatment, and that inhibition was more significant with SL treatment. SL SPEMF increased expression of parathyroid hormone related protein (PTHrP) but decreased expression of Sost gene, which encodes sclerostin. Together, the early osteogenic effect of SPEMF utilizes the canonical Wnt signaling pathway while the inhibitory effect of long term SPEMF on sclerostin may be attributable to PTHrP upregulation. This study enhances our understanding of cellular mechanisms to support the previous finding and may provide new insight for clinical applications. (C) 2015 Wiley Periodicals, Inc.
C1 [Lin, Chih Chun; Lin, Ru Wei; Wang, Gwo Jaw; Lai, Kuo An] Natl Cheng Kung Univ, Bone & Joint Res Ctr, Tainan 701, Taiwan.
   [Lin, Chih Chun] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 701, Taiwan.
   [Lin, Ru Wei] Natl Cheng Kung Univ, Coll Med, Tainan 70101, Taiwan.
   [Chang, Chih Wei; Lai, Kuo An] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Orthoped, Tainan 70101, Taiwan.
   [Wang, Gwo Jaw] Univ Virginia, Dept Orthoped Surg, Charlottesville, VA USA.
   [Wang, Gwo Jaw] Natl Cheng Kung Univ, Grad Inst Biomed Engn, Tainan 701, Taiwan.
C3 National Cheng Kung University; National Cheng Kung University; National
   Cheng Kung University; National Cheng Kung University; National Cheng
   Kung University Hospital; University of Virginia; National Cheng Kung
   University
RP Lai, KA (通讯作者)，Natl Cheng Kung Univ Hosp & Coll Med, Dept Orthoped, 138 Sheng Li Rd, Tainan 704, Taiwan.
EM laikuoan@mail.ncku.edu.tw
RI Huang, Chih Chung/AAL 2138 2021; Lin, Ru Wei/HMP 0707 2023
OI Lin, Chih Chun/0000 0001 7544 9257; 
FU Ministry of Science and Technology of Taiwan [MOST: 103 2314 B 006 032]
FX Grant sponsor: Ministry of Science and Technology of Taiwan; grant
   number: MOST: 103 2314 B 006 032.
CR Albers J, 2011, J CELL BIOL, V192, P1057, DOI 10.1083/jcb.201008012
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Balemans W, 1999, AM J HUM GENET, V64, P1661, DOI 10.1086/302416
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   BASSETT CAL, 1977, CLIN ORTHOP RELAT R, P128
   BASSETT CAL, 1989, CRIT REV BIOMED ENG, V17, P451
   BASSETT CAL, 1984, ORTHOP CLIN N AM, V15, P61
   BEIGHTON P, 1976, ANN INTERN MED, V84, P393, DOI 10.7326/0003 4819 84 4 393
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Bodamyali T, 1998, BIOCHEM BIOPH RES CO, V250, P458, DOI 10.1006/bbrc.1998.9243
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Caverzasio J, 2007, ENDOCRINOLOGY, V148, P5323, DOI 10.1210/en.2007 0520
   Chang K, 2003, BIOELECTROMAGNETICS, V24, P189, DOI 10.1002/bem.10078
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Church VL, 2002, INT J DEV BIOL, V46, P927
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   Esmail MY, 2012, ELECTROMAGN BIOL MED, V31, P375, DOI 10.3109/15368378.2012.662196
   Eyres KS, 1996, BONE, V18, P505, DOI 10.1016/8756 3282(96)00070 1
   de Castro LF, 2012, J CELL PHYSIOL, V227, P1752, DOI 10.1002/jcp.22902
   Fu YC, 2014, PLOS ONE, V14
   Fukuda T, 2010, DIFFERENTIATION, V80, P46, DOI 10.1016/j.diff.2010.05.002
   Guo AJY, 2011, J BIOL CHEM, V286, P27882, DOI 10.1074/jbc.M111.236281
   Heilmann A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084232
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Huang LQ, 2008, CHINESE MED J PEKING, V121, P2095, DOI 10.1097/00029330 200810020 00028
   Ibiwoye MO, 2004, J ORTHOP RES, V22, P1086, DOI 10.1016/j.orthres.2003.12.017
   Jing D, 2014, J BONE MINER RES, V29, P2250, DOI 10.1002/jbmr.2260
   Jing D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079377
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lu WY, 2008, FEBS LETT, V582, P643, DOI 10.1016/j.febslet.2008.01.035
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mahmood T, 2012, N AM J MED SCI, V4, P429, DOI 10.4103/1947 2714.100998
   MAMMI GI, 1993, CLIN ORTHOP RELAT R, P246
   Martin TJ, 2005, J CLIN INVEST, V115, P2322, DOI 10.1172/JCI26239
   Massagué J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   Massari L, 2006, J BONE JOINT SURG AM, V88A, P56, DOI 10.2106/JBJS.F.00536
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   MISHIMA S, 1988, Journal of UOEH, V10, P31
   Papanicolaou SE, 2009, BIORHEOLOGY, V46, P389, DOI 10.3233/BIR 2009 0550
   Paszty C, 2010, J BONE MINER RES, V25, P1897, DOI 10.1002/jbmr.161
   Powell WF, 2011, J ENDOCRINOL, V209, P21, DOI 10.1530/JOE 10 0308
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Schiffer IB, 2003, BIOELECTROMAGNETICS, V24, P241, DOI 10.1002/bem.10097
   Schmidt Rohlfing B, 2011, Z ORTHOP UNFALLCHIR, V149, P265, DOI 10.1055/s 0030 1250518
   Sert C, 2002, J BONE MINER METAB, V20, P345, DOI 10.1007/s007740200050
   Shellock FG, 2004, RADIOLOGY, V232, P635, DOI 10.1148/radiol.2323030830
   Tabrah FL, 1998, BIOELECTROMAGNETICS, V19, P75, DOI 10.1002/(SICI)1521 186X(1998)19:2<75::AID BEM3>3.0.CO;2 0
   TRUSWELL AS, 1958, J BONE JOINT SURG BR, V40, P208, DOI 10.1302/0301 620X.40B2.208
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   van Bezooijen RL, 2007, J BONE MINER RES, V22, P19, DOI 10.1359/JBMR.061002
   Varani K, 2002, BRIT J PHARMACOL, V136, P57, DOI 10.1038/sj.bjp.0704695
   Wang ZY, 2006, J BONE JOINT SURG AM, V88A, P1053, DOI 10.2106/JBJS.E.00443
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Wysolmerski JJ, 2012, J CLIN ENDOCR METAB, V97, P2947, DOI 10.1210/jc.2012 2142
   Yamaguchi Sekino S, 2011, MAGN RESON MED SCI, V10, P1, DOI 10.2463/mrms.10.1
   Yonemori K, 1996, BONE, V19, P173, DOI 10.1016/8756 3282(96)00169 X
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhou J, 2012, ARCH MED RES, V43, P274, DOI 10.1016/j.arcmed.2012.06.002
NR 73
TC 27
Z9 27
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0197 8462
EI 1521 186X
J9 BIOELECTROMAGNETICS
JI Bioelectromagnetics
PD OCT
PY 2015
VL 36
IS 7
BP 494
EP 505
DI 10.1002/bem.21933
PG 12
WC Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Biophysics
GA CT3UB
UT WOS:000362731300002
PM 26364557
DA 2025 08 17
ER

PT J
AU Yang, YM
   Blair, HC
   Shapiro, IM
   Wang, B
AF Yang, Yanmei
   Blair, Harry C.
   Shapiro, Irving M.
   Wang, Bin
TI The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid
   Hormone induced Osteoclastogenesis through a RANKL mediated Signaling
   Pathway
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID KAPPA B LIGAND; MULTIPLE MYELOMA; RECEPTOR ACTIVATOR; GENE EXPRESSION;
   BONE FORMATION; BETA CATENIN; OSTEOBLASTS; DIFFERENTIATION; DEGRADATION;
   CELLS
AB Parathyroid hormone (PTH) induces osteoclast formation and activity by increasing the ratio of RANKL/OPG in osteoblasts. The proteasome inhibitor carfilzomib (CFZ) has been used as an effective therapy for multiple myeloma via the inhibition of pathologic bone destruction. However, the effect of combination of PTH and CFZ on osteoclastogenesis is unknown. We now report that CFZ inhibits PTH induced RANKL expression and secretion without affecting PTH inhibition of OPG expression, and it does so by blocking HDAC4 proteasomal degradation in osteoblasts. Furthermore, we used different types of culture systems, including co culture, indirect co culture, and transactivation, to assess the effect of CFZ on PTH action to induce osteoclastogenesis. Our results demonstrated that CFZ blocks PTH induced osteoclast formation and bone resorption by its additional effect to inhibit RANKL mediated I kappa B degradation and NF kappa B activation in osteoclasts. This study showed for the first time that CFZ targets both osteoblasts and osteoclasts to suppress PTH induced osteoclast differentiation and bone resorption. These findings warrant further investigation of this novel combination in animal models of osteoporosis and in patients.
C1 [Yang, Yanmei; Wang, Bin] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Ctr Translat Med, Dept Med, Philadelphia, PA 19107 USA.
   [Shapiro, Irving M.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Ctr Translat Med, Dept Orthopaed Surg, Philadelphia, PA 19107 USA.
   [Blair, Harry C.] Dept Vet Affairs Med Ctr, Pittsburgh, PA 15240 USA.
   [Blair, Harry C.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA.
   [Blair, Harry C.] Univ Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA 15261 USA.
C3 Thomas Jefferson University; Thomas Jefferson University; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Wang, B (通讯作者)，Ctr Translat Med, Dept Med, Locust St, Philadelphia, PA 19107 USA.
EM bin.wang@jefferson.edu
FU National Institutes of Health [AR062705, AR063289]; Department of
   Veterans Affairs
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants AR062705 and AR063289 (to B. W.). This work was also
   supported by funds from the Department of Veterans Affairs (to H. C.
   B.). The authors declare that they have no conflicts of interest with
   the contents of this article.
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Ang E, 2009, J CELL PHYSIOL, V220, P450, DOI 10.1002/jcp.21787
   Backs J, 2011, J CELL BIOL, V195, P403, DOI 10.1083/jcb.201105063
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Berenson JR, 2014, LEUKEMIA, V28, P1529, DOI 10.1038/leu.2014.27
   Blair HC, 2007, ANN NY ACAD SCI, V1116, P165, DOI 10.1196/annals.1402.029
   Boissy P, 2008, LEUKEMIA RES, V32, P1661, DOI 10.1016/j.leukres.2008.02.019
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cernotta N, 2011, MOL BIOL CELL, V22, P278, DOI 10.1091/mbc.E10 07 0616
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   Eda H, 2014, LEUKEMIA, V28, P1892, DOI 10.1038/leu.2014.69
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Fu Q, 2006, MOL CELL BIOL, V26, P6453, DOI 10.1128/MCB.00356 06
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Hu B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074191
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Hurchla MA, 2013, LEUKEMIA, V27, P430, DOI 10.1038/leu.2012.183
   Karatoprak C, 2012, INDIAN J PHARMACOL, V44, P270, DOI 10.4103/0253 7613.93869
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Marino Silvia, 2014, Bonekey Rep, V3, P570, DOI 10.1038/bonekey.2014.65
   Mori K, 2006, J CELL BIOCHEM, V98, P1629, DOI 10.1002/jcb.20891
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   O'Brien CA, 2002, BONE, V30, P453, DOI 10.1016/S8756 3282(01)00692 5
   Obri A, 2014, J CELL BIOL, V205, P771, DOI 10.1083/jcb.201403138
   Pennisi A, 2009, AM J HEMATOL, V84, P6, DOI 10.1002/ajh.21310
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   Qiang YW, 2010, BRIT J HAEMATOL, V148, P726, DOI 10.1111/j.1365 2141.2009.08009.x
   Romero G, 2010, J BIOL CHEM, V285, P14756, DOI 10.1074/jbc.M110.102970
   Shinoda Y, 2010, J CELL BIOCHEM, V109, P755, DOI 10.1002/jcb.22454
   Takahashi Naoyuki, 2007, V135, P285
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang B, 2004, ARTHRITIS RHEUM US, V50, P2995, DOI 10.1002/art.20459
   Wang B, 2013, BONE, V52, P268, DOI 10.1016/j.bone.2012.10.001
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Zavrski I, 2005, BIOCHEM BIOPH RES CO, V333, P200, DOI 10.1016/j.bbrc.2005.05.098
   Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092 8674(02)00861 9
   Zhao L, 2010, J BONE MINER RES, V25, P1246, DOI 10.1002/jbmr.28
   Zhu Q, 2007, ONCOGENE, V26, P4199, DOI 10.1038/sj.onc.1210191
NR 39
TC 20
Z9 23
U1 1
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 3
PY 2015
VL 290
IS 27
BP 16918
EP 16928
DI 10.1074/jbc.M115.663963
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA CM3HN
UT WOS:000357572800036
PM 25979341
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Wada, A
   Tsuchiya, M
   Ozaki Honda, Y
   Kayamori, K
   Sakamoto, K
   Yamaguchi, A
   Ikeda, T
AF Wada, Akane
   Tsuchiya, Maiko
   Ozaki Honda, Yuu
   Kayamori, Kou
   Sakamoto, Kei
   Yamaguchi, Akira
   Ikeda, Tohru
TI A new osteoclastogenesis pathway induced by cancer cells targeting
   osteoclast precursor cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteoclastogenesis; Osteoclast precursor cell; Bone resorption; Tumor
ID KAPPA B LIGAND; RECEPTOR ACTIVATOR; TNF ALPHA; BONE RESORPTION;
   DIFFERENTIATION; MECHANISMS; RANKL; EXPRESSION; OSTEOBLAST; OSTEOPENIA
AB The precise mechanism of osteolysis induced by tumors infiltrating into the bone remains unclear. The main hypothesis is that tumor cells generate receptor activator of nuclear factor kappa B ligand (RANKL), tumor necrosis factor alpha (TNF alpha), or other molecules that activate the expression of RANKL in osteoblasts, osteocytes, or bone marrow stromal cells. Administration of bisphosphonates or anti RANKL antibody drugs, which suppress systemic bone resorption, prevents osteolysis induced by tumors infiltrating into the bone. However, these therapeutic agents may cause medication related osteonecrosis of the jaw. In this study, we found a novel tumor associated osteoclastogenesis pathway in osteoclast precursor cells. Co culture with human oral squamous cell carcinoma cells, 3A or NEM, or culture with each of their conditioned medium induced many osteoclasts from osteoclast precursor cells, which were generated by a 24 h pretreatment of RANKL or TNF alpha. Osteoprotegerin, a decoy RANKL receptor, denosumab, an anti RANKL antibody drug, and infliximab, an anti TNF alpha antibody drug, did not prevent this tumor associated osteoclastogenesis. Quantitative RT PCR analysis showed that the expression of NFATc1 was decreased in this tumor associated osteoclastogenesis, which was suggested to be independent of NFATc1. These results revealed a novel pathway for tumor associated osteoclastogenesis, which may be a new therapeutic target for osteolysis induced by tumors infiltrating into the bone without affecting systemic bone metabolism. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Wada, Akane; Tsuchiya, Maiko; Kayamori, Kou; Sakamoto, Kei; Ikeda, Tohru] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Oral Pathol, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138549, Japan.
   [Ozaki Honda, Yuu] Nagasaki Univ, Dept Clin Physiol, Grad Sch Biomed Sci, 1 7 1 Sakamoto, Nagasaki 8528588, Japan.
   [Yamaguchi, Akira] Tokyo Dent Coll, Res Branding Project, Oral Hlth Sci Ctr, Tokyo 1010061, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Nagasaki University; Tokyo Dental College
RP Ikeda, T (通讯作者)，Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Oral Pathol, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138549, Japan.
EM tohrupth.mpa@tmd.ac.jp
RI ; Yamaguchi, Akira/AAX 9286 2020; 栢森, 高/JPK 5150 2023
OI Wada, Akane/0000 0002 1161 4214; Tsuchiya, Maiko/0009 0001 1747 8102; 
FU Tokyo Medical; Dental University
FX We thank Dr. Shoko Ishida for her technical advice for quantitative real
   time PCR analysis. OSCC cell lines, 3A, and NEM were generously provided
   by Professor Emeritus Nobuo Tsuchida in Tokyo Medical and Dental
   University, and infliximab was provided by Nippon Kayaku Co., Ltd. This
   research was supported by the research fund from Tokyo Medical and
   Dental University.
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   de Vries TJ, 2016, J PERIODONTAL RES, V51, P186, DOI 10.1111/jre.12297
   Favia G, 2017, AM J CASE REP, V18, DOI 10.12659/AJCR.905355
   Ganguly K, 2013, J BIOL CHEM, V288, P20978, DOI 10.1074/jbc.M113.457903
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Herrero AB, 2016, AM J PATHOL, V186, P2171, DOI 10.1016/j.ajpath.2016.04.003
   Ikeda T, 2003, J BIOL CHEM, V278, P47217, DOI 10.1074/jbc.M304636200
   Ju JH, 2008, J IMMUNOL, V181, P1507, DOI 10.4049/jimmunol.181.2.1507
   Kanazawa K, 2005, J BONE MINER RES, V20, P840, DOI 10.1359/JBMR.041225
   Kayamori K, 2010, AM J PATHOL, V176, P968, DOI 10.2353/ajpath.2010.090299
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Lau RYC, 2011, J OSTEOPOROS, V2011, DOI 10.4061/2011/293808
   Ledingham J, 2005, RHEUMATOLOGY, V44, P157, DOI 10.1093/rheumatology/keh464
   Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Mitchell J, 2011, AM J PHYSIOL ENDOC M, V300, pE633, DOI 10.1152/ajpendo.00515.2010
   Mizoguchi T, 2009, J CELL BIOL, V184, P541, DOI 10.1083/jcb.200806139
   Nabavi N, 2011, BONE, V49, P965, DOI 10.1016/j.bone.2011.07.036
   Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875 009 9316 6
   O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301
   Ohata Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191865
   Rantakokko J, 1999, J BONE MINER RES, V14, P1934, DOI 10.1359/jbmr.1999.14.11.1934
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Witwicka H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128275
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Yamashita Y, 2015, ARCH ORAL BIOL, V60, P1273, DOI 10.1016/j.archoralbio.2015.06.002
NR 34
TC 5
Z9 5
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 29
PY 2019
VL 509
IS 1
BP 108
EP 113
DI 10.1016/j.bbrc.2018.12.078
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HI5KV
UT WOS:000456491800016
PM 30578079
DA 2025 08 17
ER

PT J
AU Brito, FMJD
   Butcher, A
   Pisconti, A
   Poulet, B
   Prior, A
   Charlesworth, G
   Sperinck, C
   di Mase, MS
   Liu, K
   Bou Gharios, G
   van 't Hof, RJ
   Daroszewska, A
AF Johnson de Sousa Brito, Francesca Manuela
   Butcher, Andrew
   Pisconti, Addolorata
   Poulet, Blandine
   Prior, Amanda
   Charlesworth, Gemma
   Sperinck, Catherine
   Scotto di Mase, Michele
   Liu, Ke
   Bou Gharios, George
   Jurgen van 't Hof, Robert
   Daroszewska, Anna
TI Syndecan 3 enhances anabolic bone formation through WNT signaling
SO FASEB JOURNAL
LA English
DT Article
DE bone; frizzled; osteoblast; Syndecan&#8208; 3; WNT
AB Osteoporosis is the most common age related metabolic bone disorder, which is characterized by low bone mass and deterioration in bone architecture, with a propensity to fragility fractures. The best treatment for osteoporosis relies on stimulation of osteoblasts to form new bone and restore bone structure, however, anabolic therapeutics are few and their use is time restricted. Here, we report that Syndecan 3 increases new bone formation through enhancement of WNT signaling in osteoblasts. Young adult Sdc3( / ) mice have low bone volume, reduced bone formation, increased bone marrow adipose tissue, increased bone fragility, and a blunted anabolic bone formation response to mechanical loading. This premature osteoporosis like phenotype of Sdc3( / ) mice is due to delayed osteoblast maturation and impaired osteoblast function, with contributing increased osteoclast mediated bone resorption. Indeed, overexpressing Sdc3 in osteoblasts using the Col1a1 promoter rescues the low bone volume phenotype of the Sdc3( / ) mice, and also increases bone volume in WT mice. Mechanistically, SDC3 enhances canonical WNT signaling in osteoblasts through stabilization of Frizzled 1, making SDC3 an attractive target for novel bone anabolic drug development.
C1 [Johnson de Sousa Brito, Francesca Manuela; Butcher, Andrew; Poulet, Blandine; Prior, Amanda; Charlesworth, Gemma; Sperinck, Catherine; Scotto di Mase, Michele; Liu, Ke; Bou Gharios, George; Jurgen van 't Hof, Robert; Daroszewska, Anna] Univ Liverpool, Inst Ageing & Chron Dis, Dept Musculoskeletal & Ageing Sci, Dept Musculoskeletal Biol,Inst Life Course & Med, Liverpool, Merseyside, England.
   [Pisconti, Addolorata] Univ Liverpool, Dept Biochem, IIB, Liverpool, Merseyside, England.
   [Pisconti, Addolorata] SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.
   [Daroszewska, Anna] Liverpool Univ Hosp NHS Fdn Trust, Dept Clin Biochem & Metab Med, Liverpool, Merseyside, England.
   [Daroszewska, Anna] Liverpool Univ Hosp NHS Fdn Trust, Dept Rheumatol, Liverpool, Merseyside, England.
C3 University of Liverpool; University of Liverpool; State University of
   New York (SUNY) System; Stony Brook University
RP van 't Hof, RJ; Daroszewska, A (通讯作者)，Univ Liverpool, Inst Life Course & Med Sci, Dept Musculoskeletal & Ageing Sci, 6 West Derby St, Liverpool L7 8TX, Merseyside, England.
EM r.vanthof@liverpool.ac.uk; a.daroszewska@liverpool.ac.uk
OI Pisconti, Addolorata/0000 0002 9631 8720; Johnson de Sousa Brito,
   Francesca/0000 0001 9376 0487; Daroszewska, Anna/0000 0002 6692 6610
FU Medical Research Council [MR/R002819/1]; Institute of Ageing and Chronic
   Disease, University of Liverpool, UK; MRC [MR/R002819/1] Funding Source:
   UKRI; Medical Research Council [MR/P020941/1] Funding Source:
   researchfish
FX This project was financially supported by the Medical Research Council
   (grant MR/R002819/1) and funding from the Institute of Ageing and
   Chronic Disease, University of Liverpool, UK. We would like to thank
   Andy Houghton and Euan Owen, Institute of Life Course and Medical
   Sciences (formerly Institute of Ageing and Chronic Disease), University
   of Liverpool, for their help with animal work.
CR Abdallah BM, 2015, BONE, V70, P28, DOI 10.1016/j.bone.2014.07.028
   Afratis NA, 2017, FEBS J, V284, P27, DOI 10.1111/febs.13940
   Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bell SM, 2008, DEVELOPMENT, V135, P1049, DOI 10.1242/dev.013359
   Bhat V, 2016, STEM CELLS DEV, V25, P522, DOI 10.1089/scd.2015.0315
   Canalis E, 2018, EUR J ENDOCRINOL, V178, pR33, DOI 10.1530/EJE 17 0920
   Couchman JR, 2015, INT J EXP PATHOL, V96, P1, DOI 10.1111/iep.12112
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   De Souza RL, 2005, BONE, V37, P810, DOI 10.1016/j.bone.2005.07.022
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dijksterhuis JP, 2015, J BIOL CHEM, V290, P6789, DOI 10.1074/jbc.M114.612648
   Dong YF, 2006, J CELL PHYSIOL, V208, P77, DOI 10.1002/jcp.20656
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Eijken M, 2008, J CELL BIOCHEM, V104, P568, DOI 10.1002/jcb.21651
   Fisher MC, 2006, MATRIX BIOL, V25, P27, DOI 10.1016/j.matbio.2005.07.008
   Ghali O, 2015, BMC CELL BIOL, V16, DOI 10.1186/s12860 015 0056 6
   GOULD SE, 1995, DEV BIOL, V168, P438, DOI 10.1006/dbio.1995.1093
   Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521 1878(200002)22:2<138::AID BIES5>3.0.CO;2 4
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Idris AI, 2009, ENDOCRINOLOGY, V150, P5, DOI 10.1210/en.2008 0998
   Imai S, 1998, J CELL BIOL, V143, P1113, DOI 10.1083/jcb.143.4.1113
   Imai S, 2009, BONE, V44, P785, DOI 10.1016/j.bone.2009.01.004
   Itzstein C, 2012, METHODS MOL BIOL, V816, P177, DOI 10.1007/978 1 61779 415 5_12
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kaksonen M, 2002, MOL CELL NEUROSCI, V21, P158, DOI 10.1006/mcne.2002.1167
   Katoh M, 2007, INT J MOL MED, V19, P529
   Kim JM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1167 8
   Koyama E, 1996, J ORTHOPAED RES, V14, P403, DOI 10.1002/jor.1100140310
   KOYAMA E, 1995, DEV DYNAM, V203, P152, DOI 10.1002/aja.1002030204
   Koyama E, 2007, DEVELOPMENT, V134, P2159, DOI 10.1242/dev.001586
   Lebensohn AM, 2018, ELIFE, V7, DOI 10.7554/eLife.33126
   Lehoczky JA, 2018, NATURE, V557, P495, DOI 10.1038/d41586 018 04820 y
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Lu WY, 2008, FEBS LETT, V582, P643, DOI 10.1016/j.febslet.2008.01.035
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Mansouri R, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.287
   Newton PT, 2019, NATURE, V567, P234, DOI 10.1038/s41586 019 0989 6
   Ohkawara B, 2011, DEV CELL, V20, P303, DOI 10.1016/j.devcel.2011.01.006
   Ornitz DM, 2015, GENE DEV, V29, P1463, DOI 10.1101/gad.266551.115
   Pacifici M, 2005, J BONE MINER METAB, V23, P191, DOI 10.1007/s00774 004 0584 1
   Pataki CA, 2015, J HISTOCHEM CYTOCHEM, V63, P465, DOI 10.1369/0022155415586961
   Pisconti A, 2016, SKELET MUSCLE, V6, DOI 10.1186/s13395 016 0104 8
   Pisconti A, 2010, J CELL BIOL, V190, P427, DOI 10.1083/jcb.201003081
   RAULO E, 1994, J BIOL CHEM, V269, P12999
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Shimazu A, 1996, EXP CELL RES, V229, P126, DOI 10.1006/excr.1996.0350
   Shimo T, 2004, DEV DYNAM, V229, P607, DOI 10.1002/dvdy.20009
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Simmons GE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098861
   Szenker Ravi E, 2018, NATURE, V557, P564, DOI 10.1038/s41586 018 0118 y
   Taipaleenmäki H, 2011, EXP CELL RES, V317, P745, DOI 10.1016/j.yexcr.2010.12.015
   Tamamura Y, 2005, J BIOL CHEM, V280, P19185, DOI 10.1074/jbc.M414275200
   van Amerongen R, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007914
   van't Hof RJ, 2017, BONE, V99, P69, DOI 10.1016/j.bone.2017.03.051
   van't Hof RJ, 2012, METHODS MOL BIOL, V816, P461, DOI 10.1007/978 1 61779 415 5_27
   Varanasi SS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010692
   Wang XD, 2018, JBMR PLUS, V2, P164, DOI 10.1002/jbm4.10030
   Weivoda MM, 2016, J BONE MINER RES, V31, P65, DOI 10.1002/jbmr.2599
   Wuelling M, 2019, NATURE, V567, P178, DOI 10.1038/d41586 019 00527 w
   Yu SB, 2013, BONE, V56, P234, DOI 10.1016/j.bone.2013.06.019
NR 61
TC 9
Z9 9
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2021
VL 35
IS 4
AR e21246
DI 10.1096/fj.202002024R
PG 18
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA RG0GY
UT WOS:000635216100022
PM 33769615
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Ma, QL
   Wang, SY
   Xie, ZA
   Shen, Y
   Zheng, BJ
   Jiang, C
   Yuan, PT
   Yu, CC
   Li, LP
   Zhao, XD
   Chen, JX
   Qin, A
   Fan, SW
   Jie, ZW
AF Ma, Qingliang
   Wang, Shiyu
   Xie, Ziang
   Shen, Yang
   Zheng, Bingjie
   Jiang, Chao
   Yuan, Putao
   Yu, Congcong
   Li, Liangping
   Zhao, Xiangde
   Chen, Junxin
   Qin, An
   Fan, Shunwu
   Jie, Zhiwei
TI The SFRP1 Inhibitor WAY 316606 Attenuates Osteoclastogenesis Through
   Dual Modulation of Canonical Wnt Signaling
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOCLAST; OSTEOPOROSIS; secreted frizzled related protein 1 (SFRP1;
   WAY 316606; WNT SIGNALING
ID FRIZZLED RELATED PROTEIN 1; OSTEOPOROSIS MECHANISMS; CONTROLS
   OSTEOBLAST; BONE HOMEOSTASIS; DIFFERENTIATION; REGULATOR; PATHWAY;
   GENES; RANKL
AB Osteoporosis, a noteworthy age related disease induced by imbalanced osteogenesis and osteoclastogenesis, is a serious economic burden on both individuals and society. Small molecule drugs with dual effects on both bone resorption and mineralization are pressingly needed. Secreted frizzled related protein 1 (SFRP1), a well known extracellular repressor of canonical Wnt signaling, has been reported to regulate osteogenesis. Global SFRP1 knockout mice show significantly elevated bone mass. Although osteoclasts (OCs) express and secrete SFRP1, the role of SFRP1 produced by OCs in osteoclastogenesis and osteoporosis remains unclear. In this work, the levels of SFRP1 were found to be increased in patients with osteoporosis compared with healthy controls. Pharmacological inhibition of SFRP1 by WAY 316606 (WAY)  attenuated osteoclastogenesis and bone resorption in vitro. The expressions of OC specific genes were suppressed by the SFRP1 inhibitor, WAY. Mechanistically, both extracellular and intracellular SFRP1 could block activation of the canonical Wnt signaling pathway, and WAY reverse the silent status of canonical Wnt through dual effects, leading to osteoclastogenesis inhibition and osteogenesis promotion. Severe osteopenia was observed in the ovariectomized (OVX) mouse model, and WAY treatment effectively improved the OVX induced osteoporosis. In summary, this work found that SFRP1 supports OC differentiation and function, which could be attenuated by WAY through dual modulation of canonical Wnt signaling, suggesting its therapeutic potential. (c) 2021 American Society for Bone and Mineral Research (ASBMR).
C1 [Ma, Qingliang; Wang, Shiyu; Xie, Ziang; Shen, Yang; Zheng, Bingjie; Jiang, Chao; Yuan, Putao; Yu, Congcong; Li, Liangping; Zhao, Xiangde; Chen, Junxin; Fan, Shunwu; Jie, Zhiwei] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Sch Med, Hangzhou, Peoples R China.
   [Ma, Qingliang; Wang, Shiyu; Xie, Ziang; Shen, Yang; Zheng, Bingjie; Jiang, Chao; Yuan, Putao; Yu, Congcong; Li, Liangping; Zhao, Xiangde; Chen, Junxin; Fan, Shunwu; Jie, Zhiwei] Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou, Peoples R China.
   [Qin, An] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthopaed, Shanghai Key Lab Orthopaed Implant,Sch Med, Shanghai, Peoples R China.
C3 Zhejiang University; Shanghai Jiao Tong University
RP Fan, SW; Jie, ZW (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Sch Med, Hangzhou, Peoples R China.
EM 0099203@zju.edu.cn; jiezhiwei@zju.edu.cn
RI Shen, Yang/LRC 0895 2024; li, liangping/LVR 1411 2024; Qin,
   An/J 2518 2019
OI Li, Liangping/0000 0002 5809 1940; Yu, Congcong/0000 0001 6586 5775
FU National Nature Science Fund of China [82002334, 81972089, 82000837];
   Key Project of Natural Science Fund of Zhejiang Province [Z20H060003];
   Natural Science Fund of Zhejiang Province [Q20H060042, 119000 5405A1]
FX This work was supported in part by grants from the National Nature
   Science Fund of China (grant nos. 82002334, 81972089, 82000837), Key
   Project of Natural Science Fund of Zhejiang Province (grant no.
   Z20H060003), the Natural Science Fund of Zhejiang Province (grant no.
   Q20H060042), Innovation Research Grant Program for 8 year system medical
   students at Zhejiang University (grant no. 119000 5405A1). No benefits
   in any form have been or will be received from a commercial party
   related directly or indirectly to the subject of this manuscript.Author
   Contributions
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Appelman Dijkstra NM, 2018, NAT REV ENDOCRINOL, V14, P605, DOI 10.1038/s41574 018 0087 0
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180
   Baron R, 2006, CURR TOP DEV BIOL, V76, P103, DOI 10.1016/S0070 2153(06)76004 5
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Bodine PVN, 2009, BONE, V44, P1063, DOI 10.1016/j.bone.2009.02.013
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Bodine PVN, 2005, J CELL BIOCHEM, V96, P1212, DOI 10.1002/jcb.20599
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Chong JM, 2002, J BIOL CHEM, V277, P5134, DOI 10.1074/jbc.M108533200
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Esteve P, 2011, NAT NEUROSCI, V14, P562, DOI 10.1038/nn.2794
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gu HJ, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115444
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Häusler KD, 2004, J BONE MINER RES, V19, P1873, DOI 10.1359/JBMR.040807
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131
   Huang J, 2014, J BONE MINER RES, V29, P1715, DOI 10.1002/jbmr.2297
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Johnson ML, 2004, J BONE MINER RES, V19, P1749, DOI 10.1359/JBMR.040816
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Leimeister C, 1998, MECH DEVELOP, V75, P29, DOI 10.1016/S0925 4773(98)00072 0
   Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614
   Liang CJ, 2019, CELL REP, V28, P1511, DOI 10.1016/j.celrep.2019.07.023
   Liu DW, 2007, BONE, V41, P266, DOI 10.1016/j.bone.2007.04.181
   Liu HP, 2019, EUR REV MED PHARMACO, V23, P9754, DOI 10.26355/eurrev_201911_19538
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Manolagas SC, 2018, J BONE MINER RES, V33, P371, DOI 10.1002/jbmr.3400
   Martin TJ, 2015, REV ENDOCR METAB DIS, V16, P131, DOI 10.1007/s11154 014 9308 6
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Moore WJ, 2010, BIOORGAN MED CHEM, V18, P190, DOI 10.1016/j.bmc.2009.11.002
   Otero K, 2012, J IMMUNOL, V188, P2612, DOI 10.4049/jimmunol.1102836
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Recker RR, 2011, BONE, V49, P955, DOI 10.1016/j.bone.2011.07.017
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sierra AM, 1997, MYCOTAXON, V63, P155
   Takayanagi Hiroshi, 2007, Clin Calcium, V17, P484
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Üren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang Y, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 271
   Yao W, 2010, J BONE MINER RES, V25, P190, DOI 10.1359/jbmr.090719
   Zhang XG, 2018, J CELL PHYSIOL, V233, P6798, DOI 10.1002/jcp.26430
   Zhang Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045 020 00990 3
NR 64
TC 9
Z9 9
U1 4
U2 26
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2022
VL 37
IS 1
BP 152
EP 166
DI 10.1002/jbmr.4435
EA SEP 2021
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA YI7CE
UT WOS:000700080900001
PM 34490916
OA Bronze
DA 2025 08 17
ER

PT J
AU Wang, M
   Luo, KT
   Sha, TT
   Li, Q
   Dong, ZC
   Dou, YJ
   Zhang, HX
   Zhou, GY
   Ba, Y
   Yu, FF
AF Wang, Miao
   Luo, Kangting
   Sha, Tongtong
   Li, Qian
   Dong, Zaichao
   Dou, Yanjie
   Zhang, Huanxia
   Zhou, Guoyu
   Ba, Yue
   Yu, Fangfang
TI Apoptosis and Inflammation Involved with Fluoride Induced Bone Injuries
SO NUTRIENTS
LA English
DT Article
DE fluoride; bone injuries; apoptosis; inflammation
ID SODIUM FLUORIDE; OSTEOCLAST FORMATION; RECEPTOR ACTIVATOR;
   MESSENGER RNA; EXPRESSION; INHIBITION; FLUOROSIS; PROTEIN;
   MINERALIZATION; EXPOSURE
AB Background: Excessive fluoride exposure induces skeletal fluorosis, but the specific mechanism responsible is still unclear. Therefore, this study aimed to identify the pathogenesis of fluoride induced bone injuries. Methods: We systematically searched fluoride induced bone injury related genes from five databases. Then, these genes were subjected to enrichment analyses. A TF (transcription factor) mRNA miRNA network and protein protein interaction (PPI) network were constructed using Cytoscape, and the Human Protein Atlas (HPA) database was used to screen the expression of key proteins. The candidate pharmacological targets were predicted using the Drug Signature Database. Results: A total of 85 studies were included in this study, and 112 osteoblast , 35 osteoclast , and 41 chondrocyte related differential expression genes (DEGs) were identified. Functional enrichment analyses showed that the Atf4, Bcl2, Col1a1, Fgf21, Fgfr1 and Il6 genes were significantly enriched in the PI3K Akt signaling pathway of osteoblasts, Mmp9 and Mmp13 genes were enriched in the IL 17 signaling pathway of osteoclasts, and Bmp2 and Bmp7 genes were enriched in the TGF beta signaling pathway of chondrocytes. With the use of the TF mRNA miRNA network, the Col1a1, Bcl2, Fgfr1, Mmp9, Mmp13, Bmp2, and Bmp7 genes were identified as the key regulatory factors. Selenium methyl cysteine, CGS 27023A, and calcium phosphate were predicted to be the potential drugs for skeletal fluorosis. Conclusions: These results suggested that the PI3K Akt signaling pathway being involved in the apoptosis of osteoblasts, with the IL 17 and the TGF beta signaling pathways being involved in the inflammation of osteoclasts and chondrocytes in fluoride induced bone injuries.
C1 [Wang, Miao; Luo, Kangting; Sha, Tongtong; Li, Qian; Dong, Zaichao; Dou, Yanjie; Zhang, Huanxia; Zhou, Guoyu; Ba, Yue; Yu, Fangfang] Zhengzhou Univ, Sch Publ Hlth, Zhengzhou 450001, Peoples R China.
C3 Zhengzhou University
RP Yu, FF (通讯作者)，Zhengzhou Univ, Sch Publ Hlth, Zhengzhou 450001, Peoples R China.
EM wangmiao_9842@163.com; lkt1307@163.com; shatongtong0802@163.com;
   lqian0103@163.com; dzc0609@163.com; 18835520074@163.com;
   zhanghuanxia2002@163.com; zhouguoyu@zzu.edu.cn; byyue@zzu.edu.cn;
   yufangfang@zzu.edu.cn
RI Zhang, Huanxia/AGL 3483 2022
FU National Natural Scientific Foundation of China [82003400]; Science and
   Technology Program of Henan Province [232102311079]
FX This research was funded by the National Natural Scientific Foundation
   of China (82003400), Science and Technology Program of Henan Province
   (232102311079).
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Asada H, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 35813 1
   Bar Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553
   Beederman M., 2013, J BIOMEDICAL SCI ENG, V6, P32, DOI DOI 10.4236/JBISE.2013.68A1004
   Behrends M, 2015, BIOORGAN MED CHEM, V23, P3809, DOI 10.1016/j.bmc.2015.03.078
   Bibi S, 2023, SCI TOTAL ENVIRON, V880, DOI 10.1016/j.scitotenv.2023.163359
   Chen J., 2003, Chin. J. Public Health, V19, P34
   Chen KD, 2024, J TRANSL MED, V22, DOI 10.1186/s12967 024 05261 0
   Chen L, 2022, CHEM BIOL INTERACT, V356, DOI 10.1016/j.cbi.2022.109870
   [陈偲 Chen Si], 2016, [中华地方病学杂志, Chinese Journal of Endemiology], V35, P89
   Chen XiShan Chen XiShan, 2013, Chinese Journal of Endemiology, V32, P140
   [陈修文 Chen Xiuwen], 2016, [中国公共卫生, China Journal of Public Health], V32, P195
   Chen XiuWen Chen XiuWen, 2016, Journal of Environmental & Occupational Medicine, V33, P494
   Chi G., 2008, J. Inn. Mong. Univ. Natl, V23, P184
   Christodoulou M, 2024, AGE AGEING, V53, DOI 10.1093/ageing/afae096
   Collins MT, 2022, NAT REV ENDOCRINOL, V18, P473, DOI 10.1038/s41574 022 00682 7
   Corbeau J, 2024, GENET SEL EVOL, V56, DOI 10.1186/s12711 024 00909 3
   Dai QK, 2024, EXP BIOL MED, V249, DOI 10.3389/ebm.2024.10111
   Daiwile AP, 2018, ENVIRON TOXICOL PHAR, V57, P159, DOI 10.1016/j.etap.2017.12.015
   Deng C N, 2020, Zhonghua Bing Li Xue Za Zhi, V49, P168, DOI 10.3760/cma.j.issn.0529 5807.2020.02.012
   Deng ChaoNan Deng ChaoNan, 2014, Chinese Journal of Endemiology, V33, P609
   Ding DD, 2024, TRANSL ONCOL, V43, DOI 10.1016/j.tranon.2024.101895
   Ding HW, 2023, ENVIRON POLLUT, V332, DOI 10.1016/j.envpol.2023.121931
   Doncheva NT, 2019, J PROTEOME RES, V18, P623, DOI 10.1021/acs.jproteome.8b00702
   Duan XQ, 2014, J TRACE ELEM MED BIO, V28, P278, DOI 10.1016/j.jtemb.2014.02.004
   Edderkaoui B, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25010381
   Gao Y, 2020, ENVIRON TOXICOL PHAR, V73, DOI 10.1016/j.etap.2019.103275
   Gokce AB, 2020, TOXICOL IND HEALTH, V36, P84, DOI 10.1177/0748233720909043
   Gu XL, 2019, TOXICOL IN VITRO, V57, P28, DOI 10.1016/j.tiv.2019.02.006
   Gu XL, 2016, ONCOTARGET, V7, P65218, DOI 10.18632/oncotarget.11573
   Guo X., 2011, Chin. J. Integr. Med, V24, P3
   Guo X., 2012, Chin. J. Endem, V27, P165
   Guo X., 2011, J. Hyg. Res, V40, P304
   Gyemi L, 2024, J ORTHOP SURG HONG K, V32, DOI 10.1177/10225536241254200
   Han B., 2008, Masters Thesis
   Hu CY, 2012, BIOL TRACE ELEM RES, V150, P297, DOI 10.1007/s12011 012 9482 x
   Hu YJ, 2024, J HAZARD MATER, V465, DOI 10.1016/j.jhazmat.2023.133411
   Jiang NN, 2022, BIOL TRACE ELEM RES, V200, P740, DOI 10.1007/s12011 021 02686 2
   Jiang NN, 2020, BIOL TRACE ELEM RES, V193, P226, DOI 10.1007/s12011 019 01684 9
   Jing L., 2006, Ph.D. Thesis
   [井玲 JING Ling], 2006, [中国地方病学杂志, Chinese Journal of Endemiology], V25, P629
   Kim D, 2024, FEBS LETT, V598, P935, DOI 10.1002/1873 3468.14862
   Li D., 2006, Ph.D. Thesis
   Li X., 2014, Ph.D. Thesis
   [李希宁 Li Xining], 2016, [中华地方病学杂志, Chinese Journal of Endemiology], V35, P863
   Li YY, 2016, FLUORIDE, V49, P47
   Li Y, 2024, ECOTOX ENVIRON SAFE, V276, DOI 10.1016/j.ecoenv.2024.116284
   Li YM, 2024, BIOMED PHARMACOTHER, V173, DOI 10.1016/j.biopha.2024.116346
   Liu Bing ci, 2003, Zhonghua Yufang Yixue Zazhi, V37, P243
   Liu XL, 2015, J HUAZHONG U SCI MED, V35, P712, DOI 10.1007/s11596 015 1495 1
   Liu Y., 2008, J. Xinjiang Med. Univ, V31, P940
   Liu Y., 2007, Masters Thesis
   Lv P., 2015, Ph.D. Thesis
   Lv YG, 2016, BIOCHEM BIOPH RES CO, V479, P372, DOI 10.1016/j.bbrc.2016.09.083
   Ma L, 2023, ECOTOX ENVIRON SAFE, V252, DOI 10.1016/j.ecoenv.2023.114626
   Ma L, 2021, CHEM BIOL INTERACT, V349, DOI 10.1016/j.cbi.2021.109659
   Matsuda SS, 2014, BIOL TRACE ELEM RES, V161, P123, DOI 10.1007/s12011 014 0086 5
   Meng HM, 2014, INT J MOL MED, V33, P351, DOI 10.3892/ijmm.2013.1576
   Moradifard S, 2020, MUTAT RES REV MUTAT, V786, DOI 10.1016/j.mrrev.2020.108339
   Otasek D, 2019, GENOME BIOL, V20, DOI 10.1186/s13059 019 1758 4
   Park KC, 2020, J TRACE ELEM MED BIO, V61, DOI 10.1016/j.jtemb.2020.126534
   Park YA, 2024, JBMR PLUS, V8, DOI 10.1093/jbmrpl/ziae032
   Pei JR, 2017, INT J CLIN EXP MED, V10, P15260
   Pei JR, 2016, ENVIRON TOXICOL PHAR, V46, P241, DOI 10.1016/j.etap.2016.08.001
   Pei JR, 2014, ENVIRON TOXICOL, V29, P588, DOI 10.1002/tox.21784
   Pei JR, 2012, FLUORIDE, V45, P86
   Peng RP, 2024, CELL DEATH DIS, V15, DOI 10.1038/s41419 024 06475 2
   Pivetta E, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3047
   Qin M, 2023, ENVIRON SCI POLLUT R, V30, P106059, DOI 10.1007/s11356 023 29698 w
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Shanthakumari D, 2004, TOXICOLOGY, V204, P219, DOI 10.1016/j.tox.2004.06.058
   Shim MY, 2011, POULTRY SCI, V90, P1967, DOI 10.3382/ps.2010 01240
   Sikura KÉ, 2021, J ADV RES, V27, P165, DOI 10.1016/j.jare.2020.07.005
   Srivastava S, 2020, CURR ENV HLTH REP, V7, P140, DOI 10.1007/s40572 020 00270 9
   [孙殿军 SUN Dian jun], 2008, [中国地方病学杂志, Chinese Journal of Endemiology], V27, P364
   [唐莉 TANG Li], 2011, [中国地方病学杂志, Chinese Journal of Endemiology], V30, P389
   Tang YB, 2023, BONE, V174, DOI 10.1016/j.bone.2023.116817
   Tsukasaki M, 2020, NAT METAB, V2, DOI 10.1038/s42255 020 00318 y
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Veneri F, 2023, CURR ENV HLTH REP, V10, P417, DOI 10.1007/s40572 023 00412 9
   Wan LiangBin Wan LiangBin, 2012, Chinese Preventive Medicine, V13, P641
   Wan W., 2012, J. GuiYang Med. Coll, V37, P221
   Wang C., 2006, Ph.D. Thesis
   Wang JM, 2020, FOOD FUNCT, V11, P1155, DOI [10.1039/c9fo02491c, 10.1039/C9FO02491C]
   Wang JinMing Wang JinMing, 2019, Acta Veterinaria et Zootechnica Sinica, V50, P183
   Wang Mei Wang Mei, 2009, Scientia Agricultura Sinica, V42, P2629
   Wang TT, 2024, MOLECULES, V29, DOI 10.3390/molecules29071541
   Wang Y., 2007, Chin. J. Public Health, V23, P333
   Wang Y, 2015, Masters Thesis
   Wang YJ, 2021, ECOTOX ENVIRON SAFE, V217, DOI 10.1016/j.ecoenv.2021.112225
   Wang Y, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/5553811
   Wei H., 2007, Masters Thesis
   Wei Z, 2023, MOL MED, V29, DOI 10.1186/s10020 023 00722 6
   Wu SY, 2019, ACS BIOMATER SCI ENG, V5, P817, DOI 10.1021/acsbiomaterials.8b00570
   Wu SY, 2022, ENVIRON POLLUT, V304, DOI 10.1016/j.envpol.2022.119241
   Xiang GM, 2022, GENES BASEL, V13, DOI 10.3390/genes13111971
   [谢莹 Xie Ying], 2013, [中国公共卫生, China Public Health], V29, P530
   Xie Ying, 2012, Chinese Journal of Pathology, V41, P761, DOI 10.3760/cma.j.issn.0529 5807.2012.11.011
   Xiong WF, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04235 0
   Xu J., 2004, Chin. J. Endem, V23, P20
   Xu JX, 2024, ECOTOX ENVIRON SAFE, V277, DOI 10.1016/j.ecoenv.2024.116367
   Yan LH, 2023, EXP BIOL MED, V248, P1159, DOI 10.1177/15353702231191117
   Yan XY, 2015, CHEMOSPHERE, V128, P36, DOI 10.1016/j.chemosphere.2014.12.090
   [杨丹 YANG Dan], 2011, [中国公共卫生, China Public Health], V27, P1008
   Yang Qing Yang Qing, 2017, Chinese Journal of Endemiology, V36, P408
   Yang SY, 2011, BIOCHEM BIOPH RES CO, V410, P910, DOI 10.1016/j.bbrc.2011.06.094
   Yang X., 2019, J ENVIRON HEALTH, V36, P305, DOI [10.16241/j.cnki.1001 5914.2019.04.006, DOI 10.16241/J.CNKI.1001 5914.2019.04.006]
   Yu FF, 2024, BIOL TRACE ELEM RES, V202, P2100, DOI 10.1007/s12011 023 03805 x
   Yu FF, 2021, ECOTOX ENVIRON SAFE, V225, DOI 10.1016/j.ecoenv.2021.112796
   Yu FF, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241813703
   Yu HL, 2018, TOXICOLOGY, V393, P73, DOI 10.1016/j.tox.2017.11.009
   Yu Yan ni, 2012, Chinese Journal of Pathology, V41, P622, DOI 10.3760/cma.j.issn.0529 5807.2012.09.011
   Zeng XN, 2021, ECOTOX ENVIRON SAFE, V222, DOI 10.1016/j.ecoenv.2021.112460
   Zhang JM, 2019, BIOL TRACE ELEM RES, V187, P492, DOI 10.1007/s12011 018 1387 x
   Zhang R., 2020, Masters Thesis
   Zhang W., 2003, Chin. J. Prev. Med, V37, P30
   [张文岚 ZHANG Wenlan], 2006, [中国地方病学杂志, Chinese Journal of Endemiology], V25, P125
   [张秀云 Zhang Xiuyun], 2011, [中国地方病学杂志, Chinese Journal of Endemiology], V30, P502
   Zhang Y, 2023, CHEM BIOL INTERACT, V381, DOI 10.1016/j.cbi.2023.110555
   Zhao WW, 2016, J ORTHOP RES, V34, P763, DOI 10.1002/jor.23079
   Zhao YF, 2018, FOOD CHEM TOXICOL, V115, P26, DOI 10.1016/j.fct.2018.02.065
   Zhao YF, 2016, FLUORIDE, V49, P13
   [赵轶卓 ZHAO Yizhuo], 2006, [吉林大学学报. 医学版, Journal of Jilin Univeristy. Medicine edition], V32, P956
   Zhong J., 2006, Ph.D. Thesis
   Zhong Y., 2011, Masters Thesis
   Zhou T., 2007, Masters Thesis
   Zhu GC, 2022, INT J BIOL SCI, V18, P5522, DOI 10.7150/ijbs.72211
   [朱海振 ZHU Haizhen], 2011, [中国地方病学杂志, Chinese Journal of Endemiology], V30, P261
   Zhu SQ, 2022, ENVIRON POLLUT, V315, DOI 10.1016/j.envpol.2022.120396
   Zhu WQ, 2019, J MOL MED, V97, P1003, DOI 10.1007/s00109 019 01785 x
   [朱志坚 Zhu Zhijian], 2018, [中国公共卫生, China Journal of Public Health], V34, P241
   [朱志坚 Zhu Zhijian], 2015, [中国公共卫生, China Journal of Public Health], V31, P574
NR 132
TC 1
Z9 1
U1 4
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD AUG
PY 2024
VL 16
IS 15
AR 2500
DI 10.3390/nu16152500
PG 15
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA C1R4I
UT WOS:001287200200001
PM 39125380
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU O'Connell, MB
AF O'Connell, Mary Beth
TI Prescription drug therapies for prevention and treatment of
   postmenopausal osteoporosis
SO JOURNAL OF MANAGED CARE PHARMACY
LA English
DT Article; Proceedings Paper
CT 18th Annual Meeting of the Academy of Managed Care Pharmacy
CY APR 06, 2006
CL Seattle, WA
SP Acad Managed Care Pharm
DE bisphosphonates; calcitonin salmon; bone remodeling; postmenopausal
   osteoporosis; raloxitene; teriparatide
ID BONE MINERAL DENSITY; INTRANASAL SALMON CALCITONIN; RANDOMIZED
   CONTROLLED TRIAL; PARATHYROID HORMONE 1 34; ESTROGEN PLUS PROGESTIN;
   ONCE WEEKLY ALENDRONATE; BIOCHEMICAL MARKERS; VERTEBRAL FRACTURES;
   WOMEN; IBANDRONATE
AB OBJECTIVE: To characterize the changes in bone mass with age in women and men, explain the physiology and pathophysiology of the bone remodeling process, identify the targets for prescription osteoporosis drugs in this process, and provide details about the uses, efficacy, safety, and economics of prescription drug therapies for osteoporosis prevention and treatment.
   BACKGROUND: Preventing accelerated bone loss and decreasing age related decreases in bone density are the primary goals of prescription drug therapy for osteoporosis. Bisphosphonates are the drugs of choice for preventing and treating postmenopausal osteoporosis. Alternatives for patients who cannot take bisphosphonates include raloxifene and calcitonin salmon.
   SUMMARY. Menopause is accompanied by a rapid loss in bone mass that is followed by annual losses due to aging in women, which are similar to age related bone mass decreases in men. Most prescription drug therapies for osteoporosis prevention or treatment reduce bone resorption by inhibiting osteoclast activation and activity, with only one medication class able to increase bone formation by stimulating osteoblasts. Denosumab, an investigational monoclonal antibody that inhibits nuclear factor kappa B ligand, would be a new class of antiresorptive medications. Bisphosphonates currently are the drugs of choice for preventing and treating osteoporosis, with 7  and 10 year safety data available for risedronate and alendronate, respectively. Weekly and monthly regimens of bisphosphonates improve patient acceptance. Recently, an injectable form of ibandronate received U.S. Food and Drug Administration approval for once every 3 months administration. Raloxifene and calcitonin salmon are alternatives for patients who cannot take bisphosphonates because of contraindications or adverse effects. Teriparatide, a recombinant parathyroid hormone fragment, not only increases bone mineral density but also increases bone connectivity.
   CONCLUSIONS: Osteoporosis medications are usually safe, especially if used correctly with proper patient education. Treating osteopenia has not been found to be cost effective in women. However, obtaining a dual energy X ray absorptiometry scan and treating osteoporosis has resulted in cost savings in senior women living in community and nursing home residences. Pharmacists have multiple opportunities for preventing and treating osteoporosis.
C1 Wayne State Univ, Dept Pharm Practice, Eugene Applebaum Coll Pharm & Hlth Sci, Detroit, MI 48201 USA.
C3 Wayne State University
RP O'Connell, MB (通讯作者)，Wayne State Univ, Dept Pharm Practice, Eugene Applebaum Coll Pharm & Hlth Sci, 259 Mack Ave,Suite 2190, Detroit, MI 48201 USA.
EM mboconnell@wayne.edu
CR *AD INT LTD, 2003, DRUGS RD, V4, P231
   Anderson GL, 2004, JAMA J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   [Anonymous], ACT PACK INS
   Bagger YZ, 2003, BONE, V33, P301, DOI 10.1016/S8756 3282(03)00112 1
   Barrett Connor E, 2002, JAMA J AM MED ASSOC, V287, P847, DOI 10.1001/jama.287.7.847
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Bolognese M, 2005, J BONE MINER RES, V20, pS96
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Cauley JA, 2003, JAMA J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001 2002
   Cranney A, 2002, ENDOCR REV, V23, P524, DOI 10.1210/er.2001 4002
   Cranney A, 2002, ENDOCR REV, V23, P517, DOI 10.1210/er.2001 3002
   Cummings SR, 1999, JAMA J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Delaney MF, 2006, AM J OBSTET GYNECOL, V194, pS12, DOI 10.1016/j.ajog.2005.08.049
   Delmas PD, 2002, J CLIN ENDOCR METAB, V87, P3609, DOI 10.1210/jc.87.8.3609
   *E LILL CO, 2004, FORT PACK INS
   Emkey R, 2005, CURR MED RES OPIN, V21, P1895, DOI 10.1185/030079905X74862
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Gallagher JC, 2002, MENOPAUSE, V9, P84
   GERTZ BJ, 1995, CLIN PHARMACOL THER, V58, P288, DOI 10.1016/0009 9236(95)90245 7
   Hodgson Stephen F, 2003, Endocr Pract, V9, P544
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Johnell O, 2002, J CLIN ENDOCR METAB, V87, P985, DOI 10.1210/jc.87.3.985
   Kraenzlin ME, 1996, CALCIFIED TISSUE INT, V58, P216
   Lanza FL, 2000, GASTROENTEROLOGY, V119, P631, DOI 10.1053/gast.2000.16517
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   LINDSAY R, 2005, HARRISONS PRINCIPLES, P2268
   Lyritis GP, 2002, BONE, V30, p71S
   McClung Michael R, 2006, Curr Osteoporos Rep, V4, P28, DOI 10.1007/s11914 006 0012 7
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   MCEVOY GK, 2006, AHFS DRUG INFORM 200, P3059
   *MERCK CO INC, 2006, FOS PACK INS
   Miller PD, 2005, J BONE MINER RES, V20, P1315, DOI 10.1359/JBMR.050313
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   *NOV PHARM CORP, 2005, ZOM PACK INS
   *NOV PHARM CORP, 2005, AR PACK INS
   *NOV PHARM CORP, 2002, MIAC INJ SYNTH PACK
   *NOV PHARM CORP, 2003, MIAC NAS SPRAY PACK
   *NOV PHARM CORP, 2002, MIAC NAS SPRAY PACK
   OCONNELL MB, 2005, PHARMACOTHERAPY PATH, P1645
   PUN KK, 1989, CLIN THER, V11, P205
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   *ROCH LAB INC, 2006, BON INJ PACK INS
   *ROCH LAB INC, 2005, BON TABL PACK INS
   Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Schousboe JT, 2005, J AM GERIATR SOC, V53, P1697, DOI 10.1111/j.1532 5415.2005.53504.x
   Schousboe JT, 2005, ANN INTERN MED, V142, P734, DOI 10.7326/0003 4819 142 9 200505030 00008
   Shrader SP, 2005, ANN PHARMACOTHER, V39, P1511, DOI 10.1345/aph.1G146
   Silverman SL, 2002, OSTEOPOROSIS INT, V13, P858, DOI 10.1007/s001980200118
   Tankó LB, 2003, BONE, V32, P421, DOI 10.1016/S8756 3282(03)00033 4
   U.S. Department of Health and Human Services, 2004 SURG GEN REP BO
   *US DEP HHS, 2004, BAS BON HLTH DIS BON, pCH2
   VONDRACEK SF, 2004, CLIN REV BONE MIN ME, V2, P293
   Wells G, 2002, ENDOCR REV, V23, P529, DOI 10.1210/er.2001 5002
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   *WYETH PHARM INC, 2005, PREMPR PREMPH PACK I
NR 61
TC 7
Z9 7
U1 0
U2 3
PU ACAD MANAGED CARE PHARMACY
PI ALEXANDRIA
PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314 3134 USA
SN 1083 4087
J9 J MANAGE CARE PHARM
JI J. Manag. Care Pharm.
PD JUL
PY 2006
VL 12
IS 6
SU S
BP S10
EP S19
DI 10.18553/jmcp.2006.12.S6 A.S10
PG 10
WC Health Care Sciences & Services; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Health Care Sciences & Services; Pharmacology & Pharmacy
GA 077BI
UT WOS:000240002300003
PM 17269853
OA Green Published
DA 2025 08 17
ER

PT J
AU Sato, AY
   Cregor, M
   McAndrews, K
   Li, T
   Condon, KW
   Plotkin, LI
   Bellido, T
AF Sato, Amy Y.
   Cregor, Meloney
   McAndrews, Kevin
   Li, Troy
   Condon, Keith W.
   Plotkin, Lilian I.
   Bellido, Teresita
TI Glucocorticoid Induced Bone Fragility Is Prevented in Female Mice by
   Blocking Pyk2/Anoikis Signaling
SO ENDOCRINOLOGY
LA English
DT Article
ID 11 BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1; OSTEOCLAST APOPTOSIS;
   INDUCED OSTEOPOROSIS; OSTEOCYTES; OSTEONECROSIS; OSTEOBLASTS;
   ALENDRONATE; BISPHOSPHONATES; TERIPARATIDE; MECHANISMS
AB Excess of glucocorticoids (GCs) is a leading cause of bone fragility, and therapeutic targets are sorely needed. We report that genetic deletion or pharmacological inhibition of proline rich tyrosine kinase 2 (Pyk2) prevents GC induced bone loss by overriding GC effects of detachment induced bone cell apoptosis (anoikis). In wild type or vehicle treated mice, GCs either prevented osteoclast apoptosis or promoted osteoblast/osteocyte apoptosis. In contrast, mice lacking Pyk2 [knockout (KO)] or treated with Pyk2 kinase inhibitor PF 431396 (PF) were protected. KO or PF treated mice were also protected from GC induced bone resorption, microarchitecture deterioration, and weakening of biomechanical properties. In KO and PF treated mice, GC increased osteoclasts in bone and circulating tartrate resistant acid phosphatase form 5b, an index of osteoclast number. However, bone surfaces covered by osteoclasts and circulating C terminal telopeptides of type I collagen, an index of osteoclast function, were not increased. The mismatch between osteoclast number vs function induced by Pyk2 deficiency/inhibition was due to osteoclast detachment and anoikis. Further, GC prolongation of osteoclast lifespan was absent in KO and PF treated osteoclasts, demonstrating Pyk2 as an intrinsic osteoclast survival regulator. Circumventing Pyk2 activation preserves skeletal integrity by preventing GC effects on bone cell survival (proapoptotic for osteoblasts/osteocytes, antiapoptotic for osteoclasts) and GC induced bone resorption. Thus, Pyk2/anoikis signaling as a therapeutic target for GC induced osteoporosis.
C1 [Sato, Amy Y.; Cregor, Meloney; McAndrews, Kevin; Li, Troy; Condon, Keith W.; Plotkin, Lilian I.; Bellido, Teresita] Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS5045A, Indianapolis, IN 46202 USA.
   [Bellido, Teresita] Indiana Univ Sch Med, Div Endocrinol, Dept Med, Indianapolis, IN 46202 USA.
   [Bellido, Teresita] Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.
   [Bellido, Teresita] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Richard L.
   Roudebush VA Medical Center
RP Bellido, T (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS5045A, Indianapolis, IN 46202 USA.; Bellido, T (通讯作者)，Indiana Univ Sch Med, Dept Med, Endocrinol, 635 Barnhill Dr,MS5045A, Indianapolis, IN 46202 USA.
EM tbellido@iupui.edu
RI ; Plotkin, Lilian/H 7188 2019
OI Li, Troy/0000 0002 8163 187X; Sato, Amy/0000 0001 5061 1369; Plotkin,
   Lilian/0000 0002 9537 4544; Bellido, Teresita/0000 0002 8203 7004
FU National Institutes of Health [R01 AR059357, T32 AR065971]; Veterans
   Administration [I01 BX002104]
FX This research was supported by the National Institutes of Health
   (R01 AR059357 to T.B.; T32 AR065971 to A.Y.S.) and the Veterans
   Administration (I01 BX002104 to T.B.).
CR Allen MR, 2006, BONE, V39, P872, DOI 10.1016/j.bone.2006.04.028
   Allen MR., 2007, IBMS BoneKEy, V4, P49, DOI [10.1138/20060248, DOI 10.1138/20060248]
   Bellido T, 2014, BASIC AND APPLIED BONE BIOLOGY, P27, DOI 10.1016/B978 0 12 416015 6.00002 2
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Buckbinder L, 2007, P NATL ACAD SCI USA, V104, P10619, DOI 10.1073/pnas.0701421104
   Cooper MS, 2003, J CLIN ENDOCR METAB, V88, P3874, DOI 10.1210/jc.2003 022025
   Cooper MS, 2002, J BONE MINER RES, V17, P979, DOI 10.1359/jbmr.2002.17.6.979
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Gallant KMH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108262
   Gil Henn H, 2007, J CELL BIOL, V178, P1053, DOI 10.1083/jcb.200701148
   Hajjawi MOR, 2014, BONE, V69, P139, DOI 10.1016/j.bone.2014.09.016
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Jilka RL, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P237, DOI 10.1016/B978 0 12 373884 4.00032 X
   Littooij AS, 2017, BRIT J HAEMATOL, V176, P637, DOI 10.1111/bjh.14452
   Mok CC, 2015, BONE, V75, P222, DOI 10.1016/j.bone.2015.03.002
   Necela Brian M, 2004, Proc Am Thorac Soc, V1, P239, DOI 10.1513/pats.200402 005MS
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   O'Ryan FS, 2009, J ORAL MAXIL SURG, V67, P1363, DOI 10.1016/j.joms.2009.03.005
   Okigaki M, 2003, P NATL ACAD SCI USA, V100, P10740, DOI 10.1073/pnas.1834348100
   Parfitt AM, 1996, SKELETAL HETEROGENEI, P315
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2007, J BIOL CHEM, V282, P24120, DOI 10.1074/jbc.M611435200
   Rhee Y, 2011, J BONE MINER RES, V26, P1035, DOI 10.1002/jbmr.304
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
   Rizzoli R, 2012, CALCIFIED TISSUE INT, V91, P225, DOI 10.1007/s00223 012 9630 5
   ROSS EJ, 1982, LANCET, V2, P646
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   Sato AY, 2018, CLIN REV BONE MINER, V16, P33, DOI 10.1007/s12018 018 9242 3
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Sato AY, 2015, BONE, V73, P60, DOI 10.1016/j.bone.2014.12.012
   Shiwaku Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132903
   Tomlinson JW, 2004, ENDOCR REV, V25, P831, DOI 10.1210/er.2003 0031
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   van Staa TP, 2006, CALCIFIED TISSUE INT, V79, P129, DOI 10.1007/s00223 006 0019 1
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Waning DL, 2015, NAT MED, V21, P1262, DOI 10.1038/nm.3961
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Weinstein RS, 2000, J CLIN ENDOCR METAB, V85, P2907, DOI 10.1210/jc.85.8.2907
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Zhao HB, 2005, MOL ENDOCRINOL, V19, P771, DOI 10.1210/me.2004 0161
NR 45
TC 26
Z9 27
U1 0
U2 7
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD JUL
PY 2019
VL 160
IS 7
BP 1659
EP 1673
DI 10.1210/en.2019 00237
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IS7FV
UT WOS:000482316600008
PM 31081900
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Esen, E
   Lee, SY
   Wice, BM
   Long, FX
AF Esen, Emel
   Lee, Seung Yon
   Wice, Burton M.
   Long, Fanxin
TI PTH Promotes Bone Anabolism by Stimulating Aerobic Glycolysis via IGF
   Signaling
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PARATHYROID HORMONE; PTH; BONE ANABOLISM; AEROBIC GLYCOLYSIS; IGF
ID GROWTH FACTOR I; PARATHYROID HORMONE INCREASES; OSTEOBLAST ENRICHED
   CULTURES; SKELETAL GROWTH; GROWING MICE; LINING CELLS; RAT BONE;
   ACTIVATION; RECEPTOR; CALVARIA
AB Teriparatide, a recombinant peptide corresponding to amino acids 1 34 of human parathyroid hormone (PTH), has been an effective bone anabolic drug for over a decade. However, the mechanism whereby PTH stimulates bone formation remains incompletely understood. Here we report that in cultures of osteoblast lineage cells, PTH stimulates glucose consumption and lactate production in the presence of oxygen, a hallmark of aerobic glycolysis, also known as Warburg effect. Experiments with radioactively labeled glucose demonstrate that PTH suppresses glucose entry into the tricarboxylic acid cycle (TCA cycle). Mechanistically, the increase in aerobic glycolysis is secondary to insulin like growth factor (Igf) signaling induced by PTH, whereas the metabolic effect of Igf is dependent on activation of mammalian target of rapamycin complex 2 (mTORC2). Importantly, pharmacological perturbation of glycolysis suppresses the bone anabolic effect of intermittent PTH in the mouse. Thus, stimulation of aerobic glycolysis via Igf signaling contributes to bone anabolism in response to PTH. (c) 2015 American Society for Bone and Mineral Research.
C1 [Esen, Emel; Long, Fanxin] Washington Univ, Div Biol & Biomed Sci, Sch Med, St Louis, MO 63110 USA.
   [Esen, Emel; Lee, Seung Yon; Long, Fanxin] Washington Univ, Dept Orthopaed Surg, Sch Med, St Louis, MO 63110 USA.
   [Wice, Burton M.; Long, Fanxin] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Long, Fanxin] Washington Univ, Dept Dev Biol, Sch Med, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL); Washington University (WUSTL)
RP Long, FX (通讯作者)，Washington Univ, Dept Orthopaed Surg, Sch Med, St Louis, MO 63110 USA.
EM flong@wustl.edu
FU NIH [AR060456, AR055923, P30 AR057235]
FX This work is supported by NIH grants AR060456, AR055923 (FL), and P30
   AR057235 (Washington University Musculoskeletal Research Center).
CR Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bikle DD, 2002, J BONE MINER RES, V17, P1570, DOI 10.1359/jbmr.2002.17.9.1570
   BORLE AB, 1960, J BIOL CHEM, V235, P1211
   Chen JQ, 2015, J BONE MINER RES, V30, P369, DOI 10.1002/jbmr.2348
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Esen E, 2014, CURR OSTEOPOROS REP, V12, P433, DOI 10.1007/s11914 014 0235 y
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   García Martínez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668
   Gesty Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200
   HERNANDEZSANCHEZ C, 1995, J BIOL CHEM, V270, P29176, DOI 10.1074/jbc.270.49.29176
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Karner CM, 2015, J CLIN INVEST, V125, P551, DOI 10.1172/JCI78470
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200
   LINKHART TA, 1989, ENDOCRINOLOGY, V125, P1484, DOI 10.1210/endo 125 3 1484
   Long FX, 2006, DEV BIOL, V298, P327, DOI 10.1016/j.ydbio.2006.06.042
   MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353
   MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo 124 3 1247
   McCauley LK, 1996, J CELL BIOCHEM, V61, P638, DOI 10.1002/(SICI)1097 4644(19960616)61:4<638::AID JCB18>3.3.CO;2 9
   Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P4349, DOI 10.1210/en.142.10.4349
   NEUMAN WF, 1978, AM J PHYSIOL, V234, pC41, DOI 10.1152/ajpcell.1978.234.1.C41
   PFEILSCHIFTER J, 1995, J CLIN INVEST, V96, P767, DOI 10.1172/JCI118121
   Potts JT, 2005, J ENDOCRINOL, V187, P311, DOI 10.1677/joe.1.06057
   Qiu T, 2010, NAT CELL BIOL, V12, P224, DOI 10.1038/ncb2022
   Regan JN, 2014, P NATL ACAD SCI USA, V111, P8673, DOI 10.1073/pnas.1324290111
   REITZER LJ, 1979, J BIOL CHEM, V254, P2669
   RODAN GA, 1978, ENDOCRINOLOGY, V102, P1501, DOI 10.1210/endo 102 5 1501
   Tahimic Candice G T, 2013, Front Endocrinol (Lausanne), V4, P6, DOI 10.3389/fendo.2013.00006
   Wan M, 2008, GENE DEV, V22, P2968, DOI 10.1101/gad.1702708
   Wan M, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001464
   Wang YM, 2007, J BONE MINER RES, V22, P1329, DOI 10.1359/JBMR.070517
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
NR 34
TC 116
Z9 138
U1 0
U2 13
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2015
VL 30
IS 11
BP 1959
EP 1968
DI 10.1002/jbmr.2556
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CU1MV
UT WOS:000363286900003
PM 25990470
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Clément Lacroix, P
   Ai, MR
   Morvan, F
   Roman Roman, S
   Vayssière, B
   Belleville, C
   Estrera, K
   Warman, ML
   Baron, R
   Rawadi, G
AF Clément Lacroix, P
   Ai, MR
   Morvan, F
   Roman Roman, S
   Vayssière, B
   Belleville, C
   Estrera, K
   Warman, ML
   Baron, R
   Rawadi, G
TI Lrp5 independent activation of Wnt signaling by lithium chloride
   increases bone formation and bone mass in mice
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE anabolic; osteoporosis; therapy
ID GLYCOGEN SYNTHASE KINASE 3; RECEPTOR RELATED PROTEIN 5; MURINE MODEL;
   MOLECULAR MECHANISM; PARATHYROID HORMONE; LONG TERM; OSTEOBLAST;
   THERAPY; LRP5; HYPERPARATHYROIDISM
AB one of the well characterized cell biologic actions of lithium is the inhibition of glycogen synthase kinase 3 beta and the consequent activation of canonical Wnt signaling. Because deficient Wnt signaling has been implicated in disorders of reduced bone mass, we tested whether lithium could improve bone mass in mice. We gavage fed lithium chloride to 8 week old mice from three different strains (Lrp5( / ), SAMP6, and C57BL/6) and assessed the effect on bone metabolism after 4 weeks of therapy. Lrp5( / ) mice lack the Wnt coreceptor low density lipoprotein receptor related protein 5 and have markedly reduced bone mass. Lithium, which is predicted to act downstream of this receptor, restored bone metabolism and bone mass to near wild type levels in these mice. SAMP6 mice have accelerated osteoporosis due to inadequate osteoblast renewal. Lithium significantly improved bone mass in these mice and in wild type C57BL/6 mice. We found that lithium activated canonical Wnt signaling in cultured calvarial osteoblasts from Lrp5( / ) mice ex vivo and that lithium treated mice had increased expression of Wnt responsive genes in their bone marrow cells in vivo. These data lead us to conclude that lithium enhances bone formation and improves bone mass in mice and that it may do so via activation of the canonical Writ pathway. Lithium has been used safely and effectively for over half a century in the treatment of bipolar illness. Prospective studies in patients receiving lithium should determine whether it also improves bone mass in humans.
C1 Prostrakan Pharmaceut, F 93230 Romainville, France.
   Howard Hughes Med Inst, Cleveland, OH 44106 USA.
   Case Sch Med, Dept Genet, Cleveland, OH 44106 USA.
   Case Sch Med, Ctr Human Genet, Cleveland, OH 44106 USA.
   Univ Hosp Cleveland, Cleveland, OH 44106 USA.
   Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA.
   Yale Univ, Sch Med, Dept Orthopaed, New Haven, CT 06510 USA.
C3 Howard Hughes Medical Institute; University System of Ohio; Case Western
   Reserve University; University System of Ohio; Case Western Reserve
   University; University Hospitals of Cleveland; Yale University; Yale
   University
RP Rawadi, G (通讯作者)，Prostrakan Pharmaceut, 102 Route Noisy, F 93230 Romainville, France.
EM georges.rawadi@prostrakan.com
RI Roman Roman, Sergio/K 9993 2014
OI Roman Roman, Sergio/0000 0001 6459 2613; Rawadi,
   Georges/0000 0003 4735 2188
CR ALEXANDER GV, 1951, J BIOL CHEM, V192, P489
   Awad SS, 2003, WORLD J SURG, V27, P486, DOI 10.1007/s00268 002 6824 4
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   BARAN DT, 1978, J CLIN INVEST, V61, P1691, DOI 10.1172/JCI109090
   BELLWINKEL S, 1975, INT PHARMACOPSYCHIAT, V10, P9, DOI 10.1159/000468163
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Berg C, 2003, NAT REV DRUG DISCOV, V2, P257, DOI 10.1038/nrd1068
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   EdwallArvidsson C, 1996, ANAT EMBRYOL, V193, P453
   El Khoury A, 2002, PROG NEURO PSYCHOPH, V26, P1063, DOI 10.1016/S0278 5846(02)00223 3
   Engler TA, 2004, J MED CHEM, V47, P3934, DOI 10.1021/jm049768a
   Garcia T, 2002, BONE, V31, P205, DOI 10.1016/S8756 3282(02)00781 0
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gould TD, 2003, PHARMACOL RES, V48, P49, DOI 10.1016/S0143 6618(03)00096 3
   Haden ST, 1997, J CLIN ENDOCR METAB, V82, P2844, DOI 10.1210/jc.82.9.2844
   Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552
   HENNEMAN D, 1974, ENDOCRINOLOGY, V94, P915, DOI 10.1210/endo 94 3 915
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   HOLMEN SL, 2005, J BIOL CHEM, V31, P31
   JACKSON A, 2005, BONE, V14, P14
   Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600
   Kajkenova O, 1997, J BONE MINER RES, V12, P1772, DOI 10.1359/jbmr.1997.12.11.1772
   KALLNER G, 1995, ACTA PSYCHIAT SCAND, V91, P48, DOI 10.1111/j.1600 0447.1995.tb09741.x
   Kallner G, 2000, PHARMACOPSYCHIATRY, V33, P8, DOI 10.1055/s 2000 7965
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092 8674(00)81333 1
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Locklin RM, 2003, J CELL BIOCHEM, V89, P180, DOI 10.1002/jcb.10490
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Mak TWL, 1998, J CLIN ENDOCR METAB, V83, P3857, DOI 10.1210/jc.83.11.3857
   Misra M, 2004, J CLIN PSYCHIAT, V65, P1607, DOI 10.4088/JCP.v65n1205
   NORDENSTROM J, 1994, METABOLISM, V43, P1563, DOI 10.1016/0026 0495(94)90017 5
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   Pieri Balandraud N, 2001, REV MED INTERNE, V22, P460, DOI 10.1016/S0248 8663(01)00371 X
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683
   Samuels A, 2001, CALCIFIED TISSUE INT, V69, P164, DOI 10.1007/s002230020026
   Schou M, 2001, J AFFECT DISORDERS, V67, P21, DOI 10.1016/S0165 0327(01)00380 9
   Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597 19
   Sims NA, 2000, J CLIN INVEST, V106, P1095, DOI 10.1172/JCI10753
   TAKEDA T, 1994, ARCH GERONTOL GERIAT, V19, P185, DOI 10.1016/0167 4943(94)90039 6
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
NR 51
TC 424
Z9 494
U1 5
U2 70
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 29
PY 2005
VL 102
IS 48
BP 17406
EP 17411
DI 10.1073/pnas.0505259102
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 990RX
UT WOS:000233762000027
PM 16293698
OA Green Published
DA 2025 08 17
ER

PT J
AU Yuan, ZY
   Li, Q
   Luo, SH
   Liu, Z
   Luo, DW
   Zhang, B
   Zhang, DD
   Rao, PC
   Xiao, JG
AF Yuan, Zongyi
   Li, Qing
   Luo, Shihong
   Liu, Zhi
   Luo, Daowen
   Zhang, Bo
   Zhang, Dongdong
   Rao, Pengcheng
   Xiao, Jingang
TI PPARγ and Wnt Signaling in Adipogenic and Osteogenic Differentiation of
   Mesenchymal Stem Cells
SO CURRENT STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Adipocyte differentiation; mesenchymal stem cells; microRNA; osteoblast
   differentiation; peroxisome proliferator activated receptor gamma;
   regenerative therapy; Wnt signaling
ID ACTIVATED RECEPTOR GAMMA; ADIPOCYTE DIFFERENTIATION; BETA CATENIN;
   INHIBITS ADIPOGENESIS; BONE FORMATION; OSTEOBLAST DIFFERENTIATION;
   OSTEOCLAST FORMATION; STROMAL CELLS; EXPRESSION; MICRORNAS
AB Mesenchymal stem cells (MSCs) arise from a variety of tissues, including bone marrow and adipose tissue and, accordingly, have the potential to differentiate into multiple cell types, including osteoblasts and adipocytes. Research on MSCs to date has demonstrated that a large number of transcription factors and ectocytic or intrastitial signaling pathways regulate adipogenic and osteogenic differentiation. A theoretical inverse relationship exists in adipogenic and osteogenic lineage commitment and differentiation, such that signaling pathways induce adipogenesis at the expense of osteogenesis and vice versa. For example, peroxisome proliferator activated receptor gamma (PPAR gamma), which belongs to the nuclear hormone receptor superfamily of ligand activated transcription factors, is known to function as a master transcriptional regulator of adipocyte differentiation, and inhibit osteoblast differentiation. Moreover, recent studies have demonstrated that inducers of osteogenic differentiation, such as bone morphogenetic protein (BMP) and Wnt, inhibit the function of PPAR gamma transactivation during MSC differentiation towards adipocytes through a variety of mechanisms. To illustrate this, the canonical Wnt/beta catenin pathway represses expression of PPAR gamma mRNA, whereas the noncanonical Wnt pathway activates histone methyltransferases that inhibit PPAR gamma transactivation via histone H3 lysine 9 (H3K9) methylation of its target genes. The role of microRNAs (miRNAs) in adipogenesis and osteoblastogenesis is garnering increased attention, and studies in this area have shed light on the integration of miRNAs with Wnt signaling and transcription factors such as Runx2 and PPAR gamma. This review summarizes our current understanding of the mechanistic basis of these signaling pathways, and indicates future clinical applications for stem cell based cell transplantation and regenerative therapy.
C1 [Yuan, Zongyi; Luo, Shihong; Liu, Zhi; Xiao, Jingang] Luzhou Med Coll, Hosp Stomatol, Dept Oral & Maxillofacial Surg, 2 Jiang Yang Nan Rd, Luzhou 646000, Peoples R China.
   [Li, Qing; Luo, Daowen; Zhang, Bo; Zhang, Dongdong; Rao, Pengcheng] Luzhou Med Coll, Hosp Stomatol, Orofacial Reconstruct & Regenerat Lab, Luzhou 646000, Peoples R China.
C3 Southwest Medical University; Southwest Medical University
RP Xiao, JG (通讯作者)，Luzhou Med Coll, Hosp Stomatol, Dept Oral & Maxillofacial Surg, 2 Jiang Yang Nan Rd, Luzhou 646000, Peoples R China.
EM drxiaojg@sohu.com
RI zhang, dd/HGE 1546 2022; LI, QI/KHA 7880 2024; Sokolov,
   Andrey/N 1933 2013
FU National Natural Science Foundation of China [81371125]; Program of
   Sichuan Provincial Science and Technology Bureau [2014JY0044]; Project
   of Sichuan Provincial Education department [10ZB030]; Project of
   Department of Health of Sichuan Province [80170]; Key Project of Luzhou
   Medical College [201207]; Academy of Finland (AKA) [80170] Funding
   Source: Academy of Finland (AKA)
FX This work was supported by the National Natural Science Foundation of
   China (81371125), the Program of Sichuan Provincial Science and
   Technology Bureau (2014JY0044), the Project of Sichuan Provincial
   Education department (10ZB030), the Project of Department of Health of
   Sichuan Province (No. 80170), and the Key Project of Luzhou Medical
   College (201207).
CR Adami S, 2013, BONE RES, V1, P323, DOI 10.4248/BR201304003
   Adler RA, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.1
   Almario RU, 2014, HORM METAB RES
   Almeida M, 2009, J BIOL CHEM, V284, P27438, DOI 10.1074/jbc.M109.023572
   Antal Salamon, 2009, Orvosi Hetilap, V150, P1259, DOI 10.1556/OH.2009.28666
   Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027
   Baghaban Eslaminejad Mohamadreza, 2014, World J Stem Cells, V6, P344, DOI 10.4252/wjsc.v6.i3.344
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Berendsen AD, 2014, CELL MOL LIFE SCI, V71, P493, DOI 10.1007/s00018 013 1440 z
   Bilkovski R, 2010, J BIOL CHEM, V285, P6170, DOI 10.1074/jbc.M109.054338
   Bloom DC, 2010, BBA GENE REGUL MECH, V1799, P246, DOI 10.1016/j.bbagrm.2009.12.001
   Byun MR, 2014, BONE, V58, P72, DOI 10.1016/j.bone.2013.09.024
   Cai XX, 2007, CELL BIOL INT, V31, P776, DOI 10.1016/j.cellbi.2007.01.011
   Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200
   Chen H, 2014, FEBS LETT, V588, P429, DOI 10.1016/j.febslet.2013.12.002
   Chen JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013704
   Chen L, 2014, STEM CELLS, V32, P510, DOI 10.1002/stem.1549
   Chen L, 2014, MOL CELL ENDOCRINOL, V393, P65, DOI 10.1016/j.mce.2014.05.022
   Chen YC, 2012, MOL NEUROBIOL, V46, P114, DOI 10.1007/s12035 012 8259 8
   Cho ES, 2012, MOL CELLS, V33, P173, DOI 10.1007/s10059 012 2240 z
   Corona JC, 2014, NEUROCHEM RES
   D'Alimonte I, 2013, STEM CELL REV REP, V9, P642, DOI 10.1007/s12015 013 9436 5
   Davies BM, 2013, REGEN MED, V8, P613, DOI 10.2217/rme.13.55
   De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079
   Dong SW, 2012, BIOCHEM BIOPH RES CO, V418, P587, DOI 10.1016/j.bbrc.2012.01.075
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Floyd ZE, 2012, BBA MOL BASIS DIS, V1822, P1090, DOI 10.1016/j.bbadis.2012.03.014
   Fu N, 2013, CELL PROLIFERAT, V46, P312, DOI 10.1111/cpr.12031
   Ge WS, 2014, BIOMATERIALS, V35, P6015, DOI 10.1016/j.biomaterials.2014.04.055
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Gómez Orte E, 2013, TRENDS GENET, V29, P545, DOI 10.1016/j.tig.2013.06.003
   Granchi D, 2010, BONE, V46, P780, DOI 10.1016/j.bone.2009.10.044
   Granéli C, 2014, CONNECT TISSUE RES, V55, P262, DOI 10.3109/03008207.2014.910198
   Grottkau BE, 2013, BONE RES, V1, P282, DOI 10.4248/BR201303006
   Grottkau BE, 2013, BONE RES, V1, DOI 10.4248/BR201302003
   Grünberg JR, 2014, J BIOL CHEM, V289, P6899, DOI 10.1074/jbc.M113.511964
   Gustafson B, 2010, J BIOL CHEM, V285, P14031, DOI 10.1074/jbc.M110.102855
   Hammarstedt A, 2013, P NATL ACAD SCI USA, V110, P2563, DOI 10.1073/pnas.1211255110
   Hassan MQ, 2012, J BIOL CHEM, V287, P42084, DOI 10.1074/jbc.M112.377515
   Hassumi MY, 2009, INT IMMUNOPHARMACOL, V9, P1150, DOI 10.1016/j.intimp.2009.06.002
   He XJ, 2009, J CELL MOL MED, V13, P606, DOI 10.1111/j.1582 4934.2009.00696.x
   Henjes F, 2014, J PROTEOME RES, V13, P5218, DOI 10.1021/pr500775a
   Hoshiba T, 2009, J BIOL CHEM, V284, P31164, DOI 10.1074/jbc.M109.054676
   James Richard G., 2008, V468, P131, DOI 10.1007/978 1 59745 249 6_10
   Kang BY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079503
   Kang T, 2013, J BIOL CHEM, V288, P34394, DOI 10.1074/jbc.M113.514372
   Kawai M, 2010, AM J PHYSIOL ENDOC M, V299, pE3, DOI 10.1152/ajpendo.00157.2010
   Kim MB, 2014, BIOCHEM BIOPH RES CO, V445, P433, DOI 10.1016/j.bbrc.2014.02.017
   Kim M, 2012, MECH AGEING DEV, V133, P215, DOI 10.1016/j.mad.2012.03.014
   Kim TH, 2013, YONSEI MED J, V54, P545, DOI 10.3349/ymj.2013.54.3.545
   Kim YJ, 2014, MOL BIOL REP, V41, P5267, DOI 10.1007/s11033 014 3398 9
   Ko JY, 2013, BONE, V57, P468, DOI 10.1016/j.bone.2013.09.019
   Korvala J, 2012, BMC MED GENET, V13, DOI 10.1186/1471 2350 13 26
   Kozinski K, 2013, POSTEP HIG MED DOSW, V67, P1098, DOI 10.5604/17322693.1077719
   Laudes M, 2011, J MOL ENDOCRINOL, V46, pR65, DOI 10.1530/JME 10 0169
   Lee MJ, 2013, J CELL MOL MED, V17, P1188, DOI 10.1111/jcmm.12098
   Lee YH, 2013, CELL MOL LIFE SCI, V70, P3959, DOI 10.1007/s00018 013 1363 8
   Lefterova MI, 2014, TRENDS ENDOCRIN MET, V25, P293, DOI 10.1016/j.tem.2014.04.001
   Li G, 2013, CELL PROLIFERAT, V46, P586, DOI 10.1111/cpr.12053
   Li HL, 2013, STEM CELL RES, V10, P313, DOI 10.1016/j.scr.2012.11.007
   Li HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071568
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Lim MH, 2014, EXPERT REV MOL MED, V16, DOI 10.1017/erm.2014.8
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Lin Q, 2009, FEBS J, V276, P2348, DOI 10.1111/j.1742 4658.2009.06967.x
   Lin YF, 2005, J CELL MOL MED, V9, P929, DOI 10.1111/j.1582 4934.2005.tb00389.x
   Lin YF, 2008, HISTOCHEM CELL BIOL, V129, P203, DOI 10.1007/s00418 007 0351 1
   Lin YF, 2007, J BIOMED MATER RES A, V81A, P900, DOI 10.1002/jbm.a.31149
   Ling HY, 2011, CLIN EXP PHARMACOL P, V38, P239, DOI 10.1111/j.1440 1681.2011.05493.x
   Ling HY, 2009, CLIN EXP PHARMACOL P, V36, pe32, DOI 10.1111/j.1440 1681.2009.05207.x
   Lisse TS, 2013, CRIT REV EUKAR GENE, V23, P195, DOI 10.1615/CritRevEukaryotGeneExpr.2013007147
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Malhotra Deepti, 2014, Bonekey Rep, V3, P541, DOI 10.1038/bonekey.2014.36
   Maung SMTW, 2011, ORGANOGENESIS, V7, P165, DOI 10.4161/org.7.3.18143
   Maupin KA, 2013, BONE RES, V1, DOI 10.4248/BR201301004
   McGregor RA, 2011, CURR MOL MED, V11, P304
   Miller RK, 2013, PROG MOL BIOL TRANSL, V116, P387, DOI 10.1016/B978 0 12 394311 8.00017 0
   Nemoto E, 2012, BIOCHEM BIOPH RES CO, V422, P627, DOI 10.1016/j.bbrc.2012.05.039
   Okamoto M, 2014, SCI REP UK, V4, DOI 10.1038/srep04493
   Okubo Masashi, 2013, Clin Calcium, V23, P1705, DOI CliCa131217051713
   Otsuru S, 2012, BLOOD, V120, P1933, DOI 10.1182/blood 2011 12 400085
   Pan SF, 2014, J CELL PHYSIOL, V229, P631, DOI 10.1002/jcp.24486
   Patel JJ, 2014, CELL BIOCHEM FUNCT, V32, P368, DOI 10.1002/cbf.3025
   Perez VADJ, 2009, J CELL BIOL, V184, P83, DOI 10.1083/jcb.200806049
   Peröbner I, 2012, INT J BIOCHEM CELL B, V44, P1970, DOI 10.1016/j.biocel.2012.07.025
   Pillai HK, 2014, ENVIRON HEALTH PERSP, V122, P1225, DOI 10.1289/ehp.1408111
   Qin LM, 2010, BMC GENOMICS, V11, DOI 10.1186/1471 2164 11 320
   Roberto VP, 2014, ARCH BIOCHEM BIOPHYS, V564, P173, DOI 10.1016/j.abb.2014.09.006
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Rozen WM, 2009, MICROSURG, V29, P16, DOI 10.1002/micr.20550
   Sampson S, 2013, PHYSICIAN SPORTSMED, V41, P7, DOI 10.3810/psm.2013.09.2022
   Scott EL, 2013, BRAIN RES, V1514, P63, DOI 10.1016/j.brainres.2012.12.015
   Shang YC, 2007, ACTA PHARMACOL SIN, V28, P1761, DOI 10.1111/j.1745 7254.2007.00671.x
   Shen J, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.2
   Spreafico A, 2013, CLIN CANCER RES, V19, P4149, DOI 10.1158/1078 0432.CCR 12 3140
   Sun JK, 2014, J TRANSL MED, V12, DOI 10.1186/1479 5876 12 168
   Takada I, 2010, PPAR RES, V2010, DOI 10.1155/2010/341671
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Takada I, 2009, EXPERT OPIN THER TAR, V13, P593, DOI [10.1517/14728220902915310 , 10.1517/14728220902915310]
   Tamura M, 2013, MOL MED REP, V8, P1807, DOI 10.3892/mmr.2013.1713
   Taniguchi M, 2014, MOL BIOL REP, V41, P1081, DOI 10.1007/s11033 013 2954 z
   Tella SH, 2014, EUR J CLIN PHARMACOL, V70, P1291, DOI 10.1007/s00228 014 1735 5
   TheinHan WW, 2013, BONE RES, V1, P371, DOI 10.4248/BR201304008
   van de Vyver M, 2014, J ENDOCRINOL, V223, P119, DOI 10.1530/JOE 14 0425
   Velasco J, 2010, OSTEOPOROSIS INT, V21, P109, DOI 10.1007/s00198 009 0931 0
   Viladomiu M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047525
   Wang J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.356
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072266
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Wei X, 2013, CELL PROLIFERAT, V46, P416, DOI 10.1111/cpr.12044
   Wen X, 2011, BIOMATERIALS, V32, P6478, DOI 10.1016/j.biomaterials.2011.05.045
   Wu L, 2013, J CELL PHYSIOL, V228, P938, DOI 10.1002/jcp.24255
   Wu L, 2010, J CELL MOL MED, V14, P922, DOI 10.1111/j.1582 4934.2009.00709.x
   Xiao JG, 2008, MOL CELL BIOCHEM, V309, P143, DOI 10.1007/s11010 007 9652 x
   Xiao JG, 2013, MOL CELL BIOCHEM, V377, P107, DOI 10.1007/s11010 013 1575 0
   Xie HM, 2009, DIABETES, V58, P1050, DOI 10.2337/db08 1299
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Yamashita A, 2006, FEBS LETT, V580, P4121, DOI 10.1016/j.febslet.2006.06.057
   Yamashita T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085878
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
   Yang X, 2012, CELL PROLIFERAT, V45, P158, DOI 10.1111/j.1365 2184.2011.00802.x
   Yi C, 2011, FEBS LETT, V585, P3303, DOI 10.1016/j.febslet.2011.09.015
   Zhang J, 2011, J BONE MINER RES, V26, P1953, DOI 10.1002/jbmr.377
   Zhang JF, 2011, RNA BIOL, V8, P829, DOI 10.4161/rna.8.5.16043
   Zhang WB, 2014, BONE, V58, P59, DOI 10.1016/j.bone.2013.09.015
   Zhang XR, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.15
   Zhou C, 2015, CELL PROLIFERAT, V48, P39, DOI 10.1111/cpr.12152
   Zuo B, 2014, J BONE MINER RES
NR 129
TC 177
Z9 206
U1 3
U2 67
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574 888X
EI 2212 3946
J9 CURR STEM CELL RES T
JI Curr. Stem Cell Res. Ther.
PY 2016
VL 11
IS 3
BP 216
EP 225
DI 10.2174/1574888X10666150519093429
PG 10
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DG8KS
UT WOS:000372333300006
PM 25986621
DA 2025 08 17
ER

PT J
AU Anastasilakis, AD
   Polyzos, SA
   Toulis, KA
AF Anastasilakis, Athanasios D.
   Polyzos, Stergios A.
   Toulis, Konstantinos A.
TI Role of wingless tail signaling pathway in osteoporosis: an update of
   current knowledge
SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
LA English
DT Article
DE Dickkopf; osteoblast; osteoporosis; sclerostin; wingless tail
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; OSTEOBLAST DIFFERENTIATION;
   SCLEROSTIN ANTIBODY; SERUM DICKKOPF 1; DKK1 EXPRESSION; MASS;
   POLYMORPHISMS; ASSOCIATION; REPLICATION
AB Purpose of review
   Wingless tail (Wnt) pathway is crucial for osteoblast activation and action. This review summarizes the evidence published during the previous year on the emerging role of Wnt signaling alterations in the pathogenesis, diagnosis, and potential therapeutic approaches of osteoporosis.
   Recent findings
   New insights into the mechanisms regulating Wnt/beta catenin canonical pathway, including the role of Kremen 2 receptor, lamin A/C protein, periostin, and pleiotropin in bone physiology, the crosstalk between the RUNX 2 transcription factor cascade and the Wnt pathway, and the concept that individual Wnt ligands may have a unique and distinct mission in bone milieu, are presented. Nutritional habits may affect Wnt signaling in bone. Serum sclerostin and dickkopf 1 levels may serve as markers of bone metabolism and disease, although further standardization methods are required. Finally, the effect of current antiosteoporotic treatments on Wnt signaling is discussed, as well as the therapeutic potential of drugs targeting either Wnt signaling amplification or Wnt antagonists' attenuation.
   Summary
   Although Wnt pathway is currently a field of thorough investigation, it is still far from been fully elucidated. Understanding its complex pathophysiology has evoked promising therapeutic approaches for osteoporosis. However, given that Wnt signaling is crucial for many tissues, emerging knowledge should be cautiously translated in therapeutics.
C1 [Anastasilakis, Athanasios D.; Toulis, Konstantinos A.] Aristotle Univ Thessaloniki, Ippokration Hosp, Gen Mil Hosp 424, Dept Endocrinol, GR 54006 Thessaloniki, Greece.
   [Polyzos, Stergios A.] Aristotle Univ Thessaloniki, Ippokration Hosp, Med Clin 2, Sch Med, GR 54006 Thessaloniki, Greece.
C3 Aristotle University of Thessaloniki; Aristotle University of
   Thessaloniki
RP Anastasilakis, AD (通讯作者)，Soulini 4, Sykies 56625, Greece.
EM anastath@endo.gr
RI ; Polyzos, Stergios/H 2844 2019; Anastasilakis,
   Athanasios/AAF 7669 2020; Toulis, Konstantinos/E 7951 2012
OI Anastasilakis, Athanasios/0000 0002 9624 6296; Polyzos,
   Stergios/0000 0001 9232 4042; 
CR Abdelkarim M, 2010, J BIOL CHEM, V285, P36759, DOI 10.1074/jbc.M110.166231
   Agholme F, 2010, J BONE MINER RES, V25, P2412, DOI 10.1002/jbmr.135
   Agueda L, 2011, J BONE MINER RES, V26, P1133, DOI 10.1002/jbmr.293
   Almeida M, 2009, J BIOL CHEM, V284, P27438, DOI 10.1074/jbc.M109.023572
   Anastasilakis AD, 2010, CLIN ENDOCRINOL, V72, P752, DOI 10.1111/j.1365 2265.2009.03728.x
   Betts AM, 2010, J PHARMACOL EXP THER, V333, P2, DOI 10.1124/jpet.109.164129
   Bhat RA, 2010, J CELL BIOCHEM, V109, P876, DOI 10.1002/jcb.22447
   Bodine PVN, 2009, BONE, V44, P1063, DOI 10.1016/j.bone.2009.02.013
   Bonnet N, 2009, J BIOL CHEM, V284, P35939, DOI 10.1074/jbc.M109.060335
   Butler JS, 2011, J ORTHOP RES, V29, P414, DOI 10.1002/jor.21260
   Butler JS, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 210
   Chen JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013704
   Chen JR, 2010, J BONE MINER RES, V25, P2399, DOI 10.1002/jbmr.137
   D'Amelio P, 2011, OSTEOPOROSIS INT, V22, P2869, DOI 10.1007/s00198 010 1496 7
   Drake MT, 2010, J CLIN ENDOCR METAB, V95, P5056, DOI 10.1210/jc.2010 0720
   Duque G, 2011, BONE, V49, P412, DOI 10.1016/j.bone.2011.04.023
   Gao G, 2010, BMC MED GENET, V11, DOI 10.1186/1471 2350 11 1
   Gatti D, 2011, J CLIN ENDOCR METAB, V96, P1555, DOI 10.1210/jc.2010 2552
   Gaudio A, 2010, J CLIN ENDOCR METAB, V95, P2248, DOI 10.1210/jc.2010 0067
   Glantschnig H, 2011, J PHARMACOL EXP THER, V338, P568, DOI 10.1124/jpet.111.181404
   Glantschnig H, 2010, J BIOL CHEM, V285, P40135, DOI 10.1074/jbc.M110.166892
   He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652
   Jilka RL, 2010, J BONE MINER RES, V25, P2427, DOI 10.1002/jbmr.145
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097 2765(01)00224 6
   McNulty M, 2011, J CLIN ENDOCR METAB, V96, pE1159, DOI 10.1210/jc.2011 0254
   Mencej Bedrac S, 2011, MOL GENET METAB, V103, P76, DOI 10.1016/j.ymgme.2011.01.017
   Milat F, 2009, MOL CELL ENDOCRINOL, V310, P52, DOI 10.1016/j.mce.2009.06.002
   Mödder UI, 2011, BONE, V49, P202, DOI 10.1016/j.bone.2011.04.015
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Olivares Navarrete R, 2010, BIOMATERIALS, V31, P2015, DOI 10.1016/j.biomaterials.2009.11.071
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Polyzos SA, 2012, OSTEOPOROSIS INT, V23, P1171, DOI 10.1007/s00198 010 1525 6
   Reppe S, 2010, BONE, V46, P604, DOI 10.1016/j.bone.2009.11.007
   Riancho JA, 2011, EUR J ENDOCRINOL, V164, P123, DOI 10.1530/EJE 10 0582
   Rybchyn MS, 2011, J BIOL CHEM, V286, P23771, DOI 10.1074/jbc.M111.251116
   Schulze J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010309
   Shum KT, 2011, BIOCHEM J, V434, P493, DOI 10.1042/BJ20101096
   Stevens JR, 2010, J BONE MINER RES, V25, P2138, DOI 10.1002/jbmr.118
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Tian XY, 2011, BONE, V48, P197, DOI 10.1016/j.bone.2010.09.009
   Trost Z, 2010, BONE, V46, P72, DOI 10.1016/j.bone.2009.09.015
   Valero C, 2011, MENOPAUSE, V18, P802, DOI 10.1097/gme.0b013e3182091664
   van Lierop AH, 2010, EUR J ENDOCRINOL, V163, P833, DOI 10.1530/EJE 10 0699
   Verkaar F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019185
   Voskaridou E, 2009, HAEMATOL HEMATOL J, V94, P725, DOI [10.3324/haematol.2008.000893, 10.3324/haema tol.2008.000893]
   Zhang JF, 2010, MOL CELL ENDOCRINOL, V314, P70, DOI 10.1016/j.mce.2009.08.012
NR 49
TC 19
Z9 19
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 1752 296X
J9 CURR OPIN ENDOCRINOL
JI Curr. Opin. Endocrinol. Diabetes Obes.
PD DEC
PY 2011
VL 18
IS 6
BP 383
EP 388
DI 10.1097/MED.0b013e32834afff2
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 841EV
UT WOS:000296496200008
PM 21897222
DA 2025 08 17
ER

PT J
AU Watanabe, A
   Kumagai, M
   Mishima, T
   Ito, J
   Otoki, Y
   Harada, T
   Kato, T
   Yoshida, M
   Suzuki, M
   Yoshida, I
   Fujita, K
   Watai, M
   Nakagawa, K
   Miyazawa, T
AF Watanabe, Akio
   Kumagai, Momochika
   Mishima, Takashi
   Ito, Junya
   Otoki, Yurika
   Harada, Teppei
   Kato, Tsuyoshi
   Yoshida, Mikihiko
   Suzuki, Misora
   Yoshida, Izumi
   Fujita, Kazuhiro
   Watai, Masatoshi
   Nakagawa, Kiyotaka
   Miyazawa, Teruo
TI Toddaculin, Isolated from of Toddalia asiatica (L.) Lam.,
   Inhibited Osteoclastogenesis in RAW 264 Cells and Enhanced
   Osteoblastogenesis in MC3T3 E1 Cells
SO PLOS ONE
LA English
DT Article
ID PARATHYROID HORMONE; DIFFERENTIATION; EXPRESSION; OSTEOPOROSIS;
   BISPHOSPHONATES; COUMARIN
AB Osteoporosis with bone loss is widely recognized as a major health problem. Bone homeostasis is maintained by balancing bone formation and bone resorption. The imbalance caused by increased bone resorption over bone formation can lead to various bone related diseases such as osteoporosis and rheumatoid arthritis. Osteoclasts are the principal cells responsible for bone resorption and the main targets of anti resorptive therapies. However, excessive inhibition of osteoclast differentiation may lead to inhibition of osteoblast differentiation. Therefore, it is important to screen for new compounds capable of inhibiting bone resorption and enhancing bone formation. Toddalia asiatica (L.) Lam. has been utilized traditionally for medicinal purposes such as the treatment of rheumatism. Currently, the extract is considered to be a good source of pharmacological agents for the treatment of bone related diseases, but the active compounds have yet to be identified. We investigated whether toddaculin, derived from Toddalia asiatica (L.) Lam., affects both processes by inhibiting bone resorption and enhancing bone formation. Towards this end, we used pre osteoclastic RAW 264 cells and pre osteoblastic MC3T3 E1 cells. We found that toddaculin not only inhibited the differentiation of osteoclasts via activation of the NF kappa B, ERK 1/2, and p38 MAPK signaling pathways, but it also induced differentiation and mineralization of osteoblasts by regulating differentiation factors. Thus, toddaculin might be beneficial for the prevention and treatment of osteoporosis.
C1 [Watanabe, Akio; Kumagai, Momochika; Mishima, Takashi; Harada, Teppei; Yoshida, Izumi; Fujita, Kazuhiro; Watai, Masatoshi] Japan Food Res Labs, Saito Lab, Food Funct Res Team, Ibaraki, Osaka, Japan.
   [Watanabe, Akio; Ito, Junya; Otoki, Yurika; Nakagawa, Kiyotaka; Miyazawa, Teruo] Tohoku Univ, Grad Sch Agr Sci, Food & Biodynam Chem Lab, Sendai, Miyagi 980, Japan.
   [Kato, Tsuyoshi] Japan Food Res Labs, Tama Lab, Sect Appl Testing, Tama, Tokyo, Japan.
   [Yoshida, Mikihiko] Japan Food Res Labs, Saito Lab, Sect Nutraceut Anal, Ibaraki, Osaka, Japan.
   [Suzuki, Misora] Japan Food Res Labs, Tama Lab, Sect Biol Safety Res, Tama, Tokyo, Japan.
C3 Tohoku University
RP Watanabe, A (通讯作者)，Japan Food Res Labs, Saito Lab, Food Funct Res Team, Ibaraki, Osaka, Japan.
EM watanabea@jfrl.or.jp
RI ; Ito, Junya/KPA 7635 2024; FUJITA, KAZUHIRO/KPY 3560 2024
OI Ito, Junya/0000 0001 9190 4969; 
CR Aaseth J, 2012, J TRACE ELEM MED BIO, V26, P149, DOI 10.1016/j.jtemb.2012.03.017
   AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097 4644(19980201)68:2<269::AID JCB13>3.0.CO;2 A
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Duraipandiyan V, 2006, BMC COMPLEM ALTERN M, V4, P311
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Gallacher SJ, 2010, CALCIFIED TISSUE INT, V87, P469, DOI 10.1007/s00223 010 9420 x
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Ishiyama M, 1997, TALANTA, V44, P1299, DOI 10.1016/S0039 9140(97)00017 9
   Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002
   Kitahara K, 2003, ENDOCRINOLOGY, V144, P2132, DOI 10.1210/en.2002 220996
   Kono SJ, 2007, BONE, V40, P68, DOI 10.1016/j.bone.2006.07.024
   Leboime A, 2010, JOINT BONE SPINE, V77, pS107, DOI 10.1016/S1297 319X(10)70004 X
   Matsuguchi T, 2009, J BONE MINER RES, V24, P398, DOI 10.1359/JBMR.081107
   Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298
   Nakamura T, 2009, J NAT MED TOKYO, V63, P15, DOI 10.1007/s11418 008 0268 6
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   REDDY SV, 1995, J BONE MINER RES, V10, P601
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664
   Vázquez R, 2012, PHYTOMEDICINE, V19, P737, DOI 10.1016/j.phymed.2012.03.008
   Watanabe A, 2014, BIOCHEM BIOPH RES CO, V453, P787, DOI 10.1016/j.bbrc.2014.10.027
   Yang K, 2013, J ETHNOPHARMACOL, V146, P355, DOI 10.1016/j.jep.2013.01.004
NR 29
TC 15
Z9 19
U1 4
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 18
PY 2015
VL 10
IS 5
AR e0127158
DI 10.1371/journal.pone.0127158
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CI7BG
UT WOS:000354917300098
PM 25993011
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Bartsch, R
   Steger, GG
AF Bartsch, Rupert
   Steger, Guenther G.
TI Role of denosumab in breast cancer
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE bisphosphonates; bone metastases; breast cancer; denosumab;
   osteoporosis; osteoprotegerin; RANK; zoledronic acid
ID KAPPA B LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; NECROSIS FACTOR
   RECEPTOR; HUMAN RANKL ANTIBODY; BONE RESORPTION; SKELETAL COMPLICATIONS;
   MULTIPLE MYELOMA; PROSTATE CANCER; ZOLEDRONIC ACID; PHASE II
AB Recent advances in adjuvant treatment have improved progression free and overall survival in patients with early stage breast cancer. However, up to one third of women will experience tumour recurrence, with bone being a common metastatic site. Current treatment options for metastases to bone comprise systemic antitumour therapy, irradiation, surgery and biphosphonates. As osteoclast activation is mediated by the receptor activator of NF kappa B (RANK)/RANK ligand pathway and inhibited by osteoprotegerin (OPG), it was suggested that inhibition of this system may treat bone metastases. Recombinant Fc OPG was evaluated in women with osteoporosis and malignant bone disease. The fully human antibody denosumab has demonstrated superior activity in reducing markers of bone turnover; therefore this drug was further developed in clinical settings. In advanced breast cancer, denosumab reduced urinary N telopeptide:creatinine ratio with potentially fewer side effects compared with bisphosphonates. Proof of direct antitumor activity is missing. Here we review the development and current status of denosumab in breast cancer. Data were obtained by searching the Medline database and abstracts from the American Society for Clinical Oncology (ASCO) annual meeting, European Cancer organization (ECCO), European Society for Medical Oncology (ESMO) and the San Antonio Breast Cancer Symposium, using search terms including bone metastases, bisphosphonates, breast cancer, denosumab, osteoprotegerin, RANK and skeletal related events.
C1 [Bartsch, Rupert; Steger, Guenther G.] Med Univ Vienna, Ctr Canc, Dept Med 1, A 1090 Vienna, Austria.
C3 Medical University of Vienna
RP Steger, GG (通讯作者)，Med Univ Vienna, Ctr Canc, Dept Med 1, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
EM guenther.steger@meduniwien.ac.at
CR Allen MR, 2006, BONE, V39, P872, DOI 10.1016/j.bone.2006.04.028
   [Anonymous], 2007, AM CANC SOC FACTS FI
   Atkinson J, 2005, J BONE MINER RES, V20, pS294
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   BELL R, 2005, ONCOLOGIST S, V10, pS8
   Beslija S, 2007, ANN ONCOL, V18, P215, DOI 10.1093/annonc/mdl155
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Brown JE, 2003, BRIT J CANCER, V89, P2031, DOI 10.1038/sj.bjc.6601437
   Brown JM, 2001, UROLOGY, V57, P611, DOI 10.1016/S0090 4295(00)01122 5
   Cascinu S, 1998, SUPPORT CARE CANCER, V6, P139, DOI 10.1007/s005200050148
   Chikatsu N, 2000, BIOCHEM BIOPH RES CO, V267, P632, DOI 10.1006/bbrc.1999.2008
   *CLIN TRIALS, NCT00556374 CLIN TRI
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   DEMULDER A, 1993, ENDOCRINOLOGY, V133, P1978, DOI 10.1210/en.133.5.1978
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Eidtmann H, 2009, CANCER RES, V69, p74S
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Faneyte IF, 2004, CLIN CANCER RES, V10, P4457, DOI 10.1158/1078 0432.CCR 03 0054
   Farrugia AN, 2003, CANCER RES, V63, P5438
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Flick LM, 2003, J ORTHOP RES, V21, P676, DOI 10.1016/S0736 0266(03)00011 1
   GALASKO CSB, 1976, NATURE, V263, P507, DOI 10.1038/263507a0
   Giuliani Nicola, 2004, Acta Biomed, V75, P143
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Green LL, 1999, J IMMUNOL METHODS, V231, P11, DOI 10.1016/S0022 1759(99)00137 4
   GREGORETTI MG, 1995, LEUKEMIA, V9, P1392
   Hofbauer LC, 2001, ARTHRITIS RHEUM US, V44, P253, DOI 10.1002/1529 0131(200102)44:2<253::AID ANR41>3.0.CO;2 S
   KALLIONIEMI OP, 1991, INT J CANCER, V49, P650, DOI 10.1002/ijc.2910490504
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kitazawa S, 2002, J PATHOL, V198, P228, DOI 10.1002/path.1199
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kostenuik PJ, 2005, J BONE MINER RES, V20, pS259
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   KOSTENUIK PJ, 1992, CLIN EXP METASTAS, V10, P403, DOI 10.1007/BF00133469
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lai FPL, 2004, BRIT J HAEMATOL, V126, P192, DOI 10.1111/j.1365 2141.2004.05018.x
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lane NE, 2006, ARTHRITIS RHEUM, V54, pS225
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Lipton A, 2008, CLIN CANCER RES, V14, P6690, DOI 10.1158/1078 0432.CCR 07 5234
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Massey HM, 1999, BRIT J HAEMATOL, V106, P167
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Miller RE, 2007, J IMMUNOL, V179, P266, DOI 10.4049/jimmunol.179.1.266
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Okada T, 2003, CLIN EXP METASTAS, V20, P639, DOI 10.1023/A:1027362507683
   Ominsky MS, 2006, J BONE MINER RES, V21, pS72
   ORR W, 1979, SCIENCE, V203, P176, DOI 10.1126/science.569363
   PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103
   PETERSON MC, 2006, J CLIN ONCOL S18, V24
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Ross JS, 2003, ONCOLOGIST, V8, P307, DOI 10.1634/theoncologist.8 4 307
   Saad F, 2007, SEMIN ONCOL, V34, pS17, DOI 10.1053/j.seminoncol.2007.10.006
   Schwarz EM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2171
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Smith MR, 2005, CANCER TREAT REV, V31, pS19, DOI 10.1016/j.ctrv.2005.09.004
   Solomayer EF, 2000, BREAST CANCER RES TR, V59, P271, DOI 10.1023/A:1006308619659
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Stolina M, 2003, CLIN IMMUNOL, V109, P347, DOI 10.1016/j.clim.2003.09.001
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Terpos E, 2005, ANN ONCOL, V16, P1223, DOI 10.1093/annonc/mdi235
   Terpos E, 2009, EXPERT OPIN BIOL TH, V9, P465, DOI [10.1517/14712590902845610, 10.1517/14712590902845610 ]
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vega D, 2007, J CLIN ENDOCR METAB, V92, P4514, DOI 10.1210/jc.2007 0646
   *WHO, WHO FACTS FIG
   Winter MC, 2008, CANCER TREAT REV, V34, P453, DOI 10.1016/j.ctrv.2008.02.004
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Yonemori K, 2008, CANCER SCI, V99, P1237, DOI 10.1111/j.1349 7006.2008.00803.x
   Yun TJ, 2001, J IMMUNOL, V166, P1482, DOI 10.4049/jimmunol.166.3.1482
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 77
TC 6
Z9 8
U1 0
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471 2598
EI 1744 7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD SEP
PY 2009
VL 9
IS 9
BP 1225
EP 1233
DI 10.1517/14712590903146877
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 489CV
UT WOS:000269398200011
PM 19653867
DA 2025 08 17
ER

PT J
AU Gao, Y
   Wu, X
   Terauchi, M
   Li, JY
   Grassi, F
   Galley, S
   Yang, X
   Weitzmann, MN
   Pacifici, R
AF Gao, Yuhao
   Wu, Xiaojun
   Terauchi, Masakazu
   Li, Jau Yi
   Grassi, Francesco
   Galley, Sarah
   Yang, Xiaoying
   Weitzmann, M. Neale
   Pacifici, Roberto
TI T cells potentiate PTH induced cortical bone loss through CD40L
   signaling
SO CELL METABOLISM
LA English
DT Article
ID HUMAN PARATHYROID HORMONE; TUMOR NECROSIS FACTOR; MARROW STROMAL CELLS;
   LOSS IN VIVO; POSTMENOPAUSAL WOMEN; OSTEOCLAST FORMATION; HUMAN
   OSTEOBLASTS; ANABOLIC ACTIONS; ANIMAL MODEL; PROTEIN
AB Parathyroid hormone (PTH) promotes bone catabolism by targeting bone marrow (BM) stromal cells (SCs) and their osteoblastic progeny. Here we show that a continuous infusion of PTH that mimics hyperparathyroidism fails to induce osteoclast formation, bone resorption, and cortical bone loss in mice lacking T cells. T cells provide proliferative and survival cues to SCs and sensitize SCs to PTH through CD40 ligand (CD40L), a surface molecule of activated T cells that induces CD40 signaling in SCs. As a result, deletion of T cells or T cell expressed CD40L blunts the bone catabolic activity of PTH by decreasing bone marrow SC number, the receptor activator of nuclear factor kappa B ligand (RANKL)/OSTEOPROTE GERN (OPG) ratio, and osteoclastogenic activity. Therefore, T cells play an essential permissive role in hyperparathyroidism as they influence SC proliferation, life span, and function through CD40L. T cell SC crosstalk pathways may thus provide pharmacological targets for PTH induced bone disease.
C1 [Gao, Yuhao; Wu, Xiaojun; Terauchi, Masakazu; Li, Jau Yi; Grassi, Francesco; Galley, Sarah; Yang, Xiaoying; Weitzmann, M. Neale; Pacifici, Roberto] Emory Univ, Dept Med, Div Endocrinol, Atlanta, GA 30322 USA.
   [Pacifici, Roberto] Emory Univ, Immunol & Mol Pathogenesis Program, Atlanta, GA 30322 USA.
C3 Emory University; Emory University
RP Pacifici, R (通讯作者)，Emory Univ, Dept Med, Div Endocrinol, Atlanta, GA 30322 USA.
EM roberto.pacifici@emory.edu
RI ; Grassi, Francesco/AAE 2443 2021
OI Grassi, Francesco/0000 0002 5127 9561; 
FU NIAMS NIH HHS [P30 AR046031, AR54625, R01 AR054625, AR053607,
   P30 AR46031, R21 AR053607] Funding Source: Medline; NIA NIH HHS
   [AG28278, R01 AG028278] Funding Source: Medline; NIDDK NIH HHS
   [DK067389, R21 DK067389, T32 DK007298] Funding Source: Medline
CR Ahuja SS, 2003, ENDOCRINOLOGY, V144, P1761, DOI 10.1210/en.2002 221136
   ALEXIEWICZ JM, 1990, J AM SOC NEPHROL, V1, P236
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   Chen SH, 2000, MOL THER, V2, P39, DOI 10.1006/mthe.2000.0086
   Cheng X, 2007, BONE, V40, P169, DOI 10.1016/j.bone.2006.06.018
   CLARK P, 1990, AM J CLIN PATHOL, V94, P632, DOI 10.1093/ajcp/94.5.632
   Clowes JA, 2005, IMMUNOL REV, V208, P207, DOI 10.1111/j.0105 2896.2005.00334.x
   Corbi AL, 1997, LEUKEMIA LYMPHOMA, V25, P415, DOI 10.3109/10428199709039028
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   Dempster DW, 1999, J CLIN ENDOCR METAB, V84, P1562, DOI 10.1210/jc.84.5.1562
   Di Rosa F, 2005, TRENDS IMMUNOL, V26, P360, DOI 10.1016/j.it.2005.04.011
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   Gao YH, 2004, P NATL ACAD SCI USA, V101, P16618, DOI 10.1073/pnas.0404888101
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Grcevic D, 2000, J IMMUNOL, V165, P4231, DOI 10.4049/jimmunol.165.8.4231
   Grey AB, 1996, CLIN ENDOCRINOL, V44, P697
   GUISE TA, 1992, LAB INVEST, V67, P477
   Hory BG, 2000, J ENDOCRINOL INVEST, V23, P273, DOI 10.1007/BF03343723
   Iida Klein A, 2005, J ENDOCRINOL, V186, P549, DOI 10.1677/joe.1.06270
   Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838
   Koh AJ, 2005, ENDOCRINOLOGY, V146, P4584, DOI 10.1210/en.2005 0333
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Lee SK, 2006, J BONE MINER RES, V21, P1704, DOI 10.1359/JBMR.060726
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Lotinun S, 2004, J BONE MINER RES, V19, P1165, DOI 10.1359/JBMR.040404
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   MEHDIZADEH S, 1989, BIOCHEM BIOPH RES CO, V161, P1166, DOI 10.1016/0006 291X(89)91364 8
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   O'Sullivan B, 2003, CURR OPIN HEMATOL, V10, P272, DOI 10.1097/00062752 200307000 00004
   OBRIEN C, 2006, J BONE MINER RES, V21, P1111
   PARISIEN M, 2001, PARATHYROIDS BASIC C, P423
   Partlow D. P., 1987, Journal of Materials Research, V2, P595, DOI 10.1557/JMR.1987.0595
   Potts J, 1998, METABOLIC BONE DIS, P411
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Rifas L, 1999, J BONE MINER RES, V14, P1096, DOI 10.1359/jbmr.1999.14.7.1096
   Rifas L, 2003, ARTHRITIS RHEUM US, V48, P993, DOI 10.1002/art.10872
   Rifas L, 2003, J CELL BIOCHEM, V88, P650, DOI 10.1002/jcb.10436
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605
   SCHACHTER P, 1990, SURGERY, V108, P1040
   SHURTZSWIRSKI R, 1995, NEPHRON, V70, P21, DOI 10.1159/000188538
   SILVERBERG SJ, 1989, J BONE MINER RES, V4, P283, DOI 10.1002/jbmr.5650040302
   Strieth S, 2005, TRANSPLANTATION, V79, P392, DOI 10.1097/01.TP.0000151633.92173.75
   Tanaka Y, 2000, J BONE MINER RES, V15, P1912, DOI 10.1359/jbmr.2000.15.10.1912
   Taubman MA, 2001, CRIT REV ORAL BIOL M, V12, P125, DOI 10.1177/10454411010120020301
   Teitelbaum SL, 2004, P NATL ACAD SCI USA, V101, P16711, DOI 10.1073/pnas.0407335101
   Toraldo G, 2003, P NATL ACAD SCI USA, V100, P125, DOI 10.1073/pnas.0136772100
   UY HL, 1995, ENDOCRINOLOGY, V136, P3207, DOI 10.1210/en.136.8.3207
   Weir EC, 1996, J BONE MINER RES, V11, P1474
   Weitzmann MN, 2005, IMMUNOL REV, V208, P154, DOI 10.1111/j.0105 2896.2005.00324.x
   Young N, 2005, J IMMUNOL, V175, P8287, DOI 10.4049/jimmunol.175.12.8287
   Zhou H, 2001, J BONE MINER RES, V16, P1300, DOI 10.1359/jbmr.2001.16.7.1300
NR 55
TC 105
Z9 124
U1 0
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1550 4131
EI 1932 7420
J9 CELL METAB
JI Cell Metab.
PD AUG 6
PY 2008
VL 8
IS 2
BP 132
EP 145
DI 10.1016/j.cmet.2008.07.001
PG 14
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 335AH
UT WOS:000258262700006
PM 18680714
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Smargiassi, A
   Bertacchini, J
   Checchi, M
   Potì, F
   Tenedini, E
   Montosi, G
   Magarò, MS
   Amore, E
   Cavani, F
   Ferretti, M
   Grisendi, G
   Maurel, DB
   Palumbo, C
AF Smargiassi, Alberto
   Bertacchini, Jessika
   Checchi, Marta
   Poti, Francesco
   Tenedini, Elena
   Montosi, Giuliana
   Magaro, Maria Sara
   Amore, Emanuela
   Cavani, Francesco
   Ferretti, Marzia
   Grisendi, Giulia
   Maurel, Delphine B.
   Palumbo, Carla
TI WISP 2 expression induced by Teriparatide treatment affects in
   vitro osteoblast differentiation and improves in vivo
   osteogenesis
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Bone cells; Wnt signaling; Teriparatide; Wisp 2
ID PARATHYROID HORMONE 1 34; BONE; OSTEOCYTES; MECHANISMS; DENSITY;
   SKELETAL; RANKL; CELLS; PTH
AB The Osteocyte, recognized as a major orchestrator of osteoblast and osteoclast activity, is the most important key player during bone remodeling processes. Imbalances occurring during bone remodeling, caused by hormone perturbations or by mechanical loading alterations, can induce bone pathologies such as osteoporosis. Recently, the active fraction of parathormone, PTH (1 34) or Teriparatide (TPTD), was chosen as election treatment for osteoporosis. The effect of such therapy is dependent on the temporal manner of administration. The molecular reasons why the type of administration regimen is so critical for the fate of bone remodeling are numerous and not yet well known. Our study attempts to analyze diverse signaling pathways directly activated in osteocytes upon TPTD treatment. By means of gene array analysis, we found many molecules upregulated or downregulated in osteocytes. Later, we paid attention to Wisp 2, a protein involved in the Wnt pathway, that is secreted by MLO Y4 cells and increases upon TPTD treatment and that is able to positively influence the early phases of osteogenic differentiation. We also confirmed the pro osteogenic property of Wisp 2 during mesenchymal stem cell differentiation into the preliminary osteoblast phenotype. The same results were confirmed with an in vivo approach confirming a remarkable Wisp 2 expression in metaphyseal trabecular bone. These results highlighted the anabolic roles unrolled by osteocytes in controlling the action of neighboring cells, suggesting that the perturbation of certain signaling cascades, such as the Wnt pathway, is crucial for the positive regulation of bone formation.
C1 [Smargiassi, Alberto] Indiana Ctr Musculoskeletal Hlth ICMH, Univ Bldg, Indianapolis, IN USA.
   [Bertacchini, Jessika; Checchi, Marta; Magaro, Maria Sara; Amore, Emanuela; Cavani, Francesco; Ferretti, Marzia; Palumbo, Carla] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Sect Human Morphol, Modena, Italy.
   [Poti, Francesco] Univ Parma, Dept Med & Surg, Unit Neurosci, Parma, Italy.
   [Tenedini, Elena] Univ Modena & Reggio Emilia, Ctr Genome Res, Dept Med & Surg Sci, Modena, Italy.
   [Montosi, Giuliana] Univ Modena & Reggio Emilia, Ctr Hemochromatosis, Dept Internal Med 2, Modena, Italy.
   [Grisendi, Giulia] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Lab Expt Epileptol, Modena, Italy.
   [Maurel, Delphine B.] Univ Bordeaux, Pharmaceut Sci Dept, INSERM, BioTis,Unit 1026, Bordeaux, France.
C3 Universita di Modena e Reggio Emilia; University of Parma; Universita di
   Modena e Reggio Emilia; Universita di Modena e Reggio Emilia; Universita
   di Modena e Reggio Emilia; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Bordeaux
RP Bertacchini, J; Checchi, M (通讯作者)，Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Sect Human Morphol, Modena, Italy.
EM jbertacchini@unimore.it
RI Grisendi, Giulia/J 6360 2016; Ferretti, Marzia/F 1153 2016; Cavani,
   Francesco/B 2907 2016; Palumbo, Carla/V 5905 2019; Poti,
   Francesco/O 6600 2016; Checchi, Marta/GOH 0179 2022; BERTACCHINI,
   JESSIKA/F 4382 2017; Amore, Emanuela/LSK 3949 2024; tenedini,
   elena/ABB 3411 2020
OI Amore, Emanuela/0000 0001 6348 4960; TENEDINI,
   Elena/0000 0003 0285 765X; Poti, Francesco/0000 0002 1708 0719; Checchi,
   Marta/0000 0002 6399 3172; 
FU University of Modena; Eli Lilly (U.S.A); funds "Department of Excellence
   2018 2021" (Department of Biomedical, Metabolic and Neural Sciences);
   Reggio Emilia
FX This study was supported by funds from the University of Modena and
   Reggio Emilia, Departmental grant FAR 2015 FAR 2017. Grant from
   Eli Lilly (U.S.A). The study was also supported by funds "Department of
   Excellence 2018 2021" (Department of Biomedical, Metabolic and Neural
   Sciences).
CR Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Bellido T, 2013, BONE, V54, P250, DOI 10.1016/j.bone.2012.09.016
   Bertacchini J, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6020061
   Bertacchini J, 2017, J ANAT, V231, P823, DOI 10.1111/joa.12685
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Cavani F, 2017, J ANAT, V230, P75, DOI 10.1111/joa.12533
   DODDS RA, 1993, J BONE MINER RES, V8, P261
   Ferretti M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030753
   Giannotti S, 2013, CLIN CASES MINER BON, V10, P116, DOI 10.11138/ccmbm/2013.10.2.116
   Grisendi G., 2011, J UROLOGY, V185, P751, DOI [10.1016/j.juro.2010.10.008, DOI 10.1016/J.JURO.2010.10.008]
   Grünberg JR, 2014, J BIOL CHEM, V289, P6899, DOI 10.1074/jbc.M113.511964
   Guimaraes GN, 2013, ARCH ORAL BIOL, V58, P638, DOI 10.1016/j.archoralbio.2012.11.011
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hammarstedt A, 2013, P NATL ACAD SCI USA, V110, P2563, DOI 10.1073/pnas.1211255110
   Hao ZC, 2017, RSC ADV, V7, P50200, DOI 10.1039/c7ra09308j
   Iida Klein A, 2005, J ENDOCRINOL, V186, P549, DOI 10.1677/joe.1.06270
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097 2765(01)00224 6
   Marotti G, 2007, EUR J HISTOCHEM, V51, P15
   Maycas M, 2015, J BONE MINER RES, V30, P1231, DOI 10.1002/jbmr.2439
   Nakashima Tomoki, 2012, Clin Calcium, V22, P685, DOI CliCa1205685696
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ono M, 2011, J BONE MINER RES, V26, P193, DOI 10.1002/jbmr.205
   Osagie Clouard L, 2017, BONE JOINT RES, V6, P14, DOI 10.1302/2046 3758.61.BJR 2016 0085.R1
   Pietrzyk B, 2017, ADV CLIN EXP MED, V26, P1283, DOI 10.17219/acem/68739
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Riek Amy E, 2011, Mo Med, V108, P118
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Sims NA, 2012, CURR OSTEOPOROS REP, V10, P109, DOI 10.1007/s11914 012 0096 1
   SKERRY TM, 1989, J BONE MINER RES, V4, P783, DOI 10.1002/jbmr.5650040519
   Sugiura T, 2015, SPINE J, V15, P298, DOI 10.1016/j.spinee.2014.08.001
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Vezeridis PS, 2006, BIOCHEM BIOPH RES CO, V348, P1082, DOI 10.1016/j.bbrc.2006.07.146
   Weinstein RS, 2011, ENDOCRINOLOGY, V152, P3323, DOI 10.1210/en.2011 0170
   Woo SM, 2011, J BONE MINER RES, V26, P2634, DOI 10.1002/jbmr.465
   Xiong JH, 2014, BONE, V66, P146, DOI 10.1016/j.bone.2014.06.006
NR 42
TC 10
Z9 10
U1 2
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
EI 1872 8057
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD AUG 1
PY 2020
VL 513
AR 110817
DI 10.1016/j.mce.2020.110817
PG 14
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA MK3WH
UT WOS:000548713200002
PM 32439416
DA 2025 08 17
ER

PT J
AU Wein, MN
   Kronenberg, HM
AF Wein, Marc N.
   Kronenberg, Henry M.
TI Regulation of Bone Remodeling by Parathyroid Hormone
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID KAPPA B LIGAND; SALT INDUCIBLE KINASES; MESENCHYMAL STEM CELLS;
   GROWTH FACTOR I; T CELLS; RECEPTOR ACTIVATOR; ANABOLIC ACTIVITY;
   OSTEOBLAST DIFFERENTIATION; GENE EXPRESSION; PTH RECEPTOR
AB Parathyroid hormone (PTH) exerts profound effects on skeletal homeostasis through multiple cellular and molecular mechanisms. Continuous hyperparathyroidism causes net loss of bone mass, despite accelerating bone formation by osteoblasts. Intermittent treatment with PTH analogs represents the only food and Drug Administration (FDA) approved bone anabolic osteoporosis treatment strategy. Functional PTH receptors are present on cells of the osteoblast lineage, ranging from early skeletal stem cells to matrix embedded osteocytes. In addition, bone remodeling by osteoclasts liberates latent growth factors present within bone matrix. Here, we will provide an overview of the multiple cellular and molecular mechanisms through which PTH influences bone homeostasis. Notably, net skeletal effects of continuous versus intermittent can differ significantly. Where possible, we will highlight mechanisms through which continuous hyperparathyroidism leads to bone loss, and through which intermittent hyperparathyroidism boosts bone mass. Given the therapeutic usage of intermittent PTH (iPTH) treatment for osteoporosis, particular attention will be paid toward mechanisms underlying the bone anabolic effects of once daily PTH administration.
C1 [Wein, Marc N.; Kronenberg, Henry M.] Harvard Med Sch, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard Medical School
RP Wein, MN (通讯作者)，Harvard Med Sch, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
EM mnwein@mgh.harvard.edu
RI KRONENBERG, HENRY/MXK 0923 2025
FU NIAMS NIH HHS [K08 AR067285] Funding Source: Medline
CR Akhouayri O, 2005, MOL CELL BIOL, V25, P3452, DOI 10.1128/MCB.25.9.3452 3460.2005
   Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324
   Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004
   Atfi A, 2010, NAT CELL BIOL, V12, P205, DOI 10.1038/ncb0310 205
   Baertschi S, 2014, J BIOL CHEM, V289, P24995, DOI 10.1074/jbc.M114.564997
   Balani DH, 2017, J CLIN INVEST, V127, P3333, DOI 10.1172/JCI91699
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bedi B, 2012, P NATL ACAD SCI USA, V109, pE725, DOI 10.1073/pnas.1120735109
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Ben Awadh AN, 2014, ENDOCRINOLOGY, V155, P2797, DOI 10.1210/en.2014 1046
   Bikle Daniel D, 2012, Curr Mol Pharmacol, V5, P135
   Bikle DD, 2002, J BONE MINER RES, V17, P1570, DOI 10.1359/jbmr.2002.17.9.1570
   Bilezikian JP, 2011, J BONE MINER RES, V26, P2317, DOI 10.1002/jbmr.483
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Burnett SH, 2004, J LEUKOCYTE BIOL, V75, P612, DOI 10.1189/jlb.0903442
   CAMERON DA, 1967, J CELL BIOL, V33, P1, DOI 10.1083/jcb.33.1.1
   CANAS F, 1969, AM J PHYSIOL, V217, P117, DOI 10.1152/ajplegacy.1969.217.1.117
   Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Cho SW, 2014, P NATL ACAD SCI USA, V111, P1545, DOI 10.1073/pnas.1315153111
   Clark K, 2012, P NATL ACAD SCI USA, V109, P16986, DOI 10.1073/pnas.1215450109
   Collette NM, 2012, P NATL ACAD SCI USA, V109, P14092, DOI 10.1073/pnas.1207188109
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   Crane JL, 2014, J MOL MED, V92, P107, DOI 10.1007/s00109 013 1084 3
   Croft M, 2017, NAT REV RHEUMATOL, V13, P217, DOI 10.1038/nrrheum.2017.22
   D'Amelio P, 2015, OSTEOPOROSIS INT, V26, P2785, DOI 10.1007/s00198 015 3189 8
   Delgado Calle J, 2017, J BONE MINER RES, V32, P522, DOI 10.1002/jbmr.3011
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Esen E, 2015, J BONE MINER RES, V30, P2137, DOI 10.1002/jbmr.2714
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   Fan Y, 2017, CELL METAB, V25, P661, DOI 10.1016/j.cmet.2017.01.001
   Fei YR, 2015, J BIOL CHEM, V290, P8373, DOI 10.1074/jbc.M114.602763
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Finkelstein JS, 2006, J CLIN ENDOCR METAB, V91, P2882, DOI 10.1210/jc.2006 0190
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Finkelstein JS, 2009, J CLIN ENDOCR METAB, V94, P2495, DOI 10.1210/jc.2009 0154
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Fu Q, 2006, MOL CELL BIOL, V26, P6453, DOI 10.1128/MCB.00356 06
   Galli C, 2008, ENDOCRINOLOGY, V149, P146, DOI 10.1210/en.2007 0734
   Gao Y, 2008, CELL METAB, V8, P132, DOI 10.1016/j.cmet.2008.07.001
   Gensure RC, 2005, BIOCHEM BIOPH RES CO, V328, P666, DOI 10.1016/j.bbrc.2004.11.069
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Hariri HP, 2017, CURR MOL BIOL REP, V141, P28
   HELLER M, 1950, AM J ANAT, V87, P315, DOI 10.1002/aja.1000870302
   Henriksson E, 2012, BIOCHEM J, V444, P503, DOI 10.1042/BJ20111932
   Hurley MM, 2006, BIOCHEM BIOPH RES CO, V341, P989, DOI 10.1016/j.bbrc.2006.01.044
   Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436
   Jähn K, 2017, J BONE MINER RES, V32, P1761, DOI 10.1002/jbmr.3167
   Jang MG, 2016, J BONE MINER METAB, V34, P532, DOI 10.1007/s00774 015 0707 x
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kedlaya R, 2016, ENDOCRINOLOGY, V157, P3047, DOI 10.1210/en.2015 1587
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kim SW, 2017, J BONE MINER RES, V32, P892, DOI 10.1002/jbmr.3038
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Kim S, 2007, MOL ENDOCRINOL, V21, P197, DOI 10.1210/me.2006 0315
   Kim S, 2006, MOL CELL BIOL, V26, P6469, DOI 10.1128/MCB.00353 06
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Kovacs CS, 1997, ENDOCR REV, V18, P832, DOI 10.1210/er.18.6.832
   Kozhemyakina E, 2009, MOL CELL BIOL, V29, P5751, DOI 10.1128/MCB.00415 09
   Kramer I, 2012, J BONE MINER RES, V27, P360, DOI 10.1002/jbmr.1492
   Kramer I, 2010, J BONE MINER RES, V25, P178, DOI 10.1359/jbmr.090730
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   LEAFFER D, 1995, ENDOCRINOLOGY, V136, P3624, DOI 10.1210/en.136.8.3624
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Li C., 2015, ANN NY ACAD SCI, V1364, P62
   Li CJ, 2013, J BONE MINER RES, V28, P2094, DOI 10.1002/jbmr.1962
   Li JY, 2015, CELL METAB, V22, P799, DOI 10.1016/j.cmet.2015.09.012
   Li JY, 2014, J BONE MINER RES, V29, P43, DOI 10.1002/jbmr.2044
   Li JY, 2013, BLOOD, V122, P2346, DOI 10.1182/blood 2013 03 487801
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Lim J, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.49
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Lu Y, 2007, J DENT RES, V86, P320, DOI 10.1177/154405910708600404
   Matic I, 2016, STEM CELLS, V34, P2930, DOI 10.1002/stem.2474
   Matsuoka K, 2014, J BONE MINER RES, V29, P1522, DOI 10.1002/jbmr.2187
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   MILLER SC, 1980, ANAT RECORD, V198, P163, DOI 10.1002/ar.1091980204
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nango N, 2016, BONE, V84, P279, DOI 10.1016/j.bone.2015.12.006
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Nioi P, 2015, J BONE MINER RES, V30, P1457, DOI 10.1002/jbmr.2482
   NISHIDA S, 1994, BONE, V15, P717, DOI 10.1016/8756 3282(94)90322 0
   O'Brien CA, 2013, BONE, V54, P258, DOI 10.1016/j.bone.2012.08.121
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Obri A, 2014, J CELL BIOL, V205, P771, DOI 10.1083/jcb.201403138
   Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017
   Ono N, 2014, NAT CELL BIOL, V16, P1157, DOI 10.1038/ncb3067
   OWEN M, 1988, CIBA F SYMP, V136, P42
   Pacifici R, 2016, ANN NY ACAD SCI, V1364, P11, DOI 10.1111/nyas.12969
   Pacifici R, 2013, ENDOCRINE, V44, P576, DOI 10.1007/s12020 013 9960 8
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Pellicelli M, 2014, MOL CELL BIOL, V34, P1622, DOI 10.1128/MCB.01434 13
   PFEILSCHIFTER J, 1995, J CLIN INVEST, V96, P767, DOI 10.1172/JCI118121
   Prideaux M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125731
   Qing H, 2012, J BONE MINER RES, V27, P1018, DOI 10.1002/jbmr.1567
   Qiu T, 2010, NAT CELL BIOL, V12, P224, DOI 10.1038/ncb2022
   Rhee Y, 2013, J BIOL CHEM, V288, P29809, DOI 10.1074/jbc.M113.485938
   Rhee Y, 2011, J BONE MINER RES, V26, P1035, DOI 10.1002/jbmr.304
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Romero G, 2010, J BIOL CHEM, V285, P14756, DOI 10.1074/jbc.M110.102970
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Shimazu J, 2016, CELL REP, V15, P27, DOI 10.1016/j.celrep.2016.03.003
   Shimizu E, 2014, J BIOL CHEM, V289, P21340, DOI 10.1074/jbc.M114.550699
   Shimizu E, 2010, J BIOL CHEM, V285, P9616, DOI 10.1074/jbc.M109.094862
   Shu L, 2013, J BONE MINER RES, V28, P1925, DOI 10.1002/jbmr.1938
   Silva BC, 2011, J ENDOCRINOL INVEST, V34, P801, DOI 10.3275/7925
   Sinder BP, 2017, J BONE MINER RES, V32, P2116, DOI 10.1002/jbmr.3196
   Sinha P, 2016, J BIOL CHEM, V291, P1631, DOI 10.1074/jbc.M115.679753
   Sinha P, 2014, J BONE MINER RES, V29, P2414, DOI 10.1002/jbmr.2270
   Spatz JM, 2015, J BIOL CHEM, V290, P16744, DOI 10.1074/jbc.M114.628313
   St John HC, 2016, J STEROID BIOCHEM, V164, P277, DOI 10.1016/j.jsbmb.2015.09.005
   St John HC, 2015, BONE, V72, P81, DOI 10.1016/j.bone.2014.11.010
   St John HC, 2014, MOL ENDOCRINOL, V28, P1150, DOI 10.1210/me.2014 1091
   Sundberg TB, 2016, ACS CHEM BIOL, V11, P2105, DOI 10.1021/acschembio.6b00217
   Sundberg TB, 2014, P NATL ACAD SCI USA, V111, P12468, DOI 10.1073/pnas.1412308111
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Takeshita S, 2013, J CLIN INVEST, V123, P3914, DOI 10.1172/JCI69493
   Takyar FM, 2013, J BONE MINER RES, V28, P912, DOI 10.1002/jbmr.1820
   TALMAGE RV, 1970, AM J ANAT, V129, P467, DOI 10.1002/aja.1001290408
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tawfeek H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012290
   Tazawa K, 2004, J BONE MINER METAB, V22, P524, DOI 10.1007/s00774 004 0519 x
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Tobimatsu T, 2006, ENDOCRINOLOGY, V147, P2583, DOI 10.1210/en.2005 1627
   Tonna S, 2014, FASEB J, V28, P4482, DOI 10.1096/fj.14 254300
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Walker EC, 2008, J BONE MINER RES, V23, P2025, DOI [10.1359/jbmr.080706, 10.1359/JBMR.080706]
   Wan M, 2008, GENE DEV, V22, P2968, DOI 10.1101/gad.1702708
   Wang YM, 2007, J BONE MINER RES, V22, P1329, DOI 10.1359/JBMR.070517
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Wein MN, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13176
   Wein Marc N, 2015, J Bone Miner Res, V30, P400, DOI 10.1002/jbmr.2381
   WEISBRODE SE, 1974, AM J PATHOL, V75, P529
   Woo SM, 2011, J BONE MINER RES, V26, P2634, DOI 10.1002/jbmr.465
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
   Wu XW, 2010, CELL STEM CELL, V7, P571, DOI 10.1016/j.stem.2010.09.012
   Wysolmerski JJ, 2013, BONE, V54, P230, DOI 10.1016/j.bone.2013.01.025
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xiong JH, 2014, BONE, V66, P146, DOI 10.1016/j.bone.2014.06.006
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yang MY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05401 1
   Zhang JZ, 2016, J BONE MINER RES, V31, P2001, DOI 10.1002/jbmr.2877
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 168
TC 173
Z9 193
U1 2
U2 22
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157 1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD AUG
PY 2018
VL 8
IS 8
AR a031237
DI 10.1101/cshperspect.a031237
PG 20
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GS4FG
UT WOS:000443592800011
PM 29358318
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Ma, S
   Wang, DD
   Ma, CY
   Zhang, YD
AF Ma, Shu
   Wang, Dan Dan
   Ma, Cheng Yuan
   Zhang, Yan Dong
TI microRNA 96 promotes osteoblast differentiation and bone formation in
   ankylosing spondylitis mice through activating the Wnt signaling pathway
   by binding to SOST
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE ankylosing spondylitis; bone formation; microRNA 96; osteoblast
   differentiation; sclerostin; Wnt signaling pathway
ID EXPRESSION; CELLS; PROGRESSION; SCLEROSTIN; THERAPY; TARGETS; BETA
AB Ankylosing spondylitis (AS) refers to a type of arthritis manifested with chronic inflammation of spine joints. microRNAs (MiRNAs) have been identified as new therapeutic targets for inflammatory diseases. In this study, we evaluated the influence of microRNA 96 (miR 96) on osteoblast differentiation together with bone formation in a murine model of AS. The speculated relationship that miR 96 could bind to sclerostin (SOST) was verified by dual luciferase reporter assay. After successful model establishment, the mice with AS and osteoblasts isolated from mice with AS were treated with mimics or inhibitors of miR 96, or DKK 1 (a Wnt signaling inhibitor). The effects of gain  or loss of function of miR 96 on the inflammatory cytokine release (IL 6, IL 10, and TNF alpha), alkaline phosphatase (ALP) activity, calcium nodule formation, along with the viability of osteoblasts were determined. It was observed that miR 96 might target and regulate SOST. Besides, miR 96 was expressed at a high level in AS mice while SOST expressed at a low level. TOP/FOP Flash luciferase reporter assay confirmed that miR 96 activated the Wnt signaling pathway. Moreover, AS mice overexpressing miR 96 exhibited increased contents of IL 6, IL 10 and TNF alpha, ALP activity, calcium nodule numbers, and viability of osteoblasts. In contrast, inhibition of miR 96 resulted in suppression of the osteoblast differentiation and bone formation. In conclusion, the study implicates that overexpressing miR 96 could improve osteoblast differentiation and bone formation in AS mice via Wnt signaling pathway activation, highlighting a potential new target for AS treatment.
C1 [Ma, Shu; Zhang, Yan Dong] Jilin Univ, Hosp 1, Dept Rheumatol, 71 Xinminzhu St, Changchun 130021, Jilin, Peoples R China.
   [Wang, Dan Dan] Jilin Univ, Hosp 1, Dept Neurol, Changchun, Jilin, Peoples R China.
   [Ma, Cheng Yuan] Jilin Univ, Hosp 1, Dept Neurosurg, Changchun, Jilin, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Zhang, YD (通讯作者)，Jilin Univ, Hosp 1, Dept Rheumatol, 71 Xinminzhu St, Changchun 130021, Jilin, Peoples R China.
EM zhangyd78@126.com
CR Azzouzi I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022838
   Bleil J, 2015, SCAND J RHEUMATOL, V44, P296, DOI 10.3109/03009742.2014.1000371
   Brown MA, 2016, NAT REV RHEUMATOL, V12, P81, DOI 10.1038/nrrheum.2015.133
   Chang JL, 2010, EMBO REP, V11, P765, DOI 10.1038/embor.2010.135
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen L, 2017, ANN RHEUM DIS, V76, P620, DOI 10.1136/annrheumdis 2016 210175
   Corr M, 2014, CLIN RHEUMATOL, V33, P759, DOI 10.1007/s10067 014 2663 6
   Di GJ, 2018, BIOMED PHARMACOTHER, V97, P1243, DOI 10.1016/j.biopha.2017.11.067
   Duchartre Y, 2016, CRIT REV ONCOL HEMAT, V99, P141, DOI 10.1016/j.critrevonc.2015.12.005
   Gao F, 2015, MOL MED REP, V11, P1200, DOI 10.3892/mmr.2014.2854
   Haynes KR, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0823 8
   Haynes KR, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4096
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   Jethwa H, 2016, CLIN EXP IMMUNOL, V183, P30, DOI 10.1111/cei.12670
   Jia J, 2017, MOL MED REP, V15, P1539, DOI 10.3892/mmr.2017.6168
   Jiang Y, 2016, MOL MED REP, V13, P35, DOI 10.3892/mmr.2015.4494
   Lai NS, 2013, CLIN EXP IMMUNOL, V173, P47, DOI 10.1111/cei.12089
   Li JQ, 2016, J BONE MINER METAB, V34, P367, DOI 10.1007/s00774 015 0734 7
   Li J, 2015, TUMOR BIOL, V36, P685, DOI 10.1007/s13277 014 2698 y
   Li Z, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003325
   Liu H, 2018, CLIN EXP PHARMACOL P, V45, P602, DOI 10.1111/1440 1681.12912
   Tricás Moreno JM, 2016, J PHYS THER SCI, V28, P1392, DOI 10.1589/jpts.28.1392
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Mohammadi H, 2018, J CELL PHYSIOL, V233, P5564, DOI 10.1002/jcp.26500
   Perrotta FM, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/9101964
   Solmaz D, 2018, INT J RHEUM DIS, V21, P502, DOI 10.1111/1756 185X.13186
   Stebbings SM, 2009, J RHEUMATOL, V36, P797, DOI 10.3899/jrheum.080964
   Taipaleenmäki H, 2012, EUR J ENDOCRINOL, V166, P359, DOI 10.1530/EJE 11 0646
   Ustun N, 2014, ACTA REUMATOL PORT, V39, P146
   Vishwamitra D, 2012, AM J PATHOL, V180, P1772, DOI 10.1016/j.ajpath.2012.01.008
   Wang XB, 2017, GENES IMMUN, V18, P184, DOI 10.1038/gene.2017.19
   Wang YH, 2017, CELL PHYSIOL BIOCHEM, V42, P2481, DOI 10.1159/000480211
   Xia Y, 2015, MOD RHEUMATOL, V25, P784, DOI 10.3109/14397595.2015.1023887
   Xie Jianmin, 2015, Zhonghua Yi Xue Za Zhi, V95, P1300
   Xie WQ, 2016, ANN NY ACAD SCI, V1364, P25, DOI 10.1111/nyas.12968
   Yang MF, 2014, FEBS LETT, V588, P4761, DOI 10.1016/j.febslet.2014.11.008
   Yildiz F, 2016, ACTA ORTHOP TRAUMATO, V50, P63, DOI 10.3944/AOTT.2016.14.0059
   Yu B, 2017, CELL PHYSIOL BIOCHEM, V41, P2489, DOI 10.1159/000475941
   Zhang N, 2015, EXP CELL RES, V336, P33, DOI 10.1016/j.yexcr.2015.05.023
NR 39
TC 55
Z9 64
U1 1
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP
PY 2019
VL 120
IS 9
BP 15429
EP 15442
DI 10.1002/jcb.28810
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA IK7WN
UT WOS:000476804200116
PM 31111563
DA 2025 08 17
ER

PT J
AU Palani, HK
   Ganesan, S
   Balasundaram, N
   Venkatraman, A
   Korula, A
   Abraham, A
   George, B
   Mathews, V
AF Palani, Hamenth Kumar
   Ganesan, Saravanan
   Balasundaram, Nithya
   Venkatraman, Arvind
   Korula, Anu
   Abraham, Aby
   George, Biju
   Mathews, Vikram
TI Ablation of Wnt signaling in bone marrow stromal cells overcomes
   microenvironment mediated drug resistance in acute myeloid leukemia
SO SCIENTIFIC REPORTS
LA English
DT Article
ID STEM CELLS; NICHE; CHEMOTHERAPY; KINASE; INHIBITION; ACTIVATION;
   INDUCTION; ALPHA
AB The survival of leukemic cells is significantly influenced by the bone marrow microenvironment, where stromal cells play a crucial role. While there has been substantial progress in understanding the mechanisms and pathways involved in this crosstalk, limited data exist regarding the impact of leukemic cells on bone marrow stromal cells and their potential role in drug resistance. In this study, we identify that leukemic cells prime bone marrow stromal cells towards osteoblast lineage and promote drug resistance. This biased differentiation of stroma is accompanied by dysregulation of the canonical Wnt signaling pathway. Inhibition of Wnt signaling in stroma reversed the drug resistance in leukemic cells, which was further validated in leukemic mice models. This study evaluates the critical role of leukemic cells in establishing a drug resistant niche by influencing the bone marrow stromal cells. Additionally, it highlights the potential of targeting Wnt signaling in the stroma by repurposing an anthelmintic drug to overcome the microenvironment mediated drug resistance.
C1 [Palani, Hamenth Kumar; Ganesan, Saravanan; Balasundaram, Nithya; Venkatraman, Arvind; Korula, Anu; Abraham, Aby; George, Biju; Mathews, Vikram] Christian Med Coll & Hosp, Dept Haematol, Ranipet Campus, Vellore 632517, India.
C3 Christian Medical College & Hospital (CMCH) Vellore
RP Mathews, V (通讯作者)，Christian Med Coll & Hosp, Dept Haematol, Ranipet Campus, Vellore 632517, India.
EM vikram@cmcvellore.ac.in
RI ganesan, saravanan/AAA 3775 2019; Abraham, Aby/HZH 9492 2023
FU DST Core Research Grant [CRG/2019/001214]; Wellcome DBT India Alliance
   research grant [IA/CPHS/18/1/503930]; DBT COE grant, New Delhi, India
   [BT/COE/34/SP13432/2015]
FX This study is supported by the DST Core Research Grant (CRG/2019/001214)
   and partly from the Wellcome DBT India Alliance research grant
   (IA/CPHS/18/1/503930) and DBT COE grant (BT/COE/34/SP13432/2015), New
   Delhi, India. We acknowledge Intas Pharmaceutical Ltd, India, and NATCO
   Pharmaceutical Ltd, India, for kindly providing us with the API of the
   pharmaceutical drug (arsenic trioxide) for this study.
CR Abu Alex A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01357
   Azadniv M, 2020, LEUKEMIA, V34, P391, DOI 10.1038/s41375 019 0568 8
   Battula VL, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90036
   Ben Batalla I, 2013, BLOOD, V122, P2443, DOI 10.1182/blood 2013 03 491431
   Bowers M, 2015, BLOOD, V125, P2678, DOI 10.1182/blood 2014 06 582924
   Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chen YY, 2020, BLOOD ADV, V4, P5257, DOI 10.1182/bloodadvances.2020001808
   Chendamarai E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121912
   de la Guardia RD, 2017, STEM CELL REP, V8, P1573, DOI 10.1016/j.stemcr.2017.04.019
   Dosen Dahl G, 2008, INT J CANCER, V123, P2759, DOI 10.1002/ijc.23833
   Ganesan S, 2016, LEUKEMIA, V30, P2169, DOI 10.1038/leu.2016.227
   Ganesan S, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1964 8
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hanoun M, 2014, CELL STEM CELL, V15, P365, DOI 10.1016/j.stem.2014.06.020
   Ianevski A, 2022, NUCLEIC ACIDS RES, V50, pW739, DOI 10.1093/nar/gkac382
   Kode A, 2016, LEUKEMIA, V30, P1, DOI 10.1038/leu.2015.161
   Kode A, 2014, NATURE, V506, P240, DOI 10.1038/nature12883
   Konopleva M, 2002, LEUKEMIA, V16, P1713, DOI 10.1038/sj.leu.2402608
   Kumar B, 2018, LEUKEMIA, V32, P575, DOI 10.1038/leu.2017.259
   Lane SW, 2009, BLOOD, V114, P1150, DOI 10.1182/blood 2009 01 202606
   Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714
   Passaro D, 2017, CANCER CELL, V32, P324, DOI 10.1016/j.ccell.2017.08.001
   Pievani A, 2021, HAEMATOLOGICA, V106, P865, DOI 10.3324/haematol.2020.247205
   Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851
   Roozendaal R, 2011, ANNU REV IMMUNOL, V29, P23, DOI 10.1146/annurev immunol 031210 101357
   Schepers K, 2013, CELL STEM CELL, V13, P285, DOI 10.1016/j.stem.2013.06.009
   Son B, 2017, ONCOTARGET, V8, P3933, DOI 10.18632/oncotarget.13907
   Tabe Y, 2004, BLOOD, V103, P1815, DOI 10.1182/blood 2003 03 0802
   Tabe Y, 2007, CANCER RES, V67, P684, DOI 10.1158/0008 5472.CAN 06 3166
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Tarapore RS, 2016, J BONE MINER RES, V31, P52, DOI 10.1002/jbmr.2592
   Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453
   Ye HB, 2016, CELL STEM CELL, V19, P23, DOI 10.1016/j.stem.2016.06.001
   Zeng ZH, 2009, BLOOD, V113, P6215, DOI 10.1182/blood 2008 05 158311
   Zhang L, 2009, BLOOD, V114, P1545, DOI 10.1182/blood 2009 03 206672
NR 36
TC 5
Z9 5
U1 0
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD APR 10
PY 2024
VL 14
IS 1
AR 8404
DI 10.1038/s41598 024 58860 8
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NK3D0
UT WOS:001200298900004
PM 38600158
OA gold
DA 2025 08 17
ER

PT J
AU Saini, V
   Marengi, DA
   Barry, KJ
   Fulzele, KS
   Heiden, E
   Liu, X
   Dedic, C
   Maeda, A
   Lotinun, S
   Baron, R
   Pajevic, PD
AF Saini, Vaibhav
   Marengi, Dean A.
   Barry, Kevin J.
   Fulzele, Keertik S.
   Heiden, Erica
   Liu, Xiaolong
   Dedic, Christopher
   Maeda, Akira
   Lotinun, Sutada
   Baron, Roland
   Pajevic, Paola Divieti
TI Parathyroid Hormone (PTH)/PTH related Peptide Type 1 Receptor (PPR)
   Signaling in Osteocytes Regulates Anabolic and Catabolic Skeletal
   Responses to PTH
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID INCREASES BONE FORMATION; LINING CELLS; EXPRESSION; SOST; MASS;
   SCLEROSTIN; PROTEIN; OSTEOBLASTS; ACTIVATION; PREVENTION
AB Parathyroid hormone (PTH) is the only Food and Drug Administration approved anabolic agent to treat osteoporosis; however, the cellular targets of PTH action in bone remain controversial. PTH modulates bone turnover by binding to the PTH/PTH related peptide (PTHrP) type 1 receptor (PPR), a G protein coupled receptor highly expressed in bone and kidneys. Osteocytes, the most abundant cells in adult bone, also express PPR. However, the physiological relevance of PPR signaling in osteocytes remains to be elucidated. Toward this goal, we generated mice with PPR deletion in osteocytes (Ocy PPRKO). Skeletal analysis of these mice revealed a significant increase in bone mineral density and trabecular and cortical bone parameters. Osteoblast activities were reduced in these animals, as demonstrated by decreased collagen type I alpha 1 mRNA and receptor activator of NF kappa B ligand (RANKL) expression. Importantly, when subjected to an anabolic or catabolic PTH regimen, Ocy PPRKO animals demonstrated blunted skeletal responses. PTH failed to suppress SOST/Sclerostin or induce RANKL expression in Ocy PPRKO animals compared with controls. In vitro, osteoclastogenesis was significantly impaired in Ocy PPRKO upon PTH administration, indicating that osteocytes control osteoclast formation through a PPR mediated mechanism. Taken together, these data indicate that PPR signaling in osteocytes is required for bone remodeling, and receptor signaling in osteocytes is needed for anabolic and catabolic skeletal responses.
C1 [Saini, Vaibhav; Marengi, Dean A.; Barry, Kevin J.; Fulzele, Keertik S.; Heiden, Erica; Liu, Xiaolong; Dedic, Christopher; Maeda, Akira; Baron, Roland; Pajevic, Paola Divieti] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02114 USA.
   [Lotinun, Sutada; Baron, Roland] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Harvard University; Harvard
   School of Dental Medicine
RP Pajevic, PD (通讯作者)，Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Thier 1101, Boston, MA 02114 USA.
EM divieti@helix.mgh.harvard.edu
RI Pajevic, Paola/M 3236 2019
OI Divieti Pajevic, Paola/0000 0001 9853 9837
FU National Institutes of Health from the NIDDK [DK079161]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant DK079161 from the NIDDK (to P.D.P.).
CR Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Bonnet N, 2012, P NATL ACAD SCI USA, V109, P15048, DOI 10.1073/pnas.1203085109
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Collette NM, 2012, P NATL ACAD SCI USA, V109, P14092, DOI 10.1073/pnas.1207188109
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   FINKELSTEIN JS, 1994, NEW ENGL J MED, V331, P1618, DOI 10.1056/NEJM199412153312404
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Fulzele K, 2013, BLOOD, V121, P930, DOI 10.1182/blood 2012 06 437160
   Genetos DC, 2010, J CELL BIOCHEM, V110, P457, DOI 10.1002/jcb.22559
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Kobayashi T, 2002, DEVELOPMENT, V129, P2977
   Kramer I, 2012, J BONE MINER RES, V27, P360, DOI 10.1002/jbmr.1492
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   PARFITT AM, 1988, CALCIFIED TISSUE INT, V42, P284, DOI 10.1007/BF02556360
   Powell WF, 2011, J ENDOCRINOL, V209, P21, DOI 10.1530/JOE 10 0308
   Qing H, 2012, J BONE MINER RES, V27, P1018, DOI 10.1002/jbmr.1567
   Rhee Y, 2011, J BONE MINER RES, V26, P1035, DOI 10.1002/jbmr.304
   Riancho JA, 2012, PHARMACOGENOMICS, V13, P815, DOI [10.2217/PGS.12.50, 10.2217/pgs.12.50]
   Schaffler MB, 2012, CURR OSTEOPOROS REP, V10, P118, DOI 10.1007/s11914 012 0105 4
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Semenov MV, 2006, J BIOL CHEM, V281, P38276, DOI 10.1074/jbc.M609509200
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
NR 31
TC 123
Z9 157
U1 1
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 12
PY 2013
VL 288
IS 28
BP 20122
EP 20134
DI 10.1074/jbc.M112.441360
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 182BI
UT WOS:000321715100003
PM 23729679
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Chouinard, L
   Felx, M
   Mellal, N
   Varela, A
   Mann, P
   Jolette, J
   Samadfam, R
   Smith, SY
   Locher, K
   Buntich, S
   Ominsky, MS
   Pyrah, I
   Boyce, RW
AF Chouinard, Luc
   Felx, Melanie
   Mellal, Nacera
   Varela, Aurora
   Mann, Peter
   Jolette, Jacquelin
   Samadfam, Rana
   Smith, Susan Y.
   Locher, Kathrin
   Buntich, Sabina
   Ominsky, Michael S.
   Pyrah, Ian
   Boyce, Rogely Waite
TI Carcinogenicity risk assessment of romosozumab: A review of scientific
   weight of evidence and findings in a rat lifetime pharmacology study
SO REGULATORY TOXICOLOGY AND PHARMACOLOGY
LA English
DT Article
DE Romosozumab; Sclerostin antibody; Carcinogenicity; Chronic toxicity;
   Null antibody
ID PARATHYROID HORMONE 1 34; SCLEROSTIN ANTIBODY TREATMENT; INCREASES
   BONE FORMATION; OVARIECTOMIZED RATS; OSTEOBLAST LINEAGE; NEGATIVE
   REGULATOR; MINERAL DENSITY; MAMMARY GLANDS; CORTICAL BONE; IN VIVO
AB Romosozumab is a humanized immunoglobulin G(2) monoclonal antibody that binds and blocks the action of sclerostin, a protein secreted by the osteocyte and an extracellular inhibitor of canonical Wnt signaling. Blockade of sclerostin binding to low density lipoprotein receptor related proteins 5 and 6 (LRP5 and LRP6) allows Wnt ligands to activate canonical Wnt signaling in bone, increasing bone formation and decreasing bone resorption, making sclerostin an attractive target for osteoporosis therapy. Because romosozumab is a bone forming agent and an activator of canonical Wnt signaling, questions have arisen regarding a potential carcinogenic risk. Weight of evidence factors used in the assessment of human carcinogenic risk of romosozumab included features of canonical Wnt signaling, expression pattern of sclerostin, phenotype of loss of function mutations in humans and mice, mode and mechanism of action of romosozumab, and findings from romosozumab chronic toxicity studies in rats and monkeys. Although the weight of evidence factors supported that romosozumab would pose a low carcinogenic risk to humans, the carcinogenic potential of romosozumab was assessed in a rat lifetime study. There were no romosozumab related effects on tumor incidence in rats. The findings of the lifetime study and the weight of evidence factors collectively indicate that romosozumab administration would not pose a carcinogenic risk to humans. (C) 2016 Amgen Inc. Published by Elsevier Inc.
C1 [Chouinard, Luc; Felx, Melanie; Mellal, Nacera; Varela, Aurora; Jolette, Jacquelin; Samadfam, Rana; Smith, Susan Y.] Montreal ULC, Charles River Labs, 22022 Transcanadienne, Senneville, PQ H9X 3R3, Canada.
   [Mann, Peter] EPL NorthWest, 600 North 36th St,Suite 220, Seattle, WA 98103 USA.
   [Locher, Kathrin; Buntich, Sabina; Ominsky, Michael S.; Pyrah, Ian; Boyce, Rogely Waite] One Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.
RP Boyce, RW (通讯作者)，One Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.
EM rboyce@amgen.com
FU Amgen Inc.; UCB
FX Amgen Inc. and UCB provided funding for this study and the preparation
   of this article. The study sponsor was involved in study design, writing
   of the report, and in the decision to submit the article for
   publication.
CR Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Andrews EB, 2012, J BONE MINER RES, V27, P2429, DOI 10.1002/jbmr.1768
   BAILER AJ, 1988, BIOMETRICS, V44, P417, DOI 10.2307/2531856
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   BIELER GS, 1993, BIOMETRICS, V49, P793, DOI 10.2307/2532200
   BRADBURY JM, 1995, DEV BIOL, V170, P553, DOI 10.1006/dbio.1995.1236
   Food and Drug Administration (Fda), 2001, US FDA DRAFT GUID IN
   Fox J, 2006, CALCIFIED TISSUE INT, V79, P262, DOI 10.1007/s00223 006 0108 1
   Gesty Palmer D, 2013, MOL ENDOCRINOL, V27, P296, DOI 10.1210/me.2012 1091
   Gong J., 2016, ANN M ASBMR ATL GA
   Hall AP, 2015, TOXICOL PATHOL, V43, P384, DOI 10.1177/0192623314544468
   Harris D, 2015, PHARMACOEPIDEM DR S, V24, P547
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   ICH, 2015, S1 ICH
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Jolette J., 2014, ANN M AM SOC BON MIN
   Jolette J, 2006, TOXICOL PATHOL, V34, P929, DOI 10.1080/01926230601072301
   Jones Kevin B., 2011, Sarcoma, V2011, P1, DOI 10.1155/2011/694136
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593
   Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130
   Lewiecki EM, 2014, THER ADV MUSCULOSKEL, V6, P48, DOI 10.1177/1759720X13510479
   Li XD, 2014, ENDOCRINOLOGY, V155, P4785, DOI 10.1210/en.2013 1905
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200
   Liu HJ, 2010, J CELL BIOCHEM, V111, P529, DOI 10.1002/jcb.22749
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Nioi P, 2015, J BONE MINER RES, V30, P1457, DOI 10.1002/jbmr.2482
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092 8674(82)90409 3
   Ominsky MS, 2015, BONE, V81, P380, DOI 10.1016/j.bone.2015.08.007
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Peto R, 1980, IARC Monogr Eval Carcinog Risk Chem Hum Suppl, P311
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Qin L, 2005, J BIOL CHEM, V280, P3104, DOI 10.1074/jbc.M409846200
   Reddy MV, 2010, VET PATHOL, V47, P614, DOI 10.1177/0300985810373242
   ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519
   Schett G, 2014, CELL METAB, V20, P394, DOI 10.1016/j.cmet.2014.08.009
   Sistare FD, 2011, TOXICOL PATHOL, V39, P716, DOI 10.1177/0192623311406935
   Stolina M, 2014, BONE, V67, P305, DOI 10.1016/j.bone.2014.07.031
   Taylor S, 2016, BONE, V84, P148, DOI 10.1016/j.bone.2015.12.013
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Wang XY, 2006, J CELL BIOL, V172, P115, DOI 10.1083/jcb.200507106
   Watanabe A, 2012, J TOXICOL SCI, V37, P617
NR 50
TC 56
Z9 59
U1 0
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0273 2300
EI 1096 0295
J9 REGUL TOXICOL PHARM
JI Regul. Toxicol. Pharmacol.
PD NOV
PY 2016
VL 81
BP 212
EP 222
DI 10.1016/j.yrtph.2016.08.010
PG 11
WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Legal Medicine; Pharmacology & Pharmacy; Toxicology
GA EE8HF
UT WOS:000389865600024
PM 27569204
OA hybrid
DA 2025 08 17
ER

PT J
AU Enukashvily, NI
   Belik, LA
   Semenova, NY
   Kostroma, II
   Motyko, EV
   Gritsaev, SV
   Bessmeltsev, SS
   Sidorkevich, SV
   Martynkevich, IS
AF Enukashvily, Natella I. I.
   Belik, Liubov. A.
   Semenova, Natalia Yu.
   Kostroma, Ivan I. I.
   Motyko, Ekaterina V. V.
   Gritsaev, Sergey V. V.
   Bessmeltsev, Stanislav S. S.
   Sidorkevich, Sergey V. V.
   Martynkevich, Irina S. S.
TI Transcription of WNT Genes in Hematopoietic Niche's Mesenchymal
   Stem Cells in Multiple Myeloma Patients with Different Responses to
   Treatment
SO GENES
LA English
DT Article
DE multiple myeloma; WNT signaling; hematopoietic niche; mesenchymal
   stromal cells; prognostic markers
ID MEDIATED DRUG RESISTANCE; BONE DISEASE; EXPRESSION; OSTEOBLASTS;
   ACTIVATION; PATHWAY
AB Mesenchymal stromal cells (MSCs) are involved in bone tissue remodeling due to their ability to differentiate into osteoblasts and to influence osteoclasts' activity. Multiple myeloma (MM) is associated with bone resorption. During disease progression, MSCs acquire a tumorassociated phenotype, losing their osteogenic potential. The process is associated with impaired osteoblasts/osteoclasts balance. The WNT signaling pathway plays a major role in maintaining the balance. In MM, it functions in an aberrant way. It is not known yet whether the WNT pathway is restored in patients' bone narrow after treatment. The aim of the study was to compare the level of WNT family gene transcription in the bone marrow MSCs of healthy donors and MM patients before and after therapy. The study included healthy donors (n = 3), primary patients (n = 3) and patients with different response status to therapy (bortezomib containing induction regimens) (n = 12). The transcription of the WNT and CTNNB1 (encoding fi catenin) genes was accessed using qPCR. The mRNA quantity of ten WNT genes, as well as CTNNB1 mRNA encoding fi catenin, a key mediator in canonical signaling, was evaluated. The observed differences between the groups of patients indicated that aberrant functioning of the WNT pathway was retained after treatment. The differences that we detected for WNT2B, WNT9B and CTNNB1 suggested their possible application as prognostic molecular markers.
C1 [Enukashvily, Natella I. I.; Belik, Liubov. A.; Semenova, Natalia Yu.; Kostroma, Ivan I. I.; Motyko, Ekaterina V. V.; Gritsaev, Sergey V. V.; Bessmeltsev, Stanislav S. S.; Sidorkevich, Sergey V. V.; Martynkevich, Irina S. S.] Russian Res Inst Hematol & Transfusiol, FMBA Russian Federat, St Petersburg 191024, Russia.
   [Enukashvily, Natella I. I.; Belik, Liubov. A.] Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia.
   [Enukashvily, Natella I. I.] North Western State Med Univ, Cell Technol Lab, St Petersburg 191015, Russia.
   [Belik, Liubov. A.] Cell Technol Ctr Pokrovsky, St Petersburg 199066, Russia.
C3 Russian Research Institute of Hematology & Transfusiology; Russian
   Academy of Sciences; St. Petersburg Scientific Centre of the Russian
   Academy of Sciences; Institute of Cytology RAS; North Western State
   Medical University named after I.I. Mechnikov
RP Enukashvily, NI; Martynkevich, IS (通讯作者)，Russian Res Inst Hematol & Transfusiol, FMBA Russian Federat, St Petersburg 191024, Russia.; Enukashvily, NI (通讯作者)，Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia.; Enukashvily, NI (通讯作者)，North Western State Med Univ, Cell Technol Lab, St Petersburg 191015, Russia.
EM n.enukashvily@incras.ru; mis2907@mail.ru
RI ; Semenova, Natalia/R 1145 2017; Belik, Liubov/GQH 9769 2022;
   Enukashvily, Natella/A 6444 2009; Kostroma, I.I./ABE 9298 2021
OI Gritsaev, S.V./0000 0001 7586 4709; Semenova,
   Natalia/0000 0003 4069 0678; Enukashvily, Natella/0000 0002 5971 7917;
   Kostroma, I.I./0000 0003 3768 0831; Belik, Liubov/0000 0002 4589 8702
FU Ministry of Science and Higher Education of the Russian Federation
   [15.BRC.21.0011, 075 15 2021 1063]
FX This research was funded by the Ministry of Science and Higher Education
   of the Russian Federation (project 15.BRC.21.0011, Agreement No.
   075 15 2021 1063).
CR Albagoush SA., 2023, Statpearls [Internet]. treasure Island (fl)
   Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Baryawno N, 2019, CELL, V177, P1915, DOI 10.1016/j.cell.2019.04.040
   Bessmeltsev S.S., 2013, Clin. Oncohematol, V6, P237
   Bessmeltsev S.S., 2016, GUIDE PHYS
   Bolzoni M, 2013, LEUKEMIA, V27, P451, DOI 10.1038/leu.2012.190
   Bunaciu RP, 2008, ONCOL REP, V20, P195
   Chen X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0692 9
   Dazzi F, 2006, BLOOD REV, V20, P161, DOI 10.1016/j.blre.2005.11.002
   Edwards CM, 2008, BONE, V42, P1007, DOI 10.1016/j.bone.2008.01.027
   Enukashvily NI, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23063359
   Frenquelli M, 2020, LEUKEMIA, V34, P257, DOI 10.1038/s41375 019 0486 9
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Ivanovic Z, 2009, J CELL PHYSIOL, V219, P271, DOI 10.1002/jcp.21690
   Katoh M, 2007, STEM CELL REV, V3, P30, DOI 10.1007/s12015 007 0006 6
   Kirikoshi H, 2001, INT J ONCOL, V19, P1221
   Kobune M, 2007, MOL CANCER THER, V6, P1774, DOI 10.1158/1535 7163.MCT 06 0684
   Komori T, 2010, J ORAL BIOSCI, V52, P22
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Lu SL, 2021, AM J SURG PATHOL, V45, P1633, DOI 10.1097/PAS.0000000000001784
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Mahtouk K, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 198
   Man Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.621214
   Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714
   Nakamura Y, 2005, AM J PATHOL, V167, P97, DOI 10.1016/S0002 9440(10)62957 4
   Noll JE, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.38
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Qiang YW, 2008, BLOOD, V112, P374, DOI 10.1182/blood 2007 10 120253
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074 7613(00)00004 2
   Richter J, 2018, GENES BASEL, V9, DOI 10.3390/genes9020066
   Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957
   SCHOFIELD R, 1978, BLOOD CELLS, V4, P7
   Schulze M, 2014, AM J ROENTGENOL, V202, P170, DOI 10.2214/AJR.12.10367
   Semenova N.Y., 2014, CLIN ONCOHEMATOL, V7, P501
   Shi CW, 2022, DIFFERENTIATION, V125, P35, DOI 10.1016/j.diff.2022.03.004
   Shi YF, 2017, NAT REV DRUG DISCOV, V16, P35, DOI 10.1038/nrd.2016.193
   Song S, 2021, ONCOGENE, V40, P5393, DOI 10.1038/s41388 021 01939 7
   Spaan I, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045 018 0615 3
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Subramanian R, 2007, PATHOLOGY, V39, P512, DOI 10.1080/00313020701570038
   Suthon S, 2021, FRONT CELL DEV BIOL, V09, DOI 10.3389/fcell.2021.667581
   Vallet S, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040202
   van Andel H, 2019, LEUKEMIA, V33, P1063, DOI 10.1038/s41375 019 0404 1
   Wend P, 2012, ACTA PHYSIOL, V204, P34, DOI 10.1111/j.1748 1716.2011.02296.x
   Zmuda JM, 2009, J BONE MINER RES, V24, P437, DOI 10.1359/JBMR.081106
NR 46
TC 0
Z9 0
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4425
J9 GENES BASEL
JI Genes
PD MAY 17
PY 2023
VL 14
IS 5
AR 1097
DI 10.3390/genes14051097
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA H5TZ2
UT WOS:000996599000001
PM 37239457
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Clines, GA
AF Clines, Gregory A.
TI Mechanisms and treatment of hypercalcemia of malignancy
SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
LA English
DT Article
DE bisphosphonate; bone metastasis; hypercalcemia; malignancy; parathyroid
   hormone related protein
ID HORMONE RELATED PROTEIN; CANCER ASSOCIATED HYPERCALCEMIA; ACUTE
   LYMPHOBLASTIC LEUKEMIA; CELL LUNG CANCER; PARATHYROID HORMONE;
   BREAST CANCER; HUMORAL HYPERCALCEMIA; ECTOPIC PRODUCTION;
   IMMUNORADIOMETRIC ASSAY; MOLECULAR MECHANISMS
AB Purpose of review
   Hypercalcemia of malignancy is a common paraneoplastic syndrome and a frequent complication of advanced breast and lung cancer, and multiple myeloma. The development of this malignancy complication often purports a poor prognosis. Thorough evaluation to establish the cause of hypercalcemia is essential because some patients may actually have undiagnosed primary hyperparathyroidism.
   Recent findings
   Production of humoral factors by the primary tumor, collectively known as humoral hypercalcemia of malignancy (HHM), is the mechanism responsible for 80% of cases. The vast majority of HHM is caused by tumor produced parathyroid hormone related protein followed by infrequent tumor production of 1,25 dihydroxyvitamin D and parathyroid hormone. The remaining 20% of cases are caused by bone metastasis with consequent bone osteolysis and release of skeletal calcium. Key therapies are saline hydration to promote calciuresis and bisphosphonates to reduce pathologic osteoclastic bone resorption. Calcitonin and glucocorticoids, especially in 1,25 dihydroxyvitamin D mediated HHM, also have calcium lowering effects.
   Summary
   Recent discoveries on mechanisms of malignancy associated hypercalcemia highlight the critical role of the osteoclast. Bisphosphonates and other novel therapies being evaluated in clinical trial target this bone resorbing cell type and provide effective and durable serum calcium reduction.
C1 [Clines, Gregory A.] Univ Alabama Birmingham, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA.
   [Clines, Gregory A.] Vet Affairs Med Ctr, Birmingham, AL USA.
C3 University of Alabama System; University of Alabama Birmingham; US
   Department of Veterans Affairs; Veterans Health Administration (VHA)
RP Clines, GA (通讯作者)，Univ Alabama Birmingham, Dept Med, Div Endocrinol Diabet & Metab, 1808 7th Ave S,BDB 730, Birmingham, AL 35294 USA.
EM clines@uab.edu
FU National Institutes of Health [CA118428, AR056826]; Department of
   Defense [W81XWH 08 1 0030]
FX The author receives funding from the National Institutes of Health
   (CA118428 and AR056826) and the Department of Defense
   (W81XWH 08 1 0030).
CR ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   Adachi I, 1986, Gan To Kagaku Ryoho, V13, P2637
   Ansari K, 2003, J Assoc Physicians India, V51, P1023
   Bickle DA., 2008, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, P141
   BINSTOCK ML, 1980, ANN INTERN MED, V93, P269, DOI 10.7326/0003 4819 93 2 269
   BUNDRED NJ, 1992, EUR J CANCER, V28A, P690, DOI 10.1016/S0959 8049(05)80127 3
   Bundred NJ, 1996, ANN ROY COLL SURG, V78, P354
   BURT ME, 1980, ARCH SURG CHICAGO, V115, P704, DOI 10.1001/archsurg.1980.01380060012004
   BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603
   Carnaille B, 1998, AUST NZ J SURG, V68, P117, DOI 10.1111/j.1445 2197.1998.tb04719.x
   Cavestro Giulia Martina, 2002, Acta Biomed, V73, P37
   Cheung WC, 2002, LEUKEMIA, V16, P1182, DOI 10.1038/sj.leu.2402481
   Choi SJ, 2000, BLOOD, V96, P671
   Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   des Grottes JM, 2001, MELANOMA RES, V11, P477, DOI 10.1097/00008390 200110000 00006
   DUMON JC, 1992, CALCIFIED TISSUE INT, V51, P18, DOI 10.1007/BF00296210
   Dunford JE, 2010, CURR PHARM DESIGN, V16, P2961
   Earm JH, 1998, J AM SOC NEPHROL, V9, P2181
   Evans KN, 2004, AM J PATHOL, V165, P807, DOI 10.1016/S0002 9440(10)63343 3
   FENTON AJ, 1991, ENDOCRINOLOGY, V129, P3424, DOI 10.1210/endo 129 6 3424
   FETCHICK DA, 1986, J CLIN INVEST, V78, P592, DOI 10.1172/JCI112614
   FRASER WD, 1993, CLIN CHEM, V39, P414
   GALLACHER SJ, 1990, ANN CLIN BIOCHEM, V27, P551, DOI 10.1177/000456329002700605
   Ganesan P, 2009, J PEDIATR ENDOCR MET, V22, P463
   GESEK FA, 1992, J CLIN INVEST, V90, P749, DOI 10.1172/JCI115947
   Gilmore JL, 2009, MOL CANCER RES, V7, P1714, DOI 10.1158/1541 7786.MCR 09 0131
   Gover A, 2002, SOUTH MED J, V95, P258
   GRILL V, 1991, J CLIN ENDOCR METAB, V73, P1309, DOI 10.1210/jcem 73 6 1309
   Grill V, 2000, Rev Endocr Metab Disord, V1, P253, DOI 10.1023/A:1026597816193
   GUCALP R, 1992, J CLIN ONCOL, V10, P134, DOI 10.1200/JCO.1992.10.1.134
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   GUISE TA, 1994, J BONE MINER RES  S1, V9, pS128
   Hens JR, 2005, BREAST CANCER RES, V7, P220, DOI 10.1186/bcr1306
   Hewison M, 2003, J BONE MINER RES, V18, P579, DOI 10.1359/jbmr.2003.18.3.579
   Hiraki A, 2004, LUNG CANCER J IASLC, V43, P301, DOI 10.1016/j.lungcan.2003.09.006
   Horwitz M., 2008, PRIMER METABOLIC BON, P307
   Horwitz MJ, 2005, J BONE MINER RES, V20, P1792, DOI 10.1359/JBMR.050602
   HOSKING DJ, 1981, Q J MED, V50, P473
   HUTCHESSON ACJ, 1995, POSTGRAD MED J, V71, P28, DOI 10.1136/pgmj.71.831.28
   Iguchi H, 1998, J CLIN ENDOCR METAB, V83, P2653, DOI 10.1210/jc.83.8.2653
   IKEDA K, 1994, J CLIN ENDOCR METAB, V79, P1322, DOI 10.1210/jc.79.5.1322
   Khanna A, 2006, SEMIN NEPHROL, V26, P244, DOI 10.1016/j.semnephrol.2006.03.004
   Kobayashi T, 2002, DEVELOPMENT, V129, P2977
   Kondegowda NG, 2010, DIABETES, V59, P3131, DOI 10.2337/db09 1796
   Koo WS, 1996, NEPHRON, V72, P424, DOI 10.1159/000188907
   Kremer R, 1996, AM J MED, V100, P406, DOI 10.1016/S0002 9343(97)89515 0
   LAFFAN MA, 1986, J CLIN PATHOL, V39, P1143, DOI 10.1136/jcp.39.10.1143
   Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood 2003 06 1992
   LeGrand SB, 2008, ANN INTERN MED, V149, P259, DOI 10.7326/0003 4819 149 4 200808190 00007
   Luparello C, 2001, J BONE MINER RES, V16, P2173, DOI 10.1359/jbmr.2001.16.12.2173
   Luparello C, 2010, THESCIENTIFICWORLDJO, V10, P1016, DOI 10.1100/tsw.2010.97
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Mantzoros CS, 1997, CLIN ENDOCRINOL, V46, P373, DOI 10.1046/j.1365 2265.1997.1090921.x
   Matsuhashi Y, 2004, LEUKEMIA LYMPHOMA, V45, P397, DOI 10.1080/10428190310001593139
   Matsui T, 1998, DERMATOLOGY, V197, P65, DOI 10.1159/000017960
   Miki T, 2004, INT J CANCER, V108, P511, DOI 10.1002/ijc.11586
   MOSELEY JM, 1987, P NATL ACAD SCI USA, V84, P5048, DOI 10.1073/pnas.84.14.5048
   MUNDY GR, 1978, AM J MED, V65, P600, DOI 10.1016/0002 9343(78)90847 1
   MUNDY GR, 1982, METABOLISM, V31, P1247, DOI 10.1016/0026 0495(82)90012 9
   Nielsen PK, 1996, J CLIN ENDOCR METAB, V81, P3793, DOI 10.1210/jc.81.10.3793
   NUSSBAUM SR, 1993, AM J MED, V95, P297, DOI 10.1016/0002 9343(93)90282 T
   NUSSBAUM SR, 1990, NEW ENGL J MED, V323, P1324, DOI 10.1056/NEJM199011083231907
   Otto S, 2011, J CRANIOMAXILLOFAC S
   Paget S, 1889, LANCET, V133, P565
   Papworth K, 2005, TUMOR BIOL, V26, P201, DOI 10.1159/000086953
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   PECHERSTORFER M, 1994, J CLIN ENDOCR METAB, V78, P1268, DOI 10.1210/jc.78.5.1268
   Pecherstorfer M, 2003, SUPPORT CARE CANCER, V11, P539, DOI 10.1007/s00520 003 0477 1
   Pepper K, 2007, J GEN INTERN MED, V22, P1042, DOI 10.1007/s11606 007 0189 1
   Pfister MF, 1997, J BIOL CHEM, V272, P20125, DOI 10.1074/jbc.272.32.20125
   Pioszak AA, 2009, J BIOL CHEM, V284, P28382, DOI 10.1074/jbc.M109.022905
   Pun K K, 1995, Endocr Pract, V1, P166
   PUROHIT OP, 1995, BRIT J CANCER, V72, P1289, DOI 10.1038/bjc.1995.502
   RALSTON SH, 1990, ANN INTERN MED, V112, P499, DOI 10.7326/0003 4819 112 7 499
   RIZZOLI R, 1994, J CLIN ENDOCR METAB, V79, P912, DOI 10.1210/jc.79.3.912
   Rizzoli R, 1999, J CLIN ENDOCR METAB, V84, P3545, DOI 10.1210/jc.84.10.3545
   SAIKAWA T, 1988, CLIN CARDIOL, V11, P75, DOI 10.1002/clc.4960110205
   SCHILLING T, 1993, J CLIN ENDOCR METAB, V76, P801, DOI 10.1210/jc.76.3.801
   SEYMOUR JF, 1993, BLOOD, V82, P1383
   Shimonodan H, 2005, PEDIATR BLOOD CANCER, V45, P333, DOI 10.1002/pbc.20357
   Stewart AF, 2005, NEW ENGL J MED, V352, P373, DOI 10.1056/NEJMcp042806
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   STREWLER GJ, 1993, J CLIN ENDOCR METAB, V76, P1373, DOI 10.1210/jc.76.5.1373
   STREWLER GJ, 1987, J CLIN INVEST, V80, P1803, DOI 10.1172/JCI113275
   STRODEL WE, 1988, J SURG ONCOL, V37, P10, DOI 10.1002/jso.2930370104
   Sultan I, 2004, PEDIATR BLOOD CANCER, V43, P66, DOI 10.1002/pbc.20063
   SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618
   Takasaki H, 2006, AM J HEMATOL, V81, P439, DOI 10.1002/ajh.20559
   THIEBAUD D, 1990, ARCH INTERN MED, V150, P2125, DOI 10.1001/archinte.150.10.2125
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   VanHouten JN, 2006, J CLIN ENDOCR METAB, V91, P580, DOI 10.1210/jc.2005 2095
   VanHouten JN, 2003, J CLIN INVEST, V112, P1429, DOI 10.1172/JCI200319504
   Wang CC, 2009, AM J EMERG MED, V27, P1021, DOI 10.1016/j.ajem.2008.12.028
   Wolf ME, 2000, J CLIN PSYCHOPHARM, V20, P260, DOI 10.1097/00004714 200004000 00022
   Wong K, 2005, ENDOCRINE, V27, P83, DOI 10.1385/ENDO:27:1:083
   YOSHIDA T, 1994, INTERNAL MED, V33, P673, DOI 10.2169/internalmedicine.33.673
   YOSHIMOTO K, 1989, J CLIN ENDOCR METAB, V68, P976, DOI 10.1210/jcem 68 5 976
   Zehnder D, 2001, J CLIN ENDOCR METAB, V86, P888, DOI 10.1210/jc.86.2.888
   ZHENG MH, 1994, J CELL BIOCHEM, V54, P145, DOI 10.1002/jcb.240540203
NR 102
TC 81
Z9 88
U1 1
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1752 296X
EI 1752 2978
J9 CURR OPIN ENDOCRINOL
JI Curr. Opin. Endocrinol. Diabetes Obes.
PD DEC
PY 2011
VL 18
IS 6
BP 339
EP 346
DI 10.1097/MED.0b013e32834b4401
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 841EV
UT WOS:000296496200002
PM 21897221
DA 2025 08 17
ER

PT J
AU Einhorn, TA
AF Einhorn, Thomas A.
TI The Wnt Signaling Pathway as a Potential Target for Therapies to Enhance
   Bone Repair
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID RECEPTOR RELATED PROTEIN 5; SOST GENE; MUTATION; IDENTIFICATION;
   SCLEROSTIN; DENSITY; MASS
AB The development of new technologies to enhance skeletal healing after fracture or surgery is an important goal of musculoskeletal regenerative medicine. Although the bone morphogenetic proteins have shown some efficacy in this area, there is a need for more effective and less expensive therapies for bone repair and regeneration. A recent report demonstrating that Wnt signaling could be used to stimulate bone healing may provide a new direction for designing anabolic therapies for the skeleton. The identification of human phenotypes demonstrating robust bone formation as a result of mutations in Wnt signaling provides a strong basis for pursuing this area of investigation.
C1 [Einhorn, Thomas A.] Boston Univ, Sch Med, Dept Orthopaed Surg, Boston, MA 02118 USA.
   [Einhorn, Thomas A.] Boston Med Ctr, Boston, MA 02118 USA.
C3 Boston University; Boston Medical Center
RP Einhorn, TA (通讯作者)，Boston Univ, Sch Med, Dept Orthopaed Surg, Boston, MA 02118 USA.
EM thomas.einhorn@bmc.org
OI Einhorn, Thomas/0000 0002 5075 4885
FU Smith and Nephew; Anika; Lilly; Kuros; Amgen; Osteotech
FX T.A.E. receives consulting fees from Smith and Nephew, Anika, Lilly,
   Kuros, and Amgen. He holds ownership interest (stocks, stock options, or
   other ownership interest, excluding diversified mutual funds) in
   Biomineral Holdings, HealthpointCapital, OsteoGenix, and Implant
   Protection. He is a member of the Smith and Nephew scientific review
   board and of the Osteotech scientific advisory board and receives
   royalties from Osteotech.
CR Axelrad TW, 2009, CYTOKINE GROWTH F R, V20, P481, DOI 10.1016/j.cytogfr.2009.10.003
   Balemans W, 2005, BONE, V36, P943, DOI 10.1016/j.bone.2005.02.019
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843
   Einhorn TA, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001149
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Johnson ML, 1997, AM J HUM GENET, V60, P1326, DOI 10.1086/515470
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P6741, DOI 10.1210/jc.2005 2370
   PRAEMER A, 1999, MUSCULOSKELETAL COND, P185
   SCHULTZ DG, 2004, COMMUNICATION   0430
   SCHULTZ DG, 2004, COMMUNICATION   0507
   SCHULTZ DG, 2001, COMMUNICATION   1117
   SCHULTZ DG, 2002, COMMUNICATION   0702
   URIST MARSHALL R., 1967, CLIN ORTHOP RELATED RESIN COMPLICATIONS OF ORTHOPAEDIC SURGERY, V53, P243
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
NR 21
TC 13
Z9 18
U1 0
U2 9
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD JUL 28
PY 2010
VL 2
IS 42
AR 42ps36
DI 10.1126/scitranslmed.3001149
PG 3
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 735RE
UT WOS:000288433900001
PM 20668295
DA 2025 08 17
ER

PT J
AU Yang, DS
   Tan, YJ
   Xie, X
   Xiao, WB
   Kang, J
AF Yang, Daishui
   Tan, Yejun
   Xie, Xi
   Xiao, Wenbiao
   Kang, Jin
TI Zingerone attenuates Ti particle induced inflammatory osteolysis by
   suppressing the NF KB signaling pathway in osteoclasts
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Aseptic loosening; Periprosthetic osteolysis; Osteoporosis; Osteoclast;
   NF KB; Zingerone
ID TOTAL HIP ARTHROPLASTY; KAPPA B; BISPHOSPHONATES; OSTEOPOROSIS; CANCER;
   OSTEONECROSIS; DENOSUMAB; DIFFERENTIATION; HYDROXYAPATITE; POLYETHYLENE
AB Aseptic loosening caused by inflammatory osteolysis is one of the most frequent and serious long term com plications after total joint arthroplasty (TJA). Development of a new therapeutic drug is required due to the lack of effective therapy and serious adverse effects. This study aimed to explore the pharmacological properties of zingerone (ZO) in attenuating osteoclast mediated periprosthetic osteolysis and how ZO modulates osteoclas togenesis. The nontoxic concentration of ZO was clarified by the CCK 8 method. Then, we explored the efficacy of ZO on suppressing osteoclast differentiation, F actin ring formation, bone resorption, and NF KB luciferase activity in vitro as well as osteoprotection in vivo. Polymerase chain reaction and western blotting were applied to detect the underlying mechanisms involved in osteoclastogenesis. ZO showed an obvious inhibitory effect on osteoclastogenesis and bone resorption in a dose dependent manner by mainly suppressing the activation of NF  KB signaling pathways. Furthermore, ZO administration successfully attenuated titanium (Ti) particle stimulated periprosthetic osteolysis and osteoporosis by regulating osteoclast formation. Our findings demonstrated the pharmacological properties of ZO in inhibiting osteoclast formation and function by downregulation of NF KB signaling activation. As a result, these findings could be expected to provide a novel reagent for regulating in flammatory osteolysis caused by prosthetic loosening.
C1 [Yang, Daishui] Cent South Univ, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
   [Tan, Yejun; Xie, Xi; Kang, Jin] Cent South Univ, Xiangya Hosp 2, Dept Rheumatol & Immunol, Changsha 410011, Hunan, Peoples R China.
   [Tan, Yejun] Univ Minnesota Twin Cities, Sch Math, Minneapolis, MN 55455 USA.
   [Xiao, Wenbiao] Cent South Univ, Xiangya Hosp 2, Dept Geriatr, Changsha 410011, Hunan, Peoples R China.
C3 Central South University; Central South University; University of
   Minnesota System; University of Minnesota Twin Cities; Central South
   University
RP Kang, J (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Rheumatol & Immunol, Changsha 410011, Hunan, Peoples R China.
EM kangjin2015@csu.edu.cn
RI ; Tan, Yejun/HQY 2787 2023
OI Tan, Yejun/0009 0000 9567 0186; 
FU National Natural Science Foundation of China [81873882]
FX Funding This work was supported by a research grant from the National
   Natural Science Foundation of China (No. 81873882) .
CR Ahmad Bilal, 2015, ScientificWorldJournal, V2015, P816364, DOI 10.1155/2015/816364
   Bashir N, 2021, REDOX REP, V26, P62, DOI 10.1080/13510002.2021.1907518
   Bilezikian JP, 2011, ANN NY ACAD SCI, V1218, P1, DOI 10.1111/j.1749 6632.2010.05929.x
   Bordukalo Niksic T, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.869422
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317
   Cheong KO, 2016, ARCH PHARM RES, V39, P279, DOI 10.1007/s12272 015 0696 2
   Choi JS, 2015, PHYTOTHER RES, V29, P1783, DOI 10.1002/ptr.5435
   Coathup MJ, 2005, BIOMATERIALS, V26, P4161, DOI 10.1016/j.biomaterials.2004.10.020
   Das BK, 2022, CELLS BASEL, V11, DOI 10.3390/cells11010013
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Florschutz AV, 2015, J ORTHOP TRAUMA, V29, P121, DOI 10.1097/BOT.0000000000000291
   Goodman SB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122091
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hart A, 2019, J BONE JOINT SURG AM, V101, P1563, DOI 10.2106/JBJS.18.01218
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Hodges NA, 2021, BIOMATERIALS, V278, DOI 10.1016/j.biomaterials.2021.121127
   Howie DW, 2013, INFLAMMOPHARMACOLOGY, V21, P389, DOI 10.1007/s10787 013 0192 6
   Hu XT, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00385
   Issa K, 2013, BONE JOINT J, V95B, P46, DOI 10.1302/0301 620X.95B11.32644
   Juárez P, 2011, BONE, V48, P23, DOI 10.1016/j.bone.2010.08.004
   Kazemi Modje, 2021, J Complement Integr Med, V18, P303, DOI 10.1515/jcim 2019 0135
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim SY, 2011, J BONE MINER RES, V26, P993, DOI 10.1002/jbmr.288
   Langlois J, 2011, INT ORTHOP, V35, P245, DOI 10.1007/s00264 010 1143 0
   Laroche M, 2016, PRESSE MED, V45, P4, DOI 10.1016/j.lpm.2015.12.010
   Lee J, 2018, CHEM BIOL INTERACT, V279, P27, DOI 10.1016/j.cbi.2017.11.004
   Li FS, 2017, NAT PLANTS, V3, DOI 10.1038/nplants.2017.109
   Li HW, 2013, BIOCHEM BIOPH RES CO, V430, P951, DOI 10.1016/j.bbrc.2012.12.051
   Li T, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.789552
   Liu C, 2019, J CELL MOL MED, V23, P6466, DOI 10.1111/jcmm.14540
   Migliorati CA, 2011, NAT REV ENDOCRINOL, V7, P34, DOI 10.1038/nrendo.2010.195
   Nakashima Tomoki, 2011, Clin Calcium, V21, P93, DOI CliCa111218431852
   Nicolatou Galitis O, 2019, OR SURG OR MED OR PA, V127, P117, DOI 10.1016/j.oooo.2018.09.008
   Park JH, 2017, MOL CELLS, V40, P706
   Pathak N, 2020, J ARTHROPLASTY, V35, P3673, DOI 10.1016/j.arth.2020.06.069
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Purdue P Edward, 2006, HSS J, V2, P102, DOI 10.1007/s11420 006 9003 6
   Qi WX, 2013, CURR MED RES OPIN, V29, P1067, DOI 10.1185/03007995.2013.813840
   Rahbek O, 2005, ACTA ORTHOP, V76, P375, DOI 10.1080/00016470510030850
   Reid IR, 2011, SKELETAL RADIOL, V40, P1191, DOI 10.1007/s00256 011 1164 9
   Rizzoli R, 2018, BEST PRACT RES CL EN, V32, P739, DOI 10.1016/j.beem.2018.09.005
   Ruangsuriya J, 2017, PLANTA MED, V83, P268, DOI 10.1055/s 0042 113387
   Ryoo GH, 2020, BIOCHEM BIOPH RES CO, V531, P508, DOI 10.1016/j.bbrc.2020.07.083
   Sadoghi P, 2013, J ARTHROPLASTY, V28, P1329, DOI 10.1016/j.arth.2013.01.012
   Saleh KJ, 2004, CLIN ORTHOP RELAT R, P138, DOI 10.1097/01.blo.0000142288.66246.4d
   Song YX, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.919309
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Srinaath N, 2019, BIOFACTORS, V45, P575, DOI 10.1002/biof.1515
   Subedi S, 2019, DRUG DES DEV THER, V13, P2491, DOI 10.2147/DDDT.S200147
   Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749 6632.2011.06283.x
   Veronesi F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030499
   Wang P, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 04458 4
   Wilkinson GS, 2010, J CLIN ONCOL, V28, P4898, DOI 10.1200/JCO.2010.28.7524
   Xie XX, 2014, INT IMMUNOPHARMACOL, V19, P103, DOI 10.1016/j.intimp.2013.12.028
   Yaacobi E, 2021, ISR MED ASSOC J, V23, P497
   Yee AJ, 2012, CLIN INTERV AGING, V7, P331, DOI 10.2147/CIA.S14566
   Yu TS, 2017, JOVE J VIS EXP, DOI 10.3791/55025
   Zhang Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01028
   Zhao QX, 2007, FRONT BIOSCI LANDMRK, V12, P2519, DOI 10.2741/2252
   Zhu LX, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw6143
   Zhu X, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106847
NR 62
TC 4
Z9 5
U1 1
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD FEB
PY 2023
VL 115
AR 109720
DI 10.1016/j.intimp.2023.109720
EA JAN 2023
PG 13
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 8L5BO
UT WOS:000923797000001
PM 37724956
DA 2025 08 17
ER

PT J
AU Oh, WT
   Yang, YS
   Xie, J
   Ma, H
   Kim, JM
   Park, KH
   Oh, DS
   Park Min, KH
   Greenblatt, MB
   Gao, GP
   Shim, JH
AF Oh, Won Taek
   Yang, Yeon Suk
   Xie, Jun
   Ma, Hong
   Kim, Jung Min
   Park, Kwang Hwan
   Oh, Daniel S.
   Park Min, Kyung Hyun
   Greenblatt, Matthew B.
   Gao, Guangping
   Shim, Jae Hyuck
TI WNT modulating gene silencers as a gene therapy for osteoporosis, bone
   fracture, and critical sized bone defects
SO MOLECULAR THERAPY
LA English
DT Article
ID PARATHYROID HORMONE; SCLEROSTIN; MICE; DENOSUMAB; PLATFORM; ANALOGS;
   MASS
AB Treating osteoporosis and associated bone fractures remains challenging for drug development in part due to potential off target side effects and the requirement for long term treatment. Here, we identify recombinant adeno associated virus (rAAV) mediated gene therapy as a complementary approach to existing osteoporosis therapies, offering long lasting targeting of multiple targets and/or previously undruggable intracellular non enzymatic targets. Treatment with a bone targeted rAAV carrying artificial microRNAs (miRNAs) silenced the expression of WNT antagonists, schnurri 3 (SHN3), and sclerostin (SOST), and enhanced WNT/b catenin signaling, osteoblast function, and bone formation. A single systemic administration of rAAVs effectively reversed bone loss in both postmenopausal and senile osteoporosis. Moreover, the healing of bone fracture and critical sized bone defects was also markedly improved by systemic injection or transplantation of AAV bound allograft bone to the osteotomy sites. Collectively, our data demonstrate the clinical potential of bone specific gene silencers to treat skeletal disorders of low bone mass and impaired fracture repair.
C1 [Oh, Won Taek; Yang, Yeon Suk; Kim, Jung Min; Shim, Jae Hyuck] Univ Massachusetts, Dept Med, Div Rheumatol, Chan Med Sch, 364 Plantat St LRB 217, Worcester, MA 01605 USA.
   [Oh, Won Taek; Park, Kwang Hwan] Yonsei Univ, Dept Orthoped Surg, Coll Med, Seoul 03722, South Korea.
   [Xie, Jun; Ma, Hong; Gao, Guangping; Shim, Jae Hyuck] Univ Massachusetts, Horae Gene Therapy Ctr, Chan Med Sch, 368 Plantat St AS6 2049, Worcester, MA 01605 USA.
   [Xie, Jun; Ma, Hong; Gao, Guangping] Univ Massachusetts, Dept Microbiol & Physiol Syst, Chan Med Sch, 368 Plantat St AS6 2049, Worcester, MA 01605 USA.
   [Xie, Jun; Ma, Hong; Gao, Guangping] Univ Massachusetts, Viral Vector Core, Chan Med Sch, 368 Plantat St AS6 2049, Worcester, MA 01605 USA.
   [Oh, Daniel S.] Osteogene Tech, Norwood, NJ 07648 USA.
   [Park Min, Kyung Hyun] Hosp Special Surg, David Z Rosensweig Genom Res Ctr, Arthrit & Tissue Degenerat Program, New York, NY 10021 USA.
   [Park Min, Kyung Hyun; Greenblatt, Matthew B.] Hosp Special Surg, Res Div, New York, NY 10021 USA.
   [Greenblatt, Matthew B.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA.
   [Gao, Guangping; Shim, Jae Hyuck] Univ Massachusetts, Li Weibo Inst Rare Dis Res, Chan Med Sch, 368 Plantat St AS6 2049, Worcester, MA 01605 USA.
   [Gao, Guangping] Univ Massachusetts, Li Weibo Inst Rare Dis Res, Horae Gene Therapy Ctr, Chan Med Sch, 368 Plantat St AS6 2049, Worcester, MA 01605 USA.
   [Shim, Jae Hyuck] Univ Massachusetts, Li Weibo Inst Rare Dis Res, Horae Gene Therapy Ctr, Dept Med,Div Rheumatol,Chan Med Sch, 364 Plantat St LRB 217, Worcester, MA 01605 USA.
C3 University of Massachusetts System; UMass Chan Medical School;
   University of Massachusetts Worcester; Yonsei University; Yonsei
   University Health System; University of Massachusetts System; UMass Chan
   Medical School; University of Massachusetts Worcester; University of
   Massachusetts System; UMass Chan Medical School; University of
   Massachusetts Worcester; University of Massachusetts System; UMass Chan
   Medical School; University of Massachusetts Worcester; Cornell
   University; Weill Cornell Medicine; University of Massachusetts System;
   UMass Chan Medical School; University of Massachusetts Worcester;
   University of Massachusetts System; University of Massachusetts
   Worcester; UMass Chan Medical School; University of Massachusetts
   System; UMass Chan Medical School; University of Massachusetts Worcester
RP Gao, GP; Shim, JH (通讯作者)，Univ Massachusetts, Horae Gene Therapy Ctr, Chan Med Sch, 368 Plantat St AS6 2049, Worcester, MA 01605 USA.; Gao, GP (通讯作者)，Univ Massachusetts, Li Weibo Inst Rare Dis Res, Horae Gene Therapy Ctr, Chan Med Sch, 368 Plantat St AS6 2049, Worcester, MA 01605 USA.; Shim, JH (通讯作者)，Univ Massachusetts, Li Weibo Inst Rare Dis Res, Horae Gene Therapy Ctr, Dept Med,Div Rheumatol,Chan Med Sch, 364 Plantat St LRB 217, Worcester, MA 01605 USA.
EM guangping.gao@umassmed.edu; jaehyuck.shim@umassmed.edu
RI Oh, Wontaek/GSN 6491 2022; Kim, Jung Min/JDW 1037 2023
OI Shim, Jae Hyuck/0000 0002 4947 3293; Park, Kwang
   Hwan/0000 0002 2110 0559; Oh, Won Taek/0000 0003 1815 0851; Kim,
   Jung Min/0000 0002 9072 4293
FU NIH [P01AI100263, R01NS076991, P01HD080642, R01AI12135]; NIH/NIAMS
   [R21AR077557, R01AR078230, R01AR075585]; International FOP Association;
   AAVAA Therapeutics; Burroughs Wellcome Fund; Pershing Square Sohn Cancer
   Research Alliance
FX We thank Dr. Laurie Glimcher (Department of Cancer Immunology and
   Virology, Dana Farber Cancer Institute and Harvard Medical School) for
   providing Schnurri 3 knockout and floxed mice; Tadatoshi Sato, Ji Hea
   Kim, Ok sun Lee, Zhihao Chen, and Eunhye Son for providing technical
   support; and Drs. Merin MacDonald and Melanie Trombly for reviewing the
   manuscript. We also thank the many individuals who provided valuable
   reagents. G.G. is supported by grants from the NIH (P01AI100263,
   R01NS076991, P01HD080642, R01AI12135) . J. H.S. is supported by
   NIH/NIAMS (R21AR077557, R01AR078230) , the International FOP
   Association, and AAVAA Therapeutics. M.B.G. is supported by NIH/NIAMS
   (R01AR075585) , a Career Award for Medical Scientists from the Burroughs
   Wellcome Fund, and the Pershing Square Sohn Cancer Research Alliance.
CR Appelman Dijkstra NM, 2018, NAT REV ENDOCRINOL, V14, P605, DOI 10.1038/s41574 018 0087 0
   Augustine M, 2013, CURR OSTEOPOROS REP, V11, P400, DOI 10.1007/s11914 013 0171 2
   Baldwin P, 2019, J ORTHOP TRAUMA, V33, P203, DOI 10.1097/BOT.0000000000001420
   Bao QW, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02705 0
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   Bovijn J, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay6570
   Bulcha JT, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00487 6
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   D'Onofrio DJ, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00140
   Eastell R, 2011, J BONE MINER RES, V26, P530, DOI 10.1002/jbmr.251
   Esbrit P, 2013, BIOCHEM PHARMACOL, V85, P1417, DOI 10.1016/j.bcp.2013.03.002
   Ferrer Vaquer A, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471 213X 10 121
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115
   Gao G., 2012, MOL CLON LAB MANUAL, V2, P1209
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hofstaetter JG, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10226
   Holdsworth G, 2019, J MOL ENDOCRINOL, V62, pR167, DOI 10.1530/JME 18 0176
   Hulsart Billström G, 2015, J TISSUE ENG REGEN M, V9, P799, DOI 10.1002/term.1655
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   Jones DC, 2010, P NATL ACAD SCI USA, V107, P8254, DOI 10.1073/pnas.1003727107
   Khosla S, 2016, J BONE MINER RES, V31, P1485, DOI 10.1002/jbmr.2888
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Li SX, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.719589
   MacNabb C, 2016, J OSTEOPOROS, V2016, DOI 10.1155/2016/6217286
   McBride JL, 2008, P NATL ACAD SCI USA, V105, P5868, DOI 10.1073/pnas.0801775105
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Morse A, 2017, CALCIFIED TISSUE INT, V101, P217, DOI 10.1007/s00223 017 0275 2
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Ogawa K, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14149 7
   Oh DS, 2015, JOVE J VIS EXP, DOI 10.3791/52947
   Oukka M, 2002, MOL CELL, V9, P121, DOI 10.1016/S1097 2765(01)00434 8
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rasmusson L, 2014, INT J DENT, V2014, DOI 10.1155/2014/471035
   Russow G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010083
   Shim JH, 2013, J CLIN INVEST, V123, P4010, DOI 10.1172/JCI69443
   Spatz JM, 2015, J BIOL CHEM, V290, P16744, DOI 10.1074/jbc.M114.628313
   Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573 019 0012 9
   Wein MN, 2012, P NATL ACAD SCI USA, V109, P8173, DOI 10.1073/pnas.1205848109
   Windolf M, 2021, INJURY, V52, P71, DOI 10.1016/j.injury.2020.10.050
   Xie J, 2018, MOL THER, V26, P436
   Xie J, 2017, MOL THER, V25, P1363, DOI 10.1016/j.ymthe.2017.03.028
   Xu R., 2017, J BONE MINER RES
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Yang YS, 2020, MOL THER METH CLIN D, V17, P922, DOI 10.1016/j.omtm.2020.04.010
   Yang YS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10809 6
   Yukata K, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31345 1
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
NR 52
TC 34
Z9 38
U1 2
U2 30
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525 0016
EI 1525 0024
J9 MOL THER
JI Mol. Ther.
PD FEB 1
PY 2023
VL 31
IS 2
DI 10.1016/j.ymthe.2022.09.018
EA FEB 2023
PG 19
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA C9IT5
UT WOS:000964978700001
PM 36184851
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Vives, V
   Cres, G
   Richard, C
   Busson, M
   Ferrandez, Y
   Planson, AG
   Zeghouf, M
   Cherfils, J
   Malaval, L
   Blangy, A
AF Vives, Virginie
   Cres, Gaelle
   Richard, Christian
   Busson, Muriel
   Ferrandez, Yann
   Planson, Anne Gaelle
   Zeghouf, Mahel
   Cherfils, Jacqueline
   Malaval, Luc
   Blangy, Anne
TI Pharmacological inhibition of Dock5 prevents osteolysis by affecting
   osteoclast podosome organization while preserving bone formation
SO NATURE COMMUNICATIONS
LA English
DT Article
ID PARATHYROID HORMONE; SIGNALING PATHWAY; OSTEOPOROSIS; PATHOGENESIS;
   ALENDRONATE; CHEMOKINE; MODEL
AB Osteoporosis is caused by excessive activity of bone degrading osteoclasts over bone forming osteoblast. Standard antiosteolytic treatments inhibit bone resorption by inducing osteoclast loss, with the adverse effect of hindering also bone formation. Formation of the osteoclast sealing zone requires Dock5, a guanine nucleotide exchange factor for the small GTPase Rac, and C21, a chemical inhibitor of Dock5, decreases bone resorption by cultured osteoclasts. Here we show that C21 directly inhibits the exchange activity of Dock5 and disrupts osteoclast podosome organization. Remarkably, C21 administration protects mice against bone degradation in models recapitulating major osteolytic diseases: menopause, rheumatoid arthritis and bone metastasis. Furthermore, C21 administration does not affect bone formation and is not toxic. Our results validate the pharmacological inhibition of Dock5 as a novel therapeutic route for fighting osteolytic diseases while preserving bone formation.
C1 [Vives, Virginie; Cres, Gaelle; Richard, Christian; Blangy, Anne] Ctr Rech Biochim Macromol, CNRS UMR 5237, F 34293 Montpellier 5, France.
   [Vives, Virginie; Cres, Gaelle; Richard, Christian; Blangy, Anne] Univ Montpellier, F 34095 Montpellier 5, France.
   [Busson, Muriel] Inst Rech Cancerol Montpellier, INSERM U896, F 34298 Montpellier 5, France.
   [Ferrandez, Yann; Planson, Anne Gaelle; Zeghouf, Mahel; Cherfils, Jacqueline] Ctr Rech Gif, CNRS, Lab Enzymol & Biochim Struct, F 91198 Gif Sur Yvette, France.
   [Malaval, Luc] Univ St Etienne, INSERM U1059, F 42023 St Etienne 02, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite de
   Montpellier; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite Paris Saclay; Centre National de la Recherche
   Scientifique (CNRS); Universite Jean Monnet; Institut National de la
   Sante et de la Recherche Medicale (Inserm)
RP Blangy, A (通讯作者)，Ctr Rech Biochim Macromol, CNRS UMR 5237, F 34293 Montpellier 5, France.
EM anne.blangy@crbm.cnrs.fr
RI ; Malaval, Luc/D 2206 2011; Malaval, Luc/K 3060 2019; VIVES,
   Virginie/JVZ 4304 2024; Planson, Anne Gaëlle/AAK 9595 2021
OI BLANGY, Anne/0000 0001 7043 0784; Malaval, Luc/0000 0002 8640 2646;
   Busson, Muriel/0000 0001 5936 4026; Planson,
   Anne Gaelle/0000 0003 4343 3386; ferrandez, yann/0000 0002 5248 0742;
   Zeghouf, Mahel/0000 0003 3686 2510; 
FU Fondation pour la Recherche Medicale (FRM) [DVO20081013473]; Institut
   National du Cancer [INCa 4361]; Agence Nationale de la Recherche (ANR)
   [ANR 2011 BLAN 006]; Ligue contre le Cancer [7FI9556JQSC]
FX We thank P. Balaguer (INSERM U896, Institut de Recherche en Cancerologie
   de Montpellier, France) for luciferase expressing B16BL6 cells; R.
   Lebrun (Montpellier RIO Imaging platform and LabEx CeMEB mu CT
   facility), G. Valette and G. Cazals (Mass spectrometry platform,
   Institut des Biomolecules Max Mousseron, Montpellier, France), K. Chebli
   (Institut de Genetique Moleculaire de Montpellier, France), I. Ait Arsa
   (IRCM animal facility, Montpellier, France), M. Plays and S. Mennechet
   (CNRS animal facilities, Montpellier, France) for the technical help
   with animals; F. Apparailly, P. Plence, D. Matyre and J. Quentin (INSERM
   U844, Institut des Neurosciences de Montpellier, France) for CIA
   procedure training; and Anne Morel and Clement Kerneur (CNRS UMR 5237,
   CRBM, Montpellier, France) for the technical assistance. Imaging was
   performed with the equipment of the Montpellier RIO Imaging platform
   (www.mri.cnrs.fr) and the University of Saint Etienne PLEXAN facility.
   We also thank Lionel Duarte (LEBS, Gifsur Yvette, France) for protein
   purifications, Christophe Velours (IMAGIF platform, Centre de Recherche
   de Gif, France) for size exclusion chromatography coupled to multi angle
   light scattering analysis and Raphael Rodriguez and Angelica Mariani
   (Institut de Chimie de Substances Naturelles, CNRS, Gif sur Yvette) for
   complementary LC MS and NMR analysis of C21. This work was supported by
   research grants from the Fondation pour la Recherche Medicale (FRM grant
   # DVO20081013473 to A.B.), the Institut National du Cancer (grant #
   INCa 4361 to A.B.), the Agence Nationale de la Recherche (ANR grant #
   ANR 2011 BLAN 006 to A.B.) and the Ligue contre le Cancer (Grant
   7FI9556JQSC, comite de l'Aude, to A.B.).
CR ARGUELLO F, 1988, CANCER RES, V48, P6876
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Béraud Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Bouquier N, 2009, CHEM BIOL, V16, P657, DOI 10.1016/j.chembiol.2009.04.012
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Brazier H, 2009, INT J BIOCHEM CELL B, V41, P1391, DOI 10.1016/j.biocel.2008.12.007
   Frenkel B, 2010, J CELL PHYSIOL, V224, P305, DOI 10.1002/jcp.22159
   Gedmintas L, 2013, J BONE MINER RES, V28, P1729, DOI 10.1002/jbmr.1893
   Henriksen K, 2014, CALCIFIED TISSUE INT, V94, P88, DOI 10.1007/s00223 013 9741 7
   Kim BJ, 2012, BONE, V51, P431, DOI 10.1016/j.bone.2012.06.015
   Klinck J, 2008, CALCIFIED TISSUE INT, V83, P70, DOI 10.1007/s00223 008 9150 5
   Kulkarni K, 2011, J BIOL CHEM, V286, P25341, DOI 10.1074/jbc.M111.236455
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Nakamura K, 2002, LIFE SCI, V70, P791, DOI 10.1016/S0024 3205(01)01454 0
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Pierroz DD, 2010, J BIOL CHEM, V285, P28164, DOI 10.1074/jbc.M110.101964
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Seeman E, 2003, J APPL PHYSIOL, V95, P2142, DOI 10.1152/japplphysiol.00564.2003
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Takayanagi H, 2012, NAT REV RHEUMATOL, V8, P684, DOI 10.1038/nrrheum.2012.167
   Toomer KH, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00116
   Touaitahuata Heiani, 2014, Small GTPases, V5, pe28119, DOI 10.4161/sgtp.28119
   Touaitahuata H, 2014, DEV BIOL, V393, P57, DOI 10.1016/j.ydbio.2014.06.020
   Vives V, 2011, J BONE MINER RES, V26, P1099, DOI 10.1002/jbmr.282
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Yamashita Junro, 2012, J Evid Based Dent Pract, V12, P233, DOI 10.1016/S1532 3382(12)70046 5
NR 27
TC 49
Z9 51
U1 0
U2 21
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD FEB
PY 2015
VL 6
AR 6218
DI 10.1038/ncomms7218
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CC2UW
UT WOS:000350201100027
PM 25645278
OA gold
DA 2025 08 17
ER

PT J
AU Harvey, HA
   Cream, LV
AF Harvey, Harold A.
   Cream, Leah von Reyn
TI Biology of bone metastases: Causes and consequences
SO CLINICAL BREAST CANCER
LA English
DT Article
DE bisphosphonates; denosumab; osteoclasts; RANK; skeletal complications
ID BREAST CANCER PATIENTS; LONG TERM EFFICACY; SKELETAL COMPLICATIONS;
   ZOLEDRONIC ACID; POSTMENOPAUSAL WOMEN; RECEPTOR ACTIVATOR;
   MULTIPLE MYELOMA; RANDOMIZED TRIAL; DOUBLE BLIND; BISPHOSPHONATE
AB Breast cancer is a highly osteotropic neoplasm, and as many as 75% of patients with metastatic disease will have involvement of the bony skeleton. On radiologic examination, these metasfases are predominantly osteolytic but can be osfeoblastic or mixed. The mechanisms by which metastases are formed are complex, involving many steps that include angiogenesis, invasion, and proliferation In the bone microenvironment. Tumor cells in the bone microenvironment produce a large number of cytokines that stimulate osteoclastic activity. Increased osteoclastic activity, in turn, leads to production of a variety of lymphokines and growth factors that can increase tumor cell proliferation. Thus, a cytokine network is established, which results in an imbalance of the processes of bone formation and bone resorption. As tumor burden in bone increases, osteoclasf mediated bone resorption is accelerated, resulting in loss of bone strength, fractures, pain, and other morbidities. Tumor cells metastatic to bone can also secrete growth factors, leading to increased osteoblastic activity. Osteoblasts lay down an excess of new bone that is structurally weak. There is considerable crosstalk between osteoclasts, osteoblasts, macrophages, and other cellular elements within the bone environment. The increasing understanding of the biology of bone metastases has opened the door to improved management of this important clinical problem. Current treatment strategies include approaches to reduce tumor burden and developing treatments that directly inhibit osteoclast function. The bisphosphonates are a class of drugs that inhibit osteoclast recruitment and function. Several highly potent bisphosphonates are now available for clinical use and represent an important adjunct in the management of bone mefasfases from breast cancer, multiple myeloma, and several other types of malignancies. Some newer therapeutic approaches Include agents designed to inhibit the osteoclast osteoblasf signaling interactions or alter processes of adhesion and invasion.
C1 Penn State Coll Med, Milton S Hershey Med Ctr, Hershey, PA 17033 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health
RP Harvey, HA (通讯作者)，Penn State Coll Med, Milton S Hershey Med Ctr, 500 Univ Dr,H046, Hershey, PA 17033 USA.
EM hharvey@psu.edu
CR Bauman G, 2005, RADIOTHER ONCOL, V75, P258, DOI 10.1016/j.radonc.2005.03.003
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   Brufsky A, 2006, SEMIN ONCOL, V33, pS13, DOI 10.1053/j.seminoncol.2006.03.022
   Chirgwin J. M., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P308
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331
   Delea T, 2004, ONCOLOGY BASEL, V67, P390, DOI 10.1159/000082923
   Demers LM, 2003, CLIN ORTHOP RELAT R, pS138, DOI 10.1097/01.blo.0000092979.12414.54
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Eastell R, 2006, J BONE MINER RES, V21, P1215, DOI 10.1359/JBMR.060508
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Gnant M, 2006, CANCER INVEST, V24, P328, DOI 10.1080/07357900600633759
   Guise T. A., 2005, CLIN BREAST CANC S2, V5, P46
   Guise TA, 2003, CLIN ORTHOP RELAT R, pS32, DOI 10.1097/01.blo.0000093055.96273.69
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Hamaoka T, 2004, J CLIN ONCOL, V22, P2942, DOI 10.1200/jco.2004.08.181
   Harvey HA, 2004, SEMIN ONCOL, V31, P23, DOI 10.1053/j.seminoncol.2004.09.023
   HARVEY HA, 1995, SUPPORT CARE CANCER, V3, P123, DOI 10.1007/BF00365852
   Hei YJ, 2005, BREAST CANCER RES TR, V94, pS260
   Hillner BE, 2001, SEMIN ONCOL, V28, P64, DOI 10.1053/sonc.2001.25432
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Lipton A, 2006, J CLIN ONCOL, V24, p6S
   Lipton A, 2006, CANCER TREAT REV, V32, P20, DOI 10.1016/S0305 7372(06)80005 8
   Lipton A, 2004, CLIN CANCER RES, V10, p6397S, DOI 10.1158/1078 0432.CCR 040030
   Lipton A, 2002, CANCER INVEST, V20, P45, DOI 10.1081/CNV 120014886
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Lipton Allan, 2005, Curr Treat Options Oncol, V6, P161, DOI 10.1007/s11864 005 0023 0
   Major P, 2002, ONCOLOGIST, V7, P481, DOI 10.1634/theoncologist.7 6 481
   Manabe Jun, 2005, Int J Clin Oncol, V10, P103
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Mohammad KS, 2003, CLIN ORTHOP RELAT R, pS67, DOI 10.1097/01.blo.0000093047.96273.4e
   Mundy G, 2001, SEMIN ONCOL, V28, P2, DOI 10.1053/sonc.2001.25441
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Ryan CW, 2006, J UROLOGY, V176, P972, DOI 10.1016/j.juro.2006.04.078
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saarto T, 2001, J CLIN ONCOL, V19, P10, DOI 10.1200/JCO.2001.19.1.10
   Sabino Mary Ann C, 2005, J Support Oncol, V3, P15
   Smid M, 2006, J CLIN ONCOL, V24, P2261, DOI 10.1200/JCO.2005.03.8802
   Smith Matthew R, 2004, Oncology (Williston Park), V18, P21
   Thürlimann B, 2005, NEW ENGL J MED, V353, P2747
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 51
TC 29
Z9 33
U1 2
U2 6
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219 3931 USA
SN 1526 8209
EI 1938 0666
J9 CLIN BREAST CANCER
JI Clin. Breast Cancer
PD JUL
PY 2007
VL 7
SU 1
BP S7
EP S13
DI 10.3816/CBC.2007.s.001
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 196MO
UT WOS:000248486900001
PM 17683652
DA 2025 08 17
ER

PT J
AU Yu, TS
   Witten, PE
   Huysseune, A
   Buettner, A
   To, TT
   Winkler, C
AF Yu, Tingsheng
   Witten, Paul Eckhard
   Huysseune, Ann
   Buettner, Anita
   Thuy Thanh To
   Winkler, Christoph
TI Live imaging of osteoclast inhibition by bisphosphonates in a medaka
   osteoporosis model
SO DISEASE MODELS & MECHANISMS
LA English
DT Article
DE Osteoporosis; Bone modeling; Remodeling; Homeostasis;
   Osteoblast osteoclast coupling; Medaka
ID ORYZIAS LATIPES; BONE; ZEBRAFISH; MINERALIZATION; MECHANISMS;
   OSTEOBLASTS; ALENDRONATE; ETIDRONATE; FISH
AB Osteoclasts are bone resorbing cells derived from the monocyte/macrophage lineage. Excess osteoclast activity leads to reduced bone mineral density, a hallmark of diseases such as osteoporosis. Processes that regulate osteoclast activity are therefore targeted in current osteoporosis therapies. To identify and characterize drugs for treatment of bone diseases, suitable in vivo models are needed to complement cell culture assays. We have previously reported transgenic medaka lines expressing the osteoclast inducing factor receptor activator of nuclear factor kappa B ligand (Rankl) under control of a heat shock inducible promoter. Forced Rankl expression resulted in ectopic osteoclast formation, as visualized by live imaging in fluorescent reporter lines. This led to increased bone resorption and a dramatic reduction of mineralized matrix similar to the situation in humans with osteoporosis. In an attempt to establish the medaka as an in vivo model for osteoporosis drug screening, we treated Rankl expressing larvae with etidronate and alendronate, two bisphosphonates commonly used in human osteoporosis therapy. Using live imaging, we observed an efficient, dose dependent inhibition of osteoclast activity, which resulted in the maintenance of bone integrity despite an excess of osteoclast formation. Strikingly, we also found that bone recovery was efficiently promoted after inhibition of osteoclast activity and that osteoblast distribution was altered, suggesting effects on osteoblast osteoclast coupling. Our data show that transgenic medaka lines are suitable in vivo models for the characterization of antiresorptive or bone anabolic compounds by live imaging and for screening of novel osteoporosis drugs.
C1 [Yu, Tingsheng; Buettner, Anita; Thuy Thanh To; Winkler, Christoph] Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore.
   [Yu, Tingsheng; Buettner, Anita; Thuy Thanh To; Winkler, Christoph] NUS Ctr Bioimaging Sci CBIS, Singapore 117557, Singapore.
   [Witten, Paul Eckhard; Huysseune, Ann] Univ Ghent, Dept Biol, B 9000 Ghent, Belgium.
   [Buettner, Anita] Tech Univ Dresden, Dept Chem & Food Chem, Dresden, Germany.
   [Thuy Thanh To] VNU Univ Sci, Fac Biol, Hanoi, Vietnam.
C3 National University of Singapore; Ghent University; Technische
   Universitat Dresden; Vietnam National University Hanoi (VNU Hanoi)
   System
RP Winkler, C (通讯作者)，Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore.; Winkler, C (通讯作者)，NUS Ctr Bioimaging Sci CBIS, Singapore 117557, Singapore.
EM dbswcw@nus.edu.sg
RI ; Witten, Paul Eckhard/AAY 3113 2020; Winkler, Christoph/G 4822 2012
OI Witten, Paul Eckhard/0000 0002 2928 5762; Yu,
   Tingsheng/0000 0002 8106 7981; Winkler, Christoph/0000 0003 4688 6241; 
FU Singapore A Star Biomedical Research Council (BMRC) [10/1/21/19/661];
   Singapore Ministry of Education (MOE) [2013 T2 2 126]
FX This project is funded by grants from the Singapore A Star Biomedical
   Research Council (BMRC) [grant number 10/1/21/19/661]; and a Tier 2
   grant from the Singapore Ministry of Education (MOE) [grant number
   2013 T2 2 126].
CR Ablain J, 2013, TRENDS CELL BIOL, V23, P584, DOI 10.1016/j.tcb.2013.09.009
   Apschner A, 2014, DIS MODEL MECH, V7, P811, DOI 10.1242/dmm.015693
   Apschner A, 2011, METHOD CELL BIOL, V105, P239, DOI 10.1016/B978 0 12 381320 6.00010 2
   Barrett Ruth, 2006, Biotechnology Journal, V1, P651, DOI 10.1002/biot.200600043
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Dominguez LJ, 2011, BIOGERONTOLOGY, V12, P397, DOI 10.1007/s10522 011 9344 5
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Fleming A, 2005, J BIOMOL SCREEN, V10, P823, DOI 10.1177/1087057105279952
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Iwamatsu T, 2004, MECH DEVELOP, V121, P605, DOI 10.1016/j.mod.2004.03.012
   Iwamoto J, 2005, YONSEI MED J, V46, P750, DOI 10.3349/ymj.2005.46.6.750
   Jobke B, 2014, BONE, V59, P37, DOI 10.1016/j.bone.2013.10.024
   Khosla S, 2005, ENDOCRIN METAB CLIN, V34, P1015, DOI 10.1016/j.ecl.2005.07.009
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mackay Eirinn W, 2013, Bonekey Rep, V2, P445, DOI 10.1038/bonekey.2013.179
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Nanda I, 2002, P NATL ACAD SCI USA, V99, P11778, DOI 10.1073/pnas.182314699
   Nanes MS, 2009, FERTIL STERIL, V92, P403, DOI 10.1016/j.fertnstert.2009.05.049
   Renn J, 2009, DEV DYNAM, V238, P241, DOI 10.1002/dvdy.21836
   Renn J, 2013, DEV BIOL, V381, P134, DOI 10.1016/j.ydbio.2013.05.030
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Shanthanagouda AH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088165
   Takeyama K, 2014, DEV BIOL, V394, P292, DOI 10.1016/j.ydbio.2014.08.007
   To TT, 2012, DEVELOPMENT, V139, P141, DOI 10.1242/dev.071035
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Willems B, 2012, DEV BIOL, V364, P128, DOI 10.1016/j.ydbio.2012.01.023
   Witten PE, 2009, BIOL REV, V84, P315, DOI 10.1111/j.1469 185X.2009.00077.x
NR 29
TC 34
Z9 35
U1 0
U2 30
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 1754 8403
EI 1754 8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD FEB 1
PY 2016
VL 9
IS 2
BP 155
EP 163
DI 10.1242/dmm.019091
PG 9
WC Cell Biology; Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Pathology
GA DF6AX
UT WOS:000371438400007
PM 26704995
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Luo, JY
   Chen, J
   Deng, ZL
   Luo, XJ
   Song, WX
   Sharff, KA
   Tang, N
   Haydon, RC
   Luu, HH
   He, TC
AF Luo, Jinyong
   Chen, Jin
   Deng, Zhong Liang
   Luo, Xiaoji
   Song, Wen Xin
   Sharff, Katie A.
   Tang, Ni
   Haydon, Rex C.
   Luu, Hue H.
   He, Tong Chuan
TI Wnt signaling and human diseases: what are the therapeutic implications?
SO LABORATORY INVESTIGATION
LA English
DT Article
DE beta catenin/Tcf signaling; stem cells; targeted therapy; tumorigenesis;
   Wnt signaling
ID FAMILIAL EXUDATIVE VITREORETINOPATHY; BETA CATENIN; CELL PROLIFERATION;
   STEM CELLS; BONE MASS; IN VIVO; GENE; MUTATIONS; EXPRESSION; ACTIVATION
AB Wnt signaling plays an important role in regulating cell proliferation and differentiation. De regulation of these signaling pathways has been implicated in many human diseases, ranging from cancers to skeletal disorders. Wnt proteins are a large family of secreted factors that bind to the Frizzled receptors and LRP5/6 co receptors and initiate complex signaling cascades. Over the past two decades, our understanding of Wnt signaling has been significantly improved due to the identification of many key regulators and mediators of these pathways. Given that Wnt signaling is tightly regulated at multiple cellular levels, these pathways themselves offer ample nodal points for targeted therapeutics. Here, we focus on our current understanding of these pathways, the associations of Wnt signaling with human disorders, and the opportunities to target key components of Wnt signaling for rational drug discovery.
C1 Univ Chicago, Med Ctr, Mol Oncol Lab, Dept Surg, Chicago, IL 60637 USA.
   Chongqing Univ Med Sci, Minist Educ, Key Lab Diagnost Med, Chongqing, Peoples R China.
   Chongqing Univ Med Sci, Affiliated Hosp 2, Dept Orthopaed Surg, Chongqing, Peoples R China.
C3 University of Chicago; University of Chicago Medical Center; Chongqing
   Medical University; Chongqing Medical University
RP He, TC (通讯作者)，Univ Chicago, Med Ctr, Mol Oncol Lab, Dept Surg, 5841 S Maryland Ave,MC 3079, Chicago, IL 60637 USA.
EM tche@surgery.bsd.uchicago.edu
CR Barandon L, 2003, CIRCULATION, V108, P2282, DOI 10.1161/01.CIR.0000093186.22847.4C
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Caricasole A, 2003, TRENDS PHARMACOL SCI, V24, P233, DOI 10.1016/S0165 6147(03)00100 7
   Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399
   Christodoulides C, 2006, DIABETOLOGIA, V49, P678, DOI 10.1007/s00125 006 0144 4
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Cobas M, 2004, J EXP MED, V199, P221, DOI 10.1084/jem.20031615
   Cong F, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471 2199 4 10
   Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867
   Daniels DL, 2001, TRENDS BIOCHEM SCI, V26, P672, DOI 10.1016/S0968 0004(01)01952 1
   Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092 8674(04)00255 7
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Guo N, 2004, P NATL ACAD SCI USA, V101, P9277, DOI 10.1073/pnas.0402802101
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   Hartmann C, 2000, DEVELOPMENT, V127, P3141
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092 8674(00)81664 5
   Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008 5472.CAN 03 1952
   Jordan BK, 2003, P NATL ACAD SCI USA, V100, P10866, DOI 10.1073/pnas.1834480100
   Katsu T, 2003, NEUROSCI LETT, V353, P53, DOI 10.1016/j.neulet.2003.09.017
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092 8674(00)81333 1
   Kohn AD, 2005, CELL CALCIUM, V38, P439, DOI 10.1016/j.ceca.2005.06.022
   Kondo H, 2003, BRIT J OPHTHALMOL, V87, P1291, DOI 10.1136/bjo.87.10.1291
   Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270
   Kozlovsky N, 2002, EUR NEUROPSYCHOPHARM, V12, P13, DOI 10.1016/S0924 977X(01)00131 6
   Lammi L, 2004, AM J HUM GENET, V74, P1043, DOI 10.1086/386293
   Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535 6108(03)00334 9
   Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535 6108(03)00268 X
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Liu J, 2004, BIOCHEM BIOPH RES CO, V313, P1023, DOI 10.1016/j.bbrc.2003.12.035
   Loughlin J, 2004, P NATL ACAD SCI USA, V101, P9757, DOI 10.1073/pnas.0403456101
   Luu HH, 2004, CURR CANCER DRUG TAR, V4, P653, DOI 10.2174/1568009043332709
   Miyaoka T, 1999, SCHIZOPHR RES, V38, P1, DOI 10.1016/S0920 9964(98)00179 0
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521 1878(199912)22:1<1021::AID BIES6>3.0.CO;2 P
   Mudher A, 2002, TRENDS NEUROSCI, V25, P22, DOI 10.1016/S0166 2236(00)02031 2
   Niemann S, 2004, AM J HUM GENET, V74, P558, DOI 10.1086/382196
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092 8674(82)90409 3
   Okamura RM, 1998, IMMUNITY, V8, P11, DOI 10.1016/S1074 7613(00)80454 9
   Olson EN, 2003, GENE DEV, V17, P1937, DOI 10.1101/gad.1110103
   Perantoni AO, 2003, SEMIN CELL DEV BIOL, V14, P201, DOI 10.1016/S1084 9521(03)00022 3
   Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959 437X(99)80003 3
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Robitaille J, 2002, NAT GENET, V32, P326, DOI 10.1038/ng957
   Rodova M, 2002, J BIOL CHEM, V277, P29577, DOI 10.1074/jbc.M203570200
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448
   Sekiya T, 2002, CANCER RES, V62, P3322
   Shih IM, 2000, CANCER RES, V60, P1671
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Su YY, 2003, P NATL ACAD SCI USA, V100, P12729, DOI 10.1073/pnas.2133261100
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Toomes C, 2004, AM J HUM GENET, V74, P721, DOI 10.1086/383202
   Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534
   Tsuji T, 2001, BIOCHEM BIOPH RES CO, V289, P257, DOI 10.1006/bbrc.2001.5972
   Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202
   van Gijn ME, 2002, CARDIOVASC RES, V55, P16, DOI 10.1016/S0008 6363(02)00221 3
   VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691
   Varallo VM, 2003, ONCOGENE, V22, P3680, DOI 10.1038/sj.onc.1206415
   Verma UN, 2003, CLIN CANCER RES, V9, P1291
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Yu HMI, 2005, DEVELOPMENT, V132, P1995, DOI 10.1242/dev.01786
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhou L, 2003, CANCER LETT, V193, P161, DOI 10.1016/S0304 3835(03)00013 2
   ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700
NR 67
TC 154
Z9 211
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 0023 6837
EI 1530 0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2007
VL 87
IS 2
BP 97
EP 103
DI 10.1038/labinvest.3700509
PG 7
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pathology
GA 136IP
UT WOS:000244216100001
PM 17211410
OA Bronze
DA 2025 08 17
ER

PT J
AU Wang, JH
   Zhang, YJ
   Li, HY
   Liu, YY
   Sun, T
AF Wang, Jian Hang
   Zhang, Yuanjin
   Li, Hong Yan
   Liu, Yun Yan
   Sun, Tao
TI Dickkopf 1 negatively regulates the expression of osteoprotegerin, a key
   osteoclastogenesis inhibitor, by sequestering Lrp6 in primary and
   metastatic lytic bone lesions
SO MEDICINE
LA English
DT Article
DE bone pain; bone resorption; negative regulator; osteoclast; osteolysis;
   Wnt signaling
ID MULTIPLE MYELOMA; SERUM LEVELS; PATHWAY; BREAST
AB Recently, an inverse role for Wnt signaling in the development of osteoclasts in the bone was demonstrated. In the present study, we examined whether there is a commonality in the mechanism of bone resorption and lysis that occur in a diverse set of bone metastatic lesions, as well as in primary bone lesions. Compared with control bone tissue and bone biopsies from patients with nonmetastatic primary tumors (i.e., breast carcinoma, lung adenocarcinoma, and prostate carcinoma), patients with bone metastatic lesions from the three aforementioned primary tumors, as well as osteolytic lesions obtained from the bone biopsies of patients with multiple myeloma, demonstrated an upregulated expression of the glycoprotein Dickkopf 1 at both the mRNA and protein levels. Additionally, by coimmunoprecipitation, Dickkopf 1 pulled down low density lipoprotein receptor related protein 6 (Lrp6), which is a key downstream effector of the Wnt signaling pathway. The expression of Lrp6 was unaltered in the osteometastatic lesions. This negative regulation was associated with a lowered expression of osteoprotegerin in the osteometastatic lesions, an observation that was previously reported to promote osteoclastogenesis. These findings provide a common mechanism for the inverse relationship between the Wnt signaling pathway and the development of primary or metastatic bone lesions. Pharmacological modulation of the Wnt signaling pathway might benefit the clinical management of primary and metastatic bone lesions.
C1 [Wang, Jian Hang; Li, Hong Yan; Liu, Yun Yan; Sun, Tao] Yantaishan Hosp, Trauma Dept Orthoped, 91 Jiefang Rd, Yantai, Shandong, Peoples R China.
   [Zhang, Yuanjin] Hubei Polytech Univ, Dept Orthoped, Huangshi Cent Hosp, Affiliated Hosp, Huangshi, Hubei, Peoples R China.
C3 Hubei Polytechnic University
RP Sun, T (通讯作者)，Yantaishan Hosp, Trauma Dept Orthoped, 91 Jiefang Rd, Yantai, Shandong, Peoples R China.
EM taosun_med@126.com
RI Liu, You Nian/G 2697 2013; yu, yingying/GRR 7851 2022
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   [Anonymous], J CELL BIOCH
   Colaianni G, 2014, WORLD J ORTHOP, V5, P242, DOI 10.5312/wjo.v5.i3.242
   Frey JL, 2015, MOL CELL BIOL, V35, P1979, DOI 10.1128/MCB.01343 14
   Garcia Martín A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111703
   Hamamura K, 2014, CELL SIGNAL, V26, P2358, DOI 10.1016/j.cellsig.2014.07.018
   Hameed A, 2014, CANCER GROWTH METAST, V7, P33, DOI 10.4137/CGM.S16817
   Hu TH, 2014, CANCER LETT, V354, P417, DOI 10.1016/j.canlet.2014.08.012
   Iyer SP, 2014, BRIT J HAEMATOL, V167, P366, DOI 10.1111/bjh.13056
   Johnstone C, 2014, ANN PALLIAT MED, V3, P114, DOI 10.3978/j.issn.2224 5820.2014.04.06
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Milat F, 2009, MOL CELL ENDOCRINOL, V310, P52, DOI 10.1016/j.mce.2009.06.002
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Nickman NA, 2015, J COMMUNITY SUPPORT, V13, P95, DOI 10.12788/jcso.0115
   Piccioli A, 2015, J ORTHOP TRAUMATOL, V16, P81, DOI 10.1007/s10195 015 0344 0
   Quayle L, 2015, CURR CANCER DRUG TAR, V15, P469, DOI 10.2174/1568009615666150506092443
   Rachner TD, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 649
   Rachner TD, 2014, CANCER LETT, V346, P172, DOI 10.1016/j.canlet.2014.01.010
   Rossini M, 2015, CLIN EXP RHEUMATOL, V33, P77
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sottnik Joseph L, 2012, Bonekey Rep, V1, P101, DOI 10.1038/bonekey.2012.101
   Suvannasankha A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058 014 0484 9
   Takahashi N, 2011, FRONT BIOSCI LANDMRK, V16, P21, DOI 10.2741/3673
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   Ueda S, 2015, MED MOL MORPHOL, V48, P69, DOI 10.1007/s00795 014 0077 9
   Wan Y, 2015, TRENDS PHARMACOL SCI
NR 26
TC 8
Z9 8
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUN
PY 2016
VL 95
IS 24
AR e3767
DI 10.1097/MD.0000000000003767
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA DO8SD
UT WOS:000378053000013
PM 27310953
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tanaka, Y
   Ohira, T
AF Tanaka, Yoshiya
   Ohira, Takeshi
TI Mechanisms and therapeutic targets for bone damage in rheumatoid
   arthritis, in particular the RANK RANKL system
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID MODIFYING ANTIRHEUMATIC DRUGS; POSTMENOPAUSAL WOMEN; JAPANESE PATIENTS;
   ZOLEDRONIC ACID; MINERAL DENSITY; DOUBLE BLIND; VERTEBRAL FRACTURES;
   DENOSUMAB TREATMENT; BIOLOGIC THERAPIES; COST EFFECTIVENESS
AB Rheumatoid arthritis (RA), a chronic inflammatory disorder, causes swelling, bone erosion, and joint deformity. Bone erosion in RA affected joints arises from activation of osteoclasts by inflammatory processes. RA patients may also have primary, disease related, or glucocorticoid induced osteoporosis, caused by a disrupted balance between osteoclasts and osteoblasts. Disease modifying antirheumatic drugs (DMARDs) interfere with the processes causing inflammation in the joint but do not sufficiently treat bone erosion and osteoporosis. Denosumab, an inhibitor of receptor activator of nuclear factor kappa B ligand (RANKL), protects bones in osteoporosis patients. Clinical studies have demonstrated that denosumab can also prevent bone erosion in RA patients. Because joint destruction progresses in some patients treated with DMARDs alone, denosumab will likely become standard treatment for some RA patients.
C1 [Tanaka, Yoshiya] Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, 1 1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.
   [Ohira, Takeshi] Daiichi Sankyo Co Ltd, R&D Div, Clin Dev Dept, Shinagawa Ku, 1 2 58 Hiromachi, Tokyo 1408710, Japan.
C3 University of Occupational & Environmental Health   Japan; Daiichi
   Sankyo Company Limited
RP Tanaka, Y (通讯作者)，Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, 1 1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.
EM tanaka@med.uoeh u.ac.jp
CR Amgen, PROL
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Boleto G, 2017, CLIN RHEUMATOL, V36, P1699, DOI 10.1007/s10067 017 3722 6
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Buckley L, 2017, ARTHRIT CARE RES, V69, P1095, DOI 10.1002/acr.23279
   Chiu YG, 2017, EXPERT OPIN BIOL TH, V17, P119, DOI 10.1080/14712598.2017.1263614
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Cummings SR, 2017, J BONE MINER RES, V32, P3, DOI 10.1002/jbmr.3039
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Curtis JR, 2015, ARTHRITIS RHEUMATOL, V67, P1456, DOI 10.1002/art.39075
   Danks L, 2016, ANN RHEUM DIS, V75, P1187, DOI 10.1136/annrheumdis 2014 207137
   Deodhar A, 2010, ARTHRIT CARE RES, V62, P569, DOI 10.1002/acr.20004
   Dimitroulas T, 2013, AUTOIMMUN REV, V12, P958, DOI 10.1016/j.autrev.2013.03.015
   Dore RK, 2010, ANN RHEUM DIS, V69, P872, DOI 10.1136/ard.2009.112920
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Hasegawa T, 2017, JOINT BONE SPINE, V84, P379, DOI 10.1016/j.jbspin.2016.05.010
   Haugeberg G, 2000, ARTHRITIS RHEUM, V43, P522, DOI 10.1002/1529 0131(200003)43:3<522::AID ANR7>3.0.CO;2 Y
   Hayer S, 2016, DIS MODEL MECH, V9, P1329, DOI 10.1242/dmm.025460
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hensvold AH, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0760 9
   Hirabayashi Y, 2016, MOD RHEUMATOL, V26, P828, DOI 10.3109/14397595.2016.1160991
   Japan College of Rheumatology, 2014, GUID MAN RHEUM ARTH
   Jarrett SJ, 2006, ARTHRITIS RHEUM US, V54, P1410, DOI 10.1002/art.21824
   Jimenez Boj E, 2005, J IMMUNOL, V175, P2579, DOI 10.4049/jimmunol.175.4.2579
   Jönsson B, 2011, OSTEOPOROSIS INT, V22, P967, DOI 10.1007/s00198 010 1424 x
   Lindqvist E, 2003, ANN RHEUM DIS, V62, P611, DOI 10.1136/ard.62.7.611
   Mahlich J, 2017, CURR MED RES OPIN, V33, P101, DOI 10.1080/03007995.2016.1239191
   McClung MR, 2016, OSTEOPOROSIS INT, V27, P1677, DOI 10.1007/s00198 016 3553 3
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Meednu N, 2016, ARTHRITIS RHEUMATOL, V68, P805, DOI 10.1002/art.39489
   Meinen R, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1167 8
   Miller PD, 2016, J CLIN ENDOCR METAB, V101, P3163, DOI 10.1210/jc.2016 1801
   Mori T, 2017, OSTEOPOROSIS INT, V28, P1733, DOI 10.1007/s00198 017 3940 4
   Nakamura T, 2014, J CLIN ENDOCR METAB, V99, P2599, DOI 10.1210/jc.2013 4175
   Ochi K, 2015, OSTEOPOROSIS INT, V26, P961, DOI 10.1007/s00198 014 2911 2
   Ochi K, 2014, CLIN RHEUMATOL, V33, P477, DOI 10.1007/s10067 013 2415 z
   Papapoulos S, 2015, OSTEOPOROSIS INT, V26, P2773, DOI 10.1007/s00198 015 3234 7
   Parthan A, 2014, BONE, V59, P105, DOI 10.1016/j.bone.2013.11.002
   Rossini M, 2017, REUMATISMO, V69, P30, DOI 10.4081/reumatismo.2017.922
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2166
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Seeman E, 2010, J BONE MINER RES, V25, P1886, DOI 10.1002/jbmr.81
   Sharp JT, 2010, ARTHRIT CARE RES, V62, P537, DOI 10.1002/acr.20172
   Silverman S, 2015, J OSTEOPOROS, V2015, DOI 10.1155/2015/627631
   Singh JA, 2016, ARTHRIT CARE RES, V68, P1, DOI 10.1002/acr.22783
   Smolen JS, 2016, LANCET, V388, P1984
   Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis 2016 210715
   Stopeck AT, 2016, SUPPORT CARE CANCER, V24, P447, DOI 10.1007/s00520 015 2904 5
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Takeuchi T, 2017, ANN RHEUM DIS, V76, P841, DOI 10.1136/annrheumdis 2017 eular.1081
   Takeuchi T, 2016, ANN RHEUM DIS, V75, P983, DOI 10.1136/annrheumdis 2015 208052
   Tanaka E, 2017, MOD RHEUMATOL, V27, P227, DOI 10.1080/14397595.2016.1205799
   Tanaka S., 2017, MOD RHEUMATOL, P1
   Tanaka Y, 2011, INFLAMM REGEN, V31, P344
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Tanaka Y, 2016, KOREAN J INTERN MED, V31, P210, DOI 10.3904/kjim.2015.137
   Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
   Vis M, 2013, OSTEOPOROSIS INT, V24, P2541, DOI 10.1007/s00198 013 2334 5
   Yeo L, 2015, ANN RHEUM DIS, V74, P928, DOI 10.1136/annrheumdis 2013 204116
   Yoneda T, 2017, J BONE MINER METAB, V35, P6, DOI 10.1007/s00774 016 0810 7
   Yue J, 2017, ARTHRIT CARE RES, V69, P1156, DOI 10.1002/acr.23133
   Zebaze RM, 2014, BONE, V59, P173, DOI 10.1016/j.bone.2013.11.016
   Zerbini CAF, 2017, OSTEOPOROSIS INT, V28, P429, DOI 10.1007/s00198 016 3769 2
NR 67
TC 59
Z9 64
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471 4892
EI 1471 4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD JUN
PY 2018
VL 40
BP 110
EP 119
DI 10.1016/j.coph.2018.03.006
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GM6YE
UT WOS:000438324100018
PM 29702364
DA 2025 08 17
ER

PT J
AU Rajpar, S
   Fizazi, K
AF Rajpar, Shanna
   Fizazi, Karim
TI Bone Targeted Therapies in Metastatic Castration Resistant Prostate
   Cancer
SO CANCER JOURNAL
LA English
DT Article
DE Bone microenvironment; bisphosphonates; denosumab; RANK L; SRC;
   Alpharadin
ID PHASE II TRIAL; PLACEBO CONTROLLED TRIAL; SKELETAL RELATED EVENTS; SRC
   FAMILY KINASES; QUALITY OF LIFE; ZOLEDRONIC ACID; DOUBLE BLIND; ADJUVANT
   THERAPY; BREAST CANCER; SOLID TUMORS
AB Prostate cancer is the most common male cancer. About 90% of metastatic patients will develop bone metastases. Bone disease is responsible of pain, deterioration of quality of life and serious bone complications. Proliferation of prostate cancer cells in the bone marrow induces osteoclast activation and osteolysis. Targeting the bone micro environment reduces morbidity. Relevant preclinical and clinical studies of bone targeted therapies in castration resistant prostate cancer were identified in PubMed and clinical trial databases. Different drugs are available or in development that target bone resorption (bisphosphonates, RANK ligand inhibitors), bone formation (endothelin 1 inhibitors), cancer cell migration (SRC family kinase inhibitors, vascular endothelial growth factor MET inhibitors), and survival (radiopharmaceuticals). In phase III trials, zoledronic acid, denosumab, and radium 223 were shown to significantly delay skeletal related events. Radium 223 was also shown to improve overall survival. Biomarkers of bone resorption (urinary N telopeptide) and bone making (alkaline phosphatase) have an independent prognostic impact. Targeting the bone microenvironment is an important component of castration resistant prostate cancer management to reduce bone complications and improve overall survival. Biomarkers of bone turnover have an independent prognostic impact.
C1 [Rajpar, Shanna; Fizazi, Karim] Univ Paris Sud, Dept Canc Med, Inst Gustave Roussy, F 94800 Villejuif, France.
C3 UNICANCER; Gustave Roussy; Universite Paris Saclay
RP Rajpar, S (通讯作者)，Univ Paris Sud, Dept Canc Med, Inst Gustave Roussy, 39 Rue Camille Desmoulins, F 94800 Villejuif, France.
EM shanna.rajpar@igr.fr
CR ACKERY D, 1993, SEMIN ONCOL, V20, P27
   Akhavan A, 2006, NEOPLASIA, V8, P725, DOI 10.1593/neo.06388
   [Anonymous], J UROL
   Araujo J, 2009, INT J CANCER, V124, P1, DOI 10.1002/ijc.23998
   Araujo JC, 2012, CANCER AM CANCER SOC, V118, P63, DOI 10.1002/cncr.26204
   Armstrong AJ, 2007, J CLIN ONCOL, V25, P3965, DOI 10.1200/JCO.2007.11.4769
   Bagnato Anna, 2004, J Transl Med, V2, P16, DOI 10.1186/1479 5876 2 16
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Basch E, 2012, ANN ONCOL S9, V23
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Brubaker KD, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 15
   Cheetham PJ, 2012, ONCOLOGY NY, V26, P330
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Cook RJ, 2006, CLIN CANCER RES, V12, P3361, DOI 10.1158/1078 0432.CCR 06 0269
   Costa L, 2008, SUPPORT CARE CANCER, V16, P879, DOI 10.1007/s00520 008 0418 0
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140 6736(10)61389 X
   Dearnaley DP, 2009, LANCET ONCOL, V10, P872, DOI 10.1016/S1470 2045(09)70201 3
   Drake JM, 2010, CANCER BIOL THER, V9, P607, DOI 10.4161/cbt.9.8.11112
   Fizazi K, 2007, ANN ONCOL, V18, P1765, DOI 10.1093/annonc/mdm086
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   Fizazi K, 2012, ASCO M, P4642
   Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470 2045(12)70379 0
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Fizazi K, 2009, J CLIN ONCOL, V27, P2429, DOI 10.1200/JCO.2008.18.9811
   Fizazi K, 2009, J UROLOGY, V182, P509, DOI 10.1016/j.juro.2009.04.023
   Guise TA, 2008, CANCER TREAT REV, V34, pS19, DOI 10.1016/j.ctrv.2008.03.006
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Halabi S, 2008, J CLIN ONCOL, V26, P2544, DOI 10.1200/JCO.2007.15.0367
   Hussain M, 2012, ASCO M, P4516
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Karabulut B, 2009, CELL BIOL INT, V33, P239, DOI 10.1016/j.cellbi.2008.11.011
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Kelly WK, 2012, J CLIN ONCOL, V30, P1534, DOI 10.1200/JCO.2011.39.4767
   LEWINGTON VJ, 1991, EUR J CANCER, V27, P954, DOI 10.1016/0277 5379(91)90257 E
   Lipton A, 2008, CANCER AM CANCER SOC, V113, P193, DOI 10.1002/cncr.23529
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Logothetis C, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.4520
   Nelson JB, 1996, CANCER RES, V56, P663
   Nelson JB, 2012, CANCER AM CANCER SOC, V118, P5709, DOI 10.1002/cncr.27674
   Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008 5472.CAN 07 2997
   Parker C, 2012, ECCO M, V8
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   PORTER AT, 1993, INT J RADIAT ONCOL, V25, P805, DOI 10.1016/0360 3016(93)90309 J
   Quinn D, 2012, ASCO M, P4511
   Rajpar S, 2010, ANN ONCOL, V21, P1864, DOI 10.1093/annonc/mdq037
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Sabbatini P, 1999, J CLIN ONCOL, V17, P948, DOI 10.1200/JCO.1999.17.3.948
   Sartor O, 2004, UROLOGY, V63, P940, DOI 10.1016/j.urology.2004.01.034
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159 8290.CD 11 0240
   Siegel R, 2012, CA CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Silberstein EB, 1996, J NUCL MED, V37, P249
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smith MR, 2012, ASCO M, P4513
   Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750
   Tanaka T, 2009, ANTICANCER RES, V29, P1089
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Tatarov O, 2009, CLIN CANCER RES, V15, P3540, DOI 10.1158/1078 0432.CCR 08 1857
   Tu SM, 2001, LANCET, V357, P336, DOI 10.1016/S0140 6736(00)03639 4
   Ullén A, 2005, ACTA ONCOL, V44, P644, DOI 10.1080/02841860510029617
   Vandyke K, 2010, J BONE MINER RES, V25, P1759, DOI 10.1002/jbmr.85
   Weinfurt KP, 2005, ANN ONCOL, V16, P579, DOI 10.1093/annonc/mdi122
   Yakes FM, 2011, MOL CANCER THER, V10, P2298, DOI 10.1158/1535 7163.MCT 11 0264
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   Yu EY, 2011, UROLOGY, V77, P1166, DOI 10.1016/j.urology.2011.01.006
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 70
TC 27
Z9 30
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1528 9117
EI 1540 336X
J9 CANCER J
JI Cancer J.
PD JAN FEB
PY 2013
VL 19
IS 1
BP 66
EP 70
DI 10.1097/PPO.0b013e31827f123e
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 075SN
UT WOS:000313906900010
PM 23337759
DA 2025 08 17
ER

PT J
AU Nagano, A
   Arioka, M
   Takahashi Yanaga, F
   Matsuzaki, E
   Sasaguri, T
AF Nagano, Akihiro
   Arioka, Masaki
   Takahashi Yanaga, Fumi
   Matsuzaki, Etsuko
   Sasaguri, Toshiyuki
TI Celecoxib inhibits osteoblast maturation by suppressing the expression
   of Wnt target genes
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Osteoblast; Celecoxib; Wnt/beta catenin signaling pathway;
   Mineralization; Fracture healing
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLON CANCER CELLS; BETA CATENIN;
   CYCLOOXYGENASE 2; DIFFERENTIATION; PROSTAGLANDINS; MECHANISMS; PROMISE;
   REPAIR; CBFA1
AB Non steroidal anti inflammatory drugs (NSAIDs) have been shown to impair bone healing. We previously reported that in colon cancer cells, celecoxib, a COX 2 selective NSAID, inhibited the canonical Wnt/b catenin signaling pathway. Since this pathway also plays an important role in osteoblast growth and differentiation, we examined the effect of celecoxib on maturation of osteoblast like cell line MC3T3 E1. Celecoxib induced degradation of transcription factor 7 like 2, a key transcription factor of the canonical Wnt pathway. Subsequently, we analyzed the effect of celecoxib on two osteoblast differentiation markers; runt related transcription factor 2 (RUNX2) and alkaline phosphatase (ALP), both of which are the products of the canonical Wnt pathway target genes. Celecoxib inhibited the expression of both RUNX2 and ALP by suppressing their promoter activity. Consistent with these observations, celecoxib also strongly inhibited osteoblast mediated mineralization. These results suggest that celecoxib inhibits osteoblast maturation by suppressing Wnt target genes, and this could be the mechanism that NSAIDs inhibit bone formation and fracture healing. (C) 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
C1 [Nagano, Akihiro; Arioka, Masaki; Takahashi Yanaga, Fumi; Sasaguri, Toshiyuki] Kyushu Univ, Dept Clin Pharmacol, Fac Med Sci, Fukuoka 8128582, Japan.
   [Nagano, Akihiro; Matsuzaki, Etsuko] Kyushu Univ, Fac Dent Sci, Periodontol Sect, Div Oral Rehabil, Fukuoka, Japan.
   [Takahashi Yanaga, Fumi] Kyushu Univ, Fac Med Sci, Global Med Sci Educ Unit, Fukuoka, Japan.
   [Matsuzaki, Etsuko] Fukuoka Dent Coll, Sect Operat Dent & Endodontol, Dept Odontol, Fukuoka, Japan.
C3 Kyushu University; Kyushu University; Kyushu University; Fukuoka Dental
   College (FDC)
RP Takahashi Yanaga, F (通讯作者)，Kyushu Univ, Dept Clin Pharmacol, Fac Med Sci, Fukuoka 8128582, Japan.
EM yanaga@clipharm.med.kyushu u.ac.jp
RI Arioka, Masaki/HHR 9578 2022
OI Arioka, Masaki/0000 0001 7722 0843
FU Ministry of Education, Culture, Sports, Science and Technology;
   Grants in Aid for Scientific Research [15K18990] Funding Source: KAKEN
FX We thank Fumie Shiraishi (Kyushu University) for assistance with
   construction of the RUNX2 pGL3 basic luciferase reporter plasmid. This
   study was supported by a Grant in Aid for Scientific Research from the
   Ministry of Education, Culture, Sports, Science and Technology. We would
   like to thank the Research Support Center, Graduate School of Medical
   Sciences, Kyushu University.
CR Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Casrellone MD, 2005, SCIENCE, V310, P1504
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535 6108(03)00310 6
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gerstenfeld LC, 2007, J BONE JOINT SURG AM, V89A, P114, DOI 10.2106/JBJS.F.00495
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Harder AT, 2003, J CLIN PHARMACOL, V43, P807, DOI 10.1177/0091270003256061
   Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471 4906(01)02154 8
   Henriquez B, 2011, J CELL PHYSIOL, V226, P3043, DOI 10.1002/jcp.22652
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Macsai CE, 2008, J CELL PHYSIOL, V215, P578, DOI 10.1002/jcp.21342
   Matsuzaki E, 2006, J BONE MINER RES, V21, P1307, DOI 10.1359/JBMR.060512
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Naot D, 2011, BONE, V49, P217, DOI 10.1016/j.bone.2011.04.002
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Sakoguchi Okada N, 2007, BIOCHEM PHARMACOL, V73, P1318, DOI 10.1016/j.bcp.2006.12.033
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603
   Suponitzky I, 1998, J ENDOCRINOL, V156, P51, DOI 10.1677/joe.0.1560051
   Takahashi Yanaga F, 2008, BIOCHEM BIOPH RES CO, V377, P1185, DOI 10.1016/j.bbrc.2008.10.115
   Tuynman JB, 2008, CANCER RES, V68, P1213, DOI 10.1158/0008 5472.CAN 07 5172
   Vuolteenaho K, 2008, BASIC CLIN PHARMACOL, V102, P10, DOI 10.1111/j.1742 7843.2007.00149.x
   Weinreb M, 1997, BONE, V20, P521, DOI 10.1016/S8756 3282(97)00033 1
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 29
TC 31
Z9 31
U1 0
U2 6
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD JAN
PY 2017
VL 133
IS 1
BP 18
EP 24
DI 10.1016/j.jphs.2016.11.003
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA EO2EO
UT WOS:000396509600003
PM 28007462
OA gold
DA 2025 08 17
ER

PT J
AU Hahm, ER
   Kim, SH
   Pore, SK
   Mathan, SV
   Singh, RP
   Singh, SV
AF Hahm, Eun Ryeong
   Kim, Su Hyeong
   Pore, Subrata K.
   Mathan, Sivapar V.
   Singh, Rana P.
   Singh, Shivendra V.
TI Mechanism of synergistic inhibitory effect of benzyl isothiocyanate and
   zoledronic acid combination on breast cancer induction of osteoclast
   differentiation
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE benzyl isothiocyanate; bone metastasis; osteoclast; zoledronic acid
ID BONE METASTASES; DENOSUMAB; PATHWAY
AB Bone is the most favored site for metastasis for each major subtype of breast cancer. Therapeutic modalities for alleviation of clinical symptoms associated with bone metastasis include surgical resection, radiation, and bone targeted therapies, including bisphosphonates (e.g., zoledronic acid; ZA) and a humanized antibody against receptor activator of nuclear factor kappa B ligand (denosumab). However, the bone targeted therapies are expensive, and have poor pharmacokinetic attributes and/or serious adverse effects. Therefore, novel strategies are needed for treatment of bone metastasis or to increase effectiveness of existing bone targeted therapies. We have shown previously that benzyl isothiocyanate (BITC) is a novel inhibitor of osteoclast differentiation in vitro and bone metastasis in vivo. The present study shows that BITC + ZA combination synergistically inhibits osteoclast differentiation induced by addition of conditioned media from breast cancer cells. These effects were associated with a significant increase in levels of several antiosteoclastogenic cytokines, including interferons, interleukin (IL) 3, IL 4, and IL 27. Kyoto Encyclopedia of Genes and Genomes pathway analysis of RNA seq data from BITC and/or ZA treated cells revealed downregulation of genes of many pathways (e.g., actin cytoskeleton, Hippo signaling, etc.) by treatment with BITC + ZA combination, but not by BITC alone or ZA alone. Confocal microscopy confirmed severe disruption of actin cytoskeleton upon treatment of MCF 7 and MDA MB 231 cells with the BITC + ZA combination. This combination also decreased the nuclear level of yes associated protein, a core component of Hippo signaling. In conclusion, the present study offers a novel combination for prevention or treatment of bone metastasis of breast cancer.
C1 [Hahm, Eun Ryeong; Kim, Su Hyeong; Mathan, Sivapar V.; Singh, Shivendra V.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA.
   [Pore, Subrata K.] Amity Univ, Amity Inst Mol Med & Stem Cell Res, Noida, India.
   [Singh, Rana P.] Jawaharlal Nehru Univ, Sch Life Sci, Canc Biol Lab, New Delhi, India.
   [Singh, Shivendra V.] Univ Pittsburgh, Sch Med, UPMC Hillman Canc Ctr, Pittsburgh, PA USA.
   [Singh, Shivendra V.] Univ Pittsburgh, Sch Med, UPMC Hillman Canc Ctr, Dept Pharmacol & Chem Biol, 2 32A Hillman Canc Ctr Res Pavilion,5117 Ctr Ave, Pittsburgh, PA 15213 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Amity University Noida; Jawaharlal Nehru University, New
   Delhi; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh
RP Singh, SV (通讯作者)，Univ Pittsburgh, Sch Med, UPMC Hillman Canc Ctr, Dept Pharmacol & Chem Biol, 2 32A Hillman Canc Ctr Res Pavilion,5117 Ctr Ave, Pittsburgh, PA 15213 USA.
EM singhs@upmc.edu
RI ; Singh, Rana/JZT 2038 2024; Mathan, Sivapar V/JOJ 9112 2023
OI Mathan, Sivapar V/0000 0002 3642 656X; Pore,
   Subrata/0000 0002 6324 6994; Hahm, Eun Ryeong/0000 0002 3197 4575;
   Singh, Rana Pratap/0000 0003 4261 7044
FU This study was supported by the National Cancer Institute at the
   National Institutes of Health grant R01 CA219180. This study used the
   UPMC Hillman Cancer Center resources supported by the National Cancer
   Institute at the National Institutes of Health gran [P30 CA047904];
   National Cancer Institute at the National Institutes of Health; UPCI
   Cancer Biomarkers Facility: Luminex Core Laboratory
FX Eun Ryeong Hahm designed the study and conducted experiments, prepared
   the first draft. Su Hyeong Kim, Subrata K. Pore, and Sivapar V. Mathan
   conducted experiments. Rana P. Singh supervised the study and edited the
   manuscript. Shivendra V. Singh supervised the study and prepared the
   final manuscript.r This study was supported by the National Cancer
   Institute at the National Institutes of Health grant R01 CA219180. This
   study used the UPMC Hillman Cancer Center resources supported by the
   National Cancer Institute at the National Institutes of Health grant P30
   CA047904. This project used the UPCI Cancer Biomarkers Facility: Luminex
   Core Laboratory.
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Brook N, 2018, INT J BIOCHEM CELL B, V96, P63, DOI 10.1016/j.biocel.2018.01.003
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Drooger JC, 2013, EUR J PHARMACOL, V717, P12, DOI 10.1016/j.ejphar.2013.03.034
   Harold CM, 2021, GENES BASEL, V12, DOI 10.3390/genes12040502
   He MJ, 2016, CELL DIV, V11, DOI 10.1186/s13008 016 0013 6
   Insalaco L, 2012, J CELL MOL MED, V16, P2186, DOI 10.1111/j.1582 4934.2012.01527.x
   Jackson C, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246441
   Jiang P, 2009, CANCER LETT, V284, P122, DOI 10.1016/j.canlet.2009.02.034
   Kashyap D, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/9605439
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Kim EJ, 2012, MOL CELL BIOCHEM, V359, P431, DOI 10.1007/s11010 011 1039 3
   Kim SH, 2020, CARCINOGENESIS, V41, P778, DOI 10.1093/carcin/bgaa009
   Kim SH, 2013, CANCER PREV RES, V6, P782, DOI 10.1158/1940 6207.CAPR 13 0100
   Kim SH, 2012, BREAST CANCER RES TR, V134, P1067, DOI 10.1007/s10549 012 2043 3
   Kurata T, 2012, JPN J CLIN ONCOL, V42, P663, DOI 10.1093/jjco/hys088
   Kyriazoglou A, 2021, BREAST CARE, V16, P6, DOI 10.1159/000507538
   Mancino AT, 2001, J SURG RES, V100, P18, DOI 10.1006/jsre.2001.6204
   O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4
   Piezzo M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186479
   Pore SK, 2018, CARCINOGENESIS, V39, P134, DOI 10.1093/carcin/bgx114
   Rossi L, 2020, CHIN CLIN ONCOL, V9, DOI 10.21037/cco.2020.01.07
   Scully OJ, 2012, CANCER GENOM PROTEOM, V9, P311
   Shi PG, 2015, ACTA BIOCH BIOPH SIN, V47, P53, DOI 10.1093/abbs/gmu114
   Tahara RK, 2019, ADV EXP MED BIOL, V1152, P105, DOI 10.1007/978 3 030 20301 6_7
   Tahata S, 2018, CANCER PREV RES, V11, P429, DOI 10.1158/1940 6207.CAPR 17 0268
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Venetis K, 2021, CELLS BASEL, V10, DOI 10.3390/cells10061377
   Vishal M, 2017, INT J BIOL MACROMOL, V99, P608, DOI 10.1016/j.ijbiomac.2017.03.021
   Wang DY, 2021, CANCER LETT, V519, P2, DOI 10.1016/j.canlet.2021.05.020
   Xu Y, 2022, Nan Fang Yi Ke Da Xue Xue Bao, V42, P740, DOI 10.12122/j.issn.1673 4254.2022.05.16
   Yang M, 2020, SUPPORT CARE CANCER, V28, P2533, DOI 10.1007/s00520 020 05355 7
   Yang M, 2019, DISCOV MED, V27, P211
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zheng XW, 2022, TRANSL ONCOL, V26, DOI 10.1016/j.tranon.2022.101534
NR 37
TC 2
Z9 2
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0899 1987
EI 1098 2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD FEB
PY 2024
VL 63
IS 2
BP 301
EP 313
DI 10.1002/mc.23653
EA NOV 2023
PG 13
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA FB1Z6
UT WOS:001096661300001
PM 37921547
DA 2025 08 17
ER

PT J
AU Sreekumar, A
   Chakravarty, K
AF Sreekumar, Amrutha
   Chakravarty, Koyel
TI EXPLORING THE IMPACT OF PTH THERAPY ON BONE REMODELING: A MATHEMATICAL
   INVESTIGATION
SO JOURNAL OF BIOLOGICAL SYSTEMS
LA English
DT Article
DE Bone; Parathyroid Hormone; Mathematical Modeling; Sensitivity Analysis;
   Stability Analysis
ID SENSITIVITY ANALYSIS; PARATHYROID HORMONE; MODEL
AB The regulatory influence of the parathyroid hormone (PTH) is exerted on bone, which serves as a vital reservoir of calcium within the body. While various aspects of bone growth, turnover, and mechanisms operate independently of gonadal hormones, a crucial role is assumed by sex steroids, particularly estrogen, in maintaining bone equilibrium in adults. In order to unravel the underlying mechanisms of bone remodeling mediated by PTH, a distinguished mathematical model of this intricate process is presented. Subsequently, the temporal effects of Plasma PTH and PTH external dosages are investigated using the proposed mathematical model. Among the limited repertoire of approved and accessible anabolic treatments for severe osteoporosis, daily injections of PTH stand out. This pharmaceutical marvel possesses a unique dual action, capable of acting either anabolically or catabolically, contingent upon the mode of administration. The study aims to accurately predict osteogenic responses to introduced and endogenous PTH, incorporating factors such as TGF beta, RANKL, and bisphosphonates in osteoblast osteoclast signaling, as well as considering PTH's influence on the gland and the regulatory roles of Runx2, pCREB, and Bcl2 in osteoblast apoptosis and bone volume effects. Through diverse methods including illustrative depictions, numerical simulations, sensitivity analysis, and stability analysis, this work seeks to comprehend how PTH therapy impacts bone volume, enhancing its therapeutic relevance.
C1 [Sreekumar, Amrutha; Chakravarty, Koyel] SRM Univ AP, Dept Math, Amaravati 522240, Andhra Pradesh, India.
C3 SRM University AP
RP Chakravarty, K (通讯作者)，SRM Univ AP, Dept Math, Amaravati 522240, Andhra Pradesh, India.
EM amrutha_sreekumar@srmap.edu.in; koyelchakravarty@gmail.com
RI ; Chakravarty, Koyel/ABD 9763 2020
OI chakravarty, santabrata/0000 0001 6823 1292; Chakravarty,
   Koyel/0000 0002 0532 5192; 
CR Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Chitnis N, 2008, B MATH BIOL, V70, P1272, DOI 10.1007/s11538 008 9299 0
   Lavaill M, 2020, BIOMECH MODEL MECHAN, V19, P1765, DOI 10.1007/s10237 020 01307 6
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Martonová D, 2023, PLOS ONE, V18, DOI 10.1371/journal.pone.0283544
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2010, BONE, V47, P181, DOI 10.1016/j.bone.2010.04.601
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Rattanakul C, 2003, BIOSYSTEMS, V70, P55, DOI 10.1016/S0303 2647(03)00040 6
   Ross DS, 2017, B MATH BIOL, V79, P117, DOI 10.1007/s11538 016 0229 2
   Samsuzzoha M, 2013, APPL MATH MODEL, V37, P903, DOI 10.1016/j.apm.2012.03.029
   Satterwhite J, 2010, CALCIFIED TISSUE INT, V87, P485, DOI 10.1007/s00223 010 9424 6
   Scheiner S, 2013, COMPUT METHOD APPL M, V254, P181, DOI 10.1016/j.cma.2012.10.015
   Trichilo S, 2019, J THEOR BIOL, V473, P67, DOI 10.1016/j.jtbi.2019.04.020
NR 14
TC 1
Z9 1
U1 0
U2 1
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0218 3390
EI 1793 6470
J9 J BIOL SYST
JI J. Biol. Syst.
PD JUN
PY 2024
VL 32
IS 02
BP 809
EP 843
DI 10.1142/S021833902450027X
EA APR 2024
PG 35
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Mathematical & Computational
   Biology
GA RT8M8
UT WOS:001209390600001
DA 2025 08 17
ER

PT J
AU Scholtysek, C
   Katzenbeisser, J
   Fu, H
   Uderhardt, S
   Ipseiz, N
   Stoll, C
   Zaiss, MM
   Stock, M
   Donhauser, L
   Böhm, C
   Kleyer, A
   Hess, A
   Engelke, K
   David, JP
   Djouad, F
   Tuckermann, JP
   Desvergne, B
   Schett, G
   Krönke, G
AF Scholtysek, Carina
   Katzenbeisser, Julia
   Fu, He
   Uderhardt, Stefan
   Ipseiz, Natacha
   Stoll, Cornelia
   Zaiss, Mario M.
   Stock, Michael
   Donhauser, Laura
   Boehm, Christina
   Kleyer, Arnd
   Hess, Andreas
   Engelke, Klaus
   David, Jean Pierre
   Djouad, Farida
   Tuckermann, Jan Peter
   Desvergne, Beatrice
   Schett, Georg
   Kroenke, Gerhard
TI PPARβ/δ governs Wnt signaling and bone turnover
SO NATURE MEDICINE
LA English
DT Article
ID ACTIVATED RECEPTOR DELTA; OSTEOCLAST FORMATION; METABOLIC SYNDROME;
   ADENOMA GROWTH; GAMMA; DIFFERENTIATION; ADIPOGENESIS; AGONISTS;
   TRANSACTIVATION; ROSIGLITAZONE
AB Peroxisome proliferator activated receptors (PPARs) act as metabolic sensors and central regulators of fat and glucose homeostasis(1). Furthermore, PPAR gamma has been implicated as major catabolic regulator of bone mass in mice and humans(2 5). However, a potential involvement of other PPAR subtypes in the regulation of bone homeostasis has remained elusive. Here we report a previously unrecognized role of PPAR beta/delta as a key regulator of bone turnover and the crosstalk between osteoblasts and osteoclasts. In contrast to activation of PPAR gamma, activation of PPAR beta/delta amplified Wnt dependent and beta catenin dependent signaling and gene expression in osteoblasts, resulting in increased expression of osteoprotegerin (OPG) and attenuation of osteoblast mediated osteoclastogenesis. Accordingly, PPAR beta/delta deficient mice had lower Wnt signaling activity, lower serum concentrations of OPG, higher numbers of osteoclasts and osteopenia. Pharmacological activation of PPAR beta/delta in a mouse model of postmenopausal osteoporosis led to normalization of the altered ratio of tumor necrosis factor superfamily, member 11 (RANKL, also called TNFSF11) to OPG, a rebalancing of bone turnover and the restoration of normal bone density. Our findings identify PPAR beta/delta as a promising target for an alternative approach in the treatment of osteoporosis and related diseases.
C1 [Scholtysek, Carina; Katzenbeisser, Julia; Uderhardt, Stefan; Ipseiz, Natacha; Stoll, Cornelia; Zaiss, Mario M.; Stock, Michael; Donhauser, Laura; Boehm, Christina; Kleyer, Arnd; David, Jean Pierre; Schett, Georg; Kroenke, Gerhard] Univ Erlangen Nurnberg, Dept Internal Med 3, D 91054 Erlangen, Germany.
   [Scholtysek, Carina; Katzenbeisser, Julia; Uderhardt, Stefan; Ipseiz, Natacha; Stoll, Cornelia; Zaiss, Mario M.; Stock, Michael; Donhauser, Laura; Boehm, Christina; Kleyer, Arnd; David, Jean Pierre; Schett, Georg; Kroenke, Gerhard] Univ Erlangen Nurnberg, Inst Clin Immunol, D 91054 Erlangen, Germany.
   [Scholtysek, Carina; Uderhardt, Stefan; Ipseiz, Natacha; Stoll, Cornelia; Stock, Michael; Donhauser, Laura; Kleyer, Arnd; Kroenke, Gerhard] Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, D 91054 Erlangen, Germany.
   [Fu, He; Desvergne, Beatrice] Univ Lausanne, Ctr Integrat Gen, Fac Biol & Med, Lausanne, Switzerland.
   [Hess, Andreas] Univ Erlangen Nurnberg, Inst Expt & Clin Pharmacol & Toxicol, D 91054 Erlangen, Germany.
   [Engelke, Klaus] Univ Erlangen Nurnberg, Inst Med Phys, D 91054 Erlangen, Germany.
   [Djouad, Farida] Inst Natl Sante & Rech Med, U844, Montpellier, France.
   [Djouad, Farida] Univ Montpellier I, Unite Format & Rech UFR Medecine, Montpellier, France.
   [Tuckermann, Jan Peter] Fritz Lipmann Inst, Leibniz Inst Age Res, Jena, Germany.
   [Tuckermann, Jan Peter] Univ Ulm, Inst Gen Zool & Endocrinol, D 89069 Ulm, Germany.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   University of Erlangen Nuremberg; University of Lausanne; University of
   Erlangen Nuremberg; University of Erlangen Nuremberg; Universite de
   Montpellier; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Montpellier; Leibniz Association; Leibniz
   Institut fur Alternsforschung   Fritz Lipmann Institut (FLI); Ulm
   University
RP Krönke, G (通讯作者)，Univ Erlangen Nurnberg, Dept Internal Med 3, D 91054 Erlangen, Germany.
EM gerhard.kroenke@uk erlangen.de
RI Scholtysek, Carina/LXA 1619 2024; Zaiss, Mario/ABE 7125 2021; Uderhardt,
   Stefan/AAA 5224 2022; Kleyer, Arnd/AAB 2292 2022; Ipseiz,
   Natacha/AAG 6390 2019; Stock, Michael/B 9829 2009; Desvergne,
   Beatrice/C 8892 2016; Kronke, Gerhard/C 6615 2014; Krönke,
   Gerhard/C 6615 2014
OI Stock, Michael/0009 0003 0554 3194; Stock, Michael/0000 0002 3322 0961;
   Djouad, Farida/0000 0001 8248 6822; Scholtysek,
   Carina/0009 0001 2197 5179; Ipseiz, Natacha/0000 0001 5008 8889;
   Desvergne, Beatrice/0000 0001 5483 288X; Kleyer,
   Arnd/0000 0002 2026 7728; Kronke, Gerhard/0000 0002 7566 4325; 
FU Deutsche Forschungsgemeinschaft [KR3523, FG 661, SFB643,
   SPP1468 IMMUNOBONE]; Bundesministerium fur Bildung und Forschung (BMBF);
   University of Erlangen Nuremberg; European Union; Interdisciplinary
   Centre for Clinical Research (IZKF) Erlangen; Bayrische
   Forschungsstftung
FX We thank M. Steffen, U. Hillienhoff and I. Schmidt for technical
   assistance and J. Wittmann for his help during the analysis of the Lrp5
   promoter. Wnt3a expressing L cells were kindly provided by K.
   Tanneberger (Department of Experimental Medicine II, University of
   Erlangen). This study was supported by the Deutsche
   Forschungsgemeinschaft (KR3523, FG 661, SFB643 and SPP1468 IMMUNOBONE),
   the Bundesministerium fur Bildung und Forschung (BMBF; project
   ANCYLOSS); the ELAN Program of the University of Erlangen Nuremberg; the
   MASTERS WITCH and IMI projects of the European Union; the
   Interdisciplinary Centre for Clinical Research (IZKF) Erlangen; and the
   Bayrische Forschungsstftung.
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Barish GD, 2006, J CLIN INVEST, V116, P590, DOI 10.1172/JCI27955
   Chan BY, 2007, BONE, V40, P149, DOI 10.1016/j.bone.2006.07.029
   Cho ES, 2012, MOL CELLS, V33, P173, DOI 10.1007/s10059 012 2240 z
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025
   Giaginis C, 2007, FUND CLIN PHARMACOL, V21, P231, DOI 10.1111/j.1472 8206.2007.00486.x
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Grey A, 2008, OSTEOPOROSIS INT, V19, P129, DOI 10.1007/s00198 007 0477 y
   Hayashi S, 2002, MECH DEVELOP, V119, pS97, DOI 10.1016/S0925 4773(03)00099 6
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Kawai M, 2010, NAT REV ENDOCRINOL, V6, P629, DOI 10.1038/nrendo.2010.155
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Kubota T, 2009, J BONE MINER METAB, V27, P265, DOI 10.1007/s00774 009 0064 8
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003 0034
   Nadra K, 2006, MOL CELL BIOL, V26, P3266, DOI 10.1128/MCB.26.8.3266 3281.2006
   Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051
   Okamura M, 2009, P NATL ACAD SCI USA, V106, P5819, DOI 10.1073/pnas.0901676106
   Olson EJ, 2012, ARTERIOSCL THROM VAS, V32, P2289, DOI 10.1161/ATVBAHA.112.247890
   Still K, 2008, CALCIFIED TISSUE INT, V83, P285, DOI 10.1007/s00223 008 9175 9
   Takada I, 2007, ANN NY ACAD SCI, V1116, P182, DOI 10.1196/annals.1402.034
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Viccica G, 2010, J Endocrinol Invest, V33, P9
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wang DZ, 2004, CELL CYCLE, V3, P1512, DOI 10.4161/cc.3.12.1288
   Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
NR 28
TC 87
Z9 99
U1 1
U2 29
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
J9 NAT MED
JI Nat. Med.
PD MAY
PY 2013
VL 19
IS 5
BP 608
EP 613
DI 10.1038/nm.3146
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 139LA
UT WOS:000318583000033
PM 23542786
DA 2025 08 17
ER

PT J
AU Miller, K
   Stenzl, A
   Tombal, B
AF Miller, Kurt
   Stenzl, Arnulf
   Tombal, Bertrand
TI Advances in the Therapy of Prostate Cancer Induced Bone Disease: Current
   Insights and Future Perspectives on the RANK/RANKL Pathways
SO EUROPEAN UROLOGY SUPPLEMENTS
LA English
DT Article; Proceedings Paper
CT 2nd World Congress on Controversies in Urology
CY FEB 05 08, 2009
CL Lisbon, PORTUGAL
DE Bone diseases; Bone formation; Bone metastases; Bone resorption;
   Osteoblasts; Osteoclasts; Prostate cancer; RANK ligand
ID MITOXANTRONE PLUS PREDNISONE; X RAY ABSORPTIOMETRY; RANDOMIZED PHASE II;
   ANDROGEN DEPRIVATION; MINERAL DENSITY; OSTEOCLAST DIFFERENTIATION;
   RECEPTOR ACTIVATOR; CONTROLLED TRIAL; ZOLEDRONIC ACID; OSTEOPOROSIS
AB Context: Prostate cancer (PCa) cells are characterised by an exquisite tropism for the bone, which translates into one of the highest rates of bone metastases and skeletal morbidity. New, effective treatments have emerged from a better understanding of the physiopathology of bone metastases.
   Objective: To summarise current insights and future perspectives in the therapy of PCa induced bone disease.
   Evidence acquisition: This manuscript is based on presentations given at a satellite symposium held at the 2nd World Congress on Controversies in Urology (CURy) in Lisbon, Portugal. Data were retrieved from original and recent review papers on PCa induced bone disease.
   Evidence synthesis: In normal, healthy bone, there is a balance between bone resorption and bone formation through the coordinated activity of osteoclasts and osteoblasts. The receptor activator of nuclear factor kappa B ligand (RANKL) is an essential mediator of osteoclast formation, function, and survival. The RANKL pathway represents a therapeutic target for osteoclast induced bone destruction in pathologic conditions, including treatment induced bone loss and metastatic cancer. Based on a multicentre, randomised, open label, active controlled phase 2 trial, denosumab, a fully human monoclonal antibody against RANKL, reduced the incidence of skeletal morbidity in patients with bone metastases from PCa, breast cancer, or other neoplasms.
   Conclusions: In a phase 2 clinical study, denosumab reduced skeletal related events in patients with bone metastases from PCa. In addition, the potential role of denosumab in the management of treatment induced bone loss and the prevention of bone metastases is currently under investigation. (C) 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.
C1 [Miller, Kurt] Charite, Dept Urol, D 12200 Berlin, Germany.
   [Stenzl, Arnulf] Uniklinikum Tubingen, Dept Urol, Tubingen, Germany.
   [Tombal, Bertrand] Catholic Univ Louvain, Dept Urol, Clin Univ St Luc, B 3000 Louvain, Belgium.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Eberhard Karls University of Tubingen;
   Eberhard Karls University Hospital; Universite Catholique Louvain;
   Cliniques Universitaires Saint Luc
RP Miller, K (通讯作者)，Charite, Dept Urol, Hindenburgdamm 30, D 12200 Berlin, Germany.
EM kurt.miller@charite.de
OI TOMBAL, Bertrand/0000 0002 0093 8408
CR [Anonymous], SEER CANC STAT REV 1
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Berruti A, 2002, J UROLOGY, V167, P2361, DOI 10.1016/S0022 5347(05)64985 3
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
   Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006 0346
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Daniell HW, 2000, J UROLOGY, V163, P181, DOI 10.1016/S0022 5347(05)68000 7
   ERIKSSON S, 1995, CALCIFIED TISSUE INT, V57, P97, DOI 10.1007/BF00298427
   Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498
   Fili S, 2009, CANCER LETT, V283, P10, DOI 10.1016/j.canlet.2009.01.011
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Fizazi K, 2009, J UROLOGY, V182, P509, DOI 10.1016/j.juro.2009.04.023
   Heidenreich A, 2008, EUR UROL, V53, P68, DOI 10.1016/j.eururo.2007.09.002
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hussain SA, 2003, BJU INT, V92, P690, DOI 10.1046/j.1464 410X.2003.04471.x
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Maillefert JF, 1999, J UROLOGY, V161, P1219, DOI 10.1016/S0022 5347(01)61639 2
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Mittan D, 2002, J CLIN ENDOCR METAB, V87, P3656, DOI 10.1210/jc.87.8.3656
   Nelson JB, 2008, CANCER AM CANCER SOC, V113, P2478, DOI 10.1002/cncr.23864
   Oudard S, 2005, J CLIN ONCOL, V23, P3343, DOI 10.1200/JCO.2005.12.187
   Parkin DM, 2005, CA CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Roudier MP, 2003, CLIN EXP METASTAS, V20, P171, DOI 10.1023/A:1022627421000
   Saad F, 2006, EUR UROL, V49, P429, DOI 10.1016/j.eururo.2005.12.045
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saad F, 2008, BJU INT, V101, P1071, DOI 10.1111/j.1464 410X.2007.07364.x
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Smith Matthew R, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P247, DOI 10.1097/MED.0b013e32814db88c
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Zhang J, 2003, CANCER RES, V63, P7883
NR 35
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1569 9056
EI 1878 1500
J9 EUR UROL SUPPL
JI Eur. Urol. Suppl.
PD SEP
PY 2009
VL 8
IS 9
BP 747
EP 752
DI 10.1016/j.eursup.2009.07.001
PG 6
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Urology & Nephrology
GA 497PI
UT WOS:000270071900008
OA Bronze
DA 2025 08 17
ER

PT J
AU Balani, DH
   Kronenberg, HM
AF Balani, Deepak H.
   Kronenberg, Henry M.
TI Withdrawal of parathyroid hormone after prolonged administration leads
   to adipogenic differentiation of mesenchymal precursors in vivo
SO BONE
LA English
DT Article
DE Stem cell; Osteoblast precursor; Stromal cell; Parathyroid hormone;
   Lineage tracing
ID BONE MARROW; STEM CELLS; OSTEOBLAST; PTH; SOX9; GENE; BETA; MICE;
   DISCONTINUATION; DELETION
AB Intermittent PTH like drugs are the only approved so called anabolic agent that increases bone mass in both mice and humans. It is well documented that PTH targets mature cells of the osteoblast lineage, with only indirect evidence of its actions on early cells of the osteoblast lineage. Using a triple transgenic mouse model that allowed labeling of very early cells of the osteoblast lineage, we traced the progeny of these into osteoblast lineage in adult mice. These early cells expressed PTH1R and multiplied when PTH (1 34) was administered daily. We also showed that the early mesenchymal cells showed accelerated differentiation into mature osteocalcin positive osteoblasts and osteocytes. Rather surprisingly, when teriparatide administration was stopped, these early mesenchymal precursors differentiated into adipocytes. We showed that the adipogenic differentiation is accompanied by a decrease in wnt signaling in osteoblast precursors. In this review, we discuss the possible clinical relevance of this finding and the possible molecular mechanisms that contribute to this phenotype in vivo.
C1 [Balani, Deepak H.; Kronenberg, Henry M.] Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St, Boston, MA 02114 USA.
   [Balani, Deepak H.; Kronenberg, Henry M.] Harvard Med Sch, 50 Blossom St, Boston, MA 02114 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard Medical School
RP Kronenberg, HM (通讯作者)，Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St, Boston, MA 02114 USA.
EM dbalani@mgh.harvard.edu; hkronenberg@mgh.harvard.edu
RI KRONENBERG, HENRY/MXK 0923 2025
FU NIH [DK011794]
FX The research from Dr. Kronenberg's group described in this review was
   funded by NIH grant DK011794.
CR Addison WN, 2014, MOL CELL BIOL, V34, P3076, DOI 10.1128/MCB.00185 14
   Balani DH, 2017, J CLIN INVEST, V127, P3333, DOI 10.1172/JCI91699
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Bianco Paolo, 2015, Development, V142, P1023, DOI 10.1242/dev.102210
   Brault V, 2001, DEVELOPMENT, V128, P1253
   Christodoulides C, 2009, TRENDS ENDOCRIN MET, V20, P16, DOI 10.1016/j.tem.2008.09.002
   Cohen A, 2015, J CLIN ENDOCR METAB, V100, P4208, DOI 10.1210/jc.2015 2829
   Esbrit P, 2013, BIOCHEM PHARMACOL, V85, P1417, DOI 10.1016/j.bcp.2013.03.002
   Fan Y, 2017, CELL METAB, V25, P661, DOI 10.1016/j.cmet.2017.01.001
   Formeister EJ, 2009, AM J PHYSIOL GASTR L, V296, pG1108, DOI 10.1152/ajpgi.00004.2009
   Furuyama K, 2011, NAT GENET, V43, P34, DOI 10.1038/ng.722
   GIMBLE JM, 1995, J CELL BIOCHEM, V58, P393, DOI 10.1002/jcb.240580312
   Greenbaum A, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah6518
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   HARDOUIN P, 2016, FRONT ENDOCRINOL, V7, DOI DOI 10.3389/FENDO.2016.00085
   Hock J. M., 2001, Journal of Musculoskeletal & Neuronal Interactions, V2, P33
   Janderová L, 2003, OBES RES, V11, P65, DOI 10.1038/oby.2003.11
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Kang S, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001433
   Kaufman JM, 2005, OSTEOPOROSIS INT, V16, P510, DOI 10.1007/s00198 004 1713 3
   Kawaguchi Y, 2013, J CLIN INVEST, V123, P1881, DOI 10.1172/JCI66022
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Lee M, 2009, CURR OPIN NEPHROL HY, V18, P298, DOI 10.1097/MNH.0b013e32832c2264
   Liu JJ, 2006, MOL CELL BIOL, V26, P5827, DOI 10.1128/MCB.00441 06
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Migliaccio S, 2011, DIABETES METAB SYNDR, V4, P273, DOI 10.2147/DMSO.S11920
   Millward CA, 2007, DIABETES, V56, P161, DOI 10.2337/db06 0310
   Morris EV, 2016, J BONE ONCOL, V5, P121, DOI 10.1016/j.jbo.2016.03.006
   Nowak JA, 2008, CELL STEM CELL, V3, P33, DOI 10.1016/j.stem.2008.05.009
   Ono N, 2014, NAT CELL BIOL, V16, P1157, DOI 10.1038/ncb3067
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Prestwich TC, 2007, CURR OPIN CELL BIOL, V19, P612, DOI 10.1016/j.ceb.2007.09.014
   Rendina Ruedy E, 2017, ADIPOCYTE, V6, P250, DOI 10.1080/21623945.2017.1356505
   ROSS SE, 2000, SCIENCE, V289, P950, DOI DOI 10.1126/SCIENCE.289.5481.950
   Scheller EL, 2014, METHOD ENZYMOL, V537, P123, DOI 10.1016/B978 0 12 411619 1.00007 0
   Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15080
   Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694
   Spiegelman BM, 1997, BIOCHIMIE, V79, P111, DOI 10.1016/S0300 9084(97)81500 3
   Ushiku C, 2010, J ORTHOP RES, V28, P1338, DOI 10.1002/jor.21105
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
   Yu B, 2012, J BONE MINER RES, V27, P2001, DOI 10.1002/jbmr.1663
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 48
TC 13
Z9 13
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2019
VL 118
SI SI
BP 16
EP 19
DI 10.1016/j.bone.2018.05.024
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HE9VK
UT WOS:000453804800004
PM 29800694
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Sun, WW
   Shi, Y
   Lee, WC
   Lee, SY
   Long, FX
AF Sun, Weiwei
   Shi, Yu
   Lee, Wen Chih
   Lee, Seung Yon
   Long, Fanxin
TI Rictor is required for optimal bone accrual in response to
   anti sclerostin therapy in the mouse
SO BONE
LA English
DT Article
DE Rictor; mTORC2; Wnt; Sost; Bone; Osteoblast; Osteoclast
ID SKELETAL GROWTH; WNT1 MUTATIONS; BETA CATENIN; MASS; DIFFERENTIATION;
   OSTEOBLASTS; STIMULATION; ACTIVATION; PROGENITOR; RESORPTION
AB Wnt signaling has emerged as a major target pathway for the development of novel bone anabolic therapies. Neutralizing antibodies against the secreted Wnt antagonist sclerostin (Scl Ab) increase bone mass in both animal models and humans. Because we have previously shown that Rictor dependent mTORC2 activity contributes to Wnt signaling, we test here whether Rictor is required for Scl Ab to promote bone anabolism. Mice with Rictor deleted in the early embryonic limb mesenchyme (Prxl Cre;Rictor(f/f), hereafter RiCKO) were subjected to Sd Ab treatment for 5 weeks starting at 4 months of age. In vivo micro computed tomography (mu CT) analyses before the treatment showed that the RICK mice displayed normal trabecular, but less cortical bone mass than the littermate controls. After 5 weeks of treatment, Scl Ab dose dependently increased trabecular and cortical bone mass in both control and RiCKO mice, but the increase was significantly blunted in the latter. Dynamic histomorphometry revealed that the RiCKO mice formed less bone than the control in response to Scl Ab. In addition, the RiCKO mice possessed fewer osteoclasts than normal under the basal condition and exhibited lesser suppression in osteoclast number by Scl Ab. Consistent with the fewer osteoclasts in vivo, bone marrow stromal cells (BMSC) from the RiCKO mice expressed less Rankl but normal levels of Opg or M CSF, and were less effective than the control cells in supporting osteoclastogenesis in vitro. The reliance of Rankl on Rictor appeared to be independent of Wnt beta catenin or Wnt mTORC2 signaling as Wnt3a had no effect on Rankl expression by BMSC from either control or RICKO mice. Overall, Rictor in the limb mesenchymal lineage is required for the normal response to the anti sclerostin therapy in both bone formation and resorption. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Sun, Weiwei; Shi, Yu; Lee, Wen Chih; Lee, Seung Yon; Long, Fanxin] Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA.
   [Long, Fanxin] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Long, Fanxin] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.
   [Sun, Weiwei] Nanjing Med Univ, Dept Anat Histol & Embryol, Nanjing, Jiangsu, Peoples R China.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL); Nanjing Medical University
RP Long, FX (通讯作者)，Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA.; Long, FX (通讯作者)，Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Long, FX (通讯作者)，Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.
EM flong@wustl.edu
RI Shi, Yu/J 5370 2018; sun, weiwei/GQA 5041 2022
FU NIH [R01 AR060456]; National Natural Science Foundation of China
   [81200431]
FX We thank Dr. Wei Zou (Steve Teitelbaum Lab, Washington University School
   of Medicine) for advice on in vitro osteoclastogenesis assays. The work
   is supported by NIH R01 AR060456 (FL). WS is a visiting scholar
   supported by National Natural Science Foundation of China 81200431.
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Chen Jia Shing, 2014, BMC Res Notes, V7, P15, DOI 10.1186/1756 0500 7 15
   Chen JQ, 2015, J BONE MINER RES, V30, P369, DOI 10.1002/jbmr.2348
   Chen JQ, 2014, DEVELOPMENT, V141, P2848, DOI 10.1242/dev.108811
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Fahiminiya S, 2013, J MED GENET, V50, P345, DOI 10.1136/jmedgenet 2013 101567
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Joeng KS, 2011, DEV BIOL, V359, P222, DOI 10.1016/j.ydbio.2011.08.020
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2011, ENDOCRINOLOGY, V152, P3312, DOI 10.1210/en.2011 0252
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Pyott SM, 2013, AM J HUM GENET, V92, P590, DOI 10.1016/j.ajhg.2013.02.009
   Riddle RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063323
   Shiota C, 2006, DEV CELL, V11, P583, DOI 10.1016/j.devcel.2006.08.013
   Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694
   Stevens JR, 2010, J BONE MINER RES, V25, P2138, DOI 10.1002/jbmr.118
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Tian XY, 2011, BONE, V48, P197, DOI 10.1016/j.bone.2010.09.009
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200
   Zou W, 2001, J CELL BIOCHEM, V83, P70, DOI 10.1002/jcb.1202
   Zou W, 2015, J CELL BIOL, V208, P125, DOI 10.1083/jcb.201410123
NR 41
TC 23
Z9 29
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2016
VL 85
BP 1
EP 8
DI 10.1016/j.bone.2016.01.013
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DH4QJ
UT WOS:000372770200001
PM 26780446
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Lezcano, V
   Bellido, T
   Plotkin, LI
   Boland, R
   Morelli, S
AF Lezcano, V.
   Bellido, T.
   Plotkin, L. I.
   Boland, R.
   Morelli, S.
TI Role of connexin 43 in the mechanism of action of alendronate:
   Dissociation of anti apoptotic and proliferative signaling pathways
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Bisphosphonates; Cx43 hemichannels; AF ALN uptake; Osteoblast survival
ID NITROGEN CONTAINING BISPHOSPHONATES; CELLS IN VITRO; BONE; OSTEOCLASTS;
   LOCALIZATION; HEMICHANNELS; ACTIVATION; OSTEOBLAST; OSTEOCYTE; BINDING
AB Bisphosphonates (Bps) inhibit osteocyte and osteoblast apoptosis via opening of connexin (Cx) 43 hemichannels and activating the extracellular signal regulated kinases ERKs. Previously, we hypothesized that intracellular survival signaling is initiated by interaction of BPs with Cx43. However, using whole cell binding assays with [H 3] alendronate, herein we demonstrated the presence of saturable, specific and high affinity binding sites in the Cx43 expressing ROS 17/2.8 osteoblastic cells, authentic osteoblasts and MLO Y4 cells expressing Cx43 or not, as well as in HeLa cells lacking Cx43 expression and ROS 17/2.8 cells pretreated with agents that disassemble Cx channels. In addition, both BPs and the PIP inhibitor Na3VO4 increased proliferation of cells expressing Cx43 or not. Furthermore, although BPs are internalized and inhibit intracellular enzymes in osteoclasts, whether the drugs penetrate non resorptive bone cells is not known. To clarify this, we evaluated the osteoblastic uptake of AF ALN, a fluorescently labeled analog of alendronate. AF ALN was rapidly internalized in cells expressing Cx43 or not indicating that this process is not mediated via Cx43 hemichannels. Altogether, these findings suggest that although required for triggering intracellular survival signaling by BPs, Cx43 is dispensable for cellular BP binding, its uptake, as well as the proliferative effects of these agents. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Lezcano, V.; Boland, R.; Morelli, S.] Univ Nacl Sur, Dept Biol Bioquim & Farm, RA 8000 Bahia Blanca, Buenos Aires, Argentina.
   [Bellido, T.; Plotkin, L. I.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN USA.
   [Bellido, T.] Indiana Univ, Dept Med, Div Endocrinol, Indianapolis, IN USA.
C3 National University of the South; Instituto de Investigaciones en
   Ingenieria Electrica (IIIE); Indiana University System; Indiana
   University Indianapolis; Indiana University System; Indiana University
   Indianapolis
RP Morelli, S (通讯作者)，Univ Nacl Sur, Dept Biol Bioquim & Farm, San Juan 670,B80001CN, RA 8000 Bahia Blanca, Buenos Aires, Argentina.
EM smorelli@criba.edu.ar
RI ; Plotkin, Lilian/H 7188 2019
OI Bellido, Teresita/0000 0002 8203 7004; Plotkin,
   Lilian/0000 0002 9537 4544
FU National Institutes of Health [FIRCA R03 TW006919]; Florencio Fiorini
   Foundation; Universidad Nacional del Sur [PGI 24/B161]
FX This research was supported by grants from the National Institutes of
   Health [FIRCA R03 TW006919] to Drs. Teresita Bellido and Ricardo Boland,
   and from the Florencio Fiorini Foundation and the Universidad Nacional
   del Sur [PGI 24/B161] to Dr Susana Morelli.
CR Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Carr G, 2007, CELL PHYSIOL BIOCHEM, V20, P507, DOI 10.1159/000107534
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   FELIX R, 1984, CALCIFIED TISSUE INT, V36, P108, DOI 10.1007/BF02405302
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Frith JC, 2003, J BONE MINER RES, V18, P204, DOI 10.1359/jbmr.2003.18.2.204
   Giepmans BNG, 2003, CELL COMMUN ADHES, V10, P201, DOI 10.1080/714040427
   Gurley KA, 2006, AM J HUM GENET, V79, P1017, DOI 10.1086/509881
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Katz S, 2011, ARCH BIOCHEM BIOPHYS, V513, P144, DOI 10.1016/j.abb.2011.06.013
   Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Mathov I, 2001, J BONE MINER RES, V16, P2050, DOI 10.1359/jbmr.2001.16.11.2050
   Morelli S, 2011, ARCH BIOCHEM BIOPHYS, V507, P248, DOI 10.1016/j.abb.2010.12.013
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Rogers MJ., 2003, CURRENT PHARM DESIGN, V11, P196
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Snedecor G.W. C., 1989, Statistical methods/George W. Snedecor and William G. Cochran
   Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
NR 29
TC 25
Z9 29
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0003 9861
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD FEB 15
PY 2012
VL 518
IS 2
BP 95
EP 102
DI 10.1016/j.abb.2011.12.022
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 895CF
UT WOS:000300473100001
PM 22230328
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Ebetino, FH
   Sun, ST
   Cherian, P
   Roshandel, S
   Neighbors, JD
   Hu, E
   Dunford, JE
   Sedghizadeh, PP
   McKenna, CE
   Srinivasan, V
   Boeckman, RK
   Russell, RGG
AF Ebetino, Frank H.
   Sun, Shuting
   Cherian, Philip
   Roshandel, Sahar
   Neighbors, Jeffrey D.
   Hu, Eric
   Dunford, James E.
   Sedghizadeh, Parish P.
   McKenna, Charles E.
   Srinivasan, Venkat
   Boeckman, Robert K.
   Russell, R. Graham G.
TI Bisphosphonates: The role of chemistry in understanding their biological
   actions and structure activity relationships, and new directions for
   their therapeutic use
SO BONE
LA English
DT Article
DE Bisphosphonates; Farnesyl diphosphate synthase (FDPS/FPPS); Osteoclasts;
   Bone resorption; Hydroxyapatite; Bone targeting
ID FLUORESCENTLY LABELED BISPHOSPHONATES; NITROGEN CONTAINING
   BISPHOSPHONATES; CATALYZED GREEN SYNTHESIS; DIPHOSPHATE SYNTHASE;
   IN VITRO; APOMINE SR 45023A; AMINOMETHYLENE BISPHOSPHONATES; TRIAZOLE
   BISPHOSPHONATES; CLICK CHEMISTRY; ZOLEDRONIC ACID
AB The bisphosphonates ((HO)(2)P(O)(CRRP) R 1 P 2(O)(OH)(2), BPs) were first shown to inhibit bone resorption in the 1960s, but it was not until 30 years later that a detailed molecular understanding of the relationship between their varied chemical structures and biological activity was elucidated. In the 1990s and 2000s, several potent bisphosphonates containing nitrogen in their R 2 side chains (N BPs) were approved for clinical use including alendronate, risedronate, ibandronate, and zoledronate. These are now mostly generic drugs and remain the leading therapies for several major bone related diseases, including osteoporosis and skeletal related events associated with bone metastases. The early development of chemistry in this area was largely empirical and only a few common structural features related to strong binding to calcium phosphate were clear. Attempts to further develop structure activity relationships to explain more dramatic pharmacological differences in vivo at first appeared inconclusive, and evidence for mechanisms underlying cellular effects on osteoclasts and macrophages only emerged after many years of research. The breakthrough came when the intracellular actions on the osteoclast were first shown for the simpler bisphosphonates, via the in vivo formation of P C P derivatives of ATP. The synthesis and biological evaluation of a large number of nitrogen containing bisphosphonates in the 1980s and 1990s led to the key discovery that the antiresorptive effects of these more complex analogs on osteoclasts result mostly from their potency as inhibitors of the enzyme farnesyl diphosphate synthase (FDPS/FPPS). This key branch point enzyme in the mevalonate pathway of cholesterol biosynthesis is important for the generation of isoprenoid lipids that are utilized for the post translational modification of small GTP binding proteins essential for osteoclast function. Since then, it has become even more clear that the overall pharmacological effects of individual bisphosphonates on bone depend upon two key properties: the affinity for bone mineral and inhibitory effects on biochemical targets within bone cells, in particular FDPS. Detailed enzyme ligand crystal structure analysis began in the early 2000s and advances in our understanding of the structure activity relationships, based on interactions with this target within the mevalonate pathway and related enzymes in osteoclasts and other cells have continued to be the focus of research efforts to this day. In addition, while many members of the bisphosphonate drug class share common properties, now it is more clear that chemical modifications to create variations in these properties may allow customization of BPs for different uses.
   Thus, as the appreciation for new potential opportunities with this drug class grows, new chemistry to allow ready access to an ever widening variety of bisphosphonates continues to be developed. Potential new uses of the calcium phosphate binding mechanism of bisphosphonates for the targeting of other drugs to the skeleton, and effects discovered on other cellular targets, even at non skeletal sites, continue to intrigue scientists in this research field.
C1 [Ebetino, Frank H.; Sun, Shuting; Cherian, Philip; Roshandel, Sahar; Hu, Eric] BioVinc LLC, 2265 E Foothill Blvd, Pasadena, CA 91107 USA.
   [Ebetino, Frank H.; Srinivasan, Venkat; Boeckman, Robert K.] Univ Rochester, Dept Chem, Rochester, NY 14617 USA.
   [Ebetino, Frank H.; Russell, R. Graham G.] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
   [Neighbors, Jeffrey D.] Penn State Univ, Hershey, PA USA.
   [Dunford, James E.; Russell, R. Graham G.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Inst Musculoskeletal Sci, Botnar Res Ctr,Nuffield Orthopaed Ctr, Oxford OX3 7LD, England.
   [Sedghizadeh, Parish P.] Univ Southern Calif, Herman Ostrow Sch Dent, Los Angeles, CA 90089 USA.
   [McKenna, Charles E.] Univ Southern Calif, Dept Chem, Los Angeles, CA 90089 USA.
   [Russell, R. Graham G.] Univ Sheffield, Mellanby Ctr Musculoskeletal Res, Sheffield, S Yorkshire, England.
C3 University of Rochester; University of Sheffield; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Penn State Health; University of Oxford; Nuffield
   Orthopaedic Centre; University of Southern California; University of
   Southern California; University of Sheffield
RP Sun, ST (通讯作者)，BioVinc LLC, 2265 E Foothill Blvd, Pasadena, CA 91107 USA.; Ebetino, FH (通讯作者)，Univ Rochester, Dept Chem, Rochester, NY 14617 USA.
EM halebetino@biovinc.com; shuting.sun@biovinc.com
RI Russell, R/JEF 5877 2023; Hu, Eric/KTI 5622 2024; Sedghizadeh,
   Parish/AAI 8453 2020; Russell, Robert Graham G/JEF 5877 2023
OI Cherian, Philip/0000 0002 1070 6483; Russell, Robert Graham
   G/0000 0002 4136 1828
FU NIH; NIAMS [R43 AR073727]; NCI [R41 CA235996]; NIAID [R44 AI125060]; NIH
   (NIDCR) [R42 DE025789]; NIHR Biomedical Research Centre, Oxford, UK;
   NIDCR [R42 DE025789, R44 DE025524]; National Institute of Allergy and
   Infectious Diseases [R44AI125060] Funding Source: NIH RePORTER
FX The authors wish to dedicate this article to the memory of Professor
   Robert K. Boeckman who sadly passed away while this manuscript was being
   prepared. He made outstanding contributions to synthetic chemistry
   throughout his long career. He played an important role in generating
   novel bisphosphonates and in the bone targeted drug field. FHE & SS are
   supported by small business grants from the NIH including the NIDCR
   (R42 DE025789 and R44 DE025524), NIAMS (R43 AR073727), NCI
   (R41 CA235996) and NIAID (R44 AI125060). PPS is supported by grant
   (R42 DE025789) from the NIH (NIDCR). JED was supported by the NIHR
   Biomedical Research Centre, Oxford, UK. We also wish to acknowledge the
   many friends and colleagues who have contributed to this work over the
   years.
CR Adjei Sowah E, 2021, ANTIBIOTICS BASEL, V10, DOI 10.3390/antibiotics10060732
   Alberts DS, 2001, CLIN CANCER RES, V7, P1246
   Amin D, 1996, ARZNEIMITTEL FORSCH, V46, P759
   AMIN D, 1992, J LIPID RES, V33, P1657
   Amorim T., 2020, J BONE MINER RES
   [Anonymous], US Patent,, DOI 10.1021/jm200521a, Patent No. [8,252,774, 101021200521]
   Aripirala S, 2014, ACTA CRYSTALLOGR D, V70, P802, DOI 10.1107/S1399004713033221
   Balakrishna A, 2011, EUR J MED CHEM, V46, P1798, DOI 10.1016/j.ejmech.2011.02.038
   Bálint E, 2016, BEILSTEIN J ORG CHEM, V12, P1493, DOI 10.3762/bjoc.12.146
   Baranyi M, 2020, PATHOL ONCOL RES, V26, P1957, DOI 10.1007/s12253 019 00789 9
   Barbosa JS, 2020, MOLECULES, V25, DOI 10.3390/molecules25122821
   Baron RA, 2009, J BIOL CHEM, V284, P6861, DOI 10.1074/jbc.M806952200
   Bentley KLD, 2017, J BONE MINER RES, V32, P985, DOI 10.1002/jbmr.3055
   Blazewska KM, 2011, EUR J MED CHEM, V46, P4820, DOI 10.1016/j.ejmech.2011.04.063
   Bonate PL, 2004, BRIT J CLIN PHARMACO, V58, P142, DOI 10.1111/j.1365 2125.2004.02111.x
   Center JR, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115566
   Chamberlain BT, 2011, J ORG CHEM, V76, P5132, DOI 10.1021/jo200045a
   Chen CKM, 2008, J MED CHEM, V51, P5594, DOI 10.1021/jm800325y
   Cheong S, 2014, J ORAL MAXIL SURG, V72, P2461, DOI 10.1016/j.joms.2014.07.004
   Chiminazzo A, 2019, CHEM EUR J, V25, P3617, DOI 10.1002/chem.201805436
   CIOSEK CP, 1993, J BIOL CHEM, V268, P24832
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   Cremers S., 2020, PRINCIPLES BONE BIOL, P1671
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   Cummings SR, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115411
   Ebetino FH, 2005, J ORGANOMET CHEM, V690, P2679, DOI 10.1016/j.jorganchem.2005.03.005
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Ebetino Frank H., 1995, P139
   Edwards CM, 2007, INT J CANCER, V120, P1657, DOI 10.1002/ijc.22478
   Egorov M, 2011, EUR J ORG CHEM, V2011, P7148, DOI 10.1002/ejoc.201101094
   Engelsma SB, 2017, ANGEW CHEM INT EDIT, V56, P2955, DOI 10.1002/anie.201611878
   Ezra A, 2000, J MED CHEM, V43, P3641, DOI 10.1021/jm980645y
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Flach J, 2000, BIOCHEM BIOPH RES CO, V270, P240, DOI 10.1006/bbrc.2000.2421
   Garay T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117021
   Grün A, 2015, LETT DRUG DES DISCOV, V12, P253, DOI 10.2174/1570180811666141010220427
   Haratipour P, 2020, J ORG CHEM, V85, P14592, DOI 10.1021/acs.joc.0c01204
   Heidel KM, 2019, FUTURE MED CHEM, V11, P1625, DOI 10.4155/fmc 2018 0591
   Hein CD, 2008, PHARM RES DORDR, V25, P2216, DOI 10.1007/s11095 008 9616 1
   Hokugo A, 2019, BONE, V123, P115, DOI 10.1016/j.bone.2019.03.027
   Hokugo A, 2013, BONE, V53, P59, DOI 10.1016/j.bone.2012.11.030
   Holstein SA, 2019, EXPERT OPIN THER PAT, V29, P315, DOI 10.1080/13543776.2019.1608180
   Houghton TJ, 2008, J MED CHEM, V51, P6955, DOI 10.1021/jm801007z
   Jackson B, 2000, ARZNEIMITTEL FORSCH, V50, pE380
   Jiang LY, 2021, COMPUT STRUCT BIOTEC, V19, P2148, DOI 10.1016/j.csbj.2021.04.029
   Junankar S, 2015, CANCER DISCOV, V5, P35, DOI 10.1158/2159 8290.CD 14 0621
   Junka A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169565
   Kang WS, 2015, OTOL NEUROTOL, V36, P953, DOI 10.1097/MAO.0000000000000786
   Kashemirov BA, 2008, BIOCONJUGATE CHEM, V19, P2308, DOI 10.1021/bc800369c
   Keglevich G, 2011, TETRAHEDRON LETT, V52, P2744, DOI 10.1016/j.tetlet.2011.03.093
   Kempfle JS, 2021, FRONT CELL NEUROSCI, V15, DOI 10.3389/fncel.2021.666706
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521 3773(20010601)40:11<2004::AID ANIE2004>3.3.CO;2 X
   Kourounakis AP, 2020, ARCH PHARM, V353, DOI 10.1002/ardp.202000085
   Kovacs R, 2014, GREEN PROCESS SYNTH, V3, P111, DOI 10.1515/gps 2013 0107
   Kovács R, 2013, LETT DRUG DES DISCOV, V10, P733, DOI 10.2174/15701808113109990026
   Kuznik A, 2020, EUR J PHARMACOL, V866, DOI 10.1016/j.ejphar.2019.172773
   Lacbay CM, 2018, J MED CHEM, V61, P6904, DOI 10.1021/acs.jmedchem.8b00886
   Larson Casey JL, 2019, J CLIN INVEST, V129, P4962, DOI [10.1172/JCl127959, 10.1172/JCI127959]
   Lawson MA, 2017, J BONE MINER RES, V32, P1860, DOI 10.1002/jbmr.3138
   Lenin R, 2013, MED CHEM RES, V22, P1624, DOI 10.1007/s00044 012 0153 4
   Leung CY, 2013, J MED CHEM, V56, P7939, DOI 10.1021/jm400946f
   Lewis KD, 2006, INVEST NEW DRUG, V24, P89, DOI 10.1007/s10637 005 4544 y
   Li GZ, 2015, SYNTHESIS STUTTGART, V47, P3783, DOI 10.1055/s 0035 1560463
   Li X, 2019, ACS APPL MATER INTER, V11, P7311, DOI 10.1021/acsami.8b16588
   Li X, 2017, INT J PHARMACEUT, V526, P69, DOI 10.1016/j.ijpharm.2017.04.053
   Lisnyansky M, 2019, MOL PHARMACOL, V96, P580, DOI 10.1124/mol.119.117499
   Lisnyansky M, 2018, MOL PHARMACOL, V94, P1391, DOI 10.1124/mol.118.113670
   Lowe LC, 2005, BIOCHEM BIOPH RES CO, V329, P772, DOI 10.1016/j.bbrc.2005.02.032
   Lundy MW, 2007, J BONE MINER RES, V22, pS443
   Lundy M, 2014, J BONE MINER RES, V29, pS262
   Malwal SR, 2019, J MED CHEM, V62, P2564, DOI 10.1021/acs.jmedchem.8b01878
   Manaswiyoungkul P, 2020, RSC MED CHEM, V11, P51, DOI 10.1039/c9md00442d
   Marma MS, 2007, J MED CHEM, V50, P5967, DOI 10.1021/jm0702884
   Matsumoto T, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115432
   Matthiesen RA, 2018, BIOORGAN MED CHEM, V26, P376, DOI 10.1016/j.bmc.2017.10.023
   Mazur A., 2012, US Patent, Patent No. [8,252,774, 8252774]
   McCloskey E, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115715
   McClung MR, 2012, OSTEOPOROSIS INT, V23, P267, DOI 10.1007/s00198 011 1791 y
   McClung MR, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115407
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   McKenna C.E., 2020, Encyclopedia of Bone Biology, P551, DOI DOI 10.1016/B978 0 12 801238 3.11260 7
   Misra J, 2016, STEM CELLS, V34, P756, DOI 10.1002/stem.2255
   Mitchell A, 2019, BMC VET RES, V15, DOI 10.1186/s12917 019 1966 x
   Mohan G, 2017, MONATSH CHEM, V148, P1843, DOI 10.1007/s00706 017 2000 2
   Moriceau G, 2012, CANCER AM CANCER SOC, V118, P750, DOI 10.1002/cncr.26336
   Morioka M, 2010, BIOORGAN MED CHEM, V18, P1143, DOI 10.1016/j.bmc.2009.12.041
   Mucha A, 2011, J MED CHEM, V54, P5955, DOI 10.1021/jm200587f
   Mustafa DA, 2011, TETRAHEDRON LETT, V52, P2285, DOI 10.1016/j.tetlet.2011.02.058
   Nagy DI, 2019, LETT DRUG DES DISCOV, V16, P238, DOI 10.2174/1570180815666180626122630
   Nagy DI, 2018, LETT DRUG DES DISCOV, V15, P713, DOI 10.2174/1570180814666171027160324
   Nagy DI, 2018, SYNTHETIC COMMUN, V48, P663, DOI 10.1080/00397911.2017.1410894
   Niesor EJ, 2001, CURR PHARM DESIGN, V7, P231, DOI 10.2174/1381612013398185
   No JH, 2012, P NATL ACAD SCI USA, V109, P4058, DOI 10.1073/pnas.1118215109
   NUGENT RA, 1993, J MED CHEM, V36, P134, DOI 10.1021/jm00053a017
   Osborn Heaford HL, 2015, FREE RADICAL BIO MED, V86, P47, DOI 10.1016/j.freeradbiomed.2015.04.031
   Papapoulos SE, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115244
   Park J, 2021, FRONT CHEM, V8, DOI 10.3389/fchem.2020.612728
   Park J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186447
   Pavlov VA, 2016, PHOSPHORUS SULFUR, V191, P1504, DOI 10.1080/10426507.2016.1212342
   Pourpak A, 2007, INVEST NEW DRUG, V25, P107, DOI 10.1007/s10637 006 9015 6
   Pradere U, 2014, CHEM REV, V114, P9154, DOI 10.1021/cr5002035
   Reddy C.B., 2020, P INT C RECENT TREND
   Reid IR, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115390
   Reilly JE, 2017, CANCER BIOL THER, V18, P872, DOI 10.1080/15384047.2016.1219817
   Rennert G, 2014, GYNECOL ONCOL, V133, P309, DOI 10.1016/j.ygyno.2014.02.014
   Richard ET, 2021, BIOCONJUGATE CHEM, V32, P916, DOI 10.1021/acs.bioconjchem.1c00036
   Roca Ayats N, 2018, J BONE MINER RES, V33, P2091, DOI 10.1002/jbmr.3580
   Roca Ayats N, 2017, NEW ENGL J MED, V376, P1794, DOI 10.1056/NEJMc1612804
   Roelofs AJ, 2007, J PHARMACOL EXP THER, V322, P228, DOI 10.1124/jpet.106.116467
   Roelofs AJ, 2012, J BONE MINER RES, V27, P835, DOI 10.1002/jbmr.1543
   Roelofs AJ, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1737, DOI 10.1016/B978 0 12 373884 4.00095 1
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Roitelman J, 2004, J BIOL CHEM, V279, P6465, DOI 10.1074/jbc.M308094200
   Romanenko VD, 2019, CURR ORG CHEM, V23, P530, DOI 10.2174/1385272823666190401141844
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sabol HM, 2021, CANCER RES, V81, P5102, DOI 10.1158/0008 5472.CAN 21 0524
   Sedghizadeh PP, 2017, J MED CHEM, V60, P2326, DOI 10.1021/acs.jmedchem.6b01615
   Seist R, 2020, FRONT MOL NEUROSCI, V13, DOI 10.3389/fnmol.2020.00087
   Shaik M.S., 2020, SYNTHETIC COMMUN, P1, DOI [10.1080/00397911, DOI 10.1080/00397911]
   Shang N, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004114
   Shull LW, 2006, BIOORGAN MED CHEM, V14, P4130, DOI 10.1016/j.bmc.2006.02.010
   Shull LW, 2005, J ORGANOMET CHEM, V690, P2521, DOI 10.1016/j.jorganchem.2004.10.013
   Sudileti M, 2019, CHEMISTRYSELECT, V4, P13006, DOI 10.1002/slct.201903191
   Sun ST, 2021, BRIT J PHARMACOL, V178, P2008, DOI 10.1111/bph.15251
   Sun ST, 2016, BIOCONJUGATE CHEM, V27, P329, DOI 10.1021/acs.bioconjchem.5b00369
   Suva LJ, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115711
   Tanaka KSE, 2010, BIOORG MED CHEM LETT, V20, P1355, DOI 10.1016/j.bmcl.2010.01.006
   Tejera E, 2020, MOLECULES, V25, DOI 10.3390/molecules25215172
   Tellamekala S, 2020, MONATSH CHEM, V151, P251, DOI 10.1007/s00706 020 02551 3
   Toyota Y, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2020.115576
   Tseng HC, 2015, ONCOTARGET, V6, P20002, DOI 10.18632/oncotarget.4755
   Tsoumpra M.K., ELUCIDATING
   Tsoumpra MK, 2014, J BONE MINER RES, V29, pS404
   Turek J, 2012, CALCIFIED TISSUE INT, V90, P202, DOI 10.1007/s00223 012 9570 0
   Vepsäläinen JJ, 2002, CURR MED CHEM, V9, P1201, DOI 10.2174/0929867023369998
   Verhulst A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121861
   Vermeer JAF, 2013, BONE, V57, P242, DOI 10.1016/j.bone.2013.08.007
   Wang H, 2020, J BONE MINER RES, V35, P343, DOI 10.1002/jbmr.3889
   Wang H, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030154
   Watts NB, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115222
   Webster MR, 2011, J MED CHEM, V54, P6647, DOI 10.1021/jm200521a
   Wiemer AJ, 2007, BIOCHEM BIOPH RES CO, V353, P921, DOI 10.1016/j.bbrc.2006.12.094
   Wiemer AJ, 2015, TOP CURR CHEM, V360, P115, DOI 10.1007/128_2014_561
   Wills VS, 2015, ACS MED CHEM LETT, V6, P1195, DOI 10.1021/acsmedchemlett.5b00334
   Xia YF, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010382
   Xing LP, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115492
   Yakubovich DC, 2017, BONE, V97, P192, DOI 10.1016/j.bone.2017.01.020
   Yang G, 2015, ANTIMICROB AGENTS CH, V59, P7530, DOI 10.1128/AAC.01873 15
   Yao Z., 2016, J BONE MINER RES, V31, pS225
   Yokoyama T, 2015, J MED CHEM, V58, P7549, DOI 10.1021/acs.jmedchem.5b01147
   Young RN, 2018, CURR OPIN PHARMACOL, V40, P87, DOI 10.1016/j.coph.2018.03.010
   Zarb Y, 2019, BRAIN, V142, P885, DOI 10.1093/brain/awz032
   Zhang C, 2018, ORG CHEM FRONT, V5, P1288, DOI 10.1039/c8qo00009c
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
   Zhou X, 2014, BEILSTEIN J ORG CHEM, V10, P1645, DOI 10.3762/bjoc.10.171
   Zhou X, 2014, BIOORGAN MED CHEM, V22, P2791, DOI 10.1016/j.bmc.2014.03.014
   Zhou X, 2013, BIOORG MED CHEM LETT, V23, P764, DOI 10.1016/j.bmcl.2012.11.089
   Zhu WW, 2019, FASEB J, V33, P5208, DOI 10.1096/fj.201801791RR
   Zhu ZX, 2018, SYNTHESIS STUTTGART, V50, P2601, DOI 10.1055/s 0036 1591555
   Zinnen SP, 2019, ONCOLOGIST, V24, P303, DOI 10.1634/theoncologist.2018 0707
NR 164
TC 47
Z9 54
U1 5
U2 73
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2022
VL 156
AR 116289
DI 10.1016/j.bone.2021.116289
PG 29
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ZZ8ZH
UT WOS:000773552400001
PM 34896359
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wei, SZ
   Wu, Q
   Cao, CL
   Yang, ZN
   Shi, JR
   Huang, JQ
   He, H
   Lai, YJ
   Li, J
AF Wei, Suzhen
   Wu, Qiang
   Cao, Chunlai
   Yang, Zhuoni
   Shi, Jianrui
   Huang, Jingqun
   He, Hua
   Lai, Yongjie
   Li, Jing
TI A mechanism of action reflective, dual cell based bioassay for
   determining the bioactivity of sclerostin neutralizing antibodies
SO SLAS DISCOVERY
LA English
DT Article
DE Bioassay; Bioactivity; Sclerostin; Neutralizing; Antibody
ID BONE FORMATION; DIFFERENTIATION PATHWAY; WNT; OSTEOPOROSIS; BLOSOZUMAB;
   SOST; MASS
AB Osteoporosis is a major threat to the elderly worldwide. The Wnt signaling pathway plays a critical role in bone development and homeostasis. Sclerostin, a Wnt ligand inhibitor, competes with Wnt ligands for low density lipoprotein receptor related protein 5 or 6 (LRP5/6) on osteoblasts, thereby suppressing bone formation. Sclerostin neutralizing monoclonal antibodies (mAbs) have emerged as a potential bone forming therapy for osteoporosis. A cell based bioassay which determines the relative activity of a product, related to its mechanism of action, is of great importance from drug discovery to quality control and batch release. Currently used cell  based bioassays for sclerostin neutralizing mAbs usually use Wnt1 or Wnt3a to stimulate the Wnt pathway; sclerostin is a direct inhibitor of Wnt1 but not Wnt3a. Wnt1 is a highly hydrophobic protein that binds to the producing cell membrane and acts in a juxtacrine manner to stimulate the Wnt pathway in neighboring cells. Bioassays for drugs that induce Wnt1 signaling should be performed in a juxtacrine manner. Here, we present a mechanism of action reflective, dual cell based reporter gene assay. In this assay, Wnt1 producer cells are co  cultured with cells containing the Wnt reporter genes, Wnt1 on the producer cells activates the Wnt signaling pathway in the reporter cells that are in direct cell to cell contact, and sclerostin neutralizing mAbs specifically and effectively antagonize the sclerostin mediated Wnt reporter gene suppression. This bioassay demonstrates good specificity, accuracy, linearity, and precision and is suitable for quality control, stability testing, batch release, and biosimilarity assessment of sclerostin neutralizing mAbs.
C1 [Wei, Suzhen; Cao, Chunlai; Yang, Zhuoni; Shi, Jianrui; Huang, Jingqun; He, Hua; Li, Jing] Zhuhai United Biopharm Co Ltd, 399 Airport West Rd, Zhuhai, Guangdong, Peoples R China.
   [Wu, Qiang; Li, Jing] Zhuhai United Labs Co Ltd, 2428 Anji Rd, Zhuhai, Guangdong, Peoples R China.
   [Lai, Yongjie] Zunyi Med Univ, Dept Microbiol & Immunol, Zhuhai Campus,368 Golden Coast Ave, Zhuhai, Guangdong, Peoples R China.
C3 Zunyi Medical University
RP Li, J (通讯作者)，Zhuhai United Biopharm Co Ltd, 399 Airport West Rd, Zhuhai, Guangdong, Peoples R China.; Li, J (通讯作者)，Zhuhai United Labs Co Ltd, 2428 Anji Rd, Zhuhai, Guangdong, Peoples R China.; Lai, YJ (通讯作者)，Zunyi Med Univ, Dept Microbiol & Immunol, Zhuhai Campus,368 Golden Coast Ave, Zhuhai, Guangdong, Peoples R China.
EM laiyongjie121@163.com; lijvica@163.com
RI 我, 我实在/GVW 4463 2022; LI, Evelyn/LXW 4890 2024
FU Zhuhai United Laboratories Co., Ltd, Zhuhai United Biopharma Co., Ltd;
   Natural Science Foundation of Guizhou Province [20201Y297,
   ZK YIBAN2023510]
FX This work was supported by Zhuhai United Laboratories Co., Ltd, Zhuhai
   United Biopharma Co., Ltd, and the Natural Science Foundation of Guizhou
   Province (Grant Number: 20201Y297, ZK YIBAN2023510) . The funders were
   not involved in the study design, collection, analysis, interpretation
   of data, the writing of this article, or the decision to submit it for
   publication.
CR Aditya S, 2021, J MID LIFE HEALTH, V12, P267, DOI 10.4103/jmh.JMH_106_20
   [Anonymous], 2013, DES DEV BIOASS
   [Anonymous], 2005, VAL AN PROC TEXT MET, P4
   Armingol E, 2021, NAT REV GENET, V22, P71, DOI 10.1038/s41576 020 00292 x
   Beckett K, 2013, TRAFFIC, V14, P82, DOI 10.1111/tra.12016
   Cao C, 2018, BIOMATERIALS, V172, P1, DOI 10.1016/j.biomaterials.2018.04.042
   Chaurasia SN, 2022, ELIFE, V11, DOI 10.7554/eLife.79590
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Dai ZJ, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1168757
   Dai ZJ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.770073
   DeBruine ZJ, 2017, BRIT J PHARMACOL, V174, P4564, DOI 10.1111/bph.14048
   FDA Pregnancy Outcomes Working Group, 2001, Guidance for Industry: bioanalytical method validation
   Fleetwood Kelly, 2015, PDA J Pharm Sci Technol, V69, P248, DOI 10.5731/pdajpst.2015.01016
   Föger Samwald U, 2020, EXCLI J, V19, P1017, DOI 10.17179/excli2020 2591
   Gao XQ, 2013, CELL TRANSPLANT, V22, P2393, DOI 10.3727/096368912X658854
   Glorieux FH, 2024, J BONE MINER RES, V39, P1215, DOI 10.1093/jbmr/zjae112
   Gong Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012682
   Gross JC, 2012, NAT CELL BIOL, V14, P1036, DOI 10.1038/ncb2574
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Hsieh CM., 2015, US patent, Patent No. 8999331
   Huybrechts Y, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00165
   Izumiya M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147752
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kerschan Schindl K, 2020, WIEN MED WOCHENSCHR, V170, P124, DOI 10.1007/s10354 019 00721 5
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Kim J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 19155 4
   Kneissel M., 2008, Patent Appl., Patent No. [US20080249050, 20080249050]
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Li WW, 2019, MOL MED REP, V19, P3676, DOI 10.3892/mmr.2019.10040
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024
   MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880
   McColm J, 2014, J BONE MINER RES, V29, P935, DOI 10.1002/jbmr.2092
   Michelini E, 2010, ANAL BIOANAL CHEM, V398, P227, DOI 10.1007/s00216 010 3933 z
   Momiji H, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1007030
   Nakashima A, 2005, J BIOL CHEM, V280, P37660, DOI 10.1074/jbc.M504612200
   Paszty C., 2006, Patent Appl, Patent No. [US20060411003, 20060411003]
   Pharmacopoeia E., Statistical analysis of results of biological assays and tests general
   Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124
   Rauch F, 2017, J CLIN INVEST, V127, P2539, DOI 10.1172/JCI95386
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Ren Q, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.670960
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Smith EM., 2010, US patent, Patent No. 7744874
   Tan CW, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752 0509 8 44
   Tan CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031882
   Tan RJ, 2014, KIDNEY INT SUPPL, V4, P84, DOI 10.1038/kisup.2014.16
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Vlashi R, 2023, GENES DIS, V10, P1291, DOI 10.1016/j.gendis.2022.07.011
   Wang F, 2019, J BONE MINER RES, V34, P1129, DOI 10.1002/jbmr.3680
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Zenjiro S., 2023, US patent, Patent No. 11608374
   Zhang L, 2012, BIOCHEM BIOPH RES CO, V419, P83, DOI 10.1016/j.bbrc.2012.01.132
NR 56
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2472 5552
EI 2472 5560
J9 SLAS DISCOV
JI SLAS Discov.
PD OCT
PY 2024
VL 29
IS 7
AR 100187
DI 10.1016/j.slasd.2024.100187
EA OCT 2024
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry
GA O1F8M
UT WOS:001368678800001
PM 39389544
OA gold
DA 2025 08 17
ER

PT J
AU Iolascon, G
   Resmini, G
   Tarantino, U
AF Iolascon, Giovanni
   Resmini, Giuseppina
   Tarantino, Umberto
TI Inhibition of RANK ligand: a new option for preventing fragility
   fractures
SO AGING CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Denosumab; fragility fractures; RANK ligand
ID LOW BONE MASS; POSTMENOPAUSAL WOMEN; DENOSUMAB; OSTEOPROTEGERIN;
   TURNOVER; DENSITY; ALENDRONATE; STRENGTH; THERAPY
AB Cortical and trabecular bone undergo a continuous and balanced remodeling process, consisting of an osteoclast mediated bone resorption phase and an osteoblast mediated bone formation phase. An imbalance in this process, which favours bone resorption, results in bone loss and in damage to the skeletal microarchitecture. A new targeted anti resorptive approach is represented by the inhibition of RANK ligand (RANKL), which is one of the primary mediators of osteoclast activity, essential for osteoclast formation, function and survival. (Aging Clin Exp Res 2011; 23 (Suppl. to No. 2): 28 29) (C) 2011, Editrice Kurtis
C1 [Iolascon, Giovanni] Univ Naples 2, Dept Orthoped & Rehabil, I 80138 Naples, Italy.
   [Resmini, Giuseppina] Treviglio Caravaggio Hosp, Sect Orthopaed & Traumatol, Ctr Study Osteoporosis & Metab Bone Dis, Bergamo, Italy.
   [Tarantino, Umberto] Univ Tor Vergata, Dept Orthoped & Traumatol, Rome, Italy.
C3 Universita della Campania Vanvitelli; Ospedale di Treviglio Caravaggio;
   University of Rome Tor Vergata
RP Iolascon, G (通讯作者)，Univ Naples 2, Dept Orthoped & Rehabil, I 80138 Naples, Italy.
EM giovanni.iolascon@unina2.it
RI Iolascon, Giovanni/T 6220 2017
OI Iolascon, Giovanni/0000 0002 0976 925X; TARANTINO,
   Umberto/0000 0003 0330 2189
CR Beck TJ, 2008, J CLIN DENSITOM, V11, P351, DOI 10.1016/j.jocd.2007.12.017
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Delmas PD, 2008, J CLIN DENSITOM, V11, P325, DOI 10.1016/j.jocd.2008.02.002
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kostenuik PJ, 2001, ENDOCRINOLOGY, V142, P4295, DOI 10.1210/en.142.10.4295
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Ominsky MS, 2008, J BONE MINER RES, V23, P672, DOI 10.1359/JBMR.080109
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
NR 14
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1594 0667
EI 1720 8319
J9 AGING CLIN EXP RES
JI Aging Clin. Exp. Res.
PD APR
PY 2011
VL 23
SU S
BP 28
EP 29
PG 2
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA 817DQ
UT WOS:000294651900012
PM 21970913
DA 2025 08 17
ER

PT J
AU Miranda, R
   Vinga, S
   Valério, D
AF Miranda, Raquel
   Vinga, Susana
   Valerio, Duarte
TI Studying Bone Remodelling and Tumour Growth for Therapy Predictive
   Control
SO MATHEMATICS
LA English
DT Article
DE bone remodelling; PK; PD; bone metastasis; model predictive control;
   particle swarm optimization
ID OPTIMIZATION; METASTASIS; MECHANISMS; MODELS
AB Bone remodelling consists of cycles of bone resorption and formation executed mainly by osteoclasts and osteoblasts. Healthy bone remodelling is disrupted by diseases such as Multiple Myeloma and bone metastatic diseases. In this paper, a simple mathematical model with differential equations, which takes into account the evolution of osteoclasts, osteoblasts, bone mass and bone metastasis growth, is improved with a pharmacokinetic and pharmacodynamic (PK/PD) scheme of the drugs denosumab, bisphosphonates, proteasome inhibitors and paclitaxel. The major novelty is the inclusion of drug resistance phenomena, which resulted in two variations of the model, corresponding to different paradigms of the origin and development of the tumourous cell resistance condition. These models are then used as basis for an optimization of the drug dose applied, paving the way for personalized medicine. A Nonlinear Model Predictive Control scheme is used, which takes advantage of the convenient properties of a suggested adaptive and democratic variant of Particle Swarm Optimization. Drug prescriptions obtained in this way provide useful insights into dose administration strategies. They also show how results may change depending on which of the two very different paradigms of drug resistance is used to model the behaviour of the tumour.
C1 [Miranda, Raquel; Vinga, Susana; Valerio, Duarte] Univ Lisbon, Inst Super Tecn, IDMEC, P 1049001 Lisbon, Portugal.
   [Vinga, Susana] Univ Lisbon, Inst Super Tecn, INESC ID, P 1049001 Lisbon, Portugal.
C3 Universidade de Lisboa; Universidade de Lisboa; INESC ID
RP Valério, D (通讯作者)，Univ Lisbon, Inst Super Tecn, IDMEC, P 1049001 Lisbon, Portugal.
EM raquellopesmiranda@tecnico.ulisboa.pt; susanavinga@tecnico.ulisboa.pt;
   duarte.valerio@tecnico.ulisboa.pt
RI Valerio, Duarte/C 9339 2012; Valério, Duarte/C 9339 2012; Vinga,
   Susana/B 8450 2008
OI Valerio, Duarte/0000 0001 9388 4308; Vinga, Susana/0000 0002 1954 5487
FU FCT through IDMEC under LAETA [UID/EMS/50022/2020]; FCT through INESC ID
   [UIDB/50021/2020]; FCT through project PERSEIDS [PTDC/EMS SIS/0642/2014]
FX This work was supported by FCT, through IDMEC, under LAETA, project
   UID/EMS/50022/2020, through INESC ID, project UIDB/50021/2020, and
   through project PERSEIDS, PTDC/EMS SIS/0642/2014.
CR [Anonymous], 2013, MODEL PREDICTIVE CON, DOI DOI 10.23919/ECC51009.2020.9143671
   [Anonymous], 1995, P 6 INT S MICR HUM S
   Araujo RP, 2004, B MATH BIOL, V66, P1039, DOI 10.1016/j.bulm.2003.11.002
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   BALDONEDO J, 2020, MATHEMATICS BASEL, V8, DOI DOI 10.3390/math8010087
   Bartl R., 2017, Bone Disorders: Biology, Diagnosis, Prevention, Therapy, P31
   Bassingthwaighte James B, 2012, Methods Mol Biol, V929, P391
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Christ L.F., 2018, J APPL NONLINEAR DYN, V7, P81, DOI [10.5890/JAND.2018.03.007, DOI 10.5890/JAND.2018.03.007]
   Coelho JP, 2005, COMPUT ELECTRON AGR, V49, P330, DOI 10.1016/j.compag.2005.08.003
   Coelho R.M., 2020, COMPUTATIONAL MECH B
   Coelho RM, 2016, J THEOR BIOL, V391, P1, DOI 10.1016/j.jtbi.2015.11.024
   Colli P, 2019, MATHEMATICS BASEL, V7, DOI 10.3390/math7090792
   DiPiro J.T., 2010, CONCEPTS CLIN PHARMA, V5th
   Goldie J.H., 2009, DRUG RESISTANCE CANC
   Grüne L, 2011, COMMUN CONTROL ENG, P43, DOI 10.1007/978 0 85729 501 9_3
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Kaveh A, 2014, COMPUT STRUCT, V130, P10, DOI 10.1016/j.compstruc.2013.09.002
   Kennedy J, 1995, 1995 IEEE INTERNATIONAL CONFERENCE ON NEURAL NETWORKS PROCEEDINGS, VOLS 1 6, P1942, DOI 10.1109/icnn.1995.488968
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Liu LZ, 2019, J TISSUE ENG, V10, DOI 10.1177/2041731419827167
   Martin RB, 2000, BONE, V26, P1, DOI 10.1016/S8756 3282(99)00241 0
   Martin TJ, 2016, PHYSIOL REV, V96, P831, DOI 10.1152/physrev.00031.2015
   Mercieca J., 2011, P ADVCOMP, P88
   Michor F, 2015, CELL, V163, P1059, DOI 10.1016/j.cell.2015.11.002
   Miranda R., 2018, P INT C FRACT DIFF I
   Monro HC, 2009, J THEOR BIOL, V257, P292, DOI 10.1016/j.jtbi.2008.12.006
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Neto J.P., 2018, LINEAR NONLINEAR FRA, P1
   Neto JP, 2018, COMPUT MATH APPL, V75, P3147, DOI 10.1016/j.camwa.2018.01.037
   Owen R, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00134
   Papandreou CN, 2004, J CLIN ONCOL, V22, P2108, DOI 10.1200/JCO.2004.02.106
   Pinheiro JV, 2011, IEEE DECIS CONTR P, P65
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Ratnaweera A, 2004, IEEE T EVOLUT COMPUT, V8, P240, DOI 10.1109/tevc.2004.826071
   Schmiedel BJ, 2013, CANCER RES, V73, P683, DOI 10.1158/0008 5472.CAN 12 2280
   Sieberath A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030912
   Taherkhani M, 2016, APPL SOFT COMPUT, V38, P281, DOI 10.1016/j.asoc.2015.10.004
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Valério D, 2019, B POL ACAD SCI TECH, V67, P501, DOI 10.24425/bpasts.2019.129649
   Valério D, 2011, IET CONTROL THEORY A, V5, P1033, DOI 10.1049/iet cta.2010.0332
   Valerio D, 2013, An Introduction to Fractional Control
NR 44
TC 2
Z9 3
U1 0
U2 13
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2227 7390
J9 MATHEMATICS BASEL
JI Mathematics
PD MAY
PY 2020
VL 8
IS 5
AR 679
DI 10.3390/math8050679
PG 22
WC Mathematics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Mathematics
GA MB6UZ
UT WOS:000542738100131
OA gold
DA 2025 08 17
ER

PT J
AU Chandra, A
   Lin, T
   Zhu, J
   Tong, W
   Huo, YY
   Jia, HR
   Zhang, YJ
   Liu, XS
   Cengel, K
   Xia, B
   Qin, L
AF Chandra, Abhishek
   Lin, Tiao
   Zhu, Ji
   Tong, Wei
   Huo, Yanying
   Jia, Haoruo
   Zhang, Yejia
   Liu, X. Sherry
   Cengel, Keith
   Xia, Bing
   Qin, Ling
TI PTH1 34 Blocks Radiation induced Osteoblast Apoptosis by Enhancing DNA
   Repair through Canonical Wnt Pathway
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Apoptosis; DNA Repair; Osteoblast; Parathyroid Hormone; Wnt Pathway;
   Ionizing Radiation
ID PELVIC INSUFFICIENCY FRACTURES; PARATHYROID HORMONE; BONE FORMATION;
   IONIZING RADIATION; INTERMITTENT PTH; PROTEIN KINASE; IN VITRO; CELLS;
   IRRADIATION; EXPRESSION
AB Background: PTH1 34 alleviates radiation induced osteoporosis in a preclinical radiotherapy model. Results: PTH1 34 attenuates radiation damage on osteoblasts by increasing Ku70 amount, accelerating DNA repair, and suppressing osteoblast apoptosis. Pathway analyses identify canonical Wnt pathway as an important mediator. Conclusion: PTH1 34 blocks radiation induced osteoblast apoptosis through activation of  catenin. Significance: PTH1 34 or Wnt agonist could be possible therapy for radiation induced osteoporosis.
   Focal radiotherapy for cancer patients has detrimental effects on bones within the radiation field and the primary clinical signs of bone damage include the loss of functional osteoblasts. We reported previously that daily injection of parathyroid hormone (PTH, 1 34) alleviates radiation induced osteopenia in a preclinical radiotherapy model by improving osteoblast survival. To elucidate the molecular mechanisms, we irradiated osteoblastic UMR 106 01 cells and calvarial organ culture and demonstrated an anti apoptosis effect of PTH1 34 on these cultures. Inhibitor assay indicated that PTH exerts its radioprotective action mainly through protein kinase A/ catenin pathway.  H2AX foci staining and comet assay revealed that PTH efficiently promotes the repair of DNA double strand breaks (DSBs) in irradiated osteoblasts via activating the  catenin pathway. Interestingly, Wnt3a alone also blocked cell death and accelerated DNA repair in primary osteoprogenitors, osteoblastic and osteocytic cells after radiation through the canonical signaling. Further investigations revealed that both Wnt3a and PTH increase the amount of Ku70, a core protein for initiating the assembly of DSB repair machinery, in osteoblasts after radiation. Moreover, down regulation of Ku70 by siRNA abrogated the prosurvival effect of PTH and Wnt3a on irradiated osteoblasts. In summary, our results identify a novel role of PTH and canonical Wnt signaling in regulating DSB repair machinery and apoptosis in osteoblasts and shed light on using PTH1 34 or Wnt agonist as possible therapy for radiation induced osteoporosis.
C1 [Chandra, Abhishek; Lin, Tiao; Zhu, Ji; Tong, Wei; Jia, Haoruo; Liu, X. Sherry; Qin, Ling] Univ Penn, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Zhang, Yejia] Univ Penn, Dept Phys Med & Rehabil, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Zhang, Yejia] Univ Penn, Dept Orthoped Surg, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Cengel, Keith] Univ Penn, Dept Radiat Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Lin, Tiao] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthopaed Surg, Hangzhou 310009, Zhejiang, Peoples R China.
   [Tong, Wei] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Orthopaed Surg, Wuhan 430022, Hubei, Peoples R China.
   [Xia, Bing] Rutgers State Univ, Dept Radiat Oncol, Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA.
   [Xia, Bing] Rutgers State Univ, Dept Radiat Oncol, Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA.
   [Zhang, Yejia] Philadelphia Vet Affairs Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania; University of
   Pennsylvania; University of Pennsylvania; Zhejiang University; Huazhong
   University of Science & Technology; Rutgers University System; Rutgers
   University New Brunswick; Rutgers University Biomedical & Health
   Sciences; Rutgers Cancer Institute of New Jersey; Rutgers University
   System; Rutgers University New Brunswick; Rutgers University Biomedical
   & Health Sciences; University of Pennsylvania; Pennsylvania Medicine; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Philadelphia Veterans Affairs Medical Center
RP Qin, L (通讯作者)，Univ Penn, Dept Orthopaed Surg, Perelman Sch Med, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA.
EM qinling@mail.med.upenn.edu
RI Chandra, Abhishek/AAG 8781 2020; Jia, Haoruo/AAI 1747 2019; Liu,
   Xiaowei/H 1664 2017; Xia, Bing/LWK 4160 2024; Liu, Xiaowei
   Sherry/H 1664 2017; tong, wei/AAJ 1093 2021; Zhang, Yejia/IST 0016 2023;
   Tong, Wei/AAJ 1093 2021; qin, ling/KIB 1029 2024
OI Chandra, Abhishek/0000 0001 9423 9669; HUO, YANYING/0000 0003 4747 4951;
   Liu, Xiaowei Sherry/0000 0001 7247 2232; tong, wei/0000 0001 8031 0380; 
FU National Institutes of Health [R01DK095803, R01CA138804]; Penn Center
   for Musculoskeletal Disorder [P30AR050950]; ASBMR Junior Faculty
   Osteoporosis Basic Research Award; McCabe Pilot Award
FX This work was supported by National Institutes of Health Grants
   R01DK095803 (to L. Q.) and R01CA138804 (to B. X.), Penn Center for
   Musculoskeletal Disorder Grant P30AR050950 (NIAMS, National Institutes
   of Health), the ASBMR Junior Faculty Osteoporosis Basic Research Award
   (to L. Q.), and the McCabe Pilot Award (to X. S. L.).
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   de Oliveira ECA, 2010, CALCIFIED TISSUE INT, V87, P424, DOI 10.1007/s00223 010 9396 6
   Amsel AD, 2008, P NATL ACAD SCI USA, V105, P5117, DOI 10.1073/pnas.0706700105
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baxter NN, 2005, JAMA J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Chandra A, 2014, BONE, V67, P33, DOI 10.1016/j.bone.2014.06.030
   Chandra A, 2013, J BIOL CHEM, V288, P20488, DOI 10.1074/jbc.M112.447250
   Chandra A, 2013, BONE, V55, P449, DOI 10.1016/j.bone.2013.02.023
   CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dudziak ME, 2000, PLAST RECONSTR SURG, V106, P1049, DOI 10.1097/00006534 200010000 00015
   Fei YR, 2012, J CELL PHYSIOL, V227, P3539, DOI 10.1002/jcp.24075
   Gal TJ, 2000, ARCH OTOLARYNGOL, V126, P1124, DOI 10.1001/archotol.126.9.1124
   Gortazar AR, 2013, J BIOL CHEM, V288, P8168, DOI 10.1074/jbc.M112.437921
   Gu YS, 2000, P NATL ACAD SCI USA, V97, P2668, DOI 10.1073/pnas.97.6.2668
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jilka RL, 2009, BONE, V44, P275, DOI 10.1016/j.bone.2008.10.037
   JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941
   Kanis JA, 2003, BONE, V32, P468, DOI 10.1016/S8756 3282(03)00061 9
   Kitase Y, 2010, J BONE MINER RES, V25, P2381, DOI 10.1002/jbmr.168
   Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097 2765(00)80108 2
   Li H, 2007, MOL CELL BIOL, V27, P8205, DOI 10.1128/MCB.00785 07
   Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200
   Matsumura S, 1996, CALCIFIED TISSUE INT, V59, P307, DOI 10.1007/s002239900129
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Mitchell MJ, 1998, RADIOGRAPHICS, V18, P1125, DOI 10.1148/radiographics.18.5.9747611
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Mohammad Khalid S., 2008, V455, P37, DOI 10.1007/978 1 59745 104 8_3
   Moreno A, 1999, INT J RADIAT ONCOL, V44, P61, DOI 10.1016/S0360 3016(98)00534 3
   Motyl KJ, 2012, J CELL PHYSIOL, V227, P1326, DOI 10.1002/jcp.22844
   Mumber MP, 1997, SKELETAL RADIOL, V26, P94, DOI 10.1007/s002560050200
   Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5
   PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo 108 1 220
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Qin L, 2012, TOPICS BONE BIOL, P1
   Romero G, 2010, J BIOL CHEM, V285, P14756, DOI 10.1074/jbc.M110.102970
   Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100
   Schnoke M, 2009, BONE, V45, P590, DOI 10.1016/j.bone.2009.05.006
   Semënov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960 9822(01)00290 1
   SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411
   Szymczyk KH, 2004, BONE, V34, P148, DOI 10.1016/j.bone.2003.09.003
   Tobimatsu T, 2006, ENDOCRINOLOGY, V147, P2583, DOI 10.1210/en.2005 1627
   Uezono H, 2013, J RADIAT RES, V54, P1102, DOI 10.1093/jrr/rrt055
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Vignard J, 2013, RADIOTHER ONCOL, V108, P362, DOI 10.1016/j.radonc.2013.06.013
   Wan M, 2008, GENE DEV, V22, P2968, DOI 10.1101/gad.1702708
   Wang B, 2014, CELL DEATH DIFFER, V21, P1160, DOI 10.1038/cdd.2014.42
   Weinstein RS, 2010, ENDOCRINOLOGY, V151, P2641, DOI 10.1210/en.2009 1488
   Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104
NR 53
TC 53
Z9 56
U1 1
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 2
PY 2015
VL 290
IS 1
BP 157
EP 167
DI 10.1074/jbc.M114.608158
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA AX9OG
UT WOS:000347231200014
PM 25336648
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Dore, RK
AF Dore, Robin K.
TI The RANKL Pathway and Denosumab
SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
LA English
DT Article
DE Denosumab; RANKL; RANK; FREEDOM; Osteoporosis
ID HUMAN MONOCLONAL ANTIBODY; BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN;
   OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN; TURNOVER; RESORPTION;
   LIGAND; ALENDRONATE; FRACTURES
AB Denosumab (Prolia) is a fully human monoclonal antibody directed against receptor activator of nuclear factor kappa B ligand (RANKL), which interferes with the formation, activation, and survival of osteoclasts. It was approved by the Food and Drug Administration in June 2010 as a new treatment for postmenopausal osteoporosis in women who are at high risk for fracture. Given its mechanism of action, it is an antiresorptive therapy that is administered as a 60 mg subcutaneous injection every 6 months. It is the first biologic antiresorptive therapy for osteoporosis, and the first osteoporosis therapy to show efficacy and safety in patients with renal impairment.
C1 [Dore, Robin K.] Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP Dore, RK (通讯作者)，18102 Irvine Blvd 104, Tustin, CA 92780 USA.
EM rkdmail@sbglobal.net
CR Adami S, 2010, ECTS 2010, p0P24
   [Anonymous], 2010, PROLIA DENOSUMAB PRE
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2009, J BONE MINER RES S1, V24
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Browner WS, 2001, J CLIN ENDOCR METAB, V86, P631, DOI 10.1210/jc.86.2.631
   Chupurlat R, 2011, AM COLL RHEUM ANN M, pS903
   Compston JE, 2007, J BONE MINER RES, V22, P1031, DOI 10.1359/JBMR.070407
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Ellis GK, 2009, BREAST CANCER RES TR, V118, P81, DOI 10.1007/s10549 009 0352 y
   Fahrleitner A, 2003, BONE, V89, P180
   Genant HK, 2010, BONE, V47, P131, DOI 10.1016/j.bone.2010.04.594
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Jamal SA, 2010, ANN M AM SOC BON MIN
   Kendler DL, 2010, OSTEOPOROSIS INT, V21, P837, DOI 10.1007/s00198 009 1023 x
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Kendler DL, 2011, J CLIN DENSITOM, V14, P158
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lewiecki EM, 2007, J BONE MINER RES, V22, P1832, DOI 10.1359/JBMR.070809
   Martin T. J., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P243
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Miller PD, 2011, J CLIN ENDOCR METAB, V96, P394, DOI 10.1210/jc.2010 1805
   Reid IR, 2010, J BONE MINER RES, V25, P2256, DOI 10.1002/jbmr.149
   Sasaki N, 2001, NEPHROL DIAL TRANSPL, V16, P479, DOI 10.1093/ndt/16.3.479
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Smith MR, 2009, J UROLOGY, V182, P2670, DOI 10.1016/j.juro.2009.08.048
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Stolina M, 2006, J BONE MINER RES, V21, pS153
   Turner CH, 2002, CALCIFIED TISSUE INT, V70, P435, DOI 10.1007/s00223 001 1024 z
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Zhao L, 2010, J BONE MINER RES, V25, P1246, DOI 10.1002/jbmr.28
NR 39
TC 24
Z9 27
U1 0
U2 10
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0889 857X
EI 1558 3163
J9 RHEUM DIS CLIN N AM
JI Rheum. Dis. Clin. North Am.
PD AUG
PY 2011
VL 37
IS 3
BP 433
EP +
DI 10.1016/j.rdc.2011.07.004
PG 22
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 853PU
UT WOS:000297439000009
PM 22023901
DA 2025 08 17
ER

PT S
AU Goessl, C
   Katz, L
   Dougall, WC
   Kostenuik, PJ
   Zoog, HB
   Braun, A
   Dansey, R
   Wagman, RB
AF Goessl, Carsten
   Katz, Leonid
   Dougall, William C.
   Kostenuik, Paul J.
   Zoog, Holly Brenza
   Braun, Ada
   Dansey, Roger
   Wagman, Rachel B.
GP NYAS
TI The development of denosumab for the treatment of diseases of bone loss
   and cancer induced bone destruction
SO PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2011
SE Annals of the New York Academy of Sciences
LA English
DT Article; Book Chapter
DE denosumab; RANKL; postmenopausal osteoporosis; bone metastases
ID OSTEOCLAST DIFFERENTIATION FACTOR; ANDROGEN DEPRIVATION THERAPY; KAPPA B
   LIGAND; POSTMENOPAUSAL WOMEN; BREAST CANCER; PROSTATE CANCER; ZOLEDRONIC
   ACID; MINERAL DENSITY; OSTEOPROTEGERIN LIGAND; RECEPTOR ACTIVATOR
AB Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL), an essential cytokine for the formation, function, and survival of osteoclasts. The role of excessive RANKL as a contributor to conditions characterized by bone loss or bone destruction has been well studied. With its novel mechanism of action, denosumab offers a significant advance in the treatment of postmenopausal osteoporosis; bone loss associated with hormone ablation therapy in women with breast cancer and men with prostate cancer; and the prevention of skeletal related events in patients with bone metastases from solid tumors by offering clinical benefit to these patients in need.
C1 [Goessl, Carsten; Katz, Leonid; Kostenuik, Paul J.; Zoog, Holly Brenza; Braun, Ada; Dansey, Roger; Wagman, Rachel B.] Amgen Inc, Thousand Oaks, CA 91320 USA.
   [Dougall, William C.] Amgen Inc, Seattle, WA USA.
C3 Amgen; Amgen
RP Goessl, C (通讯作者)，Amgen Inc, 1 Amgen Ctr Dr,MS 38 2 A, Thousand Oaks, CA 91320 USA.
EM cgoessl@amgen.com
OI Dougall, William/0000 0001 9487 251X
CR Alibhai SMH, 2009, J CLIN ONCOL, V27, P3452, DOI 10.1200/JCO.2008.20.0923
   Amir E, 2011, JNCI J NATL CANCER I, V103, P1299, DOI 10.1093/jnci/djr242
   [Anonymous], 2012, PROL US PRESCR INF
   [Anonymous], J UROL
   Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678
   Asselin Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   Austin M, 2012, J BONE MINER RES, V27, P687, DOI 10.1002/jbmr.1472
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Beleut M, 2010, P NATL ACAD SCI USA, V107, P2989, DOI 10.1073/pnas.0915148107
   Blay J.Y., 2011, J CLIN ONCOL S, V29
   Bliuc D, 2009, JAMA J AM MED ASSOC, V301, P513, DOI 10.1001/jama.2009.50
   Body JJ, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 384
   Bone H. G., 2012, 94 ANN M END SOC HOU
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Boyd SK, 2011, BONE, V48, pS182, DOI 10.1016/j.bone.2011.03.423
   Brown JP, 2011, J BONE MINER RES, V26, P2737, DOI 10.1002/jbmr.448
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Buijs JT, 2009, CANCER LETT, V273, P177, DOI 10.1016/j.canlet.2008.05.044
   Canon J, 2010, BONE, V46, P1613, DOI 10.1016/j.bone.2010.03.001
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Cramer JA, 2007, OSTEOPOROSIS INT, V18, P1023, DOI 10.1007/s00198 006 0322 8
   Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002 9343(01)01124 X
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Dougall WC, 2012, CLIN CANCER RES, V18, P326, DOI 10.1158/1078 0432.CCR 10 2507
   Edwards BJ, 2011, CLIN CANCER RES, V17, P560, DOI 10.1158/1078 0432.CCR 10 1595
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Ferrari Lacraz S, 2011, OSTEOPOROSIS INT, V22, P435, DOI 10.1007/s00198 010 1326 y
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi K, 2009, J UROLOGY, V182, P509, DOI 10.1016/j.juro.2009.04.023
   Gold Deborah T, 2006, Curr Osteoporos Rep, V4, P21, DOI 10.1007/s11914 006 0011 8
   Gonzalez Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
   Haentjens P, 2010, ANN INTERN MED, V152, P380, DOI 10.7326/0003 4819 152 6 201003160 00008
   Henry D.H., 2010, J CLIN ONCOL S, V28
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Holland PM, 2010, CANCER BIOL THER, V9, P539, DOI 10.4161/cbt.9.7.11266
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hu M.I., 2011, AM SOC HEM SAN DIEG
   Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091
   Kanis JA., 2007, WHO technical report, V66
   Kawano H, 2003, P NATL ACAD SCI USA, V100, P9416, DOI 10.1073/pnas.1533500100
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kostenuik PJ, 2011, BONE, V49, P151, DOI 10.1016/j.bone.2011.03.769
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li XD, 2009, BONE, V45, P669, DOI 10.1016/j.bone.2009.06.011
   Li ZQ, 2001, STAT MED, V20, P3175, DOI 10.1002/sim.984
   Lipton A, 2010, ANN ONCOL, V21, P380
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Lloyd SAJ, 2008, CALCIFIED TISSUE INT, V82, P361, DOI 10.1007/s00223 008 9133 6
   McClung MR, 2011, ARTHRITIS RHEUM US, V63, pS433
   Melton LJ III, 2011, J BONE MINER RES, V26, P1808, DOI 10.1002/jbmr.405
   Miller RE, 2007, J IMMUNOL, V179, P266, DOI 10.4049/jimmunol.179.1.266
   National Osteoporosis Foundation, 2009, CLIN GUID PREV TREAT
   Oefelein MG, 2002, J UROLOGY, V168, P1005, DOI 10.1016/S0022 5347(05)64561 2
   Ominsky MS, 2011, BONE, V49, P162, DOI 10.1016/j.bone.2011.04.001
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Proell V, 2009, BONE, V45, P677, DOI 10.1016/j.bone.2009.05.024
   Prolia EU Prescribing Information, 2012, PROLIA EU PRESCRIBIN
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Roodman GD, 2008, CANCER TREAT REV, V34, P92, DOI 10.1016/j.ctrv.2007.09.002
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F., 2011, ANN ONCOL
   Scher HI, 2005, CLIN CANCER RES, V11, P5223, DOI 10.1158/1078 0432.CCR 05 0109
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Seeman E, 2010, J BONE MINER RES, V25, P1886, DOI 10.1002/jbmr.81
   Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008 5472.CAN 04 2442
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Silverman S, 2006, RHEUM DIS CLIN N AM, V32, P721, DOI 10.1016/j.rdc.2006.07.003
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Siris ES, 2009, AM J MED, V122, P3, DOI 10.1016/j.amjmed.2008.12.002
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Solomon DH, 2005, ARCH INTERN MED, V165, P2414, DOI 10.1001/archinte.165.20.2414
   Stolina M, 2003, CLIN IMMUNOL, V109, P347, DOI 10.1016/j.clim.2003.09.001
   Stolina M, 2007, J IMMUNOL, V179, P7497, DOI 10.4049/jimmunol.179.11.7497
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Watts NB, 2012, OSTEOPOROSIS INT, V23, P327, DOI 10.1007/s00198 011 1755 2
   Watts NB, 2005, J BONE MINER RES, V20, P2097, DOI 10.1359/JBMR.050814
   Xgeva US prescribing information, 2012, XGEV US PRESCR INF
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zebaze RMD, 2010, LANCET, V375, P1729, DOI 10.1016/S0140 6736(10)60320 0
   Zometa US prescribing information, 2010, ZOM US PRESCR INF
NR 95
TC 33
Z9 36
U1 0
U2 15
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077 8923
BN 978 1 57331 858 7
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2012
VL 1263
BP 29
EP 40
DI 10.1111/j.1749 6632.2012.06674.x
PG 12
WC Multidisciplinary Sciences; Pharmacology & Pharmacy
WE Book Citation Index– Science (BKCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA BDB69
UT WOS:000312492600004
PM 22831177
DA 2025 08 17
ER

PT J
AU Yan, HL
   Li, ZY
   Zhang, ZW
AF Yan, Huili
   Li, Zongying
   Zhang, Zhongwen
TI Exploring the pharmacological mechanism of Xianlingubao against diabetic
   osteoporosis based on network pharmacology and molecular docking: An
   observational study
SO MEDICINE
LA English
DT Article
DE diabetes mellitus; drug repurposing; osteoporosis; pharmacology;
   traditional Chinese medicine
ID BONE MINERAL DENSITY; DIFFERENTIATION; ADIPOCYTES; QUERCETIN;
   OSTEOBLAST; PATHWAYS; RESOURCE
AB Xianlinggubao formula (XLGB), is a traditional Chinese compound Medicine that has been extensively used in osteoarthritis and aseptic osteonecrosis, but its curative effect on diabetic osteoporosis (DOP) and its pharmacological mechanisms remains not clear. The aim of the present study was to investigate the possible mechanism of drug repurposing of XLGB in DOP therapy. We acquired XLGB active compounds from the traditional Chinese medicine systems pharmacology and traditional Chinese medicines integrated databases and discovered potential targets for these compounds by conducting target fishing using the traditional Chinese medicine systems pharmacology and Swiss Target Prediction databases. Gene Cards and Online Mendelian Inheritance in Man (R) database were used to identify the DOP targets. Overlapping related targets between XLGB and DOP was selected to build a protein protein interaction network. Next, the Metascape database was utilized to enrich the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathways. In addition, Auto Dock Vina software was used to verify drug and target binding. In total, 48 hub targets were obtained as the candidate targets responsible for DOP therapy. The anti DOP effect mediated by XLGB was primarily centralized on the advanced glycation end products (AGEs) receptor for AGE signaling pathway in diabetic complications and osteoclast differentiation. In addition, AKT serine/threonine kinase 1, tumor necrosis factor, Interleukin 6, vascular endothelial growth factor A and peroxisome proliferator activated receptor gamma, which were considered as potential therapeutic targets. Furthermore, molecular docking results confirm the credibility of the predicted therapeutic targets. This study elucidates that XLGB may through regulating AGEs formation and osteoclast differentiation as well as angiogenesis and adipogenesis against DOP. And this study provides new promising points to find the exact regulatory mechanisms of XLGB mediated anti DOP effect.
C1 [Yan, Huili; Li, Zongying] Changzhi Peoples Hosp, Dept Clin Lab, Changzhi, Peoples R China.
   [Zhang, Zhongwen] Shandong First Med Univ, Affiliated Hosp 3, Dept Endocrinol & Metabol, Jinan 25003, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical Sciences
RP Zhang, ZW (通讯作者)，Shandong First Med Univ, Affiliated Hosp 3, Dept Endocrinol & Metabol, Jinan 25003, Shandong, Peoples R China.
EM yanhl5556@126.com; 41850110@qq.com; zhangzhongwen521@126.com
FU Natural Science Foundation of China [82000788]; Key Research &
   Development Plan of Shandong Province [2018GSF118176]; Natural Science
   Foundation of Shandong Province [ZR2016HQ26]; Bethune Merck Diabetes
   Research Foundation [B 0307 H20200302]; Guangdong Basic and Applied
   Basic Research Foundation [2019A1515110023]
FX This work was supported by Natural Science Foundation of China
   (82000788), the Key Research & Development Plan of Shandong Province
   (No. 2018GSF118176), Natural Science Foundation of Shandong Province
   (No. ZR2016HQ26), the Bethune Merck Diabetes Research Foundation
   (B 0307 H20200302), the Guangdong Basic and Applied Basic Research
   Foundation (2019A1515110023).
CR Abd El Fattah AI, 2017, CHEM BIOL INTERACT, V271, P30, DOI 10.1016/j.cbi.2017.04.026
   Adil C, 2015, J PHYS THER SCI, V27, P179, DOI 10.1589/jpts.27.179
   Ai L, 2021, IN VITRO CELL DEV AN, V57, P3, DOI 10.1007/s11626 020 00530 w
   Ali D, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.981487
   Bao HS, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906 020 03007 1
   Bateman A, 2017, NUCLEIC ACIDS RES, V45, pD158, DOI 10.1093/nar/gkw1099
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Brown GR, 2015, NUCLEIC ACIDS RES, V43, pD36, DOI 10.1093/nar/gku1055
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chen YL, 2024, J TRANSL MED, V22, DOI 10.1186/s12967 024 05191 x
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752 0509 8 S4 S11
   Cui R, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 021 01030 4
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Dandia H, 2019, BIOMATER SCI UK, V7, P3480, DOI 10.1039/c9bm00184k
   Dhaon Pooja, 2014, Indian J Endocrinol Metab, V18, P159, DOI 10.4103/2230 8210.129105
   Foessl I, 2023, NAT REV ENDOCRINOL, V19, P520, DOI 10.1038/s41574 023 00866 9
   Gendrisch F, 2021, BIOFACTORS, V47, P170, DOI 10.1002/biof.1699
   Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514
   He LL, 2023, J STEROID BIOCHEM, V225, DOI 10.1016/j.jsbmb.2022.106182
   Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007 1110
   Huang XP, 2022, BMC ENDOCR DISORD, V22, DOI 10.1186/s12902 022 01103 6
   Jackuliak Peter, 2021, Vnitr Lek, V67, P291
   Kaneshiro S, 2014, J BONE MINER METAB, V32, P378, DOI 10.1007/s00774 013 0514 1
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Kitaura H, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/181849
   Lee EJ, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10071052
   Lee JW, 2009, CYTOTECHNOLOGY, V61, P125, DOI 10.1007/s10616 010 9253 5
   Li N, 2023, INFLAMMATION, V46, P1901, DOI 10.1007/s10753 023 01849 8
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875 5364(13)60037 0]
   Li XM, 2014, J AGR FOOD CHEM, V62, P12152, DOI 10.1021/jf504132x
   Li Y, 2018, CURR STEM CELL RES T, V13, P185, DOI 10.2174/1574888X12666171012141908
   Luo G, 2018, MOL MED REP, V17, P6605, DOI 10.3892/mmr.2018.8698
   Mohsin S, 2019, EXPERT OPIN BIOL TH, V19, P937, DOI 10.1080/14712598.2019.1618266
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muruganandan S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072277
   Muruganandan S, 2014, IUBMB LIFE, V66, P147, DOI 10.1002/iub.1254
   Rebhan M, 1998, BIOINFORMATICS, V14, P656, DOI 10.1093/bioinformatics/14.8.656
   Ribatti D, 2023, FRONT CELL DEV BIOL, V11, DOI 10.3389/fcell.2023.1244372
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Schacter GI, 2017, ENDOCRIN METAB CLIN, V46, P63, DOI 10.1016/j.ecl.2016.09.010
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shen CY, 2020, MOLECULES, V25, DOI 10.3390/molecules25235591
   Sun Y, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12866
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tomasiuk JM, 2023, REUMATOLOGIA, V61, P294, DOI 10.5114/reum/170048
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Varadi M, 2020, NUCLEIC ACIDS RES, V48, pD344, DOI 10.1093/nar/gkz853
   Wang ZY, 2021, J AGR FOOD CHEM, V69, P1441, DOI 10.1021/acs.jafc.0c08085
   Wattel A, 2003, BIOCHEM PHARMACOL, V65, P35, DOI 10.1016/S0006 2952(02)01445 4
   Wong SK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176448
   Wu B, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1052592
   Wu LC, 2017, J CELL BIOCHEM, V118, P1308, DOI 10.1002/jcb.25672
   Wu ZH, 2017, J BIOL REG HOMEOS AG, V31, P359
   Xue RC, 2013, NUCLEIC ACIDS RES, V41, pD1089, DOI 10.1093/nar/gks1100
   Yen ML, 2005, MOL PHARMACOL, V68, P1061, DOI 10.1124/mol.104.010082
   Zhao YT, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/9872243
   Zheng L, 2021, CURR PHARM BIOTECHNO, V22, P1538, DOI 10.2174/1389201021666201216150442
   Zheng ZG, 2017, EUR J PHARMACOL, V809, P156, DOI 10.1016/j.ejphar.2017.05.017
   Zhou JG, 2023, BIOMED PHARMACOTHER, V165, DOI 10.1016/j.biopha.2023.115044
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
   Zhu HM, 2012, OSTEOPOROSIS INT, V23, P1317, DOI 10.1007/s00198 011 1577 2
NR 61
TC 1
Z9 1
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG 2
PY 2024
VL 103
IS 31
AR e39138
DI 10.1097/MD.0000000000039138
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA A5T5Y
UT WOS:001283157500043
PM 39093780
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Martin, TJ
AF Martin, T. John
TI Aspects of intercellular communication in bone and implications in
   therapy
SO BONE
LA English
DT Article
DE Osteoblasts; Osteoclasts; Bone remodelling; Coupling; Bone formation;
   Bone resorption; Osteoporosis
ID OSTEOCLAST DIFFERENTIATION FACTOR; SCLEROSTIN ANTIBODY TREATMENT;
   BREAST CANCER CELLS; PARATHYROID HORMONE; POSTMENOPAUSAL WOMEN;
   GAP JUNCTIONS; VERTEBRAL FRACTURES; OSTEOBLASTIC CELLS; RECEPTOR
   ACTIVATOR; INHIBITORY FACTOR
AB Communication processes among the cells of bone are essential for the structure and function of the organ. After it was proposed that communication from the osteoblast lineage to hemopoietic cells initiated osteoclastogenesis, the molecular controls were identified to be the tumour necrosis factor ligand and receptor families. This was followed by revelation of very many signalling processes among the cells of bone that regulate the three phases of bone remodelling, the resorption, reversal and formation phases. In many instances the ways in which these mechanisms operate can determine how drugs act on bone, whether they be inhibitors of resorption or promoters of formation.
C1 [Martin, T. John] Univ Melbourne, St Vincents Inst Med Res, Dept Med, St Vincents Hosp, Fitzroy, Vic 3065, Australia.
C3 St. Vincent's Institute of Medical Research; University of Melbourne; St
   Vincent's Health; St Vincent's Hospital Melbourne; NSW Health; St
   Vincents Hospital Sydney
RP Martin, TJ (通讯作者)，Univ Melbourne, St Vincents Inst Med Res, Dept Med, St Vincents Hosp, Fitzroy, Vic 3065, Australia.
EM jmartin@svi.edu.au
FU Victorian State Government OIS Program
FX The comments and advice of Prof Ego Seeman are acknowledged. St
   Vincent's Institute of Medical Research acknowledges the support of the
   Victorian State Government OIS Program.
CR Abdelgawad ME, 2016, HISTOCHEM CELL BIOL, V145, P603, DOI 10.1007/s00418 016 1414 y
   Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324
   Anastasilakis AD, 2019, J BONE MINER RES, V34, P2220, DOI 10.1002/jbmr.3853
   Andersen TL, 2013, AM J PATHOL, V183, P235, DOI 10.1016/j.ajpath.2013.03.006
   Ansari N, 2018, J BONE MINER RES, V33, P137, DOI 10.1002/jbmr.3291
   Asano T, 2019, NAT METAB, V1, P868, DOI 10.1038/s42255 019 0104 1
   Balani DH, 2017, J CLIN INVEST, V127, P3333, DOI 10.1172/JCI91699
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R., 1977, Toulouse, P179
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Boyce Rogely Waite, 2018, Bone Rep, V8, P90, DOI 10.1016/j.bonr.2018.03.001
   Canalis Ernesto, 2000, P153
   CHAMBERS TJ, 1980, CLIN ORTHOP RELAT R, P283
   CHAMBERS TJ, 1982, J CELL SCI, V57, P247
   CHAMBERS TJ, 1985, J CLIN PATHOL, V38, P241, DOI 10.1136/jcp.38.3.241
   Chavassieux P, 2019, J BONE MINER RES, V34, P1597, DOI 10.1002/jbmr.3735
   CORNISH J, 1993, ENDOCRINOLOGY, V132, P1359, DOI 10.1210/en.132.3.1359
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cummings SR, 2018, J BONE MINER RES, V33, P190, DOI 10.1002/jbmr.3337
   Dalby MJ, 2006, BIOMATERIALS, V27, P1306, DOI 10.1016/j.biomaterials.2005.08.028
   Dempster DW, 2020, J BONE MINER RES, V35, P1282, DOI 10.1002/jbmr.4006
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   DOTY SB, 1981, CALCIFIED TISSUE INT, V33, P509, DOI 10.1007/BF02409482
   ELMARDI AS, 1990, CALCIFIED TISSUE INT, V46, P239, DOI 10.1007/BF02555002
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Furuya Y, 2013, J BIOL CHEM, V288, P5562, DOI 10.1074/jbc.M112.426080
   Gardella TJ, 2015, PHARMACOL REV, V67, P310, DOI 10.1124/pr.114.009464
   Gray C, 1996, BONE, V18, P115, DOI 10.1016/8756 3282(95)00456 4
   HATTNER R, 1965, NATURE, V206, P489, DOI 10.1038/206489a0
   Hauge EM, 2001, J BONE MINER RES, V16, P1575, DOI 10.1359/jbmr.2001.16.9.1575
   Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002 9440(10)63712 1
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Holdsworth G, 2018, BONE, V107, P93, DOI 10.1016/j.bone.2017.11.003
   Hughes DE, 1997, J CLIN PATHOL MOL PA, V50, P132, DOI 10.1136/mp.50.3.132
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Jacome Galarza CE, 2013, J BONE MINER RES, V28, P1203, DOI 10.1002/jbmr.1822
   Jacquin C, 2006, J BONE MINER RES, V21, P67, DOI 10.1359/JBMR.051007
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jimi E, 1999, J IMMUNOL, V163, P434
   Karsdal MA, 2005, AM J PATHOL, V166, P467, DOI 10.1016/S0002 9440(10)62269 9
   Karsdal MA, 2007, J BONE MINER RES, V22, P487, DOI 10.1359/JBMR.070109
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   Martin TJ, 2021, ENDOCR REV, V42, P383, DOI 10.1210/endrev/bnab005
   Martin TJ, 2017, J BONE MINER RES, V32, P11, DOI 10.1002/jbmr.3042
   Martin TJ, 2016, PHYSIOL REV, V96, P831, DOI 10.1152/physrev.00031.2015
   Martin TJ, 2009, CRIT REV EUKAR GENE, V19, P73, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.40
   McCauley LK, 2012, J BONE MINER RES, V27, P1231, DOI 10.1002/jbmr.1617
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Misof BM, 2003, J CLIN ENDOCR METAB, V88, P1150, DOI 10.1210/jc.2002 021988
   Mizoguchi T, 2009, J CELL BIOL, V184, P541, DOI 10.1083/jcb.200806139
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nioi P, 2015, J BONE MINER RES, V30, P1457, DOI 10.1002/jbmr.2482
   Noble BS, 2003, AM J PHYSIOL CELL PH, V284, pC934, DOI 10.1152/ajpcell.00234.2002
   Ominsky MS, 2015, J BONE MINER RES, V30, P1280, DOI 10.1002/jbmr.2480
   Ominsky MS, 2017, BONE, V96, P63, DOI 10.1016/j.bone.2016.10.019
   Parfitt A. M., 1996, P315
   Plotkin LI, 2013, BONE, V52, P157, DOI 10.1016/j.bone.2012.09.030
   Riggs BL, 2004, J BONE MINER RES, V19, P1945, DOI 10.1359/JBMR.040916
   RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Seeman E, 2015, J BONE MINER RES, V30, P753, DOI 10.1002/jbmr.2496
   Seeman E, 2010, J BONE MINER RES, V25, P1886, DOI 10.1002/jbmr.81
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sims NA, 2005, J BONE MINER RES, V20, P1093, DOI 10.1359/JBMR.050209
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Sims NA, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00041
   Sims NA, 2010, BMB REP, V43, P513, DOI 10.5483/BMBRep.2010.43.8.513
   Smith SY, 2003, BONE, V32, P45, DOI 10.1016/S8756 3282(02)00923 7
   Stains JP, 2005, BBA BIOMEMBRANES, V1719, P69, DOI 10.1016/j.bbamem.2005.10.012
   Stolina M, 2014, BONE, V67, P305, DOI 10.1016/j.bone.2014.07.031
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Suzuki R, 2000, ANAT EMBRYOL, V202, P119, DOI 10.1007/s004290000101
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   TAKAHASHI T, 1986, ARCH ORAL BIOL, V31, P703, DOI 10.1016/0003 9969(86)90101 9
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takyar FM, 2013, J BONE MINER RES, V28, P912, DOI 10.1002/jbmr.1820
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Taylor S, 2016, BONE, V84, P148, DOI 10.1016/j.bone.2015.12.013
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Tonna S, 2014, FASEB J, V28, P4482, DOI 10.1096/fj.14 254300
   Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo 125 4 1805
   Vrahnas C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11373 9
   Walker EC, 2010, J CLIN INVEST, V120, P582, DOI 10.1172/JCI40568
   Walker EC, 2008, J BONE MINER RES, V23, P2025, DOI [10.1359/jbmr.080706, 10.1359/JBMR.080706]
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
   Xiong JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05244 y
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 115
TC 3
Z9 3
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2021
VL 153
AR 116148
DI 10.1016/j.bone.2021.116148
EA AUG 2021
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA US3QH
UT WOS:000697347500035
PM 34389478
DA 2025 08 17
ER

PT J
AU Hiraga, T
   Horibe, K
   Koide, M
   Yamashita, T
   Kobayashi, Y
AF Hiraga, Toru
   Horibe, Kanji
   Koide, Masanori
   Yamashita, Teruhito
   Kobayashi, Yasuhiro
TI Sclerostin blockade promotes bone metastases of Wnt responsive breast
   cancer cells
SO CANCER SCIENCE
LA English
DT Article
DE bone metastasis; breast cancer; canonical Wnt signaling; osteoclasts;
   sclerostin
ID EXPRESSION; DIFFERENTIATION; OSTEOPROTEGERIN; ANTIBODY; MODEL; GENE;
   LUNG; MASS
AB The secreted protein sclerostin is primarily produced by osteocytes and suppresses osteoblast differentiation and function by inhibiting the canonical Wnt signaling pathway. Genetic and pharmacological inhibition of sclerostin has been shown to increase bone formation and an anti sclerostin antibody has been clinically approved for the treatment of osteoporosis. Canonical Wnt signaling is also involved in the progression of several types of cancers including breast cancer. Here, we studied the effects of sclerostin inhibition on the development of bone metastases of breast cancer using mouse models. TOPFLASH assay and real time PCR analysis of AXIN2, a target of canonical Wnt signaling, revealed that, among four cell lines tested, MDA MB 231 human breast cancer cells responded highly to the canonical Wnt ligand Wnt3a, whereas other cell lines exhibited marginal responses. Consistent with these results, treatment with an anti sclerostin antibody significantly increased the bone metastases of MDA MB 231 but not those of other breast cancer cells. Immunohistochemical studies demonstrated that an anti sclerostin antibody induced intracellular accumulation of beta catenin in bone colonized MDA MB 231 cells. Suspension culture assays showed that Wnt3a accelerated the tumorsphere formation of MDA MB 231 cells, whereas monolayer cell proliferation and migration were not affected. Furthermore, the numbers of osteoclasts and their precursor cells in bone metastases of MDA MB 231 were significantly increased in mice treated with an anti sclerostin antibody. These results collectively suggest that sclerostin blockade activates canonical Wnt signaling in ligand responsive breast cancer cells metastasized to bone, thereby increasing bone metastases, likely to have been mediated at least in part by enhancing stem cell like properties of cancer cells and osteoclastogenesis.
C1 [Hiraga, Toru; Horibe, Kanji] Matsumoto Dent Univ, Dept Histol & Cell Biol, Nagano, Japan.
   [Koide, Masanori; Yamashita, Teruhito; Kobayashi, Yasuhiro] Matsumoto Dent Univ, Inst Oral Sci, Nagano, Japan.
   [Hiraga, Toru] Matsumoto Dent Univ, Dept Histol & Cell Biol, 1780 Gobara Hirooka, Nagano 3990781, Japan.
C3 Matsumoto Dental University; Matsumoto Dental University; Matsumoto
   Dental University
RP Hiraga, T (通讯作者)，Matsumoto Dent Univ, Dept Histol & Cell Biol, 1780 Gobara Hirooka, Nagano 3990781, Japan.
EM toru.hiraga@mdu.ac.jp
FU Grants in Aid for Scientific Research [22K18402, 22K19638, 21K09863]
   Funding Source: KAKEN
CR ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   Brent MB, 2022, BONE, V160, DOI 10.1016/j.bone.2022.116417
   Bu GJ, 2008, INT J CANCER, V123, P1034, DOI 10.1002/ijc.23625
   Charafe Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008 5472.CAN 08 2741
   Costa S, 2019, BONE, V123, P211, DOI 10.1016/j.bone.2019.03.038
   Delgado Calle J, 2017, LEUKEMIA, V31, P2686, DOI 10.1038/leu.2017.152
   Doumpas N, 2019, EMBO J, V38, DOI 10.15252/embj.201798873
   de Castro LF, 2012, J CELL PHYSIOL, V227, P1752, DOI 10.1002/jcp.22902
   Gattinoni L, 2009, NAT MED, V15, P808, DOI 10.1038/nm.1982
   Glorieux FH, 2017, J BONE MINER RES, V32, P1496, DOI 10.1002/jbmr.3143
   Hamaya Etsuro, 2020, Folia Pharmacologica Japonica, V155, P258, DOI 10.1254/fpj.20007
   Hesse E, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125543
   Hiraga T, 2006, CANCER RES, V66, P2067, DOI 10.1158/0008 5472.CAN 05 2012
   Hiraga T, 2019, J ORAL BIOSCI, V61, P95, DOI 10.1016/j.job.2019.02.002
   Hiraga T, 2019, J BONE MINER METAB, V37, P235, DOI 10.1007/s00774 018 0927 y
   Hiraga T, 2016, INT J CANCER, V138, P1698, DOI 10.1002/ijc.29921
   Hiraga T, 2013, CANCER RES, V73, P4112, DOI 10.1158/0008 5472.CAN 12 3801
   Iwamoto R, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23094895
   Johnson RW, 2014, CLIN EXP METASTAS, V31, P945, DOI 10.1007/s10585 014 9682 1
   Koide M, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 70817 1
   Kuchimaru T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05366 3
   Lamb R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067811
   Levenson AS, 1997, CANCER RES, V57, P3071
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   McDonald MM, 2017, BLOOD, V129, P3452, DOI 10.1182/blood 2017 03 773341
   Ominsky MS, 2017, BONE, V96, P63, DOI 10.1016/j.bone.2016.10.019
   Parsons MJ, 2021, CANCER DISCOV, V11, P2413, DOI 10.1158/2159 8290.CD 21 0190
   Sato T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17099 3
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Singh T, 2011, INT J ONCOL, V38, P769, DOI 10.3892/ijo.2011.899
   Takase R, 2022, J ORTHOP SURG RES, V17, DOI 10.1186/s13018 022 03276 1
   Takeuchi Y, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abc6424
   Tanaka S, 2021, J BONE MINER METAB, V39, P332, DOI 10.1007/s00774 020 01176 0
   Yi B, 2002, CANCER RES, V62, P917
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhu MH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11913 7
   Zhuang XQ, 2017, NAT CELL BIOL, V19, P1274, DOI 10.1038/ncb3613
NR 39
TC 11
Z9 11
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1347 9032
EI 1349 7006
J9 CANCER SCI
JI Cancer Sci.
PD JUN
PY 2023
VL 114
IS 6
BP 2460
EP 2470
DI 10.1111/cas.15765
EA MAR 2023
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA H8TQ1
UT WOS:000946255300001
PM 36840409
OA gold
DA 2025 08 17
ER

PT J
AU Greco, T
   Mascio, A
   Comisi, C
   Polichetti, C
   Caravelli, S
   Mosca, M
   Mondanelli, N
   Troiano, E
   Maccauro, G
   Perisano, C
AF Greco, Tommaso
   Mascio, Antonio
   Comisi, Chiara
   Polichetti, Chiara
   Caravelli, Silvio
   Mosca, Massimiliano
   Mondanelli, Nicola
   Troiano, Elisa
   Maccauro, Giulio
   Perisano, Carlo
TI RANKL RANK OPG Pathway in Charcot Diabetic Foot: Pathophysiology and
   Clinical Therapeutic Implications
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE charcot foot; RANKL; OPG; osteoarthopathy; diabetes mellitus; denosumab;
   bisphosphonates; calcitonin
ID BONE RESORPTION; NEURO OSTEOARTHROPATHY; DENOSUMAB; NEUROARTHROPATHY;
   BISPHOSPHONATES; ARTHROPATHY; PAMIDRONATE; OSTEOCLASTOGENESIS;
   OSTEOPOROSIS; ARTHRODESIS
AB Charcot Foot (CF), part of a broader condition known as Charcot Neuro Osteoarthropathy (CNO), is characterized by neuropathic arthropathy with a progressive alteration of the foot. CNO is one of the most devastating complications in patients with diabetes mellitus and peripheral neuropathy but can also be caused by neurological or infectious diseases. The pathogenesis is multifactorial; many studies have demonstrated the central role of inflammation and the Receptor Activator of NF kappa B ligand (RANKL) Receptor Activator of NF kappa B (RANK) Osteoprotegerin (OPG) pathway in the acute phase of the disease, resulting in the serum overexpression of RANKL. This overexpression and activation of this signal lead to increased osteoclast activity and osteolysis, which is a prelude to bone destruction. The aim of this narrative review is to analyze this signaling pathway in bone remodeling, and in CF in particular, to highlight its clinical aspects and possible therapeutic implications of targeting drugs at different levels of the pathway. Drugs that act at different levels in this pathway are anti RANKL monoclonal antibodies (Denosumab), bisphosphonates (BP), and calcitonin. The literature review showed encouraging data on treatment with Denosumab, although in a few studies and in small sample sizes. In contrast, BPs have been re evaluated in recent years in relation to the high possibility of side effects, while calcitonin has shown little efficacy on CNO.
C1 [Greco, Tommaso; Mascio, Antonio; Comisi, Chiara; Polichetti, Chiara; Maccauro, Giulio; Perisano, Carlo] Fdn Policlin Univ A Gemelli, Univ Cattolica Sacro Cuore, Dept Ageing Neurosci Head Neck & Orthoped Sci, Orthoped & Trauma Surg Unit,IRCCS, I 00168 Rome, Italy.
   [Caravelli, Silvio; Mosca, Massimiliano] IRCCS Ist Ortoped Rizzoli, UOC Clin Orthopaed & Traumatol 2, I 40136 Bologna, Italy.
   [Mondanelli, Nicola; Troiano, Elisa] Univ Siena, Dept Med Surg & Neurosci, I 53100 Siena, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   University of Siena
RP Greco, T (通讯作者)，Fdn Policlin Univ A Gemelli, Univ Cattolica Sacro Cuore, Dept Ageing Neurosci Head Neck & Orthoped Sci, Orthoped & Trauma Surg Unit,IRCCS, I 00168 Rome, Italy.
EM greco.tommaso@outlook.it
RI Greco, Tommaso/HZJ 3754 2023; Comisi, Chiara/JDD 8125 2023; Perisano,
   Carlo/N 9056 2015; Mondanelli, Nicola/AAD 8542 2019; Caravelli,
   Silvio/HDM 8629 2022
OI Caravelli, Silvio/0000 0001 9092 225X; Troiano,
   Elisa/0000 0003 3308 4290; Greco, Tommaso/0000 0002 0463 9536;
   Mondanelli, Nicola/0000 0002 0684 4197; COMISI,
   CHIARA/0000 0001 8555 7411
CR Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Baumhauer JF, 2006, FOOT ANKLE INT, V27, P797, DOI 10.1177/107110070602701007
   Bem R, 2006, DIABETES CARE, V29, P1392, DOI 10.2337/dc06 0376
   Berg EE, 1997, J BONE JOINT SURG BR, V79B, P742, DOI 10.1302/0301 620X.79B5.7612
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   BRODSKY JW, 1993, CLIN ORTHOP RELAT R, P21
   Bruhn Olszewska B, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00563 4
   Busch Westbroek TE, 2018, DIABETES CARE, V41, pE21, DOI 10.2337/dc17 1517
   Caputo GM, 1998, AM FAM PHYSICIAN, V57, P2705
   Carrillo López N, 2021, CALCIFIED TISSUE INT, V108, P439, DOI 10.1007/s00223 020 00803 2
   Carvès S, 2021, JOINT BONE SPINE, V88, DOI 10.1016/j.jbspin.2021.105241
   Castellano D, 2011, ONCOLOGIST, V16, P136, DOI 10.1634/theoncologist.2010 0154
   Chiu YG, 2017, EXPERT OPIN BIOL TH, V17, P119, DOI 10.1080/14712598.2017.1263614
   Cianni L, 2020, ORTHOP REV, V12, P64, DOI 10.4081/or.2020.8670
   Connors JC, 2018, J FOOT ANKLE SURG, V57, P1067, DOI 10.1053/j.jfas.2018.03.023
   Das L, 2019, DIABETES CARE, V42, pE185, DOI 10.2337/dc19 1659
   Deeks ED, 2018, DRUG AGING, V35, P163, DOI 10.1007/s40266 018 0525 7
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Durgia H, 2018, WORLD J DIABETES, V9, P115, DOI 10.4239/wjd.v9.i7.115
   Game FL, 2012, DIABETOLOGIA, V55, P32, DOI 10.1007/s00125 011 2354 7
   Grant McDonald L, 2022, CLIN PODIATR MED SUR, V39, P543, DOI 10.1016/j.cpm.2022.05.002
   Greco T, 2020, ORTHOP REV, V12, P69, DOI 10.4081/or.2020.8671
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Guis S, 1999, J RHEUMATOL, V26, P1843
   GUPTA R, 1993, CLIN ORTHOP RELAT R, P43
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733
   Jeffcoate WJ, 2008, DIABETES METAB RES, V24, pS62, DOI 10.1002/dmrr.837
   Jeffcoate William J, 2005, Curr Diab Rep, V5, P430, DOI 10.1007/s11892 005 0050 z
   Jeffcoate WJ, 2005, LANCET, V366, P2058, DOI 10.1016/S0140 6736(05)67029 8
   Jude EB, 2001, DIABETOLOGIA, V44, P2032, DOI 10.1007/s001250100008
   Kloska A, 2020, DIABETES RES CLIN PR, V166, DOI 10.1016/j.diabres.2020.108337
   Lambert AP, 2005, DIABETES CARE, V28, P984, DOI 10.2337/diacare.28.4.984
   Lin JG, 2021, CHEM BIOL DRUG DES, V97, P121, DOI 10.1111/cbdd.13767
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Mabilleau G, 2008, DIABETOLOGIA, V51, P1035, DOI 10.1007/s00125 008 0992 1
   Marmolejo VS, 2018, AM FAM PHYSICIAN, V97, P594
   Mascio Antonio, 2022, Int J Physiol Pathophysiol Pharmacol, V14, P161
   Matsumoto M, 2000, FEBS LETT, V486, P23, DOI 10.1016/S0014 5793(00)02231 6
   Milne TE, 2013, J FOOT ANKLE RES, V6, DOI 10.1186/1757 1146 6 30
   Molines L, 2010, DIABETES METAB, V36, P251, DOI 10.1016/j.diabet.2010.04.002
   Moreno M, 2007, REUMATOL CLIN, V3, P257, DOI 10.1016/S1699 258X(07)73700 2
   Mumoli N, 2012, CAN MED ASSOC J, V184, P1392, DOI 10.1503/cmaj.111972
   Nagy V, 2015, GERONTOLOGY, V61, P534, DOI 10.1159/000371845
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Naqvi A, 2008, AM J MED SCI, V335, P145, DOI 10.1097/MAJ.0b013e3180a5e957
   Pakarinen T K, 2002, Scand J Surg, V91, P195
   Pakarinen TK, 2011, DIABETES CARE, V34, P1514, DOI 10.2337/dc11 0396
   Patel Amit, 2018, Case Rep Orthop, V2018, P9301496, DOI 10.1155/2018/9301496
   Pazianas M, 2007, CLIN THER, V29, P1548, DOI 10.1016/j.clinthera.2007.08.008
   Perisano C, 2018, J Biol Regul Homeost Agents, V32, P157
   PHILLIPS S, 1995, DIABETES CARE, V18, P867, DOI 10.2337/diacare.18.6.867
   Pitocco D, 2005, DIABETES CARE, V28, P1214, DOI 10.2337/diacare.28.5.1214
   Pitocco D, 2020, CURR DIABETES REV, V16, P62, DOI 10.2174/1573399815666190502121945
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reszka Alfred A, 2003, Curr Rheumatol Rep, V5, P65, DOI 10.1007/s11926 003 0085 6
   Richard JL, 2012, DIABETOLOGIA, V55, P1258, DOI 10.1007/s00125 012 2507 3
   RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454
   Rogers Lee C, 2008, Clin Podiatr Med Surg, V25, P43, DOI 10.1016/j.cpm.2007.10.006
   Rosskopf AB, 2019, INSIGHTS IMAGING, V10, DOI 10.1186/s13244 019 0768 9
   SaiPrathiba A, 2019, INT J LOW EXTR WOUND, V18, P287, DOI 10.1177/1534734619859730
   Sanders LJ, 2004, DIABETES METAB RES, V20, pS4, DOI 10.1002/dmrr.451
   Schweitzer M, 2022, CLIN PODIATR MED SUR, V39, P585, DOI 10.1016/j.cpm.2022.05.005
   SHIBATA T, 1990, J BONE JOINT SURG AM, V72A, P749, DOI 10.2106/00004623 199072050 00016
   Shofler D, 2021, J FOOT ANKLE SURG, V60, P354, DOI 10.1053/j.jfas.2020.09.018
   Sisay M, 2017, ONCOTARGETS THER, V10, P3801, DOI 10.2147/OTT.S135867
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tanaka S, 2021, J BONE MINER METAB, V39, P106, DOI 10.1007/s00774 020 01159 1
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wu H, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2022.e12288
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
NR 73
TC 18
Z9 19
U1 3
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2023
VL 24
IS 3
AR 3014
DI 10.3390/ijms24033014
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 8V6LW
UT WOS:000930741700001
PM 36769345
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lemaire, V
   Cox, DR
AF Lemaire, Vincent
   Cox, David R.
TI Dynamics of Bone Cell Interactions and Differential Responses to PTH and
   Antibody Based Therapies
SO BULLETIN OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE Mathematical modeling; Bone remodeling; Wnt pathway; Intermittent PTH;
   Pharmacokinetics of monoclonal antibodies; Denosumab (anti RANKL
   antibody); Romosozumab (anti sclerostin antibody); Osteoporosis;
   Combination therapies
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; PARATHYROID HORMONE;
   MATHEMATICAL MODEL; MINERAL DENSITY; POSTMENOPAUSAL WOMEN;
   MONOCLONAL ANTIBODY; VITAMIN D; DENOSUMAB; SCLEROSTIN; PHARMACOKINETICS
AB We propose a mathematical model describing the dynamics of osteoblasts and osteoclasts in bone remodeling. The goal of this work is to develop an integrated modeling framework for bone remodeling and bone cell signaling dynamics that could be used to explore qualitatively combination treatments for osteoporosis in humans. The model has been calibrated using 57 checks from the literature. Specific global optimization methods based on qualitative objectives have been developed to perform the model calibration. We also added pharmacokinetics representations of three drugs to the model, which are teriparatide (PTH(1 34)), denosumab (a RANKL antibody) and romosozumab (a sclerostin antibody), achieving excellent goodness of fit of human clinical data. The model reproduces the paradoxical effects of PTH on the bone mass, where continuous administration of PTH results in bone loss but intermittent administration of PTH leads to bone gain, thus proposing an explanation of this phenomenon. We used the model to simulate different categories of osteoporosis. The main attributes of each disease are qualitatively well captured by the model, for example changes in bone turnover in the disease states. We explored dosing regimens for each disease based on the combination of denosumab and romosozumab, identifying adequate ratios and doses of both drugs for subpopulations of patients in function of categories of osteoporosis and the degree of severity of the disease.
C1 [Lemaire, Vincent; Cox, David R.] Rinat Pfizer Inc, 230 East Grand Ave, San Francisco, CA 94080 USA.
   [Lemaire, Vincent] Genentech Inc, 1 DNA Way,MS 463A, San Francisco, CA 94080 USA.
C3 Pfizer; Pfizer USA; Roche Holding; Roche Holding USA; Genentech
RP Lemaire, V (通讯作者)，Rinat Pfizer Inc, 230 East Grand Ave, San Francisco, CA 94080 USA.; Lemaire, V (通讯作者)，Genentech Inc, 1 DNA Way,MS 463A, San Francisco, CA 94080 USA.
EM vincent514@gmail.com
RI Lemaire, Vincent/D 7610 2013
OI Lemaire, Vincent/0000 0003 2086 6787
CR Allen RJ, 2016, CPT PHARMACOMET SYST, V5, P140, DOI 10.1002/psp4.12063
   Aloia John F, 2006, Endocr Pract, V12, P137
   Amgen, 2009, ROM NONPR DRUG NAM
   Amgen, 2010, PROL DEN
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bergwitz C, 2010, ANNU REV MED, V61, P91, DOI 10.1146/annurev.med.051308.111339
   Berkhout J, 2015, CPT PHARMACOMET SYST, V4, P516, DOI 10.1002/psp4.12006
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Cho C, 2000, PARATHYROID HORMONE
   Chu NN, 2007, PHARMAZIE, V62, P869, DOI 10.1691/ph.2007.11.7576
   Clausen JO, 2009, OSTEOPOROSIS INT, V20, P1631, DOI 10.1007/s00198 008 0812 y
   Daddona PE, 2011, PHARM RES DORDR, V28, P159, DOI 10.1007/s11095 010 0192 9
   Daoussis D, 2011, SEMIN ARTHRITIS RHEU, V41, P170, DOI 10.1016/j.semarthrit.2011.01.006
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Eudy RJ, 2015, CPT PHARMACOMET SYST, V4, P527, DOI 10.1002/psp4.12013
   FERMOR B, 1995, J BONE MINER RES, V10, P1935
   FRAHER LJ, 1995, J CLIN ENDOCR METAB, V80, P60, DOI 10.1210/jc.80.1.60
   Fromigué O, 2004, CURR PHARM DESIGN, V10, P2593, DOI 10.2174/1381612043383773
   Furuya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02541 w
   Gadkar K, 2014, CPT PHARMACOMET SYST, V3, DOI 10.1038/psp.2014.47
   Gibiansky Leonid, 2012, Clin Pharmacokinet, V51, P247, DOI 10.2165/11598090 000000000 00000
   Gogakos AI, 2009, EXPERT REV ENDOCRINO, V4, P639, DOI DOI 10.1586/eem.09.38
   Goldring SR, 2007, NAT MED, V13, P133, DOI 10.1038/nm0207 133
   Graham JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063884
   Hämmerle SP, 2012, BONE, V50, P965, DOI 10.1016/j.bone.2012.01.009
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   ISHIBASHI Y, 1993, BIOL MASS SPECTROM, V22, P98, DOI 10.1002/bms.1200220113
   Jabbar S, 2011, J CLIN PATHOL, V64, P354, DOI 10.1136/jcp.2010.086595
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kassem M, 2011, AGING CELL, V10, P191, DOI 10.1111/j.1474 9726.2011.00669.x
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Komarova SV, 2005, ENDOCRINOLOGY, V146, P3589, DOI 10.1210/en.2004 1642
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Kumagai Y, 2011, BONE, V49, P1101, DOI 10.1016/j.bone.2011.08.007
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lewiecki EM, 2011, EXPERT OPIN BIOL TH, V11, P117, DOI 10.1517/14712598.2011.540565
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   LINDSAY R, 1993, J CLIN ENDOCR METAB, V77, P1535, DOI 10.1210/jc.77.6.1535
   Liu CZ, 2010, J IMMUNOL, V184, P6910, DOI 10.4049/jimmunol.0904033
   Lorentzon M, 2015, J INTERN MED, V277, P650, DOI 10.1111/joim.12369
   Marathe A, 2008, J PHARMACOL EXP THER, V326, P555, DOI 10.1124/jpet.108.137703
   Marathe DD, 2011, BIOPHARM DRUG DISPOS, V32, P471, DOI 10.1002/bdd.770
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Mosekilde L, 2008, CLIN ENDOCRINOL, V69, P1, DOI 10.1111/j.1365 2265.2007.03162.x
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Paszty C, 2010, J BONE MINER RES, V25, P1897, DOI 10.1002/jbmr.161
   Paton DM, 2014, DRUG FUTURE, V39, P553, DOI 10.1358/dof.2014.039.08.2164452
   Peterson MC, 2012, CPT PHARMACOMET SYST, V1, DOI 10.1038/psp.2012.15
   Peterson MC, 2010, BONE, V46, P49, DOI 10.1016/j.bone.2009.08.053
   Pfützner A, 2003, HORM METAB RES, V35, P319
   Pietschmann P, 2009, GERONTOLOGY, V55, P3, DOI 10.1159/000166209
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2010, BONE, V47, P181, DOI 10.1016/j.bone.2010.04.601
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Post TM, 2013, J PHARMACOKINET PHAR, V40, P143, DOI 10.1007/s10928 012 9294 9
   Post TM, 2010, CLIN PHARMACOKINET, V49, P89, DOI 10.2165/11318150 000000000 00000
   Potter LK, 2005, BONE, V37, P159, DOI 10.1016/j.bone.2005.04.011
   Riggs MM, 2012, J CLIN PHARMACOL, V52, p45S, DOI 10.1177/0091270011412967
   Ross DS, 2012, DISCRETE CONT DYN B, V17, P2185, DOI 10.3934/dcdsb.2012.17.2185
   Ryser MD, 2009, J BONE MINER RES, V24, P860, DOI 10.1359/JBMR.081229
   Scheiner S, 2014, INT J NUMER METH BIO, V30, P1, DOI 10.1002/cnm.2584
   Schmidt S, 2011, J PHARMACOKINET PHAR, V38, P873, DOI 10.1007/s10928 011 9224 2
   Sigma Aldrich, 2008, PAR HORM FRAGM 1 34
   Sipos W, 2009, WIEN MED WOCHENSCHR, V159, P230, DOI 10.1007/s10354 009 0647 y
   Sutjandra L, 2011, CLIN PHARMACOKINET, V50, P793, DOI 10.2165/11594240 000000000 00000
   Tang L, 2004, J PHARM SCI US, V93, P2184, DOI 10.1002/jps.20125
   Vacanti C., 2008, Musculoskeletal Tissue Regeneration: Biological Materials and Methods
   Vasikaran SD, 2008, CRIT REV CL LAB SCI, V45, P221, DOI [10.1080/10408360801949442, 10.1080/10408360801949442 ]
   Wang Y, 2012, SILICO INVESTIGATION
   Wang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027494
   Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155
   Yonemori K, 2008, CANCER SCI, V99, P1237, DOI 10.1111/j.1349 7006.2008.00803.x
   Zhang SQ, 2009, ARCH BIOCHEM BIOPHYS, V487, P49, DOI 10.1016/j.abb.2009.04.008
   Zumsande M, 2011, BONE, V48, P910, DOI 10.1016/j.bone.2010.12.010
NR 88
TC 11
Z9 12
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0092 8240
EI 1522 9602
J9 B MATH BIOL
JI Bull. Math. Biol.
PD SEP
PY 2019
VL 81
IS 9
SI SI
BP 3575
EP 3622
DI 10.1007/s11538 018 0533 0
PG 48
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Mathematical & Computational
   Biology
GA IU7ZV
UT WOS:000483802700008
PM 30460589
DA 2025 08 17
ER

PT J
AU Ho, JW
AF Ho, Joon Wee
TI Bisphosphonate stimulation of osteoblasts and osteoblastic metastasis as
   a mechanism of hypocalcaemia
SO MEDICAL HYPOTHESES
LA English
DT Article
ID ZOLEDRONIC ACID; CONTROLLED TRIAL; BONE METASTASES; RISK FACTORS;
   PROLIFERATION
AB Bisphosphonates are used in the oncological setting to treat and prevent skeletal related events and preserve bone mineral density. Bisphosphonates also possess a hypocalcaemic effect. When undesired, hypocalcaemia can result in increased morbidity and complications. The currently understood mechanism of bisphosphonate induced hypocalcaemia is by osteoclast inhibition. The effect of bisphosphonates on osteoblasts is less well understood. Laboratory studies demonstrate that bisphosphonates increase osteoblast and osteoblastic metastases maturation, activity and bone mineralization. We hypothesize that where large populations of osteoblasts exist increased mineralization may result in hypocalcaemia. Consequently patients with bone metastatic prostate cancer may be more susceptible to symptomatic hypocalcaemia following bisphosphonate therapy. We are currently designing a study to investigate our hypothesis and to identify the risk factors of hypocalcaemia. (C) 2011 Elsevier Ltd. All rights reserved.
C1 Nottingham Univ Hosp NHS Trust, Nottingham NG5 1PB, England.
C3 Nottingham University Hospital NHS Trust
RP Ho, JW (通讯作者)，Nottingham Univ Hosp NHS Trust, City Hosp Campus, Nottingham NG5 1PB, England.
EM joon.ho@nhs.net
CR Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Cancer Research UK, 2010, PROST CANC STAT KEY
   Chennuru S, 2008, INTERN MED J, V38, P635, DOI 10.1111/j.1445 5994.2007.01580.x
   Corey E, 2003, CLIN CANCER RES, V9, P295
   Fokkema MI, 2005, NETH J MED, V63, P34
   Hanamura M, 2010, BIOL PHARM BULL, V33, P721, DOI 10.1248/bpb.33.721
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Koch FP, 2010, HEAD FACE MED, V6, DOI 10.1186/1746 160X 6 12
   Lee YP, 2002, CANCER RES, V62, P5564
   Lim S. C., 2000, SMJ, V41, P74
   Murray RML, 2001, J CLIN ENDOCR METAB, V86, P4133, DOI 10.1210/jc.86.9.4133
   Novartis, 2010, ZOM SUMM PROD CHAR
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Ryan C, 2005, J UROLOGY, V176, P972
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Szentirmai M, 1995, WESTERN J MED, V163, P577
   Zuradelli M, 2009, ONCOLOGIST, V14, P548, DOI 10.1634/theoncologist.2008 0227
NR 19
TC 6
Z9 6
U1 0
U2 9
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD MAR
PY 2012
VL 78
IS 3
BP 377
EP 379
DI 10.1016/j.mehy.2011.12.002
PG 3
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 904TW
UT WOS:000301221800007
PM 22206806
DA 2025 08 17
ER

PT J
AU Zhang, T
   Han, WQ
   Zhao, KX
   Yang, WL
   Lu, XY
   Jia, YW
   Qin, A
   Qian, Y
AF Zhang, Tan
   Han, Weiqi
   Zhao, Kangxian
   Yang, Wanlei
   Lu, Xuanyuan
   Jia, Yewei
   Qin, An
   Qian, Yu
TI Psoralen accelerates bone fracture healing by activating both
   osteoclasts and osteoblasts
SO FASEB JOURNAL
LA English
DT Article
DE natural products; bone repair; osteoclastogenesis; osteoblastogenesis;
   ERK signaling pathway
ID EXTRACELLULAR MATRIX; HEPATIC FIBROSIS; CATHEPSIN K; DIFFERENTIATION;
   INHIBITION; PATHWAYS; ERK; POPULATION; REPAIR; CELLS
AB Bone fracture healing is a complex, dynamic process that involves various cell types, with osteoclasts and osteoblasts playing indispensable roles. In this study, we found that psoralen, the main active ingredient in Psoralea corylifolia L. fruit extract, enhanced bone fracture healing through activation of osteoclast and osteoblast activity via the ERK signaling pathway. In detail, psoralen promoted receptor activator of nuclear factor kappa B ligand induced osteoclastogenesis, mRNA expression of osteoclast specific genes, and osteoclastic bone resorption in primary bone marrow derived macrophages. Meanwhile, psoralen induced osteogenic differentiation by promoting the mRNA expression of the osteoblast differentiation markers alkaline phosphatase, runt related transcription factor 2, osterix, and osteocalcin. At the molecular level, psoralen preferentially activated ERK1/2 but not JNK or p38 MAPKs. Further experiments revealed that psoralen induced osteoclast and osteoblast differentiation was abrogated by a specific inhibitor of phosphorylated ERK. In addition, psoralen accelerated bone fracture healing in a rat tibial fracture model, and the numbers of osteoclasts and osteoblasts were increased in psoralen treated fracture callus. Taken together, our findings indicate that psoralen accelerates bone fracture healing through activation of osteoclasts and osteoblasts via ERK signaling and has potential as a novel drug in the orthopedic clinic for the treatment of bone fractures.
C1 [Zhang, Tan; Han, Weiqi; Zhao, Kangxian; Yang, Wanlei; Lu, Xuanyuan; Jia, Yewei; Qian, Yu] Zhejiang Univ, Sch Med, Shaoxing Peoples Hosp, Dept Orthopaed, 568 Zhongxing North Rd, Shaoxing 312000, Zhejiang, Peoples R China.
   [Qin, An] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthoped Implants, Dept Orthoped,Shanghai Peoples Hosp 9, Shanghai, Peoples R China.
C3 Zhejiang University; Shanghai Jiao Tong University
RP Qian, Y (通讯作者)，Zhejiang Univ, Sch Med, Shaoxing Peoples Hosp, Dept Orthopaed, 568 Zhongxing North Rd, Shaoxing 312000, Zhejiang, Peoples R China.
EM doctor120@hotmail.com
RI ; Qin, An/J 2518 2019
OI Jia, Yewei/0000 0001 5447 973X; 
FU National Natural Science Foundation of China [81871801, 81572126];
   Natural Science Foundation of Zhejiang Province [LY15H060005]; Zhejiang
   Basic Public Welfare Research Project [LGF18H060010]
FX The authors thank Wang Linxia (Shaoxing University, Zhejiang, China) for
   skillful molecular technical assistance. This study was funded by the
   National Natural Science Foundation of China (Grant 81871801), the
   National Natural Science Foundation of China (Grant 81572126), the
   Natural Science Foundation of Zhejiang Province (Grant LY15H060005), and
   the Zhejiang Basic Public Welfare Research Project (LGF18H060010). The
   authors declare no conflicts of interest.
CR Amin S, 2014, J BONE MINER RES, V29, P581, DOI 10.1002/jbmr.2072
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Che CT, 2016, MOLECULES, V21, DOI 10.3390/molecules21030239
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Fang QL, 2018, BBA MOL BASIS DIS, V1864, P252, DOI 10.1016/j.bbadis.2017.09.026
   Gentile MA, 2014, BONE, V66, P72, DOI 10.1016/j.bone.2014.04.032
   Gómez Barrena E, 2015, BONE, V70, P93, DOI 10.1016/j.bone.2014.07.033
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Hak DJ, 2014, INJURY, V45, pS3, DOI 10.1016/j.injury.2014.04.002
   Han WQ, 2016, SCI REP UK, V6, DOI 10.1038/srep36330
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Hankenson KD, 2014, INJURY, V45, pS8, DOI 10.1016/j.injury.2014.04.003
   He LH, 2017, SCI REP UK, V7, DOI 10.1038/srep42385
   He YX, 2012, OSTEOPOROSIS INT, V23, P377, DOI 10.1007/s00198 011 1812 x
   Kameda Y, 2013, J BONE MINER RES, V28, P2463, DOI 10.1002/jbmr.1989
   Karvande A, 2017, J PHARM PHARMACOL, V69, P1381, DOI 10.1111/jphp.12764
   Kim BS, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.95
   Kostenuik P, 2017, J ORTHOP RES, V35, P213, DOI 10.1002/jor.23460
   Li FM, 2017, EXP THER MED, V14, P2385, DOI 10.3892/etm.2017.4771
   Lin X, 2016, CELL PHYSIOL BIOCHEM, V40, P1422, DOI 10.1159/000453194
   Linder M, 2018, CELL DEATH DIFFER, V25, P1094, DOI 10.1038/s41418 017 0054 7
   Luchetti F, 2014, J PINEAL RES, V56, P382, DOI 10.1111/jpi.12133
   Marsell R, 2011, INJURY, V42, P551, DOI 10.1016/j.injury.2011.03.031
   Mehta S, 2015, J MED ECON, V18, P1102, DOI 10.3111/13696998.2015.1083361
   Mills LA, 2017, ACTA ORTHOP, V88, P434, DOI 10.1080/17453674.2017.1321351
   Oh JH, 2015, MOL CELLS, V38, P279, DOI 10.14348/molcells.2015.2340
   Okada T, 2006, DIABETES, V55, P1666, DOI 10.2337/db05 1285
   Pajarinen J, 2019, BIOMATERIALS, V196, P80, DOI 10.1016/j.biomaterials.2017.12.025
   PARFITT AM, 1988, BONE, V9, P67, DOI 10.1016/8756 3282(88)90029 4
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Soung DY, 2013, BONE, V55, P248, DOI 10.1016/j.bone.2013.02.010
   Srivastava S, 2014, BIOCHIMIE, V101, P132, DOI 10.1016/j.biochi.2014.01.005
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Tang DZ, 2011, BIOCHEM BIOPH RES CO, V405, P256, DOI 10.1016/j.bbrc.2011.01.021
   Wang P, 2017, INT J BIOL SCI, V13, P996, DOI 10.7150/ijbs.19986
   Wang T, 2017, J CELL PHYSIOL, V232, P913, DOI 10.1002/jcp.25641
   Wong RWK, 2011, J ORTHOP RES, V29, P158, DOI 10.1002/jor.21124
   Wu CY, 2013, FITOTERAPIA, V91, P205, DOI 10.1016/j.fitote.2013.09.005
   Wu HB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0540 y
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Xu LL, 2015, FASEB J, V29, P1143, DOI 10.1096/fj.14 254169
   Yang BY, 2016, J ETHNOPHARMACOL, V191, P107, DOI 10.1016/j.jep.2016.05.017
   Yang HL, 2016, BIOMATERIALS, V80, P1, DOI 10.1016/j.biomaterials.2015.11.046
   Yang WL, 2018, J CELL PHYSIOL, V233, P4606, DOI 10.1002/jcp.26372
   Zalli D, 2016, J BONE MINER RES, V31, P1701, DOI 10.1002/jbmr.2851
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
   Zhang XP, 2012, ACUPUNCT MED, V30, P324, DOI 10.1136/acupmed 2012 010167
   Zhang ZR, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060588
   Zou WG, 2011, J CLIN INVEST, V121, P4383, DOI 10.1172/JCI59041
NR 53
TC 55
Z9 67
U1 0
U2 42
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2019
VL 33
IS 4
BP 5399
EP 5410
DI 10.1096/fj.201801797R
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA HR1JP
UT WOS:000462888500062
PM 30702934
DA 2025 08 17
ER

PT J
AU Haffner Luntzer, M
AF Haffner Luntzer, Melanie
TI Experimental agents to improve fracture healing: utilizing the WNT
   signaling pathway
SO INJURY INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Fracture healing; WNT signaling; bone repair
ID BONE FORMATION; POSTMENOPAUSAL WOMEN; SCLEROSTIN ANTIBODY; MIDKINE MK;
   MICE; ROMOSOZUMAB; EXPRESSION; FAMILY; DICKKOPF 1; GROWTH
AB The process of bone healing largely recapitulates bone development in the embryo and ideally achieves complete restoration of bone shape and structure. However, because successful fracture healing requires tight interactions of numerous cell types and signaling molecules, any disruption of this highly coordinated processes can result in delayed healing or even non union formation. The rate of fracture healing complications in orthopedic patients is reported to be 5 20%. Therefore, there is a need for new therapeutic strategies to improve fracture healing in patients with healing complications. One treatment strategy would include the easy and safe application of a pharmacological agent inducing osteoanabolic effects during fracture healing. One potential promising molecular target is the osteoanabolic WNT signaling pathway. This pathway plays an important role during embryonic bone development, homeostasis, mechanotransduction, development of osteoporosis and bone regeneration. This review focuses on pre clinical studies targeting WNT signaling molecules to accelerate fracture healing. The three main investigated antagonists of the WNT signaling pathway, which can be blocked experimentally by antibodies, are Sclerostin, Dickkopf 1 and Midkine. Treating animals with antibodies against these proteins enhanced bone formation in the fracture callus. This indicates a therapeutic potential for these antibodies to accelerate fracture healing in patients with orthopedic complications.
   (c) 2021 The Author. Published by Elsevier Ltd.
   This is an open access article under the CC BY NC ND license ( http://creativecommons.org/licenses/by nc nd/4.0/ )
C1 [Haffner Luntzer, Melanie] Univ Med Ctr Ulm, Inst Orthoped Res & Biomech, Helmholtzstr 14, D 89081 Ulm, Germany.
C3 Ulm University
RP Haffner Luntzer, M (通讯作者)，Univ Med Ctr Ulm, Inst Orthoped Res & Biomech, Helmholtzstr 14, D 89081 Ulm, Germany.
EM melanie.haffner luntzer@uni ulm.de
RI Haffner Luntzer, Melanie/L 3562 2019
OI Haffner Luntzer, Melanie/0000 0002 3333 2613
FU Osteosynthesis and Trauma Care Foundation (OTCF); Stryker
FX This paper is part of a supplement supported by the Osteosynthesis and
   Trauma Care Foundation (OTCF) through a research grant from Stryker.
CR Albers J, 2011, J CELL BIOL, V192, P1057, DOI 10.1083/jcb.201008012
   Amling A, 2014, PLOS ONE, P9
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bhandari M, 2003, J ORTHOP TRAUMA, V17, P353, DOI 10.1097/00005131 200305000 00006
   Burgers TA, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.25
   Caminis J, J BONE JOINT SURG AM, V2020
   Chae WJ, 2019, DIFFERENTIATION, V108, P33, DOI 10.1016/j.diff.2019.05.003
   Chen Y, 2009, J CELL BIOCHEM, V106, P353, DOI 10.1002/jcb.22020
   Cheung WH, 2016, INJURY, V47, pS21, DOI 10.1016/S0020 1383(16)47004 X
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Diamond Stanic MK, 2011, AM J PHYSIOL RENAL, V300, pF139, DOI 10.1152/ajprenal.00249.2010
   DU SJ, 1995, MOL CELL BIOL, V15, P2625
   EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623 199506000 00016
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Gregory CA, 2006, DRUG NEWS PERSPECT, V19, P445, DOI 10.1358/dnp.2006.19.8.1043960
   Haffner Luntzer M, 2017, EUR J MED RES, V22, DOI 10.1186/s40001 017 0264 y
   Haffner Luntzer M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159278
   Haffner Luntzer M, 2016, BRIT J PHARMACOL, V173, P2237, DOI 10.1111/bph.13503
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Holstein TW, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007922
   Houschyar KS, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00170
   Jawad MU, 2013, J ORTHOP RES, V31, P155, DOI 10.1002/jor.22186
   Kadomatsu K, 2013, J BIOCHEM, V153, P511, DOI 10.1093/jb/mvt035
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Kruck B, 2018, J BONE MINER RES, V33, P1686, DOI 10.1002/jbmr.3454
   Lewiecki EM, 2014, THER ADV MUSCULOSKEL, V6, P48, DOI 10.1177/1759720X13510479
   Li CY, 2011, BONE, V49, P1178, DOI 10.1016/j.bone.2011.08.012
   Li XD, 2011, J BONE MINER RES, V26, P2610, DOI 10.1002/jbmr.472
   Liedert A, 2014, BRIT J PHARMACOL, V171, P870, DOI 10.1111/bph.12412
   Liedert A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103250
   Liedert M, 2018, INT J MOL SCI, P19
   Lu YQ, 2018, BONE, V114, P144, DOI 10.1016/j.bone.2018.06.018
   Macsai CE, 2008, J CELL PHYSIOL, V215, P578, DOI 10.1002/jcp.21342
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McGee Lawrence ME, 2013, BIOCHEM BIOPH RES CO, V441, P886, DOI 10.1016/j.bbrc.2013.10.155
   MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092 8674(89)90506 0
   Morse A, 2015, BONE, V71, P155, DOI 10.1016/j.bone.2014.10.018
   NAKAMOTO M, 1992, J BIOCHEM TOKYO, V112, P346, DOI 10.1093/oxfordjournals.jbchem.a123903
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Nusse R, 2012, EMBO J, V31, P2670, DOI 10.1038/emboj.2012.146
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Panigrahi I, 2018, EUR J MED GENET, V61, P369, DOI 10.1016/j.ejmg.2018.01.017
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Rawadi G, 2005, EXPERT OPIN THER TAR, V9, P1063, DOI 10.1517/14728222.9.5.1063
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Schemitsch EH, 2020, J BONE JOINT SURG AM, V102, P693, DOI 10.2106/JBJS.19.00790
   Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349
   Song DY, 2020, BONE RES, V8, DOI 10.1038/s41413 019 0081 8
   Suen PK, 2016, J ORTHOP TRANSL, V4, P1, DOI 10.1016/j.jot.2015.08.004
   TSUTSUI J, 1991, BIOCHEM BIOPH RES CO, V176, P792, DOI 10.1016/S0006 291X(05)80255 4
   Weckbach LT, 2011, THESCIENTIFICWORLDJO, V11, P2491, DOI 10.1100/2011/517152
   Yee CS, 2016, BONE, V82, P122, DOI 10.1016/j.bone.2015.04.048
NR 56
TC 15
Z9 16
U1 0
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020 1383
EI 1879 0267
J9 INJURY
JI Injury Int. J. Care Inj.
PD JUN
PY 2021
VL 52
SU 2
BP S44
EP S48
DI 10.1016/j.injury.2020.11.051
EA JUN 2021
PG 5
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA SN4ZL
UT WOS:000658299600008
PM 33234263
OA hybrid
DA 2025 08 17
ER

PT J
AU Grey, A
   Chaussade, C
   Empson, V
   Lin, JM
   Watson, M
   O'Sullivan, S
   Rewcastle, G
   Naot, D
   Cornish, J
   Shepherd, P
AF Grey, Andrew
   Chaussade, Claire
   Empson, Victoria
   Lin, Jian Ming
   Watson, Maureen
   O'Sullivan, Susannah
   Rewcastle, Gordon
   Naot, Dorit
   Cornish, Jillian
   Shepherd, Peter
TI Evidence for a role for the p110 α isoform of PI3K in skeletal function
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Phosphatidylinositol 3 kinase; Bone; Osteoblast; Osteoclast; Inhibitor
ID STIMULATING FACTOR I; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE
   3 KINASE; OSTEOBLAST DIFFERENTIATION; SIGNALING PATHWAYS;
   LYSOPHOSPHATIDIC ACID; G(I) PROTEINS; KINASE; CELLS; BONE
AB Signaling through phosphatidylinositol 3 kinases (PI3K) regulates fundamental cellular processes Such is survival and growth, and these lipid kinases are Currently being investigated as therapeutic targets in several contexts. In skeletal tissue, experiments using pan specific PI3K inhibitors have suggested that PI3K signaling influences both osteoclast and osteoblast function, but the contributions of specific PI3K isoforms to these effects have not been examined. In the Current work. we assessed the effects of pharmacological inhibitors of the class la PI3Ks, alpha, beta, and delta, on bone cell growth, differentiation and function in vitro. Each of the class la PI3K isoforms is expressed and functionally active in bone cells. No consistent effects of inhibitors of p110 beta or p110 delta on bone cells were observed. Inhibitors of p110 alpha decreased osteoclastogenesis by 60 80% (p < 0.001 vs control) by direct actions on osteoclast precuisors, and decreased the resorptive activity of mature osteoclasts by 60% (p < 0 01 vs control). The p110 alpha inhibitors also decreased the growth of osteoblastic and stromal cells (p < 0.001 vs control), and decreased differentiated osteoblast function by 30% (p < 0.05 vs control) These data suggest that signaling through the p110 alpha isoform of class Ia PI3Ks positively regulates the development and function of both osteoblasts and osteoclasts. Therapeutic agents that target this enzyme have the potential to significantly affect bone homeostasis, and evaluation of skeletal endpoints in clinical trials of such agents is warranted (C) 2009 Elsevier Inc. All rights reserved.
C1 [Grey, Andrew; Empson, Victoria; Lin, Jian Ming; Watson, Maureen; O'Sullivan, Susannah; Naot, Dorit; Cornish, Jillian] Univ Auckland, Dept Med, Auckland, New Zealand.
   [Chaussade, Claire; Shepherd, Peter] Univ Auckland, Dept Mol Med, Auckland, New Zealand.
   [Rewcastle, Gordon] Univ Auckland, Auckland Canc Soc, Res Ctr, Auckland, New Zealand.
C3 University of Auckland; University of Auckland; University of Auckland
RP Grey, A (通讯作者)，Univ Auckland, Dept Med, Private Bag 92 019, Auckland, New Zealand.
EM a.grey@auckland.ac.nz
OI Lin, Jian/0000 0002 8362 6951; Empson, Victoria/0000 0003 3819 2370;
   Naot, Dorit/0000 0001 9498 2639
FU Health Research Council of New Zealand; Auckland Medical Research
   Foundation; Maurice Wilkins Center for Molecular Biodiscovery
FX This work was funded by grants from the Health Research Council of New
   Zealand, the Auckland Medical Research Foundation and the Maurice
   Wilkins Center for Molecular Biodiscovery. Neither of these funding
   bodies played a role in the design or performance of the experimental
   work.
CR Baumann P, 2009, EXP CELL RES, V315, P485, DOI 10.1016/j.yexcr.2008.11.007
   Beeton CA, 2000, BIOCHEM J, V350, P353, DOI 10.1042/0264 6021:3500353
   Burguera B, 2006, MED SCI MONITOR, V12, pBR341
   Cantrell DA, 2001, J CELL SCI, V114, P1439
   Carpio L, 2001, AM J PHYSIOL ENDOC M, V281, pE489, DOI 10.1152/ajpendo.2001.281.3.E489
   Chaussade C, 2007, BIOCHEM J, V404, P449, DOI 10.1042/BJ20070003
   Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743
   Cornish J, 2001, BONE, V29, P162, DOI 10.1016/S8756 3282(01)00494 X
   Cornish J, 2002, J ENDOCRINOL, V175, P405, DOI 10.1677/joe.0.1750405
   Danciu TE, 2003, FEBS LETT, V536, P193, DOI 10.1016/S0014 5793(03)00055 3
   Dufour C, 2008, AM J PHYSIOL ENDOC M, V294, pE794, DOI 10.1152/ajpendo.00791.2007
   Duong L, 2000, MATRIX BIOL, V19, P97, DOI 10.1016/S0945 053X(00)00051 2
   FELIX R, 1994, J CELL BIOCHEM, V55, P340, DOI 10.1002/jcb.240550311
   Ghosh Choudhury N, 2007, J BIOL CHEM, V282, P4983, DOI 10.1074/jbc.M606706200
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Golden LH, 2004, BONE, V34, P3, DOI 10.1016/j.bone.2003.09.005
   Gori F, 2000, ENDOCRINOLOGY, V141, P4768, DOI 10.1210/en.141.12.4768
   Grey A, 2000, ENDOCRINOLOGY, V141, P2129, DOI 10.1210/en.141.6.2129
   Grey A, 2003, ENDOCRINOLOGY, V144, P4886, DOI 10.1210/en.2003 0350
   Grey A, 2002, ENDOCRINOLOGY, V143, P4755, DOI 10.1210/en.2002 220347
   Grey A, 2001, ENDOCRINOLOGY, V142, P1098, DOI 10.1210/en.142.3.1098
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232
   Jia SD, 2008, NATURE, V454, P776, DOI 10.1038/nature07091
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim JE, 2009, BIOCHEM BIOPH RES CO, V379, P830, DOI 10.1016/j.bbrc.2008.12.089
   Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee SH, 2002, J BIOCHEM, V131, P161, DOI 10.1093/oxfordjournals.jbchem.a003071
   Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200
   Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104
   Nakamura I, 1997, J CELL PHYSIOL, V172, P230, DOI 10.1002/(SICI)1097 4652(199708)172:2<230::AID JCP10>3.3.CO;2 Z
   NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014 5793(95)00153 Z
   O'Sullivan S, 2007, J BONE MINER RES, V22, P1679, DOI 10.1359/JBMR.070719
   Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056
   Okkenhaug K, 2002, SCIENCE, V297, P1031
   Palacio S, 2001, EUR J ENDOCRINOL, V144, P431, DOI 10.1530/eje.0.1440431
   Shepherd PR, 1997, J BIOL CHEM, V272, P19000, DOI 10.1074/jbc.272.30.19000
   Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701
   Viñals F, 2002, FEBS LETT, V510, P99, DOI 10.1016/S0014 5793(01)03236 7
   Ward SG, 2003, CURR OPIN PHARMACOL, V3, P426, DOI 10.1016/S1471 4892(03)00078 X
   Yamamoto T, 2007, BONE, V40, P354, DOI 10.1016/j.bone.2006.09.002
   Zhang XY, 2008, J BONE MINER RES, V23, P1238, DOI [10.1359/jbmr.080326, 10.1359/JBMR.080326]
   Zhang Y, 2007, BIOMED PHARMACOTHER, V61, P277, DOI 10.1016/j.biopha.2007.02.014
   Zhao JJ, 2006, P NATL ACAD SCI USA, V103, P16296, DOI 10.1073/pnas.0607899103
   Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102
NR 46
TC 11
Z9 13
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 1
PY 2010
VL 391
IS 1
BP 564
EP 569
DI 10.1016/j.bbrc.2009.11.099
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 544AV
UT WOS:000273624500099
PM 19931507
DA 2025 08 17
ER

PT J
AU Liu, HB
   Zhang, RR
   Ko, SY
   Oyajobi, B
   Papasian, CJ
   Deng, HW
   Zhang, SJ
   Zhao, M
AF Liu, Hongbin
   Zhang, Rongrong
   Ko, Seon Yle
   Oyajobi, Babatunde
   Papasian, Christopher J.
   Deng, Hong Wen
   Zhang, Shujun
   Zhao, Ming
TI Microtubule Assembly Affects Bone Mass by Regulating Both Osteoblast and
   Osteoclast Functions: Stathmin Deficiency Produces an Osteopenic
   Phenotype in Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE STATHMIN; MICROTUBULE; BONE MASS; OSTEOBLAST; OSTEOCLAST
ID GROWTH PLATE CHONDROCYTES; SIGNAL TRANSDUCTION; DOWN REGULATION; CELLS;
   EXPRESSION; TUBULIN; PROTEIN; CANCER; PROLIFERATION; FAMILY
AB Cytoskeleton microtubules regulate various cell signaling pathways that are involved in bone cell function. We recently reported that inhibition of microtubule assembly by microtubule targeting drugs stimulates osteoblast differentiation and bone formation. To further elucidate the role of microtubules in bone homeostasis, we characterized the skeletal phenotype of mice null for stathmin, an endogenous protein that inhibits microtubule assembly. In vivo micro computed tomography (mu CT) and histology revealed that stathmin deficiency results in a significant reduction of bone mass in adult mice concurrent with decreased osteoblast and increased osteoclast numbers in bone tissues. Phenotypic analyses of primary calvarial cells and bone marrow cells showed that stathmin deficiency inhibited osteoblast differentiation and induced osteoclast formation. In vitro overexpression studies showed that increased stathmin levels enhanced osteogenic differentiation of preosteoblast MC3T3 E1 cells and mouse bone marrow derived cells and attenuated osteoclast formation from osteoclast precursor Raw264.7 cells and bone marrow cells. Results of immunofluorescent studies indicated that overexpression of stathmin disrupted radial microtubule filaments, whereas deficiency of stathmin stabilized the microtubule network structure in these bone cells. In addition, microtubule targeting drugs that inhibit microtubule assembly and induce osteoblast differentiation lost these effects in the absence of stathmin. Collectively, these results suggest that stathmin, which alters microtubule dynamics, plays an essential role in maintenance of postnatal bone mass by regulating both osteoblast and osteoclast functions in bone. (C) 2011 American Society for Bone and Mineral Research.
C1 [Liu, Hongbin; Zhang, Shujun] Huazhong Agr Univ, Key Lab Agr Anim Genet, Wuhan, Peoples R China.
   [Liu, Hongbin; Zhang, Rongrong; Papasian, Christopher J.; Deng, Hong Wen; Zhao, Ming] Univ Missouri, Dept Basic Med Sci, Kansas City, MO 64110 USA.
   [Ko, Seon Yle] Dankook Univ, Sch Dent, Cheonan, Choongnam, South Korea.
   [Oyajobi, Babatunde] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
C3 Huazhong Agricultural University; University of Missouri System;
   University of Missouri Kansas City; Dankook University; University of
   Texas System; University of Texas Health Science Center at San Antonio
RP Zhao, M (通讯作者)，1440 Canal St,Suite 2001, New Orleans, LA 70112 USA.
EM mzhao1@tulane.edu
RI ; zhang, rongrong/G 1775 2016; 章, 述军/HJZ 0859 2023; Zhao,
   Mingduo/NMK 6268 2025
OI Deng, Hong Wen/0000 0002 0387 8818; Oyajobi,
   Babatunde/0000 0002 1064 3072; 
CR Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955 0674(01)00289 7
   Charbaut E, 2001, J BIOL CHEM, V276, P16146, DOI 10.1074/jbc.M010637200
   Chung MK, 2010, CLIN EXP MED, V10, P51, DOI 10.1007/s10238 009 0068 7
   Clément MJ, 2005, BIOCHEMISTRY US, V44, P14616, DOI 10.1021/bi0512492
   Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375
   Curmi PA, 1999, CELL STRUCT FUNCT, V24, P345
   Destaing O, 2005, J CELL SCI, V118, P2901, DOI 10.1242/jcs.02425
   Fujikawa Y, 1996, ENDOCRINOLOGY, V137, P4058, DOI 10.1210/en.137.9.4058
   Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955 0674(99)80010 6
   Higuchi S, 1998, J BONE MINER RES, V13, P44, DOI 10.1359/jbmr.1998.13.1.44
   Hummert TW, 2001, ENDOCRINE, V15, P93, DOI 10.1385/ENDO:15:1:093
   Hummert TW, 2000, J CELL BIOCHEM, V79, P150, DOI 10.1002/1097 4644(2000)79:1<150::AID JCB140>3.3.CO;2 2
   Iancu C, 2001, J CELL SCI, V114, P909
   Iancu Rubin C, 2005, CELL CYCLE, V4, P1774, DOI 10.4161/cc.4.12.2171
   Jeon TY, 2010, BRIT J CANCER, V102, P710, DOI 10.1038/sj.bjc.6605537
   Jiang L, 2009, CANCER LETT, V274, P101, DOI 10.1016/j.canlet.2008.09.017
   Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317
   Jung YJ, 2003, J BIOL CHEM, V278, P7445, DOI 10.1074/jbc.M209804200
   KUMAR R, 1994, BIOCHEM BIOPH RES CO, V201, P861, DOI 10.1006/bbrc.1994.1780
   Lawler S, 1998, FEBS LETT, V421, P55, DOI 10.1016/S0014 5793(97)01519 6
   Liedtke W, 2002, AM J PATHOL, V160, P469, DOI 10.1016/S0002 9440(10)64866 3
   Mackenzie GG, 2006, J NEUROCHEM, V99, P402, DOI 10.1111/j.1471 4159.2006.04005.x
   MARCUS B, 2008, OSTEOPOROSIS
   Martel G, 2008, P NATL ACAD SCI USA, V105, P14620, DOI 10.1073/pnas.0807507105
   Matayoshi A, 1996, P NATL ACAD SCI USA, V93, P10785, DOI 10.1073/pnas.93.20.10785
   MISTRY S, 1995, CELL MOL BIOL RES, V41, P103
   Mistry SJ, 2002, MT SINAI J MED, V69, P299
   Nogales E, 2006, CURR OPIN CELL BIOL, V18, P179, DOI 10.1016/j.ceb.2006.02.009
   Ogden SK, 2003, CURR BIOL, V13, P1998, DOI 10.1016/j.cub.2003.10.004
   Ohkawa N, 2007, NEUROSCI RES, V59, P93, DOI 10.1016/j.neures.2007.06.1464
   Ohkawa N, 2007, J CELL SCI, V120, P1447, DOI 10.1242/jcs.001461
   Purev E, 2009, MOL BIOL CELL, V20, P4021, DOI 10.1091/mbc.E09 03 0248
   Ravelli RBG, 2004, NATURE, V428, P198, DOI 10.1038/nature02393
   Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092 8674(00)80331 1
   ROSEN V, 1994, J BONE MINER RES, V9, P1759
   ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111
   Rowning BA, 1997, P NATL ACAD SCI USA, V94, P1224, DOI 10.1073/pnas.94.4.1224
   Rubin CI, 2004, J CELL BIOCHEM, V93, P242, DOI 10.1002/jcb.20187
   Rubin CI, 2003, EXP HEMATOL, V31, P389, DOI 10.1016/S0301 472X(03)00043 2
   Salinas PC, 2007, TRENDS CELL BIOL, V17, P333, DOI 10.1016/j.tcb.2007.07.003
   Schubart UK, 1996, J BIOL CHEM, V271, P14062, DOI 10.1074/jbc.271.24.14062
   Shumyatsky GP, 2005, CELL, V123, P697, DOI 10.1016/j.cell.2005.08.038
   SOBEL A, 1989, J BIOL CHEM, V264, P3765
   Stegman MA, 2000, J BIOL CHEM, V275, P21809, DOI 10.1074/jbc.C000043200
   Steinmetz MO, 2007, J STRUCT BIOL, V158, P137, DOI 10.1016/j.jsb.2006.07.018
   Vincent C, 2009, J BONE MINER METAB, V27, P114, DOI 10.1007/s00774 008 0018 6
   Wang R, 2007, MOL MED, V13, P567, DOI 10.2119/2007 00046.Wang
   Watabe Uchida M, 2006, NEURON, V51, P727, DOI 10.1016/j.neuron.2006.07.020
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Yoshie M, 2006, MOL REPROD DEV, V73, P164, DOI 10.1002/mrd.20408
   Zahedi K, 2006, AM J PHYSIOL RENAL, V290, pF1559, DOI 10.1152/ajprenal.00424.2005
   Zhang Y, 2008, BMB REP, V41, P765, DOI 10.5483/BMBRep.2008.41.11.765
   Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012
   Zhao M, 2006, MOL CELL BIOL, V26, P6197, DOI 10.1128/MCB.02214 05
   Zhao M, 2009, MOL CELL BIOL, V29, P1291, DOI 10.1128/MCB.01566 08
NR 57
TC 20
Z9 23
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD SEP
PY 2011
VL 26
IS 9
BP 2052
EP 2067
DI 10.1002/jbmr.419
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 814JG
UT WOS:000294444300008
PM 21557310
OA Bronze
DA 2025 08 17
ER

PT J
AU Krönke, G
   Uderhardt, S
   Kim, KA
   Stock, M
   Scholtysek, C
   Zaiss, MM
   Surmann Schmitt, C
   Luther, J
   Katzenbeisser, J
   David, JP
   Abdollahi Roodsaz, S
   Tran, K
   Bright, JM
   Binnerts, ME
   Akhmetshina, A
   Böhm, C
   Distler, JH
   Joosten, LAB
   Schett, G
   Abo, A
AF Kroenke, Gerhard
   Uderhardt, Stefan
   Kim, Kyung Ah
   Stock, Michael
   Scholtysek, Carina
   Zaiss, Mario M.
   Surmann Schmitt, Cordula
   Luther, Julia
   Katzenbeisser, Julia
   David, Jean Pierre
   Abdollahi Roodsaz, Shahla
   Tran, Karolyn
   Bright, Jessica M.
   Binnerts, Minke E.
   Akhmetshina, Alfiya
   Boehm, Christina
   Distler, Joerg H.
   Joosten, Leo A. B.
   Schett, Georg
   Abo, Arie
TI R Spondin 1 Protects Against Inflammatory Bone Damage During Murine
   Arthritis by Modulating the Wnt Pathway
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; BETA CATENIN; EXPRESSION; R SPONDIN1;
   CHONDROCYTES; INHIBITION; DICKKOPF 1; RECEPTORS; REGULATOR; MECHANISM
AB Objective. During the course of different musculoskeletal diseases, joints are progressively damaged by inflammatory, infectious, or mechanical stressors, leading to joint destruction and disability. While effective strategies to inhibit joint inflammation, such as targeted cytokine blocking therapy, have been developed during the last decade, the molecular mechanisms of joint damage are still poorly understood. This study was undertaken to investigate the role of the Wnt pathway modulator R Spondin 1 (RSpo1) in protecting bone and cartilage in a mouse model of arthritis.
   Methods. Tumor necrosis factor alpha (TNF alpha) transgenic mice were treated with vehicle or Rspo1. Mice were evaluated for signs of arthritis, and histologic analysis of the hind paws was performed. Moreover, we determined the effect of Rspo1 on Wnt signaling activity and osteoprotegerin (OPG) expression in murine primary osteoblasts.
   Results. The secreted Wnt pathway modulator RSpo1 was highly effective in preserving the structural integrity of joints in a TNF alpha transgenic mouse model of arthritis by protecting bone and cartilage from inflammation related damage. RSpo1 antagonized the Wnt inhibitor Dkk 1 and modulated Wnt signaling in mouse mesenchymal cells. In osteoblasts, RSpo1 induced differentiation and expression of OPG, thereby inhibiting osteoclastogenesis in vitro. In vivo, RSpo1 promoted osteoblast differentiation and bone formation while blocking osteoclast development, thereby contributing to the integrity of joints during inflammatory arthritis.
   Conclusion. Our results demonstrate the therapeutic potential of RSpo1 as an anabolic agent for the preservation of joint architecture.
C1 [Schett, Georg] Univ Erlangen Nurnberg, Dept Internal Med 3, D 91054 Erlangen, Germany.
   [Kim, Kyung Ah; Tran, Karolyn; Bright, Jessica M.; Binnerts, Minke E.; Abo, Arie] Nuvelo Inc, San Carlos, CA USA.
   [Stock, Michael; Surmann Schmitt, Cordula] Nikolaus Fiebiger Ctr Mol Med, Erlangen, Germany.
   [Abdollahi Roodsaz, Shahla; Joosten, Leo A. B.] Radboud Univ Nijmegen, Med Ctr, NL 6525 ED Nijmegen, Netherlands.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   Radboud University Nijmegen
RP Schett, G (通讯作者)，Univ Erlangen Nurnberg, Dept Internal Med 3, Krankenhausstr 12, D 91054 Erlangen, Germany.
EM georg.schett@uk erlangen.de
RI Stock, Michael/B 9829 2009; Kronke, Gerhard/C 6615 2014; Uderhardt,
   Stefan/AAA 5224 2022; Joosten, Leo/H 3138 2015; Abdollahi Roodsaz,
   Shahla/A 6620 2015; Scholtysek, Carina/LXA 1619 2024; Surmann Schmitt,
   Cordula/B 9792 2009; Krönke, Gerhard/C 6615 2014; Zaiss,
   Mario/ABE 7125 2021
OI zaiss, mario/0000 0003 3844 1664; Kronke, Gerhard/0000 0002 7566 4325;
   Stock, Michael/0000 0002 3322 0961; Stock, Michael/0009 0003 0554 3194;
   Scholtysek, Carina/0009 0001 2197 5179; 
CR Bejsovec A, 2005, CELL, V120, P11, DOI 10.1016/S0092 8674(04)01246 2
   Binnerts ME, 2007, P NATL ACAD SCI USA, V104, P14700, DOI 10.1073/pnas.0702305104
   Bodine PVN, 2008, CELL RES, V18, P248, DOI 10.1038/cr.2008.13
   Bu GJ, 2008, INT J CANCER, V123, P1034, DOI 10.1002/ijc.23625
   DasGupta R, 1999, DEVELOPMENT, V126, P4557
   DESBOIS C, 1994, J BIOL CHEM, V269, P1183
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Kim KA, 2006, CELL CYCLE, V5, P23, DOI 10.4161/cc.5.1.2305
   Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521
   Kim KA, 2008, MOL BIOL CELL, V19, P2588, DOI 10.1091/mbc.E08 02 0187
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Li P, 2003, SPRINGER SEMIN IMMUN, V25, P19, DOI 10.1007/s00281 003 0125 3
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lu WY, 2008, FEBS LETT, V582, P643, DOI 10.1016/j.febslet.2008.01.035
   Macsai CE, 2008, J CELL PHYSIOL, V215, P578, DOI 10.1002/jcp.21342
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Schmidl M, 2006, J BIOL CHEM, V281, P31790, DOI 10.1074/jbc.M603419200
   Semënov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960 9822(01)00290 1
   Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097 2765(03)00484 2
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Voorzanger Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Yates KE, 2005, DNA CELL BIOL, V24, P446, DOI 10.1089/dna.2005.24.446
   Yuasa T, 2008, LAB INVEST, V88, P264, DOI 10.1038/labinvest.3700747
   Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185
   Zhang C, 2008, P NATL ACAD SCI USA, V105, P6936, DOI 10.1073/pnas.0710831105
   ZHOU G, 1995, J CELL SCI, V108, P3677
NR 37
TC 48
Z9 57
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD AUG
PY 2010
VL 62
IS 8
BP 2303
EP 2312
DI 10.1002/art.27496
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 661WA
UT WOS:000282762100014
PM 20506554
DA 2025 08 17
ER

PT J
AU Coxon, FP
   Taylor, A
   Stewart, CA
   Baron, R
   Seabra, MC
   Ebetino, FH
   Rogers, MJ
AF Coxon, Fraser P.
   Taylor, Adam
   Stewart, Charlotte A.
   Baron, Rudi
   Seabra, Miguel C.
   Ebetino, F. Hal
   Rogers, Michael J.
TI The gunmetal mouse reveals Rab geranylgeranyl transferase to be
   the major molecular target of phosphonocarboxylate analogues of
   bisphosphonates
SO BONE
LA English
DT Article
DE Phosphonocarboxylate; Bisphosphonate; Osteoclast; Rab prenylation; Rab
   geranylgeranyl transferase
ID NITROGEN CONTAINING BISPHOSPHONATES; IN VITRO; BONE RESORPTION;
   OSTEOCLAST FORMATION; SIGNAL TRANSDUCTION; SMALL GTPASES; PRENYLATION;
   INHIBITION; MECHANISM; PROTEINS
AB The described ability of phosphonocarboxylate analogues of bisphosphonates (BPs) to inhibit Rab geranylgeranyl transferase (RGGT) is thought to be the mechanism underlying their cellular effects, including their ability to reduce macrophage cell viability and to inhibit osteoclast mediated resorption. However, until now the possibility that at least some of the effects of these drugs may be mediated through other targets has not been excluded. Since RGGT is the most distal enzyme in the process of Rab prenylation, it has not proved possible to confirm the mechanism underlying the effects of these drugs by adding back downstream intermediates of the mevalonate pathway, the approach used to demonstrate that bisphosphonates act through this pathway. We now confirm that RGGT is the major pharmacological target of phosphonocarboxylates by using several alternative approaches. Firstly, analysis of several different phosphonocarboxylate drugs demonstrates a very good correlation between the ability of these drugs to inhibit RGGT with their ability to: (a) reduce macrophage cell viability; (b) induce apoptosis; and (c) induce vacuolation in rabbit osteoclasts. Secondly, we have found that cells from the gunmetal (gm/gm) mouse, which bear a homozygous mutation in RGGT that results in similar to 80% reduced activity of this enzyme compared to wild type or heterozygous mice, are more sensitive to the effects of active phosphonocarboxylates (including reducing macrophage cell viability, inhibiting osteoclast formation and inhibiting fluid phase endocytosis), confirming that these effects are mediated through inhibition of RGGT. In conclusion, these data demonstrate that all of the pharmacological effects of phosphonocarboxylates found thus far appear to be mediated through the specific inhibition of RGGT, highlighting the potential therapeutic value of this class of drugs.
   This article is part of a Special Issue entitled Bisphosphonates. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Coxon, Fraser P.; Taylor, Adam; Stewart, Charlotte A.; Rogers, Michael J.] Univ Aberdeen, Inst Med Sci, Div Appl Med, Musculoskeletal Programme, Aberdeen AB25 2ZD, Scotland.
   [Baron, Rudi; Seabra, Miguel C.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England.
   [Ebetino, F. Hal] Warner Chilcott, Dundalk, Co Louth, Ireland.
C3 University of Aberdeen; Imperial College London
RP Coxon, FP (通讯作者)，Univ Aberdeen, Inst Med Sci, Div Appl Med, Musculoskeletal Programme, Foresterhill, Aberdeen AB25 2ZD, Scotland.
EM f.p.coxon@abdn.ac.uk
RI Seabra, Miguel/M 3280 2013
OI Seabra, Miguel/0000 0002 6404 4892; Rogers, Michael/0000 0002 1818 9249
FU Procter & Gamble Pharmaceuticals; Nuffield Foundation; MRC [G9805886]
   Funding Source: UKRI; Medical Research Council [G9805886] Funding
   Source: researchfish; Versus Arthritis [17285] Funding Source:
   researchfish
FX We would like to thank Prof. Charles McKenna (Department of Chemistry,
   University of Southern California), for supplying 3 IPEHPC and its
   separated stereoisomers. We would also like to thank Dr Anke Roelofs and
   Dr Keith Thompson for assistance with flow cytometry. This work was
   supported by Procter & Gamble Pharmaceuticals (now Warner Chilcott) and
   by a studentship to AT from the Nuffield Foundation's Oliver Bird
   Rheumatism Programme.
CR Ali BR, 2010, BIOCHEM BIOPH RES CO, V397, P34, DOI 10.1016/j.bbrc.2010.05.045
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Barbieri MA, 2004, EUR J CELL BIOL, V83, P305, DOI 10.1078/0171 9335 00381
   Baron RA, 2009, J BIOL CHEM, V284, P6861, DOI 10.1074/jbc.M806952200
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Bergman M, 2003, J MUSCLE RES CELL M, V24, P417, DOI 10.1023/A:1027367022415
   Bhuin T, 2009, CELL TISSUE RES, V336, P489, DOI 10.1007/s00441 009 0782 1
   Cheng KW, 2005, CANCER RES, V65, P2516, DOI 10.1158/0008 5472.CAN 05 0573
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   Coxon FP, 2005, BONE, V37, P349, DOI 10.1016/j.bone.2005.04.021
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Detter JC, 2000, P NATL ACAD SCI USA, V97, P4144, DOI 10.1073/pnas.080517697
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ebetino FH, 1996, PHOSPHORUS SULFUR, V109, P217
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fournier PGJ, 2008, CANCER RES, V68, P8945, DOI 10.1158/0008 5472.CAN 08 2195
   Frith JC, 2003, J BONE MINER RES, V18, P204, DOI 10.1359/jbmr.2003.18.2.204
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Ghittoni R, 2005, FASEB J, V19, P605, DOI 10.1096/fj.04 2702fje
   Gomes AQ, 2003, MOL BIOL CELL, V14, P1882, DOI 10.1091/mbc.E02 10 0639
   Gordiyenko NV, 2010, INVEST OPHTH VIS SCI, V51, P1143, DOI 10.1167/iovs.09 4117
   ITZSTEIN C, SMALL GTPAS IN PRESS
   Lackner MR, 2005, CANCER CELL, V7, P325, DOI 10.1016/j.ccr.2005.03.024
   Leung KF, 2007, J BIOL CHEM, V282, P1487, DOI 10.1074/jbc.M605557200
   Liu YJ, 2007, WORLD J GASTROENTERO, V13, P1010, DOI 10.3748/wjg.v13.i7.1010
   Marma MS, 2007, J MED CHEM, V50, P5967, DOI 10.1021/jm0702884
   McKenna CE, 2010, J MED CHEM, V53, P3454, DOI 10.1021/jm900232u
   Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092 8674(04)00117 5
   Miserey Lenkei S, 2007, TRAFFIC, V8, P1385, DOI 10.1111/j.1600 0854.2007.00612.x
   Moosajee M, 2009, INVEST OPHTH VIS SCI, V50, P3009, DOI 10.1167/iovs.08 2755
   Rodman JS, 2000, J CELL SCI, V113, P183
   Roelofs AJ, 2006, INT J CANCER, V119, P1254, DOI 10.1002/ijc.21977
   ROGERS MJ, 2010, BONE            1126
   Sakamoto K, 2007, FASEB J, V21, P4087, DOI 10.1096/fj.07 8713com
   Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471 4914(01)02227 4
   Stenbeck G, 2004, J CELL SCI, V117, P827, DOI 10.1242/jcs.00935
   Taylor A, 2007, CALCIFIED TISSUE INT, V80, P132, DOI 10.1007/s00223 006 0245 6
   TAYLOR A, IMPAIRED PRENYLATION, DOI DOI 10.4161/SGTP.2.3.16488
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   Westwood FR, 2005, TOXICOL PATHOL, V33, P246, DOI 10.1080/01926230590908213
   Yu XZ, 2007, EUR J CELL BIOL, V86, P25, DOI 10.1016/j.ejcb.2006.10.002
   Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055
   Zhang Q, 2002, BRIT J HAEMATOL, V117, P414, DOI 10.1046/j.1365 2141.2002.03444.x
NR 45
TC 5
Z9 7
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2011
VL 49
IS 1
SI SI
BP 111
EP 121
DI 10.1016/j.bone.2011.03.686
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 782MD
UT WOS:000292012900015
PM 21419243
DA 2025 08 17
ER

PT J
AU Krüger, BT
   Steppe, L
   Vettorazzi, S
   Haffner Luntzer, M
   Lee, S
   Dorn, AK
   Ignatius, A
   Tuckermann, J
   Ahmad, M
AF Krueger, Benjamin Thilo
   Steppe, Lena
   Vettorazzi, Sabine
   Haffner Luntzer, Melanie
   Lee, Sooyeon
   Dorn, Ann Kristin
   Ignatius, Anita
   Tuckermann, Jan
   Ahmad, Mubashir
TI Inhibition of Cdk5 Ameliorates Skeletal Bone Loss in
   Glucocorticoid Treated Mice
SO BIOMEDICINES
LA English
DT Article
DE osteoblasts; osteoclasts; osteocytes; bone; cyclin dependent kinase 5;
   roscovitine; glucocorticoids; glucocorticoid induced osteoporosis;
   fracture healing
ID CYCLIN DEPENDENT KINASE 5; CORTICOSTEROID INDUCED OSTEOPOROSIS;
   PARATHYROID HORMONE; VITAMIN D; FRACTURE; EXPRESSION; RECEPTOR;
   REGENERATION; MECHANISMS; BISPHOSPHONATES
AB Glucocorticoids (GCs) are widely used to treat inflammatory diseases. However, their long term use leads to glucocorticoid induced osteoporosis, increasing morbidity and mortality. Both anabolic and anti resorptive drugs are used to counteract GC induced bone loss, however, they are expensive and/or have major side effects. Therefore, identifying new targets for cost effective, small molecule inhibitors is essential. We recently identified cyclin dependent kinase 5 (Cdk5) as a suppressor of osteoblast differentiation and showed that its inhibition with roscovitine promoted osteoblastogenesis, thus improving the skeletal bone mass and fracture healing. Here, we assessed whether Cdk5 knockdown or inhibition could also reverse the GC mediated suppression of osteoblast differentiation, bone loss, and fracture healing. We first demonstrated that Cdk5 silencing abolished the dexamethasone (Dex) induced downregulation of alkaline phosphatase (Alp) activity, osteoblast specific marker gene expression (Runx2, Sp7, Alpl, and Bglap), and mineralization. Similarly, Cdk5 inhibition rescued Dex induced suppression of Alp activity. We further demonstrated that Cdk5 inhibition reversed prednisolone (Pred) induced bone loss in mice, due to reduced osteoclastogenesis rather than improved osteoblastogenesis. Moreover, we revealed that Cdk5 inhibition failed to improve Pred mediated impaired fracture healing. Taken together, we demonstrated that Cdk5 inhibition with roscovitine ameliorated GC mediated bone loss but did not reverse GC induced compromised fracture healing in mice.
C1 [Krueger, Benjamin Thilo; Steppe, Lena; Haffner Luntzer, Melanie; Ignatius, Anita; Ahmad, Mubashir] Ulm Univ, Inst Orthoped Res & Biomech, Helmholtzstr 14, D 89081 Ulm, Germany.
   [Vettorazzi, Sabine; Lee, Sooyeon; Dorn, Ann Kristin; Tuckermann, Jan; Ahmad, Mubashir] Ulm Univ, Inst Comparat Mol Endocrinol CME, Helmholtzstr 8 1, D 89081 Ulm, Germany.
C3 Ulm University; Ulm University
RP Ignatius, A; Ahmad, M (通讯作者)，Ulm Univ, Inst Orthoped Res & Biomech, Helmholtzstr 14, D 89081 Ulm, Germany.; Tuckermann, J; Ahmad, M (通讯作者)，Ulm Univ, Inst Comparat Mol Endocrinol CME, Helmholtzstr 8 1, D 89081 Ulm, Germany.
EM benjamin.krueger@uni ulm.de; lena.steppe@uni ulm.de;
   sabine.vettorazzi@uni ulm.de; melanie.haffner luntzer@uni ulm.de;
   sooyeon.lee@uni ulm.de; ann.kristin.picke@gmail.com;
   anita.ignatius@uni ulm.de; jan.tuckermann@uni ulm.de;
   ahmad.mubashir@uni ulm.de
RI ; LEE, SOOYEON/KAM 6204 2024; Ignatius, Anita/M 6012 2013; Ahmad,
   Mubashir/HHS 0865 2022; Haffner Luntzer, Melanie/L 3562 2019
OI Steppe, Lena/0000 0003 0968 5627; Ahmad, Mubashir/0000 0001 9012 4039;
   Ignatius, Anita/0000 0002 4782 1979; Vettorazzi, Dr.
   Sabine/0000 0001 8667 9488; Kruger, Benjamin Thilo/0000 0002 2856 9069;
   Tuckermann, Jan/0000 0003 3691 275X; Haffner Luntzer,
   Melanie/0000 0002 3333 2613; Lee, Sooyeon/0000 0001 6244 4975
CR Adami G, 2019, CURR OPIN RHEUMATOL, V31, P388, DOI 10.1097/BOR.0000000000000608
   Agusti A, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01219 2018
   Ahmad M., 2021, BONE RES, DOI [10.1038/boneres.01886, DOI 10.1038/BONERES.01886]
   Ahmad M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02460
   Ahmad M, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 32364 8
   Allen CS, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001347.pub2
   Amiche MA, 2018, J BONE MINER RES, V33, P419, DOI 10.1002/jbmr.3318
   Amin S, 1999, ARTHRITIS RHEUM US, V42, P1740, DOI 10.1002/1529 0131(199908)42:8<1740::AID ANR25>3.0.CO;2 E
   Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982
   Askew D, 2017, BLOOD, V129, P246, DOI 10.1182/blood 2016 05 702738
   Baron R., 1993, HDB EXPT PHARM, V107, P111
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Brent MB, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 91729 8
   Bruscoli S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691480
   Bultink IEM, 2013, EXPERT OPIN PHARMACO, V14, P185, DOI 10.1517/14656566.2013.761975
   Buttgereit F, 2005, LANCET, V365, P801
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Chang KH, 2012, J CELL SCI, V125, P5124, DOI 10.1242/jcs.108183
   Cicenas J, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305 5839.2015.03.61
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Compston J, 2003, HORM RES, V60, P77, DOI 10.1159/000074506
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019
   Do PA, 2021, CANCERS, V13, DOI 10.3390/cancers13010101
   Dorand RD, 2016, SCIENCE, V353, P399, DOI 10.1126/science.aae0477
   Doyon A, 2010, CALCIFIED TISSUE INT, V87, P68, DOI 10.1007/s00223 010 9370 3
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Ersek A, 2016, SCI REP UK, V6, DOI 10.1038/srep36513
   Frenkel B, 2015, ADV EXP MED BIOL, V872, P179, DOI 10.1007/978 1 4939 2895 8_8
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Hachemi Y, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.628287
   Hachemi Y, 2018, J MOL ENDOCRINOL, V61, pR75, DOI 10.1530/JME 18 0024
   Hartmann K, 2016, PHYSIOL REV, V96, P409, DOI 10.1152/physrev.00011.2015
   Hildebrand G.K., 2021, STATPEARLS
   Hildebrandt S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26300 z
   Hofbauer LC, 2009, ARTHRITIS RHEUM, V60, P1427, DOI 10.1002/art.24445
   Homik J., 2000, Cochrane Database Syst. Rev, V2, DOI [DOI 10.1002/14651858.CD000952, DOI 10.1002/14651858.CD001347]
   Hsu E, 2017, CURR OPIN ENDOCRINOL, V24, P411, DOI 10.1097/MED.0000000000000368
   Humphrey EL, 2006, BONE, V38, P652, DOI 10.1016/j.bone.2005.10.004
   Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822
   Jonason JH, 2014, METHODS MOL BIOL, V1130, P295, DOI 10.1007/978 1 62703 989 5_22
   Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108
   Kawano Tetsuya, 2017, Osteoporos Sarcopenia, V3, P185, DOI 10.1016/j.afos.2017.11.001
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kino T, 2007, MOL ENDOCRINOL, V21, P1552, DOI 10.1210/me.2006 0345
   Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
   Liebl J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8274
   Liebl J, 2011, ANGIOGENESIS, V14, P281, DOI 10.1007/s10456 011 9212 6
   Liebl J, 2010, J BIOL CHEM, V285, P35932, DOI 10.1074/jbc.M110.126177
   Liu P, 2017, CELL DEATH DIFFER, V24, P672, DOI 10.1038/cdd.2016.165
   Liu YZ, 2018, CLIN INTERV AGING, V13, P1465, DOI 10.2147/CIA.S167431
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Lopes JP, 2011, PROG NEUROBIOL, V94, P49, DOI 10.1016/j.pneurobio.2011.03.006
   Luppen CA, 2003, J BONE MINER RES, V18, P1186, DOI 10.1359/jbmr.2003.18.7.1186
   LYRITIS G, 1975, ACTA ORTHOP SCAND, V46, P25, DOI 10.3109/17453677508989188
   Manolagas SC, 2013, J CLIN INVEST, V123, P1919, DOI 10.1172/JCI68062
   MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Mazziotti G, 2009, THER ADV MUSCULOSKEL, V1, P27, DOI 10.1177/1759720X09343222
   Merk H, 2016, ONCOTARGET, V7, P6088, DOI 10.18632/oncotarget.6842
   Miller Paul D, 2008, Curr Osteoporos Rep, V6, P12, DOI 10.1007/s11914 008 0003 y
   Morgan EF, 2009, BONE, V44, P335, DOI 10.1016/j.bone.2008.10.039
   Murphy DR, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 213
   Najafova Z, 2021, CELL DEATH DIFFER, V28, P700, DOI 10.1038/s41418 020 00614 w
   NEWMAN RJ, 1987, CLIN ORTHOP RELAT R, P253
   Nguyen MD, 2003, NEUROSIGNALS, V12, P215, DOI 10.1159/000074623
   Otto S, 2018, CANCER TREAT REV, V69, P177, DOI 10.1016/j.ctrv.2018.06.007
   Paoletti P, 2008, J NEUROSCI, V28, P10090, DOI 10.1523/JNEUROSCI.3237 08.2008
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Peng Y, 2020, J BONE MINER RES, V35, P1188, DOI 10.1002/jbmr.3987
   Pfänder P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01554
   Piemontese M, 2016, AM J PHYSIOL ENDOC M, V311, pE587, DOI 10.1152/ajpendo.00219.2016
   Postnov A, 2009, CALCIFIED TISSUE INT, V85, P530, DOI 10.1007/s00223 009 9301 3
   Rapp AE, 2018, FASEB J, V32, P2235, DOI 10.1096/fj.201700459RR
   Raterman HG, 2019, DRUGS, V79, P1065, DOI 10.1007/s40265 019 01145 6
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Reginster JY, 1999, OSTEOPOROSIS INT, V9, P75, DOI 10.1007/s001980050118
   Röntgen V, 2010, J ORTHOP RES, V28, P1456, DOI 10.1002/jor.21148
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 2018, LANCET DIABETES ENDO, V6, P445, DOI 10.1016/S2213 8587(18)30075 5
   SAAG KG, 1994, AM J MED, V96, P115, DOI 10.1016/0002 9343(94)90131 7
   Sandberg OH, 2015, BONE JOINT RES, V4, P170, DOI 10.1302/2046 3758.410.2000414
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schmidt Bleek K, 2015, TISSUE ENG PART B RE, V21, P354, DOI [10.1089/ten.teb.2014.0677, 10.1089/ten.TEB.2014.0677]
   Sharma S, 2020, P NATL ACAD SCI USA, V117, P8001, DOI 10.1073/pnas.1912617117
   Thiele Sylvia, 2014, Bonekey Rep, V3, P552, DOI 10.1038/bonekey.2014.47
   Thiele S, 2012, J BONE MINER RES, V27, P2242, DOI 10.1002/jbmr.1688
   Thomas GP, 2001, J ENDOCRINOL, V170, P451, DOI 10.1677/joe.0.1700451
   TSAI LH, 1993, DEVELOPMENT, V119, P1029
   Tuckermann J, 2021, NAT REV RHEUMATOL, V17, P608, DOI 10.1038/s41584 021 00682 3
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Waters RV, 2000, ACTA ORTHOP SCAND, V71, P316, DOI 10.1080/000164700317411951
   Weinstein RS, 2017, ENDOCRINOLOGY, V158, P3817, DOI 10.1210/en.2017 00662
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wildemann B, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572 021 00289 8
   Yao W, 2008, ARTHRITIS RHEUM, V58, P3485, DOI 10.1002/art.23954
NR 101
TC 6
Z9 7
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD FEB
PY 2022
VL 10
IS 2
AR 404
DI 10.3390/biomedicines10020404
PG 18
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA ZR4PN
UT WOS:000767767100001
PM 35203613
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Gustafson, CT
   Mamo, T
   Maran, A
   Yaszemski, MJ
AF Gustafson, Carl T.
   Mamo, Tewodros
   Maran, Avudaiappan
   Yaszemski, Michael J.
TI Molecular strategies for modulating wnt signaling
SO FRONTIERS IN BIOSCIENCE LANDMARK
LA English
DT Article
DE Wnt Pathway; Small Molecule; Canonical Signaling; Non Canonical
   Signaling; Beta catenin; Review
ID MULTIPLE INTESTINAL NEOPLASIA; ANDROGEN RECEPTOR INHIBITION; EMBRYONIC
   STEM CELLS; WNT/BETA CATENIN; BETA CATENIN; PROTEIN KINASE; IN VITRO;
   SELECTIVE INHIBITION; ALZHEIMERS DISEASE; POTENT INHIBITORS
AB The importance of the Wnt signaling cascade in the fields of developmental biology, regenerative medicine, cancer genetics, and neurobiology has fueled a wide search for potent pharmacological agents capable of controlling Wnt signaling. Numerous fields of study have lent assistance to this endeavor, yielding both natural and synthetic compounds that are capable of inducing or inhibiting Wnt at multiple stages within the pathway. Further, there is a large of body research which has investigated endogenous Wnt inducers and inhibitors, namely the secreted Wnts, Dickkof proteins (Dkks), secreted Frizzled Related Proteins (sFRPs), and Wnt Inhibitory Factor 1 (WIF 1), along with others which may act via indirect means to stimulate or inhibit Wnt (e.g. the Smads, bone morphogenetic proteins, and Hedgehog proteins). This review will summarize the research surrounding currently available small molecules used to target Wnt signaling. These compounds will be classified based upon their ability to stimulate or inhibit Wnt, their derivation (natural or synthetic), and their specific mechanism of action.
C1 [Gustafson, Carl T.; Mamo, Tewodros] Mayo Clin, Mayo Clin Coll Med, Mayo Grad Sch, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55902 USA.
   [Maran, Avudaiappan; Yaszemski, Michael J.] Mayo Clin, Mayo Clin Coll Med, Dept Orthopaed Surg, Rochester, MN 55902 USA.
   [Maran, Avudaiappan; Yaszemski, Michael J.] Mayo Clin, Mayo Clin Coll Med, Dept Biomed Engn, Rochester, MN 55902 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Gustafson, CT (通讯作者)，Mayo Clin, Mayo Grad Sch, Dept Mol Pharmacol & Expt Therapeut, 200 1st Street SW, Rochester, MN 55901 USA.
EM gustafson.carl@mayo.edu
OI Mamo, Theodros/0000 0002 3474 576X
FU John and Posy Krehbiel Endowed Professorship of Orthopedic Surgery and
   Biomedical Engineering; Mayo Clinic Pharmacology T32 Training Grant [NIH
   T32 GM072474]
FX Special thanks to the Mayo Clinic College of Medicine, the Mayo Graduate
   School, and the Mayo Clinic Department of Molecular Pharmacology and
   Experimental Therapeutics. Funding for this work was provided by the
   John and Posy Krehbiel Endowed Professorship of Orthopedic Surgery and
   Biomedical Engineering (Michael J. Yaszemski), and by the Mayo Clinic
   Pharmacology T32 Training Grant (NIH T32 GM072474) (Carl T. Gustafson).
   The funding organizations had no role in manuscript topic, structure,
   preparation, or decision to publish.
CR Alvarez Medina R, 2009, DEVELOPMENT, V136, P3301, DOI 10.1242/dev.041772
   Amado NG, 2014, J BIOL CHEM, V289, P35456, DOI 10.1074/jbc.M114.621599
   Amado NG, 2012, CURR TOP MED CHEM, V12, P2103
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Ann EJ, 2012, J BIOL CHEM, V287, P36814, DOI 10.1074/jbc.M112.356048
   [Anonymous], ONCOGENE
   Archibald A, 2015, ONCOGENE, V34, P3199, DOI 10.1038/onc.2014.242
   Arensman MD, 2014, ONCOGENE, V33, P899, DOI 10.1038/onc.2013.23
   Atkinson JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125028
   Azim K, 2014, GLIA, V62, P778, DOI 10.1002/glia.22641
   Bengoa Vergniory N, 2014, STEM CELLS, V32, P3196, DOI 10.1002/stem.1807
   Bernatik O, 2011, J BIOL CHEM, V286, P10396, DOI 10.1074/jbc.M110.169870
   Bhat RV, 2004, J NEUROCHEM, V89, P1313, DOI 10.1111/j.1471 4159.2004.02422.x
   Blitzer JT, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471 2121 7 28
   Bose S, 2015, CELL DIV, V10, DOI 10.1186/s13008 015 0012 z
   Boulter L, 2015, J CLIN INVEST, V125, P1269, DOI 10.1172/JCI76452
   Burn SF, 2011, DEV BIOL, V352, P288, DOI 10.1016/j.ydbio.2011.01.033
   Cadigan K. M., 2012, COLD SPRING HARBOR P, V4
   Chakraborti S, 2013, BIOCHEMISTRY US, V52, P7449, DOI 10.1021/bi400734e
   Chen MY, 2009, BIOCHEMISTRY US, V48, P10267, DOI 10.1021/bi9009677
   Chen Z, 2008, ONCOGENE, V27, P3483, DOI 10.1038/sj.onc.1211006
   Cheng H, 2011, J MOL CELL CARDIOL, V51, P607, DOI 10.1016/j.yjmcc.2010.11.020
   Choi S. H., 2015, CLIN CANC RES OFFICI
   Ciani L, 2011, P NATL ACAD SCI USA, V108, P10732, DOI 10.1073/pnas.1018132108
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0
   Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074 5521(00)00025 9
   Corrêa S, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 303
   Cruciat CM, 2014, CURR OPIN CELL BIOL, V31, P46, DOI 10.1016/j.ceb.2014.08.003
   Cui L, 2014, J PHARM PHARMACOL, V66, P1615, DOI 10.1111/jphp.12283
   D'Amato L, 2015, EPIGENETICS US, V10, P6, DOI 10.4161/15592294.2014.988035
   del Ser T, 2013, J ALZHEIMERS DIS, V33, P205, DOI 10.3233/JAD 2012 120805
   del Valle Pérez B, 2011, MOL CELL BIOL, V31, P2877, DOI 10.1128/MCB.01466 10
   Demozay D, 2011, DIABETES, V60, P2892, DOI 10.2337/db11 0341
   Dodge ME, 2012, J BIOL CHEM, V287, P23246, DOI 10.1074/jbc.M112.372029
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Engler TA, 2004, J MED CHEM, V47, P3934, DOI 10.1021/jm049768a
   FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460 2075.1994.tb06830.x
   Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132 5141.2001
   Gang EJ, 2014, ONCOGENE, V33, P2169, DOI 10.1038/onc.2013.169
   Genander M, 2014, CELL STEM CELL, V15, P619, DOI 10.1016/j.stem.2014.09.009
   Ghaedi M, 2013, J CLIN INVEST, V123, P4950, DOI 10.1172/JCI68793
   Gon H, 2013, MOL BIOL CELL, V24, P3764, DOI 10.1091/mbc.E13 07 0357
   Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189
   Griesmann H, 2013, NEOPLASIA, V15, P11, DOI 10.1593/neo.121312
   Gupta SC, 2013, AAPS J, V15, P195, DOI 10.1208/s12248 012 9432 8
   Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010
   Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203
   Haikarainen T, 2014, CURR PHARM DESIGN, V20, P6472, DOI 10.2174/1381612820666140630101525
   Hammitzsch A, 2015, P NATL ACAD SCI USA, V112, P10768, DOI 10.1073/pnas.1501956112
   Han GW, 2006, DEV CELL, V11, P301, DOI 10.1016/j.devcel.2006.06.014
   Hao F., 2015, APOPTOSIS INT J PROG
   Higuchi Y., 2015, CURRENT MOL PHARM
   Hisamitsu T, 2012, MOL CELL BIOL, V32, P3265, DOI 10.1128/MCB.00145 12
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674
   Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131 139.2003
   Jacob A, 2013, IMMUNOLOGY, V139, P328, DOI 10.1111/imm.12079
   JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0
   Jaiswal AS, 2002, ONCOGENE, V21, P8414, DOI 10.1038/sj.onc.1205947
   Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110
   Jones JO, 2009, P NATL ACAD SCI USA, V106, P7233, DOI 10.1073/pnas.0807282106
   Jung YS, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.48
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kim GH, 2008, J CELL BIOL, V182, P1073, DOI 10.1083/jcb.200710188
   Kim H, 2013, INT J ONCOL, V43, P1319, DOI 10.3892/ijo.2013.2036
   Kim I, 2013, J CELL BIOL, V200, P419, DOI 10.1083/jcb.201206096
   King ML, 2015, ONCOGENE, V34, P3452, DOI 10.1038/onc.2014.277
   Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Kohn AD, 2005, CELL CALCIUM, V38, P439, DOI 10.1016/j.ceca.2005.06.022
   Koo BK, 2015, P NATL ACAD SCI USA, V112, P7548, DOI 10.1073/pnas.1508113112
   Kühl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701
   Kurahashi T, 2005, MOL BIOL CELL, V16, P4705, DOI 10.1091/mbc.E05 05 0470
   Larabell CA, 1997, J CELL BIOL, V136, P1123, DOI 10.1083/jcb.136.5.1123
   Lee SC, 2012, BIOORG MED CHEM LETT, V22, P4221, DOI 10.1016/j.bmcl.2012.05.060
   Lee SC, 2012, BIOORG MED CHEM LETT, V22, P1891, DOI 10.1016/j.bmcl.2012.01.065
   Li HF, 2014, J MED CHEM, V57, P6458, DOI 10.1021/jm500802j
   Lim MY, 2014, ACS CHEM BIOL, V9, P692, DOI 10.1021/cb400759d
   Liu CC, 2014, J BIOL CHEM, V289, P27562, DOI 10.1074/jbc.M113.533927
   Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110
   Liu W, 2006, EMBO J, V25, P1646, DOI 10.1038/sj.emboj.7601057
   LIVINGSTON BT, 1990, DEVELOPMENT, V108, P403
   Locht C, 2011, FEBS J, V278, P4668, DOI 10.1111/j.1742 4658.2011.08237.x
   Lovestone S, 2015, J ALZHEIMERS DIS, V45, P75, DOI 10.3233/JAD 141959
   Lu JM, 2009, BIOORG MED CHEM LETT, V19, P3825, DOI 10.1016/j.bmcl.2009.04.040
   Lum L, 2012, SCIENCE, V337, P922, DOI 10.1126/science.1228179
   Luna Medina R, 2007, J NEUROSCI, V27, P5766, DOI 10.1523/JNEUROSCI.1004 07.2007
   MacDonald BT, 2012, COLD SPRING HARBOR P, V4
   Maran A, 2002, BONE, V30, P393, DOI 10.1016/S8756 3282(01)00681 0
   Marin O, 2003, P NATL ACAD SCI USA, V100, P10193, DOI 10.1073/pnas.1733909100
   McCubrey JA, 2014, LEUKEMIA, V28, P15, DOI 10.1038/leu.2013.184
   Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Mojsin M, 2014, FOOD FUNCT, V5, P2564, DOI [10.1039/c4fo00484a, 10.1039/C4FO00484A]
   Mook RA, 2015, BIOORGAN MED CHEM, V23, P5829, DOI 10.1016/j.bmc.2015.07.001
   MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722
   Narwal M, 2012, J MED CHEM, V55, P1360, DOI 10.1021/jm201510p
   Nemoto E, 2012, BIOCHEM BIOPH RES CO, V422, P627, DOI 10.1016/j.bbrc.2012.05.039
   Niehrs C, 2010, CELL MOL LIFE SCI, V67, P2551, DOI 10.1007/s00018 010 0329 3
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092 8674(82)90409 3
   OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866
   Osada T, 2011, CANCER RES, V71, P4172, DOI 10.1158/0008 5472.CAN 10 3978
   Park S, 2010, J CELL BIOCHEM, V110, P1376, DOI 10.1002/jcb.22654
   Picaud S., 2015, CANC RES
   Piersma B, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00059
   Poewe W, 2015, MOVEMENT DISORD, V30, P1528, DOI 10.1002/mds.26334
   Port F, 2008, NAT CELL BIOL, V10, P178, DOI 10.1038/ncb1687
   Proffitt KD, 2013, CANCER RES, V73, P502, DOI 10.1158/0008 5472.CAN 12 2258
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Reumann S, 2016, J CELL BIOCHEM, V117, P751, DOI 10.1002/jcb.25360
   Richter J, 2014, J MED CHEM, V57, P7933, DOI 10.1021/jm500600b
   Riffell JL, 2012, NAT REV DRUG DISCOV, V11, P923, DOI 10.1038/nrd3868
   Rybakowski JK, 2014, HARVARD REV PSYCHIAT, V22, P353, DOI 10.1097/HRP.0000000000000006
   Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a
   Sanz Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043
   Sarkar S, 2014, ONCOGENE, V33, P26, DOI 10.1038/onc.2012.561
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Saxena M, 2015, ONCOGENE, V34, P188, DOI 10.1038/onc.2013.549
   Schaible EV, 2014, J NEUROCHEM, V129, P940, DOI 10.1111/jnc.12708
   Schlessinger K, 2009, GENE DEV, V23, P265, DOI 10.1101/gad.1760809
   SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037 4041.1990
   Sebo P, 2014, EXPERT REV VACCINES, V13, P1215, DOI 10.1586/14760584.2014.944900
   Shan BE, 2009, CANCER INVEST, V27, P604, DOI 10.1080/07357900802337191
   Simonetti M, 2014, NEURON, V83, P104, DOI 10.1016/j.neuron.2014.05.037
   SINGH J, 1986, J PHARMACOL EXP THER, V236, P488
   Singh S. K., 2015, CLIN CANC RES OFFICI
   Singh S, 2015, NEUROCHEM RES, V40, P1758, DOI 10.1007/s11064 015 1658 2
   Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138
   Smrcka AV, 2008, CELL MOL LIFE SCI, V65, P2191, DOI 10.1007/s00018 008 8006 5
   Song IS, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.104
   Stankiewicz TR, 2015, J BIOL CHEM, V290, P9363, DOI 10.1074/jbc.M114.575217
   Stefater JA, 2013, BLOOD, V121, P2574, DOI 10.1182/blood 2012 06 434621
   SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108
   Sugimura R, 2012, CELL, V150, P351, DOI 10.1016/j.cell.2012.05.041
   Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219
   Takada R, 2006, DEV CELL, V11, P791, DOI 10.1016/j.devcel.2006.10.003
   Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097 2765(03)00484 2
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Tarapore RS, 2012, CARCINOGENESIS, V33, P483, DOI 10.1093/carcin/bgr305
   Novo MCT, 2015, IMMUNOBIOLOGY, V220, P60, DOI 10.1016/j.imbio.2014.09.001
   Tchao J, 2014, SCI REP UK, V4, DOI 10.1038/srep06614
   Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453
   Tiwari S. K., 2015, MOL NEUROBIOLOGY
   Tiwari SK, 2014, ACS NANO, V8, P76, DOI 10.1021/nn405077y
   Tripodo G, 2015, BIOMACROMOLECULES, V16, P550, DOI 10.1021/bm501616e
   van Amerongen R, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007914
   Wada A, 2009, FRONT BIOSCI LANDMRK, V14, P1558, DOI 10.2741/3324
   Wimbauer F, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 93
   Winkler BS, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00009
   Xu HM, 2014, J BIOL CHEM, V289, P26290, DOI 10.1074/jbc.M114.572560
   Xu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071508
   Yamamoto H, 2006, DEV CELL, V11, P213, DOI 10.1016/j.devcel.2006.07.003
   Yochum GS, 2008, MOL CELL BIOL, V28, P7368, DOI 10.1128/MCB.00744 08
   Zhang M, 2009, J CELL BIOCHEM, V108, P896, DOI 10.1002/jcb.22319
   Zhang XL, 2015, P NATL ACAD SCI USA, V112, P9734, DOI 10.1073/pnas.1505420112
   Zhang Y, 2011, NAT CELL BIOL, V13, P623, DOI 10.1038/ncb2222
   [张志镇 Zhang Zhizhen], 2015, [岩石力学与工程学报, Chinese Journal of Rock Mechanics and Engineering], V34, P1
   Zhou BY, 2012, J BIOL CHEM, V287, P7026, DOI 10.1074/jbc.M111.276311
   Zhou LL, 2008, LEUKEMIA RES, V32, P1674, DOI 10.1016/j.leukres.2008.03.039
   Zhu YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037823
   Zoni E, 2015, J ONCOL, V2015, DOI 10.1155/2015/198967
NR 166
TC 8
Z9 8
U1 0
U2 17
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093 9946
EI 1093 4715
J9 FRONT BIOSCI LANDMRK
JI Front. Biosci.
PD JAN 1
PY 2017
VL 22
BP 137
EP 156
DI 10.2741/4477
PG 20
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA EQ2OE
UT WOS:000397908600009
PM 27814607
DA 2025 08 17
ER

PT J
AU Jeong, S
   Kim, I
   Moon, H
   Kim, H
   Song, BW
   Choi, JW
   Kim, SW
   Lee, S
   Chae, DS
   Lim, S
AF Jeong, Seongtae
   Kim, Il Kwon
   Moon, Hanbyeol
   Kim, Hojin
   Song, Byeong Wook
   Choi, Jung Won
   Kim, Sang Woo
   Lee, Seahyoung
   Chae, Dong Sik
   Lim, Soyeon
TI A 70% Ethanol Neorhodomela munita Extract Attenuates
   RANKL Induced Osteoclast Activation and
   H2O2 Induced Osteoblast Apoptosis In Vitro
SO MOLECULES
LA English
DT Article
DE keyword ethanol extract of Neorhodomela munita; osteoclast; osteoblast;
   in vitro osteoporosis
ID BONE MINERAL DENSITY; ANTIOXIDANT ACTIVITY; OSTEOPOROSIS; PREVENTION;
   BISPHOSPHONATES; DIFFERENTIATION; INHIBITION; EFFICACY
AB The rapid aging of the population worldwide presents a significant social and economic challenge, particularly due to osteoporotic fractures, primarily resulting from an imbalance between osteoclast mediated bone resorption and osteoblast mediated bone formation. While conventional therapies offer benefits, they also present limitations and a range of adverse effects. This study explores the protective impact of Neorhodomela munita ethanol extract (EN) on osteoporosis by modulating critical pathways in osteoclastogenesis and apoptosis. Raw264.7 cells and Saos 2 cells were used for in vitro osteoclast and osteoblast models, respectively. By utilizing various in vitro methods to detect osteoclast differentiation/activation and osteoblast death, it was demonstrated that the EN's potential to inhibit RANKL induced osteoclast formation and activation by targeting the MAPKs NFATc1/c Fos pathway and reducing H2O2 induced cell death through the downregulation of apoptotic signals. This study highlights the potential benefits of EN for osteoporosis and suggests that EN is a promising natural alternative to traditional treatments.
C1 [Jeong, Seongtae] Yonsei Univ, Interdisciplinary Grad Program Integrat Biotechnol, Seoul 21983, South Korea.
   [Kim, Il Kwon] Catholic Kwandong Univ, Int St Marys Hosp, Coll Med, Dept Convergence Sci, Incheon 22711, South Korea.
   [Moon, Hanbyeol] Yonsei Univ, Grad Sch, Dept Integrated Om Biomed Sci, Seoul 03722, South Korea.
   [Kim, Hojin] Catholic Kwandong Univ, Coll Med, Dept Med Sci, Gangneung Si 25601, South Korea.
   [Song, Byeong Wook; Kim, Sang Woo; Lee, Seahyoung; Lim, Soyeon] Catholic Kwandong Univ, Coll Med, Dept Convergence Sci, Gangneung Si 25601, South Korea.
   [Choi, Jung Won] Catholic Kwandong Univ, Med Sci Res Inst, Coll Med, Incheon Metropolitan City 22711, South Korea.
   [Chae, Dong Sik] Catholic Kwandong Univ, Int St Marys Hosp, Dept Orthoped Surg, Gangneung Si 25601, South Korea.
C3 Yonsei University; Catholic Kwandong University; Yonsei University;
   Catholic Kwandong University; Catholic Kwandong University; Catholic
   Kwandong University; Catholic Kwandong University
RP Lim, S (通讯作者)，Catholic Kwandong Univ, Coll Med, Dept Convergence Sci, Gangneung Si 25601, South Korea.; Chae, DS (通讯作者)，Catholic Kwandong Univ, Int St Marys Hosp, Dept Orthoped Surg, Gangneung Si 25601, South Korea.
EM 91seongtae@gmail.com; ilkwonkim@cku.ac.kr; moonstar3636@naver.com;
   blue_expanse@naver.com; songbw@ish.ac.kr; gardinia@hanmail.net;
   doctor7408@gmail.com; sam1017@ish.ac.kr; drchaeos@gmail.com;
   slim724@cku.ac.kr
RI Song, Byeong Wook/R 1077 2019; Kim, Soo/P 7880 2016
OI Jeong, Seongtae/0000 0002 9705 531X; Kim, Sang Woo/0000 0002 3144 4822
FU National Research Foundation of Korea
FX No Statement Available
CR Abdel Naim AB, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/5106469
   Airanthi MKWA, 2011, J FOOD SCI, V76, pC104, DOI 10.1111/j.1750 3841.2010.01915.x
   Almeida M, 2013, J CLIN INVEST, V123, P394, DOI 10.1172/JCI65910
   Blake J, 2021, MENOPAUSE, V28, P973, DOI 10.1097/GME.0000000000001831
   Brändström H, 2001, BIOCHEM BIOPH RES CO, V280, P831, DOI 10.1006/bbrc.2000.4223
   Carvalhal F, 2019, MAR DRUGS, V17, DOI 10.3390/md17030170
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Dai PP, 2017, CELL PHYSIOL BIOCHEM, V41, P661, DOI 10.1159/000457945
   Feng W, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 07357 3
   Giardino I, 1996, J CLIN INVEST, V97, P1422, DOI 10.1172/JCI118563
   Ginaldi Lia, 2005, Immun Ageing, V2, P14, DOI 10.1186/1742 4933 2 14
   Han DD, 2017, ONCOTARGET, V8, P14680, DOI 10.18632/oncotarget.14747
   Iantomasi T, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043772
   Jiang ZL, 2021, MITOCHONDRIAL DNA B, V6, P2746, DOI 10.1080/23802359.2021.1966343
   KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659
   Kang KA, 2005, PHYTOTHER RES, V19, P506, DOI 10.1002/ptr.1692
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim SK, 2011, ADV FOOD NUTR RES, V64, P111, DOI 10.1016/B978 0 12 387669 0.00009 0
   LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Lim CS, 2006, BIOL PHARM BULL, V29, P1212, DOI 10.1248/bpb.29.1212
   Miller PD, 2011, THER ADV MUSCULOSKEL, V3, P271, DOI 10.1177/1759720X11424220
   Moayyeri A, 2023, OSTEOPOROSIS INT, DOI 10.1007/s00198 023 06895 4
   Muelas MW, 2020, METABOLOMICS, V16, DOI 10.1007/s11306 020 01725 8
   Nedeva IR, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.641162
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Oyen J, 2017, J NUTR, V147, P572, DOI 10.3945/jn.116.243006
   Park JH, 2017, MOL CELLS, V40, P706
   Park SH, 2012, MAR DRUGS, V10, P2222, DOI 10.3390/md10102222
   Ramos Romero S, 2021, NUTRIENTS, V13, DOI 10.3390/nu13020563
   Rashki Kemmak Asma, 2020, Med J Islam Repub Iran, V34, P154, DOI 10.34171/mjiri.34.154
   Reid DM, 2009, LANCET, V373, P1253, DOI 10.1016/S0140 6736(09)60250 6
   Saadaoui I, 2020, MAR DRUGS, V18, DOI 10.3390/md18040197
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02821 8
   Sarafrazi N., 2021, Osteoporosis or Low Bone Mass in Older Adults: United States, 2017 2018, DOI DOI 10.15620/CDC:103477
   Shen YY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.882241
   Spector TD, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 85
   Teramoto S, 1999, JPN J PHARMACOL, V79, P33, DOI 10.1254/jjp.79.33
   Trovas GP, 2002, J BONE MINER RES, V17, P521, DOI 10.1359/jbmr.2002.17.3.521
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   Ukon Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102557
   Villa I, 2017, J TRANSL MED, V15, DOI 10.1186/s12967 017 1233 5
   Wang YJ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.723988
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Wu AM, 2021, LANCET HEALTH LONGEV, V2, pE580, DOI 10.1016/S2666 7568(21)00172 0
   Wu L, 2017, CURR TOP MED CHEM, V17, P1670, DOI 10.2174/1568026617666161116141033
   Xu HH, 2022, BIOMED PHARMACOTHER, V149, DOI 10.1016/j.biopha.2022.112902
   Xu HH, 2020, CHEM BIOL INTERACT, V331, DOI 10.1016/j.cbi.2020.109235
   Xu J, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1222129
   Yang JI, 2012, MOLECULES, V17, P7241, DOI 10.3390/molecules17067241
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zenz R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2338
   Zha L, 2018, BIOMED PHARMACOTHER, V102, P369, DOI 10.1016/j.biopha.2018.03.080
   Zhou J, 2016, OSTEOPOROSIS INT, V27, P3289, DOI 10.1007/s00198 016 3654 z
NR 55
TC 0
Z9 0
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD APR
PY 2024
VL 29
IS 8
AR 1741
DI 10.3390/molecules29081741
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PA1Q1
UT WOS:001211271600001
PM 38675559
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Romanello, M
   Bivi, N
   Pines, A
   Deganuto, M
   Quadrifoglio, F
   Moro, L
   Tell, G
AF Romanello, Milena
   Bivi, Nicoletta
   Pines, Alex
   Deganuto, Marta
   Quadrifoglio, Franco
   Moro, Luigi
   Tell, Gianluca
TI Bisphosphonates activate nucleotide receptors signaling and induce the
   expression of Hsp90 in osteoblast like cell lines
SO BONE
LA English
DT Article
DE osteoblasts; P2 receptors; bisphosphonates; ATP release; Hsp90
ID EXTRACELLULAR NUCLEOTIDES; BONE RESORPTION; OSTEOCLAST FORMATION;
   MEVALONATE PATHWAY; PROTEIN KINASE; ATP RELEASE; MECHANISM; APOPTOSIS;
   INHIBITION; GROWTH
AB Bisphosphonates are the most important drugs used in the treatment of osteoporosis as they inhibit osteoclast resorption and stimulate proliferation of osteoblasts. However, the molecular mechanisms responsible for these effects are still poorly elucidated. It is known that nucleotide receptors mediated signaling plays a central role in modulating osteoblasts growth in response to mechanical stress. By using osteoblast like cell lines (i.e., HOBIT, MG 63, ROS P2Y), which express P2Y receptors, we found that the treatment with risedronate promotes non lytic ATP release leading to activation of ERKs through the involvement of P2Y receptors triggering. A major role in this signal transduction pathway seems to be the involvement of P2Y(1) and P2Y(2) receptors, since the stimulatory effect of risedronate on ERKs is not appreciable in ROS 17/2.8 cells, which do not express these two receptors. Differential proteomics analysis identified Hsp90 upregulation as a result of risedronate effect on HOBIT and MG 63 cells. The stimulatory effect is dependent on ERKs activation involving nucleotide receptors triggering and leads to increased proliferation of osteoblast like cells. In fact, functional inactivation of Hsp90 by the specific inhibitor 17 AAG prevents the bisphosphonate induced mitogenic effects in osteoblasts. These findings show that bisphosphonates, by inducing ATP release, may also act through nucleotide receptors signaling leading to ERKs activation and may exert their mitogenic role on osteoblasts through the involvement of Hsp90. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Udine, Dept Biomed Sci & Technol, I 33100 Udine, Italy.
   Univ Udine, Ctr Regenerat Med, I 33100 Udine, Italy.
   Univ Trieste, Dept Biochem Biophys & Macromol Chem, Trieste, Italy.
   Ctr Metab Bone Dis, Gorizia, Italy.
C3 University of Udine; University of Udine; University of Trieste
RP Tell, G (通讯作者)，Univ Udine, Dept Biomed Sci & Technol, P Le Kolbe 4, I 33100 Udine, Italy.
EM gtell@mail.dstb.uniud.it
OI Tell, Gianluca/0000 0001 8845 6448
CR Barker CR, 2006, INT J CANCER, V118, P2685, DOI 10.1002/ijc.21717
   Barker CR, 2006, NUCLEIC ACIDS RES, V34, P1148, DOI 10.1093/nar/gkj516
   Bowler WB, 1999, J BIOL CHEM, V274, P14315, DOI 10.1074/jbc.274.20.14315
   Bowler WB, 1998, BONE, V22, P195, DOI 10.1016/S8756 3282(97)00280 9
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Cesaratto L, 2005, FREE RADICAL RES, V39, P255, DOI 10.1080/10715760400029603
   Coco S, 2003, J BIOL CHEM, V278, P1354, DOI 10.1074/jbc.M209454200
   *COMM ENZ SOC FRAN, 1982, ANN BIOL CLIN, V40, P291
   Costessi A, 2005, BONE, V36, P418, DOI 10.1016/j.bone.2004.10.016
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Gallagher J. A., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P432
   Gartland A, 2001, J BONE MINER RES, V16, P846, DOI 10.1359/jbmr.2001.16.5.846
   Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009
   Grygorczyk R, 1997, AM J PHYSIOL CELL PH, V272, pC1058
   Hoebertz A, 2003, TRENDS PHARMACOL SCI, V24, P290, DOI 10.1016/S0165 6147(03)00123 8
   HOMBURG CHE, 1995, BLOOD, V85, P532
   HUANG NN, 1989, P NATL ACAD SCI USA, V86, P7904, DOI 10.1073/pnas.86.20.7904
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Jorgensen NR, 1997, J CELL BIOL, V139, P497, DOI 10.1083/jcb.139.2.497
   Kamal A, 2004, TRENDS MOL MED, V10, P283, DOI 10.1016/j.molmed.2004.04.006
   Korcok J, 2004, J BONE MINER RES, V19, P642, DOI 10.1359/JBMR.040108
   Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074 7613(01)00229 1
   Mathov I, 2001, J BONE MINER RES, V16, P2050, DOI 10.1359/jbmr.2001.16.11.2050
   Novak I, 2003, NEWS PHYSIOL SCI, V18, P12, DOI 10.1152/nips.01409.2002
   Pines A, 2003, BIOCHEM J, V373, P815, DOI 10.1042/BJ20030208
   Plotkin LI, 2001, CELL COMMUN ADHES, V8, P377, DOI 10.3109/15419060109080757
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200
   Quist AP, 2000, J CELL BIOL, V148, P1063, DOI 10.1083/jcb.148.5.1063
   Ralevic V, 1998, PHARMACOL REV, V50, P413
   Rodan GA, 2003, J BONE JOINT SURG AM, V85A, P8, DOI 10.2106/00004623 200300003 00003
   Romanello M, 2005, BIOCHEM BIOPH RES CO, V331, P1429, DOI 10.1016/j.bbrc.2005.03.246
   Romanello M, 2001, BIOCHEM BIOPH RES CO, V289, P1275, DOI 10.1006/bbrc.2001.6124
   Romanello M, 2001, J BONE MINER RES, V16, P1465, DOI 10.1359/jbmr.2001.16.8.1465
   SHAKOORI AR, 1992, J CELL BIOCHEM, V48, P277, DOI 10.1002/jcb.240480308
   Shao WJ, 2005, AM J PHYSIOL CELL PH, V289, pC248, DOI 10.1152/ajpcell.00393.2004
   Taylor AL, 1998, AM J PHYSIOL CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391
   Tornquist K, 1996, J CELL PHYSIOL, V166, P241
   TWENTYMAN PR, 1987, BRIT J CANCER, V56, P279, DOI 10.1038/bjc.1987.190
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022 1759(95)00072 I
   Wiebe SH, 1999, CELL PHYSIOL BIOCHEM, V9, P323, DOI 10.1159/000016326
   YEGUTLIN G, 2000, BRIT J PHARMACOL, P921
   You J, 2002, J BIOL CHEM, V277, P48724, DOI 10.1074/jbc.M209245200
NR 48
TC 29
Z9 39
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2006
VL 39
IS 4
BP 739
EP 753
DI 10.1016/j.bone.2006.03.011
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 088DW
UT WOS:000240792700008
PM 16697713
DA 2025 08 17
ER

PT J
AU Mönkkönen, H
   Auriola, S
   Lehenkari, P
   Kellinsalmi, M
   Hassinen, IE
   Vepsäläinen, J
   Mönkkönen, J
AF Mönkkönen, H
   Auriola, S
   Lehenkari, P
   Kellinsalmi, M
   Hassinen, IE
   Vepsäläinen, J
   Mönkkönen, J
TI A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine
   nucleotide translocase (ANT) and is responsible for the apoptosis
   induced by nitrogen containing bisphosphonates
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE bisphosphonate; mevalonate pathway; FPP synthase; ATP analog; ANT;
   apoptosis
ID BONE RESORPTION; IN VITRO; CLODRONATE; METABOLITES; OSTEOCLAST;
   MECHANISM; DISEASE; VIVO
AB 1 Bisphosphonates are currently the most important class of antiresorptive drugs used for the treatment of diseases with excess bone resorption. On the basis of their molecular mechanism of action, bisphosphonates can be divided into two pharmacological classes; nitrogen containing (N BPs) and non nitrogen containing bisphosphonates (non N BP). Both classes induce apoptosis but they evoke it differently; N BPs by inhibiting the intracellular mevalonate pathway and protein isoprenylation, and non N BPs via cytotoxic ATP analog type metabolites. N BPs are not metabolized to ATP analogs, but we report here that these bisphosphonates can induce formation of a novel ATP analog (ApppI) as a consequence of the inhibition of the mevalonate pathway in cells. We also investigated whether ApppI is involved in the apoptosis induced by N BPs.
   2 Mass spectrometry and NMR were used to identify ApppI in N BP treated osteoclasts, macrophages and glioma cells. The potency of different bisphosphonates to promote ApppI production was tested in J774 macrophages. The effects of ApppI on ADP/ATP translocase in isolated mitochondria and its capability to induce apoptosis in osteoclasts were also studied.
   3 ApppI production correlated well with the capacity of N BPs to inhibit mevalonate pathway. ApppI inhibited the mitochondrial ADP/ATP translocase and caused apoptosis in osteoclasts.
   4 In conclusion, these findings provide the basis for a new mechanism of action for N BPs. Some of these very potent bisphosphonates, such as zoledronic acid, represent a third class of bisphosphonates that can act both via the inhibition of the mevalonate pathway and by the blockade of mitochondrial ADP/ATP translocase, which is known to be involved in the induction of apoptosis.
C1 Univ Kuopio, Dept Pharmaceut, FIN 70211 Kuopio, Finland.
   Univ Kuopio, Dept Pharmaceut Chem, Kuopio, Finland.
   Univ Oulu, Dept Surg, FIN 90014 Oulu, Finland.
   Univ Oulu, Dept Med Biochem & Mol Biol, FIN 90014 Oulu, Finland.
   Univ Kuopio, Dept Chem, FIN 70211 Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland; University
   of Oulu; University of Oulu; University of Eastern Finland
RP Univ Kuopio, Dept Pharmaceut, POB 1627, FIN 70211 Kuopio, Finland.
EM hannu.monkkonen@uku.fi
RI Lehenkari, Petri/O 3009 2016
OI Lehenkari, Petri/0000 0002 0055 5183; Valkealahti,
   Maarit/0000 0003 2135 6922
CR Auriola S, 1997, J CHROMATOGR B, V704, P187, DOI 10.1016/S0378 4347(97)00490 8
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313
   CHAMBERS TJ, 1984, J CELL SCI, V70, P61
   Chávez E, 1999, FEBS LETT, V445, P189, DOI 10.1016/S0014 5793(99)00128 3
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   EGGERER H, 1960, LIEBIGS ANN CHEM, V630, P58
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Halestrap AP, 2004, NATURE, V430, DOI 10.1038/nature02816
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Mayer B, 2003, NEWS PHYSIOL SCI, V18, P89, DOI 10.1152/nips.01433.2002
   Mönkkönen H, 2000, J CHROMATOGR B, V738, P395, DOI 10.1016/S0378 4347(99)00559 9
   Mönkkönen H, 2001, PHARMACEUT RES, V18, P1550, DOI 10.1023/A:1013026313647
   MONKKONEN J, 1994, J DRUG TARGET, V2, P299, DOI 10.3109/10611869409015910
   MONKKONEN J, 1994, INT J PHARM, V107, P189, DOI 10.1016/0378 5173(94)90433 2
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   PAULSON DJ, 1984, BIOCHIM BIOPHYS ACTA, V766, P70, DOI 10.1016/0005 2728(84)90218 4
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rogers MJ, 1996, BIOCHEM BIOPH RES CO, V224, P863, DOI 10.1006/bbrc.1996.1113
   Roux C, 1999, DRUGS, V58, P823, DOI 10.2165/00003495 199958050 00005
   Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   WATANABE F, 1985, J BIOCHEM, V97, P1229, DOI 10.1093/oxfordjournals.jbchem.a135168
   Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014 5793(96)00280 3
NR 31
TC 238
Z9 268
U1 1
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD FEB
PY 2006
VL 147
IS 4
BP 437
EP 445
DI 10.1038/sj.bjp.0706628
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 017BB
UT WOS:000235668000012
PM 16402039
OA Green Published
DA 2025 08 17
ER

PT J
AU Sinder, BP
   Eddy, MM
   Ominsky, MS
   Caird, MS
   Marini, JC
   Kozloff, KM
AF Sinder, Benjamin P.
   Eddy, Mary M.
   Ominsky, Michael S.
   Caird, Michelle S.
   Marini, Joan C.
   Kozloff, Kenneth M.
TI Sclerostin Antibody Improves Skeletal Parameters in a Brtl/+ Mouse Model
   of Osteogenesis Imperfecta
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOGENESIS IMPERFECTA; SCLEROSTIN ANTIBODY; COLLAGEN; BONE MASS;
   ANABOLIC THERAPY
ID SUPPRESSED BONE TURNOVER; MICRODAMAGE ACCUMULATION; BIOMECHANICAL
   PROPERTIES; DOG RIB; STRENGTH; CHILDREN; MICE; BISPHOSPHONATES; GROWTH;
   GENE
AB Osteogenesis imperfecta (OI) is a genetic bone dysplasia characterized by osteopenia and easy susceptibility to fracture. Symptoms are most prominent during childhood. Although antiresorptive bisphosphonates have been widely used to treat pediatric OI, controlled trials show improved vertebral parameters but equivocal effects on long bone fracture rates. New treatments for OI are needed to increase bone mass throughout the skeleton. Sclerostin antibody (Scl Ab) therapy is potently anabolic in the skeleton by stimulating osteoblasts via the canonical wnt signaling pathway, and may be beneficial for treating OI. In this study, Scl Ab therapy was investigated in mice heterozygous for a typical OI causing Gly  > Cys substitution in col1a1. Two weeks of Scl Ab successfully stimulated osteoblast bone formation in a knock in model for moderately severe OI (Brtl/+) and in WT mice, leading to improved bone mass and reduced long bone fragility. Image guided nanoindentation revealed no alteration in local tissue mineralization dynamics with Scl Ab. These results contrast with previous findings of antiresorptive efficacy in OI both in mechanism and potency of effects on fragility. In conclusion, short term Scl Ab was successfully anabolic in osteoblasts harboring a typical OI causing collagen mutation and represents a potential new therapy to improve bone mass and reduce fractures in pediatric OI. (C) 2013 American Society for Bone and Mineral Research.
C1 [Sinder, Benjamin P.; Eddy, Mary M.; Caird, Michelle S.; Kozloff, Kenneth M.] Univ Michigan, Orthopaed Res Labs, Dept Orthopaed Surg, Ann Arbor, MI 48109 USA.
   [Sinder, Benjamin P.; Kozloff, Kenneth M.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Ominsky, Michael S.] Amgen Inc, Dept Metab Disorders, Thousand Oaks, CA 91320 USA.
   [Marini, Joan C.] NICHHD, Bone & Extracellular Matrix Branch, NIH, Bethesda, MD 20892 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; Amgen; National Institutes of
   Health (NIH)   USA; NIH Eunice Kennedy Shriver National Institute of
   Child Health & Human Development (NICHD)
RP Kozloff, KM (通讯作者)，2015 Biomed Sci Res Bldg,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.
EM kenkoz@umich.edu
FU NIAMS NIH HHS [R01 AR062522] Funding Source: Medline; Intramural NIH HHS
   [ZIA HD008830] Funding Source: Medline
CR Allen MR, 2008, CALCIFIED TISSUE INT, V82, P354, DOI 10.1007/s00223 008 9131 8
   Busa B, 2005, CALCIFIED TISSUE INT, V77, P386, DOI 10.1007/s00223 005 0148 y
   Davis MS, 2012, BONE, V50, P784, DOI 10.1016/j.bone.2011.12.007
   Donnelly E, 2010, J BIOMED MATER RES A, V92A, P1048, DOI 10.1002/jbm.a.32442
   Forlino A, 1999, J BIOL CHEM, V274, P37923, DOI 10.1074/jbc.274.53.37923
   Forlino A, 2007, MATRIX BIOL, V26, P604, DOI 10.1016/j.matbio.2007.06.005
   Forlino A, 2011, NAT REV ENDOCRINOL, V7, P540, DOI 10.1038/nrendo.2011.81
   Gatti D, 2005, J BONE MINER RES, V20, P758, DOI 10.1359/JBMR.041232
   Hildebrand T, 1997, J MICROSC OXFORD, V185, P67, DOI 10.1046/j.1365 2818.1997.1340694.x
   Komatsubara S, 2004, J BONE MINER RES, V19, P999, DOI 10.1359/JBMR.040126
   Kozloff KM, 2004, J BONE MINER RES, V19, P614, DOI 10.1359/JBMR.040111
   Letocha AD, 2005, J BONE MINER RES, V20, P977, DOI 10.1359/JBMR.050109
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   Li J, 2001, CALCIFIED TISSUE INT, V69, P281, DOI 10.1007/s002230010036
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Marenzana M, 2011, ARTHRITIS RHEUM US, V63, P2385, DOI 10.1002/art.30385
   Marini JC, 2003, J BONE MINER RES, V18, P237, DOI 10.1359/jbmr.2003.18.2.237
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Mashiba T, 2001, BONE, V28, P524, DOI 10.1016/S8756 3282(01)00414 8
   Meganck JA, 2009, BONE, V45, P1104, DOI 10.1016/j.bone.2009.07.078
   Oliver WC, 1992, J MATER RES, V7, P1565
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Papapoulos SE, 2007, NEW ENGL J MED, V356, P1075, DOI 10.1056/NEJMc062792
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Rauch F, 2009, J BONE MINER RES, V24, P1282, DOI [10.1359/jbmr.090213, 10.1359/JBMR.090213]
   Reich A, 2011, J BONE MINER RES S1, V26
   Sakkers R, 2004, LANCET, V363, P1427, DOI 10.1016/S0140 6736(04)16101 1
   Uveges TE, 2009, J BONE MINER RES, V24, P849, DOI [10.1359/jbmr.081238, 10.1359/JBMR.081238]
   Uveges TE, 2008, J BONE MINER RES, V23, P1983, DOI 10.1359/JBMR.080804
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Ward LM, 2011, J CLIN ENDOCR METAB, V96, P355, DOI 10.1210/jc.2010 0636
   Whyte MP, 2008, J BONE MINER RES, V23, P1698, DOI 10.1359/JBMR.080511
NR 37
TC 108
Z9 125
U1 0
U2 14
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2013
VL 28
IS 1
BP 73
EP 80
DI 10.1002/jbmr.1717
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 092EY
UT WOS:000315103200008
PM 22836659
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Reginster, JY
   Neuprez, A
   Dardenne, N
   Beaudart, C
   Emonts, P
   Bruyere, O
AF Reginster, J. Y.
   Neuprez, A.
   Dardenne, N.
   Beaudart, C.
   Emonts, P.
   Bruyere, O.
TI Efficacy and safety of currently marketed anti osteoporosis medications
SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE osteoporosis; treatment; efficacy; safety
ID BONE MINERAL DENSITY; VERTEBRAL FRACTURE RISK; ATYPICAL FEMORAL
   FRACTURES; MONTHLY ORAL IBANDRONATE; BISPHOSPHONATE ASSOCIATED
   OSTEONECROSIS; CONTINUING OUTCOMES RELEVANT; SYSTEMIC SYMPTOMS DRESS;
   POSTMENOPAUSAL WOMEN; STRONTIUM RANELATE; PARATHYROID HORMONE
AB During the past 2 decades, many interventions were proven effective in the management of postmenopausal osteoporosis. The objective of an anti osteoporosis treatment is to reduce fracture rates, ideally at all skeletal sites (i.e. spine, hip, and other non spine). The armamentarium against osteoporosis includes anti resorptive agents (i.e. bisphosphonates, selective estrogen receptor modulators and denosumab), bone forming agents (i.e. peptides from the parathyroid hormone family) and one agent with a dual mechanism of action (i.e. strontium ranelate). All these medications combine antifracture efficacy with a reasonable benefit/risk profile. However, the choice of a particular chemical entity, in one individual patient is based on the knowledge and expertise of the physician. Prioritization of drugs should be based on the individual profile of the patient, the severity of osteoporosis and the specific contraindications, warnings and precautions of use of the various available medications. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Reginster, J. Y.; Neuprez, A.; Dardenne, N.; Beaudart, C.; Emonts, P.; Bruyere, O.] Univ Liege, CHU Sart Tilman, Dept Publ Hlth Epidemiol & Hlth Econ, B 4020 Liege, Belgium.
   [Reginster, J. Y.; Neuprez, A.; Dardenne, N.; Beaudart, C.; Bruyere, O.] Univ Liege, CHU Ctr Ville, Bone & Cartilage Metab Unit, B 4020 Liege, Belgium.
C3 University of Liege; University of Liege
RP Reginster, JY (通讯作者)，Univ Liege, Dept Publ Hlth Epidemiol & Hlth Econ, Ave Hop,1,B23 Sart Tilman, B 4020 Liege, Belgium.
EM jyreginster@ulg.ac.be; audrey.neuprez@studentulg.ac.be;
   ndardenne@ulg.ac.be; C.Beaudart@ulg.ac.be; olivier.bruyere@ulg.ac.be
RI Beaudart, Charlotte/AAL 3044 2020; Bruyere, Olivier/H 8302 2019;
   Reginster, Jean Yves/AGC 6097 2022
OI Bruyere, Olivier/0000 0003 4269 9393; Beaudart,
   Charlotte/0000 0002 0827 5303
FU Servier; Novartis; Negma; Lilly; Wyeth; Amgen; GlaxoSmithKline; Roche;
   Merckle; Nycomed Takeda; NPS; IBSA Genevrier; Theramex; UCB; Asahi
   Kasei; Endocyte; Merck Sharp and Dohme; Rottapharm; IBSA; Genevrier;
   Teijin; Teva; Analis; Nycomed; NovoNordisk; Ebewee Pharma; Zodiac;
   Danone; Will Pharma; Bristol Myers Squibb; Merck Sharp Dohme; Pfizer;
   Organon; Therabel; Boehringer; Chiltern; Galapagos; Bayer; SMB;
   Nutraveris
FX Consulting fees or paid advisory boards: Servier, Novartis, Negma,
   Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed Takeda,
   NPS, IBSA Genevrier, Theramex, UCB, Asahi Kasei, Endocyte. Lecture fees
   when speaking at the invitation of a commercial sponsor: Merck Sharp and
   Dohme, Lilly, Rottapharm, IBSA, Genevrier, Novartis, Servier, Roche,
   GlaxoSmithKline, Merckle, Teijin, Teva, Analis, Theramex, Nycomed,
   NovoNordisk, Ebewee Pharma, Zodiac, Danone, Will Pharma, Amgen. Grant
   Support from Industry: Bristol Myers Squibb, Merck Sharp & Dohme,
   Rottapharm, Teva, Roche, Amgen, Lilly, Novartis, GlaxoSmithKline,
   Servier, Pfizer, Theramex, Danone, Organon, Therabel, Boehringer,
   Chiltern, Galapagos. Consulting fees or paid advisory boards: Bayer,
   Genevrier, IBSA, Rottapharm, Servier, SMB. Lecture fees when speaking at
   the invitation of a commercial sponsor: IBSA, Merck Sharp & Dohme,
   Novartis, Pfizer, Rottapharm, Servier, Theramex. Grant Support from
   Industry: IBSA, Merck Sharp & Dohme, Novartis, Nutraveris, Pfizer,
   Rottapharm, Servier, Theramex. Grant Support from Industry: Amgen,
   Servier.
CR Abdallah BM, 2005, CALCIFIED TISSUE INT, V76, P90, DOI 10.1007/s00223 004 0074 4
   Abrahamsen B, 2014, OSTEOPOROSIS INT, V25, P757, DOI 10.1007/s00198 013 2469 4
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   [Anonymous], PROT EPAR SCI DISC
   [Anonymous], EMA847492014
   [Anonymous], J BONE MINER RES
   [Anonymous], QUEST ANSW SAF PROT
   Archer DF, 2009, MENOPAUSE, V16, P1109, DOI 10.1097/gme.0b013e3181a818db
   Barrett Connor E, 2002, JAMA J AM MED ASSOC, V287, P847, DOI 10.1001/jama.287.7.847
   Barrett Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2012, J BONE MINER RES, V27, P243, DOI 10.1002/jbmr.1494
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Body JJ, 2010, OSTEOPOROSIS INT, V21, P1657, DOI 10.1007/s00198 010 1223 4
   Bone HG, 2013, J CLIN ENDOCR METAB, V98, P4483, DOI 10.1210/jc.2013 1597
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Boonen S, 2005, OSTEOPOROSIS INT, V16, P239, DOI 10.1007/s00198 004 1812 1
   Boonen S, 2004, J AM GERIATR SOC, V52, P1832, DOI 10.1111/j.1532 5415.2004.52506.x
   Boonen S, 2004, J INTERN MED, V255, P1, DOI 10.1046/j.0954 6820.2003.01258.x
   Boonen S, 2008, KIDNEY INT, V74, P641, DOI 10.1038/ki.2008.193
   Breart G, 2010, OSTEOPOROSIS INT, V21, P1181, DOI 10.1007/s00198 009 1050 7
   Brown JP, 2013, J BONE MINER RES, V28, P746, DOI 10.1002/jbmr.1808
   Brown JP, 2002, CALCIFIED TISSUE INT, V71, P103, DOI 10.1007/s00223 002 2011 8
   Brown JP., 2009, J BONE MINER RES, V14, P1, DOI DOI 10.1359/JBMR.080910
   Bruyère O, 2007, CURR MED RES OPIN, V23, P3041, DOI 10.1185/030079907X242818
   Bruyere O, 2007, J CLIN ENDOCR METAB, V92, P3076, DOI 10.1210/jc.2006 2758
   Cacoub P, 2013, OSTEOPOROSIS INT, V24, P1751, DOI 10.1007/s00198 013 2265 1
   Carvalho NNC, 2011, J CLIN ENDOCR METAB, V96, P2675, DOI 10.1210/jc.2011 0593
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Chiang CY, 2013, BONE, V52, P360, DOI 10.1016/j.bone.2012.10.006
   Christiansen C, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 130
   Colón Emeric CS, 2010, J BONE MINER RES, V25, P91, DOI 10.1359/jbmr.090704
   Cooper C, 2014, OSTEOPOROSIS INT, V25, P737, DOI 10.1007/s00198 013 2582 4
   Cooper C, 2012, CURR MED RES OPIN, V28, P475, DOI 10.1185/03007995.2012.663750
   Cooper C, 2010, OSTEOPOROSIS INT, V21, P569, DOI 10.1007/s00198 009 1003 1
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cosman F, 2010, J CLIN ENDOCR METAB, V95, P151, DOI 10.1210/jc.2009 0358
   Cranney A, 2009, OSTEOPOROSIS INT, V20, P291, DOI 10.1007/s00198 008 0653 8
   Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001 2002
   Cummings SR, 1999, JAMA J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Dansereau RJ, 2009, CURR MED RES OPIN, V25, P449, DOI [10.1185/03007990802648903, 10.1185/03007990802648903 ]
   de Villiers TJ, 2011, OSTEOPOROSIS INT, V22, P567, DOI 10.1007/s00198 010 1302 6
   deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403
   Delmas PD, 2003, BONE, V33, P522, DOI 10.1016/S8756 3282(03)00241 2
   Delmas PD, 2006, BONE, V39, P237, DOI 10.1016/j.bone.2006.02.003
   Delmas PD, 2002, J CLIN ENDOCR METAB, V87, P3609, DOI 10.1210/jc.87.8.3609
   Delmas PD, 2006, ARTHRITIS RHEUM US, V54, P1838, DOI 10.1002/art.21918
   Donneau AF, 2014, OSTEOPOROSIS INT, V25, P397, DOI 10.1007/s00198 013 2583 3
   Drampalos E, 2014, ACTA ORTHOP, V85, P3, DOI 10.3109/17453674.2013.854668
   Dunstan CR, 2007, NAT CLIN PRACT ONCOL, V4, P42, DOI 10.1038/ncponc0688
   Eastell R, 2011, J BONE MINER RES, V26, P530, DOI 10.1002/jbmr.251
   Eastell R, 2009, J BONE MINER RES, V24, P726, DOI 10.1359/JBMR.081215
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Ettinger B, 2013, BONE, V55, P495, DOI 10.1016/j.bone.2013.02.004
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Ettinger Mark P, 2006, Endocr Pract, V12, P522
   Fujita T, 2014, CALCIFIED TISSUE INT, V94, P170, DOI 10.1007/s00223 013 9777 8
   Gallacher SJ, 2010, CALCIFIED TISSUE INT, V87, P469, DOI 10.1007/s00223 010 9420 x
   Gomberg SJ, 2011, J CLIN ENDOCR METAB, V96, P1627, DOI 10.1210/jc.2010 2520
   Grbic JT, 2008, J AM DENT ASSOC, V139, P32, DOI 10.14219/jada.archive.2008.0017
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Grosso A, 2008, BRIT J CLIN PHARMACO, V66, P689, DOI 10.1111/j.1365 2125.2008.03273.x
   Harris ST, 2009, BONE, V44, P758, DOI 10.1016/j.bone.2009.01.002
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Harvey JA, 2009, MENOPAUSE, V16, P1193, DOI 10.1097/gme.0b013e3181a7fb1e
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Henriksen K, 2013, BONE, V53, P160, DOI 10.1016/j.bone.2012.11.045
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Huang HT, 2012, MENOPAUSE, V19, P1360, DOI 10.1097/gme.0b013e318260143d
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198 012 2074 y
   Kanis JA, 2003, BONE, V33, P293, DOI 10.1016/S8756 3282(03)00200 X
   Kanis JA, 2010, BONE, V47, P729, DOI 10.1016/j.bone.2010.06.009
   Kanis JA, 2009, BONE, V44, P1049, DOI 10.1016/j.bone.2009.02.014
   Karpf DB, 1997, JAMA J AM MED ASSOC, V277, P1159
   Kaufman JM, 2013, OSTEOPOROSIS INT, V24, P2561, DOI 10.1007/s00198 013 2341 6
   Kaufman JM, 2013, BONE, V53, P134, DOI 10.1016/j.bone.2012.11.018
   Kawate H, 2011, CLIN INTERV AGING, V6, P151, DOI 10.2147/CIA.S15711
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Khan A, 2010, BMJ BRIT MED J, V340, DOI 10.1136/bmj.c246
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kwon YD, 2012, OSTEOPOROSIS INT, V23, P2721, DOI 10.1007/s00198 011 1882 9
   Langdahl BL, 2009, CALCIFIED TISSUE INT, V85, P484, DOI 10.1007/s00223 009 9299 6
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   Lesclous P, 2009, BONE, V45, P843, DOI 10.1016/j.bone.2009.07.011
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lindsay R, 2004, ARCH INTERN MED, V164, P2024, DOI 10.1001/archinte.164.18.2024
   Ljunggren Ö, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 251
   Loke YK, 2009, DRUG SAFETY, V32, P219, DOI 10.2165/00002018 200932030 00004
   Lufkin EG, 1998, J BONE MINER RES, V13, P1747, DOI 10.1359/jbmr.1998.13.11.1747
   Negri AL, 2012, CLIN CASES MINER BON, V9, P166
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Marcus R, 2003, J BONE MINER RES, V18, P18, DOI 10.1359/jbmr.2003.18.1.18
   Maricic M, 2002, ARCH INTERN MED, V162, P1140, DOI 10.1001/archinte.162.10.1140
   Marie PJ, 2011, OSTEOPOROSIS INT, V22, P1659, DOI 10.1007/s00198 010 1369 0
   Martino S, 2004, J NATL CANCER I, V96, P1751, DOI 10.1093/jnci/djh319
   McCloskey EV, 2012, J BONE MINER RES, V27, P1480, DOI 10.1002/jbmr.1606
   Meunier PJ, 2009, OSTEOPOROSIS INT, V20, P1663, DOI 10.1007/s00198 008 0825 6
   Meunier PJ, 2002, J CLIN ENDOCR METAB, V87, P2060, DOI 10.1210/jc.87.5.2060
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Migliorati CA, 2006, LANCET ONCOL, V7, P508, DOI 10.1016/S1470 2045(06)70726 4
   Miller PD, 2014, OSTEOPOROSIS INT, V25, P349, DOI 10.1007/s00198 013 2518 z
   Miller PD, 2008, CURR MED RES OPIN, V24, P207, DOI 10.1185/030079908X253889
   Mirkin S, 2013, CLIMACTERIC, V16, P338, DOI 10.3109/13697137.2012.717994
   Musette P, 2010, OSTEOPOROSIS INT, V21, P723, DOI 10.1007/s00198 009 1097 5
   Nakamura T, 2012, J CLIN ENDOCR METAB, V97, P3097, DOI 10.1210/jc.2011 3479
   Nakano T, 2014, J BONE MINER METAB, V32, P441, DOI 10.1007/s00774 013 0505 2
   Neele SJM, 2002, BONE, V30, P599, DOI 10.1016/S8756 3282(01)00706 2
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Neuprez A, 2014, OSTEOPOROSIS INT, V25, P393, DOI 10.1007/s00198 013 2437 z
   Otto S, 2013, J CRANIO MAXILL SURG, V41, P694, DOI 10.1016/j.jcms.2013.05.038
   Palacios S, 2013, MATURITAS, V76, P81, DOI 10.1016/j.maturitas.2013.06.008
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Paparodis R, 2013, ENDOCR PRACT, V19, pE64, DOI 10.4158/EP12367.CR
   Prince R, 2005, J BONE MINER RES, V20, P1507, DOI 10.1359/JBMR.050501
   Rabenda V, 2008, J BONE JOINT SURG AM, V90A, P2142, DOI 10.2106/JBJS.G.00864
   Recker RR, 2009, AM J MED, V122, P22, DOI 10.1016/j.amjmed.2008.12.004
   Reginster JY, 2014, PANMINERVA MED, V56, P97
   Reginster JY, 2009, BONE, V45, P1059, DOI 10.1016/j.bone.2009.08.004
   Reginster JY, 2007, INT J CLIN PRACT, V61, P324, DOI 10.1111/j.1742 1241.2006.01249.x
   Reginster JY, 2012, OSTEOPOROSIS INT, V23, P1115, DOI 10.1007/s00198 011 1847 z
   Reginster JY, 2014, CURR MED RES OPIN, V30, P1165, DOI 10.1185/03007995.2014.890927
   Reginster JY, 2013, EXPERT OPIN DRUG SAF, V12, P507, DOI 10.1517/14740338.2013.793669
   Reginster JY, 2011, DRUGS, V71, P65, DOI 10.2165/11587570 000000000 00000
   Reginster JY, 2006, ANN RHEUM DIS, V65, P654, DOI 10.1136/ard.2005.044958
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Reginster JY, 1997, OSTEOPOROSIS INT, V7, P163, DOI 10.1007/BF03194365
   Reid IR, 2013, J CLIN ENDOCR METAB, V98, P557, DOI 10.1210/jc.2012 2868
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Ringe JD, 2009, RHEUMATOL INT, V30, P213, DOI 10.1007/s00296 009 0940 5
   Rizzoli R, 2011, OSTEOPOROSIS INT, V22, P373, DOI 10.1007/s00198 010 1453 5
   Rizzoli R, 2008, BONE, V42, P841, DOI 10.1016/j.bone.2008.01.003
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Roux C, 2008, ANN RHEUM DIS, V67, P1736, DOI 10.1136/ard.2008.094516
   Roux C, 2006, J BONE MINER RES, V21, P536, DOI 10.1359/JBMR.060101
   Roux C, 2014, BONE, V58, P48, DOI 10.1016/j.bone.2013.10.006
   Schnitzer T, 2000, AGING CLIN EXP RES, V12, P1
   Sebba AI, 2009, BONE, V44, P423, DOI 10.1016/j.bone.2008.10.052
   Seeman E, 2006, J BONE MINER RES, V21, P1113, DOI 10.1359/JBMR.060404
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shrader SP, 2005, ANN PHARMACOTHER, V39, P1511, DOI 10.1345/aph.1G146
   Silverman S, 2012, OSTEOPOROSIS INT, V23, P797, DOI 10.1007/s00198 011 1775 y
   Silverman SL, 2012, OSTEOPOROSIS INT, V23, P351, DOI 10.1007/s00198 011 1691 1
   Silverman SL, 2008, J BONE MINER RES, V23, P1923, DOI 10.1359/JBMR.080710
   Siris E, 2002, OSTEOPOROSIS INT, V13, P907, DOI 10.1007/s001980200125
   Siris ES, 2005, J BONE MINER RES, V20, P1514, DOI 10.1359/JBMR.050509
   Sivolella S, 2013, ANTICANCER RES, V33, P1793
   Sorensen OH, 2003, BONE, V32, P120, DOI 10.1016/S8756 3282(02)00946 8
   Stakkestad JA, 2008, CLIN RHEUMATOL, V27, P955, DOI 10.1007/s10067 007 0824 6
   Svanström H, 2014, ANN RHEUM DIS, V73, P1037, DOI 10.1136/annrheumdis 2014 205283
   Tadrous M, 2014, OSTEOPOROSIS INT, V25, P1225, DOI 10.1007/s00198 013 2576 2
   Tas S, 2003, DERMATOLOGY, V206, P353, DOI 10.1159/000069956
   Thompson RN, 2012, J BONE JOINT SURG BR, V94B, P385, DOI 10.1302/0301 620X.94B3.27999
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Vogel VG, 2006, JAMA J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074
   Walker MD, 2013, ENDOCRINE, V44, P237, DOI 10.1007/s12020 012 9819 4
   Walsh JB, 2012, CALCIFIED TISSUE INT, V90, P373, DOI 10.1007/s00223 012 9590 9
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
NR 163
TC 46
Z9 54
U1 1
U2 21
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1521 690X
EI 1532 1908
J9 BEST PRACT RES CL EN
JI Best Pract. Res. Clin. Endoc. Metab.
PD DEC
PY 2014
VL 28
IS 6
BP 809
EP 834
DI 10.1016/j.beem.2014.09.003
PG 26
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AY5CI
UT WOS:000347590500005
PM 25432354
DA 2025 08 17
ER

PT J
AU Barrio, DA
   Etcheverry, SB
AF Barrio, D. A.
   Etcheverry, S. B.
TI Vanadium and bone development: putative signaling pathways
SO CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
LA English
DT Article; Proceedings Paper
CT 12th International Conference on Second Messengers and Phosphoproteins
   (SMP)
CY AUG 03 07, 2004
CL Montreal, CANADA
SP Univ Calgary, McGill Canc Ctr, Dept Oncol, Fac Med, McGill Univ Hlth Ctr, Univ Montreal, Ctr Rech, Ctr Hosp Univ Montreal, Canadian Inst Hlth Res, Govt Quebec, Dev Econ & Reg Rech, Amgen, AstraZeneca, BD Biosci, Bethl Labs Inc, Biosource, Biochem Journal, Cell, Pharma Genom, Sci STKE AAAS
DE vanadium; osteoblast; signaling pathways
ID OSTEOBLAST LIKE CELLS; GROWTH FACTOR I; ALKALINE PHOSPHATASE ACTIVITY;
   CATION SENSING MECHANISM; PROTEIN MAP KINASES; DIABETIC RATS;
   PARATHYROID HORMONE; MC3T3 E1 OSTEOBLASTS; TYROSINE KINASE;
   PHOSPHATIDYLINOSITOL 3 KINASE
AB Vanadium is a trace element present in practically all cells in plants and animals. It exerts interesting actions in living systems. At pharmacological doses, vanadium compounds display relevant biological actions such as mimicking insulin and growth factors as well as having osteogenic activity. Some vanadium compounds also show antitumoral properties. The importance of vanadium in bone arises from the studies developed to establish the essentiality of this element in animals and humans. Bone tissue, where the element seems to play an important role, accumulates great amounts of vanadium. This paper reviews the physiology of osteoblasts, the involvement of different growth factors on bone development, and the effects of vanadium derivatives on the skeletal system of animal models and bone related cells. Two cellular lines are discussed in particular; one derived from a rat osteosarcoma (UMR106) and the other is a nontransformed osteoblast cell line (MC3T3 E1). The effects of different growth factors and their mechanisms of action in these cellular lines are reviewed. These models of osteoblasts are especially useful in understanding the intracellular signaling pathways of vanadium derivatives in hard tissues. Vanadium uses an intricate interplay of intracellular mechanisms to exert different biochemical and pharmacological actions. The effects of vanadium derivatives on some cellular signaling pathways related to insulin are compiled in this review. The comprehension of these intracellular signaling pathways may facilitate the design of vanadium compounds with promising therapeutic applications as well as the understanding of secondary side effects derived from the use of vanadium as a therapeutic agent.
C1 UNLP, Fac Ciencias Exactas, Catedra Bioquim Patol, RA 1900 La Plata, Argentina.
   UNLP, CEQUINOR, CONICET, Fac Ciencias Exactas, RA 1900 La Plata, Argentina.
C3 National University of La Plata; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); National University of La Plata
RP Etcheverry, SB (通讯作者)，UNLP, Fac Ciencias Exactas, Catedra Bioquim Patol, RA 1900 La Plata, Argentina.
EM etchever@biol.unlp.edu.ar
RI Barrio, Daniel/AAG 6938 2019
CR AMARNANI S, 1993, J BONE MINER RES, V8, P157
   ANKE M, 1989, 6TH INTERNATIONAL TRACE ELEMENT SYMP 1989, VOLS 1 5, P17
   Barrio DA, 2003, J BIOL INORG CHEM, V8, P459, DOI 10.1007/s00775 002 0438 z
   BARRIO DA, 2006, CAN J PHYSL PHARM, V84
   BAYLINK DJ, 1993, J BONE MINER RES, V8, pS565
   Bonnefont Rousselot Dominique, 2004, Treat Endocrinol, V3, P41
   Borgatti P, 2000, FEBS LETT, V477, P27, DOI 10.1016/S0014 5793(00)01758 0
   CANALIS E, 1985, ENDOCRINOLOGY, V116, P855, DOI 10.1210/endo 116 3 855
   CHASTEEN ND, 1986, BIOCHIM BIOPHYS ACTA, V884, P84, DOI 10.1016/0304 4165(86)90230 8
   Chaudhary LR, 1998, MOL CELL BIOCHEM, V178, P59, DOI 10.1023/A:1006807221545
   Chihara K, 1997, HORM RES, V48, P45, DOI 10.1159/000191328
   Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079 6107(98)00056 X
   Cortizo AM, 2000, EUR J PHARMACOL, V400, P279, DOI 10.1016/S0014 2999(00)00356 3
   Cortizo AM, 1997, BIOMETALS, V10, P127, DOI 10.1023/A:1018335324447
   CORTIZO AM, 1995, MOL CELL BIOCHEM, V145, P97, DOI 10.1007/BF00935481
   Crans D.C., 1994, COMMENT INORG CHEM, V16, P35
   CRANS DC, 1998, VANADIUM COMPOUNDS C, V1, P2
   DAI S, 1994, PHARMACOL TOXICOL, V75, P265, DOI 10.1111/j.1600 0773.1994.tb00359.x
   DJORDJEVIC C, 1985, J INORG BIOCHEM, V25, P51, DOI 10.1016/0162 0134(85)83007 5
   Domingo JL, 1995, MOL CELL BIOCHEM, V153, P233, DOI 10.1007/BF01075942
   Domingo JL, 2000, MOL CELL BIOCHEM, V203, P185, DOI 10.1023/A:1007067011338
   DONOFRIO F, 1994, FEBS LETT, V340, P269, DOI 10.1016/0014 5793(94)80152 5
   Eldar Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471 4914(01)02266 3
   Etcheverry S.B., 1998, Vanadium Compounds. Chemistry, Biochemistry, P270
   Etcheverry SB, 2002, J INORG BIOCHEM, V88, P94, DOI 10.1016/S0162 0134(01)00368 3
   Etcheverry SB, 1997, ARCH BIOCHEM BIOPHYS, V338, P7, DOI 10.1006/abbi.1996.9778
   Etcheverry SB, 2002, BIOMETALS, V15, P37, DOI 10.1023/A:1013183910203
   ETCHEVERRY SB, 1984, J INORG BIOCHEM, V20, P269, DOI 10.1016/0162 0134(84)85025 4
   Etcheverry SB, 2000, J INORG BIOCHEM, V80, P169, DOI 10.1016/S0162 0134(00)00026 X
   Evangelou AM, 2002, CRIT REV ONCOL HEMAT, V42, P249, DOI 10.1016/S1040 8428(01)00221 9
   Facchini DM, 2006, BONE, V38, P368, DOI 10.1016/j.bone.2005.08.015
   FANTUS IG, 1989, BIOCHEMISTRY US, V28, P8864, DOI 10.1021/bi00448a027
   FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235
   GOLDFINE AB, 1995, J CLIN ENDOCR METAB, V80, P3311, DOI 10.1210/jc.80.11.3311
   Gurlek A, 2001, CRIT REV EUKAR GENE, V11, P299, DOI 10.1615/CritRevEukarGeneExpr.v11.i4.30
   Hendy GN, 2005, HORM METAB RES, V37, P375, DOI 10.1055/s 2005 870152
   HEYLIGER CE, 1985, SCIENCE, V227, P1474, DOI 10.1126/science.3156405
   HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo 122 1 254
   HOPKINS LL, 1966, AM J PHYSIOL, V211, P169
   ITUARTE EA, 1989, CALCIFIED TISSUE INT, V45, P27, DOI 10.1007/BF02556657
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   KANO J, 1994, BIOCHEM BIOPH RES CO, V199, P271, DOI 10.1006/bbrc.1994.1224
   KATO Y, 1987, J CELL BIOL, V104, P311, DOI 10.1083/jcb.104.2.311
   Kawane T, 1999, ENDOCRINOLOGY, V140, P871, DOI 10.1210/en.140.2.871
   Kelly G S, 2000, Altern Med Rev, V5, P109
   Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200
   KOZAWA O, 1989, FEBS LETT, V243, P183, DOI 10.1016/0014 5793(89)80126 7
   Krejsa CM, 1997, J BIOL CHEM, V272, P11541
   LAU KHW, 1988, ENDOCRINOLOGY, V123, P2858, DOI 10.1210/endo 123 6 2858
   Leopardi P, 2005, TOXICOL LETT, V158, P39, DOI 10.1016/j.toxlet.2005.02.009
   Martínez Linares J, 2000, PROG T CHEM, V3, P3
   MOELLER K, 1991, J BONE MINER RES, V6, pS221
   Mohan S., 1991, CLIN ORTHOP RELAT R, V263, P30
   Molinuevo MS, 2004, CANCER CHEMOTH PHARM, V53, P163, DOI 10.1007/s00280 003 0708 7
   MONGOLD JJ, 1990, PHARMACOL TOXICOL, V67, P192, DOI 10.1111/j.1600 0773.1990.tb00812.x
   NARDA GE, 1992, Z NATURFORSCH B, V47, P395, DOI 10.1515/znb 1992 0316
   Nemsadze O D, 1977, Stomatologiia (Mosk), V56, P1
   NIELSEN FH, 1995, MET IONS BIOL SYST, V31, P543
   NODA M, 1986, BIOCHEM BIOPH RES CO, V140, P56, DOI 10.1016/0006 291X(86)91057 0
   OKADA T, 1994, J BIOL CHEM, V269, P3568
   Pandey SK, 1998, BIOCHEMISTRY US, V37, P7006, DOI 10.1021/bi9726786
   Pandey SK, 1995, MOL CELL BIOCHEM, V153, P69, DOI 10.1007/BF01075920
   PARTRIDGE NC, 1983, CANCER RES, V43, P4308
   PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024
   Poucheret P, 1998, MOL CELL BIOCHEM, V188, P73, DOI 10.1023/A:1006820522587
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   QUARLES LD, 1994, J CELL BIOCHEM, V56, P106, DOI 10.1002/jcb.240560115
   Quarles LD, 1997, J BONE MINER RES, V12, P393, DOI 10.1359/jbmr.1997.12.3.393
   RAISZ LG, 1983, NEW ENGL J MED, V309, P29, DOI 10.1056/NEJM198307073090107
   RAMANADHAM S, 1991, BIOL TRACE ELEM RES, V30, P119, DOI 10.1007/BF02990348
   Reddy SV, 2004, CRIT REV EUKAR GENE, V14, P255, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.20
   REHDER D, 1995, MET IONS BIOL SYST, V31, P1
   Rendell MS, 2000, ANN PHARMACOTHER, V34, P878
   Sakurai H, 2002, CHEM REC, V2, P237, DOI 10.1002/tcr.10029
   Setyawati IA, 1998, J APPL PHYSIOL, V84, P569, DOI 10.1152/jappl.1998.84.2.569
   Shechter Y., 1998, VANADIUM COMPOUNDS C, VVolume 711, P308
   SHISHEVA A, 1992, FEBS LETT, V300, P93, DOI 10.1016/0014 5793(92)80171 C
   SHISHEVA A, 1993, J BIOL CHEM, V268, P6463
   SIDDHANTI SR, 1995, ENDOCRINOLOGY, V136, P4834, DOI 10.1210/en.136.11.4834
   Srivastava AK, 2005, DIABETIC MED, V22, P2, DOI 10.1111/j.1464 5491.2004.01381.x
   STANKIEWICZ PJ, 1995, MET IONS BIOL SYST, V31, P287
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Suzuki A, 1998, BONE, V23, P197, DOI 10.1016/S8756 3282(98)00099 4
   Suzuki A, 2002, BONE, V30, P91, DOI 10.1016/S8756 3282(01)00660 3
   SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006 291X(82)90635 0
   Takeuchi Y, 1996, J BIOL CHEM, V271, P3938
   Thomas DM, 1996, J BONE MINER RES, V11, P1312
   Thomas DM, 1996, BIOCHEM BIOPH RES CO, V218, P789, DOI 10.1006/bbrc.1996.0140
   Thomas HC, 1996, J VIRAL HEPATITIS, V3, P1
   Thompson KH, 2003, J BIOL INORG CHEM, V8, P66, DOI 10.1007/s00775 002 0388 5
   THRAILKILL KM, 1995, BONE, V17, P307, DOI 10.1016/8756 3282(95)00223 Z
   TRACEY AS, 1986, P NATL ACAD SCI USA, V83, P609, DOI 10.1073/pnas.83.3.609
   TREMOLLIERES F, 1994, ANN ENDOCRINOL PARIS, V55, P95
   Tsiani E, 1997, AM J PHYSIOL CELL PH, V272, pC156, DOI 10.1152/ajpcell.1997.272.1.C156
   UTHUS EO, 1990, MAGNESIUM TRACE ELEM, V9, P219
   VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331
   Wang YZ, 2000, AM J RESP CELL MOL, V22, P590, DOI 10.1165/ajrcmb.22.5.3882
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Yeh GY, 2003, DIABETES CARE, V26, P1277, DOI 10.2337/diacare.26.4.1277
   YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107
   YUEN VG, 1993, CAN J PHYSIOL PHARM, V71, P263, DOI 10.1139/y93 041
   Zhang SQ, 2005, J INORG BIOCHEM, V99, P1064, DOI 10.1016/j.jinorgbio.2005.01.015
   Zhang Z, 2001, ARCH BIOCHEM BIOPHYS, V392, P311, DOI 10.1006/abbi.2001.2464
   Zhen XC, 1997, J BONE MINER RES, V12, P36, DOI 10.1359/jbmr.1997.12.1.36
NR 104
TC 61
Z9 68
U1 0
U2 22
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 0008 4212
EI 1205 7541
J9 CAN J PHYSIOL PHARM
JI Can. J. Physiol. Pharmacol.
PD JUL
PY 2006
VL 84
IS 7
BP 677
EP 686
DI 10.1139/Y06 022
PG 10
WC Pharmacology & Pharmacy; Physiology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Pharmacology & Pharmacy; Physiology
GA 087XF
UT WOS:000240775400004
PM 16998531
DA 2025 08 17
ER

PT J
AU Thouverey, C
   Caverzasio, J
AF Thouverey, Cyril
   Caverzasio, Joseph
TI The p38α MAPK positively regulates osteoblast function and postnatal
   bone acquisition
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE p38 alpha MAPK; Osteoblast; Bone formation; Postnatal
ID ACTIVATED PROTEIN KINASE; ALKALINE PHOSPHATASE ACTIVITY; MATRIX
   MINERALIZATION; PARATHYROID HORMONE; ANABOLIC THERAPIES; P38;
   STIMULATION; EXPRESSION; PHOSPHORYLATION; MECHANISMS
AB Bone continuously remodels throughout life by coordinated actions of osteoclasts and osteoblasts. Abnormalities in either osteoclast or osteoblast functions lead to bone disorders. The p38 MAPK pathway has been shown to be essential in controlling osteoblast differentiation and skeletogenesis. Although p38 alpha is the most abundant p38 member in osteoblasts, its specific individual contribution in regulating postnatal osteoblast activity and bone metabolism is unknown. To elucidate the specific role of p38 alpha in regulating osteoblast function and bone homeostasis, we generated mice lacking p38 alpha in differentiated osteoblasts. Osteoblast specific p38a knockout mice were of normal weight and size. Despite non significant bone alterations until 5 weeks of age, mutant mice demonstrated significant and progressive decrease in bone mineral density from that age. Adult mice deficient in p38a in osteoblasts displayed a striking reduction in cancellous bone volume at both axial and appendicular skeletal sites. At 6 months of age, trabecular bone volume was reduced by 62 % in those mice. Mutant mice also exhibited progressive decrease in cortical thickness of long bones. These abnormalities correlated with decreased endocortical and trabecular bone formation rate and reduced expressions of type 1 collagen, alkaline phosphatase, osteopontin and osteocalcin whereas bone resorption and osteoclasts remained unaffected. Finally, osteoblasts lacking p38 alpha showed impaired marker gene expressions and defective mineralization in vitro. These findings indicate that p38 alpha is an essential positive regulator of osteoblast function and postnatal bone formation in vivo.
C1 [Thouverey, Cyril; Caverzasio, Joseph] Univ Hosp Geneva, Serv Bone Dis, Dept Internal Med, CH 1205 Geneva, Switzerland.
C3 University of Geneva
RP Caverzasio, J (通讯作者)，Univ Hosp Geneva, Serv Bone Dis, Dept Internal Med, 64 Ave Roseraie, CH 1205 Geneva, Switzerland.
EM Cyril.Thouverey@unige.ch; joseph.caverzasio@unige.ch
OI Thouverey, Cyril/0000 0002 2741 1825
FU Swiss National Science Foundation [310030 127638]; Novartis Foundation
   (Basel, Switzerland); Swiss National Science Foundation (SNF)
   [310030_127638] Funding Source: Swiss National Science Foundation (SNF)
FX We would like to thank Sabina Troccaz and Pierre Apostolides for their
   expert technical assistance. We thank Professor Manolis Pasparakis for
   providing p38a<SUP>f/f</SUP> mice and Professor Thomas L. Clemens for
   Ocn Cre mice. This work was supported by the Swiss National Science
   Foundation (310030 127638) and by the Novartis Foundation (Basel,
   Switzerland).
CR Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097 2765(00)00012 5
   Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104
   Baek WY, 2009, J BONE MINER RES, V24, P1055, DOI [10.1359/JBMR.081248, 10.1359/jbmr.081248]
   Baron R, 2006, CURR TOP DEV BIOL, V76, P103, DOI 10.1016/S0070 2153(06)76004 5
   Bonnet N, 2009, J BIOL CHEM, V284, P35939, DOI 10.1074/jbc.M109.060335
   Canalis E, 2010, J CLIN ENDOCR METAB, V95, P1496, DOI 10.1210/jc.2009 2677
   Caverzasio J, 2008, J BONE MINER RES, V23, P1389, DOI 10.1359/JBMR.080410
   Caverzasio J, 2007, ENDOCRINOLOGY, V148, P5323, DOI 10.1210/en.2007 0520
   Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Fulzele K, 2010, CELL, V142, P309, DOI 10.1016/j.cell.2010.06.002
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Heinrichsdorff J, 2008, EMBO REP, V9, P1048, DOI 10.1038/embor.2008.149
   Ortuño MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Mbalaviele G, 2006, J PHARMACOL EXP THER, V317, P1044, DOI 10.1124/jpet.105.100362
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rey A, 2007, BONE, V41, P59, DOI 10.1016/j.bone.2007.02.031
   Richman C, 2001, J BONE MINER RES, V16, P386, DOI 10.1359/jbmr.2001.16.2.386
   Schieven GL, 2009, CURR TOP MED CHEM, V9, P1038, DOI 10.2174/156802609789630974
   Suzuki A, 1999, ENDOCRINOLOGY, V140, P3177, DOI 10.1210/en.140.7.3177
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Tan XH, 2007, J CELL SCI, V120, P2162, DOI 10.1242/jcs.03466
   Trivedi R, 2010, EXPERT OPIN INV DRUG, V19, P995, DOI 10.1517/13543784.2010.501077
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Whitehouse CA, 2010, P NATL ACAD SCI USA, V107, P12913, DOI 10.1073/pnas.0913058107
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092 8674(00)00211 7
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
   Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012
   Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238
   Zou WG, 2011, J CLIN INVEST, V121, P4383, DOI 10.1172/JCI59041
NR 38
TC 52
Z9 58
U1 2
U2 16
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420 682X
EI 1420 9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD SEP
PY 2012
VL 69
IS 18
BP 3115
EP 3125
DI 10.1007/s00018 012 0983 8
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 995VI
UT WOS:000308041500010
PM 22527716
OA Green Published
DA 2025 08 17
ER

PT J
AU Intini, G
   Nyman, JS
AF Intini, Giuseppe
   Nyman, Jeffry S.
TI Dkk1 haploinsufficiency requires expression of Bmp2 for bone anabolic
   activity
SO BONE
LA English
DT Article
DE Dkk1; Wnt signaling; Bmp2; BMP signaling; Bone homeostasis; Fracture
   healing
ID MORPHOGENETIC PROTEIN 2; NON UNIONS; SKELETAL DISORDERS; FRACTURE
   REPAIR; HEAD INDUCTION; PATHWAY; GROWTH; MOUSE; OSTEOBLASTS; GENE
AB Bone fractures remain a serious health burden and prevention and enhanced healing of fractures have been obtained by augmenting either BMP or Wnt signaling. However, whether BMP and Wnt signaling are both required or are self sufficient for anabolic and fracture healing activities has never been fully elucidated. Mice haploinsufficient for Dkk1 (Dkk1(+/ )) exhibit a high bone mass phenotype due to an up regulation of canonical Wnt signaling while mice lacking Bmp2 expression in the limbs (Bmp2(c/c);Prx1::cre) succumb to spontaneous fracture and are unable to initiate fracture healing; combined, these mice offer an opportunity to examine the requirement for activated BMP signaling on the anabolic and fracture healing activity of Wnts. When Okk1(+/ ) mice were crossed with Bmp2(c/c);Prx1::cre mice, the offspring bearing both genetic alterations were unable to increase bone mass and heal fractures, indicating that increased canonical Wnt signaling is unable to exploit its activity in absence of Bmp2. Thus, our data suggest that BMP signaling is required for Wnt mediated anabolic activity and that therapies aimed at preventing fractures and fostering fracture repair may need to target both pathways for maximal efficacy. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Intini, Giuseppe] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
   [Intini, Giuseppe] Harvard Stem Cell Inst, Boston, MA 02114 USA.
   [Nyman, Jeffry S.] Vanderbilt Univ, Med Ctr, Dept Orthopaed & Rehabil, Nashville, TN 37232 USA.
   [Nyman, Jeffry S.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN USA.
C3 Harvard University; Harvard School of Dental Medicine; Harvard
   University; Vanderbilt University; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); VA Tennessee Valley Healthcare
   System
RP Intini, G (通讯作者)，Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, 188 Longwood Ave,REB 403, Boston, MA 02115 USA.
EM Giuseppe_Intini@hsdm.harvard.edu
RI ; Nyman, Jeffry/L 5736 2013
OI Nyman, Jeffry/0000 0001 7403 7605; 
FU NIH/NIDCR [K99/R00 DE021069]; NIH/NIAMS [R01AR055904]
FX This project was supported by grant # K99/R00 DE021069 to Dr. Giuseppe
   Intini (NIH/NIDCR) and in part by, grant # R01AR055904 to Dr. Vicki
   Rosen (NIH/NIAMS) while Dr. Intini was a postdoctoral fellow in Dr.
   Rosen's laboratory at the Harvard School of Dental Medicine. Authors
   thank Dr. Vicki Rosen for releasing the data and permitting publication
   and the members of the Rosen's laboratory for their assistance and
   technical support during the execution of the studies. Authors also wish
   to acknowledge Dr. J. Robert Chang (OsteoInvent Inc., USA) for reviewing
   and editing the manuscript and for assisting with the interpretation and
   discussion of the results.
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   BESSHO K, 1993, ANN CHIR GYNAECOL FE, V82, P49
   Blokhuis TJ, 2013, INJURY, V44, pS40, DOI 10.1016/S0020 1383(13)70009 3
   Calori GM, 2008, INJURY, V39, P1391, DOI 10.1016/j.injury.2008.08.011
   Carreira AC, 2014, J DENT RES, V93, P335, DOI 10.1177/0022034513518561
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Chen Y, 2009, J CELL BIOCHEM, V106, P353, DOI 10.1002/jcb.22020
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   Dimitriou R, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 44
   Fernandez P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049010
   Fleet JC, 1996, ENDOCRINOLOGY, V137, P4605, DOI 10.1210/en.137.11.4605
   Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151
   Gamie Z, 2012, EXPERT OPIN INV DRUG, V21, P1523, DOI 10.1517/13543784.2012.713936
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Grotewold L, 1999, MECH DEVELOP, V89, P151, DOI 10.1016/S0925 4773(99)00194 X
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Kanakaris NK, 2008, INJURY, V39, pS83, DOI 10.1016/S0020 1383(08)70019 6
   Kloen P, 2002, J BONE JOINT SURG AM, V84A, P1909, DOI 10.2106/00004623 200211000 00001
   Komatsu DE, 2010, J ORTHOP RES, V28, P928, DOI 10.1002/jor.21078
   Kozloff KM, 2004, J BONE MINER RES, V19, P614, DOI 10.1359/JBMR.040111
   Kulkarni MM, 2011, CURR PROTOC MOL S94
   Kwong FNK, 2009, J ORTHOP RES, V27, P752, DOI 10.1002/jor.20794
   Li CY, 2011, BONE, V49, P1178, DOI 10.1016/j.bone.2011.08.012
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Li XD, 2011, J BONE MINER RES, V26, P2610, DOI 10.1002/jbmr.472
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Macsai CE, 2008, J CELL PHYSIOL, V215, P578, DOI 10.1002/jcp.21342
   Marvin MJ, 2001, GENE DEV, V15, P316, DOI 10.1101/gad.855501
   Matsumoto A, 2001, J PERIODONTAL RES, V36, P175, DOI 10.1034/j.1600 0765.2001.360306.x
   Meyer RA, 2001, J ORTHOP RES, V19, P428, DOI 10.1016/S0736 0266(00)90034 2
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534 5807(01)00041 7
   Payton JE, 2009, J CLIN INVEST, V119, P1714, DOI 10.1172/JCI38248
   Pogue R, 2006, CURR TOP DEV BIOL, V76, P1, DOI 10.1016/S0070 2153(06)76001 X
   Quek SI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045656
   Ronga M, 2013, INJURY, V44, pS34, DOI 10.1016/S0020 1383(13)70008 1
   Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   Styrkarsdottir U, 2003, PLOS BIOL, V1, P351, DOI 10.1371/journal.pbio.0000069
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Yang WC, 2013, J CELL SCI, V126, P4085, DOI 10.1242/jcs.118596
   Zanotti S, 2012, CALCIFIED TISSUE INT, V90, P69, DOI 10.1007/s00223 011 9541 x
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zimmermann G, 2007, UNFALLCHIRURG, V110, P931, DOI 10.1007/s00113 007 1347 y
NR 47
TC 10
Z9 10
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2015
VL 75
BP 151
EP 160
DI 10.1016/j.bone.2015.01.008
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CG1ZQ
UT WOS:000353075100021
PM 25603465
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Baek, JM
   Kim, JY
   Yoon, KH
   Oh, J
   Lee, MS
AF Baek, Jong Min
   Kim, Ju Young
   Yoon, Kwon Ha
   Oh, Jaemin
   Lee, Myeung Su
TI Ebselen Is a Potential Anti Osteoporosis Agent by Suppressing Receptor
   Activator of Nuclear Factor Kappa B Ligand Induced Osteoclast
   Differentiation In vitro and Lipopolysaccharide Induced
   Inflammatory Bone Destruction In vivo
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE Ebselen; Osteodast; Bone resorption; Osteoporosis
ID ORGANOSELENIUM COMPOUND; GLUTATHIONE PEROXIDASE; PARATHYROID HORMONE;
   KEY REGULATOR; FREE RADICALS; C FOS; RESORPTION; OSTEOPROTEGERIN; RANKL;
   PROSTAGLANDIN
AB Ebselen is a non toxic seleno organic drug with anti inflammatory and antioxidant properties that is currently being examined in clinical trials to prevent and treat various diseases, including atherosclerosis, stroke, and cancer. However, no reports are available for verifying the pharmacological effects of ebselen on major metabolic bone diseases such as osteoporosis. In this study, we observed that ebselen suppressed the formation of tartrate resistant acid phosphatase (TRAP)  positive multinucleated cells in an osteoblast/osteoclast co culture by regulating the ratio of receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin secreted by osteoblasts. In addition, ebselen treatment in the early stage of osteoclast differentiation inhibited RANKL dependent osteoclastogenesis by decreasing the phosphorylation of IKB, PI3K, and Akt in early signaling pathways and by subsequently inducing c Fos and nuclear factor of activated T cells cl. Further, ebselen induced apoptosis of osteoclasts in the late stage of osteoclast differentiation. In addition, ebselen treatment suppressed filamentous actin ring formation and bone resorption activity of mature osteoclasts. Reflecting these in vitro effects, administration of ebselen recovered bone loss and its p CT parameters in lipopolysaccharide mediated mouse model. Histological analysis confirmed that ebselen prevented trabecular bone matrix degradation and osteoclast formation in the bone tissues. Finally, it was proved that the anti osteoclastogenic action of ebselen is achieved through targeting N methyl D aspartate (NMDA) receptor. These results indicate that ebselen is a potentially safe drug for treating metabolic bone diseases such as osteoporosis.
C1 [Baek, Jong Min; Oh, Jaemin] Wonkwang Univ, Sch Med, Dept Anat, 460 Iksandae Ro, Iksan 570749, Jeonbuk, South Korea.
   [Kim, Ju Young; Yoon, Kwon Ha; Oh, Jaemin; Lee, Myeung Su] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, Iksan 570749, Jeonbuk, South Korea.
   [Yoon, Kwon Ha] Wonkwang Univ, Dept Radiol, Sch Med, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Myeung Su] Wonkwang Univ, Div Rheumatol, Dept Internal Med, Iksan 570749, Jeonbuk, South Korea.
   [Oh, Jaemin; Lee, Myeung Su] Wonkwang Univ, Inst Skeletal Dis, Iksan 570749, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University
RP Oh, J (通讯作者)，Wonkwang Univ, Sch Med, Dept Anat, 460 Iksandae Ro, Iksan 570749, Jeonbuk, South Korea.; Lee, MS (通讯作者)，Wonkwang Univ, Dept Internal Med, Sch Med, Div Rheumatol, 460 Iksandae Ro, Iksan 570749, Jeonbuk, South Korea.
EM jmoh@wku.ac.kr; ckhlms@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
FU Korean Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea [HI12C0110]
FX This study was supported by a grant from the Korean Health Technology
   R&D Project, Ministry of Health & Welfare, Republic of Korea
   (HI12C0110).
CR Baek JM, 2014, EVID BASED COMPL ALT, V2014
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bruunsgaard H, 2002, EUR CYTOKINE NETW, V13, P389
   Chew P, 2009, ARTERIOSCL THROM VAS, V29, P823, DOI 10.1161/ATVBAHA.109.186619
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Ginaldi Lia, 2005, Immun Ageing, V2, P14, DOI 10.1186/1742 4933 2 14
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   HAKEDA Y, 1991, Acta Anatomica Nipponica, V66, P215
   Hanavan PD, 2015, ONCOTARGET, V6, P18418, DOI 10.18632/oncotarget.4099
   Herin GA, 2001, J NEUROCHEM, V78, P1307, DOI 10.1046/j.1471 4159.2001.00517.x
   ISHIHARA Y, 1991, J PERIODONTAL RES, V26, P155, DOI 10.1111/j.1600 0765.1991.tb01639.x
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim JY, 2014, BONE, V60, P104, DOI 10.1016/j.bone.2013.12.013
   Kim JH, 2009, J IMMUNOL, V183, P1862, DOI 10.4049/jimmunol.0803007
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817
   Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Merle B, 2003, J CELL BIOCHEM, V90, P424, DOI 10.1002/jcb.10625
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Mukherjee S, 2014, ACS CHEM BIOL, V9, P2393, DOI 10.1021/cb500512z
   MULLER A, 1984, BIOCHEM PHARMACOL, V33, P3235, DOI 10.1016/0006 2952(84)90083 2
   Müller B, 2002, CYTOKINE, V18, P334, DOI 10.1006/cyto.2002.0882
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   ORCEL P, 1993, AM J PHYSIOL, V264, pE391, DOI 10.1152/ajpendo.1993.264.3.E391
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9
   Sakuma Y, 2000, INFECT IMMUN, V68, P6819, DOI 10.1128/IAI.68.12.6819 6825.2000
   Saluk J, 2013, BIOORG CHEM, V50, P26, DOI 10.1016/j.bioorg.2013.07.003
   Schneeweis LA, 2005, J BIOL CHEM, V280, P41155, DOI 10.1074/jbc.M506366200
   Shalhoub V, 1999, J CELL BIOCHEM, V72, P251
   Singh N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2320
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tewari R, 2009, MOL ONCOL, V3, P77, DOI 10.1016/j.molonc.2008.10.004
   Tung S, 2007, ANN NY ACAD SCI, V1116, P499, DOI 10.1196/annals.1402.080
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   VAANANEN HK, 1995, J CELL SCI, V108, P2729
   WENDEL A, 1984, BIOCHEM PHARMACOL, V33, P3241, DOI 10.1016/0006 2952(84)90084 4
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yi T, 2008, J CELL PHYSIOL, V217, P409, DOI 10.1002/jcp.21511
   Yoshizumi M, 2002, BRIT J PHARMACOL, V136, P1023, DOI 10.1038/sj.bjp.0704808
NR 45
TC 31
Z9 34
U1 0
U2 22
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2016
VL 12
IS 5
BP 478
EP 488
DI 10.7150/ijbs.13815
PG 11
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA DF9VD
UT WOS:000371709100001
PM 27019631
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Maheshwari, S
   Singh, A
   Verma, A
AF Maheshwari, Shubhrat
   Singh, Aditya
   Verma, Amita
TI Ferroptosis: A Frontier in Osteoporosis
SO HORMONE AND METABOLIC RESEARCH
LA English
DT Article
DE osteoclasts; postmenopausal osteoporosis; osteoblasts; pathophysiology;
   ferroptosis
AB Reduced bone mass and degeneration of the microarchitecture of bone tissue are the hallmarks of osteoporosis, a bone metabolic disease that increases skeletal fragility and fracture susceptibility. Osteoporosis is primarily caused by unbalanced bone remodeling, in which bone synthesis is outpaced by bone resorption caused by osteoclasts. Along with the bone building vitamins calcium and vitamin D, typical medications for treating osteoporosis include bisphosphonates and calcitonin. The present therapies effectively stop osteoclast activation that is too high, however they come with varying degrees of negative effects. Numerous factors can contribute to osteoporosis, which is characterized by a loss of bone mass and density due to the deterioration of the bone's microstructure, which makes the bone more fragile. As a result, it is a systemic bone condition that makes patients more likely to fracture. Interest in the function of ferroptosis in the pathophysiology of osteoporosis is developing. In this review, we go through the shape of the cell, the fundamental mechanisms of ferroptosis, the relationship between osteoclasts and osteoblasts, the association between ferroptosis and diabetic osteoporosis, steroid induced osteoporosis, and the relationship between ferroptosis and postmenopausal osteoporosis. The functions of ferroptosis and osteoporosis in cellular function, signaling cascades, pharmacological inhibition, and gene silencing have been better understood thanks to recent advances in biomedical research.
C1 [Maheshwari, Shubhrat; Verma, Amita] Sam Higginbottom Univ Agr Technol & Sci, Dept Pharmaceut Sci, Bioorgan & Med Chem Res Lab, Prayagraj, India.
   [Maheshwari, Shubhrat] Rama Univ, Fac Pharmaceut Sci, Bithoor Rd, Kanpur 209217, Uttar Pradesh, India.
   [Singh, Aditya] Integral Univ, Fac Pharm, Lucknow, Uttar Pradesh, India.
C3 Sam Higginbottom University of Agriculture, Technology & Sciences; Rama
   University; Integral University
RP Maheshwari, S (通讯作者)，Rama Univ, Fac Pharmaceut Sci, Bithoor Rd, Kanpur 209217, Uttar Pradesh, India.
EM shubhrat.maheshwari@gmail.com
CR Al Hetty HRAK, 2023, J MEMBRANE BIOL, V256, P223, DOI 10.1007/s00232 023 00282 0
   Cao FF, 2022, ACS NANO, V16, P855, DOI 10.1021/acsnano.1c08464
   Chang SY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.955069
   Chen JY, 2022, CELL DEATH DIFFER, V29, P467, DOI 10.1038/s41418 022 00941 0
   Chen Q, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23168997
   Chen X, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 34096 w
   Cheng Ying, 2021, Oxid Med Cell Longev, V2021, P5005136, DOI 10.1155/2021/5005136
   Cui JW, 2022, ECOTOX ENVIRON SAFE, V242, DOI 10.1016/j.ecoenv.2022.113944
   Forcina GC, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2118646119
   Gao L, 2022, CELLS BASEL, V11, DOI 10.3390/cells11192979
   Guo Z, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1199951
   Han T, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 31541 8
   Hassannia B, 2021, ANTIOXID REDOX SIGN, V35, P487, DOI 10.1089/ars.2020.8175
   He Q, 2023, BIOMED PHARMACOTHER, V157, DOI 10.1016/j.biopha.2022.113915
   Hu WL, 2022, CELLS BASEL, V11, DOI 10.3390/cells11132040
   Jo A, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04660 9
   Koppula P, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 29905 1
   Lei G, 2022, NAT REV CANCER, V22, P381, DOI 10.1038/s41568 022 00459 0
   Lei G, 2021, ONCOGENE, V40, P3533, DOI 10.1038/s41388 021 01790 w
   Lei JW, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00231
   Li JH, 2022, CELL BIOSCI, V12, DOI 10.1186/s13578 022 00807 5
   Li M., 2023, Zhongguo Zuzhi Gongcheng Yanjiu, V27, P2723
   Li Y, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15111432
   Li Y, 2022, PHARMACOL THERAPEUT, V238, DOI 10.1016/j.pharmthera.2022.108174
   Li ZP, 2022, NAT CHEM BIOL, V18, P751, DOI 10.1038/s41589 022 01033 3
   Liang DG, 2022, MOL CELL, V82, P2215, DOI 10.1016/j.molcel.2022.03.022
   Lil N, 2022, INT J BIOL SCI, V18, P4118, DOI 10.7150/ijbs.72528
   Liu HL, 2022, CELLS BASEL, V11, DOI 10.3390/cells11213430
   Liu J, 2022, FEBS J, V289, P7038, DOI 10.1111/febs.16059
   Liu J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 20904 2
   Liu L, 2021, CELL BIOL INT, V45, P422, DOI 10.1002/cbin.11505
   Liu YQ, 2022, CELL DEATH DIFFER, V29, P895, DOI 10.1038/s41418 022 00943 y
   Lu JS, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 52513 x
   Luo HS, 2021, EXP THER MED, V21, DOI 10.3892/etm.2020.9504
   Lv M, 2022, INFLAMM RES, V71, P461, DOI 10.1007/s00011 022 01547 5
   Lv ZY, 2022, EBIOMEDICINE, V84, DOI 10.1016/j.ebiom.2022.104258
   Maheshwari S, 2023, HORM METAB RES, V55, P819, DOI 10.1055/a 2084 3561
   Distéfano AM, 2022, BIOCHEM J, V479, P857, DOI 10.1042/BCJ20210682
   Miao RY, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419 023 05708 0
   Miao Y, 2022, EBIOMEDICINE, V76, DOI 10.1016/j.ebiom.2022.103847
   Mishima E, 2022, NATURE, V608, P778, DOI 10.1038/s41586 022 05022 3
   Musheshe N, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11020314
   Niu X., 2022, FERROPTOSIS NECROPTO
   Pan WL, 2022, BIOMATERIALS, V283, DOI 10.1016/j.biomaterials.2022.121449
   Plascencia Villa G., 2020, ALZHEIMERS DEMENT, V16
   Qiu YM, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104919
   Reichert CO, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228765
   Riegger J, 2022, EBIOMEDICINE, V84, DOI 10.1016/j.ebiom.2022.104279
   Rogers JT, 2020, LEARN MEMORY, V27, P395, DOI 10.1101/lm.052282.120
   Shan K, 2022, EUR J NUTR, V61, P4059, DOI 10.1007/s00394 022 02940 w
   Stockwell BR, 2022, CELL, V185, P2401, DOI 10.1016/j.cell.2022.06.003
   Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021
   Sun WJ, 2022, INT J GEN MED, V15, P253, DOI 10.2147/IJGM.S343046
   Sun YR, 2023, AGEING RES REV, V87, DOI 10.1016/j.arr.2023.101899
   Tan YW, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04764 2
   Tang MZ, 2018, J CELL PHYSIOL, V233, P9179, DOI 10.1002/jcp.26954
   Vitalakumar D, 2021, J BIOCHEM MOL TOXIC, V35, DOI 10.1002/jbt.22830
   Wan YP, 2023, FREE RADICAL BIO MED, V196, P108, DOI 10.1016/j.freeradbiomed.2023.01.006
   Wang SF, 2019, CHINESE CHEM LETT, V30, P847, DOI 10.1016/j.cclet.2019.03.025
   Wang WJ, 2022, ANGEW CHEM INT EDIT, V61, DOI 10.1002/anie.202115247
   Wang X., 2022, BREAST CANCER RES TR, V1, P1
   Wang XZ, 2022, CHEM BIOL INTERACT, V366, DOI 10.1016/j.cbi.2022.110148
   Wang YL, 2022, CELL DEATH DIFFER, V29, P1982, DOI 10.1038/s41418 022 00990 5
   Weiland A, 2019, MOL NEUROBIOL, V56, P4880, DOI 10.1007/s12035 018 1403 3
   Wu L., 2023, MOL NEUROBIOL, P1
   Xie Z, 2023, BIOCHEM PHARMACOL, V207, DOI 10.1016/j.bcp.2022.115374
   Xin S, 2022, CELL DEATH DIFFER, V29, P670, DOI 10.1038/s41418 021 00883 z
   Xiong Z., 2023, CHIN J TISSUE ENG RE, V27, P5884
   Xu GR, 2023, NAT PROD COMMUN, V18, DOI 10.1177/1934578X231194837
   Xu W., 2023, Ferroptosis plays a role in human chondrocyte of osteoarthritis induced by IL 1Beta in vitro Cartilage
   Xu W., 2023, RES SQUARE, DOI [10.21203/rs.3.rs 2712369/v1, DOI 10.21203/RS.3.RS 2712369/V1]
   Yan HF, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 020 00428 9
   Yang J, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.789948
   Yuan SY, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13158
   Zhang Y, 2021, OSTEOARTHR CARTILAGE, V29, P1324, DOI 10.1016/j.joca.2021.06.010
   Zhou LP, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1042060
   Zhou M, 2023, J IMMUNOL RES, V2023, DOI 10.1155/2023/2061071
   Zhou X., 2023, MEDIAT INFLAMM
   Zhou XM, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13134
NR 79
TC 3
Z9 3
U1 3
U2 27
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D 70469 STUTTGART, GERMANY
SN 0018 5043
EI 1439 4286
J9 HORM METAB RES
JI Horm. Metab. Res.
PD SEP
PY 2024
VL 56
IS 09
BP 625
EP 632
DI 10.1055/a 2230 2664
EA FEB 2024
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA E6R1L
UT WOS:001156443800002
PM 38307092
DA 2025 08 17
ER

PT J
AU Ma, CY
   Xu, K
   Meng, JH
   Ran, JS
   Moqbel, SAA
   Liu, A
   Yan, SG
   Wu, LD
AF Ma, Chiyuan
   Xu, Kai
   Meng, Jiahong
   Ran, Jisheng
   Moqbel, Safwat Adel Abdo
   Liu, An
   Yan, Shigui
   Wu, Lidong
TI Tectorigenin inhibits RANKL induced osteoclastogenesis via suppression
   of NF κB signalling and decreases bone loss in ovariectomized C57BL/6
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE NF kappa B; osteoclast; osteoporosis; tectorigenin
ID OVARIAN CANCER; OSTEOPOROSIS; DIFFERENTIATION; MECHANISMS; PATHWAY;
   BISPHOSPHONATES; ACTIVATION; OSTEOLYSIS; FRACTURES; CELLS
AB Metabolism of bone is regulated by the balance between osteoblast mediated bone formation and osteoclast mediated bone resorption. Activation of osteoclasts could lead to osteoporosis. Thus, inhibiting the activity of osteoclasts becomes an available strategy for the treatment of osteoporosis. Tectorigenin is an extract of Belamcanda chinensis In the present study, the anti osteoclastogenesis effects of tectorigenin were investigated in vitro and in vivo. The results showed preventive and therapeutic effects of tectorigenin at concentrations of 0, 10, 40, and 80 mu mol/L in the maturation and activation of osteoclasts. A signalling study also indicated that tectorigenin treatment reduces activation of NF kappa B signalling in osteoclastogenesis. Animal experiment demonstrated that tectorigenin treatment (1 10 mg/kg, abdominal injection every 3 days) significantly inhibits bone loss in ovariectomized C57BL/6. Our data suggest that tectorigenin is a potential pharmacological choice for osteoporosis.
C1 [Ma, Chiyuan; Xu, Kai; Meng, Jiahong; Ran, Jisheng; Moqbel, Safwat Adel Abdo; Liu, An; Yan, Shigui; Wu, Lidong] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Orthopaed Surg, 88th Jiefang Rd, Hangzhou 310000, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Wu, LD (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Orthopaed Surg, 88th Jiefang Rd, Hangzhou 310000, Zhejiang, Peoples R China.
EM wulidong@zju.edu.cn
OI Wu, Lidong/0000 0002 2561 6069
FU National Natural Science Foundation of China [81572173, 81371996,
   81401824]; Natural Science Foundation of Zhejiang Province [Y14H060014,
   Y17H060027]
FX This study is funded by National Natural Science Foundation of China
   (NO. 81572173, 81371996, 81401824) and Natural Science Foundation of
   Zhejiang Province (NO. Y14H060014, Y17H060027).
CR Adapala NS, 2014, BONE, V67, P1, DOI 10.1016/j.bone.2014.06.013
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cauley JA, 2013, J GERONTOL A BIOL, V68, P1243, DOI 10.1093/gerona/glt093
   Cicek M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017522
   Dominguez LJ, 2011, BIOGERONTOLOGY, V12, P397, DOI 10.1007/s10522 011 9344 5
   Henriksen K, 2011, WOMENS HEALTH, V7, P689, DOI [10.2217/whe.11.74, 10.2217/WHE.11.74]
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   KANNUS P, 1995, LANCET, V346, P50, DOI 10.1016/S0140 6736(95)92679 8
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lacey JV, 2002, JAMA J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334
   Li QY, 2015, PHARM BIOL, V53, P1567, DOI 10.3109/13880209.2014.993038
   Lin TH, 2014, ACTA BIOMATER, V10, P1, DOI 10.1016/j.actbio.2013.09.034
   Masud T, 2003, AGING CLIN EXP RES, V15, P89
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Pan CH, 2008, ARCH PHARM RES, V31, P1447, DOI 10.1007/s12272 001 2129 7
   Proff P, 2009, CLIN ORAL INVEST, V13, P355, DOI 10.1007/s00784 009 0268 2
   Qin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034132
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Rejnmark L, 2011, CURR DRUG SAF, V6, P75, DOI 10.2174/157488611795684686
   Ren LR, 2017, MED SCI MONITOR, V23, P4579, DOI 10.12659/MSM.903371
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Wang CL, 2017, BIOL OPEN, V6, P1130, DOI 10.1242/bio.024562
   Wang Q, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0066417, 10.1371/journal.pone.0068894]
   Yang YI, 2012, CARCINOGENESIS, V33, P2488, DOI 10.1093/carcin/bgs302
   Zeng R, 2015, J BONE MINER RES, V30, P2287, DOI 10.1002/jbmr.2584
   Zeng XZ, 2017, BIOCHEM PHARMACOL, V124, P57, DOI 10.1016/j.bcp.2016.10.007
   Zhai ZJ, 2014, BIOMATERIALS, V35, P6299, DOI 10.1016/j.biomaterials.2014.04.044
NR 29
TC 13
Z9 13
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD OCT
PY 2018
VL 22
IS 10
BP 5121
EP 5131
DI 10.1111/jcmm.13801
PG 11
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA GU8TX
UT WOS:000445616300049
PM 30063119
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Dell'Aquila, E
   Armento, G
   Iuliani, M
   Simonetti, S
   D'Onofrio, L
   Zeppola, T
   Madaudo, C
   Russano, M
   Citarella, F
   Ribelli, G
   Pantano, F
   Vincenzi, B
   Tonini, G
   Santini, D
AF Dell'Aquila, Emanuela
   Armento, Grazia
   Iuliani, Michele
   Simonetti, Sonia
   D'Onofrio, Loretta
   Zeppola, Tea
   Madaudo, Cristina
   Russano, Marco
   Citarella, Fabrizio
   Ribelli, Giulia
   Pantano, Francesco
   Vincenzi, Bruno
   Tonini, Giuseppe
   Santini, Daniele
TI Denosumab for cancer related bone loss
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE Cancer treatment induced bone loss (CTLIB); denosumab; bone health;
   osteoporosis
ID GIANT CELL TUMOR; ANDROGEN DEPRIVATION THERAPY; ADVANCED BREAST CANCER;
   RANDOMIZED CONTROLLED TRIAL; FRACTURE RISK REDUCTION; ZOLEDRONIC ACID;
   MINERAL DENSITY; PROSTATE CANCER; POSTMENOPAUSAL WOMEN; DOUBLE BLIND
AB Introduction Prolonged use of anti cancer treatments in breast and prostate tumors alters physiological bone turnover leading to adverse skeletal related events, such as osteoporosis, loss of bone mass, and increased risk of fractures. These complications known as cancer treatment induced bone loss (CTIBL) should be managed with bone targeting agents such as the bisphosphonates and denosumab. The latter is a monoclonal antibody against the receptor activator of nuclear factor kB ligand (RANKL) that suppresses osteoclasts function and survival increasing bone mass. Areas covered This review will focus on the mechanisms associated with bone loss induced by cancer treatments and the most recent evidence about the use of denosumab as preventive and therapeutic strategy to protect bone health. Moreover, we will discuss several key aspects regarding the clinical practical use of denosumab to optimize the management of CTLIB in breast and prostate cancer. Expert opinion Denosumab treatment strongly prevents cancer therapies related skeletal issues in breast and prostate cancer with a good safety profile. Adjuvant six monthly denosumab delays the time to first fracture onset in early stage breast cancer patients with normal or altered bone mineral density (BMD). Similarly, denosumab treatment is able to prevent fractures and BMD loss in nonmetastatic prostate cancer patients.
C1 [Dell'Aquila, Emanuela; Armento, Grazia; Iuliani, Michele; Simonetti, Sonia; D'Onofrio, Loretta; Zeppola, Tea; Madaudo, Cristina; Russano, Marco; Citarella, Fabrizio; Ribelli, Giulia; Pantano, Francesco; Vincenzi, Bruno; Tonini, Giuseppe; Santini, Daniele] Campus Biomed Univ Rome, Dept Med Oncol, I 00128 Rome, Italy.
C3 University Campus Bio Medico   Rome Italy
RP Iuliani, M (通讯作者)，Campus Biomed Univ Rome, Dept Med Oncol, I 00128 Rome, Italy.
EM m.iuliani@unicampus.it
RI ; Pantano, Francesco/D 8459 2012; Dell'Aquila, Emanuela/HZI 5685 2023;
   D'Onofrio, Loretta/AAC 5131 2022; Citarella, Fabrizio/NSU 3976 2025
OI Dell'Aquila, Emanuela/0000 0002 7258 1364; Madaudo,
   Cristina/0000 0002 9151 4335; Pantano, Francesco/0000 0002 2894 9686;
   Citarella, Fabrizio/0000 0003 3096 4452; 
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Adler RA, 2016, J BONE MINER RES, V31, P1910, DOI 10.1002/jbmr.2918
   Alibhai SMH, 2013, OSTEOPOROSIS INT, V24, P2571, DOI 10.1007/s00198 013 2343 4
   Amir E, 2011, JNCI J NATL CANCER I, V103, P1299, DOI 10.1093/jnci/djr242
   Anagnostis P, 2017, MATURITAS, V101, P23, DOI 10.1016/j.maturitas.2017.04.008
   Anastasilakis AD, 2016, OSTEOPOROSIS INT, V27, P1929, DOI 10.1007/s00198 015 3459 5
   Anastasilakis AD, 2017, EUR J ENDOCRINOL, V176, P677, DOI 10.1530/EJE 16 1027
   [Anonymous], 2015, Lancet, V386
   Aspenberg P, 2014, ACTA ORTHOP, V85, P1, DOI 10.3109/17453674.2013.859423
   Atkinson EG, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10186
   Aubry Rozier B, 2016, OSTEOPOROSIS INT, V27, P1923, DOI 10.1007/s00198 015 3380 y
   Axelsen CT, 2018, MOL CLIN ONCOL, V8, P767, DOI 10.3892/mco.2018.1615
   Barrett Lee P, 2014, LANCET ONCOL, V15, pE52
   Beebe Dimmer JL, 2009, RARE TUMORS, V1, DOI 10.4081/rt.2009.e52
   Bilezikian JP, 2019, OSTEOPOROSIS INT, V30, P1855, DOI 10.1007/s00198 019 05020 8
   Black DM, 2012, J BONE MINER RES, V27, P2612, DOI 10.1002/jbmr.1744
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI DOI 10.1056/NEJMOA067312
   Body JJ, 2007, OSTEOPOROSIS INT, V18, P1439, DOI 10.1007/s00198 007 0439 4
   Body JJ, 2016, CANCER TREAT REV, V51, P46, DOI 10.1016/j.ctrv.2016.10.004
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Bray F, 2018, CA CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Brown JP, 2013, J BONE MINER RES, V28, P746, DOI 10.1002/jbmr.1808
   Carmeliet G, 2015, BEST PRACT RES CL EN, V29, P621, DOI 10.1016/j.beem.2015.06.001
   Cenci S, 2001, J CLIN INVEST, V06
   Chakarun CJ, 2013, RADIOGRAPHICS, V33, P197, DOI 10.1148/rg.331125089
   Chawla S, 2019, LANCET ONCOL, V20, P1719, DOI 10.1016/S1470 2045(19)30663 1
   Cheung A. S., 2014, ENDOCRINE RELATED CA, V21, pR371
   Cho H, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011470
   Chu GCY, 2014, CANCER METAST REV, V33, P497, DOI 10.1007/s10555 013 9488 7
   Ciucci T, 2015, GUT, V64, P1072, DOI 10.1136/gutjnl 2014 306947
   Clarke BL, 2009, STEROIDS, V74, P296, DOI 10.1016/j.steroids.2008.10.003
   Cleeland CS, 2013, CANCER AM CANCER SOC, V119, P832, DOI 10.1002/cncr.27789
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coleman RE, 2018, J BONE ONCOL, V13, P123, DOI 10.1016/j.jbo.2018.09.008
   Coleman R, 2020, LANCET ONCOL, V21, P60, DOI 10.1016/S1470 2045(19)30687 4
   Coleman RE, 2007, LANCET ONCOL, V8, P119, DOI 10.1016/S1470 2045(07)70003 7
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Compston J, 2014, MATURITAS, V77, P195, DOI 10.1016/j.maturitas.2013.11.004
   Cosman F, 2015, OSTEOPOROSIS INT, V26, P2045, DOI 10.1007/s00198 015 3037 x
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Cummings SR, 2009, NEW ENGL J MED, V361, P1914
   D'Oronzo S, 2015, CANCER TREAT REV, V41, P798, DOI 10.1016/j.ctrv.2015.09.003
   De Oliveira DHA, 2012, MINERVA ENDOCRINOL, V37, P305
   Delgado Calle J, 2016, CANCER RES, V76, P1089, DOI 10.1158/0008 5472.CAN 15 1703
   DeSantis CE, 2019, CA CANCER J CLIN, V69, P211, DOI 10.3322/caac.21555
   Doria C, 2016, CLIN CASES MINER BON, V13, P195, DOI 10.11138/ccmbm/2016.13.3.195
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Ellis GK, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.546
   Emerton KB, 2010, BONE, V46, P577, DOI 10.1016/j.bone.2009.11.006
   Eriksen EF, 1999, J BONE MINER RES, V14, P1217, DOI 10.1359/jbmr.1999.14.7.1217
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Ettinger B, 2010, OSTEOPOROSIS INT, V21, P25, DOI 10.1007/s00198 009 1032 9
   Felsenfeld A, 2013, CURR OPIN NEPHROL HY, V22, P371, DOI 10.1097/MNH.0b013e328362141e
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fleurence RL, 2006, OSTEOPOROSIS INT, V17, P29, DOI 10.1007/s00198 005 1943 z
   Galvano A, 2019, J BONE ONCOL, V18, DOI 10.1016/j.jbo.2019.100252
   GARNICK MB, 1984, NEW ENGL J MED, V311, P1281
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Gluhak Heinrich J, 2003, J BONE MINER RES, V18, P807, DOI 10.1359/jbmr.2003.18.5.807
   Gnant M, 2015, LANCET, V386, P433, DOI 10.1016/S0140 6736(15)60995 3
   Gonzalez Rodriguez Elena, 2019, Rev Med Suisse, V15, P831
   Gossiel F, 2016, BONE, V92, P94, DOI 10.1016/j.bone.2016.08.010
   Greenspan SL, 2008, J CLIN ONCOL, V26, P4426, DOI 10.1200/JCO.2007.15.1233
   Greep NC, 2003, AM J MED, V114, P653, DOI 10.1016/S0002 9343(03)00127 X
   Guida L, 2018, TRATTAMENTO METASTAS
   Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11 10 1121
   Hadji P, 2017, J BONE ONCOL, V7, P1, DOI 10.1016/j.jbo.2017.03.001
   Hamilton EJ, 2010, J CLIN ENDOCRINOL ME, V95, pE456, DOI 10.1210/jc.2010 0902
   Henneman ZJ, 2008, J BIOMED MATER RES A, V85A, P993, DOI 10.1002/jbm.a.31599
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hershman DL, 2008, J CLIN ONCOL, V26, P4739, DOI 10.1200/JCO.2008.16.4707
   Hershman DL, 2016, JAMA ONCOL, V2, P453, DOI 10.1001/jamaoncol.2015.4655
   Higgs J, 2017, EFORT OPEN REV, V2, P300, DOI 10.1302/2058 5241.2.160079
   Hiligsmann M, 2012, VALUE HEALTH, V15, P604, DOI 10.1016/j.jval.2012.02.001
   Huber DM, 2001, ENDOCRINOLOGY, V142, P3800, DOI 10.1210/en.142.9.3800
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Hussain M, 2013, NEW ENGL J MED, V368, P1314, DOI 10.1056/NEJMoa1212299
   Inanir A, 2004, J INT MED RES, V32, P570, DOI 10.1177/147323000403200602
   Jo VY, 2014, PATHOLOGY, V46, P95, DOI 10.1097/PAT.0000000000000050
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Kanis JA, 2007, OSTEOPOROSIS INT, V18, P1033, DOI 10.1007/s00198 007 0343 y
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P737, DOI 10.1007/s00198 004 1734 y
   Kanis JA, 2010, OSTEOPOROS INT S2, V21, pS407
   Kanis JA., 2007, WHO Technical Report: Assessment of Osteoporosis at the Primary Health care Level, P66
   Kanis JA, 2012, CALCIFIED TISSUE INT, V90, P1, DOI 10.1007/s00223 011 9544 7
   Kasperk CH, 1997, J BONE MINER RES, V12, P464, DOI 10.1359/jbmr.1997.12.3.464
   Khow KSF, 2015, J BONE MINER METAB, V33, P355, DOI 10.1007/s00774 014 0606 6
   Khundmiri SJ, 2016, COMPR PHYSIOL, V6, P561, DOI 10.1002/cphy.c140071
   Kim SH, 2017, SCI REP UK, V7, DOI 10.1038/srep39562
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kyvernitakis I, 2014, J CANCER RES CLIN, V140, P1671, DOI 10.1007/s00432 014 1726 z
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lamy O, 2017, J CLIN ENDOCR METAB, V102, P354, DOI 10.1210/jc.2016 3170
   Leder BZ, 2009, J CLIN ENDOCR METAB, V94, P2915, DOI 10.1210/jc.2008 2630
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Loblaw DA, 2007, J CLIN ONCOL, V25, P1596, DOI 10.1200/JCO.2006.10.1949
   López Pousa A, 2015, CLIN TRANSL ONCOL, V17, P419, DOI 10.1007/s12094 014 1268 5
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Martin M, 2012, CLIN CANCER RES, V18, P4841, DOI 10.1158/1078 0432.CCR 11 3310
   McClung MR, 2016, OSTEOPOROSIS INT, V27, P1677, DOI 10.1007/s00198 016 3553 3
   McClung M.R., 2006, NEW ENGL J MED, V354, P821, DOI DOI 10.1056/NEJMOA044459
   McCune Jeannine S, 2005, J Oncol Pharm Pract, V11, P37, DOI 10.1191/1078155205jp144oa
   Michaelson MD, 2007, J CLIN ONCOL, V25, P1038, DOI 10.1200/JCO.2006.07.3361
   Morote J, 2006, J UROLOGY, V175, P1679, DOI 10.1016/S0022 5347(05)00999 7
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Naylor KE, 2010, BONE, V46, P592, DOI 10.1016/j.bone.2009.10.043
   Ng VY, 2014, EXPERT REV ANTICANC, V14, P783, DOI 10.1586/14737140.2014.901891
   Pacifici R, 2010, BONE, V47, P461, DOI 10.1016/j.bone.2010.04.611
   Palmqvist P, 2006, J BIOL CHEM, V281, P2414, DOI 10.1074/jbc.M510160200
   Pelekanou V, 2016, J LEUKOCYTE BIOL, V99, P333, DOI 10.1189/jlb.3A0914 430RR
   Polyzos SA, 2016, ENDOCRINE, V51, P4, DOI 10.1007/s12020 015 0803 7
   Popp AW, 2016, OSTEOPOROSIS INT, V27, P1917, DOI 10.1007/s00198 015 3458 6
   Pouillès JM, 2001, OSTEOPOROSIS INT, V12, P71, DOI 10.1007/s001980170160
   Poulsen MH, 2014, SCAND J UROL, V48, P350, DOI 10.3109/21681805.2014.884160
   Prince R, 2005, J BONE MINER RES, V20, P1507, DOI 10.1359/JBMR.050501
   Qi HL, 2003, P NATL ACAD SCI USA, V100, P3305, DOI 10.1073/pnas.0532693100
   Rabaglio M, 2009, ANN ONCOL, V20, P1489, DOI 10.1093/annonc/mdp033
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470 2045(18)30072 X
   Raphael I, 2015, CYTOKINE, V74, P5, DOI 10.1016/j.cyto.2014.09.011
   Raskin KA, 2013, J AM ACAD ORTHOP SUR, V21, P118, DOI 10.5435/JAAOS 21 02 118
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003 4819 114 11 919
   Rutkowski P, 2015, ANN SURG ONCOL, V22, P2860, DOI 10.1245/s10434 015 4634 9
   Ryan CW, 2006, J UROLOGY, V176, P972, DOI 10.1016/j.juro.2006.04.078
   Saad F, 2016, LANCET ONCOL, V17, P1306, DOI 10.1016/S1470 2045(16)30173 5
   Saarto T, 1997, J CLIN ONCOL, V15, P1341, DOI 10.1200/JCO.1997.15.4.1341
   Santini D, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen 2019 000652
   Schilcher J, 2014, ACTA ORTHOP, V85, P6, DOI 10.3109/17453674.2014.885355
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Shapiro CL, 2019, J CLIN ONCOL, V37, P2916, DOI 10.1200/JCO.19.01696
   Shapiro CL, 2001, J CLIN ONCOL, V19, P3306, DOI 10.1200/JCO.2001.19.14.3306
   Sharifi N, 2005, JAMA J AM MED ASSOC, V294, P238, DOI 10.1001/jama.294.2.238
   Shea B, 2002, ENDOCR REV, V23, P552, DOI 10.1210/er.2001 7002
   Shea BJ, 2017, BMJ BRIT MED J, V358, DOI 10.1136/bmj.j4008
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Smith MR, 2011, J BONE MINER RES, V26, P2827, DOI 10.1002/jbmr.492
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Smith MR, 2005, J CLIN ONCOL, V23, P7897, DOI 10.1200/JCO.2004.00.6908
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Smith MR, 2001, NEW ENGL J MED, V345, P948, DOI 10.1056/NEJMoa010845
   Solling ASK, 2016, OSTEOPOROSIS INT, V27, P2383, DOI 10.1007/s00198 016 3535 5
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Stumpf U, 2020, J BONE ONCOL, V22, DOI 10.1016/j.jbo.2020.100292
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   van der Heijden L, 2012, ACTA ORTHOP, V83, P401, DOI 10.3109/17453674.2012.711193
   Van Poznak C, 2017, J CLIN ONCOL, V35, P3978, DOI 10.1200/JCO.2017.75.4614
   Vehmanen LK, 2014, ACTA ONCOL, V53, P75, DOI 10.3109/0284186X.2013.792992
   Viswanathan M, 2018, JAMA J AM MED ASSOC, V319, P2532, DOI 10.1001/jama.2018.6537
   Weitzmann MN, 2002, J CLIN INVEST, V110, P1643, DOI 10.1172/JCI200215687
   Williams N, 2008, LANCET ONCOL, V9, P45, DOI 10.1016/S1470 2045(07)70385 6
   World Health Organization Collaborating Centre for Metabolic Bone Diseases, FRAX FRACT RISK ASS
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Zaiss MM, 2010, J IMMUNOL, V184, P7238, DOI 10.4049/jimmunol.0903841
   Zethraeus N, 2007, OSTEOPOROSIS INT, V18, P9, DOI 10.1007/s00198 006 0257 0
NR 162
TC 21
Z9 21
U1 1
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471 2598
EI 1744 7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD NOV 1
PY 2020
VL 20
IS 11
BP 1261
EP 1274
DI 10.1080/14712598.2020.1814731
EA SEP 2020
PG 14
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA OK3HN
UT WOS:000567611000001
PM 32835531
DA 2025 08 17
ER

PT J
AU Nicolin, V
   Bareggi, R
   Baldini, G
   Bortul, R
   Martinelli, B
   Narducci, P
AF Nicolin, Vanessa
   Bareggi, Renato
   Baldini, Giovanna
   Bortul, Roberta
   Martinelli, Bruno
   Narducci, Paola
TI Effects of neridronic acid on osteoclasts derived by physiological
   dual cell cultures
SO ACTA HISTOCHEMICA
LA English
DT Article
DE bisphosphonates; neridronic acid; osteoclasts; co culture; actin;
   ultrastructure
ID BISPHOSPHONATES; DIFFERENTIATION
AB Increased osteoclastic activity is observed in many osteopathic disorders   including postmenopausal osteoporosis, Paget's disease, primary bone turnours, lytic bone metastases, multiple myeloma and rheumatoid arthritis   that involve increased bone resorption and a loss of bone mass. Bisphosphonates are highly effective inhibitors of bone resorption that selectively affect the osteoclasts. The aim of this study was to obtain more information about the mechanism of action of bisphosphonates such as neridronic acid using a dual cell culture model. As a model, of osteoclastogenesis we used a murine monocyte/macrophage cell tine RAW 264.7 type CRL 2278 co cultured with murine osteoblasts. The monocyte osteoblast system allows physiological experimentation of bone anti resorption drugs, Simulating bone turnover in pathologies such as osteoporosis. The direct actions of neridronic acid on cell proliferation and functionality in the co culture model were examined using tart rate  resistant acid phosphatase (TRAP) assay, immunohistochemical, localization of actin, and transmission and scanning electron microscopy (SEM). Results showed that the percentage of TRAP positive cells, an early marker of osteoclastic differentiation, was significantly higher in control. cultures than in cocultures treated with variable concentrations of neridronic acid. Neridronic acid induced dramatic morphological changes, characterized by the toss of the ruffled border. The actin ring associated with the ptasma membrane of the cells treated with neridronic acid was shown to break down. The tissue specific targeting of neridronic acid to bone mineral suggests that it may inhibit bone resorption by direct effects on osteoclasts or other bone cells in the immediate microenvironment of the osteoclasts. From our study, we conclude that structural alterations induced by neridronic acid in our co cutture system lead to decreased osteoctast function. This may encourage the use of neridronic acid to reduce bone resorption in the therapy of demineralizing metabolic bone disorders. (C) 2007 Elsevier GmbH. All rights reserved.
C1 Univ Trieste, Dept Biomed, I 34138 Trieste, Italy.
C3 University of Trieste
RP Nicolin, V (通讯作者)，Univ Trieste, Dept Biomed, Via Manzoni 16, I 34138 Trieste, Italy.
EM nicotin@units.it
OI Nicolin, Vanessa/0000 0002 5665 6493
CR BAB IA, 1994, J CELL BIOCHEM, V158, P247
   Body JJ, 1998, J CLIN ONCOL, V16, P3890, DOI 10.1200/JCO.1998.16.12.3890
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Husheem M, 2005, CALCIFIED TISSUE INT, V76, P222, DOI 10.1007/s00223 004 0123 z
   Nicolin V, 2006, J HISTOTECHNOL, V29, P167, DOI 10.1179/his.2006.29.3.167
   Nicolin V, 2006, J MOL HISTOL, V37, P171, DOI 10.1007/s10735 006 9058 1
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Santini D, 2003, ANN ONCOL, V14, P1468, DOI 10.1093/annonc/mdg401
   SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   VESELY P, 1992, J ANAT, V181, P277
   WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201
NR 13
TC 10
Z9 11
U1 0
U2 5
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0065 1281
J9 ACTA HISTOCHEM
JI Acta Histochem.
PY 2007
VL 109
IS 5
BP 397
EP 402
DI 10.1016/j.acthis.2007.04.002
PG 6
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 228FS
UT WOS:000250713600007
PM 17574655
DA 2025 08 17
ER

PT J
AU Ross, DS
   Mehta, K
   Cabal, A
AF Ross, David S.
   Mehta, Khamir
   Cabal, Antonio
TI Mathematical Model of Bone Remodeling Captures the Antiresorptive and
   Anabolic Actions of Various Therapies
SO BULLETIN OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE Osteoporosis; Mechanistic model; Osteoclast; Osteoblast; Anabolic window
ID GROWTH FACTOR BETA; PARATHYROID HORMONE; TRANSFORMING
   GROWTH FACTOR BETA 1; CALCIUM HOMEOSTASIS; IN VIVO; OSTEOPROTEGERIN;
   RESORPTION; OSTEOCLAST; BISPHOSPHONATES; INHIBITION
AB A better understanding of the molecular pathways regulating the bone remodeling process should help in the development of new antiresorptive regulators and anabolic regulators, that is, regulators of bone resorption and of bone formation. Understanding the mechanisms by which parathyroid hormone (PTH) influences bone formation and how it switches from anabolic to catabolic action is important for treating osteoporosis (Poole and Reeve in Curr Opin Pharmacol 5:612 617, 2005). In this paper we describe a mathematical model of bone remodeling that incorporates, extends, and integrates several models of particular aspects of this biochemical system (Cabal et al. in J Bone Miner Res 28(8):1830 1836, 2013; Lemaire et al. in J Theor Biol 229:293 309, 2004; Peterson and Riggs in Bone 46:49 63, 2010; Raposo et al. in J Clin Endocrinol Metab 87(9):4330 4340, 2002; Ross et al. in J Disc Cont Dyn Sys Series B 17(6):2185 2200, 2012). We plan to use this model as a bone homeostasis platform to develop anabolic and antiresorptive compounds. The model will allow us to test hypotheses about the dynamics of compounds and to test the potential benefits of combination therapies. At the core of the model is the idealized account of osteoclast and osteoblast signaling given by Lemaire et al. (J Theor Biol 229:293 309, 2004). We have relaxed some of their assumptions about the roles of osteoprotegerin, transforming growth factor , and receptor activator of nuclear factor B ligand; we have devised more detailed models of the interactions of these species. We have incorporated a model of the effect of calcium sensing receptor antagonists on remodeling (Cabal et al. in J Bone Miner Res 28(8):1830 1836, 2013). We have also incorporated a basic model of the effects of vitamin D on calcium homeostasis. We have included a simple model of the mechanism proposed by Bellido et al. (2003), Ross et al. (J Disc Cont Dyn Sys Series B 17(6):2185 2200, 2012), of the influence of PTH on osteoblast apoptosis, a mechanism that accounts for the anabolic response to pulsatile PTH administration. Finally, we have devised a simple model of the administration and effects of bisphosphonates. The biomarkers in the model are procollagen type 1 amino terminal propeptide and C terminal telopeptide. Bone mineral density is the model's principal endpoint.
C1 [Ross, David S.] Rochester Inst Technol, Ctr Appl & Computat Math, Rochester, NY 14623 USA.
   [Mehta, Khamir; Cabal, Antonio] Merck & Co Inc, Quantitat Pharmacol & Pharmacometr, Merck Res Labs, Kenilworth, NJ 07033 USA.
   [Cabal, Antonio] 351 N Sumneytown Pike,POB 1000, N Wales, PA 19454 USA.
C3 Rochester Institute of Technology; Merck & Company; Merck & Company USA
RP Cabal, A (通讯作者)，Merck & Co Inc, Quantitat Pharmacol & Pharmacometr, Merck Res Labs, Kenilworth, NJ 07033 USA.; Cabal, A (通讯作者)，351 N Sumneytown Pike,POB 1000, N Wales, PA 19454 USA.
EM antonio.cabal@merck.com
FU Merck & Co., Inc., Kenilworth, NJ
FX This study was funded by Merck & Co., Inc., Kenilworth, NJ.
CR Aslan D, 2012, SCAND J CLIN LAB INV, V72, P14, DOI 10.3109/00365513.2011.624631
   Aubin JE, 2000, OSTEOPOROSIS INT, V11, P905, DOI 10.1007/s001980070028
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312
   Cabal A, 2013, J BONE MINER RES, V28, P1830, DOI 10.1002/jbmr.1900
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Filaroff E, 1998, CURR BIOL, V8, pR679
   Fox SW, 2005, MOL CELL ENDOCRINOL, V243, P19, DOI 10.1016/j.mce.2005.09.008
   Günther T, 2000, TRENDS ENDOCRIN MET, V11, P189, DOI 10.1016/S1043 2760(00)00256 3
   Halladay DL, 2002, J CELL BIOCHEM, V84, P1, DOI 10.1002/jcb.1273
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Houde N, 2009, J BIOL CHEM, V284, P23397, DOI 10.1074/jbc.M109.019372
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   Marathe A, 2008, J PHARMACOL EXP THER, V326, P555, DOI 10.1124/jpet.108.137703
   Nishimura R, 2009, IBMS BONEKEY, V6, P434
   Peterson MC, 2010, BONE, V46, P49, DOI 10.1016/j.bone.2009.08.053
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   Raposo JF, 2002, J CLIN ENDOCR METAB, V87, P4330, DOI 10.1210/jc.2002 011870
   Rejnmark L, 2008, EUR J ENDOCRINOL, V158, P571, DOI 10.1530/EJE 07 0844
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Ross DS, 2012, DISCRETE CONT DYN B, V17, P2185, DOI 10.3934/dcdsb.2012.17.2185
   Ruffoni D, 2007, BONE, V40, P1308, DOI 10.1016/j.bone.2007.01.012
   Seeman E, 2001, TRENDS ENDOCRIN MET, V12, P281, DOI 10.1016/S1043 2760(01)00460 X
   Shrestha RP, 2010, MATH BIOSCI, V226, P46, DOI 10.1016/j.mbs.2010.04.001
   Souberbielle JC, 2001, J CLIN ENDOCR METAB, V86, P3086, DOI 10.1210/jc.86.7.3086
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
NR 33
TC 13
Z9 14
U1 0
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0092 8240
EI 1522 9602
J9 B MATH BIOL
JI Bull. Math. Biol.
PD JAN
PY 2017
VL 79
IS 1
BP 117
EP 142
DI 10.1007/s11538 016 0229 2
PG 26
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Mathematical & Computational
   Biology
GA EI0WH
UT WOS:000392195500006
PM 27905067
DA 2025 08 17
ER

PT J
AU Wang, Y
   Panasiuk, A
   Grainger, DW
AF Wang, Yuwei
   Panasiuk, Alexandra
   Grainger, David W.
TI Small Interfering RNA Knocks Down the Molecular Target of Alendronate,
   Farnesyl Pyrophosphate Synthase, in Osteoclast and Osteoblast Cultures
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE farnesyl pyrophosphate synthase; siRNA; osteoclasts; osteoblasts;
   alendronate; bone metabolism; mineralization
ID NITROGEN CONTAINING BISPHOSPHONATES; IN VITRO; MEVALONATE PATHWAY;
   BONE RESORPTION; POTENTIAL COMPLICATION; ZOLEDRONIC ACID; RAT BONE;
   CELLS; PROLIFERATION; APOPTOSIS
AB Farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway, is the inhibition target of alendronate, a potent FDA approved nitrogen containing bisphosphonate (N BP) drug, at the molecular level. Alendronate not only inhibits osteoclasts but also has been reported to positively affect osteoblasts. This study assesses the knockdown effects of siRNA targeting FPPS compared with alendronate in both osteoclast and osteoblast cultures. Primary murine bone marrow cell induced osteoclasts and the preosteoblast MC3T3 E1 cell line were used to assess effects of anti FPPS siRNA compared with alendronate. Results show that both FPPS mRNA message and protein knockdown in serum based culture is correlated with reduced osteoclast viability. FPPS siRNA is more potent than 10 PM alendronate, but less potent than 50 mu M alendronate on reducing osteoclast viability. Despite FPPS knockdown, no significant changes were observed in osteoblast proliferation. FPPS knockdown promotes osteoblast differentiation significantly but not cell mineral deposition. However, compared with 50 mu M alendronate dosing, FPPS siRNA does not exhibit cytotoxic effects on osteoblasts while producing significant effects on ostoblast differentiation. Both siRNA and alendronate at tested concentrations do not have significant effects on cultured osteoblast mineralization. Overall, results indicate that siRNA against FPPS could be useful for selectively inhibiting osteoclast mediated bone resorption and improving bone mass maintenance by influencing both osteoclasts and osteoblasts in distinct ways.
C1 [Wang, Yuwei; Grainger, David W.] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA.
   [Panasiuk, Alexandra; Grainger, David W.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah
RP Grainger, DW (通讯作者)，Univ Utah, Dept Pharmaceut & Pharmaceut Chem, 30 S 2000 E, Salt Lake City, UT 84112 USA.
EM David.Grainger@utah.edu
OI Grainger, David/0000 0003 1506 7286
FU National Institutes of Health [EB00894]
FX The authors appreciate the generous gift of the sRANKL plasmid
   expression construct from Professor M. F. Manolson, University of
   Toronto, Canada, and the alendronate from Professor J. Kopecek,
   University of Utah, USA. This work was partially supported by National
   Institutes of Health Grant EB00894.
CR Aigner A., 2006, BIOMED BIOTECHNOL, V2006, P1
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Calle Y, 2004, BLOOD, V103, P3552, DOI 10.1182/blood 2003 04 1259
   CECCHINI MG, 1987, J BONE MINER RES, V2, P135
   Chamberlain LM, 2009, J BIOMED MATER RES A, V88A, P858, DOI 10.1002/jbm.a.31930
   CONSTANTZ BR, 1995, SCIENCE, V267, P1796, DOI 10.1126/science.7892603
   de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310
   Dodson TB, 2004, J ORAL MAXIL SURG, V62, P62, DOI 10.1016/j.joms.2002.12.002
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   García Moreno C, 1998, BONE, V22, P233, DOI 10.1016/S8756 3282(97)00270 6
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Giuliani N, 1998, SCAND J RHEUMATOL, V27, P38
   Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107
   Häusler KD, 2004, J BONE MINER RES, V19, P1873, DOI 10.1359/JBMR.040807
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Issack Paul S, 2007, HSS J, V3, P169, DOI 10.1007/s11420 007 9042 7
   Ito M, 1999, BONE, V25, P447, DOI 10.1016/S8756 3282(99)00197 0
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Khan SA, 1997, J BONE MINER RES, V12, P1700, DOI 10.1359/jbmr.1997.12.10.1700
   KHOKHER MA, 1989, METABOLISM, V38, P184, DOI 10.1016/0026 0495(89)90260 6
   Kim HK, 2009, CLIN ORTHOP RELAT R, V467, P3121, DOI 10.1007/s11999 008 0409 y
   Klein BY, 1998, J CELL BIOCHEM, V68, P186, DOI 10.1002/(SICI)1097 4644(19980201)68:2<186::AID JCB5>3.0.CO;2 R
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lacal JC, 1997, FEBS LETT, V410, P73, DOI 10.1016/S0014 5793(97)00444 4
   Lambrinoudaki I, 2006, ANN NY ACAD SCI, V1092, P397, DOI 10.1196/annals.1365.036
   Lee YK, 2004, J BIOMED MATER RES A, V69A, P188, DOI 10.1002/jbm.a.20137
   LOWIK CWGM, 1988, J BONE MINER RES, V3, P185
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Naidu A, 2008, ORAL SURG ORAL MED O, V106, P5, DOI 10.1016/j.tripleo.2008.03.036
   Nishikawa M, 1996, BONE, V18, P9, DOI 10.1016/8756 3282(95)00426 2
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Reinholz GG, 2002, BREAST CANCER RES TR, V71, P257, DOI 10.1023/A:1014418017382
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Sebba A, 2008, CURR OPIN ENDOCRINOL, V15, P502, DOI 10.1097/MED.0b013e328317ca83
   Sellmeyer DE, 2010, JAMA J AM MED ASSOC, V304, P1480, DOI 10.1001/jama.2010.1360
   Shipman CM, 1998, CANCER RES, V58, P5294
   Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516
   Tenenbaum HC, 2002, J PERIODONTOL, V73, P813, DOI 10.1902/jop.2002.73.7.813
   Trebec DP, 2007, J CELL BIOCHEM, V101, P205, DOI 10.1002/jcb.21171
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Vitte C, 1996, ENDOCRINOLOGY, V137, P2324, DOI 10.1210/en.137.6.2324
   Wang YQ, 2008, J BONE MINER RES, V23, P260, DOI 10.1359/JBMR.071013
   Wang YW, 2010, PHARM RES DORDR, V27, P1273, DOI 10.1007/s11095 010 0099 5
   Yang KY, 2007, YONSEI MED J, V48, P653, DOI 10.3349/ymj.2007.48.4.653
NR 58
TC 14
Z9 16
U1 1
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543 8384
EI 1543 8392
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUL AUG
PY 2011
VL 8
IS 4
SI SI
BP 1016
EP 1024
DI 10.1021/mp100374n
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 799SW
UT WOS:000293307400004
PM 21186792
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Sun, YQ
   Hu, TX
   Zhang, MD
   Song, JX
   Qin, Z
   Liu, M
   Ji, JL
   Li, ZY
   Qiu, ZX
   Bian, JL
AF Sun, Yongqiang
   Hu, Tianxing
   Zhang, Mengdi
   Song, Jiaxing
   Qin, Zhen
   Liu, Mai
   Ji, Jinliang
   Li, Zhiyu
   Qiu, Zhixia
   Bian, Jinlei
TI Structure Guided Discovery of Potent and Selective CLK2 Inhibitors for
   the Treatment of Knee Osteoarthritis
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID SR PROTEIN; STEM CELLS; KINASE; PATHWAY; PHOSPHORYLATION; CHONDROCYTES;
   MODULATION; DISEASE
AB Osteoarthritis is the most common joint disorder. However, there are no disease modifying drugs approved for OA treatment. CDC2 like kinase 2 (CLK2) could modulate Wnt signaling via alternative splicing of Wnt target genes and further affect bone differentiation, chondrocyte function, and inflammation, making CLK2 an attractive target for OA therapy. In this study, we designed and synthesized a series of highly potent CLK2 inhibitors based on Indazole 1. Among them, compound LQ23 showed more elevated inhibitory activity against CLK2 than the lead compound (IC50, 1.4 nM) with high CLK2/CLK3 selectivity (>70 fold). Furthermore, LQ23 showed outstanding antiosteoarthritis effects in vitro and in vivo, with the roles specific in decreased inflammatory cytokines, downregulated cartilage degradative enzymes, and increased joint cartilage via suppressing CLK2/Wnt signaling pathway. Overall, these data support LQ23 as a potential candidate for intra articular knee OA therapy, leveraging its unique mechanism of action for targeted treatment.
C1 [Hu, Tianxing; Song, Jiaxing; Qin, Zhen; Liu, Mai; Li, Zhiyu; Bian, Jinlei] China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Peoples R China.
   [Sun, Yongqiang; Ji, Jinliang; Qiu, Zhixia] China Pharmaceut Univ, Sch Pharm, Dept Pharmacol, Nanjing 210009, Peoples R China.
   [Zhang, Mengdi] China Pharmaceut Univ, Sch Basic Med Sci & Clin Pharm, Nanjing 210009, Peoples R China.
C3 China Pharmaceutical University; China Pharmaceutical University; China
   Pharmaceutical University
RP Li, ZY; Bian, JL (通讯作者)，China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Peoples R China.; Qiu, ZX (通讯作者)，China Pharmaceut Univ, Sch Pharm, Dept Pharmacol, Nanjing 210009, Peoples R China.
EM zhiyuli@cpu.edu.cn; zxqiu@cpu.edu.cn; bianjl@cpu.edu.cn
RI yq, s/AFI 3359 2022
OI Bian, Jinlei/0000 0003 4552 1195
FU China Association for Science and Technology [82073702, 82274013,
   81872746, 82204328]; National Natural Science Foundation of China
   [BK20211580]; Outstanding Youth Foundation of Jiangsu Province of China
   (CN); Qinglan Project of Jiangsu Province of China [202110316015,
   202110316014Z, CPUQNJC22_05]; National Innovation and Entrepreneurship
   Training Program for Undergraduate; State Key Laboratory of Natural
   Medicines, China Pharmaceutical University [2022QNRC002]; Young Elite
   Scientists Sponsorship Program by CAST
FX The authors gratefully acknowledge financial support from the National
   Natural Science Foundation of China (nos. 82073702, 82274013, 81872746,
   and 82204328), Outstanding Youth Foundation of Jiangsu Province of China
   (CN) (Grant BK20211580), Qinglan Project of Jiangsu Province of China,
   the National Innovation and Entrepreneurship Training Program for
   Undergraduate (no. 202110316015, 202110316002Zs, and 202110316014Z),
   CPUQNJC22_05, the Project Program of State Key Laboratory of Natural
   Medicines, China Pharmaceutical University, and the Young Elite
   Scientists Sponsorship Program by CAST (2022QNRC002).
CR Aubol BE, 2018, BIOCHEM J, V475, P677, DOI 10.1042/BCJ20170672
   Aubol BE, 2013, J MOL BIOL, V425, P2894, DOI 10.1016/j.jmb.2013.05.013
   Bidinosti M, 2016, SCIENCE, V351, P1199, DOI 10.1126/science.aad5487
   Chung H, 2019, BLOOD, V134, DOI 10.1182/blood 2019 130500
   Dahlin RL, 2014, BIOMATERIALS, V35, P123, DOI 10.1016/j.biomaterials.2013.09.086
   Dell'Accio F, 2018, OSTEOARTHR CARTILAGE, V26, P4, DOI 10.1016/j.joca.2017.10.014
   Deshmukh V, 2019, OSTEOARTHR CARTILAGE, V27, P1347, DOI 10.1016/j.joca.2019.05.006
   Deshmukh V, 2018, OSTEOARTHR CARTILAGE, V26, P18, DOI 10.1016/j.joca.2017.08.015
   El Marabti E, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00080
   ElHady AK, 2017, J MED CHEM, V60, P5377, DOI 10.1021/acs.jmedchem.6b01915
   Escobar Hoyos L, 2019, ANNU REV CANC BIOL, V3, P167, DOI 10.1146/annurev cancerbio 030617 050407
   Gallego Paez LM, 2017, HUM GENET, V136, P1015, DOI 10.1007/s00439 017 1790 y
   Ghouri A, 2021, CALCIFIED TISSUE INT, V109, P339, DOI 10.1007/s00223 020 00672 9
   Gigout A, 2017, OSTEOARTHR CARTILAGE, V25, P1858, DOI 10.1016/j.joca.2017.08.004
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Iwai K, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708289
   Jiang Y, 2022, OSTEOARTHR CARTILAGE, V30, P207, DOI 10.1016/j.joca.2021.11.009
   Johnson K, 2012, SCIENCE, V336, P717, DOI 10.1126/science.1215157
   Kallen J, 2018, CHEMMEDCHEM, V13, P1997, DOI 10.1002/cmdc.201800344
   Keshwani MM, 2015, BIOCHEM J, V466, P311, DOI 10.1042/BJ20141373
   Khor B, 2015, ELIFE, V4, DOI 10.7554/eLife.05920
   Lee JY, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/6125068
   Leung VYL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002356
   Liang YJ, 2022, THERANOSTICS, V12, P4866, DOI 10.7150/thno.69368
   Lindberg MF, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22116047
   Moyano PM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207549
   Nakata K, 2018, OSTEOARTHR CARTILAGE, V26, P1263, DOI 10.1016/j.joca.2018.05.021
   Nayler O, 1997, BIOCHEM J, V326, P693, DOI 10.1042/bj3260693
   Ohe K, 2015, ACS CHEM BIOL, V10, P914, DOI 10.1021/cb500697f
   Pastor F, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.658721
   Prak K, 2016, BIOCHEMISTRY US, V55, P608, DOI 10.1021/acs.biochem.5b01128
   Qin Z, 2021, J MED CHEM, V64, P13191, DOI 10.1021/acs.jmedchem.1c00985
   Safiri S, 2020, ANN RHEUM DIS, V79, P819, DOI 10.1136/annrheumdis 2019 216515
   Sferrazza G, 2020, ACTA PHARM SIN B, V10, P1814, DOI 10.1016/j.apsb.2019.12.019
   Shang XB, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22189887
   Song MQ, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01409 4
   Stücker S, 2021, BEST PRACT RES CL RH, V35, DOI 10.1016/j.berh.2021.101722
   Sun QZ, 2017, J MED CHEM, V60, P6337, DOI 10.1021/acs.jmedchem.7b00665
   Tabata M, 2014, DIABETES, V63, P1519, DOI 10.2337/db13 1304
   Tunnicliffe RB, 2019, MBIO, V10, DOI 10.1128/mBio.02551 19
   van Helvoort EM, 2022, CARTILAGE, V13, DOI 10.1177/19476035221098167
   Wong R, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742 4690 8 47
   Wu YY, 2013, EXP CELL RES, V319, P2684, DOI 10.1016/j.yexcr.2013.08.027
   Yazici Y, 2021, OSTEOARTHR CARTILAGE, V29, P654, DOI 10.1016/j.joca.2021.02.004
   Yoon HJ, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0599 x
   Yoshida T, 2015, CANCER RES, V75, P1516, DOI 10.1158/0008 5472.CAN 14 2443
   Yu SF, 2022, ACTA PHARM SIN B, V12, P2150, DOI 10.1016/j.apsb.2022.01.012
   Zanotti S, 2012, J CELL BIOCHEM, V113, P449, DOI 10.1002/jcb.23365
   Zhou HB, 2022, NEOPLASMA, V69, P657, DOI 10.4149/neo_2022_220206N138
   Zhou Y, 2022, CANCER LETT, V525, P84, DOI 10.1016/j.canlet.2021.10.034
   Zhou ZH, 2013, CHROMOSOMA, V122, P191, DOI 10.1007/s00412 013 0407 z
NR 51
TC 5
Z9 5
U1 4
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD MAR 19
PY 2024
VL 67
IS 6
BP 4603
EP 4623
DI 10.1021/acs.jmedchem.3c02092
EA MAR 2024
PG 21
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA MI3A0
UT WOS:001187669000001
PM 38500250
DA 2025 08 17
ER

PT J
AU Zimmerman, ZF
   Moon, RT
   Chien, AJ
AF Zimmerman, Zachary F.
   Moon, Randall T.
   Chien, Andy J.
TI Targeting Wnt Pathways in Disease
SO COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY
LA English
DT Article
ID FRIZZLED RELATED PROTEIN; BETA CATENIN EXPRESSION; INCREASES
   BONE FORMATION; EMBRYONIC STEM CELLS; COLORECTAL CANCER;
   MONOCLONAL ANTIBODY; TUMOR GROWTH; CYCLOOXYGENASE 2 INHIBITOR;
   EPIGENETIC INACTIVATION; ADENOMATOUS POLYPOSIS
AB Wnt mediated signal transduction pathways have long been recognized for their roles in regulating embryonic development, and have more recently been linked to cancer, neurologic diseases, inflammatory diseases, and disorders of endocrine function and bone metabolism in adults. Although therapies targeting Wnt signaling are attractive in theory, in practice it has been difficult to obtain specific therapeutics because many components of Wnt signaling pathways are also involved in other cellular processes, thereby reducing the specificity of candidate therapeutics. New technologies, and advances in understanding the mechanisms of Wnt signaling, have improved our understanding of the nuances of Wnt signaling and are leading to promising new strategies to target Wnt signaling pathways.
C1 [Zimmerman, Zachary F.; Moon, Randall T.; Chien, Andy J.] Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA.
   [Zimmerman, Zachary F.] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA.
   [Moon, Randall T.] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.
   [Moon, Randall T.] Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA.
   [Chien, Andy J.] Univ Washington, Dept Med, Div Dermatol, Seattle, WA 98195 USA.
C3 University of Washington; University of Washington Seattle; University
   of Washington; University of Washington Seattle; University of
   Washington; University of Washington Seattle; Howard Hughes Medical
   Institute; University of Washington; University of Washington Seattle;
   University of Washington; University of Washington Seattle
RP Chien, AJ (通讯作者)，Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA.
EM andchien@u.washington.edu
RI Moon, Randall/B 1743 2014; Moon, Randall/M 5605 2019
OI Moon, Randall/0000 0002 9352 1408; 
FU T32 training grant through the National Institutes of Health [T32 CA00
   9515 2]; K08 Career Development Award from NIH/NCI [K08 CA128565]
FX Z.Z. is funded by a T32 training grant through the National Institutes
   of Health (T32 CA00 9515 2). R.T.M. is an Investigator of the Howard
   Hughes Medical Institute. A.J.C. is funded by a K08 Career Development
   Award from NIH/NCI (K08 CA128565). We are indebted to our funding
   agencies for their continued support of our research endeavors. As with
   any attempt to review a broad and dynamically changing field, we had to
   limit our scope and exclude certain studies, so we apologize in advance
   for any unintended omissions. The views detailed in this publication do
   not represent the official views of the National Institutes of Health or
   the Howard Hughes Medical Institute.
CR Agholme F, 2010, J BONE MINER RES, V25, P2412, DOI 10.1002/jbmr.135
   Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078 0432.CCR 05 0011
   Bakre MM, 2007, J BIOL CHEM, V282, P31703, DOI 10.1074/jbc.M704287200
   Biechele TL, 2010, CHEM BIOL, V17, P1177, DOI 10.1016/j.chembiol.2010.08.012
   Bilechele Travis L., 2008, V468, P99, DOI 10.1007/978 1 59745 249 6_8
   Blackwood DHR, 2001, AM J HUM GENET, V69, P428, DOI 10.1086/321969
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Boon EMJ, 2004, BRIT J CANCER, V90, P224, DOI 10.1038/sj.bjc.6601505
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Bu GJ, 2008, INT J CANCER, V123, P1034, DOI 10.1002/ijc.23625
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008 5472.CAN 03 1346
   Cantrell VA, 2010, CANCER LETT, V287, P54, DOI 10.1016/j.canlet.2009.05.041
   Cappuccio I, 2005, J NEUROSCI, V25, P2647, DOI 10.1523/JNEUROSCI.5230 04.2005
   Caricasole A, 2004, J NEUROSCI, V24, P6021, DOI 10.1523/JNEUROSCI.1381 04.2004
   Carroll Anzinger D, 2007, J VIROL, V81, P5864, DOI 10.1128/JVI.02234 06
   Cheah PY, 2002, CANCER AM CANCER SOC, V95, P2479, DOI 10.1002/cncr.10986
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Chien AJ, 2009, J INVEST DERMATOL, V129, P1614, DOI 10.1038/jid.2008.445
   Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106
   Cirone P, 2008, ANGIOGENESIS, V11, P347, DOI 10.1007/s10456 008 9116 2
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   De Ferrari GV, 2006, ONCOGENE, V25, P7545, DOI 10.1038/sj.onc.1210064
   De Ferrari GV, 2007, P NATL ACAD SCI USA, V104, P9434, DOI 10.1073/pnas.0603523104
   DeAlmeida VI, 2007, CANCER RES, V67, P5371, DOI 10.1158/0008 5472.CAN 07 0266
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Ding Y, 2008, NAT MED, V14, P162, DOI 10.1038/nm1707
   Dorsky RI, 2000, GENE DEV, V14, P158
   Edamura K, 2007, CANCER GENE THER, V14, P765, DOI 10.1038/sj.cgt.7701071
   Elzagheid A, 2008, WORLD J GASTROENTERO, V14, P3866, DOI 10.3748/wjg.14.3866
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Engler TA, 2004, J MED CHEM, V47, P3934, DOI 10.1021/jm049768a
   Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179
   Ford CE, 2009, CELL CYCLE, V8, P1838, DOI 10.4161/cc.8.12.8863
   Freyberg Z, 2010, AM J PSYCHIAT, V167, P388, DOI 10.1176/appi.ajp.2009.08121873
   Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777
   Fukukawa C, 2008, CANCER SCI, V99, P432, DOI 10.1111/j.1349 7006.2007.00701.x
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002 9440(10)65148 6
   Gattinoni L, 2009, NAT MED, V15, P808, DOI 10.1038/nm.1982
   GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805
   Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587
   Glantschnig H, 2010, J BIOL CHEM, V285, P40135, DOI 10.1074/jbc.M110.166892
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gonsalves FC, 2011, P NATL ACAD SCI USA, V108, P5954, DOI 10.1073/pnas.1017496108
   Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153
   Graham JA, 2010, J BIOL CHEM, V285, P32852, DOI 10.1074/jbc.M110.150904
   Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092 8674(00)00192 6
   Guettler S, 2011, CELL, V147, P1340, DOI 10.1016/j.cell.2011.10.046
   Gunn WG, 2011, BLOOD, V117, P1641, DOI 10.1182/blood 2010 09 308171
   He B, 2004, NEOPLASIA, V6, P7, DOI 10.1016/S1476 5586(04)80048 4
   He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511
   He B, 2005, CLIN LUNG CANCER, V7, P54, DOI 10.3816/CLC.2005.n.022
   Heiser PW, 2008, GASTROENTEROLOGY, V135, P1288, DOI 10.1053/j.gastro.2008.06.089
   Henderson WR, 2010, P NATL ACAD SCI USA, V107, P14309, DOI 10.1073/pnas.1001520107
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hornyak TJ, 2001, MECH DEVELOP, V101, P47, DOI 10.1016/S0925 4773(00)00569 4
   Horvath LG, 2005, INT J CANCER, V113, P415, DOI 10.1002/ijc.20599
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092 8674(01)00330 0
   Itasaki N, 2003, DEVELOPMENT, V130, P4295, DOI 10.1242/dev.00674
   Jeannet G, 2010, P NATL ACAD SCI USA, V107, P9777, DOI 10.1073/pnas.0914127107
   Jensen M, 2008, INVEST NEW DRUG, V26, P139, DOI 10.1007/s10637 007 9106 z
   Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365 2133.2001.04336.x
   Kameoka M, 2009, AIDS RES HUM RETROV, V25, P1005, DOI 10.1089/aid.2008.0284
   Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092 8674(02)00970 4
   Katoh M, 2002, INT J MOL MED, V10, P11
   Kawasaki K, 2009, CANCER GENE THER, V16, P65, DOI 10.1038/cgt.2008.58
   Kho DH, 2009, GUT, V58, P509, DOI 10.1136/gut.2008.150938
   Kim SY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008979
   KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Komatsu DE, 2010, J ORTHOP RES, V28, P928, DOI 10.1002/jor.21078
   Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Kumar A, 2008, J VIROL, V82, P2813, DOI 10.1128/JVI.02498 07
   Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008 5472.CAN 06 2359
   LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016 5085(91)90519 Q
   Lavergne E, 2011, ONCOGENE, V30, P423, DOI 10.1038/onc.2010.432
   Le MN, 2010, J INVEST DERMATOL, V130, P2240, DOI 10.1038/jid.2010.126
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Lee JH, 2004, CANCER RES, V64, P4235, DOI 10.1158/0008 5472.CAN 04 0275
   Lee JK, 2009, FEBS LETT, V583, P711, DOI 10.1016/j.febslet.2009.01.014
   Lee SH, 2011, PHYTOTHER RES, V25, P1629, DOI 10.1002/ptr.3469
   Lengerke C, 2008, CELL STEM CELL, V2, P72, DOI 10.1016/j.stem.2007.10.022
   Lengerke C, 2009, ANN NY ACAD SCI, V1176, P219, DOI 10.1111/j.1749 6632.2009.04606.x
   Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535 6108(03)00334 9
   Levaot N, 2011, CELL, V147, P1324, DOI 10.1016/j.cell.2011.10.045
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lugli A, 2007, HISTOPATHOLOGY, V50, P453, DOI 10.1111/j.1365 2559.2007.02620.x
   Mahmoud NN, 1998, CARCINOGENESIS, V19, P87, DOI 10.1093/carcin/19.1.87
   Mahmoudi T, 2009, EMBO J, V28, P3329, DOI 10.1038/emboj.2009.285
   Major MB, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.2000037
   Manicassamy S, 2010, SCIENCE, V329, P849, DOI 10.1126/science.1188510
   Mao YW, 2009, CELL, V136, P1017, DOI 10.1016/j.cell.2008.12.044
   Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377
   Mazieres J, 2005, INT J CANCER, V117, P326, DOI 10.1002/ijc.21160
   Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/sj.onc.1208568
   Mikami I, 2005, BMC CANCER, V5, DOI 10.1186/1471 2407 5 53
   Milovanovic T, 2004, INT J ONCOL, V25, P1337
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Miyamoto S, 2004, ONCOL REP, V12, P245
   Miyaoka T, 1999, SCHIZOPHR RES, V38, P1, DOI 10.1016/S0920 9964(98)00179 0
   Mælandsmo GM, 2003, CLIN CANCER RES, V9, P3383
   Moore WJ, 2009, J MED CHEM, V52, P105, DOI 10.1021/jm801144h
   Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045
   Mudher A, 2001, J NEUROSCI, V21, P4987, DOI 10.1523/JNEUROSCI.21 14 04987.2001
   Mukhopadhyay M, 2006, DEVELOPMENT, V133, P2149, DOI 10.1242/dev.02381
   Nakamura Y, 2005, AM J PATHOL, V167, P97, DOI 10.1016/S0002 9440(10)62957 4
   Namkoong J, 2007, CANCER RES, V67, P2298, DOI 10.1158/0008 5472.CAN 06 3665
   Ng SS, 2010, BIOL CHEM, V391, P171, DOI [10.1515/BC.2010.028, 10.1515/bc.2010.028]
   NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563
   Nostro MC, 2008, CELL STEM CELL, V2, P60, DOI 10.1016/j.stem.2007.10.011
   Notani D, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000296
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092 8674(82)90409 3
   Nusse R, 2008, CELL RES, V18, P523, DOI 10.1038/cr.2008.47
   Okino K, 2003, ONCOL REP, V10, P1219
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Paige SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011134
   Pálmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028
   Pan WJ, 2008, SCIENCE, V321, P1350, DOI 10.1126/science.1160741
   Phillips RKS, 2002, GUT, V50, P857, DOI 10.1136/gut.50.6.857
   Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148
   Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920
   RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092 8674(87)90038 9
   Robitaille J, 2002, NAT GENET, V32, P326, DOI 10.1038/ng957
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Roh MS, 2007, EXP MOL MED, V39, P353, DOI 10.1038/emm.2007.39
   Säfholm A, 2006, J BIOL CHEM, V281, P2740, DOI 10.1074/jbc.M508386200
   Salinas PC, 2008, ANNU REV NEUROSCI, V31, P339, DOI 10.1146/annurev.neuro.31.060407.125649
   Saraswati S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015521
   Schwartz AL, 2009, CLIN CANCER RES, V15, P4114, DOI 10.1158/1078 0432.CCR 09 0005
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Sen M, 2000, P NATL ACAD SCI USA, V97, P2791, DOI 10.1073/pnas.050574297
   Sen M, 2001, ARTHRITIS RHEUM, V44, P772, DOI 10.1002/1529 0131(200104)44:4<772::AID ANR133>3.3.CO;2 C
   Sen M, 2002, ARTHRITIS RHEUM, V46, P2867, DOI 10.1002/art.10593
   Shafer B, 2011, DEV CELL, V20, P177, DOI 10.1016/j.devcel.2011.01.002
   Shan JF, 2005, BIOCHEMISTRY US, V44, P15495, DOI 10.1021/bi0512602
   Sheng YJ, 2011, RHEUMATOLOGY, V50, P682, DOI 10.1093/rheumatology/keq313
   Spence JR, 2011, NATURE, V470, P105, DOI 10.1038/nature09691
   Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603
   Stoick Cooper CL, 2007, DEVELOPMENT, V134, P479, DOI 10.1242/dev.001123
   SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519
   Sugimura R, 2010, BIRTH DEFECTS RES C, V90, P243, DOI 10.1002/bdrc.20195
   Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016
   Surendran K, 2005, J AM SOC NEPHROL, V16, P2373, DOI 10.1681/ASN.2004110949
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Takada R, 2006, DEV CELL, V11, P791, DOI 10.1016/j.devcel.2006.10.003
   Takahashi S, 2011, P NATL ACAD SCI USA, V108, P4938, DOI 10.1073/pnas.1014850108
   Takayama S, 2006, J BIOL CHEM, V281, P17856, DOI 10.1074/jbc.M602290200
   Takeda K, 2000, J BIOL CHEM, V275, P14013, DOI 10.1074/jbc.C000113200
   Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Toledo EM, 2010, MOL PSYCHIATR, V15, P272, DOI 10.1038/mp.2009.72
   Trowbridge JJ, 2010, STEM CELLS, V28, P1379, DOI 10.1002/stem.457
   Tveita AA, 2011, ARTHRITIS RHEUM US, V63, P513, DOI 10.1002/art.30116
   Ueki Y, 2007, CELL, V128, P71, DOI 10.1016/j.cell.2006.10.047
   Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817
   Uematsu K, 2003, CANCER RES, V63, P4547
   Ueno K, 2011, MOL CARCINOGEN, V50, P449, DOI 10.1002/mc.20729
   Ueno S, 2007, P NATL ACAD SCI USA, V104, P9685, DOI 10.1073/pnas.0702859104
   Üren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374
   Vijayaragavan K, 2009, CELL STEM CELL, V4, P248, DOI 10.1016/j.stem.2008.12.011
   Vincan E, 2005, DIFFERENTIATION, V73, P142, DOI 10.1111/j.1432 0436.2005.00015.x
   von Marschall Z, 2010, BIOCHEM BIOPH RES CO, V400, P299, DOI 10.1016/j.bbrc.2010.08.043
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Wang FS, 2007, BONE, V40, P485, DOI 10.1016/j.bone.2006.09.004
   Wang HM, 2011, ACS CHEM BIOL, V6, P192, DOI 10.1021/cb100323z
   Wang W, 2011, CELL RES, V21, P730, DOI 10.1038/cr.2011.30
   Wang Y, 2009, STEM CELL RES, V3, P113, DOI 10.1016/j.scr.2009.06.001
   Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535 6108(02)00045 4
   Wei W, 2011, MOL CANCER, V10, DOI 10.1186/1476 4598 10 16
   Wei W, 2009, MOL CANCER, V8, DOI 10.1186/1476 4598 8 76
   White BD, 2010, STEM CELLS, V28, P297, DOI 10.1002/stem.268
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Witze ES, 2008, SCIENCE, V320, P365, DOI 10.1126/science.1151250
   Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035
   Wortman B, 2002, J VIROL, V76, P11159, DOI 10.1128/JVI.76.21.11159 11165.2002
   Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960 9822(00)00868 X
   Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Yamamoto H, 2008, DEV CELL, V15, P37, DOI 10.1016/j.devcel.2008.04.015
   Yamauchi K, 2010, GENES CELLS, V15, P1216, DOI 10.1111/j.1365 2443.2010.01455.x
   Yang JZ, 2003, BIOL PSYCHIAT, V54, P1298, DOI 10.1016/S0006 3223(03)00291 9
   Yang K, 2003, CARCINOGENESIS, V24, P605, DOI 10.1093/carcin/24.3.605
   Yip D, 2009, CLIN CANCER RES, V15, P3896, DOI 10.1158/1078 0432.CCR 08 3303
   You L, 2004, ONCOGENE, V23, P6170, DOI 10.1038/sj.onc.1207844
   You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008 5472.CAN 04 1227
   Yu Q, 2010, IMMUNOL RES, V47, P45, DOI 10.1007/s12026 009 8137 2
   Zamani A, 2009, BONE, V44, P331, DOI 10.1016/j.bone.2008.10.001
   Zhang Y, 2006, CHEM BIOL, V13, P1001, DOI 10.1016/j.chembiol.2006.07.010
   Zhang YN, 2009, NAT CHEM BIOL, V5, P217, DOI 10.1038/nchembio.152
   Zhao DM, 2010, J IMMUNOL, V184, P1191, DOI 10.4049/jimmunol.0901199
   Zhou XY, 2010, IMMUNITY, V33, P229, DOI 10.1016/j.immuni.2010.08.002
   Zou HZ, 2005, INT J CANCER, V116, P584, DOI 10.1002/ijc.21045
NR 207
TC 61
Z9 66
U1 0
U2 24
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1943 0264
J9 CSH PERSPECT BIOL
JI Cold Spring Harbor Perspect. Biol.
PD NOV
PY 2012
VL 4
IS 11
AR a008086
DI 10.1101/cshperspect.a008086
PG 24
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 054MR
UT WOS:000312348400004
PM 23001988
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Zhu, SW
   Wei, WF
   Liu, ZW
   Yang, Y
   Jia, HB
AF Zhu, Shaowen
   Wei, Wanfu
   Liu, Zhiwei
   Yang, Yang
   Jia, Haobo
TI 被撤回的出版物: Tanshinone IIA attenuates the deleterious effects of oxidative
   stress in osteoporosis through the NF κB signaling pathway (Retracted
   Article)
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article; Retracted Publication
DE osteoclasts; tanshinone IIA; oxidative stress; nuclear factor kappa B
ID BONE MINERAL DENSITY; IN VITRO; CELLS; EXPRESSION
AB Osteoclasts are responsible for bone resorption caused by bone microstructural damage and bonerelated disorders. Evidence shows that tanshinone IIA (Tan IIA), a traditional Chinese medicine, is used clinically as a drug for the treatment of cardiovascular and cerebrovascular diseases. However, the efficacy and mechanism underlying the effect of Tan IIA on the viability of osteoclasts remain to be fully elucidated. The present study investigated the therapeutic effects of Tan IIA on osteoblast differentiation and oxidative stress in vitro and in vivo. Cell viability was analyzed and oxidative stress was examined in the osteoblasts. Wnt1(sw/sw) mice were used to investigate the therapeutic effects of Tan IIA on spontaneous tibia fractures and severe osteopenia. The bone strength, collagen and mineral were examined in the tibia. Osteoblast activity was also analyzed in the experimental mice. The Tan IIA induced differentiation of osteoclasts and the mechanism of action were investigated in osteocytes. The data showed that Tan IIA treatment improved cell viability. The data also demonstrated that Tan IIA decreased the levels of H2O2, accumulation of reactive oxygen species and apoptosis of osteoblasts. Tan IIA inhibited the deleterious outcomes triggered by oxidative stress. In addition, Tan IIA inhibited the activation of nuclear factor (NF) kappa B and its target genes, tumor necrosis factor (TNF) alpha, inducible nitric oxide synthase and cyclooxygenase 2, and increased the levels of TNF receptor associated factor 1 and inhibitor of apoptosis protein 1/2 in the osteocytes. Furthermore, it was shown that Tan IIA reduced the propensity to fractures and severe osteopenia in mice with osteoporosis. Tan IIA also exhibited improved bone strength, mineral and collagen in the bone matrix of the experimental mice. It was found that the Tan IIA mediated benefits on osteoblast activity and function were through the NF kappa B signaling pathway. Taken together, the data obtained in the present study suggested that Tan IIA had protective effects against oxidative stress in osteoblastic differentiation in mice with osteoporosis by regulating the NF kappa B signaling pathway.
C1 [Zhu, Shaowen] Tianjin Med Univ Gen Hosp, Dept Orthoped, Tianjin 300052, Peoples R China.
   [Wei, Wanfu; Yang, Yang; Jia, Haobo] Tianjin Hosp, Dept Orthoped, 406 Jiefang South Rd, Tianjin 300211, Peoples R China.
   [Liu, Zhiwei] Peking Univ, Basic Med Inst, Publ Hlth Ctr, Beijing 100871, Peoples R China.
C3 Tianjin Medical University; Peking University
RP Wei, WF (通讯作者)，Tianjin Hosp, Dept Orthoped, 406 Jiefang South Rd, Tianjin 300211, Peoples R China.
EM weiwanfutianjin@163.com
RI jia, haobo/LKJ 6756 2024; zhu, shaowen/U 8777 2019; liu,
   Liu/GXV 5581 2022
FU Natural Science Foundation of Tianjin [2011TJH1104PU]
FX This study was supported by grant from the Natural Science Foundation of
   Tianjin (grant no. 2011TJH1104PU).
CR Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Bai YQ, 2016, EXP THER MED, V11, P1085, DOI 10.3892/etm.2016.2984
   Cervellati C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/569563
   Chavan SN, 2007, INDIAN J CLIN BIOCHE, V22, P101, DOI 10.1007/BF02913324
   Cornelius C, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00120
   Couzin Frankel J, 2014, SCIENCE, V344, P679, DOI 10.1126/science.344.6185.679
   Elsafadi M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.196
   Gartland A, 2012, METHODS MOL BIOL, V806, P337, DOI 10.1007/978 1 61779 367 7_22
   Ghosh M, 2014, ENDOCRINE, V46, P397, DOI 10.1007/s12020 014 0167 4
   Handzlik Orlik G, 2016, THER ADV ENDOCRINOL, V7, P128, DOI 10.1177/2042018816641351
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Jiang Q, 2016, AM J PHYSIOL CELL PH, V311, pC136, DOI 10.1152/ajpcell.00252.2015
   Kim EO, 2016, INT J ONCOL, V48, P2205, DOI 10.3892/ijo.2016.3441
   Kim IH, 2016, INT J MED MUSHROOMS, V18, P39, DOI 10.1615/IntJMedMushrooms.v18.i1.50
   Koga Takako, 2015, Clin Calcium, V25, P1293, DOI CliCa150912931300
   Kondo Takeshi, 2014, Nihon Rinsho, V72, P1774
   Kurian GA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1656450
   Kushwaha P, 2016, EUR J PHARMACOL, V788, P65, DOI 10.1016/j.ejphar.2016.06.003
   Lambert MF, 2014, PRIM HEALTH CARE RES, V15, P396, DOI 10.1017/S146342361400005X
   Lee WS, 2017, KOREAN J INTERN MED
   Li De chuan, 2015, Yaoxue Xuebao, V50, P635
   Li F, 2016, BIOMED RES INT, V2016
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma S, 2016, J PERIODONTAL RES, V51, P567, DOI 10.1111/jre.12335
   Mao CP, 2009, AM J CHINESE MED, V37, P1031, DOI 10.1142/S0192415X09007478
   Miyazaki T, 2014, PATIENT PREFER ADHER, V8, P463, DOI 10.2147/PPA.S46192
   Ouyang DS, 2016, CHIN MED UK, V11, DOI 10.1186/s13020 016 0083 z
   Puntmann VO, 2011, GERONTOLOGY, V57, P295, DOI 10.1159/000316577
   Ramachandran A, 2008, VET PATHOL, V45, P698, DOI 10.1354/vp.45 5 698
   Sadat Ali M, 2014, ANN MED HEALTH SCI R, V4, P198, DOI 10.4103/2141 9248.129038
   Saito Mitsuru, 2015, Clin Calcium, V25, P1301, DOI CliCa150913011306
   Sánchez Rodríguez MA, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 124
   Scott LJ, 2014, DRUG AGING, V31, P555, DOI 10.1007/s40266 014 0191 3
   Shum LC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155709
   Spilmont M, 2014, EUR J NUTR, V53, P1155, DOI 10.1007/s00394 013 0615 6
   Su CC, 2016, ONCOL REP, V36, P1173, DOI 10.3892/or.2016.4857
   Wai Hoe L, 2009, BIOL PROCED ONLINE, V11, P145, DOI 10.1007/s12575 009 9007 y
   Williams EL, 2013, METHODS MOL BIOL, V1035, P67, DOI 10.1007/978 1 62703 508 8_7
   Wilson Carol, 2014, Nat Rev Endocrinol, V10, P3, DOI 10.1038/nrendo.2013.225
   Wu Qian, 2015, Med Sci Monit, V21, P2428, DOI 10.12659/MSM.894347
   Yang YH, 2014, FREE RADICAL BIO MED, V77, P10, DOI 10.1016/j.freeradbiomed.2014.08.028
   Yilmaz N, 2009, AGING CLIN EXP RES, V21, P353
   Yin H, 2012, EUR J PHARMACOL, V674, P200, DOI 10.1016/j.ejphar.2011.11.024
   Yu SD, 2014, BMC NEUROL, V14, DOI 10.1186/1471 2377 14 110
NR 44
TC 26
Z9 37
U1 1
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAY
PY 2018
VL 17
IS 5
BP 6969
EP 6976
DI 10.3892/mmr.2018.8741
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GD5OR
UT WOS:000430556800097
PM 29568934
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Hansen, MS
   Soe, K
   Christensen, LL
   Fernandez Guerra, P
   Hansen, NW
   Wyatt, RA
   Martin, C
   Hardy, RS
   Andersen, TL
   Olesen, JB
   Hartmann, B
   Rosenkilde, MM
   Kassem, M
   Rauch, A
   Gorvin, CM
   Frost, M
AF Hansen, Morten S.
   Soe, Kent
   Christensen, Line L.
   Fernandez Guerra, Paula
   Hansen, Nina W.
   Wyatt, Rachael A.
   Martin, Claire
   Hardy, Rowan S.
   Andersen, Thomas L.
   Olesen, Jacob B.
   Hartmann, Bolette
   Rosenkilde, Mette M.
   Kassem, Moustapha
   Rauch, Alexander
   Gorvin, Caroline M.
   Frost, Morten
TI GIP reduces osteoclast activity and improves osteoblast survival in
   primary human bone cells
SO EUROPEAN JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
DE GIPR; bone remodeling; osteoporosis; resorption; Akt1/2; c Src; NFATc1;
   NF kappa B
ID DEPENDENT INSULINOTROPIC POLYPEPTIDE; KINASE ACTIVITY; RESORPTION;
   DIFFERENTIATION; MICE; OBESITY; LEADS; TIME
AB Objective Drugs targeting the glucose dependent insulinotropic polypeptide (GIP) receptor (GIPR) are emerging as treatments for type 2 diabetes and obesity. GIP acutely decreases serum markers of bone resorption and transiently increases bone formation markers in short term clinical investigations. However, it is unknown whether GIP acts directly on bone cells to mediate these effects. Using a GIPR specific antagonist, we aimed to assess whether GIP acts directly on primary human osteoclasts and osteoblasts.Methods Osteoclasts were differentiated from human CD14(+) monocytes and osteoblasts from human bone. GIPR expression was determined using RNA seq in primary human osteoclasts and in situ hybridization in human femoral bone. Osteoclastic resorptive activity was assessed using microscopy. GIPR signaling pathways in osteoclasts and osteoblasts were assessed using LANCE cAMP and AlphaLISA phosphorylation assays, intracellular calcium imaging and confocal microscopy. The bioenergetic profile of osteoclasts was evaluated using Seahorse XF 96.Results GIPR is robustly expressed in mature human osteoclasts. GIP inhibits osteoclastogenesis, delays bone resorption, and increases osteoclast apoptosis by acting upon multiple signaling pathways (Src, cAMP, Akt, p38, Akt, NF?B) to impair nuclear translocation of nuclear factor of activated T cells 1 (NFATc1) and nuclear factor ?B (NF?B). Osteoblasts also expressed GIPR, and GIP improved osteoblast survival. Decreased bone resorption and improved osteoblast survival were also observed after GIP treatment of osteoclast osteoblast co cultures. Antagonizing GIPR with GIP(3 30)NH2 abolished the effects of GIP on osteoclasts and osteoblasts.Conclusions GIP inhibits bone resorption and improves survival of human osteoblasts, indicating that drugs targeting GIPR may impair bone resorption, whilst preserving bone formation.
C1 [Hansen, Morten S.; Christensen, Line L.; Fernandez Guerra, Paula; Hansen, Nina W.; Kassem, Moustapha; Rauch, Alexander; Frost, Morten] Odense Univ Hosp, Dept Endocrinol, Mol Endocrinol Lab KMEB, DK 5000 Odense C, Denmark.
   [Hansen, Morten S.; Soe, Kent; Andersen, Thomas L.; Kassem, Moustapha; Rauch, Alexander; Frost, Morten] Univ Southern Denmark, Fac Hlth Sci, Dept Clin Res, DK 5000 Odense C, Denmark.
   [Hansen, Morten S.; Wyatt, Rachael A.; Martin, Claire; Hardy, Rowan S.; Gorvin, Caroline M.] Univ Birmingham, Inst Metab & Syst Res IMSR, Birmingham B15 2TT, England.
   [Hansen, Morten S.; Wyatt, Rachael A.; Martin, Claire; Hardy, Rowan S.; Gorvin, Caroline M.] Univ Birmingham, Ctr Diabet Endocrinol & Metab CEDAM, Birmingham B15 2TT, England.
   [Hansen, Morten S.; Wyatt, Rachael A.; Gorvin, Caroline M.] Univ Birmingham, Ctr Membrane Prot & Receptors COMPARE, Birmingham B15 2TT, England.
   [Hansen, Morten S.; Wyatt, Rachael A.; Gorvin, Caroline M.] Univ Nottingham, Ctr Membrane Prot & Receptors COMPARE, Birmingham B15 2TT, England.
   [Soe, Kent; Andersen, Thomas L.; Olesen, Jacob B.] Odense Univ Hosp, Dept Pathol, Clin Cell Biol, DK 5000 Odense C, Denmark.
   [Soe, Kent; Andersen, Thomas L.] Univ Southern Denmark, Dept Mol Med, DK 5000 Odense C, Denmark.
   [Hartmann, Bolette; Rosenkilde, Mette M.] Univ Copenhagen, Dept Biomed Sci, DK 2200 Copenhagen N, Denmark.
   [Rauch, Alexander; Frost, Morten] Odense Univ Hosp, Steno Diabet Ctr Odense, DK 5000 Odense C, Denmark.
C3 University of Southern Denmark; Odense University Hospital; University
   of Southern Denmark; University of Birmingham; University of Birmingham;
   University of Birmingham; University of Nottingham; University of
   Southern Denmark; Odense University Hospital; University of Southern
   Denmark; University of Copenhagen; University of Southern Denmark;
   Odense University Hospital
RP Frost, M (通讯作者)，Odense Univ Hosp, Dept Endocrinol, Mol Endocrinol Lab KMEB, DK 5000 Odense C, Denmark.; Gorvin, CM (通讯作者)，Univ Birmingham, Inst Metab & Syst Res IMSR, Birmingham B15 2TT, England.; Gorvin, CM (通讯作者)，Univ Birmingham, Ctr Diabet Endocrinol & Metab CEDAM, Birmingham B15 2TT, England.
EM c.gorvin@bham.ac.uk; mmfnielsen@health.sdu.dk
RI Levin Andersen, Thomas/AAY 6777 2021; Frost, Morten/G 9410 2011; Gorvin,
   Caroline/T 2406 2019; Kassem, Moustapha/J 7688 2013; Hardy,
   Rowan/N 9185 2018; Rauch, Alexander/AAY 5235 2021; Soe,
   Kent/N 3618 2017; Hansen, Morten/AAX 6228 2020
OI Gorvin, Caroline/0000 0002 1361 9174; Hartmann,
   Bolette/0000 0001 8509 2036; Rauch, Alexander/0000 0002 9429 7356;
   Fernandez Guerra, Paula/0000 0002 0855 9971; Hardy,
   Rowan/0000 0001 6938 6739; Levin Andersen, Thomas/0000 0002 6981 7276;
   Hansen, Morten Svarer/0000 0001 8269 8542; Wyatt, Rachael
   A./0000 0002 6199 7751; Soe, Kent/0000 0001 7402 314X; Rosenkilde, Mette
   Marie/0000 0001 9600 3254; /0000 0002 5608 1589
FU Novo Nordisk Foundation [NNF18OC0052699, NNF18OC0055047]; Region of
   Southern Denmark [18/17553]; Odense University Hospital [SBF004|1034];
   Academy of Medical Sciences Springboard Award   British Heart
   Foundation, Diabetes UK; Global Challenges Research Fund; Government
   Department of Business, Energy and Industrial Strategy; Wellcome Trust; 
   [A3147]; Medical Research Council [MR/P021220/1] Funding Source:
   researchfish; MRC Arthritis UK Centre for MAR [UoB_Maastrict_Hardy]
   Funding Source: researchfish; Novo Nordisk Fonden [NNF17SA0030962 1]
   Funding Source: researchfish; Steno Diabetes Center Odense (SDCO) [SDCO
   Research 001] Funding Source: researchfish; Versus Arthritis [19859,
   20843] Funding Source: researchfish; MRC [MR/P021220/1] Funding Source:
   UKRI
FX This work was funded by grants from the Novo Nordisk Foundation
   (NNF18OC0052699 (M.S.H.) and NNF18OC0055047 (M.F.)), Region of Southern
   Denmark (ref: 18/17553 (M.S.H)) and Odense University Hospital (ref:
   A3147 (M.F.)), and an Academy of Medical Sciences Springboard Award
   supported by the British Heart Foundation, Diabetes UK, the Global
   Challenges Research Fund, the Government Department of Business, Energy
   and Industrial Strategy and the Wellcome Trust (ref: SBF004|1034,
   C.M.G).
CR Abdelgawad ME, 2016, HISTOCHEM CELL BIOL, V145, P603, DOI 10.1007/s00418 016 1414 y
   Abrahamsen H, 2003, J BIOL CHEM, V278, P17170, DOI 10.1074/jbc.M211426200
   Balwierz PJ, 2014, GENOME RES, V24, P869, DOI 10.1101/gr.169508.113
   Bergmann NC, 2019, J CLIN ENDOCR METAB, V104, P2953, DOI 10.1210/jc.2019 00008
   Bollag RJ, 2000, ENDOCRINOLOGY, V141, P1228, DOI 10.1210/en.141.3.1228
   Chavassieux P, 2019, J BONE MINER RES, V34, P1597, DOI 10.1002/jbmr.3735
   Christensen MB, 2018, J CLIN ENDOCR METAB, V103, P288, DOI 10.1210/jc.2017 01949
   Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07 03 0227
   Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960
   Fernandez Guerra P, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11070961
   Finan B, 2015, NAT MED, V21, P27, DOI 10.1038/nm.3761
   Frías JP, 2021, NEW ENGL J MED, V385, P503, DOI 10.1056/NEJMoa2107519
   Gabe MBN, 2022, PHARMACOL RES, V176, DOI 10.1016/j.phrs.2022.106058
   Gabe MBN, 2020, PEPTIDES, V125, DOI 10.1016/j.peptides.2019.170224
   Gasbjerg LS, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115079
   Gaudin Audrain C, 2013, BONE, V53, P221, DOI 10.1016/j.bone.2012.11.039
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Gorvin CM, 2018, CELL REP, V22, P1054, DOI 10.1016/j.celrep.2017.12.089
   Hansen LS, 2016, BRIT J PHARMACOL, V173, P826, DOI 10.1111/bph.13384
   Hansen MS, 2022, SEMIN CELL DEV BIOL, V123, P74, DOI 10.1016/j.semcdb.2021.06.024
   Helsted MM, 2020, BONE, V140, DOI 10.1016/j.bone.2020.115553
   Hobolt Pedersen AS, 2014, CALCIFIED TISSUE INT, V95, P73, DOI 10.1007/s00223 014 9864 5
   Holroyd C, 2008, BEST PRACT RES CL EN, V22, P671, DOI 10.1016/j.beem.2008.06.001
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585
   Killion EA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18751 8
   Killion EA, 2020, ENDOCR REV, V41, P1, DOI 10.1210/endrev/bnz002
   Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200
   Lassen NE, 2017, J BONE MINER RES, V32, P1395, DOI 10.1002/jbmr.3091
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   LERNER UH, 1989, BONE, V10, P377, DOI 10.1016/8756 3282(89)90134 8
   Lin J, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005867
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Luttrell DK, 2004, ONCOGENE, V23, P7969, DOI 10.1038/sj.onc.1208162
   Mabilleau G, 2016, BONE, V91, P102, DOI 10.1016/j.bone.2016.07.014
   Merrild DMH, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.32
   Mieczkowska A, 2015, BONE, V74, P29, DOI 10.1016/j.bone.2015.01.003
   Mieczkowska A, 2013, BONE, V56, P337, DOI 10.1016/j.bone.2013.07.003
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Miyazaki T, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.385369
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Nasteska D, 2014, DIABETES, V63, P2332, DOI 10.2337/db13 1563
   Nissen A, 2014, J CLIN ENDOCR METAB, V99, pE2325, DOI 10.1210/jc.2014 2547
   Norregaard PK, 2018, DIABETES OBES METAB, V20, P60, DOI 10.1111/dom.13034
   Pirapaharan DC, 2019, J CELL SCI, V132, DOI 10.1242/jcs.229351
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Skov Jeppesen K, 2021, J BONE MINER RES, V36, P1448, DOI 10.1002/jbmr.4308
   Soe K, 2017, J CELL SCI, V130, P2026, DOI 10.1242/jcs.202036
   Soe K, 2010, J BONE MINER RES, V25, P2184, DOI 10.1002/jbmr.113
   Tsukiyama K, 2006, MOL ENDOCRINOL, V20, P1644, DOI 10.1210/me.2005 0187
   Viloria K, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107761
   Xie D, 2005, BONE, V37, P759, DOI 10.1016/j.bone.2005.06.021
   Xie D, 2007, BONE, V40, P1352, DOI 10.1016/j.bone.2007.01.007
   Yang YM, 2009, J BONE MINER RES, V24, P1763, DOI [10.1359/JBMR.090420, 10.1359/jbmr.090420]
   Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147
NR 58
TC 18
Z9 20
U1 1
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0804 4643
EI 1479 683X
J9 EUR J ENDOCRINOL
JI Eur. J. Endocrinol.
PD JAN 10
PY 2023
VL 188
IS 1
AR lvac004
DI 10.1093/ejendo/lvac004
EA FEB 2023
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA F8NR2
UT WOS:000984865500001
PM 36747334
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Olkku, A
   Leskinen, JJ
   Lammi, MJ
   Hynynen, K
   Mahonen, A
AF Olkku, Anu
   Leskinen, Jarkko J.
   Lammi, Mikko J.
   Hynynen, Kullervo
   Mahonen, Anitta
TI Ultrasound induced activation of Wnt signaling in human MG 63
   osteoblastic cells
SO BONE
LA English
DT Article
DE Wnt signaling; Ultrasound; Osteoblast; Fracture healing; Bone
ID INTENSITY PULSED ULTRASOUND; GUIDED FOCUSED ULTRASOUND; GROWTH FACTOR I;
   BETA CATENIN; BONE REGENERATION; GENE EXPRESSION; HEAT SHOCK;
   THERAPEUTIC ULTRASOUND; ACOUSTIC CAVITATION; ANABOLIC RESPONSE
AB The benefit from an ultrasound (US) exposure for fracture healing has been clearly shown. However, the molecular mechanisms behind this effect are not fully known. Recently, the canonical Wnt signaling pathway has been recognized as one of the essential regulators of osteoblastogenesis and bone mass, and thereby considered crucial for bone health. Mechanical loading and fluid shear stress have been reported to activate the canonical Wnt signaling pathway in bone cells, but previous reports on the effects of therapeutic US on Wnt signaling in general or in bone, in particular, have not been published yet. Therefore, activation of Wnt signaling pathway was assayed in human osteoblastic cells, and indeed, this pathway was found to be activated in MG 63 cells through the phosphoinositol 3 kinase/Akt (PI3K/Akt) and mTOR cascades following a single 10 min US exposure (2 W, 1.035 MHz). In addition to the reporter assay results, the Wnt pathway activation was also observed as nuclear localization of beta catenin. Wnt activation showed also temperature dependence at elevated temperatures, and the expression of canonical Wnt ligands was induced under the thermal exposures. However, existence of a specific, non thermal US component was evident as well, perhaps evidence of a potential dual action of therapeutic US on bone. Neither US nor heat exposures affected cell viability in our experiments. In summary, this is the first study to report that Wnt signaling cascade, important for osteoblast function and bone health, is one of the pathways activated by therapeutic US as well as by hyperthermia in human osteoblastic cells. Our results provide evidence for the potential molecular mechanisms behind the beneficial effects of US on fracture healing. Combinations of US, heat, and possible pharmacological treatment could provide useful flexibility for clinical cases in treating various bone disorders. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Leskinen, Jarkko J.; Hynynen, Kullervo] Univ Eastern Finland, Dept Math & Phys, FIN 70211 Kuopio, Finland.
   [Olkku, Anu; Mahonen, Anitta] Univ Eastern Finland, Sch Med, Inst Biomed, FIN 70211 Kuopio, Finland.
   [Lammi, Mikko J.] Univ Eastern Finland, Dept Biosci, FIN 70211 Kuopio, Finland.
   [Lammi, Mikko J.] Univ Eastern Finland, Bioctr Kuopio, FIN 70211 Kuopio, Finland.
   [Hynynen, Kullervo] Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A1, Canada.
   [Hynynen, Kullervo] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
   [Mahonen, Anitta] Kuopio Univ Hosp, Dept Orthopaed Traumatol & Hand Surg, Kuopio, Finland.
   [Mahonen, Anitta] Univ Eastern Finland, Bone & Cartilage Res Unit, FIN 70211 Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland; University
   of Eastern Finland; University of Eastern Finland; University of
   Toronto; University of Toronto; Sunnybrook Health Science Center;
   Sunnybrook Research Institute; Kuopio University Hospital; University of
   Eastern Finland; University of Eastern Finland Hospital; University of
   Eastern Finland
RP Leskinen, JJ (通讯作者)，Univ Eastern Finland, Dept Math & Phys, POB 1627, FIN 70211 Kuopio, Finland.
EM jarkko.leskinen@uef.fi
RI Lammi, Mikko/B 9291 2008
OI Lammi, Mikko/0000 0002 6181 9904
FU Academy of Finland [206113, 128117]; Sigrid Juselius Foundation; Finnish
   Cultural Foundation; Kuopio University Hospital; Academy of Finland
   (AKA) [206113, 128117] Funding Source: Academy of Finland (AKA)
FX This study was supported by the grants from the Academy of Finland
   (#206113 and #128117), Sigrid Juselius Foundation, Finnish Cultural
   Foundation North Savo Regional Fund, and Kuopio University Hospital
   EVO grant.
CR Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Bodine PVN, 2008, CELL RES, V18, P248, DOI 10.1038/cr.2008.13
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Burger E H, 1999, Adv Dent Res, V13, P93
   Chang WHS, 2002, BIOELECTROMAGNETICS, V23, P256, DOI 10.1002/bem.10009
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Chen Y, 2009, J CELL BIOCHEM, V106, P353, DOI 10.1002/jcb.22020
   CIARAVINO V, 1981, ULTRASOUND MED BIOL, V7, P159, DOI 10.1016/0301 5629(81)90005 3
   Claes L, 2007, PROG BIOPHYS MOL BIO, V93, P384, DOI 10.1016/j.pbiomolbio.2006.07.021
   Cochran SA, 2001, ULTRASOUND MED BIOL, V27, P841, DOI 10.1016/S0301 5629(01)00382 9
   Diederich CJ, 1999, ULTRASOUND MED BIOL, V25, P871, DOI 10.1016/S0301 5629(99)00048 4
   Dyson M, 1983, Ultrasound Med Biol, VSuppl 2, P61
   EAGLESON WM, 1967, CAN MED ASSOC J, V97, P274
   FRY WJ, 1954, J ACOUST SOC AM, V26, P311, DOI 10.1121/1.1907333
   FRY WJ, 1954, J ACOUST SOC AM, V26, P294, DOI 10.1121/1.1907332
   Glass DA, 2006, CURR TOP DEV BIOL, V73, P43, DOI 10.1016/S0070 2153(05)73002 7
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gregory CA, 2005, ANN NY ACAD SCI, V1049, P97, DOI 10.1196/annals.1334.010
   Harle J, 2005, Eur Cell Mater, V10, P70
   Harle J, 2001, J MATER SCI MATER M, V12, P1001, DOI 10.1023/A:1012825519114
   Harle J, 2001, ULTRASOUND MED BIOL, V27, P579, DOI 10.1016/S0301 5629(00)00326 4
   Harrison EM, 2006, J IMMUNOL METHODS, V310, P182, DOI 10.1016/j.jim.2005.11.022
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   HASKIN CL, 1993, BIOCHEM CELL BIOL, V71, P361, DOI 10.1139/o93 054
   Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210
   Hofmann A, 2008, BONE, V42, P894, DOI 10.1016/j.bone.2008.01.013
   HYNYNEN K, 1989, MED PHYS, V16, P618, DOI 10.1118/1.596364
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   ISHIHARA Y, 1995, MAGNET RESON MED, V34, P814, DOI 10.1002/mrm.1910340606
   Jin TR, 2008, CELL SIGNAL, V20, P1697, DOI 10.1016/j.cellsig.2008.04.014
   Johnson ML, 2004, J BONE MINER RES, V19, P1749, DOI 10.1359/JBMR.040816
   Khan Y, 2008, J BONE JOINT SURG AM, V90A, P138, DOI 10.2106/JBJS.G.01218
   Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860
   Klein Nulend J, 2005, PATHOL BIOL, V53, P576, DOI 10.1016/j.patbio.2004.12.005
   KLUG W, 1986, EUR J NUCL MED, V11, P494
   Koay MA, 2005, TRENDS MOL MED, V11, P129, DOI 10.1016/j.molmed.2005.01.004
   KOBER LO, 1989, J ACOUST SOC AM, V86, P6, DOI 10.1121/1.398222
   Kopakkala Tani M, 2006, BIORHEOLOGY, V43, P271
   Kopelman D, 2007, ANN SURG ONCOL, V14, P1540, DOI 10.1245/s10434 006 9326 z
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   KUHN PK, 1986, IEEE T BIO MED ENG, V33, P536, DOI 10.1109/TBME.1986.325745
   Lau KHW, 2006, J BIOL CHEM, V281, P9576, DOI 10.1074/jbc.M509205200
   LEON SA, 1993, INT J HYPERTHER, V9, P77, DOI 10.3109/02656739309061480
   Leskinen JJ, 2008, BIORHEOLOGY, V45, P345, DOI 10.3233/BIR 2008 0480
   Li JGR, 2002, ULTRASOUND MED BIOL, V28, P683, DOI 10.1016/S0301 5629(02)00485 4
   Lu HB, 2009, BIOCHEM BIOPH RES CO, V378, P569, DOI 10.1016/j.bbrc.2008.11.074
   Maddi A, 2006, BONE, V39, P283, DOI 10.1016/j.bone.2006.01.162
   Malizos KN, 2006, INJURY, V37, pS56, DOI 10.1016/j.injury.2006.02.037
   Mason Deborah J, 2004, Eur Cell Mater, V7, P12
   Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067
   Moonen CTW, 2007, CLIN CANCER RES, V13, P3482, DOI 10.1158/1078 0432.CCR 07 0204
   Naruse K, 2003, J BONE MINER RES, V18, P360, DOI 10.1359/jbmr.2003.18.2.360
   NGUYEN VT, 1989, J BIOL CHEM, V264, P10487
   Niu TH, 2005, GENE, V361, P38, DOI 10.1016/j.gene.2005.07.016
   OGAWA H, 1990, NIPPON KYOSEI SHIKA, V9, P485
   Olkku A, 2008, BONE, V43, P483, DOI 10.1016/j.bone.2008.04.016
   Reher P, 2002, BONE, V31, P236, DOI 10.1016/S8756 3282(02)00789 5
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   RUIZ MC, 1991, J BIOCHEM BIOPH METH, V23, P237, DOI 10.1016/0165 022X(91)90016 P
   Rutten S, 2008, BONE, V43, P348, DOI 10.1016/j.bone.2008.04.010
   SAPARETO SA, 1984, INT J RADIAT ONCOL, V10, P787, DOI 10.1016/0360 3016(84)90379 1
   Shui CX, 2001, J BONE MINER RES, V16, P731, DOI 10.1359/jbmr.2001.16.4.731
   Silkstone D, 2008, NAT CLIN PRACT RHEUM, V4, P413, DOI 10.1038/ncprheum0838
   *SMITH NEPH INC, 2009, EXOGEN 4000 LOW INT
   STEWART HF, ESSENTIALS MED ULTRA, P81
   Sun JS, 2001, J BIOMED MATER RES, V57, P449, DOI 10.1002/1097 4636(20011205)57:3<449::AID JBM1188>3.0.CO;2 0
   Sun JS, 1999, J BIOMED MATER RES, V46, P253, DOI 10.1002/(SICI)1097 4636(199908)46:2<253::AID JBM15>3.3.CO;2 Y
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Takayama T, 2007, LIFE SCI, V80, P965, DOI 10.1016/j.lfs.2006.11.037
   Takeuchi R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2451
   Tempany CMC, 2003, RADIOLOGY, V226, P897, DOI 10.1148/radiol.2271020395
   Turner CH, 1998, BONE, V23, P399, DOI 10.1016/S8756 3282(98)00118 5
   Unsworth J, 2007, ULTRASOUND MED BIOL, V33, P1468, DOI 10.1016/j.ultrasmedbio.2006.12.003
   Wang FS, 2004, BONE, V35, P114, DOI 10.1016/j.bone.2004.02.012
   Warden SJ, 2001, BIOCHEM BIOPH RES CO, V286, P443, DOI 10.1006/bbrc.2001.5412
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959 437X(98)80068 3
   WILTINK A, 1995, ULTRASOUND MED BIOL, V21, P121, DOI 10.1016/0301 5629(94)00092 1
   Woo SK, 2002, MOL CELL BIOL, V22, P5753, DOI 10.1128/MCB.22.16.5753 5760.2002
   Yang RS, 2005, BONE, V36, P276, DOI 10.1016/j.bone.2004.10.009
   Ye CP, 2007, CELL BIOCHEM FUNCT, V25, P267, DOI 10.1002/cbf.1330
NR 84
TC 28
Z9 37
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD AUG
PY 2010
VL 47
IS 2
BP 320
EP 330
DI 10.1016/j.bone.2010.04.604
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 632SW
UT WOS:000280449300019
PM 20435172
DA 2025 08 17
ER

PT J
AU Canalis, E
AF Canalis, Ernesto
TI NEW TREATMENT MODALITIES IN OSTEOPOROSIS
SO ENDOCRINE PRACTICE
LA English
DT Article; Proceedings Paper
CT AACE 19th Annual Meeting and Clinical Congress
CY APR 21 25, 2010
CL Boston, MA
SP AACE
ID BONE MINERAL DENSITY; GROWTH FACTOR I; CATHEPSIN K; POSTMENOPAUSAL
   WOMEN; PARATHYROID HORMONE; TARGETED DISRUPTION; STRONTIUM RANELATE;
   VERTEBRAL FRACTURE; DOUBLE BLIND; SRC KINASE
AB Objective: To describe recently discovered agents for the management of osteoporosis.
   Methods: A literature review (PubMed search) was conducted to identify agents at various stages of development for osteoporosis treatment. Agents under study or review for approval were included.
   Results: In menopause, bone remodeling is increased, and agents that suppress bone resorption can stabilize bone mass. In contrast, agents that target the osteoblast can increase bone formation and bone mass. Novel antiresorptive agents can target the formation or the activity of osteoclasts. They include denosumab, an antibody to receptor activated nuclear factor kappa B; new selective estrogen receptor modulators, such as bazedoxifene; and cathepsin K inhibitors, such as odanacatib. Src kinase inhibitors are in the early phases of development. Parathyroid hormone is the only approved anabolic agent for the treatment of osteoporosis. Novel anabolic therapies for osteoporosis may include the use of factors with anabolic properties for bone or the neutralization of growth factor antagonists. Recent discoveries have demonstrated that the Wnt/beta catenin signaling pathway has a central role in osteoblastic cell differentiation. Antibodies to Wnt antagonists, such as sclerostin, are under development as new therapeutic approaches for osteoporosis. Anabolic therapies have the potential to enhance bone mass, but their long term safety must be proven.
   Conclusions: New developments in the treatment of osteoporosis include novel antiresorptive and anabolic agents. Their success will depend on their long term effectiveness and safety profile. (Endocr Pract. 2010;16:855 863)
C1 St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06105 USA.
   [Canalis, Ernesto] Univ Connecticut, Sch Med, Farmington, CT USA.
C3 Saint Francis Hospital & Medical Center; University of Connecticut
RP Canalis, E (通讯作者)，St Francis Hosp & Med Ctr, Dept Res, 114 Woodland St, Hartford, CT 06105 USA.
EM ecanalis@stfranciscare.org
FU NIAMS NIH HHS [AR021707, R37 AR021707, R01 AR021707] Funding Source:
   Medline; NIDDK NIH HHS [DK042424, R01 DK045227, R01 DK042424, DK045227]
   Funding Source: Medline
CR Archer DF, 2009, MENOPAUSE, V16, P1109, DOI 10.1097/gme.0b013e3181a818db
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI DOI 10.1056/NEJMOA067312
   Bodine PVN, 2009, BONE, V44, P1063, DOI 10.1016/j.bone.2009.02.013
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Brömme D, 2009, EXPERT OPIN INV DRUG, V18, P585, DOI [10.1517/13543780902832661, 10.1517/13543780902832661 ]
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Bühling F, 1999, AM J RESP CELL MOL, V20, P612
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Canalis E, 2005, NEW ENGL J MED, V352, P2014, DOI 10.1056/NEJMe058080
   CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885
   CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250
   Cosman F, 2010, J CLIN ENDOCR METAB, V95, P151, DOI 10.1210/jc.2009 0358
   Cummings SR, 2008, J BONE MINER RES, V23, pS81
   Cummings SR, 2008, NEW ENGL J MED, V359, P697, DOI 10.1056/NEJMoa0800743
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810
   Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood 2007 03 077685
   Fajardo RJ, 2010, BONE, V46, P64, DOI 10.1016/j.bone.2009.09.018
   Fratzl Zelman N, 2004, J CLIN ENDOCR METAB, V89, P1538, DOI 10.1210/jc.2003 031055
   Gaddy Kurten D, 2002, ENDOCRINOLOGY, V143, P74, DOI 10.1210/en.143.1.74
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Gazzerro Elisabetta, 2006, Expert Rev Endocrinol Metab, V1, P47, DOI 10.1586/17446651.1.1.47
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Giles RH, 2003, BBA REV CANCER, V1653, P1, DOI 10.1016/S0304 419X(03)00005 2
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Gowen M, 2000, J CLIN INVEST, V105, P1595, DOI 10.1172/JCI9038
   Grinspoon S, 2002, J CLIN ENDOCR METAB, V87, P2883, DOI 10.1210/jc.87.6.2883
   Grinspoon S, 1996, J CLIN ENDOCR METAB, V81, P3864, DOI 10.1210/jc.81.11.3864
   Grisanti M, 2006, J BONE MINER RES, V21, pS25
   Hannon RA, 2010, J BONE MINER RES, V25, P463, DOI 10.1359/jbmr.090830
   Ho N, 1999, J BONE MINER RES, V14, P1649, DOI 10.1359/jbmr.1999.14.10.1649
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Horne WC, 2005, IMMUNOL REV, V208, P106, DOI 10.1111/j.0105 2896.2005.00335.x
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002 021122
   Hou WS, 2001, AM J PATHOL, V159, P2167, DOI 10.1016/S0002 9440(10)63068 4
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Khosla S, 2009, NEW ENGL J MED, V361, P818, DOI 10.1056/NEJMe0905480
   Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074 5521(01)00056 4
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015
   Langlois JA, 1998, J CLIN ENDOCR METAB, V83, P4257, DOI 10.1210/jc.83.12.4257
   LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003 4819 122 1 199501010 00009
   Li CY, 2006, J BONE MINER RES, V21, P865, DOI 10.1359/JBMR.060313
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   McClung MR, 2006, MENOPAUSE, V13, P377, DOI 10.1097/01.gme.0000188736.69617.4f
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Parfitt AM, 2001, J BONE MINER RES, V16, P1583, DOI 10.1359/jbmr.2001.16.9.1583
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Pennypacker B, 2009, BONE, V44, P199, DOI 10.1016/j.bone.2008.08.130
   Recker R, 2004, J BONE MINER RES, V19, P1628, DOI 10.1359/JBMR.040710
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Ruckle J, 2009, J BONE MINER RES, V24, P744, DOI 10.1359/JBMR.081208
   Silverman SL, 2008, J BONE MINER RES, V23, P1923, DOI 10.1359/JBMR.080710
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Wang YM, 2006, J BONE MINER RES, V21, P1350, DOI 10.1359/JBMR.060610
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Yakar S, 2009, J BONE MINER RES, V24, P1481, DOI [10.1359/JBMR.090226, 10.1359/jbmr.090226]
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674
NR 68
TC 24
Z9 30
U1 0
U2 4
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1530 891X
EI 1934 2403
J9 ENDOCR PRACT
JI Endocr. Pract.
PD SEP OCT
PY 2010
VL 16
IS 5
BP 855
EP 863
DI 10.4158/EP10048.RA
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Endocrinology & Metabolism
GA 672FZ
UT WOS:000283569700018
PM 20350910
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Gong, W
   Chen, XR
   Shi, TS
   Shao, XY
   An, XY
   Qin, JH
   Chen, X
   Jiang, Q
   Guo, BS
AF Gong, Wang
   Chen, Xingren
   Shi, Tianshu
   Shao, Xiaoyan
   An, Xueying
   Qin, Jianghui
   Chen, Xiang
   Jiang, Qing
   Guo, Baosheng
TI Network Pharmacology Based Strategy for the Investigation of the
   Anti Osteoporosis Effects and Underlying Mechanism of Zhuangguguanjie
   Formulation
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE osteoporosis; Zhuangguguanjie; network pharmacology; PI3K; AKT; mTOR
ID TRADITIONAL CHINESE MEDICINE; BONE; TRANSLATION; EFFICACY
AB As the society is aging, the increasing prevalence of osteoporosis has generated huge social and economic impact, while the drug therapy for osteoporosis is limited due to multiple targets involved in this disease. Zhuangguguanjie formulation (ZG) is extensively used in the clinical treatment of bone and joint diseases, but the underlying mechanism has not been fully described. This study aimed to examine the therapeutic effect and potential mechanism of ZG on postmenopausal osteoporosis. The ovariectomized (OVX) mice were treated with normal saline or ZG for 4 weeks after ovariectomy following a series of analyses. The bone mass density (BMD) and trabecular parameters were examined by micro CT. Bone remodeling was evaluated by the bone histomorphometry analysis and ELISA assay of bone turnover biomarkers in serum. The possible drug disease common targets were analyzed by network pharmacology. To predict the potential biological processes and related pathways, GO/KEGG enrichment analysis was performed. The effects of ZG on the differentiation phenotype of osteoclasts and osteoblasts and the predicted pathway were verified in vitro. The results showed that ZG significantly improved the bone mass and micro trabecular architecture in OVX mice compared with untreated OVX mice. ZG could promote bone formation and inhibit bone resorption to ameliorate ovariectomy induced osteoporosis as evidenced by increased number of osteoblast (N.Ob/Tb.Pm) and decreased number of osteoclast (N.Oc/Tb.Pm) in treated group compared with untreated OVX mice. After identifying potential drug disease common targets by network pharmacology, GO enrichment analysis predicted that ZG might affect various biological processes including osteoblastic differentiation and osteoclast differentiation. The KEGG enrichment analysis suggested that PI3K/Akt and mTOR signaling pathways could be the possible pathways. Furthermore, the experiments in vitro validated our findings. ZG significantly down regulated the expression of osteoclast differentiation markers, reduced osteoclastic resorption, and inhibited the phosphorylation of PI3K/Akt, while ZG obviously up regulated the expression of osteogenic biomarkers, promoted the formation of calcium nodules, and hampered the phosphorylation of 70S6K1/mTOR, which can be reversed by the corresponding pathway activator. Thus, our study suggested that ZG could inhibit the PI3K/Akt signaling pathway to reduce osteoclastic bone resorption as well as hamper the mTORC1/S6K1 signaling pathway to promote osteoblastic bone formation.
C1 [Gong, Wang; Chen, Xingren; Shi, Tianshu; Shao, Xiaoyan; An, Xueying; Qin, Jianghui; Chen, Xiang; Jiang, Qing; Guo, Baosheng] Nanjing Univ, Dept Sports Med & Adult Reconstruct Surg, Affiliated Hosp, Med Sch, Nanjing, Peoples R China.
   [Gong, Wang; Chen, Xingren; Shi, Tianshu; Shao, Xiaoyan; An, Xueying; Qin, Jianghui; Chen, Xiang; Jiang, Qing; Guo, Baosheng] Nanjing Univ, Nanjing Drum Tower Hosp, Med Sch, State Key Lab Pharmaceut Biotechnol, Nanjing, Peoples R China.
   [Chen, Xiang; Jiang, Qing; Guo, Baosheng] Nanjing Univ, Med Sch, Jiangsu Key Lab Mol Med, Nanjing, Peoples R China.
   [Jiang, Qing] Nanjing Univ, Model Anim Res Ctr MARC, Med Sch, Lab Bone & Joint Dis, Nanjing, Peoples R China.
C3 Nanjing University; Nanjing University; Nanjing University; Nanjing
   University
RP Jiang, Q; Guo, BS (通讯作者)，Nanjing Univ, Dept Sports Med & Adult Reconstruct Surg, Affiliated Hosp, Med Sch, Nanjing, Peoples R China.; Jiang, Q; Guo, BS (通讯作者)，Nanjing Univ, Nanjing Drum Tower Hosp, Med Sch, State Key Lab Pharmaceut Biotechnol, Nanjing, Peoples R China.; Jiang, Q; Guo, BS (通讯作者)，Nanjing Univ, Med Sch, Jiangsu Key Lab Mol Med, Nanjing, Peoples R China.; Jiang, Q (通讯作者)，Nanjing Univ, Model Anim Res Ctr MARC, Med Sch, Lab Bone & Joint Dis, Nanjing, Peoples R China.
EM qingi@nju.edu.cn; borisguo@nju.edu.cn
RI qin, jh/IWM 7624 2023; Gong, Wang/GPP 3300 2022; Shao,
   Xiaoyan/LSL 7461 2024; Xiang, Chen/LNP 2768 2024; Guo,
   Baosheng/ABD 4800 2021; Jiang, Qing/JXM 6827 2024
OI Guo, Baosheng/0000 0002 4510 5418; 
FU National Key Research and Development Program of China [2020YFC2004900];
   National Science Foundation of China [82000069, 81730067, 81991514,
   81972124]; Natural Science Foundation of Jiangsu Province of China
   [BK20200314]; Youth Thousand Talents Program of China [13004001];
   Research Team Start up Funds of Nanjing University [14912203]; Jiangsu
   Provincial Key Medical Center Foundation; Jiangsu Provincial Medical
   Outstanding Talent Foundation; Jiangsu Provincial Medical Youth Talent
   Foundation; Jiangsu Provincial Key Medical Talent Foundation;
   Fundamental Research Funds for the Central Universities [14380493,
   14380494]
FX This work was supported by research grants from the National Key
   Research and Development Program of China (No. 2020YFC2004900); the
   National Science Foundation of China (Nos. 82000069, 81730067, 81991514,
   and 81972124); the Natural Science Foundation of Jiangsu Province of
   China (No. BK20200314); the Youth Thousand Talents Program of China (No.
   13004001); the Research Team Start up Funds of Nanjing University (No.
   14912203), the Jiangsu Provincial Key Medical Center Foundation, the
   Jiangsu Provincial Medical Outstanding Talent Foundation, the Jiangsu
   Provincial Medical Youth Talent Foundation, and the Jiangsu Provincial
   Key Medical Talent Foundation; and the Fundamental Research Funds for
   the Central Universities (Nos. 14380493 and 14380494).
CR Brommage R, 2020, HANDB EXP PHARMACOL, V262, P451, DOI 10.1007/164_2019_329
   Chai LJ, 2018, CELL PHYSIOL BIOCHEM, V48, P2123, DOI 10.1159/000492554
   Chan T O, 2001, Sci STKE, V2001, ppe1, DOI 10.1126/stke.2001.66.pe1
   Chao J, 2017, BIOCHEM PHARMACOL, V139, P94, DOI 10.1016/j.bcp.2017.06.123
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Dai QG, 2017, CELL DEATH DIFFER, V24, P1886, DOI 10.1038/cdd.2017.110
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Estell EG, 2021, NAT REV ENDOCRINOL, V17, P31, DOI 10.1038/s41574 020 00426 5
   Fuggle NR, 2019, NAT REV ENDOCRINOL, V15, P535, DOI 10.1038/s41574 019 0220 8
   Gao JL, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6666836
   Gatti D, 2019, J POPUL THER CLIN PH, V26, pE1, DOI 10.15586/jptcp.v26.i4.646
   Holz MK, 2021, CELL, V184, P2255, DOI 10.1016/j.cell.2021.03.060
   Hoxhaj G, 2020, NAT REV CANCER, V20, P74, DOI 10.1038/s41568 019 0216 7
   Huang B, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005426
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim BJ, 2019, CELL MOL LIFE SCI, V76, P1243, DOI 10.1007/s00018 018 2981 y
   Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580 019 0199 y
   Liu YX, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005467.pub2
   Lu K, 2018, AM J TRANSL RES, V10, P411
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Mosca E, 2012, BIOTECHNOL ADV, V30, P131, DOI 10.1016/j.biotechadv.2011.08.004
   Reagan Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07 9574LSF
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Wang X, 2021, CHIN J NAT MEDICINES, V19, P1, DOI 10.1016/S1875 5364(21)60001 8
   Weitzmann MN, 2016, NAT REV ENDOCRINOL, V12, P518, DOI 10.1038/nrendo.2016.91
   Xu Q, 2019, BIOCHEM BIOPH RES CO, V508, P902, DOI 10.1016/j.bbrc.2018.11.201
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang XL, 2016, CHINESE MED J PEKING, V129, P891, DOI 10.4103/0366 6999.179789
   Zhao HY, 2020, J CELL PHYSIOL, V235, P2997, DOI 10.1002/jcp.29205
   Zhao JL, 2021, COMPLEMENT THER CLIN, V44, DOI 10.1016/j.ctcp.2021.101419
   Zhou ZC, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/1646905
   Zhu H, 2010, OSTEOPOROSIS INT, V21, P765, DOI 10.1007/s00198 009 1010 2
NR 34
TC 6
Z9 7
U1 1
U2 25
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 1
PY 2021
VL 12
AR 727808
DI 10.3389/fphar.2021.727808
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WH6JR
UT WOS:000707781900001
PM 34658868
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ohishi, M
   Chiusaroli, R
   Ominsky, M
   Asuncion, F
   Thomas, C
   Khatri, R
   Kostenuik, P
   Schipani, E
AF Ohishi, Masanobu
   Chiusaroli, Riccardo
   Ominsky, Michael
   Asuncion, Frank
   Thomas, Clare
   Khatri, Richa
   Kostenuik, Paul
   Schipani, Ernestina
TI Osteoprotegerin Abrogated Cortical Porosity and Bone Marrow Fibrosis in
   a Mouse Model of Constitutive Activation of the PTH/PTHrP Receptor
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID MCCUNE ALBRIGHT SYNDROME; GROWTH FACTOR BETA; PRIMARY
   HYPERPARATHYROIDISM; PARATHYROID HORMONE; IN VIVO; CYNOMOLGUS MONKEYS;
   TARGETED DELETION; CANCELLOUS BONE; MEDICAL THERAPY; TRABECULAR BONE
AB Intracortical porosities and marrow fibrosis are hallmarks of hyperparathyroidism and are present in bones of transgenic mice expressing constitutively active parathyroid hormone/parathyroid hormone related protein receptors (PPR*Tg). Cortical porosity is the result of osteoclast activity; however, the etiology of marrow fibrosis is poorly understood. While osteoclast numbers and activity are regulated by osteoprotegerin (OPG), bisphosphonates suppress osteoclast activity but not osteoclast numbers. We therefore used OPG and bisphosphonates to evaluate the extent to which osteoclasts, as opposed to bone resorption, regulate marrow fibrosis in PPR*Tg mice after treatment of animals with vehicle, OPG, alendronate, or zoledronate. All three agents similarly increased trabecular bone volume in both PPR*Tg and control mice, suggesting that trabecular bone resorption was comparably suppressed by these agents. However, the number of trabecular osteoclasts was greatly decreased by OPG but not by either alendronate or zoledronate. Furthermore, intracortical porosity and marrow fibrosis were virtually abolished by OPG treatment, whereas alendronate and zoledronate only partially reduced these two parameters. The greater reductions in cortical porosity and increments in cortical bone mineral density with OPG in PPR*Tg mice were associated with greater improvements in bone strength. The differential effect of OPG versus bisphosphonates on marrow fibrosis, despite similar effects on trabecular bone volume, suggests that marrow fibrosis was related not only to bone resorption but also to the presence of osteoclasts. (Am J Pathol 2009, 174:2160 2171; DOI:10.2353/ajpath.2009.081026)
C1 [Ohishi, Masanobu; Chiusaroli, Riccardo; Thomas, Clare; Khatri, Richa; Kostenuik, Paul; Schipani, Ernestina] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA USA.
   [Ominsky, Michael; Asuncion, Frank; Kostenuik, Paul] Amgen Inc, Metab Disorders, Thousand Oaks, CA 91320 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard Medical School; Amgen
RP Schipani, E (通讯作者)，Thier 11 MGH,50 Blossom St, Boston, MA 02114 USA.
EM paulk@amgen.com
OI Asuncion, Frank/0000 0003 2684 3244
FU Amgen Inc
FX Supported by a grant from Amgen Inc to E.S.
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Augat P, 2006, AGE AGEING, V35, P27, DOI 10.1093/ageing/afl081
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   BALENA R, 1993, J CLIN INVEST, V92, P2577, DOI 10.1172/JCI116872
   Breuil V, 1998, J BONE MINER RES, V13, P1721, DOI 10.1359/jbmr.1998.13.11.1721
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Chapurlat RD, 2006, J BONE MINER RES, V21, pP114, DOI 10.1359/JBMR.06S222
   Crowther M, 2001, J LEUKOCYTE BIOL, V70, P478
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   GLORIEUX FH, 2002, J BONE MINER RES S2, V21, pP110
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Hansen MF, 2006, J BONE MINER RES, V21, pP58, DOI 10.1359/JBMR.06S211
   HENE RJ, 1990, BONE, V11, P15, DOI 10.1016/8756 3282(90)90066 8
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Khan A, 2000, CAN MED ASSOC J, V163, P184
   Khosla S, 2002, J BONE MINER RES, V17, pN103
   Kuter DJ, 2007, BRIT J HAEMATOL, V139, P351, DOI 10.1111/j.1365 2141.2007.06807.x
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Leet AI, 2004, J BONE MINER RES, V19, P571, DOI 10.1359/JBMR.0301262
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Lloyd SAJ, 2008, CALCIFIED TISSUE INT, V82, P361, DOI 10.1007/s00223 008 9133 6
   Lotinun S, 2005, ENDOCRINOLOGY, V146, P4074, DOI 10.1210/en.2005 0480
   Lotinun S, 2004, J BONE MINER RES, V19, P1165, DOI 10.1359/JBMR.040404
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   MARSHALL MJ, 1993, CALCIFIED TISSUE INT, V52, P21, DOI 10.1007/BF00675622
   MCCALDEN RW, 1993, J BONE JOINT SURG AM, V75A, P1193, DOI 10.2106/00004623 199308000 00009
   Miller MA, 1998, BONE, V23, P257, DOI 10.1016/S8756 3282(98)00098 2
   MOHAN S, 1991, CLIN ORTHOP RELAT R, P30
   Monier Faugere MC, 1999, J BONE MINER RES, V14, P1768, DOI 10.1359/jbmr.1999.14.10.1768
   Morony S, 2005, ENDOCRINOLOGY, V146, P3235, DOI 10.1210/en.2004 1583
   Nakamura M, 2003, ENDOCRINOLOGY, V144, P5441, DOI 10.1210/en.2003 0717
   Ominsky MS, 2007, OSTEOPOROSIS INT, V18, P1073, DOI 10.1007/s00198 007 0363 7
   PARISIEN M, 1990, J CLIN ENDOCR METAB, V70, P930, DOI 10.1210/jcem 70 4 930
   Plotkin H, 2003, J CLIN ENDOCR METAB, V88, P4569, DOI 10.1210/jc.2003 030050
   PYRAH LN, 1966, BRIT J SURG, V53, P245, DOI 10.1002/bjs.1800530402
   Pysklywec MW, 2000, J MATER SCI MATER M, V11, P313, DOI 10.1023/A:1008913501297
   RAO DS, 1993, NEW ENGL J MED, V328, P171, DOI 10.1056/NEJM199301213280304
   Redlich K, 2004, AM J PATHOL, V164, P543, DOI 10.1016/S0002 9440(10)63144 6
   Riminucci A, 2003, BONE, V33, P434, DOI 10.1016/S8756 3282(03)00064 4
   Robinson JA, 1996, ENDOCRINOLOGY, V137, P615, DOI 10.1210/en.137.2.615
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Roschger P, 2001, BONE, V29, P185, DOI 10.1016/S8756 3282(01)00485 9
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Samadfam R, 2007, ENDOCRINOLOGY, V148, P2778, DOI 10.1210/en.2006 1475
   Shimada M, 2008, J BIOL CHEM, V283, P21002, DOI 10.1074/jbc.M710354200
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Steiniche T, 2000, BONE, V26, P535, DOI 10.1016/S8756 3282(00)00260 X
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Turner CH, 2002, OSTEOPOROSIS INT, V13, P97, DOI 10.1007/s001980200000
   Wang JC, 2004, EXP HEMATOL, V32, P905, DOI 10.1016/j.exphem.2004.07.006
   Weinstein LS, 2006, J BONE MINER RES, V21, pP120, DOI 10.1359/JBMR.06S223
   Wise LM, 2005, CALCIFIED TISSUE INT, V77, P367, DOI 10.1007/s00223 005 0062 3
   Yeni YN, 1997, BONE, V21, P453, DOI 10.1016/S8756 3282(97)00173 7
NR 54
TC 27
Z9 27
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0002 9440
EI 1525 2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD JUN
PY 2009
VL 174
IS 6
BP 2160
EP 2171
DI 10.2353/ajpath.2009.081026
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA 449ZT
UT WOS:000266370600020
PM 19389927
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Gartrell, BA
   Coleman, RE
   Fizazi, K
   Miller, K
   Saad, F
   Sternberg, CN
   Galsky, MD
AF Gartrell, Benjamin A.
   Coleman, Robert E.
   Fizazi, Karim
   Miller, Kurt
   Saad, Fred
   Sternberg, Cora N.
   Galsky, Matthew D.
TI Toxicities Following Treatment with Bisphosphonates and Receptor
   Activator of Nuclear Factor κB Ligand Inhibitors in Patients with
   Advanced Prostate Cancer
SO EUROPEAN UROLOGY
LA English
DT Article
DE Prostate cancer; Systematic review; Bone targeted agents;
   Bisphosphonates; Denosumab; Adverse events
ID ANDROGEN DEPRIVATION THERAPY; BONE MINERAL DENSITY; RANDOMIZED
   CONTROLLED TRIAL; ZOLEDRONIC ACID; RISK FACTORS; MULTIPLE MYELOMA;
   PREVENTIVE MEASURES; JAW ONJ; OSTEONECROSIS; MEN
AB Context: Advanced prostate cancer (PCa) is associated with skeletal complications, both as a result of bone metastases and because of fractures associated with fragility due to androgen deprivation therapy (ADT). Osteoclast inhibitors are commonly used to reduce skeletal complications but are associated with a number of potential adverse events.
   Objective: To review clinical trials of osteoclast inhibitors in advanced PCa, to discuss the adverse event profile of these agents, and to discuss strategies to address specific adverse events.
   Evidence acquisition: PubMed was searched for reports of clinical trials of osteoclast inhibitors in advanced PCa. As zoledronic acid and denosumab are used most commonly in this disease, these trials were the focus. The literature was reviewed to identify key publications addressing the prevention and management of adverse events associated with these drugs.
   Evidence synthesis: The major findings of the trials and the adverse events are discussed. Prevention and management of common adverse events are addressed.
   Conclusions: Zoledronic acid prevents loss of bone mineral density associated with ADT and delays skeletal related events in metastatic castration resistant PCa (mCRPC). Denosumab reduces the incidence of fragility fractures associated with ADT, delays the onset of bone metastases in nonmetastatic castration resistant disease, and is superior to zoledronic acid in the prevention of skeletal complications in mCRPC. Adverse events associated with both agents include osteonecrosis of the jaw and hypocalcemia. Hypocalcemia is more common with denosumab. Zoledronic acid requires dose modifications for renal insufficiency, is contraindicated in severe renal insufficiency, and has been associated with deterioration of renal function. Appropriate patient selection with close attention to dental health, supplementation with calcium and vitamin D, and monitoring of laboratory values are effective strategies to minimize the impact of adverse events associated with osteoclast inhibitors in advanced PCa. (C) 2013 European Association of Urology. Published by Elsevier B. V. All rights reserved.
C1 [Gartrell, Benjamin A.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med Oncol, Bronx, NY 10467 USA.
   [Coleman, Robert E.] CR UK YCR Sheffield Canc Res Ctr, Weston Pk Hosp, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England.
   [Fizazi, Karim] Univ Paris 11, Inst Gustave Roussy, Dept Canc Med, Villejuif, France.
   [Miller, Kurt] Univ Hosp Charite, Dept Urol, Berlin, Germany.
   [Saad, Fred] Ctr Hosp Univ Montreal, CRCHUM, Div Urol, Montreal, PQ, Canada.
   [Sternberg, Cora N.] San Camillo & Forlanini Hosp, Dept Med Oncol, Rome, Italy.
   [Galsky, Matthew D.] Mt Sinai Sch Med, Tisch Canc Ctr Inst, New York, NY USA.
C3 Montefiore Medical Center; Albert Einstein College of Medicine; Yeshiva
   University; Weston Park Hospital; Universite Paris Saclay; UNICANCER;
   Gustave Roussy; Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin; Universite de Montreal;
   Azienda Ospedaliera San Camillo Forlanini; Icahn School of Medicine at
   Mount Sinai
RP Gartrell, BA (通讯作者)，Montefiore Med Ctr, Albert Einstein Coll Med, 111 E 210th St,Hofheimer 100, Bronx, NY 10467 USA.
EM bgartrel@montefiore.org
RI Saad, Fred/ADN 9925 2022
FU Novartis
FX Benjamin A. Gartrell certifies that all conflicts of interest, including
   specific financial interests and relationships and affiliations relevant
   to the subject matter or materials discussed in the manuscript (eg,
   employment/affiliation, grants or funding, consultancies, honoraria,
   stock ownership or options, expert testimony, royalties, or patents
   filed, received, or pending), are the following: Robert Coleman has
   received honoraria from Amgen and Bayer and has provided expert
   testimony for and received research funding from Novartis; Matthew
   Galsky has been on advisory boards for GSK, Astellas, Dendreon, and
   Jannsen; Fred Saad has been a consultant and conducted research for, and
   has received honoraria from, Novartis and Amgen; Karim Fizazi has
   participated in advisory boards for and received honoraria from Amgen,
   Bayer, and Novartis; Cora Sternberg: Novartis.
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   [Anonymous], 2012, XGEV DEN
   Aragon Ching JB, 2009, CANCER INVEST, V27, P221, DOI 10.1080/07357900802208608
   Bagan JV, 2006, ORAL ONCOL, V42, P327, DOI 10.1016/j.oraloncology.2005.08.001
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Bhoopalam N, 2009, J UROLOGY, V182, P2257, DOI 10.1016/j.juro.2009.07.046
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Buonerba C, 2013, EXPERT OPIN BIOL TH, V13, P149, DOI 10.1517/14712598.2012.756470
   Campbell SC, 2010, UROLOGY, V75, P1138, DOI 10.1016/j.urology.2009.11.083
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Dearnaley DP, 2003, J NATL CANCER I, V95, P1300, DOI 10.1093/jnci/djg038
   Dimopoulos MA, 2009, ANN ONCOL, V20, P117, DOI 10.1093/annonc/mdn554
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Fizazi K, 2009, J UROLOGY, V182, P509, DOI 10.1016/j.juro.2009.04.023
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Israeli RS, 2007, CLIN GENITOURIN CANC, V5, P271, DOI 10.3816/CGC.2007.n.003
   JACOBS SC, 1983, UROLOGY, V21, P337, DOI 10.1016/0090 4295(83)90147 4
   Jadu F, 2007, ANN ONCOL, V18, P2015, DOI 10.1093/annonc/mdm370
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   López AM, 2005, OSTEOPOROSIS INT, V16, P707, DOI 10.1007/s00198 004 1799 7
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mavrokokki T, 2007, J ORAL MAXIL SURG, V65, P415, DOI 10.1016/j.joms.2006.10.061
   Michaelson MD, 2007, J CLIN ONCOL, V25, P1038, DOI 10.1200/JCO.2006.07.3361
   Olson Karin, 2007, J Oncol Pharm Pract, V13, P223, DOI 10.1177/1078155207080806
   Polascik TJ, 2005, UROLOGY, V66, P1054, DOI 10.1016/j.urology.2005.05.035
   Ripamonti CI, 2009, ANN ONCOL, V20, P137, DOI 10.1093/annonc/mdn526
   Rodrigues P, 2007, INT J UROL, V14, P317, DOI 10.1111/j.1442 2042.2006.01721.x
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Ryan CW, 2006, J UROLOGY, V176, P972, DOI 10.1016/j.juro.2006.04.078
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Sathiakumar N, 2011, PROSTATE CANCER P D, V14, P177, DOI 10.1038/pcan.2011.7
   Siegel R, 2012, CA CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Smith MR, 2005, J CLIN ONCOL, V23, P2918, DOI 10.1200/JCO.2005.01.529
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Snedecor Sonya J, 2013, J Med Econ, V16, P19, DOI 10.3111/13696998.2012.719054
   Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584
   Walter C, 2008, EUR UROL, V54, P1066, DOI 10.1016/j.eururo.2008.06.070
   Wark JD, 2012, OSTEOPOROSIS INT, V23, P503, DOI 10.1007/s00198 011 1563 8
   Weinfurt KP, 2006, ANN ONCOL, V17, P986, DOI 10.1093/annonc/mdl041
   Wessel JH, 2008, J ORAL MAXIL SURG, V66, P625, DOI 10.1016/j.joms.2007.11.032
   Zervas K, 2006, BRIT J HAEMATOL, V134, P620, DOI 10.1111/j.1365 2141.2006.06230.x
NR 50
TC 36
Z9 38
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302 2838
EI 1873 7560
J9 EUR UROL
JI Eur. Urol.
PD FEB
PY 2014
VL 65
IS 2
BP 278
EP 286
DI 10.1016/j.eururo.2013.05.015
PG 9
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 289EL
UT WOS:000329664100008
PM 23706567
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Reagan, P
   Pani, A
   Rosner, MH
AF Reagan, Patrick
   Pani, Antonello
   Rosner, Mitchell H.
TI Approach to Diagnosis and Treatment of Hypercalcemia in a Patient With
   Malignancy
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Hypercalcemia; cancer; parathyroid hormone related protein;
   bisphosphonate
ID CANCER RELATED HYPERCALCEMIA; CALCIUM SENSING RECEPTOR; HORMONE RELATED
   PROTEIN; HIGH DOSE PAMIDRONATE; GALLIUM NITRATE; MULTIPLE MYELOMA; HUMAN
   VOLUNTEERS; BONE RESORPTION; DOUBLE BLIND; MECHANISMS
AB Hypercalcemia is a common complication of malignancy and portends a worse prognosis. It causes a variety of symptoms in patients, which can range from confusion and polyuria to coma and death. There are 4 broad mechanistic categories to classify hypercalcemia of malignancy: local osteolysis secondary to metastatic cancer or multiple myeloma, excess parathyroid related hormone, excess 1,25 dihydroxyvitamin D production, and ectopic parathyroid hormone production. Volume expansion with normal saline solution and treatment with intravenous bisphosphonates to decrease osteoclast mediated bone destruction are effective initial therapies. Calcitonin, gallium nitrate, and corticosteroids can serve as adjunctive therapies. Denosumab is an attractive therapeutic option for refractory cases of hypercalcemia, although more data are required before this therapy can be recommended. (C) 2013 by the National Kidney Foundation, Inc.
C1 [Reagan, Patrick; Rosner, Mitchell H.] Univ Virginia Hlth Syst, Div Nephrol, Charlottesville, VA 22908 USA.
   [Pani, Antonello] Azienda Osped G Brotzu, Div Nephrol & Dialysis, Cagliari, Italy.
C3 University of Virginia; University of Virginia (UVA) Health System
RP Rosner, MH (通讯作者)，Univ Virginia Hlth Syst, Div Nephrol, Box 800133, Charlottesville, VA 22908 USA.
EM mhr9r@virginia.edu
RI Reagan, Patrick/AAN 3314 2020; Pani, Antonello/HDN 3366 2022
CR Akhtari M, 2008, CANCER BIOL THER, V7, P3, DOI 10.4161/cbt.7.1.5163
   AMIN D, 1992, J LIPID RES, V33, P1657
   BINSTOCK ML, 1980, ANN INTERN MED, V93, P269, DOI 10.7326/0003 4819 93 2 269
   Bodmer M, 2007, NEPHROL DIAL TRANSPL, V22, P2366, DOI 10.1093/ndt/gfm209
   Boikos SA, 2012, J CLIN ONCOL, V30, pE299, DOI 10.1200/JCO.2012.41.7923
   Bringhurst R., 2011, Williams Textbook of Endocrinology: Hormones and disorders of mineral metabolism, V12th, P1237
   Chistensen SE, 2011, CURR OPIN ENDOCRINOL, V18, P359
   Christensen SE, 2008, CLIN ENDOCRINOL, V69, P713, DOI 10.1111/j.1365 2265.2008.03259.x
   Cvitkovic FR, 2006, CANCER J, V12, P47, DOI 10.1097/00130404 200601000 00009
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   Desikan R, 2002, BRIT J HAEMATOL, V119, P496, DOI 10.1046/j.1365 2141.2002.03826.x
   DODWELL DJ, 1992, POSTGRAD MED J, V68, P434, DOI 10.1136/pgmj.68.800.434
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   HALL TJ, 1990, BONE MINER, V8, P211, DOI 10.1016/0169 6009(90)90106 P
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hiroi Furuya E, 1999, CALCIFIED TISSUE INT, V64, P219, DOI 10.1007/s002239900606
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P1603, DOI 10.1210/jc.2002 020773
   Horwitz MJ, 2005, J BONE MINER RES, V20, P1792, DOI 10.1359/JBMR.050602
   Hutchesson AC, 1995, POSTGRAD MED J, V71, P29
   Johnson RW, 2011, CANCER RES, V71, P822, DOI 10.1158/0008 5472.CAN 10 2993
   LeGrand SB, 2008, ANN INTERN MED, V149, P259, DOI 10.7326/0003 4819 149 4 200808190 00007
   Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003 4819 145 4 200608150 00004
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Markowitz GS, 2003, KIDNEY INT, V64, P281, DOI 10.1046/j.1523 1755.2003.00071.x
   Markowitz GS, 2002, AM J KIDNEY DIS, V39, P1118, DOI 10.1053/ajkd.2002.32797
   Markowitz GS, 2001, J AM SOC NEPHROL, V12, P1164, DOI 10.1681/ASN.V1261164
   NUSSBAUM SR, 1993, AM J MED, V95, P297, DOI 10.1016/0002 9343(93)90282 T
   Roodman GD, 2010, J CELL BIOCHEM, V109, P283, DOI 10.1002/jcb.22403
   Roodman GD, 1997, CANCER, V80, P1557, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1557::AID CNCR5>3.3.CO;2 K
   Rosner MH, 2012, CLIN J AM SOC NEPHRO, V7, P1722, DOI 10.2215/CJN.02470312
   Sanders JL, 2000, ENDOCRINOLOGY, V141, P4357, DOI 10.1210/en.141.12.4357
   STEWART A F, 1980, New England Journal of Medicine, V303, P1377, DOI 10.1056/NEJM198012113032401
   Stewart AF, 2005, NEW ENGL J MED, V352, P373, DOI 10.1056/NEJMcp042806
   Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306
   SUKI WN, 1970, NEW ENGL J MED, V283, P836, DOI 10.1056/NEJM197010152831603
   Syed MA, 2001, J CLIN ENDOCR METAB, V86, P1525, DOI 10.1210/jc.86.4.1525
   Toka HR, 2012, J AM SOC NEPHROL, V23, P1879, DOI 10.1681/ASN.2012030323
   VanHouten JN, 2006, J CLIN ENDOCR METAB, V91, P580, DOI 10.1210/jc.2005 2095
   VASSILOPOULOUSELLIN R, 1993, CANCER, V71, P1309, DOI 10.1002/1097 0142(19930215)71:4<1309::AID CNCR2820710423>3.0.CO;2 M
   VAUGHN CB, 1974, CANCER AM CANCER SOC, V34, P1268, DOI 10.1002/1097 0142(197410)34:4<1268::AID CNCR2820340437>3.0.CO;2 X
   WARRELL RP, 1988, ANN INTERN MED, V108, P669, DOI 10.7326/0003 4819 108 5 669
   WARRELL RP, 1984, J CLIN INVEST, V73, P1487, DOI 10.1172/JCI111353
   WARRELL RP, 1987, J CLIN ONCOL, V5, P292, DOI 10.1200/JCO.1987.5.2.292
   Wysolmerski JJ, 2012, J CLIN ENDOCR METAB, V97, P2947, DOI 10.1210/jc.2012 2142
NR 45
TC 39
Z9 40
U1 0
U2 8
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0272 6386
EI 1523 6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD JAN
PY 2014
VL 63
IS 1
BP 141
EP 147
DI 10.1053/j.ajkd.2013.06.025
PG 7
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 281PA
UT WOS:000329112300022
PM 24021907
DA 2025 08 17
ER

PT J
AU Kennedy, K
   Patel, H
AF Kennedy, Kenneth
   Patel, Hetalkumari
TI Update on the Pharmacological Prevention of Skeletal related Events in
   Cancer Patients
SO ORTHOPEDICS
LA English
DT Article
ID THERAPEUTIC OPPORTUNITIES; MULTIPLE MYELOMA; BONE METASTASIS; ZOLEDRONIC
   ACID; BREAST CANCER; DOUBLE BLIND; MECHANISMS
AB Metastases to the bone are a frequent complication of advanced cancer. Bone metastases have been linked to skeletal related events, which is the composite endpoint used in clinical trials evaluating therapy to minimize these complications. This article discusses bisphosphonates, which are the historical standard for the prevention of skeletal related events in patients with metastases from solid tumors and multiple myeloma, and denosumab, which is the first Food and Drug Administration approved receptor activator of nuclear factor kappa beta ligand (RANKL) inhibitor.
C1 [Kennedy, Kenneth; Patel, Hetalkumari] UK HealthCare Pharm Serv, Lexington, KY 40536 USA.
RP Patel, H (通讯作者)，UK HealthCare Pharm Serv, 800 Rose St H 110, Lexington, KY 40536 USA.
EM hspate00@email.uky.edu
CR [Anonymous], XGEV DEN PACK INS
   Bottiglieri S, 2010, ORTHOPEDICS, V33, P577, DOI 10.3928/01477447 20100625 20
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Green J, 2010, SEMIN ONCOL, V37, pS3, DOI 10.1053/j.seminoncol.2010.06.003
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   PERCIVAL RC, 1987, EUR J SURG ONCOL, V13, P41
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen LS, 2001, CANCER J, V7, P377
   SAAD F, 2011, ANN ONCOL IN PRESS
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Van Poznak CH, 2011, J CLIN ONCOL, V29, P1221, DOI 10.1200/JCO.2010.32.5209
   Zervas K, 2006, BRIT J HAEMATOL, V134, P620, DOI 10.1111/j.1365 2141.2006.06230.x
NR 14
TC 3
Z9 3
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0147 7447
J9 ORTHOPEDICS
JI Orthopedics
PD DEC
PY 2011
VL 34
IS 12
BP 982
EP 985
DI 10.3928/01477447 20111021 21
PG 4
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 864AJ
UT WOS:000298209100022
PM 22147215
DA 2025 08 17
ER

PT J
AU Lee, SY
   Kim, M
   Hong, SY
   Kim, EJ
   Kim, JH
   Sohn, Y
   Jung, HS
AF Lee, Sungyub
   Kim, Minsun
   Hong, Sooyeon
   Kim, Eom Ji
   Kim, Jae Hyun
   Sohn, Youngjoo
   Jung, Hyuk Sang
TI Effects of Sparganii Rhizoma on Osteoclast Formation and
   Osteoblast Differentiation and on an OVX Induced Bone Loss Model
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE sparganii rhizoma; bone remodeling; osteoclast; osteoblast;
   ovariectomized
ID NF KAPPA B; TUMOR NECROSIS FACTOR; CARBONIC ANHYDRASE II; RECEPTOR
   ACTIVATOR; TRANSCRIPTION FACTOR; UP REGULATION; RANKL; FUSION; ACID;
   OSTEOPETROSIS
AB Postmenopausal osteoporosis is caused by an imbalance between osteoclasts and osteoblasts and causes severe bone loss. Osteoporotic medicines are classified into bone resorption inhibitors and bone formation promoters according to the mechanism of action. Long term use of bisphosphonate and selective estrogen receptor modulators (SERMs) can cause severe side effects in postmenopausal osteoporosis patients. Therefore, it is important to find alternative natural products that reduce osteoclast activity and increase osteoblast formation. Sparganii Rhizoma (SR) is the dried tuberous rhizome of Sparganium stoloniferum Buchanan Hamilton and is called "samreung" in Korea. However, to date, the effect of SR on osteoclast differentiation and the ovariectomized (OVX) induced bone loss model has not been reported. In vitro, tartrate resistant acid phosphatase (TRAP) staining, western blots, RT PCR and other methods were used to examine the effect of SR on osteoclast differentiation and osteoblasts. In vivo, we confirmed the effect of SR in a model of OVX induced postmenopausal osteoporosis. SR inhibited osteoclast differentiation and decreased the expression of TNF receptor associated factor 6 (TRAF6), nuclear factor of activated T cells 1 (NFATc1) and c Fos pathway. In addition, SR stimulates osteoblast differentiation and increased protein expression of the bone morphogenetic protein 2 (BMP 2)/SMAD signaling pathway. Moreover, SR protected against bone loss in OVX induced rats. Our results appear to advance our knowledge of SR and successfully demonstrate its potential role as a osteoclastogenesis inhibiting and osteogenesis promoting herbal medicine for the treatment of postmenopausal osteoporosis.
C1 [Lee, Sungyub; Kim, Minsun; Hong, Sooyeon; Kim, Eom Ji; Kim, Jae Hyun; Sohn, Youngjoo; Jung, Hyuk Sang] Kyung Hee Univ, Dept Anat, Coll Korean Med, Seoul, South Korea.
C3 Kyung Hee University
RP Sohn, Y; Jung, HS (通讯作者)，Kyung Hee Univ, Dept Anat, Coll Korean Med, Seoul, South Korea.
EM youngjoos@khu.ac.kr; jhs@khu.ac.kr
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI)   Ministry of Health and Welfare, Republic
   of Korea [HF21C0092]
FX Funding This research was supported by a grant from the Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute (KHIDI), funded by the Ministry of Health and Welfare,
   Republic of Korea (Grant Number: HF21C0092).
CR Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Azuma K, 2018, MED MOL MORPHOL, V51, P139, DOI 10.1007/s00795 018 0188 9
   Ballanti P, 1997, OSTEOPOROSIS INT, V7, P39, DOI 10.1007/BF01623458
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Barrow AD, 2011, J CLIN INVEST, V121, P3505, DOI 10.1172/JCI45913
   Beeton Christine, 2007, J Vis Exp, P266, DOI 10.3791/266
   BILLS CE, 1971, JOHNS HOPKINS MED J, V128, P194
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bradford PG, 2010, PHYSIOL BEHAV, V99, P181, DOI 10.1016/j.physbeh.2009.04.025
   Bradley Elizabeth W., 2008, V455, P19, DOI 10.1007/978 1 59745 104 8_2
   Cao Y, 2005, CANCER RES, V65, P1124, DOI 10.1158/0008 5472.CAN 04 2128
   Clohisy JC, 2003, J ORTHOPAED RES, V21, P202, DOI 10.1016/S0736 0266(02)00133 X
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Colnot C, 2003, DEVELOPMENT, V130, P4123, DOI 10.1242/dev.00559
   David JP, 2001, J CELL PHYSIOL, V188, P89, DOI 10.1002/jcp.1099
   Doss HM, 2018, LIFE SCI, V207, P284, DOI 10.1016/j.lfs.2018.06.013
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Duraiyan J, 2012, J PHARM BIOALLIED SC, V4, pS307, DOI 10.4103/0975 7406.100281
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Ekeuku SO, 2021, DRUG DES DEV THER, V15, P259, DOI 10.2147/DDDT.S287280
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Genant HK, 2008, RHEUMATOLOGY, V47, P9, DOI 10.1093/rheumatology/ken180
   Ginaldi Lia, 2005, Immun Ageing, V2, P14, DOI 10.1186/1742 4933 2 14
   Glister C, 2019, J MOL ENDOCRINOL, V62, P15, DOI 10.1530/JME 18 0198
   Grande R, 2015, CLIN ORAL INVEST, V19, P841, DOI 10.1007/s00784 014 1304 4
   Gu YQ, 2016, SCI REP UK, V6, DOI 10.1038/srep25282
   Guardia T, 2001, FARMACO, V56, P683, DOI 10.1016/S0014 827X(01)01111 9
   Guo AJ, 2012, CHIN MED UK, V7, DOI 10.1186/1749 8546 7 10
   Hartley JW, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742 4690 5 1
   Haÿ E, 2001, J BIOL CHEM, V276, P29028, DOI 10.1074/jbc.M011265200
   Heinrich M, 2020, J ETHNOPHARMACOL, V246, DOI 10.1016/j.jep.2019.112230
   Herman S, 2008, ARTHRITIS RHEUM US, V58, P3041, DOI 10.1002/art.23943
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jia J, 2021, J ETHNOPHARMACOL, V268, DOI 10.1016/j.jep.2020.113571
   Jiang Y., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P45
   Kadioglu O, 2015, ANTICANCER RES, V35, P2645
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kim CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010125
   Kim JH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.690113
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim M, 2021, MOL MED REP, V24, DOI 10.3892/mmr.2021.12248
   Kim M, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906 020 2841 9
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Kyung TW, 2008, EXP MOL MED, V40, P52, DOI 10.3858/emm.2008.40.1.52
   Lee KY, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906 019 2611 8
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2159 z
   Liu MYJ, 2020, PHYTOCHEM ANALYSIS, V31, P835, DOI 10.1002/pca.2949
   Liu TJ, 2007, J CELL PHYSIOL, V211, P728, DOI 10.1002/jcp.20988
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Luo LY, 2019, METABOLOMICS, V15, DOI 10.1007/s11306 019 1614 2
   MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696
   Matsubara T, 2017, BIOCHEM BIOPH RES CO, V489, P472, DOI 10.1016/j.bbrc.2017.05.174
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Osterhoff G, 2016, INJURY, V47, pS11, DOI 10.1016/S0020 1383(16)47003 8
   Ozer J, 2008, TOXICOLOGY, V245, P194, DOI 10.1016/j.tox.2007.11.021
   Pai SG, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045 017 0471 6
   Pragasam SJ, 2013, INFLAMMATION, V36, P169, DOI 10.1007/s10753 012 9532 8
   PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Sagar T, 2016, CYTOTECHNOLOGY, V68, P1963, DOI 10.1007/s10616 016 0009 8
   Schieferdecker A, 2014, ONCOTARGET, V5, P6647, DOI 10.18632/oncotarget.2160
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   SLY WS, 1983, P NATL ACAD SCI BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752
   Small Ralph E, 2005, MedGenMed, V7, P3
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tiedemann K, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00054
   Tschöp MH, 2012, NAT METHODS, V9, P57, DOI [10.1038/nmeth.1806, 10.1038/NMETH.1806]
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang XS, 2013, J CHROMATOGR SCI, V51, P371, DOI 10.1093/chromsci/bms150
   Wang XS, 2012, MOLECULES, V17, P6769, DOI 10.3390/molecules17066769
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   WRONSKI TJ, 1988, CALCIFIED TISSUE INT, V43, P179, DOI 10.1007/BF02571317
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yepuri N, 2019, SHOCK, V52, P568, DOI 10.1097/SHK.0000000000001326
   Yuan HD, 2016, MOLECULES, V21, DOI 10.3390/molecules21050559
   Zhao Ming Ming, 2018, Zhongguo Zhong Yao Za Zhi, V43, P1554, DOI 10.19540/j.cnki.cjcmm.20180122.001
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
   Zielinska D, 2021, NUTRIENTS, V13, DOI 10.3390/nu13020554
NR 93
TC 9
Z9 9
U1 0
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 4
PY 2022
VL 12
AR 797892
DI 10.3389/fphar.2021.797892
PG 23
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA YK4RM
UT WOS:000745202000001
PM 35058781
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yao, LP
   Zhang, QY
   Sun, P
   Qin, LP
   Zhang, L
AF Yao, Liping
   Zhang, Qiaoyan
   Sun, Peng
   Qin, Luping
   Zhang, Lu
TI Effect of Cinnamon and Aconite on Bone Formation Bone Absorption
   Coupling in Bone Microenvironment
SO REVISTA BRASILEIRA DE FARMACOGNOSIA BRAZILIAN JOURNAL OF PHARMACOGNOSY
LA English
DT Article
DE Compatibility of Chinese medicine; Osteoporosis; Osteoblasts;
   Osteoclasts; AMPK/SIRT1; Co culture
ID OSTEOBLAST DIFFERENTIATION; ACTIVATION
AB Aconite and cinnamon can treat many diseases. The study aimed to assess the effectiveness and mechanism of aconite, cinnamon, and aconite cinnamon in bone formation bone resorption. The co culture system was treated with serum containing aconite, cinnamon, and aconite cinnamon, and the effects on osteoblast and osteoclast differentiation were evaluated through ALP activity, ALP staining, alizarin red staining, TRAP activity detection, TRAP staining, and F actin staining. The study also examined the effects of aconite cinnamon on intercellular factors using ELISA kits, and the effects on different genes were detected through RT qPCR and Western blotting. Results showed that aconite cinnamon improved osteoblast differentiation and activity, reduced the release of RANKL, inhibited osteoclast differentiation and activity, and activated the AMPK/SIRT1 signaling pathway in both osteoblasts and osteoclasts. Therefore, aconite cinnamon can improve osteogenic differentiation activity and reducing osteoclast differentiation and activity, while activating the AMPK/SIRT1 signaling pathway in both osteoblasts and osteoclasts.
C1 [Yao, Liping; Zhang, Qiaoyan; Sun, Peng; Qin, Luping] Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Hangzhou, Peoples R China.
   [Zhang, Lu] Chongqing Coll Tradit Chinese Med, Chongqing, Peoples R China.
C3 Zhejiang Chinese Medical University; Chongqing College of Traditional
   Chinese Medicine
RP Qin, LP (通讯作者)，Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Hangzhou, Peoples R China.; Zhang, L (通讯作者)，Chongqing Coll Tradit Chinese Med, Chongqing, Peoples R China.
EM lpqin@zcmu.edu.cn; 103143@cqmu.edu.cn
RI ; Liping, Yao/IXN 1804 2023
OI Sun, Peng/0000 0002 5029 7127; qin, luping/0000 0002 5056 6497
FU National Outstanding Youth Science Fund Project of National Natural
   Science Foundation of China; Public Research Platform of the Academy of
   Chinese Medical Sciences, Zhejiang Chinese Medical University
FX We appreciate the support from the Public Research Platform of the
   Academy of Chinese Medical Sciences, Zhejiang Chinese Medical
   University.
CR Borciani G, 2020, ACTA BIOMATER, V108, P22, DOI 10.1016/j.actbio.2020.03.043
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Chen YH, 2022, J CELL BIOCHEM, V123, P275, DOI 10.1002/jcb.30165
   Darnay BG, 2007, ADV EXP MED BIOL, V597, P152
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Fukuyasu S, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10020426
   Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032
   Gruenwald J, 2010, CRIT REV FOOD SCI, V50, P822, DOI 10.1080/10408390902773052
   Guo J, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.12979
   Hapidin H, 2022, MOLECULES, V27, DOI 10.3390/molecules27020451
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Hsiao YM, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9060685
   Hwang SY, 2012, FASEB J, V26, P1484, DOI 10.1096/fj.11 194399
   Jann J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207597
   Kim DY, 2018, BIOCHEM BIOPH RES CO, V495, P1497, DOI 10.1016/j.bbrc.2017.11.200
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Lewiecki EM, 2018, THER ADV MUSCULOSKEL, V10, P209, DOI 10.1177/1759720X18805759
   Lim HJ, 2021, MOLECULES, V26, DOI 10.3390/molecules26226820
   Liu TJ, 2007, J CELL PHYSIOL, V211, P728, DOI 10.1002/jcp.20988
   Ma J, 2018, MED SCI MONITOR, V24, P2045, DOI 10.12659/MSM.905703
   Macías I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051653
   Marycz K, 2021, MATERIALS, V14, DOI 10.3390/ma14175010
   Nyirimigabo E, 2015, J PHARM PHARMACOL, V67, P1, DOI 10.1111/jphp.12310
   Ping ZC, 2017, ACTA BIOMATER, V62, P362, DOI 10.1016/j.actbio.2017.08.046
   Soltanoff CS, 2009, CRIT REV EUKAR GENE, V19, P1, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.10
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Wang MY, 2018, LIFE SCI, V200, P31, DOI 10.1016/j.lfs.2018.03.025
   Wang Q, 2022, BIOENGINEERED, V13, P431, DOI 10.1080/21655979.2021.2008667
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Watanabe A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127158
   Xiong JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05244 y
   Xu G, 2021, J ORTHOP TRANSL, V28, P74, DOI 10.1016/j.jot.2021.02.001
   Yan J, 2016, P NATL ACAD SCI USA, V113, pE7554, DOI 10.1073/pnas.1607235113
   Yao ZQ, 2022, CELLS BASEL, V11, DOI 10.3390/cells11010132
   Zainabadi K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178520
   Zeng Z, 2022, FRONT GENET, V12, DOI 10.3389/fgene.2021.783352
NR 38
TC 2
Z9 2
U1 0
U2 13
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0102 695X
EI 1981 528X
J9 REV BRAS FARMACOGN
JI Rev. Bras. Farmacogn. Braz. J. Pharmacogn.
PD JUN
PY 2024
VL 34
IS 3
BP 511
EP 521
DI 10.1007/s43450 023 00504 5
EA DEC 2023
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA OU3J4
UT WOS:001132085600001
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Costa, AG
   Bilezikian, JP
   Lewiecki, EM
AF Costa, Aline G.
   Bilezikian, John P.
   Lewiecki, E. Michael
TI Update on romosozumab: a humanized monoclonal antibody to sclerostin
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE anabolic; monoclonal antibody; osteoporosis; romosozumab; sderostin
ID VAN BUCHEM DISEASE; BONE MORPHOGENETIC PROTEIN; PARATHYROID HORMONE;
   SOST GENE; CIRCULATING SCLEROSTIN; POSTMENOPAUSAL WOMEN; MINERAL
   DENSITY; WNT; MASS; DELETION
AB Introduction: Disorders with inactivating mutations of the SOST gene result in reduced or absent expression of sclerostin and are associated with high bone mass. Sclerostin is an important regulator of bone formation due to its inhibitory actions in the osteoanabolic Wnt signaling pathway. Advances in understanding the mechanisms of action of this signaling molecule have led to the development of a pharmacological inhibitor of sclerostin with potential clinical applications as an osteoanabolic drug for the treatment of osteoporosis.
   Areas covered: Romosozumab is the first humanized monoclonal sclerostin antibody to be tested in clinical trials. Similar to preclinical animal studies with sclerostin antibodies, initial clinical studies show that romosozumab increases bone formation and bone mineral density.
   Expert opinion: Blocking sclerostin action with romosozumab is a promising new therapeutic approach to osteoanabolic therapy of osteoporosis; efficacy and safety data on large controlled studies are awaited.
C1 [Costa, Aline G.; Bilezikian, John P.] Columbia Univ, Coll Phys & Surg, Div Endocrinol, Dept Med,Metab Bone Dis Unit, New York, NY 10032 USA.
   [Costa, Aline G.] Sao Paulo Fed Univ, Dept Med, Div Endocrinol, Sao Paulo, Brazil.
   [Lewiecki, E. Michael] New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM 87106 USA.
C3 Columbia University; Universidade Federal de Sao Paulo (UNIFESP); New
   Mexico Clinical Research & Osteoporosis Center
RP Lewiecki, EM (通讯作者)，New Mexico Clin Res & Osteoporosis Ctr, 300 Oak St NE, Albuquerque, NM 87106 USA.
EM mlewiecki@gmail.com
RI Lewiecki, E./B 3706 2018; Costa, Aline/JDM 2967 2023
FU Amgen; Merck; Eli Lilly; NPS Pharmaceuticals
FX A Costa has no disclosures. In the past year, EM Lewiecki has received
   institutional grant/research support from Amgen, Merck, and Eli Lilly;
   he has served on scientific advisory boards for Amgen, Merck, Eli Lilly,
   Radius Health, and AgNovos Healthcare. JP Bilezikian has received
   research support from Amgen and NPS Pharmaceuticals. He serves on
   Advisory Boards for Amgen, Merck, Eli Lilly, NPS, Radius, and Bristol
   Meyers Squibb. The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR Agholme F, 2010, J BONE MINER RES, V25, P2412, DOI 10.1002/jbmr.135
   ALVES AFD, 1982, REV BRAS GENET, V5, P825
   [Anonymous], 2001, South Med J, V94, P569
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   BEIGHTON P, 1977, CLIN GENET, V11, P1
   BEIGHTON P, 1988, J MED GENET, V25, P200, DOI 10.1136/jmg.25.3.200
   BEIGHTON P, 1984, CLIN GENET, V25, P175
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bilezikian J P, 2005, J Endocrinol Invest, V28, P41
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   BUENO M, 1994, J MED GENET, V31, P976, DOI 10.1136/jmg.31.12.976
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Chen PQ, 2005, J BONE MINER RES, V20, P962, DOI 10.1359/JBMR.050105
   Costa AG, 2012, CURR OSTEOPOROS REP, V10, P64, DOI 10.1007/s11914 011 0089 5
   Costa AG, 2011, J CLIN ENDOCR METAB, V96, P3804, DOI 10.1210/jc.2011 0566
   Cui L, 2013, J MUSCULOSKEL NEURON, V13, P178
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Drake MT, 2010, J CLIN ENDOCR METAB, V95, P5056, DOI 10.1210/jc.2010 0720
   Eddleston A, 2009, J BONE MINER RES, V24, P1662, DOI [10.1359/JBMR.090403, 10.1359/jbmr.090403]
   Gardner JC, 2005, J CLIN ENDOCR METAB, V90, P6392, DOI 10.1210/jc.2005 1235
   Gaudio A, 2010, J CLIN ENDOCR METAB, V95, P2248, DOI 10.1210/jc.2010 0067
   Genant HK, 2013, J BONE MINER RES S1, V28
   Girotra M, 2006, REV ENDOCR METAB DIS, V7, P113, DOI 10.1007/s11154 006 9007 z
   Graeff C, 2013, ECTS ABSTR
   Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399 0004.2003.00036.x
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Il Mödder U, 2011, J BONE MINER RES, V26, P27, DOI 10.1002/jbmr.128
   Johnson ML, 2007, CURR OPIN RHEUMATOL, V19, P376, DOI 10.1097/BOR.0b013e32816e06f9
   Johnson ML, 2004, J BONE MINER RES, V19, P1749, DOI 10.1359/JBMR.040816
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kim CA, 2008, GENET TEST, V12, P475, DOI 10.1089/gte.2008.0036
   Kramer I, 2010, TRENDS ENDOCRIN MET, V21, P237, DOI 10.1016/j.tem.2009.12.002
   Krause C, 2010, J BIOL CHEM, V285, P41614, DOI 10.1074/jbc.M110.153890
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200
   Lewiecki EM, 2011, EXPERT OPIN BIOL TH, V11, P117, DOI 10.1517/14712598.2011.540565
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2011, ENDOCRINOLOGY, V152, P3312, DOI 10.1210/en.2011 0252
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Marenzana M, 2011, ARTHRITIS RHEUM US, V63, P2385, DOI 10.1002/art.30385
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McColm J., 2013, J. Bone Miner. Res, DOI 10. 1002/jbmr.2092
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Padhi D., 2013, J Clin Pharmacol
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Ross RD, 2014, J BONE MINER RES
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Silvestrini G, 2007, J MOL HISTOL, V38, P261, DOI 10.1007/s10735 007 9096 3
   Spatz JM, 2013, J BONE MINER RES, V28, P865, DOI 10.1002/jbmr.1807
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   STEIN SA, 1983, NEUROLOGY, V33, P267, DOI 10.1212/WNL.33.3.267
   SUGIURA Y, 1975, J BONE JOINT SURG AM, VA 57, P273, DOI 10.2106/00004623 197557020 00026
   Tacconi P, 1998, CLIN GENET, V53, P497
   Tashjian AH, 2002, J BONE MINER RES, V17, P1151, DOI 10.1359/jbmr.2002.17.7.1151
   Tian XY, 2011, BONE, V48, P197, DOI 10.1016/j.bone.2010.09.009
   Toumi H, 2013, J BONE MINER RES, V28
   TRUSWELL AS, 1958, J BONE JOINT SURG BR, V40, P208, DOI 10.1302/0301 620X.40B2.208
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   van Bezooijen RL, 2007, J BONE MINER RES, V22, P19, DOI 10.1359/JBMR.061002
   van Lierop AH, 2010, EUR J ENDOCRINOL, V163, P833, DOI 10.1530/EJE 10 0699
   van Lierop AH, 2013, J BONE MINER RES, V28, P848, DOI 10.1002/jbmr.1794
   van Lierop AH, 2011, J BONE MINER RES, V26, P2804, DOI 10.1002/jbmr.474
   VANBUCHEM FSP, 1955, ACTA RADIOL, V44, P109, DOI 10.3109/00016925509170789
   Veverka V, 2009, J BIOL CHEM, V284, P10890, DOI 10.1074/jbc.M807994200
   Watts NB, 2014, J CLIN ENDOCRINOL ME
   Wergedal JE, 2003, J CLIN ENDOCR METAB, V88, P5778, DOI 10.1210/jc.2003 030201
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
NR 77
TC 24
Z9 27
U1 2
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471 2598
EI 1744 7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD MAY
PY 2014
VL 14
IS 5
BP 697
EP 707
DI 10.1517/14712598.2014.895808
PG 11
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AG5AC
UT WOS:000335430500011
PM 24665957
DA 2025 08 17
ER

PT J
AU Farooki, A
AF Farooki, Azeez
TI Refractory hypercalcemia of malignancy: a problem with many potential
   roots
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE hypercalcemia of malignancy; denosumab; intravenous bisphosphonates;
   calcitriol; bone resorption; bone resorption and formation;
   hypercalciuria; PTHrP (parathyroid hormone related protein)
ID KETOCONAZOLE; DENOSUMAB
AB Hypercalcemia of malignancy (HCM) is a common clinical problem that is associated with considerable morbidity and negative effects on quality of life. Despite the availability of effective medical treatments for HCM, options are needed for cases that are refractory to conventional therapies. In this context, "refractory" refers to reasonable control of calcium in the setting of inpatient hospitalization (after receipt of standard of care therapies, such as continuous intravenous fluids, calcitonin, and intravenous bisphosphonates) with relapse into severe hypercalcemia within days or weeks of discharge from the hospital. Here we discuss drivers of hypercalcemia of malignancy and the physiologic mechanisms whereby they operate to increase serum calcium. Additionally, we discuss multiple available treatments targeted to a given contributory mechanism and also briefly discuss potential future treatments in need of further study.
C1 [Farooki, Azeez] Mem Sloan Kettering Canc Ctr, Dept Med, Endocrinol Serv, New York, NY 10022 USA.
   [Farooki, Azeez] NewYork Presbyterian Weill Cornell Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, New York, NY 10065 USA.
C3 Memorial Sloan Kettering Cancer Center; Cornell University; Weill
   Cornell Medicine
RP Farooki, A (通讯作者)，Mem Sloan Kettering Canc Ctr, Dept Med, Endocrinol Serv, New York, NY 10022 USA.; Farooki, A (通讯作者)，NewYork Presbyterian Weill Cornell Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, New York, NY 10065 USA.
CR ADAMS JS, 1990, J CLIN ENDOCR METAB, V70, P1090, DOI 10.1210/jcem 70 4 1090
   Chukir T, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz278
   CONNOR TB, 1956, J CLIN ENDOCR METAB, V16, P945
   Conron M, 2000, SARCOIDOSIS VASC DIF, V17, P277
   GOLDSMITH RS, 1966, NEW ENGL J MED, V274, P1, DOI 10.1056/NEJM196601062740101
   Horwitz MJ, 2005, J BONE MINER RES, V20, P1792, DOI 10.1359/JBMR.050602
   Hu MI, 2014, J CLIN ENDOCR METAB, V99, P3144, DOI 10.1210/jc.2014 1001
   Leaf DE, 2013, J CLIN ENDOCR METAB, V98, P887, DOI 10.1210/jc.2012 3473
   O'Callaghan S, 2021, ENDOCR CONNECT, V10, pR13, DOI 10.1530/EC 20 0487
   Rico Bautista E., 2022, ENDO 2022 ANN C ATL
   Sheehan M, 2020, CASE REP ONCOL, V13, P321, DOI 10.1159/000506100
   Tebben PJ, 2016, ENDOCR REV, V37, P521, DOI 10.1210/er.2016 1070
   Yang SP, 2017, ONCOLOGIST, V22, P438, DOI 10.1634/theoncologist.2016 0192
NR 13
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD MAY 17
PY 2023
VL 14
AR 1088984
DI 10.3389/fendo.2023.1088984
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA H6OA9
UT WOS:000997122300001
PM 37265703
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Teitelbaum, SL
AF Teitelbaum, S. L.
TI Glucocorticoids and the osteoclast
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Article
DE glucocorticoids; bisphophonates; osteoclasts
ID BONE RESORPTION; THERAPY; CORTICOSTEROIDS; METABOLISM; MECHANISMS
AB Glucocorticoid induced osteoporosis uniformly represents suppression of bone formation. The steroid's effects on osteoclasts are, however, controversial. While glucocorticoid administration to patients with inflammatory diseases accelerates bone resorption, osteoclast function falls below normal with prolonged treatment. Thus, administration of anti resorptive agents, such as bisphosphonates, is justified during early glucocorticoid therapy, but further suppression of osteoclasts, by these drugs, in chronically treated patients will dampen bone remodelling and may compromise skeletal quality, predisposing to fracture.
C1 Washington Univ, Sch Med, St Louis, MO 63130 USA.
C3 Washington University (WUSTL)
RP Teitelbaum, SL (通讯作者)，Washington Univ, Sch Med, St Louis, MO 63130 USA.
EM teitelbs@wustl.edu
OI Teitelbaum, Steven/0000 0002 4054 6679
CR DEMPSTER DW, 1989, J BONE MINER RES, V4, P137
   Dore RK, 2010, ANN RHEUM DIS, V69, P872, DOI 10.1136/ard.2009.112920
   Dovio A, 2004, J CLIN ENDOCR METAB, V89, P4923, DOI 10.1210/jc.2004 0164
   HALL GM, 1995, ARTHRITIS RHEUM, V38, P902, DOI 10.1002/art.1780380705
   Hong JM, 2011, J BONE MINER RES, V26, P657, DOI 10.1002/jbmr.241
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   PRUMMEL MF, 1991, J CLIN ENDOCR METAB, V72, P382, DOI 10.1210/jcem 72 2 382
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Teitelbaum S.L., 2011, International Bone Mineral Society, V8, P74, DOI DOI 10.1138/20110493
   Ton FN, 2005, J BONE MINER RES, V20, P464, DOI 10.1359/JBMR.041125
   Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
   Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083
NR 14
TC 34
Z9 37
U1 0
U2 6
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392 856X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PD JUL AUG
PY 2015
VL 33
IS 4
SU 92
BP S37
EP S39
PG 3
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA CV6BX
UT WOS:000364356800009
PM 26458014
DA 2025 08 17
ER

PT J
AU El Farrash, RA
   Ali, RH
   Barakat, NM
AF El Farrash, Rania Ali
   Ali, Radwa Hassan
   Barakat, Noha Mokhtar
TI Post natal bone physiology
SO SEMINARS IN FETAL & NEONATAL MEDICINE
LA English
DT Article
DE Bone cells; Osteoblast; Osteoclast; Bone remodeling; Mechanical
   stimulation; Bone growth
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; PARATHYROID HORMONE;
   LINING CELLS; CHONDROCYTE DIFFERENTIATION; ENDOCHONDRAL OSSIFICATION;
   ANABOLIC ACTIONS; EXPRESSION; SKELETAL; PROLIFERATION
AB Post natal bone development is characterized by substantial longitudinal bone growth and changes in skeletal size and shape. Bone is in a dynamic process of continuous remodeling which helps to regulate calcium homeostasis, repair micro damage to bones from everyday stress, and to shape the skeleton during growth. Bone growth is regulated by systemic hormones and locally generated factors. Understanding their mechanisms of action enables us to obtain a better appreciation of the cellular and molecular basis of bone remodeling and could therefore be valuable in approaches to new therapies. This article will review molecular and cellular control of skeletal growth in the post natal period, the physiology of each bone cell with their systemic and local regulators, as well as the physiology of bone remodeling.
C1 [El Farrash, Rania Ali; Barakat, Noha Mokhtar] Ain Shams Univ, Fac Med, Dept Pediat, Abbassya Sq, Cairo 11566, Egypt.
   [Ali, Radwa Hassan] Ain Shams Univ, Fac Med, Physiol Dept, Abbassya Sq, Cairo 11566, Egypt.
C3 Egyptian Knowledge Bank (EKB); Ain Shams University; Egyptian Knowledge
   Bank (EKB); Ain Shams University
RP El Farrash, RA (通讯作者)，Ain Shams Univ, Fac Med, Dept Pediat, Abbassya Sq, Cairo 11566, Egypt.
EM rania.elfarrash@med.asu.edu.eg; dr.radwahassan@med.asu.edu.eg;
   noha_mokhtar84@yahoo.com
RI El Farrash, Rania/AAI 1001 2019
CR Agostoni C, 2010, J PEDIATR GASTR NUTR, V50, P85, DOI 10.1097/MPG.0b013e3181adaee0
   Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Anusuya GS, 2016, J PHARM BIOALLIED SC, V8, P39, DOI 10.4103/0975 7406.191964
   Bianco P, 2010, HUM GENE THER, V21, P1057, DOI 10.1089/hum.2010.136
   Bikle DD, 2002, J BONE MINER RES, V17, P1570, DOI 10.1359/jbmr.2002.17.9.1570
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Candela ME, 2014, J ORTHOP RES, V32, P661, DOI 10.1002/jor.22583
   Chen L, 2001, HUM MOL GENET, V10, P457, DOI 10.1093/hmg/10.5.457
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   El Farrash RA, 2019, AM J PERINATOL
   Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   GIRAUDGUILLE MM, 1988, CALCIFIED TISSUE INT, V42, P167, DOI 10.1007/BF02556330
   Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521 1878(200002)22:2<138::AID BIES5>3.0.CO;2 4
   HALL BK, 1992, ANAT EMBRYOL, V186, P107
   Harvey NC, 2010, J DEV ORIG HLTH DIS, V1, P35, DOI 10.1017/S2040174409990055
   Hosaki Takamiya R, 2016, J BONE MINER METAB, V34, P491, DOI 10.1007/s00774 015 0692 0
   Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   Kim SW, 2017, J BONE MINER RES, V32, P892, DOI 10.1002/jbmr.3038
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kovacs CS, 2014, PEDIATR NEPHROL, V29, P793, DOI 10.1007/s00467 013 2461 4
   Kronenberg HM, 2006, ANN NY ACAD SCI, V1068, P1, DOI 10.1196/annals.1346.002
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Land C, 2008, BEST PRACT RES CL EN, V22, P107, DOI 10.1016/j.beem.2007.09.005
   Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663
   Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797 307
   Lupu F, 2001, DEV BIOL, V229, P141, DOI 10.1006/dbio.2000.9975
   Luxenburg C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000179
   Mackie EJ, 2008, INT J BIOCHEM CELL B, V40, P46, DOI 10.1016/j.biocel.2007.06.009
   Maes C, 2012, POSTNATAL BONE GROWT
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Martin TJ, 2008, BEST PRACT RES CL EN, V22, P701, DOI 10.1016/j.beem.2008.07.006
   Matic I, 2016, STEM CELLS, V34, P2930, DOI 10.1002/stem.2474
   Miller S.C., 1989, SCANNING MICROSCOPY, V3, P60
   MILLER SC, 1989, SCANNING MICROSCOPY, V3, P953
   Minina E, 2001, DEVELOPMENT, V128, P4523
   Mosig RA, 2007, HUM MOL GENET, V16, P1113, DOI 10.1093/hmg/ddm060
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nilsson O, 2005, HORM RES, V64, P157, DOI 10.1159/000088791
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Ornitz DM, 2015, WIRES DEV BIOL, V4, P215, DOI 10.1002/wdev.176
   Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702
   Ornitz DM, 2005, CYTOKINE GROWTH F R, V16, P205, DOI 10.1016/j.cytogfr.2005.02.003
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Ruchon AF, 2000, J BONE MINER RES, V15, P1440, DOI 10.1359/jbmr.2000.15.8.1440
   Sacchetti B, 2016, STEM CELL REP, V6, P897, DOI 10.1016/j.stemcr.2016.05.011
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034
   Tanaka T, 2018, J BONE MINER METAB, V36, P519, DOI 10.1007/s00774 017 0868 x
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Tsang KY, 2015, DEV GROWTH DIFFER, V57, P179, DOI 10.1111/dgd.12203
   Walsh S, 2001, RHEUMATOLOGY, V40, P74, DOI 10.1093/rheumatology/40.1.74
   Xiao ZS, 2006, J BIOL CHEM, V281, P30884, DOI 10.1074/jbc.M604772200
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197
   Zhu J, 2007, J BIOL CHEM, V282, P26656, DOI 10.1074/jbc.M705064200
   Zhu J, 2011, J CELL BIOCHEM, V112, P1749, DOI 10.1002/jcb.23094
NR 68
TC 9
Z9 10
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1744 165X
EI 1878 0946
J9 SEMIN FETAL NEONAT M
JI Semin. Fetal Neonatal Med.
PD FEB
PY 2020
VL 25
IS 1
AR 101077
DI 10.1016/j.siny.2019.101077
PG 7
WC Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics
GA KW9PU
UT WOS:000521516400005
PM 31889637
DA 2025 08 17
ER

PT J
AU Hung, KC
   Chang, JF
   Hsu, YH
   Hsieh, CY
   Wu, MS
   Wu, MY
   Chiu, IJ
   Syu, RS
   Wang, TM
   Wu, CC
   Hung, LY
   Zheng, CM
   Lu, KC
AF Hung, Kuo Chin
   Chang, Jia Feng
   Hsu, Yung Ho
   Hsieh, Chih Yu
   Wu, Mai Szu
   Wu, Mei Yi
   Chiu, I Jen
   Syu, Ren Si
   Wang, Ting Ming
   Wu, Chang Chin
   Hung, Lie Yee
   Zheng, Cai Mei
   Lu, Kuo Cheng
TI Therapeutic Effect of Calcimimetics on Osteoclast Osteoblast Crosslink
   in Chronic Kidney Disease and Mineral Bone Disease
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE chronic kidney disease mineral bone disease; cinacalcet; wnt; bone
   mineral density; osteoclast&#8211; osteoblast interaction; sclerostin;
   procollagen type 1 amino terminal propeptide; tartrate resistant acid
   phosphatase isoform 5b
ID RESISTANT ACID PHOSPHATASE; HEMODIALYSIS PATIENTS; CIRCULATING
   SCLEROSTIN; CINACALCET; FRACTURE; CALCITRIOL; PATHWAY; TRACP; WNT; 5B
AB We have previously demonstrated calcimimetics optimize the balance between osteoclastic bone resorption and osteoblastic mineralization through upregulating Wingless and int 1 (Wnt) signaling pathways in the mouse and cell model. Nonetheless, definitive human data are unavailable concerning therapeutic effects of Cinacalcet on chronic kidney disease and mineral bone disease (CKD MBD) and osteoclast osteoblast interaction. We aim to investigate whether Cinacalcet therapy improves bone mineral density (BMD) through optimizing osteocytic homeostasis in a human model. Hemodialysis patients with persistently high intact parathyroid hormone (iPTH) levels > 300 pg/mL for more than 3 months were included and received fixed dose Cinacalcet (25 mg/day, orally) for 6 months. Bone markers presenting osteoclast osteoblast communication were evaluated at baseline, the 3rd and the 6th month. Eighty percent of study patients were responding to Cinacalcet treatment, capable of improving BMD, T score and Z score (16.4%, 20.7% and 11.1%, respectively). A significant correlation between BMD improvement and iPTH changes was noted (r =  0.26, p < 0.01). Nonetheless, baseline lower iPTH level was associated with better responsiveness to Cinacalcet therapy. Sclerostin, an inhibitor of canonical Wnt/beta catenin signaling, was decreased from 127.3 +/  102.3 pg/mL to 57.9 +/  33.6 pg/mL. Furthermore, Wnt 10b/Wnt 16 expressions were increased from 12.4 +/  24.2/166.6 +/  73.3 pg/mL to 33.8 +/  2.1/217.3 +/  62.6 pg/mL. Notably, procollagen type I amino terminal propeptide (PINP), a marker of bone formation and osteoblastic activity, was increased from baseline 0.9 +/  0.4 pg/mL to 91.4 +/  42.3 pg/mL. In contrast, tartrate resistant acid phosphatase isoform 5b (TRACP 5b), a marker of osteoclast activity, was decreased from baseline 16.5 +/  0.4 mIU/mL to 7.7 +/  2.2 mIU/mL. Moreover, C reactive protein levels were suppressed from 2.5 +/  0.6 to 0.8 +/  0.5 mg/L, suggesting the systemic inflammatory burden may be benefited after optimizing the parathyroid bone axis. In conclusion, beyond iPTH suppression, our human model suggests Cinacalcet intensifies BMD through inhibiting sclerostin expression and upregulating Wnt 10b/Wnt 16 signaling that activates osteoblastic bone formation and inhibits osteoclastic bone resorption and inflammation. From the perspective of translation to humans, this research trial brings a meaningful insight into the osteoblast osteoclast homeostasis in Cinacalcet therapy for CKD MBD.
C1 [Hung, Kuo Chin; Syu, Ren Si] Min Sheng Gen Hosp, Dept Med, Div Nephrol, Taoyuan 330, Taiwan.
   [Chang, Jia Feng; Hsu, Yung Ho; Wu, Mai Szu; Wu, Mei Yi; Chiu, I Jen; Hung, Lie Yee; Zheng, Cai Mei] Taipei Med Univ Shuang Ho Hosp, Dept Internal Med, Div Nephrol, New Taipei 235, Taiwan.
   [Chang, Jia Feng; Hsu, Yung Ho; Hsieh, Chih Yu; Wu, Mai Szu; Wu, Mei Yi; Chiu, I Jen; Hung, Lie Yee; Zheng, Cai Mei] Taipei Med Univ, Coll Med, Sch Med, Div Nephrol,Dept Internal Med, Taipei 110, Taiwan.
   [Chang, Jia Feng; Hsu, Yung Ho; Wu, Mai Szu; Wu, Mei Yi; Chiu, I Jen; Hung, Lie Yee; Zheng, Cai Mei] Taipei Med Univ, Taipei Med Univ Res Ctr Urol & Kidney TMU RCUK, Coll Med, Sch Med, Taipei 110, Taiwan.
   [Chang, Jia Feng; Hsu, Yung Ho] Taipei Med Univ, Hsin Kuo Min Hosp, Dept Internal Med, Div Nephrol, Taoyuan 320, Taiwan.
   [Chang, Jia Feng] Yuanpei Univ Med Technol, Dept Nursing, Hsinchu 300, Taiwan.
   [Chang, Jia Feng; Hsieh, Chih Yu] En Chu Kong Hosp, Dept Internal Med, Div Nephrol, New Taipei 237, Taiwan.
   [Chang, Jia Feng; Hsieh, Chih Yu] Renal Care Joint Fdn, New Taipei 220, Taiwan.
   [Wang, Ting Ming] Natl Taiwan Univ, Sch Med, Dept Orthopaed Surg, Taipei 106, Taiwan.
   [Wang, Ting Ming] Natl Taiwan Univ Hosp, Dept Orthopaed Surg, Taipei 106, Taiwan.
   [Wu, Chang Chin] En Chu Kong Hosp, Dept Orthoped, New Taipei 237, Taiwan.
   [Wu, Chang Chin] Yuanpei Univ Med Technol, Dept Biomed Engn, Hsinchu 300, Taiwan.
   [Lu, Kuo Cheng] Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Dept Med, Div Nephrol, New Taipei 231, Taiwan.
C3 Taipei Medical University; Shuang Ho Hospital; Taipei Medical
   University; Taipei Medical University; National Taiwan University;
   National Taiwan University; National Taiwan University Hospital;
   Buddhist Tzu Chi General Hospital; Taipei Tzu Chi Hospital
RP Zheng, CM (通讯作者)，Taipei Med Univ Shuang Ho Hosp, Dept Internal Med, Div Nephrol, New Taipei 235, Taiwan.; Zheng, CM (通讯作者)，Taipei Med Univ, Coll Med, Sch Med, Div Nephrol,Dept Internal Med, Taipei 110, Taiwan.; Zheng, CM (通讯作者)，Taipei Med Univ, Taipei Med Univ Res Ctr Urol & Kidney TMU RCUK, Coll Med, Sch Med, Taipei 110, Taiwan.; Lu, KC (通讯作者)，Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Dept Med, Div Nephrol, New Taipei 231, Taiwan.
EM corey926@gmail.com; cjf6699@gmail.com; yhhsu@s.tmu.edu.tw;
   fish37435@Hotmail.com; maiszuwu@gmail.com; 09643@shh.org.tw;
   08888@s.tmu.edu.tw; M001324@e ms.com.tw; dtorth76@yahoo.com.tw;
   dtorth65@yahoo.com.tw; masusuwin@yahoo.com.tw; 11044@s.tmu.edu.tw;
   kuochenglu@gmail.com
RI Chang, Jia Feng/AAW 1326 2020; Wu, Shawn/J 8611 2014; Chiu,
   I Jen/ABG 4484 2020; Hsieh, Chih Yu/GWQ 8343 2022
OI Wang, Ting Ming/0000 0002 2263 5993; Hung, Kuo Chin/0000 0001 9023 8925;
   Cai mei, Zheng/0000 0003 0370 3951; Hsieh, Chih Yu/0000 0001 9770 6779;
   Chang, Jia Feng/0000 0002 9903 7473; 
FU Renal Care Joint Foundation; Academia and Industry Collaboration Project
   of Taipei Medical University [A 108 031]; En Chu Kong Hospital &
   Pharmofoods Medical Editing Co., Ltd. [A 108 031];  [MOST
   109 2628 B 385 001];  [MOST 108 2314 B 038 045];  [TMU IIT 107 010]; 
   [IIT 1091 15]
FX This work was supported by the grant of MOST 109 2628 B 385 001; MOST
   108 2314 B 038 045; TMU IIT 107 010, IIT 1091 15; Renal Care Joint
   Foundation; and the Academia and Industry Collaboration Project of
   Taipei Medical University & En Chu Kong Hospital & Pharmofoods Medical
   Editing Co., Ltd. (A 108 031).
CR Akizawa T, 2016, SCI REP UK, V6, DOI 10.1038/srep19612
   Appelman Dijkstra NM, 2018, NAT REV ENDOCRINOL, V14, P605, DOI 10.1038/s41574 018 0087 0
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Catalano A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134779
   Chang JF, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.00102
   Chen DQ, 2017, REDOX BIOL, V12, P505, DOI 10.1016/j.redox.2017.03.017
   Cici D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225552
   Costa AG, 2017, BONE, V96, P24, DOI 10.1016/j.bone.2016.10.012
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   Drechsler C, 2015, NEPHROL DIAL TRANSPL, V30, P288, DOI 10.1093/ndt/gfu301
   Evans M, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 20552 5
   Gong L, 2018, INT UROL NEPHROL, V50, P955, DOI 10.1007/s11255 018 1795 z
   Gori F, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.36
   Hale LV, 2007, BONE, V40, P1103, DOI 10.1016/j.bone.2006.11.027
   Halleen JM, 2006, CLIN LAB, V52, P499
   Hong LY, 2020, APPL SCI BASEL, V10, DOI 10.3390/app10030832
   Isakova T, 2017, AM J KIDNEY DIS, V70, P737, DOI 10.1053/j.ajkd.2017.07.019
   Janckila AJ, 2008, J BONE MINER RES, V23, P1287, DOI 10.1359/JBMR.080329
   Kanbay M, 2014, J CLIN ENDOCR METAB, V99, pE1854, DOI 10.1210/jc.2014 2042
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Ko WC, 2018, J CLIN MED, V7, DOI 10.3390/jcm7100300
   Kuczera P, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882 016 0392 6
   Lu KC, 2006, BLOOD PURIFICAT, V24, P423, DOI 10.1159/000094899
   Lu KC, 2014, SCI WORLD J, DOI 10.1155/2014/637065
   Macías I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051653
   Moe SM, 2015, J AM SOC NEPHROL, V26, P1466, DOI 10.1681/ASN.2014040414
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Qureshi AR, 2015, KIDNEY INT, V88, P1356, DOI 10.1038/ki.2015.194
   Susantitaphong P, 2019, RENAL FAILURE, V41, P326, DOI 10.1080/0886022X.2018.1562356
   Tentori F, 2014, KIDNEY INT, V85, P166, DOI 10.1038/ki.2013.279
   Tsuruta Y, 2013, CLIN EXP NEPHROL, V17, P120, DOI 10.1007/s10157 012 0665 8
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Weivoda MM, 2017, BONE, V96, P45, DOI 10.1016/j.bone.2016.11.024
   Wu CC, 2011, TOHOKU J EXP MED, V223, P153, DOI 10.1620/tjem.223.153
   Zheng CM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112800
   Zheng CM, 2018, NUTRIENTS, V10, DOI 10.3390/nu10020196
   Zhong ZD, 2014, WIRES DEV BIOL, V3, P489, DOI 10.1002/wdev.159
NR 37
TC 11
Z9 13
U1 1
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2020
VL 21
IS 22
AR 8712
DI 10.3390/ijms21228712
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA OZ5GH
UT WOS:000594953700001
PM 33218086
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Bidwell, JP
   Childress, P
   Alvarez, MB
   Hood, M
   He, YZ
   Pavalko, FM
   Kacena, MA
   Yang, FC
AF Bidwell, Joseph P.
   Childress, Paul
   Alvarez, Marta B.
   Hood, Mark, Jr.
   He, Yongzheng
   Pavalko, Fredrick M.
   Kacena, Melissa A.
   Yang, Feng Chun
TI Nmp4/CIZ Closes the Parathyroid Hormone Anabolic Window
SO CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
LA English
DT Article
DE BMP2; osteoblasts; osteoclast; osteoporosis; osteoprogenitors; p130Cas
ID NUCLEOCYTOPLASMIC SHUTTLING PROTEIN; INCREASES BONE FORMATION;
   NUCLEAR MATRIX PROTEINS; ZINC FINGER PROTEIN; TRANSCRIPTION FACTORS;
   OSTEOBLASTIC CELLS; EXPRESSION; PTH; TERIPARATIDE; OSTEOPOROSIS
AB Chronic degenerative diseases are increasing with the aging U.S. population. One consequence of this phenomenon is the need for long term osteoporosis therapies. Parathyroid hormone (PTH), the only FDA approved treatment that adds bone to the aged skeleton, loses its potency within two years of initial treatment but the mechanism regulating its limited "anabolic window" is unknown. We have discovered that disabling the nucleocytoplasmic shuttling transcription factor nuclear matrix protein 4/cas interacting zinc finger protein (Nmp4/CIZ) in mice extends the PTH bone forming capacity. Nmp4 was discovered during our search for nuclear matrix transcription factors that couple this hormone's impact on osteoblast cytoskeletal and nuclear organization with its anabolic capacity. CIZ was independently discovered as a protein that associates with the focal adhesion associated mechanosensor p130Cas. The Nmp4/CIZ knockout (KO) skeletal phenotype exhibits a modestly enhanced bone mineral density but manifests an exaggerated response to both PTH and to BMP2 and is resistant to disuse induced bone loss. The cellular basis of the global Nmp4/CIZ KO skeletal phenotype remains to be elucidated but may involve an expansion of the bone marrow osteoprogenitor population along with modestly enhanced osteoblast and osteoclast activities supporting anabolic bone turnover. As a shuttling Cys(2)His(2) zinc finger protein, Nmp4/CIZ acts as a repressive transcription factor perhaps associated with epigenetic remodeling complexes, but the functional significance of its interaction with p130Cas is not known. Despite numerous remaining questions, Nmp4/CIZ provides insights into how the anabolic window is regulated, and itself may provide an adjuvant therapy target for the treatment of osteoporosis by extending PTH anabolic efficacy.
C1 [Bidwell, Joseph P.; Childress, Paul; Alvarez, Marta B.; Hood, Mark, Jr.] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [He, Yongzheng; Yang, Feng Chun] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA.
   [He, Yongzheng; Yang, Feng Chun] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA.
   [Pavalko, Fredrick M.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA.
   [Kacena, Melissa A.] Indiana Univ Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington; Indiana University System; Indiana
   University Bloomington
RP Bidwell, JP (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, Med Sci Bldg 5035,635 Barnhill Dr, Indianapolis, IN 46202 USA.
EM jbidwell@iupui.edu
RI Childress, Paul/AAD 4684 2020
FU National Institute of Diabetes and Digestive and Kidney Diseases
   (NI DDK, NIH) [DK053796]
FX Some of the data described in this review were supported by a grant from
   the National Institute of Diabetes and Digestive and Kidney Diseases
   (NI DDK, NIH), Grant No., DK053796 (to J.P.B.)
CR Abassi YA, 2003, J BIOL CHEM, V278, P35636, DOI 10.1074/jbc.M306438200
   Alvarez M, 1998, J CELL BIOCHEM, V69, P336, DOI 10.1002/(SICI)1097 4644(19980601)69:3<336::AID JCB11>3.0.CO;2 A
   Alvarez M, 2003, GENE, V313, P43, DOI 10.1016/S0378 1119(03)00627 9
   Alvarez MB, 2012, J CELL PHYSIOL, V227, P1873, DOI 10.1002/jcp.22915
   Alvarez MB, 2001, CYTOGENET CELL GENET, V94, P244, DOI 10.1159/000048824
   Beard MK, 2012, CURR MED RES OPIN, V28, P141, DOI 10.1185/03007995.2011.643296
   Bidwell JP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3153pe51
   Bidwell JP, 1998, J BONE MINER RES, V13, P155, DOI 10.1359/jbmr.1998.13.2.155
   Bilezikian John P, 2008, Curr Osteoporos Rep, V6, P24, DOI 10.1007/s11914 008 0005 9
   Blacklow RS, 2007, AM J CLIN NUTR, V86, p1560S, DOI 10.1093/ajcn/86.5.1560S
   Brecher E, 2010, U TORONTO MED J, V88, P44
   Cabodi S, 2004, J CELL SCI, V117, P1603, DOI 10.1242/jcs.01025
   Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P101
   Centers for Disease Control and Prevention (CDC), 2003, MMWR MORB MORTAL WKL, V52, P106
   Childress P, 2011, CALCIFIED TISSUE INT, V89, P74, DOI 10.1007/s00223 011 9496 y
   Coles LS, 2004, ANN NY ACAD SCI, V1019, P490, DOI 10.1196/annals.1297.090
   Compston JE, 2007, BONE, V40, P1447, DOI 10.1016/j.bone.2006.09.008
   Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157
   Cosman F, 2009, J CLIN ENDOCR METAB, V94, P3772, DOI 10.1210/jc.2008 2719
   Cusano N.E., 2010, IBMS BoneKEy, V7, P84
   Cusano NE, 2011, CURR MED RES OPIN, V27, P1705, DOI 10.1185/03007995.2011.599837
   Davies J, 2004, J ENDOCRINOL, V180, P505, DOI 10.1677/joe.0.1800505
   DHAWAN J, 1991, J BIOL CHEM, V266, P8470
   Di Stefano P, 2011, AM J CANCER RES, V1, P663
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   EGAN JJ, 1991, J CELL BIOCHEM, V45, P101, DOI 10.1002/jcb.240450117
   Feister HA, 2000, BONE, V26, P227, DOI 10.1016/S8756 3282(99)00269 0
   Feister HA, 2000, J CELL BIOCHEM, V79, P506, DOI 10.1002/1097 4644(20001201)79:3<506::AID JCB150>3.0.CO;2 A
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Finkelstein JS, 2009, J CLIN ENDOCR METAB, V94, P2495, DOI 10.1210/jc.2009 0154
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092 8674(92)90129 Z
   Gonzalo P, 2010, DEV CELL, V18, P77, DOI 10.1016/j.devcel.2009.11.012
   Guadalupe Grau A, 2009, SPORTS MED, V39, P439, DOI 10.2165/00007256 200939060 00002
   He Y, 2012, 10 ANN MIDW BLOOD CL
   He YZ, 2013, STEM CELLS DEV, V22, P492, DOI 10.1089/scd.2012.0308
   Hino K, 2007, BONE, V40, P852, DOI 10.1016/j.bone.2006.03.019
   Hirata Hiroaki, 2008, Commun Integr Biol, V1, P192
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Janssen H, 2006, EXP CELL RES, V312, P1194, DOI 10.1016/j.yexcr.2006.02.001
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Karasik D, 2008, HUM GENET, V124, P349, DOI 10.1007/s00439 008 0559 8
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Krane SM, 2005, J EXP MED, V201, P841, DOI 10.1084/jem.20050354
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849
   Margolis RL, 1997, HUM GENET, V100, P114, DOI 10.1007/s004390050476
   MATTHEWS JL, 1981, CLIN ORTHOP RELAT R, P27
   Morinobu M, 2005, J EXP MED, V201, P961, DOI 10.1084/jem.20041097
   Nakamoto T, 2004, GENES CELLS, V9, P575, DOI 10.1111/j.1356 9597.2004.00746.x
   Nakamoto T, 2000, MOL CELL BIOL, V20, P1649, DOI 10.1128/MCB.20.5.1649 1658.2000
   Nakamura I, 2007, J BONE MINER METAB, V25, P337, DOI 10.1007/s00774 007 0773 9
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Norvell SM, 2004, CALCIFIED TISSUE INT, V75, P396, DOI 10.1007/s00223 004 0213 y
   Park Wyllie LY, 2011, JAMA J AM MED ASSOC, V305, P783, DOI 10.1001/jama.2011.190
   Pavalko FM, 2003, J CELL BIOCHEM, V88, P104, DOI 10.1002/jcb.10284
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Rizzoli R, 2011, OSTEOPOROSIS INT, V22, P373, DOI 10.1007/s00198 010 1453 5
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Robling AG, 2009, J CELL PHYSIOL, V219, P734, DOI 10.1002/jcp.21717
   Sawada Y, 2006, CELL, V127, P1015, DOI 10.1016/j.cell.2006.09.044
   Schneider Stock R, 2012, FRONT BIOSCI LANDMRK, V17, P129, DOI 10.2741/3919
   Shah R, 2004, AM J PHYSIOL ENDOC M, V287, pE289, DOI 10.1152/ajpendo.00517.2003
   Shen ZJ, 2002, J BIOL CHEM, V277, P29840, DOI 10.1074/jbc.M203157200
   Shimizu E, 2010, J BIOL CHEM, V285, P9616, DOI 10.1074/jbc.M109.094862
   Shivaram GM, 2010, PHILOS T R SOC A, V368, P605, DOI 10.1098/rsta.2009.0231
   Stroup J, 2008, AM J HEALTH SYST PH, V65, P532, DOI 10.2146/ajhp070171
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Thomas CH, 2002, P NATL ACAD SCI USA, V99, P1972, DOI 10.1073/pnas.032668799
   Thunyakitpisal P, 2001, J BONE MINER RES, V16, P10, DOI 10.1359/jbmr.2001.16.1.10
   Tikhmyanova N, 2010, CELL MOL LIFE SCI, V67, P1025, DOI 10.1007/s00018 009 0213 1
   Torrungruang K, 1998, BONE, V22, P317, DOI 10.1016/S8756 3282(97)00300 1
   Torrungruang K, 2002, J BIOL CHEM, V277, P16153, DOI 10.1074/jbc.M107496200
   Trivedi R, 2010, EXPERT OPIN INV DRUG, V19, P995, DOI 10.1517/13543784.2010.501077
   Vives V, 2011, J BONE MINER RES, V26, P1099, DOI 10.1002/jbmr.282
   Wagner EF, 2010, ANN RHEUM DIS, V69, P86, DOI 10.1136/ard.2009.119396
   Wang YH, 2005, J BONE MINER RES, V20, P5, DOI 10.1359/JBMR.041016
   Wang YH, 2007, AM J PHYSIOL ENDOC M, V292, pE594, DOI 10.1152/ajpendo.00216.2006
   Williams BO, 2009, J BONE MINER RES, V24, P171, DOI [10.1359/JBMR.081235, 10.1359/jbmr.081235]
   Yang Z, 2010, J CELL PHYSL, V223, P35
   Zhang J, 2011, RHEUM DIS CLIN N AM, V37, P387, DOI 10.1016/j.rdc.2011.08.001
   Zhang JS, 2006, J BONE MINER RES, V21, P1729, DOI 10.1359/JBMR.060722
NR 83
TC 5
Z9 6
U1 0
U2 1
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 1045 4403
EI 2162 6502
J9 CRIT REV EUKAR GENE
JI Crit. Rev. Eukaryot. Gene Expr.
PY 2012
VL 22
IS 3
BP 205
EP 218
DI 10.1615/CritRevEukarGeneExpr.v22.i3.40
PG 14
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 036HQ
UT WOS:000311017400004
PM 23140162
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kedlaya, R
   Kang, KS
   Hong, JM
   Bettagere, V
   Lim, KE
   Horan, D
   Divieti Pajevic, P
   Robling, AG
AF Kedlaya, Rajendra
   Kang, Kyung Shin
   Hong, Jung Min
   Bettagere, Vidya
   Lim, Kyung Eun
   Horan, Daniel
   Divieti Pajevic, Paola
   Robling, Alexander G.
TI Adult Onset Deletion of β Catenin in <SUP>10kb</SUP>Dmp1 Expressing
   Cells Prevents Intermittent PTH Induced Bone Gain
SO ENDOCRINOLOGY
LA English
DT Article
ID MOUSE OSTEOBLASTIC CELLS; PARATHYROID HORMONE 1 34; WNT SIGNALING
   PATHWAY; MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; TERIPARATIDE;
   RECEPTOR; LRP5; MICE; OSTEOCYTES
AB beta Catenin (beta cat) is a major downstream signaling node in canonical Wingless related integration site (Wnt) signaling pathway, and its activity is crucial for canonical Wnt signal transduction. Wnt signaling has recently been implicated in the osteo anabolic response to PTH, a potent calcium regulating factor. We investigated whether beta cat is essential for the anabolic action of intermittent PTH by generating male mice with adult onset deletion of beta cat in a subpopulation of bone cells (osteocytes and late stage osteoblasts), treating them with an anabolic regimen of PTH, and measuring the skeletal responses. Male (10kb)Dmp1 CreERt2 transgenic mice that also harbored floxed loss of function beta cat alleles (beta cat(f/f)) were induced for Cre activity using tamoxifen, then injected daily with human PTH 1 34 (30 beta g/kg) or vehicle for 5 weeks. Mice in which beta cat was deleted showed either total lack of bone mineral density (BMD) gain, or BMD loss, and did not respond to PTH treatment. However, bone mass measurements in the trabecular compartment of the femur and spine revealed PTH induced bone gain whether beta cat was deleted or not. PTH stimulated increases in periosteal and cancellous bone formation rates were not impaired by beta cat deletion, but resorption markers and cortical porosity were significantly increased in induced mice, particularly induced mice treated with PTH. These results suggest that beta cat is required for net positive BMD effects of PTH therapy but that the anabolic effects per se of PTH treatment might not require osteocytic/osteoblastic beta cat.
C1 [Kedlaya, Rajendra; Kang, Kyung Shin; Hong, Jung Min; Bettagere, Vidya; Lim, Kyung Eun; Horan, Daniel; Robling, Alexander G.] Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS 5035, Indianapolis, IN 46202 USA.
   [Divieti Pajevic, Paola] Boston Univ, Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02215 USA.
   [Robling, Alexander G.] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
   [Robling, Alexander G.] Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Boston
   University; Purdue University System; Purdue University; Purdue
   University in Indianapolis; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Richard L. Roudebush VA Medical Center
RP Robling, AG (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS 5035, Indianapolis, IN 46202 USA.
EM arobling@iupui.edu
RI Park, Mi Kyung/J 9643 2017; Pajevic, Paola/M 3236 2019
FU National Institutes of Health [AR53237]; Veterans Administration Grant
   [BX001478]
FX This work was supported by National Institutes of Health Grant AR53237
   and Veterans Administration Grant BX001478 (to A.G.R.).
CR Body JJ, 2002, J CLIN ENDOCR METAB, V87, P4528, DOI 10.1210/jc.2002 020334
   Brault V, 2001, DEVELOPMENT, V128, P1253
   Briot K, 2009, OSTEOPOROSIS INT, V20, P625, DOI 10.1007/s00198 008 0698 8
   Cervenka I, 2011, MOL CELL BIOL, V31, P179, DOI 10.1128/MCB.00550 10
   Conwell LJ, 2011, AM J GERIATR PHARMAC, V9, P241, DOI 10.1016/j.amjopharm.2011.04.009
   Cui YJ, 2014, NAT MED, V20, P1229, DOI 10.1038/nm.3697
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   HAEGEL H, 1995, DEVELOPMENT, V121, P3529
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324
   Iwaniec UT, 2007, J BONE MINER RES, V22, P394, DOI 10.1359/JBMR.061118
   Kalajzic I, 2013, BONE, V54, P296, DOI 10.1016/j.bone.2012.09.040
   Kim JE, 2004, AM J PATHOL, V165, P1875, DOI 10.1016/S0002 9440(10)63240 3
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Li CJ, 2013, J BONE MINER RES, V28, P2094, DOI 10.1002/jbmr.1962
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Mi KH, 2005, J CELL BIOCHEM, V95, P328, DOI 10.1002/jcb.20400
   Mulgund M, 2009, THER ADV MUSCULOSKEL, V1, P5, DOI 10.1177/1759720X09339551
   Munugalavadla V, 2008, MOL CELL BIOL, V28, P7182, DOI 10.1128/MCB.00920 08
   Murphy DR, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 213
   Muschitz C, 2013, J BONE MINER RES, V28, P196, DOI 10.1002/jbmr.1716
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Niziolek PJ, 2011, BONE, V49, P1010, DOI 10.1016/j.bone.2011.07.034
   Powell WF, 2011, J ENDOCRINOL, V209, P21, DOI 10.1530/JOE 10 0308
   Revollo L, 2015, J BONE MINER RES, V30, P274, DOI 10.1002/jbmr.2323
   Riddle RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063323
   Robling AG, 2011, ENDOCRINOLOGY, V152, P2963, DOI 10.1210/en.2011 0049
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Sando R, 2013, NAT METHODS, V10, P1085, DOI [10.1038/NMETH.2640, 10.1038/nmeth.2640]
   Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200
   Silva BC, 2011, J ENDOCRINOL INVEST, V34, P801, DOI 10.3275/7925
   Stern AR, 2012, BIOTECHNIQUES, V52, P361, DOI 10.2144/0000113876
   Stroup JS, 2007, PHARMACOTHERAPY, V27, P779, DOI 10.1592/phco.27.6.779
   Syme CA, 2005, J BIOL CHEM, V280, P11281, DOI 10.1074/jbc.M413393200
   Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117
   Tian Y, 2011, MOL CELL BIOCHEM, V355, P211, DOI 10.1007/s11010 011 0856 8
   Tobimatsu T, 2006, ENDOCRINOLOGY, V147, P2583, DOI 10.1210/en.2005 1627
   Tu XL, 2013, J BONE MINER RES, V28
   Tzeng HE, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0580 8
   Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551
   Wan M, 2008, GENE DEV, V22, P2968, DOI 10.1101/gad.1702708
   Williams BO, 2009, J BONE MINER RES, V24, P171, DOI [10.1359/JBMR.081235, 10.1359/jbmr.081235]
   Yano F, 2013, ARTHRITIS RHEUM US, V65, P429, DOI 10.1002/art.37779
   Yano M, 2012, ENDOCR J, V59, P653, DOI 10.1507/endocrj.EJ12 0022
   Zhang MS, 2015, DIS MODEL MECH, V8, P1155, DOI 10.1242/dmm.021204
   Zhao LM, 2013, BONE, V54, P35, DOI 10.1016/j.bone.2013.01.033
NR 49
TC 19
Z9 21
U1 1
U2 7
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD AUG
PY 2016
VL 157
IS 8
BP 3047
EP 3057
DI 10.1210/en.2015 1587
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DS4JG
UT WOS:000380746800012
PM 27253995
OA Green Published
DA 2025 08 17
ER

PT J
AU Yamaza, T
   Miura, Y
   Bi, YM
   Liu, YZ
   Akiyama, K
   Sonoyama, W
   Patel, V
   Gutkind, S
   Young, M
   Gronthos, S
   Le, A
   Wang, CY
   Chen, WJ
   Shi, ST
AF Yamaza, Takayoshi
   Miura, Yasuo
   Bi, Yanming
   Liu, Yongzhong
   Akiyama, Kentaro
   Sonoyama, Wataru
   Patel, Voymesh
   Gutkind, Silvio
   Young, Marian
   Gronthos, Stan
   Le, Anh
   Wang, Cun Yu
   Chen, WanJun
   Shi, Songtao
TI Pharmacologic Stem Cell Based Intervention as a New Approach to
   Osteoporosis Treatment in Rodents
SO PLOS ONE
LA English
DT Article
ID BONE MINERAL DENSITY; T CELLS; OSTEOBLAST APOPTOSIS; STROMAL CELLS;
   MARROW; OSTEOCYTE; ASPIRIN; BISPHOSPHONATES; COMPLICATIONS; THERAPY
AB Background: Osteoporosis is the most prevalent skeletal disorder, characterized by a low bone mineral density (BMD) and bone structural deterioration, leading to bone fragility fractures. Accelerated bone resorption by osteoclasts has been established as a principal mechanism in osteoporosis. However, recent experimental evidences suggest that inappropriate apoptosis of osteoblasts/osteocytes accounts for, at least in part, the imbalance in bone remodeling as occurs in osteoporosis. The aim of this study is to examine whether aspirin, which has been reported as an effective drug improving bone mineral density in human epidemiology studies, regulates the balance between bone resorption and bone formation at stem cell levels.
   Methods and Findings: We found that T cell mediated bone marrow mesenchymal stem cell (BMMSC) impairment plays a crucial role in ovariectomized induced osteoporosis. Ex vivo mechanistic studies revealed that T cell mediated BMMSC impairment was mainly attributed to the apoptosis of BMMSCs via the Fas/Fas ligand pathway. To explore potential of using pharmacologic stem cell based intervention as an approach for osteoporosis treatment, we selected ovariectomy (OVX) induced ostoeporosis mouse model to examine feasibility and mechanism of aspirin mediated therapy for osteoporosis. We found that aspirin can inhibit T cell activation and Fas ligand induced BMMSC apoptosis in vitro. Further, we revealed that aspirin increases osteogenesis of BMMSCs by aiming at telomerase activity and inhibits osteoclast activity in OVX mice, leading to ameliorating bone density.
   Conclusion: Our findings have revealed a novel osteoporosis mechanism in which activated T cells induce BMMSC apoptosis via Fas/Fas ligand pathway and suggested that pharmacologic stem cell based intervention by aspirin may be a new alternative in osteoporosis treatment including activated osteoblasts and inhibited osteoclasts.
C1 [Yamaza, Takayoshi; Akiyama, Kentaro; Sonoyama, Wataru; Le, Anh; Shi, Songtao] Univ So Calif, Ctr Craniofacial Mol Biol, Sch Dent, Los Angeles, CA 90033 USA.
   [Miura, Yasuo] Kyoto Univ, Grad Sch Med, Kyoto, Japan.
   [Bi, Yanming; Liu, Yongzhong; Patel, Voymesh; Gutkind, Silvio; Young, Marian; Chen, WanJun] NIH, NIDCR, Bethesda, MD USA.
   [Gronthos, Stan] Inst Med & Vet Sci, Div Haematol, Mesenchymal Stem Cell Grp, Adelaide, SA, Australia.
   [Wang, Cun Yu] Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Los Angeles, CA USA.
C3 University of Southern California; Kyoto University; National Institutes
   of Health (NIH)   USA; NIH National Institute of Dental & Craniofacial
   Research (NIDCR); Institute Medical & Veterinary Science Australia;
   University of California System; University of California Los Angeles
RP Yamaza, T (通讯作者)，Univ So Calif, Ctr Craniofacial Mol Biol, Sch Dent, 2250 Alcazar St, Los Angeles, CA 90033 USA.
EM wchen@mail.nih.gov; songtaos@usc.edu
RI ; Gutkind, J Silvio/J 1201 2016; Sonoyama, Wataru/B 2160 2011; Wang,
   Chunlei/F 3593 2012; Gutkind, J. Silvio/J 1201 2016; Gronthos,
   Stan/Y 4419 2019
OI Young, Marian F/0000 0003 0929 8854; Yamaza,
   Takayoshi/0000 0001 7055 3370; Gronthos, Stan/0000 0002 6225 3084;
   Gutkind, J Silvio/0000 0002 5150 4482; Miura, Yasuo/0000 0001 9654 1300;
   
FU University of Southern California School of Dentistry; NIH [R01DE17449];
   NIDCR
FX This research was supported by University of Southern California School
   of Dentistry starting fund for S.S., an extramural grant from NIH (NIDCR
   R01DE17449 for S.S.), and NIDCR intramural fund.
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood 2004 04 1559
   Bauer DC, 1996, J BONE MINER RES, V11, P29
   Bernstein CN, 2002, CURR OPIN GASTROEN, V18, P428, DOI 10.1097/00001574 200207000 00006
   BERNSTEIN CN, 2006, OSTEOPOROS REP, V4, P116
   Bode Böger SM, 2005, BIOCHEM BIOPH RES CO, V334, P1226, DOI 10.1016/j.bbrc.2005.07.014
   Brunner T, 2003, SEMIN IMMUNOL, V15, P167, DOI 10.1016/S1044 5323(03)00035 6
   BUKOWSKI JF, 2005, BIOCHEM BIOPH RES CO, V21, P373
   Carbone LD, 2003, J BONE MINER RES, V18, P1795, DOI 10.1359/jbmr.2003.18.10.1795
   Chapurlat RD, 2006, NAT CLIN PRACT ENDOC, V2, P211, DOI 10.1038/ncpendmet0121
   Chen X, 2006, IMMUNOL CELL BIOL, V84, P413, DOI 10.1111/j.1440 1711.2006.01458.x
   Chiang CY, 1999, INFECT IMMUN, V67, P4231, DOI 10.1128/IAI.67.8.4231 4236.1999
   Clowes JA, 2005, IMMUNOL REV, V208, P207, DOI 10.1111/j.0105 2896.2005.00334.x
   FRIEDENSTEIN AJ, 1974, TRANSPLANTATION, V17, P331, DOI 10.1097/00007890 197404000 00001
   Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975
   Jilka RL, 2007, J BONE MINER RES, V22, P1492, DOI 10.1359/JBMR.070518
   Kataoka T, 1996, J IMMUNOL, V156, P3678
   Kogianni G, 2004, LIFE SCI, V75, P2879, DOI 10.1016/j.lfs.2004.04.048
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Manolagas SC, 1999, ENDOCRINOLOGY, V140, P4377, DOI 10.1210/en.140.10.4377
   Marie PJ, 2005, CURR OPIN PHARMACOL, V5, P633, DOI 10.1016/j.coph.2005.05.005
   Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427
   MORRISSEY PJ, 1993, J EXP MED, V178, P237, DOI 10.1084/jem.178.1.237
   OWEN M, 1988, CIBA F SYMP, V136, P42
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   POWRIE F, 1993, INT IMMUNOL, V5, P1461, DOI 10.1093/intimm/5.11.1461
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Rothfuss KS, 2006, WORLD J GASTROENTERO, V12, P4819
   Scholz M, 2005, MED RES REV, V25, P331, DOI 10.1002/med.20025
   Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602 587
   Sylvester FA, 2005, INFLAMM BOWEL DIS, V11, P1020, DOI 10.1097/01.MIB.0000188341.96726.15
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Weitzmann MN, 2005, IMMUNOL REV, V208, P154, DOI 10.1111/j.0105 2896.2005.00324.x
   Whitfield JF, 2006, CURR OPIN INVEST DR, V7, P349
   Xing LP, 2005, BIOCHEM BIOPH RES CO, V328, P709, DOI 10.1016/j.bbrc.2004.11.072
NR 40
TC 154
Z9 187
U1 0
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 9
PY 2008
VL 3
IS 7
AR e2615
DI 10.1371/journal.pone.0002615
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 417GZ
UT WOS:000264065800017
PM 18612428
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Plotkin, LI
AF Plotkin, Lilian I.
TI Apoptotic Osteocytes and the Control of Targeted Bone Resorption
SO CURRENT OSTEOPOROSIS REPORTS
LA English
DT Article
DE Osteocyte; Apoptosis; Bone remodeling
ID OSTEOBLAST APOPTOSIS; ESTROGEN WITHDRAWAL; OXIDATIVE STRESS;
   OSTEOCLASTS; SURVIVAL; BISPHOSPHONATES; GLUCOCORTICOIDS; CONNEXIN 43;
   HMGB1; ACTIVATION
AB Studies from the 1950s and 1960s already recognize the fact that osteocytes, although long living cells, die, as evidenced by accumulation of osteocytic lacunae devoid of cells. More recently, it was demonstrated that these cells die by apoptosis. The rate of osteocyte apoptosis is regulated by the age of the bone, as well as by systemic hormones, local growth factors, cytokines, pharmacological agents, and mechanical forces. Apoptotic osteocytes, in turn, recruit osteoclasts to initiate targeted bone resorption. This results in the removal of "dead" bone and may improve the mechanical properties of the skeleton. However, the molecular regulators of osteocyte survival and targeted bone remodeling are not completely known. In this review, the current knowledge on the molecular mechanism that lead to osteocyte death or survival, and the signals that mediate targeted bone resorption is discussed.
C1 Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington
RP Plotkin, LI (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS 5035, Indianapolis, IN 46202 USA.
EM lplotkin@iupui.edu
RI ; Plotkin, Lilian/H 7188 2019
OI Plotkin, Lilian/0000 0002 9537 4544; 
FU National Institutes of Health [R01 AR053643]; Indiana University School
   of Medicine
FX This research was supported by National Institutes of Health
   (R01 AR053643) and by a Biomedical Research Grant and a Developing
   Diverse Researchers with InVestigative Expertise (DRIVE) Grant from
   Indiana University School of Medicine.
CR Aguirre JI, 2007, J BIOL CHEM, V282, P25501, DOI 10.1074/jbc.M702231200
   Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bellido T, 2014, CALCIFIED TISSUE INT, V94, P25, DOI 10.1007/s00223 013 9774 y
   Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548
   Bivi N, 2011, J CELL BIOCHEM, V112, P2920, DOI 10.1002/jcb.23208
   Boabaid F, 2001, TISSUE CELL, V33, P318, DOI 10.1054/tice.2001.0179
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Cardoso L, 2009, J BONE MINER RES, V24, P597, DOI 10.1359/JBMR.081210
   Cerri PS, 2003, J PERIODONTAL RES, V38, P223, DOI 10.1034/j.1600 0765.2003.02006.x
   ELMARDI AS, 1990, CALCIFIED TISSUE INT, V46, P239, DOI 10.1007/BF02555002
   Emerton KB, 2010, BONE, V46, P577, DOI 10.1016/j.bone.2009.11.006
   Frost HM, 2003, ANAT REC PART A, V275A, P1081, DOI 10.1002/ar.a.10119
   FROST HM, 1960, J BONE JOINT SURG AM, V42, P138, DOI 10.2106/00004623 196042010 00011
   Gohel A, 1999, ENDOCRINOLOGY, V140, P5339, DOI 10.1210/en.140.11.5339
   Huber C, 2007, CALCIFIED TISSUE INT, V81, P139, DOI 10.1007/s00223 007 9049 6
   Jia JJ, 2011, FASEB J, V25, P3366, DOI 10.1096/fj.11 182519
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 2014, J BONE MINER RES, V29, P103, DOI 10.1002/jbmr.2007
   Jilka RL, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P237, DOI 10.1016/B978 0 12 373884 4.00032 X
   Kennedy OD, 2012, BONE, V50, P1115, DOI 10.1016/j.bone.2012.01.025
   Kitase Y, 2010, J BONE MINER RES, V25, P2381, DOI 10.1002/jbmr.168
   Klune JR, 2008, MOL MED, V14, P476, DOI 10.2119/2008 00034.Klune
   Kogianni G, 2008, J BONE MINER RES, V23, P915, DOI 10.1359/JBMR.080207
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Lloyd SA, 2013, BONE, V57, P76, DOI 10.1016/j.bone.2013.07.022
   Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010
   Morse LR, 2011, TRANSL STROKE RES, V2, P643, DOI 10.1007/s12975 011 0118 9
   Noble BS, 1997, BONE, V20, P273, DOI 10.1016/S8756 3282(96)00365 1
   Noble BS, 2003, AM J PHYSIOL CELL PH, V284, pC934, DOI 10.1152/ajpcell.00234.2002
   Noble BS, 2000, MOL CELL ENDOCRINOL, V159, P7, DOI 10.1016/S0303 7207(99)00174 4
   Plotkin LI, 2011, BONE, V49, P122, DOI 10.1016/j.bone.2010.08.011
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, AM J PHYSIOL CELL PH, V289, pC633, DOI 10.1152/ajpcell.00278.2004
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200
   Plotkin LI, 2008, J BONE MINER RES, V23, P1712, DOI [10.1359/jbmr.080617, 10.1359/JBMR.080617]
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Plotkin LI, 2007, J BIOL CHEM, V282, P24120, DOI 10.1074/jbc.M611435200
   Rogers Maurice, 2011, Scottish Forestry, V65, P34
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   Taniguchi N, 2007, MOL CELL BIOL, V27, P5650, DOI 10.1128/MCB.00130 07
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128
   Tomkinson A, 1998, J BONE MINER RES, V13, P1243, DOI 10.1359/jbmr.1998.13.8.1243
   van Essen HW, 2007, CALCIFIED TISSUE INT, V81, P183, DOI 10.1007/s00223 007 9050 0
   Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60
   Verborgt O, 2002, J BONE MINER RES, V17, P907, DOI 10.1359/jbmr.2002.17.5.907
   Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004 1050
   Weinstein RS, 2010, AGING CELL, V9, P147, DOI 10.1111/j.1474 9726.2009.00545.x
   Weinstein RS, 2000, J CLIN ENDOCR METAB, V85, P2907, DOI 10.1210/jc.85.8.2907
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wu AC, 2013, CALCIFIED TISSUE INT, V92, P566, DOI 10.1007/s00223 013 9718 6
   Yang JP, 2008, J CELL PHYSIOL, V214, P730, DOI 10.1002/jcp.21268
   Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023516
   Zhou Z, 2008, J BONE MINER RES, V23, P1084, DOI 10.1359/JBMR.080234
NR 61
TC 66
Z9 84
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1544 1873
EI 1544 2241
J9 CURR OSTEOPOROS REP
JI Curr. Osteoporos. Rep.
PD MAR
PY 2014
VL 12
IS 1
BP 121
EP 126
DI 10.1007/s11914 014 0194 3
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AY0IZ
UT WOS:000347281700016
PM 24470254
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Wei, HJ
   Xu, YH
   Wang, YB
   Xu, LT
   Mo, CY
   Li, LZ
   Shen, B
   Sun, Y
   Cheng, PZ
   Yang, L
   Pang, YC
   Qin, A
   Cao, Y
   Morrison, SJ
   Yue, R
AF Wei, Hanjing
   Xu, Yanhua
   Wang, Yibin
   Xu, Liting
   Mo, Chunyang
   Li, Liangzi
   Shen, Bo
   Sun, Yao
   Cheng, Pengzhen
   Yang, Liu
   Pang, Yichuan
   Qin, An
   Cao, Ying
   Morrison, Sean J.
   Yue, Rui
TI Identification of Fibroblast Activation Protein as an Osteogenic
   Suppressor and Anti osteoporosis Drug Target
SO CELL REPORTS
LA English
DT Article
ID MESENCHYMAL STROMAL CELLS; GROWTH FACTOR; POSTMENOPAUSAL WOMEN;
   MOLECULAR CLONING; SKELETAL MUSCLE; STEM CELLS; BONE; MOUSE; EXPRESSION;
   ROMOSOZUMAB
AB Osteogenic suppressors such as Sclerostin not only regulate skeletal development and regeneration but also serve as anti osteoporosis drug targets. However, very few druggable suppressors have been identified due to limited understanding of the molecular mechanisms governing osteogenesis. Here, we show that fibroblast activation protein (Fap), a serine protease inhibited by the bone growth factor Osteolectin, is an osteogenic suppressor. Genetic deletion of Fap significantly ameliorates limb trabecular bone loss during aging. Pharmacological inhibition of Fap significantly promotes bone formation and inhibits bone resorption in wildtype mice by differentially regulating canonical Wnt and nuclear factor kappa B (NF kappa B) pathways. Pharmacological inhibition of Fap promotes osteoblast differentiation, inhibits osteoclast differentiation, and significantly attenuates osteoporosis in ovariectomized mice. Epistasis analyses in zebrafish show that Osteolectin functions as an endogenous inhibitor of Fap to promote vertebrae mineralization. Taken together, we identify Fap as an important osteogenic suppressor and a potential drug target to treat osteoporosis.
C1 [Wei, Hanjing; Xu, Yanhua; Wang, Yibin; Xu, Liting; Mo, Chunyang; Li, Liangzi; Cao, Ying; Yue, Rui] Tongji Univ, Sch Life Sci & Technol, Shanghai Key Lab Signaling & Dis Res, Inst Regenerat Med,Shanghai East Hosp,Frontier Sc, Shanghai 200092, Peoples R China.
   [Morrison, Sean J.] Univ Texas Southwestern Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA.
   [Shen, Bo; Morrison, Sean J.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA.
   [Shen, Bo; Morrison, Sean J.] Univ Texas Southwestern Med Ctr Dallas, Childrens Res Inst, Dallas, TX 75390 USA.
   [Sun, Yao] Tongji Univ, Sch & Hosp Stomatol, Dept Implantol, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Shanghai 200072, Peoples R China.
   [Cheng, Pengzhen; Yang, Liu] Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped Surg, Xian 710032, Peoples R China.
   [Pang, Yichuan; Qin, An] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Sch Med, Dept Orthoped,Shanghai Key Lab Orthoped Implant, Shanghai 200011, Peoples R China.
   [Xu, Yanhua] Tongji Univ Sch Med, Shanghai Peoples Hosp 10, Dept Cardiol, 1239 Siping Rd, Shanghai 200072, Peoples R China.
C3 Tongji University; Howard Hughes Medical Institute; University of Texas
   System; University of Texas Southwestern Medical Center; University of
   Texas System; University of Texas Southwestern Medical Center;
   University of Texas System; University of Texas Southwestern Medical
   Center; Tongji University; Air Force Medical University; Shanghai Jiao
   Tong University; Tongji University
RP Yue, R (通讯作者)，Tongji Univ, Sch Life Sci & Technol, Shanghai Key Lab Signaling & Dis Res, Inst Regenerat Med,Shanghai East Hosp,Frontier Sc, Shanghai 200092, Peoples R China.
EM ryue@tongji.edu.cn
RI Wang, Xiaojing/HNI 4384 2023; pang, yichuan/GWQ 7981 2022; Qin,
   An/J 2518 2019; Morrison, Sean/ABD 5326 2021; sun, yao/MEP 9275 2025;
   Shen, Bo/G 2012 2014
OI Yue, Rui/0000 0002 3401 369X; Yang, Liu/0000 0002 6498 4702; Shen,
   Bo/0000 0002 5237 6144
FU National Key Program on Stem Cell and Translational Research
   [2017YFA0106400]; National Natural Science Foundation of China
   [91749124, 81772389]; Fundamental Research Funds for the Central
   Universities [22120190149, kx0200020173386]
FX This work was supported by grants from the National Key Program on Stem
   Cell and Translational Research (2017YFA0106400), the National Natural
   Science Foundation of China (91749124 and 81772389), and the Fundamental
   Research Funds for the Central Universities (22120190149 and
   kx0200020173386).
CR Acar M, 2015, NATURE, V526, P126, DOI 10.1038/nature15250
   Bianco P, 2015, DEVELOPMENT, V142, P1023, DOI 10.1242/dev.102210
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chen X, 1999, MOL CELL BIOL, V19, P4695
   Chung KM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088772
   COLLEN D, 1991, BLOOD, V78, P3114
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Ding L, 2013, NATURE, V495, P231, DOI 10.1038/nature11885
   Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783
   Du SJ, 2001, DEV BIOL, V238, P239, DOI 10.1006/dbio.2001.0390
   Dunshee DR, 2016, J BIOL CHEM, V291, P5986, DOI 10.1074/jbc.M115.710582
   Edosada CY, 2006, J BIOL CHEM, V281, P7437, DOI 10.1074/jbc.M511112200
   Egan KP, 2012, HISTOPATHOLOGY, V61, P1168, DOI 10.1111/j.1365 2559.2012.04333.x
   Gan XQ, 2008, J CELL BIOL, V180, P1087, DOI 10.1083/jcb.200710050
   Goldstein LA, 1997, BBA MOL BASIS DIS, V1361, P11, DOI 10.1016/S0925 4439(97)00032 X
   Hamson EJ, 2014, PROTEOM CLIN APPL, V8, P454, DOI 10.1002/prca.201300095
   Han XP, 2018, CELL, V172, P1091, DOI 10.1016/j.cell.2018.02.001
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hu RK, 2019, FASEB J, V33, P5248, DOI 10.1096/fj.201802140R
   Ikeno S, 2019, J BIOL CHEM, V294, P4966, DOI 10.1074/jbc.RA118.004153
   Kalajzic Z, 2002, BONE, V31, P654, DOI 10.1016/S8756 3282(02)00912 2
   Kanno Y, 2017, INT J MOL MED, V40, P854, DOI 10.3892/ijmm.2017.3055
   Keane FM, 2011, FEBS J, V278, P1316, DOI 10.1111/j.1742 4658.2011.08051.x
   KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302
   Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300
   Laize Vincent., 2014, Drug Discovery Today: Disease Models, V13, P29
   Lee KN, 2006, BLOOD, V107, P1397, DOI 10.1182/blood 2005 08 3452
   Lee KN, 2004, BLOOD, V103, P3783, DOI 10.1182/blood 2003 12 4240
   Lee MS, 2012, METABOLISM, V61, P1142, DOI 10.1016/j.metabol.2012.01.012
   Li XD, 2017, J BONE MINER RES, V32, P834, DOI 10.1002/jbmr.2936
   Marguet D, 2000, P NATL ACAD SCI USA, V97, P6874, DOI 10.1073/pnas.120069197
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Mei B, 2019, HUM GENET, V138, P151, DOI 10.1007/s00439 019 01969 y
   MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432 1033.1993.tb17986.x
   Mio H, 1998, BIOCHEM BIOPH RES CO, V249, P124, DOI 10.1006/bbrc.1998.9073
   Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092 8674(00)80860 0
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Niedermeyer J, 2000, MOL CELL BIOL, V20, P1089, DOI 10.1128/MCB.20.3.1089 1094.2000
   Niedermeyer J, 2001, INT J DEV BIOL, V45, P445
   Parichy DM, 2009, DEV DYNAM, V238, P2975, DOI 10.1002/dvdy.22113
   Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505
   PineiroSanchez ML, 1997, J BIOL CHEM, V272, P7595, DOI 10.1074/jbc.272.12.7595
   RETTIG WJ, 1994, INT J CANCER, V58, P385, DOI 10.1002/ijc.2910580314
   Roberts EW, 2013, J EXP MED, V210, P1137, DOI 10.1084/jem.20122344
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657
   Shen B, 2019, ELIFE, V8, DOI 10.7554/eLife.42274
   Suire C, 2012, BLOOD, V119, pE86, DOI 10.1182/blood 2011 08 372334
   Tran E, 2013, J EXP MED, V210, P1125, DOI 10.1084/jem.20130110
   Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960 9822(03)00240 9
   Venkatesh B, 2014, NATURE, V505, P174, DOI 10.1038/nature12826
   Wei W, 2012, P NATL ACAD SCI USA, V109, P3143, DOI 10.1073/pnas.1200797109
   Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471 4914(02)02340 7
   Yu YH, 2016, INT IMMUNOPHARMACOL, V38, P144, DOI 10.1016/j.intimp.2016.05.026
   Yue R, 2016, ELIFE, V5, DOI 10.7554/eLife.18782
   Yue R, 2016, CELL STEM CELL, V18, P782, DOI 10.1016/j.stem.2016.02.015
   Zhao HX, 2015, DEV BIOL, V398, P242, DOI 10.1016/j.ydbio.2014.12.007
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zhou F, 2016, NATURE, V533, P487, DOI 10.1038/nature17997
NR 59
TC 45
Z9 48
U1 4
U2 70
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211 1247
J9 CELL REP
JI Cell Reports
PD OCT 13
PY 2020
VL 33
IS 2
AR 108252
DI 10.1016/j.celrep.2020.108252
PG 21
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA OC9QU
UT WOS:000579490800009
PM 33053358
OA gold
DA 2025 08 17
ER

PT J
AU Zhu, S
   Häussling, V
   Aspera Werz, RH
   Chen, T
   Braun, B
   Weng, WD
   Histing, T
   Nussler, AK
AF Zhu, Sheng
   Haeussling, Victor
   Aspera Werz, Romina H.
   Chen, Tao
   Braun, Bianca
   Weng, Weidong
   Histing, Tina
   Nussler, Andreas K.
TI Bisphosphonates Reduce Smoking Induced Osteoporotic Like Alterations by
   Regulating RANKL/OPG in an Osteoblast and Osteoclast Co Culture Model
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE co culture; osteoblasts; osteoclasts; cigarette smoking;
   bisphosphonates; osteoporosis
ID NITROGEN CONTAINING BISPHOSPHONATE; CIGARETTE SMOKING; BONE RESORPTION;
   ZOLEDRONIC ACID; OSTEOPROTEGERIN; EXPRESSION; DIFFERENTIATION;
   RESVERATROL; ACTIVATION; INHIBITION
AB Co culture models have become mandatory for obtaining better insights into bone homeostasis, which relies on the balance between osteoblasts and osteoclasts. Cigarette smoking (CS) has been proven to increase the risk of osteoporosis; however, there is currently no proven treatment for osteoporosis in smokers excluding cessation. Bisphosphonates (BPs) are classical anti osteoclastic drugs that are commonly used in examining the suitability of bone co culture systems in vitro as well as to verify the response to osteoporotic stimuli. In the present study, we tested the effects of BPs on cigarette smoke extract (CSE) affected cells in the co culture of osteoblasts and osteoclasts. Our results showed that BPs were able to reduce CSE induced osteoporotic alterations in the co culture of osteoblasts and osteoclasts such as decreased matrix remodeling, enhanced osteoclast activation, and an up regulated receptor activator of nuclear factor (NF) kB ligand (RANKL)/osteoprotegerin (OPG) ratio. In summary, BPs may be an effective alternative therapy for reversing osteoporotic alterations in smokers, and the potential mechanism is through modulation of the RANKL/OPG ratio.
C1 [Zhu, Sheng; Haeussling, Victor; Aspera Werz, Romina H.; Chen, Tao; Braun, Bianca; Weng, Weidong; Histing, Tina; Nussler, Andreas K.] Eberhard Karls Univ Tuebingen, Siegfried Weller Inst Trauma Res, BG Trauma Ctr Tuebingen, Dept Trauma & Reconstruct Surg, D 72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Nussler, AK (通讯作者)，Eberhard Karls Univ Tuebingen, Siegfried Weller Inst Trauma Res, BG Trauma Ctr Tuebingen, Dept Trauma & Reconstruct Surg, D 72076 Tubingen, Germany.
EM zhusheng8686@gmail.com; victor.haeussling@student.uni tuebingen.de;
   rominaaspera@hotmail.com; zzuchentao@yahoo.com; bibi.braun@gmx.de;
   wengweidong5657@gmail.com; thisting@bgu tuebingen.de;
   andreas.nuessler@med.uni tuebingen.de
RI ; Zhu, Sheng/AAW 6108 2021
OI Zhu, Sheng/0000 0001 7078 4371; Aspera Werz, Romina/0000 0002 5160 2111;
   Chen, Tao/0000 0002 1156 2899
FU Open Access Publishing Fund of University of Tubingen
FX We would like to thank Hanna Scheffler for her technical assistance. We
   also thank Marc Ruoss, Yangmengfan Chen and Helen Rinderknecht for their
   valuable suggestions. We acknowledge support by Open Access Publishing
   Fund of University of Tubingen.
CR Açil Y, 2018, J CRANIO MAXILL SURG, V46, P538, DOI 10.1016/j.jcms.2017.12.015
   Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Amin N, 2020, AGING CLIN EXP RES, V32, P363, DOI 10.1007/s40520 019 01223 5
   Aspera Werz RH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122915
   Aspera Werz RH, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3172480
   Bai P, 2011, RESP RES, V12, DOI 10.1186/1465 9921 12 157
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Bernhardt A, 2017, EUR CELLS MATER, V33, P28, DOI 10.22203/eCM.v033a03
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   Bon J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105066
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   D'Amelio P, 2010, OSTEOPOROSIS INT, V21, P1741, DOI 10.1007/s00198 009 1129 1
   de Castro LF, 2019, J BONE MINER RES, V34, P290, DOI 10.1002/jbmr.3602
   Dobnig H, 2006, OSTEOPOROSIS INT, V17, P693, DOI 10.1007/s00198 005 0035 4
   Dong W, 2018, BIOCHEM BIOPH RES CO, V505, P1195, DOI 10.1016/j.bbrc.2018.10.059
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Ehnert S., 2020, SciMedicine Journal, V2, P157, DOI [10.28991/SciMedJ 2020 0203 6, DOI 10.28991/SCIMEDJ 2020 0203 6]
   Ehnert S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082239
   Ehnert S, 2012, BMC MED, V10, DOI 10.1186/1741 7015 10 101
   Feng M, 2020, LAB INVEST, V100, P1400, DOI 10.1038/s41374 020 0445 0
   Franck FC, 2018, INT J ORAL MAX SURG, V47, P541, DOI 10.1016/j.ijom.2017.08.004
   Fu YX, 2013, POULTRY SCI, V92, P1613, DOI 10.3382/ps.2012 02756
   Giacomino CM, 2019, J ENDODONT, V45, P51, DOI 10.1016/j.joen.2018.08.007
   Habermann B, 2007, ACTA ORTHOP, V78, P221, DOI 10.1080/17453670710013717
   Hamdy RC, 2020, J CLIN DENSITOM, V23, P337, DOI 10.1016/j.jocd.2020.06.005
   Heinemann C, 2019, BIOMED MATER, V14, DOI 10.1088/1748 605X/ab0fad
   Huang KC, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0818 5
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Javaheri B, 2019, CURR OSTEOPOROS REP, V17, P560, DOI 10.1007/s11914 019 00553 7
   Jeong JW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061439
   Kim YH, 2002, EXP MOL MED, V34, P145, DOI 10.1038/emm.2002.21
   Ko CH, 2015, CALCIFIED TISSUE INT, V96, P389, DOI 10.1007/s00223 015 9966 8
   Ko FC, 2017, J BONE MINER RES, V32, P814, DOI 10.1002/jbmr.3052
   Koch FP, 2012, CLIN ORAL INVEST, V16, P79, DOI 10.1007/s00784 010 0477 8
   Koch FP, 2010, HEAD FACE MED, V6, DOI 10.1186/1746 160X 6 12
   Kolkesen Sahin Ö, 2016, TURK J MED SCI, V46, P1203, DOI 10.3906/sag 1501 109
   Lehenkari P, 1998, EXP CELL RES, V242, P128, DOI 10.1006/excr.1998.4071
   Lennerås M, 2015, CLIN IMPLANT DENT R, V17, pE486, DOI 10.1111/cid.12276
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Li ZH, 2017, MOL MED REP, V16, P8380, DOI 10.3892/mmr.2017.7625
   Lin S, 2009, HUM REPROD, V24, P386, DOI 10.1093/humrep/den419
   Maria S, 2017, AGING US, V9, P256, DOI 10.18632/aging.101158
   Marinucci L, 2018, FREE RADICAL BIO MED, V117, P6, DOI 10.1016/j.freeradbiomed.2018.01.017
   Mulcahy LE, 2015, EUR CELLS MATER, V30, P271, DOI 10.22203/eCM.v030a19
   Owen R, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00134
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   Park E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112784
   Pasquier J, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16365 7
   Reumann MK, 2020, ARCH TOXICOL, V94, P2163, DOI 10.1007/s00204 020 02769 4
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   Roeder I, 2011, BLOOD CELL MOL DIS, V46, P308, DOI 10.1016/j.bcmd.2011.03.001
   Ruoss M, 2020, METHOD PROTOCOL, V3, DOI 10.3390/mps3010001
   Schulze S, 2018, J CELL PHYSIOL, V233, P4391, DOI 10.1002/jcp.26076
   Serra Vinardell J, 2020, J INHERIT METAB DIS, V43, P133, DOI 10.1002/jimd.12097
   Shen GS, 2015, INJURY, V46, P1333, DOI 10.1016/j.injury.2015.04.008
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Sieberath A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030912
   Sreekumar V, 2017, ARCH TOXICOL, V91, P1353, DOI 10.1007/s00204 016 1796 6
   Strozyk D, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0426 8
   Su YC, 1998, AM J RESP CELL MOL, V19, P819, DOI 10.1165/ajrcmb.19.5.3091
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Tang TH, 2009, J CLIN PERIODONTOL, V36, P713, DOI 10.1111/j.1600 051X.2009.01444.x
   Tsubaki M, 2012, MOL CELL ENDOCRINOL, V361, P219, DOI 10.1016/j.mce.2012.05.002
   Verde María E, 2015, Acta odontol. latinoam., V28, P215
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Wehner C, 2020, BMC ORAL HEALTH, V20, DOI 10.1186/s12903 020 01089 4
   Weng WD, 2020, BIOENGINEERING BASEL, V7, DOI 10.3390/bioengineering7020052
   Wessel JH, 2008, J ORAL MAXIL SURG, V66, P625, DOI 10.1016/j.joms.2007.11.032
   Wu ZJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168990
   Xu F, 2016, MOL MED REP, V14, P2289, DOI 10.3892/mmr.2016.5515
   Yang Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00731
   Yeam CT, 2018, OSTEOPOROSIS INT, V29, P2623, DOI 10.1007/s00198 018 4759 3
   Yoon V, 2012, OSTEOPOROSIS INT, V23, P2081, DOI 10.1007/s00198 012 1940 y
   Yu J, 2018, J CELL BIOCHEM, V119, P9334, DOI 10.1002/jcb.27212
   Yuan H, 2016, ACTA BIOMATER, V31, P312, DOI 10.1016/j.actbio.2015.12.009
   Zhu S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082284
NR 78
TC 24
Z9 25
U1 0
U2 31
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2021
VL 22
IS 1
AR 53
DI 10.3390/ijms22010053
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PP8SQ
UT WOS:000606126100001
PM 33374546
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, K
   Da, JL
   Wang, JQ
   Liu, LX
   Liu, XP
   Yuan, HZ
   Jiang, LL
   Geng, YW
   Liu, XY
   Jiang, ZL
   Jin, H
   Li, Y
   Zhang, B
AF Zhang, Kai
   Da, Junlong
   Wang, Jianqun
   Liu, Lixue
   Liu, Xinpeng
   Yuan, Haoze
   Jiang, Lili
   Geng, Yawei
   Liu, Xiaoyao
   Jiang, Zhuling
   Jin, Han
   Li, Ying
   Zhang, Bin
TI Multifunctional Alendronate PEI Carbon Dots for the Treatment of
   Bone Destructive Diseases via Bidirectional Regulation of
   Osteoblast Osteoclast Function
SO ADVANCED THERAPEUTICS
LA English
DT Article
DE bone homeostasis; bone targeting; carbon dots; gene vectors
ID DELIVERY; DIFFERENTIATION; OSTEOGENESIS; HYDROGEL; BMP 2
AB Bone damage results from the imbalance of bone homeostasis maintained by osteoblast regulated bone formation and osteoclast mediated bone resorption. Conventional drug therapy and gene therapy may not optimally regulate the bone remodeling process due to the unitary pharmacological mechanism of drug and the safety and targeting of gene vectors. In the present study, multifunctional fluorescent alendronate polyethyleneimine carbon dots (Alen PEI CDs) are innovatively synthesized, which have excellent biocompatibility, selective bone targeting, gene carrying capacity, and anti bone absorption effect. As gene vectors, bone morphogenic protein 2 (BMP2) gene loaded Alen PEI CDs greatly enhance osteoblast differentiation and bone regeneration. Notably, Alen PEI CDs are found to directly inhibit the formation and function of osteoclasts, effectively attenuating the LPS induced skull osteolysis in mice. Furthermore, their cumulative toxicity is lower than that of Alen, indicating their potential as an anti bone resorptive nanodrug. These results show that the bone targeting Alen PEI CDs significantly reverse the imbalance of bone homeostasis through a dual directional mechanism directly suppressing bone resorption and indirectly inducing bone formation by transfection of osteogenic therapeutic genes. Overall, the study expands the application for carbon dots in biomedicine, providing new insights for the further development of novel selectively targeted multifunctional nanodrugs for the treatment of bone destructive diseases.
C1 [Zhang, Kai; Da, Junlong; Wang, Jianqun; Liu, Lixue; Liu, Xinpeng; Yuan, Haoze; Jiang, Lili; Geng, Yawei; Jiang, Zhuling; Jin, Han; Li, Ying; Zhang, Bin] Harbin Med Univ, Affiliated Hosp 2, Heilongjiang Prov Key Lab Hard Tissue Dev & Regen, Harbin 150001, Peoples R China.
   [Liu, Xiaoyao] Harbin Med Univ, Affiliated Hosp 1, Dept Orthodont, Harbin 150000, Peoples R China.
   [Jiang, Zhuling] Harbin Med Univ, Affiliated Hosp 2, Dept Implantol, Harbin 150001, Peoples R China.
   [Zhang, Bin] Heilongjiang Acad Med Sci, Harbin 150001, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University
RP Jin, H; Li, Y; Zhang, B (通讯作者)，Harbin Med Univ, Affiliated Hosp 2, Heilongjiang Prov Key Lab Hard Tissue Dev & Regen, Harbin 150001, Peoples R China.; Zhang, B (通讯作者)，Heilongjiang Acad Med Sci, Harbin 150001, Peoples R China.
EM jinhan@hrbmu.edu.cn; liying@hrbmu.edu.cn; zhangbin@hrbmu.edu.cn
RI Da, Junlong/HLW 4090 2023; lili, Jiang/AAP 4020 2021
FU Natural Science Foundation of Heilongjiang Province of China
   [YQ2020H018, LH2020H057]; National Natural Science Foundation of China
   [81870736]
FX This work was supported by the Natural Science Foundation of
   Heilongjiang Province of China (Grant No. YQ2020H018, LH2020H057) and
   the National Natural Science Foundation of China (Grant No. 81870736).
CR Alliston T, 2002, NATURE, V416, P686, DOI 10.1038/416686a
   Arlt H, 2020, BONE REP, V13, DOI 10.1016/j.bonr.2020.100291
   Benoit DSW, 2007, ADV FUNCT MATER, V17, P2085, DOI 10.1002/adfm.200700012
   Bu WH, 2020, ACS APPL MATER INTER, V12, P50287, DOI 10.1021/acsami.0c15425
   Cai HJ, 2020, J MATER CHEM B, V8, P5655, DOI 10.1039/d0tb00795a
   Chandrasekaran AR, 2019, NUCLEIC ACIDS RES, V47, P10489, DOI 10.1093/nar/gkz580
   Chen MJ, 2020, ACS APPL MATER INTER, V12, P22410, DOI 10.1021/acsami.0c00714
   Chung YJ, 2020, ACS NANO, V14, P6470, DOI 10.1021/acsnano.0c02114
   Curtin CM, 2015, ADV HEALTHC MATER, V4, P223, DOI 10.1002/adhm.201400397
   Dolatabadi JEN, 2015, DRUG DEV IND PHARM, V41, P1431, DOI 10.3109/03639045.2014.956111
   Duan L, 2021, NANOSCALE, V13, DOI 10.1039/d0nr07622h
   Freeman FE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb5093
   Hanna A, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00140
   Huang CC, 2020, ACTA BIOMATER, V109, P182, DOI 10.1016/j.actbio.2020.04.017
   Huntley R, 2019, BONE REP, V10, DOI 10.1016/j.bonr.2019.100207
   Ivey KN, 2010, CELL STEM CELL, V7, P36, DOI 10.1016/j.stem.2010.06.012
   Jackson NM, 2008, DRUG METAB DISPOS, V36, P2030, DOI 10.1124/dmd.108.022558
   Jin H, 2019, RSC ADV, V9, P26598, DOI 10.1039/c9ra05164c
   Kim YH, 2020, BIOCHEM BIOPH RES CO, V529, P169, DOI 10.1016/j.bbrc.2020.06.013
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Kurotaki D, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115471
   Lee KK, 2019, RSC ADV, V9, P2708, DOI 10.1039/c8ra09729a
   Lee MS, 2016, INT J NANOMED, V11, P4583, DOI 10.2147/IJN.S112415
   Li L, 2020, ACS APPL MATER INTER, V12, P18250, DOI 10.1021/acsami.0c00283
   Li X, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 020 00599 1
   Lin YJ, 2018, ADV MATER, V30, DOI 10.1002/adma.201705605
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Maisani M, 2018, DRUG DELIV TRANSL RE, V8, P178, DOI 10.1007/s13346 017 0451 y
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Michaud V, 2021, NANOSCALE, V13, P13116, DOI 10.1039/d1nr02562g
   Nemeth CL, 2019, ADV DRUG DELIVER REV, V148, P60, DOI 10.1016/j.addr.2019.05.003
   Neuberg P, 2014, ADV GENET, V88, P263, DOI 10.1016/B978 0 12 800148 6.00009 2
   Onuora S, 2019, NAT REV RHEUMATOL, V15, P513, DOI 10.1038/s41584 019 0288 5
   Park JS, 2016, ACS APPL MATER INTER, V8, P30387, DOI 10.1021/acsami.6b08343
   Peng ZL, 2017, NANOSCALE, V9, P17533, DOI 10.1039/c7nr05731h
   Raftery RM, 2016, ADV MATER, V28, P5447, DOI 10.1002/adma.201505088
   Raisin S, 2016, BIOMATERIALS, V104, P223, DOI 10.1016/j.biomaterials.2016.07.017
   Ralston SH, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115465
   Ryan DA, 2020, TISSUE ENG PART C ME, V26, P577, DOI [10.1089/ten.tec.2020.0217, 10.1089/ten.TEC.2020.0217]
   Sanchez Casanova S, 2020, BIOMATERIALS, V241, DOI 10.1016/j.biomaterials.2020.119909
   Seo BB, 2017, BIOMATERIALS, V122, P91, DOI 10.1016/j.biomaterials.2017.01.016
   Sharma R, 2017, NEW ENGL J MED, V376, P395, DOI 10.1056/NEJMc1615367
   Shui YM, 2017, AM J CHINESE MED, V45, P1093, DOI [10.1142/S0192415X17500598, 10.1142/s0192415x17500598]
   Song YL, 2020, CELL RES, V30, P854, DOI 10.1038/s41422 020 0334 5
   Vanderburgh J, 2020, ACS NANO, V14, P311, DOI 10.1021/acsnano.9b04571
   Wang C, 2019, ADV MATER, V31, DOI 10.1002/adma.201904329
   Wang JP, 2019, BIOMATERIALS, V217, DOI 10.1016/j.biomaterials.2019.119296
   Wareing TC, 2021, ACS NANO, V15, P15471, DOI 10.1021/acsnano.1c03886
   Yang QQ, 2018, COLLOID SURFACE B, V164, P165, DOI 10.1016/j.colsurfb.2018.01.031
   Zhang HY, 2017, SCIENCE, V358, P1127, DOI 10.1126/science.aar2640
NR 50
TC 6
Z9 6
U1 1
U2 41
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2366 3987
J9 ADV THER GERMANY
JI Adv. Therap.
PD FEB
PY 2023
VL 6
IS 2
DI 10.1002/adtp.202200149
EA OCT 2022
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 8Z5RT
UT WOS:000869647300001
DA 2025 08 17
ER

PT J
AU DeMauro, S
   Wysolmerski, J
AF DeMauro, S
   Wysolmerski, J
TI Hypercalcemia in breast cancer: An echo of bone mobilization during
   lactation?
SO JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
LA English
DT Article
DE bone metastases; calcium metabolism; parathyroid hormone related
   protein; bisphosphonate; cancer
ID HORMONE RELATED PROTEIN; IN VIVO; SKELETAL COMPLICATIONS; HUMORAL
   HYPERCALCEMIA; RECEPTOR ACTIVATOR; ZOLEDRONIC ACID; CLINICAL COURSE;
   MALIGNANCY; PAMIDRONATE; METASTASES
AB Hypercalcemia is a frequent complication of breast cancer which causes significant morbidity and mortality. Most commonly, it occurs in patients with multiple skeletal metastases. However, in a significant minority of patients, calcium levels become elevated in the absence of skeletal disease. In both instances, hypercalcemia is the result of pathological bone resorption caused by the secretion of cytokines that stimulate osteoclast differentiation and activity. One of these cytokines is parathyroid hormone related protein (PTHrP). PTHrP is also secreted by normal breast cells during lactation to increase bone resorption and liberate skeletal calcium stores for the purposes of milk production. Therefore, the pathophysiology of hypercalcemia in breast cancer patients mimics the physiological processes that normally regulate calcium metabolism during lactation. Current therapy for hypercalcemia in breast cancer patients relies on the inhibition of bone resorption by a class of drugs known as bisphophonates. Newer therapies in development target cytokines involved in the recruitment and activation of osteoclasts by tumor cells.
C1 Yale Univ, Sch Med, Sect Endocrinol & Metab, New Haven, CT 06520 USA.
C3 Yale University
RP Wysolmerski, J (通讯作者)，Yale Univ, Sch Med, Sect Endocrinol & Metab, TAC S131,333 Cedar St, New Haven, CT 06520 USA.
EM john.wysolmerski@yale.edu
CR Baron R., 2003, GEN PRINCIPLES BONE, P1
   Bendre MS, 2002, CANCER RES, V62, P5571
   Broadus AE., 2003, PRIMER METABOLIC BON, P105
   BUDAYR AA, 1989, P NATL ACAD SCI USA, V86, P7183, DOI 10.1073/pnas.86.18.7183
   BURTIS WJ, 1987, J BIOL CHEM, V262, P7151
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Dunbar ME, 1999, J MAMMARY GLAND BIOL, V4, P21, DOI 10.1023/A:1018700502518
   FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo 127 5 2592
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Guise TA, 2002, BONE, V30, P670, DOI 10.1016/S8756 3282(02)00685 3
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   GURNEY H, 1993, LANCET, V341, P1611, DOI 10.1016/0140 6736(93)90756 7
   Hillner BE, 2000, J CLIN ONCOL, V18, P72, DOI 10.1200/JCO.2000.18.1.72
   Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378
   Hofbauer LC, 2000, J CLIN ENDOCR METAB, V85, P2355, DOI 10.1210/jc.85.7.2355
   Hortobagyi GN, 2002, SEMIN ONCOL, V29, P134, DOI 10.1053/sonc.2002.34066
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   ISALES C, 1987, AM J MED, V82, P1143, DOI 10.1016/0002 9343(87)90216 6
   Jemal A, 2004, CA CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8
   JUPPNER HW, 2001, ENDOCRINOLOGY, P969
   Kovacs CS, 1997, ENDOCR REV, V18, P832, DOI 10.1210/er.18.6.832
   LEBOFF MS, 2003, PRIMER METABOLIC BON, P225
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Mundy GR, 1997, AM J MED, V103, P134, DOI 10.1016/S0002 9343(97)80047 2
   Oyajobi BO, 2001, CANCER RES, V61, P2572
   Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127
   POWELL GJ, 1991, CANCER RES, V51, P3059
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Sanders JL, 2000, ENDOCRINOLOGY, V141, P4357, DOI 10.1210/en.141.12.4357
   Sato K, 2003, SEMIN ONCOL, V30, P167, DOI 10.1053/j.seminoncol.2003.08.019
   Saunders Y, 2004, PALLIATIVE MED, V18, P418, DOI 10.1191/0269216304pm914ra
   SCHEID V, 1986, CANCER AM CANCER SOC, V58, P2589, DOI 10.1002/1097 0142(19861215)58:12<2589::AID CNCR2820581206>3.0.CO;2 O
   SOUTHBY J, 1990, CANCER RES, V50, P7710
   Sowers MF, 1996, JAMA J AM MED ASSOC, V276, P549, DOI 10.1001/jama.276.7.549
   STEWART A F, 1980, New England Journal of Medicine, V303, P1377, DOI 10.1056/NEJM198012113032401
   SUN B, 1998, J BONE MINER RES, V13, pS330
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   THIEDE MA, 1988, SCIENCE, V242, P278, DOI 10.1126/science.3175653
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Van der Pluijm G, 2001, J BONE MINER RES, V16, P1077, DOI 10.1359/jbmr.2001.16.6.1077
   VanHouten J, 2004, J CLIN INVEST, V113, P598, DOI 10.1172/JCI200418776
   Vanhouten JN, 2003, ENDOCRINOLOGY, V144, P5521, DOI 10.1210/en.2003 0892
   VanHouten JN, 2003, J CLIN INVEST, V112, P1429, DOI 10.1172/JCI200319504
   VARGAS SJ, 1992, J BONE MINER RES, V7, P971
   WALLS J, 1994, BRIT J CANCER, V70, P169, DOI 10.1038/bjc.1994.270
   WIMALAWANSA SJ, 1994, CLIN ENDOCRINOL, V41, P591, DOI 10.1111/j.1365 2265.1994.tb01823.x
   WIMALAWANSA SJ, 1994, CANCER, V73, P2223, DOI 10.1002/1097 0142(19940415)73:8<2223::AID CNCR2820730831>3.0.CO;2 C
   WYSOLMERSKI JJ, 1994, ANNU REV MED, V45, P189, DOI 10.1146/annurev.med.45.1.189
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
NR 52
TC 16
Z9 17
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1083 3021
EI 1573 7039
J9 J MAMMARY GLAND BIOL
JI J. Mammary Gland Biol. Neoplasia
PD APR
PY 2005
VL 10
IS 2
BP 157
EP 167
DI 10.1007/s10911 005 5398 9
PG 11
WC Oncology; Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Endocrinology & Metabolism; Physiology
GA 946IR
UT WOS:000230566100006
PM 16025222
DA 2025 08 17
ER

PT J
AU Bae, YJ
   Yang, T
   Zeng, HC
   Campeau, PM
   Chen, YQ
   Bertin, T
   Dawson, BC
   Munivez, E
   Tao, JN
   Lee, BH
AF Bae, Yangjin
   Yang, Tao
   Zeng, Huan Chang
   Campeau, Philippe M.
   Chen, Yuqing
   Bertin, Terry
   Dawson, Brian C.
   Munivez, Elda
   Tao, Jianning
   Lee, Brendan H.
TI miRNA 34c regulates Notch signaling during bone development
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID OSTEOBLASTIC CELL DIFFERENTIATION; TUMOR SUPPRESSOR; SPONDYLOCOSTAL
   DYSOSTOSIS; TRANSCRIPTIONAL CONTROL; MUTATIONS; CANCER; RUNX2;
   SKELETOGENESIS; PATHWAYS; FAMILIES
AB During bone homeostasis, osteoblast and osteoclast differentiation is coupled and regulated by multiple signaling pathways and their downstream transcription factors. Here, we show that microRNA 34 (miR 34) is significantly induced by BMP2 during osteoblast differentiation. In vivo, osteoblast specific gain of miR 34c in mice leads to an age dependent osteoporosis due to the defective mineralization and proliferation of osteoblasts and increased osteoclastogenesis. In osteoblasts, miR 34c targets multiple components of the Notch signaling pathway, including Notch1, Notch2 and Jag1 in a direct manner, and influences osteoclast differentiation in a non cell autonomous fashion. Taken together, our results demonstrate that miR 34c is critical during osteoblastogenesis in part by regulating Notch signaling in bone homeostasis. Furthermore, miR 34c mediated post transcriptional regulation of Notch signaling in osteoblasts is one possible mechanism to modulate the proliferative effect of Notch in the committed osteoblast progenitors which may be important in the pathogenesis of osteosarcomas. Therefore, understanding the functional interaction of miR 34 and Notch signaling in normal bone development and in bone cancer could potentially lead to therapies modulating miR 34 signaling.
C1 [Bae, Yangjin; Yang, Tao; Campeau, Philippe M.; Chen, Yuqing; Bertin, Terry; Dawson, Brian C.; Munivez, Elda; Tao, Jianning; Lee, Brendan H.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Zeng, Huan Chang; Lee, Brendan H.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA.
   [Chen, Yuqing; Dawson, Brian C.; Lee, Brendan H.] Howard Hughes Med Inst, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Baylor College of Medicine; Howard Hughes
   Medical Institute
RP Lee, BH (通讯作者)，Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.
EM blee@bcm.edu
RI Yang, Tao/ITU 1429 2023; Campeau, Philippe/J 8614 2015; Bae,
   Yangjin/AAO 1866 2021; Tao, Jianning/U 5213 2017
OI Campeau, Philippe/0000 0001 9713 7107; Tao, Jianning/0000 0001 5678 9272
FU National Institute of Health [AI053831, AR061565, HD22657, DE016990];
   Cancer Prevention Institute of Texas [RP101017]
FX This work was supported by the National Institute of Health (AI053831 to
   Y.B., AR061565 to J.T., HD22657 to B. H. L., DE016990 to B. H. L.); and
   the Cancer Prevention Institute of Texas (RP101017 to B.H.L.).
CR Baldridge D, 2010, ANNU REV GENOM HUM G, V11, P189, DOI 10.1146/annurev genom 082908 150158
   Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068
   Bulman MP, 2000, NAT GENET, V24, P438, DOI 10.1038/74307
   Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008 5472.CAN 07 1585
   Deregowski V, 2006, J BIOL CHEM, V281, P6203, DOI 10.1074/jbc.M508370200
   Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Engin F, 2010, BONE, V46, P274, DOI 10.1016/j.bone.2009.05.027
   Engin F, 2009, HUM MOL GENET, V18, P1464, DOI 10.1093/hmg/ddp057
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gaur T, 2010, DEV BIOL, V340, P10, DOI 10.1016/j.ydbio.2010.01.008
   Hashimi ST, 2009, BLOOD, V114, P404, DOI 10.1182/blood 2008 09 179150
   He CL, 2009, BIOCHEM BIOPH RES CO, V388, P35, DOI 10.1016/j.bbrc.2009.07.101
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   Isidor B, 2011, NAT GENET, V43, P306, DOI 10.1038/ng.778
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Krantz ID, 1998, AM J HUM GENET, V62, P1361, DOI 10.1086/301875
   Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008 5472.CAN 09 0529
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Majewski J, 2011, HUM MUTAT, V32, P1114, DOI 10.1002/humu.21546
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186
   Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001
   Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003 0463
   Sun GH, 2010, NUCLEIC ACIDS RES, V38, P239, DOI 10.1093/nar/gkp870
   Tanaka M, 2009, BRIT J CANCER, V100, P1957, DOI 10.1038/sj.bjc.6605060
   Tao JN, 2010, ANN NY ACAD SCI, V1192, P257, DOI 10.1111/j.1749 6632.2009.05307.x
   Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231
   Turnpenny PD, 2003, J MED GENET, V40, P333, DOI 10.1136/jmg.40.5.333
   Valencia Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806
   Wang ZW, 2010, CANCER LETT, V292, P141, DOI 10.1016/j.canlet.2009.11.012
   Wang ZW, 2009, CANCER LETT, V279, P8, DOI 10.1016/j.canlet.2008.09.030
   Weng AP, 2004, CURR OPIN GENET DEV, V14, P48, DOI 10.1016/j.gde.2003.11.004
   Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160
   Zanotti S, 2008, ENDOCRINOLOGY, V149, P3890, DOI 10.1210/en.2008 0140
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
   Zhou G, 2006, P NATL ACAD SCI USA, V103, P19004, DOI 10.1073/pnas.0605170103
NR 44
TC 204
Z9 227
U1 0
U2 22
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964 6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUL 1
PY 2012
VL 21
IS 13
BP 2991
EP 3000
DI 10.1093/hmg/dds129
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 961II
UT WOS:000305457700013
PM 22498974
OA Green Published
DA 2025 08 17
ER

PT J
AU Wang, J
   Stern, PH
AF Wang, J.
   Stern, P. H.
TI Dose dependent differential effects of risedronate on gene expression in
   osteoblasts
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Bisphosphonate; Risedronate; Osteoblast; Gene; Bone
ID ZOLEDRONIC ACID; CELL GROWTH; SKELETAL COMPLICATIONS; TRANSCRIPTION
   FACTOR; BREAST CARCINOMA; CANCER CELLS; BISPHOSPHONATES; PROLIFERATION;
   EGR 1; APOPTOSIS
AB Bisphosphonates have multiple effects on bone. Their actions on osteoclasts lead to inhibition of bone resorption, at least partially through apoptosis. Effects on osteoblasts vary, with modifications in the molecule and concentration both resulting in qualitatively different responses. To understand the mechanism of the differential effects of high and low bisphosphonate concentrations on osteoblast activity, we compared the effects of 10( 8) M and 10( 4) M risedronate on gene expression in UMR 106 rat osteoblastic cells. Two targeted arrays, an 84 gene signaling array and an 84 gene osteogeneic array were used. Gene expression was measured at 1 and 24 h. Although some genes were regulated similarly by low and high concentrations of the drug, there was also differential regulation. At 1 h, 11 genes (1 signaling and 10 osteogenesis) were solely regulated by the low concentration, and 7 genes (3 signaling, 4 osteogenesis) were solely regulated by the high concentration. At 24 h, 8 genes (3 signaling, 5 osteogenesis) were solely regulated by the low concentration and 30 genes (16 signaling and 14 osteogenesis) were solely regulated by the high concentration. Interestingly, the low, but not the high concentration of risedronate transiently and selectively upregulated several genes associated with cell differentiation. A number of genes related to apoptosis were regulated, and could be involved in effects of bisphosphonates to promote osteoblast apoptosis. Also, observed gene changes associated with decreased angiogenesis and decreased metastasis could, if they occur in other cell types, provide a basis for the effectiveness of bisphosphonates in the prevention of cancer metastases. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Wang, J.; Stern, P. H.] Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine
RP Stern, PH (通讯作者)，Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, S 215,303 E Chicago Ave, Chicago, IL 60611 USA.
EM j wang4@northwestern.edu; p stern@northwestern.edu
OI Wang, Jun/0000 0002 2678 2456
FU National Institutes of Health [R01 AR11262]; Procter and Gamble
FX This study was supported in part by a grant from the National Institutes
   of Health (R01 AR11262) and in part by funds from Procter and Gamble.
   Risedronate was provided by Procter and Gamble.
CR Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711
   Alexander D, 2002, BIOL CHEM, V383, P1845, DOI 10.1515/BC.2002.208
   Allen MR, 2008, OSTEOPOROSIS INT, V19, P329, DOI 10.1007/s00198 007 0533 7
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Cabiling DS, 2007, PLAST RECONSTR SURG, V120, P614, DOI 10.1097/01.prs.0000270292.89388.a3
   Cetinkaya BO, 2008, J PERIODONTOL, V79, P1950, DOI [10.1902/jop.2008.080041, 10.1902/jop.2008.080041 ]
   Chen SJ, 2006, J BIOL CHEM, V281, P21183, DOI 10.1074/jbc.M603270200
   Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541 7786.MCR 08 0077
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945 053X(00)00094 9
   de Jong DS, 2004, J BONE MINER RES, V19, P947, DOI 10.1359/JBMR.040216
   Eapen A, 2010, J BIOL CHEM, V285, P36339, DOI 10.1074/jbc.M110.145607
   Ehrenschwender M, 2009, ADV EXP MED BIOL, V647, P64, DOI 10.1007/978 0 387 89520 8_5
   Frost A, 2001, BONE, V28, P268, DOI 10.1016/S8756 3282(00)00449 X
   Gourion Arsiquaud S, 2010, BONE, V46, P666, DOI 10.1016/j.bone.2009.11.011
   Guan CC, 2009, BONE, V45, P1146, DOI 10.1016/j.bone.2009.08.009
   Hiraga T, 2003, INT J CANCER, V106, P973, DOI 10.1002/ijc.11330
   Ho AM, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 35
   Hu JCC, 2003, CRIT REV ORAL BIOL M, V14, P387, DOI 10.1177/154411130301400602
   Huojia M, 2005, DEV GROWTH DIFFER, V47, P141
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Iizuka S, 2011, MOL CELL BIOL, V31, P783, DOI 10.1128/MCB.00912 10
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Jeong BC, 2010, BONE, V46, P479, DOI 10.1016/j.bone.2009.09.019
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Li HY, 2010, AM J PHYSIOL CELL PH, V299, pC422, DOI 10.1152/ajpcell.00562.2009
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Liu CT, 1998, CANCER GENE THER, V5, P3
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378 1119(03)00748 0
   Ohba S, 2008, DEV CELL, V14, P689, DOI 10.1016/j.devcel.2008.03.007
   Onoe Y, 1996, J IMMUNOL, V156, P758
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Perrelet D, 2002, NAT CELL BIOL, V4, P175, DOI 10.1038/ncb751
   Pines A, 2003, BIOCHEM J, V373, P815, DOI 10.1042/BJ20030208
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Siggins SL, 2009, BLOOD, V114, P995, DOI 10.1182/blood 2009 03 208330
   Stresing V, 2011, BONE, V48, P259, DOI 10.1016/j.bone.2010.09.035
   Takano S, 2010, J ONCOL, V2010, DOI 10.1155/2010/351908
   Tamura D, 2008, INT J ONCOL, V33, P17
   Tan LJ, 2003, J BIOL CHEM, V278, P17688, DOI 10.1074/jbc.M301676200
   van Driel M, 2004, CURR PHARM DESIGN, V10, P2535
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   YOON RS, 2010, ORTHOPEDICS, P267, DOI DOI 10.3928/01477447 20100225 21
   Zhang WQ, 2010, MOL BIOL CELL, V21, P2500, DOI 10.1091/mbc.E09 08 0715
   Zolochevska O, 2011, PROSTATE, V71, P353, DOI 10.1002/pros.21249
   Zolochevska O, 2009, PROSTATE, V69, P1586, DOI 10.1002/pros.21007
NR 54
TC 7
Z9 8
U1 0
U2 7
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD APR 15
PY 2011
VL 81
IS 8
BP 1036
EP 1042
DI 10.1016/j.bcp.2011.01.025
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 743RM
UT WOS:000289036400008
PM 21300031
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Sarmah, S
   Curtis, C
   Mahin, J
   Farrell, M
   Engler, TA
   Sanchez Felix, MV
   Sato, M
   Ma, YFLD
   Chu, SY
   Marrs, JA
AF Sarmah, Swapnalee
   Curtis, Courtney
   Mahin, Jennifer
   Farrell, Mark
   Engler, Thomas A.
   Sanchez Felix, Manuel, V
   Sato, Masahiko
   Ma, Yanfai Linda
   Chu, Shaoyou
   Marrs, James A.
TI The Glycogen Synthase Kinase 3β Inhibitor LSN 2105786 Promotes Zebrafish
   Fin Regeneration
SO BIOMEDICINES
LA English
DT Article
DE zebrafish; glycogen synthase kinase 3 beta; bone healing; regeneration;
   caudal fin
ID PARATHYROID HORMONE; FRACTURE REPAIR; BONE FORMATION; BETA CATENIN;
   OSTEOBLASTS; DIFFERENTIATION; PROLIFERATION; TERIPARATIDE; EXPRESSION;
   HEDGEHOG
AB The Wnt pathway has been shown to regulate bone homeostasis and to influence some bone disease states. We utilized a zebrafish model system to study the effects of a synthetic, orally bioavailable glycogen synthase kinase 3 beta (GSK3 beta) inhibitor LSN 2105786, which activates Wnt signaling during bone healing and embryogenesis. GSK3 beta inhibitor treatment was used to phenocopy GSK3 beta morpholino oligonucleotide (MO) knockdown in zebrafish embryos. Human and zebrafish synthetic mRNA injection were similarly effective at rescue of GSK3 beta MO knockdown. During caudal fin regeneration, bony rays are the first structure to differentiate in zebrafish fins, providing a useful model to study bone healing. Caudal fin regeneration experiments were conducted using various concentrations of a GSK3 beta inhibitor, examining duration and concentration dependence on regenerative outgrowth. Experiments revealed continuous low concentration (4 5 nM) treatment to be more effective at increasing regeneration than intermittent dosing. Higher concentrations inhibited fin growth, perhaps by excessive stimulation of differentiation programs. Increased Wnt responsive gene expression and differentiation were observed in response to GSK3b inhibitor treatment. Activating Wnt signaling also increased cell proliferation and osteoblast differentiation in fin regenerates. Together, these data indicate that bone healing in zebrafish fin regeneration was improved by activating Wnt signaling using GSK3b inhibitor treatment. In addition, caudal fin regeneration is useful to evaluate dose dependent pharmacological efficacy in bone healing, various dosing regimens and possible toxicological effects of compounds.
C1 [Sarmah, Swapnalee; Curtis, Courtney; Mahin, Jennifer; Farrell, Mark; Marrs, James A.] Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA.
   [Engler, Thomas A.; Sanchez Felix, Manuel, V; Sato, Masahiko; Ma, Yanfai Linda; Chu, Shaoyou] Lilly Res Labs, Indianapolis, IN 46225 USA.
   [Sanchez Felix, Manuel, V] Novartis Inst BioMed Res, Cambridge, MA 02139 USA.
   [Chu, Shaoyou] Mol Templates, Austin, TX 78729 USA.
C3 Purdue University System; Purdue University; Purdue University in
   Indianapolis; Eli Lilly; Lilly Research Laboratories; Novartis; Novartis
   USA
RP Marrs, JA (通讯作者)，Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA.
EM ssarmah@iupui.edu; clcurtis@iupui.edu; jmahin@iupui.edu;
   mfarrell@iupui.edu; engler_thomas@lilly.com;
   Manuel.sanchez felix@novartis.com; msato@iupui.edu; ma_linda@lilly.com;
   syc1321@gmail.com; jmarrs@iupui.edu
RI CHU, SHAOYOU/MZS 0672 2025
OI sarmah, Swapnalee/0000 0002 3651 7680
FU Lilly Research Laboratories, Lilly Research Award Program
FX This research was funded by Lilly Research Laboratories, Lilly Research
   Award Program (S.C. Principle Investigator; J.A.M. External
   Collaborator).
CR Agholme F, 2011, ACTA ORTHOP, V82, P125, DOI [10.3109/17453674.2011.572252, 10.3109/17453674.2011.625539]
   Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Asnani A, 2014, DIS MODEL MECH, V7, P763, DOI 10.1242/dmm.016170
   Aspenberg P, 2010, ACTA ORTHOP, V81, P236, DOI 10.3109/17453671003761946
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Blum N, 2012, DEVELOPMENT, V139, P107, DOI 10.1242/dev.065391
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dorsky RI, 2002, DEV BIOL, V241, P229, DOI 10.1006/dbio.2001.0515
   Fleming A, 2005, J BIOMOL SCREEN, V10, P823, DOI 10.1177/1087057105279952
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Kawakami Y, 2006, GENE DEV, V20, P3232, DOI 10.1101/gad.1475106
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Lee HC, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471 213X 7 93
   Li XD, 2011, J BONE MINER RES, V26, P2610, DOI 10.1002/jbmr.472
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Murciano C, 2002, DEV BIOL, V252, P214, DOI 10.1006/dbio.2002.0848
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Poss KD, 2000, DEV DYNAM, V219, P282, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1045>3.3.CO;2 3
   Poss KD, 2003, DEV DYNAM, V226, P202, DOI 10.1002/dvdy.10220
   Quint E, 2002, P NATL ACAD SCI USA, V99, P8713, DOI 10.1073/pnas.122571799
   Sarmah S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122123
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Stoick Cooper CL, 2007, GENE DEV, V21, P1292, DOI 10.1101/gad.1540507
   Stoick Cooper CL, 2007, DEVELOPMENT, V134, P479, DOI 10.1242/dev.001123
   van de Water S, 2001, DEVELOPMENT, V128, P3877
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   WESTERFIELD M, 2000, ZEBRAFISH BOOK
   Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006
   Zhong N, 2006, BONE, V39, P5, DOI 10.1016/j.bone.2005.12.008
NR 39
TC 3
Z9 3
U1 3
U2 16
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD JUN
PY 2019
VL 7
IS 2
AR 30
DI 10.3390/biomedicines7020030
PG 15
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA II1BM
UT WOS:000474939800007
PM 31010223
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Linder, M
   Hecking, M
   Glitzner, E
   Zwerina, K
   Holcmann, M
   Bakiri, L
   Ruocco, MG
   Tuckermann, J
   Schett, G
   Wagner, EF
   Sibilia, M
AF Linder, Markus
   Hecking, Manfred
   Glitzner, Elisabeth
   Zwerina, Karin
   Holcmann, Martin
   Bakiri, Latifa
   Ruocco, Maria Grazia
   Tuckermann, Jan
   Schett, Georg
   Wagner, Erwin F.
   Sibilia, Maria
TI EGFR controls bone development by negatively regulating mTOR signaling
   during osteoblast differentiation
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
ID GROWTH FACTOR RECEPTOR; FACTOR BINDING PROTEIN 3; TYPE 1 IGF RECEPTOR;
   ENDOCHONDRAL OSSIFICATION; SKELETAL DEVELOPMENT; MICE; OSTEOARTHRITIS;
   ACTIVATION; EXPRESSION; RESISTANCE
AB Mice deficient in epidermal growth factor receptor (Egfr( / ) mice) are growth retarded and exhibit severe bone defects that are poorly understood. Here we show that EGFR deficient mice are osteopenic and display impaired endochondral and intramembranous ossification resulting in irregular mineralization of their bones. This phenotype is recapitulated in mice lacking EGFR exclusively in osteoblasts, but not in mice lacking EGFR in osteoclasts indicating that osteoblasts are responsible for the bone phenotype. Experiments are presented demonstrating that signaling via EGFR stimulates osteoblast proliferation and inhibits their differentiation by suppression of the IGF 1R/mTOR pathway via ERK1/2 dependent up regulation of IGFBP 3. Osteoblasts from Egfr( / ) mice show increased levels of IGF 1R and hyperactivation of mTOR pathway proteins, including enhanced phosphorylation of 4E BP1 and S6. The same changes are also seen in Egfr( / ) bones. Importantly, pharmacological inhibition of mTOR with rapamycin decreases osteoblasts differentiation as well as rescues the low bone mass phenotype of Egfr( / ) fetuses. Our results demonstrate that suppression of the IGF 1R/mTOR pathway by EGFR/ERK/IGFBP 3 signaling is necessary for balanced osteoblast maturation providing a mechanism for the skeletal phenotype observed in EGFR deficient mice.
C1 [Linder, Markus; Hecking, Manfred; Glitzner, Elisabeth; Holcmann, Martin; Sibilia, Maria] Med Univ Vienna, Inst Canc Res, Ctr Comprehens Canc, Dept Internal Med 1, Vienna, Austria.
   [Zwerina, Karin; Schett, Georg] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen, Dept Internal Med 3, Erlangen, Germany.
   [Ruocco, Maria Grazia] Med Univ Vienna, Dept Internal Med 3, Vienna, Austria.
   [Bakiri, Latifa; Wagner, Erwin F.] Spanish Natl Canc Res Ctr CNIO, Madrid, Spain.
   [Tuckermann, Jan] Univ Ulm, Inst Comparat Mol Endocrinol, Ulm, Germany.
   [Hecking, Manfred] Med Univ Vienna, Dept Internal Med 3, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
C3 Medical University of Vienna; University of Erlangen Nuremberg; Medical
   University of Vienna; Centro Nacional de Investigaciones Oncologicas
   (CNIO); Ulm University; Medical University of Vienna
RP Sibilia, M (通讯作者)，Med Univ Vienna, Inst Canc Res, Ctr Comprehens Canc, Dept Internal Med 1, Vienna, Austria.
EM Sibilia Office@meduniwien.ac.at
RI ; Bakiri, Latifa/AAP 1674 2020; Hecking/AAK 7399 2021
OI Wagner, Erwin F/0000 0001 7872 0196; Sibilia, Maria/0000 0001 6129 5613;
   bakiri, latifa/0000 0002 6300 2420; Linder, Markus/0000 0003 0696 4444;
   Glitzner, Elisabeth/0000 0002 1541 4076; Schett,
   Georg/0000 0001 8740 9615; Hecking, Manfred/0000 0002 8047 2395; 
FU Austrian Science Fund (FWF) [DK W1212]; FWF grant [I764 B13]; Deutsche
   Forschungsgemeinschaft [CRC 1149, Immunobone Tu220/6]; Fonds der Stadt
   Wien fur innovative interdisziplinare Krebsforschung [AP00288OFF];
   ERC Advanced grant [694883]; Austrian Science Fund (FWF) [I764, W1212]
   Funding Source: Austrian Science Fund (FWF); Austrian Science Fund (FWF)
   [I 764] Funding Source: researchfish
FX We thank Mruniya Vaibhavkumar Gawali, Theresia Lengheimer and Martina
   Hammer for maintaining mouse colonies, Sarah Bardakji and Malgorzata
   Tryniecki for genotyping, Temenuschka Baykuscheva Gentscheva for
   technical assistance and Alexander Kainz for helping with statistical
   analysis. The authors also thank Reinhold Erben for helpful discussions.
   This work was supported by the Austrian Science Fund (FWF) (DK W1212),
   the FWF grant I764 B13, the Deutsche Forschungsgemeinschaft (CRC 1149,
   Priority Program Immunobone Tu220/6 to J.T.) and "Fonds der Stadt Wien
   fur innovative interdisziplinare Krebsforschung" (AP00288OFF). M.S. is
   supported by an ERC Advanced grant (ERC 2015 AdG TNT Tumors 694883).
CR Caramés B, 2012, ANN RHEUM DIS, V71, P575, DOI 10.1136/annrheumdis 2011 200557
   Chakravarti A, 2002, CANCER RES, V62, P200
   Chandra A, 2013, J BIOL CHEM, V288, P20488, DOI 10.1074/jbc.M112.447250
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Cohen MM, 2006, AM J MED GENET A, V140A, P2646, DOI 10.1002/ajmg.a.31368
   Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588
   Guntur Anyonya R, 2013, Bonekey Rep, V2, P437, DOI 10.1038/bonekey.2013.171
   Hall KC, 2013, MOL CELL BIOL, V33, P3077, DOI 10.1128/MCB.00291 13
   Jia HR, 2016, P NATL ACAD SCI USA, V113, P14360, DOI 10.1073/pnas.1608938113
   Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676
   Jones HE, 2006, ENDOCR RELAT CANCER, V13, pS45, DOI 10.1677/erc.1.01275
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Lanaya H, 2014, NAT CELL BIOL, V16, P972, DOI 10.1038/ncb3031
   Liu KJ, 2007, NATURE, V446, P79, DOI 10.1038/nature05557
   MohseniZadeh S, 1997, ENDOCRINOLOGY, V138, P5645, DOI 10.1210/en.138.12.5645
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Ricort JM, 2001, ENDOCRINOLOGY, V142, P108, DOI 10.1210/en.142.1.108
   Riddle RC, 2014, MOL CELL BIOL, V34, P1850, DOI 10.1128/MCB.00075 14
   Sibilia M, 2003, DEVELOPMENT, V130, P4515, DOI 10.1242/dev.00664
   SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085
   Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092 8674(00)00026 X
   Sibilia M, 2007, DIFFERENTIATION, V75, P770, DOI 10.1111/j.1432 0436.2007.00238.x
   Silha JV, 2003, J BONE MINER RES, V18, P1834, DOI 10.1359/jbmr.2003.18.10.1834
   Takaoka M, 2004, CANCER RES, V64, P7711, DOI 10.1158/0008 5472.CAN 04 0715
   THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084
   Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959 437X(00)00228 8
   WALLIN J, 1994, DEVELOPMENT, V120, P1109
   Wang K, 2004, J BIOL CHEM, V279, P53848, DOI 10.1074/jbc.M403114200
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Yakar S, 2009, FASEB J, V23, P709, DOI 10.1096/fj.08 118976
   Yang G, 2015, EXP THER MED, V10, P1327, DOI 10.3892/etm.2015.2660
   Yarden Y, 2001, EUR J CANCER, V37, pS3
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhang XR, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.15
   Zhang XR, 2011, J BONE MINER RES, V26, P1022, DOI 10.1002/jbmr.295
   Zhang Y, 2015, ANN RHEUM DIS, V74, P1432, DOI 10.1136/annrheumdis 2013 204599
   Zhu J, 2011, J CELL BIOCHEM, V112, P1749, DOI 10.1002/jcb.23094
NR 39
TC 69
Z9 78
U1 0
U2 24
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350 9047
EI 1476 5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD JUN
PY 2018
VL 25
IS 6
BP 1094
EP 1106
DI 10.1038/s41418 017 0054 7
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GI4IF
UT WOS:000434334000009
PM 29445126
OA Green Accepted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Lu, W
   Qi, GB
   Yang, XY
   Li, DF
   Chen, WB
   Zeng, QM
   Jiang, ZX
AF Lu, Wei
   Qi, Guobin
   Yang, Xiuying
   Li, Defang
   Chen, Weibin
   Zeng, Qingmin
   Jiang, Zengxin
TI Farrerol suppresses osteoclast differentiation and postmenopausal
   osteoporosis by inhibiting the nuclear factor kappa B signaling pathway
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Farrerol; Osteoclast; Osteoporosis; Bone resorption; Receptor activator
   of nuclear factor kappa B; ligand
ID BONE; RANKL; MECHANISMS
AB Excessive bone resorption caused by upregulated osteoclast activity is a key factor in osteoporosis pathogenesis. Farrerol is a typical natural flavanone and exhibits various pharmacological actions. However, the role and mechanism of action of farrerol in osteoclast differentiation regulation remain unclear. This study aimed to evaluate the effects and mechanism of farrerol on the inhibition of osteoclastogenesis. Tartrate resistant acid phosphatase staining, F actin staining, and the pit formation assay were performed to examine the differentiation and functions of osteoclasts in vitro. The expression of proteins associated with the nuclear factor kappa B and mitogen activated protein kinase signaling pathways was analyzed by western blotting. Dual X ray absorptiometry, microcomputed tomography, and histopathological and immunohistochemical analyses were performed to determine the therapeutic effect of farrerol in vivo bone loss prevention. The effects of farrerol on osteoblastic bone formation were assessed using alkaline phosphatase, alizarin red S staining, and calcein alizarin red S double labeling. Farrerol inhibited osteoclastogenesis and bone resorption in osteoclasts by suppressing nuclear factor kappa B signaling rather than mitogen activated protein kinase signaling in vitro. Farrerol protected mice against ovariectomy induced bone loss by inhibiting osteoclast mediated bone resorption, instead of promoting osteoblast mediated bone formation in vivo. The findings of the current study revealed that farrerol is a potential therapeutic agent for osteoporosis.
C1 [Lu, Wei] Shanghai Univ TCM, SHANGHAI TCM INTEGRATED Hosp, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Qi, Guobin; Jiang, Zengxin] Shanghai Sixth Peoples Hosp, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Yang, Xiuying] Fudan Univ, Jinshan Hosp, Dept Radiol, Shanghai, Peoples R China.
   [Li, Defang; Chen, Weibin; Zeng, Qingmin] Fudan Univ, Jinshan Hosp, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Jiang, Zengxin] Shanghai Sixth Peoples Hosp, 600 Yishan Rd, Shanghai, Peoples R China.
   [Zeng, Qingmin] Fudan Univ, Jinshan Hosp, 1508 Longhang Rd, Shanghai 201508, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai Jiao Tong
   University; Fudan University; Fudan University; Shanghai Jiao Tong
   University; Fudan University
RP Jiang, ZX (通讯作者)，Shanghai Sixth Peoples Hosp, 600 Yishan Rd, Shanghai, Peoples R China.; Zeng, QM (通讯作者)，Fudan Univ, Jinshan Hosp, 1508 Longhang Rd, Shanghai 201508, Peoples R China.
EM qingminzeng1703@163.com; Dr_Jiangzx@163.com
RI Qi, Guobin/IXD 9658 2023
FU Shanghai Health Commission [20204Y0176]
FX <STRONG> </STRONG>The work was supported by the Shanghai Health
   Commission (grant numbers: 20204Y0176) .
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Cai CH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.772540
   Chen RF, 2020, NANOSCALE, V12, P16229, DOI 10.1039/d0nr02848g
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   de Paula FJA, 2013, BONE RES, V1, DOI 10.4248/BR201301005
   Dong MM, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829741
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Jiang ZX, 2022, IUBMB LIFE, V74, P1052, DOI 10.1002/iub.2656
   Jimi E, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121636
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li YH, 2019, INT IMMUNOPHARMACOL, V75, DOI 10.1016/j.intimp.2019.105739
   Li YK, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051471
   Liu YD, 2022, BONE JOINT RES, V11, P200, DOI [10.1302/2046 3758.114.BJR 2020 0308.R2, 10.1302/2046 3758.114.BJR 2020 0308 R2]
   Lu Y, 2001, J BONE MINER RES, V16, P901, DOI 10.1359/jbmr.2001.16.5.901
   Ma N, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01419
   Pennanen P, 2021, MOL BIOL REP, V48, P1243, DOI 10.1007/s11033 020 06128 5
   Qin XJ, 2022, PHARM BIOL, V60, P9, DOI 10.1080/13880209.2021.2006723
   Ran X, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072037
   Rossini M, 2016, EXPERT OPIN DRUG SAF, V15, P321, DOI 10.1517/14740338.2016.1136287
   Siddiqui JA, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15563 7
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52
   Takakura N, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115316
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2021, J BONE MINER METAB, V39, P13, DOI 10.1007/s00774 020 01191 1
   Tian H, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.780590
   Tian Z, 2021, J FOOD BIOCHEM, V45, DOI 10.1111/jfbc.13585
   Tu Kristie N, 2018, P T, V43, P92
   Wang G, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.810322
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wu ZX, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.793087
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yin JT, 2019, MOLECULES, V24, DOI 10.3390/molecules24193470
NR 42
TC 2
Z9 2
U1 2
U2 3
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD FEB
PY 2024
VL 154
IS 2
BP 113
EP 126
DI 10.1016/j.jphs.2023.12.011
EA JAN 2024
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HW9O7
UT WOS:001162667500001
PM 38246725
OA gold
DA 2025 08 17
ER

PT J
AU Morikawa, N
   Kato, Y
   Takeshita, N
   Shimizu, Y
AF Morikawa, Noriyuki
   Kato, Yasuko
   Takeshita, Nobuaki
   Shimizu, Yasuaki
TI Pharmacological characterization of AS2690168, a novel small molecule
   RANKL signal transduction inhibitor
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE RANKL; Inhibitor; Osteoporosis
ID CORTICAL BONE MASS; OSTEOCLAST DIFFERENTIATION; MECHANICAL PROPERTIES;
   DENOSUMAB; LIGAND; ALFACALCIDOL; DERIVATIVES; ALENDRONATE
AB Pathological osteolysis is associated with excessive bone resorption by activated osteoclasts. Given that receptor activator of NF kappa B and its ligand (RANKL) are key players in the differentiation and activation of osteoclasts, the RANKL/RANK signaling pathway is considered a promising target for the development of effective osteoclastogenesis inhibitors. We previously found that the orally available compound, AS2690168, suppresses RANKL induced osteoclastogenesis of RAW264 cells. In this report, we further characterized the pharmacological profiles of AS2690168 in vitro and in vivo. AS2690168 suppressed soluble RANKL (sRANKL) induced NFATc1 mRNA expression in RAW264 cells at 0.3 and 3.0 mu M. It also suppressed calcium release from parathyroid hormone stimulated mouse calvaria with an IC50 value of 0.46 mu M. Oral administration of AS2690168 completely suppressed the decrease in femoral bone mineral content in an sRANKL induced osteopenic mice model at 3.0 mg/kg. It also significantly suppressed the decrease in femoral bone mineral density and increase in serum tartrate resistant acid phosphatase 5b levels in ovariectomized rats at doses of 0.3, 1 and 3 mg/kg. Finally, AS260168 suppressed the increase in urine deoxypyridinoline in a rat prednisolone induced osteoporosis model at 10 mg/kg. These results suggest that AS2690168 is a promising treatment for bone disorders with excessive bone resorption.
C1 [Morikawa, Noriyuki; Kato, Yasuko; Takeshita, Nobuaki; Shimizu, Yasuaki] Astellas Pharma Inc, Drug Discovery Res, Miyukigaoka 21, Tsukuba, Ibaraki 3058585, Japan.
C3 Astellas Pharmaceuticals
RP Takeshita, N (通讯作者)，Astellas Pharma Inc, Drug Discovery Res, Miyukigaoka 21, Tsukuba, Ibaraki 3058585, Japan.
EM takeshita.nobuaki.gb@un.tsukuba.ac.jp
FU Astellas Pharma Inc
FX The study was supported by Astellas Pharma Inc.
CR Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chen TS, 2006, ASSAY DRUG DEV TECHN, V4, P387, DOI 10.1089/adt.2006.4.387
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Guerrini MM, 2015, IMMUNITY, V43, P1174, DOI 10.1016/j.immuni.2015.10.017
   Iwamoto J, 2006, J NUTR SCI VITAMINOL, V52, P1, DOI 10.3177/jnsv.52.1
   Iwamoto J, 2006, EXP ANIM TOKYO, V55, P357, DOI 10.1538/expanim.55.357
   Kobza AO, 2021, OPEN ACCESS RHEUMATO, V13, P177, DOI 10.2147/OARRR.S282606
   Miyata J, 2012, BIOORG MED CHEM LETT, V22, P5681, DOI 10.1016/j.bmcl.2012.06.087
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nakai Y, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0036 5
   Ominsky MS, 2011, BONE, V49, P162, DOI 10.1016/j.bone.2011.04.001
   Pokhrel NK, 2019, J PERIODONTOL, V90, P546, DOI 10.1002/JPER.18 0334
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   TAKAHASHI N, 1991, J BONE MINER RES, V6, P977
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeuchi T, 2016, ANN RHEUM DIS, V75, P983, DOI 10.1136/annrheumdis 2015 208052
   Tanaka S, 2018, MOD RHEUMATOL, V28, P9, DOI 10.1080/14397595.2017.1369491
   Tokuyama Naoto, 2015, Bone Rep, V2, P1, DOI 10.1016/j.bonr.2014.12.002
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Tseng CH, 2011, J MED CHEM, V54, P3103, DOI 10.1021/jm1016494
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   Wang YX, 2019, J CELL PHYSIOL, V234, P10432, DOI 10.1002/jcp.27711
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhao XD, 2019, J BONE MINER RES, V34, P911, DOI 10.1002/jbmr.3655
NR 26
TC 3
Z9 4
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JUN 5
PY 2022
VL 924
AR 174941
DI 10.1016/j.ejphar.2022.174941
EA APR 2022
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 1J7EL
UT WOS:000798078300003
PM 35398031
DA 2025 08 17
ER

PT J
AU Zhang, YQ
   Liu, MM
   Li, HS
   Chen, ZT
   Liang, N
   Xu, JG
   Zhang, XL
   Zhang, YH
AF Zhang, Yongqing
   Liu, Mingming
   Li, Haisheng
   Chen, Zetao
   Liang, Na
   Xu, Jianguo
   Zhang, Xiaoli
   Zhang, Yihang
TI Traditional Chinese medicine Bushen Jianpi Huoxue decoction prevents
   diabetic osteoporosis in rats via Wnt and nuclear factor kappa B
   signaling pathways
SO INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
LA English
DT Article
DE bone metabolism; Bushen Jianpi Huoxue decoction; diabetic osteoporosis;
   NF kappa B signaling pathway; Wnt signaling pathway
ID ER XIAN DECOCTION; OVX INDUCED OSTEOPOROSIS; OVARIECTOMIZED RATS; HERBAL
   MEDICINE; BONE; OSTEOCLASTOGENESIS; DIFFERENTIATION; OSTEOBLASTS;
   ACTIVATION; MECHANISMS
AB AimThe aim of this study was to evaluate the therapeutic effect of a traditional Chinese medicine (TCM), Bushen Jianpi Huoxue decoction (BJHD), on diabetic osteoporosis (DOP) and the action mechanisms likely mediated by nuclear factor kappa B (NF B) and Wnt signaling pathways.
   MethodsFifty five male Wistar rats were used in this study; they were divided into normal control (n = 10) and established DOP model (n = 45) groups. The DOP model was induced using a combination high carbohydrate   high fat diet and intraperitoneal injections of streptozotocin (STZ). The successfully induced animals were randomized to the model, Western medicine, TCM and control groups. Levels of fasting blood glucose; insulin; serum Ca, P and alkaline phosphatase, and the femoral bone mineral density (BMD) were measured. Furthermore, messenger RNA (mRNA) levels of cytokines in the Wnt and NF B signaling pathways were measured using reverse transcription polymerase chain reaction (RT PCR).
   ResultsThirty rats were successfully established as the DOP model (10/group). After treatment, the levels of fasting blood glucose, insulin resistance and alkaline phosphatase in the TCM group rats were lower, while P and BMD were higher than those in the model groups. The mRNA levels of cytokines in the Wnt signaling pathway were higher in the TCM group than those in the model group. Moreover, the expressions of factors in the NF B pathway were markedly lower in the TCM group than they were in the model group.
   ConclusionBushen Jianpi Huoxue decoction relieved DOP by activating the Wnt signaling pathway while inhibiting NF B signaling.
C1 [Zhang, Yongqing; Li, Haisheng] Shouguang Tradit Chinese Med Hosp, Dept Orthoped, Shouguang, Peoples R China.
   [Liu, Mingming] Shouguang Tradit Chinese Med Hosp, Dept Endocrinol, Shouguang, Peoples R China.
   [Chen, Zetao] Shandong Univ, Affiliated Hosp, TCM, Dept Healthcare, Jinan, Shandong, Peoples R China.
   [Liang, Na] Shandong Prov Qianfoshan Hosp, Dept Tradit Chinese Med, Jinan, Shandong, Peoples R China.
   [Xu, Jianguo] Taishan Coal Sanatorum, Dept Tradit Chinese Med, Tai An, Shandong, Peoples R China.
   [Zhang, Xiaoli] Shandong Univ Tradit Chinese Med, Dept Endocrinol, Affiliated Hosp, Jinan, Shandong, Peoples R China.
   [Zhang, Yihang] Shandong Acad Med Sci, 18777 Jingshi Rd, Jinan 250062, Shandong, Peoples R China.
C3 Shandong University; Shandong First Medical University & Shandong
   Academy of Medical Sciences; Shandong University of Traditional Chinese
   Medicine; University of Jinan; Shandong First Medical University &
   Shandong Academy of Medical Sciences
RP Zhang, YH (通讯作者)，Shandong Acad Med Sci, 18777 Jingshi Rd, Jinan 250062, Shandong, Peoples R China.
EM zhangyhz43@163.com
RI xu, jianguo/JZD 9552 2024; Liang, Na/HSC 0425 2023
CR [Anonymous], EVID BASED COMPLEMEN, DOI [10.1155/2015/184802256481664305618, DOI 10.1155/2015/18480225648166]
   Catalfamo DL, 2013, ORAL DIS, V19, P303, DOI 10.1111/odi.12002
   Chen HY, 2012, J ETHNOPHARMACOL, V142, P80, DOI 10.1016/j.jep.2012.04.017
   Cheng M, 2011, J ETHNOPHARMACOL, V138, P279, DOI 10.1016/j.jep.2011.09.030
   Ding Y, 2016, VALUE HEALTH, V19, pA199, DOI 10.1016/j.jval.2016.03.1321
   FRICKE M, 1975, Z ORTHOP GRENZGEB, V113, P1043
   Gao Z, 2013, CHIN J INTEGR MED, V19, P862, DOI 10.1007/s11655 013 1328 z
   Gui YY, 2015, BIOSCI TRENDS, V9, P169, DOI 10.5582/bst.2015.01011
   Guo YB, 2014, J ETHNOPHARMACOL, V155, P1401, DOI 10.1016/j.jep.2014.07.058
   Ha H, 2003, ARCH PHARM RES, V26, P929, DOI 10.1007/BF02980202
   Hamann C, 2011, AM J PHYSIOL ENDOC M, V301, pE1220, DOI 10.1152/ajpendo.00378.2011
   Han Y, 2012, J MED FOOD, V15, P505, DOI 10.1089/jmf.2011.1940
   Hua X, 1997, CHINESE TRAD HERBAL, V1
   Ju DH, 2014, FRONT MED PRC, V8, P389, DOI 10.1007/s11684 014 0362 y
   Kahler RA, 2003, J BIOL CHEM, V278, P11937, DOI 10.1074/jbc.M211443200
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Li W, 2013, MED MED SCI, V1, P1
   Li Y, 2014, CHIN J NAT MEDICINES, V12, P204, DOI 10.1016/S1875 5364(14)60034 0
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Meng Hai yan, 2009, Zhong Yao Cai, V32, P179
   Motyl KJ, 2012, J CELL PHYSIOL, V227, P1326, DOI 10.1002/jcp.22844
   Nian H, 2006, J ETHNOPHARMACOL, V108, P96, DOI 10.1016/j.jep.2006.04.020
   Ou L, 2013, CHINESE J HOSP PHARM, V16
   PARFITT AM, 1979, CALCIFIED TISSUE INT, V28, P1, DOI 10.1007/BF02441211
   Qin LP, 2008, J ETHNOPHARMACOL, V118, P271, DOI 10.1016/j.jep.2008.04.009
   Räkel A, 2008, DIABETES METAB, V34, P193, DOI 10.1016/j.diabet.2007.10.008
   Ralston S, 2010, NEW ENGL J MED, V363, P2027
   Sui CZ, 2005, CHINESE J INTEGRA TR, V25, P456
   Sun YJ, 2013, J ETHNOPHARMACOL, V150, P514, DOI 10.1016/j.jep.2013.08.057
   Takahashi N, 2010, FRONTIERS BIOSCI, V16, P21
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang HD, 2015, ACUPUNCT MED, V33, P465, DOI 10.1136/acupmed 2014 010743
   Wang LL, 2016, CURR PHARM DESIGN, V22, P328, DOI 10.2174/1381612822666151112145907
   Wang XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118184
   Wong KC, 2014, AM J CHINESE MED, V42, P409, DOI 10.1142/S0192415X1450027X
   Wongdee K, 2011, WORLD J DIABETES, V2, P41, DOI 10.4239/wjd.v2.i3.41
   Wu CM, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 277
   Xia BJ, 2014, J ETHNOPHARMACOL, V153, P133, DOI 10.1016/j.jep.2014.01.040
   Xu G, 2014, J ETHNOPHARMACOL, V151, P237, DOI 10.1016/j.jep.2013.10.030
   Xu H, 2005, AM J CHINESE MED, V33, P299, DOI 10.1142/S0192415X05002916
   Xu J, 2010, CLIN RES TREATING TY
   Yavropoulou Maria P, 2007, Hormones (Athens), V6, P279
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
   Zhang WP, 2012, AM J CHINESE MED, V40, P735, DOI 10.1142/S0192415X12500553
NR 46
TC 16
Z9 22
U1 2
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1756 1841
EI 1756 185X
J9 INT J RHEUM DIS
JI Int. J. Rheum. Dis.
PD AUG
PY 2017
VL 20
IS 8
BP 941
EP 948
DI 10.1111/1756 185X.13050
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA FF1ET
UT WOS:000408643300004
PM 28294540
DA 2025 08 17
ER

PT J
AU Idris, AI
   Krishnan, M
   Simic, P
   Landao Bassonga, E
   Mollat, P
   Vukicevic, S
   Ralston, SH
AF Idris, Aymen I.
   Krishnan, Maala
   Simic, Petra
   Landao Bassonga, Euphemie
   Mollat, Patrick
   Vukicevic, Slobodan
   Ralston, Stuart H.
TI Small molecule inhibitors of IκB kinase signaling inhibit osteoclast
   formation in vitro and prevent ovariectomy induced bone loss
   in vivo
SO FASEB JOURNAL
LA English
DT Article
DE IKK; TAK1; NF kappa B; osteoblast; osteoporosis
ID HIGHLY SELECTIVE INHIBITOR; MICE; DIFFERENTIATION; ARTHRITIS; APOPTOSIS;
   BLOCKS; ALPHA; INFLAMMATION; PARTHENOLIDE; BMS 345541
AB The NF kappa B pathway plays a critical role in the regulation of osteoclast activity, and activation of the pathway is dependent on I kappa B kinase (IKK), which phosphorylates I kappa B, targeting it for proteasomal degradation. Pharmacological inhibitors of IKK exhibit anti inflammatory properties and prevent bone erosions in models of inflammatory arthritis. However, the effects of these agents on osteoblast function and ovariectomy induced bone loss remain unknown. Here we examined the effects of the IKK inhibitors celastrol, BMS 345541, and parthenolide on bone cell function in vitro and ovariectomy induced bone loss in vivo. All three compounds inhibited RANKL induced signaling in osteoclasts, caused osteoclast apoptosis, and inhibited osteoclast formation. Although parthenolide and BMS 345541 had no inhibitory effects on osteoblast function, celastrol prevented IL1 beta induced TAK1 activation and inhibited osteoblast growth, differentiation, and bone nodule formation. The selective IKK inhibitors parthenolide and BMS 345541 prevented ovariectomy induced bone loss by inhibiting osteoclastic bone resorption. We conclude that pharmacological inhibitors of IKK inhibit several critical signaling pathways in osteoclasts necessary for cell survival, formation, and activity in vitro and bone loss in vivo. Accordingly, IKK inhibitors may be of value in the prevention and treatment of bone diseases characterized by increased bone loss such as postmenopausal osteoporosis. Idris, A. I., Krishnan, M., Simic, P., Landao Bassonga, E., Mollat, P., Vukicevic, S., Ralston, S. H. Small molecule inhibitors of I kappa B kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy induced bone loss in vivo. FASEB J. 24, 4545 4555 (2010). www.fasebj.org
C1 [Idris, Aymen I.; Krishnan, Maala; Landao Bassonga, Euphemie; Ralston, Stuart H.] Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Simic, Petra; Vukicevic, Slobodan] Univ Zagreb, Sch Med, Dept Anat, Zagreb 41001, Croatia.
   [Mollat, Patrick] Galapagos Soc Act Simplifiee Unipersonnelle, Romainville, France.
C3 University of Edinburgh; University of Zagreb
RP Ralston, SH (通讯作者)，Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
EM stuart.ralston@ed.ac.uk
RI Idris, Aymen/AAX 1138 2020; Vukicevic, Slobodan/AEG 2646 2022
OI Landao Bassonga, Euphemie/0000 0002 5142 2946; Idris,
   Aymen/0000 0003 4327 5306; 
FU Arthritis Research Campaign (UK) (ARC) [17687, 15389]; European
   Calcified Tissue Society (ECTS)/Amgen
FX These studies were supported in part by grants from the Arthritis
   Research Campaign (UK) (ARC 17687 and 15389) and by an European
   Calcified Tissue Society (ECTS)/Amgen fellowship grant to A.I.I.
CR [Anonymous], BONE RES PROTOCOLS
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200
   Chaisson ML, 2004, J BIOL CHEM, V279, P54841, DOI 10.1074/jbc.M406392200
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Hehner SP, 1999, J IMMUNOL, V163, P5617
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris A, 2008, BIOCHEM BIOPH RES CO, V371, P94, DOI 10.1016/j.bbrc.2008.04.014
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Idris AI, 2009, MOL CANCER THER, V8, P2339, DOI 10.1158/1535 7163.MCT 09 0133
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320
   Karin M, 2008, CELL RES, V18, P334, DOI 10.1038/cr.2008.30
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074 5521(01)00049 7
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   McIntyre KW, 2003, ARTHRITIS RHEUM US, V48, P2652, DOI 10.1002/art.11131
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Schopf L, 2006, ARTHRITIS RHEUM US, V54, P3163, DOI 10.1002/art.22081
   Sethi G, 2007, BLOOD, V109, P2727, DOI 10.1182/blood 2006 10 050807
   Stewart TL, 2005, CALCIFIED TISSUE INT, V77, P113, DOI 10.1007/s00223 004 0188 8
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Yang JM, 2006, CLIN CANCER RES, V12, P950, DOI 10.1158/1078 0432.CCR 05 1220
   Yip KH, 2004, J BONE MINER RES, V19, pS284
NR 36
TC 41
Z9 46
U1 0
U2 14
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD NOV
PY 2010
VL 24
IS 11
BP 4545
EP 4555
DI 10.1096/fj.10 164095
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA 675UA
UT WOS:000283861100039
PM 20647545
DA 2025 08 17
ER

PT J
AU Xi, YJ
   Shen, JY
   Li, XH
   Bao, Y
   Zhao, T
   Li, B
   Zhang, XY
   Wang, J
   Bao, YY
   Gao, JM
   Xie, ZH
   Wang, Q
   Luo, Q
   Shi, HL
   Li, ZF
   Qin, DD
AF Xi, Yujiang
   Shen, Jiayan
   Li, Xiahuang
   Bao, Yi
   Zhao, Ting
   Li, Bo
   Zhang, Xiaoyu
   Wang, Jian
   Bao, Yanyuan
   Gao, Jiamei
   Xie, Zhaohu
   Wang, Qi
   Luo, Qiu
   Shi, Hongling
   Li, Zhaofu
   Qin, Dongdong
TI Regulatory Effects of Quercetin on Bone Homeostasis: Research Updates
   and Future Perspectives
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Bone Homeostasis; Quercetin; Therapeutic Mechanisms; Bioavailability;
   Review
ID NF KAPPA B; PI3K/AKT SIGNALING PATHWAY; CELL CYCLE ARREST; OXIDATIVE
   STRESS; OSTEOBLASTIC DIFFERENTIATION; HYDROGEN PEROXIDE; INDUCED
   APOPTOSIS; DELIVERY SYSTEM; ACTIVATION; MAPK
AB The imbalance of bone homeostasis has become a major public medical problem amid the background of an aging population, which is closely related to the occurrence of osteoporosis, osteoarthritis, and fractures. Presently, most drugs used in the clinical treatment of bone homeostasis imbalance are bisphosphonates, calcitonin, estrogen receptor modulators, and biological agents that inhibit bone resorption or parathyroid hormone analogs that promote bone formation. However, there are many adverse reactions. Therefore, it is necessary to explore potential drugs. Quercetin, as a flavonol compound with various biological activities, is widely distributed in plants. Studies have found that quercetin can regulate bone homeostasis through multiple pathways and targets. An in depth exploration of the pharmacological mechanism of quercetin is of great significance for the development of new drugs. This review discusses the therapeutic mechanisms of quercetin on bone homeostasis, such as regulating the expression of long non coding RNA, signaling pathways of bone metabolism, various types of programmed cell death, bone nutrients supply pathways, anti oxidative stress, anti inflammation, and activation of Sirtuins. We also summarize recent progress in improving quercetin bioavailability and propose some issues worth paying attention to, which may help guide future research efforts.
C1 [Xi, Yujiang; Shen, Jiayan; Xie, Zhaohu; Li, Zhaofu; Qin, Dongdong] Yunnan Univ Chinese Med, Sch Basic Med Sci, 1076 Yuhua Rd, Kunming 650500, Yunnan, Peoples R China.
   [Xi, Yujiang; Shen, Jiayan; Zhao, Ting; Li, Bo; Zhang, Xiaoyu; Wang, Jian; Bao, Yanyuan; Gao, Jiamei; Wang, Qi; Li, Zhaofu] Yunnan Univ Chinese Med, Sch Clin Med 1, Kunming 650500, Yunnan, Peoples R China.
   [Xi, Yujiang; Shen, Jiayan; Qin, Dongdong] Tradit Chinese Med Sci & Technol Resources Yunnan, Open & Shared Publ Sci & Technol Serv Platform, Kunming 650500, Yunnan, Peoples R China.
   [Li, Xiahuang] Yunnan Univ Chinese Med, Peoples Hosp Mengzi, Affiliated Hosp, Mengzi 661100, Yunnan, Peoples R China.
   [Bao, Yi; Luo, Qiu] Yunnan Univ, Affiliated Hosp, Dept Rehabil Med, Kunming 650021, Yunnan, Peoples R China.
   [Shi, Hongling] Third Peoples Hosp Yunnan Prov, Dept Rehabil Med, 292 Beijing Rd, Kunming 650011, Yunnan, Peoples R China.
C3 Yunnan University of Chinese Medicine; Yunnan University of Chinese
   Medicine; Yunnan University
RP Li, ZF; Qin, DD (通讯作者)，Yunnan Univ Chinese Med, Sch Basic Med Sci, 1076 Yuhua Rd, Kunming 650500, Yunnan, Peoples R China.; Li, ZF (通讯作者)，Yunnan Univ Chinese Med, Sch Clin Med 1, Kunming 650500, Yunnan, Peoples R China.; Qin, DD (通讯作者)，Tradit Chinese Med Sci & Technol Resources Yunnan, Open & Shared Publ Sci & Technol Serv Platform, Kunming 650500, Yunnan, Peoples R China.; Shi, HL (通讯作者)，Third Peoples Hosp Yunnan Prov, Dept Rehabil Med, 292 Beijing Rd, Kunming 650011, Yunnan, Peoples R China.
EM kmshl1@126.com; lzf0817@126.com; qindong108@163.com
RI Zhang, Xiaoyu/K 6918 2019; Xi, Yujiang/AGA 1045 2022
OI Xi, Yujiang/0000 0003 1175 3975; 
FU National Natural Science Foundation of China [81960870]; Construction
   Project of National Traditional Chinese Medicine Clinical Research Base
   (2018) [131]; Clinical Cooperative Project of Chinese and Western
   Medicine for Major and Knotty Diseases; Yunnan Provincial Key Laboratory
   Construction Project Funding; Yunnan Provincial Key Laboratory of
   Chinese Medicine Rheumatologyand Immunology; Yunnan Provincial Ten
   Thousands Program Famous Doctor Special; Yunnan Province Qingguo Wang
   Expert Workstation Construction Project [202005AF150017]; Yunnan Applied
   Basic Research Projects Union Foundation [2019FF002( 031)]; Applied
   Basic Research Programs of Science and Technology Commission Foundation
   of Yunnan Province [2019FA007]; Scientific Research Fund Project of
   Yunnan Provincial Department of Education [2022Y348, 2021Y461]
FX This work was supported by the National Natural Science Foundation of
   China (81960870); Construction Project of National Traditional Chinese
   Medicine Clinical Research Base (2018 No. 131); Clinical Cooperative
   Project of Chinese and Western Med icine for Major and Knotty Diseases;
   Yunnan Provincial Key Laboratory Construction Project Funding; Yunnan
   Provincial Key Laboratory of Chinese Medicine Rheumatologyand
   Immunology; Yunnan Provincial Ten Thousands Program Famous Doctor
   Special; Yunnan Province Qingguo Wang Expert Workstation Construction
   Project (202005AF150017); Yunnan Applied Basic Research Projects Union
   Foundation [2019FF002( 031)]; Applied Basic Research Programs of Science
   and Technology Commission Foundation of Yunnan Province (2019FA007);
   Scientific Research Fund Project of Yunnan Provincial Department of
   Education (2022Y348); and Scientific Research Fund Project of Yunnan
   Provincial Department of Education (2021Y461).
CR Amjadi Moheb F, 2019, J CELL PHYSIOL, V234, P14641, DOI 10.1002/jcp.28207
   Badila AE, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11020318
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Bian W, 2021, BMC COMPLEMENT MED, V21, DOI 10.1186/s12906 021 03418 8
   Braun KF, 2011, THESCIENTIFICWORLDJO, V11, P2348, DOI 10.1100/2011/471426
   Buravlev EV, 2018, CHEM PAP, V72, P201, DOI 10.1007/s11696 017 0272 y
   CERVELLATI C, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/569563
   Chen WJ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.739615
   Chen Y, 2022, J OVARIAN RES, V15, DOI 10.1186/s13048 022 01080 3
   Choi EM, 2012, EXP TOXICOL PATHOL, V64, P211, DOI 10.1016/j.etp.2010.08.008
   Coipeau P, 2009, CYTOTHERAPY, V11, P584, DOI 10.1080/14653240903079385
   Cui ZF, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.943321
   Deng X, 2022, AM J CHINESE MED, V50, P1529, DOI 10.1142/S0192415X22500641
   Deshmukh Prashant, 2017, Biophys Rev, V9, P41, DOI 10.1007/s12551 016 0244 4
   Ding A, 2020, MOL MED REP, V21, P1581, DOI 10.3892/mmr.2020.10965
   Ding P, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00221 0
   Diomede F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093242
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Fayed HA, 2019, EUR J PHARMACOL, V865, DOI 10.1016/j.ejphar.2019.172785
   Feng L, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065965
   Feng Y., 2021, J TRADIT CHIN MED, V46, P5185
   Feric NT, 2014, BIOMATER SCI UK, V2, P1384, DOI 10.1039/c4bm00073k
   Föger Samwald U, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052701
   Forte L, 2017, J BIOMED MATER RES A, V105, P3293, DOI 10.1002/jbm.a.36192
   Ge YW, 2020, J CELL MOL MED, V24, P3203, DOI 10.1111/jcmm.14995
   Grosso A, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00068
   Gu YX, 2013, J BIOMED MATER RES A, V101, P748, DOI 10.1002/jbm.a.34377
   Guo C, 2023, PHYTOMEDICINE, V114, DOI 10.1016/j.phymed.2023.154768
   Guo C, 2017, CELL PHYSIOL BIOCHEM, V43, P1547, DOI 10.1159/000481978
   Hah YS, 2013, MOL BIOL REP, V40, P4869, DOI 10.1007/s11033 013 2586 3
   Hannan A, 2023, INFLAMMOPHARMACOLOGY, V31, P287, DOI 10.1007/s10787 022 01118 4
   He ZY, 2023, INT J BIOL MACROMOL, V224, P1361, DOI 10.1016/j.ijbiomac.2022.10.222
   Hirata N, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020368
   Hsu CL, 2006, MOL NUTR FOOD RES, V50, P1072, DOI 10.1002/mnfr.200600040
   Hu SW, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.893678
   Huang YF, 2012, J BONE MINER RES, V27, P1093, DOI 10.1002/jbmr.1548
   Inchingolo AD, 2022, NUTRIENTS, V14, DOI 10.3390/nu14173519
   Isika DK, 2022, MOLECULES, V27, DOI 10.3390/molecules27238133
   [金乐 Jin Le], 2021, [中国临床药理学与治疗学, Chinese Journal of Clinical Pharmacology and Therapeutics], V26, P1344
   Kim HI, 2021, AM J CHINESE MED, V49, P767, DOI 10.1142/S0192415X21500361
   Kim J, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.827626
   Kim JM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081803
   Kim YK, 2016, PROG NEURO PSYCHOPH, V64, P277, DOI 10.1016/j.pnpbp.2015.06.008
   Lan DM, 2022, J MOL ENDOCRINOL, V69, P401, DOI 10.1530/JME 22 0086
   Lei X., 2021, JINAN U, V9, P1
   Li M, 2019, CONNECT TISSUE RES, V60, P189, DOI 10.1080/03008207.2018.1483358
   Li X., 2020, J TRADIT CHIN MED, V35, P6011
   Li XC, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9030205
   Li Y, 2015, EXP THER MED, V9, P2072, DOI 10.3892/etm.2015.2388
   [李阳杰 Li Yangjie], 2021, [中国药学杂志, Chinese Pharmaceutical Journal], V56, P175
   Li Y, 2019, MOL THER NUCL ACIDS, V17, P590, DOI 10.1016/j.omtn.2019.06.023
   Liu CH, 2022, FOOD RES INT, V151, DOI 10.1016/j.foodres.2022.111273
   Liu MM, 2022, AM J CHINESE MED, V50, P2011, DOI 10.1142/S0192415X22500860
   [刘昭明 Liu Zhaoming], 2022, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V28, P1740
   Lu H, 2018, BIOCHEM PHARMACOL, V154, P203, DOI 10.1016/j.bcp.2018.05.007
   Lu LQ, 2020, J CLIN PHARM THER, V45, P45, DOI 10.1111/jcpt.13056
   Luo X, 2022, LIFE SCI, V291, DOI 10.1016/j.lfs.2021.120064
   Ma C., 2022, J TRADIT CHIN MED, V40, P114
   Ma XJ, 2014, BIOCHEM BIOPH RES CO, V445, P282, DOI 10.1016/j.bbrc.2014.01.145
   Magar RT, 2020, J MICROBIOL BIOTECHN, V30, P11, DOI 10.4014/jmb.1907.07003
   Mao Y., 2022, CHINESE J ORG CHEM, V42, P1
   Min J., 2019, NANCHANG U, V12, P1
   Mo J., 2022, CHIN J EXP TRADIT ME, V10, P1
   Mun JG, 2021, AM J CHINESE MED, V49, P1535, DOI 10.1142/S0192415X21500725
   Nair P, 2014, METHOD ENZYMOL, V544, P99, DOI 10.1016/B978 0 12 417158 9.00005 4
   Pang XG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4178021
   Papakyriakopoulou P, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15081019
   Park JE, 2022, AM J CHINESE MED, V50, P1703, DOI 10.1142/S0192415X22500720
   Park KR, 2021, AM J CHINESE MED, V49, P2017, DOI 10.1142/S0192415X21500956
   Qi ZM, 2017, BIOMED PHARMACOTHER, V88, P252, DOI 10.1016/j.biopha.2017.01.067
   Qu D, 2011, J BIOMED MATER RES A, V96A, P543, DOI 10.1002/jbm.a.33009
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Saputra OA, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 25095 4
   Seeto AH, 2023, BONE, V167, DOI 10.1016/j.bone.2022.116610
   Shabir I, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.999752
   Shao Jia le, 2020, Chinese Journal of Biologicals, V33, P956
   Singh R, 2019, NAT REV MOL CELL BIO, V20, P175, DOI 10.1038/s41580 018 0089 8
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Sugiyama T, 2015, OSTEOPOROSIS INT, V26, P443, DOI 10.1007/s00198 014 2923 y
   Tang J, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7039802
   Tang SM, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109604
   Tu WJ, 2019, AGING DIS, V10, P637, DOI 10.14336/AD.2018.0513
   Wang F, 2022, PHYTOMEDICINE, V104, DOI 10.1016/j.phymed.2022.154304
   Wang GZ, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/3997190
   Wang N, 2021, PHYTOTHER RES, V35, P2639, DOI 10.1002/ptr.7010
   Wang P., 2020, MED PHARM J CHIN PLA, V32, P6
   Wang Q, 2022, J BIOCHEM MOL TOXIC, V36, DOI 10.1002/jbt.22951
   Wang SH, 2022, AM J CHINESE MED, V50, P1281, DOI 10.1142/S0192415X22500537
   Warnakulasuriya SN, 2016, MOLECULES, V21, DOI 10.3390/molecules21040452
   Wattel A, 2003, BIOCHEM PHARMACOL, V65, P35, DOI 10.1016/S0006 2952(02)01445 4
   Wei B., 2022, SHENZHEN J INTEGR TR, V32, P1
   Wong SK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176448
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Xie BC, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.739326
   Xing XT, 2023, ACTA BIOMATER, V157, P352, DOI 10.1016/j.actbio.2022.11.056
   Yamaguchi M, 2011, INT J MOL MED, V28, P521, DOI 10.3892/ijmm.2011.749
   Yang Y, 2022, J ETHNOPHARMACOL, V285, DOI 10.1016/j.jep.2021.114834
   Yerra VG, 2013, REDOX BIOL, V1, P394, DOI 10.1016/j.redox.2013.07.005
   Yuan HS, 2021, BIOCHEM PHARMACOL, V186, DOI 10.1016/j.bcp.2021.114486
   [张波 Zhang Bo], 2022, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V28, P1765
   Zhang LB, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170961
   Zhao YN, 2016, BIOCHIMIE, V127, P50, DOI 10.1016/j.biochi.2016.04.011
   Zhou XM, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.791585
   Zhou Y., 2022, FRONT ENDOCRINOL, V13
   Zhou YN, 2017, J MATER CHEM B, V5, P612, DOI 10.1039/c6tb02312f
   Zhou YN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129605
   Zhou Z., 2021, FRONT CELL DEV BIOL, V9
   Zhu JZ, 2019, FOOD FUNCT, V10, P6312, DOI 10.1039/c9fo01333d
   Zhuang Q, 2023, J AGR FOOD CHEM, V71, P411, DOI 10.1021/acs.jafc.2c05954
   Zou JR, 2019, MOL MED REP, V19, P759, DOI 10.3892/mmr.2018.9712
   Zou WJ, 2015, J BONE MINER METAB, V33, P615, DOI 10.1007/s00774 014 0627 1
NR 112
TC 11
Z9 11
U1 5
U2 28
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192 415X
EI 1793 6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2023
VL 51
IS 08
BP 2077
EP 2094
DI 10.1142/S0192415X23500891
EA OCT 2023
PG 18
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA ED9A4
UT WOS:001084387400001
PM 37815494
DA 2025 08 17
ER

PT J
AU Sun, X
   Li, KX
   Hase, M
   Zha, RR
   Feng, Y
   Li, BY
   Yokota, H
AF Sun, Xun
   Li, Kexin
   Hase, Misato
   Zha, Rongrong
   Feng, Yan
   Li, Bai Yan
   Yokota, Hiroki
TI Suppression of breast cancer associated bone loss with osteoblast
   proteomes via Hsp90ab1/moesin mediated inhibition of TGFβ/FN1/CD44
   signaling
SO THERANOSTICS
LA English
DT Article
DE breast cancer; osteoblasts; Hsp90ab1; Moesin; CD44
ID METASTASIS; CELLS; SECRETOME; CD44
AB Background: Bone is a frequent site of metastases from breast cancer, but existing therapeutic options are not satisfactory. Although osteoblasts have active roles in cancer progression by assisting the vicious bone destructive cycle, we employed a counterintuitive approach of activating pro tumorigenic Wnt signaling and examined the paradoxical possibility of developing osteoblast derived tumor suppressive, bone protective secretomes.
   Methods: Wnt signaling was activated by the overexpression of Lrp5 and beta catenin in osteoblasts as well as a pharmacological agent (BML284), and the therapeutic effects of their conditioned medium (CM) were evaluated using in vitro cell cultures, ex vivo breast cancer tissues, and a mouse model of osteolysis. To explore the unconventional regulatory mechanism of the action of Wnt activated osteoblasts, whole genome proteomics analysis was conducted, followed by immunoprecipitation and gain  and loss of function assays.
   Results: While osteoblasts did not present any innate tumor suppressing ability, we observed that the overexpression of Lrp5 and beta catenin in Wnt signaling made their CM tumor suppressive and bone protective. The growth of breast cancer cells and tissues was inhibited by Lrp5 overexpressing CM (Lrp5 CM), which suppressed mammary tumors and tumor driven bone destruction in a mouse model. Lrp5 CM also inhibited the differentiation and maturation of bone resorbing osteoclasts by downregulating NFATc1 and cathepsin K. The overexpression of Lrp5 upregulated osteopontin that enriched Hsp90ab1 (Hsp90 beta) and moesin (MSN) in Lrp5 CM. Hsp90ab1 and MSN are atypical tumor suppressing proteins since they are multi tasking, moonlighting proteins that promote tumorigenesis in tumor cells. Importantly, Hsp90ab1 immuno precipitated latent TGF beta and inactivated TGF beta, whereas MSN interacted with CD44, a cancer stem cell marker, as well as fibronectin 1, an ECM protein. Furthermore, Hsp90ab1 and MSN downregulated KDM3A that demethylated histones, together with PDL1 that inhibited immune responses.
   Conclusion: In contrast to inducing tumor enhancing secretomes and chemoresistance in general by inhibiting varying oncogenic pathways in chemotherapy, this study presented the unexpected outcome of generation tumor suppressive secretomes by activating the pro tumorigenic Wnt pathway. The results shed light on the contrasting role of oncogenic signaling in tumor cells and osteoblast derived secretomes, suggesting a counterintuitive option for the treatment of breast cancer associated bone metastasis.
C1 [Sun, Xun; Li, Kexin; Zha, Rongrong; Feng, Yan; Li, Bai Yan; Yokota, Hiroki] Harbin Med Univ, Sch Pharm, Dept Pharmacol, Harbin 150081, Peoples R China.
   [Sun, Xun; Li, Kexin; Hase, Misato; Zha, Rongrong; Feng, Yan; Yokota, Hiroki] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
   [Hase, Misato] Mie Univ, Grad Sch Engn, Tsu, Mie 514, Japan.
   [Yokota, Hiroki] Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.
   [Yokota, Hiroki] Indiana Univ Sch Med, Simon Canc Ctr, Indianapolis, IN 46202 USA.
C3 Harbin Medical University; Purdue University System; Purdue University;
   Purdue University in Indianapolis; Mie University; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington
RP Li, BY; Yokota, H (通讯作者)，Harbin Med Univ, Sch Pharm, Dept Pharmacol, Harbin 150081, Peoples R China.; Yokota, H (通讯作者)，Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
RI Li, Ke Xin/AAG 5874 2021
FU 100 Voices of Hope
FX The authors appreciate Dr. Harikrishna Nakshatri (Indiana University)
   for providing epithelial cells, Dr. Yao Fan (Indiana University) for
   assisting data interpretation, and the funding from 100 Voices of Hope
   (to H.Y.).
CR Ali NA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001914
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Buijs Jeroen T, 2012, Bonekey Rep, V1, P96, DOI 10.1038/bonekey.2012.96
   Chen A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03811 9
   Chiechi Antonella, 2013, Adv Biosci Biotechnol, V4, P15
   Daassi D, 2020, NAT REV IMMUNOL, V20, P209, DOI 10.1038/s41577 019 0264 y
   Dandawate P, 2019, GASTROENTEROLOGY, V157, P1646, DOI 10.1053/j.gastro.2019.08.018
   Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200
   Devignes CS, 2018, P NATL ACAD SCI USA, V115, pE992, DOI 10.1073/pnas.1718009115
   Donatello S, 2012, AM J PATHOL, V181, P2172, DOI 10.1016/j.ajpath.2012.08.025
   Ewens A, 2005, ANTICANCER RES, V25, P3905
   Fan Y, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0083 6
   Feng Y, 2021, CANCERS, V13, DOI 10.3390/cancers13020267
   Gajos Michniewicz A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144852
   Goodison S, 1999, J CLIN PATHOL MOL PA, V52, P189
   Haase M, 2016, GENE, V575, P171, DOI 10.1016/j.gene.2015.08.063
   Haider MT, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00335
   Icer MA, 2018, CLIN BIOCHEM, V59, P17, DOI 10.1016/j.clinbiochem.2018.07.003
   Kolb AD, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058 019 1117 0
   Kumar B, 2018, CANCER RES, V78, P5107, DOI 10.1158/0008 5472.CAN 18 0509
   Li BF, 2019, ONCOTARGETS THER, V12, P3207, DOI 10.2147/OTT.S195703
   Li FJ, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 42132 x
   Li KX, 2021, CANCERS, V13, DOI 10.3390/cancers13225593
   Liu S. Z., 2021, ONCO, V1, P101
   Liu SZ, 2021, THERANOSTICS, V11, P8517, DOI 10.7150/thno.61006
   Liu SZ, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00152 2
   Liu SZ, 2018, CANCER RES, V78, P3865, DOI 10.1158/0008 5472.CAN 18 0056
   Madden EC, 2020, TRENDS CANCER, V6, P489, DOI 10.1016/j.trecan.2020.02.020
   MERRY K, 1993, J CELL SCI, V104, P1013
   Ottewell PD, 2016, J BONE ONCOL, V5, P124, DOI 10.1016/j.jbo.2016.03.007
   Pawitan JA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/965849
   Poojan S, 2018, JOVE J VIS EXP, DOI 10.3791/57369
   Roodman GD, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.122
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sano T, 2021, CANCERS, V13, DOI 10.3390/cancers13051061
   Senbanjo LT, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00018
   Stewart S, 2014, CELL REP, V6, P482, DOI 10.1016/j.celrep.2014.01.010
   Sun X, 2021, THERANOSTICS, V11, P5143, DOI 10.7150/thno.58779
   Tai S, 2011, PROSTATE, V71, P1668, DOI 10.1002/pros.21383
   Wang LQ, 2018, INT J ONCOL, V53, P1001, DOI 10.3892/ijo.2018.4481
   Wang MN, 2020, BONE RES, V8, DOI 10.1038/s41413 020 00105 1
   Wu XQ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00076
   Xu WX, 2015, CELL SIGNAL, V27, P2332, DOI 10.1016/j.cellsig.2015.08.014
   Yamashita T, 2012, WORLD J ORTHOP, V3, P175, DOI 10.5312/wjo.v3.i11.175
   Yan YM, 2015, STEM CELL TRANSL MED, V4, P1033, DOI 10.5966/sctm.2015 0048
   Yin LJ, 2016, J MOL ENDOCRINOL, V57, P61, DOI 10.1530/JME 15 0142
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhang W, 2018, ONCOTARGET, V9, P3690, DOI [10.18632/oncotarget.24286, 10.18632/oncotarget.23196]
   Zhao HL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0391 6
   Zheng Y, 2013, J BONE ONCOL, V2, P47, DOI 10.1016/j.jbo.2012.11.002
   Zollinger AJ, 2017, MATRIX BIOL, V60 61, P27, DOI 10.1016/j.matbio.2016.07.011
NR 51
TC 47
Z9 51
U1 8
U2 32
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2022
VL 12
IS 2
BP 929
EP 943
DI 10.7150/thno.66148
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA YD0MS
UT WOS:000740076300026
PM 34976221
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Gallagher, JC
   Tella, SH
AF Gallagher, J. Christopher
   Tella, Sri Harsha
TI Controversies in Osteoporosis Management: Antiresorptive Therapy for
   Preventing Bone Loss: When to Use One or Two Antiresorptive Agents?
SO CLINICAL OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE osteoporosis; bisphosphonates; teriparatide; denosumab; SERMs;
   calcitriol
ID HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; MEDROXYPROGESTERONE
   ACETATE; COMBINATION TREATMENT; MINERAL DENSITY; ALENDRONATE; ESTROGEN;
   CALCITRIOL; RALOXIFENE; LIPIDS
AB Women who have significant bone loss or a new fracture on monotherapy are considered for combination therapy. Combination therapies increase bone density more than monotherapy by targeting different parts of the osteoclast pathway.In early postmenopausal women who are symptomatic, the use of combination antiresorptives should include hormone therapy with a bisphosphonate or with bazodoxifene. In women who initially receive a weaker antiresorptive such as the SERM raloxifene, a combination with bisphosphonates and calcium supplementation is necessary to prevent bone loss. In older women over 65 years of age who often have impaired calcium absorption, the combination of calcitriol with bisphosphonates has been shown to increase bone density more than monotherapy.
C1 [Gallagher, J. Christopher] Creighton Univ, Sch Med, Dept Endocrinol, Omaha, NE 68178 USA.
   [Tella, Sri Harsha] Creighton Univ, Sch Med, Dept Internal Med, Omaha, NE USA.
C3 Creighton University; Creighton University
RP Gallagher, JC (通讯作者)，Creighton Univ, Sch Med, Dept Endocrinol, Suite 6718, Omaha, NE 68178 USA.
EM jcg@creighton.edu
OI gallagher, john christopher/0000 0002 5129 9183
FU NIA NIH HHS [R01 AG028168] Funding Source: Medline
CR [Anonymous], 2011, I MED US COMM REV DI
   Bone HG, 2000, J CLIN ENDOCR METAB, V85, P720, DOI 10.1210/jc.85.2.720
   Gallagher JC, 2001, J CLIN ENDOCR METAB, V86, P3618, DOI 10.1210/jc.86.8.3618
   GALLAGHER JC, 1987, J BONE MINER RES, V2, P491
   Greenspan SL, 2003, JAMA J AM MED ASSOC, V289, P2525, DOI 10.1001/jama.289.19.2525
   Harris ST, 2001, J CLIN ENDOCR METAB, V86, P1890, DOI 10.1210/jc.86.5.1890
   Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801
   Johnell O, 2002, J CLIN ENDOCR METAB, V87, P985, DOI 10.1210/jc.87.3.985
   Lindsay R, 2002, JAMA J AM MED ASSOC, V287, P2668, DOI 10.1001/jama.287.20.2668
   Lindsay R, 2005, OSTEOPOROSIS INT, V16, P372, DOI 10.1007/s00198 004 1773 4
   Lindsay R, 1999, J CLIN ENDOCR METAB, V84, P3076, DOI 10.1210/jc.84.9.3076
   Lindsay R, 2009, FERTIL STERIL, V92, P1045, DOI 10.1016/j.fertnstert.2009.02.093
   Malavolta N, 1999, INT J TISSUE REACT, V21, P51
   Masud T, 1998, ANN RHEUM DIS, V57, P346, DOI 10.1136/ard.57.6.346
   Nieves JW, 1998, AM J CLIN NUTR, V67, P18, DOI 10.1093/ajcn/67.1.18
   Reid IR, 2010, J BONE MINER RES, V25, P2256, DOI 10.1002/jbmr.149
   Reid IR, 2004, ARCH INTERN MED, V164, P871, DOI 10.1001/archinte.164.8.871
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Speroff L, 1996, JAMA J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397
   Tseng LN, 2006, METABOLISM, V55, P741, DOI 10.1016/j.metabol.2006.01.008
   Wimalawansa SJ, 1998, AM J MED, V104, P219, DOI 10.1016/S0002 9343(98)00029 1
NR 21
TC 8
Z9 9
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009 9201
EI 1532 5520
J9 CLIN OBSTET GYNECOL
JI Clin. Obstet. Gynecol.
PD DEC
PY 2013
VL 56
IS 4
BP 749
EP 756
DI 10.1097/GRF.0b013e3182a982c2
PG 8
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology
GA 244OV
UT WOS:000326399800015
PM 24036481
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Jullien, N
   Maudinet, A
   Leloutre, B
   Ringe, J
   Häupl, T
   Marie, PJ
AF Jullien, Nicolas
   Maudinet, Adrien
   Leloutre, Benjamin
   Ringe, Jochen
   Haeupl, Thomas
   Marie, Pierre J.
TI Downregulation of ErbB3 by Wnt3a contributes to wnt induced osteoblast
   differentiation in mesenchymal cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Wnt SIGNALING; ErbB3; OSTEOBLAST; MESENCHYMAL CELLS
ID EPIDERMAL GROWTH FACTOR; RECEPTOR TYROSINE KINASES; STEM CELLS;
   BONE FORMATION; GENE EXPRESSION; CANCER THERAPY; ENDOTHELIN 1;
   PROGENITORS; PATHWAY; OSTEOSARCOMA
AB Mesenchymal stem cells (MSC) can differentiate into osteoblasts upon activation of Wnt signaling. Identifying targets of Wnt signaling in MSC may help promote MSC osteoblast differentiation for bone regeneration. In this study, using microarray analysis we found that Wnt3a upregulates neuregulin 1 (NRG 1) during Wnt3a induced osteoblast differentiation in primary human MSC and murine C3H10T1/2 mesenchymal cells. Western blot and qPCR analyses confirmed that NRG 1 is upregulated by Wnt3a, and that this effect was counterbalanced by decreased expression of the NRG 1 receptor ErbB3. Consistently, exogenous NRG 1 had no effect on alkaline phosphatase (ALP) activity, an early marker of osteoblast differentiation. In contrast, small interfering RNA mediated silencing of endogenous NRG 1 increased basal and Wnt3a induced ALP activity in MSC. We showed that short hairpin (sh) ErbB3 and Wnt3a additively increased beta catenin transcriptional activity and ALP activity in MSC. These effects were abrogated by DKK1, indicating that cross talk between Wnt3a and ErbB3 control MSC osteoblast differentiation via Wnt/beta catenin signaling. Furthermore, ErbB3 silencing decreased Src expression. Pharmacological inhibition of Src signaling promoted ErbB3  and Wnt induced ALP activity, suggestive of a role of Src signaling in the modulation of osteoblast differentiation by ErbB3 and Wnt3a. The results indicate that downregulation of ErbB3 induced by Wnt3a contributes to Wnt3a induced early osteoblast differentiation of MSCs through increased canonical Wnt/beta catenin signaling and decreased Src signaling. J. Cell. Biochem. 113: 20472056, 2012. (C) 2012 Wiley Periodicals, Inc.
C1 [Jullien, Nicolas; Maudinet, Adrien; Leloutre, Benjamin; Marie, Pierre J.] Hop Lariboisiere, INSERM, U606, F 75475 Paris 10, France.
   [Jullien, Nicolas; Maudinet, Adrien; Leloutre, Benjamin; Marie, Pierre J.] Univ Paris Diderot, Paris, France.
   [Ringe, Jochen] Charite, Berlin Brandenburg Ctr Regenerat Therapies, Berlin, Germany.
   [Haeupl, Thomas] Charite, Dept Rheumatol, Berlin, Germany.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Lariboisiere Fernand Widal   APHP; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite
   Paris Cite; Free University of Berlin; Humboldt University of Berlin;
   Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin
RP Marie, PJ (通讯作者)，Hop Lariboisiere, INSERM, U606, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM pierre.marie@inserm.fr
RI JULLIEN, Nicolas/HPC 7826 2023
FU Fondation pour la Recherche Medicale, Paris, France [DVO20081013486]
FX Grant sponsor: Fondation pour la Recherche Medicale, Paris, France;
   Grant number: DVO20081013486.
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Birchmeier C, 2009, EXP CELL RES, V315, P611, DOI 10.1016/j.yexcr.2008.10.035
   Blume Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Britsch S, 2007, ADV ANAT EMBRYOL CEL, V190, P1
   CANALIS E, 1979, ENDOCRINOLOGY, V104, P862, DOI 10.1210/endo 104 4 862
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Carraway KL, 2001, CURR OPIN CELL BIOL, V13, P125, DOI 10.1016/S0955 0674(00)00188 5
   Chan SY, 2000, J BIOL CHEM, V275, P38693, DOI 10.1074/jbc.M004189200
   Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014 4827(02)00101 5
   Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407
   Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006 0346
   Clines GA, 2011, J BONE MINER RES, V26, P2523, DOI 10.1002/jbmr.450
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Denny WA, 2002, PHARMACOL THERAPEUT, V93, P253, DOI 10.1016/S0163 7258(02)00194 8
   Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014 4827(02)00102 7
   Fisher MC, 2007, DEV GROWTH DIFFER, V49, P503, DOI 10.1111/j.1440 169x.2007.00941.x
   Fromigué O, 2008, J BIOL CHEM, V283, P30549, DOI 10.1074/jbc.M801436200
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200
   Häupl T, 2007, J BIOMOL SCREEN, V12, P328, DOI 10.1177/1087057107299261
   Hamidouche Z, 2008, FASEB J, V22, P3813, DOI 10.1096/fj.08 106302
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Hay E, 2005, J BIOL CHEM, V280, P13616, DOI 10.1074/jbc.M411999200
   Haÿ E, 2009, MOL CELL BIOL, V29, P953, DOI 10.1128/MCB.00349 08
   Hickinson DM, 2010, CLIN CANCER RES, V16, P1159, DOI 10.1158/1078 0432.CCR 09 2353
   Ishizawar RC, 2007, ONCOGENE, V26, P3503, DOI 10.1038/sj.onc.1210138
   Johnson ML, 2004, J BONE MINER RES, V19, P1749, DOI 10.1359/JBMR.040816
   Kaabeche K, 2004, J BIOL CHEM, V279, P36259, DOI 10.1074/jbc.M402469200
   Kassem M, 2008, CELL TISSUE RES, V331, P157, DOI 10.1007/s00441 007 0509 0
   Katoh Y, 2006, INT J MOL MED, V17, P1163
   Kimelman N, 2006, REGEN MED, V1, P549, DOI 10.2217/17460751.1.4.549
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389
   Lin SH, 2008, ONCOGENE, V27, P5195, DOI 10.1038/onc.2008.156
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   MARIE PJ, 1990, AM J PHYSIOL, V258, pE275, DOI 10.1152/ajpendo.1990.258.2.E275
   Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311
   Niger C, 2008, J CELL BIOCHEM, V103, P110, DOI 10.1002/jcb.21390
   Nusse R, 2008, CELL RES, V18, P523, DOI 10.1038/cr.2008.47
   Olayioye MA, 2001, EXP CELL RES, V267, P81, DOI 10.1006/excr.2001.5242
   Orosco A, 2007, CANCER RES, V67, P3708, DOI 10.1158/0008 5472.CAN 06 4164
   Pentassuglia L, 2009, EXP CELL RES, V315, P627, DOI 10.1016/j.yexcr.2008.08.015
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Samaga R, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000438
   Schneider MR, 2009, TRENDS ENDOCRIN MET, V20, P517, DOI 10.1016/j.tem.2009.06.008
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Suzuki A, 1997, BONE, V21, P143, DOI 10.1016/S8756 3282(97)00096 3
   Sweeney C, 2000, ONCOGENE, V19, P5568, DOI 10.1038/sj.onc.1203913
   Tamama K, 2006, STEM CELLS, V24, P686, DOI 10.1634/stemcells.2005 0176
   von Schroeder HP, 2003, BONE, V33, P673, DOI 10.1016/S8756 3282(03)00215 1
   Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014 4827(03)00002 8
   Xu YB, 2009, CURR OPIN PHARMACOL, V9, P214, DOI 10.1016/j.coph.2008.11.004
   Zhang X, J BONE MINER RES, V26, P1022
NR 56
TC 39
Z9 45
U1 0
U2 17
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JUN
PY 2012
VL 113
IS 6
BP 2047
EP 2056
DI 10.1002/jcb.24076
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 923IN
UT WOS:000302613100024
PM 22274864
DA 2025 08 17
ER

PT J
AU Chen, HY
   Cai, GH
   Ruan, XL
   Lu, YH
   Li, G
   Chen, ZW
   Guan, ZL
   Zhang, HW
   Sun, W
   Wang, H
AF Chen, Hongyu
   Cai, Guanhui
   Ruan, Xiaolei
   Lu, Yahui
   Li, Gen
   Chen, Zhenwei
   Guan, Zhaolan
   Zhang, Hengwei
   Sun, Wen
   Wang, Hua
TI Bone targeted bortezomib increases bone formation within Calvarial
   trans sutural distraction osteogenesis
SO BONE
LA English
DT Article
DE Bone targeted bortezomib; Bisphosphonates; Trans sutural distraction
   osteogenesis; Osteoblast differentiation; Bone volume
ID INDUCED PERIPHERAL NEUROTOXICITY; MESENCHYMAL STEM CELLS; OSTEOBLAST
   DIFFERENTIATION; IN VIVO; PROTEASOME INHIBITORS; CRANIAL SUTURES;
   REGENERATION; EXPRESSION; PHENOTYPE; EXPANSION
AB The high rate of relapse in craniofacial disharmony treatment via trans sutural distraction osteogenesis (TSDO) is due to the failure to form a stable bone bridge in the suture gap. Bisphosphonates (BP) have a high propensity to localize to hydroxyapatite in the bone matrix and are commonly used as targeting ligands for local delivery of therapeutics into bone microenvironment. Bone targeted Bortezomib (BP Btz) is chemosynthetic by linking Btz (Bortezomib) to a BP residue and could target bone tissue to promote osteoblast differentiation and inhibit osteoclastogenesis. Here, suture derived mesenchymal stem cells (SuSCs) and osteoclasts were treated with Btz and BP Btz. Aforesaid drugs were injected locally into the sagittal sutures to explore their effects in TSDO. Further, pharmacological properties of BP Btz in the suture expansion model were assessed by fluorescent BP analogs and levels of total ubiquitinated (Ub) proteins. The results showed that BP Btz could stimulate osteo genic differentiation of SuSCs, bind to bone matrix and inhibit osteoclastogenesis. Biological effects of BP Btz were similar with those of Btz in osteoblast differentiation and osteoclastogenesis inhibition in vitro. Acti vated bone metabolism were detected after 14 days in the sagittal suture expansion model. Increased osteoid area, remarkably decreased osteoclast surface and enhanced osteogenesis were detected in vivo after treatment with BP Btz. Green fluorescence signal detection and pharmacodynamic studies revealed that BP Btz bound to suture edge, released Btz in remodeling conditions, had a higher local concentration and sustained longer than free Btz. This study delineated the clinical potential of bone targeted Btz conjugate as an efficacious strategy to promote trans sutural distraction osteogenesis.
C1 [Chen, Hongyu; Cai, Guanhui; Ruan, Xiaolei; Lu, Yahui; Li, Gen; Chen, Zhenwei; Guan, Zhaolan; Sun, Wen; Wang, Hua] Nanjing Med Univ, Jiangsu Prov Engn Res Ctr Stomatol Translat Med, Jiangsu Key Lab Oral Dis, Dept Orthodont,Affiliated Hosp Stomatol, Nanjing, Peoples R China.
   [Zhang, Hengwei] Univ Rochester, Dept Pathol & Lab Med, Med Ctr, Rochester, NY USA.
   [Sun, Wen] Nanjing Med Univ, Affiliated Stomatol Hosp, Dept Basic Sci Stomatol, 136 Hanzhong Rd, Nanjing 210029, Peoples R China.
   [Wang, Hua] Nanjing Med Univ, Affiliated Stomatol Hosp, Dept Orthodont, 136 Hanzhong Rd, Nanjing 210029, Peoples R China.
C3 Nanjing Medical University; University of Rochester; Nanjing Medical
   University; Nanjing Medical University
RP Sun, W (通讯作者)，Nanjing Med Univ, Affiliated Stomatol Hosp, Dept Basic Sci Stomatol, 136 Hanzhong Rd, Nanjing 210029, Peoples R China.; Wang, H (通讯作者)，Nanjing Med Univ, Affiliated Stomatol Hosp, Dept Orthodont, 136 Hanzhong Rd, Nanjing 210029, Peoples R China.
EM wensun@njmu.edu.cn; huawang@njmu.edu.cn
RI Zhang, hengwei/S 9114 2019; Wang, Hua/MHP 9513 2025; Chen,
   Hongyu/HSH 7147 2023
FU National Natural Science Foundation of China [81970961, 81670965];
   JiangSu Province Natural Science Foundation [BK20191346]; Medical
   Scientific Research Project of Jiangsu Provincial Health Commission
   [H2019032]; Jiangsu Provincial Key Medical Discipline [ZDXKA2016026]
FX This study was supported in part by the National Natural Science
   Foundation of China (81970961 and 81670965) , JiangSu Province Natural
   Science Foundation (BK20191346) , Medical Scientific Research Project of
   Jiangsu Provincial Health Commission (H2019032) , and Jiangsu Provincial
   Key Medical Discipline (ZDXKA2016026) . Thanks to Robert K Boeckman Jr.
   (Department of Chemistry, University of Rochester) for design and
   preparation of Bp Btz analogues.
CR Agyin JK, 2013, BIOORG MED CHEM LETT, V23, P6455, DOI 10.1016/j.bmcl.2013.09.043
   Cavaletti G, 2007, EXP NEUROL, V204, P317, DOI 10.1016/j.expneurol.2006.11.010
   Chen JX, 2020, INT J PHARMACEUT, V585, DOI 10.1016/j.ijpharm.2020.119477
   Cheong S, 2014, J ORAL MAXIL SURG, V72, P2461, DOI 10.1016/j.joms.2014.07.004
   Cohen M M Jr, 1979, Birth Defects Orig Artic Ser, V15, P13
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Doro DH, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00956
   Duarte C, 2017, EUR J ORTHODONT, V39, P227, DOI 10.1093/ejo/cjw037
   Dutta S, 2016, LIFE SCI, V152, P244, DOI 10.1016/j.lfs.2015.10.025
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Ekizer A, 2015, ANGLE ORTHOD, V85, P394, DOI 10.2319/031114 177.1
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Hengst V, 2007, INT J PHARMACEUT, V331, P224, DOI 10.1016/j.ijpharm.2006.11.024
   Hokugo A, 2013, BONE, V53, P59, DOI 10.1016/j.bone.2012.11.030
   Hwang S, 2020, KOREAN J ORTHOD, V50, P42, DOI 10.4041/kjod.2020.50.1.42
   Ikegame M, 2019, J HISTOCHEM CYTOCHEM, V67, P107, DOI 10.1369/0022155418793588
   James AW, 2008, PLAST RECONSTR SURG, V122, P53, DOI 10.1097/PRS.0b013e31817747b5
   Jiang GM, 2017, CANCER IMMUNOL RES, V5, P42, DOI 10.1158/2326 6066.CIR 16 0102
   Jiang L, 2017, J PERIODONTOL, V88, P473, DOI 10.1902/jop.2016.160396
   Khedgikar V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.294
   Koons GL, 2020, NAT REV MATER, V5, P584, DOI 10.1038/s41578 020 0204 2
   Li WL, 2020, J CELL PHYSIOL, V235, P5972, DOI 10.1002/jcp.29522
   Liu CC, 2015, J BONE MINER RES, V30, P670, DOI 10.1002/jbmr.2382
   Liu JH, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12010051
   Liu L, 2020, INT J PHARMACEUT, V590, DOI 10.1016/j.ijpharm.2020.119885
   Liu SSY, 2013, AM J ORTHOD DENTOFAC, V144, P210, DOI 10.1016/j.ajodo.2013.03.017
   Maruyama T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10526
   Maseda D, 2008, CELL DEATH DIFFER, V15, P600, DOI 10.1038/sj.cdd.4402297
   Meregalli C, 2015, J BIOL REG HOMEOS AG, V29, P115
   Morinobu M, 2003, J BONE MINER RES, V18, P1706, DOI 10.1359/jbmr.2003.18.9.1706
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Murai K, 2014, EUR J HAEMATOL, V93, P290, DOI 10.1111/ejh.12342
   Opperman LA, 2000, DEV DYNAM, V219, P472, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1073>3.0.CO;2 F
   Qiang YW, 2012, SEMIN HEMATOL, V49, P243, DOI 10.1053/j.seminhematol.2012.04.011
   Qiang YW, 2009, BLOOD, V113, P4319, DOI 10.1182/blood 2008 08 174300
   Ramakrishnan V, 2018, J PHARMACOL EXP THER, V365, P734, DOI 10.1124/jpet.118.247924
   Shi DS, 2014, J CLIN INVEST, V124, P3757, DOI 10.1172/JCI75247
   Slater BJ, 2008, PLAST RECONSTR SURG, V121, p170E, DOI 10.1097/01.prs.0000304441.99483.97
   Speltz ML, 2015, PEDIATRICS, V135, pE615, DOI 10.1542/peds.2014 1634
   STEENVOORDEN GP, 1990, EUR J ORTHODONT, V12, P330, DOI 10.1093/ejo/12.3.330
   Sun ST, 2021, BRIT J PHARMACOL, V178, P2008, DOI 10.1111/bph.15251
   Takeshita N, 2017, J BONE MINER METAB, V35, P40, DOI 10.1007/s00774 016 0737 z
   Tao JG, 2022, J BONE MINER RES, V37, P629, DOI 10.1002/jbmr.4496
   Terpos E, 2012, INT J CANCER, V131, P1466, DOI 10.1002/ijc.27342
   Tong HZ, 2015, PLAST RECONSTR SURG, V136, P144, DOI 10.1097/PRS.0000000000001375
   Toscani D, 2016, J BONE MINER RES, V31, P815, DOI 10.1002/jbmr.2741
   Twigg SRF, 2015, AM J HUM GENET, V97, P359, DOI 10.1016/j.ajhg.2015.07.006
   Uy GL, 2007, CLIN LYMPHOMA MYELOM, V7, P587, DOI 10.3816/CLM.2007.n.045
   Uysal T, 2011, J OROFAC ORTHOP, V72, P290, DOI 10.1007/s00056 011 0034 3
   VARDIMON AD, 1989, EUR J ORTHODONT, V11, P107, DOI 10.1093/oxfordjournals.ejo.a035971
   Wang H, 2020, J BONE MINER RES, V35, P343, DOI 10.1002/jbmr.3889
   Wang H, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030154
   Wang H, 2015, J BIOMECH, V48, P432, DOI 10.1016/j.jbiomech.2014.12.032
   Weathington NM, 2014, J CLIN INVEST, V124, P6, DOI 10.1172/JCI71602
   White HE, 2021, FRONT CELL DEV BIOL, V09, DOI 10.3389/fcell.2021.653579
   Wilk K, 2017, STEM CELL REP, V8, P933, DOI 10.1016/j.stemcr.2017.03.002
   Xu Y, 2007, PLAST RECONSTR SURG, V119, P819, DOI 10.1097/01.prs.0000255540.91987.a0
   Yao ZQ, 2008, J BIOL CHEM, V283, P9917, DOI 10.1074/jbc.M706415200
   Yu MF, 2021, CELL, V184, P243, DOI 10.1016/j.cell.2020.11.037
   Zechi Ceide RM, 2012, AM J MED GENET A, V158A, P1680, DOI 10.1002/ajmg.a.35367
   Zhang GR, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8868593
   Zhang HW, 2010, J BONE MINER RES, V25, P640, DOI 10.1359/jbmr.090812
   Zhang HW, 2013, STEM CELLS, V31, P1574, DOI 10.1002/stem.1395
   Zhao H, 2015, NAT CELL BIOL, V17, P386, DOI 10.1038/ncb3139
NR 65
TC 2
Z9 3
U1 1
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2023
VL 169
AR 116677
DI 10.1016/j.bone.2023.116677
EA JAN 2023
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 8J6VV
UT WOS:000922551700001
PM 36646264
DA 2025 08 17
ER

PT J
AU Marino, S
   Bishop, RT
   Logan, JG
   Mollat, P
   Idris, AI
AF Marino, Silvia
   Bishop, Ryan T.
   Logan, John G.
   Mollat, Patrick
   Idris, Aymen I.
TI Pharmacological evidence for the bone autonomous contribution of the
   NFκB/β catenin axis to breast cancer related osteolysis
SO CANCER LETTERS
LA English
DT Article
DE NF kappa B; beta Catenin; Breast cancer; Osteolysis; Bone
ID B KINASE; OSTEOCLAST DIFFERENTIATION; BLOCKS OSTEOCLASTOGENESIS;
   MOLECULAR MECHANISMS; NFATC1 INDUCTION; UBIQUITIN LIGASE; IN VITRO;
   CELLS; METASTASIS; RECEPTOR
AB The NF kappa B signaling pathway is implicated in breast cancer and bone metastasis. However, the bone autonomous contribution of NF kappa B to breast cancer induced osteolysis is poorly understood. Here, we report that pretreatment of osteoblasts with the sesquiterpene lactone Parthenolide (PTN), a verified NF kappa B inhibitor, prior to exposure to conditioned medium from human and mouse breast cancer cell lines enhanced osteoblast differentiation and reduced osteoblast ability to stimulate osteoclastogenesis. PTN prevented breast cancer induced osteoclast formation and reduced the ability of breast cancer cells to prolong osteoclast survival and to inhibit osteoclast apoptosis. In vivo, administration of PTN in immunocompetent mice reduced osteolytic bone loss and skeletal tumour growth following injection of the syngeneic 4T1 BT1 cells and reduced local osteolysis caused by conditioned medium from human and mouse osteotropic breast cancer cell lines. Mechanistic studies revealed that NF kappa B inhibition by PTN in osteoblasts and osteoclasts was accompanied by a significant increase in beta catenin activation and expression. Collectively, these results raise the possibility that combined targeting of NF kappa B and beta catenin signalling in the tumour microenvironment may be of value in the treatment of breast cancer related osteolysis. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Marino, Silvia; Bishop, Ryan T.; Idris, Aymen I.] Univ Sheffield, Dept Oncol & Metab, Med Sch, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
   [Marino, Silvia; Logan, John G.; Idris, Aymen I.] Univ Edinburgh, MRC, Inst Genet & Mol Med, Bone & Canc Grp,Edinburgh Canc Res Ctr, Edinburgh EH4 2XR, Midlothian, Scotland.
   [Mollat, Patrick] Galapagos SASU, 102 Ave Gaston Roussel, F 93230 Romainville, France.
C3 University of Sheffield; University of Edinburgh; Galapagos NV
RP Idris, AI (通讯作者)，Med Sch, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM aymen.idris@sheffield.ac.uk
RI ; Idris, Aymen/AAX 1138 2020
OI Bishop, Ryan/0000 0002 1332 4798; Logan, John/0000 0003 2801 700X;
   Idris, Aymen/0000 0003 4327 5306
FU Cancer Research UK (University of Edinburgh); Medical Research Council
   [MR/P020941/1] Funding Source: researchfish; MRC [MR/P020941/1] Funding
   Source: UKRI
FX This work was supported in part by a pump prime grant from Cancer
   Research UK (University of Edinburgh) grant to Aymen I. Idris.
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   [Anonymous], SCI REP UK
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   Campbell Graeme M, 2014, Bonekey Rep, V3, P564, DOI 10.1038/bonekey.2014.59
   Chaisson ML, 2004, J BIOL CHEM, V279, P54841, DOI 10.1074/jbc.M406392200
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chung JY, 2002, J CELL SCI, V115, P679
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   Du Qiang, 2010, For Immunopathol Dis Therap, V1, P155
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Ghantous A, 2010, DRUG DISCOV TODAY, V15, P668, DOI 10.1016/j.drudis.2010.06.002
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Hehner SP, 1999, J IMMUNOL, V163, P5617
   Idris AI, 2010, FASEB J, V24, P4545, DOI 10.1096/fj.10 164095
   Idris AI, 2009, MOL CANCER THER, V8, P2339, DOI 10.1158/1535 7163.MCT 09 0133
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Kim JY, 2014, BMB REP, V47, P451, DOI 10.5483/BMBRep.2014.47.8.206
   Kishida S, 2005, GENES CELLS, V10, P447, DOI 10.1111/j.1365 2443.2005.00852.x
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074 5521(01)00049 7
   Lamothe B, 2007, BIOCHEM BIOPH RES CO, V359, P1044, DOI 10.1016/j.bbrc.2007.06.017
   Le Henaff C, 2015, J BIOL CHEM, V290, P18009, DOI 10.1074/jbc.M115.646208
   Logan JG, 2013, J BONE MINER RES, V28, P1229, DOI 10.1002/jbmr.1847
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Matsumoto Y, 2017, J CLIN INVEST, V127, P1303, DOI 10.1172/JCI90527
   McIntyre KW, 2003, ARTHRITIS RHEUM US, V48, P2652, DOI 10.1002/art.11131
   Mendoza Villanueva D, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3048
   Mercer RR, 2004, CLIN EXP METASTAS, V21, P427, DOI 10.1007/s10585 004 1867 6
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Otero JE, 2010, J BONE MINER RES, V25, P1282, DOI 10.1002/jbmr.4
   Otero K, 2012, J IMMUNOL, V188, P2612, DOI 10.4049/jimmunol.1102836
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541 7786.MCR 07 0119
   Rucci N, 2004, BONE, V34, P697, DOI 10.1016/j.bone.2003.07.012
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Sethi G, 2007, BLOOD, V109, P2727, DOI 10.1182/blood 2006 10 050807
   Siclari VA, 2006, CANCER METAST REV, V25, P621, DOI 10.1007/s10555 006 9023 1
   Sophocleous A, 2015, J BIOL CHEM, V290, P22049, DOI 10.1074/jbc.M115.649608
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Taylor Sarah E B, 2014, Bonekey Rep, V3, P585, DOI 10.1038/bonekey.2014.80
   Teitelbaum SL, 1997, J LEUKOCYTE BIOL, V61, P381, DOI 10.1002/jlb.61.4.381
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
NR 48
TC 12
Z9 12
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PD DEC 1
PY 2017
VL 410
BP 180
EP 190
DI 10.1016/j.canlet.2017.09.034
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FN1VB
UT WOS:000415778200017
PM 28965856
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kobelski, MM
   Ramchand, SK
   Tsai, JN
   Leder, BZ
   Demay, MB
AF Kobelski, Margaret M.
   Ramchand, Sabashini K.
   Tsai, Joy N.
   Leder, Benjamin Z.
   Demay, Marie B.
TI Evaluation of Osteogenic Phenotype in Postmenopausal Women Receiving
   Anabolic and Antiresorptive Osteoporosis Therapies
SO ENDOCRINOLOGY
LA English
DT Article
DE osteoporosis; anabolic; antiresorptive; bone marrow stromal cells; LGR6
ID INTRAVENOUS ZOLEDRONIC ACID; TERIPARATIDE; DENOSUMAB; HORMONE
AB Aging of the general population has led to a substantial increase in the prevalence of osteoporosis over the past decades. While there are effective pharmacological agents that increase bone formation, decrease bone resorption, and decrease fracture risk, they do not uniformly cure osteoporosis. This has prompted investigations to examine whether combination therapy (COMBO) with these agents can result in an additive benefit. Since concomitant therapy with denosumab and teriparatide has shown promise in this respect, investigations were undertaken to explore whether the changes in osteogenic phenotype could provide insight into the cellular and molecular mechanism of this effect. Investigations were performed in postmenopausal women receiving denosumab, teriparatide, or both for 3 months. Histomorphometric parameters were the primary outcome, while exploratory studies examined RNA expression in bone biopsies as well as in sorted and cultured bone marrow stromal cells (BMSCs). Osteogenic colony forming units of BMSCs were also evaluated. The studies demonstrated that COMBO results in an increase in osteoprogenitors, evidenced by an increase in osteoblastic colony forming units. This was associated with an increased in BMSC expression of LGR6 (leucine rich repeat containing G protein coupled receptor 6), a stem cell marker and activator of the canonical Wnt signaling pathway. These data suggest that enhancement of canonical Wnt signaling contributes to the increase in osteoprogenitors and consequently an increase in bone density in postmenopausal women receiving COMBO for osteoporosis.
C1 [Kobelski, Margaret M.; Ramchand, Sabashini K.; Tsai, Joy N.; Leder, Benjamin Z.; Demay, Marie B.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Ramchand, Sabashini K.; Tsai, Joy N.; Leder, Benjamin Z.; Demay, Marie B.] Harvard Med Sch, Boston, MA 02115 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard Medical School
RP Demay, MB (通讯作者)，Harvard Med Sch, Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St,Thier 1101, Boston, MA 02114 USA.
EM demay@helix.mgh.harvard.edu
FU National Institutes of Health (NIH) [R01 AR073191, P30 AR075042]; NIH
   National Center for Advancing Translational Sciences [1UL1TR002541 01]
FX This work was supported by the National Institutes of Health (NIH grant
   Nos. R01 AR073191 and P30 AR075042) and NIH National Center for
   Advancing Translational Sciences (grant No. 1UL1TR002541 01).
CR Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Dempster DW, 2016, J CLIN ENDOCR METAB, V101, P1353, DOI 10.1210/jc.2015 4181
   Doherty L, 2023, BONE, V169, DOI 10.1016/j.bone.2023.116681
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756 3282(03)00202 3
   Khedgikar V, 2022, BONE, V155, DOI 10.1016/j.bone.2021.116267
   Leder BZ, 2014, J CLIN ENDOCR METAB, V99, P1694, DOI 10.1210/jc.2013 4440
   Li C, 2020, ENDOCRINE, V68, P669, DOI 10.1007/s12020 020 02248 x
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mödder UI, 2012, BONE, V50, P804, DOI 10.1016/j.bone.2011.12.014
   Recker RR, 2008, J BONE MINER RES, V23, P6, DOI 10.1359/JBMR.070906
   Seike M, 2018, GENE DEV, V32, P359, DOI 10.1101/gad.311068.117
   Sfeir JG, 2022, MAYO CLIN PROC, V97, P1194, DOI 10.1016/j.mayocp.2022.03.011
   Shoback D, 2020, J CLIN ENDOCR METAB, V105, P587, DOI 10.1210/clinem/dgaa048
   Zhang JZ, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2026176118
NR 15
TC 1
Z9 1
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD OCT 30
PY 2024
VL 165
IS 12
AR bqae142
DI 10.1210/endocr/bqae142
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA K9P2L
UT WOS:001347138700001
PM 39445778
DA 2025 08 17
ER

PT S
AU Russell, RGG
   Xia, Z
   Dunford, JE
   Oppermann, U
   Kwaasi, A
   Hulley, PA
   Kavanagh, KL
   Triffitt, JT
   Lundy, MW
   Phipps, RJ
   Barnett, BL
   Coxon, FP
   Rogers, MJ
   Watts, NB
   Ebetino, FH
AF Russell, R. Graham G.
   Xia, Zhidao
   Dunford, James E.
   Oppermann, Udo
   Kwaasi, Aaron
   Hulley, Philippa A.
   Kavanagh, Kathryn L.
   Triffitt, James T.
   Lundy, Mark W.
   Phipps, Roger J.
   Barnett, Bobby L.
   Coxon, Fraser P.
   Rogers, Michael J.
   Watts, Nelson B.
   Ebetino, Frank H.
BE Zaidi, M
TI Bisphosphonates   An update on mechanisms of action and how these relate
   to clinical efficacy
SO SKELETAL BIOLOGY AND MEDICINE, PT B: DISEASE MECHANISMS AND THERAPEUTIC
   CHALLENGES
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT 2nd Conference on Skeletal Biology and Medicine
CY APR 25 28, 2007
CL New York, NY
SP Mt Sinai Sch Med, New York Acad Sci
DE bone resorption; osteoclasts; bisphosphonates; protein prenylation; bone
   metastases; myeloma; osteoporosis
ID NITROGEN CONTAINING BISPHOSPHONATES; FARNESYL DIPHOSPHATE SYNTHASE;
   POSTERIOR LONGITUDINAL LIGAMENT; INTRAVENOUS ZOLEDRONIC ACID;
   DOSE RESPONSE RELATIONSHIPS; BONE MINERAL DENSITY; CRYSTALS IN VITRO;
   FRACTURE RISK; POSTMENOPAUSAL OSTEOPOROSIS; INORGANIC PYROPHOSPHATE
AB The bisphosphonates (BPs) are well established as the treatments of choice for disorders of excessive bone resorption, including Paget's disease of bone, myeloma and bone metastases, and osteoporosis. There is considerable new knowledge about how BPs work. Their classical pharmacological effects appear to result from two key properties: their affinity for bone mineral and their inhibitory effects on osteoclasts. Mineral binding affinities differ among the clinically used BPs and may influence their differential distribution within bone, their biological potency, and their duration of action. The inhibitory effects of the nitrogen containing BPs (including alendronate, risedronate, ibandronate, and zoledronate) on osteoclasts appear to result from their inhibition of farnesyl pyrophosphate synthase (FPPS), a key branch point enzyme in the mevalonate pathway. FPPS generates isoprenoid lipids used for the post translational modification of small GTP binding proteins essential for osteoclast function. Effects on other cellular pathways, such as preventing apoptosis in osteocytes, are emerging as other potentially important mechanisms of action. As a class, BPs share several common properties. However, as with other classes of drugs, there are obvious chemical, biochemical, and pharmacological differences among the various individual BPs. Each BP has a unique profile that may help to explain potential important clinical differences among the BPs, in terms of speed of onset of fracture reduction, antifracture efficacy at different skeletal sites, and the degree and duration of suppression of bone turnover. As we approach the 40th anniversary of the discovery of their biological effects, there remain further opportunities for using their properties for medical purposes.
C1 [Russell, R. Graham G.; Xia, Zhidao; Dunford, James E.; Oppermann, Udo; Kwaasi, Aaron; Hulley, Philippa A.; Triffitt, James T.] Univ Oxford, Inst Musculosleletal Sci, Botnar Res Ctr, Nuffield Dept Orthopaed Surg,Nuffield Orthopaed C, Oxford OX3 7LD, England.
   [Oppermann, Udo; Kavanagh, Kathryn L.] Nuffield Orthopaed Ctr, Botnar Res Ctr, Struct Genom Consortium, Oxford OX3 7LD, England.
   [Lundy, Mark W.; Phipps, Roger J.; Ebetino, Frank H.] Procter & Gamble Pharmaceut Inc, Mason, OH USA.
   [Barnett, Bobby L.] Univ Cincinnati, Dept Chem, Cincinnati, OH 45221 USA.
   [Coxon, Fraser P.; Rogers, Michael J.] Univ Aberdeen, Inst Med Sci, Bone & Musculoskeletal Programme, Aberdeen, Scotland.
   [Watts, Nelson B.] Univ Cincinnati, Coll Med, Bone Hlth & Osteoporosis Ctr, Cincinnati, OH USA.
C3 Nuffield Orthopaedic Centre; University of Oxford; Nuffield Orthopaedic
   Centre; University of Oxford; Procter & Gamble; University System of
   Ohio; University of Cincinnati; University of Aberdeen; University
   System of Ohio; University of Cincinnati
RP Russell, RGG (通讯作者)，Univ Oxford, Inst Musculosleletal Sci, Botnar Res Ctr, Nuffield Dept Orthopaed Surg,Nuffield Orthopaed C, Oxford OX3 7LD, England.
EM graham.russell@ndos.ox.ac.uk
RI Hulley, Philippa/A 8538 2011; Russell, R/JEF 5877 2023; Xia,
   Zhidao/AAA 5192 2019; Russell, Robert Graham G/JEF 5877 2023
OI Hulley, Philippa/0000 0002 4994 2264; Dunford,
   James/0000 0002 9932 4042; Xia, Zhidao/0000 0002 2047 7282; Russell,
   Robert Graham G/0000 0002 4136 1828; Rogers, Michael/0000 0002 1818 9249
CR Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   Anderson HC, 2005, AM J PATHOL, V166, P1711, DOI 10.1016/S0002 9440(10)62481 9
   [Anonymous], 2001, BIOESSAYS, V23, P1, DOI 10.1002/1521 1878(200101)23:1<1::AID BIES1000>3.0.CO;2 O
   AZUMA Y, 1995, BONE, V16, P235, DOI 10.1016/8756 3282(94)00035 X
   BALENA R, 1993, J CLIN INVEST, V92, P2577, DOI 10.1172/JCI116872
   BASSETT CAL, 1969, LANCET, V2, P845
   Bauss F, 2002, J RHEUMATOL, V29, P2200
   Bauss F, 2004, OSTEOPOROSIS INT, V15, P423, DOI 10.1007/s00198 004 1612 7
   Bauss Frieder, 2004, Journal of Pharmacological and Toxicological Methods, V50, P25, DOI 10.1016/j.vascn.2003.11.003
   Benedict J J., 1982, Symposium CEMO (Centre dEtude des Maladies Osteoarticulaires de Geneve) IV. Diphosphonates and bone, P1
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Blomen Leo J. M. J., 1995, P111
   Bobyn JD, 2005, J BONE JOINT SURG BR, V87B, P416, DOI 10.1302/0301 620X.87B3
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Bone HG, 1997, J CLIN ENDOCR METAB, V82, P265, DOI 10.1210/jc.82.1.265
   BONEWALD L, 2007, ANN N Y ACAD SCI, V1402
   Bonnick S, 2006, J CLIN ENDOCR METAB, V91, P2631, DOI 10.1210/jc.2005 2602
   BOONEKAMP PM, 1986, BONE MINER, V1, P27
   Boonen S, 2005, OSTEOPOROSIS INT, V16, P1291, DOI 10.1007/s00198 005 1945 x
   Borah B, 2005, BONE, V37, P1, DOI 10.1016/j.bone.2005.03.017
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Christiansen C, 2003, OSTEOPOROSIS INT, V14, pS38
   Coleman RE, 2005, ANN ONCOL, V16, P687, DOI 10.1093/annonc/mdi162
   CONRAD KA, 1981, CLIN PHARMACOL THER, V30, P114, DOI 10.1038/clpt.1981.135
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Cremers S, 2002, EUR J CLIN PHARMACOL, V57, P883, DOI 10.1007/s00228 001 0411 8
   CREMERS S, 2004, THESIS U LEIDEN
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Delmas PD, 2004, BONE, V34, P599, DOI 10.1016/j.bone.2003.12.022
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   DUNFORD JE, 2007, KINETIC ANAL CONFORM
   Durchschlag E, 2006, J BONE MINER RES, V21, P1581, DOI 10.1359/JBMR.060701
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Eastell R, 2007, J BONE MINER RES, V22, P1656, DOI 10.1359/JBMR.07090B
   Ebetino FH, 2006, J BONE MINER RES, V21, pS342
   Ebetino FH, 1996, PHOSPHORUS SULFUR, V109, P217
   Ebetino FH, 1998, REV CONTEMP PHARMACO, V9, P233
   Ebetino Frank H., 1995, P139
   Ebrahimpour Arman, 1995, P125
   Emsley J., 2000, SORDID TALE MURDER F
   Eriksen EF, 2002, BONE, V31, P620, DOI 10.1016/S8756 3282(02)00869 4
   Fairney A, 1998, BRIT J RHEUMATOL, V37, P51
   Fedde KN, 1999, J BONE MINER RES, V14, P2015, DOI 10.1359/jbmr.1999.14.12.2015
   Finkelstein JS, 2006, J CLIN ENDOCR METAB, V91, P2882, DOI 10.1210/jc.2006 0190
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FLEISCH H, 1966, P SOC EXP BIOL MED, V122, P317
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   FLEISCH H, 1968, CALC TISS RES, VS  2, P10, DOI 10.1007/BF02065192
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   Fleisch H., 2000, BISPHOSPHONATES BONE
   FLEISCH HA, 1970, EUR J CLIN INVEST, V1, P12, DOI 10.1111/j.1365 2362.1970.tb00591.x
   FLORA L, 1981, METAB BONE DIS RELAT, V3, P289, DOI 10.1016/0221 8747(81)90045 X
   FOGELMAN I, 1978, J NUCL MED, V19, P270
   Follet H, 2007, BONE, V40, P1172, DOI 10.1016/j.bone.2006.12.052
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   FRANCIS MD, 1980, P 1 INT S DIPH THERA, P33
   FRANCIS MD, 1987, BONE SCANNING CLIN P, P7
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754
   GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693
   Gasser J. A., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P53
   GASSER JA, 2002, BONE S1, V30, pS14
   Geddes A D., 1994, Bone and Mineral Research, P265
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Green JR, 2002, DRUG DEVELOP RES, V55, P210, DOI 10.1002/ddr.10071
   Gurley KA, 2006, AM J HUM GENET, V79, P1017, DOI 10.1086/509881
   Harrington JT, 2004, CALCIFIED TISSUE INT, V74, P129, DOI 10.1007/s00223 003 0042 4
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Heaney RP, 2002, OSTEOPOROSIS INT, V13, P501, DOI 10.1007/s001980200061
   Hellstein JW, 2005, J ORAL MAXIL SURG, V63, P682, DOI 10.1016/j.joms.2005.01.010
   HENNEMAN ZJ, 2007, J BIOMED MAT RES A
   Ho AM, 2000, SCIENCE, V289, P265, DOI 10.1126/science.289.5477.265
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   Inamasu J, 2006, NEUROSURGERY, V58, P1027, DOI 10.1227/01.NEU.0000215867.87770.73
   JOHNSON S, 1998, REVS CONTEMP PHARM, V9
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kavanagh KL, 2006, J BIOL CHEM, V281, P22004, DOI 10.1074/jbc.M602603200
   Khan SA, 1997, J BONE MINER RES, V12, P1700, DOI 10.1359/jbmr.1997.12.10.1700
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kogianni G, 2004, LIFE SCI, V75, P2879, DOI 10.1016/j.lfs.2004.04.048
   Kurth AHA, 2005, BONE, V37, P204, DOI 10.1016/j.bone.2004.12.017
   Lai KA, 2005, J BONE JOINT SURG AM, V87A, P2155, DOI 10.2106/JBJS.D.02959
   Lawson MA, 2005, J BONE MINER RES, V20, pS396
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Leu CT, 2006, BONE, V38, P628, DOI 10.1016/j.bone.2005.07.023
   Liberman UA, 2006, INT J CLIN PRACT, V60, P1394, DOI 10.1111/j.1742 1241.2006.01148.x
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Ling Y, 2005, J MED CHEM, V48, P3130, DOI 10.1021/jm040132t
   Lipton A, 2007, CLIN BREAST CANCER, V7, pS14, DOI 10.3816/CBC.2007.s.002
   Little DG, 2003, J BONE MINER RES, V18, P2016, DOI 10.1359/jbmr.2003.18.11.2016
   Little DG, 2005, J BONE MINER RES, V20, P2044, DOI 10.1359/JBMR.050712
   Little DG, 2003, J BONE MINER RES, V18, P1300, DOI 10.1359/jbmr.2003.18.7.1300
   Little DG, 2005, J ORTHOP RES, V23, P862, DOI 10.1016/j.orthres.2004.11.015
   LOWIK CWGM, 1988, J BONE MINER RES, V3, P185
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Lundy MW, 2007, J BONE MINER RES, V22, pS443
   Mao JH, 2006, J AM CHEM SOC, V128, P14485, DOI 10.1021/ja061737c
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Mashiba T, 2005, J BONE MINER METAB, V23, P36, DOI 10.1007/BF03026321
   Mayhew PM, 2005, LANCET, V366, P129, DOI 10.1016/S0140 6736(05)66870 5
   McCloskey EV, 2007, J BONE MINER RES, V22, P135, DOI 10.1359/JBMR.061008
   McClung M, 2007, BONE, V41, P122, DOI 10.1016/j.bone.2007.03.011
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Menschutkin N., 1865, ANN CHEM PHARM, V133, P317
   Miller PD, 2007, SEMIN DIALYSIS, V20, P186, DOI 10.1111/j.1525 139X.2007.00271.x
   Miller Paul D, 2005, Curr Osteoporos Rep, V3, P103, DOI 10.1007/s11914 005 0018 6
   Mitchell DY, 2001, PHARMACEUT RES, V18, P166, DOI 10.1023/A:1011024200280
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Moreno B, 2001, BIOCHEM BIOPH RES CO, V284, P632, DOI 10.1006/bbrc.2001.5009
   Nakamura I, 1999, HUM GENET, V104, P492, DOI 10.1007/s004390050993
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nürnberg P, 2001, NAT GENET, V28, P37, DOI 10.1038/ng0501 37
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P1897, DOI 10.1210/jc.2005 0057
   PAPAPOULOS SE, 1995, BISPHOSPHONATES BONE, pCH15
   Papapoulos SE, 2006, BONE, V38, P613, DOI 10.1016/j.bone.2006.01.141
   PARFITT AM, 1976, METABOLISM, V25, P809, DOI 10.1016/0026 0495(76)90151 7
   Parker CC, 2005, BJU INT, V95, P935, DOI 10.1111/j.1464 410X.2005.05441.x
   Pendleton A, 2002, AM J HUM GENET, V71, P933, DOI 10.1086/343054
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Pols HAP, 1999, OSTEOPOROSIS INT, V9, P461, DOI 10.1007/PL00004171
   Power J, 2001, CALCIFIED TISSUE INT, V69, P13, DOI 10.1007/s00223 001 0013 6
   Price PA, 2002, J BIOL CHEM, V277, P3926, DOI 10.1074/jbc.M106366200
   Rauch F, 2005, AM J MED GENET C, V139C, P31, DOI 10.1002/ajmg.c.30072
   Recker R, 2004, J BONE MINER RES, V19, P1628, DOI 10.1359/JBMR.040710
   Recker R R, 2004, Osteoporos Int, V15, P231, DOI 10.1007/s00198 003 1530 0
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Reichenberger E, 2001, AM J HUM GENET, V68, P1321, DOI 10.1086/320612
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241
   REITSMA PH, 1980, CALCIFIED TISSUE INT, V32, P145, DOI 10.1007/BF02408534
   Rodriguez N, 2002, J INFECT DIS, V186, P138, DOI 10.1086/341074
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rogers MJ, 2004, CALCIFIED TISSUE INT, V75, P451, DOI 10.1007/s00223 004 0024 1
   ROGERS MJ, 1994, BIOCHEM J, V303, P303, DOI 10.1042/bj3030303
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141
   Ross JR, 2004, HEALTH TECHNOL ASSES, V8, pIII
   Roux C, 2004, CURR MED RES OPIN, V20, P433, DOI 10.1185/030079903125003125
   Ruf Nico, 2005, Hum Mutat, V25, P98, DOI 10.1002/humu.9297
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   RUSSELL RGG, 1970, CALC TISS RES, V6, P183, DOI 10.1007/BF02196199
   RUSSELL RGG, 1971, J CLIN INVEST, V50, P961, DOI 10.1172/JCI106589
   RUSSELL RGG, 1965, LANCET, V2, P461
   Sanders JM, 2004, J MED CHEM, V47, P375, DOI 10.1021/jm0303709
   Sanz Rodríguez CE, 2007, J BIOL CHEM, V282, P12377, DOI 10.1074/jbc.M607286200
   SATO M, 1990, J BONE MINER RES, V5, P31, DOI 10.1002/jbmr.5650050107
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   SCHIBLER D, 1968, CLIN SCI, V35, P363
   SIETSEMA WK, 1989, DRUG EXP CLIN RES, V15, P389
   Silverman SL, 2007, OSTEOPOROSIS INT, V18, P25, DOI 10.1007/s00198 006 0274 z
   Sirohi B, 2004, LANCET, V363, P875, DOI 10.1016/S0140 6736(04)15736 X
   SMITH R, 1971, LANCET, V1, P945
   STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Szabo CM, 2002, J MED CHEM, V45, P2185, DOI 10.1021/jm010412y
   Terkeltaub RA, 2001, AM J PHYSIOL CELL PH, V281, pC1, DOI 10.1152/ajpcell.2001.281.1.C1
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   THOMPSON K, 2006, BONEKEY OSTEOVISION, V3, P5, DOI DOI 10.1138/20060224
   Timms AE, 2002, RHEUMATOLOGY, V41, P725, DOI 10.1093/rheumatology/41.7.725
   TRECHSEL U, 1987, J CLIN INVEST, V80, P1679, DOI 10.1172/JCI113257
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   Van den Wyngaert T, 2006, ANN ONCOL, V17, P1197, DOI 10.1093/annonc/mdl294
   Van den Wyngaerta T, 2007, CURR OPIN ONCOL, V19, P315, DOI 10.1097/CCO.0b013e32819f820b
   vanBeek E, 1996, J BONE MINER RES, V11, P1492
   VONBAEYER H, 1897, BERICHTE DTSCH CHEM, V20, P1973
   Watts N, 2004, BONE, V34, pS99
   Watts NB, 2004, J CLIN DENSITOM, V7, P255, DOI 10.1385/JCD:7:3:255
   Watts NB, 2005, J BONE MINER RES, V20, P2097, DOI 10.1359/JBMR.050814
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Williams CJ, 2002, AM J HUM GENET, V71, P985, DOI 10.1086/343053
   WRONSKI TJ, 1991, J BONE MINER RES, V6, P387
   Zhang Y, 2005, ARTHRITIS RHEUM US, V52, P1110, DOI 10.1002/art.20978
NR 196
TC 322
Z9 371
U1 0
U2 54
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077 8923
BN 978 1 57331 728 3
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2007
VL 1117
BP 209
EP 257
DI 10.1196/annals.1402.089
PG 49
WC Endocrinology & Metabolism; Multidisciplinary Sciences; Pathology;
   Physiology
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Science & Technology   Other Topics;
   Pathology; Physiology
GA BHD19
UT WOS:000252266600020
PM 18056045
DA 2025 08 17
ER

PT J
AU Bai, YD
   Yang, FS
   Xuan, K
   Bai, YX
   Wu, BL
AF Bai, Yu Di
   Yang, Fu Sheng
   Xuan, Kun
   Bai, Yu Xiang
   Wu, Bu Ling
TI Inhibition of RANK/RANKL signal transduction pathway: A promising
   approach for osteoporosis treatment
SO MEDICAL HYPOTHESES
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; BONE RESORPTION; OSTEOPROTEGERIN LIGAND;
   REGULATORY MECHANISMS; RANK LIGAND; RECEPTOR; CELLS; OSTEOBLAST;
   EXPRESSION
AB Osteoporosis is a bone disease causing impaired bone strength. It is characterized by increased osteoclast formation or enhanced bone resorption, leading to an increased risk of fragility fractures. its prevalence increases with age. The advent of an aging population suggests that progressively more individuals will develop this disease in the aging population. A number of drugs for the prevention and treatment of osteoporosis act by inhibiting bone resorption. However, the effectiveness of osteoporosis treatment in clinical practice is limited. Since the osteoclast is the only cell in the body that is capable of resorbing bone, understanding its biology will be necessary for developing a new therapeutic approach for osteoporosis. Recently, it was discovered that the receptor activator of nuclear factor kappa B (RANK)/RANK Ligand (RANKL)/osteoprotegerin (OPG) system is an important signal transduction pathway that regulates osteoclast formation. The binding of OPG to RANKL inhibits the binding between RANKL and RANK; this, in turn, prevents osteoclast precursors from differentiating and fusing to form mature osteoclasts. Therefore, the inhibition of the RANK/RANKL pathway inhibits osteoclast formation, differentiation, activation, and bone resorption. A potential clinical antiresorptive therapy can be developed by using an anti RANKL monoclonal antibody, such as denosumab, that binds to RANKL with high affinity and specificity and blocks RANKL RANK interactions. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Bai, Yu Xiang] Fourth Mil Med Univ, Dept Hlth Stat, Xian 710033, Peoples R China.
   [Bai, Yu Di; Yang, Fu Sheng; Xuan, Kun] Fourth Mil Med Univ, Sch Stomatol, Dept Paediat Dent, Xian 710032, Peoples R China.
   [Wu, Bu Ling] Fourth Mil Med Univ, Sch Stomatol, Dept Operat Dent & Endodont, Xian 710032, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University
RP Bai, YX (通讯作者)，Fourth Mil Med Univ, Dept Hlth Stat, 17 W Changle Rd, Xian 710033, Peoples R China.
EM baiyux@fmmu.edu.cn; wu_bu ling@163.com
OI Wu, Buling/0000 0002 9678 6962
CR Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Blair JM, 2007, INT J BIOCHEM CELL B, V39, P1077, DOI 10.1016/j.biocel.2006.11.008
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   CHRISCHILLES EA, 1991, ARCH INTERN MED, V151, P2026, DOI 10.1001/archinte.151.10.2026
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Gori F, 2000, ENDOCRINOLOGY, V141, P4768, DOI 10.1210/en.141.12.4768
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   KEARNS AE, 2007, ENDOCR REV, P5
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Schwarz EM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2171
   Vega D, 2007, J CLIN ENDOCR METAB, V92, P4514, DOI 10.1210/jc.2007 0646
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 21
TC 22
Z9 30
U1 0
U2 10
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD AUG
PY 2008
VL 71
IS 2
BP 256
EP 258
DI 10.1016/j.mehy.2008.03.021
PG 3
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 331LN
UT WOS:000258013800017
PM 18445511
DA 2025 08 17
ER

PT J
AU Frey, JL
   Stonko, DP
   Faugere, MC
   Riddle, RC
AF Frey, Julie L.
   Stonko, David P.
   Faugere, Marie Claude
   Riddle, Ryan C.
TI Hypoxia inducible factor 1α restricts the anabolic actions of
   parathyroid hormone
SO BONE RESEARCH
LA English
DT Article
ID OSTEOBLAST LIKE CELLS; BONE HISTOMORPHOMETRY; MAMMALIAN TARGET;
   RAPAMYCIN MTOR; GROWTH FACTOR; IGF I; RECEPTOR; EXPRESSION; HIF 1;
   ACTIVATION
AB The hypoxia inducible factors (Hifs) are evolutionarily conserved transcriptional factors that control homeostatic responses to low oxygen. In developing bone, Hif 1 generated signals induce angiogenesis necessary for osteoblast specification, but in mature bone, loss of Hif 1 in osteoblasts resulted in a more rapid accumulation of bone. These findings suggested that Hif 1 exerts distinct developmental functions and acts as a negative regulator of bone formation. To investigate the function of Hif 1 alpha in osteoanabolic signaling, we assessed the effect of Hif 1 alpha loss of function on bone formation in response to intermittent parathyroid hormone (PTH). Mice lacking Hif 1 alpha in osteoblasts and osteocytes form more bone in response to PTH, likely through a larger increase in osteoblast activity and increased sensitivity to the hormone. Consistent with this effect, exposure of primary mouse osteoblasts to PTH resulted in the rapid induction of Hif 1 alpha protein levels via a post transcriptional mechanism. The enhanced anabolic response appears to result from the removal of Hif 1 alpha mediated suppression of beta catenin transcriptional activity. Together, these data indicate that Hif 1 alpha functions in the mature skeleton to restrict osteoanabolic signaling. The availability of pharmacological agents that reduce Hif 1 alpha function suggests the value in further exploration of this pathway to optimize the therapeutic benefits of PTH.
C1 [Frey, Julie L.; Stonko, David P.; Riddle, Ryan C.] Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD 21218 USA.
   [Faugere, Marie Claude] Univ Kentucky, Div Nephrol Bone & Mineral Metab, Lexington, KY USA.
   [Riddle, Ryan C.] Vet Adm Med Ctr, Baltimore, MD 21218 USA.
C3 Johns Hopkins University; University of Kentucky; US Department of
   Veterans Affairs; Veterans Health Administration (VHA)
RP Riddle, RC (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD 21218 USA.
EM rriddle1@jhmi.edu
OI Stonko, David/0000 0002 2804 2857
FU Career Development Award from the Veterans Administration [BX001284]
FX We thank Dr C Lynch for providing the mTOR<SUP>flox/flox</SUP> mice.
   Support was provided by a Career Development Award (RCR, BX001284) from
   the Veterans Administration.
CR ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   Akeno N, 2002, ENDOCRINOLOGY, V143, P420, DOI 10.1210/en.143.2.420
   Alam H, 2004, J BIOL CHEM, V279, P19431, DOI 10.1074/jbc.M401235200
   Blancquaert S, 2010, MOL ENDOCRINOL, V24, P1453, DOI 10.1210/me.2010 0087
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804
   Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002
   Childress P, 2011, CALCIFIED TISSUE INT, V89, P74, DOI 10.1007/s00223 011 9496 y
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   Feldser D, 1999, CANCER RES, V59, P3915
   FINKELSTEIN JS, 1994, NEW ENGL J MED, V331, P1618, DOI 10.1056/NEJM199412153312404
   Girotra M, 2006, REV ENDOCR METAB DIS, V7, P113, DOI 10.1007/s11154 006 9007 z
   Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104
   Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583
   Hansen S, 2013, J BONE MINER RES, V28, P736, DOI 10.1002/jbmr.1784
   Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004 7014.2002
   Iida Klein A, 2002, J BONE MINER RES, V17, P808, DOI 10.1359/jbmr.2002.17.5.808
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395 06
   Kurland ES, 2000, J CLIN ENDOCR METAB, V85, P3069, DOI 10.1210/jc.85.9.3069
   Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200
   Lang CH, 2010, AM J PHYSIOL ENDOC M, V298, pE1283, DOI 10.1152/ajpendo.00676.2009
   Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106
   Li CJ, 2013, J BONE MINER RES, V28, P2094, DOI 10.1002/jbmr.1962
   Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200
   Milkiewicz M, 2007, J PHYSIOL LONDON, V583, P753, DOI 10.1113/jphysiol.2007.136325
   Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200
   Niziolek PJ, 2009, J CELL PHYSIOL, V221, P579, DOI 10.1002/jcp.21887
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Prisby R, 2011, J BONE MINER RES, V26, P2583, DOI 10.1002/jbmr.459
   Qiu T, 2010, NAT CELL BIOL, V12, P224, DOI 10.1038/ncb2022
   Riddle RC, 2011, J BIOL CHEM, V286, P44449, DOI 10.1074/jbc.M111.276683
   Robling AG, 2011, ENDOCRINOLOGY, V152, P2963, DOI 10.1210/en.2011 0049
   Robling AG, 2009, J CELL PHYSIOL, V219, P734, DOI 10.1002/jcp.21717
   RODAN SB, 1974, J BIOL CHEM, V249, P3068
   Rubin MR, 2003, CLIN GERIATR MED, V19, P415, DOI 10.1016/S0749 0690(02)00074 5
   Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005
   Semenza GL, 2000, GENE DEV, V14, P1983
   Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006 2952(02)01168 1
   Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092 8674(01)00518 9
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   Shomento SH, 2010, J CELL BIOCHEM, V109, P196, DOI 10.1002/jcb.22396
   Simon MC, 2006, ADV EXP MED BIOL, V588, P165
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Wang YM, 2007, J BONE MINER RES, V22, P1329, DOI 10.1359/JBMR.070517
   Wong CCL, 2012, J MOL MED, V90, P803, DOI 10.1007/s00109 011 0855 y
   Wu XW, 2010, CELL STEM CELL, V7, P571, DOI 10.1016/j.stem.2010.09.012
   Yakar S, 2006, J ENDOCRINOL, V189, P289, DOI 10.1677/joe.1.06657
   Yamaguchi M, 2005, ENDOCRINOLOGY, V146, P2620, DOI 10.1210/en.2004 1511
   Yamashita R, 2008, NUCLEIC ACIDS RES, V36, P3707, DOI 10.1093/nar/gkn248
   Zhang HP, 2008, STAT INTERFACE, V1, P1
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
NR 59
TC 25
Z9 26
U1 1
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD MAY 13
PY 2014
VL 2
AR 14005
DI 10.1038/boneres.2014.5
PG 10
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AT5QP
UT WOS:000344997400002
PM 26273518
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhou, SR
   Dai, QG
   Huang, XR
   Jin, AT
   Yang, YL
   Gong, XY
   Xu, HY
   Gao, X
   Jiang, LY
AF Zhou, Siru
   Dai, Qinggang
   Huang, Xiangru
   Jin, Anting
   Yang, Yiling
   Gong, Xinyi
   Xu, Hongyuan
   Gao, Xin
   Jiang, Lingyong
TI STAT3 is critical for skeletal development and bone homeostasis by
   regulating osteogenesis
SO NATURE COMMUNICATIONS
LA English
DT Article
ID HYPER IGE SYNDROME; SIGNAL TRANSDUCER; MUTATIONS; MICE; DEFICIENCY;
   RESORPTION; INFECTIONS; FRACTURES; ACTIVATOR; DEFECTS
AB Autosomal dominant hyper immunoglobulin E syndrome (AD HIES) is associated with mutations in STAT3, and clinical manifestations include skeletal deformities. Here, the authors show that inactivation of STAT3 in osteoblast induces AD HIES like skeletal defects by impairing osteogenesis, and show that pharmacological STAT3 activation rescues the phenotype.
   Skeletal deformities are typical AD HIES manifestations, which are mainly caused by heterozygous and loss of function mutations in Signal transducer and activator of transcription 3 (STAT3). However, the mechanism is still unclear and the treatment strategy is limited. Herein, we reported that the mice with Stat3 deletion in osteoblasts, but not in osteoclasts, induced AD HIES like skeletal defects, including craniofacial malformation, osteoporosis, and spontaneous bone fracture. Mechanistic analyses revealed that STAT3 in cooperation with Msh homeobox 1(MSX1) drove osteoblast differentiation by promoting Distal less homeobox 5(Dlx5) transcription. Furthermore, pharmacological activation of STAT3 partially rescued skeletal deformities in heterozygous knockout mice, while inhibition of STAT3 aggravated bone loss. Taken together, these data show that STAT3 is critical for modulating skeletal development and maintaining bone homeostasis through STAT3 indcued osteogenesis and suggest it may be a potential target for treatments.
C1 [Zhou, Siru; Huang, Xiangru; Jin, Anting; Yang, Yiling; Gong, Xinyi; Xu, Hongyuan; Gao, Xin; Jiang, Lingyong] Shanghai Jiao Tong Univ, Coll Stomatol,Natl Clin Res Ctr Oral Dis,Shanghai, Sch Med,Shanghai Peoples Hosp 9,Natl Ctr Stomatol, Ctr Craniofacial Orthodont,Dept Oral & Cranio Max, Shanghai 200011, Peoples R China.
   [Dai, Qinggang] Shanghai Jiao Tong Univ, Sch Med, Coll Stomatol,Natl Ctr Stomatol,Shanghai Key Lab, Dent Ctr 2,Shanghai Peoples Hosp 9,Natl Clin Res, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Jiang, LY (通讯作者)，Shanghai Jiao Tong Univ, Coll Stomatol,Natl Clin Res Ctr Oral Dis,Shanghai, Sch Med,Shanghai Peoples Hosp 9,Natl Ctr Stomatol, Ctr Craniofacial Orthodont,Dept Oral & Cranio Max, Shanghai 200011, Peoples R China.
EM jianglingyong@sjtu.edu.cn
RI huang, xiangru/HJH 8638 2023; Qinggang, Dai/HLV 8212 2023
OI Yang, Yiling/0000 0001 9044 2897; xu, hongyuan/0000 0002 5558 1629; Dai,
   Qinggang/0000 0002 8177 2496
FU National Natural Science Foundation of China (NSFC) [81870740, 81570950,
   82071083, 81800949, 81371121]; Program of Shanghai Academic/Technology
   Research Leader [20XD1422300]; Cross disciplinary Research Fund of
   Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School
   of Medicine [JYJC201902]; Shanghai "Rising Stars of Medical Talent"
   Youth Development Program Outstanding Youth Medical Talents
   [SHWJRS2019 72]; Clinical Research Plan of SHDC [SHDC2020CR4084];
   Project of Biobank of Shanghai Ninth People's Hospital, Shanghai Jiao
   Tong University School of Medicine [YBKB201909]; Clinical Research
   Program of Ninth People's Hospital, affiliated to Shanghai Jiao Tong
   University School of Medicine [JYLJ201807]; National Science Foundation
   of Shanghai [21ZR1436900]; SHIPM mu Fund from the Shanghai Institute of
   Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong
   University School of Medicine [JC201809]; Innovation Research Team of
   High Level Local Universities in Shanghai [SSMU ZLCX20180501]
FX We thank Prof. Weiguo Zou and Prof. Jinsong Li, State Key Laboratory of
   Cell Biology, CAS Center for Excellence in Molecular Cell Sciences,
   Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of
   Sciences, University of Chinese Academy of Sciences, for reagents, mice
   and helpful discussion. We thank Prof. Xinhua Feng for reagents. We
   thank Dr. Qian Bian from the Shanghai Institute of Precision Medicine,
   Shanghai Ninth People's Hospital for useful discussion. We also thank
   the Cell Biology Core Facility and the Animal Core Facility of Shanghai
   Institute of Biochemistry and Cell Biology and the Laboratory for
   Digitized Stomatology and Research Center for Craniofacial Anomalies of
   Shanghai Ninth People's Hospital for assistance. Thanks for the support
   of bioimaging facility, Shanghai Institute of Precision Medicine. This
   work was supported in part by grants from the National Natural Science
   Foundation of China (NSFC) [81870740, 81570950, 82071083 81800949,
   81371121], the Program of Shanghai Academic/Technology Research Leader
   (20XD1422300), Shanghai "Rising Stars of Medical Talent" Youth
   Development Program Outstanding Youth Medical Talents (SHWJRS2019 72),
   the Cross disciplinary Research Fund of Shanghai Ninth People's
   Hospital, Shanghai Jiao Tong University School of Medicine (JYJC201902),
   Clinical Research Plan of SHDC (SHDC2020CR4084), the Project of Biobank
   of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University
   School of Medicine (YBKB201909), the Clinical Research Program of Ninth
   People's Hospital, affiliated to Shanghai Jiao Tong University School of
   Medicine [JYLJ201807], the National Science Foundation of Shanghai
   (21ZR1436900), the SHIPM mu Fund from the Shanghai Institute of
   Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong
   University School of Medicine (JC201809), the Innovation Research Team
   of High Level Local Universities in Shanghai (SSMU ZLCX20180501).
CR Acampora D, 1999, DEVELOPMENT, V126, P3795
   Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   Alappat S, 2003, CELL RES, V13, P429, DOI 10.1038/sj.cr.7290185
   Artigas N, 2017, CELL DEATH DIFFER, V24, P2022, DOI 10.1038/cdd.2017.113
   Asano T, 2021, J EXP MED, V218, DOI 10.1084/jem.20202592
   Béziat V, 2020, J EXP MED, V217, DOI 10.1084/jem.20191804
   Béziat V, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat4956
   Blin Wakkach C, 2001, P NATL ACAD SCI USA, V98, P7336, DOI 10.1073/pnas.131497098
   Bocchini CE, 2016, BLOOD, V128, P3061, DOI 10.1182/blood 2016 02 702373
   Chandesris MO, 2012, MEDICINE, V91, pE1, DOI 10.1097/MD.0b013e31825f95b9
   Chaudhry A, 2009, SCIENCE, V326, P986, DOI 10.1126/science.1172702
   Chowdhury P, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.12
   Chung IH, 2010, GENESIS, V48, P645, DOI 10.1002/dvg.20671
   COHENSOLAL M, 1995, CLIN IMMUNOL IMMUNOP, V76, P75, DOI 10.1006/clin.1995.1090
   Corry KA, 2019, BONE REP, V11, DOI 10.1016/j.bonr.2019.100218
   Dai QG, 2017, CELL DEATH DIFFER, V24, P1886, DOI 10.1038/cdd.2017.110
   Davey RA, 2012, TRANSGENIC RES, V21, P885, DOI 10.1007/s11248 011 9581 z
   Depew MJ, 1999, DEVELOPMENT, V126, P3831
   Dibbs R, 2020, J CRANIOFAC SURG, V31, pE251, DOI 10.1097/SCS.0000000000006187
   Dirckx N, 2019, NAT REV ENDOCRINOL, V15, P651, DOI 10.1038/s41574 019 0246 y
   Dmitrieva NI, 2020, J CLIN INVEST, V130, P4167, DOI 10.1172/JCI135490
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Flanagan SE, 2014, NAT GENET, V46, P812, DOI 10.1038/ng.3040
   Grimbacher B, 2005, IMMUNOL REV, V203, P244, DOI 10.1111/j.0105 2896.2005.00228.x
   Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904
   Han J, 2009, DEVELOPMENT, V136, P4225, DOI 10.1242/dev.036723
   He LJ, 2017, J CLIN INVEST, V127, P2968, DOI 10.1172/JCI93868
   Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687
   Huang W, 2015, TRANSGENIC RES, V24, P167, DOI 10.1007/s11248 014 9828 6
   JingWu, 2017, J CLIN IMMUNOL, V37, P166, DOI 10.1007/s10875 017 0369 7
   Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8
   Keles S, 2016, J ALLERGY CLIN IMMUN, V138, P1384, DOI 10.1016/j.jaci.2016.04.023
   Kodama Y, 1997, J BONE MINER RES, V12, P1058, DOI 10.1359/jbmr.1997.12.7.1058
   Kreins AY, 2015, J EXP MED, V212, P1641, DOI 10.1084/jem.20140280
   LEUNG DYM, 1988, J IMMUNOL, V140, P84
   Liu Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11149
   Lloyd SA, 2014, J BONE MINER RES, V29, P1118, DOI 10.1002/jbmr.2113
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Marie PJ, 2013, NAT REV ENDOCRINOL, V9, P288, DOI 10.1038/nrendo.2013.4
   Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096
   Myles IA, 2018, J CLIN INVEST, V128, P3595, DOI 10.1172/JCI121486
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092 8674(02)00701 8
   Renner ED, 2008, J ALLERGY CLIN IMMUN, V122, P181, DOI 10.1016/j.jaci.2008.04.037
   Sassi A, 2014, J ALLERGY CLIN IMMUN, V133, P1410, DOI 10.1016/j.jaci.2014.02.025
   Scheuerman O, 2013, J CLIN IMMUNOL, V33, P903, DOI 10.1007/s10875 013 9895 0
   Schwerd T, 2017, J EXP MED, V214, P2547, DOI 10.1084/jem.20161810
   Shahin T, 2019, HAEMATOLOGICA, V104, P609, DOI 10.3324/haematol.2018.194233
   Sowerwine KJ, 2014, J CLIN IMMUNOL, V34, P260, DOI 10.1007/s10875 013 9982 2
   Spencer S, 2019, J EXP MED, V216, P1986, DOI 10.1084/jem.20190344
   Boone ATS, 2016, PEDIATR BLOOD CANCER, V63, P2054, DOI 10.1002/pbc.26119
   Steward Tharp SM, 2014, BLOOD, V123, P2978, DOI 10.1182/blood 2013 09 523167
   Sugii H, 2017, DEVELOPMENT, V144, P4037, DOI 10.1242/dev.155176
   Vogel TP, 2015, J CLIN IMMUNOL, V35, P615, DOI 10.1007/s10875 015 0187 8
   Wang G, 2016, ONCOGENE, V35, P4422, DOI 10.1038/onc.2016.145
   Wang X, 2020, CELLS BASEL, V9, DOI 10.3390/cells9020331
   Weber Nordt RM, 1998, LEUKEMIA LYMPHOMA, V28, P459, DOI 10.3109/10428199809058353
   Wilkie AOM, 2001, NAT REV GENET, V2, P458, DOI 10.1038/35076601
   Woellner C, 2010, J ALLERGY CLIN IMMUN, V125, P424, DOI 10.1016/j.jaci.2009.10.059
   Yang YL, 2019, J BIOL CHEM, V294, P15395, DOI 10.1074/jbc.RA119.010139
   Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506
   Zhang ZY, 2005, BIOCHEM BIOPH RES CO, V328, P800, DOI 10.1016/j.bbrc.2005.01.019
   Zhou HK, 2011, BONE, V49, P404, DOI 10.1016/j.bone.2011.04.020
   Ziros PG, 2004, J BONE MINER RES, V19, P1892, DOI 10.1359/JBMR.040701
NR 65
TC 73
Z9 82
U1 7
U2 69
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD NOV 25
PY 2021
VL 12
IS 1
AR 6891
DI 10.1038/s41467 021 27273 w
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA XD7EG
UT WOS:000722866700021
PM 34824272
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, L
   Huang, XY
   Qin, JR
   Qi, BY
   Sun, CR
   Guo, XY
   Liu, QQ
   Liu, YC
   Ma, Y
   Wei, X
   Zhang, YL
AF Wang, Liang
   Huang, Xinyi
   Qin, Jinran
   Qi, Baoyu
   Sun, Chuanrui
   Guo, Xiangyun
   Liu, Qingqing
   Liu, Yichen
   Ma, Yong
   Wei, Xu
   Zhang, Yili
TI The Role of Traditional Chinese Medicines in the Treatment of
   Osteoporosis
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article; Early Access
DE Osteoporosis; Bone Remodeling; Traditional Chinese Medicine; Bioactive
   Constituents; Mechanism; Review
ID MESENCHYMAL STEM CELLS; FRUCTUS LIGUSTRI LUCIDI; NF KAPPA B; OXIDATIVE
   STRESS; SIGNALING PATHWAY; TOTAL FLAVONOIDS; BONE LOSS; OSTEOGENIC
   DIFFERENTIATION; POPULATION PHARMACOKINETICS; OSTEOBLAST PROLIFERATION
AB Osteoporosis (OP) represents a substantial public health issue and is associated with increasing rates of morbidity and mortality. It is characterized by reduced bone mineral density, deterioration of bone tissue quality, disruption of the microarchitecture of bones, and compromised bone strength. These changes may be attributed to the following factors: intercellular communication between osteoblasts and osteoclasts; imbalanced bone remodeling; imbalances between osteogenesis and adipogenesis; imbalances in hormonal regulation; angiogenesis; chronic inflammation; oxidative stress; and intestinal microbiota imbalances. Treating a single aspect of the disease is insufficient to address its multifaceted nature. In recent decades, traditional Chinese medicine (TCM) has shown great potential in the treatment of OP, and the therapeutic effects of Chinese patent drugs and Chinese medicinal herbs have been scientifically proven. TCMs, which contain multiple components, can target the diverse pathogeneses of OP through a multitargeted approach. Herbs such as XLGB, JTG, GSB, Yinyanghuo, Gusuibu, Buguzhi, and Nvzhenzi are among the TCMs that can be used to treat OP and have demonstrated promising effects in this context. They exert their therapeutic effects by targeting various pathways involved in bone metabolism. These TCMs balance the activity of osteoblasts (bone forming cells) and osteoclasts (bone resorbing cells), and they exhibit anti inflammatory, immunomodulatory, anti oxidative, and estrogen like functions. These multifaceted mechanisms underlie the efficacy of these herbs in the management and treatment of OP. Herein, we examine the efficacy of various Chinese herbs and Chinese patent drugs in treating OP by reviewing previous clinical trials and basic experiments, and we examine the potential mechanism of these therapies to provide evidence regarding the use of TCM for treating OP.
C1 [Wang, Liang; Qin, Jinran; Guo, Xiangyun; Liu, Qingqing; Liu, Yichen; Ma, Yong; Zhang, Yili] Nanjing Univ Chinese Med, Sch Integrated Chinese & Western Med, 138 Xianlin Ave, Nanjing 210023, Peoples R China.
   [Huang, Xinyi] Nanjing Med Univ, Sch Publ Hlth, P, R China, Nanjing 210029, Peoples R China.
   [Qi, Baoyu; Sun, Chuanrui; Wei, Xu] China Acad Chinese Med Sci, Wangjing Hosp, 6 Zhonghuan South Rd, Beijing 100102, Peoples R China.
   [Ma, Yong] Nanjing Univ Chinese Med, Jiangsu CM Clin Innovat Ctr Degenerat Bone & Joint, Wuxi TCM Hosp, Wuxi 214071, Peoples R China.
   [Wei, Xu] Inst Orthopaed Beijing Integrat Med, Beijing 100061, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing Medical University;
   China Academy of Chinese Medical Sciences; Wang Jing Hospital, CACMS;
   Nanjing University of Chinese Medicine
RP Ma, Y; Zhang, YL (通讯作者)，Nanjing Univ Chinese Med, Sch Integrated Chinese & Western Med, 138 Xianlin Ave, Nanjing 210023, Peoples R China.; Wei, X (通讯作者)，China Acad Chinese Med Sci, Wangjing Hosp, 6 Zhonghuan South Rd, Beijing 100102, Peoples R China.
EM 260758@njucm.edu.cn; weixu.007@163.com; zhangyili823@126.com
RI Huang, Xinyi/KIL 5964 2024; Sun, Chuanrui/MIK 4968 2025; liu,
   yang/HHZ 8976 2022; Li, Mengyuan/GZM 6335 2022
OI Guo, Xiangyun/0009 0004 2853 6859; sun, chuan rui/0000 0003 0185 0499;
   Wang, Liang/0009 0004 9980 3440; Wei, Xu/0000 0001 6723 9604
FU National Natural Science Foundation of China [82205140, 82174416,
   82374497, U23A20505, T2341023]; Basic Research Program of Jiangsu
   Province (Natural Science Foundation) [BK20220468]; National Natural
   Science Foundation of China (NSFC) Matching Project of Nanjing
   University of Chinese Medicine [XPT82205140]; Young Talent Lifting
   Project of the Chinese Society of Traditional Chinese Medicine
   [CACM 2022 QNRC2 B28]; Foundation of Jiangsu CM Clinical Innovation
   Centre of Degenerative Bone & Joint Disease (Jiangsu science and
   education of traditional Chinese medicine) [4]
FX This study was supported by the National Natural Science Foundation of
   China (grantnos. 82205140, 82174416, 82374497, U23A20505 and T2341023),
   the Basic Research Program of Jiangsu Province (Natural Science
   Foundation; grant no. BK20220468), the National Natural Science
   Foundation of China (NSFC) Matching Project of Nanjing University of
   Chinese Medicine (grant no. XPT82205140), the Young Talent Lifting
   Project of the Chinese Society of Traditional Chinese Medicine
   (CACM 2022 QNRC2 B28), and the Foundation of Jiangsu CM Clinical
   Innovation Centre of Degenerative Bone & Joint Disease (Jiangsu science
   and education of traditional Chinese medicine2021 No.4).
CR Abdurahman A, 2022, BONE, V157, DOI 10.1016/j.bone.2022.116346
   Abiramasundari G, 2018, J AYURVEDA INTEGR ME, V9, P161, DOI 10.1016/j.jaim.2017.04.003
   Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Allison H, 2019, AM J PHYSIOL CELL PH, V317, pC969, DOI 10.1152/ajpcell.00168.2019
   Aspray Terry J, 2019, Subcell Biochem, V91, P453, DOI 10.1007/978 981 13 3681 2_16
   Byun MR, 2012, BONE, V50, P364, DOI 10.1016/j.bone.2011.10.035
   Cai B, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/792161
   Cao MYJ, 2023, J ETHNOPHARMACOL, V301, DOI 10.1016/j.jep.2022.115789
   Chai S, 2019, PHYTOMEDICINE, V64, DOI 10.1016/j.phymed.2019.153063
   Chen BB, 2017, MOLECULES, V22, DOI 10.3390/molecules22091469
   Chen FP, 2022, BIOACT MATER, V10, P335, DOI 10.1016/j.bioactmat.2021.09.001
   Chen GH, 2017, PLANTA MED, V83, P1264, DOI 10.1055/s 0043 108761
   Chen JM, 2019, EUR J PHARMACOL, V856, DOI 10.1016/j.ejphar.2019.172418
   Chen LL, 2023, CHIN MED UK, V18, DOI 10.1186/s13020 022 00704 6
   Chen LH., 2021, CHINA PHARMACY, V32, P697, DOI [DOI 10.6039/j.issn.1001 0408.2021.06.09, 10.6039/j.issn.1001 0408.2021.06.09]
   Chen L, 2021, FREE RADICAL BIO MED, V163, P356, DOI 10.1016/j.freeradbiomed.2020.12.235
   Chen WH, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1010937
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Cheng BR, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.870277
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Cheng L, 2018, AM J TRANSL RES, V10, P1457
   Chinese Society of Osteoporosis and Bone Mineral Research, 2023, Gen Pract China, V26, P1671, DOI 10.12114/j.issn.1007 9572.2023.0121
   Chiou WF, 2011, LIFE SCI, V88, P335, DOI 10.1016/j.lfs.2010.12.009
   Cryan JF, 2019, PHYSIOL REV, V99, P1877, DOI 10.1152/physrev.00018.2018
   Dar Hamid Y, 2018, Bone Rep, V8, P46, DOI 10.1016/j.bonr.2018.02.001
   Diomede F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093242
   Diseases S.P.G.f.t.C.A.G.o.T.C.M.i.T.P., 2022, Chin. J. Integr. Tradit. West. Medi, V42, P393
   Donnapee S, 2014, J ETHNOPHARMACOL, V157, P292, DOI 10.1016/j.jep.2014.09.032
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Essawy AE, 2021, PEERJ, V9, DOI 10.7717/peerj.11930
   Feng R, 2019, AM J CHINESE MED, V47, P457, DOI 10.1142/S0192415X1950023X
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Fu R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14076 3
   Gao L, 2008, BIOL PHARM BULL, V31, P2245, DOI 10.1248/bpb.31.2245
   Gregson CL, 2022, ARCH OSTEOPOROS, V17, DOI 10.1007/s11657 022 01061 5
   Gu CZ, 2018, NAT PROD RES, V32, P294, DOI 10.1080/14786419.2017.1356833
   Guan J., 2021, J. Liaoning. Univ. TCM, V23, P57, DOI [10.13194/j.issn.1673 842x.2021.02.014, DOI 10.13194/J.ISSN.1673 842X.2021.02.014]
   [郭晛 Guo Xian], 2023, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V38, P1208
   Han JF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181175
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   He XR, 2017, J ETHNOPHARMACOL, V203, P260, DOI 10.1016/j.jep.2017.03.035
   Hu H, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/8412468
   Huang AY, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1011561
   Huang M., 2021, Chin. J. Tissu. Engine. Rese, V25, P5116
   Huang Q, 2014, BONE, V66, P306, DOI 10.1016/j.bone.2014.06.010
   Huang YQ, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10372
   Iantomasi T, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043772
   Inchingolo AM, 2023, EUR REV MED PHARMACO, V27, P2659, DOI 10.26355/eurrev_202303_31803
   Ji Z, 2015, IN VITRO CELL DEV AN, V51, P950, DOI 10.1007/s11626 015 9915 x
   Jing L, 2018, MOL MED REP, V17, P2415, DOI 10.3892/mmr.2017.8128
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Karimi SM, 2024, J TRADIT COMPL MED, V14, P1, DOI 10.1016/j.jtcme.2023.08.001
   Ke K, 2016, SCI REP UK, V6, DOI 10.1038/srep35233
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim B, 2018, PHYTOMEDICINE, V51, P181, DOI 10.1016/j.phymed.2018.06.020
   Kim CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010125
   Kim HJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061467
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kimball JS, 2021, J BONE JOINT SURG AM, V103, P1451, DOI 10.2106/JBJS.20.00989
   Kong XH, 2018, PHYTOTHER RES, V32, P115, DOI 10.1002/ptr.5955
   Krum SA, 2010, NAT REV RHEUMATOL, V6, P607, DOI 10.1038/nrrheum.2010.133
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Kwak HB, 2008, EUR J PHARMACOL, V601, P30, DOI 10.1016/j.ejphar.2008.10.034
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Lee WS, 2014, INFLAMMATION, V37, P1221, DOI 10.1007/s10753 014 9849 6
   Li CX, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.579323
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Li J., 2017, Chin. J. Prosth, V18, P28
   Li Li Li Li, 2016, Journal of Hainan Medical University, V22, P1809
   Li S., 2024, Liaoning. J. Tradit. Chin. Medi, V1, P1
   Li SY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.675470
   Li WT, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00265
   Li XL, 2022, PHARM BIOL, V60, P2098, DOI 10.1080/13880209.2022.2132029
   Li X, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/4186102
   Li XT, 2012, INT J MOL SCI, V13, P1747, DOI 10.3390/ijms13021747
   Li YH, 2015, BBA GEN SUBJECTS, V1850, P813, DOI 10.1016/j.bbagen.2015.01.007
   Liang GuangSheng Liang GuangSheng, 2016, Chinese Journal of Integrated Traditional and Western Medicine, V36, P614
   Liang HT, 2022, J ORTHOP TRANSL, V35, P53, DOI 10.1016/j.jot.2022.05.002
   Liao CS, 2017, BONE, V101, P10, DOI 10.1016/j.bone.2017.04.003
   Lin X, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.796227
   Liu F, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.101963
   Liu MQ, 2021, J ETHNOPHARMACOL, V275, DOI 10.1016/j.jep.2021.114129
   Liu Q, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.593820
   Liu YB, 2020, Chin. J. Clin. Rational Drug. Use, V13, P77
   Lu LY, 2021, FASEB J, V35, DOI 10.1096/fj.202100451R
   Luo MH, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.839885
   Ma JW, 2022, BONE, V164, DOI 10.1016/j.bone.2022.116511
   Ma Z., 2023, Oxid. Med. Cell Longev, V2023, P7212642, DOI [10.1155/2023/7212642, DOI 10.1155/2023/7212642]
   Marahleh A, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1121727
   Marahleh A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02925
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Mo H, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414 431X20198754, 10.1590/1414 431x20198754]
   Mohamad NV, 2020, ENDOCR METAB IMMUNE, V20, P1478, DOI 10.2174/1871530320666200604160614
   Mu PY, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.10050
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nam B, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249771
   Nowak B, 2017, PHARMACOL REP, V69, P1113, DOI 10.1016/j.pharep.2017.05.002
   Ohori F, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/9716758
   Ou L, 2019, ACTA CIR BRAS, V34, DOI 10.1590/s0102 865020190050000002
   Parr MK, 2014, MOL NUTR FOOD RES, V58, P1861, DOI 10.1002/mnfr.201300806
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Peng ZC, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.911326
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Qin XY, 2023, PHARM BIOL, V61, P391, DOI 10.1080/13880209.2023.2168019
   Ren X., 2020, Gansu. Medi. J, V39, P196
   Riegger J, 2023, CELL MOL BIOL LETT, V28, DOI 10.1186/s11658 023 00489 y
   Saxena Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687037
   Sromová V, 2023, CELLS BASEL, V12, DOI 10.3390/cells12212576
   Sun LJ, 2021, CURR PHARM BIOTECHNO, V22, P168, DOI 10.2174/1389201021666200123102550
   Sun WP, 2021, BIOMED PHARMACOTHER, V138, DOI 10.1016/j.biopha.2021.111480
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Tang YH, 2018, MOL MED REP, V17, P158, DOI 10.3892/mmr.2017.7840
   Tang YQ, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906 018 2171 3
   Tresguerres FGF, 2020, ANN ANAT, V227, DOI 10.1016/j.aanat.2019.151422
   Wang F, 2021, INT J BIOL SCI, V17, P1821, DOI 10.7150/ijbs.57681
   Wang GW, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020908
   Wang J., 2022, World. Chin. Medi, V17, P1697
   Wang J., 2007, Herald. Medi, V11, P1325
   Wang J., 2022, Effects of Epimedium Flavonoids on wnt/ catenin signaling pathway in SAMP6 mouse osteoblasts
   Wang JN, 2012, CHIN J INTEGR MED, V18, P925, DOI 10.1007/s11655 012 1296 0
   Wang JN, 2015, J TRADIT CHIN MED, V35, P141, DOI 10.1016/S0254 6272(15)30021 2
   Wang LT, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065814
   Wang LL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00266
   Wang LY, 2019, TOXICOL APPL PHARM, V376, P9, DOI 10.1016/j.taap.2019.05.014
   [王鸥 Wang Ou], 2022, [中华骨质疏松和骨矿盐疾病杂志, Chinese Journal of Osteoporosis and Bone Mineral Research], V15, P142
   Wang SQ, 2020, NAT PROD RES, V34, P2249, DOI 10.1080/14786419.2018.1452014
   Wang W, 2022, CLIN EXP PHARMACOL P, V49, P113, DOI 10.1111/1440 1681.13591
   Wang Y, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1304 9
   Wattel A, 2003, BIOCHEM PHARMACOL, V65, P35, DOI 10.1016/S0006 2952(02)01445 4
   Wei X, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 1617 3
   Wu D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687551
   Xiang S., 2023, Icariin promotes osteogenic differentiation of bone marrow mesenchymal stem cells by activating sclerostin/Wnt/ catenin signaling pathway
   Xie Q., 2022, J Cervicodynia Lumbodynia, V43, P912
   Xie Yan Ming, 2021, Zhongguo Zhong Yao Za Zhi, V46, P5992, DOI 10.19540/j.cnki.cjcmm.20210709.501
   Xu Q, 2022, INT IMMUNOPHARMACOL, V110, DOI 10.1016/j.intimp.2022.108998
   Xu Z., 2020, CHINA PHARMACY, V31, P2333, DOI DOI 10.6039/j.issn.1001 0408.2020.19.06
   Xue XY, 2023, PHYTOMEDICINE, V108, DOI 10.1016/j.phymed.2022.154517
   Yan CP, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.883228
   Yang N, 2020, CHIN MED UK, V15, DOI 10.1186/s13020 020 00323 z
   Yang QK, 2023, BBA MOL BASIS DIS, V1869, DOI 10.1016/j.bbadis.2023.166795
   Yang XC, 2019, AGING US, V11, P8777, DOI 10.18632/aging.102264
   Yang YJ, 2018, ACTA PHARMACOL SIN, V39, P633, DOI 10.1038/aps.2017.134
   Yang YJ, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1092746
   Yang Z, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/5338182
   Yano JM, 2015, CELL, V161, P264, DOI 10.1016/j.cell.2015.02.047
   Yin BF, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02911 2
   Yun DW, 2022, CARBOHYD POLYM, V291, DOI 10.1016/j.carbpol.2022.119618
   Zeng N., 2013, Shandong. J. Tradit. Chine. Medi, V32, P387
   Zhang C, 2023, BIOMED PHARMACOTHER, V163, DOI 10.1016/j.biopha.2023.114834
   Zhang J, 2018, INTRACTABLE RARE DIS, V7, P148, DOI 10.5582/irdr.2018.01055
   Zhang J, 2017, SCI REP UK, V7, DOI 10.1038/srep43935
   Zhang ML, 2018, INT J BIOL MACROMOL, V112, P433, DOI 10.1016/j.ijbiomac.2018.01.204
   [张强 Zhang Qiang], 2022, [世界科学技术：中医药现代化, Modernization of Traditional Chinese Medicine and Materia Medica  World Science and Technology], V24, P2245
   Zhang XH, 2014, DRUG DEVELOP RES, V75, P195, DOI 10.1002/ddr.21170
   Zhang Y, 2006, BIOL PHARM BULL, V29, P291, DOI 10.1248/bpb.29.291
   Zhang Y, 2008, BRIT J NUTR, V99, P494, DOI 10.1017/S0007114507801589
   Zhang Y, 2008, MENOPAUSE, V15, P558, DOI 10.1097/gme.0b013e31814fad27
   Zhang Y, 2021, LIFE SCI, V272, DOI 10.1016/j.lfs.2021.119204
   Zhao JL, 2021, COMPLEMENT THER CLIN, V44, DOI 10.1016/j.ctcp.2021.101419
   Zhao P, 2018, EUR REV MED PHARMACO, V22, P3962, DOI 10.26355/eurrev_201806_15280
   Zhao Yi Ru, 2019, Zhongguo Zhong Yao Za Zhi, V44, P186, DOI 10.19540/j.cnki.cjcmm.20180709.007
   Zhu CY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.898634
   Zhu HM, 2012, OSTEOPOROSIS INT, V23, P1317, DOI 10.1007/s00198 011 1577 2
   Zi H., 2020, Chin. Archi. Tradit. Chin. Medi, V38, P212
   Zou Y, 2015, TOXICOL SCI, V147, P28, DOI [10.1093/toxsci/kfv111, 10.1093/toxsci/kfv1]
NR 168
TC 9
Z9 9
U1 4
U2 28
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192 415X
EI 1793 6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PD 2024 JUN 14
PY 2024
DI 10.1142/S0192415X24500393
EA JUN 2024
PG 38
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA UQ0P1
UT WOS:001249409200003
PM 38879748
DA 2025 08 17
ER

PT J
AU Robling, AG
AF Robling, Alexander G.
TI The Interaction of Biological Factors with Mechanical Signals in Bone
   Adaptation: Recent Developments
SO CURRENT OSTEOPOROSIS REPORTS
LA English
DT Article
DE Mechanical loading; Stress; Strain; Osteocytes; Osteoblasts;
   Mechanotransduction; Biological factors; Mechanical signals; Bone
   adaptation
ID FLUID SHEAR STRESS; PARATHYROID HORMONE; OSTEOCYTES; RECEPTOR; CELLS;
   ACTIVATION; CONNEXIN43; PATHWAYS; INTEGRIN
AB Mechanotransduction in bone is fundamental to proper skeletal development. Deficiencies in signaling mechanisms that transduce physical forces to effector cells can have severe consequences for skeletal integrity. Therefore, a solid understanding of the cellular and molecular components of mechanotransduction is crucial for correcting skeletal modeling and remodeling errors and designing effective therapies. In recent years, progress has been made on many fronts regarding our understanding of bone cell mechanotransduction, including subcellular localization of mechanosensitive components in bone cells, the discovery of mechanosensitive G protein coupled receptors, identification of new ion channels and larger pores (eg, hemichannels) involved in physical signal transduction, and cell adhesion proteins, among others. These and other recent mechanisms are reviewed to provide a synthesis of recent experimental findings, in the larger context of whole bone adaptation.
C1 [Robling, Alexander G.] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [Robling, Alexander G.] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Purdue
   University System; Purdue University; Purdue University in Indianapolis
RP Robling, AG (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS 5035, Indianapolis, IN 46202 USA.
EM arobling@iupui.edu
FU NIAMS NIH HHS [R01 AR053237] Funding Source: Medline; BLRD VA [I01
   BX001478] Funding Source: Medline
CR Adachi T, 2009, J BIOMECH, V42, P1989, DOI 10.1016/j.jbiomech.2009.04.034
   Batra N, 2012, P NATL ACAD SCI USA, V109, P3359, DOI 10.1073/pnas.1115967109
   Bivi N., 2011, J BONE MINER RES, V25, pS11
   Burra S, 2010, P NATL ACAD SCI USA, V107, P13648, DOI 10.1073/pnas.1009382107
   Chachisvilis M, 2006, P NATL ACAD SCI USA, V103, P15463, DOI 10.1073/pnas.0607224103
   Chow JWM, 1998, AM J PHYSIOL ENDOC M, V274, pE146, DOI 10.1152/ajpendo.1998.274.1.E146
   Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200
   Grimston SK., 2011, 2011 Annual Meeting of the American Society of Bone and Mineral Research, San Diego, CA, pS75
   Grimston SK, 2006, ANN NY ACAD SCI, V1068, P214, DOI 10.1196/annals.1346.023
   Grimston SK, 2011, J BONE MINER RES, V26, P2151, DOI 10.1002/jbmr.425
   Gudi S, 1998, P NATL ACAD SCI USA, V95, P2515, DOI 10.1073/pnas.95.5.2515
   HERT J, 1972, ACTA ANAT, V82, P218
   Iqbal J, 2005, BIOCHEM BIOPH RES CO, V328, P751, DOI 10.1016/j.bbrc.2004.12.087
   Kamel MA, 2010, BONE, V47, P872, DOI 10.1016/j.bone.2010.08.007
   Kwon RY, 2010, FASEB J, V24, P2859, DOI 10.1096/fj.09 148007
   Li J, 2010, J MUSCULOSKEL NEURON, V10, P180
   Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200
   Litzenberger JB, 2010, CALCIFIED TISSUE INT, V86, P325, DOI 10.1007/s00223 010 9343 6
   Lu XL, 2012, J BONE MINER RES, V27, P563, DOI 10.1002/jbmr.1474
   Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104
   McNamara LM, 2009, ANAT REC, V292, P355, DOI 10.1002/ar.20869
   Mizoguchi F, 2008, J CELL PHYSIOL, V216, P47, DOI 10.1002/jcp.21374
   Norvell SM, 2004, CALCIFIED TISSUE INT, V75, P396, DOI 10.1007/s00223 004 0213 y
   Phillips JA, 2008, MATRIX BIOL, V27, P609, DOI 10.1016/j.matbio.2008.05.003
   Rawlinson SCF, 1996, BONE, V19, P609, DOI 10.1016/S8756 3282(96)00260 8
   Riddle RC, 2009, J ORTHOP RES, V27, P143, DOI 10.1002/jor.20723
   Siller Jackson AJ, 2008, J BIOL CHEM, V283, P26374, DOI 10.1074/jbc.M803136200
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Turner C H, 1998, J Orthop Sci, V3, P346, DOI 10.1007/s007760050064
   Watabe H, 2011, EXP CELL RES, V317, P2642, DOI 10.1016/j.yexcr.2011.07.015
   Wu D, 2011, J BIOMECH, V44, P1702, DOI 10.1016/j.jbiomech.2011.03.034
   Xiao ZS, 2010, ANN NY ACAD SCI, V1192, P410, DOI 10.1111/j.1749 6632.2009.05239.x
   Xiao ZS, 2011, FASEB J, V25, P2418, DOI 10.1096/fj.10 180299
   You LD, 2004, ANAT REC PART A, V278A, P505, DOI 10.1002/ar.a.20050
   Zhang YL, 2009, AM J PHYSIOL CELL PH, V296, pC1391, DOI 10.1152/ajpcell.00549.2008
   Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023516
NR 36
TC 27
Z9 33
U1 2
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1544 1873
EI 1544 2241
J9 CURR OSTEOPOROS REP
JI Curr. Osteoporos. Rep.
PD JUN
PY 2012
VL 10
IS 2
BP 126
EP 131
DI 10.1007/s11914 012 0099 y
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA V35YS
UT WOS:000209181600004
PM 22538521
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Morita, M
   Sato, Y
   Iwasaki, R
   Kobayashi, T
   Watanabe, R
   Oike, T
   Miyamoto, K
   Toyama, Y
   Matsumoto, M
   Nakamura, M
   Kawana, H
   Nakagawa, T
   Miyamoto, T
AF Morita, Mayu
   Sato, Yuiko
   Iwasaki, Ryotaro
   Kobayashi, Tami
   Watanabe, Ryuichi
   Oike, Takatsugu
   Miyamoto, Kana
   Toyama, Yoshiaki
   Matsumoto, Morio
   Nakamura, Masaya
   Kawana, Hiromasa
   Nakagawa, Taneaki
   Miyamoto, Takeshi
TI Selective Estrogen Receptor Modulators Suppress Hif1α Protein
   Accumulation in Mouse Osteoclasts
SO PLOS ONE
LA English
DT Article
ID VERTEBRAL FRACTURE RISK; BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN;
   CLINICAL TRIAL; TISSUE SPECIFICITY; BREAST CANCER; CORTICAL BONE; FEMALE
   MICE; OSTEOPOROSIS; ALPHA
AB Anti bone resorptive drugs such as bisphosphonates, the anti RANKL antibody (denosumab), or selective estrogen receptor modulators (SERMs) have been developed to treat osteoporosis. Mechanisms underlying activity of bisphosphonates or denosumab in this context are understood, while it is less clear how SERMs like tamoxifen, raloxifene, or bazedoxifene inhibit bone resorption. Recently, accumulation of hypoxia inducible factor 1 alpha (Hif1 alpha) in osteoclasts was shown to be suppressed by estrogen in normal cells. In addition, osteoclast activation and decreased bone mass seen in estrogen deficient conditions was found to require Hif1a. Here, we used western blot analysis of cultured osteoclast precursor cells to show that tamoxifen, raloxifene, or bazedoxifene all suppress Hif1 alpha protein accumulation. The effects of each SERM on osteoclast differentiation differed in vitro. Our results suggest that interventions such as the SERMs evaluated here could be useful to inhibit Hif1 alpha and osteoclast activity under estrogen deficient conditions.
C1 [Morita, Mayu; Iwasaki, Ryotaro; Kawana, Hiromasa; Nakagawa, Taneaki] Keio Univ, Div Oral & Maxillofacial Surg, Dept Dent & Oral Surg, Sch Med,Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
   [Sato, Yuiko; Kobayashi, Tami; Watanabe, Ryuichi; Oike, Takatsugu; Miyamoto, Kana; Toyama, Yoshiaki; Matsumoto, Morio; Nakamura, Masaya; Miyamoto, Takeshi] Keio Univ, Dept Orthoped Surg, Sch Med, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
   [Kobayashi, Tami] Keio Univ, Dept Musculoskeletal Reconstruct & Regenerat Surg, Sch Med, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
   [Sato, Yuiko; Miyamoto, Takeshi] Keio Univ, Dept Adv Therapy Musculoskeletal Disorders, Sch Med, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
C3 Keio University; Keio University; Keio University; Keio University
RP Miyamoto, T (通讯作者)，Keio Univ, Dept Orthoped Surg, Sch Med, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.; Miyamoto, T (通讯作者)，Keio Univ, Dept Adv Therapy Musculoskeletal Disorders, Sch Med, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
EM miyamoto@z5.keio.jp
RI Toyama, Yoshiaki/K 5743 2013; Nakamura, Masaya/K 4111 2013
OI Morita, Mayu/0009 0003 8092 0762
FU Japan Agency for Medical Research and Development; Chugai Scientific
   foundation; Pfizer Japan Inc.; Eli Lilly Scientific foundation;
   Grants in Aid for Scientific Research [15K10490, 15H04963, 16K10917]
   Funding Source: KAKEN
FX This study was funded by Grant in aid for Scientific Research in Japan
   and a grant from Japan Agency for Medical Research and Development. This
   study was also funded in part by a research grant from Chugai Scientific
   foundation, Pfizer Japan Inc. and Eli Lilly Scientific foundation. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Almeida M, 2013, J CLIN INVEST, V123, P394, DOI 10.1172/JCI65910
   CHRISTIANSEN C, 1981, LANCET, V1, P459
   Collin Osdoby P, 2003, METH MOLEC MED, V80, P153
   Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987
   Diez Perez Adolfo, 2006, Arq Bras Endocrinol Metab, V50, P720, DOI 10.1590/S0004 27302006000400017
   Edwards BJ, 2013, J BONE JOINT SURG AM, V95A, P297, DOI 10.2106/JBJS.K.01181
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Gedmintas L, 2013, J BONE MINER RES, V28, P1729, DOI 10.1002/jbmr.1893
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Layton D, 2005, OSTEOPOROSIS INT, V16, P490, DOI 10.1007/s00198 004 1710 6
   Lello S, 2011, CLIN CASES MINER BON, V8, P29
   Li BJ, 2011, J CELL BIOCHEM, V112, P1229, DOI 10.1002/jcb.23049
   Li FX, 2016, CANCER CHEMOTH PHARM, V77, P895, DOI 10.1007/s00280 016 2959 0
   LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302
   Luckey M, 2004, MENOPAUSE, V11, P405, DOI 10.1097/01.GME.0000119981.77837.1F
   Määttä JA, 2013, FASEB J, V27, P478, DOI 10.1096/fj.12 213587
   Maeda SS, 2014, ARQ BRAS ENDOCRINOL, V58, P162, DOI 10.1590/0004 2730000003039
   Martin Millan M, 2010, MOL ENDOCRINOL, V24, P323, DOI 10.1210/me.2009 0354
   Martinkovich S, 2014, CLIN INTERV AGING, V9, P1437, DOI 10.2147/CIA.S66690
   Martino S, 2005, CURR MED RES OPIN, V21, P1441, DOI 10.1185/030079905X61839
   Matsumoto T, 2011, BONE, V49, P605, DOI 10.1016/j.bone.2011.07.011
   Mazziotti G, 2012, ENDOCRINE, V41, P58, DOI 10.1007/s12020 011 9570 2
   Melville KM, 2014, J BONE MINER RES, V29, P370, DOI 10.1002/jbmr.2082
   Miller CP, 2001, J MED CHEM, V44, P1654, DOI 10.1021/jm010086m
   Miyamoto K, 2011, J EXP MED, V208, P2175, DOI 10.1084/jem.20101890
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Pinkerton JV, 2014, J STEROID BIOCHEM, V142, P142, DOI 10.1016/j.jsbmb.2013.12.011
   PIPER K, 1992, ANAT EMBRYOL, V186, P291
   Powles T, 1996, J CLIN ONCOL, V14, P78, DOI 10.1200/JCO.1996.14.1.78
   RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092 8674(78)90101 0
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Ronkin S, 2005, OBSTET GYNECOL, V105, P1397, DOI 10.1097/01.AOG.0000163253.27610.b9
   Ryan HE, 2000, CANCER RES, V60, P4010
   Sato Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111845
   Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537
   Silverman SL, 2008, J BONE MINER RES, V23, P1923, DOI 10.1359/JBMR.080710
   Tando T, 2016, BIOCHEM BIOPH RES CO, V470, P391, DOI 10.1016/j.bbrc.2016.01.033
   TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315
   Vanderschueren D, 2014, ENDOCR REV, V35, P906, DOI 10.1210/er.2014 1024
   Whyte MP, 2008, J BONE MINER RES, V23, P1698, DOI 10.1359/JBMR.080511
   Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513
NR 46
TC 16
Z9 16
U1 1
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD NOV 1
PY 2016
VL 11
IS 11
AR e0165922
DI 10.1371/journal.pone.0165922
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EA6CX
UT WOS:000386714200069
PM 27802325
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Saranya, I
   Selvamurugan, N
AF Saranya, Iyyappan
   Selvamurugan, Nagarajan
TI Regulation of TGF β/BMP signaling during osteoblast development by
   non coding RNAs: Potential therapeutic applications
SO LIFE SCIENCES
LA English
DT Article
DE Osteoblast differentiation; TGF beta/BMP signaling; Non coding RNAs
ID MESENCHYMAL STEM CELLS; PROMOTES OSTEOGENIC DIFFERENTIATION; CIRCULAR
   RNA; POSTMENOPAUSAL OSTEOPOROSIS; STIMULATES OSTEOGENESIS;
   BONE FORMATION; EXPRESSION; PROLIFERATION; BIOGENESIS; MECHANISMS
AB Bone is a connective tissue that is metabolically active and serves multiple functions, including movement, structural support, and organ protection. It is comprised primarily of three types of bone cells, namely osteoblasts, osteocytes, and osteoclasts. Osteoblasts are bone forming cells, and the differentiation of mesenchymal stem cells towards osteoblasts is regulated by several growth factors, cytokines, and hormones via various signaling pathways, including TGF beta/BMP (transforming growth factor beta/bone morphogenetic protein) signaling as a primary one. Non coding RNAs (ncRNAs), such as microRNAs and long ncRNAs, play crucial roles in regulating osteoblast differentiation via the TGF beta/BMP signaling cascade. Dysregulation of these ncRNAs leads to bone pathological conditions such as osteoporosis, skeletal dysplasia, and osteosclerosis. This review provides a concise overview of the latest advancements in understanding the involvement of ncRNAs/TGF beta/BMP axis in osteoblast differentiation. These findings have the potential to identify new molecular targets for early detection of bone metabolism disorders and the development of innovative therapy strategies.
C1 [Saranya, Iyyappan; Selvamurugan, Nagarajan] SRM Inst Sci & Technol, Sch Bioengn, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India.
C3 SRM Institute of Science & Technology Chennai
RP Selvamurugan, N (通讯作者)，SRM Inst Sci & Technol, Sch Bioengn, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India.
EM selvamun@srmist.edu.in
RI Selvamurugan, Nagarajan/P 7894 2016
FU Indian Council of Medical Research [2020 0282/SCR/ADHOC BMS]; Department
   of Science and Technology (DST/INSPIRE Fellowship) [2021/IF210073]
FX The Indian Council of Medical Research (2020 0282/SCR/ADHOC BMS to N.S.)
   and the Department of Science and Technology (DST/INSPIRE Fellowship:
   2021/IF210073 to I. S.) funded this research.
CR Abdallah BM, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929 019 0544 7
   Ahmad SNS, 2022, J MOL HISTOL, V53, P691, DOI 10.1007/s10735 022 10078 6
   Akshaya RL, 2022, INT J BIOL MACROMOL, V222, P1974, DOI 10.1016/j.ijbiomac.2022.09.286
   Arfat Y, 2018, MOL THER NUCL ACIDS, V11, P323, DOI 10.1016/j.omtn.2017.11.009
   Arumugam B, 2018, J CELL COMMUN SIGNAL, V12, P561, DOI 10.1007/s12079 018 0449 3
   Bonilauri B, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25042013
   Briata P, 2020, NON CODING RNA, V6, DOI 10.3390/ncrna6030040
   Bridges MC, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202009045
   Cai HN, 2019, J CELL PHYSIOL, V234, P11391, DOI 10.1002/jcp.27796
   Castaño IM, 2019, TISSUE ENG PT A, V25, P24, DOI 10.1089/ten.tea.2017.0460
   Che N, 2019, EUR REV MED PHARMACO, V23, P3183, DOI 10.26355/eurrev_201904_17676
   Chen GQ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00135
   Chen GQ, 2019, DEV DYNAM, V248, P1009, DOI 10.1002/dvdy.97
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen J, 2020, BIOMATER SCI UK, V8, P3430, DOI 10.1039/c9bm01761e
   Chen L, 2022, JACC BASIC TRANSL SC, V7, P899, DOI 10.1016/j.jacbts.2022.06.009
   Chen QJ, 2025, CELLS TISSUES ORGANS, V214, P14, DOI 10.1159/000525703
   Chen S. C., 2022, Stem Cell Res. Ther., V13, P1, DOI [10.1186/S13287 022 03150 1/FIGURES/5, DOI 10.1186/S13287 022 03150 1/FIGURES/5]
   Chen ZQ, 2018, DNA CELL BIOL, V37, P791, DOI 10.1089/dna.2018.4294
   Chen ZQ, 2019, AM J TRANSL RES, V11, P974
   Chipman LB, 2019, TRENDS GENET, V35, P215, DOI 10.1016/j.tig.2018.12.005
   Cui Q, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1428 1
   Dong HD, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12633
   Dong JY, 2021, J EXP MED, V218, DOI 10.1084/jem.20192423
   Du X, 2024, BMC MUSCULOSKEL DIS, V25, DOI 10.1186/s12891 024 07303 6
   El Gewely MR, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25010024
   Fan FY, 2019, ONCOL LETT, V18, P6536, DOI 10.3892/ol.2019.10992
   Fan FY, 2019, ONCOL LETT, V18, P6339, DOI 10.3892/ol.2019.10994
   Farzaneh M, 2023, CLIN TRANSL ONCOL, V25, P21, DOI 10.1007/s12094 022 02876 x
   Feng XB, 2022, MOL THER NUCL ACIDS, V28, P99, DOI 10.1016/j.omtn.2022.02.017
   Fu D, 2019, AGING US, V11, P8374, DOI 10.18632/aging.102325
   Fu HL, 2016, EUR REV MED PHARMACO, V20, P3911
   Fu LG, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01688 5
   Ge XY, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01877 3
   Gu SJ, 2020, GASTROENTEROLOGY, V158, P238, DOI 10.1053/j.gastro.2019.09.023
   Gu YZ, 2024, ORAL DIS, V30, P2398, DOI 10.1111/odi.14705
   Gu ZT, 2020, J CELL MOL MED, V24, P12619, DOI 10.1111/jcmm.15826
   Ha M, 2008, BBA GENE REGUL MECH, V1779, P735, DOI 10.1016/j.bbagrm.2008.03.004
   Han YN, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02781 8
   Hao YQ, 2021, J CELL MOL MED, V25, P4608, DOI 10.1111/jcmm.16294
   Harrison CA, 2011, GROWTH FACTORS, V29, P174, DOI 10.3109/08977194.2011.608666
   Hart M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 018 1295 1
   He GS, 2019, EXP THER MED, V18, P312, DOI 10.3892/etm.2019.7570
   He H, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046 020 01664 1
   He JY, 2021, MOL BIOL REP, V48, P6151, DOI 10.1007/s11033 021 06603 7
   He QT, 2021, J GENE MED, V23, DOI 10.1002/jgm.3366
   Heldin CH, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022053
   Huang XQ, 2019, AM J TRANSL RES, V11, P4776
   Huang XQ, 2021, CELL TRANSPLANT, V30, DOI 10.1177/09636897211052959
   Huminiecki L, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471 2148 9 28
   Ji F, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00470
   Jiang TC, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01723 6
   Jin SL, 2020, EUR REV MED PHARMACO, V24, P4095, DOI 10.26355/eurrev_202004_20987
   Jin SJ, 2021, MOL BIOL REP, V48, P4837, DOI 10.1007/s11033 021 06476 w
   Kaikkonen MU, 2011, CARDIOVASC RES, V90, P430, DOI 10.1093/cvr/cvr097
   Karimi N, 2019, J CHIN MED ASSOC, V82, P215, DOI 10.1097/JCMA.0000000000000031
   Krishnan RH, 2023, INT J BIOL MACROMOL, V225, P1152, DOI 10.1016/j.ijbiomac.2022.11.176
   Kumar D, 2020, GENES BASEL, V11, DOI 10.3390/genes11020164
   Lanzillotti C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.646032
   Li BC, 2023, STEM CELL REV REP, V19, P170, DOI 10.1007/s12015 022 10408 x
   Li HL, 2018, AGING DIS, V9, P1058, DOI 10.14336/AD.2018.0214
   Li HQ, 2015, MOL MED REP, V12, P1561, DOI 10.3892/mmr.2015.3497
   Li JZ, 2022, ARCH ORAL BIOL, V135, DOI 10.1016/j.archoralbio.2022.105357
   Li J, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02694 x
   Li M, 2020, ELIFE, V9, DOI 10.7554/eLife.59079
   Li Q, 2015, TUMOR BIOL, V36, P2007, DOI 10.1007/s13277 014 2807 y
   Li X, 2018, MOL CELL, V71, P428, DOI 10.1016/j.molcel.2018.06.034
   Lin H, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018 023 04425 w
   Lin LY, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0834 9
   Lin ZY, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12688
   Liu C, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03877 4
   Liu HX, 2018, INT J MOL MED, V41, P3379, DOI 10.3892/ijmm.2018.3526
   Liu ZT, 2021, BIOENGINEERED, V12, P4911, DOI 10.1080/21655979.2021.1959865
   Lu QM, 2022, CELL SIGNAL, V90, DOI 10.1016/j.cellsig.2021.110187
   Lu XD, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109378
   Luo B, 2020, FEBS OPEN BIO, V10, P1793, DOI 10.1002/2211 5463.12929
   Luo KL, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1263 3
   Luo Y, 2018, J CELL PHYSIOL, V233, P6929, DOI 10.1002/jcp.26596
   Ma J, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00260
   Ma S, 2019, J CELL BIOCHEM, V120, P15429, DOI 10.1002/jcb.28810
   Martin EC, 2016, BIOCHIMIE, V124, P98, DOI 10.1016/j.biochi.2015.02.012
   Massagué J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434
   Mattick JS, 2023, NAT REV MOL CELL BIO, V24, P430, DOI 10.1038/s41580 022 00566 8
   Mazziotta C, 2024, THERANOSTICS, V14, P143, DOI 10.7150/thno.89066
   McGovern JA, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.033084
   Michlewski G, 2019, RNA, V25, P1, DOI 10.1261/rna.068692.118
   Misir S, 2020, BREAST CANCER TOKYO, V27, P1048, DOI 10.1007/s12282 020 01140 w
   Mitash N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194933
   Miyake T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031057
   Morenikeji OB, 2021, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.582953
   Morikawa M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021873
   Moses HL, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021865
   Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338
   Murayama K, 2020, J STRUCT BIOL, V212, DOI 10.1016/j.jsb.2020.107661
   Naeli P, 2023, FEBS J, V290, P2508, DOI 10.1111/febs.16422
   Nakano M, 2019, ONCOGENE, V38, P780, DOI 10.1038/s41388 018 0480 0
   Niu ZS, 2020, WORLD J GASTROENTERO, V26, DOI 10.3748/wjg.v26.i29.4240
   O'Brien J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00402
   Park JH, 2021, EMBO J, V40, DOI 10.15252/embj.2020106151
   Qiao L, 2020, EUR REV MED PHARMACO, V24, P3459, DOI 10.26355/eurrev_202004_20804
   Qin HC, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13010123
   Qin S, 2024, J CELL MOL MED, V28, DOI 10.1111/jcmm.18287
   Qin WW, 2019, ENDOCRINE, V65, P426, DOI 10.1007/s12020 019 01952 7
   Qin XB, 2021, ACTA HISTOCHEM, V123, DOI 10.1016/j.acthis.2021.151786
   Ren LJ, 2023, BMC MUSCULOSKEL DIS, V24, DOI 10.1186/s12891 023 06473 z
   Rohini M, 2018, BIOCHIMIE, V154, P10, DOI 10.1016/j.biochi.2018.07.023
   Saiganesh S, 2019, INT J BIOL MACROMOL, V132, P541, DOI 10.1016/j.ijbiomac.2019.04.003
   Santos Rodriguez G, 2021, ELIFE, V10, DOI [10.7554/eLife.69148, 10.7554/eLife.69148.sa1, 10.7554/eLife.69148.sa2]
   Saranya I, 2024, INT J BIOL MACROMOL, V266, DOI 10.1016/j.ijbiomac.2024.131075
   Saranya I, 2024, NON CODING RNA RES, V9, P153, DOI 10.1016/j.ncrna.2023.11.002
   Saranya I, 2022, DIFFERENTIATION, V128, P57, DOI 10.1016/j.diff.2022.10.003
   Sebastian delaCruz M, 2021, NON CODING RNA, V7, DOI 10.3390/ncrna7010003
   Sharma AR, 2021, MOL THER NUCL ACIDS, V25, P355, DOI 10.1016/j.omtn.2021.05.022
   Shu T, 2019, BIOCHEM BIOPH RES CO, V514, P316, DOI 10.1016/j.bbrc.2019.04.140
   Singh A, 2019, CLIN RHEUMATOL, V38, P877, DOI 10.1007/s10067 018 4380 z
   Song YX, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.919309
   Tang SA, 2019, STEM CELLS, V37, P270, DOI 10.1002/stem.2937
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tao Y, 2020, INT J BIOL SCI, V16, P471, DOI 10.7150/ijbs.39123
   Tzavlaki K, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030487
   Ueharu H, 2023, FRONT PHYSIOL, V14, DOI 10.3389/fphys.2023.1170511
   Valenti MT, 2024, CELLS BASEL, V13, DOI 10.3390/cells13120999
   Valenti MT, 2020, CELLS BASEL, V9, DOI 10.3390/cells9081911
   Vishal M, 2017, J CELL PHYSIOL, V232, P371, DOI 10.1002/jcp.25434
   Voisin A, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 57839 5
   Von Euw S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44620 6
   Wakefield LM, 2013, NAT REV CANCER, V13, P328, DOI 10.1038/nrc3500
   Wang B, 2019, J CELL PHYSIOL, V234, P6173, DOI 10.1002/jcp.27394
   Wang CX, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018 023 03883 6
   Wang JF, 2019, CANCER BIOTHER RADIO, V34, P671, DOI 10.1089/cbr.2019.2925
   Wang JC, 2020, CURR STEM CELL RES T, V15, P243, DOI 10.2174/1574888X15666191227113742
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wang T, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 1579 0
   Wang XJ, 2020, HUM EXP TOXICOL, V39, P1390, DOI 10.1177/0960327120924080
   Wang YJ, 2018, J CELL PHYSIOL, V233, P7435, DOI 10.1002/jcp.26589
   Wang YW, 2022, CELL COMMUN SIGNAL, V20, DOI 10.1186/s12964 022 01002 2
   Wang ZG, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6697749
   Wu M, 2021, PEERJ, V9, DOI 10.7717/peerj.12228
   Wu SM, 2019, MOL MED REP, V19, P177, DOI 10.3892/mmr.2018.9664
   Xi JJ, 2022, EMBO REP, V23, DOI 10.15252/embr.202153015
   Xiao MS, 2020, TRENDS CELL BIOL, V30, P226, DOI 10.1016/j.tcb.2019.12.004
   Xiao XX, 2017, INT J CARDIOL, V243, P404, DOI 10.1016/j.ijcard.2017.05.037
   Xiong Y, 2020, INT J BIOL SCI, V16, P1604, DOI 10.7150/ijbs.38930
   Xu YX, 2021, J CELL MOL MED, V25, P5025, DOI 10.1111/jcmm.16451
   Yang JW, 2024, J CLIN INVEST, V134, DOI 10.1172/JCI165787
   Ye Y, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/5177488
   Yin P, 2023, INT IMMUNOPHARMACOL, V116, DOI 10.1016/j.intimp.2023.109844
   Yu L, 2019, BIOCHEM BIOPH RES CO, V516, P546, DOI 10.1016/j.bbrc.2019.06.087
   Yue Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109640
   Zhang ND, 2019, BIOCHEM BIOPH RES CO, V519, P790, DOI 10.1016/j.bbrc.2019.09.058
   Zhang Q, 2019, WORLD J GASTROENTERO, V25, P5300, DOI 10.3748/wjg.v25.i35.5300
   Zhang RF, 2019, EUR REV MED PHARMACO, V23, P6774, DOI 10.26355/eurrev_201908_18715
   Zhang WW, 2019, THERANOSTICS, V9, P2198, DOI 10.7150/thno.30798
   Zhang YZ, 2019, PATHOL RES PRACT, V215, P525, DOI 10.1016/j.prp.2018.12.034
   Zhang Z, 2024, NPJ MICROGRAVITY, V10, DOI 10.1038/s41526 024 00382 8
   Zhao B, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1512 3
   Zhao WS, 2020, AM J TRANSL RES, V12, P5882
   Zhao X, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163926
   Zhao YW, 2020, MOL MED REP, V22, P5428, DOI 10.3892/mmr.2020.11635
   Zheng JZ, 2022, LIFE SCI ALLIANCE, V5, DOI 10.26508/lsa.202101330
   Zhong ZY, 2017, CANCER LETT, V403, P305, DOI 10.1016/j.canlet.2017.06.027
   Zhou RK, 2021, BIOENGINEERED, V12, P3824, DOI 10.1080/21655979.2021.1949514
NR 163
TC 3
Z9 3
U1 2
U2 7
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD OCT 15
PY 2024
VL 355
AR 122969
DI 10.1016/j.lfs.2024.122969
EA AUG 2024
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA E2Q0B
UT WOS:001301485400001
PM 39142506
DA 2025 08 17
ER

PT J
AU Bakker, AD
   Jaspers, RT
AF Bakker, Astrid D.
   Jaspers, Richard T.
TI IL 6 and IGF 1 Signaling Within and Between Muscle and Bone: How
   Important is the mTOR Pathway for Bone Metabolism?
SO CURRENT OSTEOPOROSIS REPORTS
LA English
DT Article
DE Osteocyte; Osteoblast; Myoblast; Hypertrophy; mTOR; Mechanical loading;
   Aging; Osteoporosis
ID GROWTH FACTOR I; MESENCHYMAL STEM CELLS; PROMOTES OSTEOBLAST
   DIFFERENTIATION; HUMAN SKELETAL MUSCLE; BINDING PROTEIN BETA; OSTEOCLAST
   FORMATION; OSTEOGENIC DIFFERENTIATION; INTERLEUKIN (IL) 6; UBIQUITIN
   LIGASES; STIMULATES GROWTH
AB Insulin like growth factor 1 (IGF 1) and interleukin 6 (IL 6) play an important role in the adaptation of both muscle and bone to mechanical stimuli. Here, we provide an overview of the functions of IL 6 and IGF 1 in bone and muscle metabolism, and the intracellular signaling pathways that are well known to mediate these functions. In particular, we discuss the Akt/mammalian target of rapamycin (mTOR) pathway which in skeletal muscle is known for its key role in regulating the rate of mRNA translation (protein synthesis). Since the role of the mTOR pathway in bone is explored to a much lesser extent, we discuss what is known about this pathway in bone and the potential role of this pathway in bone remodeling. We will also discuss the possible ways of influencing IGF 1 or IL 6 signaling by osteocytes and the clinical implications of pharmacological or nutritional modulation of the Akt/mTOR pathway.
C1 [Jaspers, Richard T.] Vrije Univ Amsterdam, Lab Myol, MOVE Res Inst Amsterdam, Fac Human Movement Sci, NL 1081 BT Amsterdam, Netherlands.
   [Bakker, Astrid D.] Univ Amsterdam, Dept Oral Cell Biol, Acad Ctr Dent Amsterdam ACTA, NL 1081 LA Amsterdam, Netherlands.
   [Bakker, Astrid D.] Vrije Univ Amsterdam, MOVE Res Inst Amsterdam, NL 1081 LA Amsterdam, Netherlands.
C3 Vrije Universiteit Amsterdam; University of Amsterdam; Vrije
   Universiteit Amsterdam; Academic Center for Dentistry Amsterdam; Vrije
   Universiteit Amsterdam
RP Jaspers, RT (通讯作者)，Vrije Univ Amsterdam, Lab Myol, MOVE Res Inst Amsterdam, Fac Human Movement Sci, Boechorststr 9, NL 1081 BT Amsterdam, Netherlands.
EM a.bakker@acta.nl; r.t.jaspers@vu.nl
RI Bakker, Astrid/AAD 1286 2019
OI Jaspers, Richard/0000 0002 6951 0952
CR Abu Taha M, 2009, J IMMUNOL, V183, P1393, DOI 10.4049/jimmunol.0803157
   Al Khalili L, 2006, MOL ENDOCRINOL, V20, P3364, DOI 10.1210/me.2005 0490
   Alzghoul MB, 2004, FASEB J, V18, P221, DOI 10.1096/fj.03 0293fje
   Ardawi MSM, 2012, J CLIN ENDOCR METAB, V97, P3691, DOI 10.1210/jc.2011 3361
   Bakker AD, 2006, OSTEOPOROSIS INT, V17, P827, DOI 10.1007/s00198 006 0072 7
   Bakker AD, 2014, J DENT RES, V93, P394, DOI 10.1177/0022034514522485
   Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666
   Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200
   Bolster DR, 2003, EXERC SPORT SCI REV, V31, P111, DOI 10.1097/00003677 200307000 00002
   CANALIS E, 1988, ENDOCRINOLOGY, V122, P22, DOI 10.1210/endo 122 1 22
   Carson JA, 2010, EXERC SPORT SCI REV, V38, P168, DOI 10.1097/JES.0b013e3181f44f11
   Chen JQ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004145
   Cheung WY, 2012, BONE, V50, P104, DOI 10.1016/j.bone.2011.09.052
   Croisier JL, 1999, MUSCLE NERVE, V22, P208, DOI 10.1002/(SICI)1097 4598(199902)22:2<208::AID MUS8>3.0.CO;2 B
   Dallas DJ, 1999, BONE, V25, P9, DOI 10.1016/S8756 3282(99)00099 X
   Dame JB, 2000, EARLY HUM DEV, V58, P25, DOI 10.1016/S0378 3782(00)00064 5
   De Benedetti F, 2001, ENDOCRINOLOGY, V142, P4818, DOI 10.1210/en.142.11.4818
   Deldicque L, 2008, AMINO ACIDS, V35, P147, DOI 10.1007/s00726 007 0607 z
   Deng MY, 2011, INT ORTHOP, V35, P1099, DOI 10.1007/s00264 010 1141 2
   Duplomb L, 2008, ENDOCRINOLOGY, V149, P3688, DOI 10.1210/en.2007 1719
   Elis S, 2010, J BONE MINER RES, V25, P1257, DOI 10.1002/jbmr.20
   Erices A, 2002, EXP CELL RES, V280, P24, DOI 10.1006/excr.2002.5627
   Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01 0876rev
   Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802
   Franchimont N, 1997, ENDOCRINOLOGY, V138, P5248, DOI 10.1210/en.138.12.5248
   Glass DJ, 2005, CANCER CELL, V8, P351, DOI 10.1016/j.ccr.2005.10.016
   Goldspink G, 2005, PHYSIOLOGY, V20, P232, DOI 10.1152/physiol.00004.2005
   GOODSHIP AE, 1979, J BONE JOINT SURG AM, V61, P539, DOI 10.2106/00004623 197961040 00008
   Haddad F, 2005, J APPL PHYSIOL, V98, P911, DOI 10.1152/japplphysiol.01026.2004
   Hamrick MW, 2007, BONE, V40, P1544, DOI 10.1016/j.bone.2007.02.012
   Hamrick MW, 2010, J MUSCULOSKEL NEURON, V10, P64
   Hardie DG, 2011, P NUTR SOC, V70, P92, DOI 10.1017/S0029665110003915
   Heinemeier KM, 2007, J APPL PHYSIOL, V102, P573, DOI 10.1152/japplphysiol.00866.2006
   Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297
   Hill PA, 1997, ENDOCRINOLOGY, V138, P3849, DOI 10.1210/en.138.9.3849
   HILL PA, 1995, ENDOCRINOLOGY, V136, P124, DOI 10.1210/en.136.1.124
   HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo 122 1 254
   Iyer VV, 2004, EXP CELL RES, V295, P128, DOI 10.1016/j.yexcr.2004.01.004
   Jaspers RT, 2008, PFLUG ARCH EUR J PHY, V457, P161, DOI 10.1007/s00424 008 0499 0
   Jaspers RT, 2014, CLIN REV BONE MINER, V12, P27, DOI 10.1007/s12018 014 9156 7
   Jonsdottir IH, 2000, J PHYSIOL LONDON, V528, P157, DOI 10.1111/j.1469 7793.2000.00157.x
   Juffer P, 2014, CELL BIOCHEM BIOPHYS, V69, P411, DOI 10.1007/s12013 013 9812 4
   Juffer P, 2014, CALCIFIED TISSUE INT, V94, P319, DOI 10.1007/s00223 013 9813 8
   Juffer P, 2012, AM J PHYSIOL ENDOC M, V302, pE389, DOI 10.1152/ajpendo.00320.2011
   Kellum E, 2009, BONE, V44, P17, DOI 10.1016/j.bone.2008.08.126
   Kitase Y, 2014, J DENT RES, V93, P1108, DOI 10.1177/0022034514553008
   Krawiec BJ, 2007, AM J PHYSIOL ENDOC M, V292, pE1555, DOI 10.1152/ajpendo.00622.2006
   Kume K, 2014, RHEUMATOLOGY, V53, P900, DOI 10.1093/rheumatology/ket468
   Kurosaka M, 2013, CELL PROLIFERAT, V46, P365, DOI 10.1111/cpr.12045
   Lang CH, 2007, AM J PHYSIOL ENDOC M, V293, pE453, DOI 10.1152/ajpendo.00204.2007
   Lau KHW, 2013, AM J PHYSIOL ENDOC M, V305, pE271, DOI 10.1152/ajpendo.00092.2013
   Mihara M, 2012, CLIN SCI, V122, P143, DOI 10.1042/CS20110340
   Mills P, 2007, AM J TRANSPLANT, V7, P2247, DOI 10.1111/j.1600 6143.2007.01927.x
   Muñoz Cánoves P, 2013, FEBS J, V280, P4131, DOI 10.1111/febs.12338
   Pantovic A, 2013, BONE, V52, P524, DOI 10.1016/j.bone.2012.10.024
   Pedersen BK, 2009, J APPL PHYSIOL, V107, P1006, DOI 10.1152/japplphysiol.00734.2009
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   Reijnders CMA, 2007, J ENDOCRINOL, V192, P131, DOI 10.1677/joe.1.06880
   Rufo A, 2011, J BONE MINER RES, V26, P1891, DOI 10.1002/jbmr.410
   Santos A, 2010, BIOCHEM BIOPH RES CO, V391, P364, DOI 10.1016/j.bbrc.2009.11.064
   SCHOENLE E, 1982, NATURE, V296, P252, DOI 10.1038/296252a0
   Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054
   Serrano AL, 2008, CELL METAB, V7, P33, DOI 10.1016/j.cmet.2007.11.011
   Shen H, 2015, J BONE MINER RES, V30, P596, DOI 10.1002/jbmr.2389
   Sheng MHC, 2013, BONE, V52, P133, DOI 10.1016/j.bone.2012.09.027
   Smink JJ, 2012, J MOL MED, V90, P25, DOI 10.1007/s00109 011 0823 6
   Smith GC, 2013, FEBS J, V280, P5337, DOI 10.1111/febs.12428
   Spangenburg EE, 2004, ENDOCRINOLOGY, V145, P2054, DOI 10.1210/en.2003 1476
   Srinivas V, 2009, CELL CYCLE, V8, P391, DOI 10.4161/cc.8.3.7545
   Steensberg A, 2002, AM J PHYSIOL ENDOC M, V283, pE1272, DOI 10.1152/ajpendo.00255.2002
   Steensberg A, 2000, J PHYSIOL LONDON, V529, P237, DOI 10.1111/j.1469 7793.2000.00237.x
   Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005
   Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097 2765(04)00211 4
   Suryawan A, 2008, AM J PHYSIOL ENDOC M, V295, pE868, DOI 10.1152/ajpendo.90314.2008
   Taguchi Y, 1998, P ASSOC AM PHYSICIAN, V110, P559
   Tanck E, 2009, BONE, V44, P590, DOI 10.1016/j.bone.2008.12.022
   Taylor AF, 2007, AM J PHYSIOL CELL PH, V292, pC545, DOI 10.1152/ajpcell.00611.2005
   Tominaga H, 2008, MOL BIOL CELL, V19, P5373, DOI 10.1091/mbc.E08 03 0329
   Tong JF, 2009, J CELL BIOCHEM, V108, P458, DOI 10.1002/jcb.22272
   UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461
   Vervloet MG, 2014, LANCET DIABETES ENDO, V2, P427, DOI 10.1016/S2213 8587(14)70059 2
   Wang YM, 2006, ENDOCRINOLOGY, V147, P4753, DOI 10.1210/en.2006 0196
   Wang ZH, 2013, CELL BIOCHEM BIOPHYS, V67, P567, DOI 10.1007/s12013 013 9543 6
   Washington TA, 2011, ACTA PHYSIOL, V202, P657, DOI 10.1111/j.1748 1716.2011.02281.x
   Weigert C, 2005, AM J PHYSIOL ENDOC M, V289, pE251, DOI 10.1152/ajpendo.00448.2004
   Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014 5793(97)01548 2
   White JP, 2013, AM J PHYSIOL ENDOC M, V304, pE1042, DOI 10.1152/ajpendo.00410.2012
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Yang SY, 2002, FEBS LETT, V522, P156, DOI 10.1016/S0014 5793(02)02918 6
   Yang X, 2007, BONE, V41, P928, DOI 10.1016/j.bone.2007.07.022
   Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674
NR 91
TC 46
Z9 60
U1 2
U2 41
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1544 2241
J9 CURR OSTEOPOROS REP
JI Curr. Osteoporos. Rep.
PD JUN
PY 2015
VL 13
IS 3
BP 131
EP 139
DI 10.1007/s11914 015 0264 1
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CH2CS
UT WOS:000353833000001
PM 25712618
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Williams, BO
   Insogna, KL
AF Williams, Bart O.
   Insogna, Karl L.
TI Where Wnts Went: The Exploding Field of Lrp5 and Lrp6 Signaling in Bone
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE Lrp5; Lrp6; Wnt; beta catenin; osteoporosis
ID RECEPTOR RELATED PROTEIN 5; FAMILIAL EXUDATIVE VITREORETINOPATHY;
   BETA CATENIN; OSTEOBLAST DIFFERENTIATION; MOLECULAR CLONING; MINERAL
   DENSITY; MICE LACKING; MUTATIONS; GENE; MASS
AB Wnt signaling has emerged as a central regulator of skeletal modeling and remodeling. Loss  or gain of function mutations in two Writ co receptors, Lrp5 and (more recently) Lrp6, have drawn attention to the importance of the Writ pathway in bone biology. This review summarizes our current understanding of how the Wilt pathway operates on bone and the implications this has for skeletal physiology and drug discovery. Over the past 9 yr, rapid advances have been made in our understanding of the cellular targets for Writ signaling and of the important regulatory molecules in this metabolic pathway. Both canonical and noncanonical signaling pathways seem to be important for mediating the effects of Writ in bone. A rapidly expanding catalog of genetically engineered mice has been used to establish the importance of downstream effector molecules (such as beta catenin) in the Writ pathway, as well as the critical role of endogenous inhibitors of Writ signaling (such as Dkk1 and sclerostin) in bone metabolism. Indeed, regulation of sclerostin in osteocytes is emerging as an Important final pathway for regulating bone anabolism in response to diverse trophic stimuli, from mechnotransduction to the anabolic actions of PTH. From the outset, it had been assumed that the effects of Writ signaling in bone were caused by direct actions in osteoblast precursors, osteoblasts, and osteocytes. However, starting recent findings have challenged this view and suggest that a key target, at least in mice, is the duodenal enterochromaffin cell. There, Writ signaling transduced by Lrp5 regulates serotonin synthesis, which acts in an endocrine fashion to regulate bone cell metabolism. It will take time to reconcile this new information with the considerable body of information we already have regarding the actions of Writ in bone. The Writ pathway has rapidly emerged as a therapeutic target for drug discovery. Neutralizing antibodies and small molecule inhibitors of endogenous Wnt inhibitors have shown early promise as bone anabolic agents. However, given the central role of the Writ pathway in regulating growth and development in extraskeletal tissues, as well as our still rudimentary understanding of how this signaling cascade actually affects bone metabolism, considerable work will be needed to ensure the safety of these new therapies.
C1 [Williams, Bart O.] Van Andel Res Inst, Grand Rapids, MI 49503 USA.
   [Insogna, Karl L.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
C3 Van Andel Institute; Van Andel Research Institute; Yale University
RP Williams, BO (通讯作者)，Van Andel Res Inst, 333 Bostwick NE, Grand Rapids, MI 49503 USA.
EM bart.williams@vai.org
RI Williams, Bart/A 3539 2013
OI Insogna, Karl/0000 0001 6973 5679; Williams, Bart/0000 0002 5261 5301
FU NIAMS/NIH [AR053293]; Van Andel Research Institute; NIH [AR46032,
   DK045228, DE012459]
FX The authors thank David Nadziejka for assistance in the preparation of
   this manuscript. BOW is supported by a grant from NIAMS/NIH (AR053293)
   and the Van Andel Research Institute. KLI is supported in part by NIH
   Grants AR46032, DK045228, and DE012459.
CR Albers J, 2008, J BONE MINER RES, V23, pS3
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Belsky JL, 2003, J CLIN ENDOCR METAB, V88, P2081, DOI 10.1210/jc.2002 021726
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Bhat BM, 2007, GENE, V391, P103, DOI 10.1016/j.gene.2006.12.014
   Björklund P, 2007, PLOS MED, V4, P1829, DOI 10.1371/journal.pmed.0040328
   Bodine PV, 2007, J BONE MINER RES, V22, pS4
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061
   Carter M, 2005, P NATL ACAD SCI USA, V102, P12843, DOI 10.1073/pnas.0501963102
   Chen D, 1999, GENOMICS, V55, P314, DOI 10.1006/geno.1998.5688
   Cselenyi CS, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.18pe10
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   De Ferrari GV, 2006, ONCOGENE, V25, P7545, DOI 10.1038/sj.onc.1210064
   de Vernejoul MC, 2008, BEST PRACT RES CL RH, V22, P71, DOI 10.1016/j.berh.2007.12.011
   DELONGH RU, 2006, FRONT BIOSCI, V11, P2442
   Diem SJ, 2007, ARCH INTERN MED, V167, P1240, DOI 10.1001/archinte.167.12.1240
   Dong Y, 1998, BIOCHEM BIOPH RES CO, V251, P784, DOI 10.1006/bbrc.1998.9545
   Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100
   Glantschnig H, 2008, J BONE MINER RES, V23, pS60
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05 0116
   Haney EM, 2007, ARCH INTERN MED, V167, P1246, DOI 10.1001/archinte.167.12.1246
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Hendrickx M, 2008, DEV GROWTH DIFFER, V50, P229, DOI [10.1111/j.1440 169x.2008.01016.x, 10.1111/j.1440 169X.2008.01016.x]
   Hey PJ, 1998, GENE, V216, P103, DOI 10.1016/S0378 1119(98)00311 4
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hsieh JC, 2003, CELL, V112, P355, DOI 10.1016/S0092 8674(03)00045 X
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Jiao XD, 2004, AM J HUM GENET, V75, P878, DOI 10.1086/425080
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kelly OG, 2004, DEVELOPMENT, V131, P2803, DOI 10.1242/dev.01137
   Kim DH, 1998, J BIOCHEM TOKYO, V124, P1072, DOI 10.1093/oxfordjournals.jbchem.a022223
   Kokubu C, 2004, DEVELOPMENT, V131, P5469, DOI 10.1242/dev.01405
   Kruit JK, 2008, CLIN GENET, V73, P227, DOI 10.1111/j.1399 0004.2007.00952_1.x
   Kubota T, 2008, J BONE MINER RES, V23, P1661, DOI 10.1359/JBMR.080512
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   LI X, 2008, J BONE MINER RES, V23, pS60
   Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614
   Lindvall C, 2007, STEM CELL REV, V3, P157, DOI 10.1007/s12015 007 0025 3
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Lobov IB, 2005, NATURE, V437, P417, DOI 10.1038/nature03928
   Magoori K, 2003, J BIOL CHEM, V278, P11331, DOI 10.1074/jbc.M211987200
   Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370
   Millar JBA, 2002, GENOME BIOL, V3
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Nakamura T, 2008, J CELL MOL MED, V12, P391, DOI 10.1111/j.1582 4934.2007.00201.x
   Nakanishi R, 2008, J BONE MINER RES, V23, P271, DOI 10.1359/JBMR.071007
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Padhi D, 2007, J BONE MINER RES, V22, pS37
   Pan WJ, 2008, SCIENCE, V321, P1350, DOI 10.1126/science.1160741
   Panáková D, 2005, NATURE, V435, P58, DOI 10.1038/nature03504
   Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Pospisil H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471 2164 7 148
   Qin MH, 2005, HUM MUTAT, V26, P104, DOI 10.1002/humu.20191
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Richards JB, 2008, LANCET, V371, P1505, DOI 10.1016/S0140 6736(08)60599 1
   Richards JB, 2007, ARCH INTERN MED, V167, P188, DOI 10.1001/archinte.167.2.188
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200
   Schulze J, 2008, J BONE MINER RES, V23, pS2
   Semënov MV, 2008, J BIOL CHEM, V283, P21427, DOI 10.1074/jbc.M800014200
   Shitashige M, 2008, CANCER SCI, V99, P631, DOI 10.1111/j.1349 7006.2007.00716.x
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Toomes C, 2004, AM J HUM GENET, V74, P721, DOI 10.1086/383202
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Tzahor E, 2007, DEV CELL, V13, P10, DOI 10.1016/j.devcel.2007.06.006
   van Meurs JBJ, 2008, JAMA J AM MED ASSOC, V299, P1277, DOI 10.1001/jama.299.11.1277
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
   Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534 5807(03)00266 1
   Wan M, 2008, GENE DEV, V22, P2968, DOI 10.1101/gad.1702708
   Wang K, 2008, J BIOL CHEM, V283, P23371, DOI 10.1074/jbc.M802376200
   Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052
   Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092 8674(04)00216 8
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
NR 84
TC 163
Z9 190
U1 0
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2009
VL 24
IS 2
BP 171
EP 178
DI 10.1359/JBMR.081235
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 396ER
UT WOS:000262575500001
PM 19072724
OA Green Published
DA 2025 08 17
ER

PT J
AU Zanotti, S
   Canalis, E
AF Zanotti, Stefano
   Canalis, Ernesto
TI Parathyroid hormone inhibits Notch signaling in osteoblasts and
   osteocytes
SO BONE
LA English
DT Article
DE PTH; Notch; Rbpjk; Osteoblast; Osteocyte
ID TRABECULAR BONE MASS; OSTEOCLAST DIFFERENTIATION; GROWTH FACTOR;
   ANABOLIC THERAPIES; COLLAGEN SYNTHESIS; CELLS; EXPRESSION; LIGAND;
   ACTIVATION; RECEPTOR
AB Parathyroid hormone (PTH) and Notch receptors regulate bone formation by governing the function of osteoblastic cells. To determine whether PTH interacts with Notch signaling as a way to control osteoblast function, we tested the effects of PTH on Notch activity in osteoblast  and osteocyte enriched cultures. Notch signaling was activated in osteoblast enriched cells from wild type C57BL/6J mice following exposure to the Notch ligand Delta like (D11)1 or by the transient transfection of the Notch intracellular domain (NICD), the transcriptionally active fragment of Notch1. To induce Notch signaling in osteocyte enriched cultures, a murine model of Notch2 gain of function was used. PTH opposed the stimulatory effects of Dll1 on Hey1, Hey2 and HeyL mRNA levels in osteoblast enriched cells and suppressed the expression of selected Notch target genes in osteocyte enriched cultures, either under basal conditions or in the context of Notch2 gain of function. Induction of Notch signaling in osteocytes did not alter the inhibitory effect of PTH on Sost expression, but reduced the stimulation of Tnfsf1 1 mRNA levels by PTH. In agreement with these in vitro observations, male mice administered with PTH displayed suppressed Hey1 and HeyL expression in parietal bones. Transactivation experiments with a Notch reporter construct and electrophoretic mobility shift assays in osteoblast enriched cells suggest that PTH acts by decreasing the capacity of Rbpjk to bind to DNA. In conclusion, downregulation of Notch in osteoblasts and osteocytes may represent a mechanism contributing to the anabolic effects of PTH in bone. (C) 2017 Elsevier Inc. All rights reserved.
C1 UConn Hlth, UConn Musculoskeletal Inst, Dept Orthopaed Surg, Farmington, CT 06030 USA.
   UConn Hlth, UConn Musculoskeletal Inst, Dept Med, Farmington, CT 06030 USA.
RP Zanotti, S (通讯作者)，UConn Hlth, Dept Orthopaed Surg, Farmington, CT 06030 USA.
EM zanotti@uchc.edu
RI Zanotti, Stefano/C 6006 2009
OI Zanotti, Stefano/0000 0001 9711 5522
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS) [AR063049, AR068160]; National Institute of Diabetes and
   Digestive and Kidney Diseases (NIDDK) [DK045227]
FX This work was supported by [Grants AR063049 and AR068160] from the
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS) and [Grant DK045227] from the National Institute of Diabetes and
   Digestive and Kidney Diseases (NIDDK). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   CANALIS E, 1983, METABOLISM, V32, P14, DOI 10.1016/0026 0495(83)90149 X
   Canalis E., 2016, J CELL BIOCH
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Canalis E, 2016, J BIOL CHEM, V191, P1538, DOI 10.1074/jbc.M115.685453
   Canalis E, 2016, AM J PHYSIOL ENDOC M, V310, pE171, DOI 10.1152/ajpendo.00395.2015
   Canalis E, 2014, J CELL PHYSIOL, V229, P1736, DOI 10.1002/jcp.24625
   Canalis E, 2014, BONE, V64, P273, DOI 10.1016/j.bone.2014.04.028
   Canalis E, 2013, J BIOL CHEM, V288, P25614, DOI 10.1074/jbc.M113.470492
   Canalis E, 2013, ENDOCRINOLOGY, V154, P623, DOI 10.1210/en.2012 1732
   Canalis E, 2010, J CLIN ENDOCR METAB, V95, P1496, DOI 10.1210/jc.2009 2677
   CENTRELLA M, 1988, P NATL ACAD SCI USA, V85, P5889, DOI 10.1073/pnas.85.16.5889
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   del Alamo D, 2011, CURR BIOL, V21, pR40, DOI 10.1016/j.cub.2010.10.034
   DIETRICH JW, 1976, ENDOCRINOLOGY, V98, P943, DOI 10.1210/endo 98 4 943
   Duggan SP, 2016, CELL SIGNAL, V28, P1, DOI 10.1016/j.cellsig.2015.10.006
   FERMOR B, 1995, J BONE MINER RES, V10, P1935
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Gibson DG, 2009, NAT METHODS, V6, P343, DOI [10.1038/NMETH.1318, 10.1038/nmeth.1318]
   Halleux C, 2012, METHODS MOL BIOL, V816, P55, DOI 10.1007/978 1 61779 415 5_5
   HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Ishitani T, 2010, NAT CELL BIOL, V12, P278, DOI 10.1038/ncb2028
   Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208
   Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071 6079.2001
   Kedlaya R, 2016, ENDOCRINOLOGY, V157, P3047, DOI 10.1210/en.2015 1587
   Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045
   Kouadjo KE, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 127
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lawal R.A., 2017, J BONE MINER RES
   Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552
   LIAN J, 1989, P NATL ACAD SCI USA, V86, P1143, DOI 10.1073/pnas.86.4.1143
   Liang YY, 2004, J VIROL, V78, P6818, DOI 10.1128/JVI.78.13.6818 6826.2004
   Mahalingam CD, 2013, J ENDOCRINOL, V216, P315, DOI 10.1530/JOE 12 0372
   MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo 124 3 1247
   Murray TM, 2005, ENDOCR REV, V26, P78, DOI 10.1210/er.2003 0024
   Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e37
   Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, P2089, DOI 10.1093/nar/30.9.2089
   Nifuji A, 2010, EXP CELL RES, V316, P1127, DOI 10.1016/j.yexcr.2010.01.023
   Nioi P, 2015, J BONE MINER RES, V30, P1457, DOI 10.1002/jbmr.2482
   NODA M, 1988, J BIOL CHEM, V263, P18574
   NYE JS, 1994, DEVELOPMENT, V120, P2421
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Öberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200
   Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761 7774.2001
   Robling AG, 2011, ENDOCRINOLOGY, V152, P2963, DOI 10.1210/en.2011 0049
   ROULEAU MF, 1988, ENDOCRINOLOGY, V123, P187, DOI 10.1210/endo 123 1 187
   SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349
   Shi M, 2012, J CELL SCI, V125, P4320, DOI 10.1242/jcs.102152
   Shirayoshi Y, 1997, GENES CELLS, V2, P213, DOI 10.1046/j.1365 2443.1997.d01 310.x
   Six EM, 2004, J BIOL CHEM, V279, P55818, DOI 10.1074/jbc.M408022200
   Strobl LJ, 1997, IMMUNOBIOLOGY, V198, P299, DOI 10.1016/S0171 2985(97)80050 2
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Weber JM, 2006, BONE, V39, P485, DOI 10.1016/j.bone.2006.03.002
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Xu X, 2015, STRUCTURE, V23, P1227, DOI 10.1016/j.str.2015.05.001
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yorgan T, 2016, BONE, V87, P136, DOI 10.1016/j.bone.2016.04.012
   Youngstrom DW, 2016, BONE, V91, P64, DOI 10.1016/j.bone.2016.07.006
   Yuan ZY, 2012, J BIOL CHEM, V287, P34904, DOI 10.1074/jbc.M112.403287
   Zanotti S., 2015, J CELL BIOCH
   Zanotti S, 2008, ENDOCRINOLOGY, V149, P3890, DOI 10.1210/en.2008 0140
   Zanotti S, 2016, ENDOCR REV, V37, P223, DOI 10.1210/er.2016 1002
   Zanotti S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086757
   Zanotti S, 2013, J BIOL CHEM, V288, P624, DOI 10.1074/jbc.M112.340455
   Zanotti S, 2012, J CELL BIOCHEM, V113, P449, DOI 10.1002/jcb.23365
   Zanotti S, 2011, J BIOL CHEM, V286, P4576, DOI 10.1074/jbc.M110.161893
NR 72
TC 34
Z9 38
U1 1
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2017
VL 103
BP 159
EP 167
DI 10.1016/j.bone.2017.06.027
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FF0NY
UT WOS:000408599600020
PM 28676438
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Edwards, JR
   Perrien, DS
   Fleming, N
   Nyman, JS
   Ono, K
   Connelly, L
   Moore, MM
   Lwin, ST
   Yull, FE
   Mundy, GR
   Elefteriou, F
AF Edwards, James R.
   Perrien, Daniel S.
   Fleming, Nicole
   Nyman, Jeffry S.
   Ono, Koichiro
   Connelly, Linda
   Moore, Megan M.
   Lwin, Seint T.
   Yull, Fiona E.
   Mundy, Gregory R.
   Elefteriou, Florent
TI Silent information regulator (Sir)T1 inhibits NF B signaling to maintain
   normal skeletal remodeling
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE AGING; NF B; OSTEOBLAST; OSTEOCLAST; SirT1
ID FACTOR KAPPA B; MESENCHYMAL STEM CELLS; LIFE SPAN; CALORIE RESTRICTION;
   OSTEOCLAST DIFFERENTIATION; CAENORHABDITIS ELEGANS; TRABECULAR BONE;
   MOUSE MODELS; SIRTUIN 1; RESVERATROL
AB Silent information regulator T1 (SirT1) is linked to longevity and negatively controls NF B signaling, a crucial mediator of survival and regulator of both osteoclasts and osteoblasts. Here we show that NF B repression by SirT1 in both osteoclasts and osteoblasts is necessary for proper bone remodeling and may contribute to the mechanisms linking aging and bone loss. Osteoclast  or osteoblast specific SirT1 deletion using the Sirtflox/flox mice crossed to lysozyme M cre and the 2.3kb col1a1 cre transgenic mice, respectively, resulted in decreased bone mass caused by increased resorption and reduced bone formation. In osteoclasts, lack of SirT1 promoted osteoclastogenesis in vitro and activated NF B by increasing acetylation of Lysine 310. Importantly, this increase in osteoclastogenesis was blocked by pharmacological inhibition of NF B. In osteoblasts, decreased SirT1 reduced osteoblast differentiation, which could also be rescued by inhibition of NF B. In further support of the critical role of NF B signaling in bone remodeling, elevated NF B activity in IB+/ mice uncoupled bone resorption and formation, leading to reduced bone mass. These findings support the notion that SirT1 is a genetic determinant of bone mass, acting in a cell autonomous manner in both osteoblasts and osteoclasts, through control of NF B and bone cell differentiation. (c) 2013 American Society for Bone and Mineral Research.
C1 [Edwards, James R.; Perrien, Daniel S.; Fleming, Nicole; Nyman, Jeffry S.; Ono, Koichiro; Moore, Megan M.; Lwin, Seint T.; Mundy, Gregory R.; Elefteriou, Florent] Vanderbilt Univ, Med Ctr, Dept Med, Vanderbilt Ctr Bone Biol, Nashville, TN USA.
   [Edwards, James R.; Lwin, Seint T.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford OX3 7LD, England.
   [Perrien, Daniel S.; Fleming, Nicole; Nyman, Jeffry S.] Vanderbilt Univ, Med Ctr, Dept Orthopaed & Rehabil, Nashville, TN 37232 USA.
   [Perrien, Daniel S.; Mundy, Gregory R.] Vanderbilt Univ, Med Ctr, Inst Imaging Sci, Nashville, TN USA.
   [Nyman, Jeffry S.; Mundy, Gregory R.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN USA.
   [Connelly, Linda; Yull, Fiona E.; Mundy, Gregory R.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA.
C3 Vanderbilt University; University of Oxford; Vanderbilt University;
   Vanderbilt University; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); VA Tennessee Valley Healthcare System;
   Vanderbilt University
RP Edwards, JR (通讯作者)，Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford OX3 7LD, England.
EM James.Edwards@ndorms.ox.ac.uk; Florent.Elefteriou@Vanderbilt.edu
RI Nyman, Jeffry/L 5736 2013; Perrien, Daniel/ISV 0029 2023; Connelly,
   Linda/GVS 4612 2022; Elefteriou, Florent/P 2586 2017
OI Perrien, Daniel/0000 0002 5488 3932; Nyman, Jeffry/0000 0001 7403 7605;
   Elefteriou, Florent/0000 0002 2972 5633
FU American Federation for Aging Research; Vanderbilt Department of
   Medicine; Vanderbilt Orthopaedic Institute Pilot Award
FX We are grateful to the American Federation for Aging Research (JE),
   Vanderbilt Department of Medicine (GM and FE), and the Vanderbilt
   Orthopaedic Institute Pilot Award (DP) for funding this work, and to
   Drs. Jack Martin, Claire Edwards, and Xiangli Yang for comments,
   assistance, and review of the manuscript.
CR Bäckesjö CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   Cantó C, 2012, PHARMACOL REV, V64, P166, DOI 10.1124/pr.110.003905
   Cantó C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Cao JJ, 2005, J BONE MINER RES, V20, P1659, DOI 10.1359/JBMR.050503
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chen CL, 2000, J IMMUNOL, V165, P5418, DOI 10.4049/jimmunol.165.10.5418
   Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200
   Chen TT, 2011, AGING CELL, V10, P908, DOI 10.1111/j.1474 9726.2011.00722.x
   Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Cohen Kfir E, 2011, ENDOCRINOLOGY, V152, P4514, DOI 10.1210/en.2011 1128
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   Elefteriou F, 2011, BONE, V49, P1242, DOI 10.1016/j.bone.2011.08.021
   Erben RG, 1997, J HISTOCHEM CYTOCHEM, V45, P307, DOI 10.1177/002215549704500215
   ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv 7 4 379
   Everhart MB, 2006, J IMMUNOL, V176, P4995, DOI 10.4049/jimmunol.176.8.4995
   Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000
   Gan L, 2008, NEURON, V58, P10, DOI 10.1016/j.neuron.2008.03.015
   Gao XZ, 2012, ANN RHEUM DIS, V71, P129, DOI 10.1136/ard.2011.149831
   Gerhart Hines Z, 2011, MOL CELL, V44, P851, DOI 10.1016/j.molcel.2011.12.005
   Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506
   Han LM, 2010, NUCLEIC ACIDS RES, V38, P7458, DOI 10.1093/nar/gkq609
   He WJ, 2010, J CLIN INVEST, V120, P1056, DOI 10.1172/JCI41563
   Helenius M, 1996, BIOCHEM J, V318, P603, DOI 10.1042/bj3180603
   Helenius M, 2001, ANTIOXID REDOX SIGN, V3, P147, DOI 10.1089/152308601750100669
   Henriksen K, 2007, OSTEOPOROSIS INT, V18, P751, DOI 10.1007/s00198 006 0298 4
   Herskind AM, 1996, HUM GENET, V97, P319, DOI 10.1007/s004390050042
   Hjelmborg JV, 2006, HUM GENET, V119, P312, DOI 10.1007/s00439 006 0144 y
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jeong JY, 2011, BRIT J HAEMATOL, V155, P93, DOI 10.1111/j.1365 2141.2011.08800.x
   Jimi E, 1999, J IMMUNOL, V163, P434
   Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570
   Korhonen P, 1997, NEUROSCI LETT, V225, P61, DOI 10.1016/S0304 3940(97)00190 0
   Kupisiewicz K, 2010, CALCIFIED TISSUE INT, V87, P437, DOI 10.1007/s00223 010 9399 3
   Lee YM, 2011, J PERIODONTAL RES, V46, P712, DOI 10.1111/j.1600 0765.2011.01394.x
   Lei M, 2012, EUR J PHARMACOL, V674, P73, DOI 10.1016/j.ejphar.2011.10.015
   LIPS P, 1978, CALC TISS RES, V26, P13, DOI 10.1007/BF02013227
   Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl
   Lombard DB, 2011, NATURE, V477, P410, DOI 10.1038/477410a
   McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38 54.2003
   Mitchell BD, 2001, AM J MED GENET, V102, P346, DOI 10.1002/ajmg.1483
   Outeiro TF, 2007, SCIENCE, V317, P516, DOI 10.1126/science.1143780
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101
   Seeman E, 1996, AM J PHYSIOL ENDOC M, V270, pE320, DOI 10.1152/ajpendo.1996.270.2.E320
   Su JL, 2007, J BIOL CHEM, V282, P19385, DOI 10.1074/jbc.M702452200
   Timmers S, 2011, CELL METAB, V14, P612, DOI 10.1016/j.cmet.2011.10.002
   Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Viswanathan M, 2011, NATURE, V477, pE1, DOI 10.1038/nature10440
   Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Yi CO, 2011, ANAT CELL BIOL, V44, P194, DOI 10.5115/acb.2011.44.3.194
   Yu W, 2012, J CELL BIOCHEM, V113, P752, DOI 10.1002/jcb.23431
   Yuan HF, 2012, J MOL MED, V90, P389, DOI 10.1007/s00109 011 0825 4
NR 56
TC 110
Z9 118
U1 0
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2013
VL 28
IS 4
BP 960
EP 969
DI 10.1002/jbmr.1824
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 112EB
UT WOS:000316573900026
PM 23172686
DA 2025 08 17
ER

PT J
AU Qiu, WM
   Kassem, M
AF Qiu, Weimin
   Kassem, Moustapha
TI miR 141 3p inhibits human stromal (mesenchymal) stem cell proliferation
   and differentiation
SO BIOCHIMICA ET BIOPHYSICA ACTA MOLECULAR CELL RESEARCH
LA English
DT Article
DE Human stromal (mesenchymal) stern cell; miRNA; Cell proliferation and
   differentiation; Wnt signaling; CDC25A
ID OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; GENE EXPRESSION;
   BONE; MICRORNA; TARGETS; CANCER; CARCINOMA; FATE
AB Wnt signaling determines human stromal (mesenchymal) stem cell (hMSC) differentiation fate into the osteoblast or adipocyte lineage. microRNAs (miRNAs) are small RNA molecules of 21 25 nucleotides that regulate many aspects of osteoblast biology. Thus, we examined miRNAs regulated by Wnt signaling in hMSC We identified miRNA (miR) 141 3p as a Wnt target which in turn inhibited Wnt signaling. Moreover, miR 141 3p inhibited hMSC proliferation by arresting cells at the G1 phase of the cell cycle. miR 141 3p inhibited osteoblast differentiation of hMSC as evidenced by reduced alkaline phosphatase activity, gene expression and in vitro mineralized matrix formation. Bioinformatic studies, Western blot analysis and 3'UTR reporter assay demonstrated that cell division cycle 25A (CDC25A) is a direct target of miR 141 3p. siRNA mediated knock down of CDC25A inhibited hMSC proliferation and osteoblast differentiation. In summary, miR 141 3p acts as a negative regulator of hMSC proliferation and osteoblast differentiation. Targeting miR 141 3p could be used as an anabolic therapy of low bone mass diseases, e.g. osteoporosis. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Qiu, Weimin; Kassem, Moustapha] Odense Univ Hosp, Dept Endocrinol, Mol Endocrinol Lab KMEB, DK 5000 Odense C, Denmark.
   [Kassem, Moustapha] Univ Copenhagen, Danish Stem Cell Ctr DanStem, Copenhagen, Denmark.
C3 University of Southern Denmark; Odense University Hospital; University
   of Copenhagen
RP Qiu, WM (通讯作者)，Odense Univ Hosp, Dept Endocrinol, Mol Endocrinol Lab KMEB, Winslowspk 25 1, DK 5000 Odense C, Denmark.
EM wqiu@health.sdu.dk
RI Kassem, Moustapha/J 7688 2013
OI Kassem, Moustapha/0000 0003 1557 0869; , weimin/0000 0003 0046 6639
FU Fabrikant Vilhelm Pedersen og Hustrus; Novo Nordisk Foundation; Odense
   University Hospital
FX We thank Linda Harkness for proofreading. This work was supported by
   grants from Fabrikant Vilhelm Pedersen og Hustrus, Novo Nordisk
   Foundation, a local grant from Odense University Hospital.
CR Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067
   Al Nbaheen M, 2013, STEM CELL REV REP, V9, P32, DOI 10.1007/s12015 012 9365 8
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169
   Du Y, 2009, J GASTROENTEROL, V44, P556, DOI 10.1007/s00535 009 0037 7
   Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181
   Eguchi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058796
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   He L., 2004, NAT REV GENET, V5, P522
   Hutvágner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Itoh T, 2009, J BIOL CHEM, V284, P19272, DOI 10.1074/jbc.M109.014001
   Janowski BA, 2007, NAT CHEM BIOL, V3, P166, DOI 10.1038/nchembio860
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Kapinas K, 2009, J CELL BIOCHEM, V108, P216, DOI 10.1002/jcb.22243
   Khraiwesh B, 2010, CELL, V140, P111, DOI 10.1016/j.cell.2009.12.023
   Korpal M, 2008, RNA BIOL, V5, P115, DOI 10.4161/rna.5.3.6558
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Lee G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015561
   Lee G, 2009, P NATL ACAD SCI USA, V106, P4701, DOI 10.1073/pnas.0900751106
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311
   Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Qiu WM, 2011, BIOCHEM BIOPH RES CO, V413, P98, DOI 10.1016/j.bbrc.2011.08.061
   Qiu WM, 2010, J BIOL CHEM, V285, P14438, DOI 10.1074/jbc.M109.052001
   Renthal NE, 2013, NAT REV ENDOCRINOL, V9, P391, DOI 10.1038/nrendo.2013.96
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Taipaleenmäki H, 2012, EUR J ENDOCRINOL, V166, P359, DOI 10.1530/EJE 11 0646
   Vergoulis T, 2012, NUCLEIC ACIDS RES, V40, pD222, DOI 10.1093/nar/gkr1161
   Wang T, 2010, BIOCHEM BIOPH RES CO, V402, P186, DOI 10.1016/j.bbrc.2010.08.031
   Yu XY, 2013, ONCOTARGETS THER, V6, P349, DOI 10.2147/OTT.S41343
   Zhang J, 2011, J BONE MINER RES, V26, P1953, DOI 10.1002/jbmr.377
   Zhang LM, 2010, CARCINOGENESIS, V31, P559, DOI 10.1093/carcin/bgp335
NR 38
TC 58
Z9 70
U1 0
U2 26
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167 4889
EI 1879 2596
J9 BBA MOL CELL RES
JI Biochim. Biophys. Acta Mol. Cell Res.
PD SEP
PY 2014
VL 1843
IS 9
BP 2114
EP 2121
DI 10.1016/j.bbamcr.2014.06.004
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AM0KU
UT WOS:000339535300030
PM 24937190
OA Bronze
DA 2025 08 17
ER

PT J
AU Cu, H
   Yao, MK
   Duan, DX
   Yang, ZT
   Cheng, ZM
   Hou, XD
   Wang, HY
   Xiang, Q
AF Cu, Haifeng
   Yao, Mingkai
   Duan, Daxin
   Yang, Ziting
   Cheng, Ziming
   Hou, Xiaodan
   Wang, Haiyang
   Xiang, Qian
TI Targeted Therapy in Osteoporosis: The Promise of Monoclonal Antibodies
   and Small Molecules
SO IRANIAN RED CRESCENT MEDICAL JOURNAL
LA English
DT Article
DE Osteoporosis; Monoclonal antibodies; Denosumab; Romosozumab;
   Teriparatide; RANKL
ID BONE MINERAL DENSITY; ANTIRESORPTIVE AGENTS; POSTMENOPAUSAL WOMEN;
   COMBINATION THERAPY; TERIPARATIDE; FRACTURE; RISK; SCLEROSTIN;
   PREVENTION; DENOSUMAB
AB Background and Objectives: Osteoporosis is a widespread disease affecting over 500 million people worldwide, with one in three women and one in five men over the age of 50 sustaining an osteoporotic fracture. Conventional treatment methods, such as bisphosphonates and SERMs, address the inhibition of bone resorption but are restricted by side effects and differences in efficacy. Targeted therapies provide novel options, such as monoclonal antibodies and small molecules that interfere with specific molecular pathways. Methods: A systematic review of PubMed/MEDLINE and Google Scholar literature until September 2024 was performed. The search keywords were "osteoporosis," "monoclonal antibodies," "small molecules," and "bone resorption." We included clinical and preclinical studies that assessed efficacy, mechanisms, and safety and minimized bias through independent screening by two reviewers. Results: Several monoclonal antibodies (e.g., denosumab, romosozumab) act by inhibiting important pathways (e.g., RANKL, sclerostin) regulating bone resorption and formation. These agents include small molecules, such as teriparatide and abaloparatide, that mimic the parathyroid hormone that stimulates bone formation. Although these therapies increase bone density and decrease fractures, concerns regarding longterm safety, including cardiovascular risks and rebound effects following cessation, persist. Combination therapies and personalized approaches may overcome these problems. Conclusion: Targeted therapies for the management of osteoporosis and fracture prevention have come a long way in dealing with bone resorption and formation. Integrating genetic biomarkers and machine learning will enable personalized treatment strategies for safer and more effective solutions for patients, which is an exciting avenue for future research.
C1 [Cu, Haifeng; Yao, Mingkai; Duan, Daxin; Yang, Ziting; Cheng, Ziming] 964th Hosp PLA Joint Logist Support Force, Traumatol Dept, Changchun 130062, Peoples R China.
   [Hou, Xiaodan] 964th Hosp PLA Joint Logist Support Force, Pharm Dept, Changchun 130062, Peoples R China.
   [Wang, Haiyang] 964 Hosp, Joint Logist Support Force, Med Serv Training Ctr, Changchun 130062, Peoples R China.
   [Xiang, Qian] 964th Hosp PLA Joint Logist Support Force, Endocrinol Dept, Changchun 130062, Peoples R China.
RP Wang, HY (通讯作者)，964 Hosp, Joint Logist Support Force, Med Serv Training Ctr, Changchun 130062, Peoples R China.; Xiang, Q (通讯作者)，964th Hosp PLA Joint Logist Support Force, Endocrinol Dept, Changchun 130062, Peoples R China.
EM wanghaiyang0512@126.com; 179416782@qq.com
CR Akel M, 2024, StatPearls Internet
   Altman AR, 2015, J BIOMECH ENG T ASME, V137, DOI 10.1115/1.4028823
   Anagnostis P, 2019, MATURITAS, V120, P1, DOI 10.1016/j.maturitas.2018.11.010
   Atesok K, 2020, ORTHOP REV, V12, P64, DOI 10.4081/or.2020.8590
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bone HG, 2018, J CLIN ENDOCR METAB, V103, P2949, DOI 10.1210/jc.2018 00163
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Brett AD, 2015, J ORTHOP TRANSL, V3, P178, DOI 10.1016/j.jot.2015.08.006
   Chandran M, 2022, ARCH ENDOCRIN METAB, V66, P724, DOI 10.20945/2359 3997000000564
   Chavassieux P, 2019, J BONE MINER RES, V34, P1597, DOI 10.1002/jbmr.3735
   Cheng SH, 2025, DRUG SAFETY, V48, P7, DOI 10.1007/s40264 024 01475 9
   Choi JUA, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.770143
   Clarke BL, 2010, RADIOL CLIN N AM, V48, P483, DOI 10.1016/j.rcl.2010.02.014
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cosman Felicia, 2005, Curr Osteoporos Rep, V3, P143, DOI 10.1007/s11914 996 0017 2
   Cosman F, 2018, J BONE MINER RES, V33, P1219, DOI 10.1002/jbmr.3427
   Dai R, 2020, Front Cell Dev Biol, P8
   Delgado Calle J, 2017, BONE, V96, P29, DOI 10.1016/j.bone.2016.10.007
   Dempster DW, 2021, J BONE MINER RES, V36, P644, DOI 10.1002/jbmr.4243
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Föger Samwald U, 2020, EXCLI J, V19, P1017, DOI 10.17179/excli2020 2591
   Gallagher JC, 2005, J CLIN ENDOCR METAB, V90, P1583, DOI 10.1210/jc.2004 0826
   Gao YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158182
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Hildebrand GK, 2024, StatPearls Internet
   Hunziker J, 2000, J DENT RES, V79, P1431, DOI 10.1177/00220345000790061301
   Inoue D, 2016, CALCIFIED TISSUE INT, V98, P114, DOI 10.1007/s00223 015 0071 9
   Jiang HW, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.847387
   Jordan N, 2006, CLIN INTERV AGING, V1, P377, DOI 10.2147/ciia.2006.1.4.377
   Kendler DL, 2022, ADV THER, V39, P58, DOI 10.1007/s12325 021 01936 y
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Krupa KN, 2024, StatPearls Internet
   Kulcsar Z, 2014, ARTHRITIS RHEUMATOL, V66, pS983
   Lane J, 2024, OSTEOPOROSIS INT, V35, P1195, DOI 10.1007/s00198 024 07049 w
   Leder BZ, 2014, J CLIN ENDOCR METAB, V99, P1694, DOI 10.1210/jc.2013 4440
   Leung P, 2011, BONE, V49, P623, DOI 10.1016/j.bone.2011.06.014
   Lewiecki EM, 2021, ENDOCRINOL METAB, V36, P270, DOI 10.3803/EnM.2021.970
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Liang B, 2022, CELL MOL BIOL LETT, V27, DOI 10.1186/s11658 022 00371 3
   Lindsay R, 2016, OSTEOPOROSIS INT, V27, P2395, DOI 10.1007/s00198 016 3534 6
   Lu J, 2018, J ENZYM INHIB MED CH, V33, P890, DOI 10.1080/14756366.2018.1465417
   Makitie RE, 2019, Front Endocrinol (Lausanne), P10
   Matsumoto T, 2022, J CLIN ENDOCR METAB, V107, pE4222, DOI 10.1210/clinem/dgac486
   McClung Michael R, 2018, Osteoporos Sarcopenia, V4, P11, DOI 10.1016/j.afos.2018.03.002
   McColm J, 2014, J BONE MINER RES, V29, P935, DOI 10.1002/jbmr.2092
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Mohammed ZA, 2019, INDO AM J PHARM SCI, V6, P357, DOI 10.5281/zenodo.2530873
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Morello KC, 2003, CLIN PHARMACOKINET, V42, P361, DOI 10.2165/00003088 200342040 00004
   Nakamura Y, 2015, BMC ENDOCR DISORD, V15, DOI 10.1186/s12902 015 0077 3
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nishikawa A, 2016, CLIN INTERV AGING, V11, P913, DOI 10.2147/CIA.S107285
   Noble JA, 2021, THER ADV ENDOCRINOL, V12, DOI 10.1177/20420188211010052
   Pennypacker BL, 2014, J BONE MINER RES, V29, P1847, DOI 10.1002/jbmr.2211
   Pouresmaeili F, 2018, THER CLIN RISK MANAG, V14, P2029, DOI 10.2147/TCRM.S138000
   Recker R, 2020, J BONE MINER RES, V35, P1289, DOI 10.1002/jbmr.3994
   Recknor CP, 2015, J BONE MINER RES, V30, P1717, DOI 10.1002/jbmr.2489
   Reginster JY, 2014, BEST PRACT RES CL EN, V28, P809, DOI 10.1016/j.beem.2014.09.003
   Reginster JY, 2018, CALCIFIED TISSUE INT, V103, P540, DOI 10.1007/s00223 018 0450 0
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Schilling AF, 2007, OSTEOPOROSIS INT, V18, P659, DOI 10.1007/s00198 006 0311 y
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Su Yanlin, 2022, Ann Palliat Med, V11, P3203, DOI 10.21037/apm 22 998
   Tay WL, 2022, ENDOCRINOL METAB, V37, P183, DOI 10.3803/EnM.2021.1369
   Tella SH, 2017, Cureus
   Tonk CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031393
   Tsai JN, 2015, J BONE MINER RES, V30, P39, DOI 10.1002/jbmr.2315
   World Health Organization, Guidelines for preclinical evaluation and clinical trials in osteoporosis
   Wright HL, 2009, CURR REV MUSCULOSKE, V2, P56, DOI 10.1007/s12178 009 9046 7
   Wu XP, 2003, BRIT J RADIOL, V76, P605, DOI 10.1259/bjr/56839904
   Zhang CG, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.607017
NR 77
TC 0
Z9 0
U1 0
U2 0
PU Dubai Iranian Hosp
PI Dubai
PA Al Wasl Road , Jumeirah 1, P.O.BOX: 2330, Dubai, U ARAB EMIRATES
SN 2074 1804
EI 2074 1812
J9 IRAN RED CRESCENT ME
JI Iran. Red Crescent Med. J.
PY 2024
VL 26
IS 1
AR 1507
DI 10.22034/ircmj.2025.480818.1507
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 3FS3K
UT WOS:001499250100001
DA 2025 08 17
ER

PT J
AU Lim, KE
   Hoggatt, AM
   Bullock, WA
   Horan, DJ
   Yokota, H
   Pavalko, FM
   Robling, AG
AF Lim, Kyung Eun
   Hoggatt, April M.
   Bullock, Whitney A.
   Horan, Daniel J.
   Yokota, Hiroki
   Pavalko, Frederick M.
   Robling, Alexander G.
TI Pten deletion in Dmp1 expressing cells does not rescue the osteopenic
   effects of Wnt/β catenin suppression
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE Akt; osteoporosis; Pten; Wnt; beta catenin
ID WNT SIGNALING PATHWAY; MICE LACKING PTEN; TUMOR SUPPRESSOR;
   BETA CATENIN; BONE; PHOSPHATASE; OSTEOBLASTS; INHIBITION; MUTATIONS;
   PORCUPINE
AB Skeletal homeostasis is sensitive to perturbations in Wnt signaling. Beyond its role in the bone, Wnt is a major target for pharmaceutical inhibition in a wide range of diseases, most notably cancers. Numerous clinical trials for Wnt based candidates are currently underway, and Wnt inhibitors will likely soon be approved for clinical use. Given the bone suppressive effects accompanying Wnt inhibition, there is a need to expose alternate pathways/molecules that can be targeted to counter the deleterious effects of Wnt inhibition on bone properties. Activation of the Pi3k/Akt pathway via Pten deletion is one possible osteoanabolic pathway to exploit. We investigated whether the osteopenic effects of beta catenin deletion from bone cells could be rescued by Pten deletion in the same cells. Mice carrying floxed alleles for Pten and beta catenin were bred to Dmp1 Cre mice to delete Pten alone, beta catenin alone, or both genes from the late stage osteoblast/osteocyte population. The mice were assessed for bone mass, density, strength, and formation parameters to evaluate the potential rescue effect of Pten deletion in Wnt impaired mice. Pten deletion resulted in high bone mass and beta catenin deletion resulted in low bone mass. Compound mutants had bone properties similar to beta catenin mutant mice, or surprisingly in some assays, were further compromised beyond beta catenin mutants. Pten inhibition, or one of its downstream nodes, is unlikely to protect against the bone wasting effects of Wnt/beta cat inhibition. Other avenues for preserving bone mass in the presence of Wnt inhibition should be explored to alleviate the skeletal side effects of Wnt inhibitor based therapies.
C1 [Lim, Kyung Eun; Hoggatt, April M.; Bullock, Whitney A.; Horan, Daniel J.; Pavalko, Frederick M.; Robling, Alexander G.] Indiana Univ Sch Med, Dept Anat Cell Biol & Physiol, Indianapolis, IN 46202 USA.
   [Yokota, Hiroki; Pavalko, Frederick M.; Robling, Alexander G.] Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN USA.
   [Yokota, Hiroki; Robling, Alexander G.] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
   [Robling, Alexander G.] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA.
C3 Indiana University System; Indiana University Bloomington; Purdue
   University System; Purdue University; Purdue University in Indianapolis;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Richard L. Roudebush VA Medical Center
RP Robling, AG (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS 5035, Indianapolis, IN 46202 USA.
EM arobling@iupui.edu
RI Park, Mi Kyung/J 9643 2017
FU U.S. Department of Veterans Affairs [BX001478, BX003783]; National
   Institutes of Health [AR053237, AR065971, AR069029, AR070624]
FX U.S. Department of Veterans Affairs, Grant/Award Numbers: BX001478,
   BX003783; National Institutes of Health, Grant/Award Numbers: AR053237,
   AR065971, AR069029, AR070624
CR Bononi A, 2013, CELL DEATH DIFFER, V20, P1631, DOI 10.1038/cdd.2013.77
   Brault V, 2001, DEVELOPMENT, V128, P1253
   Burgers TA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063857
   Cao JX, 2013, MOL CELL, V51, P409, DOI 10.1016/j.molcel.2013.08.010
   Castillo AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043291
   Cheung WMW, 2006, BONE, V39, P470, DOI 10.1016/j.bone.2006.02.069
   Collins CJ, 2015, J BIOMECH, V48, P310, DOI 10.1016/j.jbiomech.2014.11.028
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535 6108(03)00021 7
   Georgopoulos NT, 2014, J CELL SCI, V127, P2967, DOI 10.1242/jcs.150888
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Harb J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912 019 0763 9
   Hjelmeland AB, 2005, CANCER RES, V65, P11276, DOI 10.1158/0008 5472.CAN 05 3016
   Hopkins BD, 2013, SCIENCE, V341, P399, DOI 10.1126/science.1234907
   Jaldin Fincati JR, 2017, TRENDS ENDOCRIN MET, V28, P597, DOI 10.1016/j.tem.2017.05.002
   Javaheri B, 2014, J BONE MINER RES, V29, P705, DOI 10.1002/jbmr.2064
   Jhanwar Uniyal Meena, 2019, Advances in Biological Regulation, V72, P51, DOI 10.1016/j.jbior.2019.03.003
   Johnson ML, 2017, CURR OSTEOPOROS REP, V15, P153, DOI 10.1007/s11914 017 0357 0
   Kang KS, 2016, BONE, V88, P138, DOI 10.1016/j.bone.2016.04.028
   Kedlaya R, 2016, ENDOCRINOLOGY, V157, P3047, DOI 10.1210/en.2015 1587
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036
   Lin HK, 2004, MOL ENDOCRINOL, V18, P2409, DOI 10.1210/me.2004 0117
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110
   Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104
   Lu Y, 2007, J DENT RES, V86, P320, DOI 10.1177/154405910708600404
   Madan B, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0017 8
   Madan B, 2016, KIDNEY INT, V89, P1062, DOI 10.1016/j.kint.2016.01.017
   Moon J, 2017, P NATL ACAD SCI USA, V114, P1649, DOI 10.1073/pnas.1621346114
   Niziolek PJ, 2011, BONE, V49, P1010, DOI 10.1016/j.bone.2011.07.034
   Paszty C, 2010, J BONE MINER RES, V25, P1897, DOI 10.1002/jbmr.161
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
   Yamada KM, 2001, J CELL SCI, V114, P2375
   Yang F, 2017, ONCOTARGETS THER, V10, P4413, DOI 10.2147/OTT.S145601
   Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109
NR 38
TC 2
Z9 3
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD DEC
PY 2020
VL 235
IS 12
BP 9785
EP 9794
DI 10.1002/jcp.29792
EA JUN 2020
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA NT9RO
UT WOS:000539573800001
PM 32529635
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Trinkaus, M
   Ooi, WS
   Amir, E
   Popovic, S
   Kalina, M
   Kahn, H
   Singh, G
   Gainford, MC
   Clemons, M
AF Trinkaus, Mateya
   Ooi, Wei Seong
   Amir, Ethan
   Popovic, Snezana
   Kalina, Marion
   Kahn, Hariette
   Singh, Gurmit
   Gainford, Mary Corona
   Clemons, Mark
TI Examination of the mechanisms of osteolysis in patients with metastatic
   breast cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE bone metastases; breast cancer; osteolysis; receptor activator of
   nuclear factor kappa B ligand; vascular endothelial growth factor
ID PLACEBO CONTROLLED TRIAL; KAPPA B LIGAND; BONE METASTASES; SKELETAL
   COMPLICATIONS; OSTEOPROTEGERIN LIGAND; RECEPTOR ACTIVATOR;
   PROSTATE CANCER; IN VITRO; OSTEOCLAST DIFFERENTIATION; PAMIDRONATE
AB The benefits of bisphosphonates (BPs) in reducing skeletal related events (SREs) in patients with bone metastases has mainly been attributed to their potent osteoclast inhibiting effect. However, despite the use of modern systemic anticancer therapy including potent BPs, many patients with bone metastases continue to have SREs. An improved understanding of the fundamental mechanisms of bone destruction allows for further development of appropriate targeted treatments. In this study, archival paraffin embedded bone metastases specimens from patients with metastatic breast cancer were examined for the presence of osteoclasts, expression of the receptor activator of nuclear factor kappa B (RANK), RANK Ligand (RANKL), osteoprotegerin (OPG) and vascular endothelial growth factor (VEGF). Histological specimens were available for primary breast cancer, lymph node metastases, normal breast and normal bone tissues for comparison. Bone metastasis specimens were available for 20 BP naive patients and two BP treated patients. Osteoclasts were significantly increased in the bone metastases of the BP naive group compared to normal bone. No osteoclasts were detected in the BP treated group. RANKL was predominantly expressed in osteoblasts and in the stromal elements of metastatic tissue. Conversely, RANK was present in osteoclasts of bone metastases and normal bone, as well as in tumor cells of metastatic lymph nodes and bone metastases. VEGF was strongly expressed in the control bone and bone metastases regardless of BP treatment. In summary, osteoclasts may not be the singular obligatory factor for osteolysis in bone metastases. An increased expression of RANKL in stromal tissue surrounding bone metastases, RANK in osteoclasts and VEGF may serve as future targeted therapies possibly in conjunction with bisphosphonates. The mechanisms for osteoclast expression and the expression of RANKL, RANK, OPG and VEGF merit further prospective analysis, particularly in the context of BP treatment and progressive bone metastases.
C1 [Trinkaus, Mateya; Amir, Ethan; Clemons, Mark] Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada.
   [Ooi, Wei Seong; Kahn, Hariette] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada.
   [Popovic, Snezana] McMaster Univ, Hamilton, ON, Canada.
   [Kalina, Marion; Singh, Gurmit] Juravinski Canc Ctr, Hamilton, ON, Canada.
   [Gainford, Mary Corona] Univ Sydney, Sydney, NSW 2006, Australia.
C3 University of Toronto; University Health Network Toronto; Princess
   Margaret Cancer Centre; University of Toronto; Sunnybrook Research
   Institute; Sunnybrook Health Science Center; McMaster University;
   McMaster University; University of Sydney
RP Clemons, M (通讯作者)，Princess Margaret Hosp, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.
EM mark.clemons@uhn.on.ca
RI Amir, Eitan/L 6052 2019; Singh, Gurmit/C 6744 2014
OI Amir, Eitan/0000 0002 3706 525X
CR Aldridge SE, 2005, BRIT J CANCER, V92, P1531, DOI 10.1038/sj.bjc.6602417
   Bekker PJ, 2005, J BONE MINER RES, V20, P2274, DOI 10.1359/jbmr.2005.20.12.2274
   Bravenboer N, 1999, OSTEOPOROSIS INT, V9, P489, DOI 10.1007/s001980050175
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Chikatsu N, 2000, BIOCHEM BIOPH RES CO, V267, P632, DOI 10.1006/bbrc.1999.2008
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Conte PF, 1996, J CLIN ONCOL, V14, P2552, DOI 10.1200/JCO.1996.14.9.2552
   FERLAY J, 2004, GLOBOCAN 2002 CANC I
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   GALASKO CSB, 1976, NATURE, V263, P507, DOI 10.1038/263507a0
   Healey John H., 2000, Cancer, V88, P2940, DOI 10.1002/1097 0142(20000615)88:12+<2940::AID CNCR10>3.0.CO;2 W
   Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038
   Hultborn R, 1999, ANTICANCER RES, V19, P3383
   Kitazawa S, 2002, J PATHOL, V198, P228, DOI 10.1002/path.1199
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Kostenuik P. J., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P375
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Mancino AT, 2001, J SURG RES, V100, P18, DOI 10.1006/jsre.2001.6204
   McCloskey EV, 2001, DRUGS, V61, P1253, DOI 10.2165/00003495 200161090 00003
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Mori K, 2007, BONE, V40, P981, DOI 10.1016/j.bone.2006.11.006
   Morony S, 1999, J BONE MINER RES, V14, P1478, DOI 10.1359/jbmr.1999.14.9.1478
   Morrissey C, 2007, BMC CANCER, V7, DOI 10.1186/1471 2407 7 148
   MUNDY GR, 1974, NEW ENGL J MED, V291, P1041, DOI 10.1056/NEJM197411142912001
   Nakamura M, 2003, ENDOCRINOLOGY, V144, P5441, DOI 10.1210/en.2003 0717
   O'Brien EA, 2000, BIOCHEM BIOPH RES CO, V274, P281, DOI 10.1006/bbrc.2000.3129
   ORR W, 1979, SCIENCE, V203, P176, DOI 10.1126/science.569363
   Paget S., 1889, Cancer Metastasis Rev, V133, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pataki A, 1997, ANAT REC, V249, P458, DOI 10.1002/(SICI)1097 0185(199712)249:4<458::AID AR5>3.0.CO;2 N
   Phadke PA, 2006, CLIN CANCER RES, V12, P1431, DOI 10.1158/1078 0432.CCR 05 1806
   Plunkett TA, 2000, EUR J CANCER, V36, P476, DOI 10.1016/S0959 8049(99)00331 7
   Quinn JE, 2005, PROSTATE CANCER P D, V8, P253, DOI 10.1038/sj.pcan.4500815
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Schneeweis LA, 2005, J BIOL CHEM, V280, P41155, DOI 10.1074/jbc.M506366200
   SUAREZ T, 2006, J CLIN ONCOL ASCO 1, V24
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Van Poznak C, 2006, J CLIN PATHOL, V59, P56, DOI 10.1136/jcp.2005.026534
   Vukmirovic Popovic S, 2002, BONE, V31, P529, DOI 10.1016/S8756 3282(02)00847 5
   Waterman EA, 2007, INT J CANCER, V121, P1958, DOI 10.1002/ijc.22946
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yuan YY, 2006, J BONE MINER RES, V21, pS163
   Yuan YY, 2005, J BONE MINER RES, V20, pS161
   YUAN YY, OSTEOPOROS IN PRESS
   Zheng Y, 2007, BONE, V40, P471, DOI 10.1016/j.bone.2006.09.016
NR 54
TC 13
Z9 13
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021 335X
EI 1791 2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAY
PY 2009
VL 21
IS 5
BP 1153
EP 1159
DI 10.3892/or_00000335
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 434KV
UT WOS:000265274500003
PM 19360288
OA Bronze
DA 2025 08 17
ER

PT J
AU Li, BJ
   Chau, JFL
   Wang, XY
   Leong, WF
AF Li, Baojie
   Chau, Jenny Fung Ling
   Wang, Xueying
   Leong, Wai Fook
TI Bisphosphonates, Specific Inhibitors of Osteoclast Function and a Class
   of Drugs for Osteoporosis Therapy
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE OSTEOCLAST; OSTEOPOROSIS; BISPHOSPHONATES
ID NITROGEN CONTAINING BISPHOSPHONATES; GLUCOCORTICOID INDUCED
   OSTEOPOROSIS; PLASMA PROTEIN BINDING; BONE RESORPTION; ZOLEDRONIC ACID;
   MEVALONATE PATHWAY; PAGETS DISEASE; IN VITRO; RANKL EXPRESSION;
   HEARING LOSS
AB Osteoporosis is a result of the disruption of bone homeostasis that is carried out by bone forming osteoblasts and bone degrading osteoclasts. The most common treatment of osteoporosis is N containing bisphosphonates, a class of non hydrolyzable pyrophosphate analogs. They have strong affinity to Ca2+ of hydroxyapatite with high specificity and can only be liberated from the bone in an acidic environment. These properties bestow them unique pharmacokinetic features including specific and strong retention at bone resorption surface, uptaken specifically by osteoclasts, quick excretion of non retained free bisphosphonates, long half life, and recyclability. Such properties underlie the drugs' high efficacy, minor side effects, and intermittent dosing regimens. Further studies show that bisphosphonates inhibit farnesyl pyrophosphate synthase, a critical enzyme required for synthesis of isoprenyl and geranylgeranyl, and inhibit prenylation and geranylgeranylation of small G proteins such as Rac and Rho. This leads to defective actin ring formation at the sealed zone, a subcellular structure essential for bone resorption, and a decrease in bone resorption. Bisphosphonates are also used to treat Paget's disease of bone, osteolytic bone metastases, and hypercalcemia. Moreover, these properties also make N BPs a good candidate as a bone seeking agent. Here we update our understanding of this remarkable class of anti resorption drugs. J. Cell. Biochem. 112: 1229 1242, 2011. (C) 2011 Wiley Liss, Inc.
C1 [Li, Baojie] Shanghai Jiao Tong Univ, Minist Educ, Bio X Ctr, Key Lab Genet Dev & Neuropsychiat Disorders, Shanghai 200030, Peoples R China.
   [Chau, Jenny Fung Ling; Leong, Wai Fook] ASTAR, IMCB, Singapore 138673, Singapore.
   [Wang, Xueying] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Canc Sci Inst Singapore, Singapore 117595, Singapore.
C3 Shanghai Jiao Tong University; Agency for Science Technology & Research
   (A*STAR); A*STAR   Institute of Molecular & Cell Biology (IMCB);
   National University of Singapore
RP Li, BJ (通讯作者)，Shanghai Jiao Tong Univ, Minist Educ, Bio X Ctr, Key Lab Genet Dev & Neuropsychiat Disorders, Shanghai 200030, Peoples R China.
EM libj@sjtu.edu.cn; leong_wai_fook@sbic.a star.edu.sg
RI Leong, Wai Fook Peter/GXG 9911 2022
OI leong, wai yie/0000 0002 5389 1121; Leong, Wai Fook/0000 0002 2438 2715
CR Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104
   Amanat N, 2007, J BONE MINER RES, V22, P867, DOI 10.1359/JBMR.070318
   Ambrosetti D, 2008, MOL CELL BIOL, V28, P4759, DOI 10.1128/MCB.01849 07
   AMIN D, 1992, J LIPID RES, V33, P1657
   [Anonymous], ONCOLOGY WILLISTON P
   [Anonymous], ONCOLOGY WILLISTON P
   [Anonymous], ONCOLOGY WILLISTON P
   [Anonymous], BONE
   AZUMA Y, 1995, BONE, V16, P235, DOI 10.1016/8756 3282(94)00035 X
   Barrett J, 2004, J CLIN PHARMACOL, V44, P951, DOI 10.1177/0091270004267594
   Bauss F, 2002, J RHEUMATOL, V29, P2200
   Bauss F, 2004, OSTEOPOROSIS INT, V15, P423, DOI 10.1007/s00198 004 1612 7
   Bauss F, 2008, J BONE MINER METAB, V26, P406, DOI 10.1007/s00774 007 0837 x
   Berenson JR, 1997, J CLIN PHARMACOL, V37, P285, DOI 10.1002/j.1552 4604.1997.tb04304.x
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Blanchoin L, 2000, J MOL BIOL, V295, P203, DOI 10.1006/jmbi.1999.3336
   Bone HG, 2000, CLIN THER, V22, P15, DOI 10.1016/S0149 2918(00)87974 6
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Breton S, 2007, AM J PHYSIOL RENAL, V292, pF1, DOI 10.1152/ajprenal.00340.2006
   Breuil V, 2006, JOINT BONE SPINE, V73, P349, DOI 10.1016/j.jbspin.2005.10.019
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Clowes JA, 2005, IMMUNOL REV, V208, P207, DOI 10.1111/j.0105 2896.2005.00334.x
   Cocquyt V, 1999, J CLIN PHARMACOL, V39, P385, DOI 10.1177/00912709922007958
   Coleman RE, 1999, ANN ONCOL, V10, P311, DOI 10.1023/A:1008386501738
   Corrado A, 2007, JOINT BONE SPINE, V74, P32, DOI 10.1016/j.jbspin.2006.06.005
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Cramer JA, 2007, OSTEOPOROSIS INT, V18, P1023, DOI 10.1007/s00198 006 0322 8
   Cramer JA, 2006, AM J MED, V119, p12S, DOI 10.1016/j.amjmed.2005.12.018
   Cremers S, 2002, EUR J CLIN PHARMACOL, V57, P883, DOI 10.1007/s00228 001 0411 8
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   De Biase P, 2005, INJURY, V36, P43, DOI 10.1016/j.injury.2005.07.034
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   Fujisaki J, 1995, J DRUG TARGET, V3, P273, DOI 10.3109/10611869509015956
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Glass DA, 2007, ENDOCRINOLOGY, V148, P2630, DOI 10.1210/en.2006 1372
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Hamdy NAT, 2008, DRUG TODAY, V44, P7, DOI 10.1358/dot.2008.44.1.1178467
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Henneman ZJ, 2008, J BIOMED MATER RES A, V85A, P993, DOI 10.1002/jbm.a.31599
   Hess LM, 2008, AM J MED, V121, P475, DOI 10.1016/j.amjmed.2008.01.047
   HOGGARTH CR, 1991, CALCIFIED TISSUE INT, V49, P416, DOI 10.1007/BF02555853
   Huang CLH, 2006, CELL MOL BIOL, V52, P33
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kanzaki S, 2006, BONE, V39, P414, DOI 10.1016/j.bone.2006.01.155
   Kanzaki S, 2009, J BONE MINER RES, V24, P43, DOI [10.1359/jbmr.080812, 10.1359/JBMR.080812]
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Khan A, 2003, CAN FAM PHYSICIAN, V49, P441
   Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood 2003 01 0305
   Labrie F, 2007, NAT CLIN PRACT ENDOC, V3, P584, DOI 10.1038/ncpendmet0559
   LEYVRAZ S, 1992, J NATL CANCER I, V84, P788, DOI 10.1093/jnci/84.10.788
   Li Baojie, 2008, Endocrine Metabolic & Immune Disorders Drug Targets, V8, P208, DOI 10.2174/187153008785700127
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   LIN JH, 1994, DRUG METAB DISPOS, V22, P400
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895
   MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Martini G, 2007, BONE, V40, P457, DOI 10.1016/j.bone.2006.08.003
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Miller CP, 2002, CURR PHARM DESIGN, V8, P2089, DOI 10.2174/1381612023393404
   Miwa S, 2005, CANCER RES, V65, P8818, DOI 10.1158/0008 5472.CAN 05 0540
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Monkkonen J, 1987, Toxicol Appl Pharmacol, V89, P287
   MURAKAMI H, 1995, BONE, V17, P137, DOI 10.1016/S8756 3282(95)00150 6
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nishida S, 2005, BIOCHEM BIOPH RES CO, V328, P91, DOI 10.1016/j.bbrc.2004.12.145
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   Papapoulos SE, 2006, BONE, V38, P613, DOI 10.1016/j.bone.2006.01.141
   Perez EA, 2006, ONCOLOGY NY, V20, P1029
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Ralston SH, 2008, BONE, V43, P819, DOI 10.1016/j.bone.2008.06.015
   Rauch F, 2005, ANN MED, V37, P295, DOI 10.1080/07853890510007386
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092 8674(92)90163 7
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Rodan G, 2004, CURR MED RES OPIN, V20, P1291, DOI 10.1185/030079904125004475
   RODAN GA, 1992, BONE, V13, pS3, DOI 10.1016/S8756 3282(09)80003 3
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092 8674(00)80732 1
   Rosen CJ, 2004, TRENDS ENDOCRIN MET, V15, P229, DOI 10.1016/j.tem.2004.05.005
   Ruggiero SL, 2009, ANNU REV MED, V60, P85, DOI 10.1146/annurev.med.60.063007.134350
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Sawicki M, 2008, EUR J MED CHEM, V43, P2768, DOI 10.1016/j.ejmech.2008.01.018
   Schindeler A, 2007, J PHARM SCI US, V96, P1872, DOI 10.1002/jps.20904
   Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756 3282(99)00278 1
   SEEDOR JG, 1991, J BONE MINER RES, V6, P339
   Shaw NJ, 2005, ARCH DIS CHILD, V90, P494, DOI 10.1136/adc.2003.036590
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Takami M, 2003, BONE, V32, P341, DOI 10.1016/S8756 3282(03)00024 3
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Tsushima N, 2000, J PHARM PHARMACOL, V52, P27, DOI 10.1211/0022357001773652
   Väänänen HK, 2000, J CELL SCI, V113, P377
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   Van Beek ER, 2002, BONE, V30, P64, DOI 10.1016/S8756 3282(01)00655 X
   VANBEEK E, 1994, J BONE MINER RES, V9, P1875, DOI 10.1002/jbmr.5650091206
   Wang XY, 2007, ENDOCRINOLOGY, V148, P1629, DOI 10.1210/en.2006 1000
   WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Weiss HM, 2008, DRUG METAB DISPOS, V36, P2043, DOI 10.1124/dmd.108.021071
   Weitzmann MN, 2006, ANN NY ACAD SCI, V1068, P256, DOI 10.1196/annals.1346.030
   Whyte MP, 2006, NEW ENGL J MED, V355, P593, DOI 10.1056/NEJMcp060278
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Zacharis CK, 2008, J PHARMACEUT BIOMED, V48, P483, DOI 10.1016/j.jpba.2008.05.028
   Zaidi M, 2001, J BONE MINER RES, V16, P1747, DOI 10.1359/jbmr.2001.16.10.1747
   Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955 0674(93)90130 I
   Zgani I, 2004, J MED CHEM, V47, P4600, DOI 10.1021/jm049861z
   ZHANG D, 1995, J CELL SCI, V108, P2285
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
   Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597
NR 137
TC 45
Z9 56
U1 0
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAY
PY 2011
VL 112
IS 5
BP 1229
EP 1242
DI 10.1002/jcb.23049
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 748AH
UT WOS:000289361900001
PM 21465521
OA Bronze
DA 2025 08 17
ER

PT J
AU Adam, S
   Simon, N
   Steffen, U
   Andes, FT
   Scholtysek, C
   Müller, DIH
   Weidner, D
   Andreev, D
   Kleyer, A
   Culemann, S
   Hahn, M
   Schett, G
   Krönke, G
   Frey, S
   Hueber, AJ
AF Adam, Susanne
   Simon, Nils
   Steffen, Ulrike
   Andes, Fabian T.
   Scholtysek, Carina
   Mueller, Dorothea I. H.
   Weidner, Daniela
   Andreev, Darja
   Kleyer, Arnd
   Culemann, Stephan
   Hahn, Madelaine
   Schett, Georg
   Kroenke, Gerhard
   Frey, Silke
   Hueber, Axel J.
TI JAK inhibition increases bone mass in steady state conditions and
   ameliorates pathological bone loss by stimulating osteoblast function
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID STROMAL CELLS; STEM CELLS; ACTIVATION; DIFFERENTIATION; TOFACITINIB;
   PATHWAY; METHOTREXATE; CYTOKINES; TURNOVER; CATENIN
AB Janus kinase (JAK) mediated cytokine signaling has emerged as an important therapeutic target for the treatment of inflammatory diseases such as rheumatoid arthritis (RA). Accordingly, JAK inhibitors compose a new class of drugs, among which tofacitinib and baricitinib have been approved for the treatment of RA. Periarticular bone erosions contribute considerably to the pathogenesis of RA. However, although the immunomodulatory aspect of JAK inhibition (JAKi) is well defined, the current knowledge of how JAKi influences bone homeostasis is limited. Here, we assessed the effects of the JAK inhibitors tofacitinib and baricitinib on bone phenotype (i) in mice during steady state conditions or in mice with bone loss induced by (ii) estrogen deficiency (ovariectomy) or (iii) inflammation (arthritis) to evaluate whether effects of JAKi on bone metabolism require noninflammatory/inflammatory challenge. In all three models, JAKi increased bone mass, consistent with reducing the ratio of receptor activator of NF kappa B ligand/osteoprotegerin in serum. In vitro, effects of tofacitinib and baricitinib on osteoclast and osteoblast differentiation were analyzed. JAKi significantly increased osteoblast function (P < 0.05) but showed no direct effects on osteoclasts. Additionally, mRNA sequencing and ingenuity pathway analyses were performed in osteoblasts exposed to JAKi and revealed robust up regulation of markers for osteoblast function, such as osteocalcin and Wnt signaling. The anabolic effect of JAKi was illustrated by the stabilization of beta catenin. In humans with RA, JAKi induced bone anabolic effects as evidenced by repair of arthritic bone erosions. Results support that JAKi is a potent therapeutic tool for increasing osteoblast function and bone formation.
C1 [Adam, Susanne; Simon, Nils; Steffen, Ulrike; Andes, Fabian T.; Scholtysek, Carina; Mueller, Dorothea I. H.; Weidner, Daniela; Andreev, Darja; Kleyer, Arnd; Culemann, Stephan; Hahn, Madelaine; Schett, Georg; Kroenke, Gerhard; Frey, Silke; Hueber, Axel J.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany.
   [Adam, Susanne; Simon, Nils; Steffen, Ulrike; Andes, Fabian T.; Scholtysek, Carina; Mueller, Dorothea I. H.; Weidner, Daniela; Andreev, Darja; Kleyer, Arnd; Culemann, Stephan; Hahn, Madelaine; Schett, Georg; Kroenke, Gerhard; Frey, Silke; Hueber, Axel J.] DZI, Erlangen, Germany.
   [Culemann, Stephan] Univ Klinikum Erlangen, Nikolaus Fiebiger Ctr Mol Med, Erlangen, Germany.
   [Culemann, Stephan] Friedrich Alexander Univ Erlangen Nurnberg FAU, Erlangen, Germany.
   [Hueber, Axel J.] Sozialstiftung Bamberg, Sekt Rheumatol, Buger Str 80, D 96049 Bamberg, Germany.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   University of Erlangen Nuremberg
RP Frey, S (通讯作者)，Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany.; Frey, S (通讯作者)，DZI, Erlangen, Germany.
EM silke.frey@uk erlangen.de
RI ; Krönke, Gerhard/C 6615 2014; Scholtysek, Carina/LXA 1619 2024; Kronke,
   Gerhard/C 6615 2014; Kleyer, Arnd/AAB 2292 2022; Culemann,
   Stephan/AAW 2778 2021; Andreev, Darja/LLL 5373 2024
OI Frey, Silke/0000 0001 9411 8357; Andreev, Darja/0000 0002 9959 0201;
   Adam, Susanne/0000 0002 3394 4767; Kronke, Gerhard/0000 0002 7566 4325;
   Steffen, Ulrike/0000 0003 2934 3202; Simon, Nils/0000 0002 6559 1863;
   Schett, Georg/0000 0001 8740 9615; Kleyer, Arnd/0000 0002 2026 7728
FU Deutsche Forschungsgemeinschaft [FOR 2886 PANDORA, TP3/TP4/TP5, DFG CRC
   1181, A01/A03/A05, HA 8163/1 1, 1583/14 1]; Eli Lilly; Pfizer;
   Bundesministerium fur Bildung und Forschung (BMBF) (METARTHROS);
   European Union [ERC StG 640087 SOS]; European Union (ERC 4D NanoScope);
   EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking RTCure
   grant [777357]; Interdisciplinary Center for Clinical Research (IZKF) at
   the Universitatsklinikum Erlangen of the Friedrich Alexander University
   Erlangen Nurnberg
FX This work was supported by the Deutsche Forschungsgemeinschaft (FOR 2886
   PANDORA project no. TP3/TP4/TP5), DFG CRC 1181 project no. A01/A03/A05,
   project SCHE (1583/14 1), project HA 8163/1 1, research grants from Eli
   Lilly and Pfizer, the Bundesministerium fur Bildung und Forschung (BMBF)
   (METARTHROS), the European Union (ERC StG 640087 SOS and ERC 4D
   NanoScope) and the EU/EFPIA Innovative Medicines Initiative 2 Joint
   Undertaking RTCure grant no. 777357, and the Interdisciplinary Center
   for Clinical Research (IZKF) at the Universitatsklinikum Erlangen of the
   Friedrich Alexander University Erlangen Nurnberg.
CR [Anonymous], 2017, ASS REP XELJ INT NON
   [Anonymous], 2018, MED GUID FULL PRESCR
   [Anonymous], 2016, ASS REP OL INT NONPR
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bouffi C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014247
   Cantwell MT, 2018, CYTOKINE, V111, P434, DOI 10.1016/j.cyto.2018.05.023
   Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200
   Choi J, 2018, LEUKEMIA, V32, P2483, DOI 10.1038/s41375 018 0123 z
   Clark JD, 2014, J MED CHEM, V57, P5023, DOI 10.1021/jm401490p
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fragoso MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046892
   Fridman JS, 2010, J IMMUNOL, V184, P5298, DOI 10.4049/jimmunol.0902819
   Garnero P, 2010, ARTHRITIS RHEUM US, V62, P33, DOI 10.1002/art.25053
   Ghoreschi K, 2011, J IMMUNOL, V186, P4234, DOI 10.4049/jimmunol.1003668
   Hirahara K, 2016, CURR OPIN IMMUNOL, V43, P89, DOI 10.1016/j.coi.2016.10.001
   Idris AI, 2012, METHODS MOL BIOL, V816, P545, DOI 10.1007/978 1 61779 415 5_34
   Ito M, 2017, J PHARMACOL SCI, V133, P25, DOI 10.1016/j.jphs.2016.12.001
   Itoh S, 2006, BONE, V39, P505, DOI 10.1016/j.bone.2006.02.074
   Kaneshiro S, 2014, J BONE MINER METAB, V32, P378, DOI 10.1007/s00774 013 0514 1
   Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303
   Kobayashi Y, 2016, J BIOCHEM, V159, P387, DOI 10.1093/jb/mvv124
   Krämer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   LaBranche TP, 2012, ARTHRITIS RHEUM US, V64, P3531, DOI 10.1002/art.34649
   Lacey DC, 2009, OSTEOARTHR CARTILAGE, V17, P735, DOI 10.1016/j.joca.2008.11.011
   Levy JB, 1996, ENDOCRINOLOGY, V137, P1159, DOI 10.1210/en.137.4.1159
   Li J., 2014, JAK STAT, V2
   Matsushita K, 2014, J CELL BIOCHEM, V115, P1262, DOI 10.1002/jcb.24777
   Matzelle MM, 2012, ARTHRITIS RHEUM US, V64, P1540, DOI 10.1002/art.33504
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Migita K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3333
   Murakami K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181126
   O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301
   Oluminat (European Medicine Agency, 2016, OL, V2019
   Pacifici R, 2012, J BONE MINER RES, V27, P231, DOI 10.1002/jbmr.1500
   Pacifici R, 2010, ARCH BIOCHEM BIOPHYS, V503, P41, DOI 10.1016/j.abb.2010.05.027
   Peruzzi B, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1651
   Pilling C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11040 3
   Shin M, 2016, MOL CELLS, V39, P821, DOI 10.14348/molcells.2016.0212
   Sims NA, 2004, J CLIN INVEST, V113, P379, DOI 10.1172/JCI200419872
   Steffen Ulrike, 2019, Curr Protoc Immunol, V125, pe74, DOI 10.1002/cpim.74
   Tajima K, 2010, J ORTHOP RES, V28, P937, DOI 10.1002/jor.21086
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tong JL, 2019, EUR REV MED PHARMACO, V23, P5235, DOI 10.26355/eurrev_201906_18189
   van der Heijde D, 2018, RMD OPEN, V4, DOI 10.1136/rmdopen 2018 000662
   van der Heijde D, 2013, ARTHRITIS RHEUM US, V65, P559, DOI 10.1002/art.37816
   van Vollenhoven RF, 2013, CURR OPIN RHEUMATOL, V25, P391, DOI 10.1097/BOR.0b013e32835fd828
   Wang SP, 2014, ANN RHEUM DIS, V73, P2213, DOI 10.1136/annrheumdis 2014 205615
   Winthrop KL, 2017, NAT REV RHEUMATOL, V13, P234, DOI 10.1038/nrrheum.2017.23
   Xeljanz (European Medicine Agency, 2017, XELJ, V2019
   Ye SD, 2016, J CELL SCI, V129, P269, DOI 10.1242/jcs.177675
NR 53
TC 106
Z9 111
U1 1
U2 29
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD FEB 12
PY 2020
VL 12
IS 530
AR eaay4447
DI 10.1126/scitranslmed.aay4447
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA KM5OG
UT WOS:000514186600005
PM 32051226
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Liu, PJ
   Li, J
   Li, K
   Teng, Y
   Wang, X
   Li, X
AF Zhang, Yan
   Liu, Peijun
   Li, Juan
   Li, Kun
   Teng, Yue
   Wang, Xiang
   Li, Xu
TI Communication Factors Promising Targets in Osteoporosis Treatment
SO CURRENT DRUG TARGETS
LA English
DT Article
DE Osteoclast; osteoblast; communication; osteoporosis
ID BONE FORMATION; GROWTH FACTOR; GAP JUNCTIONS; CONDITIONAL DELETION;
   SIGNAL TRANSMISSION; SEMAPHORIN 7A; OSTEOCLASTS; EXPRESSION; OSTEOBLAST;
   MIGRATION
AB Osteoporosis is one of the most serious under diagnosed and under treated recessive diseases, leading to increased mortality and morbidity as well as huge economic burden. The fundamental reason for the occurrence of osteoporosis lies in the disequilibrium between bone resorption mediated by osteoclasts and bone formation mediated by osteoblasts. Osteoclast osteoblast communication plays important roles in the maintenance of hemeostasis. In this review, we present the detailed mechanisms of this communication, including modes of diffusible paracrine factors, cell cell direct contact and cell bone matrix interaction. We demonstrate that osteoclasts (or osteoblasts) could not only secrete cytokines, growth factors, chemokines and function in a paracrine manner, but also express molecules on their membranes to bind to the receptors on osteoblasts (or osteoclasts) to transduce bidirectional signals. Moreover, growth factors and cytokines deliberated from bone matrix during bone resorption could also regulate the function of both osteoblasts and osteoclasts. This review gives the latest knowledge of communication factors, some of which are emerging as novel therapeutic targets for future development of antiosteoporotic drugs.
C1 [Zhang, Yan; Liu, Peijun; Li, Juan; Li, Kun; Teng, Yue; Wang, Xiang; Li, Xu] Xi An Jiao Tong Univ, Affiliated Hosp 1, Coll Med, Ctr Translat Med, Xian 710061, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University
RP Li, X (通讯作者)，Xi An Jiao Tong Univ, Affiliated Hosp 1, Coll Med, Ctr Translat Med, 277 West Yanta Rd, Xian 710061, Shaanxi, Peoples R China.
EM lixuxjtu@126.com
RI ; Teng, Yue/HLP 5246 2023
OI , Yan/0000 0003 3957 8312; 
FU Specialized Research Fund for the Doctoral Program of Ministry of
   Education of China [20120201120089]; Scientific Research Fund of Shaanxi
   Provincial Department of Health [2012D59]
FX This work is supported by Specialized Research Fund for the Doctoral
   Program of Ministry of Education of China (No. 20120201120089) and
   Scientific Research Fund of Shaanxi Provincial Department of Health (No.
   2012D59).
CR ANTONIADES HN, 1991, BAILLIERE CLIN ENDOC, V5, P595, DOI 10.1016/S0950 351X(10)80005 9
   Batra N, 2012, BBA BIOMEMBRANES, V1818, P1909, DOI 10.1016/j.bbamem.2011.09.018
   Becker David J, 2010, Curr Rheumatol Rep, V12, P186, DOI 10.1007/s11926 010 0097 y
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Canalis E, 2009, J CELL BIOCHEM, V108, P769, DOI 10.1002/jcb.22322
   Caplan AI, 2011, J ORTHOP RES, V29, P1795, DOI 10.1002/jor.21462
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Delorme G, 2005, BIOL CELL, V97, P589
   Diab DL, 2013, ENDOCRIN METAB CLIN, V42, P305, DOI 10.1016/j.ecl.2013.02.007
   Esbrit P, 2013, BIOCHEM PHARMACOL, V85, P1417, DOI 10.1016/j.bcp.2013.03.002
   Giacobini P, 2013, SEMIN CELL DEV BIOL, V24, P190, DOI 10.1016/j.semcdb.2012.11.005
   Govoni KE, 2007, ENDOCRINOLOGY, V148, P5706, DOI 10.1210/en.2007 0608
   Graham S, 2009, EXPERT OPIN INV DRUG, V18, P1633, DOI 10.1517/13543780903241607
   Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Harada Suguru, 2011, Clin Calcium, V21, P1121, DOI CliCa110811211130
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Herman AP, 2013, CURR OPIN PHARMACOL, V13, P435, DOI 10.1016/j.coph.2013.02.002
   Horowitz MC, 2004, CURR OPIN RHEUMATOL, V16, P464, DOI 10.1097/01.bor.0000127825.05580.eb
   Hughes A, 2012, CALCIFIED TISSUE INT, V90, P151, DOI 10.1007/s00223 011 9560 7
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   Jabbar S, 2011, J CLIN PATHOL, V64, P354, DOI 10.1136/jcp.2010.086595
   Jiang JX, 2007, FRONT BIOSCI LANDMRK, V12, P1450, DOI 10.2741/2159
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Koh JM, 2006, J HUM GENET, V51, P112, DOI 10.1007/s10038 005 0331 z
   Komori T, 2011, J CELL BIOCHEM, V112, P750, DOI 10.1002/jcb.22994
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257
   Li X, 2007, J BIOL CHEM, V282, P33098, DOI 10.1074/jbc.M611781200
   Li Z, 1999, BONE, V25, P661, DOI 10.1016/S8756 3282(99)00227 6
   Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756 3282(96)00138 X
   Lotinun S, 2005, J BONE MINER RES, V20, P644, DOI 10.1359/JBMR.041209
   Marie PJ, 2012, GROWTH FACTORS, V30, P117, DOI 10.3109/08977194.2012.656761
   Marie PJ, 2012, GENE, V498, P1, DOI 10.1016/j.gene.2012.01.086
   Mayr Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756 3282(01)00690 1
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Nakamura Midori, 2011, Clin Calcium, V21, P1149, DOI CliCa110811491155
   Negishi Koga Takako, 2012, Bonekey Rep, V1, P183, DOI 10.1038/bonekey.2012.183
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Okamoto M, 2011, J BONE MINER RES, V26, P2511, DOI 10.1002/jbmr.477
   Park JB, 2011, J CRANIOFAC SURG, V22, P1880, DOI 10.1097/SCS.0b013e31822e8434
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Sanchez Fernandez MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003537
   Saunders MM, 2001, AM J PHYSIOL CELL PH, V281, pC1917, DOI 10.1152/ajpcell.2001.281.6.C1917
   Silva Fernandez L, 2013, REUMATOL CLIN, V9, P42, DOI [10.1016/j.reuma.2012.06.007, 10.1016/j.reumae.2012.06.020]
   Sutton ALM, 2008, MOL ENDOCRINOL, V22, P1370, DOI 10.1210/me.2007 0363
   Suzuki K, 2008, NAT IMMUNOL, V9, P17, DOI 10.1038/ni1553
   Tamma Roberto, 2012, Inflammation & Allergy Drug Targets, V11, P196
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Walker EC, 2008, J BONE MINER RES, V23, P2025, DOI [10.1359/jbmr.080706, 10.1359/JBMR.080706]
   Yellowley CE, 2000, J BONE MINER RES, V15, P209, DOI 10.1359/jbmr.2000.15.2.209
   Zelzer E, 2005, CURR TOP DEV BIOL, V65, P169
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 59
TC 3
Z9 4
U1 1
U2 15
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389 4501
EI 1873 5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD FEB
PY 2014
VL 15
IS 2
BP 156
EP 163
DI 10.2174/13894501113149990200
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AE9ST
UT WOS:000334350800002
PM 23919828
DA 2025 08 17
ER

PT J
AU Zeng, QH
   Xu, R
   Ling, HF
   Zhao, S
   Wang, X
   Yuan, WH
   Gu, MC
   Xu, TT
   Wang, PE
   Ruan, HF
   Jin, HT
   Qu, HB
   Ye, FS
   Chen, JL
AF Zeng, Qinghe
   Xu, Rui
   Ling, Houfu
   Zhao, Shan
   Wang, Xu
   Yuan, Wenhua
   Gu, Mancang
   Xu, Taotao
   Wang, Pinger
   Ruan, Hongfeng
   Jin, Hongting
   Qu, Hangbo
   Ye, Fusheng
   Chen, Jiali
TI N Butanol Extract of Modified You Gui Yin Attenuates Osteoclastogenesis
   and Ameliorates Osteoporosis by Inhibiting RANKL Mediated NF κB
   Signaling
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE N butanol extraction; Modified You Gui Yin; postmenopausal osteoporosis;
   osteoclast formation; NF kappa B pathway
ID HERBAL MEDICINES CHALLENGES; BONE RESORPTION; IN VITRO; DIFFERENTIATION;
   PREVENTS; PROLIFERATION; MECHANISMS; TARGETS; RISK; ACID
AB Postmenopausal Osteoporosis (PMOP) is the most prevalent primary osteoporosis, attributable to an imbalance in osteoblast and osteoclast activity. Modified You Gui Yin (MYGY), a traditional Chinese herbal formula, is able to effectively treat PMOP, while the critical components and pharmacological mechanisms of MYGY are still unclear. In this study, we aimed to investigate the therapeutic effects and underlying mechanisms of N butanol extract of MYGY (MYGY Nb) in ovariectomized (OVX) induced osteoporosis mice. Histological staining and micro computed tomography (mu CT) analysis showed that MYGY Nb was more effective in the suppression of OVX induced bone loss than MYGY original formula. Subsequently, liquid chromatography and mass spectrometry analysis identified 16 critical compounds of MYGY Nb and some of them are reported to affect osteoclast functions. Furthermore, in vivo and in vitro experiments demonstrated that MYGY Nb significantly attenuated osteoclastogenesis by down regulating RANKL mediated NF kappa B signaling. In conclusion, our study indicated that MYGY Nb suppresses NF kappa B signaling and osteoclast formation to mitigate bone loss in PMOP, implying that MYGY Nb and its compounds are potential candidates for development of anti PMOP drugs.
C1 [Zeng, Qinghe; Wang, Xu; Yuan, Wenhua; Wang, Pinger; Ruan, Hongfeng; Jin, Hongting; Chen, Jiali] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Inst Orthoped & Traumatol, Hangzhou, Peoples R China.
   [Zeng, Qinghe] Zhejiang Chinese Med Univ, Coll Clin Med 1, Hangzhou, Peoples R China.
   [Xu, Rui] Jiangxi Univ Tradit Chinese Med, Affiliated Hosp, Dept Orthopaed, Nanchang, Peoples R China.
   [Ling, Houfu; Xu, Taotao] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Orthopaed, Hangzhou, Peoples R China.
   [Zhao, Shan; Gu, Mancang] Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou, Peoples R China.
   [Qu, Hangbo] Zhejiang Hosp, Dept Orthopaed Surg, Hangzhou, Peoples R China.
   [Ye, Fusheng] Hangzhou Normal Univ, Affiliated Xiaoshan Hosp, Hangzhou, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Jiangxi University of Traditional Chinese Medicine;
   Affiliated Hospital of Jiangxi University of Traditional Chinese
   Medicine; Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Hangzhou Normal University
RP Chen, JL (通讯作者)，Zhejiang Chinese Med Univ, Affiliated Hosp 1, Inst Orthoped & Traumatol, Hangzhou, Peoples R China.; Qu, HB (通讯作者)，Zhejiang Hosp, Dept Orthopaed Surg, Hangzhou, Peoples R China.; Ye, FS (通讯作者)，Hangzhou Normal Univ, Affiliated Xiaoshan Hosp, Hangzhou, Peoples R China.
EM quhb1222@163.com; yefusheng0520@163.com; chenjiali1585@163.com
RI ; Ruan, Hongfeng/HKO 1118 2023; xu, rui/KTI 8349 2024; Xu,
   Taotao/GPW 7374 2022
OI RUAN, Hongfeng/0000 0001 8868 9313; 
FU Natural Science Foundation of China [81904223]; Hangzhou Medical and
   health science and Technology Project [B20200552]
FX This research has been partially supported by the Natural Science
   Foundation of China (Grant nos. 81904223), Hangzhou Medical and health
   science and Technology Project (B20200552).
CR Andreopoulou P, 2015, ANNU REV MED, V66, P329, DOI 10.1146/annurev med 070313 022841
   Barnes J, 2016, EXPERT REV CLIN PHAR, V9, P905, DOI 10.1586/17512433.2016.1171712
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cappola AR, 2016, JAMA J AM MED ASSOC, V316, P715, DOI 10.1001/jama.2016.11032
   Chauhan S, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906 018 2299 1
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   de la Rica L, 2015, GENOME BIOL, V16, DOI 10.1186/s13059 014 0561 5
   Del Fattore A, 2008, ARCH BIOCHEM BIOPHYS, V473, P147, DOI 10.1016/j.abb.2008.01.011
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Gao Z, 2013, CHIN J INTEGR MED, V19, P862, DOI 10.1007/s11655 013 1328 z
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092 8674(02)00703 1
   Hu H, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9856
   Jakob F, 2015, UNFALLCHIRURG, V118, P925, DOI 10.1007/s00113 015 0085 9
   Jiang WY, 2005, TRENDS PHARMACOL SCI, V26, P558, DOI 10.1016/j.tips.2005.09.006
   Jin R, 2013, J INTEGR MED JIM, V11, P352, DOI 10.3736/jintegrmed2013051
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   Kim Jung Young, 2012, J Bone Metab, V19, P121, DOI 10.11005/jbm.2012.19.2.121
   Kim K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020601
   Kim MH, 2020, PHARMACEUTICALS BASE, V13, DOI 10.3390/ph13120468
   Krum SA, 2010, NAT REV RHEUMATOL, V6, P607, DOI 10.1038/nrrheum.2010.133
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Lewiecki EM, 2011, NAT REV RHEUMATOL, V7, P631, DOI 10.1038/nrrheum.2011.130
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Moriwaki S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097177
   Mukherjee K, 2016, BIOCHEM PHARMACOL, V117, P10, DOI 10.1016/j.bcp.2016.04.010
   Park JH, 2017, MOL CELLS, V40, P706
   Qian Z, 2020, J CELL MOL MED, V24, P10112, DOI 10.1111/jcmm.15622
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sammons HM, 2016, EXPERT REV CLIN PHAR, V9, P1117, DOI 10.1080/17512433.2016.1189326
   Sasidharan S, 2011, AFR J TRADIT COMPLEM, V8, P1
   Shinohara Masahiro, 2007, Curr Osteoporos Rep, V5, P67
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Wang CD, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00407
   Wang PE, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1437 3
   Wang QL, 2017, EUR REV MED PHARMACO, V21, P1911
   Wang XL, 2008, CHEM PHARM BULL, V56, P46, DOI 10.1248/cpb.56.46
   Warren JT, 2015, J CELL BIOCHEM, V116, P2476, DOI 10.1002/jcb.25191
   Wei SJ, 2021, PHARM BIOL, V59, P262, DOI 10.1080/13880209.2021.1876100
   Wu C, 2020, J SEP SCI, V43, P2105, DOI 10.1002/jssc.201901203
   Xia CJ, 2019, J CELL PHYSIOL, V234, P18535, DOI 10.1002/jcp.28491
   Xu HH, 2020, J ETHNOPHARMACOL, V263, DOI 10.1016/j.jep.2020.113217
   Xu R, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.711004
   Yin ZQ, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172550
   Zhang Y, 2017, J BONE MINER RES, V32, P1829, DOI 10.1002/jbmr.3172
   Zhao SN, 2014, CRIT REV FOOD SCI, V54, P1283, DOI 10.1080/10408398.2011.632698
   Zhong ZY, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01530
   Zhou J, 2014, J TRADIT CHIN MED, V34, P100, DOI 10.1016/S0254 6272(14)60062 5
NR 49
TC 4
Z9 4
U1 0
U2 17
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD JUN 24
PY 2022
VL 13
AR 925848
DI 10.3389/fendo.2022.925848
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 3B7KJ
UT WOS:000828115300001
PM 35813633
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhang, KF
   Wang, MM
   Li, YJ
   Li, CP
   Tang, SD
   Qu, XX
   Feng, NH
   Wu, Y
AF Zhang, Kefan
   Wang, Miaomiao
   Li, Yingjiang
   Li, Chunping
   Tang, Shaidi
   Qu, Xiuxia
   Feng, Ninghan
   Wu, Yu
TI The PERK EIF2α ATF4 signaling branch regulates osteoblast
   differentiation and proliferation by PTH
SO AMERICAN JOURNAL OF PHYSIOLOGY ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE cell proliferation; HSP90; osteoblast differentiation; PERK; PTH
ID UNFOLDED PROTEIN RESPONSE; BONE MINERAL DENSITY; PARATHYROID HORMONE;
   POSTMENOPAUSAL WOMEN; OSTEOPOROSIS; EXPRESSION; STRESS; KINASE; ATF4;
   TRANSCRIPTION
AB Parathyroid hormone (PTH) and its related peptide (PTH related peptide 1 34) are two of the Food and Drug Administration approved bone promoting drugs for age related osteoporosis. Treatment with PTH stimulates bone formation. However, the molecular mechanisms of PTH mediated osteoblast differentiation and cell proliferation are still not completely understood. In this study. we showed that PTH induced endoplasmic reticulum (ER) stress in osteoblasts through the PKR like endoplasmic reticulum kinase (PERK) eukaryotic initiation factor 2 alpha (EIF2 alpha) activating transcription factor 4 (ATF4) signaling pathway. After separately blocking PERK EIF2 alpha ATF4 signaling with two different inhibitors [AMG'44 and integrated stress response inhibitor (ISRIB)] or specific small interfering RNA for PERK and ATF4, the following targets were all downregulated: expression of osteoblast differentiation markers [runt related transcription factor 2 (Runx2), alkaline phosphatase (Alp), type I collagen (Collal), and osteocalcin (Ocn)], cell proliferation markers (CyclinE, CyclinD, and CDC2), amino acid import (Glyt1). and metabolism related genes (Asns). Additionally, Alp positive staining cells, Alp activity, matrix mineralization, Ocn secretion, and cell proliferation indexes were inhibited. Interestingly, we found that salubrinal enhanced PTH induced osteoblast differentiation and proliferation by maintenance of phosphorylation of EIF2 alpha. Furthermore, we observed that PTH increased the association between heat shock protein 90 (HSP90) and PERK and maintained PERK protein stabilization in the early stages of PTH induced ER stress. Treatment of MC3T3 E1 cells with geldanamycin. an HSP90 inhibitor, decreased PERK protein expression and inhibited osteoblast differentiation and cell proliferation upon PTH treatment. Taken together, our data demonstrate that PTH regulates osteoblast differentiation and cell proliferation, partly by activating the HSP90 dependent PERK EIF2 alpha ATF4 signaling pathway.
C1 [Zhang, Kefan; Tang, Shaidi; Qu, Xiuxia; Wu, Yu] Jiangnan Univ, Wuxi Med Sch, Lab Mol & Cellular Biol, Wuxi, Jiangsu, Peoples R China.
   [Wang, Miaomiao; Li, Chunping] Wuxi Ctr Dis Control & Prevent, Dept Occupat Hlth, Wuxi, Jiangsu, Peoples R China.
   [Li, Yingjiang; Feng, Ninghan] Nanjing Med Univ, Affiliated Wuxi Peoples Hosp 2, Nanjing, Jiangsu, Peoples R China.
   [Wu, Yu] Jiangnan Univ, Publ Hlth Res Ctr, Wuxi, Jiangsu, Peoples R China.
C3 Jiangnan University; Nanjing Medical University; Jiangnan University
RP Wu, Y (通讯作者)，Jiangnan Univ, Wuxi Med Sch, Lihu St 1800, Wuxi 214122, Jiangsu, Peoples R China.
EM wuyu@jiangnan.edu.cn
RI Wu, Yu/HIK 1398 2022; 李, 迎江/AAH 7170 2020; Feng, Ninghan/ABA 8996 2021
FU National Natural Science Foundation of China [81670808, 81541103,
   81602833]; Natural Science Foundation of Jiangsu Province Basic Research
   Program [BK20161136]; Health Bureau of Wuxi [QNRC006]; Jiangnan
   University Science Research Program [JUSRP115A32, JUPH201503,
   JUSRP51710A]; National First Class Discipline Program of Food Science
   and Technology [JUFSTR20180101]; Jiangsu Medical Leading Talents Project
   [CXTDA2017047]; Jiangsu Provincial Key Research and Development Program
   Project Social Development Grant [BE2018629]
FX This work was supported by National Natural Science Foundation of China
   Grants 81670808 and 81541103, Natural Science Foundation of Jiangsu
   Province Basic Research Program Grant BK20161136 (to Y. Wu). M. Wang
   received the support from National Natural Science Foundation of China
   Grant 81602833 and Health Bureau of Wuxi Grant QNRC006. Y. Wu received
   the intramural funding from the Jiangnan University Science Research
   Program Grants JUSRP115A32, JUPH201503, and JUSRP51710A. This work was
   partially supported by the National First Class Discipline Program of
   Food Science and Technology Grant JUFSTR20180101. N. Feng received the
   support from Jiangsu Medical Leading Talents Project Grant CXTDA2017047
   and Jiangsu Provincial Key Research and Development Program Project
   Social Development Grant BE2018629.
CR [Anonymous], 2017, BIOMED RES INT
   Augustine M, 2013, CURR OSTEOPOROS REP, V11, P400, DOI 10.1007/s11914 013 0171 2
   Boyce EG, 2018, ANN PHARMACOTHER, V52, P462, DOI 10.1177/1060028017748649
   Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902
   Cupp ME, 2013, J PHARMACOL EXP THER, V345, P404, DOI 10.1124/jpet.112.199752
   Du YY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00180
   Díaz Villanueva JF, 2015, INT J MOL SCI, V16, P17193, DOI 10.3390/ijms160817193
   Garcia Gomez A, 2014, CLIN CANCER RES, V20, P1542, DOI 10.1158/1078 0432.CCR 13 1657
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097 2765(03)00105 9
   He L, 2013, CELL SIGNAL, V25, P552, DOI 10.1016/j.cellsig.2012.11.015
   Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491
   Isogai Y, 1996, J BONE MINER RES, V11, P1384
   Jiang Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.200
   Karner CM, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00253 16
   Kawabata T, 2017, MOL MED REP, V16, P8507, DOI 10.3892/mmr.2017.7639
   Leder BZ, 2017, CURR OSTEOPOROS REP, V15, P110, DOI 10.1007/s11914 017 0353 4
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Lee HY, 2017, FREE RADICAL BIO MED, V113, P26, DOI 10.1016/j.freeradbiomed.2017.09.010
   Li YY, 2009, MOL PHARMACEUT, V6, P1152, DOI 10.1021/mp900037p
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Marcu MG, 2002, MOL CELL BIOL, V22, P8506, DOI 10.1128/MCB.22.24.8506 8513.2002
   Moore KA, 2012, ANNU REV GENET, V46, P165, DOI 10.1146/annurev genet 110711 155644
   NAKATANI Y, 1984, BIOCHEM BIOPH RES CO, V123, P894, DOI 10.1016/S0006 291X(84)80219 3
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Rojas Rivera D, 2017, CELL DEATH DIFFER, V24, P1100, DOI 10.1038/cdd.2017.58
   Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900
   Sato AY, 2015, BONE, V73, P60, DOI 10.1016/j.bone.2014.12.012
   Schilcher J, 2014, NEW ENGL J MED, V371, P974, DOI 10.1056/NEJMc1403799
   Sekine Y, 2015, SCIENCE, V348, P1027, DOI 10.1126/science.aaa6986
   Senn H, 2012, MOL BIOL CELL, V23, P268, DOI 10.1091/mbc.E11 08 0729
   Shrestha L, 2016, CURR TOP MED CHEM, V16, P2753, DOI 10.2174/1568026616666160413141911
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200
   Tohmonda T, 2011, EMBO REP, V12, P451, DOI 10.1038/embor.2011.34
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wang XW, 2012, NUCLEIC ACIDS RES, V40, pD1144, DOI 10.1093/nar/gkr1013
   Wei JW, 2008, J CELL PHYSIOL, V217, P693, DOI 10.1002/jcp.21543
   Wu Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.427
   Wu Y, 2018, BIOCHEM BIOPH RES CO, V503, P737, DOI 10.1016/j.bbrc.2018.06.069
   Yang D, 2007, BONE, V40, P1453, DOI 10.1016/j.bone.2007.02.001
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yu SB, 2008, ENDOCRINOLOGY, V149, P1960, DOI 10.1210/en.2007 1573
   Yu SB, 2013, INT J BIOL SCI, V9, P256, DOI 10.7150/ijbs.5898
   Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864 3874.2002
   Zhu K, 2013, J BONE MINER RES, V28, P1870, DOI 10.1002/jbmr.1958
NR 48
TC 57
Z9 63
U1 1
U2 31
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193 1849
EI 1522 1555
J9 AM J PHYSIOL ENDOC M
JI Am. J. Physiol. Endocrinol. Metab.
PD APR
PY 2019
VL 316
IS 4
BP E590
EP E604
DI 10.1152/ajpendo.00371.2018
PG 15
WC Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Physiology
GA HS0BG
UT WOS:000463524900004
PM 30668150
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Kim, JM
   Choi, JS
   Kim, YH
   Jin, SH
   Lim, S
   Jang, HJ
   Kim, KT
   Ryu, SH
   Suh, PG
AF Kim, Jung Min
   Choi, Jin Seok
   Kim, Yun Hee
   Jin, Seong Hui
   Lim, Seyoung
   Jang, Hyun Jun
   Kim, Kyong Tai
   Ryu, Sung Ho
   Suh, Pann Ghill
TI An activator of the cAMP/PKA/CREB pathway promotes osteogenesis from
   human mesenchymal stem cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID PROTEIN KINASE A; BONE MASS; PARATHYROID HORMONE; LEPTIN SECRETION;
   OVARIECTOMIZED MICE; GENE TRANSCRIPTION; SIGNALING PATHWAY; INTERMITTENT
   PTH; IN VITRO; OSTEOPOROSIS
AB Mesenchymal stem cells (MSCs) are multipotent adult stem cells capable of differentiating along the osteoblast, adipocyte, and chondrocyte lineages. Regulation of MSCs differentiation may be a useful tool for regenerative medicine and cell based therapy. The discovery of small molecule that activates the osteogenic differentiation of MSCs could aid in the development of a new anabolic drug for osteoporosis treatment. We identified CW008, a derivative of pyrazolepyridine, that stimulates osteoblast differentiation of human MSCs and increases bone formation in ovariectomized mice. CW008 promotes osteogenesis by activating cAMP/PKA/CREB signaling pathway and inhibiting leptin secretion. These results suggest that CW008 is an agonist of cAMP/PKA/CREB pathway in osteogenic differentiation and that application of CW008 may be useful for the treatment of bone related diseases and for the study of bone biology. J. Cell. Physiol. 228: 617626, 2013. (C) 2012 Wiley Periodicals, Inc.
C1 [Kim, Jung Min; Lim, Seyoung; Jang, Hyun Jun; Suh, Pann Ghill] Ulsan Natl Inst Sci & Technol, Sch Nanobiosci & Chem Engn, Ulsan, South Korea.
   [Kim, Jung Min; Jin, Seong Hui; Jang, Hyun Jun; Kim, Kyong Tai; Ryu, Sung Ho] Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang, South Korea.
   [Choi, Jin Seok] JW Pharmaceut, Cent Res Inst, Hwaseong, South Korea.
   [Kim, Yun Hee] Natl Canc Ctr, Goyang, South Korea.
C3 Ulsan National Institute of Science & Technology (UNIST); Pohang
   University of Science & Technology (POSTECH); National Cancer Center  
   Korea (NCC)
RP Suh, PG (通讯作者)，Ulsan Natl Inst Sci & Technol, Sch Nanobiosci & Chem Engn, Ulsan, South Korea.
EM pgsuh@unist.ac.kr
RI Suh, Pann Ghill/F 3610 2010; Kim, Jung Min/JDW 1037 2023; Park,
   Mi Kyung/J 9643 2017
OI Ryu, Sung Ho/0000 0003 0913 3048; KIM, KYONG TAI/0000 0001 7292 2627;
   Kim, Jung Min/0000 0002 9072 4293; Jang, Hyun Jun/0000 0002 2261 0067
FU Ministry of Knowledge Economy [10027895]; National Research Foundation
   of Korea [PGB013]; Industrial Strategic technology development program
   [10027895]; Ministry of Knowledge Economy (MKE, Korea)
FX Contract grant sponsor: Ministry of Knowledge Economy;Contract grant
   number: 10027895.Contract grant sponsor: National Research Foundation of
   Korea;Contract grant number: PGB013.This work was supported by the
   Industrial Strategic technology development program (10027895) funded by
   the Ministry of Knowledge Economy (MKE, Korea) and supported by the
   Fusion Pioneer Project (PGB013) from the National Research Foundation of
   Korea.
CR Alexander JM, 2001, J BONE MINER RES, V16, P1665, DOI 10.1359/jbmr.2001.16.9.1665
   Altarejos JY, 2011, NAT REV MOL CELL BIO, V12, P141, DOI 10.1038/nrm3072
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Bidwell P, 2010, PROSTAG OTH LIPID M, V91, P18, DOI 10.1016/j.prostaglandins.2009.12.002
   Cammisotto PG, 2002, AM J PHYSIOL CELL PH, V283, pC244, DOI 10.1152/ajpcell.00033.2002
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Elefteriou F, 2004, P NATL ACAD SCI USA, V101, P3258, DOI 10.1073/pnas.0308744101
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Hartikka H, 2005, J BONE MINER RES, V20, P783, DOI 10.1359/JBMR.050101
   Hsu HT, 2006, J CLIN ENDOCR METAB, V91, P2761, DOI 10.1210/jc.2005 2383
   Huang WC, 2005, CANCER RES, V65, P2303, DOI 10.1158/0008 5472.CAN 04 3448
   Ionescu AM, 2004, J CELL PHYSIOL, V198, P428, DOI 10.1002/jcp.10421
   Isogai Y, 1996, J BONE MINER RES, V11, P1384
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Jerome CP, 2001, BONE, V29, P1, DOI 10.1016/S8756 3282(01)00477 X
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   KURABAYASHI M, 1995, MOL CELL BIOL, V15, P6386
   Lane NE, 2006, NAT CLIN PRACT RHEUM, V2, P562, DOI 10.1038/ncprheum0298
   Matsuo N, 2006, J BIOL CHEM, V281, P5445, DOI 10.1074/jbc.M509923200
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reseland JE, 2001, J BONE MINER RES, V16, P1426, DOI 10.1359/jbmr.2001.16.8.1426
   Sahu A, 2004, ENDOCRINOLOGY, V145, P2613, DOI 10.1210/en.2004 0032
   Sands WA, 2008, CELL SIGNAL, V20, P460, DOI 10.1016/j.cellsig.2007.10.005
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Smoum R, 2010, P NATL ACAD SCI USA, V107, P17710, DOI 10.1073/pnas.0912479107
   STREWLER GJ, 1987, J CLIN INVEST, V80, P1803, DOI 10.1172/JCI113275
   Szkudelski T, 2007, PHYSIOL RES, V56, P503, DOI 10.33549/physiolres.931038
   Szkudelski T, 2005, PHYSIOL RES, V54, P79, DOI 10.33549/physiolres.930570
   Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630
   Tintut Y, 1998, J BIOL CHEM, V273, P7547, DOI 10.1074/jbc.273.13.7547
   Yamane H, 2009, BONE, V44, P1055, DOI 10.1016/j.bone.2008.05.010
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yasothan U, 2008, NAT REV DRUG DISCOV, V7, P725, DOI 10.1038/nrd2620
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677 4684.2004
NR 43
TC 69
Z9 76
U1 2
U2 60
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAR
PY 2013
VL 228
IS 3
BP 617
EP 626
DI 10.1002/jcp.24171
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 048LL
UT WOS:000311912900015
PM 22886506
OA Bronze
DA 2025 08 17
ER

PT S
AU Zallone, A
AF Zallone, Alberta
BE Zaidi, M
TI Direct and indirect estrogen actions on osteoblasts and osteoclasts
SO SKELETAL DEVELOPMENT AND REMODELING IN HEALTH, DISEASE, AND AGING
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Conference on Skeletal Development and Remodeling in Health, Disease and
   Aging
CY MAY 18 21, 2005
CL New York, NY
SP NY Acad Sci, Alliance Better Bone Hlth, Procter & Gamble Pharmaceut, Sanofi Aventis, Novartis Pharmaceut Corp, Roche Pharmaceut, Merck & Co
DE osteoclasts; osteoblast; estrogen; bone remodeling
ID HORMONE REPLACEMENT THERAPY; TUMOR NECROSIS FACTOR; GENE EXPRESSION;
   BONE RESORPTION; SEX STEROIDS; MONONUCLEAR CELLS; RECEPTOR;
   OSTEOPROTEGERIN; ANDROGENS; CYTOKINES
AB Cells of osteoblast and osteoclast lineage are provided with the receptor for sex steroids, but discrepancies concerning mechanism of action still exist. Skeletal estrogen (ER) agonists induce osteoblastic osteoprotegerin (OPG) production through ER receptor alpha activation in vitro, while immune cells appear to overexpress RANKL in ER deficiency in vivo, not reproduced in in vitro study. It has also been evident that the effects of ER on bone to a large extent are mediated via its action on immune cells. We know now that ER regulates the expression of cytokines that target cell types involved in modulating bone turnover, as IL 1 and IL 6, and the latest findings confirm and expand the concept that T cells are key mediators of bone loss following gonadal failure. Although early work demonstrated that tumor necrosis factor alpha plays an important role in regulating bone mass, recent studies also implicate the lymphopoietic molecule IL 7: it suppresses the bone forming osteoblasts, while stimulating formation and function of osteoclasts. More recent in vitro studies, however, indicate a stimulating effect of ER on osteoclastogenesis, which could have a positive effect on maintaining a high level of bone cell activity.
C1 Univ Bari, Fac Med & Chirurg, Dipartimento Anat Umana & Istol, Policlin Pza Giulio Cesare, I 70124 Bari, Italy.
C3 Universita degli Studi di Bari Aldo Moro
RP Zallone, A (通讯作者)，Univ Bari, Fac Med & Chirurg, Dipartimento Anat Umana & Istol, Policlin Pza Giulio Cesare, I 70124 Bari, Italy.
EM a.zallone@anatomia.uniba.it
CR Bashir A, 2005, STEROIDS, V70, P847, DOI 10.1016/j.steroids.2005.04.011
   BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995
   BENZ DJ, 1991, ENDOCRINOLOGY, V128, P2723, DOI 10.1210/endo 128 6 2723
   Bernard Poenaru O, 2001, OSTEOPOROSIS INT, V12, P769, DOI 10.1007/s001980170054
   Bilezikian JP, 2002, J BONE MINER RES, V17, P563, DOI 10.1359/jbmr.2002.17.4.563
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Braidman IP, 2000, J PATHOL, V192, P90
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   COLAIANNI G, 2005, J BONE MINER RES S, V20, P1102
   Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358
   Eriksen EF, 1999, J BONE MINER RES, V14, P1217, DOI 10.1359/jbmr.1999.14.7.1217
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Huang W, 2003, ARTHRITIS RES THER, V5, pR49, DOI 10.1186/ar612
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   KITAZAWA R, 1994, J CLIN INVEST, V94, P2397, DOI 10.1172/JCI117606
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   KOUSTENI S, 2005, J BONE MINER RES, V20, P1098
   Lin SC, 1997, J CLIN INVEST, V100, P1980, DOI 10.1172/JCI119729
   Manolagas SC, 1999, ENDOCRINOLOGY, V140, P4377, DOI 10.1210/en.140.10.4377
   Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385
   MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756 3282(95)00180 L
   MANOLAGAS SC, 1992, CALCIFIED TISSUE INT, V50, P199, DOI 10.1007/BF00296282
   PACIFICI R, 1991, J CLIN INVEST, V87, P221, DOI 10.1172/JCI114975
   Palacios VG, 2005, J BIOL CHEM, V280, P13720, DOI 10.1074/jbc.M410995200
   Parfitt AM, 1996, J BONE MINER RES, V11, P150
   Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094
   Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561
   STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15
   Takayanagi H, 2002, ARTHRITIS RES THER, V4, pS227, DOI 10.1186/ar581
   Toraldo G, 2003, P NATL ACAD SCI USA, V100, P125, DOI 10.1073/pnas.0136772100
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Weitzmann MN, 2002, J CLIN INVEST, V110, P1643, DOI 10.1172/JCI200215687
NR 33
TC 104
Z9 134
U1 1
U2 9
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077 8923
BN 1 57331 583 4
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2006
VL 1068
BP 173
EP 179
DI 10.1196/annals.1346.019
PG 7
WC Multidisciplinary Sciences; Orthopedics
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Orthopedics
GA BFA92
UT WOS:000240548200017
PM 16831916
DA 2025 08 17
ER

PT J
AU Ansari, N
   Ho, PWM
   Crimeen Irwin, B
   Poulton, IJ
   Brunt, AR
   Forwood, MR
   Pajevic, PD
   Gooi, JH
   Martin, TJ
   Sims, NA
AF Ansari, Niloufar
   Ho, Patricia W. M.
   Crimeen Irwin, Blessing
   Poulton, Ingrid J.
   Brunt, Athena R.
   Forwood, Mark R.
   Pajevic, Paola Divieti
   Gooi, Jonathan H.
   Martin, T. John
   Sims, Natalie A.
TI Autocrine and Paracrine Regulation of the Murine Skeleton by
   Osteocyte Derived Parathyroid Hormone Related Protein
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOCYTES; GENETIC ANIMAL MODELS; PTHrP; ANABOLICS; CELL; TISSUE
   SIGNALING; PARACRINE PATHWAYS
ID PTH RELATED PROTEIN; NUCLEAR LOCALIZATION SEQUENCE; ENDOCHONDRAL
   BONE FORMATION; SMOOTH MUSCLE CELLS; BREAST CANCER; OSTEOCLAST
   FORMATION; NULL MICE; IN VIVO; NUCLEOLAR LOCALIZATION; GENE EXPRESSION
AB Parathyroid hormone related protein (PTHrP) and parathyroid hormone (PTH) have N terminal domains that bind a common receptor, PTHR1. N terminal PTH (teriparatide) and now a modified N terminal PTHrP (abaloparatide) are US Food and Drug Administration (FDA) approved therapies for osteoporosis. In physiology, PTHrP does not normally circulate at significant levels, but acts locally, and osteocytes, cells residing within the bone matrix, express both PTHrP and the PTHR1. Because PTHR1 in osteocytes is required for normal bone resorption, we determined how osteocyte derived PTHrP influences the skeleton. We observed that adult mice with low PTHrP in osteocytes (targeted with the Dmp1(10kb) Cre) have low trabecular bone volume and osteoblast numbers, but osteoclast numbers were unaffected. In addition, bone size was normal, but cortical bone strength was impaired. Osteocyte derived PTHrP therefore stimulates bone formation and bone matrix strength, but is not required for normal osteoclastogenesis. PTHrP knockdown and overexpression studies in cultured osteocytes indicate that osteocyte secreted PTHrP regulates their expression of genes involved in matrix mineralization. We determined that osteocytes secrete full length PTHrP with no evidence for secretion of lower molecular weight forms containing the N terminus. We conclude that osteocyte derived full length PTHrP acts through both PTHR1 receptor mediated and receptor independent actions in a paracrine/autocrine manner to stimulate bone formation and to modify adult cortical bone strength. (c) 2017 American Society for Bone and Mineral Research.
C1 [Ansari, Niloufar; Ho, Patricia W. M.; Crimeen Irwin, Blessing; Poulton, Ingrid J.; Martin, T. John; Sims, Natalie A.] St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.
   [Ansari, Niloufar; Gooi, Jonathan H.; Martin, T. John; Sims, Natalie A.] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic, Australia.
   [Brunt, Athena R.; Forwood, Mark R.] Griffith Univ, Sch Med Sci, Gold Coast, Qld, Australia.
   [Brunt, Athena R.; Forwood, Mark R.] Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Qld, Australia.
   [Pajevic, Paola Divieti] Boston Univ, Dept Mol & Cell Biol, Goldman Sch Dent Med, Boston, MA 02215 USA.
C3 St. Vincent's Institute of Medical Research; NSW Health; St Vincents
   Hospital Sydney; St Vincent's Health; St Vincent's Hospital Melbourne;
   University of Melbourne; Griffith University; Griffith University   Gold
   Coast Campus; Menzies Health Institute Queensland; Griffith University;
   Griffith University   Gold Coast Campus; Boston University
RP Sims, NA (通讯作者)，St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.
EM nsims@svi.edu.au
RI Gooi, Jonathan/AAS 7982 2020; Pajevic, Paola/M 3236 2019; Sims,
   Natalie/A 7192 2012; Forwood, Mark/ABA 9040 2021; Ansari,
   Niloufar/V 5273 2019
OI Sims, Natalie/0000 0003 1421 8468; Divieti Pajevic,
   Paola/0000 0001 9853 9837; Forwood, Mark/0000 0002 9963 1616; Ansari,
   Niloufar/0000 0002 9824 9087; Gooi, Jonathan/0000 0002 8839 1602
FU National Health and Medical Research Council (Australia) [1042129,
   1081242]; Victorian Government's Operational Infrastructure Support
   Programme; National Health and Medical Research Council of Australia
   [1081242] Funding Source: NHMRC
FX This work was partially supported by National Health and Medical
   Research Council (Australia) Project Grants 1042129 and 1081242. NAS is
   supported by a National Health and Medical Research Council (Australia)
   Senior Research Fellowship. St. Vincent's Institute is supported by the
   Victorian Government's Operational Infrastructure Support Programme. The
   authors thank the staff of the St. Vincent's Health Bioresources Centre
   for excellent animal care and assistance, and Carl R Walkley and Emma C
   Walker for advice on detecting PTHrP recombination.
CR Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324
   AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Bonewald LF, 2017, ENDOCRIN METAB CLIN, V46, P1, DOI [10.1016/j.ec1.2016.09.003, 10.1016/j.ecl.2016.09.003]
   Buenzli PR, 2015, BONE, V75, P144, DOI 10.1016/j.bone.2015.02.016
   BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cb.03.110187.001331
   Chia LY, 2015, BONE, V72, P34, DOI 10.1016/j.bone.2014.11.005
   Cho DC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00920 x
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   Delgado Calle J, 2017, J BONE MINER RES, V32, P522, DOI 10.1002/jbmr.3011
   DIEFENBACHJAGGER H, 1995, EUR J BIOCHEM, V229, P91, DOI 10.1111/j.1432 1033.1995.0091l.x
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Fulzele K, 2013, BLOOD, V121, P930, DOI 10.1182/blood 2012 06 437160
   García Martín A, 2014, MOL ENDOCRINOL, V28, P925, DOI 10.1210/me.2013 1225
   GRILL V, 1991, J CLIN ENDOCR METAB, V73, P1309, DOI 10.1210/jcem 73 6 1309
   Halleux C, 2012, METHODS MOL BIOL, V816, P55, DOI 10.1007/978 1 61779 415 5_5
   HAMMONDS RG, 1989, J BIOL CHEM, V264, P14806
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   He B, 2001, ENDOCRINOLOGY, V142, P2070, DOI 10.1210/en.142.5.2070
   HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064
   Ho PWM, 2015, ONCOGENE, V34, P2922, DOI 10.1038/onc.2014.217
   Hochane M, 2013, ENDOCRINOLOGY, V154, P853, DOI 10.1210/en.2012 1802
   Horwitz MJ, 2010, J CLIN ENDOCR METAB, V95, P1279, DOI 10.1210/jc.2009 0233
   Jans DA, 2003, VITAM HORM, V66, P345, DOI 10.1016/S0083 6729(03)01010 0
   Johnson RW, 2014, J BONE MINER RES, V29, P1492, DOI 10.1002/jbmr.2159
   Kalajzic I, 2004, BONE, V35, P74, DOI 10.1016/j.bone.2004.03.006
   Kalajzic I, 2013, BONE, V54, P296, DOI 10.1016/j.bone.2012.09.040
   KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277
   Kartsogiannis V, 1997, BONE, V21, P385, DOI 10.1016/S8756 3282(97)00180 4
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   KEMP BE, 1987, SCIENCE, V238, P1568, DOI 10.1126/science.3685995
   Kim W, 2016, CANCER RES, V76, P5348, DOI 10.1158/0008 5472.CAN 15 2614
   Lam MHC, 2000, IMMUNOL CELL BIOL, V78, P395, DOI 10.1046/j.1440 1711.2000.00919.x
   Lam MHC, 2002, MOL ENDOCRINOL, V16, P390, DOI 10.1210/me.16.2.390
   Lam MHC, 1999, J BIOL CHEM, V274, P18559, DOI 10.1074/jbc.274.26.18559
   Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Lu Y, 2007, J DENT RES, V86, P320, DOI 10.1177/154405910708600404
   Martin TJ, 2017, J BONE MINER RES, V32, P11, DOI 10.1002/jbmr.3042
   Martin TJ, 2016, PHYSIOL REV, V96, P831, DOI 10.1152/physrev.00031.2015
   Martin TJ, 2013, GENETICS OF BONE BIOLOGY AND SKELETAL DISEASE, P53, DOI 10.1016/B978 0 12 387829 8.00004 4
   Martin TJ, 2005, J CLIN INVEST, V115, P2322, DOI 10.1172/JCI26239
   Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630
   McCauley LK, 2012, J BONE MINER RES, V27, P1231, DOI 10.1002/jbmr.1617
   McGregor NE, 2010, CALCIFIED TISSUE INT, V86, P261, DOI 10.1007/s00223 010 9337 4
   Miao DS, 2008, P NATL ACAD SCI USA, V105, P20309, DOI 10.1073/pnas.0805690105
   Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817
   Miao DS, 2004, ENDOCRINOLOGY, V145, P3554, DOI 10.1210/en.2003 1695
   Miao DS, 2004, ENDOCRINOLOGY, V145, P2046, DOI 10.1210/en.2003 1097
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nordstrand A, 2009, CLIN EXP METASTAS, V26, P945, DOI 10.1007/s10585 009 9285 4
   Okazaki M, 2008, P NATL ACAD SCI USA, V105, P16525, DOI 10.1073/pnas.0808750105
   Orloff JJ, 1996, ENDOCRINOLOGY, V137, P5376, DOI 10.1210/en.137.12.5376
   Paic F, 2009, BONE, V45, P682, DOI 10.1016/j.bone.2009.06.010
   Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127
   POWELL GJ, 1991, CANCER RES, V51, P3059
   Raison D, 2013, AM J PHYSIOL RENAL, V305, pF333, DOI 10.1152/ajprenal.00503.2012
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   Sheng MHC, 2013, BONE, V52, P133, DOI 10.1016/j.bone.2012.09.027
   Simmonds CS, 2010, CRIT REV EUKAR GENE, V20, P235, DOI 10.1615/CritRevEukarGeneExpr.v20.i3.40
   Sims NA, 2005, J BONE MINER RES, V20, P1093, DOI 10.1359/JBMR.050209
   Sims NA, 2000, J CLIN INVEST, V106, P1095, DOI 10.1172/JCI10753
   Sims NA, 2016, OSTEOIMMUNOLOGY: INTERACTIONS OF THE IMMUNE AND SKELETAL SYSTEMS, 2ND EDITION, P169, DOI 10.1016/B978 0 12 800571 2.00010 4
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   SOIFER NE, 1992, J BIOL CHEM, V267, P18236
   Spatz JM, 2015, J BIOL CHEM, V290, P16744, DOI 10.1074/jbc.M114.628313
   SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618
   Takyar FM, 2013, J BONE MINER RES, V28, P912, DOI 10.1002/jbmr.1820
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Toribio RE, 2010, FASEB J, V24, P1947, DOI 10.1096/fj.09 147033
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Vrahnas C, 2016, BONE, V93, P146, DOI 10.1016/j.bone.2016.09.022
   Walia MK, 2016, ELIFE, V5, DOI 10.7554/eLife.13446
   Walker EC, 2010, J CLIN INVEST, V120, P582, DOI 10.1172/JCI40568
   Wein MN, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13176
   Wein Marc N, 2015, J Bone Miner Res, V30, P400, DOI 10.1002/jbmr.2381
   Windahl SH, 2013, J BONE MINER RES, V28, P291, DOI 10.1002/jbmr.1754
   WYSOLMERSKI JJ, 1995, DEVELOPMENT, V121, P3539
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yamamoto H, 2016, BONE, V84, P120, DOI 10.1016/j.bone.2015.12.055
   YANG KH, 1994, BIOCHEMISTRY US, V33, P7460, DOI 10.1021/bi00189a054
NR 88
TC 47
Z9 52
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2018
VL 33
IS 1
BP 137
EP 153
DI 10.1002/jbmr.3291
PG 17
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FS9FX
UT WOS:000422723400017
PM 28914969
DA 2025 08 17
ER

PT J
AU Fowler, TW
   Mitchell, TL
   Janda, CY
   Xie, LQ
   Tu, SJ
   Chen, H
   Zhang, HL
   Ye, JJ
   Ouyang, B
   Yuan, TZ
   Lee, SJ
   Newman, M
   Tripuraneni, N
   Rego, ES
   Mutha, D
   Dilip, A
   Vuppalapaty, M
   Baribault, H
   Yeh, WC
   Li, Y
AF Fowler, Tristan W.
   Mitchell, Troy L.
   Janda, Claudia Y.
   Xie, Liqin
   Tu, Shengjiang
   Chen, Hui
   Zhang, Haili
   Ye, Jingjing
   Ouyang, Brian
   Yuan, Tom Z.
   Lee, Sung Jin
   Newman, Maureen
   Tripuraneni, Nikita
   Rego, Erica S.
   Mutha, Devin
   Dilip, Archana
   Vuppalapaty, Meghah
   Baribault, Helene
   Yeh, Wen Chen
   Li, Yang
TI Development of selective bispecific Wnt mimetics for bone loss and
   repair
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CANONICAL WNT; STRUCTURAL BASIS; RISK; DIFFERENTIATION; PROLIFERATION;
   OSTEOBLASTS; INHIBITION; SCLEROSTIN; EXPRESSION; DISEASE
AB The Wnt signaling pathway is intricately connected with bone mass regulation in humans and rodent models. We designed an antibody based platform that generates potent and selective Wnt mimetics. Using this platform, we engineer bi specific Wnt mimetics that target Frizzled and low density lipoprotein receptor related proteins and evaluate their effects on bone accrual in murine models. These synthetic Wnt agonists induce rapid and robust bone building effects, and correct bone mass deficiency and bone defects in various disease models, including osteoporosis, aging, and long bone fracture. Furthermore, when these Wnt agonists are combined with antiresorptive bisphosphonates or anti sclerostin antibody therapies, additional bone accrual/maintenance effects are observed compared to monotherapy, which could benefit individuals with severe and/or acute bone building deficiencies. Our data support the continued development of Wnt mimetics for the treatment of diseases of low bone mineral density, including osteoporosis. Antibody based Wnt agonists are able to phenocopy Wnt signaling in vivo resulting in increased bone density, repair, and strength. Here, the authors show that Wnt agonists can reverse bone loss associated with ovariectomy and build stronger bone when administered after fracture.
C1 [Fowler, Tristan W.; Mitchell, Troy L.; Janda, Claudia Y.; Xie, Liqin; Tu, Shengjiang; Chen, Hui; Zhang, Haili; Ye, Jingjing; Ouyang, Brian; Yuan, Tom Z.; Lee, Sung Jin; Newman, Maureen; Tripuraneni, Nikita; Rego, Erica S.; Mutha, Devin; Dilip, Archana; Vuppalapaty, Meghah; Baribault, Helene; Yeh, Wen Chen; Li, Yang] Surrozen Inc, San Francisco, CA 94080 USA.
   [Janda, Claudia Y.] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands.
C3 Princess Maxima Center
RP Yeh, WC; Li, Y (通讯作者)，Surrozen Inc, San Francisco, CA 94080 USA.
EM wenchen@surrozen.com; yang@surrozen.com
RI ; Tu, Shengjiang/K 7868 2012; Chen, Hui/AAE 6559 2019
OI Janda, Claudia/0000 0002 3307 2559; Li, Yang/0000 0002 7134 5685; 
CR Ahn VE, 2011, DEV CELL, V21, P862, DOI 10.1016/j.devcel.2011.09.003
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bliuc D, 2016, CURR OPIN RHEUMATOL, V28, P413, DOI 10.1097/BOR.0000000000000300
   Bloomfield Susan A, 2010, Curr Osteoporos Rep, V8, P91, DOI 10.1007/s11914 010 0013 4
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Borhan S, 2019, J BONE MINER RES, V34, P838, DOI 10.1002/jbmr.3666
   Bourhis E, 2010, J BIOL CHEM, V285, P9172, DOI 10.1074/jbc.M109.092130
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chen H, 2020, CELL CHEM BIOL, V27, P598, DOI 10.1016/j.chembiol.2020.02.009
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Chouinard L, 2016, REGUL TOXICOL PHARM, V81, P212, DOI 10.1016/j.yrtph.2016.08.010
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cosman Felicia, 2014, Bonekey Rep, V3, P518, DOI 10.1038/bonekey.2014.13
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109
   Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677
   Janda CY, 2017, NATURE, V545, P234, DOI 10.1038/nature22306
   Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Khosla S, 2016, J BONE MINER RES, V31, P1485, DOI 10.1002/jbmr.2888
   Langdahl BL, 2021, BRIT J PHARMACOL, V178, P1891, DOI 10.1111/bph.15024
   Lewiecki EM, 2011, DISCOV MED, V12, P263
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Lippuner K, 2009, OSTEOPOROSIS INT, V20, P1131, DOI 10.1007/s00198 008 0779 8
   Lou SH, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen 2016 015187
   Majidinia M, 2018, J CELL PHYSIOL, V233, P2937, DOI 10.1002/jcp.26042
   Marini JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.52
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Morgan EF, 2009, BONE, V44, P335, DOI 10.1016/j.bone.2008.10.039
   Niehrs C, 2012, EMBO J, V31, P2705, DOI 10.1038/emboj.2012.124
   Odén A, 2015, OSTEOPOROSIS INT, V26, P2243, DOI 10.1007/s00198 015 3154 6
   Pedersen AB, 2017, OSTEOPOROSIS INT, V28, P3421, DOI 10.1007/s00198 017 4213 y
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Ryman JT, 2017, CPT PHARMACOMET SYST, V6, P576, DOI 10.1002/psp4.12224
   Toth E, 2020, J BONE MINER RES, V35, P861, DOI 10.1002/jbmr.3953
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910
   Silva DMW, 2019, ARCH OSTEOPOROS, V14, DOI 10.1007/s11657 019 0597 y
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Weivoda MM, 2016, J BONE MINER RES, V31, P65, DOI 10.1002/jbmr.2599
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Zhao L, 2009, CALCIFIED TISSUE INT, V84, P56, DOI 10.1007/s00223 008 9189 3
   Zhong N, 2006, BONE, V39, P5, DOI 10.1016/j.bone.2005.12.008
NR 46
TC 30
Z9 37
U1 2
U2 28
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAY 31
PY 2021
VL 12
IS 1
AR 3247
DI 10.1038/s41467 021 23374 8
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA SO7TR
UT WOS:000659178700003
PM 34059688
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wei, GJ
   Liang, TH
   Wei, CM
   Nong, XL
   Lu, QT
   Zhao, JM
AF Wei, Gejin
   Liang, Tihong
   Wei, Chengming
   Nong, Xiaolian
   Lu, Qiteng
   Zhao, Jinmin
TI 被撤回的出版物: Daidzin inhibits RANKL induced osteoclastogenesis in vitro and
   prevents LPS induced bone loss in vivo (Retracted article. See vol. 123,
   pg. 1119, 2022)
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE daidzin; osteoclast; osteoclastogenesis; osteolytic diseases
ID NF KAPPA B; DIFFERENTIATION; PROLIFERATION; ACTIVATION; GENISTIN;
   SKELETAL; NFATC1; LIGAND; FOS
AB Osteoclasts are multinuclear giant cells responsible for bone resorption in bone loss diseases, including rheumatoid arthritis, periodontitis, and the aseptic loosening of orthopedic implants. Because of injurious side effects with currently available drugs, it is necessary to continue research novel bone protective therapies. Daidzin, a naturally occurring isoflavone found in leguminous plants, has numerous beneficial pharmacologic effects, including anti cancer, anti cholesterol, and anti angiocardiopathy, promoting osteoblasts differentiation, and even anti osteoporosis. However, the effect of daidzin on the regulation of osteoclast activity has not yet been investigated. In this study, our study showed that daidzin significantly inhibited receptor activator of nuclear factor kB ligand (RANKL) induced osteoclast differentiation of bone marrow macrophages and the hydroxyapatite resorbing activity of mature osteoclasts by inhibiting RANKL induced NF kB signaling pathway. In addition, daidzin could inhibit the expression of osteoclast marker genes, including nuclear factor of activated T cells cytoplasmic 1 (NFATc1), cellular oncogene fos (c Fos), tartrate resistant acid phosphatase (TRAP), and cathepsin K (CTSK). Consistent with in vitro results, daidzin inhibited lipopolysaccharide induced bone loss by suppressing the osteoclast differentiation. Together our data demonstrated that daidzin inhibits RANKL induced osteoclastogenesis through suppressing NF kappa B signaling pathway and that daidzin is a promising agent in the treatment of osteolytic diseases.
C1 [Wei, Gejin; Wei, Chengming; Nong, Xiaolian; Lu, Qiteng; Zhao, Jinmin] Guangxi Med Univ, Postdoctoral Res Stn, Guangxi 530021, Peoples R China.
   [Wei, Gejin] 303 Hosp PLA, Dept Orthoped, Guangxi, Peoples R China.
   [Liang, Tihong] Guizhou Med Univ, Affiliated Hosp, Dept Orthoped, Guiyang, Guizhou, Peoples R China.
C3 Guangxi Medical University; Guizhou Medical University
RP Zhao, JM (通讯作者)，Guangxi Med Univ, Postdoctoral Res Stn, Guangxi 530021, Peoples R China.
EM zhaojinmin@126.com
RI ; zhao, jin/LBH 0351 2024
OI Zhao, Jinmin/0000 0002 1047 8820; Zhao, Jinmin/0000 0001 8423 0425; WEI,
   Gejin/0009 0001 2103 3800
FU Guangxi Medical University Postdoctoral Research Station [02305217038X,
   02306217008D]
FX This study was supported by Guangxi Medical University Postdoctoral
   Research Station (02305217038X, 02306217008D).
CR Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   BISKOBING DM, 1995, J BONE MINER RES, V10, P1025
   Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Choi H, 2011, J AM SOC HYPERTENS, V5, P154, DOI 10.1016/j.jash.2011.02.005
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Fu J, 2016, J CLIN INVEST, V126, P1759, DOI 10.1172/JCI80276
   Fukuda M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05187 4
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Grössinger EM, 2018, J IMMUNOL, V200, P749, DOI 10.4049/jimmunol.1701170
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kartsogiannis V, 2004, MOL CELL ENDOCRINOL, V228, P79, DOI 10.1016/j.mce.2003.06.002
   Kartsogiannis V, 1999, BONE, V25, P525, DOI 10.1016/S8756 3282(99)00214 8
   Kato K, 2000, JPN J CANCER RES, V91, P786, DOI 10.1111/j.1349 7006.2000.tb01014.x
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li XH, 2005, ACTA PHARMACOL SIN, V26, P1081, DOI 10.1111/j.1745 7254.2005.00161.x
   Lietman SA, 2008, BIOCHEM BIOPH RES CO, V371, P644, DOI 10.1016/j.bbrc.2008.04.080
   Lu LJW, 1996, CANCER EPIDEM BIOMAR, V5, P63
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   Murata K, 2017, IMMUNITY, V47, P66, DOI 10.1016/j.immuni.2017.06.018
   Niu CG, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00626
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Pyo YH, 2009, J AGR FOOD CHEM, V57, P8617, DOI 10.1021/jf901878c
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   Tanaka T, 2011, J AGR FOOD CHEM, V59, P13230, DOI 10.1021/jf2031617
   Thaler R, 2016, J BIOL CHEM, V291, P6754, DOI 10.1074/jbc.M115.678235
   Wei CM, 2018, CELL PHYSIOL BIOCHEM, V48, P644, DOI 10.1159/000491892
   Wu HB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0540 y
   Yin YR, 2017, AM J TRANSL RES, V9, P5743
   Zhang XJ, 2018, J CELL BIOCHEM, V119, P8981, DOI 10.1002/jcb.27154
   Zhou J, 2015, CALCIFIED TISSUE INT, V96, P465, DOI 10.1007/s00223 015 9967 7
   Zhu X, 2016, BIOCHEM PHARMACOL, V104, P118, DOI 10.1016/j.bcp.2016.02.013
NR 36
TC 18
Z9 20
U1 0
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD APR
PY 2019
VL 120
IS 4
BP 5304
EP 5314
DI 10.1002/jcb.27806
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HL8RK
UT WOS:000459010100056
PM 30378146
DA 2025 08 17
ER

PT J
AU Tonna, S
   Takyar, FM
   Vrahnas, C
   Crimeen Irwin, B
   Ho, PWM
   Poulton, IJ
   Brennan, HJ
   McGregor, NE
   Allan, EH
   Nguyen, H
   Forwood, MR
   Tatarczuch, L
   Mackie, EJ
   Martin, TJ
   Sims, NA
AF Tonna, Stephen
   Takyar, Farzin M.
   Vrahnas, Christina
   Crimeen Irwin, Blessing
   Ho, Patricia W. M.
   Poulton, Ingrid J.
   Brennan, Holly J.
   McGregor, Narelle E.
   Allan, Elizabeth H.
   Nguyen, Huynh
   Forwood, Mark R.
   Tatarczuch, Liliana
   Mackie, Eleanor J.
   Martin, T. John
   Sims, Natalie A. z
TI EphrinB2 signaling in osteoblasts promotes bone mineralization by
   preventing apoptosis
SO FASEB JOURNAL
LA English
DT Article
DE osteocyte; osteoclast; bone matrix; bone strength
ID PARATHYROID HORMONE; COLLAGEN SECRETION; KAPOSI SARCOMA; EPH RECEPTORS;
   TUMOR GROWTH; IN VIVO; INHIBITION; GENE; MICE; DIFFERENTIATION
AB Cells that form bone (osteoblasts) express both ephrinB2 and EphB4, and previous work has shown that pharmacological inhibition of the ephrinB2/EphB4 interaction impairs osteoblast differentiation in vitro and in vivo. The purpose of this study was to determine the role of ephrinB2 signaling in the osteoblast lineage in the process of bone formation. Cultured osteoblasts from mice with osteoblast specific ablation of ephrinB2 showed delayed expression of osteoblast differentiation markers, a finding that was reproduced by ephrinB2, but not EphB4, RNA interference. Microcomputed tomography, histomorphometry, and mechanical testing of the mice lacking ephrinB2 in osteoblasts revealed a 2 fold delay in bone mineralization, a significant reduction in bone stiffness, and a 50% reduction in osteoblast differentiation induced by anabolic parathyroid hormone (PTH) treatment, compared to littermate sex  and age matched controls. mRNA levels of late osteoblast differentiation markers and greater levels of osteoblast and osteocyte apoptosis, indicated by TUNEL staining and transmission electron microscopy of bone samples, and a 2 fold increase in annexin V staining and 7 fold increase in caspase 8 activation in cultured ephrinB2 deficient osteoblasts. We conclude that osteoblast differentiation and bone strength are maintained by antiapoptotic actions of ephrinB2 signaling within the osteoblast lineage. Tonna, S., Takyar, F. M., Vrahnas, C., Crimeen Irwin, B., Ho, P. W. M., Poulton, I. J., Brennan, H. J., McGregor, N. E., Allan, E. H., Nguyen, H., Forwood, M. R., Tatarczuch, L., Mackie, E. J., Martin, T. J., Sims, N. A. EphrinB2 signaling in osteoblasts promotes bone mineralization by preventing apoptosis.
C1 [Tonna, Stephen; Takyar, Farzin M.; Vrahnas, Christina; Crimeen Irwin, Blessing; Ho, Patricia W. M.; Poulton, Ingrid J.; Brennan, Holly J.; McGregor, Narelle E.; Allan, Elizabeth H.; Martin, T. John; Sims, Natalie A. z] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia.
   [Tonna, Stephen; Takyar, Farzin M.; Vrahnas, Christina; Martin, T. John; Sims, Natalie A. z] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia.
   [Tatarczuch, Liliana; Mackie, Eleanor J.] Univ Melbourne, Fac Vet Sci, Parkville, Vic 3052, Australia.
   [Nguyen, Huynh; Forwood, Mark R.] Griffith Univ, Sch Med Sci, Griffith Hlth Inst, Gold Coast, Qld, Australia.
C3 St. Vincent's Institute of Medical Research; St Vincent's Health; St
   Vincent's Hospital Melbourne; NSW Health; St Vincents Hospital Sydney;
   University of Melbourne; University of Melbourne; Griffith University;
   Griffith University   Gold Coast Campus; Menzies Health Institute
   Queensland
RP Sims, NA (通讯作者)，St Vincents Inst Med Res, Bone Cell Biol & Dis Unit, 9 Princes St, Fitzroy, Vic 3065, Australia.
EM nsims@svi.edu.au
RI ; Forwood, Mark/ABA 9040 2021; Mackie, Eleanor/B 2045 2008; Sims,
   Natalie/A 7192 2012
OI Mackie, Eleanor/0000 0002 8057 5407; Tatarczuch,
   Liliana/0000 0001 9556 0753; Forwood, Mark/0000 0002 9963 1616; Sims,
   Natalie/0000 0003 1421 8468
FU National Health and Medical Research Council (NHMRC; Australia) [620600,
   1042129]; NHMRC; University of Melbourne at Melbourne Research
   Scholarship; Melbourne International Fee Remission Scholarship; St.
   Vincent's Institute Foundation; Victorian State Government Operational
   Infrastructure Program
FX The authors thank Joshua Johnson for technical assistance, St. Vincent's
   BioResources Centre staff for animal care, and Carl Walkley and Brian
   Liddicoat for helpful advice and assistance with the preparation of
   lenti Cre reagents. This work was supported by National Health and
   Medical Research Council (NHMRC; Australia) project grants 620600 and
   1042129; N.A.S. is supported by an NHMRC Senior Research Fellowship.
   S.T. is supported by an NHMRC Peter Doherty Postdoctoral Fellowship.
   F.T. was supported by a University of Melbourne at Melbourne Research
   Scholarship, a Melbourne International Fee Remission Scholarship, and a
   St. Vincent's Institute Foundation Scholarship. St. Vincent's Institute
   receives support from the Victorian State Government Operational
   Infrastructure Program. N.A.S. and T.J.M. jointly conceived the study;
   S.T., F.M.T., C.V., B.C. I., P.W.M.H., N.E.M., E.H.A., I.J.P., and
   H.J.B. performed experiments and carried out analyses; H.N. and M.J.F.
   carried out 3 point bending tests with C.V. and provided interpretation;
   L.T. and E.J.M. carried out TEM analysis and provided interpretation;
   N.A.S., T.J.M., and S.T. wrote the manuscript; all authors discussed the
   results and commented on the manuscript at all stages. The authors
   declare no conflicts of interest.
CR Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   Allan EH, 2003, J CELL BIOCHEM, V90, P158, DOI 10.1002/jcb.10614
   Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324
   Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Arthur A, 2013, J BONE MINER RES, V28, P926, DOI 10.1002/jbmr.1821
   Arthur A, 2011, BONE, V48, P533, DOI 10.1016/j.bone.2010.10.180
   Boskey AL, 1998, BONE, V23, P187, DOI 10.1016/S8756 3282(98)00092 1
   Boyadjiev SA, 2006, NAT GENET, V38, P1192, DOI 10.1038/ng1876
   Cerri PS, 2005, ANAT REC PART A, V286A, P833, DOI 10.1002/ar.a.20220
   Davydova N, 2012, PROTEIN EXPRES PURIF, V82, P232, DOI 10.1016/j.pep.2012.01.001
   Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651
   Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309
   Flanagan JG, 2000, METHOD ENZYMOL, V327, P19, DOI 10.1016/S0076 6879(00)27264 9
   Frost HM., 1964, Bone Biodyn, V6, P315
   Gerety SS, 2002, DEVELOPMENT, V129, P1397
   HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356
   HOUSSAMI S, 1994, ENDOCRINOLOGY, V135, P183, DOI 10.1210/en.135.1.183
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   Johnson RW, 2014, J BONE MINER RES, V29, P1492, DOI 10.1002/jbmr.2159
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kelly PN, 2011, CELL DEATH DIFFER, V18, P1414, DOI 10.1038/cdd.2011.17
   Kertesz N, 2006, BLOOD, V107, P2330, DOI 10.1182/blood 2005 04 1655
   Koolpe M, 2005, J BIOL CHEM, V280, P17301, DOI 10.1074/jbc.M500363200
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   Martin TJ, 2010, ADV EXP MED BIOL, V658, P51, DOI 10.1007/978 1 4419 1050 9_6
   Martiny Baron G, 2004, NEOPLASIA, V6, P248, DOI 10.1593/neo.03457
   Masood R, 2005, BLOOD, V105, P1310, DOI 10.1182/blood 2004 03 0933
   MELSEN F, 1980, ACTA PATH MICRO IM A, V88, P83
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625
   Nagase Y, 2009, J BIOL CHEM, V284, P36659, DOI 10.1074/jbc.M109.016915
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Noren NK, 2009, BIOCHEM J, V422, P433, DOI 10.1042/BJ20090014
   Paic F, 2009, BONE, V45, P682, DOI 10.1016/j.bone.2009.06.010
   Parfitt AM, 1996, ANN INTERN MED, V125, P413, DOI 10.7326/0003 4819 125 5 199609010 00009
   Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806
   Quinn JMW, 2008, J IMMUNOL, V181, P5720, DOI 10.4049/jimmunol.181.8.5720
   Roche B, 2012, BONE, V50, P390, DOI 10.1016/j.bone.2011.09.051
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683
   Sarathchandra P, 2000, J PATHOL, V192, P385
   Scehnet JS, 2009, BLOOD, V113, P254, DOI 10.1182/blood 2008 02 140020
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Takyar FM, 2013, J BONE MINER RES, V28, P912, DOI 10.1002/jbmr.1820
   Townley AK, 2008, J CELL SCI, V121, P3025, DOI 10.1242/jcs.031070
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Walker EC, 2012, J BONE MINER RES, V27, P902, DOI 10.1002/jbmr.1506
   Weiler S, 2009, DEV GROWTH DIFFER, V51, P809, DOI 10.1111/j.1440 169X.2009.01140.x
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wilson DG, 2011, J CELL BIOL, V193, P935, DOI 10.1083/jcb.201007162
   Xing WR, 2010, MOL CELL BIOL, V30, P711, DOI 10.1128/MCB.00610 09
   Yadav MC, 2012, J BONE MINER RES, V27, P1722, DOI 10.1002/jbmr.1619
   Zhang C, 2008, P NATL ACAD SCI USA, V105, P6936, DOI 10.1073/pnas.0710831105
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhou RP, 1998, PHARMACOL THERAPEUT, V77, P151, DOI 10.1016/S0163 7258(97)00112 5
NR 57
TC 73
Z9 82
U1 2
U2 26
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD OCT
PY 2014
VL 28
IS 10
BP 4482
EP 4496
DI 10.1096/fj.14 254300
PG 15
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA AP6XU
UT WOS:000342222700025
PM 24982128
DA 2025 08 17
ER

PT J
AU Lei, YT
   Su, JY
   Xu, HX
   Yu, Q
   Zhao, M
   Tian, J
AF Lei, Yutian
   Su, Jinyu
   Xu, Haixia
   Yu, Qiang
   Zhao, Ming
   Tian, Jing
TI Pulsed electromagnetic fields inhibit osteoclast differentiation in
   RAW264.7 macrophages via suppression of the protein kinase B/mammalian
   target of rapamycin signaling pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE pulsed electromagnetic fields; receptor activator of nuclear
   factor kappa B ligand; osteoclast differentiation; protein kinase B;
   mammalian target of rapamycin; osteoporosis
ID OSTEOGENIC DIFFERENTIATION; BONE RESORPTION; IN VITRO; OSTEOPOROSIS;
   PROLIFERATION; EXPRESSION; CELLS; WOMEN; MEDICATION; ACTIVATION
AB When bone resorption, aided by the activity of osteoclasts, exceeds bone formation induced by ostcoblasts, bone metabolism loses equilibration, which results in the development of bone diseases, including osteoporosis. Pulsed electromagnetic fields (PEMFs) are known to be involved in various biological processes, including cell proliferation, differentiation and apoptosis. However, the exact mechanism of action of osteoclasts remains poorly understood. In the present study, the effects of PEMFs on osteoclast differentiation and associated signaling pathways were systematically investigated in RAW264.7 macrophages. RAW264.7 cells were induced by receptor activator of nuclear factor kappa B ligand (RANKL) to obtain osteoclasts in vitro. The results of the present study demonstrated that PEMF exposure decreased osteoclast formation, limited tartrate resistant acid phosphatase activity, contracted bone resorption area and inhibited osteoclastic specific gene and protein expression. Furthermore, western blot analysis indicated that PEMFs distinctly abolished the upregulation of phosphorylated protein kinase B (Akt),  mammalian target of rapamycin (mTOR) and  ribosome S6 protein kinase (p70S6K) induced by RANKL, which was consistent with the effects of pharmacological inhibitor perifosine and rapamycin. Therefore, the present study suggested that PEMFs reduced osteoclast formation from RAW264.7 macrophages via inhibition of the Akt/mTOR signaling pathway. These findings provided novel insight into the mechanisms through which PEMFs suppress osteoclast differentiation.
C1 [Lei, Yutian; Xu, Haixia; Yu, Qiang; Tian, Jing] Southern Med Univ, Zhujiang Hosp, Dept Orthopaed, 253 Ind Ave, Guangzhou 510280, Guangdong, Peoples R China.
   [Su, Jinyu; Zhao, Ming] Southern Med Univ, Dept Pathophysiol, Key Lab Shock & Microcirculat Res Guangdong, Guangzhou 510515, Guangdong, Peoples R China.
C3 Southern Medical University   China; Southern Medical University   China
RP Tian, J (通讯作者)，Southern Med Univ, Zhujiang Hosp, Dept Orthopaed, 253 Ind Ave, Guangzhou 510280, Guangdong, Peoples R China.
EM tianjing_ortho@163.com
RI 余, 强/AAG 9061 2021
CR Barnaba SA, 2012, RHEUMATOL INT, V32, P1025, DOI 10.1007/s00296 010 1724 7
   BASSETT CAL, 1974, SCIENCE, V184, P575
   BASSETT CAL, 1974, ANN NY ACAD SCI, V238, P242, DOI 10.1111/j.1749 6632.1974.tb26794.x
   Bone HG, 2015, OSTEOPOROSIS INT, V26, P2721, DOI 10.1007/s00198 015 3274 z
   Bonnick S, 2013, J CLIN ENDOCR METAB, V98, P4727, DOI 10.1210/jc.2013 2020
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang K, 2005, J ORTHOP RES, V23, P1308, DOI 10.1016/j.orthres.2005.03.012
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Gartlehner G, 2017, JAMA J AM MED ASSOC, V318, P2234, DOI 10.1001/jama.2017.16952
   Hadji P, 2015, OSTEOPOROSIS INT, V26, P2479, DOI 10.1007/s00198 015 3164 4
   Halleen JM, 2006, CLIN LAB, V52, P499
   Hannon RA, 2010, J BONE MINER RES, V25, P463, DOI 10.1359/jbmr.090830
   He JQ, 2015, AGING CLIN EXP RES, V27, P13, DOI 10.1007/s40520 014 0239 6
   Hsieh CJ, 2015, INT J ONCOL, V46, P555, DOI 10.3892/ijo.2014.2769
   Jing D, 2016, SCI REP UK, V6, DOI 10.1038/srep32045
   Jing D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079377
   Kang KS, 2015, J TISSUE ENG REGEN M, V9, P1161, DOI 10.1002/term.1664
   Kapetanakis NI, 2015, ONCOTARGET, V6, P36815, DOI 10.18632/oncotarget.5766
   Lei T, 2018, BONE, V108, P10, DOI 10.1016/j.bone.2017.12.008
   Li L, 2017, EUR J PHARMACOL, V815, P202, DOI 10.1016/j.ejphar.2017.09.015
   Lin HY, 2011, BIOELECTROMAGNETICS, V32, P552, DOI 10.1002/bem.20668
   Liu HR, 2018, HISTOCHEM CELL BIOL, V149, P343, DOI 10.1007/s00418 017 1629 6
   Liu HF, 2015, TRIALS, V16, DOI 10.1186/s13063 015 0780 4
   Liu W, 2015, MINERVA MED, V106, P203
   Muramatsu Y, 2017, IN VIVO, V31, P61, DOI 10.21873/invivo.11026
   Musette P, 2010, OSTEOPOROSIS INT, V21, P723, DOI 10.1007/s00198 009 1097 5
   Navé BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264 6021:3440427
   Park KH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478 811X 11 74
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752
   Urnukhsaikhan E, 2016, LIFE SCI, V151, P130, DOI 10.1016/j.lfs.2016.02.066
   Visagie A, 2015, INT J ENV RES PUB HE, V12, P13779, DOI 10.3390/ijerph121113779
   Wang TT, 2017, BIOELECTROMAGNETICS, V38, P63, DOI 10.1002/bem.22018
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Xie YF, 2016, BONE, V93, P22, DOI 10.1016/j.bone.2016.09.008
   Xu HX, 2016, BIOCHEM BIOPH RES CO, V479, P97, DOI 10.1016/j.bbrc.2016.09.044
   Yang J, 2017, BIOL TRACE ELEM RES, DOI [10. 1007/s12011 017 1161 5, DOI 10.1007/S12011 017 1161 55992240]
   Zhang DW, 2016, MED SCI MONITOR, V22, P2187, DOI 10.12659/MSM.896690
   Zhou J, 2012, ARCH MED RES, V43, P274, DOI 10.1016/j.arcmed.2012.06.002
NR 39
TC 8
Z9 9
U1 0
U2 29
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUL
PY 2018
VL 18
IS 1
BP 447
EP 454
DI 10.3892/mmr.2018.8999
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GP1OB
UT WOS:000440584500053
PM 29749519
OA Bronze
DA 2025 08 17
ER

PT J
AU Yang, L
   Fan, LY
   Wang, KX
   Chen, YP
   Liang, L
   Qin, XM
   Lu, AP
   Cao, P
   Yu, B
   Guan, DG
   Peng, JX
AF Yang, Lang
   Fan, Liuyi
   Wang, Kexin
   Chen, Yupeng
   Liang, Lan
   Qin, Xuemei
   Lu, Aiping
   Cao, Peng
   Yu, Bin
   Guan, Daogang
   Peng, Junxiang
TI Analysis of Molecular Mechanism of Erxian Decoction in Treating
   Osteoporosis Based on Formula Optimization Model
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID BONE MINERAL DENSITY; ER XIAN DECOCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;
   SITOSTEROL INDUCED APOPTOSIS; CHINESE HERBAL FORMULA; CELL CYCLE ARREST;
   BETA SITOSTEROL; MORINDA OFFICINALIS; WEB SERVER; OSTEOGENIC
   DIFFERENTIATION
AB Osteoporosis (OP) is a highly prevalent orthopedic condition in postmenopausal women and the elderly. Currently, OP treatments mainly include bisphosphonates, receptor activator of nuclear factor kappa B ligand (RANKL) antibody therapy, selective estrogen receptor modulators, teriparatide (PTH1 34), and menopausal hormone therapy. However, increasing evidence has indicated these treatments may exert serious side effects. In recent years, Traditional Chinese Medicine (TCM) has become popular for treating orthopedic disorders. Erxian Decoction (EXD) is widely used for the clinical treatment of OP, but its underlying molecular mechanisms are unclear thanks to its multiple components and multiple target features. In this research, we designed a network pharmacology method, which used a novel node importance calculation model to identify critical response networks (CRNs) and effective proteins. Based on these proteins, a target coverage contribution (TCC) model was designed to infer a core active component group (CACG). This approach decoded the mechanisms underpinning EXD's role in OP therapy. Our data indicated that the drug response network mediated by the CACG effectively retained information of the component target (C T) network of pathogenic genes. Functional pathway enrichment analysis showed that EXD exerted therapeutic effects toward OP by targeting PI3K Akt signaling (hsa04151), calcium signaling (hsa04020), apoptosis (hsa04210), estrogen signaling (hsa04915), and osteoclast differentiation (hsa04380) via JNK, AKT, and ERK. Our method furnishes a feasible methodological strategy for formula optimization and mechanism analysis and also supplies a reference scheme for the secondary development of the TCM formula.
C1 [Yang, Lang; Peng, Junxiang] Southern Med Univ, Nanfang Hosp, Dept Neurosurg, Guangzhou, Peoples R China.
   [Fan, Liuyi; Yu, Bin] Southern Med Univ, Nanfang Hosp, Dept Orthopaed & Traumatol, Guangzhou, Peoples R China.
   [Wang, Kexin; Qin, Xuemei] Shanxi Univ, Modern Res Ctr Tradit Chinese Med, Taiyuan, Peoples R China.
   [Wang, Kexin; Lu, Aiping] Hong Kong Baptist Univ, Inst Integrated Bioinformed & Translat Sci, Hong Kong, Peoples R China.
   [Chen, Yupeng; Guan, Daogang] Southern Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Guangzhou, Peoples R China.
   [Chen, Yupeng; Guan, Daogang] Guangdong Prov Key Lab Single Cell Technol & Appl, Guangzhou, Peoples R China.
   [Liang, Lan] Hong Kong Baptist Univ, Dept Comp Sci, Hong Kong, Peoples R China.
   [Cao, Peng] Chinese Peoples Liberat Army 96608 Mil Hosp, Dept Surg, Taiyuan, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Shanxi University; Hong Kong Baptist University; Southern Medical
   University   China; Hong Kong Baptist University
RP Peng, JX (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Neurosurg, Guangzhou, Peoples R China.; Yu, B (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Orthopaed & Traumatol, Guangzhou, Peoples R China.; Guan, DG (通讯作者)，Southern Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Guangzhou, Peoples R China.; Guan, DG (通讯作者)，Guangdong Prov Key Lab Single Cell Technol & Appl, Guangzhou, Peoples R China.
EM yubinol@163.com; guandg0929@hotmail.com; pjxlaozong@126.com
RI ; Cheng, Pei/KFS 9495 2024; yang, lang/LXW 3773 2024; LU,
   Aiping/JDX 0577 2023
OI Chen, Yupeng/0000 0002 2346 5826; Guan, Daogang/0000 0003 1414 0189;
   Yang, Lang/0000 0002 2759 6014; 
FU Southern Medical University [G820282016]; Natural Science Foundation of
   Guangdong Province [2019A1515012140]; Natural Science Foundation Council
   of China [31501080]; Hong Kong Baptist University Strategic Development
   Fund [SDF19 0402 P02]
FX This study is financially supported by the Startup fund from Southern
   Medical University (grant No. G820282016), the Natural Science
   Foundation of Guangdong Province (grant No. 2019A1515012140), the
   Natural Science Foundation Council of China (grant No. 31501080), and
   the Hong Kong Baptist University Strategic Development Fund (grant No.
   SDF19 0402 P02).
CR Bao L.L., 2010, CHINA PHARMACY, V15, P1415
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Cao ZQ, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01525
   Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939
   Chen CC, 2010, LIFE SCI, V87, P743, DOI 10.1016/j.lfs.2010.10.014
   Chen GM, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000013936
   Chen XW, 2019, J MOL ENDOCRINOL, V63, P63, DOI 10.1530/JME 19 0003
   Cheng F, 2019, EUR REV MED PHARMACO, V23, P7766, DOI 10.26355/eurrev_201909_18986
   Ciubean AD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225776
   Dong CY, 2019, MINERVA MED, V110, P595, DOI 10.23736/S0026 4806.19.06060 9
   Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607
   Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732
   Feng J, 2019, EUR REV MED PHARMACO, V23, P7757, DOI 10.26355/eurrev_201909_18985
   Feng Y., 2019, J LIAONING U TRADITI, V10, P128
   Gao Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.512877
   Ge JR, 2018, CHIN J INTEGR MED, V24, P415, DOI 10.1007/s11655 016 2744 2
   Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293
   Gong AGW, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00036
   Goto T, 2015, CYTOTECHNOLOGY, V67, P357, DOI 10.1007/s10616 014 9694 3
   Greendale GA, 2010, AM J EPIDEMIOL, V171, P1214, DOI 10.1093/aje/kwq067
   Guan DG, 2014, NUCLEIC ACIDS RES, V42, pW130, DOI 10.1093/nar/gku471
   Guan DG, 2014, BIOINFORMATICS, V30, P1190, DOI 10.1093/bioinformatics/btt761
   He XF, 2017, BOSNIAN J BASIC MED, V17, P295, DOI 10.17305/bjbms.2017.2596
   Hong GJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010203
   Hong Ying L.I., 2013, J HUBEI U NATL, V1, P104
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Huang Q., 2016, CLIN J TRADITIONAL C, V28
   Jiang KM, 2018, INT J BIOL MACROMOL, V120, P170, DOI 10.1016/j.ijbiomac.2018.08.082
   Jiang ZS, 2016, MOL MED REP, V14, P4415, DOI 10.3892/mmr.2016.5755
   Jiao L, 2009, PHYTOMEDICINE, V16, P874, DOI 10.1016/j.phymed.2009.01.005
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim TH, 2011, J NUTR BIOCHEM, V22, P8, DOI 10.1016/j.jnutbio.2009.11.002
   Krela Kazmierczak I, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091306
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Lee HJ, 2010, OSTEOPOROSIS INT, V21, P1351, DOI 10.1007/s00198 009 1106 8
   Li JY, 2017, CLIN INTERV AGING, V12, P45, DOI 10.2147/CIA.S117597
   Li MY, 2010, MOLECULES, V15, P7403, DOI 10.3390/molecules15107403
   Li R, 2018, J BUON, V23, P1420
   Li WX, 2018, J TRADIT CHIN MED, V38, P33
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169 409X(00)00129 0
   Liu HP, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/2960372
   Liu XP, 2013, BIOINFORMATICS, V29, P1910, DOI 10.1093/bioinformatics/btt303
   Liz R, 2013, J PHARM PHARMACOL, V65, P115, DOI 10.1111/j.2042 7158.2012.01568.x
   Luo LM, 2014, MOL BIOL REP, V41, P3235, DOI 10.1007/s11033 014 3186 6
   Luo WJ, 2017, NUCLEIC ACIDS RES, V45, pW501, DOI 10.1093/nar/gkx372
   Luther J, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aau7137
   Majchrzycki M, 2017, GINEKOL POL, V88, P414, DOI 10.5603/GP.a2017.0077
   Majchrzycki M, 2015, GINEKOL POL, V86, P907, DOI 10.17772/gp/60550
   Mäkitie RE, 2018, J CLIN ENDOCR METAB, V103, P1985, DOI 10.1210/jc.2017 02585
   Marques CPC, 2016, CLIN EXP IMMUNOL, V183, P187, DOI 10.1111/cei.12708
   Mencej Bedrac S, 2011, MATURITAS, V69, P263, DOI 10.1016/j.maturitas.2011.02.010
   Meng FH, 2005, PHYTOMEDICINE, V12, P189, DOI 10.1016/j.phymed.2004.03.007
   Mondockova V, 2018, BMC MED GENET, V19, DOI 10.1186/s12881 018 0684 8
   Moon DO, 2007, INT IMMUNOPHARMACOL, V7, P1044, DOI 10.1016/j.intimp.2007.03.010
   Morón FJ, 2006, BONE, V39, P213, DOI 10.1016/j.bone.2005.12.079
   Nakamichi Y, 2017, J BONE MINER RES, V32, P1297, DOI 10.1002/jbmr.3096
   Napoli N, 2009, BONE, V44, P442, DOI 10.1016/j.bone.2008.09.018
   Nian H, 2006, J ETHNOPHARMACOL, V108, P96, DOI 10.1016/j.jep.2006.04.020
   Nian H, 2006, ACTA PHARMACOL SIN, V27, P728, DOI 10.1111/j.1745 7254.2006.00328.x
   Oates JC, 2003, J RHEUMATOL, V30, P60
   Méndez JP, 2013, GENE, V528, P216, DOI 10.1016/j.gene.2013.07.008
   Park C, 2008, ACTA PHARMACOL SIN, V29, P341, DOI 10.1111/j.1745 7254.2008.00761.x
   Qin LP, 2008, J ETHNOPHARMACOL, V118, P271, DOI 10.1016/j.jep.2008.04.009
   Rajavel T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 20311 6
   Rivadeneira F, 2006, J BONE MINER RES, V21, P1443, DOI 10.1359/JBMR.060605
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Shang DP, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15028106
   Shultz MD, 2019, J MED CHEM, V62, P1701, DOI 10.1021/acs.jmedchem.8b00686
   Sook SH, 2014, PHYTOTHER RES, V28, P387, DOI 10.1002/ptr.4999
   Sriraman S, 2015, J PHARMACEUT BIOMED, V115, P55, DOI 10.1016/j.jpba.2015.06.024
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Tang ZZ, 2012, HUM MOL GENET, V21, P1312, DOI 10.1093/hmg/ddr568
   Tao WY, 2013, J ETHNOPHARMACOL, V145, P1, DOI 10.1016/j.jep.2012.09.051
   Tural S, 2013, GENE, V515, P167, DOI 10.1016/j.gene.2012.10.041
   Varsavsky M, 2013, OSTEOPOROSIS INT, V24, P713, DOI 10.1007/s00198 012 2012 z
   Wang C, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00841
   Wang KX, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.567088
   Wang KX, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01035
   Wang LL, 2016, CURR PHARM DESIGN, V22, P328, DOI 10.2174/1381612822666151112145907
   Wang NN, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00988
   Wang NN, 2019, J ETHNOPHARMACOL, V241, DOI 10.1016/j.jep.2019.111977
   [汪滢 Wang Ying], 2012, [中国药学杂志, Chinese Pharmaceutical Journal], V47, P375
   Wang YL, 2014, J ETHNOPHARMACOL, V153, P42, DOI 10.1016/j.jep.2014.02.013
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Wong KC, 2014, AM J CHINESE MED, V42, P409, DOI 10.1142/S0192415X1450027X
   Wong SK, 2019, DRUG DES DEV THER, V13, P3497, DOI 10.2147/DDDT.S227738
   Wu J, 2017, INT J RHEUM DIS, V20, P903, DOI 10.1111/1756 185X.13052
   Wu YB, 2009, MOLECULES, V14, P573, DOI 10.3390/molecules14010573
   Xia G, 2017, BIOCHEM BIOPH RES CO, V491, P807, DOI 10.1016/j.bbrc.2017.06.184
   Xia TS, 2019, J PHARMACEUT BIOMED, V166, P336, DOI 10.1016/j.jpba.2019.01.019
   Xie QF, 2012, J ETHNOPHARMACOL, V144, P567, DOI 10.1016/j.jep.2012.09.041
   Xie X, 2019, BONE JOINT RES, V8, P323, DOI [10.1302/2046 3758.87.BJR 2018 0223.R2, 10.1302/2046 3758.87BJR 2018 0223.R2]
   Xu F, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000011659, 10.1097/md.0000000000011659]
   Xu GY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/290531
   Xue RC, 2013, NUCLEIC ACIDS RES, V41, pD1089, DOI 10.1093/nar/gks1100
   Yan QF, 2019, EXP THER MED, V17, P2161, DOI 10.3892/etm.2019.7214
   Yin H, 2018, BIOMED PHARMACOTHER, V97, P995, DOI 10.1016/j.biopha.2017.11.029
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yu X., 2014, J GANSU COLL TRADITI, V1, P19
   Yuan R.W., 2014, GUANGZHOU CHEM IND, V13
   Zha XY, 2014, ENDOCRINE, V47, P590, DOI 10.1007/s12020 013 0155 0
   Zhang L, 2020, J CLIN ENDOCR METAB, V105, P2678, DOI 10.1210/clinem/dgaa319
   Zhang L, 2018, SCI REP UK, V8, DOI 10.1038/s41598 017 18670 7
   Zhang N.D., 2016, SCH PHARM 2 MILITARY, V5, P40
   Zhang WJ, 2019, LIFE SCI, V235, DOI 10.1016/j.lfs.2019.116820
   Zhang ZG, 2016, FITOTERAPIA, V110, P166, DOI 10.1016/j.fitote.2016.03.013
   Zhang ZG, 2014, INT J MOL SCI, V15, P17130, DOI 10.3390/ijms150917130
   Zhao GM, 2017, ONCOL REP, V37, P2277, DOI 10.3892/or.2017.5450
   Zhao HJ, 2017, RHEUMATOLOGY, V56, P835, DOI 10.1093/rheumatology/kew508
   Zhao S, 2016, IRISH J MED SCI, V185, P581, DOI 10.1007/s11845 015 1309 2
   Zhao YH, 2009, J AGR FOOD CHEM, V57, P5211, DOI 10.1021/jf803878n
   Zhou LP, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00779
   Zhu W, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5305014
NR 113
TC 35
Z9 36
U1 5
U2 50
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942 0900
EI 1942 0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD JUN 21
PY 2021
VL 2021
AR 6641838
DI 10.1155/2021/6641838
PG 20
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA TH6UE
UT WOS:000672221700007
PM 34239693
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Terpos, E
   Kastritis, E
   Dimopoulos, M
AF Terpos, Evangelos
   Kastritis, Efstathios
   Dimopoulos, Meletios A.
TI Prevention and Treatment of Myeloma Bone Disease
SO CURRENT HEMATOLOGIC MALIGNANCY REPORTS
LA English
DT Article
DE Multiple myeloma; Bone disease; Bisphosphonates; Zoledronic acid;
   Pamidronate; Clodronate; Receptor activator of nuclear factor kappa B
   ligand (RANKL); Activin; Sclerostin; Dickkopf 1; Sotatercept; Denosumab;
   Treatment
ID ADVANCED MULTIPLE MYELOMA; SINGLE CENTER EXPERIENCE; SKELETAL RELATED
   EVENTS; ZOLEDRONIC ACID; DOUBLE BLIND; RANDOMIZED TRIAL; KAPPA B;
   OSTEOLYTIC LESIONS; RESORPTION MARKERS; RECEPTOR ACTIVATOR
AB Osteolytic bone disease is the most common complication of multiple myeloma, resulting in skeletal related events (SREs) that cause significant morbidity. Bone destruction in myeloma is due to an increased activity of osteoclasts coupled with suppressed bone formation by osteoblasts. Currently, bisphosphonates are the mainstay of the treatment of myeloma bone disease. Zoledronic acid and pamidronate have shown similar efficacy in reducing SREs in a randomized study in the conventional chemotherapy era. However, in a recent study (the Myeloma IX trial of the UK Medical Research Council, MRC), zoledronic acid was found to be superior to clodronate in reducing SREs, but also it produced a survival advantage of approximately 10 months in patients with bone disease at baseline. During recent years, novel agents targeting bone have been used in myeloma. This review focuses on the established therapy of myeloma bone disease and also on recent advances in treatment that take advantage of the better understanding of the pathophysiology of bone disease.
C1 [Terpos, Evangelos; Kastritis, Efstathios; Dimopoulos, Meletios A.] Univ Athens, Alexandra Gen Hosp, Sch Med, Dept Clin Therapeut, Athens 11528, Greece.
C3 National & Kapodistrian University of Athens; Alexandra Hospital
RP Terpos, E (通讯作者)，Univ Athens, Alexandra Gen Hosp, Sch Med, Dept Clin Therapeut, 80 Vas Sofias Ave, Athens 11528, Greece.
EM eterpos@hotmail.com
RI Dimopoulos, Meletios/AAD 4130 2019; Terpos, Evangelos/AAD 3667 2019;
   Kastritis, Efstathios/AAD 3656 2019
OI Terpos, Evangelos/0000 0001 5133 1422; Dimopoulos,
   Meletios/0000 0001 8990 3254; Kastritis, Efstathios/0000 0001 8191 5832
FU Janssen Cilag
FX E. Terpos: institutional grant from Janssen Cilag, honoraria from Amgen,
   Novartis, Janssen Cilag, and Onyx. E. Kastritis: none. M. Dimopoulos:
   honoraria from Novartis and Janssen Cilag.
CR Anderson G, 2006, BLOOD, V107, P3098, DOI 10.1182/blood 2005 08 3450
   Anderson Kenneth C, 2007, J Natl Compr Canc Netw, V5, P118
   Badros A, 2008, J CLIN ONCOL, V26, P5904, DOI 10.1200/JCO.2008.16.9300
   Balducci M, 2011, STRAHLENTHER ONKOL, V187, P114, DOI 10.1007/s00066 010 2155 9
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   BELCH AR, 1991, J CLIN ONCOL, V9, P1397, DOI 10.1200/JCO.1991.9.8.1397
   Berenson J, 2011, LANCET ONCOL, V12, P225, DOI 10.1016/S1470 2045(11)70008 0
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593
   Bhargava A, 2009, J CLIN ONCOL, V27
   Bouza Carmen, 2009, BMC Palliat Care, V8, P12, DOI 10.1186/1472 684X 8 12
   Breitkreutz I, 2008, LEUKEMIA, V22, P1925, DOI 10.1038/leu.2008.174
   Brincker H, 1998, BRIT J HAEMATOL, V101, P280, DOI 10.1046/j.1365 2141.1998.00695.x
   Bruce NJ, 1999, BRIT J HAEMATOL, V104, P358, DOI 10.1046/j.1365 2141.1999.01194.x
   Christoulas D, 2009, EXPERT REV HEMATOL, V2, P385, DOI 10.1586/ehm.09.36
   Cocks K, 2007, EUR J CANCER, V43, P1670, DOI 10.1016/j.ejca.2007.04.022
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Corso A, 2007, LEUKEMIA, V21, P1545, DOI 10.1038/sj.leu.2404682
   Daragon A, 1993, Eur J Med, V2, P449
   Delforge M, 2011, EUR J HAEMATOL, V86, P372, DOI 10.1111/j.1600 0609.2011.01599.x
   Dimopoulos MA, 2009, ANN ONCOL, V20, P117, DOI 10.1093/annonc/mdn554
   Dimopoulos MA, 2006, HAEMATOL HEMATOL J, V91, P968
   Durie BGM, 2007, MAYO CLIN PROC, V82, P516, DOI 10.4065/82.4.516
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Gavriatopoulou M, 2009, EXPERT OPIN THER TAR, V13, P839, DOI 10.1517/14728220903025770
   Gimsing P, 2010, LANCET ONCOL, V11, P973, DOI 10.1016/S1470 2045(10)70198 4
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Gkotzamanidou M, 2012, EXPERT OPIN THER TAR, V16, P761, DOI 10.1517/14728222.2012.697154
   Harrouseau JL, 2005, ANN ONCOL, V16, P45, DOI 10.1093/annonc/mdi818
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hurchla MA, 2013, LEUKEMIA, V27, P430, DOI 10.1038/leu.2012.183
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   LAAKSO M, 1994, BRIT J HAEMATOL, V87, P725, DOI 10.1111/j.1365 2141.1994.tb06730.x
   Lacy MQ, 2006, MAYO CLIN PROC, V81, P1047, DOI 10.4065/81.8.1047
   LAHTINEN R, 1992, LANCET, V340, P1049, DOI 10.1016/0140 6736(92)93075 X
   Lewiecki EM, 2011, DISCOV MED, V12, P263
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   McCloskey EV, 2001, BRIT J HAEMATOL, V113, P1035, DOI 10.1046/j.1365 2141.2001.02851.x
   McCloskey EV, 1998, BRIT J HAEMATOL, V100, P317
   McDonald RJ, 2008, AM J NEURORADIOL, V29, P642, DOI 10.3174/ajnr.A0918
   Menssen HD, 2002, J CLIN ONCOL, V20, P2353, DOI 10.1200/JCO.2002.02.032
   Migliorati CA, 2005, J AM DENT ASSOC, V136, P1658, DOI 10.14219/jada.archive.2005.0108
   Montefusco V, 2008, LEUKEMIA LYMPHOMA, V49, P2156, DOI 10.1080/10428190802483778
   Morgan GJ, 2012, BLOOD, V119, P5374, DOI 10.1182/blood 2011 11 392522
   Morgan GJ, 2011, LANCET ONCOL, V12, P743, DOI 10.1016/S1470 2045(11)70157 7
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Musto P, 2008, CANCER AM CANCER SOC, V113, P1588, DOI 10.1002/cncr.23783
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Politou MC, 2006, INT J CANCER, V119, P1728, DOI 10.1002/ijc.22033
   Polyzos SA, 2012, OSTEOPOROSIS INT, V23, P1171, DOI 10.1007/s00198 010 1525 6
   PRICE P, 1986, RADIOTHER ONCOL, V6, P247, DOI 10.1016/S0167 8140(86)80191 8
   Rades D, 2007, J CLIN ONCOL, V25, P50, DOI 10.1200/JCO.2006.08.7155
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Steinman RM, 2005, ADV EXP MED BIOL, V560, P83
   Sugatani T, 2003, J CELL BIOCHEM, V90, P59, DOI 10.1002/jcb.10613
   Terpos E, 2005, LEUKEMIA, V19, P1969, DOI 10.1038/sj.leu.2403890
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Terpos E, 2010, LEUKEMIA, V24, P1700, DOI 10.1038/leu.2010.173
   Terpos E, 2010, HAEMATOL HEMATOL J, V95, P384
   Terpos E, 2010, ANN ONCOL, V21, P1561, DOI 10.1093/annonc/mdq259
   Terpos E, 2009, ANN ONCOL, V20, P1303, DOI 10.1093/annonc/mdn796
   Terpos E, 2008, LEUKEMIA, V22, P2247, DOI 10.1038/leu.2008.235
   Terpos E, 2012, ANN ONCOL IN PRESS
   Terpos E, 2011, HAEMATOLOGICA S1, V96
   Terpos E, 2006, BRIT J HAEMATOL, V135, P688, DOI 10.1111/j.1365 2141.2006.06356.x
   Terpos E, 2012, INT J CANCER, V131, P1466, DOI 10.1002/ijc.27342
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Tosi P, 2006, EUR J HAEMATOL, V76, P399, DOI 10.1111/j.0902 4441.2005.t01 1 EJH2520.x
   Utzschneider S, 2011, INT ORTHOP, V35, P1209, DOI 10.1007/s00264 010 1127 0
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
   Vanderkerken K, 2003, CANCER RES, V63, P287
   Voskaridou E, 2012, HORM METAB IN PRESS
   Wedin R, 2001, ACTA ORTHOP SCAND, V72, P3
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Zangari M, 2011, EUR J HAEMATOL, V86, P484, DOI 10.1111/j.1600 0609.2011.01602.x
   Zervas K, 2006, BRIT J HAEMATOL, V134, P620, DOI 10.1111/j.1365 2141.2006.06230.x
NR 82
TC 9
Z9 10
U1 1
U2 3
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1558 8211
EI 1558 822X
J9 CURR HEMATOL MALIG R
JI Curr. Hematol. Malig. Rep.
PD DEC
PY 2012
VL 7
IS 4
BP 249
EP 257
DI 10.1007/s11899 012 0135 0
PG 9
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA 035MS
UT WOS:000310951900001
PM 22941027
DA 2025 08 17
ER

PT J
AU Komarova, SV
AF Komarova, SV
TI Mathematical model of paracrine interactions between osteoclasts and
   osteoblasts predicts anabolic action of parathyroid hormone on bone
SO ENDOCRINOLOGY
LA English
DT Article
ID GROWTH FACTOR; RESORPTION; DIFFERENTIATION; ALENDRONATE; OSTEOPOROSIS;
   INTERMITTENT; INHIBITION; ACTIVATION; EXPRESSION; MECHANISM
AB To restore falling plasma calcium levels, PTH promotes calcium liberation from bone. PTH targets bone forming cells, osteoblasts, to increase expression of the cytokine receptor activator of nuclear factor kappa B ligand ( RANKL), which then stimulates osteoclastic bone resorption. Intriguingly, whereas continuous administration of PTH decreases bone mass, intermittent PTH has an anabolic effect on bone, which was proposed to arise from direct effects of PTH on osteoblastic bone formation. However, antiresorptive therapies impair the ability of PTH to increase bone mass, indicating a complex role for osteoclasts in the process. We developed a mathematical model that describes the actions of PTH at a single site of bone remodeling, where osteoclasts and osteoblasts are regulated by local autocrine and paracrine factors. It was assumed that PTH acts only to increase the production of RANKL by osteoblasts. As a result, PTH stimulated osteoclasts upon application, followed by compensatory osteoblast activation due to the coupling of osteoblasts to osteoclasts through local paracrine factors. Continuous PTH administration resulted in net bone loss, because bone resorption preceded bone formation at all times. In contrast, over a wide range of model parameters, short application of PTH resulted in a net increase in bone mass, because osteoclasts were rapidly removed upon PTH withdrawal, enabling osteoblasts to rebuild the bone. In excellent agreement with experimental findings, increase in the rate of osteoclast death abolished the anabolic effect of PTH on bone. This study presents an original concept for the regulation of bone remodeling by PTH, currently the only approved anabolic treatment for osteoporosis.
C1 McGill Univ, Fac Dent, Montreal, PQ H3A 2B2, Canada.
C3 McGill University
RP Komarova, SV (通讯作者)，McGill Univ, Fac Dent, 3640 Univ St, Montreal, PQ H3A 2B2, Canada.
EM svetlana.komarova@mcgill.ca
RI Komarova, Svetlana/MTR 5042 2025
OI Komarova, Svetlana/0000 0003 3570 3147
CR Berg C, 2003, NAT REV DRUG DISCOV, V2, P257, DOI 10.1038/nrd1068
   Bikle DD, 2002, J BONE MINER RES, V17, P1570, DOI 10.1359/jbmr.2002.17.9.1570
   Black AJ, 2000, J BONE MINER RES, V15, P557, DOI 10.1359/jbmr.2000.15.3.557
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burr DB, 2002, BONE, V30, P2, DOI 10.1016/S8756 3282(01)00619 6
   Buxton EC, 2004, J CLIN ENDOCR METAB, V89, P3332, DOI 10.1210/jc.2003 032066
   Canalis E, 1996, CALCIFIED TISSUE INT, V58, P133, DOI 10.1007/BF02526877
   DELMAS PD, 1995, BONE, V16, P603, DOI 10.1016/8756 3282(95)00113 R
   Dempster DW, 2005, J CELL BIOCHEM, V95, P139, DOI 10.1002/jcb.20388
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FROST HM, 1990, ANAT RECORD, V226, P414, DOI 10.1002/ar.1092260403
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   HODSMAN AB, 1993, BONE, V14, P523, DOI 10.1016/8756 3282(93)90190 L
   Hodsman AB, 2000, BONE, V27, P311, DOI 10.1016/S8756 3282(00)00316 1
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Karaplis A C, 2000, Rev Endocr Metab Disord, V1, P331, DOI 10.1023/A:1026526703898
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Kroll MH, 2000, B MATH BIOL, V62, P163, DOI 10.1006/bulm.1999.0146
   Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Locklin RM, 2003, J CELL BIOCHEM, V89, P180, DOI 10.1002/jcb.10490
   Martin MJ, 2004, BONE, V35, P918, DOI 10.1016/j.bone.2004.06.010
   Martin TJ, 2004, TRENDS ENDOCRIN MET, V15, P49, DOI 10.1016/j.tem.2004.01.002
   NISHIDA S, 1994, BONE, V15, P717, DOI 10.1016/8756 3282(94)90322 0
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   Parfitt AM, 2000, BONE, V26, P319, DOI 10.1016/S8756 3282(00)80937 0
   Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787
   Rattanakul C, 2003, BIOSYSTEMS, V70, P55, DOI 10.1016/S0303 2647(03)00040 6
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rubin MR, 2003, ENDOCRIN METAB CLIN, V32, P285, DOI 10.1016/S0889 8529(02)00056 7
   SAVAGEAU MA, 1969, J THEOR BIOL, V25, P365, DOI 10.1016/S0022 5193(69)80026 3
   Schett G, 2004, JAMA J AM MED ASSOC, V291, P1108, DOI 10.1001/jama.291.9.1108
   Swarthout JT, 2002, J BONE MINER RES, V17, P1401, DOI 10.1359/jbmr.2002.17.8.1401
   Takata Shinjiro, 2001, Journal of Medical Investigation, V48, P147
   Troen BR, 2003, EXP GERONTOL, V38, P605, DOI 10.1016/S0531 5565(03)00069 X
   Voit EO, 2002, DRUG DISCOV TODAY, V7, P621, DOI 10.1016/S1359 6446(02)02280 8
NR 41
TC 73
Z9 95
U1 0
U2 9
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD AUG
PY 2005
VL 146
IS 8
BP 3589
EP 3595
DI 10.1210/en.2004 1642
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 944KR
UT WOS:000230427400043
PM 15860557
OA Bronze
DA 2025 08 17
ER

PT J
AU Kong, YH
   Ma, XN
   Zhang, X
   Wu, LL
   Chen, DC
   Su, B
   Liu, DQ
   Wang, XT
AF Kong, Yuanhang
   Ma, Xinnan
   Zhang, Xin
   Wu, Leilei
   Chen, Dechun
   Su, Bo
   Liu, Daqian
   Wang, Xintao
TI The potential mechanism of Fructus Ligustri Lucidi promoting
   osteogenetic differentiation of bone marrow mesenchymal stem cells based
   on network pharmacology, molecular docking and experimental
   identification
SO BIOENGINEERED
LA English
DT Article
DE Fructus Ligustri Lucidi; traditional Chinese medicine; bone marrow
   mesenchymal stem cells; osteogenic differentiation; PI3K; AKT signaling
   pathway; network pharmacology
ID OSTEOBLAST DIFFERENTIATION; EXPRESSION; PI3K/AKT; EXTRACT; KINASE;
   BMSCS; RATS
AB Recent studies have shown that the differentiation of bone marrow mesenchymal stem cells (BMSCs) into osteogenic lineages can promotes bone formation and maintains bone homeostasis, which has become a promising therapeutic strategy for skeletal diseases such as osteoporosis. Fructus Ligustri Lucidi (FLL) has been widely used for the treatment of osteoporosis and other orthopedic diseases for thousands of years. However, whether FLL plays an anti osteoporosis role in promoting the osteogenic differentiation of BMSCs, as well as its active components, targets, and specific molecular mechanisms, has not been fully elucidated. First, we obtained 13 active ingredients of FLL from the Traditional Chinese Medicine Systems Pharmacology (TCSMP) database, and four active ingredients without any target were excluded. Subsequently, 102 common drug disease targets were subjected to protein protein interaction (PPI) analysis, Gene Oncology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. The results of the three analyses were highly consistent, indicating that FLL promoted the osteogenic differentiation of BMSCs by activating the PI3K/AKT signaling pathway. Finally, we validated previous predictions using in vitro experiments, such as alkaline phosphatase (ALP) staining, alizarin red staining (ARS), and western blot analysis of osteogenic related proteins. The organic combination of network pharmacological predictions with in vitro experimental validation comprehensively confirmed the reliability of FLL in promoting osteogenic differentiation of BMSCs. This study provides a strong theoretical support for the specific molecular mechanism and clinical application of FLL in the treatment of bone formation deficiency.
C1 [Kong, Yuanhang; Ma, Xinnan; Zhang, Xin; Wu, Leilei; Chen, Dechun; Su, Bo; Liu, Daqian; Wang, Xintao] Harbin Med Univ, Dept Orthoped Surg, Affiliated Hosp 2, 246 Xuefu Rd, Harbin 150000, Heilongjiang, Peoples R China.
C3 Harbin Medical University
RP Wang, XT (通讯作者)，Harbin Med Univ, Dept Orthoped Surg, Affiliated Hosp 2, 246 Xuefu Rd, Harbin 150000, Heilongjiang, Peoples R China.
EM xintaog8@163.com
RI Liu, Daqian/NTR 2242 2025
OI Wang, Xintao/0009 0002 8213 0556
FU National Natural Science Foundation of China [81772362]; Excellent Youth
   Foundation of Heilongjiang Province of China [JQ2020H003]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81772362) and Excellent Youth Foundation of
   Heilongjiang Province of China (Grant JQ2020H003).
CR Bai JW, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.607635
   Bhargavan B, 2012, J NUTR BIOCHEM, V23, P27, DOI 10.1016/j.jnutbio.2010.11.002
   Burley SK, 2021, NUCLEIC ACIDS RES, V49, pD437, DOI 10.1093/nar/gkaa1038
   Chen B., 2017, PHYTOCHEMISTRY PHARM, V22, P1469
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Cheng YH, 2019, WORLD J STEM CELLS, V11, P1084, DOI 10.4252/wjsc.v11.i12.1084
   Cui HQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2723 6
   Dai J, 2013, INT J BIOL SCI, V9, P1089, DOI 10.7150/ijbs.7367
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Egermann M, 2005, OSTEOPOROSIS INT, V16, pS120, DOI 10.1007/s00198 004 1817 9
   Fröhlich M, 2008, CURR STEM CELL RES T, V3, P254, DOI 10.2174/157488808786733962
   Fu SQ, 2020, CHEM BIODIVERS, V17, DOI 10.1002/cbdv.202000056
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Gfeller D, 2013, BIOINFORMATICS, V29, P3073, DOI 10.1093/bioinformatics/btt540
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Hann SY, 2021, ACTA BIOMATER, V123, P263, DOI 10.1016/j.actbio.2021.01.012
   He FW, 2018, MOLECULES, V23, DOI 10.3390/molecules23123353
   Hidaka K, 2001, INT J BIOCHEM CELL B, V33, P1094, DOI 10.1016/S1357 2725(01)00067 X
   Hu SS, 2020, INT J MED SCI, V17, P2240, DOI 10.7150/ijms.47555
   Huang ZF, 2020, MOL MED REP, V21, P1590, DOI 10.3892/mmr.2020.10954
   Ko Chun Hay, 2010, Chin Med, V5, P39, DOI 10.1186/1749 8546 5 39
   Li G, 2010, PHYTOTHER RES, V24, P571, DOI 10.1002/ptr.2987
   Li L, 2019, AGING US, V11, P9348, DOI 10.18632/aging.102376
   Li QM, 2021, NANOSCALE RES LETT, V16, DOI 10.1186/s11671 021 03559 2
   Li Y, 2019, J CELL MOL MED, V23, P6140, DOI 10.1111/jcmm.14490
   Li ZY, 2011, J PHARM ANA, V1, P8, DOI 10.1016/S2095 1779(11)70002 8
   Liu WJ, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112871
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   Matsushita K, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2892840
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Niu L, 2021, ONCOL LETT, V22, DOI 10.3892/ol.2021.12855
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Polymeri A, 2016, HORM METAB RES, V48, P700, DOI 10.1055/s 0042 118458
   Qi PF, 2020, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.589588
   Qiao JB, 2012, BIOCHEM BIOPH RES CO, V424, P421, DOI 10.1016/j.bbrc.2012.06.125
   Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Smith BT, 2020, TISSUE ENG PT A, V26, P239, DOI [10.1089/ten.tea.2019.0204, 10.1089/ten.TEA.2019.0204]
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang LL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00266
   Xiong YX, 2020, IRAN J BASIC MED SCI, V23, P954, DOI 10.22038/IJBMS.2020.44070.10351
   Xu LF, 2017, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.00398
   Yang SH, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01629
   Ye CY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1904 7
   Zhong WC, 2020, BIOMATER SCI UK, V8, P3664, DOI 10.1039/d0bm00459f
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
   Zou D, 2011, CELL PROLIFERAT, V44, P234, DOI 10.1111/j.1365 2184.2011.00747.x
NR 49
TC 9
Z9 12
U1 1
U2 33
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2165 5979
EI 2165 5987
J9 BIOENGINEERED
JI Bioengineered
PD APR 1
PY 2022
VL 13
IS 4
BP 10640
EP 10653
DI 10.1080/21655979.2022.2065753
PG 14
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA 1E2FA
UT WOS:000794309600001
PM 35473508
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Standal, T
   Johnson, RW
   McGregor, NE
   Poulton, IJ
   Ho, PWM
   Martin, TJ
   Sims, NA
AF Standal, Therese
   Johnson, Rachelle W.
   McGregor, Narelle E.
   Poulton, Ingrid J.
   Ho, Patricia W. M.
   Martin, T. John
   Sims, Natalie A.
TI gp130 in late osteoblasts and osteocytes is required for PTH induced
   osteoblast differentiation
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
DE glycoprotein 130 (gp130); osteoblast; osteocyte; osteoclast; PTH; PTH1R;
   trabecular; cortical; bone formation
ID LEUKEMIA INHIBITORY FACTOR; BONE MARROW CULTURES; KAPPA B LIGAND;
   PARATHYROID HORMONE; OSTEOCLAST FORMATION; IN VIVO; ONCOSTATIN M;
   RECEPTOR ACTIVATOR; RANKL EXPRESSION; LINING CELLS
AB Parathyroid hormone (PTH) treatment stimulates osteoblast differentiation and bone formation, and is the only currently approved anabolic therapy for osteoporosis. In cells of the osteoblast lineage, PTH also stimulates the expression of members of the interleukin 6 (IL 6) cytokine superfamily. Although the similarity of gene targets regulated by these cytokines and PTH suggest cooperative action, the dependence of PTH anabolic action on IL 6 cytokine signaling is unknown. To determine whether cytokine signaling in the osteocyte through glycoprotein 130 (gp130), the common IL 6 superfamily receptor subunit, is required for PTH anabolic action, male mice with conditional gp130 deletion in osteocytes (Dmp1Cre.gp130(f/f)) and littermate controls (Dmp1Cre.gp130(w/w)) were treated with hPTH(1 34) (30 mg/kg 5x per week for 5 weeks). PTH dramatically increased bone formation in Dmp1Cre.gp130(w/w) mice, as indicated by elevated osteoblast number, osteoid surface, mineralizing surface, and increased serum N terminal propeptide of type 1 collagen (P1NP). However, in mice with Dmp1Cre directed deletion of gp130, PTH treatment changed none of these parameters. Impaired PTH anabolic action was associated with a 50% reduction in Pth1r mRNA levels in Dmp1Cre.gp130(f/f) femora compared with Dmp1Cre.gp130(w/w). Furthermore, lentiviral Cre infection of gp130(f/f) primary osteoblasts also lowered Pth1r mRNA levels to 16% of that observed in infected C57/BL6 cells. In conclusion, osteocytic gp130 is required to maintain PTH1R expression in the osteoblast lineage, and for the stimulation of osteoblast differentiation that occurs in response to PTH.
C1 [Standal, Therese; Johnson, Rachelle W.; McGregor, Narelle E.; Poulton, Ingrid J.; Ho, Patricia W. M.; Martin, T. John; Sims, Natalie A.] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia.
   [Martin, T. John; Sims, Natalie A.] Univ Melbourne, St Vincents Hosp Melbourne, Dept Med, Fitzroy, Vic 3065, Australia.
   [Standal, Therese] Norwegian Univ Sci & Technol, KG Jebsen Ctr Myeloma Res, Dept Canc Res & Mol Med, N 7034 Trondheim, Norway.
   [Standal, Therese] Norwegian Univ Sci & Technol, Ctr Mol Inflammat Res, N 7034 Trondheim, Norway.
C3 St. Vincent's Institute of Medical Research; University of Melbourne; St
   Vincent's Health; St Vincent's Hospital Melbourne; Norwegian University
   of Science & Technology (NTNU); Norwegian University of Science &
   Technology (NTNU)
RP Sims, NA (通讯作者)，St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.
EM nsims@svi.edu.au
RI ; Sims, Natalie/A 7192 2012; Johnson, Rachelle/AFL 3690 2022
OI Standal, Therese/0000 0003 3314 8522; Sims, Natalie/0000 0003 1421 8468;
   
FU National Health and Medical Research Council (Australia) [1002728];
   Norwegian Cancer Society [538153]; Victorian State Government
   Operational Infrastructure Support Scheme
FX This work was supported by a National Health and Medical Research
   Council (Australia) Project Grant 1002728. N A S is supported by a
   National Health and Medical Research Council (Australia) Senior Research
   Fellowship. T S is supported by a Senior Research Fellowship from the
   Norwegian Cancer Society (project number 538153). The Victorian State
   Government Operational Infrastructure Support Scheme provides support to
   St. Vincent's Institute of Medical Research.
CR Allan EH, 2003, J CELL BIOCHEM, V90, P158, DOI 10.1002/jcb.10614
   Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324
   Balic A, 2010, BONE, V47, P948, DOI 10.1016/j.bone.2010.08.009
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955
   CORNISH J, 1993, ENDOCRINOLOGY, V132, P1359, DOI 10.1210/en.132.3.1359
   Dai JC, 2006, BONE, V38, P509, DOI 10.1016/j.bone.2005.10.007
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Greenfield EM, 1996, J BIOL CHEM, V271, P10984, DOI 10.1074/jbc.271.18.10984
   GREENFIELD EM, 1995, J CLIN INVEST, V96, P1238, DOI 10.1172/JCI118157
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Johnson RW, 2014, BONE, V64, P47, DOI 10.1016/j.bone.2014.03.053
   Johnson RW, 2014, J BONE MINER RES, V29, P1492, DOI 10.1002/jbmr.2159
   Kartsogiannis V, 1997, BONE, V21, P385, DOI 10.1016/S8756 3282(97)00180 4
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Kramer I, 2010, J BONE MINER RES, V25, P178, DOI 10.1359/jbmr.090730
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   Lu Y, 2007, J DENT RES, V86, P320, DOI 10.1177/154405910708600404
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   McGregor NE, 2010, CALCIFIED TISSUE INT, V86, P261, DOI 10.1007/s00223 010 9337 4
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   REEVE J, 1980, BMJ BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340
   Richards CD, 2000, CYTOKINE, V12, P613, DOI 10.1006/cyto.1999.0635
   Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Sims NA, 2006, AM J PHYSIOL ENDOC M, V290, pE456, DOI 10.1152/ajpendo.00311.2005
   Sims NA, 2010, BMB REP, V43, P513, DOI 10.5483/BMBRep.2010.43.8.513
   SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618
   Takyar FM, 2013, J BONE MINER RES, V28, P912, DOI 10.1002/jbmr.1820
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Tonna S, 2014, FASEB J, V28, P4482, DOI 10.1096/fj.14 254300
   Torreggiani E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075204
   TOSATO G, 1988, SCIENCE, V239, P502, DOI 10.1126/science.2829354
   Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756 3282(99)00210 0
   Walker EC, 2012, J BONE MINER RES, V27, P902, DOI 10.1002/jbmr.1506
   Walker EC, 2010, J CLIN INVEST, V120, P582, DOI 10.1172/JCI40568
   Walker EC, 2008, J BONE MINER RES, V23, P2025, DOI [10.1359/jbmr.080706, 10.1359/JBMR.080706]
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yao GQ, 2011, J BONE MINER METAB, V29, P141, DOI 10.1007/s00774 010 0202 3
NR 52
TC 22
Z9 24
U1 0
U2 7
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0022 0795
EI 1479 6805
J9 J ENDOCRINOL
JI J. Endocrinol.
PD NOV
PY 2014
VL 223
IS 2
BP 181
EP 190
DI 10.1530/JOE 14 0424
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AR5YT
UT WOS:000343659000011
PM 25228504
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Cepeda, SB
   Sandoval, MJ
   Crescitelli, MC
   Rauschemberger, MB
   Massheimer, VL
AF Cepeda, Sabrina B.
   Sandoval, Marisa J.
   Crescitelli, Maria Carla
   Rauschemberger, Maria Belen
   Massheimer, Virginia L.
TI The isoflavone genistein enhances osteoblastogenesis: signaling pathways
   involved
SO JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Genistein; Osteoblasts; Osteoclasts; Differentiation markers;
   Extracellular matrix
ID ESTROGEN RECEPTOR ALPHA; BONE MINERAL DENSITY; NITRIC OXIDE; OSTEOGENIC
   DIFFERENTIATION; PHYTOESTROGEN GENISTEIN; IN VITRO; CELLS;
   PROLIFERATION; ACTIVATION; EXPRESSION
AB Phytoestrogens have been proposed as a natural therapy for prevention of bone loss. In this work, we studied the mechanism of action of genistein on osteoblast differentiation. Primary cell cultures of calvarial osteoblasts isolated from female Wistar rats were in vitro exposed to genistein. Osteoblast differentiation markers were measured. Genistein stimulated osteoblast migration (71 257% above control). An earlier upregulation of estrogen receptor alpha gene expression and an enhancement of mRNA levels of the Runt related transcription factor 2 were detected after 3 days of culture. The isoflavone significantly increased osteocalcin expression, extracellular collagen deposition, and alkaline phosphatase activity. The mechanism displayed by genistein involved estrogen receptor and nitric oxide pathway participation, since cell preincubation with the estrogen receptor antagonist ICI 182780, or the nitric oxide synthase inhibitor L NAME, suppressed the phytoestrogen action. Evidence of MAPK and PI3K transduction systems participation on the stimulatory action of genistein on extracellular collagen deposition and alkaline phosphatase activity was also obtained. Genistein favored monocyte adhesion to osteoblasts (77% above control) in an ER; NOS; and MAPK kinase dependent and PI3K dependent manner. Co cultured osteoblast monocyte long term exposed (21 days) to genistein exhibited a high number of multinucleated and tartrate resistant acid phosphatase positive cells added to osteoblasts, suggesting that the phytoestrogen promotes osteoclast differentiation. In conclusion, genistein promoted osteoblastogenesis through the participation of ER and NOS pathways, and the contribution of ERK or PI3K signal transduction pathways, and also stimulates osteoclast differentiation from its mononuclear progenitor.
C1 [Cepeda, Sabrina B.; Sandoval, Marisa J.; Crescitelli, Maria Carla; Rauschemberger, Maria Belen; Massheimer, Virginia L.] Univ Nacl Sur, Inst Ciencias Biol & Biomed Sur INBIOSUR, CONICET, Dept Biol Bioquim & Farm, San Juan 670,B8000ICN, Bahia Blanca, Buenos Aires, Argentina.
C3 National University of the South; Instituto de Investigaciones en
   Ingenieria Electrica (IIIE); Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET)
RP Massheimer, VL (通讯作者)，Univ Nacl Sur, Inst Ciencias Biol & Biomed Sur INBIOSUR, CONICET, Dept Biol Bioquim & Farm, San Juan 670,B8000ICN, Bahia Blanca, Buenos Aires, Argentina.
EM massheim@uns.edu.ar
OI Crescitelli, Maria Carla/0009 0000 5259 0557
FU Universidad Nacional del Sur (UNS), Bahia Blanca, Argentina [24/B247];
   Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET,
   Argentina) [PIP D 4061]
FX This work was supported by Universidad Nacional del Sur (UNS), Bahia
   Blanca, Argentina (grant number 24/B247); and Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET, Argentina, grant number
   PIP D 4061).
CR Abdia F, 2016, CLIMACTERIC, V19, P535, DOI 10.1080/13697137.2016.1238451
   Cepeda SB, 2017, J NUTR BIOCHEM, V50, P26, DOI 10.1016/j.jnutbio.2017.08.009
   Cutini PH, 2016, J MOL CELL CARDIOL, V100, P83, DOI 10.1016/j.yjmcc.2016.08.017
   de GorterDavid J., 2013, PRIMER METABOLIC BON, V8th, P15, DOI DOI 10.1002/9781118453926.CH2
   Gao YH, 2000, INT J MOL MED, V5, P261
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Han YY, 2018, DRUG DES DEV THER, V12, P137, DOI 10.2147/DDDT.S148457
   Kalyanaraman H, 2018, NITRIC OXIDE BIOL CH, V76, P62, DOI 10.1016/j.niox.2018.03.007
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Liao MH, 2014, BRIT J NUTR, V111, P55, DOI 10.1017/S0007114513002043
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   McGarry JG, 2005, BIOCHEM BIOPH RES CO, V330, P341, DOI 10.1016/j.bbrc.2005.02.175
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   O'Shaughnessy MC, 2000, BIOCHEM BIOPH RES CO, V277, P604, DOI 10.1006/bbrc.2000.3714
   Papachristou DJ, 2009, BIOESSAYS, V31, P794, DOI 10.1002/bies.200800223
   Pratap J, 2003, CANCER RES, V63, P5357
   Pratsinis H, 2007, EUR SPINE J, V16, P1858, DOI 10.1007/s00586 007 0408 9
   Pundt N, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2607
   Qi SS, 2017, BIOL TRACE ELEM RES, V177, P281, DOI 10.1007/s12011 016 0882 1
   Qiao XY, 2016, SCI REP UK, V6, DOI 10.1038/srep18732
   Liao QC, 2007, ACTA PHARMACOL SIN, V28, P1597, DOI 10.1111/j.1745 7254.2007.00632.x
   Sandoval MJ, 2010, BRIT J NUTR, V104, P171, DOI 10.1017/S0007114510000413
   Shin S, 2013, BRIT J NUTR, V110, P1926, DOI 10.1017/S0007114513001219
   Sowers MR, 2006, J CLIN ENDOCR METAB, V91, P1261, DOI 10.1210/jc.2005 1836
   Stenbeck G, 2004, J CELL SCI, V117, P827, DOI 10.1242/jcs.00935
   Tullberg Reinert H, 1999, HISTOCHEM CELL BIOL, V112, P271, DOI 10.1007/s004180050447
   Valiente M, 2010, CURR OPIN NEUROBIOL, V20, P68, DOI 10.1016/j.conb.2009.12.003
   Wang CY, 2018, MOL MED REP, V17, P1166, DOI 10.3892/mmr.2017.7971
   Wang J, 2017, INT J MOL MED, V39, P527, DOI 10.3892/ijmm.2017.2880
   Wimalawansa SJ, 2010, ANN NY ACAD SCI, V1192, P391, DOI 10.1111/j.1749 6632.2009.05230.x
   Wiren KM, 2002, J ENDOCRINOL, V175, P683, DOI 10.1677/joe.0.1750683
   Wu YQ, 2015, CELL PROLIFERAT, V48, P375, DOI 10.1111/cpr.12185
NR 33
TC 27
Z9 30
U1 1
U2 18
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1138 7548
EI 1877 8755
J9 J PHYSIOL BIOCHEM
JI J. Physiol. Biochem.
PD FEB
PY 2020
VL 76
IS 1
BP 99
EP 110
DI 10.1007/s13105 019 00722 3
EA JAN 2020
PG 12
WC Biochemistry & Molecular Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Physiology
GA KU8ZY
UT WOS:000505364800002
PM 31898015
DA 2025 08 17
ER

PT J
AU Vrscaj, LA
   Marc, J
   Ostanek, B
AF Vrscaj, Lucija Ana
   Marc, Janja
   Ostanek, Barbara
TI Interactome of PTH Regulated miRNAs and Their Predicted Target Genes for
   Investigating the Epigenetic Effects of PTH (1 34) in Bone Metabolism
SO GENES
LA English
DT Article
DE osteoporosis; osteoporosis treatment; microRNA; parathyroid hormone;
   teriparatide; network; Cytoscape; biological pathway; gene enrichment
   biomarker
ID PARATHYROID HORMONE PTH; OSTEOGENIC DIFFERENTIATION; SIGNALING PATHWAY;
   CELLS; OSTEOCLASTOGENESIS; OSTEOPOROSIS; TERIPARATIDE; MICRORNAS;
   PROFILE
AB Osteoporosis is a metabolic bone disease that mostly affects the elderly. A lot of drugs are available, mostly with an antiresorptive effect but just a few with an osteoanabolic effect, meaning they promote bone building. PTH (1 34) or teriparatide is an osteoanabolic drug, but its efficacy varies between individuals. We performed a literature review and extracted a dataset of 62 microRNAs (miRNAs) from 10 different studies; predicted miRNA target interactions (MTIs) were obtained with the help of four software tools: DIANA, miRWalk, miRDB and TargetScan. With the construction of an interactome of PTH regulated miRNAs and their predicted target genes, we elucidated miR 146a 5p, miR 551b 5p, miR 205 3p, miR 33a 3p, miR 338 5p as miRNAs with the most interactions and miR 410 3p as the miRNA targeting bone related pathways with the highest significance. These miRNAs could help in further understanding the mechanism of action of PTH on bone metabolism and osteoporosis. They also have the potential for novel network based biomarkers for osteoporosis treatment efficacy and safety and as new therapeutic targets.
C1 [Vrscaj, Lucija Ana; Marc, Janja; Ostanek, Barbara] Univ Ljubljana, Fac Pharm, Dept Clin Biochem, Ljubljana 1000, Slovenia.
C3 University of Ljubljana
RP Ostanek, B (通讯作者)，Univ Ljubljana, Fac Pharm, Dept Clin Biochem, Ljubljana 1000, Slovenia.
EM barbara.ostanek@ffa.uni lj.si
OI Vrscaj, Lucija/0000 0003 0815 2562
FU Slovenian Research Agency, Slovenia [P3 0298, J3 1759, 53726]
FX This research was supported by the Slovenian Research Agency, Slovenia
   (research programme P3 0298, project J3 1759 and a young researcher
   grant to L.A.V. (53726)).
CR Akshaya N, 2022, CURR MOL MED, V22, P549, DOI 10.2174/1566524021666210830093232
   Anastasilakis AD, 2018, J CLIN ENDOCR METAB, V103, P1206, DOI 10.1210/jc.2017 02406
   Arumugam B, 2019, BIOCHIMIE, V158, P43, DOI 10.1016/j.biochi.2018.12.006
   Bottani M, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.01044
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chai Y, 2019, ONCOL LETT, V17, P468, DOI 10.3892/ol.2018.9508
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chen YH, 2020, NUCLEIC ACIDS RES, V48, pD127, DOI 10.1093/nar/gkz757
   Cheng C, 2020, ANNU REV MED, V71, P277, DOI 10.1146/annurev med 052218 020620
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   De Ugarte L, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920 015 0149 2
   Durbano HW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186909
   ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv 7 4 379
   Fang T, 2016, EXP CELL RES, V347, P74, DOI 10.1016/j.yexcr.2016.07.010
   Han YN, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02781 8
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Huang HY, 2020, NUCLEIC ACIDS RES, V48, pD148, DOI 10.1093/nar/gkz896
   Huang R, 2022, ACTA BIOCHIM POL, V69, P371, DOI 10.18388/abp.2020_5813
   Hubbard BP, 2014, TRENDS PHARMACOL SCI, V35, P146, DOI 10.1016/j.tips.2013.12.004
   Ishtiaq S, 2015, J ENDOCRINOL INVEST, V38, P13, DOI 10.1007/s40618 014 0152 z
   Karvande A, 2018, BONE, V117, P98, DOI 10.1016/j.bone.2018.09.007
   Kavakiotis I, 2022, NUCLEIC ACIDS RES, V50, pD1055, DOI 10.1093/nar/gkab733
   Kim HN, 2015, MOL ENDOCRINOL, V29, P1498, DOI 10.1210/me.2015 1133
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Kocijan R, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115104
   Laxman N, 2016, BONE, V84, P181, DOI 10.1016/j.bone.2015.12.053
   Lei NB, 2019, EUR REV MED PHARMACO, V23, P11043, DOI 10.26355/eurrev_201912_19812
   Li Q, 2019, ARCH ORAL BIOL, V100, P23, DOI 10.1016/j.archoralbio.2019.01.020
   Li Y, 2018, INT J MOL MED, V41, P2535, DOI 10.3892/ijmm.2018.3498
   Li YM, 2021, ACS BIOMATER SCI ENG, V7, P4933, DOI 10.1021/acsbiomaterials.1c00880
   Liu Q, 2022, BIOENGINEERED, V13, P11269, DOI 10.1080/21655979.2022.2066046
   Lu TX, 2018, J ALLERGY CLIN IMMUN, V141, P1202, DOI 10.1016/j.jaci.2017.08.034
   Malavkia D, 2020, J CELL PHYSIOL, V235, P7996, DOI 10.1002/jcp.29454
   McGeary SE, 2019, SCIENCE, V366, P1470, DOI 10.1126/science.aav1741
   Mohanakrishnan V, 2018, J CELL BIOCHEM, V119, P6181, DOI 10.1002/jcb.26827
   Nogueiras R, 2012, PHYSIOL REV, V92, P1479, DOI 10.1152/physrev.00022.2011
   Okita Keisuke, 2006, Curr Stem Cell Res Ther, V1, P103, DOI 10.2174/157488806775269061
   Onyia JE, 2005, J CELL BIOCHEM, V95, P403, DOI 10.1002/jcb.20438
   Page MJ, 2021, BMJ BRIT MED J, V372, DOI 10.1136/bmj.n160
   Pala E, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190667
   Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pW169, DOI 10.1093/nar/gkt393
   Rached MT, 2010, CELL METAB, V11, P147, DOI 10.1016/j.cmet.2010.01.001
   Rickard DJ, 2006, BONE, V39, P1361, DOI 10.1016/j.bone.2006.06.010
   Schröder A, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127868
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Siddiqui JA, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15563 7
   Soltanoff CS, 2009, CRIT REV EUKAR GENE, V19, P1, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.10
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Sticht C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206239
   Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403
   Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925 4773(97)00203 7
   Weigl M, 2021, J BONE MINER RES, V36, P1131, DOI 10.1002/jbmr.4276
   Weilner S, 2016, AGING CELL, V15, P744, DOI 10.1111/acel.12484
   Wein MN, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031237
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Yang WL, 2018, J CELL PHYSIOL, V233, P4606, DOI 10.1002/jcp.26372
   Yavropoulou MP, 2020, J CLIN ENDOCR METAB, V105, pE2885, DOI 10.1210/clinem/dgaa368
   Zhang HY, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 22095 1
   Zheng MX, 2021, BONE REP, V14, DOI 10.1016/j.bonr.2021.101013
   Zhou GD, 2015, DEVELOPMENT, V142, P385, DOI 10.1242/dev.108530
   Zou ML, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.593310
NR 63
TC 5
Z9 5
U1 2
U2 11
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4425
J9 GENES BASEL
JI Genes
PD AUG
PY 2022
VL 13
IS 8
AR 1443
DI 10.3390/genes13081443
PG 15
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA 4D3NT
UT WOS:000847051600001
PM 36011354
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shafqat, H
   Alquadan, KF
   Olszewski, AJ
AF Shafqat, H.
   Alquadan, K. F.
   Olszewski, A. J.
TI Severe hypocalcemia after denosumab in a patient with acquired Fanconi
   syndrome
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Denosumab; Fanconi syndrome; Hypocalcemia; Monoclonal gammopathy of
   unknown significance; Osteomalacia
ID OSTEOCLAST DIFFERENTIATION; BONE; OSTEOPROTEGERIN; PREVENTION; THERAPY;
   DENSITY
AB We report the case of a 48 year old man with acquired Fanconi syndrome due to IgG kappa monoclonal gammopathy, who received a single dose of denosumab 60 mg for secondary prevention of skeletal fractures, in conjunction with oral calcium and vitamin D supplementation. The treatment was complicated with a severe, symptomatic hypocalcemia occurring 1 month after the injection and necessitating 4 weeks of intravenous calcium gluconate therapy. Similarly to bisphosphonates, inhibitors of the receptor activator of nuclear factor kappa B ligand may not be appropriate for the treatment of acquired Fanconi syndrome and other forms of osteomalacia regardless of the degree of renal insufficiency and vitamin D levels. Clinicians should carefully interpret the radiographic and bone densitometry results in light of diverse mechanisms of bone demineralization and potential dependence of calcium homeostasis on high bone turnover.
C1 [Shafqat, H.; Alquadan, K. F.; Olszewski, A. J.] Mem Hosp Rhode Isl, Pawtucket, RI 02860 USA.
   [Shafqat, H.; Alquadan, K. F.; Olszewski, A. J.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
C3 Brown University
RP Olszewski, AJ (通讯作者)，Mem Hosp Rhode Isl, 111 Brewster St, Pawtucket, RI 02860 USA.
EM adam_olszewski@brown.edu
RI Alquadan, kawther/AAW 1220 2020; Olszewski, Adam/F 8449 2013
OI Olszewski, Adam/0000 0002 6472 6658; Shafqat, Hammad/0000 0001 5842 4322
CR Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   CLARKE BL, 1995, CLIN ENDOCRINOL, V43, P479, DOI 10.1111/j.1365 2265.1995.tb02621.x
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dore RK, 2011, RHEUM DIS CLIN N AM, V37, P433, DOI 10.1016/j.rdc.2011.07.004
   Eastell R, 2011, J BONE MINER RES, V26, P530, DOI 10.1002/jbmr.251
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Jamal SA, 2011, J BONE MINER RES, V26, P1829, DOI 10.1002/jbmr.403
   Jüppner H, 2011, KIDNEY INT, V79, pS24, DOI 10.1038/ki.2011.27
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kitaoka T, 2011, J BONE MINER METAB, V29, P598, DOI 10.1007/s00774 011 0262 z
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003 4819 145 4 200608150 00004
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Ma CX, 2004, BLOOD, V104, P40, DOI 10.1182/blood 2003 10 3400
   McCormick BB, 2012, AM J KIDNEY DIS, V60, P626, DOI 10.1053/j.ajkd.2012.06.019
   Milat F, 2013, BONE, V55, P305, DOI 10.1016/j.bone.2013.04.012
   Rosen CJ, 2003, NEW ENGL J MED, V348, P1503, DOI 10.1056/NEJM200304103481521
   Stewart I, 2006, BONE, V39, P369, DOI 10.1016/j.bone.2006.01.163
   Terpos E, 2013, BLOOD, V121, P3325, DOI 10.1182/blood 2012 10 435750
   Ungprasert P, 2013, AM J EMERG MED, V31, DOI 10.1016/j.ajem.2012.11.011
   WALD H, 1984, PFLUG ARCH EUR J PHY, V402, P116, DOI 10.1007/BF00584840
   Witteveen JE, 2013, EUR J ENDOCRINOL, V168, pR45, DOI 10.1530/EJE 12 0528
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 24
TC 9
Z9 9
U1 0
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAR
PY 2014
VL 25
IS 3
BP 1187
EP 1190
DI 10.1007/s00198 013 2533 0
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AB1NN
UT WOS:000331559200042
PM 24158473
DA 2025 08 17
ER

PT J
AU Thent, ZC
   Das, S
   Mahakkanukrauh, P
   Lanzotti, V
AF Thent, Zar Chi
   Das, Srijit
   Mahakkanukrauh, Pasuk
   Lanzotti, Virginia
TI Osteoporosis: Possible Pathways Involved and the Role of Natural
   Phytoestrogens in Bone Metabolism
SO SAINS MALAYSIANA
LA English
DT Article
DE Fracture; oestrogen; pharmacology; post menopausal; treatment
ID OSTEOCLASTOGENESIS INHIBITORY FACTOR; SOY ISOFLAVONES; POSTMENOPAUSAL
   WOMEN; RECEPTOR ACTIVATOR; OSTEOPROTEGERIN LIGAND; VASCULAR
   INFLAMMATION; MENOPAUSAL SYMPTOMS; EQUOL PRODUCTION; PHYTO ESTROGENS;
   MINERAL DENSITY
AB The incidence of post menopausal osteoporosis is increasing globally. In post menopausal osteoporosis, there is deficiency in oestrogen level resulting in bone loss and fractures. Bone formation is under the control of different hormones. In the present review, we highlight few pathways such as RANKL/RANK, apoptosis and Wnt/beta catenin signalling pathways and phytoestrogens involved in the bone metabolism. RANKL/RANK signalling is responsible for regulating the formation and activation of multinucleated osteoclasts from their precursors which is responsible for the survival of normal bone remodelling. Apoptosis regulates the development, growth and maintains the bone tissues .The Wnt pathway is an important pharmacological target for bone anabolic drugs and its future discovery. In today's world, herbal remedies are used to treat post menopausal osteoporosis as these products contain phytoestrogens. These phytoestrogens are oestrogen like compounds which influence bone metabolism. The phytoestrogens provide better therapeutic effect in reducing the RANKL, osteoclastogenesis, inflammatory markers, and increase the osteogenic markers in the bone cells or osteoblasts. We discuss the mechanism of action of few phytoestrogens such as genistein, daidzein and equol which are beneficial for improvement of the bone health. Daidzein enhances osteoblast growth via the upregulation of BMP expression in primary osteoblast cells and it is a potential antiosteoporotic agent. Genistein also possesses antioestrogenic property by virtue of its competitive binding to the same receptors as oestradiol. Equol regulates the bone loss via hemopoiesis and inflammatory cytokine production. Thus, phytoestrogens could be efficiently used as osteoprotective agents for the treatment of individuals with post menopausal osteoporosis.
C1 [Thent, Zar Chi] Univ Teknol MARA, Fac Med, Anat Discipline, Basic Med Sci Cluster, Sungai Buloh Campus, Uitm Sungai Buloh 47000, Selangor Darul, Malaysia.
   [Das, Srijit] Univ Kebangsaan Malaysia, Fac Med, Dept Anat, Med Ctr, Jalan Yaacob Latif,Bandar Tun Razak, Kuala Lumpur 56000, Federal Territo, Malaysia.
   [Mahakkanukrauh, Pasuk] Chiang Mai Univ, Forens Osteol Res & Training Ctr, Excellence Ctr Osteol Res & Training Ctr, Chiang Mai 50200, Thailand.
   [Mahakkanukrauh, Pasuk] Chiang Mai Univ, Dept Anat, Fac Med, Chiang Mai 50200, Thailand.
   [Lanzotti, Virginia] Univ Naples Federico II, Dipartimento Agr, Via Univ 100, I 80055 Naples, Italy.
C3 Universiti Kebangsaan Malaysia; Chiang Mai University; Chiang Mai
   University; University of Naples Federico II
RP Das, S (通讯作者)，Univ Kebangsaan Malaysia, Fac Med, Dept Anat, Med Ctr, Jalan Yaacob Latif,Bandar Tun Razak, Kuala Lumpur 56000, Federal Territo, Malaysia.
EM drsrijit@gmail.com
RI Mahakkanukrauh, Pasuk/AAE 3791 2020; Das, Srijit/E 8457 2017; theint,
   zar/AAA 5780 2019
CR Adjakly M, 2013, ANTICANCER RES, V33, P39
   Adlercreutz H, 2002, LANCET ONCOL, V3, P364, DOI 10.1016/S1470 2045(02)00777 5
   Ajdzanovic V, 2018, EXCLI J, V17, P279, DOI 10.17179/excli2017 956
   Al Anazi Abdullah Foraih, 2011, J Nat Sci Biol Med, V2, P154, DOI 10.4103/0976 9668.92322
   Almeida M, 2013, J CLIN INVEST, V123, P394, DOI 10.1172/JCI65910
   Ambati S, 2018, J MED FOOD, V21, P1044, DOI 10.1089/jmf.2017.0113
   Atmaca A, 2008, MENOPAUSE, V15, P748, DOI 10.1097/gme.0b013e31815c1e7f
   Ayyanan A, 2011, MOL ENDOCRINOL, V25, P1915, DOI 10.1210/me.2011 1129
   Babu PVA, 2012, J NUTR, V142, P724, DOI 10.3945/jn.111.152322
   Bakre MM, 2007, J BIOL CHEM, V282, P31703, DOI 10.1074/jbc.M704287200
   Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097 4644(19970701)66:1<1::AID JCB1>3.0.CO;2 V
   Benassayag C, 2002, J CHROMATOGR B, V777, P233, DOI 10.1016/S1570 0232(02)00340 9
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bliuc D, 2013, J BONE MINER RES, V28, P2317, DOI 10.1002/jbmr.1968
   Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061
   CARLSEN E, 1993, IRISH MED J, V86, P85
   Cassidy A, 2006, P NUTR SOC, V65, P76, DOI 10.1079/PNS2005476
   Chan CY, 2018, SAINS MALAYS, V47, P1801, DOI 10.17576/jsm 2018 4708 19
   CHANG HHS, 1975, CAN J BIOCHEM CELL B, V53, P223, DOI 10.1139/o75 031
   Chen YL, 2015, BIOORG MED CHEM LETT, V25, P5377, DOI 10.1016/j.bmcl.2015.09.027
   Chen YM, 2003, J CLIN ENDOCR METAB, V88, P4740, DOI 10.1210/jc.2003 030290
   Chiodini I, 1998, J CLIN ENDOCR METAB, V83, P1863, DOI 10.1210/jc.83.6.1863
   Cornwell T, 2004, PHYTOCHEMISTRY, V65, P995, DOI 10.1016/j.phytochem.2004.03.005
   Danciu C, 2012, CHEM CENT J, V6, DOI 10.1186/1752 153X 6 58
   De Wilde A, 2004, J CELL PHYSIOL, V200, P253, DOI 10.1002/jcp.20008
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Dixon RA, 2004, ANNU REV PLANT BIOL, V55, P225, DOI 10.1146/annurev.arplant.55.031903.141729
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fritz H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081968
   Froyen EB, 2009, J MED FOOD, V12, P1227, DOI 10.1089/jmf.2009.0084
   Fujioka M, 2004, J NUTR, V134, P2623, DOI 10.1093/jn/134.10.2623
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Ge YB, 2006, YAKUGAKU ZASSHI, V126, P651, DOI 10.1248/yakushi.126.651
   Giner M, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 41
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Good CR, 2002, J SURG ONCOL, V79, P174, DOI 10.1002/jso.10067
   Greenspan SL, 2012, J AM GERIATR SOC, V60, P684, DOI 10.1111/j.1532 5415.2011.03884.x
   Hajirahimkhan A, 2013, PLANTA MED, V79, P538, DOI 10.1055/s 0032 1328187
   Hughes DE, 1998, ENDOCRINOLOGIST, V8, P55, DOI 10.1097/00019616 199803000 00002
   Hwang JK, 2013, LIFE SCI, V93, P367, DOI 10.1016/j.lfs.2013.07.020
   Ibarreta D, 2001, APMIS, V109, P161, DOI 10.1034/j.1600 0463.2001.090301.x
   Idrus RBTH, 2018, SAINS MALAYS, V47, P2741, DOI 10.17576/jsm 2018 4711 17
   Jia TL, 2003, BIOCHEM PHARMACOL, V65, P709, DOI 10.1016/S0006 2952(02)01585 X
   Jin D, 2018, AM J TRANSL RES, V10, P1498
   Jou HJ, 2008, INT J GYNECOL OBSTET, V102, P44, DOI 10.1016/j.ijgo.2008.01.028
   Kanazawa A, 2004, AM J HUM GENET, V75, P832, DOI 10.1086/425340
   Kang JS, 2007, INT IMMUNOPHARMACOL, V7, P491, DOI 10.1016/j.intimp.2006.12.004
   Kawamoto EM, 2012, BRAZ J MED BIOL RES, V45, P58, DOI 10.1590/S0100 879X2011007500157
   Kolios L, 2009, PLANTA MED, V75, P459, DOI 10.1055/s 0029 1185380
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kong YY, 1999, IMMUNOL CELL BIOL, V77, P188, DOI 10.1046/j.1440 1711.1999.00815.x
   Kwon Y, 2014, FOOD SCI NUTR, V2, P613, DOI 10.1002/fsn3.142
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   LAMPE JW, 2003, J NUTR S3, V133, pS95
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lee SR, 2013, J KOREAN MED SCI, V28, P1089, DOI 10.3346/jkms.2013.28.7.1089
   Liu Chang Geng, 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P1658
   Liu DW, 2008, BONE, V42, P644, DOI 10.1016/j.bone.2007.09.058
   Liu Xiangchun, 2017, Afr J Tradit Complement Altern Med, V14, P265, DOI 10.21010/ajtcam.v14i4.29
   Marrian GF, 1932, BIOCHEM J, V26, P1227, DOI 10.1042/bj0261227
   Marriott I, 2004, IMMUNOL RES, V30, P291, DOI 10.1385/IR:30:3:291
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Masilamani M, 2012, IMMUNOL RES, V54, P95, DOI 10.1007/s12026 012 8331 5
   Mense SM, 2008, ENVIRON HEALTH PERSP, V116, P426, DOI 10.1289/ehp.10538
   Messina M, 2006, JNCI J NATL CANCER I, V98, P1275, DOI 10.1093/jnci/djj356
   Miao Q, 2012, INT J MOL SCI, V13, P56, DOI 10.3390/ijms13010056
   Michel T, 2013, PLANTA MED, V79, P514, DOI 10.1055/s 0032 1328300
   Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Moreira AC, 2014, J STEROID BIOCHEM, V143, P61, DOI 10.1016/j.jsbmb.2014.01.016
   Ohtomo T, 2008, EUR J NUTR, V47, P273, DOI 10.1007/s00394 008 0723 x
   Palacios VG, 2005, J BIOL CHEM, V280, P13720, DOI 10.1074/jbc.M410995200
   Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164
   Paterni I, 2014, STEROIDS, V90, P13, DOI 10.1016/j.steroids.2014.06.012
   Rietjens IMCM, 2013, MOL NUTR FOOD RES, V57, P100, DOI 10.1002/mnfr.201200439
   Saika M, 2001, ENDOCRINOLOGY, V142, P2205, DOI 10.1210/en.142.6.2205
   Saitoh S, 2004, BBA GEN SUBJECTS, V1674, P122, DOI 10.1016/j.baggen.2004.06.006
   Schürer C, 2015, DTSCH ARZTEBL INT, V112, P365, DOI 10.3238/arztebl.2015.0365
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Setchell KDR, 2002, J NUTR, V132, P3577, DOI 10.1093/jn/132.12.3577
   Setchell KDR, 2001, J AM COLL NUTR, V20, p354S, DOI 10.1080/07315724.2001.10719168
   Setchell KDR, 2010, J NUTR, V140, p1355S, DOI 10.3945/jn.109.119776
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sims NA, 2012, CURR OSTEOPOROS REP, V10, P109, DOI 10.1007/s11914 012 0096 1
   Sliwinski L, 2009, ACTA BIOCHIM POL, V56, P261
   Smith MG, 2004, ANN ROY COLL SURG, V86, P344, DOI 10.1308/147870804371
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   Stains Joseph P, 2005, Birth Defects Res C Embryo Today, V75, P72, DOI 10.1002/bdrc.20034
   Streicher C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06614 0
   Strong AL, 2014, ACS MED CHEM LETT, V5, P143, DOI 10.1021/ml400397k
   Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117
   Taylor JA, 2011, J STEROID BIOCHEM, V127, P83, DOI 10.1016/j.jsbmb.2011.07.005
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Thirunavukkarasu K, 2000, J BIOL CHEM, V275, P25163, DOI 10.1074/jbc.M000322200
   Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017
   Törmälä R, 2008, CLIMACTERIC, V11, P409, DOI 10.1080/13697130802251344
   Tousen Y, 2014, INT J FOOD SCI NUTR, V65, P360, DOI 10.3109/09637486.2013.858238
   Tousen Y, 2011, MENOPAUSE, V18, P563, DOI 10.1097/gme.0b013e3181f85aa7
   Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603
   Van Pottelbergh I, 2004, J CLIN ENDOCR METAB, V89, P4949, DOI 10.1210/jc.2003 032081
   Vatanparast H, 2007, NUTR REV, V65, P294, DOI [10.1301/nr.2007.jun.294 299, 10.1111/j.1753 4887.2007.tb00307.x]
   Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534 5807(03)00266 1
   Vitale DC, 2013, EUR J DRUG METAB PH, V38, P15, DOI 10.1007/s13318 012 0112 y
   Wade SW, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657 014 0182 3
   Wang XX, 2003, J BONE MINER METAB, V21, P268, DOI 10.1007/s00774 003 0420 z
   Watkins AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028745
   Watts N B, 1999, Obstet Gynecol Surv, V54, P532, DOI 10.1097/00006254 199908000 00024
   Williamson Hughes PS, 2006, MENOPAUSE, V13, P831, DOI 10.1097/01.gme.0000227330.49081.9e
   Wong KH, 2011, J ETHNOPHARMACOL, V134, P584, DOI 10.1016/j.jep.2011.02.001
   Yahaya MF, 2018, SAINS MALAYS, V47, P2731, DOI 10.17576/jsm 2018 4711 16
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoshikata R, 2018, J ALTERN COMPLEM MED, V24, P701, DOI 10.1089/acm.2018.0050
   Younes M, 2011, ARCH PATHOL LAB MED, V135, P63, DOI 10.1043/2010 0448 RAR.1
   Yuan JP, 2007, MOL NUTR FOOD RES, V51, P765, DOI 10.1002/mnfr.200600262
   Zhang HP, 2016, ENVIRON TOXICOL PHAR, V42, P118, DOI 10.1016/j.etap.2016.01.011
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 119
TC 2
Z9 3
U1 2
U2 12
PU UNIV KEBANGSAAN MALAYSIA
PI SELANGOR
PA FACULTY SCIENCE & TECHNOLOGY, BANGI, SELANGOR, 43600, MALAYSIA
SN 0126 6039
J9 SAINS MALAYS
JI Sains Malays.
PD SEP
PY 2019
VL 48
IS 9
BP 2007
EP 2019
DI 10.17576/jsm 2019 4809 22
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA JM0GM
UT WOS:000495902400022
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Vanderschueren, D
   Gaytant, J
   Boonen, S
   Venken, K
AF Vanderschueren, Dirk
   Gaytant, Jemima
   Boonen, Steven
   Venken, Katrien
TI Androgens and bone
SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
LA English
DT Article
DE bone formation; bone resorption; osteoporosis; sex steroids
AB Purpose of review The present review will focus on the most important recent findings with respect to skeletal androgen action. Many studies have indicated that part of the androgen action may be related to the conversion of androgens into estrogens. Therefore, some of the most recent findings of skeletal estrogen action relevant for male skeletal physiology will also be discussed.
   Recent findings Androgens and estrogens stimulate bone formation and inhibit bone resorption. Sex steroids may interact with different receptors, target cells and other bone anabolic pathways. Androgen receptor and estrogen receptor signalling appear to be important for male bone formation during growth. Sex steroid signalling may involve genomic and nongenomic pathways, interaction with mechanical loading, the growth hormone/insulin like growth factor I axis and/or other bone anabolic pathways. Estrogen receptor a in osteoclasts appears to regulate bone resorption in women but not men, whereas androgen receptor signalling in osteoblasts may only partly regulate bone resorption in males.
   Summary The latest developments indicate that androgens and estrogens are important for male bone metabolism and homeostasis and therefore selective estrogen receptor a and androgen receptor signalling remain interesting drug targets for the stimulation of bone formation and male skeletal integrity.
C1 [Vanderschueren, Dirk; Gaytant, Jemima; Boonen, Steven; Venken, Katrien] Katholieke Univ Leuven, Lab Expt Med & Endocrinol, Dept Expt Med, Bone Res Unit, B 3000 Leuven, Belgium.
C3 KU Leuven
RP Vanderschueren, D (通讯作者)，Katholieke Univ Leuven, Lab Expt Med & Endocrinol, Dept Expt Med, Bone Res Unit, Herestr 49,Box 902, B 3000 Leuven, Belgium.
EM dirk.vanderschueren@uz.kuleuven.ac.be
OI vanderschueren, dirk/0000 0003 1395 0104
CR Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Amory JK, 2004, J CLIN ENDOCR METAB, V89, P503, DOI 10.1210/jc.2003 031110
   Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Bjornerem Å, 2007, EUR J ENDOCRINOL, V157, P119, DOI 10.1530/EJE 07 0032
   Borst SE, 2007, AM J PHYSIOL ENDOC M, V293, pE507, DOI 10.1152/ajpendo.00130.2007
   Bouillon R, 2004, J CLIN ENDOCR METAB, V89, P6025, DOI 10.1210/jc.2004 0602
   Chen JY, 2005, MOL INTERV, V5, P173, DOI 10.1124/mi.5.3.7
   Gao JJ, 2007, ENDOCRINOLOGY, V148, P2613, DOI 10.1210/en.2006 1404
   Gao WQ, 2005, ENDOCRINOLOGY, V146, P4887, DOI 10.1210/en.2005 0572
   Jilka RL, 2007, J BONE MINER RES, V22, P1492, DOI 10.1359/JBMR.070518
   Jones MEE, 2007, NAT CLIN PRACT ENDOC, V3, P414, DOI 10.1038/ncpendmet0477
   Juul A, 2001, HUM REPROD UPDATE, V7, P303, DOI 10.1093/humupd/7.3.303
   Kawano H, 2003, P NATL ACAD SCI USA, V100, P9416, DOI 10.1073/pnas.1533500100
   Kearbey JD, 2007, PHARM RES, V24, P328, DOI 10.1007/s11095 006 9152 9
   Kilbourne EJ, 2007, CURR OPIN INVEST DR, V8, P821
   Kousteni S, 2007, MOL CELL BIOL, V27, P1516, DOI 10.1128/MCB.01550 06
   Leder Benjamin, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P241, DOI 10.1097/MED.0b013e32814db87b
   LIU XH, 2007, ANN N Y ACAD SCI
   Lorentzon M, 2007, J BONE MINER RES, V22, P1165, DOI 10.1359/JBMR.070416
   Miner JN, 2007, ENDOCRINOLOGY, V148, P363, DOI 10.1210/en.2006 0793
   Nakamura T, 2004, J BONE MINER RES, V19, pS3
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Napoli N, 2007, CALCIFIED TISSUE INT, V80, P227, DOI 10.1007/s00223 007 9014 4
   Notini AJ, 2007, J BONE MINER RES, V22, P347, DOI 10.1359/JBMR.061117
   Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828
   Rochira V, 2007, BONE, V40, P1662, DOI 10.1016/j.bone.2007.01.022
   Seibel MJ, 2006, CELL, V127, P1079, DOI 10.1016/j.cell.2006.12.002
   Sobel V, 2006, J CLIN ENDOCR METAB, V91, P3017, DOI 10.1210/jc.2005 2809
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Swanson C, 2007, J CLIN ENDOCR METAB, V92, P3697, DOI 10.1210/jc.2007 0530
   Takai H, 2007, J CELL BIOCHEM, V102, P240, DOI 10.1002/jcb.21297
   Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003 0003
   Venken K, 2006, J BONE MINER RES, V21, P576, DOI 10.1359/JBMR.060103
   Venken K, 2007, J BONE MINER RES, V22, P72, DOI 10.1359/JBMR.060911
   Wang XG, 2007, CALCIFIED TISSUE INT, V80, P374, DOI 10.1007/s00223 007 9026 0
   Williams GR, 2007, ENDOCRINOLOGY, V148, P2610, DOI 10.1210/en.2007 0337
   Windahl SH, 2007, ENDOCRINOLOGY, V148, P5688, DOI 10.1210/en.2007 0508
   Windahl SH, 2006, J CLIN INVEST, V116, P2500, DOI 10.1172/JCI28809
   Zarrabeitia MT, 2007, EUR J ENDOCRINOL, V156, P117, DOI 10.1530/eje.1.02318
NR 39
TC 59
Z9 68
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 1752 296X
J9 CURR OPIN ENDOCRINOL
JI Curr. Opin. Endocrinol. Diabetes Obes.
PD JUN
PY 2008
VL 15
IS 3
BP 250
EP 254
DI 10.1097/MED.0b013e3282fe6ca9
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA V14ST
UT WOS:000207754800006
PM 18438173
DA 2025 08 17
ER

PT J
AU Luo, XH
   Guo, LJ
   Xie, H
   Yuan, LQ
   Wu, XP
   Zhou, HD
   Liao, EY
AF Luo, Xiang Hang
   Guo, Li Juan
   Xie, Hui
   Yuan, Ling Qing
   Wu, Xian Ping
   Zhou, Hou De
   Liao, Er Yuan
TI Adiponectin stimulates RANKL and inhibits OPG expression in human
   osteoblasts through the MAPK signaling pathway
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE adiponectin; osteoblast; osteoclast; RANKL; osteoprotegerin
ID KAPPA B LIGAND; BONE MINERAL DENSITY; RECEPTOR ACTIVATOR; OSTEOCLAST
   DIFFERENTIATION; CELLS; OSTEOPROTEGERIN; GROWTH; PROLIFERATION;
   PROGESTERONE; OSTEOPOROSIS
AB Our study indicates that recombinant adiponectin induced RANKL and inhibited OPG expression in human osteoblasts through the AdipoR1/p38 MAPK pathway, and these responses contributed to the adiponectin induced osteoclasts formation in the co culture of osteoblast and peripheral blood monocytes systems. These findings showed that adiponectin increased osteoclast formation indirectly through stimulating RANKL and inhibiting OPG production in osteoblasts. It also suggests the pharmacological nature of recombinant adiponectin that indirectly induces osteoclasts formation.
C1 Cent S Univ, Xiangya Hosp 2, Inst Endocrinol & Metab, Changsha 410011, Hunan, Peoples R China.
C3 Central South University
RP Liao, EY (通讯作者)，Cent S Univ, Xiangya Hosp 2, Inst Endocrinol & Metab, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
EM liaoey1986@sina.com
RI Yuan, Ling Qing/D 2102 2019; Zhou, Hou De/IQU 6646 2023; Yuan,
   Ling Qing/HZL 9093 2023
OI Yuan, Ling Qing/0000 0001 8602 7113; XIE, HUI/0000 0002 8526 2637; Zhou,
   Hou De/0000 0001 9131 4141; 
CR Aubin JE, 2000, OSTEOPOROSIS INT, V11, P905, DOI 10.1007/s001980070028
   Berner HS, 2004, BONE, V35, P842, DOI 10.1016/j.bone.2004.06.008
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Cheung J, 2003, J ENDOCRINOL, V177, P423, DOI 10.1677/joe.0.1770423
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Holloway WR, 2002, J BONE MINER RES, V17, P200, DOI 10.1359/jbmr.2002.17.2.200
   Ishida A, 2002, J BIOL CHEM, V277, P26217, DOI 10.1074/jbc.M111093200
   Itonaga I, 2004, BONE, V34, P57, DOI 10.1016/j.bone.2003.08.008
   JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955 0674(94)90141 4
   Jürimäe J, 2005, HORM METAB RES, V37, P297, DOI 10.1055/s 861483
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kusumi A, 2005, J BONE MINER METAB, V23, P373, DOI 10.1007/s00774 005 0615 6
   Lenchik L, 2003, BONE, V33, P646, DOI 10.1016/S8756 3282(03)00237 0
   Li FH, 2005, J BONE MINER RES, V20, P1161, DOI 10.1359/JBMR.050207
   Liao EY, 2001, ENDOCRINE, V15, P291, DOI 10.1385/ENDO:15:3:291
   Liao EY, 2002, J ENDOCRINOL INVEST, V25, P785, DOI 10.1007/BF03345513
   Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021
   Luo XH, 2002, CALCIFIED TISSUE INT, V71, P329, DOI 10.1007/s00223 001 2129 0
   Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Nakamura S, 2003, REC RES DEV MAGNET M, V1, P1
   Nakano Y, 1996, J BIOCHEM TOKYO, V120, P803
   Nakayamada S, 2003, J BIOL CHEM, V278, P45368, DOI 10.1074/jbc.M308786200
   Nicholson GC, 2000, CLIN SCI, V99, P133, DOI 10.1042/CS19990355
   Oshima K, 2005, BIOCHEM BIOPH RES CO, V331, P520, DOI 10.1016/j.bbrc.2005.03.210
   ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826
   SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746
   SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337
   SHINODA Y, 2006, IN PRESS J CELL BIOC
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105
NR 36
TC 302
Z9 343
U1 0
U2 42
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD OCT
PY 2006
VL 21
IS 10
BP 1648
EP 1656
DI 10.1359/JBMR.060707
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 088KG
UT WOS:000240810000017
PM 16995820
DA 2025 08 17
ER

PT J
AU Li, WF
   Hou, SX
   Yu, B
   Jin, D
   Férec, C
   Chen, JM
AF Li, Wen Feng
   Hou, Shu Xun
   Yu, Bin
   Jin, Dan
   Ferec, Claude
   Chen, Jian Min
TI Genetics of osteoporosis: perspectives for personalized medicine
SO PERSONALIZED MEDICINE
LA English
DT Article
DE BMD; bone formation; bone resorption; estrogen replacement therapy;
   osteoblasts; osteoclasts; osteoporosis susceptibility gene; osteoporotic
   fracture; rare variants; sclerostin antibody; serotonin; SNP
ID BONE MINERAL DENSITY; ESTROGEN RECEPTOR ALPHA; HORMONE REPLACEMENT
   THERAPY; SCLEROSTIN ANTIBODY; SEROTONIN SYNTHESIS; CANDIDATE GENES;
   BUCHEM DISEASE; LRP5 MUTATIONS; MASS; OSTEOPROTEGERIN
AB Osteoporosis is the most common metabolic bone disorder worldwide. At least 15 genes (e.g., ESR1, LRP5, SOST, OPG, RANK and RANKL) have been confirmed as osteoporosis susceptibility genes, and another 30 have been highlighted as promising susceptibility genes. Notably, these genes are clustered in three biological pathways: the estrogen endocrine pathway, the Wnt/beta catenin signaling pathway and the RANK/RANKL/osteoprotegerin (OPG) pathway. In this article, using data pertaining to these three biological pathways as examples, we illustrate possible principles of personalized therapy for osteoporosis. In particular, we propose to use inhibitors (e.g., denosumab) of the RANK/RANKL/OPG signaling pathway to circumvent resistance to estrogen replacement therapy: a novel idea resulting from the consideration of a mechanistic link between the estrogen endocrine pathway and the RANK/RANKL/OPG signaling pathway. In addition, we call for more attention to be focused on rare variants of major effects in future studies.
C1 [Ferec, Claude; Chen, Jian Min] INSERM, U613, F 29278 Brest, France.
   Gen Hosp Peoples Liberat Army, Affiliated Hosp 1, Dept Orthopaed, Beijing, Peoples R China.
   So Med Univ, Dept Orthopaed Trauma, Nantang Hosp, Guangzhou, Guangdong, Peoples R China.
   Univ Bretagne Occidentale, Fac Med & Sci Sante, Brest, France.
   EFS, Brest, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Bretagne Occidentale; Southern Medical University   China;
   Universite de Bretagne Occidentale
RP Chen, JM (通讯作者)，INSERM, U613, 46 Rue Felix Dante, F 29278 Brest, France.
RI ; Chen, Jian Min/LZG 2264 2025; Ferec, Claude/ABG 9699 2020; Li,
   Wenfeng/KRQ 8098 2024
OI Chen, Jian Min/0000 0002 2424 3969; 
FU National Natural Science Foundation of China [30672133]; National Basic
   Research Program of China [2009cb930003]; Institut National de la Sante
   et de la Recherche Medicate (INSERM), France
FX This work was supported by the National Natural Science Foundation of
   China (Grant number 30672133), the National Basic Research Program of
   China (Grant number 2009cb930003) and the Institut National de la Sante
   et de la Recherche Medicate (INSERM), France.
CR *23ANDME, HLTH REP COMPL LIST
   Agholme F, 2010, J BONE MINER RES, V25, P2412, DOI 10.1002/jbmr.135
   [Anonymous], Sorting Intolerant from Tolerant (SIFT)
   Ashley EA, 2010, LANCET, V375, P1525, DOI 10.1016/S0140 6736(10)60452 7
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Balemans W, 2008, CALCIFIED TISSUE INT, V82, P445, DOI 10.1007/s00223 008 9130 9
   Bickston SJ, 2010, EXPERT REV CLIN IMMU, V6, P513, DOI [10.1586/eci.10.38, 10.1586/ECI.10.38]
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003 4819 122 1 199501010 00002
   Chamberlain MC, 2010, CANCER AM CANCER SOC, V116, P3988, DOI 10.1002/cncr.25256
   Chen JM, 2010, CLIN GENET, V78, P310, DOI 10.1111/j.1399 0004.2010.01474.x
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Cundy T, 2002, HUM MOL GENET, V11, P2119, DOI 10.1093/hmg/11.18.2119
   Deng HW, 1998, HUM GENET, V103, P576, DOI 10.1007/s004390050872
   Dickson SP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000294
   Dong SS, 2009, CALCIFIED TISSUE INT, V85, P104, DOI 10.1007/s00223 009 9255 5
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601
   Frost M, 2010, J BONE MINER RES, V25, P673, DOI 10.1002/jbmr.44
   Gaudio A, 2010, J CLIN ENDOCR METAB, V95, P2248, DOI 10.1210/jc.2010 0067
   Gilad Y, 2009, TRENDS GENET, V25, P463, DOI 10.1016/j.tig.2009.09.003
   Glass DA, 2006, ANN NY ACAD SCI, V1068, P117, DOI 10.1196/annals.1346.015
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Guo Y, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000806
   Han KO, 1997, J CLIN ENDOCR METAB, V82, P991, DOI 10.1210/jc.82.4.991
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hsu YH, 2006, HUM GENET, V118, P568, DOI 10.1007/s00439 005 0062 4
   Huang QY, 2009, BONE, V45, P289, DOI 10.1016/j.bone.2009.03.676
   Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667
   Ioannidis JPA, 2004, JAMA J AM MED ASSOC, V292, P2105, DOI 10.1001/jama.292.17.2105
   Jackson Rebecca D, 2007, Curr Osteoporos Rep, V5, P153
   Kapur RP, 2004, J BONE MINER RES, V19, P1689, DOI 10.1359/JBMR.040713
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kiel DP, 2007, BONE, V40, P587, DOI 10.1016/j.bone.2006.09.029
   Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Kung AWC, 2010, AM J HUM GENET, V86, P229, DOI 10.1016/j.ajhg.2009.12.014
   Li WF, 2010, HUM GENET, V127, P249, DOI 10.1007/s00439 009 0773 z
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lin CJ, 2009, J GASTROEN HEPATOL, V24, pA116
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Liu QY, 2008, J PHARMACOL EXP THER, V325, P47, DOI 10.1124/jpet.107.132670
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Metzker Michael L, 2010, Nat Rev Genet, V11, P31, DOI 10.1038/nrg2626
   Mödder UI, 2010, J BONE MINER RES, V25, P415, DOI 10.1359/jbmr.090721
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   *NAV, COND MED RESP
   Ng PC, 2009, NATURE, V461, P724, DOI 10.1038/461724a
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Ongphiphadhanakul B, 2000, CLIN ENDOCRINOL, V52, P581, DOI 10.1046/j.1365 2265.2000.00979.x
   PADHI D, 2010, J BONE MINER RES, DOI DOI 10.1002/JBMR.I73
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Ralston SH, 2006, GENE DEV, V20, P2492, DOI 10.1101/gad.1449506
   Ralston SH, 2010, ENDOCR REV, V31, P629, DOI 10.1210/er.2009 0044
   Rapuri PB, 2006, MATURITAS, V53, P371, DOI 10.1016/j.maturitas.2005.07.007
   Richards JB, 2008, LANCET, V371, P1505, DOI 10.1016/S0140 6736(08)60599 1
   Richards JB, 2009, ANN INTERN MED, V151, P528, DOI 10.7326/0003 4819 151 8 200910200 00006
   Riches PL, 2009, NEW ENGL J MED, V361, P1459, DOI 10.1056/NEJMoa0810925
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Rivadeneira F, 2009, NAT GENET, V41, P1199, DOI 10.1038/ng.446
   Rodriguez SPR, 2010, ENDOCR REV, V31
   Rosen CJ, 1997, ENDOCRIN METAB CLIN, V26, P295, DOI 10.1016/S0889 8529(05)70248 6
   Saarinen A, 2010, BONE, V46, P940, DOI 10.1016/j.bone.2009.12.022
   Saarinen A, 2010, CLIN ENDOCRINOL, V72, P481, DOI 10.1111/j.1365 2265.2009.03680.x
   Salmén T, 2000, J BONE MINER RES, V15, pS261
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Schork NJ, 2009, CURR OPIN GENET DEV, V19, P212, DOI 10.1016/j.gde.2009.04.010
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Semenov MV, 2006, J BIOL CHEM, V281, P38276, DOI 10.1074/jbc.M609509200
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sims AM, 2008, J BONE MINER RES, V23, P499, DOI 10.1359/JBMR.071113
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Smith MR, 2009, J UROLOGY, V182, P2670, DOI 10.1016/j.juro.2009.08.048
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Sobacchi C, 2007, NAT GENET, V39, P960, DOI 10.1038/ng2076
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   STYRKARSDOTRIR U, 2008, AT ENGL J MED, V358, P2355
   Styrkarsdottir U, 2009, NAT GENET, V41, P15, DOI 10.1038/ng.284
   Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097
   Uitterlinden AG, 2004, AM J HUM GENET, V75, P1032, DOI 10.1086/426458
   Urano T, 2009, ENDOCR J, V56, P625, DOI 10.1507/endocrj.K09E 133
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   van Meurs JBJ, 2008, JAMA J AM MED ASSOC, V299, P1277, DOI 10.1001/jama.299.11.1277
   Warden SJ, 2010, BONE, V46, P4, DOI 10.1016/j.bone.2009.06.029
   Whyte MP, 2002, NEW ENGL J MED, V347, P175, DOI 10.1056/NEJMoa013096
   Whyte MP, 2002, J BONE MINER RES, V17, P26, DOI 10.1359/jbmr.2002.17.1.26
   Williams BO, 2009, J BONE MINER RES, V24, P171, DOI [10.1359/JBMR.081235, 10.1359/jbmr.081235]
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Wright HL, 2009, CURR REV MUSCULOSKE, V2, P56, DOI 10.1007/s12178 009 9046 7
   Xiong DH, 2006, J BONE MINER RES, V21, P1678, DOI 10.1359/JBMR.060808
   Xu XH, 2010, ENDOCR REV, V31, P447, DOI 10.1210/er.2009 0032
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Yahata T, 2005, HUM REPROD, V20, P1860, DOI 10.1093/humrep/deh895
   Yerges LM, 2009, J BONE MINER RES, V24, P2039, DOI [10.1359/JBMR.090524, 10.1359/jbmr.090524]
NR 108
TC 8
Z9 9
U1 0
U2 10
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1741 0541
EI 1744 828X
J9 PERS MED
JI Pers. Med.
PD NOV
PY 2010
VL 7
IS 6
BP 655
EP 668
DI 10.2217/PME.10.55
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 699ZL
UT WOS:000285701800010
PM 29788568
DA 2025 08 17
ER

PT J
AU Chang, YY
   Zhang, JW
   Liu, ZQ
   Chu, WX
   Li, HW
AF Chang Yongyun
   Zhang Jingwei
   Liu Zhiqing
   Chu Wenxiang
   Li Huiwu
TI Andrographolide stimulates osteoblastogenesis and bone formation by
   inhibiting nuclear factor kappa B signaling both in vivo and
   in vitro
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Andrographolide; NF kB; Osteoblast; Osteoporosis; TNF alpha
ID MESENCHYMAL STEM CELLS; POSTMENOPAUSAL WOMEN; NATURAL PRODUCTS;
   OSTEOPOROSIS; ALENDRONATE; DIFFERENTIATION; MECHANISMS; TERIPARATIDE;
   INFLAMMATION; ROMOSOZUMAB
AB Osteoporosis is a bone disease that is associated with a decrease in bone mineral density, deterioration of bone microarchitecture and increased fracture risk. Currently, available treatments mainly focus on either inhibiting osteoclast function, such as administration of bisphosphonate, calcitonin, oestrogen, selective oestrogen receptor modulator and so on, or stimulating osteoblasts, such as parathyroid hormone, to improve bone mass and skeletal microarchitecture. However, there is no option that is completely satisfactory because of the limitations of monotherapy with either class. Thus, it is highly appealing to investigate novel drugs with both antiresorptive and osteoanabolic activities that have the potential to be more beneficial than monotherapy because of the different mechanism of action. As has been proven in previous study that andrographolide (AP), as a key herbal medicine, could suppress osteoclast formation and function both in vivo and in vitro. The purpose of this present study was to identify the effect of AP on osteoblast differentiation and oestrogen deficiency   induced osteoporosis. It was concluded that AP significantly reduced oestrogen deficiency   induced bone loss in vivo. Furthermore, it was proved that tumor necrosis factor alpha severely impaired bone morphogenetic protein 2 (BMP 2) induced osteoblast differentiation, and this inhibition could be greatly attenuated by AP. This was further supported by the fact that AP significantly increases the expression of osteoblast specific markers, including runtrelated transcription factor 2, osteocalcin and osteopontin. In addition, molecular analysis revealed that AP greatly ceased tumor necrosis factor alpha mediated stimulation of nuclear factor kappa B activity, whereas overexpression of the nuclear factor kappa B subunit p65 reversed the stimulatory effects of AP on osteoblast differentiation. Thus, combined with previous study, AP was demonstrated to be a novel agent with both antiresorptive and osteoanabolic activities and had the potential to be developed as an antiosteoporosis alternative.
   The translational potential of this article: This study provides strong evidence for the identification that AP has both antiresorptive and osteoanabolic activities and thus has great potential to be developed as a novel antiosteoporosis agent. (C) 2019 The Authors. Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society.
C1 [Chang Yongyun; Zhang Jingwei; Liu Zhiqing; Chu Wenxiang; Li Huiwu] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthopaed, Shanghai Key Lab Orthopaed Implants,Sch Med, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University
RP Li, HW (通讯作者)，Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM huiwu1223@163.com
RI ; Liu, Zhiqing/AIE 6030 2022
OI li, huiwu/0000 0002 2084 2737; 
FU National Natural Science Foundation [81672181]; Shanghai JiaoTong
   University Medical and Engineering Cross Fund [YG2017MS09]
FX This work was supported by the National Natural Science Foundation
   (Grant No. 81672181) and Shanghai JiaoTong University Medical and
   Engineering Cross Fund (Grant No. YG2017MS09).
CR Altman AR, 2014, BONE, V61, P149, DOI 10.1016/j.bone.2014.01.008
   Amugongo SK, 2014, OSTEOPOROSIS INT, V25, P1735, DOI 10.1007/s00198 014 2678 5
   An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   [Anonymous], 2018, OXID MED CELL LONGEV
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Che CT, 2016, MOLECULES, V21, DOI 10.3390/molecules21030239
   Chen HW, 2014, TOXICOL APPL PHARM, V280, P1, DOI 10.1016/j.taap.2014.07.024
   Chen HW, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/982689
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cusano NE, 2011, CURR MED RES OPIN, V27, P1705, DOI 10.1185/03007995.2011.599837
   Ding Y, 2017, MICROBES INFECT, V19, P605, DOI 10.1016/j.micinf.2017.08.009
   Edwin ES, 2016, ACTA TROP, V163, P167, DOI 10.1016/j.actatropica.2016.07.009
   Eliseev RA, 2006, EXP CELL RES, V312, P40, DOI 10.1016/j.yexcr.2005.09.016
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Gilbert LC, 2005, AM J PHYSIOL ENDOC M, V288, pE1011, DOI 10.1152/ajpendo.00534.2004
   Guañabens N, 2013, HEPATOLOGY, V58, P2070, DOI 10.1002/hep.26466
   Houlihan DD, 2012, NAT PROTOC, V7, P2103, DOI 10.1038/nprot.2012.125
   Ji XQ, 2016, MOL CELL ENDOCRINOL, V437, P268, DOI 10.1016/j.mce.2016.06.029
   Jimi E, 2010, JPN DENT SCI REV, V46, P33, DOI 10.1016/j.jdsr.2009.10.003
   Keaveny TM, 2014, J BONE MINER RES, V29, P158, DOI 10.1002/jbmr.2024
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Lin TH, 2017, J ORTHOP RES, V35, P281, DOI 10.1002/jor.23270
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Papapoulos SE, 2013, NAT REV RHEUMATOL, V9, P263, DOI 10.1038/nrrheum.2013.57
   Peng T, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/735056
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Tan WSD, 2017, BIOCHEM PHARMACOL, V139, P71, DOI 10.1016/j.bcp.2017.03.024
   Wang TY, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0010 2
   Wedemeyer C, 2007, CALCIFIED TISSUE INT, V81, P394, DOI 10.1007/s00223 007 9077 2
   Wen L, 2014, EUR J PHARMACOL, V740, P421, DOI 10.1016/j.ejphar.2014.06.053
   Wong SY, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974 016 0498 6
   Zhang MS, 2016, DRUG DES DEV THER, V10, P3143, DOI 10.2147/DDDT.S113838
   Zhao JX, 2002, PHYTOCHEM ANALYSIS, V13, P222, DOI 10.1002/pca.644
NR 36
TC 18
Z9 19
U1 2
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD OCT
PY 2019
VL 19
BP 47
EP 57
DI 10.1016/j.jot.2019.02.001
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA JS5UR
UT WOS:000500371900006
PM 31844613
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Plotkin, LI
   Mathov, I
   Aguirre, JI
   Parfitt, AM
   Manolagas, SC
   Bellido, T
AF Plotkin, LI
   Mathov, I
   Aguirre, JI
   Parfitt, AM
   Manolagas, SC
   Bellido, T
TI Mechanical stimulation prevents osteocyte apoptosis: requirement of
   integrins, Src kinases, and ERKs
SO AMERICAN JOURNAL OF PHYSIOLOGY CELL PHYSIOLOGY
LA English
DT Article
DE bone; mechanotransduction; osteoblastic cells; caveolae; stretching
ID FOCAL ADHESION KINASE; DIFFERENT SIGNALING PATHWAYS; HORMONE REPLACEMENT
   THERAPY; ADAPTER PROTEIN SHC; OSTEOBLAST APOPTOSIS; REGULATED KINASE;
   BONE FORMATION; CELL SURVIVAL; SHEAR STRESS; PARATHYROID HORMONE
AB Osteocytes, former osteoblasts entombed in the bone matrix, form an extensive cell communication network that is thought to detect microdamage and mechanical strains and to transmit signals leading to repair and compensatory bone augmentation or reduction. Bone active hormones and drugs control the integrity of this network by regulating osteocyte apoptosis, which might be a determinant of bone strength. Herein we demonstrate that mechanical stimulation by stretching activates the ERKs, which in turn are responsible for the attenuation of osteocyte apoptosis. The effect of osteocyte stretching is transmitted by integrins and cytoskeletal and catalytic molecules, such as Src kinases. Stretch induced antiapoptosis also requires nuclear translocation of ERKs and new gene transcription. The evidence linking mechanical stimulation, activation of an integrin/cytoskeleton/Src/ERK signaling pathway, and osteocyte survival provides a mechanistic basis for the profound role of mechanical forces, or lack thereof, on skeletal health and disease.
C1 Univ Arkansas Med Sci, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA.
   Univ Arkansas Med Sci, Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Central Arkansas Veterans Healthcare System
RP Bellido, T (通讯作者)，Univ Arkansas Med Sci, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, 4301 W Markham,Mail Slot 587, Little Rock, AR 72205 USA.
EM tmbellido@uams.edu
RI Plotkin, Lilian/H 7188 2019; Aguirre, J./AAX 2217 2021
OI Plotkin, Lilian/0000 0002 9537 4544; Bellido,
   Teresita/0000 0002 8203 7004; 
CR AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304
   Aarden EM, 1996, BONE, V18, P305, DOI 10.1016/8756 3282(96)00010 5
   Aguirre JI, 2003, J BONE MINER RES, V18, pS71
   Alenghat Francis J, 2002, Sci STKE, V2002, ppe6, DOI 10.1126/stke.2002.119.pe6
   Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358
   Boutahar N, 2004, J BIOL CHEM, V279, P30588, DOI 10.1074/jbc.M313244200
   Boyce B.F.X., 2002, PRINCIPLES BONE BIOL, P151
   Braith RW, 2003, J HEART LUNG TRANSPL, V22, P1082, DOI 10.1016/S1053 2498(02)01184 1
   Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329
   Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393
   CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514
   Dodd JS, 1999, AM J PHYSIOL CELL PH, V277, pC598, DOI 10.1152/ajpcell.1999.277.3.C598
   ELASHOFF JD, 2000, NQUERY ADVISOR USERS
   Ferraro JT, 2004, AM J PHYSIOL CELL PH, V286, pC831, DOI 10.1152/ajpcell.00224.2003
   Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793
   Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955 0674(97)80124 X
   Gendron S, 2003, J BIOL CHEM, V278, P48633, DOI 10.1074/jbc.M305169200
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Globus RK, 1998, J CELL SCI, V111, P1385
   GOHEL AR, 1995, J HISTOCHEM CYTOCHEM, V43, P1085, DOI 10.1177/43.11.7560891
   Going S, 2003, OSTEOPOROSIS INT, V14, P637, DOI 10.1007/s00198 003 1436 x
   Goldschmidt ME, 2001, CIRC RES, V88, P674, DOI 10.1161/hh0701.089749
   Granet C, 2002, CELL SIGNAL, V14, P679, DOI 10.1016/S0898 6568(02)00008 6
   Granet C, 2001, BIOCHEM BIOPH RES CO, V284, P622, DOI 10.1006/bbrc.2001.5023
   GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699 0463.1988.tb05320.x
   HUGHES DE, 1993, J BONE MINER RES, V8, P527
   Jessop HL, 2002, BONE, V31, P186, DOI 10.1016/S8756 3282(02)00797 4
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kawamura S, 2003, J BIOL CHEM, V278, P31111, DOI 10.1074/jbc.M300725200
   Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092 8674(00)81189 7
   KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261
   Lee K, 2003, NATURE, V424, P389, DOI 10.1038/424389a
   Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455
   Liang FQ, 2000, J BIOL CHEM, V275, P20355, DOI 10.1074/jbc.M001660200
   Lindsay R, 1999, J CLIN ENDOCR METAB, V84, P3076, DOI 10.1210/jc.84.9.3076
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857
   Marotti G., 1990, ITALIAN J MIN ELECTR, V2, P93
   McGarry JG, 2004, FASEB J, V18, P482, DOI 10.1096/fj.04 2210fje
   Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406
   Noble BS, 2003, AM J PHYSIOL CELL PH, V284, pC934, DOI 10.1152/ajpcell.00234.2002
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Owan I, 1997, AM J PHYSIOL CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810
   Park H, 2000, AM J PHYSIOL HEART C, V278, pH1285, DOI 10.1152/ajpheart.2000.278.4.H1285
   Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200
   Reyes Reyes M, 2002, BIOCHEM J, V363, P273, DOI 10.1042/0264 6021:3630273
   Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961
   Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349
   Sanders MA, 2000, J BIOL CHEM, V275, P38040, DOI 10.1074/jbc.M003871200
   Schwartz MA, 2001, J CELL SCI, V114, P2553
   Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775
   Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200
   Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128
   Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60
   Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521 4141(199808)28:08<2265::AID IMMU2265>3.0.CO;2 P
   Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092 8674(00)81392 6
   Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Weyts FAA, 2002, J CELL BIOCHEM, V87, P85, DOI 10.1002/jcb.10278
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   You LD, 2004, ANAT REC PART A, V278A, P505, DOI 10.1002/ar.a.20050
   You LD, 2001, J BIOMECH, V34, P1375, DOI 10.1016/S0021 9290(01)00107 5
   ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161
   Zhang ZY, 2000, J BIOL CHEM, V275, P37219, DOI 10.1074/jbc.M001818200
   Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
   Zhao WG, 2000, J CLIN INVEST, V106, P941, DOI 10.1172/JCI10158
   Ziros PG, 2002, J BIOL CHEM, V277, P23934, DOI 10.1074/jbc.M109881200
NR 76
TC 207
Z9 257
U1 1
U2 24
PU AMER PHYSIOLOGICAL SOC
PI Rockville
PA 6120 Executive Blvd, Suite 600, Rockville, MD, UNITED STATES
SN 0363 6143
EI 1522 1563
J9 AM J PHYSIOL CELL PH
JI Am. J. Physiol. Cell Physiol.
PD SEP
PY 2005
VL 289
IS 3
BP C633
EP C643
DI 10.1152/ajpcell.00278.2004
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 955EI
UT WOS:000231207800016
PM 15872009
DA 2025 08 17
ER

PT J
AU Li, J
   Li, Y
   Wang, SJ
   Che, H
   Wu, J
   Ren, YX
AF Li, Jie
   Li, You
   Wang, Shengjie
   Che, Hui
   Wu, Jun
   Ren, Yongxin
TI miR 101 3p/Rap1b signal pathway plays a key role in osteoclast
   differentiation after treatment with bisphosphonates
SO BMB REPORTS
LA English
DT Article
DE Bisphosphonates; miR 101 3p; Osteoclast; Osteoporosis; Rap1b
ID TARGETS; RAP1B
AB Bisphosphonates are the mainstay of therapy worldwide for osteoporosis. However, bisphosphonates also have limitations. The objective of this study was to determine the role of miR 101 3p/Rap1b signal pathway in osteoclast differentiation after treatment with bisphosphonates. Our results revealed that miR 101 3p was an important regulator in bisphosphonates treated osteoclasts. When miR 101 3p was down regulated in bone marrow derived macrophage like cells (BMMs), the development of mature osteoclasts was promoted, and vice versa. However, alendronate decreased multinucleated cell number regardless of whether miR 101 3p was knocked down or over expressed. TRAP activity assay confirmed the above results. Luciferase assay indicated that miR 101 3p was a negative regulator of Rap1b. Western blot analysis revealed that protein expression level of Rap1b in BMMs transfectecl with OV miR 101 3p was lower than that in BMMs transfected with an empty vector. Rap1b overexpression increased TRAP positive multinucleated cells, while Rap1b inhibition decreased the cell numbers. In vivo data showed that miR 101 3p inhibited osteoclast differentiation in ovariectomizecl mice while overexpressed of Rap1b blocked the differentiation. Taken together, our data demonstrate that miR 101 3p/Rap1b signal pathway plays a key role in osteoclast differentiation after treatment with bisphosphonates.
C1 [Li, Jie] Xuzhou Med Univ, Clin Sch, Xuzhou Cent Hosp, Dept Orthopaed, Xuzhou 221009, Jiangsu, Peoples R China.
   [Li, You; Che, Hui; Ren, Yongxin] Nanjing Med Univ, Affiliated Hosp 1, Dept Orthopaed, Nanjing 210029, Jiangsu, Peoples R China.
   [Wang, Shengjie] Henan Prov Peoples Hosp, Dept Orthoped Surg, Zhengzhou 450003, Henan, Peoples R China.
   [Wu, Jun] Nanjing Med Univ, Res Ctr Bone & Stem Cells, Dept Anat Histol & Embryol, Nanjing 211166, Jiangsu, Peoples R China.
C3 Xuzhou Medical University; Nanjing Medical University; Zhengzhou
   University; Nanjing Medical University
RP Ren, YX (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Orthopaed, Nanjing 210029, Jiangsu, Peoples R China.; Wu, J (通讯作者)，Nanjing Med Univ, Res Ctr Bone & Stem Cells, Dept Anat Histol & Embryol, Nanjing 211166, Jiangsu, Peoples R China.
EM wjxue.happy@163.com; renyongxin2018@aliyun.com
OI Li, You/0000 0002 0426 7760
FU National Natural Science Foundation of China [81572149, 81600697];
   National Basic Research Program of China [2014CB942903]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81572149 and No. 81600697) and from the
   National Basic Research Program of China (2014CB942903).
CR Bindea G, 2013, BIOINFORMATICS, V29, P661, DOI 10.1093/bioinformatics/btt019
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Fordham JB, 2016, SCI REP UK, V6, DOI 10.1038/srep24980
   Gong J, 2016, ONCOL REP, V35, P463, DOI 10.3892/or.2015.4379
   Hu CH, 2017, SCI REP UK, V7, DOI 10.1038/srep43191
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Ji X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030349
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Ke K, 2015, BONE, V81, P237, DOI 10.1016/j.bone.2015.07.006
   Kohl M, 2011, METHODS MOL BIOL, V696, P291, DOI 10.1007/978 1 60761 987 1_18
   Lee D, 2016, SCI REP UK, V6, DOI 10.1038/srep27336
   Liu J, 2017, SCI REP UK, V7, DOI 10.1038/srep40487
   Liu P, 2016, ONCOTARGET, V7, P35188, DOI 10.18632/oncotarget.9072
   Maruyama T, 2017, J BONE MINER RES, V32, P1816, DOI 10.1002/jbmr.3171
   Sang S, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3173547
   Sheng YR, 2014, BIOCHEM CELL BIOL, V92, P152, DOI 10.1139/bcb 2013 0128
   Soares AP, 2016, ENVIRON TOXICOL PHAR, V42, P212, DOI 10.1016/j.etap.2016.01.015
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Wang HR, 2016, SCI REP UK, V6, DOI 10.1038/srep36988
   Yuen T, 2014, P NATL ACAD SCI USA, V111, P17989, DOI 10.1073/pnas.1421410111
   Zhang L, 2017, J BONE MINER RES, V32, P2466, DOI 10.1002/jbmr.3230
   Zhang XH, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15037674
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
   Zou W, 2013, MOL CELL BIOL, V33, P830, DOI 10.1128/MCB.00790 12
NR 24
TC 14
Z9 16
U1 0
U2 4
PU KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
PI SEOUL
PA KOREA SCIENCE & TECHNOLOGY CENTER, # 801,  635 4 , YEOKSAM DONG,
   KANGNAM KU, SEOUL, 135 703, SOUTH KOREA
SN 1976 6696
EI 1976 670X
J9 BMB REP
JI BMB Rep.
PD SEP 30
PY 2019
VL 52
IS 9
BP 572
EP 576
DI 10.5483/BMBRep.2019.52.9.076
PG 5
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA JB7OR
UT WOS:000488752900007
PM 31462380
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhao, AS
   Liu, Y
   Mulvey, JJ
   Tchang, BG
AF Zhao, Alice S.
   Liu, Yi
   Mulvey, Joseph J.
   Tchang, Beverly G.
TI Treatment of glucocorticoid induced osteoporosis with concurrent
   denosumab and romosozumab: a case report
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Denosumab; Osteoporosis; Romosozumab
ID POSTMENOPAUSAL WOMEN; PARATHYROID HORMONE; TERIPARATIDE; ALENDRONATE;
   FRACTURES; COMBINATION; PREVENTION
AB Osteoporosis is a metabolic bone disorder for which treatment options include antiresorptive therapies (e.g., bisphosphonates, denosumab); anabolics (e.g., teriparatide, abaloparatide); and dual mechanisms (e.g., romosozumab). Management of osteoporosis with concurrent antiresorptive and anabolic agents may be superior to monotherapy, as demonstrated in the DATA trial with the combination of denosumab and teriparatide. However, there is limited experience with the combination of denosumab and romosozumab, which may be an alternative antiresorptive/anabolic regimen for individuals who are not candidates for PTH receptor agonists. In this case, we present a young man with glucocorticoid induced osteoporosis who could not tolerate a daily injectable anabolic and who experienced improvement in bone mineral density with concurrent denosumab and off label romosozumab administration.
C1 [Zhao, Alice S.] Weill Cornell Med Coll, New York Presbyterian, New York, NY USA.
   [Liu, Yi; Tchang, Beverly G.] Weill Cornell Med, New York, NY 10065 USA.
   [Mulvey, Joseph J.] Montefiore Med Ctr, New York, NY USA.
C3 Cornell University; Weill Cornell Medicine; NewYork Presbyterian
   Hospital; Cornell University; Weill Cornell Medicine; Montefiore Medical
   Center
RP Tchang, BG (通讯作者)，Weill Cornell Med, New York, NY 10065 USA.
EM acr9011@nyp.org; bgt9001@med.cornell.edu
RI Mulvey, Joseph/KMY 7237 2024
OI , Alice Zhao/0009 0007 1372 8876
CR Adami G, 2024, JBMR PLUS, V8, DOI 10.1093/jbmrpl/ziae016
   [Anonymous], 2019, EVENITY PACKAGE INSE, P91320
   Beier EE, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.13
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Cain CJ, 2012, J BONE MINER RES, V27, P1451, DOI 10.1002/jbmr.1608
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cosman F, 2022, OSTEOPOROSIS INT, V33, P1243, DOI 10.1007/s00198 021 06174 0
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cosman F, 2009, J CLIN ENDOCR METAB, V94, P3772, DOI 10.1210/jc.2008 2719
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   England BR, 2018, BMJ BRIT MED J, V361, DOI 10.1136/bmj.k1036
   Finkelstein JS, 2006, J CLIN ENDOCR METAB, V91, P2882, DOI 10.1210/jc.2006 0190
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Gulyas K, 2020, CLIN RHEUMATOL, V39, P167, DOI 10.1007/s10067 019 04771 3
   Hayat S, 2020, CLEV CLIN J MED, V87, P417, DOI 10.3949/ccjm.87a.19039
   Humphrey MB, 2023, ARTHRITIS RHEUMATOL, V75, P2088, DOI 10.1002/art.42646
   Jacobsson M, 2020, JBMR PLUS, V4, DOI 10.1002/jbm4.10341
   Juhász B, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 04708 5
   Kanis JA, 2004, J BONE MINER RES, V19, P893, DOI 10.1359/JBMR.040134
   Kobayakawa T, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 91248 6
   Kobza AO, 2021, OPEN ACCESS RHEUMATO, V13, P177, DOI 10.2147/OARRR.S282606
   Kostopoulou M, 2020, CURR VASC PHARMACOL, V18, P549, DOI 10.2174/1570161118666191227101636
   Laurent MR, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.908727
   Leder BZ, 2018, JBMR PLUS, V2, P62, DOI 10.1002/jbm4.10041
   Maruotti N, 2012, EUR J CLIN PHARMACOL, V68, P1013, DOI 10.1007/s00228 012 1216 7
   McClung MR, 2018, J BONE MINER RES, V33, P1397, DOI 10.1002/jbmr.3452
   Mok CC, ROMOSOZUMAB VERSUS D
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Seeman E, 2015, J BONE MINER RES, V30, P753, DOI 10.1002/jbmr.2496
   Shoback D, 2020, J CLIN ENDOCR METAB, V105, DOI DOI 10.1210/CLINEM/DGAA048
   Thiele S, 2019, ENDOCR CONNECT, V8, P923, DOI 10.1530/EC 19 0104
   Tsai JN, 2019, LANCET DIABETES ENDO, V7, P767, DOI 10.1016/S2213 8587(19)30255 4
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Walker MD, 2013, ENDOCRINE, V44, P237, DOI 10.1007/s12020 012 9819 4
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yao W, 2016, OSTEOPOROSIS INT, V27, P283, DOI 10.1007/s00198 015 3308 6
NR 43
TC 1
Z9 1
U1 5
U2 5
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD NOV
PY 2024
VL 35
IS 11
BP 2061
EP 2068
DI 10.1007/s00198 024 07243 w
EA SEP 2024
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA J8Y8P
UT WOS:001314845200001
PM 39289209
DA 2025 08 17
ER

PT J
AU Rogers, MJ
   Mönkkönen, J
   Munoz, MA
AF Rogers, Michael J.
   Monkkonen, Jukka
   Munoz, Marcia A.
TI Molecular mechanisms of action of bisphosphonates and new insights into
   their effects outside the skeleton
SO BONE
LA English
DT Article
DE Bisphosphonate; Bone resorption; Osteoclast; Mevalonate; Isoprenoid;
   Farnesyl; Geranylgeranyl; FPP; GGPP; IPP; Small GTPase; Prenylation;
   Clodronate; Zoledronate; Macrophage; gamma,delta T cell
ID NITROGEN CONTAINING BISPHOSPHONATES; FARNESYL DIPHOSPHATE SYNTHASE; RAB
   GERANYLGERANYL TRANSFERASE; CELLS IN VITRO; HETEROCYCLE CONTAINING
   BISPHOSPHONATES; MEVALONATE KINASE DEFICIENCY; INHIBIT BONE RESORPTION;
   ZOLEDRONIC ACID; PROTEIN PRENYLATION; DICTYOSTELIUM DISCOIDEUM
AB Bisphosphonates (BP) are a class of calcium binding drug used to prevent bone resorption in skeletal disorders such as osteoporosis and metastatic bone disease. They act by selectively targeting bone resorbing osteoclasts and can be grouped into two classes depending on their intracellular mechanisms of action. Simple BPs cause osteoclast apoptosis after cytoplasmic conversion into toxic ATP analogues. In contrast, nitrogen containing BPs potently inhibit FPP synthase, an enzyme of the mevalonate (cholesterol biosynthesis) pathway. This results in production of a toxic metabolite (ApppI) and the loss of long chain isoprenoid lipids required for protein prenylation, a process necessary for the function of small GTPase proteins essential for the survival and activity of osteoclasts. In this review we provide a state of the art overview of these mechanisms of action and a historical perspective of how they were discovered. Finally, we challenge the long held dogma that BPs act only in the skeleton and highlight recent studies that reveal insights into hitherto unknown effects on tumour associated and tissue resident macrophages.
C1 [Rogers, Michael J.; Munoz, Marcia A.] Garvan Inst Med Res, Sydney, NSW, Australia.
   [Monkkonen, Jukka] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio, Finland.
   [Rogers, Michael J.; Munoz, Marcia A.] UNSW Sydney, St Vincents Clin Sch, Sydney, NSW, Australia.
C3 Garvan Institute of Medical Research; University of Eastern Finland;
   University of New South Wales Sydney
RP Rogers, MJ (通讯作者)，Garvan Inst Med Res, Sydney, NSW, Australia.
EM m.rogers@garvan.org.au; jukka.monkkonen@uef.fi; m.munoz@garvan.org.au
OI Munoz, Marcia/0000 0001 7603 0351; Rogers, Michael/0000 0002 1818 9249
FU Arthritis Research UK; JG Graves Medical Research Fellowship; National
   Association for the Relief of Paget's Disease; Medical Research Council;
   Cancer Research UK; Leukaemia Research Fund; Oliver Bird Rheumatism
   Programme; Scottish Hospital Endowments Research Trust; Bone Cancer
   Research Trust; Moonlight Prowl; Academy of Finland; Technical
   Development Centre of Finland; Kuopio University Foundation; Procter &
   Gamble Pharmaceuticals; Novartis; Merck; Cancer Council NSW; National
   Health & Medical Research Council; Mrs. Janice Gibson and the Ernest
   Heine Family Foundation
FX This review is dedicated to the memory of Steven Luckman (1973 2010).
   The authors' work that is described in the review was funded by grants
   from Arthritis Research UK, JG Graves Medical Research Fellowship,
   National Association for the Relief of Paget's Disease, the Medical
   Research Council, Cancer Research UK, Leukaemia Research Fund, Oliver
   Bird Rheumatism Programme, Scottish Hospital Endowments Research Trust,
   Bone Cancer Research Trust, Moonlight Prowl, the Academy of Finland,
   Technical Development Centre of Finland, Kuopio University Foundation,
   Procter & Gamble Pharmaceuticals, Novartis, Merck, Cancer Council NSW,
   National Health & Medical Research Council, Mrs. Janice Gibson and the
   Ernest Heine Family Foundation.
CR Ali Naveid, 2015, Small GTPases, V6, P202, DOI 10.1080/21541248.2015.1085485
   Amin D, 1996, ARZNEIMITTEL FORSCH, V46, P759
   AMIN D, 1992, J LIPID RES, V33, P1657
   Auriola S, 1997, J CHROMATOGR B, V704, P187, DOI 10.1016/S0378 4347(97)00490 8
   Baron RA, 2009, J BIOL CHEM, V284, P6861, DOI 10.1074/jbc.M806952200
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Berndt N, 2011, NAT PROTOC, V6, P1775, DOI 10.1038/nprot.2011.387
   Blazewska KM, 2011, EUR J MED CHEM, V46, P4820, DOI 10.1016/j.ejmech.2011.04.063
   Boissier S, 2000, CANCER RES, V60, P2949
   Boissier S, 1997, CANCER RES, V57, P3890
   Bolland MJ, 2010, J CLIN ENDOCR METAB, V95, P1174, DOI 10.1210/jc.2009 0852
   BOONEKAMP PM, 1986, BONE MINER, V1, P27
   Castella B, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15663
   Center JR, 2011, J CLIN ENDOCR METAB, V96, P1006, DOI 10.1210/jc.2010 2730
   Chinault SL, 2012, CLIN CANCER RES, V18, P4136, DOI 10.1158/1078 0432.CCR 12 0642
   Clézardin P, 2012, ANTI CANCER AGENT ME, V12, P102, DOI 10.2174/187152012799014977
   Clézardin P, 2011, BONE, V48, P71, DOI 10.1016/j.bone.2010.07.016
   Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
   Coscia M, 2010, J CELL MOL MED, V14, P2803, DOI 10.1111/j.1582 4934.2009.00926.x
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   Coxon FP, 2005, BONE, V37, P349, DOI 10.1016/j.bone.2005.04.021
   Coxon FP, 1998, MOL PHARMACOL, V54, P631
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Coxon FP, 2011, BONE, V49, P111, DOI 10.1016/j.bone.2011.03.686
   Cremers S, 2002, EUR J CLIN PHARMACOL, V57, P883, DOI 10.1007/s00228 001 0411 8
   Das S, 2014, BBA MOL CELL BIOL L, V1841, P569, DOI 10.1016/j.bbalip.2013.12.010
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   EBETINO FH, 1990, PHOSPHORUS SULFUR, V51, P23, DOI 10.1080/10426509008040673
   Fiore F, 2007, BLOOD, V110, P921, DOI 10.1182/blood 2006 09 044321
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Green JR, 2002, DRUG DEVELOP RES, V55, P210, DOI 10.1002/ddr.10071
   Grove JE, 2000, J BONE MINER RES, V15, P971, DOI 10.1359/jbmr.2000.15.5.971
   Guenther A, 2010, INT J CANCER, V126, P239, DOI 10.1002/ijc.24758
   Sillero MAG, 2006, FEBS LETT, V580, P5723, DOI 10.1016/j.febslet.2006.09.026
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   Jauhiainen M, 2009, J CHROMATOGR B, V877, P2967, DOI 10.1016/j.jchromb.2009.07.010
   Junankar S, 2015, CANCER DISCOV, V5, P35, DOI 10.1158/2159 8290.CD 14 0621
   Jurczyluk J, 2016, IMMUNOL CELL BIOL, V94, P994, DOI 10.1038/icb.2016.58
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kavanagh KL, 2006, J BIOL CHEM, V281, P22004, DOI 10.1074/jbc.M602603200
   Keller RK, 1999, BIOCHEM BIOPH RES CO, V266, P560, DOI 10.1006/bbrc.1999.1849
   KLEIN G, 1988, BIOCHEMISTRY US, V27, P1897, DOI 10.1021/bi00406a015
   Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914
   Lee P, 2016, J CLIN ENDOCR METAB, V101, P1945, DOI 10.1210/jc.2015 3467
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Leung KF, 2006, J LIPID RES, V47, P467, DOI 10.1194/jlr.R500017 JLR200
   Levy ME, 2007, MATURITAS, V57, P247, DOI 10.1016/j.maturitas.2007.01.005
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Malwal SR, 2018, J AM CHEM SOC, V140, P7568, DOI 10.1021/jacs.8b02363
   Marma MS, 2007, J MED CHEM, V50, P5967, DOI 10.1021/jm0702884
   Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   McKenna CE, 2010, J MED CHEM, V53, P3454, DOI 10.1021/jm900232u
   Mitrofan LM, 2009, BONE, V45, P1153, DOI 10.1016/j.bone.2009.08.010
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Mönkkönen H, 2001, PHARMACEUT RES, V18, P1550, DOI 10.1023/A:1013026313647
   Mönkkönen H, 2008, ANTI CANCER DRUG, V19, P391, DOI 10.1097/CAD.0b013e3282f632bf
   Montalvetti A, 2001, J BIOL CHEM, V276, P33930, DOI 10.1074/jbc.M103950200
   Munoz MA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01900
   Munoz MA, 2017, J ALLERGY CLIN IMMUN, V140, P873, DOI 10.1016/j.jaci.2017.02.033
   Nguyen U.T., 2010, CURR PROTOC PROTEIN
   Nguyen UTT, 2009, NAT CHEM BIOL, V5, P227, DOI 10.1038/nchembio.149
   Ory B, 2008, J CELL MOL MED, V12, P928, DOI 10.1111/j.1582 4934.2008.00141.x
   Ory S, 2008, EUR J CELL BIOL, V87, P469, DOI 10.1016/j.ejcb.2008.03.002
   Palsuledesai CC, 2016, ACS CHEM BIOL, V11, P2820, DOI 10.1021/acschembio.6b00421
   Palsuledesai CC, 2015, ACS CHEM BIOL, V10, P51, DOI 10.1021/cb500791f
   Pathria P, 2019, TRENDS IMMUNOL, V40, P310, DOI 10.1016/j.it.2019.02.003
   Pavlos NJ, 2005, MOL CELL BIOL, V25, P5253, DOI 10.1128/MCB.25.12.5253 5269.2005
   Pazianas M, 2012, OSTEOPOROSIS INT, V23, P2693, DOI 10.1007/s00198 012 1902 4
   Pazianas M, 2011, JNCI J NATL CANCER I, V103, P232, DOI 10.1093/jnci/djq516
   PELORGEAS S, 1992, BIOCHEM PHARMACOL, V44, P2157, DOI 10.1016/0006 2952(92)90342 G
   PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200
   Plotkin LI, 2008, J BONE MINER RES, V23, P1712, DOI [10.1359/jbmr.080617, 10.1359/JBMR.080617]
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   REITSMA PH, 1982, J CLIN INVEST, V70, P927, DOI 10.1172/JCI110704
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193
   Riganti C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01246
   Roca Ayats N, 2018, J BONE MINER RES, V33, P2091, DOI 10.1002/jbmr.3580
   Roca Ayats N, 2017, NEW ENGL J MED, V376, P1794, DOI 10.1056/NEJMc1612804
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Roelofs AJ, 2012, J BONE MINER RES, V27, P835, DOI 10.1002/jbmr.1543
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   Rogers MJ, 2018, ELIFE, V7, DOI 10.7554/eLife.38847
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   ROGERS MJ, 1994, BIOCHEM J, V303, P303, DOI 10.1042/bj3030303
   Rogers MJ, 1996, BIOCHEM BIOPH RES CO, V224, P863, DOI 10.1006/bbrc.1996.1113
   ROGERS MJ, 1992, BIOCHEM BIOPH RES CO, V189, P414, DOI 10.1016/0006 291X(92)91574 A
   Rogers MJ, 1997, PHARMACEUT RES, V14, P625, DOI 10.1023/A:1012157212793
   Rogers MJ, 1996, J BONE MINER RES, V11, P1482
   ROGERS MJ, 1994, J BONE MINER RES, V9, P1029
   ROGERS MJ, 1995, MOL PHARMACOL, V47, P398
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Roskoski R, 2003, BIOCHEM BIOPH RES CO, V303, P1, DOI 10.1016/S0006 291X(03)00323 1
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270
   Salomo M, 2003, BRIT J HAEMATOL, V122, P202, DOI 10.1046/j.1365 2141.2003.04437.x
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219
   Schulman RC, 2016, ENDOCR PRACT, V22, P799, DOI 10.4158/EP151050.OR
   Selander KS, 1996, MOL PHARMACOL, V50, P1127
   Shipman CM, 1998, CANCER RES, V58, P5294
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Sinensky M, 2000, BBA MOL CELL BIOL L, V1484, P93, DOI 10.1016/S1388 1981(00)00009 3
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Storck EM, 2019, NAT CHEM, V11, P552, DOI 10.1038/s41557 019 0237 6
   Suri S, 2001, BONE, V29, P336, DOI 10.1016/S8756 3282(01)00589 0
   Sutherland KA, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2681
   ter Haar NM, 2016, ARTHRITIS RHEUMATOL, V68, P2795, DOI 10.1002/art.39763
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   Thompson K, 2002, BIOCHEM BIOPH RES CO, V290, P869, DOI 10.1006/bbrc.2001.6289
   Thompson K, 2011, BONE, V49, P140, DOI 10.1016/j.bone.2010.10.177
   Thompson K, 2010, ADV EXP MED BIOL, V658, P11, DOI 10.1007/978 1 4419 1050 9_2
   Valachis A, 2013, ONCOLOGIST, V18, P353, DOI 10.1634/theoncologist.2012 0261
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   VANBEEK E, 1994, J BONE MINER RES, V9, P1875, DOI 10.1002/jbmr.5650091206
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Wiemer AJ, 2008, BIOORGAN MED CHEM, V16, P390, DOI 10.1016/j.bmc.2007.09.029
   Yu Z, 2018, ELIFE, V7, DOI 10.7554/eLife.36620
   Yuen T, 2014, P NATL ACAD SCI USA, V111, P17989, DOI 10.1073/pnas.1421410111
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
   Zhao HB, 2001, J BIOL CHEM, V276, P39295, DOI 10.1074/jbc.M010999200
NR 149
TC 115
Z9 122
U1 4
U2 46
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2020
VL 139
AR 115493
DI 10.1016/j.bone.2020.115493
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA NH5PS
UT WOS:000564722400005
PM 32569873
DA 2025 08 17
ER

PT J
AU Goblirsch, MJ
   Zwolak, PP
   Clohisy, DR
AF Goblirsch, Michael J.
   Zwolak, Pawel P.
   Clohisy, Denis R.
TI Biology of bone cancer pain
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Proceedings Paper
CT Conference on Advances in Treating Metastatic Bone Cancer
CY OCT 28 29, 2005
CL Cambridge, MA
ID GENE RELATED PEPTIDE; SUBSTANCE P; SPINAL CORD; SKELETAL PAIN;
   TUMOR GROWTH; IN VITRO; MODEL; INNERVATION; NEURONS; BISPHOSPHONATES
AB Bone cancer pain is a devastating manifestation of metastatic cancer. Unfortunately current therapies can be ineffective, and when they are effective, the duration of the patient's survival typically exceeds the duration of pain relief. New, mechanistically based therapies are desperately needed. Study of experimental animal models has provided insight into the mechanisms that drive bone cancer pain and provides an opportunity for developing targeted therapies. Mechanisms that drive bone cancer pain include tumor directed osteoclast mediated osteolysis, tumor cells themselves, tumor induced nerve injury, stimulation of transient receptor potential vanilloid type 1 ion channel, endothelin A, and host cell production of nerve growth factor. Current and future therapies include external beam radiation, osteoclast targeted inhibiting agents, anti inflammatory drugs, transient receptor potential vanilloid type 1 antagonists, and antibody therapies that target nerve growth factor or tumor angiogenesis. It is likely that a combination of these therapies will be superior to any one therapy alone.
C1 Univ Minnesota, Dept Orthopaed Surg, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities
RP Clohisy, DR (通讯作者)，Univ Minnesota, Dept Orthopaed Surg, 420 Delaware St SE,MMC 806, Minneapolis, MN 55455 USA.
EM clohi001@umn.edu
CR Artico M, 2002, INT J MOL MED, V10, P77
   BAINES M, 1989, BRIT MED J, V298, P36, DOI 10.1136/bmj.298.6665.36
   Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819
   BJURHOLM A, 1988, PEPTIDES, V9, P165, DOI 10.1016/0196 9781(88)90023 X
   Boissier S, 2000, CANCER RES, V60, P2949
   Breuil V, 1998, J BONE MINER RES, V13, P1721, DOI 10.1359/jbmr.1998.13.11.1721
   Cain DM, 2001, PAIN MED, V2, P15, DOI 10.1046/j.1526 4637.2001.002001015.x
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coyle N, 1990, J Pain Symptom Manage, V5, P83
   Foley KM, 1999, ARCH NEUROL CHICAGO, V56, P413, DOI 10.1001/archneur.56.4.413
   Ghilardi JR, 2005, J NEUROSCI, V25, P3126, DOI 10.1523/JNEUROSCI.3815 04.2005
   Goblirsch M, 2004, RADIAT RES, V161, P228, DOI 10.1667/RR3108
   Goblirsch MJ, 2005, J CELL BIOCHEM, V96, P682, DOI 10.1002/jcb.20589
   Hiraga T, 2001, CANCER RES, V61, P4418
   Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306 4522(00)00110 X
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   Honoré P, 2002, J PAIN, V3, P3, DOI 10.1054/jpai.2002.27001
   Honore P, 2000, Prog Brain Res, V129, P389
   Honore P, 2000, PAIN MED, V1, P303, DOI 10.1046/j.1526 4637.2000.00047.x
   Hoskin PJ, 2000, LANCET, V355, P1428, DOI 10.1016/S0140 6736(00)02144 9
   HUKKANEN M, 1992, INT J TISSUE REACT, V14, P1
   HUKKANEN M, 1992, J RHEUMATOL, V19, P1252
   Imai S, 1997, J ORTHOP RES, V15, P133, DOI 10.1002/jor.1100150120
   Lesage, 1999, Cancer Control, V6, P136
   Mach DB, 2002, NEUROSCIENCE, V113, P155, DOI 10.1016/S0306 4522(02)00165 3
   MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937
   Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304 3959(01)00437 7
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304 3959(01)00324 4
   Neville Webbe HL, 2003, PALLIATIVE MED, V17, P539, DOI 10.1191/0269216303pm800ra
   Neville Webbe HL, 2002, CANCER TREAT REV, V28, P305, DOI 10.1016/S0305 7372(02)00095 6
   Olson TH, 1998, NEUROREPORT, V9, P1109, DOI 10.1097/00001756 199804200 00028
   Peters CM, 2004, NEUROSCIENCE, V126, P1043, DOI 10.1016/j.neuroscience.2004.04.027
   Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140 6736(99)01310 0
   Sabino MAC, 2002, CANCER RES, V62, P7343
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19 24 10886.1999
   Seong J, 2004, ANN NY ACAD SCI, V1030, P179, DOI 10.1196/annals.1329.023
   Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022
   Sevcik MA, 2004, PAIN, V111, P169, DOI 10.1016/j.pain.2004.06.015
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Slavin KV, 2004, DRUGS TODAY, V40, P235, DOI 10.1358/dot.2004.40.3.820087
   TONG D, 1982, CANCER AM CANCER SOC, V50, P893, DOI 10.1002/1097 0142(19820901)50:5<893::AID CNCR2820500515>3.0.CO;2 Y
   Töyräs A, 2003, EUR J PHARM SCI, V19, P223, DOI 10.1016/S0928 0987(03)00108 8
   Vasikaran SD, 2001, ANN CLIN BIOCHEM, V38, P608, DOI 10.1258/0004563011901037
   Wacnik PW, 2003, PAIN, V101, P175, DOI 10.1016/S0304 3959(02)00312 3
   Zhao CS, 2004, J PAIN, V5, P104, DOI 10.1016/j.jpain.2003.12.001
NR 46
TC 81
Z9 100
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2006
VL 12
IS 20
SU S
BP 6231S
EP 6235S
DI 10.1158/1078 0432.CCR 06 0682
PN 2
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Oncology
GA 099AC
UT WOS:000241563900005
PM 17062706
OA Bronze
DA 2025 08 17
ER

PT J
AU Kushwaha, P
   Khedgikar, V
   Gautam, J
   Dixit, P
   Chillara, R
   Verma, A
   Thakur, R
   Mishra, DP
   Singh, D
   Maurya, R
   Chattopadhyay, N
   Mishra, PR
   Trivedi, R
AF Kushwaha, P.
   Khedgikar, V.
   Gautam, J.
   Dixit, P.
   Chillara, R.
   Verma, A.
   Thakur, R.
   Mishra, D. P.
   Singh, D.
   Maurya, R.
   Chattopadhyay, N.
   Mishra, P. R.
   Trivedi, R.
TI A novel therapeutic approach with Caviunin based isoflavonoid that en
   routes bone marrow cells to bone formation via BMP2/Wnt β catenin
   signaling
SO CELL DEATH & DISEASE
LA English
DT Article
ID PARATHYROID HORMONE; POSTMENOPAUSAL WOMEN; DALBERGIA SISSOO;
   OSTEOPOROSIS; DIFFERENTIATION; EXPRESSION; OSTEOCLAST; ALENDRONATE;
   MODULATION; INJURY
AB Recently, we reported that extract of Dalbergia sissoo made from leaves and pods have antiresorptive and bone forming effects. The positive skeletal effect attributed because of active molecules present in the extract of Dalbergia sissoo. Caviunin 7 O [beta D apiofuranosyl (1 6) beta D glucopyranoside] (CAFG), a novel isoflavonoid show higher percentage present in the extract. Here, we show the osteogenic potential of CAFG as an alternative for anabolic therapy for the treatment of osteoporosis by stimulating bone morphogenetic protein 2 (BMP2) and Wnt/beta catenin mechanism. CAFG supplementation improved trabecular micro architecture of the long bones, increased biomechanical strength parameters of the vertebra and femur and decreased bone turnover markers better than genistein. Oral administration of CAFG to osteopenic ovariectomized mice increased osteoprogenitor cells in the bone marrow and increased the expression of osteogenic genes in femur and show new bone formation without uterine hyperplasia. CAFG increased mRNA expression of osteoprotegerin in bone and inhibited osteoclast activation by inhibiting the expression of skeletal osteoclastogenic genes. CAFG is also an effective accelerant for chondrogenesis and has stimulatory effect on the repair of cortical bone after drill hole injury at the tissue, cell and gene level in mouse femur. At cellular levels, CAFG stimulated osteoblast proliferation, survival and differentiation. Signal transduction inhibitors in osteoblast demonstrated involvement of p 38 mitogen activated protein kinase pathway stimulated by BMP2 to initiate Wnt/beta catenin signaling to reduce phosphorylation of GSK3 beta and subsequent nuclear accumulation of beta catenin. Osteogenic effects were abrogated by Dkk1, Wnt receptor blocker and FH535, inhibitor of TCF complex by reduction in beta catenin levels. CAFG modulated MSC responsiveness to BMP2, which promoted osteoblast differentiation via Wnt/beta catenin mechanism. CAFG at 1 mg/kg/day dose in ovariectomy mice (human dose similar to 0.081 mg/kg) led to enhanced bone formation, reduced bone resorption and bone turnover better than well known phytoestrogen genistein. Owing to CAFG's inherent properties for bone, it could be positioned as a potential drug, food supplement, for postmenopausal osteoporosis and fracture repair.
C1 [Kushwaha, P.; Khedgikar, V.; Gautam, J.; Thakur, R.; Mishra, D. P.; Singh, D.; Chattopadhyay, N.; Trivedi, R.] CSIR, Cent Drug Res Inst, Ctr Res Anabol Skeletal Targets Hlth & Illness AS, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
   [Dixit, P.; Chillara, R.; Maurya, R.] CSIR, Cent Drug Res Inst, Med & Proc Chem Div, Lucknow 226031, Uttar Pradesh, India.
   [Verma, A.; Mishra, P. R.] CSIR, Cent Drug Res Inst, India Div Pharmaceut, Lucknow 226031, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI); Council of Scientific & Industrial Research (CSIR)  
   India; CSIR   Central Drug Research Institute (CDRI)
RP Trivedi, R (通讯作者)，CSIR, Cent Drug Res Inst, Ctr Res Anabol Skeletal Targets Hlth & Illness AS, Div Endocrinol, Sect 10,Jankipuram Extens,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
EM ritu_trivedi@cdri.res.in
RI Chattopadhyay, Naibedya/AAQ 3213 2021; maurya, rakesh/AAV 7598 2021;
   Verma, Ashwni/CAI 3987 2022; Thakur, Ravi/AGH 8433 2022; Mishra,
   Prabhat/C 3814 2009; Verma, Ashwni Kumar/CAI 3987 2022
OI Chattopadhyay, Naibedya/0000 0003 2473 0246; THAKUR,
   RAVI/0000 0003 2505 9757; Gautam, Jyoti/0000 0003 2961 9547; Verma,
   Ashwni Kumar/0000 0003 3717 0233
FU CSIR [BSC0201]; ASTHI; Department of Biotechnology (DBT), Government of
   India; CDRI [184/2014/RT]
FX Grant from CSIR (BSC0201), ASTHI and Department of Biotechnology (DBT),
   Government of India are acknowledged. Scientist and In charge of
   Electron Microscopy for confocal imaging. The CDRI communication number
   is 184/2014/RT.
CR Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   ASAHINA I, 1993, J CELL BIOL, V123, P921, DOI 10.1083/jcb.123.4.921
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Bhargavan B, 2012, J NUTR BIOCHEM, V23, P27, DOI 10.1016/j.jnutbio.2010.11.002
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Chandra P, TOXICOL IND HLTH
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Chou MY, 2009, ORTHOD CRANIOFAC RES, V12, P141, DOI 10.1111/j.1601 6343.2009.01447.x
   Cipriano Cara A, 2009, HSS J, V5, P149, DOI 10.1007/s11420 009 9109 8
   Cosman Felicia, 2005, MedGenMed, V7, P73
   Dixit P, 2012, BIOORG MED CHEM LETT, V22, P890, DOI 10.1016/j.bmcl.2011.12.036
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Furumatsu T, 2014, CONNECT TISSUE RES, V55, P89, DOI 10.3109/03008207.2013.852544
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Guo AJY, 2011, J BIOL CHEM, V286, P27882, DOI 10.1074/jbc.M111.236281
   He YX, 2011, BONE, V48, P1388, DOI 10.1016/j.bone.2011.03.720
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Ivergård M, 2010, BONE, V47, P966, DOI 10.1016/j.bone.2010.07.024
   Jordan VC, 2001, J NATL CANCER I, V93, P1449, DOI 10.1093/jnci/93.19.1449
   Khan K, 2012, MOL NUTR FOOD RES, V56, P1860, DOI 10.1002/mnfr.201200200
   Khedgikar V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.294
   Khedgikar V, 2012, MENOPAUSE, V19, P1336, DOI 10.1097/gme.0b013e318256b6ae
   Kloen P, 2003, BONE, V33, P362, DOI 10.1016/S8756 3282(03)00191 1
   Knight MN, 2013, ADV WOUND CARE, V2, P306, DOI 10.1089/wound.2012.0420
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Mi M, 2013, GENE, V512, P211, DOI 10.1016/j.gene.2012.09.130
   ORWOLL ES, 1995, ENDOCR REV, V16, P87, DOI 10.1210/er.16.1.87
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Sashidhara KV, 2013, J MED CHEM, V56, P109, DOI 10.1021/jm301281e
   Secreto Frank J, 2009, Curr Osteoporos Rep, V7, P64
   Siddiqui JA, 2010, MOL CELL ENDOCRINOL, V323, P256, DOI 10.1016/j.mce.2010.03.024
   Singh US, 2008, BIOORGAN MED CHEM, V16, P8482, DOI 10.1016/j.bmc.2008.08.024
   Stepan J J, 2003, Endocr Regul, V37, P225
   Tanaka K, 2010, BONE, V47, P1006, DOI 10.1016/j.bone.2010.08.016
   Tyagi AM, 2010, MOL CELL ENDOCRINOL, V325, P101, DOI 10.1016/j.mce.2010.05.016
   Wardlaw S L, 1998, Endocr Rev, V19, P516
   Wuelling M, 2011, ENDOCR DEV, V21, P1, DOI 10.1159/000328081
   Yamazaki M, 1999, J BONE JOINT SURG BR, V81B, P508, DOI 10.1302/0301 620X.81B3.9398
   Zhang L, 2012, PHYTOTHER RES, V26, P1385, DOI 10.1002/ptr.3733
NR 40
TC 63
Z9 69
U1 2
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD SEP
PY 2014
VL 5
AR e1422
DI 10.1038/cddis.2014.350
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AQ9HS
UT WOS:000343162000023
PM 25232676
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chen, E
AF Chen, Eleanor
TI Wnt Signaling in Rhabdomyosarcoma   A Potential Targeted Therapy Option
SO CURRENT DRUG TARGETS
LA English
DT Article
DE Wnt; rhabdomyosarcoma; cancer; myogenesis
ID WNT/BETA CATENIN PATHWAY; SMALL MOLECULE INHIBITORS; CANCER STEM CELLS;
   BETA CATENIN; PHARMACOLOGICAL INHIBITION; BREAST CANCER; IN VITRO;
   GROWTH; EXPRESSION; MUTATIONS
AB Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in the pediatric population and recapitulates many of the phenotypic and biological features of embryonic skeletal muscle. RMS is pathologically characterized by myogenic differentiation arrest. Dysregulation of pathways essential for myogenesis like contribute to the tumorigenesis of RMS. The Wnt signaling pathway is one of the major pathways required for normal myogenesis. Aberrant Wnt signaling has also been demonstrated in many types of cancer. The role of Wnt pathway in the pathogenesis of RMS is beginning to be appreciated. This review will go over current knowledge on biological roles of Wnt pathway in RMS and potential translational application in therapeutics.
C1 [Chen, Eleanor] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
C3 University of Washington; University of Washington Seattle
RP Chen, E (通讯作者)，Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
EM echen791@gmail.com
FU NIH [K08 AR063165]; St. Baldrick's Foundation Scholar Award; Sarcoma
   Foundation of America; Rally Foundation
FX EC is supported by NIH K08 AR063165, St. Baldrick's Foundation Scholar
   Award, Sarcoma Foundation of America and Rally Foundation.
CR Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Annavarapu SR, 2013, LAB INVEST, V93, P1090, DOI 10.1038/labinvest.2013.97
   Azzi S, 2011, J NATL CANCER I, V103, P1884, DOI 10.1093/jnci/djr451
   BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293 113
   Baryawno N, 2010, CANCER RES, V70, P266, DOI 10.1158/0008 5472.CAN 09 0578
   Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006
   Busch AM, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 211
   Charytonowicz E, 2012, J CLIN INVEST, V122, P886, DOI 10.1172/JCI60015
   Chen EY, 2014, P NATL ACAD SCI USA, V111, P5349, DOI 10.1073/pnas.1317731111
   Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002
   Chen YY, 2006, GENE CHROMOSOME CANC, V45, P583, DOI 10.1002/gcc.20322
   Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106
   Chim CS, 2007, LEUKEMIA, V21, P2527, DOI 10.1038/sj.leu.2404939
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030
   Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951
   Ellison DW, 2005, J CLIN ONCOL, V23, P7951, DOI 10.1200/JCO.2005.01.5479
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Ewan K, 2010, CANCER RES, V70, P5963, DOI 10.1158/0008 5472.CAN 10 1028
   Fujii N, 2007, CANCER RES, V67, P573, DOI 10.1158/0008 5472.CAN 06 2726
   Fukukawa C, 2008, CANCER SCI, V99, P432, DOI 10.1111/j.1349 7006.2007.00701.x
   Gallagher SJ, 2013, ONCOGENE, V32, P2230, DOI 10.1038/onc.2012.229
   Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002 9440(10)65148 6
   Gandhirajan RK, 2010, CURR CANCER DRUG TAR, V10, P716
   Gonsalves FC, 2011, P NATL ACAD SCI USA, V108, P5954, DOI 10.1073/pnas.1017496108
   Grandy D, 2009, J BIOL CHEM, V284, P16256, DOI 10.1074/jbc.M109.009647
   Gros J, 2009, NATURE, V457, P589, DOI 10.1038/nature07564
   Hallett RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033976
   Horvath LG, 2005, INT J CANCER, V113, P415, DOI 10.1002/ijc.20599
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Ignatius MS, 2012, CANCER CELL, V21, P680, DOI 10.1016/j.ccr.2012.03.043
   James RG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050457
   Jope RS, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00016
   Le Grand F, 2009, CELL STEM CELL, V4, P535, DOI 10.1016/j.stem.2009.03.013
   Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535 6108(03)00334 9
   Li XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068525
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092 8674(89)90506 0
   Mo ML, 2013, ONCOL LETT, V5, P1719, DOI 10.3892/ol.2013.1256
   MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911
   Nambotin SB, 2011, J HEPATOL, V54, P288, DOI 10.1016/j.jhep.2010.06.033
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092 8674(82)90409 3
   NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0
   Palacios J, 1998, CANCER RES, V58, P1344
   Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092 8674(03)00437 9
   Previdi S, 2010, EUR J CANCER, V46, P1679, DOI 10.1016/j.ejca.2010.02.036
   Proffitt KD, 2013, CANCER RES, V73, P502, DOI 10.1158/0008 5472.CAN 12 2258
   Rephaeli A, 2005, INT J CANCER, V116, P226, DOI 10.1002/ijc.21030
   Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448
   Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159 8290.CD 13 0639
   Singh S, 2010, AM J PATHOL, V177, P2055, DOI 10.2353/ajpath.2010.091195
   STONE RM, 1988, BLOOD, V71, P690
   STRATTON MR, 1990, ONCOGENE, V5, P1297
   Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104
   Tajbakhsh S, 1998, DEVELOPMENT, V125, P4155
   TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879
   Thorne CA, 2015, NAT CHEM BIOL, V11, P58, DOI 10.1038/nchembio.1690
   Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453
   Tian W, 2012, BIOCHEMISTRY US, V51, P724, DOI 10.1021/bi201428h
   Torrente Y, 2004, J CLIN INVEST, V114, P182, DOI 10.1172/JCI200420325
   Trumpp A, 2008, NAT CLIN PRACT ONCOL, V5, P337, DOI 10.1038/ncponc1110
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Waaler J, 2012, CANCER RES, V72, P2822, DOI 10.1158/0008 5472.CAN 11 3336
   Walter D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019506
   Wang W, 2011, CELL RES, V21, P730, DOI 10.1038/cr.2011.30
   Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624
   Wei W, 2010, INT J CANCER, V126, P2426, DOI 10.1002/ijc.24810
   West NW, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 256
   Willert K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007864
   Yang ZH, 2009, GENE DEV, V23, P694, DOI 10.1101/gad.1765109
   Zhang YN, 2009, NAT CHEM BIOL, V5, P217, DOI 10.1038/nchembio.152
NR 74
TC 5
Z9 8
U1 0
U2 1
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389 4501
EI 1873 5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PY 2016
VL 17
IS 11
BP 1245
EP 1251
DI 10.2174/1389450116666150630110625
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA EB0VN
UT WOS:000387064500004
PM 26122033
DA 2025 08 17
ER

PT J
AU Scheller, EL
   Krebsbach, PH
AF Scheller, Erica L.
   Krebsbach, Paul H.
TI The Use of Soluble Signals to Harness the Power of the Bone
   Microenvironment for Implant Therapeutics
SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS
LA English
DT Article
DE bone; cell signaling; dental implant; differentiation; growth factors;
   regeneration; tissue engineering
ID FIBROBLAST GROWTH FACTOR; STEM CELL NICHE; POSTMENOPAUSAL WOMEN;
   ENDOTHELIAL CELLS; FACTOR I; SKELETAL DEVELOPMENT; MESSENGER RNA;
   TISSUE REPAIR; STROMAL CELLS; CATHEPSIN K
AB The use of soluble signals for modulation of bone formation has become a significant area of clinical research in recent years. Improvements in implant site preparation and osseointegration have already been achieved with the use of recombinant platelet derived growth factor and bone morphogenetic proteins on osteogenic scaffolds. Other states of insufficient bone such as osteoporosis are frequently treated with inhibitors of osteoclast function or osteoblast anabolic agents. However, despite the existence of promising therapies targeting osteoblasts and osteoclasts directly, therapies utilizing indirect regulation through secondary cellular nodes of control (NOC) are just beginning to emerge. This article will review current strategies for regulation of bone formation by targeting two primary NOCs, the osteoblast and osteoclast, as well as four secondary NOCs, the vascular, hematopoietic, mesenchymal, and neural. Int J Oral Maxillofac Implants 2011;26(suppl):70 79
C1 [Scheller, Erica L.; Krebsbach, Paul H.] Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan
RP Krebsbach, PH (通讯作者)，Univ Michigan, Dept Biol & Mat Sci, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
EM paulk@umich.edu
RI Scheller, Erica/H 6993 2019; Krebsbach, Paul/AAC 4765 2021
OI Scheller, Erica/0000 0002 1551 3816
FU NIDCR NIH HHS [F30 DE019577] Funding Source: Medline
CR Akagawa Y, 2009, J PROSTHODONT RES, V53, P41, DOI 10.1016/j.jpor.2008.08.009
   Akeno N, 2002, ENDOCRINOLOGY, V143, P420, DOI 10.1210/en.143.2.420
   Andreana Sebastiano, 2008, N Y State Dent J, V74, P67
   [Anonymous], 1889, Ann Surg, V10, P352
   Asahina I, 1996, EXP CELL RES, V222, P38, DOI 10.1006/excr.1996.0005
   Bashutski JD, 2010, NEW ENGL J MED, V363, P2396, DOI 10.1056/NEJMoa1005361
   Bodine PVN, 2009, BONE, V44, P1063, DOI 10.1016/j.bone.2009.02.013
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Bouletreau PJ, 2002, PLAST RECONSTR SURG, V109, P2384, DOI 10.1097/00006534 200206000 00033
   CANALIS E, 1980, J CLIN INVEST, V66, P709, DOI 10.1172/JCI109908
   Canalis E, 2009, J CELL BIOCHEM, V108, P769, DOI 10.1002/jcb.22322
   CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Chang PC, 2010, GENE THER, V17, P95, DOI 10.1038/gt.2009.117
   Cooke JW, 2006, TISSUE ENG, V12, P1441, DOI 10.1089/ten.2006.12.1441
   Deal C, 2009, CURR OPIN RHEUMATOL, V21, P380, DOI 10.1097/BOR.0b013e32832cbc2a
   Devin JK, 2008, GROWTH HORM IGF RES, V18, P253, DOI 10.1016/j.ghir.2007.11.001
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Dimitriou Rozalia, 2005, Injury, V36 Suppl 3, pS28, DOI 10.1016/j.injury.2005.07.031
   Edgar CM, 2007, BONE, V40, P1389, DOI 10.1016/j.bone.2007.01.001
   Fintini Danilo, 2009, Ther Clin Risk Manag, V5, P553
   GASTON MS, 2008, J BONE JOINT SURG BR, V90, P365
   GATTI RA, 1968, LANCET, V2, P1366
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   Granero Molto F, 2008, EXPERT OPIN BIOL TH, V8, P255, DOI 10.1517/14712598.8.3.255 
   Henriksen DB, 2007, BONE, V40, P723, DOI 10.1016/j.bone.2006.09.025
   Hotten GC, 1996, GROWTH FACTORS, V13, P65, DOI 10.3109/08977199609034567
   Huang YC, 2005, J BONE MINER RES, V20, P848, DOI 10.1359/JBMR.041226
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Kaigler D, 2006, J DENT RES, V85, P633, DOI 10.1177/154405910608500710
   Kaigler D, 2006, J BONE MINER RES, V21, P735, DOI 10.1359/JBMR.060120
   Kaigler D, 2005, FASEB J, V19, P665, DOI 10.1096/fj.04 2529fje
   Kaigler D, 2003, TISSUE ENG, V9, P95, DOI 10.1089/107632703762687573
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   KAWAI T, 1993, CLIN ORTHOP RELAT R, P296
   Khan SA, 1997, J BONE MINER RES, V12, P1700, DOI 10.1359/jbmr.1997.12.10.1700
   Krech S., 2004, ENCY WORLD ENV HIST, V3
   Kubler NR, 1998, INT J ORAL MAX SURG, V27, P305, DOI 10.1016/S0901 5027(05)80621 6
   Lan J, 2006, J PERIODONTOL, V77, P357, DOI 10.1902/jop.2006.050016
   Levander G., 1938, Surgery Gynecology and Obstetrics, V67, P705
   Li Y, 2008, BIOMATERIALS, V29, P2025, DOI 10.1016/j.biomaterials.2008.01.009
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432 003 0431 0
   Metcalf D, 2007, STEM CELLS, V25, P2390, DOI 10.1634/stemcells.2007 0544
   Mitlak BH, 1996, J BONE MINER RES, V11, P238
   MOCHIZUKI H, 1992, ENDOCRINOLOGY, V131, P1075, DOI 10.1210/en.131.3.1075
   MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297
   Murakami S, 2003, J PERIODONTAL RES, V38, P97, DOI 10.1034/j.1600 0765.2003.00640.x
   Naveiras O, 2009, NATURE, V460, P259, DOI 10.1038/nature08099
   Olney RC, 2003, MED PEDIATR ONCOL, V41, P228, DOI 10.1002/mpo.10342
   Patel MS, 2007, CALCIFIED TISSUE INT, V80, P337, DOI 10.1007/s00223 007 9015 3
   Pettway GJ, 2008, BONE, V42, P806, DOI 10.1016/j.bone.2007.11.017
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   PILCHER E, 2010, HIST DENT IMPLANTS
   Poehling S, 2006, J PERIODONTOL, V77, P1582, DOI 10.1902/jop.2006.050328
   Pounder NM, 2008, ULTRASONICS, V48, P330, DOI 10.1016/j.ultras.2008.02.005
   Raschke M, 2007, EUR J ENDOCRINOL, V156, P341, DOI 10.1530/EJE 06 0598
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Ripa RS, 2006, EUR HEART J, V27, P1785, DOI 10.1093/eurheartj/ehl117
   Romeo E, 2004, INT J ORAL MAX IMPL, V19, P247
   ROSEN V, 1989, CONNECT TISSUE RES, V20, P313, DOI 10.3109/03008208909023902
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   Sasano Y, 1997, ANAT RECORD, V247, P472, DOI 10.1002/(SICI)1097 0185(199704)247:4<472::AID AR5>3.0.CO;2 T
   Sato T, 2010, J PHARMACOL EXP THER, V334, P99, DOI 10.1124/jpet.110.167643
   Scheller EL, 2009, J ORAL REHABIL, V36, P368, DOI 10.1111/j.1365 2842.2009.01939.x
   Scheller EL, 2009, J DENT RES, V88, P585, DOI 10.1177/0022034509337480
   Scheven BAA, 2009, MED HYPOTHESES, V73, P591, DOI 10.1016/j.mehy.2009.05.032
   Schneider A, 2003, J ORTHOP RES, V21, P859, DOI 10.1016/S0736 0266(03)00042 1
   Solmesky LJ, 2009, STEM CELLS DEV, V18, P1283, DOI 10.1089/scd.2009.0020
   Song JH, 2010, BLOOD, V115, P2592, DOI 10.1182/blood 2009 01 200071
   Stanford CM, 2010, INT J MOL SCI, V11, P354, DOI 10.3390/ijms11010354
   Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600 0765.2005.00814.x
   THOMAS DB, 1970, J ANAT, V107, P194
   Tran GT, 2009, EXPERT OPIN INV DRUG, V18, P887, DOI 10.1517/13543780902893069
   TRUETA J, 1963, J BONE JOINT SURG BR, V45, P572, DOI 10.1302/0301 620X.45B3.572
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 80
TC 2
Z9 3
U1 0
U2 9
PU QUINTESSENCE PUBLISHING CO INC
PI HANOVER PARK
PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA
SN 0882 2786
EI 1942 4434
J9 INT J ORAL MAX IMPL
JI Int. J. Oral Maxillofac. Implants
PY 2011
VL 26
SU S
BP 70
EP 79
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 724HD
UT WOS:000287565800008
PM 21465000
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Ye, TT
   Gong, SQ
   Hong, ZP
   Zhou, XS
   Liu, HB
   Qu, HB
   Qian, J
AF Zhang, Yan
   Ye, Tingting
   Gong, Shuqing
   Hong, Zhuping
   Zhou, Xiangshan
   Liu, Haibin
   Qu, Haibin
   Qian, Jing
TI RNA sequencing based bone marrow cell transcriptome analysis reveals the
   potential mechanisms of E'jiao against blood deficiency in mice
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Blood deficiency syndrome; E'jiao; RNA seq; Hematopoiesis; Signaling
   pathway
ID COLLA CORII ASINI; HEMATOPOIETIC STEM CELLS; ANGELICA SINENSIS;
   SELF RENEWAL; MYELOSUPPRESSION; IDENTIFICATION; SIALOPROTEIN;
   METABOLOMICS; PATHWAY; IRX3
AB As a health care food and traditional Chinese medicine, E'jiao, from the skin of Equus animus L, has been used to nourish blood in China for more than 2000 years. In modern medicine, there are also evidences indicate it has a beneficial effect on chemotherapy caused blood deficiency. However, its mechanism of action for blood invigoration remains unclear. In the present study, we investigated the hematopoietic effect of E'jiao in 5 Fluorouracil treated mice. In addition to the counting of bone marrow nucleated cells (BMNCs), flow cytometry was used to detect the population of hematopoietic stem cells (HSCs), and colony forming unit (CFU) was used to assay the differentiation ability of hematopoietic progenitor cells (HPCs). Gene expression profiles of bone marrow cells were obtained from RNA sequencing (RNA seq) and differentially expressed genes (DEGs) were analyzed with an emphasis on hematopoiesis related pathways. The results show that E'jiao promotes the proliferation of both BMNCs and HSCs, as well as the differentiation of HPCs. By providing a hematopoiesis related molecular regulatory network of E'jiao, we point out that the mechanism of E'jiao is associated with pathways including ECM receptor interaction, Wnt signaling pathway, PI3K Akt signaling pathway, TGF beta signaling pathway, Hematopoietic cell lineage and Osteoclast differentiation, in which Ibsp, Col1a1, Col1a2, Notum, Sost, Dkk1, Irx5, Irx3 and Dcn are the key regulatory molecules. These findings provide valuable molecular basis for the mechanism of action of E'jiao.
C1 [Zhang, Yan; Ye, Tingting; Gong, Shuqing; Hong, Zhuping; Qu, Haibin; Qian, Jing] Zhejiang Univ, Coll Pharmaceut Sci, Pharmaceut Informat Inst, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Yan; Zhou, Xiangshan; Liu, Haibin] Dong EE Jiao Co Ltd, Natl Engn Res Ctr Gelatin Based Tradit Chinese Me, Liaocheng, Shandong, Peoples R China.
C3 Zhejiang University
RP Qu, HB; Qian, J (通讯作者)，Zhejiang Univ, Coll Pharmaceut Sci, Pharmaceut Informat Inst, Hangzhou, Zhejiang, Peoples R China.; Liu, HB (通讯作者)，Dong EE Jiao Co Ltd, Natl Engn Res Ctr Gelatin Based Tradit Chinese Me, Liaocheng, Shandong, Peoples R China.
EM liuhaibin@dongeejiao.com; jingqian@zju.edu.cn
RI Liu, Haibin/AGX 9622 2022; QIAN, JING/Q 1447 2017; ye,
   ting/HGC 5924 2022; Qu, Haibin/A 1462 2015
FU project for Taishan Industry Leading Talents [TSCY20180234]; National
   Key Research and Development Program of China [2018YFC1706300]
FX This study was financially supported by the project for Taishan Industry
   Leading Talents (TSCY20180234) and the National Key Research and
   Development Program of China (2018YFC1706300).
CR Aguila HL, 2005, IMMUNOL REV, V208, P7, DOI 10.1111/j.0105 2896.2005.00333.x
   Bai HM, 2015, ONCOTARGET, V6, P25520, DOI 10.18632/oncotarget.4550
   Bouleftour W, 2016, MATRIX BIOL, V52 54, P60, DOI 10.1016/j.matbio.2015.12.011
   Brenet F, 2013, J EXP MED, V210, P623, DOI 10.1084/jem.20121610
   Cabello Verrugio C, 2007, J BIOL CHEM, V282, P18842, DOI 10.1074/jbc.M700243200
   Carey PJ, 2003, DRUG SAFETY, V26, P691, DOI 10.2165/00002018 200326100 00003
   Fleming HE, 2008, CELL STEM CELL, V2, P274, DOI 10.1016/j.stem.2008.01.003
   Gazit R, 2013, STEM CELL REP, V1, P266, DOI 10.1016/j.stemcr.2013.07.004
   Hua YL, 2017, PHARM BIOL, V55, P853, DOI 10.1080/13880209.2017.1281969
   Ji P, 2018, J ETHNOPHARMACOL, V211, P101, DOI 10.1016/j.jep.2017.09.028
   Jiang N, 2016, SCI REP UK, V6, DOI 10.1038/srep36411
   Kakugawa S, 2015, NATURE, V519, P187, DOI 10.1038/nature14259
   Kim SJ, 2003, LEUKEMIA, V17, P1731, DOI 10.1038/sj.leu.2403069
   Kruger TE, 2014, CRIT REV ONCOL HEMAT, V89, P330, DOI 10.1016/j.critrevonc.2013.08.013
   Kuzmac S, 2014, EXP HEMATOL, V42, P966, DOI 10.1016/j.exphem.2014.07.262
   Laurenti E, 2018, NATURE, V553, P418, DOI 10.1038/nature25022
   Leiva O, 2018, AM J HEMATOL, V93, P430, DOI 10.1002/ajh.25008
   Li DY, 2014, DEV CELL, V29, P233, DOI 10.1016/j.devcel.2014.03.001
   Li PL, 2015, J ETHNOPHARMACOL, V166, P261, DOI 10.1016/j.jep.2015.03.010
   Li X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00616
   Li X, 2017, INT J NANOMED, V12, P4443, DOI 10.2147/IJN.S136819
   Liu TT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010055
   Mansour A, 2012, J EXP MED, V209, P537, DOI 10.1084/jem.20110994
   Marinov GK, 2017, BRIEF FUNCT GENOMICS, V16, P326, DOI 10.1093/bfgp/elw043
   Nagalakshmi U., 2010, CURRENT PROTOCOL S89
   Osada M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009062
   Seita J, 2010, WIRES SYST BIOL MED, V2, P640, DOI 10.1002/wsbm.86
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Somerville TDD, 2018, CELL REP, V22, P638, DOI 10.1016/j.celrep.2017.12.063
   Staal FJT, 2008, EUR J IMMUNOL, V38, P1788, DOI 10.1002/eji.200738118
   Staal FJT, 2016, EXP HEMATOL, V44, P451, DOI 10.1016/j.exphem.2016.03.004
   Staal FJT, 2010, J CELL BIOCHEM, V109, P844, DOI 10.1002/jcb.22467
   Wang DL, 2014, DRUG DISCOV THER, V8, P201, DOI 10.5582/ddt.2014.01038
   Wang DL, 2012, BIOL PHARM BULL, V35, P2128, DOI 10.1248/bpb.b12 00238
   Wang SS, 2015, LIFE SCI, V123, P86, DOI 10.1016/j.lfs.2015.01.002
   Wenzhou Zhang H.D., 2013, CHINA MOD MED, V20, P16
   Wu HZ, 2007, AM J CHINESE MED, V35, P853, DOI 10.1142/S0192415X07005326
   Wu HZ, 2016, J ETHNOPHARMACOL, V182, P129, DOI 10.1016/j.jep.2016.02.019
   Yang YL, 2013, J CHROMATOGR A, V1305, P171, DOI 10.1016/j.chroma.2013.07.027
   Zhang H, 2014, J ETHNOPHARMACOL, V154, P818, DOI 10.1016/j.jep.2014.05.008
   Zhang L., 2011, Acta Chin. Med, V26, P309, DOI [10.16368/j.issn.1674 8999.2011.03.018, DOI 10.16368/J.ISSN.1674 8999.2011.03.018]
   Zhang XJ, 2015, DEV CELL, V32, P719, DOI 10.1016/j.devcel.2015.02.014
   Zhang Y, 2019, J ETHNOPHARMACOL, V238, DOI 10.1016/j.jep.2019.111869
   Zhang ZY, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41315 w
NR 44
TC 22
Z9 24
U1 3
U2 54
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2019
VL 118
AR 109291
DI 10.1016/j.biopha.2019.109291
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA IY4WZ
UT WOS:000486395000102
PM 31401395
OA gold
DA 2025 08 17
ER

PT J
AU Jafari, A
   Siersbaek, MS
   Chen, L
   Qanie, D
   Zaher, W
   Abdallah, BM
   Kassem, M
AF Jafari, Abbas
   Siersbaek, Majken S.
   Chen, Li
   Qanie, Diyako
   Zaher, Walid
   Abdallah, Basem M.
   Kassem, Moustapha
TI Pharmacological Inhibition of Protein Kinase G1 Enhances Bone Formation
   by Human Skeletal Stem Cells Through Activation of RhoA Akt Signaling
SO STEM CELLS
LA English
DT Article
DE Human skeletal (mesenchymal) stem cells; Osteoblast differentiation;
   Bone formation; Kinase inhibitor; Akt signaling
ID IN VIVO; OSTEOBLAST DIFFERENTIATION; MARROW ASPIRATE; PHOSPHORYLATION;
   EXPRESSION; REGENERATION; MECHANISMS; ADIPOGENESIS; POPULATION;
   PHENOTYPE
AB Development of novel approaches to enhance bone regeneration is needed for efficient treatment of bone defects. Protein kinases play a key role in regulation of intracellular signal transduction pathways, and pharmacological targeting of protein kinases has led to development of novel treatments for several malignant and nonmalignant conditions. We screened a library of kinase inhibitors to identify small molecules that enhance bone formation by human skeletal (stromal or mesenchymal) stem cells (hMSC). We identified H 8 (known to inhibit protein kinases A, C, and G) as a potent enhancer of ex vivo osteoblast (OB) differentiation of hMSC, in a stage  and cell type specific manner, without affecting adipogenesis or osteoclastogenesis. Furthermore, we showed that systemic administration of H 8 enhances in vivo bone formation by hMSC, using a preclinical ectopic bone formation model in mice. Using functional screening of known H 8 targets, we demonstrated that inhibition of protein kinase G1 (PRKG1) and consequent activation of RhoA Akt signaling is the main mechanism through which H 8 enhances osteogenesis. Our studies revealed PRKG1 as a novel negative regulator of OB differentiation and suggest that pharmacological inhibition of PRKG1 in hMSC implanted at the site of bone defect can enhance bone regeneration. Stem Cells 2015;33:2219 2231
C1 [Jafari, Abbas; Siersbaek, Majken S.; Chen, Li; Qanie, Diyako; Zaher, Walid; Abdallah, Basem M.; Kassem, Moustapha] Odense Univ Hosp, Dept Endocrinol & Metab, Endocrine Res Lab KMEB, DK 5000 Odense C, Denmark.
   [Jafari, Abbas; Siersbaek, Majken S.; Chen, Li; Qanie, Diyako; Zaher, Walid; Abdallah, Basem M.; Kassem, Moustapha] Univ Southern Denmark, Dept Endocrinol, Lab Mol Endocrinol KMEB, DK 5000 Odense C, Denmark.
   [Jafari, Abbas; Siersbaek, Majken S.; Kassem, Moustapha] Univ Copenhagen, Inst Cellular & Mol Med, Danish Stem Cell Ctr DanStem, Copenhagen, Denmark.
C3 University of Southern Denmark; Odense University Hospital; University
   of Southern Denmark; University of Copenhagen
RP Kassem, M (通讯作者)，Univ Southern Denmark, Dept Endocrinol, Lab Mol Endocrinol KMEB, JB Winsloesvej 25,1st Floor, DK 5000 Odense C, Denmark.
EM mkassem@health.sdu.dk
RI Siersbaek, Majken/NGR 8928 2025; Jafari, Abbas/AAF 6256 2019; Jafari
   Kermani, Abbas/I 5074 2015; Abdallah, Basem/G 5667 2017; Chen,
   Li/AAN 7309 2020; Kassem, Moustapha/J 7688 2013
OI Jafari Kermani, Abbas/0000 0003 2443 6231; Siersbaek,
   Majken/0000 0003 1030 182X; Abdallah, Basem/0000 0003 0324 8055; Kassem,
   Moustapha/0000 0003 1557 0869; Chen, Li/0000 0001 5561 7612
FU University of Southern Denmark; local government of Southern Denmark
   [SDU647 68]; NovoNordisk foundation's exploratory pre seed grant
   [1015746]; Lundbeck foundation; Danish Arthritis association
   (Gigtforeningen) [A1562]; Simon Fougner Hartmanns family foundation;
   Novo Nordisk Fonden [NNF14OC0010309, NNF15CC0018344] Funding Source:
   researchfish
FX We thank Dr. Henrik Daa Shroder (Department of Pathology, University of
   Southern Denmark) for help with histopathological analysis of mouse
   kidneys, Dr. Charles Frary for establishing hpMSC cultures, Dr. Stephen
   Cohen, and Dr. Hung Thanh Nguyen (University of Copenhagen) for helpful
   discussions, and Lone Christiansen for excellent technical assistance.
   The work was supported by a grant from University of Southern Denmark
   and local government of Southern Denmark (project SDU647 68),
   NovoNordisk foundation's exploratory pre seed grant (project 1015746),
   Lundbeck foundation, Danish Arthritis association (Gigtforeningen,
   project A1562), and Simon Fougner Hartmanns family foundation.
CR Abdallah Basem M., 2008, V455, P89, DOI 10.1007/978 1 59745 104 8_6
   Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059
   Akritopoulou Zanze I, 2006, IDRUGS, V9, P481
   Andersen MO, 2010, MOL THER, V18, P2018, DOI 10.1038/mt.2010.166
   BELLOWS CG, 1990, DEV BIOL, V140, P132, DOI 10.1016/0012 1606(90)90060 V
   Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006 2952(92)90148 C
   Cohen P, 2000, TRENDS BIOCHEM SCI, V25, P596, DOI 10.1016/S0968 0004(00)01712 6
   Dawson JI, 2014, STEM CELLS, V32, P35, DOI 10.1002/stem.1559
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Grant S, 2009, CELL MOL LIFE SCI, V66, P1163, DOI 10.1007/s00018 008 8539 7
   Gupta DM, 2008, J CRANIOFAC SURG, V19, P192, DOI 10.1097/scs.0b013e31815c93b7
   Hamamura K, 2012, CONNECT TISSUE RES, V53, P398, DOI 10.3109/03008207.2012.671398
   Harkness L, 2011, BONE, V48, P231, DOI 10.1016/j.bone.2010.09.023
   Harmey D, 2004, J BONE MINER RES, V19, P661, DOI 10.1359/JBMR.040105
   Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592 6602.2005
   Janicki P, 2010, ACTA BIOMATER, V6, P3292, DOI 10.1016/j.actbio.2010.01.037
   Jia J, 2009, NAT REV DRUG DISCOV, V8, P111, DOI 10.1038/nrd2683
   Ortuño MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612
   Kaipel M, 2012, J ORTHOP RES, V30, P1563, DOI 10.1002/jor.22132
   Kassem M, 2011, AGING CELL, V10, P191, DOI 10.1111/j.1474 9726.2011.00669.x
   Kato M, 2012, J BIOL CHEM, V287, P41342, DOI 10.1074/jbc.M112.421040
   Khatiwala CB, 2009, J BONE MINER RES, V24, P886, DOI [10.1359/jbmr.081240, 10.1359/JBMR.081240]
   Larsen KH, 2010, J BONE MINER RES, V25, P796, DOI 10.1359/jbmr.091018
   Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341
   Liu LY, 2010, BIOMECH MODEL MECHAN, V9, P659, DOI 10.1007/s10237 010 0206 x
   Luo ZR, 2010, PANMINERVA MED, V52, P1
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Meyers VE, 2005, J BONE MINER RES, V20, P1858, DOI 10.1359/JBMR.050611
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Neen D, 2006, SPINE, V31, pE636, DOI 10.1097/01.brs.0000232028.97590.12
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Ploumis A, 2010, J NEUROSURG SPINE, V13, P211, DOI 10.3171/2010.3.SPINE09603
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Qiu WM, 2010, J BIOL CHEM, V285, P14438, DOI 10.1074/jbc.M109.052001
   Sachsenmaier C, 2001, ONKOLOGIE, V24, P346, DOI 10.1159/000055106
   Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200
   Sawada N, 2009, MOL CELL BIOL, V29, P6018, DOI 10.1128/MCB.00225 09
   Schmeisser MJ, 2012, J NEUROSCI, V32, P5688, DOI 10.1523/JNEUROSCI.0111 12.2012
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Suire C, 2012, BLOOD, V119, pE86, DOI 10.1182/blood 2011 08 372334
   Sundaramoorthi R, 2003, BIOORG MED CHEM LETT, V13, P3063, DOI 10.1016/S0960 894X(03)00647 4
   Ubersax JA, 2007, NAT REV MOL CELL BIO, V8, P530, DOI 10.1038/nrm2203
   van Beuge MM, 2012, EXPERT OPIN DRUG DEL, V9, P59, DOI 10.1517/17425247.2012.638625
   Via MC, 2011, INSIGHT PHARMA REPOR
   Wang CY, 2013, J BONE MINER METAB, V31, P381, DOI 10.1007/s00774 013 0428 y
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200
   Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559
NR 55
TC 19
Z9 20
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD JUL
PY 2015
VL 33
IS 7
BP 2219
EP 2231
DI 10.1002/stem.2013
PG 13
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA CL0YE
UT WOS:000356668200013
PM 25858613
OA Bronze
DA 2025 08 17
ER

PT J
AU Nakasa, T
   Yoshizuka, M
   Usman, MA
   Mahmoud, EE
   Ochi, M
AF Nakasa, Tomoyuki
   Yoshizuka, Masaaki
   Usman, Muhammad Andry
   Mahmoud, Elhussein Elbadry
   Ochi, Mitsuo
TI MicroRNAs and Bone Regeneration
SO CURRENT GENOMICS
LA English
DT Article
DE Bone; Osteoblast; microRNA; Transcription factor; Signaling pathway
ID MESENCHYMAL STEM CELLS; PROMOTES OSTEOBLAST DIFFERENTIATION; REGULATES
   OSTEOGENIC DIFFERENTIATION; HUMAN ADIPOSE TISSUE; OSTEOCLAST
   DIFFERENTIATION; TRANSCRIPTION FACTOR; OSTEOPOROTIC FRACTURE; LINEAGE
   PROGRESSION; POSITIVE REGULATION; CALVARIAL DEFECTS
AB Bone has multiple functions, both morphologically and physiologically, and it frequently features in the pathological condition, including fracture and osteoporosis. For bone regeneration therapy, the regulation of osteoblast differentiation is important. MicroRNA (miRNA)s are short noncoding RNA which regulate gene expression at the post transcriptional level. MiRNAs play an important role not only in a variety of other cellular processes including differentiation, proliferation, and apoptosis but also in the pathogenesis of human diseases. Recently, miRNAs have been known to participate in osteoblast differentiation by regulating several signaling pathways including transcription factors. New insight into the mechanism during osteogenes is affected by miRNAs has been gained. Moreover, therapeutic trials for bone diseases including osteoporosis, fracture and bone defects targeting miRNAs have been examined in animal models. MiRNA therapy will enable development of a bone regeneration therapy.
C1 [Nakasa, Tomoyuki; Yoshizuka, Masaaki; Usman, Muhammad Andry; Mahmoud, Elhussein Elbadry; Ochi, Mitsuo] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Orthopaed Surg, Integrated Hlth Sci,Minami Ku, Hiroshima 7348551, Japan.
C3 Hiroshima University
RP Nakasa, T (通讯作者)，Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Orthopaed Surg, Integrated Hlth Sci,Minami Ku, 1 2 3 Kasumi, Hiroshima 7348551, Japan.
EM tnakasa0@gmail.com
RI Mahmoud, Elhussein/AAH 5876 2019
FU Grants in Aid for Scientific Research [25253089] Funding Source: KAKEN
CR Aguda BD, 2008, P NATL ACAD SCI USA, V105, P19678, DOI 10.1073/pnas.0811166106
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   [Anonymous], ANN REV CELL DEV BIO
   [Anonymous], 2005, ANN REV CELL DEV BIO
   Arvidson K, 2011, J CELL MOL MED, V15, P718, DOI 10.1111/j.1582 4934.2010.01224.x
   Bae YJ, 2012, HUM MOL GENET, V21, P2991, DOI 10.1093/hmg/dds129
   Bakhshandeh B, 2012, MOL BIOL REP, V39, P7569, DOI 10.1007/s11033 012 1591 2
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Bliuc D, 2009, JAMA J AM MED ASSOC, V301, P513, DOI 10.1001/jama.2009.50
   Bliuc D, 2013, J BONE MINER RES, V28, P2317, DOI 10.1002/jbmr.1968
   Borchert GM, 2006, NAT STRUCT MOL BIOL, V13, P1097, DOI 10.1038/nsmb1167
   Bueno EM, 2009, NAT REV RHEUMATOL, V5, P685, DOI 10.1038/nrrheum.2009.228
   Canalis E, 2013, ENDOCRINOLOGY, V154, P623, DOI 10.1210/en.2012 1732
   Cao Z., 2014, PLOS ONE, V9
   Cho HH, 2010, J CELL PHYSIOL, V223, P168, DOI 10.1002/jcp.22024
   Cui L, 2007, BIOMATERIALS, V28, P5477, DOI 10.1016/j.biomaterials.2007.08.042
   De Santis G, 2010, J NEUROIMMUNOL, V226, P165, DOI 10.1016/j.jneuroim.2010.06.009
   Deng Y, 2014, INVEST OPHTH VIS SCI, V55, P6016, DOI 10.1167/iovs.14 14977
   Deng Y, 2014, EUR CELLS MATER, V27, P13, DOI 10.22203/eCM.v027a02
   Deng Y, 2013, BIOMATERIALS, V34, P6717, DOI 10.1016/j.biomaterials.2013.05.042
   Duan ZF, 2011, MOL CANCER THER, V10, P1337, DOI 10.1158/1535 7163.MCT 11 0096
   Egea V, 2012, P NATL ACAD SCI USA, V109, pE309, DOI 10.1073/pnas.1115083109
   Esbrit P, 2013, BIOCHEM PHARMACOL, V85, P1417, DOI 10.1016/j.bcp.2013.03.002
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Evans CH, 2012, J CELL PHYSIOL, V227, P416, DOI 10.1002/jcp.23031
   Gao J, 2011, J CELL BIOCHEM, V112, P1844, DOI 10.1002/jcb.23106
   Gordeladze JO, 2010, ILAR J, V51, P42, DOI 10.1093/ilar.51.1.42
   Gordeladze JO, 2009, ACTA PHARMACOL SIN, V30, P1369, DOI 10.1038/aps.2009.143
   Guo JW, 2012, J BONE MINER RES, V27, P1607, DOI 10.1002/jbmr.1597
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hassan MQ, 2012, J BIOL CHEM, V287, P42084, DOI 10.1074/jbc.M112.377515
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Hu R, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176099
   Hu WH, 2013, MOL MED REP, V7, P689, DOI 10.3892/mmr.2012.1207
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   Itoh T, 2012, FEBS LETT, V586, P1693, DOI 10.1016/j.febslet.2012.04.014
   Itoh T, 2010, J BIOL CHEM, V285, P27745, DOI 10.1074/jbc.M110.105080
   Itoh T, 2009, J BIOL CHEM, V284, P19272, DOI 10.1074/jbc.M109.014001
   James EN, 2014, ACTA BIOMATER, V10, P3571, DOI 10.1016/j.actbio.2014.04.026
   Janssen HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMoa1209026
   Jensen ED, 2010, BIOFACTORS, V36, P25, DOI 10.1002/biof.72
   Jin Z., 2014, MOL ENDOCRINOL, V30
   Kahai S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007535
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Kapinas K, 2009, J CELL BIOCHEM, V108, P216, DOI 10.1002/jcb.22243
   Kawaguchi H, 2010, J BONE MINER RES, V25, P2459, DOI 10.1002/jbmr.146
   Kim EJ, 2013, LIFE SCI, V92, P562, DOI 10.1016/j.lfs.2013.01.015
   Kim KM, 2012, J BONE MINER RES, V27, P1669, DOI 10.1002/jbmr.1604
   Kim SE, 2012, J MATER SCI MATER M, V23, P2739, DOI 10.1007/s10856 012 4729 9
   Kneser U, 2006, J CELL MOL MED, V10, P7, DOI 10.1111/j.1582 4934.2006.tb00287.x
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Kooijmans SAA, 2012, INT J NANOMED, V7, P1525, DOI 10.2147/IJN.S29661
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Laine SK, 2012, J CELL BIOCHEM, V113, P2687, DOI 10.1002/jcb.24144
   Leboy PS, 2006, ANN NY ACAD SCI, V1068, P14, DOI 10.1196/annals.1346.003
   Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Li Y, 2013, BIOMATERIALS, V34, P5048, DOI 10.1016/j.biomaterials.2013.03.052
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Lisse TS, 2013, J BONE MINER RES, V28, P1478, DOI 10.1002/jbmr.1882
   Liu H, 2013, J BIOL CHEM, V288, P9261, DOI 10.1074/jbc.M112.433730
   Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011
   Mizuno Y, 2008, BIOCHEM BIOPH RES CO, V368, P267, DOI 10.1016/j.bbrc.2008.01.073
   Mizuno Y, 2009, FEBS LETT, V583, P2263, DOI 10.1016/j.febslet.2009.06.006
   Mukozawa A, 2011, CLIN ORAL IMPLAN RES, V22, P1327, DOI 10.1111/j.1600 0501.2010.02135.x
   Murata K, 2014, J BONE MINER RES, V29, P316, DOI 10.1002/jbmr.2040
   Nakasa T, 2008, ARTHRITIS RHEUM US, V58, P1284, DOI 10.1002/art.23429
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Qureshi AT, 2015, ACTA BIOMATER, V12, P166, DOI 10.1016/j.actbio.2014.10.010
   Raouf A, 2000, ONCOGENE, V19, P6455, DOI 10.1038/sj.onc.1204037
   Samorezov JE, 2015, ADV DRUG DELIVER REV, V84, P45, DOI 10.1016/j.addr.2014.11.018
   Saran U, 2014, ARCH BIOCHEM BIOPHYS, V561, P109, DOI 10.1016/j.abb.2014.07.006
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   Shegarfi Hamid, 2009, J Orthop Surg (Hong Kong), V17, P206
   Shi CG, 2014, BONE, V68, P67, DOI 10.1016/j.bone.2014.08.004
   Shimbo K, 2014, BIOCHEM BIOPH RES CO, V445, P381, DOI 10.1016/j.bbrc.2014.02.007
   Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104
   Tortelli F, 2009, TISSUE ENG PT A, V15, P2373, DOI 10.1089/ten.tea.2008.0501
   Townley Tilson WHD, 2010, INT J BIOCHEM CELL B, V42, P1252, DOI 10.1016/j.biocel.2009.03.002
   Tsai KW, 2010, GENE CHROMOSOME CANC, V49, P969, DOI 10.1002/gcc.20804
   Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534 5807(03)00266 1
   Wang T, 2010, BIOCHEM BIOPH RES CO, V402, P186, DOI 10.1016/j.bbrc.2010.08.031
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034641
   Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057
   Wu TT, 2012, J BIOL CHEM, V287, P7503, DOI 10.1074/jbc.M111.292722
   Yan J, 2014, BIOMATERIALS, V35, P7734, DOI 10.1016/j.biomaterials.2014.05.089
   Yang L, 2012, J BONE MINER RES, V27, P1598, DOI 10.1002/jbmr.1621
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
   You L, 2014, INT J CLIN EXP PATHO, V7, P7249
   Yu FC, 2011, BIOSCI TRENDS, V5, P46, DOI 10.5582/bst.2011.v5.2.46
   Zeng Y, 2012, FEBS LETT, V586, P2375, DOI 10.1016/j.febslet.2012.05.049
   Zhang J, 2011, J BONE MINER RES, V26, P1953, DOI 10.1002/jbmr.377
   Zhang JF, 2011, RNA BIOL, V8, P829, DOI 10.4161/rna.8.5.16043
   Zhang JF, 2011, MOL BIOL CELL, V22, P3955, DOI 10.1091/mbc.E11 04 0356
   Zhang Y, 2012, J BIOL CHEM, V287, P21926, DOI 10.1074/jbc.M112.340398
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
   Zuo B, 2015, J BONE MINER RES, V30, P330, DOI 10.1002/jbmr.2352
NR 102
TC 38
Z9 39
U1 0
U2 39
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389 2029
EI 1875 5488
J9 CURR GENOMICS
JI Curr. Genomics
PY 2015
VL 16
IS 6
BP 441
EP 452
DI 10.2174/1389202916666150817213630
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CS2EJ
UT WOS:000361880300010
PM 27019619
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Shao, Y
   Wichern, E
   Childress, PJ
   Adaway, M
   Misra, J
   Klunk, A
   Burr, DB
   Wek, RC
   Mosley, AL
   Liu, YL
   Robling, AG
   Brustovetsky, N
   Hamilton, J
   Jacobs, K
   Vashishth, D
   Stayrook, KR
   Allen, MR
   Wallace, JM
   Bidwell, JP
AF Shao, Yu
   Wichern, Emily
   Childress, Paul J.
   Adaway, Michele
   Misra, Jagannath
   Klunk, Angela
   Burr, David B.
   Wek, Ronald C.
   Mosley, Amber L.
   Liu, Yunlong
   Robling, Alexander G.
   Brustovetsky, Nickolay
   Hamilton, James
   Jacobs, Kylie
   Vashishth, Deepak
   Stayrook, Keith R.
   Allen, Matthew R.
   Wallace, Joseph M.
   Bidwell, Joseph P.
TI Loss of Nmp4 optimizes osteogenic metabolism and secretion to
   enhance bone quality
SO AMERICAN JOURNAL OF PHYSIOLOGY ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE bone biomechanics; metabolism; osteoporosis; parathyroid hormone;
   transcriptome
ID UNFOLDED PROTEIN RESPONSE; LEUCINE RICH PROTEOGLYCANS; MESENCHYMAL
   STEM CELLS; ENDOPLASMIC RETICULUM STRESS; PARATHYROID HORMONE;
   OSTEOBLAST DIFFERENTIATION; SKELETAL MINERALIZATION;
   ALKALINE PHOSPHATASE; SIGNALING PATHWAYS; ANABOLIC AGENTS
AB A goal of osteoporosis therapy is to restore lost bone with structurally sound tissue. Mice lacking the transcription factor nuclear matrix protein 4 (Nmp4, Zfp384, Ciz, ZNF384) respond to several classes of osteoporosis drugs with enhanced bone formation compared with wild type (WT) animals. Nmp4( / ) mesenchymal stem/progenitor cells (MSPCs) exhibit an accelerated and enhanced mineralization during osteoblast differentiation. To address the mechanisms underlying this hyperanabolic phenotype. we carried out RNA sequencing and molecular and cellular analyses of WT and Nmp4( / ) MSPCs during osteogenesis to define pathways and mechanisms associated with elevated matrix production. We determined that Nmp4 has a broad impact on the transcriptome during osteogenic differentiation, contributing to the expression of over 5,000 genes. Phenotypic anchoring of transcriptional data was performed for the hypothesis testing arm through analysis of cell metabolism, protein synthesis and secretion, and bone material properties. Mechanistic studies confirmed that Nmp4( / ) MSPCs exhibited an enhanced capacity for glycolytic conversion: a key step in bone anabolism. Nmp4( / )   cells showed elevated collagen translation and secretion. The expression of matrix genes that contribute to bone material level mechanical properties was elevated in Nmp4( / ) cells, an observation that was supported by biomechanical testing of bone samples from Nmp4( / ) and WT mice. We conclude that loss of Nmp4 increases the magnitude of glycolysis upon the metabolic switch, which fuels the conversion of the osteoblast into a super secretor of matrix resulting in more bone with improvements in intrinsic quality.
C1 [Shao, Yu; Liu, Yunlong; Bidwell, Joseph P.] Indiana Univ, Dept Med & Mol Genet, Sch Med, Indiana, PA 46202 USA.
   [Wichern, Emily; Adaway, Michele; Klunk, Angela; Burr, David B.; Robling, Alexander G.; Allen, Matthew R.; Bidwell, Joseph P.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Med Sci Bldg 5035,635 Barnhill Dr, Indianapolis, IN 46202 USA.
   [Childress, Paul J.; Wallace, Joseph M.] Indiana Univ, Dept Orthopaed Surg, Sch Med, Indiana, PA 46202 USA.
   [Childress, Paul J.; Burr, David B.; Robling, Alexander G.; Allen, Matthew R.; Wallace, Joseph M.; Bidwell, Joseph P.] Indiana Univ, Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.
   [Misra, Jagannath; Wek, Ronald C.; Mosley, Amber L.] Indiana Univ, Dept Biochem & Mol Biol, Sch Med, Indiana, PA 46202 USA.
   [Burr, David B.; Wallace, Joseph M.] Indiana Univ Purdue Univ, Dept Biomed Engn, Indiana, PA USA.
   [Brustovetsky, Nickolay; Hamilton, James] Indiana Univ, Dept Pharmacol & Toxicol, Sch Med, Indianapolis, IN 46202 USA.
   [Jacobs, Kylie] Indiana Univ, Dept Microbiol & Immunol, Sch Med, Indianapolis, IN 46202 USA.
   [Vashishth, Deepak] Rensselaer Polytech Inst, Ctr Biotechnol & Interdisciplinary Studies, Troy, NY USA.
   [Vashishth, Deepak] Rensselaer Polytech Inst, Dept Biomed Engn, Troy, NY USA.
   [Stayrook, Keith R.] Eli Lilly & Co, Lilly Res Labs, Indiana, PA USA.
   [Allen, Matthew R.] Roudebush Vet Athninistrat Med Ctr, Indianapolis, IN USA.
C3 Pennsylvania State System of Higher Education (PASSHE); Indiana
   University of Pennsylvania; Indiana University System; Indiana
   University Indianapolis; Pennsylvania State System of Higher Education
   (PASSHE); Indiana University of Pennsylvania; Indiana University System;
   Indiana University Indianapolis; Pennsylvania State System of Higher
   Education (PASSHE); Indiana University of Pennsylvania; Indiana
   University System; Indiana University Indianapolis; Indiana University
   System; Indiana University Indianapolis; Indiana University System;
   Indiana University Indianapolis; Rensselaer Polytechnic Institute;
   Rensselaer Polytechnic Institute; Eli Lilly; Lilly Research
   Laboratories; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Richard L. Roudebush VA Medical Center
RP Bidwell, JP (通讯作者)，Indiana Univ, Sch Med, Dept Anat & Cell Biol, Med Sci Bldg 5035,635 Barnhill Dr, Indianapolis, IN 46202 USA.
EM jbidwell@iupui.edu
RI Childress, Paul/AAD 4684 2020; Misra, Jagannath/AAW 8774 2021; Wallace,
   Joseph/G 7906 2012; Allen, Matthew/A 8799 2015
OI Misra, Jagannath/0000 0001 9713 0298; Zielinski,
   Emily/0000 0002 0420 0718; Wallace, Joseph/0000 0001 6077 8058; Mosley,
   Amber/0000 0001 5822 2894; Vashishth, Deepak/0000 0001 5712 0167
FU Department of Defense [PR120563]; NIH [AR 067221, AR 062002, GM 049164,
   AR 053237, NS 098772, AR073739]; Indiana University School of Medicine
   Clinical and Translational Science Institute Biomedical Research Grant
FX This work was supported, in whole or in part, by Department of Defense
   Grant PR120563, NIH Grant AR073739 and Indiana University School of
   Medicine Clinical and Translational Science Institute Biomedical
   Research Grant (to J. P. Bidwell), and NIH Grants AR 067221 (to J. M.
   Wallace), AR 062002 (to M. R. Allen), GM 049164 (to R. C. Wek),
   AR 053237 (to A. G. Robling), and NS 098772 (to N. Brustovetsky).
CR Alford AI, 2010, BONE, V46, P464, DOI 10.1016/j.bone.2009.08.058
   [Anonymous], duction to the practice of statistics
   Baird TD, 2014, MOL BIOL CELL, V25, P1686, DOI 10.1091/mbc.E14 02 0704
   Bandeira L, 2017, EXPERT OPIN BIOL TH, V17, P255, DOI 10.1080/14712598.2017.1280455
   Bart ZR, 2014, CONNECT TISSUE RES, V55, P4, DOI 10.3109/03008207.2014.923860
   BELLOWS CG, 1991, BONE MINER, V14, P27, DOI 10.1016/0169 6009(91)90100 E
   Boskey Adele L, 2013, Bonekey Rep, V2, P447, DOI 10.1038/bonekey.2013.181
   Boudin E, 2013, SEMIN ARTHRITIS RHEU, V43, P220, DOI 10.1016/j.semarthrit.2013.01.004
   Buckwalter JA, 1996, AAOS INSTR COURS LEC, V45, P371
   Canalis E, 2014, J CELL PHYSIOL, V229, P1736, DOI 10.1002/jcp.24625
   CARTER D R, 1990, Journal of Bone and Mineral Research, V5, pS177
   Charoenpanich A, 2011, TISSUE ENG PT A, V17, P2615, DOI 10.1089/ten.tea.2011.0107
   Chen SJ, 2013, FEBS J, V280, P2120, DOI 10.1111/febs.12136
   Chevalier Y, 2010, BONE, V46, P41, DOI 10.1016/j.bone.2009.09.032
   Chiellini C, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471 2199 9 26
   Childress P, 2015, MOL ENDOCRINOL, V29, P1269, DOI 10.1210/me.2014 1406
   Childress P, 2011, CALCIFIED TISSUE INT, V89, P74, DOI 10.1007/s00223 011 9496 y
   Choi YA, 2010, J PROTEOME RES, V9, P2946, DOI 10.1021/pr901110q
   Cipriani C, 2013, J BONE MINER RES, V28, P431, DOI 10.1002/jbmr.1837
   Currey JD, 1998, P I MECH ENG H, V212, P399, DOI 10.1243/0954411981534178
   Dalton LE, 2012, PROG MOL BIOL TRANSL, V106, P189, DOI 10.1016/B978 0 12 396456 4.00003 1
   Dede AD, 2017, EXPERT OPIN INV DRUG, V26, P1137, DOI 10.1080/13543784.2017.1371136
   Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264 6021:3500219
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Doultsinos D, 2017, SLAS DISCOV, V22, P787, DOI 10.1177/2472555217701685
   Dufey E, 2014, AM J PHYSIOL CELL PH, V307, pC582, DOI 10.1152/ajpcell.00258.2014
   Eriksen EF, 2016, BONE, V86, P139, DOI 10.1016/j.bone.2016.02.009
   Esen E, 2015, J BONE MINER RES, V30, P1959, DOI 10.1002/jbmr.2556
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Fox J, 2007, J BONE MINER RES, V22, P260, DOI 10.1359/JBMR.061101
   Gallacher SJ, 2010, CALCIFIED TISSUE INT, V87, P469, DOI 10.1007/s00223 010 9420 x
   Gamsjaeger S, 2011, BONE, V49, P1160, DOI 10.1016/j.bone.2011.08.015
   Garcia Cao I, 2012, CELL, V149, P49, DOI 10.1016/j.cell.2012.02.030
   Guntur AR, 2018, J BONE MINER RES, V33, P1052, DOI 10.1002/jbmr.3390
   Guntur AR, 2011, DEVELOPMENT, V138, P1433, DOI 10.1242/dev.058016
   Hamamura K, 2013, J BONE MINER METAB, V31, P618, DOI 10.1007/s00774 013 0450 0
   Han HS, 2018, J CELL BIOCHEM, V119, P3220, DOI 10.1002/jcb.26478
   Hann SR, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014399
   Hawkins KE, 2016, CELL REP, V14, P1883, DOI 10.1016/j.celrep.2016.02.003
   He L, 2013, CELL SIGNAL, V25, P552, DOI 10.1016/j.cellsig.2012.11.015
   He YZ, 2013, STEM CELLS DEV, V22, P492, DOI 10.1089/scd.2012.0308
   Hopkins A, 2016, J CELL BIOCHEM, V117, P1707, DOI 10.1002/jcb.25464
   Huesa C, 2011, BONE, V48, P1066, DOI 10.1016/j.bone.2011.01.010
   Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379 1389.2003
   Ji HK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026057
   Jilka RL, 2009, J BONE MINER RES, V24, P575, DOI [10.1359/JBMR.090228, 10.1359/jbmr.090228]
   Kalamajski S, 2010, MATRIX BIOL, V29, P248, DOI 10.1016/j.matbio.2010.01.001
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Karner CM, 2015, J CLIN INVEST, V125, P551, DOI 10.1172/JCI78470
   Kress TR, 2015, NAT REV CANCER, V15, P593, DOI 10.1038/nrc3984
   Kristensen LP, 2012, MOL CELL PROTEOMICS, V11, P989, DOI 10.1074/mcp.M111.012138
   Leder BZ, 2017, CURR OSTEOPOROS REP, V15, P110, DOI 10.1007/s11914 017 0353 4
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Li J, 2017, BONE, V97, P2, DOI 10.1016/j.bone.2016.12.009
   Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200
   Li QQ, 2017, PROTEIN CELL, V8, P439, DOI 10.1007/s13238 017 0385 7
   Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Lindsay R, 2016, OSTEOPOROSIS INT, V27, P2395, DOI 10.1007/s00198 016 3534 6
   Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104
   Lovato C, 2017, EXPERT OPIN EMERG DR, V22, P247, DOI 10.1080/14728214.2017.1362389
   Luppen CA, 2003, J BIOL CHEM, V278, P44995, DOI 10.1074/jbc.M306730200
   Ma YFL, 2003, ENDOCRINOLOGY, V144, P2008, DOI 10.1210/en.2002 221061
   Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378 1119(02)01106 X
   McBride Sarah H, 2012, Bonekey Osteovision, V1
   Meury T, 2010, MOL CELL BIOL, V30, P43, DOI 10.1128/MCB.00378 09
   Millán JL, 2013, CALCIFIED TISSUE INT, V93, P299, DOI 10.1007/s00223 012 9672 8
   Morgan S, 2015, CALCIFIED TISSUE INT, V97, P281, DOI 10.1007/s00223 015 0016 3
   Morinobu M, 2005, J EXP MED, V201, P961, DOI 10.1084/jem.20041097
   Morita M, 2015, CELL CYCLE, V14, P473, DOI 10.4161/15384101.2014.991572
   Ng F, 2008, BLOOD, V112, P295, DOI 10.1182/blood 2007 07 103697
   Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033
   Nifuji A, 2010, EXP CELL RES, V316, P1127, DOI 10.1016/j.yexcr.2010.01.023
   Nikel O, 2013, LANGMUIR, V29, P13873, DOI 10.1021/la403203w
   Nikitovic D, 2012, J BIOL CHEM, V287, P33926, DOI 10.1074/jbc.R112.379602
   Ortega Molina A, 2013, TRENDS ENDOCRIN MET, V24, P184, DOI 10.1016/j.tem.2012.11.002
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Palomäki S, 2013, STEM CELLS, V31, P1902, DOI 10.1002/stem.1435
   Pandey AC, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt90
   Pattappa G, 2011, J CELL PHYSIOL, V226, P2562, DOI 10.1002/jcp.22605
   Pellegrini GG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171161
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Poundarik AA, 2012, P NATL ACAD SCI USA, V109, P19178, DOI 10.1073/pnas.1201513109
   Regan JN, 2014, P NATL ACAD SCI USA, V111, P8673, DOI 10.1073/pnas.1324290111
   RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203
   Rivas A, 2015, EXPERT OPIN THER TAR, V19, P1203, DOI 10.1517/14728222.2015.1053869
   Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb 2010 11 3 r25
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Robling AG, 2009, J CELL PHYSIOL, V219, P734, DOI 10.1002/jcp.21717
   Romero IG, 2014, BMC BIOL, V12, DOI 10.1186/1741 7007 12 42
   Rozpedek W, 2015, CURR MED CHEM, V22, P3169, DOI 10.2174/0929867322666150818104254
   Sánchez Riera L, 2017, BEST PRACT RES CL RH, V31, P169, DOI 10.1016/j.berh.2017.10.001
   Schmidt K, 2005, J CELL BIOL, V168, P899, DOI 10.1083/jcb.200408013
   Shah AD, 2015, INT J WOMENS HEALTH, V7, P565, DOI 10.2147/IJWH.S73244
   Shao Y, 2017, ENDOCRINOLOGY, V158, P2722, DOI 10.1210/en.2017 00355
   Shum LC, 2016, STEM CELLS DEV, V25, P114, DOI 10.1089/scd.2015.0193
   Shyh Chang N, 2017, GENE DEV, V31, P336, DOI 10.1101/gad.293167.116
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   SOGAARD CH, 1994, BONE, V15, P393, DOI 10.1016/8756 3282(94)90815 X
   Sroga GE, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.006718
   Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898
   Tan Z, 2015, J BIOL CHEM, V290, P46, DOI 10.1074/jbc.M114.603589
   Teske BF, 2011, METHOD ENZYMOL, V490, P333, DOI 10.1016/B978 0 12 385114 7.00019 2
   Valenzuela V, 2016, BRAIN RES, V1648, P561, DOI 10.1016/j.brainres.2016.04.064
   Wang XM, 2006, PHYSIOLOGY, V21, P362, DOI 10.1152/physiol.00024.2006
   Wei JW, 2015, CELL, V162, P1169, DOI 10.1016/j.cell.2015.08.018
   Wickham H, 2009, USE R, P1, DOI 10.1007/978 0 387 98141 3
   Wolf E, 2015, TRENDS CELL BIOL, V25, P241, DOI 10.1016/j.tcb.2014.10.006
   Wu XH, 2006, HUM MOL GENET, V15, P2837, DOI 10.1093/hmg/ddl208
   Xi G, 2014, J BONE MINER RES, V29, P2427, DOI 10.1002/jbmr.2282
   Xiao Liping, 2018, Bone Rep, V9, P136, DOI 10.1016/j.bonr.2018.09.003
   Yadav MC, 2016, J BONE MINER RES, V31, P1275, DOI 10.1002/jbmr.2790
   Yadav MC, 2011, J BONE MINER RES, V26, P286, DOI 10.1002/jbmr.195
   Young SK, 2016, J BIOL CHEM, V291, P13780, DOI 10.1074/jbc.M116.729830
NR 114
TC 13
Z9 18
U1 3
U2 9
PU AMER PHYSIOLOGICAL SOC
PI Rockville
PA 6120 Executive Blvd, Suite 600, Rockville, MD, UNITED STATES
SN 0193 1849
EI 1522 1555
J9 AM J PHYSIOL ENDOC M
JI Am. J. Physiol. Endocrinol. Metab.
PD MAY
PY 2019
VL 316
IS 5
BP E749
EP E772
DI 10.1152/ajpendo.00343.2018
PG 24
WC Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Physiology
GA HX0MT
UT WOS:000467084600007
PM 30645175
OA Green Published, Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Chen, PC
   Liu, SC
   Lin, TH
   Lin, LW
   Wu, HC
   Tai, HC
   Wang, SW
   Tang, CH
AF Chen, Po Chun
   Liu, Shan Chi
   Lin, Tien Huang
   Lin, Liang Wei
   Wu, Hsi Chin
   Tai, Huai Ching
   Wang, Shih Wei
   Tang, Chih Hsin
TI Prostate cancer secreted CCN3 uses the GSK3β and β catenin pathways to
   enhance osteogenic factor levels in osteoblasts
SO ENVIRONMENTAL TOXICOLOGY
LA English
DT Article
DE bone metastasis; CCN3; osteoblasts; prostate cancer
ID BONE METASTASIS; ANGIOGENESIS; EXPRESSION
AB Prostate cancer osteoblastic bone metastases are incurable and associated with chronic bone pain and a high mortality rate. Osteoclast targeting drugs intended to prevent skeletal related events associated with prostate cancer bone metastases do not prolong overall survival. Improved understanding of the bone derived factors that contribute to prostate cancer osteoblastic bone metastases is required to design treatments that will improve morbidities and overall survival. Activated osteoblasts stimulate prostate cancer growth in bone. In this study, we report that prostate cancer conditioned medium (CM) promoted bone morphogenetic protein (BMP) 2,  4 and  7 production and the expression of osteogenic transcription factors Runx2 and osterix in osteoblasts. Treating the prostate cancer CM with antibody against CCN3 (nephroblastoma overexpressed), a cysteine rich protein that belongs to the CCN family, reduced all of these increases. Incubation of osteoblasts with CCN3 facilitated phosphorylation of GSK3 beta and beta catenin. GSK3 beta and beta catenin inhibitors or siRNAs all abolished CCN3 induced promotion of BMPs, Runx2 and osterix expression in osteoblasts. Our results indicate that prostate cancer secreted CCN3 enhances BMP, Runx2 and osterix expression in osteoblasts via the GSK3 beta and beta catenin signaling pathways. This understanding of the role played by CCN3 in osteoblastic prostate bone metastasis may lead to more efficient targeted therapies.
C1 [Chen, Po Chun] Shin Kong Wu Ho Su Mem Hosp, Cent Lab, Taipei, Taiwan.
   [Liu, Shan Chi] China Med Univ, Dept Med Educ & Res, Beigang Hosp, Beigang Township, Yunlin, Taiwan.
   [Lin, Tien Huang] Buddhist Tzu Chi Gen Hosp, Dept Urol, Taichung Branch, Taichung, Taiwan.
   [Lin, Tien Huang] Tzu Chi Univ, Sch Postbaccalaureate Chinese Med, Hualien, Taiwan.
   [Lin, Liang Wei; Tang, Chih Hsin] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.
   [Wu, Hsi Chin; Tang, Chih Hsin] China Med Univ, Sch Med, Taichung, Taiwan.
   [Wu, Hsi Chin] China Med Univ, Dept Urol, Beigang Hosp, Beigang Township, Yunlin, Taiwan.
   [Tai, Huai Ching] Fu Jen Catholic Univ, Sch Med, New Taipei, Taiwan.
   [Tai, Huai Ching] Fu Jen Catholic Univ Hosp, Dept Urol, New Taipei, Taiwan.
   [Wang, Shih Wei] MacKay Med Coll, Dept Med, New Taipei, Taiwan.
   [Wang, Shih Wei] Kaohsiung Med Univ, Grad Inst Nat Prod, Coll Pharm, Kaohsiung, Taiwan.
   [Tang, Chih Hsin] China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan.
   [Tang, Chih Hsin] Asia Univ, Coll Hlth Sci, Dept Biotechnol, Taichung, Taiwan.
C3 Shin Kong Wu Ho Su Memorial Hospital; China Medical University Taiwan;
   Buddhist Tzu Chi General Hospital; Taichung Tzu Chi Hospital; Tzu Chi
   University; China Medical University Taiwan; China Medical University
   Taiwan; China Medical University Taiwan; Fu Jen Catholic University; Fu
   Jen Catholic University; Fu Jen Catholic University Hospital; Mackay
   Medical University; Kaohsiung Medical University; China Medical
   University Taiwan; Asia University Taiwan
RP Tang, CH (通讯作者)，China Med Univ, Sch Med, Dept Pharmacol, Taichung, Taiwan.
EM chtang@mail.cmu.edu.tw
RI Tang, Chih/O 5212 2015; Wang, Shih Wei/AAH 1967 2020; WU,
   HSI CHIN/A 2306 2013
FU China Medical University [CMU109 MF 44]; Taiwan's Ministry of Science
   and Technology [MOST 109 2320 B 030 005, MOST 107 2320 B 341 001 MY2];
   China Medical University Hosptial [DMR 110 156]
FX China Medical University, Grant/Award Number: CMU109 MF 44; Taiwan's
   Ministry of Science and Technology, Grant/Award Numbers: MOST
   109 2320 B 030 005, MOST 107 2320 B 341 001 MY2; China Medical
   University Hosptial, Grant/Award Number: (DMR 110 156)
CR Baron R, 2018, CURR OPIN PHARMACOL, V40, P134, DOI 10.1016/j.coph.2018.04.011
   Chen PC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133300
   Chen PC, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045 017 0390 6
   Chen PC, 2013, CARCINOGENESIS, V34, P1669, DOI 10.1093/carcin/bgt103
   Gdowski AS, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046 017 0578 1
   Girardi F, 2018, PROG MOL BIOL TRANSL, V153, P157, DOI 10.1016/bs.pmbts.2017.11.026
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Jia LL, 2020, ENVIRON POLLUT, V264, DOI 10.1016/j.envpol.2020.114819
   Kruger TE, 2014, CRIT REV ONCOL HEMAT, V89, P330, DOI 10.1016/j.critrevonc.2013.08.013
   Lee HP, 2020, FOOD AGR IMMUNOL, V31, P193, DOI 10.1080/09540105.2020.1713055
   Lee HP, 2019, FOOD AGR IMMUNOL, V30, P1033, DOI 10.1080/09540105.2019.1660623
   Lee HP, 2019, J FUNCT FOODS, V52, P537, DOI 10.1016/j.jff.2018.11.040
   Letarouilly JG, 2019, GENOMICS, V111, P793, DOI 10.1016/j.ygeno.2018.05.001
   Li X, 2018, CURR MOL MED, V18, P233, DOI 10.2174/1566524018666181004113128
   Lin SC, 2018, CURR OSTEOPOROS REP, V16, P642, DOI 10.1007/s11914 018 0480 6
   Lin TH, 2013, BBA GEN SUBJECTS, V1830, P4917, DOI 10.1016/j.bbagen.2013.06.033
   Liu SC, 2019, FOOD AGR IMMUNOL, V30, P620, DOI 10.1080/09540105.2019.1611745
   Liu Y, 2018, OSTEOPOROSIS INT, V29, P1009, DOI 10.1007/s00198 018 4507 8
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Miao CG, 2013, CELL SIGNAL, V25, P2069, DOI 10.1016/j.cellsig.2013.04.002
   Minamizato T, 2007, BIOCHEM BIOPH RES CO, V354, P567, DOI 10.1016/j.bbrc.2007.01.029
   Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475 2867 3 15
   Quiroz Munoz M, 2019, J ENDOCR SOC, V3, P655, DOI 10.1210/js.2018 00425
   Rydziel S, 2007, J BIOL CHEM, V282, P19762, DOI 10.1074/jbc.M700212200
   Su CM, 2018, BIOCHEM PHARMACOL, V154, P234, DOI 10.1016/j.bcp.2018.05.001
   Tan TW, 2012, J CELL PHYSIOL, V227, P2531, DOI 10.1002/jcp.22991
   Teufel S, 2019, CURR TOP DEV BIOL, V133, P235, DOI 10.1016/bs.ctdb.2018.11.010
   Wang JM, 2019, J AGR FOOD CHEM, V67, P10285, DOI 10.1021/acs.jafc.9b03835
   Wang MF, 2019, BIOCHEM PHARMACOL, V166, P23, DOI 10.1016/j.bcp.2019.05.005
   Wu DH, 2019, EXP BIOL MED, V244, P147, DOI 10.1177/1535370219828694
   Wu TJ, 2018, ENVIRON TOXICOL, V33, P1061, DOI 10.1002/tox.22618
   Xiang LS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040999
   Yang YC, 2019, ENVIRON TOXICOL, V34, P203, DOI 10.1002/tox.22674
NR 35
TC 13
Z9 14
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1520 4081
EI 1522 7278
J9 ENVIRON TOXICOL
JI Environ. Toxicol.
PD MAR
PY 2021
VL 36
IS 3
BP 425
EP 432
DI 10.1002/tox.23048
EA OCT 2020
PG 8
WC Environmental Sciences; Toxicology; Water Resources
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Toxicology; Water Resources
GA QB2ZN
UT WOS:000582523400001
PM 33107671
DA 2025 08 17
ER

PT J
AU Kimachi, K
   Kajiya, H
   Nakayama, S
   Ikebe, T
   Okabe, K
AF Kimachi, Keiichiro
   Kajiya, Hiroshi
   Nakayama, Shuji
   Ikebe, Tetsuro
   Okabe, Koji
TI Zoledronic acid inhibits RANK expression and migration of osteoclast
   precursors during osteoclastogenesis
SO NAUNYN SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
LA English
DT Article
DE TNF alpha; RANKL; Zoledronic acid; RANK; Cell migration; Osteoclast
   precursor cells
ID NECROSIS FACTOR RECEPTOR; NF KAPPA B; BONE RESORPTION; IN VITRO;
   BISPHOSPHONATES INHIBIT; PROTEIN PRENYLATION; MEVALONATE PATHWAY;
   SIGNALING PATHWAYS; PAGETS DISEASE; TUMOR
AB Bisphosphonates have been known to directly inhibit bone resorption and promote apoptosis in mature osteoclasts. Although bisphosphonates have been recognized as the most effective drugs to treat osteoporosis and bone cancer metastasis, the exact effects and mechanism(s) of bisphosphonates on osteoclastogenesis are unclear. The aim of this study was to clarify whether nitrogen containing bisphosphonates affect recruitment and differentiation in osteoclasts. We examined the effects of zoledronic acid on receptor activator of NF kappa B (RANK) expression and cell migration during osteoclastogenesis in two types of osteoclast precursors, RAW264.7 cells and Bone marrow cells (BMCs). Tumor necrosis factor alpha (TNF alpha) and RANK ligand (RANKL) upregulated RANK expression in RAW264.7 and BMCs in the presence of macrophage colony stimulating factor in a time dependent manner. Zoledronic acid (30 and 50 mu M) had no effect on cell viability in osteoclast precursors after 36 h of cultivation. Zoledronic acid (10 and 30 mu M) strongly inhibited TNF alpha and RANKL induced upregulation of RANK in a dose dependent manner. The inhibitory effects on RANK expression were likely to be associated with the suppression of the NF kappa B pathway, but not other downstream signaling pathways. Zoledronic acid (30 mu M) also suppressed the TNF alpha and RANKL induced migration of precursors by inhibiting the mevalonic acid pathway. Our results suggest that nitrogen containing bisphosphonates not only inhibit mature osteoclasts but also prevent osteoclast precursors from differentiating and migrating towards inflammatory osteolysis lesions.
C1 [Kimachi, Keiichiro; Kajiya, Hiroshi; Nakayama, Shuji; Okabe, Koji] Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, Sawara Ku, Fukuoka 8140193, Japan.
   [Kimachi, Keiichiro; Nakayama, Shuji; Ikebe, Tetsuro] Fukuoka Dent Coll, Dept Oral & Maxillofacial Surg, Fukuoka 8140193, Japan.
C3 Fukuoka Dental College (FDC); Fukuoka Dental College (FDC)
RP Kajiya, H (通讯作者)，Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, Sawara Ku, Tamura 2 15 1, Fukuoka 8140193, Japan.
EM kajiya@college.fdcnet.ac.jp
OI Kajiya, Hiroshi/0000 0003 3275 3632
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [21592381, 20592383]; Frontier Research Grant; Grants in Aid for
   Scientific Research [21592381, 20592383] Funding Source: KAKEN
FX This work was supported by Grants in Aid for Scientific Research from
   the Ministry of Education, Culture, Sports, Science and Technology of
   Japan (no. 21592381 and 20592383) and a Frontier Research Grant.
CR Ahn KS, 2008, INT J CANCER, V123, P1733, DOI 10.1002/ijc.23745
   AMIN D, 1992, J LIPID RES, V33, P1657
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Boudot C, 2010, BONE, V46, P1416, DOI 10.1016/j.bone.2010.01.383
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287
   Caraglia M, 2005, CURR DRUG TARGETS, V6, P301, DOI 10.2174/1389450053765833
   CASEY PJ, 1995, BIOCHEM SOC T, V23, P161, DOI 10.1042/bst0230161
   Delmas PD, 1997, NEW ENGL J MED, V336, P558, DOI 10.1056/NEJM199702203360807
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fleisch H, 1997, HORM METAB RES, V29, P145, DOI 10.1055/s 2007 979008
   Fournier P, 2002, CANCER RES, V62, P6538
   Fromigué O, 2002, J ENDOCRINOL INVEST, V25, P539, DOI 10.1007/BF03345497
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092 8674(94)90308 5
   Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538 7836.2006.02259.x
   Huber AV, 2006, PLACENTA, V27, P127, DOI 10.1016/j.placenta.2005.02.012
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Ikebe T, 1998, INT J CANCER, V77, P578
   Jilka RL, 1998, J CLIN INVEST, V101, P1942, DOI 10.1172/JCI1039
   Kakiashvili E, 2009, J BIOL CHEM, V284, P11454, DOI 10.1074/jbc.M805933200
   Kim YH, 2002, EXP MOL MED, V34, P145, DOI 10.1038/emm.2002.21
   Kwak HB, 2009, BIOL PHARM BULL, V32, P1193, DOI 10.1248/bpb.32.1193
   Lesclous P, 2009, BONE, V45, P843, DOI 10.1016/j.bone.2009.07.011
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Liao TS, 2005, J ORTHOP RES, V23, P203, DOI 10.1016/j.orthres.2004.06.018
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Monier Faugere MC, 1999, J BONE MINER RES, V14, P1768, DOI 10.1359/jbmr.1999.14.10.1768
   Nishikawa M, 1996, BONE, V18, P9, DOI 10.1016/8756 3282(95)00426 2
   Parfitt AM, 1996, J BONE MINER RES, V11, P150
   Porter KE, 2004, CARDIOVASC RES, V64, P507, DOI 10.1016/j.cardiores.2004.07.020
   RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092 8674(92)90164 8
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Roodman GD, 1996, BONE, V19, P209, DOI 10.1016/8756 3282(96)00211 6
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049
   Seabra MC, 1998, METH MOL B, V84, P251
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   TLOCZEK AM, 2009, APMIS, V117, P558
   Turner NA, 2007, J MOL CELL CARDIOL, V43, P168, DOI 10.1016/j.yjmcc.2007.05.006
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200
   Zhang CY, 1996, MOL PHARMACOL, V50, P864
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
   Zhang Q, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2391
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 51
TC 71
Z9 81
U1 1
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0028 1298
EI 1432 1912
J9 N S ARCH PHARMACOL
JI Naunyn Schmiedebergs Arch. Pharmacol.
PD MAR
PY 2011
VL 383
IS 3
BP 297
EP 308
DI 10.1007/s00210 010 0596 4
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 733RT
UT WOS:000288281200009
PM 21225243
DA 2025 08 17
ER

PT J
AU Chung, HJ
   Cho, L
   Shin, JS
   Lee, J
   Ha, IH
   Park, HJ
   Lee, SK
AF Chung, Hwa Jin
   Cho, Lan
   Shin, Joon Shik
   Lee, Jinho
   Ha, In Hyuk
   Park, Hyen Joo
   Lee, Sang Kook
TI Effects of JSOG 6 on protection against bone loss in ovariectomized mice
   through regulation of osteoblast differentiation and osteoclast
   formation
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE JSOG 6; Ovariectomized mice; Bone loss; Osteoclast; Osteoblast
ID GENE EXPRESSION; HARPAGOPHYTUM PROCUMBENS; PARATHYROID HORMONE;
   TNF ALPHA; CELLS; RALOXIFENE; ESTROGEN; OSTEOPROTEGERIN; OSTEOPOROSIS;
   ACTIVATION
AB Background: JSOG 6 is used as a traditional medicine to relieve the symptoms associated with inflammation, rheumatism, and osteoporosis in Korea. In the present study, we investigated the effects of JSOG 6 on bone loss prevention both in in vitro and in vivo as well as its underlying mechanism of action.
   Methods: Protection against bone loss was assessed in an ovariectomized (OVX) mouse model. Bone microarchitecture was measured using a micro computed tomography to detect the parameters of three dimensional structure of a trabecular bone. Serum biomarkers were also evaluated in an OVX induced model. Osteoclasts derived from mouse bone marrow cells (BMCs) and osteoblastic MC3T3 E1 cells were also employed to investigate the mechanism of action.
   Results: Oral administration of JSOG 6 significantly increased the bone mineral density (BMD) of the femur in OVX mice in vivo. Especially, the reduced Tb.No (trabecular bone number) in the OVX group was significantly recovered by JSOG 6 treatment. The serum levels of alkaline phosphatase (ALP), osteocalcin, C terminal telopeptide, and tartrate resistant acid phosphatase, biomarkers of bone resorption, were significantly elevated in OVX mice, but JSOG 6 effectively inhibited the increase in OVX mice. JSOG 6 was also found to enhance the osteoblastic differentiation and maturation with the increase of the density and ALP activity, a marker of osteoblastic differentiation, as well as calcium deposition, a marker of osteoblastic maturation in MC3T3 E1 cells. The effects of JSOG 6 on osteoblastic differentiation were also associated in part with the increase of ALP and OPN mRNA expressions and the decrease of RANKL mRNA expression in MC3T3 E1 cells.
   Conclusions: The findings demonstrate that JSOG 6 induced protection against bone loss in OVX mice, and its anti osteoporotic property might be, in part, a function of the stimulation of osteoblast differentiation and the inhibition of osteoclast formation. These findings suggest that JSOG 6 might be an applicable therapeutic traditional medicine for the regulation of the osteoporotic response.
C1 [Chung, Hwa Jin; Cho, Lan; Park, Hyen Joo; Lee, Sang Kook] Seoul Natl Univ, Inst Nat Prod Res, Coll Pharm, San 56 1 Sillim Dong, Seoul 151742, South Korea.
   [Shin, Joon Shik; Lee, Jinho; Ha, In Hyuk] Jaseng Hosp Korean Med, Jaseng Med Fdn, Jaseng Spine & Joint Res Inst, Seoul 135896, South Korea.
C3 Seoul National University (SNU)
RP Lee, SK (通讯作者)，Seoul Natl Univ, Inst Nat Prod Res, Coll Pharm, San 56 1 Sillim Dong, Seoul 151742, South Korea.
EM sklee61@snu.ac.kr
RI ; Lee, Yoon/ABA 8808 2020
OI Lee, Jinho/0000 0003 0672 6892; Shin, Joon Shik/0000 0001 5488 3273; HA,
   IN HYUK/0000 0002 5020 6723; 
CR Alexander JM, 2001, J BONE MINER RES, V16, P1665, DOI 10.1359/jbmr.2001.16.9.1665
   Anuja GI, 2010, J ETHNOPHARMACOL, V132, P456, DOI 10.1016/j.jep.2010.08.038
   Bahlous Afef, 2006, Tunis Med, V84, P751
   Bhargavan B, 2009, J CELL BIOCHEM, V108, P388, DOI 10.1002/jcb.22264
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cano A, 2008, OSTEOPOROSIS INT, V19, P793, DOI 10.1007/s00198 007 0498 6
   Chen LL, 2011, ARCH ORAL BIOL, V56, P1655, DOI 10.1016/j.archoralbio.2011.06.008
   Chen WF, 2006, BRIT J NUTR, V95, P1039, DOI 10.1079/BJN20061735
   Fiebich BL, 2012, PHYTOTHER RES, V26, P806, DOI 10.1002/ptr.3636
   Frolik CA, 1996, BONE, V18, P621, DOI 10.1016/8756 3282(96)00085 3
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Han Y, 2012, J MED FOOD, V15, P505, DOI 10.1089/jmf.2011.1940
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hohenhaus MH, 2007, DRUGS, V67, P2311, DOI 10.2165/00003495 200767160 00002
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Inaba K, 2010, J NAT MED TOKYO, V64, P219, DOI 10.1007/s11418 010 0395 8
   Jadlowiec J, 2004, J BIOL CHEM, V279, P53323, DOI 10.1074/jbc.M404934200
   KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006 291X(05)80208 6
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim HR, 2008, IMMUNOPHARM IMMUNOT, V30, P333, DOI 10.1080/08923970801949125 
   Levine JP, 2007, GERIATRICS US, V62, P22
   Martin TJ, 2013, WORLD J ORTHOP, V4, P186, DOI 10.5312/wjo.v4.i4.186
   Nukaya H, 1996, CHEM PHARM BULL, V44, P847, DOI 10.1248/cpb.44.847
   OWEN TA, 1991, ENDOCRINOLOGY, V128, P1496, DOI 10.1210/endo 128 3 1496
   Papachroni KK, 2009, TRENDS MOL MED, V15, P208, DOI 10.1016/j.molmed.2009.03.001
   Rahman MM, 2006, J LIPID RES, V47, P1739, DOI 10.1194/jlr.M600151 JLR200
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Ross FP, 2005, IMMUNOL REV, V208, P88, DOI 10.1111/j.0105 2896.2005.00331.x
   Sanders M, 2011, ALTERN MED REV, V16, P228
   Sato M, 1996, J PHARMACOL EXP THER, V279, P298
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Suda K, 2002, J CELL PHYSIOL, V190, P101, DOI 10.1002/jcp.10041
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo 122 4 1373
   Takayanagi H, 2005, IMMUNOL REV, V208, P181, DOI 10.1111/j.0105 2896.2005.00337.x
   Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600 0765.2005.00814.x
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teitelbaum SL, 2000, J BONE MINER METAB, V18, P344, DOI 10.1007/s007740070007
   YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Zhang Y, 2007, BIOL PHARM BULL, V30, P898, DOI 10.1248/bpb.30.898
NR 43
TC 18
Z9 18
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD JUN 6
PY 2014
VL 14
AR 184
DI 10.1186/1472 6882 14 184
PG 11
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA AK1FS
UT WOS:000338161400001
PM 24903150
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, B
   Khan, S
   Wang, PT
   Wang, XF
   Liu, YX
   Chen, JJ
   Tu, XL
AF Wang, Bo
   Khan, Saima
   Wang, Pengtao
   Wang, Xiaofang
   Liu, Yangxi
   Chen, Jingjing
   Tu, Xiaolin
TI A Highly Selective GSK 3β Inhibitor CHIR99021 Promotes Osteogenesis by
   Activating Canonical and Autophagy Mediated Wnt Signaling
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE CHIR99021; Wnt/beta catenin signaling; autophagy; integrated 3D
   printing; PCL scaffold; osteoporosis; slow release hydrogel; osteoblast
   differentiation
ID MULTIPLE INTESTINAL NEOPLASIA; BONE; OSTEOBLAST; MUTATION; CATENIN;
   LITHIUM; METABOLISM; RAPAMYCIN; DISEASE; TARGET
AB The discovery and application of small molecules is one of the practical strategies of safe osteogenic drugs. The small molecule CHIR99021 (C91) is a highly specific, safe, and most effective GSK 3 beta Inhibitor. This study found that it efficiently activates the canonical Wnt signaling of bone marrow stromal cell ST2 and promotes osteoblast differentiation and mineralization. C91 increases the production and biochemical activity of osteoblast marker alkaline phosphatase, the expression of osteoblast marker genes Alpl, Bglap, Runx2, and Sp7, and the formation of bone nodules. Triptonide is a transcription inhibitor of Wnt target gene, which diminishes C91 induced osteoblast differentiation in a dose dependent manner. Meanwhile, C91 also induces autophagy through autophagosome formation and conversion of autophagy biomarker LC 3I into LC 3II. Autophagy inhibitor 3MA partially reduces C91 induced osteoblast differentiation and mineralization; autophagy inducer Rapamycin increases the expression of beta catenin to promote osteogenic differentiation, but cannot alleviate the inhibition of Triptonide on C91 induced osteogenic differentiation, indicating the crosstalk of canonical Wnt signaling and autophagy regulates C91 induced osteoblast differentiation. Furthermore, in order to simulate the in vivo detection of C91 in osteogenesis process, we made a C91 slow release hydrogel with our newly established polycaprolactone and cell integrated 3D printing system (PCCI3D module). The sustained release C91 promotes the differentiation and mineralization of ST2 cells. C91 can also enhance the proliferative activity of ST2 cells. The release rate of C91 from hydrogel gradually decreases within 7 days. During this period, the C91 is released by 83.0% and the cell viability maintained at 96.4%. Therefore, the small molecule Wnt agonist C91 promotes osteogenesis through caonical and autophagy mediated Wnt signaling pathway with an option for translational application.
C1 [Wang, Bo; Khan, Saima; Wang, Pengtao; Wang, Xiaofang; Liu, Yangxi; Chen, Jingjing; Tu, Xiaolin] Chongqing Med Univ, Inst Life Sci, Lab Skeletal Dev & Regenerat, Chongqing, Peoples R China.
   [Khan, Saima] Gambat Inst Med Sci, Gambat, Khairpur, Pakistan.
C3 Chongqing Medical University
RP Tu, XL (通讯作者)，Chongqing Med Univ, Inst Life Sci, Lab Skeletal Dev & Regenerat, Chongqing, Peoples R China.
EM xtu@cqmu.edu.cn
RI CHEN, Jingjing/JFA 0829 2023; Tu, Xiaolin/JAC 9492 2023
OI Tu, Xiaolin/0000 0002 7923 2722; 
FU National Natural Science Foundation of China; Chongqing Science and
   Technology Commission Basic Science and Frontier Technology Key Project
   [U1601220, 81672118, 82072450]; Chongqing Postgraduate Research and
   Innovation Project [cstc2015jcyjBX0119];  [CYB20167];  [CYS20219]
FX This research was funded by the National Natural Science Foundation of
   China U1601220, 81672118, and 82072450 (XT), and Chongqing Science and
   Technology Commission Basic Science and Frontier Technology Key Project
   cstc2015jcyjBX0119 (XT). The Chongqing Postgraduate Research and
   Innovation Project (CYB20167, CYS20219).
CR An W.F., 2010, Probe Reports from the NIH Molecular Libraries Program
   Banaszynski LA, 2006, CELL, V126, P995, DOI 10.1016/j.cell.2006.07.025
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200
   Ceccariglia S, 2020, AUTOPHAGY, V16, P28, DOI 10.1080/15548627.2019.1630223
   Chang KH, 2014, CELL REP, V9, P2084, DOI 10.1016/j.celrep.2014.11.031
   Chen X, 2020, CYTOKINE, V136, DOI 10.1016/j.cyto.2020.155292
   Cheng Y, 2019, INT J MOL MED, V44, P652, DOI 10.3892/ijmm.2019.4216
   Chinison J, 2016, SCI REP UK, V6, DOI 10.1038/srep32779
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Cline GW, 2002, DIABETES, V51, P2903, DOI 10.2337/diabetes.51.10.2903
   Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415
   Comeau Gauthier M, 2020, INJURY, V51, P2449, DOI 10.1016/j.injury.2020.07.035
   Edwards SR, 2007, J BIOL CHEM, V282, P13395, DOI 10.1074/jbc.M700498200
   Griffin JN, 2018, DEV CELL, V44, P248, DOI 10.1016/j.devcel.2017.12.001
   Jilka RL, 2007, J BONE MINER RES, V22, P1492, DOI 10.1359/JBMR.070518
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Kanis JA, 2019, CALCIFIED TISSUE INT, V104, P235, DOI 10.1007/s00223 018 00512 x
   LAZARUS JH, 1987, MINER ELECTROL METAB, V13, P63
   Li LL, 2015, CELL MOL NEUROBIOL, V35, P615, DOI 10.1007/s10571 015 0166 x
   Li XH, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 1138 4
   Little RD, 2002, NEW ENGL J MED, V347, P943
   Liu F, 2013, J BONE MINER RES, V28, P2414, DOI 10.1002/jbmr.1971
   Liu YX, 2022, CELLS BASEL, V11, DOI 10.3390/cells11050831
   Mak TWL, 1998, J CLIN ENDOCR METAB, V83, P3857, DOI 10.1210/jc.83.11.3857
   MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722
   Noda M, 2016, CANCER SCI, V107, P576, DOI 10.1111/cas.12924
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   NORDENSTROM J, 1994, METABOLISM, V43, P1563, DOI 10.1016/0026 0495(94)90017 5
   Ontoria JM, 2009, J MED CHEM, V52, P6782, DOI 10.1021/jm900555u
   Panicker LM, 2018, HUM MOL GENET, V27, P811, DOI 10.1093/hmg/ddx442
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Pierrefite Carle V, 2015, AGEING RES REV, V24, P206, DOI 10.1016/j.arr.2015.08.004
   Rangaraju S, 2010, J NEUROSCI, V30, P11388, DOI 10.1523/JNEUROSCI.1356 10.2010
   Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588
   Wang RL, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 020 00663 w
   Ryynänen J, 2017, J STEROID BIOCHEM, V173, P185, DOI 10.1016/j.jsbmb.2017.02.005
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Stern ST, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743 8977 9 20
   SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108
   Takahashi Yanaga F, 2013, BIOCHEM PHARMACOL, V86, P191, DOI 10.1016/j.bcp.2013.04.022
   Tang CH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222312725
   Tosti A, 2016, J COSMET DERMATOL US, V15, P469, DOI 10.1111/jocd.12225
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   Wang L, 2021, ACTA BIOMATER, V122, P160, DOI 10.1016/j.actbio.2020.12.031
   Wang PT, 2022, BIO DES MANUF, V5, P497, DOI 10.1007/s42242 022 00196 1
   Xi G, 2016, ENDOCRINOLOGY, V157, P268, DOI 10.1210/en.2015 1690
   Zhang HT, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 020 03364 2
NR 49
TC 28
Z9 31
U1 0
U2 22
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD JUL 18
PY 2022
VL 13
AR 926622
DI 10.3389/fendo.2022.926622
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 4X0KC
UT WOS:000860540300001
PM 35923616
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, FL
   Chen, CL
   Lee, CC
   Wu, CC
   Hsu, TH
   Tsai, CY
   Huang, HS
   Chang, DM
AF Liu, Fei Lan
   Chen, Chun Liang
   Lee, Chia Chung
   Wu, Cheng Chi
   Hsu, Teng Hsu
   Tsai, Chang Youh
   Huang, Hsu Shan
   Chang, Deh Ming
TI The Simultaneous Inhibitory Effect of Niclosamide on RANKL Induced
   Osteoclast Formation and Osteoblast Differentiation
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Niclosamide; Osteoclast Formation; Osteoblast Differentiation
ID NF KAPPA B; RECEPTOR ACTIVATOR; BONE FORMATION; TRANSCRIPTION FACTOR;
   GENE EXPRESSION; IN VITRO; MECHANISMS; SALICYLANILIDE; OSTEOPOROSIS;
   PATHWAYS
AB The bone destruction disease including osteoporosis and rheumatoid arthritis are caused by the imbalance between osteoblastogenesis and osteoclastogenesis. Inhibition of the NF kappa B pathway was responsible for decreased osteoclastogenesis. Recently many studies indicated that niclosamide, the FDA approved an antihelminth drug, inhibits prostate and breast cancer cells growth by targeting NF kappa B signaling pathways. This study evaluated the effects of niclosamide on osteoclast and osteoblast differentiation and function in vitro.
   In RANKL induced murine osteoclast precursor cell RAW264.7 and M CSF/RANKL stimulated primary murine bone marrow derived macrophages (BMM), niclosamide dose dependently inhibited the formation of TRAP positive multinucleated osteoclasts and resorption pits formation between 0.5uM and 1uM. In addition, niclosamide suppressed the expression of nuclear factor of activated T cells c1 (NFATc1) and osteoclast differentiated related genes in M CSF/RANKL stimulated BMM by interference with TRAF 6, Erk1/2, JNK and NF kappa B activation pathways. However, the cytotoxic effects of niclosamide obviously appeared at the effective concentrations for inhibiting osteoclastogenesis (0.5 1uM) with increase of apoptosis through caspase 3 activation in osteoblast precursor cell line, MC3T3 E1. Niclosamide also inhibited ALP activity, bone mineralization and osteoblast differentiation related genes expression in MC3T3 E1. Therefore, our findings suggest the new standpoint that niclosamide's effects on bones must be considered before applying it in any therapeutic treatment.
C1 [Liu, Fei Lan; Wu, Cheng Chi; Hsu, Teng Hsu; Tsai, Chang Youh; Chang, Deh Ming] Taipei Vet Gen Hosp, Rheumatol Immunol Allergy, Taipei, Taiwan.
   [Liu, Fei Lan; Chang, Deh Ming] Natl Def Med Ctr, Grad Inst Med Sci, Taipei, Taiwan.
   [Chen, Chun Liang; Lee, Chia Chung; Wu, Cheng Chi; Hsu, Teng Hsu; Huang, Hsu Shan; Chang, Deh Ming] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.
C3 Taipei Veterans General Hospital; National Defense Medical University;
   National Defense Medical University
RP Chang, DM (通讯作者)，Taipei Vet Gen Hosp, Rheumatol Immunol Allergy, Taipei, Taiwan.
EM ming0503@ms3.hinet.net
RI Tsai, Chang Youh/G 1747 2013; Zhang, Yu/J 5225 2014; Wu,
   Cheng Chi/MXL 2497 2025
OI Huang, Hsu Shan/0000 0001 8162 5608
FU Ministry of Science and Technology, Taiwan, Republic of China [Most
   104 2811 B 075 006, Most 105 2811 B 075 002, Most
   102 2314 B 075 083 MY3, Most 105 2314 B 075 054 MY3]
FX Fei Lan Liu was supported by the Ministry of Science and Technology,
   Taiwan, Republic of China (Most 104 2811 B 075 006 and Most
   105 2811 B 075 002).This work was supported by the Ministry of Science
   and Technology, Taiwan, Republic of China (Most 102 2314 B 075 083 MY3
   and Most 105 2314 B 075 054 MY3)
CR ANDERSON HC, 1989, LAB INVEST, V60, P320
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Aronson JK, 2007, BRIT J CLIN PHARMACO, V64, P563, DOI 10.1111/j.1365 2125.2007.03058.x
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Body JJ, 2002, BONE, V30, p75S
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown ME, 2008, BIOORGAN MED CHEM, V16, P8760, DOI 10.1016/j.bmc.2008.07.024
   Bruzzaniti A, 2006, REV ENDOCR METAB DIS, V7, P123, DOI 10.1007/s11154 006 9009 x
   Chaudhary LR, 2004, BONE, V34, P402, DOI 10.1016/j.bone.2003.11.014
   Chen CL, 2014, J MED CHEM, V57, P8072, DOI 10.1021/jm5007897
   Cheng CP, 2012, J CLIN IMMUNOL, V32, P762, DOI 10.1007/s10875 012 9660 9
   Cheon YH, 2016, BIOCHEM BIOPH RES CO, V470, P343, DOI 10.1016/j.bbrc.2016.01.048
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   De La Fuente R, 2006, BRIT J PHARMACOL, V149, P551, DOI 10.1038/sj.bjp.0706873
   Ding WX, 2004, HEPATOLOGY, V40, P403, DOI 10.1002/hep.20310
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Hodge JM, 2013, BIOL PSYCHIAT, V74, P32, DOI 10.1016/j.biopsych.2012.11.003
   Hsu YC, 2011, J RHEUMATOL, V38, P1844, DOI 10.3899/jrheum.101223
   Huang X, 2016, MOL MED REP, V13, P613, DOI 10.3892/mmr.2015.4627
   Jin YL, 2010, CANCER RES, V70, P2516, DOI 10.1158/0008 5472.CAN 09 3950
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Karmakar S, 2010, RHEUM DIS CLIN N AM, V36, P385, DOI 10.1016/j.rdc.2010.03.003
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kraljevic S, 2004, EMBO REP, V5, P837, DOI 10.1038/sj.embor.7400236
   Lamothe B, 2007, BIOCHEM BIOPH RES CO, V359, P1044, DOI 10.1016/j.bbrc.2007.06.017
   Lee CC, 2015, EUR J MED CHEM, V98, P115, DOI 10.1016/j.ejmech.2015.05.015
   Li R, 2013, MOL CANCER THER, V12, P2200, DOI 10.1158/1535 7163.MCT 13 0095
   Li YH, 2014, CANCER LETT, V349, P8, DOI 10.1016/j.canlet.2014.04.003
   Lloyd M, 1998, NEW ENGL J MED, V339, P202
   Lu WY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029290
   Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168 9525(03)00176 8
   Niu YB, 2012, OSTEOPOROSIS INT, V23, P2649, DOI 10.1007/s00198 012 1932 y
   Osada T, 2011, CANCER RES, V71, P4172, DOI 10.1158/0008 5472.CAN 10 3978
   Otevrel J, 2010, MOLECULES, V15, P8122, DOI 10.3390/molecules15118122
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Poblenz AT, 2007, BIOCHEM BIOPH RES CO, V359, P510, DOI 10.1016/j.bbrc.2007.05.151
   Post TM, 2010, CLIN PHARMACOKINET, V49, P89, DOI 10.2165/11318150 000000000 00000
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sack U, 2011, JNCI J NATL CANCER I, V103, P1018, DOI 10.1093/jnci/djr190
   Saftig P, 2000, ADV EXP MED BIOL, V477, P293
   Shiotani A, 2002, ANAT REC, V268, P137, DOI 10.1002/ar.10121
   Strampel W, 2007, DRUG SAFETY, V30, P755, DOI 10.2165/00002018 200730090 00003
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644
   Vinsova J, 2007, MOLECULES, V12, P1, DOI 10.3390/12010001
   Wang BL, 2015, J INORG BIOCHEM, V142, P118, DOI 10.1016/j.jinorgbio.2014.10.003
   Wei J, 2010, RECENT PATENTS INFLA, V4, P105, DOI 10.2174/187221310791163071
   Weissmann G, 1981, HOSP PRACT, V16, P37
   Wennberg C, 2000, J BONE MINER RES, V15, P1879, DOI 10.1359/jbmr.2000.15.10.1879
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Ye TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085887
   Yo YT, 2012, MOL CANCER THER, V11, P1703, DOI 10.1158/1535 7163.MCT 12 0002
   Yu MJ, 2011, J IMMUNOL, V187, P1797, DOI 10.4049/jimmunol.1002628
NR 61
TC 15
Z9 18
U1 0
U2 9
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2017
VL 14
IS 9
BP 840
EP 852
DI 10.7150/ijms.19268
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA FE3ZP
UT WOS:000408154500006
PM 28824321
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Cui, YZ
   Lv, B
   Li, ZY
   Ma, CM
   Gui, ZW
   Geng, YT
   Liu, GH
   Sang, LC
   Xu, C
   Min, Q
   Kong, L
   Zhang, ZP
   Liu, Y
   Qi, XB
   Fu, DH
AF Cui, Yongzhi
   Lv, Bin
   Li, Zhongying
   Ma, Chunming
   Gui, Zhengwei
   Geng, Yongtao
   Liu, Guohui
   Sang, Linchao
   Xu, Chen
   Min, Qi
   Kong, Li
   Zhang, Zhiping
   Liu, Yang
   Qi, Xiangbei
   Fu, Dehao
TI Bone Targeted Biomimetic Nanogels Re Establish Osteoblast/Osteoclast
   Balance to Treat Postmenopausal Osteoporosis
SO SMALL
LA English
DT Article
DE biomimetic nanogels; bone targeting; postmenopausal osteoporosis; PTH
   1 34; RANKL neutralization
ID PARATHYROID HORMONE; RANKL; NANOPARTICLES; THERAPY; CELLS;
   DIFFERENTIATION; NANOCARRIERS; TERIPARATIDE; METABOLISM; DELIVERY
AB Insufficient bone formation and excessive bone resorption caused by estrogen deficiency are the major factors resulting in the incidence of postmenopausal osteoporosis (PMOP). The existing drugs usually fail to re establish the osteoblast/osteoclast balance from both sides and generate side effects owing to the lack of bone targeting ability. Here, engineered cell membrane coated nanogels PNG@mR&C capable of scavenging receptor activator of nuclear factor kappa B ligand (RANKL) and responsively releasing therapeutic PTH 1 34 in the bone microenvironment are prepared from RANK and CXCR4 overexpressed bone mesenchymal stem cell (BMSC) membrane coated chitosan biopolymers. The CXCR4 on the coated membranes confer bone targeting ability, and abundant RANK effectively absorb RANKL to inhibit osteoclastogenesis. Meanwhile, the release of PTH 1 34 triggered by osteoclast mediated acid microenvironment promote osteogenesis. In addition, the dose and frequency are greatly reduced due to the smart release property, prolonged circulation time, and bone specific accumulation. Thus, PNG@mR&C exhibits satisfactory therapeutic effects in the ovariectomized (OVX) mouse model. This study provides a new paradigm re establishing the bone metabolic homeostasis from multitargets and shows great promise for the treatment of PMOP.
   Genetically manipulated bone mesenchymal stem cell (BMSC) membrane is extracted and coated on chitosan based nanogels containing PTH 1 34 to construct biomimetic nanogels. Abundant membrane CXCR4 confers these nanogels bone targeting ability. The RANK confers them receptor activator of nuclear factor kappa B ligand (RANKL) absorbing ability to inhibit osteoclastogenesis. Osteoclast mediated acid microenvironment contributes to PTH 1 34 release, thus promoting osteogenic differentiation and re establishing osteoblast/osteoclast balance to treat postmenopausal osteoporosis (PMOP).image
C1 [Cui, Yongzhi; Fu, Dehao] Shanghai Jiao Tong Univ, Dept Orthopaed, Shanghai Peoples Hosp 6, Sch Med, Shanghai 200233, Peoples R China.
   [Lv, Bin; Geng, Yongtao; Liu, Guohui] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China.
   [Li, Zhongying; Ma, Chunming] Hubei Univ Med, Taihe Hosp, Dept Rehabil, Shiyan 442000, Hubei, Peoples R China.
   [Gui, Zhengwei] Huazhong Univ Sci & Technol, Dept Thyroid & Breast, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.
   [Sang, Linchao; Qi, Xiangbei] Hebei Med Univ, Hosp 3, Dept Orthopaed, Shijiazhuang 050051, Hebei, Peoples R China.
   [Xu, Chen; Min, Qi; Liu, Yang] Naval Med Univ, Changzheng Hosp, Dept Spine Surg, Shanghai 200003, Peoples R China.
   [Kong, Li; Zhang, Zhiping] Huazhong Univ Sci & Technol, Tongji Sch Pharm, Wuhan 430030, Peoples R China.
C3 Shanghai Jiao Tong University; Huazhong University of Science &
   Technology; Hubei University of Medicine; Huazhong University of Science
   & Technology; Hebei Medical University; Naval Medical University;
   Huazhong University of Science & Technology
RP Fu, DH (通讯作者)，Shanghai Jiao Tong Univ, Dept Orthopaed, Shanghai Peoples Hosp 6, Sch Med, Shanghai 200233, Peoples R China.; Qi, XB (通讯作者)，Hebei Med Univ, Hosp 3, Dept Orthopaed, Shijiazhuang 050051, Hebei, Peoples R China.; Liu, Y (通讯作者)，Naval Med Univ, Changzheng Hosp, Dept Spine Surg, Shanghai 200003, Peoples R China.
EM liuyangspine@hotmail.com; qixiangbei126@126.com; fudehao@sjtu.edu.cn
RI ; Xu, Chen/AAQ 5514 2020; zhang, zhiping/H 1786 2011; Ma,
   Chunming/HMD 9613 2023; Fu, Dehao/AAM 4137 2020
OI Cui, Yongzhi/0000 0002 7532 0151; Xu, Chen/0000 0001 8068 2109; 
FU Y.C., B.L., and Z.L. contributed equally to this work. The authors thank
   Huazhong University of Science and Technology Analytical and Testing
   Center Medical Sub Center for providing the equipment of micro CT. This
   research was funded by the National Natura [81874026, 82070911];
   National Natural Science Foundation of China
FX Y.C., B.L., and Z.L. contributed equally to this work. The authors thank
   Huazhong University of Science and Technology Analytical and Testing
   Center Medical Sub Center for providing the equipment of micro CT. This
   research was funded by the National Natural Science Foundation of China
   (Grant Nos.: 81874026 and 82070911).
CR Bloebaum RD, 2007, J BIOMED MATER RES A, V81A, P505, DOI 10.1002/jbm.a.31087
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen LL, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.110093
   Chen X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0035 6
   Chen YT, 2023, BIOMATER ADV, V144, DOI 10.1016/j.bioadv.2022.213232
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Conceiça M, 2021, BIOMATERIALS, V266, DOI 10.1016/j.biomaterials.2020.120435
   Cui YZ, 2022, ACS NANO, V16, P11076, DOI 10.1021/acsnano.2c03781
   Dar A, 2005, NAT IMMUNOL, V6, P1038, DOI 10.1038/ni1251
   Estell EG, 2021, NAT REV ENDOCRINOL, V17, P31, DOI 10.1038/s41574 020 00426 5
   Fang RH, 2023, NAT REV CLIN ONCOL, V20, P33, DOI 10.1038/s41571 022 00699 x
   Fang RH, 2018, ADV MATER, V30, DOI 10.1002/adma.201706759
   Feng LS, 2021, ACS NANO, V15, P2263, DOI 10.1021/acsnano.0c07973
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Fu LW, 2022, BIOACT MATER, V17, P221, DOI 10.1016/j.bioactmat.2022.01.035
   Gavali S, 2019, BBA MOL CELL RES, V1866, P1498, DOI 10.1016/j.bbamcr.2019.06.014
   Hartley JW, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742 4690 5 1
   Henaff C. L., 2020, J BONE MINER RES, V35, P714
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Hu Y, 2021, BIOACT MATER, V6, P2905, DOI 10.1016/j.bioactmat.2021.02.014
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kim Y, 2021, METHODS MOL BIOL, V2230, P169, DOI 10.1007/978 1 0716 1028 2_11
   Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood 2004 11 4349
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lavrador P, 2018, J CONTROL RELEASE, V273, P51, DOI 10.1016/j.jconrel.2018.01.021
   Li Chang Jun, 2021, Cell Metab, V33, P1957, DOI 10.1016/j.cmet.2021.08.009
   Li ZH, 2021, NAT NANOTECHNOL, V16, P942, DOI 10.1038/s41565 021 00923 2
   Lin XF, 2020, J AM CHEM SOC, V142, P17543, DOI 10.1021/jacs.0c07309
   Luo GF, 2021, CHEM SOC REV, V50, P945, DOI 10.1039/d0cs00152j
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   Matsumoto Y, 2013, STEROIDS, V78, P513, DOI 10.1016/j.steroids.2013.02.011
   Narayanan D, 2012, J BIOMED NANOTECHNOL, V8, P98, DOI 10.1166/jbn.2012.1367
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   PECK WA, 1993, AM J MED, V94, P646
   Qu Y, 2022, ADV MATER, V34, DOI 10.1002/adma.202107883
   Rao L, 2020, P NATL ACAD SCI USA, V117, P27141, DOI 10.1073/pnas.2014352117
   Rao L, 2020, ACS NANO, V14, P2569, DOI 10.1021/acsnano.0c01665
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Shang LH, 2022, ACTA PHARM SIN B, V12, P2550, DOI 10.1016/j.apsb.2021.11.004
   Silva BC, 2011, J ENDOCRINOL INVEST, V34, P801, DOI 10.3275/7925
   Song L, 2017, ADV CLIN CHEM, V82, P1, DOI 10.1016/bs.acc.2017.06.005
   Spanjers JM, 2020, ADV BIOSYST, V4, DOI 10.1002/adbi.202000174
   Tokuyama Naoto, 2015, Bone Rep, V2, P1, DOI 10.1016/j.bonr.2014.12.002
   Wang HL, 2023, BIOACT MATER, V21, P531, DOI 10.1016/j.bioactmat.2022.09.012
   Xie J, 2019, ACS NANO, V13, P5268, DOI 10.1021/acsnano.8b09681
   Xiong JQ, 2021, ACS NANO, V15, P19756, DOI 10.1021/acsnano.1c07180
   Yamamoto T, 2016, ENDOCRINOLOGY, V157, P2604, DOI 10.1210/en.2015 2028
   Yu H, 2019, THERANOSTICS, V9, P7033, DOI 10.7150/thno.35748
   Zhang Y, 2018, NANO LETT, V18, P1908, DOI 10.1021/acs.nanolett.7b05263
   Zhou Y, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abl6432
NR 51
TC 33
Z9 33
U1 22
U2 91
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613 6810
EI 1613 6829
J9 SMALL
JI Small
PD FEB
PY 2024
VL 20
IS 6
DI 10.1002/smll.202303494
EA OCT 2023
PG 14
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA HL8H1
UT WOS:001075351800001
PM 37794621
DA 2025 08 17
ER

PT J
AU Wang, W
   Gao, Y
   Zheng, WW
   Li, MQ
   Zheng, XX
AF Wang, Wei
   Gao, Yuan
   Zheng, Wenwen
   Li, Minqi
   Zheng, Xuexing
TI Phenobarbital inhibits osteoclast differentiation and function through
   NF κB and MAPKs signaling pathway
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Phenobarbital; Osteoclast; NF kappa B pathway; MAPKs pathway; Bone loss
ID TERM ANTICONVULSANT THERAPY; BONE MINERAL DENSITY; ANTIEPILEPTIC DRUGS;
   PHENYTOIN; RANKL; ACTIVATION; RESORPTION; TURNOVER; EPILEPSY; KINASE
AB The purpose of this study was to determine the direct effects of phenobarbital (PB) on receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation and function in vitro and in vivo. Here, PB significantly inhibited osteoclast formation and bone resorption ability induced by RANKL in vitro. Meanwhile, intracellular signaling transduction analysis revealed PB specifically decreasing the phosphorylation level of nuclear factor kappa light chain enhancer of activated B cells (NF kappa B) and mitogen activated protein kinase (MAPK), respectively. Besides, oral administration of PB at the dose of 60 mg/kg/day for 6 weeks led to improve the bone loss and to decrease the activity on both osteoblast and osteoclast. This suppression effect is more obvious in osteoblast induced bone formation than that on osteoclast induced bone resorption. Taken together, our findings demonstrated that PB down regulate osteoclast differentiation and activity through modulation of NF kappa B and MAPKs signaling pathway. The direct suppression effect on osteoclast can induce bone loss after long term oral administration. This bone loss is due to reducing bone turnover rate on both sides of bone formation and bone resorption.
C1 [Wang, Wei; Gao, Yuan; Li, Minqi] Shandong Univ, Dept Bone Metab, Sch Stomatol, Shandong Prov Key Lab Oral Tissue Regenerat, Jinan, Shandong, Peoples R China.
   [Wang, Wei; Zheng, Wenwen; Zheng, Xuexing] Shandong Univ, Sch Publ Hlth, Wenhua West Rd 44 1, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University; Shandong University
RP Li, MQ; Zheng, XX (通讯作者)，Shandong Univ, Sch Publ Hlth, Wenhua West Rd 44 1, Jinan 250012, Shandong, Peoples R China.; Li, MQ; Zheng, XX (通讯作者)，Shandong Univ, Sch Stomatol, Wenhua West Rd 44 1, Jinan 250012, Shandong, Peoples R China.
EM liminqi@sdu.edu.cn; zhengxx2513@hotmail.com
RI wang, wei/AAQ 8113 2021; GAO, YUAN/B 9221 2008
OI wang, wei/0009 0006 6757 7674
FU Shandong Provincial Natural Science Foundation [ZR2016CQ18]; China
   Postdoctoral Science Foundation [2015M580592, 2016T90637]; National
   Natural Science Foundation of China [81470719, 81611140133]
FX We thank all the subjects who participated in this study. This work was
   supported by Shandong Provincial Natural Science Foundation (No.
   ZR2016CQ18), the China Postdoctoral Science Foundation funded project
   (Nos. 2015M580592, 2016T90637) to Zheng X, and the National Natural
   Science Foundation of China (Nos. 81470719, 81611140133) to Li M.
CR Andress DL, 2002, ARCH NEUROL CHICAGO, V59, P781, DOI 10.1001/archneur.59.5.781
   Ang E, 2011, J CELL BIOCHEM, V112, P89, DOI 10.1002/jcb.22800
   [Anonymous], 2016, Int J Mol Sci
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   CHAMBERS TJ, 1982, J PATHOL, V136, P27, DOI 10.1002/path.1711360104
   DENT CE, 1970, BRIT MED J, V4, P69, DOI 10.1136/bmj.4.5727.69
   Engel J, 1998, NEUROLOGY, V51, P1243, DOI 10.1212/WNL.51.5.1243
   Feldkamp J, 2000, EXP CLIN ENDOCR DIAB, V108, P37
   Fitzpatrick LA, 2004, EPILEPSY BEHAV, V5, pS3, DOI 10.1016/j.yebeh.2003.11.026
   HAHN TJ, 1972, J CLIN INVEST, V51, P741, DOI 10.1172/JCI106868
   HAHN TJ, 1978, J CLIN INVEST, V62, P406, DOI 10.1172/JCI109142
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Jetté N, 2011, ARCH NEUROL CHICAGO, V68, P107, DOI 10.1001/archneurol.2010.341
   Kanda J, 2017, BIOL PHARM BULL, V40, P1934, DOI 10.1248/bpb.b17 00482
   Khalid AB, 2016, BONE, V87, P130, DOI 10.1016/j.bone.2016.03.016
   Koide M, 2009, J BONE MINER RES, V24, P1469, DOI [10.1359/jbmr.090302, 10.1359/JBMR.090302]
   Lee RH, 2010, AM J GERIATR PHARMAC, V8, P34, DOI 10.1016/j.amjopharm.2010.02.003
   Li MQ, 2013, HISTOL HISTOPATHOL, V28, P327, DOI 10.14670/HH 28.327
   Lowe SA, 2001, BEST PRACT RES CL OB, V15, P863, DOI 10.1053/beog.2001.0234
   NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014 5793(95)00153 Z
   Nicholas JM, 2013, SEIZURE EUR J EPILEP, V22, P37, DOI 10.1016/j.seizure.2012.10.002
   Nicholas JM, 2012, SEIZURE EUR J EPILEP, V21, P466, DOI 10.1016/j.seizure.2012.04.014
   Oda K, 1999, J BIOCHEM, V126, P694, DOI 10.1093/oxfordjournals.jbchem.a022505
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Suzuki H, 1996, ENDOCRINOLOGY, V137, P4685, DOI 10.1210/en.137.11.4685
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tao HR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023199
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tsukahara H, 2002, PEDIATR INT, V44, P247, DOI 10.1046/j.1442 200X.2002.01561.x
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Verrotti A, 2000, ANN NEUROL, V47, P385, DOI 10.1002/1531 8249(200003)47:3<385::AID ANA18>3.0.CO;2 W
   Wlodarczyk BJ, 2012, AM J MED GENET A, V158A, P2071, DOI 10.1002/ajmg.a.35438
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Yan Y, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00349
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zhao HB, 2006, J BONE MINER RES, V21, P456, DOI 10.1359/JBMR.051204
NR 38
TC 6
Z9 8
U1 1
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD APR
PY 2019
VL 69
BP 118
EP 125
DI 10.1016/j.intimp.2019.01.033
PG 8
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA HR4OG
UT WOS:000463125200014
PM 30703706
DA 2025 08 17
ER

PT J
AU Zeng, JW
   Li, C
   Gu, ZC
AF Zeng, Jianwei
   Li, Cheng
   Gu, Zuchao
TI A network pharmacological study to unveil the mechanisms of
   xianlinggubao capsule in the treatment of osteoarthritis and
   osteoporosis
SO ARCHIVES OF MEDICAL SCIENCE
LA English
DT Article
DE network pharmacology; traditional Chinese medicine; osteoarthritis;
   osteoporosis; KEGG
ID ESTROGEN RECEPTOR MODULATOR; BONE MASS; OSTEOBLAST; CELLS; KINASE;
   ENDOMETRIUM; INHIBITION; PATHWAY; DRUGS; TRIAL
AB Introduction: Xianlinggubao (XLGB) capsule is a traditional Chinese medicine, which is approved by the Chinese State Food and Drug Administration (CFDA) for osteoarthritis (OA) and osteoporosis (OP). However, as a capsule with complex ingredients, the molecular mechanisms supporting the therapeutic effects have not been explored. Material and methods: A network pharmacology  based approach was conducted to explore the complex interactome among the targets of the XLGB active compounds. Results: The herbs in the capsule contain 41 compounds with 246 high score targets, which cover four known OA targets (PTGS1, PTGS2, PTGER4 and TNF) and six known OP targets (AR, ESR1, PGR, PTGER2, TNFSF11 and VDR) of FDA  approved drugs or drugs undergoing clinical trials. The protein  protein interaction (PPI) network of the 246 targets had six key modules. Among the six modules, neuroactive ligand receptor interaction, cAMP signaling pathway and calcium signaling pathway are the key pathways, which are all closely associated with the degeneration of joint cartilage and bone formation and resorption. Conclusions: Neuroactive ligand receptor interaction, cAMP signaling pathway, and calcium signaling pathway might be the critical pathways upon which the capsule might act. The present study laid down a foundation to understand the molecular mechanisms of the XLGB capsule and also provided fundamental information for better improvement of the drug with the concept "less herbal materials for achieving equal treatment efficacy".
C1 [Zeng, Jianwei; Li, Cheng; Gu, Zuchao] Chengdu Integrated TCM & Western Med Hosp, Dept Orthopaed, Chengdu, Peoples R China.
RP Gu, ZC (通讯作者)，Chengdu Integrated TCM & Western Med Hosp, Dept Orthopaed, Chengdu, Peoples R China.
EM zuchaogu@foxmail.com
RI jianwei, zeng/ABH 1004 2021
CR Archer DF, 2009, MENOPAUSE, V16, P1109, DOI 10.1097/gme.0b013e3181a818db
   ATKINSON MH, 1995, CLIN THER, V17, P827, DOI 10.1016/0149 2918(95)80061 1
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 2
   Cheng YM, 2013, J ETHNOPHARMACOL, V145, P85, DOI 10.1016/j.jep.2012.09.055
   Deal CL, 2006, WOMENS HEALTH, V2, P199, DOI 10.2217/17455057.2.2.199
   Edelstein Daniel, 2006, Expert Opin Emerg Drugs, V11, P685, DOI 10.1517/14728214.11.4.685
   Fisch KM, 2018, OSTEOARTHR CARTILAGE, V26, P1531, DOI 10.1016/j.joca.2018.07.012
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609
   Giacobini P, 2013, SEMIN CELL DEV BIOL, V24, P190, DOI 10.1016/j.semcdb.2012.11.005
   Herber CB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08046 4
   Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007 1110
   Kalyanaraman H, 2017, J BONE MINER RES, V32, P46, DOI 10.1002/jbmr.2909
   Kao R, 2012, ENDOCRINE, V42, P622, DOI 10.1007/s12020 012 9717 9
   Koskinen A, 2011, CLIN EXP RHEUMATOL, V29, P57
   Li YH, 2018, NUCLEIC ACIDS RES, V46, pD1121, DOI 10.1093/nar/gkx1076
   Liu Q, 2018, J ORAL REHABIL, V45, P442, DOI 10.1111/joor.12629
   Liu ZY, 2016, SCI REP UK, V6, DOI 10.1038/srep21146
   Luo J, 2009, DEVELOPMENT, V136, P2747, DOI 10.1242/dev.033571
   Mullard A, 2011, NAT REV DRUG DISCOV, V10, P82, DOI 10.1038/nrd3370
   Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v
   Plebanczyk M, 2019, INFLAMMATION, V42, P375, DOI 10.1007/s10753 018 0901 9
   Qin L, 2005, J BONE MINER METAB, V23, P55, DOI 10.1007/BF03026324
   Rangaswami H, 2012, J BIOL CHEM, V287, P21509, DOI 10.1074/jbc.M112.347245
   Rong J, 2019, CALCIFIED TISSUE INT, V104, P331, DOI 10.1007/s00223 018 0494 1
   Schiller M, 2010, J BIOL CHEM, V285, P409, DOI 10.1074/jbc.M109.038620
   Sharan K, 2011, J BONE MINER RES, V26, P2096, DOI 10.1002/jbmr.434
   Silva Fernández L, 2010, NEW ENGL J MED, V362, P2228
   Studer RK, 2003, J ORTHOPAED RES, V21, P914, DOI 10.1016/S0736 0266(03)00029 9
   Tamma Roberto, 2012, Inflammation & Allergy Drug Targets, V11, P196
   Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875
   Van Hecken A, 2000, J CLIN PHARMACOL, V40, P1109
   Wang F, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/1827528
   Wang XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118184
   Wang XL, 2011, PHYTOMEDICINE, V18, P868, DOI 10.1016/j.phymed.2011.01.022
   Wegiel B, 2010, PHYTOTHER RES, V24, pS139, DOI 10.1002/ptr.3026
   Wu XL, 2017, EXP CELL RES, V360, P281, DOI 10.1016/j.yexcr.2017.09.018
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Xia BJ, 2014, CALCIFIED TISSUE INT, V95, P495, DOI 10.1007/s00223 014 9917 9
   Yao ZQ, 2008, J BIOL CHEM, V283, P9917, DOI 10.1074/jbc.M706415200
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zhang Y, 2014, CURR DRUG TARGETS, V15, P156, DOI 10.2174/13894501113149990200
   Zhu HM, 2012, OSTEOPOROSIS INT, V23, P1317, DOI 10.1007/s00198 011 1577 2
NR 43
TC 2
Z9 2
U1 3
U2 6
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA 2, POZNAN, 61 615, POLAND
SN 1734 1922
EI 1896 9151
J9 ARCH MED SCI
JI Arch. Med. Sci.
PY 2024
VL 20
IS 2
BP 557
EP 566
DI 10.5114/aoms.2020.92931
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA QV5D0
UT WOS:001223648100024
PM 38757042
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Shiomi, K
   Nagata, Y
   Kiyono, T
   Harada, A
   Hashimoto, N
AF Shiomi, Kosuke
   Nagata, Yuki
   Kiyono, Tohru
   Harada, Atsushi
   Hashimoto, Naohiro
TI Differential impact of the Bisphosphonate Alendronate on
   undifferentiated and terminally differentiated human myogenic cells
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE bioassay approaches; drug characterization studies; molecular and
   clinical pharmacology; pharmaceutical analysis; tissue and cellular
   pharmacology
ID SKELETAL MUSCLE; IN VITRO; STEM CELLS; BONE; MACROPHAGES; MECHANISM;
   KINASE; GROWTH; PROLIFERATION; CONNEXIN 43
AB ObjectivesAlendronate, a nitrogen containing bisphosphonate, is well established as a treatment for osteoporosis through regulation of osteoclast activity. Previously, the pharmacological effects of bisphosphonates on cells outside the bone environment have been considered irrelevant because of the bone targeting property of bisphosphonates. However, the chronic effects of bisphosphonates on tissue neighbouring bone, in particular skeletal muscles, should not be ignored because patients are treated with bisphosphonates for long periods.
   MethodsHere, we show that the impact of alendronate on immortalized human myogenic cells depends on growth and differentiation inducing conditions.
   Key findingsAlendronate disrupted cytoskeletal structures and prevented migration, proliferation and differentiation of undifferentiated human myogenic cells that are involved in muscle regeneration. In contrast, alendronate did not affect the morphology, gene expression or survival of terminally differentiated human myotubes.
   ConclusionsThe present results suggest that the muscle regeneration capacity of osteoporosis patients treated with bisphosphonates for long periods may be attenuated. The present research on the pharmacological effects of alendronate on cultured human myogenic cells will contribute to improvement of therapeutic strategies and optimization of rehabilitation programmes for locomotive activity in osteoporosis patients treated with bisphosphonates.
C1 [Shiomi, Kosuke; Nagata, Yuki; Hashimoto, Naohiro] Natl Ctr Geriatr & Gerontol, Dept Regenerat Med, Natl Inst Longev Sci, Oobu, Aichi 4748522, Japan.
   [Kiyono, Tohru] Natl Canc Ctr, Res Inst, Div Virol, Chuo Ku, Tokyo 104, Japan.
   [Harada, Atsushi] Hosp Oobu, Natl Ctr Geriatr & Gerontol, Div Orthoped Surg, Oobu, Aichi, Japan.
C3 National Center for Geriatrics & Gerontology; National Cancer Center  
   Japan; National Center for Geriatrics & Gerontology
RP Hashimoto, N (通讯作者)，Natl Ctr Geriatr & Gerontol, Dept Regenerat Med, 35 Gengo, Oobu, Aichi 4748522, Japan.
EM nao@ncgg.go.jp
FU Ministry of Health, Labor and Welfare of Japan; Grants in Aid for
   Scientific Research [23592176, 25462531] Funding Source: KAKEN
FX This study was supported by grants to N.H. from the Ministry of Health,
   Labor and Welfare of Japan.
CR BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763
   CECCHINI MG, 1990, J BONE MINER RES, V5, P1019
   CECCHINI MG, 1987, J BONE MINER RES, V2, P135
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723
   Girgis CM, 2013, ENDOCR REV, V34, P33, DOI 10.1210/er.2012 1012
   Goodpaster BH, 2004, PEDIATR DIABETES, V5, P219, DOI 10.1111/j.1399 543X.2004.00071.x
   Goodpaster BH, 2001, J APPL PHYSIOL, V90, P2157, DOI 10.1152/jappl.2001.90.6.2157
   HASHIMOTO N, 1994, FEBS LETT, V352, P236, DOI 10.1016/0014 5793(94)00964 3
   HASHIMOTO N, 1995, EUR J BIOCHEM, V227, P379, DOI 10.1111/j.1432 1033.1995.tb20400.x
   Hashimoto N, 2006, BIOCHEM BIOPH RES CO, V348, P1383, DOI 10.1016/j.bbrc.2006.08.006
   Lezcano V, 2012, ARCH BIOCHEM BIOPHYS, V518, P95, DOI 10.1016/j.abb.2011.12.022
   Matzno S, 2009, J PHARM PHARMACOL, V61, P781, DOI [10.1211/jpp/61.06.0011, 10.1211/jpp.61.06.0011]
   Mukai A, 2008, EXP CELL RES, V314, P387, DOI 10.1016/j.yexcr.2007.10.006
   Mukai A, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471 2121 14 37
   Mukai A, 2009, EXP CELL RES, V315, P3052, DOI 10.1016/j.yexcr.2009.07.010
   Muller S, 2005, ANTICANCER RES, V25, P2655
   Park JH, 2013, MENOPAUSE, V20, P747, DOI [10.1097/GME.0b013e31827cabca, 10.1097/gme.0b013e31827cabca]
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2008, J BONE MINER RES, V23, P1712, DOI [10.1359/jbmr.080617, 10.1359/JBMR.080617]
   Rivas D, 2007, PPAR RES, V2007, DOI 10.1155/2007/81654
   Rogers MJ, 1996, J BONE MINER RES, V11, P1482
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Shiomi K, 2011, GENE THER, V18, P857, DOI 10.1038/gt.2011.44
   STEVENSON PH, 1986, CALCIFIED TISSUE INT, V38, P227, DOI 10.1007/BF02556715
   Susa M, 2009, ANTICANCER RES, V29, P1879
   Töyräs A, 2003, EUR J PHARM SCI, V19, P223, DOI 10.1016/S0928 0987(03)00108 8
   Wada MR, 2002, DEVELOPMENT, V129, P2987
   Widrick JJ, 2007, MENOPAUSE, V14, P528, DOI 10.1097/01.gme.0000227861.35226.fa
   Yanagisawa M, 2011, EXP CELL RES, V317, P221, DOI 10.1016/j.yexcr.2010.10.011
NR 33
TC 14
Z9 15
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3573
EI 2042 7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD MAR
PY 2014
VL 66
IS 3
BP 418
EP 427
DI 10.1111/jphp.12171
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AA8PI
UT WOS:000331357000009
PM 24533824
OA Bronze
DA 2025 08 17
ER

PT J
AU Hou, J
   Su, HJ
   Kuang, XC
   Qin, WC
   Liu, KB
   Pan, KX
   Zhang, BK
   Yang, SJ
   Yang, SH
   Peng, X
   Nie, XY
   Hua, QK
AF Hou, Jun
   Su, Hongjie
   Kuang, Xiaocong
   Qin, Wencong
   Liu, Kaibing
   Pan, Kaixiang
   Zhang, Bokai
   Yang, Sijie
   Yang, Shenghui
   Peng, Xiao
   Nie, Xinyu
   Hua, Qikai
TI Knowledge Domains and Emerging Trends of Osteoblasts Osteoclasts in Bone
   Disease From 2002 to 2021: A Bibliometrics Analysis and Visualization
   Study
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE osteoblasts; osteoclasts; bone diseases; bibliometrics; citespace;
   vosviewer
ID RHEUMATOID ARTHRITIS; REGULATORY MECHANISM; POSTMENOPAUSAL WOMEN; RANKL;
   DIFFERENTIATION; DENOSUMAB; RESORPTION; NFATC1; OSTEOPROTEGERIN;
   HOMEOSTASIS
AB BackgroundOsteoblasts Osteoclasts has been a major area in bone disease research for a long time. However, there are few systematic studies in this field using bibliometric analysis. We aimed to perform a bibliometric analysis and visualization study to determine hotspots and trends of osteoblasts osteoclasts in bone diseases, identify collaboration and influence among authors, countries, institutions, and journals, and assess the knowledge base to develop basic and clinical research in the future. MethodsWe collected articles and reviews for osteoblasts osteoclasts in bone diseases from the Web of Science Core Collection. In addition, we utilized scientometrics software (CiteSpace5.8 and VOSviewer1.6.18) for visual analysis of countries/regions, institutions, authors, references, and keywords in the field. ResultsIn total, 16,832 authors from 579 institutions in 73 countries/regions have published 3,490 papers in 928 academic journals. The literature in this field is rapidly increasing, with Bone publishing the most articles, whereas Journal of Bone and Mineral Research had the most co cited journals. These two journals mainly focused on molecular biology and the clinical medicine domain. The countries with the highest number of publications were the US and China, and the University of Arkansas for Medical Sciences was the most active institution. Regarding authors, Stavros C. Manolagas published the most articles, and Hiroshi Takayanagi had the most co cited papers. Research in this field mainly includes molecular expression and regulatory mechanisms, differentiation, osteoprotection, inflammation, and tumors. The latest research hotspots are oxidative stress, mutation, osteocyte formation and absorption, bone metabolism, tumor therapy, and in depth mechanisms. ConclusionWe identified the research hotspots and development process of osteoblasts osteoclasts in bone disease using bibliometric and visual methods. Osteoblasts osteoclasts have attracted increasing attention in bone disease. This study will provide a valuable reference for researchers concerned with osteoblasts osteoclasts in bone diseases.
C1 [Hou, Jun; Su, Hongjie; Kuang, Xiaocong; Qin, Wencong; Liu, Kaibing; Pan, Kaixiang; Zhang, Bokai; Yang, Sijie; Yang, Shenghui; Peng, Xiao; Hua, Qikai] Guangxi Med Univ, Res Ctr Regenerat Med, Dept Bone & Joint Surg, Affiliated Hosp 1, Nanning, Peoples R China.
   [Hou, Jun; Su, Hongjie; Kuang, Xiaocong; Qin, Wencong; Liu, Kaibing; Pan, Kaixiang; Zhang, Bokai; Yang, Sijie; Yang, Shenghui; Peng, Xiao; Hua, Qikai] Guangxi Med Univ, Guangxi Diabetic Foot Salvage Engn Res Ctr, Nanning, Peoples R China.
   [Nie, Xinyu] Jilin Univ, Hosp 2, Dept Orthopaed, Changchun, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Jilin University
RP Hua, QK (通讯作者)，Guangxi Med Univ, Res Ctr Regenerat Med, Dept Bone & Joint Surg, Affiliated Hosp 1, Nanning, Peoples R China.; Hua, QK (通讯作者)，Guangxi Med Univ, Guangxi Diabetic Foot Salvage Engn Res Ctr, Nanning, Peoples R China.; Nie, XY (通讯作者)，Jilin Univ, Hosp 2, Dept Orthopaed, Changchun, Peoples R China.
EM niexy21@mails.jlu.edu.cn; hqk100@sr.gxmu.edu.cn
RI Su, Hongjie/KHY 8690 2024; ZHANG, BO KAI/B 1965 2017
FU Guangxi Key Research and Development Plan [2021AB11027]; Clinical
   research climbing plan of the First Affiliated Hospital of Guangxi
   Medical University [YYZS2020010]; Key Research and Development Plan of
   Qingxiu District, Nanning City [2020053]
FX Funding This study was supported by grants from the Guangxi Key Research
   and Development Plan(2021AB11027);Clinical research climbing plan of the
   First Affiliated Hospital of Guangxi Medical University(YYZS2020010);Key
   Research and Development Plan of Qingxiu District, Nanning City(2020053)
CR Abbasi M, 2019, J CELL PHYSIOL, V234, P10018, DOI 10.1002/jcp.27860
   Aspray Terry J, 2019, Subcell Biochem, V91, P453, DOI 10.1007/978 981 13 3681 2_16
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bullock J, 2018, MED PRIN PRACT, V27, P501, DOI 10.1159/000493390
   Burmester GR, 2017, LANCET, V389, P2338, DOI 10.1016/S0140 6736(17)31491 5
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Chen CM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223994
   Chen CM, 2010, J AM SOC INF SCI TEC, V61, P1386, DOI 10.1002/asi.21309
   Chen CM, 2006, J AM SOC INF SCI TEC, V57, P359, DOI 10.1002/asi.20317
   Chen CM, 2004, P NATL ACAD SCI USA, V101, P5303, DOI 10.1073/pnas.0307513100
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   Choy E, 2012, RHEUMATOLOGY, V51, pV3, DOI 10.1093/rheumatology/kes113
   Combs MD, 2009, CIRC RES, V105, P565, DOI 10.1161/CIRCRESAHA.109.196469
   Conigliaro P, 2019, AUTOIMMUN REV, V18, P706, DOI 10.1016/j.autrev.2019.05.007
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Deane KD, 2017, BEST PRACT RES CL RH, V31, P3, DOI 10.1016/j.berh.2017.08.003
   Diab DL, 2014, EXPERT OPIN DRUG SAF, V13, P247, DOI 10.1517/14740338.2014.860133
   Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood 2007 03 077685
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Gabriel SE, 2001, RHEUM DIS CLIN N AM, V27, P269, DOI 10.1016/S0889 857X(05)70201 5
   Gao Y, 2019, INT IMMUNOPHARMACOL, V72, P374, DOI 10.1016/j.intimp.2019.03.045
   Ghisi ND, 2020, SCI TOTAL ENVIRON, V733, DOI 10.1016/j.scitotenv.2020.139359
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Hu R, 2010, EXPERT OPIN THER TAR, V14, P1109, DOI 10.1517/14728222.2010.512916
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   Jeong Dae hyun, 2016, International Journal of Contents, V12, P54, DOI 10.5392/IJoC.2016.12.3.054
   Jönsson B, 2011, OSTEOPOROSIS INT, V22, P967, DOI 10.1007/s00198 010 1424 x
   Ke LX, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00842
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kerschan Schindl K, 2016, WIEN MED WOCHENSCHR, V166, P22, DOI 10.1007/s10354 015 0417 y
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Köhler BM, 2019, J CLIN MED, V8, DOI 10.3390/jcm8070938
   Li C, 2015, J DENT RES, V94, P455, DOI 10.1177/0022034514566431
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li YN, 2021, CHEMOSPHERE, V263, DOI 10.1016/j.chemosphere.2020.128238
   Liang YD, 2017, J PAIN RES, V10, P951, DOI 10.2147/JPR.S132808
   Lin YJ, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040880
   Liu CZ, 2010, J IMMUNOL, V184, P6910, DOI 10.4049/jimmunol.0904033
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Ma CQ, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.627891
   Ma D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.731933
   Malemud CJ, 2018, THER ADV MUSCULOSKEL, V10, P117, DOI 10.1177/1759720X18776224
   Malemud CJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030484
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Mizuno Y, 2008, BIOCHEM BIOPH RES CO, V368, P267, DOI 10.1016/j.bbrc.2008.01.073
   Mizuno Y, 2009, FEBS LETT, V583, P2263, DOI 10.1016/j.febslet.2009.06.006
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Niedzwiedzki T, 2015, J MOL ENDOCRINOL, V55, pR23, DOI 10.1530/JME 15 0067
   Park JH, 2017, MOL CELLS, V40, P706
   Phan TCA, 2004, HISTOL HISTOPATHOL, V19, P1325, DOI 10.14670/HH 19.1325
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Qin Y, 2020, BRAIN RES BULL, V156, P15, DOI 10.1016/j.brainresbull.2019.12.004
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rajkumar SV, 2011, NAT REV CLIN ONCOL, V8, P479, DOI 10.1038/nrclinonc.2011.63
   Rein P, 2017, RHEUMATOL THER, V4, P247, DOI 10.1007/s40744 017 0073 3
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Smith DR, 2008, CONTACT DERMATITIS, V59, P133, DOI 10.1111/j.1600 0536.2008.01405.x
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Tanaka S, 2021, J BONE MINER METAB, V39, P106, DOI 10.1007/s00774 020 01159 1
   Tateiwa D, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080818
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   van Andel H, 2019, LEUKEMIA, V33, P1063, DOI 10.1038/s41375 019 0404 1
   van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192 009 0146 3
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang YZ, 2021, NEURAL PLAST, V2021, DOI 10.1155/2021/6634644
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Zaheer S, 2015, EXPERT OPIN DRUG MET, V11, P461, DOI 10.1517/17425255.2015.1000860
   Zaiss MM, 2011, J IMMUNOL, V186, P6097, DOI 10.4049/jimmunol.1003487
   Zhang J, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.686726
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 90
TC 17
Z9 18
U1 2
U2 42
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD JUL 22
PY 2022
VL 13
AR 922070
DI 10.3389/fendo.2022.922070
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 3O8KA
UT WOS:000837082400001
PM 35937845
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Manzano Moreno, FJ
   Costela Ruiz, VJ
   Melguizo Rodríguez, L
   Illescas Montes, R
   García Martínez, O
   Ruiz, C
   Ramos Torrecillas, J
AF Javier Manzano Moreno, Francisco
   Javier Costela Ruiz, Victor
   Melguizo Rodriguez, Lucia
   Illescas Montes, Rebeca
   Garcia Martinez, Olga
   Ruiz, Concepcion
   Ramos Torrecillas, Javier
TI Inhibition of VEGF gene expression in osteoblast cells by different
   NSAIDs
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Osteoblast; NSAIDs; VEGF; Gene expression; PCR
ID ENDOTHELIAL GROWTH FACTOR; CULTURED HUMAN OSTEOBLASTS; SKELETAL
   DEVELOPMENT; PHAGOCYTIC CAPACITY; T LYMPHOCYTES; TGF BETA; BONE;
   PROLIFERATION; DRUGS; LINE
AB Objective: To determine the effect of different nonsteroidal anti inflammatory drugs (NSAIDs) on vascular endothelial growth factor (VEGF) gene expression in two osteoblast cell populations.
   Design: Osteoblasts obtained by primary culture (HOp) and human osteosarcoma cell line MG63 (MG 63), which were treated with 10 mu M doses of acetaminophen, indomethacin, ketoprofen, diclofenac, ibuprofen, ketorolac, naproxen or piroxicam. At 24 h of treatment, their gene expression of VEGF was evaluated by real time polymerase chain reaction (RT PCR) and compared with the expression in untreated cells (control group).
   Results: The treatment with the different NSAIDs significantly reduced VEGF expression regardless of the cell line and NSAID studied.
   Conclusion: The results of this study suggest that these drugs may have undesirable effects on the osteoblast and its bone forming capacity, given the effect of this growth factor on these cells. Further studies are warranted to determine their repercussions on bone tissue and to elucidate the cell signaling mechanism/s involved.
C1 [Javier Manzano Moreno, Francisco] Univ Granada, Sch Dent, Dept Stomatol, Biomed Grp BIO277, Granada, Spain.
   [Javier Manzano Moreno, Francisco; Melguizo Rodriguez, Lucia; Illescas Montes, Rebeca; Garcia Martinez, Olga; Ruiz, Concepcion; Ramos Torrecillas, Javier] Ibs Granada, Inst Invest Biosanitaria, Granada, Spain.
   [Javier Costela Ruiz, Victor; Melguizo Rodriguez, Lucia; Garcia Martinez, Olga; Ruiz, Concepcion; Ramos Torrecillas, Javier] Univ Granada, Fac Hlth Sci, Dept Nursing, Biomed Grp BIO277, Granada, Spain.
   [Illescas Montes, Rebeca] Univ Granada, Fac Hlth Sci, Dept Nursing, Biomed Grp BIO277, Melilla, Spain.
   [Ruiz, Concepcion] Univ Granada, Inst Neurosci, Parque Tecnol Ciencias Salud, Granada, Spain.
C3 University of Granada; Instituto de Investigacion Biosanitaria IBS
   Granada; University of Granada; University of Granada; University of
   Granada
RP Ruiz, C (通讯作者)，Univ Granada, Fac Hlth Sci, Avda Ilustrac S N, Granada 18016, Spain.
EM crr@ugr.es
RI Melguizo Rodríguez, Lucía/F 4683 2018; Garcia Martinez,
   Olga/L 2782 2014; García Martínez, Olga/L 2782 2014; Concepcion,
   Ruiz/L 2808 2014; Ramos Torrecillas, Javier/F 3746 2012; Ruiz,
   Concepcion/L 2808 2014; Illescas Montes, Rebeca/F 8700 2016;
   Costela Ruiz, Victor/I 5045 2018; Manzano Moreno, Francisco/B 1771 2015;
   Illescas Montes, Rebeca/N 5375 2018
OI Garcia Martinez, Olga/0000 0003 1912 4639; Concepcion,
   Ruiz/0000 0003 4332 6812; Ramos Torrecillas, Javier/0000 0002 6631 7866;
   Melguizo  Rodriguez, Lucia/0000 0002 9176 6997; Illescas Montes,
   Rebeca/0000 0001 9795 8159
FU Junta de Andalucia [BIO277]; Department of Nursing (University of
   Granada)
FX This study was supported by the research group BIO277 (Junta de
   Andalucia) and Department of Nursing (University of Granada).
CR Berendsen AD, 2015, BONE, V80, P14, DOI 10.1016/j.bone.2015.04.035
   Chang JK, 2009, TOXICOLOGY, V258, P148, DOI 10.1016/j.tox.2009.01.016
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Clarkin CE, 2013, CELL BIOCHEM FUNCT, V31, P1, DOI 10.1002/cbf.2911
   Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   De Luna Bertos E, 2013, SCI WORLD J, DOI 10.1155/2013/809891
   De Luna Bertos E, 2015, BIOL RES NURS, V17, P62, DOI 10.1177/1099800414527155
   Díaz Rodríguez L, 2009, ANN NY ACAD SCI, V1173, pE46, DOI 10.1111/j.1749 6632.2009.04950.x
   Díaz Rodríguez L, 2012, J BONE MINER METAB, V30, P554, DOI 10.1007/s00774 012 0356 2
   Díaz Rodríguez L, 2012, BIOL RES NURS, V14, P98, DOI 10.1177/1099800411398933
   Díaz Rodríguez L, 2010, ACTA PHARMACOL SIN, V31, P1495, DOI 10.1038/aps.2010.129
   Esser JS, 2015, ARTERIOSCL THROM VAS, V35, P358, DOI 10.1161/ATVBAHA.114.304345
   García Martínez O, 2015, LIFE SCI, V123, P72, DOI 10.1016/j.lfs.2015.01.009
   HARADA S, 1995, CLIN ORTHOP RELAT R, P76
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Huang HC, 2016, AM J ORTHOD DENTOFAC, V149, P366, DOI 10.1016/j.ajodo.2015.09.021
   Ikeda Kyoji, 2014, J Bone Metab, V21, P163, DOI 10.11005/jbm.2014.21.3.163
   Kasagi S, 2013, CELL BIOSCI, V3, DOI 10.1186/2045 3701 3 4
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lisignoli G, 2004, J CELL PHYSIOL, V198, P388, DOI 10.1002/jcp.10427
   Loboda A., 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/8319283
   Lucena G, 2013, BIOL RES NURS, V15, P56, DOI 10.1177/1099800411414870
   Ornitz DM, 2015, GENE DEV, V29, P1463, DOI 10.1101/gad.266551.115
   Ragni E, 2013, J CELL MOL MED, V17, P168, DOI 10.1111/j.1582 4934.2012.01660.x
   Song YH, 2016, MOL MED REP, V14, P3336, DOI 10.3892/mmr.2016.5646
   Stanley KT, 2006, J BONE MINER RES, V21, P29, DOI 10.1359/JBMR.051004
   Whynott RM, 2016, EUR J GYNAECOL ONCOL, V37, P164
   Yamamoto N, 2015, MOL CELL ENDOCRINOL, V405, P35, DOI 10.1016/j.mce.2015.02.002
   Zelzer E, 2005, CURR TOP DEV BIOL, V65, P169
   Zuo C, 2012, OSTEOPOROSIS INT, V23, P1653, DOI 10.1007/s00198 012 1909 x
NR 32
TC 16
Z9 17
U1 1
U2 13
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003 9969
EI 1879 1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD AUG
PY 2018
VL 92
BP 75
EP 78
DI 10.1016/j.archoralbio.2018.05.006
PG 4
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA GL2AM
UT WOS:000436915400011
PM 29763781
DA 2025 08 17
ER

PT J
AU Leng, YX
   Li, JT
   Long, ZS
   Li, C
   Zhang, L
   Huang, ZT
   Xi, JF
   Liu, YY
AF Leng, Yuanxi
   Li, Jingtang
   Long, Zhisheng
   Li, Chen
   Zhang, Liang
   Huang, Zutai
   Xi, Jinfeng
   Liu, Yayun
TI Osteoblast derived exosomes promote osteogenic differentiation of
   osteosarcoma cells via URG4/Wnt signaling pathway
SO BONE
LA English
DT Article
DE Osteosarcoma; Differentiation therapy; Osteoblasts; Exosomes; URG4
ID WNT; GENE
AB Osteosarcoma is a primary malignant bone tumor. Although surgery and chemotherapy are the main treatment methods, the overall curative effect remains unsatisfactory. Therefore, there is an urgent need to develop new therapeutic options for osteosarcoma. In this study, the effect and molecular mechanism of osteoblast derived exosomes on the treatment of osteosarcoma were evaluated. Human primary osteoblasts were cultured to observe the effects of osteoblast derived exosomes on the osteogenic differentiation of osteosarcoma cells both in vitro and in vivo. Alizarin red staining and alkaline phosphatase detection were used to evaluate the degree of osteogenic differentiation, and immunofluorescence and Western blotting were used to detect protein expression. The results showed that osteoblast derived exosomes effectively inhibited the proliferation of osteosarcoma cells and promoted their mineralization in vitro. The exosomes also significantly inhibited tumor growth and promoted tumor tissue mineralization in vivo. Osteoblast derived exosomes upregulated the expression of bone sialoprotein, osteonectin, osteopontin, runt related transcription factor 2, and Wnt inhibitory factor 1, down regulated the expression of cyclin D1, and suppressed the nuclear accumulation of beta catenin and promoted its phosphorylation in vitro and in vivo. However, these effects were significantly reversed by upregulated gene (URG) 4 overexpression. These findings suggest that osteoblast derived exosomes could activate the osteogenic differentiation process in osteosarcoma cells and promote their differentiation by targeting the URG4/Wnt signaling pathway.
C1 [Leng, Yuanxi] Jiangxi Univ Tradit Chinese Med, Orthoped & Traumatol Dept 6, Affiliated Hongdu Tradit Chinese Med Hosp, Nanchang 330008, Jiangxi, Peoples R China.
   [Li, Jingtang; Long, Zhisheng; Li, Chen; Zhang, Liang; Huang, Zutai; Xi, Jinfeng; Liu, Yayun] Jiangxi Prov Peoples Hosp, Nanchang Med Coll, Dept Orthopaed, Jiangxi Prov Peoples Hosp,Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China.
C3 Jiangxi University of Traditional Chinese Medicine; Nanchang Medical
   College
RP Liu, YY (通讯作者)，Jiangxi Prov Peoples Hosp, Nanchang Med Coll, Dept Orthopaed, Jiangxi Prov Peoples Hosp,Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China.
EM nclyy2005265@126.com
FU National Natural Science Founda  tion of China [82160528, 32060222];
   Science Technology Foundation of Jiangxi Province [20212BAB206059]
FX <BOLD>Funding</BOLD> This study was supported by the National Natural
   Science Founda  tion of China (82160528 and 32060222) and Science
   Technology Foundation of Jiangxi Province (20212BAB206059) .
CR Adamopoulos C, 2016, EXP BIOL MED, V241, P1296, DOI 10.1177/1535370216648806
   Avci CB, 2013, TUMOR BIOL, V34, P3853, DOI 10.1007/s13277 013 0970 1
   Baker EK, 2015, BONE, V73, P223, DOI 10.1016/j.bone.2014.12.063
   Cai Y, 2014, J CELL BIOCHEM, V115, P625, DOI 10.1002/jcb.24708
   Chang XY, 2021, J BONE ONCOL, V29, DOI 10.1016/j.jbo.2021.100372
   Colozza G, 2021, DEV GROWTH DIFFER, V63, P199, DOI 10.1111/dgd.12718
   Czarnecka AM, 2020, CANCERS, V12, DOI 10.3390/cancers12082130
   de Thé H, 2018, NAT REV CANCER, V18, P117, DOI 10.1038/nrc.2017.103
   Denduluri SK, 2016, J BIOMED RES, V30, P5, DOI 10.7555/JBR.30.20150075
   Dodurga Y, 2018, GENE, V668, P12, DOI 10.1016/j.gene.2018.05.047
   Dodurga Y, 2013, WSPOLCZESNA ONKOL, V17, P346, DOI 10.5114/wo.2013.34634
   DUDLEY HR, 1961, J BIOPHYS BIOCHEM CY, V11, P627, DOI 10.1083/jcb.11.3.627
   Ge M, 2015, BIOCHEM BIOPH RES CO, V467, P27, DOI 10.1016/j.bbrc.2015.09.135
   Jeppesen DK, 2019, CELL, V177, P428, DOI 10.1016/j.cell.2019.02.029
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kerekes K, 2019, GROWTH FACTORS, V37, P29, DOI 10.1080/08977194.2019.1626380
   Lee DF, 2015, CELL, V161, P240, DOI 10.1016/j.cell.2015.02.045
   Liu J, 2017, CURR OPIN PHARMACOL, V34, P64, DOI 10.1016/j.coph.2017.08.008
   Liu YY, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01681 y
   Lou GH, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045 015 0220 7
   Lu KH, 2020, PHARMACOL THERAPEUT, V214, DOI 10.1016/j.pharmthera.2020.107611
   Masaoutis C, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/9417914
   Matsuoka K, 2020, CELL RES, V30, P885, DOI 10.1038/s41422 020 0370 1
   Osuna MAL, 2019, CANCER RES, V79, P1054, DOI 10.1158/0008 5472.CAN 18 1255
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Ratti C, 2017, CLIN CANCER RES, V23, P5149, DOI 10.1158/1078 0432.CCR 16 3186
   Rickel K, 2017, BONE, V102, P69, DOI 10.1016/j.bone.2016.10.017
   Sarhadi VK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222011035
   Singla A, 2020, ADV EXP MED BIOL, V1258, P125, DOI 10.1007/978 3 030 43085 6_8
   Steinhart Z, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146589
   Sui C, 2019, EXP THER MED, V17, P2235, DOI 10.3892/etm.2019.7171
   Teufel S, 2019, CURR TOP DEV BIOL, V133, P235, DOI 10.1016/bs.ctdb.2018.11.010
   Tufan NLS, 2002, NEOPLASIA, V4, P355, DOI 10.1038/sj.neo.7900241
   Wei HX, 2019, INT J NANOMED, V14, P8603, DOI 10.2147/IJN.S218988
   Yuan HR, 2021, J CELL PHYSIOL, V236, P1810, DOI 10.1002/jcp.29963
   Zhang Y, 2020, INT J NANOMED, V15, P6917, DOI 10.2147/IJN.S264498
   Zhao B, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9290728
NR 37
TC 8
Z9 9
U1 6
U2 39
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2024
VL 178
AR 116933
DI 10.1016/j.bone.2023.116933
EA OCT 2023
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA Y6PE0
UT WOS:001106451500001
PM 37832904
DA 2025 08 17
ER

PT J
AU Chen, B
   Luo, YQ
   Zhang, ZX
   Lin, SH
   Wang, RK
   Li, BF
AF Chen, Bei
   Luo, Yeqiang
   Zhang, Zhongxiu
   Lin, Shanghui
   Wang, Renkai
   Li, Baofeng
TI Extracorporeal shock wave therapy inhibits osteoclast differentiation by
   targeting NF κB signaling pathway
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Extracorporeal shock wave therapy; Osteoclast differentiation; NF kappa
   B signaling pathway; NTAFc1
ID FRACTURE
AB Background Extracorporeal shock wave therapy (ESWT) has been reported to promote osteoblast differentiation. However, the role of ESWT on osteoclast differentiation is still elusive.Methods This study analyzed the differentiation of osteoclasts in the shock wave group and the control group in vitro, and TRAP staining, RT PCR, WB assays, and MTT assays were assessed between the two groups. Furthermore, we analyzed the bone formation in these two groups in vivo and micro CT and trap staining were assessed between the two groups.Results We found that ESWT inhibited osteoclast maturation in vitro and ESW treatment of femur promoted bone formation in vivo. Mechanically, osteoclast differentiation was inhibited as the number of impulses increased and ESWT decreased endogenous levels of NTAFc1 and P65 protein.Conclusions ESWT may be a potential therapy of osteoporosis through NF kappa B signaling pathway.
C1 [Chen, Bei; Li, Baofeng] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China.
   [Luo, Yeqiang; Lin, Shanghui; Wang, Renkai; Li, Baofeng] Gen Hosp Southern Theater Command PLA, Dept Orthopaed, Guangdong Key Lab Orthoped Technol & Implant Mat, Guangzhou, Peoples R China.
   [Zhang, Zhongxiu] Gen Hosp Southern Theater Command PLA, Dept Anesthesiol, Guangzhou, Peoples R China.
C3 Southern Medical University   China; Southern Theater Command General
   Hospital; Southern Theater Command General Hospital
RP Li, BF (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China.; Wang, RK; Li, BF (通讯作者)，Gen Hosp Southern Theater Command PLA, Dept Orthopaed, Guangdong Key Lab Orthoped Technol & Implant Mat, Guangzhou, Peoples R China.
EM 501214241@qq.com; niren79817@163.com
FU National Natural Science Foundation of China [81972895]; General
   Hospital of Southern Theater Command of PLA Fund project [2022NZA002,
   2021NZC018]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81972895) and General Hospital of Southern Theater Command of
   PLA Fund project (Nos. 2022NZA002 and 2021NZC018)
CR Chen HS, 2001, CLIN ORTHOP RELAT R, P41
   Clark D, 2017, CURR OSTEOPOROS REP, V15, P601, DOI 10.1007/s11914 017 0413 9
   Fiani B, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.11200
   Hsu RWW, 2004, J ORTHOP RES, V22, P221, DOI 10.1016/S0736 0266(03)00138 4
   Huang J, 2018, THERANOSTICS, V8, P2435, DOI 10.7150/thno.22144
   Li BF, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.627718
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Maffulli G, 2014, TRANSL MED UNISA, V10, P46
   Maffulli N, 2023, CLIN ORTHOP RELAT R, V481, P835, DOI 10.1097/CORR.0000000000002587
   Ogden JA, 2001, CLIN ORTHOP RELAT R, P47, DOI 10.1097/00003086 200106000 00007
   Roehrig Gregory J, 2005, Foot Ankle Clin, V10, P699, DOI 10.1016/j.fcl.2005.06.002
   Rompe JD, 2001, CLIN ORTHOP RELAT R, P72
   Schleusser S, 2020, CLIN ORTHOP RELAT R, V478, P127, DOI 10.1097/CORR.0000000000000993
   Schmitz C, 2015, BRIT MED BULL, V116, P115, DOI 10.1093/bmb/ldv047
   Shi L, 2017, OSTEOPOROSIS INT, V28, P2945, DOI 10.1007/s00198 017 4136 7
   Wang FS, 2001, BIOCHEM BIOPH RES CO, V287, P648, DOI 10.1006/bbrc.2001.5654
   Wang RK, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2377 4
   Wu WK, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02852 1
   Xu SY, 2021, J CELL MOL MED, V25, P4572, DOI 10.1111/jcmm.16216
   Zhang H, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.666140
NR 20
TC 3
Z9 4
U1 1
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD OCT 27
PY 2023
VL 18
IS 1
AR 805
DI 10.1186/s13018 023 04166 w
PG 7
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA X1MW3
UT WOS:001096166700002
PM 37891600
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Henriksen, K
   Tanko, LB
   Qvist, P
   Delmas, PD
   Christiansen, C
   Karsdal, MA
AF Henriksen, K.
   Tanko, L. B.
   Qvist, P.
   Delmas, P. D.
   Christiansen, C.
   Karsdal, M. A.
TI Assessment of osteoclast number and function: application in the
   development of new and improved treatment modalities for bone diseases
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE CTX I; osteoclast number; resorption; TRAcP; TRAP 5b
ID RESISTANT ACID PHOSPHATASE; AUTOSOMAL DOMINANT OSTEOPETROSIS;
   ALENDRONATE TREATMENT; BIOCHEMICAL MARKERS; POSTMENOPAUSAL WOMEN;
   PARATHYROID HORMONE; CATHEPSIN K; I COLLAGEN; TERMINAL TELOPEPTIDE;
   RESORPTION
AB Numerous experimental and clinical observations suggest that overall changes in bone resorption during menopause or treatment with hormone replacement therapy (HRT) are combined effects of changes in osteoclast number and function. Moreover, due to a coupling between osteoclastic bone resorption and osteoblastic bone formation, pronounced alteration of osteoclast number will eventually lead to alteration of osteoblastic bone formation. Fragments of type I collagen, such as the C  and N terminal telopeptides of collagen type I (CTX and NTX, respectively), are generated during bone resorption and hence can be used as surrogate markers of osteoclast function. Circulating levels of different enzymes in the serum, such as TRAP 5b and cathepsin K are proportional to the number of osteoclasts, and hence can be used as surrogate markers of osteoclast number. Since antiresorptive effects can be obtained in different ways, we felt it was timely to discuss the different scenarios, highlight differences specific to different pharmacological interventions with different mechanisms of action, and discuss how these bone markers can assist us in a deeper analysis of the pharmacodynamics and safety profile of existing and upcoming drug candidates.
C1 Nordic Biosci AS, DK 2730 Herlev, Denmark.
   CCBR, Ballerup, Denmark.
   INSERM, F 69008 Lyon, France.
   Univ Lyon 1, F 69365 Lyon, France.
C3 Center Clinical & Basic Research; Synarc; Institut National de la Sante
   et de la Recherche Medicale (Inserm); Universite Claude Bernard Lyon 1
RP Karsdal, MA (通讯作者)，Nordic Biosci AS, Herlev Hovedgade 207, DK 2730 Herlev, Denmark.
EM mk@nordicbioscience.com
OI Karsdal, Morten/0000 0001 5026 8740
CR Alatalo SL, 2004, CLIN CHEM, V50, P883, DOI 10.1373/clinchem.2003.029355
   Baron R., 2003, ASBMR, P1
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   BOLLERSLEV J, 1993, BONE, V14, P865, DOI 10.1016/8756 3282(93)90316 3
   CAPPARELLI C, 2000, J BONE MINER RES S1, V15
   Christgau S, 2000, BONE, V26, P505, DOI 10.1016/S8756 3282(00)00248 9
   Del Fattore A, 2006, J MED GENET, V43, P315, DOI 10.1136/jmg.2005.036673
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Garnero P, 2000, J BONE MINER RES, V15, P1526, DOI 10.1359/jbmr.2000.15.8.1526
   Gertz BJ, 1998, CALCIFIED TISSUE INT, V63, P102, DOI 10.1007/s002239900497
   Halleen JM, 2003, ANTICANCER RES, V23, P1027
   Halleen JM, 2000, J BONE MINER RES, V15, P1337, DOI 10.1359/jbmr.2000.15.7.1337
   Hamdy Neveen A T, 2006, Curr Rheumatol Rep, V8, P50
   Hannon RA, 2004, BONE, V34, P187, DOI 10.1016/j.bone.2003.04.002
   HANNON RA, 2005, EUR CALC TISS SOC C
   Hansdóttir H, 2004, J AM GERIATR SOC, V52, P779, DOI 10.1111/j.1532 5415.2004.52218.x
   Hart SM, 1999, CURR OPIN NEPHROL HY, V8, P421, DOI 10.1097/00041552 199907000 00005
   Heaney RP, 2003, BONE, V33, P457, DOI 10.1016/S8756 3282(03)00236 9
   Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002 9440(10)63712 1
   Holzer G, 2005, J LAB CLIN MED, V146, P13, DOI 10.1016/j.lab.2005.03.016
   Karsdal MA, 2005, AM J PATHOL, V166, P467, DOI 10.1016/S0002 9440(10)62269 9
   Karsdal MA, 2003, J BIOL CHEM, V278, P44975, DOI 10.1074/jbc.M303905200
   Kirstein B, 2006, J CELL BIOCHEM, V98, P1085, DOI 10.1002/jcb.20835
   Koh AJ, 2005, ENDOCRINOLOGY, V146, P4584, DOI 10.1210/en.2005 0333
   KOSTENUIK P, 2005, J BONE MINER RES S1, V20
   Ljusberg J, 2005, J BIOL CHEM, V280, P28370, DOI 10.1074/jbc.M502469200
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   MARTINEZ E, 1993, DIFFER GEOM APPL, V3, P1, DOI 10.1016/0926 2245(93)90020 2
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Meier C, 2006, CLIN LAB, V52, P1
   Nenonen A, 2005, J BONE MINER RES, V20, P1804, DOI 10.1359/JBMR.050403
   Plé PA, 2004, J MED CHEM, V47, P871, DOI 10.1021/jm030317k
   Qvist P, 2002, BONE, V31, P57, DOI 10.1016/S8756 3282(02)00791 3
   Ravn P, 1999, BONE, V24, P237, DOI 10.1016/S8756 3282(98)00183 5
   Ravn P, 1999, J CLIN ENDOCR METAB, V84, P2363, DOI 10.1210/jc.84.7.2363
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   RISSANEN JP, 2005, J BONE MINER RES S1, V20
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Schaller S, 2004, J BONE MINER RES, V19, P1144, DOI 10.1359/JBMR.040302
   SCHLEMMER A, 1992, J CLIN ENDOCR METAB, V74, P476, DOI 10.1210/jc.74.3.476
   SIMMONS DJ, 1988, ANAT RECORD, V222, P228, DOI 10.1002/ar.1092220303
   Tähtelä R, 2005, OSTEOPOROSIS INT, V16, P1109, DOI 10.1007/s00198 004 1819 7
   Vaananen HK, 1996, MATURITAS, V23, pS65
   Woitge HW, 1999, J BONE MINER RES, V14, P792, DOI 10.1359/jbmr.1999.14.5.792
NR 45
TC 110
Z9 122
U1 0
U2 4
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAY
PY 2007
VL 18
IS 5
BP 681
EP 685
DI 10.1007/s00198 006 0286 8
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 152KQ
UT WOS:000245361300013
PM 17124552
DA 2025 08 17
ER

PT J
AU Wu, J
   Shen, Q
   Cui, W
   Zhao, Y
   Huai, Y
   Zhang, YC
   Bao, BH
   Liu, CX
   Jiang, Q
   Li, JX
AF Wu, Jing
   Shen, Qi
   Cui, Wei
   Zhao, Yu
   Huai, Yue
   Zhang, Yu chao
   Bao, Bei hua
   Liu, Chen xi
   Jiang, Qing
   Li, Jian xin
TI Dual roles of QOA 8a in antiosteoporosis: a combination of bone anabolic
   and anti resorptive effects
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE QOA 8a; oleanolic acid; antiosteoporosis; osteoclasts; osteoblasts; OVX
   rat model; bone mineral density; dual energy X ray absorptiometry;
   microcomputed tomography
ID OSTEOCLAST DIFFERENTIATION; STRONTIUM RANELATE; OSTEOPOROSIS; JNK
AB Osteoporotic treatments have largely depended on antiresorptive or anabolic drugs; but the former also suppresses new bone formation, and the latter only includes human parathyroid hormone. There is no drug that has a dual effect to inhibit bone resorption and to stimulate bone formation simultaneously. Here, we report a small molecule, a quinoxaline derivative of oleanolic acid (QOA 8a) that plays such dual roles in osteoblasts and osteoclasts in the treatment of osteoporosis. Osteoclast differentiation was induced by incubation of primary mouse bone marrow derived macrophages in the presence of RANKL and M CSF, treatment with QOA 8a dose dependently inhibited the osteoclast formation with an IC50 value of 0.098 mu mol/L. QOA 8a also directly acted on osteoblasts, and stimulated new bone formation in murine calvarial bones in vitro and in vivo. In an OVX rat model, administration of QOA 8a (1, 5 mg.kg( 1).d( 1), po) for 16 weeks effectively prevented OVX induced bone loss, accompanied by decreased serum levels of the bone resorption marker CTX 1 and increased serum levels of osteoblast marker N MID OT. Meaningfully, our preliminary study revealed that QOA 8a down regulated the ERK1/2 signal in osteoclasts and up regulated the signal in osteoblasts. QOA 8a showed dual functions in both animal and human osteoclastogenesis and osteoblastogenesis. Our results demonstrate that QOA 8a might serve as a lead compound with a dual function of bone anabolic and anti resorptive effects in the development of anti osteoporosis agents.
C1 [Wu, Jing; Shen, Qi; Cui, Wei; Zhao, Yu; Huai, Yue; Zhang, Yu chao; Bao, Bei hua; Liu, Chen xi; Li, Jian xin] Nanjing Univ, Sch Chem & Chem Engn, State Key Lab Analyt Chem Life Sci, Nanjing 210023, Jiangsu, Peoples R China.
   [Wu, Jing; Shen, Qi; Cui, Wei; Zhao, Yu; Huai, Yue; Zhang, Yu chao; Bao, Bei hua; Liu, Chen xi; Li, Jian xin] Nanjing Univ, Sch Chem & Chem Engn, Collaborat Innovat Ctr Chem Life Sci, Nanjing 210023, Jiangsu, Peoples R China.
   [Wu, Jing; Jiang, Qing] Nanjing Univ, Med Sch, Nanjing 210093, Jiangsu, Peoples R China.
C3 Nanjing University; Nanjing University; Nanjing University
RP Li, JX (通讯作者)，Nanjing Univ, Sch Chem & Chem Engn, State Key Lab Analyt Chem Life Sci, Nanjing 210023, Jiangsu, Peoples R China.; Li, JX (通讯作者)，Nanjing Univ, Sch Chem & Chem Engn, Collaborat Innovat Ctr Chem Life Sci, Nanjing 210023, Jiangsu, Peoples R China.
EM lijxnju@nju.edu.cn
RI ; Zhang, Yuchao/IAM 9288 2023; Liu, Zhipeng/IUM 2978 2023; Zhao,
   Yu/HCH 7024 2022; Wu, Jing/NOE 3383 2025; Li, Jianxin/IWE 1439 2023
OI Zhang, Yuchao/0009 0003 2029 9871; Bao, Bei hua/0000 0002 6067 3093; 
FU National Natural Science Foundation of China [21272114, 90913023]
FX This work was supported by the National Natural Science Foundation of
   China (No 21272114, 90913023). We thank the Shanghai Synchrotron
   Radiation Facility (SSRF) for the micro computed tomography (mu CT)
   analysis of bone. We thank Prof Shigetoshi KADOTA and Dr Feng LI from
   the University of Toyama, Japan, for the peripheral quantitative
   computed tomography (pQCT) analysis of bone.
CR Aw D, 2016, POSTGRAD MED J, V92, P267, DOI 10.1136/postgradmedj 2015 133454
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bell KJL, 2012, J BONE MINER RES, V27, P195, DOI 10.1002/jbmr.525
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006 0346
   Deal C, 2009, NAT CLIN PRACT RHEUM, V5, P20, DOI 10.1038/ncprheum0977
   Deeks ED, 2010, DRUG AGING, V27, P771, DOI 10.2165/11206440 000000000 00000
   Dempster David W, 2011, Am J Manag Care, V17 Suppl 6, pS164
   Fuchs RK, 2008, OSTEOPOROSIS INT, V19, P1331, DOI 10.1007/s00198 008 0602 6
   Garber K, 2016, NAT REV DRUG DISCOV, V15, P445, DOI 10.1038/nrd.2016.132
   GeneralOffice of the Ministry of Health of the Peoples Republic ofChina, 2011, CAP J PUBLICHEALTH, V5, P146
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Gupta A, 2016, AUST PRESCR, V39, P40, DOI 10.18773/austprescr.2016.028
   Harslof T, 2016, CURR OPIN PHARMACOL, V28, P38, DOI 10.1016/j.coph.2016.02.012
   He CC, 2010, J ETHNOPHARMACOL, V127, P229, DOI 10.1016/j.jep.2009.11.016
   Herrero S, 2016, EUR J PHARMACOL, V779, P8, DOI 10.1016/j.ejphar.2016.02.053
   Hofbauer LC, 2015, LANCET, V386, P1116, DOI 10.1016/S0140 6736(15)61175 8
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Ilic D, 2016, VOJNOSANIT PREGL, V73, P261, DOI 10.2298/VSP140909090I
   Johnell O, 2004, OSTEOPOROSIS INT, V15, P38, DOI 10.1007/s00198 003 1490 4
   Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198 012 2074 y
   Kharkwal G, 2012, J MOL ENDOCRINOL, V48, P261, DOI 10.1530/JME 11 0061
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Koch Linda, 2013, Nat Rev Endocrinol, V9, P442, DOI 10.1038/nrendo.2013.112
   Li Jiliang, 2013, JAKSTAT, V2, pe23930, DOI 10.4161/jkst.23930
   Li JF, 2009, EUR J MED CHEM, V44, P2796, DOI 10.1016/j.ejmech.2008.12.024
   Li JX, 2005, PLANTA MED, V71, P673, DOI 10.1055/s 2005 871275
   Ma YFL, 2011, ENDOCRINOLOGY, V152, P1767, DOI 10.1210/en.2010 1112
   McClung MR, 2015, ENDOCRINOL METAB, V30, P429, DOI 10.3803/EnM.2015.30.4.429
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nadri S, 2007, INT J DEV BIOL, V51, P723, DOI 10.1387/ijdb.072352ns
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Nikander R, 2010, BMC MED, V8, DOI 10.1186/1741 7015 8 47
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Opar A, 2009, NAT REV DRUG DISCOV, V8, P757, DOI 10.1038/nrd3015
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Tian XY, 2011, BONE, V48, P197, DOI 10.1016/j.bone.2010.09.009
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Wei ZL, 2013, INT J DISTRIB SENS N, DOI 10.1155/2013/147839
   Zhao Y, 2011, MENOPAUSE, V18, P690, DOI 10.1097/gme.0b013e3181fd7f4b
   Zhou HK, 2011, BONE, V49, P404, DOI 10.1016/j.bone.2011.04.020
NR 43
TC 4
Z9 4
U1 0
U2 17
PU ACTA PHARMACOLOGICA SINICA
PI SHANGHAI
PA 294 TAI YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1671 4083
EI 1745 7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD FEB
PY 2018
VL 39
IS 2
BP 230
EP 242
DI 10.1038/aps.2017.63
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA FU5BQ
UT WOS:000423868000009
PM 28816232
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Shim, JH
   Greenblatt, MB
   Zou, WG
   Huang, ZW
   Wein, MN
   Brady, N
   Hu, D
   Charron, J
   Brodkin, HR
   Petsko, GA
   Zaller, D
   Zhai, B
   Gygi, S
   Glimcher, LH
   Jones, DC
AF Shim, Jae Hyuck
   Greenblatt, Matthew B.
   Zou, Weiguo
   Huang, Zhiwei
   Wein, Marc N.
   Brady, Nicholas
   Hu, Dorothy
   Charron, Jean
   Brodkin, Heather R.
   Petsko, Gregory A.
   Zaller, Dennis
   Zhai, Bo
   Gygi, Steven
   Glimcher, Laurie H.
   Jones, Dallas C.
TI Schnurri 3 regulates ERK downstream of WNT signaling in osteoblasts
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID WNT/BETA CATENIN; SKELETAL DEVELOPMENT; KINASE ACTIVATION; BETA CATENIN;
   MAP KINASES; DIFFERENTIATION; GROWTH; MICE; SUBSTRATE; MOTIF
AB Mice deficient in Schnurri 3 (SHN3; also known as HIVEP3) display increased bone formation, but harnessing this observation for therapeutic benefit requires an improved understanding of how SHN3 functions in osteoblasts. Here we identified SHN3 as a dampener of ERK activity that functions in part downstream of WNT signaling in osteoblasts. A D domain motif within SHN3 mediated the interaction with and inhibition of ERK activity and osteoblast differentiation, and knockin of a mutation in Shn3 that abolishes this interaction resulted in aberrant ERK activation and consequent osteoblast hyperactivity in vivo. Additionally, in vivo genetic interaction studies demonstrated that crossing to Lrp5( / ) mice partially rescued the osteosclerotic phenotype of Shn3( / ) mice; mechanistically, this corresponded to the ability of SHN3 to inhibit ERK mediated suppression of GSK3 beta. Inducible knockdown of Shn3 in adult mice resulted in a high bone mass phenotype, providing evidence that transient blockade of these pathways in adults holds promise as a therapy for osteoporosis.
C1 [Shim, Jae Hyuck] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA.
   [Greenblatt, Matthew B.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   [Zou, Weiguo] Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai, Peoples R China.
   [Huang, Zhiwei] Harbin Inst Technol, BIO X Ctr, Harbin 150006, Peoples R China.
   [Wein, Marc N.; Hu, Dorothy] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Brady, Nicholas] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
   [Brady, Nicholas] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA.
   [Charron, Jean] Univ Laval, Ctr Rech Cancerol, Quebec City, PQ, Canada.
   [Brodkin, Heather R.; Petsko, Gregory A.] Brandeis Univ, Dept Biochem, Waltham, MA 02254 USA.
   [Zaller, Dennis; Jones, Dallas C.] Merck Res Labs, Boston, MA USA.
   [Zhai, Bo; Gygi, Steven] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA.
   [Glimcher, Laurie H.] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA.
C3 Cornell University; Weill Cornell Medicine; Harvard University; Harvard
   University Medical Affiliates; Brigham & Women's Hospital; Chinese
   Academy of Sciences; Center for Excellence in Molecular Cell Science,
   CAS; Harbin Institute of Technology; Harvard University; Harvard
   University Medical Affiliates; Massachusetts General Hospital;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   Laval University; Brandeis University; Merck & Company; Harvard
   University; Harvard Medical School; Cornell University; Weill Cornell
   Medicine
RP Shim, JH (通讯作者)，Weill Cornell Med Coll, 1300 York Ave E907, New York, NY 10065 USA.
EM jas2060@med.cornell.edu; lglimche@med.cornell.edu
RI Brady, Nicholas/AAB 2888 2019; Huang, Zhiwei/AAF 6846 2019; Charron,
   Jean/A 9792 2013; Petsko, Gregory/AAO 7962 2020
OI Charron, Jean/0000 0002 5133 0056; Shim, Jae Hyuck/0000 0002 4947 3293;
   Brady, Nicholas/0000 0002 2928 0232; 
FU NIH [HD055601, K99AR055668]; Arthritis Foundation; NRSA postdoctoral
   fellowship (DFCI/NCI) [T32 CA070083]
FX We thank Henry Kronenberg and Antonios Aliprantis for helpful
   discussions and Michelle Schweitzer, Pamela Okerholm, Rebecca Drapp,
   Chantel Lester, Heather De Rivera, Christina Raekyung Lee, Yeon Suk
   Yang, Alfred Zullo, and Kirsten Sigrist for technical support. We also
   thank the many individuals who provided valuable reagents. This work was
   supported by NIH grants HD055601 (to L.H. Glimcher) and K99AR055668 (to
   D.C. Jones). J. H. Shim was supported by a fellowship from the Arthritis
   Foundation and by an NRSA postdoctoral fellowship (DFCI/NCI T32
   CA070083).
CR Akella R, 2008, BBA PROTEINS PROTEOM, V1784, P48, DOI 10.1016/j.bbapap.2007.09.016
   Barsyte Lovejoy D, 2002, J BIOL CHEM, V277, P9896, DOI 10.1074/jbc.M108145200
   BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014 5793(94)00958 9
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009
   Dinkel H, 2012, NUCLEIC ACIDS RES, V40, pD242, DOI 10.1093/nar/gkr1064
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Hill TP, 2006, DEVELOPMENT, V133, P1219, DOI 10.1242/dev.02298
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Joeng KS, 2011, DEV BIOL, V359, P222, DOI 10.1016/j.ydbio.2011.08.020
   Jones DC, 2007, ADV EXP MED BIOL, V602, P1, DOI 10.1109/OCEANS.2007.4449207
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   Jones DC, 2010, P NATL ACAD SCI USA, V107, P8254, DOI 10.1073/pnas.1003727107
   Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200
   Kolpakova E, 2005, DEV CELL, V8, P626, DOI 10.1016/j.devcel.2005.04.008
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Liu SJ, 2006, P NATL ACAD SCI USA, V103, P5326, DOI 10.1073/pnas.0510506103
   Lou Y, 2009, HUM MOL GENET, V18, P556, DOI 10.1093/hmg/ddn383
   MacDonald B.T., 2012, COLD SPRING HERB PER, V4
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   Nagao M, 2011, J CELL PHYSIOL, V226, P573, DOI 10.1002/jcp.22521
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Saita Y, 2007, J BIOL CHEM, V282, P12907, DOI 10.1074/jbc.M611203200
   Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968 0004(00)01627 3
   Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065
   Weatheritt RJ, 2012, NUCLEIC ACIDS RES, V40, pW364, DOI 10.1093/nar/gks444
   Wein MN, 2012, P NATL ACAD SCI USA, V109, P8173, DOI 10.1073/pnas.1205848109
   Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671
   Wu LC, 2002, GENE EXPRESSION, V10, P137, DOI 10.3727/000000002783992479
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Zou WG, 2011, J CLIN INVEST, V121, P4383, DOI 10.1172/JCI59041
NR 36
TC 50
Z9 54
U1 0
U2 15
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021 9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD SEP
PY 2013
VL 123
IS 9
BP 4010
EP 4022
DI 10.1172/JCI69443
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 220DQ
UT WOS:000324562600042
PM 23945236
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Thiele, S
   Rachner, TD
   Rauner, M
   Hofbauer, LC
AF Thiele, Stefanie
   Rachner, Tilman D.
   Rauner, Martina
   Hofbauer, Lorenz C.
TI WNT5A and Its Receptors in the Bone Cancer Dialogue
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE WNT5A; WNT RECEPTORS; BONE; CANCER
ID EPITHELIAL OVARIAN CANCER; TO MESENCHYMAL TRANSITION; TYROSINE KINASE
   ROR2; PROSTATE CANCER; WNT/BETA CATENIN; BREAST CANCER; UP REGULATION;
   CELL PROLIFERATION; SIGNALING PATHWAY; IN VITRO
AB Wnt signaling is critical for tumorigenesis and skeletal remodeling. However, its contribution to the formation of metastatic bone lesions remains poorly defined. One major challenge of unraveling its role in cancer progression is the high complexity of Wnt signaling, which includes numerous ligands, receptors, and inhibitors, with intricate biological effects and specific signaling pathways depending on the cellular context. In this perspective, we summarize the role of the noncanonical Wnt ligand WNT5A in the development and metastatic process of osteotropic cancer entities. We focus on its tumor suppressive function in breast cancer, tumor promoting effects in melanoma, and ambiguous role in prostate cancer, and discuss potential challenges and opportunities that may be associated with targeting Wnt signaling for cancer therapy and treatment of bone metastases. (C) 2016 American Society for Bone and Mineral Research.
C1 [Thiele, Stefanie; Rachner, Tilman D.; Rauner, Martina; Hofbauer, Lorenz C.] Tech Univ Dresden, Med Ctr, Dept Med 3, Div Endocrinol & Metab Bone Dis, Fetscherstr 74, D 01307 Dresden, Germany.
   [Hofbauer, Lorenz C.] German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany.
   [Hofbauer, Lorenz C.] German Canc Res Ctr, Heidelberg, Germany.
   [Hofbauer, Lorenz C.] Tech Univ Dresden, Med Ctr, Ctr Hlth Aging, Dresden, Germany.
C3 Technische Universitat Dresden; Helmholtz Association; German Cancer
   Research Center (DKFZ); Helmholtz Association; German Cancer Research
   Center (DKFZ); Technische Universitat Dresden
RP Hofbauer, LC (通讯作者)，Tech Univ Dresden, Med Ctr, Dept Med 3, Div Endocrinol & Metab Bone Dis, Fetscherstr 74, D 01307 Dresden, Germany.
EM lorenz.lofbauer@uniklinikum dresden.de
RI Hofbauer, Lorenz C./G 2490 2010; Rauner, Martina/A 1665 2015; Hofbauer,
   Lorenz/G 2490 2010
OI Hofbauer, Lorenz C./0000 0002 8691 8423; Rauner,
   Martina/0000 0002 4067 6799; Conrad, Stefanie/0000 0001 9345 026X
FU DFG Forschergruppe [1586 SKELMET]
FX This work was supported by the DFG Forschergruppe 1586 SKELMET to TDR,
   MR, and LCH.
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Albers J, 2011, J CELL BIOL, V192, P1057, DOI 10.1083/jcb.201008012
   Anastas JN, 2014, J CLIN INVEST, V124, P2877, DOI 10.1172/JCI70156
   Asad M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.302
   Badiglian L, 2009, ONCOL REP, V21, P313, DOI 10.3892/or_00000223
   Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618
   Bazhin AV, 2010, CELL MOL LIFE SCI, V67, P817, DOI 10.1007/s00018 009 0214 0
   Benhaj K, 2006, ONCOL REP, V15, P701
   Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0
   Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092 8674(00)81726 2
   Bian WJ, 2015, DEV NEUROBIOL, V75, P805, DOI 10.1002/dneu.22250
   Bitler BG, 2011, CANCER RES, V71, P6184, DOI 10.1158/0008 5472.CAN 11 1341
   Blakely BD, 2013, STEM CELLS DEV, V22, P2132, DOI 10.1089/scd.2013.0066
   Bo HJ, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 496
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Borcherding N, 2015, CANCER RES, V75, P1972, DOI 10.1158/0008 5472.CAN 14 2761
   Boudin E, 2013, SEMIN ARTHRITIS RHEU, V43, P220, DOI 10.1016/j.semarthrit.2013.01.004
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Cai JC, 2013, J CLIN INVEST, V123, P566, DOI 10.1172/JCI65871
   Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808
   Chien HP, 2016, VIRCHOWS ARCH, V468, P589, DOI 10.1007/s00428 016 1911 3
   Clark CEJ, 2014, GROWTH FACTORS, V32, P11, DOI 10.3109/08977194.2013.875544
   Clezardin P, 2007, CLIN EXP METASTAS, V24, P599, DOI 10.1007/s10585 007 9112 8
   Coscio A, 2014, CARCINOGENESIS, V35, P1284, DOI 10.1093/carcin/bgu034
   Cui B, 2013, CANCER RES, V73, P3649, DOI 10.1158/0008 5472.CAN 12 3832
   Da Forno PD, 2008, CLIN CANCER RES, V14, P5825, DOI 10.1158/1078 0432.CCR 07 5104
   Dai W, 2011, CLIN CANCER RES, V17, P4052, DOI 10.1158/1078 0432.CCR 10 3021
   Dejmek J, 2005, CANCER RES, V65, P9142, DOI 10.1158/0008 5472.CAN 05 1710
   Dijksterhuis JP, 2014, BRIT J PHARMACOL, V171, P1195, DOI 10.1111/bph.12364
   Dissanayake SK, 2008, CANCER RES, V68, P10205, DOI 10.1158/0008 5472.CAN 08 2149
   Ekström EJ, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 88
   Formosa A, 2014, ONCOGENE, V33, P5173, DOI 10.1038/onc.2013.451
   Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985
   Gómez Orte E, 2013, TRENDS GENET, V29, P545, DOI 10.1016/j.tig.2013.06.003
   Gong C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6406
   Grossmann AH, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003398
   Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008 5472.CAN 10 0244
   Habu M, 2014, J BIOCHEM, V156, P29, DOI 10.1093/jb/mvu015
   Halford MM, 2000, NAT GENET, V25, P414, DOI 10.1038/78099
   Hansen C, 2009, J BIOL CHEM, V284, P27533, DOI 10.1074/jbc.M109.048884
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652
   Heilmann A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084232
   Henry C, 2015, J CANCER RES CLIN, V141, P243, DOI 10.1007/s00432 014 1824 y
   Henry C, 2015, ONCOTARGET, V6, P40310, DOI 10.18632/oncotarget.5643
   Hojjat Farsangi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061167
   Huang CL, 2005, J CLIN ONCOL, V23, P8765, DOI 10.1200/JCO.2005.02.2871
   Huang LW, 2009, DEV BIOL, V328, P188, DOI 10.1016/j.ydbio.2009.01.003
   Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089
   Jiang Q, 2016, TUMOR BIOL, V37, P5001, DOI 10.1007/s13277 015 4342 x
   Jin FC, 2013, MOL MED REP, V8, P1486, DOI 10.3892/mmr.2013.1698
   Jing LL, 2009, NEURON, V61, P721, DOI 10.1016/j.neuron.2008.12.025
   Jönsson M, 2002, CANCER RES, V62, P409
   Karachaliou N, 2014, TRANSL LUNG CANCER R, V3, P122, DOI 10.3978/j.issn.2218 6751.2014.03.02
   Katso RMT, 2000, CLIN CANCER RES, V6, P3271
   Kawasaki A, 2007, CELL SIGNAL, V19, P2498, DOI 10.1016/j.cellsig.2007.07.023
   Keeble TR, 2006, INT J BIOCHEM CELL B, V38, P2011, DOI 10.1016/j.biocel.2006.07.005
   Khaja ASS, 2012, CANCER MED US, V1, P96, DOI 10.1002/cam4.5
   Kikuchi A, 2012, ACTA PHYSIOL, V204, P17, DOI 10.1111/j.1748 1716.2011.02294.x
   Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978 0 12 386035 4.00002 1
   Kilander MBC, 2014, CELL SIGNAL, V26, P1943, DOI 10.1016/j.cellsig.2014.05.012
   Kim BK, 2015, BMB REP, V48, P360, DOI 10.5483/BMBRep.2015.48.6.031
   King TD, 2012, CELL SIGNAL, V24, P846, DOI 10.1016/j.cellsig.2011.12.009
   Kirikoshi H, 2001, INT J ONCOL, V19, P111
   Kirikoshi H, 2001, INT J ONCOL, V19, P767
   Kremenevskaja N, 2005, ONCOGENE, V24, P2144, DOI 10.1038/sj.onc.1208370
   Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008 5472.CAN 06 2359
   Lee GT, 2014, BRIT J CANCER, V110, P1634, DOI 10.1038/bjc.2014.23
   Leris ACA, 2005, ANTICANCER RES, V25, P731
   Li B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022920
   Li JS, 2010, CANCER BIOL THER, V10, P617, DOI 10.4161/cbt.10.6.12609
   Linnskog R, 2014, MOL ONCOL, V8, P1365, DOI 10.1016/j.molonc.2014.05.008
   Liu Y, 2007, MOL ENDOCRINOL, V21, P376, DOI 10.1210/me.2006 0342
   Lories RJ, 2013, NAT REV RHEUMATOL, V9, P328, DOI 10.1038/nrrheum.2013.25
   Lu CL, 2015, ONCOTARGET, V6, P24912, DOI 10.18632/oncotarget.4701
   Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019
   Lyashenko N, 2010, DEV DYNAM, V239, P2266, DOI 10.1002/dvdy.22362
   MacMillan CD, 2014, SCI REP UK, V4, DOI 10.1038/srep06315
   Macsai CE, 2012, BONE, V50, P1081, DOI 10.1016/j.bone.2012.02.013
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Matsumoto Shinji, 2012, Methods Mol Biol, V839, P215, DOI 10.1007/978 1 61779 510 7_17
   McDonald SL, 2009, BRIT J CANCER, V101, P209, DOI 10.1038/sj.bjc.6605174
   Mei HJ, 2014, BIOCHEM BIOPH RES CO, V453, P703, DOI 10.1016/j.bbrc.2014.09.141
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Mikels A, 2009, J BIOL CHEM, V284, P30167, DOI 10.1074/jbc.M109.041715
   Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245
   Milovanovic T, 2004, INT J ONCOL, V25, P1337
   Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Moradi F, 2016, TRANSL RES, V172, P45, DOI 10.1016/j.trsl.2016.02.007
   Müller HAJ, 1999, DEVELOPMENT, V126, P577
   Nishita M, 2010, MOL CELL BIOL, V30, P3610, DOI 10.1128/MCB.00177 10
   Norgaard M, 2010, J UROLOGY, V184, P162, DOI 10.1016/j.juro.2010.03.034
   O'Connell MP, 2010, ONCOGENE, V29, P34, DOI 10.1038/onc.2009.305
   O'Connell MP, 2013, CANCER DISCOV, V3, P1378, DOI 10.1158/2159 8290.CD 13 0005
   O'Connell MP, 2009, PIGM CELL MELANOMA R, V22, P724, DOI 10.1111/j.1755 148X.2009.00627.x
   Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365 2443.2003.00662.x
   Peradziryi H, 2012, ARCH BIOCHEM BIOPHYS, V524, P71, DOI 10.1016/j.abb.2011.12.019
   Prasad CP, 2015, CANCERS, V7, P1900, DOI 10.3390/cancers7030868
   Qi XY, 2016, GENES CELLS, V21, P325, DOI 10.1111/gtc.12342
   Qian D, 2007, DEV BIOL, V306, P121, DOI 10.1016/j.ydbio.2007.03.011
   Rabbani SA, 2013, CANCER MED US, V2, P625, DOI 10.1002/cam4.111
   Ren W, 2016, BIOCHEM BIOPH RES CO, V469, P633, DOI 10.1016/j.bbrc.2015.12.054
   Roarty K, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2244
   Saitoh T, 2002, INT J MOL MED, V10, P345
   Santiago F, 2012, BIOCHEM BIOPH RES CO, V417, P223, DOI 10.1016/j.bbrc.2011.11.089
   Schwabe GC, 2004, DEV DYNAM, V229, P400, DOI 10.1002/dvdy.10466
   Sen M, 2000, P NATL ACAD SCI USA, V97, P2791, DOI 10.1073/pnas.050574297
   Sherwood V, 2014, CARCINOGENESIS, V35, P784, DOI 10.1093/carcin/bgt390
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Syed Khaja Azharuddin Sajid, 2011, PLoS One, V6, pe26539, DOI 10.1371/journal.pone.0026539
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   Takiguchi G, 2016, CANCER SCI, V107, P290, DOI 10.1111/cas.12871
   Tao JQ, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046 015 0253 3
   Tapper J, 2001, CANCER GENET CYTOGEN, V128, P1, DOI 10.1016/S0165 4608(01)00386 7
   Tennis M, 2010, NEOPLASIA, V12, P244, DOI 10.1593/neo.91690
   Terasaki H, 2002, INT J MOL MED, V9, P107
   Thiele S, 2015, J BONE MINER RES, V30, P488, DOI 10.1002/jbmr.2362
   Thiele S, 2011, J CELL BIOCHEM, V112, P1593, DOI 10.1002/jcb.23070
   Tiwary S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147638
   Ueno K, 2009, BRIT J CANCER, V101, P1374, DOI 10.1038/sj.bjc.6605307
   Vasiljevic N, 2014, BIOMARK MED, V8, P1143, DOI [10.2217/BMM.14.41, 10.2217/bmm.14.41]
   Wang Q, 2007, ONCOGENE, V26, P6560, DOI 10.1038/sj.onc.1210472
   Wang Q, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010456
   Wang W, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.15
   Webster MR, 2015, PIGM CELL MELANOMA R, V28, P184, DOI 10.1111/pcmr.12330
   Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535 6108(02)00045 4
   Winn RA, 2006, J BIOL CHEM, V281, P26943, DOI 10.1074/jbc.M604145200
   Witze ES, 2008, SCIENCE, V320, P365, DOI 10.1126/science.1151250
   Wong SCC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079481
   Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211
   Yamamoto H, 2010, ONCOGENE, V29, P2036, DOI 10.1038/onc.2009.496
   Yang L, 2011, ONCOGENE, V30, P4437, DOI 10.1038/onc.2011.145
   Yerges LM, 2009, J BONE MINER RES, V24, P87, DOI 10.1359/JBMR.080816
   Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078 0432.CCR 07 1644
   Yoshikawa S, 2003, NATURE, V422, P583, DOI 10.1038/nature01522
   Zhang SP, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0031127, 10.1371/journal.pone.0046853]
   Zhang Xiao, 2016, Zhonghua Nan Ke Xue, V22, P128
   Zhao SJ, 2014, TUMOR BIOL, V35, P9725, DOI 10.1007/s13277 014 2206 4
   Zhao Yajun, 2014, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V30, P462
   Zhong ZhenBin, 2016, Med Sci Monit, V22, P1
   Zhu YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037823
NR 143
TC 11
Z9 12
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2016
VL 31
IS 8
BP 1488
EP 1496
DI 10.1002/jbmr.2899
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DW5WC
UT WOS:000383717200002
PM 27355180
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, DC
   Qin, H
   Yang, JZ
   Yang, L
   He, SH
   Chen, SX
   Bao, QW
   Zhao, YF
   Zong, ZW
AF Liu, Daocheng
   Qin, Hao
   Yang, Jiazhi
   Yang, Lei
   He, Sihao
   Chen, Sixu
   Bao, Quanwei
   Zhao, Yufeng
   Zong, Zhaowen
TI Different effects of Wnt/β catenin activation and PTH activation in
   adult and aged male mice metaphyseal fracture healing
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Wnt/beta catenin; PTH; Fracture healing; Adult; Aged
ID BONE MINERAL DENSITY; PARATHYROID HORMONE; GROWTH FACTOR; ANGIOGENESIS;
   CELLS; OSTEOPOROSIS; ENHANCEMENT; STRENGTH; MUTATION; SPINE
AB Background Fractures in older men are not uncommon and need to be healed as soon as possible to avoid related complications. Anti osteoporotic drugs targeting Wnt/beta catenin and PTH (parathyroid hormone) to promote fracture healing have become an important direction in recent years. The study is to observe whether there is a difference in adult and aged situations by activating two signal paths. Methods A single cortical hole with a diameter of 0.6 mm was made in the femoral metaphysis of Catnb(lox(ex3)) mice and wild type mice. The fracture healing effects of CA (Wnt/beta catenin activation) and PTH (activated by PTH (1 34) injections) were assessed by X ray and CT imaging on days 7, 14, and 21 after fracture. The mRNA levels of beta catenin, PTH1R(Parathyroid hormone 1 receptor), and RUNX2(Runt related transcription factor 2) in the fracture defect area were detected using RT PCR. Angiogenesis and osteoblasts were observed by immunohistochemistry and osteoclasts were observed by TRAP (Tartrate resistant Acid Phosphatase). Result Adult CA mice and adult PTH mice showed slightly better fracture healing than adult wild type (WT) mice, but there was no statistical difference. Aged CA mice showed better promotion of angiogenesis and osteoblasts and better fracture healing than aged PTH mice. Conclusion The application of Wnt/beta catenin signaling pathway drugs for fracture healing in elderly patients may bring better early effects than PTH signaling pathway drugs, but the long term effects need to be observed.
C1 [Liu, Daocheng; Qin, Hao; Yang, Jiazhi; Yang, Lei; He, Sihao; Chen, Sixu; Bao, Quanwei; Zhao, Yufeng; Zong, Zhaowen] Army Med Univ, Base Army Hlth Serv Training, Dept War Wound Rescue Skills Training, State Key Lab Trauma Burn & Combined Injury, Chongqing 400042, Peoples R China.
C3 Army Medical University
RP Zong, ZW (通讯作者)，Army Med Univ, Base Army Hlth Serv Training, Dept War Wound Rescue Skills Training, State Key Lab Trauma Burn & Combined Injury, Chongqing 400042, Peoples R China.
EM zongzhaowen@tmmu.edu.cn
RI Yang, Jiazhi/G 3659 2013
CR Agholme F, 2014, J ORTHOP RES, V32, P471, DOI 10.1002/jor.22525
   Agholme F, 2010, J BONE MINER RES, V25, P2412, DOI 10.1002/jbmr.135
   Araujo AB, 2007, OSTEOPOROSIS INT, V18, P943, DOI 10.1007/s00198 006 0321 9
   Bailey AJ, 1999, CALCIFIED TISSUE INT, V65, P203, DOI 10.1007/s002239900683
   BAK B, 1989, CALCIFIED TISSUE INT, V45, P292, DOI 10.1007/BF02556022
   Bao QW, 2017, EXP CELL RES, V350, P123, DOI 10.1016/j.yexcr.2016.11.013
   Barnes GL, 2006, CLIN REV BONE MINER, V4, P269, DOI 10.1385/BMM:4:4:269
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bergman RJ, 1996, J BONE MINER RES, V11, P568
   Bernhardsson M, 2018, ACTA ORTHOP, V89, P457, DOI 10.1080/17453674.2018.1481682
   Bliuc D, 2014, J CLIN ENDOCR METAB, V99, P415, DOI 10.1210/jc.2013 3461
   Bogazzi F, 2011, J ENDOCRINOL INVEST, V34, pE200, DOI 10.3275/7228
   BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756 3282(87)90015 9
   Calori GM, 2007, INJURY, V38, pS11, DOI 10.1016/S0020 1383(07)80004 0
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Cauley JA, 2005, OSTEOPOROSIS INT, V16, P1525, DOI 10.1007/s00198 005 1866 8
   Chen HG, 2017, INT J BIOL SCI, V13, P1254, DOI 10.7150/ijbs.21258
   Chen SX, 2015, J BONE MINER RES, V30, P1184, DOI 10.1002/jbmr.2453
   Chen T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 017 18375 x
   Choi SH, 2017, ONCOTARGET, V8, P58974, DOI 10.18632/oncotarget.19769
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Dovjak P, 2019, Z GERONTOL GERIATR, V52, P421, DOI 10.1007/s00391 019 01548 w
   EKELAND A, 1982, ACTA ORTHOP SCAND, V53, P527, DOI 10.3109/17453678208992252
   Gao F, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018 018 0837 7
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Giannoudis P, 2007, INJURY, V38, pS90, DOI 10.1016/j.injury.2007.02.014
   Gruber R, 2006, EXP GERONTOL, V41, P1080, DOI 10.1016/j.exger.2006.09.008
   Haxaire C, 2016, AM J PATHOL, V186, P1598, DOI 10.1016/j.ajpath.2016.01.016
   Hu K, 2016, BONE, V91, P30, DOI 10.1016/j.bone.2016.06.013
   Huang TW, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003626
   Karki S, 2017, AM J PHYSIOL HEART C, V313, pH200, DOI 10.1152/ajpheart.00776.2016
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Li JF, 2017, J ORTHOP RES, V35, P812, DOI 10.1002/jor.23339
   Li XM, 2005, J CELL BIOCHEM, V95, P189, DOI 10.1002/jcb.20373
   Liedert A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103250
   Lombardo F, 2004, FASEB J, V18, P52, DOI 10.1096/fj.03 0521com
   Lowe CJM, 2019, OSTEOPOROSIS INT, V30, P1403, DOI 10.1007/s00198 019 04973 0
   Mäkitie RE, 2017, BONE, V101, P3, DOI 10.1016/j.bone.2017.04.001
   Marsell R, 2011, INJURY, V42, P551, DOI 10.1016/j.injury.2011.03.031
   McGee Lawrence ME, 2013, BIOCHEM BIOPH RES CO, V441, P886, DOI 10.1016/j.bbrc.2013.10.155
   MCKIBBIN B, 1978, J BONE JOINT SURG BR, V60, P150, DOI 10.1302/0301 620X.60B2.350882
   Milstrey A, 2017, J SURG RES, V220, P327, DOI 10.1016/j.jss.2017.07.019
   Mosekilde L, 2000, Z RHEUMATOL, V59, P1
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Olsen Jun Jun, 2017, Clin Biochem Rev, V38, P131
   Pietrogrande L, 2013, INJURY, V44, pS54, DOI 10.1016/S0020 1383(13)70013 5
   Rudnicki MA, 2015, BONE, V80, P60, DOI 10.1016/j.bone.2015.02.009
   Ryan ZC, 2014, BIOCHEM BIOPH RES CO, V448, P83, DOI 10.1016/j.bbrc.2014.04.092
   Sandberg O, 2014, BONE, V63, P15, DOI 10.1016/j.bone.2014.02.008
   Saran U, 2014, ARCH BIOCHEM BIOPHYS, V561, P109, DOI 10.1016/j.abb.2014.07.006
   Skripitz R, 2001, CLIN ORTHOP RELAT R, P427
   Skripitz R, 2001, J BONE JOINT SURG BR, V83B, P437, DOI 10.1302/0301 620X.83B3.10256
   Strube P, 2008, BONE, V42, P758, DOI [10.1016/j.bone.2007.12.223, 10.1016/S0021 9290(08)70350 6]
   Van Staa TP, 2001, BONE, V29, P517, DOI 10.1016/S8756 3282(01)00614 7
   VILLAREAL DT, 1994, DRUG AGING, V4, P492, DOI 10.2165/00002512 199404060 00005
   Xie C, 2009, AM J PATHOL, V175, P772, DOI 10.2353/ajpath.2009.081099
   Xie YL, 2016, INT J BIOL SCI, V12, P990, DOI 10.7150/ijbs.14077
   Yu B, 2012, J BONE MINER RES, V27, P2001, DOI 10.1002/jbmr.1663
   Zanotti S, 2017, BONE, V103, P159, DOI 10.1016/j.bone.2017.06.027
NR 59
TC 5
Z9 5
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD FEB 19
PY 2020
VL 21
IS 1
AR 110
DI 10.1186/s12891 020 3138 3
PG 13
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA KQ9GO
UT WOS:000517229200001
PM 32075627
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Farrier, AJ
   Franco, LCS
   Shoaib, A
   Gulati, V
   Johnson, N
   Uzoigwe, CE
   Choudhury, MZ
AF Farrier, A. J.
   Franco, L. C. Sanchez
   Shoaib, A.
   Gulati, V.
   Johnson, N.
   Uzoigwe, C. E.
   Choudhury, M. Z.
TI New anti resorptives and antibody mediated anti resorptive therapy
SO BONE & JOINT JOURNAL
LA English
DT Article
ID ATYPICAL FEMORAL FRACTURES; SKELETAL RELATED EVENTS; POSTMENOPAUSAL
   OSTEOPOROSIS; BONE METASTASES; ZOLEDRONIC ACID; CANCER PATIENTS;
   DENOSUMAB; BISPHOSPHONATES; PREVENTION; AGENTS
AB The ageing population and an increase in both the incidence and prevalence of cancer pose a healthcare challenge, some of which is borne by the orthopaedic community in the form of osteoporotic fractures and metastatic bone disease. In recent years there has been an increasing understanding of the pathways involved in bone metabolism relevant to osteoporosis and metastases in bone. Newer therapies may aid the management of these problems. One group of drugs, the antibody mediated anti resorptive therapies (AMARTs) use antibodies to block bone resorption pathways. This review seeks to present a synopsis of the guidelines, pharmacology and potential pathophysiology of AMARTs and other new anti resorptive drugs.
   We evaluate the literature relating to AMARTs and new anti resorptives with special attention on those approved for use in clinical practice.
   Denosumab, a monoclonal antibody against Receptor Activator for Nuclear Factor KappaB Ligand. It is the first AMART approved by the National Institute for Health and Clinical Excellence and the US Food and Drug Administration. Other novel anti resorptives awaiting approval for clinical use include Odanacatib.
   Denosumab is indicated for the treatment of osteoporosis and prevention of the complications of bone metastases. Recent evidence suggests, however, that denosumab may have an adverse event profile similar to bisphosphonates, including atypical femoral fractures. It is, therefore, essential that orthopaedic surgeons are conversant with these medications and their safe usage.
C1 [Farrier, A. J.; Franco, L. C. Sanchez; Shoaib, A.; Gulati, V.; Johnson, N.; Uzoigwe, C. E.; Choudhury, M. Z.] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England.
   [Farrier, A. J.] Freeman Rd Hosp, Trauma & Orthopaed, Newcastle Upon Tyne, Tyne & Wear, England.
   [Franco, L. C. Sanchez] Stepping Hill Hosp, Acute Med, Stockport SK2 7JE, Lancs, England.
   [Shoaib, A.] Hull Royal Infirm, Trauma & Orthopaed, Kingston Upon Hull HU3 2JZ, N Humberside, England.
   [Gulati, V.] Chelsea & Westminster Hosp, Trauma & Orthopaed, London, England.
   [Johnson, N.] Univ Hosp Leicester, Trauma & Orthopaed, Leicester, Leics, England.
   [Uzoigwe, C. E.] Harcourt House, Sheffield, S Yorkshire, England.
   [Choudhury, M. Z.] Royal Orthopaed Hosp, Trauma & Orthopaed, Bristol Rd S, Birmingham B31 2AP, W Midlands, England.
C3 Newcastle University   UK; Newcastle Freeman Hospital; Newcastle
   University   UK; Newcastle Freeman Hospital; University of Hull;
   Imperial College London; University of Leicester; University Hospitals
   of Leicester NHS Trust; Royal Orthopaedic Hospital
RP Uzoigwe, CE (通讯作者)，Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England.; Uzoigwe, CE (通讯作者)，Harcourt House, Sheffield, S Yorkshire, England.
EM chika@doctors.org.uk
RI ; Johnson, Nicholas/KSQ 0041 2024; Farrier, Adam/K 5141 2015; FRANCO
   AYALA, LUIS CARLOS/KHD 5634 2024
OI Shoaib, Ahmed/0000 0001 7480 1079; johnson, Nick/0000 0002 5543 6384;
   Farrier, Adam/0000 0003 1964 9822; 
CR Ahmad AS, 2015, BRIT J CANCER, V112, P943, DOI 10.1038/bjc.2014.606
   Andrews NA., 2008, IBMS BONEKEY, V5, P351, DOI [10.1138/20080340, DOI 10.1138/20080340]
   Anghel R, 2013, WIEN KLIN WOCHENSCHR, V125, P439, DOI 10.1007/s00508 013 0385 4
   Bone HG, 2015, OSTEOPOROSIS INT, V26, P699, DOI 10.1007/s00198 014 2944 6
   Cheung FH, 2014, ORTHOP CLIN N AM, V45, P109, DOI 10.1016/j.ocl.2013.09.003
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Coleman RE, 2011, BONE, V49, P71, DOI 10.1016/j.bone.2011.02.003
   Darba J, 2015, CLINICOECONOMIC OUTC, V7, P105, DOI 10.2147/CEOR.S78349
   DEWAURE C, 2014, BIOMED RES INT, V2014
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Freemantle N, 2013, OSTEOPOROSIS INT, V24, P209, DOI 10.1007/s00198 012 2068 9
   Freemantle N, 2012, OSTEOPOROSIS INT, V23, P317, DOI 10.1007/s00198 011 1780 1
   Grimer RJ, 2013, BONE JOINT 360, V360, P43
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Lewiecki EM, 2011, NAT REV RHEUMATOL, V7, P631, DOI 10.1038/nrrheum.2011.130
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Meling T, 2014, BONE JOINT J, V96B, P1035, DOI 10.1302/0301 620X.96B8.33306
   Messori A, 2014, J ENDOCRINOL INVEST, V37, P769, DOI 10.1007/s40618 014 0124 3
   Parthan A, 2014, BONE, V59, P105, DOI 10.1016/j.bone.2013.11.002
   Parthan A, 2013, APPL HEALTH ECON HEA, V11, P485, DOI 10.1007/s40258 013 0047 8
   Peddi P, 2013, CANCER TREAT REV, V39, P97, DOI 10.1016/j.ctrv.2012.07.002
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Shah AD, 2015, INT J WOMENS HEALTH, V7, P565, DOI 10.2147/IJWH.S73244
   Silva Fernandez L, 2013, REUMATOL CLIN, V9, P42, DOI [10.1016/j.reuma.2012.06.007, 10.1016/j.reumae.2012.06.020]
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Sun L, 2013, AM J CLIN ONCOL CANC, V36, P399, DOI 10.1097/COC.0b013e31824be20e
   Thompson RN, 2012, J BONE JOINT SURG BR, V94B, P385, DOI 10.1302/0301 620X.94B3.27999
   van der Heijden L, 2014, BONE JOINT J, V96B, P1111, DOI [10.1302/0301 620X.96B8.33608, 10.1302/0301 620X.9688]
   Wang X, 2014, ONCOL LETT, V7, P1997, DOI 10.3892/ol.2014.1982
   Wang ZY, 2015, ONCOLOGIST, V20, P440, DOI 10.1634/theoncologist.2014 0328
   White SM, 2011, INJURY, V42, P1230, DOI 10.1016/j.injury.2010.11.010
   Xu SF, 2013, CURR ONCOL, V20, pE442, DOI 10.3747/co.20.1497
NR 33
TC 16
Z9 16
U1 0
U2 3
PU BRITISH EDITORIAL SOC BONE JOINT SURGERY
PI LONDON
PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND
SN 2049 4394
J9 BONE JOINT J
JI Bone Joint J.
PD FEB
PY 2016
VL 98B
IS 2
BP 160
EP 165
DI 10.1302/0301 620X.98B2.36161
PG 6
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA DD0TS
UT WOS:000369633400004
PM 26850419
DA 2025 08 17
ER

PT J
AU Kawada, S
   Harada, A
   Hashimoto, N
AF Kawada, Shigeo
   Harada, Atsushi
   Hashimoto, Naohiro
TI Impairment of cold injury induced muscle regeneration in mice receiving
   a combination of bone fracture and alendronate treatment
SO PLOS ONE
LA English
DT Article
ID HUMAN MYOGENIC CELLS; IN VITRO; BISPHOSPHONATES; MACROPHAGES;
   DIFFERENTIATION; PROLIFERATION; OSTEOBLASTS; GROWTH; INHIBITION;
   EXPRESSION
AB Alendronate, a nitrogen containing bisphosphonate, is well established as a treatment for osteoporosis through regulation of osteoclast activity. Previously, the pharmacological effects of bisphosphonates on cells outside the bone environment have been considered irrelevant because bisphosphonates target bone. Here we show that administration of alendronate impairs muscle regeneration in mice after bone fracture. A series of injections of alendronate alone or bone fracture alone did not affect muscle regeneration induced by cold injury. In contrast, alendronate treatment plus bone fracture severely impaired the regeneration of muscle that closely contacts the bone fracture site after cold injury. After cold injury, M cadherin positive myogenic cells disappeared in the damaged muscle areas of mice receiving the combination of alendronate treatment and bone fracture. The present results suggest that the muscle regeneration capacity is impaired by bone fracture in mice receiving alendronate treatment. The present research on the pharmacological effects of alendronate on muscle regeneration will aid in understanding of the in vivo action of alendronate on skeletal muscles.
C1 [Kawada, Shigeo; Hashimoto, Naohiro] Natl Ctr Geriatr & Gerontol, Dept Regenerat Med, Oobu, Aichi, Japan.
   [Harada, Atsushi] Natl Ctr Geriatr & Gerontol, Dept Orthoped Surg, Oobu, Aichi, Japan.
   [Kawada, Shigeo] Teikyo Univ, Dept Sport & Med Sci, Fac Med Technol, 359 Otsuka, Hachioji, Tokyo, Japan.
C3 National Center for Geriatrics & Gerontology; National Center for
   Geriatrics & Gerontology; Teikyo University
RP Hashimoto, N (通讯作者)，Natl Ctr Geriatr & Gerontol, Dept Regenerat Med, Oobu, Aichi, Japan.
EM nao@ncgg.go.jp
OI Hashimoto, Naohiro/0000 0002 9231 8053
FU Ministry of Health, Labor and Welfare of Japan [H25 Chouju ippan 004];
   Grants in Aid for Scientific Research [15K10426, 16K01837] Funding
   Source: KAKEN
FX The study was funded by the Ministry of Health, Labor and Welfare of
   Japan (H25 Chouju ippan 004). The funder had no role in study design,
   data collection, and analysis, decision to publish, or preparation of
   the manuscript.
CR CECCHINI MG, 1990, J BONE MINER RES, V5, P1019
   CECCHINI MG, 1987, J BONE MINER RES, V2, P135
   Christov C, 2007, MOL BIOL CELL, V18, P1397, DOI 10.1091/mbc.E06 08 0693
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Furukawa Y, 2003, NEUROMUSCULAR DISORD, V13, P32, DOI 10.1016/S0960 8966(02)00185 2
   Harada Atsushi, 2015, English, V1, P53
   Hashimoto N, 2004, DEVELOPMENT, V131, P5481, DOI 10.1242/dev.01395
   Hashimoto N., 2008, RECENT ADV SKELETAL, P1
   IRINTCHEV A, 1994, DEV DYNAM, V199, P326, DOI 10.1002/aja.1001990407
   Kawada S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072603
   LEWIS RB, 1951, AM J MED SCI, V222, P300, DOI 10.1097/00000441 195109000 00008
   Matzno S, 2009, J PHARM PHARMACOL, V61, P781, DOI [10.1211/jpp/61.06.0011, 10.1211/jpp.61.06.0011]
   McLennan IS, 1996, J ANAT, V188, P17
   Muller S, 2005, ANTICANCER RES, V25, P2655
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2008, J BONE MINER RES, V23, P1712, DOI [10.1359/jbmr.080617, 10.1359/JBMR.080617]
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Rizzoli R, 2011, QJM INT J MED, V104, P281, DOI 10.1093/qjmed/hcq259
   Rogers MJ, 1996, J BONE MINER RES, V11, P1482
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Saclier M, 2013, FEBS J, V280, P4118, DOI 10.1111/febs.12166
   Shiomi K, 2011, GENE THER, V18, P857, DOI 10.1038/gt.2011.44
   Shiomi K, 2014, J PHARM PHARMACOL, V66, P418, DOI 10.1111/jphp.12171
   STEVENSON PH, 1986, CALCIFIED TISSUE INT, V38, P227, DOI 10.1007/BF02556715
   Susa M, 2009, ANTICANCER RES, V29, P1879
   Töyräs A, 2003, EUR J PHARM SCI, V19, P223, DOI 10.1016/S0928 0987(03)00108 8
   Vitte C, 1996, ENDOCRINOLOGY, V137, P2324, DOI 10.1210/en.137.6.2324
   Widrick JJ, 2007, MENOPAUSE, V14, P528, DOI 10.1097/01.gme.0000227861.35226.fa
NR 29
TC 3
Z9 3
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 17
PY 2017
VL 12
IS 7
AR e0181457
DI 10.1371/journal.pone.0181457
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GS8PU
UT WOS:000443975500058
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Saxena, R
   Pan, G
   Dohm, ED
   McDonald, JM
AF Saxena, Ritu
   Pan, George
   Dohm, Erik D.
   McDonald, Jay M.
TI Modeled microgravity and hindlimb unloading sensitize osteoclast
   precursors to RANKL mediated osteoclastogenesis
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Modeled microgravity; Osteoblasts; Osteoclasts; Hindlimb unloading;
   Rotary cell culture system
ID MESENCHYMAL STEM CELLS; MOUSE LONG BONES; SIMULATED WEIGHTLESSNESS;
   SPACE FLIGHT; PARATHYROID HORMONE; CANCELLOUS BONE; GROWING RATS;
   OSTEOBLAST DIFFERENTIATION; GENE EXPRESSION; BED REST
AB Mechanical forces are essential to maintain skeletal integrity, and microgravity exposure leads to bone loss. The underlying molecular mechanisms leading to the changes in osteoblasts and osteoclast differentiation and function remain to be fully elucidated. Because of the infrequency of spaceflights and payload constraints, establishing in vitro and in vivo systems that mimic microgravity conditions becomes necessary. We have established a simulated microgravity (modeled microgravity, MMG) system to study the changes induced in osteoclast precursors. We observed that MMG, on its own, was unable to induce osteoclastogenesis of osteoclast precursors; however, 24 h of MMG activates osteoclastogenesis related signaling molecules ERK, p38, PLC gamma 2, and NFATc1. Receptor activator of NFkB ligand (RANKL) (with or without M CSF) stimulation for 3 4 days in gravity of cells that had been exposed to MMG for 24 h enhanced the formation of very large tartrate resistant acid phosphatase (TRAP) positive multinucleated (> 30 nuclei) osteoclasts accompanied by an upregulation of the osteoclast marker genes TRAP and cathepsin K. To validate the in vitro system, we studied the hindlimb unloading (HLU) system using BALB/c mice and observed a decrease in BMD of femurs and a loss of 3D microstructure of both cortical and trabecular bone as determined by micro CT. There was a marked stimulation of osteoclastogenesis as determined by the total number of TRAP positive multinucleated osteoclasts formed and also an increase in RANKL stimulated osteoclastogenesis from precursors removed from the tibias of mice after 28 days of HLU. In contrast to earlier reported findings, we did not observe any histomorphometric changes in the bone formation parameters. Thus, the foregoing observations indicate that microgravity sensitizes osteoclast precursors for increased differentiation. The in vitro model system described here is potentially a valid system for testing drugs for preventing microgravity induced bone loss by targeting the molecular events occurring in microgravity induced enhanced osteoclastogenesis.
C1 [McDonald, Jay M.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.
   [McDonald, Jay M.] Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA.
   [Saxena, Ritu] Univ Illinois, Coll Med Peoria, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA.
   [Pan, George] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30329 USA.
   [Dohm, Erik D.] Univ Alabama, Anim Resources Program, Birmingham, AL 35294 USA.
   [McDonald, Jay M.] Vet Adm Med Ctr, Birmingham, AL 35233 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Illinois System; University of Illinois Peoria; Emory
   University; University of Alabama System; University of Alabama
   Birmingham; US Department of Veterans Affairs; Veterans Health
   Administration (VHA)
RP McDonald, JM (通讯作者)，Univ Alabama, Dept Pathol, LHRB 509,701 S 19th St, Birmingham, AL 35294 USA.
EM mcdonald@uab.edu
OI Dohm, Erik/0000 0001 7477 6264
FU National Institute of Health [R01 AR050235, P30 AR046031]; NASA
   [NNJ04HB27G (NAG 9 1562)]
FX This work was supported by National Institute of Health Grants R01
   AR050235 and P30 AR046031 and a NASA grant, NNJ04HB27G (NAG 9 1562).
CR ABRAM AC, 1988, J BIOMECH, V21, P755, DOI 10.1016/0021 9290(88)90284 9
   Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   Baek K, 2009, J BONE MINER RES, V24, P792, DOI [10.1359/JBMR.081241, 10.1359/jbmr.081241]
   Berezovska OP, 1998, ADV SPACE RES, V21, P1059, DOI 10.1016/S0273 1177(98)00028 3
   BIKLE DD, 1994, J BONE MINER RES, V9, P1777
   Blanc S, 1998, J CLIN ENDOCR METAB, V83, P4289, DOI 10.1210/jc.83.12.4289
   Caillot Augusseau A, 1998, CLIN CHEM, V44, P578
   Collet P, 1997, BONE, V20, P547, DOI 10.1016/S8756 3282(97)00052 5
   Davis BA, 1998, CALCIFIED TISSUE INT, V63, P416, DOI 10.1007/s002239900550
   Dehority W, 1999, AM J PHYSIOL ENDOC M, V276, pE62
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   FOWLER JF, 1991, CUTIS, V48, P291
   GLOBUS RK, 1984, ENDOCRINOLOGY, V114, P2264, DOI 10.1210/endo 114 6 2264
   HALLORAN BP, 1988, AM J PHYSIOL, V255, pE875, DOI 10.1152/ajpendo.1988.255.6.E875
   Hammond TG, 2001, AM J PHYSIOL RENAL, V281, pF12, DOI 10.1152/ajprenal.2001.281.1.F12
   Hefferan TE, 2003, J APPL PHYSIOL, V95, P1775, DOI 10.1152/japplphysiol.00455.2002
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110
   Huang Da wei, 2003, Space Med Med Eng (Beijing), V16, P418
   Kanematsu M, 2002, BONE, V30, P553, DOI 10.1016/S8756 3282(02)00680 4
   Kaplansky A S, 1991, Physiologist, V34, pS196
   Lang T, 2004, J BONE MINER RES, V19, P1006, DOI 10.1359/JBMR.040307
   LI XJ, 1990, ANAT RECORD, V227, P12, DOI 10.1002/ar.1092270103
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Lloyd SAJ, 2008, J APPL PHYSIOL, V104, P729, DOI 10.1152/japplphysiol.00632.2007
   Locklin RM, 2003, J CELL BIOCHEM, V89, P180, DOI 10.1002/jcb.10490
   MACHWATE M, 1993, AM J PHYSIOL, V264, pE790, DOI 10.1152/ajpendo.1993.264.5.E790
   MACHWATE M, 1994, ENDOCRINOLOGY, V134, P1031, DOI 10.1210/en.134.3.1031
   Matsumoto T, 1998, BONE, V22, p89S, DOI 10.1016/S8756 3282(98)00018 0
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Meyers VE, 2005, J BONE MINER RES, V20, P1858, DOI 10.1359/JBMR.050611
   Meyers VE, 2004, J CELL BIOCHEM, V93, P697, DOI 10.1002/jcb.20229
   Monici M, 2006, J CELL BIOCHEM, V98, P65, DOI 10.1002/jcb.20747
   MONICI M, 2002, J GRAVITATIONAL PHYS, V9, P261
   MOREY ER, 1978, SCIENCE, V201, P1138, DOI 10.1126/science.150643
   Morey Holton ER, 1998, BONE, V22, p83S, DOI 10.1016/S8756 3282(98)00019 2
   Ono N, 2007, J BIOL CHEM, V282, P25509, DOI 10.1074/jbc.M610782200
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rucci N, 2007, J CELL BIOCHEM, V100, P464, DOI 10.1002/jcb.21059
   Sakata T, 1999, J BONE MINER RES, V14, P1596, DOI 10.1359/jbmr.1999.14.9.1596
   Sarkar D, 2000, J Gravit Physiol, V7, pP71
   Saxena R, 2007, ANN NY ACAD SCI, V1116, P494, DOI 10.1196/annals.1402.033
   Scheld K, 2001, CLIN CHEM, V47, P1688
   Seales EC, 2006, J CELL BIOCHEM, V97, P45, DOI 10.1002/jcb.20659
   SIMSKE SJ, 1992, J BIOMECH, V25, P489, DOI 10.1016/0021 9290(92)90089 J
   Smith SM, 2005, J BONE MINER RES, V20, P208, DOI 10.1359/JBMR.041105
   Smith SM, 1998, J CLIN ENDOCR METAB, V83, P3584, DOI 10.1210/jc.83.10.3584
   SPENGLER DM, 1983, P SOC EXP BIOL MED, V174, P224
   Tamma R, 2009, FASEB J, V23, P2549, DOI 10.1096/fj.08 127951
   Turner R T, 1985, Physiologist, V28, pS67
   Turner RT, 2007, J BONE MINER RES, V22, P64, DOI 10.1359/JBMR.061006
   VANLOON JJWA, 1995, J BONE MINER RES, V10, P550
   Vernikos J, 1996, BIOESSAYS, V18, P1029, DOI 10.1002/bies.950181215
   Vico L, 1998, BONE, V22, p95S, DOI 10.1016/S8756 3282(98)00017 9
   VICO L, 1993, J APPL PHYSIOL, V75, P2203, DOI 10.1152/jappl.1993.75.5.2203
   VICO L, 1987, BONE, V8, P95, DOI 10.1016/8756 3282(87)90077 9
   WRONSKI TJ, 1983, METAB BONE DIS RELAT, V4, P347
   WRONSKI TJ, 1983, MED SCI SPORT EXER, V15, P410
   WRONSKI TJ, 1982, METAB BONE DIS RELAT, V4, P69, DOI 10.1016/0221 8747(82)90011 X
   Yeo H, 2007, BONE, V40, P1502, DOI 10.1016/j.bone.2007.02.017
   Zayzafoon M, 2005, IMMUNOL REV, V208, P267, DOI 10.1111/j.0105 2896.2005.00330.x
   Zayzafoon M, 2005, J BIOL CHEM, V280, P7049, DOI 10.1074/jbc.M412680200
   Zayzafoon M, 2004, ENDOCRINOLOGY, V145, P2421, DOI 10.1210/en.2003 1156
   Zerath E, 2000, J Gravit Physiol, V7, pS155
NR 64
TC 64
Z9 74
U1 1
U2 18
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JAN
PY 2011
VL 29
IS 1
BP 111
EP 122
DI 10.1007/s00774 010 0201 4
PG 12
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 705HH
UT WOS:000286119000014
PM 20589403
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Noguchi, T
   Sakamoto, A
   Murotani, Y
   Murata, K
   Hirata, M
   Yamada, Y
   Toguchida, J
   Matsuda, S
AF Noguchi, Takashi
   Sakamoto, Akio
   Murotani, Yoshiki
   Murata, Koichi
   Hirata, Masahiro
   Yamada, Yosuke
   Toguchida, Junya
   Matsuda, Shuichi
TI Inhibition of RANKL Expression in Osteocyte like Differentiated Tumor
   Cells in Giant Cell Tumor of Bone after Denosumab Treatment
SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
LA English
DT Article
DE denosumab; giant cell tumor of bone; immunohistochemistry; RANKL; TRAP
ID H3F3A
AB Giant cell tumors of bone (GCTBs) are locally aggressive tumors with the histological features of giant cells and stromal cells. Denosumab is a human monoclonal antibody that binds to the cytokine receptor activator of nuclear factor kappa B ligand (RANKL). RANKL inhibition blocks tumor induced osteoclastogenesis, and survival, and is used to treat unresectable GCTBs. Denosumab treatment induces osteogenic differentiation of GCTB cells. In this study, the expression of RANKL, special AT rich sequence binding protein 2 (SATB2, a marker of osteoblast differentiation), and sclerostin/SOST (a marker of mature osteocytes) was analyzed before and after treatment with denosumab in six cases of GCTB. Denosumab therapy was administered a mean of five times over a mean 93.5 day period. Before denosumab treatment, RANKL expression was observed in one of six cases. After denosumab therapy, spindle like cells devoid of giant cell aggregation were RANKL positive in four of six cases. Bone matrix embedded osteocyte markers were observed, although RANKL was not expressed. Osteocyte like cells were confirmed to have mutations, as identified using mutation specific antibodies. Our study results suggest that treatment of GCTBs with denosumab results in osteoblast osteocyte differentiation. Denosumab played a role in the suppression of tumor activity via inhibition of the RANK RANKL pathway, which triggers osteoclast precursors to differentiate into osteoclasts.
C1 [Noguchi, Takashi; Sakamoto, Akio; Murotani, Yoshiki; Murata, Koichi; Matsuda, Shuichi] Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Kyoto, Japan.
   [Hirata, Masahiro; Yamada, Yosuke] Kyoto Univ, Grad Sch Med, Dept Diagnost Pathol, Kyoto, Japan.
   [Toguchida, Junya] Kyoto Univ, Ctr iPS Cell Res & Applicat, Kyoto, Japan.
   [Sakamoto, Akio] Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto 6068507, Japan.
C3 Kyoto University; Kyoto University; Kyoto University; Kyoto University
RP Sakamoto, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto 6068507, Japan.
EM akiosaka@kuhp.kyoto u.ac.jp
RI ; Murata, Koichi/HLH 5882 2023; Hirata, Masahiro/JVO 6179 2024; Matsuda,
   Shuichi/CAA 3095 2022
OI Murata, Koichi/0000 0002 7896 3937; Hirata,
   Masahiro/0000 0001 9211 0511; Yamada, Yosuke/0000 0001 7952 2706; 
CR Body JJ., 2017, SUPPORT CARE CANCER, V25
   Brodowicz T, 2015, FUTURE ONCOL, V11, P1881, DOI [10.2217/FON.15.94, 10.2217/fon.15.94]
   Cleven AHG, 2015, AM J SURG PATHOL, V39, P1576, DOI 10.1097/PAS.0000000000000512
   Deeks ED, 2018, DRUG AGING, V35, P163, DOI 10.1007/s40266 018 0525 7
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Kelly SP, 2022, J SURG ONCOL, V126, P571, DOI 10.1002/jso.26903
   Kerr DA, 2021, AM J SURG PATHOL, V45, P93, DOI 10.1097/PAS.0000000000001555
   Kervarrec T, 2017, MODERN PATHOL, V30, P393, DOI 10.1038/modpathol.2016.212
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lim J, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13887 y
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   ODONNELL RJ, 1994, J BONE JOINT SURG AM, V76A, P1827, DOI 10.2106/00004623 199412000 00009
   Oh JH, 2006, INT ORTHOP, V30, P490, DOI 10.1007/s00264 006 0154 3
   Presneau N, 2015, J PATHOL CLIN RES, V1, P113, DOI 10.1002/cjp2.13
   Sano K, 2020, J ORTHOP SURG HONG K, V28, DOI 10.1177/2309499020929786
   Szendröi M, 2004, J BONE JOINT SURG BR, V86B, P5, DOI 10.1302/0301 620X.86B1.14053
   Treffel M, 2020, AM J SURG PATHOL, V44, P1, DOI 10.1097/PAS.0000000000001388
   Ubaidus S, 2009, J ELECTRON MICROSC, V58, P381, DOI 10.1093/jmicro/dfp032
   Uchida T, 2020, ENDOCR J, V67, P31, DOI 10.1507/endocrj.EJ19 0198
   van der Heijden L, 2017, EUR J CANCER, V77, P75, DOI 10.1016/j.ejca.2017.02.021
NR 20
TC 4
Z9 4
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0022 1554
EI 1551 5044
J9 J HISTOCHEM CYTOCHEM
JI J. Histochem. Cytochem.
PD MAR
PY 2023
VL 71
IS 3
BP 131
EP 138
DI 10.1369/00221554231163638
EA MAR 2023
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA C3KS5
UT WOS:000956651400001
PM 36971322
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Maycas, M
   McAndrews, KA
   Sato, AY
   Pellegrini, GG
   Brown, DM
   Allen, MR
   Plotkin, LI
   Gortazar, AR
   Esbrit, P
   Bellido, T
AF Maycas, Marta
   McAndrews, Kevin A.
   Sato, Amy Y.
   Pellegrini, Gretel G.
   Brown, Drew M.
   Allen, Matthew R.
   Plotkin, Lilian I.
   Gortazar, Arancha R.
   Esbrit, Pedro
   Bellido, Teresita
TI PTHrP Derived Peptides Restore Bone Mass and Strength in Diabetic Mice:
   Additive Effect of Mechanical Loading
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE DIABETES; OSTEOCYTES; SOST/SCLEROSTIN; PTHrP; OSTEOCYTE APOPTOSIS
ID HORMONE RELATED PROTEIN; OSTEOCYTE; RECEPTOR; TYPE 1; EXPRESSION;
   PATHWAY; MECHANOTRANSDUCTION; OSTEOPOROSIS; STIMULATION; INHIBITION
AB There is an unmet need to understand the mechanisms underlying skeletal deterioration in diabetes mellitus (DM) and to develop therapeutic approaches to treat bone fragility in diabetic patients. We demonstrate herein that mice with type 1 DM induced by streptozotocin exhibited low bone mass, inferior mechanical and material properties, increased bone resorption, decreased bone formation, increased apoptosis of osteocytes, and increased expression of the osteocyte derived bone formation inhibitor Sost/sclerostin. Further, short treatment of diabetic mice with parathyroid hormone related protein ( PTHrP) derived peptides corrected these changes to levels undistinguishable from non diabetic mice. In addition, diabetic mice exhibited reduced bone formation in response to mechanical stimulation, which was corrected by treatment with the PTHrP peptides, and higher prevalence of apoptotic osteocytes, which was reduced by loading or by the PTHrP peptides alone and reversed by a combination of loading and PTHrP peptide treatment. In vitro experiments demonstrated that the PTHrP peptides or mechanical stimulation by fluid flow activated the survival kinases ERKs and induced nuclear translocation of the canonical Wnt signaling mediator beta catenin, and prevented the increase in osteocytic cell apoptosis induced by high glucose. Thus, PTHrP derived peptides cross talk with mechanical signaling pathways to reverse skeletal deterioration induced by DM in mice. These findings suggest a crucial role of osteocytes in the harmful effects of diabetes on bone and raise the possibility of targeting these cells as a novel approach to treat skeletal deterioration in diabetes. Moreover, our study suggests the potential therapeutic efficacy of combined pharmacological and mechanical stimuli to promote bone accrual and maintenance in diabetic subjects. (C) 2016 American Society for Bone and Mineral Research.
C1 [Maycas, Marta; McAndrews, Kevin A.; Sato, Amy Y.; Pellegrini, Gretel G.; Brown, Drew M.; Allen, Matthew R.; Plotkin, Lilian I.; Bellido, Teresita] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [Maycas, Marta; Esbrit, Pedro] Fdn Jimenez Diaz, Inst Invest Sanitaria, Madrid, Spain.
   [McAndrews, Kevin A.; Plotkin, Lilian I.; Bellido, Teresita] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN USA.
   [Gortazar, Arancha R.] Univ San Pablo CEU, Inst Med Mol Aplicada, Madrid, Spain.
   [Bellido, Teresita] Indiana Univ Sch Med, Dept Med, Div Endocrinol, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Fundacion
   Jimenez Diaz; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Richard L. Roudebush VA Medical Center; San Pablo
   CEU University; Indiana University System; Indiana University
   Bloomington
RP Bellido, T (通讯作者)，635 Barnhill Dr,Med Sci Bldg,Room 5045A, Indianapolis, IN 46022 USA.; Esbrit, P (通讯作者)，Avda Reyes Catolicos 2, Madrid 28040, Spain.
EM PEsbrit@fjd.es; tbellido@iupui.edu
RI ; pellegrini, gretel/JXL 3464 2024; Plotkin, Lilian/H 7188 2019; Maycas,
   Marta/L 8145 2014; Gortazar, Arancha/G 5385 2017; Allen,
   Matthew/A 8799 2015
OI Bellido, Teresita/0000 0002 8203 7004; Plotkin,
   Lilian/0000 0002 9537 4544; Sato, Amy/0000 0001 5061 1369; Gortazar,
   Arancha/0000 0001 5072 3141; 
FU National Institutes of Health [R01 AR059357]; Veterans Administration [1
   I01 BX002104 01]; Spanish Instituto de Salud Carlos III [PI11/00449,
   RD12/0043/0008]; Universidad San Pablo CEU; European Molecular and
   Biology Organization (EMBO); Conchita Rabago Foundation; Boehringer
   Ingelheim; Spanish Ministerio de Economia y Competitividad [FI12/00458]
FX This research was supported by the National Institutes of Health
   (R01 AR059357 to TB); the Veterans Administration (1 I01 BX002104 01 to
   TB); the Spanish Instituto de Salud Carlos III (PI11/00449 and
   RD12/0043/0008); and Universidad San Pablo CEU (emerging group). MM
   received short term fellowships from The European Molecular and Biology
   Organization (EMBO), Conchita Rabago Foundation, and Boehringer
   Ingelheim, and was also supported by Spanish Ministerio de Economia y
   Competitividad (FI12/00458).
CR Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bellido T, 2014, CALCIFIED TISSUE INT, V94, P25, DOI 10.1007/s00223 013 9774 y
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Botolin S, 2005, ENDOCRINOLOGY, V146, P3622, DOI 10.1210/en.2004 1677
   Botolin S, 2007, ENDOCRINOLOGY, V148, P198, DOI 10.1210/en.2006 1006
   De Castro LF, 2015, J CELL PHYSIOL, V230, P278, DOI 10.1002/jcp.24734
   Delgado Calle J, 2017, J BONE MINER RES, V32, P522, DOI 10.1002/jbmr.3011
   Delgado Calle J, 2016, CANCER RES, V76, P1089, DOI 10.1158/0008 5472.CAN 15 1703
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Esbrit P, 2016, CALCIFIED TISSUE INT, V98, P359, DOI 10.1007/s00223 015 0050 1
   Esbrit P, 2013, BIOCHEM PHARMACOL, V85, P1417, DOI 10.1016/j.bcp.2013.03.002
   de Castro LF, 2012, J CELL PHYSIOL, V227, P1752, DOI 10.1002/jcp.22902
   Gortazar AR, 2013, J BIOL CHEM, V288, P8168, DOI 10.1074/jbc.M112.437921
   Grosso MJ, 2015, J ORTHOP RES, V33, P163, DOI 10.1002/jor.22748
   Hamada Y, 2007, BONE, V40, P1408, DOI 10.1016/j.bone.2006.12.057
   Hie M, 2011, INT J MOL MED, V28, P455, DOI 10.3892/ijmm.2011.697
   Hofbauer LC, 2007, J BONE MINER RES, V22, P1317, DOI 10.1359/JBMR.070510
   Jiao HL, 2015, CURR OSTEOPOROS REP, V13, P327, DOI 10.1007/s11914 015 0286 8
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Lai XH, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.9
   López Herradón A, 2013, J CELL BIOCHEM, V114, P1908, DOI 10.1002/jcb.24535
   Lozano D, 2011, BRIT J PHARMACOL, V162, P1424, DOI 10.1111/j.1476 5381.2010.01155.x
   Lozano D, 2009, ENDOCRINOLOGY, V150, P2027, DOI 10.1210/en.2008 1108
   Maycas M, 2015, J BONE MINER RES, V30, P1231, DOI 10.1002/jbmr.2439
   Motyl K, 2009, BIOL PROCED ONLINE, V11, P296, DOI 10.1007/s12575 009 9000 5
   Motyl KJ, 2012, J CELL PHYSIOL, V227, P1326, DOI 10.1002/jcp.22844
   Motyl KJ, 2009, J CELL PHYSIOL, V218, P575, DOI 10.1002/jcp.21626
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Pacheco Costa R, 2015, BONE, V81, P632, DOI 10.1016/j.bone.2015.09.011
   Parajuli A, 2015, BONE, V81, P152, DOI 10.1016/j.bone.2015.07.012
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, AM J PHYSIOL CELL PH, V289, pC633, DOI 10.1152/ajpcell.00278.2004
   Portal Núñez S, 2010, FEBS LETT, V584, P3095, DOI 10.1016/j.febslet.2010.05.047
   Portal Núñez S, 2016, J GERONTOL A BIOL, V71, P290, DOI 10.1093/gerona/glv160
   Rhee Y, 2011, J BONE MINER RES, V26, P1035, DOI 10.1002/jbmr.304
   Robling AG, 2002, BONE, V31, P562, DOI 10.1016/S8756 3282(02)00871 2
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Rodríguez de la Rosa L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087536
   ROUFFET J, 1994, REPROD NUTR DEV, V34, P473, DOI 10.1051/rnd:19940508
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Valín A, 2001, ENDOCRINOLOGY, V142, P2752, DOI 10.1210/en.142.7.2752
   Verhaeghe J, 2000, BONE, V27, P249, DOI 10.1016/S8756 3282(00)00308 2
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Wittrant Y, 2008, BONE, V42, P1122, DOI 10.1016/j.bone.2008.02.006
NR 49
TC 44
Z9 47
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2017
VL 32
IS 3
BP 486
EP 497
DI 10.1002/jbmr.3007
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EQ4NY
UT WOS:000398055900009
PM 27683064
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Young, RJ
   Coleman, RE
AF Young, Robin J.
   Coleman, Robert E.
TI Zoledronic acid to prevent and treat cancer metastasis: new prospects
   for an old drug
SO FUTURE ONCOLOGY
LA English
DT Article
DE bisphosphonate; bone metastasis; osteoclast; skeletal related event;
   zoledronate
ID RANDOMIZED CONTROLLED TRIAL; PLACEBO CONTROLLED TRIAL;
   NITROGEN CONTAINING BISPHOSPHONATES; DIRECT ANTITUMOR ACTIVITY; ADVANCED
   BREAST CANCER; LONG TERM EFFICACY; INDUCED BONE LOSS; CELLS IN VITRO;
   DELTA T CELLS; PROSTATE CANCER
AB Zoledronic acid (zoledronate, Zometa T; Novartis Pharmaceuticals, Basel, Switzerland) is a nitrogen containing bisphosphonate. Zoledronate rapidly binds to bone mineral where it is then ingested by osteoclasts. Once internalized, zoledronate inhibits the mevalonate pathway, which stops osteoclast function, and thus slows bone resorption. Zoledronate is approved for the prevention of skeletal morbidity in metastatic bone disease from solid tumors and multiple myeloma. Zoledronate is also recommended as an option for the treatment of cancer therapy induced bone loss. In recent large Phase III studies in early breast cancer, zoledronate reduced both local and distant recurrences in women with induced or established natural menopause. Postulated mechanisms underlying the anticancer properties of zoledronate include antiangiogenic and immunomodulatory effects. A clearer understanding of these mechanisms will enable the full potential of zoledronate to be realized.
C1 [Young, Robin J.; Coleman, Robert E.] Weston Pk Hosp, Acad Unit Clin Oncol, CR UK YCR Sheffield Canc Res Ctr, Sheffield S10 2SJ, S Yorkshire, England.
C3 Weston Park Hospital
RP Young, RJ (通讯作者)，Weston Pk Hosp, Acad Unit Clin Oncol, CR UK YCR Sheffield Canc Res Ctr, Whitham Rd, Sheffield S10 2SJ, S Yorkshire, England.
EM r.j.young@sheffield.ac.uk
FU Novartis
FX RE Coleman receives research funding from Novartis and provided expert
   testimony for Novartis. RE Coleman also receives honoraria from Amgen.
   The authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Aft R, 2010, LANCET ONCOL, V11, P421, DOI 10.1016/S1470 2045(10)70054 1
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2010, NEW ENGL J MED, V362, P1761, DOI 10.1056/NEJMoa1001086
   Bosch Barrera J, 2011, CLIN TRANSL ONCOL, V13, P148, DOI 10.1007/s12094 011 0634 9
   Brown JE, 2007, CLIN CANCER RES, V13, P5406, DOI 10.1158/1078 0432.CCR 07 0247
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
   Coleman R, 2011, BREAST CANCER RES TR, V127, P429, DOI 10.1007/s10549 011 1429 y
   Coleman RE, 2010, BRIT J CANCER, V102, P1099, DOI 10.1038/sj.bjc.6605604
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Coleman R, 2011, CRIT REV ONCOL HEMAT, V80, P411, DOI 10.1016/j.critrevonc.2011.02.005
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Dieli F, 2003, BLOOD, V102, P2310, DOI 10.1182/blood 2003 05 1655
   Dieli F, 2007, CANCER RES, V67, P7450, DOI 10.1158/0008 5472.CAN 07 0199
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   FOGELMAN I, 1979, J NUCL MED, V20, P98
   Gnant M, 2008, LANCET ONCOL, V9, P840, DOI 10.1016/S1470 2045(08)70204 3
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Hadji P, 2012, CANCER TREAT REV, V38, P798, DOI 10.1016/j.ctrv.2012.02.008
   Hadji P, 2011, ANN ONCOL, V22, P2546, DOI 10.1093/annonc/mdr017
   Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538 7836.2006.02259.x
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Lang JM, 2011, CANCER IMMUNOL IMMUN, V60, P1447, DOI 10.1007/s00262 011 1049 8
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Lopez Olivo MA, 2012, SUPPORT CARE CANCER, V20, P2985, DOI 10.1007/s00520 012 1563 z
   Lumachi F, 2009, ANTICANCER RES, V29, P1551
   Lustberg MB, 2012, J CLIN ONCOL, V30, P3665, DOI 10.1200/JCO.2012.42.2097
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Meraviglia S, 2010, CLIN EXP IMMUNOL, V161, P290, DOI 10.1111/j.1365 2249.2010.04167.x
   Michaelson MD, 2007, J CLIN ONCOL, V25, P1038, DOI 10.1200/JCO.2006.07.3361
   Mitrofan LM, 2009, BONE, V45, P1153, DOI 10.1016/j.bone.2009.08.010
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Neville Webbe HL, 2006, TUMOR BIOL, V27, P92, DOI 10.1159/000092489
   Ottewell PD, 2010, INT J CANCER, V126, P522, DOI 10.1002/ijc.24756
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   Rogers Maurice, 2011, Scottish Forestry, V65, P34
   Rogers TL, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 177
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Ross JR, 2003, BMJ BRIT MED J, V327, P469, DOI 10.1136/bmj.327.7413.469
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Scagliotti GV, 2012, ANN ONCOL, V23, P2082, DOI 10.1093/annonc/mds128
   Schilcher J, 2013, BONE, V52, P389, DOI 10.1016/j.bone.2012.10.016
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Solomayer EF, 2012, ANN ONCOL, V23, P2271, DOI 10.1093/annonc/mdr612
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Stresing V, 2011, BONE, V48, P259, DOI 10.1016/j.bone.2010.09.035
   Sun S, 2011, EXPERT OPIN THER PAT, V21, P1433
   Wang GL, 2012, J BIOMED MATER RES A, V100A, P684, DOI 10.1002/jbm.a.34002
   Weiss HM, 2008, DRUG METAB DISPOS, V36, P2043, DOI 10.1124/dmd.108.021071
   Welton JL, 2013, J BONE MINER RES, V28, P464, DOI 10.1002/jbmr.1797
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Wilson C, 2012, CANCER TREAT REV, V38, P877, DOI 10.1016/j.ctrv.2012.02.007
   Winter M, 2010, 33 ANN CTRC AACR SAN
   Zhao XM, 2010, BREAST CANCER RES TR, V124, P733, DOI 10.1007/s10549 010 1183 6
NR 64
TC 22
Z9 24
U1 0
U2 8
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1479 6694
J9 FUTURE ONCOL
JI Future Oncol.
PD MAY
PY 2013
VL 9
IS 5
BP 633
EP 643
DI 10.2217/FON.13.28
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 141MO
UT WOS:000318729500010
PM 23647292
DA 2025 08 17
ER

PT J
AU Hussein, O
   Tiedemann, K
   Murshed, M
   Komarova, SV
AF Hussein, Osama
   Tiedemann, Kerstin
   Murshed, Monzur
   Komarova, Svetlana V.
TI Rapamycin inhibits osteolysis and improves survival in a model of
   experimental bone metastases
SO CANCER LETTERS
LA English
DT Article
DE Bone metastases; Breast cancer; Osteoclast; mTOR; Rapamycin
ID BREAST CANCER CELLS; SKELETAL COMPLICATIONS; OSTEOCLAST FORMATION;
   MAMMALIAN TARGET; PHASE II; ZOLEDRONIC ACID; MTOR INHIBITOR; STROMAL
   CELLS; SOLID TUMORS; DIFFERENTIATION
AB Breast cancer metastasis to bone results in pain, pathological fractures and hypercalcemia. Activation of osteoclasts is critical for the formation of osteolytic lesions by metastasizing tumors. Although the potent drugs, zoledronic acid and Denosumab were introduced, the presence of resistant or intolerant cases necessitated the continued search of osteoclast targeting treatments. Rapamycin acts through the mTOR pathway, which is important for osteoclast formation. Mouse mammary carcinoma 4T1 cells were injected into the tibia of balb/c mice. Rapamycin treatment significantly decreased the osteoclast population and osteolysis associated with experimental metastases. Our data indicate the benefit of rapamycin in treating metastases associated osteolytic disease. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Hussein, Osama; Tiedemann, Kerstin; Murshed, Monzur; Komarova, Svetlana V.] McGill Univ, Fac Dent, Montreal, PQ H3A 1A4, Canada.
   [Murshed, Monzur] McGill Univ, Fac Med, Dept Med, Montreal, PQ H3A 1A4, Canada.
C3 McGill University; McGill University
RP Komarova, SV (通讯作者)，740 Dr Penfield Ave,2201, Montreal, PQ H3A 1A4, Canada.
EM svetlana.komarova@mcgill.ca
RI ; Hussein, Osama/AAA 2620 2019; Komarova, Svetlana/MTR 5042 2025
OI Hussein, Osama/0000 0002 9563 0528; Komarova,
   Svetlana/0000 0003 3570 3147; 
FU Government of Quebec; Lloyd Carr Harris Fellowship; McGill University;
   Fonds de la recherche en sante du Quebec; Cancer Research Society
FX The authors are grateful to Dr. P.M. Siegel (McGill University) and Dr.
   M.F. Manolson (University of Toronto) for supplying the reagents used in
   this study. The authors also thank Jenna Fong, Gulzhakhan Sadvakassova
   and Iris Boraschi Diaz for their help with animal studies. O.H. was
   supported by the Merit Doctoral Research Scholarship from the Government
   of Quebec, by Lloyd Carr Harris Fellowship and by McGill University.
   M.M. receives salary award from Fonds de la recherche en sante du
   Quebec. S.V.K. holds a Canada Research Chair in Osteoclast Biology. This
   work was supported by an operating grant from The Cancer Research
   Society.
CR Araki K, 2009, NATURE, V460, P108, DOI 10.1038/nature08155
   Awada A, 2008, EUR J CANCER, V44, P84, DOI 10.1016/j.ejca.2007.10.003
   Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391
   Bendre M, 2003, CLIN ORTHOP RELAT R, pS39, DOI 10.1097/01.blo.0000093844.72468.f4
   Berenson JR, 2006, CANCER BIOL THER, V5, P1078, DOI 10.4161/cbt.5.9.3306
   Beslija S, 2009, ANN ONCOL, V20, P1771, DOI 10.1093/annonc/mdp261
   Brown JE, 2010, BREAST CANCER RES TR, V123, P767, DOI 10.1007/s10549 010 0981 1
   Buijs JT, 2009, BONE, V44, P380, DOI 10.1016/j.bone.2008.10.047
   Cardoso F, 2009, ANN ONCOL, V20, P15, DOI 10.1093/annonc/mdp115
   Cejka D, 2010, ARTHRITIS RHEUM US, V62, P2294, DOI 10.1002/art.27504
   Chan S, 2005, J CLIN ONCOL, V23, P5314, DOI 10.1200/JCO.2005.66.130
   Chen YC, 2009, CARCINOGENESIS, V30, P1941, DOI 10.1093/carcin/bgp227
   Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159, DOI 10.1615/CritRevEukarGeneExpr.v10.i2.50
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   COLEMAN RE, 1988, BRIT J CANCER, V58, P621, DOI 10.1038/bjc.1988.272
   Corey E, 2002, PROSTATE, V52, P20, DOI 10.1002/pros.10091
   Ellard SL, 2009, J CLIN ONCOL, V27, P4536, DOI 10.1200/JCO.2008.21.3033
   Fisher JL, 2006, CANCER RES, V66, P3620, DOI 10.1158/0008 5472.CAN 05 3119
   Fong JE, 2010, J BIOL CHEM, V285, P31427, DOI 10.1074/jbc.M110.114496
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Guo YB, 2008, BONE, V43, P386, DOI 10.1016/j.bone.2008.03.026
   Hamaoka T, 2004, J CLIN ONCOL, V22, P2942, DOI 10.1200/jco.2004.08.181
   Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778
   Hiraga T, 2001, CANCER RES, V61, P4418
   Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Hussein O, 2011, BONE, V48, P202, DOI 10.1016/j.bone.2010.09.006
   Kerba M, 2010, J CLIN ONCOL, V28, P4892, DOI 10.1200/JCO.2010.28.6559
   Kiefer JA, 2004, CLIN EXP METASTAS, V21, P381, DOI 10.1007/s10585 004 2869 0
   Kinder M, 2008, EXP CELL RES, V314, P173, DOI 10.1016/j.yexcr.2007.09.021
   Lipton A, 2008, CLIN CANCER RES, V14, P6690, DOI 10.1158/1078 0432.CCR 07 5234
   Lipton A, 2008, CANCER AM CANCER SOC, V113, P193, DOI 10.1002/cncr.23529
   Lipton A, 2007, ONCOLOGIST, V12, P1035, DOI 10.1634/theoncologist.12 9 1035
   Luegmayr E, 2004, CELL DEATH DIFFER, V11, pS108, DOI 10.1038/sj.cdd.4401399
   Martin SK, 2010, J BONE MINER RES, V25, P2126, DOI 10.1002/jbmr.114
   Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352
   Morgan H, 2004, INT J CANCER, V109, P653, DOI 10.1002/ijc.20056
   Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074 7613(00)80025 4
   Noh WC, 2004, CLIN CANCER RES, V10, P1013, DOI 10.1158/1078 0432.CCR 03 0043
   Ohtani M, 2008, BLOOD, V112, P635, DOI 10.1182/blood 2008 02 137430
   Okui T, 2010, MOL CANCER THER, V9, P2960, DOI 10.1158/1535 7163.MCT 10 0489
   Pericle F, 1997, J IMMUNOL, V159, P2580
   Ravaud A, 2010, B CANCER, V97, pS45, DOI 10.1684/bdc.2010.1069
   Rosenthal DI, 1997, CANCER, V80, P1595, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1595::AID CNCR10>3.0.CO;2 V
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Strober W., 2001, CURRENT PROTOCOLS IM
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Tateishi U, 2008, RADIOLOGY, V247, P189, DOI 10.1148/radiol.2471070567
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Tiedemann K, 2009, J BIOL CHEM, V284, P33662, DOI 10.1074/jbc.M109.010785
   Vassiliou V, 2007, CLIN EXP METASTAS, V24, P49, DOI 10.1007/s10585 007 9056 z
   Welte T, 1999, SCIENCE, V283, P222, DOI 10.1126/science.283.5399.222
   WONG SW, 2010, BREAST CANC RES TREA
   Yao ZJ, 2006, P NATL ACAD SCI USA, V103, P1000, DOI 10.1073/pnas.0507350103
   Zeng Q, 2010, EUR J CANCER, V46, P1132, DOI 10.1016/j.ejca.2010.01.014
NR 56
TC 39
Z9 48
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PD JAN 28
PY 2012
VL 314
IS 2
BP 176
EP 184
DI 10.1016/j.canlet.2011.09.026
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 868OG
UT WOS:000298532000006
PM 22014409
DA 2025 08 17
ER

PT J
AU Chen, HX
   Guo, TY
   Wang, DR
   Qin, RJ
AF Chen, Hongxi
   Guo, Tongya
   Wang, Dianrong
   Qin, Rujie
TI Vaccaria hypaphorine impairs RANKL induced osteoclastogenesis by
   inhibition of ERK, p38, JNK and NF κB pathway and prevents inflammatory
   bone loss in mice
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Osteoclast differentiation; Bone resorption; vaccaria hypaphorine;
   RAW264.7 cells
ID DIFFERENTIATION; OSTEOBLAST; RESORPTION; MECHANISM; MEDICINE; CELLS
AB Osteoclasts are sole bone resorbing cells which exert a profound effect on skeletal metabolism. The search for medicines that affect the differentiation and function of osteoclasts is crucial in developing therapies for os teoclast based diseases. Vaccaria hypaphorine, the main active compound of the traditionally used Chinese herb Vaccaria segetalis, has anti inflammatory activity. The present study demonstrated for the first time that vaccaria hypaphorine could significantly inhibit the receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclastic differentiation in vitro and alleviate lipopolysaccharide (LPS) induced bone loss in vivo. Further study showed that vaccaria hypaphorine decreased osteoclastogenesis in a dose dependent manner. Furthermore, vaccaria hypaphorine was confirmed to inhibit osteoclasts differentiation at early stage but not at later stage. Pit formation assay and F actin ring staining showed that vaccaria hypaphorine inhibited the bone resorbing activity of osteoclasts. Mechanistically, vaccaria hypaphorine impaired RANKL induced osteoclastogenesis through reduction of extracellular signal regulated kinases (ERK), p38, c Jun N terminal kinase (JNK) and NF kappa B p65 phosphorylation. Taken together, our results provided evidences that vaccaria hypaphorine might be considered as potential therapeutic agent for treating osteoclast based bone loss.
C1 [Chen, Hongxi; Wang, Dianrong] First Peoples Hosp Lianyungang, Dept Pharm, Lianyungang 222002, Jiangsu, Peoples R China.
   [Guo, Tongya] Nanjing Univ Chinese Med, Xuzhou Cent Hosp, Dept Bone & Joint Surg, Xuzhou 221009, Jiangsu, Peoples R China.
   [Qin, Rujie] First Peoples Hosp Lianyungang, Dept Spine Surg, 182 Tongguan North Rd, Lianyungang 222002, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine
RP Qin, RJ (通讯作者)，First Peoples Hosp Lianyungang, Dept Spine Surg, 182 Tongguan North Rd, Lianyungang 222002, Jiangsu, Peoples R China.
EM qinrujie_hospital@126.com
RI Chen, hongxi/KBQ 1342 2024
FU Six Talent Peaks Project in Jiangsu Province [2015 wsw similar to 082]
FX This work was supported by The Six Talent Peaks Project in Jiangsu
   Province [grant numbers 2015 wsw similar to 082].
CR [Anonymous], 2008, P WORLD C ENG COMP S, DOI DOI 10.1175/2008JAMC1963.1
   Balsevich JJ, 2012, FITOTERAPIA, V83, P170, DOI 10.1016/j.fitote.2011.10.010
   Bandow K, 2010, BIOCHEM BIOPH RES CO, V402, P755, DOI 10.1016/j.bbrc.2010.10.103
   Chen F., 2014, BIOCHEM PHARMACOL, V33, P796
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Guo SY, 2016, INT J BIOL SCI, V12, P1155, DOI 10.7150/ijbs.14654
   Ikeda K, 2016, J BIOCHEM, V159, P1, DOI 10.1093/jb/mvv112
   Jiang YN, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0334 7
   Kanazawa K, 2005, J BONE MINER RES, V20, P840, DOI 10.1359/JBMR.041225
   Kang H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.339
   Li M, 2016, J ETHNOPHARMACOL, V185, P120, DOI 10.1016/j.jep.2016.03.023
   Mollica A, 2012, MOLECULES, V17, P6083, DOI 10.3390/molecules17056083
   Mukwaya E, 2014, PHARM BIOL, V52, P1223, DOI 10.3109/13880209.2014.884606
   Novack DV, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD 0011 2015
   Phan TCA, 2004, HISTOL HISTOPATHOL, V19, P1325, DOI 10.14670/HH 19.1325
   Sang CL, 2016, BONE, V84, P78, DOI 10.1016/j.bone.2015.12.012
   Sang Sheng min, 2000, Zhongguo Zhongyao Zazhi, V25, P221
   Sun HJ, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 1635 1
   Sun YX, 2008, BIORESOURCE TECHNOL, V99, P900, DOI 10.1016/j.biortech.2007.01.029
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Väänänen K, 2005, ADV DRUG DELIVER REV, V57, P959, DOI 10.1016/j.addr.2004.12.018
   Xu D, 2016, MOL MED REP, V14, P4767, DOI 10.3892/mmr.2016.5849
   Yang X., 2017, J CELL BIOCH
   Yu B, 2014, NAT MED, V20, P1009, DOI 10.1038/nm.3586
NR 25
TC 17
Z9 17
U1 1
U2 20
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JAN
PY 2018
VL 97
BP 1155
EP 1163
DI 10.1016/j.biopha.2017.11.044
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FR4NC
UT WOS:000419041300139
PM 29136954
DA 2025 08 17
ER

PT J
AU Oh, JE
   Kim, HJ
   Kim, WS
   Lee, ZH
   Ryoo, HM
   Hwang, SJ
   Lee, Y
   Kim, HH
AF Oh, Ji Eun
   Kim, Hyung Joon
   Kim, Woo Shin
   Lee, Zang Hee
   Ryoo, Hyun Mo
   Hwang, Soon Jung
   Lee, Youngkyun
   Kim, Hong Hee
TI PlexinA2 mediates osteoblast differentiation via regulation of Runx2
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE AXON GUIDANCE MOLECULE; PLEXINA2; OSTEOBLAST DIFFERENTIATION; RUNX2; BMP
   SIGNALING
ID GROWTH FACTOR BETA; BONE FORMATION; ALKALINE PHOSPHATASE; EXPRESSION;
   P38; KINASE; ACTIVATION; PROTEIN; CELLS; PATHWAYS
AB The imbalance between bone resorbing osteoclasts and bone forming osteoblasts often leads to bone destructive diseases such as osteoporosis. In contrast to the development of several antiresorptive agents for osteoporosis therapy, discovery of anabolic drugs has been difficult because of an insufficient understanding of the complex mechanism of bone formation. In a microarray analysis with mouse preosteoblast cells, we found that PlexinA2 (PlxnA2), a molecule previously known to mediate axon guidance in neural development, was upregulated by the osteogenic factor BMP2. PlxnA2 specific siRNA decreased Runx2 expression, osteoblast differentiation, and mineralization. Runx2 overexpression restored osteoblastic differentiation of PlxnA2 knockdown cells. PlxnA2 was associated with both type 1 and 2 BMP receptors, and BMP2 increased the interaction between PlxnA2 and type 1 receptors. PlxnA2 also affected Smad and Akt signaling pathways downstream of BMP2. Taken together, the results of our study reveal that PlxnA2 has a pro osteogenic function by modulating BMP2 signaling. Therefore, PlxnA2 may be a useful target for development of bone anabolic therapeutics. (c) 2012 American Society for Bone and Mineral Research
C1 [Oh, Ji Eun; Kim, Hyung Joon; Kim, Woo Shin; Lee, Zang Hee; Lee, Youngkyun; Kim, Hong Hee] Seoul Natl Univ, Dept Cell & Dev Biol, Sch Dent, BK21, Seoul 110749, South Korea.
   [Oh, Ji Eun; Kim, Hyung Joon; Kim, Woo Shin; Lee, Zang Hee; Ryoo, Hyun Mo; Lee, Youngkyun; Kim, Hong Hee] Seoul Natl Univ, DRI, Sch Dent, Seoul 110749, South Korea.
   [Oh, Ji Eun] Far E Univ, Dept Biomed Lab Sci, Chungbuk, South Korea.
   [Ryoo, Hyun Mo] Seoul Natl Univ, Dept Mol Genet, Sch Dent, BK21, Seoul 110749, South Korea.
   [Hwang, Soon Jung] Seoul Natl Univ, Dept Oral & Maxillofacial Surg, Sch Dent, Seoul 110749, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University (SNU)
RP Kim, HH (通讯作者)，Seoul Natl Univ, Dept Cell & Dev Biol, Sch Dent, BK21, 28 Yeongon Dong, Seoul 110749, South Korea.
EM hhbkim@snu.ac.kr
RI ; Kim, Jae hyung/J 8504 2012; Ryoo, Hyun Mo/D 5839 2012; Oh,
   Ji Eun/HMV 9113 2023; Kim, Hyung Joon/ABD 3143 2020
OI Ryoo, Hyun Mo/0000 0001 6769 8341; Kim, Hyung Joon/0000 0002 2962 9553; 
FU 21C Frontier Functional Proteomics Project [FPR08B1 170]; Science
   Research Center [2010 0001744]; National Research Foundation of Korea;
   Korean Government [NRF 2009 351 C00044]
FX This work was supported by the 21C Frontier Functional Proteomics
   Project (FPR08B1 170) and Science Research Center (2010 0001744) to H H
   K. This work was also supported by a grant from the National Research
   Foundation of Korea funded by the Korean Government
   (NRF 2009 351 C00044).
CR Basile JR, 2005, MOL CELL BIOL, V25, P6889, DOI 10.1128/MCB.25.16.6889 6898.2005
   Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0
   Delorme G, 2005, BIOL CELL, V97, P589
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Elefteriou F, 2005, CELL MOL LIFE SCI, V62, P2339, DOI 10.1007/s00018 005 5175 3
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Garrett IR, 2003, METH MOLEC MED, V80, P183
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Ha J, 2010, J IMMUNOL, V184, P4717, DOI 10.4049/jimmunol.0902444
   Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161
   Hassan MQ, 2006, J BIOL CHEM, V281, P40515, DOI 10.1074/jbc.M604508200
   Huang H, 2009, CELL DEATH DIFFER, V16, P1332, DOI 10.1038/cdd.2009.74
   Ortuño MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612
   Kanda T, 2007, J CELL BIOCHEM, V101, P1329, DOI 10.1002/jcb.21306
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kim YJ, 2004, J BIOL CHEM, V279, P50773, DOI 10.1074/jbc.M404145200
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Lee MH, 2005, J BIOL CHEM, V280, P35579, DOI 10.1074/jbc.M502267200
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104
   Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Nöth U, 2003, EXP CELL RES, V291, P201, DOI 10.1016/S0014 4827(03)00386 0
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Suzuki A, 2002, BONE, V30, P91, DOI 10.1016/S8756 3282(01)00660 3
   Takegahara N, 2006, NAT CELL BIOL, V8, P615, DOI 10.1038/ncb1416
   Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962 8924(00)01816 X
   Tamagnone L, 2006, NAT CELL BIOL, V8, P545, DOI 10.1038/ncb0606 545
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Wang XY, 2007, ENDOCRINOLOGY, V148, P1629, DOI 10.1210/en.2006 1000
   Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328
NR 36
TC 17
Z9 19
U1 0
U2 7
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2012
VL 27
IS 3
BP 552
EP 562
DI 10.1002/jbmr.1471
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 897UG
UT WOS:000300682500006
PM 22095611
DA 2025 08 17
ER

PT J
AU Supsavhad, W
   Hassan, BB
   Simmons, JK
   Dirksen, WP
   Elshafae, SM
   Kohart, NA
   Demirer, AA
   Rosol, TJ
AF Supsavhad, Wachiraphan
   Hassan, Bardes B.
   Simmons, Jessica K.
   Dirksen, Wessel P.
   Elshafae, Said M.
   Kohart, Nicole A.
   Demirer, Aylin A.
   Rosol, Thomas J.
TI Effect of Dickkopf 1 (Dkk 1) and SP600125, a JNK Inhibitor, on Wnt
   Signaling in Canine Prostate Cancer Growth and Bone Metastases
SO VETERINARY SCIENCES
LA English
DT Article
DE prostate cancer; SP600125; bone metastasis; Wnt signaling; JNK
   inhibitor; dog
ID MEMBRANE ANTIGEN; TRANSCRIPTION FACTORS; TUMOR GROWTH; EXPRESSION;
   CELLS; PATHWAY; OSTEOCLASTOGENESIS; PROGRESSION; MECHANISM; TWIST
AB Human Dickkopf 1 (Dkk 1) upregulates a noncanonical Wnt/JNK pathway, resulting in osteoclast stimulation, cell proliferation, and epithelial to mesenchymal transition (EMT) of cancer cells. Ace 1 Dkk 1, a canine prostate cancer (PCa) cell line overexpressing Dkk 1, was used to investigate Wnt signaling pathways in PCa tumor growth. SP600125, a JNK inhibitor, was used to examine whether it would decrease tumor growth and bone tumor phenotype in canine PCa cells in vitro and in vivo. Ace 1 Vector(YFP Luc) and Ace 1 Dkk 1(YFP Luc) cells were transplanted subcutaneously, while Ace 1 Dkk 1(YFP Luc) was transplanted intratibially into nude mice. The effects of Dkk 1 and SP600125 on cell proliferation, in vivo tumor growth, and bone tumor phenotype were investigated. The mRNA expression levels of Wnt/JNK related genes were measured using RT qPCR. Dkk 1 significantly increased the mRNA expression of Wnt/JNK signaling related genes. SP600125 significantly upregulated the mRNA expression of osteoblast differentiation genes and downregulated osteoclastic bone lysis related genes in vitro. SP600125 significantly decreased tumor volume and induced spindle shaped tumor cells in vivo. Mice bearing intratibial tumors had increased radiographic density of the intramedullary new bone, large foci of osteolysis, and increased cortical lysis with abundant periosteal new bone formation. Finally, SP600125 has the potential to serve as an alternative adjuvant therapy in some early stage PCa patients, especially those with high Dkk 1 expression.
C1 [Supsavhad, Wachiraphan; Hassan, Bardes B.; Simmons, Jessica K.; Dirksen, Wessel P.; Elshafae, Said M.; Kohart, Nicole A.; Demirer, Aylin A.] Ohio State Univ, Coll Vet Med, Dept Vet Biosci, Columbus, OH 43210 USA.
   [Supsavhad, Wachiraphan] Kasetsart Univ, Fac Vet Med, Dept Pathol, Bangkok 10900, Thailand.
   [Hassan, Bardes B.] Cairo Univ, Fac Vet Med, Dept Pathol, Giza 12211, Egypt.
   [Elshafae, Said M.] Univ Iowa, Dept Neurosci & Pharmacol, Iowa City, IA 52242 USA.
   [Elshafae, Said M.] Benha Univ, Fac Vet Med, Dept Pathol, Kalyubia 13736, Egypt.
   [Demirer, Aylin A.] Bursa Uludag Univ, Fac Vet Med, Pathol Dept, TR 16059 Bursa, Turkey.
   [Rosol, Thomas J.] Ohio Univ, Heritage Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA.
C3 University System of Ohio; Ohio State University; Kasetsart University;
   Egyptian Knowledge Bank (EKB); Cairo University; University of Iowa;
   Egyptian Knowledge Bank (EKB); Benha University; Uludag University;
   University System of Ohio; Ohio University
RP Rosol, TJ (通讯作者)，Ohio Univ, Heritage Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA.
EM wachiraphan.s@ku.th; dr_bardis@cu.edu.eg; jsimmons@seagen.com;
   dirksen.8@osu.edu; saidelshafae@yahoo.com; nicolekcromwell@gmail.com;
   aylindemirer@gmail.com; rosolt@ohio.edu
RI ; Elshafae, Said/HHY 7375 2022; Rosol, Thomas/G 9585 2011
OI Hassan, Bardes/0000 0003 0026 5239; Elshafae, Said/0000 0001 6285 5483; 
FU U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
   [21702 5012, W81XWH 14 1 0321]; Kasetsart University, Thailand
FX This research was funded through a grant from the U.S. Army Medical
   Research and Materiel Command Fort Detrick, Maryland, 21702 5012 grant
   (W81XWH 14 1 0321), and from Kasetsart University, Thailand.
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100
   Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298
   Carroll SH, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.2
   Curtin JF, 2004, J BIOL CHEM, V279, P17090, DOI 10.1074/jbc.M307629200
   D'Amelio P, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472 6890 14 11
   Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008 5472.CAN 07 6541
   Ecke TH, 2007, ANTICANCER RES, V27, P4143
   Ecke TH, 2010, ANTICANCER RES, V30, P1579
   Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209
   Elshafae SM, 2016, PROSTATE, V76, P796, DOI 10.1002/pros.23154
   Gasinska A, 2013, FOLIA HISTOCHEM CYTO, V51, P66, DOI 10.5603/FHC.2013.0010
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Hall CL, 2008, PROSTATE, V68, P1396, DOI 10.1002/pros.20805
   Hall CL, 2006, CANCER METAST REV, V25, P551, DOI 10.1007/s10555 006 9022 2
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Hofman MS, 2018, RADIOGRAPHICS, V38, P200, DOI 10.1148/rg.2018170108
   Jemaà M, 2012, EMBO MOL MED, V4, P500, DOI 10.1002/emmm.201200228
   Kagey MH, 2017, BRIT J PHARMACOL, V174, P4637, DOI 10.1111/bph.13894
   Khan MA, 2013, TUMOR BIOL, V34, P2497, DOI 10.1007/s13277 013 1002 x
   Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978 0 12 386035 4.00002 1
   Kim JY, 2016, CANCER RES TREAT, V48, P1338, DOI 10.4143/crt.2015.430
   Le PN, 2015, PHARMACOL THERAPEUT, V146, P1, DOI 10.1016/j.pharmthera.2014.08.005
   Lee AY, 2004, BIOCHEM BIOPH RES CO, V323, P1246, DOI 10.1016/j.bbrc.2004.09.001
   Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008 5472.CAN 10 4374
   Li FQ, 2005, CURR NEUROVASC RES, V2, P331, DOI 10.2174/156720205774322557
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Masuda H, 2003, PROSTATE, V54, P268, DOI 10.1002/pros.10193
   Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008 5472.CAN 05 0712
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Obradovich J, 1987, J Vet Intern Med, V1, P183, DOI 10.1111/j.1939 1676.1987.tb02013.x
   Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008 5472.CAN 07 6055
   Papachristou DJ, 2003, BONE, V32, P364, DOI 10.1016/S8756 3282(03)00026 7
   Paramio JM, 1999, ONCOGENE, V18, P7462, DOI 10.1038/sj.onc.1203151
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Rachner TD, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 649
   Rinehart Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097 0215(20001015)88:2<180::AID IJC6>3.0.CO;2 H
   Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03 0132fje
   Schulte G, 2010, PHARMACOL REV, V62, P632, DOI 10.1124/pr.110.002931
   Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502 e131
   Shorning BY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124507
   Siegel RL, 2021, CA CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654
   Simmons J. K., 2014, Veterinary Sciences, V1, P16
   Singleton DC, 2012, EXPERT OPIN THER TAR, V16, P1189, DOI 10.1517/14728222.2012.728207
   Sirohi D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218618
   Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989
   Sorenmo K U, 2003, Vet Comp Oncol, V1, P48, DOI 10.1046/j.1476 5829.2003.00007.x
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Suzman DL, 2014, CANCER METAST REV, V33, P619, DOI 10.1007/s10555 013 9480 2
   Takahashi N, 2011, FRONT BIOSCI LANDMRK, V16, P21, DOI 10.2741/3673
   Tan HL, 2020, J CELL BIOCHEM, V121, P81, DOI 10.1002/jcb.28870
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Thudi NK, 2008, PROSTATE, V68, P1116, DOI 10.1002/pros.20776
   Thudi NK, 2011, PROSTATE, V71, P615, DOI 10.1002/pros.21277
   Tweedle MF, 2018, PROSTATE, V78, P1111, DOI 10.1002/pros.23686
   Voorzanger Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   Wang L, 2014, TUMOR BIOL, V35, P463, DOI 10.1007/s13277 013 1064 9
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yang YM, 2003, CLIN CANCER RES, V9, P391
   Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185
   Zhang MF, 2013, CANCER EPIDEM BIOMAR, V22, P2354, DOI 10.1158/1055 9965.EPI 13 0668
NR 62
TC 8
Z9 10
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2306 7381
J9 VET SCI
JI Vet. Sci.
PD AUG
PY 2021
VL 8
IS 8
AR 153
DI 10.3390/vetsci8080153
PG 19
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA UH6LK
UT WOS:000690039600001
PM 34437475
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ghosh Choudhury, N
   Mandal, CC
   Das, F
   Ganapathy, S
   Ahuja, S
   Choudhury, GG
AF Ghosh Choudhury, Nandini
   Mandal, Chandi C.
   Das, Falguni
   Ganapathy, Suthakar
   Ahuja, Seema
   Choudhury, Goutam Ghosh
TI c Abl dependent Molecular Circuitry Involving Smad5 and
   Phosphatidylinositol 3 Kinase Regulates Bone Morphogenetic
   Protein 2 induced Osteogenesis
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID GROWTH FACTOR BETA; ACTIVATED PROTEIN KINASE; BMP 2 GENE TRANSCRIPTION;
   TGF BETA; TYROSINE KINASE; OSTEOBLAST DIFFERENTIATION;
   SIGNAL TRANSDUCTION; IMATINIB MESYLATE; CELL DIFFERENTIATION; PRECURSOR
   CELLS
AB Skeletal remodeling consists of timely formation and resorption of bone by osteoblasts and osteoclasts in a quantitative manner. Patients with chronic myeloid leukemia receiving inhibitors of c Abl tyrosine kinase often show reduced bone remodeling due to impaired osteoblast and osteoclast function. BMP 2 plays a significant role in bone generation and resorption by contributing to the formation of mature osteoblasts and osteoclasts. The effects of c Abl on BMP 2 induced bone remodeling and the underlying mechanisms are not well studied. Using a pharmacological inhibitor and expression of a dominant negative mutant of c Abl, we show an essential role of this tyrosine kinase in the development of bone nodules containing mature osteoblasts and formation of multinucleated osteoclasts in response to BMP 2. Calvarial osteoblasts prepared from c Abl null mice showed the absolute requirement of this tyrosine kinase in maturation of osteoblasts and osteoclasts. Activation of phosphatidylinositol 3 kinase (PI 3 kinase)/Akt signaling by BMP 2 leads to osteoblast differentiation. Remarkably, inhibition of c Abl significantly suppressed BMP 2 stimulated PI 3 kinase activity and its downstream Akt phosphorylation. Interestingly, c Abl regulated BMP 2 induced osteoclastogenic CSF 1 expression. More importantly, we identified the requirements of c Abl in BMP 2 autoregulation and the expressions of alkaline phosphatase and osterix that are necessary for osteoblast differentiation. c Abl contributed to BMP receptor specific Smad dependent transcription of CSF 1, osterix, and BMP 2. Finally, c Abl associates with BMP receptor IA and regulates phosphorylation of Smad in response to BMP 2. We propose that activation of c Abl is an important step, which induces into two signaling pathways involving noncanonical PI 3 kinase and canonical Smads to integrate BMP 2 induced osteogenesis.
C1 [Ghosh Choudhury, Nandini; Ahuja, Seema; Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Vet Affairs Res, San Antonio, TX 78229 USA.
   [Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
   [Ghosh Choudhury, Nandini; Mandal, Chandi C.; Ganapathy, Suthakar] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
   [Das, Falguni; Ahuja, Seema; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Audie L. Murphy Memorial Veterans Hospital; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial
   Veterans Hospital; Geriatric Research Education & Clinical Center;
   University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio
RP Ghosh Choudhury, N (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
EM choudhury@uthscsa.edu
RI Ganapathy, Suthakar/C 1266 2013
OI Mandal, Chandi/0000 0002 2292 6635
FU National Institutes of Health [RO1 AR52425, RO1 DK50190]; Veterans
   Affairs Merit Review grant; CTRC P30 Cancer Center Support Grant [CA
   054174]; Veterans Affairs Merit Review grants; Cancer Prevention
   Research Institute of Texas; Veterans Affairs Senior Research Career
   Scientist Award
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants RO1 AR52425 (to N. G. C.) and RO1 DK50190 (to G. G. C.).
   This work was also supported by Veterans Affairs Merit Review grant and
   CTRC P30 Cancer Center Support Grant CA 054174 (to N. G. C.) and in part
   by Veterans Affairs Merit Review grants (to G. G. C.).Recipient of a
   fellowship from the Cancer Prevention Research Institute of
   Texas.Recipient of Veterans Affairs Senior Research Career Scientist
   Award.
CR Allendorph GP, 2006, P NATL ACAD SCI USA, V103, P7643, DOI 10.1073/pnas.0602558103
   Allington TM, 2011, CELLS TISSUES ORGANS, V193, P98, DOI 10.1159/000320163
   Antoku S, 2008, J CELL SCI, V121, P3071, DOI 10.1242/jcs.031575
   Arnold SJ, 2006, DEV BIOL, V296, P104, DOI 10.1016/j.ydbio.2006.04.442
   Atfi A, 2005, EMBO REP, V6, P985, DOI 10.1038/sj.embor.7400501
   Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140
   Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200
   CARPENTER CL, 1990, BIOCHEMISTRY US, V29, P11147, DOI 10.1021/bi00503a001
   Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295
   Chen S, 2009, AM J PHYSIOL HEART C, V297, pH533, DOI 10.1152/ajpheart.00237.2009
   Choudhury GG, 1998, J CLIN INVEST, V101, P2751, DOI 10.1172/JCI1044
   Colicelli J, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3139re6
   Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Ghosh Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351
   Ghosh Choudhury N, 2007, J BIOL CHEM, V282, P4983, DOI 10.1074/jbc.M606706200
   Ghosh Choudhury N, 2006, J BIOL CHEM, V281, P20160, DOI 10.1074/jbc.M511071200
   Ghosh Choudhury Nandini, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P345
   Ghosh Choudhury NG, 2003, J BIOL CHEM, V278, P21998, DOI 10.1074/jbc.M302277200
   GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331
   GhoshChoudhury N, 1997, BIOCHEM BIOPH RES CO, V231, P196, DOI 10.1006/bbrc.1996.5962
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280
   Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092 8674(03)00191 0
   HARRIS SE, 1994, J BONE MINER RES, V9, P855
   Jadrich JL, 2006, DEVELOPMENT, V133, P1529, DOI 10.1242/dev.02333
   Jain SK, 1996, BLOOD, V88, P1542
   Kaplan MS, 2003, J GERONTOL A BIOL, V58, P1018
   Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314
   Kirsch T, 2000, NAT STRUCT BIOL, V7, P492
   Kirsch T, 2000, FEBS LETT, V468, P215, DOI 10.1016/S0014 5793(00)01214 X
   Kua HY, 2012, NAT CELL BIOL, V14, P727, DOI 10.1038/ncb2528
   Lechleider RJ, 2001, DEV BIOL, V240, P157, DOI 10.1006/dbio.2001.0469
   Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542
   Mandal CC, 2011, BIOCHEM J, V433, P393, DOI 10.1042/BJ20100357
   Mandal CC, 2009, ENDOCRINOLOGY, V150, P4989, DOI 10.1210/en.2009 0026
   Mandal CC, 2011, J BIOL CHEM, V286, P11314, DOI 10.1074/jbc.M110.193714
   Mandal CC, 2010, CALCIFIED TISSUE INT, V87, P533, DOI 10.1007/s00223 010 9419 3
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marie PJ, 2002, HISTOL HISTOPATHOL, V17, P877, DOI 10.14670/HH 17.877
   Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067
   Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Nurmio M, 2011, TOXICOL APPL PHARM, V254, P267, DOI 10.1016/j.taap.2011.04.019
   Plattner R, 2004, MOL CELL BIOL, V24, P2573, DOI 10.1128/mcb.24.6.2573 2583.2004
   Qiu ZZ, 2010, P NATL ACAD SCI USA, V107, P1136, DOI 10.1073/pnas.0913131107
   Rastogi MV, 2012, PEDIATR BLOOD CANCER, V59, P840, DOI 10.1002/pbc.24121
   Ren SY, 2005, EXP HEMATOL, V33, P1222, DOI 10.1016/j.exphem.2005.06.030
   Sattler M, 1996, ONCOGENE, V12, P839
   SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092 8674(94)90240 2
   Schlatterer SD, 2011, J MOL NEUROSCI, V45, P445, DOI 10.1007/s12031 011 9588 1
   SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092 8674(91)90012 N
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457
   Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884 3896.2003
   TENDIJKE P, 1994, J BIOL CHEM, V269, P16985
   Teti Anna, 2011, Curr Osteoporos Rep, V9, P264, DOI 10.1007/s11914 011 0078 8
   Tokonzaba E, 2006, CHEM BIOL DRUG DES, V67, P230, DOI 10.1111/j.1747 0285.2006.00361.x
   Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092 8674(00)81701 8
   TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092 8674(91)90011 M
   VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092 8674(89)90102 5
   VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107
   Wang SN, 2010, AM J PHYSIOL RENAL, V298, pF142, DOI 10.1152/ajprenal.00320.2009
   Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460 2075.1996.tb00503.x
   WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0
   WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212
   Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011
   YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008
   Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092 8674(00)00211 7
   Yu PB, 2005, J BIOL CHEM, V280, P24443, DOI 10.1074/jbc.M502825200
   Zhao Jean J, 2006, Sci STKE, V2006, ppe52, DOI 10.1126/stke.3652006pe52
NR 78
TC 30
Z9 37
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 23
PY 2013
VL 288
IS 34
BP 24503
EP 24517
DI 10.1074/jbc.M113.455733
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 302NW
UT WOS:000330612300019
PM 23821550
OA Green Published
DA 2025 08 17
ER

PT J
AU Stewart, JP
   Shaughnessy, JD
AF Stewart, JP
   Shaughnessy, JD
TI Role of osteoblast suppression in multiple myeloma
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE osteoblast; osteoclast; multiple rnyeloma; DKKI; FRZB; Wnt
ID BREAST CANCER METASTASIS; ADULT STEM CELLS; UNDETERMINED SIGNIFICANCE;
   MONOCLONAL GAMMOPATHY; BONE FORMATION; WNT; EXPRESSION; GENE;
   DIFFERENTIATION; MECHANISMS
AB Multiple myeloma is the most common form of plasma cell dyscrasia and virtually all cases of myeloma exhibit osteolytic lesions, which result in bone pain, pathological fractures, spinal cord compression, and hypercalcaemia. Malignant plasma cells disrupt the delicate balance between bone formation and bone resorption, which ultimately leads to the debilitating osteolytic lesions. This review focuses principally on mechanisms of osteoblast inhibition by malignant plasma cells with emphasis placed on our experimental findings, which Support a model for abnormal Wnt signaling in osteoblast suppression. We describe how excessive amounts of soluble Wnt inhibitors secreted by malignant plasma cells in Multiple myeloma could promote osteolytic lesions, tumor growth, suppress hematopoiesis, prevent proper engraftment, and expansion of transplanted stemcells. Finally, we detail current therapies shown to disrupt the interaction between the myeloma cell and the microenvironment, leading to activation of osteoblasts.
C1 Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Donna D & Donald M Lambert Lab Myeloma Genet, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences
RP Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Donna D & Donald M Lambert Lab Myeloma Genet, Little Rock, AR 72205 USA.
EM shaughnessyjohn@uams.edu
OI Stewart, James/0000 0002 2297 3546
CR Abildgaard N, 2000, EUR J HAEMATOL, V64, P121, DOI 10.1034/j.1600 0609.2000.90074.x
   Asosingh K, 2002, CLIN EXP METASTAS, V19, P583, DOI 10.1023/A:1020987830132
   Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088
   BARLOGIE B, 1993, STEM CELLS, V11, P88, DOI 10.1002/stem.5530110203
   BATAILLE R, 1989, J CLIN ONCOL, V7, P1909, DOI 10.1200/JCO.1989.7.12.1909
   Bergsagel PL, 2005, J CLIN ONCOL, V23, P6333, DOI 10.1200/JCO.2005.05.021
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Calvani N, 2005, BRIT J HAEMATOL, V130, P926, DOI 10.1111/j.1365 2141.2005.05710.x
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Caricasole A, 2004, J NEUROSCI, V24, P6021, DOI 10.1523/JNEUROSCI.1381 04.2004
   Das SK, 2000, J BIOL CHEM, V275, P28834, DOI 10.1074/jbc.M003827200
   Davies FE, 2003, BLOOD, V102, P4504, DOI 10.1182/blood 2003 01 0016
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771
   Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101
   DJULBEGOVIC B, 2002, COCHRANE DB SYST REV, V3
   Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164
   Ehrlich LA, 2005, BLOOD, V106, P1407, DOI 10.1182/blood 2005 03 1080
   Ely SA, 2002, AM J PATHOL, V160, P1293, DOI 10.1016/S0002 9440(10)62556 4
   Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465
   Fox SW, 2005, MOL CELL ENDOCRINOL, V243, P19, DOI 10.1016/j.mce.2005.09.008
   FRANZODENDAAL TA, 2005, DEV DYN ADV ELECT PU
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gonzálex Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303
   Gregory CA, 2005, ANN NY ACAD SCI, V1049, P97, DOI 10.1196/annals.1334.010
   Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200
   Gregory CA, 2005, J BIOL CHEM, V280, P2309, DOI 10.1074/jbc.M406275200
   Gu GL, 2005, BIOCHEM BIOPH RES CO, V335, P1095, DOI 10.1016/j.bbrc.2005.06.211
   Guise TA, 2002, BONE, V30, P670, DOI 10.1016/S8756 3282(02)00685 3
   GUNN WG, 2005, STEM CELLS      1117
   GUO J, 2004, 26 ANN M AM SOC BON, P1018
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Karadag A, 2000, J BONE MINER RES, V15, P1935, DOI 10.1359/jbmr.2000.15.10.1935
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100
   Lacy MQ, 1997, AM J HEMATOL, V56, P288, DOI 10.1002/(SICI)1096 8652(199712)56:4<288::AID AJH16>3.0.CO;2 5
   Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood 2003 06 1992
   Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Maricic Michael, 2005, Curr Osteoporos Rep, V3, P25, DOI 10.1007/s11914 005 0024 8
   NERI A, 1993, BLOOD, V81, P128
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   OYAJOBI BO, 2004, 26 ANN M AM SOC BON, P1011
   Qiang YW, 2005, BLOOD, V106, P1786, DOI 10.1182/blood 2005 01 0049
   Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Shaughnessy John, 2002, Blood, V100, P781
   Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200
   Takai E, 2004, J BONE MINER RES, V19, P1403, DOI 10.1359/JBMR.040516
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Vaes BLT, 2005, BONE, V36, P803, DOI 10.1016/j.bone.2005.02.001
   Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503
   YACCOBY S, 2005, 26 ANN M AM SOC BON, P1125
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
   Zhan F., 2004, BLOOD, V104
   Zhan FH, 2003, BLOOD, V101, P1128, DOI 10.1182/blood 2002 06 1737
   Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 69
TC 24
Z9 25
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAY 1
PY 2006
VL 98
IS 1
BP 1
EP 13
DI 10.1002/jcb.20774
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 034KN
UT WOS:000236928000001
PM 16440324
DA 2025 08 17
ER

PT J
AU Senarath Yapa, K
   Li, SL
   Walmsley, GG
   Zielins, E
   Paik, K
   Britto, JA
   Grigoriadis, AE
   Wan, DC
   Liu, KJ
   Longaker, MT
   Quarto, N
AF Senarath Yapa, Kshemendra
   Li, Shuli
   Walmsley, Graham G.
   Zielins, Elizabeth
   Paik, Kevin
   Britto, Jonathan A.
   Grigoriadis, Agamemnon E.
   Wan, Derrick C.
   Liu, Karen J.
   Longaker, Michael T.
   Quarto, Natalina
TI Small Molecule Inhibition of Transforming Growth Factor Beta Signaling
   Enables the Endogenous Regenerative Potential of the Mammalian Calvarium
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID TGF BETA; STEM CELLS; BONE FORMATION; TRANSCRIPTIONAL CONTROL; KINASE
   INHIBITOR; STROMAL CELLS; IN VITRO; OSTEOGENESIS; OSTEOBLASTS;
   EXPRESSION
AB Current approaches for the treatment of skeletal defects are suboptimal, principally because the ability of bone to repair and regenerate is poor. Although the promise of effective cellular therapies for skeletal repair is encouraging, these approaches are limited by the risks of infection, cellular contamination, and tumorigenicity. Development of a pharmacological approach would therefore help avoid some of these potential risks. This study identifies transforming growth factor beta (TGF beta) signaling as a potential pathway for pharmacological modulation in vivo. We demonstrate that inhibition of TGF beta signaling by the small molecule SB431542 potentiates calvarial skeletal repair through activation of bone morphogenetic protein (BMP) signaling on osteoblasts and dura mater cells participating in healing of calvarial defects. Cells respond to inhibition of TGF beta signaling by producing higher levels of BMP2 that upregulates inhibitory Smad6 expression, thus providing a negative feedback loop to contain excessive BMP signaling. Importantly, study on human osteoblasts indicates that molecular mechanism(s) triggered by SB431542 are conserved. Collectively, these data provide insights into the use of small molecules to modulate key signaling pathways for repairing skeletal defects.
C1 [Senarath Yapa, Kshemendra; Li, Shuli; Walmsley, Graham G.; Zielins, Elizabeth; Paik, Kevin; Wan, Derrick C.; Longaker, Michael T.; Quarto, Natalina] Stanford Univ, Sch Med, Dept Surg, Hagey Lab Pediat Regenerat Med, 257 Campus Dr,MC 5148, Stanford, CA 94305 USA.
   [Senarath Yapa, Kshemendra; Grigoriadis, Agamemnon E.; Liu, Karen J.] Kings Coll London, Inst Dent, Dept Craniofacial Dev & Stem Cell Biol, London, England.
   [Senarath Yapa, Kshemendra] Dept Plast & Reconstruct Surg, Manchester, Lancs, England.
   [Walmsley, Graham G.; Longaker, Michael T.] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA USA.
   [Britto, Jonathan A.] Great Ormond St Hosp Sick Children, Dept Craniofacial Surg, London, England.
   [Quarto, Natalina] Univ Naples Federico II, Dipartimento Sci Biomed Avanzate, Naples, Italy.
C3 Stanford University; University of London; King's College London;
   Stanford University; University of London; University College London;
   Great Ormond Street Hospital for Children NHS Foundation Trust;
   University of Naples Federico II
RP Longaker, MT; Quarto, N (通讯作者)，Stanford Univ, Sch Med, Dept Surg, Hagey Lab Pediat Regenerat Med, 257 Campus Dr,MC 5148, Stanford, CA 94305 USA.
EM longaker@stanford.edu; quarto@unina.it
RI ; Liu, Karen/F 2870 2010
OI Wan, Derrick/0000 0003 4666 1683; Liu, Karen/0000 0002 2483 2165
FU Oak Foundation; Gunn/Olivier fund; Hagey Laboratory for Pediatric
   Regenerative Medicine; National Institutes of Health NIH [R01
   DE021683 01, R01 DE19434, U01HL099776]; "Transplant and Tissue
   Engineering Program Endowment Awards" Lucille Packard Children Hospital
   Translational Medicine/Transplant" Stanford University; Child Health
   Research Institute Fellowship, Stanford University; Medical Research
   Council [MR/L017237/1]; MRC [MR/L017237/1] Funding Source: UKRI; Medical
   Research Council [MR/L017237/1] Funding Source: researchfish
FX This work was supported by the Oak Foundation, the Gunn/Olivier fund,
   the Hagey Laboratory for Pediatric Regenerative Medicine, and the
   National Institutes of Health NIH grants R01 DE021683 01, R01 DE19434,
   U01HL099776 to M.T.L.; "Transplant and Tissue Engineering Program
   Endowment Awards" Lucille Packard Children Hospital Translational
   Medicine/Transplant" Stanford University, Child Health Research
   Institute Fellowship, Stanford University to K.S. Y.; Medical Research
   Council Grant MR/L017237/1 to K.S. Y. and K.J.L.
CR Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Baroli B, 2009, J PHARM SCI US, V98, P1317, DOI 10.1002/jps.21528
   Behr B, 2012, TISSUE ENG PT A, V18, P1079, DOI [10.1089/ten.tea.2011.0537, 10.1089/ten.TEA.2011.0537]
   Behr B, 2010, BONE, V47, P281, DOI 10.1016/j.bone.2010.05.008
   Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018 9027.2000
   BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312
   Bruens ML, 2003, J CRANIOFAC SURG, V14, P63, DOI 10.1097/00001665 200301000 00011
   Cabello Verrugio C, 2011, CELL SIGNAL, V23, P449, DOI 10.1016/j.cellsig.2010.10.019
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   Dallas SL, 2005, J BIOL CHEM, V280, P18871, DOI 10.1074/jbc.M410762200
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195
   Gosain AK, 2003, PLAST RECONSTR SURG, V112, P515, DOI 10.1097/01.PRS.0000070728.56716.51
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Hong CC, 2009, CYTOKINE GROWTH F R, V20, P409, DOI 10.1016/j.cytogfr.2009.10.021
   IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092 8674(87)90146 2
   Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65
   Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075
   Jiang XB, 2002, DEV BIOL, V241, P106, DOI 10.1006/dbio.2001.0487
   Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Levi B, 2011, STEM CELLS, V29, P2018, DOI 10.1002/stem.757
   Li SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058610
   Li SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014033
   Lind M, 1998, ACTA ORTHOP SCAND, V69, P2
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40
   Nakamura R, 2015, BIOCHEM BIOPH RES CO, V458, P777, DOI 10.1016/j.bbrc.2015.02.013
   NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo 124 6 2991
   Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105
   Quarto N, 2008, BONE, V42, P1040, DOI 10.1016/j.bone.2008.01.026
   Quarto N, 2015, STEM CELLS, V33, P833, DOI 10.1002/stem.1907
   Quarto N, 2012, STEM CELLS, V30, P2709, DOI 10.1002/stem.1250
   Quarto N, 2010, J BONE MINER RES, V25, P1680, DOI 10.1359/jbmr.091116
   Quarto N, 2009, CELLS TISSUES ORGANS, V190, P158, DOI 10.1159/000202789
   Rah DK, 2000, YONSEI MED J, V41, P756, DOI 10.3349/ymj.2000.41.6.756
   Ripamonti U, 2009, J CRANIOFAC SURG, V20, P1544, DOI 10.1097/SCS.0b013e3181b09ca6
   ROBEY PG, 1987, J CELL BIOL, V105, P457, DOI 10.1083/jcb.105.1.457
   RUSSELL HK, 1972, ARCH PATHOL, V94, P187
   Schindeler A, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 105
   Senarath Yapa K, 2013, INT J MOL SCI, V14, P5978, DOI 10.3390/ijms14035978
   SHENAQ S M, 1988, Microsurgery, V9, P154, DOI 10.1002/micr.1920090218
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Srouji S., 2004, Cell and Tissue Banking, V5, P223, DOI 10.1007/s10561 004 0503 7
   St John Thomas A, 2003, Am J Orthop (Belle Mead NJ), V32, P18
   Steiner Claudia, 2002, Eff Clin Pract, V5, P143
   Sugiyama K, 2008, CANCER SCI, V99, P1021, DOI 10.1111/j.1349 7006.2008.00761.x
   Tachi K, 2011, TISSUE ENG PT A, V17, P597, DOI [10.1089/ten.tea.2010.0094, 10.1089/ten.TEA.2010.0094]
   Takeuchi K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009870
   Tanaka H, 2010, ONCOL REP, V24, P1637, DOI 10.3892/or_00001028
   Waghabi MC, 2009, ANTIMICROB AGENTS CH, V53, P4694, DOI 10.1128/AAC.00580 09
   Wallace EM, 2005, CURR TOP MED CHEM, V5, P215, DOI 10.2174/1568026053507723
   Wang J, 1999, CALCIFIED TISSUE INT, V65, P486, DOI 10.1007/s002239900737
   Wang Q, 2007, J BIOL CHEM, V282, P10742, DOI 10.1074/jbc.M610997200
   Zhang H, 2003, BIOMATERIALS, V24, P2013, DOI 10.1016/S0142 9612(02)00616 6
NR 56
TC 21
Z9 23
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD MAY
PY 2016
VL 22
IS 9 10
BP 707
EP 720
DI 10.1089/ten.tea.2015.0527
PG 14
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA DN9DX
UT WOS:000377380600001
PM 27036931
OA Green Published
DA 2025 08 17
ER

PT J
AU Lau, CPY
   Huang, L
   Wong, KC
   Kumta, SM
AF Lau, Carol P. Y.
   Huang, Lin
   Wong, Kwok Chuen
   Kumta, Shekhar Madhukar
TI Comparison of the anti tumor effects of denosumab and zoledronic acid on
   the neoplastic stromal cells of giant cell tumor of bone
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE Bisphosphonates; cell viability; cell apoptosis; OPG; RANKL; M CSF
ID SKELETAL RELATED EVENTS; BREAST CANCER CELLS; OSTEOBLAST
   DIFFERENTIATION; IN VITRO; STEM CELLS; BISPHOSPHONATES; METASTASIS;
   EXPRESSION; APOPTOSIS; PAMIDRONATE
AB Denosumab and Zoledronic acid (ZOL) are two antiresorptive drugs currently in use for treating osteoporosis. They have different mechanisms of action but both have been shown to delay the onset of skeletal related events in patients with giant cell tumor of bone (GCT). However, the anti tumor mechanisms of denosumab on the neoplastic GCT stromal cells remain unknown. In this study, we focused on the direct effects of denosumab on the neoplastic GCT stromal cells and compared with ZOL. The microscopic view demonstrated a reduced cell growth in ZOL treated but not in denosumab treated GCT stromal cells. ZOL was found to exhibit a dose dependent inhibition in cell growth in all GCT stromal cell lines tested and cause apoptosis in two out of three cell lines. In contrast, denosumab only exerted a minimal inhibitory effect in one cell line and did not induce any apoptosis. ZOL significantly inhibited the mRNA expression of receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in two GCT stromal cell lines whereas their protein levels remained unchanged. On the contrary, denosumab did not regulate RANKL and OPG expression at both mRNA and protein levels. Moreover, the protein expression of Macrophage Colony Stimulating Factor (M CSF), Alkaline Phosphatase (ALP), and Collagen alpha 1 Type I were not regulated by denosumab and ZOL either. Our findings provide new insights in the anti tumor effect of denosumab on GCT stromal cells and raise a concern that tumor recurrence may occur after the withdrawal of the drug.
C1 [Lau, Carol P. Y.; Wong, Kwok Chuen; Kumta, Shekhar Madhukar] Chinese Univ Hong Kong, Dept Orthoped & Traumatol, Shatin, Hong Kong, Peoples R China.
   [Huang, Lin] Chinese Univ Hong Kong, Dept Surg, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong
RP Kumta, SM (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Dept Orthoped & Traumatol, Room 74034 5 F,Clin Sci Bldg, Shatin, Hong Kong, Peoples R China.
EM kumta@cuhk.edu.hk
RI Lau, Carol/G 2577 2017; Kumta, Shekhar/K 1080 2013
OI Lau, Carol/0000 0002 9240 092X; Kumta, Shekhar/0000 0001 5507 9674
FU Research Grants Council of the Hong Kong SAR [466811]; CUHK [2012.1.033]
FX This study was supported by the Research Grants Council of the Hong Kong
   SAR (to Prof. Kumta SM; GRF project no. 466811) and CUHK Direct Grant
   (reference no. 2012.1.033).
CR Balke M, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 462
   Basso FG, 2013, GERONTOLOGY, V6, P1
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Cheng YY, 2004, CALCIFIED TISSUE INT, V75, P71, DOI 10.1007/s00223 004 0120 2
   Cheng YY, 2003, ULTRASTRUCT PATHOL, V27, P385, DOI 10.1080/01913120390248629
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Henk H, 2012, CURR MED RES OPIN, V28, P1119, DOI 10.1185/03007995.2012.689254
   Hiraga T, 2001, CANCER RES, V61, P4418
   Huang L, 2004, BONE, V34, P393, DOI 10.1016/j.bone.2003.10.013
   Insalaco L, 2012, J CELL MOL MED, V16, P2186, DOI 10.1111/j.1582 4934.2012.01527.x
   Iranikhah M, 2012, PHARMACOTHERAPY, V32, P274, DOI 10.1002/j.1875 9114.2011.01092.x
   Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P591, DOI 10.1007/s11999 010 1501 7
   Koto K, 2009, CANCER LETT, V274, P271, DOI 10.1016/j.canlet.2008.09.026
   Lacey DC, 2009, OSTEOARTHR CARTILAGE, V17, P735, DOI 10.1016/j.joca.2008.11.011
   Lan J, 2012, J SURG ONCOL, V106, P826, DOI 10.1002/jso.23151
   Lau CPY, 2011, J ORTHOP RES, V29, P403, DOI 10.1002/jor.21249
   Mani J, 2012, PROSTATE CANCER P D, V15, P250, DOI 10.1038/pcan.2012.9
   Mathews S, 2012, DIFFERENTIATION, V84, P185, DOI 10.1016/j.diff.2012.05.001
   Maurice B, 2010, LANCET ONCOL, V11, P218
   Misso G, 2012, CANCER BIOL THER, V13, P1491, DOI 10.4161/cbt.22274
   Patntirapong S, 2012, J ORAL PATHOL MED, V41, P713, DOI 10.1111/j.1600 0714.2012.01154.x
   ROBINSON D, 1994, J CELL BIOCHEM, V55, P300, DOI 10.1002/jcb.240550305
   Roland B, 2011, BONE, V48, P677
   Roux S, 2002, AM J CLIN PATHOL, V117, P210
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Salerno M, 2008, CLIN ORTHOP RELAT R, V466, P2081, DOI 10.1007/s11999 008 0327 z
   Scheper MA, 2009, SUPPORT CARE CANCER, V17, P1553, DOI 10.1007/s00520 009 0710 7
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   Sonnemann J, 2001, ANTI CANCER DRUG, V12, P459, DOI 10.1097/00001813 200106000 00007
   Steensma MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069101
   SUNG HW, 1982, J BONE JOINT SURG AM, V64, P755, DOI 10.2106/00004623 198264050 00015
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Tse LF, 2008, BONE, V42, P68, DOI 10.1016/j.bone.2007.08.038
   Werner M, 2006, INT ORTHOP, V30, P484, DOI 10.1007/s00264 006 0215 7
   Wülling M, 2003, HUM PATHOL, V34, P983, DOI 10.1053/S0046 8177(03)00413 1
   Yip MH, 1996, CLIN ORTHOP RELAT R, P60, DOI 10.1097/00003086 199602000 00008
   Yu DB, 2008, MED HYPOTHESES, V71, P256
   Zheng MH, 2001, HISTOL HISTOPATHOL, V16, P297, DOI 10.14670/HH 16.297
NR 40
TC 70
Z9 76
U1 0
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PY 2013
VL 54
IS 6
BP 439
EP 449
DI 10.3109/03008207.2013.848202
PG 11
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA 249BT
UT WOS:000326752400014
PM 24060052
DA 2025 08 17
ER

PT J
AU Ono, S
   Tsuji, N
   Sakamoto, T
   Oguchi, S
   Nakamura, T
   Hoshi, K
   Hikita, A
AF Ono, Sayaka
   Tsuji, Naoki
   Sakamoto, Tomoaki
   Oguchi, Shuya
   Nakamura, Takashi
   Hoshi, Kazuto
   Hikita, Atsuhiko
TI Inhibition of cysteine protease disturbs the topological relationship
   between bone resorption and formation in vitro
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Bone remodeling; Coupling; Two photon microscopy; Cathepsin K;
   Osteoclast; Osteoblast
ID CATHEPSIN K; OSTEOCLAST FORMATION; ODANACATIB; OSTEOPOROSIS;
   ALENDRONATE; MASS; TURNOVER; PATHWAY
AB IntroductionOsteoporosis is a global health issue. Bisphosphonates that are commonly used to treat osteoporosis suppress both bone resorption and subsequent bone formation. Inhibition of cathepsin K, a cysteine proteinase secreted by osteoclasts, was reported to suppress bone resorption while preserving or increasing bone formation. Analyses of the different effects of antiresorptive reagents such as bisphosphonates and cysteine proteinase inhibitors will contribute to the understanding of the mechanisms underlying bone remodeling.Materials and MethodsOur team has developed an in vitro system in which bone remodeling can be temporally observed at the cellular level by 2 photon microscopy. We used this system in the present study to examine the effects of the cysteine proteinase inhibitor E 64 and those of zoledronic acid on bone remodeling.ResultsIn the control group, the amount of the reduction and the increase in the matrix were correlated in each region of interest, indicating the topological and quantitative coordination of bone resorption and formation. Parameters for osteoblasts, osteoclasts, and matrix resorption/formation were also correlated. E 64 disrupted the correlation between resorption and formation by potentially inhibiting the emergence of spherical osteoblasts, which are speculated to be reversal cells in the resorption sites.ConclusionThese new findings help clarify coupling mechanisms and will contribute to the development of new drugs for osteoporosis.
C1 [Ono, Sayaka; Hoshi, Kazuto] Univ Tokyo, Grad Sch Med, Dept Sensory & Motor Syst Med, Tokyo 1138655, Japan.
   [Tsuji, Naoki; Sakamoto, Tomoaki; Hoshi, Kazuto; Hikita, Atsuhiko] Univ Tokyo Hosp, Dept Tissue Engn, Tokyo 1138655, Japan.
   [Oguchi, Shuya; Hoshi, Kazuto] Univ Tokyo Hosp, Dept Oral Maxillofacial Surg & Orthodont, Tokyo 1138655, Japan.
   [Nakamura, Takashi] Tokyo Dent Coll, Dept Biochem, Tokyo 1010061, Japan.
C3 University of Tokyo; University of Tokyo; University of Tokyo; Tokyo
   Dental College
RP Hikita, A (通讯作者)，Univ Tokyo Hosp, Dept Tissue Engn, Tokyo 1138655, Japan.
EM ahikita tky@g.ecc.u tokyo.ac.jp
OI Tsuji, Naoki/0000 0003 1106 8564
FU The Japan Society for the Promotion of Science (JSPS) KAKENH [18K09718,
   21K10085, 22K10260]; Japan Society for the Promotion of Science (JSPS)
   KAKENHI; Naito Foundation; Grants in Aid for Scientific Research
   [21K10085, 22K10260] Funding Source: KAKEN
FX We thank Shigeaki Kato (Fukushima Medical University, Iryo Sosei
   University, Fukushima, Japan) for providing Ctsk Cre mice. This study
   was supported by grants from the Japan Society for the Promotion of
   Science (JSPS) KAKENHI (#18K09718, #21K10085, and #22K10260) and a
   research grant from the Naito Foundation.
CR Abed Hassan H., 2018, General Dentistry, V66, P18
   Arnett TR, 2018, BONE, V115, P25, DOI 10.1016/j.bone.2017.12.021
   Binkley N, 2021, OSTEOPOROSIS INT, V32, P173, DOI 10.1007/s00198 020 05701 9
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Brixen K, 2013, J CLIN ENDOCR METAB, V98, P571, DOI 10.1210/jc.2012 2972
   Chevalier C, 2021, STAR PROTOC, V2, DOI 10.1016/j.xpro.2021.100452
   Cusick T, 2012, J BONE MINER RES, V27, P524, DOI 10.1002/jbmr.1477
   Da WCL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.675385
   Delaisse Jean Marie, 2014, Bonekey Rep, V3, P561, DOI 10.1038/bonekey.2014.56
   Duong LT, 2022, OSTEOPOROSIS INT, V33, P2165, DOI 10.1007/s00198 022 06406 x
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Hikita A, 2015, BONE, V76, P5, DOI 10.1016/j.bone.2015.02.030
   HILL PA, 1994, J CELL BIOCHEM, V56, P118, DOI 10.1002/jcb.240560116
   Holliday LS, 1997, J BIOL CHEM, V272, P22053, DOI 10.1074/jbc.272.35.22053
   Holroyd C, 2008, BEST PRACT RES CL EN, V22, P671, DOI 10.1016/j.beem.2008.06.001
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Imai Y, 2009, ANN NY ACAD SCI, V1173, pE31, DOI 10.1111/j.1749 6632.2009.04954.x
   Inui T, 1999, BIOCHEM BIOPH RES CO, V258, P173, DOI 10.1006/bbrc.1999.0473
   Jensen PR, 2021, BONE, V145, DOI 10.1016/j.bone.2021.115850
   Jensen PR, 2014, CALCIFIED TISSUE INT, V94, P212, DOI 10.1007/s00223 013 9800 0
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lacombe J, 2013, CELL CYCLE, V12, P2744, DOI 10.4161/cc.25825
   Liu HX, 2019, CONNECT TISSUE RES, V60, P240, DOI 10.1080/03008207.2018.1487413
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Masarachia PJ, 2012, J BONE MINER RES, V27, P509, DOI 10.1002/jbmr.1475
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsuoka K, 2014, J BONE MINER RES, V29, P1522, DOI 10.1002/jbmr.2187
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Mukherjee K, 2016, BIOCHEM PHARMACOL, V117, P10, DOI 10.1016/j.bcp.2016.04.010
   Murray EJB, 1997, METABOLISM, V46, P1090, DOI 10.1016/S0026 0495(97)90284 5
   Narazaki A, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 07521 9
   Nishikawa K, 2021, EMBO REP, V22, DOI 10.15252/embr.202153035
   Oguchi S, 2023, J BONE MINER METAB, V41, P3, DOI 10.1007/s00774 022 01381 z
   Palmer L, 2015, INT J LAB HEMATOL, V37, P287, DOI 10.1111/ijlh.12327
   PIPER K, 1992, ANAT EMBRYOL, V186, P291
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Recker R, 2020, J BONE MINER RES, V35, P1289, DOI 10.1002/jbmr.3994
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Ren ZY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132513
   Silvestrini G, 2005, J MOL HISTOL, V36, P59, DOI 10.1007/s10735 004 3839 1
   Stralberg F, 2017, J LEUKOCYTE BIOL, V101, P1233, DOI 10.1189/jlb.3A1016 433R
   Strålberg F, 2013, FASEB J, V27, P2687, DOI 10.1096/fj.12 211748
   Sudhoff H, 2003, ANN OTO RHINOL LARYN, V112, P780, DOI 10.1177/000348940311200907
   Takeshita S, 2013, J CLIN INVEST, V123, P3914, DOI 10.1172/JCI69493
   Tsuji N, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10689
   Unnanuntana A, 2011, CLIN ORTHOP RELAT R, V469, P2194, DOI 10.1007/s11999 010 1694 9
   Xiang A, 2007, BONE, V40, P1231, DOI 10.1016/j.bone.2007.01.010
   Yamada H, 2019, INT J RHEUMATOL, V2019, DOI 10.1155/2019/5710340
   Zhuo Y, 2014, BONE, V67, P269, DOI 10.1016/j.bone.2014.07.013
NR 50
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAR
PY 2024
VL 42
IS 2
BP 166
EP 184
DI 10.1007/s00774 023 01489 w
EA FEB 2024
PG 19
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA MR8J8
UT WOS:001168936300001
PM 38376670
OA hybrid
DA 2025 08 17
ER

PT J
AU Sun, TH
   Li, ZY
   Zhong, X
   Cai, Z
   Ning, ZY
   Hou, TH
   Xiong, LF
   Feng, Y
   Leung, F
   Lu, WW
   Peng, SL
AF Sun, Tianhao
   Li, Zhaoyang
   Zhong, Xing
   Cai, Zhe
   Ning, Ziyu
   Hou, Tianheng
   Xiong, Lifeng
   Feng, Yu
   Leung, Frankie
   Lu, William W.
   Peng, Songlin
TI Strontium inhibits osteoclastogenesis by enhancing LRP6 and
    catenin mediated OPG targeted by miR 181d 5p
SO JOURNAL OF CELL COMMUNICATION AND SIGNALING
LA English
DT Article
DE Strontium; Osteoclast; MiR 181; Osteoprotegerin; beta catenin
ID WNT/BETA CATENIN; BONE RESORPTION; BETA CATENIN; OSTEOBLAST
   DIFFERENTIATION; NUCLEAR FACTOR; KAPPA B; PROMOTES; RANELATE;
   INVOLVEMENT; CELLS
AB Strontium is a drug with the bone formation and anti resorption effects on bone. The underlying mechanisms for the dual effect of strontium on bone metabolism, especially for the anti resorption effects remain unknown. Thus, we aim to investigate the mechanisms of effects of strontium on osteoclastogenesis. Firstly, we found that strontium decreased the levels of important biomarkers of receptor activator of nuclear factor kappa B ligand (RANKL) which induced osteoclast differentiation, indicating that strontium might directly inhibit osteoclast differentiation. Next, we revealed that strontium enhanced Low Density Lipoprotein Receptor Related Protein 6 (LRP6)/ catenin/osteoprotegerin (OPG) signaling pathway in MC3T3 E1 cells. The signaling pathway may negatively regulate osteoclastogenesis. Thus, strontium indirectly inhibited RANKL induced osteoclast differentiation. Finally, we revealed that OPG was targeted by miR 181d 5p as determined by luciferase reporter assay and downregulated by miR 181d 5p at both mRNA and protein levels as determined by western blot.
C1 [Sun, Tianhao; Peng, Songlin] Jinan Univ, Coll Med 2, Shenzhen Peoples Hosp, Dept Spine Surg, Shenzhen 518000, Peoples R China.
   [Sun, Tianhao; Zhong, Xing; Cai, Zhe; Ning, Ziyu; Hou, Tianheng; Xiong, Lifeng; Leung, Frankie; Lu, William W.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Orthopaed & Traumatol, Hong Kong, Peoples R China.
   [Li, Zhaoyang] Tianjin Univ, Sch Mat Sci & Engn, Tianjin 300072, Peoples R China.
   [Feng, Yu] Ningxia Med Univ, Gen Hosp, Dept Traumatol, Yinchuan, Ningxia Hui Aut, Peoples R China.
C3 Jinan University; University of Hong Kong; Tianjin University; Ningxia
   Medical University
RP Peng, SL (通讯作者)，Jinan Univ, Coll Med 2, Shenzhen Peoples Hosp, Dept Spine Surg, Shenzhen 518000, Peoples R China.; Leung, F; Lu, WW (通讯作者)，Univ Hong Kong, Li Ka Shing Fac Med, Dept Orthopaed & Traumatol, Hong Kong, Peoples R China.; Feng, Y (通讯作者)，Ningxia Med Univ, Gen Hosp, Dept Traumatol, Yinchuan, Ningxia Hui Aut, Peoples R China.
EM fengyu_7072@163.com; klleunga@hku.hk; wwlu@hku.hk; songlin824@gmail.com
RI ; peng, sl/ISA 1370 2023; Xiong, Lifeng/KVZ 0882 2024; Li,
   Zhaoyang/JPA 0792 2023; Yu, Feng/U 9998 2019; CAI, Zhe/AAC 1132 2020
OI Peng, Songlin/0000 0002 4042 7071; XIONG, LIFENG/0000 0001 5216 9236;
   Hou, Tianheng/0000 0003 1946 1635; 
FU National Natural Science Foundation of China [NSFC81371989,
   NSFC81270967]; Guangdong Science and Technology Department Project
   [2015A030313776, 2016A050503008]; Shenzhen Municipal Science and
   Technology Innovation Committee Project [CXZZ20151015151249563,
   CXZZ20150401152251209, JCYJ20140416122812013, JCYJ20150403101146318];
   General Research Fund of Research Grant Council of Hong Kong [RGC
   715213, RGC 17205714]; Strategic Research Theme of Biomedical
   Engineering and Nanotechnology, Shenzhen Science and Technology Funding
   [JCYJ20160429185449249]; Guangdong Scientific Plan [2014A030313743]; HK
   RGC [T13 402/17 N]
FX This work was supported by grants from the National Natural Science
   Foundation of China (NSFC81371989 and NSFC81270967), Guangdong Science
   and Technology Department Project (2015A030313776, 2016A050503008),
   Shenzhen Municipal Science and Technology Innovation Committee Project
   (CXZZ20151015151249563, CXZZ20150401152251209, JCYJ20140416122812013 and
   JCYJ20150403101146318), General Research Fund of Research Grant Council
   of Hong Kong (RGC 715213 and RGC 17205714), Strategic Research Theme of
   Biomedical Engineering and Nanotechnology, Shenzhen Science and
   Technology Funding (JCYJ20160429185449249), Guangdong Scientific Plan
   (2014A030313743), and HK RGC (Ref No. T13 402/17 N).
CR Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Buehler J, 2001, BONE, V29, P176, DOI 10.1016/S8756 3282(01)00484 7
   Burgers TA, 2013, BONE, V54, P244, DOI 10.1016/j.bone.2013.02.022
   Cai T, 2016, EXP CELL RES, V345, P206, DOI 10.1016/j.yexcr.2016.06.007
   Capaccione KM, 2013, CARCINOGENESIS, V34, P1420, DOI 10.1093/carcin/bgt127
   Caudrillier A, 2010, MOL PHARMACOL, V78, P569, DOI 10.1124/mol.109.063347
   Chen C, 2015, ACTA PHARMACOL SIN, V36, P1053, DOI 10.1038/aps.2015.65
   Chen JQ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004145
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834
   Cheng CP, 2013, RHEUMATOLOGY, V52, P609, DOI 10.1093/rheumatology/kes343
   Deregowski V, 2006, J BIOL CHEM, V281, P6203, DOI 10.1074/jbc.M508370200
   Dige MS, 2013, INDIAN J ANIM RES, V47, P335
   Fromigué O, 2010, J BIOL CHEM, V285, P25251, DOI 10.1074/jbc.M110.110502
   Hurtel Lemaire AS, 2009, J BIOL CHEM, V284, P575, DOI 10.1074/jbc.M801668200
   Jin HT, 2015, BONE, V71, P63, DOI 10.1016/j.bone.2014.07.039
   Jovanovic M, 2006, ONCOGENE, V25, P6176, DOI 10.1038/sj.onc.1209912
   Lee YS, 2005, J BIOL CHEM, V280, P16635, DOI 10.1074/jbc.M412247200
   Li SF, 2014, BONE, V61, P164, DOI 10.1016/j.bone.2014.01.010
   Lumetti S, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 016 5678 5
   Ma J, 2013, MOL BIOL REP, V40, P2097, DOI 10.1007/s11033 012 2268 6
   Matsuzaki E, 2013, BONE, V55, P315, DOI 10.1016/j.bone.2013.04.008
   Mi BG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02491 9
   Muguruma Y, 2017, J CELL PHYSIOL, V232, P2569, DOI 10.1002/jcp.25647
   Peng SL, 2011, BONE, V49, P1290, DOI 10.1016/j.bone.2011.08.031
   Peng SL, 2011, J BONE MINER RES, V26, P1272, DOI 10.1002/jbmr.325
   Riddle RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063323
   Roy M, 2013, BIOMATER SCI UK, V1, P74, DOI [10.1039/C2BM00012A, 10.1039/c2bm00012a]
   Roy M, 2012, J BIOMED MATER RES A, V100A, P2450, DOI 10.1002/jbm.a.34181
   Su R, 2015, ONCOGENE, V34, P3226, DOI 10.1038/onc.2014.274
   Sun TH, 2018, MOL CARCINOGEN, V57, P262, DOI 10.1002/mc.22753
   Sun TH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171281
   Sun TH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020236
   Takahashi N, 2003, J BONE MINER RES, V18, P1082, DOI 10.1359/jbmr.2003.18.6.1082
   Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091
   Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468
   Wang BL, 2015, SCI REP UK, V5, DOI 10.1038/srep13667
   Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531
   Wornham DP, 2014, OSTEOPOROSIS INT, V25, P2477, DOI 10.1007/s00198 014 2791 5
   Yamaguchi M, 2012, MOL CELL BIOCHEM, V359, P399, DOI 10.1007/s11010 011 1034 8
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Yao QQ, 2017, BONE, V97, P175, DOI 10.1016/j.bone.2017.01.028
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhao BH, 2012, J EXP MED, V209, P319, DOI 10.1084/jem.20111566
   Zhong ZDA, 2015, DEV DYNAM, V244, P1347, DOI 10.1002/dvdy.24316
NR 46
TC 20
Z9 21
U1 1
U2 28
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1873 9601
EI 1873 961X
J9 J CELL COMMUN SIGNAL
JI J. Cell Commun. Signal
PD MAR
PY 2019
VL 13
IS 1
BP 85
EP 97
DI 10.1007/s12079 018 0478 y
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HT9IT
UT WOS:000464883300008
PM 30009331
OA Green Published
DA 2025 08 17
ER

PT J
AU Ventura, C
   Nunez, SV
   Goncalves, A
   Abreu, C
   Costa, L
AF Ventura, Carla
   Nunez, Soledad Vanesa
   Goncalves, Adriana
   Abreu, Catarina
   Costa, Luis
TI Bone Health in Metastatic Cancer
SO SEMINARS IN ONCOLOGY NURSING
LA English
DT Article
DE Bone metastases; Bone targeted agents; Bisphosphonates; Denosumab;
   Adverse effects
ID BREAST CANCER; ZOLEDRONIC ACID; DOUBLE BLIND; DENOSUMAB; UPDATE; AGENTS;
   PAIN
AB Objective: This article reviews the epidemiology and treatment of bone metastases. Also, it revisits the mechanism of action, indications, benefits, and complications of antiresorptive agents; discusses the adverse event profile of these agents; and addresses the prevention and management of these side effects. Data Sources: For this review, peer reviewed articles, research publications, and relevant clinical guidelines identified from PubMed were used. Conclusion: Bone metastases are common in advanced cancer and much more frequently than in primary bone cancer, especially in adults. Bisphosphonates and Denosumab are potent antiresorptives and signifi cantly reduce the risk of skeletal related events. These complications are related to poor quality of life, bone pain, functional disability, and decreased survival. Prolonged therapy with these antiresorptive agents in patients with advanced malignancy is generally well tolerated, but some side effects are potentially serious and require periodic monitoring. Furthermore, some of them can be avoided. Implications for Nursing Practice: The role of health care providers and specially nurses on identifying patients at risk of complications from these antiresorptive agents, and providing information on how to prevent them, is essential for health and quality of life maintenance in these patients.(c) 2022 Published by Elsevier Inc.
C1 [Ventura, Carla; Nunez, Soledad Vanesa; Goncalves, Adriana; Abreu, Catarina; Costa, Luis] Ctr Hospitalar Univ Lisboa Norte, Hosp Santa Maria, Oncol Div, Lisbon, Portugal.
   [Abreu, Catarina; Costa, Luis] Univ Lisbon, Fac Med, Lisbon, Portugal.
   [Costa, Luis] Univ Lisbon, Fac Med, Inst Med Mol Joao Lobo Antunes, Lisbon, Portugal.
   [Costa, Luis] Ctr Hospitalar Univ Lisboa Norte, Hosp Santa Maria, Oncol Div, Lisbon, Portugal.
C3 Universidade de Lisboa; Hospital Santa Maria; Universidade de Lisboa;
   Universidade de Lisboa; Universidade de Lisboa; Hospital Santa Maria
RP Costa, L (通讯作者)，Ctr Hospitalar Univ Lisboa Norte, Hosp Santa Maria, Oncol Div, Lisbon, Portugal.
EM luis.costa@chln.min saude.pt
RI ; Ventura, Carla/KFQ 7260 2024
OI Marques, Catarina/0000 0003 3558 3966; 
CR Abreu C, 2019, ENCYCLOPED ENDOCR DI, V4, P296, DOI [10.1016/B978 0 12 801238 3.66136 6, DOI 10.1016/B978 0 12 801238 3.66136 6]
   Arboleya L, 2011, REUMATOL CLIN, V7, P189, DOI [10.1007/s00223 010 9364 1, 10.1016/S2173 5743(11)70039 9, 10.1016/j.reuma.2010.10.005]
   Barrett Lee P, 2014, LANCET ONCOL, V15, P114, DOI 10.1016/S1470 2045(13)70539 4
   Cleeland CS, 2006, CLIN CANCER RES, V12, p6236S, DOI 10.1158/1078 0432.CCR 06 0988
   Coleman R, 2020, ANN ONCOL, V31, P1650, DOI 10.1016/j.annonc.2020.07.019
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004
   Dionísio MR, 2019, BRIT J CLIN PHARMACO, V85, P1114, DOI 10.1111/bcp.13852
   Domschke C, 2014, BREAST CARE, V9, P332, DOI 10.1159/000368844
   Albiach CF, 2019, J PAIN RES, V12, P2125, DOI 10.2147/JPR.S194881
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   Hiraga T, 2019, J ORAL BIOSCI, V61, P95, DOI 10.1016/j.job.2019.02.002
   Jackson C, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246441
   Nicolatou Galitis O, 2019, OR SURG OR MED OR PA, V127, P117, DOI 10.1016/j.oooo.2018.09.008
   Otto S, 2018, CANCER TREAT REV, V69, P177, DOI 10.1016/j.ctrv.2018.06.007
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Shapiro CL, 2017, J CLIN ONCOL, V35, P3949, DOI 10.1200/JCO.2017.73.7437
   Southcott D, 2020, CURR ONCOL, V27, P220, DOI 10.3747/co.27.6631
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Van Poznak C, 2017, J ONCOL PRACT, V13, P822, DOI 10.1200/JOP.2017.027672
   von Moos R, 2019, CANCER TREAT REV, V76, P57, DOI 10.1016/j.ctrv.2019.05.003
   Yang M, 2020, SUPPORT CARE CANCER, V28, P2533, DOI 10.1007/s00520 020 05355 7
NR 23
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0749 2081
EI 1878 3449
J9 SEMIN ONCOL NURS
JI Semin. Oncol. Nurs.
PD APR
PY 2022
VL 38
IS 2
SI SI
AR 151278
DI 10.1016/j.soncn.2022.151278
PG 6
WC Oncology; Nursing
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Oncology; Nursing
GA 1T8OK
UT WOS:000804985000005
PM 35431084
DA 2025 08 17
ER

PT J
AU Vanderburgh, JP
   Kwakwa, KA
   Werfel, TA
   Merkel, AR
   Gupta, MK
   Johnson, RW
   Guelcher, SA
   Duvall, CL
   Rhoades, JA
AF Vanderburgh, Joseph P.
   Kwakwa, Kristin A.
   Werfel, Thomas A.
   Merkel, Alyssa R.
   Gupta, Mukesh K.
   Johnson, Rachelle W.
   Guelcher, Scott A.
   Duvall, Craig L.
   Rhoades (Sterling), Julie A.
TI Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits
   tumor induced bone disease
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Bone metastasis; Breast cancer; Nanoparticle; Gli2; PTHrP; GANT58
ID HORMONE RELATED PROTEIN; IN SITU GROWTH; INTEGRIN BETA 3; PHASE I;
   CANCER; METASTASIS; PATHWAY; MARROW; LUNG; RESISTANCE
AB Solid tumors frequently metastasize to bone and induce bone destruction leading to severe pain, fractures, and other skeletal related events (SREs). Osteoclast inhibitors such as bisphosphonates delay SREs but do not prevent skeletal complications or improve overall survival. Because bisphosphonates can cause adverse side effects and are contraindicated for some patients, we sought an alternative therapy to reduce tumor associated bone destruction. Our previous studies identified the transcription factor Gli2 as a key regulator of parathyroid hormone related protein (PTHrP), which is produced by bone metastatic tumor cells to promote osteoclast mediated bone destruction. In this study, we tested the treatment effect of a Gli antagonist GANT58, which inhibits Gli2 nuclear translocation and PTHrP expression in tumor cells. In initial testing, GANT58 did not have efficacy in vivo due to its low water solubility and poor bioavailability. We therefore developed a micellar nanoparticle (NP) to encapsulate and colloidally stabilize GANT58, providing a fully aqueous, intravenously injectable formulation based on the polymer poly(propylene sulfide)(135) b poly[(oligoethylene glycol)(9) methyl ether acrylate](17)(PPS135 b POEGA(17)). POEGA forms the hydrophilic NP surface while PPS forms the hydrophobic NP core that sequesters GANT58. In response to reactive oxygen species (ROS), PPS becomes hydrophilic and degrades to enable drug release. In an intratibial model of breast cancer bone metastasis, treatment with GANT58 NPs decreased bone lesion area by 49% (p < .01) and lesion number by 38% (p < .05) and resulted in a 2.5 fold increase in trabecular bone volume (p < .001). Similar results were observed in intracardiac and intratibial models of breast and lung cancer bone metastasis, respectively. Importantly, GANT58 NPs reduced tumor cell proliferation but did not alter mesenchymal stem cell proliferation or osteoblast mineralization in vitro, nor was there evidence of cytotoxicity after repeated in vivo treatment. Thus, inhibition of Gli2 using GANT58 NPs is a potential therapy to reduce bone destruction that should be considered for further testing and development toward clinical translation.
C1 [Vanderburgh, Joseph P.; Guelcher, Scott A.] Vanderbilt Univ, Dept Chem & Biomol Engn, Nashville, TN 37235 USA.
   [Kwakwa, Kristin A.; Johnson, Rachelle W.; Guelcher, Scott A.; Rhoades (Sterling), Julie A.] Vanderbilt Univ, Program Canc Biol, Nashville, TN 37232 USA.
   [Vanderburgh, Joseph P.; Kwakwa, Kristin A.; Merkel, Alyssa R.; Johnson, Rachelle W.; Guelcher, Scott A.; Rhoades (Sterling), Julie A.] Vanderbilt Univ, Ctr Bone Biol, Med Ctr, Nashville, TN 37232 USA.
   [Vanderburgh, Joseph P.; Kwakwa, Kristin A.; Merkel, Alyssa R.; Rhoades (Sterling), Julie A.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN 37212 USA.
   [Werfel, Thomas A.; Gupta, Mukesh K.; Guelcher, Scott A.; Duvall, Craig L.; Rhoades (Sterling), Julie A.] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA.
   [Merkel, Alyssa R.; Johnson, Rachelle W.; Guelcher, Scott A.; Rhoades (Sterling), Julie A.] Vanderbilt Univ, Dept Med, Div Clin Pharmacol, Med Ctr, Nashville, TN 37232 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University; US
   Department of Veterans Affairs; Veterans Health Administration (VHA); VA
   Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt
   University
RP Rhoades, JA (通讯作者)，Vanderbilt Univ, Med Ctr, 1155D Med Res Bldg 4,2215 B Garland Ave, Nashville, TN 37232 USA.
EM julie.sterling@vumc.org
RI Gupta, Mukesh/B 4180 2016; Rhoades, Julie/LNU 1104 2024; Johnson,
   Rachelle/AFL 3690 2022
OI Gupta, Mukesh/0000 0002 9571 3454; Merkel, Alyssa/0000 0001 6498 4211; 
FU NCI/NIH [U01CA091664, 5P30 CA68485 19]; NIH [R00CA194198, R01CA163499];
   VA Merit Award [1I01BX001957]; DOD CDMRP [W81XWH 18 1 0029,
   W81XWH15 1 0627, W81XWH 15 1 0622];  [1S10RR027027631]
FX The authors wish to acknowledge Joshua Johnson for histological
   processing and sectioning of femora/tibiae as well as Kelli Boyd, D.V.M.
   Ph.D., veterinary pathologist, for pathological assessment of
   liver/kidney tissues. In addition, we thank Professors T.J. Martin and
   Natalie Sims from the St. Vincent's Institute of Medical Research and
   The University of Melbourne for kindly providing the PTHrP antibody used
   in the immunohistochemistry studies. We also acknowledge the CHTN
   Western Division supported by the NCI/NIH grant U01CA091664,
   Translational Pathology Shared Resource (TPSR) core which is supported
   by the NCI/NIH grant 5P30 CA68485 19, and the mu CT core funding
   1S10RR027027631. We are also grateful to the Vanderbilt Institute for
   Nanoscale Science and Engineering (VINSE) for access to the DLS and TEM
   for nanoparticle characterization. This work was supported by the NIH
   grant R01CA163499 (S.A.G. and J.A.S.), VA Merit Award1I01BX001957
   (J.A.S.), and the DOD CDMRP AwardsW81XWH15 1 0627 (C.L.D.) and
   W81XWH 15 1 0622 (J.A.S). R.W.J. is supported in part by the NIH grant
   R00CA194198 and DOD CDMRP award W81XWH 18 1 0029.
CR Ansari N, 2018, J BONE MINER RES, V33, P137, DOI 10.1002/jbmr.3291
   Ashton S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad2355
   Atwood SX, 2015, CANCER CELL, V27, P342, DOI 10.1016/j.ccell.2015.02.002
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330
   Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598
   Buijs JT, 2009, CANCER LETT, V273, P177, DOI 10.1016/j.canlet.2008.05.044
   Cannonier SA, 2015, CANCERS, V7, P1658, DOI 10.3390/cancers7030856
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chenna V, 2012, MOL CANCER THER, V11, P165, DOI 10.1158/1535 7163.MCT 11 0341
   Coleman R, 2011, BREAST CANCER RES TR, V127, P429, DOI 10.1007/s10549 011 1429 y
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229
   Dollinger BR, 2017, TISSUE ENG PT A, V23, P1120, DOI 10.1089/ten.tea.2016.0495
   Edwards BJ, 2016, J BONE MINER RES, V31, P1569, DOI 10.1002/jbmr.2818
   Fan CM, 2017, BREAST CANCER RES TR, V165, P41, DOI 10.1007/s10549 017 4308 3
   Fonseca H, 2016, OSTEOPOROSIS INT, V27, P3465, DOI 10.1007/s00198 016 3672 x
   Gao WP, 2010, P NATL ACAD SCI USA, V107, P16432, DOI 10.1073/pnas.1006044107
   Gao WP, 2009, P NATL ACAD SCI USA, V106, P15231, DOI 10.1073/pnas.0904378106
   Gonnissen A, 2016, ONCOTARGET, V7, P84286, DOI 10.18632/oncotarget.12483
   Green DE, 2014, BONE, V63, P87, DOI 10.1016/j.bone.2014.02.018
   GUISE TA, 1993, J CLIN ENDOCR METAB, V77, P40, DOI 10.1210/jc.77.1.40
   Guo R, 2016, J MATER CHEM B, V4, P3584, DOI 10.1039/c5tb02747k
   Gupta MK, 2014, J AM CHEM SOC, V136, P14896, DOI 10.1021/ja507626y
   Gupta MK, 2012, J CONTROL RELEASE, V162, P591, DOI 10.1016/j.jconrel.2012.07.042
   Gurer Orhan H, 2018, CURR MED CHEM, V25, P4084, DOI 10.2174/0929867324666170711114336
   Hu WY, 2016, CLIN CANCER RES, V22, P2000, DOI 10.1158/1078 0432.CCR 15 1421
   Huang LL, 2014, CLIN CANCER RES, V20, P1566, DOI 10.1158/1078 0432.CCR 13 2195
   Hyman JM, 2009, P NATL ACAD SCI USA, V106, P14132, DOI 10.1073/pnas.0907134106
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601
   Jansen LE, 2015, J MECH BEHAV BIOMED, V50, P299, DOI 10.1016/j.jmbbm.2015.06.023
   Jimeno A, 2013, CLIN CANCER RES, V19, P2766, DOI 10.1158/1078 0432.CCR 12 3654
   Johnson RW, 2014, CLIN EXP METASTAS, V31, P945, DOI 10.1007/s10585 014 9682 1
   Johnson RW, 2011, CANCER RES, V71, P822, DOI 10.1158/0008 5472.CAN 10 2993
   Joshi RV, 2013, ACTA BIOMATER, V9, P6526, DOI 10.1016/j.actbio.2013.01.041
   Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962
   Kim DW, 2007, ANN ONCOL, V18, P2009, DOI 10.1093/annonc/mdm374
   Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008 5472.CAN 04 0416
   Kwak EL, 2007, CLIN CANCER RES, V13, P5232, DOI 10.1158/1078 0432.CCR 07 1385
   Lam MHC, 2002, MOL ENDOCRINOL, V16, P390, DOI 10.1210/me.16.2.390
   Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104
   Li CL, 2017, NAT CELL BIOL, V19, P106, DOI 10.1038/ncb3464
   Li HM, 2015, BIOMACROMOLECULES, V16, P192, DOI 10.1021/bm501394m
   LoRusso PM, 2011, CLIN CANCER RES, V17, P2502, DOI 10.1158/1078 0432.CCR 10 2745
   Mazumdar T, 2011, CANCER RES, V71, P5904, DOI 10.1158/0008 5472.CAN 10 4173
   MBALAVIELE G, 1995, J CLIN INVEST, V95, P2757, DOI 10.1172/JCI117979
   Metcalfe C, 2011, CANCER RES, V71, P5057, DOI 10.1158/0008 5472.CAN 11 0923
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   Mizrachi A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14292
   MONFARDINI C, 1995, BIOCONJUGATE CHEM, V6, P62, DOI 10.1021/bc00031a006
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Neelakantan D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15773
   O'Grady KP, 2018, ACS BIOMATER SCI ENG, V4, P1251, DOI 10.1021/acsbiomaterials.6b00804
   Page JM, 2015, BIOMATERIALS, V64, P33, DOI 10.1016/j.biomaterials.2015.06.026
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Poole KM, 2015, BIOMATERIALS, V41, P166, DOI 10.1016/j.biomaterials.2014.11.016
   POWELL GJ, 1991, CANCER RES, V51, P3059
   Pozzi S, 2009, CLIN CANCER RES, V15, P5829, DOI 10.1158/1078 0432.CCR 09 0426
   Ramasamy T, 2017, J CONTROL RELEASE, V258, P226, DOI 10.1016/j.jconrel.2017.04.043
   Ross MH, 2017, CANCER RES, V77, P6299, DOI 10.1158/0008 5472.CAN 17 1225
   Ruppender NS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015451
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Schmid D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01830 8
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Sousa S, 2018, CALCIFIED TISSUE INT, V102, P227, DOI 10.1007/s00223 017 0353 5
   Sparreboom A, 1999, CANCER RES, V59, P1454
   Sterling JA, 2006, CANCER RES, V66, P7548, DOI 10.1158/0008 5472.CAN 06 0452
   Sterling JA, 2011, BONE, V48, P6, DOI 10.1016/j.bone.2010.07.015
   Tatem AJ, 2011, LANCET, V377, P30, DOI 10.1016/S0140 6736(11)61226 9
   Tietjen GT, 2017, NANOMED NANOTECHNOL, V13, P1863, DOI 10.1016/j.nano.2017.04.003
   Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011
   Uddin MJ, 2016, BIOMATERIALS, V92, P71, DOI 10.1016/j.biomaterials.2016.03.028
   Wagner AJ, 2015, CLIN CANCER RES, V21, P1044, DOI 10.1158/1078 0432.CCR 14 1116
   Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391
   Wei T, 2015, P NATL ACAD SCI USA, V112, P2978, DOI 10.1073/pnas.1418494112
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Werfel TA, 2017, J CONTROL RELEASE, V255, P12, DOI 10.1016/j.jconrel.2017.03.389
   Wicki A, 2015, J CONTROL RELEASE, V200, P138, DOI 10.1016/j.jconrel.2014.12.030
   Wright LE, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.31
   Xu Y, 2012, CLIN CANCER RES, V18, P1291, DOI 10.1158/1078 0432.CCR 11 0950
   Yamashita S, 2018, BIOMATERIALS, V154, P74, DOI 10.1016/j.biomaterials.2017.10.053
   Yang SP, 2017, ONCOLOGIST, V22, P438, DOI 10.1634/theoncologist.2016 0192
   Yuan Z, 2007, ONCOGENE, V26, P1046, DOI 10.1038/sj.onc.1209860
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
   Zheng HQ, 2017, CANCER CELL, V32, P731, DOI 10.1016/j.ccell.2017.11.002
NR 88
TC 27
Z9 30
U1 1
U2 45
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD OCT
PY 2019
VL 311
BP 257
EP 272
DI 10.1016/j.jconrel.2019.08.038
PG 16
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA JP0US
UT WOS:000497990100023
PM 31494183
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Deng, LL
   Wang, YP
   Peng, Y
   Wu, Y
   Ding, YD
   Jiang, YH
   Shen, ZH
   Fu, QA
AF Deng, Lili
   Wang, Yaping
   Peng, Ying
   Wu, Yu
   Ding, Yuedi
   Jiang, Yuhai
   Shen, Zhenhai
   Fu, Qiang
TI Osteoblast derived microvesicles: A novel mechanism for communication
   between osteoblasts and osteoclasts
SO BONE
LA English
DT Article
DE Microvesicles; Cellular communication; Osteoblast; Osteoclast;
   RANKL RANK pathway
ID MESSENGER RNA; MICROPARTICLES; MEDIATORS
AB The maintenance of bone homeostasis is largely dependent upon cellular communication between osteoclasts and osteoblasts. Microvesicles (MVs) have received a good deal of attention and are increasingly considered as mediators of intercellular communication due to their capacity to merge with and transfer a repertoire of bioactive molecular content (cargo) to recipient cells, triggering a variety of biologic responses. Here, we demonstrated that MVs shed from osteoblasts contain RANKL protein and can transfer it to osteoclast precursors through receptor ligand (RANKL RANK), leading to stimulation of RANKL RANK signaling to facilitate osteoclast formation. Such MV mediated intercellular communication between osteoblasts and osteoclasts may represent a novel mechanism of bone modeling and remodeling. It may be worthwhile to further explore MVs as tools to modify the biological responses of bone cells or develop an alternative drug to treat bone diseases. (C) 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
C1 [Deng, Lili; Peng, Ying; Wu, Yu; Ding, Yuedi; Fu, Qiang] Jiangsu Inst Nucl Med, Jiangsu Key Lab Mol Nucl Med, Key Lab Nucl Med, Minist Hlth, Wuxi 214063, Jiangsu, Peoples R China.
   [Wang, Yaping; Jiang, Yuhai] Nanjing Med Univ, Wuxi Peoples Hosp 2, Wuxi, Jiangsu, Peoples R China.
   [Shen, Zhenhai] Jiangsu Prov Taihu Rehabil Hosp, Wuxi, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Fu, QA (通讯作者)，Jiangsu Inst Nucl Med, QianRong Rd 20, Wuxi 214063, Jiangsu, Peoples R China.
EM denglili@jsinm.org; ypwnag0301@126.com; fuqiang@jsinm.org
RI Wu, Yu/HIK 1398 2022; Deng, Lili/LWI 7526 2024
FU Natural Science Foundation of Jiangsu Province [BK20131096, BK2012104];
   National Natural Science Foundation of China [81200645]
FX This work was supported by Natural Science Foundation of Jiangsu
   Province grant BK20131096 to Yaping Wang and BK2012104 to Yuedi Ding;
   and by National Natural Science Foundation of China 81200645 to Yu Wu.
CR Al Nedawi K, 2009, CELL CYCLE, V8, P2014, DOI 10.4161/cc.8.13.8988
   Antonyak MA, 2011, P NATL ACAD SCI USA, V108, P4852, DOI 10.1073/pnas.1017667108
   Baj Krzyworzeka M, 2006, CANCER IMMUNOL IMMUN, V55, P808, DOI 10.1007/s00262 005 0075 9
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Fu Q, 2006, MOL CELL BIOL, V26, P6453, DOI 10.1128/MCB.00356 06
   Ghosh AK, 2010, BLOOD, V115, P1755, DOI 10.1182/blood 2009 09 242719
   Grange C, CANC RES, V71, P5346
   Horstman LL, 2004, FRONT BIOSCI LANDMRK, V9, P1118, DOI 10.2741/1270
   Lee TH, 2011, SEMIN IMMUNOPATHOL, V33, P455, DOI 10.1007/s00281 011 0250 3
   Leroyer AS, 2008, J INTERN MED, V263, P528, DOI 10.1111/j.1365 2796.2008.01957.x
   Martins SAM, 2009, ANAL BIOANAL CHEM, V394, P1711, DOI 10.1007/s00216 009 2843 4
   MURALIDHARANCHA.V, J CELL SCI, V123, P1603
   Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296
   Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132
   Simak J, 2006, TRANSFUS MED REV, V20, P1, DOI 10.1016/j.tmrv.2005.08.001
   Tamma Roberto, 2012, Inflammation & Allergy Drug Targets, V11, P196
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang J, PLANT CELL, V22, P4009
   Wysoczynski M, 2009, INT J CANCER, V125, P1595, DOI 10.1002/ijc.24479
NR 21
TC 164
Z9 189
U1 0
U2 31
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2015
VL 79
BP 37
EP 42
DI 10.1016/j.bone.2015.05.022
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CO9QF
UT WOS:000359509700006
PM 26013558
OA hybrid
DA 2025 08 17
ER

PT J
AU McDonald, GLK
   Wang, MD
   Hammond, CL
   Bergen, DJM
AF McDonald, Georgina L. K.
   Wang, Mengdi
   Hammond, Chrissy L.
   Bergen, Dylan J. M.
TI Pharmacological Manipulation of Early Zebrafish Skeletal Development
   Shows an Important Role for Smad9 in Control of Skeletal Progenitor
   Populations
SO BIOMOLECULES
LA English
DT Article
DE osteoblast; biomolecule; musculoskeletal; zebrafish; BMP signalling;
   Smad9; osteoporosis
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; RETINOIC ACID; POSTMENOPAUSAL
   WOMEN; BONE; OSTEOBLAST; PREDNISOLONE; IDENTIFICATION; SCLEROSTEOSIS;
   OSTEOGENESIS; ROMOSOZUMAB
AB Osteoporosis and other conditions associated with low bone density or quality are highly prevalent, are increasing as the population ages and with increased glucocorticoid use to treat conditions with elevated inflammation. There is an unmet need for therapeutics which can target skeletal precursors to induce osteoblast differentiation and osteogenesis. Genes associated with high bone mass represent interesting targets for manipulation, as they could offer ways to increase bone density. A damaging mutation in SMAD9 has recently been associated with high bone mass. Here we show that Smad9 labels groups of osteochondral precursor cells, which are not labelled by the other Regulatory Smads: Smad1 or Smad5. We show that Smad9(+) cells are proliferative, and that the Smad9(+) pocket expands following osteoblast ablation which induced osteoblast regeneration. We further show that treatment with retinoic acid, prednisolone, and dorsomorphin all alter Smad9 expression, consistent with the effects of these drugs on the skeletal system. Taken together these results demonstrate that Smad9(+) cells represent an undifferentiated osteochondral precursor population, which can be manipulated by commonly used skeletal drugs. We conclude that Smad9 represents a target for future osteoanabolic therapies.
C1 [McDonald, Georgina L. K.; Wang, Mengdi; Hammond, Chrissy L.; Bergen, Dylan J. M.] Univ Bristol, Fac Life Sci, Sch Physiol Pharmacol & Neurosci, Bristol BS8 1TD, Avon, England.
   [Bergen, Dylan J. M.] Univ Bristol, Translat Hlth Sci, Musculoskeletal Res Unit, Bristol Med Sch, Bristol BS10 5FN, Avon, England.
C3 University of Bristol; University of Bristol
RP Hammond, CL; Bergen, DJM (通讯作者)，Univ Bristol, Fac Life Sci, Sch Physiol Pharmacol & Neurosci, Bristol BS8 1TD, Avon, England.; Bergen, DJM (通讯作者)，Univ Bristol, Translat Hlth Sci, Musculoskeletal Res Unit, Bristol Med Sch, Bristol BS10 5FN, Avon, England.
EM gm15811@bristol.ac.uk; mengdi.wang@bristol.ac.uk;
   chrissy.hammond@bristol.ac.uk; dylan.bergen@bristol.ac.uk
RI Bergen, Dylan/AAU 4547 2020; Hammond, Chrissy/D 6568 2013
OI Bergen, Dylan/0000 0001 7808 6121; Hammond, Chrissy/0000 0002 4935 6724
FU Versus Arthritis [29137, 22044]; Wellcome Trust Dynamic Cell doctoral
   training programme [108907/Z/15/Z]; China Scholarship Council; Versus
   Arthritis [21937] Funding Source: researchfish
FX C.L.H. and D.J.M.B. received funding from Versus Arthritis (29137 and
   22044 respectively). G.L.K.Mc.D is funded by the Wellcome Trust Dynamic
   Cell doctoral training programme (108907/Z/15/Z). M.W. is funded by the
   China Scholarship Council.
CR Abarca Buis RF, 2011, DEV GROWTH DIFFER, V53, P780, DOI 10.1111/j.1440 169X.2011.01285.x
   Aleström P, 2020, LAB ANIM UK, V54, P213, DOI 10.1177/0023677219869037
   Alexander C, 2011, DEVELOPMENT, V138, P5135, DOI 10.1242/dev.067801
   Askary A, 2016, ELIFE, V5, DOI 10.7554/eLife.16415
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bergemann D, 2018, WOUND REPAIR REGEN, V26, P238, DOI 10.1111/wrr.12633
   Bergen DJM, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00006
   Bergström I, 2018, BONE, V112, P10, DOI 10.1016/j.bone.2018.04.002
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Brunt LH, 2017, DEVELOPMENT, V144, P2798, DOI 10.1242/dev.153528
   Carney TJ, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000907
   Chen JR, 2017, MOLECULES, V22, DOI 10.3390/molecules22122068
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   de Vrieze E, 2014, OSTEOPOROSIS INT, V25, P567, DOI 10.1007/s00198 013 2441 3
   de Vrieze E, 2015, BONE, V74, P106, DOI 10.1016/j.bone.2015.01.006
   Dee CT, 2016, J IMMUNOL, V197, P3520, DOI 10.4049/jimmunol.1600959
   DeLaurier A, 2010, GENESIS, V48, P505, DOI 10.1002/dvg.20639
   Dutton JR, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 105
   Eames BF, 2013, BMC DEV BIOL, V13, DOI 10.1186/1471 213X 13 23
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Geurtzen K, 2017, J BONE MINER RES, V32, P2476, DOI 10.1002/jbmr.3231
   Gregson CL, 2012, OSTEOPOROSIS INT, V23, P643, DOI 10.1007/s00198 011 1603 4
   Gregson CL, 2020, J BONE MINER RES, V35, P92, DOI 10.1002/jbmr.3875
   Hammond CL, 2009, DEVELOPMENT, V136, P3991, DOI 10.1242/dev.042150
   He HL, 2018, BIOMED PHARMACOTHER, V101, P981, DOI 10.1016/j.biopha.2018.02.082
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Huang Z, 2009, HUM MOL GENET, V18, P2791, DOI 10.1093/hmg/ddp214
   Huo L, 2018, BIOL OPEN, V7, DOI 10.1242/bio.029405
   Jeradi S, 2016, DEVELOPMENT, V143, P1205, DOI 10.1242/dev.129189
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kemp JP, 2017, NAT GENET, V49, P1468, DOI 10.1038/ng.3949
   Kimmel CB, 2001, DEV BIOL, V233, P239, DOI 10.1006/dbio.2001.0201
   Lassmann T, 2009, NUCLEIC ACIDS RES, V37, P858, DOI 10.1093/nar/gkn1006
   Laue K, 2008, DEVELOPMENT, V135, P3775, DOI 10.1242/dev.021238
   Laue K, 2011, AM J HUM GENET, V89, P595, DOI 10.1016/j.ajhg.2011.09.015
   Lleras Forero L, 2020, DEV BIOL, V457, P191, DOI 10.1016/j.ydbio.2019.07.009
   Lowery JW, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022327
   MacRae CA, 2015, NAT REV DRUG DISCOV, V14, P721, DOI 10.1038/nrd4627
   Mantoku A, 2016, DEV BIOL, V409, P370, DOI 10.1016/j.ydbio.2015.12.002
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Metcalf LM, 2017, BONE, V99, P39, DOI 10.1016/j.bone.2017.03.007
   Moro E, 2012, DEV BIOL, V366, P327, DOI 10.1016/j.ydbio.2012.03.023
   Morris JA, 2019, NAT GENET, V51, P258, DOI 10.1038/s41588 018 0302 x
   Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353
   Pasqualetti S, 2015, INT J EXP PATHOL, V96, P11, DOI 10.1111/iep.12106
   Potnuru P, 2020, CUREUS J MED SCIENCE, V12, DOI [10.1038/nature12111, 10.7759/cureus.11549]
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schmidt JR, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00674
   Shintani N, 2011, Eur Cell Mater, V22, P302
   Singh SP, 2012, DEV CELL, V22, P879, DOI 10.1016/j.devcel.2012.03.006
   Spoorendonk KM, 2008, DEVELOPMENT, V135, P3765, DOI 10.1242/dev.024034
   Svedbom A, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0137 0
   Tobias JH, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.630875
   Trajanoska K, 2019, BONE, V126, P2, DOI 10.1016/j.bone.2019.04.005
   Tsukamoto S, 2014, SCI REP UK, V4, DOI 10.1038/srep07596
   Watanabe A, 2012, J TOXICOL SCI, V37, P617
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Witten PE, 2009, BIOL REV, V84, P315, DOI 10.1111/j.1469 185X.2009.00077.x
   Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888
   Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54
NR 62
TC 4
Z9 4
U1 2
U2 9
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2218 273X
J9 BIOMOLECULES
JI Biomolecules
PD FEB
PY 2021
VL 11
IS 2
AR 277
DI 10.3390/biom11020277
PG 18
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA QN0LK
UT WOS:000622162400001
PM 33668680
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Dai, JL
   Hall, CL
   Escara Wilke, J
   Mizokami, A
   Keller, JM
   Keller, ET
AF Dai, Jinlu
   Hall, Christopher L.
   Escara Wilke, June
   Mizokami, Atsushi
   Keller, Jill M.
   Keller, Evan T.
TI Prostate cancer induces bone metastasis through Wnt induced bone
   morphogenetic protein dependent and independent mechanisms
SO CANCER RESEARCH
LA English
DT Article
ID MESSENGER RNA EXPRESSION; BETA CATENIN; OSTEOBLAST DIFFERENTIATION;
   GENE EXPRESSION; RETINOIC ACID; CELLS; RAT; BMP 2; ANTAGONISTS; RECEPTOR
AB Prostate cancer (PCa) is frequently accompanied by osteosclerotic (i.e., excessive bone production) bone metastases. Although bone morphogenetic proteins (BMP) and Wnts are mediators of PCa induced osteoblastic activity, the relation between them in PCa bone metastases is unknown. The goal of this study was to define this relationship. Wnt3a and Wnt5a administration or knockdown of DKK 1, a Wnt inhibitor, induced BMP 4 and 6 expression and promoter activation in PCa cells. DKK 1 blocked Wnt activation of the BMP promoters. Transfection of C4 2B cells with axin, an inhibitor of canonical Wnt signaling, blocked Wnt3a but not Wnt5a induction of the BMP promoters. In contrast, Jnk inhibitor I blocked Wnt5a but not Wnt3a induction of the BMP promoters. Wnt3a, Wnt5a, and conditioned medium (CM) from C4 2B or LuCaP23.1 cells induced osteoblast differentiation in vitro. The addition of DKK 1 and Noggin, a BMP inhibitor, to CM diminished PCa CM induced osteoblast differentiation in a synergistic fashion. However, pretreatment of PCa cells with DKK 1 before collecting CM blocked osteoblast differentiation, whereas pretreatment with Noggin only partially reduced osteoblast differentiation, and pretreatment with both DKK 1 and Noggin had no greater effect than pretreatment with DKK 1 alone. Additionally, knockdown of BMP expression in C4 2B cells inhibited Wnt induced osteoblastic activity. These results show that PCa promotes osteoblast differentiation through canonical and noncanonical Wnt signaling pathways that stimulate both BMP dependent and BMP independent osteoblast differentiation. These results show a clear link between Wnts and BMPs in PCa induced osteoblast differentiation and provide novel targets, including the noncanonical Wnt pathway, for therapy of PCa.
C1 [Dai, Jinlu; Hall, Christopher L.; Escara Wilke, June; Keller, Jill M.; Keller, Evan T.] Univ Michigan Hlth Syst, Dept Urol, Ann Arbor, MI USA.
   [Mizokami, Atsushi] Kanazawa Univ, Dept Urol, Kanazawa, Ishikawa, Japan.
C3 University of Michigan System; University of Michigan; Kanazawa
   University
RP Keller, ET (通讯作者)，Univ Michigan, Sch Med, Dept Urol, 5111 CCC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM etkeller@umich.edu
RI Dai, Jin/GVT 2414 2022; Keller, Evan/M 1446 2016
OI Hall, Christopher/0000 0003 1421 1733
FU National Cancer Institute [P01CA093900] Funding Source: NIH RePORTER;
   NCI NIH HHS [P01 CA093900] Funding Source: Medline
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Barnes J, 1995, WORLD J UROL, V13, P337
   Barrow JR, 2003, GENE DEV, V17, P394, DOI 10.1101/gad.1044903
   BENTLEY H, 1992, BRIT J CANCER, V66, P1159, DOI 10.1038/bjc.1992.427
   Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Corey E, 2002, PROSTATE, V52, P20, DOI 10.1002/pros.10091
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008 5472.CAN 05 1891
   Dai JL, 2004, CANCER RES, V64, P994, DOI 10.1158/0008 5472.CAN 03 1382
   Doak SH, 2007, CANCER GENET CYTOGEN, V176, P161, DOI 10.1016/j.cancergencyto.2007.03.011
   Faucheux C, 1999, J CELL BIOCHEM, V73, P11, DOI 10.1002/(SICI)1097 4644(19990401)73:1<11::AID JCB2>3.0.CO;2 4
   FENG JQ, 1994, BBA GENE STRUCT EXPR, V1218, P221, DOI 10.1016/0167 4781(94)90017 5
   FENG JQ, 1995, J BIOL CHEM, V270, P28364, DOI 10.1074/jbc.270.47.28364
   Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154 006 9000 6
   Godin RE, 1998, DEVELOPMENT, V125, P3473
   Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200
   Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522
   Grimsrud CD, 1998, J ORTHOPAED RES, V16, P247, DOI 10.1002/jor.1100160212
   Haegele L, 2003, MOL CELL NEUROSCI, V24, P696, DOI 10.1016/S1044 7431(03)00232 X
   Hall CL, 2006, J CELL BIOCHEM, V97, P661, DOI 10.1002/jcb.20735
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Hamdy FC, 1997, CANCER RES, V57, P4427
   HARRIS SE, 1994, PROSTATE, V24, P204, DOI 10.1002/pros.2990240406
   Helvering LM, 2000, GENE, V256, P123, DOI 10.1016/S0378 1119(00)00364 4
   HUGHES FJ, 1995, ENDOCRINOLOGY, V136, P2671, DOI 10.1210/en.136.6.2671
   Itäranta P, 2006, DEV BIOL, V293, P473, DOI 10.1016/j.ydbio.2006.02.019
   Kawai S, 2001, BONE, V29, P54, DOI 10.1016/S8756 3282(01)00470 7
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Keller ET, 2002, DRUG TODAY, V38, P91, DOI 10.1358/dot.2002.38.2.820105
   Kim JS, 2002, CANCER RES, V62, P2744
   Li IWS, 1996, J CELL PHYSIOL, V169, P115, DOI 10.1002/(SICI)1097 4652(199610)169:1<115::AID JCP12>3.0.CO;2 C
   MALIAKAL JC, 1994, GROWTH FACTORS, V11, P227, DOI 10.3109/08977199409046920
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Mohammad KS, 2003, CLIN ORTHOP RELAT R, pS67, DOI 10.1097/01.blo.0000093047.96273.4e
   Nakashima A, 2005, J BIOL CHEM, V280, P37660, DOI 10.1074/jbc.M504612200
   Nelson JB, 1999, UROLOGY, V53, P1063, DOI 10.1016/S0090 4295(98)00658 X
   Ozkaynak E, 1997, BIOCHEM BIOPH RES CO, V234, P242, DOI 10.1006/bbrc.1997.6624
   Paralkar VM, 2002, J CELL PHYSIOL, V190, P207, DOI 10.1002/JCP.10048
   Parker SL, 1997, CA CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359 6101(96)00049 4
   Reddi AH, 2003, J BONE MINER RES, V18, P190, DOI 10.1359/jbmr.2003.18.2.190
   Rosen V, 2006, ANN NY ACAD SCI, V1068, P19, DOI 10.1196/annals.1346.005
   Tamada H, 1998, BBA GENE STRUCT EXPR, V1395, P247, DOI 10.1016/S0167 4781(97)00191 7
   Tenta R, 2004, PROSTATE, V59, P120, DOI 10.1002/pros.10363
   THALMANN GN, 1994, CANCER RES, V54, P2577
   Thomas R, 1998, PROSTATE, V37, P236, DOI 10.1002/(SICI)1097 0045(19981201)37:4<236::AID PROS5>3.0.CO;2 C
   van Bezooijen RL, 2007, J BONE MINER RES, V22, P19, DOI 10.1359/JBMR.061002
   Wan M, 2001, J BIOL CHEM, V276, P10119, DOI 10.1074/jbc.M006918200
   Weber KL, 1998, J ORTHOPAED RES, V16, P8, DOI 10.1002/jor.1100160103
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200
   Yanagita M, 2005, CYTOKINE GROWTH F R, V16, P309, DOI 10.1016/j.cytogfr.2005.02.007
   Yang LJ, 2006, J DERMATOL SCI, V42, P111, DOI 10.1016/j.jdermsci.2005.12.011
NR 58
TC 121
Z9 138
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2008
VL 68
IS 14
BP 5785
EP 5794
DI 10.1158/0008 5472.CAN 07 6541
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 327ZZ
UT WOS:000257768300036
PM 18632632
OA Green Submitted, Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Iwasaki Ishizuka, Y
   Yamato, H
   Nii Kono, T
   Kurokawa, K
   Fukagawa, M
AF Iwasaki Ishizuka, Y
   Yamato, H
   Nii Kono, T
   Kurokawa, K
   Fukagawa, M
TI Downregulation of parathyroid hormone receptor gene expression and
   osteoblastic dysfunction associated with skeletal resistance to
   parathyroid hormone in a rat model of renal failure with low turnover
   bone
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT 36th Annual Meeting of the American Society of Nephrology
CY NOV 12 17, 2003
CL SAN DIEGO, CA
SP Amer Soc Nephrol
DE adynamic bone disease; animal model; bone histomorphometry; renal
   failure; skeletal resistance to parathyroid hormone
ID MESSENGER RNA; OSTEOPROTEGERIN; PTH
AB Background. Adynamic bone disease (ABD), which is characterized by reduced bone formation and resorption, has become an increasingly common manifestation of bone abnormalities in patients with end stage renal failure. It has been recognized that skeletal resistance to parathyroid hormone (PTH) underlies the pathogenesis of ABD; however, the mechanisms of such resistance remain unclear.
   Methods. We established a rat model simulating ABD under chronic renal failure conditions by thyroparathyroidectomy and partial nephrectomy (TPTx Nx). TPTx Nx rats were infused subcutaneously with a physiological dose of PTH. We analysed bone histomorphometric parameters and demonstrated gene expression using semi quantitative reverse transcription polymerase chain reaction.
   Results. Reduced bone formation was observed in this model, simulating ABD. The reduction was dependent on the degree of renal dysfunction. Bone formation rate was 6.4 +/  2.7 mu m(3)/m(2)/year in TPTx 5/6Nx rats and 22.7 +/  7.2 mu m(3)/m(2)/year in TPTx rats (P < 0.05). Osteoblast surface was also significantly depressed (P < 0.05) in TPTx 5/6Nx (3.8 +/  2.7 %) compared with TPTx rats (15.9 +/  8.6). The expression of PTH/parathyroid hormone related peptide (PTHrP) receptor and alkaline phosphatase genes was reduced significantly in TPTx Nx compared with TPTx rats (P < 0.05). Reduced bone formation in TPTx Nx rats was ameliorated by intermittent injection of pharmacological doses of PTH.
   Conclusions. Renal dysfunction without secondary hyperparathyroidism induces osteoblast dysfunction and reduces bone formation. Skeletal resistance to PTH develops in renal failure even at low or normal PTH levels, possibly through downregulation of PTH/PTHrP receptor and dysfunction of osteoblasts.
C1 Kobe Univ, Sch Med, Div Nephrol, Kobe, Hyogo 6500017, Japan.
   Kobe Univ, Sch Med, Dialysis Ctr, Kobe, Hyogo 6500017, Japan.
   Oita Univ Nursing & Hlth Sci, Dept Hlth Sci, Oita 8701201, Japan.
   Kureha Special Lab Co Ltd, Fukushima 9748232, Japan.
   Tokai Univ, Sch Med, Inst Med Sci, Kanagawa 2591193, Japan.
C3 Kobe University; Kobe University; Oita University; Tokai University
RP Fukagawa, M (通讯作者)，Kobe Univ, Sch Med, Div Nephrol, Kobe, Hyogo 6500017, Japan.
EM fukagawa@med.kobe u.ac.jp
OI Fukagawa, Masafumi/0000 0002 7832 2339
CR Atsumi K, 1999, AM J KIDNEY DIS, V33, P287, DOI 10.1016/S0272 6386(99)70302 1
   Berdud I, 1998, CALCIFIED TISSUE INT, V62, P457, DOI 10.1007/s002239900460
   Buxton EC, 2004, J CLIN ENDOCR METAB, V89, P3332, DOI 10.1210/jc.2003 032066
   Couttenye MM, 1999, KIDNEY INT, V56, pS70, DOI 10.1046/j.1523 1755.1999.07308.x
   Disthabanchong S, 2004, KIDNEY INT, V65, P897, DOI 10.1111/j.1523 1755.2004.00472.x
   Goodman WG, 2002, J NEPHROL, V15, pS82
   HERCZ G, 1993, KIDNEY INT, V44, P860, DOI 10.1038/ki.1993.323
   HUTCHISON AJ, 1994, AM J NEPHROL, V14, P19, DOI 10.1159/000168681
   Kazama JJ, 2002, AM J KIDNEY DIS, V39, P525, DOI 10.1053/ajkd.2002.31402
   KURZ P, 1994, KIDNEY INT, V46, P855, DOI 10.1038/ki.1994.342
   Lund RJ, 2004, J AM SOC NEPHROL, V15, P359, DOI 10.1097/01.ASN.0000109671.99498.08
   MALLUCHE HH, 1976, KIDNEY INT, V9, P355, DOI 10.1038/ki.1976.42
   MASSRY SG, 1973, ANN INTERN MED, V78, P357, DOI 10.7326/0003 4819 78 3 357
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Picton ML, 2000, KIDNEY INT, V58, P1440, DOI 10.1046/j.1523 1755.2000.00306.x
   SHERRARD DJ, 1993, KIDNEY INT, V43, P436, DOI 10.1038/ki.1993.64
   Slatopolsky E, 2000, KIDNEY INT, V58, P753, DOI 10.1016/S0085 2538(15)47156 X
   Szabó A, 1999, EUR J CLIN INVEST, V29, P529, DOI 10.1046/j.1365 2362.1999.00499.x
   Tallon S, 1996, KIDNEY INT, V49, P1441, DOI 10.1038/ki.1996.203
   Tanaka S, 2004, J BONE MINER RES, V19, P1813, DOI 10.1359/JBMR.040808
   URENA P, 1995, KIDNEY INT, V47, P1797, DOI 10.1038/ki.1995.248
NR 21
TC 71
Z9 76
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931 0509
EI 1460 2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD SEP
PY 2005
VL 20
IS 9
BP 1904
EP 1911
DI 10.1093/ndt/gfh876
PG 8
WC Transplantation; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Transplantation; Urology & Nephrology
GA 959KZ
UT WOS:000231517900021
PM 15985520
OA Bronze
DA 2025 08 17
ER

PT J
AU Zheng, L
   Gao, JW
   Jin, KT
   Chen, ZZ
   Yu, WY
   Zhu, KJ
   Huang, WJ
   Liu, FJ
   Mei, LW
   Lou, C
   He, DW
AF Zheng, Lin
   Gao, Jiawei
   Jin, Kangtao
   Chen, Zhenzhong
   Yu, Weiyang
   Zhu, Kejun
   Huang, Wenjun
   Liu, Feijun
   Mei, Liangwei
   Lou, Chao
   He, Dengwei
TI Macrophage migration inhibitory factor (MIF) inhibitor 4 IPP suppresses
   osteoclast formation and promotes osteoblast differentiation through the
   inhibition of the NF κB signaling pathway
SO FASEB JOURNAL
LA English
DT Article
DE osteoporosis; osteoclastogenesis; osteogenesis; therapeutics
ID THIOREDOXIN INTERACTING PROTEIN; FACTOR EXPRESSION; IN VITRO; CELLS;
   MICE; IDENTIFICATION; PROLIFERATION; OSTEOPOROSIS; PROGRESSION;
   ACTIVATION
AB Current pharmacological intervention for the treatment of osteolytic bone diseases such as osteoporosis focuses on the prevention of excessive osteoclastic bone resorption but does not enhance osteoblast mediated bone formation. In our study, we have shown that 4 iodo 6 phenylpyrimidine (4 IPP), an irreversible inhibitor of macrophage migration inhibitory factor (MIF), can inhibit receptor activator of NF kappa B ligand (RANKL) induced osteoclastogenesis and potentiate osteoblast mediated mineralization and bone nodule formation in vitro. Mechanistically, 4 IPP inhibited RANKL induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin interacting protein p65 complexes. This led to the suppression of late osteoclast marker genes such as nuclear factor of activated T cells cytoplasmic 1, resulting in impaired osteoclast formation. In contrast, 4 IPP potentiated osteoblast differentiation and mineralization also through the inhibition of the p65/NF kappa B signaling cascade. In the murine model of pathologic osteolysis induced by titanium particles, 4 IPP protected against calvarial bone destruction. Similarly, in the murine model of ovariectomy induced osteoporosis, 4 IPP treatment ameliorated the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation. Collectively, these findings provide evidence for the pharmacological targeting of MIF for the treatment of osteolytic bone disorders. Zheng, L., Gao, J., Jin, K., Chen, Z., Yu, W., Zhu, K., Huang, W., Liu, F., Mei, L., Lou, C., He, D. Macrophage migration inhibitory factor (MIF) inhibitor 4 IPP suppresses osteoclast formation and promotes osteoblast differentiation through the inhibition of the NF kappa B signaling pathway.
C1 [Zheng, Lin; Gao, Jiawei; Jin, Kangtao; Chen, Zhenzhong; Yu, Weiyang; Zhu, Kejun; Huang, Wenjun; Liu, Feijun; Mei, Liangwei; Lou, Chao; He, Dengwei] Zhejiang Univ, Affiliated Lishui Hosp, Dept Orthoped,Wenzhou Med Univ, Affiliated Hosp 5,Lishui Cent Hosp, 289 Kuocang Rd, Lishui 323000, Peoples R China.
C3 Zhejiang University; Wenzhou Medical University
RP Lou, C; He, DW (通讯作者)，Zhejiang Univ, Affiliated Lishui Hosp, Dept Orthoped,Wenzhou Med Univ, Affiliated Hosp 5,Lishui Cent Hosp, 289 Kuocang Rd, Lishui 323000, Peoples R China.
EM dr_louchao@foxmail.com; hedw120@163.com
RI Chen, Zhenzhong/C 2529 2015; huang, wenjun/KVY 9101 2024; Zheng,
   Lin/AAE 8093 2021
OI He, Dengwei/0000 0003 2394 2124; Zheng, Lin/0000 0002 7585 6968
FU Natural Science Foundation of Zhejiang Provincial (CN) [LY17C100002];
   Public Welfare Project of Zhejiang Provincial Science and Technology
   Department [2016C33245]; Zhejiang Province Scientific Project of Health
   and Medicine of China [2018KY936]; Zhejiang Experimental Animal and
   Technology Program Foundation of China [2018C37099]
FX This work was supported by grants from the Natural Science Foundation of
   Zhejiang Provincial (CN) (Grant LY17C100002), Public Welfare Project of
   Zhejiang Provincial Science and Technology Department (Grant
   2016C33245), the Zhejiang Province Scientific Project of Health and
   Medicine of China (Grant 2018KY936), and the Zhejiang Experimental
   Animal and Technology Program Foundation of China (Grant 2018C37099).
   The authors declare no conflicts of interest.
CR Aitken CJ, 2004, J BONE MINER RES, V19, P2057, DOI 10.1359/JBMR.040913
   Bacher M, 1997, AM J PATHOL, V150, P235
   Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0
   Cao WG, 2005, BIOL REPROD, V73, P565, DOI 10.1095/biolreprod.104.038331
   Chen S, 2015, SCI REP UK, V5, DOI 10.1038/srep12853
   Chen ZH, 2015, J BIOL CHEM, V290, P30163, DOI 10.1074/jbc.M115.663518
   DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Gore Y, 2008, J BIOL CHEM, V283, P2784, DOI 10.1074/jbc.M703265200
   Gu R, 2015, CYTOKINE, V72, P135, DOI 10.1016/j.cyto.2014.11.015
   Harvey NC, 2017, LANCET, V390, P2243, DOI 10.1016/S0140 6736(17)32850 7
   Hermanowski Vosatka A, 1999, BIOCHEMISTRY US, V38, P12841, DOI 10.1021/bi991352p
   Hu W, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16008 x
   Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375
   Jacquin C, 2009, BONE, V45, P640, DOI 10.1016/j.bone.2009.06.028
   Kim HR, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3279
   Kim K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020601
   Kim KW, 2016, KOREAN J INTERN MED, V31, P634, DOI 10.3904/kjim.2016.098
   Kim MJ, 2017, CELL SIGNAL, V34, P110, DOI 10.1016/j.cellsig.2017.03.007
   Kindt N, 2013, INT J ONCOL, V43, P185, DOI 10.3892/ijo.2013.1944
   Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591
   Kobayashi T, 2011, OSTEOPOROSIS INT, V22, P1955, DOI 10.1007/s00198 010 1385 0
   Krum SA, 2010, NAT REV RHEUMATOL, V6, P607, DOI 10.1038/nrrheum.2010.133
   Lizotte J, 2012, TOXICOL LETT, V215, P167, DOI 10.1016/j.toxlet.2012.10.006
   Ma JJ, 2015, BIOCHEM J, V469, P399, DOI 10.1042/BJ20150151
   Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100
   Madeira MFM, 2012, MICROBES INFECT, V14, P198, DOI 10.1016/j.micinf.2011.09.005
   Movila A, 2016, J BONE MINER RES, V31, P1688, DOI 10.1002/jbmr.2854
   Nishihira J, 1998, CYTOKINE, V10, P199, DOI 10.1006/cyto.1997.0276
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Onodera S, 2002, J BIOL CHEM, V277, P7865, DOI 10.1074/jbc.M106020200
   Onodera S, 1996, IMMUNOLOGY, V89, P430, DOI 10.1046/j.1365 2567.1996.d01 751.x
   Onodera S, 1999, SEMIN THROMB HEMOST, V25, P563, DOI 10.1055/s 2007 994966
   Onodera S, 2006, J BONE MINER RES, V21, P876, DOI 10.1359/JBMR.060310
   Oshima S, 2006, FEBS LETT, V580, P1251, DOI 10.1016/j.febslet.2006.01.038
   Ranganathan V, 2017, ARTHRITIS RHEUMATOL, V69, P1796, DOI 10.1002/art.40175
   Rocklin R E, 1975, Rheumatology, V6, P98
   Rowe MA, 2017, ARTHRITIS RHEUMATOL, V69, P352, DOI 10.1002/art.39844
   Sampey AV, 2001, ARTHRITIS RHEUM US, V44, P1273, DOI 10.1002/1529 0131(200106)44:6<1273::AID ART219>3.0.CO;2 8
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020
   Subbannayya T, 2016, J CELL COMMUN SIGNAL, V10, P165, DOI 10.1007/s12079 016 0326 x
   Varinelli L, 2015, ENDOCR RELAT CANCER, V22, P759, DOI 10.1530/ERC 15 0299
   Winner M, 2008, CANCER RES, V68, P7253, DOI 10.1158/0008 5472.CAN 07 6227
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Yamada K, 2012, NUTR RES, V32, P116, DOI 10.1016/j.nutres.2011.12.010
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zheng YH, 2016, JNCI J NATL CANCER I, V108, DOI 10.1093/jnci/djw131
NR 54
TC 32
Z9 33
U1 1
U2 17
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2019
VL 33
IS 6
BP 7667
EP 7683
DI 10.1096/fj.201802364RR
PG 17
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA IJ7YD
UT WOS:000476114200080
PM 30893559
OA Bronze
DA 2025 08 17
ER

PT J
AU Li, XY
   Lu, XC
   Fan, DP
   Li, L
   Lu, C
   Tan, Y
   Xia, Y
   Zhao, HY
   Fan, MX
   Xiao, C
AF Li, Xiaoya
   Lu, Xiangcheng
   Fan, Danping
   Li, Li
   Lu, Cheng
   Tan, Yong
   Xia, Ya
   Zhao, Hongyan
   Fan, Miaoxuan
   Xiao, Cheng
TI Synergistic Effects of Erzhi Pill Combined With Methotrexate on
   Osteoblasts Mediated via the Wnt1/LRP5/β Catenin Signaling
   Pathway in Collagen Induced Arthritis Rats
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE rheumatoid arthritis; Erzhi Pill; Methotrexate; Wnt; beta catenin
   signaling pathway; Osteoblasts; synergistic effects
ID TRADITIONAL CHINESE MEDICINE; ER ZHI WAN; RHEUMATOID ARTHRITIS;
   CHEMOTHERAPEUTIC AGENTS; HERBAL PREPARATION; BONE; OSTEOPOROSIS;
   DIFFERENTIATION; OSTEOGENESIS; THERAPY
AB Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by chronic synovitis, bone erosion, and bone loss. Erzhi Pill (EZP), a classic Chinese patent medicine, is often used to treat osteoporosis and shows a capacity for bone metabolism regulation. Methotrexate (MTX), an essential drug for RA treatment, has been reported to inhibit generalized bone loss in RA patients. However, the combined therapeutic effects and mechanism of EZP and MTX in RA have not been fully elucidated. The aim of this study was to investigate the synergistic effect of EZP and MTX on RA and to explore the underlying mechanism through network pharmacological prediction and experimental verification. Chemical compounds of EZP, human target proteins of EZP and MTX, and RA related human genes were identified in the Encyclopedia of Traditional Chinese Medicine database, PubChem database, and NCBI database, respectively. The molecular network of EZP and MTX in RA was generated and analyzed with Ingenuity Pathway Analysis software according to the datasets. Then, MTX monotherapy, EZP monotherapy, and combined MTX and EZP therapy were administered to collagen induced arthritis rats, followed by assessment of pathological score, bone damage, bone alkaline phosphatases (BALP), and tartrate resistant acid phosphatase (TRACP), and of gene levels related to the Wnt1/LRP5/beta catenin pathway according to network pharmacological analysis. Finally, serum samples from MTX , EZP  and MTX+EZP treated rats were used to treat the rat osteoblast (OB) like UMR 106 cell line to evaluate gene levels related to Wnt1/LRP5/beta catenin. Network pharmacological analysis showed that the Wnt/beta catenin signaling pathway was the top signaling pathway shared among MTX, EZP, and RA. The results from in vivo experiments indicated that EZP combined with MTX reduced arthritis severity, alleviated ankle bone damage, increased BALP and decreased TRACP serum levels, and regulated the mRNA expression of Wnt1, LRP5, beta catenin, Runx2, BALP, and BGP in the ankles. In vitro experiments showed that EZP combined with MTX could also improve the expression of genes related to the Wnt1/LRP5/beta catenin pathway. This study demonstrated that EZP in combination with MTX played a synergistic role in regulating OBs in RA, which was connected to the modulatory effect of EZP and MTX on the Wnt1/LRP5/beta catenin signaling pathway.
C1 [Li, Xiaoya; Xiao, Cheng] China Japan Friendship Hosp, Dept Emergency, Beijing, Peoples R China.
   [Li, Xiaoya; Lu, Xiangcheng; Fan, Danping; Xia, Ya; Xiao, Cheng] China Japan Friendship Hosp, Inst Clin Med, Beijing, Peoples R China.
   [Li, Xiaoya; Fan, Danping; Xiao, Cheng] Chinese Acad Med Sci, Peking Union Med Coll, Grad Sch, Beijing, Peoples R China.
   [Lu, Xiangcheng; Xia, Ya] Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing, Peoples R China.
   [Li, Li; Lu, Cheng; Tan, Yong] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China.
   [Zhao, Hongyan] China Acad Chinese Med Sci, Beijing Key Lab Res Chinese Med Prevent & Treatme, Expt Res Ctr, Beijing, Peoples R China.
   [Fan, Miaoxuan] Beijing Inst Drug Control, NMPA Key Lab Qual Evaluat Tradit Chinese Med Trad, Beijing Key Lab Anal & Evaluat Chinese Med, Beijing, Peoples R China.
C3 China Japan Friendship Hospital; China Japan Friendship Hospital;
   Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College; Beijing University of Chinese Medicine;
   Institute of Basic Research In Clinical Medicine, CACMS; China Academy
   of Chinese Medical Sciences; China Academy of Chinese Medical Sciences;
   Experimental Research Center, CACMS
RP Xiao, C (通讯作者)，China Japan Friendship Hosp, Dept Emergency, Beijing, Peoples R China.; Xiao, C (通讯作者)，China Japan Friendship Hosp, Inst Clin Med, Beijing, Peoples R China.; Xiao, C (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll, Grad Sch, Beijing, Peoples R China.
EM xc2002812@126.com
RI Xiao, Cheng/AAM 7764 2020; Li, Xiaoya/Y 8476 2019
OI xiao, Cheng/0000 0002 5601 9670
CR Abasolo L, 2019, CLIN RHEUMATOL, V38, P691, DOI 10.1007/s10067 018 4335 4
   Alabarse PVG, 2018, J CACHEXIA SARCOPENI, V9, P603, DOI 10.1002/jcsm.12280
   [Anonymous], 2012, EVID BASED COMPL ALT
   Bijlsma JWJ, 2016, RHEUMATOLOGY, V55, P3, DOI 10.1093/rheumatology/kew344
   Chang MK, 2014, J BONE MINER RES, V29, P29, DOI 10.1002/jbmr.2059
   Cheng M, 2011, J ETHNOPHARMACOL, V138, P279, DOI 10.1016/j.jep.2011.09.030
   Daans M, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2518
   Davies JH, 2003, J CLIN ENDOCR METAB, V88, P6088, DOI 10.1210/jc.2003 030712
   Davies JH, 2002, CALCIFIED TISSUE INT, V70, P408, DOI 10.1007/s002230020039
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hazlewood GS, 2016, BMJ BRIT MED J, V353, DOI 10.1136/bmj.i1777
   He B, 2016, J CELL MOL MED, V20, P2231, DOI 10.1111/jcmm.12930
   Huang MC, 2015, J ETHNOPHARMACOL, V176, P9, DOI 10.1016/j.jep.2015.10.024
   Jiang ZW, 2017, ACS APPL MATER INTER, V9, P34674, DOI 10.1021/acsami.7b10184
   Jung SM, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/263625
   Kanagawa H, 2016, J BONE MINER METAB, V34, P526, DOI 10.1007/s00774 015 0702 2
   Kato G, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0753 8
   Khilfeh I, 2019, J MANAG CARE SPEC PH, V25, P461, DOI 10.18553/jmcp.2019.25.4.461
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Le Henaff C, 2015, J BIOL CHEM, V290, P18009, DOI 10.1074/jbc.M115.646208
   Li XL, 2019, FASEB J, V33, P8913, DOI 10.1096/fj.201802711R
   Liang WN, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/9210490
   Linder CH, 2017, CALCIFIED TISSUE INT, V101, P92, DOI 10.1007/s00223 017 0259 2
   Peres RS, 2015, P NATL ACAD SCI USA, V112, P2509, DOI 10.1073/pnas.1424792112
   Rufus P, 2013, CURR DRUG TARGETS, V14, P1689, DOI 10.2174/1389450114666131220160357
   Sindhavajiva PR, 2018, J CELL BIOCHEM, V119, P3474, DOI 10.1002/jcb.26519
   Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis 2016 210715
   Sun W, 2014, J HUAZHONG U SCI MED, V34, P114, DOI 10.1007/s11596 014 1241 0
   Swierkot J, 2015, ARCH IMMUNOL THER EX, V63, P397, DOI 10.1007/s00005 015 0338 x
   Takeuchi T, 2016, ANN RHEUM DIS, V75, P983, DOI 10.1136/annrheumdis 2015 208052
   Tarp S, 2017, RHEUMATOLOGY, V56, P417, DOI 10.1093/rheumatology/kew442
   Wang Q, 2019, EUR REV MED PHARMACO, V23, P4541, DOI 10.26355/eurrev_201906_18029
   Wang WY, 2018, EUR J MED CHEM, V158, P502, DOI 10.1016/j.ejmech.2018.09.027
   Wu N, 2014, CLIN THER, V36, P1231, DOI 10.1016/j.clinthera.2014.06.014
   Zhang H, 2008, MATURITAS, V61, P334, DOI 10.1016/j.maturitas.2008.09.023
   Zhang WJ, 2016, CURR PHARM DESIGN, V22, P3171, DOI 10.2174/1381612822666160224142812
   Zhang YQ, 2015, ACTA PHARMACOL SIN, V36, P724, DOI 10.1038/aps.2014.124
   Zhao HY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00262
   Zhao HY, 2017, INT IMMUNOPHARMACOL, V51, P114, DOI 10.1016/j.intimp.2017.08.013
   Zhao N, 2015, ACTA PHARMACOL SIN, V36, P716, DOI 10.1038/aps.2015.15
   Zheng CS, 2016, EXP THER MED, V12, P87, DOI 10.3892/etm.2016.3329
NR 42
TC 14
Z9 15
U1 5
U2 43
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 11
PY 2020
VL 11
AR 228
DI 10.3389/fphar.2020.00228
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA LE6XX
UT WOS:000526868100001
PM 32218732
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liu, J
   Li, DF
   Wu, XH
   Dang, L
   Lu, AP
   Zhang, G
AF Liu, Jin
   Li, Defang
   Wu, Xiaohao
   Dang, Lei
   Lu, Aiping
   Zhang, Ge
TI Bone derived exosomes
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID MESENCHYMAL STEM CELLS; EXTRACELLULAR VESICLES; MARROW; DIFFERENTIATION;
   OSTEOBLASTS; MECHANISM; COMMUNICATION; MICROVESICLES; REGENERATION;
   OSTEOCLASTS
AB Exosomes are endosomal derived vesicles secreted by a wide range of cell types for transporting functional proteins, microRNAs (miRNAs) and messenger RNAs (mRNA) from their parental cells to affect the recipient cells. Emerging evidence indicates that exosomes also play an important role in the intercellular communication among the bone cells, that is, osteoblasts, osteoclasts and bone marrow stromal cells, within bone microenvironment. Here, we reviewed the local and systemic effects of bone derived exosomes, and discussed the potential of exosomes as targeted delivery systems for molecular therapy in skeletal disorders.
C1 [Liu, Jin; Wu, Xiaohao; Dang, Lei; Lu, Aiping; Zhang, Ge] Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong, Hong Kong, Peoples R China.
   [Li, Defang] Binzhou Med Univ, Yantai, Peoples R China.
C3 Binzhou Medical University
RP Zhang, G (通讯作者)，Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong, Hong Kong, Peoples R China.
EM zhangge@hkbu.edu.hk
RI LU, Aiping/JDX 0577 2023; Xiaohao, Wu/HNI 5943 2023; Zhang,
   Ge/N 4150 2013
OI Li, Defang/0000 0003 4151 9151; Liu, Jin/0000 0001 6308 6719
FU Ministry of Science and Technology of China [2013ZX09301307]; Hong Kong
   General Research Fund [HKBU479111, HKBU478312, HKBU262913, HKBU12102914,
   HKBU261113]; Natural Science Foundation Council of China [81272045];
   Research Grants Council and Natural Science Foundation Council of China
   [N_HKBU435/12]; Croucher Foundation [CAS14BU/CAS14201];
   Interdisciplinary Research Matching Scheme (IRMS) of Hong Kong Baptist
   University [RC IRMS/12 13/02, RC IRMS/13 14/02]; Hong Kong Baptist
   University Strategic Development Fund [SDF13 1209 P01]; Hong Kong
   Research Grants Council Early Career Scheme [489213];
   Inter institutional Collaborative Research Scheme of Hong Kong Baptist
   University [RC ICRS/14 15/01]; Faculty Research Grant of Hong Kong
   Baptist University [FRG1/13 14/024, FRG2/13 14/006, FRG2/14 15/010]
FX This work was supported by the Ministry of Science and Technology of
   China (2013ZX09301307 to A.L.), the Hong Kong General Research Fund
   (HKBU479111 to G.Z., HKBU478312 to G.Z., HKBU262913 to G.Z.,
   HKBU12102914 to G.Z., HKBU261113 to A.L), the Natural Science Foundation
   Council of China (81272045 to G.Z.), the Research Grants Council and
   Natural Science Foundation Council of China (N_HKBU435/12 to G.Z.), the
   Croucher Foundation (Gnt#CAS14BU/CAS14201 to G.Z.), the
   Interdisciplinary Research Matching Scheme (IRMS) of Hong Kong Baptist
   University (RC IRMS/12 13/02 to A.L. and RC IRMS/13 14/02 to G.Z.), the
   Hong Kong Baptist University Strategic Development Fund (SDF13 1209 P01
   to A.L.), the Hong Kong Research Grants Council Early Career Scheme
   (489213 to G.Z.), the Inter institutional Collaborative Research Scheme
   of Hong Kong Baptist University (RC ICRS/14 15/01 to G.Z.), the Faculty
   Research Grant of Hong Kong Baptist University (FRG1/13 14/024 to G.Z.,
   FRG2/13 14/006 to G.Z. and FRG2/14 15/010 to G.Z.).
CR Abdi J, 2014, BIOMARK RES, V2, DOI 10.1186/2050 7771 2 10
   Amigorena S., 2006, CURR PROTOC CELL BIO
   [Anonymous], BONEKEY REP
   Armstrong J.K., 2003, BLOOD, V102
   Baglio SR, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0116 z
   Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413
   Braicu C, 2015, CELL DEATH DIFFER, V22, P34, DOI 10.1038/cdd.2014.130
   Buehring B, 2013, CURR OSTEOPOROS REP, V11, P407, DOI 10.1007/s11914 013 0160 5
   Cui YZ, 2016, FEBS LETT, V590, P185, DOI 10.1002/1873 3468.12024
   Deng LL, 2015, BONE, V79, P37, DOI 10.1016/j.bone.2015.05.022
   Ekström K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075227
   Ge M, 2015, BIOCHEM BIOPH RES CO, V467, P27, DOI 10.1016/j.bbrc.2015.09.135
   Huynh N, 2016, J DENT RES, V95, P673, DOI 10.1177/0022034516633189
   Koppers Lalic D, 2013, ADV DRUG DELIVER REV, V65, P348, DOI 10.1016/j.addr.2012.07.006
   Kordelas L, 2014, LEUKEMIA, V28, P970, DOI 10.1038/leu.2014.41
   Leger RM, 2001, TRANSFUSION, V41, p29S
   Lener T, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.30087
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Lin Z, 2016, BONE, V88, P47, DOI 10.1016/j.bone.2016.03.018
   Liu J, 2016, AGING CELL
   Malda J, 2016, NAT REV RHEUMATOL, V12, P243, DOI 10.1038/nrrheum.2015.170
   Martin PJ, 2015, BMC CELL BIOL, V16, DOI 10.1186/s12860 015 0057 5
   Martins M, 2016, STEM CELL REP, V6, P284, DOI 10.1016/j.stemcr.2016.01.001
   Morhayim J, 2015, FASEB J, V29, P274, DOI 10.1096/fj.14 261404
   Ono M, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005231
   Peterson MF, 2015, METHODS, V87, P31, DOI 10.1016/j.ymeth.2015.04.015
   Qin YW, 2017, J BIOL CHEM, V292, P11021, DOI 10.1074/jbc.M116.770941
   Qin YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050712
   Qin YH, 2016, SCI REP UK, V6, DOI 10.1038/srep21961
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517
   Sato M, 2017, BIOMED REP, V6, P223, DOI 10.3892/br.2016.824
   Schneider A, 2013, CELL TISSUE RES, V352, P33, DOI 10.1007/s00441 012 1428 2
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15
   Takagi K, 2008, J BONE MINER METAB, V26, P13, DOI 10.1007/s00774 007 0787 3
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Xu JF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114627
   Yáñez Mó M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066
   Yang M, 2011, MOL CANCER, V10, DOI 10.1186/1476 4598 10 117
   Yoon J, 2015, BIOMATERIALS, V59, P12, DOI 10.1016/j.biomaterials.2015.04.028
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
NR 43
TC 40
Z9 44
U1 0
U2 18
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471 4892
EI 1471 4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD JUN
PY 2017
VL 34
BP 64
EP 69
DI 10.1016/j.coph.2017.08.008
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FR9TT
UT WOS:000419416700010
PM 28881252
DA 2025 08 17
ER

PT J
AU Yu, Z
   Surface, LE
   Park, CY
   Horlbeck, MA
   Wyant, GA
   Abu Remaileh, M
   Peterson, TR
   Sabatini, DM
   Weissman, JS
   O'Shea, EK
AF Yu, Zhou
   Surface, Lauren E.
   Park, Chong Yon
   Horlbeck, Max A.
   Wyant, Gregory A.
   Abu Remaileh, Monther
   Peterson, Timothy R.
   Sabatini, David M.
   Weissman, Jonathan S.
   O'Shea, Erin K.
TI Identification of a transporter complex responsible for the cytosolic
   entry of nitrogen containing bisphosphonates
SO ELIFE
LA English
DT Article
ID FARNESYL DIPHOSPHATE SYNTHASE; IN VIVO; MEVALONATE PATHWAY;
   BONE RESORPTION; AMINO ACIDS; PROTEIN; MECHANISM; APOPTOSIS; DRUGS;
   PRENYLATION
AB Nitrogen containing bisphosphonates (N BPs) are a class of drugs widely prescribed to treat osteoporosis and other bone related diseases. Although previous studies have established that N BPs function by inhibiting the mevalonate pathway in osteoclasts, the mechanism by which N BPs enter the cytosol from the extracellular space to reach their molecular target is not understood. Here, we implemented a CRISPRi mediated genome wide screen and identified SLC37A3 (solute carrier family 37 member A3) as a gene required for the action of N BPs in mammalian cells. We observed that SLC37A3 forms a complex with ATRAID (all trans retinoic acid induced differentiation factor), a previously identified genetic target of N BPs. SLC37A3 and ATRAID localize to lysosomes and are required for releasing N BP molecules that have trafficked to lysosomes through fluid phase endocytosis into the cytosol. Our results elucidate the route by which N BPs are delivered to their molecular target, addressing a key aspect of the mechanism of action of N BPs that may have significant clinical relevance.
C1 [Yu, Zhou; Surface, Lauren E.; O'Shea, Erin K.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
   [Yu, Zhou; O'Shea, Erin K.] Howard Hughes Med Inst, Janelia Res Campus, Ashburn, VA USA.
   [Surface, Lauren E.; O'Shea, Erin K.] Harvard Univ, Ctr Syst Biol, Fac Arts & Sci, Cambridge, MA 02138 USA.
   [Surface, Lauren E.; O'Shea, Erin K.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
   [Surface, Lauren E.; Horlbeck, Max A.; Wyant, Gregory A.; Abu Remaileh, Monther; Sabatini, David M.; Weissman, Jonathan S.; O'Shea, Erin K.] Howard Hughes Med Inst, Bethesda, MD 20817 USA.
   [Park, Chong Yon; Horlbeck, Max A.; Weissman, Jonathan S.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.
   [Horlbeck, Max A.; Weissman, Jonathan S.] Univ Calif San Francisco, Ctr RNA Syst Biol, San Francisco, CA 94143 USA.
   [Wyant, Gregory A.; Abu Remaileh, Monther; Sabatini, David M.] Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
   [Wyant, Gregory A.; Abu Remaileh, Monther; Sabatini, David M.] MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Wyant, Gregory A.; Abu Remaileh, Monther; Sabatini, David M.] Koch Inst Integrat Canc Res, Cambridge, MA USA.
   [Wyant, Gregory A.; Abu Remaileh, Monther; Sabatini, David M.] Broad Inst MIT & Harvard, Cambridge, MA USA.
   [Peterson, Timothy R.] Washington Univ, Sch Med, Inst Publ Hlth, Div Bone & Mineral Dis Dept Genet, St Louis, MO USA.
C3 Harvard University; Howard Hughes Medical Institute; Harvard University;
   Harvard University; Howard Hughes Medical Institute; University of
   California System; University of California San Francisco; University of
   California System; University of California San Francisco; Massachusetts
   Institute of Technology (MIT); Whitehead Institute; Massachusetts
   Institute of Technology (MIT); Harvard University; Massachusetts
   Institute of Technology (MIT); Broad Institute; Washington University
   (WUSTL)
RP O'Shea, EK (通讯作者)，Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.; O'Shea, EK (通讯作者)，Howard Hughes Med Inst, Janelia Res Campus, Ashburn, VA USA.; O'Shea, EK (通讯作者)，Harvard Univ, Ctr Syst Biol, Fac Arts & Sci, Cambridge, MA 02138 USA.; O'Shea, EK (通讯作者)，Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.; O'Shea, EK (通讯作者)，Howard Hughes Med Inst, Bethesda, MD 20817 USA.
EM osheae@hhmi.org
RI ; sabatini, david/JJC 2011 2023; Abu Remaileh, Monther/M 3747 2016
OI Weissman, Jonathan/0000 0003 2445 670X; Yu, Zhou/0000 0003 3213 4583;
   Horlbeck, Max/0000 0002 3875 871X; Abu Remaileh,
   Monther/0000 0003 3772 0477; Sabatini, David M./0000 0002 1446 7256;
   Surface, Lauren/0000 0003 4055 0237
FU Howard Hughes Medical Institute
FX Howard Hughes Medical Institute Zhou Yu Lauren E Surface Chong Yon Park
   Max A Horlbeck Gregory A Wyant Monther Abu Remaileh David M Sabatini
   Jonathan S Weissman Erin K O'SheaThe funders had no role in study
   design, data collection and interpretation, or the decision to submit
   the work for publication.
CR Abu Remaileh M, 2017, SCIENCE, V358, P807, DOI 10.1126/science.aan6298
   Chou JY, 2013, MOL ASPECTS MED, V34, P601, DOI 10.1016/j.mam.2012.05.010
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Ding XD, 2015, BIOCHEM BIOPH RES CO, V460, P915, DOI 10.1016/j.bbrc.2015.03.127
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029
   Horlbeck MA, 2016, ELIFE, V5, DOI 10.7554/eLife.19760
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Huttlin EL, 2017, NATURE, V545, P505, DOI 10.1038/nature22366
   Jost M, 2017, MOL CELL, V68, P210, DOI 10.1016/j.molcel.2017.09.012
   Kampmann M, 2013, P NATL ACAD SCI USA, V110, pE2317, DOI 10.1073/pnas.1307002110
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Liu XY, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002373
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Makrides V, 2014, COMPR PHYSIOL, V4, P367, DOI 10.1002/cphy.c130028
   Martín D, 2007, BBA MOL CELL RES, V1773, P419, DOI 10.1016/j.bbamcr.2006.11.015
   Pan CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023157
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Roca Ayats N, 2017, NEW ENGL J MED, V376, P1794, DOI 10.1056/NEJMc1612804
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Tiwari V, 2014, EUR J PHARMACOL, V741, P156, DOI 10.1016/j.ejphar.2014.07.048
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Wyant GA, 2017, CELL, V171, P642, DOI 10.1016/j.cell.2017.09.046
NR 26
TC 35
Z9 38
U1 0
U2 14
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD MAY 10
PY 2018
VL 7
AR e36620
DI 10.7554/eLife.36620
PG 20
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA GK9CB
UT WOS:000436533400001
PM 29745899
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Tao, ZS
   Wu, XJ
   Yang, M
   Shen, CL
AF Tao, Zhou Shan
   Wu, Xing Jing
   Yang, Min
   Shen, Cai Liang
TI Astaxanthin prevents bone loss in osteoporotic rats with palmitic acid
   through suppressing oxidative stress
SO REDOX REPORT
LA English
DT Article
DE Astaxanthin; Osteoporosis; Palmitic acid; Oxidative stress; Bone
   metabolism
ID PARATHYROID HORMONE 1 34; DIABETES MELLITUS; TITANIUM RODS;
   OSSEOINTEGRATION; PATHWAY; MARROW; REPAIR
AB Objectives: The study aimed to assess the role of Astaxanthin (ATX) in palmitic acid(PA)  induced bone loss in Ovariectomized(OVX) rats. Methods: In the OVX rat model, we observed that PA affects bone metabolism and accelerates bone loss. Additionally, treatment with ATX was able to suppress the deleterious effects of PA and a simultaneous decrease in serum MDA levels and an increase in SOD was observed. Results: In addition, rats treated with ATX were observed to have significantly increased bone mass and elevated activity of SIRT1 and SOD2 in bone tissue. When MC3T3 E1 and RAW264.7 cells induced osteoblast and osteoclast differentiation, the ATX intervention was able to significantly restore the restriction of osteogenic differentiation and the up regulation of osteoclast differentiation with PA therapy. Furthermore, we confirm that PA damage to cells is caused by increased oxidative stress, and that ATX can target and modulate the activity of SIRT1 to regulate the levels of oxidative stress in cells. Conclusion: Summarizing, ATX may inhibit PA induced bone loss through its antioxidant properties via the SIRT1 signaling pathway.
   [GRAPHICS]
C1 [Tao, Zhou Shan; Wu, Xing Jing; Yang, Min] Wannan Med Coll, Yijishan Hosp, Dept Orthoped, Affiliated Hosp 1, 2,Zhe Shan Xi Rd, Wuhu, Anhui, Peoples R China.
   [Tao, Zhou Shan] Anhui Prov Key Lab Noncoding RNA Basic & Clin Tran, 2,Zhe Shan Xi Rd, Wuhu, Anhui, Peoples R China.
   [Tao, Zhou Shan; Shen, Cai Liang] Anhui Med Univ, Dept Spinal Surg, Affiliated Hosp 1, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China.
C3 Wannan Medical College; Anhui Medical University
RP Shen, CL (通讯作者)，Anhui Med Univ, Dept Spinal Surg, Affiliated Hosp 1, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China.
EM SCL20231990@126.com
RI Feng, yin/JQI 8627 2023
OI tao, zhoushan/0000 0001 6300 9289
FU Health Research Project of Anhui Province10.13039/501100009558
   [AHWJ2023A20550]; Health Research Project of Anhui Province [2022jc61];
   Wuhu Science and Technology Project [2023AH020050]; Outstanding Youth
   Project of Anhui University Natural Science [KJ2021A0822]; Anhui
   University Natural Science Key Project
FX This study was supported by a grant from Health Research Project of
   Anhui Province (AHWJ2023A20550), Wuhu Science and Technology Project
   (2022jc61), Outstanding Youth Project of Anhui University Natural
   Science (2023AH020050) and Anhui University Natural Science Key Project
   (KJ2021A0822).
CR Benlarbi Ben Khedher M, 2019, FOOD SCI NUTR, V7, P3979, DOI 10.1002/fsn3.1259
   D'Amelio P, 2008, BONE, V43, P1010, DOI 10.1016/j.bone.2008.08.107
   Gabet Y, 2008, J BONE MINER RES, V23, P48, DOI 10.1359/JBMR.070901
   Griffith JF, 2009, BONE, V44, P1092, DOI 10.1016/j.bone.2009.02.022
   Gwak Y, 2014, J EXP BOT, V65, P4317, DOI 10.1093/jxb/eru206
   Hoffmann DB, 2016, MOL THER NUCL ACIDS, V5, DOI 10.1038/mtna.2016.15
   Hoshi H, 2020, BIOCHEM BIOPH RES CO, V527, P270, DOI 10.1016/j.bbrc.2020.04.013
   Ji SY, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.29
   Jing XZ, 2019, J CELL PHYSIOL, V234, P10123, DOI 10.1002/jcp.27678
   Kim J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127970
   Kim SK, 2020, ORTHOP SURG, V12, P388, DOI 10.1111/os.12589
   Koka S, 2014, AM J PHYSIOL HEART C, V306, pH1558, DOI 10.1152/ajpheart.00865.2013
   Leitch JW, 1997, HEART, V78, P166, DOI 10.1136/hrt.78.2.166
   Li HQ, 2017, HUM MOL GENET, V26, P2701, DOI 10.1093/hmg/ddx158
   Li XM, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23063008
   Li XM, 2021, J CELL MOL MED, V25, P11278, DOI 10.1111/jcmm.17054
   Li YF, 2013, OSTEOPOROSIS INT, V24, P1063, DOI 10.1007/s00198 012 2258 5
   Liu JQ, 2016, APPL BIOCHEM BIOTECH, V178, P1015, DOI 10.1007/s12010 015 1925 3
   Ma LN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127849
   Mamun Or Rashid ANM, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10010054
   Meng HZ, 2015, J BIOL CHEM, V290, P28189, DOI 10.1074/jbc.M115.669499
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Schwartz AV, 2003, CALCIFIED TISSUE INT, V73, P515, DOI 10.1007/s00223 003 0023 7
   Sun L, 2019, PAK J MED SCI, V35, P691, DOI 10.12669/pjms.35.3.84
   Sun XL, 2020, J ORTHOP TRANSL, V24, P76, DOI 10.1016/j.jot.2020.04.007
   Tao ZS, 2023, J MATER SCI MATER M, V34, DOI 10.1007/s10856 022 06708 w
   Tao ZS, 2022, CHEM BIOL INTERACT, V366, DOI 10.1016/j.cbi.2022.110168
   Tao ZS, 2022, J MATER SCI MATER M, V33, DOI 10.1007/s10856 022 06684 1
   Tao ZS, 2022, MOL MED, V28, DOI 10.1186/s10020 022 00503 7
   Tao ZS, 2022, J MATER SCI MATER M, V33, DOI 10.1007/s10856 021 06627 2
   Tao ZS, 2021, J ORTHOP TRANSL, V27, P67, DOI 10.1016/j.jot.2020.10.006
   Tao ZS, 2016, Z GERONTOL GERIATR, V49, P423, DOI 10.1007/s00391 015 0949 1
   Tao ZS, 2016, J BIOMATER APPL, V30, P952, DOI 10.1177/0885328215610898
   Tao ZS, 2022, CALCIFIED TISSUE INT, V110, P723, DOI 10.1007/s00223 021 00936 y
   Wako Y, 2021, J APPL TOXICOL, V41, P1304, DOI 10.1002/jat.4118
   Xu DJ, 2020, J PINEAL RES, V69, DOI 10.1111/jpi.12690
   Xue XL, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 016 0464 3
   Yang J, 2018, EXP THER MED, V16, P3686, DOI 10.3892/etm.2018.6601
   Zhang YZ, 2020, CALCIFIED TISSUE INT, V107, P474, DOI 10.1007/s00223 020 00741 z
   Zheng XW, 2018, FRONT NEUROSCI SWITZ, V12, DOI 10.3389/fnins.2018.00911
   Zhou MS, 2022, BONE JOINT RES, V11, P751, DOI 10.1302/2046 3758.1111.BJR 2022 0017.R2
NR 41
TC 8
Z9 8
U1 2
U2 32
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1351 0002
EI 1743 2928
J9 REDOX REP
JI Redox Rep.
PD DEC 31
PY 2024
VL 29
IS 1
AR 2333096
DI 10.1080/13510002.2024.2333096
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA OE8F4
UT WOS:001205673800001
PM 38623993
OA gold
DA 2025 08 17
ER

PT J
AU Chiu, YG
   Ritchlin, CT
AF Chiu, Yahui Grace
   Ritchlin, Christopher T.
TI Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE Denosumab; rheumatoid arthritis; RANKL; osteoclast
ID BONE MINERAL DENSITY; TUMOR NECROSIS FACTOR; ADVANCED BREAST CANCER;
   REGULATES OSTEOCLAST DIFFERENTIATION; KAPPA B LIGAND; POSTMENOPAUSAL
   WOMEN; DOUBLE BLIND; T CELLS; OSTEOPROTEGERIN LIGAND; VERTEBRAL
   FRACTURES
AB Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by focal pathologic bone resorption due to excessive activity of osteoclasts (OC). Receptor activator of nuclear factor kappa B ligand (RANKL) is essential for the proliferation, differentiation, and survival of OC. Denosumab (DMab) is a humanized monoclonal antibody that binds to RANKL with high affinity and blocks its subsequent association with its receptor RANK on the surface of OC precursors.
   Area covered: The authors review the molecular and cellular mechanisms underlying therapeutic applications of DMab, provide recent highlights on pharmacology, efficacy and safety of DMab, and discuss the potential of DMab as a novel therapeutic option for the treatment of rheumatoid arthritis.
   Expert opinion: Clinical results suggest that DMab is efficient both in systemic and articular bone loss in RA with limited side effects. Diminished bone erosion activity was also noted in RA patients on corticosteroids and bisphosphonates. Combination of DMab with an anti TNF agent was not associated with increased infection rates. Collectively, these data indicate that DMab, in combination with methotrexate and possibly other conventional synthetic Disease Modifying Anti Rheumatic Drugs (csDMARDs), is an effective, safe and cost effective option for the treatment of RA.
C1 [Chiu, Yahui Grace; Ritchlin, Christopher T.] Univ Rochester, Dept Med, Div Allergy Immunol & Rheumatol, Rochester, NY 14642 USA.
C3 University of Rochester
RP Ritchlin, CT (通讯作者)，Univ Rochester, Dept Med, Div Allergy Immunol & Rheumatol, Rochester, NY 14642 USA.
EM Christopher_Ritchlin@urmc.rochester.edu
OI ritchlin, christopher/0000 0002 2602 1219
FU National Institutes of Health [R01 AR069000 01]
FX The authors are funded by National Institutes of Health [Grant Number:
   R01 AR069000 01].
CR Adami G, 2016, CALCIFIED TISSUE INT, V99, P360, DOI 10.1007/s00223 016 0161 3
   Adami S, 2012, J BONE JOINT SURG AM, V94A, P2113, DOI 10.2106/JBJS.K.00774
   Anandarajah A, 2014, J RHEUMATOL, V41, P2153, DOI 10.3899/jrheum.140411
   [Anonymous], 2013, Case Rep Rheumatol, DOI DOI 10.1155/2013/249872
   Ashcroft AJ, 2003, IMMUNITY, V19, P849, DOI 10.1016/S1074 7613(03)00326 1
   Bachmann MF, 1999, J EXP MED, V189, P1025, DOI 10.1084/jem.189.7.1025
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201
   Baud'huin M, 2007, CELL MOL LIFE SCI, V64, P2334, DOI 10.1007/s00018 007 7104 0
   Baum R, 2016, CLIN REV ALLERG IMMU, V51, P1, DOI 10.1007/s12016 015 8515 6
   Bengtsson ÅK, 2002, CRIT REV IMMUNOL, V22, P201
   Body JJ, 2015, EUR J CANCER, V51, P1812, DOI 10.1016/j.ejca.2015.05.016
   Boers M, 1997, Ned Tijdschr Geneeskd, V141, P2428
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Brown AK, 2006, ARTHRITIS RHEUM, V54, P3761, DOI 10.1002/art.22190
   Brown JE, 2012, NAT REV CLIN ONCOL, V9, P110, DOI 10.1038/nrclinonc.2011.197
   Brown Glaberman U, 2013, CLIN PHARMACOL ADV A, V5, P117, DOI 10.2147/CPAA.S30330
   Castellano D, 2011, ONCOLOGIST, V16, P136, DOI 10.1634/theoncologist.2010 0154
   Chiu YH, 2012, J BONE MINER RES, V27, P79, DOI 10.1002/jbmr.531
   Cleeland CS, 2013, CANCER AM CANCER SOC, V119, P832, DOI 10.1002/cncr.27789
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Curtis JR, 2015, ARTHRITIS RHEUMATOL, V67, P1456, DOI 10.1002/art.39075
   Povoa RCD, 2016, SPEC CARE DENT, V36, P231, DOI 10.1111/scd.12168
   Deodhar A, 2010, ARTHRIT CARE RES, V62, P569, DOI 10.1002/acr.20004
   Di Nisio C, 2015, EUR J HISTOCHEM, V59, P45, DOI 10.4081/ejh.2015.2455
   Diedhiou D, 2015, ANN ENDOCRINOL PARIS, V76, P650, DOI 10.1016/j.ando.2015.10.009
   Dohn UM, 2009, ANN RHEUM DIS, V68, P1585, DOI 10.1136/ard.2008.097048
   Dore RK, 2011, RHEUM DIS CLIN N AM, V37, P433, DOI 10.1016/j.rdc.2011.07.004
   Dore RK, 2010, ANN RHEUM DIS, V69, P872, DOI 10.1136/ard.2009.112920
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Edrees AF, 2005, CLIN EXP RHEUMATOL, V23, P469
   Edwards BJ, 2016, OSTEOPOROSIS INT, V27, P499, DOI 10.1007/s00198 015 3246 3
   Edwards BJ, 2016, J BONE MINER RES, V31, P1569, DOI 10.1002/jbmr.2818
   Gatti D, 2012, J BONE MINER RES, V27, P2259, DOI 10.1002/jbmr.1681
   Green EA, 2002, IMMUNITY, V16, P183, DOI 10.1016/S1074 7613(02)00279 0
   Hasegawa T, 2017, JOINT BONE SPINE, V84, P379, DOI 10.1016/j.jbspin.2016.05.010
   Hazlewood GS, 2016, BMJ BRIT MED J, V353, DOI 10.1136/bmj.i1777
   Helas S, 2009, AM J PATHOL, V175, P473, DOI 10.2353/ajpath.2009.080957
   Hensvold AH, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0760 9
   Hoyer Kuhn H, 2016, J MUSCULOSKEL NEURON, V16, P24
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Humphrey MB, 2005, IMMUNOL REV, V208, P50, DOI 10.1111/j.0105 2896.2005.00325.x
   Humphrey MB, 2006, J BONE MINER RES, V21, P237, DOI 10.1359/JBMR.051016
   Iolascon G, 2013, CLIN CASES MINER BON, V10, P47, DOI 10.11138/ccmbm/2013.10.1.047
   Kanzaki H, 2016, REDOX BIOL, V8, P186, DOI 10.1016/j.redox.2016.01.006
   Kelesidis T, 2014, AIDS REV, V16, P123
   Kiechl Stefan, 2006, Expert Rev Cardiovasc Ther, V4, P801, DOI 10.1586/14779072.4.6.801
   Kikuta J, 2013, J CLIN INVEST, V123, P866, DOI 10.1172/JCI65054
   Kinoshita H, 2017, MOD RHEUMATOL, V27, P582, DOI 10.1080/14397595.2016.1232776
   Kleyer A, 2014, ANN RHEUM DIS, V73, P854, DOI 10.1136/annrheumdis 2012 202958
   Kohli Sarvraj Singh, 2011, Indian J Endocrinol Metab, V15, P175, DOI 10.4103/2230 8210.83401
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kostenuik PJ, 2015, J BONE MINER RES, V30, P657, DOI 10.1002/jbmr.2401
   Kyrgidis A, 2011, OSTEOPOROSIS INT, V22, P369, DOI 10.1007/s00198 010 1177 6
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Langdahl BL, 2015, J CLIN ENDOCR METAB, V100, P1335, DOI 10.1210/jc.2014 4079
   Laskowski LK, 2016, J MED TOXICOL, V12, P305, DOI 10.1007/s13181 016 0543 y
   Li CH, 2016, INFLAMM RES, V65, P193, DOI 10.1007/s00011 015 0905 y
   Loser K, 2006, NAT MED, V12, P1372, DOI 10.1038/nm1518
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Malan J, 2012, OR SURG OR MED OR PA, V114, P671, DOI 10.1016/j.oooo.2012.08.439
   MANICOURT DH, 1993, ARTHRITIS RHEUM, V36, P490, DOI 10.1002/art.1780360409
   Martin M, 2012, CLIN CANCER RES, V18, P4841, DOI 10.1158/1078 0432.CCR 11 3310
   Matsushita Y, 2016, MOL CLIN ONCOL, V4, P191, DOI 10.3892/mco.2015.696
   Meednu N, 2016, ARTHRITIS RHEUMATOL, V68, P805, DOI 10.1002/art.39489
   Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875 009 9316 6
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Nicolin Vanessa, 2016, Italian Journal of Anatomy and Embryology, V121, P37, DOI 10.13128/IJAE 18342
   Nimmerjahn F, 2007, ADV IMMUNOL, V96, P179, DOI 10.1016/S0065 2776(07)96005 8
   O'Halloran M, 2014, AUST DENT J, V59, P516, DOI 10.1111/adj.12217
   Okada N, 2013, BIOL PHARM BULL, V36, P1622, DOI 10.1248/bpb.b13 00496
   Onal M, 2012, J BIOL CHEM, V287, P29851, DOI 10.1074/jbc.M112.377945
   Ostertag A, 2009, BONE, V44, P413, DOI 10.1016/j.bone.2008.11.004
   Panizo S, 2009, CIRC RES, V104, P1041, DOI 10.1161/CIRCRESAHA.108.189001
   Papapoulos S, 2015, OSTEOPOROSIS INT, V26, P2773, DOI 10.1007/s00198 015 3234 7
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Pichardo SEC, 2016, OR SURG OR MED OR PA, V122, P272, DOI 10.1016/j.oooo.2016.03.008
   Popp AW, 2016, OSTEOPOROSIS INT, V27, P1917, DOI 10.1007/s00198 015 3458 6
   Rodan G, 2004, CURR MED RES OPIN, V20, P1291, DOI 10.1185/030079904125004475
   Rossini M, 2015, CLIN EXP RHEUMATOL, V33, P77
   Rossini M, 2016, ENDOCRINE, V53, P857, DOI 10.1007/s12020 015 0723 6
   Rossini M, 2016, ANN RHEUM DIS, V75, pE70, DOI 10.1136/annrheumdis 2016 210022
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   SAKITO S, 1995, RHEUMATOL INT, V15, P31, DOI 10.1007/BF00286766
   Schett G, 2016, ANN RHEUM DIS, V75, P1428, DOI 10.1136/annrheumdis 2016 209201
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Selga J, 2016, OSTEOPOROSIS INT, V27, P827, DOI 10.1007/s00198 015 3355 z
   Sharp JT, 2010, ARTHRIT CARE RES, V62, P537, DOI 10.1002/acr.20172
   Sivolella S, 2013, ANTICANCER RES, V33, P1793
   Stopeck Alison, 2010, Clin Adv Hematol Oncol, V8, P159
   Stopeck AT, 2016, SUPPORT CARE CANCER, V24, P447, DOI 10.1007/s00520 015 2904 5
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeuchi T, 2016, ANN RHEUM DIS, V75, pE71, DOI 10.1136/annrheumdis 2016 210027
   Takeuchi T, 2016, ANN RHEUM DIS, V75, P983, DOI 10.1136/annrheumdis 2015 208052
   Teixeira MZ, 2012, HOMEOPATHY, V101, P231, DOI 10.1016/j.homp.2012.07.001
   Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109
   Törring O, 2015, THER ADV MUSCULOSKEL, V7, P88, DOI 10.1177/1759720X15579189
   Totsuka T, 2009, J IMMUNOL, V182, P6079, DOI 10.4049/jimmunol.0711823
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wang X, 2014, ONCOL LETT, V7, P1997, DOI 10.3892/ol.2014.1982
   Wang XF, 2013, MOL MED REP, V7, P1169, DOI 10.3892/mmr.2013.1335
   Wasilewska A, 2010, PEDIATR NEPHROL, V25, P2067, DOI 10.1007/s00467 010 1583 1
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Xue Y, 2016, AM J CLIN DERMATOL, V17, P147, DOI 10.1007/s40257 015 0167 z
   Yen J H, 1992, Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi, V25, P232
   Yeo L, 2015, ANN RHEUM DIS, V74, P928, DOI 10.1136/annrheumdis 2013 204116
   Yerram P, 2017, J ONCOL PHARM PRACT, V23, P179, DOI 10.1177/1078155216628325
   Yue J, 2017, ARTHRIT CARE RES, V69, P1156, DOI 10.1002/acr.23133
   Zaidi M, 2016, NAT MED, V22, P460, DOI 10.1038/nm.4104
   Zebaze R, 2016, J BONE MINER RES, V31, P1827, DOI 10.1002/jbmr.2855
   Zhou ZY, 2014, INT J CLIN EXP PATHO, V7, P2113
NR 117
TC 63
Z9 73
U1 0
U2 20
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471 2598
EI 1744 7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PY 2017
VL 17
IS 1
BP 119
EP 128
DI 10.1080/14712598.2017.1263614
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA EE5LE
UT WOS:000389648200009
PM 27871200
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Rhodes, SD
   Wu, XH
   He, YZ
   Chen, S
   Yang, H
   Staser, KW
   Wang, JP
   Zhang, P
   Jiang, C
   Yokota, H
   Dong, RZ
   Peng, XH
   Yang, XL
   Murthy, S
   Azhar, M
   Mohammad, KS
   Xu, MJ
   Guise, TA
   Yang, FC
AF Rhodes, Steven D.
   Wu, Xiaohua
   He, Yongzheng
   Chen, Shi
   Yang, Hao
   Staser, Karl W.
   Wang, Jiapeng
   Zhang, Ping
   Jiang, Chang
   Yokota, Hiroki
   Dong, Ruizhi
   Peng, Xianghong
   Yang, Xianlin
   Murthy, Sreemala
   Azhar, Mohamad
   Mohammad, Khalid S.
   Xu, Mingjiang
   Guise, Theresa A.
   Yang, Feng Chun
TI Hyperactive Transforming Growth Factor β1 Signaling Potentiates Skeletal
   Defects in a Neurofibromatosis Type 1 Mouse Model
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE TRANSFORMING GROWTH FACTOR BETA; TGF ; SMAD; NEUROFIBROMATOSIS TYPE 1;
   FRACTURE NONUNION; OSTEOPOROSIS
ID BONE MINERAL DENSITY; GROWTH FACTOR BETA; LOEYS DIETZ SYNDROME;
   TGF BETA; MARFAN SYNDROME; CONGENITAL PSEUDOARTHROSIS; TIBIAL
   PSEUDOARTHROSIS; OSTEOCLAST FUNCTIONS; DESCRIPTIVE ANALYSIS; DOUBLE
   INACTIVATION
AB Dysregulated transforming growth factor beta (TGF ) signaling is associated with a spectrum of osseous defects as seen in Loeys Dietz syndrome, Marfan syndrome, and Camurati Engelmann disease. Intriguingly, neurofibromatosis type 1 (NF1) patients exhibit many of these characteristic skeletal features, including kyphoscoliosis, osteoporosis, tibial dysplasia, and pseudarthrosis; however, the molecular mechanisms mediating these phenotypes remain unclear. Here, we provide genetic and pharmacologic evidence that hyperactive TGF 1 signaling pivotally underpins osseous defects in Nf1(flox/ );Col2.3Cre mice, a model which closely recapitulates the skeletal abnormalities found in the human disease. Compared to controls, we show that serum TGF 1 levels are fivefold to sixfold increased both in Nf1(flox/ );Col2.3Cre mice and in a cohort of NF1 patients. Nf1 deficient osteoblasts, the principal source of TGF 1 in bone, overexpress TGF 1 in a gene dosage dependent fashion. Moreover, Nf1 deficient osteoblasts and osteoclasts are hyperresponsive to TGF 1 stimulation, potentiating osteoclast bone resorptive activity while inhibiting osteoblast differentiation. These cellular phenotypes are further accompanied by p21 Ras dependent hyperactivation of the canonical TGF 1 Smad pathway. Reexpression of the human, full length neurofibromin guanosine triphosphatase (GTPase) activating protein (GAP) related domain (NF1 GRD) in primary Nf1 deficient osteoblast progenitors, attenuated TGF 1 expression levels and reduced Smad phosphorylation in response to TGF 1 stimulation. As an in vivo proof of principle, we demonstrate that administration of the TGF  receptor 1 (TRI) kinase inhibitor, SD 208, can rescue bone mass deficits and prevent tibial fracture nonunion in Nf1(flox/ );Col2.3Cre mice. In sum, these data demonstrate a pivotal role for hyperactive TGF 1 signaling in the pathogenesis of NF1 associated osteoporosis and pseudarthrosis, thus implicating the TGF  signaling pathway as a potential therapeutic target in the treatment of NF1 osseous defects that are refractory to current therapies. (c) 2013 American Society for Bone and Mineral Research.
C1 [Rhodes, Steven D.; Yang, Feng Chun] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [Rhodes, Steven D.; Wu, Xiaohua; He, Yongzheng; Chen, Shi; Wang, Jiapeng; Zhang, Ping; Yang, Xianlin; Azhar, Mohamad; Xu, Mingjiang; Yang, Feng Chun] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA.
   [Wu, Xiaohua; He, Yongzheng; Chen, Shi; Yang, Hao; Staser, Karl W.; Wang, Jiapeng; Zhang, Ping; Dong, Ruizhi; Yang, Xianlin; Azhar, Mohamad; Xu, Mingjiang; Yang, Feng Chun] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA.
   [Jiang, Chang; Yokota, Hiroki] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
   [Peng, Xianghong; Murthy, Sreemala; Mohammad, Khalid S.; Guise, Theresa A.] Indiana Univ Sch Med, Dept Internal Med, Indianapolis, IN 46202 USA.
   [Xu, Mingjiang] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Purdue University System; Purdue
   University; Purdue University in Indianapolis; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington
RP Yang, FC (通讯作者)，Indiana Univ Sch Med, Canc Res Inst, 1044 W Walnut St,Bldg R4,Room 427, Indianapolis, IN 46202 USA.
EM fyang@iupui.edu
RI Mohammad, Khalid/AFE 4205 2022; Xinliang, Yan/L 7284 2019; zhang,
   ping/L 3901 2017
FU U.S. Department of Defense (DOD) [NF043032, NF073112]; March of Dimes
   [YF08 246]; Children's Tumor Foundation [2011 01 010]; Indiana Clinical
   and Translational Sciences Institute PHS NCCR [5TL1RR025759 03]
FX This research was supported by the U.S. Department of Defense (DOD)
   (NF043032 to FCY; NF073112 to FCY; March of Dimes (YF08 246 to FCY);
   Children's Tumor Foundation (2011 01 010 to SDR); and Indiana Clinical
   and Translational Sciences Institute PHS NCCR (5TL1RR025759 03 to SDR).
CR Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229
   Atti E, 2002, BONE, V31, P675, DOI 10.1016/S8756 3282(02)00905 5
   Avivi E, 2008, ISR MED ASSOC J, V10, P186
   Balooch G, 2005, P NATL ACAD SCI USA, V102, P18813, DOI 10.1073/pnas.0507417102
   Ben Amor IM, 2012, J BONE MINER RES, V27, P713, DOI 10.1002/jbmr.1470
   BIRCH JG, 1987, J PEDIATR ORTHOPED, V7, P546, DOI 10.1097/01241398 198709000 00009
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Colnot C, 2003, DEVELOPMENT, V130, P4123, DOI 10.1242/dev.00559
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Demetracopoulos CA, 2007, ORTHOP CLIN N AM, V38, P563, DOI 10.1016/j.ocl.2007.04.003
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Dulai S, 2007, J PEDIATR ORTHOPED, V27, P472, DOI 10.1097/01.bpb.0000271310.87997.ae
   Edwards JR, 2010, J BONE MINER RES, V25, P2419, DOI 10.1002/jbmr.139
   Ehnert S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014073
   Elefteriou F, 2006, CELL METAB, V4, P441, DOI 10.1016/j.cmet.2006.10.010
   Fajardo M, 2010, J ORTHOP TRAUMA, V24, P557, DOI 10.1097/BOT.0b013e3181ed294c
   Filvaroff E, 1999, DEVELOPMENT, V126, P4267
   Friedman JM, 1997, AM J MED GENET, V70, P138, DOI 10.1002/(SICI)1096 8628(19970516)70:2<138::AID AJMG7>3.0.CO;2 U
   Geiser AG, 1998, BONE, V23, P87, DOI 10.1016/S8756 3282(98)00078 7
   GILBERT A, 1995, CLIN ORTHOP RELAT R, P37
   Heervä E, 2012, J BONE MINER RES, V27, P2333, DOI 10.1002/jbmr.1685
   Heervä E, 2012, BONE, V50, P798, DOI 10.1016/j.bone.2011.12.011
   Heervä E, 2010, BONE, V47, P583, DOI 10.1016/j.bone.2010.06.001
   Hiatt KK, 2001, J BIOL CHEM, V276, P7240, DOI 10.1074/jbc.M009202200
   Illés T, 2001, OSTEOPOROSIS INT, V12, P823, DOI 10.1007/s001980170032
   Ippolito E, 2000, J PEDIATR ORTHOP B, V9, P3, DOI 10.1097/01202412 200001000 00002
   JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794 353
   Janssens K, 2006, J MED GENET, V43, P1, DOI 10.1136/jmg.2005.033522
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Jones KB, 2002, SPINE, V27, P2003, DOI 10.1097/00007632 200209150 00008
   Kirmani S, 2010, AM J MED GENET A, V152A, P1016, DOI 10.1002/ajmg.a.33356
   KOHLMEIER L, 1995, J BONE MINER RES, V10, P1550
   Kolanczyk M, 2007, HUM MOL GENET, V16, P874, DOI 10.1093/hmg/ddm032
   Kuorilehto T, 2005, OSTEOPOROSIS INT, V16, P928, DOI 10.1007/s00198 004 1801 4
   Lammert M, 2005, OSTEOPOROSIS INT, V16, P1161, DOI 10.1007/s00198 005 1940 2
   Le Parc JM, 1999, OSTEOPOROSIS INT, V10, P475, DOI 10.1007/s001980050257
   Lee SM, 2012, J ORTHOP RES, V30, P1535, DOI 10.1002/jor.22121
   Lieu S, 2011, DIS MODEL MECH, V4, P203, DOI 10.1242/dmm.006304
   Loeys BL, 2005, NAT GENET, V37, P275, DOI 10.1038/ng1511
   Mohammad KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005275
   MORRISSY RT, 1981, J BONE JOINT SURG BR, V63, P367, DOI 10.1302/0301 620X.63B3.6790551
   Moura B, 2006, JOINT BONE SPINE, V73, P733, DOI 10.1016/j.jbspin.2006.01.026
   Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092 8674(00)80545 0
   NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo 124 6 2991
   Nyman JS, 2011, J BONE MINER RES, V26, P1252, DOI 10.1002/jbmr.326
   Peltier L F, 1982, Clin Orthop Relat Res, P2
   Pollari S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037361
   Schindeler A, 2008, J ORTHOP RES, V26, P1053, DOI 10.1002/jor.20628
   SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923
   SOFIELD HA, 1971, CLIN ORTHOP RELAT R, P33, DOI 10.1097/00003086 197105000 00008
   Sousa SB, 2011, AM J MED GENET A, V155A, P1178, DOI 10.1002/ajmg.a.33813
   Stevenson DA, 2006, AM J HUM GENET, V79, P143, DOI 10.1086/504441
   Stevenson DA, 1999, AM J MED GENET, V84, P413, DOI 10.1002/(SICI)1096 8628(19990611)84:5<413::AID AJMG5>3.0.CO;2 1
   Stevenson DA, 2007, J PEDIATR US, V150, P83, DOI 10.1016/j.jpeds.2006.10.048
   Stevenson DA, 2011, AM J MED GENET A, V155A, P1050, DOI 10.1002/ajmg.a.33965
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tucker T, 2009, J MED GENET, V46, P259, DOI 10.1136/jmg.2008.061895
   Vitale MG, 2002, CLIN ORTHOP RELAT R, P107, DOI 10.1097/01.blo.0000022199.37246.c9
   Wang WX, 2011, HUM MOL GENET, V20, P3910, DOI 10.1093/hmg/ddr310
   Wang WX, 2010, J BONE MINER RES, V25, P1658, DOI 10.1002/jbmr.42
   WILNER HI, 1964, JAMA J AM MED ASSOC, V187, P490
   Wu X, 2011, PLOS ONE, V6
   Wu XH, 2006, HUM MOL GENET, V15, P2837, DOI 10.1093/hmg/ddl208
   Xu MJ, 2005, BLOOD, V105, P4508, DOI 10.1182/blood 2004 08 3238
   Yang FC, 2006, HUM MOL GENET, V15, P2421, DOI 10.1093/hmg/ddl165
   Yang FC, 2006, J CLIN INVEST, V116, P2880, DOI 10.1172/JCI29092
   Yilmaz K, 2007, ACTA PAEDIATR, V96, P1220, DOI 10.1111/j.1651 2227.2007.00401.x
   Yu Q, 2000, GENE DEV, V14, P163
   Yu X, 2005, BONE, V36, P793, DOI 10.1016/j.bone.2005.01.022
   Zhang W, 2011, BONE, V48, P1378, DOI 10.1016/j.bone.2011.03.760
   Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101
NR 71
TC 39
Z9 43
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2013
VL 28
IS 12
BP 2476
EP 2489
DI 10.1002/jbmr.1992
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 295FQ
UT WOS:000330102400005
PM 23703870
OA Green Accepted, Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Wang, Y
   Lin, B
AF Wang, Yan
   Lin, Bo
TI In silico investigations of potential anabolic treatments in multiple
   myeloma induced bone disease
SO BONE
LA English
DT Article
DE Bortezomib; Multiple myeloma; Bone microenvironment; Mathematical
   modeling; Anabolic
ID KAPPA B LIGAND; PROTEASOME INHIBITOR BORTEZOMIB; EMERGING THERAPEUTIC
   TARGET; PARATHYROID HORMONE; ALKALINE PHOSPHATASE; RECEPTOR ACTIVATOR;
   OSTEOBLAST ACTIVITY; OSTEOLYTIC LESIONS; ZOLEDRONIC ACID; DOUBLE BLIND
AB No anabolic drugs are currently approved to treat multiple myeloma (MM) induced bone disease and the anti MM agent bortezomib exhibits the anabolic effects in the clinic. In this study, we focus on investigating potential anabolic treatments of MM induced bone disease using our previously proposed MM bone model, with the goal for clarifying the underlying molecular/cellular mechanisms. Firstly, a variety of virtual drug treatments are explored by the parametric study to clarify the anabolic related molecular/cellular mechanisms. The real drug (i.e., bortezomib) treatments are further examined by developing an integrated model with bortezomib to validate the clarified anabolic related molecular/cellular mechanisms. The simulated responses to the bortezomib treatments that are validated by the clinical data are consistent with the simulated responses to the virtual drug treatments. Our study clarifies that the anabolic effects in the treatment of MM induced bone disease are associated with promoting the differentiation of bone marrow stromal cells (BMSC) and inhibiting the apoptosis of active osteoblasts, while promoting the differentiation of osteoblast precursors is instead suggested to be associated with the anti catabolic effects. Compared with the individual anabolic therapies, the anabolic therapies that promote the differentiation of BMSC in combination with the anti MM/anti catabolic therapies are found to induce a greater increase in the bone volume, while the anabolic therapies that inhibit the apoptosis of active osteoblasts in combination with the anti MM/anti catabolic therapies induce a lower increase in the bone volume. The simulations also suggest that the direct inhibition of bortezomib on the osteoclast activity is probably a redundant mechanism. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Wang, Yan] Univ Melbourne, Dept Infrastruct Engn, Sch Engn, Melbourne, Vic 3010, Australia.
   [Lin, Bo] Henan Univ, Sch Med, Kaifeng, Peoples R China.
C3 University of Melbourne; Henan University
RP Wang, Y (通讯作者)，Univ Melbourne, Dept Infrastruct Engn, Sch Engn, Melbourne, Vic 3010, Australia.
EM wangyan00@tsinghua.org.cn
CR Abrahamsen B, 2005, CURR OPIN MOL THER, V7, P604
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   Azaïs I, 2010, JOINT BONE SPINE, V77, P20, DOI 10.1016/j.jbspin.2009.10.009
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Bodine PVN, 2007, J CELL PHYSIOL, V210, P352, DOI 10.1002/jcp.20834
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Bringhen S, 2010, BLOOD, V116, P4745, DOI 10.1182/blood 2010 07 294983
   Delforge M, 2011, EUR J HAEMATOL, V86, P372, DOI 10.1111/j.1600 0609.2011.01599.x
   Diamond T, 1997, BRIT J HAEMATOL, V97, P641, DOI 10.1046/j.1365 2141.1997.1042920.x
   Dimopoulos MA, 2011, EUR J HAEMATOL, V86, P23, DOI 10.1111/j.1600 0609.2010.01533.x
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fulciniti M, 2009, BLOOD
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   GOMEZ B, 1995, CLIN CHEM, V41, P1560
   Harousseau JL, 2009, NEW ENGL J MED, V360, P2645, DOI 10.1056/NEJMct0805626
   Heider U, 2006, EUR J CANCER, V42, P1544, DOI 10.1016/j.ejca.2005.11.034
   Heider U, 2006, EUR J HAEMATOL, V77, P233, DOI 10.1111/j.1600 0609.2006.00692.x
   Heider U, 2009, EUR J HAEMATOL, V82, P31, DOI 10.1111/j.1600 0609.2008.01164.x
   Hideshima T, 2001, CANCER RES, V61, P3071
   Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170
   Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lane NE, 2003, ARTHRITIS RES THER, V5, P214, DOI 10.1186/ar797
   LEAFFER D, 1995, ENDOCRINOLOGY, V136, P3624, DOI 10.1210/en.136.8.3624
   LEUNG KS, 1993, J BONE JOINT SURG BR, V75, P288, DOI 10.1302/0301 620X.75B2.8444951
   Liu F, 2008, CELL SIGNAL, V20, P999, DOI 10.1016/j.cellsig.2007.11.011
   Lund T, 2010, EUR J HAEMATOL, V85, P290, DOI 10.1111/j.1600 0609.2010.01485.x
   Malpas J., 2004, Myeloma: biology and management
   Mitchell BS, 2003, NEW ENGL J MED, V348, P2597, DOI 10.1056/NEJMp030092
   Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099
   Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood 2002 06 1768
   Moreau P, 2008, HAEMATOL HEMATOL J, V93, P1908, DOI 10.3324/haematol.13285
   Ogawa Y, 2008, CANCER SCI, V99, P140, DOI 10.1111/j.1349 7006.2007.00638.x
   Ott SM, 2008, CLIN J AM SOC NEPHRO, V3, pS151, DOI 10.2215/CJN.04301206
   Palumbo A, 2009, LEUKEMIA, V23, P1716, DOI 10.1038/leu.2009.122
   Papandreou CN, 2004, J CLIN ONCOL, V22, P2108, DOI 10.1200/JCO.2004.02.106
   Pennisi A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015233
   Pennisi A, 2009, AM J HEMATOL, V84, P6, DOI 10.1002/ajh.21310
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Rawadi G, 2008, CURR DRUG TARGETS, V9, P581, DOI 10.2174/138945008784911778
   Reece DE, 2011, CANCER CHEMOTH PHARM, V67, P57, DOI 10.1007/s00280 010 1283 3
   Reeder CB, 2009, LEUKEMIA, V23, P1337, DOI 10.1038/leu.2009.26
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Richardson PG, 2012, EUR J HAEMATOL, V88, P446, DOI 10.1111/j.1600 0609.2012.01765.x
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Seibel MJ, 2008, CLIN ENDOCRINOL, V68, P839, DOI 10.1111/j.1365 2265.2007.03112.x
   Silbermann R, 2010, CURR CLIN ONCOL, P1, DOI 10.1007/978 1 60761 554 5_1
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200
   Terpos E, 2000, EUR J HAEMATOL, V65, P331, DOI 10.1034/j.1600 0609.2000.065005331.x
   Terpos E, 2010, ANN ONCOL, V21, P1561, DOI 10.1093/annonc/mdq259
   Terpos E, 2003, EUR J HAEMATOL, V70, P34, DOI 10.1034/j.1600 0609.2003.02823.x
   Terpos E, 2006, BRIT J HAEMATOL, V135, P688, DOI 10.1111/j.1365 2141.2006.06356.x
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241
   Vanderkerken K, 2003, CANCER RES, V63, P287
   Vij R, 2009, AM J HEMATOL, V84, P650, DOI 10.1002/ajh.21509
   Wang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044868
   Wang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027494
   Woitge HW, 1996, CLIN CHEM, V42, P1796
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Yeh HS, 2006, EUR J CANCER, V42, P1554, DOI 10.1016/j.ejca.2005.11.035
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
   Zangari M, 2011, HAEMATOL HEMATOL J, V96, P333, DOI 10.3324/haematol.2010.031302
   Zavrski I, 2007, CURR PHARM DESIGN, V13, P471, DOI 10.2174/138161207780162908
   Zavrski I, 2005, BIOCHEM BIOPH RES CO, V333, P200, DOI 10.1016/j.bbrc.2005.05.098
   Zhou H, 2008, J BIOL CHEM, V283, P1936, DOI 10.1074/jbc.M702687200
NR 77
TC 2
Z9 2
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2013
VL 55
IS 1
BP 132
EP 149
DI 10.1016/j.bone.2013.02.003
PG 18
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 150DR
UT WOS:000319370900018
PM 23416846
DA 2025 08 17
ER

PT J
AU Greenberg, DD
   Lee, FY
AF Greenberg, David D.
   Lee, Francis Y.
TI Bisphosphonate loaded Bone Cement as a Local Adjuvant Therapy for Giant
   Cell Tumor of Bone A 1 to 12 Year Follow up Study
SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY CANCER CLINICAL TRIALS
LA English
DT Article
DE giant cell tumor; bisphosphonates; local surgical adjuvant
ID ARGON BEAM COAGULATION; ZOLEDRONIC ACID; RECURRENCE; DENOSUMAB; PHENOL
AB Background: Historically, nontargeted adjuvant therapies such as liquid nitrogen, phenol, argon beam, and alcohol have been applied locally after curettage of giant cell tumors (GCT) in the extremities. Systemic bisphosphonates (BP) and denosumab have emerged as osteoclast targeting therapies because osteoclast like giant cells, responsible for aggressive bone resorption, are susceptible to BP or denosumab. However, such drugs may cause systemic side effects. We examined the effects of an alternative intraoperative local delivery of BP on GCTs. Materials and Methods: In total, 17 patients with GCTs underwent extended surgical curettage procedures consisting of high speed burring, traditional adjuvant therapy, and application of BP loaded polymethylmethacrylate bone cement. Clinical data and follow up radiographs were reviewed to investigate local recurrence (LR) rate and complications in a retrospective manner. Results: There were 6 males and 11 females (mean age, 33.7 y). There were no cases of pulmonary metastases. Patient follow up ranged from 1 to 12 years. There was 1 LR during the follow up period for an LR rate of 5.9%. The mean final Musculoskeletal Tumor Society (MSTS) score was 29. There were no systemic or localized avascular necrosis or atypical fractures related to BPs noted. Conclusions: BP loaded polymethylmethacrylate is a targeted local adjuvant therapy that is feasible, safe, and may reduce LRs while alleviating the risk of systemic side effects of BPs such as avascular necrosis of jaw and atypical femur fractures. Future prospective randomized clinical trials will strengthen the level of evidence of this proposed targeted therap
C1 [Greenberg, David D.] St Louis Univ, Dept Orthopaed Surg, St Louis, MO 63110 USA.
   [Lee, Francis Y.] Yale Univ, Dept Orthopaed Surg, New Haven, CT USA.
C3 Saint Louis University; Yale University
RP Greenberg, DD (通讯作者)，St Louis Univ, Dept Orthopaed Surg, St Louis, MO 63110 USA.
EM david.greenberg@health.slu.edu
CR Algawahmed H., 2010, Sarcoma, V2010, P586090, DOI 10.1155/2010/586090
   Avnet S, 2013, AM J PATHOL, V182, P1357, DOI 10.1016/j.ajpath.2012.12.021
   Benevenia J, 2012, ORTHOPEDICS, V35, pE371, DOI 10.3928/01477447 20120222 22
   Campanacci M., 1999, BONE SOFT TISSUE TUM
   Chang SS, 2004, CLIN ORTHOP RELAT R, P103, DOI 10.1097/01.blo.0000141372.54456.80
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Cheng YY, 2004, CALCIFIED TISSUE INT, V75, P71, DOI 10.1007/s00223 004 0120 2
   Dürr HR, 1999, EUR J SURG ONCOL, V25, P610, DOI 10.1053/ejso.1999.0716
   ENNEKING WF, 1993, CLIN ORTHOP RELAT R, P241
   Errani C, 2010, CANCER TREAT REV, V36, P1, DOI 10.1016/j.ctrv.2009.09.002
   Gao ZH, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 330
   Huang L, 2004, BONE, V34, P393, DOI 10.1016/j.bone.2003.10.013
   Jones Kevin B, 2006, Iowa Orthop J, V26, P69
   Kafchitsas K, 2010, ANTICANCER RES, V30, P3795
   Kim Y, 2012, CLIN ORTHOP SURG, V4, P107, DOI 10.4055/cios.2012.4.2.107
   Kivioja AH, 2008, ACTA ORTHOP, V79, P86, DOI 10.1080/17453670710014815
   Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P1181, DOI 10.1007/s11999 010 1560 9
   Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P591, DOI 10.1007/s11999 010 1501 7
   Knochentumoren A, 2008, J BONE JOINT SURG AM, V90A, P1060, DOI 10.2106/JBJS.D.02771
   Kundu ZS, 2013, INDIAN J ORTHOP, V47, P295, DOI 10.4103/0019 5413.111507
   Lewis VO, 2007, CLIN ORTHOP RELAT R, P192, DOI 10.1097/01.blo.0000238784.98606.d4
   Liao TS, 2005, J ORTHOP RES, V23, P203, DOI 10.1016/j.orthres.2004.06.018
   Lin WH, 2011, CLIN ORTHOP RELAT R, V469, P3200, DOI 10.1007/s11999 011 1962 3
   Liu YP, 2012, CLIN ORTHOP RELAT R, V470, P2886, DOI 10.1007/s11999 012 2464 7
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Malawer MM, 1999, CLIN ORTHOP RELAT R, P176
   Nishisho T, 2011, ORTHOPEDICS, V34, pE312, DOI 10.3928/01477447 20110526 22
   Raskin KA, 2013, J AM ACAD ORTHOP SUR, V21, P118, DOI 10.5435/JAAOS 21 02 118
   Sabokbar A, 1998, ANN RHEUM DIS, V57, P614, DOI 10.1136/ard.57.10.614
   SUNG HW, 1982, J BONE JOINT SURG AM, V64, P755, DOI 10.2106/00004623 198264050 00015
   Tan PK, 2009, ANN ACAD MED SINGAP, V38, P192
   Tse LF, 2008, BONE, V42, P68, DOI 10.1016/j.bone.2007.08.038
   Turcotte RE, 2002, CLIN ORTHOP RELAT R, P248
   Wülling M, 2001, J CANCER RES CLIN, V127, P467, DOI 10.1007/s004320100234
   Xu SF, 2013, CURR ONCOL, V20, pE442, DOI 10.3747/co.20.1497
   Xu W, 2013, ANN SURG ONCOL, V20, P804, DOI 10.1245/s10434 012 2707 6
   Yu NYC, 2008, J BIOMED MATER RES B, V87B, P482, DOI 10.1002/jbm.b.31130
   Yu XC, 2013, ONCOL LETT, V5, P447, DOI 10.3892/ol.2012.1036
   Zwolak P, 2010, J BONE JOINT SURG AM, V92A, P162, DOI 10.2106/JBJS.H.01679
NR 39
TC 25
Z9 28
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277 3732
EI 1537 453X
J9 AM J CLIN ONCOL CANC
JI Am. J. Clin. Oncol. Cancer Clin. Trials
PD MAR
PY 2019
VL 42
IS 3
BP 231
EP 237
DI 10.1097/COC.0000000000000504
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA HN8CU
UT WOS:000460422800001
PM 30811352
DA 2025 08 17
ER

PT J
AU Kuritani, M
   Sakai, N
   Karakawa, A
   Isawa, M
   Chatani, M
   Negishi Koga, T
   Funatsu, T
   Takami, M
AF Kuritani, Miku
   Sakai, Nobuhiro
   Karakawa, Akiko
   Isawa, Motoki
   Chatani, Masahiro
   Negishi Koga, Takako
   Funatsu, Takahiro
   Takami, Masamichi
TI Anti mouse RANKL Antibodies Inhibit Alveolar Bone Destruction in
   Periodontitis Model Mice
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE denosumab; periodontitis; bone; osteoclast; molecularly targeted drug;
   bisphosphonate
ID IN MICE; EXPRESSION; INCREASES; ACTIVATOR; CELLS
AB Denosumab is an anti bone resorptive drug consisting of complete human monoclonal antibodies that targets receptor activator of nuclear factor kappa B ligand (RANKL), which is responsible for osteoclast formation. The drug has been adapted for bone diseases, such as osteoporosis and bone metastasis related to cancer, but is not used for alveolar bone destruction related to periodontitis. In the present study, we aimed to clarify whether denosumab prevents bone destruction associated with lipopolysaccharide (LPS) induced calvaria inflammation and experimental periodontitis in model mice. Denosumab does not bind to mouse RANKL, thus we used anti mouse monoclonal RANKL antibodies. We also examined the inhibitory effects toward bone destruction of another anti bone resorptive drug zoledronate, a nitrogen containing bisphosphonate. Local administration of anti  RANKL antibodies into the calvaria area inhibited LPS induced osteoclast formation and bone destruction, while zoledronate inhibited bone destruction but not osteoclast formation due to its different action mechanism. In periodontitis model mice, in which the second molars were ligated with a silk suture to induce inflammation, intraperitoneal administration of anti RANKL antibodies significantly inhibited alveolar bone destruction and tooth root exposure. On the other hand, zoledronate only weakly repressed alveolar bone destruction and failed to inhibit root exposure. These results suggest that denosumab is a promising candidate to prevent alveolar bone destruction associated with periodontitis.
C1 [Kuritani, Miku; Sakai, Nobuhiro; Karakawa, Akiko; Isawa, Motoki; Chatani, Masahiro; Negishi Koga, Takako; Takami, Masamichi] Showa Univ, Sch Dent, Dept Pharmacol, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.
   [Kuritani, Miku; Funatsu, Takahiro] Showa Univ, Dept Special Needs Dent, Div Dent Persons Disabil,Sch Dent, Ota Ku, 2 1 1 Kitasenzoku, Tokyo 1458515, Japan.
   [Isawa, Motoki] Showa Univ, Sch Dent, Dept Pediat Dent, Ota Ku, 2 1 1 Kitasenzoku, Tokyo 1458515, Japan.
C3 Showa University; Showa University; Showa University
RP Takami, M (通讯作者)，Showa Univ, Sch Dent, Dept Pharmacol, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.
EM takami@dent.showa u.ac.jp
OI Chatani, Masahiro/0000 0002 1002 1775
FU Private University Research Branding Project of the Ministry of
   Education, Culture, Sports, Science and Technology (MEXT) of Japan; MEXT
   [S1411009, S1201014, S0801016]; Japan Society for the Promotion of
   Science [24659830, 26293398, 25293066, 17K11993, 15K15538, 16K20655,
   16H01635, 16K15778]; Science Research Promotion Fund; Uehara Memorial
   Foundation; Naito Foundation; Takeda Science Foundation; Moritani
   Scholarship Foundation; Grants in Aid for Scientific Research [17K11993,
   16K15778, 15K15538, 17H04050, 25293066, 26293398, 16H01635, 24659830,
   16K20655] Funding Source: KAKEN
FX We thank Dr. Haruka Fukamachi, Dr. Hirobumi Morisaki, and Professor
   Hirotaka Kuwata (Department of Microbiology, School of Dentistry, Showa
   University) for their technical assistance. This work was supported in
   part by the Private University Research Branding Project of the Ministry
   of Education, Culture, Sports, Science and Technology (MEXT) of Japan to
   Showa University, and the Industry to Support Private Universities
   Building up Their Foundations of Strategic Research of MEXT (S1411009,
   S1201014, S0801016) to M.T., Grant in Aids for Scientific Research (B)
   to M. T. (Nos. 24659830, 26293398) and to T. N. K. (No. 25293066), and
   Grant in Aids for Scientific Research (C) to N. S. (No. 17K11993),
   Grant in Aid for Challenging Exploratory Research to T. N. K. (No.
   15K15538), Grant in Aid for Young Scientists (B) to A. K. (No.
   16K20655), Grant in Aid for Scientific Research on Innovative Areas to
   M. C. (No. 16H01635), and Grant in Aid for Challenging Exploratory
   Research to M. C. (No. 16K15778) from the Japan Society for the
   Promotion of Science, as well as Grants in Aid from The Science Research
   Promotion Fund to A. K., The Uehara Memorial Foundation to T. N. K, The
   Naito Foundation to T. N. K, the Takeda Science Foundation to T. N. K,
   and the Moritani Scholarship Foundation to M. C.
CR Abe T, 2016, CYTOKINE, V83, P1, DOI 10.1016/j.cyto.2016.03.012
   Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002
   Aghaloo TL, 2014, J BONE MINER RES, V29, P843, DOI 10.1002/jbmr.2097
   Bartold PM, 2010, PERIODONTOL 2000, V53, P55, DOI 10.1111/j.1600 0757.2010.00347.x
   Furuya Y, 2011, J BIOL CHEM, V286, P37023, DOI 10.1074/jbc.M111.246280
   Hanada R, 2011, J MOL MED, V89, P647, DOI 10.1007/s00109 011 0749 z
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Kressin NR, 2003, J DENT RES, V82, P223, DOI 10.1177/154405910308200314
   Mochizuki A, 2006, J IMMUNOL, V177, P4360, DOI 10.4049/jimmunol.177.7.4360
   Myokai F, 1999, P NATL ACAD SCI USA, V96, P4518, DOI 10.1073/pnas.96.8.4518
   Okamatsu N, 2017, BIOCHEM BIOPH RES CO, V491, P614, DOI 10.1016/j.bbrc.2017.07.154
   Paquette DW, 2004, J PERIODONTOL, V75, P531, DOI 10.1902/jop.2004.75.4.531
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Suda K, 2004, J IMMUNOL, V172, P2504, DOI 10.4049/jimmunol.172.4.2504
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Tanabe N, 2005, LIFE SCI, V77, P615, DOI 10.1016/j.lfs.2004.10.079
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
NR 19
TC 19
Z9 21
U1 0
U2 4
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD APR
PY 2018
VL 41
IS 4
BP 637
EP 643
DI 10.1248/bpb.b18 00026
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GB7ZT
UT WOS:000429294400024
PM 29607937
OA gold
DA 2025 08 17
ER

PT J
AU Baud'huin, M
   Lamoureux, F
   Jacques, C
   Calleja, LR
   Quillard, T
   Charrier, C
   Amiaud, J
   Berreur, M
   Brounais LeRoyer, B
   Owen, R
   Reilly, GC
   Bradner, JE
   Heymann, D
   Ory, B
AF Baud'huin, Marc
   Lamoureux, Francois
   Jacques, Camille
   Calleja, Lidia Rodriguez
   Quillard, Thibaut
   Charrier, Celine
   Amiaud, Jerome
   Berreur, Martine
   Brounais LeRoyer, Benedicte
   Owen, Robert
   Reilly, Gwendolen C.
   Bradner, James E.
   Heymann, Dominique
   Ory, Benjamin
TI Inhibition of BET proteins and epigenetic signaling as a potential
   treatment for osteoporosis
SO BONE
LA English
DT Article
DE Osteoporosis; Epigenetic; Bromodomain; Inhibitor; Osteoblast; Osteoclast
ID AUTOSOMAL DOMINANT OSTEOPETROSIS; OSTEOCLAST DIFFERENTIATION;
   BROMODOMAIN INHIBITION; SELECTIVE INHIBITION; ONCOSTATIN M; BONE; CELLS;
   OSTEOSARCOMA; TARGET; MECHANISMS
AB Histone modifications are important for maintaining the transcription program. BET proteins, an important class of "histone reading proteins", have recently been described as essential in bone biology. This study presents the therapeutic opportunity of BET protein inhibition in osteoporosis. We find that the pharmacological BET protein inhibitor JQ1 rescues pathologic bone loss in a post ovariectomy osteoporosis model by increasing the trabecular bone volume and restoring mechanical properties. The BET protein inhibition suppresses osteoclast differentiation and activity as well as the osteoblastogenesis in vitro. Moreover, we show that treated non resorbing osteoclasts could still activate osteoblast differentiation. In addition, specific inhibition of BRD4 using RNA interference inhibits osteoclast differentiation but strongly activates osteoblast mineralization activity. Mechanistically, JQ1 inhibits expression of the master osteoclast transcription factor NFATc1 and the transcription factor of osteoblast Runx2. These findings strongly support that targeting epigenetic chromatin regulators such as BET proteins may offer a promising alternative for the treatment of bone related disorders such as osteoporosis. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Baud'huin, Marc; Lamoureux, Francois; Jacques, Camille; Calleja, Lidia Rodriguez; Quillard, Thibaut; Charrier, Celine; Amiaud, Jerome; Berreur, Martine; Brounais LeRoyer, Benedicte; Heymann, Dominique; Ory, Benjamin] INSERM, UMR 957, Equipe Labellisee Ligue 2012, 1 Rue Gaston Veil, F 44035 Nantes, France.
   [Baud'huin, Marc; Lamoureux, Francois; Jacques, Camille; Calleja, Lidia Rodriguez; Quillard, Thibaut; Charrier, Celine; Amiaud, Jerome; Berreur, Martine; Brounais LeRoyer, Benedicte; Heymann, Dominique; Ory, Benjamin] Univ Nantes, Physiopathol Resorpt Osseuse & Therapie Tumeurs O, Nantes Atlantique Univ, EA3822, 1 Rue Gaston Veil, F 44035 Nantes, France.
   [Baud'huin, Marc; Heymann, Dominique] Nantes Univ Hosp, Nantes, France.
   [Owen, Robert; Reilly, Gwendolen C.] Univ Sheffield, Dept Mat Sci & Engn, INSIGNEO, Inst In Silico Med, Sheffield, S Yorkshire, England.
   [Bradner, James E.] Harvard Med Sch, Dept Med Oncol, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
   [Bradner, James E.] Harvard Med Sch, Dept Med, 25 Shattuck St, Boston, MA 02115 USA.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Nantes Universite; Nantes Universite; CHU de Nantes; University of
   Sheffield; Harvard University; Harvard University Medical Affiliates;
   Dana Farber Cancer Institute; Harvard Medical School; Harvard
   University; Harvard Medical School
RP Ory, B (通讯作者)，INSERM, UMR 957, 1 Rue Gaston Veil, F 44035 Nantes, France.
EM Benjamin.ory@univ nantes.fr
RI ory, benjamin/K 8231 2015; Owen, Robert/J 2553 2019; Reilly,
   Gwendolen/C 3456 2009; Amiaud, Jérôme/AAZ 3008 2020; Heymann,
   Dominique/AAC 6014 2019; Lamoureux, Francois/K 8021 2015; Baud'huin,
   Marc/K 8519 2015; Charrier, Céline/K 9198 2015; ROYER,
   Bénédicte/AAY 8894 2020; Quillard, Thibaut/K 8150 2015
OI Reilly, Gwendolen/0000 0003 1456 1071; CHARRIER,
   Celine/0000 0002 4487 5066; Baud'huin, Marc/0000 0002 3357 329X;
   /0000 0002 4556 9853; ory, benjamin/0000 0002 2622 7356; Lamoureux,
   Francois/0000 0002 2738 0758; Quillard, Thibaut/0000 0002 8096 2597;
   Owen, Robert/0000 0003 1961 0733; Heymann,
   Dominique/0000 0001 7777 0669; Jacques, Camille/0000 0002 8044 0545
FU Seventh Framework Programme [FP7] [264817]; Region Pays de la Loire
   [000381794]; Engineering and Physical Sciences Research Council
   [1624225] Funding Source: researchfish
FX This paper was written as a part of research project which received
   funding from the Seventh Framework Programme ([FP7/2007 2013]) under
   grant agreement no. 264817   BONE NET.Camille Jacques is founded by
   INSERM (Institut National de la Sante et de la Recherche Medicale) and
   Region Pays de la Loire (grant no. 000381794).
CR [Anonymous], 2014, J BONE MINER RES
   Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229
   Baud'huin M, 2007, EXPERT REV ANTICANC, V7, P221, DOI 10.1586/14737140.7.2.221
   Baud'huin M, 2012, P NATL ACAD SCI USA, V109, P12207, DOI 10.1073/pnas.1204929109
   BOLLERSLEV J, 1993, BONE, V14, P865, DOI 10.1016/8756 3282(93)90316 3
   BOLLERSLEV J, 1989, BONE, V10, P19, DOI 10.1016/8756 3282(89)90142 7
   Brounais B, 2008, CLIN CANCER RES, V14, P5400, DOI 10.1158/1078 0432.CCR 07 4781
   Chaidos A, 2015, THER ADV HEMATOL, V6, P128, DOI 10.1177/2040620715576662
   Chipoy C, 2004, J BONE MINER RES, V19, P1850, DOI 10.1359/JBMR.040817
   Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Duplomb L, 2008, ENDOCRINOLOGY, V149, P3688, DOI 10.1210/en.2007 1719
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Gjoksi B, 2015, BONE, V78, P114, DOI 10.1016/j.bone.2015.05.004
   Gobin B, 2015, INT J CANCER, V136, P784, DOI 10.1002/ijc.29040
   Hewings D.S., 2012, J MED CHEM
   Ivashkiv LB, 2015, NAT MED, V21, P212, DOI 10.1038/nm.3815
   Karsdal MA, 2007, J BONE MINER RES, V22, P487, DOI 10.1359/JBMR.070109
   Lamoureux F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4511
   Liu Y., 2016, PROG BIOPHYS MOL BIO
   Matzuk MM, 2012, CELL, V150, P673, DOI 10.1016/j.cell.2012.06.045
   Meng S, 2014, J DENT RES, V93, P657, DOI 10.1177/0022034514534261
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Ott C. J., 2012, BLOOD
   Park Min KH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6418
   Prinjha RK, 2012, TRENDS PHARMACOL SCI, V33, P146, DOI 10.1016/j.tips.2011.12.002
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Trichet V, 2006, J IMMUNOL, V177, P6129, DOI 10.4049/jimmunol.177.9.6129
   Vrtacnik P, 2014, CLIN CHEM LAB MED, V52, P589, DOI 10.1515/cclm 2013 0770
   Yasui T, 2011, ANN NY ACAD SCI, V1240, P7, DOI 10.1111/j.1749 6632.2011.06245.x
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 34
TC 48
Z9 51
U1 0
U2 29
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2017
VL 94
BP 10
EP 21
DI 10.1016/j.bone.2016.09.020
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EE0QC
UT WOS:000389283000002
PM 27669656
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Jung, JH
   Park, JS
   Chun, J
   Al Nawas, B
   Ziebart, T
   Kwon, YD
AF Jung, Junho
   Park, Jung Soo
   Chun, Jeewan
   Al Nawas, Bilal
   Ziebart, Thomas
   Kwon, Yong Dae
TI Geranylgeraniol Application in Human Osteoblasts and Osteoclasts for
   Reversal of the Effect of Bisphosphonates
SO LIFE BASEL
LA English
DT Article
DE geranylgeraniol; GGOH; bisphosphonates; medication related osteonecrosis
   of the jaw; MRONJ; mevalonate pathway
ID MEDICATION RELATED OSTEONECROSIS; ANGIOGENIC GENE EXPRESSION; ZOLEDRONIC
   ACID; CELLULAR BEHAVIOR; PRENYLATION; JAW; PAMIDRONATE; MANAGEMENT;
   THERAPY
AB Nitrogen containing bisphosphonates lead to the depletion of geranylgeranyl pyrophosphate involved in the mevalonate pathway. The effect of geranylgeraniol (GGOH) on human osteoblast and osteoclast activities suppressed by zoledronate was investigated in this study. The effect of GGOH on human osteoblasts and osteoclasts subjected to treatment with zoledronate was analyzed by assessing cell viability, osteoclast differentiation, resorption ability, gene expression, and protein synthesis. Cell viability suppressed by bisphosphonates in osteoblasts and osteoprogenitor cells was restored with GGOH. Osteoclast differentiation was analyzed by vitronectin receptor immunofluorescence staining, and the addition of GGOH to zoledronate significantly increased osteoclast differentiation compared with zoledronate alone. A trend of reversal of osteoclast resorption by GGOH was observed; however, it was not significant in all groups. The expression of ALP, type 1 collagen, and RUNX2 in osteoblasts was recovered by the addition of GGOH. Only CALCR expression in osteoclasts was significantly recovered by GGOH addition in the zoledronate group. Although the activities of osteoblasts and osteoclasts were not entirely restored, the possibility that the topical application of GGOH in MRONJ patients or patients with dental problems and bisphosphonates might lessen the risk of development and recurrence of MRONJ is shown.
C1 [Jung, Junho; Kwon, Yong Dae] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Surg, Seoul 02447, South Korea.
   [Park, Jung Soo] Korea Univ Anam Hosp, Dept Periodontol, Seoul 02841, South Korea.
   [Chun, Jeewan] Kyung Hee Univ, Grad Sch, Dept Dent, Seoul 02447, South Korea.
   [Al Nawas, Bilal] Johannes Gutenberg Univ Mainz, Dept Oral & Maxillofacial Surg, Univ Med Ctr, D 55131 Mainz, Germany.
   [Ziebart, Thomas] Philipps Univ Marburg, Univ Hosp Giessen & Marburg, Dept Oral & Maxillofacial Surg, D 35043 Marburg, Germany.
C3 Kyung Hee University; Korea University; Korea University Medicine (KU
   Medicine); Kyung Hee University; Johannes Gutenberg University of Mainz;
   University Hospital of Giessen & Marburg; Philipps University Marburg
RP Jung, JH; Kwon, YD (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Surg, Seoul 02447, South Korea.
EM ssa204@khu.ac.kr; yongdae.kwon@gmail.com
RI Kwon, Yong Dae/ABF 2991 2020; Jung, Junho/AAI 9768 2020; Al Nawas,
   Bilal/C 8885 2013
OI Kwon, Yong Dae/0000 0001 9620 4814; Jung, Junho/0000 0002 7007 0974; 
FU International Team for Implantology (ITI) [1171_2016]
FX This study was supported by the International Team for Implantology
   (ITI) (grant no. 1171_2016).
CR Abrahamsen B, 2010, CALCIFIED TISSUE INT, V86, P421, DOI 10.1007/s00223 010 9364 1
   CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323
   Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13
   Favia G, 2018, ORAL DIS, V24, P238, DOI 10.1111/odi.12764
   Fliefel RM, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4351327
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Ho HJ, 2018, BIOSCI BIOTECH BIOCH, V82, P956, DOI 10.1080/09168451.2017.1415129
   Hosaka S, 2018, INT J CLIN ONCOL, V23, P1127, DOI 10.1007/s10147 018 1310 7
   Jeong A, 2018, CRIT REV BIOCHEM MOL, V53, P279, DOI 10.1080/10409238.2018.1458070
   Jung J, 2017, J BONE MINER RES, V32, P2445, DOI 10.1002/jbmr.3237
   Koneski F, 2018, J CRANIO MAXILL SURG, V46, P230, DOI 10.1016/j.jcms.2017.11.007
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Majoor BCJ, 2017, J BONE MINER RES, V32, P264, DOI 10.1002/jbmr.2999
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   McGowan K, 2018, ORAL DIS, V24, P527, DOI 10.1111/odi.12708
   McKeage K, 2008, PHARMACOECONOMICS, V26, P251, DOI 10.2165/00019053 200826030 00007
   Owosho AA, 2016, OR SURG OR MED OR PA, V122, P455, DOI 10.1016/j.oooo.2016.06.019
   Pabst AM, 2017, CLIN ORAL INVEST, V21, P771, DOI 10.1007/s00784 016 1842 z
   Pabst AM, 2015, J CRANIO MAXILL SURG, V43, P688, DOI 10.1016/j.jcms.2015.03.014
   Palsuledesai CC, 2015, ACS CHEM BIOL, V10, P51, DOI 10.1021/cb500791f
   Parisi MS, 2001, J CLIN DENSITOM, V4, P167, DOI 10.1385/JCD:4:2:167
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Saad Fred, 2005, Clin Prostate Cancer, V4, P31, DOI 10.3816/CGC.2005.n.009
   SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106
   Smith Matthew R, 2005, Cancer Treat Rev, V31 Suppl 3, P19, DOI 10.1016/j.ctrv.2005.09.004
   Walsh JP, 2004, BONE, V34, P747, DOI 10.1016/j.bone.2003.12.011
   Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660
   Yamada S, 2019, CLIN ORAL INVEST, V23, P3203, DOI 10.1007/s00784 018 2743 0
   Zafar S, 2016, CLIN ORAL INVEST, V20, P2023, DOI 10.1007/s00784 015 1706 y
   Zafar S, 2014, J ORAL PATHOL MED, V43, P711, DOI 10.1111/jop.12181
   Zafar S, 2020, J ORAL SCI, V62, P79, DOI 10.2334/josnusd.19 0130
   Ziebart T, 2011, ORAL ONCOL, V47, P195, DOI 10.1016/j.oraloncology.2010.12.003
NR 36
TC 2
Z9 2
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2075 1729
J9 LIFE BASEL
JI Life Basel
PD JUN
PY 2023
VL 13
IS 6
AR 1353
DI 10.3390/life13061353
PG 13
WC Biology; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Microbiology
GA K2PU1
UT WOS:001014918100001
PM 37374134
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Bone, H
AF Bone, Henry
TI Future Directions in Osteoporosis Therapeutics
SO ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
LA English
DT Article
DE Osteoporosis; Osteocytes; Antiresorptives; Anabolic agents
ID CATHEPSIN K INHIBITOR; POSTMENOPAUSAL WOMEN; PARATHYROID HORMONE; BONE
   MASS; AMERICAN SOCIETY; TASK FORCE; ESTROGEN; ALENDRONATE; PREVENTION;
   FRACTURES
AB Future directions in osteoporosis treatment will include development of medications with increasingly precise mechanistic targets, including the RANK ligand pathway, cathepsin K inhibition, and Wnt signaling manipulation. More gains are likely with anabolics and newer antiresorptives that cause little or no suppression of formation. Optimal treatment of osteoporosis may require coordination of anabolic and antiresorptive treatment, following stimulation of bone formation with consolidation and long term maintenance. Some well established drugs may be useful in such regimens. We can also anticipate emphasis on cost containment using currently available drugs, especially as they become generic. Effective implementation and treatment continuity will be important themes.
C1 St John Hosp & Med Ctr, Michigan Bone & Mineral Clin, Sect Endocrinol & Metab, Detroit, MI 48236 USA.
C3 St. John Hospital & Medical Center
RP Bone, H (通讯作者)，St John Hosp & Med Ctr, Michigan Bone & Mineral Clin, Sect Endocrinol & Metab, 22201 Moross Rd, Detroit, MI 48236 USA.
EM hgbone.md@att.net
CR Anderson GL, 2004, JAMA J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   [Anonymous], 2012, MENOPAUSE, V19, P257, DOI 10.1097/gme.0b013e31824b970a
   Binkley N, 2005, AM SOC BON MIN RES M
   Binkley N, 2012, J BONE MINER RES, V27, P1821, DOI 10.1002/jbmr.1602
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Bone HG, 2000, J CLIN ENDOCR METAB, V85, P720, DOI 10.1210/jc.85.2.720
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Davison KS, 2006, SEMIN ARTHRITIS RHEU, V36, P22, DOI 10.1016/j.semarthrit.2006.04.002
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Fitzpatrick LA, 2011, J CLIN ENDOCR METAB, V96, P2441, DOI 10.1210/jc.2010 2855
   FROST HM, 1987, BONE MINER, V2, P73
   FROST HM, 1979, CLIN ORTHOP RELAT R, P227
   Greenspan SL, 2003, JAMA J AM MED ASSOC, V289, P2525, DOI 10.1001/jama.289.19.2525
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Knopp Sihota JA, 2012, OSTEOPOROSIS INT, V23, P17, DOI 10.1007/s00198 011 1676 0
   Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914
   LINDSAY R, 1976, LANCET, V1, P1038
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003 4819 117 1 1
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Rittmaster RS, 2000, J CLIN ENDOCR METAB, V85, P2129, DOI 10.1210/jc.85.6.2129
   Rossouw JE, 2007, JAMA J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Rünger TM, 2012, J AM ACAD DERMATOL, V66, pE89, DOI 10.1016/j.jaad.2010.11.033
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Stevenson JC, 2011, MATURITAS, V70, P197, DOI 10.1016/j.maturitas.2011.05.017
   Stolina M, 2007, ADV EXP MED BIOL, V602, P143
   Turner CH, 2002, OSTEOPOROSIS INT, V13, P97, DOI 10.1007/s001980200000
NR 31
TC 16
Z9 22
U1 1
U2 18
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0889 8529
EI 1558 4410
J9 ENDOCRIN METAB CLIN
JI Endocrinol. Metabol. Clin. North Amer.
PD SEP
PY 2012
VL 41
IS 3
BP 655
EP +
DI 10.1016/j.ecl.2012.05.003
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 000IO
UT WOS:000308380100013
PM 22877435
DA 2025 08 17
ER

PT J
AU Deodati, A
   Fintini, D
   Levtchenko, E
   Rossi, M
   Ubertini, G
   Segers, H
   Battafarano, G
   Cappa, M
   Del Fattore, A
AF Deodati, A.
   Fintini, D.
   Levtchenko, E.
   Rossi, M.
   Ubertini, G.
   Segers, H.
   Battafarano, G.
   Cappa, M.
   Del Fattore, A.
TI Mechanisms of acute hypercalcemia in pediatric patients following the
   interruption of Denosumab
SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
LA English
DT Article
DE Hypercalcemia; Osteoclast; Denosumab; Osteoclast precursor
ID GIANT CELL TUMOR; KAPPA B LIGAND; RECEPTOR ACTIVATOR; THERAPY;
   DISCONTINUATION; OSTEOPROTEGERIN; TURNOVER; ANTIBODY
AB Purpose Denosumab is a fully human monoclonal anti RANK L antibody that is clinically used to counteract the bone loss induced by exacerbated osteoclast activity. Indeed, its binding to RANK L prevents the interaction RANK L/receptor RANK that is essential for osteoclastogenesis and bone resorbing activity. Although there are many medications available to treat bone loss diseases, including bisphosphonates, Denosumab is highly effective since it reduces the bone erosion. The use in pediatric patients is safe. However, some concerns are related to the interruption of the treatment. Indeed, in this study, we reported hypercalcemia in two pediatric patients and alterations of circulating osteoclast precursors. Methods Peripheral Blood Mononuclear Cells (PBMC) were isolated from two pediatric patients with hypercalcemia after Denosumab interruption and from 10 controls. Cytofluorimetric analysis and in vitro osteoclastogenesis experiments were performed. Results Increase of CD16( )CD14(+)CD11b(+) cells was revealed in PBMC from patients reflecting the enhanced in vitro osteoclastogenesis. Conclusion Our data suggest that precautions must be taken when Denosumab therapy is interrupted and gradual decrease of dose and/or timing of treatment should be performed. To prevent the onset of hypercalcemia that could be in the discontinuation phase, cytofluorimetric analysis of PBMC should be performed to evaluate osteoclast precursors.
C1 [Deodati, A.; Fintini, D.; Ubertini, G.; Cappa, M.] Bambino Gesu Pediat Hosp, Endocrinol Unit, Univ Pediat Clin Dept, IRCCS, I 00146 Rome, Italy.
   [Levtchenko, E.; Segers, H.] Univ Hosp Leuven, Dept Pediat, B 3000 Leuven, Belgium.
   [Rossi, M.; Battafarano, G.; Del Fattore, A.] Bambino Gesu Pediat Hosp, Bone Physiopathol Res Unit, Genet & Rare Dis Res Div, IRCCS, Viale San Paolo 15, I 00146 Rome, Italy.
C3 IRCCS Bambino Gesu; KU Leuven; University Hospital Leuven; IRCCS Bambino
   Gesu
RP Del Fattore, A (通讯作者)，Bambino Gesu Pediat Hosp, Bone Physiopathol Res Unit, Genet & Rare Dis Res Div, IRCCS, Viale San Paolo 15, I 00146 Rome, Italy.
EM andrea.delfattore@opbg.net
RI Rossi, Michela/AAI 1642 2019; deodati, annalisa/K 4078 2018; Del
   Fattore, Andrea/H 4409 2015; Levtchenko, Elena/AAO 7125 2020; Del
   Fattore, Andrea/AAP 2045 2020; Battafarano, Giulia/N 8048 2013; fintini,
   danilo/AAA 7688 2020
OI Levtchenko, Elena/0000 0002 8352 7312; Del Fattore,
   Andrea/0000 0003 3848 412X; Battafarano, Giulia/0000 0002 9297 5184;
   ROSSI, MICHELA/0000 0002 6844 6469; ubertini,
   graziamaria/0009 0001 2134 6639; CAPPA, MARCO/0000 0001 5647 7519
FU Ministero della Salute (Ricerca Corrente 2020)
FX The present study received funding from Ministero della Salute (Ricerca
   Corrente 2020) to ADF.
CR Ahern E, 2018, NAT REV CLIN ONCOL, V15, P676, DOI 10.1038/s41571 018 0095 y
   An SY, 2012, IMAGNG SCI DENT, V42, P35, DOI 10.5624/isd.2012.42.1.35
   Anastasilakis AD, 2020, BONE REP, V12, DOI 10.1016/j.bonr.2020.100267
   Anastasilakis AD, 2017, EUR J ENDOCRINOL, V176, P677, DOI 10.1530/EJE 16 1027
   Auron A, 2018, PEDIATR NEPHROL, V33, P1475, DOI 10.1007/s00467 017 3788 z
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Boyce AM, 2017, CURR OSTEOPOROS REP, V15, P283, DOI 10.1007/s11914 017 0380 1
   Bredell M, 2018, J ORAL MAXIL SURG, V76, P775, DOI 10.1016/j.joms.2017.09.013
   Chen X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0035 6
   Choe M, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.28778
   Colia V, 2016, REP PRACT ONCOL RADI, V21, P361, DOI 10.1016/j.rpor.2015.12.005
   Del Fattore A, 2006, J MED GENET, V43, P315, DOI 10.1136/jmg.2005.036673
   Dubois EA, 2011, BRIT J CLIN PHARMACO, V71, P804, DOI 10.1111/j.1365 2125.2011.03969.x
   Gossai N, 2015, PEDIATR BLOOD CANCER, V62, P1078, DOI 10.1002/pbc.25393
   Grasemann C, 2013, J CLIN ENDOCR METAB, V98, P3121, DOI 10.1210/jc.2013 1143
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Hoyer Kuhn H, 2016, J MUSCULOSKEL NEURON, V16, P24
   Iranikhah M, 2018, CONSULT PHARM, V33, P142, DOI 10.4140/TCP.n.2018.142
   Jeyaraj Priya, 2019, Ann Maxillofac Surg, V9, P37, DOI 10.4103/ams.ams_232_18
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Komano Y, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2046
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Leithner A, 1999, CLIN ORTHOP RELAT R, P176
   Lipplaa A, 2019, CURR OPIN ONCOL, V31, P329, DOI 10.1097/CCO.0000000000000529
   Marcucci G, 2019, ANN ONCOL, V30, P908, DOI 10.1093/annonc/mdz120
   McClung MR, 2017, OSTEOPOROSIS INT, V28, P1723, DOI 10.1007/s00198 017 3919 1
   McClung Michael R, 2017, Osteoporos Sarcopenia, V3, P8
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   Palmerini E, 2018, TUMORI J, V104, P344, DOI 10.1177/0300891618784808
   Park HY, 2016, CURR REV MUSCULOSKE, V9, P435, DOI 10.1007/s12178 016 9371 6
   Setsu N, 2016, J BONE MINER METAB, V34, P118, DOI 10.1007/s00774 015 0677 z
   Sobacchi C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00629
   Sydlik C, 2020, WORLD J PEDIATR, V16, P520, DOI 10.1007/s12519 020 00378 w
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Uday S, 2018, J CLIN ENDOCR METAB, V103, P596, DOI 10.1210/jc.2017 02025
   Wang YQ, 2019, J OTOLARYNGOL HEAD N, V48, DOI 10.1186/s40463 019 0356 5
   Wilson Carol, 2011, Nat Rev Endocrinol, V7, P693, DOI 10.1038/nrendo.2011.176
   Xiong JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05244 y
   Yu XL, 2016, ONCOL LETT, V11, P1481, DOI 10.3892/ol.2016.4080
NR 40
TC 15
Z9 16
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0391 4097
EI 1720 8386
J9 J ENDOCRINOL INVEST
JI J. Endocrinol. Invest.
PD JAN
PY 2022
VL 45
IS 1
BP 159
EP 166
DI 10.1007/s40618 021 01630 4
EA JUL 2021
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA YD3EY
UT WOS:000669308800002
PM 34216372
DA 2025 08 17
ER

PT J
AU Sampei, C
   Kato, K
   Arasaki, Y
   Kimura, Y
   Konno, T
   Otsuka, K
   Kohara, Y
   Noda, M
   Ezura, Y
   Hayata, T
AF Sampei, Chisato
   Kato, Kosuke
   Arasaki, Yasuhiro
   Kimura, Yuta
   Konno, Takuto
   Otsuka, Kanon
   Kohara, Yukihiro
   Noda, Masaki
   Ezura, Yoichi
   Hayata, Tadayoshi
TI Gprc5a is a novel parathyroid hormone inducible gene and
   negatively regulates osteoblast proliferation and differentiation
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE Gprc5a; osteoblast; osteoporosis; parathyroid hormone (PTH);
   teriparatide
ID TUMOR SUPPRESSOR GPRC5A; BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN;
   RETINOIC ACID; 1,25 DIHYDROXYVITAMIN D 3; ANABOLIC ACTION; RECEPTOR;
   CELLS; PTH; EXPRESSION
AB Teriparatide is a peptide derived from a parathyroid hormone (PTH) and an osteoporosis therapeutic drug with potent bone formation promoting activity. To identify novel druggable genes that act downstream of PTH signaling and are potentially involved in bone formation, we screened PTH target genes in mouse osteoblast like MC3T3 E1 cells. Here we show that Gprc5a, encoding an orphan G protein coupled receptor, is a novel PTH inducible gene and negatively regulates osteoblast proliferation and differentiation. PTH treatment induced Gprc5a expression in MC3T3 E1 cells, rat osteosarcoma ROS17/2.8 cells, and mouse femurs. Induction of Gprc5a expression by PTH occurred in the absence of protein synthesis and was mediated primarily via the cAMP pathway, suggesting that Gprc5a is a direct target of PTH signaling. Interestingly, Gprc5a expression was induced additively by co treatment with PTH and 1 alpha, 25 dihydroxyvitamin D3 (calcitriol), or retinoic acid in MC3T3 E1 cells. Reporter analysis of a 1 kb fragment of human GPRC5A promoter revealed that the promoter fragment showed responsiveness to PTH via the cAMP response element, suggesting that GPRC5A is also a PTH inducible gene in humans. Gprc5a knockdown promoted cell viability and proliferation, as demonstrated by MTT and BrdU assays. Gprc5a knockdown also promoted osteoblast differentiation, as indicated by gene expression analysis and mineralization assay. Mechanistic studies showed that Gprc5a interacted with BMPR1A and suppressed BMP signaling induced by BMP 2 and constitutively active BMP receptors, ALK2 (ACVR1) Q207D and ALK3 (BMPR1A) Q233D. Thus, our results suggest that Gprc5a is a novel gene induced by PTH that acts in an inhibitory manner on both cell proliferation and osteoblast differentiation and is a candidate for drug targets for osteoporosis.
C1 [Sampei, Chisato; Kato, Kosuke; Arasaki, Yasuhiro; Kimura, Yuta; Konno, Takuto; Otsuka, Kanon; Kohara, Yukihiro; Hayata, Tadayoshi] Tokyo Univ Sci, Grad Sch Pharmaceut Sci, Dept Mol Pharmacol, 2641 Yamazaki, Noda, Chiba 2788510, Japan.
   [Sampei, Chisato; Kato, Kosuke; Arasaki, Yasuhiro; Kimura, Yuta; Konno, Takuto; Otsuka, Kanon; Kohara, Yukihiro; Hayata, Tadayoshi] Tokyo Univ Sci, Fac Pharmaceut Sci, 2641 Yamazaki, Noda, Chiba 2788510, Japan.
   [Noda, Masaki; Ezura, Yoichi; Hayata, Tadayoshi] Tokyo Med & Dent Univ TMDU, Med Res Inst, Dept Mol Pharmacol, Bunkyo Ku, Tokyo, Japan.
   [Noda, Masaki] Tokyo Med & Dent Univ, Ctr Stem Cell & Regenerat Med, Bunkyo Ku, Tokyo, Japan.
   [Ezura, Yoichi] Tokyo Med & Dent Univ, Dept Joint Surg & Sports Med, Bunkyo Ku, Tokyo, Japan.
   [Ezura, Yoichi] Teikyo Heisei Univ, Fac Hlth & Med Sci, Dept Occupat Therapy, Toshima Ku, Toshima, Japan.
C3 Tokyo University of Science; Tokyo University of Science; Institute of
   Science Tokyo; Tokyo Medical & Dental University (TMDU); Institute of
   Science Tokyo; Tokyo Medical & Dental University (TMDU); Institute of
   Science Tokyo; Tokyo Medical & Dental University (TMDU)
RP Hayata, T (通讯作者)，Tokyo Univ Sci, Grad Sch Pharmaceut Sci, Dept Mol Pharmacol, 2641 Yamazaki, Noda, Chiba 2788510, Japan.; Hayata, T (通讯作者)，Tokyo Univ Sci, Fac Pharmaceut Sci, 2641 Yamazaki, Noda, Chiba 2788510, Japan.
EM hayata.tadayoshi.mph@rs.tus.ac.jp
RI Hayata, Tadayoshi/E 5298 2015; Hayata, Tadayoshi/AAE 9712 2021; Kato,
   Kosuke/NFU 0093 2025
OI Hayata, Tadayoshi/0000 0001 5083 4300; 
FU JSPS KAKENHI;  [JP25462287];  [JP25670639];  [JP26253085]; 
   [JP18K09053];  [JP21H03381]
FX We thank Drs. Aristidis Moustakas, Tomohiro Nakajo, Satoshi Karasawa,
   Ken W.Y. Cho, Kohei Miyazono, and Makoto Asashima for providing
   plasmids. This work was supported by JSPS KAKENHI Grant Numbers,
   JP25462287, JP25670639, JP26253085, JP18K09053, and JP21H03381.
CR ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   Balani DH, 2017, J CLIN INVEST, V127, P3333, DOI 10.1172/JCI91699
   Bulanova DR, 2017, CELL ADHES MIGR, V11, P434, DOI 10.1080/19336918.2016.1245264
   Cheng YJ, 1998, J BIOL CHEM, V273, P35008, DOI 10.1074/jbc.273.52.35008
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Datta NS, 2007, J BONE MINER RES, V22, P951, DOI 10.1359/JBMR.070328
   Deng JO, 2010, CANCER PREV RES, V3, P424, DOI 10.1158/1940 6207.CAPR 10 0032
   Gerdhem P, 2013, BEST PRACT RES CL RH, V27, P743, DOI 10.1016/j.berh.2014.01.002
   Goltzman D, 2018, HISTOCHEM CELL BIOL, V149, P305, DOI 10.1007/s00418 018 1648 y
   Hanyu R, 2012, P NATL ACAD SCI USA, V109, P7433, DOI 10.1073/pnas.1109036109
   Harada Y, 2007, BIOCHEM BIOPH RES CO, V358, P968, DOI 10.1016/j.bbrc.2007.04.208
   Hein MY, 2015, CELL, V163, P712, DOI 10.1016/j.cell.2015.09.053
   Hirano M, 2006, BIOCHEM BIOPH RES CO, V351, P185, DOI 10.1016/j.bbrc.2006.10.016
   Hong SHH, 2009, J MOL ENDOCRINOL, V43, P197, DOI 10.1677/JME 09 0012
   Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743
   Hwang PW, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44575 8
   Insel PA, 2019, TRENDS PHARMACOL SCI, V40, P378, DOI 10.1016/j.tips.2019.04.001
   Jiang XX, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1823726
   Jin CY, 2020, BIOCHEM BIOPH RES CO, V524, P516, DOI 10.1016/j.bbrc.2020.01.098
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kaneshiro S, 2014, J BONE MINER METAB, V32, P378, DOI 10.1007/s00774 013 0514 1
   Khan MP, 2016, BONE, V92, P132, DOI 10.1016/j.bone.2016.08.018
   Kim HS, 2018, J PERIODONTAL IMPLAN, V48, P34, DOI 10.5051/jpis.2018.48.1.34
   KRISHNAN AV, 1995, ENDOCRINOLOGY, V136, P705, DOI 10.1210/en.136.2.705
   Le Henaff C, 2020, J BONE MINER RES, V35, P714, DOI 10.1002/jbmr.3930
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Liu SX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120402
   Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460 2075.1996.tb00826.x
   Miles RR, 2000, ENDOCRINOLOGY, V141, P28, DOI 10.1210/en.141.1.28
   Moriya S, 2015, J CELL BIOCHEM, V116, P142, DOI 10.1002/jcb.24953
   Nagasawa H, 2005, J NUTR SCI VITAMINOL, V51, P311, DOI 10.3177/jnsv.51.311
   Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Raja E, 2016, ONCOTARGET, V7, P1120, DOI 10.18632/oncotarget.6683
   Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581
   Sawada Y, 2020, INT J CANCER, V146, P1369, DOI 10.1002/ijc.32554
   Schiller PC, 1999, J BONE MINER RES, V14, P1504, DOI 10.1359/jbmr.1999.14.9.1504
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shirakawa J, 2016, CALCIFIED TISSUE INT, V98, P306, DOI 10.1007/s00223 015 0083 5
   Standal T, 2014, J ENDOCRINOL, V223, P181, DOI 10.1530/JOE 14 0424
   von Bubnoff A, 2005, DEV BIOL, V281, P210, DOI 10.1016/j.ydbio.2005.02.014
   Wang J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11795
   Wang YH, 2007, AM J PHYSIOL ENDOC M, V292, pE594, DOI 10.1152/ajpendo.00216.2006
   Watson PH, 2000, BONE, V26, P221, DOI 10.1016/S8756 3282(99)00264 1
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Ye XF, 2009, CANCER BIOL THER, V8, P951, DOI 10.4161/cbt.8.10.8244
   Yee MMF, 2021, MOLECULES, V26, DOI 10.3390/molecules26061757
   Yoshimura N, 2009, J BONE MINER METAB, V27, P620, DOI 10.1007/s00774 009 0080 8
   Yuan WH, 2007, J BIOL CHEM, V282, P29821, DOI 10.1074/jbc.M705495200
   Zhang L, 2017, INT J CANCER, V140, P2734, DOI 10.1002/ijc.30698
   Zhong SS, 2015, CANCER RES, V75, P1801, DOI 10.1158/0008 5472.CAN 14 2005
   Zhou Honglei, 2014, Oncoscience, V1, P765
   Zhou Yan jiao, 2019, Nature Communications, V10, DOI [10.1038/s41467 019 12821 2, 10.1038/s41467 019 13698 x]
   Zweifler LE, 2021, J BONE MINER RES, V36, P1979, DOI 10.1002/jbmr.4389
NR 54
TC 3
Z9 3
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD AUG
PY 2024
VL 239
IS 8
DI 10.1002/jcp.31297
EA MAY 2024
PG 16
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA C9R6J
UT WOS:001227766400001
PM 38769895
DA 2025 08 17
ER

PT J
AU Spadazzi, C
   Recine, F
   Mercatali, L
   Miserocchi, G
   Liverani, C
   De Vita, A
   Bongiovanni, A
   Fausti, V
   Ibrahim, T
AF Spadazzi, Chiara
   Recine, Federica
   Mercatali, Laura
   Miserocchi, Giacomo
   Liverani, Chiara
   De Vita, Alessandro
   Bongiovanni, Alberto
   Fausti, Valentina
   Ibrahim, Toni
TI mTOR inhibitor and bone targeted drugs break the vicious cycle between
   clear cell renal carcinoma and osteoclasts in an in vitro co culture
   model
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Bone metastasis; Renal carcinoma; Osteoclasts; Vicious cycle;
   Co culture; Targeted therapy
ID ZOLEDRONIC ACID; SKELETAL METASTASIS; CANCER; DIFFERENTIATION;
   EVEROLIMUS; MICROENVIRONMENT; CABOZANTINIB; EXPRESSION; MANAGEMENT;
   DENOSUMAB
AB The skeleton is one of the most common sites of metastatic spread from advanced clear cell renal carcinoma (ccRCC). Most of the bone lesions observed in RCC patients are classified as osteolytic, causing severe pain and morbidity due to pathological bone destruction. Nowadays, it is well known that cancer induced bone loss in lyric metastasis is caused by the triggering of a vicious cycle between cancer and bone resident cells that leads to an imbalance between bone formation and degradation. Targeting the mammalian target of rapamycin (mTOR) is an efficient treatment option for metastatic renal carcinoma patients. Moreover, bone targeted therapy could benefit bone metastatic cancer patients caused by advanced RCC. However, more data is needed to support the hypothesis of the beneficial effect of a combined therapy. The aim of this work is to investigate the effect of targeting mTOR and the sequential combination with bone targeted therapy as a strategy to break the vicious cycle between ccRCC cells and osteoclasts. A previously optimized fully human co culture model is used to mimic the crosstalk between Caki 2 cells (ccRCC) and osteoclasts. Cells are treated at fixed timing with everolimus, zoledronic acid and denosumab as single or sequential combined treatment. We show that Caki 2 cells can induce osteoclast cells differentiation from isolated human monocytes, as demonstrated by specific tartrate resistant acid phosphatase (TRAP) staining and f actin ring formation, in a statistically significant manner. Moreover, differentiated osteoclasts proved to be functionally active by pit formation assay. Caki 2 cells co cultured with osteoclasts acquire a more aggressive phenotype based on gene expression analysis. Interestingly, the sequential combined treatment of everolimus and zoledronic acid is the most effective in the inhibition of both Caki 2 cells survival and osteoclastogenic potential, making it an effective strategy to inhibit the vicious cycle of bone metastasis. At preclinical level, this observation confirms the value of our co culture model as a useful tool to mimic the bone microenvironment and to assess drug sensitivity in vitro. A better understanding of the molecular mechanisms involved in tumor bone cells crosstalk will be investigated next.
C1 [Spadazzi, Chiara; Recine, Federica; Mercatali, Laura; Miserocchi, Giacomo; Liverani, Chiara; De Vita, Alessandro; Bongiovanni, Alberto; Fausti, Valentina; Ibrahim, Toni] Ist Scientif Romagnolo Studio & Cura Tumori IRST, Osteoncol & Rare Tumors Ctr, Via P Maroncelli 40, I 47014 Meldola, FC, Italy.
RP Mercatali, L (通讯作者)，Ist Scientif Romagnolo Studio & Cura Tumori IRST, Osteoncol & Rare Tumors Ctr, Via P Maroncelli 40, I 47014 Meldola, FC, Italy.
EM chiara.spadazzi@irst.emr.it; federica.recine@irst.emr.it;
   laura.mercatali@irst.emr.it; giacomo.miserocchi@irst.emr.it;
   chiara.liverani@irst.emr.it; alessandro.devita@irst.emr.it;
   alberto.bongiovanni@irst.emr.it; valentina.fausti@irst.emr.it;
   toni.ibrahim@irst.emr.it
RI ; Fausti, Valentina/AAA 6071 2021; De Vita, Alessandro/K 1534 2016;
   Spadazzi, Chiara/AAB 5917 2021; Liverani, Chiara/K 3913 2016;
   Miserocchi, Giacomo/AAA 7159 2021; Mercatali, Laura/J 9154 2016;
   Ibrahim, Toni/IQR 9219 2023; Bongiovanni, Alberto/J 9802 2018
OI Bongiovanni, Alberto/0000 0002 3845 4687; De Vita,
   Alessandro/0000 0002 1677 5797; Spadazzi, Chiara/0000 0001 6710 5980;
   Liverani, Chiara/0000 0002 4279 1926; Fausti,
   Valentina/0000 0003 0432 1445; 
CR Battelli Chiara, 2011, Therapy, V8, P359
   Bertoldo F, 2014, BBA REV CANCER, V1845, P248, DOI 10.1016/j.bbcan.2014.01.009
   Beuselinck B, 2015, BRIT J CANCER, V113, P1313, DOI 10.1038/bjc.2015.352
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Broom RJ, 2015, CLIN GENITOURIN CANC, V13, P50, DOI 10.1016/j.clgc.2014.07.002
   Buti S, 2016, CORE EVID, V11, P23, DOI 10.2147/CE.S98687
   Chambers TJ, 2000, J PATHOL, V192, P4
   Chen JQ, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0004 5
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Choueiri TK, 2016, LANCET ONCOL, V17, P917, DOI 10.1016/S1470 2045(16)30107 3
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Conti A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/419176
   Dai QG, 2017, J BIOL CHEM, V292, P196, DOI 10.1074/jbc.M116.764761
   De Vita A, 2016, MOLECULES, V21, DOI 10.3390/molecules21121662
   Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008
   Escudier B, 2018, J CLIN ONCOL, V36, P765, DOI 10.1200/JCO.2017.74.7352
   Esposito M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031252
   Esposito M, 2014, PHARMACOL THERAPEUT, V141, P222, DOI 10.1016/j.pharmthera.2013.10.006
   Faust J, 1999, J CELL BIOCHEM, V72, P67, DOI 10.1002/(SICI)1097 4644(19990101)72:1<67::AID JCB8>3.0.CO;2 A
   Flanigan Robert C, 2003, Curr Treat Options Oncol, V4, P385, DOI 10.1007/s11864 003 0039 2
   Garcia JA, 2009, CURR OPIN ONCOL, V21, P266, DOI 10.1097/CCO.0b013e32832a05c8
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Ibrahim T, 2016, ONCOL LETT, V12, P2970, DOI 10.3892/ol.2016.4977
   Ibrahim T, 2009, TUMORI J, V95, P291
   Jeganathan S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104498
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kato Y, 2013, CANCER CELL INT, V13, DOI 10.1186/1475 2867 13 89
   Keizman D, 2014, WORLD J UROL, V32, P39, DOI 10.1007/s00345 013 1059 6
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Le Pape F, 2016, J BONE ONCOL, V5, P93, DOI 10.1016/j.jbo.2016.02.008
   Lieberthal W, 2009, J AM SOC NEPHROL, V20, P2493, DOI 10.1681/ASN.2008111186
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Liverani C, 2014, BONE, V66, P214, DOI 10.1016/j.bone.2014.06.017
   Maggiani F, 2011, J CLIN PATHOL, V64, P701, DOI 10.1136/jcp.2011.090852
   Mercatali L, 2017, JOVE J VIS EXP, DOI 10.3791/56311
   Mercatali L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081655
   Mercatali L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111827
   Mikami S, 2009, J PATHOL, V218, P530, DOI 10.1002/path.2567
   Motzer RJ, 2018, BRIT J CANCER, V118, P1176, DOI 10.1038/s41416 018 0061 6
   Motzer RJ, 2011, J NATL COMPR CANC NE, V9, P960, DOI 10.6004/jnccn.2011.0082
   Mulders P, 2009, BJU INT, V104, P1585, DOI 10.1111/j.1464 410X.2009.08987.x
   Pal SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063341
   Brufau BP, 2013, RADIOGRAPHICS, V33, P1691, DOI 10.1148/rg.336125110
   Patel LR, 2011, FUTURE ONCOL, V7, P1285, DOI [10.2217/fon.11.112, 10.2217/FON.11.112]
   Ren GW, 2015, J MOL MED, V93, P1203, DOI 10.1007/s00109 015 1329 4
   Sahi Chakshu, 2010, Ther Adv Med Oncol, V2, P75, DOI 10.1177/1758834009358417
   Santini D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083026
   Santoni M, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046 015 0122 0
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Simone V, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1717 8
   Sisay M, 2017, ONCOTARGETS THER, V10, P3801, DOI 10.2147/OTT.S135867
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Swartz MA, 2012, CANCER RES, V72, P2473, DOI 10.1158/0008 5472.CAN 12 0122
   Ullén A, 2009, SCAND J UROL NEPHROL, V43, P98, DOI 10.1080/00365590802475904
   Umer M, 2018, ANN MED SURG, V27, P9, DOI 10.1016/j.amsu.2018.01.002
   Weiss HM, 2008, DRUG METAB DISPOS, V36, P2043, DOI 10.1124/dmd.108.021071
   Wood SL, 2012, CANCER TREAT REV, V38, P284, DOI 10.1016/j.ctrv.2011.06.011
   Yoneda T, 2015, BBA BIOMEMBRANES, V1848, P2677, DOI 10.1016/j.bbamem.2015.02.004
   Zhang Y, 2017, J BONE MINER RES, V32, P1829, DOI 10.1002/jbmr.3172
   Zhou XX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030301
NR 62
TC 8
Z9 8
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD JUN
PY 2019
VL 16
AR 100227
DI 10.1016/j.jbo.2019.100227
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA IM0TA
UT WOS:000477701100005
PM 30911462
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Singh, M
   Del Carpio Cano, F
   Belcher, JY
   Crawford, K
   Frara, N
   Owen, TA
   Popoff, SN
   Safadi, FF
AF Singh, Maneet
   Del Carpio Cano, Fabiola
   Belcher, Joyce Y.
   Crawford, Kevin
   Frara, Nagat
   Owen, Thomas A.
   Popoff, Steven N.
   Safadi, Fayez F.
TI Functional Roles of Osteoactivin in Normal and Disease Processes
SO CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
LA English
DT Article
DE osteoactivin; glycoprotein nmb; DC HIL; HGFIN; PMEL17; type I
   transmembrane glycoprotein; adhesion; osteoblasts; osteoclasts; cancer
ID ANTIBODY DRUG CONJUGATE; MELANOMA PROTEIN B; OSTEOBLAST DIFFERENTIATION;
   BREAST CANCER; DC HIL; TRANSMEMBRANE PROTEIN; PIGMENTARY GLAUCOMA;
   MICROARRAY ANALYSIS; THERAPEUTIC TARGET; GENE EXPRESSION
AB Osteoactivin (OA) protein was discovered in bone cells a decade ago. Recent literature suggests that osteoactivin is crucial for the differentiation and functioning of different cell types, including bone forming osteoblasts and bone resorbing osteoclast cells. Here, we review the literature to date on various regulatory functions of osteoactivin, as well as its discovery, structure, expression, and function in different tissues and cells. The transcriptional regulation of osteoactivin and its mechanism of action in normal and diseased conditions with special emphasis on bone are also covered in this review. In addition, we touch on the therapeutic potential of osteoactivin in cancer and bone diseases.
C1 [Singh, Maneet; Del Carpio Cano, Fabiola; Belcher, Joyce Y.; Crawford, Kevin; Frara, Nagat; Popoff, Steven N.; Safadi, Fayez F.] Temple Univ, Sch Med, Dept Anat & Cell Biol, Philadelphia, PA 19140 USA.
   [Owen, Thomas A.] Ramapo Coll, Dept Theoret & Appl Sci, Mahwah, NJ USA.
   [Popoff, Steven N.; Safadi, Fayez F.] Temple Univ, Sch Med, Dept Orthopaed Surg & Sport Med, Philadelphia, PA 19122 USA.
   [Safadi, Fayez F.] Temple Univ, Sch Med, Dept Otolaryngol, Philadelphia, PA 19122 USA.
   [Safadi, Fayez F.] Weill Cornell Med Coll Qatar, Dept Cell & Dev Biol, Doha, Qatar.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University; Ramapo College New Jersey (RCNJ); Pennsylvania Commonwealth
   System of Higher Education (PCSHE); Temple University; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Temple University;
   Qatar Foundation (QF); Weill Cornell Medical College Qatar
RP Safadi, FF (通讯作者)，Temple Univ, Sch Med, Dept Anat & Cell Biol, 3500 N Broad St,Room 446 MERB, Philadelphia, PA 19140 USA.
EM fsafadi@temple.edu
RI Safadi, Fayez/AAU 8699 2021
CR Abdelmagid SM, 2008, EXP CELL RES, V314, P2334, DOI 10.1016/j.yexcr.2008.02.006
   Abdelmagid SM, 2007, J CELL PHYSIOL, V210, P26, DOI 10.1002/jcp.20841
   Abdelmagid SM, 2010, J CELL BIOCHEM, V111, P295, DOI 10.1002/jcb.22702
   Abe H, 2007, BIOCHEM BIOPH RES CO, V356, P610, DOI 10.1016/j.bbrc.2007.03.035
   Adema GJ, 1996, BRIT J CANCER, V73, P1044, DOI 10.1038/bjc.1996.202
   Ahn JH, 2002, BLOOD, V100, P1742, DOI 10.1182/blood.V100.5.1742.h81702001742_1742_1754
   Akiyama Y, 2002, INT J ONCOL, V21, P509
   Akiyoshi H, 2010, J IMMUNOL, V184, P3554, DOI 10.4049/jimmunol.0903250
   Anderson MG, 2002, NAT GENET, V30, P81, DOI 10.1038/ng794
   Anderson MG, 2006, BMC BIOL, V4, DOI 10.1186/1741 7007 4 20
   Anderson MG, 2001, BMC GENET, V2, DOI 10.1186/1471 2156 2 1
   Bachner Dietmar, 2002, Brain Res Gene Expr Patterns, V1, P159
   Bandari PS, 2003, REGUL PEPTIDES, V111, P169, DOI 10.1016/S0167 0115(02)00288 4
   Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451
   Brunberg E, 2006, BMC GENET, V7, DOI 10.1186/1471 2156 7 46
   BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143
   Chung JS, 2007, J IMMUNOL, V179, P5778, DOI 10.4049/jimmunol.179.9.5778
   Chung JS, 2007, BLOOD, V109, P4320, DOI 10.1182/blood 2006 11 053769
   Chung JS, 2009, EUR J IMMUNOL, V39, P965, DOI 10.1002/eji.200838990
   Furochi Harumi, 2007, J Med Invest, V54, P248, DOI 10.2152/jmi.54.248
   Furochi H, 2007, FEBS LETT, V581, P5743, DOI 10.1016/j.febslet.2007.11.036
   Ghilardi C, 2008, BMC GENOMICS, V9, DOI 10.1186/1471 2164 9 201
   Haralanova Ilieva B, 2005, J HEPATOL, V42, P565, DOI 10.1016/j.jhep.2004.12.021
   Haraszti T, 2011, PIGM CELL MELANOMA R, V24, P187, DOI 10.1111/j.1755 148X.2010.00788.x
   Harper DC, 2008, J BIOL CHEM, V283, P2307, DOI 10.1074/jbc.M708007200
   Helip Wooley A, 2007, J INVEST DERMATOL, V127, P1471, DOI 10.1038/sj.jid.5700737
   Hoashi T, 2006, J BIOL CHEM, V281, P21198, DOI 10.1074/jbc.M601643200
   Hoashi T, 2010, FASEB J, V24, P1616, DOI 10.1096/fj.09 151019
   Howell GR, 2007, BMC GENET, V8, DOI 10.1186/1471 2156 8 45
   Karlsson C, 2010, OSTEOARTHR CARTILAGE, V18, P581, DOI 10.1016/j.joca.2009.12.002
   Kemp EH, 2001, CLIN EXP IMMUNOL, V124, P509, DOI 10.1046/j.1365 2249.2001.01516.x
   Kuan CT, 2006, CLIN CANCER RES, V12, P1970, DOI 10.1158/1078 0432.CCR 05 2797
   Lai CF, 2005, J BONE MINER RES, V20, P330, DOI 10.1359/JBMR.041013
   Lally KM, 2001, INT J CANCER, V93, P841, DOI 10.1002/ijc.1420
   Lennerz V, 2005, P NATL ACAD SCI USA, V102, P16013, DOI 10.1073/pnas.0500090102
   Li QS, 2009, J IMMUNOL, V183, P1975, DOI 10.4049/jimmunol.0803222
   Loftus SK, 2009, PIGM CELL MELANOMA R, V22, P99, DOI 10.1111/j.1755 148X.2008.00518.x
   Mendes O, 2005, CLIN EXP METASTAS, V22, P237, DOI 10.1007/s10585 005 8115 6
   Metz RL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1764
   Metz RL, 2005, CELL CYCLE, V4, P315
   Mo JS, 2003, J EXP MED, V197, P1335, DOI 10.1084/jem.20022041
   Mokarram P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007012
   NAKAMURA A, 2007, EXP TOXICOL PATHOL
   Nichols SE, 2003, J INVEST DERMATOL, V121, P821, DOI 10.1046/j.1523 1747.2003.12474.x
   Ogawa T, 2005, AM J PHYSIOL CELL PH, V289, pC697, DOI 10.1152/ajpcell.00565.2004
   Okamoto I, 2005, NEOPLASIA, V7, P303, DOI 10.1593/neo.04514
   Onaga M, 2003, J HEPATOL, V39, P779, DOI 10.1016/S0168 8278(03)00361 1
   Orlichenko LS, 2008, CLIN EXP METASTAS, V25, P593, DOI 10.1007/s10585 008 9143 9
   Ott C, 2003, J BIOL CHEM, V278, P44305, DOI 10.1074/jbc.M309140200
   Owen TA, 2003, CRIT REV EUKAR GENE, V13, P205, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.130
   Pahl MV, 2010, CLIN J AM SOC NEPHRO, V5, P56, DOI 10.2215/CJN.03390509
   Piccirillo R, 2006, J CELL SCI, V119, P2003, DOI 10.1242/jcs.02930
   Pollack VA, 2007, CANCER CHEMOTH PHARM, V60, P423, DOI 10.1007/s00280 007 0490 z
   Qian XZ, 2008, MOL ONCOL, V2, P81, DOI 10.1016/j.molonc.2008.02.002
   Rahman S, 1998, BIOCHEM J, V335, P247, DOI 10.1042/bj3350247
   Reiter F, 2007, ONCOGENE, V26, P1769, DOI 10.1038/sj.onc.1209975
   Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200
   Ripoll VM, 2008, GENE, V413, P32, DOI 10.1016/j.gene.2008.01.014
   Ripoll VM, 2007, J IMMUNOL, V178, P6557, DOI 10.4049/jimmunol.178.10.6557
   Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541 7786.MCR 07 0119
   Rose AAN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012093
   Rose AAN, 2010, CLIN CANCER RES, V16, P2147, DOI 10.1158/1078 0432.CCR 09 1611
   Rose AAN, 2010, FUTURE ONCOL, V6, P55, DOI [10.2217/fon.09.138, 10.2217/FON.09.138]
   Rose AAN, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1791
   Safadi FF, 2002, J CELL BIOCHEM, V84, P12, DOI 10.1002/jcb.1259
   Scheffers MS, 2002, HUM MOL GENET, V11, P59, DOI 10.1093/hmg/11.1.59
   Schneider GB, 2001, J DENT RES, V80, P1540, DOI 10.1177/00220345010800061201
   Selim AA, 2003, CRIT REV EUKAR GENE, V13, P265, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.180
   Selim AA, 2007, MED SCI MONITOR, V13, pBR259
   Selim AA, 2009, MED SCI MONITOR, V15, pMT19
   Sensi M, 2002, TISSUE ANTIGENS, V59, P273, DOI 10.1034/j.1399 0039.2002.590404.x
   Setaluri V, 2000, PIGM CELL RES, V13, P128, DOI 10.1034/j.1600 0749.2000.130302.x
   Sheng MHC, 2008, FEBS LETT, V582, P1451, DOI 10.1016/j.febslet.2008.03.030
   Shikano S, 2001, J BIOL CHEM, V276, P8125, DOI 10.1074/jbc.M008539200
   Theos AC, 2006, MOL BIOL CELL, V17, P3598, DOI 10.1091/mbc.E06 01 0081
   Tomihari M, 2010, CANCER RES, V70, P5778, DOI 10.1158/0008 5472.CAN 09 2538
   Tomihari M, 2009, EXP DERMATOL, V18, P586, DOI 10.1111/j.1600 0625.2008.00830.x
   Tse KF, 2006, CLIN CANCER RES, V12, P1373, DOI 10.1158/1078 0432.CCR 05 2018
   Turque N, 1996, EMBO J, V15, P3338, DOI 10.1002/j.1460 2075.1996.tb00699.x
   WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111
   Yasumoto K, 2004, J BIOL CHEM, V279, P28330, DOI 10.1074/jbc.M401269200
   ZERIVITZ K, 1989, GENE ANAL TECH, V6, P101, DOI 10.1016/0735 0651(89)90016 2
NR 82
TC 33
Z9 39
U1 0
U2 7
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 1045 4403
EI 2162 6502
J9 CRIT REV EUKAR GENE
JI Crit. Rev. Eukaryot. Gene Expr.
PY 2010
VL 20
IS 4
BP 341
EP 357
DI 10.1615/CritRevEukarGeneExpr.v20.i4.50
PG 17
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 737OJ
UT WOS:000288577800005
PM 21395506
DA 2025 08 17
ER

PT J
AU Dolci, LS
   Panzavolta, S
   Torricelli, P
   Albertini, B
   Sicuro, L
   Fini, M
   Bigi, A
   Passerini, N
AF Dolci, Luisa Stella
   Panzavolta, Silvia
   Torricelli, Paola
   Albertini, Beatrice
   Sicuro, Laura
   Fini, Milena
   Bigi, Adriana
   Passerini, Nadia
TI Modulation of Alendronate release from a calcium phosphate bone cement:
   An in vitro osteoblast osteoclast co culture study
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Solid Lipid Microparticles; Calcium phosphate bone cements; Sodium
   Alendronate; Spray congealing; Osteoblast osteoclast cell cultures
ID DRUG DELIVERY; MOLECULAR MECHANISMS; BISPHOSPHONATES; MICROPARTICLES;
   SYSTEM
AB In this study, we loaded a biomimetic calcium phosphate bone cement (CPC) with relatively high amounts of a bisphosphonate through the use of Solid Lipid Microparticles (MPs) and investigated bone cells response to the composite cements. 10, 20 and 30% w/w of Alendronate (AL) were successfully introduced into microparticles of Cutina HR and Precirol, which were prepared by means of spray congealing technique. Addition of AL loaded MPs to the cement composition provoked a lengthening of the setting and of the hardening processes. However, setting times were still in a range useful for clinical applications, except for the cements at the highest Alendronate content. The composite cements displayed a sustained drug release over time. Cements with the best performances in terms of setting, hardening, mechanical properties and drug release were submitted to in vitro tests using a co culture model of osteoblast and osteoclast. The results showed that the use of MPs to enrich the cement composition with Alendronate provides materials able to inhibit osteoclast viability and activity, while promoting osteoblast viability and earlier differentiation, indicating that the MPs cements are good delivery systems for bisphosphonates.
C1 [Dolci, Luisa Stella; Albertini, Beatrice; Passerini, Nadia] Univ Bologna, Dept Pharm & BioTechnol, Via S Donato 19 2, I 40127 Bologna, Italy.
   [Panzavolta, Silvia; Bigi, Adriana] Univ Bologna, Dept Chem G Ciamician, Via Selmi 2, I 40126 Bologna, Italy.
   [Torricelli, Paola; Sicuro, Laura; Fini, Milena] IRCCS Rizzoli Orthopaed Inst, Lab Preclin & Surg Studies, Via Barbiano 1 10, I 40136 Bologna, Italy.
C3 University of Bologna; University of Bologna; IRCCS Istituto Ortopedico
   Rizzoli
RP Panzavolta, S (通讯作者)，Univ Bologna, Dept Chem G Ciamician, Via Selmi 2, I 40126 Bologna, Italy.
EM silvia.panzavolta@unibo.it
RI Panzavolta, Silvia/Q 1550 2019; Bigi, Adriana/R 6341 2016; Torricelli,
   Paola/J 5298 2016; Fini, Milena/J 4808 2016
OI Sicuro, Laura/0000 0002 1917 5850; Bigi, Adriana/0000 0003 2668 8627;
   Panzavolta, Silvia/0000 0002 2937 2284; Fini,
   Milena/0000 0002 3732 3570; TORRICELLI, PAOLA/0000 0001 7494 9970
FU Rizzoli Orthopaedic Institute [6879]
FX The authors are grateful to Rizzoli Orthopaedic Institute (funds 5 X
   1000 year 2015, cod. 6879).
CR Akkineni AR, 2015, ACTA BIOMATER, V27, P264, DOI 10.1016/j.actbio.2015.08.036
   Al Deeb SK, 2004, TALANTA, V64, P695, DOI 10.1016/j.talanta.2004.03.044
   Albertini B, 2014, INT J PHARMACEUT, V469, P67, DOI 10.1016/j.ijpharm.2014.04.055
   Amadori S., 2015, J MATER SCI MATER M, V26, P1
   [Anonymous], ORTHOPEDICS
   Bertoni S, 2018, EUR J PHARM BIOPHARM, V132, P1, DOI 10.1016/j.ejpb.2018.08.014
   Bigi A, 2004, CHEM MATER, V16, P3740, DOI 10.1021/cm049363e
   Bigi A, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9010006
   Bohner M, 2007, J MATER CHEM, V17, P3980, DOI 10.1039/b706411j
   Burr D, 2011, BONE, V49, P1, DOI 10.1016/j.bone.2011.05.019
   Dolci LS, 2018, EUR J PHARM BIOPHARM, V122, P6, DOI 10.1016/j.ejpb.2017.10.002
   Dorozhkin SV, 2008, J MATER SCI, V43, P3028, DOI 10.1007/s10853 008 2527 z
   Dorozhkin SV, 2013, J FUNCT BIOMATER, V4, P209, DOI 10.3390/jfb4040209
   Faucheux C, 2008, J BIOMED MATER RES A, V46, P56
   Favia G, 2009, BONE, V45, P406, DOI 10.1016/j.bone.2009.05.008
   Fazil M, 2015, DRUG DELIV, V22, P1, DOI 10.3109/10717544.2013.870259
   Ginebra MP, 2012, ADV DRUG DELIVER REV, V64, P1090, DOI 10.1016/j.addr.2012.01.008
   Giocondi JL, 2010, PHILOS T R SOC A, V368, P1937, DOI 10.1098/rsta.2010.0006
   Kim CW, 2010, J CONTROL RELEASE, V147, P45, DOI 10.1016/j.jconrel.2010.06.016
   Kyllönen L, 2015, ACTA BIOMATER, V11, P412, DOI 10.1016/j.actbio.2014.09.006
   Lanao RPF, 2013, J BIOMED MATER RES A, V101, P3123, DOI 10.1002/jbm.a.34623
   Li M, 2010, CLIN ORTHOP RELAT R, V468, P1978, DOI 10.1007/s11999 010 1321 9
   Li YH, 2015, EXP BIOL MED, V240, P1465, DOI 10.1177/1535370215579142
   Matos AC, 2015, INT J PHARMACEUT, V485, P317, DOI 10.1016/j.ijpharm.2015.03.035
   Matos AC, 2014, MAT SCI ENG C MATER, V38, P218, DOI 10.1016/j.msec.2014.02.002
   Panzavolta S, 2010, J INORG BIOCHEM, V104, P1099, DOI 10.1016/j.jinorgbio.2010.06.008
   Panzavolta S, 2009, J INORG BIOCHEM, V103, P101, DOI 10.1016/j.jinorgbio.2008.09.012
   Panzavolta S, 2011, J INORG BIOCHEM, V105, P1060, DOI 10.1016/j.jinorgbio.2011.05.006
   Passerini N, 2016, INT J PHARMACEUT, V512, P126, DOI 10.1016/j.ijpharm.2016.08.024
   Peter B, 2005, BONE, V36, P52, DOI 10.1016/j.bone.2004.10.004
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Rizzoli R, 2011, OSTEOPOROSIS INT, V22, P373, DOI 10.1007/s00198 010 1453 5
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Roy A, 2016, MAT SCI ENG C MATER, V59, P92, DOI 10.1016/j.msec.2015.09.081
   Schnitzler V, 2011, ACTA BIOMATER, V7, P759, DOI 10.1016/j.actbio.2010.09.017
   Shen ZH, 2014, MAT SCI ENG C MATER, V42, P303, DOI 10.1016/j.msec.2014.05.043
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Vargas Franco JW, 2018, J CELL PHYSIOL, V233, P5696, DOI 10.1002/jcp.26465
   Verron E, 2014, DRUG DISCOV TODAY, V19, P312, DOI 10.1016/j.drudis.2013.08.010
   Verron E, 2012, ACTA BIOMATER, V8, P3541, DOI 10.1016/j.actbio.2012.06.022
   Zhang JT, 2014, ACTA BIOMATER, V10, P1035, DOI 10.1016/j.actbio.2013.11.001
NR 41
TC 33
Z9 35
U1 2
U2 90
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JAN 10
PY 2019
VL 554
BP 245
EP 255
DI 10.1016/j.ijpharm.2018.11.023
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HF7LR
UT WOS:000454421400024
PM 30423416
DA 2025 08 17
ER

PT J
AU Kim, JW
   Lee, KK
   Park, KW
   Kim, M
   Lee, CS
AF Kim, Jong Won
   Lee, Kyung Kwan
   Park, Kyoung Woo
   Kim, Moonil
   Lee, Chang Soo
TI Genetically Modified Ferritin Nanoparticles with Bone Targeting Peptides
   for Bone Imaging
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE bone targeting peptides; ferritin nanoparticles; osteoblasts;
   hydroxyapatite; bioimaging
ID DRUG DELIVERY; OSTEOPOROSIS; PROTEIN; MECHANISMS; THERAPY; ALPHA
AB Bone homeostasis plays a major role in supporting and protecting various organs as well as a body structure by maintaining the balance of activities of the osteoblasts and osteoclasts. Unbalanced differentiation and functions of these cells result in various skeletal diseases, such as osteoporosis, osteopetrosis, and Paget's disease. Although various synthetic nanomaterials have been developed for bone imaging and therapy through the chemical conjugation, they are associated with serious drawbacks, including heterogeneity and random orientation, in turn resulting in low efficiency. Here, we report the synthesis of bone targeting ferritin nanoparticles for bone imaging. Ferritin, which is a globular protein composed of 24 subunits, was employed as a carrier molecule. Bone targeting peptides that have been reported to specifically bind to osteoblast and hydroxyapatite were genetically fused to the N terminus of the heavy subunit of human ferritin in such a way that the peptides faced outwards. Ferritin nanoparticles with fused bone targeting peptides were also conjugated with fluorescent dyes to assess their binding ability using osteoblast imaging and a hydroxyapatite binding assay; the results showed their specific binding with osteoblasts and hydroxyapatite. Using in vivo analysis, a specific fluorescent signal from the lower limb was observed, demonstrating a highly selective affinity of the modified nanoparticles for the bone tissue. These promising results indicate a specific binding ability of the nanoscale targeting system to the bone tissue, which might potentially be used for bone disease therapy in future clinical applications.
C1 [Kim, Jong Won; Lee, Kyung Kwan; Park, Kyoung Woo; Kim, Moonil; Lee, Chang Soo] Korea Res Inst Biosci & Biotechnol KRIBB, Bionanotechnol Res Ctr, Daejeon 34141, South Korea.
   [Lee, Kyung Kwan] Kyung Hee Univ, Dept Life & Nanopharmaceut Sci, Coll Pharm, Seoul 02447, South Korea.
   [Park, Kyoung Woo; Kim, Moonil; Lee, Chang Soo] Univ Sci & Technol UST, Dept Biotechnol, Daejeon 34113, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB); Kyung
   Hee University; University of Science & Technology (UST)
RP Kim, M; Lee, CS (通讯作者)，Korea Res Inst Biosci & Biotechnol KRIBB, Bionanotechnol Res Ctr, Daejeon 34141, South Korea.; Kim, M; Lee, CS (通讯作者)，Univ Sci & Technol UST, Dept Biotechnol, Daejeon 34113, South Korea.
EM kimjw@kribb.re.kr; lkk@kribb.re.kr; qkrruddn94@kribb.re.kr;
   kimm@kribb.re.kr; cslee@kribb.re.kr
OI Lee, Chang Soo/0000 0002 4965 5070
FU National Research Council of Science & Technology (NST)
   [QLT CRC 18 01 ETRI]; National Research Foundation
   [NRF 2019R1A2C1084687]; Government of Korea (MSIT); Korea Research
   Institute of Bioscience and Biotechnology (KRIBB) Research Initiative
   Program [KGM5472113]
FX This work was supported by the National Research Council of Science &
   Technology (NST) (No. QLT CRC 18 01 ETRI) and the National Research
   Foundation (NRF 2019R1A2C1084687) grant by the Government of Korea
   (MSIT), and the Korea Research Institute of Bioscience and Biotechnology
   (KRIBB) Research Initiative Program (KGM5472113).
CR Amarasekara DS, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/832127
   Carrodeguas RG, 2011, ACTA BIOMATER, V7, P3536, DOI 10.1016/j.actbio.2011.06.019
   Chen YB, 2020, VACCINE, V38, P5647, DOI 10.1016/j.vaccine.2020.06.063
   Feng LH, 2013, CHEM SOC REV, V42, P6620, DOI 10.1039/c3cs60036j
   He JY, 2019, J CONTROL RELEASE, V311, P288, DOI 10.1016/j.jconrel.2019.09.002
   Huard DJE, 2013, NAT CHEM BIOL, V9, P169, DOI [10.1038/NCHEMBIO.1163, 10.1038/nchembio.1163]
   Jeon H, 2017, MOL PHARMACEUT, V14, P3772, DOI 10.1021/acs.molpharmaceut.7b00520
   Jiang ZX, 2019, BIOMATER SCI UK, V7, P461, DOI 10.1039/c8bm01340c
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   Khoshnejad M, 2018, J CONTROL RELEASE, V282, P13, DOI 10.1016/j.jconrel.2018.02.042
   Kim JW, 2017, ANAL CHIM ACTA, V988, P81, DOI 10.1016/j.aca.2017.07.060
   Kim M, 2011, BIOMACROMOLECULES, V12, P1629, DOI 10.1021/bm200026v
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Li K, 2012, NANOSCALE, V4, P188, DOI 10.1039/c1nr11132a
   Li X, 2012, SMALL, V8, P2505, DOI 10.1002/smll.201200066
   Lin X, 2011, NANO LETT, V11, P814, DOI 10.1021/nl104141g
   Lin X, 2011, ANGEW CHEM INT EDIT, V50, P1569, DOI 10.1002/anie.201006757
   Litvin J, 2004, J CELL BIOCHEM, V92, P1044, DOI 10.1002/jcb.20115
   Luhmann T, 2012, J CONTROL RELEASE, V161, P198, DOI 10.1016/j.jconrel.2011.10.001
   Luther DC, 2020, ADV DRUG DELIVER REV, V156, P188, DOI 10.1016/j.addr.2020.06.020
   Maiti D, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01401
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Murphy MB, 2007, BIOMACROMOLECULES, V8, P2237, DOI 10.1021/bm070121s
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Park CS, 2018, BIOSENS BIOELECTRON, V105, P151, DOI 10.1016/j.bios.2018.01.018
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Ryu TK, 2016, J CONTROL RELEASE, V232, P152, DOI 10.1016/j.jconrel.2016.04.025
   Sercombe L, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00286
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Spicer CD, 2018, CHEM SOC REV, V47, P3574, DOI 10.1039/c7cs00877e
   Sun W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07626 8
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Thanh NTK, 2010, NANO TODAY, V5, P213, DOI 10.1016/j.nantod.2010.05.003
   THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.bi.56.070187.001445
   Wang MN, 2020, BONE RES, V8, DOI 10.1038/s41413 020 00105 1
   Wang XY, 2019, J CONTROL RELEASE, V316, P381, DOI 10.1016/j.jconrel.2019.11.005
   Wang ZT, 2017, FRONT CHEM SCI ENG, V11, P633, DOI 10.1007/s11705 017 1620 8
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
NR 40
TC 13
Z9 13
U1 3
U2 28
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2021
VL 22
IS 9
AR 4854
DI 10.3390/ijms22094854
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA SB9YG
UT WOS:000650340000001
PM 34063731
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lesniewski Kmak, K
   Radecka, B
   Litwiniuk, M
AF Lesniewski Kmak, Krzysztof
   Radecka, Barbara
   Litwiniuk, Maria
TI Bone tissue as the site of action of oncological drugs
SO WSPOLCZESNA ONKOLOGIA CONTEMPORARY ONCOLOGY
LA English
DT Article
DE bone tissue; chemotherapy; targeted therapy; hormonal treatment;
   bisphosphonates
ID ANDROGEN DEPRIVATION THERAPY; OSTEOCLAST DIFFERENTIATION FACTOR;
   HORMONE RELATED PROTEIN; PRIMARY BREAST CANCER; GROWTH FACTOR I;
   NONMETASTATIC PROSTATE CANCER; HUMANIZED MONOCLONAL ANTIBODY; HEALTHY
   POSTMENOPAUSAL WOMEN; OSTEOBLAST LIKE CELLS; X RAY ABSORPTIOMETRY
AB Anticancer therapy has multiple, sometimes life threatening side effects, and their influence on bone is not seen as important. Data have been published confirming the existence of side effects chemotherapy has on bone, which affect patients' quality of life. They influence a bone tissue not only in a direct way, but also when suppressing the activity of gonads. We have no information on the impact of drugs on bone belonging to the "targeted therapies". There are, however, some attempts to create antibodies that target proteins involved in bone physiology. Relatively well known is the impact of anti cancer hormone therapy on bone metabolism. The most commonly used drugs in this type of therapy are: analogues of luteinizing hormone releasing hormone (LHRH), selective oestrogen receptor modulators (SERMs), aromatase inhibitors and antiandrogens. A group of preparations particularly connected with this issue is the bisphosphonates, entering into interaction both with bone cells and colonizing tumour cells.
C1 [Lesniewski Kmak, Krzysztof] Med Univ Gdansk, Dept Oncol Propaedeut, PL 81519 Gdynia, Poland.
   [Litwiniuk, Maria] Poznan Univ Med Sci, Dept Oncol, Poznan, Poland.
C3 Fahrenheit Universities; Medical University Gdansk; Poznan University of
   Medical Sciences
RP Lesniewski Kmak, K (通讯作者)，Med Univ Gdansk, Dept Oncol Propaedeut, Powstania Styczniowego 9B, PL 81519 Gdynia, Poland.
EM klkmak@gumed.edu.pl
RI ; Litwiniuk, Maria/ABE 8460 2021
OI Litwiniuk, Maria/0000 0001 8428 3877; 
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Albrand G, 2003, BONE, V32, P78, DOI 10.1016/S8756 3282(02)00919 5
   Baum M, 2003, Cancer, V98, P1802
   Berruti A, 2002, J UROLOGY, V167, P2361, DOI 10.1016/S0022 5347(05)64985 3
   BISHOP MC, 1989, BRIT J UROL, V64, P290, DOI 10.1111/j.1464 410X.1989.tb06016.x
   BOKEMEYER C, 1994, ANN HEMATOL, V68, P105, DOI 10.1007/BF01727413
   BOLOGNA C, 1994, ARTHRITIS RHEUM, V37, P1770, DOI 10.1002/art.1780371210
   Boyce BF, 2003, KIDNEY INT, V63, pS2, DOI 10.1046/j.1523 1755.63.s85.2.x
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   Brufsky AM, 2009, CLIN BREAST CANCER, V9, P77, DOI 10.3816/CBC.2009.n.015
   BRUNING PF, 1990, BRIT J CANCER, V61, P308, DOI 10.1038/bjc.1990.58
   BURK CD, 1990, J PEDIATR US, V117, P331, DOI 10.1016/S0022 3476(05)80557 8
   Byar D P, 1988, NCI Monogr, P165
   Carani C, 1997, NEW ENGL J MED, V337, P91, DOI 10.1056/NEJM199707103370204
   Castaneda S, 1997, CALCIFIED TISSUE INT, V60, P343, DOI 10.1007/s002239900240
   CHATTERJEE R, 1994, BONE MARROW TRANSPL, V13, P511
   Chien AJ, 2006, J CLIN ONCOL, V24, P5305, DOI 10.1200/JCO.2006.07.5382
   Coates AS, 2007, J CLIN ONCOL, V25, P486, DOI 10.1200/JCO.2006.08.8617
   Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331
   Cuzick J, 2002, LANCET, V360, P817
   Daniell HW, 2000, J UROLOGY, V163, P181, DOI 10.1016/S0022 5347(05)68000 7
   De Laet C, 2005, OSTEOPOROSIS INT, V16, P1330, DOI 10.1007/s00198 005 1863 y
   DEQUEKER J, 1995, CLIN EXP RHEUMATOL, V13, P21
   DESCHEPPER J, 1994, ARCH DIS CHILD, V71, P346, DOI 10.1136/adc.71.4.346
   Diamond T, 1998, CANCER, V83, P1561, DOI 10.1002/(SICI)1097 0142(19981015)83:8<1561::AID CNCR11>3.0.CO;2 Z
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Ecklund K, 1997, RADIOLOGY, V202, P543, DOI 10.1148/radiology.202.2.9015088
   Eidtmann H, 2010, ANN ONCOL, V21, P2188, DOI 10.1093/annonc/mdq217
   ERIKSSON S, 1995, CALCIFIED TISSUE INT, V57, P97, DOI 10.1007/BF00298427
   ERNST M, 1989, ENDOCRINOLOGY, V125, P825, DOI 10.1210/endo 125 2 825
   Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Fogelman I, 2003, OSTEOPOROSIS INT, V14, P1001, DOI 10.1007/s00198 003 1508 y
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Giuliani N, 1998, SCAND J RHEUMATOL, V27, P38
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Gnant M, 2008, LANCET ONCOL, V9, P840, DOI 10.1016/S1470 2045(08)70204 3
   GNUDI S, 1988, Italian Journal of Orthopaedics and Traumatology, V14, P227
   Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312
   Goss PE, 2005, JNCI J NATL CANCER I, V97, P1262, DOI 10.1093/jnci/dji250
   Halton JM, 1996, J BONE MINER RES, V11, P1774
   Hannon RA, 2010, J BONE MINER RES, V25, P463, DOI 10.1359/jbmr.090830
   Hellerstedt BA, 2002, CA CANCER J CLIN, V52, P154, DOI 10.3322/canjclin.52.3.154
   Hershman DL, 2008, J CLIN ONCOL, V26, P4739, DOI 10.1200/JCO.2008.16.4707
   Hofbauer LC, 1999, EUR J ENDOCRINOL, V140, P271, DOI 10.1530/eje.0.1400271
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   HOLMES SJ, 1994, BRIT J CANCER, V70, P371, DOI 10.1038/bjc.1994.308
   Hui LF, 1996, AM J HEMATOL, V52, P184, DOI 10.1002/(SICI)1096 8652(199607)52:3<184::AID AJH8>3.0.CO;2 P
   Ito M, 1999, BONE, V25, P447, DOI 10.1016/S8756 3282(99)00197 0
   Jakesz R, 2005, LANCET, V366, P455, DOI 10.1016/S0140 6736(05)67059 6
   Joensuu H, 2005, ACTA ONCOL, V44, P23, DOI 10.1080/02841860510007468
   JOHANSEN JS, 1988, J CLIN ENDOCR METAB, V67, P701, DOI 10.1210/jcem 67 4 701
   Kanis JA, 2004, BONE, V35, P1029, DOI 10.1016/j.bone.2004.06.017
   KATZ JN, 1989, CLIN RES, V37, pA509
   Kokufu I, 2004, P AN M AM SOC CLIN, V23, P9
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Kother M, 1992, In Vivo, V6, P219
   KREUSER ED, 1992, ANN ONCOL, V3, pS105, DOI 10.1093/annonc/3.suppl_4.S105
   KRISTENSEN B, 1994, J CLIN ONCOL, V12, P992, DOI 10.1200/JCO.1994.12.5.992
   Langlois JA, 1998, J CLIN ENDOCR METAB, V83, P4257, DOI 10.1210/jc.83.12.4257
   Lesniewski Kmak K, 2002, BREAST CANCER RES TR, V73, P189, DOI 10.1023/A:1015808417792
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302
   Maenaut K, 1996, J RHEUMATOL, V23, P2156
   Maillefert JF, 1999, J UROLOGY, V161, P1219, DOI 10.1016/S0022 5347(01)61639 2
   MARTIN TJ, 1992, J STEROID BIOCHEM, V43, P123, DOI 10.1016/0960 0760(92)90196 P
   Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586
   McCloskey EV, 2007, EUR J CANCER, V43, P2523, DOI 10.1016/j.ejca.2007.08.029
   MEISTER B, 1994, MED PEDIATR ONCOL, V23, P493, DOI 10.1002/mpo.2950230608
   MURAKAMI H, 1995, BONE, V17, P137, DOI 10.1016/S8756 3282(95)00150 6
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   NESBIT M, 1976, CANCER AM CANCER SOC, V37, P1048, DOI 10.1002/1097 0142(197602)37:2+<1048::AID CNCR2820370811>3.0.CO;2 V
   NEVINNY HB, 1965, METABOLIS, V14, P135, DOI 10.1016/S0026 0495(65)80035 X
   Ockrim JL, 2004, J UROLOGY, V172, P2203, DOI 10.1097/01.ju.0000145511.56476.00
   Oefelein MG, 2002, J UROLOGY, V168, P1005, DOI 10.1016/S0022 5347(05)64561 2
   Onuma E, 2004, ANTICANCER RES, V24, P2665
   OREGAN S, 1973, AM J DIS CHILD, V126, P489, DOI 10.1001/archpedi.1973.02110190403008
   OURSLER MJ, 1991, ENDOCRINOLOGY, V129, P3313, DOI 10.1210/endo 129 6 3313
   Perez EA, 2006, J CLIN ONCOL, V24, P3629, DOI 10.1200/JCO.2005.05.4882
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Powles T, 1996, J CLIN ONCOL, V14, P78, DOI 10.1200/JCO.1996.14.1.78
   Powles TJ, 1998, J NATL CANCER I, V90, P704, DOI 10.1093/jnci/90.9.704
   PRESTON SJ, 1993, ANN RHEUM DIS, V52, P582, DOI 10.1136/ard.52.8.582
   RAGAB AH, 1970, CANCER, V25, P580, DOI 10.1002/1097 0142(197003)25:3<580::AID CNCR2820250313>3.0.CO;2 M
   RATCLIFFE MA, 1992, HEMATOL ONCOL, V10, P181, DOI 10.1002/hon.2900100308
   REDMAN JR, 1988, AM J MED, V85, P65, DOI 10.1016/0002 9343(88)90504 9
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Saito H, 2005, ANTICANCER RES, V25, P3817
   Sato K, 2003, SEMIN ONCOL, V30, P167, DOI 10.1053/j.seminoncol.2003.08.019
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   SCHAPIRA D, 1995, CLIN EXP RHEUMATOL, V13, P130
   SCHEVEN BAA, 1995, J BONE MINER RES, V10, P874
   Schimmer AD, 1998, J CLIN ONCOL, V16, P2359, DOI 10.1200/JCO.1998.16.7.2359
   SCHWARTZ AM, 1984, SKELETAL RADIOL, V11, P13, DOI 10.1007/BF00361126
   Sieber PR, 2004, J UROLOGY, V171, P2272, DOI 10.1097/01.ju.0000127738.94221.da
   Siris ES, 2004, ARCH INTERN MED, V164, P1108, DOI 10.1001/archinte.164.10.1108
   SKINNER R, 1990, ARCH DIS CHILD, V65, P732, DOI 10.1136/adc.65.7.732
   SMEITINK J, 1988, EUR J PEDIATR, V148, P164, DOI 10.1007/BF00445929
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Smith MR, 2005, J CLIN ONCOL, V23, P7897, DOI 10.1200/JCO.2004.00.6908
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Smith MR, 2001, NEW ENGL J MED, V345, P948, DOI 10.1056/NEJMoa010845
   STANISAVLJEVIC S, 1977, CLIN ORTHOP RELAT R, V125, P139
   Strasser Weippl K, 2005, J CLIN ONCOL, V23, P1751, DOI 10.1200/JCO.2005.11.038
   Tattersfield Anne E, 2004, Proc Am Thorac Soc, V1, P171, DOI 10.1513/pats.200402 016MS
   Teinturier C, 1998, BONE MARROW TRANSPL, V22, P989, DOI 10.1038/sj.bmt.1701483
   Townsend MF, 1997, CANCER, V79, P545, DOI 10.1002/(SICI)1097 0142(19970201)79:3<545::AID CNCR17>3.0.CO;2 3
   TURNER RT, 1994, ENDOCR REV, V15, P275, DOI 10.1210/er.15.3.275
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   VanderVeen MJ, 1996, BRIT J RHEUMATOL, V35, P342
   Vitte C, 1996, ENDOCRINOLOGY, V137, P2324, DOI 10.1210/en.137.6.2324
   Wang YM, 2006, J BONE MINER RES, V21, P1350, DOI 10.1359/JBMR.060610
   WARD SB, 1992, ARTHRITIS RHEUM S5, V35, pR5
   Yakar S, 2009, J BONE MINER RES, V24, P1481, DOI [10.1359/JBMR.090226, 10.1359/jbmr.090226]
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674
   Zonneveld IM, 1996, ARCH DERMATOL, V132, P184, DOI 10.1001/archderm.132.2.184
NR 120
TC 1
Z9 1
U1 0
U2 2
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61 615, POLAND
SN 1428 2526
EI 1897 4309
J9 WSPOLCZESNA ONKOL
JI Wspolczesna Onkol.
PD JUN
PY 2011
VL 15
IS 3
BP 147
EP 154
DI 10.5114/wo.2011.23004
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 791QQ
UT WOS:000292680100004
OA Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Posritong, S
   Hong, JM
   Eleniste, PP
   McIntyre, PW
   Wu, JL
   Himes, ER
   Patel, V
   Kacena, MA
   Bruzzaniti, A
AF Posritong, Sumana
   Hong, Jung Min
   Eleniste, Pierre P.
   McIntyre, Patrick W.
   Wu, Jennifer L.
   Himes, Evan R.
   Patel, Vruti
   Kacena, Melissa A.
   Bruzzaniti, Angela
TI Pyk2 deficiency potentiates osteoblast differentiation and mineralizing
   activity in response to estrogen or raloxifene
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Pyk2; Estrogen receptor; SERMs; Osteoblast; Bone formation;
   Mineralization
ID PROTEASOME DEPENDENT DEGRADATION; ACTIVATED PROTEIN KINASE;
   RECEPTOR ALPHA; BONE FORMATION; BREAST CANCER; MECHANICAL STRAIN;
   GENE EXPRESSION; GROWTH FACTOR; ER ALPHA; BETA
AB Bone remodeling is controlled by the actions of bone degrading osteoclasts and bone forming osteoblasts (OBs). Aging and loss of estrogen after menopause affects bone mass and quality. Estrogen therapy, including selective estrogen receptor modulators (SERMs), can prevent bone loss and increase bone mineral density in post menopausal women. Although investigations of the effects of estrogen on osteoclast activity are well advanced, the mechanism of action of estrogen on OBs is still unclear. The proline rich tyrosine kinase 2 (Pyk2) is important for bone formation and female mice lacking Pyk2 (Pyk2 KO) exhibit elevated bone mass, increased bone formation rate and reduced osteoclast activity. Therefore, in the current study, we examined the role of estrogen signaling on the mechanism of action of Pyk2 in OBs. As expected, Pyk2 KO OBs showed significantly higher proliferation, matrix formation, and mineralization than WT OBs. In addition we found that Pyk2 KO OBs cultured in the presence of either 17 beta estradiol (E2) or raloxifene, a SERM used for the treatment of post menopausal osteoporosis, showed a further robust increase in alkaline phosphatase (ALP) activity and mineralization. We examined the possible mechanism of action and found that Pyk2 deletion promotes the proteasome mediated degradation of estrogen receptor alpha (ER alpha), but not estrogen receptor beta (ER beta). As a consequence, E2 signaling via ER beta was enhanced in Pyk2 KO OBs. In addition, we found that Pyk2 deletion and E2 stimulation had an additive effect on ERK phosphorylation, which is known to stimulate cell differentiation and survival. Our findings suggest that in the absence of Pyk2, estrogen exerts an osteogenic effect on OBs through altered ER alpha and ER beta signaling. Thus, targeting Pyk2, in combination with estrogen or raloxifene, may be a novel strategy for the prevention and/or treatment of bone loss diseases. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Posritong, Sumana; Hong, Jung Min; Eleniste, Pierre P.; McIntyre, Patrick W.; Wu, Jennifer L.; Patel, Vruti; Bruzzaniti, Angela] Indiana Univ, Sch Dent, Dept Biomed & Appl Sci, Indianapolis, IN 46202 USA.
   [Himes, Evan R.; Kacena, Melissa A.] Indiana Univ Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Indianapolis; Indiana
   University System; Indiana University Bloomington
RP Bruzzaniti, A (通讯作者)，Indiana Univ, Sch Dent, 1121 W Michigan St,DS 243, Indianapolis, IN 46202 USA.
EM sposrito@iupui.edu; hongjung@iupui.edu; pelenist@iu.edu;
   pwmcinty@iu.edu; jenwu@iu.edu; himese88@hotmail.com; vrutpate@iu.edu;
   mkacena@iupui.edu; abruzzan@iu.edu
RI Bruzzaniti, Angela/AAP 2225 2020
FU National Institute of Health, NIAMS [R01 AR060332]; Indiana Clinical and
   Translational Science Institute, Collaboration in
   Biomedical/Translational Research (CBR/CTR) Pilot Program [RR025761,
   TR000006]; IUPUI Office of the Vice Chancellor for Research (OVCR)
   Research Support Funds Grant (RSFG); IUPUI Biomechanics and Biomaterials
   Research Center (BBRC) Grant
FX Grant sponsors and numbers: National Institute of Health, NIAMS
   R01 AR060332; Indiana Clinical and Translational Science Institute,
   Collaboration in Biomedical/Translational Research (CBR/CTR) Pilot
   Program Grants, RR025761, TR000006; IUPUI Office of the Vice Chancellor
   for Research (OVCR) Research Support Funds Grant (RSFG); IUPUI
   Biomechanics and Biomaterials Research Center (BBRC) Grant. We thank
   past and present members of our laboratories for technical assistance.
   We also thank Dr. Russell P. Main and Dr. Sarah H. Windahl for
   thoughtful suggestions and comments regarding these studies.
CR Almeida M, 2013, J CLIN INVEST, V123, P394, DOI 10.1172/JCI65910
   [Anonymous], J SIGNAL TRANSDUCT
   Arts J, 1997, ENDOCRINOLOGY, V138, P5067, DOI 10.1210/en.138.11.5067
   Ayala Peña VB, 2013, EXP CELL RES, V319, P2028, DOI 10.1016/j.yexcr.2013.05.006
   BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496
   Bonnelye E, 2002, J BONE MINER RES, V17, P1392, DOI 10.1359/jbmr.2002.17.8.1392
   Bonnelye E, 2001, J CELL BIOL, V153, P971, DOI 10.1083/jcb.153.5.971
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Boutahar N, 2004, J BIOL CHEM, V279, P30588, DOI 10.1074/jbc.M313244200
   Bruzzaniti A, 2005, MOL BIOL CELL, V16, P3301, DOI 10.1091/mbc.E04 12 1117
   Buckbinder L, 2007, P NATL ACAD SCI USA, V104, P10619, DOI 10.1073/pnas.0701421104
   Burr DB., 2013, BASIC APPL BONE BIOL
   Cao LH, 2003, J CELL BIOCHEM, V89, P152, DOI 10.1002/jcb.10486
   Carmeci C, 1997, GENOMICS, V45, P607, DOI 10.1006/geno.1997.4972
   Chai F, 2015, BIOCHEM BIOPH RES CO, V456, P534, DOI 10.1016/j.bbrc.2014.11.124
   Chen Fang Ping, 2004, Chang Gung Med J, V27, P107
   Cheng MZ, 2002, J BONE MINER RES, V17, P593, DOI 10.1359/jbmr.2002.17.4.593
   Cheng YH, 2013, J BONE MINER RES, V28, P1434, DOI 10.1002/jbmr.1876
   Clarke BL, 2010, RADIOL CLIN N AM, V48, P483, DOI 10.1016/j.rcl.2010.02.014
   Compston JE, 2001, PHYSIOL REV, V81, P419, DOI 10.1152/physrev.2001.81.1.419
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Eleniste PP, 2016, J CELL BIOCHEM, V117, P1396, DOI 10.1002/jcb.25430
   Evans NJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152138
   Ford J, 2011, J BONE MINER RES, V26, P298, DOI 10.1002/jbmr.209
   Galea GL, 2013, J BIOL CHEM, V288, P9035, DOI 10.1074/jbc.M112.405456
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Gil Henn H, 2007, J CELL BIOL, V178, P1053, DOI 10.1083/jcb.200701148
   Hadjimarkou MM, 2018, J STEROID BIOCHEM, V176, P57, DOI 10.1016/j.jsbmb.2017.04.012
   Hegde V, 2016, OSTEOPOROSIS INT, V27, P861, DOI 10.1007/s00198 015 3331 7
   Heino TJ, 2008, J ENDOCRINOL, V197, pR1, DOI 10.1677/JOE 07 0629
   Hsiao YH, 2016, ENDOCR RELAT CANCER, V23, P651, DOI 10.1530/ERC 16 0122
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Imai Y, 2013, PHYSIOL REV, V93, P481, DOI 10.1152/physrev.00008.2012
   Imai Y, 2010, MOL ENDOCRINOL, V24, P877, DOI 10.1210/me.2009 0238
   Ismail A, 2005, IUBMB LIFE, V57, P483, DOI 10.1080/15216540500147163
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Jordan VC, 2001, J NATL CANCER I, V93, P1449, DOI 10.1093/jnci/93.19.1449
   Kacena MA, 2012, J BIOL CHEM, V287, P17257, DOI 10.1074/jbc.M111.309880
   Kang WB, 2015, J STEROID BIOCHEM, V154, P237, DOI 10.1016/j.jsbmb.2015.07.002
   Kassem M, 1997, APMIS Suppl, V71, P1
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Kretzer NM, 2010, J BIOL CHEM, V285, P41863, DOI 10.1074/jbc.M110.183723
   Krum SA, 2008, CELL CYCLE, V7, P1348, DOI 10.4161/cc.7.10.5892
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   LeviMontalcini R, 1996, TRENDS NEUROSCI, V19, P514, DOI 10.1016/S0166 2236(96)10058 8
   Lin Y, 2004, J ENDOCRINOL INVEST, V27, P416, DOI 10.1007/BF03345284
   MACHWATE M, 1995, J CELL BIOCHEM, V57, P62, DOI 10.1002/jcb.240570108
   Mandal CC, 2016, J BIOL CHEM, V291, P1148, DOI 10.1074/jbc.M115.668939
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Marino M, 2006, CURR GENOMICS, V7, P497, DOI 10.2174/138920206779315737
   Matsumori H, 2009, J ORTHOP SCI, V14, P640, DOI 10.1007/s00776 009 1357 4
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   McCauley LK, 2003, CONNECT TISSUE RES, V44, P250, DOI 10.1080/03008200390181744
   Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858
   Noda Seino H, 2013, J ENDOCRINOL INVEST, V36, P21, DOI 10.3275/8301
   Okigaki M, 2003, P NATL ACAD SCI USA, V100, P10740, DOI 10.1073/pnas.1834348100
   Onoe Y, 1997, ENDOCRINOLOGY, V138, P4509, DOI 10.1210/en.138.10.4509
   Parikka V, 2005, EUR J ENDOCRINOL, V152, P301, DOI 10.1530/eje.1.01832
   Park YM, 2009, BIOL PHARM BULL, V32, P2057, DOI 10.1248/bpb.32.2057
   Petrel TA, 2003, J CELL BIOCHEM, V88, P181, DOI 10.1002/jcb.10353
   Ren J, 2012, CALCIFIED TISSUE INT, V90, P411, DOI 10.1007/s00223 012 9581 x
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Roforth MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095987
   Russell RGG, 2015, CURR OPIN PHARMACOL, V22, P115, DOI 10.1016/j.coph.2015.05.005
   Sanchez M, 2013, ONCOGENE, V32, P117, DOI 10.1038/onc.2012.19
   Soares CJ, 2008, J PROSTHET DENT, V99, P444, DOI 10.1016/S0022 3913(08)60106 7
   Somjen D, 2011, J CELL BIOCHEM, V112, P625, DOI 10.1002/jcb.22959
   Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756 3282(01)00685 8
   Tateishi Y, 2006, MOL CELL BIOL, V26, P7966, DOI 10.1128/MCB.00713 06
   Tee MK, 2004, MOL BIOL CELL, V15, P1262, DOI 10.1091/mbc.E03 06 0360
   Teplyuk NM, 2008, J BIOL CHEM, V283, P27585, DOI 10.1074/jbc.M802453200
   Vinel A, 2016, ENDOCRINOLOGY, V157, P2533, DOI 10.1210/en.2015 1994
   Wagner EF, 2002, ANN RHEUM DIS, V61, P40, DOI 10.1136/ard.61.suppl_2.ii40
   Wang XY, 2007, ENDOCRINOLOGY, V148, P1629, DOI 10.1210/en.2006 1000
   Wiren KM, 2002, J ENDOCRINOL, V175, P683, DOI 10.1677/joe.0.1750683
   Yang YH, 2013, APOPTOSIS, V18, P1363, DOI 10.1007/s10495 013 0867 x
   Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105
   Zhou S, 2001, J CELL BIOCHEM, P144
   Zhou W, 2014, NAT REV CANCER, V14, P26, DOI 10.1038/nrc3622
   Zhu BT, 2006, ENDOCRINOLOGY, V147, P4132, DOI 10.1210/en.2006 0113
NR 83
TC 17
Z9 20
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
EI 1872 8057
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD OCT 15
PY 2018
VL 474
BP 35
EP 47
DI 10.1016/j.mce.2018.02.005
PG 13
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA GX7UI
UT WOS:000447983100004
PM 29428397
OA Green Submitted, Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Muise, ES
   Podtelezhnikov, AA
   Pickarski, M
   Loboda, A
   Tan, YJ
   Hu, GH
   Thomspon, JR
   Duong, LT
AF Muise, Eric S.
   Podtelezhnikov, Alexei A.
   Pickarski, Maureen
   Loboda, Andrey
   Tan, Yejun
   Hu, Guanghui
   Thomspon, John R.
   Duong, Le T.
TI Effects of Long Term Odanacatib Treatment on Bone Gene Expression in
   Ovariectomized Adult Rhesus Monkeys: Differentiation From Alendronate
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; ANTIRESORPTIVES; OSTEOCLASTS; OSTEOBLASTS; PRECLINICAL
   STUDIES
ID MESENCHYMAL STEM CELLS; CATHEPSIN K INHIBITOR; POSTMENOPAUSAL WOMEN;
   OSTEOBLAST DIFFERENTIATION; OSTEOCLAST DIFFERENTIATION; MINERAL DENSITY;
   OSTEOPOROSIS; RESORPTION; STRENGTH; MARKERS
AB Similar efficacy of the cathepsin K inhibitor odanacatib (ODN) and the bisphosphonate alendronate (ALN) in reducing bone turnover markers and increasing bone mineral density in spine and hip were previously demonstrated in ovariectomized (OVX) monkeys treated for 20 months in prevention mode. Here, we profiled RNA from tibial metaphysis and diaphysis of the same study using Affymetrix microarrays, and selected 204 probe sets (p<0.001, three group ANOVA) that were differentially regulated by ODN or ALN versus vehicle. Both drugs produced strikingly different effects on known bone related genes and pathways at the transcriptional level. Although ALN either reduced or had neutral effects on bone resorption related genes, ODN significantly increased the expression of osteoclast genes (eg, APC5, TNFRSF11A, CTSK, ITGB3, and CALCR), consistent with previous findings on the effects of this agent in enhancing the number of nonresorbing osteoclasts. Conversely, ALN reduced the expression of known bone formation related genes (eg, TGFBR1, SPP1, RUNX2, and PTH1R), whereas ODN either increased or had neutral effects on their expression. These differential effects of ODN versus ALN on bone resorption and formation were highly correlative to the changes in bone turnover markers, cathepsin K (Catk) target engagement marker serum C terminal cross linked telopeptide (1 CTP) and osteoclast marker tartrate resistant acid phosphatase isoform 5b (TRAP5b) in the same monkeys. Overall, the molecular profiling results are consistent with the known pharmacological actions of these agents on bone remodeling and clearly differentiate the molecular mechanisms of ODN from the bisphosphonates. (c) 2016 American Society for Bone and Mineral Research.
C1 [Muise, Eric S.; Podtelezhnikov, Alexei A.; Loboda, Andrey; Tan, Yejun; Hu, Guanghui; Thomspon, John R.] Merck & Co Inc, Dept Genet & Pharmacogenom, Kenilworth, NJ USA.
   [Pickarski, Maureen; Duong, Le T.] Merck & Co Inc, Dept Bone Biol, Kenilworth, NJ USA.
C3 Merck & Company; Merck & Company USA; Merck & Company; Merck & Company
   USA
RP Duong, LT (通讯作者)，Merck Res Labs, Bone Biol, West Point, PA 19486 USA.
EM le_duong@merck.com
RI ; Tan, Yejun/HQY 2787 2023
OI Muise, Eric/0000 0002 1238 5118; Tan, Yejun/0009 0000 9567 0186; 
CR [Anonymous], J BONE MINER RES S1
   Baron R, 2012, NAT REV ENDOCRINOL, V8, P76, DOI 10.1038/nrendo.2011.207
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Cabal A, 2013, BONE, V56, P497, DOI 10.1016/j.bone.2013.06.011
   Cusick T, 2012, J BONE MINER RES, V27, P524, DOI 10.1002/jbmr.1477
   Dacic S, 2001, J BONE MINER RES, V16, P1228, DOI 10.1359/jbmr.2001.16.7.1228
   Duong L, 2010, J BONE MINER RES S1, V25
   Duong Le T, 2012, Bonekey Rep, V1, P67, DOI 10.1038/bonekey.2012.67
   Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Engelke K, 2015, J BONE MINER RES, V30, P30, DOI 10.1002/jbmr.2292
   Ferrari S, 2014, BEST PRACT RES CL EN, V28, P859, DOI 10.1016/j.beem.2014.08.002
   Feurer E, 2014, EXPERT OPIN EMERG DR, V19, P385, DOI 10.1517/14728214.2014.936377
   Friedman MS, 2009, J BIOL CHEM, V284, P14117, DOI 10.1074/jbc.M808337200
   Fujimori S, 2002, BIOCHEM BIOPH RES CO, V293, P1445, DOI 10.1016/S0006 291X(02)00405 9
   Garnero P, 2014, BONE, V66, P46, DOI 10.1016/j.bone.2014.05.016
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Hayman AR, 1996, DEVELOPMENT, V122, P3151
   Henriksen K, 2014, CALCIFIED TISSUE INT, V94, P88, DOI 10.1007/s00223 013 9741 7
   Hoshino A, 2010, J BIOL CHEM, V285, P28826, DOI 10.1074/jbc.M109.099424
   Kameda Y, 2013, J BONE MINER RES, V28, P2463, DOI 10.1002/jbmr.1989
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kling JM, 2014, J WOMENS HEALTH, V23, P563, DOI 10.1089/jwh.2013.4611
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Langdahl B, 2012, J BONE MINER RES, V27, P2251, DOI 10.1002/jbmr.1695
   LEE SK, 1995, ENDOCRINOLOGY, V136, P4572, DOI 10.1210/en.136.10.4572
   Leung P, 2011, BONE, V49, P623, DOI 10.1016/j.bone.2011.06.014
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Masarachia PJ, 2012, J BONE MINER RES, V27, P509, DOI 10.1002/jbmr.1475
   Minisola G, 2014, REUMATISMO, V66, P112, DOI 10.4081/reumatismo.2014.784
   Muise ES, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088908
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Ochi Y, 2014, BONE, V65, P1, DOI 10.1016/j.bone.2014.04.023
   OKADA Y, 1995, LAB INVEST, V72, P311
   Pennypacker B, 2009, BONE, V44, P199, DOI 10.1016/j.bone.2008.08.130
   Pennypacker B, 2011, J BONE MINER RES S1, V26
   Pennypacker BL, 2014, J BONE MINER RES, V29, P1847, DOI 10.1002/jbmr.2211
   Pennypacker BL, 2011, J BONE MINER RES, V26, P252, DOI 10.1002/jbmr.223
   Pickarski M, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 197
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Schilling AF, 2007, OSTEOPOROSIS INT, V18, P659, DOI 10.1007/s00198 006 0311 y
   Sims NA, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00041
   Stoch SA, 2009, CLIN PHARMACOL THER, V86, P175, DOI 10.1038/clpt.2009.60
   Williams DS, 2013, BONE, V56, P489, DOI 10.1016/j.bone.2013.06.008
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Yang SY, 2007, GENE DEV, V21, P1803, DOI 10.1101/gad.1544107
NR 48
TC 12
Z9 13
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2016
VL 31
IS 4
BP 839
EP 851
DI 10.1002/jbmr.2752
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DJ2BH
UT WOS:000374008200016
PM 26587671
OA Bronze
DA 2025 08 17
ER

PT J
AU Kim, HY
   Choi, S
   Yoon, JH
   Lim, HJ
   Lee, H
   Choi, J
   Ro, EJ
   Heo, JN
   Lee, W
   No, KT
   Choi, KY
AF Kim, Hyun Yi
   Choi, Sehee
   Yoon, Ji Hye
   Lim, Hwan Jung
   Lee, Hyuk
   Choi, Jiwon
   Ro, Eun Ji
   Heo, Jung Nyoung
   Lee, Weontae
   No, Kyoung Tai
   Choi, Kang Yell
TI Small molecule inhibitors of the Dishevelled CXXC5 interaction are new
   drug candidates for bone anabolic osteoporosis therapy
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE CXXC5; Dishevelled; negative feedback regulation; osteoporosis;
   Wnt/beta catenin pathway
ID SCLEROSTIN ANTIBODY; BETA CATENIN; PDZ DOMAIN; IN VITRO; GROWTH;
   DIFFERENTIATION; ANTAGONIST; MECHANISMS; DICKKOPF 1; REGULATOR
AB Bone anabolic agents promoting bone formation and rebuilding damaged bones would ideally overcome the limitations of anti resorptive therapy, the current standard prescription for osteoporosis. However, the currently prescribed parathyroid hormone (PTH) based anabolic drugs present limitations and adverse effects including osteosarcoma during long term use. Also, the antibody based anabolic drugs that are currently being developed present the potential limits in clinical application typical of macromolecule drugs. We previously identified that CXXC5 is a negative feedback regulator of the Wnt/ catenin pathway via its interaction with Dishevelled (Dvl) and suggested the Dvl CXXC5 interaction as a potential target for anabolic therapy of osteoporosis. Here, we screened small molecule inhibitors of the Dvl CXXC5 interaction via a newly established invitro assay system. The screened compounds were found to activate the Wnt/ catenin pathway and enhance osteoblast differentiation in primary osteoblasts. The bone anabolic effects of the compounds were shown using exvivo cultured calvaria. Nuclear magnetic resonance (NMR) titration analysis confirmed interaction between Dvl PDZ domain and KY 02061, a representative of the screened compounds. Oral administration of KY 02327, one of 55 newly synthesized KY 02061 analogs, successfully rescued bone loss in the ovariectomized (OVX) mouse model. In conclusion, small molecule inhibitors of the Dvl CXXC5 interaction that block negative feedback regulation of Wnt/ catenin signaling are potential candidates for the development of bone anabolic anti osteoporosis drugs.
C1 [Kim, Hyun Yi; Choi, Sehee; Ro, Eun Ji; Choi, Kang Yell] Yonsei Univ, Translat Res Ctr Prot Funct Control, Seoul 120749, South Korea.
   [Kim, Hyun Yi; Choi, Sehee; Ro, Eun Ji; No, Kyoung Tai; Choi, Kang Yell] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Seoul 120749, South Korea.
   [Yoon, Ji Hye; Lee, Weontae] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Seoul 120749, South Korea.
   [Lim, Hwan Jung; Lee, Hyuk; Heo, Jung Nyoung] Korea Res Inst Chem Technol, Daejeon, South Korea.
   [Choi, Jiwon; No, Kyoung Tai] Yonsei Univ, Bioinformat & Mol Design Res Ctr, Seoul 120749, South Korea.
C3 Yonsei University; Yonsei University; Yonsei University; Korea Research
   Institute of Chemical Technology (KRICT); Yonsei University
RP Choi, KY (通讯作者)，Yonsei Univ, Translat Res Ctr Prot Funct Control, Seoul 120749, South Korea.; Choi, KY (通讯作者)，Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Seoul 120749, South Korea.
EM kychoi@yonsei.ac.kr
RI Kim, Jong Yeup/ISA 2120 2023; LEE, WEON/AAQ 9088 2021; No,
   Kyoung/P 1644 2015
OI Lee, Weontae/0000 0003 2347 1262; 
FU Ministry of Future Creation and Science (MFCS) of Korea through National
   Research Foundation (NRF); Translational Research Center for Protein
   Function Control [2009 0083522]; Mid career Researcher Program
   [2015R1A2A1A05001873]; Ministry of Knowledge Economy through Korea
   Research Institute of Chemical Technology [SI 0905, SI 1005, SI 1105,
   SI 1205, SI 1304]
FX We thank Bum Tae Kim and Sung Youn Chang for discussion on the design
   and the synthesis of molecules. This work was supported by grants from
   the Ministry of Future Creation and Science (MFCS) of Korea through
   National Research Foundation (NRF); Translational Research Center for
   Protein Function Control (2009 0083522); and Mid career Researcher
   Program (2015R1A2A1A05001873). This work is also supported by the
   Ministry of Knowledge Economy through Korea Research Institute of
   Chemical Technology (SI 0905, SI 1005, SI 1105, SI 1205, SI 1304).
CR Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Cha PH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085546
   Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534 5807(02)00140 5
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Ferrari S, 2014, BEST PRACT RES CL EN, V28, P859, DOI 10.1016/j.beem.2014.08.002
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Geissler JR, 2015, J BIOMECH, V48, P883, DOI 10.1016/j.jbiomech.2015.01.032
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Ishtiaq S, 2015, J ENDOCRINOL INVEST, V38, P13, DOI 10.1007/s40618 014 0152 z
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kim HY, 2015, CELL DEATH DIFFER, V22, P912, DOI 10.1038/cdd.2014.238
   Lazner F, 1999, HUM MOL GENET, V8, P1839, DOI 10.1093/hmg/8.10.1839
   Lee HJ, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478 811X 8 8
   Lee HJ, 2009, ANGEW CHEM INT EDIT, V48, P6448, DOI 10.1002/anie.200902981
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Mahindroo N, 2008, BIOORG MED CHEM LETT, V18, P946, DOI 10.1016/j.bmcl.2007.12.039
   Manton KJ, 2007, J MOL HISTOL, V38, P415, DOI 10.1007/s10735 007 9121 6
   Marks BD, 2002, ASSAY DRUG DEV TECHN, V1, P73, DOI 10.1089/154065802761001329
   MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165 1161(83)90010 9
   Martin T John, 2014, J Bone Metab, V21, P8, DOI 10.11005/jbm.2014.21.1.8
   Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092 8674(00)80112 9
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   PALL HS, 1987, LANCET, V2, P596
   Piper DR, 2008, ASSAY DRUG DEV TECHN, V6, P213, DOI 10.1089/adt.2008.137
   Polakis P, 2000, GENE DEV, V14, P1837
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Regard JB, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007997
   Reinhold MI, 2007, J BIOL CHEM, V282, P3653, DOI 10.1074/jbc.M608995200
   REYNOLDS JJ, 1972, CALC TISS RES, V10, P302, DOI 10.1007/BF02012561
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Wu GS, 2003, J COMPUT CHEM, V24, P1549, DOI 10.1002/jcc.10306
   You L, 2008, MOL CANCER THER, V7, P1633, DOI 10.1158/1535 7163.MCT 08 0155
   Zahoor M, 2014, J BONE MINER RES, V29, P1196, DOI 10.1002/jbmr.2147
   Zhu CH, 2012, STEM CELLS, V30, P2065, DOI 10.1002/stem.1139
NR 43
TC 37
Z9 44
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1757 4676
EI 1757 4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD APR
PY 2016
VL 8
IS 4
BP 375
EP 387
DI 10.15252/emmm.201505714
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA DI7XK
UT WOS:000373715100007
PM 26941261
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Walker, EC
   McGregor, NE
   Poulton, IJ
   Solano, M
   Pompolo, S
   Fernandes, TJ
   Constable, MJ
   Nicholson, GC
   Zhang, JG
   Nicola, NA
   Gillespie, MT
   Martin, J
   Sims, NA
AF Walker, Emma C.
   McGregor, Narelle E.
   Poulton, Ingrid J.
   Solano, Melissa
   Pompolo, Sueli
   Fernandes, Tania J.
   Constable, Matthew J.
   Nicholson, Geoff C.
   Zhang, Jian Guo
   Nicola, Nicos A.
   Gillespie, Matthew T.
   Martin, John
   Sims, Natalie A.
TI Oncostatin M promotes bone formation independently of resorption when
   signaling through leukemia inhibitory factor receptor in mice
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID KAPPA B LIGAND; OSTEOCLAST DIFFERENTIATION; TARGETED DISRUPTION;
   GENE TRANSCRIPTION; CELL LINES; IN VITRO; INTERLEUKIN 6; EXPRESSION;
   INFLAMMATION; OSTEOBLASTS
AB Effective osteoporosis therapy requires agents that increase the amount and/or quality of bone. Any modification of osteoclast mediated bone resorption by disease or drug treatment, however, elicits a parallel change in osteoblast mediated bone formation because the processes are tightly coupled. Anabolic approaches now focus on uncoupling osteoblast action from osteoclast formation, for example, by inhibiting sclerostin, an inhibitor of bone formation that does not influence osteoclast differentiation. Here, we report that oncostatin M (OSM) is produced by osteoblasts and osteocytes in mouse bone and that it has distinct effects when acting through 2 different receptors, OSM receptor (OSMR) and leukemia inhibitory factor receptor (LIFR). Specifically, mouse OSM (mOSM) inhibited sclerostin production in a stromal cell line and in primary murine osteoblast cultures by acting through LIFR. In contrast, when acting through OSMR, mOSM stimulated RANKL production and osteoclast formation. A key role for OSMR in bone turnover was confirmed by the osteopetrotic phenotype of mice lacking OSMR. Furthermore, in contrast to the accepted model, in which mOSM acts only through OSMR, mOSM inhibited sclerostin expression in Osmr( / ) osteoblasts and enhanced bone formation in vivo. These data reveal what we believe to be a novel pathway by which bone formation can be stimulated independently of bone resorption and provide new insights into OSMR and LIFR signaling that are relevant to other medical conditions, including cardiovascular and neurodegenerative diseases and cancer.
C1 [Walker, Emma C.; McGregor, Narelle E.; Poulton, Ingrid J.; Solano, Melissa; Pompolo, Sueli; Gillespie, Matthew T.; Martin, John; Sims, Natalie A.] St Vincents Inst, Melbourne, Vic, Australia.
   [Fernandes, Tania J.; Constable, Matthew J.; Nicholson, Geoff C.] Univ Melbourne, Dept Clin & Biomed Sci Barwon Hlth, Geelong, Vic, Australia.
   [Fernandes, Tania J.; Constable, Matthew J.; Nicholson, Geoff C.] Univ Melbourne, Barwon Biomed Res, Geelong, Vic, Australia.
   [Zhang, Jian Guo; Nicola, Nicos A.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.
   [Gillespie, Matthew T.; Martin, John; Sims, Natalie A.] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia.
C3 St. Vincent's Institute of Medical Research; University of Melbourne;
   University of Melbourne; Melbourne Health; Royal Melbourne Hospital;
   Walter & Eliza Hall Institute; University of Melbourne; St Vincent's
   Health; St Vincent's Hospital Melbourne; NSW Health; St Vincents
   Hospital Sydney
RP Sims, NA (通讯作者)，St Vincents Inst, 9 Princes St, Fitzroy, Vic 3065, Australia.
EM nsims@svi.edu.au
RI Nicola, Nicos/D 2989 2011; Nicholson, Geoffrey/F 1901 2010; Sims,
   Natalie/A 7192 2012
OI Nicola, Nicos/0000 0003 1054 7889; Zhang, Jian Guo/0009 0003 0655 3810;
   Nicholson, Geoffrey/0000 0002 0152 1153; Sims,
   Natalie/0000 0003 1421 8468; Gillespie, Matthew/0000 0001 6543 8909
FU National Health and Medical Research Council (NHMRC) (Australia)
   [345401, 461219]
FX We thank John Wark and Susan Kantor at the Department of Medicine, Royal
   Melbourne Hospital, for use of their pQCT; Atsushi Miyajima, Tokyo
   University, and Anne Reutens, Monash University for Osmr<SUP> / </SUP>
   mice; and Gerard Karsenty, Columbia University, for the 6xOSE2
   construct. We also thank staff at the Bioresources Centre, St. Vincent's
   Health, for excellent animal care. The work was supported by National
   Health and Medical Research Council (NHMRC) (Australia) program grants
   345401 (to N.A. Sims, M.T. Gillespie, and T.J. Martin) and 461219 (to
   N.A. Nicola and J.G. Zhang). N.A. Sims is supported by a NHMRC
   (Australia) Senior Research Fellowship.
CR ALLAN EH, 1990, J CELL PHYSIOL, V145, P110, DOI 10.1002/jcp.1041450116
   Allan EH, 2003, J CELL BIOCHEM, V90, P158, DOI 10.1002/jcb.10614
   Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399
   BROWN TJ, 1987, J IMMUNOL, V139, P2977
   Dagoneau N, 2004, AM J HUM GENET, V74, P298, DOI 10.1086/381715
   de Hooge ASK, 2002, AM J PATHOL, V160, P1733, DOI 10.1016/S0002 9440(10)61120 0
   Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084
   Eddleston A, 2009, J BONE MINER RES, V24, P1662, DOI [10.1359/JBMR.090403, 10.1359/jbmr.090403]
   Fairlie WD, 2004, J BIOL CHEM, V279, P2125, DOI 10.1074/jbc.M310103200
   Fischer P, 2008, BRIT J PHARMACOL, V153, pS414, DOI 10.1038/bjp.2008.1
   Ganapathi MK, 1996, CELL GROWTH DIFFER, V7, P923
   GIMBLE JM, 1994, J CELL BIOCHEM, V54, P122, DOI 10.1002/jcb.240540113
   Gronthos S, 1999, J BONE MINER RES, V14, P47, DOI 10.1359/jbmr.1999.14.1.47
   Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200
   Halfter H, 1998, GROWTH FACTORS, V15, P135, DOI 10.3109/08977199809117189
   HILTON DJ, 1991, J CELL PHYSIOL, V146, P207, DOI 10.1002/jcp.1041460204
   HILTON DJ, 1992, CIBA F SYMP, V167, P227
   Ichihara M, 1997, BLOOD, V90, P165
   Jay PR, 1996, ENDOCRINOLOGY, V137, P1151, DOI 10.1210/en.137.4.1151
   Kartsogiannis V, 1999, BONE, V25, P525, DOI 10.1016/S8756 3282(99)00214 8
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Langdon C, 2000, AM J PATHOL, V157, P1187, DOI 10.1016/S0002 9440(10)64634 2
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lin SC, 1997, J CLIN INVEST, V100, P1980, DOI 10.1172/JCI119729
   Linker RA, 2009, CRIT REV IMMUNOL, V29, P43, DOI 10.1615/CritRevImmunol.v29.i1.20
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   Quinn JMW, 2002, BONE, V30, P164, DOI 10.1016/S8756 3282(01)00654 8
   Quinn JMW, 2008, J IMMUNOL, V181, P5720, DOI 10.4049/jimmunol.181.8.5720
   Richards CD, 2000, CYTOKINE, V12, P613, DOI 10.1006/cyto.1999.0635
   Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581
   Savarese TM, 2002, CYTOKINE, V17, P324, DOI 10.1006/cyto.2002.1022
   Shin CS, 2006, J MOL ENDOCRINOL, V36, P531, DOI 10.1677/jme.1.01944
   Shin HI, 2004, ENDOCRINOLOGY, V145, P1376, DOI 10.1210/en.2003 0839
   Sims NA, 2006, AM J PHYSIOL ENDOC M, V290, pE456, DOI 10.1152/ajpendo.00311.2005
   Sims NA, 2009, MOL CELL ENDOCRINOL, V310, P30, DOI 10.1016/j.mce.2008.08.025
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Song HY, 2007, J CELL BIOCHEM, V101, P1238, DOI 10.1002/jcb.21245
   SUDA T, 1995, BONE, V17, pS87, DOI 10.1016/8756 3282(95)00185 G
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Tanaka M, 2003, BLOOD, V102, P3154, DOI 10.1182/blood 2003 02 0367
   Truong T, 2007, J BONE MINER RES, V22, P7, DOI 10.1359/JBMR.061012
   Underhill Day N, 2006, CANCER RES, V66, P10891, DOI 10.1158/0008 5472.CAN 06 1766
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Walker EC, 2008, J BONE MINER RES, V23, P2025, DOI [10.1359/jbmr.080706, 10.1359/JBMR.080706]
   Wang Q, 2007, J BIOL CHEM, V282, P10742, DOI 10.1074/jbc.M610997200
   WARE CB, 1995, DEVELOPMENT, V121, P1283
NR 52
TC 233
Z9 255
U1 1
U2 16
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD FEB
PY 2010
VL 120
IS 2
BP 582
EP 592
DI 10.1172/JCI40568
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 549IA
UT WOS:000274040000017
PM 20051625
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Gómez Moreno, G
   Arribas Fernández, MC
   Fernández Guerrero, M
   Boquete Castro, A
   Aguilar Salvatierra, A
   Guardia, J
   Botticelli, D
   Calvo Guirado, JL
AF Gomez Moreno, G.
   Arribas Fernandez, M. C.
   Fernandez Guerrero, M.
   Boquete Castro, A.
   Aguilar Salvatierra, A.
   Guardia, J.
   Botticelli, D.
   Calvo Guirado, J. L.
TI Bisphosphonate associated osteonecrosis of the jaw 2 years after teeth
   extractions: a case report solved with non invasive treatment
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Bisphosphonates; Osteonecrosis of the jaw; Chlorhexidine
ID ZOLEDRONIC ACID; CANCER PATIENTS; MULTIPLE MYELOMA; NATURAL HISTORY;
   RISK FACTORS; BREAST; BONE; EXPERIENCE; THERAPY; MANAGEMENT
AB Bisphosphonates are a type of drugs known to inhibit bone resorption through complex interventions. Their primary mechanism of action is aimed at the cellular level, inhibiting osteoclast activity and, thus, bone resorption. Bisphosphonates are, therefore, very widely used, with many patients receiving continuous treatment for years. But it is well known that these drugs can produce osteonecrosis of the jaw and this is their principal risk. A 75 year old woman received dental treatment before starting intravenous BP therapy for a breast cancer. She started intravenous bisphosphonate treatment with monthly protocol and after two years the patient presented a wound compatible with osteonecrosis of the jaw.
C1 [Gomez Moreno, G.; Fernandez Guerrero, M.; Boquete Castro, A.; Aguilar Salvatierra, A.; Guardia, J.] Univ Granada, Fac Dent, Pharmacol Res Dent Grp, Granada, Spain.
   [Botticelli, D.] Univ State Sao Paulo, Fac Odontol Aracatuba, Sao Paulo, Brazil.
   [Calvo Guirado, J. L.] Univ Murcia, Fac Med Dent, E 30001 Murcia, Spain.
C3 University of Granada; Universidade Estadual Paulista; University of
   Murcia
RP Gómez Moreno, G (通讯作者)，Univ Granada, Fac Dent, Pharmacol Res Dent Grp, Granada, Spain.
EM ggomez@ugr.es
RI guirado, jose/O 3104 2016; Gomez Moreno, Gerardo/L 8123 2014;
   Gómez Moreno, Gerardo/L 8123 2014; Botticelli, Daniele/ABF 6494 2020
OI Gomez Moreno, Gerardo/0000 0001 9094 4985; Boquete Castro,
   Ana/0000 0003 1388 1639; Botticelli, Daniele/0000 0003 2804 1632; 
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Agrillo A, 2012, EUR REV MED PHARMACO, V16, P1741
   Agrillo A, 2012, EUR REV MED PHARMACO, V16, P952
   Almasan HA, 2011, ROM J MORPHOL EMBRYO, V52, P1233
   Assouline Dayan Y, 2002, SEMIN ARTHRITIS RHEU, V32, P94, DOI 10.1053/sarh.2002.33724
   Badros A, 2008, J CLIN ONCOL, V26, P5904, DOI 10.1200/JCO.2008.16.9300
   Bagan J, 2007, MED ORAL PATOL ORAL, V12, P336
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Bedogni A, 2008, ORAL SURG ORAL MED O, V105, P358, DOI 10.1016/j.tripleo.2007.08.040
   Body JJ, 2006, CLIN CANCER RES, V12, p6258S, DOI 10.1158/1078 0432.CCR 06 0840
   Boonyapakorn T, 2008, ORAL ONCOL, V44, P857, DOI 10.1016/j.oraloncology.2007.11.012
   Brown JE, 2007, CLIN CANCER RES, V13, P5406, DOI 10.1158/1078 0432.CCR 07 0247
   Brown JE, 2004, ENDOCR RELAT CANCER, V11, P207, DOI 10.1677/erc.0.0110207
   Carlson ER, 2009, J ORAL MAXIL SURG, V67, P85, DOI 10.1016/j.joms.2009.01.006
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Clemons MJ, 2006, J CLIN ONCOL, V24, P4895, DOI 10.1200/JCO.2006.05.9212
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Conte P, 2004, ONCOLOGIST, V9, P28, DOI 10.1634/theoncologist.9 90004 28
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Dimopoulos MA, 2006, HAEMATOL HEMATOL J, V91, P968
   Estilo CL, 2008, ONCOLOGIST, V13, P911, DOI 10.1634/theoncologist.2008 0091
   Favia G, 2011, CLIN IMPLANT DENT R, V13, P58, DOI 10.1111/j.1708 8208.2009.00181.x
   Fitzpatrick SG, 2012, J ORAL MAXIL SURG, V70, P325, DOI 10.1016/j.joms.2011.02.049
   Gnant Michael, 2011, Ther Adv Med Oncol, V3, P293, DOI 10.1177/1758834011420599
   Hoefert S, 2011, J ORAL MAXIL SURG, V69, P362, DOI 10.1016/j.joms.2010.06.200
   Kyrgidis A, 2008, J CLIN ONCOL, V26, P4634, DOI 10.1200/JCO.2008.16.2768
   Lo JC, 2010, J ORAL MAXIL SURG, V68, P243, DOI 10.1016/j.joms.2009.03.050
   Mariotti A, 2008, J DENT EDUC, V72, P919
   Merigo Elisabetta, 2006, Acta Biomed, V77, P109
   Migliorati CA, 2005, CANCER, V104, P83, DOI 10.1002/cncr.21130
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Palaska PK, 2009, ONCOLOGIST, V14, P1154, DOI 10.1634/theoncologist.2009 0115
   Piesold JU, 2006, ORAL MAXILLOFAC SURG, V10, P287, DOI 10.1007/s10006 006 0017 5
   Ruggiero S, 2006, J ONCOL PRACT, V2, P7, DOI 10.1200/JOP.2.1.7
   Soolari N, 2011, OPEN DENT J, V5, P163, DOI 10.2174/1874210601105010163
   Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584
   Van den Wyngaert T, 2006, ANN ONCOL, V17, P1197, DOI 10.1093/annonc/mdl294
   Van den Wyngaert T, 2009, ANN ONCOL, V20, P331, DOI 10.1093/annonc/mdn630
   Van den Wyngaert T, 2009, ONCOLOGIST, V14, P181, DOI 10.1634/theoncologist.2008 0209
   Wilkinson GS, 2007, JNCI J NATL CANCER I, V99, P1016, DOI 10.1093/jnci/djm025
   Woo SB, 2007, JNCI J NATL CANCER I, V99, P1016
   Zervas K, 2006, BRIT J HAEMATOL, V134, P620, DOI 10.1111/j.1365 2141.2006.06230.x
NR 42
TC 7
Z9 13
U1 0
U2 3
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD MAY
PY 2014
VL 18
IS 9
BP 1391
EP 1397
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AP3KE
UT WOS:000341974000014
PM 24867519
DA 2025 08 17
ER

PT J
AU Dai, QG
   Xie, FR
   Han, YJ
   Ma, XH
   Zhou, SR
   Jiang, LY
   Zou, WG
   Wang, J
AF Dai, Qinggang
   Xie, Furong
   Han, Yujiao
   Ma, Xuhui
   Zhou, Siru
   Jiang, Lingyong
   Zou, Weiguo
   Wang, Jun
TI Inactivation of Regulatory associated Protein of mTOR (Raptor)/Mammalian
   Target of Rapamycin Complex 1 (mTORC1) Signaling in Osteoclasts
   Increases Bone Mass by Inhibiting Osteoclast Differentiation in Mice
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MAMMALIAN TARGET; EVEROLIMUS; MARKER; GROWTH; ROLES; PROLIFERATION;
   ACTIVATION; PROMOTES; SURVIVAL; CANCER
AB Mammalian target of rapamycin complex 1 (mTORC1) is involved in anabolic metabolism in both osteoblasts and chondrocytes, but the role of mTORC1 in osteoclast biology in vivo remains to be elucidated. In this study, we showed that deletion of regulatory associated protein of mTOR (Raptor) in osteoclasts led to an increase in bone mass with decreased bone resorption. Raptor deficient bone marrow derived macrophages exhibited lower mTORC1 S6K1 signaling and retarded osteoclast differentiation, as determined by the number of osteoclasts, tartrate resistant acid phosphatase activity, and expression of osteoclast specific genes. Enforced expression of constitutively active S6K1 rescued the impaired osteoclast differentiation in Raptor deficient bone marrow derived macrophages. Furthermore, pharmacological inhibition of mTORC1 signaling by rapamycin could also inhibit osteoclast differentiation and osteoclast specific gene expression. Taken together, our findings demonstrate that mTORC1 plays a key role in the network of catabolic bone resorption in osteoclasts and may serve as a potential pharmacological target for the regulation of osteoclast activity in bone metabolic disorders.
C1 [Dai, Qinggang; Xie, Furong; Wang, Jun] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Pediat Dent,Shanghai Key Lab Stomatol, Shanghai 200011, Peoples R China.
   [Ma, Xuhui] Shanghai Jiao Tong Univ, Sch Med, Dept Oral & Maxillofacial Head & Neck Oncol, Shanghai Key Lab Stomatol,Peoples Hosp 9, Shanghai 200011, Peoples R China.
   [Zhou, Siru; Jiang, Lingyong] Shanghai Jiao Tong Univ, Dept Oral & Craniomaxillofacial Sci, Ctr Craniofacial Orthodont, Shanghai Key Lab Stomatol,Sch Med,Peoples Hosp 9, Shanghai 200011, Peoples R China.
   [Dai, Qinggang; Han, Yujiao; Zou, Weiguo] Chinese Acad Sci, Shanghai Inst Biol Sci, Ctr Excellence Mol Cell Sci, State Key Lab Cell Biol,Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Chinese Academy of Sciences; Center for Excellence
   in Molecular Cell Science, CAS
RP Jiang, LY (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Oral & Craniomaxillofacial Sci, Ctr Craniofacial Orthodont,Sch Med, 639 Zhi Zao Ju Rd, Shanghai 200011, Peoples R China.; Wang, J (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Pediat Dent, 639 Zhi Zao Ju Rd, Shanghai 200011, Peoples R China.
EM jly117@sina.com; zouwg94@sibcb.ac.cn; wangjun202@126.com
RI ; Qinggang, Dai/HLV 8212 2023
OI Han, Yujiao/0000 0001 8838 9089; Dai, Qinggang/0000 0002 8177 2496
FU 973 Program from the Chinese Ministry of Science and Technology
   [2014CB964704, 2015CB964503]; Science and Technology Commission of
   Shanghai [124119b0101]; National Natural Science Foundation of China
   [31371463, 81371121, 81570950]; Shanghai Summit and Plateau Disciplines;
   "Chen Xing" project from Shanghai Jiaotong University; National Science
   Fund for Excellent Young Scholars [81322027]
FX This work was supported in part by grants from the 973 Program from the
   Chinese Ministry of Science and Technology (2014CB964704 and
   2015CB964503), the Science and Technology Commission of Shanghai
   (124119b0101), the National Natural Science Foundation of China
   (31371463, 81371121, and 81570950), Shanghai Summit and Plateau
   Disciplines, and the "Chen Xing" project from Shanghai Jiaotong
   University. The authors declare that they have no conflicts of interest
   with the contents of this article.r A scholar of the National 1000 Young
   Talents Program of China. Supported by the National Science Fund for
   Excellent Young Scholars (81322027). To whom correspondence may be
   addressed: Institute of Biochemistry and Cell Biology, Shanghai
   Institutes for Biological Sciences, Chinese Academy of Sciences, 320
   Yueyang Rd., SIBCB Bldg., Rm. 1401, Shanghai 200031, China. Tel.:
   86 21 54921320; Fax: 86 21 54921320; E mail: zouwg94@sibcb.ac.cn.
CR ANDERSSON GN, 1989, J HISTOCHEM CYTOCHEM, V37, P115, DOI 10.1177/37.1.2461980
   Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen C, 2015, J EXP MED, V212, P73, DOI 10.1084/jem.20140643
   Chen J. H., 2015, BIOMED RES INT, V2015, P1, DOI DOI 10.1037/COU0000095
   Chen JQ, 2014, DEVELOPMENT, V141, P2848, DOI 10.1242/dev.108811
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Gnant M, 2013, JNCI J NATL CANCER I, V105, P654, DOI 10.1093/jnci/djt026
   Greenblatt MB, 2015, J EXP MED, V212, P1283, DOI 10.1084/jem.20150407
   Hadji P, 2013, CRIT REV ONCOL HEMAT, V87, P101, DOI 10.1016/j.critrevonc.2013.05.015
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hu YW, 2016, J CELL BIOCHEM, V117, P413, DOI 10.1002/jcb.25287
   Huang B, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005426
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Lee KW, 2010, STEM CELLS DEV, V19, P557, DOI 10.1089/scd.2009.0147
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Martin SK, 2015, STEM CELLS, V33, P1359, DOI 10.1002/stem.1931
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Simone V, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1717 8
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Wang SY, 2011, BIOMATERIALS, V32, P4546, DOI 10.1016/j.biomaterials.2011.03.014
   Xia TT, 2012, DIABETES, V61, P2461, DOI 10.2337/db11 1278
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Xu S, 2016, J BONE MINER RES, V31, P1320, DOI 10.1002/jbmr.2800
   Yan B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11151
   Yeh LCC, 2013, J CELL BIOCHEM, V114, P1760, DOI 10.1002/jcb.24519
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
   Zou DH, 2011, BIOMATERIALS, V32, P9707, DOI 10.1016/j.biomaterials.2011.09.005
   Zou WG, 2013, J EXP MED, V210, P1793, DOI 10.1084/jem.20111790
NR 36
TC 68
Z9 82
U1 0
U2 31
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021 9258
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 6
PY 2017
VL 292
IS 1
BP 196
EP 204
DI 10.1074/jbc.M116.764761
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA EH2DQ
UT WOS:000391578000017
PM 27879318
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Adami, G
   Orsolini, G
   Adami, S
   Viapiana, O
   Idolazzi, L
   Gatti, D
   Rossini, M
AF Adami, Giovanni
   Orsolini, Giovanni
   Adami, Silvano
   Viapiana, Ombretta
   Idolazzi, Luca
   Gatti, Davide
   Rossini, Maurizio
TI Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling
   Antagonists in Rheumatoid Arthritis
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE TNF blocking antibody; Wnt pathway; parathyroid hormone; Dkk1;
   Rheumatoid arthritis
ID SERUM LEVELS; BONE LOSS; DICKKOPF 1; METABOLISM; ALPHA
AB Tumor necrosis factor alpha inhibitors (TNFi) are the major class of biologic drug used for the treatment of Rheumatoid arthritis (RA). Their effects on inflammation and disease control are well established, but this is not true also for bone metabolism, especially for key factors as parathyroid hormone and Wnt pathway. Those two pathways are gaining importance in the pathogenesis RA bone damage, both systemic and local, but how the new treatment affects them is still largely unknown. We studied 54 RA patients who were starting an anti TNF alpha treatment due to the failure of the conventional synthetic disease modifying antirheumatic drugs. Serum levels of Wnt/beta catenin pathway inhibitors (Dickkopf related protein 1, Dkk1, and Sclerostin), Parathyroid hormone (PTH), vitamin D, and bone turnover markers were measured at baseline in the morning after fasting and after 6 months of therapy. We found a significant percentage increase in serum PTH (+32 +/  55 %; p = 0.002) and a decrease in Dkk1 mean serum levels ( 2.9 +/  12.1; p = 0.05). PTH percentage changes were positively correlated both with C terminal telopeptide of type I collagen and Dkk1 percentage changes. Sclerostin serum levels showed no significant difference. TNFi treatment provokes in the short term a rise in PTH levels and a decrease in Dkk1 serum levels. The increase of PTH might promote bone resorption and blunt the normalization of Dkk1 serum levels in RA. Those data give a new insight into TNFi metabolic effects on bone and suggest new strategies to achieve better results in terms of prevention of bone erosions and osteoporosis with TNFi treatment in RA.
C1 [Adami, Giovanni; Orsolini, Giovanni; Adami, Silvano; Viapiana, Ombretta; Idolazzi, Luca; Gatti, Davide; Rossini, Maurizio] Univ Verona, Rheumatol Sect, Dept Med, Policlin GB Rossi, Piazzale Ludovico Scuro 10, I 37134 Verona, Italy.
C3 University of Verona; Azienda Ospedaliera Universitaria Integrata Verona
RP Adami, G (通讯作者)，Univ Verona, Rheumatol Sect, Dept Med, Policlin GB Rossi, Piazzale Ludovico Scuro 10, I 37134 Verona, Italy.
EM gio90it90@gmail.com
RI ; Idolazzi, Luca/X 4024 2019; rossini, maurizio/D 6610 2011; Adami,
   Giovanni/AAQ 2160 2021; orsolini, giovanni/AAC 4774 2022; Davide,
   Gatti/ABP 6506 2022
OI Rossini, Maurizio/0000 0001 9692 2293; Idolazzi,
   Luca/0000 0002 7254 4686; VIAPIANA, Ombretta/0000 0003 1917 5655; gatti,
   davide/0000 0002 7471 3076; Adami, Giovanni/0000 0002 8915 0755; 
CR Adamopoulos IE, 2015, NAT REV RHEUMATOL, V11, P189, DOI 10.1038/nrrheum.2014.198
   Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]
   Augustine MV, 2014, J CLIN ENDOCR METAB, V99, pE991, DOI 10.1210/jc.2013 3846
   Borggrefe J, 2010, J BONE MINER RES, V25, P472, DOI 10.1359/jbmr.090820
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Garnero P, 2008, J RHEUMATOL, V35, P2313, DOI 10.3899/jrheum.080356
   Gatti D, 2011, J CLIN ENDOCR METAB, V96, P1555, DOI 10.1210/jc.2010 2552
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   Heiland GR, 2010, ANN RHEUM DIS, V69, P2152, DOI 10.1136/ard.2010.132852
   Jilani AA, 2015, INT J RHEUMATOL, V2015, DOI 10.1155/2015/728610
   Kotake S, 2014, BBA GEN SUBJECTS, V1840, P1209, DOI 10.1016/j.bbagen.2013.12.013
   Lim MJ, 2014, KOREAN J INTERN MED, V29, P807, DOI 10.3904/kjim.2014.29.6.807
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   Manara M, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2015 000065
   Orsolini G, 2016, CALCIFIED TISSUE INT, V98, P580, DOI 10.1007/s00223 016 0114 x
   Pacifici R, 2013, ENDOCRINE, V44, P576, DOI 10.1007/s12020 013 9960 8
   PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107
   Rossini M, 2015, CLIN EXP RHEUMATOL, V33, P77
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Roux S, 2000, ARTHRITIS RES, V2, P451, DOI 10.1186/ar127
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Szentpetery A, 2013, J RHEUMATOL, V40, P653, DOI 10.3899/jrheum.120397
   Tawfeek H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012290
   Viapiana O, 2013, CALCIFIED TISSUE INT, V92, P324, DOI 10.1007/s00223 012 9665 7
   Vis M, 2006, ANN RHEUM DIS, V65, P1495, DOI 10.1136/ard.2005.044198
   Wang SY, 2011, J RHEUMATOL, V38, P821, DOI 10.3899/jrheum.100089
NR 27
TC 46
Z9 53
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD OCT
PY 2016
VL 99
IS 4
BP 360
EP 364
DI 10.1007/s00223 016 0161 3
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DV0TT
UT WOS:000382633200004
PM 27307275
DA 2025 08 17
ER

PT J
AU Jensen, PR
   Andersen, TL
   Chavassieux, P
   Roux, JP
   Delaisse, JM
AF Jensen, Pia Rosgaard
   Andersen, Thomas Levin
   Chavassieux, Pascale
   Roux, Jean Paul
   Delaisse, Jean Marie
TI Bisphosphonates impair the onset of bone formation at remodeling sites
SO BONE
LA English
DT Article
DE Anti resorptives; Osteoporosis; Osteoblasts; Bone remodeling; Human bone
   histomorphometry
AB Bisphosphonates are widely used anti osteoporotic drugs targeting osteoclasts. They strongly inhibit bone resorption, but also strongly reduce bone formation. This reduced formation is commonly ascribed to the mechanism maintaining the resorption/formation balance during remodeling. The present study provides evidence for an additional mechanism where bisphosphonates actually impair the onset of bone formation after resorption. The evidence is based on morphometric parameters recently developed to assess the activities reversing resorption to formation. Herein, we compare these parameters in cancellous bone of alendronateand placebo treated postmenopausal osteoporotic patients. Alendronate increases the prevalence of eroded surfaces characterized by reversal cells/osteoprogenitors at low cell density and remote from active bone surfaces. This indicates deficient cell expansion on eroded surfaces   an event that is indispensable to start formation. Furthermore, alendronate decreases the coverage of these eroded surfaces by remodeling compartment canopies, a putative source of reversal cells/osteoprogenitors. Finally, alendronate strongly decreases the activation frequency of bone formation, and decreases more the formative compared to the eroded surfaces. All these parameters correlate with each other. These observations lead to a model where bisphosphonates hamper the osteoprogenitor recruitment required to initiate bone formation. This effect results in a larger eroded surface, thereby explaining the well known paradox that bisphosphonates strongly inhibit bone resorption without strongly decreasing eroded surfaces. The possible mechanism for hampered osteoprogenitor recruitment is discussed: bisphosphonates may decrease the release of osteogenic factors by the osteoclasts, and/or bisphosphonates released by osteoclasts may act directly on neighboring osteoprogenitor cells as reported in preclinical studies.
C1 [Jensen, Pia Rosgaard; Andersen, Thomas Levin; Delaisse, Jean Marie] Univ Southern Denmark, Dept Reg Hlth Res, Lillebaelt Hosp, Clin Cell Biol, Vejle, Denmark.
   [Andersen, Thomas Levin; Delaisse, Jean Marie] Univ Southern Denmark, Clin Cell Biol, Dept Pathol, Odense Univ Hosp,Dept Clin Res,Dept Mol Med, Odense, Denmark.
   [Andersen, Thomas Levin] Aarhus Univ, Dept Forens Med, Aarhus, Denmark.
   [Chavassieux, Pascale; Roux, Jean Paul] Univ Lyon, INSERM Unite 1033, Lyon, France.
C3 University of Southern Denmark; University of Southern Denmark; Odense
   University Hospital; Aarhus University; Institut National de la Sante et
   de la Recherche Medicale (Inserm)
RP Delaisse, JM (通讯作者)，JB Winslows Vej 25, DK 5000 Odense, Denmark.
EM piarosgaardjensen@hotmail.com; thomas.levin.andersen@rsyd.dk;
   pascale.chavassieux@univ lyon1.fr; jean paul.roux@univ lyon1.fr;
   jean marie.delaisse@rsyd.dk
RI ; Chavassieux, Pascale/L 9071 2018; Levin Andersen,
   Thomas/AAY 6777 2021; Roux, Jean Paul/AAI 9499 2020
OI Levin Andersen, Thomas/0000 0002 6981 7276; Delaisse,
   Jean Marie/0000 0001 7370 1500
FU foundation of the Region of Southern Denmark [14/24245]
FX This work was supported by the foundation of the Region of Southern
   Denmark 14/24245.
CR Abdelgawad ME, 2016, HISTOCHEM CELL BIOL, V145, P603, DOI 10.1007/s00418 016 1414 y
   Alakangas A, 2002, CALCIFIED TISSUE INT, V70, P40, DOI 10.1007/s002230010047
   Andersen TL, 2014, AM J PATHOL, V184, P1142, DOI 10.1016/j.ajpath.2013.12.005
   Andersen TL, 2013, AM J PATHOL, V183, P235, DOI 10.1016/j.ajpath.2013.03.006
   Andersen TL, 2010, BRIT J HAEMATOL, V148, P551, DOI 10.1111/j.1365 2141.2009.07980.x
   Andersen TL, 2009, AM J PATHOL, V174, P239, DOI 10.2353/ajpath.2009.080627
   Andreasen C.M., OSTEOPOROTIC FRACT S
   Baron R., 1983, Clinical Disorders of Bone and Mineral Metabolism, V1, P191
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Black DM, 2015, J BONE MINER RES, V30, P934, DOI 10.1002/jbmr.2442
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Bone HG, 1997, J CLIN ENDOCR METAB, V82, P265, DOI 10.1210/jc.82.1.265
   Bravenboer N, 1999, OSTEOPOROSIS INT, V9, P489, DOI 10.1007/s001980050175
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Chavassieux PM, 2000, J BONE MINER RES, V15, P754, DOI 10.1359/jbmr.2000.15.4.754
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Cornish J, 2011, BONE, V49, P710, DOI 10.1016/j.bone.2011.07.020
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Delaisse JM, 2020, BONE, V141, DOI [10.1016/j/bone.2020.115628, 10.1016/j.bone.2020.115628]
   Delaisse Jean Marie, 2014, Bonekey Rep, V3, P561, DOI 10.1038/bonekey.2014.56
   Dempster DW, 2017, J BONE MINER RES, V32, P1389, DOI 10.1002/jbmr.3169
   Dufresne TE, 2003, CALCIFIED TISSUE INT, V73, P423, DOI 10.1007/s00223 002 2104 4
   Eastell R, 2011, BONE, V49, P82, DOI 10.1016/j.bone.2011.02.011
   Eriksen EF, 2002, BONE, V31, P620, DOI 10.1016/S8756 3282(02)00869 4
   ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv 7 4 379
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Green J, 2010, SEMIN ONCOL, V37, pS3, DOI 10.1053/j.seminoncol.2010.06.003
   Hauge EM, 2001, J BONE MINER RES, V16, P1575, DOI 10.1359/jbmr.2001.16.9.1575
   Huang KC, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0818 5
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   Iwata K, 2006, BONE, V39, P1053, DOI 10.1016/j.bone.2006.05.006
   Jensen PR, 2015, BONE, V73, P16, DOI 10.1016/j.bone.2014.12.004
   Jensen PR, 2014, BIOCHEM BIOPH RES CO, V443, P694, DOI 10.1016/j.bbrc.2013.12.036
   Jensen PR, 2014, CALCIFIED TISSUE INT, V94, P212, DOI 10.1007/s00223 013 9800 0
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kristensen HB, 2014, AM J PATHOL, V184, P778, DOI 10.1016/j.ajpath.2013.11.022
   Kristensen HB, 2013, J BONE MINER RES, V28, P574, DOI 10.1002/jbmr.1760
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Lassen NE, 2017, J BONE MINER RES, V32, P1395, DOI 10.1002/jbmr.3091
   McClung M, 1998, ANN INTERN MED, V128, P253, DOI 10.7326/0003 4819 128 4 199802150 00001
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Parfitt A.M., 1983, Bone Histomorphometry: Techniques and Interpretation, P143
   Pierroz DD, 2010, J BIOL CHEM, V285, P28164, DOI 10.1074/jbc.M110.101964
   Qiu S, 2010, CALCIFIED TISSUE INT, V87, P392, DOI 10.1007/s00223 010 9411 y
   Recker R, 2005, CURR MED RES OPIN, V21, P185, DOI 10.1185/030079904X20259
   Recker RR, 2008, J BONE MINER RES, V23, P6, DOI 10.1359/JBMR.070906
   Recker RR, 2010, BONE, V46, P660, DOI 10.1016/j.bone.2009.11.004
   Reid IR, 2010, J BONE MINER RES, V25, P2256, DOI 10.1002/jbmr.149
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Ste Marie LG, 2004, CALCIFIED TISSUE INT, V75, P469, DOI 10.1007/s00223 004 0039 7
   Stepan JJ, 2007, BONE, V41, P378, DOI 10.1016/j.bone.2007.04.198
   Taylor Adam, 2011, Small GTPases, V2, P131
   Walter C, 2011, ORAL DIS, V17, P194, DOI 10.1111/j.1601 0825.2010.01720.x
   Weiss HM, 2008, DRUG METAB DISPOS, V36, P2043, DOI 10.1124/dmd.108.021071
   Weivoda M.M., 2014, Orthopedic Muscular System: Current Research, V3, P161, DOI [DOI 10.4172/2161 0533.1000161, 10.4172/2161 0533.1000161]
   Zebaze RM, 2014, BONE, V59, P173, DOI 10.1016/j.bone.2013.11.016
NR 61
TC 48
Z9 56
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2021
VL 145
AR 115850
DI 10.1016/j.bone.2021.115850
EA JAN 2021
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA QO4MU
UT WOS:000623118400010
PM 33465485
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Abo Elenin, MHH
   Kamel, R
   Nofal, S
   Ahmed, AAE
AF Abo Elenin, Mohannad Hakam Hamed
   Kamel, Rehab
   Nofal, Shahira
   Ahmed, Amany Ali Eissa
TI The crucial role of beta catenin in the osteoprotective effect of
   semaglutide in an ovariectomized rat model of osteoporosis
SO NAUNYN SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
LA English
DT Article
DE Osteoporosis; Ovariectomy; Semaglutide; beta catenin; Wnt signaling
ID PARATHYROID HORMONE; OSTEOGENIC DIFFERENTIATION; PEPTIDE 1 RECEPTOR;
   BONE RESORPTION; IN VITRO; PHOSPHORYLATION; EXPRESSION; CALCIUM;
   METABOLISM; DIAGNOSIS
AB Postmenopausal osteoporosis is a common chronic medical illness resulting from an imbalance between bone resorption and bone formation along with microarchitecture degeneration attributed to estrogen deficiency and often accompanied by other medical conditions such as weight gain, depression, and insomnia. Semaglutide (SEM) is a recently introduced GLP 1 receptor agonist (GLP 1RA) for the treatment of obesity and type 2 diabetes mellitus by mitigating insulin resistance. It has been discovered that the beneficial effects of GLP 1 are associated with alterations in lipolysis, adipogenesis, and anti inflammatory processes. GLP 1 analogs transmit signals directly to adipose tissue. Mesenchymal stem cells (MSCs) are multidisciplinary cells that originate from bone marrow, migrate to injury sites, and promote bone regeneration. MSCs can differentiate into osteoblasts, adipose cells, and cartilage cells. Our aim is to investigate the role of semaglutide on bone formation and the Wnt signaling pathway. Osteoporosis was induced in female rats by ovariectomy, and the ovariectomized rats were treated with alendronate as standard treatment with a dose of 3 mg/kg orally and semaglutide with two doses (150 mcg/kg and 300 mcg/kg) S.C. for 10 successive weeks. Semaglutide ameliorates bone detrimental changes induced by ovariectomy. It improves bone microarchitecture and preserves bone mineral content. Semaglutide ameliorates ovariectomy induced osteoporosis and increases the expression of beta catenin, leading to increased bone formation and halted receptor activator of nuclear factor kappa Beta ligand (RANKL's) activation. Semaglutide can be used as a potential prophylactic and therapeutic drug against osteoporosis, possibly by activating Wnt signaling and decreasing bone resorption.
C1 [Abo Elenin, Mohannad Hakam Hamed; Kamel, Rehab; Nofal, Shahira; Ahmed, Amany Ali Eissa] Helwan Univ, Fac Pharm, Pharmacol & Toxicol Dept, Cairo, Egypt.
C3 Egyptian Knowledge Bank (EKB); Helwan University
RP Abo Elenin, MHH (通讯作者)，Helwan Univ, Fac Pharm, Pharmacol & Toxicol Dept, Cairo, Egypt.
EM Mohannad.hakam@pharm.helwan.edu.eg
RI Ahmed, Amany Ali Eissa/T 2497 2019; Hakam, Mohannad/KPA 4667 2024;
   Nofal, Shahira/AAH 3313 2021
OI Abo Elenin, Mohannad/0009 0009 7811 1951; Nofal,
   Shahira/0000 0003 0405 9002
FU Helwan University
FX Our deepest thanks and appreciation to Dr. Mohammed Abdelrazek, Cytology
   and Histology Department, Faculty of Veterinary Medicine, Cairo
   University for his professional aid in the histopathology and analysis
   of this manuscript. The authors also would like to thank Dr. Lalia
   Rashed, Biochemistry Department, Faculty of Medicine, Cairo University
   for help throughout Western blot assays and RT PCR.
CR Abo Elenin MHH, 2024, CLIN TRANSL METAB, V22, DOI 10.1007/s12018 024 09291 6
   Anam M, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.32610
   Aoyama E, 2014, INT J MOL MED, V34, P475, DOI 10.3892/ijmm.2014.1787
   Armbrecht HJ, 2003, ARCH BIOCHEM BIOPHYS, V409, P298, DOI 10.1016/S0003 9861(02)00636 7
   Babaei Parvin, 2010, Menopause Int, V16, P100, DOI 10.1258/mi.2010.010028
   Bae YJ, 2010, CALCIFIED TISSUE INT, V87, P365, DOI 10.1007/s00223 010 9410 z
   Bao QW, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02705 0
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Blundell J, 2017, DIABETES OBES METAB, V19, P1242, DOI 10.1111/dom.12932
   Bonnet N, 2008, J CELL PHYSIOL, V217, P819, DOI 10.1002/jcp.21564
   Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   El Miedany Y, 2021, EGYPT RHEUMATOL REH, V48, DOI 10.1186/s43166 020 00056 9
   Enzo Maria Vittoria, 2015, Mol Cell Ther, V3, P1
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Gabery S, 2020, JCI
   Galvao JFD, 2013, J VET EMERG CRIT CAR, V23, P134, DOI 10.1111/vec.12036
   Gillespie JR, 2013, ENDOCRINOLOGY, V154, P3702, DOI 10.1210/en.2013 1155
   González Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757 4768.2004
   Greenblatt MB, 2017, CLIN CHEM, V63, P464, DOI 10.1373/clinchem.2016.259085
   Grigorie D, 2018, ACTA ENDOCRINOL BUCH, V14, P90, DOI 10.4183/aeb.2018.90
   Guo YY, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00976 4
   Habib HA, 2021, EUR J PHARMACOL, V892, DOI 10.1016/j.ejphar.2020.173721
   Halloran D, 2020, J DEV BIOL, V8, DOI 10.3390/jdb8030019
   Harmer D, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00788
   Hebert SC, 1997, J EXP BIOL, V200, P295
   Henry JP, 2022, STATPEARLS
   Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063 9072.2005
   Houschyar KS, 2019, FRONTIERS CELL DEVEL, V6
   Ivaska KK, 2004, J BIOL CHEM, V279, P18361, DOI 10.1074/jbc.M314324200
   Jeon YK, 2014, ENDOCRINOL METAB, V29, P567, DOI 10.3803/EnM.2014.29.4.567
   Kawai M, 2012, J INTERN MED, V272, P317, DOI 10.1111/j.1365 2796.2012.02564.x
   Khajuria DK, 2017, MAT SCI ENG C MATER, V71, P698, DOI 10.1016/j.msec.2016.10.066
   Khajuria DK, 2012, REV BRAS REUMATOL, V52, P462
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Kim TH, 2011, J NUTR BIOCHEM, V22, P8, DOI 10.1016/j.jnutbio.2009.11.002
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Li Q, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117531
   Luo GJ, 2016, BRIT J CLIN PHARMACO, V81, P78, DOI 10.1111/bcp.12777
   Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378
   Ma MY, 2023, MOLECULES, V28, DOI 10.3390/molecules28186652
   Mai QG, 2011, J CELL BIOCHEM, V112, P2902, DOI 10.1002/jcb.23206
   Medina Miguel, 2011, Int J Alzheimers Dis, V2011, P479249, DOI 10.4061/2011/479249
   Moor MB, 2016, AM J PHYSIOL RENAL, V310, pF1337, DOI 10.1152/ajprenal.00273.2015
   RADER JI, 1979, AM J PHYSIOL, V236, pE118, DOI 10.1152/ajpendo.1979.236.2.E118
   Rajfer RA, 2019, J OSTEOPOROS, V2019, DOI 10.1155/2019/1592328
   Regard JB, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007997
   Ren W, 2020, ACTA ENDOCRINOL BUCH, V16, P156, DOI 10.4183/aeb.2020.156
   Riccardi D, 2010, AM J PHYSIOL RENAL, V298, pF485, DOI 10.1152/ajprenal.00608.2009
   Roh E, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043384
   Rowe P., 2023, StatPearls
   Rubino D, 2021, JAMA J AM MED ASSOC, V325, P1414, DOI 10.1001/jama.2021.3224
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Salazar M, 2015, ARCH ORAL BIOL, V60, P776, DOI 10.1016/j.archoralbio.2015.02.003
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Shi C, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2020.107473
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Smajilovic S, 2010, OPEN CARDIOVASC MED, V4, P110, DOI 10.2174/1874192401004010110
   Sophocleous Antonia, 2014, Bonekey Rep, V3, P614, DOI 10.1038/bonekey.2014.109
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898
   Ström JO, 2012, JOVE J VIS EXP, DOI 10.3791/4013
   Takeuchi T, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102884
   Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200
   Tebben PJ, 2016, ENDOCR REV, V37, P521, DOI 10.1210/er.2016 1070
   Vlashi R, 2023, GENES DIS, V10, P1291, DOI 10.1016/j.gendis.2022.07.011
   Wang T, 2017, J CELL PHYSIOL, V232, P913, DOI 10.1002/jcp.25641
   Wawrzyniak A, 2022, ANIMALS BASEL, V12, DOI 10.3390/ani12151946
   Wawrzyniak N, 2021, NUTRIENTS, V13, DOI 10.3390/nu13072334
   Weitzmann MN, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/125705
   Wu L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061519
   Xu HH, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108650
   Yoon KH, 2012, J KOREAN NEUROSURG S, V51, P323, DOI 10.3340/jkns.2012.51.6.323
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Zierold C, 2003, J CELL BIOCHEM, V88, P234, DOI 10.1002/jcb.10341
NR 76
TC 2
Z9 2
U1 8
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0028 1298
EI 1432 1912
J9 N S ARCH PHARMACOL
JI Naunyn Schmiedebergs Arch. Pharmacol.
PD MAR
PY 2025
VL 398
IS 3
BP 2677
EP 2693
DI 10.1007/s00210 024 03378 z
EA SEP 2024
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 0NF2B
UT WOS:001309932800003
PM 39254876
OA hybrid
DA 2025 08 17
ER

PT J
AU Muniyasamy, R
   Manjubala, I
AF Muniyasamy, Rajeshwari
   Manjubala, I.
TI Identification of potential sclerostin inhibiting flavonoids from
   Oroxylum indicum: an insilico approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article
DE Sclerostin inhibitor; flavonoids; Oroxylum indicum; in silico drug
   screening; canonical wnt signaling; bone related disorders
ID BONE; ANTAGONISTS; MECHANISMS; BIND
AB Flavonoids are secondary metabolites that are widely found in various medicinal plants. They are known for their medicinal benefits and have been extensively used in healthcare industries and in the management of age related diseases. This paper focuses on flavonoids from Oroxylum indicum, a significant medicinal tree in the practice of traditional Indian medicine. O. indicum has been utilized in a variety of polyherbal formulations for the management of musculoskeletal disorders, however the mechanism of action of its bioactive flavonoids remains unknown. The present study aimed to identify the flavonoids of O. indicum with the potential to target sclerostin, an antagonist of canonical Wnt signaling pathway for the treatment of bone related disorders. Molecular docking, coarse grained and molecular dynamics simulations were performed to screen the major flavonoids and investigate their interaction with sclerostin. Flavonoids with highest binding affinity and interacting with at least one of the amino acids of the PNAIG motif residues were selected from docking studies and subjected to further drug likeness and ADMET screening. Further screening from coarse grained and molecular dynamic simulations results showed that baicalein, compared to other screened flavonoids, stably binds with the important residues of the LRP6 binding site of sclerostin, resulting in pronounced structural changes in the protein. These findings suggest that baicalein from O. indicum can potentially inhibit sclerostin and can elicit skeletal protective effects, providing an insight for further in vitro and in vivo studies.Communicated by Ramaswamy H. Sarma
C1 [Muniyasamy, Rajeshwari; Manjubala, I.] Vellore Inst Technol, Sch Biosci & Technol, Vellore, India.
C3 Vellore Institute of Technology (VIT); VIT Vellore
RP Manjubala, I (通讯作者)，Vellore Inst Technol, Sch Biosci & Technol, Vellore, India.
EM i.manjubala@vit.ac.in
RI ; Manjubala, I/B 9020 2012; Manjubala, I./LIF 6281 2024
OI , Rajeshwari/0000 0002 7381 916X; Manjubala, I/0000 0003 4873 2377; 
FU Vellore Institute of Technology (VIT), Vellore
FX The author (RM) sincerely thanks Vellore Institute of Technology (VIT),
   Vellore for providing Teaching cum research assistant (TRA) fellowship
   asthe financial support
CR Abraham Mark James, 2015, SoftwareX, V1 2, P19, DOI 10.1016/j.softx.2015.06.001
   Ahmad S, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.578970
   An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   Barker Nick, 2008, V468, P5, DOI 10.1007/978 1 59745 249 6_1
   Baron R, 2018, CURR OPIN PHARMACOL, V40, P134, DOI 10.1016/j.coph.2018.04.011
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Begum MM, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/1562038
   BIOVIA, 2021, Free Download: BIOVIA Discovery Studio Visualizer Dassault Systemes
   Boschert V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081710
   Bourhis E, 2011, STRUCTURE, V19, P1433, DOI 10.1016/j.str.2011.07.005
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834
   Daina A, 2017, SCI REP UK, V7, DOI 10.1038/srep42717
   Dinda B, 2015, J ETHNOPHARMACOL, V161, P255, DOI 10.1016/j.jep.2014.12.027
   Dretcanu G, 2022, PLANTS BASEL, V11, DOI 10.3390/plants11091117
   Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458
   Holdsworth G, 2012, J BIOL CHEM, V287, P26464, DOI 10.1074/jbc.M112.350108
   Hollingsworth SA, 2018, NEURON, V99, P1129, DOI 10.1016/j.neuron.2018.08.011
   Ivanova L, 2022, MOLECULES, V27, DOI 10.3390/molecules27249041
   Jamroz M, 2014, BIOINFORMATICS, V30, P2150, DOI 10.1093/bioinformatics/btu184
   Karnati M, 2013, PHARMACOGN RES, V5, P121, DOI 10.4103/0974 8490.110543
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kumar M, 2021, PLANTS BASEL, V10, DOI 10.3390/plants10091842
   Kumar S, 2013, SCI WORLD J, DOI 10.1155/2013/162750
   Kuriata A, 2018, NUCLEIC ACIDS RES, V46, pW338, DOI 10.1093/nar/gky356
   Lewiecki EM, 2014, THER ADV MUSCULOSKEL, V6, P48, DOI 10.1177/1759720X13510479
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Muthusamy K, 2016, PHYSIOL RES, V65, P871, DOI 10.33549/physiolres.933267
   Nair A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133292
   Salleh NNHN, 2020, MOLECULES, V25, DOI 10.3390/molecules25235677
   Pai SG, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045 017 0471 6
   Panche AN, 2016, J NUTR SCI, V5, DOI 10.1017/jns.2016.41
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Prapaipittayakhun Jaruthai, 2023, OpenNano, DOI 10.1016/j.onano.2022.100117
   Prasathkumar M, 2021, Phytomedicine Plus, V1, DOI [DOI 10.1016/J.PHYPLU.2021.100029, 10.1016/j.phyplu.2021.100029]
   Rathi B, 2020, INT J AYURVEDIC MED, V11, P175
   Schrodinger L., 2021, PyMol molecular graphics system
   Schüttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Sen S., 2015, BOT TARGET THER, V5, P33, DOI [10.2147/btat.s66308, 10.2147/BTAT.S66308, DOI 10.2147/BTAT.S66308]
   Tungmunnithum Duangjai, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030093
   Veverka V, 2009, J BIOL CHEM, V284, P10890, DOI 10.1074/jbc.M807994200
   Yooin W, 2020, J BIOMOL STRUCT DYN, V38, P1272, DOI 10.1080/07391102.2019.1599427
NR 41
TC 8
Z9 9
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739 1102
EI 1538 0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
PD SEP 1
PY 2024
VL 42
IS 13
BP 6588
EP 6599
DI 10.1080/07391102.2023.2239955
EA JUL 2023
PG 12
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA C4F9S
UT WOS:001036832100001
PM 37493468
DA 2025 08 17
ER

PT J
AU Kim, HM
   Kim, DH
   Han, HJ
   Park, CM
   Ganipisetti, SR
   Arasu, MV
   Kim, YO
   Park, CG
   Kim, BY
   Soung, NK
AF Kim, Hye Min
   Kim, Dong Hyun
   Han, Ho Jin
   Park, Chan Mi
   Ganipisetti, Srinivas Rao
   Arasu, Mariadhas Valan
   Kim, Young Ock
   Park, Chun Geun
   Kim, Bo Yeon
   Soung, Nak Kyun
TI Ginsenoside Re Promotes Osteoblast Differentiation in Mouse Osteoblast
   Precursor MC3T3 E1 Cells and a Zebrafish Model
SO MOLECULES
LA English
DT Article
DE bone; osteoblast differentiation; Ginsenoside Re
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; ALKALINE PHOSPHATASE ACTIVITY; P38
   MAPK PATHWAYS; NF KAPPA B; IN VITRO; INHIBITS OSTEOCLASTOGENESIS; BONE;
   SCALES; MINERALIZATION; BISPHOSPHONATE
AB Bone homeostasis is tightly regulated to balance bone formation and bone resorption. Many anabolic drugs are used as bone targeted therapeutic agents for the promotion of osteoblast mediated bone formation or inhibition of osteoclast mediated bone resorption. Previous studies showed that ginsenoside Re has the effect of the suppression of osteoclast differentiation in mouse bone marrow derived macrophages and zebrafish. Herein, we investigated whether ginsenoside Re affects osteoblast differentiation and mineralization in in vitro and in vivo models. Mouse osteoblast precursor MC3T3 E1 cells were used to investigate cell viability, alkaline phosphatase (ALP) activity, and mineralization. In addition, we examined osteoblastic signaling pathways. Ginsenoside Re affected ALP activity without cytotoxicity, and we also observed the stimulation of osteoblast differentiation through the activation of osteoblast markers including runt related transcription factor 2, type 1 collagen, ALP, and osteocalcin in MC3T3 E1 cells. Moreover, Alizarin red S staining indicated that ginsenoside Re increased osteoblast mineralization in MC3T3 E1 cells and zebrafish scales compared to controls. These results suggest that ginsenoside Re promotes osteoblast differentiation as well as inhibits osteoclast differentiation, and it could be a potential therapeutic agent for bone diseases.
C1 [Kim, Hye Min; Kim, Dong Hyun; Han, Ho Jin; Ganipisetti, Srinivas Rao; Kim, Bo Yeon; Soung, Nak Kyun] Korea Res Inst Biosci & Biotechnol KRIBB, Anticanc Agent Res Ctr, Cheongju 28116, South Korea.
   [Kim, Hye Min; Kim, Dong Hyun; Han, Ho Jin; Park, Chan Mi; Ganipisetti, Srinivas Rao; Kim, Bo Yeon; Soung, Nak Kyun] Korea Res Inst Biosci & Biotechnol KRIBB, World Class Inst, Cheongju 28116, South Korea.
   [Arasu, Mariadhas Valan] King Saud Univ, Dept Bot & Microbiol, Coll Sci, Addiriyah Chair Environm Studies, POB 2455, Riyadh 11451, Saudi Arabia.
   [Kim, Young Ock; Park, Chun Geun] Rural Dev Adm, Natl Inst Hort & Herbal Sci, Dept Med Crop Res Inst, Eumseong 27709, South Korea.
   [Kim, Hye Min; Kim, Dong Hyun; Han, Ho Jin; Kim, Bo Yeon; Soung, Nak Kyun] Univ Sci & Technol, Dept Biomol Sci, Daejeon 34113, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea
   Research Institute of Bioscience & Biotechnology (KRIBB); King Saud
   University; Rural Development Administration (RDA), Republic of Korea;
   National Institute of Horticultural & Herbal Science (NIHHS), Republic
   of Korea; University of Science & Technology (UST)
RP Kim, BY; Soung, NK (通讯作者)，Korea Res Inst Biosci & Biotechnol KRIBB, Anticanc Agent Res Ctr, Cheongju 28116, South Korea.; Kim, BY; Soung, NK (通讯作者)，Korea Res Inst Biosci & Biotechnol KRIBB, World Class Inst, Cheongju 28116, South Korea.; Kim, BY; Soung, NK (通讯作者)，Univ Sci & Technol, Dept Biomol Sci, Daejeon 34113, South Korea.
EM hyemin88@kribb.re.kr; waikiki@kribb.re.kr; hjhan@kribb.re.kr;
   springcm@kribb.re.kr; raogs@kribb.re.kr; mvalanarasu@gmail.com;
   kyo9128@korea.kr; pcg@korea.kr; bykim@kribb.re.kr; soungnak@kribb.re.kr
RI GANIPISETTI, SRINIVASRAO/AAA 6802 2022; Kim, Duk Hwan/AAC 5666 2022;
   Valan Arasu, Mariadhas/K 9671 2015; Kim, Seonhwa/JUU 3314 2023; Valan
   Arasu, Mariadhas/AAB 3681 2020
OI Valan Arasu, Mariadhas/0000 0001 5898 2121; GANIPISETTI,
   SRINIVASRAO/0000 0001 9803 8813; 
FU Medicinal Crops Division, Ginseng and Medicinal Plants Research
   Institute, Rural Development Administration [PJ010221]; KRIBB Research
   Initiative Program [KGS531162]
FX This work was supported by the Medicinal Crops Division, Ginseng and
   Medicinal Plants Research Institute, Rural Development Administration
   (PJ010221) and the KRIBB Research Initiative Program (KGS531162).
CR [Anonymous], CHIN MED
   Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006 2952(99)00212 9
   Cheng BB, 2012, FOOD CHEM TOXICOL, V50, P1610, DOI 10.1016/j.fct.2012.02.019
   de Vrieze E, 2014, OSTEOPOROSIS INT, V25, P567, DOI 10.1007/s00198 013 2441 3
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gu YQ, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/305071
   Han SH, 2011, J PERIODONTAL IMPLAN, V41, P227, DOI 10.5051/jpis.2011.41.5.227
   He L, 2012, BONE, V50, P1207, DOI 10.1016/j.bone.2012.03.022
   Jang DJ, 2008, BRIT J CLIN PHARMACO, V66, P444, DOI 10.1111/j.1365 2125.2008.03236.x
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Khajuria DK, 2011, REV BRAS REUMATOL, V51, P365
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kim DY, 2012, FITOTERAPIA, V83, P215, DOI 10.1016/j.fitote.2011.10.017
   Kim DY, 2011, BMB REP, V44, P659, DOI 10.5483/BMBRep.2011.44.10.659
   Kim DY, 2011, INT J MOL MED, V28, P753, DOI 10.3892/ijmm.2011.750
   Kim J, 2015, J GINSENG RES, V39, P46, DOI 10.1016/j.jgr.2014.06.001
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lee DCW, 2009, J TRANSL MED, V7, DOI 10.1186/1479 5876 7 34
   Lee HY, 2015, J FUNCT FOODS, V13, P192, DOI 10.1016/j.jff.2014.12.039
   Lee JH, 2013, J GINSENG RES, V37, P435, DOI 10.5142/jgr.2013.37.435
   Metz JR, 2012, J APPL ICHTHYOL, V28, P382, DOI 10.1111/j.1439 0426.2012.01990.x
   Miao DS, 2002, J HISTOCHEM CYTOCHEM, V50, P333, DOI 10.1177/002215540205000305
   Park C. M., 2016, MOL CELLS, DOI 10.14348/molcells.2016.0111
   Pasqualetti S, 2015, INT J EXP PATHOL, V96, P11, DOI 10.1111/iep.12106
   Peng DC, 2012, CHIN MED UK, V7, DOI [10.1186/1749 8546 7 2, 10.1186/1749 8546 7 23]
   Peng L, 2012, CARDIOVASC THER, V30, pe183, DOI 10.1111/j.1755 5922.2011.00271.x
   Phan TCA, 2004, HISTOL HISTOPATHOL, V19, P1325, DOI 10.14670/HH 19.1325
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Raisz LG, 1999, CLIN CHEM, V45, P1353
   Rhee CW, 2012, OSTEOPOROSIS INT, V23, P247, DOI 10.1007/s00198 011 1608 z
   SABOKBAR A, 1994, BONE MINER, V27, P57, DOI 10.1016/S0169 6009(08)80187 0
   Siddiqi MH, 2015, PHYTOTHER RES, V29, P1286, DOI 10.1002/ptr.5374
   Siddiqi MH, 2014, J PHARM PHARMACOL, V66, P1763, DOI 10.1111/jphp.12306
   Siddiqi MH, 2014, PHYTOTHER RES, V28, P1447, DOI 10.1002/ptr.5146
   Siddiqi MH, 2013, J GINSENG RES, V37, P261, DOI 10.5142/jgr.2013.37.261
   Sila Asna Monnipha, 2007, Kobe J Med Sci, V53, P25
   Sire JY, 2004, INT J DEV BIOL, V48, P233, DOI 10.1387/ijdb.15272389
   Suzuki N, 2009, LIFE SCI, V84, P482, DOI 10.1016/j.lfs.2009.01.008
   Wysowski DK, 2009, NEW ENGL J MED, V360, P89, DOI 10.1056/NEJMc0808738
   Xie JT, 2005, BBA MOL BASIS DIS, V1740, P319, DOI 10.1016/j.bbadis.2004.10.010
   Xie JT, 2006, EUR J PHARMACOL, V532, P201, DOI 10.1016/j.ejphar.2006.01.001
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Young MF, 2003, OSTEOPOROSIS INT, V14, pS35, DOI 10.1007/s00198 002 1342 7
NR 43
TC 20
Z9 20
U1 5
U2 40
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD JAN
PY 2017
VL 22
IS 1
AR 42
DI 10.3390/molecules22010042
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EM7EE
UT WOS:000395473500042
PM 28036069
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Salie, R
   Kneissel, M
   Vukevic, M
   Zamurovic, N
   Kramer, I
   Evans, G
   Gerwin, N
   Mueller, M
   Kinzel, B
   Susa, M
AF Salie, Rishard
   Kneissel, Michaela
   Vukevic, Mirko
   Zamurovic, Natasa
   Kramer, Ina
   Evans, Glenda
   Gerwin, Nicole
   Mueller, Matthias
   Kinzel, Bernd
   Susa, Mira
TI Ubiquitous overexpression of Hey1 transcription factor leads to
   osteopenia and chondrocyte hypertrophy in bone
SO BONE
LA English
DT Article
DE Hey1; HES; Osteopenia; Osteoblast; Osteoclast; Chondrocyte hypertrophy
ID OSTEOCLAST DIFFERENTIATION; NOTCH; CELLS; RECEPTOR; PATHWAY; EXPRESSION;
   REPRESSION; PROTEINS; MARROW; LIGAND
AB The transcription factor Hey1, a known Notch target gene of the HES family, has recently been described as a target gene of bone morphogenetic protein 2 (BMP 2) during osteoblastic differentiation in vitro. As the role of Hey1 in skeletal physiology is unknown, we analyzed bones of mice ubiquitously lacking overexpressing Hey1. This strategy enabled us to evaluate whether Hey1 modulation in the whole organism could serve as a drug or antibody target for therapy of diseases associated with bone loss. Hey1 deficiency resulted in modest osteopenia in vivo and increased number and activity of osteoclasts generated ex vivo. Hey1 overexpression resulted in distinct progressive osteopenia and inhibition of osteoblasts ex vivo, all effect apparently dominant to a mild inhibition of osteoclasts. In both Hey1 deficient and overexpressing mice, males were less affected than females and skeleton was not affected during development. Bone histomorphometry did not reveal major changes in animals at 20 weeks, suggesting that modulation had occurred before. Adult Hey1 transgenics also displayed increased type X collagen expression and an enlarged hypertrophic zone in the growth plate. Taken together, our data suggest that ubiquitous in vivo Hey1 regulation affects osteoblasts, osteoclasts and chondrocytes. Due to the complex role of Hey1 in bone, inhibition of Hey1 does not appear to be a straightforward therapeutic strategy to increase the bone mass. (C) 2009 Elsevier Inc. All rights reserved
C1 [Salie, Rishard; Kneissel, Michaela; Vukevic, Mirko; Kramer, Ina; Evans, Glenda; Gerwin, Nicole; Susa, Mira] Novartis Inst BioMed Res, Musculoskeletal Dis Area, CH 4002 Basel, Switzerland.
C3 Novartis
RP Susa, M (通讯作者)，Novartis Inst BioMed Res, Musculoskeletal Dis Area, WKL 125 13 18, CH 4002 Basel, Switzerland.
EM mira.susa_spring@novartis.com
CR Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Belandia B, 2005, MOL CELL BIOL, V25, P1425, DOI 10.1128/MCB.25.4.1425 1436.2005
   Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200
   Chandrasegaran AL, 2007, CHEM EDUC RES PRACT, V8, P293
   David JP, 1998, J BONE MINER RES, V13, P1730, DOI 10.1359/jbmr.1998.13.11.1730
   de Jong DS, 2004, BIOCHEM BIOPH RES CO, V320, P100, DOI 10.1016/j.bbrc.2004.05.150
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004
   Fischer A, 2007, CIRC RES, V100, P856, DOI 10.1161/01.RES.0000260913.95642.3b
   Frank RN, 2003, INVEST OPHTH VIS SCI, V44, P1
   Garrett IR, 2007, CURR TOP DEV BIOL, V78, P127, DOI 10.1016/S0070 2153(06)78004 8
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208
   Jägle U, 2007, GENESIS, V45, P659, DOI 10.1002/dvg.20342
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kokubo H, 2007, DEVELOPMENT, V134, P747, DOI 10.1242/dev.02777
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   OLSEN BR, 2006, PRIMER METABOLIC BON, P20
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Phinney DG, 1999, J CELL BIOCHEM, V72, P570
   Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008 5472.CAN 07 5744
   Ross F.P., 2006, PRIMER METABOLIC BON, VSixth, P30
   Rutenberg JB, 2006, DEVELOPMENT, V133, P4381, DOI 10.1242/dev.02607
   Salie R, 2008, CALCIFIED TISSUE INT, V83, P212, DOI 10.1007/s00223 008 9154 1
   SANDERSON C, 1995, BIOTECH HISTOCHEM, V70, P12, DOI 10.3109/10520299509108310
   Shawber CJ, 2003, ANN NY ACAD SCI, V995, P162, DOI 10.1111/j.1749 6632.2003.tb03219.x
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Susa M, 1997, BIOCHEM BIOPH RES CO, V235, P680, DOI 10.1006/bbrc.1997.6864
   WEZEMAN FH, 1990, CALCIFIED TISSUE INT, V46, P263, DOI 10.1007/BF02555006
   Zamurovic N, 2004, J BIOL CHEM, V279, P37704, DOI 10.1074/jbc.M403813200
NR 31
TC 51
Z9 61
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2010
VL 46
IS 3
BP 680
EP 694
DI 10.1016/j.bone.2009.10.022
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 564WJ
UT WOS:000275248600016
PM 19857617
DA 2025 08 17
ER

PT J
AU Esbrit, P
   Alcaraz, MJ
AF Esbrit, Pedro
   Jose Alcaraz, Maria
TI Current perspectives on parathyroid hormone (PTH) and PTH related
   protein (PTHrP) as bone anabolic therapies
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE PTH; PTHrP; Bone formation; Bone repair; Bone anabolic therapy
ID ENDOTHELIAL GROWTH FACTOR; HUMAN OSTEOBLASTIC CELLS; C TERMINAL
   FRAGMENTS; INTERMITTENT TREATMENT; PTH/PTHRP RECEPTOR; DIABETIC MICE;
   TARGET GENES; IN VIVO; OSTEOPOROSIS; ACTIVATION
AB Osteoporosis is characterized by low bone mineral density and/or poor bone microarchitecture leading to an increased risk of fractures. The skeletal alterations in osteoporosis are a consequence of a relative deficit of bone formation compared to bone resorption. Osteoporosis therapies have mostly relied on antiresorptive drugs. An alternative therapeutic approach for osteoporosis is currently available, based on the intermittent administration of parathyroid hormone (PTH). Bone anabolism caused by PTH therapy is mainly accounted for by the ability of PTH to increase osteoblastogenesis and osteoblast survival. PTH and PTH related protein (PTHrP) an abundant local factor in bone  interact with the common PTH type 1 receptor with similar affinities in osteoblasts. Studies mainly in osteoporosis rodent models and limited data in postmenopausal women suggest that N terminal PTHrP peptides might be considered a promising bone anabolic therapy. In addition, putative osteogenic actions of PTHrP might be ascribed not only to its N terminal domain but also to its PTH unrelated C terminal region. In this review, we discuss the underlying cellular and molecular mechanisms of the anabolic actions of PTH and the similar potential of PTH related protein (PTHrP) to increase bone mass and improve bone regeneration. (c) 2013 Elsevier Inc. All rights reserved.
C1 [Esbrit, Pedro] Fdn Jimenez Diaz, IIS, Lab Metab Mineral & Oseo, E 28040 Madrid, Spain.
   [Esbrit, Pedro; Jose Alcaraz, Maria] Inst Salud Carlos III, RETICEF, Madrid 28029, Spain.
   [Jose Alcaraz, Maria] Univ Valencia, Dept Farmacol & IDM, E 46100 Valencia, Spain.
C3 Fundacion Jimenez Diaz; Instituto de Salud Carlos III; University of
   Valencia
RP Esbrit, P (通讯作者)，Fdn Jimenez Diaz, IIS, Lab Metab Mineral & Oseo, Avda Reyes Catolicos 2, E 28040 Madrid, Spain.
EM pesbrit@fjd.es
RI Alcaraz, María José/D 8195 2018
FU Instituto de Salud Carlos III [RETICEF RD06/0013/1002, RD12/0043/0008,
   0013, PI080922, PI11/00449]; Ministerio de Ciencia e Innovacion
   [SAF2005 05254, SAF2010 22048]; Comunidad Autonoma de Madrid
   [S2009/MAT 1472]; Generalitat Valenciana [Prometeo2010 047]; Fundacion
   de Investigacion Medica Mutua Madrilena
FX The authors of this review were granted from Instituto de Salud Carlos
   III (RETICEF RD06/0013/1002 and 2001, RD12/0043/0008 and 0013, PI080922
   and PI11/00449), Ministerio de Ciencia e Innovacion (SAF2005 05254,
   SAF2010 22048), Comunidad Autonoma de Madrid (S2009/MAT 1472),
   Generalitat Valenciana (Prometeo2010 047) and Fundacion de Investigacion
   Medica Mutua Madrilena. We are indebted to Mark Stanley Davis for
   proofreading the manuscript.
CR Alonso V, 2008, J CELL PHYSIOL, V217, P717, DOI 10.1002/jcp.21547
   Arvidson K, 2011, J CELL MOL MED, V15, P718, DOI 10.1111/j.1582 4934.2010.01224.x
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bikle D.D., 2011, IBMS BoneKEy, V8, P328, DOI DOI 10.1138/20110521
   Bivi N, 2011, J CELL BIOCHEM, V112, P2920, DOI 10.1002/jcb.23208
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Chen HL, 2002, J BIOL CHEM, V277, P19374, DOI 10.1074/jbc.M108913200
   Compston JE, 2007, BONE, V40, P1447, DOI 10.1016/j.bone.2006.09.008
   Cornish J, 1999, J BONE MINER RES, V14, P915, DOI 10.1359/jbmr.1999.14.6.915
   Cornish J, 1997, ENDOCRINOLOGY, V138, P1299, DOI 10.1210/en.138.3.1299
   Cusano NE, 2011, CURR MED RES OPIN, V27, P1705, DOI 10.1185/03007995.2011.599837
   Datta NS, 2007, J BONE MINER RES, V22, P951, DOI 10.1359/JBMR.070328
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   de Gortázar AR, 2006, CALCIFIED TISSUE INT, V79, P360, DOI 10.1007/s00223 006 0099 y
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   de Castro LF, 2010, TISSUE ENG PT A, V16, P1157, DOI [10.1089/ten.tea.2009.0355, 10.1089/ten.TEA.2009.0355]
   de Castro LF, 2012, J CELL PHYSIOL, V227, P1752, DOI 10.1002/jcp.22902
   Gesty Palmer D, 2011, BRIT J PHARMACOL, V164, P59, DOI 10.1111/j.1476 5381.2011.01450.x
   Glass DA, 2007, ENDOCRINOLOGY, V148, P2630, DOI 10.1210/en.2006 1372
   Goltzman D, 2008, ARCH BIOCHEM BIOPHYS, V473, P218, DOI 10.1016/j.abb.2008.03.003
   Gruber R, 2006, EXP GERONTOL, V41, P1080, DOI 10.1016/j.exger.2006.09.008
   Hamann C, 2012, NAT REV ENDOCRINOL, V8, P297, DOI 10.1038/nrendo.2011.233
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002 021122
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jilka RL, 2010, AGING CELL, V9, P851, DOI 10.1111/j.1474 9726.2010.00616.x
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Khosla S, 2011, J BONE MINER RES, V26, P441, DOI 10.1002/jbmr.262
   Krishnan V, 2003, MOL ENDOCRINOL, V17, P423, DOI 10.1210/me.2002 0225
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Lindsay R, 2006, J BONE MINER RES, V21, P366, DOI 10.1359/JBMR.051109
   Lozano D, 2011, BRIT J PHARMACOL, V162, P1424, DOI 10.1111/j.1476 5381.2010.01155.x
   Lozano D, 2012, ACTA BIOMATER, V8, P2770, DOI 10.1016/j.actbio.2012.04.002
   Lozano D, 2009, ENDOCRINOLOGY, V150, P2027, DOI 10.1210/en.2008 1108
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Martínez ME, 1999, CALCIFIED TISSUE INT, V64, P280, DOI 10.1007/s002239900619
   Martínez P, 2002, OSTEOPOROSIS INT, V13, P874, DOI 10.1007/s001980200120
   Miao DS, 2004, ENDOCRINOLOGY, V145, P3554, DOI 10.1210/en.2003 1695
   Moen MD, 2006, DRUGS, V66, P2371, DOI 10.2165/00003495 200666180 00008
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Ono N, 2012, J CELL PHYSIOL, V227, P408, DOI 10.1002/jcp.22986
   Pape HC, 2010, J ORTHOP TRAUMA, V24, P522, DOI 10.1097/BOT.0b013e3181ed1361
   Portal Núñez S, 2010, FEBS LETT, V584, P3095, DOI 10.1016/j.febslet.2010.05.047
   Portal Núñez S, 2013, AGE, V35, P383, DOI 10.1007/s11357 011 9372 8
   Portal Núñez S, 2012, HISTOL HISTOPATHOL, V27, P559, DOI 10.14670/HH 27.559
   Qin L, 2005, J BIOL CHEM, V280, P3104, DOI 10.1074/jbc.M409846200
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Recker RR, 2011, BONE, V49, P955, DOI 10.1016/j.bone.2011.07.017
   Rickard DJ, 2006, BONE, V39, P1361, DOI 10.1016/j.bone.2006.06.010
   Sabbieti MG, 2009, J CELL PHYSIOL, V219, P143, DOI 10.1002/jcp.21661
   Salinas AJ, 2013, BIOMATER SCI UK, V1, P40, DOI 10.1039/c2bm00071g
   Schnoke M, 2009, BONE, V45, P590, DOI 10.1016/j.bone.2009.05.006
   Silva BC, 2011, J ENDOCRINOL INVEST, V34, P801, DOI 10.3275/7925
   Silverman SL, 2011, RHEUM DIS CLIN N AM, V37, P471, DOI 10.1016/j.rdc.2011.08.002
   Sneddon WB, 2004, ENDOCRINOLOGY, V145, P2815, DOI 10.1210/en.2003 1185
   Sowa H, 2003, J BIOL CHEM, V278, P52240, DOI 10.1074/jbc.M302566200
   Stewart AF, 2000, J BONE MINER RES, V15, P1517, DOI 10.1359/jbmr.2000.15.8.1517
   Suda N, 1996, J CELL PHYSIOL, V166, P94, DOI 10.1002/(SICI)1097 4652(199601)166:1<94::AID JCP11>3.0.CO;2 P
   Takahata M, 2012, CELL TISSUE RES, V347, P545, DOI 10.1007/s00441 011 1188 4
   Tashjian AH, 2008, J BONE MINER RES, V23, P803, DOI 10.1359/JBMR.080208
   Teitelbaum SL, 2011, ARTHRITIS RHEUM US, V63, P325, DOI 10.1002/art.30135
   Toribio RE, 2010, FASEB J, V24, P1947, DOI 10.1096/fj.09 147033
   Trejo CG, 2010, BIOMATERIALS, V31, P8564, DOI 10.1016/j.biomaterials.2010.07.103
   Vaes BLT, 2006, BONE, V39, P724, DOI 10.1016/j.bone.2006.04.024
   Wan M, 2008, GENE DEV, V22, P2968, DOI 10.1101/gad.1702708
   Watanabe A, 2012, J TOXICOL SCI, V37, P617
   Weinstein RS, 2010, ENDOCRINOLOGY, V151, P2641, DOI 10.1210/en.2009 1488
   Wongdee K, 2011, WORLD J DIABETES, V2, P41, DOI 10.4239/wjd.v2.i3.41
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yamamoto T, 2007, BONE, V40, P354, DOI 10.1016/j.bone.2006.09.002
NR 75
TC 99
Z9 115
U1 1
U2 31
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAY 15
PY 2013
VL 85
IS 10
BP 1417
EP 1423
DI 10.1016/j.bcp.2013.03.002
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 150EA
UT WOS:000319371800002
PM 23500550
DA 2025 08 17
ER

PT J
AU Tsubaki, M
   Komai, M
   Itoh, T
   Imano, M
   Sakamoto, K
   Shimaoka, H
   Takeda, T
   Ogawa, N
   Mashimo, K
   Fujiwara, D
   Mukai, J
   Sakaguchi, K
   Satou, T
   Nishida, S
AF Tsubaki, Masanobu
   Komai, Makiko
   Itoh, Tatsuki
   Imano, Motohiro
   Sakamoto, Kotaro
   Shimaoka, Hirotaka
   Takeda, Tomoya
   Ogawa, Naoki
   Mashimo, Kenji
   Fujiwara, Daiichiro
   Mukai, Junji
   Sakaguchi, Katsuhiko
   Satou, Takao
   Nishida, Shozo
TI Nitrogen containing bisphosphonates inhibit RANKL  and M CSF induced
   osteoclast formation through the inhibition of ERK1/2 and Akt activation
SO JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
DE Nitrogen containing bisphosphonate; Geranylgeranyl pyrophosphate;
   MEK1/2; PI3K
ID BONE RESORPTION; CELL INVASION; YM529; RECEPTOR; ALENDRONATE;
   METASTASIS; EXPRESSION; PATHWAY; LIGAND; DIFFERENTIATION
AB Background: Bisphosphonates are an important class of antiresorptive drugs used in the treatment of metabolic bone diseases. Recent studies have shown that nitrogen containing bisphosphonates induced apoptosis in rabbit osteoclasts and prevented prenylated small GTPase. However, whether bisphosphonates inhibit osteoclast formation has not been determined. In the present study, we investigated the inhibitory effect of minodronate and alendronate on the osteoclast formation and clarified the mechanism involved in a mouse macrophage like cell lines C7 and RAW264.7.
   Results: It was found that minodronate and alendronate inhibited the osteoclast formation of C7 cells induced by receptor activator of NF kB ligand and macrophage colony stimulating factor, which are inhibited by the suppression of geranylgeranyl pyrophosphate (GGPP) biosynthesis. It was also found that minodronate and alendronate inhibited the osteoclast formation of RAW264.7 cells induced by receptor activator of NF kappa B ligand. Furthermore, minodronate and alendornate decreased phosphorylated extracellular signal regulated kinase 1/2 (ERK1/2) and Akt; similarly, U0126, a mitogen protein kinase kinase 1/2 (MEK1/2) inhibitor, and LY294002, a phosphatidylinositol 3 kinase (PI3K) inhibitor, inhibited osteoclast formation.
   Conclusions: This indicates that minodronate and alendronate inhibit GGPP biosynthesis in the mevalonate pathway and then signal transduction in the MEK/ERK and PI3K/Akt pathways, thereby inhibiting osteoclast formation. These results suggest a novel effect of bisphosphonates that could be effective in the treatment of bone metabolic diseases, such as osteoporosis.
C1 [Tsubaki, Masanobu; Komai, Makiko; Sakamoto, Kotaro; Shimaoka, Hirotaka; Takeda, Tomoya; Ogawa, Naoki; Mashimo, Kenji; Fujiwara, Daiichiro; Nishida, Shozo] Kinki Univ, Div Pharmacotherapy, Sch Pharm, Higashiosaka, Osaka 5778502, Japan.
   [Itoh, Tatsuki; Satou, Takao] Kinki Univ, Sch Med, Dept Pathol, Osaka 589, Japan.
   [Imano, Motohiro] Kinki Univ, Sch Med, Dept Surg, Osaka 589, Japan.
   [Ogawa, Naoki; Mukai, Junji] Izumi Municipal Hosp, Dept Pharm, Osaka, Japan.
   [Mashimo, Kenji; Fujiwara, Daiichiro; Sakaguchi, Katsuhiko] Japanese Red Cross Soc Wakayama, Med Ctr, Dept Pharm, Wakayama, Japan.
C3 Kindai University (Kinki University); Kindai University (Kinki
   University); Kindai University (Kinki University)
RP Nishida, S (通讯作者)，Kinki Univ, Div Pharmacotherapy, Sch Pharm, Higashiosaka, Osaka 5778502, Japan.
EM nishida@phar.kindai.ac.jp
RI 正寛, 椿/JDF 1457 2023
FU Japan Society for the Promotion of Science (JSPS); Grants in Aid for
   Scientific Research [26350597] Funding Source: KAKEN
FX This work was supported in part by a Grant in Aid for Scientific
   Research (C) and Grant in Aid for Young Scientists (B) from the Japan
   Society for the Promotion of Science (JSPS).
CR Abe K, 2012, INT J MOL MED, V29, P1007, DOI 10.3892/ijmm.2012.952
   Boissier S, 2000, CANCER RES, V60, P2949
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Clezardin P, 2007, CLIN EXP METASTAS, V24, P599, DOI 10.1007/s10585 007 9112 8
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Cui NH, 2005, CLIN CANCER RES, V11, P2713, DOI 10.1158/1078 0432.CCR 04 1767
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   Esteve FR, 2007, BEST PRACT RES CL HA, V20, P613, DOI 10.1016/j.beha.2007.08.003
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Keller RK, 1999, BIOCHEM BIOPH RES CO, V266, P560, DOI 10.1006/bbrc.1999.1849
   Kimachi K, 2011, N S ARCH PHARMACOL, V383, P297, DOI 10.1007/s00210 010 0596 4
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Lerner UH, 2004, CRIT REV ORAL BIOL M, V15, P64, DOI 10.1177/154411130401500202
   Miwa S, 2005, CANCER RES, V65, P8818, DOI 10.1158/0008 5472.CAN 05 0540
   Miyamoto A, 1998, BIOCHEM BIOPH RES CO, V242, P703, DOI 10.1006/bbrc.1997.8046
   Neville Webbe HL, 2010, EUR J CANCER, V46, P1211, DOI 10.1016/j.ejca.2010.02.041
   Nishida S, 2005, BIOCHEM BIOPH RES CO, V328, P91, DOI 10.1016/j.bbrc.2004.12.145
   Nishida S, 2003, LIFE SCI, V73, P2655, DOI 10.1016/S0024 3205(03)00664 7
   Rogers Maurice, 2011, Scottish Forestry, V65, P34
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Sevcik MA, 2004, PAIN, V111, P169, DOI 10.1016/j.pain.2004.06.015
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Tanimori Y, 2010, CLIN EXP METASTAS, V27, P529, DOI 10.1007/s10585 010 9342 z
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tsubaki M, 2008, CANCER SCI, V99, P152, DOI 10.1111/j.1349 7006.2007.00651.x
   Tsubaki M, 2013, BIOCHEM PHARMACOL, V85, P163, DOI 10.1016/j.bcp.2012.10.009
   Tsubaki M, 2012, MOL CELL ENDOCRINOL, V361, P219, DOI 10.1016/j.mce.2012.05.002
   Tsubaki M, 2012, TOXICOL APPL PHARM, V259, P402, DOI 10.1016/j.taap.2012.01.024
   Tsubaki M, 2010, J CELL BIOCHEM, V111, P1661, DOI 10.1002/jcb.22907
   Yonou H, 2007, PROSTATE, V67, P999, DOI 10.1002/pros.20592
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zhang HL, 2003, CLIN EXP METASTAS, V20, P153, DOI 10.1023/A:1022621622063
NR 40
TC 54
Z9 62
U1 0
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1021 7770
EI 1423 0127
J9 J BIOMED SCI
JI J. Biomed. Sci.
PD FEB 3
PY 2014
VL 21
AR 10
DI 10.1186/1423 0127 21 10
PG 14
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA AF3WB
UT WOS:000334642000001
PM 24490900
OA gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Jin, KT
   Zheng, L
   Ye, L
   Xie, Z
   Gao, JW
   Lou, C
   Pan, WZ
   Pan, B
   Liu, SJ
   Chen, ZZ
   He, DW
AF Jin, Kangtao
   Zheng, Lin
   Ye, Lin
   Xie, Ziang
   Gao, Jiawei
   Lou, Chao
   Pan, Wenzheng
   Pan, Bin
   Liu, Shijie
   Chen, Zhenzhong
   He, Dengwei
TI Chicago sky blue 6B (CSB6B), an allosteric inhibitor of macrophage
   migration inhibitory factor (MIF), suppresses osteoclastogenesis and
   promotes osteogenesis through the inhibition of the NF KB signaling
   pathway
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Osteoclast; Osteoblast; Osteoporosis; MIF; CSB6B
ID KAPPA B; NUCLEAR FACTOR; OSTEOBLAST DIFFERENTIATION; BONE FORMATION;
   IN VITRO; C FOS; ACTIVATION; EXPRESSION; RANKL; MICE
AB Macrophage migration inhibitory factor (MIF) is a pleiotropic pro inflammatory mediator involved in various pathophysiological and inflammatory states. Accumulating line of evidence suggests a role for MIF in regulating bone metabolism and therefore a prime candidate for therapeutic targeting. In this study, we showed that Chicago sky blue 6B (CSB6B) suppresses RANKL induced osteoclast and bone resorption in vitro via the inhibition of NF KB signaling activation and promoting proteasome mediated degradation of MIF. Consequently, the induction of NFATc1 was impaired resulting in downregulation of NFATc1 responsive osteoclast genes. We also demonstrated that CSB6B treatment enhanced primary calvarial osteoblast differentiation and bone mineralization in vitro via the suppression of NF KB activation and upregulation of Runx expression. Using two murine models of osteolytic bone disorders, we further showed that administration of CSB6B protected mice against pathological inflammatoryc calvarial bone destruction induced by titanium particles mice as well as estrogendeficiency induced bone loss as a result of ovariectomy. Together, as an MIF inhibitor, CSB6B can inhibit osteoclast differentiation and bone resorption function and enhance the mineralization of osteoblasts through the inhibition of NF KB pathway. MIF is a prime target for therapeutic targeting for the treatment of osteolytic bone disorders and the MIF inhibitor CSB6B could be potential anti osteoporosis drug.
C1 [Jin, Kangtao; Zheng, Lin; Ye, Lin; Gao, Jiawei; Lou, Chao; Pan, Wenzheng; Pan, Bin; Liu, Shijie; Chen, Zhenzhong; He, Dengwei] Zhejiang Univ, Lishui Cent Hosp, Wenzhou Med Univ, Affiliated Hosp 5,Affiliated Lishui Hosp,Dept Ort, 289 Kuocang Rd, Lishui 323000, Peoples R China.
   [Zheng, Lin; Xie, Ziang] Zhejiang Univ Sch Med, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Hangzhou, Zhejiang, Peoples R China.
   [Zheng, Lin; Xie, Ziang; Chen, Zhenzhong] Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Zhejiang University; Zhejiang University
RP He, DW (通讯作者)，Zhejiang Univ, Lishui Cent Hosp, Wenzhou Med Univ, Affiliated Hosp 5,Affiliated Lishui Hosp,Dept Ort, 289 Kuocang Rd, Lishui 323000, Peoples R China.
EM hedw120@zju.edu.cn
RI ; Chen, Zhenzhong/C 2529 2015; Zheng, Lin/AAE 8093 2021
OI He, Dengwei/0000 0003 2394 2124; Zheng, Lin/0000 0002 7585 6968
FU Zhejiang Province Scientific Project of Health and Medicine of China
   [2018KY936]; Zhejiang Experimental Animal and Technology Program
   Foundation of China [2018C37099]; Medical key (support) discipline
   construction project of China [2017ZDXK06]
FX This work was funded by grants from the Zhejiang Province Scientific
   Project of Health and Medicine of China (Grant No.2018KY936), the
   Zhejiang Experimental Animal and Technology Program Foundation of China
   (Grant No.2018C37099) and the Medical key (support) discipline
   construction project of China (Grant No.2017ZDXK06).
CR Alles N, 2010, ENDOCRINOLOGY, V151, P4626, DOI 10.1210/en.2010 0399
   Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Bai FW, 2012, J BIOL CHEM, V287, P30653, DOI 10.1074/jbc.M112.385583
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Blair HC, 2005, BIOCHEM BIOPH RES CO, V328, P728, DOI 10.1016/j.bbrc.2004.11.077
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chen ZL, 2014, RHEUMATOL INT, V34, P1481, DOI 10.1007/s00296 013 2877 y
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Gu R, 2015, CYTOKINE, V72, P135, DOI 10.1016/j.cyto.2014.11.015
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Howait M, 2019, J IMMUNOL, V202, P2035, DOI 10.4049/jimmunol.1801161
   Ilyas Z, 2019, CURR OPIN ENDOCRINOL, V26, P335, DOI 10.1097/MED.0000000000000501
   Kim HR, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3279
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kobayashi T, 2011, OSTEOPOROSIS INT, V22, P1955, DOI 10.1007/s00198 010 1385 0
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Madeira MFM, 2012, MICROBES INFECT, V14, P198, DOI 10.1016/j.micinf.2011.09.005
   Movila A, 2016, J BONE MINER RES, V31, P1688, DOI 10.1002/jbmr.2854
   O'Reilly C, 2016, MED RES REV, V36, P440, DOI 10.1002/med.21385
   Onodera S, 2002, J BIOL CHEM, V277, P7865, DOI 10.1074/jbc.M106020200
   Onodera S, 1996, IMMUNOLOGY, V89, P430, DOI 10.1046/j.1365 2567.1996.d01 751.x
   Onodera S, 2006, J BONE MINER RES, V21, P876, DOI 10.1359/JBMR.060310
   Oshima S, 2006, FEBS LETT, V580, P1251, DOI 10.1016/j.febslet.2006.01.038
   Ranganathan V, 2017, ARTHRITIS RHEUMATOL, V69, P1796, DOI 10.1002/art.40175
   Schulz R, 2012, J EXP MED, V209, P275, DOI 10.1084/jem.20111117
   Sharma SM, 2007, J BIOL CHEM, V282, P15921, DOI 10.1074/jbc.M609723200
   Singh A, 2013, RHEUMATOL INT, V33, P2301, DOI 10.1007/s00296 013 2713 4
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yamazaki M, 2009, J BIOL CHEM, V284, P35987, DOI 10.1074/jbc.M109.070540
   Yao Y, 2016, STEM CELL REP, V7, P249, DOI 10.1016/j.stemcr.2016.07.003
   Yao ZQ, 2014, J BONE MINER RES, V29, P866, DOI 10.1002/jbmr.2108
   Zheng L, 2019, FASEB J, V33, P7667, DOI 10.1096/fj.201802364RR
NR 45
TC 12
Z9 12
U1 1
U2 11
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD OCT
PY 2021
VL 192
AR 114734
DI 10.1016/j.bcp.2021.114734
EA SEP 2021
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA UZ9IB
UT WOS:000702511300001
PM 34411569
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Dhillon, RS
   Schwarz, EM
AF Dhillon, Robinder S.
   Schwarz, Edward M.
TI Teriparatide Therapy as an Adjuvant for Tissue Engineering and
   Integration of Biomaterials
SO MATERIALS
LA English
DT Article
DE Parathyroid Hormone (PTH); teriparatide; osseointegration;
   bio integration; fracture healing; non union; allograft repair;
   biomaterials
ID PARATHYROID HORMONE 1 34; MESENCHYMAL STEM CELLS; OSTEOCLAST
   DIFFERENTIATION FACTOR; FRACTURE HEALING PROCESS; INCREASED
   BONE FORMATION; HUMAN PARATHYROID HORMONE (1 34); INTERMITTENT
   TREATMENT; POSTMENOPAUSAL WOMEN; ANABOLIC RESPONSE; CONTINUOUS PTH
AB Critically sized large bone defects commonly result from trauma, radical tumor resections or infections. Currently, massive allografting remain as the clinical standard to treat these critical defects. Unfortunately, allograft healing is limited by the lack of osteogenesis and bio integration of the graft to the host bone. Based on its widely studied anabolic effects on the bone, we have proposed that teriparatide [recombinant parathyroid hormone (PTH1 34)] could be an effective adjuvant for massive allograft healing. In support of this theory, here we review studies that have demonstrated that intermittent PTH1 34 treatment enhances and accelerates the skeletal repair process via a number of mechanisms including: effects on mesenchymal stem cells (MSC), angiogenesis, chondrogenesis, bone formation and remodeling. We also review the current literature on the effects of PTH1 34 therapy on bone healing, and discuss this drug's long term potential as an adjuvant for endogenous tissue engineering.
C1 [Dhillon, Robinder S.; Schwarz, Edward M.] Univ Rochester, Dept Orthopaed, Rochester, NY 14623 USA.
   [Dhillon, Robinder S.; Schwarz, Edward M.] Univ Rochester, Ctr Musculoskeletal Res, Rochester, NY 14623 USA.
C3 University of Rochester; University of Rochester
RP Schwarz, EM (通讯作者)，Univ Rochester, Dept Orthopaed, Rochester, NY 14623 USA.
EM robin_dhillon@urmc.rochester.edu; edward_schwarz@urmc.rochester.edu
FU National Institutes of Health [DE19902, AR054041]
FX This work was funded by grants from the National Institutes of Health
   (DE19902, AR054041).
CR Aleksyniene R, 2009, ACTA ORTHOP, V80, P716, DOI 10.3109/17453670903350032
   Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Andreassen TT, 2004, CALCIFIED TISSUE INT, V74, P351, DOI 10.1007/s00223 003 0093 6
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   [Anonymous], HDB EXPT PHARM PHYSL
   Aslan H, 2006, STEM CELLS, V24, P1728, DOI 10.1634/stemcells.2005 0546
   Aslan H, 2006, TISSUE ENG, V12, P877, DOI 10.1089/ten.2006.12.877
   Aspenberg P, 2010, ACTA ORTHOP, V81, P236, DOI 10.3109/17453671003761946
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Beaver R, 1997, J La State Med Soc, V149, P200
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Boden SD, 2002, SPINE, V27, P2662, DOI 10.1097/00007632 200212010 00005
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   Bruder SP, 1998, J ORTHOPAED RES, V16, P155, DOI 10.1002/jor.1100160202
   Bukata Susan V, 2010, Curr Osteoporos Rep, V8, P28, DOI 10.1007/s11914 010 0006 3
   Chavassieux P, 2008, J BONE MINER RES, V23, P1076, DOI 10.1359/JBMR.080231
   Chintamaneni S, 2010, OSTEOPOROSIS INT, V21, P1059, DOI 10.1007/s00198 009 1061 4
   Dayoub H, 2003, TISSUE ENG, V9, P347, DOI 10.1089/107632703764664819
   Einhorn TA, 2003, J BONE JOINT SURG AM, V85A, P82, DOI 10.2106/00004623 200300003 00014
   Einhorn TA, 2003, J BONE JOINT SURG AM, V85A, P1425, DOI 10.2106/00004623 200308000 00002
   Etoh M, 2010, J BONE MINER METAB, V28, P641, DOI 10.1007/s00774 010 0181 4
   *FDN OC, 2010, OR CANC FACTS
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Gazit D, 1999, J GENE MED, V1, P121, DOI 10.1002/(SICI)1521 2254(199903/04)1:2<121::AID JGM26>3.0.CO;2 J
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Horwitz MJ, 2005, J BONE MINER RES, V20, P1792, DOI 10.1359/JBMR.050602
   Ito Masako, 2007, Clin Calcium, V17, P1858
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jilka RL, 2010, AGING CELL, V9, P851, DOI 10.1111/j.1474 9726.2010.00616.x
   Jilka RL, 2009, BONE, V44, P275, DOI 10.1016/j.bone.2008.10.037
   Kaback LA, 2008, J CELL BIOCHEM, V105, P219, DOI 10.1002/jcb.21816
   Kaback LA, 2008, J CELL PHYSIOL, V214, P173, DOI 10.1002/jcp.21176
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Khan SN, 2005, J AM ACAD ORTHOP SUR, V13, P77, DOI 10.5435/00124635 200501000 00010
   Komatsu DE, 2009, ENDOCRINOLOGY, V150, P1570, DOI 10.1210/en.2008 0814
   Komatsubara S, 2005, BONE, V36, P678, DOI 10.1016/j.bone.2005.02.002
   Manabe T, 2007, BONE, V40, P1475, DOI 10.1016/j.bone.2007.01.015
   Martin TJ, 2004, TRENDS ENDOCRIN MET, V15, P49, DOI 10.1016/j.tem.2004.01.002
   Moutsatsos IK, 2001, MOL THER, V3, P449, DOI 10.1006/mthe.2001.0291
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Nakazawa T, 2005, BONE, V37, P711, DOI 10.1016/j.bone.2005.06.013
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   NISHIDA S, 1994, BONE, V15, P717, DOI 10.1016/8756 3282(94)90322 0
   Okazaki K, 2003, J ORTHOPAED RES, V21, P511, DOI 10.1016/S0736 0266(02)00161 4
   Oteo Alvaro A., 2010, Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons ... [et al.], V19, pe22, DOI [DOI 10.1016/J.JSE.2010.05.005, 10.1016/j.jse.2010.05.005]
   PEICHL P, 2009, P ASBMR 31 ANN M COL
   Pierroz DD, 2010, J BIOL CHEM, V285, P28164, DOI 10.1074/jbc.M110.101964
   Potts JT., 1997, METABOLIC BONE DIS, P51
   Puzas J Edward, 2006, J Am Acad Orthop Surg, V14, pS145
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Resmini Giuseppina, 2007, Aging Clin Exp Res, V19, P30
   Reynolds DG, 2009, J BONE MINER RES, V24, P899, DOI 10.1359/JBMR.081232
   Rickard DJ, 2006, BONE, V39, P1361, DOI 10.1016/j.bone.2006.06.010
   Rubery PT, 2010, J SPINAL DISORD TECH, V23, P151, DOI 10.1097/BSD.0b013e31819a8b7a
   Ryder KM, 2010, J BONE MINER METAB, V28, P233, DOI 10.1007/s00774 009 0123 1
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Skripitz R, 2000, J BONE JOINT SURG BR, V82B, P138, DOI 10.1302/0301 620X.82B1.9729
   Stansbury LG, 2008, J ORTHOP TRAUMA, V22, P43, DOI 10.1097/BOT.0b013e31815b35aa
   Tiyapatanaputi P, 2004, J ORTHOP RES, V22, P1254, DOI 10.1016/j.orthres.2004.03.017
   Tsujimoto M, 2011, BONE, V48, P798, DOI 10.1016/j.bone.2010.12.006
   Turgeman G, 2001, J GENE MED, V3, P240
   UZAWA T, 1995, BONE, V16, P477
   Valentin Opran A, 2002, CLIN ORTHOP RELAT R, P110
   Virk MS, 2011, MOL THER, V19, P960, DOI 10.1038/mt.2011.2
   Xie C, 2007, TISSUE ENG, V13, P435, DOI 10.1089/ten.2006.0182
   Yang CM, 2009, BIOCHEM BIOPH RES CO, V380, P791, DOI 10.1016/j.bbrc.2009.01.167
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoon ST, 2002, CLIN ORTHOP RELAT R, P33
   Yu EW, 2011, BONE, V48, P713, DOI 10.1016/j.bone.2010.11.012
   Zati A, 2011, J RHEUMATOL, V38, P778, DOI 10.3899/jrheum.100980
   Zhang XP, 2005, J BONE MINER RES, V20, P2124, DOI 10.1359/JBMR.050806
NR 73
TC 18
Z9 23
U1 0
U2 11
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1996 1944
J9 MATERIALS
JI Materials
PD JUN
PY 2011
VL 4
IS 6
BP 1117
EP 1131
DI 10.3390/ma4061117
PG 15
WC Chemistry, Physical; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science; Metallurgy & Metallurgical Engineering;
   Physics
GA 864MU
UT WOS:000298245100011
OA Green Published, Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Yu, M
   Qin, K
   Fan, JM
   Zhao, GZ
   Zhao, P
   Zeng, W
   Chen, C
   Wang, A
   Wang, YH
   Zhong, JM
   Zhu, Y
   Wagstaff, W
   Haydon, RC
   Luu, HH
   Ho, S
   Lee, MJ
   Strelzow, J
   Reid, RR
   He, TC
AF Yu, Michael
   Qin, Kevin
   Fan, Jiaming
   Zhao, Guozhi
   Zhao, Piao
   Zeng, Wei
   Chen, Connie
   Wang, Annie
   Wang, Yonghui
   Zhong, Jiamin
   Zhu, Yi
   Wagstaff, William
   Haydon, Rex C.
   Luu, Hue H.
   Ho, Sherwin
   Lee, Michael J.
   Strelzow, Jason
   Reid, Russell R.
   He, Tong Chuan
TI The evolving roles of Wnt signaling in stem cell proliferation and
   differentiation, the development of human diseases, and therapeutic
   opportunities
SO GENES & DISEASES
LA English
DT Article
DE 13 Catenin; Cancer; Canonical Wnt; Disease; Non canonical Wnt; Stem
   cells; Targeted therapy; Wnt signaling
ID WNT/BETA CATENIN PATHWAY; RECEPTOR RELATED PROTEIN 5;
   EPITHELIAL MESENCHYMAL TRANSITION; HAIR FOLLICLE MORPHOGENESIS;
   GLYCOGEN SYNTHASE KINASE 3; FRIZZLED RELATED PROTEINS; BETA CATENIN;
   SELF RENEWAL; ADIPOSE TISSUE; POSTMENOPAUSAL WOMEN
AB The evolutionarily conserved Wnt signaling pathway plays a central role in develop ment and adult tissue homeostasis across species. Wnt proteins are secreted, lipid modified signaling molecules that activate the canonical (13 catenin dependent) and non canonical (13 catenin independent) Wnt signaling pathways. Cellular behaviors such as proliferation, differ entiation, maturation, and proper body axis specification are carried out by the canonical pathway, which is the best characterized of the known Wnt signaling paths. Wnt signaling has emerged as an important factor in stem cell biology and is known to affect the self renewal of stem cells in various tissues. This includes but is not limited to embryonic, hematopoietic, mesenchymal, gut, neural, and epidermal stem cells. Wnt signaling has also been implicated in tumor cells that exhibit stem cell like properties. Wnt signaling is crucial for bone formation and presents a potential target for the development of therapeutics for bone disorders. Not surprisingly, aberrant Wnt signaling is also associated with a wide variety of diseases, including cancer. Mutations of Wnt pathway members in cancer can lead to unchecked cell proliferation, epithelialemesenchymal transition, and metastasis. Altogether, advances in the understand ing of dysregulated Wnt signaling in disease have paved the way for the development of novel therapeutics that target components of the Wnt pathway. Beginning with a brief overview of the mechanisms of canonical and non canonical Wnt, this review aims to summarize the cur rent knowledge of Wnt signaling in stem cells, aberrations to the Wnt pathway associated with diseases, and novel therapeutics targeting the Wnt pathway in preclinical and clinical studies. (c) 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY NC ND license (http://creativecommons. org/licenses/by nc nd/4.0/).
C1 [Yu, Michael; Qin, Kevin] Rosalind Franklin Univ Med & Sci, Sch Med, N Chicago, IL 60064 USA.
   [Yu, Michael; Qin, Kevin; Fan, Jiaming; Zhao, Guozhi; Zhao, Piao; Zeng, Wei; Chen, Connie; Wang, Annie; Wang, Yonghui; Zhong, Jiamin; Zhu, Yi; Wagstaff, William; Haydon, Rex C.; Luu, Hue H.; Ho, Sherwin; Lee, Michael J.; Strelzow, Jason; Reid, Russell R.; He, Tong Chuan] Univ Chicago Med Ctr, Dept Orthoped Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA.
   [Fan, Jiaming; Zhong, Jiamin] Chongqing Med Univ, Sch Lab Med, Minist Educ Key Lab Diagnost Med, Chongqing 400016, Peoples R China.
   [Fan, Jiaming; Zhong, Jiamin] Chongqing Med Univ, Sch Lab Med, Dept Clin Biochem, Chongqing 400016, Peoples R China.
   [Zhao, Guozhi; Zhao, Piao] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Chongqing 400016, Peoples R China.
   [Zhao, Guozhi; Zhao, Piao] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing 400016, Peoples R China.
   [Wang, Yonghui] Shanghai Jiao Tong Univ, Sch Med, Dept Clin Lab Med, Shanghai 200000, Peoples R China.
   [Zhu, Yi] Chinese Acad Med Sci & Peking Union Med Coll, Dept Orthopaed Surg, Beijing 100730, Peoples R China.
   [Reid, Russell R.; He, Tong Chuan] Univ Chicago Med Ctr, Dept Surg Sect Plast Surg, Lab Craniofacial Suture Biol & Dev, Chicago, IL 60637 USA.
   [Zeng, Wei] Guangdong Med Univ, Dongguan Affiliated Hosp 1, Dept Neurol, Dongguan 523475, Guangdong, Peoples R China.
   [He, Tong Chuan] Univ Chicago Med Ctr, Mol Oncol Lab, 5841 South Maryland Ave,MC3079, Chicago, IL 60637 USA.
   [Reid, Russell R.] Univ Chicago Med Ctr, Dept Surg Sect Plast Surg, Lab Craniofacial Suture Biol & Dev, 5841 S Maryland Ave,Rm J 641,MC 6035, Chicago, IL 60637 USA.
C3 Rosalind Franklin University of Medicine & Science; University of
   Illinois System; University of Chicago; University Chicago Hospital;
   University of Chicago Medical Center; Chongqing Medical University;
   Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; Shanghai Jiao Tong University; Chinese Academy of
   Medical Sciences   Peking Union Medical College; Peking Union Medical
   College; University of Illinois System; University of Chicago;
   University Chicago Hospital; University of Chicago Medical Center;
   Guangdong Medical University; University of Chicago; University Chicago
   Hospital; University of Illinois System; University of Chicago Medical
   Center; University of Chicago; University of Chicago Medical Center;
   University Chicago Hospital; University of Illinois System
RP He, TC (通讯作者)，Univ Chicago Med Ctr, Mol Oncol Lab, 5841 South Maryland Ave,MC3079, Chicago, IL 60637 USA.; Reid, RR (通讯作者)，Univ Chicago Med Ctr, Dept Surg Sect Plast Surg, Lab Craniofacial Suture Biol & Dev, 5841 S Maryland Ave,Rm J 641,MC 6035, Chicago, IL 60637 USA.
EM rreid@surgery.bsd.uchicago.edu; tche@uchicago.edu
RI ; Liao, Jian/GRX 4579 2022; Strelzow, Jason/H 8154 2019; Reid,
   Russell/LIF 6227 2024
OI Chen, Connie/0000 0002 4260 1897; Strelzow, Jason/0000 0002 1072 1595;
   Wang, Annie/0009 0001 4576 1802; 
FU National Institutes of Health [CA226303, DE030480]; Natural Science
   Foundation of China [82102696]; Science and Technology Research Plan
   Project of Chongqing Education Commission(China) [KJQN201900410];
   University of Chicago Cancer Center Support Grant [P30CA014599]; Funding
   for Postdoctoral Research (Chongqing Human Resources and Social Security
   Bureau, Chongqing, China); National Center for Advancing Translational
   Sciences (NCATS) of the National Institutes of Health [5UL1TR002389];
   Mabel Green Myers Research Endowment Fund; University of Chicago
   Orthopaedics Alumni Fund
FX The reported work was supported in part by research grants from the
   National Institutes of Health (No. CA226303 to TCH and No. DE030480 to
   RRR). JF was supported in part by research grants from the Natural
   Science Foundation of China (No. 82102696), the 2019 Science and
   Technology Research Plan Project of Chongqing Education
   Commission(China) (No. KJQN201900410), and the 2019 Funding for
   Postdoctoral Research (Chongqing Human Resources and Social Security
   Bureau No. 298, Chongqing, China). WW was supported by the Medical
   Scientist Training Program of the National Institutes of Health (No. T32
   GM007281). This project was also supported in part by The University of
   Chicago Cancer Center Support Grant (No. P30CA014599) and the National
   Center for Advancing Translational Sciences (NCATS) of the National
   Institutes of Health (No.5UL1TR002389). TCH was also supported by the
   Mabel Green Myers Research Endowment Fund and The University of Chicago
   Orthopaedics Alumni Fund. Funding sources were not involved in the study
   design; in the collection, analysis, and interpretation of data; in the
   writing of the report; and in the decision to submit the paper for
   publication.
CR Agarwal S., 2022, Statpearls
   Anagnostis P, 2021, HORM INT J ENDOCRINO, V20, P13, DOI 10.1007/s42000 020 00218 6
   Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534 5807(02)00167 3
   Aoki R, 2016, CELL MOL GASTROENTER, V2, P175, DOI 10.1016/j.jcmgh.2015.12.004
   Aros CJ, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003 021 02118 w
   Arozarena I, 2011, ONCOGENE, V30, P4531, DOI 10.1038/onc.2011.162
   Arredondo SB, 2020, STEM CELLS, V38, P422, DOI 10.1002/stem.3121
   Atit R, 2006, DEV BIOL, V296, P164, DOI 10.1016/j.ydbio.2006.04.449
   Atkinson JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125028
   Augustin I, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah6829
   Bacakova L, 2018, BIOTECHNOL ADV, V36, P1111, DOI 10.1016/j.biotechadv.2018.03.011
   Bajaj J, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201911053
   Bakre MM, 2007, J BIOL CHEM, V282, P31703, DOI 10.1074/jbc.M704287200
   Balestrino R, 2020, EUR J NEUROL, V27, P27, DOI 10.1111/ene.14108
   Bao Bin, 2013, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1425s61
   Bao J, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003028
   Barandon L, 2011, ARTERIOSCL THROM VAS, V31, pE80, DOI 10.1161/ATVBAHA.111.232280
   Barker N, 2012, CELL STEM CELL, V11, P452, DOI 10.1016/j.stem.2012.09.009
   Barkó S, 2010, J BIOL CHEM, V285, P13154, DOI 10.1074/jbc.M109.093914
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Behr B, 2010, DEV BIOL, V344, P922, DOI 10.1016/j.ydbio.2010.06.009
   Belenkaya TY, 2008, DEV CELL, V14, P120, DOI 10.1016/j.devcel.2007.12.003
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Berger H, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00031
   Berwick DC, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024 017 0153 4
   Bordonaro M, 2016, JMIR RES PROTOC, V5, DOI 10.2196/resprot.5495
   Bostwick B, 2008, GeneReviews
   Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096
   Bovolenta P, 2006, DEVELOPMENT, V133, P4399, DOI 10.1242/dev.02592
   Bowman AN, 2013, P NATL ACAD SCI USA, V110, P7324, DOI 10.1073/pnas.1305411110
   Bradford EM, 2017, J IMMUNOL, V199, P1886, DOI 10.4049/jimmunol.1601066
   Brion JP, 2001, BIOCHEM SOC SYMP, V67, P81
   Bryder D, 2006, AM J PATHOL, V169, P338, DOI 10.2353/ajpath.2006.060312
   Buczacki SJA, 2013, NATURE, V495, P65, DOI 10.1038/nature11965
   Butler MT, 2017, NAT REV MOL CELL BIO, V18, P375, DOI 10.1038/nrm.2017.11
   Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906
   Cai C, 2012, MOL MED REP, V5, P1191, DOI 10.3892/mmr.2012.802
   Caira FC, 2006, J AM COLL CARDIOL, V47, P1707, DOI 10.1016/j.jacc.2006.02.040
   Calder A, 2013, STEM CELLS DEV, V22, P279, DOI 10.1089/scd.2012.0168
   Canesin G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184418
   Cao HZ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.393
   Carmon KS, 2012, MOL CELL BIOL, V32, P2054, DOI 10.1128/MCB.00272 12
   Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108
   Carstensen Kirberg M, 2017, CARDIOVASC DIABETOL, V16, DOI 10.1186/s12933 017 0591 x
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Cefalu CA, 2004, CURR MED RES OPIN, V20, P341, DOI 10.1185/030079903125003062
   Chae WJ, 2018, TRENDS IMMUNOL, V39, P830, DOI 10.1016/j.it.2018.08.006
   Chelko SP, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85923
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen HJ, 2012, BIOCHEM PHARMACOL, V84, P1143, DOI 10.1016/j.bcp.2012.08.011
   Chen MY, 2009, BIOCHEMISTRY US, V48, P10267, DOI 10.1021/bi9009677
   Chen Y, 2009, AM J PATHOL, V175, P2676, DOI 10.2353/ajpath.2009.080945
   Cheng RF, 2014, J CELL PHYSIOL, V229, P1908, DOI 10.1002/jcp.24566
   Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106
   Christman MA, 2008, AM J PHYSIOL HEART C, V294, pH2864, DOI 10.1152/ajpheart.00982.2007
   Christodoulides C, 2006, DIABETOLOGIA, V49, P678, DOI 10.1007/s00125 006 0144 4
   Christodoulides C, 2006, J CELL SCI, V119, P2613, DOI 10.1242/jcs.02975
   Cobas M, 2004, J EXP MED, V199, P221, DOI 10.1084/jem.20031615
   Colozza G, 2021, DEV GROWTH DIFFER, V63, P199, DOI 10.1111/dgd.12718
   Coombs GS, 2010, J CELL SCI, V123, P3357, DOI 10.1242/jcs.072132
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092 8674(05)80018 2
   Crowley RK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163777
   Cruciat CM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a015081
   Cui JJ, 2012, CURR PHARM DESIGN, V18, P2464, DOI 10.2174/13816128112092464
   Das Soumyashree, 2012, Front Biol (Beijing), V7, P587
   Dasgupta C, 2009, AM J PHYSIOL LUNG C, V296, pL1031, DOI 10.1152/ajplung.90392.2008
   Davidson KC, 2012, P NATL ACAD SCI USA, V109, P4485, DOI 10.1073/pnas.1118777109
   De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079
   De Ferrari GV, 2007, P NATL ACAD SCI USA, V104, P9434, DOI 10.1073/pnas.0603523104
   De Jaime Soguero A, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006682
   Degreef I, 2009, CLIN ORTHOP RELAT R, V467, P838, DOI 10.1007/s11999 008 0590 z
   Deng YL, 2016, CELL PHYSIOL BIOCHEM, V39, P871, DOI 10.1159/000447797
   Dodsworth BT, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 67376 w
   Dolmans GH, 2011, NEW ENGL J MED, V365, P307, DOI 10.1056/NEJMoa1101029
   Dratwa M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.589929
   Dravid G, 2005, STEM CELLS, V23, P1489, DOI 10.1634/stemcells.2005 0034
   Duchartre Y, 2016, CRIT REV ONCOL HEMAT, V99, P141, DOI 10.1016/j.critrevonc.2015.12.005
   Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955 0674(99)80031 3
   Eghrari AO, 2015, PROG MOL BIOL TRANSL, V134, P7, DOI 10.1016/bs.pmbts.2015.04.001
   Ehrlund A, 2013, J CLIN ENDOCR METAB, V98, pE503, DOI 10.1210/jc.2012 3416
   Enomoto M, 2009, ONCOGENE, V28, P3197, DOI 10.1038/onc.2009.175
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   Eyers CE, 2005, BIOCHEM J, V389, P127, DOI 10.1042/BJ20050387
   Fahiminiya S, 2013, J MED GENET, V50, P345, DOI 10.1136/jmedgenet 2013 101567
   Famili F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.380
   Fang L, 2016, CANCER RES, V76, P891, DOI 10.1158/0008 5472.CAN 15 1519
   Farin HF, 2012, GASTROENTEROLOGY, V143, P1518, DOI 10.1053/j.gastro.2012.08.031
   Fatehullah A, 2021, NAT CELL BIOL, V23, P1299, DOI 10.1038/s41556 021 00793 9
   Folke J, 2019, MOL NEUROBIOL, V56, P873, DOI 10.1007/s12035 018 1103 z
   Foo R, 2009, PLAST RECONSTR SURG, V124, P2085, DOI 10.1097/PRS.0b013e3181bf83ce
   Friedman MS, 2009, J BIOL CHEM, V284, P14117, DOI 10.1074/jbc.M808337200
   Gala MK, 2014, GASTROENTEROLOGY, V146, P520, DOI 10.1053/j.gastro.2013.10.045
   Galicia Garcia U, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176275
   Gao XX, 2015, MOL VIS, V21, P665
   Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gehart H, 2019, NAT REV GASTRO HEPAT, V16, P19, DOI 10.1038/s41575 018 0081 y
   Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127
   Gilmour DF, 2015, EYE, V29, P1, DOI 10.1038/eye.2014.70
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Glorieux FH, 2017, J BONE MINER RES, V32, P1496, DOI 10.1002/jbmr.3143
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732
   Griffiths Carrie L, 2012, J Pharm Pract, V25, P319, DOI 10.1177/0897190012442062
   Grouls S, 2012, J AM SOC NEPHROL, V23, P63, DOI 10.1681/ASN.2010121257
   Grubbs H., 2022, StatPearls
   Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710
   Gudjonsson JE, 2010, J INVEST DERMATOL, V130, P1849, DOI 10.1038/jid.2010.67
   Gujral TS, 2014, CELL, V159, P844, DOI 10.1016/j.cell.2014.10.032
   Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302
   Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109
   Guzon Illescas O, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1226 6
   Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203
   Haegebarth A, 2009, AM J PATHOL, V174, P715, DOI 10.2353/ajpath.2009.080758
   Half E, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750 1172 4 22
   Halt K, 2014, PEDIATR NEPHROL, V29, P737, DOI 10.1007/s00467 013 2733 z
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304 3940(92)90774 2
   Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019
   Hao J, 2006, DEV BIOL, V290, P81, DOI 10.1016/j.ydbio.2005.11.011
   Harris Johnson KS, 2009, P NATL ACAD SCI USA, V106, P16287, DOI 10.1073/pnas.0902274106
   Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960 9822(99)80091 8
   Hartmann C, 2000, DEVELOPMENT, V127, P3141
   Hayat R, 2022, CELL BIOL INT, V46, P863, DOI 10.1002/cbin.11797
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756 3282(92)90364 3
   He BC, 2011, MOL PHARMACOL, V79, P211, DOI 10.1124/mol.110.068668
   He BC, 2011, INT J ONCOL, V38, P437, DOI 10.3892/ijo.2010.858
   He GX, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.16
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092 8674(00)81664 5
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Heit JJ, 2006, NATURE, V443, P345, DOI 10.1038/nature05097
   Henry C, 2015, ONCOTARGET, V6, P40310, DOI 10.18632/oncotarget.5643
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Hoffmeyer K, 2012, SCIENCE, V336, P1549, DOI 10.1126/science.1218370
   Hossain MZ, 2008, INT IMMUNOL, V20, P925, DOI 10.1093/intimm/dxn051
   Hou N, 2016, CIRC HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.116.003010
   Howe LR, 2003, CANCER RES, V63, P1906
   Hrckulak D, 2016, CANCERS, V8, DOI 10.3390/cancers8070070
   Hsu CC, 2015, J CHIN MED ASSOC, V78, P323, DOI 10.1016/j.jcma.2014.10.002
   Hu L, 2015, STEM CELLS, V33, P2483, DOI 10.1002/stem.2052
   Huang L, 2016, EXP THER MED, V12, P3851, DOI 10.3892/etm.2016.3885
   Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092 8674(01)00336 1
   Inestrosa NC, 2010, NAT REV NEUROSCI, V11, P77, DOI 10.1038/nrn2755
   Isern J, 2011, BLOOD, V117, P4924, DOI 10.1182/blood 2010 10 313676
   ISHIGURO K, 1992, NEUROSCI LETT, V148, P202, DOI 10.1016/0304 3940(92)90839 Y
   Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674
   Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131 139.2003
   Islam MM, 2015, BBA GENE REGUL MECH, V1849, P210, DOI 10.1016/j.bbagrm.2014.06.001
   Jeannet G, 2008, BLOOD, V111, P142, DOI 10.1182/blood 2007 07 102558
   Jenny A, 2005, NAT CELL BIOL, V7, P691, DOI 10.1038/ncb1271
   Jeong GR, 2020, CELLS BASEL, V9, DOI 10.3390/cells9122565
   Jiang CL, 2017, ONCOL REP, V38, P2351, DOI 10.3892/or.2017.5924
   Jin K, 2007, J NEUROIMMUNE PHARM, V2, P236, DOI 10.1007/s11481 007 9076 0
   Kalani MYS, 2008, P NATL ACAD SCI USA, V105, P16970, DOI 10.1073/pnas.0808616105
   Kalliolias GD, 2016, NAT REV RHEUMATOL, V12, P49, DOI 10.1038/nrrheum.2015.169
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Katoh M, 2017, INT J ONCOL, V51, P1357, DOI 10.3892/ijo.2017.4129
   Katoh M, 2017, INT J MOL MED, V40, P587, DOI 10.3892/ijmm.2017.3071
   Kawaguchi Ihara N, 2008, ANTICANCER RES, V28, P2701
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Kim J, 2010, J IMMUNOL, V185, P1274, DOI 10.4049/jimmunol.1000181
   King TD, 2012, J CELL BIOCHEM, V113, P13, DOI 10.1002/jcb.23350
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092 8674(00)81333 1
   Knopman DS, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572 021 00269 y
   Koch U, 2008, BLOOD, V111, P160, DOI 10.1182/blood 2007 07 099754
   Koles K, 2012, J BIOL CHEM, V287, P16820, DOI 10.1074/jbc.M112.342667
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270
   Korvala J, 2012, BMC MED GENET, V13, DOI 10.1186/1471 2350 13 26
   Krause K, 2006, SEMIN CUTAN MED SURG, V25, P2, DOI 10.1016/j.sder.2006.01.002
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kunnimalaiyaan S, 2018, BMC CANCER, V18, DOI 10.1186/s12885 018 4474 7
   L'Episcopo F, 2011, NEUROBIOL DIS, V41, P508, DOI 10.1016/j.nbd.2010.10.023
   Lagathu C, 2010, INT J OBESITY, V34, P1695, DOI 10.1038/ijo.2010.107
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Lammi L, 2004, AM J HUM GENET, V74, P1043, DOI 10.1086/386293
   Lane SW, 2010, SEMIN CANCER BIOL, V20, P71, DOI 10.1016/j.semcancer.2009.12.001
   Lathia JD, 2017, TARGET ONCOL, V12, P387, DOI 10.1007/s11523 017 0508 3
   Le PN, 2015, PHARMACOL THERAPEUT, V146, P1, DOI 10.1016/j.pharmthera.2014.08.005
   Lebensohn AM, 2018, ELIFE, V7, DOI 10.7554/eLife.33126
   Lee SMK, 2000, DEVELOPMENT, V127, P457
   Lewiecki EM, 2014, THER ADV MUSCULOSKEL, V6, P48, DOI 10.1177/1759720X13510479
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Li KN, 2021, EMBO J, V40, DOI 10.15252/embj.2020107135
   Li Y, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964 020 00627 5
   Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535 6108(03)00268 X
   Liao Z, 2015, CURR CANCER DRUG TAR, V15, P726, DOI 10.2174/1568009615666150629132157
   Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108
   Lindsley RC, 2006, DEVELOPMENT, V133, P3787, DOI 10.1242/dev.02551
   Liu C, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.156166
   Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859
   LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960 9822(00)00246 3
   Lowry WE, 2005, GENE DEV, V19, P1596, DOI 10.1101/gad.1324905
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   Luis TC, 2009, BLOOD, V113, P546, DOI 10.1182/blood 2008 06 163774
   Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203
   Luu HH, 2004, CURR CANCER DRUG TAR, V4, P653, DOI 10.2174/1568009043332709
   Ma DK, 2009, CELL RES, V19, P672, DOI 10.1038/cr.2009.56
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Malhotra S, 2008, J IMMUNOL, V181, P3955, DOI 10.4049/jimmunol.181.6.3955
   Malinauskas T, 2011, NAT STRUCT MOL BIOL, V18, P886, DOI 10.1038/nsmb.2081
   Mandel H, 2008, AM J HUM GENET, V82, P39, DOI 10.1016/j.ajhg.2007.08.005
   Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Marchetti B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123743
   Marini JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.52
   Martínez Cerdeño V, 2018, FRONT NEUROANAT, V12, DOI 10.3389/fnana.2018.00104
   Marzo A, 2016, CURR BIOL, V26, P2551, DOI 10.1016/j.cub.2016.07.024
   McClung MR, 2018, J BONE MINER RES, V33, P1397, DOI 10.1002/jbmr.3452
   McColm J, 2014, J BONE MINER RES, V29, P935, DOI 10.1002/jbmr.2092
   MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092 8674(90)90385 R
   McQuate A, 2017, CELL REP, V21, P60, DOI 10.1016/j.celrep.2017.09.023
   Menck K, 2021, CELLS BASEL, V10, DOI 10.3390/cells10010142
   Meng QH, 2011, PROTEIN CELL, V2, P889, DOI 10.1007/s13238 011 1113 3
   Meredith GE, 2011, J PARKINSON DIS, V1, P19, DOI 10.3233/JPD 2011 11023
   Meyer IS, 2017, EMBO MOL MED, V9, P1279, DOI 10.15252/emmm.201707565
   Miller SA, 2021, J PHARM TECHNOL, V37, P45, DOI 10.1177/8755122520967632
   Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001
   Mitchell RK, 2015, HUM MOL GENET, V24, P1390, DOI 10.1093/hmg/ddu553
   Miyabayashi T, 2007, P NATL ACAD SCI USA, V104, P5668, DOI 10.1073/pnas.0701331104
   Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229
   Mizutani A, 2018, CANCER SCI, V109, P4003, DOI 10.1111/cas.13805
   Mohammed MK, 2016, GENES DIS, V3, P11, DOI 10.1016/j.gendis.2015.12.004
   Montanari T, 2017, OBES REV, V18, P495, DOI 10.1111/obr.12520
   Montgomery RK, 2011, P NATL ACAD SCI USA, V108, P179, DOI 10.1073/pnas.1013004108
   Mori H, 2012, J CLIN INVEST, V122, P2405, DOI 10.1172/JCI63604
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Nakamura K, 2016, J BIOL CHEM, V291, P2566, DOI 10.1074/jbc.M115.693937
   Narimatsu M, 2009, CELL, V137, P295, DOI 10.1016/j.cell.2009.02.025
   Nemeth MJ, 2007, P NATL ACAD SCI USA, V104, P15436, DOI 10.1073/pnas.0704747104
   Ng OH, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.12
   Niehrs C, 2012, EMBO J, V31, P2705, DOI 10.1038/emboj.2012.124
   Niemann S, 2004, AM J HUM GENET, V74, P558, DOI 10.1086/382196
   Nostro MC, 2008, CELL STEM CELL, V2, P60, DOI 10.1016/j.stem.2007.10.011
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092 8674(82)90409 3
   Nygaard R, 2021, CELL, V184, P194, DOI 10.1016/j.cell.2020.11.038
   Oerlemans MIFJ, 2010, BASIC RES CARDIOL, V105, P631, DOI 10.1007/s00395 010 0100 9
   Okamoto M, 2011, FASEB J, V25, P3570, DOI 10.1096/fj.11 184697
   Okamoto M, 2014, SCI REP UK, V4, DOI 10.1038/srep04493
   Okumura R, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.20
   Osman J, 2019, ANTICANCER RES, V39, P1719, DOI 10.21873/anticanres.13278
   Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026
   Ouchi N, 2010, SCIENCE, V329, P454, DOI 10.1126/science.1188280
   Panhuysen M, 2004, MOL CELL NEUROSCI, V26, P101, DOI 10.1016/j.mcn.2004.01.011
   Paszty C, 2010, J BONE MINER RES, V25, P1897, DOI 10.1002/jbmr.161
   Peng YT, 2019, ACTA BIOMATER, V88, P86, DOI 10.1016/j.actbio.2019.02.015
   Person AD, 2010, DEV DYNAM, V239, P327, DOI 10.1002/dvdy.22156
   Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608
   Petropoulos K, 2008, J EXP MED, V205, P515, DOI 10.1084/jem.20071875
   Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820
   Pilichou K, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023 016 0407 1
   Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103
   Pittenger MF, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536 019 0083 6
   Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Pouresmaeili F, 2018, THER CLIN RISK MANAG, V14, P2029, DOI 10.2147/TCRM.S138000
   Povinelli BJ, 2014, STEM CELLS, V32, P105, DOI 10.1002/stem.1513
   Prakash N, 2007, NEURODEGENER DIS, V4, P333, DOI 10.1159/000101891
   Proffitt KD, 2012, J BIOL CHEM, V287, P34167, DOI 10.1074/jbc.M112.381970
   Purro SA, 2012, J NEUROSCI, V32, P3492, DOI 10.1523/JNEUROSCI.4562 11.2012
   Pyott SM, 2013, AM J HUM GENET, V92, P590, DOI 10.1016/j.ajhg.2013.02.009
   Qi YY, 2020, FASEB J, V34, P11115, DOI 10.1096/fj.202000280R
   Qian CN, 2005, J BIOL CHEM, V280, P3938, DOI 10.1074/jbc.M410697200
   Qin L, 2015, ONCOTARGET, V6, P10239, DOI 10.18632/oncotarget.3518
   Qiu F, 2014, EYE, V28, P402, DOI 10.1038/eye.2013.229
   Qu F, 2013, FRONT BIOSCI LANDMRK, V18, P493, DOI 10.2741/4116
   Qu QH, 2010, NAT CELL BIOL, V12, P31, DOI 10.1038/ncb2001
   Quasnichka H, 2006, CIRC RES, V99, P1329, DOI 10.1161/01.RES.0000253533.65446.33
   Rauner M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040787
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Recknor CP, 2015, J BONE MINER RES, V30, P1717, DOI 10.1002/jbmr.2489
   Reischl J, 2007, J INVEST DERMATOL, V127, P163, DOI 10.1038/sj.jid.5700488
   Relling I, 2018, J CLIN ENDOCR METAB, V103, P4253, DOI 10.1210/jc.2018 01007
   Rendon A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061475
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074 7613(00)00004 2
   RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092 8674(87)90038 9
   Rishikaysh P, 2014, INT J MOL SCI, V15, P1647, DOI 10.3390/ijms15011647
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Rodríguez Carballo E, 2011, J BONE MINER RES, V26, P718, DOI 10.1002/jbmr.260
   Rowe RG, 2019, NAT REV GENET, V20, P377, DOI 10.1038/s41576 019 0100 z
   Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790
   Ruffner H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040976
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Saely CH, 2012, GERONTOLOGY, V58, P15, DOI 10.1159/000321319
   Sakhneny L, 2018, DIABETES, V67, P437, DOI 10.2337/db17 0697
   Saraswati S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015521
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637
   Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448
   Schilham MW, 1998, J IMMUNOL, V161, P3984
   Schmitt M, 2015, CELL DEATH DIFFER, V22, P677, DOI 10.1038/cdd.2014.156
   Schneider MR, 2009, CURR BIOL, V19, pR132, DOI 10.1016/j.cub.2008.12.005
   Schulte DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032437
   Schulte G, 2005, J NEUROCHEM, V92, P1550, DOI 10.1111/j.1471 4159.2004.03022.x
   Sebastian A, 2018, METABOLISM, V80, P38, DOI 10.1016/j.metabol.2017.10.005
   Seita J, 2010, WIRES SYST BIOL MED, V2, P640, DOI 10.1002/wsbm.86
   Sengenès C, 2005, J CELL PHYSIOL, V205, P114, DOI 10.1002/jcp.20381
   Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017
   Shah K, 2021, PHARMACOL RES, V167, DOI 10.1016/j.phrs.2021.105532
   Shen X, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929 017 0337 9
   Shi SQ, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.656077
   Shin SH, 2017, EBIOMEDICINE, V25, P22, DOI 10.1016/j.ebiom.2017.09.029
   Shirai F, 2020, J MED CHEM, V63, P4183, DOI 10.1021/acs.jmedchem.0c00045
   Simon M, 2005, ONCOGENE, V24, P2410, DOI 10.1038/sj.onc.1208431
   Singh R, 2013, HUM MUTAT, V34, P1221, DOI 10.1002/humu.22360
   Singla DK, 2006, BIOCHEM BIOPH RES CO, V345, P789, DOI 10.1016/j.bbrc.2006.04.125
   Sklepkiewicz P, 2015, CIRC HEART FAIL, V8, P362, DOI 10.1161/CIRCHEARTFAILURE.114.001274
   Slusarski DC, 2007, DEV BIOL, V307, P1, DOI 10.1016/j.ydbio.2007.04.043
   Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694
   Staal FJT, 2001, EUR J IMMUNOL, V31, P285, DOI 10.1002/1521 4141(200101)31:1<285::AID IMMU285>3.3.CO;2 4
   Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898
   Stern CD, 2006, CURR OPIN CELL BIOL, V18, P692, DOI 10.1016/j.ceb.2006.09.002
   Sterneckert JL, 2014, NAT REV GENET, V15, P625, DOI 10.1038/nrg3764
   Stevens JR, 2010, J BONE MINER RES, V25, P2138, DOI 10.1002/jbmr.118
   Sturgeon CM, 2014, NAT BIOTECHNOL, V32, P554, DOI 10.1038/nbt.2915
   Sugimura R, 2012, CELL, V150, P351, DOI 10.1016/j.cell.2012.05.041
   Suh HN, 2017, CELL REP, V21, P2571, DOI 10.1016/j.celrep.2017.10.118
   Takahashi H, 2011, ANN SURG ONCOL, V18, P1166, DOI 10.1245/s10434 010 1373 9
   Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755
   Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637
   Takashima S, 2013, DEV GENES EVOL, V223, P85, DOI 10.1007/s00427 012 0422 8
   Takeda H, 2006, NAT MED, V12, P395, DOI 10.1038/nm1386
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Tanjore H, 2013, AM J RESP CRIT CARE, V187, P630, DOI 10.1164/rccm.201205 0972OC
   ten Dam EJPM, 2016, J CELL COMMUN SIGNAL, V10, P33, DOI 10.1007/s12079 015 0312 8
   Thorvaldsen TE, 2017, BASIC CLIN PHARMACOL, V121, P81, DOI 10.1111/bcpt.12786
   Toledo EM, 2010, MOL PSYCHIATR, V15, P272, DOI 10.1038/mp.2009.72
   Tomaszewski M, 2009, ARTERIOSCL THROM VAS, V29, P1316, DOI 10.1161/ATVBAHA.109.185355
   Tong Y, 2009, BMC MED GENET, V10, DOI 10.1186/1471 2350 10 15
   Toyama T, 2010, MOL CANCER RES, V8, P254, DOI 10.1158/1541 7786.MCR 09 0238
   Trojian TH, 2007, AM FAM PHYSICIAN, V76, P86
   Tsaousi A, 2011, CURR OPIN LIPIDOL, V22, P350, DOI 10.1097/MOL.0b013e32834aa701
   Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436
   Tuo JS, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0683 x
   Ueland T, 2009, ARTERIOSCL THROM VAS, V29, P1228, DOI 10.1161/ATVBAHA.109.189761
   Umeda K, 2004, DEVELOPMENT, V131, P1869, DOI 10.1242/dev.01065
   Valencia A, 2009, LEUKEMIA, V23, P1658, DOI 10.1038/leu.2009.86
   Vallée A, 2017, J MOL NEUROSCI, V62, P368, DOI 10.1007/s12031 017 0947 4
   van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092 8674(02)01014 0
   van Es JH, 2005, NAT CELL BIOL, V7, P381, DOI 10.1038/ncb1240
   Van Mater D, 2003, GENE DEV, V17, P1219, DOI 10.1101/gad.1076103
   Varacallo MA, 2014, MED CLIN N AM, V98, P817, DOI 10.1016/j.mcna.2014.03.007
   Varallo VM, 2003, ONCOGENE, V22, P3680, DOI 10.1038/sj.onc.1206415
   Varela Nallar L, 2010, P NATL ACAD SCI USA, V107, P21164, DOI 10.1073/pnas.1010011107
   Wagner Eric R, 2011, Curr Mol Pharmacol, V4, P14
   Wall JA, 2020, EXPERT OPIN INV DRUG, V29, P639, DOI 10.1080/13543784.2020.1769065
   Walter RJ, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04607 0
   Wang HY, 2003, SCIENCE, V300, P1529, DOI 10.1126/science.1085259
   Wang JQ, 2013, NAT CELL BIOL, V15, P1455, DOI 10.1038/ncb2867
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Wang XL, 2007, NAT GENET, V39, P836, DOI 10.1038/ng2057
   Wang YF, 2016, SCI REP UK, V6, DOI 10.1038/srep24606
   Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624
   Wang YP, 2016, J AM SOC NEPHROL, V27, P417, DOI 10.1681/ASN.2014100998
   Wang ZX, 2019, PROG RETIN EYE RES, V70, P110, DOI 10.1016/j.preteyeres.2018.11.008
   Wang ZX, 2015, ARTERIOSCL THROM VAS, V35, P855, DOI 10.1161/ATVBAHA.114.304627
   Wexler EM, 2009, STEM CELLS, V27, P1130, DOI 10.1002/stem.36
   White J, 2015, AM J HUM GENET, V96, P612, DOI 10.1016/j.ajhg.2015.02.015
   White J, 2005, STEM CELL REV, V1, P131, DOI 10.1385/SCR:1:2:131
   Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104
   Wilson SI, 2001, NATURE, V411, P325, DOI 10.1038/35077115
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Wong HSC, 2015, ONCOTARGET, V6, P42169, DOI 10.18632/oncotarget.5888
   Woods CG, 2006, AM J HUM GENET, V79, P402, DOI 10.1086/506332
   Wu GY, 2015, ONCOTARGET, V6, P28882, DOI 10.18632/oncotarget.4921
   Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109
   Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P11312, DOI 10.1073/pnas.1203015109
   Xavier GD, 2009, DIABETES, V58, P894, DOI 10.2337/db08 1187
   Xie YY, 2018, DIABETES, V67, P2569, DOI 10.2337/db18 0311
   Xu LL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1288 8
   Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092 8674(04)00216 8
   Xu XF, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01276 5
   Xu ZJ, 2016, P NATL ACAD SCI USA, V113, pE6382, DOI 10.1073/pnas.1613849113
   Yamanaka S, 2008, CELL TISSUE RES, V331, P5, DOI 10.1007/s00441 007 0520 5
   Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004
   Yan Y, 2009, J CELL SCI, V122, P3566, DOI 10.1242/jcs.051904
   Yang K, 2016, LAB INVEST, V96, P116, DOI 10.1038/labinvest.2015.144
   Yang L, 2011, ONCOGENE, V30, P4437, DOI 10.1038/onc.2011.145
   Yang LL, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4927
   Yang L, 2015, STEM CELLS, V33, P2913, DOI 10.1002/stem.2083
   Yang YZ, 2012, CELL BIOSCI, V2, DOI 10.1186/2045 3701 2 14
   Yardy GW, 2009, EUR UROL, V56, P486, DOI 10.1016/j.eururo.2008.05.029
   Ye X, 2010, TRENDS MOL MED, V16, P417, DOI 10.1016/j.molmed.2010.07.003
   Yu BQ, 2017, CIRCULATION, V136, P1022, DOI 10.1161/CIRCULATIONAHA.117.027690
   Yu HM, 2010, DEVELOPMENT, V137, P3707, DOI 10.1242/dev.052001
   Yu P, 2016, AM J HUM GENET, V99, P195, DOI 10.1016/j.ajhg.2016.05.012
   Yu XY, 2018, CELL PHYSIOL BIOCHEM, V47, P957, DOI 10.1159/000490140
   Yu YJ, 2012, CARCINOGENESIS, V33, P68, DOI 10.1093/carcin/bgr246
   Yuzugullu H, 2009, MOL CANCER, V8, DOI 10.1186/1476 4598 8 90
   Zakrzewski W, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1165 5
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhang FG, 2016, GENES DIS, V3, P263, DOI 10.1016/j.gendis.2016.09.004
   Zhang HJ, 2008, J CELL BIOCHEM, V103, P709, DOI 10.1002/jcb.21460
   Zhang K, 2017, CANCER RES, V77, P2534, DOI 10.1158/0008 5472.CAN 16 1887
   Zhang M, 2009, J CELL BIOCHEM, V108, P896, DOI 10.1002/jcb.22319
   Zhang Y, 2013, INT J MED SCI, V10, P738, DOI 10.7150/ijms.5693
   Zhang Y, 2012, J BIOL CHEM, V287, P32494, DOI 10.1074/jbc.M112.368282
   Zhang YK, 2017, INT J OPHTHALMOL CHI, V10, P1791, DOI 10.18240/ijo.2017.12.01
   Zhang Z, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2021.110009
   Zhao JH, 2016, PHARMACOL THERAPEUT, V160, P145, DOI 10.1016/j.pharmthera.2016.02.008
   Zhao Y, 2018, SEMIN CANCER BIOL, V53, P139, DOI 10.1016/j.semcancer.2018.08.002
   Zheng M, 2015, ONCOTARGET, V6, P6794
   Zhong Z, 2020, MOL PHARMACOL, V97, P72, DOI 10.1124/mol.119.117978
   ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700
   Zhou YD, 2014, HUM MOL GENET, V23, P6419, DOI 10.1093/hmg/ddu359
   Zhu XJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004687
   Zou WY, 2018, CELL REP, V22, P1003, DOI 10.1016/j.celrep.2017.12.093
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 413
TC 49
Z9 49
U1 19
U2 32
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, DONGCHENG
   DISTRICT 100009, PEOPLES R CHINA
SN 2352 4820
EI 2352 3042
J9 GENES DIS
JI Genes Dis.
PD MAY
PY 2024
VL 11
IS 3
AR 101026
DI 10.1016/j.gendis.2023.04.042
PG 33
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA PL1W4
UT WOS:001214152300001
PM 38292186
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU He, YH
   Li, MH
   Tong, GJ
   Meng, Y
   Hao, S
   Hu, SY
   Yan, WJ
   Yang, DH
AF He, Youhua
   Li, Minghan
   Tong, Guojun
   Meng, Yue
   Hao, Song
   Hu, Shaoyu
   Yan, Wenjuan
   Yang, Dehong
TI hPTH(3 34)(29 34) selectively activated PKC and mimicked osteoanabolic
   effects of hPTH(1 34)
SO BONE
LA English
DT Article
DE Osteo differentiation; Osteoporosis; Peptide engineering; Parathyroid
   hormone; Protein kinase C
ID PARATHYROID HORMONE PTH; PROTEIN KINASE A; (PTH)/PTH RELATED PEPTIDE
   RECEPTOR; MESSENGER RNA EXPRESSION; STABILIZES BETA CATENIN;
   PHOSPHOLIPASE C; CONTINUOUS INFUSION; SIGNALING PATHWAYS;
   PHOSPHORYLATION; CELLS
AB Teriparatide (hPTH(1 34)) exhibits both osteoanabolic and osteocatabolic effects. We generated a novel PTH analog by duplicating the PTH(29 34) domain to hPTH(3 34) (named MY 1), which was identified to activate PKC but not PLC and cAMP/PKA signaling. It increased osteo differentiation but did not affect osteoclastogenesis and RANKL expression in primary osteoblasts or bone marrow cells. MY 1 and hPTH(1 34) increased the synthesis and decreased the degradation of beta catenin protein in osteoblasts, while PKC inhibitor blunted such effects. In vivo results indicated that intermittent MY 1 and hPTH(1 34) prevented bone loss in ovariectomized mice, and that MY 1 infusion increased bone volume in normal mice. Histological analysis observed more osteoclasts surrounding the cancellous bone surface in hPTH(1 34), but not MY 1 treated mice. We conclude that MY 1 mimicked the osteoanabolic but not the osteocatabolic effects of hPTH(1 34), which is related to PKC and beta catenin signaling. Such anabolic only analog provides a new strategy to study PTH's versatile functions and design new medicines to treat osteoporosis and bone defects.
C1 [He, Youhua; Li, Minghan; Tong, Guojun; Meng, Yue; Hao, Song; Hu, Shaoyu; Yang, Dehong] Southern Med Univ, Nanfang Hosp, Dept Orthoped Spine Surg, 1838 Guangzhou North Ave, Guangzhou 510515, Peoples R China.
   [Yan, Wenjuan] Southern Med Univ, Nanfang Hosp, Dept Stomatol, 1838 Guangzhou North Ave, Guangzhou 510515, Peoples R China.
C3 Southern Medical University   China; Southern Medical University   China
RP Yang, DH (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Orthoped Spine Surg, 1838 Guangzhou North Ave, Guangzhou 510515, Peoples R China.; Yan, WJ (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Stomatol, 1838 Guangzhou North Ave, Guangzhou 510515, Peoples R China.
EM 645613053@qq.com; drmyang@yahoo.com
OI Yan, Wenjuan/0000 0002 5761 5423; Yang, Dehong/0000 0001 7896 8474
FU National Natural Science Foundation of China [81272043]; Natural Science
   Foundation of Guangdong Province [2015A030313256, 2019A1515012178]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81272043) and the Natural Science Foundation of
   Guangdong Province (Grant No. 2015A030313256 and 2019A1515012178). We
   thank Dr. Fangmei Peng and Dr. Shuangjie Tang (Center for
   Musculoskeletal Disorders Research, Guangdong Pharmaceutical University)
   for the technical support on histomorphometry, and Dr. Xiuhua Wu
   (Department of Spine Surgery, Nanfang Hospital, Southern Medical
   University) for the technical support in micro CT analysis. We thank Mr.
   Damian Barnett for language editing.
CR [Anonymous], ENDOCRINOLOGY
   [Anonymous], J BIOL
   Choudhary S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120164
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cupp ME, 2013, J PHARMACOL EXP THER, V345, P404, DOI 10.1124/jpet.112.199752
   Duong M, 2017, J BIOL CHEM, V292, P12100, DOI 10.1074/jbc.M117.775700
   FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29
   Gardella TJ, 1996, ENDOCRINOLOGY, V137, P3936, DOI 10.1210/en.137.9.3936
   Gentili C, 2001, BBA MOL CELL RES, V1540, P201, DOI 10.1016/S0167 4889(01)00134 3
   Guo J, 2010, ENDOCRINOLOGY, V151, P3502, DOI 10.1210/en.2009 1494
   Gwak J, 2006, J CELL SCI, V119, P4702, DOI 10.1242/jcs.03256
   Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063 9072.2005
   Horwitz MJ, 2011, J BONE MINER RES, V26, P2287, DOI 10.1002/jbmr.415
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Iida Klein A, 2005, J ENDOCRINOL, V186, P549, DOI 10.1677/joe.1.06270
   JOUISHOMME H, 1992, ENDOCRINOLOGY, V130, P53, DOI 10.1210/en.130.1.53
   Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198 012 2074 y
   Kondo H, 2002, J BONE MINER RES, V17, P1667, DOI 10.1359/jbmr.2002.17.9.1667
   Kraus D, 2012, CLIN ORAL INVEST, V16, P611, DOI 10.1007/s00784 011 0541 z
   Lee SK, 2002, BONE, V31, P252, DOI 10.1016/S8756 3282(02)00804 9
   Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200
   Liu BY, 2002, ENDOCRINOLOGY, V143, P627, DOI 10.1210/en.143.2.627
   Liu S, 2018, P NATL ACAD SCI USA, V115, P12383, DOI 10.1073/pnas.1815294115
   Lovatt M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012794
   Makino A, 2018, CALCIFIED TISSUE INT, V103, P289, DOI 10.1007/s00223 018 0422 4
   MERRITT BS, 1992, J CELL PHYSIOL, V152, P520, DOI 10.1002/jcp.1041520311
   Miao DS, 2001, J BIOL CHEM, V276, P32204, DOI 10.1074/jbc.M101084200
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Nakao Y, 2009, BONE, V44, P872, DOI 10.1016/j.bone.2009.01.370
   Obri A, 2014, J CELL BIOL, V205, P771, DOI 10.1083/jcb.201403138
   Ogata N, 2011, J BIOL CHEM, V286, P13733, DOI 10.1074/jbc.M110.200196
   Pfister MF, 1999, AM J PHYSIOL RENAL, V276, pF720, DOI 10.1152/ajprenal.1999.276.5.F720
   Pirih FQ, 2003, BIOCHEM BIOPH RES CO, V306, P144, DOI 10.1016/S0006 291X(03)00931 8
   Sabatini M, 1996, BONE, V18, P59, DOI 10.1016/8756 3282(95)00427 0
   Shin J, 2014, MOL CELLS, V37, P747, DOI 10.14348/molcells.2014.0220
   Sinha P, 2016, J BIOL CHEM, V291, P1631, DOI 10.1074/jbc.M115.679753
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Takasu H, 1999, BIOCHEMISTRY US, V38, P13453, DOI 10.1021/bi990437n
   Takasu H, 1999, J BONE MINER RES, V14, P11, DOI 10.1359/jbmr.1999.14.1.11
   Tarantino U, 2017, J ORTHOP TRAUMATOL, V18, pS3, DOI 10.1007/s10195 017 0474 7
   Tian Y, 2011, MOL CELL BIOCHEM, V355, P211, DOI 10.1007/s11010 011 0856 8
   Tobimatsu T, 2006, ENDOCRINOLOGY, V147, P2583, DOI 10.1210/en.2005 1627
   Tong G, 2017, MED SCI MONITOR, V23, P1896, DOI 10.12659/MSM.903699
   Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125
   Wang BL, 2006, J ENDOCRINOL INVEST, V29, P101, DOI 10.1007/BF03344081
   Wein MN, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13176
   Whitfield JF, 2001, J BONE MINER RES, V16, P441, DOI 10.1359/jbmr.2001.16.3.441
   Wolf M, 2013, ANN ANAT, V195, P455, DOI 10.1016/j.aanat.2013.04.006
   Yang D, 2007, BONE, V40, P1453, DOI 10.1016/j.bone.2007.02.001
   Yang DH, 2008, ENDOCRINOLOGY, V149, P1728, DOI 10.1210/en.2007 0826
   Yang DH, 2006, BONE, V38, P485, DOI 10.1016/j.bone.2005.10.009
   Yang YM, 2015, BIOCHEM BIOPH RES CO, V464, P27, DOI 10.1016/j.bbrc.2015.05.082
   Yao J, 2015, J CELL PHYSIOL, V230, P1235, DOI 10.1002/jcp.24858
NR 53
TC 11
Z9 11
U1 7
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2020
VL 135
AR 115326
DI 10.1016/j.bone.2020.115326
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LJ3LI
UT WOS:000530069000017
PM 32200023
OA hybrid
DA 2025 08 17
ER

PT J
AU Georgiadis, GF
   Balanika, AP
   Vasilakis, AE
   Begkas, DG
   Baltas, CS
   Pastroudis, AP
AF Georgiadis, George F.
   Balanika, Alexia P.
   Vasilakis, Alexandros E.
   Begkas, Dimitrios G.
   Baltas, Christos S.
   Pastroudis, Alexandros P.
TI Atypical femoral fracture in a metastatic bone disease patient six
   months after discontinuation of denosumab received sequentially to
   previous bisphosphonate therapy   A case report
SO JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS
LA English
DT Article
DE Atypical Femoral Fracture; Bisphosphonates; Denosumab; Metastatic Bone
   Disease; Zoledronic Acid
ID FEMUR FRACTURES; CANCER; MECHANISMS
AB Although, both bisphosphonates and denosumab are effective in reducing the risk of skeletal related events in patients with metastatic bone disease, many concerns were being raised about the possible association between their use and atypical femoral fractures. A case of an atypical femoral fracture in a metastatic bone disease patient, six months after discontinuation of long term zoledronic acid therapy and sequential treatment with denosumab is reported. After extensive laboratory and imaging examination, the fracture was classified as atypical and it was finally treated with discontinuation of denosumab. long cephalomedullary interlocking nailing and vitamin D administration. Sequential treatment with bisphosphonates and denosumab in patients with metastatic bone disease, may lead to an overlapping treatment effect, increasing bone suppression and the risk of atypical femoral fracture. In addition, discontinuation of denosumab may activate bone remodeling units in an area with microdamage accumulation in cortical bone caused by the previous bone suppression from the antiresorptive treatment. The activation of bone remodeling units may accelerate the occurrence of the atypical femoral fractures.
C1 [Georgiadis, George F.] Asclepieion Voulas Gen Hosp, Orthopaed Dept 4, Athens, Greece.
   [Georgiadis, George F.; Balanika, Alexia P.; Begkas, Dimitrios G.; Baltas, Christos S.; Pastroudis, Alexandros P.] Asclepieion Voulas Gen Hosp, Osteoporosis Dept, Athens, Greece.
   [Balanika, Alexia P.] Asclepieion Voulas Gen Hosp, Computed Tomog Dept, Athens, Greece.
   [Vasilakis, Alexandros E.] Asclepieion Voulas Gen Hosp, Orthopaed Dept 2, Athens, Greece.
   [Begkas, Dimitrios G.; Pastroudis, Alexandros P.] Asclepieion Voulas Gen Hosp, Orthopaed Dept 6, Athens, Greece.
   [Baltas, Christos S.] Asclepieion Voulas Gen Hosp, Georgios Gennimatas Gen Hosp, Radiol Dept, Athens, Greece.
RP Georgiadis, GF (通讯作者)，1 Vosileos Povlou St, Athens 16673, Greece.
EM gegeorgiades@yahoo.com
CR Chang ST, 2012, BONE, V51, P524, DOI 10.1016/j.bone.2012.05.010
   Cummings SR, 2018, J BONE MINER RES, V33, P190, DOI 10.1002/jbmr.3337
   Dempster DW, 2012, CLIN THER, V34, P521, DOI 10.1016/j.clinthera.2012.02.002
   Edwards BJ, 2016, J BONE MINER RES, V31, P1569, DOI 10.1002/jbmr.2818
   Fayad LM, 2005, SKELETAL RADIOL, V34, P245, DOI 10.1007/s00256 004 0872 9
   Hagen JE, 2014, J BONE JOINT SURG AM, V96A, P1905, DOI 10.2106/JBJS.N.00075
   Kim D, 2016, RHEUMATOL INT, V36, P65, DOI 10.1007/s00296 015 3323 0
   Koh JH, 2017, OSTEOPOROSIS INT, V28, P3251, DOI 10.1007/s00198 017 4169 y
   Lim SJ, 2018, OSTEOPOROSIS INT, V29, P2427, DOI 10.1007/s00198 018 4640 4
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Mahjoub Z, 2016, J BONE MINER RES, V31, P767, DOI 10.1002/jbmr.2748
   Puhaindran ME, 2011, J BONE JOINT SURG AM, V93A, P1235, DOI 10.2106/JBJS.J.01199
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Takahashi M, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 6236 6
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   Yang SP, 2017, ONCOLOGIST, V22, P438, DOI 10.1634/theoncologist.2016 0192
   Yeh WL, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1878 5
   Yoo Hyunseung, 2017, Hip Pelvis, V29, P127, DOI 10.5371/hp.2017.29.2.127
NR 19
TC 0
Z9 0
U1 0
U2 1
PU JMNI
PI NAFPLION
PA 7 SPILIADOU SQ, NAFPLION, 21 100, GREECE
SN 1108 7161
J9 J MUSCULOSKEL NEURON
JI J. Musculoskelet. Neuronal Interact.
PD SEP
PY 2021
VL 21
IS 3
BP 429
EP 433
PG 5
WC Neurosciences; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Physiology
GA UK2HK
UT WOS:000691795700013
PM 34465683
DA 2025 08 17
ER

PT J
AU Dong, MM
   Zeng, JC
   Yang, CY
   Qiu, YS
   Wang, XJ
AF Dong, Mingming
   Zeng, Jican
   Yang, Chenyu
   Qiu, Yisen
   Wang, Xinjia
TI Asiatic Acid Attenuates Osteoporotic Bone Loss in Ovariectomized Mice
   Through Inhibiting NF kappaB/MAPK/Protein Kinase B Signaling Pathway
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE asiatic acid; protein kinase B; osteoclastogenesis; osteoblast;
   osteoporosis
ID OSTEOCLAST DIFFERENTIATION; KAPPA B; FUSION; CELLS; AKT
AB Osteoporosis is a condition associated with osteolytic bone disease that is primarily characterized by inordinate osteoclast activation. Protein kinase B (Akt) pathways activated by receptor activator of nuclear factor kappa B ligand (RANKL) are essential for osteoclastogenesis. Asiatic acid (AA) is a natural pentacyclic triterpenoid compound extracted from a traditional Chinese herb that exhibits a wide range of biological activities. AA has been found to alleviate the hypertrophic and fibrotic phenotype of chondrocytes via the Akt signaling pathway. In this study, we investigated whether AA alleviated bone loss by inhibiting the Akt signaling pathway during osteoclastogenesis and its effect on osteoblasts. The effect of AA cytotoxicity on mouse bone marrow derived macrophages/monocytes (BMMs) was evaluated in vitro using a Cell Counting Kit 8 assay. The effects of AA on osteoclast differentiation and function were detected using tartrate resistant acid phosphatase (TRAP) staining and a pit formation assay. A Western blot and qRT PCR were conducted to evaluate the expression of osteoclast specific genes and protein signaling molecules. In addition, alkaline phosphatase and alizarin red staining were performed to assess osteoblast differentiation and mineralization. The bone protective effect of AA was investigated in vivo using ovariectomized mice. we found that AA could dose dependently inhibit RANKL induced osteoclastogenesis. Moreover, the pit formation assay revealed that osteoclast function was suppressed by treatment with AA. Moreover, the expression of osteoclast specific genes was found to be substantially decreased during osteoclastogenesis. Analysis of the molecular mechanisms showed that AA could inhibit NF kappaB/MAPK/Akt signaling pathway, as well as the downstream factors of NFATc1 in the osteoclast signaling pathway activated by RANKL. However, AA did not significantly promote osteoblast differentiation and mineralization. The in vivo experiments suggested that AA could alleviate ovariectomy induced bone loss in ovariectomized mice. Our results demonstrate that AA can inhibit osteoclastogenesis and prevent ovariectomy induced bone loss by inhibiting the NF kappaB/MAPK/Akt signaling pathway. The discovery of the new molecular mechanism that AA inhibits osteoclastogenesis provides essential evidence to support the use of AA as a potential drug for the treatment of osteoclast related diseases.
C1 [Dong, Mingming; Zeng, Jican; Yang, Chenyu; Qiu, Yisen; Wang, Xinjia] Shantou Univ Med Coll, Affiliated Hosp 2, Dept Spine Surg, Shantou, Peoples R China.
   [Wang, Xinjia] Shantou Univ Med Coll, Affiliated Canc Hosp, Dept Orthoped, Shantou, Peoples R China.
C3 Shantou University; Shantou University
RP Wang, XJ (通讯作者)，Shantou Univ Med Coll, Affiliated Hosp 2, Dept Spine Surg, Shantou, Peoples R China.; Wang, XJ (通讯作者)，Shantou Univ Med Coll, Affiliated Canc Hosp, Dept Orthoped, Shantou, Peoples R China.
EM xj.wang2000@163.com
RI Dong, Mingming/HGU 2624 2022; yang, chenyu/IUP 9513 2023
FU Guangdong Science and Technology Special Fund Mayor Project
   [20190301 65]; 2020 Li Ka Shing Foundation Cross Disciplinary Research
   [2020LKSFG01D]; Shantou City Science and Technology Plan Project,
   Guangdong Province, China [2019 106 37]; Shantou Medical and Health
   Science Technology Project [20197916]
FX This work was supported by the Guangdong Science and Technology Special
   Fund Mayor Project (No. 20190301 65), 2020 Li Ka Shing Foundation
   Cross Disciplinary Research Grant (2020LKSFG01D), Shantou City Science
   and Technology Plan Project, Guangdong Province, China (No. 2019 106 37)
   and Shantou Medical and Health Science Technology Project (No.
   20197916).
CR Andersson G, 2003, J BONE MINER RES, V18, P1912, DOI 10.1359/jbmr.2003.18.10.1912
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Barasch A, 2011, J DENT RES, V90, P439, DOI 10.1177/0022034510397196
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bruzzaniti A, 2006, REV ENDOCR METAB DIS, V7, P123, DOI 10.1007/s11154 006 9009 x
   Chang EJ, 2008, J CELL SCI, V121, P2555, DOI 10.1242/jcs.028217
   Chen D, 2019, BIOMOL THER, V27, P442, DOI 10.4062/biomolther.2018.188
   Cong Q, 2017, SCI REP UK, V7, DOI 10.1038/srep45964
   Cui J, 2020, J CELL MOL MED, V24, P6149, DOI 10.1111/jcmm.15229
   Gou XJ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/1874387
   Guo W, 2021, J ORTHOP TRANSL, V28, P148, DOI 10.1016/j.jot.2021.01.005
   Halleen JM, 2003, J BONE MINER RES, V18, P1908, DOI 10.1359/jbmr.2003.18.10.1908
   Hanley DA, 2017, AM J MED, V130, DOI 10.1016/j.amjmed.2017.03.002
   Hao YJ, 2018, ONCOL LETT, V15, P8223, DOI 10.3892/ol.2018.8417
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Hong GJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00331
   Huang J, 2019, CALCIFIED TISSUE INT, V105, P531, DOI 10.1007/s00223 019 00596 z
   Jang HD, 2013, BONE, V55, P126, DOI 10.1016/j.bone.2013.02.005
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Lin X, 2019, MOL CELL ENDOCRINOL, V494, DOI 10.1016/j.mce.2019.110494
   Liu N, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02193 0
   Liu WJ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.641277
   Lu SH, 2019, MAR DRUGS, V17, DOI 10.3390/md17060345
   MacMillan AK, 2014, INT J NANOMED, V9, P5627, DOI 10.2147/IJN.S66852
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Park JH, 2017, MOL CELLS, V40, P706
   Ren L, 2016, PHARM BIOL, V54, P2377, DOI 10.3109/13880209.2016.1156709
   Sattui SE, 2014, NAT REV ENDOCRINOL, V10, P592, DOI 10.1038/nrendo.2014.125
   Schell H, 2006, BONE, V38, P547, DOI 10.1016/j.bone.2005.09.018
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Wang ZH, 2018, EPILEPSY RES, V139, P28, DOI 10.1016/j.eplepsyres.2017.11.003
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Wu TC, 2017, ACTA PHARM SIN B, V7, P65, DOI 10.1016/j.apsb.2016.04.003
   Xiao DL, 2020, J CELL BIOCHEM, V121, P4542, DOI 10.1002/jcb.29677
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yahara Y, 2020, NAT CELL BIOL, V22, P49, DOI 10.1038/s41556 019 0437 8
   Yan DY, 2020, J CELL MOL MED, V24, P2330, DOI 10.1111/jcmm.14915
   Yuyun Xiong, 2018, Oncotarget, V9, P15036, DOI 10.18632/oncotarget.24542
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang WH, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm 20 4255
NR 49
TC 11
Z9 11
U1 1
U2 23
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD FEB 8
PY 2022
VL 13
AR 829741
DI 10.3389/fphar.2022.829741
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA ZH0HV
UT WOS:000760630900001
PM 35211021
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Le Henaff, C
   Mansouri, R
   Modrowski, D
   Zarka, M
   Geoffroy, V
   Marty, C
   Tarantino, N
   Laplantine, E
   Marie, PJ
AF Le Henaff, Carole
   Mansouri, Rafik
   Modrowski, Dominique
   Zarka, Mylene
   Geoffroy, Valerie
   Marty, Caroline
   Tarantino, Nadine
   Laplantine, Emmanuel
   Marie, Pierre J.
TI Increased NF κB Activity and Decreased Wnt/β Catenin
   Signaling Mediate Reduced Osteoblast Differentiation and Function in
   ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mice
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BONE MINERAL DENSITY; OSTEOPENIA; SMURF1; DEGRADATION; INHIBITION;
   ADULTS; CELLS; PREVALENCE; ACTIVATION; DISEASE
AB The prevalent human Delta F508 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) is associated with reduced bone formation and bone loss in mice. The molecular mechanisms by which the Delta F508 CFTR mutation causes alterations in bone formation are poorly known. In this study, we analyzed the osteoblast phenotype in Delta F508 CFTR mice and characterized the signaling mechanisms underlying this phenotype. Ex vivo studies showed that the Delta F508 CFTR mutation negatively impacted the differentiation of bone marrow stromal cells into osteoblasts and the activity of osteoblasts, demonstrating that the Delta F508 CFTR mutation alters both osteoblast differentiation and function. Treatment with a CFTR corrector rescued the abnormal collagen gene expression in Delta F508 CFTR osteoblasts. Mechanistic analysis revealed that NF kappa B signaling and transcriptional activity were increased in mutant osteoblasts. Functional studies showed that the activation of NF kappa B transcriptional activity in mutant osteoblasts resulted in increased beta catenin phosphorylation, reduced osteoblast beta catenin expression, and altered expression of Wnt/beta catenin target genes. Pharmacological inhibition of NF kappa B activity or activation of canonical Wnt signaling rescued Wnt target gene expression and corrected osteoblast differentiation and function in bone marrow stromal cells and osteoblasts from Delta F508 CFTR mice. Overall, the results show that the Delta F508 CFTR mutation impairs osteoblast differentiation and function as a result of overactive NF kappa B and reduced Wnt/beta catenin signaling. Moreover, the data indicate that pharmacological inhibition of NF kappa B or activation of Wnt/beta catenin signaling can rescue the abnormal osteoblast differentiation and function induced by the prevalent Delta F508 CFTR mutation, suggesting novel therapeutic strategies to correct the osteoblast dysfunctions in cystic fibrosis.
C1 [Le Henaff, Carole; Mansouri, Rafik; Modrowski, Dominique; Zarka, Mylene; Geoffroy, Valerie; Marty, Caroline; Marie, Pierre J.] INSERM, UMR 1132, F 75475 Paris, France.
   [Le Henaff, Carole; Mansouri, Rafik; Modrowski, Dominique; Zarka, Mylene; Geoffroy, Valerie; Marty, Caroline; Marie, Pierre J.] Univ Paris Diderot, Sorbonne Paris Cite, F 75013 Paris, France.
   [Tarantino, Nadine; Laplantine, Emmanuel] Inst Pasteur, Lab Signalisat & Pathogenese, F 75015 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Paris Cite; Universite Paris Cite; Pasteur Network;
   Universite Paris Cite; Institut Pasteur Paris
RP Marie, PJ (通讯作者)，Hop Lariboisiere, INSERM, UMR 1132, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM pierre.marie@inserm.fr
RI ; Geoffroy, Valerie/P 1521 2014; Modrowski, Dominique/N 6578 2018
OI LAPLANTINE, Emmanuel/0000 0002 5916 4654; Geoffroy,
   Valerie/0000 0003 3920 7482; Modrowski, Dominique/0000 0003 1103 7127;
   Zarka, Mylene/0000 0003 3179 4432
FU Association Prevention and Traitement des Decalcifications, Paris,
   France; Association Rhumatisme et Travail, Paris, France; Vaincre La
   Mucoviscidose (VLM) [RF20110600482]
FX This work was supported by grants from the Association Prevention and
   Traitement des Decalcifications and the Association Rhumatisme et
   Travail (to P. J. M.), Paris, France, and by Grant RF20110600482 from
   Vaincre La Mucoviscidose (VLM 2012 2013, to C. L. H.). The authors
   declare that they have no conflicts of interest with the contents of
   this article.
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Becq F, 2010, DRUGS, V70, P241, DOI 10.2165/11316160 000000000 00000
   Bodas M, 2010, DISCOV MED, V9, P346
   Borot F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007116
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   Bronckers A, 2010, BONE, V46, P1188, DOI 10.1016/j.bone.2009.12.002
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Conway SP, 2000, THORAX, V55, P798, DOI 10.1136/thorax.55.9.798
   Dif F, 2004, BONE, V35, P595, DOI 10.1016/j.bone.2004.05.021
   Du Qiang, 2010, For Immunopathol Dis Therap, V1, P155
   Edelman A, 2012, ARCH PEDIATRIE, V19, pS13, DOI 10.1016/S0929 693X(12)71101 6
   Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282
   Guilbault C, 2007, AM J RESP CELL MOL, V36, P1, DOI 10.1165/rcmb.2006 0184TR
   Guo R, 2008, J BIOL CHEM, V283, P23084, DOI 10.1074/jbc.M709848200
   Haston CK, 2008, AM J RESP CRIT CARE, V177, P309, DOI 10.1164/rccm.200705 659OC
   Haworth CS, 1999, THORAX, V54, P961, DOI 10.1136/thx.54.11.961
   Hay E, 2005, J BIOL CHEM, V280, P13616, DOI 10.1074/jbc.M411999200
   Hunter MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011598
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Krum SA, 2010, NAT REV RHEUMATOL, V6, P607, DOI 10.1038/nrrheum.2010.133
   Laplantine E, 2009, EMBO J, V28, P2885, DOI 10.1038/emboj.2009.241
   Le Henaff C, 2014, AM J PATHOL, V184, P1132, DOI 10.1016/j.ajpath.2013.12.027
   Le Henaff C, 2012, AM J PATHOL, V180, P2068, DOI 10.1016/j.ajpath.2012.01.039
   Legroux Gérot I, 2012, JOINT BONE SPINE, V79, P73, DOI 10.1016/j.jbspin.2011.05.009
   Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200
   Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   MODROWSKI D, 1993, CELL TISSUE RES, V271, P499, DOI 10.1007/BF02913733
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Paccou J, 2010, CALCIFIED TISSUE INT, V86, P1, DOI 10.1007/s00223 009 9316 9
   Pacifici R, 2010, ARCH BIOCHEM BIOPHYS, V503, P41, DOI 10.1016/j.abb.2010.05.027
   Paradis J, 2010, J CYST FIBROS, V9, P239, DOI 10.1016/j.jcf.2010.05.001
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Pashuck TD, 2009, PEDIATR RES, V65, P311, DOI 10.1203/PDR.0b013e3181961e80
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Sermet Gaudelus I, 2007, AM J RESP CRIT CARE, V175, P951, DOI 10.1164/rccm.200606 776OC
   Shead EF, 2007, THORAX, V62, P650, DOI 10.1136/thx.2006.075887
   Stalvey MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080098
   Tabary O, 2006, CELL SIGNAL, V18, P652, DOI 10.1016/j.cellsig.2005.06.004
   Vij N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004664
   Weitzmann MN, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/125705
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
NR 45
TC 32
Z9 36
U1 0
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 17
PY 2015
VL 290
IS 29
BP 18009
EP 18017
DI 10.1074/jbc.M115.646208
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA CN5ZB
UT WOS:000358511700033
PM 26060255
OA Green Published
DA 2025 08 17
ER

PT J
AU Nakamura, A
   Towheed, T
AF Nakamura, Akihiro
   Towheed, Tanveer
TI Pathogenesis, assessment, and management of bone loss in axial
   spondyloarthritis
SO SEMINARS IN ARTHRITIS AND RHEUMATISM
LA English
DT Article
DE Axial Spondyloarthritis (axSpA); DXA (dual x ray absorptiometry);
   Interleukin 17; Macrophage migration inhibitory factor (MIF); Mechanical
   stress; Microbiome; Osteoblast; Osteoclast; Osteoporosis; RANKL
   (Receptor activator of nuclear factor; kappa B ligand); Trabecular Bone
   Score; Tumor Necrosis Factor; Vertebral Fracture
ID MESENCHYMAL STEM CELLS; ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS;
   MINERAL DENSITY; NECROSIS FACTOR; OSTEOCLAST DIFFERENTIATION;
   QUANTITATIVE ULTRASOUND; VERTEBRAL FRACTURES; SPINAL PROGRESSION;
   RECEPTOR ACTIVATOR
AB Introduction: Axial spondyloarthritis (axSpA) presents a complex scenario where both new bone formation in entheseal tissues and significant trabecular bone loss coexist, emphasizing the intricate nature of bone dynamics in this context. Methods: A search of the literature was conducted to compose a narrative review exploring the pathogenesis, possible assessment methods, and potential management options for axSpA. Results: While chronic systemic and local inflammation contribute to bone loss, the mechanisms behind axSpAassociated bone loss exhibit distinct characteristics influenced by factors like mechanical stress and the gut microbiome. These factors directly or indirectly stimulate osteoclast differentiation and activation through the RANK RANKL axis, while simultaneously impeding osteoblast differentiation via negative regulation of bone anabolic pathways, including the Wnt signaling pathway. This disruption in the balance between bone resorbing osteoclasts and bone forming osteoblasts contributes to overall bone loss in axSpA. Early evaluation at diagnosis is prudent for detecting bone changes. While traditional dual x ray absorptiometry (DXA) has limitations due to potential overestimation from spinal new bone formation, alternative methods like trabecular bone score (TBS), quantitative CT (QCT), and quantitative ultrasound (QUS) show promise. However, their integration into routine clinical practice remains limited. In addition to approved anti inflammatory drugs, lifestyle adjustments like regular exercise play a key role in preserving bone health. Tailoring interventions based on individual risk profiles holds potential for mitigating bone loss progression. Conclusion: Recognizing the pivotal role of bone loss in axSpA underscores the importance of integrating regular assessments and effective management strategies into clinical practice. Given the multifaceted contributors to bone loss in axSpA, a multidisciplinary approach is essential.
C1 [Nakamura, Akihiro; Towheed, Tanveer] Queens Univ, Dept Med, Div Rheumatol, Kingston, ON, Canada.
   [Nakamura, Akihiro; Towheed, Tanveer] Queens Univ, Translat Inst Med, Sch Med, Kingston, ON, Canada.
   [Nakamura, Akihiro; Towheed, Tanveer] Kingston Hlth Sci Ctr, Kingston, ON, Canada.
   [Nakamura, Akihiro] Queens Univ, Translat Inst Med, Sch Med, Dept Med,Div Rheumatol, 94 Stuart St, Kingston, ON K7L 3N6, Canada.
   [Towheed, Tanveer] Queens Univ, Dept Med, Div Rheumatol, 94 Stuart St, Kingston, ON K7L 3N6, Canada.
C3 Queens University   Canada; Queens University   Canada; Queens
   University   Canada; Queens University   Canada
RP Nakamura, A (通讯作者)，Queens Univ, Translat Inst Med, Sch Med, Dept Med,Div Rheumatol, 94 Stuart St, Kingston, ON K7L 3N6, Canada.; Towheed, T (通讯作者)，Queens Univ, Dept Med, Div Rheumatol, 94 Stuart St, Kingston, ON K7L 3N6, Canada.
EM akihiro.nakamura@queensu.ca; tt5@queensu.ca
CR Adam S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay4447
   Adamopoulos IE, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2936
   Ali T, 2009, AM J MED, V122, P599, DOI 10.1016/j.amjmed.2009.01.022
   Allali F, 2003, ANN RHEUM DIS, V62, P347, DOI 10.1136/ard.62.4.347
   Andreev D, 2020, J CLIN INVEST, V130, P4811, DOI 10.1172/JCI134214
   Arends S, 2021, BRIT J CLIN PHARMACO, V87, P644, DOI 10.1111/bcp.14431
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Aschermann S, 2016, JOINT BONE SPINE, V83, P43, DOI 10.1016/j.jbspin.2015.03.019
   Atas N, 2022, CLIN RHEUMATOL, V41, P1381, DOI 10.1007/s10067 022 06070 w
   Balani D, 2013, ARTHRITIS RHEUM US, V65, P436, DOI 10.1002/art.37762
   Beek KJ, 2019, J BONE MINER RES, V34, P1041, DOI 10.1002/jbmr.3684
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Boussoualim K, 2018, JOINT BONE SPINE, V85, P727, DOI 10.1016/j.jbspin.2018.02.006
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Bratengeier C, 2020, FASEB J, V34, P3755, DOI 10.1096/fj.201901458R
   Braun J, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 04930 1
   Braun J, 2019, RHEUMATOLOGY, V58, P859, DOI 10.1093/rheumatology/key375
   Briot K, 2008, J RHEUMATOL, V35, P855
   Bruckmann NM, 2022, ARTHRITIS RHEUMATOL, V74, P1497, DOI 10.1002/art.42149
   Bruni C, 2021, EUR J RHEUMATOL, V8, P190, DOI 10.5152/eurjrheum.2020.21162
   Chang XY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1029475
   Charbord P, 2010, HUM GENE THER, V21, P1045, DOI 10.1089/hum.2010.115
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Daoussis D, 2010, SEMIN ARTHRITIS RHEU, V39, P369, DOI 10.1016/j.semarthrit.2008.10.008
   de Mara CS, 2011, CLINICS, V66, P487, DOI 10.1590/S1807 59322011000300022
   Deminger A, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1665 1
   Deminger A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1480 0
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Deodhar A, 2022, LANCET, V400, P369, DOI 10.1016/S0140 6736(22)01212 0
   Diao MH, 2022, FRONT MED LAUSANNE, V9, DOI 10.3389/fmed.2022.972586
   Ding N, 2019, CONNECT TISSUE RES, V60, P107, DOI 10.1080/03008207.2018.1459588
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Elolemy G, 2021, CURR RHEUMATOL REV, V17, P365, DOI 10.2174/1573397117666210308122515
   Erices A, 2002, EXP CELL RES, V280, P24, DOI 10.1006/excr.2002.5627
   Eun I, 2021, J CLIN NEUROSCI, V92, P153, DOI 10.1016/j.jocn.2021.08.016
   Fakhreldin S, 2020, EGYPT RHEUMATOL, V42, P297, DOI 10.1016/j.ejr.2020.07.009
   Fassio A, 2019, CLIN EXP RHEUMATOL, V37, P133
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fitzgerald GE, 2020, CLIN RHEUMATOL, V39, P1971, DOI 10.1007/s10067 019 04876 9
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Garnero P, 2010, ARTHRITIS RHEUM US, V62, P33, DOI 10.1002/art.25053
   Gimble JM, 2013, ORGANOGENESIS, V9, P3, DOI 10.4161/org.24279
   Gluer CC, 1997, J BONE MINER RES, V12, P1280, DOI 10.1359/jbmr.1997.12.8.1280
   González C, 2018, REUMATOL CLIN, V14, P346, DOI 10.1016/j.reuma.2017.03.011
   Gulyas K, 2020, CLIN RHEUMATOL, V39, P167, DOI 10.1007/s10067 019 04771 3
   Hamar A, 2021, OSTEOPOROSIS INT, V32, P1621, DOI 10.1007/s00198 021 05871 0
   Hansen KE, 2022, THER ADV MUSCULOSKEL, V14, DOI 10.1177/1759720X221142346
   Harmer D, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00788
   Haroon NN, 2014, SEMIN ARTHRITIS RHEU, V44, P155, DOI 10.1016/j.semarthrit.2014.05.008
   Harvey NC, 2015, BONE, V78, P216, DOI 10.1016/j.bone.2015.05.016
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Ishijima M, 2001, J EXP MED, V193, P399, DOI 10.1084/jem.193.3.399
   Jacquin C, 2009, BONE, V45, P640, DOI 10.1016/j.bone.2009.06.028
   Jansen TLTA, 2003, CLIN EXP RHEUMATOL, V21, P599
   Jo S, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1582 3
   Jung JY, 2020, SEMIN ARTHRITIS RHEU, V50, P827, DOI 10.1016/j.semarthrit.2020.07.009
   Jung JY, 2019, MOD RHEUMATOL, V29, P829, DOI 10.1080/14397595.2018.1510877
   Jura Póltorak A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10132905
   Kaaij MH, 2020, J EXP MED, V217, DOI 10.1084/jem.20200288
   Kang KY, 2020, J RHEUMATOL, V47, P1330, DOI 10.3899/jrheum.190749
   Kang KY, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4581
   Karmacharya P, 2020, ARTHRITIS RHEUMATOL, V72, P733, DOI 10.1002/art.41206
   Killinger Z, 2021, PHYSIOL RES, V70, pS53, DOI 10.33549/physiolres.934774
   Kim JW, 2022, J CLIN MED, V11, DOI 10.3390/jcm11102830
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Klingberg E, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4368
   Klingberg E, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3833
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Korkosz M, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 121
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Kusuda M, 2022, MOD RHEUMATOL, V32, P484, DOI 10.1093/mr/roab057
   Kwon SR, 2012, RHEUMATOL INT, V32, P2523, DOI 10.1007/s00296 011 1981 0
   Langdahl BL, 2017, LANCET, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Le Goff B, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/8659302
   Lee CS, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/580135
   Li G, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010738
   Li X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154677
   Lim MJ, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.569449
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Llorente I, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.601618
   Lucas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02490 4
   Ma YB, 2018, INT IMMUNOPHARMACOL, V59, P227, DOI 10.1016/j.intimp.2018.04.019
   Machado PM, 2016, ANN RHEUM DIS, V75, P1486, DOI 10.1136/annrheumdis 2015 208011
   Malysheva K, 2016, CROAT MED J, V57, P89, DOI 10.3325/cmj.2016.57.89
   Manolagas SC, 2014, MATURITAS, V78, P233, DOI 10.1016/j.maturitas.2014.04.013
   Marahleh A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02925
   McInnes IB, 2022, RHEUMATOLOGY, V61, P1783, DOI 10.1093/rheumatology/keab740
   MIELANTS H, 1988, BRIT J RHEUMATOL, V27, P95
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Mok CC, 2015, SCAND J RHEUMATOL, V44, P480, DOI 10.3109/03009742.2015.1038300
   MOTTAHENNESSY C, 1990, J NUCL MED, V31, P1510
   Movila A, 2016, J BONE MINER RES, V31, P1688, DOI 10.1002/jbmr.2854
   Nakamura A, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abg1210
   Nakamura A, 2021, CURR RHEUMATOL REP, V23, DOI 10.1007/s11926 021 00995 y
   Nakamura A, 2019, BEST PRACT RES CL RH, V33, DOI 10.1016/j.berh.2020.101491
   Naskar D, 2017, J IMMUNOL, V198, P1855, DOI 10.4049/jimmunol.1601776
   Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892
   Orsolini G, 2020, ANN RHEUM DIS, V79, DOI 10.1136/annrheumdis 2019 215896
   Papapoulos SE, 2008, BEST PRACT RES CL EN, V22, P831, DOI 10.1016/j.beem.2008.07.001
   Qaiyum Z, 2023, J RHEUMATOL, V50, P1090, DOI 10.3899/jrheum.2022 1272
   Qaiyum Z, 2019, ANN RHEUM DIS, V78, P1566, DOI 10.1136/annrheumdis 2019 215349
   Qin L, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0099 y
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Ramírez J, 2018, SEMIN ARTHRITIS RHEU, V48, P44, DOI 10.1016/j.semarthrit.2017.12.001
   Ramiro S, 2022, ARTHRITIS RHEUMATOL, V74, P1094, DOI 10.1136/ard 2022 223296
   Ranganathan V, 2017, ARTHRITIS RHEUMATOL, V69, P1796, DOI 10.1002/art.40175
   Ranganathan V, 2017, NAT REV RHEUMATOL, V13, P359, DOI 10.1038/nrrheum.2017.56
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Saalbach A, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.925503
   Seror R, 2016, SCI REP UK, V6, DOI 10.1038/srep18421
   Shah M, 2020, RMD OPEN, V6, DOI 10.1136/rmdopen 2020 001306
   Shaw AT, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 0998 x
   Shi JF, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9295313
   Shoback D, 2020, J CLIN ENDOCR METAB, V105, P587, DOI 10.1210/clinem/dgaa048
   Singh HJ, 2013, J CLIN DIAGN RES, V7, P2832, DOI 10.7860/JCDR/2013/6779.3770
   Singh P, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 77806 4
   Song IH, 2011, ANN RHEUM DIS, V70, P1257, DOI 10.1136/ard.2010.147033
   Sternes PR, 2022, ARTHRITIS RES THER, V24, DOI 10.1186/s13075 022 02853 3
   Suniaga S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21776 1
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2021, J BONE MINER METAB, V39, P13, DOI 10.1007/s00774 020 01191 1
   Tam HKJ, 2022, CURR RHEUMATOL REP, V24, P310, DOI 10.1007/s11926 022 01084 4
   Tan S, 2022, ARTHRITIS RHEUMATOL, V74, P1352, DOI 10.1002/art.42120
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Toussirot É, 2007, CURR OPIN RHEUMATOL, V19, P340
   Trikudanathan G, 2012, DRUGS, V72, P2333, DOI 10.2165/11638120 000000000 00000
   Uda Y, 2017, CURR OSTEOPOROS REP, V15, P318, DOI 10.1007/s11914 017 0373 0
   UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461
   van der Heijde D, 2019, LANCET, V394, P2108, DOI 10.1016/S0140 6736(19)32534 6
   van der Weijden MAC, 2012, OSTEOPOROSIS INT, V23, P1683, DOI 10.1007/s00198 011 1766 z
   van Tok MN, 2019, ARTHRITIS RHEUMATOL, V71, P612, DOI 10.1002/art.40770
   Viapiana O, 2014, RHEUMATOLOGY, V53, P90, DOI 10.1093/rheumatology/ket321
   Wang QX, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13172
   Wang YK, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006970
   Ward MM, 2019, ARTHRITIS RHEUMATOL, V71, P1599, DOI [10.1002/art.41042, 10.1002/acr.24025]
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Wu B, 2022, CURR RHEUMATOL REP, V24, P269, DOI 10.1007/s11926 022 01081 7
   Xie ZY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 017 0766 0
   Yahara Y, 2022, DEVELOPMENT, V149, DOI 10.1242/dev.199908
   Yeremenko N, 2015, ARTHRITIS RHEUMATOL, V67, P2071, DOI 10.1002/art.39183
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
   Yu LY, 2017, MOL MED REP, V16, P8699, DOI 10.3892/mmr.2017.7720
   Yu MC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14148 4
   Zha L, 2018, BIOMED PHARMACOTHER, V102, P369, DOI 10.1016/j.biopha.2018.03.080
   Zuchowski P, 2022, RHEUMATOL INT, V42, P839, DOI 10.1007/s00296 022 05109 0
NR 148
TC 5
Z9 5
U1 2
U2 7
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0049 0172
EI 1532 866X
J9 SEMIN ARTHRITIS RHEU
JI Semin. Arthritis Rheum.
PD FEB
PY 2024
VL 64
AR 152345
DI 10.1016/j.semarthrit.2023.152345
EA DEC 2023
PG 13
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA EJ7Q4
UT WOS:001138627200001
PM 38103486
DA 2025 08 17
ER

PT J
AU Liu, JS
   Zhang, HL
   Dong, YW
   Jin, YF
   Hu, XH
   Cai, KY
   Ma, JF
   Wu, G
AF Liu, Jinsong
   Zhang, Hualin
   Dong, Yiwen
   Jin, Yifan
   Hu, Xiaohui
   Cai, Kaiyong
   Ma, Jianfeng
   Wu, Gang
TI Bi directionally selective bone targeting delivery for anabolic and
   antiresorptive drugs: A novel combined therapy for osteoporosis?
SO MEDICAL HYPOTHESES
LA English
DT Article
ID PARATHYROID HORMONE; TERIPARATIDE; ALENDRONATE; ESTROGEN; COMBINATION;
   CONJUGATE; WOMEN
AB Osteoporosis is a progressive systemic skeletal disease, in which the equilibrium of bone resorption and bone formation is disturbed. The drugs for osteoporosis can be divided into two categories according to their predominant effects: antiresorptive drugs and anabolic drugs. Antiresorptive drugs are designed to inhibit bone resorption and anabolic drugs are aiming to stimulate bone formation. On the other hand, most antiresorptive drugs usually decrease anabolic activities and reduce bone formation, while anabolic drugs can unintendedly increase bone resorption. Furthermore, both types of drugs show no preferential distribution in bone and can locate generally in the areas of both bone formation and bone resorption. Consequently, the non specific interaction of these drugs with non targeting area and cells can lead to a compromised efficacy. Combined therapies of antiresorptive and anabolic drugs do not necessarily yield superiority when compared to monotherapy. Here, basing on the targeting cells of these two kinds of drugs and the spatial distribution of osteoblasts and osteoclasts, we propose a novel drug delivery system of bi directionally selective targeting in order to facilitate the efficacy of antiresorptive and anabolic drugs in combined therapy. In the system, an antiresorptive drug will be linked with a peptide of the eight repeating sequences of aspartate   (Asp)8 that can preferentially guide the drugs to bone resorption zone; while an anabolic drug linked with a peptide of six repeats of the sequence aspartate, serine, serine   (Asp Ser Ser)(6) that can favorably guide the drugs to bone formation zone. The novel delivery system will improve the specific interaction between the drugs and their targeting cells. Furthermore, the system will reduce the non specific interaction of the anabolic and antiresorptive drugs with their respective non targeting cells, which will maximally reduce their side effects. Therefore, we postulate that the new bone targeting drug delivery system will be a blessing for osteoporotic patients. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Liu, Jinsong; Cai, Kaiyong] Chongqing Univ, Coll Bioengn, Minist Educ, Key Lab Biorheol Sci & Technol, Chongqing 400044, Peoples R China.
   [Liu, Jinsong; Dong, Yiwen; Jin, Yifan; Hu, Xiaohui; Ma, Jianfeng; Wu, Gang] Wenzhou Med Univ, Sch & Hosp Stomatol, Wenzhou 325027, Peoples R China.
   [Zhang, Hualin] Ningxia Med Univ, Coll Stomatol, Yinchuan 750004, Peoples R China.
   [Wu, Gang] Vrije Univ Amsterdam, Res Inst MOVE, Acad Ctr Dent Amsterdam ACTA, Dept Oral Implantol & Prosthet Dent, Amsterdam, Netherlands.
   [Wu, Gang] Univ Amsterdam, Amsterdam, Netherlands.
C3 Chongqing University; Wenzhou Medical University; Ningxia Medical
   University; Academic Center for Dentistry Amsterdam; Vrije Universiteit
   Amsterdam; University of Amsterdam
RP Cai, KY (通讯作者)，Chongqing Univ, Coll Bioengn, Minist Educ, Key Lab Biorheol Sci & Technol, Chongqing 400044, Peoples R China.
EM kaiyong_cai@cqu.edu.cn; dentistmacn@aliyun.com
RI ; wu, gang/C 5072 2012; Cai, Kaiyong/G 1233 2011; Zhang,
   Hualin/A 2318 2008
OI dong, yiwen/0000 0001 5848 1554; Cai, Kaiyong/0000 0001 9029 680X; 
FU Natural Science Foundation of Zhejiang Province [LY13H140005, Y2110400];
   National Natural Science Foundation of China [81371182, 81200818,
   81360269]; Science Foundation of Zhejiang Provincial Department of
   Health [2013KYA124]
FX This study was supported by the Natural Science Foundation of Zhejiang
   Province (Nos. LY13H140005 and Y2110400), the National Natural Science
   Foundation of China (Grant Nos. 81371182, 81200818, and 81360269),
   Science Foundation of Zhejiang Provincial Department of Health (No.
   2013KYA124).
CR Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Buenzli PR, 2011, BONE, V48, P918, DOI 10.1016/j.bone.2010.12.009
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Dawson Hughes B, 2008, OSTEOPOROSIS INT, V19, P449, DOI 10.1007/s00198 008 0559 5
   Deal C, 2005, J BONE MINER RES, V20, P1905, DOI 10.1359/JBMR.050714
   Fazil M, 2013, EXPERT OPIN DRUG DEL, V10, P1123, DOI 10.1517/17425247.2013.785518
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Hodgson Stephen F, 2003, Endocr Pract, V9, P544
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Miller SC, 2008, PHARM RES DORDR, V25, P2889, DOI 10.1007/s11095 008 9706 0
   Muschitz C, 2013, J BONE MINER RES, V28, P196, DOI 10.1002/jbmr.1716
   Nasim S, 2010, BIOORG MED CHEM LETT, V20, P7450, DOI 10.1016/j.bmcl.2010.10.023
   Neale JR, 2009, BIOORG MED CHEM LETT, V19, P680, DOI 10.1016/j.bmcl.2008.12.051
   Riggs BL, 2003, OSTEOPOROSIS INT, V14, P728, DOI 10.1007/s00198 003 1437 9
   Segal E, 2011, BIOMATERIALS, V32, P4450, DOI 10.1016/j.biomaterials.2011.02.059
   Smith DW, 2012, PLOS ONE, P7
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   WILLIAMS C, 1984, BONE SCINTIGRAPHY, P13
   Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848
   Yarbrough DK, 2010, CALCIFIED TISSUE INT, V86, P58, DOI 10.1007/s00223 009 9312 0
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
NR 23
TC 6
Z9 7
U1 0
U2 30
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD DEC
PY 2014
VL 83
IS 6
BP 694
EP 696
DI 10.1016/j.mehy.2014.09.020
PG 3
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA AY5EJ
UT WOS:000347595600014
PM 25459136
DA 2025 08 17
ER

PT J
AU Furuya, Y
   Inagaki, A
   Khan, M
   Mori, K
   Penninger, JM
   Nakamura, M
   Udagawa, N
   Aoki, K
   Ohya, K
   Uchida, K
   Yasuda, H
AF Furuya, Yuriko
   Inagaki, Atsushi
   Khan, Masud
   Mori, Kaoru
   Penninger, Josef M.
   Nakamura, Midori
   Udagawa, Nobuyuki
   Aoki, Kazuhiro
   Ohya, Keiichi
   Uchida, Kohji
   Yasuda, Hisataka
TI Stimulation of Bone Formation in Cortical Bone of Mice Treated with a
   Receptor Activator of Nuclear Factor κB Ligand (RANKL) binding Peptide
   That Possesses Osteoclastogenesis Inhibitory Activity
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID POSTMENOPAUSAL WOMEN; PARATHYROID HORMONE; RANK LIGAND; OSTEOBLAST
   DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; IN VITRO; RESORPTION;
   OSTEOPOROSIS; MECHANISM; CELLS
AB To date, parathyroid hormone is the only clinically available bone anabolic drug. The major difficulty in the development of such drugs is the lack of clarification of the mechanisms regulating osteoblast differentiation and bone formation. Here, we report a peptide (W9) known to abrogate osteoclast differentiation in vivo via blocking receptor activator of nuclear factor kappa B ligand (RANKL) RANK signaling that we surprisingly found exhibits a bone anabolic effect in vivo. Subcutaneous administration of W9 three times/day for 5 days significantly augmented bone mineral density in mouse cortical bone. Histomorphometric analysis showed a decrease in osteoclastogenesis in the distal femoral metaphysis and a significant increase in bone formation in the femoral diaphysis. Our findings suggest that W9 exerts bone anabolic activity. To clarify the mechanisms involved in this activity, we investigated the effects of W9 on osteoblast differentiation/mineralization in MC3T3 E1 (E1) cells. W9 markedly increased alkaline phosphatase (a marker enzyme of osteoblasts) activity and mineralization as shown by alizarin red staining. Gene expression of several osteogenesis related factors was increased in W9 treated E1 cells. Addition of W9 activated p38 MAPK and Smad1/5/8 in E1 cells, and W9 showed osteogenesis stimulatory activity synergistically with BMP 2 in vitro and ectopic bone formation. Knockdown of RANKL expression in E1 cells reduced the effect of W9. Furthermore, W9 showed a weak effect on RANKL deficient osteoblasts in alkaline phosphatase assay. Taken together, our findings suggest that this peptide may be useful for the treatment of bone diseases, and W9 achieves its bone anabolic activity through RANKL on osteoblasts accompanied by production of several autocrine factors.
C1 [Furuya, Yuriko; Uchida, Kohji; Yasuda, Hisataka] Oriental Yeast Co Ltd, Nagahama Inst Biochem Sci, Nagahama, Shiga 5260804, Japan.
   [Inagaki, Atsushi; Mori, Kaoru] Oriental Yeast Co Ltd, Biochem Prod & Dev Ctr, Nagahama, Shiga 5260804, Japan.
   Oriental Yeast Co Ltd, Bioind Div, Itabashi Ku, Tokyo 1748505, Japan.
   [Khan, Masud; Aoki, Kazuhiro; Ohya, Keiichi] Tokyo Med & Dent Univ, Grad Sch, Dept Biomatrix, Bunkyo Ku, Tokyo 1138549, Japan.
   [Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, A 1030 Vienna, Austria.
   [Nakamura, Midori; Udagawa, Nobuyuki] Matsumoto Dent Univ, Dept Biochem, Nagano 3990781, Japan.
C3 Oriental Yeast Co., Ltd.; Oriental Yeast Co., Ltd.; Oriental Yeast Co.,
   Ltd.; Institute of Science Tokyo; Tokyo Medical & Dental University
   (TMDU); Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute
   of Molecular Biotechnology (IMBA); Matsumoto Dental University
RP Furuya, Y (通讯作者)，50 Kano Cho, Nagahama, Shiga 5260804, Japan.
EM furuya y@oyc.co.jp; hyasuda@oyc.co.jp
RI AOKI, Kazuhiro/G 2258 2016; Penninger, Josef/I 6860 2013
OI AOKI, Kazuhiro/0000 0001 6643 6315; Penninger,
   Josef/0000 0002 8194 3777; Yasuda, Hisataka/0000 0003 3511 609X
FU Grants in Aid for Scientific Research [24390413, 23593054, 25293377]
   Funding Source: KAKEN
CR Aoki K, 2006, J CLIN INVEST, V116, P1525, DOI 10.1172/JCI22513
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885
   Chen NJ, 2001, J IMMUNOL, V166, P270, DOI 10.4049/jimmunol.166.1.270
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Eissner G, 2004, CYTOKINE GROWTH F R, V15, P353, DOI 10.1016/j.cytogfr.2004.03.011
   Furuya Y, 2011, J BIOL CHEM, V286, P37023, DOI 10.1074/jbc.M111.246280
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   ISGAARD J, 1986, AM J PHYSIOL, V250, pE367, DOI 10.1152/ajpendo.1986.250.4.E367
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Nakamura M, 2003, ENDOCRINOLOGY, V144, P5441, DOI 10.1210/en.2003 0717
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Takasaki W, 1997, NAT BIOTECHNOL, V15, P1266, DOI 10.1038/nbt1197 1266
   TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo 110 2 506
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Watts AD, 1999, EMBO J, V18, P2119, DOI 10.1093/emboj/18.8.2119
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 37
TC 63
Z9 73
U1 0
U2 16
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 22
PY 2013
VL 288
IS 8
BP 5562
EP 5571
DI 10.1074/jbc.M112.426080
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 095NY
UT WOS:000315342500030
PM 23319583
OA Green Published
DA 2025 08 17
ER

PT J
AU Yang, Q
   Mu, ZS
   Ma, XY
   Yang, XM
   Fu, BF
   Chang, ZH
   Cheng, SZ
   Du, M
AF Yang, Qi
   Mu, Zhishen
   Ma, Xiaoyu
   Yang, Ximing
   Fu, Baifeng
   Chang, Zhihui
   Cheng, Shuzhen
   Du, Ming
TI Collagen peptides alleviate estrogen deficiency induced osteoporosis by
   enhancing osteoblast differentiation and mineralization
SO JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE
LA English
DT Article
DE sheepskin collagen peptide; osteoporosis; osteoblast differentiation;
   bone mineral density; WNT/beta catenin and BMP
   signaling pathways
ID BONE METABOLISM
AB BACKGROUNDOsteoporosis is a systemic skeletal disorder characterized by decreased bone mass and impaired bone microarchitecture because of an imbalance between bone resorption and formation. Existing pharmacological treatments often have significant side effects and mainly focus on inhibiting bone resorption. Other than inhibiting osteoclast mediated bone resorption, the present study also investigates the potential role of sheepskin collagen peptide (SSCP) in bone formation by promoting osteoblast proliferation, differentiation and mineralization.RESULTSSSCP improved bone mineral density in ovariectomized mice by improving bone volume, trabecular thickness and trabecular number. Histological analysis and tartrate resistant acid phosphatase (TRAP) staining revealed denser trabeculae and decreased osteoclast activity, accompanied by a normalized receptor activator of nuclear factor kappa B ligand/osteoprotegerin ratio and reduced serum TRAP levels. SSCP promotes the proliferation, differentiation and mineralization of MC3T3 E1 osteoblast cells by upregulating osteogenic markers such as bone morphogenetic protein (BMO) 2, runt related transcription factor (RUNX) 2 and beta catenin. SSCP enhanced bone formation and suppressed bone resorption by activating the WNT/beta catenin and BMP/Smad signaling pathways.CONCLUSIONSSCP offers a dual modulatory approach to bone health, addressing both bone formation and resorption. Its activation of key osteogenic pathways and improvement in bone structural integrity highlight its therapeutic potential for managing osteoporosis and enhancing skeletal health. By activating key osteogenic pathways and normalizing bone metabolism markers, SSCP presents a promising therapeutic candidate for osteoporosis and other bone related conditions. Further clinical studies are needed to confirm these findings and explore its potential applications. (c) 2024 Society of Chemical Industry.
C1 [Yang, Qi; Ma, Xiaoyu; Yang, Ximing; Fu, Baifeng; Chang, Zhihui; Cheng, Shuzhen; Du, Ming] Dalian Polytech Univ, Sch Food Sci & Technol, SKL Marine Food Proc & Safety Control, Dalian, Peoples R China.
   [Yang, Qi; Ma, Xiaoyu; Yang, Ximing; Fu, Baifeng; Chang, Zhihui; Cheng, Shuzhen; Du, Ming] Dalian Polytech Univ, Natl Engn Res Ctr Seafood, Collaborat Innovat Ctr Seafood Deep Proc, Dalian, Peoples R China.
   [Mu, Zhishen] Inner Mongolia Mengniu Dairy Grp Co Ltd, Inner Mongolia Enterprise Key Lab Dairy Nutr Hlth, Hohhot, Peoples R China.
C3 Dalian Polytechnic University; Dalian Polytechnic University
RP Cheng, SZ (通讯作者)，Dalian Polytech Univ, Natl Engn Res Ctr Seafood, Sch Food Sci & Technol, 1 Qinggongyuan, Dalian 116034, Peoples R China.
EM chengshuzhen0547@yeah.net
RI Cheng, Shuzhen/GQZ 1196 2022; Fu, Baifeng/JOZ 6455 2023; Ma,
   Xiaoyu/GSE 0908 2022
FU the Dalian High level Innovative Talent Team Project [2023RG005]; Dalian
   High level Innovative Talent Team Project
FX This study was supported by the Dalian High level Innovative Talent Team
   Project (2023RG005).
CR Aghebati Maleki L, 2019, J CELL PHYSIOL, V234, P8570, DOI 10.1002/jcp.27833
   Ahmad O., 2020, LIFE SCI, V264, P118681
   Anderson PA, 2021, J BONE JOINT SURG AM, V103, P741, DOI 10.2106/JBJS.20.01248
   Ayub N, 2021, J CLIN MED, V10, DOI 10.3390/jcm10133002
   Bolognese MA, 2010, REV ENDOCR METAB DIS, V11, P253, DOI 10.1007/s11154 010 9137 1
   Chen Y., 2020, CRIT REV FOOD SCI, V62, P11
   Chen ZB, 2022, FOOD BIOSCI, V46, DOI 10.1016/j.fbio.2022.101572
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   Donsante S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22083989
   Durbano HW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186909
   Fu QS, 2023, CELL COMMUN SIGNAL, V21, DOI 10.1186/s12964 023 01119 y
   Hao X, 2024, INT J BIOL MACROMOL, V265, DOI 10.1016/j.ijbiomac.2024.130855
   He HT, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.791880
   Hou CJ, 2021, INT J MOL MED, V48, DOI 10.3892/ijmm.2021.4995
   Huang JM, 2024, CHEM BIOL INTERACT, V393, DOI 10.1016/j.cbi.2024.110955
   Jin Y, 2023, ENVIRON POLLUT, V336, DOI 10.1016/j.envpol.2023.122407
   Jung Y, 2019, J BONE MINER METAB, V37, P134, DOI 10.1007/s00774 018 0904 5
   Li J, 2020, CYTOKINE GROWTH F R, V52, P88, DOI 10.1016/j.cytogfr.2020.02.003
   Li YT, 2020, AGING US, V12, P2226, DOI 10.18632/aging.102742
   Liang XX, 2019, J CELL BIOCHEM, V120, P13121, DOI 10.1002/jcb.28585
   Licini C, 2019, CYTOKINE GROWTH F R, V49, P59, DOI 10.1016/j.cytogfr.2019.09.001
   Liu ZY, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2863 y
   Lu ZK, 2018, GENE, V674, P143, DOI 10.1016/j.gene.2018.06.039
   Mouradian S, 2024, NUCLEIC ACIDS RES, V52, P3667, DOI 10.1093/nar/gkae060
   Ni XM, 2023, PHYTOMEDICINE, V108, DOI 10.1016/j.phymed.2022.154509
   Oh Y, 2023, PROCESS BIOCHEM, V125, P121, DOI 10.1016/j.procbio.2022.12.019
   Palacios S, 2022, CLIMACTERIC, V25, P43, DOI 10.1080/13697137.2021.1951697
   PINKEL D, 1958, CANCER RES, V18, P853
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Saag JL, 2022, CURR TREAT OPT RHEUM, V8, P143, DOI 10.1007/s40674 022 00195 4
   Scott M., 2023, INT J MOL SCI, V24, P17
   Souza ATP, 2024, LIFE SCI, V340, DOI 10.1016/j.lfs.2024.122463
   Wang J, 2024, HELIYON, V10, DOI 10.1016/j.heliyon.2023.e23531
   Wang QQ, 2022, BIOMED PHARMACOTHER, V154, DOI 10.1016/j.biopha.2022.113622
   Wang QS, 2024, FOOD SCI HUM WELL, V13, P1258, DOI 10.26599/FSHW.2022.9250105
   Wang YY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03899 z
   Wu MJ, 2023, NAT PRODUCT BIOPROSP, V13, DOI 10.1007/s13659 023 00383 2
   Yang ML, 2024, J AGR FOOD CHEM, V72, P9691, DOI 10.1021/acs.jafc.3c06700
   Yang ML, 2022, FOOD FUNCT, V13, P1975, DOI [10.1039/D1FO03696C, 10.1039/d1fo03696c]
   Ye ML, 2020, FOOD FUNCT, V11, P1498, DOI [10.1039/c9fo01944h, 10.1039/C9FO01944H]
   Zhang K, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091325
   Zhong WY, 2023, FOOD FUNCT, V14, P10107, DOI [10.1039/d3fo03125j, 10.1039/D3FO03125J]
   Zhu LY, 2020, J FUNCT FOODS, V64, DOI 10.1016/j.jff.2019.103697
NR 43
TC 1
Z9 1
U1 9
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 5142
EI 1097 0010
J9 J SCI FOOD AGR
JI J. Sci. Food Agric.
PD APR
PY 2025
VL 105
IS 6
BP 3284
EP 3295
DI 10.1002/jsfa.14086
EA DEC 2024
PG 12
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA 0SW5Q
UT WOS:001380358600001
PM 39704042
DA 2025 08 17
ER

PT J
AU Yao, ZQ
   Ayoub, A
   Srinivasan, V
   Wu, J
   Tang, CR
   Duan, R
   Milosavljevic, A
   Xing, LP
   Ebetino, FH
   Frontier, AJ
   Boyce, BF
AF Yao, Zhenqiang
   Ayoub, Akram
   Srinivasan, Venkatesan
   Wu, Jun
   Tang, Churou
   Duan, Rong
   Milosavljevic, Aleksa
   Xing, Lianping
   Ebetino, Frank H.
   Frontier, Alison J.
   Boyce, Brendan F.
TI Hydroxychloroquine and a low antiresorptive activity bisphosphonate
   conjugate prevent and reverse ovariectomy induced bone loss in mice
   through dual antiresorptive and anabolic effects
SO BONE RESEARCH
LA English
DT Article
ID FARNESYL PYROPHOSPHATE SYNTHASE; PARATHYROID HORMONE; POSTMENOPAUSAL
   WOMEN; OSTEOCLAST FORMATION; OSTEOPOROSIS; INHIBITION; ALENDRONATE;
   DENOSUMAB; THERAPY; ACCUMULATION
AB Osteoporosis remains incurable. The most widely used antiresorptive agents, bisphosphonates (BPs), also inhibit bone formation, while the anabolic agent, teriparatide, does not inhibit bone resorption, and thus they have limited efficacy in preventing osteoporotic fractures and cause some side effects. Thus, there is an unmet need to develop dual antiresorptive and anabolic agents to prevent and treat osteoporosis. Hydroxychloroquine (HCQ), which is used to treat rheumatoid arthritis, prevents the lysosomal degradation of TNF receptor associated factor 3 (TRAF3), an NF kappa B adaptor protein that limits bone resorption and maintains bone formation. We attempted to covalently link HCQ to a hydroxyalklyl BP (HABP) with anticipated low antiresorptive activity, to target delivery of HCQ to bone to test if this targeting increases its efficacy to prevent TRAF3 degradation in the bone microenvironment and thus reduce bone resorption and increase bone formation, while reducing its systemic side effects. Unexpectedly, HABP HCQ was found to exist as a salt in aqueous solution, composed of a protonated HCQ cation and a deprotonated HABP anion. Nevertheless, it inhibited osteoclastogenesis, stimulated osteoblast differentiation, and increased TRAF3 protein levels in vitro. HABP HCQ significantly inhibited both osteoclast formation and bone marrow fibrosis in mice given multiple daily PTH injections. In contrast, HCQ inhibited marrow fibrosis, but not osteoclast formation, while the HABP alone inhibited osteoclast formation, but not fibrosis, in the mice. HABP HCQ, but not HCQ, prevented trabecular bone loss following ovariectomy in mice and, importantly, increased bone volume in ovariectomized mice with established bone loss because HABP HCQ increased bone formation and decreased bone resorption parameters simultaneously. In contrast, HCQ increased bone formation, but did not decrease bone resorption parameters, while HABP also restored the bone lost in ovariectomized mice, but it inhibited parameters of both bone resorption and formation. Our findings suggest that the combination of HABP and HCQ could have dual antiresorptive and anabolic effects to prevent and treat osteoporosis.
C1 [Yao, Zhenqiang; Ayoub, Akram; Wu, Jun; Tang, Churou; Duan, Rong; Xing, Lianping; Boyce, Brendan F.] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA.
   [Srinivasan, Venkatesan; Milosavljevic, Aleksa; Ebetino, Frank H.; Frontier, Alison J.] Univ Rochester, Dept Chem, Rochester, NY 14627 USA.
   [Tang, Churou] Univ Rochester, Sch Arts & Sci, Rochester, NY 14627 USA.
   [Ebetino, Frank H.] BioVinc LLC, Pasadena, CA 91107 USA.
C3 University of Rochester; University of Rochester; University of
   Rochester
RP Yao, ZQ; Boyce, BF (通讯作者)，Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA.
EM Zhenqiang_Yao@urmc.rochester.edu; Brendan_Boyce@urmc.rochester.edu
OI Xing, Lianping/0000 0002 2588 7766; Tang, Churou/0009 0003 5634 4849;
   Yao, Zhenqiang/0000 0002 4664 3648
FU U.S. Department of Health & Human Services | NIH | National Institute on
   Aging (U.S. National Institute on Aging) [NIH/NIAMS P30 AR069655]; Core
   Services from Center for Musculoskeletal Research (CMSR); University of
   Rochester Medical Center
FX The authors sincerely thank Lindsay Schnur for micro CT imaging and
   analysis, and the Core Services from Center for Musculoskeletal Research
   (CMSR) (NIH/NIAMS P30 AR069655), University of Rochester Medical Center.
CR Anastasilakis AD, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010152
   Baghdadi S, 2023, BMC MUSCULOSKEL DIS, V24, DOI 10.1186/s12891 023 06825 9
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brown JP, 2021, ENDOCRINOL METAB, V36, P544, DOI 10.3803/EnM.2021.301
   Capriani C, 2012, J BONE MINER RES, V27, P2419, DOI 10.1002/jbmr.1800
   Chavassieux P, 2019, J BONE MINER RES, V34, P1597, DOI 10.1002/jbmr.3735
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2017, J BONE MINER RES, V32, P198, DOI 10.1002/jbmr.3051
   Costedoat Chalumeau N, 2015, CLIN REV ALLERG IMMU, V49, P317, DOI 10.1007/s12016 015 8469 8
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Cummings SR, 2018, J BONE MINER RES, V33, P190, DOI 10.1002/jbmr.3337
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Eastell R, 2011, J BONE MINER RES, V26, P530, DOI 10.1002/jbmr.251
   Ebetino FH, 2022, BONE, V156, DOI 10.1016/j.bone.2021.116289
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Jobke B, 2014, BONE, V59, P37, DOI 10.1016/j.bone.2013.10.024
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Leder BZ, 2017, BONE, V98, P54, DOI 10.1016/j.bone.2017.03.006
   Li JB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10677 0
   Looker AC, 2010, J BONE MINER RES, V25, P64, DOI 10.1359/jbmr.090706
   Mäkitie RE, 2018, OSTEOPOROSIS INT, V29, P479, DOI 10.1007/s00198 017 4309 4
   Maruotti N, 2012, EUR J CLIN PHARMACOL, V68, P1013, DOI 10.1007/s00228 012 1216 7
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Motten AG, 1999, PHOTOCHEM PHOTOBIOL, V69, P282, DOI 10.1562/0031 8655(1999)069<0282:PSOAD>2.3.CO;2
   Murtha LA, 2019, AGING DIS, V10, P419, DOI 10.14336/AD.2018.0601
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Ni CZ, 2000, P NATL ACAD SCI USA, V97, P10395, DOI 10.1073/pnas.97.19.10395
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rosenbaum JT, 2021, ARTHRITIS RHEUMATOL, V73, P908, DOI 10.1002/art.41683
   Shen GY, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.101767
   Shoback D, 2020, J CLIN ENDOCR METAB, V105, P587, DOI 10.1210/clinem/dgaa048
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Sleeman A, 2019, AM J HEALTH SYST PH, V76, P130, DOI 10.1093/ajhp/zxy022
   Solling ASK, 2019, DRUG AGING, V36, P625, DOI 10.1007/s40266 019 00675 8
   Sun ST, 2021, BRIT J PHARMACOL, V178, P2008, DOI 10.1111/bph.15251
   Tsoumpra MK, 2015, BONE, V81, P478, DOI 10.1016/j.bone.2015.08.020
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Wang Y, 2015, AGING CELL, V14, P678, DOI 10.1111/acel.12350
   Wasnich RD, 2000, J CLIN ENDOCR METAB, V85, P231, DOI 10.1210/jc.85.1.231
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Weivoda MM, 2011, ENDOCRINOLOGY, V152, P3113, DOI 10.1210/en.2011 0016
   Xing LP, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115492
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Yao ZQ, 2017, J BIOL CHEM, V292, P10169, DOI 10.1074/jbc.M116.771816
   Yao ZQ, 2009, J CLIN INVEST, V119, P3024, DOI 10.1172/JCI38716
   Yi XJ, 2021, J BONE MINER RES, V36, P2426, DOI 10.1002/jbmr.4447
NR 53
TC 6
Z9 6
U1 5
U2 11
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD SEP 5
PY 2024
VL 12
IS 1
AR 52
DI 10.1038/s41413 024 00352 6
PG 11
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA E7C0L
UT WOS:001304536200001
PM 39231935
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Dong, C
   Yang, H
   Wang, YK
   Yan, X
   Li, DZ
   Cao, ZM
   Ning, YM
   Zhang, CL
AF Dong, Chao
   Yang, Hong
   Wang, Yongkui
   Yan, Xu
   Li, Dongzhe
   Cao, Zhengming
   Ning, Yongming
   Zhang, Chunlin
TI Anagliptin stimulates osteoblastic cell differentiation and
   mineralization
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Osteoporosis; Osteoblast differentiation; Anagliptin; RUNX2;
   Wnt/beta catenin pathway
ID MESENCHYMAL STEM CELLS; GLUCAGON LIKE PEPTIDE 1; OSTEOPOROSIS;
   EXPRESSION; BMP 2; INHIBITORS; CATENIN; RUNX2; WNT
AB Osteoporosis is a common debilitating bone disease characterized by loss of bone mass and degradation of the bone architecture, which is primarily driven by dysregulated differentiation of mesenchymal stem cells into bone producing osteoblasts. Osteoblasts contribute to bone formation by secreting various proteins that guide the deposition of bone extracellular matrix, such as alkaline phosphatase (ALP), osteocalcin (OCN), and osteopontin (OPN). The Wnt/beta catenin pathway is widely recognized as a regulator of bone mass and is required to maintain bone homeostasis. Hormones have long been recognized as playing a key role in bone metabolism, and in recent years, growing evidence has shown that diabetes is a risk factor for osteoporosis. In the present study, we investigated the effects of the antidiabetic drug anagliptin on the differentiation and mineralization of osteoblasts induced by osteogenic medium. Anagliptin promotes insulin production via inhibition of dipeptidyl peptidase IV (DPP 4), an enzyme that targets the incretin hormone glucagon like peptide 1 (GLP 1) for degradation. Our findings show that anagliptin significantly increases the differentiation of MSCs into osteoblasts via activation of RUNX2. Anagliptin significantly increased matrix deposition and mineralization by osteoblasts, as evidenced by elevated levels of ALP, OCN, OPN, and BMP 2. We further demonstrate that anagliptin activates the canonical and noncannonical Wnt signaling pathways and that silencing of Wnt/beta catenin signaling completely abolished the effects of anagliptin. Thus, anagliptin might be a safe, effective therapy for type II diabetes that might show promise as a therapy against osteoporosis.
C1 [Dong, Chao; Wang, Yongkui; Yan, Xu; Li, Dongzhe; Cao, Zhengming; Ning, Yongming; Zhang, Chunlin] Zhengzhou Univ, Dept Orthoped, Affiliated Hosp 1, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.
   [Yang, Hong] Gen Hosp Jinshui Dist, Dept Internal Med, Zhengzhou 450052, Peoples R China.
C3 Zhengzhou University
RP Dong, C (通讯作者)，Zhengzhou Univ, Dept Orthoped, Affiliated Hosp 1, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.
EM dongchao425@163.com
RI Cao, Zhengming/MGU 7917 2025; Li, Dongzhe/J 3300 2015
FU Doctoral Scientific Research Foundation of The First Affiliated Hospital
   of Zhengzhou University
FX This study is funded by the "The Doctoral Scientific Research Foundation
   of The First Affiliated Hospital of Zhengzhou University".
CR Berger JP, 2018, ENDOCRIN DIAB METAB, V1, DOI 10.1002/edm2.2
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Chabi B, 2018, J BIOENERG BIOMEMBR, V50, P131, DOI 10.1007/s10863 018 9752 1
   Chang IC, 2010, OSTEOPOROSIS INT, V21, P1401, DOI 10.1007/s00198 009 1107 7
   Charoenphandhu N, 2018, CAN J DIABETES, V42, P545, DOI 10.1016/j.jcjd.2018.01.006
   Choi SY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180393
   del Real A, 2017, EPIGENETICS US, V12, P113, DOI 10.1080/15592294.2016.1271854
   Driessen JHM, 2017, DIABETES OBES METAB, V19, P421, DOI 10.1111/dom.12843
   Feng YY, 2016, J MOL ENDOCRINOL, V56, P189, DOI 10.1530/JME 15 0264
   Fukuda T, 2010, DIFFERENTIATION, V80, P46, DOI 10.1016/j.diff.2010.05.002
   Garg P, 2017, ORTHOP SURG, V9, P13, DOI 10.1111/os.12304
   Hansen MSS, 2018, BASIC CLIN PHARMACOL, V122, P25, DOI 10.1111/bcpt.12850
   Hofbauer LC, 2007, J BONE MINER RES, V22, P1317, DOI 10.1359/JBMR.070510
   Iepsen EW, 2015, J CLIN ENDOCR METAB, V100, P2909, DOI 10.1210/jc.2015 1176
   Ishida M, 2019, BIOMED PHARMACOTHER, V109, P242, DOI 10.1016/j.biopha.2018.10.052
   Jagtap VR, 2011, BONE, V2, P5
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim IR, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1320 9
   Li J, 2017, MED SCI MONITOR, V23, P5410, DOI 10.12659/MSM.906603
   Liu HH, 2019, INT IMMUNOPHARMACOL, V75, DOI 10.1016/j.intimp.2019.105801
   Liu Y, EUR REV MED PHARM SC, V17, P1611
   Mansur SA, 2019, CALCIFIED TISSUE INT, V104, P437, DOI 10.1007/s00223 018 0507 0
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   McIntosh CHS, 2005, REGUL PEPTIDES, V128, P159, DOI 10.1016/j.regpep.2004.06.001
   Meng JR, 2016, STEM CELL REP, V6, P579, DOI 10.1016/j.stemcr.2016.02.002
   Migliorini E, 2016, CYTOKINE GROWTH F R, V27, P43, DOI 10.1016/j.cytogfr.2015.11.008
   Nuche Berenguer B, 2009, CALCIFIED TISSUE INT, V84, P453, DOI 10.1007/s00223 009 9220 3
   Phetfong J, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658 016 0013 1
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Rodríguez JP, 1999, J CELL BIOCHEM, V75, P414, DOI 10.1002/(SICI)1097 4644(19991201)75:3<414::AID JCB7>3.3.CO;2 3
   Sethe S, 2006, AGEING RES REV, V5, P91, DOI 10.1016/j.arr.2005.10.001
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Singh S, 2015, J CLIN DIAGN RES, V9, pRC4, DOI 10.7860/JCDR/2015/14857.6318
   Visweswaran M, 2015, INT J BIOCHEM CELL B, V68, P139, DOI 10.1016/j.biocel.2015.09.008
   Wang C, 2016, MED SCI MONITOR, V22, P226, DOI 10.12659/MSM.897044
   Wang CS, 2019, ARTIF CELL NANOMED B, V47, P603, DOI 10.1080/21691401.2019.1573189
   Wright NC, 2017, OSTEOPOROSIS INT, V28, P1225, DOI 10.1007/s00198 016 3865 3
   Xu XL, 2017, ARTIF CELL NANOMED B, V45, P330, DOI 10.3109/21691401.2016.1153480
   Yang J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187537
   Yang YQ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00487
   Zhang P, 2018, J BIOENERG BIOMEMBR, V50, P271, DOI 10.1007/s10863 018 9763 y
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhang YQ, 2017, AM J TRANSL RES, V9, P126
NR 43
TC 24
Z9 26
U1 2
U2 13
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD SEP
PY 2020
VL 129
AR 109796
DI 10.1016/j.biopha.2019.109796
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NJ9QD
UT WOS:000566377400003
PM 32559615
OA gold
DA 2025 08 17
ER

PT J
AU Riggs, BL
   Parfitt, AM
AF Riggs, BL
   Parfitt, AM
TI Drugs used to treat osteoporosis: The critical need for a uniform
   nomenclature based on their action on bone remodeling
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE bone densitometry; bone histomorphometry; osteoblasts; osteoporosis;
   novel entities
ID PARATHYROID HORMONE 1 34; VERTEBRAL FRACTURE RISK; POSTMENOPAUSAL WOMEN;
   MINERAL DENSITY; OSTEOBLAST APOPTOSIS; REPLACEMENT THERAPY; BIOCHEMICAL
   MARKERS; TRABECULAR BONE; LONG TERM; ESTROGEN
AB There continues to be uncertainty about the classification of available drugs for treating osteoporosis. We find that grouping them into anti catabolic and anabolic classes based on the mechanisms of their action on bone remodeling and fracture reduction removes ambiguities and provides a relatively straightforward classification.
C1 Mayo Clin, Coll Med, Endocrine Res Unit, Div Endocrinol & Metab,Dept Internal Med, Rochester, MN 55905 USA.
   Univ Arkansas Med Sci, Dept Internal Med, Ctr Osteoporosis & Metab Bone Dis, Div Endocrinol & Metab, Little Rock, AR 72205 USA.
C3 Mayo Clinic; University of Arkansas System; University of Arkansas
   Medical Sciences
RP Riggs, BL (通讯作者)，Mayo Clin, Coll Med, Endocrine Res Unit, Div Endocrinol & Metab,Dept Internal Med, 200 1st St SW,5 194 Joseph, Rochester, MN 55905 USA.
EM Riggs.Lawrence@mayo.edu
FU NIAMS NIH HHS [AR27065] Funding Source: Medline; NIA NIH HHS [P01
   AG13918, P01 AG004875] Funding Source: Medline
CR AARON JE, 1992, BONE MINER, V17, P399, DOI 10.1016/0169 6009(92)90789 G
   BALENA R, 1992, J BONE MINER RES, V7, P1475
   BAUER DC, 2002, IOF WORLD C OST LISB
   Beck TJ, 2000, J BONE MINER RES, V15, P2297, DOI 10.1359/jbmr.2000.15.12.2297
   BELL G. H., 1967, CALCIFIED TISSUE RES, V1, P75, DOI 10.1007/BF02008077
   Bouxsien ML., 2001, Osteoporosis, V2nd, P509, DOI [10.1016/B978 012470862 4/50020 9, DOI 10.1016/B978 012470862 4/50020 9, 10.1016/b978 012470862 4/50020 9]
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   CHESTNUT CH, 1995, AM J MED, V99, P144, DOI 10.1016/S0002 9343(99)80134 X
   Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301
   Delmas PD, 2000, BONE, V26, P553, DOI 10.1016/S8756 3282(00)00271 4
   Dempster DW, 2001, J BONE MINER RES, V16, pS179
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Eastell R, 2003, J BONE MINER RES, V18, P1051, DOI 10.1359/jbmr.2003.18.6.1051
   EASTELL R, 2002, IOF WORLD C OST LISB
   Eriksen EF, 1999, J BONE MINER RES, V14, P1217, DOI 10.1359/jbmr.1999.14.7.1217
   Falahati Nini A, 2000, J CLIN INVEST, V106, P1553, DOI 10.1172/JCI10942
   Frost H M, 1998, J Orthop Sci, V3, P282, DOI 10.1007/s007760050054
   GARNERO P, 1994, J CLIN ENDOCR METAB, V78, P955, DOI 10.1210/jc.78.4.955
   Garnero P, 2000, J BONE MINER RES, V15, P1526, DOI 10.1359/jbmr.2000.15.8.1526
   Hock JM, 1999, J CLIN INVEST, V104, P371, DOI 10.1172/JCI7991
   Hodsman AB, 2003, J CLIN ENDOCR METAB, V88, P5212, DOI 10.1210/jc.2003 030768
   HODSMAN AB, 1993, BONE, V14, P523, DOI 10.1016/8756 3282(93)90190 L
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Jerome CP, 2001, BONE, V28, P150, DOI 10.1016/S8756 3282(00)00430 0
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kenny AM, 2001, J GERONTOL A BIOL, V56, pM266, DOI 10.1093/gerona/56.5.M266
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   LINDSAY R, 2003, J BONE MINER RES, V18, pS1
   LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003 4819 117 1 1
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Modelska K, 2002, J CLIN ENDOCR METAB, V87, P16, DOI 10.1210/jc.87.1.16
   MOSEKILDE L, 1987, BONE, V8, P79, DOI 10.1016/8756 3282(87)90074 3
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   *OST METH GROUP OS, 2002, ENDOCR REV, V23, P495
   Parfitt A.M., 2002, DISORDERS BONE MINER, V2nd, P469
   PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096
   Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756 3282(01)00642 1
   Parfitt AM, 1996, J BONE MINER RES, V11, P150
   PARFITT AM, 1980, MINER ELECTROL METAB, V4, P273
   PARFITT AM, 2002, RECENT CONTRIBUTION
   PARFITT AM, 1993, OSTEOPOROSIS, P164
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Rehman Q, 2003, OSTEOPOROSIS INT, V14, P77, DOI 10.1007/s00198 002 1312 0
   RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203
   Riggs BL, 2002, J BONE MINER RES, V17, P11, DOI 10.1359/jbmr.2002.17.1.11
   RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605
   RIGGS BL, 1996, BONE, V18, P197
   RIGGS BL, 1993, 4 INT S OST CONS DEV, P13
   Rittmaster RS, 2000, J CLIN ENDOCR METAB, V85, P2129, DOI 10.1210/jc.85.6.2129
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rosen CJ, 2003, J BONE MINER RES, V18, P406, DOI 10.1359/jbmr.2003.18.3.406
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Sarkar S, 2002, J BONE MINER RES, V17, P1, DOI 10.1359/jbmr.2002.17.1.1
   Sarkar S, 2004, J BONE MINER RES, V19, P394, DOI 10.1359/JBMR.0301243
   UUSIRASI K, 2002, J BONE MINER RES, V17, pS1
   Vedi S, 1999, OSTEOPOROSIS INT, V10, P52, DOI 10.1007/s001980050194
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
NR 63
TC 276
Z9 312
U1 0
U2 16
PU AMER SOC BONE & MINERAL RES
PI WASHINGTON
PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036 3309 USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2005
VL 20
IS 2
BP 177
EP 184
DI 10.1359/JBMR.041114
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 889RT
UT WOS:000226460800001
PM 15647810
DA 2025 08 17
ER

PT J
AU Wang, H
   Ashton, R
   Hensel, JA
   Lee, JH
   Khattar, V
   Wang, Y
   Deshane, JS
   Ponnazhagan, S
AF Wang, Hong
   Ashton, Reading
   Hensel, Jonathan A.
   Lee, Joo Hyoung
   Khattar, Vinayak
   Wang, Yong
   Deshane, Jessy S.
   Ponnazhagan, Selvarangan
TI RANKL Targeted Combination Therapy with Osteoprotegerin Variant Devoid
   of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and
   Antitumor Immunity
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID REGULATORY T CELLS; FACTOR KAPPA B; BREAST CANCER; TUMOR
   MICROENVIRONMENT; RECEPTOR ACTIVATOR; OSTEOCLAST DIFFERENTIATION; CCL22
   CHEMOKINES; DOUBLE BLIND; LIGAND; BONE
AB Complexities in treating breast cancer with bone metastasis are enhanced by a vicious protumorigenic pathology, involving a shift in skeletal homeostasis toward aggressive osteoclast activity and polarization of immune cells supporting tumor growth and immunosuppression. Recent studies signify the role of receptor activator of NF kappa B ligand (RANKL) beyond skeletal pathology in breast cancer, including tumor growth and immunosuppression. By using an osteoprotegerin (OPG) variant, which we developed recently through protein engineering to uncouple TNF related apoptosis inducing ligand (TRAIL) binding, this study established the potential of a cell based OPG(Y49R) therapy for both bone damage and immunosuppression in an immunocompetent mouse model of orthotopic and metastatic breast cancers. In combination with agonistic death receptor (DR5) activation, the OPG(Y49R) therapy significantly increased both bone remolding and long term antitumor immunity, protecting mice from breast cancer relapse and osteolytic pathology. With limitations, cost, and toxicity issues associated with the use of denosumab, bisphosphonates, and chemotherapy for bone metastatic disease, use of OPG(Y49R) combination could offer a viable alternate therapeutic approach.
C1 [Wang, Hong; Ashton, Reading; Hensel, Jonathan A.; Lee, Joo Hyoung; Khattar, Vinayak; Ponnazhagan, Selvarangan] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Wang, Yong; Deshane, Jessy S.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Ponnazhagan, S (通讯作者)，Univ Alabama Birmingham, 1825 Univ Blvd,SHEL 814, Birmingham, AL 35294 USA.
EM sponnazh@uabmc.edu
RI Khattar, Vinayak/K 6269 2019; Lee, Joo/A 7713 2017
FU NIH [R01 AR060948, R01CA184770, R01HL128502]; Breast Cancer Research
   Foundation of Alabama
FX This work was supported by NIH grants R01 AR060948 and R01CA184770 (to
   S. Ponnazhagan) and R01HL128502 (to J.S. Deshane), and grants from the
   Breast Cancer Research Foundation of Alabama (to S. Ponnazhagan). We
   thank the Heflin Center Genomics Core, the Pathology Research Core, the
   Small Animal Bone Phenotyping Core, the Preclinical Shared Imaging
   Facility, and the Comprehensive Flow Cytometry Core at UAB for support
   with DNA sequencing, histology, mu CT scan, IVIS imaging, and flow
   cytometry analyses, respectively.
CR Adler RA, 2011, CLIN INTERV AGING, V6, P119, DOI 10.2147/CIA.S14565
   Ahern E, 2018, NAT REV CLIN ONCOL, V15, P676, DOI 10.1038/s41571 018 0095 y
   Ahern E, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1431088
   Ahern E, 2017, CLIN CANCER RES, V23, P5789, DOI 10.1158/1078 0432.CCR 17 0606
   Arlauckas SP, 2018, THERANOSTICS, V8, P5842, DOI 10.7150/thno.26888
   Barriga V, 2019, CANCERS, V11, DOI 10.3390/cancers11081205
   Bhatia P, 2005, CLIN CANCER RES, V11, P162
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chypre M, 2016, IMMUNOL LETT, V171, P5, DOI 10.1016/j.imlet.2016.01.003
   D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004
   Del Alcazar CRG, 2020, CANCER IMMUNOL RES, V8, P422, DOI 10.1158/2326 6066.CIR 19 0786
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Dou C, 2018, J BONE MINER RES, V33, P899, DOI 10.1002/jbmr.3364
   Force J, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864 019 0634 5
   Francisconi CF, 2018, J DENT RES, V97, P917, DOI 10.1177/0022034518759302
   Fujimura T, 2016, EXP DERMATOL, V25, P397, DOI 10.1111/exd.12949
   Fujimura T, 2015, J INVEST DERMATOL, V135, P2884, DOI 10.1038/jid.2015.209
   Gnant M, 2019, LANCET ONCOL, V20, P339, DOI 10.1016/S1470 2045(18)30862 3
   Gnant M, 2015, LANCET, V386, P433, DOI 10.1016/S0140 6736(15)60995 3
   Gonzalez Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
   Guo BC, 2016, SCI REP UK, V6, DOI 10.1038/srep36107
   Higgs JT, 2017, BLOOD ADV, V1, P2375, DOI 10.1182/bloodadvances.2017007310
   Higgs JT, 2015, MOL CANCER RES, V13, P819, DOI 10.1158/1541 7786.MCR 14 0492
   Huang Y, 2019, MOL IMMUNOL, V107, P1, DOI 10.1016/j.molimm.2018.12.027
   Infante M, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 018 1001 2
   Khan AA, 2017, J CLIN DENSITOM, V20, P8, DOI 10.1016/j.jocd.2016.09.005
   Lin JQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10562
   Maruyama T, 2010, DIS ESOPHAGUS, V23, P422, DOI 10.1111/j.1442 2050.2009.01029.x
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Meng YH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.505
   Mizukami Y, 2008, INT J CANCER, V122, P2286, DOI 10.1002/ijc.23392
   Nolan E, 2016, NAT MED, V22, P933, DOI 10.1038/nm.4118
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Rao S, 2018, TRENDS CELL BIOL, V28, P213, DOI 10.1016/j.tcb.2017.11.001
   Reck M, 2013, LUNG CANCER, V82, P441, DOI 10.1016/j.lungcan.2013.09.014
   Reyes ME, 2017, BREAST CANCER RES TR, V164, P57, DOI 10.1007/s10549 017 4233 5
   Sarink D, 2017, CANCER PREV RES, V10, P525, DOI 10.1158/1940 6207.CAPR 17 0125
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Shi HF, 2018, CANCER SCI, V109, P3826, DOI 10.1111/cas.13809
   Shipman CM, 2003, CANCER RES, V63, P912
   Smyth MJ, 2016, J CLIN ONCOL, V34, pE104, DOI 10.1200/JCO.2013.51.3572
   Takeda K, 2004, J EXP MED, V199, P437, DOI 10.1084/jem.20031457
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Thosani S, 2015, FUTURE ONCOL, V11, P2865, DOI 10.2217/fon.15.232
   Turner MD, 2014, BBA MOL CELL RES, V1843, P2563, DOI 10.1016/j.bbamcr.2014.05.014
   van Dam PA, 2019, CRIT REV ONCOL HEMAT, V133, P85, DOI 10.1016/j.critrevonc.2018.10.011
   Voronov E, 2017, CURR PHARM DESIGN, V23, P4893, DOI 10.2174/1381612823666170613080919
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang N, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0876 3
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Xia LZ, 2018, ONCOTARGETS THER, V11, P2063, DOI 10.2147/OTT.S161109
NR 51
TC 7
Z9 7
U1 1
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD DEC 1
PY 2020
VL 19
IS 12
BP 2585
EP 2597
DI 10.1158/1535 7163.MCT 20 0378
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA QE7GE
UT WOS:000616373800016
PM 33199500
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Lee, J
   Kim, JH
   Kim, K
   Jin, HM
   Lee, KB
   Chung, DJ
   Kim, N
AF Lee, Junwon
   Kim, Jung Ha
   Kim, Kabsun
   Jin, Hey Mi
   Lee, Keun Bae
   Chung, Dong Jin
   Kim, Nacksung
TI Ribavirin enhances osteoclast formation through osteoblasts via
   up regulation of TRANCE/RANKL
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE ribavirin; TRANCE; RANKL; osteoclastogenesis; hepatitis C
ID CHRONIC HEPATITIS C; RECEPTOR GENE EXPRESSION; NECROSIS FACTOR RECEPTOR;
   BONE MINERAL DENSITY; ALPHA INTERFERON; DIFFERENTIATION; OSTEODYSTROPHY;
   COMBINATION; INDUCTION; CIRRHOSIS
AB Hepatitis C combination therapy comprising ribavirin and interferon alpha causes dramatic improvement with the sustained virological response; however, this treatment may result in the loss of bone mineral density. To investigate the effects of ribavirin on bone cells, we examined osteoblast differentiation as well as the formation of osteoclasts from their precursors. Ribavirin enhances osteoclast formation through osteoblasts by up regulation of TRANCE/RANKL gene expression, whereas it has no significant effect on either osteoblast differentiation or on bone formation. Understanding ribavirin's underlying mechanism of action on bone cells will enable the improved management of bone loss in chronic hepatitis C patients.
C1 Chonnam Natl Univ, Sch Med, Med Res Ctr Gene Regulat, Kwangju 501746, South Korea.
   Chonnam Natl Univ, Sch Med, Res Inst Med Sci, Kwangju 501746, South Korea.
C3 Chonnam National University; Chonnam National University
RP Kim, N (通讯作者)，Chonnam Natl Univ, Sch Med, Med Res Ctr Gene Regulat, Hak Dong 5, Kwangju 501746, South Korea.
EM nacksung@jnu.ac.kr
RI ; lee, Jaeho/KEH 5184 2024
OI Lee, junwon/0009 0006 9313 3612; 
CR Coelho LFL, 2005, P NATL ACAD SCI USA, V102, P11917, DOI 10.1073/pnas.0502188102
   Crosbie OM, 1999, CALCIFIED TISSUE INT, V64, P295, DOI 10.1007/s002239900622
   Gallego Rojo FJ, 1998, HEPATOLOGY, V28, P695, DOI 10.1002/hep.510280315
   Glue P, 1999, SEMIN LIVER DIS, V19, P17
   GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841
   HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   McHutchison JG, 1999, SEMIN LIVER DIS, V19, P57
   Moreira RO, 2004, CALCIFIED TISSUE INT, V75, P160, DOI 10.1007/s00223 004 0175 0
   So H, 2003, J BIOL CHEM, V278, P24209, DOI 10.1074/jbc.M302940200
   Solís Herruzo JA, 2000, J HEPATOL, V33, P812, DOI 10.1016/S0168 8278(00)80314 1
   Suda T, 1997, METHOD ENZYMOL, V282, P223
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Trombetti A, 2002, HEPATOLOGY, V36, P255, DOI 10.1053/jhep.2002.33711
   Tsuneoka K, 1996, J GASTROENTEROL, V31, P669, DOI 10.1007/BF02347615
   van der Merwe SW, 2003, GUT, V52, P580, DOI 10.1136/gut.52.4.580
   Weide R, 1996, ANN HEMATOL, V72, P41
   Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301
NR 19
TC 16
Z9 17
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300 8177
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD FEB
PY 2007
VL 296
IS 1 2
BP 17
EP 24
DI 10.1007/s11010 006 9293 5
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 143AH
UT WOS:000244691900003
PM 16909305
DA 2025 08 17
ER

PT J
AU Plotkin, LI
   Bivi, N
   Bellido, T
AF Plotkin, L. I.
   Bivi, Nicoletta
   Bellido, T.
TI A bisphosphonate that does not affect osteoclasts prevents osteoblast
   and osteocyte apoptosis and the loss of bone strength induced by
   glucocorticoids in mice
SO BONE
LA English
DT Article
DE Bisphosphonate; Apoptosis; Osteocyte; Osteoblast; Glucocorticoid; Bone
   strength
ID IN VIVO; OSTEOPOROSIS; ALENDRONATE; HISTOMORPHOMETRY; ACTIVATION;
   DISSOCIATION; INTERMITTENT; CONNEXIN 43; RISEDRONATE; INHIBITION
AB Although a major effect of bisphosphonates on bone is inhibition of resorption resulting from their ability to interfere with osteoclast function, these agents also prevent osteoblast and osteocyte apoptosis in vitro and in vivo. However, the contribution of the latter property to the overall beneficial effects of the drugs on bone remains unknown. We compared herein the action on glucocorticoid induced bone disease of the classical bisphosphonate alendronate with that of IG9402, a bisphosphonate analog that preserves osteoblast and osteocyte viability but does not induce osteoclast apoptosis in vitro. The bisphosphonates were injected daily (2.3 mu mol/kg) to 5 month old Swiss Webster mice (6 11 per group), starting 3 days before implantation of pellets releasing the glucocorticoid prednisolone (2.1 mg/kg/day). IG9402 did not affect levels of circulating C telopeptide or osteocalcin, markers of resorption and formation, respectively, nor did it decrease mRNA levels of osteocalcin or collagen 1a1 in bone. On the other hand, alendronate decreased all these parameters. Moreover, IG9402 did not reduce cancellous mineralizing surface, mineral apposition rate, or bone formation rate, whereas alendronate induced a decrease in each of these bone formation measures. These findings demonstrate that, in contrast to alendronate, IG9402 does not inhibit bone turnover. Both alendronate and IG9402, on the other hand, activated survival kinase signaling in vivo, as evidenced by induction of ERK phosphorylation in bone. Furthermore, both bisphosphonates prevented the increase in osteoblast and osteocyte apoptosis as well as the decrease in vertebral bone mass and strength induced by glucocorticoids. We conclude that a bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice.
   This article is part of a Special Issue entitled Bisphosphonates. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Plotkin, L. I.; Bivi, Nicoletta; Bellido, T.] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [Bellido, T.] Indiana Univ Sch Med, Dept Med, Div Endocrinol, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington
RP Plotkin, LI (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS 5035, Indianapolis, IN 46202 USA.
EM lplotkin@iupui.edu; nicobivi@iupui.edu; tbellido@iupui.edu
RI ; Plotkin, Lilian/H 7188 2019
OI Bellido, Teresita/0000 0002 8203 7004; Plotkin,
   Lilian/0000 0002 9537 4544
FU National Institutes of Health [R01 AR053643, KO2 AR02127, R03 TW006919,
   R01 DK076007, P01 AG13918]
FX The authors thank Kanan Vyas, Joseph Goellner, Keith Condon, and Jeffrey
   Benson for technical assistance; the histomorphometry core at UAMS for
   processing the bone samples; and Stavros C. Manolagas, Robert S.
   Weinstein, A. Michael Parfitt, and other members of the UAMS Center for
   Osteoporosis and Metabolic Bone Diseases, and David Burr and Matthew
   Allen from the Anatomy and Cell Biology Department at IUSM, for advice
   and insightful discussions. This research was supported by the National
   Institutes of Health (R01 AR053643 to LIP and, KO2 AR02127, R03
   TW006919, R01 DK076007, and P01 AG13918 to TB).
CR Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   BALENA R, 1993, J CLIN INVEST, V92, P2577, DOI 10.1172/JCI116872
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   BOYCE RW, 1995, J BONE MINER RES, V10, P211
   Brown RJ, 1998, J BONE MINER RES, V13, P253, DOI 10.1359/jbmr.1998.13.2.253
   Brumsen C, 1997, MEDICINE, V76, P266, DOI 10.1097/00005792 199707000 00005
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Cheung MS, 2009, J BONE MINER RES, V24, P669, DOI 10.1359/JBMR.081225
   Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195
   Follet H, 2007, BONE, V40, P1172, DOI 10.1016/j.bone.2006.12.052
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Jilka RL, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P237, DOI 10.1016/B978 0 12 373884 4.00032 X
   Kogianni G, 2004, LIFE SCI, V75, P2879, DOI 10.1016/j.lfs.2004.04.048
   Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Owens JM, 1997, J CELL PHYSIOL, V172, P79, DOI 10.1002/(SICI)1097 4652(199707)172:1<79::AID JCP9>3.0.CO;2 A
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200
   Plotkin LI, 2008, J BONE MINER RES, V23, P1712, DOI [10.1359/jbmr.080617, 10.1359/JBMR.080617]
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Rogers MJ, 2004, CALCIFIED TISSUE INT, V75, P451, DOI 10.1007/s00223 004 0024 1
   Sanders JM, 2004, J MED CHEM, V47, P375, DOI 10.1021/jm0303709
   STORM T, 1993, J BONE MINER RES, V8, P199
   vanBeek E, 1996, J BONE MINER RES, V11, P1492
   Weinstein RS, 2010, ENDOCRINOLOGY, V151, P2641, DOI 10.1210/en.2009 1488
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Weinstein RS, 2004, ENDOCRINOLOGY, V145, P1980, DOI 10.1210/en.2003 1133
NR 34
TC 73
Z9 87
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD JUL
PY 2011
VL 49
IS 1
SI SI
BP 122
EP 127
DI 10.1016/j.bone.2010.08.011
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 782MD
UT WOS:000292012900016
PM 20736091
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Jiang, M
   Wang, TQ
   Yan, XM
   Liu, ZC
   Yan, YF
   Yang, K
   Qi, J
   Zhou, HB
   Qian, ND
   Zhou, Q
   Chen, B
   Xu, X
   Xi, XB
   Yang, CH
   Deng, LF
AF Jiang, Min
   Wang, Tianqi
   Yan, Xueming
   Liu, Zhuochao
   Yan, Yufei
   Yang, Kai
   Qi, Jin
   Zhou, Hanbing
   Qian, Niandong
   Zhou, Qi
   Chen, Bo
   Xu, Xing
   Xi, Xiaobing
   Yang, Chunhao
   Deng, Lianfu
TI A Novel Rhein Derivative Modulates Bone Formation and Resorption and
   Ameliorates Estrogen Dependent Bone Loss
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOCLASTS; OSTEOBLASTS; OSTEOPOROSIS; THERAPEUTICS; BONE QCT/MICRO CT
ID HYDROGEN SULFIDE; OSTEOCLAST DIFFERENTIATION; IN VITRO; RANKL;
   GASOTRANSMITTER; PROLIFERATION; OSTEOBLAST; REGULATOR; STRONTIUM;
   DISEASE
AB Osteoporosis, an osteolytic disease that affects millions of people worldwide, features a bone remodeling imbalance between bone resorption by osteoclasts and bone formation by osteoblasts. Identifying dual target directed agents that inhibit excessive bone resorption and increase bone formation is considered an efficient strategy for developing new osteoporosis treatments. Rhein, a natural anthraquinone, can be isolated from various Asian herbal medicines. Rhein and its derivatives have been reported to have various beneficial pharmacological effects, especially their bone targeting ability and anti osteoclastogenesis activity. Moreover, hydrogen sulfide (H2S) was reported to prevent ovariectomy  (OVX ) induced bone loss by enhancing bone formation, and sulfur replacement therapy has been considered a novel and plausible therapeutic option. Based on this information, we synthesized a rhein derived thioamide (RT) and investigated its effects on bone resorption and bone formation in vitro and in vivo. It has been found that the RT inhibited receptor activator of the nuclear factor kappa B (NF kappa B) ligand  (RANKL ) induced osteoclastogenesis and bone resorption in a dose dependent manner. The expression of osteoclast marker genes was also suppressed by RT treatment. Furthermore, exploration of signal transduction pathways indicated that RT markedly blocked RANKL induced osteoclastogenesis by attenuating MAPK pathways. However, RT treatment in an osteoblastic cell line, MC3TE E1, indicated that RT led to an increase in the deposition of minerals and the expression of osteoblast marker genes, as demonstrated by Alizarin Red staining and alkaline phosphatase activity. Importantly, an OVX mouse model showed that RT could attenuate the bone loss in estrogen deficiency induced osteoporosis in vivo with a smart H2S releasing property and that there was a considerable improvement in the biomechanical properties of bone. Accordingly, our current work highlights the dual regulation of bone remodeling by the rhein derived molecule RT. This may be a highly promising approach for a new type of anti osteoporosis agent. (c) 2018 American Society for Bone and Mineral Research.
C1 [Jiang, Min; Wang, Tianqi; Yan, Xueming; Liu, Zhuochao; Yan, Yufei; Yang, Kai; Qi, Jin; Zhou, Hanbing; Qian, Niandong; Zhou, Qi; Chen, Bo; Xu, Xing; Xi, Xiaobing; Deng, Lianfu] Shanghai Jiao Tong Univ, Shanghai Key Lab Bone & Joint Dis, Shanghai Inst Traumatol & Orthopaed, Shanghai Ruijin Hosp,Sch Med, 197 2nd Ruijin Rd, Shanghai 200025, Peoples R China.
   [Yang, Chunhao] Chinese Acad Sci, State Key Lab Drug Res, Dept Med Chem, Shanghai Inst Mat Med, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China.
   [Xi, Xiaobing] Shanghai Jiao Tong Univ, Dept Traumatol, Shanghai Ruijin Hosp, Sch Med, 197 2nd Ruijin Rd, Shanghai 20025, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai
   Institute of Materia Medica, CAS; Shanghai Jiao Tong University
RP Xu, X (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Key Lab Bone & Joint Dis, Shanghai Inst Traumatol & Orthopaed, Shanghai Ruijin Hosp,Sch Med, 197 2nd Ruijin Rd, Shanghai 200025, Peoples R China.; Yang, CH (通讯作者)，Chinese Acad Sci, State Key Lab Drug Res, Dept Med Chem, Shanghai Inst Mat Med, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China.; Xi, XB (通讯作者)，Shanghai Jiao Tong Univ, Dept Traumatol, Shanghai Ruijin Hosp, Sch Med, 197 2nd Ruijin Rd, Shanghai 20025, Peoples R China.
EM xuxing0510315@126.com; skxixiaobing@163.com; chyang@simm.ac.cn
RI Zhou, Han/ISU 2803 2023; Yang, Kai/JQW 2039 2023; Wang,
   Tianqi/ABC 2166 2020; Zhou, Qi/JGM 4026 2023
OI Yang, Kai/0000 0002 5544 7817; Jiang, Min/0000 0003 1530 6830
FU NSFC [81703576, 81502902]; Shanghai Municipal Health Bureau young
   scientific research project [201840185, 20154Y0005]; Committee of
   Science and Technology youngscientific research foundation of Shanghai
   [16ZR1431900]; Guangci Distinguished Young Scholars Training Program
   [GCQN 2017 A16, GCQN 2017 B22]
FX This work was supported by the NSFC (No. 81703576, 81502902), Shanghai
   Municipal Health Bureau young scientific research project (No.
   201840185, No. 20154Y0005), Committee of Science and Technology
   youngscientific research foundation of Shanghai (No. 16ZR1431900),
   Guangci Distinguished Young Scholars Training Program (No.
   GCQN 2017 A16, GCQN 2017 B22).
CR Al Rashid M, 2015, ORTHOP CLIN N AM, V46, P577, DOI 10.1016/j.ocl.2015.06.008
   Bab I, 2008, BRIT J PHARMACOL, V153, P182, DOI 10.1038/sj.bjp.0707593
   Boileau C, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2444
   Boskey AL, 1996, CONNECT TISSUE RES, V35, P357, DOI 10.3109/03008209609029212
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cai J, 2012, EUR J MED CHEM, V55, P409, DOI 10.1016/j.ejmech.2012.07.053
   Chahl LA, 2004, BRIT J PHARMACOL, V142, P1, DOI 10.1038/sj.bjp.0705765
   Chan MV, 2013, AM J PHYSIOL GASTR L, V305, pG467, DOI 10.1152/ajpgi.00169.2013
   Corrado A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061272
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Ge Jian hua, 2015, Zhongguo Zhong Yao Za Zhi, V40, P2309
   Grassi F, 2016, J BONE MINER RES, V31, P949, DOI 10.1002/jbmr.2757
   Haouzi P, 2016, ANN NY ACAD SCI, V1374, P29, DOI 10.1111/nyas.13015
   Heath DJ, 2007, CANCER RES, V67, P202, DOI 10.1158/0008 5472.CAN 06 1287
   Kim JY, 2014, J BONE MINER RES, V29, P1541, DOI 10.1002/jbmr.2183
   Kimura H, 2005, ANTIOXID REDOX SIGN, V7, P795, DOI 10.1089/ars.2005.7.795
   Kong YY, 2000, EXP GERONTOL, V35, P947, DOI 10.1016/S0531 5565(00)00178 9
   Kurabayashi M, 2014, ARTERIOSCL THROM VAS, V34, P471, DOI 10.1161/ATVBAHA.114.303072
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li L, 2005, FASEB J, V19, P1196, DOI 10.1096/fj.04 3583fje
   Lv M, 2017, AM J TRANSL RES, V9, P1183
   Martelli A, 2013, ACS MED CHEM LETT, V4, P904, DOI 10.1021/ml400239a
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   NAWA H, 1961, J ORG CHEM, V26, P979, DOI 10.1021/jo01062a628
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Okamoto K, 2011, INT IMMUNOPHARMACOL, V11, P543, DOI 10.1016/j.intimp.2010.11.010
   Pilmane M, 2017, MAT SCI ENG C MATER, V78, P1222, DOI 10.1016/j.msec.2017.05.042
   Reid IR, 2011, SKELETAL RADIOL, V40, P1191, DOI 10.1007/s00256 011 1164 9
   Reuter S, 2012, BRIT J PHARMACOL, V165, P2127, DOI 10.1111/j.1476 5381.2011.01702.x
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Seeman Ego, 2004, Curr Osteoporos Rep, V2, P90, DOI 10.1007/s11914 004 0016 0
   Sharif PS, 2011, RHEUMATOL INT, V31, P289, DOI 10.1007/s00296 010 1586 z
   Shi CG, 2016, J BONE MINER RES, V31, P1003, DOI 10.1002/jbmr.2770
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Sun H, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00247
   Tsubota M, 2014, YAKUGAKU ZASSHI, V134, P1245, DOI 10.1248/yakushi.14 00209 2
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959 437X(00)00228 8
   Wang R, 2003, ANTIOXID REDOX SIGN, V5, P493, DOI 10.1089/152308603768295249
   Wang Y, 2011, MOL CELL ENDOCRINOL, V344, P59, DOI 10.1016/j.mce.2011.06.027
   Xu X, 2016, EUR J MED CHEM, V123, P769, DOI 10.1016/j.ejmech.2016.08.004
   Xu ZS, 2011, FREE RADICAL BIO MED, V50, P1314, DOI 10.1016/j.freeradbiomed.2011.02.016
   Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471 4914(02)02340 7
   YDE B, 1984, TETRAHEDRON, V40, P2047, DOI 10.1016/S0040 4020(01)88445 3
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
   Zhou YX, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/578107
   Zou W, 2010, ANN NY ACAD SCI, V1192, P27, DOI 10.1111/j.1749 6632.2009.05245.x
NR 50
TC 40
Z9 47
U1 1
U2 39
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2019
VL 34
IS 2
BP 361
EP 374
DI 10.1002/jbmr.3604
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HL3ZC
UT WOS:000458653600016
PM 30320929
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhang, YH
   Ma, JL
   Zhang, WF
AF Zhang, Yuhan
   Ma, Jinlong
   Zhang, Weifen
TI Berberine for bone regeneration: Therapeutic potential and molecular
   mechanisms
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Berberine; Bone regeneration; Traditional Chinese medicine; Drug
   delivery; Cellular mechanism
ID ATTENUATES OSTEOCLAST DIFFERENTIATION; RESORPTION IN VITRO; NF KAPPA B;
   OSTEOBLAST DIFFERENTIATION; KAMPO FORMULAS; ILIAC CREST; STEM CELLS;
   TISSUE; RANKL; GRAFT
AB Ethnopharmacological relevance: Berberine is a quaternary ammonium isoquinoline alkaloid, mainly extracted from plants berberaceae, papaveraceae, ranunculaceae and rutaceae such as coptis chinensis Franch, Phellodendron chinense, and berberis pruinosa. The plants are extensively used in traditional medicine for treating infection, diabetes, arrhythmia, tumor, osteoporosis et al. Pharmacological studies showed berberine has effects of antiinflammation, anti tumor, lower blood lipid, lower blood glucose, anti osteoporosis, anti osteoarthritis et al.
   Aim of the study: This review aims to summarize the application of natural herbs that contain berberine, the further use and development of berberine, the effects as well as mechanism of berberine on osteoblasts and osteoclasts, the recent advances of in vivo studies, in order to provide a scientific basis for its traditional uses and to prospect of the potential applications of berberine in clinics.
   Method: The research was achieved by retrieving from the online electronic database, including PubMed, Web of Science, Google Scholar and China national knowledge infrastructure (CNKI). Patents, doctoral dissertations and master dissertations are also searched.
   Results: Berberine has a long history of medicinal use to treat various diseases including bone disease in China. Recent studies have defined its function in promoting bone regeneration and great potential in developing new drugs. But the systemic mechanism of berberine on bone regeneration still needs more research to clarify.
   Conclusion: This review has systematically summarized the application, pharmacological effects, mechanism as well as in vivo studies of berberine and herbs which contain berberine. Berberine has a definite effect in promoting the proliferation and differentiation of osteoblasts as well as inhibiting the production of osteoclasts to promote bone regeneration. However, the present studies about the system mechanisms and pharmacological activity of berberine were incomplete. Applying berberine for new drug development remains an exciting and promising alternative to bone regeneration engineering, with broad potential for therapeutic and clinical practice.
C1 [Zhang, Yuhan] Weifang Med Univ, Clin Coll, Weifang 261053, Peoples R China.
   [Ma, Jinlong; Zhang, Weifen] Weifang Med Univ, Coll Pharm, Weifang 261053, Peoples R China.
   [Zhang, Yuhan; Ma, Jinlong; Zhang, Weifen] Weifang Med Univ, Collaborat Innovat Ctr Target Drug Delivery Syst, Weifang 261053, Shandong, Peoples R China.
   [Zhang, Yuhan; Zhang, Weifen] Weifang Med Univ, Shandong Engn Res Ctr Smart Mat & Regenerat Med, Weifang 261053, Shandong, Peoples R China.
C3 Shandong Second Medical University; Shandong Second Medical University;
   Shandong Second Medical University; Shandong Second Medical University
RP Ma, JL; Zhang, WF (通讯作者)，Weifang Med Univ, Coll Pharm, Weifang 261053, Peoples R China.
EM majinlong99@hotmail.com; zhangwf@wfmc.edu.cn
RI Zhang, Wei Fen/AAM 7180 2020; zhang, yuhan/HLH 1222 2023
OI Ma, Jinlong/0000 0002 4321 9024; 
FU National Natural Science Foundation of China [81774125, 81973671]; major
   innovation and technology engineering project of Shandong Province
   [2019JZZY011106]
FX The authors are indebted to the financial support from the National
   Natural Science Foundation of China (No.81774125, 81973671) and the
   major innovation and technology engineering project of Shandong Province
   (2019JZZY011106) .
CR Adil M, 2017, BIOMED PHARMACOTHER, V94, P1010, DOI 10.1016/j.biopha.2017.08.001
   Ali IHA, 2014, BRIT J PHARMACOL, V171, P3620, DOI 10.1111/bph.12724
   [Anonymous], 2009, MODERN TRAD CHIN MED
   Awale G, 2017, CURR PHARM DESIGN, V23, P3585, DOI 10.2174/1381612823666170516145800
   Baker DD, 2004, CURR OPIN BIOTECH, V15, P576, DOI 10.1016/j.copbio.2004.09.003
   Basha RY, 2015, MAT SCI ENG C MATER, V57, P452, DOI 10.1016/j.msec.2015.07.016
   Bebek G, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471 2105 8 335
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cai B, 2018, ACS APPL MATER INTER, V10, P25099, DOI 10.1021/acsami.8b06648
   Chen PF, 2018, MAT SCI ENG C MATER, V91, P190, DOI 10.1016/j.msec.2018.05.034
   Chen W, 2011, AAPS PHARMSCITECH, V12, P705, DOI 10.1208/s12249 011 9632 z
   Chinese Pharmacopoeia Commission, 2020, CHINESE PHARMACOPOEI, V1, P305
   Delloye C, 2007, J BONE JOINT SURG BR, V89B, P574, DOI 10.1302/0301 620X.89B5.19039
   Deng YJ, 2016, CELL REP, V14, P2224, DOI 10.1016/j.celrep.2016.02.021
   Dimitriou R, 2011, INJURY, V42, pS3, DOI 10.1016/j.injury.2011.06.015
   Dinesh P, 2018, CYTOKINE, V106, P54, DOI 10.1016/j.cyto.2018.03.005
   Duplomb L, 2007, STEM CELLS, V25, P544, DOI 10.1634/stemcells.2006 0395
   Gentile P, 2014, INT J MOL SCI, V15, P3640, DOI 10.3390/ijms15033640
   Gerstenfeld LC, 2003, J BONE MINER RES, V18, P1584, DOI 10.1359/jbmr.2003.18.9.1584
   Giannoudis PV, 2005, INJURY, V36, P20, DOI 10.1016/j.injury.2005.07.029
   Goulet JA, 1997, CLIN ORTHOP RELAT R, P76
   Gu CM, 2020, BMC BIOL, V18, DOI 10.1186/s12915 020 00766 8
   Haidar ZS, 2009, BIOTECHNOL LETT, V31, P1825, DOI 10.1007/s10529 009 0100 8
   Han SY, 2019, AM J CHINESE MED, V47, P439, DOI [10.1142/S0192415X19500228, 10.1142/s0192415x19500228]
   Han Y, 2018, BIOCHEM BIOPH RES CO, V504, P340, DOI 10.1016/j.bbrc.2018.08.192
   Han Y, 2017, PHARMACOL RES, V119, P463, DOI 10.1016/j.phrs.2017.03.002
   He XF, 2017, BOSNIAN J BASIC MED, V17, P295, DOI 10.17305/bjbms.2017.2596
   Holick MF, 2010, J BONE MINER METAB, V28, P342, DOI 10.1007/s00774 009 0141 z
   Holmes D, 2017, NATURE, V550, pS193, DOI 10.1038/550S193a
   Hu JP, 2008, EUR J PHARMACOL, V580, P70, DOI 10.1016/j.ejphar.2007.11.013
   Hu ZL, 2011, ARTHRITIS RHEUM US, V63, P949, DOI 10.1002/art.30202
   Huang C, 2006, BIOCHEM BIOPH RES CO, V348, P571, DOI 10.1016/j.bbrc.2006.07.095
   Huang D, 2011, J BIOMAT SCI POLYM E, V22, P931, DOI 10.1163/092050610X496576
   Imenshahidi M, 2016, PHYTOTHER RES, V30, P1745, DOI 10.1002/ptr.5693
   Isfort I, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 56247 8
   Ishikawa S, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/7262054
   Ishikawa S, 2015, IN VIVO, V29, P671
   Issa JP, 2016, CLIN ORAL IMPLAN RES, V27, P558, DOI 10.1111/clr.12622
   Jia X, 2019, J DENT RES, V98, P107, DOI 10.1177/0022034518797275
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Kong WJ, 2004, NAT MED, V10, P1344, DOI 10.1038/nm1135
   Lamb JJ, 2011, NUTR RES, V31, P347, DOI 10.1016/j.nutres.2011.03.016
   Laurencin C, 2006, EXPERT REV MED DEVIC, V3, P49, DOI 10.1586/17434440.3.1.49
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Lee JW, 2012, J NAT MED TOKYO, V66, P8, DOI 10.1007/s11418 011 0537 7
   Lee JW, 2010, BIOL PHARM BULL, V33, P1733, DOI 10.1248/bpb.33.1733
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lee YS, 2010, BONE, V47, P926, DOI 10.1016/j.bone.2010.08.001
   LeGeros RZ, 2008, CHEM REV, V108, P4742, DOI 10.1021/cr800427g
   Li A., 2014, [No title captured], Patent No. [104083466A, 104083466]
   Li H, 1998, BIOL PHARM BULL, V21, P1322, DOI 10.1248/bpb.21.1322
   Li H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113698
   Li HY, 1999, BIOL PHARM BULL, V22, P391, DOI 10.1248/bpb.22.391
   Li Q.j., 2018, CHIN J TISSUE ENG RE, V22, P4620
   Li WY, 2016, EXP THER MED, V12, P4041, DOI 10.3892/etm.2016.3866
   Li Z., 2017, [No title captured], Patent No. [107296929A, 107296929]
   Liu B., 2018, J PRACTICAL TRAD CHI, V34, P818
   Liu CS, 2016, FITOTERAPIA, V109, P274, DOI 10.1016/j.fitote.2016.02.001
   Liu Fang, 2013, Zhongguo Zhong Yao Za Zhi, V38, P3713
   Liu M, 2021, PHARMACOLOGY, V106, P70, DOI 10.1159/000508972
   Liu Z., 2020, J N PHARM, V17, P96
   Lu L, 2015, EVID BASED COMPL ALT, V2015, P824259
   Luo Y., 2016, CHIN J TISSUE ENG RE, V20, P4883
   Martiniakova M, 2020, J PHYSIOL PHARMACOL, V71, P307, DOI 10.26402/jpp.2020.3.01
   McCarty MF, 2014, AGE, V36, P641, DOI 10.1007/s11357 013 9595 y
   McMahon RE, 2013, J BIOMED MATER RES B, V101B, P387, DOI 10.1002/jbm.b.32823
   Moore WR, 2001, ANZ J SURG, V71, P354, DOI 10.1046/j.1440 1622.2001.2128.x
   Moussa Nabil Takahiro, 2020, Dent Clin North Am, V64, P473, DOI 10.1016/j.cden.2019.12.011
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Olivares Navarrete R, 2012, J BONE MINER RES, V27, P1773, DOI 10.1002/jbmr.1628
   Owen GR, 2018, J BIOMED MATER RES B, V106, P2493, DOI 10.1002/jbm.b.34049
   Park JW, 2017, MOLECULES, V22, DOI 10.3390/molecules22081259
   Qin LP, 2008, J ETHNOPHARMACOL, V118, P271, DOI 10.1016/j.jep.2008.04.009
   Qiu HW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051514
   Rahigude AB, 2012, MED HYPOTHESES, V79, P440, DOI 10.1016/j.mehy.2012.06.016
   Salgado AJ, 2004, MACROMOL BIOSCI, V4, P743, DOI 10.1002/mabi.200400026
   Sandra L.Colby., 2014, The Baby Boom cohort in the United States: 2012 to 2060: Population estimates and projections
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Schlundt C, 2018, BONE, V106, P78, DOI 10.1016/j.bone.2015.10.019
   Shao AL, 2018, ARTIF CELL NANOMED B, V46, pS359, DOI 10.1080/21691401.2018.1493489
   Sujitha S, 2020, EUR J PHARM BIOPHARM, V149, P170, DOI 10.1016/j.ejpb.2020.02.007
   Sujitha S, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105703
   Sun Q, 2019, J DENT, V82, P91, DOI 10.1016/j.jdent.2019.01.015
   Tang D, 2016, BIOMATERIALS, V83, P363, DOI 10.1016/j.biomaterials.2016.01.024
   Tang PF, 2014, RNA BIOL, V11, P1355, DOI 10.1080/15476286.2014.996462
   Tao K, 2016, TOXICOL LETT, V240, P68, DOI 10.1016/j.toxlet.2015.10.007
   Teo BHD, 2012, BIOCHEM J, V447, P229, DOI 10.1042/BJ20120888
   Wang JB, 2015, ACS APPL MATER INTER, V7, P26244, DOI 10.1021/acsami.5b08534
   Wang NN, 2019, J ETHNOPHARMACOL, V241, DOI 10.1016/j.jep.2019.111977
   Wang X., 2005, MED J COMMUN, P81
   Wei Peng, 2009, Zhong Xi Yi Jie He Xue Bao, V7, P342, DOI 10.3736/jcim20090408
   Wong SK, 2020, PHYTOMEDICINE, V73, DOI 10.1016/j.phymed.2019.152892
   Xian XY, 2014, J SEP SCI, V37, P1533, DOI 10.1002/jssc.201400012
   Xin BC, 2020, PATHOL ONCOL RES, V26, P1677, DOI 10.1007/s12253 019 00746 6
   Xing Fei, 2018, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V32, P1358, DOI 10.7507/1002 1892.201712118
   Xu DH, 2010, PLANTA MED, V76, P1809, DOI 10.1055/s 0030 1250040
   [许彦枝 Xu Yan zhi], 2009, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V13, P7341
   [许彦枝 XU Yanzhi], 2006, [牙体牙髓牙周病学杂志, Chinese journal of conservative dentistry], V16, P678
   [许彦枝 Xu Yanzhi], 2005, [重庆医科大学学报, Acta Universitatis Scientiae Medicinae Chongqing], V30, P78
   Xue LM, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/490843
   Yang BN, 2020, J CELL PHYSIOL, V235, P4698, DOI 10.1002/jcp.29348
   Yang X, 2007, BONE, V41, P928, DOI 10.1016/j.bone.2007.07.022
   Ye F, 2017, MOL MED REP, V16, P6228, DOI 10.3892/mmr.2017.7338
   Yelin E, 2016, SEMIN ARTHRITIS RHEU, V46, P259, DOI 10.1016/j.semarthrit.2016.07.013
   Yin J, 2008, METABOLISM, V57, P712, DOI 10.1016/j.metabol.2008.01.013
   Yu J, 2012, CHIN MED HERALD, V9, P13
   Yuan J.M., 2019, PHARM CLIN CHIN MAT, V10, P23
   Zhai T, 2005, ACTA MEDICINAE SINIC, P615
   Zhang JT, 2014, ACTA BIOMATER, V10, P1035, DOI 10.1016/j.actbio.2013.11.001
   Zhang R, 2019, EUR J PHARMACOL, V851, P144, DOI 10.1016/j.ejphar.2019.02.026
   Zhang XM, 2019, CARBOHYD POLYM, V213, P27, DOI 10.1016/j.carbpol.2019.02.038
   Zhao YR, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201900709
   Zhao Z., 2007, JTRAD CHIN ORTHOPEDI, P55
   Zhou L, 2015, INT J MOL SCI, V16, P27087, DOI 10.3390/ijms161125998
   Zhou R, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2021.11989
   Zhou XX, 2012, J SURG RES, V173, pE47, DOI 10.1016/j.jss.2011.11.004
   Zhou Y, 2015, APOPTOSIS, V20, P1187, DOI 10.1007/s10495 015 1152 y
   Zou K, 2017, ACTA PHARMACOL SIN, V38, P157, DOI 10.1038/aps.2016.125
   Zou Q, 2009, J BIOMED MATER RES A, V89A, P1108, DOI 10.1002/jbm.a.32199
   Zuo Yan Zuo Yan, 2013, Journal of Chongqing Medical University, V38, P997
NR 120
TC 47
Z9 51
U1 6
U2 117
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD SEP 15
PY 2021
VL 277
AR 114249
DI 10.1016/j.jep.2021.114249
EA JUN 2021
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA SV4EP
UT WOS:000663773900004
PM 34058315
DA 2025 08 17
ER

PT J
AU Zhang, SZ
   Zhan, JG
   Li, M
   Wang, JY
   Chen, HY
   Wang, YX
   Fan, YC
   Zhang, BQ
   Wang, X
   Zhang, XZ
   Wu, CM
AF Zhang, Shaozhuo
   Zhan, Jiaguo
   Li, Mai
   Wang, Junyi
   Chen, Huiyou
   Wang, Yuxing
   Fan, Yuchen
   Zhang, Bingqi
   Wang, Xi
   Zhang, Xizhe
   Wu, Chongming
TI Therapeutic Potential of Traditional Chinese Medicine Against
   Osteoarthritis: Targeting the Wnt Signaling Pathway
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Osteoarthritis; Traditional Chinese Medicine (TCM); Wingless Type (Wnt)
   Signaling Pathway; Active Components; Review
ID REGULATES CHONDROCYTE DIFFERENTIATION; WNT/BETA CATENIN;
   ARTICULAR CARTILAGE; RAT CHONDROCYTES; INHIBITS MMPS; CYCLIN D1;
   KAPPA B; EXPRESSION; PROLIFERATION; ASSOCIATION
AB Osteoarthritis (OA) is a chronic degenerative articular disease that leads to physical disability and reduced quality of life. The key pathological events in OA are cartilage degradation and synovial inflammation. Conventional therapies often lead to adverse effects that some patients are unwilling to endure. Traditional Chinese Medicines (TCMs) have long been known for their efficacy in treating OA with minimal side effects. The wingless type (Wnt) signaling pathway is believed to play a role in OA progression, but there is still a lack of comprehensive understanding on how TCM may treat OA via the Wnt signaling pathway. This study aims to fill this gap by reviewing relevant research on the association between the Wnt signaling pathway and cartilage degradation and synovial inflammation in OA. Meanwhile, we also summarized and categorized TCMs and their active components, such as alkaloids, polysaccharides, flavonoids, sesquiterpene lactones, etc., which have shown varying efficacy in treating OA through modulation of the Wnt/beta catenin signaling pathway. This work underscores the pivotal role of the Wnt signaling pathway in OA pathogenesis and progression, suggesting that targeting this pathway holds promise as a prospective therapeutic strategy for OA management in the future. TCMs and their active components have the potential to alleviate OA by modulating the Wnt signaling cascade. Harnessing TCMs and their active components to regulate the Wnt signaling pathway presents an encouraging avenue for delivering substantial therapeutic benefits to individuals with OA.
C1 [Zhang, Shaozhuo; Zhan, Jiaguo; Li, Mai; Wang, Junyi; Chen, Huiyou; Wang, Yuxing; Fan, Yuchen; Zhang, Bingqi; Wang, Xi; Zhang, Xizhe; Wu, Chongming] Tianjin Univ Tradit Chinese Med, Sch Chinese Mat Med, Poyanghu Rd 10, Tianjin 301617, Peoples R China.
   [Wu, Chongming] Tianjin Key Lab Therapeut Subst Tradit Chinese Med, Tianjin 301617, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine
RP Wu, CM (通讯作者)，Tianjin Univ Tradit Chinese Med, Sch Chinese Mat Med, Poyanghu Rd 10, Tianjin 301617, Peoples R China.
EM chomingwu@163.com
RI wang, yuxing/LXV 6834 2024; Zhang, Xizhe/J 7630 2019; Wu,
   Chongming/AAQ 9085 2021; Fan, Yu Chen/A 8035 2013
OI jiaguo, zhan/0009 0001 3921 1396; wang, jun yi/0009 0004 3073 8054; 
CR Allen KD, 2022, OSTEOARTHR CARTILAGE, V30, P184, DOI 10.1016/j.joca.2021.04.020
   Betancourt MCC, 2012, P NATL ACAD SCI USA, V109, P8218, DOI 10.1073/pnas.1119899109
   Bierma Zeinstra SMA, 2017, BEST PRACT RES CL RH, V31, P613, DOI 10.1016/j.berh.2018.08.006
   Blom AB, 2009, ARTHRITIS RHEUM, V60, P501, DOI 10.1002/art.24247
   Bougault C, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4599
   Bradley EW, 2011, J CELL PHYSIOL, V226, P1683, DOI 10.1002/jcp.22499
   Bradley EW, 2010, MOL ENDOCRINOL, V24, P1581, DOI 10.1210/me.2010 0037
   Cai X.Y., 2022, NEW CHIN MED, V54, P25, DOI DOI 10.13457/J.CNKI.JNCM.2022.03.006
   Cao X, 2021, BONE, V150, DOI 10.1016/j.bone.2021.116006
   Chan BY, 2011, OSTEOARTHR CARTILAGE, V19, P874, DOI 10.1016/j.joca.2011.04.014
   Chen WP, 2017, CELL PHYSIOL BIOCHEM, V43, P937, DOI 10.1159/000481645
   Cruciat CM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a015081
   de Lau WBM, 2012, GENOME BIOL, V13, DOI 10.1186/gb 2012 13 3 242
   Deshmukh V, 2019, OSTEOARTHR CARTILAGE, V27, P1347, DOI 10.1016/j.joca.2019.05.006
   Deshmukh V, 2018, OSTEOARTHR CARTILAGE, V26, P18, DOI 10.1016/j.joca.2017.08.015
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Ding ZF, 2020, INT IMMUNOPHARMACOL, V82, DOI 10.1016/j.intimp.2020.106367
   Dong XR, 2022, ACUPUNCT HERB MED, V2, P130, DOI 10.1097/HM9.0000000000000031
   Du GQ, 2015, CELL PHYSIOL BIOCHEM, V36, P2480, DOI 10.1159/000430208
   Duncan EJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12427
   Gao SG, 2016, EXP THER MED, V11, P1405, DOI 10.3892/etm.2016.3049
   Hall AJ, 2016, EUR J PREV CARDIOL, V23, P938, DOI 10.1177/2047487315610663
   Haynes KR, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4096
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He YZ, 2019, MOL MED REP, V20, P312, DOI 10.3892/mmr.2019.10239
   Hsu PS, 2017, OSTEOARTHR CARTILAGE, V25, P1026, DOI 10.1016/j.joca.2016.10.027
   Huang G, 2017, OSTEOARTHR CARTILAGE, V25, P1505, DOI 10.1016/j.joca.2017.05.018
   Huang JJ, 2020, STEM CELLS DEV, V29, P401, DOI 10.1089/scd.2019.0260
   Huang XB, 2021, CARTILAGE, V12, P496, DOI 10.1177/1947603519841676
   Hui TQ, 2018, INT J ORAL SCI, V10, DOI 10.1038/s41368 018 0016 z
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Hwang SG, 2005, FEBS LETT, V579, P4837, DOI 10.1016/j.febslet.2005.07.067
   Imai K, 2006, BIOCHEM BIOPH RES CO, V345, P1615, DOI 10.1016/j.bbrc.2006.05.075
   Jiang Y, 2022, OSTEOARTHR CARTILAGE, V30, P207, DOI 10.1016/j.joca.2021.11.009
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Krause Ulf, 2012, Curr Mol Pharmacol, V5, P164
   Kulkarni P, 2021, ADV CLIN CHEM, V100, P37, DOI 10.1016/bs.acc.2020.04.002
   Lee YH, 2021, CELL J, V22, P437, DOI 10.22074/cellj.2021.6927
   Lei SG, 2017, INT J BIOL MACROMOL, V99, P293, DOI 10.1016/j.ijbiomac.2017.02.087
   Li HT, 2013, INT J MOL MED, V32, P1329, DOI 10.3892/ijmm.2013.1527
   Li LQ, 2023, ACUPUNCT HERB MED, V3, P96, DOI 10.1097/HM9.0000000000000061
   LI Y, 2016, BIOMED RES INT, V2016, DOI DOI 10.1155/2016/9561058
   Liu FE, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.105954
   Liu SS, 2016, MOL MED REP, V13, P1999, DOI 10.3892/mmr.2016.4798
   Liu S, 2017, EXP THER MED, V14, P5057, DOI 10.3892/etm.2017.5165
   Liu W.G., 2017, HENAN TRADIT CHIN ME, V37, P911
   Liu ZF, 2018, EXP THER MED, V16, P5384, DOI 10.3892/etm.2018.6877
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lories RJU, 2007, ARTHRITIS RHEUM US, V56, P4095, DOI 10.1002/art.23137
   Loughlin J, 2004, P NATL ACAD SCI USA, V101, P9757, DOI 10.1073/pnas.0403456101
   Lu JW, 2018, BIOMED PHARMACOTHER, V108, P1029, DOI 10.1016/j.biopha.2018.09.075
   Ma CY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00700
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Marsh S, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.908507
   Monteagudo S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15889
   Nalesso G, 2013, OSTEOARTHR CARTILAGE, V21, pS226, DOI 10.1016/j.joca.2013.02.466
   Oh H, 2012, ARTHRITIS RHEUM US, V64, P2568, DOI 10.1002/art.34481
   Okura T, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 39393 x
   Pashirzad M, 2017, J CELL PHYSIOL, V232, P1611, DOI 10.1002/jcp.25687
   Peng Z., 2015, HUNAN J TRADIT CHIN, V31, P87
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Song H.B., 2021, SHAANXI J TRADIT CHI, V42, P18
   Song X.H., 2023, GUIZHOU MED J, V47, P749
   Staal F J, 2000, Hematol J, V1, P3, DOI 10.1038/sj.thj.6200001
   Stebbings S, 2016, CLIN RHEUMATOL, V35, P1829, DOI 10.1007/s10067 015 3110 z
   Sun B.R., 2023, CHIN MED MOD 501 EDU, V21, P97
   Sun MH, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02260 5
   Surmann Schmitt C, 2009, J CELL SCI, V122, P3627, DOI 10.1242/jcs.048926
   Tamamura Y, 2005, J BIOL CHEM, V280, P19185, DOI 10.1074/jbc.M414275200
   Tambiah JRS, 2022, AM J SPORT MED, V50, P630, DOI 10.1177/03635465211067201
   Tan M.Z., 2019, J HUBEI TRADIT CHIN, V21, P8
   Teufel S, 2022, J BONE MINER RES, V37, P1335, DOI 10.1002/jbmr.4569
   van den Bosch MH, 2017, ARTHRITIS RHEUMATOL, V69, P1978, DOI 10.1002/art.40206
   van den Bosch MH, 2016, J RHEUMATOL, V43, P1874, DOI 10.3899/jrheum.160270
   van den Bosch MH, 2015, AM J PATHOL, V185, P1970, DOI 10.1016/j.ajpath.2015.03.013
   Wang HR, 2016, SCI REP UK, V6, DOI 10.1038/srep39672
   Wang S., 2022, YUNNAN J TRADIT CHIN, V43, P33
   Wang S, 2021, BIOMED ENG ONLINE, V20, DOI 10.1186/s12938 021 00939 8
   Wang YD, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0411 x
   Wen YC, 2015, ONCOTARGET, V6, P21120, DOI 10.18632/oncotarget.4229
   Weng XP, 2014, INT J MOL MED, V34, P1045, DOI 10.3892/ijmm.2014.1869
   Wu S., 2016, CHIN J PHARMACOEPIDE, V25, P342
   Xia HT, 2020, BIOMED PHARMACOTHER, V122, DOI 10.1016/j.biopha.2019.109708
   Xie WQ, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906 019 2607 4
   Xu K, 2018, INT IMMUNOPHARMACOL, V63, P246, DOI 10.1016/j.intimp.2018.08.013
   Xu X.M., 2023, J PRACTICAL MED, V39
   Xu XL, 2019, CONNECT TISSUE RES, V60, P571, DOI 10.1080/03008207.2019.1601187
   Yan Chun Lu, 2018, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V34, P177, DOI 10.12047/j.cjap.5603.2018.043
   Yang YN, 2023, CHIN HERB MED, V15, P564, DOI 10.1016/j.chmed.2023.02.003
   Yang YA, 2022, FOOD FUNCT, V13, P7409, DOI [10.1039/D2FO01252A, 10.1039/d2fo01252a]
   Yao N, 2021, J TRADIT CHIN MED, V41, P935, DOI 10.19852/j.cnki.jtcm.2021.06.010
   Yasuhara R, 2011, LAB INVEST, V91, P1739, DOI 10.1038/labinvest.2011.144
   Yazici Y, 2021, OSTEOARTHR CARTILAGE, V29, P654, DOI 10.1016/j.joca.2021.02.004
   Yazici Y, 2017, OSTEOARTHR CARTILAGE, V25, P1598, DOI 10.1016/j.joca.2017.07.006
   Yu T, 2018, J CELL BIOCHEM, V119, P7419, DOI 10.1002/jcb.27051
   Yuan Qin, 2012, Zhongguo Gu Shang, V25, P761
   Yuan TB, 2022, ALTERN THER HEALTH M, V28, P28
   Yuasa T, 2009, AM J PATHOL, V175, P1993, DOI 10.2353/ajpath.2009.081173
   Zeng L, 2014, INT IMMUNOPHARMACOL, V18, P175, DOI 10.1016/j.intimp.2013.11.021
   Zeng LT, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.891822
   Zhao Y., 2023, MOD CHIN MED, V25, P314
   Zheng WW, 2017, INT J MOL MED, V40, P1377, DOI 10.3892/ijmm.2017.3148
   Zhong Gang, 2018, Cell Physiol Biochem, V51, P2575, DOI 10.1159/000495926
   Zhou R, 2020, N S ARCH PHARMACOL, V393, P991, DOI 10.1007/s00210 019 01766 4
   Zhou XD, 2016, INT IMMUNOPHARMACOL, V34, P129, DOI 10.1016/j.intimp.2016.02.029
   Zhou XD, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/809579
   Zhou Y, 2016, EUR J PHARMACOL, V789, P109, DOI 10.1016/j.ejphar.2016.07.027
   Zhu M, 2008, ARTHRITIS RHEUM US, V58, P2053, DOI 10.1002/art.23614
   Zhu M, 2009, J BONE MINER RES, V24, P12, DOI [10.1359/jbmr.080901, 10.1359/JBMR.080901]
   Zhu P., 2020, MED J W CHINA, V32, P1110
   Zhu YF, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.755260
   Zou LE, 2024, BIOMED PHARMACOTHER, V172, DOI 10.1016/j.biopha.2024.116302
NR 112
TC 2
Z9 2
U1 8
U2 9
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192 415X
EI 1793 6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2024
VL 52
IS 07
BP 2021
EP 2052
DI 10.1142/S0192415X24500782
EA NOV 2024
PG 32
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA P0C5U
UT WOS:001358001600001
PM 39562354
DA 2025 08 17
ER

PT J
AU Li, P
   Liu, CL
   Hu, M
   Long, M
   Zhang, D
   Huo, B
AF Li, Ping
   Liu, Chenglin
   Hu, Man
   Long, Mian
   Zhang, Ding
   Huo, Bo
TI Fluid Flow Induced Calcium Response in Osteoclasts: Signaling Pathways
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE Osteoclasts; Fluid shear stress; Calcium response; Signaling pathway;
   Differentiation
ID WAVE PROPAGATION; MEMBRANE STRETCH; DIFFERENTIATION; ATP; RECEPTOR;
   CA2+; ACTIVATION; INHIBITION; EXPRESSION; PROTEIN
AB Intracellular calcium oscillation and its downstream signaling in osteoclasts is believed to play critical roles in regulating bone resorption. Our previous study demonstrated that fluid shear stress (FSS) induced more calcium responsive peaks in the late differentiated osteoclasts than the early ones. In this paper, the signaling pathways of FSS induced calcium response for the osteoclasts in different differentiation stages were studied. RAW264.7 macrophage cells were induced to differentiate into osteoclasts with the conditioned medium from MC3T3 E1 osteoblasts. Furthermore pharmacological agents were added to block the specific signaling pathways. Finally the cells were exposed to FSS at different levels (1 or 10 dyne/cm(2)) after being induced for 4 or 8 days. The results showed that the mechanosensitive, cation selective channels, phospholipase C (PLC) and endoplasmic reticulum constituted the major signaling pathway for mechanical stimulation induced calcium response in osteoclasts. Extracellular calcium or ATP involved with calcium oscillation in a FSS magnitude dependent manner. This pathway study may help to give insight into the molecular mechanism of mechanical stimulation regulated bone remodeling.
C1 [Li, Ping; Liu, Chenglin; Huo, Bo] Beijing Inst Technol, Sch Aerosp Engn, Dept Mech, Beijing 100081, Peoples R China.
   [Li, Ping; Zhang, Ding] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Stomatol,Fac Surg, Beijing 100730, Peoples R China.
   [Li, Ping; Hu, Man; Long, Mian; Huo, Bo] Chinese Acad Sci, Inst Mech, Key Lab Micrograv, Beijing 100190, Peoples R China.
   [Li, Ping; Hu, Man; Long, Mian; Huo, Bo] Chinese Acad Sci, Inst Mech, Ctr Biomech & Bioengn, Beijing 100190, Peoples R China.
   [Li, Ping] Tianjin Med Univ, Canc Inst & Hosp, Dept Maxillofacial & ENT Oncol, Tianjin 300060, Peoples R China.
C3 Beijing Institute of Technology; Chinese Academy of Medical Sciences  
   Peking Union Medical College; Peking Union Medical College Hospital;
   Peking Union Medical College; Chinese Academy of Sciences; Institute of
   Mechanics, CAS; Chinese Academy of Sciences; Institute of Mechanics,
   CAS; Tianjin Medical University
RP Zhang, D (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Stomatol,Fac Surg, Beijing 100730, Peoples R China.
EM dingz77@sina.com; huobo@bit.edu.cn
RI Liu, Cheng Lin/JCO 6642 2023; Ma, Yulin/GRO 5114 2022; Hu,
   man/HPG 9675 2023; Huo, Bo/AAA 1331 2020
FU National Natural Science Foundation of China [11372043, 31070829];
   National Key Basic Research Foundation of China [2011CB710904];
   Fundamental Research Funds for the Central Universities [GZ2013015101]
FX This work was supported by the National Natural Science Foundation of
   China [11372043 (BH) and 31070829 (DZ)], National Key Basic Research
   Foundation of China grant [2011CB710904 (ML)] and the Fundamental
   Research Funds for the Central Universities [GZ2013015101 (BH)].
CR Adinolfi E, 2012, J OSTEOPOROS, V2012, DOI 10.1155/2012/637863
   Batra N, 2012, BBA BIOMEMBRANES, V1818, P1909, DOI 10.1016/j.bbamem.2011.09.018
   Bennett BD, 2001, ENDOCRINOLOGY, V142, P1968, DOI 10.1210/en.142.5.1968
   Brandao Burch Andrea, 2012, Front Endocrinol (Lausanne), V3, P41, DOI 10.3389/fendo.2012.00041
   Combs CE, 2012, J ENDOCRINOL, V212, P187, DOI 10.1530/JOE 11 0254
   Everaerts W, 2010, PROG BIOPHYS MOL BIO, V103, P2, DOI 10.1016/j.pbiomolbio.2009.10.002
   Fahlgren A, 2010, ACTA ORTHOP, V81, P508, DOI 10.3109/17453674.2010.504610
   Hazama R, 2009, GENES CELLS, V14, P871, DOI 10.1111/j.1365 2443.2009.01317.x
   Henriksen Z, 2006, CELL CALCIUM, V39, P435, DOI 10.1016/j.ceca.2006.01.012
   Hiken JF, 2004, AM J PHYSIOL CELL PH, V287, pC403, DOI 10.1152/ajpcell.00361.2003
   Huo B, 2010, CELL CALCIUM, V47, P234, DOI 10.1016/j.ceca.2009.12.005
   Huo B, 2010, PHILOS T R SOC A, V368, P617, DOI 10.1098/rsta.2009.0221
   Huo B, 2008, CELL MOL BIOENG, V1, P58, DOI 10.1007/s12195 008 0011 0
   Hwang SY, 2012, FASEB J, V26, P1484, DOI 10.1096/fj.11 194399
   Ilvesaro J, 2003, CRIT REV EUKAR GENE, V13, P133, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.70
   Johansson L, 2009, J BIOMECH ENG T ASME, V131, DOI 10.1115/1.3194756
   Kajiya H, 2012, ADV EXP MED BIOL, V740, P917, DOI 10.1007/978 94 007 2888 2_41
   Kim K, 2012, MOL CELLS, V33, P401, DOI 10.1007/s10059 012 0009 2
   Kuroda Y, 2008, P NATL ACAD SCI USA, V105, P8643, DOI 10.1073/pnas.0800642105
   Lemaire Irma, 2012, Front Biosci (Elite Ed), V4, P41
   Lev S, 2012, J BIOL CHEM, V287, P1436, DOI 10.1074/jbc.M111.266585
   Li P, 2012, ANN BIOMED ENG, V40, P1874, DOI 10.1007/s10439 012 0554 z
   Liu B, 2011, CARDIOVASC RES, V91, P124, DOI 10.1093/cvr/cvr033
   Lu XL, 2012, BONE, V51, P466, DOI 10.1016/j.bone.2012.05.021
   Lu XL, 2012, J BONE MINER RES, V27, P563, DOI 10.1002/jbmr.1474
   Masuyama R, 2008, CELL METAB, V8, P257, DOI 10.1016/j.cmet.2008.08.002
   Matemba SF, 2006, J CELL BIOCHEM, V99, P528, DOI 10.1002/jcb.20866
   Mentaverri R, 2006, FASEB J, V20, P2562, DOI 10.1096/fj.06 6304fje
   Miyazaki T, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.385369
   Mizoguchi F, 2008, J CELL PHYSIOL, V216, P47, DOI 10.1002/jcp.21374
   Nishii N, 2009, BIOL PHARM BULL, V32, P18, DOI 10.1248/bpb.32.18
   Noh ALSM, 2011, LIFE SCI, V89, P159, DOI 10.1016/j.lfs.2011.05.009
   O'Neil RG, 2005, PFLUG ARCH EUR J PHY, V451, P193, DOI 10.1007/s00424 005 1424 4
   Reyes Juan P, 2011, Front Biosci (Schol Ed), V3, P1101
   Sakai H, 2010, AM J PHYSIOL CELL PH, V299, pC570, DOI 10.1152/ajpcell.00486.2009
   Schilling AF, 2008, J CELL MOL MED, V12, P2497, DOI 10.1111/j.1582 4934.2008.00275.x
   Son A, 2012, KOREAN J PHYSIOL PHA, V16, P31, DOI 10.4196/kjpp.2012.16.1.31
   Sukharev Sergei, 2004, Sci STKE, V2004, pre4, DOI 10.1126/stke.2192004re4
   Thompson WR, 2011, J BONE MINER RES, V26, P2125, DOI 10.1002/jbmr.437
   Tsuzuki T, 2000, JPN J PHYSIOL, V50, P67, DOI 10.2170/jjphysiol.50.67
   Wiebe SH, 1999, CELL PHYSIOL BIOCHEM, V9, P323, DOI 10.1159/000016326
   WILTINK A, 1995, PFLUG ARCH EUR J PHY, V429, P663, DOI 10.1007/BF00373987
   XIA SL, 1995, J CELL PHYSIOL, V163, P493, DOI 10.1002/jcp.1041630309
   Xia SL, 1996, J CELL PHYSIOL, V167, P148, DOI 10.1002/(SICI)1097 4652(199604)167:1<148::AID JCP17>3.0.CO;2 7
   Yasuda E, 2008, BIOL PHARM BULL, V31, P719, DOI 10.1248/bpb.31.719
NR 45
TC 27
Z9 35
U1 0
U2 51
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0090 6964
EI 1573 9686
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD JUN
PY 2014
VL 42
IS 6
BP 1250
EP 1260
DI 10.1007/s10439 014 0984 x
PG 11
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA AG8FA
UT WOS:000335653000011
PM 24710796
DA 2025 08 17
ER

PT J
AU Southcott, D
   Awan, A
   Ghate, K
   Clemons, M
   Fernandes, R
AF Southcott, D.
   Awan, A.
   Ghate, K.
   Clemons, M.
   Fernandes, R.
TI Practical update for the use of bone targeted agents in patients with
   bone metastases from metastatic breast cancer or castration resistant
   prostate cancer
SO CURRENT ONCOLOGY
LA English
DT Article
DE Bony metastases; bisphosphonates; skeletal related events; bone targeted
   agents; denosumab
ID SKELETAL RELATED EVENTS; ZOLEDRONIC ACID; DOUBLE BLIND;
   CONTROLLED TRIAL; PHASE III; BISPHOSPHONATES; DENOSUMAB; PAMIDRONATE;
   PREVENTION; DISEASE
AB Bone metastases are a significant source of morbidity and mortality for patients with breast and prostate cancer. In this review, we discuss key practical themes regarding the use of bone targeted agents (BTAS) such as bisphosphonates and denosumab for managing bony metastatic disease. The BTAS both delay the onset and reduce the incidence of skeletal related events (SRES), defined as any or all of a need for radiation therapy or surgery to bone, pathologic fracture, spinal cord compression, or hypercalcemia of malignancy. They have more modest benefits for pain and other quality of life measures.
   Regardless of the benefits of BTAS, it should always be remembered that the palliative management of metastatic bone disease is multimodal and multidisciplinary. The collaboration of all disciplines is essential for optimal patient care.
   Special consideration is given to these key questions:
   What are BTAS, and what is their efficacy?
   What are their common toxicities?
   When should they be initiated?
   How do we choose the appropriate BTA?
   What is the appropriate dose, schedule, and duration of BTAS?
C1 [Southcott, D.; Fernandes, R.] Western Univ, Schulich Sch Med & Dent, Dept Oncol, Div Med Oncol, London, ON, Canada.
   [Awan, A.; Clemons, M.] Ottawa Hosp, Dept Med, Div Med Oncol, Ottawa, ON, Canada.
   [Awan, A.; Clemons, M.] Univ Ottawa, Ottawa, ON, Canada.
   [Ghate, K.] Oakville Trafalgar Mem Hosp, Div Med Oncol, Dept Med, Oakville, ON, Canada.
C3 Western University (University of Western Ontario); University of
   Ottawa; Ottawa Hospital Research Institute; University of Ottawa
RP Fernandes, R (通讯作者)，Univ Western Ontario, Div Med Oncol, London Reg Canc Program, 790 Commissioners Rd East, London N6A 4L6, England.
EM ricardo.fernandes@lhsc.on.ca
CR Adami S, 1997, CANCER, V80, P1674, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1674::AID CNCR18>3.0.CO;2 X
   Alibhai SMH, 2017, CLIN ONCOL UK, V29, P348, DOI 10.1016/j.clon.2017.01.007
   Amadori D, 2013, LANCET ONCOL, V14, P663, DOI 10.1016/S1470 2045(13)70174 8
   [Anonymous], 2017, COCHRANE DB SYST REV
   Awan AA, 2019, BREAST CANCER RES TR, V176, P507, DOI 10.1007/s10549 019 05265 1
   Body JJ, 2015, EUR J CANCER, V51, P1812, DOI 10.1016/j.ejca.2015.05.016
   Bouganim N, 2011, SUPPORT CARE CANCER, V19, P1687, DOI 10.1007/s00520 011 1230 9
   Bouganim N, 2011, FUTURE ONCOL, V7, P381, DOI [10.2217/FON.10.192, 10.2217/fon.10.192]
   Clemons M, 2012, CURR ONCOL, V19, P259, DOI 10.3747/co.19.1011
   Clemons M, 2019, ANN ONCOL, V30, piii72
   Clemons MJ, 2019, J CLIN ONCOL, V37
   Coleman R, 2004, ANN ONCOL, V25, piii124
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Coleman RE, 2010, CANCER TREAT REV, V36, P615, DOI 10.1016/j.ctrv.2010.04.003
   DJULBEGOVIC B, 2002, COCHRANE DB SYST REV
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Jacobs C, 2016, BREAST CANCER RES TR, V155, P77, DOI 10.1007/s10549 015 3646 2
   James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140 6736(15)01037 5
   Kawai AT, 2019, PROSTATE CANCER US, V2019, DOI 10.1155/2019/5971615
   Khan SA, 1997, J BONE MINER RES, V12, P1700, DOI 10.1359/jbmr.1997.12.10.1700
   KOIZUMI M, 1995, J CANCER RES CLIN, V121, P542, DOI 10.1007/BF01197767
   Lipton A, 2003, CANCER, V98, P962, DOI 10.1002/cncr.11571
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Martin M, 2012, CLIN CANCER RES, V18, P4841, DOI 10.1158/1078 0432.CCR 11 3310
   Mastro AM, 2003, CLIN EXP METASTAS, V20, P275, DOI 10.1023/A:1022995403081
   Munier A, 2005, ANN PHARMACOTHER, V39, P1194, DOI 10.1345/aph.1E589
   Neville Webbe HL, 2010, EUR J CANCER, V46, P1211, DOI 10.1016/j.ejca.2010.02.041
   Palmieri C, 2013, CLIN CANCER RES, V19, P6863, DOI 10.1158/1078 0432.CCR 13 2275
   Pavlakis N, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub2
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Rosen LS, 2001, CANCER J, V7, P377
   Ross JR, 2003, BMJ BRIT MED J, V327, P469, DOI 10.1136/bmj.327.7413.469
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saad F, 2010, SEMIN ONCOL, V37, pS38, DOI 10.1053/j.seminoncol.2010.06.001
   Saylor PJ, 2020, J CLIN ONCOL, V38, P1736, DOI 10.1200/JCO.19.03148
   Shapiro CL, 2017, J CLIN ONCOL, V35, P3949, DOI 10.1200/JCO.2017.73.7437
   Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147
   Smith MR, 2014, J CLIN ONCOL, V32, P1143, DOI 10.1200/JCO.2013.51.6500
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Templeton AJ, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.tps5095
   Van Poznak C, 2017, J CLIN ONCOL, V35, P3978, DOI 10.1200/JCO.2017.75.4614
   Wang Gillam A, 2008, ONCOLOGIST, V13, P821, DOI 10.1634/theoncologist.2008 0013
   Wong R, 2002, COCHRANE DB SYST REV, V2002
NR 46
TC 7
Z9 7
U1 0
U2 3
PU MULTIMED INC
PI TORONTO
PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA
SN 1198 0052
J9 CURR ONCOL
JI Curr. Oncol.
PD AUG
PY 2020
VL 27
IS 4
BP 220
EP 224
DI 10.3747/co.27.6631
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA PI3OL
UT WOS:000601004100019
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huang, XD
   Zhou, Z
   Zheng, YY
   Fan, GS
   Ni, BH
   Liu, MC
   Zhao, MH
   Zeng, LF
   Wang, WG
AF Huang, Xudong
   Zhou, Zhou
   Zheng, Yingyi
   Fan, Guoshuai
   Ni, Baihe
   Liu, Meichen
   Zhao, Minghua
   Zeng, Lingfeng
   Wang, Weiguo
TI Network Pharmacological Study on Mechanism of the Therapeutic Effect of
   Modified Duhuo Jisheng Decoction in Osteoporosis
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE osteoporosis; network pharmacology; TNF signaling pathway; molecular
   docking; Modified Duhuo Jisheng Decoction
ID OSTEOBLAST DIFFERENTIATION; BONE; PROTEIN; CYTOKINES
AB BackgroundModified Duhuo Jisheng Decoction (MDHJSD) is a traditional Chinese medicine prescription for the treatment of osteoporosis (OP), but its mechanism of action has not yet been clarified. This study aims to explore the mechanism of MDHJSD in OP through a combination of network pharmacology analysis and experimental verification. MethodsThe active ingredients and corresponding targets of MDHJSD were acquired from the Traditional Chinese Medicine System Pharmacology (TCMSP) database. OP related targets were acquired from databases, including Genecards, OMIM, Drugbank, CTD, and PGKB. The key compounds, core targets, major biological processes, and signaling pathways of MDHJSD that improve OP were identified by constructing and analysing the relevant networks. The binding affinities between key compounds and core targets were verified using AutoDock Vina software. A rat model of ovariectomized OP was used for the experimental verification. ResultsA total of 100 chemical constituents, 277 targets, and 4734 OP related targets of MDHJSD were obtained. Subsequently, five core components and eight core targets were identified in the analysis. Pathway enrichment analysis revealed that overlapping targets were significantly enriched in the tumour necrosis factor alpha (TNF alpha) signaling pathway, an inflammation signaling pathway, which contained six of the eight core targets, including TNF alpha, interleukin 6 (IL 6), transcription factor AP 1, mitogen activated protein kinase 3, RAC alpha serine/threonine protein kinase, and caspase 3 (CASP3). Molecular docking analysis revealed close binding of the six core targets of the TNF signaling pathway to the core components. The results of experimental study show that MDHJSD can protect bone loss, inhibit the inflammatory response, and downregulate the expression levels of TNF alpha, IL 6, and CASP3 in ovariectomized rats. ConclusionThe mechanism of MDHJSD in the treatment of OP may be related to the regulation of the inflammatory response in the bone tissue.
C1 [Huang, Xudong; Zhou, Zhou; Fan, Guoshuai; Ni, Baihe; Liu, Meichen; Zhao, Minghua; Wang, Weiguo] Shandong Univ Tradit Chinese Med, Clin Med Coll 1, Jinan, Peoples R China.
   [Zheng, Yingyi] Zhejiang Univ Tradit Chinese Med, Sch Basic Med Sci, Hangzhou, Peoples R China.
   [Zeng, Lingfeng] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.
   [Wang, Weiguo] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Jinan, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Zhejiang Chinese
   Medical University; Guangzhou University of Chinese Medicine; Shandong
   University of Traditional Chinese Medicine
RP Wang, WG (通讯作者)，Shandong Univ Tradit Chinese Med, Clin Med Coll 1, Jinan, Peoples R China.; Zeng, LF (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.; Wang, WG (通讯作者)，Shandong Univ Tradit Chinese Med, Affiliated Hosp, Jinan, Peoples R China.
EM zenglf6768@163.com; wjbwwg@hotmail.com
RI Huang, Zhihua/GLT 5306 2022; Huang, Xudong/MVW 7414 2025; zhong,
   feng/G 4623 2015
FU Shandong Provincial Scientific and Technological Innovation Program for
   Medical Workers [202014]; Science and Technology Project of Shandong
   Health Science and Technology Association [2017004]
FX Funding Shandong Provincial Scientific and Technological Innovation
   Program for Medical Workers (No.202014), Science and Technology Project
   of Shandong Health Science and Technology Association (No.2017004).
CR Blanchard F, 2009, CYTOKINE GROWTH F R, V20, P19, DOI 10.1016/j.cytogfr.2008.11.004
   Burley SK, 2017, METHODS MOL BIOL, V1606, P627, DOI 10.1007/978 1 4939 7000 1_26
   Caetano Lopes J, 2009, AUTOIMMUN REV, V8, P250, DOI 10.1016/j.autrev.2008.07.038
   Canalis E, 2010, ENDOCR PRACT, V16, P855, DOI 10.4158/EP10048.RA
   Clowes JA, 2005, IMMUNOL REV, V208, P207, DOI 10.1111/j.0105 2896.2005.00334.x
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dai WR, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.920485
   Ding C, 2008, J CLIN ENDOCR METAB, V93, P1952, DOI 10.1210/jc.2007 2325
   Doncheva NT, 2019, J PROTEOME RES, V18, P623, DOI 10.1021/acs.jproteome.8b00702
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Gillet C, 2015, ENDOCRINOLOGY, V156, P4081, DOI 10.1210/en.2015 1303
   Glass GE, 2011, P NATL ACAD SCI USA, V108, P1585, DOI 10.1073/pnas.1018501108
   Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007 1110
   Jiao XL, 2012, BIOINFORMATICS, V28, P1805, DOI 10.1093/bioinformatics/bts251
   Kanazawa K, 2005, J BONE MINER RES, V20, P2053, DOI 10.1359/JBMR.050706
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Lencel P, 2011, MED HYPOTHESES, V76, P317, DOI 10.1016/j.mehy.2010.09.023
   Li BJ, 2019, J ETHNOPHARMACOL, V233, P158, DOI 10.1016/j.jep.2018.12.033
   Li JY, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/6957825
   Lu XH, 2006, J BIOL CHEM, V281, P6297, DOI 10.1074/jbc.M507804200
   Luo TT, 2020, CHIN J INTEGR MED, V26, P72, DOI 10.1007/s11655 019 3064 0
   Marwick C, 2000, JAMA J AM MED ASSOC, V283, P2093, DOI 10.1001/jama.283.16.2093
   Migliorini F, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02678 x
   Miyamoto Takeshi, 2015, Keio Journal of Medicine, V64, P44, DOI 10.2302/kjm.2015 0003 RE
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Pasco JA, 2006, JAMA J AM MED ASSOC, V296, P1353, DOI 10.1001/jama.296.11.1353
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Szklarczyk D, 2016, NUCLEIC ACIDS RES, V44, pD380, DOI 10.1093/nar/gkv1277
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Wong PKK, 2003, ARTHRITIS RHEUM US, V48, P1177, DOI 10.1002/art.10943
   Xiong ZC, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/5510290
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Yu H, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944 015 0057 7
   Yun AJ, 2004, MED HYPOTHESES, V63, P532, DOI 10.1016/S0306 9877(03)00326 8
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang Q, 2021, J BIOCHEM MOL TOXIC, V35, DOI 10.1002/jbt.22832
NR 40
TC 6
Z9 7
U1 0
U2 17
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD MAR 31
PY 2022
VL 13
AR 860649
DI 10.3389/fendo.2022.860649
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 0P3VR
UT WOS:000784148900001
PM 35432213
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chew, CK
   Clarke, BL
AF Chew, Chee Kian
   Clarke, Bart L.
TI Biochemical Testing Relevant to Bone
SO ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
LA English
DT Article
DE Metabolic bone disease; Calcium; Phosphorus; Vitamin D; Parathyroid
   hormone; Parathyroid hormone related protein; Biochemical markers
ID PARATHYROID HORMONE FRAGMENTS; AUTOMATED SERUM ASSAY; COLLAGEN TYPE I;
   TURNOVER MARKERS; PRIMARY HYPERPARATHYROIDISM; ALKALINE PHOSPHATASE;
   N TELOPEPTIDES; VITAMIN D; IMMUNORADIOMETRIC ASSAY; POSTMENOPAUSAL WOMEN
AB Laboratory biochemical testing is critical to the clinical understanding of bone disorders. Patients with skeletal diseases have underlying themes in their pathophysiology that would be impossible to detect without biochemical assessment of serum and urine minerals, vitamin D, parathyroid hormone, parathyroid hormone related peptide, and bone turnover markers. Bone disorders are caused by abnormalities in signaling pathways that affect bone formation and resorption. Therapies for common bone diseases were developed in direct response to underlying biochemical abnormalities.
C1 [Chew, Chee Kian; Clarke, Bart L.] Mayo Clin, Div Endocrinol Diabet Metab & Nutr, E 18A,200 1st St Southwest, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Clarke, BL (通讯作者)，Mayo Clin, Div Endocrinol Diabet Metab & Nutr, E 18A,200 1st St Southwest, Rochester, MN 55905 USA.
EM clarke.bart@mayo.edu
CR [Anonymous], 1998, OST PROD INF
   Bandeira F, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P309, DOI 10.1016/B978 0 12 397166 1.00020 5
   BARTON RN, 1993, EUR J CLIN INVEST, V23, P171, DOI 10.1111/j.1365 2362.1993.tb00757.x
   Bieglmayer C, 2006, CLIN CHEM, V52, P1112, DOI 10.1373/clinchem.2005.065490
   Bikle D, 2013, PRIMER METABOLIC BON, P235
   Bilezikian JP, 2011, J BONE MINER RES, V26, P2317, DOI 10.1002/jbmr.483
   Boudou P, 2006, CLIN CHEM, V52, P757, DOI 10.1373/clinchem.2005.060962
   Brown EM, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P101, DOI 10.1016/B978 0 12 397166 1.00006 0
   Brown JP, 2009, CLIN BIOCHEM, V42, P929, DOI 10.1016/j.clinbiochem.2009.04.001
   CANTINI F, 1995, CLIN RHEUMATOL, V14, P663, DOI 10.1007/BF02207933
   Carneiro Pla DM, 2006, J AM COLL SURGEONS, V202, P715, DOI 10.1016/j.jamcollsurg.2006.02.003
   Chang CY, 2016, RADIOGRAPHICS, V36, P1871, DOI 10.1148/rg.2016160004
   Clemens JD, 1997, CLIN CHEM, V43, P2058
   Coe FL, 2016, NAT REV NEPHROL, V12, P519, DOI 10.1038/nrneph.2016.101
   Coen G, 2002, AM J KIDNEY DIS, V40, P348, DOI 10.1053/ajkd.2002.34519
   Cohen FJ, 1998, CALCIFIED TISSUE INT, V63, P277, DOI 10.1007/s002239900526
   COLE DEC, 1987, J CLIN ENDOCR METAB, V65, P290, DOI 10.1210/jcem 65 2 290
   Cortet B, 2000, CALCIFIED TISSUE INT, V66, P11, DOI 10.1007/s002230050004
   D'Amour P, 2005, CLIN CHEM, V51, P169, DOI 10.1373/clinchem.2004.040485
   D'Amour P, 2005, CURR OPIN NEPHROL HY, V14, P330, DOI 10.1097/01.mnh.0000172718.49476.64
   DAWSONHUGHES B, 1993, BONE MINER, V21, P41, DOI 10.1016/S0169 6009(08)80119 5
   DELMAS PD, 1985, BONE, V6, P339, DOI 10.1016/8756 3282(85)90326 6
   DELMAS PD, 1983, J CLIN ENDOCR METAB, V57, P1028, DOI 10.1210/jcem 57 5 1028
   Delmas PD, 2000, OSTEOPOROSIS INT, V11, P2, DOI 10.1007/s001980070002
   DUDA RJ, 1988, J CLIN ENDOCR METAB, V66, P951, DOI 10.1210/jcem 66 5 951
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Eliakim A, 1997, J BONE MINER RES, V12, P1708, DOI 10.1359/jbmr.1997.12.10.1708
   Farr JN, 2016, BONE, V82, P28, DOI 10.1016/j.bone.2015.07.027
   Fatayerji D, 1999, J BONE MINER RES, V14, P1203, DOI 10.1359/jbmr.1999.14.7.1203
   Fitzpatrick LA, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P401, DOI 10.1016/B978 0 12 397166 1.00026 6
   Gallagher J. C., 2013, PRIMER METABOLIC BON, P624
   Gallagher JC, 2016, NAT REV ENDOCRINOL, V12, P680, DOI 10.1038/nrendo.2016.123
   Gao P, 2001, J BONE MINER RES, V16, P605, DOI 10.1359/jbmr.2001.16.4.605
   Garnero P, 2003, J BONE MINER RES, V18, P1789, DOI 10.1359/jbmr.2003.18.10.1789
   Garnero P, 2001, CLIN CHEM, V47, P694
   GARNERO P, 1995, BONE, V16, P499, DOI 10.1016/8756 3282(95)00075 O
   Garnero P, 2008, CLIN CHEM, V54, P188, DOI 10.1373/clinchem.2007.094953
   Gass ML, 2008, MENOPAUSE, V15, P667, DOI 10.1097/gme.0b013e31815f8917
   Gertz BJ, 1998, CALCIFIED TISSUE INT, V63, P102, DOI 10.1007/s002239900497
   Gram J, 1998, BONE, V23, P297, DOI 10.1016/S8756 3282(98)00097 0
   Gundberg CM, 2002, BONE, V31, P703, DOI 10.1016/S8756 3282(02)00902 X
   Herrmann M, 2008, CLIN CHIM ACTA, V393, P57, DOI 10.1016/j.cca.2008.03.020
   Herrmann W, 2013, CLIN CHEM LAB MED, V51, P639, DOI 10.1515/cclm 2012 0599
   Hortin GL, 2002, ARCH PATHOL LAB MED, V126, P1045
   Horwitz MJ, 2008, PRIMER METABOLIC BON, P562
   Ivaska KK, 2007, J BONE MINER RES, V22, P1155, DOI 10.1359/JBMR.070505
   Kalkwarf HJ, 1999, J CLIN ENDOCR METAB, V84, P464, DOI 10.1210/jc.84.2.464
   Lafferty FW, 2006, J CLIN ENDOCR METAB, V91, P3826, DOI 10.1210/jc.2006 0273
   Lam A, 2003, LARYNGOSCOPE, V113, P2196, DOI 10.1097/00005537 200312000 00029
   Lehmann G, 2005, KIDNEY INT, V68, P1206, DOI 10.1111/j.1523 1755.2005.00513.x
   Lepage R, 1998, CLIN CHEM, V44, P805
   Marshall LA, 1996, OBSTET GYNECOL, V87, P350, DOI 10.1016/0029 7844(95)00424 6
   McClung MR, 2015, ENDOCRINOL METAB, V30, P429, DOI 10.3803/EnM.2015.30.4.429
   McLeod IK, 2006, THYROID, V16, P259, DOI 10.1089/thy.2006.16.259
   MELKKO J, 1994, J EXP MED, V179, P405, DOI 10.1084/jem.179.2.405
   Monier Faugere MC, 2001, KIDNEY INT, V60, P1460, DOI 10.1046/j.1523 1755.2001.00949.x
   Murray TM, 2005, ENDOCR REV, V26, P78, DOI 10.1210/er.2003 0024
   Nakamura K, 2004, NUTRITION, V20, P340, DOI 10.1016/j.nut.2003.12.004
   Naylor KE, 2000, J BONE MINER RES, V15, P129, DOI 10.1359/jbmr.2000.15.1.129
   NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364
   OIKARINEN A, 1992, BRIT J DERMATOL, V126, P172, DOI 10.1111/j.1365 2133.1992.tb07816.x
   Okabe R, 2001, CLIN CHEM, V47, P1410
   Omar H, 2001, ANN CLIN BIOCHEM, V38, P561, DOI 10.1258/0004563011901172
   Pantazi H, 2000, J CLIN ENDOCR METAB, V85, P1099, DOI 10.1210/jc.85.3.1099
   PANTEGHINI M, 1995, SCAND J CLIN LAB INV, V55, P609, DOI 10.3109/00365519509110260
   Panteghini M., 1998, LIGAND ASSAY, V3, P176
   Park SM, 2015, EUR J CLIN NUTR, V69, P361, DOI 10.1038/ejcn.2014.284
   Perry HM, 1996, J CLIN ENDOCR METAB, V81, P1108, DOI 10.1210/jc.81.3.1108
   Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127
   Räkel A, 2005, CLIN ENDOCRINOL, V62, P721, DOI 10.1111/j.1365 2265.2005.02286.x
   Reilly RF, 2011, NAT REV NEPHROL, V7, P669, DOI 10.1038/nrneph.2011.138
   Rubin MR, 2004, J BONE MINER RES, V19, pS327
   Ruppe MD., 2013, PRIMER METABOLIC BON, P601, DOI [10.1002/9781118453926.ch74, DOI 10.1002/9781118453926.CH74]
   Salusky IB, 2003, KIDNEY INT, V63, P1801, DOI 10.1046/j.1523 1755.2003.00915.x
   Scariano JK, 2001, CLIN BIOCHEM, V34, P639, DOI 10.1016/S0009 9120(01)00273 9
   Schleicher RL, 2016, AM J CLIN NUTR, V104, P454, DOI 10.3945/ajcn.115.127985
   Schlemmer A, 1999, EUR J ENDOCRINOL, V140, P332, DOI 10.1530/eje.0.1400332
   Schmidt Gayk H, 2004, CLIN CHEM LAB MED, V42, P90, DOI 10.1515/CCLM.2004.017
   Scott JPR, 2010, J CLIN ENDOCR METAB, V95, P3918, DOI 10.1210/jc.2009 2516
   Shoback DM, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P687, DOI 10.1016/B978 0 12 397166 1.00047 3
   Silverberg SJ, 2014, J CLIN ENDOCR METAB, V99, P3580, DOI 10.1210/jc.2014 1415
   SMEDSROD B, 1990, BIOCHEM J, V271, P345, DOI 10.1042/bj2710345
   Souberbielle JC, 2006, CLIN CHIM ACTA, V366, P81, DOI 10.1016/j.cca.2005.10.010
   STEINBERG KK, 1991, ANN CLIN LAB SCI, V21, P305
   Streeten EA, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P607, DOI 10.1016/B978 0 12 397166 1.00041 2
   Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306
   Sturgeon CM, 2005, UK NEQAS ANN REV 200
   Tebben PJ, 2016, ENDOCR REV, V37, P521, DOI 10.1210/er.2016 1070
   US Department of Health and Human Services, 2004, BON HLTH OST REP SUR, V113, P805
   VALIMAKI MJ, 1994, J BONE MINER RES, V9, P631
   Vasikaran S, 2011, CLIN CHEM LAB MED, V49, P1271, DOI 10.1515/CCLM.2011.602
   WANG M, 1995, AM J KIDNEY DIS, V26, P836, DOI 10.1016/0272 6386(95)90453 0
   White K. E., 2013, PRIMER METABOLIC BON, P188
   Woitge HW, 1998, J CLIN ENDOCR METAB, V83, P68, DOI 10.1210/jc.83.1.68
   Wysolmerski JJ, 2013, PRIMER METABOLIC BON, P215
   Zerwekh JE, 1998, J BONE MINER RES, V13, P1594, DOI 10.1359/jbmr.1998.13.10.1594
NR 96
TC 9
Z9 9
U1 0
U2 9
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0889 8529
EI 1558 4410
J9 ENDOCRIN METAB CLIN
JI Endocrinol. Metabol. Clin. North Amer.
PD SEP
PY 2017
VL 46
IS 3
BP 649
EP +
DI 10.1016/j.ecl.2017.04.003
PG 20
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FF3HO
UT WOS:000408786300006
PM 28760231
DA 2025 08 17
ER

PT J
AU Aicher, A
   Kollet, O
   Heeschen, C
   Liebner, S
   Urbich, C
   Ihling, C
   Orlandi, A
   Lapidot, T
   Zeiher, AM
   Dimmeler, S
AF Aicher, Alexandra
   Kollet, Orit
   Heeschen, Christopher
   Liebner, Stefan
   Urbich, Carmen
   Ihling, Christian
   Orlandi, Alessia
   Lapidot, Tsvee
   Zeiher, Andreas M.
   Dimmeler, Stefanie
TI The Wnt antagonist Dickkopf 1 mobilizes vasculogenic progenitor cells
   via activation of the bone marrow endosteal stem cell niche
SO CIRCULATION RESEARCH
LA English
DT Article
DE Wnt signaling; angiogenesis; vasculogenesis; bone marrow
   microenvironment
ID COLONY STIMULATING FACTOR; ACUTE MYOCARDIAL INFARCTION; CATHEPSIN K;
   ENDOTHELIAL CELLS; BETA CATENIN; IN VIVO; TUMOR ANGIOGENESIS; RECEPTOR
   ACTIVATOR; MULTIPLE ROLES; DEFICIENT MICE
AB Therapeutic mobilization of vasculogenic progenitor cells is a novel strategy to enhance neovascularization for tissue repair. Prototypical mobilizing agents such as granulocyte colony stimulating factor mobilize vasculogenic progenitor cells from the bone marrow concomitantly with inflammatory cells. In the bone marrow, mobilization is regulated in the stem cell niche, in which endosteal cells such as osteoblasts and osteoclasts play a key role. Because Wnt signaling regulates endosteal cells, we examined whether the Wnt signaling antagonist Dickkopf (Dkk) 1 is involved in the mobilization of vasculogenic progenitor cells. Using TOP GAL transgenic mice to determine activation of beta catenin, we demonstrate that Dkk 1 regulates endosteal cells in the bone marrow stem cell niche and subsequently mobilizes vasculogenic and hematopoietic progenitors cells without concomitant mobilization of inflammatory neutrophils. The mobilization of vasculogenic progenitors required the presence of functionally active osteoclasts, as demonstrated in PTP epsilon deficient mice with defective osteoclast function. Mechanistically, Dkk 1 induced the osteoclast differentiation factor RANKL, which subsequently stimulated the release of the major bone resorbing protease cathepsin K. Eventually, the Dkk 1 induced mobilization of bone marrow derived vasculogenic progenitors enhanced neovascularization in Matrigel plugs. Thus, these data show that Dkk 1 is a mobilizer of vasculogenic progenitors but not of inflammatory cells, which could be of great clinical importance to enhance regenerative cell therapy.
C1 [Aicher, Alexandra; Heeschen, Christopher; Urbich, Carmen; Orlandi, Alessia; Zeiher, Andreas M.; Dimmeler, Stefanie] Goethe Univ Frankfurt, Dept Internal Med 3, Frankfurt, Germany.
   [Liebner, Stefan] Goethe Univ Frankfurt, Dept Neurol, Frankfurt, Germany.
   [Kollet, Orit; Lapidot, Tsvee] Weizmann Inst Sci, Dept Immunol, IL 76100 Rehovot, Israel.
   [Ihling, Christian] Pathol Associates Inc, Frankfurt, Germany.
C3 Goethe University Frankfurt; Goethe University Frankfurt; Weizmann
   Institute of Science
RP Aicher, A (通讯作者)，Nottingham Trent Univ, Sch Sci & Technol, Interdisciplinary Biomed Res Ctr, Nottingham, England.
EM aicher_a@yahoo.com
RI ; Zirlik, Andreas/A 6400 2011; Kollet, Orit/A 6861 2008; Liebner,
   Stefan/JQJ 2908 2023; Aicher, Alexandra/GZK 8031 2022; Lapidot,
   Tsvee/A 1812 2010; Dimmeler, Stefanie/D 3108 2011; Guba,
   Markus/M 4309 2019
OI Dimmeler, Stefanie/0000 0002 1045 2436; Aicher,
   Alexandra/0000 0002 8920 9577; Heeschen,
   Christopher/0000 0002 1158 8554; 
FU Sonderforschungsbereich (SFB) [553 B6]; European Vascular Genomics
   Network; Leducq Foundation
FX This work was supported by the Sonderforschungsbereich (SFB) 553 B6, the
   European Vascular Genomics Network, and the Leducq Foundation.
CR Aicher A, 2007, CIRC RES, V100, P581, DOI 10.1161/01.RES.0000259562.63718.35
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD
   Assmus B, 2006, NEW ENGL J MED, V355, P1222, DOI 10.1056/NEJMoa051779
   Barandon L, 2003, CIRCULATION, V108, P2282, DOI 10.1161/01.CIR.0000093186.22847.4C
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chenga CW, 2003, EXP CELL RES, V291, P415, DOI 10.1016/S0014 4827(03)00411 7
   Chiusaroli R, 2004, MOL BIOL CELL, V15, P234, DOI 10.1091/mbc.e03 04 0207
   DasGupta R, 1999, DEVELOPMENT, V126, P4557
   De Palma M, 2003, NAT MED, V9, P789, DOI 10.1038/nm871
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dodds RA, 2001, J BONE MINER RES, V16, P478, DOI 10.1359/jbmr.2001.16.3.478
   Dufourcq P, 2002, CIRCULATION, V106, P3097, DOI 10.1161/01.CIR.0000039342.85015.5C
   Fleming HE, 2008, CELL STEM CELL, V2, P274, DOI 10.1016/j.stem.2008.01.003
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Honold J, 2006, ARTERIOSCL THROM VAS, V26, P2238, DOI 10.1161/01.ATV.0000240248.55172.dd
   Ingram DA, 2005, BLOOD, V105, P2783, DOI 10.1182/blood 2004 08 3057
   Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood 2004 04 1396
   Iwakura A, 2003, CIRCULATION, V108, P3115, DOI 10.1161/01.CIR.0000106906.56972.83
   Janssens S, 2006, LANCET, V367, P113, DOI 10.1016/S0140 6736(05)67861 0
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kahler RA, 2003, J BIOL CHEM, V278, P11937, DOI 10.1074/jbc.M211443200
   Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381
   Kollet O, 2007, ANNU REV IMMUNOL, V25, P51, DOI 10.1146/annurev.immunol.25.022106.141631
   Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417
   Kopp HG, 2006, CURR OPIN HEMATOL, V13, P175, DOI 10.1097/01.moh.0000219664.26528.da
   Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015
   Lee AY, 2004, BIOCHEM BIOPH RES CO, V323, P1246, DOI 10.1016/j.bbrc.2004.09.001
   Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184 1193.2002
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101 1194
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Min JK, 2007, BLOOD, V109, P1495, DOI 10.1182/blood 2006 06 029298
   Mirotsou M, 2007, P NATL ACAD SCI USA, V104, P1643, DOI 10.1073/pnas.0610024104
   Naruko T, 2002, CIRCULATION, V106, P2894, DOI 10.1161/01.CIR.0000042674.89762.20
   Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103
   Ohki Y, 2005, FASEB J, V19, P2005, DOI 10.1096/fj.04 3496fje
   Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898
   PASSANITI A, 1992, LAB INVEST, V67, P519
   Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092 8674(03)00437 9
   Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603 702
   Rajantie I, 2004, BLOOD, V104, P2084, DOI 10.1182/blood 2004 01 0336
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Schächinger V, 2006, NEW ENGL J MED, V355, P1210, DOI 10.1056/NEJMoa060186
   Scheller M, 2006, NAT IMMUNOL, V7, P1037, DOI 10.1038/ni1387
   Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood 2004 01 0272
   Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Steelman CA, 2006, FASEB J, V20, P580, DOI 10.1096/fj.05 5125fje
   Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C
   Takagi Y, 2005, J PHARMACOL SCI, V99, P45, DOI 10.1254/jphs.FP0040966
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Troen BR, 2006, ANN NY ACAD SCI, V1068, P165, DOI 10.1196/annals.1346.018
   Trowbridge JJ, 2006, NAT IMMUNOL, V7, P1021, DOI 10.1038/ni1006 1021
   Trowbridge JJ, 2006, NAT MED, V12, P89, DOI 10.1038/nm1339
   Urbich C, 2005, J MOL CELL CARDIOL, V39, P733, DOI 10.1016/j.yjmcc.2005.07.003
   van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614
   Wang FS, 2007, BONE, V40, P485, DOI 10.1016/j.bone.2006.09.004
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140 6736(04)16626 9
   Yang L, 2008, NATURE, V453, P524, DOI 10.1038/nature06894
   Yoon CH, 2005, CIRCULATION, V112, P1618, DOI 10.1161/CIRCULATIONAHA.104.503433
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 66
TC 60
Z9 66
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 0009 7330
J9 CIRC RES
JI Circ.Res.
PD OCT 10
PY 2008
VL 103
IS 8
BP 796
EP 803
DI 10.1161/CIRCRESAHA.107.172718
PG 8
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology; Hematology
GA 358NX
UT WOS:000259925900007
PM 18776043
DA 2025 08 17
ER

PT J
AU Huang, JC
   Thulin, MH
   Damber, JE
   Welén, K
AF Huang, Junchi
   Thulin, Malin Hagberg
   Damber, Jan Erik
   Welen, Karin
TI The roles of RUNX2 and osteoclasts in regulating expression of
   steroidogenic enzymes in castration resistant prostate cancer cells
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Castration resistant prostate cancer; Bone metastasis; Osteoclasts;
   RUNX2; Intratumoral steroidogenesis; Androgen receptor signaling
ID ESTROGEN RECEPTOR BETA; ANDROGEN DEPRIVATION THERAPY; BONE RESORPTION;
   UP REGULATION; IN VITRO; OSTEOBLASTS; METASTASES; GENES; MECHANISMS;
   CARCINOMA
AB Intratumoral steroidogenesis is involved in development of castration resistant prostate cancer (CRPC) as bone metastases. The osteoblast transcription factor RUNX2 influences steroidogenesis and is induced in CRPC cells by osteoblasts. This study investigates osteoclastic influence on RUNX2 in intratumoral steroidogenesis. Steroidogenic enzymes and steroid receptors were detected with immunohistochemistry in xenograft intratibial tumors from CRPC cells. In vitro, expression of RUNX2 was increased by osteoclasts in osteoblastic LNCaP19 cells, but not in osteolytic PC 3. Silencing of RUNX2 downregulates expression of CYP11A1, CYP17A1 and HSD3B1 in LNCaP 19 cells co cultured with osteoclasts, leading to inhibition of KLK3 expression. Osteoclasts promoted CYP11A1 and RUNX2 promoted AKR1C3, HSD17B3 and CYP19A1, but suppressed ESR2 in PC 3 cells. This study shows that osteoclasts promote RUNX2 regulated induction of key steroidogenic enzymes, influencing activation of androgen receptor in CRPC cells. The potential of RUNX2 as a target to inhibit progression of skeletal metastases of CRPC needs further investigation.
C1 [Huang, Junchi; Thulin, Malin Hagberg; Damber, Jan Erik; Welen, Karin] Univ Gothenburg, Sahlgrenska Acad, Sahlgrenska Ctr Canc Res, Inst Clin Sci,Dept Urol, Gothenburg, Sweden.
   [Thulin, Malin Hagberg] Univ Gothenburg, Sahlgrenska Acad, Ctr Bone & Arthrit Res, Inst Med,Dept Internal Med & Clin Nutr, Gothenburg, Sweden.
   [Damber, Jan Erik] Sahlgrens Univ Hosp, Dept Urol, Reg Vastra Gotaland, Gothenburg, Sweden.
C3 University of Gothenburg; University of Gothenburg; Sahlgrenska
   University Hospital
RP Welén, K (通讯作者)，Univ Gothenburg, Sahlgrenska Ctr Canc Res, Box 425, S 40530 Gothenburg, Sweden.
EM Karin.welen@gu.se
RI Huang, Junchi/C 2601 2019; WelÃ©n, Karin/AAQ 8765 2020
OI Huang, Junchi/0000 0003 2759 7962; Hagberg Thulin,
   Malin/0000 0002 8673 1247; 
FU Swedish Cancer Society [CAN 2017/478, CAN 2017/380, 20 1055 PjF];
   Swedish government [ALFGBG 138351]; research foundation of A.
   Gabrielsson [FB19 107]; research foundation of U and K Winberg
FX The authors would like to acknowledge PhD Karin Larsson, PhD Anna
   Linder, and MD Elin Schoultz for methodological and technical guidance
   and support. The authors also would like to acknowledge Andreas
   Josefsson, Umea University for help with the illustrations. This work
   was supported by the Swedish Cancer Society [grant numbers CAN 2017/478,
   CAN 2017/380, and 20 1055 PjF] ; the Swedish state under the agreement
   between the Swedish government and the county coun cils, the
   ALF agreement [grant number ALFGBG 138351] , research foundations of A.
   Gabrielsson [grant number FB19 107] , and U and K Winberg.
CR Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389
   Bäck TA, 2020, EJNMMI RES, V10, DOI 10.1186/s13550 020 0600 z
   Baniwal SK, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 258
   Baniwal SK, 2009, MOL ENDOCRINOL, V23, P1203, DOI 10.1210/me.2008 0470
   Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008 5472.CAN 03 3851
   Buchanan G, 2004, PROSTATE, V60, P352, DOI 10.1002/pros.20079
   Chaurasiya S, 2020, P NATL ACAD SCI USA, V117, P26347, DOI 10.1073/pnas.2007160117
   Cheng J, 2004, FEBS LETT, V566, P169, DOI 10.1016/j.febslet.2004.04.025
   Chiang C, 2009, J BONE MINER RES, V24, P621, DOI [10.1359/jbmr.081217, 10.1359/JBMR.081217]
   Clines GA, 2005, ENDOCR RELAT CANCER, V12, P549, DOI 10.1677/erc.1.00543
   Das K, 2009, EUR J CANCER, V45, P2239, DOI 10.1016/j.ejca.2009.06.021
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470 2045(12)70379 0
   Fowler M, 2006, J CELL BIOCHEM, V97, P1, DOI 10.1002/jcb.20664
   Gupta S, 2020, GENE CHROMOSOME CANC, V59, P225, DOI 10.1002/gcc.22824
   Gustavsson H, 2005, PROSTATE, V62, P364, DOI 10.1002/pros.20145
   Hofbauer LC, 1999, EUR J ENDOCRINOL, V140, P271, DOI 10.1530/eje.0.1400271
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hofland J, 2010, CANCER RES, V70, P1256, DOI 10.1158/0008 5472.CAN 09 2092
   Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002 9440(10)63112 4
   Jennbacken K., 2011, PROSTATE
   Jennbacken K, 2006, PROSTATE, V66, P1631, DOI 10.1002/pros.20469
   Jernberg E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077407
   Kawate H, 2007, J STEROID BIOCHEM, V105, P46, DOI 10.1016/j.jsbmb.2006.11.020
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Lai JS, 2004, UROLOGY, V64, P814, DOI 10.1016/j.urology.2004.05.036
   Leav I, 2001, AM J PATHOL, V159, P79, DOI 10.1016/S0002 9440(10)61676 8
   Lee HL, 2003, INT J ONCOL, V22, P921
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Little GH, 2014, CANCER RES, V74, P2857, DOI 10.1158/0008 5472.CAN 13 2003
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Michaelson MD, 2004, CLIN CANCER RES, V10, P2705, DOI 10.1158/1078 0432.CCR 03 0735
   Mödder UI, 2011, BONE, V49, P202, DOI 10.1016/j.bone.2011.04.015
   Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078 0432.CCR 1146 03
   Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008 5472.CAN 08 0249
   Nishiyama T, 2004, CLIN CANCER RES, V10, P7121, DOI 10.1158/1078 0432.CCR 04 0913
   Notini AJ, 2007, J BONE MINER RES, V22, P347, DOI 10.1359/JBMR.061117
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555 006 9032 0
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Roudier MP, 2003, HUM PATHOL, V34, P646, DOI 10.1016/S0046 8177(03)00190 4
   Roudier MP, 2003, CLIN EXP METASTAS, V20, P171, DOI 10.1023/A:1022627421000
   Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096
   Sieh S, 2010, ORGANOGENESIS, V6, P181, DOI 10.4161/org.6.3.12041
   Silva RD, 2018, INT J BIOCHEM CELL B, V96, P40, DOI 10.1016/j.biocel.2018.01.008
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008 5472.CAN 05 4000
   Tao XF, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.391
   Teplyuk NM, 2009, MOL ENDOCRINOL, V23, P849, DOI 10.1210/me.2008 0270
   Thulin MH, 2016, MOL CELL ENDOCRINOL, V422, P182, DOI 10.1016/j.mce.2015.11.013
   Thulin MH, 2014, CLIN EXP METASTAS, V31, P269, DOI 10.1007/s10585 013 9626 1
   Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078 0432.CCR 05 0525
   Vessella RL, 2006, CLIN CANCER RES, V12, p6285S, DOI 10.1158/1078 0432.CCR 06 0813
   Wang G, 2009, CANCER RES, V69, P3433, DOI 10.1158/0008 5472.CAN 08 3506
   Yang YH, 2018, CLIN CANCER RES, V24, P834, DOI 10.1158/1078 0432.CCR 17 2006
   Zhou C, 2018, BIOMED RES INT, V2018
NR 58
TC 5
Z9 6
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
EI 1872 8057
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD SEP 15
PY 2021
VL 535
AR 111380
DI 10.1016/j.mce.2021.111380
EA JUL 2021
PG 9
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA UE5YA
UT WOS:000687962100001
PM 34216642
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Tarantino, U
   Celi, M
   Feola, M
   Liuni, FM
   Resmini, G
   Iolascon, G
AF Tarantino, Umberto
   Celi, Monica
   Feola, Maurizio
   Liuni, Federico Maria
   Resmini, Giuseppina
   Iolascon, Giovanni
TI A new antiresorptive approach to the treatment of fragility fractures:
   long term efficacy and safety of denosumab
SO AGING CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Denosumab; Osteoporosis; Fragility fracture; Fracture healing
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS;
   OSTEOPOROSIS; ALENDRONATE; TURNOVER; PREVENTION; THERAPY; TRIAL
AB An imbalance of the remodeling process for bone resorption leads to a loss of tissue with consequent microarchitectural damage, evident in conditions such as osteoporosis and related fragility fractures. Currently, pharmacological therapies are able to prevent or slow down bone resorption by inhibiting osteoclast activity. An innovative and targeted anti resorptive approach is represented by the inhibition of RANK ligand (RANK L), essential for the proliferation and activity of osteoclastic cells. The human monoclonal antibody against RANK L (denosumab) has been approved for the treatment of osteoporosis. In clinical trials of patients with osteoporosis, inhibition of RANK L has reduced bone loss and damage to the microarchitecture and was associated with an increase in mass and resistance at different skeletal sites, with most significant effects than those demonstrated by any other antiresorptive drugs. In addition, after 3 years of treatment, it showed a reduction in vertebral and non vertebral fracture risk. Denosumab treatment also has not revealed any alteration in the physiological processes of fracture repair, showing no increase in the onset of complications 3 years after the fracture. The data show that denosumab offers an
C1 [Tarantino, Umberto; Celi, Monica; Feola, Maurizio; Liuni, Federico Maria] Univ Roma Tor Vergata, Policlin Tor Vergata Fdn, Dept Orthoped & Traumatol, I 00133 Rome, Italy.
   [Resmini, Giuseppina] Treviglio Caravaggio Hosp, Ctr Study Osteoporot & Metab Bone Dis, Sect Orthoped & Traumatol, Bergamo, Italy.
   [Iolascon, Giovanni] Univ Naples 2, Dept Med & Surg Specialties & Dent, Naples, Italy.
C3 University of Rome Tor Vergata; Ospedale di Treviglio Caravaggio;
   Universita della Campania Vanvitelli
RP Tarantino, U (通讯作者)，Univ Roma Tor Vergata, Policlin Tor Vergata Fdn, Dept Orthoped & Traumatol, Vle Oxford 81, I 00133 Rome, Italy.
EM umberto.tarantino@uniroma2.it
RI ; Iolascon, Giovanni/T 6220 2017
OI TARANTINO, Umberto/0000 0003 0330 2189; Iolascon,
   Giovanni/0000 0002 0976 925X
CR Adami S, 2012, J BONE JOINT SURG AM, V94A, P2113, DOI 10.2106/JBJS.K.00774
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Brown JP, 2011, AM COLL RHEUM ANN SC
   Cramer JA, 2007, OSTEOPOROSIS INT, V18, P1023, DOI 10.1007/s00198 006 0322 8
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Gallacher SJ, 2007, OSTEOPOROSIS INT, V18, P185, DOI 10.1007/s00198 006 0211 1
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Iolascon G, 2011, AGING CLIN EXP RES, V23, P28
   Jiang XZ, 2013, MENOPAUSE, V20, P117, DOI 10.1097/gme.0b013e31827c44bd
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   McClung MR, 2013, OSTEOPOROSIS INT, V24, P227, DOI 10.1007/s00198 012 2052 4
   NIH Consensus Development Panel on Osteoporosis Prevention D and Therapy Conference CD, 2001, JAMA, V285, P785
   Orwoll E, 2012, J CLIN ENDOCR METAB, V97, P3161, DOI 10.1210/jc.2012 1569
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Piscitelli P, 2010, CLIN CASES MINER BON, V7, P61
   Silva Fernandez L, 2013, REUMATOL CLIN, V9, P42, DOI [10.1016/j.reuma.2012.06.007, 10.1016/j.reumae.2012.06.020]
   Smith MR, 2009, J UROLOGY, V182, P2670, DOI 10.1016/j.juro.2009.08.048
   Tarantino U, 2011, AGING CLIN EXP RES, V23, P25
   Watts NB, 2012, OSTEOPOROSIS INT, V23, P327, DOI 10.1007/s00198 011 1755 2
   Zebaze RM, 2012, OSTEOPOROSIS INT, V23, pS291
NR 22
TC 11
Z9 12
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1594 0667
EI 1720 8319
J9 AGING CLIN EXP RES
JI Aging Clin. Exp. Res.
PD OCT
PY 2013
VL 25
SU 1
BP S65
EP S69
DI 10.1007/s40520 013 0082 1
PG 5
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA 257MW
UT WOS:000327389800018
PM 24046047
DA 2025 08 17
ER

PT J
AU Huang, FQ
   Guo, HZ
   Wei, YB
   Zhao, X
   Chen, YS
   Lin, Z
   Zhou, YH
   Sun, P
AF Huang, Feiqi
   Guo, Huizhi
   Wei, Yuanbiao
   Zhao, Xiao
   Chen, Yangsheng
   Lin, Zhan
   Zhou, Yanhui
   Sun, Ping
TI In Silico Network Analysis of Ingredients of Cornus officinalis
   in Osteoporosis
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Computational Biology; Medicine, Chinese Traditional; Osteoporosis;
   Pharmacologic Actions
ID URSOLIC ACID; LINOLEIC ACID; OSTEOBLAST DIFFERENTIATION; PHARMACOLOGICAL
   MECHANISM; SYSTEMS PHARMACOLOGY; OSTEOCLAST FORMATION; CHINESE MEDICINE;
   BONE LOSS; PREVENTION; OVARIECTOMY
AB Background: Cornus officinalis (CO), also known as 'Shanzhuyu', is one of the most common traditional Chinese herbs used against osteoporosis. Although previous studies have found that CO has beneficial effects in alleviating osteoporosis, its mechanisms remain unclear.
   Material/Methods: In this study, we applied system bioinformatic approaches to investigate the possible therapeutic mechanisms of CO against osteoporosis. We collected the active ingredients of CO and their targets from the TCMSP, BATMAN TCM, and ETCM databases. Next, we obtained the osteoporosis targets from differentially expressed mRNAs from the Gene Expression Omnibus (GEO) gene series (GSE35958). Next, the shared genes of the CO pharmacological targets and osteoporosis related targets were selected to construct the protein protein interaction network, based on the results from the STRING database. Subsequently, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were carried out by using the clusterProfiler package in R software.
   Results: In all, there were 58 unique CO compounds and 518 therapeutic targets. Based on the GO and KEGG enrichment results of 98 common genes, we selected the top 25 terms, based on the terms' P values. We found that the anti osteoporotic effect of CO may mostly involve the regulation of calcium metabolism and reactive oxygen species, and the estrogen signaling pathway and osteoclast differentiation pathway.
   Conclusions: We found the possible mechanisms of CO in treating osteoporosis may be based on multiple targets and pathways. We also provided a theoretical basis and promising direction for investigating the exact anti osteoporotic mechanisms of CO.
C1 [Huang, Feiqi; Guo, Huizhi] Guangzhou Univ Chinese Med, Clin Med Coll 1, Guangzhou, Guangdong, Peoples R China.
   [Huang, Feiqi; Wei, Yuanbiao; Zhao, Xiao; Chen, Yangsheng; Lin, Zhan; Zhou, Yanhui] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Sch Clin Med, Dept Bone Orthoped, Guangzhou, Guangdong, Peoples R China.
   [Sun, Ping] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Sch Clin Med, Dept Endocrinol, Guangzhou, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangdong Pharmaceutical
   University; Guangdong Pharmaceutical University
RP Sun, P (通讯作者)，Guangdong Pharmaceut Univ, Affiliated Hosp 1, Sch Clin Med, Dept Endocrinol, Guangzhou, Guangdong, Peoples R China.
EM sing_ping928@gdpu.edu.cn
RI Chen, zhuo/JWO 5404 2024
FU National Science Fund for Excellent Young Scholars [81603641]
FX This work was funded by a grant from National Science Fund for Excellent
   Young Scholars (No. 81603641)
CR Bellavia D, 2021, TRENDS ENDOCRIN MET, V32, P76, DOI 10.1016/j.tem.2020.11.007
   Cano A, 2018, MATURITAS, V107, P7, DOI 10.1016/j.maturitas.2017.10.004
   Cao SS, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01435
   Chauhan S, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906 018 2299 1
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Fukumoto Seiji, 2017, F1000Res, V6, P625, DOI 10.12688/f1000research.10682.1
   Gan DH, 2019, MED SCI MONITOR, V25, P5700, DOI 10.12659/MSM.915170
   Gu FL, 2019, AM J TRANSL RES, V11, P6032
   Heshmati HM, 1998, J CLIN ENDOCR METAB, V83, P1916, DOI 10.1210/jc.83.6.1916
   Huang J, 2018, J ETHNOPHARMACOL, V213, P280, DOI 10.1016/j.jep.2017.11.010
   Hwang KA, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1172 3
   Jang SE, 2014, J AGR FOOD CHEM, V62, P9711, DOI 10.1021/jf501487v
   Jiang C, 2015, BIOCHIMIE, V111, P107, DOI 10.1016/j.biochi.2015.02.002
   Kanehisa M, 2020, PROTEIN SCI, V29, P28, DOI 10.1002/pro.3711
   Kharazmi Mohammad, 2019, Lakartidningen, V116
   Kharazmi M, 2014, RHEUMATOLOGY, V53, P1911, DOI 10.1093/rheumatology/keu286
   Kim HN, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68890 7
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kim Jung Young, 2012, J Bone Metab, V19, P121, DOI 10.11005/jbm.2012.19.2.121
   Lee SU, 2008, PHARMACOL RES, V58, P290, DOI 10.1016/j.phrs.2008.08.008
   Li JY, 2017, CLIN INTERV AGING, V12, P45, DOI 10.2147/CIA.S117597
   Li MY, 2010, MOLECULES, V15, P7403, DOI 10.3390/molecules15107403
   Li M, 2019, ACTA PHARM SIN B, V9, P421, DOI 10.1016/j.apsb.2018.08.008
   Lin WM, 2020, J BUON, V25, P750
   Liu LL, 2020, ORTHOP SURG, V12, P1304, DOI 10.1111/os.12750
   Liu ZY, 2016, SCI REP UK, V6, DOI 10.1038/srep21146
   Luo D, 2016, OSTEOPOROSIS INT, V27, P1093, DOI 10.1007/s00198 015 3325 5
   Ma YG, 2021, SCI TOTAL ENVIRON, V750, DOI 10.1016/j.scitotenv.2020.141638
   Maggio M, 2009, CURR PHARM DESIGN, V15, P4157, DOI 10.2174/138161209789909728
   Missiuro PV, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000350
   Mitchell P, 2016, BEST PRACT RES CL RH, V30, P536, DOI 10.1016/j.berh.2016.09.008
   Park E, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020369
   Pavelic SK, 2021, EXP BIOL MED, V246, pNP4, DOI 10.1177/15353702211004087
   Platt I, 2009, LIPIDS HEALTH DIS, V8, DOI 10.1186/1476 511X 8 15
   Pytlik M, 2004, POL J PHARMACOL, V56, P571
   Rahman MM, 2014, LIPIDS, V49, P211, DOI 10.1007/s11745 013 3872 5
   Rooney AM, 2017, ANN NY ACAD SCI, V1410, P85, DOI 10.1111/nyas.13523
   Rossini M, 2016, EXPERT OPIN DRUG SAF, V15, P321, DOI 10.1517/14740338.2016.1136287
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Sham TT, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/925302
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sheng SJ, 2014, J ETHNOPHARMACOL, V154, P735, DOI 10.1016/j.jep.2014.04.048
   [宋敏 Song Min], 2018, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V24, P130
   Still K, 2008, CALCIFIED TISSUE INT, V83, P285, DOI 10.1007/s00223 008 9175 9
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Tamechika S, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0451 7
   Tatangelo G, 2019, J BONE MINER RES, V34, P616, DOI 10.1002/jbmr.3640
   Trajanoska K, 2018, BMJ BRIT MED J, V362, DOI 10.1136/bmj.k3225
   Wang C, 2012, J BONE MINER RES, V27, P2582, DOI 10.1002/jbmr.1711
   Wang XY, 2020, FITOTERAPIA, V142, DOI 10.1016/j.fitote.2020.104482
   Wong SK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176448
   Xiao LJ, 2017, ADV EXP MED BIOL, V1010, P261, DOI 10.1007/978 981 10 5562 1_13
   Xu HY, 2019, NUCLEIC ACIDS RES, V47, pD976, DOI 10.1093/nar/gky987
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   Ye CY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1904 7
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zhang Q, 2019, P NATL ACAD SCI USA, V116, P24463, DOI 10.1073/pnas.1907956116
   Zhang WJ, 2019, LIFE SCI, V235, DOI 10.1016/j.lfs.2019.116820
   Zhang WJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00743
   Zhang YQ, 2015, SCI REP UK, V5, DOI 10.1038/srep09463
   Zhou LP, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00779
   Zhou L, 2020, INT J BIOL SCI, V16, P309, DOI 10.7150/ijbs.37162
   Zhu K, 2019, J PHARMACOL SCI, V140, P33, DOI 10.1016/j.jphs.2019.04.001
NR 66
TC 6
Z9 6
U1 1
U2 19
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
EI 1643 3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD APR 2
PY 2021
VL 27
AR e929219
DI 10.12659/MSM.929219
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA RH5JA
UT WOS:000636253500001
PM 33795629
OA Green Published
DA 2025 08 17
ER

PT J
AU Fujita, H
   Kurokawa, K
   Ogino, T
   Ono, M
   Yamamoto, M
   Oka, T
   Nakanishi, T
   Kobayashi, N
   Tanaka, N
   Ogawa, T
   Suzaki, E
   Utsumi, K
   Sasaki, J
AF Fujita, Hirofumi
   Kurokawa, Kazuko
   Ogino, Tetsuya
   Ono, Mio
   Yamamoto, Masanao
   Oka, Takashi
   Nakanishi, Tohru
   Kobayashi, Naoya
   Tanaka, Noriaki
   Ogawa, Tomohiro
   Suzaki, Etsuko
   Utsumi, Kozo
   Sasaki, Junzo
TI Effect of Risedronate on Osteoblast Differentiation, Expression of
   Receptor Activator of NF κB Ligand and Apoptosis in Mesenchymal Stem
   Cells
SO BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
LA English
DT Article
ID OSTEOCLASTS IN VITRO; MARROW STROMAL CELLS; MEVALONATE PATHWAY;
   ZOLEDRONIC ACID; INFECTED OSTEORADIONECROSIS; BISPHOSPHONATES ACT;
   PROGENITOR CELLS; NODULE FORMATION; BONE RESORPTION; AKT PATHWAY
AB Nitrogen containing bisphosphonates (BPs) are antiresorptive drugs used for the treatment of metabolic bone diseases. Bone marrow stromal cells such as mesenchymal stem cells (MSCs) and MSC derived osteoblasts that originate from MSCs are known to regulate osteoclast differentiation and activation via the expression of receptor activator of NF kappa B ligand (RANKL). Although the effects of nitrogen containing BPs on osteoclasts and osteoblasts have been well investigated, their effects in MSCs have not been clarified. In this study, we investigated the effects of risedronate (RIS), a nitrogen containing BP, on osteoblast differentiation, RANKL expression and apoptosis in human and rat MSCs. RIS suppressed the formation of mineralized nodules and mRNA expression of differentiation marker genes such as bone sialoprotein and osteocalcin in MSC derived osteoblasts. The RANKL expression induced by 1,25 (OH)(2) vitamin D(3) was not affected by RIS in human MSC derived osteoblasts. In addition, treatment with high concentration RIS induced chromatin condensation, an apoptosis feature, in MSCs. RIS induced chromatin condensation was suppressed by a pan caspase inhibitor zVAD FMK and a cell permeable isoprenoid analogue geranylgeraniol. These results indicate that RIS suppressed osteoblast differentiation and induced caspase and isoprenoid depletion dependent apoptosis and suggest that the antiresorptive effect of RIS is not mediated by a decrease in the RANKL expression in MSC derived osteoblasts.
C1 [Fujita, Hirofumi; Kurokawa, Kazuko; Ono, Mio; Yamamoto, Masanao; Utsumi, Kozo; Sasaki, Junzo] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Cytol & Histol, Okayama 7008558, Japan.
   [Ogino, Tetsuya] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathol & Expt Med, Okayama 7008558, Japan.
   [Oka, Takashi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathol, Okayama 7008558, Japan.
   [Nakanishi, Tohru] Shujitsu Univ, Sch Pharm, Okayama, Japan.
   [Kobayashi, Naoya; Tanaka, Noriaki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Surg, Okayama 7008558, Japan.
   [Ogawa, Tomohiro] Osaka City Univ, Dept Hepatol, Grad Sch Med, Osaka 558, Japan.
   [Suzaki, Etsuko] Shujitsu Univ, Sch Pharm, Dept Human Anat, Okayama, Japan.
C3 Okayama University; Okayama University; Okayama University; Okayama
   University; Osaka Metropolitan University
RP Fujita, H (通讯作者)，Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Cytol & Histol, 2 5 1 Shikatacho, Okayama 7008558, Japan.
EM fujita00@md.okayama u.ac.jp
RI OGINO, Tetsuya/B 1999 2011
FU JSPS [20791042]; Eisai Co. Ltd; Grants in Aid for Scientific Research
   [20791042, 21591945, 22791384] Funding Source: KAKEN
FX This work was supported, in part, by grants from the JSPS KAKENHI
   20791042 and the Eisai Co. Ltd We thank Ajinomoto Co. Ltd for kindly
   donating the RIS for these experiments.
CR Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Chipoy C, 2004, J BONE MINER RES, V19, P1850, DOI 10.1359/JBMR.040817
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Dobnig H, 2006, OSTEOPOROSIS INT, V17, P693, DOI 10.1007/s00198 005 0035 4
   Dodson TB, 2008, NEW ENGL J MED, V358, P1283, DOI 10.1056/NEJMcpc0800341
   Ebert R, 2009, BONE, V44, P858, DOI 10.1016/j.bone.2009.01.009
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Frediani B, 2004, BONE, V35, P859, DOI 10.1016/j.bone.2004.06.001
   Fujita H, 2005, BIOCHEM PHARMACOL, V69, P1773, DOI 10.1016/j.bcp.2005.03.006
   Fujita H, 2008, BRAIN RES, V1206, P1, DOI 10.1016/j.brainres.2008.01.081
   Fujita H, 2006, BRAIN RES, V1113, P10, DOI 10.1016/j.brainres.2006.06.079
   Gough JE, 2004, J BIOMED MATER RES A, V68A, P640, DOI 10.1002/jbm.a.20075
   Hansen T, 2006, J ORAL PATHOL MED, V35, P155, DOI 10.1111/j.1600 0714.2006.00391.x
   Hansen T, 2006, VIRCHOWS ARCH, V449, P448, DOI 10.1007/s00428 006 0261 y
   HARRIS SE, 1994, J BONE MINER RES, V9, P389
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Iwata K, 2006, BONE, V39, P1053, DOI 10.1016/j.bone.2006.05.006
   Kellinsalmi M, 2005, BASIC CLIN PHARMACOL, V97, P382, DOI 10.1111/j.1742 7843.2005.pto_176.x
   Kim YH, 2002, EXP MOL MED, V34, P145, DOI 10.1038/emm.2002.21
   Liu H, 2006, J IMMUNOL, V176, P2864, DOI 10.4049/jimmunol.176.5.2864
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Naidu A, 2008, ORAL SURG ORAL MED O, V106, P5, DOI 10.1016/j.tripleo.2008.03.036
   Nishida S, 2003, BIOL PHARM BULL, V26, P96, DOI 10.1248/bpb.26.96
   Nishikawa M, 1996, BONE, V18, P9, DOI 10.1016/8756 3282(95)00426 2
   Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872
   Nishioka K, 2003, INT J ONCOL, V23, P925
   Oka T, 2000, CELL TISSUE RES, V300, P119, DOI 10.1007/s004410050053
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219
   Sedghizadeh PP, 2008, J ORAL MAXIL SURG, V66, P767, DOI 10.1016/j.joms.2007.11.035
   Short B, 2003, ARCH MED RES, V34, P565, DOI 10.1016/j.arcmed.2003.09.007
   Tuli R, 2003, STEM CELLS, V21, P681, DOI 10.1634/stemcells.21 6 681
   Vitte C, 1996, ENDOCRINOLOGY, V137, P2324, DOI 10.1210/en.137.6.2324
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoshida T, 2006, FEBS LETT, V580, P5203, DOI 10.1016/j.febslet.2006.08.060
   ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872 6880.1991
NR 49
TC 11
Z9 11
U1 0
U2 13
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1742 7835
J9 BASIC CLIN PHARMACOL
JI Basic Clin. Pharmacol. Toxicol.
PD AUG
PY 2011
VL 109
IS 2
BP 78
EP 84
DI 10.1111/j.1742 7843.2011.00685.x
PG 7
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 790TF
UT WOS:000292611400002
PM 21332944
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, YJ
   Liu, QW
   Yin, CH
   Li, Y
   Wu, J
   Chen, QL
   Yu, HL
   Lu, AP
   Guan, DG
AF Liu, Yujie
   Liu, Qinwen
   Yin, Chuanhui
   Li, Yi
   Wu, Jie
   Chen, Quanlin
   Yu, Hailang
   Lu, Aiping
   Guan, Daogang
TI Uncovering Hidden Mechanisms of Different Prescriptions Treatment for
   Osteoporosis via Novel Bioinformatics Model and Experiment
   Validation
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE osteoporosis; Gushukang Granules; Xianling Gubao Capsules; Er xian
   Decoction; herbal medicine; functional response motif
ID BONE MINERAL DENSITY; OSTEOCLAST DIFFERENTIATION; NETWORK PHARMACOLOGY;
   PREVENTION; RECEPTORS; MICE; RESORPTION
AB Osteoporosis (OP) is a systemic disease susceptible to fracture due to the decline of bone mineral density and bone mass, the destruction of bone tissue microstructure, and increased bone fragility. At present, the treatments of OP mainly include bisphosphonates, hormone therapy, and RANKL antibody therapy. However, these treatments have observable side effects and cannot fundamentally improve bone metabolism. Currently, the prescription of herbal medicine and their derived proprietary Chinese medicines are playing increasingly important roles in the treatment of OP due to their significant curative effects and few side effects. Among these prescriptions, Gushukang Granules (GSK), Xianling Gubao Capsules (XLGB), and Er xian Decoction (EXD) are widely employed at the clinic on therapy of OP, which also is in line with the compatibility principle of "different treatments for the same disease" in herbal medicine. However, at present, the functional interpretation of "different treatments for the same disease" in herbal medicine still lacks systematic quantitative research, especially on the detection of key component groups and mechanisms. To solve this problem, we designed a new bioinformatics model based on random walk, optimized programming, and information gain to analyze the components and targets to figure out the Functional Response Motifs (FRMs) of different prescriptions for the therapy of OP. The distribution of high relevance score, the number of reported evidence, and coverage of enriched pathways were performed to verify the precision and reliability of FRMs. At the same time, the information gain and target influence of each component was calculated, and the key component groups in all FRMs of each prescription were screened to speculate the potential action mode of different prescriptions on the same disease. Results show that the relevance score and the number of reported evidence of high reliable genes in FRMs were higher than those of the pathogenic genes of OP. Furthermore, the gene enrichment pathways in FRMs could cover 79.6, 81, and 79.5% of the gene enrichment pathways in the component target (C T) network. Functional pathway enrichment analysis showed that GSK, XLGB, and EXD all treat OP through osteoclast differentiation (hsa04380), calcium signaling pathway (hsa04020), MAPK signaling pathway (hsa04010), and PI3K Akt signaling pathway (hsa04151). Combined with experiments, the key component groups and the mechanism of "different treatments for the same disease" in the three prescriptions and proprietary Chinese medicines were verified. This study provides methodological references for the optimization and mechanism speculation of Chinese medicine prescriptions and proprietary Chinese medicines.
C1 [Liu, Yujie; Liu, Qinwen; Yin, Chuanhui; Wu, Jie; Chen, Quanlin; Yu, Hailang; Guan, Daogang] Southern Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Guangzhou, Peoples R China.
   [Liu, Yujie; Liu, Qinwen; Yin, Chuanhui; Wu, Jie; Chen, Quanlin; Guan, Daogang] Southern Med Univ, Guangdong Key Lab Biochip Technol, Guangzhou, Peoples R China.
   [Li, Yi] Southern Med Univ, Nanfang Hosp, Dept Radiol, Guangzhou, Peoples R China.
   [Lu, Aiping] Hong Kong Baptist Univ, Inst Integrated Bioinformed & Translat Sci, Hong Kong, Peoples R China.
   [Lu, Aiping] Guangdong Hong Kong Macau Joint Lab Chinese Med &, Guangzhou, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Southern Medical University   China; Hong Kong Baptist University
RP Guan, DG (通讯作者)，Southern Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Guangzhou, Peoples R China.; Guan, DG (通讯作者)，Southern Med Univ, Guangdong Key Lab Biochip Technol, Guangzhou, Peoples R China.; Lu, AP (通讯作者)，Hong Kong Baptist Univ, Inst Integrated Bioinformed & Translat Sci, Hong Kong, Peoples R China.; Lu, AP (通讯作者)，Guangdong Hong Kong Macau Joint Lab Chinese Med &, Guangzhou, Peoples R China.
EM aipinglu@hkbu.edu.hk; guandg0929@hotmail.com
RI LU, Aiping/JDX 0577 2023
OI Liu, qinwen/0009 0000 0104 1718; Guan, Daogang/0000 0003 1414 0189; Li,
   Yi/0000 0001 8643 4501
FU Startup fund from Southern Medical University [G619280010]; Natural
   Science Foundation Council of China [32070676, 31501080]; National Key
   R&D Program of China [2018YFC1705205]; Natural Science Foundation of
   Guangdong Province [2021A1515010737]; Hong Kong Baptist University
   Strategic Development Fund [SDF13 1209 P01, SDF15 0324 P02,
   SDF19 0402 P02]; Hong Kong Baptist University Interdisciplinary Research
   Matching Scheme [RC/IRCs/17 18/04]; 2020 Guangdong Provincial Science
   and Technology Innovation Strategy Special Fund [2020B1212030006]
FX Funding This study is financially supported by the Startup fund from
   Southern Medical University (grant no. G619280010), the Natural Science
   Foundation Council of China (grant no. 32070676, 31501080), the National
   Key R&D Program of China (2018YFC1705205), Natural Science Foundation of
   Guangdong Province (grant no. 2021A1515010737), Hong Kong Baptist
   University Strategic Development Fund (grant no. SDF13 1209 P01,
   SDF15 0324 P02(b) and SDF19 0402 P02), Hong Kong Baptist University
   Interdisciplinary Research Matching Scheme (grant no. RC/IRCs/17 18/04),
   the 2020 Guangdong Provincial Science and Technology Innovation Strategy
   Special Fund (grant no. 2020B1212030006).
CR Agas D, 2013, J CELL PHYSIOL, V228, P2149, DOI 10.1002/jcp.24382
   Agrawal A, 2015, J MOL ENDOCRINOL, V54, pR75, DOI 10.1530/JME 14 0226
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Casado Díaz A, 2016, J NUTR BIOCHEM, V32, P151, DOI 10.1016/j.jnutbio.2016.03.005
   Chen DL, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104944
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Cho SW, 2009, MOL THER, V17, P1979, DOI 10.1038/mt.2009.153
   Conigrave AD, 2008, ANNU REV NUTR, V28, P131, DOI 10.1146/annurev.nutr.28.061807.155328
   Daina A, 2017, SCI REP UK, V7, DOI 10.1038/srep42717
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Delmas PD, 2005, CURR OPIN RHEUMATOL, V17, P462
   Fang YY, 2019, CELL BIOL INT, V43, P323, DOI 10.1002/cbin.11102
   Gao Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.512877
   [高耀 Gao Yao], 2018, [中草药, Chinese Traditional and Herbal Drugs], V49, P3483
   Guo S, 2021, MED SCI MONITOR, V27, DOI 10.12659/MSM.927421
   Guo Y, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756 9966 32 41
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   Li JY, 2017, CLIN INTERV AGING, V12, P45, DOI 10.2147/CIA.S117597
   Li S Q, 2001, Zhongguo Zhong Xi Yi Jie He Za Zhi, V21, P265
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875 5364(13)60037 0]
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169 409X(00)00129 0
   Liu XY, 2012, J ETHNOPHARMACOL, V139, P311, DOI 10.1016/j.jep.2011.11.017
   Lopes HB, 2019, J BIOMED MATER RES A, V107, P1303, DOI 10.1002/jbm.a.36643
   Lu SY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03187 w
   Mendes AB, 2012, J INHERIT METAB DIS, V35, P425, DOI 10.1007/s10545 011 9412 7
   Miller PD, 2016, EXPERT OPIN PHARMACO, V17, P473, DOI 10.1517/14656566.2016.1124856
   Moriishi T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027487
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Papapoulos S, 2008, NAT CLIN PRACT ENDOC, V4, P514, DOI 10.1038/ncpendmet0941
   Qu XH, 2014, BIOCHEM BIOPH RES CO, V443, P658, DOI 10.1016/j.bbrc.2013.12.029
   Rapisarda V, 2017, CELL REP, V18, P2480, DOI 10.1016/j.celrep.2017.02.012
   Shalev M, 2019, BBA MOL CELL RES, V1866, P114, DOI 10.1016/j.bbamcr.2018.07.005
   Silverman SL, 2003, ENDOCRIN METAB CLIN, V32, P273, DOI 10.1016/S0889 8529(02)00060 9
   Srivastava M, 2002, CLIN GERIATR MED, V18, P529, DOI 10.1016/S0749 0690(02)00022 8
   Stefanick ML, 2005, AM J MED, V118, P1407, DOI 10.1016/j.amjmed.2005.10.014
   Sun L, 1999, J CELL BIOL, V146, P1161, DOI 10.1083/jcb.146.5.1161
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Wang KX, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.567088
   Wang KX, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01035
   Wang KX, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.782060
   Wang LJ, 2020, KAOHSIUNG J MED SCI, V36, P775, DOI 10.1002/kjm2.12236
   Wang N, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21574 9
   Wang Q, 2018, J PHARMACOL SCI, V136, P155, DOI 10.1016/j.jphs.2018.01.007
   Wang Xi juan, 2007, Zhongguo Zhong Xi Yi Jie He Za Zhi, V27, P282
   Westbroek I, 2001, J BIOL CHEM, V276, P28961, DOI 10.1074/jbc.M101824200
   Wittrant Y, 2009, ENDOCRINOLOGY, V150, P4977, DOI 10.1210/en.2009 0248
   Wu ZH, 2017, J BIOL REG HOMEOS AG, V31, P359
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Xu J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199688
   Yang L, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6641838
   Yao HL, 2018, MOL MED REP, V17, P6681, DOI 10.3892/mmr.2018.8657
   Ye CY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1904 7
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang Y, 2020, J CELL PHYSIOL, V235, P5511, DOI 10.1002/jcp.29261
   Zhao C., 2019, ACTA CHIN MED, DOI [10.16368/j.issn.1674 8999.2019.11.556, DOI 10.16368/J.ISSN.1674 8999.2019.11.556]
   Zhao Ya hong, 2003, Zhongguo Zhong Xi Yi Jie He Za Zhi, V23, P943
   Zhu NQ, 2020, COMPUT BIOL CHEM, V85, DOI 10.1016/j.compbiolchem.2020.107240
   Zinnia MA, 2021, INT J BIOL MACROMOL, V186, P351, DOI 10.1016/j.ijbiomac.2021.06.197
   Zou ZH, 2021, ACTA BIOCH BIOPH SIN, V53, P294, DOI 10.1093/abbs/gmaa174
NR 60
TC 8
Z9 8
U1 2
U2 28
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD FEB 8
PY 2022
VL 10
AR 831894
DI 10.3389/fcell.2022.831894
PG 20
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA ZH0HY
UT WOS:000760631200001
PM 35211473
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Granchi, D
   Baglìo, SR
   Amato, I
   Giunti, A
   Baldini, N
AF Granchi, Donatella
   Baglio, Serena Rubina
   Amato, Ilaria
   Giunti, Armando
   Baldini, Nicola
TI Paracrine inhibition of osteoblast differentiation induced by
   neuroblastoma cells
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE neuroblastoma; bone metastasis; mesenchymal stem cells; osteoblasts;
   Wnt pathway; Dkk 1
ID MESENCHYMAL STEM CELLS; KAPPA B LIGAND; RECEPTOR ACTIVATOR; IN VITRO;
   EXPRESSION; BORTEZOMIB; GROWTH; RANKL; METASTASIS; MODEL
AB The aim of our study was to investigate whether the defective function of osteogenic cells induced by neuroblastoma might play a role in the development of skeletal metastases. This mechanism has been extensively demonstrated for multiple myeloma, in which the blockage of osteoblast differentiation has been ascribed to the inhibitors of canonical Wingless pathway (Wnt), namely Dickkopf 1 (Dkk1). Our purpose was to verify if neuroblastoma cells derived from bone marrow metastases (SH SY5Y, LAN1) or primaries (NB100, CHP212) hamper the differentiation of mesenchymal stem cells (hMSCs) into osteoblasts in a paracrine manner, and to test whether this ability depends on Dkk1 activity. We found that all neuroblastoma cells increased the proliferation of hMSCs collected from pediatric aged donors, with a corresponding decrease in osteoblast differentiation markers, including alkaline phosphatase (ALP), analyzed as gene expression, enzymatic activity and number of ALP positive colony forming units, osteoprotegerin (OPG) release, OPG and osteocalcin gene expression. Dkk1 mRNA and protein were detectable in all cell lines, and the use of neutralizing anti Dkk1 antibody reversed the effects induced by SH SY5Y cells. Taken together, Our results confirm that neuroblastoma hinders osteoblastogenesis, and that Dkk1 release seems to play a crucial role in blocking the differentiation of osteoprogenitor cells, though the ability to promote osteoclast activation remains an essential requirement for the development of skeletal metastases. Finally our findings suggest that strategies regulating Wnt signaling and Dkk1 activity could be considered for adjuvant therapies in neuroblastoma metastasizing to the skeleton. (C) 2008 Wiley Liss, Inc.
C1 [Granchi, Donatella; Baglio, Serena Rubina; Amato, Ilaria; Giunti, Armando; Baldini, Nicola] Ist Ortoped Rizzoli, Lab Pathophysiol, I 40136 Bologna, Italy.
C3 IRCCS Istituto Ortopedico Rizzoli
RP Granchi, D (通讯作者)，Ist Ortoped Rizzoli, Lab Pathophysiol, Via Barbiano 1 10, I 40136 Bologna, Italy.
EM donatella.granchi.@ior.it
RI Baldini, Nicola/J 4806 2016; Granchi, Donatella/J 3647 2016
OI Baldini, Nicola/0000 0003 2228 3833; Baglio, Serena
   Rubina/0000 0003 0503 8908; Granchi, Donatella/0000 0001 7225 0023
FU Italian Association for Cancer Research (Associazione Italiana per la
   Ricerca sul Cancro AIRC); Italian Ministry of, Health
FX Grant sponsor: Italian Association for Cancer Research (Associazione
   Italiana per la Ricerca sul Cancro AIRC): Grain sponsor: Italian
   Ministry of, Health.
CR Adams J, 2002, ONCOLOGIST, V7, P9, DOI 10.1634/theoncologist.7 1 9
   BANEY SM, 2004, J CLIN ONCOL, V22, P4804
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Brignole C, 2006, J NATL CANCER I, V98, P1142, DOI 10.1093/jnci/djj309
   Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097 4644(199702)64:2<278::AID JCB11>3.0.CO;2 F
   D'Ippolito G, 1999, J BONE MINER RES, V14, P1115, DOI 10.1359/jbmr.1999.14.7.1115
   De Bernardi B, 2003, J CLIN ONCOL, V21, P1592, DOI 10.1200/JCO.2003.05.191
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gori F, 2000, ENDOCRINOLOGY, V141, P4768, DOI 10.1210/en.141.12.4768
   Granchi D, 2006, INT J CANCER, V119, P146, DOI 10.1002/ijc.21783
   Granchi D, 2004, INT J CANCER, V111, P829, DOI 10.1002/ijc.20308
   Gregory CA, 2005, ANN NY ACAD SCI, V1049, P97, DOI 10.1196/annals.1334.010
   Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hamner JB, 2007, SURGERY, V142, P185, DOI 10.1016/j.surg.2007.04.012
   Hettmer S, 2005, CANCER LETT, V225, P141, DOI 10.1016/j.canlet.2004.11.036
   Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092 8674(00)80540 1
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140 6736(07)60983 0
   Michaelis M, 2006, INT J ONCOL, V28, P439
   Michigami T, 2001, CANCER RES, V61, P1637
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445
   Sohara Y, 2005, CANCER LETT, V228, P203, DOI 10.1016/j.canlet.2005.01.059
   Sohara Y, 2005, CANCER RES, V65, P1129, DOI 10.1158/0008 5472.CAN 04 2853
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Tonelli R, 2005, MOL CANCER THER, V4, P779, DOI 10.1158/1535 7163.MCT 04 0213
   VESSELLA RL, 2006, BONEKEY OSTEOVISION, V3, P15
   Zavrski I, 2005, BIOCHEM BIOPH RES CO, V333, P200, DOI 10.1016/j.bbrc.2005.05.098
NR 32
TC 19
Z9 21
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0020 7136
EI 1097 0215
J9 INT J CANCER
JI Int. J. Cancer
PD OCT 1
PY 2008
VL 123
IS 7
BP 1526
EP 1535
DI 10.1002/ijc.23654
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 343YO
UT WOS:000258892500006
PM 18623132
OA Bronze
DA 2025 08 17
ER

PT J
AU Chen, CW
   Li, Y
   Feng, T
   Chen, XP
   Li, CW
   Li, L
   Zhu, MB
   Chang, YQ
   Wang, SW
AF Chen, Chongwei
   Li, Yue
   Feng, Teng
   Chen, Xinping
   Li, Chengwei
   Li, Lu
   Zhu, Mengbo
   Chang, Yaqiong
   Wang, Shaowei
TI LMK 235 suppresses osteoclastogenesis and promotes osteoblastogenesis by
   inhibiting HDAC4
SO SCIENTIFIC REPORTS
LA English
DT Article
DE LMK 235; Osteoclast; Osteoblast; HDAC4; Osteolysis
ID CHONDROCYTE HYPERTROPHY; TGF BETA; BONE; DIFFERENTIATION
AB Osteoblasts and osteoclasts play an important role in maintaining the structural integrity of bone tissue, in which osteoclasts degrade bone structure and osteoblasts restore bone tissue. The imbalance of osteoblast and osteoclast function can lead to many bone related diseases, such as osteoporosis and inflammatory osteolysis. The drug that can both promote bone formation and inhibit bone loss will be able to treat those diseases. In this study, it was found that LMK 235, an selective HDAC4/5 inhibitor, inhibited the differentiation and maturation of osteoclasts by regulating NF kappa B and p Smad2/3 signaling pathways via inhibition of HDAC4. At the same time, we found that LMK 235 promoted osteoblast mineralization by upregulating Runx2 expression via inhibition of HDAC4. In vivo, LMK 235 was able to alleviate lipopolysaccharide (LPS) induced calvarial osteolysis and promote the repair of bone defects. Taken together, LMK 235 suppresses osteoclast differentiation and promotes osteoblast formation by inhibiting HDAC4. This may provide a valuable treatment for bone diseases caused by abnormal osteoclast bone resorption and osteoblast bone regeneration.
C1 [Chen, Chongwei; Feng, Teng; Chen, Xinping; Li, Chengwei; Li, Lu; Zhu, Mengbo; Wang, Shaowei] Shanxi Med Univ, Hosp 2, Shanxi Key Lab Bone & Soft Tissue Injury Repair, Dept Orthoped, Taiyuan, Peoples R China.
   [Li, Yue] Shanxi Med Univ, Basic Med Coll, Dept Biochem, Taiyuan, Peoples R China.
   [Chang, Yaqiong] Shanxi Med Univ, Hosp 2, Dept Nursing, Taiyuan, Peoples R China.
C3 Shanxi Medical University; Shanxi Medical University; Shanxi Medical
   University
RP Zhu, MB; Wang, SW (通讯作者)，Shanxi Med Univ, Hosp 2, Shanxi Key Lab Bone & Soft Tissue Injury Repair, Dept Orthoped, Taiyuan, Peoples R China.; Chang, YQ (通讯作者)，Shanxi Med Univ, Hosp 2, Dept Nursing, Taiyuan, Peoples R China.
EM coltzhu@163.com; sxykdcyq@163.com; wangshaowei@sxmu.edu.cn
RI li, cheng wei/Q 3338 2019; Chen, Xinping/C 7877 2018
FU National Natural Science Foundation of China
FX No Statement Available
CR Abbas SS, 2022, LIFE SCI, V306, DOI 10.1016/j.lfs.2022.120850
   Aprile P, 2021, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.619914
   Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004
   Chen RJ, 2019, BIOCHEM BIOPH RES CO, V516, P666, DOI 10.1016/j.bbrc.2019.06.083
   Chen Z, 2020, BONE JOINT RES, V9, P82, DOI 10.1302/2046 3758.92.BJR 2019 0172.R1
   Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732
   Erickson AG, 2018, TISSUE ENG PT A, V24, P94, DOI 10.1089/ten.tea.2017.0091
   Gao LL, 2020, MOL MED, V26, DOI 10.1186/s10020 020 00154 6
   Guo YL, 2018, LIFE SCI, V207, P386, DOI 10.1016/j.lfs.2018.06.004
   Iaquinta MR, 2021, THERANOSTICS, V11, P6573, DOI 10.7150/thno.55664
   Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729
   Li AQ, 2017, ONCOTARGET, V8, P30619, DOI 10.18632/oncotarget.17542
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Li JW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09653 5
   Li XY, 2018, CANCER BIOL THER, V19, P825, DOI 10.1080/15384047.2018.1472188
   Li YX, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026831
   Liu Z, 2018, MOL MED REP, V17, P1445, DOI 10.3892/mmr.2017.8055
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Lu JL, 2016, ONCOTARGET, V7, P37471, DOI 10.18632/oncotarget.9650
   Lu ZY, 2021, EUR J MED RES, V26, DOI 10.1186/s40001 021 00480 3
   Mazzocchi M, 2021, MOL CELL NEUROSCI, V115, DOI 10.1016/j.mcn.2021.103642
   Mohsin S, 2019, EXPERT OPIN BIOL TH, V19, P937, DOI 10.1080/14712598.2019.1618266
   Nakatani T, 2018, J BONE MINER RES, V33, P1362, DOI 10.1002/jbmr.3422
   Nakatani T, 2016, BONE, V90, P142, DOI 10.1016/j.bone.2016.06.010
   Obri A, 2014, J CELL BIOL, V205, P771, DOI 10.1083/jcb.201403138
   Parveen R, 2023, CANCER AM CANCER SOC, V129, P3372, DOI 10.1002/cncr.34974
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Shen FC, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.929334
   Squarzoni A, 2022, CANCERS, V14, DOI 10.3390/cancers14215251
   Sun SX, 2022, EUR J PHARMACOL, V927, DOI 10.1016/j.ejphar.2022.175073
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Trazzi S, 2016, HUM MOL GENET, V25, P3887, DOI 10.1093/hmg/ddw231
   Tsukamoto M, 2016, BONE, V85, P70, DOI 10.1016/j.bone.2016.01.025
   Wang ZK, 2014, EPIGENOMICS UK, V6, P139, DOI 10.2217/epi.13.73
   Wu BC, 2022, CANCERS, V14, DOI 10.3390/cancers14030552
   Xu HY, 2022, IMMUN INFLAMM DIS, V10, DOI 10.1002/iid3.692
   Yang J, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.661620
   Yu X, 2019, J CELL PHYSIOL, V234, P21284, DOI 10.1002/jcp.28733
   Zhang D, 2023, CELL BIOL TOXICOL, V39, P2243, DOI 10.1007/s10565 022 09713 5
   Zou ML, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.593310
NR 40
TC 0
Z9 1
U1 2
U2 7
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD AUG 28
PY 2024
VL 14
IS 1
AR 19973
DI 10.1038/s41598 024 70814 8
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA E1Y7Y
UT WOS:001301037700023
PM 39198677
OA gold, Green Published
DA 2025 08 17
ER

PT B
AU Bab, IA
AF Bab, Itai A.
BE Zaidi, M
TI Regulation of skeletal remodeling by the endocannabinoid system
SO SKELETAL BIOLOGY AND MEDICINE, PT A: ASPECTS OF BONE MORPHOGENESIS AND
   REMODELING
SE Annals of the New York Academy of Sciences Series
LA English
DT Article; Proceedings Paper
CT 2nd Conference on Skeletal Biology and Medicine
CY APR 25 28, 2007
CL New York, NY
SP Mt Sinai Sch Med, New York Acad Sci
DE adrenergic signaling; anandamide; bone formation; bone mass; bone
   remodeling; bone resorption; cannabinoid receptors; CB1; CB2;
   endocannabinoid system; norepinephrine; osteoblast; osteoclast;
   osteoporosis; 2 arachidonoylglycerol
ID REVERSES BONE LOSS; CANNABINOID RECEPTOR; DEFICIENT MICE; MARROW CELLS;
   CB1; ANANDAMIDE; PROTEIN; DIFFERENTIATION; OSTEOPROTEGERIN; KINASE
AB Since the discovery of the endocannabinoid system, its presence and involvement have been reported in a handful of biological systems. Recently, the skeleton has been identified as a major endocannabinoid target through both the neuronal CB1 and predominantly peripheral CB2 cannabinoid receptors. CB1 is present in sympathetic nerve terminals in bone, whereas CB2 is expressed in osteoblasts and osteoclasts, the respective bone forming and  resorbing cells. Furthermore, the skeleton appears as the main system physiologically regulated by CB2. CB2 deficient mice show a markedly accelerated age related bone loss and the CB2 locus in women is associated with low bone density and osteoporotic fractures. Since activation of CB2 attenuates experimentally induced bone loss by inhibiting bone resorption and stimulating bone formation, and because synthetic cannabinoids are stable and orally available, a therapy based on synthetic CB2 agonists is a promising novel target for antiosteoporotic drug development.
C1 Hebrew Univ Jerusalem, Bone Lab, IL 91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem
RP Bab, IA (通讯作者)，Hebrew Univ Jerusalem, Bone Lab, POB 12272, IL 91120 Jerusalem, Israel.
EM babi@cc.huji.ac.il
CR Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772
   Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092 8674(03)00771 2
   Alexander JM, 2001, J BONE MINER RES, V16, P1665, DOI 10.1359/jbmr.2001.16.9.1665
   Bab I, 2002, BIOPOLYMERS, V66, P33, DOI 10.1002/bip.10202
   BAB I, 1986, J CELL SCI, V84, P139
   Bab I., 2005, Cannabinoids as therapeutics, P201
   Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI200214588
   BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874
   Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129
   BROWN JP, 1984, LANCET, V1, P1091
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698
   Derkinderen P, 1996, SCIENCE, V273, P1719, DOI 10.1126/science.273.5282.1719
   Derkinderen P, 2001, J NEUROCHEM, V77, P957, DOI 10.1046/j.1471 4159.2001.00333.x
   DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919
   Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088
   Di Marzo V, 1999, EUR J BIOCHEM, V264, P258, DOI 10.1046/j.1432 1327.1999.00631.x
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Gabet Y, 2005, OSTEOPOROSIS INT, V16, P1436, DOI 10.1007/s00198 005 1876 6
   GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046
   GOMEZ DP, 2000, BIOCHEM J, V347, P369
   Günther T, 2000, NATURE, V406, P199, DOI 10.1038/35018111
   Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009 3084(00)00192 4
   Hanus L, 2001, P NATL ACAD SCI USA, V98, P3662, DOI 10.1073/pnas.061029898
   Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228
   Howlett AC, 2002, PROSTAG OTH LIPID M, V68 9, P619, DOI 10.1016/S0090 6980(02)00060 6
   Jorgensen NR, 2004, STEROIDS, V69, P219, DOI 10.1016/j.steroids.2003.12.005
   Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050
   Karsak M, 2005, HUM MOL GENET, V14, P3389, DOI 10.1093/hmg/ddi370
   Karsenty G, 2001, RECENT PROG HORM RES, V56, P401, DOI 10.1210/rp.56.1.401
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   KONRAD RJ, 1994, BIOCHEMISTRY US, V33, P13284, DOI 10.1021/bi00249a015
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Liu J, 2000, BIOCHEM J, V346, P835, DOI 10.1042/0264 6021:3460835
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006 2952(95)00109 D
   Melck D, 1999, FEBS LETT, V463, P235, DOI 10.1016/S0014 5793(99)01639 7
   Mombouli JV, 1999, BRIT J PHARMACOL, V126, P1593, DOI 10.1038/sj.bjp.0702483
   Most W, 1997, BONE, V20, P27, DOI 10.1016/S8756 3282(96)00309 2
   NICHOLSON GC, 1986, J CLIN INVEST, V78, P355, DOI 10.1172/JCI112584
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   ORZEL JA, 1985, J NUCL MED, V26, P125
   Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089
   PARFITT AM, 1982, METAB BONE DIS RELAT, V4, P1, DOI 10.1016/0221 8747(82)90002 9
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   POTTS JT, 1998, BONE METABOLISM BONE
   Rhee MH, 1998, J NEUROCHEM, V71, P1525
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814
   Scutt A, 2007, CALCIFIED TISSUE INT, V80, P50, DOI 10.1007/s00223 006 0171 7
   Segev E, 2006, J BONE MINER RES, V21, pS47
   Shire D, 1999, LIFE SCI, V65, P627, DOI 10.1016/S0024 3205(99)00285 4
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389
   Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015
   SUDA T, 2001, NOVART FDN SYMP, V232, P247
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   SUGIURA T, 2002, ESSENT FATTY ACIDS, V66, P173
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   TAM J, 2007, IN PRESS FASEB J
   Tam J, 2006, MOL PHARMACOL, V70, P786, DOI 10.1124/mol.106.026435
   Varga K, 1998, FASEB J, V12, P1035, DOI 10.1096/fasebj.12.11.1035
   WARTMANN M, 1995, FEBS LETT, V359, P133, DOI 10.1016/0014 5793(95)00027 7
   Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319
   Willoughby KA, 1997, J PHARMACOL EXP THER, V282, P243
   Yakar S, 2002, J CLIN INVEST, V110, P771, DOI 10.1172/JCI200215463
   Yamada Y, 2007, INT J MOL MED, V19, P791
   Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092 8674(00)00211 7
   ZHANG RW, 1995, CALCIFIED TISSUE INT, V56, P283, DOI 10.1007/BF00318048
   ZHOU H, 1994, J BONE MINER RES, V9, P1489
   Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780
   Zou W, 2002, FASEB J, V16, P274, DOI 10.1096/fj.01 0586com
NR 75
TC 18
Z9 28
U1 0
U2 8
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER STREET, HOBOKEN, NJ, UNITED STATES
BN 978 1 57331 684 2
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2007
VL 1116
BP 414
EP 422
DI 10.1196/annals.1402.014
PG 9
WC Endocrinology & Metabolism; Multidisciplinary Sciences; Orthopedics
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Science & Technology   Other Topics;
   Orthopedics
GA BHA44
UT WOS:000251898900037
PM 17646266
DA 2025 08 17
ER

PT J
AU Rachner, TD
   Khosla, S
   Hofbauer, LC
AF Rachner, Tilman D.
   Khosla, Sundeep
   Hofbauer, Lorenz C.
TI Osteoporosis: now and the future
SO LANCET
LA English
DT Article
ID CALCIUM SENSING RECEPTOR; BONE MINERAL DENSITY; CATHEPSIN K INHIBITOR;
   POSTMENOPAUSAL WOMEN; OSTEOPROTEGERIN LIGAND; SCLEROSTIN ANTIBODY;
   VERTEBRAL FRACTURE; DOUBLE BLIND; NONVERTEBRAL FRACTURES; TARGETED
   DISRUPTION
AB Osteoporosis is a common disease characterised by a systemic impairment of bone mass and microarchitecture that results in fragility fractures. With an ageing population, the medical and socioeconomic effect of osteoporosis, particularly postmenopausal osteoporosis, will increase further. A detailed knowledge of bone biology with molecular insights into the communication between bone forming osteoblasts and bone resorbing osteoclasts and the orchestrating signalling network has led to the identification of novel therapeutic targets. Novel treatment strategies have been developed that aim to inhibit excessive bone resorption and increase bone formation. The most promising novel treatments include: denosumab, a monoclonal antibody for receptor activator of NF kappa B ligand, a key osteoclast cytokine; odanacatib, a specific inhibitor of the osteoclast protease cathepsin K; and antibodies against the proteins sclerostin and dickkopf 1, two endogenous inhibitors of bone formation. This overview discusses these novel therapies and explains their underlying physiology.
C1 [Rachner, Tilman D.; Hofbauer, Lorenz C.] Tech Univ Dresden, Med Ctr, Div Endocrinol Diabet & Bone Dis, D 01307 Dresden, Germany.
   [Khosla, Sundeep] Mayo Clin, Rochester, MN USA.
   [Hofbauer, Lorenz C.] Ctr Regenerat Therapies Dresden, Dresden, Germany.
C3 Technische Universitat Dresden; Mayo Clinic; Technische Universitat
   Dresden
RP Hofbauer, LC (通讯作者)，Tech Univ Dresden, Med Ctr, Div Endocrinol Diabet & Bone Dis, Fetscherstr 74, D 01307 Dresden, Germany.
EM lorenz.hofbauer@uniklinikum dresden.de
RI ; Hofbauer, Lorenz/G 2490 2010; Khosla, Sundeep/AAE 6170 2020; Hofbauer,
   Lorenz C./G 2490 2010
OI Khosla, Sundeep/0000 0002 2936 4372; Hofbauer, Lorenz
   C./0000 0002 8691 8423
FU Amgen; Daiichi Sankyo; Merck; Novartis; Nycomed; Servier
FX TDR has received reimbursement of travel and accommodation expenses from
   Novartis. SK has received honoraria for serving on advisory boards for
   Bone Therapeutics and Pfizer. LCH has received honoraria and speakers
   fees, including reimbursement of travel and accommodation expenses, from
   Amgen, Daiichi Sankyo, Merck, Novartis, Nycomed, and Servier.
CR Balan G, 2009, BIOORG MED CHEM LETT, V19, P3328, DOI 10.1016/j.bmcl.2009.04.044
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI DOI 10.1056/NEJMOA067312
   Bolland MJ, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c3691
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   Brown E. M., 2007, V45, P139
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Brown JP, 2002, CAN MED ASSOC J, V167, pS1
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Canalis E, 2010, J CLIN ENDOCR METAB, V95, P1496, DOI 10.1210/jc.2009 2677
   Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140 6736(98)09075 8
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Compston J, 2009, MATURITAS, V62, P105, DOI 10.1016/j.maturitas.2008.11.022
   Cummings SR, 2002, JAMA J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Daddona PE, 2011, PHARM RES DORDR, V28, P159, DOI 10.1007/s11095 010 0192 9
   Delmas PD, 2002, J CLIN ENDOCR METAB, V87, P3609, DOI 10.1210/jc.87.8.3609
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363
   Fromigué O, 2009, J CELL MOL MED, V13, P2189, DOI 10.1111/j.1582 4934.2009.00673.x
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Giles RH, 2003, BBA REV CANCER, V1653, P1, DOI 10.1016/S0304 419X(03)00005 2
   Gowen M, 2000, J CLIN INVEST, V105, P1595, DOI 10.1172/JCI9038
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Hannon RA, 2010, J BONE MINER RES, V25, P463, DOI 10.1359/jbmr.090830
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Henriksen DB, 2003, J BONE MINER RES, V18, pS54
   Henriksen DB, 2009, BONE, V45, P833, DOI 10.1016/j.bone.2009.07.008
   Hodgson Stephen F, 2003, Endocr Pract, V9, P544
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Hsia J, 2007, CIRCULATION, V115, P846, DOI 10.1161/CIRCULATIONAHA.106.673491
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kumar S, 2010, BONE, V46, P534, DOI 10.1016/j.bone.2009.09.028
   Lewiecki EM, 2007, J BONE MINER RES, V22, P1832, DOI 10.1359/JBMR.070809
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Morony S, 2001, CANCER RES, V61, P4432
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   NIHPanel, 2001, JAMA J AM MED ASSOC, V285, P785, DOI DOI 10.1001/JAMA.285.6.785
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D, 2007, J BONE MINER RES, V22, pS37
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Peroni A, 2008, J AM ACAD DERMATOL, V59, P125, DOI 10.1016/j.jaad.2008.03.009
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Reid IR, 2010, J BONE MINER RES, V25, P2256, DOI 10.1002/jbmr.149
   Saftig P, 2000, ADV EXP MED BIOL, V477, P293
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Schaller S, 2004, J BONE MINER RES, V19, P1144, DOI 10.1359/JBMR.040302
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Siris ES, 2009, AM J MED, V122, P3, DOI 10.1016/j.amjmed.2008.12.002
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Steddon S, 2005, LANCET, V365, P2237, DOI 10.1016/S0140 6736(05)66782 7
   Stoch SA, 2009, CLIN PHARMACOL THER, V86, P175, DOI 10.1038/clpt.2009.60
   Stolina M, 2007, ADV EXP MED BIOL, V602, P143
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763
   Unnanuntana A, 2010, J BONE JOINT SURG AM, V92A, P743, DOI 10.2106/JBJS.I.00919
   Vestergaard P, 2005, OSTEOPOROSIS INT, V16, P134, DOI 10.1007/s00198 004 1680 8
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Zebaze RMD, 2010, LANCET, V375, P1729, DOI 10.1016/S0140 6736(10)60320 0
NR 92
TC 2115
Z9 2409
U1 32
U2 828
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140 6736
EI 1474 547X
J9 LANCET
JI Lancet
PD APR 9
PY 2011
VL 377
IS 9773
BP 1276
EP 1287
DI 10.1016/S0140 6736(10)62349 5
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 751DI
UT WOS:000289597300034
PM 21450337
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Munoz, MA
   Fletcher, EK
   Skinner, OP
   Jurczyluk, J
   Kristianto, E
   Hodson, MP
   Sun, ST
   Ebetino, FH
   Croucher, DR
   Hansbro, PM
   Center, JR
   Rogers, MJ
AF Munoz, Marcia A.
   Fletcher, Emma K.
   Skinner, Oliver P.
   Jurczyluk, Julie
   Kristianto, Esther
   Hodson, Mark P.
   Sun, Shuting
   Ebetino, Frank H.
   Croucher, David R.
   Hansbro, Philip M.
   Center, Jacqueline R.
   Rogers, Michael J.
TI Bisphosphonate drugs have actions in the lung and inhibit the mevalonate
   pathway in alveolar macrophages
SO ELIFE
LA English
DT Article
DE osteoporosis; pneumonia; bisphosphonate; prenylation; alveolar
   macrophage; inflammasome; Mouse
ID ZOLEDRONIC ACID; BONE RESORPTION; IN VIVO; MORTALITY; PYROPHOSPHATE;
   PAMIDRONATE; PRENYLATION; OSTEOCLASTS; MECHANISM; MONOCYTES
AB Bisphosphonates drugs target the skeleton and are used globally for the treatment of common bone disorders. Nitrogen containing bisphosphonates act by inhibiting the mevalonate pathway in bone resorbing osteoclasts but, surprisingly, also appear to reduce the risk of death from pneumonia. We overturn the long held belief that these drugs act only in the skeleton and show that a fluorescently labelled bisphosphonate is internalised by alveolar macrophages and large peritoneal macrophages in vivo. Furthermore, a single dose of a nitrogen containing bisphosphonate (zoledronic acid) in mice was sufficient to inhibit the mevalonate pathway in tissue resident macrophages, causing the build up of a mevalonate metabolite and preventing protein prenylation. Importantly, one dose of bisphosphonate enhanced the immune response to bacterial endotoxin in the lung and increased the level of cytokines and chemokines in bronchoalveolar fluid. These studies suggest that bisphosphonates, as well as preventing bone loss, may boost immune responses to infection in the lung and provide a mechanistic basis to fully examine the potential of bisphosphonates to help combat respiratory infections that cause pneumonia.
C1 [Munoz, Marcia A.; Fletcher, Emma K.; Skinner, Oliver P.; Jurczyluk, Julie; Croucher, David R.; Center, Jacqueline R.; Rogers, Michael J.] UNSW Sydney, Garvan Inst Med Res, Sydney, NSW, Australia.
   [Munoz, Marcia A.; Fletcher, Emma K.; Skinner, Oliver P.; Jurczyluk, Julie; Croucher, David R.; Center, Jacqueline R.; Rogers, Michael J.] UNSW Sydney, St Vincents Clin Sch, Sydney, NSW, Australia.
   [Kristianto, Esther; Hodson, Mark P.] Victor Chang Cardiac Res Inst Innovat Ctr, Sydney, NSW, Australia.
   [Hodson, Mark P.] Univ Queensland, Sch Pharm, Woolloongabba, Qld, Australia.
   [Sun, Shuting; Ebetino, Frank H.] BioVinc, Pasadena, CA USA.
   [Sun, Shuting] Univ Southern Calif, Los Angeles, CA 90007 USA.
   [Hansbro, Philip M.] Centenary Inst, Ctr Inflammat, Sydney, NSW, Australia.
   [Hansbro, Philip M.] Univ Technol Sydney, Sydney, NSW, Australia.
C3 University of New South Wales Sydney; Garvan Institute of Medical
   Research; University of New South Wales Sydney; University of
   Queensland; University of Southern California; University of Technology
   Sydney; University of Sydney; Centenary Institute; University of
   Technology Sydney
RP Rogers, MJ (通讯作者)，UNSW Sydney, Garvan Inst Med Res, Sydney, NSW, Australia.; Rogers, MJ (通讯作者)，UNSW Sydney, St Vincents Clin Sch, Sydney, NSW, Australia.
EM m.rogers@garvan.org.au
RI ; Hodson, Mark/J 7609 2013; Center, Jacqueline/AAY 8712 2021; Hansbro,
   Phil/G 7486 2013
OI Munoz, Marcia/0000 0001 7603 0351; Rogers, Michael/0000 0002 1818 9249; 
FU National Health and Medical Research Council (NHMRC) of Australia
   [1079522]; Mrs Janice Gibson and the Ernest Heine Family Foundation;
   Perpetual IMPACT grant; Australian Government Research Training Program
   Scholarship; University of Technology Sydney (UTS); New South Wales
   Government; Freedman Foundation for the Metabolomics Facility; NHMRC
   [1175134]; National Health and Medical Research Council of Australia
   [1175134, 1079522] Funding Source: NHMRC
FX We thank Prof Kirill Alexandrov (Queensland University of Technology)
   and Dr Zakir Tnimov (MRC Laboratory of Molecular Biology) for providing
   reagents for the Rab prenylation assay. This work was supported in part
   by the National Health and Medical Research Council (NHMRC) of Australia
   project grant 1079522 to MJR, by Mrs Janice Gibson and the Ernest Heine
   Family Foundation, and a Perpetual IMPACT grant to MAM. EKF was
   supported through an Australian Government Research Training Program
   Scholarship. PMH was funded by a Fellowship and grants from the NHMRC
   (1175134) and by the University of Technology Sydney (UTS). We
   gratefully acknowledge funding by the New South Wales Government for the
   Victor Chang Cardiac Research Institute Innovation Centre, as well as
   funding from the Freedman Foundation for the Metabolomics Facility.
CR Ali Naveid, 2015, Small GTPases, V6, P202, DOI 10.1080/21541248.2015.1085485
   Ghosn EEB, 2010, P NATL ACAD SCI USA, V107, P2568, DOI 10.1073/pnas.0915000107
   Byrne AJ, 2015, THORAX, V70, P1189, DOI 10.1136/thoraxjnl 2015 207020
   Cassado AD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00225
   Center JR, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115566
   Clézardin P, 2010, CURR PHARM DESIGN, V16, P3007, DOI 10.2174/138161210793563545
   Colón Emeric CS, 2010, J BONE MINER RES, V25, P91, DOI 10.1359/jbmr.090704
   Comito G, 2017, ONCOTARGET, V8, P118, DOI 10.18632/oncotarget.9497
   Coscia M, 2010, J CELL MOL MED, V14, P2803, DOI 10.1111/j.1582 4934.2009.00926.x
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Crane MJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01421
   Cyster JG, 2014, NAT REV IMMUNOL, V14, P731, DOI 10.1038/nri3755
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Einav S, 2003, J ANTIMICROB CHEMOTH, V52, P883, DOI 10.1093/jac/dkg490
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010
   Green JR, 2002, DRUG DEVELOP RES, V55, P210, DOI 10.1002/ddr.10071
   Han N, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abh3032
   Jomaa H, 1999, FEMS IMMUNOL MED MIC, V25, P371, DOI 10.1016/S0928 8244(99)00110 8
   Junankar S, 2015, CANCER DISCOV, V5, P35, DOI 10.1158/2159 8290.CD 14 0621
   Juno JA, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00233
   Kany S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236008
   Lee P, 2016, J CLIN ENDOCR METAB, V101, P1945, DOI 10.1210/jc.2015 3467
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Marakasova ES, 2017, BIOESSAYS, V39, DOI 10.1002/bies.201700014
   Morris DE, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01041
   Parihar SP, 2019, NAT REV IMMUNOL, V19, P104, DOI 10.1038/s41577 018 0094 3
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   Reid IR, 2021, CALCIFIED TISSUE INT, V109, P12, DOI 10.1007/s00223 021 00830 7
   Robertson KA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00634
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sapey E, 2019, AM J RESP CRIT CARE, V200, P1282, DOI 10.1164/rccm.201812 2328OC
   Schulman RC, 2016, ENDOCR PRACT, V22, P799, DOI 10.4158/EP151050.OR
   Sing CW, 2020, J BONE MINER RES, V35, P1676, DOI 10.1002/jbmr.4030
   Skinner OP, 2019, J ALLERGY CLIN IMMUN, V143, P2315, DOI 10.1016/j.jaci.2019.02.013
   TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0
   Tanaka Y, 2020, IMMUNOL REV, V298, P237, DOI 10.1111/imr.12917
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   Tu WW, 2011, J EXP MED, V208, P1511, DOI 10.1084/jem.20110226
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Zheng J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135999
NR 48
TC 11
Z9 11
U1 1
U2 8
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD DEC 30
PY 2021
VL 10
AR e72430
DI 10.7554/eLife.72430; 10.7554/eLife.72430.sa0; 10.7554/eLife.72430.sa1;
   10.7554/eLife.72430.sa2
PG 15
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA YB7AQ
UT WOS:000739160800001
PM 34967731
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Rotherham, M
   Henstock, JR
   Qutachi, O
   El Haj, AJ
AF Rotherham, Michael
   Henstock, James R.
   Qutachi, Omar
   El Haj, Alicia J.
TI Remote regulation of magnetic particle targeted Wnt signaling for bone
   tissue engineering
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Mesenchymal stem cells; Magnetic nanoparticles; Wnt signaling; Bone
   tissue engineering
ID MESENCHYMAL STEM CELLS; FACTOR RELEASING HYDROGELS; FEMUR DEFECT MODEL;
   BETA CATENIN; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION;
   NANOPARTICLES; PATHWAY; PROLIFERATION; TRANSDUCTION
AB Wnt signaling is critically involved in the differentiation of human Mesenchymal Stem Cells (hMSC). Wnt proteins therefore have considerable therapeutic value, but are expensive and difficult to produce. UM206 is a synthetic peptide and ligand for the Wnt receptor Frizzled. Attachment of UM206 to magnetic nanoparticles (MNP) enables the ligand MNP complex to be manipulated using magnetic fields, allowing control of Frizzled stimulation. Using this approach, Wnt signaling was activated in hMSC which resulted in Frizzled clustering, beta catenin translocalization and activation of TCF/LEF responsive transcription. During osteogenesis, UM206 MNP initiated localized mineralized matrix formation. Injection and magnetic stimulation of UM206 MNP labeled MSC in ex vivo chick femurs resulted in increased mineralization which acted synergistically with addition of bone morphogenic protein 2 (BMP2) releasing micro particles. As this facilitates external control over signal transduction, conjugated MNP technology has applications both as a research tool and for regulating tissue formation in clinical cell therapies. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Rotherham, Michael; Henstock, James R.; El Haj, Alicia J.] Keele Univ, Inst Sci & Technol Med, Stoke On Trent, Staffs, England.
   [Qutachi, Omar] Univ Nottingham, Sch Pharm, Nottingham, England.
   [Henstock, James R.] Inst Aging & Chron Dis, William Duncan Bldg,6 West Derby St, Liverpool L7 8TX, Merseyside, England.
C3 Keele University; University of Nottingham
RP Rotherham, M (通讯作者)，Keele Univ, Guy Hilton Res Ctr, Inst Sci & Technol Med, Stoke On Trent, Staffs, England.
EM m.rotherham@keele.ac.uk
RI ; Qutachi, Omar/AAD 7332 2019; Rotherham, Michael/K 7275 2019; Haj,
   Alicia/B 3315 2012
OI El Haj, Alicia/0000 0003 3544 5678; Rotherham,
   Michael/0000 0002 9297 7681; Henstock, James/0000 0002 8517 0679;
   Qutachi, Omar/0000 0002 5026 7358
FU BBSRC [BB/G010579/1]; European Union's Horizon research and innovation
   programme [686841]; BBSRC [BB/G010579/1] Funding Source: UKRI; MRC
   [MR/P020941/1] Funding Source: UKRI; Biotechnology and Biological
   Sciences Research Council [BB/G010579/1] Funding Source: researchfish;
   Medical Research Council [MR/P020941/1] Funding Source: researchfish
FX This research was funded by the BBSRC (grant no. BB/G010579/1) and the
   European Union's Horizon 2020 research and innovation programme (grant
   agreement no. 686841). The funding bodies had no involvement in the
   research and/or preparation of the article.
CR Akbarzadeh A, 2012, NANOSCALE RES LETT, V7, P1, DOI 10.1186/1556 276X 7 144
   Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Carron C, 2003, J CELL SCI, V116, P2541, DOI 10.1242/jcs.00451
   Cartmell Sarah H, 2002, IEEE Trans Nanobioscience, V1, P92, DOI 10.1109/TNB.2002.806945
   Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318
   Cong F, 2003, MOL CELL BIOL, V23, P8462, DOI 10.1128/MCB.23.23.8462 8470.2003
   Cook DA, 2014, STEM CELL RES, V12, P415, DOI 10.1016/j.scr.2013.10.002
   Coudreuse D, 2007, DEVELOPMENT, V134, P3, DOI 10.1242/dev.02699
   De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753
   Dobson J, 2006, IEEE T NANOBIOSCI, V5, P173, DOI 10.1109/TNB.2006.880823
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   Gothard D, 2014, EUR CELLS MATER, V28, P166, DOI 10.22203/eCM.v028a13
   Gothard D, 2014, EUR CELLS MATER, V28, P207
   Henstock JR, 2014, STEM CELL TRANSL MED, V3, P1363, DOI 10.5966/sctm.2014 0017
   Hu B, 2014, NANOMED NANOTECHNOL, V10, P45, DOI 10.1016/j.nano.2013.06.014
   Hu B, 2013, INT J MOL SCI, V14, P19276, DOI 10.3390/ijms140919276
   Hughes S, 2008, J R SOC INTERFACE, V5, P855, DOI 10.1098/rsif.2007.1274
   Ito A, 2004, TISSUE ENG, V10, P833, DOI 10.1089/1076327041348301
   Janeczek AA, 2016, STEM CELLS, V34, P418, DOI 10.1002/stem.2241
   Jeng HA, 2006, J ENVIRON SCI HEAL A, V41, P2699, DOI 10.1080/10934520600966177
   Kanczler JM, 2012, TISSUE ENG PART C ME, V18, P747, DOI 10.1089/ten.tec.2012.0033
   Kanczler JM, 2010, TISSUE ENG PT A, V16, P3241, DOI [10.1089/ten.tea.2009.0638, 10.1089/ten.TEA.2009.0638]
   Karahaliloglu Z, 2017, J BIOACT COMPAT POL, V32, P596, DOI 10.1177/0883911517693635
   Karlsson HL, 2009, TOXICOL LETT, V188, P112, DOI 10.1016/j.toxlet.2009.03.014
   Katoh M, 2011, CURR PHARM BIOTECHNO, V12, P160, DOI 10.2174/138920111794295710
   Kirby GTS, 2011, POLYMERS BASEL, V3, P571, DOI 10.3390/polym3010571
   Kolben T, 2012, BIOL CHEM, V393, P1433, DOI 10.1515/hsz 2012 0186
   Lee EA, 2014, ARCH PHARM RES, V37, P120, DOI 10.1007/s12272 013 0303 3
   Letamendia A, 2001, J BONE JOINT SURG AM, V83A, pS31
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Lowndes M, 2016, STEM CELL REP, V7, P126, DOI 10.1016/j.stemcr.2016.06.004
   Mahmoudi M, 2010, COLLOID SURFACE B, V75, P300, DOI 10.1016/j.colsurfb.2009.08.044
   Mannix RJ, 2008, NAT NANOTECHNOL, V3, P36, DOI 10.1038/nnano.2007.418
   Milat F, 2009, MOL CELL ENDOCRINOL, V310, P52, DOI 10.1016/j.mce.2009.06.002
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Moise S, 2017, SCI REP UK, V7, DOI 10.1038/srep39922
   Norvell SM, 2004, CALCIFIED TISSUE INT, V75, P396, DOI 10.1007/s00223 004 0213 y
   Oreffo ROC, 2005, STEM CELL REV, V1, P169, DOI 10.1385/SCR:1:2:169
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Quarto N, 2010, TISSUE ENG PT A, V16, P3185, DOI 10.1089/ten.tea.2010.0133
   Rao TP, 2010, CIRC RES, V106, P1798, DOI 10.1161/CIRCRESAHA.110.219840
   Rotherham M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121761
   Smith EL, 2014, ACTA BIOMATER, V10, P4186, DOI 10.1016/j.actbio.2014.06.011
   Smith EL, 2014, ACTA BIOMATER, V10, P4197, DOI 10.1016/j.actbio.2014.05.025
   Smith EL, 2013, EUR CELLS MATER, V26, P91, DOI 10.22203/eCM.v026a07
   Vaes BLT, 2005, BONE, V36, P803, DOI 10.1016/j.bone.2005.02.001
   Wang YXJ, 2011, QUANT IMAG MED SURG, V1, P35, DOI 10.3978/j.issn.2223 4292.2011.08.03
   Wimpenny I, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt104
NR 51
TC 43
Z9 47
U1 0
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD JAN
PY 2018
VL 14
IS 1
BP 173
EP 184
DI 10.1016/j.nano.2017.09.008
PG 12
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA FU4SG
UT WOS:000423842300017
PM 28965980
OA Green Submitted
DA 2025 08 17
ER

PT J
AU McKay, RR
   Taplin, ME
   Choueiri, TK
AF McKay, Rana R.
   Taplin, Mary Ellen
   Choueiri, Toni K.
TI Optimizing Bone Health and Minimizing Skeletal Morbidity in Men with
   Prostate Cancer
SO HEMATOLOGY ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Prostate cancer; Androgen deprivation therapy; Osteoporosis; Bone
   metastases; Skeletal related events; Bisphosphonate; Zoledronic acid;
   Denosumab
ID ANDROGEN DEPRIVATION THERAPY; ORAL SODIUM CLODRONATE; RANDOMIZED
   CONTROLLED TRIAL; PLACEBO CONTROLLED TRIAL; DOUBLE BLIND; ZOLEDRONIC
   ACID; MINERAL DENSITY; ELDERLY MEN; OLDER MEN; LONG TERM
AB Maintaining bone health is important in the management of men with prostate cancer. Patients receiving androgen deprivation therapy are at increased risk for treatment related osteoporosis, and patients with bone metastases are at increased risk for skeletal morbidity related to debilitating skeletal related events (SREs). Optimizing bone health in these patients includes lifestyle modifications, calcium/vitamin D supplementation, and osteoclast targeted agents in select high risk patients. No agent is approved for the prevention of bone metastases. Novel systemic agents have shown a beneficial effect bone by directly affecting tumor growth. Integration of these anticancer agents with osteoclast targeted agents warrants further investigation.
C1 [McKay, Rana R.; Taplin, Mary Ellen; Choueiri, Toni K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Lank Ctr Genitourinary Oncol,Dept Med Oncol,Dana, Boston, MA 02215 USA.
C3 Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Brigham & Women's Hospital
RP Choueiri, TK (通讯作者)，Harvard Univ, Brigham & Womens Hosp, Sch Med, Lank Ctr Genitourinary Oncol,Dept Med Oncol,Dana, 450 Brookline Ave, Boston, MA 02215 USA.
EM toni_choueiri@DFCI.harvard.edu
RI ; Choueiri, Toni/K 5238 2019
OI Choueiri, Toni/0000 0002 9201 3217; 
FU NCI NIH HHS [T32 CA009172] Funding Source: Medline
CR Amin S, 2006, AM J MED, V119, P426, DOI 10.1016/j.amjmed.2005.10.048
   [Anonymous], 2010, CLIN GUID PREV TREAT
   [Anonymous], J CLIN ONCOL S
   [Anonymous], 2012, J CLIN ONCOL S
   Arakawa H, 2012, BIOCHEM PHARMACOL, V84, P1070, DOI 10.1016/j.bcp.2012.07.026
   Barry MJ, 2006, BJU INT, V98, P973, DOI 10.1111/j.1464 410X.2006.06416.x
   Bilezikian JP, 1999, J CLIN ENDOCR METAB, V84, P3431, DOI 10.1210/jc.84.10.3431
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   *CAN LEUK GROUP, ZOL PREV SKEL BON RE
   Carbonare LD, 2010, DRUG HEALTHC PATIENT, V2, P121, DOI 10.2147/DHPS.S6285
   Chung M, 2011, ANN INTERN MED, V155, P827, DOI 10.7326/0003 4819 155 12 201112200 00005
   Cook RJ, 2006, CLIN CANCER RES, V12, P3361, DOI 10.1158/1078 0432.CCR 06 0269
   Cummings SR, 2006, J BONE MINER RES, V21, P1550, DOI 10.1359/JBMR.060708
   Daniell HW, 2000, J UROLOGY, V163, P181, DOI 10.1016/S0022 5347(05)68000 7
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   Dearnaley DP, 2009, LANCET ONCOL, V10, P872, DOI 10.1016/S1470 2045(09)70201 3
   Dearnaley DP, 2003, J NATL CANCER I, V95, P1300, DOI 10.1093/jnci/djg038
   Diamond TH, 2004, CANCER AM CANCER SOC, V100, P892, DOI 10.1002/cncr.20056
   Diamond TH, 2001, CANCER AM CANCER SOC, V92, P1444, DOI 10.1002/1097 0142(20010915)92:6<1444::AID CNCR1468>3.0.CO;2 M
   Donaldson MG, 2010, J BONE MINER RES, V25, P1506, DOI 10.1002/jbmr.55
   Ernst DS, 2003, J CLIN ONCOL, V21, P3335, DOI 10.1200/JCO.2003.03.042
   Falahati Nini A, 2000, J CLIN INVEST, V106, P1553, DOI 10.1172/JCI10942
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gilbert SM, 2011, UROL ONCOL SEMIN ORI, V29, P647, DOI 10.1016/j.urolonc.2009.09.004
   Goyal J, 2012, CANCER LETT, V323, P135, DOI 10.1016/j.canlet.2012.04.001
   Gralow JR, 2009, J NATL COMPR CANC NE, V7, pS1, DOI 10.6004/jnccn.2009.0076
   Greenspan SL, 2005, J CLIN ENDOCR METAB, V90, P6410, DOI 10.1210/jc.2005 0183
   Guise Theresa A, 2007, Rev Urol, V9, P163
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Khan AA, 2009, J RHEUMATOL, V36, P478, DOI 10.3899/jrheum.080759
   Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Klotz LH, 2013, EUR UROL, V63, P927, DOI 10.1016/j.eururo.2012.09.007
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lee H, 2005, CANCER AM CANCER SOC, V104, P1633, DOI 10.1002/cncr.21381
   Lee RJ, 2010, CLIN GENITOURIN CANC, V8, P29, DOI 10.3816/CGC.2010.n.005
   Lester JE, 2006, BRIT J CANCER, V94, P30, DOI 10.1038/sj.bjc.6602892
   Logothetis CJ, 2012, LANCET ONCOL, V13, P1210, DOI 10.1016/S1470 2045(12)70473 4
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   Mason MD, 2007, JNCI J NATL CANCER I, V99, P765, DOI 10.1093/jnci/djk178
   Mellström D, 2008, J BONE MINER RES, V23, P1552, DOI 10.1359/JBMR.080518
   Michaelson MD, 2007, J CLIN ONCOL, V25, P1038, DOI 10.1200/JCO.2006.07.3361
   Mittan D, 2002, J CLIN ENDOCR METAB, V87, P3656, DOI 10.1210/jc.87.8.3656
   Morabito N, 2004, J BONE MINER RES, V19, P1766, DOI 10.1359/JBMR.040813
   Nilsson S, 2005, CLIN CANCER RES, V11, P4451, DOI 10.1158/1078 0432.CCR 04 2244
   Norgaard M, 2010, J UROLOGY, V184, P162, DOI 10.1016/j.juro.2010.03.034
   Oefelein MG, 2002, J UROLOGY, V168, P1005, DOI 10.1016/S0022 5347(05)64561 2
   Papapoulos SE, 2008, BEST PRACT RES CL EN, V22, P831, DOI 10.1016/j.beem.2008.07.001
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71
   Plotkin LI, 2008, J BONE MINER RES, V23, P1712, DOI [10.1359/jbmr.080617, 10.1359/JBMR.080617]
   PORTER AT, 1993, INT J RADIAT ONCOL, V25, P805, DOI 10.1016/0360 3016(93)90309 J
   QUILTY PM, 1994, RADIOTHER ONCOL, V31, P33, DOI 10.1016/0167 8140(94)90411 1
   Rochira V, 2006, EUR J ENDOCRINOL, V154, P175, DOI 10.1530/eje.1.02088
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   *S ONC GROUP, OST JAW PAT CANC REC
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   SAAD F, 2012, ASCO M S15, V30, P4510
   Saad F, 2010, CANCER TREAT REV, V36, P177, DOI 10.1016/j.ctrv.2009.11.005
   Sartor O, 2004, UROLOGY, V63, P940, DOI 10.1016/j.urology.2004.01.034
   Saylor PJ, 2011, J CLIN ONCOL, V29, P3705, DOI 10.1200/JCO.2010.34.4994
   Saylor PJ, 2010, J UROLOGY, V183, P2200, DOI 10.1016/j.juro.2010.02.022
   Schoppet M, 2002, ARTERIOSCL THROM VAS, V22, P549, DOI 10.1161/01.ATV.0000012303.37971.DA
   Schuit SCE, 2004, BONE, V34, P195, DOI 10.1016/j.bone.2003.10.001
   Serafini AN, 1998, J CLIN ONCOL, V16, P1574, DOI 10.1200/JCO.1998.16.4.1574
   Neto AS, 2012, PROSTATE CANCER P D, V15, P36, DOI 10.1038/pcan.2011.4
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Siegel R, 2012, CA CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smith MR, 2010, J UROLOGY, V184, P1316, DOI 10.1016/j.juro.2010.06.022
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Smith MR, 2005, J CLIN ONCOL, V23, P7897, DOI 10.1200/JCO.2004.00.6908
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Smith MR, 2004, J CLIN ENDOCR METAB, V89, P3841, DOI 10.1210/jc.2003 032058
   Smith MR, 2001, NEW ENGL J MED, V345, P948, DOI 10.1056/NEJMoa010845
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Tripkovic L, 2012, AM J CLIN NUTR, V95, P1357, DOI 10.3945/ajcn.111.031070
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   WITJES W, 2006, ASCO M S18, V24, P14644
NR 87
TC 6
Z9 6
U1 0
U2 4
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0889 8588
EI 1558 1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD DEC
PY 2013
VL 27
IS 6
BP 1261
EP +
DI 10.1016/j.hoc.2013.08.009
PG 24
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA 261QV
UT WOS:000327680600010
PM 24188262
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Gazzerro, E
   Minetti, C
AF Gazzerro, Elisabetta
   Minetti, Carlo
TI Potential drug targets within bone morphogenetic protein signaling
   pathways
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID MOUSE EMBRYOS LACKING; E3 UBIQUITIN LIGASE; OSTEOBLAST DIFFERENTIATION;
   SKELETAL OVEREXPRESSION; NEGATIVE REGULATION; BMP ANTAGONIST; MICE
   LACKING; STEM CELLS; IN VIVO; NOGGIN
AB Bone morphogenetic proteins (BMPs) play an essential role in skeletal tissue, as they induce the commitment of mesenchymal cells toward cells of the osteoblastic lineage and also enhance the differentiated function of the osteoblast. BMPs are required for skeletal development, maintenance of adult bone homeostasis and fracture healing. BMP actions are tempered by extracellular and intracellular signals that block BMP signal transduction at multiple levels. Identification of these BMP regulatory molecules allows us to investigate their role in diseases that affect skeletal function and could provide a novel therapeutic intervention point for treatment. Both extracellular and intracellular antagonists are regulated by BMPs, indicating the existence and need for local feedback mechanisms to modulate BMP biological responses.
C1 Ist Giannina Gaslini, Unit Musc & Neurodegenerat Disorders, I 16148 Genoa, Italy.
C3 University of Genoa; IRCCS Istituto Giannina Gaslini
RP Gazzerro, E (通讯作者)，Ist Giannina Gaslini, Unit Musc & Neurodegenerat Disorders, I 16148 Genoa, Italy.
EM elisabettagazzerro@ospedalegaslini.ge.it; minettic@unige.it
RI Minetti, Carlo/K 4666 2018; MINETTI, Carlo/K 4666 2018
OI MINETTI, Carlo/0000 0002 0640 1804
CR Anderson HC, 2000, J HISTOCHEM CYTOCHEM, V48, P1493, DOI 10.1177/002215540004801106
   Babitt JL, 2005, J BIOL CHEM, V280, P29820, DOI 10.1074/jbc.M503511200
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Chen B, 2002, BIOCHEM BIOPH RES CO, V295, P1135, DOI 10.1016/S0006 291X(02)00828 8
   Chen D, 2003, J BONE MINER RES, V18, pS6
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810
   Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002 220918
   Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Gazzerro E, 2005, ENDOCRINOLOGY, V146, P655, DOI 10.1210/en.2004 0766
   Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459
   GAZZERRO E, 2006, P ABSTR 28 ANN M AM
   Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154 006 9000 6
   Glaser DL, 2003, J BONE JOINT SURG AM, V85A, P2332, DOI 10.2106/00004623 200312000 00010
   Gong YQ, 1999, NAT GENET, V21, P302, DOI 10.1038/6821
   Guo D, 2004, J BONE MINER RES, V19, pS14
   Gupta MC, 2005, CYTOKINE GROWTH F R, V16, P347, DOI 10.1016/j.cytogfr.2005.02.004
   Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Khokha MK, 2003, NAT GENET, V34, P303, DOI 10.1038/ng1178
   Kishigami S, 2005, CYTOKINE GROWTH F R, V16, P265, DOI 10.1016/j.cytogfr.2005.04.002
   Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200
   Lana DP, 1996, DEV DYNAM, V205, P13, DOI 10.1002/(SICI)1097 0177(199601)205:1<13::AID AJA2>3.0.CO;2 8
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Lories RJU, 2005, J CLIN INVEST, V115, P1571, DOI 10.1172/JCI23738
   LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808
   Luo KX, 2003, J BONE JOINT SURG AM, V85A, P39, DOI 10.2106/00004623 200300003 00008
   Marcelino J, 2001, P NATL ACAD SCI USA, V98, P11353, DOI 10.1073/pnas.201367598
   McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438
   Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027
   Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009
   Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02 07 0441
   Nishimura R, 2003, FRONT BIOSCI, V8, pS275, DOI 10.2741/1049
   Nohe A, 2005, J CELL SCI, V118, P643, DOI 10.1242/jcs.01402
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200
   Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P6741, DOI 10.1210/jc.2005 2370
   Pathi S, 1999, DEV BIOL, V209, P239, DOI 10.1006/dbio.1998.9181
   Peng HR, 2005, MOL THER, V12, P239, DOI 10.1016/j.ymthe.2005.02.027
   Pereira RC, 2000, ENDOCRINOLOGY, V141, P4558, DOI 10.1210/en.141.12.4558
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Samad TA, 2005, J BIOL CHEM, V280, P14122, DOI 10.1074/jbc.M410034200
   Schwaninger R, 2007, AM J PATHOL, V170, P160, DOI 10.2353/ajpath.2007.051276
   Seeherman H, 2005, CYTOKINE GROWTH F R, V16, P329, DOI 10.1016/j.cytogfr.2005.05.001
   Shen R, 2006, J BIOL CHEM, V281, P3569, DOI 10.1074/jbc.M506761200
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Solloway MJ, 1998, DEV GENET, V22, P321, DOI 10.1002/(SICI)1520 6408(1998)22:4<321::AID DVG3>3.3.CO;2 7
   Suzuki A, 2006, P NATL ACAD SCI USA, V103, P10294, DOI 10.1073/pnas.0506945103
   Suzuki H, 2004, ONCOGENE, V23, P5068, DOI 10.1038/sj.onc.1207690
   Suzuki M, 2006, CANCER LETT, V242, P222, DOI 10.1016/j.canlet.2005.11.002
   Suzuki N, 1996, DEVELOPMENT, V122, P3587
   Topol LZ, 1997, MOL CELL BIOL, V17, P4801, DOI 10.1128/MCB.17.8.4801
   Tremblay KD, 2001, DEVELOPMENT, V128, P3609
   Tsuji K, 2004, J BONE MINER RES, V19, pS11
   Tsumaki N, 2002, J BONE MINER RES, V17, P898, DOI 10.1359/jbmr.2002.17.5.898
   WARNINGTON K, 2005, P ABSTR 27 ANN M AM
   Warren SM, 2003, NATURE, V422, P625, DOI 10.1038/nature01545
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105
   Wong BR, 2003, DRUG DISCOV TODAY, V8, P746, DOI 10.1016/S1359 6446(03)02780 6
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Yi SE, 2000, DEVELOPMENT, V127, P621
   Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092 8674(00)00211 7
   Zhang HB, 1996, DEVELOPMENT, V122, P2977
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012
NR 77
TC 25
Z9 53
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471 4892
EI 1471 4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD JUN
PY 2007
VL 7
IS 3
BP 325
EP 333
DI 10.1016/j.coph.2007.01.003
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 176ZH
UT WOS:000247122900016
PM 17475557
DA 2025 08 17
ER

PT J
AU Kobayashi Sun, J
   Kobayashi, I
   Kashima, M
   Hirayama, J
   Kakikawa, M
   Yamada, S
   Suzuki, N
AF Kobayashi Sun, Jingjing
   Kobayashi, Isao
   Kashima, Makoto
   Hirayama, Jun
   Kakikawa, Makiko
   Yamada, Sotoshi
   Suzuki, Nobuo
TI Extremely low frequency electromagnetic fields facilitate both
   osteoblast and osteoclast activity through Wnt/β catenin signaling in
   the zebrafish scale
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE electromagnetic fields; osteoblast; osteoclast; zebrafish scale;
   Wnt/beta catenin signaling
ID MOLECULAR MECHANISMS; MELATONIN SUPPRESSES; BONE FORMATION;
   DIFFERENTIATION; OSTEOPROTEGERIN; PROLIFERATION; STIMULATION; INCREASES;
   EXPRESSION; PATHWAYS
AB Electromagnetic fields (EMFs) have received widespread attention as effective, noninvasive, and safe therapies across a range of clinical applications for bone disorders. However, due to the various frequencies of devices, their effects on tissues/cells are vary, which has been a bottleneck in understanding the effects of EMFs on bone tissue. Here, we developed an in vivo model system using zebrafish scales to investigate the effects of extremely low frequency EMFs (ELF EMFs) on fracture healing. Exposure to 10 millitesla (mT) of ELF EMFs at 60 Hz increased the number of both osteoblasts and osteoclasts in the fractured scale, whereas 3 or 30 mT did not. Gene expression analysis revealed that exposure to 10 mT ELF EMFs upregulated wnt10b and Wnt target genes in the fractured scale. Moreover, beta catenin expression was enhanced by ELF EMFs predominantly at the fracture site of the zebrafish scale. Inhibition of Wnt/beta catenin signaling by IWR 1 endo treatment reduced both osteoblasts and osteoclasts in the fractured scale exposed to ELF EMFs. These results suggest that ELF EMFs promote both osteoblast and osteoclast activity through activation of Wnt/beta catenin signaling in fracture healing. Our data provide in vivo evidence that ELF EMFs generated with a widely used commercial AC power supply have a facilitative effect on fracture healing.
C1 [Kobayashi Sun, Jingjing; Hirayama, Jun] Komatsu Univ, Fac Hlth Sci, Dept Clin Engn, Komatsu, Ishikawa, Japan.
   [Kobayashi Sun, Jingjing; Kobayashi, Isao; Kakikawa, Makiko] Kanazawa Univ, Inst Sci & Engn, Fac Biol Sci & Technol, Kanazawa, Ishikawa, Japan.
   [Kashima, Makoto] Toho Univ, Fac Sci, Dept Biomol Sci, Funabashi, Chiba, Japan.
   [Yamada, Sotoshi] Komatsu Univ, Fac Prod Syst Engn & Sci, Dept Prod Syst Engn & Sci, Komatsu, Ishikawa, Japan.
   [Yamada, Sotoshi; Suzuki, Nobuo] Kanazawa Univ, Inst Nat & Environm Technol, Noto Marine Lab, Kanazawa, Ishikawa, Japan.
C3 Kanazawa University; Toho University; Kanazawa University
RP Kobayashi, I (通讯作者)，Kanazawa Univ, Inst Sci & Engn, Fac Biol Sci & Technol, Kanazawa, Ishikawa, Japan.
EM ikobayashi@se.kanazawa u.ac.jp
RI SUZUKI, Nobuo/J 8420 2015
FU Japan Society for the Promotion of Science [22KJ2574, 23K14111,
   23K10933]; Watanabe Foundation [01108]; Grants in Aid for Scientific
   Research [22K12763] Funding Source: KAKEN
FX The author(s) declare financial support was received for the research,
   authorship, and/or publication of this article. This work was supported
   in part by a Grant in Aid for JSPS Fellows (22KJ2574), a Grant in Aid
   for Early Career Scientists (23K14111), a Grant in Aid for Scientific
   Research C (23K10933) from the Japan Society for the Promotion of
   Science, and Watanabe Foundation (01108).
CR Aman AJ, 2018, ELIFE, V7, DOI 10.7554/eLife.37001
   Assiotis A, 2012, J ORTHOP SURG RES, V7, DOI 10.1186/1749 799X 7 24
   Barnaba SA, 2012, RHEUMATOL INT, V32, P1025, DOI 10.1007/s00296 010 1724 7
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   BASSETT CAL, 1974, SCIENCE, V184, P575
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bergen DJM, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00006
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Caliogna L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147403
   Chang K, 2005, J ORTHOP RES, V23, P1308, DOI 10.1016/j.orthres.2005.03.012
   Chang K, 2003, BIOELECTROMAGNETICS, V24, P431, DOI 10.1002/bem.10118
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Consales C., 2012, INT J CELL BIOL, V2012, pe683897, DOI [10.1155/2012/683897, DOI 10.1155/2012/683897]
   Di Bartolomeo M, 2022, BIOLOGY BASEL, V11, DOI 10.3390/biology11030402
   Dietrich K, 2021, J BONE MINER RES, V36, P436, DOI 10.1002/jbmr.4256
   Esposito M, 2012, IN VIVO, V26, P299
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Hirayama J, 2023, J PINEAL RES, V74, DOI 10.1111/jpi.12834
   Huang MQ, 2023, CANCER MED US, V12, P2187, DOI 10.1002/cam4.5112
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Hurley MM, 1998, BONE, V22, P309, DOI 10.1016/S8756 3282(97)00292 5
   Kamitani M, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 43600 0
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Kashima Makoto, 2022, Methods Mol Biol, V2509, P69, DOI 10.1007/978 1 0716 2380 0_4
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kimura K, 2022, STEM CELLS, V40, P831, DOI 10.1093/stmcls/sxac044
   Kobayashi Y, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.82
   Kobayashi Sun J, 2020, BIOCHEM BIOPH RES CO, V530, P644, DOI 10.1016/j.bbrc.2020.07.075
   Kobayashi Sun J, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003 020 0925 1
   Liu CX, 2013, BIOELECTROMAGNETICS, V34, P453, DOI 10.1002/bem.21791
   Liu JQ, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 021 00762 6
   Liu QM, 2023, INT J BIOL MACROMOL, V253, DOI 10.1016/j.ijbiomac.2023.126842
   Liu Y, 2023, INT J STEM CELLS, V16, P342, DOI 10.15283/ijsc22101
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Madel MB, 2020, ELIFE, V9, DOI 10.7554/eLife.54493
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Markov MS, 2000, J BACK MUSCULOSKELET, V15, P17, DOI 10.3233/BMR 2000 15103
   Matsuzaki E, 2013, BONE, V55, P315, DOI 10.1016/j.bone.2013.04.008
   Miyakawa T, 2001, BIOELECTROMAGNETICS, V22, P333, DOI 10.1002/bem.58
   Pasqualetti S, 2012, CELL TISSUE RES, V350, P69, DOI 10.1007/s00441 012 1436 2
   Pi Y, 2019, MOL MED REP, V19, P4129, DOI 10.3892/mmr.2019.10079
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Razavi Shahnaz, 2014, Adv Biomed Res, V3, P25, DOI 10.4103/2277 9175.124668
   Rissanen JP, 2008, CALCIFIED TISSUE INT, V82, P108, DOI 10.1007/s00223 007 9091 4
   Shankar VS, 1998, J CELL PHYSIOL, V176, P537, DOI 10.1002/(SICI)1097 4652(199809)176:3<537::AID JCP10>3.0.CO;2 X
   Shao J, 2018, BONE, V108, P165, DOI 10.1016/j.bone.2018.01.010
   Soda A, 2008, J MED INVESTIG, V55, P267, DOI 10.2152/jmi.55.267
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Suzuki N, 2002, J PINEAL RES, V33, P253, DOI 10.1034/j.1600 079X.2002.02953.x
   Uehara S, 2018, CELL MOL LIFE SCI, V75, P3683, DOI 10.1007/s00018 018 2881 1
   WESTERFIELD M, 1995, ZEBRAFISH BOOK
   Yamaguchi S, 2006, BIOELECTROMAGNETICS, V27, P64, DOI 10.1002/bem.20177
   Zhou J, 2019, J BONE MINER RES, V34, P1336, DOI 10.1002/jbmr.3704
   Zhou J, 2013, RHEUMATOL INT, V33, P1135, DOI 10.1007/s00296 012 2499 9
NR 56
TC 1
Z9 1
U1 2
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD FEB 7
PY 2024
VL 12
AR 1340089
DI 10.3389/fcell.2024.1340089
PG 14
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA IM3D6
UT WOS:001166695200001
PM 38385024
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Gossiel, F
   Scott, JR
   Paggiosi, MA
   Naylor, KE
   McCloskey, EV
   Peel, NFA
   Walsh, JS
   Eastell, R
AF Gossiel, Fatma
   Scott, Jessica R.
   Paggiosi, Margaret A.
   Naylor, Kim E.
   McCloskey, Eugene V.
   Peel, Nicola F. A.
   Walsh, Jennifer S.
   Eastell, Richard
TI Effect of Teriparatide Treatment on Circulating Periostin and Its
   Relationship to Regulators of Bone Formation and BMD in Postmenopausal
   Women With Osteoporosis
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID PARATHYROID HORMONE 1 34; ZOLEDRONIC ACID; RAT BONE; PTH; ALENDRONATE;
   THERAPY; FRACTURES; DENOSUMAB; PROTEIN; MASS
AB Context: Treatment of postmenopausal osteoporosis with teriparatide parathyroid hormone amino terminal 1 34 increases bone formation and improves bone microarchitecture. Apossible modulator of action is periostin. In vitro experiments have shown that periostin might regulate osteoblast differentiation and bone formation through Wnt signaling. The effect of teriparatide on periostin is not currently known.
   Objectives: To determine the effect of teriparatide treatment on circulating levels of periostin and other regulators of bone formation and investigate how changes in periostin relate to changes in bone turnover markers, regulators of bone formation, and bone mineral density (BMD).
   Participants and Design: Twenty women with osteoporosis; a 2 year open label single arm study.
   Intervention: Teriparatide 20 mu g was administered by subcutaneous injection daily for 104 weeks. Periostin, sclerostin, and Dickkopf related protein 1, procollagen type I N terminal propeptide (PINP), and C telopeptide of type I collagen were measured in fasting serum collected at baseline (two visits) and then at weeks 1, 2, 4, 12, 26, 52, 78, and 104. BMD was measured at the lumbar spine, total hip, and femoral neck using dual energy x ray absorptiometry.
   Results: Periostin levels increased by 6.6% [95% confidence interval (CI),  0.4 to 13.5] after 26 weeks of teriparatide treatment and significantly by 12.5% (95% CI, 3.3 to 21.0; P < 0.01) after 52 weeks. The change in periostin correlated positively with the change in the lumbar spine BMD at week 52 (r = 0.567; 95% CI, 0.137 to 0.817; P < 0.05) and femoral neck BMD at week 104 (r = 0.682; 95% CI, 0.261 to 0.885; P < 0.01).
   Conclusions: Teriparatide therapy increases periostin secretion; it is unclear whether this increase mediates the effect of the drug on bone.
C1 [Gossiel, Fatma; Scott, Jessica R.; Paggiosi, Margaret A.; Naylor, Kim E.; McCloskey, Eugene V.; Walsh, Jennifer S.; Eastell, Richard] Univ Sheffield, Dept Oncol & Metab, Mellanby Ctr Bone Res, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
   [Peel, Nicola F. A.] Sheffield Teaching Hosp Natl Hlth Serv Fdn Trust, Metab Bone Ctr, Sheffield S10 2JF, S Yorkshire, England.
C3 University of Sheffield; University of Sheffield
RP Gossiel, F (通讯作者)，Univ Sheffield, Dept Oncol & Metab, Mellanby Ctr Bone Res, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM f.gossiel@sheffield.ac.uk
RI ; McCloskey, Eugene/T 5197 2019; Eastell, Richard/G 5851 2011
OI Walsh, Jennifer/0000 0002 7122 2650; Paggiosi,
   Margaret/0000 0002 1030 0723
FU National Institute for Health Research Bone Biomedical Research Unit
   award; MRC [MR/K006312/1, MR/P020941/1] Funding Source: UKRI; Medical
   Research Council [MR/K006312/1, MR/P020941/1] Funding Source:
   researchfish; National Institute for Health Research [NF SI 0513 10073]
   Funding Source: researchfish
FX The present study was funded by a National Institute for Health Research
   Bone Biomedical Research Unit award (National Institute for Health
   Research; available at: http://dx.doi.org/10.13039/501100000272) to R.E.
   The study drug costs were provided by Eli Lilly and Company. The
   periostin assay kitswere provided by Biomedica Gruppe. The bone turnover
   markers were provided by Immunodiagnostics Systems.
CR Aguilera O, 2007, CARCINOGENESIS, V28, P1877, DOI 10.1093/carcin/bgm094
   Anastasilakis AD, 2014, HORM METAB RES, V46, P145, DOI 10.1055/s 0033 1351250
   Anastasilakis AD, 2010, CLIN ENDOCRINOL, V72, P752, DOI 10.1111/j.1365 2265.2009.03728.x
   Arlot M, 2005, J BONE MINER RES, V20, P1244, DOI 10.1359/JBMR.050309
   Bianchi EN, 2009, BONE, V45, P716, DOI 10.1016/j.bone.2009.06.020
   Bonnet N, 2015, J CLIN ENDOCR METAB, V100, pE1014, DOI 10.1210/jc.2015 1183
   Bonnet N, 2016, MOL CELL ENDOCRINOL, V432, P85, DOI 10.1016/j.mce.2015.12.014
   Bonnet N, 2012, P NATL ACAD SCI USA, V109, P15048, DOI 10.1073/pnas.1203085109
   Bonnet N, 2009, J BIOL CHEM, V284, P35939, DOI 10.1074/jbc.M109.060335
   Chan CSL, 2008, PERIOSTIN INTERACTS
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Cosman F, 2001, J BONE MINER RES, V16, P925, DOI 10.1359/jbmr.2001.16.5.925
   Dempster DW, 2016, J CLIN ENDOCR METAB, V101, P1353, DOI 10.1210/jc.2015 4181
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Drake MT, 2010, J CLIN ENDOCR METAB, V95, P5056, DOI 10.1210/jc.2010 0720
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Fortunati D, 2010, MATRIX BIOL, V29, P594, DOI 10.1016/j.matbio.2010.07.001
   Gadermaier E, 2017, J CLIN LAB ANAL
   Gatti D, 2011, J CLIN ENDOCR METAB, V96, P1555, DOI 10.1210/jc.2010 2552
   Ghatak S, 2014, J BIOL CHEM, V289, P8545, DOI 10.1074/jbc.M113.539882
   Glover SJ, 2009, BONE, V45, P1053, DOI 10.1016/j.bone.2009.07.091
   Haertel Wiesmann M, 2000, J BIOL CHEM, V275, P32046, DOI 10.1074/jbc.M000074200
   Hansen S, 2013, J BONE MINER RES, V28, P736, DOI 10.1002/jbmr.1784
   Idolazzi L, 2016, OSTEOPOROSIS INT, V27, P3301, DOI 10.1007/s00198 016 3647 y
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Kim BJ, 2015, BONE, V81, P435, DOI 10.1016/j.bone.2015.08.014
   Kudo A, 2011, CELL MOL LIFE SCI, V68, P3201, DOI 10.1007/s00018 011 0784 5
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Leder BZ, 2014, J CLIN ENDOCR METAB, V99, P1694, DOI 10.1210/jc.2013 4440
   Lindsay R, 2006, J BONE MINER RES, V21, P366, DOI 10.1359/JBMR.051109
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   Ma YL, 2014, BONE, V59, P139, DOI 10.1016/j.bone.2013.11.011
   Maruhashi T, 2010, J BIOL CHEM, V285, P13294, DOI 10.1074/jbc.M109.088864
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Morra L, 2011, VIRCHOWS ARCH, V459, P465, DOI 10.1007/s00428 011 1151 5
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Onyia JE, 2005, J CELL BIOCHEM, V95, P403, DOI 10.1002/jcb.20438
   Paggiosi MA, 2014, CALCIFIED TISSUE INT, V94, P191, DOI 10.1007/s00223 013 9798 3
   Parfitt AM, 2002, J BONE MINER RES, V17, P1741, DOI 10.1359/jbmr.2002.17.10.1741
   Polyzos SA, 2012, OSTEOPOROSIS INT, V23, P1171, DOI 10.1007/s00198 010 1525 6
   Reppe S, 2006, BONE, V39, P189, DOI 10.1016/j.bone.2005.12.020
   Robling AG, 2011, ENDOCRINOLOGY, V152, P2963, DOI 10.1210/en.2011 0049
   Rousseau JC, 2014, J CLIN ENDOCR METAB, V99, P2533, DOI 10.1210/jc.2013 3893
   Rubin MR, 2003, CLIN GERIATR MED, V19, P415, DOI 10.1016/S0749 0690(02)00074 5
   Silvestrini G, 2007, J MOL HISTOL, V38, P261, DOI 10.1007/s10735 007 9096 3
   Tkatchenko TV, 2009, PHYSIOL GENOMICS, V39, P160, DOI 10.1152/physiolgenomics.00078.2009
   Zanchetta JR, 2003, J BONE MINER RES, V18, P539, DOI 10.1359/jbmr.2003.18.3.539
NR 48
TC 17
Z9 20
U1 1
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD APR
PY 2018
VL 103
IS 4
BP 1302
EP 1309
DI 10.1210/jc.2017 00283
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GC0BS
UT WOS:000429442000010
PM 29365099
OA Green Published, Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Adam, C
   Glück, L
   Ebert, R
   Goebeler, M
   Jakob, F
   Schmidt, M
AF Adam, Christian
   Glueck, Lucia
   Ebert, Regina
   Goebeler, Matthias
   Jakob, Franz
   Schmidt, Marc
TI The MEK5/ERK5 mitogen activated protein kinase cascade is an effector
   pathway of bone sustaining bisphosphonates that regulates osteogenic
   differentiation and mineralization
SO BONE
LA English
DT Article
DE Bisphosphonate; Osteoporosis; ERK5; Osteogenic differentiation;
   Kruppel like factor; Bone mineralization
ID MESENCHYMAL STEM CELLS; ZOLEDRONIC ACID; ERK5 ACTIVATION; ATP ANALOG;
   RAT BONE; IN VIVO; INHIBITION; ALENDRONATE; FARNESYL; PROLIFERATION
AB Bisphosphonates play an important role in the treatment of metabolic bone diseases such as osteoporosis. In addition to their anti resorptive activity by triggering osteoclast apoptosis, nitrogen containing bisphosphonates (N BP) may also influence osteogenic differentiation, which might rely on their capacity to inhibit the mevalonate pathway. In vascular endothelial cells inhibition of this pathway by cholesterol lowering statins activates the MEK5/ERK5 mitogen activated protein kinase cascade, which plays an important role in cellular differentiation, apoptosis or inflammatory processes.
   Here we evaluated whether N BP may also target the MEK5/ERK5 pathway and analysed the consequences of ERK5 activation on osteogenic differentiation.
   We show that N BP dose dependently activate ERK5 in primary human endothelial cells and osteoblasts. The mechanism likely involves farnesyl pyrophosphate synthase inhibition and subsequent functional inhibition of the small GTPase Cdc42 since siRNA mediated knockdown of both genes could reproduce N BP induced ERK5 activation. ERK5 activation resulted in regulation of several bone relevant genes and was required for calcification and osteogenic differentiation of bone marrow derived mesenchymal stems cells as evident by the lack of alkaline phosphatase induction and alizarin red S staining observed upon ERK5 knockdown or upon differentiation initiation in presence of a pharmacological ERK5 inhibitor.
   Our data provide evidence that N BP activate the MEK5/ERK5 cascade and reveal an essential role of ERK5 in osteogenic differentiation and mineralization of skeletal precursors. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Adam, Christian; Glueck, Lucia; Goebeler, Matthias; Schmidt, Marc] Univ Hosp Wurzburg, Dept Dermatol, Josef Schneider Str 2, D 97080 Wurzburg, Germany.
   [Ebert, Regina; Jakob, Franz] Univ Wurzburg, Orthoped Dept, Orthoped Ctr Muscutoskeletal Res, Wurzburg, Germany.
C3 University of Wurzburg; University of Wurzburg
RP Schmidt, M (通讯作者)，Univ Hosp Wurzburg, Dept Dermatol, Josef Schneider Str 2, D 97080 Wurzburg, Germany.
EM schmidt_M11@ukw.de
RI Goebeler, Matthias/P 3612 2019; Ebert, Regina/D 5760 2016; Schmidt,
   Marc/E 8821 2010; Jakob, Franz/D 8526 2015
OI Ebert, Regina/0000 0002 8192 869X; Adam, Christian/0000 0001 7721 4144;
   Schmidt, Marc/0000 0002 8643 1615; 
FU Deutsche Forschungsgemeinschaft [SCHM 2460/2 1]
FX We thank Helga Sennefelder and Melanie Krug for excellent technical
   assistance. This work was supported by the Deutsche
   Forschungsgemeinschaft (grant SCHM 2460/2 1 to M.S.). All authors
   declare there are no conflict of interests.
CR [Anonymous], 1993, AM J MED, V95, p1S
   Ansari N, 2018, J BONE MINER RES, V33, P137, DOI 10.1002/jbmr.3291
   Chu UB, 2015, BBA GEN SUBJECTS, V1850, P1415, DOI 10.1016/j.bbagen.2015.03.011
   Coxon FP, 2003, CALCIFIED TISSUE INT, V72, P80, DOI 10.1007/s00223 002 2017 2
   Czymai T, 2010, J BIOL CHEM, V285, P10163, DOI 10.1074/jbc.M109.056663
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Duque G, 2011, BRIT J PHARMACOL, V162, P1109, DOI 10.1111/j.1476 5381.2010.01111.x
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Ebert R, 2015, STEM CELL RES, V15, P231, DOI 10.1016/j.scr.2015.06.008
   Ebert R, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 265
   Ebert R, 2012, BONE, V50, P723, DOI 10.1016/j.bone.2011.11.025
   Ebert R, 2009, BONE, V44, P858, DOI 10.1016/j.bone.2009.01.009
   Fernandez Rebollo E, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05207 1
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Giger EV, 2013, J CONTROL RELEASE, V167, P175, DOI 10.1016/j.jconrel.2013.01.032
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Harmey D, 2006, J BONE MINER RES, V21, P1377, DOI 10.1359/JBMR.060619
   Holm E, 2014, BIOCHEM J, V464, P355, DOI 10.1042/BJ20140702
   HUNTER GK, 1994, BIOCHEM J, V300, P723, DOI 10.1042/bj3000723
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Kaneshiro S, 2015, BIOCHEM BIOPH RES CO, V463, P241, DOI 10.1016/j.bbrc.2015.05.035
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kranenburg G, 2016, ATHEROSCLEROSIS, V252, P106, DOI 10.1016/j.atherosclerosis.2016.06.039
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Li Z, 2002, NEURON, V33, P741, DOI 10.1016/S0896 6273(02)00621 9
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   MALAVAL L, 1994, J CELL PHYSIOL, V158, P555, DOI 10.1002/jcp.1041580322
   Millán JL, 2013, CALCIFIED TISSUE INT, V93, P299, DOI 10.1007/s00223 012 9672 8
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Narisawa S, 2013, J BONE MINER RES, V28, P1587, DOI 10.1002/jbmr.1901
   Nithianandarajah Jones GN, 2012, CELL SIGNAL, V24, P2187, DOI 10.1016/j.cellsig.2012.07.007
   Oesterle A, 2017, CIRC RES, V120, P229, DOI 10.1161/CIRCRESAHA.116.308537
   Ohnesorge N, 2010, J BIOL CHEM, V285, P26199, DOI 10.1074/jbc.M110.103127
   Rachner TD, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3616
   Recker RR, 2008, J BONE MINER RES, V23, P6, DOI 10.1359/JBMR.070906
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Schindeler A, 2006, J BONE MINER RES, V21, P1331, DOI 10.1359/JBMR.060603
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Touaitahuata Heiani, 2014, Small GTPases, V5, pe28119, DOI 10.4161/sgtp.28119
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Villarreal G, 2010, BIOCHEM BIOPH RES CO, V391, P984, DOI 10.1016/j.bbrc.2009.12.002
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Yang QK, 2010, CANCER CELL, V18, P258, DOI 10.1016/j.ccr.2010.08.008
   Zuo YF, 2015, J CELL BIOCHEM, V116, P124, DOI 10.1002/jcb.24950
   Zverina EA, 2012, CURR OPIN CHEM BIOL, V16, P544, DOI 10.1016/j.cbpa.2012.10.015
NR 49
TC 19
Z9 25
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2018
VL 111
BP 49
EP 58
DI 10.1016/j.bone.2018.03.020
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GE8IA
UT WOS:000431474200007
PM 29567200
DA 2025 08 17
ER

PT J
AU Coleman, R
AF Coleman, Robert
TI Clinical benefits of bone targeted agents in early breast cancer
SO BREAST
LA English
DT Article; Proceedings Paper
CT 16th St. Gallen International Breast Cancer Consensus Conference
   (SGIBCC)   Optimizing Early Breast Cancer Therapies
CY MAR 20 23, 2019
CL Vienna, AUSTRIA
DE Adjuvant therapy; bisphosphonates; denosumab; bone metastases
ID ADJUVANT ENDOCRINE THERAPY; ZOLEDRONIC ACID; POSTMENOPAUSAL WOMEN; EARLY
   DISSEMINATION; POSITION STATEMENT; OPEN LABEL; FOLLOW UP; ZO FAST;
   METASTASIS; DORMANCY
AB Through their profound effects on the bone microenvironment, bone targeted treatments can potentially modify the process of metastasis and have important effects on disease outcomes as well as on bone health. The Early Breast Cancer Trialists Collaborative Group (EBCTCG) evaluated the effect of adjuvant bisphosphonates in early breast cancer by performing a meta analysis of individual patient data (n = 18,766) from all available randomized trials initiated between the early 1990s until 2006. In postmenopausal women, bisphosphonates reduced bone recurrence (RR = 0.72; 95%CI 0.60 0.86, 2p = 0.0002) and breast cancer mortality (0.82; 95%CI 0.73 0.93, 2p = 0.002); no effects on disease outcomes could be identified in premenopausal women. Somewhat surprisingly, these effects could not be reproduced in the large adjuvant trial of denosumab (DCARE). In this study, neither bone metastasis free survival (the primary endpoint) or disease free survival were improved by the addition of this targeted antibody inhibitor of osteoclast activity. Efforts are ongoing to try to understand the biologic implications of these results. For now, the use of denosumab in early cancers is limited to its use for fracture prevention using the 60mg every 6 months dosing schedule. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Coleman, Robert] Univ Sheffield, Dept Oncol & Metab, Med Oncol, Sheffield, S Yorkshire, England.
C3 University of Sheffield
RP Coleman, R (通讯作者)，Univ Sheffield, Dept Oncol & Metab, Med Oncol, Sheffield, S Yorkshire, England.
EM r.e.coleman@sheffield.ac.uk
CR [Anonymous], J BONE ONCOL
   Brufsky AM, 2012, CANCER AM CANCER SOC, V118, P1192, DOI 10.1002/cncr.26313
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
   Coleman RE, 2018, J BONE ONCOL, V13, P123, DOI 10.1016/j.jbo.2018.09.008
   Coleman R, 2017, LANCET ONCOL, V18, P1543, DOI 10.1016/S1470 2045(17)30603 4
   Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470 2045(14)70302 X
   Coleman RE, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.501
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Dhesy Thind S, 2017, J CLIN ONCOL, V35, P2062, DOI 10.1200/JCO.2016.70.7257
   Gnant M, 2015, ANN ONCOL, V26, P313, DOI 10.1093/annonc/mdu544
   Gnant M, 2019, LANCET ONCOL, V20, P339, DOI 10.1016/S1470 2045(18)30862 3
   Gnant M, 2015, LANCET, V386, P433, DOI 10.1016/S0140 6736(15)60995 3
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gralow J, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.503
   Hadji P, 2016, ANN ONCOL, V27, P379, DOI 10.1093/annonc/mdv617
   Hadji P, 2017, J BONE ONCOL, V7, P1, DOI 10.1016/j.jbo.2017.03.001
   Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785
   Ingangi V, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00082
   Janni W, 2017, EXTENDED ADJUVANT BI
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Llombart A, 2012, CLIN BREAST CANCER, V12, P40, DOI 10.1016/j.clbc.2011.08.002
   Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002 9440(10)65628 3
   Marshall JCA, 2012, JNCI J NATL CANCER I, V104, P1306, DOI 10.1093/jnci/djs319
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Páez D, 2012, CLIN CANCER RES, V18, P645, DOI 10.1158/1078 0432.CCR 11 2186
   Pavlovic M, 2015, JNCI J NATL CANCER I, V107, DOI 10.1093/jnci/djv256
   Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6
   Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   Strobl S, 2018, CURR TREAT OPTION ON, V19, DOI 10.1007/s11864 018 0535 z
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wilson SR, 2019, J FAM COMMUN, V19, P15, DOI 10.1080/15267431.2018.1530238
NR 37
TC 13
Z9 14
U1 0
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960 9776
EI 1532 3080
J9 BREAST
JI Breast
PD NOV
PY 2019
VL 48
SU 1
BP S92
EP S96
PG 5
WC Oncology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Oncology; Obstetrics & Gynecology
GA KD9JZ
UT WOS:000508178900021
PM 31839171
DA 2025 08 17
ER

PT J
AU Hao, LZ
   Huang, SW
   Huang, TL
   Yi, D
   Wang, CM
   Cheng, LX
   Guan, M
   Wu, J
   Chen, D
   Pan, HB
   Lu, WW
   Zhao, XL
AF Hao, Liuzhi
   Huang, Shuwen
   Huang, Tongling
   Yi, Dan
   Wang, Chenmin
   Cheng, Lixin
   Guan, Min
   Wu, Jun
   Chen, Di
   Pan, Haobo
   Lu, William W.
   Zhao, Xiaoli
TI Bone targeting miR 26a loaded exosome mimetics for bone regeneration
   therapy by activating Wnt signaling pathway
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE MSCs; Exosomes; miR 26a; Osteoporosis; Bone targeting; Bone regeneration
ID MESENCHYMAL STEM CELLS; DELIVERY; NANOVESICLES; OSTEOPOROSIS; AGENTS;
   SIRNA
AB Mesenchymal stem cell derived exosomes (MSC Exos) have shown great potential in the areas of bone regen eration and treatment of age related diseases. Engineered exosomes can integrate multiple functional compo nents to achieve optimal, targeted therapeutic effects. This study combined large scale generation, bone targeting modification, and miR 26a loading for exosome mimetics (EMs) to construct a cell free delivery sys tem that promotes bone regeneration with good biocompatibility. EMs were fabricated through sequential extrusion of MSCs and reached a 15 fold production yield compared to conventional exosome secretion. Systemic injection of Asp8 EM/miR 26a in mouse models accelerated bone defect healing and prevented osteoporosis. The underlying mechanism involves miR 26a targeting glycogen synthase kinase 38 (GSK 38) to induce 8 catenin accumulation, thus activating Wnt signaling pathway and promoting bone regeneration. This study provides a feasible and effective strategy for modifying EMs to enhance bone regeneration.
C1 [Hao, Liuzhi; Huang, Shuwen; Huang, Tongling; Guan, Min; Pan, Haobo; Lu, William W.; Zhao, Xiaoli] Chinese Acad Sci, Inst Biomed & Biotechnol, Shenzhen Inst Adv Technol, Res Ctr Human Tissue & Organs Degenerat, Shenzhen 518055, Peoples R China.
   [Hao, Liuzhi; Zhao, Xiaoli] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Huang, Shuwen] Jinan Univ, Guangdong Hong Kong Macau Inst CNS Regenerat, Key Lab CNS Regenerat, Minist Educ, Guangzhou 510632, Peoples R China.
   [Yi, Dan; Chen, Di] Chinese Acad Sci, Inst Biomed & Biotechnol, Shenzhen Inst Adv Technol, Res Ctr Comp Aided Drug Discovery, Shenzhen 518055, Peoples R China.
   [Wang, Chenmin; Wu, Jun; Lu, William W.] Univ Hong Kong, Dept Orthopaed & Traumatol, Hong Kong 999077, Peoples R China.
   [Cheng, Lixin] Southern Univ Sci & Technol, Shenzhen Peoples Hosp, Affiliated Hosp 1, Shenzhen 518020, Peoples R China.
   [Wu, Jun] Univ Hong Kong, Shenzhen Hosp, Shenzhen Key Lab Innovat Technol Orthopaed Trauma, Shenzhen 518053, Peoples R China.
C3 Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology,
   CAS; Chinese Academy of Sciences; University of Chinese Academy of
   Sciences, CAS; Jinan University; Chinese Academy of Sciences; Shenzhen
   Institute of Advanced Technology, CAS; University of Hong Kong; Southern
   University of Science & Technology; Jinan University; University of Hong
   Kong
RP Zhao, XL (通讯作者)，Chinese Acad Sci, Inst Biomed & Biotechnol, Shenzhen Inst Adv Technol, Res Ctr Human Tissue & Organs Degenerat, Shenzhen 518055, Peoples R China.
EM zhao.xl@siat.ac.cn
RI Cheng, LX/G 3342 2010; Hao, Liuzhi/KVB 2073 2024; Huang,
   Shuwen/AAS 4336 2020; Lu, William Weijia/C 4358 2009; Pan,
   Haobo/LLK 2703 2024
OI Hao, Liuzhi/0009 0000 7965 2172; Lu, William Weijia/0000 0002 5780 2886;
   Cheng, Lixin/0000 0002 9427 383X; Guan, Min/0000 0003 3851 8553
FU National Natural Science Foundation of China [81972071]; Guangdong Basic
   and Applied Basic Research Foundation [2021A1515010191]; Science and
   Technology Research Funding of Shenzhen [JCYJ20210324102001003, JCYJ2020
   0109150420892]; National Natural Science Foundation of China/Research
   Grants Council Joint Research Scheme [N_HKU753/21]; Shenzhen Key
   Laboratory of Marine Biomaterials [ZDSY20 130401165820356]
FX This work was supported by the National Natural Science Foundation of
   China (81972071) ; Guangdong Basic and Applied Basic Research Foundation
   (2021A1515010191) ; Science and Technology Research Funding of Shenzhen
   (JCYJ20210324102001003, JCYJ2020 0109150420892) ; National Natural
   Science Foundation of China/Research Grants Council Joint Research
   Scheme (N_HKU753/21) ; Shenzhen Key Laboratory of Marine Biomaterials
   (ZDSY20 130401165820356) .
CR Alvarez Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807
   Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Cavazzana M, 2019, NAT REV DRUG DISCOV, V18, P447, DOI 10.1038/s41573 019 0020 9
   Chen QC, 2018, ACS APPL MATER INTER, V10, P23700, DOI 10.1021/acsami.8b08606
   Chen Y, 2021, BIOCHEM BIOPH RES CO, V534, P727, DOI 10.1016/j.bbrc.2020.11.010
   Cheng LS, 2022, NAT REV DRUG DISCOV, V21, P379, DOI 10.1038/s41573 022 00410 w
   Choi H, 2021, TISSUE ENG REGEN MED, V18, P499, DOI 10.1007/s13770 021 00361 0
   Cui YZ, 2022, BIOACT MATER, V10, P207, DOI 10.1016/j.bioactmat.2021.09.015
   Cully M, 2021, NAT REV DRUG DISCOV, V20, P6, DOI 10.1038/d41573 020 00220 y
   Debets MF, 2011, ACCOUNTS CHEM RES, V44, P805, DOI 10.1021/ar200059z
   Du Y, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202200142
   Fan JB, 2020, ACS NANO, V14, P11973, DOI 10.1021/acsnano.0c05122
   Fu Z, 2021, CELL RES, V31, P631, DOI 10.1038/s41422 021 00491 z
   Gan JJ, 2022, NANO TODAY, V47, DOI 10.1016/j.nantod.2022.101630
   Gowen A, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00149
   Huang L, 2018, BIOMATERIALS, V182, P58, DOI 10.1016/j.biomaterials.2018.07.046
   Jiang YY, 2022, NANO TODAY, V44, DOI 10.1016/j.nantod.2022.101487
   Jin Y, 2016, ADV FUNCT MATER, V26, P5804, DOI 10.1002/adfm.201601430
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Kenari AN, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800161
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Lei Q, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.aaz8697
   Li FY, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01347 3
   Li LM, 2020, NANO LETT, V20, P4298, DOI 10.1021/acs.nanolett.0c00929
   Li MJ, 2022, BIOMATER ADV, V142, DOI 10.1016/j.bioadv.2022.213161
   Lim CZJ, 2020, ACS SENSORS, V5, P4, DOI 10.1021/acssensors.9b02165
   Liu AQ, 2021, BIOMATERIALS, V272, DOI 10.1016/j.biomaterials.2021.120718
   Liu L, 2021, ACTA BIOMATER, V119, P444, DOI 10.1016/j.actbio.2020.10.038
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Longmire M, 2008, NANOMEDICINE UK, V3, P703, DOI 10.2217/17435889.3.5.703
   Patel D, 2023, DRUG DELIV TRANSL RE, V13, P419, DOI 10.1007/s13346 022 01222 6
   Qin WP, 2019, CURR OSTEOPOROS REP, V17, P548, DOI 10.1007/s11914 019 00537 7
   Qiu M, 2021, HUM GENE THER, V32, P717, DOI 10.1089/hum.2020.005
   Rennick JJ, 2021, NAT NANOTECHNOL, V16, P266, DOI 10.1038/s41565 021 00858 8
   Rohner E, 2022, NAT BIOTECHNOL, V40, P1586, DOI 10.1038/s41587 022 01491 z
   Rotman SG, 2018, J CONTROL RELEASE, V269, P88, DOI 10.1016/j.jconrel.2017.11.009
   Salunkhe S, 2020, J CONTROL RELEASE, V326, P599, DOI 10.1016/j.jconrel.2020.07.042
   Shao XR, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13272
   Shi ZY, 2020, INT J BIOL MACROMOL, V158, P530, DOI 10.1016/j.ijbiomac.2020.04.228
   Shinge SAU, 2022, EXTRACELL VESICLES C, V3, P150, DOI 10.20517/evcna.2021.25
   Tian T, 2018, BIOMATERIALS, V150, P137, DOI 10.1016/j.biomaterials.2017.10.012
   Tran PHL, 2020, ADV MATER, V32, DOI 10.1002/adma.201904040
   Nguyen TDT, 2019, NANOMED NANOTECHNOL, V16, P79, DOI 10.1016/j.nano.2018.11.011
   Wang QL, 2018, THERANOSTICS, V8, P4912, DOI 10.7150/thno.27608
   Wu PP, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120467
   Xiong Y, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 020 00622 5
   Yao JL, 2021, ACS NANO, V15, P11099, DOI 10.1021/acsnano.1c00628
   Yao XD, 2019, BIOMATERIALS, V224, DOI 10.1016/j.biomaterials.2019.119492
   Zhai MM, 2020, ADV SCI, V7, DOI 10.1002/advs.202001334
   Zhang SP, 2018, BIOMATERIALS, V156, P16, DOI 10.1016/j.biomaterials.2017.11.028
   Zhang Y, 2021, LIFE SCI, V272, DOI 10.1016/j.lfs.2021.119204
   Zhuang Y, 2022, ACTA BIOMATER, V150, P413, DOI 10.1016/j.actbio.2022.07.015
NR 53
TC 15
Z9 16
U1 9
U2 93
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD SEP 1
PY 2023
VL 471
AR 144594
DI 10.1016/j.cej.2023.144594
EA JUL 2023
PG 14
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA O2ZB6
UT WOS:001042541800001
OA Bronze
DA 2025 08 17
ER

PT J
AU Romas, E
AF Romas, E
TI Bone loss in inflammatory arthritis: mechanisms and therapeutic
   approaches with bisphosphonates
SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
LA English
DT Article
DE rheumatoid arthritis; bone erosion; bisphosphonates; osteoclast; RANKL;
   OPG
ID ACTIVE RHEUMATOID ARTHRITIS; FACTOR KAPPA B; NECROSIS FACTOR ALPHA;
   DOUBLE BLIND; RECEPTOR ACTIVATOR; JOINT DESTRUCTION; ZOLEDRONIC ACID;
   MINERAL DENSITY; TNF ALPHA; OSTEOCLAST DIFFERENTIATION
AB The inflammatory process in rheumatoid arthritis provokes intense bone resorption, evidenced as bone erosions, juxta articular osteopenia and generalized osteoporosis. These types of bone loss share a common pathogenesis, and the role of osteoclasts in focal bone erosion was verified in elegant animal studies. The tumour necrosis factor (TNF) family of cytokines and receptors specifically TNF alpha, RANKL, RANK and OPG are dominant regulators of osteoclastic bone resorption in rheumatoid arthritis. The confirmation of the osteoclast mechanism provides new insight into the structural joint protection afforded by disease modifying drugs and suggests innovative approaches to limit bone destruction. Emerging treatment strategies for bone disease in rheumatoid arthritis are the use of monoclonal antibodies to neutralize RANKL, and powerful bisphosphonates that target pathogenic osteoclasts.
C1 Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia.
C3 NSW Health; St Vincents Hospital Sydney; St Vincent's Health; St
   Vincent's Hospital Melbourne; University of Melbourne
RP Romas, E (通讯作者)，Univ Melbourne, St Vincents Hosp, Dept Med, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.
EM romase@svhm.org.au
CR ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bongi SM, 2004, AUTOIMMUNITY, V37, P495, DOI 10.1080/08916930400011965
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BROMLEY M, 1984, ARTHRITIS RHEUM US, V27, P968, DOI 10.1002/art.1780270902
   BROMLEY M, 1985, ANN RHEUM DIS, V44, P676, DOI 10.1136/ard.44.10.676
   Cantatore FP, 1999, J RHEUMATOL, V26, P2318
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Conaghan PG, 2003, ARTHRITIS RHEUM, V48, P64, DOI 10.1002/art.10747
   d'Elia HF, 2003, ANN RHEUM DIS, V62, P617, DOI 10.1136/ard.62.7.617
   de Nijs RNJ, 2001, RHEUMATOLOGY, V40, P1375, DOI 10.1093/rheumatology/40.12.1375
   Eggelmeijer F, 1996, ARTHRITIS RHEUM, V39, P396, DOI 10.1002/art.1780390307
   EGGELMEIJER F, 1994, J RHEUMATOL, V21, P2016
   FELDMANN M, 1990, ANN RHEUM DIS, P480
   FLORA L, 1979, ARTHRITIS RHEUM US, V22, P340, DOI 10.1002/art.1780220405
   FRANCIS MD, 1989, INT J TISSUE REACT, V11, P239
   Goldring SR, 2000, ARTHRITIS RES, V2, P33, DOI 10.1186/ar67
   Gough A, 1998, J RHEUMATOL, V25, P1282
   GOUGH AKS, 1994, ANN RHEUM DIS, V53, P14, DOI 10.1136/ard.53.1.14
   GOUGH AKS, 1994, LANCET, V344, P23, DOI 10.1016/S0140 6736(94)91049 9
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   HALL GM, 1995, ARTHRITIS RHEUM, V38, P902, DOI 10.1002/art.1780380705
   Harrison BJ, 2002, ANN RHEUM DIS, V61, P1007, DOI 10.1136/ard.61.11.1007
   Haugeberg G, 2000, ARTHRITIS RHEUM, V43, P522, DOI 10.1002/1529 0131(200003)43:3<522::AID ANR7>3.0.CO;2 Y
   Herrak P, 2004, ARTHRITIS RHEUM US, V50, P2327, DOI 10.1002/art.20384
   Horai R, 2004, J CLIN INVEST, V114, P1603, DOI 10.1172/JCI200420742
   Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623
   Iwamoto J, 2003, CALCIFIED TISSUE INT, V72, P491, DOI 10.1007/s00223 002 1024 7
   JARRETT S, 2004, EULAR 2004 BERL GERM
   KAARELA K, 1985, SCAND J RHEUMATO S57, V14, P1
   Kanematsu M, 2000, J BONE MINER RES, V15, P1321, DOI 10.1359/jbmr.2000.15.7.1321
   Kelly C, 2002, Eur J Intern Med, V13, P423, DOI 10.1016/S0953 6205(02)00129 2
   Kinne RW, 1995, ARTHRITIS RHEUM US, V38, P1777, DOI 10.1002/art.1780381211
   KINNE RW, 1995, SCAND J RHEUMATOL, P91
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   LAAN RFJM, 1992, ANN RHEUM DIS, V51, P826, DOI 10.1136/ard.51.6.826
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Li P, 2004, J BONE MINER RES, V19, P207, DOI 10.1359/JBMR.0301233
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Lodder MC, 2003, J RHEUMATOL, V30, P2080
   Lubberts E, 2002, ARTHRITIS RHEUM, V46, P3055, DOI 10.1002/art.10607
   MACCAGNO A, 1994, SCAND J RHEUMATOL, V23, P211, DOI 10.3109/03009749409103063
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Martin TJ, 1998, CRIT REV EUKAR GENE, V8, P107, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.10
   Matsuo A, 2003, J RHEUMATOL, V30, P1280
   Mc Gonagle D, 1999, RHEUMATOLOGY, V38, P329, DOI 10.1093/rheumatology/38.4.329
   McGonagle D, 1999, ARTHRITIS RHEUM, V42, P1706, DOI 10.1002/1529 0131(199908)42:8<1706::AID ANR20>3.0.CO;2 Z
   McQueen FM, 1998, ANN RHEUM DIS, V57, P350, DOI 10.1136/ard.57.6.350
   McQueen FM, 2003, ARTHRITIS RHEUM, V48, P1814, DOI 10.1002/art.11162
   Ng KW, 1997, BAILLIERE CLIN ENDOC, V11, P1, DOI 10.1016/S0950 351X(97)80473 9
   Ostergaard M, 2003, ARTHRITIS RHEUM US, V48, P2128, DOI 10.1002/art.11076
   OSTERMAN T, 1995, INFLAMM RES, V44, P258, DOI 10.1007/BF01782979
   Osterman T, 1997, INFLAMM RES, V46, P79, DOI 10.1007/s000110050093
   OSTERMAN T, 1994, RHEUMATOL INT, V14, P139, DOI 10.1007/BF00579699
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   RALSTON SH, 1989, ANN RHEUM DIS, V48, P396, DOI 10.1136/ard.48.5.396
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Redlich K, 2002, ARTHRITIS RHEUM, V46, P785, DOI 10.1002/art.10097
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Richards PJ, 1999, RHEUMATOLOGY, V38, P818, DOI 10.1093/rheumatology/38.9.818
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Romas E, 2000, ARTHRITIS RHEUM, V43, P821, DOI 10.1002/1529 0131(200004)43:4<821::AID ANR12>3.0.CO;2 T
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002 9440(10)64417 3
   Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756 3282(01)00682 2
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   SAMBROOK PN, 1987, ARTHRITIS RHEUM US, V30, P721, DOI 10.1002/art.1780300701
   Sambrook PN, 2000, J RHEUMATOL, V27, P2541
   Shibuya K, 2002, CLIN RHEUMATOL, V21, P150, DOI 10.1007/s10067 002 8274 7
   SHIMIZU S, 1985, ARTHRITIS RHEUM, V28, P25, DOI 10.1002/art.1780280105
   Sims NA, 2004, ARTHRITIS RHEUM US, V50, P2338, DOI 10.1002/art.20382
   Sinigaglia L, 2000, J RHEUMATOL, V27, P2582
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Valleala H, 2003, J RHEUMATOL, V30, P468
   Valleala H, 2001, INFLAMM RES, V50, P598, DOI 10.1007/PL00000240
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   VanderHeijde DMFM, 1995, BRIT J RHEUMATOL, V34, P74
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Yamane I, 2003, ARTHRITIS RHEUM, V48, P1732, DOI 10.1002/art.10987
NR 80
TC 43
Z9 53
U1 0
U2 5
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1521 6942
EI 1521 1770
J9 BEST PRACT RES CL RH
JI Best Pract. Res. Clin. Rheumatol.
PD DEC
PY 2005
VL 19
IS 6
BP 1065
EP 1079
DI 10.1016/j.berh.2005.06.008
PG 15
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 992BJ
UT WOS:000233858700014
PM 16301197
DA 2025 08 17
ER

PT J
AU Neville Webbe, HL
   Coleman, RE
AF Neville Webbe, H. L.
   Coleman, R. E.
TI Bisphosphonates and RANK ligand inhibitors for the treatment and
   prevention of metastatic bone disease
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Bone; Bisphosphonate; Osteoprotegerin; RANKL; Metastatic bone disease
ID BREAST CANCER CELLS; NITROGEN CONTAINING BISPHOSPHONATES; DELTA T CELLS;
   ENDOTHELIAL GROWTH FACTOR; PLUS ZOLEDRONIC ACID; LETROZOLE Z FAST;
   IN VITRO; PROSTATE CANCER; 3RD GENERATION BISPHOSPHONATE; MEVALONATE
   PATHWAY
AB Bisphosphonates (BPS) are potent inhibitors of osteoclast mediated bone resorption, which is increased when cancer cells invade bone. BPS are an established treatment for cancer that has spread to bone, and effectively reduce pain and other skeletal related events. New directions in metastatic bone disease (MBD) include personalised BP therapy, such as using bone markers to guide frequency of BP administration and bone targeting agents such as denosumab (AMG 162). Clinical trials strongly suggest that denosumab might play a defined role in the future management of MBD. In terms of potential anti cancer activity, early data tentatively suggest that zoledronic acid might have a role to play in the prevention of metastatic disease, though whether this is a direct effect on cancer cells, or indirect via the bone marrow micro environment, or both, is as yet undiscovered. The definitive answer as to the role of adjuvant BP in early cancer is being addressed, with over 20,000 patients with breast, prostate or lung cancer currently participating in adjuvant BP randomised trials. The results of these trials should be available in the next few years, and this will establish whether BPs given early in the course of cancer will be able to prevent the formation of metastases, bone or otherwise. Crown Copyright (C) 2010 Published by Elsevier Ltd. All rights reserved.
C1 [Neville Webbe, H. L.; Coleman, R. E.] Weston Pk Hosp, Acad Dept Clin Oncol, Sheffield S10 2SJ, S Yorkshire, England.
C3 Weston Park Hospital
RP Neville Webbe, HL (通讯作者)，Weston Pk Hosp, Acad Dept Clin Oncol, Sheffield S10 2SJ, S Yorkshire, England.
EM h.l.neville webbe@sheffield.ac.uk
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Alakangas A, 2002, CALCIFIED TISSUE INT, V70, P40, DOI 10.1007/s002230010047
   AMIN D, 1992, J LIPID RES, V33, P1657
   Bellahcène A, 2000, CIRC RES, V86, P885, DOI 10.1161/01.RES.86.8.885
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Body JJ, 2007, ANN ONCOL, V18, P1165, DOI 10.1093/annonc/mdm119
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Boissier S, 2000, CANCER RES, V60, P2949
   Boissier S, 1997, CANCER RES, V57, P3890
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Brufsky AM, 2009, CLIN BREAST CANCER, V9, P77, DOI 10.3816/CBC.2009.n.015
   Bukowski JF, 2005, BIOCHEM BIOPH RES CO, V328, P746, DOI 10.1016/j.bbrc.2004.11.075
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Coleman R, 2009, CANCER RES, V69, p733S
   Coleman RE, 2008, BRIT J CANCER, V98, P1736, DOI 10.1038/sj.bjc.6604382
   COLEMAN RE, 1992, BRIT J CANCER, V65, P766, DOI 10.1038/bjc.1992.161
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Concin N, 2003, INT J ONCOL, V22, P51
   Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464 4096.2004.04831.x
   Cramer JA, 2005, CURR MED RES OPIN, V21, P1453, DOI 10.1185/030079905X61875
   Dearnaley DP, 2009, LANCET ONCOL, V10, P872, DOI 10.1016/S1470 2045(09)70201 3
   Denoyelle C, 2003, BRIT J CANCER, V88, P1631, DOI 10.1038/sj.bjc.6600925
   Diel IJ, 2008, ANN ONCOL, V19, P2007, DOI 10.1093/annonc/mdn429
   Diel IJ, 2009, SUPPORT CARE CANCER, V17, P719, DOI 10.1007/s00520 008 0553 7
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Eidtmann H, 2008, CTRC AACR SAN ANT BR
   Gasparini G, 1997, J NATL CANCER I, V89, P139, DOI 10.1093/jnci/89.2.139
   Gnant M, 2008, LANCET ONCOL, V9, P840, DOI 10.1016/S1470 2045(08)70204 3
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Green JR, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.24154
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   Ha TC, 2007, BRIT J CANCER, V96, P1796, DOI 10.1038/sj.bjc.6603661
   Henry D, 2009, EJC SUPPL, V7, P12, DOI 10.1016/S1359 6349(09)72055 5
   Heymann D, 2005, BONE, V37, P74, DOI 10.1016/j.bone.2005.02.020
   Hiraga T, 2003, INT J CANCER, V106, P973, DOI 10.1002/ijc.11330
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065 230X(02)84003 9
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Karabulut B, 2009, CELL BIOL INT, V33, P239, DOI 10.1016/j.cellbi.2008.11.011
   Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077
   Kriege M, 2009, J CLIN ONCOL, V27, P3764, DOI 10.1200/JCO.2008.19.9067
   Kristensen B, 2008, ACTA ONCOL, V47, P740, DOI 10.1080/02841860801964988
   Kunzmann V, 2000, BLOOD, V96, P384
   Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood 2003 01 0305
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee MV, 2001, CANCER RES, V61, P2602
   Linderholm B, 1998, J CLIN ONCOL, V16, P3121, DOI 10.1200/JCO.1998.16.9.3121
   Lipton A, 2008, CLIN CANCER RES, V14, P6690, DOI 10.1158/1078 0432.CCR 07 5234
   Lipton A, 2008, CANCER AM CANCER SOC, V113, P193, DOI 10.1002/cncr.23529
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   MALKOVSKA V, 1992, CANCER RES, V52, P5610
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Mönkkönen H, 2008, ANTI CANCER DRUG, V19, P391, DOI 10.1097/CAD.0b013e3282f632bf
   Morgan C, 2007, ACTA ONCOL, V46, P669, DOI 10.1080/02841860600996447
   Neville Webbe HL, 2006, TUMOR BIOL, V27, P92, DOI 10.1159/000092489
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Ottewell PD, 2010, INT J CANCER, V126, P522, DOI 10.1002/ijc.24756
   Ozturk OH, 2007, CELL BIOL INT, V31, P1069, DOI 10.1016/j.cellbi.2007.02.004
   Paget S., LANCET, V1, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Rack B, 2008, DEUT MED WOCHENSCHR, V133, P285, DOI 10.1055/s 2008 1046707
   Riebeling C, 2002, BRIT J CANCER, V87, P366, DOI 10.1038/sj.bjc.6600476
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Saarto T, 2001, J CLIN ONCOL, V19, P10, DOI 10.1200/JCO.2001.19.1.10
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Sato K, 2005, INT J CANCER, V116, P94, DOI 10.1002/ijc.20987
   SATO M, 1990, J BONE MINER RES, V5, P31, DOI 10.1002/jbmr.5650050107
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Sauty A, 1996, BONE, V18, P133, DOI 10.1016/8756 3282(95)00448 3
   Sawada K, 2002, CANCER RES, V62, P6015
   Sciammas R, 1997, J EXP MED, V185, P1969, DOI 10.1084/jem.185.11.1969
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Sewing L, 2008, APOPTOSIS, V13, P782, DOI 10.1007/s10495 008 0211 z
   Shiozawa Y, 2008, LEUKEMIA, V22, P941, DOI 10.1038/leu.2008.48
   Shipman CM, 1998, CANCER RES, V58, P5294
   Smith MR, 2005, J CLIN ONCOL, V23, P2918, DOI 10.1200/JCO.2005.01.529
   Stearns ME, 1996, INVAS METAST, V16, P116
   Stopeck A, 2009, EJC SUPPL, V7, P2, DOI 10.1016/S1359 6349(09)72028 2
   Tassone P, 2000, LEUKEMIA, V14, P841, DOI 10.1038/sj.leu.2401770
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008 5472.CAN 04 4188
   vanderHulst H, 1996, LINGUA, V98, P3, DOI 10.1016/0024 3841(95)00030 5
   Virtanen SS, 2002, CANCER RES, V62, P2708
   Wang LS, 2001, J CLIN INVEST, V108, P1349, DOI 10.1172/JCI200113584
   Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood 2002 12 3665
   WINTER MC, 2008, CTRC AACR SAN ANT BR
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Woodward JKL, 2005, ANTI CANCER DRUG, V16, P845, DOI 10.1097/01.cad.0000175582.01446.6f
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoneda Toshiyuki, 2000, Cancer, V88, P2979, DOI 10.1002/1097 0142(20000615)88:12+<2979::AID CNCR13>3.0.CO;2 U
   Zhou ZC, 2005, CANCER AM CANCER SOC, V104, P1713, DOI 10.1002/cncr.21383
NR 100
TC 62
Z9 76
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959 8049
J9 EUR J CANCER
JI Eur. J. Cancer
PD MAY
PY 2010
VL 46
IS 7
SI SI
BP 1211
EP 1222
DI 10.1016/j.ejca.2010.02.041
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 599JF
UT WOS:000277906900006
PM 20347292
DA 2025 08 17
ER

PT J
AU Das, S
   Samant, RS
   Shevde, LA
AF Das, Shamik
   Samant, Rajeev S.
   Shevde, Lalita A.
TI Hedgehog Signaling Induced by Breast Cancer Cells Promotes
   Osteoclastogenesis and Osteolysis
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SONIC HEDGEHOG; BONE SIALOPROTEIN; CATHEPSIN K; SHORT RANGE;
   OSTEOPONTIN; METASTASIS; EXPRESSION; DIFFERENTIATION; OSTEOBLASTS;
   PATHWAY
AB Bone integrity is maintained by a dynamic equilibrium between the activities of bone forming osteoblasts and bone resorbing osteoclasts. Osteolytic lesions are a painful consequence of metastasis of breast cancer cells to bone in an overwhelming majority of breast cancer patients. Factors secreted by breast cancer cells propel a cascade of events that trigger osteoclastogenesis and elevated bone resorption. In the present study, we show that the Hedgehog (Hh) ligands secreted by breast cancer cells promote osteoclast differentiation and potentiate the activity of mature osteoclasts. Paracrine Hh signaling induced by breast cancer cells mediates a detrimental chain of events by the up regulation of osteopontin (OPN), which in turn enhances osteoclastic activity by up regulating cathepsin K and MMP9. Hh signaling is essential for osteoclasts because blocking the Hh pathway using the pharmacological Hh inhibitor, cyclopamine, results in an overall decrease in osteoclastogenesis and resorptive activity. Our studies suggest that inhibiting Hh signaling interferes with the ability of pre osteoclasts to respond to the stimulatory effects of the breast cancer cells, indicating that Hh signaling is vital to osteoclast activity.
C1 [Das, Shamik; Samant, Rajeev S.; Shevde, Lalita A.] Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36604 USA.
C3 University of South Alabama
RP Shevde, LA (通讯作者)，1660 Springhill Ave, Mobile, AL 36604 USA.
EM lsamant@usouthal.edu
OI Samant, Rajeev/0000 0001 5681 4976
FU Department of Defense [07 01 0400]; National Institutes of Health
   [1R01CA140472 01A1]; Mitchell Cancer Institute, University of South
   Alabama
FX This work was supported, in whole or in part, by Department of Defense
   IDEA Award 07 01 0400 (to L. A. S.). This work was also supported by
   National Institutes of Health Grant 1R01CA140472 01A1 (to R. S. S.) and
   support from the Mitchell Cancer Institute, University of South Alabama.
CR ABELOFF MD, 1995, CLIN ONCOLOGY
   Bailey JM, 2009, ONCOGENE, V28, P3513, DOI 10.1038/onc.2009.220
   Bendre M, 2003, CLIN ORTHOP RELAT R, pS39, DOI 10.1097/01.blo.0000093844.72468.f4
   Blair HC, 2005, BIOCHEM BIOPH RES CO, V328, P728, DOI 10.1016/j.bbrc.2004.11.077
   Bramwell VHC, 2006, CLIN CANCER RES, V12, P3337, DOI 10.1158/1078 0432.CCR 05 2354
   Carlinfante G, 2003, CLIN EXP METASTAS, V20, P437, DOI 10.1023/A:1025419708343
   CASEY G, 2006, CLIN EXP METASTAS, V23, P123
   Chellaiah MA, 2003, MOL BIOL CELL, V14, P173, DOI 10.1091/mbc.E02 06 0354
   Chellaiah MA, 2003, CALCIFIED TISSUE INT, V72, P197, DOI 10.1007/s00223 002 1025 6
   Cook AC, 2006, J BIOL CHEM, V281, P24381, DOI 10.1074/jbc.M602694200
   Czupalla C, 2005, PROTEOMICS, V5, P3868, DOI 10.1002/pmic.200402059
   Das S, 2009, J BIOL CHEM, V284, P22888, DOI 10.1074/jbc.M109.021949
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   Dillon R, 2003, P NATL ACAD SCI USA, V100, P10152, DOI 10.1073/pnas.1830500100
   Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008 5472.CAN 08 4135
   Ek Rylander B, 2010, EXP CELL RES, V316, P443, DOI 10.1016/j.yexcr.2009.10.019
   FLORES ME, 1992, EXP CELL RES, V201, P526, DOI 10.1016/0014 4827(92)90305 R
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Goetz JA, 2006, J BIOL CHEM, V281, P4087, DOI 10.1074/jbc.M511427200
   Guise TA, 2002, BONE, V30, P670, DOI 10.1016/S8756 3282(02)00685 3
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   HARADA M, 1992, ADV EXP MED BIOL, V324, P83
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kasper M, 2009, CARCINOGENESIS, V30, P903, DOI 10.1093/carcin/bgp048
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008 5472.CAN 04 0416
   Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003
   Matsubara T, 2010, J BONE MINER RES, V25, P1068, DOI 10.1359/jbmr.091039
   Maun HR, 2010, J BIOL CHEM, V285, P26570, DOI 10.1074/jbc.M110.112284
   McKee MD, 1996, MICROSC RES TECHNIQ, V33, P141, DOI 10.1002/(SICI)1097 0029(19960201)33:2<141::AID JEMT5>3.0.CO;2 W
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nemoto H, 2001, J BONE MINER RES, V16, P652, DOI 10.1359/jbmr.2001.16.4.652
   Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101
   Shijubo N, 2000, CRIT REV ONCOGENESIS, V11, P135
   Shimoyama A, 2007, MOL BIOL CELL, V18, P2411, DOI 10.1091/mbc.E06 08 0743
   Shkumatava A, 2004, DEVELOPMENT, V131, P3849, DOI 10.1242/dev.01247
   Siclari VA, 2006, CANCER METAST REV, V25, P621, DOI 10.1007/s10555 006 9023 1
   Standal T, 2004, EXP ONCOL, V26, P179
   Stecca B, 2005, TRENDS MOL MED, V11, P199, DOI 10.1016/j.molmed.2005.03.004
   Sterling JA, 2006, CANCER RES, V66, P7548, DOI 10.1158/0008 5472.CAN 06 0452
   Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200
   Terai K, 1999, J BONE MINER RES, V14, P839, DOI 10.1359/jbmr.1999.14.6.839
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Wysolmerski JJ, 2002, J BONE MINER RES, V17, P1164, DOI 10.1359/jbmr.2002.17.7.1164
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   YONEDA T, 1994, BREAST CANCER RES TR, V32, P73, DOI 10.1007/BF00666208
   Zhao M, 2006, MOL CELL BIOL, V26, P6197, DOI 10.1128/MCB.02214 05
NR 47
TC 46
Z9 48
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021 9258
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 18
PY 2011
VL 286
IS 11
BP 9612
EP 9622
DI 10.1074/jbc.M110.174920
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 733FE
UT WOS:000288247700086
PM 21169638
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Du, ML
   Yuan, SG
   Wang, JY
   Zhao, QQ
   Ye, BF
   Wu, HY
   Xu, LL
   Hou, Y
AF Du, Meilin
   Yuan, Shiguo
   Wang, Jiayang
   Zhao, Qiangqiang
   Ye, Baofei
   Wu, Haiyan
   Xu, Liangliang
   Hou, Yu
TI Shen Gu An Capsule Inhibition of Postmenopausal Osteoporosis in
   Ovariectomized Mice Using Network Pharmacology Based Mechanism
   Prediction and Pharmacological Validation
SO NATURAL PRODUCT COMMUNICATIONS
LA English
DT Article
DE postmenopausal osteoporosis; Shen Gu An capsule; NF kappa B signaling
   pathway; osteoclasts; bone
ID NF KAPPA B; TRANSCRIPTION FACTOR; SALVIA MILTIORRHIZA; OSTEOCLAST;
   PREVENTION; DIFFERENTIATION; WOMEN
AB Background Postmenopausal osteoporosis (PMOP) is characterized by low bone mass and increased bone fragility in postmenopausal women. Shen Gu An capsule (SGA) has been clinically used to treat bone diseases, especially PMOP with kidney Yang deficiency.Objectives We aimed to study the effect of SGA on the treatment of PMOP.Methodology The key candidate targets and pathways of SGA for treating PMOP were predicted by Network pharmacology analysis. Then, in vivo validation using bilaterally ovariectomized C57BL/6 mice was performed, and the bone quality was analyzed by Micro CT and histological analysis.Results In this study, we obtained 113 active compounds and 82 targets via the database of Traditional Chinese Medicine Systems Pharmacology. Subsequently, compound target and protein protein interaction networks were constructed. Then GO and KEGG analysis revealed that NF kappa B signaling pathway might be the underlying mechanism as its well known function in osteoclastogenesis. Furthermore, the in vivo experiments using ovariectomized mice demonstrated that SGA could decrease the number of osteoclasts and preserve bone mass through inhibiting the NF kappa B signaling pathway.Conclusions SGA could prevent postmenopausal osteoporosis in ovariectomized mice through inhibiting NF kappa B signaling pathway. The finding of this study provides more evidence for the clinical application of SGA to treat osteoporosis.
C1 [Du, Meilin] Shandong Univ Tradit Chinese Med, Lab Gynecol, Jinan, Chin, Myanmar.
   [Yuan, Shiguo; Ye, Baofei; Wu, Haiyan; Hou, Yu] Guangzhou Univ Chinese Med, Hainan Hosp, Guangdong Prov Hosp Chinese Med, Dept Orthopaed, Guangzhou 510000, Guangdong, Peoples R China.
   [Yuan, Shiguo; Ye, Baofei; Wu, Haiyan] Hainan Med Univ, Hainan Tradit Chinese Med Hosp, Dept Orthopaed, Haikou, Hainan, Peoples R China.
   [Wang, Jiayang] Dalian Med Univ, Lab Orthopaed & Traumatol, Dalian, Liaoning, Peoples R China.
   [Zhao, Qiangqiang; Xu, Liangliang] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Lingnan Med Res Ctr, Key Lab Orthopaed & Traumatol, Guangzhou, Guangdong, Peoples R China.
   [Hou, Yu] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Clin Coll 2, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Hainan Medical University;
   Dalian Medical University; Guangzhou University of Chinese Medicine;
   Guangzhou University of Chinese Medicine
RP Hou, Y (通讯作者)，Guangzhou Univ Chinese Med, Hainan Hosp, Guangdong Prov Hosp Chinese Med, Dept Orthopaed, Guangzhou 510000, Guangdong, Peoples R China.; Xu, LL (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Key Lab Orthopaed & Traumatol, Room 305,Key Discipline Bldg,12,Airport Rd, Guangzhou, Peoples R China.
EM xull 2016@gzucm.edu.cn; houyu@gzucm.edu.cn
RI Du, Meilin/KFS 6364 2024; XU, LIANGLIANG/AAZ 7935 2020; zhao,
   qiangq/LZG 5793 2025
OI Xu, Liangliang/0000 0002 5249 7480; 
FU National Natural Science Foundation of China (NSFC) [82360941]; Hainan
   Province Clinical Medical Center [276]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: The work was
   supported by Hainan Province Clinical Medical Center ([2021] No.276),
   and National Natural Science Foundation of China (NSFC No.82360941).
CR Awasthi H, 2018, MED RES REV, V38, P2024, DOI 10.1002/med.21504
   Bennell K, 2000, MANUAL THER, V5, P198, DOI 10.1054/math.2000.0369
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Chen XD, 2024, PHYTOMEDICINE, V129, DOI 10.1016/j.phymed.2024.155665
   Ding LL, 2023, NAT PRODUCT BIOPROSP, V13, DOI 10.1007/s13659 023 00405 z
   Duan H, 2024, FOOD SCI HUM WELL, V13, P3245, DOI 10.26599/FSHW.2023.9250011
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Guo YB, 2014, J ETHNOPHARMACOL, V155, P1401, DOI 10.1016/j.jep.2014.07.058
   Händel MN, 2023, BMJ BRIT MED J, V381, DOI 10.1136/bmj 2021 068033
   He S, 2022, J ETHNOPHARMACOL, V282, DOI 10.1016/j.jep.2021.114615
   Hou YH, 2022, CHIN MED UK, V17, DOI 10.1186/s13020 022 00639 y
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Li J, 2020, CYTOKINE GROWTH F R, V52, P88, DOI 10.1016/j.cytogfr.2020.02.003
   Lindsay R, 1997, OSTEOPOROSIS INT, V7, P1
   Liu MQ, 2021, J ETHNOPHARMACOL, V275, DOI 10.1016/j.jep.2021.114129
   Ma L., 2023, Medicine (Baltimore), V102
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Nian H, 2006, J ETHNOPHARMACOL, V108, P96, DOI 10.1016/j.jep.2006.04.020
   PRINCE RL, 1991, NEW ENGL J MED, V325, P1189, DOI 10.1056/NEJM199110243251701
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Wang J, 2023, INT J BIOL MACROMOL, V248, DOI 10.1016/j.ijbiomac.2023.125879
   Wang MY, 2002, ACTA PHARMACOL SIN, V23, P1127
   Wang P, 2021, INT J BIOCHEM CELL B, V137, DOI 10.1016/j.biocel.2021.106033
   Wong RWK, 2008, J BIOMED MATER RES A, V85A, P506, DOI 10.1002/jbm.a.31577
   Wu JJ, 2018, PHYTOMEDICINE, V44, P187, DOI 10.1016/j.phymed.2018.03.001
   Wu YJ, 2023, DRUG DES DEV THER, V17, P563, DOI 10.2147/DDDT.S397914
   Xing L, 1997, J BONE MINER RES, V12, pO1
   Xu DH, 2014, INT J BIOCHEM CELL B, V51, P1, DOI 10.1016/j.biocel.2014.03.005
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Ye XT, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.618844
   Yu H, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 00312 6
   Zhai KF, 2019, J AGR FOOD CHEM, V67, P2856, DOI 10.1021/acs.jafc.9b00185
   Zhang CD, 2022, METABOLITES, V12, DOI 10.3390/metabo12100958
   Zhang DD, 2022, J PHARMACEUT BIOMED, V207, DOI 10.1016/j.jpba.2021.114422
   Zhang JH, 2018, J ETHNOPHARMACOL, V213, P230, DOI 10.1016/j.jep.2017.10.028
   Zhang Y., 2023, Future Integr Med, V2, P117
   Zhang YD, 2020, LIFE SCI, V258, DOI 10.1016/j.lfs.2020.118093
   Zhao LH, 2020, CLIN EXP PHARMACOL P, V47, P531, DOI 10.1111/1440 1681.13228
   Zhao ZJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135728
   Zhou XY, 2019, DRUG DES DEV THER, V13, P2703, DOI 10.2147/DDDT.S208458
NR 45
TC 0
Z9 0
U1 3
U2 12
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1934 578X
EI 1555 9475
J9 NAT PROD COMMUN
JI Nat. Prod. Commun.
PD NOV
PY 2024
VL 19
IS 11
AR 1934578X241297039
DI 10.1177/1934578X241297039
PG 10
WC Chemistry, Medicinal; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Food Science & Technology
GA L7E9M
UT WOS:001352323500001
OA gold
DA 2025 08 17
ER

PT J
AU Hsieh, CJ
   Kuo, PL
   Hou, MF
   Hung, JY
   Chang, FR
   Hsu, YC
   Huang, YF
   Tsai, EM
   Hsu, YL
AF Hsieh, Chia Jung
   Kuo, Po Lin
   Hou, Ming Feng
   Hung, Jen Yu
   Chang, Fang Rong
   Hsu, Ying Chan
   Huang, Ya Fang
   Tsai, Eing Mei
   Hsu, Ya Ling
TI Wedelolactone inhibits breast cancer induced osteoclastogenesis by
   decreasing Akt/mTOR signaling
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE wedelolactone; osteoclastogenesis; breast cancer; bone metastasis
ID FACTOR KAPPA B; BONE METASTASIS; PROSTATE CANCER; RECEPTOR ACTIVATOR;
   ECLIPTA ALBA; SOLID TUMORS; GROWTH; AKT; CELLS; DIFFERENTIATION
AB The bone is the most common metastatic site of breast cancer. Bone metastasis causes pain, pathologic fractures, and severely reduces the quality of life. Breast cancer causes osteolytic bone metastasis, which is dependent on osteoclast mediated bone resorption. While current treatments rely on palliative anti resorptive agents, there is a need to develop a drug based on potential alternative therapies. This study is the first to determine that wedelolactone (WDL), a natural coumarin isolated from plants, can inhibit breast cancer mediated osteoclastogenesis. Osteoclasts were generated from human CD14(+) monocytes cultured with M CSF/RANKL and WDL suppressed human osteoclast differentiation and activity in vitro in a dose dependent manner. Moreover, WDL inhibited the upregulation of osteoclasts stimulated by MDA MB 231 breast cancer cells. The activity of WDL on osteoclasts and breast cancer mediated osteoclastogenesis was associated with the inhibition of Akt/mammalian target of the rapamycin signaling pathway (mTOR). Blocking Akt and mTOR by specific inhibitors significantly decreased osteoclast differentiation and bone resorption. Furthermore, WDL regulated breast cancer enhanced interaction of osteoblasts and osteoclasts by decreasing M CSF expression in MDA MB 231 stimulated osteoblasts. Thus, this study suggests that WDL may be a potential natural agent for preventing and treating bone destruction in patients with bone metastasis due to breast cancer.
C1 [Hsieh, Chia Jung; Tsai, Eing Mei; Hsu, Ya Ling] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan.
   [Kuo, Po Lin; Hou, Ming Feng] Kaohsiung Med Univ, Coll Med, Inst Clin Med, Kaohsiung 807, Taiwan.
   [Hung, Jen Yu] Kaohsiung Med Univ, Coll Med, Sch Med, Kaohsiung 807, Taiwan.
   [Chang, Fang Rong] Kaohsiung Med Univ, Grad Inst Nat Prod, Kaohsiung 807, Taiwan.
   [Tsai, Eing Mei] Kaohsiung Med Univ, Ctr Res Resources & Dev, Kaohsiung 807, Taiwan.
   [Tsai, Eing Mei; Hsu, Ya Ling] Kaohsiung Med Univ, Res Ctr Environm Med, Kaohsiung 807, Taiwan.
   [Hsieh, Chia Jung; Hsu, Ying Chan; Huang, Ya Fang] Kaohsiung Med Univ Hosp, Dept Chinese Med, Kaohsiung 807, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Medical
   University; Kaohsiung Medical University; Kaohsiung Medical University;
   Kaohsiung Medical University Hospital
RP Tsai, EM (通讯作者)，Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan.
EM tsaieing@yahoo.com; hsuy1326@gmail.com
RI Hsu, Ya Ling/D 5143 2009; Hou, Ming Feng/D 5506 2009; Hung,
   Jen Yu/D 4522 2009; Chang, Fang Rong/C 5692 2009; Tsai,
   Eing Mei/A 1414 2010
OI Hou, Ming Feng/0000 0001 6030 9702; Chang,
   Fang Rong/0000 0003 2549 4193; Huang, Ya Fang/0000 0002 7790 8071
FU National Science Council of Taiwan [NSC 102 2628 B 037 002 MY3, NSC
   102 2632 B 037 001 MY3, NSC 102 2314 B 037 035 MY3]; Excellence for
   Cancer Research Center Grant; Ministry of Health and Welfare, Executive
   Yuan, Taipei, Taiwan [MOHW 103 TD B 111 05]; Kaohsiung Medical
   University Hospital [KMUH102 2M61]
FX This study was supported by grants from the National Science Council of
   Taiwan (NSC 102 2628 B 037 002 MY3; NSC 102 2632 B 037 001 MY3; NSC
   102 2314 B 037 035 MY3), the Excellence for Cancer Research Center
   Grant, the Ministry of Health and Welfare, Executive Yuan, Taipei,
   Taiwan (MOHW 103 TD B 111 05), and the Kaohsiung Medical University
   Hospital (KMUH102 2M61). The authors thank the Center for Research
   Resources and Development of Kaohsiung Medical University for their
   support with the instrumentation.
CR Akhtari M, 2008, CANCER BIOL THER, V7, P3, DOI 10.4161/cbt.7.1.5163
   Azim HA, 2012, J EGYPT NATL CANCER, V24, P107, DOI 10.1016/j.jnci.2012.06.002
   Cao HL, 2013, J BIOL CHEM, V288, P30399, DOI 10.1074/jbc.M113.469973
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Furugaki K, 2011, CLIN EXP METASTAS, V28, P649, DOI 10.1007/s10585 011 9398 4
   Gupta Swati, 2013, Natl J Maxillofac Surg, V4, P151, DOI 10.4103/0975 5950.127643
   Hsu YL, 2011, J BIOL CHEM, V286, P37335, DOI 10.1074/jbc.M111.256156
   Idris AI, 2009, MOL CANCER THER, V8, P2339, DOI 10.1158/1535 7163.MCT 09 0133
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Lin FM, 2007, CARCINOGENESIS, V28, P2521, DOI 10.1093/carcin/bgm137
   McGrath EE, 2011, J THORAC ONCOL, V6, P1468, DOI 10.1097/JTO.0b013e318229421f
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Mountzios G, 2007, ACTA ONCOL, V46, P221, DOI 10.1080/02841860600635870
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rordorf T, 2014, BREAST, V23, P511, DOI 10.1016/j.breast.2014.05.023
   Rove KO, 2009, ONCOLOGY NY, V23, P21
   Roy RK, 2008, ARCH DERMATOL RES, V300, P357, DOI 10.1007/s00403 008 0860 3
   Sanchez CP, 2009, BMC PEDIATR, V9, DOI 10.1186/1471 2431 9 3
   Sarveswaran S, 2012, INT J ONCOL, V41, P2191, DOI 10.3892/ijo.2012.1664
   Singh B., 2001, Indian Journal of Physiology and Pharmacology, V45, P435
   Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022
   Sterling JA, 2011, BONE, V48, P6, DOI 10.1016/j.bone.2010.07.015
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Takayanagi H, 2010, ANN NY ACAD SCI, V1192, P117, DOI 10.1111/j.1749 6632.2009.05303.x
   Tewtrakul S, 2007, PHYTOTHER RES, V21, P1092, DOI 10.1002/ptr.2252
   Tsai CH, 2009, CLIN CANCER RES, V15, P5435, DOI 10.1158/1078 0432.CCR 09 0298
   Vadia NH, 2008, INDIAN J PHARM SCI, V70, P649, DOI [10.4103/0250 474X.45408, 10.4103/0250 474X.45421]
   Vender JR, 2008, NEUROSURGERY, V62, P1122, DOI 10.1227/01.neu.0000325874.82999.75
   Verron E, 2014, DRUG DISCOV TODAY, V19, P1419, DOI 10.1016/j.drudis.2014.04.004
   WAGNER H, 1986, PLANTA MED, P370, DOI 10.1055/s 2007 969188
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Yoneda T, 2013, WORLD J ORTHOP, V4, P178, DOI 10.5312/wjo.v4.i4.178
NR 35
TC 49
Z9 50
U1 3
U2 31
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019 6439
EI 1791 2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD FEB
PY 2015
VL 46
IS 2
BP 555
EP 562
DI 10.3892/ijo.2014.2769
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AY6IX
UT WOS:000347671200014
PM 25421824
OA Bronze
DA 2025 08 17
ER

PT J
AU Troeltzsch, M
   Woodlock, T
   Kriegelstein, S
   Steiner, T
   Messlinger, K
   Troeltzsch, M
AF Troeltzsch, Matthias
   Woodlock, Timothy
   Kriegelstein, Stefanie
   Steiner, Timm
   Messlinger, Karl
   Troeltzsch, Markus
TI Physiology and Pharmacology of Nonbisphosphonate Drugs Implicated in
   Osteonecrosis of the Jaw
SO JOURNAL OF THE CANADIAN DENTAL ASSOCIATION
LA English
DT Article
ID BISPHOSPHONATE RELATED OSTEONECROSIS; SURGEONS POSITION PAPER;
   OSTEOCLAST DIFFERENTIATION; AMERICAN ASSOCIATION; JAWS 2009 UPDATE;
   ZOLEDRONIC ACID; HUMAN HEALTH; BEVACIZUMAB; RECEPTOR; CANCER
AB Patients undergoing cancer chemotherapy are living longer and with better quality of life, and they require dental care both during and after their treatments. Bisphosphonates have been associated with drug related osteonecrosis of the jaw (ONJ) since the discoveries of Marx in 2003 and Ruggiero and Woo in 2008. Recent literature has indicated a similar association with nonbisphosphonate drugs used in cancer therapy. Denosumab, an osteoclast inhibitor with applications in orthopedics and oncology, causes ONJ at a rate comparable to that for intravenously administered bisphosphonates. Case reports and drug agency records have indicated a correlation between ONJ and the neoangiogenesis inhibitors bevacizumab and sunitinib, which are used to treat many common cancers. The pharmacologic mechanisms of these 3 drugs appear distinct, yet a common effect on bone metabolism may occur in susceptible hosts. This review explores the mechanisms of these drugs that could lead to ONJ, according to current scientific understanding. The American Academy of Oral and Maxillofacial Surgeons has provided detailed recommendations for the management of bisphosphonate related ONJ, which we suggest should also be applied in the management of patients with exposure to denosumab, bevacizumab and sunitinib.
C1 [Troeltzsch, Matthias] Ansbach Gen Hosp, Dept Oral & Maxillofacial Surg, Ansbach, Germany.
   [Troeltzsch, Matthias; Messlinger, Karl] Univ FAU Erlangen Nurnberg, Inst Physiol & Pathophysiol, Nurnberg, Germany.
   [Woodlock, Timothy] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA.
   [Woodlock, Timothy] Unity Hlth Syst, Dept Med, Rochester, NY USA.
   [Kriegelstein, Stefanie] Schon Klin Munchen Harlaching, Dept Foot & Ankle Surg, Munich, Germany.
   [Steiner, Timm] Rhein Westfal TH Aachen, Dept Oral & Maxillofacial Surg, D 52062 Aachen, Germany.
   [Troeltzsch, Markus] Ruhr Univ Bochum, Dept Oral & Maxillofacial Surg, Bochum, Germany.
C3 University of Erlangen Nuremberg; University of Rochester; RWTH Aachen
   University; Ruhr University Bochum
RP Troeltzsch, M (通讯作者)，Maximilianstr 5, D 91522 Ansbach, Germany.
EM matthias_troeltzsch@hotmail.com
RI ; Messlinger, Karl/P 8476 2019
OI Troeltzsch, Matthias/0000 0003 4893 4729; 
CR Aldridge SE, 2005, BIOCHEM BIOPH RES CO, V335, P793, DOI 10.1016/j.bbrc.2005.07.145
   [Anonymous], 2011, Prescrire Int, V20, P155
   Aragon Ching JB, 2009, CANCER INVEST, V27, P221, DOI 10.1080/07357900802208608
   Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797
   Ayllon J, 2009, ANN ONCOL, V20, P600, DOI 10.1093/annonc/mdn788
   Balla B, 2012, ORAL DIS        0131, DOI [10.1111/j.1601 0825.2012.01912.x, DOI 10.1111/J.1601 0825.2012.01912.X.[]
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bonacina R, 2011, J CAN DENT ASSOC, V77, P1
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bozas G, 2010, ONKOLOGIE, V33, P321, DOI 10.1159/000313680
   Brunello A, 2009, BONE, V44, P173, DOI 10.1016/j.bone.2008.08.132
   Chappell WH, 2011, ONCOTARGET, V2, P135, DOI 10.18632/oncotarget.240
   Chtioui H, 2011, NEW ENGL J MED, V364, P1081, DOI 10.1056/NEJMc1100730
   Colella G, 2009, J ORAL MAXIL SURG, V67, P2698, DOI 10.1016/j.joms.2009.07.097
   Compston J, 2011, OSTEOPOROSIS INT, V22, P2951, DOI 10.1007/s00198 011 1804 x
   Cornish J, 2011, BONE, V49, P710, DOI 10.1016/j.bone.2011.07.020
   Dore RK, 2011, RHEUM DIS CLIN N AM, V37, P433, DOI 10.1016/j.rdc.2011.07.004
   Doyle Maire E, 2008, Curr Osteoporos Rep, V6, P134, DOI 10.1007/s11914 008 0024 6
   Estilo CL, 2008, J CLIN ONCOL, V26, P4037, DOI 10.1200/JCO.2007.15.5424
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fleissig Y, 2012, ORAL SURG ORAL MED O
   Fusco V, 2011, J CLIN ONCOL, V29, pE521, DOI 10.1200/JCO.2011.35.1551
   Gambhir V, 2011, IMMUNOBIOLOGY, V216, P988, DOI 10.1016/j.imbio.2011.03.011
   Greuter S, 2008, ANN ONCOL, V19, P2091, DOI 10.1093/annonc/mdn653
   Guarneri V, 2010, BREAST CANCER RES TR, V122, P181, DOI 10.1007/s10549 010 0866 3
   Hansen T, 2007, VIRCHOWS ARCH, V451, P1009, DOI 10.1007/s00428 007 0516 2
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hewison M, 2004, MOL CELL ENDOCRINOL, V215, P31, DOI 10.1016/j.mce.2003.11.017
   Hewison M, 2007, J STEROID BIOCHEM, V103, P316, DOI 10.1016/j.jsbmb.2006.12.078
   Hoefert S, 2010, ORAL SURG ORAL MED O, V110, P463, DOI 10.1016/j.tripleo.2010.04.049
   Hopp RN, 2012, J ORAL MAXIL SURG, V70, P632, DOI 10.1016/j.joms.2011.02.104
   Katsenos S, 2012, ARCH BRONCONEUMOL, V48, P218, DOI [10.1016/j.arbr.2012.03.004, 10.1016/j.arbres.2012.01.007]
   Koch FP, 2011, ORAL MAXILLOFAC SURG, V15, P63, DOI 10.1007/s10006 010 0224 y
   Koch FP, 2012, CLIN ORAL INVEST, V16, P79, DOI 10.1007/s00784 010 0477 8
   Kos M, 2010, INT J ORAL MAX SURG, V39, P1097, DOI 10.1016/j.ijom.2010.04.054
   Lemound J, 2011, CLIN ORAL INVES 0805
   Mancini A, 2004, ONCOGENE, V23, P6581, DOI 10.1038/sj.onc.1207841
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mashkani B, 2010, BIOORGAN MED CHEM, V18, P1789, DOI 10.1016/j.bmc.2010.01.056
   Pazianas M, 2011, JNCI J NATL CANCER I, V103, P232, DOI 10.1093/jnci/djq516
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Reid IR, 2012, NAT REV RHEUMATOL, V8, P90, DOI 10.1038/nrrheum.2011.181
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Ruggiero SL, 2006, ORAL SURG ORAL MED O, V102, P433, DOI 10.1016/j.tripleo.2006.06.004
   Ruggiero Salvatore L, 2008, Dent Clin North Am, V52, P111, DOI 10.1016/j.cden.2007.09.002
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Serra E, 2009, INT J IMMUNOPATH PH, V22, P1121, DOI 10.1177/039463200902200429
   Siddiqi A, 2009, ORAL SURG ORAL MED O, V108, pE1, DOI 10.1016/j.tripleo.2009.04.027
   Smith MH, 2011, BMC ORAL HLTH, V11, P21
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Udagawa N, 2003, J BONE MINER METAB, V21, P337, DOI 10.1007/s00774 003 0439 1
   Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584
   Walter C, 2008, EURUROL, V54, P1066
   Wong VK, 2011, BMJ BRIT MED J, V343, DOI 10.1136/bmj.d6099
   Zelkha SA, 2010, PERIODONTOL 2000, V54, P207, DOI 10.1111/j.1600 0757.2010.00358.x
NR 55
TC 69
Z9 74
U1 0
U2 12
PU CANADIAN DENTAL ASSOC
PI OTTAWA
PA 1815 ALTA VISTA DRIVE, OTTAWA, ON K1G 3Y6, CANADA
SN 1488 2159
J9 J CAN DENT ASSOC
JI J. Can. Dent. Assoc.
PD AUG 28
PY 2012
VL 78
AR c85
PG 4
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 006ZV
UT WOS:000308859200001
PM 22985897
DA 2025 08 17
ER

PT J
AU Tang, DZ
   Hou, W
   Zhou, QA
   Zhang, MJ
   Holz, J
   Sheu, TJ
   Li, TF
   Cheng, SD
   Shi, Q
   Harris, SE
   Chen, D
   Wang, YJ
AF Tang, De Zhi
   Hou, Wei
   Zhou, Quan
   Zhang, Minjie
   Holz, Jonathan
   Sheu, Tzong Jen
   Li, Tian Fang
   Cheng, Shao Dan
   Shi, Qi
   Harris, Stephen E.
   Chen, Di
   Wang, Yong Jun
TI Osthole Stimulates Osteoblast Differentiation and Bone Formation by
   Activation of β Catenin BMP Signaling
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTHOLE; beta CATENIN; BMP 2; OSTEOBLAST; OSTEOPOROSIS; OVARIECTOMY
ID FORMATION IN VITRO; PARATHYROID HORMONE; OSTEOPOROSIS; COMBINATION;
   ALENDRONATE; RISK
AB Osteoporosis is defined as reduced bone mineral density with a high risk of fragile fracture. Current available treatment regimens include antiresorptive drugs such as estrogen receptor analogues and bisphosphates and anabolic agents such as parathyroid hormone (PTH). However, neither option is completely satisfactory because of adverse effects. It is thus highly desirable to identify novel anabolic agents to improve future osteoporosis treatment. Osthole, a coumarin like derivative extracted from Chinese herbs, has been shown to stimulate osteoblast proliferation and differentiation, but its effect on bone formation in vivo and underlying mechanism remain unknown. In this study, we found that local injection of Osthole significantly increased new bone formation on the surface of mouse calvaria. Ovariectomy caused evident bone loss in rats, whereas Osthole largely prevented such loss, as shown by improved bone microarchitecture, histomorphometric parameters, and biomechanical properties. In vitro studies demonstrated that Osthole activated Wnt/beta catenin signaling, increased Bmp2 expression, and stimulated osteoblast differentiation. Targeted deletion of the beta catenin and Bmp2 genes abolished the stimulatory effect of Osthole on osteoblast differentiation. Since deletion of the Bmp2 gene did not affect Osthole induced beta catenin expression and the deletion of the beta catenin gene inhibited Osthole regulated Bmp2 expression in osteoblasts, we propose that Osthole acts through beta catenin BMP signaling to promote osteoblast differentiation. Our findings demonstrate that Osthole could be a potential anabolic agent to stimulate bone formation and prevent estrogen deficiency induced bone loss. (C) 2010 American Society for Bone and Mineral Research.
C1 [Tang, De Zhi; Hou, Wei; Zhou, Quan; Cheng, Shao Dan; Shi, Qi; Wang, Yong Jun] Shanghai Univ Tradit Chinese Med, Spine Res Inst, Shanghai 200032, Peoples R China.
   [Tang, De Zhi; Hou, Wei; Zhang, Minjie; Holz, Jonathan; Sheu, Tzong Jen; Li, Tian Fang; Chen, Di] Univ Rochester, Dept Orthopaed, Ctr Musculoskeletal Res, Sch Med, Rochester, NY 14642 USA.
   [Shi, Qi; Wang, Yong Jun] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Orthopaed & Traumatol, Shanghai, Peoples R China.
   [Harris, Stephen E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA.
C3 Shanghai University of Traditional Chinese Medicine; University of
   Rochester; Shanghai University of Traditional Chinese Medicine;
   University of Texas System; University of Texas Health Science Center at
   San Antonio
RP Wang, YJ (通讯作者)，Shanghai Univ Tradit Chinese Med, Spine Res Inst, 725 Wan Ping S Rd, Shanghai 200032, Peoples R China.
EM di_chen@urmc.rochester.edu; yjwang88@hotmail.com
RI hou, wei/GWM 4800 2022; Chen, Di/AAJ 3665 2021; Zhang,
   Minjie/N 5225 2014
OI Holz, Jonathan/0000 0003 1486 7230; 
FU National Science Fund for Distinguished Young Scholars of China
   [30625043]; National Natural Science Foundation of China [30710103904];
   Chinese Science and Technology Committee Emphasis [2006DFA32670];
   National Institutes of Health (NIH) [R01 AR051189, R01 AR054465]
FX This work was supported in part by the National Science Fund for
   Distinguished Young Scholars of China (30625043), the International
   Cooperation Programs of National Natural Science Foundation of China
   (30710103904), the International Technical Cooperation Key Project Plan,
   Chinese Science and Technology Committee Emphasis (2006DFA32670), and
   Grants R01 AR051189 and R01 AR054465 to DC from the National Institutes
   of Health (NIH).
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Bilezikian John P, 2008, Curr Osteoporos Rep, V6, P24, DOI 10.1007/s11914 008 0005 9
   Bilican B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002863
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Cauley JA, 2009, J BONE MINER RES, V24, P943, DOI [10.1359/JBMR.081246, 10.1359/jbmr.081246]
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen M, 2008, J CELL SCI, V121, P1455, DOI 10.1242/jcs.020362
   Chesnut CH, 2001, J BONE MINER RES, V16, P2163, DOI 10.1359/jbmr.2001.16.12.2163
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   KO FN, 1992, EUR J PHARMACOL, V219, P29, DOI 10.1016/0014 2999(92)90576 P
   Kuo PL, 2005, J PHARMACOL EXP THER, V314, P1290, DOI 10.1124/jpet.105.085092
   Li XX, 2002, BIOL PHARM BULL, V25, P738, DOI 10.1248/bpb.25.738
   Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067
   Meng F, 2004, PHARMAZIE, V59, P643
   Messinger Rapport BJ, 2002, GERIATRICS, V57, P16
   Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009
   Mulligan Roseann, 2005, Dent Clin North Am, V49, P463, DOI 10.1016/j.cden.2004.10.005
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pluijm SMF, 2009, J BONE MINER RES, V24, P768, DOI [10.1359/jbmr.081244, 10.1359/JBMR.081244]
   RAMESH BL, 2005, BONE, V36, P555, DOI DOI 10.1016/J.B0NE.2004.12.005
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   Rubin CD, 2005, CURR MED RES OPIN, V21, P1049, DOI 10.1185/030079905X50525
   Styrkarsdottir U, 2003, PLOS BIOL, V1, P351, DOI 10.1371/journal.pbio.0000069
   Tang YC, 2008, CELL BIOL INT, V32, P1150, DOI 10.1016/j.cellbi.2008.06.005
   TENG CM, 1994, N S ARCH PHARMACOL, V349, P202
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Yan Y, 2009, J CELL SCI, V122, P3566, DOI 10.1242/jcs.051904
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012
   Zhao M, 2006, MOL CELL BIOL, V26, P6197, DOI 10.1128/MCB.02214 05
   Zhao M, 2009, MOL CELL BIOL, V29, P1291, DOI 10.1128/MCB.01566 08
   Zhu M, 2009, J BONE MINER RES, V24, P12, DOI [10.1359/jbmr.080901, 10.1359/JBMR.080901]
NR 36
TC 120
Z9 151
U1 2
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2010
VL 25
IS 6
BP 1234
EP 1245
DI 10.1002/jbmr.21
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 619PE
UT WOS:000279441300005
PM 20200936
OA Green Published
DA 2025 08 17
ER

PT J
AU Lipton, A
AF Lipton, Allan
TI Future treatment of bone metastases
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Proceedings Paper
CT Conference on Advances in Treating Metastatic Bone Cancer
CY OCT 28 29, 2005
CL Cambridge, MA
ID RESORPTION IN VITRO; BREAST CANCER; SKELETAL COMPLICATIONS; INHIBITOR;
   VIVO; RECEPTOR; MICE; OSTEOPROTEGERIN; ANGIOGENESIS; CARCINOMA
AB All bone surfaces are periodically remodeled by the coupled and balanced action of osteoclasts and osteoblasts, of which the activities are regulated by a variety of cytokines and growth factors. Patients with cancer metastatic to the skeleton often develop osteolytic bone lesions, in which the actions of osteoclasts and osteoblasts remain coupled, but become imbalanced in sites adjacent to the tumor. The result is net bone loss. Many cancers secrete osteoclast stimulating cytokines, which increase bone resorption by osteoclasts. In turn, factors released from the bone matrix during osteolysis can stimulate tumor growth. In this so called "viscous cycle." there are multiple sites that are targets for new bone directed therapies. A variety of new agents for the treatment and prevention of osteolytic bone metastasis are currently being developed. These include new agents that inhibit osteoclast differentiation, bone adhesion and osteoclast function. These new strategies have evolved form a better understanding of the interaction between tumor cells and cells in the bone marrow microenvironment. There is great promise that these new bone targeted therapies can decrease the frequent skeletal related events that greatly diminish quality of life of patients with bone metastases.
C1 Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Med, Hershey, PA 17033 USA.
   Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Oncol, Hershey, PA 17033 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Penn State Health
RP Lipton, A (通讯作者)，Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Med, 500 Univ Dr,H046,POB 850, Hershey, PA 17033 USA.
EM alipton@psu.edu
CR Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453
   Barille Nion Sophie, 2003, Hematology Am Soc Hematol Educ Program, P248
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   BRADBEER JN, 1996, J BONE MINER RES, V11, P1196
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Guise TA, 1997, CANCER AM CANCER SOC, V80, P1572, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1572::AID CNCR7>3.3.CO;2 D
   GUISE TA, 2001, P AM SOC CLIN ONC
   Lark MW, 2001, J BONE MINER RES, V16, P319, DOI 10.1359/jbmr.2001.16.2.319
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   LIPTON A, 2006, RANDOMIZED ACTIVE CO
   Mathew P, 2004, SEMIN ONCOL, V31, P24, DOI 10.1053/j.seminoncol.2004.03.037
   Missbach M, 1999, BONE, V24, P437, DOI 10.1016/S8756 3282(99)00020 4
   NELSON JB, 2001, P AM SOC CLIN ONC
   PELES S, 2006, PROSPECTIVE STUDY EF
   Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008 5472.CAN 05 0676
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Sasaki A, 1998, CANCER RES, V58, P462
   Shakespeare W, 2000, P NATL ACAD SCI USA, V97, P9373, DOI 10.1073/pnas.97.17.9373
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Stroup GB, 2001, J BONE MINER RES, V16, P1739, DOI 10.1359/jbmr.2001.16.10.1739
   Van der Pluijm G, 2001, J BONE MINER RES, V16, P1077, DOI 10.1359/jbmr.2001.16.6.1077
   Votta BJ, 1997, J BONE MINER RES, V12, P1396, DOI 10.1359/jbmr.1997.12.9.1396
NR 26
TC 58
Z9 78
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2006
VL 12
IS 20
SU S
BP 6305S
EP 6308S
DI 10.1158/1078 0432.CCR 06 1157
PN 2
PG 4
WC Oncology
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 099AC
UT WOS:000241563900018
PM 17062719
DA 2025 08 17
ER

PT J
AU Qiang, YW
   Hu, B
   Chen, Y
   Zhong, Y
   Shi, BY
   Barlogie, B
   Shaughnessy, JD
AF Qiang, Ya Wei
   Hu, Bo
   Chen, Yu
   Zhong, Ying
   Shi, Bingyin
   Barlogie, Bart
   Shaughnessy, John D., Jr.
TI Bortezomib induces osteoblast differentiation via Wnt independent
   activation of β catenin/TCF signaling
SO BLOOD
LA English
DT Article
ID MYELOMA BONE DISEASE; KAPPA B LIGAND; MARROW STROMAL CELLS;
   MULTIPLE MYELOMA; IN VIVO; RECEPTOR ACTIVATOR; OSTEOGENIC
   DIFFERENTIATION; OSTEOCLAST DIFFERENTIATION; PROTEASOME INHIBITION;
   SERUM CONCENTRATIONS
AB Inhibition of Wnt/beta catenin/T cell factor (TCF) signaling induces proliferation of mesenchymal stem cells and/or suppresses their differentiation into osteoblasts (OBs). Osteolysis in multiple myeloma (MM) is related to the suppression of canonical Wnt signaling caused by DKK1, a soluble inhibitor of this pathway secreted by MM cells. Bortezomib (Bzb) can induce OB differentiation in vitro and in vivo and its anti MM efficacy linked to bone anabolic effects. However, the molecular basis of the action of Bzb on bone is not completely under stood. In the present study, we show that Bzb promotes matrix mineralization and calcium deposition by osteoprogenitor cells and primary mesenchymal stem cells via Wnt independent activation of beta catenin/TCF signaling. Using affinity pull down assays with immunoblotting and immunofluorescence, we found that Bzb induced stabilization of beta catenin. Nuclear translocation of stabilized beta catenin was associated with beta catenin/TCF transcriptional activity that was independent of the effects of Wnt ligandreceptor induced signaling or GSK3 beta activation. Blocking the activation of beta catenin/TCF signaling by dominant negative TCF attenuated Bzb induced matrix mineralization. These results provide evidence that Bzb induces OB differentiation via Wnt independent activation of beta catenin/TCF pathway and suggest that proteasome inhibition therapy in MM may function in part by subverting tumor induced suppression of canonical Wnt signaling in the bone microenvironment. (Blood. 2009; 113: 4319 4330)
C1 [Qiang, Ya Wei; Hu, Bo; Chen, Yu; Zhong, Ying; Barlogie, Bart; Shaughnessy, John D., Jr.] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA.
   [Shi, Bingyin] Xi An Jiao Tong Univ, Sch Med, Dept Endocrinol, Xian 710049, Peoples R China.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   Xi'an Jiaotong University
RP Shaughnessy, JD (通讯作者)，Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, 4301 W Markham St 716, Little Rock, AR 72205 USA.
EM Qiang@uams.edu; shaughnessyjohn@uams.edu
RI ; Qiang, Ya Wei/Q 2206 2019
OI Qiang, Ya Wei/0000 0002 2479 1412; 
FU National Cancer Institute; Multiple Myeloma Research Foundation Senior
   Research Award
FX The authors thank Drs Stuart Rudikoff and Jeffery Rubin in Lab of
   Cellular and Molecular Biology, National Cancer Institute, National
   Institutes of Health for providing reagents as well as the faculty,
   staff, and patients of the Myeloma Institute for Research and Therapy.
   This work was supported by the National Cancer Institute (J.D.S.) and by
   a Multiple Myeloma Research Foundation Senior Research Award (Y. W.Q.).
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Cheng SL, 1998, J BONE MINER RES, V13, P633, DOI 10.1359/jbmr.1998.13.4.633
   Christodoulides C, 2006, J CELL SCI, V119, P2613, DOI 10.1242/jcs.02975
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Colla S, 2007, BLOOD, V109, P4470, DOI 10.1182/blood 2006 11 056747
   Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384
   Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood 2007 03 077685
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gunn WG, 2006, STEM CELLS, V24, P986, DOI 10.1634/stemcells.2005 0220
   Heider U, 2004, J CANCER RES CLIN, V130, P469, DOI 10.1007/s00432 004 0578 3
   Heider U, 2006, EUR J HAEMATOL, V77, P233, DOI 10.1111/j.1600 0609.2006.00692.x
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Jia D, 2000, BONE, V27, P785, DOI 10.1016/S8756 3282(00)00400 2
   Kaiser M, 2008, EUR J HAEMATOL, V80, P490, DOI 10.1111/j.1600 0609.2008.01065.x
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464
   Lu WY, 2008, FEBS LETT, V582, P643, DOI 10.1016/j.febslet.2008.01.035
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Oyajobi BO, 2007, BRIT J HAEMATOL, V139, P434, DOI 10.1111/j.1365 2141.2007.06829.x
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Politou MC, 2006, INT J CANCER, V119, P1728, DOI 10.1002/ijc.22033
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Qiang YW, 2008, BLOOD, V112, P374, DOI 10.1182/blood 2007 10 120253
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Qiang YW, 2008, BONE, V42, P669, DOI 10.1016/j.bone.2007.12.006
   Qiang YW, 2005, BLOOD, V106, P1786, DOI 10.1182/blood 2005 01 0049
   Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239
   Qiang YW, 2002, BLOOD, V99, P4138, DOI 10.1182/blood.V99.11.4138
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Richardson PG, 2006, ANNU REV MED, V57, P33, DOI 10.1146/annurev.med.57.042905.122625
   ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092 8674(94)90462 6
   Sezer O, 2003, BLOOD, V101, P2094, DOI 10.1182/blood 2002 09 2684
   Sezer O, 2002, BLOOD, V99, P4646, DOI 10.1182/blood 2002 01 0148
   Shaughnessy JD, 2003, IMMUNOL REV, V194, P140, DOI 10.1034/j.1600 065X.2003.00054.x
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960 9822(02)70790 2
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Terpos E, 2008, LEUKEMIA, V22, P2247, DOI 10.1038/leu.2008.235
   Terpos E, 2007, BLOOD, V110, P1098, DOI 10.1182/blood 2007 03 067710
   Terpos E, 2006, BRIT J HAEMATOL, V135, P688, DOI 10.1111/j.1365 2141.2006.06356.x
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008 5472.CAN 03 1131
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
   Zangari M, 2006, CLIN LYMPHOMA MYELOM, V7, P109, DOI 10.3816/CLM.2006.n.047
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
NR 59
TC 120
Z9 134
U1 0
U2 11
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD APR 30
PY 2009
VL 113
IS 18
BP 4319
EP 4330
DI 10.1182/blood 2008 08 174300
PG 12
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 442MW
UT WOS:000265846300028
PM 19196662
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Liu, YQ
   Nishiura, M
   Fujii, M
   Sandhu, S
   Yawaka, Y
   Yamazaki, Y
   Hasebe, A
   Iimura, T
   Kong, SW
   Lee, JW
AF Liu, Yunqing
   Nishiura, Mai
   Fujii, Mika
   Sandhu, Sumiti
   Yawaka, Yasutaka
   Yamazaki, Yutaka
   Hasebe, Akira
   Iimura, Tadahiro
   Kong, Sek Won
   Lee, Ji Won
TI Selective Pyk2 inhibition enhances bone restoration through
   SCARA5 mediated bone marrow remodeling in ovariectomized mice
SO CELL COMMUNICATION AND SIGNALING
LA English
DT Article
DE Pyk2; Bone; Mesenchymal stem cell; Osteoclast; Osteoblast; Adipocyte
ID KINASE 2 PYK2; STEM CELLS; TYROSINE PHOSPHORYLATION; ADHESION KINASE;
   FRACTURE RISK; DIFFERENTIATION; OSTEOPOROSIS; DENSITY; DISEASE;
   PROLIFERATION
AB Understanding the intricate cellular interactions involved in bone restoration is crucial for developing effective strategies to promote bone healing and mitigate conditions such as osteoporosis and fractures. Here, we provide compelling evidence supporting the anabolic effects of a pharmacological Pyk2 inhibitor (Pyk2 Inh) in promoting bone restoration. In vitro, Pyk2 signaling inhibition markedly enhances alkaline phosphatase (ALP) activity, a hallmark of osteoblast differentiation, through activation of canonical Wnt/beta catenin signaling. Notably, analysis of human mesenchymal stem cells through RNA seq revealed a novel candidate, SCARA5, identified through Pyk2 Inh treatment. We demonstrate that Scara5 plays a crucial role in suppressing the differentiation from stromal cells into adipocytes, and accelerates lineage commitment to osteoblasts, establishing Scara5 as a negative regulator of bone formation. Additionally, Pyk2 inhibition significantly impedes osteoclast differentiation and bone resorption. In a co culture system comprising osteoblasts and osteoclasts, Pyk2 Inh effectively suppressed osteoclast differentiation, accompanied by a substantial increase in the transcriptional expression of Tnfrsf11b and Csf1 in osteoblasts, highlighting a dual regulatory role in osteoblast osteoclast crosstalk. In an ovariectomized mouse model of osteoporosis, oral administration of Pyk2 Inh significantly increased bone mass by simultaneously reducing bone resorption, promoting bone formation and decreasing bone marrow fat. These results suggest Pyk2 as a potential therapeutic target for both adipogenesis and osteogenesis in bone marrow. Our findings underscore the importance of Pyk2 signaling inhibition as a key regulator of bone remodeling, offering promising prospects for the development of novel osteoporosis therapies.
C1 [Liu, Yunqing; Nishiura, Mai; Iimura, Tadahiro] Hokkaido Univ, Fac & Grad Sch Dent Med, Dept Pharmacol, Kita13 Nishi7,Kita Ku, Sapporo 0608586, Japan.
   [Liu, Yunqing] Harbin Med Univ, Affiliated Hosp 4, Dept Stomatol, Harbin 150001, Peoples R China.
   [Nishiura, Mai; Yawaka, Yasutaka] Hokkaido Univ, Fac Dent Med, Dept Oral Funct Sci, Dent Children & Disabled Persons, Kita13 Nishi7,Kita Ku, Sapporo 0608586, Japan.
   [Fujii, Mika; Yamazaki, Yutaka] Hokkaido Univ, Fac Dent Med, Dept Oral Hlth Sci, Gerodontol, Kita13 Nishi7,Kita Ku, Sapporo 0608586, Japan.
   [Sandhu, Sumiti; Kong, Sek Won] Boston Childrens Hosp, Computat Hlth & Informat Program, Boston, MA 02215 USA.
   [Hasebe, Akira; Lee, Ji Won] Hokkaido Univ, Grad Sch Dent Med, Dept Oral Pathobiol Sci, Microbiol, Kita13 Nishi7,Kita Ku, Sapporo 0608586, Japan.
   [Kong, Sek Won] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.
C3 Hokkaido University; Harbin Medical University; Hokkaido University;
   Hokkaido University; Harvard University; Harvard University Medical
   Affiliates; Boston Children's Hospital; Hokkaido University; Harvard
   University; Harvard Medical School
RP Lee, JW (通讯作者)，Hokkaido Univ, Grad Sch Dent Med, Dept Oral Pathobiol Sci, Microbiol, Kita13 Nishi7,Kita Ku, Sapporo 0608586, Japan.
EM jwlee@den.hokudai.ac.jp
RI Liu, Yunqing/LTE 8391 2024; Yawaka, Yasutaka/K 8949 2012
FU Japan Society for the Promotion of Science (JSPS KAKENHI) grant
   [23K09116, 23K16013]; Takeda Science Foundation
FX This work was supported by Grant in Aids for Scientific Research from
   the Japan Society for the Promotion of Science (JSPS KAKENHI) grant
   number 23K09116, the Takeda Science Foundation, which were awarded to
   J W.L. This work was partly supported by the JSPS KAKENHI grant number
   23K16013, which was awarded to Y.L
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bolamperti S, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00219 8
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Buckbinder L, 2007, P NATL ACAD SCI USA, V104, P10619, DOI 10.1073/pnas.0701421104
   Butler B, 2005, J BIOL CHEM, V280, P14556, DOI 10.1074/jbc.M411765200
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Diacinti D, 2023, J CLIN ENDOCR METAB, V108, pE807, DOI 10.1210/clinem/dgad116
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Duncan EL, 2010, J CLIN ENDOCR METAB, V95, P2576, DOI 10.1210/jc.2009 2406
   Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Freeman EW, 2010, MENOPAUSE, V17, P718, DOI [10.1097/gme.0b013e3181db9f8b, 10.1097/gme.0b013e3181cec85d]
   Galli C, 2013, CLIN ORAL IMPLAN RES, V24, P921, DOI 10.1111/j.1600 0501.2012.02488.x
   Gao CX, 2015, ELIFE, V4, DOI 10.7554/eLife.10072
   Gil Henn H, 2007, J CELL BIOL, V178, P1053, DOI 10.1083/jcb.200701148
   Hall JE, 2011, INT REV CEL MOL BIO, V288, P185, DOI 10.1016/B978 0 12 386041 5.00005 4
   Han S, 2009, J BIOL CHEM, V284, P13193, DOI 10.1074/jbc.M809038200
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Hou RX, 2020, BONE, V132, DOI 10.1016/j.bone.2019.115175
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kushwaha P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.350
   Lazner F, 1999, HUM MOL GENET, V8, P1839, DOI 10.1093/hmg/8.10.1839
   Lee H, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12512 2
   Lee JW, 2015, MOL NUTR FOOD RES, V59, P386, DOI 10.1002/mnfr.201400164
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Luther J, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aau7137
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Mazziotti G, 2015, J CLIN ENDOCR METAB, V100, P384, DOI 10.1210/jc.2014 2937
   Muhammad N, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/161527
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Pfaff M, 2001, J CELL SCI, V114, P2775
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Posritong S, 2019, BIOMED MATER, V14, DOI 10.1088/1748 605X/aafffa
   Posritong S, 2018, MOL CELL ENDOCRINOL, V474, P35, DOI 10.1016/j.mce.2018.02.005
   Prestwich TC, 2007, CURR OPIN CELL BIOL, V19, P612, DOI 10.1016/j.ceb.2007.09.014
   Putri GH, 2022, BIOINFORMATICS, V38, P2943, DOI 10.1093/bioinformatics/btac166
   Qi SQ, 2020, J BONE MINER RES, V35, P1798, DOI 10.1002/jbmr.4029
   Rattanawarawipa P, 2016, TISSUE CELL, V48, P425, DOI 10.1016/j.tice.2016.08.005
   Richards JB, 2012, NAT REV GENET, V13, P576, DOI 10.1038/nrg3228
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112
   Shen T, 2018, MED SCI MONITOR, V24, P8172, DOI 10.12659/MSM.913479
   Sun CH, 2016, J BONE MINER RES, V31, P2227, DOI 10.1002/jbmr.2908
   Talabattula VAN, 2017, BIOCHEM BIOPH RES CO, V491, P40, DOI 10.1016/j.bbrc.2017.07.030
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Tuck SP, 2020, CLIN MED, V20, P568, DOI 10.7861/clinmed.20.6.page
   Walker MD, 2023, NEW ENGL J MED, V389, P1979, DOI 10.1056/NEJMcp2307353
   Williams LM, 2000, J IMMUNOL, V164, P2028, DOI 10.4049/jimmunol.164.4.2028
   You CJ, 2024, EMBO REP, V25, P4465, DOI 10.1038/s44319 024 00237 z
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 55
TC 0
Z9 0
U1 6
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1478 811X
J9 CELL COMMUN SIGNAL
JI Cell Commun. Signal.
PD NOV 22
PY 2024
VL 22
IS 1
AR 561
DI 10.1186/s12964 024 01945 8
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA N0G3U
UT WOS:001361215200002
PM 39578816
OA gold
DA 2025 08 17
ER

PT J
AU Geusens, P
   Reid, D
AF Geusens, P
   Reid, D
TI Newer drug treatments: Their effects on fracture prevention
SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
LA English
DT Article
DE strontium ranelate; ibandronate; zoledronate; parathyroid hormone;
   RANKL; calcitonin
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; OSTEOPOROSIS; RISK
AB Drug treatment of osteoporosis is based on the knowledge of mechanisms of bone turnover and the manipulation of the cellular components of bone turnover in terms of recruitment, activation and apoptosis of the cells involved. Based on their mechanisms of action, drugs used in the treatment of osteoporosis can be divided into those that inhibit bone turnover (bisphosphonates, SERMs, calcitonin), those that stimulate bone turnover (parathyroid hormone), and those with mixed effects (strontium ranelate). In this chapter we discuss the anti fracture effects of some newer drugs together with innovative aspects of intake (monthly oral intake for ibandronate) or mechanisms of action (parathyroid hormone and strontium ranelate). Some new drugs that are being studied for their potential anti fracture effects are listed.
C1 Univ Hasselt, Inst Biomed Res, Diepenbeek, Belgium.
   Univ Hosp, Dept Rheumatol, NL 6202 AZ Maastricht, Netherlands.
   Univ Aberdeen, Med Sch Foresterhill, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland.
C3 Hasselt University; Maastricht University; University of Aberdeen
RP Geusens, P (通讯作者)，Univ Hasselt, Inst Biomed Res, Campus Diepenbeek, Diepenbeek, Belgium.
EM piet.geusens@scarlet.be
CR Bauer DC, 2004, ARCH INTERN MED, V164, P146, DOI 10.1001/archinte.164.2.146
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Betancourt M, 2003, J BONE MINER RES, V18, P163, DOI 10.1359/jbmr.2003.18.1.163
   Boonen S, 2002, J CLIN ENDOCR METAB, V87, P1593, DOI 10.1210/jc.87.4.1593
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Grey A, 2005, EXPERT OPIN INV DRUG, V14, P265, DOI 10.1517/13543784.14.3.265
   HODSMAN AB, 2005, ENDOCRINE REV, V15
   MARIE PJ, 2005, J BIOMEDICAL MAT RES, P1065
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   MILLER PD, J BONE MINERAL RES
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   REGINSTER JY, 2005, J CLIN ENDOCRINOLOGY
   REGINSTER JY, IN PRESS J CLIN ENDO
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
NR 18
TC 9
Z9 9
U1 0
U2 1
PU BAILLIERE TINDALL
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1521 6942
J9 BEST PRACT RES CL RH
JI Best Pract. Res. Clin. Rheumatol.
PD DEC
PY 2005
VL 19
IS 6
BP 983
EP 989
DI 10.1016/j.berh.2005.07.003
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 992BJ
UT WOS:000233858700009
PM 16301192
DA 2025 08 17
ER

PT J
AU Yang, B
   Tang, Q
   Post, J
   Zhou, H
   Huang, XB
   Zhang, XD
   Wang, Q
   Sun, YM
   Fan, FY
AF Yang, Bing
   Tang, Quan
   Post, Janine
   Zhou, Hui
   Huang, Xiao Bin
   Zhang, Xiao Dong
   Wang, Qin
   Sun, Yuan Ming
   Fan, Fei Yue
TI Effect of radiation on the Notch signaling pathway in osteoblasts
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE Notch signaling; osteoblast; radiation; MC3T3 cells; differentiation
ID COLONY STIMULATING FACTOR; OSTEOCLAST DIFFERENTIATION;
   IONIZING RADIATION; GENE FAMILY; IN VITRO; BONE; LIGAND; CELLS;
   EXPRESSION; OSTEOPETROSIS
AB Notch signaling has been shown to be important in osteoblast differentiation. Therapeutic radiation has been shown to alter the skeletal system, yet little information is available on the changes in Notch signaling in irradiated osteoblasts. The purpose of this study was to analyze the effect of radiation therapy with 2 and 4 Gy on Notch signaling in osteoblasts. In order to assess the radiation damage on osteoblast differentiation, total RNA and protein were collected three days after exposure to radiation. The effects of radiation on Notch signaling at the early and terminal stages of osteoblastic MC3T3 E1 cell differentiation was analyzed by qRT PCR and western blot analysis. Our study applied a previously established method to induce MC3T3 E1 cell differentiation into osteoblasts and osteoblast precursors. Our results showed that the expression of Notch receptors (Notch1 4), ligands (Jagged1, Jagged2 and Delta1), target of Notch signaling (Hes1) and markers (ALP, M CSF, RANKL and OPG) were altered following 2 and 4 Gy of irradiation. The present research did not indicate a strong relationship between Notch1 regulation and suppression of osteoblast differentiation. We found Hes1 may play a role in the radiation effect on osteoblast differentiation. Our results indicate that radiated osteoblast precursors and osteoblasts promoted osteoclast differentiation and proliferation.
C1 [Yang, Bing; Tang, Quan; Zhang, Xiao Dong; Wang, Qin; Sun, Yuan Ming; Fan, Fei Yue] Chinese Acad Med Sci, Inst Radiat Med, Tianjin Key Lab Mol Nucl Med, Tianjin 300192, Peoples R China.
   [Yang, Bing; Tang, Quan; Zhang, Xiao Dong; Wang, Qin; Sun, Yuan Ming; Fan, Fei Yue] Peking Union Med Coll, Tianjin 300192, Peoples R China.
   [Post, Janine] Univ Twente, Dev BioEngn MIRA Inst Biomed Technol & Tech Med, NL 7522 NB Enschede, Netherlands.
   [Zhou, Hui] Tianjin Med Univ, Sch Pharm, Tianjin 300070, Peoples R China.
   [Huang, Xiao Bin] Chongqing Univ, Sch Life Sci, Chongqing 400045, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Institute of Radiation Medicine   CAMS; Chinese Academy of Medical
   Sciences   Peking Union Medical College; Peking Union Medical College;
   University of Twente; Tianjin Medical University; Chongqing University
RP Sun, YM (通讯作者)，Chinese Acad Med Sci, Inst Radiat Med, Tianjin Key Lab Mol Nucl Med, Tianjin 300192, Peoples R China.
EM yuanmingsun@aol.com; faithyfan@yahoo.com
RI Yang, Bing/G 7096 2019; Zhang, Xiaodong/F 4665 2015; Huang,
   Xiaobin/AAI 9823 2020; Post, Janine/E 9983 2011; fan, fan/KDO 5068 2024
OI Zhang, Xiaodong/0000 0002 7212 0138; Huang, Xiaobin/0000 0002 9057 7123;
   Post, Janine/0000 0002 6645 6583; 
FU National Nature Science Foundation of China [30970867]
FX The authors thank Dr Liqing Du and Dr XiaoChun Wang for the helpful
   discussion. This study was supported by grants from the National Nature
   Science Foundation of China (no. 30970867) (http://www.nsfc.gov.cn).
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Ann EJ, 2011, J BONE MINER RES, V26, P317, DOI 10.1002/jbmr.227
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097 4644(19970701)66:1<1::AID JCB1>3.0.CO;2 V
   Baxter NN, 2005, JAMA J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587
   Brown SA, 2009, CRIT REV EUKAR GENE, V19, P47, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.20
   Caetano Lopes J, 2007, ACTA REUMATOL PORT, V32, P103
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Dallas DJ, 1999, BONE, V25, P9, DOI 10.1016/S8756 3282(99)00099 X
   Deregowski V, 2006, J BIOL CHEM, V281, P6203, DOI 10.1074/jbc.M508370200
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Dudziak ME, 2000, PLAST RECONSTR SURG, V106, P1049, DOI 10.1097/00006534 200010000 00015
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   ERGUN H, 1980, CRC CR REV DIAGN IM, V12, P225
   Florin TA, 2007, CANCER EPIDEM BIOMAR, V16, P1356, DOI 10.1158/1055 9965.EPI 07 0048
   Gal TJ, 2000, ARCH OTOLARYNGOL, V126, P1124, DOI 10.1001/archotol.126.9.1124
   Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154 006 9000 6
   Geblinger D, 2012, J R SOC INTERFACE, V9, P1599, DOI 10.1098/rsif.2011.0659
   Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11 10 1121
   Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972
   HATTERSLEY G, 1991, BIOCHEM BIOPH RES CO, V177, P526, DOI 10.1016/0006 291X(91)92015 C
   Hopewell JW, 2003, MED PEDIATR ONCOL, V41, P208, DOI 10.1002/mpo.10338
   Hori Kazuya, 2012, Commun Integr Biol, V5, P374, DOI 10.4161/cib.19995
   HOWLAND WJ, 1975, RADIOLOGY, V117, P677, DOI 10.1148/117.3.677
   Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208
   Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092 8674(00)80290 1
   LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519
   Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057
   Mancini SJC, 2005, BLOOD, V105, P2340, DOI 10.1182/blood 2004 08 3207
   Mitchell MJ, 1998, RADIOGRAPHICS, V18, P1125, DOI 10.1148/radiographics.18.5.9747611
   Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205
   Nobta M, 2005, J BIOL CHEM, V280, P15842, DOI 10.1074/jbc.M412891200
   Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185
   PARKER RG, 1976, CANCER AM CANCER SOC, V37, P1162, DOI 10.1002/1097 0142(197602)37:2+<1162::AID CNCR2820370827>3.0.CO;2 P
   Pereira RMR, 2002, J CELL BIOCHEM, V85, P252, DOI 10.1002/jcb.10125
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Sakurai T, 2007, J RADIAT RES, V48, P515, DOI 10.1269/jrr.07012
   SAMS A, 1966, INT J RADIAT BIOL RE, V11, P51, DOI 10.1080/09553006614550791
   Schnabel M, 2002, INT J MOL MED, V9, P229
   Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756
   Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003 0463
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Szymczyk KH, 2004, BONE, V34, P148, DOI 10.1016/j.bone.2003.09.003
   TAKAHASHI N, 1991, ENDOCRINOLOGY, V128, P1792, DOI 10.1210/endo 128 4 1792
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   Tao JN, 2010, J BONE MINER RES, V25, P2175, DOI 10.1002/jbmr.115
   Willey Jeffrey S, 2011, Gravit Space Biol Bull, V25, P14
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zanotti S, 2008, ENDOCRINOLOGY, V149, P3890, DOI 10.1210/en.2008 0140
   Zanotti S, 2012, CALCIFIED TISSUE INT, V90, P69, DOI 10.1007/s00223 011 9541 x
   Zanotti S, 2011, J BIOL CHEM, V286, P2648, DOI 10.1074/jbc.M110.183038
   Zanotti S, 2010, MOL CELL BIOL, V30, P886, DOI 10.1128/MCB.01285 09
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhang Y, 2009, J CELL BIOCHEM, V108, P651, DOI 10.1002/jcb.22299
NR 61
TC 15
Z9 16
U1 1
U2 22
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD MAR
PY 2013
VL 31
IS 3
BP 698
EP 706
DI 10.3892/ijmm.2013.1255
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 089IZ
UT WOS:000314905500026
PM 23340672
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Tripathi, A
   Pandey, S
   Singh, SV
   Sharma, NK
   Singh, R
AF Tripathi, Arvind
   Pandey, Saumya
   Singh, Saumyendra V.
   Sharma, Naresh Kumar
   Singh, Ronauk
TI Bisphosphonate Therapy for Skeletal Malignancies and Metastases: Impact
   on Jaw Bones and Prosthodontic Concerns
SO JOURNAL OF PROSTHODONTICS IMPLANT ESTHETIC AND RECONSTRUCTIVE DENTISTRY
LA English
DT Article
DE RANK ligand; osteoprotegerin; BRONJ; bisphosphonates
ID ESTROGEN RECEPTOR MODULATOR; OSTEOCLAST DIFFERENTIATION; SELECTIVE
   ESTROGEN; OSTEOPROTEGERIN; OSTEONECROSIS; OSTEOPOROSIS; LIGAND;
   MANAGEMENT; DENOSUMAB; CYTOKINE
AB Healthy jawbones ensure better tooth anchorage and the ability to masticate and maintain metabolism. This is achieved by a delicate balance between bone formation and resorption in response to functional demands. An imbalance in the expression of receptor activator of nuclear factor kappa B (RANK) ligand (RANKL) and osteoprotegerin (OPG) or osteoclastogenesis inhibitory factor (OCIF) is believed to be the underlying mechanism of osteolysis in metastases, multiple myelomas, and cancer therapy induced bone loss in patients. Considered mainly as bone specific agents to treat postmenopausal osteoporosis, bisphosphonates, in combination with certain chemotherapeutic agents have proved to be effective in prevention of tumor formation and metastatic osteolysis in bone tissue. Osteonecrosis of the jaws associated with them has, however, been of grave concern to the prosthodontist, as it predisposes patients to a bone deficient basal seat for dental prostheses. This manuscript reviews available information over the past 13 years on possible mechanisms of bone loss, bisphosphonate induced osteonecrosis of jaw bones, and prosthodontic concerns.
C1 [Tripathi, Arvind; Pandey, Saumya; Singh, Ronauk] Saraswati Dent Coll & Hosp, Dept Prosthodont, Lucknow, Uttar Pradesh, India.
   [Singh, Saumyendra V.] CSM Med Univ, Fac Dent, Dept Prosthodont, Lucknow, Uttar Pradesh, India.
   [Sharma, Naresh Kumar] Saraswati Dent Coll & Hosp, Dept Oral & Maxillofacial Surg, Lucknow, Uttar Pradesh, India.
C3 King George's Medical University
RP Singh, SV (通讯作者)，2 273 Viram Khand, Lucknow 226010, Uttar Pradesh, India.
EM saumyendravsingh@rediffmail.com
RI Singh, Saumyendra/AHB 3073 2022
CR Allen MR, 2008, J ORAL MAXIL SURG, V66, P987, DOI 10.1016/j.joms.2008.01.038
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Bagi CM, 2005, ADV DRUG DELIVER REV, V57, P995, DOI 10.1016/j.addr.2004.12.014
   Barni S, 2006, ANN ONCOL, V17, P91, DOI 10.1093/annonc/mdj935
   Blake GM, 2006, CLIN INTERV AGING, V1, P367, DOI 10.2147/ciia.2006.1.4.367
   Clarke BL, 2009, CURR OPIN RHEUMATOL, V21, P374, DOI 10.1097/BOR.0b013e32832ca447
   CUMMINGS SR, 2010, NEW ENGL J MED, V362, P590
   Deal C, 2009, NAT CLIN PRACT RHEUM, V5, P174, DOI 10.1038/ncprheum1027
   Deal C, 2009, CURR OPIN RHEUMATOL, V21, P380, DOI 10.1097/BOR.0b013e32832cbc2a
   Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Dutertre M, 2000, J PHARMACOL EXP THER, V295, P431
   Eck SM, 2009, BREAST CANCER RES TR, V116, P79, DOI 10.1007/s10549 008 0085 3
   Ellis GK, 2009, BREAST CANCER RES TR, V118, P81, DOI 10.1007/s10549 009 0352 y
   ESTEFANIA FR, 2006, MED ORAL PATOL ORAL, V11, P456
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Fili S, 2009, CANCER LETT, V283, P10, DOI 10.1016/j.canlet.2009.01.011
   FLEISCH H, 1991, DRUGS, V42, P919, DOI 10.2165/00003495 199142060 00003
   Gennari L, 2007, DRUG AGING, V24, P361, DOI 10.2165/00002512 200724050 00002
   Gennari L, 2010, CLIN INTERV AGING, V5, P19
   Gevorgyan A, 2008, CURR OPIN OTOLARYNGO, V16, P325, DOI 10.1097/MOO.0b013e328304b445
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   Holen I, 2010, CURR PHARM DESIGN, V16, P1262, DOI 10.2174/138161210791034003
   Iguchi Haruo, 2007, Gan To Kagaku Ryoho, V34, P1
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lewiecki EM, 2009, CURR OPIN RHEUMATOL, V21, P369, DOI 10.1097/BOR.0b013e32832ca41c
   Maeda Tomoko, 2004, Clin Calcium, V14, P85
   MARX RE, 2009, J ORAL MAXILLOFAC SU, V67, P207
   Maurya R, 2009, BIOORG MED CHEM LETT, V19, P610, DOI 10.1016/j.bmcl.2008.12.064
   MUNDY GR, 1999, DRUGS, V8, P2009
   Murthy RK, 2009, ONCOLOGY NY, V23, P9
   Neville Webbe HL, 2003, PALLIATIVE MED, V17, P539, DOI 10.1191/0269216303pm800ra
   ODONNELL S, 2006, COCHRANE DB SYST REV, V3
   Pazianas M, 2007, CLIN THER, V29, P1548, DOI 10.1016/j.clinthera.2007.08.008
   Rizzoli R, 2008, BONE, V42, P841, DOI 10.1016/j.bone.2008.01.003
   Sambrook Philip N, 2008, Curr Rheumatol Rep, V10, P97, DOI 10.1007/s11926 008 0018 5
   Santini D, 2009, CURR CANCER DRUG TAR, V9, P834, DOI 10.2174/156800909789760375
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Singh MM, 2001, MED RES REV, V21, P302, DOI 10.1002/med.1011
   Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 41
TC 5
Z9 8
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1059 941X
EI 1532 849X
J9 J PROSTHODONT
JI J. Prosthodont.
PD OCT
PY 2011
VL 20
IS 7
BP 601
EP 603
DI 10.1111/j.1532 849X.2011.00738.x
PG 3
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 845RU
UT WOS:000296841000017
PM 21883630
DA 2025 08 17
ER

PT J
AU Arora, MK
   Kumar, L
   Marwah, S
AF Arora, Mohit Kumar
   Kumar, Lalit
   Marwah, Sunil
TI Combination Therapy of Denosumab and Teriparatide in Osteoporosis
SO INDIAN JOURNAL OF ORTHOPAEDICS
LA English
DT Article; Early Access
DE Osteoporosis; Teriparatide; Denosumab; Combination therapy
ID ALENDRONATE; WOMEN
AB Osteoporosis is a chronic disease that often requires long term treatment for many years. The clinician should know about all the drugs that are currently being used for treatment in osteoporosis and their mechanism of action, efficacy, safety profile, mode of administration and number of years they can be given safely without causing significant adverse effects. The categories of drugs that are currently being used for osteoporosis are antiresorptives such as oral and intravenous bisphosphonates, denosumab, and anabolics like teriparatide. This article will focus on the combination therapy of denosumab and teriparatide and will discuss how this combination is better than other class of drugs when given alone or in combination in osteoporosis patients especially those who are at high risk of fragility fractures.
EM drmkarora@yahoo.com
RI Kumar, Lalit/GPF 4332 2022
CR Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Finkelstein JS, 2006, J CLIN ENDOCR METAB, V91, P2882, DOI 10.1210/jc.2006 0190
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Leder BZ, 2014, J CLIN ENDOCR METAB, V99, P1694, DOI 10.1210/jc.2013 4440
   Nakamura Y, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.55
   Ramchand SK, 2021, J BONE MINER RES, V36, P41, DOI 10.1002/jbmr.4161
   Tsai JN, 2016, J CLIN ENDOCR METAB, V101, P2023, DOI 10.1210/jc.2016 1160
   Tsai JN, 2019, LANCET DIABETES ENDO, V7, P767, DOI 10.1016/S2213 8587(19)30255 4
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Wang WY, 2023, EUR REV MED PHARMACO, V27, P8253, DOI 10.26355/eurrev_202309_33586
NR 11
TC 1
Z9 1
U1 5
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0019 5413
EI 1998 3727
J9 INDIAN J ORTHOP
JI Indian J. Orthop.
PD 2023 DEC 12
PY 2023
DI 10.1007/s43465 023 01051 w
EA DEC 2023
PG 3
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA AV7G6
UT WOS:001121286500002
PM 38107811
OA Green Published
DA 2025 08 17
ER

PT J
AU Suresh, E
   Abrahamsen, B
AF Suresh, Ernest
   Abrahamsen, Bo
TI Denosumab: A novel antiresorptive drug for osteoporosis
SO CLEVELAND CLINIC JOURNAL OF MEDICINE
LA English
DT Article
ID BONE MINERAL DENSITY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSAL WOMEN;
   BIOCHEMICAL MARKERS; VERTEBRAL FRACTURE; BISPHOSPHONATE THERAPY;
   ALENDRONATE THERAPY; OLDER WOMEN; TURNOVER; RISK
AB Denosumab is a novel antiresorptive drug that has been approved for use as a first line drug for primary and secondary prevention of osteoporotic fractures. The authors discuss the mechanism of action of denosumab, review the evidence for its efficacy and safety in patients with osteoporosis, and offer recommendations for its use in clinical practice.
C1 [Suresh, Ernest] Alexandra Hosp, Dept Med, Jurong Hlth, Singapore 159964, Singapore.
   [Abrahamsen, Bo] Univ Southern Denmark, Inst Clin Res, Odense Patient Data Exploratory Network OPEN, Endocrinol, Odense, Denmark.
   [Abrahamsen, Bo] Glostrup Cty Hosp, Dept Med, Res Ctr Ageing & Osteoporosis, Copenhagen, Denmark.
C3 University of Southern Denmark; University of Copenhagen
RP Suresh, E (通讯作者)，Alexandra Hosp, Dept Med, Jurong Hlth, 378 Alexandra Rd, Singapore 159964, Singapore.
EM dr_esuresh@hotmail.co
RI ; Abrahamsen, Bo/B 8920 2008
OI Abrahamsen, Bo/0000 0002 2730 6080; 
CR Abrahamsen B, 2009, OSTEOPOROSIS INT, V20, P1633, DOI 10.1007/s00198 009 0920 3
   [Anonymous], 2013, CLIN GUID PREV TREAT
   [Anonymous], NICE TECHN APPR GUID
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Biswas PN, 2003, OSTEOPOROSIS INT, V14, P507, DOI 10.1007/s00198 003 1399 y
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Bolognese MA, 2013, J CLIN DENSITOM, V16, P147, DOI 10.1016/j.jocd.2012.02.006
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2013, J CLIN ENDOCR METAB, V98, P4483, DOI 10.1210/jc.2013 1597
   Boonen S, 2011, J CLIN ENDOCR METAB, V96, P1727, DOI 10.1210/jc.2010 2784
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Confavreux CB, 2012, EUR J ENDOCRINOL, V166, P735, DOI 10.1530/EJE 11 0959
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Diez Perez A, 2012, OSTEOPOROSIS INT, V23, P2769, DOI 10.1007/s00198 012 2093 8
   Eastell R, 2003, J BONE MINER RES, V18, P1051, DOI 10.1359/jbmr.2003.18.6.1051
   Eastell R, 2011, J BONE MINER RES, V26, P1662, DOI 10.1002/jbmr.342
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Ensrud KE, 2000, J AM GERIATR SOC, V48, P241, DOI 10.1111/j.1532 5415.2000.tb02641.x
   Epstein MS, 2013, OR SURG OR MED OR PA, V116, pE437, DOI 10.1016/j.oooo.2012.01.046
   Freemantle N, 2012, OSTEOPOROSIS INT, V23, P317, DOI 10.1007/s00198 011 1780 1
   Geller M, 2014, OSTEOPOROSIS INT, V25, pS128
   Genant HK, 2010, BONE, V47, P131, DOI 10.1016/j.bone.2010.04.594
   Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Hochberg MC, 1999, ARTHRITIS RHEUM US, V42, P1246, DOI 10.1002/1529 0131(199906)42:6<1246::AID ANR22>3.0.CO;2 U
   Hopkins RB, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 209
   Hu MI, 2014, J CLIN ENDOCRINOL ME
   Ismail AA, 1998, OSTEOPOROSIS INT, V8, P291, DOI 10.1007/s001980050067
   Jalava T, 2003, J BONE MINER RES, V18, P1254, DOI 10.1359/jbmr.2003.18.7.1254
   Jamal SA, 2011, J BONE MINER RES, V26, P1829, DOI 10.1002/jbmr.403
   Johnell O, 2005, OSTEOPOROSIS INT, V16, P222, DOI 10.1007/s00198 004 1686 2
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Jönsson B, 2011, OSTEOPOROSIS INT, V22, P967, DOI 10.1007/s00198 010 1424 x
   Kado DM, 1999, ARCH INTERN MED, V159, P1215, DOI 10.1001/archinte.159.11.1215
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Landfeldt E, 2012, OSTEOPOROSIS INT, V23, P433, DOI 10.1007/s00198 011 1549 6
   Lewiecki EM, 2011, DRUG HEALTHC PATIENT, V3, P79, DOI 10.2147/DHPS.S7727
   Lindsay R, 2001, JAMA J AM MED ASSOC, V285, P320, DOI 10.1001/jama.285.3.320
   McCloskey EV, 2012, J BONE MINER RES, V27, P1480, DOI 10.1002/jbmr.1606
   McClung MR, 2013, OSTEOPOROSIS INT, V24, P227, DOI 10.1007/s00198 012 2052 4
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   McClung MR, 2012, J BONE MINER RES, V27, P211, DOI 10.1002/jbmr.536
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   McCormick BB, 2012, AM J KIDNEY DIS, V60, P626, DOI 10.1053/j.ajkd.2012.06.019
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   National Institute for Health and Care Excellence (NICE), NICE TECHN APPR TA20
   Orwoll E, 2012, J CLIN ENDOCR METAB, V97, P3161, DOI 10.1210/jc.2012 1569
   Papaioannou A, 2010, CAN MED ASSOC J, V182, P1864, DOI 10.1503/cmaj.100771
   Papapoulos S, 2013, 2013 ANN M AM SOC BO
   Parthan A, 2013, APPL HEALTH ECON HEA, V11, P485, DOI 10.1007/s40258 013 0047 8
   Piscitelli P, 2012, CLIN INTERV AGING, V7, P575, DOI 10.2147/CIA.S36828
   Premaor MO, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c6959
   Rachner TD, 2013, MAYO CLIN PROC, V88, P418, DOI 10.1016/j.mayocp.2013.01.002
   Rizzoli R, 2013, OSTEOPOROSIS INT, V24, P2929, DOI 10.1007/s00198 013 2530 3
   Rosen HN, 1998, CALCIFIED TISSUE INT, V63, P363, DOI 10.1007/s002239900541
   ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003 4819 114 11 919
   Sampalis JS, 2012, J BONE MINER RES, V27, P202, DOI 10.1002/jbmr.533
   Schwarz EM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2171
   Schwarz P, 2012, BONE, V50, P1023, DOI 10.1016/j.bone.2012.01.020
   Scotland G, 2011, PHARMACOECONOMICS, V29, P951, DOI 10.2165/11589310 000000000 00000
   Seeman E, 2010, J BONE MINER RES, V25, P1886, DOI 10.1002/jbmr.81
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Ungprasert P, 2013, AM J EMERG MED, V31
   von Keyserlingk C, 2011, SEMIN ARTHRITIS RHEU, V41, P178, DOI 10.1016/j.semarthrit.2011.03.005
   Watts NB, 2012, OSTEOPOROSIS INT, V23, P327, DOI 10.1007/s00198 011 1755 2
   Watts Nelson B, 2010, Endocr Pract, V16 Suppl 3, P1
NR 71
TC 13
Z9 13
U1 0
U2 11
PU CLEVELAND CLINIC
PI CLEVELAND
PA 9500 EUCLID AVE, CLEVELAND, OH 44106 USA
SN 0891 1150
EI 1939 2869
J9 CLEV CLIN J MED
JI Clevel. Clin. J. Med.
PD FEB
PY 2015
VL 82
IS 2
BP 105
EP 114
DI 10.3949/ccjm.82a.13173
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA CD3KO
UT WOS:000350977500007
PM 25897599
OA Bronze
DA 2025 08 17
ER

PT J
AU Kimura, A
   Toda, Y
   Matsumoto, Y
   Yamamoto, H
   Yahiro, K
   Shimada, E
   Kanahori, M
   Oyama, R
   Fukushima, S
   Nakagawa, M
   Setsu, N
   Endo, M
   Fujiwara, T
   Matsunobu, T
   Oda, Y
   Nakashima, Y
AF Kimura, Atsushi
   Toda, Yu
   Matsumoto, Yoshihiro
   Yamamoto, Hidetaka
   Yahiro, Kenichiro
   Shimada, Eijiro
   Kanahori, Masaya
   Oyama, Ryunosuke
   Fukushima, Suguru
   Nakagawa, Makoto
   Setsu, Nokitaka
   Endo, Makoto
   Fujiwara, Toshifumi
   Matsunobu, Tomoya
   Oda, Yoshinao
   Nakashima, Yasuharu
TI Nuclear β catenin translocation plays a key role in osteoblast
   differentiation of giant cell tumor of bone
SO SCIENTIFIC REPORTS
LA English
DT Article
ID H3F3A MUTATION; CYCLIN D1; H3.3 G34W; PROMOTES; DENOSUMAB;
   IMMUNOHISTOCHEMISTRY; LOCALIZATION; PATHWAY; GROWTH; RAC1
AB Denosumab is a game changing drug for giant cell tumor of bone (GCTB); however, its clinical biomarker regarding tumor ossification of GCTB has not been elucidated. In this study, we investigated the relationship between Wnt/beta catenin signaling and the ossification of GCTB and evaluated whether endogenous nuclear beta catenin expression predicted denosumab induced bone formation in GCTB. Genuine patient derived primary GCTB tumor stromal cells exhibited osteoblastic characteristics. Identified osteoblastic markers and nuclear beta catenin translocation were significantly upregulated via differentiation induction and were inhibited by treating with Wnt signaling inhibitor, GGTI 286, or selective Rac1 LEF inhibitor, NSC23766. Furthermore, we reviewed the endogenous ossification and nuclear beta catenin translocation of 86 GCTB clinical samples and elucidated that intra tumoral ossification was significantly associated with the nuclear translocation. Three dimensional quantitative analyses (n = 13) of tumoral CT images have revealed that the nuclear beta catenin translocation of naive GCTB samples was significantly involved with the denosumab induced tumor ossification. Our findings suggest a close relationship between the nuclear beta catenin translocation and the osteoblastic differentiation of GCTB. Investigations of the nuclear beta catenin in naive GCTB samples may provide a promising biomarker for predicting the ossification of GCTB following denosumab treatment.
C1 [Kimura, Atsushi; Matsumoto, Yoshihiro; Shimada, Eijiro; Kanahori, Masaya; Oyama, Ryunosuke; Nakagawa, Makoto; Setsu, Nokitaka; Endo, Makoto; Fujiwara, Toshifumi; Nakashima, Yasuharu] Kyushu Univ, Grad Sch Med Sci, Dept Orthoped Surg, Higashi Ku, 3 1 1 Maidashi, Fukuoka 8128582, Japan.
   [Toda, Yu; Yamamoto, Hidetaka; Oda, Yoshinao] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Pathol Sci, Fukuoka, Japan.
   [Yahiro, Kenichiro] Natl Hosp Org Kyushu Med Ctr, Dept Orthoped Surg, Fukuoka, Japan.
   [Fukushima, Suguru] Natl Canc Ctr, Dept Musculoskeletal Oncol & Rehabil, Tokyo, Japan.
   [Matsunobu, Tomoya] Kyushu Rosai Hosp, Dept Orthopaed Surg, Fukuoka, Japan.
C3 Kyushu University; Kyushu University; National Cancer Center   Japan
RP Matsumoto, Y (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Orthoped Surg, Higashi Ku, 3 1 1 Maidashi, Fukuoka 8128582, Japan.
EM ymatsu@ortho.med.kyushu u.ac.jp
RI Shimada, Eijiro/KUD 6689 2024; Endo, Makoto/K 2896 2012; TODA,
   Yoshiaki/U 7601 2019
OI Endo, Makoto/0000 0002 7956 2190; 
FU JSPS KAKENHI [JP18K16627, JP19K16802]; Japan Society for the Promotion
   of Science; Grants in Aid for Scientific Research [21K09325, 22K09359]
   Funding Source: KAKEN
FX This work was supported in part by JSPS KAKENHI (Grant Numbers:
   JP18K16627 and JP19K16802) from the Japan Society for the Promotion of
   Science. The role of the funding body was purchase of test reagents in
   the collection of data.
CR AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735 1097(90)90282 T
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Cai T, 2016, EXP CELL RES, V345, P206, DOI 10.1016/j.yexcr.2016.06.007
   Cowan RW, 2013, BONE, V52, P238, DOI 10.1016/j.bone.2012.10.002
   D'Alimonte I, 2013, STEM CELL REV REP, V9, P642, DOI 10.1007/s12015 013 9436 5
   Fellenberg J, 2019, CANCER LETT, V448, P61, DOI 10.1016/j.canlet.2019.02.001
   Fornasier VL, 1996, HUM PATHOL, V27, P754, DOI 10.1016/S0046 8177(96)90445 1
   Fujiwara Okada Y, 2013, BRIT J CANCER, V108, P836, DOI 10.1038/bjc.2012.579
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Huang L, 2004, BONE, V34, P393, DOI 10.1016/j.bone.2003.10.013
   Huvos A. G., 1987, Bone Tumors: Diagnosis, Treatment and Prognosis, VSecond
   Jin H, 2018, MOL THER NUCL ACIDS, V13, P493, DOI 10.1016/j.omtn.2018.09.021
   Joyce PL, 2003, CANCER RES, V63, P7959
   Kato I, 2018, HISTOPATHOLOGY, V72, P914, DOI 10.1111/his.13448
   Khazaei S, 2020, CANCER DISCOV, V10, P1968, DOI 10.1158/2159 8290.CD 20 0461
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Lüke J, 2017, HISTOPATHOLOGY, V71, P125, DOI 10.1111/his.13190
   Lujic N, 2016, INT ORTHOP, V40, P2393, DOI 10.1007/s00264 016 3292 2
   Mak IWY, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01332
   Masui F, 1998, PATHOL INT, V48, P355
   Matsubayashi S, 2009, PATHOL RES PRACT, V205, P626, DOI 10.1016/j.prp.2009.02.011
   Matsumoto Y, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 85
   Morgan T, 2005, AM J PATHOL, V167, P117, DOI 10.1016/S0002 9440(10)62959 8
   Murata A, 2005, J ORTHOP SCI, V10, P581, DOI 10.1007/s00776 005 0946 0
   Nishiya N, 2014, CHEM BIOL, V21, P530, DOI 10.1016/j.chembiol.2014.02.015
   Noh BJ, 2018, HUM PATHOL, V81, P1, DOI 10.1016/j.humpath.2018.06.017
   Palmerini E, 2020, CURR TREAT OPTION ON, V21, DOI 10.1007/s11864 020 00766 4
   Raskin KA, 2013, J AM ACAD ORTHOP SUR, V21, P118, DOI 10.5435/JAAOS 21 02 118
   Regard JB, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007997
   Ricalde A, 2018, ATHEROSCLEROSIS, V271, P142, DOI 10.1016/j.atherosclerosis.2018.02.031
   Salerno M, 2008, CLIN ORTHOP RELAT R, V466, P2081, DOI 10.1007/s11999 008 0327 z
   Sato M, 2018, PATHOL RES PRACT, V214, P586, DOI 10.1016/j.prp.2017.12.016
   Setsu N, 2012, CANCER AM CANCER SOC, V118, P1637, DOI 10.1002/cncr.26448
   Sobti A, 2016, ARCH BONE JT SURG AB, V4, P2
   Sonomoto K, 2012, ARTHRITIS RHEUM US, V64, P3355, DOI 10.1002/art.34555
   Steensma MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069101
   Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593
   Takahashi H, 2017, HISTOPATHOLOGY, V71, P227, DOI 10.1111/his.13227
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Ueda T, 2015, ANN ONCOL, V26, P2149, DOI 10.1093/annonc/mdv307
   Urakawa H, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957 018 1459 6
   Wan Y, 2014, HUM PATHOL, V45, P1459, DOI 10.1016/j.humpath.2014.02.022
   Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052
   Xie W, 2018, APPL MICROBIOL BIOT, V102, P5965, DOI 10.1007/s00253 018 9058 6
   Yahiro K, 2018, ANAL CELL PATHOL, V2017, DOI 10.1155/2018/8987568
   Yamamoto H, 2018, HUM PATHOL, V73, P41, DOI 10.1016/j.humpath.2017.11.020
NR 48
TC 5
Z9 5
U1 0
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD AUG 4
PY 2022
VL 12
IS 1
AR 13438
DI 10.1038/s41598 022 17728 5
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 3N8PA
UT WOS:000836406600048
PM 35927428
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Luo, C
   Xu, WJ
   Tang, X
   Liu, XY
   Cheng, Y
   Wu, YX
   Xie, ZS
   Wu, XH
   He, X
   Wang, Q
   Xiao, Y
   Qiu, XT
   Tang, ZR
   Shao, GH
   Tu, XL
AF Luo, Cen
   Xu, Wenjuan
   Tang, Xun
   Liu, Xinyu
   Cheng, Yu
   Wu, Yixun
   Xie, Zhengsong
   Wu, Xiaohong
   He, Xin
   Wang, Qian
   Xiao, Yao
   Qiu, Xueting
   Tang, Zhurong
   Shao, Gaohai
   Tu, Xiaolin
TI Canonical Wnt signaling works downstream of iron overload to prevent
   ferroptosis from damaging osteoblast differentiation
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Excessiveiron; Ferroptosis; Wntsignaling; Osteoblastdifferentiation;
   ROS; LPO
ID MESENCHYMAL STEM CELLS; MELATONIN; METABOLISM; EXPRESSION; RESORPTION;
   DISEASE; TARGET
AB Excessive iron has emerged in a large population of patients suffering from degenerative or hematological dis eases with a common outcome, osteoporosis. However, its underlying mechanism remains to be clarified in order to formulate effective prevention and intervention against the loss of bone forming osteoblasts. We show herein that increased intracellular iron by ferric ammonium citrate (FAC) mimicking the so called non transferrin bound iron concentrations leads to ferroptosis and impaired osteoblast differentiation. FAC upregulates the expression of Trfr and DMT1 genes to increase iron uptake, accumulating intracellular labile ferrous iron for iron overload status. Then, the excessive ferrous iron generates reactive oxygen species (ROS) and lipid peroxidation products (LPO), causing ferroptosis with its typical mitochondrial morphological changes, such as shrinkaged and condensed membrane with diminution and loss of crista and outer membrane rupture. We further examined that ferroptosis is the main cause responsible for FAC disrupted osteoblast differentiation, although apoptosis and senescence are concurrently induced as well. Mechanistically, we revealed that iron dose dependently down  regulates the expression of Wnt target genes and inhibits the transcription of Wnt reporter TopFlash construct, so as to inhibit the canonical Wnt signaling. Wnt agonist, ferroptosis inhibitor, or antioxidant melatonin reverses iron inhibited canonical Wnt signaling to restore osteoblast differentiation by reducing ROS and LPO production to prevent ferroptosis notably without reducing iron overload. This study proposes a working model against excessive iron induced osteoporosis: iron chelator deferoxamine or the above three drugs prevent ferroptosis, restore traditional Wnt signaling to maintain osteoblast differentiation no matter whether iron overload is removed or not. Additionally, iron chelator should be used to a suitable extent because iron itself is necessary for osteogenic differentiation.
C1 [Luo, Cen; Xu, Wenjuan; Liu, Xinyu; Wu, Yixun; Xie, Zhengsong; Wu, Xiaohong; He, Xin; Tang, Zhurong; Tu, Xiaolin] Chongqing Med Univ, Inst Life Sci, Lab Skeletal Dev & Regenerat, Chongqing 400016, Peoples R China.
   [Luo, Cen; Tang, Xun; Shao, Gaohai; Tu, Xiaolin] Chongqing Med Univ, Yongchuan Hosp, Dept Orthoped, Chongqing 402160, Peoples R China.
   [Cheng, Yu] Chongqing Med Univ, Univ Town Hosp, Dept Nursing, Chongqing 401331, Peoples R China.
   [Wang, Qian; Xiao, Yao; Qiu, Xueting] Chongqing Med Univ, Sch Basic Med, Chongqing 400016, Peoples R China.
   [Tu, Xiaolin] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; Chongqing Medical University; Indiana University
   System; Indiana University Bloomington
RP Tu, XL (通讯作者)，Chongqing Med Univ, Inst Life Sci, Lab Skeletal Dev & Regenerat, Chongqing 400016, Peoples R China.; Shao, GH; Tu, XL (通讯作者)，Chongqing Med Univ, Yongchuan Hosp, Dept Orthoped, Chongqing 402160, Peoples R China.
EM shaogaohai567@163.com; xtu@cqmu.edu.cn
RI Tu, Xiaolin/JAC 9492 2023; 刘, 新宇/IYJ 8231 2023
OI Tu, Xiaolin/0000 0002 7923 2722; 
FU National Natural Science Foundation of China [81672118, U1601220,
   82072450]; Chongqing Science and Technology Commission Basic Science and
   Frontier Research Technology Special Key Project [cstc2015jcyjBX0119]
FX Acknowledgements We thank Prof. Ziguo Luo for TEM technical advice and
   support. We also thank Dr. Zhurong Tang for her writing of the
   manuscript in the beginning and the intellectual contribution. This work
   was supported by the National Natural Science Foundation of China
   (81672118, U1601220, 82072450) , Chongqing Science and Technology
   Commission Basic Science and Frontier Research Technology Special Key
   Project (cstc2015jcyjBX0119) .
CR Andrews NC, 2007, ANNU REV PHYSIOL, V69, P69, DOI 10.1146/annurev.physiol.69.031905.164337
   Balogh E, 2016, BBA MOL BASIS DIS, V1862, P1640, DOI 10.1016/j.bbadis.2016.06.003
   Baschant U, 2016, HAEMATOLOGICA, V101, P1499, DOI 10.3324/haematol.2016.144808
   Benyamin B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5926
   Bogdan AR, 2016, TRENDS BIOCHEM SCI, V41, P274, DOI 10.1016/j.tibs.2015.11.012
   Borriello A., 1860, BIOCHIM BIOPHYS ACTA
   Cabantchik ZI, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00045
   Cen WJ, 2018, J CELL PHYSIOL, V233, P6779, DOI 10.1002/jcp.26405
   Chen LS, 2014, EUR RADIOL, V24, P1715, DOI 10.1007/s00330 014 3178 x
   den Brok MH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13324
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Ginzburg Y, 2011, BLOOD, V118, P4321, DOI 10.1182/blood 2011 03 283614
   Kezele TG, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092601
   Hardeland R, 2013, J PINEAL RES, V55, P325, DOI 10.1111/jpi.12090
   Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092 8674(04)00343 5
   Hirschhorn T, 2019, FREE RADICAL BIO MED, V133, P130, DOI 10.1016/j.freeradbiomed.2018.09.043
   Hossein MM, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00239
   Ikegame M, 2019, J PINEAL RES, V67, DOI 10.1111/jpi.12594
   Jian JL, 2009, ANTIOXID REDOX SIGN, V11, P2939, DOI [10.1089/ars.2009.2576, 10.1089/ARS.2009.2576]
   Jing XZ, 2019, J CELL PHYSIOL, V234, P10123, DOI 10.1002/jcp.27678
   Koyama H, 2002, J BONE MINER RES, V17, P1219, DOI 10.1359/jbmr.2002.17.7.1219
   Li T, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12548
   Ma HD, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9067610
   Maria S, 2014, J PINEAL RES, V56, P115, DOI 10.1111/jpi.12116
   Messer JG, 2009, BONE, V45, P972, DOI 10.1016/j.bone.2009.07.073
   Millot S, 2017, HAEMATOLOGICA, V102, P260, DOI 10.3324/haematol.2016.151621
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Ping ZC, 2017, ACTA BIOMATER, V62, P362, DOI 10.1016/j.actbio.2017.08.046
   Radio NM, 2006, J PINEAL RES, V40, P332, DOI 10.1111/j.1600 079X.2006.00318.x
   Rouault TA, 2013, NAT REV NEUROSCI, V14, P551, DOI 10.1038/nrn3453
   Rui TY, 2021, J PINEAL RES, V70, DOI 10.1111/jpi.12704
   Schiavi A, 2020, MECH AGEING DEV, V188, DOI 10.1016/j.mad.2020.111252
   Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004
   Simcox JA, 2013, CELL METAB, V17, P329, DOI 10.1016/j.cmet.2013.02.007
   Tian Q, 2016, PEERJ, V4, DOI 10.7717/peerj.2611
   Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495
   Trottier BJ, 2013, BLOOD, V122, P1678, DOI 10.1182/blood 2013 04 499772
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Wang M, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 02961 5
   Wawer AA, 2018, MECH AGEING DEV, V175, P55, DOI 10.1016/j.mad.2018.07.003
   Xia DM, 2019, J CELL PHYSIOL, V234, P15668, DOI 10.1002/jcp.28217
   Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158
   Xu W, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/8256261
   Yamasaki K, 2009, TOXICOL LETT, V191, P211, DOI 10.1016/j.toxlet.2009.08.023
   Yambire KF, 2019, ELIFE, V8, DOI 10.7554/eLife.51031
   Yang F, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12422
   Yang F, 2017, ONCOTARGET, V8, P31626, DOI 10.18632/oncotarget.16382
   Yang JC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092608
   Yoshida M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10991 7
   Zhang LM, 2010, J PINEAL RES, V49, P364, DOI 10.1111/j.1600 079X.2010.00803.x
   Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016
   Zhao GY, 2012, BIOL TRACE ELEM RES, V150, P487, DOI 10.1007/s12011 012 9511 9
   Zhou ZD, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024 017 0218 4
NR 53
TC 53
Z9 66
U1 2
U2 63
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891 5849
EI 1873 4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD AUG 1
PY 2022
VL 188
BP 337
EP 350
DI 10.1016/j.freeradbiomed.2022.06.236
EA JUL 2022
PG 14
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 3E8TY
UT WOS:000830252300001
PM 35752374
DA 2025 08 17
ER

PT J
AU Mei, LW
   Sang, WH
   Chen, ZZ
   Zheng, L
   Jin, KT
   Lou, C
   Huang, WJ
   He, DW
AF Mei, Liangwei
   Sang, Wenhua
   Chen, Zhenzhong
   Zheng, Lin
   Jin, Kangtao
   Lou, Chao
   Huang, Wenjun
   He, Dengwei
TI Small molecule inhibitor RepSox prevented ovariectomy induced
   osteoporosis by suppressing osteoclast differentiation and bone
   resorption
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE osteoclast; ovariectomy (OVX); RepSox; Smad3; TGFRI
ID GROWTH FACTOR BETA; PARTICLE INDUCED OSTEOLYSIS; ERK SIGNALING PATHWAY;
   TGF BETA; OSTEOBLAST DIFFERENTIATION; EXPRESSION; CELLS; RANKL; THERAPY;
   MICE
AB Osteoporosis (OP) is a serious metabolic disease that, due to the increased number or function of osteoclasts, results in increased bone brittleness and, therefore, fragile fracture. Some recent studies report the importance of the transforming growth factor (TGF) pathway in bone homeostasis. RepSox is a small molecule inhibitor of TGFRI that has a wide range of potential application in clinical medicine, except OP. The aim of our study is to evaluate the effects of RepSox on the differentiation and bone resorption of osteoclasts in vitro and in vivo in an ovariectomy (OVX) induced OP model. An initial analysis showed TGFRI messenger RNA expression in both bone samples and bone cells. In the in vitro study, RepSox inhibited the receptor activator of nuclear factor B ligand (RANKL) induced osteoclast differentiation and bone resorption activity. Real time polymerase chain reaction (PCR) analysis showed that RepSox suppressed osteoclastic marker gene expression in both dose dependent and time dependent manners. In addition, RepSox did not affect osteoblast differentiation, migration or osteoblastic specific gene expression in vitro. Furthermore, western blot analysis indicated the underlying mechanisms of the RepSox suppression of osteoclastogenesis via the Smad3 and c Jun N terminal kinase/activator protein 1 (JNK/AP 1) signaling pathways. Finally, our animal experiments revealed that RepSox prevented OVX induced bone loss in vivo. Together, our data suggest that RepSox regulates osteoclast differentiation, bone resorption, and OVX induced OP via the suppression of the Smad3 and JNK/AP 1 pathways.
C1 [Mei, Liangwei; Chen, Zhenzhong; Zheng, Lin; Jin, Kangtao; Lou, Chao; Huang, Wenjun; He, Dengwei] Wenzhou Med Univ, Lishui Municipal Cent Hosp, Affiliated Hosp 5, Dept Orthopaed Surg, 289 Kuocang Rd, Lishui 323000, Zhejiang, Peoples R China.
   [Sang, Wenhua] Wenzhou Med Univ, Sch Basic Med Sci, Wenzhou, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University
RP He, DW (通讯作者)，Wenzhou Med Univ, Lishui Municipal Cent Hosp, Affiliated Hosp 5, Dept Orthopaed Surg, 289 Kuocang Rd, Lishui 323000, Zhejiang, Peoples R China.
EM 1633142088@qq.com
RI Chen, Zhenzhong/C 2529 2015; huang, wenjun/KVY 9101 2024; Zheng,
   Lin/AAE 8093 2021
OI Zheng, Lin/0000 0002 7585 6968
FU Zhejiang Science and Technology Department Public Welfare Technology
   Application Research Project [2016KYA200]; General Project of Zhejiang
   Natural Science Foundation [Y17C100002]
FX The Zhejiang Science and Technology Department Public Welfare Technology
   Application Research Project, Grant/Award Number: 2016KYA200; the
   General Project of Zhejiang Natural Science Foundation, Grant/Award
   Number: Y17C100002
CR Akhurst RJ, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aad0416
   Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Amirhosseini M, 2018, J CELL PHYSIOL, V233, P2398, DOI 10.1002/jcp.26111
   CHENU C, 1988, P NATL ACAD SCI USA, V85, P5683, DOI 10.1073/pnas.85.15.5683
   Edwards JR, 2012, DISCOV MED, V13, P201
   Edwards JR, 2010, J BONE MINER RES, V25, P2419, DOI 10.1002/jbmr.139
   Galvin RJS, 1999, BIOCHEM BIOPH RES CO, V265, P233, DOI 10.1006/bbrc.1999.1632
   Gellibert FO, 2004, J MED CHEM, V47, P4494, DOI 10.1021/jm0400247
   Genant Harry K, 2011, Menopause Int, V17, P44, DOI 10.1258/mi.2011.011011
   Gittes GK, 2016, J PATHOL, V238, P603, DOI 10.1002/path.4676
   Gruber R, 2014, CLIN ORAL INVEST, V18, P1639, DOI 10.1007/s00784 013 1129 6
   Guo JC, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00693
   HATTERSLEY G, 1991, J BONE MINER RES, V6, P165
   Hozzein WN, 2015, CELL PHYSIOL BIOCHEM, V37, P940, DOI 10.1159/000430221
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Ide M, 2017, EXP DERMATOL, V26, P1139, DOI 10.1111/exd.13366
   Itonaga I, 2004, BONE, V34, P57, DOI 10.1016/j.bone.2003.08.008
   Jajosky AN, 2014, STEM CELL TRANSL MED, V3, P836, DOI 10.5966/sctm.2013 0193
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Jiang LS, 2008, J BONE MINER RES, V23, P475, DOI 10.1359/JBMR.071114
   Jin A, 2017, BONE JOINT RES, V6, P602, DOI 10.1302/2046 3758.610.BJR 2016 0321.R1
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Kotian P, 2016, J CLIN DIAGN RES, V10, pOC4, DOI 10.7860/JCDR/2016/17061.7021
   Lems WF, 2017, THER ADV MUSCULOSKEL, V9, P299, DOI 10.1177/1759720X17732562
   Li MJ, 2015, INT J MOL MED, V36, P1335, DOI 10.3892/ijmm.2015.2330
   Lin J, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005867
   Lin R, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.990803
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Liu YP, 2017, ACS APPL MATER INTER, V9, P23428, DOI 10.1021/acsami.7b05740
   Lou ZY, 2013, MED ONCOL, V30, DOI 10.1007/s12032 013 0606 8
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   MARCELLI C, 1990, J BONE MINER RES, V5, P1087
   Min SK, 2018, CELL DEATH DIFFER, V25, P268, DOI 10.1038/cdd.2017.153
   Muñoz Espín D, 2013, CELL, V155, P1104, DOI 10.1016/j.cell.2013.10.019
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Park SH, 2016, PHYTOTHER RES, V30, P604, DOI 10.1002/ptr.5565
   Patel V, 2018, BRIT DENT J, V224, P74, DOI 10.1038/sj.bdj.2017.1039
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   Sharifi M, 2014, EXPERT REV CLIN PHAR, V7, P281, DOI 10.1586/17512433.2014.893819
   Soysa Niroshani Surangika, 2012, J Med Dent Sci, V59, P65
   Wan XH, 2012, BONE, V50, P695, DOI 10.1016/j.bone.2011.11.022
   Weber TJ, 2003, MOL PHARMACOL, V63, P1075, DOI 10.1124/mol.63.5.1075
   Weivoda MM, 2016, J BONE MINER RES, V31, P76, DOI 10.1002/jbmr.2586
   Yu HL, 2018, TOXICOLOGY, V393, P73, DOI 10.1016/j.tox.2017.11.009
   Zhu HY, 2017, BIOTECHNOL LETT, V39, P775, DOI 10.1007/s10529 017 2308 3
   Zhu X, 2016, J BONE MINER RES, V31, P560, DOI 10.1002/jbmr.2710
NR 46
TC 9
Z9 9
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD DEC
PY 2018
VL 233
IS 12
BP 9724
EP 9738
DI 10.1002/jcp.26914
PG 15
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA GW7LE
UT WOS:000447148600060
PM 30059597
DA 2025 08 17
ER

PT J
AU Han, PP
   Ivanovski, S
   Crawford, R
   Xiao, Y
AF Han, Pingping
   Ivanovski, Saso
   Crawford, Ross
   Xiao, Yin
TI Activation of the Canonical Wnt Signaling Pathway Induces Cementum
   Regeneration
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE CANONICAL WNT SIGNALING PATHWAY; REGENERATIVE MEDICINE; CEMENTUM
   REGENERATION; TISSUE ENGINEERING
ID INCREASES BONE FORMATION; PERIODONTAL LIGAMENT; CELL SHEETS; STEM CELLS;
   STIMULATES PROLIFERATION; MOLECULAR MECHANISM; ROOT FORMATION; RAT
   MODEL; LITHIUM; SCLEROSTIN
AB Canonical Wnt signaling is important in tooth development but it is unclear whether it can induce cementogenesis and promote the regeneration of periodontal tissues lost because of disease. Therefore, the aim of this study is to investigate the influence of canonical Wnt signaling enhancers on human periodontal ligament cell (hPDLCs) cementogenic differentiation in vitro and cementum repair in a rat periodontal defect model. Canonical Wnt signaling was induced by (1) local injection of lithium chloride; (2) local injection of sclerostin antibody; and (3) local injection of a lentiviral construct overexpressing  catenin. The results showed that the local activation of canonical Wnt signaling resulted in significant new cellular cementum deposition and the formation of well organized periodontal ligament fibers, which was absent in the control group. In vitro experiments using hPDLCs showed that the Wnt signaling pathway activators significantly increased mineralization, alkaline phosphatase (ALP) activity, and gene and protein expression of the bone and cementum markers osteocalcin (OCN), osteopontin (OPN), cementum protein 1 (CEMP1), and cementum attachment protein (CAP). Our results show that the activation of the canonical Wnt signaling pathway can induce in vivo cementum regeneration and in vitro cementogenic differentiation of hPDLCs. (c) 2014 American Society for Bone and Mineral Research (c) 2015 American Society for Bone and Mineral Research
C1 [Han, Pingping; Crawford, Ross; Xiao, Yin] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
   [Ivanovski, Saso] Griffith Univ, Griffith Hlth Inst, Sch Dent & Oral Hlth, Ctr Med & Oral Hlth, Gold Coast, NSW, Australia.
C3 Queensland University of Technology (QUT); Griffith University; Griffith
   University   Gold Coast Campus; Menzies Health Institute Queensland
RP Xiao, Y (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
EM yin.xiao@qut.edu.au
RI ; Han, Pingping/L 4446 2019; Xiao, Yin/AAM 4033 2020; Ivanovski,
   Saso/I 1835 2016
OI Crawford, Ross/0000 0001 6079 1316; Xiao, Yin/0000 0003 1785 3491; Han,
   Pingping/0000 0001 7546 1635; 
FU Australian Dental Research Foundation; Australian National Health and
   Medical Research Council Foundation
FX This work was supported by grants from Australian Dental Research
   Foundation and Australian National Health and Medical Research Council
   Foundation. We thank Medical Engineering Research Facility (MERF) staff
   and core facilities at Queensland University of Technology for their
   technical assistance for animal studies. We thank Dr Nghiem Doan at Doan
   Dental Care (QLD, Australia) for his role in collecting surgical third
   molars and alveolar bone chips. We thank Dr Thor Friis for critical
   reading and editing in the preparation of this manuscript.
CR Akizuki T, 2005, J PERIODONTAL RES, V40, P245, DOI 10.1111/j.1600 0765.2005.00799.x
   Allagui MS, 2009, NEUROCHEM RES, V34, P453, DOI 10.1007/s11064 008 9804 8
   Bae CH, 2013, J PERIODONTAL RES, V48, P405, DOI 10.1111/jre.12018
   Barker Nick, 2008, V468, P5, DOI 10.1007/978 1 59745 249 6_1
   Bartold PM, 2006, PERIODONTOL 2000, V40, P164, DOI 10.1111/j.1600 0757.2005.00139.x
   Blesch A, 2004, METHODS, V33, P164, DOI 10.1016/j.ymeth.2003.11.005
   CADE JFJ, 1949, MED J AUSTRALIA, V2, P349, DOI 10.5694/j.1326 5377.1949.tb36912.x
   Cao ZG, 2012, J BONE MINER RES, V27, P1080, DOI 10.1002/jbmr.1552
   Chen JQ, 2009, DEV BIOL, V334, P174, DOI 10.1016/j.ydbio.2009.07.015
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Cohen O, 1998, HORM METAB RES, V30, P594, DOI 10.1055/s 2007 978939
   Dan HX, 2014, BIOMATERIALS, V35, P113, DOI 10.1016/j.biomaterials.2013.09.074
   Gamie Z, 2012, EXPERT OPIN INV DRUG, V21, P1523, DOI 10.1517/13543784.2012.713936
   Han C, 2010, STEM CELLS DEV, V19, P1405, DOI 10.1089/scd.2009.0277
   Han PP, 2012, BIOMATERIALS, V33, P6370, DOI 10.1016/j.biomaterials.2012.05.061
   Hasegawa M, 2005, TISSUE ENG, V11, P469, DOI 10.1089/ten.2005.11.469
   Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552
   Heo JS, 2010, MOL CELLS, V30, P449, DOI 10.1007/s10059 010 0139 3
   Huang XF, 2009, DEV BIOL, V334, P22, DOI 10.1016/j.ydbio.2009.06.034
   Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959 437X(00)00231 8
   Intini Giuseppe, 2010, Dent Clin North Am, V54, P141, DOI 10.1016/j.cden.2009.09.002
   Iwata T, 2009, BIOMATERIALS, V30, P2716, DOI 10.1016/j.biomaterials.2009.01.032
   Jin QM, 2004, MOL THER, V9, P519, DOI 10.1016/j.ymthe.2004.01.016
   Kim TH, 2012, ANAT CELL BIOL, V45, P193, DOI 10.5115/acb.2012.45.3.193
   Kim TH, 2011, BIOCHEM BIOPH RES CO, V412, P549, DOI 10.1016/j.bbrc.2011.07.116
   King GN, 1997, J DENT RES, V76, P1460, DOI 10.1177/00220345970760080801
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lim WH, 2014, J PERIODONTAL RES, V49, P751, DOI 10.1111/jre.12158
   Lin NH, 2009, PERIODONTOL 2000, V51, P239, DOI 10.1111/j.1600 0757.2009.00303.x
   Lohi M, 2010, DEV DYNAM, V239, P160, DOI 10.1002/dvdy.22047
   Makoukji J, 2012, P NATL ACAD SCI USA, V109, P3973, DOI 10.1073/pnas.1121367109
   Martínez C, 2011, J DENT RES, V90, P483, DOI 10.1177/0022034510391797
   McDonald MM, 2012, J ORTHOP RES, V30, P1541, DOI 10.1002/jor.22109
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Rooker SM, 2010, DEV DYNAM, V239, P140, DOI 10.1002/dvdy.22003
   Taut AD, 2013, J BONE MINER RES, V28, P2347, DOI 10.1002/jbmr.1984
   THOMAS HF, 1995, INT J DEV BIOL, V39, P231
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Wu CT, 2012, BIOMATERIALS, V33, P2076, DOI 10.1016/j.biomaterials.2011.11.042
   Yu HMI, 2005, DEVELOPMENT, V132, P1995, DOI 10.1242/dev.01786
NR 43
TC 89
Z9 96
U1 1
U2 32
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2015
VL 30
IS 7
BP 1160
EP 1174
DI 10.1002/jbmr.2445
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CL1PL
UT WOS:000356715900005
PM 25556853
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Kelava, T
   Sucur, A
   Kuzmac, S
   Katavic, V
AF Kelava, Tomislav
   Sucur, Alan
   Kuzmac, Sania
   Katavic, Vedran
TI Interactions between bone and immune systems: A focus on the role of
   inflammation in bone resorption and fracture healing
SO PERIODICUM BIOLOGORUM
LA English
DT Article
DE osteoimmunology; cytokine; inflammation; bone loss; fracture
ID TUMOR NECROSIS FACTOR; NF KAPPA B; INDUCED OSTEOCLAST FORMATION;
   MESENCHYMAL STEM CELLS; TNF ALPHA; OSTEOBLAST DIFFERENTIATION; RECEPTOR
   ACTIVATOR; PROSTAGLANDIN E 2; CYTOKINE PRODUCTION; SIGNALING PATHWAYS
AB Functional interactions between the immune system and bone tissues are reflected in a number of cytokines, chemokines, hormones and other mediators regulating the functions of both bone and immune cells. Investigations of the mechanisms of those interactions have become important for the understanding of the pathogeneses of diseases like inflammatory arthritis, inflammatory bowel disease, periodontal disease and osteoporosis. This review first addresses the roles of the inflammatory mediators and mechanisms by which they cause inflammation induced bone loss. In the second part of the review we stress the importance of proinflammatory mediators for normal fracture healing. Defective bone remodeling underlying different pathological processes may be caused by disturbed differentiation and function of either osteoclast or osteoblast lineage cells. Understanding of the mechanisms governing enhanced differentiation and activation of osteoclast progenitors in the inflammatory conditions on the one hand, and the role of inflammation in the recruitment and differentiation of multipotent progenitors into the skeletal lineage during the fracture healing on the other hand is a critical first step in developing interventions that modulate bone regeneration processes and in designing novel pharmacological strategies.
C1 [Kelava, Tomislav; Sucur, Alan] Univ Zagreb, Sch Med, Dept Physiol & Immunol, HR 10000 Zagreb, Croatia.
   [Kelava, Tomislav; Sucur, Alan; Kuzmac, Sania; Katavic, Vedran] Univ Zagreb, Sch Med, Lab Mol Immunol, HR 10000 Zagreb, Croatia.
   [Kuzmac, Sania; Katavic, Vedran] Univ Zagreb, Sch Med, Dept Anat, HR 10000 Zagreb, Croatia.
C3 University of Zagreb; University of Zagreb; University of Zagreb
RP Kelava, T (通讯作者)，Univ Zagreb, Sch Med, Dept Physiol & Immunol, Salata 3, HR 10000 Zagreb, Croatia.
EM tkelava@mef.hr
RI ; Sucur, Alan/AAB 9952 2021; Katavic, Vedran/E 8405 2011
OI Sucur, Alan/0000 0001 7523 1047; Kelava, Tomislav/0000 0002 6665 116X;
   Katavic, Vedran/0000 0003 2900 1974
CR Adamopoulos IE, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2936
   Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354
   Alnaeeli M, 2007, J BONE MINER RES, V22, P775, DOI 10.1359/JBMR.070314
   Amcheslavsky A, 2007, J BONE MINER RES, V22, P1301, DOI 10.1359/JBMR.070501
   Bandow K, 2010, BIOCHEM BIOPH RES CO, V402, P755, DOI 10.1016/j.bbrc.2010.10.103
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Bianco P, 2010, HUM GENE THER, V21, P1057, DOI 10.1089/hum.2010.136
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Cottrell JA, 2013, BONE JOINT RES, V2, P41, DOI 10.1302/2046 3758.22.2000066
   Cvija H, 2012, INFLAMMATION, V35, P1618, DOI 10.1007/s10753 012 9477 y
   Doyon A, 2010, CALCIFIED TISSUE INT, V87, P68, DOI 10.1007/s00223 010 9370 3
   EINHORN TA, 1995, J BONE MINER RES, V10, P1272
   Fayaz HC, 2011, INT ORTHOP, V35, P1587, DOI 10.1007/s00264 011 1338 z
   Gerstenfeld LC, 2003, J BONE MINER RES, V18, P1584, DOI 10.1359/jbmr.2003.18.9.1584
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Glass GE, 2011, P NATL ACAD SCI USA, V108, P1585, DOI 10.1073/pnas.1018501108
   Grcevic D, 2000, J IMMUNOL, V165, P4231, DOI 10.4049/jimmunol.165.8.4231
   Grcevic D, 2001, CROAT MED J, V42, P384
   Grcevic D, 2012, STEM CELLS, V30, P187, DOI 10.1002/stem.780
   Gudbrandsdottir S, 2004, CLIN EXP RHEUMATOL, V22, P118
   Hengartner NE, 2013, MOL MED, V19, P36, DOI 10.2119/molmed.2012.00058
   Henriksen K, 2009, BONE, V44, P1026, DOI 10.1016/j.bone.2009.03.671
   Hikiji H, 2009, P NATL ACAD SCI USA, V106, P21294, DOI 10.1073/pnas.0905209106
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Inada M, 2006, J IMMUNOL, V177, P1879, DOI 10.4049/jimmunol.177.3.1879
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Itoh K, 2003, J IMMUNOL, V170, P3688, DOI 10.4049/jimmunol.170.7.3688
   Ju JH, 2008, J IMMUNOL, V181, P1507, DOI 10.4049/jimmunol.181.2.1507
   Jules J, 2012, J BIOL CHEM, V287, P15728, DOI 10.1074/jbc.M111.296228
   Kadono H, 1999, INFECT IMMUN, V67, P2841, DOI 10.1128/IAI.67.6.2841 2846.1999
   KELLER J, 1993, ACTA ORTHOP SCAND, V64, P59, DOI 10.3109/17453679308994530
   Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kobayashi Y, 2005, J BIOL CHEM, V280, P24035, DOI 10.1074/jbc.M500926200
   Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004
   Lange J, 2010, J ORTHOP RES, V28, P778, DOI 10.1002/jor.21061
   Lapara NJ, 2010, J INFLAMM LOND, V7, DOI 10.1186/1476 9255 7 8
   Lee JM, 2012, J IMMUNOL, V189, P5284, DOI 10.4049/jimmunol.1003738
   Li M, 2005, BONE, V37, P46, DOI 10.1016/j.bone.2005.03.016
   Li M, 2003, J BONE MINER RES, V18, P2033, DOI 10.1359/jbmr.2003.18.11.2033
   Li P, 2004, J BONE MINER RES, V19, P207, DOI 10.1359/JBMR.0301233
   Lisignoli G, 2007, J CELL PHYSIOL, V210, P798, DOI 10.1002/jcp.20905
   LIU F, 1994, DEV BIOL, V166, P220, DOI 10.1006/dbio.1994.1309
   Liu JZ, 2009, J BIOL CHEM, V284, P12512, DOI 10.1074/jbc.M809789200
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   LORENZO J, 2010, OSTEOIMMUNOLOGY
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   Lu CY, 2012, ARCH ORTHOP TRAUM SU, V132, P1205, DOI 10.1007/s00402 012 1525 4
   Lu XH, 2006, J BIOL CHEM, V281, P6297, DOI 10.1074/jbc.M507804200
   Lubberts E, 2003, J IMMUNOL, V170, P2655, DOI 10.4049/jimmunol.170.5.2655
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Manigrasso MB, 2010, ACTA ORTHOP, V81, P748, DOI 10.3109/17453674.2010.533931
   MATTHEWS B G, 2013, J BONE MINER RES
   Medical Advisory Secretariat, 2005, Ont Health Technol Assess Ser, V5, P1
   MIYAUCHI M, 1992, J PERIODONTOL, V63, P405, DOI 10.1902/jop.1992.63.5.405
   Mörmann M, 2008, MOL IMMUNOL, V45, P3330, DOI 10.1016/j.molimm.2008.04.022
   Morita Y, 2010, CALCIFIED TISSUE INT, V86, P242, DOI 10.1007/s00223 010 9335 6
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Nagata N, 2003, BONE, V33, P721, DOI 10.1016/S8756 3282(03)00213 8
   Nam D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040044
   Ochi S, 2007, P NATL ACAD SCI USA, V104, P11394, DOI 10.1073/pnas.0701971104
   OWEN M, 1988, J CELL SCI, P63
   Ozaki A, 2000, J Orthop Sci, V5, P64, DOI 10.1007/s007760050010
   Patel Mitul, 2009, Semin Plast Surg, V23, P148, DOI 10.1055/s 0029 1214167
   Peruzzi B, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1651
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Romas E, 2006, RHEUM DIS CLIN N AM, V32, P759, DOI 10.1016/j.rdc.2006.07.004
   Rosso M, 2011, CRIT REV IMMUNOL, V31, P379, DOI 10.1615/CritRevImmunol.v31.i5.20
   Rundle CH, 2006, BONE, V38, P521, DOI 10.1016/j.bone.2005.09.015
   Sandberg O, 2012, ACTA ORTHOP, V83, P305, DOI 10.3109/17453674.2012.693018
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schroeder JE, 2011, INJURY, V42, P609, DOI 10.1016/j.injury.2011.03.029
   Silva TA, 2007, J DENT RES, V86, P306, DOI 10.1177/154405910708600403
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Sipos W, 2008, CURR MED CHEM, V15, P127, DOI 10.2174/092986708783330638
   Stanley KT, 2006, J BONE MINER RES, V21, P29, DOI 10.1359/JBMR.051004
   STASHENKO P, 1987, J IMMUNOL, V138, P1464
   Suda K, 2004, J IMMUNOL, V172, P2504, DOI 10.4049/jimmunol.172.4.2504
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   Tanaka M, 2004, BONE, V34, P940, DOI 10.1016/j.bone.2004.01.002
   TASHJIAN AH, 1987, ENDOCRINOLOGY, V120, P2029, DOI 10.1210/endo 120 5 2029
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Toben D, 2011, J BONE MINER RES, V26, P113, DOI 10.1002/jbmr.185
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Wallace A, 2011, J ORTHOP RES, V29, P1437, DOI 10.1002/jor.21367
   Wang X, 2013, CHIN J TRAUMATOL, V16, P277, DOI 10.3760/cma.j.issn.1008 1275.2013.05.004
   Waters RV, 2000, ACTA ORTHOP SCAND, V71, P316, DOI 10.1080/000164700317411951
   Yago T, 2009, J CELL BIOCHEM, V108, P947, DOI 10.1002/jcb.22326
   Yang X, 2007, BONE, V41, P928, DOI 10.1016/j.bone.2007.07.022
   Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200
   Zhang MJ, 2011, J BONE MINER RES, V26, P792, DOI 10.1002/jbmr.272
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zwerina K, 2012, EUR J IMMUNOL, V42, P413, DOI 10.1002/eji.201141871
NR 96
TC 6
Z9 6
U1 0
U2 10
PU PERIODICUM BIOLOGORUM
PI ZAGREB
PA HRVATSKO PRIRODOSLOVNO DRUSTVO ILICA 16/111, 41000 ZAGREB, CROATIA
SN 0031 5362
J9 PERIOD BIOL
JI Period. Biol.
PD MAR
PY 2014
VL 116
IS 1
BP 45
EP 52
PG 8
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA AG1VL
UT WOS:000335204200009
DA 2025 08 17
ER

PT J
AU Kirschner, G
   Balla, B
   Horváth, P
   Kövesdi, A
   Lakatos, G
   Takács, I
   Nagy, Z
   Tóbiás, B
   Arvai, K
   Kósa, JP
   Lakatos, P
AF Kirschner, Gyongyi
   Balla, Bernadett
   Horvath, Peter
   Kovesdi, Andrea
   Lakatos, Gergely
   Takacs, Istvan
   Nagy, Zsolt
   Tobias, Balint
   Arvai, Kristof
   Kosa, Janos Pal
   Lakatos, Peter
TI Effects of imatinib and nilotinib on the whole transcriptome of cultured
   murine osteoblasts
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE gene expression; MC3T3 E1 cells; pathway analysis; TKIs
ID CHRONIC MYELOGENOUS LEUKEMIA; MESENCHYMAL STEM CELLS; BONE MINERAL
   DENSITY; LONG TERM IMATINIB; OSTEOCLAST DIFFERENTIATION; IN VITRO;
   ENDOPLASMIC RETICULUM; CML PATIENTS; SEROTONIN; MESYLATE
AB Numerous clinical observations have confirmed that breakpoint cluster region abelson fusion oncoprotein tyrosine kinase inhibitors used in leukemia treatment alter bone physiology in a complex manner. The aim of the present study was to analyze the whole transcriptome of cultured murine osteoblasts and determine the changes following treatment with imatinib and nilotinib using Sequencing by Oligonucleotide Ligation and Detection next generation RNA sequencing. This study also aimed to identify candidate signaling pathways and network regulators by multivariate Ingenuity Pathway Analysis. Based on the right tailed Fisher's exact test, significantly altered pathways including upstream regulators were defined for each drug. The correlation between these pathways and bone metabolism was also examined. The preliminary results suggest the two drugs have different mechanisms of action on osteoblasts, and imatinib was shown to have a greater effect on gene expression. Data also indicated the potential role of a number of genes and signaling cascades that may contribute to identifying novel targets for the treatment of metabolic bone diseases.
C1 [Kirschner, Gyongyi; Balla, Bernadett; Horvath, Peter; Kovesdi, Andrea; Takacs, Istvan; Nagy, Zsolt; Tobias, Balint; Arvai, Kristof; Kosa, Janos Pal; Lakatos, Peter] Semmelweis Univ, Dept Internal Med 1, Koranyi Sandor 2 A, H 1083 Budapest, Hungary.
   [Lakatos, Gergely] Semmelweis Univ, Dept Internal Med 2, H 1083 Budapest, Hungary.
C3 Semmelweis University; Semmelweis University
RP Kirschner, G (通讯作者)，Semmelweis Univ, Dept Internal Med 1, Koranyi Sandor 2 A, H 1083 Budapest, Hungary.
EM pontlike@gmail.com
RI Podani, Janos/G 3074 2014; Nagy, Zsolt/AAC 2331 2019
OI Horvath, Peter/0000 0001 9966 5747
CR Aharon R, 2006, J BIOL CHEM, V281, P19305, DOI 10.1074/jbc.M601728200
   Alemán JO, 2014, ENDOCR RELAT CANCER, V21, pR247, DOI 10.1530/ERC 12 0400
   Bahamonde ME, 2001, J BONE JOINT SURG AM, V83A, pS56
   Bais M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005393
   Bais MV, 2012, BIOCHEM BIOPH RES CO, V417, P211, DOI 10.1016/j.bbrc.2011.11.087
   Battaglino R, 2004, J BONE MINER RES, V19, P1420, DOI 10.1359/JBMR.040606
   Benito R, 2012, PHARMACOGENET GENOM, V22, P381, DOI 10.1097/FPC.0b013e328351f3e9
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140
   Berman E, 2013, LEUKEMIA RES, V37, P790, DOI 10.1016/j.leukres.2013.02.005
   Bliziotes M, 2010, J CLIN ENDOCR METAB, V95, P4124, DOI 10.1210/jc.2010 0861
   Bliziotes MM, 2001, BONE, V29, P477, DOI 10.1016/S8756 3282(01)00593 2
   Chanprasertyothin S, 2010, ENDOCRINE, V38, P83, DOI 10.1007/s12020 010 9353 1
   Cohen MH, 2002, ONCOLOGIST, V7, P390, DOI 10.1634/theoncologist.7 5 390
   Dai SQ, 2014, BRAZ J MED BIOL RES, V47, P759, DOI 10.1590/1414 431X20143565
   Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810
   Ducy P, 2010, J CELL BIOL, V191, P7, DOI 10.1083/jcb.201006123
   Fierro F, 2007, CELL PROLIFERAT, V40, P355, DOI 10.1111/j.1365 2184.2007.00438.x
   Fitter S, 2008, BLOOD, V111, P2538, DOI 10.1182/blood 2007 07 104281
   Fujimori S, 2002, BIOCHEM BIOPH RES CO, V293, P1445, DOI 10.1016/S0006 291X(02)00405 9
   Hamamura K, 2007, FEBS LETT, V581, P1769, DOI 10.1016/j.febslet.2007.03.063
   Hiramitsu S, 2013, ENDOCRINOLOGY, V154, P4618, DOI 10.1210/en.2013 1387
   Hirasawa H, 2010, FEBS LETT, V584, P745, DOI 10.1016/j.febslet.2009.12.028
   Hoehn D, 2012, HUM PATHOL, V43, P2354, DOI 10.1016/j.humpath.2012.04.012
   Jönsson S, 2008, HAEMATOL HEMATOL J, V93, P1101, DOI 10.3324/haematol.12373
   Jönsson S, 2012, J BONE MINER METAB, V30, P119, DOI 10.1007/s00774 011 0323 3
   Kraus DM, 2006, J IMMUNOL, V176, P4419, DOI 10.4049/jimmunol.176.7.4419
   Lawrence L., 2013, LONG TERM TREATMENT
   Li S, 2015, CLIN ENDOCRINOL, V82, P53, DOI 10.1111/cen.12616
   Liu YJ, 2009, BIOL CELL, V101, P133, DOI 10.1042/BC20080083
   Lotinun S., 2012, CURR MOL PHARMACOL, V5, P195, DOI [10.2174/1874467211205020195, DOI 10.2174/1874467211205020195]
   Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070
   May P, 2005, CELL MOL LIFE SCI, V62, P2325, DOI 10.1007/s00018 005 5231 z
   Mentink A, 2013, BIOMATERIALS, V34, P4592, DOI 10.1016/j.biomaterials.2013.03.001
   Muhammad SI, 2013, CLIN INTERV AGING, V8, P1259, DOI 10.2147/CIA.S45943
   O'Sullivan S, 2007, J BONE MINER RES, V22, P1679, DOI 10.1359/JBMR.070719
   O'Sullivan S, 2011, BONE, V49, P281, DOI 10.1016/j.bone.2011.04.014
   O'Sullivan S, 2009, J CLIN ENDOCR METAB, V94, P1131, DOI 10.1210/jc.2008 2324
   Onishi M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.226
   Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877
   Rix U, 2007, BLOOD, V110, P4055, DOI 10.1182/blood 2007 07 102061
   Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900
   Schrauwen I, 2009, AM J HUM GENET, V84, P328, DOI 10.1016/j.ajhg.2009.01.023
   Suzuki A, 2006, P NATL ACAD SCI USA, V103, P10294, DOI 10.1073/pnas.0506945103
   Takahata Y, 2011, J BIOL CHEM, V286, P32906, DOI 10.1074/jbc.M111.253526
   Tibullo D, 2012, HEMATOL ONCOL, V30, P27, DOI 10.1002/hon.988
   Tibullo D, 2009, EXP HEMATOL, V37, P461, DOI 10.1016/j.exphem.2008.12.008
   Vandyke K, 2013, J CLIN ENDOCR METAB, V98, P67, DOI 10.1210/jc.2012 2426
   Vandyke K, 2010, BLOOD, V115, P766, DOI 10.1182/blood 2009 08 237404
   Westbroek I, 2001, J BIOL CHEM, V276, P28961, DOI 10.1074/jbc.M101824200
   Wihlidal P, 2008, LEUKEMIA RES, V32, P437, DOI 10.1016/j.leukres.2007.07.020
   Yadav VK, 2010, MEDICOGRAPHIA, V32, p[357, 363]
   Yang JY, 2009, BONE, V45, P1175, DOI 10.1016/j.bone.2009.08.012
NR 53
TC 3
Z9 5
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2016
VL 14
IS 3
BP 2025
EP 2037
DI 10.3892/mmr.2016.5459
PG 13
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DU8EF
UT WOS:000382445400021
PM 27430367
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Cornish, J
   Bava, U
   Callon, KE
   Bai, JZ
   Naot, D
   Reid, IR
AF Cornish, Jillian
   Bava, Usha
   Callon, Karen E.
   Bai, Jizhong
   Naot, Dorit
   Reid, Ian R.
TI Bone bound bisphosphonate inhibits growth of adjacent non bone cells
SO BONE
LA English
DT Article
DE Zoledronate; Alendronate; Caco 2; CHO
ID ZOLEDRONIC ACID; BREAST CANCER; DOUBLE BLIND; MULTIPLE MYELOMA;
   OSTEOBLAST APOPTOSIS; SKELETAL METASTASES; INDUCE APOPTOSIS; PHASE III;
   IN VITRO; TRIAL
AB The conventional view of the mode of action of bisphosphonates is that they are taken up by bone surfaces and then ingested by bone resorbing osteoclasts, the activity of which they inhibit through their actions on the enzyme, farnesyl pyrophosphate (FPP) synthase. This model suggests that these compounds should only have effects on osteoclasts, and does not provide an explanation for their other actions, such as the epithelial abnormalities seen in osteonecrosis of the jaw, and their possible prolongation of disease free survival in some malignancies. The present studies set out to determine whether cells other than osteoclasts are affected by bone bound bisphosphonates.
   Bone slices were incubated overnight in PBS or in solutions of bisphosphonates (100 mu M), washed, then transferred to 96 well plates (1 slice/well). Cells from 2 cell lines were seeded onto the bone slices: Caco 2 human colorectal adenocarcinoma epithelial cells and Chinese hamster ovary (CHO) cells. Cell proliferation (cell numbers and thymidine incorporation) was assessed at 4 72 h. Cell adhesion at 4 h was normal on bone slices pre treated with bisphosphonates, but there were progressive reductions in cell numbers from 48 h and even greater reductions in thymidine incorporation from 24 h (>90% with zoledronate at 72 h). Growth inhibition was related to the clinical potency of the bisphosphonate used. There was no evidence of increased apoptosis in cells grown on bisphosphonate coated bone, but levels of unprenylated Rap1A were increased, indicating inhibition of FPP synthase. Similar growth inhibition was observed in primary cultures of rat osteoblasts on bone, indicating that this was not specific to transformed cells.
   It is concluded that bisphosphonates bound to a bone surface can act on adjacent non bone cells and inhibit their growth. This greatly widens the range of potential target cells for these drugs. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Cornish, Jillian; Bava, Usha; Callon, Karen E.; Bai, Jizhong; Naot, Dorit; Reid, Ian R.] Univ Auckland, Dept Med, Fac Med & Hlth Sci, Auckland, New Zealand.
C3 University of Auckland
RP Reid, IR (通讯作者)，Univ Auckland, Dept Med, Fac Med & Hlth Sci, Private Bag 92019, Auckland, New Zealand.
EM i.reid@auckland.ac.nz
OI Reid, Ian/0000 0001 6021 5458; Bai, Jizhong/0000 0003 0667 8640; Naot,
   Dorit/0000 0001 9498 2639
FU Health Research Council of New Zealand
FX Supported by the Health Research Council of New Zealand.
CR Aft R, 2010, LANCET ONCOL, V11, P421, DOI 10.1016/S1470 2045(10)70054 1
   Avilés A, 2007, MED ONCOL, V24, P227, DOI 10.1007/BF02698044
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Cornish J, 1999, AM J PHYSIOL ENDOC M, V277, pE779, DOI 10.1152/ajpendo.1999.277.5.E779
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Cremers SCLM, 2005, J BONE MINER RES, V20, P1543, DOI 10.1359/JBMR.050522
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Fedorov SN, 2004, PHARM RES DORDR, V21, P2307, DOI 10.1007/s11095 004 7683 5
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Jarrett SJ, 2006, ARTHRITIS RHEUM US, V54, P1410, DOI 10.1002/art.21824
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   McQueen F, 2011, ANN RHEUM DIS, V70, P1091, DOI 10.1136/ard.2010.142539
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Pallet N, 2010, PHARMACOL RES, V61, P71, DOI 10.1016/j.phrs.2009.08.010
   Pantel K, 2009, NAT REV CLIN ONCOL, V6, P339, DOI 10.1038/nrclinonc.2009.44
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Rack B, 2010, ANTICANCER RES, V30, P1807
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193
   Röcken M, 2010, J CLIN INVEST, V120, P1800, DOI 10.1172/JCI43424
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   Rogers MJ, 2004, CALCIFIED TISSUE INT, V75, P451, DOI 10.1007/s00223 004 0024 1
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2001, CANCER J, V7, P377
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Scheper MA, 2009, BRIT J HAEMATOL, V144, P667, DOI 10.1111/j.1365 2141.2008.07504.x
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Suri S, 2001, BONE, V29, P336, DOI 10.1016/S8756 3282(01)00589 0
NR 34
TC 51
Z9 55
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD OCT
PY 2011
VL 49
IS 4
BP 710
EP 716
DI 10.1016/j.bone.2011.07.020
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 824ZH
UT WOS:000295240200015
PM 21807133
DA 2025 08 17
ER

PT J
AU Hong, W
   Zhang, WJ
AF Hong, Wei
   Zhang, Wenjie
TI Hesperidin promotes differentiation of alveolar osteoblasts via
   Wnt/β Catenin signaling pathway
SO JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
LA English
DT Article
DE Hesperidin; alveolar osteoblasts; differentiation; Wnt; beta catenin
   signaling
ID BONE AUGMENTATION
AB Alveolar bone has a high plasticity. The health of alveolar bones directly determines the success of oral implant surgery, and the health and functions of oral and maxillofacial system. Hesperidin (HES) has many pharmacological activities, such as anti inflammatory, anti oxidation, promotion of osteoblast differentiation, but its effect on alveolar osteoblasts is rarely reported. Healthy human alveolar osteoblasts were treated by HES (0.1, 1, 10, 100 mu mol/l) and Wnt signaling pathway inhibitor Dickkopf 1 (DKK 1). Then the cell osteogenic differentiation was detected by Alizarin Red S staining, and alkaline phosphatase (ALP) activity was detected by ALP kit. Expressions of genetic markers such as runt related transcription factor 2 (RUNX2), bone morphogenetic protein 2 (BMP2), osterix (OSX), and osteocalcin (OCN) of osteoblasts were detected by quantitative real time polymerase chain reaction (qRT PCR). Expressions of Wnt/beta Catenin pathway related proteins were measured by Western blot (WB) analysis. HES increased numbers of the cells stained red by Alizarin Red S staining, the ALP activity, and the mRNA expression of Runx2, BMP2, OSX, and OCN, and activated the Wnt/beta catenin signaling pathway. However, DKK 1 reversed the differentiation function of human alveolar osteoblasts accelerated by HES. HES promoted the differentiation of human alveolar osteoblasts through the activation of the Wnt/beta Catenin signaling pathway.
C1 [Hong, Wei; Zhang, Wenjie] Jingmen 1 Peoples Hosp, Dept Stomatol, 168 Xiangshan Ave, Jingmen 448000, Hubei, Peoples R China.
RP Zhang, WJ (通讯作者)，Jingmen 1 Peoples Hosp, Dept Stomatol, 168 Xiangshan Ave, Jingmen 448000, Hubei, Peoples R China.
EM wenjie_zh1@163.com
CR Asa'ad F, 2016, INT J DENT, V2016, DOI 10.1155/2016/1239842
   Chen LJ, 2017, ARCH ORAL BIOL, V78, P100, DOI 10.1016/j.archoralbio.2017.01.019
   Chiapasco M, 2018, PERIODONTOL 2000, V77, P213, DOI 10.1111/prd.12219
   Erdogan Ö, 2015, CLIN ORAL IMPLAN RES, V26, P1267, DOI 10.1111/clr.12450
   Hou ZY, 2019, LAB INVEST, V99, P271, DOI 10.1038/s41374 018 0149 x
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Jo SH, 2019, ARCH PHARM RES, V42, P695, DOI 10.1007/s12272 019 01174 5
   Jo S, 2019, INT J RHEUM DIS, V22, P252, DOI 10.1111/1756 185X.13419
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Kim SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067504
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Li CY, 2017, CRIT REV FOOD SCI, V57, P613, DOI 10.1080/10408398.2014.906382
   Liang WC, 2016, SCI REP UK, V6, DOI 10.1038/srep20121
   Lim EK, 2015, CHEM COMMUN, V51, P3270, DOI 10.1039/c4cc09620g
   Nakamura T, 2015, J CELL PHYSIOL, V230, P922, DOI 10.1002/jcp.24823
   Polat FR, 2018, CELL MOL BIOL, V64, P58, DOI 10.14715/cmb/2018.64.11.11
   Salazar VS, 2016, DEVELOPMENT, V143, P4352, DOI 10.1242/dev.136879
   Sharma AR, 2019, J NUTR BIOCHEM, V74, DOI 10.1016/j.jnutbio.2019.108228
   Shehata AS, 2017, EXP TOXICOL PATHOL, V69, P203, DOI 10.1016/j.etp.2017.01.008
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Wen QR, 2017, INT J GYNECOL CANCER, V27, P1096, DOI 10.1097/IGC.0000000000001028
   Yang J, 2017, SCI REP UK, V7, P1, DOI [10.1038/s41598 017 09018 2, 10.1038/srep39903]
   Yoo SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158481
   Zhang Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01028
   Zhang XF, 2017, J INTERF CYTOK RES, V37, P406, DOI 10.1089/jir.2017.0023
   Zhou TT, 2017, J MOL HISTOL, V48, P187, DOI 10.1007/s10735 017 9719 2
NR 26
TC 15
Z9 17
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1079 9893
EI 1532 4281
J9 J RECEPT SIG TRANSD
JI J. Recept. Signal Transduct.
PD SEP 2
PY 2020
VL 40
IS 5
BP 442
EP 448
DI 10.1080/10799893.2020.1752718
EA APR 2020
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA NK5VQ
UT WOS:000527580800001
PM 32308087
DA 2025 08 17
ER

PT J
AU Russell, PK
   Clarke, MV
   Skinner, JP
   Pang, TPS
   Zajac, JD
   Davey, RA
AF Russell, Patricia K.
   Clarke, Michele V.
   Skinner, Jarrod P.
   Pang, Tammy P. S.
   Zajac, Jeffrey D.
   Davey, Rachel A.
TI Identification of gene pathways altered by deletion of the androgen
   receptor specifically in mineralizing osteoblasts and osteocytes in mice
SO JOURNAL OF MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID GROWTH FACTOR BETA; REPLACEMENT THERAPY; ADIPONECTIN LEVELS;
   STEROID HORMONES; BONE RESORPTION; MOUSE MODEL; TESTOSTERONE;
   EXPRESSION; ACTIVATION; CELLS
AB Androgens play a key role in skeletal growth and maintenance in males and can mediate their actions, at least in part, via the androgen receptor (AR) in osteoblasts. To investigate the mechanisms by which androgens exert their effects via the AR in mineralizing osteoblasts and osteocytes, we identified gene targets/pathways regulated by the AR using targeted gene expression and microarray approaches on bone isolated from mice in which the AR is specifically deleted in mineralizing osteoblasts and osteocytes (mOBL ARKOs). Gene ontology mining indicated a number of biological processes to be affected in the bones of mOBL ARKOs including skeletal and muscular system development and carbohydrate metabolism. All genes identified to have altered expression in the bones of mOBL ARKOs were confirmed by Q PCR for their androgen responsiveness in an androgen deprivation and replacement mouse model. The osteoblast genes Col1a1 and Bglap and the osteoclast genes Ctsk and RANKL (Tnfs11) were upregulated in the bones of mOBL ARKOs, consistent with the increased matrix synthesis, mineralization, and bone resorption observed previously in these mice. Of significant interest, we identified genes involved in carbohydrate metabolism(adiponectin and Dpp4) and in growth and development (GH, Tgfb (Tgfb2), Wnt4) as potential targets of androgen action via the AR in mineralizing osteoblasts. Journal of Molecular Endocrinology (2012) 49, 1 10
C1 [Russell, Patricia K.; Clarke, Michele V.; Skinner, Jarrod P.; Pang, Tammy P. S.; Zajac, Jeffrey D.; Davey, Rachel A.] Univ Melbourne, Dept Med, Heidelberg, Vic 3084, Australia.
C3 University of Melbourne
RP Davey, RA (通讯作者)，Univ Melbourne, Dept Med, Studley Rd, Heidelberg, Vic 3084, Australia.
EM r.davey@unimelb.edu.au
RI Zajac, Jeffrey/ABC 3767 2021
OI DAVEY, RACHEL A/0000 0001 5121 0209; Zajac, Jeffrey/0000 0003 3933 5708;
   Russell, Patricia/0000 0003 4351 3271
FU National Health and Medical Research Council Australia [566503]
FX This study was funded by the National Health and Medical Research
   Council Australia (Project Grant 566503).
CR Abu EO, 1997, J CLIN ENDOCR METAB, V82, P3493, DOI 10.1210/jcem.82.10.4319
   Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255
   Axell AM, 2006, AM J PHYSIOL ENDOC M, V291, pE506, DOI 10.1152/ajpendo.00058.2006
   BAKER AR, 1992, MOL CELL BIOL, V12, P5541, DOI 10.1128/MCB.12.12.5541
   Basaria S, 2001, AM J MED, V110, P563, DOI 10.1016/S0002 9343(01)00663 5
   Berner HS, 2004, BONE, V35, P842, DOI 10.1016/j.bone.2004.06.008
   Biason Lauber A, 2008, SEX DEV, V2, P210, DOI 10.1159/000152037
   BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312
   Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200
   Chiang C, 2009, J BONE MINER RES, V24, P621, DOI [10.1359/jbmr.081217, 10.1359/JBMR.081217]
   COLVARD DS, 1989, P NATL ACAD SCI USA, V86, P854, DOI 10.1073/pnas.86.3.854
   Davey RAM, 2000, CALCIFIED TISSUE INT, V67, P75, DOI 10.1007/s00223001100
   Dohi O, 2009, HISTOPATHOLOGY, V55, P432, DOI 10.1111/j.1365 2559.2009.03399.x
   Drucker DJ, 2006, LANCET, V368, P1696, DOI 10.1016/S0140 6736(06)69705 5
   Franz Odendaal TA, 2006, DEV DYNAM, V235, P176, DOI 10.1002/dvdy.20603
   Grossmann M, 2010, CURR OPIN ENDOCRINOL, V17, P247, DOI 10.1097/MED.0b013e32833919cf
   Harvey S, 2010, ENDOCRINE, V38, P335, DOI 10.1007/s12020 010 9403 8
   Karsdal MA, 2002, J BIOL CHEM, V277, P44061, DOI 10.1074/jbc.M207205200
   KASPERK CH, 1989, ENDOCRINOLOGY, V124, P1576, DOI 10.1210/endo 124 3 1576
   Kawano H, 2003, P NATL ACAD SCI USA, V100, P9416, DOI 10.1073/pnas.1533500100
   KNABBE C, 1993, J STEROID BIOCHEM, V47, P137, DOI 10.1016/0960 0760(93)90067 7
   Kyle KA, 2011, ENDOCRINOLOGY, V152, P457, DOI 10.1210/en.2010 1098
   Lanfranco F, 2004, CLIN ENDOCRINOL, V60, P500, DOI 10.1111/j.1365 2265.2004.02007.x
   MacLean HE, 2008, PHYSIOL GENOMICS, V33, P133, DOI 10.1152/physiolgenomics.00260.2007
   MacLean HE, 2010, J ENDOCRINOL, V206, P93, DOI 10.1677/JOE 10 0026
   METZGER DL, 1993, J CLIN ENDOCR METAB, V76, P1147, DOI 10.1210/jc.76.5.1147
   Notini AJ, 2005, J MOL ENDOCRINOL, V35, P547, DOI 10.1677/jme.1.01884
   Notini AJ, 2007, J BONE MINER RES, V22, P347, DOI 10.1359/JBMR.061117
   Oshima K, 2005, BIOCHEM BIOPH RES CO, V331, P520, DOI 10.1016/j.bbrc.2005.03.210
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Page ST, 2005, J ANDROL, V26, P85
   Payne AH, 2004, ENDOCR REV, V25, P947, DOI 10.1210/er.2003 0030
   Rana K, 2011, AM J PHYSIOL ENDOC M, V301, pE767, DOI 10.1152/ajpendo.00584.2010
   ROBEY PG, 1987, J CELL BIOL, V105, P457, DOI 10.1083/jcb.105.1.457
   Shinoda Y, 2006, J CELL BIOCHEM, V99, P196, DOI 10.1002/jcb.20890
   Swarbrick Michael M., 2008, Metabolic Syndrome and Related Disorders, V6, P87, DOI 10.1089/met.2007.0029
   VANDERSCHUEREN D, 1992, ENDOCRINOLOGY, V130, P2906, DOI 10.1210/en.130.5.2906
   Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003 0003
   Venken K, 2006, J BONE MINER RES, V21, P576, DOI 10.1359/JBMR.060103
   Wiren KM, 2005, CURR OPIN PHARMACOL, V5, P626, DOI 10.1016/j.coph.2005.06.003
   Wiren KM, 2004, ENDOCRINOLOGY, V145, P3507, DOI 10.1210/en.2003 1016
   Wiren KM, 2008, BONE, V43, P440, DOI 10.1016/j.bone.2008.04.026
   Wong IPL, 2008, SEMIN CELL DEV BIOL, V19, P452, DOI 10.1016/j.semcdb.2008.08.001
   Xu AM, 2005, J BIOL CHEM, V280, P18073, DOI 10.1074/jbc.M414231200
   Yarrow JF, 2010, AM J PHYSIOL ENDOC M, V299, pE841, DOI 10.1152/ajpendo.00384.2010
   Yeh SY, 2002, P NATL ACAD SCI USA, V99, P13498, DOI 10.1073/pnas.212474399
NR 46
TC 23
Z9 27
U1 0
U2 2
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0952 5041
J9 J MOL ENDOCRINOL
JI J. Mol. Endocrinol.
PD AUG
PY 2012
VL 49
IS 1
BP 1
EP 10
DI 10.1530/JME 12 0014
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 990KJ
UT WOS:000307629400006
PM 22525354
OA Bronze
DA 2025 08 17
ER

PT J
AU Canalis, E
AF Canalis, Ernesto
TI Update in New Anabolic Therapies for Osteoporosis
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID GROWTH FACTOR I; GLUCOCORTICOID INDUCED OSTEOPOROSIS; BONE MORPHOGENETIC
   PROTEINS; FRIZZLED RELATED PROTEIN 1; PARATHYROID HORMONE; BETA CATENIN;
   IGF I; DIFFERENTIATED OSTEOBLASTS; SKELETAL OVEREXPRESSION; NEGATIVE
   REGULATOR
AB Skeletal anabolic agents enhance bone formation, which is determined by the number and function of osteoblasts. Cell number is controlled by factors that regulate the replication, differentiation, and death of cells of the osteoblastic lineage, whereas cell function is controlled by signals acting on the mature osteoblast. Bone morphogenetic proteins (BMP) and Wnt induce the differentiation of mesenchymal cells toward osteoblasts, and IGF I enhances the function of mature osteoblasts. The activity of BMP, Wnt, and IGF I is controlled by proteins that, by binding to the growth factor or to its receptors, can antagonize its effects. Changes in the expression or binding affinity of these extracellular antagonists can be associated with increased or decreased bone formation and bone mass. Novel approaches to anabolic therapies for osteoporosis may include the use of factors with anabolic properties, or the neutralization of a growth factor antagonist. Selected approaches include the use of neutralizing antibodies to Wnt antagonists, the enhancement of BMP signaling by proteasome inhibitors, or the use of activin soluble receptors, IGF I, or PTH analogs. An anabolic agent needs to be targeted specifically to the skeleton to avoid unwanted non skeletal effects and ensure safety. Clinical trials are being conducted to test the long term effectiveness and safety of novel bone anabolic agents. (J Clin Endocrinol Metab 95: 1496 1504, 2010)
C1 [Canalis, Ernesto] St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06105 USA.
   [Canalis, Ernesto] Univ Connecticut, Sch Med, Farmington, CT 06032 USA.
C3 Saint Francis Hospital & Medical Center; University of Connecticut
RP Canalis, E (通讯作者)，St Francis Hosp & Med Ctr, Dept Res, 114 Woodland St, Hartford, CT 06105 USA.
EM ecanalis@stfranciscare.org
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [AR021707]; National Institute of Diabetes, Digestive, Kidney Diseases
   [DK042424, DK045227]
FX This work was supported by Grant AR021707 from the National Institute of
   Arthritis and Musculoskeletal and Skin Diseases and by Grants DK042424
   and DK045227 from the National Institute of Diabetes, Digestive, Kidney
   Diseases.
CR Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744
   Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bodine PVN, 2009, BONE, V44, P1063, DOI 10.1016/j.bone.2009.02.013
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Canalis E, 2005, NEW ENGL J MED, V352, P2014, DOI 10.1056/NEJMe058080
   CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885
   Canalis E, 2008, OSTEOPOROSIS, VOLS I AND II, 3RD EDITION, P529
   CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250
   Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   Deregowski V, 2006, J BIOL CHEM, V281, P6203, DOI 10.1074/jbc.M508370200
   Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002 220918
   Doga M, 2005, REV ENDOCR METAB DIS, V6, P63, DOI 10.1007/s11154 005 5226 y
   Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood 2007 03 077685
   Fajardo RJ, 2010, BONE, V46, P64, DOI 10.1016/j.bone.2009.09.018
   Gaddy Kurten D, 2002, ENDOCRINOLOGY, V143, P74, DOI 10.1210/en.143.1.74
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Gazzerro E, 2005, ENDOCRINOLOGY, V146, P655, DOI 10.1210/en.2004 0766
   Gazzerro E, 2007, J BIOL CHEM, V282, P31549, DOI 10.1074/jbc.M701317200
   Gazzerro Elisabetta, 2006, Expert Rev Endocrinol Metab, V1, P47, DOI 10.1586/17446651.1.1.47
   Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154 006 9000 6
   GHIRON LJ, 1995, J BONE MINER RES, V10, P1844
   Giles RH, 2003, BBA REV CANCER, V1653, P1, DOI 10.1016/S0304 419X(03)00005 2
   Giustina A, 1998, ENDOCR REV, V19, P717, DOI 10.1210/er.19.6.717
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gowen M, 2000, J CLIN INVEST, V105, P1595, DOI 10.1172/JCI9038
   Grey A, 2003, ENDOCRINOLOGY, V144, P4886, DOI 10.1210/en.2003 0350
   Grinspoon S, 2002, J CLIN ENDOCR METAB, V87, P2883, DOI 10.1210/jc.87.6.2883
   Grinspoon S, 1996, J CLIN ENDOCR METAB, V81, P3864, DOI 10.1210/jc.81.11.3864
   Grisanti M, 2006, J BONE MINER RES, V21, pS25
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002 021122
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kaneko H, 2000, BONE, V27, P479, DOI 10.1016/S8756 3282(00)00358 6
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074 5521(01)00056 4
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Langlois JA, 1998, J CLIN ENDOCR METAB, V83, P4257, DOI 10.1210/jc.83.12.4257
   LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003 4819 122 1 199501010 00009
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200
   Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Mazziotti G, 2006, J BONE MINER RES, V21, P520, DOI 10.1359/JBMR.060112
   Misra M, 2006, REV ENDOCR METAB DIS, V7, P91, DOI 10.1007/s11154 006 9005 1
   Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P4349, DOI 10.1210/en.142.10.4349
   Miyazono K, 1999, BONE, V25, P91, DOI 10.1016/S8756 3282(99)00113 1
   MOCHIZUKI H, 1992, ENDOCRINOLOGY, V131, P1075, DOI 10.1210/en.131.3.1075
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017
   Parfitt AM, 2001, J BONE MINER RES, V16, P1583, DOI 10.1359/jbmr.2001.16.9.1583
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Recker R, 2004, J BONE MINER RES, V19, P1628, DOI 10.1359/JBMR.040710
   Ruckle J, 2009, J BONE MINER RES, V24, P744, DOI 10.1359/JBMR.081208
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Sims NA, 2000, J CLIN INVEST, V106, P1095, DOI 10.1172/JCI10753
   Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200
   Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Vestergaard P, 2008, CURR DRUG SAF, V3, P185, DOI 10.2174/157488608785699432
   Wang YM, 2006, J BONE MINER RES, V21, P1350, DOI 10.1359/JBMR.060610
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Yakar S, 2009, J BONE MINER RES, V24, P1481, DOI [10.1359/JBMR.090226, 10.1359/jbmr.090226]
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhang YL, 2009, BIOCHEM BIOPH RES CO, V383, P1, DOI 10.1016/j.bbrc.2009.03.086
   Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674
NR 77
TC 59
Z9 81
U1 1
U2 8
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD APR
PY 2010
VL 95
IS 4
BP 1496
EP 1504
DI 10.1210/jc.2009 2677
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 579UT
UT WOS:000276402300002
PM 20375217
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Cai, J
   Shao, X
   Yang, QJ
   Yang, YQ
   Yan, ZD
   Luo, EP
   Feng, X
   Jing, D
AF Cai, Jing
   Shao, Xi
   Yang, Qiuju
   Yang, Yongqing
   Yan, Zedong
   Luo, Erping
   Feng, Xue
   Jing, Da
TI Pulsed electromagnetic fields modify the adverse effects of
   glucocorticoids on bone architecture, bone strength and porous implant
   osseointegration by rescuing bone anabolic actions
SO BONE
LA English
DT Article
DE Glucocorticoids; Pulsed electromagnetic fields (PEMF); Osteoporosis;
   Implant osseointegration; Bone anabolism; Canonical Wnt signaling
ID SCLEROSTIN ANTIBODY TREATMENT; INDUCED OSTEOPOROSIS; SIGNALING PATHWAY;
   ELASTIC MODULUS; ZOLEDRONIC ACID; DOUBLE BLIND; MASS; RAT;
   DEXAMETHASONE; THERAPY
AB Long term glucocorticoid therapy is known to induce increased bone fragility and impaired skeletal regeneration potential. Growing evidence suggests that pulsed electromagnetic fields (PEMF) can accelerate fracture healing and increase bone mass both experimentally and clinically. However, how glucocorticoid treated bone and bone cells respond to PEMF stimulation remains poorly understood. Here we tested the effects of PEMF on bone quantity/quality, bone metabolism, and porous implant osseointegration in rabbits treated with dexamethasone (0.5 mg/kg/day, 6 weeks). The micro CT, histologic and nanoindentation results showed that PEMF ameliorated the glucocorticoid mediated deterioration of cancellous and cortical bone architecture and intrinsic material properties. Utilizing the new porous titanium implant (Ti2448) with low toxicity and low elastic modulus, we found that PEMF stimulated bone ingrowth into the pores of implants and enhanced pen implant bone material quality during osseous defect repair in glucocorticoid treated rabbits. Dynamic histomorphometric results revealed that PEMF reversed the adverse effects of glucocorticoids on bone formation, which was confirmed by increased circulating osteocalcin and P1NP. PEMF also significantly attenuated osteocyte apoptosis, promoted osteoblast related osteocalcin, Runx2 and Osx expression, and inhibited osteocyte specific DKK1 and Sost expression (negative regulators of osteoblasts) in glucocorticoid treated skeletons, revealing improved functional activities of osteoblasts and osteocytes. Nevertheless, PEMF exerted no effect on circulating bone resorbing cytokines (serum TRAcP5b and CTX 1) or skeletal gene expression of osteoclast specific markers (TRAP and cathepsin K). PEMF also significantly upregulated skeletal gene expression of canonical Wnt ligands (Wnt1, Wnt3a and Wnt10b), whereas PENT did not alter non canonical Wnt5a expression. This study demonstrates that PEMF treatment improves bone mass, strength and porous implant osseointegration in glucocorticoid treated rabbits by promoting potent bone anabolic action, which is associated with canonical Wnt mediated improvement in osteoblast and osteocyte functions. This study provides a new treatment alternative for glucocorticoid related bone disorders in a convenient and non invasive manner.
C1 [Cai, Jing] Shaanxi Univ Chinese Med, Coll Basic Med, Xianyang, Peoples R China.
   [Cai, Jing; Shao, Xi; Yang, Yongqing; Yan, Zedong; Luo, Erping; Jing, Da] Fourth Mil Med Univ, Dept Biomed Engn, 17 West Changle Rd, Xian 710032, Peoples R China.
   [Yang, Qiuju] Xinxiang Med Univ, Clin Coll 1, Dept Anesthesia, Xinxiang, Henan, Peoples R China.
   [Feng, Xue] Northwest Univ, Sch Med, Dept Cell Biol, Xian, Peoples R China.
C3 Shaanxi University of Chinese Medicine; Air Force Medical University;
   Henan Medical University; Northwest University Xi'an
RP Jing, D (通讯作者)，Fourth Mil Med Univ, Dept Biomed Engn, 17 West Changle Rd, Xian 710032, Peoples R China.; Feng, X (通讯作者)，Northwest Univ, Sch Med, 229 Taibai North Rd, Xian 710069, Peoples R China.
EM prof.fengxue@outlook.com; jingdaasq@126.com
RI Cai, Jing/JXM 0087 2024; Shao, Xi/H 9452 2016
FU National Natural Science Foundation of China [51907111, 31500760,
   11972366, 31670953]; Shaanxi Provincial Natural Science Foundation of
   China [2018JQ8056]; Supporting Project of Young Technology Nova of
   Shaanxi Province [201910XX 087]; Shaanxi Provincial Education Department
   [19JK0242]
FX The authors acknowledge the support from the National Natural Science
   Foundation of China (Nos. 51907111, 31500760, 11972366 and 31670953),
   the Shaanxi Provincial Natural Science Foundation of China (No.
   2018JQ8056), the Supporting Project of Young Technology Nova of Shaanxi
   Province (201910XX 087) and the Scientific Research Program Funded by
   Shaanxi Provincial Education Department (19JK0242).
CR Achiou Z, 2015, BONE, V81, P691, DOI 10.1016/j.bone.2015.09.010
   Balooch G, 2007, ARTHRITIS RHEUM, V56, P3726, DOI 10.1002/art.22976
   Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140 6736(09)60326 3
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   BASSETT CAL, 1993, J CELL BIOCHEM, V51, P387, DOI 10.1002/jcb.2400510402
   BASSETT CAL, 1974, SCIENCE, V184, P575
   Bayat M, 2016, LASER MED SCI, V31, P305, DOI 10.1007/s10103 015 1842 2
   Bilgin HM, 2017, BIOELECTROMAGNETICS, V38, P339, DOI 10.1002/bem.22043
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Buchman AL, 2001, J CLIN GASTROENTEROL, V33, P289, DOI 10.1097/00004836 200110000 00006
   Cai J, 2018, OSTEOPOROSIS INT, V29, P1177, DOI 10.1007/s00198 018 4392 1
   CALLAGHAN JP, 1995, J ORTHOPAED RES, V13, P809, DOI 10.1002/jor.1100130522
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   CANE V, 1993, J ORTHOPAED RES, V11, P664, DOI 10.1002/jor.1100110508
   Carvas JSB, 2010, OSTEOPOROSIS INT, V21, P1723, DOI 10.1007/s00198 009 1125 5
   Catalano A, 2018, BONE, V116, P42, DOI 10.1016/j.bone.2018.07.010
   Chang K, 2003, BIOELECTROMAGNETICS, V24, P189, DOI 10.1002/bem.10078
   Civitelli R, 2009, OSTEOPOROSIS INT, V20, P843, DOI 10.1007/s00198 009 0838 9
   Crowe MJ, 2003, SPINE, V28, P2660, DOI 10.1097/01.BRS.0000099385.46102.0D
   Daish C, 2018, ANN BIOMED ENG, V46, P525, DOI 10.1007/s10439 018 1982 1
   de Oliveira MA, 2015, CLIN ORAL IMPLAN RES, V26, pe17, DOI 10.1111/clr.12335
   de Oliveira ML, 2010, BONE, V46, P1516, DOI 10.1016/j.bone.2010.02.009
   de Castro LF, 2010, TISSUE ENG PT A, V16, P1157, DOI [10.1089/ten.tea.2009.0355, 10.1089/ten.TEA.2009.0355]
   FERRETTI JL, 1995, BONE, V16, P119, DOI 10.1016/8756 3282(95)80021 H
   Fu JH, 2012, IMPLANT DENT, V21, P362, DOI 10.1097/ID.0b013e3182611ff6
   Gafni RI, 2002, FASEB J, V16, P736, DOI 10.1096/fj.01 0640fje
   Gifre L, 2013, BONE, V57, P272, DOI 10.1016/j.bone.2013.08.016
   Guañabens N, 2014, CURR OSTEOPOROS REP, V12, P90, DOI 10.1007/s11914 014 0197 0
   Hale LV, 2007, BONE, V40, P1103, DOI 10.1016/j.bone.2006.11.027
   Hansen KE, 2011, J BONE MINER RES, V26, P1989, DOI 10.1002/jbmr.362
   Hao YL, 2007, ACTA BIOMATER, V3, P277, DOI 10.1016/j.actbio.2006.11.002
   Jing D, 2016, SCI REP UK, V6, DOI 10.1038/srep32045
   Jing D, 2010, BONE, V46, P487, DOI 10.1016/j.bone.2009.09.021
   Kawano Tetsuya, 2017, Osteoporos Sarcopenia, V3, P185, DOI 10.1016/j.afos.2017.11.001
   Kuroda D, 1998, MAT SCI ENG A STRUCT, V243, P244, DOI 10.1016/S0921 5093(97)00808 3
   Lin CC, 2015, BIOELECTROMAGNETICS, V36, P494, DOI 10.1002/bem.21933
   Marenzana M, 2011, ARTHRITIS RHEUM US, V63, P2385, DOI 10.1002/art.30385
   Markov Marko S., 2007, Environmentalist, V27, P465, DOI 10.1007/s10669 007 9128 2
   Márquez Gamiño S, 2008, BIOELECTROMAGNETICS, V29, P406, DOI 10.1002/bem.20396
   Maruotti N, 2010, PANMINERVA MED, V52, P339
   Matsuo T, 2003, BIOSCI BIOTECH BIOCH, V67, P2518, DOI 10.1271/bbb.67.2518
   MCELHANEY J H, 1968, Journal of Biomechanics, V1, P47, DOI 10.1016/0021 9290(68)90037 7
   Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168 9525(03)00176 8
   OCONNOR BT, 1969, NATURE, V222, P162, DOI 10.1038/222162a0
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564
   Ouanounou A, 2016, J CAN DENT ASSOC, V82
   Panagopoulos DJ, 2002, BIOCHEM BIOPH RES CO, V298, P95, DOI 10.1016/S0006 291X(02)02393 8
   Pichler K, 2013, HISTOL HISTOPATHOL, V28, P1185, DOI 10.14670/HH 28.1185
   Piters E, 2008, ARCH BIOCHEM BIOPHYS, V473, P112, DOI 10.1016/j.abb.2008.03.006
   Qin YX, 1996, J ORTHOPAED RES, V14, P862, DOI 10.1002/jor.1100140604
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Shen WW, 2010, BIOELECTROMAGNETICS, V31, P113, DOI 10.1002/bem.20535
   Shi J, 2015, BONE, V79, P222, DOI 10.1016/j.bone.2015.06.014
   Snäll J, 2015, MED ORAL PATOL ORAL, V20, pE621, DOI 10.4317/medoral.20553
   TROCK DH, 1993, J RHEUMATOL, V20, P456
   van Staa TP, 2006, CALCIFIED TISSUE INT, V79, P129, DOI 10.1007/s00223 006 0019 1
   Wang J, 2014, ACTA BIOMATER, V10, P975, DOI 10.1016/j.actbio.2013.10.008
   Wang P, 2019, J CELL PHYSIOL, V234, P10588, DOI 10.1002/jcp.27734
   Wang YY, 2019, J CELL PHYSIOL, V234, P2807, DOI 10.1002/jcp.27098
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Williams GA, 2011, J BONE MINER RES, V26, P1698, DOI 10.1002/jbmr.367
   Xia XC, 2010, J BONE MINER RES, V25, P2479, DOI 10.1002/jbmr.160
   Yao W, 2016, OSTEOPOROSIS INT, V27, P283, DOI 10.1007/s00198 015 3308 6
   Yoon SH, 2019, BONE, V121, P232, DOI 10.1016/j.bone.2019.01.028
   Zheng K, 2011, J MATER SCI MATER M, V22, P1579, DOI 10.1007/s10856 011 4313 8
   Zhou J, 2019, J BONE MINER RES, V34, P1336, DOI 10.1002/jbmr.3704
   Zhou J, 2012, ARCH MED RES, V43, P274, DOI 10.1016/j.arcmed.2012.06.002
   Zhu SY, 2017, BIOELECTROMAGNETICS, V38, P406, DOI 10.1002/bem.22065
NR 71
TC 30
Z9 31
U1 1
U2 40
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2020
VL 133
AR 115266
DI 10.1016/j.bone.2020.115266
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA KR1BX
UT WOS:000517355400032
PM 32044333
DA 2025 08 17
ER

PT J
AU Li, T
   Jiang, GY
   Hu, XT
   Yang, DS
   Tan, TT
   Gao, Z
   Chen, ZY
   Xiang, C
   Li, SZ
   Ouyang, ZX
   Guo, XN
AF Li, Tao
   Jiang, Guangyao
   Hu, Xuantao
   Yang, Daishui
   Tan, Tingting
   Gao, Zhi
   Chen, Zhuoyuan
   Xiang, Cheng
   Li, Shizhen
   Ouyang, Zhengxiao
   Guo, Xiaoning
TI Punicalin Attenuates Breast Cancer Associated Osteolysis by Inhibiting
   the NF κB Signaling Pathway of Osteoclasts
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE punicalin; osteoclast; osteoporosis; osteolysis; NF kappa B; breast
   cancer; bone metastasis
ID BONE METASTASIS; DIFFERENTIATION; ANTIOXIDANT; ACTIVATION; MECHANISMS;
   DENOSUMAB; PROTEASE; TANNINS; DISEASE; MODELS
AB Background: Breast cancer bone metastasis and osteoporosis are both severe diseases that seriously threaten human health. These diseases are closely associated with osteolytic lesions. And osteoclasts are the key targets of this pathological process. Given the lack of effective preventive or treatment options against these diseases, the exploitation of new pharmacological agents is critically required. Method: We assessed the efficacy of punicalin on receptor activator of nuclear factor kappa B ligand (RANKL) mediated osteoclast formation, F actin ring formation, gene expression, bone resorption, nuclear factor kappa B (NF kappa B) as well as on mitogen activated protein kinase (MAPK) signaling pathways and molecular docking in vitro. The impact of punicalin on breast cancer induced osteoclastogenesis, breast cancer cell proliferation, and apoptosis were examined. Transwell assays were also performed. Moreover, we evaluated in vivo effects of punicalin in postmenopausal osteoporosis models and breast cancer bone metastasis model by micro CT scanning and histomorphometry. Results: Punicalin inhibited osteoclast formation, F actin ring formation, bone resorption, as well as osteoclast related gene expression by suppressing the NF kappa B signaling pathway. In vitro, punicalin also suppressed the breast cancer induced osteoclastogenesis, and proliferation, migration as well as invasion of MDA MB 231 cells and dose dependently promoted their apoptosis. In vivo, punicalin significantly suppressed breast cancer induced osteolysis, breast cancer associated bone metastasis, and ovariectomized (OVX) mediated osteoporosis by repressing osteoclast and breast cancer cell. Conclusion: Punicalin is expected to offer a novel treatment for the prevention of osteolysis diseases, including osteoporosis and breast cancer associated osteolysis.
C1 [Li, Tao; Jiang, Guangyao; Hu, Xuantao; Yang, Daishui; Gao, Zhi; Chen, Zhuoyuan; Xiang, Cheng; Ouyang, Zhengxiao; Guo, Xiaoning] Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Peoples R China.
   [Tan, Tingting] Cent South Univ, Xiangya Sch Med, Dept Immunol, Changsha, Peoples R China.
   [Li, Shizhen] Cent South Univ, Xiangya Hosp 2, Dept Geriatr, Changsha, Peoples R China.
C3 Central South University; Central South University; Central South
   University
RP Ouyang, ZX; Guo, XN (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Peoples R China.
EM ouyangzhengxiao@csu.edu.cn; guoxiaoning@csu.edu.cn
RI tan, tingting/GYQ 9346 2022; Ouyang, Zhengxiao/Q 1461 2019
FU Natural Science Foundation of Hunan Province for Youth, China
   [2019JJ50883]; Natural Science Foundation of Hunan Province for
   outstanding Young Scholars [2021JJ20086]; Innovation oriented Advanced
   Technology and Industrial Technology Program Project of Hunan Province
   [2020SK2017]
FX This work was funded by the Natural Science Foundation of Hunan Province
   for Youth, China (Grant No. 2019JJ50883), the Natural Science Foundation
   of Hunan Province for outstanding Young Scholars (Grant No. 2021JJ20086)
   and Innovation oriented Advanced Technology and Industrial Technology
   Program Project of Hunan Province (Grant No. 2020SK2017).
CR Afaq F, 2005, PHOTOCHEM PHOTOBIOL, V81, P38, DOI 10.1562/2004 08 06 RA 264.1
   Akiyama H, 2001, J ANTIMICROB CHEMOTH, V48, P487, DOI 10.1093/jac/48.4.487
   Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Casas A, 2013, BREAST, V22, P585, DOI 10.1016/j.breast.2013.05.007
   Casimiro S, 2012, CLIN EXP METASTAS, V29, P155, DOI 10.1007/s10585 011 9438 0
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 1998, BRIT J CANCER, V77, P336, DOI 10.1038/bjc.1998.52
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323
   Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012
   D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004
   Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460 2075.1995.tb00305.x
   Futakuchi M, 2016, ADV DRUG DELIVER REV, V99, P206, DOI 10.1016/j.addr.2015.11.017
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   He Y, 2014, BIOCHEM BIOPH RES CO, V449, P344, DOI 10.1016/j.bbrc.2014.05.034
   Heber D, 2008, CANCER LETT, V269, P262, DOI 10.1016/j.canlet.2008.03.043
   Hu XT, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00385
   Ikeda K, 2016, J BIOCHEM, V159, P1, DOI 10.1093/jb/mvv112
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Koga Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061346
   Lee JH, 2014, BIOCHEM PHARMACOL, V91, P51, DOI 10.1016/j.bcp.2014.06.005
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lin CC, 1999, AM J CHINESE MED, V27, P371, DOI 10.1142/S0192415X99000422
   Lin CC, 2001, PHYTOTHER RES, V15, P206, DOI 10.1002/ptr.816
   Liu CL, 2016, ANTIVIR RES, V134, P97, DOI 10.1016/j.antiviral.2016.08.026
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Martino V, 2004, PHYTOTHER RES, V18, P667, DOI 10.1002/ptr.1504
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Mundy G, 2001, SEMIN ONCOL, V28, P2, DOI 10.1053/sonc.2001.25441
   Nakai Y, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0036 5
   Ouyang ZX, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00584
   Ouyang ZX, 2018, ONCOTARGET, V9, P1868, DOI 10.18632/oncotarget.22930
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sakata T, 1999, J BONE MINER RES, V14, P1596, DOI 10.1359/jbmr.1999.14.9.1596
   Shen RT, 2021, J INFLAMM RES, V14, P711, DOI 10.2147/JIR.S299163
   Siclari VA, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058 014 0458 y
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   TAUBE T, 1994, BONE, V15, P161, DOI 10.1016/8756 3282(94)90703 X
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Valkenburg KC, 2013, CHIN J CANCER, V32, P380, DOI 10.5732/cjc.012.10218
   Van Poznak CH, 2011, J CLIN ONCOL, V29, P1221, DOI 10.1200/JCO.2010.32.5209
   Wang Y, 2013, FOOD CHEM, V138, P437, DOI 10.1016/j.foodchem.2012.10.092
   Wegener B, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 232
   Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Zhai ZJ, 2014, BREAST CANCER RES TR, V144, P33, DOI 10.1007/s10549 014 2844 7
   Zhang ZC, 2020, THERANOSTICS, V10, P4042, DOI 10.7150/thno.42218
NR 54
TC 12
Z9 12
U1 0
U2 17
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 12
PY 2021
VL 12
AR 789552
DI 10.3389/fphar.2021.789552
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA XI5IE
UT WOS:000726144300001
PM 34867423
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Javed, S
   Sohail, A
   Nutini, A
AF Javed, Sana
   Sohail, Ayesha
   Nutini, Alessandro
TI Integrative modeling of drug therapy and the bone turnover
SO CLINICAL BIOMECHANICS
LA English
DT Article
DE Denosumab; Sclerostin; Bone turnover; Mathematical modeling; Multiscale
   analysis; Astrogen; NFATc1
ID MATHEMATICAL MODEL; GENE EXPRESSION; DENOSUMAB; SCLEROSTIN; RANKL;
   OSTEOCLASTOGENESIS; PHARMACODYNAMICS; DIFFERENTIATION; ACTIVATION;
   REGULATOR
AB Background: Denosumab has been successfully used for the postmenopausal osteoporosis treatment. This research is focused on the computational analysis of the effect of denosumab on bone remodeling.
   Methods: Inspired by the advancement in the field of multiscale modeling, this research encompasses on the cellular and molecular bone remodeling key players. The model is designed to cover all the dominant interacting factors and their respective gradients. During this research, we have performed numerical experiments to validate our mathematical model, by interfacing it with the parametric values available in the literature.
   Findings: The novelty of our work relies in the fact that we have considered the effect of estrogen, sclerostin and NFATc1 during osteoporosis and their combined effect with the variable effect of denosumab during therapy.
   Interpretations: From our analysis, we have concluded that denosumab suppresses osteoclast differentiation, that results in reduced bone resorption. These results are in agreement with the experimental findings.
C1 [Javed, Sana; Sohail, Ayesha] Comsats Univ Islamabad, Dept Math, Lahore Campus, Lahore 54000, Pakistan.
   [Nutini, Alessandro] Ctr Study Motor Sci, 94 Via Tiglio, I 55100 Loc Arancio, Lucca, Italy.
C3 COMSATS University Islamabad (CUI)
RP Sohail, A (通讯作者)，Comsats Univ Islamabad, Dept Math, Lahore Campus, Lahore 54000, Pakistan.
EM asohail@cuilahore.edu.pk
RI Nutini, alessandro/AAZ 6509 2020; Sohail, A/AAP 8462 2021
OI sohail, ayesha/0000 0001 6835 6212; Nutini,
   Alessandro/0000 0003 3263 7535
FU  [5420/Federal/NRPU/R&D/HEC/2016 (HEC)]
FX The research is partially funded under grant number
   5420/Federal/NRPU/R&D/HEC/2016 (HEC).
CR AARON JE, 1987, CLIN ORTHOP RELAT R, P260
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   Barger Lux M Janet, 2002, Top Magn Reson Imaging, V13, P297
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Barrett Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Chambers T J:., 1998, ADV ORG BIO A C, V5B, P627
   Chen Charpentier BM, 2016, J COMPUT APPL MATH, V291, P76, DOI 10.1016/j.cam.2014.11.025
   DEMPSTER DW, 1995, BONE, V16, P157, DOI 10.1016/8756 3282(95)80027 N
   Diab DL, 2014, EXPERT OPIN DRUG SAF, V13, P247, DOI 10.1517/14740338.2014.860133
   Iliadis L, 2015, ENG APPL NEURAL NETW, V517
   Jabbar S, 2011, J CLIN PATHOL, V64, P354, DOI 10.1136/jcp.2010.086595
   Javed S, 2017, COMPLEX ADAPT SYST M, V5, DOI 10.1186/s40294 017 0051 1
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kim YJ, 2005, J BIOL CHEM, V280, P21515, DOI 10.1074/jbc.M502230200
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Kramer I, 2010, J BONE MINER RES, V25, P178, DOI 10.1359/jbmr.090730
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lewiecki EM, 2007, J BONE MINER RES, V22, P1832, DOI 10.1359/JBMR.070809
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Liò P, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471 2105 13 S14 S12
   Marathe A, 2008, J PHARMACOL EXP THER, V326, P555, DOI 10.1124/jpet.108.137703
   Marathe DD, 2011, BIOPHARM DRUG DISPOS, V32, P471, DOI 10.1002/bdd.770
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Miller PD, 2011, J CLIN ENDOCR METAB, V96, P394, DOI 10.1210/jc.2010 1805
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Nutini A., 2016, RUSS J BIOMECH ROSS, V20
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   RIGGS BL, 1983, AM J MED, V75, P899, DOI 10.1016/0002 9343(83)90860 4
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Ryser MD, 2010, SIAM J APPL MATH, V70, P1899, DOI 10.1137/090746094
   Scheiner S, 2014, INT J NUMER METH BIO, V30, P1, DOI 10.1002/cnm.2584
   Sohail A, 2017, COMMUN THEOR PHYS, V67, P301, DOI 10.1088/0253 6102/67/3/301
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Veverka V, 2009, J BIOL CHEM, V284, P10890, DOI 10.1074/jbc.M807994200
   Waarsing J. H., 2004, 50 ANN M ORTH RES SO
   Whitfield JF., 2007, Growing Bone, VSecond
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
NR 45
TC 2
Z9 3
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0268 0033
EI 1879 1271
J9 CLIN BIOMECH
JI Clin. Biomech.
PD DEC
PY 2018
VL 60
BP 141
EP 148
DI 10.1016/j.clinbiomech.2018.10.019
PG 8
WC Engineering, Biomedical; Orthopedics; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Orthopedics; Sport Sciences
GA HE0CE
UT WOS:000452933600021
PM 30359867
DA 2025 08 17
ER

PT J
AU Langdahl, B
AF Langdahl, Bente
TI Treatment of postmenopausal osteoporosis with bone forming and
   antiresorptive treatments: Combined and sequential approaches
SO BONE
LA English
DT Article
DE Osteoporosis; Antiresorptive; Bone forming; Dual acting; Combination
   therapy; Sequential therapy
ID VERTEBRAL FRACTURE RISK; MINERAL DENSITY; PARATHYROID HORMONE;
   RANDOMIZED TRIAL; ZOLEDRONIC ACID; TERIPARATIDE TREATMENT; ORAL
   IBANDRONATE; WOMEN; ALENDRONATE; DENOSUMAB
AB Efficient therapies are available for the treatment of osteoporosis. Bisphosphonates and denosumab are the most commonly used antiresorptive therapies. Despite differences in the increase in bone mineral density seen with these drugs, the reductions in fracture risk are similar; 50 70%, 20%, and 40% for vertebral, non vertebral and hip fractures, respectively. The bone forming treatments; teriparatide and abaloparatide increase bone mineral density more than the antiresorptives and the reductions in fracture risk are 85% and 40 50% for vertebral and non vertebral fractures, respectively, compared to placebo. The VERO study demonstrated a > 50% reduction in vertebral and clinical fractures in women treated with teriparatide compared to risedronate. The dual action treatment; romosozumab leads to more pronounced increases in BMD than other treatment modalities and reduces the risk of vertebral and clinical fractures by 73% and 36% compared to placebo after 12 months and the sequential treatment regime; romosozumab for 12 months followed by alendronate reduced the risk of vertebral, non vertebral and hip fractures by 48%, 20% and 38%, respectively compared to alendronate after 2 3 years.
   The evidence for combination therapy targeting both resorption and formation is limited as only short term studies with BMD as the endpoint have been performed.
   All bone forming and dual action treatments increase BMD and reduce the fracture risk, however, the effect wears off with time and treatment is therefore only temporary and should be followed by antiresorptive treatment with a bisphosphonate or denosumab. The sequence of treatment matters as the BMD response to teriparatide is reduced in patients previously treated with bisphosphonates; however, based on the findings of the VERO trial, the anti fracture efficacy of bone forming treatment in comparison with risedronate seems to be preserved after bisphosphonate therapy. The DATA study suggested that transitioning from denosumab to teriparatide is problematic due to the increase in bone resorption occurring after stopping denosumab. Studies have shown further improvements in BMD when transitioning from oral bisphosphonates to zoledronic acid or denosumab.
   Management of osteoporosis will in many patients include a long term treatment plan. This will often include sequential therapy which in severe cases preferably should start with bone forming followed by antiresorptive treatment. The severity of osteoporosis, reaching a treatment goal, and responding to treatment failure are important factors determining the treatment sequence in the individual patient.
C1 [Langdahl, Bente] Aarhus Univ Hosp, Endocrinol & Internal Med, Palle Juul Jensen Blvd 115, DK 8200 Aarhus N, Denmark.
C3 Aarhus University
RP Langdahl, B (通讯作者)，Aarhus Univ Hosp, Endocrinol & Internal Med, Palle Juul Jensen Blvd 115, DK 8200 Aarhus N, Denmark.
EM bente.langdahl@aarhus.rm.dk
CR Anderson GL, 2004, JAMA J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   Barrionuevo P, 2019, J CLIN ENDOCR METAB, V104, P1623, DOI 10.1210/jc.2019 00192
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2018, J CLIN ENDOCR METAB, V103, P2949, DOI 10.1210/jc.2018 00163
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Boonen S, 2008, J CLIN ENDOCR METAB, V93, P852, DOI 10.1210/jc.2007 0711
   Bouxsein ML, 2019, J BONE MINER RES, V34, P632, DOI 10.1002/jbmr.3641
   Cauley JA, 2003, JAMA J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2017, MAYO CLIN PROC, V92, P200, DOI 10.1016/j.mayocp.2016.10.009
   Cosman F, 2017, J BONE MINER RES, V32, P198, DOI 10.1002/jbmr.3051
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cosman F, 2009, J CLIN ENDOCR METAB, V94, P3772, DOI 10.1210/jc.2008 2719
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Cummings SR, 2017, J BONE MINER RES, V32, P3, DOI 10.1002/jbmr.3039
   Cummings SR, 2010, NEW ENGL J MED, V362, P686, DOI 10.1056/NEJMoa0808692
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Diez Perez A, 2012, OSTEOPOROSIS INT, V23, P2769, DOI 10.1007/s00198 012 2093 8
   Eastell R., 2019, SURROGATE THRESHOLD
   Eisman JA, 2008, J RHEUMATOL, V35, P488
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Ferrari S., 2019, J BONE MINER RES, V34
   Gasser J. A., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P53
   Geusens P, 2018, J BONE MINER RES, V33, P783, DOI 10.1002/jbmr.3384
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Hoare SRJ, 1999, J PHARMACOL EXP THER, V289, P1323
   Kendler DL, 2018, LANCET, V391, P230, DOI 10.1016/S0140 6736(17)32137 2
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Langdahl B.L.K.D., 2017, CALCIFIED TISSUE INT, V100, pS22
   Langdahl BL, 2017, LANCET, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Leder BZ, 2014, J CLIN ENDOCR METAB, V99, P1694, DOI 10.1210/jc.2013 4440
   Lewiecki EM, 2013, J CLIN ENDOCR METAB, V98, P946, DOI 10.1210/jc.2012 3680
   Lindsay R, 2006, J BONE MINER RES, V21, P366, DOI 10.1359/JBMR.051109
   Lindsay R, 2004, ARCH INTERN MED, V164, P2024, DOI 10.1001/archinte.164.18.2024
   Lou S, 2019, OSTEOPOROSIS INT, V30, P59, DOI 10.1007/s00198 018 4790 4
   Martino S, 2004, J NATL CANCER I, V96, P1751, DOI 10.1093/jnci/djh319
   McCloskey EV, 2017, OSTEOPOROSIS INT, V28, P71, DOI 10.1007/s00198 016 3696 2
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Miller PD, 2016, J CLIN ENDOCR METAB, V101, P3163, DOI 10.1210/jc.2016 1801
   Miller PD, 2008, J CLIN ENDOCR METAB, V93, P3785, DOI 10.1210/jc.2008 0353
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Muschitz C, 2014, J BONE MINER RES, V29, P1777, DOI 10.1002/jbmr.2216
   Neer R.M., 2001, N ENGL J MED, V344
   Obermayer Pietsch BM, 2008, J BONE MINER RES, V23, P1591, DOI 10.1359/JBMR.080506
   Ominsky MS, 2015, J BONE MINER RES, V30, P1280, DOI 10.1002/jbmr.2480
   Papapoulos S, 2015, OSTEOPOROSIS INT, V26, P2773, DOI 10.1007/s00198 015 3234 7
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Prince R, 2005, J BONE MINER RES, V20, P1507, DOI 10.1359/JBMR.050501
   Reginster JY, 2006, ANN RHEUM DIS, V65, P654, DOI 10.1136/ard.2005.044958
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Silverman SL, 2008, J BONE MINER RES, V23, P1923, DOI 10.1359/JBMR.080710
   TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo 110 2 506
NR 61
TC 58
Z9 65
U1 1
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2020
VL 139
AR 115516
DI 10.1016/j.bone.2020.115516
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA NH5PS
UT WOS:000564722400007
PM 32622871
DA 2025 08 17
ER

PT J
AU Pore, SK
   Hahm, ER
   Latoche, JD
   Anderson, CJ
   Shuai, YL
   Singh, SV
AF Pore, Subrata K.
   Hahm, Eun Ryeong
   Latoche, Joseph D.
   Anderson, Carolyn J.
   Shuai, Yongli
   Singh, Shivendra V.
TI Prevention of breast cancer induced osteolytic bone resorption by benzyl
   isothiocyanate
SO CARCINOGENESIS
LA English
DT Article
ID EPITHELIAL MESENCHYMAL TRANSITION; CRUCIFEROUS VEGETABLES; METASTASIS;
   TUMOR; RUNX2; RISK; BISPHOSPHONATES; CONSTITUENT; INHIBITION; MECHANISMS
AB Osteolytic bone resorption is the primary cause of pain and suffering (e.g. pathological bone fracture) in women with metastatic breast cancer. The current standard of care for patients with bone metastasis for reducing the incidence of skeletal complications includes bisphosphonates and a humanized antibody (denosumab). However, a subset of patients on these therapies still develops new bone metastasis or experiences adverse effects. Moreover, some bisphosphonates have poor oral bioavailability. Therefore, orally bioavailable and non toxic inhibitors of breast cancer induced osteolytic bone resorption are still clinically desirable. We have shown previously that benzyl isothiocyanate (BITC) decreases the incidence of breast cancer in a transgenic mouse model without any side effects. The present study provides in vivo evidence for inhibition of breast cancer induced osteolytic bone resorption by BITC. Plasma achievable doses of BITC (0.5 and 1 mu M) inhibited in vitro osteoclast differentiation induced by co culture of osteoclast precursor cells (RAW264.7) and breast cancer cells representative of different subtypes. This effect was accompanied by downregulation of key mediators of osteoclast differentiation, including receptor activator of nuclear factor kappa B ligand and runt related transcription factor 2 (RUNX2), in BITC treated breast cancer cells. Doxycycline inducible knockdown of RUNX2 augmented BITC mediated inhibition of osteoclast differentiation. Oral administration of 10 mg BITC/kg body weight, 5 times per week, inhibited MDA MB 231 induced skeletal metastasis multiplicity by similar to 81% when compared with control (P = 0.04). The present study indicates that BITC has the ability to inhibit breast cancer induced osteolytic bone resorption in vivo.
C1 [Pore, Subrata K.; Hahm, Eun Ryeong; Singh, Shivendra V.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15260 USA.
   [Latoche, Joseph D.; Anderson, Carolyn J.; Singh, Shivendra V.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
   [Latoche, Joseph D.; Anderson, Carolyn J.] Univ Pittsburgh, Sch Med, In Vivo Imaging Facil, UPMC Hillman Canc Ctr, Pittsburgh, PA USA.
   [Shuai, Yongli] Univ Pittsburgh, Sch Med, Biostat Facil, UPMC Hillman Canc Ctr, Pittsburgh, PA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh
RP Singh, SV (通讯作者)，Univ Pittsburgh, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15260 USA.; Singh, SV (通讯作者)，Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
EM singhs@upmc.edu
OI Pore, Subrata/0000 0002 6324 6994; Latoche, Joseph/0000 0002 4800 5623
FU National Cancer Institute (NCI), National Institutes of Health, USA [RO1
   CA129347, P30 CA047904]
FX National Cancer Institute (NCI), National Institutes of Health, USA [RO1
   CA129347 and P30 CA047904].
CR Ambrosone CB, 2004, J NUTR, V134, P1134, DOI 10.1093/jn/134.5.1134
   Boreddy SR, 2011, CLIN CANCER RES, V17, P1784, DOI 10.1158/1078 0432.CCR 10 1891
   Coleman RE, 2002, AM J CLIN ONCOL CANC, V25, pS32, DOI 10.1097/00000421 200212001 00006
   Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911 010 9173 1
   Dougall WC, 2012, CLIN CANCER RES, V18, P326, DOI 10.1158/1078 0432.CCR 10 2507
   Duivenvoorden WCM, 2007, BRIT J CANCER, V96, P1526, DOI 10.1038/sj.bjc.6603740
   Enomoto H, 2003, J BIOL CHEM, V278, P23971, DOI 10.1074/jbc.M302457200
   Fang YZ, 2013, JNCI J NATL CANCER I, V105, P47, DOI 10.1093/jnci/djs485
   Gnant M, 2015, LANCET, V386, P433, DOI 10.1016/S0140 6736(15)60995 3
   González Suárez E, 2016, FEBS J, V283, P2018, DOI 10.1111/febs.13645
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hahm ER, 2013, JNCI J NATL CANCER I, V105, P1111, DOI 10.1093/jnci/djt153
   Hao F, 2014, BBA REV CANCER, V1846, P247, DOI 10.1016/j.bbcan.2014.07.002
   Hergueta Redondo M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090099
   Hibberd C, 2013, CANCER GROWTH METAST, V6, P23, DOI 10.4137/CGM.S11284
   HULKA BS, 1995, LANCET, V346, P883, DOI 10.1016/S0140 6736(95)92713 1
   KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Le Gall C, 2007, CANCER RES, V67, P9894, DOI 10.1158/0008 5472.CAN 06 3940
   Le Gall Celine, 2008, Curr Opin Support Palliat Care, V2, P218, DOI 10.1097/SPC.0b013e32830baea9
   Le Pape F, 2016, J BONE ONCOL, V5, P93, DOI 10.1016/j.jbo.2016.02.008
   Lee KW, 2011, NAT REV CANCER, V11, P211, DOI 10.1038/nrc3017
   Liu XJ, 2013, BREAST, V22, P309, DOI 10.1016/j.breast.2012.07.013
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu J, 2007, ACTA PHARMACOL SIN, V28, P1365, DOI 10.1111/j.1745 7254.2007.00683.x
   Manzaneque A, 2017, INT J CLIN PHARM NET, V39, P522, DOI 10.1007/s11096 017 0455 1
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Powolny AA, 2011, JNCI J NATL CANCER I, V103, P571, DOI 10.1093/jnci/djr029
   Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555 006 9032 0
   Rao CV, 2012, CURR DRUG TARGETS, V13, P1820
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sehrawat A, 2011, CANCER PREV RES, V4, P1107, DOI 10.1158/1940 6207.CAPR 10 0306
   Siegel RL, 2016, CA CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Simmons JK, 2015, VET PATHOL, V52, P827, DOI 10.1177/0300985815586223
   Singh SV, 2012, CARCINOGENESIS, V33, P1833, DOI 10.1093/carcin/bgs216
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Subik K, 2010, BREAST CANCER BASIC, V4, P35
   Tarragona M, 2012, J BIOL CHEM, V287, P21346, DOI 10.1074/jbc.M112.355834
   Thomson CA, 2016, NUTR REV, V74, P432, DOI 10.1093/nutrit/nuw010
   Tomaskovic Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416
   van Zitteren M, 2011, CANCER EPIDEM BIOMAR, V20, P9, DOI 10.1158/1055 9965.EPI 10 0329
   Warin R, 2009, CANCER RES, V69, P9473, DOI 10.1158/0008 5472.CAN 09 2960
   WATTENBERG LW, 1977, JNCI J NATL CANCER I, V58, P395, DOI 10.1093/jnci/58.2.395
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wysokinski D, 2015, INT J MOL SCI, V16, P20969, DOI 10.3390/ijms160920969
   Xiao D, 2003, CARCINOGENESIS, V24, P891, DOI 10.1093/carcin/bgg023
   Yoneda T, 2013, WORLD J ORTHOP, V4, P178, DOI 10.5312/wjo.v4.i4.178
NR 50
TC 20
Z9 20
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143 3334
EI 1460 2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD FEB
PY 2018
VL 39
IS 2
BP 134
EP 145
DI 10.1093/carcin/bgx114
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FW7HD
UT WOS:000425491600006
PM 29040431
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Thiel, Y
   Ghayor, C
   Lindhorst, D
   Essig, H
   Weber, F
   Rücker, M
   Schumann, P
AF Thiel, Yasmin
   Ghayor, Chafik
   Lindhorst, Daniel
   Essig, Harald
   Weber, Franz
   Ruecker, Martin
   Schumann, Paul
TI Antimicrobial peptide gene expression in medication related
   osteonecrosis of the jaw
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Article
DE Bisphosphonate; Osteonecrosis; Denosumab; Defensin
ID DEFENSINS; CANCER
AB Bisphosphonates and denosumab are commonly used antiresorptive therapies in patients with bone metastasis and osteoporosis. Medication related osteonecrosis of the jaw (MRONJ) is a serious side effect of these drugs, and infection has been recognized as a contributing factor. Current therapeutic options for MRONJ show limited effectiveness, therefore necessitating novel treatment strategies. Bisphosphonates have recently been reported to induce the expression of antimicrobial peptides (AMPs), an inherent component of the immune system. Therefore, the aim of the present study was to investigate and compare the influence of the anti RANKL antibody denosumab and bisphosphonates on the gene expression of selected AMPs: human a defensin 1, human alpha defensin 3, human beta defensin 1, and human beta defensin 3. Bone specimens were collected from patients with MRONJ who had been treated with bisphosphonates (n = 6) or denosumab (n = 6), and from healthy subjects (n = 6) with no history of treatment with bone metabolism influencing drugs. Reverse transcription quantitative polymerase chain reaction was used to quantify the expression levels of selected AMPs. Samples from patients treated with denosumab showed significantly higher mRNA expression of human alpha defensin 3 and human beta defensin 3 than those from healthy subjects. This finding is similar to previously described upregulated expression of human defensins in patients with MRONJ after bisphosphonates treatment. This suggests that the elevated expression of defensins may be at least a part of the mechanism underlying the pathogenesis of osteonecrosis induced by antiresorptive therapies, which can serve as a new target for potential treatment of MRONJ.
C1 [Thiel, Yasmin; Lindhorst, Daniel; Essig, Harald; Ruecker, Martin; Schumann, Paul] Univ Hosp Zurich, Dept Oral & Maxillofacial Surg, Frauenklin Str 24, CH 8091 Zurich, Switzerland.
   [Ghayor, Chafik; Weber, Franz] Univ Zurich, Ctr Dent Med Oral Biotechnol & Bioengn, Plattenstr 11, CH 8032 Zurich, Switzerland.
   [Weber, Franz] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland.
C3 University of Zurich; University Zurich Hospital; University of Zurich;
   University of Zurich; Zurich Center Integrative Human Physiology (ZIHP)
RP Thiel, Y (通讯作者)，Univ Zurich, Univ Hosp Zurich, Div Craniomaxillofacial & Oral Surg, Frauenklin Str 24, CH 8091 Zurich, Switzerland.
EM Yasmin.Thiel@usz.ch
RI Essig, Harald/E 8415 2015; Weber, Franz/I 7831 2019
OI Ghayor, Chafik/0000 0002 3016 3412
FU ITI (International Team for Implantology) Foundation for the Promotion
   of Implantology, Switzerland [1045_214]
FX This project was supported by a grant from the ITI (International Team
   for Implantology) Foundation for the Promotion of Implantology,
   Switzerland [Grant Number: 1045_214].
CR Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Dunsche A, 2001, J ORAL PATHOL MED, V30, P154, DOI 10.1034/j.1600 0714.2001.300305.x
   Gallo RL, 1998, J INVEST DERMATOL, V111, P739, DOI 10.1046/j.1523 1747.1998.00361.x
   Gursoy U.K., 2012, J ORAL MICROBIOL, V4, P1, DOI [DOI 10.3402/JOM.V4I0.15127, 10.3402/jom.v4i0.15127]
   Henry D, 2014, SUPPORT CARE CANCER, V22, P679, DOI 10.1007/s00520 013 2022 1
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maione P, 2017, CURR MED CHEM, V24, P3, DOI 10.2174/0929867324666161118125103
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mattar EH, 2016, CYTOKINE GROWTH F R, V28, P95, DOI 10.1016/j.cytogfr.2015.11.002
   Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Schibli DJ, 2002, J BIOL CHEM, V277, P8279, DOI 10.1074/jbc.M108830200
   Stockmann P, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 135
   Taylor KH, 2010, BRIT J ORAL MAX SURG, V48, P221, DOI 10.1016/j.bjoms.2009.08.030
   Wang GS, 2014, PHARMACEUTICALS BASE, V7, P545, DOI 10.3390/ph7050545
   Warnke PH, 2006, BONE, V38, P400, DOI 10.1016/j.bone.2005.09.003
   WHO Antimicrobial Resistance, 2014, Gastrointest Endosc Clin N Am, DOI [DOI 10.1016/J.GIEC.2020.06.004, 10.1007/s13312 014 0374 3]
   Wilmes M, 2014, INT J MED MICROBIOL, V304, P93, DOI 10.1016/j.ijmm.2013.08.007
   Zirk M, 2017, J CRANIO MAXILL SURG, V45, P1183, DOI 10.1016/j.jcms.2017.05.027
NR 19
TC 6
Z9 6
U1 2
U2 9
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0344 0338
EI 1618 0631
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PD DEC
PY 2020
VL 216
IS 12
AR 153245
DI 10.1016/j.prp.2020.153245
PG 5
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA PC6XM
UT WOS:000597141600006
PM 33065485
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Mounier, L
   Morel, A
   Ferrandez, Y
   Morko, J
   Vääräniemi, J
   Gilardone, M
   Roche, D
   Cherfils, J
   Blangy, A
AF Mounier, Lucile
   Morel, Anne
   Ferrandez, Yann
   Morko, Jukka
   Vaaraniemi, Jukka
   Gilardone, Marine
   Roche, Didier
   Cherfils, Jacqueline
   Blangy, Anne
TI Novel 2,7 Diazaspiro[4,4]nonane Derivatives to Inhibit Mouse and Human
   Osteoclast Activities and Prevent Bone Loss in Ovariectomized Mice
   without Affecting Bone Formation
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HISTOMORPHOMETRY; CARTILAGE; DOCK5
AB Osteoporosis is currently treated with drugs targeting the differentiation or viability osteoclasts, the cells responsible for physiological and pathological bone resorption. Nevertheless, osteoporosis drugs that target only osteoclast activity are expected to preserve bone formation by osteoblasts in contrast to current treatments. We report here the design, synthesis, and biological characterization of a series of novel N arylsufonamides featuring a diazaspiro[4,4]nonane nucleus to target the guanine nucleotide exchange activity of DOCKS, which is essential for bone resorption by osteoclasts. These compounds can inhibit both mouse and human osteoclast activity. In particular, 4 chlorobenzyl 4 hydroxy 2 phenyl 1 thia 2,7 diazaspiro[4,4]nonane 1,1 dioxide (compound E197) prevented pathological bone loss in mice. Most interestingly, treatment with E197 did not affect osteoclast and osteoblast numbers and hence did not impair bone formation. E197 could represent a lead molecule to develop new antiosteoporotic drugs targeting the mechanism of osteoclast adhesion onto the bone.
C1 [Mounier, Lucile; Morel, Anne; Blangy, Anne] Univ Montpellier, CNRS, Ctr Rech Biol Cellulaire Montpellier, F 34000 Montpellier, France.
   [Ferrandez, Yann; Cherfils, Jacqueline] Ecole Normale Super Paris Saclay, Lab Biol & Pharmacol Appl, CNRS, F 91190 Gif Sur Yvette, France.
   [Ferrandez, Yann; Cherfils, Jacqueline] Univ Paris Saclay, F 91190 Gif Sur Yvette, France.
   [Morko, Jukka; Vaaraniemi, Jukka] Pharmatest Serv Ltd, Turku 20520, Finland.
   [Gilardone, Marine; Roche, Didier] Edelris, F 69008 Lyon, France.
C3 Universite de Montpellier; Centre National de la Recherche Scientifique
   (CNRS); Universite Paris Saclay; Centre National de la Recherche
   Scientifique (CNRS); Universite Paris Saclay; Pharmatest Services
RP Blangy, A (通讯作者)，Univ Montpellier, CNRS, Ctr Rech Biol Cellulaire Montpellier, F 34000 Montpellier, France.
EM anne.blangy@crbm.cnrs.fr
OI BLANGY, Anne/0000 0001 7043 0784; ferrandez, yann/0000 0002 5248 0742
FU French Centre National de la Recherche Scientifique (CNRS), Montpellier
   University; Fondation pour la Recherche Medicale [DEQ20160334933]; grant
   AxLR Dock5 from the Societe d'Acceleration du Transfert de Technologies
   (SATT) AxLR; LabEx LERMIT; French National Research Agency
   [ANR 10 INBS 04]
FX This study was supported by the French Centre National de la Recherche
   Scientifique (CNRS), Montpellier University, by grant DEQ20160334933
   from the Fondation pour la Recherche Medicale and grant AxLR Dock5 from
   the Societe d'Acceleration du Transfert de Technologies (SATT) AxLR to
   A.B. and by a grant from the LabEx LERMIT to J.C. We specially thank
   Marc Criton from SATT AxLR for fruitful discussions and advice. We
   acknowledge the imaging facility MRI (Montpellier, France), member of
   the national infrastructure France BioImaging supported by the French
   National Research Agency (ANR 10 INBS 04, "Investments for the future").
CR Bettis T, 2018, OSTEOPOROSIS INT, V29, P1713, DOI 10.1007/s00198 018 4570 1
   Blangy A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.244798
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brazier H, 2006, J BONE MINER RES, V21, P1387, DOI 10.1359/JBMR.060613
   Brazier H, 2009, INT J BIOCHEM CELL B, V41, P1391, DOI 10.1016/j.biocel.2008.12.007
   Buckley L, 2018, NEW ENGL J MED, V379, P2547, DOI 10.1056/NEJMcp1800214
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Coury F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00679
   Craven P, 2015, BIOORGAN MED CHEM, V23, P2629, DOI 10.1016/j.bmc.2014.12.048
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Deeks ED, 2018, DRUG AGING, V35, P163, DOI 10.1007/s40266 018 0525 7
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Drissi H, 2016, J CELL BIOCHEM, V117, P1753, DOI 10.1002/jcb.25560
   Erben RG, 2012, METHODS MOL BIOL, V816, P279, DOI 10.1007/978 1 61779 415 5_19
   Ferrandez Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13619 2
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Idris AI, 2012, METHODS MOL BIOL, V816, P545, DOI 10.1007/978 1 61779 415 5_34
   Mackie EJ, 2008, INT J BIOCHEM CELL B, V40, P46, DOI 10.1016/j.biocel.2007.06.009
   Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Murphy MG, 2005, J CLIN ENDOCR METAB, V90, P2022, DOI 10.1210/jc.2004 2126
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Peurois F, 2017, BIOCHEM J, V474, P1259, DOI 10.1042/BCJ20170015
   Pozzi S, 2009, CLIN CANCER RES, V15, P5829, DOI 10.1158/1078 0432.CCR 09 0426
   Raynaud Messina B, 2019, BONE, V127, P315, DOI 10.1016/j.bone.2019.06.023
   Rissanen JP, 2010, EXPERT OPIN DRUG DIS, V5, P1163, DOI 10.1517/17460441.2010.532484
   Sato D, 2018, BONE, V116, P172, DOI 10.1016/j.bone.2018.07.026
   Stone JA, 2019, BRIT J CLIN PHARMACO, V85, P1072, DOI 10.1111/bcp.13869
   Teitelbaum SL, 2016, RHEUMATOLOGY, V55, P61, DOI 10.1093/rheumatology/kew350
   Touaitahuata H, 2014, DEV BIOL, V393, P57, DOI 10.1016/j.ydbio.2014.06.020
   van't Hof RJ, 2012, METHODS MOL BIOL, V816, P461, DOI 10.1007/978 1 61779 415 5_27
   Vives V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7218
   Vives V, 2011, J BONE MINER RES, V26, P1099, DOI 10.1002/jbmr.282
   Zhou A, 2009, ORG LETT, V11, P531, DOI 10.1021/ol802467f
NR 36
TC 10
Z9 10
U1 3
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD NOV 25
PY 2020
VL 63
IS 22
BP 13680
EP 13694
DI 10.1021/acs.jmedchem.0c01201
PG 15
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA PA3NV
UT WOS:000595545900026
PM 33175535
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Zhang, Q
   Ma, WL
   Wang, Q
   Gao, H
   Sun, JM
AF Zhang, Qiang
   Ma, Wanli
   Wang, Qing
   Gao, Hua
   Sun, Jianmin
TI Effect of Yang He Decoction on Treatment of Bone Tuberculosis via
   Phosphoinositide 3 Kinases/Protein Kinase B and Mitogen Activated
   Protein Kinase Signaling Pathways
SO NATURAL PRODUCT COMMUNICATIONS
LA English
DT Article
DE bone tuberculosis; Yang He Decoction; network pharmacology; PI3K;
   Akt MAPK signaling pathway
ID OSTEOCLAST DIFFERENTIATION; CELLS
AB Yang He Decoction (YHD), a classical Chinese medicine prescription, is used to treat bone and joint diseases. However, there are few mechanism studies for YHD on the use of YHD to treat bone tuberculosis (BT) and the corresponding mechanism of action of YHD. In the present study, the chemical ingredients of YHD and targets of the ingredients were revealed by a network pharmacology method, and an ingredient target disease network was visualized and analyzed. Then, gene ontology enrichment analysis and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis were carried out. In addition, molecular docking was performed to clarify the binding of the key active ingredients of YHD to the key targets. Further, an in vitro model of Mycobacterium tuberculosis induced BT was established, and a mechanism for the inhibitory effect of YHD on the differentiation of RAW 264.7 cells into osteoclasts was investigated. A total of 138 active ingredients in YHD and 50 targets between YHD ingredients and BT were identified. The phosphatidylinositol 3 kinase protein kinase B (PI3K Akt) and mitogen activated protein kinase (MAPK) signaling pathways were the key pathways involved in the anti BT effect of YHD. Moreover, the in vitro results showed that YHD inhibited the differentiation of RAW 264.7 cells into osteoclasts. YHD decreased the levels of tumor necrosis factor alpha and interleukin 1 beta, increased the levels of superoxide dismutase and glutathione peroxide, and decreased the level of malondialdehyde. Further, YHD inhibited the protein and messenger RNA expression of PI3K/Akt, p38 MAPK, and c Jun N terminal kinase. These findings show that YHD is a promising anti BT agent that suppresses the PI3K/Akt and MAPK signaling pathways to inhibit the differentiation of RAW 264.7 cells into osteoclasts and ameliorate inflammation and oxidative stress.
C1 [Zhang, Qiang; Wang, Qing; Gao, Hua; Sun, Jianmin] Shandong Univ, Cheeloo Coll Med, Shandong Prov Hosp, Jinan, Shandong, Peoples R China.
   [Zhang, Qiang] Shandong Univ, Cheeloo Coll Med, Shandong Prov Chest Hosp, Jinan, Shandong, Peoples R China.
   [Ma, Wanli] Shandong Univ, Hosp 2, Cheeloo Coll Med, Jinan, Shandong, Peoples R China.
C3 Shandong University; Shandong First Medical University & Shandong
   Academy of Medical Sciences; Shandong University; Shandong University
RP Sun, JM (通讯作者)，Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Spine, Jinan 250021, Shandong, Peoples R China.
EM sunjmsunjmsd@163.com
RI Ma, wanli/HPH 0786 2023; Sun, Jianmin/AAX 5094 2021
FU Traditional Chinese Medicine Science and Technology Development Plan of
   Shandong Province [2019 0524]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by the Traditional Chinese Medicine Science and Technology
   Development Plan of Shandong Province (grant number No.2019 0524).
CR Braun T, 2012, CURR OSTEOPOROS REP, V10, P101, DOI 10.1007/s11914 012 0104 5
   Casimiro S, 2012, CLIN EXP METASTAS, V29, P155, DOI 10.1007/s10585 011 9438 0
   Chen X, 2021, BONE JOINT RES, V10, P237, DOI 10.1302/2046 3758.104.BJR 2020 0255.R2
   Dai SY, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/6664489
   Elzein F, 2020, MED MYCOL CASE REP, V27, P4, DOI 10.1016/j.mmcr.2019.12.006
   Guo W, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/5556212
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Ito S, 2016, BIOSCI BIOTECH BIOCH, V80, P779, DOI 10.1080/09168451.2015.1127133
   Ji QL, 2020, PHARMAZIE, V75, P505, DOI 10.1691/ph.2020.9927
   Jiang YB, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/2361865
   Kim K, 2020, MOL CELLS, V43, P34, DOI 10.14348/molcells.2019.0232
   Konda VR, 2009, J INFLAMM LOND, V6, DOI 10.1186/1476 9255 6 26
   Li J, 2019, BIOCHIMIE, V156, P129, DOI 10.1016/j.biochi.2018.09.004
   Liu CS, 2021, PHYTOMEDICINE, V82, DOI 10.1016/j.phymed.2020.153458
   Liu H, 2020, MICROB PATHOGENESIS, V148, DOI 10.1016/j.micpath.2020.104456
   Ma BE, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.645354
   Onaitis MW, 2006, ANN SURG, V244, P420, DOI 10.1097/01.sla.0000234892.79056.63
   Prasadam I, 2014, MOL CELL BIOCHEM, V386, P15, DOI 10.1007/s11010 013 1840 2
   Saito Z, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879 016 2000 6
   Sun XC, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00360
   Teramachi J, 2010, EXP CELL RES, V316, P3254, DOI 10.1016/j.yexcr.2010.08.006
   Ueta M, 2019, MOL MED REP, V20, P4331, DOI 10.3892/mmr.2019.10662
   Wang YQ, 2018, MED SCI MONITOR, V24, P2912, DOI 10.12659/MSM.909740
   Wen SA, 2021, INT J INFECT DIS, V103, P364, DOI 10.1016/j.ijid.2020.11.203
   Xu XS, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021877
   [杨国强 Yang Guoqiang], 2020, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V36, P234
   Zhang L, 2020, J CELL BIOCHEM, V121, P497, DOI 10.1002/jcb.29247
   Zheng MX, 2014, INT ORTHOP, V38, P627, DOI 10.1007/s00264 013 2184 y
   Zhou SS, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00425
NR 29
TC 0
Z9 0
U1 1
U2 12
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1934 578X
EI 1555 9475
J9 NAT PROD COMMUN
JI Nat. Prod. Commun.
PD MAR
PY 2022
VL 17
IS 3
AR 1934578X221075080
DI 10.1177/1934578X221075080
PG 11
WC Chemistry, Medicinal; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Food Science & Technology
GA ZP1IW
UT WOS:000766179600001
OA gold
DA 2025 08 17
ER

PT J
AU Ohe, JY
   Kwon, YD
   Lee, HW
AF Ohe, Joo Young
   Kwon, Yong Dae
   Lee, Hyeon Woo
TI Bisphosphonates modulate the expression of OPG and M CSF in hMSC derived
   osteoblasts
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Bisphosphonates(BPs); BMSC; M CSF; OPG; BPONJ
ID IN VITRO; OSTEOCLAST FORMATION; MEVALONATE PATHWAY; BONE RESORPTION;
   CELLS; JAW; OSTEONECROSIS; FIBROBLASTS; INHIBITION; MECHANISM
AB Bisphosphonates have been known to suppress osteoclast activity, survival, and recruitment. In this study, we tested effects of BPs on expression of two critical genes for osteoclastogenesis, M CSF, and OPG in the process of osteoblast differentiation from hMSC. (1) The cells were cultured in osteogenic induction medium together with 0 (control group) and 10 8 M alendronate, pamidronate for up 2 and 3 weeks (for real time PCR) and 3 and 4 weeks (for ELISA). (2) The real time PCR protocol for M CSF, OPG, and glyceraldehyde 3 phosphate dehydrogenase (GAPDH) consist of 40 cycles. (3) Enzyme linked immunosorbent assay (ELISA): the amounts of M CSF and OPG in the culture medium were determined using commercially available ELISA kits for M CSF and OPG. Treatment of differentiating cells with alendronate or pamidronate, nitrogen containing BPs increase the expression of OPG, which suppresses osteoclastogenesis, whereas it decreases the expression of M CSF, which enhances preosteoclast formation. These results suggest a new mechanism by which BPs inhibit osteoclastogenesis. Results support hypothesis that progressive accumulation of bisphosphonate in jaws causes imbalance in osteogenesis and bone absorption and collateral osteoclast osteoblast interaction. Bisphosphonate related osteonecrosis of jaw (BPONJ) is one of the most serious complications of bisphosphonate (BP) therapy. However, the mechanism behind the this process of BPONJ is still unclear and there are so many hypotheses. Among many hypotheses, we focused on osteoclast osteoblast interaction in this study. The findings of this study show new light on the present BPONJ occurrence theory based on the osteoclastic activity of BPs. Also, a more advanced and developed theory for BRONJ occurrence may be obtained by combining the osteoclast inhibition mechanism and the effects on osteoblastic differentiation by BPs.
C1 [Ohe, Joo Young; Kwon, Yong Dae] Kyung Hee Univ, Dept Oral & Maxillofacial Surg, Sch Dent, Inst Oral Biol, Seoul 130701, South Korea.
   [Lee, Hyeon Woo] Kyung Hee Univ, Sch Dent, Dept Dent Pharmacol, Inst Oral Biol, Seoul 130701, South Korea.
C3 Kyung Hee University; Kyung Hee University
RP Kwon, YD (通讯作者)，Kyung Hee Univ, Dept Oral & Maxillofacial Surg, Sch Dent, Inst Oral Biol, Hoegi Dong 1, Seoul 130701, South Korea.
EM yongdae.kwon@gmail.com
RI ; Lee, Hyeon/ABF 4059 2020; Kwon, Yong Dae/ABF 2991 2020
OI Kwon, Yong Dae/0000 0001 9620 4814; 
FU Kyung Hee University [20091412]
FX This study was supported by Kyung Hee University (Grant No. 20091412).
CR Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Aubin J., 2002, PRINCIPLES BONE BIOL, V2nd
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Bertoldo F, 2007, NAT CLIN PRACT ONCOL, V4, P711, DOI 10.1038/ncponc1000
   BOONEKAMP PM, 1986, BONE MINER, V1, P27
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Hoefert S, 2010, CLIN ORAL INVEST, V14, P271, DOI 10.1007/s00784 009 0300 6
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim TW, 1999, AM J ORTHOD DENTOFAC, V115, P645, DOI 10.1016/S0889 5406(99)70290 8
   Koch FP, 2012, CLIN ORAL INVEST, V16, P79, DOI 10.1007/s00784 010 0477 8
   Kyrgidis A, 2009, CLIN ORAL INVEST, V13, P479, DOI 10.1007/s00784 009 0319 8
   Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092 8674(00)80290 1
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Pabst AM, 2012, CLIN ORAL INVEST, V16, P87, DOI 10.1007/s00784 010 0507 6
   Risbud MV, 2006, SPINE, V31, P83, DOI 10.1097/01.brs.0000193891.71672.e4
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rogers MJ, 1996, J BONE MINER RES, V11, P1482
   Rustemeyer J, 2010, CLIN ORAL INVEST, V14, P59, DOI 10.1007/s00784 009 0294 0
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Simon MJK, 2010, CLIN ORAL INVEST, V14, P51, DOI 10.1007/s00784 009 0312 2
   Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098 2795(199701)46:1<4::AID MRD2>3.0.CO;2 V
   Walter C, 2010, CLIN ORAL INVEST, V14, P35, DOI 10.1007/s00784 009 0266 4
   Ziebart T, 2011, CLIN ORAL INVEST, V15, P105, DOI 10.1007/s00784 009 0365 2
NR 28
TC 25
Z9 29
U1 0
U2 19
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD AUG
PY 2012
VL 16
IS 4
BP 1153
EP 1159
DI 10.1007/s00784 011 0614 z
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 976MW
UT WOS:000306590000018
PM 21938481
DA 2025 08 17
ER

PT J
AU Lazzaro, L
   Tonkin, BA
   Poulton, IJ
   McGregor, NE
   Ferlin, W
   Sims, NA
AF Lazzaro, Leah
   Tonkin, Brett A.
   Poulton, Ingrid J.
   McGregor, Narelle E.
   Ferlin, Walter
   Sims, Natalie A.
TI IL 6 trans signalling mediates trabecular, but not cortical, bone
   loss after ovariectomy
SO BONE
LA English
DT Article
DE IL 6; Cytokines; Ovariectomy; Histomorphometry; gp130; osteoclast;
   cortical bone
ID OSTEOCLAST FORMATION; SOLUBLE INTERLEUKIN 6; IN VIVO; RECEPTOR ALPHA;
   DEFICIENT MICE; CELLS; RESORPTION; INDUCTION; CYTOKINES; LIGAND
AB Bone loss associated with estrogen deficiency occurs due to a high level of bone remodelling, with a greater increase in the level of osteoclast mediated bone resorption than osteoblast mediated bone formation. Early studies showed that Interleukin 6 (IL 6) inhibition could prevent the increase in osteoclast numbers associated with ovariectomy. However, IL 6 signals through two possible pathways: classic IL 6 signalling (cis) utilizes a membrane bound IL 6 receptor (IL 6R), while IL 6 trans signalling occurs through a soluble IL 6R (sIL 6R). It is not known which of these pathways mediates the bone loss after ovariectomy. We therefore sought to determine whether specific pharmacological inhibition of IL 6 trans signalling could prevent ovariectomy induced bone loss in mice. We report that IL 6 trans signalling inhibition prevented the increase in osteoclasts, and trabecular bone loss, associated with ovariectomy. IL 6 trans signalling inhibition also reduced bone formation rate, but did not prevent the increase in osteoblast numbers. In contrast, cortical bone loss was not prevented by any IL 6 signalling inhibitor. This suggests that local production of sIL 6R mediates trabecular bone loss in estrogen deficiency, but the increased cortical bone resorption that leads to marrow expansion is independent of IL 6 signalling.
C1 [Lazzaro, Leah; Tonkin, Brett A.; Poulton, Ingrid J.; McGregor, Narelle E.; Sims, Natalie A.] St Vincents Inst Med Res, Fitzroy, Vic, Australia.
   [Lazzaro, Leah; Sims, Natalie A.] Univ Melbourne, Dept Med, St Vincents Hosp, Fitzroy, Vic, Australia.
   [Ferlin, Walter] NovImmune SA, Geneva, Switzerland.
C3 St. Vincent's Institute of Medical Research; NSW Health; St Vincents
   Hospital Sydney; University of Melbourne; St Vincent's Health; St
   Vincent's Hospital Melbourne; NovImmune SA
RP Sims, NA (通讯作者)，9 Princes St, Fitzroy, Vic 3065, Australia.
EM nsims@svi.edu.au
RI Sims, Natalie/A 7192 2012
OI Sims, Natalie/0000 0003 1421 8468
FU National Health and Medical Research Council (Australia) [1081242];
   State Government of Victoria OIS Program; National Health and Medical
   Research Council of Australia [1081242] Funding Source: NHMRC
FX The authors thank staff at the BioResources Centre, St. Vincent's
   Hospital Melbourne for excellent animal care, T John Martin for helpful
   reading and critique of the manuscript, and Brendan J Jenkins for advice
   in the early stages of the project. This work was supported by a
   National Health and Medical Research Council (Australia) Project Grant
   1081242 to N.A.S. and T John Martin, and by the State Government of
   Victoria OIS Program.
CR Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068
   Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666
   Briso EM, 2008, J IMMUNOL, V180, P7102, DOI 10.4049/jimmunol.180.11.7102
   Brooks GD, 2016, CANCER RES, V76, P866, DOI 10.1158/0008 5472.CAN 15 2388
   Emerton KB, 2010, BONE, V46, P577, DOI 10.1016/j.bone.2009.11.006
   Erben RG, 1996, ANAT REC, V246, P39, DOI 10.1002/(SICI)1097 0185(199609)246:1<39::AID AR5>3.0.CO;2 A
   Gao Y, 1998, BONE, V22, P487, DOI 10.1016/S8756 3282(98)00040 4
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Girasole G, 1999, CLIN ENDOCRINOL, V51, P801, DOI 10.1046/j.1365 2265.1999.00896.x
   Hashizume M, 2008, RHEUMATOLOGY, V47, P1635, DOI 10.1093/rheumatology/ken363
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   Johnson RW, 2015, BONE, V81, P343, DOI 10.1016/j.bone.2015.08.005
   Johnson RW, 2014, J BONE MINER RES, V29, P1492, DOI 10.1002/jbmr.2159
   Kimble RB, 1997, J BONE MINER RES, V12, P935, DOI 10.1359/jbmr.1997.12.6.935
   KITAZAWA R, 1994, J CLIN INVEST, V94, P2397, DOI 10.1172/JCI117606
   Lacroix M, 2015, J BIOL CHEM, V290, P26943, DOI 10.1074/jbc.M115.682138
   Lee SK, 2006, J BONE MINER RES, V21, P1704, DOI 10.1359/JBMR.060726
   Li CY, 2005, J BONE MINER RES, V20, P2150, DOI 10.1359/JBMR.050819
   Li JY, 2011, P NATL ACAD SCI USA, V108, P768, DOI 10.1073/pnas.1013492108
   Lissilaa R, 2010, J IMMUNOL, V185, P5512, DOI 10.4049/jimmunol.1002015
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Modur V, 1997, J CLIN INVEST, V100, P2752, DOI 10.1172/JCI119821
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   Scheller J, 2014, SEMIN IMMUNOL, V26, P2, DOI 10.1016/j.smim.2013.11.002
   Sims NA, 2006, AM J PHYSIOL ENDOC M, V290, pE456, DOI 10.1152/ajpendo.00311.2005
   Sims NA, 2005, J BONE MINER RES, V20, P1093, DOI 10.1359/JBMR.050209
   Sims NA, 2004, J CLIN INVEST, V113, P379, DOI 10.1172/JCI200419872
   Sims NA, 2016, INT J BIOCHEM CELL B, V79, P14, DOI 10.1016/j.biocel.2016.08.003
   Sims NA, 2014, ARCH BIOCHEM BIOPHYS, V561, P22, DOI 10.1016/j.abb.2014.05.015
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Tokuyama Naoto, 2015, Bone Rep, V2, P1, DOI 10.1016/j.bonr.2014.12.002
   Tonna S, 2016, DEVELOPMENT, V143, P648, DOI 10.1242/dev.125625
   Vermes C, 2002, J BIOL CHEM, V277, P16879, DOI 10.1074/jbc.M200546200
   Wong PKK, 2006, ARTHRITIS RHEUM US, V54, P158, DOI 10.1002/art.21537
   WRONSKI TJ, 1989, BONE, V10, P295, DOI 10.1016/8756 3282(89)90067 7
NR 37
TC 33
Z9 36
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2018
VL 112
BP 120
EP 127
DI 10.1016/j.bone.2018.04.015
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GI4WE
UT WOS:000434371100013
PM 29679733
DA 2025 08 17
ER

PT J
AU Vollersen, N
   Zhao, WB
   Rolvien, T
   Lange, F
   Schmidt, FN
   Sonntag, S
   Shmerling, D
   von Kroge, S
   Stockhausen, KE
   Sharaf, A
   Schweizer, M
   Karsak, M
   Busse, B
   Bockamp, E
   Semler, O
   Amling, M
   Oheim, R
   Schinke, T
   Yorgan, TA
AF Vollersen, Nele
   Zhao, Wenbo
   Rolvien, Tim
   Lange, Fabiola
   Schmidt, Felix Nikolai
   Sonntag, Stephan
   Shmerling, Doron
   von Kroge, Simon
   Stockhausen, Kilian Elia
   Sharaf, Ahmed
   Schweizer, Michaela
   Karsak, Meliha
   Busse, Bjoern
   Bockamp, Ernesto
   Semler, Oliver
   Amling, Michael
   Oheim, Ralf
   Schinke, Thorsten
   Yorgan, Timur Alexander
TI The WNT1<SUP>G177C</SUP> mutation specifically affects skeletal
   integrity in a mouse model of osteogenesis imperfecta type XV
SO BONE RESEARCH
LA English
DT Article
ID TRABECULAR ARCHITECTURE; INT 1 PROTOONCOGENE; WNT1 MUTATIONS; BONE;
   GENE; OSTEOPOROSIS; DENSITY; OSTEOCLASTOGENESIS; SCLEROSTIN; EXPRESSION
AB The recent identification of homozygous WNT1 mutations in individuals with osteogenesis imperfecta type XV (OI XV) has suggested that WNT1 is a key ligand promoting the differentiation and function of bone forming osteoblasts. Although such an influence was supported by subsequent studies, a mouse model of OI XV remained to be established. Therefore, we introduced a previously identified disease causing mutation (G177C) into the murine Wnt1 gene. Homozygous Wnt1(G177C/G177C) mice were viable and did not display defects in brain development, but the majority of 24 week old Wnt1(G177C/G177C) mice had skeletal fractures. This increased bone fragility was not fully explained by reduced bone mass but also by impaired bone matrix quality. Importantly, the homozygous presence of the G177C mutation did not interfere with the osteoanabolic influence of either parathyroid hormone injection or activating mutation of LRP5, the latter mimicking the effect of sclerostin neutralization. Finally, transcriptomic analyses revealed that short term administration of WNT1 to osteogenic cells induced not only the expression of canonical WNT signaling targets but also the expression of genes encoding extracellular matrix modifiers. Taken together, our data demonstrate that regulating bone matrix quality is a primary function of WNT1. They further suggest that individuals with WNT1 mutations should profit from existing osteoanabolic therapies.
C1 [Vollersen, Nele; Zhao, Wenbo; Rolvien, Tim; Lange, Fabiola; Schmidt, Felix Nikolai; von Kroge, Simon; Stockhausen, Kilian Elia; Busse, Bjoern; Amling, Michael; Oheim, Ralf; Schinke, Thorsten; Yorgan, Timur Alexander] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, D 20246 Hamburg, Germany.
   [Sonntag, Stephan; Shmerling, Doron] PolyGene AG, CH 8153 Rumlang, Switzerland.
   [Sonntag, Stephan] Swiss Fed Inst Technol, ETH Phen Ctr Epic, CH 8092 Zurich, Switzerland.
   [Sharaf, Ahmed; Karsak, Meliha] Univ Med Ctr Hamburg Eppendorf, Ctr Mol Neurobiol Hamburg ZMNH, Neuronal & Cellular Signal Transduct, D 20246 Hamburg, Germany.
   [Schweizer, Michaela] Univ Med Ctr, Ctr Mol Neurobiol Hamburg ZMNH, D 20246 Hamburg, Germany.
   [Bockamp, Ernesto] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Translat Immunol & Res Ctr Immunotherapy, D 55131 Mainz, Germany.
   [Semler, Oliver] Univ Cologne, Fac Med, Dept Pediat, D 50937 Cologne, Germany.
   [Semler, Oliver] Univ Cologne, Univ Hosp Cologne, D 50937 Cologne, Germany.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   Swiss Federal Institutes of Technology Domain; ETH Zurich; University of
   Hamburg; University Medical Center Hamburg Eppendorf; University of
   Hamburg; University Medical Center Hamburg Eppendorf; Johannes Gutenberg
   University of Mainz; University of Cologne; University of Cologne
RP Schinke, T; Yorgan, TA (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, D 20246 Hamburg, Germany.
EM schinke@uke.de; t.yorgan@uke.de
RI Oheim, Ralf/KPA 2969 2024; Busse, Björn/AAC 4033 2020
OI Bockamp, Ernesto/0000 0002 6181 1734; Sharaf, Ahmed/0009 0002 9163 5644;
   Karsak, Meliha/0000 0001 6612 6317; von Brackel,
   Felix/0000 0001 6586 6794; von Kroge, Simon/0000 0002 2898 5732; Zhao,
   Wenbo/0000 0002 3418 9433
FU Deutsche Forschungsgemeinschaft [SCHI 504/15 1, YO 299/1 1, FOR 2722,
   SE2373/1 1]; European Community's Seventh Framework Programme [602300];
   German Federal Ministry of Education and Research (BMBF); China
   Scholarship Council
FX We would like to thank the UKE research animal facility for their
   services. Moreover, we would like to express our gratitude to Stephanie
   Peters, Olga Winter, Mona Neven, Lana Rosenthal, Elke Leicht, and Marion
   Dietzmann for their technical assistance. We thank Irm Hermans Borgmeyer
   for providing access to the Flp deleter line. This project has received
   funding from the Deutsche Forschungsgemeinschaft (SCHI 504/15 1 and YO
   299/1 1), the European Community's Seventh Framework Programme under
   grant agreement no. 602300 (SYBIL), and the German Federal Ministry of
   Education and Research (BMBF) within the project "Detection and
   Individualized Management of Early Onset Osteoporosis (DIMEOS)". Parts
   of this work were supported by the Deutsche Forschungsgemeinschaft
   through FOR 2722 to O.S. (SE2373/1 1). W.Z. received funding through the
   China Scholarship Council.
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Albers J, 2011, J CELL BIOL, V192, P1057, DOI 10.1083/jcb.201008012
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bonnet N, 2016, MOL CELL ENDOCRINOL, V432, P85, DOI 10.1016/j.mce.2015.12.014
   Bonnet N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078347
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Busse B, 2010, AGING CELL, V9, P1065, DOI 10.1111/j.1474 9726.2010.00633.x
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Fahiminiya S, 2013, J MED GENET, V50, P345, DOI 10.1136/jmedgenet 2013 101567
   Gatti D, 2005, J BONE MINER RES, V20, P1323, DOI 10.1359/JBMR.050312
   Gerbaix M, 2015, BONE, V71, P94, DOI 10.1016/j.bone.2014.10.011
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   Heckt T, 2016, BONE, V92, P85, DOI 10.1016/j.bone.2016.08.016
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Joeng KS, 2014, HUM MOL GENET, V23, P4035, DOI 10.1093/hmg/ddu117
   Joiner DM, 2013, TRENDS ENDOCRIN MET, V24, P31, DOI 10.1016/j.tem.2012.10.003
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kelly NH, 2016, BONE, V86, P22, DOI 10.1016/j.bone.2016.02.007
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Koehne T, 2014, BONE, V66, P31, DOI 10.1016/j.bone.2014.05.010
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li ZQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035754
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Luther J, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aau7137
   Marini JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.52
   Marini JC, 2014, CURR OPIN PEDIATR, V26, P500, DOI 10.1097/MOP.0000000000000117
   MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092 8674(90)90385 R
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Palomo T, 2017, CURR OPIN ENDOCRINOL, V24, P381, DOI 10.1097/MED.0000000000000367
   Pyott SM, 2013, AM J HUM GENET, V92, P590, DOI 10.1016/j.ajhg.2013.02.009
   Richards JS, 2012, ONCOGENE, V31, P1504, DOI 10.1038/onc.2011.341
   Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859 017 1934 z
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Schneider AJ, 2014, INT J MOL SCI, V15, P17852, DOI 10.3390/ijms151017852
   Schulze J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010309
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Takahashi M, 2002, CANCER RES, V62, P5651
   Tashima T, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003 018 0038 2
   Tashima T, 2015, BIOCHEM BIOPH RES CO, V463, P292, DOI 10.1016/j.bbrc.2015.05.053
   THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0
   THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092 8674(91)90369 A
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   van Dijk FS, 2013, NEW ENGL J MED, V369, P1529, DOI 10.1056/NEJMoa1308223
   Wang F, 2019, J BONE MINER RES, V34, P1129, DOI 10.1002/jbmr.3680
   Yorgan TA, 2015, J BONE MINER RES, V30, P1175, DOI 10.1002/jbmr.2461
   Yorgan TA, 2020, J BONE MINER RES, V35, P1726, DOI 10.1002/jbmr.4043
   Yorgan TA, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115062
   Zimmermann EA, 2019, J BONE MINER RES, V34, P1461, DOI 10.1002/jbmr.3730
NR 53
TC 20
Z9 21
U1 1
U2 7
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD NOV 10
PY 2021
VL 9
IS 1
AR 48
DI 10.1038/s41413 021 00170 0
PG 13
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA WV0PB
UT WOS:000716937900001
PM 34759273
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jobke, B
   Milovanovic, P
   Amling, M
   Busse, B
AF Jobke, Bjorn
   Milovanovic, Petar
   Amling, Michael
   Busse, Bjorn
TI Bisphosphonate osteoclasts: Changes in osteoclast morphology and
   function induced by antiresorptive nitrogen containing bisphosphonate
   treatment in osteoporosis patients
SO BONE
LA English
DT Article
DE Osteoclasts; Bisphosphonates; Osteoporosis; Bone histomorphometry;
   Bisphosphonate osteoclasts
ID LOW BONE MASS; POSTMENOPAUSAL WOMEN; IN VIVO; FEMORAL FRACTURES;
   TURNOVER; ALENDRONATE; THERAPY; DENOSUMAB; RISEDRONATE; PREVENTION
AB Osteoclasts are unique cells capable of bone resorption and therefore have become a major target in osteoporosis treatment strategies. Bisphosphonates suppress bone turnover via interference with the internal enzymatic cell system of osteoclasts leading to cytoskeletal disruption. This mechanism found its clinical relevance in reducing bone resorption, stabilizing bone mass and reducing fracture risk in osteoporosis patients. However, knowledge about specific in vivo changes in osteoclast cell morphology and function is still insufficient. We examined osteoclasts in 23 paired bone biopsies from osteoporosis patients (18 males, 5 females; age: 52.6 +/  11.5 yrs) under nitrogen containing bisphosphonate administration with a mean treatment duration of three years. Formalin fixed, undecalcified sections were assessed by qualitative and quantitative bone histomorphometry, where the osteoclast morphology, nuclei, distribution, location as well as resorption parameters were investigated to obtain information about cell function and viability. After three years of treatment, resorption parameters decreased significantly while the number of osteoclasts remained unchanged. Out of 23 patients, nine developed previously termed "giant osteodasts" with increased size, numerous nuclei (>10 nuclei/Oc) and oftentimes detachment from the bone surface. These cells frequently had pycnotic nuclei and other morphological signs suggestive of osteoclast apoptosis. Characteristic large sized osteoclasts were uniquely found in patients treated with nitrogen containing bisphosphonates, thus being clearly distinguishable from giant osteoclasts in other bone disorders such as Paget disease, secondary hyperparathyroidism or osteopetrosis. The resorption indices of large sized osteoclasts, specifically the eroded perimeter and erosion depth, revealed significantly reduced values but not an entirely inhibited resorption capability., Bisphosphonate osteoclasts' viability and affinity to bone seem significantly disturbed while the apoptotic process may be prolonged for a yet unknown period of time in favor of maintaining a low bone turnover. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Jobke, Bjorn; Milovanovic, Petar; Amling, Michael; Busse, Bjorn] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, D 22529 Hamburg, Germany.
   [Milovanovic, Petar] Univ Belgrade, Lab Anthropol, Inst Anat, Fac Med, Belgrade, Serbia.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Belgrade
RP Busse, B (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Emmy Noether Res Grp, Dept Osteol & Biomech, Lottestr 59, D 22529 Hamburg, Germany.
EM b.busse@uke.uni hamburg.de
RI Busse, Björn/AAC 4033 2020; Milovanovic, Petar/AAH 9358 2020
OI Milovanovic, Petar/0000 0003 1461 8437; Busse,
   Bjorn/0000 0002 3099 8073; 
FU European Federation for Experimental Morphology (EFEM); DFG   Emmy
   Noether program (Deutsche Forschungsgemeinschaft   German Research
   Foundation) [BU 2562/2 1]; South Eastern European Cooperation University
   Medical Center Hamburg Eppendorf
FX Dr. Petar Milovanovic is a fellow of the DAAD (Deutscher Akademischer
   Austauschdienst   German Academic Exchange Service; A/11/83161), Serbian
   Ministry of Education and Science (III45005), and acknowledges the
   support from the European Federation for Experimental Morphology (EFEM
   Travel Grant 2013). Dr. Bjorn Busse is a fellow of the DFG   Emmy
   Noether program (Deutsche Forschungsgemeinschaft   German Research
   Foundation; BU 2562/2 1). This study was supported by grants from the
   South Eastern European Cooperation University Medical Center
   Hamburg Eppendorf.
CR Allen MR, 2010, CALCIFIED TISSUE INT, V86, P67, DOI 10.1007/s00223 009 9315 x
   Bauer DC, 2006, J BONE MINER RES, V21, P292, DOI 10.1359/JBMR.051018
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Bone HG, 1997, J CLIN ENDOCR METAB, V82, P265, DOI 10.1210/jc.82.1.265
   Boonen S, 2010, J AM GERIATR SOC, V58, P292, DOI 10.1111/j.1532 5415.2009.02673.x
   Borah B, 2005, BONE, V37, P1, DOI 10.1016/j.bone.2005.03.017
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown JP, 2011, J BONE MINER RES, V26, P2737, DOI 10.1002/jbmr.448
   Busse B, 2010, ACTA BIOMATER, V6, P4513, DOI 10.1016/j.actbio.2010.07.019
   CHAPPARD D, 1991, CALCIFIED TISSUE INT, V48, P13, DOI 10.1007/BF02555791
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Cheung MS, 2009, J BONE MINER RES, V24, P669, DOI 10.1359/JBMR.081225
   Delmas PD, 2007, J CLIN ENDOCR METAB, V92, P1296, DOI 10.1210/jc.2006 1526
   Dempster DW, 2007, J BONE MINER RES, V22, pS29
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dion N, 2008, J BONE MINER RES, V23, pS343
   DUNSTAN CR, 1980, PATHOLOGY, V12, P255, DOI 10.3109/00313028009060080
   Eriksen EF, 2002, BONE, V31, P620, DOI 10.1016/S8756 3282(02)00869 4
   EVANS RA, 1982, CLIN ORTHOP RELAT R, P290
   Fisher JE, 2006, J BONE MINER RES, V21, pS414
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   FLEISCH H, 1987, BONE, V8, pS23
   Garnero P, 1999, J BONE MINER RES, V14, P1614, DOI 10.1359/jbmr.1999.14.9.1614
   Glowacki J, 2009, NEW ENGL J MED, V360, P80, DOI 10.1056/NEJMe0806271
   GRUBER HE, 1986, MINER ELECTROL METAB, V12, P246
   Gruber HE, 1999, MINER ELECTROL METAB, V25, P127, DOI 10.1159/000057436
   HUGHES DE, 1991, DRUG EXP CLIN RES, V17, P109
   Ito M, 1999, BONE, V25, P447, DOI 10.1016/S8756 3282(99)00197 0
   Jain N, 2009, NAT REV RHEUMATOL, V5, P341, DOI 10.1038/nrrheum.2009.87
   Jobke B, 2006, J BONE MINER RES, V21, pS87
   Jobke B, 2011, CALCIFIED TISSUE INT, V89, P130, DOI 10.1007/s00223 011 9500 6
   Jobke B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023638
   Jobke B, 2009, NEW ENGL J MED, V360, P1676, DOI 10.1056/NEJMc090167
   Jobke B, 2009, CONNECT TISSUE RES, V50, P46, DOI 10.1080/03008200802412462
   JONES SJ, 1993, BONE, V14, P455, DOI 10.1016/8756 3282(93)90179 E
   Jung TI, 2010, J CANCER RES CLIN, V136, P363, DOI 10.1007/s00432 009 0662 9
   Karsdal MA, 2007, J BONE MINER RES, V22, P487, DOI 10.1359/JBMR.070109
   KATOH Y, 1991, BONE, V12, P59, DOI 10.1016/8756 3282(91)90001 Y
   KAYE M, 1985, KIDNEY INT, V27, P574, DOI 10.1038/ki.1985.49
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   MILLER SC, 1977, CALC TISS RES, V22, P243, DOI 10.1007/BF02010363
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   PIPER K, 1994, CALCIFIED TISSUE INT, V54, P56, DOI 10.1007/BF00316291
   PIPER K, 1992, ANAT EMBRYOL, V186, P291
   PLASMANS CMT, 1980, CALCIFIED TISSUE INT, V32, P247, DOI 10.1007/BF02408548
   Rasmussen H., 1974, PHYSL CELLULAR BASIS
   Ravn P, 1996, BONE, V19, P291, DOI 10.1016/8756 3282(96)00201 3
   Ravn P, 2003, BONE, V33, P150, DOI 10.1016/S8756 3282(03)00168 6
   Ravn P, 2002, DAN MED BULL, V49, P1
   Recker R R, 2004, Osteoporos Int, V15, P231, DOI 10.1007/s00198 003 1530 0
   Reid IR, 2010, J BONE MINER RES, V25, P2256, DOI 10.1002/jbmr.149
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   ROWE DJ, 1976, CALC TISS RES, V20, P53, DOI 10.1007/BF02546397
   Safadi FF, 2009, BONE PATHOLOGY, SECOND EDITION, P1, DOI 10.1007/978 1 59745 347 9_1
   Schilcher J, 2013, BONE, V52, P389, DOI 10.1016/j.bone.2012.10.016
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Schneider JP, 2012, J CLIN ENDOCR METAB, V97, P4324, DOI 10.1210/jc.2012 2590
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Shyu JF, 2007, BONE, V40, P1329, DOI 10.1016/j.bone.2007.01.014
   TEITELBAUM SL, 1981, METAB BONE DIS RELAT, V3, P99, DOI 10.1016/0221 8747(81)90027 8
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thomas T, 2013, J BONE MINER RES, V28
   THOMPSON ER, 1975, ENDOCRINOLOGY, V97, P283, DOI 10.1210/endo 97 2 283
   Walsh W., 2003, Handbook of histology methods for bone and cartilage, P35, DOI DOI 10.1007/978 1 59259 417 7_2
   Watts NB, 2008, OSTEOPOROSIS INT, V19, P365, DOI 10.1007/s00198 007 0460 7
   Weinstein RS, 2009, NEW ENGL J MED, V360, P1677
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   WEINSTEIN RS, 1988, NEW ENGL J MED, V319, P1698, DOI 10.1056/NEJM198812293192603
   ZHENG MH, 1991, BONE, V12, P317, DOI 10.1016/8756 3282(91)90017 D
NR 73
TC 105
Z9 120
U1 0
U2 40
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2014
VL 59
BP 37
EP 43
DI 10.1016/j.bone.2013.10.024
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 287QZ
UT WOS:000329558600006
PM 24211427
DA 2025 08 17
ER

PT J
AU Dong, Y
   Ma, JJ
   Pan, YQ
AF Dong, Yi
   Ma, Jingjing
   Pan, Yuanqing
TI Network Pharmacology Prediction to Explore the Potential Mechanism of
   Qing?E Pills
SO INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Qing?E pills; network pharmacology; traditional Chinese medicine;
   postmenopausal osteoporosis
ID SIGNALING PATHWAY; WEB SERVER; AUTOPHAGY; ESTROGEN; THERAPY
AB Qing'E pills are a classical formula in traditional Chinese medicine that has the effect of tonifying the kidneys and strengthening the bones, first appearing in the tonic formulae in prescriptions of peaceful benevolent dispensary (10th century CE). To preliminarily elucidate the potential mechanisms of Qing'E pills in the treatment of postmenopausal osteoporosis based on network pharmacology. The principal components and corresponding protein targets of Qing'E pills were searched on traditional Chinese medicine systems pharmacology, bioinformatics analysis tool for molecular mechanism traditional Chinese medicine, SymMap and encyclopedia of traditional Chinese medicine and the compound target network was constructed by Cytoscape 3.9.1. The targets of postmenopausal osteoporosis were searched on online mendelian inheritance in man, GeneCards, histidine triad nucleotide binding protein and DisGeNET databases. The intersection of compound target and disease target was obtained and the coincidence target was imported into the search tool for retrieval of interacting genes database to construct a protein protein interaction network. We further performed gene ontology and Kyoto encyclopedia of genes and genomes enrichment analyses on the targets. The 33 active compounds in Qing'E pills corresponded to 433 targets. 1647 targets were associated with postmenopausal osteoporosis disease. The active compounds with high degree values were quercetin, stearic acid and marine. The proteins with higher values in the protein protein interaction network were mitogen activated protein kinase 1, protein kinase B, phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit alpha, phosphoinositide 3 kinase regulatory 1, amyloid beta precursor protein, Src proto oncogene, non  receptor tyrosine kinase, mitogen activated protein kinase 8, heat shock protein 90 alpha family class A member 1, epidermal growth factor receptor, and Janus kinase 2. Gene ontology and Kyoto encyclopedia of genes and genomes analysis showed that Qing'E pills treatment of postmenopausal osteoporosis involves signaling pathways that mainly include the tumor necrosis factor signaling pathway, osteoclast differentiation, Wnt signaling pathway and estrogen signaling pathway. We revealed the active ingredients and potential molecular mechanism of Qing'E pills in the treatment of postmenopausal osteoporosis and provided a reference for subsequent basic research.
C1 [Dong, Yi] Dept Tradit Chinese Med, Tianjin, Peoples R China.
   [Ma, Jingjing] Tianjin Med Coll, Sch Pharm & Biotechnol, Dept Pharm, Tianjin 300222, Peoples R China.
   [Pan, Yuanqing] Tianjin Vocat & Tech Normal Univ, Ctr Mental Hlth Res, Tianjin 300355, Peoples R China.
C3 Tianjin Medical University
RP Dong, Y (通讯作者)，Dept Tradit Chinese Med, Tianjin, Peoples R China.
EM zxsd411@126.com
RI Dong, Yi/AAG 2823 2020
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Alam F, 2018, PHYTOTHER RES, V32, P597, DOI 10.1002/ptr.6006
   Amberger JS, 2019, NUCLEIC ACIDS RES, V47, pD1038, DOI 10.1093/nar/gky1151
   ARNAUD CD, 1967, ANNU REV PHYSIOL, V29, P349, DOI 10.1146/annurev.ph.29.030167.002025
   Baccaro LF, 2015, CLIN INTERV AGING, V10, DOI 10.2147/CIA.S54614
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Blake J, 2021, MENOPAUSE, V28, P973, DOI 10.1097/GME.0000000000001831
   Deng R, 2021, AUTOPHAGY, V17, P3011, DOI 10.1080/15548627.2020.1850609
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470 2045(05)70168 6
   Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293
   Gu YX, 2013, J BIOMED MATER RES A, V101, P748, DOI 10.1002/jbm.a.34377
   Guo YJ, 2020, EXP THER MED, V19, P1997, DOI 10.3892/etm.2020.8454
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Hirota Y, 2015, AUTOPHAGY, V11, P332, DOI 10.1080/15548627.2015.1023047
   Hou JX, 2020, J ANAL METHODS CHEM, V2020, DOI 10.1155/2020/8832736
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kim S, 2021, NUCLEIC ACIDS RES, V49, pD1388, DOI 10.1093/nar/gkaa971
   Li CG, 2017, CHIN J INTEGR MED, V23, P183, DOI 10.1007/s11655 016 2407 3
   Li J, 2020, CYTOKINE GROWTH F R, V52, P88, DOI 10.1016/j.cytogfr.2020.02.003
   Li Q, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2021.11892
   Liang D, 2012, BIOL TRACE ELEM RES, V148, P420, DOI 10.1007/s12011 012 9387 8
   McKenna M, 2021, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.619252
   Nogales C, 2022, TRENDS PHARMACOL SCI, V43, P136, DOI 10.1016/j.tips.2021.11.004
   Pai FT, 2021, LIFE BASEL, V11, DOI 10.3390/life11060587
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Perner F, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080854
   Piñero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Stelzer G., 2016, CURR PROTOC BIOINFOR, V54, p1.30.31, DOI [10.1002/cpbi.5, DOI 10.1002/CPBI.5]
   Sun YQ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.730557
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Tian DD, 2014, CURR DRUG METAB, V15, P808
   Tian WY, 2019, CANCER BIOL MED, V16, P55, DOI 10.20892/j.issn.2095 3941.2018.0157
   Wang CY, 2019, AM J CHINESE MED, V47, P259, DOI 10.1142/S0192415X19500137
   Wang J, 2019, INT J NANOMED, V14, P7987, DOI 10.2147/IJN.S216182
   Wang X, 2017, NUCLEIC ACIDS RES, V45, pW356, DOI 10.1093/nar/gkx374
   Werk AN, 2014, CLIN PHARMACOL THER, V96, P340, DOI 10.1038/clpt.2014.129
   Wu D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687551
   Wu Y, 2019, NUCLEIC ACIDS RES, V47, pD1110, DOI 10.1093/nar/gky1021
   Xie H, 2022, PHARM BIOL, V60, P785, DOI 10.1080/13880209.2022.2056208
   Xu F, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578 020 00416 0
   Xu HY, 2019, NUCLEIC ACIDS RES, V47, pD976, DOI 10.1093/nar/gky987
   Xue JF, 2017, BIOMED PHARMACOTHER, V89, P1252, DOI 10.1016/j.biopha.2017.01.130
   Yang Q, 2019, SEMIN CANCER BIOL, V59, P112, DOI 10.1016/j.semcancer.2019.04.001
   Yong HY, 2009, EXPERT OPIN INV DRUG, V18, P1893, DOI 10.1517/13543780903321490
   Zhang P, 2021, J ETHNOPHARMACOL, V276, DOI 10.1016/j.jep.2021.114198
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
NR 50
TC 0
Z9 0
U1 0
U2 4
PU INDIAN PHARMACEUTICAL ASSOC
PI MUMBAI
PA KALINA, SANTA CRUZ EAST, MUMBAI, 00000, INDIA
SN 0250 474X
EI 1998 3743
J9 INDIAN J PHARM SCI
JI Indian J. Pharm. Sci.
PD JAN FEB
PY 2023
VL 85
IS 1
BP 233
EP 240
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA E4LP1
UT WOS:000975276200025
DA 2025 08 17
ER

PT J
AU Zhang, WJ
   Xue, KY
   Gao, YG
   Huai, Y
   Wang, W
   Miao, ZP
   Dang, K
   Jiang, SF
   Qian, AR
AF Zhang, Wenjuan
   Xue, Kaiyue
   Gao, Yongguang
   Huai, Ying
   Wang, Wei
   Miao, Zhiping
   Dang, Kai
   Jiang, Shanfeng
   Qian, Airong
TI Systems pharmacology dissection of action mechanisms of Dipsaci Radix
   for osteoporosis
SO LIFE SCIENCES
LA English
DT Article
DE Systems pharmacology; Multi targets; Osteoporosis; Immune regulation
ID ANTIOSTEOPOROTIC ACTIVITY; TRANSCRIPTION FACTORS; DAIRY PRODUCTS; WATER
   EXTRACT; STEM CELLS; IN VITRO; BONE; PREVENTION; ACTIVATION; EXPRESSION
AB Aims: Osteoporosis (OP) is a systemic metabolic bone disease characterized by bone mass decrease and microstructural degradation, which may increase the risk of bone fracture and leading to high morbidity. Dipsaci Radix (DR), one typical traditional Chinese medicine (TCM), which has been applied in the treatment of OP with good therapeutic effects and few side effects. However, the underlying molecular mechanisms of DR to treat OP have not been fully elucidated. In this study, we aim to dissect the molecular mechanism of DR in the treatment of OP.
   Materials and methods: A systems pharmacology approach was employed to comprehensively dissect the action mechanisms of DR for the treatment of OP.
   Key findings: 10 compounds were screened out as the potential active ingredients with excellent biological activity based on in silico ADME (absorption, distribution, metabolism and excretion) prediction model. Then, 36 key protein targets of 6 compounds were identified by systems drug targeting model (SysDT) and they were involved in several biological processes, such as osteoclast differentiation, osteoblast differentiation and anti inflammation. The target pathway network indicated that targets are mainly mapped in multiple signaling pathways, i.e., MAPK, Tumor necrosis factor alpha (TNF alpha), NF kappa b and Toll like receptor pathways. The in vitro results indicated that the compounds ursolic acid and beta sitosterol effectively inhibited the osteoclast differentiation.
   Significance: These results systematically dissected that DR exhibits the therapeutic effects of OP by the regulation of immune system related pathways, which provide novel perspective to drug development of OP.
C1 Northwestern Polytech Univ, Sch Life Sci, Key Lab Space Biosci & Biotechnol, Lab Bone Metab, Xian 710072, Shaanxi, Peoples R China.
   Northwestern Polytech Univ, Sch Life Sci, Res Ctr Special Med & Hlth Syst Engn, Xian 710072, Shaanxi, Peoples R China.
   Northwestern Polytech Univ, Sch Life Sci, NPU UAB Joint Lab Bone Metab, Xian, Shaanxi, Peoples R China.
C3 Northwestern Polytechnical University; Northwestern Polytechnical
   University; Northwestern Polytechnical University
RP Qian, AR (通讯作者)，127 Youyixi Rd, Xian, Shanxi, Peoples R China.
EM qianair@nwpu.edu.cn
OI Gao, Yongguang/0000 0003 1754 3426
FU National Natural Science Foundation of China [31570940, 2017M623249];
   China Postdoctoral Science Foundation [2017M623249]; Fundamental
   Research Funds for the Central Universities [3102017OQD050]; Key
   Research and Development Project of Shaanxi Province [2018SF 363]
FX This work was supported by National Natural Science Foundation of China
   [2017M623249], China Postdoctoral Science Foundation [2017M623249], the
   Fundamental Research Funds for the Central Universities [3102017OQD050],
   the National Natural Science Foundation of China [31570940] and The Key
   Research and Development Project of Shaanxi Province [2018SF 363].
CR Abobului M, 2015, J Med Life, V8 Spec Issue, P119
   Baek JM, 2016, MOLECULES, V21, DOI 10.3390/molecules21030295
   Bandow K, 2010, BIOCHEM BIOPH RES CO, V402, P755, DOI 10.1016/j.bbrc.2010.10.103
   Bellei B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033021
   Blanchard F, 2009, CYTOKINE GROWTH F R, V20, P19, DOI 10.1016/j.cytogfr.2008.11.004
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Cano A, 2018, MATURITAS, V107, P7, DOI 10.1016/j.maturitas.2017.10.004
   Cartron PF, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.150
   Chauhan S, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906 018 2299 1
   CHRISCHILLES EA, 1991, ARCH INTERN MED, V151, P2026, DOI 10.1001/archinte.151.10.2026
   COOPER C, 1993, AM J EPIDEMIOL, V137, P1001, DOI 10.1093/oxfordjournals.aje.a116756
   Curtis Elizabeth M, 2015, Clin Med (Lond), V15 Suppl 6, ps92, DOI 10.7861/clinmedicine.15 6 s92
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   ESKILD W, 1994, MOL ENDOCRINOL, V8, P732, DOI 10.1210/me.8.6.732
   Foroutan T, 2016, INT J TRANSPLANT MED, V7, P91
   GALLAGHER JC, 1991, AM J MED, V90, P171
   [高歌 Gao Ge], 2018, [中草药, Chinese Traditional and Herbal Drugs], V49, P4581
   He JB, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 016 0301 4
   Ishiyama Shigemoto S, 1999, DIABETOLOGIA, V42, P98, DOI 10.1007/s001250051120
   Jia H. Y., 2016, CHINESE J OSTEOPOROS, V22, P1590
   Kar S, 2017, CURR DRUG METAB, V18, P1106, DOI 10.2174/1389200218666170607102104
   Kodama D, 2013, BRIT J PHARMACOL, V168, P1230, DOI 10.1111/bph.12000
   Kumar A, 2016, NEUROSCI LETT, V628, P98, DOI 10.1016/j.neulet.2016.05.013
   Li F, 2016, PHARM BIOL, V54, P1857, DOI 10.3109/13880209.2015.1133657
   Li JY, 2017, CLIN INTERV AGING, V12, P45, DOI 10.2147/CIA.S117597
   [李兰婷 LI Lanting], 2007, [分子科学学报, Journal of Molecular Science], V23, P286
   [李文锋 Li Wenfeng], 2011, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V17, P1
   [李知玻 Li Zhibo], 2012, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V18, P892
   Liao M., 2013, CHINESE J OSTEOPOROS, V6, P260
   Liu J. M., 2015, CHINESE J JOINT SURG, V9, P780
   Liu WQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12794
   Liu ZG, 2009, J ETHNOPHARMACOL, V123, P74, DOI 10.1016/j.jep.2009.02.025
   MacNamara P, 1998, CALCIFIED TISSUE INT, V63, P39
   MACNAMARA P, 1995, CALCIFIED TISSUE INT, V57, P436, DOI 10.1007/BF00301947
   Maraka S, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h3783
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   MCNEELEY SG, 1991, INT J GYNECOL OBSTET, V34, P253, DOI 10.1016/0020 7292(91)90359 D
   [孟艳秋 MENG Yanqiu], 2007, [中国新药杂志, Chinese Journal New Drugs], V16, P25
   Minisola S, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h5868
   Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449
   Mirzaee Fatemeh, 2017, J Tradit Complement Med, V7, P400, DOI 10.1016/j.jtcme.2016.12.013
   Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148
   Niu YB, 2012, OSTEOPOROSIS INT, V23, P2649, DOI 10.1007/s00198 012 1932 y
   Park YD, 2012, CYTOKINE, V60, P284, DOI 10.1016/j.cyto.2012.05.021
   Pengjam Y, 2016, BIOMOL THER, V24, P123, DOI 10.4062/biomolther.2015.106
   Peruzzi B, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1651
   Prior JC, 2018, CLIMACTERIC, V21, P366, DOI 10.1080/13697137.2018.1467400
   [齐尚锋 QI Shangfeng], 2009, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V15, P230
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   RUDDLE NH, 1992, CURR OPIN IMMUNOL, V4, P327, DOI 10.1016/0952 7915(92)90084 R
   SCHNEIDER GB, 1986, AM J ANAT, V177, P505, DOI 10.1002/aja.1001770408
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198 015 3093 2
   Siu WS, 2013, PHYTOTHER RES, V27, P484, DOI 10.1002/ptr.4743
   Sodhi CP, 2012, GASTROENTEROLOGY, V143, P708, DOI 10.1053/j.gastro.2012.05.053
   [宋敏 Song Min], 2018, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V24, P130
   Srivastava RK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00657
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Tamechika S, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0451 7
   Tanaka K, 2016, BRIT J PHARMACOL, V173, P1058, DOI 10.1111/bph.13418
   Tando T, 2016, BIOCHEM BIOPH RES CO, V470, P391, DOI 10.1016/j.bbrc.2016.01.033
   Tsai CH, 2015, TOXICOL SCI, V148, P517, DOI 10.1093/toxsci/kfv199
   Wadolowska L, 2013, NUTRIENTS, V5, P2684, DOI 10.3390/nu5072684
   Wang JC, 2016, INT J CARDIOL, V215, P232, DOI 10.1016/j.ijcard.2016.04.088
   Wang LL, 2016, CURR PHARM DESIGN, V22, P328, DOI 10.2174/1381612822666151112145907
   Wang XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118184
   Wang ZQ, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/356260
   Willett P, 1998, J CHEM INF COMP SCI, V38, P983, DOI 10.1021/ci9800211
   Wilson C, 2016, J BONE ONCOL, V5, P43, DOI 10.1016/j.jbo.2016.02.003
   Wlodarek D, 2014, PUBLIC HEALTH NUTR, V17, P383, DOI 10.1017/S1368980012005307
   Wozniak L, 2015, MOLECULES, V20, P20614, DOI 10.3390/molecules201119721
   Xiao Ya Ping, 2018, Zhongguo Zhong Yao Za Zhi, V43, P21, DOI 10.19540/j.cnki.cjcmm.20171106.002
   Xing LZ, 2017, BIOMED PHARMACOTHER, V89, P1136, DOI 10.1016/j.biopha.2017.02.073
   Xu D, 2016, MOL MED REP, V14, P4767, DOI 10.3892/mmr.2016.5849
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   Yamaguchi M, 2011, INT J MOL MED, V28, P521, DOI 10.3892/ijmm.2011.749
   Yamamoto Y, 1998, BONE, V22, P533, DOI 10.1016/S8756 3282(98)00034 9
   Ye H, 2011, NUCLEIC ACIDS RES, V39, pD1055, DOI 10.1093/nar/gkq1165
   Yin J, 2004, BIOL PHARM BULL, V27, P583, DOI 10.1248/bpb.27.583
   Yu H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037608
   Zeng J. Q., 2018, SHANDONG MED J, V58, P5
   Zhang J, 2015, GYNECOL ENDOCRINOL, V31, P183, DOI 10.3109/09513590.2014.975683
   Zhang L. Z., 2009, INT J ORTHOP, V30
   Zhao H, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/3673295
   Zhong Hang, 2017, Sichuan Da Xue Xue Bao Yi Xue Ban, V48, P862
   Zhu F, 2012, NUCLEIC ACIDS RES, V40, pD1128, DOI 10.1093/nar/gkr797
   Zuo CJ, 2018, ONCOTARGET, V9, P4833, DOI 10.18632/oncotarget.23373
NR 90
TC 43
Z9 47
U1 1
U2 38
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD OCT 15
PY 2019
VL 235
AR 116820
DI 10.1016/j.lfs.2019.116820
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA JG8RS
UT WOS:000492345900017
PM 31476308
DA 2025 08 17
ER

PT S
AU Russell, RGG
AF Russell, R. Graham G.
BE Zaidi, M
TI Bisphosphonates   From bench to bedside
SO SKELETAL DEVELOPMENT AND REMODELING IN HEALTH, DISEASE, AND AGING
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Conference on Skeletal Development and Remodeling in Health, Disease and
   Aging
CY MAY 18 21, 2005
CL New York, NY
SP NY Acad Sci, Alliance Better Bone Hlth, Procter & Gamble Pharmaceut, Sanofi Aventis, Novartis Pharmaceut Corp, Roche Pharmaceut, Merck & Co
DE bone resorption; osteoclasts; bisphosphonates; protein prenylation; bone
   metastases; myeloma; osteoporosis
ID NITROGEN CONTAINING BISPHOSPHONATES; GTP BINDING PROTEIN;
   HETEROCYCLE CONTAINING BISPHOSPHONATES; SUPPRESSED BONE TURNOVER;
   ACUTE PHASE RESPONSE; CRYSTALS IN VITRO; ZOLEDRONIC ACID;
   PAGETS DISEASE; DICHLOROMETHYLENE DIPHOSPHONATE; CYCLICAL ETIDRONATE
AB The discovery and development of the bisphosphonates (BPs) as a major class of drugs for the treatment of bone diseases has been a fascinating journey that is still not over. In clinical medicine, several BPs are established as the treatments of choice for various diseases of excessive bone resorption, including Paget's disease of bone, myeloma and bone metastases, and osteoporosis. Bisphosphonates are chemically stable analogues of inorganic pyrophosphate, and are resistant to breakdown by enzymatic hydrolysis. Bisphosphonates inhibit bone resorption by being selectively taken up and adsorbed to mineral surfaces in bone, where they interfere with the action of the bone resorbing osteoclasts. Bisphosphonates are internalized by osteoclasts and interfere with specific biochemical processes. Bisphosphonates can be classified into at least two groups with different molecular modes of action. The simpler non nitrogen containing bisphosphonates (such as clodronate and etidronate) can be metabolically incorporated into nonhydrolyzable analogues of adenosine triphosphate (ATP) that may inhibit ATP dependent intracellular enzymes. The more potent, nitrogen containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate, and zoledronate) are not metabolized in this way but can inhibit enzymes of the mevalonate pathway, thereby preventing the biosynthesis of isoprenoid compounds that are essential for the posttranslational modification of small GTP binding proteins (which are also GTPases) such as rab, rho, and rac. The inhibition of protein prenylation and the disruption of the function of these key regulatory proteins explain the loss of osteoclast activity and induction of apoptosis. The key target for bisphosphonates is farnesyl pyrophosphate synthase (FPPS) within osteoclasts, and the recently elucidated crystal structure of this enzyme reveals how BPs bind to and inhibit at the active site via their critical N atoms. In conclusion, bisphosphonates are now established as an important class of drugs for the treatment of many bone diseases, and their mode of action is being unraveled. As a result their full therapeutic potential is gradually being realized.
C1 Univ Oxford, Nuffield Dept Orthopaed Surg, Botnar Res Ctr, Oxford OX3 7LD, England.
   Univ Oxford, Inst Musculoskeletal Sci, Oxford OX3 7LD, England.
C3 University of Oxford; University of Oxford
RP Russell, RGG (通讯作者)，Univ Oxford, Nuffield Dept Orthopaed Surg, Botnar Res Ctr, Oxford OX3 7LD, England.
EM graham.russell@ndos.ox.ac.uk
RI Russell, Robert Graham G/JEF 5877 2023; Russell, R/JEF 5877 2023
OI Russell, Robert Graham G/0000 0002 4136 1828; 
CR Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603
   ADAMI S, 1987, CALCIFIED TISSUE INT, V41, P326, DOI 10.1007/BF02556671
   Adami S, 1996, DRUG SAFETY, V14, P158, DOI 10.2165/00002018 199614030 00003
   AMIN D, 1992, J LIPID RES, V33, P1657
   Amin M B, 1996, Anat Pathol, V1, P1
   Anderson HC, 2005, AM J PATHOL, V166, P1711, DOI 10.1016/S0002 9440(10)62481 9
   [Anonymous], 2001, BIOESSAYS, V23, P1, DOI 10.1002/1521 1878(200101)23:1<1::AID BIES1000>3.0.CO;2 O
   Auriola S, 1997, J CHROMATOGR B, V704, P187, DOI 10.1016/S0378 4347(97)00490 8
   AZUMA Y, 1995, BONE, V16, P235, DOI 10.1016/8756 3282(94)00035 X
   Bauss F, 2002, J RHEUMATOL, V29, P2200
   Bauss F, 2004, OSTEOPOROSIS INT, V15, P423, DOI 10.1007/s00198 004 1612 7
   Bauss Frieder, 2004, Journal of Pharmacological and Toxicological Methods, V50, P25, DOI 10.1016/j.vascn.2003.11.003
   Bell R, 2005, ONCOLOGIST, V10, P8, DOI 10.1634/theoncologist.10 90001 8
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   BIJVOET O, 1995, BISPHOSPHONATES BOEN
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Blomen Leo J. M. J., 1995, P111
   Bobyn JD, 2005, J BONE JOINT SURG BR, V87B, P416, DOI 10.1302/0301 620X.87B3
   Body JJ, 2004, SEMIN NEPHROL, V24, P48, DOI 10.1053/j.semnephrol.2003.08.015
   Body JJ, 2004, BRIT J CANCER, V90, P1133, DOI 10.1038/sj.bjc.6601663
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   BOONEKAMP PM, 1986, BONE MINER, V1, P27
   Boonen S, 2005, OSTEOPOROSIS INT, V16, P1291, DOI 10.1007/s00198 005 1945 x
   Borah B, 2002, J BONE MINER RES, V17, P1139, DOI 10.1359/jbmr.2002.17.7.1139
   Borah B, 2005, BONE, V37, P1, DOI 10.1016/j.bone.2005.03.017
   Borah B, 2004, BONE, V34, P736, DOI 10.1016/j.bone.2003.12.013
   Breuil V, 1998, J BONE MINER RES, V13, P1721, DOI 10.1359/jbmr.1998.13.11.1721
   CARANO A, 1990, J CLIN INVEST, V85, P456, DOI 10.1172/JCI114459
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Coleman RE, 2005, ANN ONCOL, V16, P687, DOI 10.1093/annonc/mdi162
   Coukell AJ, 1998, DRUG AGING, V12, P149, DOI 10.2165/00002512 199812020 00007
   Coxon FP, 1998, MOL PHARMACOL, V54, P631
   Daroszewska A, 2005, CLIN SCI, V109, P257, DOI 10.1042/CS20050053
   David P, 1996, J BONE MINER RES, V11, P1498, DOI 10.1002/jbmr.5650111017
   deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403
   Delmas PD, 1997, NEW ENGL J MED, V336, P558, DOI 10.1056/NEJM199702203360807
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   DOUGLAS DL, 1980, LANCET, V1, P1043
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Ebetino FH, 1996, PHOSPHORUS SULFUR, V109, P217
   Ebetino FH, 2005, J ORGANOMET CHEM, V690, P2679, DOI 10.1016/j.jorganchem.2005.03.005
   Ebetino FH, 1998, REV CONTEMP PHARMACO, V9, P233
   Ebrahimpour A., 1995, Bisphosphonate on Bones
   Endo N, 1996, J BONE MINER RES, V11, P535
   Fedde KN, 1999, J BONE MINER RES, V14, P2015, DOI 10.1359/jbmr.1999.14.12.2015
   FELIX R, 1976, BIOCHIM BIOPHYS ACTA, V429, P429, DOI 10.1016/0005 2744(76)90291 6
   FERRETTI JL, 1995, BISPHOSPHONATES BONE, pCH31
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FLANAGAN AM, 1989, BONE MINER, V6, P33, DOI 10.1016/0169 6009(89)90021 4
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   FLEISCH H, 1966, P SOC EXP BIOL MED, V122, P317
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   FLEISCH H, 1968, CALC TISS RES, VS  2, P10, DOI 10.1007/BF02065192
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   FLEISCH H, 1962, AM J PHYSIOL, V203, P671, DOI 10.1152/ajplegacy.1962.203.4.671
   Fleisch H., 2000, BISPHOSPHONATES BONE
   FLEISCH HA, 1970, EUR J CLIN INVEST, V1, P12, DOI 10.1111/j.1365 2362.1970.tb00591.x
   FLEISH H, 1961, AM J PHYSIOL, V200, P1296, DOI 10.1152/ajplegacy.1961.200.6.1296
   FLORA L, 1981, METAB BONE DIS RELAT, V3, P289, DOI 10.1016/0221 8747(81)90045 X
   FOGELMAN I, 1978, J NUCL MED, V19, P270
   FRANCIS B, 2001, SEX ED, V1, P1
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754
   GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693
   GASSER AB, 1972, CLIN SCI, V43, P31, DOI 10.1042/cs0430031
   Gasser JA, 2002, BONE, V30, p41S
   Geddes A D., 1994, Bone and Mineral Research, P265
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   Glorieux FH, 1998, NEW ENGL J MED, V339, P947, DOI 10.1056/NEJM199810013391402
   Goa KL, 1998, DRUG AGING, V13, P83, DOI 10.2165/00002512 199813010 00008
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Ho AM, 2000, SCIENCE, V289, P265, DOI 10.1126/science.289.5477.265
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   Ito M, 1998, CALCIFIED TISSUE INT, V63, P143, DOI 10.1007/s002239900505
   JOHNSON S, 1998, ETIDRONATE OSTEOPORO, V9
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   KAVANAGH K, 2006, IN PRESS P NATL ACAD
   Kurth AHA, 2005, BONE, V37, P204, DOI 10.1016/j.bone.2004.12.017
   Lai KA, 2005, J BONE JOINT SURG AM, V87A, P2155, DOI 10.2106/JBJS.D.02959
   Lalla S, 1998, OSTEOPOROSIS INT, V8, P97, DOI 10.1007/BF02672503
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   LERNER UH, 1987, BONE, V8, P179, DOI 10.1016/8756 3282(87)90018 4
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Ling Y, 2005, J MED CHEM, V48, P3130, DOI 10.1021/jm040132t
   Little DG, 2003, J BONE MINER RES, V18, P2016, DOI 10.1359/jbmr.2003.18.11.2016
   Little DG, 2005, J BONE MINER RES, V20, P2044, DOI 10.1359/JBMR.050712
   Little DG, 2003, J BONE MINER RES, V18, P1300, DOI 10.1359/jbmr.2003.18.7.1300
   Little DG, 2005, J ORTHOP RES, V23, P862, DOI 10.1016/j.orthres.2004.11.015
   LOWIK CWGM, 1988, J BONE MINER RES, V3, P185
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312
   Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   MARTODAM RR, 1983, CALCIFIED TISSUE INT, V35, P512, DOI 10.1007/BF02405086
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Mashiba T, 2005, J BONE MINER METAB, V23, P36, DOI 10.1007/BF03026321
   McCloskey EV, 1998, BRIT J HAEMATOL, V100, P317
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Mee AP, 1999, BONE, V24, p19S, DOI 10.1016/S8756 3282(99)00033 2
   Menschutkin N., 1865, ANN CHEM PHARM, V133, P317
   Michaelson MD, 2005, J CLIN ONCOL, V23, P8219, DOI 10.1200/JCO.2005.02.9579
   Monier Faugere MC, 1999, J BONE MINER RES, V14, P1768, DOI 10.1359/jbmr.1999.14.10.1768
   Moreno B, 2001, BIOCHEM BIOPH RES CO, V284, P632, DOI 10.1006/bbrc.2001.5009
   MUEHLBAUER RC, 1971, EUR J CLIN INVEST, V1, P336
   MUHLBAUER RC, 1991, J BONE MINER RES, V6, P1003
   Mumm S, 2001, J BONE MINER RES, V16, P1724, DOI 10.1359/jbmr.2001.16.9.1724
   Mundy GR, 1998, NEW ENGL J MED, V339, P398, DOI 10.1056/NEJM199808063390609
   MUNDY GR, 1995, CLIN ORTHOP RELAT R, P34
   MURAKAMI H, 1995, BONE, V17, P137, DOI 10.1016/S8756 3282(95)00150 6
   Murakami H, 1997, BONE, V20, P399, DOI 10.1016/S8756 3282(97)00025 2
   Nakamura I, 1999, HUM GENET, V104, P492, DOI 10.1007/s004390050993
   Nancollas GH., 2005, Bone
   Nishikawa M, 1996, BONE, V18, P9, DOI 10.1016/8756 3282(95)00426 2
   Nürnberg P, 2001, NAT GENET, V28, P37, DOI 10.1038/ng0501 37
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   OLPAS EE, 1997, BIOCHEM PHARMACOL, V54, P721
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P1897, DOI 10.1210/jc.2005 0057
   PAPAPOULOS SE, 1989, J BONE MINER RES, V4, P775
   PAPAPOULOS SE, 1995, BISPHOSPHONATES BONE, pCH15
   Parker CC, 2005, BJU INT, V95, P935, DOI 10.1111/j.1464 410X.2005.05441.x
   PATERSON AD, 1983, BRIT J HAEMATOL, V54, P121, DOI 10.1111/j.1365 2141.1983.tb02074.x
   Pavlakis N, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub2
   PELORGEAS S, 1992, BIOCHEM PHARMACOL, V44, P2157, DOI 10.1016/0006 2952(92)90342 G
   Pendleton A, 2002, AM J HUM GENET, V71, P933, DOI 10.1086/343054
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   RALSTON SH, 1989, LANCET, V2, P1180
   Rauch F, 2005, AM J MED GENET C, V139C, P31, DOI 10.1002/ajmg.c.30072
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Reichenberger E, 2001, AM J HUM GENET, V68, P1321, DOI 10.1086/320612
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241
   REITSMA PH, 1980, CALCIFIED TISSUE INT, V32, P145, DOI 10.1007/BF02408534
   RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092 8674(92)90164 8
   RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092 8674(92)90163 7
   Rodriguez N, 2002, J INFECT DIS, V186, P138, DOI 10.1086/341074
   Rogers MJ, 2004, CALCIFIED TISSUE INT, V75, P451, DOI 10.1007/s00223 004 0024 1
   ROGERS MJ, 1994, BIOCHEM J, V303, P303, DOI 10.1042/bj3030303
   Rogers MJ, 1996, BIOCHEM BIOPH RES CO, V224, P863, DOI 10.1006/bbrc.1996.1113
   ROGERS MJ, 1992, BIOCHEM BIOPH RES CO, V189, P414, DOI 10.1016/0006 291X(92)91574 A
   Rogers MJ, 1997, PHARMACEUT RES, V14, P625, DOI 10.1023/A:1012157212793
   Rogers MJ, 1996, J BONE MINER RES, V11, P1482
   ROGERS MJ, 1994, J BONE MINER RES, V9, P1029
   ROGERS MJ, 1995, MOL PHARMACOL, V47, P398
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Ross JR, 2004, HEALTH TECHNOL ASSES, V8, pIII
   RUF N, 2005, HUM MUTAT, V26, P495
   RUSSELL RGG, 1966, CLIN SCI, V31, P51
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   RUSSELL RGG, 1970, CALC TISS RES, V6, P183, DOI 10.1007/BF02196199
   Russell RGG, 1997, BRIT J RHEUMATOL, V36, P10
   RUSSELL RGG, 1971, J CLIN INVEST, V50, P961, DOI 10.1172/JCI106589
   RUSSELL RGG, 1974, LANCET, V1, P894
   RUSSELL RGG, 1965, LANCET, V2, P461
   RUSSELLRGG, 2003, RHEUMATOLOGY, P2075
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   Sanders JM, 2004, J MED CHEM, V47, P375, DOI 10.1021/jm0303709
   SASAKI A, 1995, CANCER RES, V55, P3551
   SATO M, 1990, J BONE MINER RES, V5, P31, DOI 10.1002/jbmr.5650050107
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Sauty A, 1996, BONE, V18, P133, DOI 10.1016/8756 3282(95)00448 3
   SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219
   SCHENK R, 1986, CALCIFIED TISSUE INT, V38, P342, DOI 10.1007/BF02555748
   SCHIBLER D, 1968, CLIN SCI, V35, P363
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068
   SCHWEITZER DH, 1995, J BONE MINER RES, V10, P956
   Selander KS, 1996, MOL PHARMACOL, V50, P1127
   SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012
   Shipman CM, 1998, CANCER RES, V58, P5294
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   SIETSEMA WK, 1989, DRUG EXP CLIN RES, V15, P389
   Singer FR, 1998, J CLIN ENDOCR METAB, V83, P1906, DOI 10.1210/jc.83.6.1906
   Siris ES, 1998, J BONE MINER RES, V13, P1032, DOI 10.1359/jbmr.1998.13.6.1032
   Sirohi B, 2004, LANCET, V363, P875, DOI 10.1016/S0140 6736(04)15736 X
   Smith Matthew R, 2005, Cancer Treat Rev, V31 Suppl 3, P19, DOI 10.1016/j.ctrv.2005.09.004
   SMITH R, 1971, LANCET, V1, P945
   SMITH R, 1995, BISPHOSPHONATE BONE, pCH31
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803
   STUTZER A, 1988, CALCIFIED TISSUE INT, V43, P294, DOI 10.1007/BF02556639
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Szabo CM, 2002, J MED CHEM, V45, P2185, DOI 10.1021/jm010412y
   Terkeltaub RA, 2001, AM J PHYSIOL CELL PH, V281, pC1, DOI 10.1152/ajpcell.2001.281.1.C1
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   Timms AE, 2002, RHEUMATOLOGY, V41, P725, DOI 10.1093/rheumatology/41.7.725
   TRECHSEL U, 1987, J CLIN INVEST, V80, P1679, DOI 10.1172/JCI113257
   *US DEP HHS OFF SU, 2004, BON HLTH OST
   Van Staa TP, 1998, BRIT J RHEUMATOL, V37, P87
   van Staa TP, 1998, REV CONTEMP PHARMACO, V9, P277
   vanBeek E, 1996, J BONE MINER RES, V11, P1492
   VANBEEK E, BIOCH BIOPHYS RES CO, V255, P491
   Vitte C, 1996, ENDOCRINOLOGY, V137, P2324, DOI 10.1210/en.137.6.2324
   VONBAEYER H, 1897, BERICHTE DTSCH CHEM, V20, P1973
   WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Williams CJ, 2002, AM J HUM GENET, V71, P985, DOI 10.1086/343053
   Yu X, 1996, BONE, V19, P339, DOI 10.1016/S8756 3282(96)00184 6
   Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955 0674(93)90130 I
   ZHANG D, 1995, J CELL SCI, V108, P2285
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
   Zhang Y, 2005, ARTHRITIS RHEUM US, V52, P1110, DOI 10.1002/art.20978
   ZIMOLO Z, 1995, J CLIN INVEST, V96, P2277, DOI 10.1172/JCI118283
NR 212
TC 342
Z9 389
U1 0
U2 48
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077 8923
BN 1 57331 583 4
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2006
VL 1068
BP 367
EP 401
DI 10.1196/annals.1346.041
PG 35
WC Multidisciplinary Sciences; Orthopedics
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Orthopedics
GA BFA92
UT WOS:000240548200039
PM 16831938
DA 2025 08 17
ER

PT S
AU Leibbrandt, A
   Penninger, JM
AF Leibbrandt, Andreas
   Penninger, Josef M.
BE Grewal, IS
TI RANK(L) as a Key Target for Controlling Bone Loss
SO THERAPEUTIC TARGETS OF THE TNF SUPERFAMILY
SE Advances in Experimental Medicine and Biology
LA English
DT Article
ID TUMOR NECROSIS FACTOR; KAPPA B LIGAND; OSTEOCLASTOGENESIS INHIBITORY
   FACTOR; OSTEOPROTEGERIN MESSENGER RNA; TNF FAMILY MEMBER;
   COLLAGEN INDUCED ARTHRITIS; EXPANSILE SKELETAL HYPERPHOSPHATASIA;
   ACTIVATION INDUCED CYTOKINE; FACTOR RECEPTOR FAMILY; N TERMINAL KINASE
AB Bone related diseases, such as osteoporosis or rheumatoid arthritis, affect hundreds of millions of people worldwide and pose a tremendous burden to health care. By deepening our understanding of the molecular mechanisms of bone metabolism and bone turnover, it became possible over the past years to devise new and promising strategies for treating such diseases. In particular, three molecules, the receptor activator of NF kappa B (RANK), its ligand RANKL and the decoy receptor of RANKL, osteoprotegerin (OPG), attracted the attention of scientists and pharmaceutical companies alike. Genetic experiments evolving around these molecules established their pivotal role as central regulators of osteoclast function. RANK RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast development, but crosstalk with other signaling pathways also fine tunes bone homeostasis both in normal physiology and disease. Consequently, novel drugs specifically targeting RANK RANKL and their signaling pathways in osteoclasts are expected to revolutionize the treatment of various ailments associated with bone loss, such as arthritis, cancer metastases, or osteoporosis.
C1 [Penninger, Josef M.] IMBA, Austrian Acad Sci, Inst Mol Biotechnol, A 1030 Vienna, Austria.
C3 Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA);
   Austrian Academy of Sciences
RP Penninger, JM (通讯作者)，IMBA, Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohr Gasse 3, A 1030 Vienna, Austria.
EM Josef.Penninger@imba.oeaw.ac.at
RI Penninger, Josef/I 6860 2013
OI Penninger, Josef/0000 0002 8194 3777
CR Abu Amer Y, 2001, J CLIN INVEST, V107, P1375, DOI 10.1172/JCI10530
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200
   Bachmann MF, 1999, J EXP MED, V189, P1025, DOI 10.1084/jem.189.7.1025
   Bendele A, 1999, TOXICOL PATHOL, V27, P134, DOI 10.1177/019262339902700125
   Bendixen AC, 2001, P NATL ACAD SCI USA, V98, P2443, DOI 10.1073/pnas.041493198
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brändström H, 1998, BIOCHEM BIOPH RES CO, V247, P338, DOI 10.1006/bbrc.1998.8783
   Brändström H, 1998, BIOCHEM BIOPH RES CO, V248, P454, DOI 10.1006/bbrc.1998.8993
   Brandt J, 2000, ARTHRITIS RHEUM US, V43, P1346, DOI 10.1002/1529 0131(200006)43:6<1346::AID ANR18>3.0.CO;2 E
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chan FKM, 2000, IMMUNITY, V13, P419, DOI 10.1016/S1074 7613(00)00041 8
   Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351
   Chesneau V, 2003, J BIOL CHEM, V278, P22331, DOI 10.1074/jbc.M302781200
   Chong B, 2003, J BONE MINER RES, V18, P2095, DOI 10.1359/jbmr.2003.18.12.2095
   Cohen SB, 2006, ARTHRITIS RHEUM, V54, pS831
   Cundy T, 2002, HUM MOL GENET, V11, P2119, DOI 10.1093/hmg/11.18.2119
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807
   Dore R, 2006, ARTHRITIS RHEUM, V54, pS240
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   DOUGALL WC, 2006, CANC METASTASIS REV
   Ebeling PR, 1998, J BONE MINER RES, V13, P1283, DOI 10.1359/jbmr.1998.13.8.1283
   Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363
   Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092 8674(00)81109 5
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   Hofbauer LC, 2001, BIOCHEM BIOPH RES CO, V280, P334, DOI 10.1006/bbrc.2000.4130
   Hofbauer LC, 1998, BIOCHEM BIOPH RES CO, V250, P776, DOI 10.1006/bbrc.1998.9394
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Horwood NJ, 2001, J IMMUNOL, V166, P4915, DOI 10.4049/jimmunol.166.8.4915
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667
   Ikeda T, 2001, ENDOCRINOLOGY, V142, P1419, DOI 10.1210/en.142.4.1419
   Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733
   IORSOVA V, 1997, NAT MED, V3, P1285
   Ito S, 2002, J BIOL CHEM, V277, P6631, DOI 10.1074/jbc.M106525200
   Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495
   Josien R, 1999, J IMMUNOL, V162, P2562
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kobayashi T, 2003, IMMUNITY, V19, P353, DOI 10.1016/S1074 7613(03)00230 9
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kong YY, 1999, IMMUNOL CELL BIOL, V77, P188, DOI 10.1046/j.1440 1711.1999.00815.x
   Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074 7613(00)80045 X
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529 0131(200105)44:5<1003::AID ANR179>3.3.CO;2 R
   Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092 8674(00)81989 3
   Kwon BS, 1998, FASEB J, V12, P845, DOI 10.1096/fasebj.12.10.845
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890
   Lane NE, 2006, ARTHRITIS RHEUM, V54, pS225
   Lee ZH, 2000, MOL PHARMACOL, V58, P1536, DOI 10.1124/mol.58.6.1536
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Lipton A, 2006, CLIN CANCER RES, V12, p6305S, DOI 10.1158/1078 0432.CCR 06 1157
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092 8674(01)00237 9
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Loser K, 2006, NAT MED, V12, P1372, DOI 10.1038/nm1518
   Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613
   Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013
   Mahamed DA, 2005, DIABETES, V54, P1477, DOI 10.2337/diabetes.54.5.1477
   ManourySchwartz B, 1997, J IMMUNOL, V158, P5501
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Mehling A, 2001, J EXP MED, V194, P615, DOI 10.1084/jem.194.5.615
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Mori H, 2002, HISTOCHEM CELL BIOL, V117, P283, DOI 10.1007/s00418 001 0376 9
   Muller Ladner U, 1998, Curr Opin Rheumatol, V10, P212
   Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723
   Nagasawa T, 2002, CLIN EXP IMMUNOL, V130, P338, DOI 10.1046/j.1365 2249.2002.01990.x
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Nakashima T, 2003, CURR OPIN RHEUMATOL, V15, P280, DOI 10.1097/00002281 200305000 00016
   OLIVERI M B, 1991, Henry Ford Hospital Medical Journal, V39, P45
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   PANAYI GS, 1992, ARTHRITIS RHEUM US, V35, P729, DOI 10.1002/art.1780350702
   Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Piepkorn B, 1997, HORM METAB RES, V29, P584, DOI 10.1055/s 2007 979106
   Redlich K, 2002, ARTHRITIS RHEUM, V46, P785, DOI 10.1002/art.10097
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002 9440(10)64417 3
   Rubin J, 2002, J CLIN ENDOCR METAB, V87, P4273, DOI 10.1210/jc.2002 020656
   Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schlöndorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200
   SEITZ M, 1985, ANN RHEUM DIS, V44, P438, DOI 10.1136/ard.44.7.438
   Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040
   STELLON AJ, 1985, GASTROENTEROLOGY, V89, P1078, DOI 10.1016/0016 5085(85)90212 4
   Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091
   Takami M, 2000, ENDOCRINOLOGY, V141, P4711, DOI 10.1210/en.141.12.4711
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 1997, BIOCHEM BIOPH RES CO, V240, P279, DOI 10.1006/bbrc.1997.7404
   Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378 1119(97)00509 X
   Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603
   Vermeire K, 1997, J IMMUNOL, V158, P5507
   Vidal NOA, 1998, J ENDOCRINOL, V159, P191, DOI 10.1677/joe.0.1590191
   Vidal ONA, 1998, BIOCHEM BIOPH RES CO, V248, P696, DOI 10.1006/bbrc.1998.9035
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203
   WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985
   Whyte MP, 2002, J BONE MINER RES, V17, P26, DOI 10.1359/jbmr.2002.17.1.26
   Whyte MP, 2000, J BONE MINER RES, V15, P2330, DOI 10.1359/jbmr.2000.15.12.2330
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yun TJ, 1998, J IMMUNOL, V161, P6113
NR 125
TC 30
Z9 36
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES
SN 0065 2598
EI 2214 8019
BN 978 0 387 89519 2
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2009
VL 647
BP 130
EP 145
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA BIX18
UT WOS:000263550700010
PM 19760071
DA 2025 08 17
ER

PT J
AU Kim, SE
   Suh, DH
   Yun, YP
   Lee, JY
   Park, K
   Chung, JY
   Lee, DW
AF Kim, Sung Eun
   Suh, Dong Hun
   Yun, Young Pil
   Lee, Jae Yong
   Park, Kyeongsoon
   Chung, Jun Young
   Lee, Deok Won
TI Local delivery of alendronate eluting chitosan scaffold can effectively
   increase osteoblast functions and inhibit osteoclast differentiation
SO JOURNAL OF MATERIALS SCIENCE MATERIALS IN MEDICINE
LA English
DT Article
ID TARGETED DRUG DELIVERY; ECTOPIC BONE FORMATION; MARROW STROMAL CELLS;
   CONTROLLED RELEASE; TITANIUM SURFACES; IN VITRO; BISPHOSPHONATES;
   MICROSPHERES; HEPARIN; FUNCTIONALIZATION
AB The aim of this study was to investigate the effect of alendronate released from chitosan scaffolds on enhancement of osteoblast functions and inhibition of osteoclast differentiation in vitro. The surface and cell morphologies of chitosan scaffolds and alendronate loaded chitosan scaffolds were characterized by variable pressure field emission scanning electron microscope (VP FE SEM). Alendronate was released in a sustained manner. For evaluating osteoblast functions in MG 63 cells, we investigated cell proliferation, alkaline phosphatase (ALP) activity, and calcium deposition. Furthermore, for evaluating inhibition of osteoclast differentiation in RAW 264.7 cells, we investigated tartrate resistant acid phosphatase (TRAP) activity, TRAP staining, and gene expressions. The in vitro studies revealed that osteoblasts grown on alendronate loaded chitosan scaffold showed a significant increment in cell proliferation, ALP activity, and calcium deposition as compared to those grown on chitosan scaffolds. In addition, the in vitro study showed that osteoclast differentiation in RAW 264.7 cells cultured on alendronate loaded chitosan scaffolds was greatly inhibited as compared to those cultured on chitosan scaffolds by the results of TRAP activity, TRAP staining, and gene expressions. Taken together, alendronate loaded chitosan scaffolds could achieve the dual functions of improvement in osteoblast functions and inhibition of osteoclast differentiation. Thus, alendronate eluting chitosan substrates are promising materials for enhancing osteoblast functions and inhibiting osteoclast differentiation in orthopedic and dental fields.
C1 [Lee, Deok Won] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Surg, Seoul 130701, South Korea.
   [Kim, Sung Eun; Yun, Young Pil; Lee, Jae Yong] Korea Univ, Coll Med, Guro Hosp, Dept Orthoped Surg, Seoul 152703, South Korea.
   [Kim, Sung Eun; Yun, Young Pil; Lee, Jae Yong] Korea Univ, Coll Med, Guro Hosp, Rare Dis Inst, Seoul 152703, South Korea.
   [Suh, Dong Hun] Korea Univ, Coll Med, Ansan Hosp, Dept Orthoped Surg, Ansan 152703, Gyeonggi Do, South Korea.
   [Park, Kyeongsoon] Korea Basic Sci Inst, Chuncheon Ctr, Div Biol Imaging, Chunchon 200701, Gangwon Do, South Korea.
   [Chung, Jun Young] Kyung Hee Univ, Sch Med, Dept Anesthesiol & Pain Med, Seoul 130701, South Korea.
C3 Kyung Hee University; Korea University; Korea University Medicine (KU
   Medicine); Korea University; Korea University Medicine (KU Medicine);
   Korea University; Korea University Medicine (KU Medicine); Korea Basic
   Science Institute (KBSI); Kyung Hee University
RP Lee, DW (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Surg, 1 Hoegi Dong, Seoul 130701, South Korea.
EM verycutebear@khu.ac.kr
RI Kim, Miyoung/C 8316 2012; Lee, Jae/P 8895 2017; Park,
   Kyeongsoon/AGQ 9584 2022
OI Park, Kyeongsoon/0000 0002 8558 3983; kim, sung eun/0000 0001 9445 2451
FU KBSI [T32513]
FX This study was supported by KBSI grant (T32513) to KP. We thank Boram
   Lee at the Chuncheon Center of the Korea Basic Science Institute for
   technical assistance in VP FE SEM image analyses (Variable Pressure
   Field Emission Scanning Electron Microscope, Carl Zeiss).
CR Bigi A, 2009, BIOMATERIALS, V30, P6168, DOI 10.1016/j.biomaterials.2009.07.066
   Blasinska A, 2008, BIOMACROMOLECULES, V9, P776, DOI 10.1021/bm7006373
   Cenni E, 2011, J BIOMATER SCI POLYM
   Chen JH, 2011, J MATER SCI MATER M, V22, P547, DOI 10.1007/s10856 011 4232 8
   Chen JD, 2010, COLLOID SURFACE B, V81, P640, DOI 10.1016/j.colsurfb.2010.08.017
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Chua PH, 2008, BIOMATERIALS, V29, P1412, DOI 10.1016/j.biomaterials.2007.12.019
   COOK SD, 1995, J BONE JOINT SURG AM, V77A, P734, DOI 10.2106/00004623 199505000 00010
   Gil G, 2004, BIOTECHNOL LETT, V26, P569, DOI 10.1023/B:BILE.0000021957.37426.9b
   Ho MH, 2005, BIOMATERIALS, V26, P3197, DOI 10.1016/j.biomaterials.2004.08.032
   Holmberg AR, 2010, INT J ONCOL, V37, P563, DOI 10.3892/ijo_00000705
   Ikemoto S, 2006, J BIOMED MATER RES A, V79A, P716, DOI 10.1002/jbm.a.30804
   Inoue Y, 2010, EXP CLIN ENDOCR DIAB, V118, P719, DOI 10.1055/s 0030 1249084
   Kim CW, 2010, J CONTROL RELEASE, V147, P45, DOI 10.1016/j.jconrel.2010.06.016
   Kim HK, 2009, TISSUE ENG PT A, V15, P923, DOI 10.1089/ten.tea.2007.0407
   Kim HK, 2009, CLIN ORTHOP RELAT R, V467, P3121, DOI 10.1007/s11999 008 0409 y
   Kim SE, 2003, J CONTROL RELEASE, V91, P365, DOI 10.1016/S0168 3659(03)00274 8
   Kim SE, 2008, J MATER CHEM, V18, P4994, DOI 10.1039/b810328c
   Kim SE, 2011, BIOMATERIALS, V32, P366, DOI 10.1016/j.biomaterials.2010.09.008
   Kim SE, 2008, J BIOMED SCI, V15, P771, DOI 10.1007/s11373 008 9277 4
   Lambrinoudaki I, 2006, ANN NY ACAD SCI, V1092, P397, DOI 10.1196/annals.1365.036
   Lu SY, 2008, BURNS, V34, P623, DOI 10.1016/j.burns.2007.08.020
   Luca L, 2010, J CONTROL RELEASE, V147, P38, DOI 10.1016/j.jconrel.2010.06.011
   Malden NJ, 2007, BRIT DENT J, V203, P93, DOI 10.1038/bdj.2007.636
   McManus Stephen, 2012, J Mol Signal, V7, P1, DOI 10.1186/1750 2187 7 1
   Moon HJ, 2011, BIOCHEM BIOPH RES CO, V413, P194, DOI 10.1016/j.bbrc.2011.08.057
   Nafea EH, 2007, J MICROENCAPSUL, V24, P525, DOI 10.1080/02652040701439807
   Oura S, 2000, Breast Cancer, V7, P307, DOI 10.1007/BF02966395
   Panzavolta S, 2010, J INORG BIOCHEM, V104, P1099, DOI 10.1016/j.jinorgbio.2010.06.008
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Sellers RS, 2000, J BONE JOINT SURG AM, V82A, P151, DOI 10.2106/00004623 200002000 00001
   Shi XT, 2009, PHARM RES DORDR, V26, P422, DOI 10.1007/s11095 008 9759 0
   Silverman SL, 2008, JCR J CLIN RHEUMATOL, V14, P299, DOI 10.1097/RHU.0b013e318188b1f3
   Tan Q, 2011, INT J NANOMED, V6, P929, DOI 10.2147/IJN.S18753
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Wang CZ, 2010, BIOMATERIALS, V31, P8674, DOI 10.1016/j.biomaterials.2010.07.096
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   Wang YJ, 2010, J BIOMAT SCI POLYM E, V21, P1227, DOI 10.1163/092050609X12481751806259
   Weir MD, 2010, J BIOMED MATER RES A, V94A, P223, DOI 10.1002/jbm.a.32665
   Yu X, 2011, BIOMACROMOLECULES, V12, P3205, DOI 10.1021/bm200681m
NR 42
TC 36
Z9 39
U1 0
U2 51
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957 4530
J9 J MATER SCI MATER M
JI J. Mater. Sci. Mater. Med.
PD NOV
PY 2012
VL 23
IS 11
BP 2739
EP 2749
DI 10.1007/s10856 012 4729 9
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 034KS
UT WOS:000310872400014
PM 22850978
DA 2025 08 17
ER

PT J
AU Su, X
   Liao, L
   Shuai, Y
   Jing, H
   Liu, S
   Zhou, H
   Liu, Y
   Jin, Y
AF Su, X.
   Liao, L.
   Shuai, Y.
   Jing, H.
   Liu, S.
   Zhou, H.
   Liu, Y.
   Jin, Y.
TI MiR 26a functions oppositely in osteogenic differentiation of BMSCs and
   ADSCs depending on distinct activation and roles of Wnt and BMP
   signaling pathway
SO CELL DEATH & DISEASE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; HUMAN ADIPOSE TISSUE; BONE MORPHOGENETIC
   PROTEIN 2; MULTIPOTENT STROMAL CELLS; OSTEOBLAST DIFFERENTIATION;
   REGENERATIVE MEDICINE; POSITIVE REGULATION; BETA CATENIN; MARROW;
   EXPRESSION
AB MicroRNAs (miRNAs) emerge as important regulators of stem cell lineage commitment and bone development. MiRNA 26a (miR 26a) is one of the important miRNAs regulating osteogenic differentiation of both bone marrow derived mesenchymal stem cells (BMSCs) and adipose tissue derived mesenchymal stem cells (ADSCs). However, miR 26a functions oppositely in osteogenic differentiation of BMSCs and ADSCs, suggesting distinct post transcriptional regulation of tissue specific MSC differentiation. However, the molecular basis is largely unknown. Here, we report that the function of miR 26a is largely depended on the intrinsic signaling regulation network of MSCs. Using bioinformatics and functional assay, we confirmed that miR 26a potentially targeted on GSK3 beta and Smad1 to regulate Wnt and BMP signaling pathway. Overall comparative analysis revealed that Wnt signaling was enhanced more potently and played a more important role than BMP signaling in osteogenic differentiation of BMSCs, whereas BMP pathway was more essential for promoting osteogenic differentiation of ADSCs. The distinct activation pattern and role of signaling pathways determined that miR 26a majorly targeted on GSK3 beta to activate Wnt signaling for promoting osteogenic differentiation of BMSCs, whereas it inhibited Smad1 to suppress BMP signaling for interfering with the osteogenic differentiation of ADSCs. Taken together, our study demonstrated that BMSCs and ADSCs applied different signaling pathway to facilitate their osteogenic differentiation, which determined the inverse function of miR 26a. The distinct transcriptional regulation and post transcriptional regulation network suggested the intrinsic molecular differences between tissue specific MSCs and the complexity in MSC research and MSC based cell therapy.
C1 [Su, X.; Zhou, H.] Xi An Jiao Tong Univ, Coll Med, Stomatol Hosp, Dept Orthodont, Xian 710004, Shaanxi, Peoples R China.
   [Su, X.; Liao, L.; Shuai, Y.; Jing, H.; Liu, S.; Jin, Y.] Fourth Mil Med Univ, Sch Stomatol, Ctr Tissue Engn, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.
   [Su, X.; Liu, Y.] Xi An Jiao Tong Univ, Coll Med, Inst Neurobiol Environm & Genes Related Dis, Key Lab,Educ Minist, Xian 710061, Shaanxi, Peoples R China.
   [Liao, L.; Shuai, Y.; Jing, H.; Liu, S.; Jin, Y.] Fourth Mil Med Univ, Res & Dev Ctr Tissue Engn, Xian 710032, Shaanxi, Peoples R China.
   [Liao, L.; Shuai, Y.; Jing, H.; Liu, S.] Fourth Mil Med Univ, Sch Stomatol, Dept Oral Histol & Pathol, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University; Air Force Medical University; Xi'an Jiaotong
   University; Air Force Medical University; Air Force Medical University
RP Jin, Y (通讯作者)，Fourth Mil Med Univ, Sch Stomatol, Ctr Tissue Engn, State Key Lab Mil Stomatol, 145 West Changle Rd, Xian 710032, Shaanxi, Peoples R China.
EM liuy5599@mail.xjtu.edu.cn; yanjin@fmmu.edu.cn
RI Jing, Huan/KKW 7423 2024; Jin, Yan/I 4204 2013; Shuai, Yi/ABQ 4038 2022;
   Liao, Li/U 6866 2017
OI Liao, Li/0000 0003 0030 1009
FU National Major Scientific Research Program of China [2011CB964700];
   Nature Science Foundation of China [31030033, 81470710]
FX This work was supported by grants from the National Major Scientific
   Research Program of China (2011CB964700) and the Nature Science
   Foundation of China (31030033, 81470710).
CR Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Clark EA, 2014, STEM CELLS, V32, P1074, DOI 10.1002/stem.1623
   Coelho MJ, 2000, BIOMATERIALS, V21, P1095, DOI 10.1016/S0142 9612(99)00192 1
   Darido C, 2011, CANCER CELL, V20, P635, DOI 10.1016/j.ccr.2011.10.014
   Deschaseaux F, 2010, J CELL MOL MED, V14, P103, DOI 10.1111/j.1582 4934.2009.00878.x
   Dey BK, 2012, GENE DEV, V26, P2180, DOI 10.1101/gad.198085.112
   Dirks PB, 2009, CELL, V138, P423, DOI 10.1016/j.cell.2009.07.025
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Flynt AS, 2007, NAT GENET, V39, P259, DOI 10.1038/ng1953
   Fraser JK, 2006, TRENDS BIOTECHNOL, V24, P150, DOI 10.1016/j.tibtech.2006.01.010
   Fu XH, 2013, P NATL ACAD SCI USA, V110, P17892, DOI 10.1073/pnas.1317397110
   Gómez Barrena E, 2011, J CELL MOL MED, V15, P1266, DOI 10.1111/j.1582 4934.2011.01265.x
   Icli B, 2013, CIRC RES, V113, P1231, DOI 10.1161/CIRCRESAHA.113.301780
   Izadpanah R, 2006, J CELL BIOCHEM, V99, P1285, DOI 10.1002/jcb.20904
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   Karbiener M, 2014, STEM CELLS, V32, P1578, DOI 10.1002/stem.1603
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kim YJ, 2012, J CELL PHYSIOL, V227, P183, DOI 10.1002/jcp.22716
   Krause U, 2010, P NATL ACAD SCI USA, V107, P4147, DOI 10.1073/pnas.0914360107
   Lagathu C, 2009, DIABETES, V58, P609, DOI 10.2337/db08 1180
   Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341
   Li Y, 2013, BIOMATERIALS, V34, P5048, DOI 10.1016/j.biomaterials.2013.03.052
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011
   Luzi E, 2012, NUCLEIC ACID THER, V22, P103, DOI 10.1089/nat.2012.0344
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   Minear S, 2010, J BONE MINER RES, V25, P1196, DOI 10.1002/jbmr.29
   Mizuno H, 2012, STEM CELLS, V30, P804, DOI 10.1002/stem.1076
   Mohamed JS, 2010, J BIOL CHEM, V285, P29336, DOI 10.1074/jbc.M110.101147
   Monaco E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032481
   Niemeyer P, 2010, BIOMATERIALS, V31, P3572, DOI 10.1016/j.biomaterials.2010.01.085
   Noël D, 2008, EXP CELL RES, V314, P1575, DOI 10.1016/j.yexcr.2007.12.022
   Oskowitz AZ, 2008, P NATL ACAD SCI USA, V105, P18372, DOI 10.1073/pnas.0809807105
   Park SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046689
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sakaguchi Y, 2005, ARTHRITIS RHEUM US, V52, P2521, DOI 10.1002/art.21212
   Salvatori B, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.151
   Shafiee A, 2011, BIOTECHNOL LETT, V33, P1257, DOI 10.1007/s10529 011 0541 8
   Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Stadler BM, 2008, CELL, V132, P563, DOI 10.1016/j.cell.2008.02.005
   Strioga M, 2012, STEM CELLS DEV, V21, P2724, DOI 10.1089/scd.2011.0722
   Sugii S, 2011, NAT PROTOC, V6, DOI 10.1038/nprot.2010.199
   Suh JH, 2012, BIOCHEM BIOPH RES CO, V423, P404, DOI 10.1016/j.bbrc.2012.05.138
   Toupadakis CA, 2010, AM J VET RES, V71, P1237, DOI 10.2460/ajvr.71.10.1237
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wei CC, 2014, CELL TRANSPLANT, V23, P505, DOI 10.3727/096368914X678328
   Winter A, 2003, ARTHRITIS RHEUM US, V48, P418, DOI 10.1002/art.10767
   Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065
   Zaidi N, 2007, ANN NY ACAD SCI, V1117, P62, DOI 10.1196/annals.1402.074
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 55
TC 115
Z9 125
U1 0
U2 43
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG
PY 2015
VL 6
AR e1851
DI 10.1038/cddis.2015.221
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA CQ4NP
UT WOS:000360581900015
PM 26247736
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Matsuyama, A
   Higashi, S
   Tanizaki, S
   Morotomi, T
   Washio, A
   Ohsumi, T
   Kitamura, C
   Takeuchi, H
AF Matsuyama, Atsushi
   Higashi, Sen
   Tanizaki, Saori
   Morotomi, Takahiko
   Washio, Ayako
   Ohsumi, Tomoko
   Kitamura, Chiaki
   Takeuchi, Hiroshi
TI Celecoxib inhibits osteoblast differentiation independent of
   cyclooxygenase activity
SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
LA English
DT Article
DE bone morphogenetic protein 2; celecoxib; cyclooxygenase; non steroidal
   anti inflammatory drugs; osteoblast; Smad1; 5 signalling pathway
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BONE FORMATION; EXPRESSION;
   NONUNION; COX 2; RESTRICTION; PHOSPHATASE; MATURATION; INCREASES;
   PROTEINS
AB Non steroidal anti inflammatory drugs (NSAIDs) exert their effects primarily by inhibiting the activity of cyclooxygenase (COX), thus suppressing prostaglandin synthesis. Some NSAIDs are known to perform functions other than pain control, such as suppressing tumour cell growth, independent of their COX inhibiting activity. To identify NSAIDs with COX independent activity, we examined various NSAIDs for their ability to inhibit osteoblastic differentiation using the mouse pre osteoblast cell line MC3T3 E1. Only celecoxib and valdecoxib strongly inhibited osteoblastic differentiation, and this effect was not correlated with COX inhibiting activity. Moreover, 2,5 dimethyl (DM) celecoxib, a celecoxib analogue that does not inhibit COX activity, also inhibited osteoblastic differentiation. Celecoxib and DM celecoxib inhibited osteoblastic differentiation induced by bone morphogenetic protein (BMP) 2 in C2C12 mouse myoblast cell line. Although celecoxib suppresses the growth of some tumour cells, the viability and proliferation of MC3T3 E1 cells were not affected by celecoxib or DM celecoxib. Instead, celecoxib and DM celecoxib suppressed BMP 2 induced phosphorylation of Smad1/5, a major downstream target of BMP receptor. Although it is well known that COX plays important roles in osteoblastic differentiation, these results suggest that some NSAIDs, such as celecoxib, have targets other than COX and regulate phospho dependent intracellular signalling, thereby modifying bone remodelling.
C1 [Matsuyama, Atsushi; Morotomi, Takahiko; Washio, Ayako; Kitamura, Chiaki] Kyushu Dent Univ, Div Endodont & Restorat Dent, Dept Oral Funct, Kitakyushu, Fukuoka, Japan.
   [Matsuyama, Atsushi; Higashi, Sen; Tanizaki, Saori; Ohsumi, Tomoko; Takeuchi, Hiroshi] Kyushu Dent Univ, Div Appl Pharmacol, Dept Hlth Promot, Kitakyushu, Fukuoka, Japan.
C3 Kyushu Dental University; Kyushu Dental University
RP Takeuchi, H (通讯作者)，Kyushu Dent Univ, Div Appl Pharmacol, Dept Hlth Promot, Kitakyushu, Fukuoka, Japan.
EM r12takeuchi@fa.kyu dent.ac.jp
RI ; Takeuchi, Hiroshi/I 8849 2019; Morotomi, Takahiko/AAR 2013 2021
OI Takeuchi, Hiroshi/0000 0003 0033 2913; 
FU Kyushu Dental University Internal Grants; Grants in Aid for Scientific
   Research [26293406, 16K11559, 17K11649] Funding Source: KAKEN
FX Kyushu Dental University Internal Grants
CR Bhattacharyya T, 2005, ARTHRIT RHEUM ARTHR, V53, P364, DOI 10.1002/art.21170
   Boursinos LA, 2009, J MUSCULOSKEL NEURON, V9, P44
   Burd TA, 2003, J BONE JOINT SURG BR, V85B, P700, DOI 10.1302/0301 620X.85B5.13970
   Chang JK, 2006, TOXICOLOGY, V228, P111, DOI 10.1016/j.tox.2006.08.028
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Duan XY, 2006, J BIOL CHEM, V281, P36526, DOI 10.1074/jbc.M605169200
   Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301 620X.82B5.9899
   Han C, 2004, CANCER RES, V64, P1369, DOI 10.1158/0008 5472.CAN 03 1086
   HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620
   Hawley SA, 2012, SCIENCE, V336, P918, DOI 10.1126/science.1215327
   Howe LR, 2002, CANCER RES, V62, P5405
   Jimi E, 2010, JPN DENT SCI REV, V46, P33, DOI 10.1016/j.jdsr.2009.10.003
   Knockaert M, 2006, P NATL ACAD SCI USA, V103, P11940, DOI 10.1073/pnas.0605133103
   Kolar P, 2009, CLIN EXP RHEUMATOL, V27, P99
   Kotake S, 2010, PHARMACEUTICALS, V3, P1394, DOI 10.3390/ph3051394
   Lee CM, 2010, J BONE MINER METAB, V28, P8, DOI 10.1007/s00774 009 0096 0
   Li CJ, 2011, BONE, V48, P286, DOI 10.1016/j.bone.2010.09.020
   Li CJ, 2010, BIOCHEM PHARMACOL, V79, P926, DOI 10.1016/j.bcp.2009.10.019
   Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044
   Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02 07 0441
   Nagano A, 2017, J PHARMACOL SCI, V133, P18, DOI 10.1016/j.jphs.2016.11.003
   Nakai K, 2006, BONE, V39, P83, DOI 10.1016/j.bone.2005.12.014
   ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014 5793(93)80263 T
   Patti R, 2002, CANCER LETT, V180, P13, DOI 10.1016/S0304 3835(02)00003 4
   Ramirez Yanez GO, 2012, ARCH ORAL BIOL, V57, P1274, DOI 10.1016/j.archoralbio.2012.03.003
   Rosen V, 2006, ANN NY ACAD SCI, V1068, P19, DOI 10.1196/annals.1346.005
   Schönthal AH, 2007, BRIT J CANCER, V97, P1465, DOI 10.1038/sj.bjc.6604049
   Schonthal Axel H, 2006, Neurosurg Focus, V20, pE21, DOI 10.3171/foc.2006.20.4.14
   Thun MJ, 2002, JNCI J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Ulrich Cornelia M, 2006, Discov Med, V6, P71
   Vane JR, 1996, SCAND J RHEUMATOL, P9
   Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006 8993(99)01389 X
   Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 35
TC 6
Z9 6
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1440 1681
J9 CLIN EXP PHARMACOL P
JI Clin. Exp. Pharmacol. Physiol.
PD JAN
PY 2018
VL 45
IS 1
BP 75
EP 83
DI 10.1111/1440 1681.12846
PG 9
WC Pharmacology & Pharmacy; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Physiology
GA FP2SM
UT WOS:000417468800010
PM 28815657
DA 2025 08 17
ER

PT J
AU Mohammad, KS
   Chen, CG
   Balooch, G
   Stebbins, E
   McKenna, CR
   Davis, H
   Niewolna, M
   Peng, XH
   Nguyen, DHN
   Ionova Martin, SS
   Bracey, JW
   Hogue, WR
   Wong, DH
   Ritchie, RO
   Suva, LJ
   Derynck, R
   Guise, TA
   Alliston, T
AF Mohammad, Khalid S.
   Chen, Carol G.
   Balooch, Guive
   Stebbins, Elizabeth
   McKenna, C. Ryan
   Davis, Holly
   Niewolna, Maria
   Peng, Xiang Hong
   Nguyen, Daniel H. N.
   Ionova Martin, Sophi S.
   Bracey, John W.
   Hogue, William R.
   Wong, Darren H.
   Ritchie, Robert O.
   Suva, Larry J.
   Derynck, Rik
   Guise, Theresa A.
   Alliston, Tamara
TI Pharmacologic Inhibition of the TGF β Type I Receptor Kinase Has
   Anabolic and Anti Catabolic Effects on Bone
SO PLOS ONE
LA English
DT Article
AB During development, growth factors and hormones cooperate to establish the unique sizes, shapes and material properties of individual bones. Among these, TGF beta has been shown to developmentally regulate bone mass and bone matrix properties. However, the mechanisms that control postnatal skeletal integrity in a dynamic biological and mechanical environment are distinct from those that regulate bone development. In addition, despite advances in understanding the roles of TGF beta signaling in osteoblasts and osteoclasts, the net effects of altered postnatal TGF beta signaling on bone remain unclear. To examine the role of TGF beta in the maintenance of the postnatal skeleton, we evaluated the effects of pharmacological inhibition of the TGF beta type I receptor (T beta RI) kinase on bone mass, architecture and material properties. Inhibition of T beta RI function increased bone mass and multiple aspects of bone quality, including trabecular bone architecture and macro mechanical behavior of vertebral bone. T beta RI inhibitors achieved these effects by increasing osteoblast differentiation and bone formation, while reducing osteoclast differentiation and bone resorption. Furthermore, they induced the expression of Runx2 and EphB4, which promote osteoblast differentiation, and ephrinB2, which antagonizes osteoclast differentiation. Through these anabolic and anti catabolic effects, T beta RI inhibitors coordinate changes in multiple bone parameters, including bone mass, architecture, matrix mineral concentration and material properties, that collectively increase bone fracture resistance. Therefore, T beta RI inhibitors may be effective in treating conditions of skeletal fragility.
RP Mohammad, KS (通讯作者)，Univ Virginia, Div Endocrinol, Dept Internal Med, Charlottesville, VA 22903 USA.
EM tamara.alliston@ucsf.edu
RI Mohammad, Khalid/AFE 4205 2022; Ritchie, Robert/A 8066 2008
OI Suva, Larry/0000 0002 2892 9757; Alliston, Tamara/0000 0001 9992 2897
FU NIDCR NIH HHS [R03 DE016868] Funding Source: Medline
CR Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Alliston Tamara, 2008, P667
   [Anonymous], E1820 ASTM
   Arany PR, 2006, P NATL ACAD SCI USA, V103, P9250, DOI 10.1073/pnas.0602473103
   ASTM, 1990, ASTM E399
   Balooch G, 2005, P NATL ACAD SCI USA, V102, P18813, DOI 10.1073/pnas.0507417102
   Bonniaud P, 2005, AM J RESP CRIT CARE, V171, P889, DOI 10.1164/rccm.200405 612OC
   Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754
   CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810
   CURREY JD, 1969, J BIOMECH, V2, P477, DOI 10.1016/0021 9290(69)90023 2
   Currey JD, 1999, J EXP BIOL, V202, P3285
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   Derynck Rik, 2008, P613
   Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903
   Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195
   Filvaroff E, 1999, DEVELOPMENT, V126, P4267
   Fox SW, 2005, MOL CELL ENDOCRINOL, V243, P19, DOI 10.1016/j.mce.2005.09.008
   Gaddy Kurten D, 2002, ENDOCRINOLOGY, V143, P74, DOI 10.1210/en.143.1.74
   Gaspar NJ, 2007, MOL PHARMACOL, V72, P152, DOI 10.1124/mol.106.029025
   Geiser AG, 1998, BONE, V23, P87, DOI 10.1016/S8756 3282(98)00078 7
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Hernandez CJ, 2006, BONE, V39, P1173, DOI 10.1016/j.bone.2006.06.001
   Hildebrand T, 1999, J BONE MINER RES, V14, P1167, DOI 10.1359/jbmr.1999.14.7.1167
   Iida Klein A, 2006, J BONE MINER RES, V21, P274, DOI 10.1359/JBMR.051017
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Kaneda T, 2000, J IMMUNOL, V165, P4254, DOI 10.4049/jimmunol.165.8.4254
   Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729
   Kapoun AM, 2006, MOL PHARMACOL, V70, P518, DOI 10.1124/mol.105.021600
   Karsdal MA, 2003, J BIOL CHEM, V278, P44975, DOI 10.1074/jbc.M303905200
   Karst M, 2004, J CELL PHYSIOL, V200, P99, DOI 10.1002/jcp.20036
   KINNEY JH, 1994, SCANNING MICROSCOPY, V8, P197
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58
   Lin AH, 2005, J IMMUNOL, V175, P547, DOI 10.4049/jimmunol.175.1.547
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067
   Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723
   Oliver WC, 2004, J MATER RES, V19, P3, DOI 10.1557/jmr.2004.19.1.3
   OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006 291X(89)92795 2
   OURSLER MJ, 1994, J BONE MINER RES, V9, P443
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Perrien DS, 2007, ENDOCRINOLOGY, V148, P1654, DOI 10.1210/en.2006 0848
   Rho JY, 1997, BIOMATERIALS, V18, P1325, DOI 10.1016/S0142 9612(97)00073 2
   RITCHIE RO, 2008, BONE
   Stabnov L, 2002, BONE, V30, P909, DOI 10.1016/S8756 3282(02)00738 X
   Suva LJ, 2008, AM J PATHOL, V172, P430, DOI 10.2353/ajpath.2008.070417
   Takahashi N, 2002, PRINCIPLES BONE BIOL, P109
   THIRUNAVUKKARAS.K, 2001, J BIOL CHEM, V12, P12
   Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008 5472.CAN 04 1013
   Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35
   Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580
   ZAHOOR A, 1989, ELECT POWER RES I
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zysset PK, 1999, J BIOMECH, V32, P1005, DOI 10.1016/S0021 9290(99)00111 6
NR 54
TC 141
Z9 171
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD APR 16
PY 2009
VL 4
IS 4
AR e5275
DI 10.1371/journal.pone.0005275
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 437TU
UT WOS:000265510600013
PM 19357790
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Jiang, Y
   Gou, H
   Wang, SR
   Zhu, J
   Tian, S
   Yu, LH
AF Jiang, Yuan
   Gou, Hui
   Wang, Sanrong
   Zhu, Jiang
   Tian, Si
   Yu, Lehua
TI Effect of Pulsed Electromagnetic Field on Bone Formation and Lipid
   Metabolism of Glucocorticoid Induced Osteoporosis Rats through Canonical
   Wnt Signaling Pathway
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID DIFFERENTIATION; PROLIFERATION; ADIPOGENESIS; EXPRESSION; STRENGTH; MASS
AB Pulsed electromagnetic field (PEMF) has been suggested as a promising method alternative to drug based therapies for treating osteoporosis (OP), but the role of PEMF in GIOP animal models still remains unknown. This study was performed to investigate the effect of PEMF on bone formation and lipid metabolism and further explored the several important components and targets of canonical Wnt signaling pathway in GIOP rats. After 12 weeks of intervention, bone mineral density (BMD) level of the whole body increased significantly, serum lipid levels decreased significantly, and trabeculae were thicker in GIOP rats of PEMF group. PEMF stimulation upregulated the mRNA and protein expression of Wnt10b, LRP5, beta catenin, OPG, and Runx2 and downregulated Axin2, PPAR gamma, C/EBP alpha, FABP4, and Dkk 1. The results of this study suggested that PEMF stimulation can prevent bone loss and improve lipid metabolism disorders in GIOP rats. Canonical Wnt signaling pathway plays an important role in bone formation and lipid metabolism during PEMF stimulation.
C1 [Jiang, Yuan; Gou, Hui; Wang, Sanrong; Zhu, Jiang; Tian, Si; Yu, Lehua] Chongqing Med Univ, Affiliated Hosp 1, Dept Rehabil Med & Phys Therapy, Chongqing 400010, Peoples R China.
C3 Chongqing Medical University
RP Yu, LH (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Rehabil Med & Phys Therapy, Chongqing 400010, Peoples R China.
EM yulehua@cqmu.edu.cn
FU National Natural Science Foundation of China [81171859]; Chongqing
   Municipal Healthcare Department Medical Research Grant [2010 1 20:2]
FX This work was supported by the grants from National Natural Science
   Foundation of China (no. 81171859) and Chongqing Municipal Healthcare
   Department Medical Research Grant (no. 2010 1 20:2). The authors also
   express their sincere thanks to Dr. Lei Yuan, Dr. Mingyuan Tian, Dr. Yi
   Yuan, and Ms. Zunzhen Zhou for their helpful assistance.
CR Ahmed HH, 2012, EUR REV MED PHARMACO, V16, P1446
   Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Bitto A, 2009, BRIT J PHARMACOL, V156, P1287, DOI 10.1111/j.1476 5381.2008.00100.x
   Cui L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034647
   Ding S, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 215
   Feng RJ, 2013, CELL BIOCHEM BIOPHYS, V67, P189, DOI 10.1007/s12013 013 9533 8
   Folwarczna J, 2011, PHARMACOL REP, V63, P1040, DOI 10.1016/S1734 1140(11)70620 X
   Fujita Y, 2011, AM J ORTHOD DENTOFAC, V139, DOI 10.1016/j.ajodo.2009.05.028
   Guañabens N, 2014, CURR OSTEOPOROS REP, V12, P90, DOI 10.1007/s11914 014 0197 0
   Hofbauer LC, 2009, ARTHRITIS RHEUM, V60, P1427, DOI 10.1002/art.24445
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193
   Jensen B, 2004, EXP CELL RES, V301, P280, DOI 10.1016/j.yexcr.2004.08.030
   Jing D, 2011, OSTEOPOROSIS INT, V22, P1885, DOI 10.1007/s00198 010 1447 3
   Jing D, 2014, J BONE MINER RES, V29, P2250, DOI 10.1002/jbmr.2260
   Jing D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079377
   Jing D, 2010, BONE, V46, P487, DOI 10.1016/j.bone.2009.09.021
   Kawai M, 2007, BIOCHEM BIOPH RES CO, V363, P276, DOI 10.1016/j.bbrc.2007.08.088
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Koromila T, 2014, J CELL BIOCHEM, V115, P27, DOI 10.1002/jcb.24646
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Li JP, 2014, BIOELECTROMAGNETICS, V35, P170, DOI 10.1002/bem.21833
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Naito M, 2013, CELL TISSUE RES, V354, P761, DOI 10.1007/s00441 013 1696 5
   Parra P, 2008, J NUTR BIOCHEM, V19, P109, DOI 10.1016/j.jnutbio.2007.01.009
   Pranic Kragic A, 2011, ACTA CLIN CROAT, V50, P563
   Rahman S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051746
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Tian L, 2015, MOL MED REP, V12, P783, DOI 10.3892/mmr.2015.3472
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Weinstein RS, 2012, ENDOCRINE, V41, P183, DOI 10.1007/s12020 011 9580 0
   Yoon HY, 2012, BIOMOL THER, V20, P89, DOI 10.4062/biomolther.2012.20.1.089
   Zhang CF, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 30
   Zhang Z., 2014, SCI WORLD J, V2014, DOI DOI 10.1155/2014/645975
   Zhong C, 2012, CHINESE MED J PEKING, V125, P367, DOI 10.3760/cma.j.issn.0366 6999.2012.02.035
   Zhou J, 2014, BIOELECTROMAGNETICS, V35, P30, DOI 10.1002/bem.21794
   Zhou J, 2015, ENDOCRINE, V49, P258, DOI 10.1007/s12020 014 0439 z
   Zhou J, 2013, RHEUMATOL INT, V33, P1135, DOI 10.1007/s00296 012 2499 9
   Zhou J, 2012, ARCH MED RES, V43, P274, DOI 10.1016/j.arcmed.2012.06.002
NR 39
TC 18
Z9 21
U1 1
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PY 2016
VL 2016
AR 4927035
DI 10.1155/2016/4927035
PG 13
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA DD4VC
UT WOS:000369919900001
PM 26941827
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Ozaki, K
   Okamoto, M
   Fukasawa, K
   Iezaki, T
   Onishi, Y
   Yoneda, Y
   Sugiura, M
   Hinoi, E
AF Ozaki, Kakeru
   Okamoto, Maika
   Fukasawa, Kazuya
   Iezaki, Takashi
   Onishi, Yuki
   Yoneda, Yukio
   Sugiura, Minoru
   Hinoi, Eiichi
TI Daily intake of β cryptoxanthin prevents bone loss by preferential
   disturbance of osteoclastic activation in ovariectomized mice
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Osteoclast; Osteoporosis; Osteoblast
ID FEMORAL TISSUES; RISK; RATS
AB Although beta cryptoxanthin, a xanthophyll carotenoid, has been shown to exert an anabolic effect on bone calcification, little attention has been paid thus far to the precise mechanism of bone remodeling. Daily oral administration of beta cryptoxanthin significantly inhibited osteoclastic activation as well as reduction of bone volume in ovariectomized mice. In vitro studies revealed that beta cryptoxanthin inhibited differentiation and maturation of osteoclasts by repression of the nuclear factor kappa B dependent transcriptional pathway. Our results suggest that supplementation with beta cryptoxanthin would be beneficial for prophylaxis and for therapy of metabolic bone diseases associated with abnormal osteoclast activation. (C) 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B. V. on behalf of Japanese Pharmacological Society.
C1 [Ozaki, Kakeru; Okamoto, Maika; Fukasawa, Kazuya; Iezaki, Takashi; Onishi, Yuki; Yoneda, Yukio; Hinoi, Eiichi] Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Pharmaceut Sci, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan.
   [Sugiura, Minoru] Natl Agr & Food Res Org, Citrus Res Div, NARO Inst Fruit Tree Sci, Shimizu, Shizuoka, Japan.
C3 Kanazawa University; National Agriculture & Food Research Organization  
   Japan
RP Hinoi, E (通讯作者)，Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.
EM hinoi@p.kanazawa u.ac.jp
RI ; Yoneda, Yukio/ABI 1864 2020
OI Yoneda, Yukio/0000 0002 4624 177X; Fukasawa, Kazuya/0000 0002 1845 0275;
   
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [23689004]; Grants in Aid for Scientific Research [23689004] Funding
   Source: KAKEN
FX This work was supported in part by Grants in Aids for Scientific
   Research to E.H. from the Ministry of Education, Culture, Sports,
   Science and Technology, Japan (23689004).
CR Burri BJ, 2014, J SCI FOOD AGR, V61, P205
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Hinoi E, 2006, MOL PHARMACOL, V70, P925, DOI 10.1124/mol.106.024398
   Hinoi E, 2012, J BONE MINER RES, V27, P938, DOI 10.1002/jbmr.1538
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kobori M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098294
   Min KB, 2014, CANCER SCI, V105, P736, DOI 10.1111/cas.12405
   Moriguchi N, 2007, BIOCHEM PHARMACOL, V73, P385, DOI 10.1016/j.bcp.2006.09.025
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Sugiura M, 2015, YAKUGAKU ZASSHI, V135, P67, DOI 10.1248/yakushi.14 00208 5
   Sugiura M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052643
   Uchiyama S, 2006, INT J MOL MED, V17, P15
   Uchiyama S, 2004, BIOL PHARM BULL, V27, P232, DOI 10.1248/bpb.27.232
   Yamaguchi M, 2003, BIOL PHARM BULL, V26, P1188, DOI 10.1248/bpb.26.1188
   Yamamoto T, 2012, BRIT J PHARMACOL, V166, P1084, DOI 10.1111/j.1476 5381.2012.01856.x
NR 15
TC 25
Z9 27
U1 0
U2 8
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD SEP
PY 2015
VL 129
IS 1
BP 72
EP 77
DI 10.1016/j.jphs.2015.08.003
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CT4BB
UT WOS:000362749800011
PM 26342276
OA gold
DA 2025 08 17
ER

PT S
AU Shi, CH
   Li, J
   Wang, WS
   Cao, WW
   Cao, X
   Wan, M
AF Shi, Chenhui
   Li, Jun
   Wang, Weishan
   Cao, Weiwei
   Cao, Xu
   Wan, Mei
GP Annals NY Acad Sci
TI Antagonists of LRP6 regulate PTH induced cAMP generation
SO SKELETAL BIOLOGY AND MEDICINE I
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT 4th New York Skeletal Biology and Medicine Conference
CY APR 27 30, 2011
CL Mt Sinai Sch Med, New York, NY
HO Mt Sinai Sch Med
DE sclerostin; DKK1; PTH; LRP6; cAMP production
ID PROTEIN KINASE C; PARATHYROID HORMONE; BONE FORMATION; SCLEROSTIN;
   RECEPTOR; DICKKOPF 1; DENSITY; MECHANISM; LIGAND; SOST
AB LRP6 is a common coreceoptor for different G protein coupled seven transmembrane receptors in production of cAMP. Extracelluar proteins sclerostin and DKK1, initially identified as antagonists for Wnt signaling by binding to LRP6, are negative regulators for bone formation. Here, we show that both sclerostin and DKK1 inhibit PTH stimulated cAMP production. In addition, PTH suppresses expression of sclerostin in osteocytes in mice. We also found that sclerostin and DKK1 binds to LRP6 as antagonists to increase the availability of LRP6 to facilitate PTH signaling in a positive feedback fashion. These studies reveal a previously unrecognized function of sclerostin and DKK1, which provides an alternative explanation for the application of sclerostin and DKK1 neutralization on enhancing bone formation as a potential therapy for skeletal diseases.
C1 [Cao, Xu; Wan, Mei] Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD 21205 USA.
   [Shi, Chenhui; Li, Jun; Wang, Weishan; Cao, Weiwei] Shihezi Univ, Shihezi Med Coll, Xinjiang, Peoples R China.
C3 Johns Hopkins University; Shihezi University
RP Wan, M (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD 21205 USA.
EM mwan4@jhmi.edu
RI Wang, Weishan/AAP 6408 2020
FU National Institutes of Health [DK083350]
FX This work was supported by grants from the National Institutes of Health
   DK083350 (to M.W.).
CR ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V124, P1107, DOI 10.1210/endo 124 3 1107
   BABICH M, 1989, J BONE MINER RES, V4, P549
   Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660
   Cole JA, 1999, ENDOCRINOLOGY, V140, P5771, DOI 10.1210/en.140.12.5771
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   DiPilato LM, 2009, MOL BIOSYST, V5, P832, DOI 10.1039/b823243a
   DiPilato LM, 2004, P NATL ACAD SCI USA, V101, P16513, DOI 10.1073/pnas.0405973101
   DONAHUE HJ, 1988, J BIOL CHEM, V263, P13522
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   GALLOPAYET N, 1989, J ENDOCRINOL, V120, P409, DOI 10.1677/joe.0.1200409
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kilianova Z, 2006, ENDOCRINOLOGY, V147, P2325, DOI 10.1210/en.2005 0991
   Kolpakova E, 2005, DEV CELL, V8, P626, DOI 10.1016/j.devcel.2005.04.008
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108
   Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097 2765(01)00224 6
   Mason JJ, 2010, J OSTEOPOROS, V2010, DOI 10.4061/2010/460120
   Murray TM, 2005, ENDOCR REV, V26, P78, DOI 10.1210/er.2003 0024
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124
   Potts JT, 2007, ANN NY ACAD SCI, V1117, P196, DOI 10.1196/annals.1402.088
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Semenov MV, 2006, J BIOL CHEM, V281, P38276, DOI 10.1074/jbc.M609509200
   Semënov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960 9822(01)00290 1
   Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200
   Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097 2765(03)00484 2
   Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Violin JD, 2008, J BIOL CHEM, V283, P2949, DOI 10.1074/jbc.M707009200
   Wan M, 2008, GENE DEV, V22, P2968, DOI 10.1101/gad.1702708
   Wan M, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001464
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   YAMAGUCHI DT, 1987, J BIOL CHEM, V262, P7711
NR 47
TC 11
Z9 13
U1 1
U2 9
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077 8923
BN 978 1 57331 846 4
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2011
VL 1237
BP 39
EP 46
DI 10.1111/j.1749 6632.2011.06226.x
PG 8
WC Multidisciplinary Sciences; Physiology
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Physiology
GA BZE87
UT WOS:000301292200006
PM 22082363
DA 2025 08 17
ER

PT J
AU Zhang, YR
   Hu, Y
   Luo, Z
   Shen, XK
   Mu, CY
   Cai, KY
AF Zhang, Yarong
   Hu, Yan
   Luo, Zhong
   Shen, Xinkun
   Mu, Caiyun
   Cai, Kaiyong
TI Simultaneous delivery of BMP 2 factor and anti osteoporotic drugs using
   hyaluronan assembled nanocomposite for synergistic regulation on the
   behaviors of osteoblasts and osteoclasts in vitro
SO JOURNAL OF BIOMATERIALS SCIENCE POLYMER EDITION
LA English
DT Article
DE osteoblasts; BMP 2; osteoclasts; hyaluronate; osteoporosis
ID ENDOTHELIAL CELLS; TIO2 NANOTUBES; BONE FORMATION; DIFFERENTIATION;
   ALENDRONATE; PROTEIN; TITANIUM; WEIGHT; BISPHOSPHONATES; INHIBITION
AB To treat the osteoporosis and regulate the biological behaviors of both osteoblasts and osteoclasts, we prepared a natural polysaccharide derived nanocomposite, containing alendronate grafted hyaluronate (HA Aln) and bone morphogenetic protein 2 (BMP 2) and investigated its synergistic regulation on the behaviors of osteoblasts and osteoclasts in vitro. The HA Aln/BMP 2 nanocomposite was fabricated through the electrostatic interactions between the HA Aln molecule and BMP 2 molecule. Here, BMP 2 was used to improve the osteoblast mediated bone formation. Alendronate (Aln), a targeting ligand to bone matrix, was used to inhibit the osteoclast mediated bone resorption. In vitro results showed that HA Aln/BMP 2 nanocomposite could effectively maintain the bioactivity of loaded drugs. The osteoblasts that treated with the HA Aln/BMP 2 nanocomposite presented a higher level of cell motility, alkaline phosphatase (ALP) activity, mineralization capacity, and osteoblast related gene expressions (runt related transcription factor 2, osterix, ALP, collagen type I, osteocalcin, and osteopontin), as compared to that of control group. Besides, the RAW264.7 cells that were treated with HA Aln/BMP 2 nanocomposite showed a lower level of osteoclastic differentiation. Overall, the HA Aln/BMP 2 nanocomposite exhibits promising potential as an efficient carrier for co delivery of anti osteoporotic drug and growth factors to promote osteoblastic differentiation and bone formation while suppressing osteoclastic activity.
C1 [Zhang, Yarong; Hu, Yan; Luo, Zhong; Shen, Xinkun; Mu, Caiyun; Cai, Kaiyong] Chongqing Univ, Coll Bioengn, Minist Educ, Key Lab Biorheol Sci & Technol, Chongqing 400044, Peoples R China.
C3 Chongqing University
RP Hu, Y (通讯作者)，Chongqing Univ, Coll Bioengn, Minist Educ, Key Lab Biorheol Sci & Technol, Chongqing 400044, Peoples R China.
EM huyan303@cqu.edu.cn; kaiyong_cai@cqu.edu.cn
RI ; Cai, Kaiyong/G 1233 2011; Luo, Zhong/AAU 2225 2020
OI Luo, Zhong/0000 0002 9019 3314; Cai, Kaiyong/0000 0001 9029 680X; 
FU Natural Science Foundation of China [31200712, 11032012, 51173216];
   Natural Science Foundation of Chongqing Municipal Government (CSTC)
   [2011JJJQ10004]; National Key Technology R&D Program of the Ministry of
   Science and Technology [2012BAI18B04]
FX This work was supported by the Natural Science Foundation of China
   [grant number 31200712], [grant number 11032012], [grant number
   51173216], Natural Science Foundation of Chongqing Municipal Government
   (CSTC) [grant number 2011JJJQ10004], and National Key Technology R&D
   Program of the Ministry of Science and Technology [grant number
   2012BAI18B04].
CR Alborzinia H, 2013, J CELL SCI, V126, P117, DOI 10.1242/jcs.109777
   Ariyoshi W, 2014, OSTEOARTHR CARTILAGE, V22, P111, DOI 10.1016/j.joca.2013.10.013
   Bezemer JM, 2000, J CONTROL RELEASE, V64, P179, DOI 10.1016/S0168 3659(99)00127 3
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Clementi C, 2011, MOL PHARMACEUT, V8, P1063, DOI 10.1021/mp2001445
   Cowan CM, 2007, J BONE MINER RES, V22, P918, DOI 10.1359/JBMR.070312
   de la Fuente M, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957 4484/19/7/075105
   de la Fuente M, 2008, INVEST OPHTH VIS SCI, V49, P2016, DOI 10.1167/iovs.07 1077
   Enoki Y, 2014, FEBS LETT, V588, P2262, DOI 10.1016/j.febslet.2014.05.009
   Fujisaki J, 1998, J DRUG TARGET, V5, P129, DOI 10.3109/10611869808995866
   Giger EV, 2013, J CONTROL RELEASE, V167, P175, DOI 10.1016/j.jconrel.2013.01.032
   Giger EV, 2011, J CONTROL RELEASE, V150, P87, DOI 10.1016/j.jconrel.2010.11.012
   Hu Y, 2012, BIOMATERIALS, V33, P3515, DOI 10.1016/j.biomaterials.2012.01.040
   Hu Y, 2012, ACTA BIOMATER, V8, P439, DOI 10.1016/j.actbio.2011.10.021
   Jobke B, 2014, BONE, V59, P37, DOI 10.1016/j.bone.2013.10.024
   Kasahara T, 2010, BONE, V47, P617, DOI 10.1016/j.bone.2010.06.014
   Komatsu K, 2013, J ENDOCRINOL, V219, P145, DOI 10.1530/JOE 13 0040
   Lai M, 2011, BIOMACROMOLECULES, V12, P1097, DOI 10.1021/bm1014365
   Lee CW, 2014, BIOCHEM BIOPH RES CO, V449, P438, DOI 10.1016/j.bbrc.2014.05.050
   Li SF, 2014, BONE, V61, P164, DOI 10.1016/j.bone.2014.01.010
   Lühe A, 2008, TOXICOL IN VITRO, V22, P899, DOI 10.1016/j.tiv.2008.01.006
   Luhmann T, 2012, J CONTROL RELEASE, V161, P198, DOI 10.1016/j.jconrel.2011.10.001
   Macdonald M, 2008, J CONTROL RELEASE, V131, P228, DOI 10.1016/j.jconrel.2008.07.032
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Meng FT, 2003, J CONTROL RELEASE, V91, P407, DOI 10.1016/S0168 3659(03)00273 6
   Moon HJ, 2011, BIOCHEM BIOPH RES CO, V413, P194, DOI 10.1016/j.bbrc.2011.08.057
   Moore NM, 2011, ACTA BIOMATER, V7, P2091, DOI 10.1016/j.actbio.2011.01.019
   Moreira MS, 2005, DENT TRAUMATOL, V21, P329, DOI 10.1111/j.1600 9657.2005.00370.x
   Morton SW, 2014, ADV HEALTHC MATER, V3, P867, DOI 10.1002/adhm.201300465
   Na SJ, 2008, INT J PHARMACEUT, V363, P149, DOI 10.1016/j.ijpharm.2008.07.013
   Correia VDP, 2006, DENT TRAUMATOL, V22, P312, DOI 10.1111/j.1600 9657.2005.00434.x
   Papapoulos SE, 2013, NAT REV RHEUMATOL, V9, P263, DOI 10.1038/nrrheum.2013.57
   Park J, 2009, SMALL, V5, P666, DOI 10.1002/smll.200801476
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Shimizu E, 2012, J DENT RES, V91, P268, DOI 10.1177/0022034511432170
   SIMONNET H, 1994, BBA BIOMEMBRANES, V1189, P152, DOI 10.1016/0005 2736(94)90060 4
   STEADMAN BL, 1992, BIOTECHNOL BIOENG, V40, P8, DOI 10.1002/bit.260400103
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Vlacic Zischke J, 2011, BIOMATERIALS, V32, P665, DOI 10.1016/j.biomaterials.2010.09.025
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Xia LU, 2013, MICROPOR MESOPOR MAT, V173, P155, DOI 10.1016/j.micromeso.2013.02.020
   Yonezawa T, 2011, BIOCHEM BIOPH RES CO, V409, P260, DOI 10.1016/j.bbrc.2011.05.001
   Zhang YY, 2010, BIOMATERIALS, V31, P8465, DOI 10.1016/j.biomaterials.2010.07.060
NR 45
TC 14
Z9 14
U1 2
U2 86
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0920 5063
EI 1568 5624
J9 J BIOMAT SCI POLYM E
JI J. Biomater. Sci. Polym. Ed.
PD MAR 24
PY 2015
VL 26
IS 5
BP 290
EP 310
DI 10.1080/09205063.2014.998588
PG 21
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science; Polymer Science
GA CB2GC
UT WOS:000349444000002
PM 25585099
DA 2025 08 17
ER

PT J
AU Chang, ZP
   Chen, DK
   Peng, J
   Liu, RY
   Li, BB
   Kang, JB
   Guo, L
   Hou, RG
   Xu, XH
   Lee, M
   Zhang, X
AF Chang, Zhuangpeng
   Chen, Dengke
   Peng, Jiao
   Liu, Rongyan
   Li, Beibei
   Kang, Jianbang
   Guo, Li
   Hou, Ruigang
   Xu, Xianghui
   Lee, Min
   Zhang, Xiao
TI Bone Targeted Supramolecular Nanoagonist Assembled by Accurate
   Ratiometric Herbal Derived Therapeutics for Osteoporosis Reversal
SO NANO LETTERS
LA English
DT Article
DE herbal derived nanomedicine; bone targeted delivery; compositional
   accuracy; Wnt signaling pathway; osteoporosis therapy
ID SELF DELIVERY; NANOPARTICLES; ACID; HOMEOSTASIS; LIPOSOMES; MEDICINE;
   PRODRUG
AB Developing novel strategies for defeating osteoporosis has become a world wide challenge with the aging of the population. In this work, novel supramolecular nanoagonists (NAs), constructed from alkaloids and phenolic acids, emerge as a carrier free nanotherapy for efficacious osteoporosis treatment. These precision nanoagonists are formed through the self assembly of berberine (BER) and chlorogenic acid (CGA), utilizing noncovalent electrostatic, pi pi, and hydrophobic interactions. This assembly results in a 100% drug loading capacity and stable nanostructure. Furthermore, the resulting weights and proportions of CGA and BER within the NAs are meticulously controlled with strong consistency when the CGA/BER assembly feed ratio is altered from 1:1 to 1:4. As anticipated, our NAs themselves could passively target osteoporotic bone tissues following prolonged blood circulation, modulate Wnt signaling, regulate osteogenic differentiation, and ameliorate bone loss in ovariectomy induced osteoporotic mice. We hope this work will open a new strategy to design efficient herbal derived Wnt NAs for dealing with intractable osteoporosis.
C1 [Chang, Zhuangpeng; Chen, Dengke; Peng, Jiao; Liu, Rongyan; Li, Beibei; Kang, Jianbang; Guo, Li; Hou, Ruigang; Zhang, Xiao] Shanxi Med Univ, Sch Pharm, Taiyuan 030001, Peoples R China.
   [Chang, Zhuangpeng; Chen, Dengke; Peng, Jiao; Liu, Rongyan; Li, Beibei; Kang, Jianbang; Guo, Li; Hou, Ruigang] Shanxi Med Univ, Shanxi Prov Key Lab Drug Synth & Novel Pharmaceut, Taiyuan 030001, Peoples R China.
   [Xu, Xianghui] Hunan Univ, Coll Biol, Dept Pharm, Changsha 410082, Hunan, Peoples R China.
   [Lee, Min] Univ Calif Los Angeles, Div Adv Prosthodont, Los Angeles, CA 90095 USA.
C3 Shanxi Medical University; Shanxi Medical University; Hunan University;
   University of California System; University of California Los Angeles
RP Hou, RG; Zhang, X (通讯作者)，Shanxi Med Univ, Sch Pharm, Taiyuan 030001, Peoples R China.; Lee, M (通讯作者)，Univ Calif Los Angeles, Div Adv Prosthodont, Los Angeles, CA 90095 USA.
EM houruigang@sxmu.edu.cn; leemin@ucla.edu; xiao.zhang1@hotmail.com
RI Li, Beibei/P 2243 2014; Chen, Dengke/MTD 5675 2025
FU National Natural Science Foundation of China [82102207]; National
   Natural Science Foundation of China [2021 173]; Shanxi Scholarship
   Council of China [20210302124036]; Natural Science Foundation of Shanxi
   Province [2023SJ158]; Shanxi graduate practice innovation project
FX This work was supported by National Natural Science Foundation of China
   (82102207), Shanxi Scholarship Council of China (2021 173), Natural
   Science Foundation of Shanxi Province (20210302124036) and Shanxi
   graduate practice innovation project (2023SJ158). We also thank
   Shiyanjia Lab (www.shiyanjia.com) for the SEM analysis.
CR [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   Bai Long, 2023, Biomater Transl, V4, P248, DOI 10.12336/biomatertransl.2023.04.005
   Bai L, 2023, BIOMATERIALS, V297, DOI 10.1016/j.biomaterials.2023.122125
   Baron R, 2018, CURR OPIN PHARMACOL, V40, P134, DOI 10.1016/j.coph.2018.04.011
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Chakraborty K., 2016, INT J HERB MED, V4, P61, DOI [DOI 10.22271/FLORA.2016.V4.I3.05, 10.22271/flora.2016.v4.i3.05]
   Chen MW, 2022, ACS NANO, V16, P15397, DOI 10.1021/acsnano.2c07200
   Cheng XM, 2022, FRONT CHEM, V10, DOI 10.3389/fchem.2022.963004
   Cui YZ, 2022, ACS NANO, V16, P11076, DOI 10.1021/acsnano.2c03781
   Deng ZY, 2020, J CONTROL RELEASE, V326, P276, DOI 10.1016/j.jconrel.2020.07.010
   Feng JX, 2020, BIOMATERIALS, V241, DOI 10.1016/j.biomaterials.2020.119907
   Freeman FE, 2023, ADV MATER, V35, DOI 10.1002/adma.202207877
   Ge YX, 2023, NANO LETT, V23, P6610, DOI 10.1021/acs.nanolett.3c01771
   Han YF, 2024, BIOACT MATER, V35, P1, DOI 10.1016/j.bioactmat.2024.01.009
   Hendrickx G, 2015, NAT REV RHEUMATOL, V11, P462, DOI 10.1038/nrrheum.2015.48
   Hogan AM, 2009, INT J COLORECTAL DIS, V24, P1367, DOI 10.1007/s00384 009 0785 0
   Hu XP, 2021, STEM CELLS DEV, V30, P641, DOI 10.1089/scd.2020.0193
   Huang Y, 2015, CURR DRUG TARGETS, V16, P1548, DOI 10.2174/1389450116666150309122334
   Hwang JH, 2023, J CONTROL RELEASE, V355, P184, DOI 10.1016/j.jconrel.2023.01.071
   Jaffery H, 2023, ARTHRITIS RHEUMATOL, V75, P2148, DOI 10.1002/art.42639
   Khosla S, 2009, NEW ENGL J MED, V361, P818, DOI 10.1056/NEJMe0905480
   Kuang LJ, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202105383
   Li HN, 2022, J CONTROL RELEASE, V352, P256, DOI 10.1016/j.jconrel.2022.10.022
   Li T, 2019, ACS NANO, V13, P6770, DOI 10.1021/acsnano.9b01346
   Li WJ, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.912933
   Lin XF, 2020, J AM CHEM SOC, V142, P17543, DOI 10.1021/jacs.0c07309
   Liu CF, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202202769
   Liu Y, 2022, AQUAT TOXICOL, V242, DOI 10.1016/j.aquatox.2021.106039
   Morgan EN, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/5570229
   Normile D, 2003, SCIENCE, V299, P188, DOI 10.1126/science.299.5604.188
   Pinna A, 2021, ACTA BIOMATER, V122, P365, DOI 10.1016/j.actbio.2020.12.029
   Qian DY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.754088
   Qiao L, 2020, J MATER CHEM B, V8, P6333, DOI 10.1039/d0tb01260b
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   Shi LL, 2021, ACS NANO, V15, P1841, DOI 10.1021/acsnano.0c10045
   Song H, 2019, NANO LETT, V19, P3040, DOI 10.1021/acs.nanolett.9b00287
   Sujitha S, 2020, EUR J PHARM BIOPHARM, V149, P170, DOI 10.1016/j.ejpb.2020.02.007
   Tian HS, 2023, NANO LETT, V23, P4101, DOI 10.1021/acs.nanolett.2c04295
   Tillhon M, 2012, BIOCHEM PHARMACOL, V84, P1260, DOI 10.1016/j.bcp.2012.07.018
   Triffitt James T, 2021, Biomater Transl, V2, P285, DOI 10.12336/biomatertransl.2021.04.002
   Venkatesan M, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100348
   Wang Gen, 2023, Biomater Transl, V4, P27, DOI 10.12336/biomatertransl.2023.01.005
   Wang Y, 2012, BIOMATERIALS, V33, P485, DOI 10.1016/j.biomaterials.2011.09.089
   Wang ZH, 2023, NANO LETT, V23, P6544, DOI 10.1021/acs.nanolett.3c01567
   Wu SL, 2023, MATER HORIZ, V10, P3507, DOI 10.1039/d3mh00042g
   Wu ZY, 2022, ACS NANO, V16, P3808, DOI 10.1021/acsnano.1c08391
   Xue TH, 2003, SCIENCE, V300, P740, DOI 10.1126/science.300.5620.740
   Yang YY, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202300325
   Yang YX, 2023, ADV MATER, V35, DOI 10.1002/adma.202301409
   Ye J, 2020, BIOACT MATER, V5, P694, DOI 10.1016/j.bioactmat.2020.05.001
   Zhang R, 2019, EUR J PHARMACOL, V851, P144, DOI 10.1016/j.ejphar.2019.02.026
   Zhang X., 2015, Angew. Chem., V127, P4363, DOI DOI 10.1002/ANGE.201500683
   Zhang X, 2023, CHEM ENG J, V465, DOI 10.1016/j.cej.2023.142698
   Zhang X, 2021, J MATER CHEM B, V9, P7741, DOI 10.1039/d1tb01256h
   Zhang X, 2020, ACS APPL MATER INTER, V12, P16088, DOI 10.1021/acsami.0c01241
   Zhang X, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909218
   Zhang X, 2018, ADV MATER, V30, DOI 10.1002/adma.201707240
   Zhao LP, 2022, ACS NANO, V16, P1182, DOI 10.1021/acsnano.1c08978
   Zhao LP, 2020, NANO LETT, V20, P2062, DOI 10.1021/acs.nanolett.0c00047
   Zhou YR, 2019, CALCIFIED TISSUE INT, V104, P70, DOI 10.1007/s00223 018 0469 2
   Zhou ZJ, 2019, BIOMATERIALS, V194, P130, DOI 10.1016/j.biomaterials.2018.12.024
   Zhu LJ, 2020, ANGEW CHEM INT EDIT, V59, P17944, DOI 10.1002/anie.202006895
NR 63
TC 9
Z9 9
U1 20
U2 68
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530 6984
EI 1530 6992
J9 NANO LETT
JI Nano Lett.
PD APR 11
PY 2024
VL 24
IS 17
BP 5154
EP 5164
DI 10.1021/acs.nanolett.4c00029
EA APR 2024
PG 11
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA TG7S8
UT WOS:001201280800001
PM 38602357
DA 2025 08 17
ER

PT J
AU Si, YH
   Li, SS
   Guo, Y
   Wang, LN
   Ma, Y
   Yin, H
AF Si, Yuhao
   Li, Shaoshuo
   Guo, Yang
   Wang, Lining
   Ma, Yong
   Yin, Heng
TI Chinese Herbal Medicine Guilu Erxian Glue Inhibits Osteoclast Formation
   and Activity via Mc3t3 Derived Extracellular Vesicles in vitro
SO ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE
LA English
DT Article
ID EXOSOMES; MEMBRANE; OSTEOPOROSIS; OSTEOBLASTS; DIFFERENTIATION;
   MICROVESICLES; HYDROGEL; PROTEINS; DELIVERY; NFATC1
AB Background Osteoporosis is a systemic bone disease characterized by decreased bone density and quality, destruction of bone microstructure, and increased bone fragility. Extracellular vesicles are lipid bilayer nanoparticles that participate in intercellular communication. Extracellular vesicles are becoming popular in the study of osteoporosis and the bone cell microenvironment. Extracellular vesicles can transmit cell signals and regulate bone homeostasis. Our previous studies revealed that the Chinese herbal medicine Guilu Erxian Glue promotes type I collagen synthesis and osteoprotegerin secretion by osteoblasts in rats, reverses the imbalance of bone homeostasis, and alleviates osteoporosis.
   Objective We investigated how osteoblast derived extracellular vesicles treated with Guilu Erxian Glue affected osteoclasts in vitro.
   Methods We quantified osteoclast differentiation of RAW 264.7 using TRAP staining, cell apoptosis using flow cytometry, extracellular vesicle uptake by fluorescence tracing, bone absorption functions by bone resorption lacuna, and transcription of key genes by quantitative real time PCR.
   Results Fluorescently labeled mouse preosteoblastic MC3T3 E1 cells secreted nanoscale substances less than 1 mu m in diameter. Mouse macrophage RAW 264.7 cells adsorbed these nanoparticles and PKH26 labeled extracellular vesicles derived from MC3T3 E1 cells on the cell membrane surface. Extracellular vesicles from MC3T3 E1 cells treated with Guilu Erxian Glue inhibited the differentiation of osteoclasts induced by receptor activator of nuclear factor .B ligand and macrophage colony stimulating factor and reduced the number of lacunae formed by osteoclasts in vitro compared with controls. Extracellular vesicles from MC3T3 E1 cells treated with Guilu Erxian Glue downregulated the relative messenger RNA expression of c Fos, cathepsin K, nuclear factor of activated T cells 1, and tartrate resistant acid phosphatase in osteoclasts, which may be part of the mechanism by which they regulate osteoclasts.
   Conclusions Our results demonstrate that extracellular vesicles are essential for signal exchange between osteoblasts and osteoclasts. Although we do not know how Guilu Erxian Glue affects the signaling molecules carried by extracellular vesicles, we have shown for the first time, to our knowledge, that Guilu Erxian Glue can inhibit osteoclast differentiation and function via osteoblast derived extracellular vesicles. Our findings are conducive to providing a new target for the development of osteoporosis drugs.
C1 [Si, Yuhao] Nanjing Univ Chinese Med, Sch Hlth Preservat & Rehabil, Sch Acupuncture Moxibust & Tuina, Nanjing, Peoples R China.
   [Si, Yuhao] Univ Chinese Med, Lab New Tech Restorat & Reconstruct Orthoped & Tr, Nanjing, Peoples R China.
   [Li, Shaoshuo; Yin, Heng] Nanjing Univ Chinese Med, Wuxi Affiliated Hosp, Dept Traumatol & Orthoped, Wuxi, Peoples R China.
   [Guo, Yang] Nanjing Univ Chinese Med, Lab New Tech Restorat & Reconstruct Orthoped & Tr, Nanjing, Peoples R China.
   [Wang, Lining; Ma, Yong] Nanjing Univ Chinese Med, Lab New Tech Restorat & Reconstruct Orthoped & Tr, Nanjing, Peoples R China.
   [Wang, Lining; Ma, Yong] Nanjing Univ Chinese Med, Coll Basic Med, Nanjing, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine; Nanjing University of
   Chinese Medicine; Nanjing University of Chinese Medicine
RP Yin, H (通讯作者)，Nanjing Univ Chinese Med, Wuxi Affiliated Hosp, Dept Traumatol & Orthoped, Wuxi, Peoples R China.
EM zhongyiyinheng@126.com
RI Yin, Heng/G 5412 2010
FU National Natural Science Foundation of China [81973878]; Jiangsu CM
   Clinical Innovation Center of Degenerative Bone Joint Disease
FX This study is supported by the National Natural Science Foundation of
   China (No. 81973878) and is a project funded by the Jiangsu CM Clinical
   Innovation Center of Degenerative Bone & Joint Disease.
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Behera Jyotirmaya, 2018, Oncoscience, V5, P181, DOI 10.18632/oncoscience.421
   Boraschi Diaz I, 2016, CYTOTECHNOLOGY, V68, P105, DOI 10.1007/s10616 014 9759 3
   Cappariello A, 2018, J BONE MINER RES, V33, P517, DOI 10.1002/jbmr.3332
   Caputto BL, 2014, BBA MOL CELL BIOL L, V1841, P1241, DOI 10.1016/j.bbalip.2014.05.007
   Chou YJ, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018 018 0967 y
   Cui YZ, 2016, FEBS LETT, V590, P185, DOI 10.1002/1873 3468.12024
   Czekanska EM, 2014, J BIOMED MATER RES A, V102, P2636, DOI 10.1002/jbm.a.34937
   Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121
   Faust J, 1999, J CELL BIOCHEM, V72, P67, DOI 10.1002/(SICI)1097 4644(19990101)72:1<67::AID JCB8>3.0.CO;2 A
   Garimella R, 2014, TRANSL ONCOL, V7, P331, DOI 10.1016/j.tranon.2014.04.011
   Ge M, 2015, BIOCHEM BIOPH RES CO, V467, P27, DOI 10.1016/j.bbrc.2015.09.135
   Ha D, 2016, ACTA PHARM SIN B, V6, P287, DOI 10.1016/j.apsb.2016.02.001
   Han JW, 2020, DRUG DES DEV THER, V14, P5235, DOI 10.2147/DDDT.S282112
   Han X, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2210853119
   Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609
   Holkar K, 2021, ACS BIOMATER SCI ENG, V7, P2687, DOI 10.1021/acsbiomaterials.1c00386
   Kamel ElSayed SA, 2015, BONE, V76, P129, DOI 10.1016/j.bone.2015.02.011
   KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248
   Kong LB, 2019, J CELL MOL MED, V23, P3077, DOI 10.1111/jcmm.14277
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Liu JM, 2019, J DIABETES, V11, P906, DOI 10.1111/1753 0407.12962
   Long L, 2001, RHEUMATOLOGY, V40, P779, DOI 10.1093/rheumatology/40.7.779
   Möbius W, 2002, J HISTOCHEM CYTOCHEM, V50, P43
   Morhayim J, 2015, FASEB J, V29, P274, DOI 10.1096/fj.14 261404
   Nabhan JF, 2012, P NATL ACAD SCI USA, V109, P4146, DOI 10.1073/pnas.1200448109
   Nair R, 2014, STEM CELLS DEV, V23, P1625, DOI 10.1089/scd.2013.0633
   Osnes EK, 2004, OSTEOPOROSIS INT, V15, P567, DOI 10.1007/s00198 003 1583 0
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Shelke GV, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24783
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198 015 3093 2
   Song FM, 2016, J CELL PHYSIOL, V231, P1983, DOI 10.1002/jcp.25304
   Théry C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   Tian H, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/736197
   TRAMS EG, 1981, BIOCHIM BIOPHYS ACTA, V645, P63, DOI 10.1016/0005 2736(81)90512 5
   Tsai CC, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/297458
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Wang W, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03915 1
   White IJ, 2006, EMBO J, V25, P1, DOI 10.1038/sj.emboj.7600759
   Wijenayake S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257633
   Yang S, 2020, ACS BIOMATER SCI ENG, V6, P1590, DOI 10.1021/acsbiomaterials.9b01363
   Yin H, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5859641
   Yin H, 2018, BIOMED PHARMACOTHER, V97, P995, DOI 10.1016/j.biopha.2017.11.029
   Yin PB, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00336
   Yin X, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0058 7
   Yuan FL, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00628
   Zhang Y, 2005, P ANN INT IEEE EMBS, P4958
   Zhe Q, 2017, CHINESE J TRADITIONA, V35, P1008
NR 48
TC 2
Z9 2
U1 1
U2 13
PU InnoVision Professional Media
PI Eagan
PA 3470 Washington Drive Suite 102, Eagan, MN 55122, UNITED STATES
SN 1078 6791
J9 ALTERN THER HEALTH M
JI Altern. Ther. Health Med.
PD SEP
PY 2023
VL 29
IS 6
BP 400
EP 407
PG 8
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA P3XJ9
UT WOS:001050004000061
PM 37384403
DA 2025 08 17
ER

PT J
AU Yorgan, T
   Vollersen, N
   Riedel, C
   Jeschke, A
   Peters, S
   Busse, B
   Amling, M
   Schinke, T
AF Yorgan, Timur
   Vollersen, Nele
   Riedel, Christoph
   Jeschke, Anke
   Peters, Stephanie
   Busse, Bjoern
   Amling, Michael
   Schinke, Thorsten
TI Osteoblast specific Notch2 inactivation causes increased trabecular bone
   mass at specific sites of the appendicular skeleton
SO BONE
LA English
DT Article
DE Notch2; Hajdu Cheney syndrome; Osteocytes
ID HAJDU CHENEY SYNDROME; CELL FATE; MUTATIONS; OSTEOCLASTOGENESIS;
   DIFFERENTIATION; PRECURSORS; RECEPTORS; FAMILIES; DISORDER; PATHWAY
AB Notch signaling is a key pathway controlling various cell fate decisions during embryogenesis and adult life. It is activated by binding of specific ligands to four different Notch receptors that are subsequently cleaved by presenilins to release an intracellular domain that enters the nucleus and activates specific transcription factors. While the skeletal analysis of various mouse models with activated or inactivated Notch signaling has demonstrated a general impact of this pathway on bone remodeling, the more recent identification of NOTCH2 mutations in individuals with Hajdu Cheney syndrome (HCS) has highlighted its human relevance. Since HCS is primarily characterized by skeletal defects, these latter findings led us to analyze the specific role of Notch2 in skeletal remodeling. After observing Notch2 expression in osteoblasts and osteoclasts, we utilized Runx2 Cre and Lyz2 Cre mice to inactivate Notch2 in cells of the osteoblast or osteoclast lineage, respectively. Whereas Notch2(fl/fl)/Lyz2 Cre mice did not display significant alterations of skeletal growth, bone mass or remodeling, Notch2(fl/fl)/Runx2 Cre mice progressively developed skeletal abnormalities in long bones. More specifically, these mice displayed a striking increase of trabecular bone mass in the proximal femur and the distal tibia at 6 and 12 months of age. Whereas undecalcified sectioning of the respective regions did not reveal impaired osteocyte differentiation as a potential trigger for the observed phenotype, ex vivo experiments with bone marrow cells identified an increased osteogenic capacity of Notch2(fl/fl)/Runx2 Cre cultures. Collectively, our findings demonstrate that Notch2 physiologically regulates bone remodeling by inhibiting trabecular bone formation in the appendicular skeleton. Understanding the underlying mechanisms may help to improve diagnosis and therapy of HCS. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Yorgan, Timur; Vollersen, Nele; Riedel, Christoph; Jeschke, Anke; Peters, Stephanie; Busse, Bjoern; Amling, Michael; Schinke, Thorsten] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Martinistr 52, D 20246 Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf
RP Schinke, T (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Martinistr 52, D 20246 Hamburg, Germany.
EM schinke@uke.de
RI ; Busse, Björn/AAC 4033 2020
OI Busse, Bjorn/0000 0002 3099 8073; Riedel, Christoph/0000 0001 8342 296X
FU European Community's Seventh Framework Programme [602300]
FX The research leading to the results has received funding from the
   European Community's Seventh Framework Programme under grant agreement
   no. 602300 (SYBIL).
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Artavanis Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Bellido T, 2014, CALCIFIED TISSUE INT, V94, P25, DOI 10.1007/s00223 013 9774 y
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Borggrefe T, 2009, CELL MOL LIFE SCI, V66, P1631, DOI 10.1007/s00018 009 8668 7
   Bulman MP, 2000, NAT GENET, V24, P438, DOI 10.1038/74307
   CABRERA CV, 1990, DEVELOPMENT, V110, P733
   Canalis E., 2015, J BIOL CHEM
   Canalis E, 2013, J BIOL CHEM, V288, P25614, DOI 10.1074/jbc.M113.470492
   Canalis E, 2013, ENDOCRINOLOGY, V154, P623, DOI 10.1210/en.2012 1732
   CHENEY WD, 1965, AMER J ROENTGENOL RA, V94, P595
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Corbin JG, 2008, J NEUROCHEM, V106, P2272, DOI 10.1111/j.1471 4159.2008.05522.x
   Dallas DJ, 1999, BONE, V25, P9, DOI 10.1016/S8756 3282(99)00099 X
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Engin F, 2010, BONE, V46, P274, DOI 10.1016/j.bone.2009.05.027
   Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010
   Fukushima H, 2008, MOL CELL BIOL, V28, P6402, DOI 10.1128/MCB.00299 08
   HAJDU N, 1948, BRIT J RADIOL, V21, P42, DOI 10.1259/0007 1285 21 241 42
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Isidor B, 2011, NAT GENET, V43, P306, DOI 10.1038/ng.778
   Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208
   Katsube KI, 2005, INT J DEV BIOL, V49, P369, DOI 10.1387/ijdb.041950kk
   Majewski J, 2011, HUM MUTAT, V32, P1114, DOI 10.1002/humu.21546
   McCright B, 2006, GENESIS, V44, P29, DOI 10.1002/gene.20181
   Milovanovic P, 2013, ACS NANO, V7, P7542, DOI 10.1021/nn401360u
   Palav S, 2014, J RADIOL CASE REP, V8, P1, DOI 10.3941/jrcr.v8i9.1833
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Regan J, 2013, CURR OSTEOPOROS REP, V11, P126, DOI 10.1007/s11914 013 0145 4
   Saita Y, 2015, THER ADV CHRONIC DIS, V6, P185, DOI 10.1177/2040622315584114
   Schulze J, 2011, J BONE MINER RES, V26, P704, DOI 10.1002/jbmr.269
   Shimizu K, 2002, BIOCHEM BIOPH RES CO, V291, P775, DOI 10.1006/bbrc.2002.6528
   Simpson MA, 2011, NAT GENET, V43, P303, DOI 10.1038/ng.779
   Takada I, 2007, ANN NY ACAD SCI, V1116, P182, DOI 10.1196/annals.1402.034
   Tu XL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002577
   Yen WC, 2015, CLIN CANCER RES, V21, P2084, DOI 10.1158/1078 0432.CCR 14 2808
   Yorgan TA, 2015, J BONE MINER RES, V30, P1175, DOI 10.1002/jbmr.2461
   Zanotti S, 2008, ENDOCRINOLOGY, V149, P3890, DOI 10.1210/en.2008 0140
   Zanotti S, 2014, BONE, V62, P22, DOI 10.1016/j.bone.2014.01.023
   Zanotti S, 2013, EUR J ENDOCRINOL, V168, pR95, DOI 10.1530/EJE 13 0115
NR 42
TC 36
Z9 41
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2016
VL 87
BP 136
EP 146
DI 10.1016/j.bone.2016.04.012
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DM0SC
UT WOS:000376055100016
PM 27102824
DA 2025 08 17
ER

PT J
AU Li, XL
   Yang, J
   Liu, DQ
   Li, J
   Niu, KJ
   Feng, SQ
   Yokota, H
   Zhang, P
AF Li, Xinle
   Yang, Jing
   Liu, Daquan
   Li, Jie
   Niu, Kaijun
   Feng, Shiqing
   Yokota, Hiroki
   Zhang, Ping
TI Knee loading inhibits osteoclast lineage in a mouse model of
   osteoarthritis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CRUCIATE LIGAMENT TRANSECTION; SUBCHONDRAL BONE; ARTICULAR CARTILAGE;
   RAT MODEL; ALENDRONATE; CELLS; HISTOPATHOLOGY; DEGENERATION;
   OSTEOBLASTS; PATHWAYS
AB Osteoarthritis (OA) is a whole joint disorder that involves cartilage degradation and periarticular bone response. Changes of cartilage and subchondral bone are associated with development and activity of osteoclasts from subchondral bone. Knee loading promotes bone formation, but its effects on OA have not been well investigated. Here, we hypothesized that knee loading regulates subchondral bone remodeling by suppressing osteoclast development, and prevents degradation of cartilage through crosstalk of bone cartilage in osteoarthritic mice. Surgery induced mouse model of OA was used. Two weeks application of daily dynamic knee loading significantly reduced OARSI scores and CC/TAC (calcified cartilage to total articular cartilage), but increased SBP (subchondral bone plate) and B.Ar/T.Ar (trabecular bone area to total tissue area). Bone resorption of osteoclasts from subchondral bone and the differentiation of osteoclasts from bone marrow derived cells were completely suppressed by knee loading. The osteoclast activity was positively correlated with OARSI scores and negatively correlated with SBP and B.Ar/T.Ar. Furthermore, knee loading exerted protective effects by suppressing osteoclastogenesis through Wnt signaling. Overall, osteoclast lineage is the hyper responsiveness of knee loading in osteoarthritic mice. Mechanical stimulation prevents OA induced cartilage degeneration through crosstalk with subchondral bone. Knee loading might be a new potential therapy for osteoarthritis patients.
C1 [Li, Xinle; Yang, Jing; Liu, Daquan; Li, Jie; Zhang, Ping] Tianjin Med Univ, Sch Basic Med Sci, Dept Anat & Histol, Tianjin 300070, Peoples R China.
   [Liu, Daquan] Tianjin Nankai Hosp, Inst Acute Abdominal Dis, Dept Pharmacol, Tianjin 300100, Peoples R China.
   [Niu, Kaijun] Tianjin Med Univ, Nutr Epidemiol Inst, Tianjin 300070, Peoples R China.
   [Niu, Kaijun] Tianjin Med Univ, Sch Publ Hlth, Tianjin 300070, Peoples R China.
   [Feng, Shiqing] Tianjin Med Univ, Gen Hosp, Dept Orthoped, Tianjin 300052, Peoples R China.
   [Yokota, Hiroki; Zhang, Ping] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
   [Zhang, Ping] Chinese Acad Med Sci, TEDA Int Cardiovasc Hosp, Tianjin 300457, Peoples R China.
   [Zhang, Ping] Peking Union Med Coll, Tianjin 300457, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Tianjin Medical
   University; Tianjin Medical University; Purdue University System; Purdue
   University; Purdue University in Indianapolis; Chinese Academy of
   Medical Sciences   Peking Union Medical College; Chinese Academy of
   Medical Sciences   Peking Union Medical College; Peking Union Medical
   College
RP Zhang, P (通讯作者)，Tianjin Med Univ, Sch Basic Med Sci, Dept Anat & Histol, Tianjin 300070, Peoples R China.; Zhang, P (通讯作者)，Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.; Zhang, P (通讯作者)，Chinese Acad Med Sci, TEDA Int Cardiovasc Hosp, Tianjin 300457, Peoples R China.; Zhang, P (通讯作者)，Peking Union Med Coll, Tianjin 300457, Peoples R China.
EM pizhang2008@163.com
RI Li, Xinle/B 8285 2016; Niu, Kaijun/ADD 6222 2022; zhang,
   ping/L 3901 2017; Li, Jie/GNP 2561 2022
OI Niu, Kaijun/0000 0002 8772 2481; 
FU National Natural Science Foundation of China [81572100]; Tianjin
   Municipal Science and Technology Commission [14JCZDJC36500]; NIH
   [AR052144]
FX This study was supported by grant (81572100 to PZ) from the National
   Natural Science Foundation of China, grant (14JCZDJC36500 to PZ) from
   the Tianjin Municipal Science and Technology Commission, and NIH
   AR052144 (to HY).
CR Assis L, 2016, OSTEOARTHR CARTILAGE, V24, P169, DOI 10.1016/j.joca.2015.07.020
   Botter SM, 2008, OSTEOARTHR CARTILAGE, V16, P506, DOI 10.1016/j.joca.2007.08.005
   Boudenot A, 2014, OSTEOARTHR CARTILAGE, V22, P1176, DOI 10.1016/j.joca.2014.05.020
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Chen Y, 2015, OSTEOARTHR CARTILAGE, V23, P2174, DOI 10.1016/j.joca.2015.07.012
   Fibel KH, 2015, WORLD J CLIN CASES, V3, P89, DOI 10.12998/wjcc.v3.i2.89
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Goldring MB, 2015, CURR OPIN PHARMACOL, V22, P51, DOI 10.1016/j.coph.2015.03.004
   Gómez R, 2015, NAT REV RHEUMATOL, V11, P159, DOI 10.1038/nrrheum.2014.209
   Hamamura K, 2014, CELL SIGNAL, V26, P2358, DOI 10.1016/j.cellsig.2014.07.018
   Hamamura K, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 312
   Hayami T, 2004, ARTHRITIS RHEUM US, V50, P1193, DOI 10.1002/art.20124
   Hunter DJ, 2006, ARTHRITIS RHEUM US, V54, P1529, DOI 10.1002/art.21789
   Iijima H, 2015, OSTEOARTHR CARTILAGE, V23, P1563, DOI 10.1016/j.joca.2015.04.015
   Javaheri B, 2014, J BONE MINER RES, V29, P705, DOI 10.1002/jbmr.2064
   Jiang YZ, 2015, NAT REV RHEUMATOL, V11, P206, DOI 10.1038/nrrheum.2014.200
   Kang KS, 2015, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00246
   Khorasani MS, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0546 0
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Lara Castillo N, 2015, BONE, V76, P58, DOI 10.1016/j.bone.2015.03.019
   Lee AMC, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/916918
   Lin CWC, 2010, PHYS THER, V90, P839, DOI [10.1002/14651858.CD004376.pub3, 10.2522/ptj.20100084]
   Liu DQ, 2015, BONE, V81, P620, DOI 10.1016/j.bone.2015.09.012
   Loeser RF, 2012, ARTHRITIS RHEUM US, V64, P1697, DOI 10.1002/art.34453
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   McErlain DD, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3727
   Pickarski M, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 197
   Prieto Potin I, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0664 5
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Seol JW, 2009, INT J MOL MED, V24, P57, DOI 10.3892/ijmm_00000206
   Shen J, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.2
   Siebelt M, 2014, BONE, V66, P163, DOI 10.1016/j.bone.2014.06.009
   Strassle BW, 2010, OSTEOARTHR CARTILAGE, V18, P1319, DOI 10.1016/j.joca.2010.06.007
   Stupina TA, 2015, B EXP BIOL MED+, V158, P820, DOI 10.1007/s10517 015 2870 4
   Sugatani T, 2009, J BIOL CHEM, V284, P4667, DOI 10.1074/jbc.M805777200
   Wang T, 2013, OSTEOARTHR CARTILAGE, V21, P574, DOI 10.1016/j.joca.2013.01.002
   Weng LH, 2012, ARTHRITIS RHEUM US, V64, P3267, DOI 10.1002/art.34602
   Westacott CI, 1997, ARTHRITIS RHEUM, V40, P1282, DOI 10.1002/1529 0131(199707)40:7<1282::AID ART13>3.0.CO;2 E
   Xiao GZ, 2012, J BIOL CHEM, V287, P21450, DOI 10.1074/jbc.M111.331249
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Yokota H, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 197
   Yuan XL, 2014, OSTEOARTHR CARTILAGE, V22, P1077, DOI 10.1016/j.joca.2014.05.023
   Zhang P, 2007, J BONE MINER RES, V22, P1979, DOI 10.1359/JBMR.070803
   Zhang P, 2011, BONE, V49, P867, DOI 10.1016/j.bone.2011.06.020
   Zhang P, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 73
   Zhang P, 2009, BONE, V44, P989, DOI 10.1016/j.bone.2009.01.367
   Zhang P, 2009, EXERC SPORT SCI REV, V37, P52, DOI 10.1097/JES.0b013e31819121c6
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
NR 52
TC 40
Z9 47
U1 2
U2 24
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD APR 18
PY 2016
VL 6
AR 24668
DI 10.1038/srep24668
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DJ5NC
UT WOS:000374254400001
PM 27087498
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Huelsmann, L
   Kim, DNW
   Hannan, R
   Watumull, LM
   Brugarolas, J
AF Huelsmann, Lorel
   Kim, D. Nathan W.
   Hannan, Raquibul
   Watumull, Lori M.
   Brugarolas, James
TI Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe
   Renal Cell Carcinoma
SO CLINICAL GENITOURINARY CANCER
LA English
DT Article
DE Bone remodeling; Everolimus; Mammalian target of rapamycin (mTOR);
   Osteoclasts; Tuberous Sclerosis Complex 1 (TSC1)
ID MTOR PATHWAY; SORAFENIB; THERAPY; CANCER
AB Evidence on the use of various targeted therapies on treatment of chromophobe renal cell carcinoma (chRCC) is lacking.
   We report a case of a patient with metastatic chRCC who experienced site  specific disease control in the bone with temsirolimus, but significant progression in the liver.
   The potential difference in the bioavailability or mechanism of action at the 2 sites by mammalian target of rapamycin complex 1 (mTORC1) inhibitors is hypothesized to cause this differential response.
   This hypothesis generating case study supports further research on the mechanism of action of mTORC1 inhibitors to potentially preferentially affect bone metastases. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Huelsmann, Lorel; Kim, D. Nathan W.; Hannan, Raquibul] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA.
   [Huelsmann, Lorel; Kim, D. Nathan W.; Brugarolas, James] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Kidney Canc Program, Dallas, TX 75390 USA.
   [Watumull, Lori M.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA.
   [Brugarolas, James] Univ Texas SW Med Ctr Dallas, Internal Med, Div Med Oncol, Dev Biol, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center; University of Texas System; University of Texas Southwestern
   Medical Center; University of Texas System; University of Texas
   Southwestern Medical Center; University of Texas System; University of
   Texas Southwestern Medical Center
RP Brugarolas, J (通讯作者)，Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Oncol, Dept Dev Biol,Simmons Comprehens Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM James.Brugarolas@UTSouthwestern.edu
OI Brugarolas, James/0000 0002 8575 499X; Hannan,
   Raquibul/0000 0003 1282 056X
CR Albiges L, 2012, ONCOLOGIST, V17, P1051, DOI 10.1634/theoncologist.2012 0038
   [Anonymous], PHASE 2 STUDY AFINIT
   Bertoldo F, 2014, BBA REV CANCER, V1845, P248, DOI 10.1016/j.bbcan.2014.01.009
   Brugarolas J, 2012, RENAL CELL CARCINOMA: TRANSLATIONAL BIOLOGY, PERSONALIZED MEDICINE, AND NOVEL THERAPEUTIC TARGETS, P161, DOI 10.1007/978 1 4614 2400 0_8
   Choueiri TK, 2008, J CLIN ONCOL, V26, P127, DOI 10.1200/JCO.2007.13.3223
   Durinck S, 2015, NAT GENET, V47, P13, DOI 10.1038/ng.3146
   Klatte T, 2008, UROL ONCOL SEMIN ORI, V26, P604, DOI 10.1016/j.urolonc.2007.07.015
   Kucejova B, 2011, MOL CANCER RES, V9, P1255, DOI 10.1158/1541 7786.MCR 11 0302
   Mckay RR, 2014, EUR UROL, V65, P577, DOI 10.1016/j.eururo.2013.08.012
   Paule B, 2011, ANTICANCER RES, V31, P331
   Shuch B, 2012, J CANCER, V3, P152, DOI 10.7150/jca.4378
   Tannir NM, EVEROLIMUS VERSUS
   Venugopal B, 2013, BMC UROL, V13, DOI 10.1186/1471 2490 13 26
NR 13
TC 2
Z9 2
U1 0
U2 1
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219 3931 USA
SN 1558 7673
EI 1938 0682
J9 CLIN GENITOURIN CANC
JI Clin. Genitourin. Cancer
PD AUG
PY 2015
VL 13
IS 4
BP E321
EP E323
DI 10.1016/j.clgc.2014.12.007
PG 3
WC Oncology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Urology & Nephrology
GA CM7NF
UT WOS:000357880000019
PM 25620636
DA 2025 08 17
ER

PT J
AU Ji, HY
   Pan, Q
   Cao, RH
   Li, YJ
   Yang, YS
   Chen, SS
   Gu, Y
   Qian, DY
   Guo, Y
   Wang, LL
   Wang, ZR
   Xiao, L
AF Ji, Hongyun
   Pan, Qian
   Cao, Ruihong
   Li, Yajun
   Yang, Yunshang
   Chen, Shuangshuang
   Gu, Yong
   Qian, Daoyi
   Guo, Yang
   Wang, Liangliang
   Wang, Zhirong
   Xiao, Long
TI Garcinone C attenuates RANKL induced osteoclast differentiation and
   oxidative stress by activating Nrf2/HO 1 and inhibiting the NF kB
   signaling pathway
SO HELIYON
LA English
DT Article
DE Osteoporosis; Garcinone C; Reactive oxygen species; NF kappa B;
   Osteoclast
ID FACTOR KAPPA B; NRF2
AB Osteoporosis is the result of osteoclast formation exceeding osteoblast production, and current osteoporosis treatments targeting excessive osteoclast bone resorption have serious adverse effects. There is a need to fully understand the mechanisms of osteoclast mediated bone resorption, identify new drug targets, and find better drugs to treat osteoporosis. Gar C (Gar C) is a major naturally occurring phytochemical isolated from mangosteen, and is a derivative of the naturally occurring phenolic antioxidant lutein. We used an OP mouse model established by ovariectomy (OVX). We found that treatment with Gar C significantly increased bone mineral density and significantly decreased the expression of TRAP, NFATC1 and CTSK relative to untreated OP mice. We found that Garcinone C could disrupt osteoclast activation and resorption functions by inhibiting RANKL induced osteoclast differentiation as well as inhibiting the formation of multinucleated osteoclasts. Immunoblotting showed that Gar C downregulated the expression of osteoclast related proteins. In addition, Gar C significantly inhibited RANKL induced ROS production and affected NF kappa B activity by inhibiting phosphorylation Formylation of P65 and phosphorylation and degradation of ikba. These data suggest that Gar C significantly reduced OVX induced osteoporosis by inhibiting osteoclastogenesis and oxidative stress in bone tissue. Mechanistically, this effect was associated with inhibition of the ROS mediated NF kappa B pathway.
C1 [Ji, Hongyun; Pan, Qian; Cao, Ruihong; Li, Yajun; Yang, Yunshang; Chen, Shuangshuang; Gu, Yong; Qian, Daoyi; Wang, Zhirong; Xiao, Long] Nanjing Univ Chinese Med, Zhangjiagang TCM Hosp, Translat Med Innovat Ctr, Zhangjiagang 215600, Peoples R China.
   [Li, Yajun; Yang, Yunshang; Gu, Yong; Qian, Daoyi; Wang, Zhirong; Xiao, Long] Nanjing Univ Chinese Med, Dept Orthoped, Zhangjiagang TCM Hosp, Zhangjiagang 215600, Peoples R China.
   [Guo, Yang] Nanjing Univ Chinese Med, Lab New Tech Restorat & Reconstruct, Orthoped & Traumatol, Nanjing 210000, Peoples R China.
   [Wang, Liangliang] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Orthoped, Changzhou 213000, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine; Nanjing Medical
   University
RP Wang, ZR; Xiao, L (通讯作者)，Nanjing Univ Chinese Med, Zhangjiagang TCM Hosp, Translat Med Innovat Ctr, Zhangjiagang 215600, Peoples R China.; Wang, LL (通讯作者)，Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Orthoped, Changzhou 213000, Peoples R China.
EM 18862238837@163.com; zjgfy_spine_wzr@njucm.edu.cn;
   zjgfy_spine_xl@njucm.edu.cn
RI chen, shuangshuang/KGK 6684 2024; Yang, Yunshang/ITU 7550 2023; Zhirong,
   Wang/AAR 5563 2021; chen, shuang shuang/KGK 6684 2024
OI chen, shuang shuang/0009 0009 6549 1449; Yang,
   Yunshang/0009 0005 0033 1138
FU Zhangjiagang Health Personnel Training Project [SKY2023079, SKY2023012];
    [ZJGWSRC2020002]
FX We greatly acknowledge the financial support from the National Natural
   Science Foundation of China (82074473, 82104892, 82305038 and 82305115)
   , the Key Disciplines in Suzhou (SZXK202120, LCZX202221 and LCZX202331)
   , the Suzhou Science and Technology Development Plan Project
   (SYSD2020009, SYSD2021175, SKY2021001, SKJY2021002, KJXW2021066,
   SKY2023081, SKY2023079 and SKY2023012) , the Zhangjiagang Health
   Personnel Training Project (ZJGWSRC2020002) .r SKY2023079 and
   SKY2023012) , the Zhangjiagang Health Personnel Training Project
   (ZJGWSRC2020002) .
CR Abate M, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15010084
   Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Blaser H, 2016, TRENDS CELL BIOL, V26, P249, DOI 10.1016/j.tcb.2015.12.002
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Chae HS, 2017, J MED FOOD, V20, P727, DOI 10.1089/jmf.2017.3944
   Chen J, 2020, PHYTOMEDICINE, V79, DOI 10.1016/j.phymed.2020.153334
   Chen XR, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00128 8
   De Vries TJ, 2015, J CELL PHYSIOL, V230, P210, DOI 10.1002/jcp.24702
   Gambari L, 2014, PHARMACOL RES, V87, P99, DOI 10.1016/j.phrs.2014.06.014
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hwang YH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072068
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Kim HJ, 2018, BIOSCI TRENDS, V12, P257, DOI 10.5582/bst.2018.01107
   Kim HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01527 y
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Li J, 2019, BIOCHIMIE, V156, P129, DOI 10.1016/j.biochi.2018.09.004
   Li XC, 2018, MOLECULES, V23, DOI 10.3390/molecules23040973
   Li YJ, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13291
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
   Nauman MC, 2022, PHARMACOL RES, V175, DOI 10.1016/j.phrs.2021.106032
   Ng AYH, 2019, ELIFE, V8, DOI 10.7554/eLife.42951
   Ni S, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12882
   Ovalle Magallanes B, 2017, FOOD CHEM TOXICOL, V109, P102, DOI 10.1016/j.fct.2017.08.021
   Ping ZC, 2017, ACTA BIOMATER, V62, P362, DOI 10.1016/j.actbio.2017.08.046
   Pouresmaeili F, 2018, THER CLIN RISK MANAG, V14, P2029, DOI 10.2147/TCRM.S138000
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   Rana T, 2012, FREE RADICAL BIO MED, V53, P2298, DOI 10.1016/j.freeradbiomed.2012.10.536
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Su XH, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111382
   Sun Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.788680
   Tang WK, 2020, J CELL MOL MED, V24, P11972, DOI 10.1111/jcmm.15821
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Tewtrakul S, 2009, J ETHNOPHARMACOL, V121, P379, DOI 10.1016/j.jep.2008.11.007
   Tran TH, 2021, FITOTERAPIA, V151, DOI 10.1016/j.fitote.2021.104880
   Vellapandian C, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5349520
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wardyn JD, 2015, BIOCHEM SOC T, V43, P621, DOI 10.1042/BST20150014
   Xia YD, 2018, ONCOL REP, V39, P1485, DOI 10.3892/or.2018.6218
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xu XH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11417 4
   Xue P, 2021, EXP MOL MED, V53, P667, DOI 10.1038/s12276 021 00596 w
   Yamakuni T, 2006, NEUROSCI LETT, V394, P206, DOI 10.1016/j.neulet.2005.10.023
   Yang LL, 2020, AMB EXPRESS, V10, DOI 10.1186/s13568 020 01060 0
   Yang XH, 2016, NEUROSCI LETT, V626, P6, DOI 10.1016/j.neulet.2016.05.012
   Zhang L, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1005665
   Zhang WK, 2022, CHIN MED UK, V17, DOI 10.1186/s13020 022 00589 5
   Zhou YM, 2022, J AGR FOOD CHEM, V70, P7941, DOI 10.1021/acs.jafc.2c01891
   Zhu XW, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00143 3
   Zhuang Q, 2023, J AGR FOOD CHEM, V71, P411, DOI 10.1021/acs.jafc.2c05954
NR 54
TC 6
Z9 7
U1 0
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2405 8440
J9 HELIYON
JI Heliyon
PD FEB 15
PY 2024
VL 10
IS 3
AR e25601
DI 10.1016/j.heliyon.2024.e25601
EA FEB 2024
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA KL7H8
UT WOS:001180181500001
PM 38333852
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, GW
   Ma, C
   Wang, PA
   Zhang, PY
   Qu, XH
   Liu, S
   Zhai, ZJ
   Yu, DG
   Gao, J
   Liang, J
   Dai, WX
   Zhou, LD
   Xia, MJ
   Yang, HL
AF Liu, Guangwang
   Ma, Chao
   Wang, Peian
   Zhang, Peiying
   Qu, Xinhua
   Liu, Shen
   Zhai, Zanjing
   Yu, Degang
   Gao, Juan
   Liang, Jun
   Dai, Weixiang
   Zhou, Lindong
   Xia, Mengjiao
   Yang, Huilin
TI Pilose antler peptide potentiates osteoblast differentiation and
   inhibits osteoclastogenesis via manipulating the NF κB pathway
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Pilose antler peptide; Inflammation; Osteoblasts; Osteoclasts; NF kappa
   B
ID NECROSIS FACTOR ALPHA; BONE RESORPTION; TNF ALPHA; OSTEOPOROSIS
AB Bones are inflexible yet ever changing metabolic organs, and bone homeostasis is maintained through two delicately regulated processes: bone construction and bone reabsorption. An imbalance in bone metabolism is linked to most orthopedic diseases, including osteoporosis and rheumatoid arthritis. Importantly, tumor necrosis factor alpha (TNF alpha) blocks osteoblast differentiation and stimulates osteoclast formation, resulting in delayed deposition of new bone and accelerated bone resorption, especially in rheumatoid arthritis patients with inflammatory conditions. Pilose antler peptide (PAP) isolated and purified from deer antlers has been shown to have beneficial effects on chronic inflammation. In the present study, we studied the impact of PAP on osteoblast differentiation and evaluated the regulatory mechanism, with particular emphasis on the effect of PAP on TNF alpha mediated NF kappa B signaling. Mouse primary osteoblast cells were activated with bone morphogenetic protein 2 (BMP 2) for osteoblast differentiation. A significant stimulatory effect of PAP in osteoblastogenesis was observed using ALP activity and Alizarin Red S staining assays. Meanwhile, PAP significantly rescued TNF alpha induced impairment of osteoblast formation as well as mineralization. Furthermore, we found a similar trend upon analyzing osteoblast specific gene expression. PAP significantly rescued TNF alpha mediated decrease in expression of osteoblast specific genes. A molecular mechanism assay indicated that PAP significantly inhibited TNF alpha mediated stimulation of NF kappa B signaling activity, as well as nuclear translocation of its subunit p65. Moreover, over expression of p65 reversed the stimulatory effects of PAP on osteoblast differentiation. Furthermore, we also identified that PAP dose dependently inhibit osteoclastogenesis, and this effect might be achieved via suppressing NF kappa B activity. In summary, this study shows that PAP promotes osteoblast differentiation and blocks TNF alpha mediated suppression of osteoblastogenesis in vitro via the NF kappa B/p65 pathway, as well as inhibits osteoclastsogenesis in vitro. Therefore, PAP, a novel drug with both antiresorptive and osteoanabolic activity, shows therapeutic potential as an alternative treatment for osteolytic diseases, including rheumatoid arthritis and osteoporosis. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Liu, Guangwang; Yang, Huilin] Soochow Univ, Dept Orthopaed, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China.
   [Liu, Guangwang; Ma, Chao; Wang, Peian; Zhang, Peiying; Gao, Juan; Liang, Jun; Dai, Weixiang; Zhou, Lindong; Xia, Mengjiao] Nanjing Univ Chinese Med, Xuzhou Clin Med Coll, Affiliated XuZhou Hosp,Xuzhou Cent Hosp,Dept Orth, Southeast Univ,Med Coll,Xuzhou Clin Sch,Xuzhou Me, Xuzhou, Jiangsu, Peoples R China.
   [Qu, Xinhua; Zhai, Zanjing; Yu, Degang] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthopaed, Sch Med, Shanghai, Peoples R China.
   [Liu, Shen] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Orthopaed, Sch Med, Shanghai, Peoples R China.
C3 Soochow University   China; Southeast University   China; Nanjing
   University of Chinese Medicine; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Liu, GW; Yang, HL (通讯作者)，Soochow Univ, Dept Orthopaed, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China.; Liu, GW (通讯作者)，Nanjing Univ Chinese Med, Xuzhou Clin Med Coll, Affiliated XuZhou Hosp,Xuzhou Cent Hosp,Dept Orth, Southeast Univ,Med Coll,Xuzhou Clin Sch,Xuzhou Me, Xuzhou, Jiangsu, Peoples R China.
EM guangwangliu@163.com; hlyang@suda.edu.cn
RI gao, juan/GXV 1381 2022; ydg, nam/GNP 5078 2022; Qu, Xinhua/Q 3950 2016;
   Zhang, Jingjing/ITV 5729 2023
OI Qu, Xinhua/0000 0002 8889 0890; 
FU Project of Xuzhou Science and Technology Program Fund [KC15SH039];
   Health Innovation Teams of Xuzhou [XWOC201601]; Xuzhou Medical
   Foundation for Youth Reserved Experts Fund [2014006]; Jiangsu Provincial
   Department of Science and Technology [BE2016640]; Clinical Medical
   Science and Technique Special Foundation of Jiangsu Provincial
   Department of Science and Technology [BL2014026]; Jiangsu Postdoctoral
   Research Funds [1501082C]; Jiangsu Provincial Medical Youth Talent
   [QNRC2016392]; Jiangsu Health & Family Planning Commission [H201673]
FX This study was supported by the Project of Xuzhou Science and Technology
   Program Fund (Grant no. KC15SH039), Health Innovation Teams of Xuzhou
   (Grant no. XWOC201601), Xuzhou Medical Foundation for Youth Reserved
   Experts Fund (Grant no. 2014006), Key Research & Development Plan of
   Jiangsu Provincial Department of Science and Technology (Grant no.
   BE2016640), the Clinical Medical Science and Technique Special
   Foundation of Jiangsu Provincial Department of Science and Technology
   (Grant no. BL2014026), Jiangsu Postdoctoral Research Funds (No.
   1501082C), Jiangsu Provincial Medical Youth Talent (QNRC2016392) and
   Jiangsu Health & Family Planning Commission (Grant no. H201673).
CR [Anonymous], CURR MED CHEM
   Appelman Dijkstra NM, 2015, DRUGS, V75, P1049, DOI 10.1007/s40265 015 0417 7
   Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Collett GP, 2006, CARCINOGENESIS, V27, P1285, DOI 10.1093/carcin/bgi368
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Goldring SR, 2002, CURR OPIN RHEUMATOL, V14, P406, DOI 10.1097/00002281 200207000 00013
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Khosla S, 2005, ENDOCRIN METAB CLIN, V34, P1015, DOI 10.1016/j.ecl.2005.07.009
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Lee HL, 2010, EXP MOL MED, V42, P437, DOI 10.3858/emm.2010.42.6.045
   Li AG, 2015, MOL CELLS, V38, P941, DOI 10.14348/molcells.2015.2353
   Lin JH, 2011, J OCCUP MED TOXICOL, V6, DOI 10.1186/1745 6673 6 27
   Mukai T, 2007, BIOCHEM BIOPH RES CO, V356, P1004, DOI 10.1016/j.bbrc.2007.03.099
   Nanjundaiah SM, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/518094
   Orriss IR, 2006, BONE, V39, P300, DOI 10.1016/j.bone.2006.02.063
   Park KM, 2010, CELL SIGNAL, V22, P977, DOI 10.1016/j.cellsig.2010.01.010
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Wang GY, 2015, MOL MED REP, V12, P877, DOI 10.3892/mmr.2015.3524
   Yang CH, 2017, INT J BIOL MACROMOL, V99, P15, DOI 10.1016/j.ijbiomac.2017.02.056
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   ZHANG Z Q, 1992, Yaoxue Xuebao, V27, P321
NR 22
TC 33
Z9 37
U1 2
U2 42
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 16
PY 2017
VL 491
IS 2
BP 388
EP 395
DI 10.1016/j.bbrc.2017.07.091
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FE5ZZ
UT WOS:000408291100023
PM 28733032
DA 2025 08 17
ER

PT J
AU Lawson, LY
   Brodt, MD
   Migotsky, N
   Chermside Scabbo, CJ
   Palaniappan, R
   Silva, MJ
AF Lawson, Lisa Y.
   Brodt, Michael D.
   Migotsky, Nicole
   Chermside Scabbo, Christopher J.
   Palaniappan, Ramya
   Silva, Matthew J.
TI Osteoblast Specific Wnt Secretion Is Required for Skeletal Homeostasis
   and Loading Induced Bone Formation in Adult Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BIOMECHANICS; GENETIC ANIMAL MODELS; OSTEOBLASTS; WNT; BETA CATENIN;
   LRPS; PARACRINE PATHWAYS
ID WNTLESS; LRP5; MECHANOTRANSDUCTION; EXPRESSION; OSTEOCYTES; PROTEINS;
   LAMELLAR; REVEALS; TIBIAE; GROWTH
AB Wnt signaling is critical to many aspects of skeletal regulation, but the importance of Wnt ligands in the bone anabolic response to mechanical loading is not well established. Recent transcriptome profiling studies by our laboratory and others show that mechanical loading potently induces genes encoding Wnt ligands, including Wnt1 and Wnt7b. Based on these findings, we hypothesized that mechanical loading stimulates adult bone formation by inducing Wnt ligand expression. To test this hypothesis, we inhibited Wnt ligand secretion in adult (5 months old) mice using a systemic (drug) and a bone targeted (conditional gene knockout) approach, and subjected them to axial tibial loading to induce lamellar bone formation. Mice treated with the Wnt secretion inhibitor WNT974 exhibited a decrease in bone formation in non loaded bones as well as a 54% decline in the periosteal bone formation response to tibial loading. Next, osteoblast specific Wnt secretion was inhibited by dosing 5 month old Osx CreERT2; Wls(F/F) mice with tamoxifen. Within 1 to 2 weeks of Wls deletion, skeletal homeostasis was altered with decreased bone formation and increased resorption, and the anabolic response to loading was reduced 65% compared to control (Wls(F/F)). Together, these findings show that Wnt ligand secretion is required for adult bone homeostasis, and furthermore establish a role for osteoblast derived Wnts in mediating the bone anabolic response to tibial loading. (c) 2021 American Society for Bone and Mineral Research (ASBMR).
C1 [Lawson, Lisa Y.; Brodt, Michael D.; Migotsky, Nicole; Chermside Scabbo, Christopher J.; Palaniappan, Ramya; Silva, Matthew J.] Washington Univ Sch Med, Dept Orthopaed Surg, 5423 Christy Blvd,Apt A, St Louis, MO 63116 USA.
   [Lawson, Lisa Y.; Brodt, Michael D.; Migotsky, Nicole; Chermside Scabbo, Christopher J.; Palaniappan, Ramya; Silva, Matthew J.] Washington Univ Sch Med, Musculoskeletal Res Ctr, 5423 Christy Blvd,Apt A, St Louis, MO 63116 USA.
   [Migotsky, Nicole; Silva, Matthew J.] Washington Univ, Dept Biomed Engn, St Louis, MO USA.
   [Chermside Scabbo, Christopher J.] Washington Univ Sch Med, Med Scientist Training Program, St Louis, MO USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL); Washington University (WUSTL)
RP Lawson, LY (通讯作者)，Washington Univ Sch Med, Dept Orthopaed Surg, 5423 Christy Blvd,Apt A, St Louis, MO 63116 USA.; Lawson, LY (通讯作者)，Washington Univ Sch Med, Musculoskeletal Res Ctr, 5423 Christy Blvd,Apt A, St Louis, MO 63116 USA.
EM lylawson@wustl.edu
RI ; Palaniappan, Ramya/GLU 0419 2022
OI Silva, Matthew/0000 0001 7375 4522; Lawson, Lisa/0000 0002 4436 5357; 
FU NIH [R01 AR047867, T32 AR060719]; Washington University Musculoskeletal
   Research Center [P30 AR074992];  [P30 CA91842];  [UL1 TR002345]
FX This work was supported by NIH grants R01 AR047867 (Matthew J Silva),
   T32 AR060719 (Roberto Civitelli) and the Washington University
   Musculoskeletal Research Center (P30 AR074992 (Matthew J Silva)). We
   thank Crystal Idleburg and Samantha Coleman for histology support. We
   thank the Genome Technology Access Center (supported by P30 CA91842 and
   UL1 TR002345) for help with gene expression assays. We thank the Core
   Laboratory for Clinical Studies for their help with serum assays.
   Finally, we thank Roberto Civitelli for advice and comments on the
   study.Authors' roles: Study design: LYL, MDB, and MJS. Study conduct and
   data collection: LYL, MDB, NM, CCS, and RP. Data analysis and
   interpretation: LYL, MDB, NM, CCS, and MJS. Drafting manuscript: LYL and
   MJS. Revising manuscript content: LYL, NM, CCS, and MJS. Approving final
   version of manuscript: all authors. LYL and MJS take responsibility for
   the integrity of the data analysis.
CR Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bänziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049
   Barrott JJ, 2011, P NATL ACAD SCI USA, V108, P12752, DOI 10.1073/pnas.1006437108
   Brodt MD, 2010, J BONE MINER RES, V25, P2006, DOI 10.1002/jbmr.96
   Burgers TA, 2013, BONE, V54, P244, DOI 10.1016/j.bone.2013.02.022
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Carpenter AC, 2010, GENESIS, V48, P554, DOI 10.1002/dvg.20651
   Chen JQ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004145
   Chermside Scabbo CJ, 2020, J BONE MINER RES, V35, P1751, DOI 10.1002/jbmr.4031
   Ching W, 2006, CELL, V125, P432, DOI 10.1016/j.cell.2006.04.018
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   FORWOOD MR, 1994, BONE, V15, P603, DOI 10.1016/8756 3282(94)90307 7
   Fu J, 2009, P NATL ACAD SCI USA, V106, P18598, DOI 10.1073/pnas.0904894106
   Funck Brentano T, 2018, J ENDOCRINOL, V238, P13, DOI 10.1530/JOE 18 0153
   Galea GL, 2017, GENE, V599, P36, DOI 10.1016/j.gene.2016.11.006
   Holguin N, 2016, J BONE MINER RES, V31, P2215, DOI 10.1002/jbmr.2900
   Holguin N, 2014, BONE, V65, P83, DOI 10.1016/j.bone.2014.05.006
   International Federation of Musculoskeletal Research Societies (IFMRS), 2019, MUSC KNOWL PORT
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116
   Kelly NH, 2016, BONE, V86, P22, DOI 10.1016/j.bone.2016.02.007
   Lara Castillo N, 2015, BONE, V76, P58, DOI 10.1016/j.bone.2015.03.019
   Li XH, 2019, ELIFE, V8, DOI 10.7554/eLife.49631
   Luther J, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aau7137
   Madan B, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0017 8
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Maes C, 2007, ANN NY ACAD SCI, V1116, P149, DOI 10.1196/annals.1402.060
   Main RP, 2020, J ORTHOP RES, V38, P233, DOI 10.1002/jor.24466
   Maupin KA, 2013, BONE RES, V1, DOI 10.4248/BR201301004
   Morris JA, 2019, NAT GENET, V51, P258, DOI 10.1038/s41588 018 0302 x
   Morse A, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115054
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Niziolek PJ, 2012, BONE, V51, P459, DOI 10.1016/j.bone.2012.05.023
   Pflanz D, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09653 9
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Rodon J, 2021, BRIT J CANCER, V125, P28, DOI 10.1038/s41416 021 01389 8
   Roosa SMM, 2011, J BONE MINER RES, V26, P100, DOI 10.1002/jbmr.193
   Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200
   Song DY, 2020, BONE RES, V8, DOI 10.1038/s41413 019 0081 8
   Sun D, 2018, J ORTHOP RES, V36, P682, DOI 10.1002/jor.23727
   Tan SH, 2014, P NATL ACAD SCI USA, V111, pE5262, DOI 10.1073/pnas.1420463111
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   TURNER CH, 1994, J BONE MINER RES, V9, P87
   Wergedal JE, 2015, ENDOCRINOLOGY, V156, P1023, DOI 10.1210/en.2014 1702
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Zannit HM, 2020, FASEB J, V34, P12739, DOI 10.1096/fj.202000614R
   Zannit HM, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10227
   Zhang LS, 2016, METHODS MOL BIOL, V1481, P111, DOI 10.1007/978 1 4939 6393 5_12
   Zhao LM, 2013, BONE, V54, P35, DOI 10.1016/j.bone.2013.01.033
   Zhao S, 2015, ONCOGENE, V34, P5069, DOI 10.1038/onc.2014.429
   Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109
NR 53
TC 27
Z9 30
U1 1
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2022
VL 37
IS 1
BP 108
EP 120
DI 10.1002/jbmr.4445
EA OCT 2021
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA YI7CE
UT WOS:000705841800001
PM 34542191
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Okamatsu, N
   Sakai, N
   Karakawa, A
   Kouyama, N
   Sato, Y
   Inagaki, K
   Kiuchi, Y
   Oguchi, K
   Negishi Koga, T
   Takami, M
AF Okamatsu, Nobuaki
   Sakai, Nobuhiro
   Karakawa, Akiko
   Kouyama, Naoka
   Sato, Yurie
   Inagaki, Katsunori
   Kiuchi, Yuji
   Oguchi, Katsuji
   Negishi Koga, Takako
   Takami, Masamichi
TI Biological effects of anti RANKL antibody administration in pregnant
   mice and their newborns
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE RANKL; Pregnancy; Bone metabolism; Denosumab; Osteoclasts
ID OSTEOCLAST DIFFERENTIATION FACTOR; DENOSUMAB TREATMENT;
   OSTEOPROTEGERIN LIGAND; CYNOMOLGUS MONKEYS; EPITHELIAL CELLS; BONE MASS;
   LACTATION; BISPHOSPHONATES; MECHANISMS; REGULATOR
AB Denosumab, a fully human monoclonal antibody that neutralizes receptor activator of nuclear factor kappa B ligand (RANKL) and blocks osteoclast differentiation, has received approval in Japan for use as an anti resorptive drug for osteoporosis and skeletal related events (SREs) in patients with solid cancer. Denosumab is contraindicated during pregnancy, though the effects of blocking RANKL activity on pregnant mothers and their newborns are unclear. We used mice to investigate the effects of an anti RANKL antibody on maternal and newborn health. Mothers injected with the anti RANKL antibody had increased bone mass as compared with the controls, while osteoclast number and the level of tartrate resistant acid phosphatase (TRAP) in serum were increased at the end of pregnancy. Newborn mice exposed to the antibody in utero were normally born, but showed increased bone mass and died within 48 h after birth. None of the newborns were found to have milk in their stomachs, suggesting that they died due to a maternal defect in lactation. Consistent with this, anti RANKL antibody injected mothers displayed impaired mammary gland development. However, fostering by healthy surrogate mothers rescued only 33% of the antibody exposed newborns, suggesting that neonatal mortality was due, at least in part, to an intrinsic defect in the newborns. Our findings show that anti RANKL antibody administration during pregnancy results in not only an undesirable increase in bone mass, but also has harmful effects on newborn survival. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Okamatsu, Nobuaki; Inagaki, Katsunori] Showa Univ, Sch Med, Dept Orthopaed Surg, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.
   [Okamatsu, Nobuaki; Kiuchi, Yuji; Oguchi, Katsuji] Showa Univ, Sch Med, Dept Pharmacol, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.
   [Okamatsu, Nobuaki; Sakai, Nobuhiro; Karakawa, Akiko; Kouyama, Naoka; Sato, Yurie; Negishi Koga, Takako; Takami, Masamichi] Showa Univ, Sch Dent, Dept Pharmacol, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.
C3 Showa University; Showa University; Showa University
RP Negishi Koga, T; Takami, M (通讯作者)，Showa Univ, Sch Dent, Dept Pharmacol, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.
EM koga@dent.showa u.ac.jp; takami@dent.showa u.ac.jp
OI Akiko, Karakawa/0000 0003 2099 7293; Takami,
   Masamichi/0000 0002 4506 3975
FU Private University Research Branding Project of the Ministry of
   Education, Culture, Sports, Science and Technology of Japan (MEXT);
   Industry to Support Private Universities Building up Their Foundations
   of Strategic Research of MEXT [S1411009, S1201014, S0801016]; Japan
   Society for the Promotion of Science [24659830, 26293398, 25293066,
   17K11993, 15K15538, 16K20655]; Science Research Promotion Fund; Uehara
   Memorial Foundation; Naito Foundation; Takeda Science Foundation;
   Grants in Aid for Scientific Research [17H04050, 25293066, 26293398,
   24659830, 16K20655, 15K15538, 17K11993] Funding Source: KAKEN
FX We thank all members of Pharmacology laboratory for their helpful
   discussion and assistance. This work was supported in part by the
   Private University Research Branding Project of the Ministry of
   Education, Culture, Sports, Science and Technology of Japan (MEXT) to
   Showa University, and the Industry to Support Private Universities
   Building up Their Foundations of Strategic Research of MEXT (S1411009,
   S1201014, S0801016) to M.T., Grant in Aids for Scientific Research (B)
   to M. T. (No. 24659830, 26293398) and to T. N. K. (No. 25293066), and
   Grant in Aids for Scientific Research (C) to N. S. (No. 17K11993),
   Grant in Aid for Challenging Exploratory Research to T. N. K. (No.
   15K15538) and Grant in Aid for Young Scientists (B) to A. K. (No.
   16K20655) from the Japan Society for the Promotion of Science, and
   grant in aids from The Science Research Promotion Fund to A. K., The
   Uehara Memorial Foundation to T. N. K, The Naito Foundation to T. N. K
   and the Takeda Science Foundation to T. N. K.
CR Boyce AM, 2012, J BONE MINER RES, V27, P1462, DOI 10.1002/jbmr.1603
   Boyce RW, 2014, BONE, V64, P314, DOI 10.1016/j.bone.2014.04.002
   Bussiere JL, 2013, REPROD TOXICOL, V42, P27, DOI 10.1016/j.reprotox.2013.07.018
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Duheron V, 2011, P NATL ACAD SCI USA, V108, P5342, DOI 10.1073/pnas.1013054108
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Furuya Y, 2011, J BIOL CHEM, V286, P37023, DOI 10.1074/jbc.M111.246280
   Gossai N, 2015, PEDIATR BLOOD CANCER, V62, P1078, DOI 10.1002/pbc.25393
   GRAEPEL P, 1992, ARZNEIMITTEL FORSCH, V42 1, P654
   Grasemann C, 2013, J CLIN ENDOCR METAB, V98, P3121, DOI 10.1210/jc.2013 1143
   Hanada R, 2009, NATURE, V462, P505, DOI 10.1038/nature08596
   Ioannis SP, 2011, HORM INT J ENDOCRINO, V10, P280, DOI 10.14310/horm.2002.1319
   Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kovacs CS, 2008, AM J CLIN NUTR, V88, p520S, DOI 10.1093/ajcn/88.2.520S
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Mastaglia SR, 2010, OSTEOPOROSIS INT, V21, P1959, DOI 10.1007/s00198 009 1138 0
   MAZOR M, 1993, ISRAEL J MED SCI, V29, P97
   Mohanty S, 2010, J REPROD IMMUNOL, V84, P133, DOI 10.1016/j.jri.2009.10.008
   Nishikawa K, 2010, J CLIN INVEST, V120, P3455, DOI 10.1172/JCI42528
   Patlas N, 1999, TERATOLOGY, V60, P68, DOI 10.1002/(SICI)1096 9926(199908)60:2<68::AID TERA10>3.0.CO;2 H
   Puvanesarajah V, 2016, SURG ONCOL, V25, P212, DOI 10.1016/j.suronc.2016.05.024
   Rossi SW, 2007, J EXP MED, V204, P1267, DOI 10.1084/jem.20062497
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Setsu N, 2016, J BONE MINER METAB, V34, P118, DOI 10.1007/s00774 015 0677 z
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Wendelboe MH, 2016, BONE, V87, P27, DOI 10.1016/j.bone.2016.03.012
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 31
TC 23
Z9 25
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 23
PY 2017
VL 491
IS 3
BP 614
EP 621
DI 10.1016/j.bbrc.2017.07.154
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FH1CI
UT WOS:000410876900008
PM 28760341
DA 2025 08 17
ER

PT J
AU Wang, T
   Guo, Y
   Shi, XW
   Gao, Y
   Zhang, JY
   Wang, CJ
   Yang, X
   Shu, Q
   Chen, XL
   Fu, XY
   Xie, WS
   Zhang, Y
   Li, B
   Guo, CQ
AF Wang, Tong
   Guo, Yan
   Shi, Xiao Wei
   Gao, Yang
   Zhang, Jia Yi
   Wang, Chun Jiu
   Yang, Xue
   Shu, Qi
   Chen, Xi Lin
   Fu, Xin Yi
   Xie, Wen Shan
   Zhang, Yi
   Li, Bin
   Guo, Chang Qing
TI Acupotomy Contributes to Suppressing Subchondral Bone Resorption in KOA
   Rabbits by Regulating the OPG/RANKL Signaling Pathway
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID KNEE OSTEOARTHRITIS; REDUCES CARTILAGE; MODEL; BISPHOSPHONATES;
   EXPRESSION; LESIONS; DAMAGE
AB Subchondral bone lesions, as the crucial inducement for accelerating cartilage degeneration, have been considered as the initiating factor and the potential therapeutic target of knee osteoarthritis (KOA). Acupotomy, the biomechanical therapy guided by traditional Chinese meridians theory, alleviates cartilage deterioration by correcting abnormal mechanics. Whether this mechanical effect of acupotomy inhibits KOA subchondral bone lesions is indistinct. This study aimed to investigate the effects of acupotomy on inhibiting subchondral bone resorption and to define the possible mechanism in immobilization induced KOA rabbits. After KOA modeling, 8 groups of rabbits (4w/6w acupotomy, 4w/6w electroacupuncture, 4w/6w model, and 4w/6w control groups) received the indicated intervention for 3 weeks. Histological and bone histomorphometry analyses revealed that acupotomy prevented both cartilage surface erosion and subchondral bone loss. Further, acupotomy suppressed osteoclast activity and enhanced osteoblast activity in KOA subchondral bone, showing a significantly decreased expression of tartrate resistant acid phosphatase (TRAP), matrix metalloproteinases 9 (MMP 9), and cathepsin K (Ctsk) and a significantly increased expression of osteocalcin (OCN); this regulation may be mediated by blocking the decrease in osteoprotegerin (OPG) and the increase in NF kappa B receptor activated protein ligand (RANKL). These findings indicated that acupotomy inhibited osteoclast activity and promoted osteoblast activity to ameliorate hyperactive subchondral bone resorption and cartilage degeneration in immobilization induced KOA rabbits, which may be mediated by the OPG/RANKL signaling pathway. Taken together, our results indicate that acupotomy may have therapeutic potential in KOA by restoring the balance between bone formation and bone resorption to attenuate subchondral bone lesions.
C1 [Wang, Tong; Gao, Yang; Wang, Chun Jiu; Yang, Xue; Shu, Qi; Chen, Xi Lin; Fu, Xin Yi; Xie, Wen Shan; Zhang, Yi; Guo, Chang Qing] Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Beijing 100029, Peoples R China.
   [Guo, Yan; Li, Bin] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Acupuncture & Moxibust Dept, Beijing 100010, Peoples R China.
   [Shi, Xiao Wei] Beijing Univ Chinese Med, Affiliated Hosp 3, Massage Dept, Beijing 100029, Peoples R China.
   [Zhang, Jia Yi] Beijing Nankou Hosp, Tradit Chinese Med Dept, Beijing 102200, Peoples R China.
C3 Beijing University of Chinese Medicine; Capital Medical University;
   Beijing University of Chinese Medicine
RP Guo, CQ (通讯作者)，Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Beijing 100029, Peoples R China.
EM 2414052309@qq.com; guoyan7777777@126.com; shixiaowei515@126.com;
   2479746967@qq.com; zhangjy@bucm.edu.cn; 20170931967@bucm.edu.cn;
   yxsnowflake@163.com; 870939948@qq.com; 353687454@qq.com;
   906162467@qq.com; 419700464@qq.com; zhangyi.acupotomology@gmail.com;
   libin@bjzhongyi.com; guochangqing0066@163.com
RI Chen, Xilin/A 1409 2012; Zhang, Jiayi/IUO 4211 2023; Wang,
   Tong/LRU 1497 2024
FU National Natural Science Foundation of China [81874504]; Beijing Natural
   Science Foundation [7192110]
FX This work was supported by research grants from the National Natural
   Science Foundation of China (Grant no. 81874504) and Beijing Natural
   Science Foundation (Grant no. 7192110).
CR An XY, 2020, AGING DIS, V11, P1116, DOI 10.14336/AD.2019.1104
   Aso K, 2019, ARTHRITIS RHEUMATOL, V71, P916, DOI 10.1002/art.40820
   Bagi CM, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0829 5
   Bartels EM, 2014, OSTEOARTHR CARTILAGE, V22, P1817, DOI 10.1016/j.joca.2014.07.027
   Bertuglia A, 2016, OSTEOARTHR CARTILAGE, V24, P555, DOI 10.1016/j.joca.2015.10.008
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chen Y, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.34
   Chen Y, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/6436420
   Dai GM, 2020, INT J MOL MED, V46, P167, DOI 10.3892/ijmm.2020.4576
   Donell S, 2019, EFORT OPEN REV, V4, P221, DOI 10.1302/2058 5241.4.180102
   Eriksen EF, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115352
   Farrokhi S, 2016, KNEE, V23, P49, DOI 10.1016/j.knee.2015.07.011
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Findlay DM, 2014, CURR OSTEOPOROS REP, V12, P127, DOI 10.1007/s11914 014 0192 5
   Fonseca JE, 2005, CLIN EXP RHEUMATOL, V23, P185
   Fu DP, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03301 6
   Guo XY, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03317 y
   Hayami T, 2012, BONE, V50, P1250, DOI 10.1016/j.bone.2012.03.025
   He ZH, 2020, J ORTHOP TRANSL, V24, P39, DOI 10.1016/j.jot.2020.05.006
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Iijima H, 2016, OSTEOARTHR CARTILAGE, V24, P354, DOI 10.1016/j.joca.2015.09.001
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Kazakia GJ, 2013, OSTEOARTHR CARTILAGE, V21, P94, DOI 10.1016/j.joca.2012.09.008
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Liang Chu Xi, 2015, Zhen Ci Yan Jiu, V40, P119
   Liphardt AM, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115149
   Little CB, 2008, CURR RHEUMATOL REV, V4, P175, DOI 10.2174/157339708785133523
   Loeser RF, 2016, NAT REV RHEUMATOL, V12, P412, DOI 10.1038/nrrheum.2016.65
   Löfvall H, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1564 5
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   Ma SN, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/4535326
   Menale C, 2019, STEM CELL TRANSL MED, V8, P22, DOI 10.1002/sctm.18 0085
   Conesa Buendía FM, 2019, ANN RHEUM DIS, V78, P1507, DOI 10.1136/annrheumdis 2019 eular.1193
   Moreau M, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3373
   Muratovic D, 2019, OSTEOARTHR CARTILAGE, V27, P1653, DOI 10.1016/j.joca.2019.07.004
   Neogi T, 2010, ANN RHEUM DIS, V69, P841, DOI 10.1136/ard.2009.110114
   Pelletier JP, 2015, ANN RHEUM DIS, V74, P422, DOI 10.1136/annrheumdis 2013 203989
   Posritong S, 2018, MOL CELL ENDOCRINOL, V474, P35, DOI 10.1016/j.mce.2018.02.005
   Poulet B, 2015, OSTEOARTHR CARTILAGE, V23, P940, DOI 10.1016/j.joca.2015.01.012
   Ryser MD, 2017, J THEOR BIOL, V418, P16, DOI 10.1016/j.jtbi.2017.01.021
   Shen WX, 2019, J ETHNOPHARMACOL, V238, DOI 10.1016/j.jep.2019.111861
   Siebelt M, 2014, BONE, V66, P163, DOI 10.1016/j.bone.2014.06.009
   Slyfield CR, 2012, J BONE MINER RES, V27, P486, DOI 10.1002/jbmr.553
   ter Heegde F, 2020, OSTEOARTHR CARTILAGE, V28, P383, DOI 10.1016/j.joca.2019.12.004
   Thompson WR, 2012, GENE, V503, P179, DOI 10.1016/j.gene.2012.04.076
   Tiraloche G, 2005, ARTHRITIS RHEUM US, V52, P1118, DOI 10.1002/art.20951
   Upton AR, 2012, RHEUMATOL INT, V32, P535, DOI 10.1007/s00296 010 1733 6
   Vaysbrot EE, 2018, OSTEOARTHR CARTILAGE, V26, P154, DOI 10.1016/j.joca.2017.11.013
   Wei CC, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9529630
   Zhang C, 2017, ACTA CIR BRAS, V32, P418, DOI 10.1590/s0102 865020170060000002
   Zhang J., 2019, EXP THER MED, V19, P232
   Zhang W, 2019, J TRADIT CHIN MED, V39, P229
   Zhang X, 2020, OSTEOARTHR CARTILAGE, V28, pS366
   Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023516
   Zhang ZM, 2010, OSTEOPOROSIS INT, V21, P1383, DOI 10.1007/s00198 009 1071 2
   Zhao ZD, 2020, ENG FRACT MECH, V233, DOI 10.1016/j.engfracmech.2020.107081
   Zheng WW, 2020, FASEB J, V34, P3399, DOI 10.1096/fj.201902117R
   Zhu JX, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.103
NR 59
TC 11
Z9 12
U1 3
U2 24
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD APR 26
PY 2021
VL 2021
AR 8168657
DI 10.1155/2021/8168657
PG 17
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA TQ7FI
UT WOS:000678444900001
PM 34335838
OA Green Published
DA 2025 08 17
ER

PT J
AU Park, KR
   Kim, JY
   Kim, EC
   Yun, HM
   Hong, JT
AF Park, Kyung Ran
   Kim, Ji Youn
   Kim, Eun Cheol
   Yun, Hyung Mun
   Hong, Jin Tae
TI RANKL induced osteoclastogenesis is suppressed by
   4 O methylhonokiol in bone marrow derived macrophages
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Article
DE Magnolia officinalis; 4 O methylhonokiol; Osteoblast; Osteoclast; RANKL
ID OSTEOBLASTIC DIFFERENTIATION; MC3T3 E1 CELLS; C FOS; OSTEOPOROSIS;
   ACTIVATION; RECEPTOR; MINERALIZATION; RESORPTION; PATHWAYS; SYSTEM
AB Magnolol, honokiol, and obovatol are well known bioactive constituents of the bark of Magnolia officinalis and have been reported to have beneficial effects in various diseases. We recently isolated a novel active compound, 4 O methylhonokiol (4 O MH) from the ethanol extract of M. officinalis, which was previously reported to have pharmacological effects including anti inflammatory, anti oxidative, and anti aging activities. Here, we examined the pharmacological properties of 4 O MH on osteoblast (bone forming cells) and osteoclast (bone resorbing cells) differentiation, and its underlying signaling pathways in primary cultured pre osteoblasts and bone marrow macrophages. Our results showed that 4 O MH did not affect cell viability in pre osteoblasts and did not influence osteoblast differentiation and mineralized nodule formation, as assessed by alkaline phosphatase activity and Alizarin red staining. However, 4 O MH significantly inhibited TRAP positive multinuclear osteoclasts and F actin ring formation during Receptor activator of NF kappa B ligand (RANKL) mediated osteoclastogenesis without cytotoxicity. In addition, 4 O MH suppressed RANKL induced critical factors (c Fos, NF ATc1, TRAP, and ITB3) for osteoclast differentiation and function. Furthermore, RANKL mediated signaling, including ERK1/2, AKT, and NF kB pathways was attenuated by 4 O MH. Taken together, 4 O MH has an inhibitory role in RANKL mediated osteoclastogenesis but not osteoblast differentiation, and our findings also suggest that 4 O MH is a potential therapeutic agent for bone destructive diseases such as osteoporosis, alveolar bone resorption, and osteoarthritis.
C1 [Park, Kyung Ran] Kyung Hee Univ, Grad Sch, Dept Oral & Maxillofacial Regenerat, Seoul 130701, South Korea.
   [Kim, Ji Youn] Gachon Univ, Dept Dent Hyg, Coll Hlth Sci, Incheon 406799, South Korea.
   [Kim, Eun Cheol; Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 1 Heogi Dong, Seoul 130701, South Korea.
   [Hong, Jin Tae] Chungbuk Natl Univ, Coll Pharm, 194 31 Osongsangmyeong1 Ro, Cheongju 361763, Chungbuk, South Korea.
   [Hong, Jin Tae] Chungbuk Natl Univ, Med Res Ctr, 194 31 Osongsangmyeong1 Ro, Cheongju 361763, Chungbuk, South Korea.
C3 Kyung Hee University; Gachon University; Kyung Hee University; Chungbuk
   National University; Chungbuk National University
RP Yun, HM (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 1 Heogi Dong, Seoul 130701, South Korea.; Hong, JT (通讯作者)，Chungbuk Natl Univ, Coll Pharm, 194 31 Osongsangmyeong1 Ro, Cheongju 361763, Chungbuk, South Korea.; Hong, JT (通讯作者)，Chungbuk Natl Univ, Med Res Ctr, 194 31 Osongsangmyeong1 Ro, Cheongju 361763, Chungbuk, South Korea.
EM yunhm@khu.ac.kr; jinthong@chungbuk.ac.kr
RI Kim, Ji Youn/A 5779 2017; Kim, Cheorl Ho/T 6753 2019
FU Kyung Hee University [KHU 20160546]; National Research Foundation of
   Korea (NRF)   Korea government (MEST) (MRC) [20080062275,
   2015R1D1A1A01059240]
FX This work was supported by a grant from Kyung Hee University in 2016
   (KHU 20160546) and the National Research Foundation of Korea (NRF) grant
   funded by the Korea government (MEST) (MRC, 20080062275;
   2015R1D1A1A01059240).
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cairoli E, 2015, J ENDOCRINOL INVEST, V38, P303, DOI 10.1007/s40618 014 0236 9
   Chang EJ, 2008, NAT MED, V14, P966, DOI 10.1038/nm.1860
   Endo Itsuro, 2012, Clin Calcium, V22, P327, DOI CliCa1203327333
   Filvaroff E, 1999, DEVELOPMENT, V126, P4267
   Jung YY, 2014, BIOMOL THER, V22, P232, DOI 10.4062/biomolther.2014.030
   Khosla S, 2005, ENDOCRIN METAB CLIN, V34, P1015, DOI 10.1016/j.ecl.2005.07.009
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Lee HS, 2011, PHYTOTHER RES, V25, P716, DOI 10.1002/ptr.3328
   Lee YJ, 2011, FREE RADICAL BIO MED, V50, P66, DOI 10.1016/j.freeradbiomed.2010.10.698
   Lee YJ, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742 2094 9 35
   Lee YJ, 2011, PHARMACOL THERAPEUT, V130, P157, DOI 10.1016/j.pharmthera.2011.01.010
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   Oh JH, 2012, J NUTR BIOCHEM, V23, P706, DOI 10.1016/j.jnutbio.2011.03.013
   Oh JH, 2009, CHEM BIOL INTERACT, V180, P506, DOI 10.1016/j.cbi.2009.03.014
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Vondracek SF, 2008, CLIN INTERV AGING, V3, P315, DOI 10.2147/CIA.S2539
   Whitmarsh AJ, 1996, J MOL MED JMM, V74, P589, DOI 10.1007/s001090050063
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Yun HM, 2007, J BIOL CHEM, V282, P5496, DOI 10.1074/jbc.M606215200
   Yun HM, 2016, SCI REP UK, V6, DOI 10.1038/srep30985
   Yun HM, 2014, PHARMACOL THERAPEUT, V142, P183, DOI 10.1016/j.pharmthera.2013.12.005
   Zanotti S, 2015, J CELL PHYSIOL, V230, P1689, DOI 10.1002/jcp.24928
NR 31
TC 21
Z9 21
U1 0
U2 12
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489 3 SUHCHO DONG, SUHCHO KU, SEOUL 137 071, SOUTH KOREA
SN 0253 6269
EI 1976 3786
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD AUG
PY 2017
VL 40
IS 8
BP 933
EP 942
DI 10.1007/s12272 017 0932 z
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FF2ZV
UT WOS:000408766200006
PM 28736799
DA 2025 08 17
ER

PT J
AU Martin, S
   Gan, ZY
   Fitter, S
   To, LB
   Zannettino, ACW
AF Martin, Sally
   Gan, Zhen Ying
   Fitter, Stephen
   To, Luen B.
   Zannettino, Andrew C. W.
TI The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic
   bone disease in multiple myeloma
SO LEUKEMIA RESEARCH
LA English
DT Article
DE BKM120; Multiple myeloma; Bone; PI3K
ID PHOSPHATIDYLINOSITOL 3 KINASE; MURINE MODEL; FACTOR I; DIFFERENTIATION;
   PATHWAYS; THERAPY; BURDEN
AB The plasma cell malignancy multiple myeloma (MM) is unique amongst haematological malignancies in its capacity to cause osteoclast mediated skeletal destruction. The PI3K/Akt pathway mediates proliferation, survival and drug resistance in MM plasma cells and is also involved in regulating the formation and activity of bone forming osteoblasts and bone resorbing osteoclasts.
   NVP BKM120 (Buparlisib, Novartis) is a PI3K inhibitor that is currently undergoing clinical evaluation in several tumour settings. In this study, we have examined the anti tumorigenic effects of BKM120 in an immunocompetent mouse model of MM and its effects on osteoblast and osteoclast formation and function. BKM120 treatment (40 mg/kg) resulted in a significant decrease in serum paraprotein and tumour burden, and mu CT analysis of the proximal tibia revealed a significant reduction in the number of osteolytic bone lesions in BKM120 treated animals. BKM120 also mediated a significant increase in serum levels of the osteoblast marker P1NP, and a significant decrease in serum levels of the osteoclast marker TRAcP5. In vitro, BKM120 decreased MM plasma cell proliferation, osteoclast formation and function, and promoted osteoblast formation and function. These findings suggest that, in addition to its anti tumour properties, BKM120 could be used to treat osteolytic bone disease in MM patients. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Martin, Sally; Gan, Zhen Ying; Fitter, Stephen; Zannettino, Andrew C. W.] Univ Adelaide, Myeloma Res Lab, Sch Med Sci, Fac Hlth Sci, Adelaide, SA 5005, Australia.
   [Martin, Sally; Fitter, Stephen; Zannettino, Andrew C. W.] Ctr Canc Biol, Adelaide, SA, Australia.
   [Martin, Sally; Fitter, Stephen; Zannettino, Andrew C. W.] Hanson Ctr Canc Res, Adelaide, SA, Australia.
   [Martin, Sally; Gan, Zhen Ying; Fitter, Stephen; Zannettino, Andrew C. W.] Univ Adelaide, Ctr Stem Cell Res, Adelaide, SA 5005, Australia.
   [Martin, Sally; Gan, Zhen Ying; Fitter, Stephen; Zannettino, Andrew C. W.] Univ Adelaide, Ctr Personalised Canc Med, Adelaide, SA 5005, Australia.
   [Martin, Sally; Gan, Zhen Ying; Fitter, Stephen; Zannettino, Andrew C. W.] SAHMRI, Adelaide, SA, Australia.
   [Gan, Zhen Ying] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia.
   [To, Luen B.] Queen Elizabeth Hosp, Women & Childrens Hosp, Flinders Med Ctr, Div Haematol,Royal Adelaide Hosp, Woodville South, SA, Australia.
   [To, Luen B.] Lyell McEwin Hosp, Elizabeth Vale, SA, Australia.
C3 University of Adelaide; Centre for Cancer Biology; University of
   Adelaide; University of Adelaide; South Australian Health & Medical
   Research Institute (SAHMRI); University of South Australia; Flinders
   Medical Centre; Royal Adelaide Hospital; Lyell McEwin Hospital
RP Martin, S (通讯作者)，SAHMRI, Myeloma Res Program, POB 11060, Adelaide, SA 5001, Australia.
EM sally.martin@adelaide.edu.au
OI Zannettino, Andrew/0000 0002 6646 6167; Martin,
   Sally/0000 0002 5700 3478; Fitter, Stephen/0000 0003 1663 6807
FU National Health and Medical Research Council of Australia [APP1030528];
   Australian Postgraduate Award; Novartis International, a Mary Overton
   Early Career Fellowship
FX This study was supported by grants awarded by the National Health and
   Medical Research Council of Australia (APP1030528) and Novartis
   International, a Mary Overton Early Career Fellowship (SKM), and an
   Australian Postgraduate Award (ZYG).
CR Abroun S, 2004, BLOOD, V103, P2291, DOI 10.1182/blood 2003 07 2187
   [Anonymous], BR J HAEMATOL
   [Anonymous], HAEMATOLOGICA
   [Anonymous], J MOL ENDOCRINOL
   [Anonymous], ENDOCRINOL
   [Anonymous], HAEMATOL
   [Anonymous], ONCOLOGY
   [Anonymous], ELIDOCRINOLOGV
   [Anonymous], MOL MED
   [Anonymous], SCIENCE
   [Anonymous], MARROW STROMAL CELL
   [Anonymous], BIOL CHEM
   Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365 2141.1998.00930.x
   Dallas SL, 1999, BLOOD, V93, P1697, DOI 10.1182/blood.V93.5.1697.405a17_1697_1706
   Farrugia AN, 2003, CANCER RES, V63, P5438
   Fitter S, 2008, BLOOD, V111, P2538, DOI 10.1182/blood 2007 07 104281
   Fowler JA, 2012, CANCER RES, V72, P2183, DOI 10.1158/0008 5472.CAN 11 2067
   Ge NL, 2000, BLOOD, V96, P2856
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood 2006 05 026112
   Heider U, 2005, BIOCHEM BIOPH RES CO, V338, P687, DOI 10.1016/j.bbrc.2005.09.146
   Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535 6108(03)00248 4
   Ogawa T, 1998, BIOCHEM BIOPH RES CO, V249, P226, DOI 10.1006/bbrc.1998.9118
   Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood 2002 12 3905
   Vanderkerken Karin, 2005, V113, P191, DOI 10.1385/1 59259 916 8:191
   Zannettino ACW, 2005, CANCER RES, V65, P1700, DOI 10.1158/0008 5472.CAN 04 1687
NR 30
TC 18
Z9 19
U1 0
U2 5
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145 2126
EI 1873 5835
J9 LEUKEMIA RES
JI Leuk. Res.
PD MAR
PY 2015
VL 39
IS 3
BP 380
EP 387
DI 10.1016/j.leukres.2014.12.015
PG 8
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA CB9NG
UT WOS:000349957800019
PM 25624048
DA 2025 08 17
ER

PT J
AU Wang, YK
   Chen, J
   Chen, J
   Dong, C
   Yan, X
   Zhu, ZP
   Lu, P
   Song, ZM
   Liu, HJ
   Chen, SF
AF Wang, Yongkui
   Chen, Jian
   Chen, Jing
   Dong, Chao
   Yan, Xu
   Zhu, Zhongpei
   Lu, Pan
   Song, Zongmian
   Liu, Hongjian
   Chen, Songfeng
TI Daphnetin ameliorates glucocorticoid induced osteoporosis via activation
   of Wnt/GSK 3β/β catenin signaling
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Daphnetin; Glucocorticoid Induced Osteoporosis; Wnt/GSK 3
   beta/beta Catenin Signaling
ID BONE HEALTH; INVOLVEMENT; ALPHA
AB Glucocorticoids have been widely used in multiple inflammatory and autoimmune diseases. However, long term glucocorticoid therapy may result in osteoporosis. The present study aimed to evaluate the potential therapeutic effects and investigate the underlying mechanisms of Daphnetin (Daph) on glucocorticoid induced osteoporosis (GIOP). In vivo, male Sprague Dawley rats were intramuscularly injected with dexamethasone (DEX) to induce GIOP and Daph was given intraperitoneally. Bone histological changes, mineral content, microstructure parameters and bone turnover markers were detected. Gut microbiota composition and intestinal barrier function were further assessed. In vitro, MC3T3 E1 pre osteoblasts were treated with DEX and the abilities of Daph on osteoblast proliferation, differentiation and mineralization were assessed. A Wnt signaling inhibitor, XAV939, was added additionally to evaluate the effect of Daph on Wnt signaling. The results showed that in vivo, Daph increased the DEX induced reduction in body weight gain, bone mineral content and microstructure parameters and restored the levels of bone turnover markers in GIOP rats. In vitro, Daph promoted osteoblast proliferation, differentiation and mineralization in DEX treated MC3T3 E1 pre osteoblasts. Moreover, Daph activated the Wnt/GSK 3 beta/beta catenin signaling pathway. XAV939 successfully abolished the beneficial effects of Daph on GIOP in vitro. Besides, Daph showed improvement on gut microbiota disorder and intestinal barrier dysfunction post GIOP. Collectively, these data demonstrated that Daph effectively ameliorates GIOP and the possible mechanism may be that Daph activated Wnt/GSK 3 beta/beta catenin signaling.
C1 [Wang, Yongkui; Dong, Chao; Yan, Xu; Zhu, Zhongpei; Lu, Pan; Song, Zongmian; Liu, Hongjian; Chen, Songfeng] Zhengzhou Univ, Dept Orthopaed, Affiliated Hosp 1, 1 Jianshe East Rd, Zhengzhou 450052, Peoples R China.
   [Chen, Jian] Shanghai Univ Tradit Chinese Med, Shanghai TCM Integrated Hosp, Dept Vasc Dis, Shanghai 200082, Peoples R China.
   [Chen, Jian] Shanghai Acad Tradit Chinese Med, Inst Vasc Anomalies, Shanghai 200082, Peoples R China.
   [Chen, Jing] Zhengzhou Univ, Henan Canc Hosp, Dept Clin Lab, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China.
C3 Zhengzhou University; Shanghai University of Traditional Chinese
   Medicine; Zhengzhou University
RP Liu, HJ; Chen, SF (通讯作者)，Zhengzhou Univ, Dept Orthopaed, Affiliated Hosp 1, 1 Jianshe East Rd, Zhengzhou 450052, Peoples R China.
EM feeliuhj@zzu.edu.cn; csfzdyfygk@163.com
RI Chen, Jian/GNM 7929 2022
OI Chen, Jian/0000 0001 5230 7141; Chen, Jing/0009 0004 2508 3380
FU National Natural Science Foundation of China [81802128]; Youth
   Innovation Fund of The First Affiliated Hospital of Zhengzhou University
   [YNQN2017039]; Promotion Program of Henan Science and Technology
   Department [192102310111, 192102310118]; Shanghai Sailing Program
   [20YF1445900]; Budgetary Projects of Shanghai University of Traditional
   Chinese Medicine [2019LK046]; Special Clinical Research Project of
   Health Profession of Shanghai Municipal Commission of Health
   [20194Y0081]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Grant No. 81802128), the Youth Innovation Fund of
   The First Affiliated Hospital of Zhengzhou University (Grant No.
   YNQN2017039), the Promotion Program of Henan Science and Technology
   Department (Grant No. 192102310111; Grant No. 192102310118), the
   Shanghai Sailing Program (Grant No. 20YF1445900), the Budgetary Projects
   of Shanghai University of Traditional Chinese Medicine (Grant No.
   2019LK046) and the Special Clinical Research Project of Health
   Profession of Shanghai Municipal Commission of Health (Grant No.
   20194Y0081).
CR Adami G, 2019, OSTEOPOROSIS INT, V30, P1145, DOI 10.1007/s00198 019 04906 x
   Adhikary S, 2018, NUTRITION, V53, P64, DOI 10.1016/j.nut.2017.12.003
   Al Daghri NM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005780
   Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   Balasubramanian A, 2018, J BONE MINER RES, V33, P1881, DOI 10.1002/jbmr.3523
   Baron R, 2018, CURR OPIN PHARMACOL, V40, P134, DOI 10.1016/j.coph.2018.04.011
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Chen X, 2020, AGING DIS, V11, P629, DOI 10.14336/AD.2019.0613
   Dardonville Q, 2019, EUR J CLIN PHARMACOL, V75, P1705, DOI 10.1007/s00228 019 02743 9
   Deng HM, 2020, CYTOKINE, V127, DOI 10.1016/j.cyto.2019.154952
   Deng Q, 2019, ELIFE, V8, DOI 10.7554/eLife.50208
   Ding K, 2020, AGING DIS, V11, P438, DOI 10.14336/AD.2019.0523
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Fan SL, 2018, LIFE SCI, V207, P205, DOI 10.1016/j.lfs.2018.06.006
   Farré R, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041185
   Fukuda H, 2016, BIOCHEM BIOPH RES CO, V471, P63, DOI 10.1016/j.bbrc.2016.01.179
   Harslof T, 2016, CURR OPIN PHARMACOL, V28, P38, DOI 10.1016/j.coph.2016.02.012
   Ibáñez L, 2019, JOINT BONE SPINE, V86, P43, DOI 10.1016/j.jbspin.2018.02.008
   König J, 2016, CLIN TRANSL GASTROEN, V7, DOI 10.1038/ctg.2016.54
   Kumar A, 2018, J PHYSIOL BIOCHEM, V74, P223, DOI 10.1007/s13105 018 0608 2
   Li LS, 2019, MICROBIOLOGYOPEN, V8, DOI 10.1002/mbo3.810
   Liang JQ, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8745487
   Lin YJ, 2018, ADV MATER, V30, DOI 10.1002/adma.201705605
   Liu XF, 2019, J CELL BIOCHEM, V120, P2304, DOI 10.1002/jcb.27555
   Lupsa BC, 2015, ENDOCRIN METAB CLIN, V44, P517, DOI 10.1016/j.ecl.2015.05.002
   Lv HM, 2020, PHYTOMEDICINE, V71, DOI 10.1016/j.phymed.2020.153241
   Ma SC, 2020, AGING US, V12, P10795, DOI 10.18632/aging.103293
   Mo H, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414 431X20198754, 10.1590/1414 431x20198754]
   Mohamed AAR, 2018, LIFE SCI, V212, P159, DOI 10.1016/j.lfs.2018.09.059
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Pavone V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00803
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ren H, 2015, STEROIDS, V102, P65, DOI 10.1016/j.steroids.2015.07.006
   Rizzoli R, 2015, NAT REV RHEUMATOL, V11, P98, DOI 10.1038/nrrheum.2014.188
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Schäcke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163 7258(02)00297 8
   Silverman MN, 2012, ANN NY ACAD SCI, V1261, P55, DOI 10.1111/j.1749 6632.2012.06633.x
   Stakheev D, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41182 5
   Villa CR, 2017, CRIT REV FOOD SCI, V57, P1664, DOI 10.1080/10408398.2015.1010034
   Wang XY, 2020, EUR J PHARMACOL, V880, DOI 10.1016/j.ejphar.2020.173212
   Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155
   Wu ZX, 2019, J CELL PHYSIOL, V234, P17812, DOI 10.1002/jcp.28408
   Xu WL, 2018, FRONT NEUROSCI SWITZ, V12, DOI 10.3389/fnins.2018.00638
   Yang L, 2019, J ENDOCRINOL INVEST, V42, P1125, DOI 10.1007/s40618 019 01034 5
   Zhi J, 2019, J CELL BIOCHEM, V120, P4132, DOI 10.1002/jcb.27698
NR 48
TC 28
Z9 35
U1 0
U2 42
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0041 008X
EI 1096 0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD DEC 15
PY 2020
VL 409
AR 115333
DI 10.1016/j.taap.2020.115333
PG 11
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA PG1MN
UT WOS:000599506800001
PM 33171191
DA 2025 08 17
ER

PT J
AU Gan, ZY
   Fitter, S
   Vandyke, K
   To, LB
   Zannettino, ACW
   Martin, SK
AF Gan, Zhen Ying
   Fitter, Stephen
   Vandyke, Kate
   To, Luen B.
   Zannettino, Andrew C. W.
   Martin, Sally K.
TI The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth
   and osteolytic bone disease in multiple myeloma
SO EUROPEAN JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE BEZ235; multiple myeloma; bone; mTOR; PI3K
ID PHOSPHATIDYLINOSITOL 3 KINASE/MAMMALIAN TARGET; OSTEOBLASTIC
   DIFFERENTIATION; MAMMALIAN TARGET; OSTEOGENIC DIFFERENTIATION;
   OSTEOCLAST FORMATION; RAPAMYCIN INHIBITOR; MURINE MODEL; STEM CELLS;
   FACTOR I; KINASE
AB The plasma cell malignancy multiple myeloma (MM) is unique among haematological malignancies in its capacity to cause osteoclast mediated skeletal destruction. The PI3K/Akt/mTOR pathway mediates proliferation, survival and drug resistance in MM plasma cells and is also involved in regulating the formation and activity of bone forming osteoblasts and bone resorbing osteoclasts. NVP BEZ235 is a dual pan class I PI3K and mTOR inhibitor that is currently undergoing clinical evaluation in several tumour settings. In this study, we examined the anti tumorigenic effects of BEZ235 in an immunocompetent mouse model of MM and assessed the effects of BEZ235 on osteoblast and osteoclast formation and function. BEZ235 treatment (50mg/kg) resulted in a significant decrease in serum paraprotein and tumour burden, and CT analysis of the proximal tibia revealed a significant reduction in the number of osteolytic bone lesions in BEZ235 treated animals. Levels of the serum osteoblast marker P1NP were significantly higher in BEZ235 treated animals, while levels of the osteoclast marker TRAcP5 were reduced. In vitro, BEZ235 decreased MM plasma cell proliferation, osteoclast formation and function and promoted osteoblast formation and function. These findings suggest that, in addition to its anti tumour properties, BEZ235 could be useful in treating osteolytic bone disease in MM patients.
C1 [Gan, Zhen Ying; Fitter, Stephen; Vandyke, Kate; Zannettino, Andrew C. W.; Martin, Sally K.] Univ Adelaide, Sch Med Sci, Myeloma Res Lab, Adelaide, SA, Australia.
   [Gan, Zhen Ying; Fitter, Stephen; Vandyke, Kate; Zannettino, Andrew C. W.; Martin, Sally K.] Univ Adelaide, Ctr Stem Cell Res, Robinson Inst, Adelaide, SA, Australia.
   [Gan, Zhen Ying; Fitter, Stephen; Vandyke, Kate; Zannettino, Andrew C. W.; Martin, Sally K.] Univ Adelaide, Ctr Personalised Canc Med, Adelaide, SA, Australia.
   [Gan, Zhen Ying] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia.
   [Vandyke, Kate; Zannettino, Andrew C. W.; Martin, Sally K.] SA Pathol, Ctr Canc Biol, Adelaide, SA 5000, Australia.
   [Vandyke, Kate; Zannettino, Andrew C. W.; Martin, Sally K.] Hanson Inst, Adelaide, SA, Australia.
   [To, Luen B.] Queen Elizabeth Hosp, Women & Childrens Hosp, Flinders Med Ctr, Div Haematol,Royal Adelaide Hosp, Adelaide, SA, Australia.
C3 University of Adelaide; Robinson Research Institute; University of
   Adelaide; University of Adelaide; University of South Australia; Centre
   for Cancer Biology; SA Pathology; Hanson Institute; Flinders Medical
   Centre; Royal Adelaide Hospital
RP Martin, SK (通讯作者)，SA Pathol, Div Haematol, Myeloma Res Program, POB 14 Rundle Mall, Adelaide, SA 5000, Australia.
EM sally.martin@health.sa.gov.au
RI ; Vandyke, Kate/G 6280 2010
OI Vandyke, Kate/0000 0002 1033 849X; Zannettino,
   Andrew/0000 0002 6646 6167; Martin, Sally/0000 0002 5700 3478; Fitter,
   Stephen/0000 0003 1663 6807
FU National Health and Medical Research Council of Australia [APP1030528];
   Novartis International; Mary Overton Early Career Fellowship; Multiple
   Myeloma Research Foundation; Australian Postgraduate Award
FX This study was supported by grants awarded by the National Health and
   Medical Research Council of Australia (APP1030528) and Novartis
   International (SF, ACWZ), a Mary Overton Early Career Fellowship (SKM),
   a Multiple Myeloma Research Foundation Research Fellowship (KV) and an
   Australian Postgraduate Award (ZYG).
CR Abroun S, 2004, BLOOD, V103, P2291, DOI 10.1182/blood 2003 07 2187
   Baumann P, 2009, EXP CELL RES, V315, P485, DOI 10.1016/j.yexcr.2008.11.007
   Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365 2141.1998.00930.x
   Chaudhary LR, 2004, BONE, V34, P402, DOI 10.1016/j.bone.2003.11.014
   Dallas SL, 1999, BLOOD, V93, P1697, DOI 10.1182/blood.V93.5.1697.405a17_1697_1706
   Farrugia AN, 2003, CANCER RES, V63, P5438
   Fitter S, 2008, BLOOD, V111, P2538, DOI 10.1182/blood 2007 07 104281
   Fitter S, 2012, J MOL ENDOCRINOL, V48, P229, DOI 10.1530/JME 12 0003
   Fowler JA, 2012, CANCER RES, V72, P2183, DOI 10.1158/0008 5472.CAN 11 2067
   Ge NL, 2000, BLOOD, V96, P2856
   Gharbi SI, 2007, BIOCHEM J, V404, P15, DOI 10.1042/BJ20061489
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Glassford J, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2011.44
   Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007
   Gundle R.S., 1998, MARROW STROMAL CELL, P43
   Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833
   HOCK JM, 1994, ENDOCRINOLOGY, V134, P1423, DOI 10.1210/en.134.3.1423
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Kawamura Naohiro, 2007, Nihon Rinsho, V65 Suppl 9, P67
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257
   Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood 2003 06 1992
   Lee KW, 2010, STEM CELLS DEV, V19, P557, DOI 10.1089/scd.2009.0147
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535 6108(03)00248 4
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535 7163.MCT 08 0017
   Marone R, 2009, MOL CANCER RES, V7, P601, DOI 10.1158/1541 7786.MCR 08 0366
   Martin SK, 2010, J BONE MINER RES, V25, P2126, DOI 10.1002/jbmr.114
   McMillin DW, 2009, CANCER RES, V69, P5835, DOI 10.1158/0008 5472.CAN 08 4285
   Noll JE, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.38
   Noll JE, 2014, HAEMATOLOGICA, V99, P163, DOI 10.3324/haematol.2013.090977
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008 5472.CAN 05 2925
   Ogawa T, 1998, BIOCHEM BIOPH RES CO, V249, P226, DOI 10.1006/bbrc.1998.9118
   Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood 2002 12 3905
   Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923
   Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008 5472.CAN 08 1385
   Smith GC, 2013, FEBS J, V280, P5337, DOI 10.1111/febs.12428
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008 5472.CAN 05 0917
   Uneda S, 2003, BRIT J HAEMATOL, V120, P53, DOI 10.1046/j.1365 2141.2003.04040.x
   Vanderkerken Karin, 2005, V113, P191, DOI 10.1385/1 59259 916 8:191
   Vandyke K, 2010, J BONE MINER RES, V25, P1759, DOI 10.1002/jbmr.85
   Viñals F, 2002, FEBS LETT, V510, P99, DOI 10.1016/S0014 5793(01)03236 7
NR 44
TC 31
Z9 32
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0902 4441
EI 1600 0609
J9 EUR J HAEMATOL
JI Eur. J. Haematol.
PD APR
PY 2015
VL 94
IS 4
BP 343
EP 354
DI 10.1111/ejh.12436
PG 12
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA CE2EW
UT WOS:000351628000010
PM 25179233
DA 2025 08 17
ER

PT J
AU Bragdon, B
   Thinakaran, S
   Moseychuk, O
   Gurski, L
   Bonor, J
   Price, C
   Wang, LY
   Beamer, WG
   Nohe, A
AF Bragdon, Beth
   Thinakaran, Shayamala
   Moseychuk, Oleksandra
   Gurski, Lauren
   Bonor, Jeremy
   Price, Christopher
   Wang, Liyun
   Beamer, Wesley G.
   Nohe, Anja
TI Casein kinase 2 regulates in vivo bone formation through its interaction
   with bone morphogenetic protein receptor type Ia
SO BONE
LA English
DT Article
DE CK2; BMP2; Bone; BMP type Ia receptor; Smad
ID CELL LINE C2C12; TRABECULAR BONE; DIFFERENTIATION; STIMULATION;
   OSTEOBLASTS; EXPRESSION; VITRO; OSTEOCLASTS; PATHWAY; RUNX2
AB Approximately 7.9 million fractures occur annually in the United States with 5 10% of these resulting in delayed or impaired healing. Nearly half of the trauma cost of $56 billion per year is used for the treatment of fractures. More importantly, fracture results in a substantial reduction in the quality of life. New approaches and therapies are needed to enhance fracture healing. Only a limited number of treatments are available including bone grafting, allogeneic and autologous bone marrow transplantation, and bone morphogenetic protein (BMP).
   We previously identified Protein Kinase CK2 to interact with BMP receptor type la (BMPRIa) and as a key protein for signal activation. Peptides approximately 30 AA were developed that mimicked BMP2 action in vitro by blocking this interaction. In this paper we extended our studies to investigate if the most promising peptide could induce in vivo bone formation in mice and to elucidate this mechanism of action. The CK2 blocking peptide activated the Wnt pathway. To identify the optimal peptide concentration and peptide concentration curves for mineralization studies were performed. We designed BMPRIa mutants with a point mutation in the CK2 phosphorylation site to establish a specific effect. Mineralization was initiated with the overexpression of the BMPRIa mutants indicating CK2 is a negative regulatory protein for osteoblast differentiation. Osteoclast differentiation and activity was decreased with the CK2 blocking peptide. Further, subcutaneous calvarial bone injections of a CK2 blocking peptide increased bone area, areal bone mineral density, and bone growth. These results indicate CK2 is crucial for osteoblast differentiation and could be a target for future therapeutics of fracture healing. Published by Elsevier Inc.
C1 [Bragdon, Beth; Thinakaran, Shayamala; Moseychuk, Oleksandra; Gurski, Lauren; Bonor, Jeremy; Nohe, Anja] Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA.
   [Bragdon, Beth] Univ Maine, Dept Mol & Biomed Sci, Orono, ME 04469 USA.
   [Price, Christopher; Wang, Liyun] Univ Delaware, Dept Mech Engn, Newark, DE 19716 USA.
   [Beamer, Wesley G.] Jackson Lab, Bar Harbor, ME 04609 USA.
C3 University of Delaware; University of Maine System; University of Maine
   Orono; University of Delaware; Jackson Laboratory
RP Nohe, A (通讯作者)，Univ Delaware, Dept Biol, Newark, DE 19716 USA.
EM anjanohe@udel.edu
RI Price, Christopher/I 4851 2018
OI Bragdon, Beth/0000 0002 3270 127X
FU NICHD
FX We the authors would like to thank Sue Seta, Jane Maynard, Harold Coumbs
   III, and Cathryn Shultz for their assistance with the calvaria
   injections. Fluorescent imaging and high resolution H&E images were
   collected with the support of the Delaware Biotechnology Institute. The
   monoclonal antibody, N27A1 Armadillo developed by Eric Wieschaus was
   obtained from the Developmental Studies Hybridoma Bank developed under
   the auspices of the NICHD and maintained by The University of Iowa,
   Department of Biology, Iowa City, IA 52242.
CR Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258
   Alam I, 2010, J BONE MINER RES, V25, P1314, DOI 10.1002/jbmr.8
   *AM COLL SURG, 2002, NAT TRAUM DAT BANK R
   American Academy of Orthopaedic Surgeons, 2000, MUSC INJ REP INC RIS
   Bishop GB, 2007, INT ORTHOP, V31, P721, DOI 10.1007/s00264 007 0424 8
   Blackwell KA, 2009, PROSTAG OTH LIPID M, V90, P76, DOI 10.1016/j.prostaglandins.2009.08.005
   Bragdon B, 2010, BIOPHYS J, V99, P897, DOI 10.1016/j.bpj.2010.04.070
   Bragdon B, 2009, BIOPHYS J, V97, P1428, DOI 10.1016/j.bpj.2009.05.061
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Deng FL, 2008, EXP PHYSIOL, V93, P872, DOI 10.1113/expphysiol.2007.041962
   FUNASAKO M, 1996, J BONE MINER METAB, V14, P153
   Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Kaneko H, 2000, BONE, V27, P479, DOI 10.1016/S8756 3282(00)00358 6
   Kasukawa Y, 2003, ENDOCRINOLOGY, V144, P4682, DOI 10.1210/en.2003 0745
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469
   Liu TJ, 2007, J CELL PHYSIOL, V211, P728, DOI 10.1002/jcp.20988
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nöth U, 2003, EXP CELL RES, V291, P201, DOI 10.1016/S0014 4827(03)00386 0
   Pohl F, 2003, RADIAT RES, V159, P345, DOI 10.1667/0033 7587(2003)159[0345:RISOTB]2.0.CO;2
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Rodriguez JES, 2009, J BONE MINER RES, V24, P1917, DOI [10.1359/JBMR.090507, 10.1359/jbmr.090507]
   Sfeir C, 2005, BONE REGENERATION AND REPAIR: BIOLOGY AND CLINICAL APPLICATIONS, P21, DOI 10.1385/1 59259 863 3:021
   Sheng MHC, 2004, BONE, V35, P711, DOI 10.1016/j.bone.2004.05.013
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Veis A, 1997, CRIT REV ORAL BIOL M, V8, P360, DOI 10.1177/10454411970080040101
   Victoria G, 2009, INDIAN J ORTHOP, V43, P117, DOI 10.4103/0019 5413.50844
   Vilk G, 2008, CELL SIGNAL, V20, P1942, DOI 10.1016/j.cellsig.2008.07.002
   Wiren KM, 2008, BONE, V43, P440, DOI 10.1016/j.bone.2008.04.026
   Wutzl A, 2010, J ORTHOP RES, V28, P1431, DOI 10.1002/jor.21144
   Yanagisawa M, 2007, LIFE SCI, V81, P405, DOI 10.1016/j.lfs.2007.06.004
   Zhang M, 2009, J CELL BIOCHEM, V108, P896, DOI 10.1002/jcb.22319
NR 37
TC 31
Z9 35
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD NOV
PY 2011
VL 49
IS 5
BP 944
EP 954
DI 10.1016/j.bone.2011.06.037
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 839YJ
UT WOS:000296405100004
PM 21763800
DA 2025 08 17
ER

PT J
AU Grasemann, C
   Schündeln, MM
   Hövel, M
   Schweiger, B
   Bergmann, C
   Herrmann, R
   Wieczorek, D
   Zabel, B
   Wieland, R
   Hauffa, BP
AF Grasemann, Corinna
   Schuendeln, Michael M.
   Hoevel, Matthias
   Schweiger, Bernd
   Bergmann, Christoph
   Herrmann, Ralf
   Wieczorek, Dagmar
   Zabel, Bernhard
   Wieland, Regina
   Hauffa, Berthold P.
TI Effects of RANK Ligand Antibody (Denosumab) Treatment on Bone Turnover
   Markers in a Girl With Juvenile Paget's Disease
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID IDIOPATHIC HYPERPHOSPHATASIA; OSTEOPROTEGERIN; CALCITONIN; DYSPLASIA;
   PHENOTYPE; GENOTYPE; THERAPY
AB Context: Juvenile Paget's disease (JPD) is an extremely rare, yet painful and debilitating bone disease with onset occurring during early childhood. JPD can be caused by loss of function of osteoprotegerin, resulting in subsequent stimulation of osteoclasts via the receptor activator of nuclear factor kappa B (RANK) pathway. Increased bone turnover and lack of bone modeling lead to severe deformities, frequent fractures, short stature, and loss of hearing.
   Setting: The treatment for JPD is challenging and has previously been based on administration of either calcitonin or bisphosphonates. However, with the development of denosumab, a receptor activator of nuclear factor kappa B ligand (RANKL) antibody, a treatment targeting the pathophysiology of JPD may be available. We report the effects of denosumab treatment on an 8 year old girl with a severe form of JPD.
   Patient: Before starting the denosumab treatment regimen, the patient had been treated for 3.5 years with iv pamidronate.
   Intervention and Outcome: The administration of denosumab resulted in improved disease control compared with bisphosphonate, as assessed by monitoring markers of bone turnover. Alkaline phosphatase levels dropped within the normal range and remained at normal levels for 5 months after the final dose of denosumab. Additionally, bone pain was more efficiently controlled with denosumab. However, concomitant with the first injection, severe hypocalcemia developed, for which the patient was hospitalized and iv calcium supplementation was required for 13 days.
   Conclusions: Denosumab appears to be significantly effective for osteoclast inhibition for the treatment of JPD. However, in our patient, denosumab administration was associated with severe hypocalcemia, indicating that close monitoring of calcium levels is required during treatment.
C1 [Grasemann, Corinna; Herrmann, Ralf; Hauffa, Berthold P.] Univ Klinikum Essen, Kinderklin 2, Dept Pediat Endocrinol & Diabetol, D 45122 Essen, Germany.
   [Grasemann, Corinna; Wieczorek, Dagmar] Univ Klinikum Essen, Essener Ctr Rare Dis, D 45122 Essen, Germany.
   [Schuendeln, Michael M.; Wieland, Regina] Univ Klinikum Essen, Kinderklin 3, Dept Pediat Oncol & Hematol, D 45122 Essen, Germany.
   [Hoevel, Matthias] Univ Klinikum Essen, Dept Orthoped, D 45122 Essen, Germany.
   [Schweiger, Bernd] Univ Klinikum Essen, Dept Radiol & Neuroradiol, D 45122 Essen, Germany.
   [Bergmann, Christoph] Univ Klinikum Essen, Dept Otorhinolaryngol, D 45122 Essen, Germany.
   [Herrmann, Ralf] Univ Klinikum Essen, Kinderklin 1, D 45122 Essen, Germany.
   [Wieczorek, Dagmar] Univ Klinikum Essen, Inst Human Genet, D 45122 Essen, Germany.
   [Wieczorek, Dagmar] Univ Duisburg Essen, D 45122 Essen, Germany.
   [Zabel, Bernhard] Univ Freiburg, Inst Human Genet, D 79106 Freiburg, Germany.
C3 University of Duisburg Essen; University of Duisburg Essen; University
   of Duisburg Essen; University of Duisburg Essen; University of Duisburg
   Essen; University of Duisburg Essen; University of Duisburg Essen;
   University of Duisburg Essen; University of Duisburg Essen; University
   of Freiburg
RP Grasemann, C (通讯作者)，Kinderklin II, Dept Pediat Endocrinol, Hufelandstr 55, D 45122 Essen, Germany.
EM corinna.grasemann@uk essen.de
RI Wieczorek, Dagmar/AAU 6008 2021; Grasemann, Corinna/AAG 3861 2021;
   Schündeln, Michael/W 3455 2018
OI Grasemann, Corinna/0000 0003 1793 4603; Schweiger,
   Bernd/0000 0002 8037 2159; Wieczorek, Dagmar/0000 0003 2812 6492;
   Schundeln, Michael/0000 0001 7495 9060; 
FU IFORES Fellowship, Faculty of Medicine, UK Essen, Essen, Germany
FX This work was supported by IFORES Fellowship, Faculty of Medicine,
   UK Essen, Essen, Germany (to C.G.).
CR Boyce AM, 2012, J BONE MINER RES, V27, P1462, DOI 10.1002/jbmr.1603
   Brunetti G, 2012, ENDOCRINE, V42, P266, DOI 10.1007/s12020 012 9705 0
   Chong B, 2003, J BONE MINER RES, V18, P2095, DOI 10.1359/jbmr.2003.18.12.2095
   Cundy T, 2005, NEW ENGL J MED, V353, P918, DOI 10.1056/NEJMoa050893
   Cundy T, 2004, J BONE MINER RES, V19, P703, DOI 10.1359/JBMR.040127
   Kerr NM, 2010, ARCH OPHTHALMOL CHIC, V128, P698, DOI 10.1001/archophthalmol.2010.76
   Michou L, 2011, DRUG DES DEV THER, V5, P225, DOI 10.2147/DDDT.S11306
   Polyzos SA, 2010, J BONE MINER METAB, V28, P706, DOI 10.1007/s00774 010 0198 8
   Roth AJ, 1996, INT ORTHOP, V20, P58, DOI 10.1007/s002640050029
   Schwarz P, 2012, BONE, V50, P1023, DOI 10.1016/j.bone.2012.01.020
   Semler O, 2012, J MUSCULOSKEL NEURON, V12, P183
   Szulc P, 2001, J CLIN ENDOCR METAB, V86, P3162, DOI 10.1210/jc.86.7.3162
   Tau C, 2004, BONE, V35, P210, DOI 10.1016/j.bone.2004.03.013
   WHALEN JP, 1977, AM J ROENTGENOL, V129, P29, DOI 10.2214/ajr.129.1.29
   Whyte MP, 2002, NEW ENGL J MED, V347, P175, DOI 10.1056/NEJMoa013096
   WOODHOUSE NJ, 1972, BMJ BRIT MED J, V4, P267, DOI 10.1136/bmj.4.5835.267
NR 16
TC 83
Z9 87
U1 0
U2 10
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815 5817 USA
SN 0021 972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD AUG
PY 2013
VL 98
IS 8
BP 3121
EP 3126
DI 10.1210/jc.2013 1143
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 196NC
UT WOS:000322781300026
PM 23788687
OA Bronze
DA 2025 08 17
ER

PT J
AU Walker, RE
   Lawson, MA
   Buckle, CH
   Snowden, JA
   Chantry, AD
AF Walker, Rebecca E.
   Lawson, Michelle A.
   Buckle, Clive H.
   Snowden, John A.
   Chantry, Andrew D.
TI Myeloma bone disease: pathogenesis, current treatments and future
   targets
SO BRITISH MEDICAL BULLETIN
LA English
DT Article
DE myeloma; bone disease; therapeutic targets
ID FACTOR KAPPA B; HEPATOCYTE GROWTH FACTOR; MARROW STROMAL CELLS;
   INFLAMMATORY PROTEIN 1 ALPHA; REFRACTORY MULTIPLE MYELOMA;
   SKELETAL RELATED EVENTS; MESENCHYMAL STEM CELLS; MALIGNANT PLASMA CELLS;
   BREAST CANCER CELLS; ZOLEDRONIC ACID
AB Introduction: Patients with myeloma develop localized and generalized bone loss leading to hypercalcaemia, accelerated osteoporosis, vertebral wedge fractures, other pathological fractures, spinal cord compression and bone pain. Bone loss is mediated by a variety of biological modifiers including osteoclast activating factors (OAF) and osteoblast (OB) inhibitory factors produced either directly by malignant plasma cells (MPCs) or as a consequence of their interaction with the bone marrow microenvironment (BMM). Raised levels of OAFs such as receptor activator of nuclear factor kappa B ligand (RANKL), macrophage inflammatory protein 1 alpha, tumour necrosis factor alpha and interleukin 6 stimulate bone resorption by recruiting additional osteoclasts. Via opposing mechanisms, increases in OB inhibitory factors, such as dickkopf 1 (Dkk 1), soluble frizzled related protein 3 and hepatocyte growth factor (HGF), suppress bone formation by inhibiting the differentiation and recruitment of OBs. These changes result in an uncoupling of physiological bone remodelling, leading to myeloma bone disease (MBD). Moreover, the altered BMM provides a fertile ground for the growth and survival of MPCs. Current clinical management of MBD is both reactive (to pain and fractures) and preventive, with bisphosphonates (BPs) being the mainstay of pharmacological treatment. However, side effects and uncertainties associated with BPs warrant the search for more targeted treatments for MBD. This review will summarize recent developments in understanding the intimate relationship between MBD and the BMM and the novel ways in which they are being therapeutically targeted.
   Sources of data: All data included were sourced and referenced from PubMed.
   Areas of agreement: The clinical utility of BP therapy is well established. However, there is general acknowledgement that BPs are only partially successful in the treatment of MBD. The number of skeletal events attributable to myeloma are reduced by BPs but not totally eliminated. Furthermore, existing damage is not repaired. It is widely recognized that more effective treatments are needed.
   Areas of controversy: There remains controversy concerning the duration of BP therapy. Whether denosumab is a viable alternative to BP therapy is also contested. Many of the new therapeutic strategies discussed are yet to translate to clinical practice and demonstrate equal efficacy or superiority to BP therapy. It also remains controversial whether reported anti tumour effects of bone modulating therapies are clinically significant.
   Growing points: The potential clinical utility of bone anabolic therapies including agents such as anti Dkk 1, anti sclerostin and anti HGF is becoming increasingly recognized.
   Areas timely for developing research: Further research effectively targeting the mediators of MBD, targeting both bone resorption and bone formation, is urgently needed. This should translate promptly to clinical trials of combination therapy comprising anti resorptives and bone anabolic therapies to demonstrate efficacy and improved outcomes over BPs.
C1 [Walker, Rebecca E.; Lawson, Michelle A.; Buckle, Clive H.; Snowden, John A.; Chantry, Andrew D.] Univ Sheffield, Dept Oncol, Sheffield Myeloma Res Team SmaRT, Sheffield, S Yorkshire, England.
   [Walker, Rebecca E.; Lawson, Michelle A.; Buckle, Clive H.; Snowden, John A.; Chantry, Andrew D.] Sheffield Teaching Hosp NHS Fdn Trust, Dept Haematol, Sheffield, S Yorkshire, England.
C3 University of Sheffield; University of Sheffield
RP Chantry, AD (通讯作者)，Univ Sheffield, Dept Oncol, Sheffield Myeloma Res Team SmaRT, Sheffield, S Yorkshire, England.
EM a.d.chantry@sheffield.ac.uk
RI Walker, Rebecca/KIH 3782 2024; Lawson, Michelle/M 6095 2019; Chantry,
   Andrew/B 3065 2009
OI SNOWDEN, JOHN/0000 0001 6819 3476; Lawson, Michelle/0000 0002 5446 923X;
   Chantry, Andrew/0000 0002 2797 7626; 
CR Abdulkadyrov KM, 2014, BRIT J HAEMATOL, V165, P814, DOI 10.1111/bjh.12835
   Abildgaard N, 2000, EUR J HAEMATOL, V64, P121, DOI 10.1034/j.1600 0609.2000.90074.x
   Abruzzese E, 2008, EXPERT OPIN INV DRUG, V17, P1379, DOI [10.1517/13543784.17.9.1379 , 10.1517/13543780802332960]
   Aggarwal R, 2006, EXP HEMATOL, V34, P1289, DOI 10.1016/j.exphem.2006.06.017
   Anderson G, 2006, BLOOD, V107, P3098, DOI 10.1182/blood 2005 08 3450
   [Anonymous], BLOO D
   Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088
   Autio KA, 2013, CANCER AM CANCER SOC, V119, P3186, DOI 10.1002/cncr.28103
   Barri YM, 2004, KIDNEY INT, V65, P634, DOI 10.1111/j.1523 1755.2004.00426.x
   Basic Kes Vanja, 2002, Acta Medica Croatica, V56, P103
   BATAILLE R, 1991, J CLIN INVEST, V88, P62, DOI 10.1172/JCI115305
   BELCH AR, 1991, J CLIN ONCOL, V9, P1397, DOI 10.1200/JCO.1991.9.8.1397
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593
   Bodine PVN, 2005, J CELL BIOCHEM, V96, P1212, DOI 10.1002/jcb.20599
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Boivin G, 2012, J TRACE ELEM MED BIO, V26, P153, DOI 10.1016/j.jtemb.2012.03.013
   Boland E, 2013, J PAIN SYMPTOM MANAG, V46, P671, DOI 10.1016/j.jpainsymman.2012.11.003
   Bolomsky A, 2014, EXP HEMATOL, V42, P516, DOI 10.1016/j.exphem.2014.03.005
   Borset M, 1996, BLOOD, V88, P3998, DOI 10.1182/blood.V88.10.3998.bloodjournal88103998
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Breitkreutz I, 2006, BLOOD, V108, p993A, DOI 10.1182/blood.V108.11.3485.3485
   Brenner H, 2008, BLOOD, V111, P2521, DOI 10.1182/blood 2007 08 104984
   Burger JA, 2013, LEUKEMIA LYMPHOMA, V54, P2385, DOI 10.3109/10428194.2013.777837
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Chantry AD, 2009, J BONE MINER RES, V25, P2633
   Choi SJ, 2001, J CLIN INVEST, V108, P1833, DOI 10.1172/JCI13116
   Choi Sun Jin, 2000, Blood, V96, P671
   Cocks K, 2007, EUR J CANCER, V43, P1670, DOI 10.1016/j.ejca.2007.04.022
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Croucher PI, 1998, BRIT J HAEMATOL, V103, P902, DOI 10.1046/j.1365 2141.1998.01082.x
   D'Souza S, 2011, BLOOD, V118, P6871, DOI 10.1182/blood 2011 04 346775
   Dairaghi DJ, 2012, BLOOD, V120, P1449, DOI 10.1182/blood 2011 10 384784
   Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658
   De Raeve HR, 2005, HISTOL HISTOPATHOL, V20, P1227, DOI 10.14670/HH 20.1227
   De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771
   Derksen PWB, 2003, LEUKEMIA, V17, P764, DOI 10.1038/sj.leu.2402875
   Derycke LDM, 2004, INT J DEV BIOL, V48, P463, DOI 10.1387/ijdb.041793ld
   Dimopoulos MA, 2011, LEUKEMIA, V25, P749, DOI 10.1038/leu.2011.3
   Dimopoulos MA, 2009, J CLIN ONCOL, V27, P6086, DOI 10.1200/JCO.2009.22.2232
   Edwards CM, 2012, BLOOD, V120, P1757, DOI 10.1182/blood 2012 07 439216
   Ehrlich LA, 2005, IMMUNOL REV, V208, P252, DOI 10.1111/j.0105 2896.2005.00323.x
   Eijken M, 2007, FASEB J, V21, P2949, DOI 10.1096/fj.07 8080com
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Forslund T, 2008, CLIN MED INSIGHT CAS, V1, P119
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Fuller K, 2000, BIOCHEM BIOPH RES CO, V268, P2, DOI 10.1006/bbrc.2000.2075
   Gedmintas L, 2013, J BONE MINER RES, V28, P1729, DOI 10.1002/jbmr.1893
   Geiser AG, 1998, BONE, V23, P87, DOI 10.1016/S8756 3282(98)00078 7
   Ghali O, 2010, J BONE MINER RES, V25, P1616, DOI 10.1002/jbmr.52
   Giammarile F, 2013, B CANCER, V100, P1223, DOI 10.1684/bdc.2013.1842
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Giuliani N, 2001, BLOOD, V98, P3527, DOI 10.1182/blood.V98.13.3527
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644
   Greenlee RT, 2000, CA CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7
   Groen RWJ, 2011, HAEMATOL HEMATOL J, V96, P1653, DOI 10.3324/haematol.2010.038133
   Gunn WG, 2006, STEM CELLS, V24, P986, DOI 10.1634/stemcells.2005 0220
   Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302
   Harousseau JL, 2010, BLOOD, V116, P3743, DOI 10.1182/blood 2010 03 275800
   Haÿ E, 2009, MOL CELL BIOL, V29, P953, DOI 10.1128/MCB.00349 08
   Heath DJ, 2007, CANCER RES, V67, P202, DOI 10.1158/0008 5472.CAN 06 1287
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Heider U, 2003, CLIN CANCER RES, V9, P1436
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Houde C, 2004, BLOOD, V104, P3697, DOI 10.1182/blood 2003 12 4114
   Hu B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074191
   Hu K, 2000, ONCOLOGY NY, V14, P101
   Hu K, 2000, ONCOLOGY WILLISTON P, V14, P115
   Hu K, 2000, ONCOLOGY WILLISTON P, V14, P111
   Hurchla MA, 2013, LEUKEMIA, V27, P430, DOI 10.1038/leu.2012.183
   Itasaki N, 2003, DEVELOPMENT, V130, P4295, DOI 10.1242/dev.00674
   Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432 1327.2000.01828.x
   Jagannath S, 2006, HAEMATOL HEMATOL J, V91, P929
   Jakob C, 2009, CLIN LYMPHOMA MYELOM, V9, P430, DOI 10.3816/CLM.2009.n.085
   James IE, 2000, OSTEOARTHR CARTILAGE, V8, P452, DOI 10.1053/joca.1999.0321
   Jundt F, 2004, BLOOD, V103, P3511, DOI 10.1182/blood 2003 07 2254
   Kaiser M, 2008, EUR J HAEMATOL, V80, P490, DOI 10.1111/j.1600 0609.2008.01065.x
   Kariyawasan CC, 2007, QJM INT J MED, V100, P635, DOI 10.1093/qjmed/hcm077
   Katz BZ, 2010, SEMIN CANCER BIOL, V20, P186, DOI 10.1016/j.semcancer.2010.04.003
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Kitisin Krit, 2007, Sci STKE, V2007, pcm1, DOI 10.1126/stke.3992007cm1
   Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378 1119(99)00365 0
   Kunzmann V, 2000, BLOOD, V96, P384
   Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21
   LAHTINEN R, 1992, LANCET, V340, P1049, DOI 10.1016/0140 6736(92)93075 X
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lawson MA, 2008, BIOCHEM BIOPH RES CO, V377, P453, DOI 10.1016/j.bbrc.2008.09.157
   Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood 2003 06 1992
   Li BZ, 2007, STEM CELLS DEV, V16, P921, DOI 10.1089/scd.2007.0074
   Libby E, 2014, LEUK LYMPHOMA
   LOWIK CWGM, 1989, BIOCHEM BIOPH RES CO, V162, P1546, DOI 10.1016/0006 291x(89)90851 6
   Mansukhani A, 2005, J CELL BIOL, V168, P1065, DOI 10.1083/jcb.200409182
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Matsumoto T, 2011, BONE, V48, P129, DOI 10.1016/j.bone.2010.05.036
   McCloskey EV, 1998, BRIT J HAEMATOL, V100, P317
   Menssen HD, 2002, J CLIN ONCOL, V20, P2353, DOI 10.1200/JCO.2002.02.032
   Mohammad KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005275
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Moore WJ, 2010, BIOORGAN MED CHEM, V18, P190, DOI 10.1016/j.bmc.2009.11.002
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Mori Y, 2004, BLOOD, V104, P2149, DOI 10.1182/blood 2004 01 0236
   MUNDY GR, 1974, NEW ENGL J MED, V291, P1041, DOI 10.1056/NEJM197411142912001
   MUNDY GR, 1995, CLIN ORTHOP RELAT R, P34
   Musto P, 2003, LEUKEMIA LYMPHOMA, V44, P1545, DOI 10.3109/10428190309178778
   Musto P, 2008, CANCER AM CANCER SOC, V113, P1588, DOI 10.1002/cncr.23783
   Nakanishi R, 2008, J BONE MINER RES, V23, P271, DOI 10.1359/JBMR.071007
   Neville Webbe HL, 2006, TUMOR BIOL, V27, P92, DOI 10.1159/000092489
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   Noll JE, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.38
   OGAWA Y, 1992, J BIOL CHEM, V267, P14233
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Ottewell PD, 2009, MOL CANCER THER, V8, P2821, DOI 10.1158/1535 7163.MCT 09 0462
   Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood 2002 12 3905
   Palumbo A, 2009, LEUKEMIA, V23, P449, DOI 10.1038/leu.2008.325
   Pennisi A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015233
   Politou MC, 2006, INT J CANCER, V119, P1728, DOI 10.1002/ijc.22033
   Pradhan P, 2012, INDIAN J ORTHOP, V46, P589, DOI 10.4103/0019 5413.101048
   Qiang YW, 2009, BLOOD, V113, P4319, DOI 10.1182/blood 2008 08 174300
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rajkumar SV, 2010, LANCET, V376, P1965, DOI 10.1016/S0140 6736(10)62178 2
   REDDY SV, 1994, J BONE MINER RES, V9, P753
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Roodman GD, 2007, BONE MARROW TRANSPL, V40, P1139, DOI 10.1038/sj.bmt.1705802
   Roodman GD, 2011, BONE, V48, P135, DOI 10.1016/j.bone.2010.06.016
   Rosen LS, 2001, CANCER J, V7, P377
   Roux S, 2004, LEUKEMIA LYMPHOMA, V45, P1111, DOI 10.1080/10428194310001593193
   Sanz Rodríguez F, 1999, BRIT J HAEMATOL, V107, P825, DOI 10.1046/j.1365 2141.1999.01762.x
   Schmaus MC, 2014, RADIOLOGE, V54, P551, DOI 10.1007/s00117 013 2630 2
   Seidel C, 1998, BLOOD, V91, P806, DOI 10.1182/blood.V91.3.806.806_806_812
   Sezer O, 2002, J CLIN ONCOL, V20, P353, DOI 10.1200/JCO.2002.20.1.353
   Shipman CM, 1998, CANCER RES, V58, P5294
   Silbermann R, 2014, LEUKEMIA, V28, P951, DOI 10.1038/leu.2013.385
   Sing CE, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.198302
   Skrtic A, 2010, HUM PATHOL, V41, P1702, DOI 10.1016/j.humpath.2010.05.002
   Snowden JA, 2011, BRIT J HAEMATOL, V154, P76, DOI 10.1111/j.1365 2141.2011.08574.x
   Sonmez M, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756 9966 27 11
   Standal T, 2002, BLOOD, V100, P3002, DOI 10.1182/blood 2002 04 1190
   Standal T, 2007, BLOOD, V109, P3024, DOI 10.1182/blood 2006 07 034884
   Tai YT, 2012, BLOOD, V120, P1877, DOI 10.1182/blood 2011 12 396853
   ten Dijke P, 2008, J BONE JOINT SURG AM, V90A, P31, DOI 10.2106/JBJS.G.01183
   Terpos E, 2003, BRIT J HAEMATOL, V123, P758, DOI 10.1046/j.1365 2141.2003.04712.x
   Terpos E, 2005, LEUKEMIA, V19, P1969, DOI 10.1038/sj.leu.2403890
   Terpos E, 2005, ANN ONCOL, V16, P1223, DOI 10.1093/annonc/mdi235
   Terpos E, 2012, ANN ONCOL, V23, P2681, DOI 10.1093/annonc/mds068
   Terpos E, 2003, BRIT J HAEMATOL, V123, P106, DOI 10.1046/j.1365 2141.2003.04561.x
   Terpos E, 2006, BRIT J HAEMATOL, V135, P688, DOI 10.1111/j.1365 2141.2006.06356.x
   Terpos E, 2012, INT J CANCER, V131, P1466, DOI 10.1002/ijc.27342
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Urashima M, 1996, BLOOD, V88, P2219, DOI 10.1182/blood.V88.6.2219.bloodjournal8862219
   VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0
   Van Camp B., 2007, CURR IMMUNOL REV, V3, P41, DOI 10.2174/157339507779802151
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   Vandyke K, 2013, BRIT J HAEMATOL, V161, P499, DOI 10.1111/bjh.12280
   Vogel CL, 2004, ONCOLOGIST, V9, P687, DOI 10.1634/theoncologist.9 6 687
   Vogt U, 2004, ONCOL REP, V12, P1109
   Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004 1050
   Wergedal JE, 2003, J CLIN ENDOCR METAB, V88, P5778, DOI 10.1210/jc.2003 030201
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 172
TC 55
Z9 57
U1 1
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007 1420
EI 1471 8391
J9 BRIT MED BULL
JI Br. Med. Bull.
PD SEP
PY 2014
VL 111
IS 1
BP 117
EP 138
DI 10.1093/bmb/ldu016
PG 22
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA AQ1YU
UT WOS:000342582000010
PM 25190762
OA Bronze
DA 2025 08 17
ER

PT J
AU Xie, Z
   Liu, GX
   Tang, P
   Sun, XW
   Chen, S
   Qin, A
   Zhu, PZ
   Zhang, JF
   Fan, SW
AF Xie, Zi'ang
   Liu, Guanxiong
   Tang, Pan
   Sun, Xuewu
   Chen, Shuai
   Qin, An
   Zhu, Peizhi
   Zhang, Jianfeng
   Fan, Shunwu
TI Bone targeted methotrexate alendronate conjugate inhibits
   osteoclastogenesis in vitro and prevents bone loss and
   inflammation of collagen induced arthritis in vivo
SO DRUG DELIVERY
LA English
DT Article
DE Rheumatoid arthritis; bone targeting; methotrexate; alendronate;
   therapeutic
ID RHEUMATOID ARTHRITIS; DOSE METHOTREXATE; DRUG DELIVERY; BISPHOSPHONATES;
   MECHANISMS; THERAPY; EROSION; RANKL; MICE
AB Rheumatoid arthritis (RA), a disease that causes joint destruction and bone erosion, is related to osteoclast activity. RA is generally treated with methotrexate (MTX). In this study, a MTX Alendronate (ALN) conjugate was synthesized and characterized. The conjugate dramatically inhibited osteoclast formation and bone resorption compared with MTX and ALN used alone or in combination. Due to the characteristics of ALN, the MTX ALN conjugate can adhere to the exposed bone surface and enhance drug accumulation in the pathological region for targeted therapy against osteoclastogenesis. Additionally, MTX was rapidly released in the presence of lysozyme under mildly acidic conditions, similar to inflammatory tissue and osteoclast surviving conditions, which contributes to inflammatory inhibition; this was confirmed by the presence of pro inflammatory cytokines. Our study highlights the use of the MTX ALN conjugate as a potential therapeutic approach for RA by targeting osteoclastogenesis.
C1 [Xie, Zi'ang; Tang, Pan; Sun, Xuewu; Chen, Shuai; Zhang, Jianfeng; Fan, Shunwu] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Orthopaed, Hangzhou, Zhejiang, Peoples R China.
   [Xie, Zi'ang; Tang, Pan; Sun, Xuewu] Key Lab Biotherapy Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China.
   [Liu, Guanxiong; Zhu, Peizhi] Yangzhou Univ, Sch Chem & Chem Engn, Yangzhou, Jiangsu, Peoples R China.
   [Qin, An] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Orthopaed,Shanghai Key Lab Orthopaed Implant, Shanghai, Peoples R China.
C3 Zhejiang University; Yangzhou University; Shanghai Jiao Tong University
RP Zhu, PZ; Zhang, JF; Fan, SW (通讯作者)，Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Orthopaed, Hangzhou, Zhejiang, Peoples R China.
EM pzz@yzu.edu.cn; dr_zhangjianfeng@163.com; 0099203@zju.edu.cn
RI Qin, An/J 2518 2019; Tang, Pan/AIC 2118 2022
CR Abe Y, 2015, J BONE MINER METAB, V33, P125, DOI 10.1007/s00774 014 0574 x
   Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833
   Asagiri M, 2008, SCIENCE, V319, P624, DOI 10.1126/science.1150110
   Chan AJ, 2014, J ONCOL PHARM PRACT, V20, P93, DOI 10.1177/1078155213482602
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Cronstein BN, 2005, PHARMACOL REV, V57, P163, DOI 10.1124/pr.57.2.3
   Fazil M, 2015, DRUG DELIV, V22, P1, DOI 10.3109/10717544.2013.870259
   Feldmann M, 2008, IMMUNOL REV, V223, P7, DOI 10.1111/j.1600 065X.2008.00626.x
   Finckh A, 2006, ARTHRITIS RHEUM US, V54, P54, DOI 10.1002/art.21491
   Goldring SR, 2000, CURR OPIN RHEUMATOL, V12, P195, DOI 10.1097/00002281 200005000 00006
   Gu Y, 2014, MEDIAT INFLAMM, V2014, P1
   Heymann D, 2004, TRENDS MOL MED, V10, P337, DOI 10.1016/j.molmed.2004.05.007
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Karacivi M, 2017, MOL PHARMACEUT, V14, P1373, DOI 10.1021/acs.molpharmaceut.6b01173
   Khan ZA, 2012, EXPERT OPIN DRUG DEL, V9, P151, DOI 10.1517/17425247.2012.642362
   Kim GW, 2015, ARCH PHARM RES, V38, P575, DOI 10.1007/s12272 015 0569 8
   Le Goff B, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2877
   Lee H, 2017, BIOCONJUGATE CHEM, V28, P1084, DOI 10.1021/acs.bioconjchem.7b00008
   Li S, 2014, ARTHRITIS RHEUMATOL, V66, P1854, DOI 10.1002/art.38521
   Mount C, 2005, NAT REV DRUG DISCOV, V4, P11, DOI 10.1038/nrd1611
   Navarro VJ, 2006, NEW ENGL J MED, V354, P731, DOI 10.1056/NEJMra052270
   Nishikawa M, 2003, ARTHRITIS RHEUM US, V48, P2670, DOI 10.1002/art.11227
   Okamoto K, 2011, INT IMMUNOPHARMACOL, V11, P543, DOI 10.1016/j.intimp.2010.11.010
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2166
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Shin JM, 2014, CHEM COMMUN, V50, P7632, DOI 10.1039/c4cc02595d
   Song HP, 2015, EXP THER MED, V10, P1483, DOI 10.3892/etm.2015.2667
   Stolina M, 2005, J BONE MINER RES, V20, P1756, DOI 10.1359/JBMR.050601
   Strand V, 1999, ARCH INTERN MED, V159, P2542, DOI 10.1001/archinte.159.21.2542
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Wang Y, 2011, MOL PHARMACEUT, V8, P1016, DOI 10.1021/mp100374n
   Yang MD, 2017, THERANOSTICS, V7, P97, DOI 10.7150/thno.16844
NR 34
TC 19
Z9 19
U1 1
U2 49
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1071 7544
EI 1521 0464
J9 DRUG DELIV
JI Drug Deliv.
PD JAN 5
PY 2018
VL 25
IS 1
BP 187
EP 197
DI 10.1080/10717544.2017.1422295
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FY5XO
UT WOS:000426911800001
PM 29303005
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Wang, FS
   Ko, JY
   Lin, CL
   Wu, HL
   Ke, HJ
   Tai, PJ
AF Wang, Feng Sheng
   Ko, Jih Yang
   Lin, Chun Liang
   Wu, Hsing Long
   Ke, Huei Jin
   Tai, Pei Ju
TI Knocking down dickkopf 1 alleviates estrogen deficiency induction of
   bone loss. A histomorphological study in ovariectomized rats
SO BONE
LA English
DT Article
DE dickkopf 1; antisense; oligonucleotide; bone mass; RANKL
ID FRIZZLED RELATED PROTEIN 1; WNT SIGNALING PATHWAY; BETA CATENIN;
   OSTEOCLAST DIFFERENTIATION; NEGATIVE REGULATOR; LITHIUM CHLORIDE;
   GENE THERAPY; OSTEOPROTEGERIN; CELLS; MASS
AB Dickkopf 1 (DKK1) has been found to act as a potent Writ signaling inhibitory factor for regulating skeletal disorders. We investigated whether modulation of DKK1 expression by end capped phosphorothioate DKK1 antisense oligonucleotide could alter estrogen loss induced bone loss. Ovariectomized or sham operated rats were given 20 mu g/kg/day DKK1 sense or antisense oligonucleotide or vehicle for 28 days. Femurs and tibiae were dissected to assess bone mass, biomechanical strength, immunohistochemistry and ex vivo osteoclast formation. We found that DKK1 antisense oligonucleotide significantly abrogated the suppressing effect of ovariectomy on weight, mineral content, mineral density and peak load of femurs. DKK1 antisense oligonucleotide treatment reduced ovariectomy promotion of ex vivo osteoclast differentiation of primary M CSF dependent bone marrow macrophages. Histomorphometric observation demonstrated that DKK1 antisense oligonucleotide treatment increased osteoblast number and impaired ovariectomy promoted trabecular bone loss and osteoclast number in bone tissue. Ostcoblastic cells adjacent to endosteum of trabecular bone and chondrocytes at calcified cartilage expressed intensive DKK1 and RANKL and weak OPG immunostaining in ovariectomized rat bone microenvironments. Osteogenic cells and chondral cells displayed weak DKK1, RANKL and OPG expression of bone tissue after DKK1 antisense oligonucleotide treatment. Taken together, attenuation of DKK1 expression in ovariectomized rat bone tissue alleviated loss of bone mass and biomechanical property. The regulatory action of DKK1 antisense oligonucleotide treatment on bone tissue appeared to suppress the promoting effect of estrogen deficiency on osteoclastogenesis stimulatory factor RANKL expression and osteoclast differentiation. Control of DKK1 signaling can be used in the future as an alternative strategy for protecting estrogen deficiency induction of bone loss. (c) 2006 Elsevier Inc. All rights reserved.
C1 Chang Gung Univ, Coll Med, Grad Inst Clin Med Sci, Chang Gung Mem Hosp,Kaohsiung Med Ctr,Dept Orthop, Kaohsiung, Taiwan.
   Chang Gung Univ, Coll Med, Grad Inst Clin Med Sci, Chang Gung Mem Hosp,Kaohsiung Med Ctr,Dept Med Re, Kaohsiung, Taiwan.
   Chayi Chang Gung Mem Hosp, Dept Nephrol, Chayi, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University; Chang Gung
   University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital
RP Ko, JY (通讯作者)，Chang Gung Univ, Coll Med, Grad Inst Clin Med Sci, Chang Gung Mem Hosp,Kaohsiung Med Ctr,Dept Orthop, Kaohsiung, Taiwan.
EM wangfs@ms33.hinet.net; kojy@adm.cgmh.org.tw
RI Lin, Chun Liang/G 8886 2012
CR Adamska M, 2004, DEV BIOL, V272, P134, DOI 10.1016/j.ydbio.2004.04.026
   Ai M, 2005, MOL CELL BIOL, V25, P4946, DOI 10.1128/MCB.25.12.4946 4955.2005
   Baltzer AWA, 2001, GENE THER, V8, P1770, DOI 10.1038/sj.gt.3301594
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cappuccio I, 2005, J NEUROSCI, V25, P2647, DOI 10.1523/JNEUROSCI.5230 04.2005
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gregory CA, 2005, J BIOL CHEM, V280, P2309, DOI 10.1074/jbc.M406275200
   Hall CL, 2006, J CELL BIOCHEM, V97, P661, DOI 10.1002/jcb.20735
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   Häusler KD, 2004, J BONE MINER RES, V19, P1873, DOI 10.1359/JBMR.040807
   Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008 5472.CAN 03 1952
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hukkanen M, 2003, BONE, V32, P142, DOI 10.1016/S8756 3282(02)00955 9
   Ikeda T, 2001, J BONE MINER RES, V16, P1416, DOI 10.1359/jbmr.2001.16.8.1416
   Jilka RL, 1998, J CLIN INVEST, V101, P1942, DOI 10.1172/JCI1039
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kostenuik PJ, 2004, BONE, V34, P656, DOI 10.1016/j.bone.2003.12.006
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Liu BN, 2003, BIOTECHNOL LETT, V25, P2117, DOI 10.1023/B:BILE.0000007079.13308.2f
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534 5807(01)00041 7
   Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Rawadi G, 2005, EXPERT OPIN THER TAR, V9, P1063, DOI 10.1517/14728222.9.5.1063
   Shin CS, 2005, J BONE MINER RES, V20, P2200, DOI 10.1359/JBMR.050809
   Silvestrini G, 2005, J MOL HISTOL, V36, P59, DOI 10.1007/s10735 004 3839 1
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   TUAN E, 2003, NEW ENGL J MED, V349, P2483
   van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614
   Wang FS, 2004, ENDOCRINOLOGY, V145, P2148, DOI 10.1210/en.2003 1074
   Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200
NR 40
TC 85
Z9 115
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2007
VL 40
IS 2
BP 485
EP 492
DI 10.1016/j.bone.2006.09.004
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 129ZD
UT WOS:000243767700027
PM 17055793
DA 2025 08 17
ER

PT J
AU Schem, C
   Tower, RJ
   Kneissl, P
   Rambow, AC
   Campbell, GM
   Desel, C
   Damm, T
   Heilmann, T
   Fuchs, S
   Zuhayra, M
   Trauzold, A
   Glüer, CC
   Schott, S
   Tiwari, S
AF Schem, Christian
   Tower, Robert J.
   Kneissl, Philipp
   Rambow, Anna Christina
   Campbell, Graeme M.
   Desel, Christine
   Damm, Timo
   Heilmann, Thorsten
   Fuchs, Sabine
   Zuhayra, Maaz
   Trauzold, Anna
   Glueer, Claus C.
   Schott, Sarah
   Tiwari, Sanjay
TI Pharmacologically Inactive Bisphosphonates as an Alternative Strategy
   for Targeting Osteoclasts: In Vivo Assessment of
   5 Fluorodeoxyuridine Alendronate in a Preclinical Model of Breast Cancer
   Bone Metastases
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BISPHOSPHONATES; ANTIRESORPTIVES; 5 FDU ALE; BONE DISEASES
ID MESENCHYMAL STEM CELLS; NF KAPPA B; ZOLEDRONIC ACID; INHIBITION; MARROW;
   ALENDRONATE; DIFFERENTIATION; OSTEOBLAST; TURNOVER; RISEDRONATE
AB Bisphosphonates have effects that are antiresorptive, antitumor, and antiapoptotic to osteoblasts and osteocytes, but an effective means of eliciting these multiple activities in the treatment of bone metastases has not been identified. Antimetabolitebisphosphonate conjugates have potential for improved performance as a class of bone specific antineoplastic drugs. The primary objective of the study was to determine whether an anti metabolite bisphosphonate conjugate will preserve bone formation concomitant with antiresorptive and antitumor activity. 5 FdU ale, a highly stable conjugate between the antimetabolite 5 fluoro 2' deoxyuridine and the bisphosphonate alendronate, was tested for its therapeutic efficacy in a mouse model of MDA MB231 breast cancer bone metastases. In vitro testing revealed osteoclasts to be highly sensitive to 5 FdU ale. In contrast, osteoblasts had significantly reduced sensitivity. Tumor cells were resistant in vitro but in vivo tumor burden was nevertheless significantly reduced compared with untreated mice. Sensitivity to 5 FdU ale was not mediated through inhibition of farnesyl diphosphate synthase activity, but cell cycle arrest was observed. Although serum tartrate resistant acid phosphatase (TRAP) levels were greatly reduced by both drugs, there was no significant decrease in the serum bone formation marker osteocalcin with 5 FdU ale treatment. In contrast, there was more than a fivefold decrease in serum osteocalcin levels with alendronate treatment (p < 0.001). This finding is supported by time lapse micro computed tomography analyses, which revealed bone formation volume to be on average 1.6 fold higher with 5 FdU ale treatment compared with alendronate (p < 0.001). We conclude that 5 FdU ale, which is a poor prenylation inhibitor but maintains potent antiresorptive activity, does not reduce bone formation and has cytostatic antitumor efficacy. These results document that conjugation of an antimetabolite with bisphosphonates offers flexibility in creating potent bone targeting drugs with cytostatic, bone protection properties that show limited nephrotoxicity. This unique class of drugs may offer distinct advantages in the setting of targeted adjuvant therapy and chemoprevention of bone diseases. (C) 2016 American Society for Bone and Mineral Research.
C1 [Schem, Christian; Kneissl, Philipp; Rambow, Anna Christina; Heilmann, Thorsten] Univ Hosp Schleswig Holstein, Dept Gynaecol, Campus Kiel, Kiel, Germany.
   [Tower, Robert J.; Campbell, Graeme M.; Desel, Christine; Damm, Timo; Glueer, Claus C.; Tiwari, Sanjay] Univ Hosp Schleswig Holstein, MOIN CC, Dept Radiol & Neuroradiol, Sect Biomed Imaging, Campus Kiel, Kiel, Germany.
   [Campbell, Graeme M.] Tech Univ Hamburg, Inst Biomech, Hamburg, Germany.
   [Heilmann, Thorsten; Trauzold, Anna] Univ Hosp Schleswig Holstein, Inst Expt Canc Res, Div Mol Oncol, Campus Kiel, Kiel, Germany.
   [Fuchs, Sabine] Univ Hosp Schleswig Holstein, Dept Trauma Surg, Sect Expt Trauma Surg, Campus Kiel, Kiel, Germany.
   [Zuhayra, Maaz] Univ Hosp Schleswig Holstein, Dept Nucl Med, Sect Radiopharmaceut Chem, Campus Kiel, Kiel, Germany.
   [Schott, Sarah] Univ Heidelberg Hosp, Dept Obstet & Gynecol, Heidelberg, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Kiel; Schleswig Holstein University Hospital; Hamburg University of
   Technology; University of Kiel; Schleswig Holstein University Hospital;
   University of Kiel; Schleswig Holstein University Hospital; University
   of Kiel; Schleswig Holstein University Hospital; Ruprecht Karls
   University Heidelberg
RP Tiwari, S (通讯作者)，Univ Hosp Schleswig Holstein, Dept Radiol & Neuroradiol, Campus Kiel, D 24118 Kiel, Germany.
EM stiwari@email.uni kiel.de
RI Glüer, Claus Christian/C 9752 2010; Damm, Timo/HGA 8541 2022; Trauzold,
   Anna/P 4398 2014; Zuhayra, Maaz/A 8475 2010; Schott, Sarah/D 5242 2018;
   Tiwari, Sanjay/Q 1853 2016; Campbell, Graeme/JPX 2238 2023
OI Tower, Robert/0000 0001 5856 5758; Trauzold, Anna/0000 0003 4697 556X;
   Schott, Sarah/0000 0002 1714 1147; Tiwari, Sanjay/0000 0002 3804 3300; 
FU Deutsche Forschungsgemeinschaft (DFG) through the Forschergruppe [1586
   SKELMET]; state of Schleswig Holstein; European Union ERDF European
   Regional Development Fund (MOIN CC, Zukunftsprogramm Wirtschaft);
   medical faculty UK SH, Campus Kiel (ST) [F355922]
FX Financial support was provided by the Deutsche Forschungsgemeinschaft
   (DFG) through the Forschergruppe 1586 SKELMET and by the research grant
   from the state of Schleswig Holstein and the European Union
   ERDF European Regional Development Fund (MOIN CC, Zukunftsprogramm
   Wirtschaft) and by the medical faculty UK SH, Campus Kiel (ST, F355922).
CR Allen MR, 2006, BONE, V39, P872, DOI 10.1016/j.bone.2006.04.028
   ARMSTRONG RD, 1983, CANCER RES, V43, P2525
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Bogazzi F, 2011, J ENDOCRINOL INVEST, V34, pE200, DOI 10.3275/7228
   Buie HR, 2007, BONE, V41, P505, DOI 10.1016/j.bone.2007.07.007
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Campbell GM, 2014, CALCIFIED TISSUE INT, V94, P282, DOI 10.1007/s00223 013 9809 4
   Clezardin Philippe, 2013, Bonekey Rep, V2, P267, DOI 10.1038/bonekey.2013.1
   Clézardin P, 2012, ANTI CANCER AGENT ME, V12, P102, DOI 10.2174/187152012799014977
   Coffelt SB, 2009, BBA REV CANCER, V1796, P11, DOI 10.1016/j.bbcan.2009.02.004
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Coscia M, 2010, J CELL MOL MED, V14, P2803, DOI 10.1111/j.1582 4934.2009.00926.x
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   D'Hondt L, 2002, J HEMATOTH STEM CELL, V11, P483, DOI 10.1089/15258160260090942
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Ebert R, 2009, BONE, V44, P858, DOI 10.1016/j.bone.2009.01.009
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Fournier PG, 2010, NEOPLASIA, V12, P571, DOI 10.1593/neo.10282
   Fournier PGJ, 2008, CANCER RES, V68, P8945, DOI 10.1158/0008 5472.CAN 08 2195
   Fu LJ, 2008, BONE, V43, P40, DOI 10.1016/j.bone.2008.03.008
   Guenther A, 2010, INT J CANCER, V126, P239, DOI 10.1002/ijc.24758
   ISHIWATA K, 1985, EUR J NUCL MED, V10, P39
   Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799
   KAUFMANN SH, 1993, CANCER RES, V53, P3976
   Kolbe M, 2011, TISSUE ENG PT A, V17, P2199, DOI [10.1089/ten.TEA.2010.0474, 10.1089/ten.tea.2010.0474]
   Korcok J, 2005, J BIOL CHEM, V280, P16909, DOI 10.1074/jbc.M410764200
   Krawetz R, 2009, EXP CELL RES, V315, P2333, DOI 10.1016/j.yexcr.2009.04.026
   Lane NE, 2003, J BONE MINER RES, V18, P2105, DOI 10.1359/jbmr.2003.18.12.2105
   Lühe A, 2008, TOXICOL IN VITRO, V22, P899, DOI 10.1016/j.tiv.2008.01.006
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Mathov I, 2001, J BONE MINER RES, V16, P2050, DOI 10.1359/jbmr.2001.16.11.2050
   McLaren J, 1996, J CLIN INVEST, V98, P482, DOI 10.1172/JCI118815
   Melani C, 2007, CANCER RES, V67, P11438, DOI 10.1158/0008 5472.CAN 07 1882
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Pennisi A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015233
   Pierroz DD, 2010, J BIOL CHEM, V285, P28164, DOI 10.1074/jbc.M110.101964
   Plotkin LI, 2011, BONE, V49, P122, DOI 10.1016/j.bone.2010.08.011
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Reinholz MM, 2010, BONE, V47, P12, DOI 10.1016/j.bone.2010.03.006
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Saidak Z, 2014, J ENDOCRINOL, V223, P25, DOI 10.1530/JOE 14 0249
   Sánchez Martín L, 2011, BLOOD, V117, P88, DOI 10.1182/blood 2009 12 258186
   Schott H, 2011, BIOORGAN MED CHEM, V19, P3520, DOI 10.1016/j.bmc.2011.04.015
   Schott S, 2015, INVEST NEW DRUG, V33, P816, DOI 10.1007/s10637 015 0253 3
   Shi Y, 2014, EUR CELLS MATER, V27, P64, DOI 10.22203/eCM.v027a06
   Song DW, 2015, BONE, V78, P46, DOI 10.1016/j.bone.2015.04.047
   Stearns ME, 1996, INVAS METAST, V16, P116
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Verhulst A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121861
   Wang Z, 2006, STEM CELLS, V24, P1573, DOI 10.1634/stemcells.2005 0399
   Wetterwald A, 2002, AM J PATHOL, V160, P1143, DOI 10.1016/S0002 9440(10)64934 6
   Yaccoby S, 2006, HAEMATOL HEMATOL J, V91, P192
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
NR 58
TC 8
Z9 9
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2017
VL 32
IS 3
BP 536
EP 548
DI 10.1002/jbmr.3012
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EQ4NY
UT WOS:000398055900013
PM 27714838
OA hybrid
DA 2025 08 17
ER

PT J
AU Zhao, XL
   Chen, JJ
   Zhang, GN
   Wang, YC
   Si, SY
   Chen, LF
   Wang, Z
AF Zhao, Xiao li
   Chen, Jin jing
   Zhang, Guo ning
   Wang, Yu Ccheng
   Si, Shu yi
   Chen, Lin Feng
   Wang, Zhen
TI Small molecule T63 suppresses osteoporosis by modulating osteoblast
   differentiation via BMP and WNT signaling pathways
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 2; MESENCHYMAL STEM CELLS; PROMOTES
   OSTEOGENESIS; COMBINED OVARIECTOMY; SKELETAL DEVELOPMENT;
   GENE EXPRESSION; RUNX2; DEXAMETHASONE; UPREGULATORS; ACTIVATION
AB Osteoporosis results from the imbalance between bone resorption and bone formation, and restoring the normal balance of bone remodeling is highly desirable for identification of better treatment. In this study, using a cell based high throughput screening model representing Runt related transcription factor 2 (RUNX2) transcriptional activity, we identified a novel small molecular weight compound, T63, as an efficient up regulator of osteogenesis. T63 increased the alkaline phosphatase (ALPL) activity and mineralization as well as gene expression of Alpl and other osteogenic marker genes in mouse osteoblasts and mesenchymal stem cell like cells. Upon induction of osteoblast differentiation, T63 inhibited adipogenic differentiation in the pluripotent mesenchymal cells. Consistently, T63 up regulated RUNX2 mRNA and protein levels, and knockdown of RUNX2 reduced the osteogenic role of T63. Mechanistically, T63 activated both BMPs and WNT/beta catenin signaling pathways. Inhibition of either signaling pathway with specific inhibitor suppressed T63 induced RUNX2 expression and the osteogenic phenotypes. Moreover, T63 markedly protected against bone mass loss in the ovariectomized and dexamethasone treated rat osteoporosis model. Collectively, our data demonstrate that T63 could be a promising drug candidate and deserves further development for potential therapeutics in osteoporosis.
C1 [Zhao, Xiao li; Zhang, Guo ning; Wang, Yu Ccheng; Si, Shu yi; Wang, Zhen] Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100050, Peoples R China.
   [Zhao, Xiao li; Zhang, Guo ning; Wang, Yu Ccheng; Si, Shu yi; Wang, Zhen] Peking Union Med Coll, Beijing 100050, Peoples R China.
   [Chen, Jin jing; Chen, Lin Feng] Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Institute of Medicinal Biotechnology   CAMS; Chinese Academy of Medical
   Sciences   Peking Union Medical College; Peking Union Medical College;
   University of Illinois System; University of Illinois Urbana Champaign
RP Wang, Z (通讯作者)，Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100050, Peoples R China.; Wang, Z (通讯作者)，Peking Union Med Coll, Beijing 100050, Peoples R China.; Chen, LF (通讯作者)，Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA.
EM lfchen@life.illinois.edu; wangzhen@imb.pumc.edu.cn
RI zhang, guoning/J 9185 2012; Zhang, Guoning/J 9185 2012; Wang,
   Zhen/HKF 3829 2023
OI Zhang, Guoning/0000 0003 1736 6749; Zhao, Xiaoli/0000 0002 2838 7687;
   Wang, Zhen/0000 0002 6377 3890; 
FU National Science Foundation of China [81328024, 81321004, 81572752,
   81373438]; Fundamental Research Funds for Governmental Universities
   [2016ZX350048]; CAMS Innovation Fund for Medical Sciences (CIFMS)
   [2016 I2M 2 002]
FX We thank Dr. Patricia Ducy (Department of Pathology, College of
   Physicians and Surgeons, Columbia University) for providing the plasmid
   of p6OSE2 luc. We also thank Prof. Weiguo Zou (Institute of Biochemistry
   and Cell Biology, Shanghai, CAS) for technical assistance. This work is
   supported by grants from the National Science Foundation of China (Nos
   81328024, 81321004, 81572752, and 81373438), Fundamental Research Funds
   for Governmental Universities (2016ZX350048) and CAMS Innovation Fund
   for Medical Sciences (CIFMS, No. 2016 I2M 2 002).
CR Almalki SG, 2016, DIFFERENTIATION, V92, P41, DOI 10.1016/j.diff.2016.02.005
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Brusgard JL., 2014, Nuclear Signaling Pathways and Targeting Transcription in Cancer, P57, DOI [10.1007/978 1 4614 8039 6_3, DOI 10.1007/978 1 4614 8039 6_3]
   Byun MR, 2014, J BIOL CHEM, V289, P9926, DOI 10.1074/jbc.M113.522870
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Chen JJ, 2013, FOOD CHEM TOXICOL, V62, P499, DOI 10.1016/j.fct.2013.09.019
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gong SQ, 2016, J BIOMOL SCREEN, V21, P738, DOI 10.1177/1087057116654657
   Govindarajan P, 2013, INT J EXP PATHOL, V94, P387, DOI 10.1111/iep.12038
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Lóotoing L, 2014, MOL NUTR FOOD RES, V58, P1239, DOI 10.1002/mnfr.201300836
   Li X, 2009, J BIOMOL SCREEN, V14, P1251, DOI 10.1177/1087057109346446
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Osorio Joana, 2015, Nat Rev Endocrinol, V11, P192, DOI 10.1038/nrendo.2015.11
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Petrik D, 2012, FASEB J, V26, P3148, DOI 10.1096/fj.11 201426
   Ren H, 2016, MENOPAUSE, V23, P441, DOI 10.1097/GME.0000000000000547
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Schilling T, 2014, J STEROID BIOCHEM, V139, P252, DOI 10.1016/j.jsbmb.2012.12.006
   Sha MQ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.383
   Shockley KR, 2009, J CELL BIOCHEM, V106, P232, DOI 10.1002/jcb.21994
   Thirunavukkarasu K, 2000, J BIOL CHEM, V275, P25163, DOI 10.1074/jbc.M000322200
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Wang XY, 2011, J BONE MINER RES, V26, P1964, DOI 10.1002/jbmr.394
   Weng JJ, 2013, BBA GEN SUBJECTS, V1830, P2839, DOI 10.1016/j.bbagen.2012.12.021
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Yu B, 2016, TRENDS MOL MED, V22, P641, DOI 10.1016/j.molmed.2016.06.002
   Yun SI, 2009, J BONE MINER METAB, V27, P140, DOI 10.1007/s00774 008 0019 5
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zhang LM, 2010, J PINEAL RES, V49, P364, DOI 10.1111/j.1600 079X.2010.00803.x
   Zhang L, 2011, DIFFERENTIATION, V81, P233, DOI 10.1016/j.diff.2011.02.005
   Zhang M, 2009, J CELL BIOCHEM, V108, P896, DOI 10.1002/jcb.22319
   Zhang X, 2006, CALCIFIED TISSUE INT, V79, P169, DOI 10.1007/s00223 006 0083 6
NR 44
TC 18
Z9 22
U1 0
U2 27
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD SEP 4
PY 2017
VL 7
AR 10397
DI 10.1038/s41598 017 10929 3
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FF5EC
UT WOS:000408997700096
PM 28871136
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sato, D
   Takahata, M
   Ota, M
   Fukuda, C
   Tsuda, E
   Shimizu, T
   Okada, A
   Hiruma, Y
   Hamano, H
   Hiratsuka, S
   Fujita, R
   Amizuka, N
   Hasegawa, T
   Iwasaki, N
AF Sato, Dai
   Takahata, Masahiko
   Ota, Masahiro
   Fukuda, Chie
   Tsuda, Eisuke
   Shimizu, Tomohiro
   Okada, Akiko
   Hiruma, Yoshiharu
   Hamano, Hiroki
   Hiratsuka, Shigeto
   Fujita, Ryo
   Amizuka, Norio
   Hasegawa, Tomoka
   Iwasaki, Norimasa
TI Siglec 15 targeting therapy increases bone mass in rats without
   impairing skeletal growth
SO BONE
LA English
DT Article
DE Siglec 15; Anti Siglec 15 Ab; Juvenile osteoporosis; Osteoclasts; Growth
   plate
ID ACUTE LYMPHOBLASTIC LEUKEMIA; OSTEOGENESIS IMPERFECTA; OSTEOCLAST
   DIFFERENTIATION; PEDIATRIC PATIENTS; GROWING RATS; OSTEOPOROSIS;
   ALENDRONATE; SIGLEC 15; CHILDREN; BISPHOSPHONATES
AB The treatment of juvenile osteoporosis has not been established due to a lack of data regarding the efficacy and adverse effects of therapeutic agents. The possible adverse effects of the long term use of antiresorptive therapies on skeletal growth in children is of particular concern. Sialic acid binding immunoglobulin like lectin 15 (Siglec15) is an immunoreceptor that regulates osteoclast development and bone resorption, and its deficiency suppresses bone remodeling in the secondary spongiosa, but not in the primary spongiosa, due to a compensatory mechanism of osteoclastogenesis. This prompted us to develop an anti Siglec 15 therapy for juvenile osteoporosis because most anti resorptive drugs have potential adverse effects on skeletal growth. Using growing rats, we investigated the effects of an anti Siglec 15 neutralizing antibody (Ab) on systemic bone metabolism and skeletal growth, comparing this drug to bisphosphonate, a first line treatment for osteoporosis. Male 6 week old F344/Jcl rats were randomized into six groups: control (PBS twice per week), anti Siglec 15 Ab (0.25, 1, or 4 mg/kg every 3 weeks), and alendronate (ALN) (0.028 or 0.14 mg/kg twice per week). Treatment commenced at 6 weeks of age and continued for the next 6 weeks, Changes in bone mass, bone metabolism, bone strength, and skeletal growth during treatment were analyzed. Both anti Siglec 15 therapy and ALN increased bone mass and the mechanical strength of both the femora and lumbar spines in a dose dependent manner. Anti Siglec 15 therapy did not have a significant effect on skeletal growth as evidenced by micro CT based measurements of femoral length and histology, whereas high dose ALN resulted in growth retardation with histological abnormalities in the growth plates of femurs. This unique property of the anti Siglec 15 Ab can probably be attributed to compensatory signaling for Siglec 15 inhibition in the primary spongiosa, but not in the secondary spongiosa. Thus, anti Siglec 15 therapy could be a safe and effective for juvenile osteoporosis.
C1 [Sato, Dai; Takahata, Masahiko; Ota, Masahiro; Shimizu, Tomohiro; Hamano, Hiroki; Hiratsuka, Shigeto; Fujita, Ryo; Iwasaki, Norimasa] Hokkaido Univ, Grad Sch Med, Fac Med, Dept Orthopaed Surg, Sapporo, Hokkaido 0608638, Japan.
   [Fukuda, Chie; Tsuda, Eisuke; Okada, Akiko] Daiichi Sankyo Co Ltd, Rare Dis Labs, Tokyo, Japan.
   [Hiruma, Yoshiharu] Daiichi Sankyo Co Ltd, Pharmacovigilance Dept, Tokyo, Japan.
   [Amizuka, Norio; Hasegawa, Tomoka] Hokkaido Univ, Dept Dev Biol Hard Tissue, Grad Sch Dent Med, Sapporo, Hokkaido, Japan.
C3 Hokkaido University; Daiichi Sankyo Company Limited; Daiichi Sankyo
   Company Limited; Hokkaido University
RP Takahata, M (通讯作者)，Hokkaido Univ, Dept Orthoped Surg, Grad Sch Med, Kita Ku, Kita 15 Nishi 7, Sapporo, Hokkaido 0608638, Japan.
EM takamasa@med.hokudai.ac.jp
RI Takahata, Masahiko/E 1929 2012; SATO, DAI/GWC 8640 2022; Amizuka,
   Norio/G 1397 2012
OI SATO, DAI/0000 0003 1479 3892
FU Daiichi Sankyo Company, Limited
FX This work was supported by a grant from research funding from Daiichi
   Sankyo Company, Limited. Author's roles: Study design: MT, MO, CF, and
   NI. Study conduct: DS, MO, TS, HH, HS, TH, and RF. Data interpretation:
   MT, DS, MO, CF, ET, AO, TS, TH, and NA. Drafting manuscript: MT and DS.
   MT takes responsibility for the integrity of the data analysis.
CR Azuma Y, 1998, J PHARMACOL EXP THER, V286, P128
   Bachrach LK, 2009, J CLIN ENDOCR METAB, V94, P400, DOI 10.1210/jc.2008 1531
   Bianchi ML, 2007, BONE, V41, P486, DOI 10.1016/j.bone.2007.07.008
   Bianchi ML, 2002, CALCIFIED TISSUE INT, V70, P384, DOI 10.1007/s00223 001 0043 0
   Canalis E., 2007, OSTEOPOROS INT, V18
   Compston J, 2010, NAT REV RHEUMATOL, V6, P82, DOI 10.1038/nrrheum.2009.259
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Evans KD, 2003, BONE, V32, P268, DOI 10.1016/S8756 3282(02)00974 2
   Glorieux FH, 1998, NEW ENGL J MED, V339, P947, DOI 10.1056/NEJM199810013391402
   Halton J, 2009, J BONE MINER RES, V24, P1326, DOI [10.1359/JBMR.090202, 10.1359/jbmr.090202]
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Heino TJ, 2008, BONE, V42, P702, DOI 10.1016/j.bone.2008.01.001
   Hiruma Y, 2013, BONE, V53, P87, DOI 10.1016/j.bone.2012.11.036
   Hiruma Y, 2011, BIOCHEM BIOPH RES CO, V409, P424, DOI 10.1016/j.bbrc.2011.05.015
   Holroyd C, 2008, BEST PRACT RES CL EN, V22, P671, DOI 10.1016/j.beem.2008.06.001
   Humphrey M. B., 2004, J BONE MINER RES, V19
   Ishida Kitagawa N, 2012, J BIOL CHEM, V287, P17493, DOI 10.1074/jbc.M111.324194
   JOHNSON PA, 1995, MED CARE, V33, P145
   Kameda Y, 2013, J BONE MINER RES, V28, P2463, DOI 10.1002/jbmr.1989
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   LEE ER, 1995, J HISTOCHEM CYTOCHEM, V43, P525, DOI 10.1177/43.5.7730591
   Lepola VT, 1996, BONE, V18, P191, DOI 10.1016/8756 3282(95)00439 4
   Marieb E.N., 2010, HUMAN ANATOMY PHYSL, V8th, DOI [10.1007/ BF00845519, DOI 10.1007/BF00845519]
   Marini JC, 2009, NAT REV ENDOCRINOL, V5, P241, DOI 10.1038/nrendo.2009.58
   Masuyama R, 2003, J BONE MINER RES, V18, P1217, DOI 10.1359/jbmr.2003.18.7.1217
   Phillipi CA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005088.pub2
   Pui CH, 2013, SEMIN HEMATOL, V50, P185, DOI 10.1053/j.seminhematol.2013.06.007
   Rauch F, 2004, LANCET, V363, P1377, DOI 10.1016/S0140 6736(04)16051 0
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   SEEDOR JG, 1991, J BONE MINER RES, V6, P339
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   Staines KA, 2013, J ENDOCRINOL, V219, pR1, DOI 10.1530/JOE 13 0276
   Stuible M, 2014, J BIOL CHEM, V289, P6498, DOI 10.1074/jbc.M113.494542
   THOMPSON DD, 1990, J BONE MINER RES, V5, P279, DOI 10.1002/jbmr.5650050312
   Thomsen JS, 1999, BONE, V25, P561, DOI 10.1016/S8756 3282(99)00212 4
   TSAI MK, 1995, J FORMOS MED ASSOC, V94, P535
   TURNER RT, 1994, ENDOCRINOLOGY, V134, P461, DOI 10.1210/en.134.1.461
   Walther F, 2006, J PEDIATR GASTR NUTR, V43, P42, DOI 10.1097/01.mpg.0000228105.91240.80
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Wilsman NJ, 1996, J ORTHOPAED RES, V14, P562, DOI 10.1002/jor.1100140410
   Zhu ED, 2014, ENDOCRINOLOGY, V155, P1188, DOI 10.1210/en.2013 1993
   Zou W, 2010, J CELL SCI, V123, P2955, DOI 10.1242/jcs.069872
NR 42
TC 28
Z9 33
U1 1
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2018
VL 116
BP 172
EP 180
DI 10.1016/j.bone.2018.07.026
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GW8ME
UT WOS:000447232100021
PM 30076992
DA 2025 08 17
ER

PT J
AU Nemoto, E
   Koshikawa, Y
   Kanaya, S
   Tsuchiya, M
   Tamura, M
   Somerman, MJ
   Shimauchi, H
AF Nemoto, Eiji
   Koshikawa, Yohei
   Kanaya, Sousuke
   Tsuchiya, Masahiro
   Tamura, Masato
   Somerman, Martha J.
   Shimauchi, Hidetoshi
TI Wnt signaling inhibits cementoblast differentiation and promotes
   proliferation
SO BONE
LA English
DT Article
DE Wnt signaling; Cementoblast; Differentiation; Proliferation; In vitro
ID MESENCHYMAL STEM CELLS; RECEPTOR RELATED PROTEIN 5; ENHANCER FACTOR I;
   OSTEOBLAST DIFFERENTIATION; BETA CATENIN; WNT3A INDUCED PROLIFERATION;
   OSTEOGENIC DIFFERENTIATION; MOLECULAR MECHANISM; BONE FORMATION; LINING
   CELLS
AB Cementoblasts, tooth root lining cells, are responsible for laying down cementum on the root surface, a process that is indispensable for establishing a functional periodontal ligament. Cementoblasts share phenotypical features with osteoblasts. Wnt signaling has been implicated in increased bone formation by controlling mesenchymal stem cell or osteoblastic cell functions; however the role of Wnt signaling on cementogenesis has not been examined. In this study, we have identified a consistent expression profile of Wnt signaling molecules in cementoblasts, in vitro by RT PCR. Exposure of cells to LiCl, which promotes canonical Wnt signaling by inhibiting GSK 3 beta, increased beta catenin nuclear translocation and up regulated the transcriptional activity of a canonical Wnt responsive promoters, suggesting that an endogenous canonical Wnt pathway functions in cementoblasts. Activation of endogenous canonical Wnt signaling with LiCl suppressed alkaline phosphatase (ALP) activity and expression of genes associated with cementum function; ALP, bone sialoprotein (BSP), and osteocalcin (OCN). Exposure to Wnt3a, as a representative canonical Wnt member, also inhibited the expression of ALP, BSP, and OCN gene. This effect was accompanied by decreased gene expression of Runx2 and Osterix and by increased gene expression of lymphoid enhancer factor 1. Pretreatment with Dickkopf (Dkk) 1, a potent canonical Wnt antagonist, which binds to a low density lipoprotein receptor related protein (LRP) 5/6 co receptor, attenuated the suppressive effects of Wnt3a on mRNA expression of Runx2 and OCN on cementoblasts. These findings suggest that canonical Wnt signaling inhibits cementoblast differentiation via regulation of expression of selective transcription factors. Wnt3a also increased the expression of cyclin D1, known as a cell cycle regulator, as well as cell proliferation. In conclusion, these observations suggest that Wnt signaling inhibits cementoblast differentiation and promotes cell proliferation. Elucidating the role of Wnt in controlling cementoblast function will provide new tools needed to improve on existing periodontal regeneration therapies. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Nemoto, Eiji; Koshikawa, Yohei; Kanaya, Sousuke; Shimauchi, Hidetoshi] Tohoku Univ, Grad Sch Dent, Dept Periodontol & Endodontol, Sendai, Miyagi 9808575, Japan.
   [Tsuchiya, Masahiro] Tohoku Univ, Grad Sch Dent, Dept Aging & Geriatr Dent, Sendai, Miyagi 9808575, Japan.
   [Tamura, Masato] Hokkaido Univ, Grad Sch Dent, Dept Biochem & Mol Biol, Sapporo, Hokkaido 0608586, Japan.
   [Somerman, Martha J.] Univ Washington, Sch Dent, Dept Periodont, Seattle, WA 98195 USA.
   [Somerman, Martha J.] Univ Washington, Sch Dent, Dept Oral Biol, Seattle, WA 98195 USA.
C3 Tohoku University; Tohoku University; Hokkaido University; University of
   Washington; University of Washington Seattle; University of Washington;
   University of Washington Seattle
RP Nemoto, E (通讯作者)，Tohoku Univ, Grad Sch Dent, Dept Periodontol & Endodontol, 4 1 Seriyo Machi Aoba, Sendai, Miyagi 9808575, Japan.
EM e nemoto@umin.ac.jp
RI tamura, masato/B 7304 2009; TSUCHIYA, MASAHIRO/C 5553 2018; Tamura,
   Masato/B 7304 2009; Tsuchiya, Masahiro/C 5553 2018
OI Tamura, Masato/0000 0003 3700 5203; Tsuchiya,
   Masahiro/0000 0002 7000 4547
FU Japan Society for the Promotion of Science [19592380, 20390527]; Tohoku
   University Biomaterial Interface Research Program; Grants in Aid for
   Scientific Research [19592380, 20390527] Funding Source: KAKEN
FX This work was supported by a Grant in Aid for Scientific Research
   (19592380 and 20390527) from the Japan Society for the Promotion of
   Science and by the Tohoku University Biomaterial Interface Research
   Program.
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534 5807(02)00167 3
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Bosshardt DD, 2005, J DENT RES, V84, P390, DOI 10.1177/154405910508400501
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Caverzasio J, 2007, ENDOCRINOLOGY, V148, P5323, DOI 10.1210/en.2007 0520
   D'Errico JA, 2000, J PERIODONTOL, V71, P63, DOI 10.1902/jop.2000.71.1.63
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   DErrico JA, 1997, BONE, V20, P117, DOI 10.1016/S8756 3282(96)00348 1
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Eijken M, 2008, J CELL BIOCHEM, V104, P568, DOI 10.1002/jcb.21651
   Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972
   Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552
   Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264
   Jackson A, 2005, BONE, V36, P585, DOI 10.1016/j.bone.2005.01.007
   Järvinen E, 2006, P NATL ACAD SCI USA, V103, P18627, DOI 10.1073/pnas.0607289103
   Kahler RA, 2006, J CELL BIOCHEM, V97, P969, DOI 10.1002/jcb.20702
   Kahler RA, 2003, J BIOL CHEM, V278, P11937, DOI 10.1074/jbc.M211443200
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kim SE, 2007, CELL SIGNAL, V19, P511, DOI 10.1016/j.cellsig.2006.08.008
   Kitagawa M, 2006, BONE, V39, P1035, DOI 10.1016/j.bone.2006.05.022
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Liu F, 2008, DEV BIOL, V313, P210, DOI 10.1016/j.ydbio.2007.10.016
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Millar JBA, 2002, GENOME BIOL, V3
   Nakashima A, 2005, J BIOL CHEM, V280, P37660, DOI 10.1074/jbc.M504612200
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Neth P, 2006, STEM CELLS, V24, P1892, DOI 10.1634/stemcells.2005 0503
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Roca H, 2005, J BIOL CHEM, V280, P30845, DOI 10.1074/jbc.M503942200
   Sarkar L, 1999, MECH DEVELOP, V85, P197, DOI 10.1016/S0925 4773(99)00095 7
   Saygin NE, 2000, PERIODONTOL 2000, V24, P73, DOI 10.1034/j.1600 0757.2000.2240105.x
   Scheller EL, 2008, J DENT RES, V87, P126, DOI 10.1177/154405910808700206
   Shen R, 2006, J BIOL CHEM, V281, P16347, DOI 10.1074/jbc.M603439200
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Vaes BLT, 2005, BONE, V36, P803, DOI 10.1016/j.bone.2005.02.001
   van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614
   VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691
   Yun MS, 2005, J CELL SCI, V118, P313, DOI 10.1242/jcs.01601
   Zhao M, 2002, J BONE MINER RES, V17, P1441, DOI 10.1359/jbmr.2002.17.8.1441
NR 50
TC 117
Z9 133
U1 0
U2 32
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD MAY
PY 2009
VL 44
IS 5
BP 805
EP 812
DI 10.1016/j.bone.2008.12.029
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 436SO
UT WOS:000265436000010
PM 19442631
DA 2025 08 17
ER

PT J
AU Xiong, ZC
   Zheng, C
   Chang, YA
   Liu, KK
   Shu, L
   Zhang, C
AF Xiong, Zhencheng
   Zheng, Can
   Chang, Yanan
   Liu, Kuankuan
   Shu, Li
   Zhang, Chi
TI Exploring the Pharmacological Mechanism of Duhuo Jisheng Decoction in
   Treating Osteoporosis Based on Network Pharmacology
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID OSTEOGENIC DIFFERENTIATION; STEM CELLS; DATABASE
AB Objective. The purpose of this work is to study the mechanism of action of Duhuo Jisheng Decoction (DHJSD) in the treatment of osteoporosis based on the methods of bioinformatics and network pharmacology. Methods. In this study, the active compounds of each medicinal ingredient of DHJSD and their corresponding targets were obtained from TCMSP database. Osteoporosis was treated as search query in GeneCards, MalaCards, DisGeNET, Therapeutic Target Database (TTD), Comparative Toxicogenomics Database (CTD), and OMIM databases to obtain disease related genes. The overlapping targets of DHJSD and osteoporosis were identified, and then GO and KEGG enrichment analysis were performed. Cytoscape was employed to construct DHJSD compounds target genes osteoporosis network and protein protein interaction (PPI) network. CytoHubba was utilized to select the hub genes. The activities of binding of hub genes and key components were confirmed by molecular docking. Results. 174 active compounds and their 205 related potential targets were identified in DHJSD for the treatment of osteoporosis, including 10 hub genes (AKT1, ALB, IL6, MAPK3, VEGFA, JUN, CASP3, EGFR, MYC, and EGF). Pathway enrichment analysis of target proteins indicated that osteoclast differentiation, AGE RAGE signaling pathway in diabetic complications, Wnt signaling pathway, MAPK signaling pathway, PI3K Akt signaling pathway, JAK STAT signaling pathway, calcium signaling pathway, and TNF signaling pathway were the specifically major pathways regulated by DHJSD against osteoporosis. Further verification based on molecular docking results showed that the small molecule compounds (Quercetin, Kaempferol, Beta sitosterol, Beta carotene, and Formononetin) contained in DHJSD generally have excellent binding affinity to the macromolecular target proteins encoded by the top 10 genes. Conclusion. This study reveals the characteristics of multi component, multi target, and multi pathway of DHJSD against osteoporosis and provides novel insights for verifying the mechanism of DHJSD in the treatment of osteoporosis.
C1 [Xiong, Zhencheng; Zhang, Chi] Peking Univ, Inst Med Technol, Hlth Sci Ctr, Beijing, Peoples R China.
   [Xiong, Zhencheng] Peking Univ Third Hosp, Beijing, Peoples R China.
   [Zheng, Can; Zhang, Chi] Peking Univ, Biomed Engn Dept, Beijing, Peoples R China.
   [Chang, Yanan; Liu, Kuankuan; Shu, Li; Zhang, Chi] Peking Univ Int Hosp, Cent Lab, Beijing, Peoples R China.
   [Zhang, Chi] Peking Univ Int Hosp, Dept Orthoped, Beijing, Peoples R China.
   [Zhang, Chi] Beijing Univ Chinese Med, Sch Chinese Mat Med, Beijing, Peoples R China.
C3 Peking University; Peking University; Peking University; Peking
   University; Peking University; Beijing University of Chinese Medicine
RP Zhang, C (通讯作者)，Peking Univ, Inst Med Technol, Hlth Sci Ctr, Beijing, Peoples R China.; Zhang, C (通讯作者)，Peking Univ, Biomed Engn Dept, Beijing, Peoples R China.; Zhang, C (通讯作者)，Peking Univ Int Hosp, Cent Lab, Beijing, Peoples R China.; Zhang, C (通讯作者)，Peking Univ Int Hosp, Dept Orthoped, Beijing, Peoples R China.; Zhang, C (通讯作者)，Beijing Univ Chinese Med, Sch Chinese Mat Med, Beijing, Peoples R China.
EM chi.zhang@case.edu
RI Zhencheng, Xiong/AAA 1619 2020
OI xiong, zhencheng/0000 0002 7834 5194
FU Beijing Municipal Science & Technology Commission [Z181100001818006]
FX This study was supported by the Beijing Municipal Science & Technology
   Commission (grant no. Z181100001818006).
CR Amberger Joanna S, 2017, Curr Protoc Bioinformatics, V58, DOI 10.1002/cpbi.27
   Chang JY, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/7617261
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752 0509 8 S4 S11
   Davis AP, 2021, NUCLEIC ACIDS RES, V49, pD1138, DOI 10.1093/nar/gkaa891
   Deng L, 2016, Clinical. J. Tradit. Chin. Med, V28, P848, DOI [DOI 10.16448/J.CJTCM.2016.0301, 10.16448/j.cjtcm.2016.0301]
   Derakhshanian H, 2013, CAN J PHYSIOL PHARM, V91, P380, DOI 10.1139/cjpp 2012 0190
   Gao SS, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/1704960
   Gene Ontology Consortium, 2015, NUCLEIC ACIDS RES, V43, pD1049, DOI DOI 10.1093/NAR/GKU1179
   Giampietro PF, 2010, OSTEOPOROSIS INT, V21, P467, DOI 10.1007/s00198 009 0981 3
   Guan X, 2015, J PRACTICAL TRADITIO, V29, P179
   Gupta A, 2019, SPINE J, V19, P1796, DOI 10.1016/j.spinee.2019.06.023
   Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004
   Huang C, 2020, BIOSCIENCE REP, V40
   Jin HM, 2019, FOOD FUNCT, V10, P6556, DOI 10.1039/c9fo00206e
   Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Li HL, 2018, AGING DIS, V9, P1058, DOI 10.14336/AD.2018.0214
   Li JY, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/6957825
   Li MY, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03006 7
   Li Z, 2019, PROGR ANATOMICAL SCI, V25, P532
   梁文娜, 2015, [中国老年学杂志, Chinese Journal of Gerontology], V35, P5333
   Liu GQ, 2019, FASEB J, V33, P11137, DOI 10.1096/fj.201900436RR
   Liu WJ, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112871
   Liu ZC, 2018, ACTA PHARMACOL SIN, V39, P912, DOI 10.1038/aps.2018.36
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Ohrndorf S., 2020, Int J Mol Sci, V21
   Piñero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Rappaport N, 2017, NUCLEIC ACIDS RES, V45, pD877, DOI 10.1093/nar/gkw1012
   Renaux A, 2018, NUCLEIC ACIDS RES, V46, P2699, DOI 10.1093/nar/gky092
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sheng S, 2021, CHIN J INTEGR MED, V27, P106, DOI 10.1007/s11655 020 3199 z
   Shuai YM, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/7049812
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsaioun K, 2016, ALTEX ALTERN ANIM EX, V33, P343, DOI 10.14573/altex.1610101
   Wang NN, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00988
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   Wu RY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1082 z
   Wu ZH, 2017, J BIOL REG HOMEOS AG, V31, P359
   Xia BJ, 2014, J ETHNOPHARMACOL, V153, P133, DOI 10.1016/j.jep.2014.01.040
   Xiao WY, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/7275057
   Xiong ZC, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/2381462
   Xu C., 2020, BIOMEDICINE PHARMACO, V133, P110962
   Yang Y, 2019, J CELL SCI, V132, DOI 10.1242/jcs.230490
   You L, 2014, INT J CLIN EXP PATHO, V7, P7249
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yu T, 2020, AGING US, V12, P9500, DOI 10.18632/aging.103223
   Yuan Z, 2018, AM J TRANSL RES, V10, P4313
   Zha JP, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01775 7
   Zhang YL, 2017, DRUG DES DEV THER, V11, P1881, DOI 10.2147/DDDT.S139804
   Zhao JJ, 2018, J CELL PHYSIOL, V233, P7182, DOI 10.1002/jcp.26548
   Zhao J, 2013, J ALTERN COMPLEM MED, V19, P111, DOI 10.1089/acm.2011.0370
   Zheng CS, 2013, MOL MED REP, V7, P1812, DOI 10.3892/mmr.2013.1411
   Zheng HY, 2020, TOXICOL APPL PHARM, V409, DOI 10.1016/j.taap.2020.115271
   Zhou D, 2019, Chin. J. Tradit. Medi. Sci. Technol., V26, P346
   Zhu NQ, 2020, COMPUT BIOL CHEM, V85, DOI 10.1016/j.compbiolchem.2020.107240
NR 59
TC 21
Z9 25
U1 3
U2 55
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD APR 7
PY 2021
VL 2021
AR 5510290
DI 10.1155/2021/5510290
PG 21
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA RP2ZY
UT WOS:000641603300002
PM 33880122
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Qu, ZC
   Zhao, SC
   Zhang, Y
   Wang, XH
   Yan, L
AF Qu, Zechao
   Zhao, Songchuan
   Zhang, Yong
   Wang, Xiaohao
   Yan, Liang
TI Natural Compounds for Bone Remodeling: Targeting osteoblasts and
   relevant signaling pathways
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Bone remodeling; Osteoblast differentiation; Signaling pathways; Natural
   compounds
ID REGULATING RUNX2 EXPRESSION; MESENCHYMAL STEM CELLS; OSTEOGENIC
   DIFFERENTIATION; PROMOTES; PROLIFERATION; ACTIVATION; NOTCH; ALBIFLORIN;
   INDUCTION; GERANIIN
AB In the process of bone metabolism and bone remodeling, bone marrow mesenchymal stem cells (BM MSCs) differentiate into osteoblasts (OBs) under certain conditions to enable the formation of new bone, and normal bone reconstruction and pathological bone alteration are closely related to the differentiation and proliferation functions of OBs. Osteogenic differentiation of BM MSCs involves multiple signaling pathways, which function individually but interconnect intricately to form a complex signaling regulatory network. Natural compounds have fewer adverse effects than chemically synthesized drugs, optimize bone health, and are more suitable for long term use. In this paper, we focus on OBs, summarize the current research progress of signaling pathways related to OBs differentiation, and review the molecular mechanisms by which chemically synthesized drugs with potential anti osteoporosis properties regulate OBs mediated bone formation.
C1 [Qu, Zechao; Zhao, Songchuan; Zhang, Yong; Wang, Xiaohao; Yan, Liang] Xi An Jiao Tong Univ, Honghui Hosp, Dept Spinal Surg, Xian, Peoples R China.
C3 Xi'an Jiaotong University
RP Yan, L (通讯作者)，Xi An Jiao Tong Univ, Honghui Hosp, Dept Spinal Surg, Xian, Peoples R China.
EM yanliangdr5583@163.com
RI Xiaohao, Wang/KEH 6038 2024
FU National Natural Science Foundation of China [82260181]; Medical
   Research Project of Xi'an Science and Technology Bureau [24YXYJ0006]
FX This work was financially supported by grants from the National Natural
   Science Foundation of China (82260181) , Medical Research Project of
   Xi'an Science and Technology Bureau (24YXYJ0102) , Medical Research
   Project of Xi'an Science and Technology Bureau (24YXYJ0006) .
CR Abuna RPF, 2019, COLLOID SURFACE B, V184, DOI 10.1016/j.colsurfb.2019.110513
   Agas D, 2013, J CELL PHYSIOL, V228, P2149, DOI 10.1002/jcp.24382
   Alekos N.S., JCI Insight, V8, P2023
   Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Andolfo I, 2020, AM J HEMATOL, V95, P188, DOI 10.1002/ajh.25683
   Banerjee S, 2017, DRUGS, V77, P521, DOI 10.1007/s40265 017 0701 9
   Boakye YD, 2016, J ETHNOPHARMACOL, V187, P17, DOI 10.1016/j.jep.2016.04.020
   Bouin S, 2023, ACTA BIOMATER, V157, P275, DOI 10.1016/j.actbio.2022.11.051
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Cai ZY, 2019, AM J TRANSL RES, V11, P7300
   Casati L, 2020, EUR J NUTR, V59, P1975, DOI 10.1007/s00394 019 02047 9
   Casati L, 2019, EUR J NUTR, V58, P1019, DOI 10.1007/s00394 018 1618 0
   Chan WCW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115445
   Chen M, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 022 04147 y
   Chen TH, 2021, BIOCHEM PHARMACOL, V192, DOI 10.1016/j.bcp.2021.114669
   Chen WH, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1010937
   Chen XJ, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108746
   Chen XJ, 2017, ACTA BIOCH BIOPH SIN, V49, P867, DOI 10.1093/abbs/gmx087
   Chen YQ, 2023, PLOS ONE, V18, DOI 10.1371/journal.pone.0289912
   Chevalier C, 2021, STAR PROTOC, V2, DOI 10.1016/j.xpro.2021.100452
   Cho JH, 2022, CALCIFIED TISSUE INT, V110, P489, DOI 10.1007/s00223 021 00923 3
   Choi JY, 2020, EXP MOL MED, V52, P1165, DOI 10.1038/s12276 020 0472 3
   Dalagiorgou G, 2017, CELL MOL LIFE SCI, V74, P921, DOI 10.1007/s00018 016 2394 8
   Ding P, 2022, ELIFE, V11, DOI 10.7554/eLife.81480
   Elbaz B, 2024, NEURON, V112, DOI 10.1016/j.neuron.2023.10.008
   Fan WX, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110915
   Feng ZF, 2022, EUR J MED CHEM, V244, DOI 10.1016/j.ejmech.2022.114867
   Ferreira A, 2022, SEMIN CANCER BIOL, V85, P95, DOI 10.1016/j.semcancer.2021.04.008
   Fortelny N, 2024, NAT IMMUNOL, DOI 10.1038/s41590 024 01804 1
   Freitas GP, 2020, BIO PROTOCOL, V10, DOI 10.21769/BioProtoc.3534
   Gao YG, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13030483
   Gao YG, 2023, BIOCHEM PHARMACOL, V207, DOI 10.1016/j.bcp.2022.115377
   Garcia J, 2021, J BONE MINER RES, V36, P1808, DOI 10.1002/jbmr.4339
   Guo A, 2022, BIOMED PHARMACOTHER, V146, DOI 10.1016/j.biopha.2021.112524
   Guo JL, 2019, PHARMACOL RES, V147, DOI [10.1016/j.plus.2019.104387, 10.1016/j.phrs.2019.104387]
   Guo LH, 2019, INT J MOL MED, V43, P830, DOI 10.3892/ijmm.2018.4013
   Guo YM, 2022, INT J NANOMED, V17, P4829, DOI 10.2147/IJN.S377036
   He J, 2017, REGEN BIOMATER, V4, P269, DOI 10.1093/rb/rbx008
   Hong S, 2022, J NUTR BIOCHEM, V101, DOI 10.1016/j.jnutbio.2021.108900
   Hou HW, 2020, EUR REV MED PHARMACO, V24, P12408, DOI 10.26355/eurrev_202012_24037
   Hrdlicka HC, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115779
   Hu B, 2017, PHARMAZIE, V72, P35, DOI 10.1691/ph.2017.6502
   Huang J, 2024, BIOMED PHARMACOTHER, V173, DOI 10.1016/j.biopha.2024.116355
   Hung YL, 2017, SCI REP UK, V7, DOI 10.1038/srep46299
   Huo LL, 2013, BIOL TRACE ELEM RES, V155, P142, DOI 10.1007/s12011 013 9770 0
   Izumiya M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147752
   Ji L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12143 3
   Jia JH, 2023, BIOMED PHARMACOTHER, V168, DOI 10.1016/j.biopha.2023.115809
   Jin XX, 2024, CELL MOL LIFE SCI, V81, DOI 10.1007/s00018 023 05043 9
   Jing H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0231 0
   Jing JJ, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01559 5
   Joung YH, 2013, MOL MED REP, V8, P891, DOI 10.3892/mmr.2013.1593
   Joung YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047477
   Ke K, 2016, SCI REP UK, V6, DOI 10.1038/srep35233
   Kim JH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.690113
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim JW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2562 5
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Lawson LY, 2022, J BONE MINER RES, V37, P108, DOI 10.1002/jbmr.4445
   Lee SW, 2012, PLANTA MED, V78, P903, DOI 10.1055/s 0031 1298482
   Li HB, 2020, CHEM BIOL DRUG DES, V95, P451, DOI 10.1111/cbdd.13659
   Li KJ, 2018, BIOMED PHARMACOTHER, V99, P319, DOI 10.1016/j.biopha.2018.01.040
   Li S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094312
   Li WW, 2019, MOL MED REP, V19, P3676, DOI 10.3892/mmr.2019.10040
   Li ZC, 2023, PHARMACOL RES, V187, DOI 10.1016/j.phrs.2022.106635
   Liu BB, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109895
   Liu DD, 2022, J DENT RES, V101, P1227, DOI 10.1177/00220345221093518
   Liu JQ, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 021 00762 6
   Liu MM, 2022, CELLS BASEL, V11, DOI 10.3390/cells11142216
   Liu MZ, 2019, EUR J PHARMACOL, V858, DOI 10.1016/j.ejphar.2019.172480
   Lu WG, 2023, CELL MOL LIFE SCI, V80, DOI 10.1007/s00018 023 04821 9
   Lu YQ, 2015, BIOORG MED CHEM LETT, V25, P673, DOI 10.1016/j.bmcl.2014.11.081
   Ludwig K, 2022, BONE, V160, DOI 10.1016/j.bone.2022.116400
   Luo C, 2022, FREE RADICAL BIO MED, V188, P337, DOI 10.1016/j.freeradbiomed.2022.06.236
   Luo JL, 2022, PHYTOMEDICINE, V102, DOI 10.1016/j.phymed.2022.154161
   Ma Y, 2019, J CELL BIOCHEM, V120, P16052, DOI 10.1002/jcb.28886
   Mikami Y, 2010, J CELL PHYSIOL, V223, P123, DOI 10.1002/jcp.22017
   Mishima E, 2023, NAT METAB, V5, P924, DOI 10.1038/s42255 023 00821 y
   Münz S, 2022, CELLS BASEL, V11, DOI 10.3390/cells11010040
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Ni XC, 2022, REDOX BIOL, V54, DOI 10.1016/j.redox.2022.102363
   Nieminen Pihala V, 2021, BONE, V146, DOI 10.1016/j.bone.2021.115884
   Ohba S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186665
   Park JH, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms242015252
   Park KR, 2022, J CELL MOL MED, V26, P4520, DOI 10.1111/jcmm.17476
   Peh HY, 2016, PHARMACOL THERAPEUT, V162, P152, DOI 10.1016/j.pharmthera.2015.12.003
   Peymanfar Y, 2022, J ORTHOP RES, V40, P2258, DOI 10.1002/jor.25253
   Ponzetti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136651
   Qi XF, 2020, TRENDS BIOCHEM SCI, V45, P397, DOI 10.1016/j.tibs.2020.01.006
   Qu ZC, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1043975
   Ricarte FR, 2018, J BIOL CHEM, V293, P20200, DOI 10.1074/jbc.RA118.004751
   Rong X, 2022, DRUG DES DEV THER, V16, P3929, DOI 10.2147/DDDT.S377001
   Rychlicka M, 2021, FOODS, V10, DOI 10.3390/foods10061417
   Saeki N, 2022, EXP CELL RES, V416, DOI 10.1016/j.yexcr.2022.113156
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Sanpaolo ER, 2020, MOL BIOL REP, V47, P9087, DOI 10.1007/s11033 020 05910 9
   Semenova D, 2020, CELL TISSUE RES, V379, P169, DOI 10.1007/s00441 019 03130 7
   Shen CY, 2017, BRIT J PHARMACOL, V174, P1395, DOI 10.1111/bph.13631
   Shen GY, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102626
   Shen JJ, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02487 3
   Shi C, 2019, J DENT RES, V98, P904, DOI 10.1177/0022034519850812
   Shi XL, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02714 5
   Shimoyama A, 2007, MOL BIOL CELL, V18, P2411, DOI 10.1091/mbc.E06 08 0743
   Silva TN, 2022, J EXP BOT, V73, P646, DOI 10.1093/jxb/erab450
   Sprinzak D, 2021, ANNU REV BIOPHYS, V50, P157, DOI 10.1146/annurev biophys 101920 082204
   Stanley A, 2019, J BONE MINER RES, V34, P1894, DOI 10.1002/jbmr.3760
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Subramaniam S, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9120758
   Suh J, 2023, CELL METAB, V35, P345, DOI 10.1016/j.cmet.2023.01.003
   Suh KS, 2013, FITOTERAPIA, V89, P33, DOI 10.1016/j.fitote.2013.05.016
   Sun K, 2020, OSTEOARTHR CARTILAGE, V28, P400, DOI 10.1016/j.joca.2020.02.027
   Tang LY, 2021, J BONE MINER RES, V36, P779, DOI 10.1002/jbmr.4230
   Tewari D, 2022, SEMIN CANCER BIOL, V80, P1, DOI 10.1016/j.semcancer.2019.12.008
   Torgbo S, 2022, FOOD CHEM, V382, DOI 10.1016/j.foodchem.2022.132332
   Uda Y, 2021, AGING US, V13, P25607, DOI 10.18632/aging.203808
   Uenaka M, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28673 2
   Villarino AV, 2017, NAT IMMUNOL, V18, P374, DOI 10.1038/ni.3691
   Vlashi R, 2023, GENES DIS, V10, P1291, DOI 10.1016/j.gendis.2022.07.011
   Wang HK, 2022, NUTRIENTS, V14, DOI 10.3390/nu14142934
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Wang SF, 2022, MOL MED, V28, DOI 10.1186/s10020 022 00530 4
   Wang YD, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0411 x
   Wang Z, 2019, AM J TRANSL RES, V11, P4984
   Watanabe Ken, 2009, Nihon Rinsho, V67, P879
   Wei YY, 2023, INT IMMUNOPHARMACOL, V120, DOI 10.1016/j.intimp.2023.110382
   Weivoda MM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14003 6
   Wu LA, 2016, J CELL PHYSIOL, V231, P1189, DOI 10.1002/jcp.25266
   Xiao YS, 2023, BIOMED PHARMACOTHER, V169, DOI 10.1016/j.biopha.2023.115864
   Xie CL, 2023, PHARMACOL RES, V197, DOI 10.1016/j.phrs.2023.106968
   Xie Y, 2023, J BONE MINER RES, V38, P1175, DOI 10.1002/jbmr.4834
   Xin P, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2020.106210
   Xu C, 2022, ELIFE, V11, DOI [10.7554/eLife.60183, 10.7554/eLife.60183.sa0, 10.7554/eLife.60183.sa1, 10.7554/eLife.60183.sa2]
   Xu YJ, 2019, BRAIN RES, V1719, P113, DOI 10.1016/j.brainres.2019.05.037
   Xu YX, 2019, EUR J PHARMACOL, V865, DOI 10.1016/j.ejphar.2019.172794
   Yin N, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658 019 0177 6
   Yin QP, 2023, MOL MED REP, V28, DOI 10.3892/mmr.2023.13086
   Yu AXD, 2020, FASEB J, V34, P4311, DOI 10.1096/fj.201902319RRR
   Yu FY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00701 5
   Yun HM, 2022, CELLS BASEL, V11, DOI 10.3390/cells11233887
   Zanotti S, 2008, ENDOCRINOLOGY, V149, P3890, DOI 10.1210/en.2008 0140
   Zhang C, 2022, J ETHNOPHARMACOL, V297, DOI 10.1016/j.jep.2022.115577
   Zhang KF, 2019, AM J PHYSIOL ENDOC M, V316, pE590, DOI 10.1152/ajpendo.00371.2018
   Zhang Q, 2022, INT J BIOL SCI, V18, P3498, DOI 10.7150/ijbs.70447
   Zhang XN, 2023, J ETHNOPHARMACOL, V309, DOI 10.1016/j.jep.2023.116304
   Zhang XN, 2016, AM J CHINESE MED, V44, P35, DOI 10.1142/S0192415X16500038
   Zhang Y, 2020, J CELL PHYSIOL, V235, P5511, DOI 10.1002/jcp.29261
   Zhang YC, 2020, ANNU REV PHYSIOL, V82, P251, DOI 10.1146/annurev physiol 021119 034500
   Zhao DF, 2018, MENOPAUSE, V25, P1459, DOI 10.1097/GME.0000000000001150
   Zhao R, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118044
   Zhao XY, 2020, J MOL CELL BIOL, V12, P55, DOI 10.1093/jmcb/mjz028
   Zhou J, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02958 1
   Zhou SR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27273 w
   Zhu Y, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1143 y
   Zhu Z, 2023, ANN ANAT, V250, DOI 10.1016/j.aanat.2023.152156
NR 154
TC 1
Z9 1
U1 2
U2 14
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD NOV
PY 2024
VL 180
AR 117490
DI 10.1016/j.biopha.2024.117490
EA SEP 2024
PG 14
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA I0W0B
UT WOS:001327533400001
PM 39332184
OA gold
DA 2025 08 17
ER

PT J
AU Schwaninger, R
   Rentsch, CA
   Wetterwald, A
   van der Horst, G
   van Bezooijen, RL
   van der Pluijm, G
   Löwik, CWGM
   Ackermann, K
   Pyerin, W
   Hamdy, FC
   Thalmann, GN
   Cecchini, MG
AF Schwaninger, Ruth
   Rentsch, Cyrill A.
   Wetterwald, Antoinette
   van der Horst, Geertje
   van Bezooijen, Rutger L.
   van der Pluijm, Gabri
   Lowik, Clemens W. G. M.
   Ackermann, Karin
   Pyerin, Walter
   Hamdy, Freddie C.
   Thalmann, George N.
   Cecchini, Marco G.
TI Lack of noggin expression by cancer cells is a determinant of the
   osteoblast response in bone metastases
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID HORMONE RELATED PROTEIN; PROSTATE SPECIFIC ANTIGEN; STIMULATING
   FACTOR I; BREAST CANCER; MORPHOGENETIC PROTEINS; BMP ANTAGONIST;
   SKELETAL OVEREXPRESSION; OSTEOCLAST FORMATION; OSTEOLYTIC LESIONS;
   CAUSAL ROLE
AB Prostate and mammary cancer bone metastases can be osteoblastic or osteolytic, but the mechanisms determining these features are unclear. Bone morphogenetic and Writ proteins are osteoinductive molecules. Their activity is modulated by antagonists such as noggin and dickkopf 1. Differential expression analysis of bone morphogenetic and Wnt protein antagonists in human prostate and mammary cancer cell lines showed that osteolytic cell lines constitutively express in vitro noggin and dickkopf 1 and at least one of the osteolytic cytokines parathyroid hormone related protein, colony stimulating factor 1, and interleukin 8. in contrast, osteoinductive cell lines express neither noggin nor dickkopf 1 nor osteolytic cytokines in vitro. The noggin differential expression profile observed in vitro was confirmed in vivo in prostate cancer cell lines xenografted into bone and in clinical samples of bone metastasis. Forced noggin expression in an osteoinductive prostate cancer cell line abolished the osteoblast response induced in vivo by its intraosseous xenografts. Basal bone resorption and tumor growth kinetics were marginally affected. Lack of noggin and possibly dickkopf 1 expression by cancer cells may be a relevant mechanism contributing to the osteoblast response in bone metastases. Concomitant lack of osteolytic cytokines; may be permissive of this effect. Noggin is a candidate drug for die adjuvant therapy of bone metastasis.
C1 Univ Bern, Urol Res Lab, Dept Urol, CH 3010 Bern, Switzerland.
   Univ Bern, Dept Clin Res, CH 3010 Bern, Switzerland.
   Leiden Univ, Dept Endocrinol, Med Ctr, Leiden, Netherlands.
   Leiden Univ, Dept Urol, Med Ctr, Leiden, Netherlands.
   Leiden Univ, Dept Mol Cell Biol, Med Ctr, Leiden, Netherlands.
   German Canc Res Ctr, D 6900 Heidelberg, Germany.
   Univ Sheffield, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England.
   Univ Sheffield, Acad Urol Unit, Sheffield, S Yorkshire, England.
C3 University of Bern; University of Bern; Leiden University   Excl LUMC;
   Leiden University; Leiden University Medical Center (LUMC); Leiden
   University; Leiden University Medical Center (LUMC); Leiden University  
   Excl LUMC; Leiden University; Leiden University Medical Center (LUMC);
   Leiden University   Excl LUMC; Helmholtz Association; German Cancer
   Research Center (DKFZ); University of Sheffield; University of Sheffield
RP Cecchini, MG (通讯作者)，Univ Bern, Urol Res Lab, Dept Urol, Murtenstr 35, CH 3010 Bern, Switzerland.
EM marco.cecchini@dkf.unibe.ch
RI Rentsch, Cyrill/HZJ 8900 2023; FENTON, MIRIAM/B 6430 2011
OI Rentsch, Cyrill A./0000 0002 8085 6006; van der Pluijm,
   Gabri/0000 0002 1351 1884; van der Horst, Geertje/0000 0003 1696 160X;
   Hamdy, Freddie Charles/0000 0003 2627 2154
CR Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Aspenberg P, 2001, J BONE MINER RES, V16, P497, DOI 10.1359/jbmr.2001.16.3.497
   Avsian Kretchmer O, 2004, MOL ENDOCRINOL, V18, P1, DOI 10.1210/me.2003 0227
   Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae
   Bello DeOcampo D, 2003, CURR DRUG TARGETS, V4, P197, DOI 10.2174/1389450033491118
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Bendre MS, 2002, CANCER RES, V62, P5571
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008 5472.CAN 05 1891
   Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002 220918
   Eisenberger S, 2004, ANAL BIOCHEM, V335, P260, DOI 10.1016/j.ab.2004.09.037
   Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015
   Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802
   Ferguson VL, 2003, BONE, V33, P387, DOI 10.1016/S8756 3282(03)00199 6
   Gazzerro E, 2005, ENDOCRINOLOGY, V146, P655, DOI 10.1210/en.2004 0766
   Gazzerro E, 2003, BONE, V32, P111, DOI 10.1016/S8756 3282(02)00948 1
   Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459
   Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092 8674(00)80196 8
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   HARRIS SE, 1994, PROSTATE, V24, P204, DOI 10.1002/pros.2990240406
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   Haudenschild DR, 2004, CANCER RES, V64, P8276, DOI 10.1158/0008 5472.CAN 04 2251
   Holen I, 2005, BREAST CANCER RES TR, V92, P207, DOI 10.1007/s10549 005 2419 8
   HORIGUCHI J, 1988, BIOCHEM BIOPH RES CO, V157, P395, DOI 10.1016/S0006 291X(88)80060 3
   Iwamura M, 1996, UROLOGY, V48, P317, DOI 10.1016/S0090 4295(96)00182 3
   Jemal A, 2002, CA CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Keller ET, 2001, CANCER METAST REV, V20, P333, DOI 10.1023/A:1015599831232
   Lee Y, 2003, J ORTHOP RES, V21, P62, DOI 10.1016/S0736 0266(02)00095 5
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Pettaway CA, 1996, CLIN CANCER RES, V2, P1627
   Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398 247
   Reno C, 1997, BIOTECHNIQUES, V22, P1082, DOI 10.2144/97226bm16
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Savarese DMF, 1998, PROSTATE, V34, P80, DOI 10.1002/(SICI)1097 0045(19980201)34:2<80::AID PROS2>3.0.CO;2 N
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   SUNDQUIST KT, 1995, BONE, V16, P39, DOI 10.1016/S8756 3282(94)00005 0
   ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016
   THALMANN GN, 1994, CANCER RES, V54, P2577
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Van Der Horst G, 2002, BONE, V31, P661, DOI 10.1016/S8756 3282(02)00903 1
   Van der Pluijm G, 2001, J BONE MINER RES, V16, P1077, DOI 10.1359/jbmr.2001.16.6.1077
   Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959 437X(01)00259 3
   WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432 0436.1991.tb00250.x
   Wetterwald A, 2002, AM J PATHOL, V160, P1143, DOI 10.1016/S0002 9440(10)64934 6
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Wozney JM, 1998, EUR J ORAL SCI, V106, P160, DOI 10.1111/j.1600 0722.1998.tb02170.x
   Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097 0215(19980911)77:6<887::AID IJC15>3.0.CO;2 Z
   Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543
   Yee LD, 2000, ANTICANCER RES, V20, P4379
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   Yoshimura Y, 2001, J BONE MINER RES, V16, P876, DOI 10.1359/jbmr.2001.16.5.876
   Zhang DH, 2002, J BONE MINER RES, V17, P293, DOI 10.1359/jbmr.2002.17.2.293
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 66
TC 83
Z9 94
U1 0
U2 5
PU AMER SOC INVESTIGATIVE PATHOLOGY, INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3993 USA
SN 0002 9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD JAN
PY 2007
VL 170
IS 1
BP 160
EP 175
DI 10.2353/ajpath.2007.051276
PG 16
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA 122RA
UT WOS:000243242900015
PM 17200191
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Bozzo, J
   D'Agostino, A
   Dulsat, C
AF Bozzo, J.
   D'Agostino, A.
   Dulsat, C.
TI Therapeutic targets for osteoporosis
SO DRUGS OF THE FUTURE
LA English
DT Article
ID FOLLICLE STIMULATING HORMONE; CALCIUM SENSING RECEPTOR; ANABOLIC
   THERAPIES; BONE RESORPTION; SEX STEROIDS; VITAMIN D; MECHANISMS;
   PATHOGENESIS; PHARMACOLOGY; PROSTANOIDS
AB Osteoporosis is the most common type of metabolic bone disease. It is characterized by low bone mass and deterioration of bone microarchitecture that leads to bone fragility and increased susceptibility to fractures. Generally, it increases progressively with age and decreased gonadal function and is the result of a negative skeletal balance observed when osteoclasts increase in number or activity, osteoblasts decrease in number or activity, or a combination of these factors. Most drugs marketed for the treatment of osteoporosis act by decreasing bone resorption or by increasing bone formation. The search for effective treatment strategies for osteoporosis continues, with special attention focused on the identification of novel targets for drug development. In the interest of facilitating access to information on the major targets for therapeutic intervention in osteoporosis, this article presents those targets that are currently under active investigation.
C1 [Bozzo, J.; D'Agostino, A.; Dulsat, C.] Prous Sci, Barcelona 08025, Spain.
RP Bozzo, J (通讯作者)，Prous Sci, Provenza 388, Barcelona 08025, Spain.
CR Balasch J, 2003, HUM REPROD UPDATE, V9, P207, DOI 10.1093/humupd/dmg017
   Blair JM, 2007, INT J BIOCHEM CELL B, V39, P1077, DOI 10.1016/j.biocel.2006.11.008
   Bos CL, 2004, INT J BIOCHEM CELL B, V36, P1187, DOI 10.1016/j.biocel.2003.08.006
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chabbert Buffet N, 2005, HUM REPROD UPDATE, V11, P293, DOI 10.1093/humupd/dmi002
   Cranney A, 2006, CAN MED ASSOC J, V175, P52, DOI 10.1503/cmaj.050929
   Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082
   Ferrari P, 2003, BEST PRACT RES CL EN, V17, P575, DOI 10.1016/S1521 690X(03)00053 8
   Francis RM, 2006, QJM INT J MED, V99, P355, DOI 10.1093/qjmed/hcl031
   Fuller PJ, 2005, HYPERTENSION, V46, P1227, DOI 10.1161/01.HYP.0000193502.77417.17
   Garcia C, 1996, J BONE MINER RES, V11, P1619
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Huang C, 2007, J CELL MOL MED, V11, P923, DOI 10.1111/j.1582 4934.2007.00114.x
   Ikeda K, 2007, ENDOCR J, V54, P1, DOI 10.1507/endocrj.KR 82
   Keen R, 2007, BEST PRACT RES CL RH, V21, P109, DOI 10.1016/j.berh.2006.10.004
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Kiechl Stefan, 2006, Expert Rev Cardiovasc Ther, V4, P801, DOI 10.1586/14779072.4.6.801
   Kirk D, 2004, AM J MANAG CARE, V10, P445
   Lane NE, 2003, ARTHRITIS RES THER, V5, P214, DOI 10.1186/ar797
   Lee SW, 2003, BONE, V32, P217, DOI 10.1016/S8756 3282(02)00976 6
   Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432 1033.2002.03014.x
   Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385
   Martin TJ, 2008, OSTEOPOROSIS INT, V19, P1125, DOI 10.1007/s00198 008 0575 5
   Mostafavi Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176
   Ohmichi M, 2005, ENDOCR J, V52, P161, DOI 10.1507/endocrj.52.161
   Osborne CK, 2005, J CLIN ONCOL, V23, P1616, DOI 10.1200/JCO.2005.10.036
   Painter Stephanie E, 2006, Endocr Pract, V12, P436
   Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100
   Pfeilschifter J, 2000, J CLIN ONCOL, V18, P1570, DOI 10.1200/JCO.2000.18.7.1570
   Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233
   Purdue BW, 2002, RECEPTOR CHANNEL, V8, P243, DOI 10.1080/10606820213681
   Rauner M, 2007, INT ARCH ALLERGY IMM, V143, P31, DOI 10.1159/000098223
   Rodriguez M, 2005, AM J PHYSIOL RENAL, V288, pF253, DOI 10.1152/ajprenal.00302.2004
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Selent J, 2007, J BIOL CHEM, V282, P16492, DOI 10.1074/jbc.M700242200
   Shoback D, 2007, J CLIN ENDOCR METAB, V92, P747, DOI 10.1210/jc.2007 0042
   Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739
   Stepan J J, 2003, Endocr Regul, V37, P225
   Stoch SA, 2008, CLIN PHARMACOL THER, V83, P172, DOI 10.1038/sj.clpt.6100450
   Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178
   Ulloa Aguirre A, 1998, HUM REPROD UPDATE, V4, P260, DOI 10.1093/humupd/4.3.260
   Ushikubi F, 2000, JPN J PHARMACOL, V83, P279, DOI 10.1254/jjp.83.279
   Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003 0003
NR 46
TC 0
Z9 0
U1 0
U2 3
PU PROUS SCIENCE, SAU THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377 8282
EI 2013 0368
J9 DRUG FUTURE
JI Drug Future
PD SEP
PY 2008
VL 33
IS 9
BP 803
EP 810
DI 10.1358/dof.2008.033.09.1243417
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 379BG
UT WOS:000261368900008
DA 2025 08 17
ER

PT J
AU Schnoke, M
   Midura, RJ
AF Schnoke, Matthew
   Midura, Ronald J.
TI Pulsed electromagnetic fields rapidly modulate intracellular signaling
   events in osteoblastic cells: Comparison to parathyroid hormone and
   insulin
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE pulsed electromagnetic field (PEMF); parathyroid hormone (PTH); insulin
   receptor substrate 1 (IRS 1); endothelial nitric oxide synthase (eNOS);
   S6 ribosomal subunit
ID NITRIC OXIDE SYNTHASE; GROWTH FACTOR I; PROTEIN S6 PHOSPHORYLATION;
   RECEPTOR SUBSTRATE 1; BONE; KINASE; IDENTIFICATION; EXPRESSION; SITES;
   IRS 1
AB Pulsed electromagnetic field (PEMF) devices are approved for the healing of bone nonunions, but there is a lack of understanding as to their mechanism of action at the cell and molecular level. Intermittent parathyroid hormone (PTH) therapy is currently utilized for treatment of osteoporosis, and is also being investigated for the purpose of augmenting fracture healing. Insulin and IGF 1 are also thought to play important anabolic roles in osteogenesis. In this report, signaling pathways activated by acute PTH or insulin treatments were compared to those activated by PEMF treatment in osteoblast like cells. Some signaling molecules like the extracellular response kinases 1/2 (Erk1/2) and the cAMP response element binding protein (CREB) were activated by insulin and PTH, respectively, but not by PEMF treatment. Other signaling molecules like the insulin receptor substrate 1 (IRS 1), the S6 ribosomal subunit kinase, and the endothelial nitric oxide synthase (eNOS) were phosphorylated by PTH, insulin, and PEMF to the same relative extent and within the same time frame. IRS 1, eNOS, and S6 have been implicated in bone anabolism, and our results suggest that the anabolic effects of PEMF may be mediated, in part, through the activation of these proteins. (c) 2007 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.
C1 Cleveland Clin, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44195 USA.
   Cleveland Clin, Orthopaed Res Ctr, Lerner Res Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation
RP Midura, RJ (通讯作者)，Cleveland Clin, Dept Biomed Engn, Lerner Res Inst, ND20,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM midurar@ccf.org
CR Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Altland OD, 2004, J THROMB HAEMOST, V2, P637, DOI 10.1111/j.1538 7836.2004.00655.x
   BANDI HR, 1993, J BIOL CHEM, V268, P4530
   Bikle DD, 2002, J BONE MINER RES, V17, P1570, DOI 10.1359/jbmr.2002.17.9.1570
   Brighton CT, 2001, J BONE JOINT SURG AM, V83A, P1514, DOI 10.2106/00004623 200110000 00009
   Cham CM, 2005, J IMMUNOL, V174, P4670, DOI 10.4049/jimmunol.174.8.4670
   Diniz P, 2002, NITRIC OXIDE BIOL CH, V7, P18, DOI 10.1016/S1089 8603(02)00004 6
   Duan W, 2006, CURR DRUG TARGETS, V7, P691, DOI 10.2174/138945006777435353
   Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683
   Heijnen HFG, 2004, J HISTOCHEM CYTOCHEM, V52, P1277, DOI 10.1369/jhc.4A6307.2004
   Hoshi K, 2004, J BONE MINER RES, V19, P214, DOI 10.1359/JBMR.0301221
   Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200
   Kawane T, 1999, ENDOCRINOLOGY, V140, P871, DOI 10.1210/en.140.2.871
   Kim SJ, 2000, BIOCHEM BIOPH RES CO, V278, P712, DOI 10.1006/bbrc.2000.3862
   Kim SS, 2002, EXP MOL MED, V34, P53, DOI 10.1038/emm.2002.8
   Lagumdzija A, 2004, ACTA PHYSIOL SCAND, V182, P29, DOI 10.1111/j.1365 201X.2004.01303.x
   Lécureuil C, 2005, MOL ENDOCRINOL, V19, P1812, DOI 10.1210/me.2004 0289
   MARTIN TJ, 1976, NATURE, V260, P436, DOI 10.1038/260436a0
   Midura RJ, 2005, J ORTHOP RES, V23, P1035, DOI 10.1016/j.orthres.2005.03.015
   Naruse K, 2003, J BONE MINER RES, V18, P360, DOI 10.1359/jbmr.2003.18.2.360
   Oudit GY, 2004, J MOL CELL CARDIOL, V37, P449, DOI 10.1016/j.yjmcc.2004.05.015
   Patterson TE, 2006, BIOELECTROMAGNETICS, V27, P535, DOI 10.1002/bem.20244
   Radimerski T, 2000, BIOCHEMISTRY US, V39, P5766, DOI 10.1021/bi9927484
   Reher P, 2002, BONE, V31, P236, DOI 10.1016/S8756 3282(02)00789 5
   Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934
   Sato M, 1997, ENDOCRINOLOGY, V138, P4330, DOI 10.1210/en.138.10.4330
   Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058
   Smith TL, 2004, J ORTHOPAED RES, V22, P80, DOI 10.1016/S0736 0266(03)00157 8
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Thrailkill KM, 2005, AM J PHYSIOL ENDOC M, V289, pE735, DOI 10.1152/ajpendo.00159.2005
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200
   Wimalawansa SJ, 2000, J BONE MINER RES, V15, P2240, DOI 10.1359/jbmr.2000.15.11.2240
   Yamaguchi M, 2005, ENDOCRINOLOGY, V146, P2620, DOI 10.1210/en.2004 1511
   Zborowski M, 2006, ANN BIOMED ENG, V34, P1030, DOI 10.1007/s10439 006 9126 4
NR 35
TC 45
Z9 51
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD JUL
PY 2007
VL 25
IS 7
BP 933
EP 940
DI 10.1002/jor.20373
PG 8
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 179AS
UT WOS:000247262300011
PM 17427956
OA Bronze
DA 2025 08 17
ER

PT J
AU Zinnia, MA
   Islam, AMMK
AF Zinnia, Maliha Afroj
   Islam, Abul Bashar Mir Md. Khademul
TI Fenugreek steroidal saponins hinder osteoclastogenic bone resorption by
   targeting CSF 1R which diminishes the RANKL/OPG ratio
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Fenugreek; CSF 1R; Osteoporosis
ID TRIGONELLA FOENUM GRAECUM; COLONY STIMULATING FACTOR; FACTOR KAPPA B;
   MOLECULAR DYNAMICS; RECEPTOR ACTIVATOR; OSTEOPOROTIC FRACTURES; WEB
   SERVER; PREVENTION; OSTEONECROSIS; BINDING
AB Osteoporosis is skeletal fragility caused by the excessive bone resorption due to osteoclastogenesis. But current drugs are less bioavailable and possess higher toxicity. Our study was conducted to identify safe oral bioavailable drugs from Fenugreek steroidal saponins and to delineate underlying mechanism of them to lower the osteoclastogenic bone resorption. We observed higher molecular docked binding affinities in finally selected eight hit compounds within the range of 11.0 to 10.1 kcal/mol which was greater than currently used drugs. Molecular Dynamics simulation with Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), Solvent Accessible Surface Area (SASA) and Gyration trajectory projection reinforced the stability of the protein ligand complexes. Pharmacokinetics analysis confirmed bioavailability of seven compounds out of eight, and drug likeliness and bioavailability profile evaluation indicated that they all are eligible to be developed as a potent oral inhibitor of CSF 1R. By literature mining knowledge driven analysis, RNAseq data and Molecular Dynamics Simulation, we proposed that, the hit derivatives block the CSF 1/CSF 1R induced phosphorylation signaling pathway in both osteoclast and osteoblast resulting in hindrance of RANK expression and formation of Reactive oxygen species (ROS) in osteoclast and osteoblast respectively, thus declines the RANKL/OPG ratio, lowering the osteoclast survival, proliferation and differentiation.
C1 [Zinnia, Maliha Afroj] East West Univ, Dept Pharm, Dhaka, Bangladesh.
   [Islam, Abul Bashar Mir Md. Khademul] Univ Dhaka, Dept Genet Engn & Biotechnol, Dhaka, Bangladesh.
C3 East West University Bangladesh; University of Dhaka
RP Islam, AMMK (通讯作者)，Univ Dhaka, Dept Genet Engn & Biotechnol, Dhaka, Bangladesh.
EM khademul@du.ac.bd
RI Zinnia, Maliha Afroj/JXY 5366 2024; Islam, Abul/AFD 1133 2022
OI Islam, Abul/0000 0002 7274 0855; Zinnia, Maliha
   Afroj/0000 0001 5930 6272
CR Al Oqail MM, 2013, ASIAN PAC J CANCER P, V14, P1829, DOI 10.7314/APJCP.2013.14.3.1829
   ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb 2010 11 10 r106
   Anjaneyulu K, 2018, ETHIOP J HEALTH SCI, V28, P787, DOI 10.4314/ejhs.v28i6.14
   Araee M, 2009, PAK J PHARM SCI, V22, P126
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Basch Ethan, 2003, Altern Med Rev, V8, P20
   Bauer DC, 2000, ARCH INTERN MED, V160, P517, DOI 10.1001/archinte.160.4.517
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010 4655(95)00042 E
   BERENDSEN HJC, 1987, J PHYS CHEM US, V91, P6269, DOI 10.1021/j100308a038
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bilezikian JP, 2006, NEW ENGL J MED, V355, P2278, DOI 10.1056/NEJMp068157
   BONDI A, 1964, J PHYS CHEM US, V68, P441, DOI 10.1021/j100785a001
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cadarette SM, 2009, OSTEOPOROSIS INT, V20, P1735, DOI 10.1007/s00198 009 0871 8
   Chen Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018689
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Daina A, 2017, SCI REP UK, V7, DOI 10.1038/srep42717
   Dodda LS, 2017, NUCLEIC ACIDS RES, V45, pW331, DOI 10.1093/nar/gkx312
   Dolan P, 1998, OSTEOPOROSIS INT, V8, P611, DOI 10.1007/s001980050107
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Droin N, 2010, J LEUKOCYTE BIOL, V87, P745, DOI 10.1189/jlb.1209780
   Fisch KM, 2018, OSTEOARTHR CARTILAGE, V26, P1531, DOI 10.1016/j.joca.2018.07.012
   Gambacciani M, 2014, MENOPAUSE REV, V13, P213, DOI 10.5114/pm.2014.44996
   Gibbs SDJ, 2005, MED J AUSTRALIA, V183, P549, DOI 10.5694/j.1326 5377.2005.tb07172.x
   Gong L, 2011, PHARMACOGENET GENOM, V21, P50, DOI 10.1097/FPC.0b013e328335729c
   Wiktorin HG, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7095902
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Harris CR, 2020, NATURE, V585, P357, DOI 10.1038/s41586 020 2649 2
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096 987X(199709)18:12<1463::AID JCC4>3.0.CO;2 H
   Huang W, 2012, MOL CELL BIOCHEM, V360, P71, DOI 10.1007/s11010 011 1045 5
   Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55
   Jiménez J, 2017, BIOINFORMATICS, V33, P3036, DOI 10.1093/bioinformatics/btx350
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kameo Y, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax0938
   Kim S, 2021, NUCLEIC ACIDS RES, V49, pD1388, DOI 10.1093/nar/gkaa971
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lanza F, 1998, AM J GASTROENTEROL, V93, P284, DOI 10.1111/j.1572 0241.1998.281_8_8.x
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Lees RL, 1999, J BONE MINER RES, V14, P937, DOI 10.1359/jbmr.1999.14.6.937
   Levin VA, 2018, OSTEOPOROSIS INT, V29, P1049, DOI 10.1007/s00198 018 4414 z
   Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097 2765(00)80231 2
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Lipsitch M, 2010, EPIDEMIOLOGY, V21, P383, DOI 10.1097/EDE.0b013e3181d61eeb
   Liu CZ, 2017, AAPS PHARMSCITECH, V18, P2067, DOI 10.1208/s12249 016 0684 y
   Melo MD, 2005, J AM DENT ASSOC, V136, P1675, DOI 10.14219/jada.archive.2005.0110
   Meyers MJ, 2010, BIOORG MED CHEM LETT, V20, P1543, DOI 10.1016/j.bmcl.2010.01.078
   Mishra H, 2009, BIOINFORMATION, V3, P384, DOI 10.6026/97320630003384
   Mozaffari Z, 2010, J MED PLANTS RES, V4, P1148
   Mun SH, 2020, EXP MOL MED, V52, P1239
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Nathiya S., 2014, Int. J. Pharm. Sci. Rev. Res, V27, P74
   Neelakantan N, 2014, NUTR J, V13, DOI 10.1186/1475 2891 13 7
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758 2946 3 33
   Osorio D, 2015, R J, V7, P4
   Panday A, 2015, CELL MOL IMMUNOL, V12, DOI 10.1038/cmi.2014.89
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Patil SP, 1997, ANN ALLERG ASTHMA IM, V78, P297, DOI 10.1016/S1081 1206(10)63185 7
   Pazianas M, 2013, THER CLIN RISK MANAG, V9, P395, DOI 10.2147/TCRM.S52291
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   R Core Team, 2018, Initial condition sensi
   RIGGS BL, 1992, NEW ENGL J MED, V327, P620
   RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605
   Ross FP, 2005, IMMUNOL REV, V208, P88, DOI 10.1111/j.0105 2896.2005.00331.x
   Ruggiero SL, 2009, ANNU REV MED, V60, P85, DOI 10.1146/annurev.med.60.063007.134350
   Schubert C, 2007, J BIOL CHEM, V282, P4094, DOI 10.1074/jbc.M608183200
   Sharma RD, 1996, PHYTOTHER RES, V10, P519, DOI 10.1002/(SICI)1099 1573(199609)10:6<519::AID PTR873>3.0.CO;2 T
   Singer A, 2015, MAYO CLIN PROC, V90, P53, DOI 10.1016/j.mayocp.2014.09.011
   Singh A.P.P., 2020, POTENTIAL PHYTOCHEMI, DOI [10.21203/rs.3.rs 35334/v1, DOI 10.21203/RS.3.RS 35334/V1]
   Siris ES, 1998, J BONE MINER RES, V13, P1032, DOI 10.1359/jbmr.1998.13.6.1032
   Siu SWI, 2012, J CHEM THEORY COMPUT, V8, P1459, DOI 10.1021/ct200908r
   Snehlata H.S., 2012, International Journal of Current Pharmaceutical Review and Research, V2, P169
   Sreeja S, 2010, INDIAN J MED RES, V131, P814
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2002, ARTHRITIS RES THER, V4, pS227, DOI 10.1186/ar581
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   Tiran Denise, 2003, Complement Ther Nurs Midwifery, V9, P155, DOI 10.1016/S1353 6117(03)00044 1
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tu Kristie N, 2018, P T, V43, P92
   Volkamer A, 2012, BIOINFORMATICS, V28, P2074, DOI 10.1093/bioinformatics/bts310
   Watts N, 1999, INT J CLIN PRACT, P51
   Weaver Connie M., 2012, Journal of Nutrition in Gerontology and Geriatrics, V31, P239, DOI 10.1080/21551197.2012.698220
   Wittrant Y, 2009, ENDOCRINOLOGY, V150, P4977, DOI 10.1210/en.2009 0248
   Yadav UCS, 2014, PHARM BIOL, V52, P243, DOI 10.3109/13880209.2013.826247
   Yang HB, 2019, BIOINFORMATICS, V35, P1067, DOI 10.1093/bioinformatics/bty707
   Yoshikawa M, 1997, CHEM PHARM BULL, V45, P81, DOI 10.1248/cpb.45.81
   Zhang YQ, 2014, MOL CELL BIOCHEM, V396, P249, DOI 10.1007/s11010 014 2160 x
   Zhang ZG, 2014, INT J MOL SCI, V15, P17130, DOI 10.3390/ijms150917130
   Zhao S, 2016, IRISH J MED SCI, V185, P581, DOI 10.1007/s11845 015 1309 2
NR 94
TC 19
Z9 19
U1 1
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD SEP 1
PY 2021
VL 186
BP 351
EP 364
DI 10.1016/j.ijbiomac.2021.06.197
EA JUL 2021
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA UF2UK
UT WOS:000688433700006
PM 34217743
DA 2025 08 17
ER

PT J
AU Kong, XY
   Li, XM
   Zhang, C
   Zhu, LL
   Wan, HY
   Zhu, J
   Liu, CL
   Su, HC
   Qin, QX
   Chen, WH
   Lin, N
AF Kong, Xiangying
   Li, Xiaomin
   Zhang, Cun
   Zhu, Liuluan
   Wan, Hongye
   Zhu, Jia
   Liu, Cuiling
   Su, Hongchang
   Qin, Qingxia
   Chen, Weiheng
   Lin, Na
TI Aqueous Fraction of Huogu Formula Promotes Osteogenic Differentiation of
   Bone Marrow Stromal Cells Through the BMP and Wnt Signaling Pathways
SO REJUVENATION RESEARCH
LA English
DT Article
DE BMP; Wnt; aqueous fraction of HG
ID MESENCHYMAL STEM CELLS; CORTICOSTEROID INDUCED OSTEONECROSIS;
   STEROID INDUCED OSTEONECROSIS; FEMORAL HEAD; OSTEOBLAST DIFFERENTIATION;
   IN VITRO; INVERSE RELATIONSHIP; PROXIMAL FEMUR; REGENERATION; VIVO
AB Our recent studies have shown that Huogu (HG) formula was effective both in clinic experience and in experimental osteonecrosis of the femoral head (ONFH). Given that defective of bone marrow stromal cells (MSCs) contribute to the development of osteonecrosis and MSCs show enormous potential in the treatment of ONFH, especially to aging people. How HG impacts the differentiation of MSCs and what is the underlying cellular and molecular mechanism remains largely unknown. Here, we found that an aqueous fraction of HG (HGA) significantly increased the alkaline phosphatase (ALP) activity, mineralized nodules, and migration of MSCs in a dose dependent manner. Meanwhile, HGA could enhance the mRNA and protein expression of Runt related transcription factor 2 (Runx2), Alp, Bmp2, osteocalcin (Ocn), and Osterix (Osx). Further investigation of the molecular mechanisms revealed that HGA treatment obviously increased expression, secretion, and activation of bone morphogenetic protein (BMP) 2 and beta catenin, two key regulators of the BMP or Wnt signaling pathway. Furthermore, osteogenic differentiation of MSCs could be blocked by using pharmacological inhibitors for these signaling pathways such as Noggin and Dkk 1. Besides, HGA could inhibit adipogenic differentiation of MSCs. Our study reveals that HGA promotes the osteogenesis of MSCs via the BMP and Wnt signaling pathways. Our findings provide mechanistic insights into the role of HG in treating ONFH.
C1 [Kong, Xiangying; Li, Xiaomin; Zhang, Cun; Wan, Hongye; Liu, Cuiling; Su, Hongchang; Qin, Qingxia; Lin, Na] China Acad Chinese Med Sci, Inst Chinese Mat Med, 16 Nanxiaojie, Beijing 100700, Peoples R China.
   [Zhu, Liuluan] Capital Med Univ, Beijing Ditan Hosp, Inst Infect Dis, Beijing, Peoples R China.
   [Zhu, Liuluan] Beijing Key Lab Emerging Infect Dis, Beijing, Peoples R China.
   [Zhu, Jia; Chen, Weiheng] China Acad Chinese Med Sci, Wangjing Hosp, Beijing 100102, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Institute of Chinese Materia
   Medica, CACMS; Capital Medical University; China Academy of Chinese
   Medical Sciences; Wang Jing Hospital, CACMS
RP Lin, N (通讯作者)，China Acad Chinese Med Sci, Inst Chinese Mat Med, 16 Nanxiaojie, Beijing 100700, Peoples R China.; Chen, WH (通讯作者)，China Acad Chinese Med Sci, Wangjing Hosp, Beijing 100102, Peoples R China.
EM drchenweiheng@163.com; nlin@icmm.ac.cn
RI ; wan, ye/AAP 9997 2021
OI Wan, Ye/0000 0002 3909 0985; 
FU National Natural Science Foundation of China [81173417, 81373656]
FX This study was supported by grants from the National Natural Science
   Foundation of China (Nos. 81173417 and 81373656).
CR Bäckesjö CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bosch Marce M, 2007, CIRC RES, V101, P1310, DOI 10.1161/CIRCRESAHA.107.153346
   Chen FP, 2013, CLIMACTERIC, V16, P154, DOI 10.3109/13697137.2012.672496
   Chen Wei heng, 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P1054
   Chen WH, 2012, CHIN J INTEGR MED, V18, P378, DOI 10.1007/s11655 012 1086 y
   Cui QJ, 2006, J BONE JOINT SURG AM, V88A, P167, DOI 10.2106/JBJS.F.00891
   Freire MO, 2011, TISSUE ENG PT A, V17, P2911, DOI 10.1089/ten.tea.2010.0584
   Gangji V, 2003, J RHEUMATOL, V30, P348
   HARRISON G, 1995, J BONE MINER RES, V10, P568, DOI 10.1002/jbmr.5650100409
   Hernigou P, 1999, J BONE JOINT SURG BR, V81B, P349, DOI 10.1302/0301 620X.81B2.8818
   Hernigou P, 1997, J BONE JOINT SURG AM, V79A, P1047, DOI 10.2106/00004623 199707000 00011
   Hong L, 2009, J STEROID BIOCHEM, V114, P180, DOI 10.1016/j.jsbmb.2009.02.001
   Itasaki N, 2010, DEV DYNAM, V239, P16, DOI 10.1002/dvdy.22009
   Jiang TR, 2015, INT J CLIN EXP PATHO, V8, P2946
   Jiang YN, 2014, J TRADIT CHIN MED, V34, P342, DOI 10.1016/S0254 6272(14)60100 X
   Jin HT, 2012, INT ORTHOP, V36, P2589, DOI 10.1007/s00264 012 1674 7
   Jureus J, 2012, ACTA ORTHOP, V83, P511, DOI 10.3109/17453674.2012.729184
   Kawate K, 2006, ARTIF ORGANS, V30, P960, DOI 10.1111/j.1525 1594.2006.00333.x
   Kempen DHR, 2008, BIOMATERIALS, V29, P3245, DOI 10.1016/j.biomaterials.2008.04.031
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lee JS, 2006, J ORTHOP RES, V24, P604, DOI 10.1002/jor.20078
   Li XiaoMin Li XiaoMin, 2015, Chinese Journal of Information on Traditional Chinese Medicine, V22, P63
   Li X, 2014, INT J CLIN EXP PATHO, V7, P5024
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Liu HY, 2011, BIOMATERIALS, V32, P6773, DOI 10.1016/j.biomaterials.2011.05.080
   Luo J, 2005, CURR GENE THER, V5, P167, DOI 10.2174/1566523053544218
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317
   Matsuya H, 2008, MOD RHEUMATOL, V18, P132, DOI 10.1007/s10165 008 0023 6
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   Müller I, 2008, LEUKEMIA, V22, P2054, DOI 10.1038/leu.2008.217
   Narayanan K, 2001, P NATL ACAD SCI USA, V98, P4516, DOI 10.1073/pnas.081075198
   Noël D, 2004, STEM CELLS, V22, P74, DOI 10.1634/stemcells.22 1 74
   Olivares Navarrete R, 2011, BIOMATERIALS, V32, P6399, DOI 10.1016/j.biomaterials.2011.05.036
   Partridge K, 2002, BIOCHEM BIOPH RES CO, V292, P144, DOI 10.1006/bbrc.2002.6623
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Sammons J, 2004, STEM CELLS DEV, V13, P273, DOI 10.1089/154732804323099208
   Sheng Hui H, 2007, J Orthop Surg Res, V2, P15, DOI 10.1186/1749 799X 2 15
   Skarzynska J, 2011, CONNECT TISSUE RES, V52, P408, DOI 10.3109/03008207.2010.551568
   Suh KT, 2005, CLIN ORTHOP RELAT R, P220, DOI 10.1097/01.blo.0000150568.16133.3c
   Taipaleenmäki H, 2011, EXP CELL RES, V317, P745, DOI 10.1016/j.yexcr.2010.12.015
   Vélez R, 2012, ARCH ORTHOP TRAUM SU, V132, P1611, DOI 10.1007/s00402 012 1584 6
   Wan Rong, 2010, Zhongguo Gu Shang, V23, P915
   Wang BL, 2008, ORTHOPEDICS, V31, P444, DOI 10.3928/01477447 20080501 33
   Wang GJ, 2000, CLIN ORTHOP RELAT R, P295, DOI 10.1097/00003086 200001000 00030
   Wang WW, 2015, ONCOTARGET, V6, P42276, DOI 10.18632/oncotarget.5514
   Watters JW, 2007, ARTHRITIS RHEUM, V56, P2999, DOI 10.1002/art.22836
   Wen Q, 2014, J TRANSL MED, V12, DOI 10.1186/1479 5876 12 114
   Xu NR, 2013, EXP MOL PATHOL, V94, P33, DOI 10.1016/j.yexmp.2012.08.003
NR 50
TC 6
Z9 10
U1 0
U2 19
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549 1684
EI 1557 8577
J9 REJUV RES
JI Rejuv. Res.
PD DEC
PY 2016
VL 19
IS 6
BP 509
EP 520
DI 10.1089/rej.2015.1795
PG 12
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA EH5TB
UT WOS:000391834700008
PM 27097330
DA 2025 08 17
ER

PT J
AU Huang, JM
   Bao, Y
   Xiang, W
   Jing, XZ
   Guo, JC
   Yao, XD
   Wang, R
   Guo, FJ
AF Huang, Jun ming
   Bao, Yuan
   Xiang, Wei
   Jing, Xing zhi
   Guo, Jia chao
   Yao, Xu dong
   Wang, Rui
   Guo, Feng jin
TI Icariin Regulates the Bidirectional Differentiation of Bone Marrow
   Mesenchymal Stem Cells through Canonical Wnt Signaling Pathway
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID AGE RELATED OSTEOPOROSIS; OSTEOGENIC DIFFERENTIATION; OSTEOBLAST
   DIFFERENTIATION; ADIPOGENIC DIFFERENTIATION; POSTMENOPAUSAL WOMEN; MASS
   PHENOTYPE; ADIPOSE TISSUE; FAT CONTENT; PPAR GAMMA; RECEPTOR
AB Fat infiltration within the bone marrow is easily observed in some post menopausal women. Those fats are mainly derived from bone marrow mesenchymal stem cells (BMMSCs). The increment of adipocytes derived from BMMSCs leads to decreased osteoblasts derived from BMMSCs, so the bidirectional differentiation of BMMSCs significantly contributes to osteoporosis. Icariin is the main extractive of Herba Epimedii which is widely used in traditional Chinese medicine. In this experiment, we investigated the effect of icariin on the bidirectional differentiation of BMMSCs through quantitative real time PCR, immunofluorescence, western blot, and tissue sections in vitro and in vivo. We found that icariin obviously promotes osteogenesis and inhibits adipogenesis through detecting staining and gene expression. Micro CT analysis showed that icariin treatment alleviated the loss of cancellous bone of the distal femur in ovariectomized (OVX) mice. H&E staining analysis showed that icariin treated OVX mice obtained higher bone mass and fewer bone marrow lipid droplets than OVX mice. Western blot and immunofluorescence showed that icariin regulates the bidirectional differentiation of BMMSCs via canonical Wnt signaling. This study demonstrates that icariin exerts its antiosteoporotic effect by regulating the bidirectional differentiation of BMMSCs through the canonical Wnt signaling pathway.
C1 [Huang, Jun ming; Bao, Yuan; Xiang, Wei; Jing, Xing zhi; Guo, Jia chao; Yao, Xu dong; Wang, Rui; Guo, Feng jin] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Orthoped, Wuhan 430030, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology
RP Guo, FJ (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Orthoped, Wuhan 430030, Hubei, Peoples R China.
EM fjguo@tjh.tjmu.edu.cn
RI ; yao, xvdong/HSG 0200 2023
OI Huang, Jun ming/0000 0002 6800 2788; 
FU National Natural Science Foundation of China [81371915]
FX The present study was supported by the National Natural Science
   Foundation of China (no. 81371915).
CR Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Bäckesjö CM, 2009, CELLS TISSUES ORGANS, V189, P93, DOI 10.1159/000151744
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bateman ME, 2017, PHYTOMEDICINE, V27, P39, DOI 10.1016/j.phymed.2017.02.003
   Bian Qin, 2012, Front Biosci (Elite Ed), V4, P1224
   Blake GM, 2009, BONE, V44, P495, DOI 10.1016/j.bone.2008.11.003
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cao J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040842
   Carbonare LD, 2009, ARTHRITIS RHEUM US, V60, P3356, DOI 10.1002/art.24884
   Casado Díaz A, 2017, EXP GERONTOL, V90, P71, DOI 10.1016/j.exger.2017.01.024
   Chen XD, 2002, J BONE MINER RES, V17, P331, DOI 10.1359/jbmr.2002.17.2.331
   Chung BH, 2008, BIOCHEM BIOPH RES CO, V376, P404, DOI 10.1016/j.bbrc.2008.09.001
   Cock TA, 2004, EMBO REP, V5, P1007, DOI 10.1038/sj.embor.7400254
   Egermann M, 2010, J ORTHOP RES, V28, P798, DOI 10.1002/jor.21041
   Gao B., 2014, PLOS ONE, V9
   Ge CX, 2016, J CELL PHYSIOL, V231, P587, DOI 10.1002/jcp.25102
   Griffith JF, 2005, RADIOLOGY, V236, P945, DOI 10.1148/radiol.2363041425
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Guntur AR, 2011, ANN NY ACAD SCI, V1237, P58, DOI 10.1111/j.1749 6632.2011.06213.x
   Hasan HF, 2017, BIOCHEM CELL BIOL, V95, P400, DOI 10.1139/bcb 2016 0142
   Hsiao HB, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 1737 9
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Huang J, 2007, LIFE SCI, V81, P832, DOI 10.1016/j.lfs.2007.07.015
   Huang YL, 2017, J NAT PROD, V80, P246, DOI 10.1021/acs.jnatprod.5b01164
   Idris AI, 2009, CELL METAB, V10, P139, DOI 10.1016/j.cmet.2009.07.006
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kim SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067504
   Kobayashi H, 2000, BIOCHEM BIOPH RES CO, V273, P630, DOI 10.1006/bbrc.2000.2981
   Li H, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00045
   Li WK, 2015, EXP CELL RES, V339, P367, DOI 10.1016/j.yexcr.2015.10.011
   Little RD, 2002, NEW ENGL J MED, V347, P943
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lu YF, 2014, MOLECULES, V19, P18179, DOI 10.3390/molecules191118179
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   Maurin AC, 2000, BONE, V26, P485, DOI 10.1016/S8756 3282(00)00252 0
   Menagh PJ, 2010, J BONE MINER RES, V25, P757, DOI 10.1359/jbmr.091015
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Sato K, 2017, BIOSCI BIOTECH BIOCH, V81, P1241, DOI 10.1080/09168451.2017.1282809
   Song L, 2004, FASEB J, V18, P980, DOI 10.1096/fj.03 1100fje
   Song Shuang Hong, 2016, Bone Rep, V5, P262, DOI 10.1016/j.bonr.2016.09.001
   Sreejit P, 2012, CELL TISSUE RES, V350, P55, DOI 10.1007/s00441 012 1458 9
   Tang XL, 2015, MOL CELL ENDOCRINOL, V413, P78, DOI 10.1016/j.mce.2015.06.013
   Tseng KY, 2015, ONCOTARGET, V6, P14874, DOI 10.18632/oncotarget.3900
   Vanella L, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt176
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wang L, 2015, CHEM BIOL INTERACT, V242, P255, DOI 10.1016/j.cbi.2015.10.010
   Wang PZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148372
   Wei QS, 2017, BIOMED PHARMACOTHER, V91, P581, DOI 10.1016/j.biopha.2017.04.019
   Weng TJ, 2014, J BONE MINER RES, V29, P820, DOI 10.1002/jbmr.2087
   WU L, 2016, BIOMED RES INT, V2016
   Wu T, 2017, INT J MOL MED, V39, P984, DOI 10.3892/ijmm.2017.2906
   Wu YQ, 2015, CELL PROLIFERAT, V48, P375, DOI 10.1111/cpr.12185
   Wu ZD, 2017, BIOMED PHARMACOTHER, V94, P1, DOI 10.1016/j.biopha.2017.07.071
   Yan YC, 2015, INT J MOL MED, V35, P1625, DOI 10.3892/ijmm.2015.2153
   Ye CY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111780
   Ye Y., 2012, BIOMEDICINE PHARMACO, V88, P384
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zhang Y., 2016, SCI REPORTS, V5
   Zheng ZG, 2016, BIOCHEM PHARMACOL, V122, P42, DOI 10.1016/j.bcp.2016.10.016
   Zhou ZB, 2016, ONCOTARGET, V7, P71998, DOI 10.18632/oncotarget.12456
NR 65
TC 29
Z9 34
U1 2
U2 31
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PY 2017
VL 2017
AR 8085325
DI 10.1155/2017/8085325
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA FS0XB
UT WOS:000419496100001
PM 29445413
OA Green Submitted, hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Lespessailles, E
   Chapurlat, R
AF Lespessailles, E.
   Chapurlat, R.
TI High fracture risk patients with glucocorticoid induced osteoporosis
   should get an anabolic treatment first
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Glucocorticoid; Fracture; Bisphosphonate; Denosumab; Teriparatide; Bone
   mineral density
ID PARATHYROID HORMONE; ZOLEDRONIC ACID; ORAL CORTICOSTEROIDS;
   BONE FORMATION; DOUBLE BLIND; TERIPARATIDE; PREVENTION; ALENDRONATE;
   MECHANISMS; MANAGEMENT
AB Long term glucocorticoid (GC) therapy induces glucocorticoid induced osteoporosis (GIOP) and its associated fractures. Most specialty organizations recommend bisphosphonates as first line therapies based only on bone mineral density efficacy data. Effective treatment of GIOP based on head to head trials with fracture endpoint has not yet been established. The pathophysiologic mechanisms of GIOP that lead to the detrimental effects on bone are not yet fully elucidated. Although GCs in an early and transitory period promote osteoclastic activity, in the current paper, we outline why GIOP is in fact a disease of the bone formation and then provide the rationale for the use of bone forming agents as first line therapy for patients with high fracture risk in GIOP.
C1 [Lespessailles, E.] Univ Orleans, Lab I3MTO, EA 4708, F 45067 Orleans, France.
   [Lespessailles, E.] Reg Hosp Orleans, Dept Rheumatol, Translat Med Res Platform, 14 Ave Hop, F 45067 Orleans 2, France.
   [Chapurlat, R.] Univ Lyon, Hop E Herriot, INSERM, UMR 1033, Lyon, France.
C3 Universite de Orleans; Centre Hospitalier Universitaire d'Orleans; CHU
   Lyon; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite Claude Bernard Lyon 1
RP Lespessailles, E (通讯作者)，Univ Orleans, Lab I3MTO, EA 4708, F 45067 Orleans, France.; Lespessailles, E (通讯作者)，Reg Hosp Orleans, Dept Rheumatol, Translat Med Res Platform, 14 Ave Hop, F 45067 Orleans 2, France.
EM eric.lespessailles@chr orleans.fr
RI LESPESSAILLES, Eric/JVM 7803 2024; CHAPURLAT, ROLAND/AAU 1165 2021
OI LESPESSAILLES, Eric/0000 0003 1009 8518; 
CR Achiou Z, 2015, BONE, V81, P691, DOI 10.1016/j.bone.2015.09.010
   Adami G, 2019, OSTEOPOROSIS INT, V30, P1145, DOI 10.1007/s00198 019 04906 x
   Albert SG, 2017, ENDOCR PRACT, V23, P841, DOI 10.4158/EP161678.RA
   Amiche MA, 2016, OSTEOPOROSIS INT, V27, P1709, DOI 10.1007/s00198 015 3455 9
   Balasubramanian A, 2016, OSTEOPOROSIS INT, V27, P3239, DOI 10.1007/s00198 016 3646 z
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Briot K, 2014, JOINT BONE SPINE, V81, P493, DOI 10.1016/j.jbspin.2014.10.001
   Buckley L, 2017, ARTHRITIS RHEUMATOL, V69, P1521, DOI [10.1002/art.40137, 10.1002/acr.23279]
   Capriani C, 2012, J BONE MINER RES, V27, P2419, DOI 10.1002/jbmr.1800
   Chandler H, 2019, OSTEOPOROSIS INT, V30, P1607, DOI 10.1007/s00198 019 04999 4
   Cipriani C, 2013, J BONE MINER RES, V28, P431, DOI 10.1002/jbmr.1837
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Dempster DW, 2016, J BONE MINER RES, V31, P1527, DOI 10.1002/jbmr.2825
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Fardet L, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000647
   Ferrari S, 2009, Rev Med Suisse, V5, P1325
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Geusens P, 2018, J BONE MINER RES, V33, P783, DOI 10.1002/jbmr.3384
   Gilsenan A, 2018, OSTEOPOROSIS INT, V29, P2335, DOI 10.1007/s00198 018 4604 8
   Glüer CC, 2013, J BONE MINER RES, V28, P1355, DOI 10.1002/jbmr.1870
   Goltzman D, 2008, ARCH BIOCHEM BIOPHYS, V473, P218, DOI 10.1016/j.abb.2008.03.003
   Guañabens N, 2014, CURR OSTEOPOROS REP, V12, P90, DOI 10.1007/s11914 014 0197 0
   Hagino H, 2019, OSTEOPOROSIS INT, V30, P2027, DOI 10.1007/s00198 019 05038 y
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Lane N.E., 2011, IBMS Bonekey, V8, P229, DOI DOI 10.1138/20110511
   Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914
   Lekamwasam S, 2012, OSTEOPOROSIS INT, V23, P2257, DOI 10.1007/s00198 012 1958 1
   Lespessailles E, 2013, JOINT BONE SPINE, V80, P258, DOI 10.1016/j.jbspin.2012.08.005
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Mellibovsky L, 2015, J BONE MINER RES, V30, P1651, DOI 10.1002/jbmr.2497
   Murphy DR, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 213
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Overman RA, 2013, ARTHRIT CARE RES, V65, P294, DOI 10.1002/acr.21796
   Pazianas M, 2007, CLIN THER, V29, P1548, DOI 10.1016/j.clinthera.2007.08.008
   Reid DM, 2009, LANCET, V373, P1253, DOI 10.1016/S0140 6736(09)60250 6
   Rossini M, 2016, REUMATISMO, V68, P1, DOI 10.4081/reumatismo.2016.870
   Ruggiero SL, 2009, AUST ENDOD J, V35, P119, DOI 10.1111/j.1747 4477.2009.00213.x
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 2019, ARTHRITIS RHEUMATOL, V71, P1174, DOI 10.1002/art.40874
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Sato D, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115331
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Subbiah V, 2010, OSTEOPOROSIS INT, V21, P1041, DOI 10.1007/s00198 009 1004 0
   Takahata M, 2012, ARTHRITIS RHEUM US, V64, P3649, DOI 10.1002/art.34639
   Ton FN, 2005, J BONE MINER RES, V20, P464, DOI 10.1359/JBMR.041125
   Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
   van Staa TP, 2000, QJM MON J ASSOC PHYS, V93, P105, DOI 10.1093/qjmed/93.2.105
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
NR 49
TC 13
Z9 13
U1 0
U2 5
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD OCT
PY 2020
VL 31
IS 10
BP 1829
EP 1834
DI 10.1007/s00198 020 05568 w
EA AUG 2020
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA NO2WR
UT WOS:000558598000002
PM 32780152
DA 2025 08 17
ER

PT J
AU Matsui, M
   Kaihara, Y
   Honda, Y
   Nishiyama, N
   Miura, Y
AF Matsui, Makoto
   Kaihara, Yuka
   Honda, Yuto
   Nishiyama, Nobuhiro
   Miura, Yutaka
TI Site activatable targeting of macromolecular alendronate for accelerated
   fracture healing
SO SCIENCE AND TECHNOLOGY OF ADVANCED MATERIALS
LA English
DT Article
DE Bone fracture; alendronate; osteoporosis; PEGylated drug; osteoclast
ID ANTI OSTEOPOROSIS THERAPY; BONE REGENERATION; CONTROLLED RELEASE;
   OSTEOBLAST PROLIFERATION; DRUG DELIVERY; BISPHOSPHONATES; REPAIR;
   DEFECT; TUMOR; GRAFT
AB Sustainable social activity is a major goal in an aging society, although this is limited by loss of athleticism, with osteoporosis related fractures being the most common cause of long term behavioral restrictions in older people. Therefore, the development of therapeutics that shorten the duration of fracture therapy is essential to improve the quality of life and social activity of older individuals. In this study, we developed a polyethylene glycol modified alendronate (PEG ALN) that can efficiently deliver the active ingredient (ALN) to fracture sites. PEG ALN released ALN in response to an acidic pH and was systemically administered to mice in a fracture model. PEG ALN exhibited selective accumulation at the fracture site and significantly accelerated bone healing compared to free ALN. This study highlights the utility of a simple polymer modification of ALN as a systemically injectable medicine for patients with bone fractures.
C1 [Matsui, Makoto; Kaihara, Yuka; Honda, Yuto; Nishiyama, Nobuhiro; Miura, Yutaka] Inst Innovat Res, Tokyo Inst Technol, Lab Chem & Life Sci, Yokohama, Japan.
   [Honda, Yuto; Nishiyama, Nobuhiro; Miura, Yutaka] Tokyo Inst Technol, Sch Life Sci & Technol, Dept Life Sci & Technol, Yokohama, Japan.
   [Honda, Yuto; Nishiyama, Nobuhiro] Kawasaki Inst Ind Promot, Innovat Ctr Nanomed iCONM, Yokohama, Japan.
   [Nishiyama, Nobuhiro; Miura, Yutaka] Inst Innovat Res, Tokyo Inst Technol, Lab Chem & Life Sci, 4259 Nagatsutacho,Midori Ku, Yokohama, Kanagawa 2268503, Japan.
C3 Institute of Science Tokyo; Tokyo Institute of Technology; Institute of
   Science Tokyo; Tokyo Institute of Technology; Institute of Science
   Tokyo; Tokyo Institute of Technology
RP Nishiyama, N; Miura, Y (通讯作者)，Inst Innovat Res, Tokyo Inst Technol, Lab Chem & Life Sci, 4259 Nagatsutacho,Midori Ku, Yokohama, Kanagawa 2268503, Japan.
EM nishiyama.n.ad@m.titech.ac.jp; miura.y.ai@m.titech.ac.jp
RI Nishiyama, Nobuhiro/F 1867 2014; Miura, Yutaka/Q 8383 2018; Honda,
   Yuto/AAH 5031 2021; Miura, Yutaka/AAT 5859 2020
OI Miura, Yutaka/0000 0002 0506 7138; 
FU Japan Science and Technology Agency (JST) [JPMJPF2202]; Science and
   Technology Platform Program for Advanced Biological Medicine from from
   Japan Agency for Medical Research and Development (AMED)
   [JP21am0401018]; Promotion of Cancer Research and Therapeutic Evolution
   (P PROMOTE) from AMED [JP23ama221221]; Research on Development of New
   Drugs from AMED [23ak0101173]; JSPS KAKENHI [18H04163, 22H00581,
   21K18322]; Five star Alliance from the Ministry of Education, Culture,
   Sports, Science and Technology (MEXT); Cooperative Research Program of
   Network Joint Research Center for Materials and Devices
FX This research was supported financially by the Japan Science and
   Technology Agency (JST) through the open innovation platform for
   industry academia co creation (COI NEXT) Program (Grant Number
   JPMJPF2202), Science and Technology Platform Program for Advanced
   Biological Medicine (JP21am0401018) from Japan Agency for Medical
   Research and Development (AMED), Promotion of Cancer Research and
   Therapeutic Evolution (P PROMOTE) (JP23ama221221) from AMED, the
   Research on Development of New Drugs (23ak0101173) from AMED, JSPS
   KAKENHI (18H04163, N.N., 22H00581, N.N., 21K18322, Y.M.), and Five star
   Alliance from the Ministry of Education, Culture, Sports, Science and
   Technology (MEXT). This work was partially supported by the Cooperative
   Research Program of Network Joint Research Center for Materials and
   Devices. We thank Materials Analysis Suzukake dai, Technical Department,
   Tokyo Institute of Technology.
CR Abdou WM, 2009, ARKIVOC, P143, DOI 10.3998/ark.5550190.0010.910
   Arrington ED, 1996, CLIN ORTHOP RELAT R, P300, DOI 10.1097/00003086 199608000 00037
   AUSTIN RT, 1983, INJURY, V14, P389, DOI 10.1016/0020 1383(83)90089 X
   Bauer TW, 2000, CLIN ORTHOP RELAT R, P10
   BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529
   Bukata SV, 2011, INJURY, V42, P605, DOI 10.1016/j.injury.2011.03.061
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   Chandrasekhar KS, 2011, CALCIFIED TISSUE INT, V89, P347, DOI 10.1007/s00223 011 9524 y
   Chen J, 2017, MOL MED REP, V16, P1801, DOI 10.3892/mmr.2017.6839
   DAMIEN CJ, 1991, J APPL BIOMATER, V2, P187, DOI 10.1002/jab.770020307
   De Laet CEDH, 2000, BEST PRACT RES CL EN, V14, P171, DOI 10.1053/beem.2000.0067
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Fallon M., 1984, Endocrine control of bone and calcium metabolism, P144
   Fujiwara S, 2008, OSTEOPOROSIS INT, V19, P429, DOI 10.1007/s00198 007 0544 4
   Furuya H, 2014, TISSUE ENG PT A, V20, P1531, DOI [10.1089/ten.tea.2012.0763, 10.1089/ten.TEA.2012.0763]
   Goldhahn J, 2010, BONE, V46, P267, DOI 10.1016/j.bone.2009.10.004
   Hokugo A, 2007, ORAL SURG ORAL MED O, V104, P44, DOI 10.1016/j.tripleo.2006.11.032
   Hu JM, 2018, CURR DRUG METAB, V19, P723, DOI 10.2174/1389200219666171207120643
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Inoue Y, 2010, EXP CLIN ENDOCR DIAB, V118, P719, DOI 10.1055/s 0030 1249084
   Kates SL, 2016, INJURY, V47, pS65, DOI 10.1016/S0020 1383(16)30015 8
   Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123
   Kim YH, 2014, BIOMATERIALS, V35, P214, DOI 10.1016/j.biomaterials.2013.09.103
   Kusamori K, 2010, J BONE MINER RES, V25, P2306, DOI 10.1002/jbmr.147
   Larsson S, 2014, ARCH ORTHOP TRAUM SU, V134, P291, DOI 10.1007/s00402 012 1558 8
   Lee SS, 2021, BIOMACROMOLECULES, V22, P2460, DOI 10.1021/acs.biomac.1c00241
   Li JL, 1999, J BONE MINER RES, V14, P969, DOI 10.1359/jbmr.1999.14.6.969
   Li XR, 2009, NANO LETT, V9, P2763, DOI 10.1021/nl901582f
   Liu WG, 2011, NEUROL RES, V33, P686, DOI 10.1179/1743132810Y.0000000031
   Lyseng Williamson KA, 2011, DRUGS, V71, P2179, DOI 10.2165/11202830 000000000 00000
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168 3659(99)00248 5
   Maeda H, 2013, ADV DRUG DELIVER REV, V65, P71, DOI 10.1016/j.addr.2012.10.002
   Mafi R, 2011, Open Orthop J, V5 Suppl 2, P242, DOI 10.2174/1874325001105010242
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Meinberg EG, 2019, INJURY, V50, pS62, DOI 10.1016/j.injury.2019.05.005
   Namkung Matthai H, 2001, BONE, V28, P80, DOI 10.1016/S8756 3282(00)00414 2
   Nishiyama N, 2003, ADV EXP MED BIOL, V519, P155
   Noguchi Y, 1998, JPN J CANCER RES, V89, P307, DOI 10.1111/j.1349 7006.1998.tb00563.x
   Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169 409X(02)00226 0
   Reiter T, 2019, BIOACT MATER, V4, P1, DOI 10.1016/j.bioactmat.2018.10.001
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   SCHENK R, 1986, CALCIFIED TISSUE INT, V38, P342, DOI 10.1007/BF02555748
   Spiro AS, 2013, J BONE MINER METAB, V31, P629, DOI 10.1007/s00774 013 0461 x
   Tabata Y, 2000, J BIOMAT SCI POLYM E, V11, P891, DOI 10.1163/156856200744084
   Tangsangasaksri M, 2016, BIOMACROMOLECULES, V17, P246, DOI 10.1021/acs.biomac.5b01334
   TARVAINEN R, 1994, BONE, V15, P701, DOI 10.1016/8756 3282(94)90320 4
   Tornetta IP., 2020, Rockwood and greens fractures in adults, V1
   TSUCHIMOTO M, 1994, JPN J PHARMACOL, V66, P25, DOI 10.1254/jjp.66.25
   Turecek PL, 2016, J PHARM SCI US, V105, P460, DOI 10.1016/j.xphs.2015.11.015
   Veronese FM, 2005, DRUG DISCOV TODAY, V10, P1451, DOI 10.1016/S1359 6446(05)03575 0
   Wang CZ, 2010, BIOMATERIALS, V31, P8674, DOI 10.1016/j.biomaterials.2010.07.096
   Wang WH, 2017, BIOACT MATER, V2, P224, DOI 10.1016/j.bioactmat.2017.05.007
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Williams JN, 2018, JOVE J VIS EXP, DOI 10.3791/58122
   Wu CT, 2010, ACTA BIOMATER, V6, P2237, DOI 10.1016/j.actbio.2009.12.022
   Yamamoto M, 2003, BIOMATERIALS, V24, P4375, DOI 10.1016/S0142 9612(03)00337 5
   Yamamoto M, 2006, TISSUE ENG, V12, P1305, DOI 10.1089/ten.2006.12.1305
   YAMAOKA T, 1995, J PHARM SCI, V84, P349, DOI 10.1002/jps.2600840316
   YAMAOKA T, 1994, J PHARM SCI, V83, P601, DOI 10.1002/jps.2600830432
   Yang F, 2009, ACTA BIOMATER, V5, P3295, DOI 10.1016/j.actbio.2009.05.023
   Zou DH, 2011, STEM CELLS, V29, P1380, DOI 10.1002/stem.693
NR 62
TC 0
Z9 0
U1 0
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1468 6996
EI 1878 5514
J9 SCI TECHNOL ADV MAT
JI Sci. Technol. Adv. Mater.
PD DEC 31
PY 2023
VL 24
IS 1
AR 2286218
DI 10.1080/14686996.2023.2286218
PG 15
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA IB2X2
UT WOS:001163807200001
OA gold
DA 2025 08 17
ER

PT J
AU Scheiner, S
   Pivonka, P
   Smith, DW
   Dunstan, CR
   Hellmich, C
AF Scheiner, S.
   Pivonka, P.
   Smith, D. W.
   Dunstan, C. R.
   Hellmich, C.
TI Mathematical modeling of postmenopausal osteoporosis and its treatment
   by the anti catabolic drug denosumab
SO INTERNATIONAL JOURNAL FOR NUMERICAL METHODS IN BIOMEDICAL ENGINEERING
LA English
DT Article
DE bone remodeling; pharmacokinetics; systems biology; micromechanics
ID HUMAN MONOCLONAL ANTIBODY; BONE MINERAL DENSITY; KAPPA B LIGAND;
   RECEPTOR ACTIVATOR; MECHANICAL STRAIN; MULTIPLE MYELOMA;
   SYSTEM ANALYSIS; WOMEN; CELLS; ALENDRONATE
AB Denosumab, a fully human monoclonal antibody, has been approved for the treatment of postmenopausal osteoporosis. The therapeutic effect of denosumab rests on its ability to inhibit osteoclast differentiation. Here, we present a computational approach on the basis of coupling a pharmacokinetics model of denosumab with a pharmacodynamics model for quantifying the effect of denosumab on bone remodeling. The pharmacodynamics model comprises an integrated systems biology continuum micromechanics approach, including a bone cell population model, considering the governing biochemical factors of bone remodeling (including the action of denosumab), and a multiscale micromechanics based bone mechanics model, for implementing the mechanobiology of bone remodeling in our model. Numerical studies of postmenopausal osteoporosis show that denosumab suppresses osteoclast differentiation, thus strongly curtailing bone resorption. Simulation results also suggest that denosumab may trigger a short term bone volume gain, which is, however, followed by constant or decreasing bone volume. This evolution is accompanied by a dramatic decrease of the bone turnover rate by more than one order of magnitude. The latter proposes dominant occurrence of secondary mineralization (which is not anymore impeded through cellular activity), leading to higher mineral concentration per bone volume. This explains the overall higher bone mineral density observed in denosumab related clinical studies. Copyright (c) 2013 John Wiley & Sons, Ltd.
C1 [Scheiner, S.; Hellmich, C.] Vienna Univ Technol, Inst Mech Mat & Struct, A 1040 Vienna, Austria.
   [Pivonka, P.] Univ Melbourne, Australian Inst Musculoskeletal Sci, Melbourne, Vic 3010, Australia.
   [Smith, D. W.] Univ Western Australia, Fac Engn Comp & Math, Nedlands, WA 6009, Australia.
   [Dunstan, C. R.] Univ Sydney, Sch Aerosp Mech & Mech Engn, Sydney, NSW 2006, Australia.
C3 Technische Universitat Wien; University of Melbourne; Australian
   Institute for Musculoskeletal Science; University of Western Australia;
   University of Sydney
RP Scheiner, S (通讯作者)，Vienna Univ Technol, Inst Mech Mat & Struct, Karlspl 13 202, A 1040 Vienna, Austria.
EM stefan.scheiner@tuwien.ac.at
RI ; Pivonka, Peter/AAL 1053 2021; Smith, David/H 5856 2014; Dunstan,
   Colin/G 6214 2013
OI Pivonka, Peter/0000 0001 9183 530X; Smith, David/0000 0003 4864 0288;
   Christian, Hellmich/0000 0003 0153 4859; Scheiner,
   Stefan/0000 0003 1078 7807; Dunstan, Colin/0000 0001 7586 4071
FU Australian Research Council [DP 0988427]; Australian Academy of Science;
   European Research Council [FP7 257023]
FX Financial support by the Australian Research Council, in the framework
   of the project Multi scale modeling of transport through deformable
   porous materials (project number DP 0988427), by the Australian Academy
   of Science, in the framework of Scientific Visits to Europe with the
   COST Action program and by the European Research Council, in the
   framework of the project Multiscale poro micromechanics of bone
   materials, with links to biology and medicine (project number
   FP7 257023), is gratefully acknowledged.
CR Alon U., 2007, INTRO SYSTEMS BIOL
   [Anonymous], 2008, NATL HLTH STAT REP
   ASHMAN RB, 1984, J BIOMECH, V17, P349, DOI 10.1016/0021 9290(84)90029 0
   Atkins P. W., 2018, ATKINSPHYSICAL CHEM
   Bala Y, 2010, BONE, V46, P1204, DOI 10.1016/j.bone.2009.11.032
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Boivin G, 2003, OSTEOPOROSIS INT, V14, pS19, DOI 10.1007/s00198 002 1347 2
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Bonnet N, 2010, IBMS BONEKEY, V7, DOI [DOI 10.1138/20100454, 10.1138/20100453, DOI 10.1138/20100453]
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Busa B, 2005, CALCIFIED TISSUE INT, V77, P386, DOI 10.1007/s00223 005 0148 y
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   CIRILLO M, 1992, HYPERTENSION, V20, P319, DOI 10.1161/01.HYP.20.3.319
   COWIN SC, 1992, J MECH PHYS SOLIDS, V40, P1459, DOI 10.1016/0022 5096(92)90029 2
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Eastell R, 2011, J BONE MINER RES, V26, P530, DOI 10.1002/jbmr.251
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903
   Fan X, 2004, ENDOCRINOLOGY, V145, P751, DOI 10.1210/en.2003 0726
   Fritsch A, 2007, J THEOR BIOL, V244, P597, DOI 10.1016/j.jtbi.2006.09.013
   Fuchs RK, 2011, BONE, V49, P701, DOI 10.1016/j.bone.2011.05.009
   Fuller K, 2000, J CELL SCI, V113, P2445
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Gerend MA, 2006, MATURITAS, V55, P227, DOI 10.1016/j.maturitas.2006.03.003
   Graham JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063884
   GREEN W, 2010, P & T, V35, P553
   GRYNPAS M, 1993, CALCIFIED TISSUE INT, V53, pS57, DOI 10.1007/BF01673403
   Hambli R, 2012, BIOMECH MODEL MECHAN, V11, P83, DOI 10.1007/s10237 011 0294 2
   Hellmich C, 2008, ANN BIOMED ENG, V36, P108, DOI [10.1007/s10439 007 9393 8, 10.1016/S0021 9290(08)70202 1]
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Holford NHG, 2000, ANNU REV PHARMACOL, V40, P209, DOI 10.1146/annurev.pharmtox.40.1.209
   Jacobs CR, 2010, ANNU REV BIOMED ENG, V12, P369, DOI 10.1146/annurev bioeng 070909 105302
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   JONES DB, 1991, BIOMATERIALS, V12, P101, DOI 10.1016/0142 9612(91)90186 E
   Kaspar D, 2002, J BIOMECH, V35, P873, DOI 10.1016/S0021 9290(02)00058 1
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Klein Nulend J, 2012, EUR CELLS MATER, V24, P278, DOI 10.22203/eCM.v024a20
   KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   LEKHNITSKII SG, 1963, THEORY ELASTICITY AN, Patent No. [2206.09653, 220609653]
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lewiecki EM, 2007, J BONE MINER RES, V22, P1832, DOI 10.1359/JBMR.070809
   Lewiecki E. Michael, 2006, Arq Bras Endocrinol Metab, V50, P694, DOI 10.1590/S0004 27302006000400015
   Lewiecki EM, 2010, MATURITAS, V66, P182, DOI 10.1016/j.maturitas.2010.02.008
   Liu C, 2010, BONE, V46, P1449, DOI 10.1016/j.bone.2010.02.006
   Looker AC, 2000, OSTEOPOROSIS INT, V11, P467, DOI 10.1007/s001980070088
   Lu Y, 2001, J BONE MINER RES, V16, P901, DOI 10.1359/jbmr.2001.16.5.901
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marathe A, 2008, J PHARMACOL EXP THER, V326, P555, DOI 10.1124/jpet.108.137703
   Martin RB., 1998, Skeletal tissue mechanics
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Miller PD, 2011, J CLIN ENDOCR METAB, V96, P394, DOI 10.1210/jc.2010 1805
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Moroz A, 2006, BIOSYSTEMS, V84, P183, DOI 10.1016/j.biosystems.2005.11.002
   Mould DR, 2007, CURR OPIN DRUG DISC, V10, P84
   Mullender M, 2004, MED BIOL ENG COMPUT, V42, P14, DOI 10.1007/BF02351006
   Murray James D., 2007, MATH BIOL, V17
   Muschitz C, 2013, J BONE MINER RES, V28, P196, DOI 10.1002/jbmr.1716
   Owan I, 1997, AM J PHYSIOL CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810
   Peterson MC, 2012, CPT PHARMACOMET SYST, V1, DOI 10.1038/psp.2012.15
   Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2013, ENG STRUCT, V47, P134, DOI 10.1016/j.engstruct.2012.09.006
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Post TM, 2010, CLIN PHARMACOKINET, V49, P89, DOI 10.2165/11318150 000000000 00000
   Post TM, 2005, PHARM RES DORDR, V22, P1038, DOI 10.1007/s11095 005 5641 5
   Rieger R, 2011, J THEOR BIOL, V274, P36, DOI 10.1016/j.jtbi.2011.01.003
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Rubin MR, 2002, CURR OPIN RHEUMATOL, V14, P433, DOI 10.1097/00002281 200207000 00018
   Scheiner S, 2013, COMPUT METHOD APPL M, V254, P181, DOI 10.1016/j.cma.2012.10.015
   Schwefel H. P., 1977, Interdisciplinary Systems Research
   Seeman E, 2003, OSTEOPOROSIS INT, V14, pS2, DOI 10.1007/s00198 002 1340 9
   Shargel L., 2005, APPL BIOPHARMACEUTIC, V5th
   Sharma A, 1996, J PHARMACOKINET BIOP, V24, P611, DOI 10.1007/BF02353483
   Sheiner LB, 1997, CLIN PHARMACOL THER, V61, P275, DOI 10.1016/S0009 9236(97)90160 0
   Stepan J J, 2003, Endocr Regul, V37, P225
   Tomkinson A, 1998, J BONE MINER RES, V13, P1243, DOI 10.1359/jbmr.1998.13.8.1243
   Vuong J, 2011, J THEOR BIOL, V287, P115, DOI 10.1016/j.jtbi.2011.07.028
   WERGEDAL JE, 1974, AM J PHYSIOL, V226, P345, DOI 10.1152/ajplegacy.1974.226.2.345
   Weyts FAA, 2003, CALCIFIED TISSUE INT, V72, P505, DOI 10.1007/s00223 002 2027 0
   Zaoui A, 2002, J ENG MECH, V128, P808, DOI 10.1061/(ASCE)0733 9399(2002)128:8(808)
NR 88
TC 38
Z9 40
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2040 7939
EI 2040 7947
J9 INT J NUMER METH BIO
JI Int. J. Numer. Meth. Biomed.
PD JAN
PY 2014
VL 30
IS 1
BP 1
EP 27
DI 10.1002/cnm.2584
PG 27
WC Engineering, Biomedical; Mathematical & Computational Biology;
   Mathematics, Interdisciplinary Applications
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Mathematical & Computational Biology; Mathematics
GA AJ4GF
UT WOS:000337630500001
PM 24039120
OA Green Published
DA 2025 08 17
ER

PT J
AU Beck, GR
   Ha, SW
   Camalier, CE
   Yamaguchi, M
   Li, Y
   Lee, JK
   Weitzmann, MN
AF Beck, George R., Jr.
   Ha, Shin Woo
   Camalier, Corinne E.
   Yamaguchi, Masayoshi
   Li, Yan
   Lee, Jin Kyu
   Weitzmann, M. Neale
TI Bioactive silica based nanoparticles stimulate bone forming osteoblasts,
   suppress bone resorbing osteoclasts, and enhance bone mineral density in
   vivo
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Bone; Nanoparticle; Osteoclast; Osteoblast; Silica
ID NF KAPPA B; TUMOR NECROSIS FACTOR; OXIDATIVE STRESS; MC3T3
   PREOSTEOBLASTS; SMAD ACTIVATION; SEX STEROIDS; FACTOR ALPHA;
   DIFFERENTIATION; CELLS; EXPRESSION
AB Bone is a dynamic tissue that undergoes renewal throughout life in a process whereby osteoclasts resorb worn bone and osteoblasts synthesize new bone. Imbalances in bone turnover lead to bone loss and development of osteoporosis and ultimately fracture, a debilitating condition with high morbidity and mortality. Silica is a ubiquitous biocontaminant that is considered to have high biocompatibility. The authors report that silica nanoparticles (NPs) mediate potent inhibitory effects on osteoclasts and stimulatory effects on osteoblasts in vitro. The mechanism of bioactivity is a consequence of an intrinsic capacity to antagonize activation of NF kappa B, a signal transduction pathway required for osteoclastic bone resorption but inhibitory to osteoblastic bone formation. We further demonstrate that silica NPs promote a significant enhancement of bone mineral density (BMD) in mice in vivo, providing a proof of principle for the potential application of silica NPs as a pharmacological agent to enhance BMD and protect against bone fracture.
   From the Clinical Editor: In this paper, silicate nanoparticles are utilized in an animal model to stimulate bone growth by inhibiting osteoclasts while enhancing the activity of osteoblasts. This result may have important ramification in future applications to a variety of bone diseases, including but not limited to osteoporosis, pathological fractures, metastatic bone lesions, different types of bone cancer, etc. Published by Elsevier Inc.
C1 [Beck, George R., Jr.; Camalier, Corinne E.; Yamaguchi, Masayoshi; Li, Yan; Weitzmann, M. Neale] Emory Univ, Sch Med, Div Endocrinol Metab & Lipids, Atlanta, GA USA.
   [Beck, George R., Jr.; Weitzmann, M. Neale] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA.
   [Ha, Shin Woo; Lee, Jin Kyu] Seoul Natl Univ, Dept Chem, Seoul, South Korea.
   [Weitzmann, M. Neale] Vet Affairs Med Ctr, Atlanta Dept, Decatur, GA 30033 USA.
C3 Emory University; Emory University; Seoul National University (SNU); US
   Department of Veterans Affairs; Veterans Health Administration (VHA)
RP Beck, GR (通讯作者)，101 Woodruff Circle,1305 WMRB, Atlanta, GA 30322 USA.
EM mweitzm@emory.edu
RI Beck, George/AAO 2117 2020
FU NIAMS [AR056090, AR059364, AR053607]; Georgia Research Alliance grant
   [GRA.VL12.C2]; Biomedical Laboratory Research & Development Service of
   the VA Office of Research and Development [5I01BX000105]; NIA
   [AG040013]; NCI [CA136059, CA136716]; SBS Foundation in Korea
FX This study was supported by a grant from NIAMS (AR056090) and by a
   Georgia Research Alliance grant (GRA.VL12.C2) to M.N. Weitzmann and G.
   R. Beck. M.N. Weitzmann is also supported in part by funding from the
   Biomedical Laboratory Research & Development Service of the VA Office of
   Research and Development (5I01BX000105) and by grants AR059364 and
   AR053607 from NIAMS and AG040013 from NIA. G. R. Beck is also supported
   in part by NCI grants (CA136059 and CA136716). J K. Lee expresses his
   thanks for a fellowship from the SBS Foundation in Korea to initiate
   this research collaboration.
CR Abramoff M.D., 2004, J. Biophot. Int., V11, P36, DOI DOI 10.1201/9781420005615.AX4
   Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Bartneck M, 2010, NANO LETT, V10, P59, DOI 10.1021/nl902830x
   Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097 4644(19980201)68:2<269::AID JCB13>3.0.CO;2 A
   Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756 3282(99)00105 2
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   Camalier CE, 2010, CANCER PREV RES, V3, P359, DOI 10.1158/1940 6207.CAPR 09 0068
   Cho MJ, 2009, TOXICOL LETT, V189, P177, DOI 10.1016/j.toxlet.2009.04.017
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Gibson IR, 1999, J BIOMED MATER RES, V44, P422, DOI 10.1002/(SICI)1097 4636(19990315)44:4<422::AID JBM8>3.0.CO;2 #
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Grassi F, 2007, P NATL ACAD SCI USA, V104, P15087, DOI 10.1073/pnas.0703610104
   Ha SW, 2009, CHEM COMMUN, P2881, DOI 10.1039/b902195g
   Hamasaki T, 2008, LANGMUIR, V24, P7354, DOI 10.1021/la704046f
   Hamilton RF, 2008, FREE RADICAL BIO MED, V44, P1246, DOI 10.1016/j.freeradbiomed.2007.12.027
   Hao J, 2011, J MATER SCI MATER M, V22, P1489, DOI 10.1007/s10856 011 4329 0
   Huang DM, 2005, FASEB J, V19, P2014, DOI 10.1096/fj.05 4288fje
   Jugdaohsingh R, 2007, J NUTR HEALTH AGING, V11, P99
   KEETING PE, 1992, J BONE MINER RES, V7, P1281, DOI 10.1002/jbmr.5650071107
   Kim JS, 2006, J VET SCI, V7, P321, DOI 10.4142/jvs.2006.7.4.321
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Li XR, 2009, NANO LETT, V9, P2763, DOI 10.1021/nl901582f
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Martin KR, 2007, J NUTR HEALTH AGING, V11, P94
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378 1119(03)00841 2
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Park EJ, 2009, TOXICOL LETT, V184, P18, DOI 10.1016/j.toxlet.2008.10.012
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   SCHWARZ K, 1972, NATURE, V239, P333, DOI 10.1038/239333a0
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Toraldo G, 2003, P NATL ACAD SCI USA, V100, P125, DOI 10.1073/pnas.0136772100
   Vikulina T, 2010, P NATL ACAD SCI USA, V107, P13848, DOI 10.1073/pnas.1003020107
   Wactawski Wende J, 2001, Ann Periodontol, V6, P197, DOI 10.1902/annals.2001.6.1.197
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Xing LP, 2003, J BONE MINER RES, V18, P260, DOI 10.1359/jbmr.2003.18.2.260
   Yamaguchi M, 2011, INT J MOL MED
   Yamaguchi M, 2011, MOL CELL BIOCH
   Yamaguchi M, 2011, INT J MOL MED, V27, P3, DOI 10.3892/ijmm.2010.562
   Yamaguchi M, 2009, INT J MOL MED, V24, P671, DOI 10.3892/ijmm_00000278
   Yamaguchi M, 2009, MOL MED REP, V2, P641, DOI 10.3892/mmr_00000150
   Yamaguchi M, 2009, INT J MOL MED, V23, P297, DOI 10.3892/ijmm_00000131
   Yoon TJ, 2006, SMALL, V2, P209, DOI [10.1002/smll.200500360, 10.1002/511111.200500360]
   Zou S, 2009, J BIOMED MATER RES B, V90B, P123, DOI 10.1002/jbm.b.31262
NR 46
TC 195
Z9 209
U1 0
U2 83
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD AUG
PY 2012
VL 8
IS 6
BP 793
EP 803
DI 10.1016/j.nano.2011.11.003
PG 11
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA 977LJ
UT WOS:000306662100001
PM 22100753
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Shen, Y
   Wang, N
   Zhang, Q
   Liu, YL
   Wu, QD
   He, YQ
   Wang, Y
   Wang, XY
   Zhao, QM
   Zhang, QL
   Qin, LP
   Zhang, QY
AF Shen, Yi
   Wang, Na
   Zhang, Qi
   Liu, Yuling
   Wu, Qudi
   He, Yuqiong
   Wang, Yang
   Wang, Xiaoyan
   Zhao, Qiming
   Zhang, Quanlong
   Qin, Luping
   Zhang, Qiaoyan
TI Jin Tian Ge ameliorates ovariectomy induced bone loss in rats and
   modulates osteoblastogenesis and osteoclastogenesis in vitro
SO CHINESE MEDICINE
LA English
DT Article
DE Jin Tian Ge; Osteoporosis; Osteoblast; Osteoclast; BMP and Wnt;
   beta catenin pathway; NF kappa B pathway
ID OSTEOPOROSIS; THERAPY; CALCIUM; HEALTH; TERM; WNT
AB Background: Tiger bone, which had been one of the most famous traditional Chinese medicine for 2000 years, was originate from the skeleton of Panthera tigris L., and had the actions of anti inflammatory, analgesic, immune regulatory and promoting healing of bone fracture, and was used for the treatment of osteoporosis and rheumatoid arthritis. Jin Tian Ge (JTG), the artificial tiger bone powder, were prepared from skeletons of several farmed animals to substitute the natural tiger bone, and has been used for the treatment of osteoporosis in clinical practice. However, the characteristic and mechanism of action of JTG for the therapy of osteoporosis need to be further evidenced by using modern pharmacological methods. The aim of this work is to investigate the bone protective effects of JTG, and explore the possible underlying mechanism.
   Methods: Ovariectomy (OVX) rats were orally administrated JTG or estradiol valerate (EV) for 12 weeks. We investigated the pharmacodynamic effects of JTG on anti bone loss in OVX rats, and also investigated the role of JTG in promoting osteogenesis and inhibiting osteoclast differentiation.
   Results: JTG increased the bone mineral density (BMD), improved the bone microarchitecture and biomechanical properties in ovariectomized rast, whereas reversed the bone high turnover in OVX rats as evidenced by serum biochemical markers in OVX rats. JTG increased osteogenic differentiation of BMSCs in vitro, and up regulated the expression of the key proteins of BMP and Wnt/beta catenin pathways. JTG also inhibited the osteoclastogenesis of BMM as evidenced by the alteration of the TRAP activity, F actin construction and the expression of nuclear factor of activated T cells cytoplasmic 1 (NFATc1), c Fos, Cathepsin K (Ctsk) and matrix metallopeptidase 9 (MMP9) of OCs induced with RANKL and LPS, reduced the expression and phosphorylation of NF kappa B in OCs.
   Conclusions: JTG prevented bone loss in OVX rats and increased osteogenic differentiation of BMSCs through regulation of the BMP and Wnt/beta catenin pathway, inhibited osteoclastogenesis by suppressing the NF kappa B pathway, suggesting that JTG had the potentials for prevention and treatment of osteoporosis by modulating formation and differentiation of osteoblast and osteoclast.
C1 [Shen, Yi; Zhang, Qi; Liu, Yuling; Wu, Qudi; Wang, Xiaoyan; Zhao, Qiming; Zhang, Quanlong; Qin, Luping; Zhang, Qiaoyan] Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Binwen Rd 584, Hangzhou 310053, Peoples R China.
   [Wang, Na] Ginwa Enterprise Grp INC, Xian 710069, Peoples R China.
   [He, Yuqiong] Shanghai Univ Tradit Chinese Med, Inst Chinese Mat Mad, Shanghai 201203, Peoples R China.
   [Wang, Yang] Zhejiang Tradit Chinese Med & Hlth Ind Grp CO LTD, Hangzhou 310016, Peoples R China.
C3 Zhejiang Chinese Medical University; Shanghai University of Traditional
   Chinese Medicine
RP Zhang, QL; Qin, LP; Zhang, QY (通讯作者)，Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Binwen Rd 584, Hangzhou 310053, Peoples R China.
EM 13484207@qq.com; lpqin@zcmu.edu.cn; zqy1965@163.com
RI Wang, Xiaoyan/IQU 1588 2023
FU National Natural Science Foundation of China [81973534]
FX The project was sponsored by the National Natural Science Foundation of
   China (No. 81973534). The funding body did not have any influence on the
   design of the study and collection, analysis, and interpretation of data
   and in writing the manuscript.
CR Akhter MP, 2001, BONE, V29, P121, DOI 10.1016/S8756 3282(01)00486 0
   [蔡攀 Cai Pan], 2017, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V23, P1621
   Cai ZP, 2020, STEM CELLS DEV, V29, P1567, DOI 10.1089/scd.2020.0117
   Calvo MS, 2013, AM J CLIN NUTR, V98, P6, DOI 10.3945/ajcn.112.053934
   Carey John J, 2018, Clin Exp Rheumatol, V36 Suppl 114, P115
   Chapurlat R, 2020, J BONE MINER RES, V35, P833, DOI 10.1002/jbmr.3924
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Crosbie EJ, 2010, CANCER EPIDEM BIOMAR, V19, P3119, DOI 10.1158/1055 9965.EPI 10 0832
   Cui W., 1998, CHIN J OSTEOPOROS, V4, P90
   Ding KH, 2018, BONE, V115, P15, DOI 10.1016/j.bone.2018.02.028
   Eastell R, 2008, P NUTR SOC, V67, P157, DOI 10.1017/S002966510800699X
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Fan YM., 2001, CHIN MED PHARMACO CL, V12, P13
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Frankel VH, 2016, J ORTHOP TRAUMA, V30, pS2, DOI 10.1097/BOT.0000000000000579
   García de Herreros A, 2019, CELLS BASEL, V8, DOI 10.3390/cells8101148
   Gratwicke B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002544
   Hao F, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2158971
   Haraguchi K, 2008, ONCOGENE, V27, P274, DOI 10.1038/sj.onc.1210644
   Hou XL., 2013, CHIN J EXP TRADIT ME, V19, P287, DOI [10.13422/j.cnki.syfjx.2013.06.091, DOI 10.13422/J.CNKI.SYFJX.2013.06.091]
   Hu H, 2019, EXP MOL PATHOL, V107, P158, DOI 10.1016/j.yexmp.2019.02.003
   Huh JE, 2014, INT J MOL SCI, V15, P13010, DOI 10.3390/ijms150713010
   Isanejad M, 2017, J NUTR HEALTH AGING, V21, P622, DOI 10.1007/s12603 016 0800 4
   Jadzic J, 2021, EXP GERONTOL, V150, DOI 10.1016/j.exger.2021.111375
   Kang JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103646
   Karner CM, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00253 16
   Kirk B, 2020, J CACHEXIA SARCOPENI, V11, P609, DOI 10.1002/jcsm.12567
   Lademann F, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.586031
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Lettini G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207526
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Li K, 2018, CLIN INTERV AGING, V13, P2443, DOI 10.2147/CIA.S157523
   Li Y., 2019, Chin J of Clinical Rational Drug Use, V12, P61, DOI [10.15887/j.cnki.13 1389/r.2019.14.037, DOI 10.15887/J.CNKI.13 1389/R.2019.14.037]
   Li YF, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/2478565
   Lin CY, 2021, MATERIALS, V14, DOI 10.3390/ma14154224
   Liu L, 2018, Chin Tradit Pat Med., V40, P2606, DOI [10.3969/j.issn.1001 1528.2018.11.053, DOI 10.3969/J.ISSN.1001 1528.2018.11.053]
   Liu P, 2020, TISSUE CELL, V67, DOI 10.1016/j.tice.2020.101449
   刘铮, 2006, [中国中医骨伤科杂志, Chinese Journal of Traditional Medicine Traumatology and Orthopedics], V14, P73
   [马信龙 Ma Xinlong], 2014, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V20, P1039
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Noirrit Esclassan E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041568
   Park JH, 2017, MOL CELLS, V40, P706
   Prakriya M, 2020, J PHYSIOL LONDON, V598, P1647, DOI 10.1113/JP279541
   Razavi P, 2010, CANCER EPIDEM BIOMAR, V19, P475, DOI 10.1158/1055 9965.EPI 09 0712
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Ren YL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.571535
   Rozenberg S, 2020, OSTEOPOROSIS INT, V31, P2271, DOI 10.1007/s00198 020 05497 8
   Seidlitz EP, 2010, CAN J PHYSIOL PHARM, V88, P929, DOI [10.1139/Y10 070, 10.1139/y10 070]
   Shi ZG, 2015, J PHYSIOL LONDON, V593, P1633, DOI 10.1113/jphysiol.2014.284638
   Su Y, 2019, BONE, V129, DOI 10.1016/j.bone.2019.115082
   Sun J, 2019, ORTHOP SURG, V11, P176, DOI 10.1111/os.12439
   Sun LH., 2002, ACAD PERI CHANGCHUN, V18, P59, DOI [10.13463/j.cnki.cczyy.2002.04.061, DOI 10.13463/J.CNKI.CCZYY.2002.04.061]
   Tempfer CB, 2020, CANCERS, V12, DOI 10.3390/cancers12082195
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   TURNER CH, 1992, J ORTHOPAED RES, V10, P581, DOI 10.1002/jor.1100100413
   Walallawita US, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197119
   Wang JH., 2018, Chin J Tradit Med Traumatol Orthop, V26, P26
   Wang QY., 2006, J TRANDIT CHIN ORTHO, V18, P70
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Zhai X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00348
   Zhang YiShan Zhang YiShan, 2008, Progress in Modern Biomedicine, V8, P321
   [赵岩 Zhao Yan], 2012, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V18, P95
   Zhu YW., 2019, WORLD CHIN MED, V14, P446
NR 65
TC 16
Z9 18
U1 4
U2 32
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 8546
J9 CHIN MED UK
JI Chin. Med.
PD OCT 5
PY 2022
VL 17
IS 1
AR 78
DI 10.1186/s13020 022 00627 2
PG 19
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA 5B8SU
UT WOS:000863839700001
PM 36195960
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kuo, YJ
   Tsuang, FY
   Sun, JS
   Lin, CH
   Chen, CH
   Li, JY
   Huang, YC
   Chen, WY
   Yeh, CB
   Shyu, JF
AF Kuo, Yi Jie
   Tsuang, Fon Yih
   Sun, Jui Sheng
   Lin, Chi Hung
   Chen, Chia Hsien
   Li, Jia Ying
   Huang, Yi Chian
   Chen, Wei Yu
   Yeh, Chin Bin
   Shyu, Jia Fwu
TI Calcitonin Inhibits SDCP Induced Osteoclast Apoptosis and Increases Its
   Efficacy in a Rat Model of Osteoporosis
SO PLOS ONE
LA English
DT Article
ID SINTERED DICALCIUM PYROPHOSPHATE; MOLECULAR MECHANISMS; OVARIECTOMIZED
   RATS; SALMON CALCITONIN; BONE FORMATION; IN VITRO; BISPHOSPHONATES;
   METABOLISM; SURVIVAL; OSTEOBLASTS
AB Introduction: Treatment for osteoporosis commonly includes the use of bisphosphonates. Serious side effects of these drugs are caused by the inhibition of bone resorption as a result of osteoclast apoptosis. Treatment using calcitonin along with bisphosphonates overcomes these side effects in some patients. Calcitonin is known to inhibit bone resorption without reducing the number of osteoclasts and is thought to prolong osteoclast survival through the inhibition of apoptosis. Further understanding of how calcitonin inhibits apoptosis could prove useful to the development of alternative treatment regimens for osteoporosis. This study aimed to analyze the mechanism by which calcitonin influences osteoclast apoptosis induced by a bisphosphate analog, sintered dicalcium pyrophosphate (SDCP), and to determine the effects of co treatment with calcitonin and SDCP on apoptotic signaling in osteoclasts.
   Methods: Isolated osteoclasts were treated with CT, SDCP or both for 48 h. Osteoclast apoptosis assays, pit formation assays, and tartrate resistant acid phosphatase (TRAP) staining were performed. Using an osteoporosis rat model, ovariectomized (OVX) rats received calcitonin, SDCP, or calcitonin + SDCP. The microarchitecture of the fifth lumbar trabecular bone was investigated, and histomorphometric and biochemical analyses were performed.
   Results: Calcitonin inhibited SDCP induced apoptosis in primary osteoclast cultures, increased Bcl 2 and Erk activity, and decreased Mcl 1 activity. Calcitonin prevented decreased osteoclast survival but not resorption induced by SDCP. Histomorphometric analysis of the tibia revealed increased bone formation, and microcomputed tomography of the fifth lumbar vertebrate showed an additive effect of calcitonin and SDCP on bone volume. Finally, analysis of the serum bone markers CTX I and P1NP suggests that the increased bone volume induced by co treatment with calcitonin and SDCP may be due to decreased bone resorption and increased bone formation.
   Conclusions: Calcitonin reduces SDCP induced osteoclast apoptosis and increases its efficacy in an in vivo model of osteoporosis.
C1 [Kuo, Yi Jie] Taipei Med Univ Hosp, Dept Orthopaed, Taipei, Taiwan.
   [Kuo, Yi Jie] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.
   [Tsuang, Fon Yih] Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei 100, Taiwan.
   [Sun, Jui Sheng] Natl Taiwan Univ Hosp, Dept Orthopaed Surg, Hsinchu, Taiwan.
   [Sun, Jui Sheng] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan.
   [Lin, Chi Hung; Chen, Chia Hsien] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan.
   [Li, Jia Ying; Chen, Wei Yu; Shyu, Jia Fwu] Natl Def Med Ctr, Dept Biol & Anat, Taipei, Taiwan.
   [Huang, Yi Chian] Natl Yang Ming Univ, Inst Anat & Cell Biol, Taipei 112, Taiwan.
   [Yeh, Chin Bin; Shyu, Jia Fwu] Triserv Gen Hosp, Dept Psychiat, Taipei, Taiwan.
C3 Taipei Medical University; Taipei Medical University Hospital; National
   Yang Ming Chiao Tung University; National Taiwan University; National
   Taiwan University Hospital; National Taiwan University; National Taiwan
   University Hospital; Taipei Medical University; National Yang Ming Chiao
   Tung University; National Defense Medical University; National Yang Ming
   Chiao Tung University; Tri Service General Hospital
RP Kuo, YJ (通讯作者)，Taipei Med Univ Hosp, Dept Orthopaed, Taipei, Taiwan.
EM jiafwu.shyu@msa.hinet.net
RI 周, 建良/HLV 8728 2023; SUN, Jus Sheng/ITU 1253 2023; chen,
   weiyu/M 5972 2018
OI SUN, JUI SHENG/0000 0001 5142 8777; Tsuang, Fon Yih/0000 0001 5797 1885;
   
FU National Defense Medical Center of Medical Research Grants
   [DOD 100 C 11 02]; Tri Service General Hospital of Medical Research
   Grants [TSGH C99 011 12 S03]
FX This work was funded by National Defense Medical Center of Medical
   Research Grants (DOD 100 C 11 02) and Tri Service General Hospital of
   Medical Research Grants (TSGH C99 011 12 S03). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   CHAMBERS TJ, 1984, J ENDOCRINOL, V102, P281, DOI 10.1677/joe.0.1020281
   Davey RA, 2005, J BONE MINER METAB, V23, P359, DOI 10.1007/s00774 005 0613 8
   Davey RA, 2008, J BONE MINER RES, V23, P1182, DOI [10.1359/jbmr.080310, 10.1359/JBMR.080310]
   de Paula FJA, 2010, HORM METAB RES, V42, P299, DOI 10.1055/s 0030 1248255
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Furuichi H, 2000, BIOL PHARM BULL, V23, P946
   Gallagher JC, 2010, MATURITAS, V65, P301, DOI 10.1016/j.maturitas.2010.01.002
   Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692
   Hoff AO, 2002, J CLIN INVEST, V110, P1849, DOI 10.1172/JCI200214218
   Horne WC, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P221, DOI 10.1016/B978 0 12 373884 4.00031 8
   Huebner AK, 2008, ARCH BIOCHEM BIOPHYS, V473, P210, DOI 10.1016/j.abb.2008.02.013
   Huebner AK, 2006, J BONE MINER RES, V21, P1924, DOI 10.1359/JBMR.060820
   Iwamoto Jun, 2009, Ther Clin Risk Manag, V5, P499
   Kanaoka K, 2000, ENDOCRINOLOGY, V141, P2995, DOI 10.1210/en.141.8.2995
   Karsdal MA, 2008, BIODRUGS, V22, P137, DOI 10.2165/00063030 200822030 00001
   Lin CL, 1996, GASTROENTEROLOGY, V111, P1263, DOI 10.1053/gast.1996.v111.pm8898640
   LIN FH, 1995, BIOMATERIALS, V16, P793, DOI 10.1016/0142 9612(95)99642 Y
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Martin TJ, 2009, CRIT REV EUKAR GENE, V19, P73, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.40
   Marzia M, 2006, J BIOL CHEM, V281, P9745, DOI 10.1074/jbc.M513516200
   Miyazaki T, 2003, J CELL BIOL, V160, P709, DOI 10.1083/jcb.200209098
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Mochizuki K, 2000, J BONE MINER METAB, V18, P194, DOI 10.1007/s007740070020
   Ogawa K, 2005, J BONE MINER METAB, V23, P351, DOI 10.1007/s00774 005 0612 9
   Ozoran K., 2007, APLAR J RHEUMATOL, V10, P17
   Penolazzi L, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472 6882 8 59
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756 3282(99)00070 8
   Selander KS, 1996, MOL CELL ENDOCRINOL, V122, P119, DOI 10.1016/0303 7207(96)03870 1
   Shyu JF, 2007, BONE, V40, P1329, DOI 10.1016/j.bone.2007.01.014
   Stern PH, 2007, J CELL BIOCHEM, V101, P1087, DOI 10.1002/jcb.21311
   Sun JS, 1999, ARTIF ORGANS, V23, P331, DOI 10.1046/j.1525 1594.1999.06235.x
   Sun JS, 2003, J BIOMED MATER RES A, V64A, P616, DOI 10.1002/jbm.a.10439
   Sun JS, 2002, J BIOMED MATER RES, V59, P246, DOI 10.1002/jbm.1238
   Sun JS, 1997, J BIOMED MATER RES, V37, P324, DOI 10.1002/(SICI)1097 4636(19971205)37:3<324::AID JBM3>3.0.CO;2 N
   Sutherland KA, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2681
   Tanaka S, 2010, ADV EXP MED BIOL, V658, P111, DOI 10.1007/978 1 4419 1050 9_12
   Woodrow JP, 2006, ENDOCRINOLOGY, V147, P4010, DOI 10.1210/en.2005 1616
   ZAIDI M, 1990, J ENDOCRINOL INVEST, V13, P119, DOI 10.1007/BF03349520
NR 41
TC 20
Z9 22
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 6
PY 2012
VL 7
IS 7
AR e40272
DI 10.1371/journal.pone.0040272
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 974UB
UT WOS:000306461800059
PM 22792258
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Zhang, YF
   Wei, LF
   Miron, RJ
   Shi, B
   Bian, ZA
AF Zhang, Yufeng
   Wei, Lingfei
   Miron, Richard J.
   Shi, Bin
   Bian, Zhuan
TI Anabolic Bone Formation Via a Site Specific Bone Targeting Delivery
   System by Interfering With Semaphorin 4d Expression
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE SEMAPHORIN; OSTEOPOROSIS; BONE TARGETING; BONE REMODELING
ID IN VIVO; GUIDANCE; OSTEOPOROSIS; HOMEOSTASIS; SIRNA; OSTEOCLASTOGENESIS;
   RECEPTORS
AB Semaphorins have been recently targeted as new molecules directly implicated in the cell cell communication that occurs between osteoclasts and osteoblasts. Overexpression of certain semaphorins, such as semaphorin4D (sema4D), is found in an osteoporotic phenotype and plays a key role in osteoclast activity by suppressing osteoblast maturation, thus significantly altering the bone modeling cycle. In the present study, we fabricate a site specific bone targeting drug delivery system from polymeric nanoparticles with the incorporation of siRNA interference molecule for sema4D and demonstrate their cellular uptake and intracellular trafficking within osteoclasts, thus preventing the suppression of osteoblast activity. We then demonstrate in an osteoporotic animal model induced by ovariectomy that weekly intravenous injections led to a significantly greater number of active osteoblasts at the bone surface, resulting in higher bone volume in compromised animals. The findings from the present study demonstrate a novel and promising site specific therapeutic option for the treatment of osteoporosis via interference of the sema4D plexin cell communication pathway between osteoclasts and osteoblasts. (c) 2014 American Society for Bone and Mineral Research.
C1 [Zhang, Yufeng; Wei, Lingfei; Miron, Richard J.; Shi, Bin; Bian, Zhuan] Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan 430072, Peoples R China.
   [Zhang, Yufeng; Wei, Lingfei; Miron, Richard J.; Shi, Bin; Bian, Zhuan] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, Key Lab Oral Biomed, Wuhan 430072, Peoples R China.
   [Zhang, Yufeng; Shi, Bin] Wuhan Univ, Sch & Hosp Stomatol, Dept Dent Implantol, Wuhan 430072, Peoples R China.
C3 Wuhan University; Wuhan University; Wuhan University
RP Bian, ZA (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, Wuhan 430072, Peoples R China.
EM bianzhuan@whu.edu.cn
RI Zhang, Yufeng/GZL 1973 2022; Miron, Richard/J 4995 2012; Wei,
   Lingfei/AAM 4323 2020
OI Zhang, Yufeng/0000 0001 8702 5291; 
FU Program for New Century Excellent Talents in University [NCET 11 0414];
   National Natural Science Foundation of China [81271108, 81120108010];
   Pre National Basic Research Program of China (973 Plan) [2012CB722404]
FX We thank Jingtao Zhu, Yanbing Zhao, and Qin Zhou for technical
   assistance. This work was supported by the Program for New Century
   Excellent Talents in University (NCET 11 0414), the National Natural
   Science Foundation of China (81271108 to YFZ and 81120108010
   [International cooperation and exchange projects] to ZB), and the
   Pre National Basic Research Program of China (973 Plan; 2012CB722404 to
   ZB).
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Dacquin R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026627
   Delorme G, 2005, BIOL CELL, V97, P589
   Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165
   Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115
   Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Howard KA, 2007, EXPERT OPIN BIOL TH, V7, P1811, DOI 10.1517/14712598.7.12.1811
   Huber AB, 2003, ANNU REV NEUROSCI, V26, P509, DOI 10.1146/annurev.neuro.26.010302.081139
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   Janssen BJC, 2010, NATURE, V467, P1118, DOI 10.1038/nature09468
   Larrivée B, 2009, CIRC RES, V104, P428, DOI 10.1161/CIRCRESAHA.108.188144
   Leah Emma, 2011, Nat Rev Rheumatol, V7, P681, DOI 10.1038/nrrheum.2011.175
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Ohlsson C, 2013, NAT REV ENDOCRINOL, V9, P72, DOI 10.1038/nrendo.2012.252
   Silva BC, 2011, ANNU REV MED, V62, P307, DOI 10.1146/annurev med 061709 145401
   Sutton ALM, 2008, MOL ENDOCRINOL, V22, P1370, DOI 10.1210/me.2007 0363
   Suzuki K, 2008, NAT IMMUNOL, V9, P17, DOI 10.1038/ni1553
   Takegahara N, 2006, NAT CELL BIOL, V8, P615, DOI 10.1038/ncb1416
   Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962 8924(00)01816 X
   Tönges L, 2006, RNA, V12, P1431, DOI 10.1261/rna.2252206
   Tran TS, 2007, ANNU REV CELL DEV BI, V23, P263, DOI 10.1146/annurev.cellbio.22.010605.093554
   Wang D, 2006, MOL PHARMACEUT, V3, P717, DOI 10.1021/mp0600539
   Wang Y, 2010, CURR DRUG METAB, V11, P182, DOI 10.2174/138920010791110863
   Wathen CA, 2013, SENSORS BASEL, V13, P6957, DOI 10.3390/s130606957
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang YF, 2012, BIOMATERIALS, V33, P6698, DOI 10.1016/j.biomaterials.2012.06.021
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 29
TC 74
Z9 83
U1 0
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2015
VL 30
IS 2
BP 286
EP 296
DI 10.1002/jbmr.2322
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CA4CM
UT WOS:000348851900011
PM 25088728
OA Bronze
DA 2025 08 17
ER

PT J
AU Wang, J
   Zhao, CY
   Zhao, WP
   Li, SN
AF Wang, Jun
   Zhao, Changyu
   Zhao, Wenpeng
   Li, Songnan
TI Deficiency of protein phosphatase 5 resists osteoporosis in diabetic
   mice
SO HELIYON
LA English
DT Article
DE Osteoporosis; Diabetes; High fat diet; Protein phosphatase 5;
   Osteoblast; Osteoclast
ID BONE TURNOVER; IN VIVO; OSTEOCLAST; HOMEOSTASIS; DISRUPTION; METABOLISM;
   RUNX2
AB Osteoporosis is a common diabetic consequence that negatively affects patients' health and quality of life. Nevertheless, there is mutual interference between clinical drugs intended to regulate blood glucose and bone metabolism. Therefore, it is crucial to look for new treatment targets that effectively control blood glucose and safely protect the bone health of patients with diabetes. In this study, mice given a high fat diet were shown to be resistant to osteoporosis and diabetes when protein phosphatase 5 (PP5) knockout (KO) mice were used. Serum markers of bone remodeling show that PP5 KO mice are resistant to decreased bone formation and increased bone resorption brought on by diabetes. The absence of PP5 resists the reduction of osteoblast differentiation and the enhancement of osteoclast differentiation in diabetic mice, according to the in vitro osteoblast differentiation of bone mesenchymal stem cells and osteoclast differentiation of bone marrow derived macrophages. Subsequent investigation revealed that PP5 deficiency increases the expression of the key regulator of osteoblast differentiation, runt related transcription factor 2, and decreases the activity of the receptor activator of the nuclear factor kappa B ligand/osteoprotegerin pathway, a crucial regulatory signaling pathway for osteoclast differentiation. In conclusion, we discovered that PP5 deficiency protects diabetic mice against osteoporosis for the first time.
C1 [Wang, Jun; Zhao, Changyu; Zhao, Wenpeng] Yangzhou Univ, Sch Tourism & Cuisine, Yangzhou 225127, Peoples R China.
   [Li, Songnan] Yangzhou Univ, Inst Agr Sci & Technol Dev, Joint Int Res Lab Agr & Agriprod Safety, Minist Educ China, Yangzhou 225009, Peoples R China.
C3 Yangzhou University; Yangzhou University
RP Li, SN (通讯作者)，Yangzhou Univ, Inst Agr Sci & Technol Dev, Joint Int Res Lab Agr & Agriprod Safety, Minist Educ China, Yangzhou 225009, Peoples R China.
EM lsnyz2020@yzu.edu.cn
RI Li, Songnan/KLZ 3263 2024
OI Li, Songnan/0000 0002 8494 9197
FU National Natural Science Foundation of China [82000791]; Natural Science
   Foundation of Jiangsu Province [BK20220585]
FX <BOLD>Funding</BOLD> This research was funded by the National Natural
   Science Foundation of China (82000791) and the Natural Science
   Foundation of Jiangsu Province (BK20220585) .
CR Anesi A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194925
   Aspray Terry J, 2019, Subcell Biochem, V91, P453, DOI 10.1007/978 981 13 3681 2_16
   Bach RG, 2013, CIRCULATION, V128, P785, DOI 10.1161/CIRCULATIONAHA.112.000678
   Carvalho AL, 2018, J CELL PHYSIOL, V233, P1585, DOI 10.1002/jcp.26062
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Delgado Calle J, 2022, PHYSIOL REV, V102, DOI 10.1152/physrev.00043.2020
   Donat A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084120
   Farr JN, 2014, J BONE MINER RES, V29, P787, DOI 10.1002/jbmr.2106
   Fowlkes JL, 2008, ENDOCRINOLOGY, V149, P1697, DOI 10.1210/en.2007 1408
   Girotra Monica, 2006, Arq Bras Endocrinol Metab, V50, P745, DOI 10.1590/S0004 27302006000400019
   Grankvist N, 2013, FEBS LETT, V587, P3869, DOI 10.1016/j.febslet.2013.10.022
   Grankvist N, 2012, DIABETOLOGIA, V55, P2005, DOI 10.1007/s00125 012 2541 1
   Green J, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c4444
   Henriksen K, 2014, CALCIFIED TISSUE INT, V94, P88, DOI 10.1007/s00223 013 9741 7
   Hinds TD, 2011, J BIOL CHEM, V286, P42911, DOI 10.1074/jbc.M111.311662
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Jiang XG, 2007, J PROTEOME RES, V6, P2287, DOI 10.1021/pr070056t
   Katsimbri P, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12740
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lecka Czernik B, 2017, DIABETOLOGIA, V60, P1163, DOI 10.1007/s00125 017 4269 4
   Lecka Czernik B, 2015, J BONE MINER RES, V30, P1356, DOI 10.1002/jbmr.2574
   Li ZP, 2006, BIOCHEM BIOPH RES CO, V343, P345, DOI 10.1016/j.bbrc.2006.02.147
   Lin YF, 2022, FASEB J, V36, DOI 10.1096/fj.202101610R
   Liu W, 2015, MINERVA MED, V106, P203
   Ma YFL, 2017, BONE, V97, P20, DOI 10.1016/j.bone.2016.12.003
   McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Ohlsson C, 2011, J BONE MINER RES, V26, P865, DOI 10.1002/jbmr.281
   Qin H, 2018, ARCH ORAL BIOL, V95, P74, DOI 10.1016/j.archoralbio.2018.07.016
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rubin MR, 2022, J CLIN ENDOCR METAB, V107, pE2405, DOI 10.1210/clinem/dgac099
   Rubin MR, 2015, CURR OSTEOPOROS REP, V13, P186, DOI 10.1007/s11914 015 0265 0
   Saito M, 2010, OSTEOPOROSIS INT, V21, P195, DOI 10.1007/s00198 009 1066 z
   Sassi F, 2018, BMC ENDOCR DISORD, V18, DOI 10.1186/s12902 018 0283 x
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Takayanagi H, 2021, J BONE MINER METAB, V39, P13, DOI 10.1007/s00774 020 01191 1
   Tong XS, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12714
   Tong XS, 2019, J CELL BIOCHEM, V120, P1630, DOI 10.1002/jcb.27468
   Wang J., 2016, Chin. J. Comp. Med., P79
   Wang J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0254 6
   Xu F, 2016, MOL MED REP, V14, P2289, DOI 10.3892/mmr.2016.5515
   Yang YQ, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00646
   Yong WD, 2007, J BIOL CHEM, V282, P14690, DOI 10.1074/jbc.C700019200
   Zhang Y, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1063815
   Zhao JY, 2019, J BONE MINER RES, V34, P2149, DOI 10.1002/jbmr.3832
   Zhu RJ, 2022, STEM CELLS INT, V2022, DOI 10.1155/2022/9359429
   Zwickl H, 2021, BMC CANCER, V21, DOI 10.1186/s12885 021 08518 9
NR 49
TC 0
Z9 0
U1 1
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2405 8440
J9 HELIYON
JI Heliyon
PD JUL 15
PY 2024
VL 10
IS 13
AR e34027
DI 10.1016/j.heliyon.2024.e34027
EA JUL 2024
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA YD5L7
UT WOS:001266561200001
PM 39071657
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU George, S
   Brenner, A
   Sarantopoulos, J
   Bukowski, RM
AF George, Saby
   Brenner, Andrew
   Sarantopoulos, John
   Bukowski, Ronald M.
TI RANK Ligand: Effects of Inhibition
SO CURRENT ONCOLOGY REPORTS
LA English
DT Article
DE RANK ligand; Inhibition; Osteoporosis; Bone metastasis; Monoclonal
   antibody
ID NF KAPPA B; TUMOR NECROSIS FACTOR; BREAST CANCER; OSTEOCLAST
   DIFFERENTIATION; POSTMENOPAUSAL WOMEN; BONE METASTASES; PROSTATE CANCER;
   OSTEOPROTEGERIN LIGAND; TAMOXIFEN THERAPY; RANDOMIZED TRIAL
AB Receptor activator of nuclear factor kappa light chain enhancer of activated B cells (RANK) and its ligand (RANKL) belong to the tumor necrosis factor (TNF) superfamily. RANK mRNA is expressed widely in bone and bone marrow. It has a significant role in stimulating osteoclast differentiation and maturation, and also in preventing apoptosis. Because osteoclast activity is an important aspect of bone resorption in malignancy, targeting these cells is a good rationale for preventing skeletal related events in malignancies. Preclinical studies have demonstrated the efficacy of denosumab in preventing bone loss in mice and improving bone mineral density. Denosumab is a fully human monoclonal antibody against RANKL, which has been shown to be effective in reducing signaling via RANK and thus osteoclast activity. It has been demonstrated in large, randomized, phase 3 studies to be effective in preventing fractures and bone loss, and improving the bone mineral density in various cancerous and noncancerous settings. This article reviews the latest evidence of RANKL inhibition and its clinical implications.
C1 [George, Saby; Brenner, Andrew; Sarantopoulos, John; Bukowski, Ronald M.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
C3 Cancer Therapy & Research Center; University of Texas System; University
   of Texas Health Science Center at San Antonio
RP George, S (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Zeller 4th Floor,7979 Wurzbach Rd, San Antonio, TX 78229 USA.
EM georges3@uthscsa.edu
OI George, Saby/0000 0002 0444 5870
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bachmann MF, 1999, J EXP MED, V189, P1025, DOI 10.1084/jem.189.7.1025
   Baum M, 2003, Cancer, V98, P1802
   Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Carlin Bruce I., 2000, Cancer, V88, P2989, DOI 10.1002/1097 0142(20000615)88:12+<2989::AID CNCR14>3.0.CO;2 Q
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331
   Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Eastell R, 2005, J STEROID BIOCHEM, V95, P151, DOI 10.1016/j.jsbmb.2005.04.009
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   FIZAZI K, 2009, EUR SOC MED ONC BERL
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Fouque Aubert A, 2008, JOINT BONE SPINE, V75, P5, DOI 10.1016/j.jbspin.2007.05.004
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312
   HENRY DR, 2009, EUR SOC MED ONC BERL
   Kim H, 2009, J CLIN INVEST, V119, P813, DOI 10.1172/JCI36809
   Kitazawa S, 2002, J PATHOL, V198, P228, DOI 10.1002/path.1199
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li P, 2004, J BONE MINER RES, V19, P207, DOI 10.1359/JBMR.0301233
   Lipton A, 2008, CLIN CANCER RES, V14, P6690, DOI 10.1158/1078 0432.CCR 07 5234
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Mémet S, 2006, BIOCHEM PHARMACOL, V72, P1180, DOI 10.1016/j.bcp.2006.09.003
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Seshasayee D, 2004, J BIOL CHEM, V279, P30202, DOI 10.1074/jbc.M403968200
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   STOPECK A, 2009, EUR SOC MED ONC BERL
   STOPECK A, 2009, 32 CANC THER RES CTR
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 34
TC 13
Z9 17
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523 3790
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD MAR
PY 2010
VL 12
IS 2
BP 80
EP 86
DI 10.1007/s11912 010 0088 1
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 723IF
UT WOS:000287499400002
PM 20425591
DA 2025 08 17
ER

PT J
AU Jiang, C
   Xiao, F
   Gu, XF
   Zhai, ZJ
   Liu, XQ
   Wang, WG
   Tang, TT
   Wang, Y
   Zhu, ZN
   Dai, KR
   Qin, A
   Wang, JW
AF Jiang, Chuan
   Xiao, Fei
   Gu, Xinfeng
   Zhai, Zanjing
   Liu, Xuqiang
   Wang, Wengang
   Tang, Tingting
   Wang, You
   Zhu, Zhenan
   Dai, Kerong
   Qin, An
   Wang, Jinwu
TI Inhibitory effects of ursolic acid on osteoclastogenesis and titanium
   particle induced osteolysis are mediated primarily via suppression of
   NF κB signaling
SO BIOCHIMIE
LA English
DT Article
DE Ursolic acid; Osteoclastogenesis; NF kappa B; Titanium particle;
   Osteolysis
ID ACTIN RING FORMATION; TNF ALPHA; IN VITRO; C FOS; BONE; DIFFERENTIATION;
   RANKL; PATHWAY; MECHANISMS; APOPTOSIS
AB Ursolic acid (UA), a pentacyclic triterpenoid found in a variety of plants, has attracted considerable attention because of its important biological and pharmacological activities. However, its effect on osteoclasts and mechanism of action require further investigation. In this study, we evaluated the effects of UA on osteoclastogenesis and osteoclast mediated osteolysis in vitro and in vivo, and explored its possible mechanism of action. The results indicated that UA could inhibit receptor activator of nuclear factor kappa B ligand (RANKL) mediated osteoclastogenesis and the bone resorptive function of osteoclasts in a concentration dependent manner in vitro. Further, UA effectively inhibited the mRNA and protein expression of NFATc1, primarily via the suppression of nuclear factor kappa B (NF kappa B) signaling, and partly through the suppression of c Jun N terminal kinase (JNK) signaling. Additionally, UA treatment downregulated the expression of NFATc1 regulated osteoclast marker genes. Likewise, UA induced dose dependent attenuation of titanium (Ti) particle induced mouse calvarial bone loss, and decreased the number of tartrate resistant acid phosphatase (TRAP) positive osteoclasts. In conclusion, these results demonstrate that UA protects against wear particle induced osteolysis by suppressing osteoclast formation and function. These effects are associated with the inhibition of the NF kappa B  and JNK related signaling pathways. (C) 2015 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.
C1 [Jiang, Chuan; Xiao, Fei; Zhai, Zanjing; Liu, Xuqiang; Wang, Wengang; Tang, Tingting; Wang, You; Zhu, Zhenan; Dai, Kerong; Qin, An; Wang, Jinwu] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp Affiliated 9, Shanghai Key Lab Orthopaed Implant, Dept Orthopaed Surg,Sch Med, Shanghai 200011, Peoples R China.
   [Gu, Xinfeng] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Qin, A (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp Affiliated 9, Shanghai Key Lab Orthopaed Implant, Dept Orthopaed Surg,Sch Med, Room 703,3 Bldg,639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM dr_qinan@l63.com; jinwu_wang@l63.com
RI zhang, xuyang/GQH 3712 2022; Tang, Tingting/B 1361 2013; Wang,
   Xuejun/K 8874 2013; Wang, Jinwu/AAG 4431 2021; Qin, An/J 2518 2019
OI Tang, Tingting/0000 0002 1670 7452; Wang, You/0000 0002 0823 3293; Wang,
   Jinwu/0000 0003 1411 057X; 
FU National Natural Science Foundation of China [81171707]; National Basic
   Research Program of China (973 Program) [2011CB013300, 2012CB933604];
   Fund for Key Disciplines of Shanghai Municipal Education Commission
   [2013ZYJB0501]
FX The project was supported by the National Natural Science Foundation of
   China (Grant No. 81171707), the National Basic Research Program of China
   (973 Program, Grant No. 2011CB013300), the Fund for Key Disciplines of
   Shanghai Municipal Education Commission (Grant No. 2013ZYJB0501), and
   the National Basic Research Program of China (973 Program, Grant No.
   2012CB933604). We would like to thank Chuandong Wang from Institute of
   Health Sciences, Shanghai Jiao Tong University School of Medicine, and
   Qinghui Zhao from School of Biomedical Engineering, Shanghai Jiao Tong
   University for his help and support with SEM. We would also acknowledge
   the facilities, technical and scientific assistance of Shanghai Key
   Laboratory of Orthopedic Implant, Shanghai Ninth People's Hospital
   Affiliated Shanghai Jiao Tong University School of Medicine, China.
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bostrom M, 2008, J AM ACAD ORTHOP SUR, V16, pS63, DOI 10.5435/00124635 200800001 00013
   Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chambers TJ, 2000, J PATHOL, V192, P4
   Checker R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031318
   Chellaiah MA, 2005, J BIOL CHEM, V280, P32930, DOI 10.1074/jbc.M500154200
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gallo J, 2008, PHYSIOL RES, V57, P339, DOI 10.33549/physiolres.931140
   Gallo J, 2013, INNATE IMMUN LONDON, V19, P213, DOI 10.1177/1753425912451779
   Gallo Jiri, 2002, Biomedical Papers (Olomouc), V146, P21
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Greenfield EM, 2002, J ORTHOPAED RES, V20, P1, DOI 10.1016/S0736 0266(01)00070 5
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hu JP, 2008, EUR J PHARMACOL, V580, P70, DOI 10.1016/j.ejphar.2007.11.013
   Jia Y, 2011, BIOORG MED CHEM LETT, V21, P5876, DOI 10.1016/j.bmcl.2011.07.095
   Jiang C, 2013, J RARE EARTH, V31, P420, DOI 10.1016/S1002 0721(12)60298 1
   Jiang YP, 2013, ACTA BIOMATER, V9, P7564, DOI 10.1016/j.actbio.2013.03.010
   Jin S, 2011, EXP MOL MED, V43, P411, DOI 10.3858/emm.2011.43.7.045
   Kim HJ, 2007, MOL PHARMACOL, V72, P418, DOI 10.1124/mol.107.034173
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Langlois J, 2011, INT ORTHOP, V35, P245, DOI 10.1007/s00264 010 1143 0
   Lee SU, 2008, PHARMACOL RES, V58, P290, DOI 10.1016/j.phrs.2008.08.008
   Li YH, 2014, J PHARMACOL SCI, V125, P202, DOI 10.1254/jphs.14017FP
   Liu H, 2005, J ETHNOPHARMACOL, V100, P92, DOI 10.1016/j.jep.2005.05.024
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Murakami S, 2004, FEBS LETT, V566, P55, DOI 10.1016/j.febslet.2004.04.036
   Naili S, 2011, J MECH BEHAV BIOMED, V4, P827, DOI 10.1016/j.jmbbm.2011.04.011
   Pathak AK, 2007, MOL CANCER RES, V5, P943, DOI 10.1158/1541 7786.MCR 06 0348
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   Qin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034132
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Saraswati S, 2013, CHEM BIOL INTERACT, V206, P153, DOI 10.1016/j.cbi.2013.09.004
   Shalhoub V, 2000, BRIT J HAEMATOL, V111, P501, DOI 10.1046/j.1365 2141.2000.02379.x
   Shin DK, 2012, ACTA BIOMATER, V8, P3524, DOI 10.1016/j.actbio.2012.05.002
   Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098 2795(199701)46:1<4::AID MRD2>3.0.CO;2 V
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Tan H, 2014, J AGR FOOD CHEM, V62, P836, DOI 10.1021/jf402735u
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   von Knoch M, 2004, J ORTHOP RES, V22, P237, DOI 10.1016/j.orthres.2003.08.013
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Xia EQ, 2011, INT J MOL SCI, V12, P5319, DOI 10.3390/ijms12085319
   Yadav VR, 2010, TOXINS, V2, P2428, DOI 10.3390/toxins2102428
NR 48
TC 38
Z9 44
U1 1
U2 27
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0300 9084
EI 1638 6183
J9 BIOCHIMIE
JI Biochimie
PD APR
PY 2015
VL 111
BP 107
EP 118
DI 10.1016/j.biochi.2015.02.002
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA CG3KE
UT WOS:000353178300009
PM 25681755
DA 2025 08 17
ER

PT J
AU O'Sullivan, S
   Naot, D
   Callon, K
   Porteous, F
   Horne, A
   Wattie, D
   Watson, M
   Cornish, J
   Browett, P
   Grey, A
AF O'Sullivan, Susannah
   Naot, Dorit
   Callon, Karen
   Porteous, Fran
   Horne, Anne
   Wattie, Diana
   Watson, Maureen
   Cornish, Jill
   Browett, Peter
   Grey, Andrew
TI Imatinib promotes osteoblast differentiation by inhibiting PDGFR
   signaling and inhibits osteoclastogenesis by both direct and stromal
   cell dependent mechanisms
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE osteoblasts; differentiation; platelet derived growth factor;
   osteoclastogenesis; osteoprotegerin
ID GROWTH FACTOR; LYSOPHOSPHATIDIC ACID; BONE FORMATION; G(I) PROTEINS;
   MESYLATE; KINASE; RECEPTOR; TARGET; PROLIFERATION; DELETION
AB Several lines of evidence suggest that imatinib may affect skeletal tissue. We show that inhibition by imatinib of PDGFR signaling in osteoblasts; activates osteoblast differentiation and inhibits osteoblast proliferation and that imatinib inhibits osteoclastogenesis by both stromal cell dependent and direct effects on osteoclast precursors.
   Introduction: Imatinib mesylate, an orally active inhibitor of the c abl, c kit, and platelet derived growth factor receptor (PDGFR) tyrosine kinases, is in clinical use for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal cell tumors. Interruption of both c kit and c abl signaling in mice induces osteopenia, suggesting that imatinib might have adverse effects on the skeleton. However, biochemical markers of bone formation increase in patients with CML starting imatinib therapy, whereas bone resorption is unchanged, despite secondary hyperparathyroidism. We assessed the actions of imatinib on bone cells in vitro to study the cellular and molecular mechanism(s) underlying the skeletal effects we observed in imatinib treated patients.
   Materials and Methods: Osteoblast differentiation was assessed using a mineralization assay, proliferation by [H 3]thymidine incorporation, and apoptosis by a TUNEL assay. Osteoclastogenesis was assessed using murine bone marrow cultures and RAW 264.7 cells. RT and multiplex PCR were performed on RNA prepared from human bone marrow samples, osteoblastic cells, and murine bone marrow cultures. Osteoprotegerin was measured by ELISA.
   Results: The molecular targets of imatinib are expressed in bone cells. In vitro, imatinib increases osteoblast differentiation and prevents PDGF induced inhibition of this process. Imatinib inhibits proliferation of osteoblast like cells induced by serum and PDGF. In murine bone marrow cultures, imatinib inhibits osteoclastogenesis stimulated by 1,25 dihydroxyvitamin D 3 and partially inhibits osteoclastogenesis induced by RANKL and macrophage colony stimulating factor. Imatinib partially inhibited osteoclastogenesis in RANKL stimulated RAW 264.7 cells. Treatment with imatinib increases the expression of osteoprotegerin in bone marrow from patients with CML and osteoblastic cells.
   Conclusions: Taken together with recent in vivo data, these results suggest a role for the molecular targets of imatinib in bone cell function, that inhibition by imatinib of PDGFR signaling in osteoblasts activates bone formation, and that the antiresorptive actions of imatinib are mediated by both stromal cell dependent and direct effects on osteoclast precursors.
C1 Univ Auckland, Dept Med, Auckland 1142, New Zealand.
   Univ Auckland, Dept Mol Med & Pathol, Auckland 1142, New Zealand.
C3 University of Auckland; University of Auckland
RP O'Sullivan, S (通讯作者)，Univ Auckland, Dept Med, Private Bag 92019, Auckland 1142, New Zealand.
EM s.osullivan@auckland.ac.nz
OI Naot, Dorit/0000 0001 9498 2639; Horne, Anne/0000 0003 2783 7452
CR Ando W, 2006, J BONE MINER METAB, V24, P274, DOI 10.1007/s00774 006 0684 1
   Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140
   Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095
   CANALIS E, 1989, J CELL PHYSIOL, V140, P530, DOI 10.1002/jcp.1041400319
   CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P13, DOI 10.1210/endo 125 1 13
   Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217
   Cornish J, 2001, BONE, V29, P162, DOI 10.1016/S8756 3282(01)00494 X
   Cornish J, 1998, AM J PHYSIOL ENDOC M, V274, pE827, DOI 10.1152/ajpendo.1998.274.5.E827
   Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood 2004 10 3967
   Dewar AL, 2006, BLOOD, V107, P4334, DOI 10.1182/blood 2005 09 3568
   Dib IE, 2006, EUR J PHARMACOL, V551, P27, DOI 10.1016/j.ejphar.2006.09.007
   Fierro F, 2007, CELL PROLIFERAT, V40, P355, DOI 10.1111/j.1365 2184.2007.00438.x
   Gallet M, 2006, APOPTOSIS, V11, P1909, DOI 10.1007/s10495 006 9507 z
   Gottardi M, 2005, NEW ENGL J MED, V353, P2722, DOI 10.1056/NEJMc052500
   Grey A, 2003, ENDOCRINOLOGY, V144, P4886, DOI 10.1210/en.2003 0350
   Grey A, 2002, ENDOCRINOLOGY, V143, P4755, DOI 10.1210/en.2002 220347
   Grey A, 2001, ENDOCRINOLOGY, V142, P1098, DOI 10.1210/en.142.3.1098
   Grey A, 2006, NEW ENGL J MED, V355, P2494, DOI 10.1056/NEJMc062388
   GROOT CG, 1985, CELL BIOL INT REP, V9, P528, DOI 10.1016/0309 1651(85)90015 3
   HERRMANNERLEE MPM, 1986, INT C 9 CALC REG HOR
   HOCK JM, 1994, ENDOCRINOLOGY, V134, P1423, DOI 10.1210/en.134.3.1423
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Kerkelä R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446
   Lassila M, 2004, ARTERIOSCL THROM VAS, V24, P935, DOI 10.1161/01.ATV.0000124105.39900.db
   Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542
   Lotinun S, 2005, J BONE MINER RES, V20, P644, DOI 10.1359/JBMR.041209
   Middleton Hardie C, 2006, J BONE MINER RES, V21, P438, DOI 10.1359/JBMR.051104
   Naot D, 2001, ENDOCRINOLOGY, V142, P1849, DOI 10.1210/en.142.5.1849
   O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457
   Paniagua RT, 2006, J CLIN INVEST, V116, P2633, DOI 10.1172/JCI28546
   Peng B, 2004, J CLIN ONCOL, V22, P935, DOI 10.1200/JCO.2004.03.050
   Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339
   Taylor JR, 2006, ONCOGENE, V25, P147, DOI 10.1038/sj.onc.1209007
   Tsao AS, 2003, CANCER, V98, P2483, DOI 10.1002/cncr.11812
   Veneri D, 2005, NEW ENGL J MED, V352, P1049, DOI 10.1056/NEJM200503103521023
   Verweij J, 2003, EUR J CANCER, V39, P2006, DOI 10.1016/S0959 8049(02)00836 5
NR 36
TC 107
Z9 108
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2007
VL 22
IS 11
BP 1679
EP 1689
DI 10.1359/JBMR.070719
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 228YJ
UT WOS:000250768200007
PM 17663639
OA Bronze
DA 2025 08 17
ER

PT J
AU Memon, AR
   Butler, JS
   O'Riordan, MV
   Guerin, E
   Dimitrov, BD
   Harty, JA
AF Memon, Adeel R.
   Butler, Joseph S.
   O'Riordan, Michael V.
   Guerin, Elizabeth
   Dimitrov, Borislav D.
   Harty, James A.
TI Comparison of Serum Dkk1 (Dickkopf 1) and Bone Mineral Density in
   Patients on Bisphosphonate Treatment Vs no Treatment
SO JOURNAL OF CLINICAL DENSITOMETRY
LA English
DT Article
DE Bisphosphonates; bone mineral density; Dkk1; DEXA; osteoporosis
ID WORLDWIDE PREVALENCE; WNT; ALENDRONATE; MECHANISMS; REGULATOR;
   OSTEOCYTE; APOPTOSIS; HIP
AB Complex pathways affect bone metabolism at the cellular level, and a balance between osteoblast and osteoclast activity is critical to bone remodeling. One of the major pathways affecting bone metabolism is Wnt/beta catenin signaling, and its disturbances lead to a wide range of bone abnormalities. An important antagonist of this pathway is Dickkopf 1 (Dkk1). Higher Dkk1 levels have been associated with increased bone loss due to inhibition of Wnt pathway. Currently, bisphosphonates are the most commonly used agents to treat primary osteoporotic patients. This study demonstrates the effect of bisphosphonates on Dkk1 levels and its correlation with bone mineral density (BMD). Eighty patients with low BMD were recruited and divided into 2 groups of 40 each (bisphosphonate treatment group and control group). The mean Dkk1 level in the treatment group was significantly reduced to 2358.18 vs 3749.80 pg/mL in the control group (p < 0.001). Pearson correlation coefficient showed negative correlation between Dkk1 and BMD at lumbar spine (r =  0.55) and femoral neck in the control group; however, no such correlation was found in the treatment group (r =  0.05). Hence, bisphosphonate therapy leads to reduction in Dkk1 levels, but it does not correlate with BMD in such patients.
C1 [Memon, Adeel R.; Butler, Joseph S.; O'Riordan, Michael V.; Guerin, Elizabeth; Harty, James A.] Cork Univ Hosp, Dept Trauma & Orthopaed, Cork, Ireland.
   [Dimitrov, Borislav D.] Royal Coll Surgeons Ireland, Dept Gen Practice, Dublin 2, Ireland.
C3 University College Cork; Royal College of Surgeons   Ireland
RP Memon, AR (通讯作者)，Cork Univ Hosp, Dept Trauma & Orthopaed, Wilton Rd, Cork, Ireland.
EM dowite2003@hotmail.com
RI ; Dimitrov, Borislav/A 1246 2010
OI Butler, Joseph S./0000 0002 8823 4631; Dimitrov,
   Borislav/0000 0002 5896 2072
CR Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Butler JS, 2010, J ORTHOP RES, V11, P11
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001 2002
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Ellwanger K, 2008, MOL CELL BIOL, V28, P4875, DOI 10.1128/MCB.00222 08
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Greenspan SL, 2002, J BONE MINER RES, V17, P1988
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Johnell O, 2004, OSTEOPOROSIS INT, V15, P38, DOI 10.1007/s00198 003 1490 4
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378 1119(99)00365 0
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Millar JBA, 2002, GENOME BIOL, V3
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Polyzos SA, 2009, HORM METAB RES, V41, P846, DOI 10.1055/s 0029 1233491
   Polyzos SA, 2010, J CLIN DENSITOM, V13, P190, DOI 10.1016/j.jocd.2010.01.006
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Rauner M, 2008, AGE, V30, P273, DOI 10.1007/s11357 008 9069 9
   Ravn P, 2000, J CLIN ENDOCR METAB, V85, P1492, DOI 10.1210/jc.85.4.1492
   Semënov MV, 2008, J BIOL CHEM, V283, P21427, DOI 10.1074/jbc.M800014200
   Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Voskaridou E, 2009, HAEMATOL HEMATOL J, V94, P725, DOI [10.3324/haematol.2008.000893, 10.3324/haema tol.2008.000893]
NR 32
TC 8
Z9 9
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1094 6950
EI 1559 0747
J9 J CLIN DENSITOM
JI J. Clin. Densitom.
PD JAN MAR
PY 2013
VL 16
IS 1
BP 118
EP 124
DI 10.1016/j.jocd.2012.07.003
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 093GA
UT WOS:000315178500024
PM 22959779
DA 2025 08 17
ER

PT J
AU Mobasheri, A
AF Mobasheri, A.
TI The Future of Osteoarthritis Therapeutics: Targeted Pharmacological
   Therapy
SO CURRENT RHEUMATOLOGY REPORTS
LA English
DT Article
DE Osteoarthritis; Therapeutics; Pharmaceuticals; Pharmacological therapy;
   Analgesics; Non steroidal anti inflammatory drugs (NSAIDs);
   Bisphosphonates; Strontium ranelate; Inducible nitric oxide synthase
   (iNOS); Anti MMP therapy; DMOADs; Biomarkers
ID KNEE OSTEOARTHRITIS; NITRIC OXIDE; MITOCHONDRIAL DYSFUNCTION;
   ARTICULAR CARTILAGE; SUBCHONDRAL BONE; MATRIX METALLOPROTEINASES;
   INFLAMMATORY CYTOKINES; STRONTIUM RANELATE; PATHOGENESIS; COMPLEMENTARY
AB Osteoarthritis (OA) is one of the most common forms of degenerative joint disease and a major cause of pain and disability affecting the aging population. It is estimated that more than 20 million Americans and 35 to 40 million Europeans suffer from OA. Analgesics and non steroidal anti inflammatory drugs (NSAIDs) are the only therapeutic treatment options for OA. Effective pharmacotherapy for OA, capable of restoring the original structure and function of damaged cartilage and other synovial tissue, is urgently needed, and research into such disease modifying osteoarthritis drugs (DMOADs) is in progress. This is the first of three reviews focusing on OA therapeutics. This paper provides an overview of current research into potential structure modifying drugs and more appropriately targeted pharmacological therapy. The challenges and opportunities in this area of research and development are reviewed, covering the most up to date initiatives, trends, and topics.
C1 [Mobasheri, A.] Univ Nottingham, Fac Med & Hlth Sci, D BOARD European Consortium Biomarker Discovery, Nottingham NG7 2RD, England.
   [Mobasheri, A.] Univ Nottingham, Arthrit Res UK Ctr Sport Exercise & Osteoarthrit, Nottingham NG7 2RD, England.
   [Mobasheri, A.] Univ Nottingham, Arthrit Res UK Pain Ctr, Loughborough LE12 5RD, England.
   [Mobasheri, A.] Univ Nottingham, MRC, Nottingham NG7 2RD, England.
   [Mobasheri, A.] Univ Nottingham, Arthrit Res UK Ctr Musculoskeletal Ageing Res, Nottingham NG7 2RD, England.
   [Mobasheri, A.] Univ Birmingham, MRC, Birmingham, W Midlands, England.
   [Mobasheri, A.] Univ Birmingham, Arthrit Res UK Ctr Musculoskeletal Ageing Res, Birmingham, W Midlands, England.
   [Mobasheri, A.] King Abdulaziz Univ, KFMRC, CEGMR, Jeddah 21589, Saudi Arabia.
   [Mobasheri, A.] Univ Nottingham, Fac Med & Hlth Sci, Musculoskeletal Res Grp, Sch Vet Med & Sci, Loughborough LE12 5RD, England.
   [Mobasheri, A.] Univ Bradford, Sch Pharm, Bradford BD7 1DP, W Yorkshire, England.
   [Mobasheri, A.] Univ Bradford, Sch Life Sci, Bradford BD7 1DP, W Yorkshire, England.
C3 University of Nottingham; University of Nottingham; University of
   Nottingham; University of Nottingham; University of Nottingham;
   University of Birmingham; University of Birmingham; King Abdulaziz
   University; University of Nottingham; University of Bradford; University
   of Bradford
RP Mobasheri, A (通讯作者)，Univ Nottingham, Fac Med & Hlth Sci, D BOARD European Consortium Biomarker Discovery, Nottingham NG7 2RD, England.
EM ali.mobasheri@nottingham.ac.uk
RI Mobasheri, Ali/D 5770 2011
OI Mobasheri, Ali/0000 0001 6261 1286
FU European Union [305815]; European Commission [305815, 2012.2.4.5 2];
   Biotechnology and Biological Sciences Research Council (BBSRC)
   [BBSRC/S/M/2006/13141, BB/G018030/1]; Engineering and Physical Sciences
   Research Council (EPSRC); National Centre for the Replacement,
   Refinement, and Reduction of Animals in Research (NC3Rs) [28102007];
   Wellcome Trust [CVRT VS 0901]; BBSRC [BB/G018030/1] Funding Source:
   UKRI; MRC [MR/K00414X/1] Funding Source: UKRI; Medical Research Council
   [MR/K00414X/1] Funding Source: researchfish
FX The research leading to these results has received partial funding from
   the European Union Seventh Framework Programme (FP7/2007 2013) under
   grant agreement no. 305815. The author is the coordinator of the D BOARD
   Consortium funded by European Commission Framework 7 program (EU FP7;
   HEALTH. 2012.2.4.5 2, project number 305815, Novel Diagnostics and
   Biomarkers for Early Identification of Chronic Inflammatory Joint
   Diseases). The author's research has also been supported by grants from
   the Biotechnology and Biological Sciences Research Council (BBSRC;
   grants BBSRC/S/M/2006/13141 and BB/G018030/1), the Engineering and
   Physical Sciences Research Council (EPSRC), the National Centre for the
   Replacement, Refinement, and Reduction of Animals in Research (NC3Rs;
   grant number: Mobasheri. A. 28102007), and the Wellcome Trust (Grant no.
   CVRT VS 0901).
CR Abramson SB, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2655
   Abramson SB, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2463
   Afonso V, 2007, JOINT BONE SPINE, V74, P324, DOI 10.1016/j.jbspin.2007.02.002
   Akhtar N, 2012, THER ADV MUSCULOSKEL, V4, P181, DOI 10.1177/1759720X11436238
   Anderson AS, 2010, BEST PRACT RES CL RH, V24, P15, DOI 10.1016/j.berh.2009.08.006
   Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989
   Bay Jensen AC, 2013, MENOPAUSE, V20, P578, DOI 10.1097/GME.0b013e3182745993
   Berenbaum F, 2013, OSTEOARTHR CARTILAGE, V21, P16, DOI 10.1016/j.joca.2012.11.012
   Berenbaum F, 2013, CURR OPIN RHEUMATOL, V25, P114, DOI 10.1097/BOR.0b013e32835a9414
   Bingham CO, 2006, ARTHRITIS RHEUM US, V54, P3494, DOI 10.1002/art.22160
   Blanco FJ, 2004, MITOCHONDRION, V4, P715, DOI 10.1016/j.mito.2004.07.022
   Blanco FJ, 2011, NAT REV RHEUMATOL, V7, P161, DOI 10.1038/nrrheum.2010.213
   Burr David B, 2004, Osteoarthritis Cartilage, V12 Suppl A, pS20
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Castañeda S, 2012, BIOCHEM PHARMACOL, V83, P315, DOI 10.1016/j.bcp.2011.09.018
   Caterson B, 2000, MATRIX BIOL, V19, P333, DOI 10.1016/S0945 053X(00)00078 0
   Cawston TE, 2006, BEST PRACT RES CL RH, V20, P983, DOI 10.1016/j.berh.2006.06.007
   Cillero Pastor B, 2008, ARTHRITIS RHEUM US, V58, P2409, DOI 10.1002/art.23644
   Clutterbuck AL, 2009, CURR DRUG TARGETS, V10, P1245, DOI 10.2174/138945009789753264
   Coppé JP, 2010, ANNU REV PATHOL MECH, V5, P99, DOI 10.1146/annurev pathol 121808 102144
   Cuzzocrea S, 2006, CURR PHARM DESIGN, V12, P3551, DOI 10.2174/138161206778343082
   Da Sylva TR, 2005, ARTHRITIS RES THER, V7, pR844, DOI 10.1186/ar1752
   Dave M, 2008, ARTHRITIS RHEUM, V58, P2786, DOI 10.1002/art.23799
   Davidson RK, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2013
   de Isla NG, 2008, BIO MED MATER ENG, V18, pS99
   Dooley M, 2001, DRUGS, V61, P1351, DOI 10.2165/00003495 200161090 00012
   Edmonds S, 2009, MATURITAS, V63, P191, DOI 10.1016/j.maturitas.2009.03.015
   Ernst E, 2006, NAT CLIN PRACT RHEUM, V2, P74, DOI 10.1038/ncprheum0093
   Ernst E, 2003, CURR OPIN RHEUMATOL, V15, P151, DOI 10.1097/00002281 200303000 00012
   Ernst E, 2000, BEST PRACT RES CL RH, V14, P731, DOI 10.1053/berh.2000.0110
   Ernst E, 2004, BEST PRACT RES CL RH, V18, P539, DOI 10.1016/j.berh.2004.03.005
   Felson DT, 2007, ARTHRITIS RHEUM US, V56, P1378, DOI 10.1002/art.22526
   Felson DT, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2531
   Fernández Moreno M, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 283
   Fidelix TSA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005117.pub2
   Findlay DM, 2007, RHEUMATOLOGY, V46, P1763, DOI 10.1093/rheumatology/kem191
   Findlay DM, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3007
   Flood J, 2010, AM J MANAG CARE, V16, pS48
   Furst DE, 1997, SEMIN ARTHRITIS RHEU, V26, P21, DOI 10.1016/S0049 0172(97)80049 2
   Goggs R, 2003, VET J, V166, P140, DOI 10.1016/S1090 0233(02)00331 3
   Goldring MB, 2007, J CELL PHYSIOL, V213, P626, DOI 10.1002/jcp.21258
   Goldring MB, 2010, ANN NY ACAD SCI, V1192, P230, DOI 10.1111/j.1749 6632.2009.05240.x
   Goldring MB, 2004, CLIN ORTHOP RELAT R, pS37, DOI 10.1097/01.blo.0000144484.69656.e4
   Griffin MR., 1998, The American Journal of Medicine, V104, p23S, DOI DOI 10.1016/S0002 9343(97)00207 6
   Grishko VI, 2009, OSTEOARTHR CARTILAGE, V17, P107, DOI 10.1016/j.joca.2008.05.009
   Hochberg MC, 2005, CURR TOP MED CHEM, V5, P443, DOI 10.2174/1568026054201695
   Hunter DJ, 2008, RHEUM DIS CLIN N AM, V34, P789, DOI 10.1016/j.rdc.2008.05.003
   Hunter DJ, 2009, MED CLIN N AM, V93, P223, DOI 10.1016/j.mcna.2008.07.011
   Johnson K, 2000, ARTHRITIS RHEUM US, V43, P1560, DOI 10.1002/1529 0131(200007)43:7<1560::AID ANR21>3.3.CO;2 J
   Johnson K, 2004, ARTHRITIS RHEUM US, V50, P1216, DOI 10.1002/art.20149
   Kim J, 2010, OSTEOARTHR CARTILAGE, V18, P424, DOI 10.1016/j.joca.2009.09.008
   Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544
   Krasnokutsky S, 2007, BULL HOSP JT DIS, V65, P222
   Kraus VB, 2011, OSTEOARTHR CARTILAGE, V19, P515, DOI 10.1016/j.joca.2010.08.019
   Lesko LJ, 2001, ANNU REV PHARMACOL, V41, P347, DOI 10.1146/annurev.pharmtox.41.1.347
   Lipsky P E, 1999, Am J Orthop (Belle Mead NJ), V28, P8
   Liu Danhui, 2013, Front Biosci (Elite Ed), V5, P734
   Loeser RF, 2009, OSTEOARTHR CARTILAGE, V17, P971, DOI 10.1016/j.joca.2009.03.002
   Loeser RF, 2013, CURR OPIN RHEUMATOL, V25, P108, DOI 10.1097/BOR.0b013e32835a9428
   Loeser RF, 2012, ARTHRITIS RHEUM US, V64, P1697, DOI 10.1002/art.34453
   Loeser RF, 2011, CURR OPIN RHEUMATOL, V23, P492, DOI 10.1097/BOR.0b013e3283494005
   Loewen Peter S, 2002, CJEM, V4, P268
   Long L, 2001, RHEUMATOLOGY, V40, P779, DOI 10.1093/rheumatology/40.7.779
   Lopez Armada MJ, 2006, OSTEOARTHR CARTILAGE, V14, P1011, DOI 10.1016/j.joca.2006.03.008
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   Lotz M, 2012, OSTEOARTHR CARTILAGE, V20, P192, DOI 10.1016/j.joca.2011.11.015
   Mahjoub M, 2012, OSTEOPOROSIS INT, V23, pS841, DOI 10.1007/s00198 012 2161 0
   Maneiro E, 2003, ARTHRITIS RHEUM, V48, P700, DOI 10.1002/art.10837
   Mapp PI, 2010, OSTEOARTHR CARTILAGE, V18, P593, DOI 10.1016/j.joca.2009.12.006
   MEISTER A, 1994, J BIOL CHEM, V269, P9397
   MEISTER A, 1994, CANCER RES, V54, pS1969
   Milner JM, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2034
   Miyasaka N, 1997, LIFE SCI, V61, P2073, DOI 10.1016/S0024 3205(97)00585 7
   Mobasheri A, 2012, OSTEOARTHR CARTILAGE, V20, P1451, DOI 10.1016/j.joca.2012.07.009
   Mobasheri A, 2002, MED HYPOTHESES, V58, P193, DOI 10.1054/mehy.2000.1180
   Mobasheri A, 2012, CHANNELS, V6, P416, DOI 10.4161/chan.22340
   Mobasheri A, 2012, CURR RHEUMATOL REP, V14, P604, DOI 10.1007/s11926 012 0288 9
   Mobasheri A, 2012, INT J MOL SCI, V13, P4202, DOI 10.3390/ijms13044202
   Morris BJ, 2013, FREE RADICAL BIO MED, V56, P133, DOI 10.1016/j.freeradbiomed.2012.10.525
   O'Donnell S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005326.pub2
   Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446
   Patel KR, 2011, ANN NY ACAD SCI, V1215, P161, DOI 10.1111/j.1749 6632.2010.05853.x
   Poole AR, 2003, BIOCHEM SOC SYMP, V70, P115, DOI 10.1042/bss0700115
   Qvist P, 2008, PHARMACOL RES, V58, P1, DOI 10.1016/j.phrs.2008.06.001
   Reginster JY, 2013, ANN RHEUM DIS, V72, P179, DOI 10.1136/annrheumdis 2012 202231
   Richette P, 2012, OSTEOPOROSIS INT, V23, pS877, DOI 10.1007/s00198 012 2165 9
   Rizzoli R, 2007, CLIMACTERIC, V10, P74, DOI 10.1080/13697130701600815
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Rosen CJ, 2000, BEST PRACT RES CL EN, V14, P181, DOI 10.1053/beem.2000.0068
   Rousseau JC, 2007, NAT CLIN PRACT RHEUM, V3, P346, DOI 10.1038/ncprheum0508
   Ruiz Romero C, 2009, MOL CELL PROTEOMICS, V8, P172, DOI 10.1074/mcp.M800292 MCP200
   Safdar A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010778
   Scott JL, 2010, ANN RHEUM DIS, V69, P1502, DOI 10.1136/ard.2009.119966
   Sellam J, 2010, NAT REV RHEUMATOL, V6, P625, DOI 10.1038/nrrheum.2010.159
   Setty AR, 2005, SEMIN ARTHRITIS RHEU, V34, P773, DOI 10.1016/j.semarthrit.2005.01.011
   Spector TD, 2005, ARTHRITIS RES THER, V7, pR625, DOI 10.1186/ar1716
   Spector TD, 2003, AGING CLIN EXP RES, V15, P413, DOI 10.1007/BF03327362
   Stevens Lapsley JE, 2010, WOMENS HEALTH, V6, P601, DOI 10.2217/WHE.10.38
   Suri S, 2012, BONE, V51, P204, DOI 10.1016/j.bone.2011.10.010
   Sutton S, 2009, VET J, V179, P10, DOI 10.1016/j.tvjl.2007.08.013
   Tanamas SK, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2971
   Vaamonde García C, 2012, ARTHRITIS RHEUM US, V64, P2927, DOI 10.1002/art.34508
   Vane JR, 1997, SEMIN ARTHRITIS RHEU, V26, P2, DOI 10.1016/S0049 0172(97)80046 7
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Walsh DA, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3448
   Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092 8674(00)80429 8
   Whitehouse M. W., 2003, Inflammopharmacology, V11, P453, DOI 10.1163/156856003322699636
   Zhang W, 2007, OSTEOARTHR CARTILAGE, V15, P981, DOI 10.1016/j.joca.2007.06.014
   Zhuo Q, 2012, NAT REV RHEUMATOL, V8, P729, DOI 10.1038/nrrheum.2012.135
NR 109
TC 83
Z9 101
U1 0
U2 21
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1523 3774
EI 1534 6307
J9 CURR RHEUMATOL REP
JI Curr. Rheumatol. Rep.
PD OCT
PY 2013
VL 15
IS 10
AR 364
DI 10.1007/s11926 013 0364 9
PG 13
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 228HO
UT WOS:000325176800004
PM 24061701
OA Green Accepted, Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Chang, JK
   Wang, GJ
   Tsai, ST
   Ho, ML
AF Chang, JK
   Wang, GJ
   Tsai, ST
   Ho, ML
TI Nonsteroidal anti inflammatory drug effects on osteoblastic cell cycle,
   cytotoxicity, and cell death
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE apoptosis; cell cycle; cytotoxicity; NSAIDs; osteoblast
ID METAPHYSEAL HARD TISSUE; COLON CANCER CELLS; FETAL RAT BONE; INDUCED
   APOPTOSIS; PHARMACOKINETIC PROPERTIES; INDEPENDENT PATHWAY; SULINDAC
   SULFIDE; FRACTURED RIBS; GROWTH FACTOR; GROWING RATS
AB Previous studies indicated that nonsteroidal anti inflammatory drugs (NSAIDs) suppress bone repair, growth, and remodeling in vivo. Our previous in vitro study demonstrated that indomethacin and ketorolac inhibited osteoblast proliferation. In this study, we further investigated the influences of 4 NSAIDs on cell cycle kinetics, cytotoxicity, and cell death pattern in osteoblast cultures from rat fetal calvaria. Our results showed that NSAIDs significantly arrested cell cycle at the G(0)/G(1) phase and induced cytotoxicity and cell death of osteoblasts. Apoptosis was more pronounced than necrosis caused by NSAIDs. Among these NSAIDs, piroxicam showed the least effect to produce osteoblastic dysfunction. Moreover, we found that the cytotoxic and apoptotic effects of NSAIDs on osteoblasts might not be prostaglandin related. These results suggest that the NSAID effects on cell cycle arrest and cell death induction in osteoblasts may be one of the important mechanisms contributing to their suppressive effect on bone formation.
C1 Kaohsiung Med Univ, Sch Med, Dept Physiol, Orthopaed Res Ctr, Kaohsiung 807, Taiwan.
   Kaohsiung Med Univ, Chug Ho Mem Hosp, Sch Med, Orthopaed Res Ctr,Dept Orthopaed, Kaohsiung, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University
RP Kaohsiung Med Univ, Sch Med, Dept Physiol, Orthopaed Res Ctr, 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.
EM homelin@cc.kmu.edu.tw
RI Ho, Mei Ling/D 5515 2009; Chang, Je Ken/A 1315 2010
OI Ho, Mei Ling/0000 0001 8064 8488
FU EAPO CDC HHS [EX94 9316EP] Funding Source: Medline
CR ALLEN HL, 1980, ACTA ORTHOP SCAND, V51, P595, DOI 10.3109/17453678008990848
   Arber N, 1997, GASTROENTEROLOGY, V113, P1892, DOI 10.1016/S0016 5085(97)70008 8
   BLOCKA KLN, 1988, J RHEUMATOL, V15, P757
   BUCKLEY MMT, 1990, DRUGS, V39, P86, DOI 10.2165/00003495 199039010 00008
   CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611
   CENTRELLA M, 1987, J BIOL CHEM, V262, P2869
   CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0
   Crowston JG, 1998, INVEST OPHTH VIS SCI, V39, P449
   FURUTA Y, 1986, ANAT RECORD, V215, P305, DOI 10.1002/ar.1092150313
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   Goldberg Y, 1996, ONCOGENE, V12, P893
   Hagiwara H, 1996, BIOCHEM BIOPH RES CO, V222, P220, DOI 10.1006/bbrc.1996.0725
   HAKEDA Y, 1986, J CELL PHYSIOL, V128, P155, DOI 10.1002/jcp.1041280204
   Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006 2952(96)00181 5
   HO ML, 1995, CLIN ORTHOP RELAT R, P270
   Ho ML, 1999, BIOCHEM PHARMACOL, V58, P983, DOI 10.1016/S0006 2952(99)00186 0
   Ho ML, 1998, PHARMACOLOGY, V57, P148, DOI 10.1159/000028236
   Hsu C, 2001, DEV NEUROSCI BASEL, V23, P399, DOI 10.1159/000048726
   Hsu HK, 2001, J NEUROPHYSIOL, V86, P2374, DOI 10.1152/jn.2001.86.5.2374
   Ikezawa K, 1998, FASEB J, V12, P1233, DOI 10.1096/fasebj.12.12.1233
   JEE WSS, 1985, CALCIFIED TISSUE INT, V37, P148, DOI 10.1007/BF02554834
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   KELLER J, 1987, ACTA ORTHOP SCAND, V58, P379, DOI 10.3109/17453678709146360
   KLAUSHOFER K, 1988, J RHEUMATOL, V15, P486
   KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188
   LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0
   Machwate M, 2001, MOL PHARMACOL, V60, P36, DOI 10.1124/mol.60.1.36
   Mesner P W Jr, 1997, Adv Pharmacol, V41, P57, DOI 10.1016/S1054 3589(08)61054 6
   MORI S, 1990, BONE, V11, P103, DOI 10.1016/8756 3282(90)90057 6
   MORRISON C, 1995, BIOMATERIALS, V16, P987, DOI 10.1016/0142 9612(95)94906 2
   NILSSON OS, 1986, CLIN ORTHOP RELAT R, P239
   NORRDIN RW, 1990, PROSTAG LEUKOTR ESS, V41, P139, DOI 10.1016/0952 3278(90)90081 U
   OBERBAUER R, 1993, CLIN PHARMACOKINET, V24, P428, DOI 10.2165/00003088 199324050 00007
   Ornberg RL, 2001, J HISTOCHEM CYTOCHEM, V49, P1059, DOI 10.1177/002215540104900815
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   PARFITT AM, 1990, OSTEOBLAST OSTEOCYTE, P351
   Piazza GA, 1997, CANCER RES, V57, P2452
   Picariello L, 1998, EUR J PHARMACOL, V360, P105, DOI 10.1016/S0014 2999(98)00665 7
   Rahman MA, 2000, CANCER RES, V60, P2085
   Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023
   SHIH MS, 1987, BONE MINER, V3, P27
   SHIH MS, 1986, BONE MINER, V1, P227
   SHIH MS, 1986, AM J VET RES, V47, P1561
   Suzuki N, 2003, LIFE SCI, V73, P2237, DOI 10.1016/S0024 3205(03)00603 9
   TODD PA, 1988, DRUGS, V35, P244, DOI 10.2165/00003495 198835030 00004
   TORNKVIST H, 1985, CLIN ORTHOP RELAT R, P264
   TORNKVIST H, 1980, SCAND J RHEUMATOL, V9, P167
   UENO K, 1985, BONE, V6, P79, DOI 10.1016/8756 3282(85)90311 4
   WONG GL, 1975, P NATL ACAD SCI USA, V72, P3167, DOI 10.1073/pnas.72.8.3167
   YAMAGUCHI DT, 1989, AM J PHYSIOL, V257, pF755, DOI 10.1152/ajprenal.1989.257.5.F755
   YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0
   Zhang GS, 2000, LEUKEMIA RES, V24, P385, DOI 10.1016/S0145 2126(99)00198 8
NR 53
TC 61
Z9 68
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PY 2005
VL 46
IS 4 5
BP 200
EP 210
DI 10.1080/03008200500344025
PG 11
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA 013TZ
UT WOS:000235434000007
PM 16546823
DA 2025 08 17
ER

PT J
AU Eid, A
   Atlas, J
AF Eid, Ahmed
   Atlas, Jennifer
TI The Role of Bisphosphonates in Medical Oncology and Their Association
   with Jaw Bone Necrosis
SO ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Bisphosphonates; Bisphosphonate related osteonecrosis of the jaw;
   Cancer; Jaw bone necrosis; Multiple myeloma; Oncology
ID LONG TERM EFFICACY; ZOLEDRONIC ACID; DOUBLE BLIND; MULTIPLE MYELOMA;
   BREAST CANCER; SKELETAL COMPLICATIONS; SOLID TUMORS; PHASE III;
   OSTEONECROSIS; MECHANISMS
AB Bisphosphonates, synthetic analogues to inorganic pyrophosphates found in the bone matrix, inhibit bone resorption. Bisphosphonates and their related effects on the jaw have been established since 2001. The pathogenesis of bisphosphonate related osteonecrosis of the jaw (BRONJ) is multifactorial and still under investigation. Currently, drugs with mechanisms of action involving remodeling suppression, osteoclast depression, and decreasing angiogenesis are under investigation for causing BRONJ like symptoms. Further studies are needed to determine the effective length of use of biphosponates and the efficacy of drug holidays to prevent BRONJ.
C1 [Eid, Ahmed] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Atlas, Jennifer] Wake Forest Sch Med, Ctr Comprehens Canc, Winston Salem, NC 27157 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; Wake Forest
   University
RP Eid, A (通讯作者)，Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 0462, Houston, TX 77030 USA.
EM aeid@mdanderson.org
RI eid, ahmed/ADJ 0405 2022
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Aghaloo TL, 2010, J ORAL MAXIL SURG, V68, P959, DOI 10.1016/j.joms.2009.10.010
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Berenson JR, 2011, AM J HEMATOL, V86, P25, DOI 10.1002/ajh.21912
   Berenson JR, 2001, CANCER, V91, P1191
   Chiu CT, 2010, J ORAL MAXIL SURG, V68, P1055, DOI 10.1016/j.joms.2009.12.030
   Coleman RE, 2000, ANN ONCOL, V11, P179, DOI 10.1023/A:1011192418904
   Diel Ingo J, 2007, J Support Oncol, V5, P475
   Domchek SM, 2000, CANCER, V89, P363, DOI 10.1002/1097 0142(20000715)89:2<363::AID CNCR22>3.0.CO;2 3
   Dunford JE, 2010, CURR PHARM DESIGN, V16, P2961
   Dunstan CR, 2007, NAT CLIN PRACT ONCOL, V4, P42, DOI 10.1038/ncponc0688
   Durie BGM, 2007, MAYO CLIN PROC, V82, P516, DOI 10.4065/82.4.516
   Estilo CL, 2008, J CLIN ONCOL, V26, P4037, DOI 10.1200/JCO.2007.15.5424
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Geusens P, 2009, CLIN INTERV AGING, V4, P241
   Gralow JR, 2009, J NATL COMPR CANC NE, V7, pS1, DOI 10.6004/jnccn.2009.0076
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Kimmel DB, 2007, J DENT RES, V86, P1022, DOI 10.1177/154405910708601102
   Kyle RA, 2000, ANN INTERN MED, V132, P734, DOI 10.7326/0003 4819 132 9 200005020 00009
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Lacy MQ, 2006, MAYO CLIN PROC, V81, P1047, DOI 10.4065/81.8.1047
   Major PP, 2000, CANCER, V88, P6, DOI 10.1002/(SICI)1097 0142(20000101)88:1<6::AID CNCR3>3.3.CO;2 4
   Markowitz GS, 2003, KIDNEY INT, V64, P281, DOI 10.1046/j.1523 1755.2003.00071.x
   Mehrotra Bhoomi, 2006, Hematology Am Soc Hematol Educ Program, P356
   Mhaskar R, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003188.pub3, 10.1002/14651858.CD003188.pub4]
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Otto S, 2010, J ORAL MAXIL SURG, V68, P1158, DOI 10.1016/j.joms.2009.07.079
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Reddy G Kesava, 2006, Support Cancer Ther, V4, P15, DOI 10.3816/SCT.2006.n.026
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers MJ, 2004, CALCIFIED TISSUE INT, V75, P451, DOI 10.1007/s00223 004 0024 1
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Ross JR, 2003, BMJ BRIT MED J, V327, P469, DOI 10.1136/bmj.327.7413.469
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P13, DOI 10.1016/j.joms.2008.10.005
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Terpos E, 2009, ANN ONCOL, V20, P1303, DOI 10.1093/annonc/mdn796
   Van Poznak CH, 2011, J CLIN ONCOL, V29, P1221, DOI 10.1200/JCO.2010.32.5209
   Wardley A, 2005, BRIT J CANCER, V92, P1869, DOI 10.1038/sj.bjc.6602551
   Weinstein RS, 2012, ENDOCRINE, V41, P183, DOI 10.1007/s12020 011 9580 0
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   West H, 2011, J CLIN ONCOL, V29, P1095, DOI 10.1200/JCO.2010.33.5596
NR 48
TC 7
Z9 8
U1 1
U2 4
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 1042 3699
EI 1558 1365
J9 ORAL MAXIL SURG CLIN
JI Oral Maxillofac. Surg. Clin. N. Am.
PD MAY
PY 2014
VL 26
IS 2
BP 231
EP +
DI 10.1016/j.coms.2014.01.009
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA AI1TA
UT WOS:000336636500010
PM 24794267
DA 2025 08 17
ER

PT J
AU Cho, YD
   Yoon, WJ
   Kim, WJ
   Woo, KM
   Baek, JH
   Lee, G
   Ku, Y
   van Wijnen, AJ
   Ryoo, HM
AF Cho, Young Dan
   Yoon, Won Joon
   Kim, Woo Jin
   Woo, Kyung Mi
   Baek, Jeong Hwa
   Lee, Gene
   Ku, Young
   van Wijnen, Andre J.
   Ryoo, Hyun Mo
TI Epigenetic Modifications and Canonical Wingless/int 1 Class (WNT)
   Signaling Enable Trans differentiation of Nonosteogenic Cells into
   Osteoblasts
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 2; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN;
   ALKALINE PHOSPHATASE EXPRESSION; DNA METHYLATION; BETA CATENIN; CPG
   ISLANDS; PATHWAY; DEDIFFERENTIATION; MUTATIONS; DISEASE
AB Mesenchymal cells alter and retain their phenotype during skeletal development through activation or suppression of signaling pathways. For example, we have shown that Wnt3a only stimulates osteoblast differentiation in cells with intrinsic osteogenic potential (e.g. MC3T3 E1 pre osteoblasts) and not in fat cell precursors or fibroblasts (3T3 L1 pre adipocytes or NIH3T3 fibroblasts, respectively). Wnt3a promotes osteogenesis in part by stimulating autocrine production of the osteoinductive ligand Bmp2. Here, we show that the promoter regions of the genes for Bmp2 and the osteoblast marker Alp are epigenetically locked to prevent their expression in nonosteogenic cells. Both genes have conserved CpG islands that exhibit increased CpG methylation, as well as decreased acetylation and increased methylation of histone H3 lysine 9 (H3 K9) specifically in nonosteogenic cells. Treatment of pre adipocytes or fibroblasts with the CpG demethylating agent 5'  aza 2'  deoxycytidine or the histone deacetylase inhibitor trichostatin A renders Bmp2 and Alp responsive to Wnt3a. Hence, drug induced epigenetic activation of Bmp2 gene expression contributes to Wnt3a mediated direct trans differentiation of pre adipocytes or fibroblasts into osteoblasts. We propose that direct conversion of nonosteogenic cells into osteoblastic cell types without inducing pluripotency may improve prospects for novel epigenetic therapies to treat skeletal afflictions.
C1 [Cho, Young Dan; Yoon, Won Joon; Kim, Woo Jin; Woo, Kyung Mi; Baek, Jeong Hwa; Lee, Gene; Ryoo, Hyun Mo] Seoul Natl Univ, Sch Dent, Dept Mol Genet, Seoul 110749, South Korea.
   [Ku, Young] Seoul Natl Univ, Sch Dent, Dept Periodontol, Seoul 110749, South Korea.
   Seoul Natl Univ, Dent Res Inst, Program BK21, Seoul 110749, South Korea.
   [van Wijnen, Andre J.] Mayo Clin, Dept Orthoped Surg & Biochem, Rochester, MN 55902 USA.
   [van Wijnen, Andre J.] Mayo Clin, Dept Mol Biol, Rochester, MN 55902 USA.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Mayo Clinic; Mayo Clinic
RP van Wijnen, AJ (通讯作者)，Mayo Clin, Dept Orthoped Surg & Biochem, 200 First St SW, Rochester, MN 55902 USA.
EM vanWijnen.Andre@mayo.edu; hmryoo@snu.ac.kr
RI kim, woojin/HPG 7753 2023; Ryoo, Hyun Mo/D 5839 2012; Baek,
   Jeong Hwa/A 8628 2012; Woo, Kyung Mi/A 2793 2009; van Wijnen,
   Andre/AAG 3578 2019; Cho, Young Dan/AAR 4573 2021; Woo,
   Kyung/A 2793 2009
OI van Wijnen, Andre J./0000 0002 4458 0946; Woo, Kyung
   Mi/0000 0002 2782 1189; Ryoo, Hyun Mo/0000 0001 6769 8341; 
FU National Institutes of Health [R01 AR049069]; National Research
   Foundation of Korea   Ministry of Science, ICT, and Future Planning
   [2013R1A1A3011102]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant R01 AR049069. This work was also supported by Basic Science
   Research Program through the National Research Foundation of Korea
   funded by the Ministry of Science, ICT, and Future Planning Grant
   2013R1A1A3011102.
CR Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022 2836(88)90122 2
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Cho Y.   D., 2011, J BONE MINER RES  S1, V26, P161
   Cho YD, 2012, J CELL PHYSIOL, V227, P2287, DOI 10.1002/jcp.24038
   Cho YD, 2009, J BIOL CHEM, V284, P25230, DOI 10.1074/jbc.M109.008391
   DiNardo DNM, 2001, ONCOGENE, V20, P5331, DOI 10.1038/sj.onc.1204697
   Fujita N, 1999, MOL CELL BIOL, V19, P6415
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022 2836(87)90689 9
   Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Graf T, 2009, NATURE, V462, P587, DOI 10.1038/nature08533
   Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002
   Jopling C, 2011, NAT REV MOL CELL BIO, V12, P79, DOI 10.1038/nrm3043
   KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   Khavinson V Kh, 2012, Adv Gerontol, V25, P11
   Kim JS, 2002, CANCER RES, V62, P2744
   Kim YJ, 2004, J BIOL CHEM, V279, P50773, DOI 10.1074/jbc.M404145200
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kuroda K, 2013, SKELET MUSCLE, V3, DOI 10.1186/2044 5040 3 5
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097 4644(19990401)73:1<114::AID JCB13>3.3.CO;2 D
   Li GH, 2005, J BONE MINER RES, V20, P1611, DOI 10.1359/JBMR.050513
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Meivar Levy I, 2007, HEPATOLOGY, V46, P898, DOI 10.1002/hep.21766
   Moon C, 2009, TRANSPL P, V41, P1848, DOI 10.1016/j.transproceed.2009.02.101
   Nusse R, 2012, EMBO J, V31, P2670, DOI 10.1038/emboj.2012.146
   Ohgane J, 2008, PLACENTA, V29, pS29, DOI 10.1016/j.placenta.2007.09.011
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Shiota K, 2004, CYTOGENET GENOME RES, V105, P325, DOI 10.1159/000078205
   Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200
   Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092 8674(04)00419 2
   Yavropoulou Maria P, 2007, Hormones (Athens), V6, P279
   Zhang M, 2009, J CELL BIOCHEM, V108, P896, DOI 10.1002/jcb.22319
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
NR 43
TC 52
Z9 61
U1 0
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 18
PY 2014
VL 289
IS 29
BP 20120
EP 20128
DI 10.1074/jbc.M114.558064
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA AL8NE
UT WOS:000339395200025
PM 24867947
OA Green Published
DA 2025 08 17
ER

PT J
AU Yu, JL
   Wang, BW
   Zhang, HL
   Yang, LQ
   Yao, JJ
   Huang, HD
   Tao, L
   Gao, Y
   Liu, ZH
AF Yu, Jin Ling
   Wang, Bo Wei
   Zhang, Hui Li
   Yang, Liu Qing
   Yao, Jing Jing
   Huang, Han Dan
   Tao, Lu
   Gao, Ying
   Liu, Zhi Hui
TI Therapeutic Potential of Berberine for Osteoporosis and its Underlying
   Mechanisms: A Bioinformatics, Network Pharmacology, Molecular Dynamics
   Simulation Study
SO NATURAL PRODUCT COMMUNICATIONS
LA English
DT Article
DE berberine; alkaloids; osteoporosis; hormonopoiesis; bioinformatics;
   network pharmacology; molecular dynamics simulation
ID DRUG TARGET IDENTIFICATION; ESTROGEN RECEPTOR ALPHA; OSTEOBLAST
   DIFFERENTIATION; OSTEOCLAST DIFFERENTIATION; POSTMENOPAUSAL WOMEN;
   THYROID HORMONE; WEB SERVER; BONE LOSS; KAPPA B; HEALTH
AB Osteoporosis is a systemic skeletal disease that can easily lead to bone fractures. Berberine has been shown to be effective in treating osteoporosis. This study was conducted to identify the potential mechanism of berberine in treating this complaint. We screened potential targets of berberine and identified the osteoporosis related differentially expressed genes (DEGs) in the microarray dataset GSE56815. Protein protein interaction (PPI) network construction, hub targets identification, and pathway enrichment were carried out to find the potential targets. Molecular docking and molecular dynamics studies were performed to verify the combination of berberine with its treatment related central targets. In addition, SwissADME preliminarily evaluated the physicochemical properties of berberine. Through data mining, 23 osteoporosis related targets of berberine were selected. PPI and module analyses suggested that AKT1, MAPK1, ESR1, AR, TP53, and PTGS2 are the core targets of berberine. Docking and molecular dynamics studies showed that berberine could stably bind to core proteins to form a protein ligand complex. The enrichment analysis showed that the estrogen signaling pathway and thyroid hormone signaling pathway play important roles in curing osteoporosis. To sum up, berberine primarily acts on AKT1, MAPK1, ESR1, AR, TP53, and PTGS2, mainly regulating the estrogen and thyroid hormone signaling pathways to treat osteoporosis in a multi target, multi pathway, and multi system manner.
C1 [Yu, Jin Ling; Zhang, Hui Li; Yang, Liu Qing; Yao, Jing Jing; Huang, Han Dan; Tao, Lu; Gao, Ying; Liu, Zhi Hui] Jilin Univ, Hosp Stomatol, Dept Prosthodont, Changchun 130021, Peoples R China.
   [Wang, Bo Wei] Second Hosp Jilin Univ, Dept Gynaecol & Obstet, Changchun, Peoples R China.
C3 Jilin University; Jilin University
RP Liu, ZH (通讯作者)，Jilin Univ, Hosp Stomatol, Dept Prosthodont, Changchun 130021, Peoples R China.
EM liu_zh@jlu.edu.cn
RI Yang, Liuqing/AGS 4244 2022; 志辉, 刘/HRC 8063 2023
OI Liu, Zhihui/0000 0001 8650 9104
FU Key Scientific and Technological Research and Development Projects,
   Medical and Health Project [20180201056YY, 20190304032YY]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by the Key Scientific and Technological Research and
   Development Projects, Medical and Health Project (grant nos.
   20180201056YY, 20190304032YY).
CR Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Bassett JHD, 2016, ENDOCR REV, V37, P135, DOI 10.1210/er.2015 1106
   Bateman A, 2021, NUCLEIC ACIDS RES, V49, pD480, DOI 10.1093/nar/gkaa1100
   Chen QC, 2021, J BONE MINER METAB, V39, P748, DOI 10.1007/s00774 021 01225 2
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Daina A, 2017, SCI REP UK, V7, DOI 10.1038/srep42717
   Fuggle NR, 2019, NAT REV ENDOCRINOL, V15, P535, DOI 10.1038/s41574 019 0220 8
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Han SY, 2019, AM J CHINESE MED, V47, P439, DOI [10.1142/S0192415X19500228, 10.1142/s0192415x19500228]
   Holick MF, 2010, J BONE MINER METAB, V28, P342, DOI 10.1007/s00774 009 0141 z
   Izawa T, 2012, MOL CELL BIOL, V32, P2943, DOI 10.1128/MCB.00077 12
   Jia X, 2019, J DENT RES, V98, P107, DOI 10.1177/0022034518797275
   Kawano H, 2003, P NATL ACAD SCI USA, V100, P9416, DOI 10.1073/pnas.1533500100
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kim HY, 2013, BONE RES, V1, DOI 10.4248/BR201302004
   Kim RY, 2015, TISSUE ENG PT A, V21, P2076, DOI [10.1089/ten.tea.2014.0585, 10.1089/ten.TEA.2014.0585]
   Kimball JS, 2021, J BONE JOINT SURG AM, V103, P1451, DOI 10.2106/JBJS.20.00989
   Kong WJ, 2020, PHARMACOL THERAPEUT, V209, DOI 10.1016/j.pharmthera.2020.107496
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Liu Tianlong, 2018, Lancet Neurol, V17, P745, DOI 10.1016/S1474 4422(18)30290 4
   Liu XF, 2010, NUCLEIC ACIDS RES, V38, pW609, DOI 10.1093/nar/gkq300
   Malde AK, 2011, J CHEM THEORY COMPUT, V7, P4026, DOI 10.1021/ct200196m
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Park HJ, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10040619
   PECK WA, 1993, AM J MED, V94, P646
   Radzki RP, 2022, BIOMED PHARMACOTHER, V146, DOI 10.1016/j.biopha.2021.112467
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Sayem ASM, 2018, BIOMED PHARMACOTHER, V100, P132, DOI 10.1016/j.biopha.2018.02.008
   Song DY, 2020, FRONT MED PRC, V14, P564, DOI 10.1007/s11684 019 0724 6
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Szklarczyk D, 2016, NUCLEIC ACIDS RES, V44, pD380, DOI 10.1093/nar/gkv1277
   Tao K, 2016, TOXICOL LETT, V240, P68, DOI 10.1016/j.toxlet.2015.10.007
   Wang X, 2017, NUCLEIC ACIDS RES, V45, pW356, DOI 10.1093/nar/gkx374
   Wang X, 2016, J CHEM INF MODEL, V56, P1175, DOI 10.1021/acs.jcim.5b00690
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   Wei Y, 2021, CELL TISSUE RES, V386, P297, DOI 10.1007/s00441 021 03496 7
   Windahl SH, 2013, P NATL ACAD SCI USA, V110, P2294, DOI 10.1073/pnas.1220811110
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wong SK, 2020, PHYTOMEDICINE, V73, DOI 10.1016/j.phymed.2019.152892
   Xie HG, 2018, BIOMED PHARMACOTHER, V108, P280, DOI 10.1016/j.biopha.2018.08.131
   Xu DH, 2010, PLANTA MED, V76, P1809, DOI 10.1055/s 0030 1250040
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang W, 2018, NAT GENET, V50, P613, DOI 10.1038/s41588 018 0091 2
   Zhou L, 2015, INT J MOL SCI, V16, P27087, DOI 10.3390/ijms161125998
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
NR 55
TC 1
Z9 1
U1 1
U2 44
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1934 578X
EI 1555 9475
J9 NAT PROD COMMUN
JI Nat. Prod. Commun.
PD MAY
PY 2022
VL 17
IS 5
AR 1934578X221094913
DI 10.1177/1934578X221094913
PG 13
WC Chemistry, Medicinal; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Food Science & Technology
GA 1H5DV
UT WOS:000796565500001
OA gold
DA 2025 08 17
ER

PT J
AU Stenzl, A
AF Stenzl, Arnulf
TI RANK Ligand: A Key Role in Cancer Induced Bone Destruction?
SO EUROPEAN UROLOGY SUPPLEMENTS
LA English
DT Article; Proceedings Paper
CT 24th Congress of the Annual European Association of Urology
CY MAR 17 21, 2009
CL Stockholm, SWEDEN
SP European Assoc Urol
DE Bone; Bone metastases; Cancer; Cancer treatment induced bone loss;
   Denosumab; OPG; Osteoprotegerin; RANK; RANK Ligand
ID KAPPA B LIGAND; PROSTATE CANCER; OSTEOCLAST DIFFERENTIATION;
   OSTEOPROTEGERIN LIGAND; ANDROGEN DEPRIVATION; RECEPTOR ACTIVATOR;
   INHIBITORY FACTOR; METASTASIS; DENSITY; MICE
AB Context: Prostate cancer(PCa) is associated with a high risk of bone metastases; androgen deprivation therapy is associated with significant bone loss. Bone metastases and bone loss are both linked to an increased risk of skeletal related events, which in turn can reduce quality of life and life expectancy. Understanding of the pathophysiology underlying bone disease in patients with cancer is therefore important for the development of new treatments that can prevent or reverse it as well as for the improvement of patient outcomes.
   Objective: To provide an overview of bone metabolism in the normal state and to describe recent developments in our understanding of the pathophysiology underlying bone disease induced by cancer as well as cancer treatment induced bone loss (CTIBL).
   Evidence acquisition: This article is based on a presentation at an Amgen sponsored satellite symposium held at the European Association of Urology Congress in Stockholm, Sweden, in March 2009.
   Evidence synthesis: Skeletal integrity is maintained by a balance between osteoclast mediated bone resorption and osteoblast mediated bone formation. The proteins osteoprotegerin and RANK Ligand play key roles in preserving this balance by preventing and promoting osteoclast activity, respectively. In bone disease associated with cancer, however, the balance shifts in favour of RANK Ligand, resulting in a vicious cycle of osteoclast activation and tumour growth; the same may be true in CTIBL. Denosumab, a fully human monoclonal antibody that binds to and inhibits RANK Ligand, has been shown to block osteoclast mediated bone resorption and is currently under development as a potential treatment for bone abnormalities associated with cancer and its treatment.
   Conclusions: Inhibition of the RANK Ligand pathway by the human monoclonal antibody denosumab may provide a novel treatment option for bone disease in PCa. Further studies are underway. (C) 2009 European Association of Urology. Published by Elsevier B. V. All rights reserved.
C1 Univ Tubingen, Dept Urol, D 72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen
RP Stenzl, A (通讯作者)，Univ Tubingen, Dept Urol, Hoppe Seyler Str 3, D 72076 Tubingen, Germany.
EM arnulf.stenzl@med.uni teubingen.de
CR [Anonymous], CLIN ONCOLOGY
   AOKI J, 1988, CANCER AM CANCER SOC, V62, P98, DOI 10.1002/1097 0142(19880701)62:1<98::AID CNCR2820620118>3.0.CO;2 8
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown JM, 2001, UROLOGY, V57, P611, DOI 10.1016/S0090 4295(00)01122 5
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   CLARKE NW, 1991, BRIT J UROL, V68, P74, DOI 10.1111/j.1464 410X.1991.tb15260.x
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Corey E, 2005, CANCER RES, V65, P1710, DOI 10.1158/0008 5472.CAN 04 2033
   Doumouchtsis KK, 2008, HEMODIAL INT, V12, P100, DOI 10.1111/j.1542 4758.2008.00249.x
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Galli C, 2008, ENDOCRINOLOGY, V149, P146, DOI 10.1210/en.2007 0734
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Israeli Ron S, 2008, Rev Urol, V10, P99
   Jung K, 2004, INT J CANCER, V111, P783, DOI 10.1002/ijc.20314
   Jung K, 2003, J UROLOGY, V170, P2302, DOI 10.1097/01.ju.0000094191.39574.cb
   Kiefer JA, 2004, CLIN EXP METASTAS, V21, P381, DOI 10.1007/s10585 004 2869 0
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lloyd SAJ, 2008, CALCIFIED TISSUE INT, V82, P361, DOI 10.1007/s00223 008 9133 6
   Messing EM, 2006, LANCET ONCOL, V7, P472, DOI 10.1016/S1470 2045(06)70700 8
   Morony S, 2001, CANCER RES, V61, P4432
   O'Brien EA, 2000, BIOCHEM BIOPH RES CO, V274, P281, DOI 10.1006/bbrc.2000.3129
   Roodman GD, 2008, CANCER TREAT REV, V34, P92, DOI 10.1016/j.ctrv.2007.09.002
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sanders JL, 2000, ENDOCRINOLOGY, V141, P4357, DOI 10.1210/en.141.12.4357
   Selvaggi G, 2005, CRIT REV ONCOL HEMAT, V56, P365, DOI 10.1016/j.critrevonc.2005.03.011
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Tat SK, 2006, BONE, V39, P706, DOI 10.1016/j.bone.2006.03.016
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yonou H, 2003, CANCER RES, V63, P2096
NR 36
TC 9
Z9 9
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1569 9056
EI 1878 1500
J9 EUR UROL SUPPL
JI Eur. Urol. Suppl.
PD NOV
PY 2009
VL 8
IS 11
BP 823
EP 828
DI 10.1016/j.eursup.2009.09.001
PG 6
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Urology & Nephrology
GA 512ZF
UT WOS:000271290500002
DA 2025 08 17
ER

PT B
AU Glimcher, LH
   Jones, DC
   Wein, MN
AF Glimcher, Laurie H.
   Jones, Dallas C.
   Wein, Marc N.
BE Zaidi, M
TI Control of postnatal bone mass by the zinc finger adapter protein
   Schnurri 3
SO SKELETAL BIOLOGY AND MEDICINE, PT A: ASPECTS OF BONE MORPHOGENESIS AND
   REMODELING
SE Annals of the New York Academy of Sciences Series
LA English
DT Article; Proceedings Paper
CT 2nd Conference on Skeletal Biology and Medicine
CY APR 25 28, 2007
CL New York, NY
SP Mt Sinai Sch Med, New York Acad Sci
DE Schnurri 3; WWP1; osteoblast; skeletal remodeling; E3 ligases
ID OSTEOBLAST DIFFERENTIATION; UBIQUITIN LIGASE; CBFA1; GENE; INTERACTS;
   BINDING; FAMILY; RUNX2; KRC; JUN
AB The completed skeleton undergoes continuous remodeling for the duration of adult life. Rates of bone formation by osteoblasts and bone resorption by osteoclasts determine adult bone mass. Abnormalities in either the osteoblast or osteoclast compartment affect bone mass and result in skeletal disorders, the most common of which is osteoporosis, a state of low bone mass. Much is known about the molecular control of bone formation and resorption from rare single gene disorders resulting in elevated or reduced bone mass. Such genetic disorders can be attributed either to osteoclast deficiencies, collectively termed "osteopetrosis," or to intrinsically elevated osteoblast activity, termed "osteosclerosis." However, an increasing need for anabolic therapies to prevent age induced bone loss has stimulated a search for additional genes that act at the level of the osteoblast to regulate matrix synthesis. Recently, we have discovered a zinc finger adaptor protein called Schnurri 3 (Shn3) that potently regulates adult bone mass. Mice that lack Shn3 have normal skeletal morphogenesis but display profoundly elevated bone mass that increases with age. The molecular mechanism was revealed to be the recruitment of WWP1, a Nedd4 family E3 ubiquitin ligase, by Shn3 to the major transcriptional regulator of the osteoblast, Runx2. In the absence of Shn3, Runx2 degradation by WWP1 is inhibited resulting in increased levels of Runx2 protein and enhanced expression of Runx2 target genes leading to increased osteoblast synthetic activity. Small molecules that inhibit Shn3 or WWP1 may be attractive candidates for the treatment of diseases of low bone mass.
C1 [Glimcher, Laurie H.; Jones, Dallas C.; Wein, Marc N.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Glimcher, Laurie H.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard Medical School
RP Glimcher, LH (通讯作者)，Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 651 Huntington Ave,FXB 205, Boston, MA 02115 USA.
EM lglimche@hsph.harvard.edu
CR Affolter M, 2001, EMBO J, V20, P3298, DOI 10.1093/emboj/20.13.3298
   Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414
   Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436
   Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097 2765(02)00538 5
   Johnson K, 2004, ACOUST RES LETT ONL, V5, P19, DOI 10.1121/1.1635751
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797 307
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092 8674(00)80260 3
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Oukka M, 2002, MOL CELL, V9, P121, DOI 10.1016/S1097 2765(01)00434 8
   Oukka M, 2004, J EXP MED, V199, P15, DOI 10.1084/jem.20030421
   Patterson Cam, 2002, Sci STKE, V2002, ppe4
   Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092 8674(03)01074 2
   Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097 2765(02)00774 8
   WU LC, 1993, NUCLEIC ACIDS RES, V21, P5067, DOI 10.1093/nar/21.22.5067
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092 8674(00)00211 7
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
NR 30
TC 17
Z9 22
U1 0
U2 6
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER STREET, HOBOKEN, NJ, UNITED STATES
BN 978 1 57331 684 2
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2007
VL 1116
BP 174
EP 181
DI 10.1196/annals.1402.044
PG 8
WC Endocrinology & Metabolism; Multidisciplinary Sciences; Orthopedics
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Science & Technology   Other Topics;
   Orthopedics
GA BHA44
UT WOS:000251898900013
PM 18083927
DA 2025 08 17
ER

PT J
AU Yang, J
   Tang, RH
   Yi, J
   Chen, YQ
   Li, XH
   Yu, T
   Fei, J
AF Yang, Jing
   Tang, Ruohui
   Yi, Jin
   Chen, Yueqi
   Li, Xianghe
   Yu, Tao
   Fei, Jun
TI Diallyl disulfide alleviates inflammatory osteolysis by suppressing
   osteoclastogenesis via NF κB NFATc1 signal pathway
SO FASEB JOURNAL
LA English
DT Article
DE natural products; osteoclast; bone resorption
ID NF KAPPA B; RANKL INDUCED OSTEOCLASTOGENESIS; CELL CELL FUSION;
   BONE RESORPTION; RECEPTOR ACTIVATOR; IN VITRO; DIFFERENTIATION; LIGAND;
   MODULATION; MECHANISMS
AB Skeletal homeostasis is closely effectuated by the regulation of bone formation and bone resorption. Osteoclasts are multinuclear giant cells responsible for bone resorption. Overactivated osteoclasts and excessive bone resorption result in various lytic bone diseases, such as osteoporosis, osteoarthritis, periprosthetic infection, and inflammatory aseptic loosening of orthopedic implants. In consideration of the severe side effects caused by the currently available drugs, exploitation of novel drugs has gradually attracted attention. Because of its anti inflammatory, antioxidant, and antitumor capacities, diallyl disulfide (DADS), a major oil soluble organosulfur ingredient compound derived from garlic, has been widely researched. However, the effects of DADS on osteoclasts and lytic bone diseases are still unknown. In this study, we investigated the effects of DADS on receptor activator of NF kappa B ligand (RANKL)  and LPS mediated osteoclastogenesis, LPS stimulated proinflammatory cytokines related to osteoclasts, and LPS induced inflammatory osteolysis. The results showed that DADS significantly inhibited RANKL mediated osteoclast formation, fusion, and bone resorption in a dose dependent manner via inhibiting the NF kappa B and signal transducer and activator of transcription 3 signaling and restraining the interaction of NF kappa B p65 with nuclear factor of activated T cells cytoplasmic 1. Furthermore, DADS also markedly suppressed LPS induced osteoclastogenesis and reduced the production of proinflammatory cytokines with LPS stimulation to indirectly mediate osteoclast formation. Consistent with the in vitro results, DADS prevented the LPS induced severe bone loss by blocking the osteoclastogenesis. All of the results indicate that DADS may be a potential and exploitable drug used for preventing and impeding osteolytic lesions. Yang, J., Tang, R., Yi, J., Chen, Y., Li, X., Yu, T., Fei, J. Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesis via NF kappa B NFATc1 signal pathway.
C1 [Yang, Jing; Tang, Ruohui; Yi, Jin; Fei, Jun] Third Mil Med Univ, Daping Hosp, Ctr Trauma, Changjiang Zhilu 10, Chongqing 400042, Peoples R China.
   [Chen, Yueqi; Yu, Tao] Third Mil Med Univ, Southwest Hosp, Dept Orthoped, Chongqing, Peoples R China.
   [Li, Xianghe] Guizhou Med Univ, Guizhou Prov Peoples Hosp, Dept Orthoped, Guiyang, Guizhou, Peoples R China.
C3 Army Medical University; Army Medical University; Guizhou Medical
   University
RP Fei, J (通讯作者)，Third Mil Med Univ, Daping Hosp, Ctr Trauma, Changjiang Zhilu 10, Chongqing 400042, Peoples R China.
EM feijundoctor@sohu.com
RI ; Chen, Yueqi/AAU 1724 2020; Tang, Ruohui/NOE 9139 2025
OI Chen, Yueqi/0000 0001 6975 2874; 
FU Medical Research Funding of People's Liberation Army (PLA) of China
   [AWS14C003]; Special Funds for Social Undertaking and Livelihood
   Security Projects of Chongqing [CSTC2016SHMSZX130068]; Youth Dvelopment
   Program of Medical Technology of PLA [16QNP103]
FX This work was funded by grants from Medical Research Funding of People's
   Liberation Army (PLA) of China (AWS14C003), Special Funds for Social
   Undertaking and Livelihood Security Projects of Chongqing
   (CSTC2016SHMSZX130068), and Youth Dvelopment Program of Medical
   Technology of PLA (16QNP103). The authors declare no conflicts of
   interest.
CR Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264 6021:3570593
   Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Blanchard F, 2009, CYTOKINE GROWTH F R, V20, P19, DOI 10.1016/j.cytogfr.2008.11.004
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   CHI MS, 1982, J NUTR, V112, P241, DOI 10.1093/jn/112.2.241
   Chiang CY, 1999, INFECT IMMUN, V67, P4231, DOI 10.1128/IAI.67.8.4231 4236.1999
   Dou C, 2016, J CELL PHYSIOL, V231, P558, DOI 10.1002/jcp.24916
   Druesne N, 2004, CARCINOGENESIS, V25, P1227, DOI 10.1093/carcin/bgh123
   Feng C, 2017, INFLAMMATION, V40, P818, DOI 10.1007/s10753 017 0526 4
   Feng W, 2017, SCI REP UK, V7, DOI 10.1038/srep41411
   Geurts J, 2016, J ORTHOP RES, V34, P262, DOI 10.1002/jor.23009
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092 8674(02)00703 1
   Guan XX, 2018, INT J CLIN EXP MED, V11, P6721
   Heymann D, 2005, DRUG DISCOV TODAY, V10, P242, DOI 10.1016/S1359 6446(04)03265 9
   Hosseinzadeh A, 2017, J CELL BIOCHEM, V118, P1879, DOI 10.1002/jcb.25907
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Jules J, 2012, J BIOL CHEM, V287, P15728, DOI 10.1074/jbc.M111.296228
   Juybari KB, 2018, CELL TISSUE RES, V373, P407, DOI 10.1007/s00441 018 2825 y
   Kanazawa K, 2005, J BONE MINER RES, V20, P840, DOI 10.1359/JBMR.041225
   Kanazawa K, 2003, J BONE MINER RES, V18, P443, DOI 10.1359/jbmr.2003.18.3.443
   Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279
   KASSEM M, 1994, J BONE MINER RES, V9, P1365
   Kimbaris AC, 2006, ULTRASON SONOCHEM, V13, P54, DOI 10.1016/j.ultsonch.2004.12.003
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Kitaura H, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/181849
   Komine M, 2001, BONE, V28, P474, DOI 10.1016/S8756 3282(01)00420 3
   Lee IC, 2014, FOOD CHEM TOXICOL, V63, P174, DOI 10.1016/j.fct.2013.11.006
   Lerner UH, 2000, MATRIX BIOL, V19, P107, DOI 10.1016/S0945 053X(00)00052 4
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006
   Miyamoto H, 2012, J BONE MINER RES, V27, P1289, DOI 10.1002/jbmr.1575
   Miyamoto Takeshi, 2003, Keio J Med, V52, P1
   Neale SD, 1999, J ORTHOP RES, V17, P686, DOI 10.1002/jor.1100170510
   Nilforoushan D, 2009, NITRIC OXIDE BIOL CH, V21, P27, DOI 10.1016/j.niox.2009.04.002
   Park EJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027739
   Park HY, 2012, TOXICOL APPL PHARM, V262, P177, DOI 10.1016/j.taap.2012.04.034
   Park H, 2015, ANTIOXID REDOX SIGN, V22, P63, DOI 10.1089/ars.2013.5748
   Pautz A, 2010, NITRIC OXIDE BIOL CH, V23, P75, DOI 10.1016/j.niox.2010.04.007
   Quan GH, 2015, INT J MOL SCI, V16, P29496, DOI 10.3390/ijms161226179
   Quinn JMW, 2005, BIOCHEM BIOPH RES CO, V328, P739, DOI 10.1016/j.bbrc.2004.11.076
   Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414
   Rose John S, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028415
   Ruscitti P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/782382
   Sabokbar A, 2003, J ORTHOP RES, V21, P73, DOI 10.1016/S0736 0266(02)00106 7
   Saud SM, 2016, CANCER PREV RES, V9, P607, DOI 10.1158/1940 6207.CAPR 16 0044
   Schuringa JJ, 2001, FEBS LETT, V495, P71, DOI 10.1016/S0014 5793(01)02354 7
   Seita J, 2010, WIRES SYST BIOL MED, V2, P640, DOI 10.1002/wsbm.86
   Shin IS, 2013, FOOD CHEM TOXICOL, V62, P506, DOI 10.1016/j.fct.2013.09.012
   Smith BJ, 2006, BONE, V38, P378, DOI 10.1016/j.bone.2005.09.008
   Song DZ, 2018, ARCH BIOCHEM BIOPHYS, V647, P76, DOI 10.1016/j.abb.2018.04.011
   Song FM, 2018, J CELL PHYSIOL, V233, P1723, DOI 10.1002/jcp.26084
   Sul OJ, 2017, MOL CELLS, V40, P880, DOI 10.14348/molcells.2017.0230
   Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516
   Tang RH, 2019, J CELL PHYSIOL, V234, P7645, DOI 10.1002/jcp.27526
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teramachi J, 2017, ORAL DIS, V23, P181, DOI 10.1111/odi.12592
   Tomomura M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130174
   Walton KJ, 2002, BLOOD, V100, P2530, DOI 10.1182/blood.V100.7.2530
   Wei CM, 2018, J CELL PHYSIOL, V233, P476, DOI 10.1002/jcp.25907
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
   Zou W, 2002, J BONE MINER RES, V17, P1211, DOI 10.1359/jbmr.2002.17.7.1211
NR 66
TC 30
Z9 32
U1 0
U2 9
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2019
VL 33
IS 6
BP 7261
EP 7273
DI 10.1096/fj.201802172R
PG 13
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA IJ7YD
UT WOS:000476114200049
PM 30857415
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Orosa, B
   Martínez, P
   González, A
   Guede, D
   Caeiro, JR
   Gómez Reino, JJ
   Conde, C
AF Orosa, Beatriz
   Martinez, Paula
   Gonzalez, Antonio
   Guede, David
   Caeiro, Jose R.
   Gomez Reino, Juan J.
   Conde, Carmen
TI Effect of lysophosphatidic acid receptor inhibition on bone changes in
   ovariectomized mice
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Lysophosphatidic acid receptor; Osteoporosis; Osteoclasts; Osteoblasts;
   Ovariectomy
ID OSTEOPOROSIS; METASTASES; CANCER; OSTEOCLAST; PROSTATE; DISEASE;
   MARKERS; BREAST; LPA
AB Pharmacological inhibition of signaling through lysophosphatidic acid (LPA) receptors reduces bone erosions in an experimental model of arthritis by mechanisms involving reduced osteoclast differentiation and bone resorption and increased differentiation of osteoblasts and bone mineralization. These results led us to hypothesize that LPA receptor inhibition would be beneficial in osteoporosis. Our aim was to test this hypothesis with the LPA receptor antagonist, Ki16425, in ovariectomized mice, a model of postmenopausal osteoporosis. Ovariectomized mice treated with Ki16425 showed bone loss similar to that observed in the controls. Osteoblast markers, Alpl, Bglap and Colla1, were increased at the mRNA level but no changes were detected in serum. No additional difference was observed in the Ki16425 treated mice relative to the ovariectomized controls with regard to osteoclast function markers or assays of matrix mineralization or osteoclast differentiation. Thus, pharmacological inhibition of LPA receptor was not beneficial for preventing bone loss in ovariectomized mice, indicating that its favorable effect on bone remodeling is less general than hypothesized.
C1 [Orosa, Beatriz; Martinez, Paula; Gonzalez, Antonio; Gomez Reino, Juan J.; Conde, Carmen] Hosp Clin Univ Santiago de Compostela CHUS, SERGAS, Lab Invest 8, Santiago De Compostela 15706, Spain.
   [Orosa, Beatriz; Martinez, Paula; Gonzalez, Antonio; Gomez Reino, Juan J.; Conde, Carmen] Hosp Clin Univ Santiago de Compostela CHUS, Serv Reumatol, Inst Invest Sanitaria IDIS, Santiago De Compostela 15706, Spain.
   [Guede, David] Technol Pk Galicia, Trabeculae SL, Orense 32900, Spain.
   [Guede, David; Caeiro, Jose R.] Inst Salud Carlos III, Red Temat Invest Cooperat Envejecimiento & Fragil, Minist Econ & Competitividad, Madrid, Spain.
   [Caeiro, Jose R.] Hosp Clin Univ Santiago de Compostela CHUS, Serv Cirugia Ortoped & Traumatol, SERGAS, Santiago De Compostela 15706, Spain.
   [Gomez Reino, Juan J.] Univ Santiago de Compostela, Dept Med, Santiago De Compostela 15782, Spain.
C3 Complexo Hospitalario Universitario de Santiago de Compostela; Complexo
   Hospitalario Universitario de Santiago de Compostela; Instituto de Salud
   Carlos III; Spanish Ministry of Economy & Competitiveness; Complexo
   Hospitalario Universitario de Santiago de Compostela; Universidade de
   Santiago de Compostela
RP Conde, C (通讯作者)，Hosp Clin Univ Santiago de Compostela CHUS, SERGAS, Lab Invest 8, Travesia Choupana S N, Santiago De Compostela 15706, Spain.
EM carmen.conde.muro@sergas.es
RI ; de Andrés González, Mª del Carmen/ABD 7612 2021; Gonzalez,
   Antonio/C 4444 2008; Gomez Reino, Juan/ABI 2853 2020; Martinez,
   Paula/KFQ 1250 2024; Caeiro, José/ABF 6604 2020; Guede,
   David/H 8886 2012; Orosa, Beatriz/AAB 1090 2020; Conde,
   Carmen/ABA 2396 2021
OI Conde, Carmen/0000 0001 5717 5483; Gonzalez,
   Antonio/0000 0002 2624 0606; Gomez Reino, Juan/0000 0001 5229 6294;
   Orosa Puente, Beatriz/0000 0002 1667 0477; 
FU RETICS Program [PI11/02197]; Fondo de Investigacion Sanitaria [RD08/0075
   (RIER)]; Instituto de Salud Carlos III; FEDER funds (European Union)
FX We thank Dra. M. Jesus Ramirez from Dpto. de Ciencias de la Salud
   (Universidad de Jaen) and Dra. L.M. Seoane and L. Senin from Instituto
   de Investigacion Sanitaria de Santiago de Compostela (IDIS) for advice
   with ovariectomy. This work was supported by grant PI11/02197, by RETICS
   Program, RD08/0075 (RIER), all from Fondo de Investigacion Sanitaria,
   Instituto de Salud Carlos III with participation of FEDER funds
   (European Union).
CR Ainola M, 2008, ARTHRITIS RHEUM US, V58, P3394, DOI 10.1002/art.23996
   Blackburn J, 2012, BONE, V50, P756, DOI 10.1016/j.bone.2011.12.002
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123
   Boucharaba A, 2006, P NATL ACAD SCI USA, V103, P9643, DOI 10.1073/pnas.0600979103
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Braun T, 2012, CURR OSTEOPOROS REP, V10, P101, DOI 10.1007/s11914 012 0104 5
   David M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009741
   Favus MJ, 2010, NEW ENGL J MED, V363, P2027, DOI 10.1056/NEJMct1004903
   de Castro LF, 2012, J CELL PHYSIOL, V227, P1752, DOI 10.1002/jcp.22902
   Gennero I, 2011, BONE, V49, P395, DOI 10.1016/j.bone.2011.04.018
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Hsiao HB, 2013, OSTEOPOROSIS INT, V24, P1663, DOI 10.1007/s00198 012 2199 z
   Koopmans N, 2007, J UROLOGY, V178, P849, DOI 10.1016/j.juro.2007.05.029
   Lapierre DM, 2010, J BIOL CHEM, V285, P25792, DOI 10.1074/jbc.M110.109322
   Leeming DJ, 2006, CANCER EPIDEM BIOMAR, V15, P32, DOI 10.1158/1055 9965.EPI 05 0492
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Orosa B, 2014, ANN RHEUM DIS, V73, P298, DOI 10.1136/annrheumdis 2012 202832
   Orosa B, 2012, ARTHRITIS RHEUM US, V64, P2460, DOI 10.1002/art.34443
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Schurigt U, 2008, ARTHRITIS RHEUM, V58, P422, DOI 10.1002/art.23224
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   van Meeteren LA, 2007, PROG LIPID RES, V46, P145, DOI 10.1016/j.plipres.2007.02.001
   Walsh NC, 2010, IMMUNOL REV, V233, P301, DOI 10.1111/j.0105 2896.2009.00857.x
   Zhao CQ, 2008, MOL PHARMACOL, V73, P587, DOI 10.1124/mol.107.038216
NR 25
TC 3
Z9 3
U1 0
U2 9
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JUL
PY 2015
VL 33
IS 4
BP 383
EP 391
DI 10.1007/s00774 014 0607 5
PG 9
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA CN1QT
UT WOS:000358195600003
PM 24994065
DA 2025 08 17
ER

PT J
AU Kamei, K
   Yahara, Y
   Kim, JD
   Tsuji, M
   Iwasaki, M
   Takemori, H
   Seki, S
   Makino, H
   Futakawa, H
   Hirokawa, T
   Nguyen, TCT
   Nakagawa, T
   Kawaguchi, Y
AF Kamei, Katsuhiko
   Yahara, Yasuhito
   Kim, Jun Dal
   Tsuji, Mamiko
   Iwasaki, Mami
   Takemori, Hiroshi
   Seki, Shoji
   Makino, Hiroto
   Futakawa, Hayato
   Hirokawa, Tatsuro
   Nguyen, Tran Canh Tung
   Nakagawa, Takashi
   Kawaguchi, Yoshiharu
TI Impact of the SIK3 pathway inhibition on osteoclast differentiation via
   oxidative phosphorylation
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE osteoclasts; mitochondria; salt inducible kinase 3; oxidative
   phosphorylation; mitochondrial respiration
ID PARATHYROID HORMONE; BONE; METABOLISM; KINASE; TERIPARATIDE; ACTIVATION
AB Maintenance of bone homeostasis and the balance between bone resorption and formation are crucial for maintaining skeletal integrity. This study sought to investigate the role of salt inducible kinase 3 (SIK3), a key regulator in cellular energy metabolism, during the differentiation of osteoclasts. Despite osteoclasts being high energy consuming cells essential for breaking down mineralized bone tissue, the specific function of SIK3 in this process remains unclear. To address this issue, we generated osteoclast specific SIK3 conditional knockout mice and assessed the impact of SIK3 deletion on bone homeostasis. Our findings revealed that SIK3 conditional knockout mice exhibited increased bone mass and an osteopetrosis phenotype, suggesting a pivotal role for SIK3 in bone resorption. Moreover, we assessed the impact of pterosin B, a SIK3 inhibitor, on osteoclast differentiation. The treatment with pterosin B inhibited osteoclast differentiation, reduced the numbers of multinucleated osteoclasts, and suppressed resorption activity in vitro. Gene expression analysis demonstrated that SIK3 deletion and pterosin B treatment influence a common set of genes involved in osteoclast differentiation and bone resorption. Furthermore, pterosin B treatment altered intracellular metabolism, particularly affecting key metabolic pathways, such as the tricarboxylic acid cycle and oxidative phosphorylation. These results provide valuable insights into the involvement of SIK3 in osteoclast differentiation and the molecular mechanisms underlying osteoclast function and bone diseases.
   Osteoporosis is a disease that causes bones to become weak and fragile, increasing the risk of fractures especially in elderly. It is caused by an imbalance between the formation of new bone and the destruction of old bone. Cells called osteoclasts are responsible for breaking down old bone. Excessive osteoclast activity results in bone loss and osteoporosis. Our research has identified a LKB1 SIK3 pathway, which acts as an energy sensor in osteoclasts. We found that this pathway is activated when osteoclast activity is increased, and we were able to reduce osteoclast activity by genetically removing or inhibiting SIK3. These findings suggest that targeting the LKB1 SIK3 pathway may be a promising new approach for the treatment of osteoporosis. Developing drugs that inhibit SIK3 may slow bone loss and reduce the risk of fractures in osteoporotic patients.
   Graphical Abstract
C1 [Kamei, Katsuhiko; Tsuji, Mamiko; Seki, Shoji; Makino, Hiroto; Futakawa, Hayato; Hirokawa, Tatsuro; Nguyen, Tran Canh Tung; Kawaguchi, Yoshiharu] Univ Toyama, Fac Med, Dept Orthopaed Surg, 2630 Sugitani, Toyama 9300194, Japan.
   [Yahara, Yasuhito] Osaka Univ, Grad Sch Med & Frontier Biosci, Dept Immunol & Cell Biol, Suita, Osaka 5650871, Japan.
   [Yahara, Yasuhito] Osaka Univ, WPI Immunol Frontier Res Ctr, Suita, Osaka 5650871, Japan.
   [Kim, Jun Dal] Univ Toyama, Inst Natl Med, Dept Res & Dev, Div Complex Biosci Res, 2630 Sugitani, Toyama 9300194, Japan.
   [Kim, Jun Dal] Japan Agcy Med Res & Dev, AMED CREST, 1 7 1 Otemachi,Chiyoda Ku, Tokyo 1000004, Japan.
   [Iwasaki, Mami] Univ Toyama, Fac Engn, Toyama 9308555, Japan.
   [Takemori, Hiroshi] Gifu Univ, Fac Engn, Dept Chem & Biomol Sci, 1 1 Yanagido, Gifu 5011193, Japan.
   [Nguyen, Tran Canh Tung] Vietnam Mil Med Univ, Dept Trauma & Orthopaed Surg, Hanoi 100000, Vietnam.
   [Nakagawa, Takashi] Univ Toyama, Fac Med, Dept Mol & Med Pharmacol, 2630 Sugitani, Toyama 9300194, Japan.
C3 University of Toyama; University of Osaka; University of Osaka;
   University of Toyama; University of Toyama; Gifu University; University
   of Toyama
RP Yahara, Y (通讯作者)，Osaka Univ, Grad Sch Med & Frontier Biosci, Dept Immunol & Cell Biol, Suita, Osaka 5650871, Japan.; Yahara, Y (通讯作者)，Osaka Univ, WPI Immunol Frontier Res Ctr, Suita, Osaka 5650871, Japan.
EM k.kamei9786@gmail.com; yyahara@icb.med.osaka u.ac.jp;
   jdkim@inm.u toyama.ac.jp; tsujimam@med.u toyama.ac.jp;
   miwasaki@eng.u toyama.ac.jp; takemori.hiroshi.r7@f.gifu u.ac.jp;
   seki@med.u toyama.ac.jp; hiroto@med.u toyama.ac.jp;
   hayato2589hayato@gmail.com; tatsuro.h13@gmail.com;
   bstungbv103@gmail.com; nakagawa@med.u toyama.ac.jp;
   zenji@med.u toyama.ac.jp
RI Yahara, Yasuhito/AAO 7487 2020; Nakagawa, Takashi/F 3015 2010
OI Jun Dal, Kim/0000 0002 7361 0999; Nakagawa, Takashi/0000 0001 5539 7605
FU KAKENHI from the Japan Society for the Promotion of Science [22H02630,
   22K19289, 21K16679]; Japan Science and Technology Agency Precursory
   Research for Embryonic Science and Technology (PRESTO) [JPMJPR214C];
   AMED CREST [JP21gm1410010]
FX This work was funded by grants from KAKENHI from the Japan Society for
   the Promotion of Science (22H02630, 22K19289 and 21K16679) and the Japan
   Science and Technology Agency Precursory Research for Embryonic Science
   and Technology (PRESTO)(JPMJPR214C). This work is also funded by
   AMED CREST (Grant Number JP21gm1410010).
CR Arnett TR, 2018, BONE, V115, P25, DOI 10.1016/j.bone.2017.12.021
   Berdeaux R, 2007, NAT MED, V13, P597, DOI 10.1038/nm1573
   CH'UAN CHANG HUI, 1931, ANAT REC, V49, P397, DOI 10.1002/ar.1090490408
   Confavreux CB, 2011, KIDNEY INT, V79, pS14, DOI 10.1038/ki.2011.25
   COPP D. H., 1963, ORAL SURG ORAL MED AND ORAL PATHOL, V16, P738, DOI 10.1016/0030 4220(63)90081 1
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   DUDLEY HR, 1961, J BIOPHYS BIOCHEM CY, V11, P627, DOI 10.1083/jcb.11.3.627
   Fujii T, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00120 2
   Ginani F, 2017, INT J MORPHOL, V35, P584, DOI 10.4067/S0717 95022017000200033
   Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Itoh Y, 2015, J BIOL CHEM, V290, P17879, DOI 10.1074/jbc.M115.640821
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Jin ZX, 2014, CELL METAB, V20, P483, DOI 10.1016/j.cmet.2014.07.011
   Kim JM, 2007, CELL PHYSIOL BIOCHEM, V20, P935, DOI 10.1159/000110454
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Lombardi MS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185426
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Morgan EF, 2018, ANNU REV BIOMED ENG, V20, P119, DOI [10.1146/annurev bioeng 062117 121139, 10.1146/annurev bioeng 062117121139]
   Nishimori S, 2019, J CLIN INVEST, V129, P5187, DOI 10.1172/JCI130126
   Park Min KH, 2019, SEMIN IMMUNOPATHOL, V41, P565, DOI 10.1007/s00281 019 00757 0
   Patel K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5535
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Rubin MR, 2002, OSTEOPOROSIS INT, V13, P267, DOI 10.1007/s001980200026
   Sasagawa S, 2012, DEVELOPMENT, V139, P1153, DOI 10.1242/dev.072652
   Sato T, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2214396119
   Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676
   Takemori H, 2008, J STEROID BIOCHEM, V108, P287, DOI 10.1016/j.jsbmb.2007.09.006
   Tang CC, 2021, ELIFE, V10, DOI 10.7554/eLife.67772
   Tong XS, 2020, BIOL CELL, V112, P251, DOI 10.1111/boc.202000008
   Walkinshaw DR, 2013, J BIOL CHEM, V288, P9345, DOI 10.1074/jbc.M113.456996
   Wang ZN, 1999, FEBS LETT, V453, P135, DOI 10.1016/S0014 5793(99)00708 5
   Wei W, 2016, CELL METAB, V23, P479, DOI 10.1016/j.cmet.2015.12.010
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Wein MN, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13176
   Yahara Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10959
NR 38
TC 4
Z9 4
U1 3
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG 3
PY 2024
VL 39
IS 9
BP 1340
EP 1355
DI 10.1093/jbmr/zjae105
EA AUG 2024
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA E5T8K
UT WOS:001282947500001
PM 39030684
DA 2025 08 17
ER

PT J
AU Wu, QJ
   Zhou, J
   Du, DH
   Guo, B
   Wang, HF
   Lv, W
AF Wu, Qijin
   Zhou, Jing
   Du, Donghua
   Guo, Bing
   Wang, Haifeng
   Lv, Wenting
TI Mongolian medicine Sugemule 7 decoction prevents osteoporosis via Erk1/
   2 and p38 MAPK signaling pathways according to network pharmacology
   analysis
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE SGML 7; Osteoporosis; MAPK signaling pathway
ID OSTEOCLAST DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC
   DIFFERENTIATION; INDUCED OSTEOPENIA; BONE LOSS; MINERALIZATION;
   QUERCETIN; PROMOTES; FORMULA; CELLS
AB Osteoporosis (OP) is a significant global public health concern that requires the development of safe and effective drugs for prevention and treatment. Sugemule 7 (SGML 7) decoction, a traditional Mongolian herbal prescription, has long been used for treating OP, but its components and mechanisms of action remain unclear. The study identified the main compounds of SGML 7 using UHPLC Q Exactive MS and explored the multi target mechanisms of SGML 7 in OP through network pharmacology and molecular docking. A retinoic acid (RA) induced mouse OP model was utilized to confirm the therapeutic effects and potential mechanism of SGML 7. Additionally, mouse pre osteoblastic (MC3T3 E1) cells treated with SGML 7 medicated serum were employed to delve deeper into the molecular mechanisms. The UHPLC Q Exactive MS analysis, network pharmacology, and molecular docking suggested that the synergistic effect of multiple active compounds could be the main contributor to SGML 7 for its anti OP activities. Moreover, MAPK1, JUN, ESR1, TP53, AKT1, NCOA1, FOS, and NR3C1 were identified as potential key targets, and the MAPK signaling pathway was among the signaling pathways possibly involved in the anti OP activities of SGML 7. Consistent with these findings, experimental studies confirmed that SGML 7 prevented bone loss, enhanced bone quality in OP mice, and promoted osteoblastic activity and bone formation in MC3T3 E1 cells by modulating MAPK associated targets. Taken together, SGML 7 shows promise as an effective and appealing anti OP drug candidate.
C1 [Zhou, Jing; Du, Donghua; Guo, Bing; Wang, Haifeng; Lv, Wenting] Hebei North Univ, Coll Anim Sci & Technol, Dept Vet Med, Zhangjiakou 075131, Hebei, Peoples R China.
   [Wu, Qijin] China Pharmaceut Univ, Ctr New Drug Safety Evaluat & Res, Nanjing 211198, Jiangsu, Peoples R China.
C3 Hebei North University; China Pharmaceutical University
RP Lv, W (通讯作者)，Hebei North Univ, Coll Anim Sci & Technol, Dept Vet Med, Zhangjiakou 075131, Hebei, Peoples R China.
EM 1620134204@cpu.edu.cn; wintonluce@163.com
FU Doctoral Scientific Fund Project of Hebei North University [BSJJ202323]
FX This research was funded by the Doctoral Scientific Fund Project of
   Hebei North University (No. BSJJ202323) .
CR Bégot L, 2011, MED SCI SPORT EXER, V43, P54, DOI 10.1249/MSS.0b013e3181e712eb
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dogan S, 2019, MODERN PATHOL, V32, P1447, DOI 10.1038/s41379 019 0285 x
   Einhorn TA, 2014, J ORTHOP TRAUMA, V28, P433, DOI 10.1097/BOT.0000000000000023
   Fu YX, 2015, MOL MED REP, V12, P6939, DOI 10.3892/mmr.2015.4284
   Gautam AK, 2011, J NUTR BIOCHEM, V22, P318, DOI 10.1016/j.jnutbio.2010.02.010
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gualeni B, 2013, BONE, V54, P83, DOI 10.1016/j.bone.2013.01.036
   Guo C, 2017, CELL PHYSIOL BIOCHEM, V43, P1547, DOI 10.1159/000481978
   He Y, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.922943
   Horcajada Molteni MN, 2000, J BONE MINER RES, V15, P2251, DOI 10.1359/jbmr.2000.15.11.2251
   Ikeda H, 2021, J NUTR METAB, V2021, DOI 10.1155/2021/8824753
   Jigmud D., 1999, Guan Zhe Zhi Xi
   Jing Z, 2019, J CELL PHYSIOL, V234, P4472, DOI 10.1002/jcp.27252
   Juhl OJ, 2021, NPJ MICROGRAVITY, V7, DOI 10.1038/s41526 021 00158 4
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim TH, 2011, J NUTR BIOCHEM, V22, P8, DOI 10.1016/j.jnutbio.2009.11.002
   Kusumi A, 2005, J BONE MINER METAB, V23, P373, DOI 10.1007/s00774 005 0615 6
   Kyrgidis A, 2011, J OSTEOPOROS, V2011, DOI 10.4061/2011/147689
   Lee CH, 2011, EUR J PHARMACOL, V668, P383, DOI 10.1016/j.ejphar.2011.06.059
   Lee JE, 2017, RSC ADV, V7, P1032, DOI 10.1039/c6ra25236b
   Li CR, 2019, J FUNCT FOODS, V58, P138, DOI 10.1016/j.jff.2019.04.048
   Li F, 2012, FITOTERAPIA, V83, P1443, DOI 10.1016/j.fitote.2012.08.008
   Li XL, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1194823
   Li Y, 2015, EXP THER MED, V9, P2072, DOI 10.3892/etm.2015.2388
   Liu HY, 2020, J FUNCT FOODS, V75, DOI 10.1016/j.jff.2020.104228
   Liu L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00228
   Liu Y, 2018, MUTAGENESIS, V33, P203, DOI 10.1093/mutage/gey010
   Lou JJ, 2017, NUCL MED COMMUN, V38, P854, DOI 10.1097/MNM.0000000000000726
   Luo XH, 2006, J BONE MINER RES, V21, P1648, DOI 10.1359/JBMR.060707
   Maclean A, 2020, HUM REPROD, V35, P2097, DOI 10.1093/humrep/deaa177
   Meng XY, 2011, CURR COMPUT AID DRUG, V7, P146
   Mengkebuhe A., 2011, J. Med. Pharm. Chin. Minor., V17, P70, DOI [10.3969/j.issn.1006 6810.2011.01.038, DOI 10.3969/J.ISSN.1006 6810.2011.01.038]
   Moura MLA, 2018, J ANAT, V233, P715, DOI 10.1111/joa.12893
   Park CM, 2015, METHOD ENZYMOL, V554, P127, DOI 10.1016/bs.mie.2014.11.032
   Proff P, 2009, CLIN ORAL INVEST, V13, P355, DOI 10.1007/s00784 009 0268 2
   Rantlha M, 2017, ARCH PHARM RES, V40, P79, DOI 10.1007/s12272 016 0790 0
   RAVEN R J, 1988, American Museum Novitates, P1
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Seeman E, 2008, J BONE MINER METAB, V26, P1, DOI 10.1007/s00774 007 0793 5
   Seo HJ, 2010, NUTR RES PRACT, V4, P356, DOI 10.4162/nrp.2010.4.5.356
   Shen DY, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/5902293
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Sritharan S, 2018, J CRANIO MAXILL SURG, V46, P1361, DOI 10.1016/j.jcms.2018.05.002
   Srivastava S, 2013, PHYTOMEDICINE, V20, P683, DOI 10.1016/j.phymed.2013.03.001
   Suntornsaratoon P, 2014, AM J PHYSIOL ENDOC M, V306, pE177, DOI 10.1152/ajpendo.00556.2013
   Tang HF, 2021, MOL CELL BIOCHEM, V476, P1939, DOI 10.1007/s11010 021 04062 z
   Tantikanlayaporn D, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110763
   Thongchote K, 2011, HISTOCHEM CELL BIOL, V136, P47, DOI 10.1007/s00418 011 0823 1
   Wang XQ, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/4370263
   Wong SK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176448
   Xiong F., 2019, J. Med. Pharm. Chin. Minor., V16, P16, DOI [10.3969/j.issn.1006 6810.2019.06.009, DOI 10.3969/J.ISSN.1006 6810.2019.06.009, 10.3969/j.issn.2096 3327.2019.01.005]
   Xu HH, 2020, CHEM BIOL INTERACT, V331, DOI 10.1016/j.cbi.2020.109235
   Yang F, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.581991
   Yang FF, 2015, EUR J PHARMACOL, V754, P123, DOI 10.1016/j.ejphar.2015.02.015
   Yang J, 2016, J SCI FOOD AGR, V96, P331, DOI 10.1002/jsfa.7098
   Yang LY, 2018, BIOCHEM BIOPH RES CO, V504, P941, DOI 10.1016/j.bbrc.2018.09.008
   Yi YD, 2004, EVID BASED COMPL ALT, V1, P125, DOI 10.1093/ecam/neh019
   Zhang Jia wei, 2022, China Rice, V28, P53, DOI 10.3969/j.issn.1006 8082.2022.01.011
   Zhang J, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906 020 02885 9
   Zhang Q, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.678685
   Zhang R, 2014, J ETHNOPHARMACOL, V155, P104, DOI 10.1016/j.jep.2014.04.031
   Zhang TT, 2020, PHARMACOGEN PERS MED, V13, P487, DOI 10.2147/PGPM.S269726
   Zhang XN, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/5639129
   Zhao J., 2021, of Mongolian medicine, West. J. Trad. Chin. Med., V34, P61, DOI [10.12174/j.issn.2096 9600.2021.07.15, DOI 10.12174/J.ISSN.2096 9600.2021.07.15]
   Zhao MD, 2021, POULTRY SCI, V100, P527, DOI 10.1016/j.psj.2020.10.053
   Zhou YN, 2017, J MATER CHEM B, V5, P612, DOI 10.1039/c6tb02312f
   Zhou YN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129605
   Zhu MR, 2021, CELL TISSUE BANK, V22, P77, DOI 10.1007/s10561 020 09867 8
NR 70
TC 0
Z9 0
U1 12
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD MAR
PY 2025
VL 292
AR 139166
DI 10.1016/j.ijbiomac.2024.139166
EA DEC 2024
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA W9R5M
UT WOS:001421852700001
PM 39743063
DA 2025 08 17
ER

PT J
AU Komatsu, K
   Shimada, A
   Shibata, T
   Wada, S
   Ideno, H
   Nakashima, K
   Amizuka, N
   Noda, M
   Nifuji, A
AF Komatsu, Koichiro
   Shimada, Akemi
   Shibata, Tatsuya
   Wada, Satoshi
   Ideno, Hisashi
   Nakashima, Kazuhisa
   Amizuka, Norio
   Noda, Masaki
   Nifuji, Akira
TI Alendronate promotes bone formation by inhibiting protein prenylation in
   osteoblasts in rat tooth replantation model
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
DE bone formation and resorption; skeletal biology; osteoblast; histology
ID MESENCHYMAL STEM CELLS; MARROW STROMAL CELLS; ZOLEDRONIC ACID; IN VITRO;
   OSTEOGENIC DIFFERENTIATION; GROWTH FACTOR; BISPHOSPHONATES; EXPRESSION;
   FIXATION; HISTOMORPHOMETRY
AB Bisphosphonates (BPs) are a major class of antiresorptive drug, and their molecular mechanisms of antiresorptive action have been extensively studied. Recent studies have suggested that BPs target bone forming cells as well as bone resorbing cells. We previously demonstrated that local application of a nitrogen containing BP (N BP), alendronate (ALN), for a short period of time increased bone tissue in a rat tooth replantation model. Here, we investigated cellular mechanisms of bone formation by ALN. Bone histomorphometry confirmed that bone formation was increased by local application of ALN. ALN increased proliferation of bone forming cells residing on the bone surface, whereas it suppressed the number of tartrate resistant acid phosphatase (TRAP) positive osteoclasts in vivo. Moreover, ALN treatment induced more alkaline phosphatase positive and osteocalcin positive cells on the bone surface than PBS treatment. In vitro studies revealed that pulse treatment with ALN promoted osteocalcin expression. To track the target cells of N BPs, we applied fluorescence labeled ALN (F ALN) in vivo and in vitro. F ALN was taken into bone forming cells both in vivo and in vitro. This intracellular uptake was inhibited by endocytosis inhibitors. Furthermore, the endocytosis inhibitor dansylcadaverine (DC) suppressed ALN stimulated osteoblastic differentiation in vitro and it suppressed the increase in alkaline phosphatase positive bone forming cells and subsequent bone formation in vivo. DC also blocked the inhibition of Rap1A prenylation by ALN in the osteoblastic cells. These data suggest that local application of ALN promotes bone formation by stimulating proliferation and differentiation of bone forming cells as well as inhibiting osteoclast function. These effects may occur through endocytic incorporation of ALN and subsequent inhibition of protein prenylation.
C1 [Komatsu, Koichiro; Shimada, Akemi; Shibata, Tatsuya; Ideno, Hisashi; Nakashima, Kazuhisa; Nifuji, Akira] Tsurumi Univ, Sch Dent Med, Dept Pharmacol, Tsurumi Ku, Yokohama, Kanagawa 2308501, Japan.
   [Wada, Satoshi] Tsurumi Univ, Sch Dent Med, Dept Orthodont, Tsurumi Ku, Yokohama, Kanagawa 2308501, Japan.
   [Ideno, Hisashi; Nifuji, Akira] Natl Inst Radiol Sci, Transcriptome Res Grp, Inage Ku, Chiba 2638555, Japan.
   [Amizuka, Norio] Hokkaido Univ, Grad Sch Dent Med, Dept Dev Biol Hard Tissue, Kita Ku, Sapporo, Hokkaido 0608586, Japan.
   [Noda, Masaki] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pharmacol, Chiyoda Ku, Tokyo 1138510, Japan.
C3 Tsurumi University; Tsurumi University; National Institutes for Quantum
   Science & Technology; Hokkaido University; Institute of Science Tokyo;
   Tokyo Medical & Dental University (TMDU)
RP Komatsu, K (通讯作者)，Tsurumi Univ, Sch Dent Med, Dept Pharmacol, Tsurumi Ku, 2 1 3 Tsurumi, Yokohama, Kanagawa 2308501, Japan.
EM komatsu k@tsurumi u.ac.jp; nifuji a@tsurumi u.ac.jp
RI Komatsu, Koichiro/AAI 9814 2020; Amizuka, Norio/G 1397 2012; Nifuji,
   Akira/AAX 7907 2021; Wada, Satoshi/G 1235 2015
OI Nifuji, Akira/0000 0002 8182 4380; Nakashima,
   Kazuhisa/0000 0003 0491 2149; 
FU Japanese MEXT.HAITEKU [2005 2009, H050151]; Ministry of Education,
   Science and Culture of Japan [21659425, 19390475]; Grants in Aid for
   Scientific Research [25670784, 23592784, 24792317, 19390475, 21659425]
   Funding Source: KAKEN
FX This work was supported by grants from Japanese MEXT.HAITEKU (2005 2009,
   H050151) and from the Ministry of Education, Science and Culture of
   Japan (21659425 and 19390475).
CR Abtahi J, 2012, BONE, V50, P1148, DOI 10.1016/j.bone.2012.02.001
   AZUMA Y, 1995, BONE, V16, P235, DOI 10.1016/8756 3282(94)00035 X
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Bobyn JD, 2009, J BONE JOINT SURG AM, V91A, P23, DOI 10.2106/JBJS.I.00518
   Chaplet ML, 2004, BIOCHEM J, V384, P591, DOI 10.1042/BJ20040380
   Chen CL, 2009, J CELL SCI, V122, P1863, DOI 10.1242/jcs.038729
   Corrado A, 2010, CLIN EXP RHEUMATOL, V28, P873
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Duque G, 2011, BRIT J PHARMACOL, V162, P1109, DOI 10.1111/j.1476 5381.2010.01111.x
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Ebert R, 2009, BONE, V44, P858, DOI 10.1016/j.bone.2009.01.009
   Fu LJ, 2008, BONE, V43, P40, DOI 10.1016/j.bone.2008.03.008
   Gao Y, 2009, BONE, V44, P225, DOI 10.1016/j.bone.2008.10.054
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   HAIGLER HT, 1980, J BIOL CHEM, V255, P1239
   Ideno H, 2009, EXP CELL RES, V315, P474, DOI 10.1016/j.yexcr.2008.11.019
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Ivanov Andrei I., 2008, V440, P15, DOI 10.1007/978 1 59745 178 9_2
   Kelley R, 2009, J CELL BIOL, V184, P597, DOI 10.1083/jcb.200808064
   Komatsu K, 2008, J PERIODONTAL RES, V43, P194, DOI 10.1111/j.1600 0765.2007.01012.x
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Masaike Y, 2010, MOL PHARMACOL, V77, P262, DOI 10.1124/mol.109.059006
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Mathov I, 2001, J BONE MINER RES, V16, P2050, DOI 10.1359/jbmr.2001.16.11.2050
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Omi H, 2007, J BONE JOINT SURG BR, V89B, P984, DOI 10.1302/0301 620X.89B7.18980
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Recker RR, 2008, J BONE MINER RES, V23, P6, DOI 10.1359/JBMR.070906
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Rogers Maurice, 2011, Scottish Forestry, V65, P34
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Schenk RK., 1984, METHODS CALCIFIED TI, P1
   Shibata T, 2004, J PERIODONTAL RES, V39, P405, DOI 10.1111/j.1600 0765.2004.00755.x
   Stefanik D, 2008, ORAL DIS, V14, P465, DOI 10.1111/j.1601 0825.2007.01402.x
   Tanzer M, 2005, CLIN ORTHOP RELAT R, P30, DOI 10.1097/01.blo.0000194728.62996.2d
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Wada Y, 1998, BONE, V22, P479, DOI 10.1016/S8756 3282(98)00039 8
   Wermelin K, 2008, BONE, V42, P365, DOI 10.1016/j.bone.2007.10.013
   Wilkinson JM, 2011, BONE, V49, P95, DOI 10.1016/j.bone.2011.01.009
   Yoshida T, 2006, FEBS LETT, V580, P5203, DOI 10.1016/j.febslet.2006.08.060
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201 1148
NR 46
TC 39
Z9 43
U1 2
U2 14
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0022 0795
EI 1479 6805
J9 J ENDOCRINOL
JI J. Endocrinol.
PD NOV
PY 2013
VL 219
IS 2
BP 145
EP 158
DI 10.1530/JOE 13 0040
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 242YD
UT WOS:000326281400008
PM 24096963
OA Bronze
DA 2025 08 17
ER

PT J
AU Zou, BH
   Zheng, JH
   Deng, WD
   Tan, YH
   Jie, LG
   Qu, Y
   Yang, Q
   Ke, MH
   Ding, ZB
   Chen, Y
   Yu, QH
   Li, XJ
AF Zou, Binhua
   Zheng, Jiehuang
   Deng, Wende
   Tan, Yanhui
   Jie, Ligang
   Qu, Yuan
   Yang, Qin
   Ke, Minhong
   Ding, Zongbao
   Chen, Yan
   Yu, Qinghong
   Li, Xiaojuan
TI Kirenol inhibits RANKL induced osteoclastogenesis and prevents
   ovariectomized induced osteoporosis via suppressing the
   Ca<SUP>2+</SUP> NFATc1 and Cav 1 signaling pathways
SO PHYTOMEDICINE
LA English
DT Article
DE Kirenol; Osteoclast; NFATc1; Cav 1; Osteoporosis
ID NF KAPPA B; COLLAGEN INDUCED ARTHRITIS; BONE METABOLISM; CA2+ ENTRY;
   CAVEOLIN 1; ACTIVATION; DIFFERENTIATION; EXPRESSION; NFATC1; DRUG
AB Background: Osteoporosis is a threat to aged people who have excessive osteoclast activation and bone resorption, subsequently causing fracture and even disability. Inhibiting osteoclast differentiation and absorptive functions has become an efficient approach to treat osteoporosis, but osteoclast targeting inhibitors available clinically remain rare. Kirenol (Kir), a bioactive diterpenoid derived from an antirheumatic Chinese herbal medicine Herba Siegesbeckiae, can treat collagen induced arthritis in vivo and promote osteoblast differentiation in vitro, while the effects of Kir on osteoclasts are still unclear.
   Purpose: We explore the role of Kir on RANKL induced osteoclastogenesis in vitro and bone loss in vivo.
   Methods: The in vitro effects of Kir on osteoclast differentiation, bone resorption and the underlying mechanisms were evaluated with bone marrow derived macrophages (BMMs). In vivo experiments were performed using an ovariectomy (OVX) induced osteoporosis model.
   Results: We found that Kir remarkably inhibited osteoclast generation and bone resorption in vitro. Mechanistically, Kir significantly inhibited F actinring formation and repressed RANKL induced NF KB p65 activation and pp38, p ERK and c Fos expression. Moreover, Kir inhibited both the expression and nuclear translocation of NFATc1. Ca2+ oscillation and caveolin 1 (Cav 1) were also reduced by Kir during osteoclastogenesis in vitro. Consistent with these findings, 2 10 mg/kg Kir attenuated OVX induced osteoporosis in vivo as evidenced by decreased osteoclast numbers and downregulated Cav 1 and NFATc1 expression.
   Conclusions: Kir suppresses osteoclastogenesis and the Cav 1/NFATc1 signaling pathway both in vitro and in vivo and protects against OVX induced osteoporosis. Our findings reveal Kir as a potential safe oral treatment for osteoporosis.
C1 [Zou, Binhua; Zheng, Jiehuang; Deng, Wende; Tan, Yanhui; Yang, Qin; Ke, Minhong; Ding, Zongbao; Chen, Yan; Li, Xiaojuan] Southern Med Univ, Sch Pharmaceut Sci, Lab Antiinflammatory & Immunomodulatory Pharmacol, Guangzhou 510515, Peoples R China.
   [Zou, Binhua; Zheng, Jiehuang; Deng, Wende; Tan, Yanhui; Yang, Qin; Ke, Minhong; Ding, Zongbao; Chen, Yan; Li, Xiaojuan] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Peoples R China.
   [Jie, Ligang; Qu, Yuan; Yu, Qinghong] Southern Med Univ, ZhuJiang Hosp, Rheumatol & Clin Immunol, Guangzhou 510515, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Southern Medical University   China
RP Li, XJ (通讯作者)，Southern Med Univ, Sch Pharmaceut Sci, Lab Antiinflammatory & Immunomodulatory Pharmacol, Guangzhou 510515, Peoples R China.; Li, XJ (通讯作者)，Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Peoples R China.; Yu, QH (通讯作者)，Southern Med Univ, ZhuJiang Hosp, Rheumatol & Clin Immunol, Guangzhou 510515, Peoples R China.
EM yuqinghong@smu.edu.cn; lixiaoj@smu.edu.cn
RI Yang, Qinfeng/GWZ 7495 2022; 邹, 斌华/CAG 5540 2022
OI Zou, Binhua/0000 0003 0731 1525; Li, Xiaojuan/0000 0002 2668 3044; 
FU National Natural Science Foundation of China [81773740, 81073119];
   Science and Technology Plan Project of Guangzhou City [201804010027]
FX This work was supported by the National Natural Science Foundation of
   China (81773740, 81073119) and the Science and Technology Plan Project
   of Guangzhou City (201804010027).
CR Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Broadhead ML, 2011, EXPERT OPIN THER TAR, V15, P169, DOI 10.1517/14728222.2011.546351
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Covic A, 2018, LANCET DIABETES ENDO, V6, P319, DOI 10.1016/S2213 8587(17)30310 8
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092 8674(00)00116 1
   De Vlam K, 2014, ACTA DERM VENEREOL, V94, P627, DOI 10.2340/00015555 1833
   di Filippo L, 2020, PITUITARY, V23, P314, DOI 10.1007/s11102 020 01041 3
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Guo ZR, 2017, ACTA PHARM SIN B, V7, P119, DOI 10.1016/j.apsb.2016.06.003
   Hada N, 2012, BONE, V50, P226, DOI 10.1016/j.bone.2011.10.028
   Huang XY, 2018, ACTA BIOCH BIOPH SIN, V50, P853, DOI 10.1093/abbs/gmy081
   Huang XY, 2019, ARTIF CELL NANOMED B, V47, P968, DOI 10.1080/21691401.2019.1584110
   Jakob F, 2015, UNFALLCHIRURG, V118, P925, DOI 10.1007/s00113 015 0085 9
   Kadam PD, 2016, INT UROGYNECOL J, V27, P155, DOI 10.1007/s00192 015 2823 5
   Kartner N, 2014, EXPERT OPIN DRUG DIS, V9, P505, DOI 10.1517/17460441.2014.902155
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim J, 2017, J MICROBIOL BIOTECHN, V27, P242, DOI 10.4014/jmb.1610.10050
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200
   Lee YD, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.77
   Lee YD, 2015, J BIOL CHEM, V290, P6522, DOI 10.1074/jbc.M114.598581
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Lu Y, 2012, PHYTOMEDICINE, V19, P882, DOI 10.1016/j.phymed.2012.04.010
   Lu YY, 2012, CHINESE J ORG CHEM, V32, P1, DOI 10.6023/cjoc1110141
   Menshawy A, 2018, SUPPORT CARE CANCER, V26, P1029, DOI 10.1007/s00520 018 4060 1
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Ong HL, 2011, CHANNELS, V5, P422, DOI 10.4161/chan.5.5.16471
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Panagopoulos PK, 2018, J MUSCULOSKEL NEURON, V18, P304
   Pani B, 2009, CELL CALCIUM, V45, P625, DOI 10.1016/j.ceca.2009.02.009
   Patel HH, 2007, FASEB J, V21, P2970, DOI 10.1096/fj.07 8424com
   Prieto Sánchez RM, 2006, ONCOGENE, V25, P2961, DOI 10.1038/sj.onc.1209333
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Soysa Niroshani Surangika, 2012, J Med Dent Sci, V59, P65
   Sun XY, 2019, THERANOSTICS, V9, P5183, DOI 10.7150/thno.33376
   Sundivakkam PC, 2009, AM J PHYSIOL CELL PH, V296, pC403, DOI 10.1152/ajpcell.00470.2008
   Syme CA, 2006, MOL ENDOCRINOL, V20, P3400, DOI 10.1210/me.2006 0178
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takito J, 2015, J CELL PHYSIOL, V230, P395, DOI 10.1002/jcp.24723
   Thouverey C, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.80
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang JB, 2019, BIOORGAN MED CHEM, V27, P1320, DOI 10.1016/j.bmc.2019.02.032
   Wang ZM, 2011, J ETHNOPHARMACOL, V137, P774, DOI 10.1016/j.jep.2011.06.037
   Wu B, 2019, J CELL MOL MED, V23, P7651, DOI 10.1111/jcmm.14638
   Wu J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01304
   Yan FR, 2019, EXP PHYSIOL, V104, P932, DOI 10.1113/EP086924
   Yuan Q, 2019, THERANOSTICS, V9, P1825, DOI 10.7150/thno.31893
   Zeng XZ, 2017, BIOCHEM PHARMACOL, V124, P57, DOI 10.1016/j.bcp.2016.10.007
   Zhang YY, 2019, PHARMACOL RES, V142, P140, DOI 10.1016/j.phrs.2019.02.015
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
   Zou BH, 2021, ACTA PHARMACOL SIN, V42, P744, DOI 10.1038/s41401 020 0477 4
   Zou BH, 2020, BIOCHEM PHARMACOL, V172, DOI 10.1016/j.bcp.2019.113762
NR 61
TC 32
Z9 38
U1 2
U2 42
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JAN
PY 2021
VL 80
AR 153377
DI 10.1016/j.phymed.2020.153377
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA OW5IU
UT WOS:000592920900020
PM 33126167
DA 2025 08 17
ER

PT J
AU Shi, WG
   Gao, YH
   Wang, YY
   Zhou, J
   Wei, ZL
   Ma, XN
   Ma, HP
   Xian, CJ
   Wang, JF
   Chen, KM
AF Shi, Wengui
   Gao, Yuhai
   Wang, Yuanyuan
   Zhou, Jian
   Wei, Zhenlong
   Ma, Xiaoni
   Ma, Huiping
   Xian, Cory J.
   Wang, Jufang
   Chen, Keming
TI The flavonol glycoside icariin promotes bone formation in growing rats
   by activating the cAMP signaling pathway in primary cilia of osteoblasts
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SOLUBLE ADENYLYL CYCLASE; ESTROGEN RECEPTOR ALPHA; MARROW STROMAL CELLS;
   OSTEOGENIC DIFFERENTIATION; IN VITRO; OSTEOCLAST FORMATION;
   HERBA EPIMEDII; CYCLIC AMP; MINERALIZATION; OSTEOPOROSIS
AB Icariin, a prenylated flavonol glycoside isolated from the herb Epimedium, has been considered as a potential alternative therapy for osteoporosis. Previous research has shown that, unlike other flavonoids, icariin is unlikely to act via the estrogen receptor, but its exact mechanism of action is unknown. In this study, using rat calvarial osteoblast culture and rat bone growth models, we demonstrated that icariin promotes bone formation by activating the cAMP/protein kinase A (PKA)/cAMP response element binding protein (CREB) pathway requiring functional primary cilia of osteoblasts. We found that icariin increases the peak bone mass attained by young rats and promotes the maturation and mineralization of rat calvarial osteoblasts. Icariin activated cAMP/PKA/CREB signaling of the osteoblasts by increasing intracellular cAMP levels and facilitating phosphorylation of both PKA and CREB. Blocking cAMP/PKA/CREB signaling with inhibitors of the cAMP synthesizing adenylyl cyclase (AC) and PKA inhibitors significantly inhibited the osteogenic effect of icariin in the osteoblasts. Icariin activated cAMP/PKA/CREB signaling was localized to primary cilia, as indicated by localization of soluble AC and phosphorylated PKA. Furthermore, blocking ciliogenesis via siRNA knockdown of a cilium assembly protein, IFT88, inhibited icariin induced PKA and CREB phosphorylation and also abolished icariin's osteogenic effect. Finally, several of these outcomes were validated in icariin treated rats. Together, these results provide new insights into icariin function and its mechanisms of action and strengthen existing ties between cAMP mediated signaling and osteogenesis.
C1 [Shi, Wengui; Gao, Yuhai; Wang, Yuanyuan; Zhou, Jian; Wei, Zhenlong; Ma, Xiaoni; Chen, Keming] CPLA, Lanzhou Gen Hosp, Inst Orthopaed, Lanzhou 730050, Gansu, Peoples R China.
   [Ma, Huiping] CPLA, Lanzhou Gen Hosp, Dept Pharm, Lanzhou 730050, Gansu, Peoples R China.
   [Xian, Cory J.] Univ South Australia, Sch Pharm & Med Sci, Sansom Inst Hlth Res, Adelaide, SA 5001, Australia.
   [Wang, Jufang] Chinese Acad Sci, Inst Modern Phys, Key Lab Space Radiobiol Gansu Prov, Lanzhou 730000, Gansu, Peoples R China.
C3 University of South Australia; Chinese Academy of Sciences; Institute of
   Modern Physics, CAS
RP Chen, KM (通讯作者)，CPLA, Lanzhou Gen Hosp, Inst Orthopaed, Lanzhou 730050, Gansu, Peoples R China.; Wang, JF (通讯作者)，Chinese Acad Sci, Inst Modern Phys, Key Lab Space Radiobiol Gansu Prov, Lanzhou 730000, Gansu, Peoples R China.
EM jufangwang@impcas.ac.cn; chenkm@lut.cn
RI Xian, Cory/D 2646 2009; Gao, Yuhai/AHB 5767 2022
OI Shi, Wengui/0000 0003 1039 3576
FU National Natural Sciences Foundation of China [81270963, 81471090,
   81770879]; International Science & Technology Cooperation Program of
   China [2015DFR30940]; Natural Sciences Foundation of Gansu province
   [1506RJZA307]; Science and Technology Research Project of Gansu Province
   [145RTSA012, 17JR5RA307]; National Health and Medical Research Council
   (NHMRC) Australia Senior Research Fellowship [1042105]
FX This work was supported in part by National Natural Sciences Foundation
   of China Grants 81270963, 81471090, and 81770879, the International
   Science & Technology Cooperation Program of China Grant 2015DFR30940,
   Natural Sciences Foundation of Gansu province Grant 1506RJZA307, and the
   Science and Technology Research Project of Gansu Province Grants
   145RTSA012 and 17JR5RA307. The authors declare that they have no
   conflicts of interest with the contents of this article.Supported by
   National Health and Medical Research Council (NHMRC) Australia Senior
   Research Fellowship number 1042105.
CR Besschetnova TY, 2010, CURR BIOL, V20, P182, DOI 10.1016/j.cub.2009.11.072
   Bodle JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062554
   Chaloupka JA, 2006, MOL REPROD DEV, V73, P361, DOI 10.1002/mrd.20409
   Chen BL, 2016, EXP THER MED, V11, P2399, DOI 10.3892/etm.2016.3177
   Chen KM, 2007, PHARMAZIE, V62, P388, DOI 10.1691/ph.2007.5.6682
   Chen KM, 2005, PHARMAZIE, V60, P939
   Clement CA, 2009, METHOD CELL BIOL, V94, P181, DOI 10.1016/S0091 679X(08)94009 7
   Garcia Morales V., 2017, BIOCHEM PHARMACOL, V2952, P30567
   Geng WD, 2009, J CELL PHYSIOL, V220, P332, DOI 10.1002/jcp.21767
   HASLAM RJ, 1978, BIOCHEM J, V176, P83, DOI 10.1042/bj1760083
   Hoey David A, 2012, Front Endocrinol (Lausanne), V3, P75, DOI 10.3389/fendo.2012.00075
   Ichikawa S, 2009, CALCIFIED TISSUE INT, V84, P97, DOI 10.1007/s00223 008 9200 z
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015
   Isogai Y, 1996, J BONE MINER RES, V11, P1384
   Koh AJ, 1999, ENDOCRINOLOGY, V140, P3154, DOI 10.1210/en.140.7.3154
   Kwon RY, 2010, FASEB J, V24, P2859, DOI 10.1096/fj.09 148007
   Labour MN, 2016, SCI REP UK, V6, DOI 10.1038/srep35542
   Liang WN, 2012, INT J MOL MED, V30, P889, DOI 10.3892/ijmm.2012.1079
   Litvin TN, 2003, J BIOL CHEM, V278, P15922, DOI 10.1074/jbc.M212475200
   Ma HP, 2011, J CELL BIOCHEM, V112, P916, DOI 10.1002/jcb.23007
   Ma XN, 2017, J ENDOCRINOL INVEST, V40, P357, DOI 10.1007/s40618 016 0568 8
   Ma X. N., 2005, PLANTA MED, V60, P939
   Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104
   Marion V, 2011, KIDNEY INT, V79, P1013, DOI 10.1038/ki.2010.538
   Ming LG, 2013, J CELL PHYSIOL, V228, P513, DOI 10.1002/jcp.24158
   Mok SK, 2010, BRIT J PHARMACOL, V159, P939, DOI 10.1111/j.1476 5381.2009.00593.x
   Mukhopadhyay S, 2013, CELL, V152, P210, DOI 10.1016/j.cell.2012.12.026
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   Park YG, 2004, INT IMMUNOPHARMACOL, V4, P779, DOI 10.1016/j.intimp.2004.03.003
   Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709
   Piggott LA, 2008, P NATL ACAD SCI USA, V105, P13835, DOI 10.1073/pnas.0712100105
   Raychowdhury MK, 2009, AM J PHYSIOL RENAL, V296, pF87, DOI 10.1152/ajprenal.90509.2008
   Reed BY, 2002, J CLIN ENDOCR METAB, V87, P1476, DOI 10.1210/jc.87.4.1476
   Rickard DJ, 2003, J CELL BIOCHEM, V89, P633, DOI 10.1002/jcb.10539
   Satir P, 2010, J CELL SCI, V123, P499, DOI 10.1242/jcs.050377
   Schmid A, 2014, BBA MOL BASIS DIS, V1842, P2584, DOI 10.1016/j.bbadis.2014.07.010
   Shi Wen Gui, 2014, Zhongguo Zhong Yao Za Zhi, V39, P2704
   Singla V, 2006, SCIENCE, V313, P629, DOI 10.1126/science.1124534
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Suzuki A, 2008, J CELL BIOCHEM, V104, P304, DOI 10.1002/jcb.21626
   Wang JH, 2016, SCI REP UK, V6, DOI 10.1038/srep23827
   Wang LL, 2016, CURR PHARM DESIGN, V22, P328, DOI 10.2174/1381612822666151112145907
   Weaver CM, 2016, OSTEOPOROSIS INT, V27, P1281, DOI 10.1007/s00198 015 3440 3
   Willoughby D, 2010, J CELL SCI, V123, P107, DOI 10.1242/jcs.062067
   Xiao HH, 2014, J STEROID BIOCHEM, V143, P141, DOI 10.1016/j.jsbmb.2014.02.019
   Xiao ZS, 2006, J BIOL CHEM, V281, P30884, DOI 10.1074/jbc.M604772200
   Xie YF, 2016, BONE, V93, P22, DOI 10.1016/j.bone.2016.09.008
   Yan JL, 2015, MOL CELL ENDOCRINOL, V404, P132, DOI 10.1016/j.mce.2015.01.031
   Zhai YK, 2014, BONE, V66, P189, DOI 10.1016/j.bone.2014.06.016
   Zhang DW, 2016, CALCIFIED TISSUE INT, V99, P187, DOI 10.1007/s00223 016 0138 2
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zheng D, 2012, BONE, V51, P85, DOI 10.1016/j.bone.2012.04.006
NR 52
TC 58
Z9 65
U1 2
U2 38
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 22
PY 2017
VL 292
IS 51
BP 20883
EP 20896
DI 10.1074/jbc.M117.809517
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA FQ6DG
UT WOS:000418453400007
PM 29089388
OA Green Published
DA 2025 08 17
ER

PT J
AU Poudyal, H
   Brown, L
AF Poudyal, Hemant
   Brown, Lindsay
TI Osteoporosis and its Association with Non Gonadal Hormones Involved in
   Hypertension, Adiposity and Hyperglycaemia
SO CURRENT DRUG TARGETS
LA English
DT Article
DE Leptin; osteoblasts; osteoclasts; osteoporosis; RANK/RANKL signalling
ID BONE MINERAL DENSITY; SERUM PARATHYROID HORMONE; TYPE 2
   DIABETES MELLITUS; VITAMIN D STATUS; FRACTURE RISK; INSULIN RESISTANCE;
   BLOOD PRESSURE; METABOLIC SYNDROME; MARROW ADIPOSITY; BODY COMPOSITION
AB Osteoporosis is a high prevalence disease, particularly in developed countries, and results in high costs both to the individual and to society through associated fragility fractures. There is an urgent need for identification of novel drug targets and development of new anti osteoporotic agents. Between 30 and 80% of osteoporotic fractures cannot be prevented despite current treatments achieving relative fracture risk reduction of up to 20%, 50%, and 70% for non vertebral, hip and spine fractures, respectively. Traditionally, the decline in gonadal hormones has been studied as the sole hormonal determinant for the loss of bone mineral density in osteoporosis. However, recent studies have identified receptors for numerous non gonadal hormones such as PTH, angiotensin II, leptin, adiponectin, insulin and insulin like growth factor 1 on the osteoblast lineage cells that directly regulate bone turnover. These hormones are also involved in the pathogenesis of metabolic syndrome risk factors, particularly hypertension, type II diabetes and obesity. By activating their respective receptors on osteoblastic lineage cells, these hormones appear to act through a common mechanism by down regulating receptors for activation of nuclear factor kappa B ligand (RANKL) and up regulating osteoprotegerin (OPG) with inverse responses for adiponectin. Receptors for amylin, gastric inhibitory polypeptide and ghrelin and have also been identified on the osteoblast lineage cells although the roles of these receptors in bone turnover are controversial or poorly studied. Moreover, bone turnover may be independently regulated by modulation of osteoclast osteoblast function and bone marrow adiposity. Leptin appears to be the only hormone that is a known regulator of both bone mineralisation and bone adiposity.
C1 [Poudyal, Hemant; Brown, Lindsay] Univ So Queensland, Ctr Syst Biol, Toowoomba, Qld 4350, Australia.
   [Brown, Lindsay] Univ So Queensland, Sch Hlth Nursing & Midwifery, Toowoomba, Qld 4350, Australia.
C3 University of Southern Queensland; University of Southern Queensland
RP Brown, L (通讯作者)，Univ So Queensland, Sch Hlth Nursing & Midwifery, Toowoomba, Qld 4350, Australia.
EM Lindsay.Brown@usq.edu.au
RI Poudyal, Hemant/HOH 9324 2023
CR Abdulameer SA, 2012, PATIENT PREFER ADHER, V6, P435, DOI 10.2147/PPA.S32745
   Ahmed LA, 2006, OSTEOPOROSIS INT, V17, P495, DOI 10.1007/s00198 005 0013 x
   Alvarez Castro P, 2013, MINI REV MED CHEM, V13, P541, DOI 10.2174/1389557511313040007
   Ambati S, 2010, ENDOCRINE, V37, P115, DOI 10.1007/s12020 009 9274 z
   [Anonymous], 2012, AUSTR HLTH
   [Anonymous], 2007, ASSESSMENT OSTEOPORO
   Antoniades C, 2009, OBES REV, V10, P269, DOI 10.1111/j.1467 789X.2009.00571.x
   Arabi A, 2012, OSTEOPOROSIS INT, V23, P971, DOI 10.1007/s00198 011 1659 1
   Asaba Y, 2009, J BONE MINER RES, V24, P241, DOI [10.1359/jbmr.081006, 10.1359/JBMR.081006]
   Aslan D, 2012, SCAND J CLIN LAB INV, V72, P14, DOI 10.3109/00365513.2011.624631
   Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054
   Barker Nick, 2008, V468, P5, DOI 10.1007/978 1 59745 249 6_1
   Bartell SM, 2011, J BONE MINER RES, V26, P1710, DOI 10.1002/jbmr.406
   Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4
   Benoit SC, 2004, RECENT PROG HORM RES, V59, P267, DOI 10.1210/rp.59.1.267
   Biver E, 2011, J CLIN ENDOCR METAB, V96, P2703, DOI 10.1210/jc.2011 0047
   Blain H, 2002, J CLIN ENDOCR METAB, V87, P1030, DOI 10.1210/jc.87.3.1030
   Bonds DE, 2006, J CLIN ENDOCR METAB, V91, P3404, DOI 10.1210/jc.2006 0614
   Bonnet N., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P94
   Bonnick Sydney L, 2006, Clin Cornerstone, V8, P28, DOI 10.1016/S1098 3597(06)80063 3
   Cappuccio FP, 1999, LANCET, V354, P971, DOI 10.1016/S0140 6736(99)01437 3
   Casabiell X, 1998, J CLIN ENDOCR METAB, V83, P2149, DOI 10.1210/jc.83.6.2149
   Chan GK, 2001, ENDOCRINOLOGY, V142, P4900, DOI 10.1210/en.142.11.4900
   Chan GK, 2002, GERONTOLOGY, V48, P62, DOI 10.1159/000048929
   Choi JH, 2010, NATURE, V466, P451, DOI 10.1038/nature09291
   Cornish J, 2002, J ENDOCRINOL, V175, P405, DOI 10.1677/joe.0.1750405
   Cornish J, 2002, CURR PHARM DESIGN, V8, P2009, DOI 10.2174/1381612023393341
   Cosman F, 2008, CURR OPIN ENDOCRINOL, V15, P495, DOI 10.1097/MED.0b013e32831a46d6
   Dacquin R, 2004, J CELL BIOL, V164, P509, DOI 10.1083/jcb.200312135
   de la Cour CD, 2005, GUT, V54, P907, DOI 10.1136/gut.2004.058578
   De Laet C, 2005, OSTEOPOROSIS INT, V16, P1330, DOI 10.1007/s00198 005 1863 y
   Delhanty PJ, 2013, BIOFACTORS OXFORD EN
   Delporte C, 2012, J OBES, V2012, DOI 10.1155/2012/535624
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Deng YF, 2010, ANN NY ACAD SCI, V1212, pE1, DOI 10.1111/j.1749 6632.2010.05875.x
   Devlin MJ, 2011, AM J HUM BIOL, V23, P577, DOI 10.1002/ajhb.21202
   Di Carlo C, 2007, MENOPAUSE, V14, P450, DOI 10.1097/01.gme.0000236936.28454.6a
   Dontas I. A., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P268
   Dunmore SJ, 2013, J ENDOCRINOL, V216, pT37, DOI 10.1530/JOE 12 0278
   Duque G, 2008, CURR OPIN RHEUMATOL, V20, P429, DOI 10.1097/BOR.0b013e3283025e9c
   Elefteriou F, 2005, CELL MOL LIFE SCI, V62, P2339, DOI 10.1007/s00018 005 5175 3
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Esposito K, 2013, J CLIN ENDOCR METAB, V98, P3306, DOI 10.1210/jc.2013 1775
   Fruhbeck G, 2004, NEW ENGL J MED, V350, P308, DOI 10.1056/NEJM200401153500323
   Fukushima N, 2005, J BONE MINER RES, V20, P790, DOI 10.1359/JBMR.041237
   Gennari L, 2007, ENDOCRIN METAB CLIN, V36, P399, DOI 10.1016/j.ecl.2007.03.008
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   Goldhahn J, 2012, CALCIFIED TISSUE INT, V90, P343, DOI 10.1007/s00223 012 9587 4
   Greco EA, 2010, INT J CLIN PRACT, V64, P817, DOI 10.1111/j.1742 1241.2009.02301.x
   Griffith JF, 2006, RADIOLOGY, V241, P831, DOI 10.1148/radiol.2413051858
   Haas JT, 2009, CURR OPIN LIPIDOL, V20, P206, DOI 10.1097/MOL.0b013e32832b2024
   HAGENFELDT Y, 1992, EUR J CLIN INVEST, V22, P223, DOI 10.1111/j.1365 2362.1992.tb01455.x
   Hamrick MW, 2004, BONE, V34, P376, DOI 10.1016/j.bone.2003.11.020
   Hanyu R, 2012, P NATL ACAD SCI USA, V109, P7433, DOI 10.1073/pnas.1109036109
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Hebebrand J, 2007, MOL PSYCHIATR, V12, P23, DOI 10.1038/sj.mp.4001909
   HICKMAN J, 1989, ENDOCRINOLOGY, V124, P701, DOI 10.1210/endo 124 2 701
   Hofbauer LC, 2007, J BONE MINER RES, V22, P1317, DOI 10.1359/JBMR.070510
   Holt E., 2011, Vitamin D, VThird, P725
   Hsu YH, 2006, AM J CLIN NUTR, V83, P146
   HULTER H N, 1986, Journal of Clinical Hypertension, V2, P360
   Ilic K, 2013, CALCIFIED TISSUE INT, V92, P217, DOI 10.1007/s00223 012 9671 9
   Isidori AM, 2000, J CLIN ENDOCR METAB, V85, P1954, DOI 10.1210/jc.85.5.1954
   Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Jorde R, 2005, J HYPERTENS, V23, P1639, DOI 10.1097/01.hjh.0000179764.40701.36
   Jürimäe J, 2008, J BONE MINER METAB, V26, P618, DOI 10.1007/s00774 008 0861 5
   Kanis JA, 2012, OSTEOPOROSIS INT, V23, P2239, DOI 10.1007/s00198 012 1964 3
   Kanis JA, 2008, BONE, V42, P467, DOI 10.1016/j.bone.2007.11.001
   Kawai M, 2012, J INTERN MED, V272, P317, DOI 10.1111/j.1365 2796.2012.02564.x
   KHAW KT, 1992, BRIT MED J, V305, P273, DOI 10.1136/bmj.305.6848.273
   Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266
   Kota S, 2013, INDIAN J ORTHOP, V47, P402, DOI 10.4103/0019 5413.114932
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Legiran S, 2012, CLIN CASES MINER BON, V9, P145
   Lewiecki EM, 2013, J CLIN DENSITOM, V16, P28, DOI 10.1016/j.jocd.2012.11.013
   Li SS, 2009, JAMA J AM MED ASSOC, V302, P179, DOI 10.1001/jama.2009.976
   Ligibel JA, 2012, J CLIN ONCOL, V30, P2940, DOI 10.1200/JCO.2012.43.7244
   Lippuner K, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13624
   London GM, 2007, J AM SOC NEPHROL, V18, P613, DOI 10.1681/ASN.2006060573
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995 950
   Looker AC, 2002, BONE, V30, P771, DOI 10.1016/S8756 3282(02)00692 0
   Lu H, 2011, OSTEOPOROSIS INT, V22, P3029, DOI 10.1007/s00198 010 1522 9
   Luo XH, 2006, J BONE MINER RES, V21, P1648, DOI 10.1359/JBMR.060707
   Mammi C, 2012, INT J ENDOCRINOL, V2012, DOI 10.1155/2012/789653
   Mann DR, 2003, J CLIN ENDOCR METAB, V88, P3339, DOI 10.1210/jc.2002 022030
   Marette A, 2004, NES NUTR WS, V9, P141, DOI 10.1159/000080650
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Marwaha RK, 2005, AM J CLIN NUTR, V82, P477, DOI 10.1093/ajcn/82.2.477
   Maury E, 2010, MOL CELL ENDOCRINOL, V314, P1, DOI 10.1016/j.mce.2009.07.031
   McLean Robert R, 2009, Curr Osteoporos Rep, V7, P134
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Metz JA, 1999, BRIT J NUTR, V81, P383, DOI 10.1017/S0007114599000665
   MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086 197110000 00021
   Misiorowski W, 2011, ENDOKRYNOL POL, V62, P73
   Misra M, 2011, CURR OPIN ENDOCRINOL, V18, P376, DOI 10.1097/MED.0b013e32834b4bdc
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Moller N, 1998, J CLIN ENDOCR METAB, V83, P931, DOI 10.1210/jc.83.3.931
   Morley JE, 2001, J GERONTOL A BIOL, V56, P81, DOI 10.1093/gerona/56.suppl_2.81
   Morley JE, 1997, AM J CLIN NUTR, V66, P760, DOI 10.1093/ajcn/66.4.760
   Morton NM, 2008, FRONT HORM RES, V36, P146, DOI 10.1159/000115363
   Motyl KJ, 2009, J CELL PHYSIOL, V218, P376, DOI 10.1002/jcp.21608
   Need AG, 2004, J CLIN ENDOCR METAB, V89, P1646, DOI 10.1210/jc.2003 031539
   Otvos L, 2008, BBA MOL CELL RES, V1783, P1745, DOI 10.1016/j.bbamcr.2008.05.007
   PECK WA, 1993, AM J MED, V94, P646
   Pérez Castrillon JL, 2005, CURR HYPERTENS REV, V1, P61, DOI 10.2174/1573402052952843
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   Pulkkinen L, 2010, INT J PEPT
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Räkel A, 2008, DIABETES METAB, V34, P193, DOI 10.1016/j.diabet.2007.10.008
   RANDOLPH JF, 1987, AM J OBSTET GYNECOL, V157, P1534, DOI 10.1016/S0002 9378(87)80258 2
   Razzaghy Azar M, 2010, ANN HUM BIOL, V37, P692, DOI 10.3109/03014460903527348
   Register TC, 2013, J CLIN ENDOCR METAB, V98, P1916, DOI 10.1210/jc.2012 4126
   Reid IR, 2008, OSTEOPOROSIS INT, V19, P595, DOI 10.1007/s00198 007 0492 z
   REID IR, 1993, AM J PHYSIOL, V265, pE655, DOI 10.1152/ajpendo.1993.265.4.E655
   Reis JP, 2009, PEDIATRICS, V124, pE371, DOI 10.1542/peds.2009 0213
   Rizzoli R, 2001, J MOL ENDOCRINOL, V26, P79, DOI 10.1677/jme.0.0260079
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Rosenbaum M, 1999, J CLIN ENDOCR METAB, V84, P1784, DOI 10.1210/jc.84.6.1784
   Roth JD, 2013, CURR OPIN ENDOCRINOL, V20, P8, DOI 10.1097/MED.0b013e32835b896f
   ROULEAU MF, 1988, ENDOCRINOLOGY, V123, P187, DOI 10.1210/endo 123 1 187
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Scariano JK, 2003, MECH AGEING DEV, V124, P281, DOI 10.1016/S0047 6374(02)00195 1
   Scheller EL, 2010, STEM CELLS, V28, P1071, DOI 10.1002/stem.432
   Schwartz AV, 2001, J CLIN ENDOCR METAB, V86, P32, DOI 10.1210/jc.86.1.32
   Silver J, 1999, KIDNEY INT, V56, pS2, DOI 10.1046/j.1523 1755.1999.07310.x
   Simpson ER, 2003, J STEROID BIOCHEM, V86, P225, DOI 10.1016/S0960 0760(03)00360 1
   South Paul JE, 2001, AM FAM PHYSICIAN, V63, P897
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Tamez H, 2012, CURR OPIN NEPHROL HY, V21, P492, DOI 10.1097/MNH.0b013e3283557bf0
   Taylor EN, 2008, J HYPERTENS, V26, P1390, DOI 10.1097/HJH.0b013e3282ffb43b
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Thrailkill KM, 2005, AM J PHYSIOL ENDOC M, V289, pE735, DOI 10.1152/ajpendo.00159.2005
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Vasikaran S, 2011, CLIN CHEM LAB MED, V49, P1271, DOI 10.1515/CCLM.2011.602
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Walker Bone K, 2012, NAT REV RHEUMATOL, V8, P480, DOI 10.1038/nrrheum.2012.93
   Welt CK, 2004, NEW ENGL J MED, V351, P987, DOI 10.1056/NEJMoa040388
   Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930
   Wilcox Gisela, 2005, Clin Biochem Rev, V26, P19
   Xue P, 2012, ENDOCRINE, V42, P546, DOI 10.1007/s12020 012 9684 1
   Yang SM, 2013, J CLIN ENDOCR METAB, V98, P2478, DOI 10.1210/jc.2012 2958
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Yu B, 2012, J BONE MINER RES, V27, P2001, DOI 10.1002/jbmr.1663
   Zhao LJ, 2008, J BONE MINER RES, V23, P17, DOI 10.1359/JBMR.070813
   Zhao LJ, 2007, J CLIN ENDOCR METAB, V92, P1640, DOI 10.1210/jc.2006 0572
NR 148
TC 8
Z9 10
U1 0
U2 12
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389 4501
EI 1873 5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD DEC
PY 2013
VL 14
IS 14
BP 1694
EP 1706
DI 10.2174/1389450119999990001
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 281SL
UT WOS:000329121200010
PM 24060147
DA 2025 08 17
ER

PT J
AU Autio, KA
   Scher, HI
   Morris, MJ
AF Autio, Karen A.
   Scher, Howard I.
   Morris, Michael J.
TI Therapeutic Strategies for Bone Metastases and Their Clinical Sequelae
   in Prostate Cancer
SO CURRENT TREATMENT OPTIONS IN ONCOLOGY
LA English
DT Article
DE Bone directed therapy; Bone metastases; Skeletal related events;
   Radiopharmaceuticals
ID QUALITY OF LIFE; MITOXANTRONE PLUS PREDNISONE; ANDROGEN DEPRIVATION
   THERAPY; RANDOMIZED CONTROLLED TRIAL; HEPATOCYTE GROWTH FACTOR;
   ZOLEDRONIC ACID; SM 153 LEXIDRONAM; DOUBLE BLIND; PHASE II; SKELETAL
   MORBIDITY
AB Skeletal metastases threaten quality of life, functionality, and longevity in patients with metastatic castration resistant prostate cancer (mCRPC). Therapeutic strategies for bone metastases in prostate cancer can palliate pain, delay/prevent skeletal complications, and prolong survival. Pharmacologic agents representing several drug classes have demonstrated the ability to achieve these treatment goals in men with mCRPC. Skeletal related events such as fracture and the need for radiation can be delayed using drugs that target the osteoclast/osteoblast pathway. Cancer related bone pain can be palliated using beta emitting bone seeking radiopharmaceuticals such as samarium 153 EDTMP and strontium 89. Also, prospective randomized studies have demonstrated that cytotoxic chemotherapy can palliate bone pain. For the first time, bone directed therapy has been shown to prolong survival using the novel alpha emitting radiopharmaceutical radium 223. Given these multifold clinical benefits, treatments targeting bone metabolism, tumor bone stromal interactions, and bone metastases themselves are now central elements of routine clinical care. Decisions about which agents, alone or in combination, will best serve the patient's and clinician's clinical goals is contingent on the treatment history to date, present disease manifestations, and symptomatology. Clinical trials exploring novel agents such as those targeting c Met and Src are under way, using endpoints that directly address how patients feel, function, and survive.
C1 [Autio, Karen A.; Scher, Howard I.; Morris, Michael J.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
C3 Memorial Sloan Kettering Cancer Center
RP Morris, MJ (通讯作者)，Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.
EM morrism@mskcc.org
OI Morris, Michael J./0000 0002 9454 0096
FU NCI NIH HHS [T32 CA009207, R25 CA020449] Funding Source: Medline
CR [Anonymous], J CLIN ONCOL
   Araujo JC., 2011, Cancer
   Baczyk Maciej, 2003, Ortop Traumatol Rehabil, V5, P364
   Berry DL, 2006, J CLIN ONCOL, V24, P2828, DOI 10.1200/JCO.2005.04.8207
   Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261
   BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706
   Brubaker KD, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 15
   Bruland OS, 2006, CLIN CANCER RES, V12, p6250S, DOI 10.1158/1078 0432.CCR 06 0841
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Coleman Robert, 1997, Cancer Treatment Reviews, V23, pS69, DOI 10.1016/S0305 7372(97)90009 8
   Corey E, 2003, CLIN CANCER RES, V9, P295
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140 6736(10)61389 X
   Finlay OG, 2005, LANCET ONCOL, V6, P392, DOI 10.1016/S1470 2045(05)70206 0
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi K, 2009, J CLIN ONCOL, V27, P2429, DOI 10.1200/JCO.2008.18.9811
   Furlow B, 2012, LANCET ONCOL, V13, pE94, DOI 10.1016/S1470 2045(12)70077 3
   Guise T, 2010, SEMIN ONCOL, V37, pS2, DOI 10.1053/j.seminoncol.2010.10.007
   Gunawardana DH, 2004, CLIN NUCL MED, V29, P81, DOI 10.1097/01.rlu.0000109721.58471.44
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   HUMPHREY PA, 1995, AM J PATHOL, V147, P386
   Hung TT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019389
   Hussain MSM, 2011, J CLIN ONCOL S, V29
   James ND, 2010, BJU INT, V106, P966, DOI 10.1111/j.1464 410X.2010.09638.x
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Kantoff PW, 1999, J CLIN ONCOL, V17, P2506, DOI 10.1200/JCO.1999.17.8.2506
   Kasalicky J, 1998, EUR J NUCL MED, V25, P1362, DOI 10.1007/s002590050309
   Knudsen BS, 2002, UROLOGY, V60, P1113, DOI 10.1016/S0090 4295(02)01954 4
   LAING AH, 1991, BRIT J RADIOL, V64, P816, DOI 10.1259/0007 1285 64 765 816
   Michaelson MD, 2007, J CLIN ONCOL, V25, P1038, DOI 10.1200/JCO.2006.07.3361
   Morris MJ, 2009, J CLIN ONCOL, V27, P2436, DOI 10.1200/JCO.2008.20.4164
   Nilsson S, 2005, CLIN CANCER RES, V11, P4451, DOI 10.1158/1078 0432.CCR 04 2244
   Nilsson S, 2007, LANCET ONCOL, V8, P587, DOI 10.1016/S1470 2045(07)70147 X
   Osoba D, 1999, J CLIN ONCOL, V17, P1654, DOI 10.1200/JCO.1999.17.6.1654
   Parker C, 2011, EUR MULT CANC C STOC
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Pons F, 1997, EUR J NUCL MED, V24, P1210, DOI 10.1007/s002590050143
   Pradhan SM, 2012, 12532028 FDA ONC DRU
   Resche I, 1997, EUR J CANCER, V33, P1583, DOI 10.1016/S0959 8049(97)00155 X
   ROBINSON RG, 1993, SEMIN ONCOL, V20, P44
   Saad F, 2004, EUR UROL, V46, P731, DOI 10.1016/j.eururo.2004.08.016
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saad F., 2011, ANN ONCOL
   Saad F, 2010, CANCER TREAT REV, V36, P177, DOI 10.1016/j.ctrv.2009.11.005
   Sartor O, 2004, UROLOGY, V63, P940, DOI 10.1016/j.urology.2004.01.034
   Sartor O, 2007, CANCER AM CANCER SOC, V109, P637, DOI 10.1002/cncr.22431
   Saylor PJ, 2011, J CLIN ONCOL, V29, P3705, DOI 10.1200/JCO.2010.34.4994
   Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487
   Serafini AN, 1998, J CLIN ONCOL, V16, P1574, DOI 10.1200/JCO.1998.16.4.1574
   Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147
   Smith HS, 2011, PAIN PHYSICIAN, V14, pE373
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tannock IF, 1996, J CLIN ONCOL, V14, P1756, DOI 10.1200/JCO.1996.14.6.1756
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   TAYLOR AJ, 1994, J NUCL MED, V35, P2054
   Tu S M, 1996, Urol Oncol, V2, P191, DOI 10.1016/S1078 1439(97)00013 6
   Tu SM, 2009, J CLIN ONCOL, V27, P3319, DOI 10.1200/JCO.2008.20.5393
   Tu SM, 2005, J CLIN ONCOL, V23, P7904, DOI 10.1200/JCO.2005.01.2310
   Tu SM, 2001, LANCET, V357, P336, DOI 10.1016/S0140 6736(00)03639 4
   TURNER JH, 1989, J CLIN ONCOL, V7, P1926, DOI 10.1200/JCO.1989.7.12.1926
   Turner SL, 2001, BRIT J CANCER, V84, P297, DOI 10.1054/bjoc.2000.1610
   U.S. Department of Health and Human Services F. a. D. A, 2010, GUID IND PAT REP OUT
   Yu EY, 2011, UROLOGY, V77, P1166, DOI 10.1016/j.urology.2011.01.006
NR 67
TC 26
Z9 29
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1527 2729
EI 1534 6277
J9 CURR TREAT OPTION ON
JI Curr. Treat. Options Oncol.
PD JUN
PY 2012
VL 13
IS 2
BP 174
EP 188
DI 10.1007/s11864 012 0190 8
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 950ND
UT WOS:000304655100004
PM 22528368
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Diel, I
   Ansorge, S
   Hohmann, D
   Giannopoulou, C
   Niepel, D
   Intorcia, M
AF Diel, Ingo
   Ansorge, Sonja
   Hohmann, David
   Giannopoulou, Christina
   Niepel, Daniela
   Intorcia, Michele
TI Real world use of denosumab and bisphosphonates in patients with solid
   tumours and bone metastases in Germany
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Bisphosphonates; Bone metastases; Compliance; Denosumab;
   Discontinuation; Persistence
ID SKELETAL RELATED EVENTS; ZOLEDRONIC ACID; BREAST CANCER; TARGETED AGENT;
   DRUG THERAPY; DOUBLE BLIND; HEALTH; METAANALYSIS; PREFERENCES;
   PERSISTENCE
AB Purpose Bisphosphonates and denosumab prevent bone complications in patients with bone metastases from solid tumours. This retrospective, longitudinal, cohort study provides data on their real world use in this setting in Germany. Methods Adults with bone metastases from breast, prostate or lung cancer who were newly initiated on a bisphosphonate or denosumab between 1 July 2011 and 31 December 2015 were identified from a German healthcare insurance claims database. Primary outcomes included persistence, compliance, discontinuation and switch rates at 12 months. Results This study included 1130 patients with bone metastases: 555 (49%) had breast cancer, 361 (32%) prostate cancer and 242 (21%) lung cancer. Mean age was 65 years for patients with breast or lung cancer and 74 years for those with prostate cancer. Across all tumour types, compared with any bisphosphonate, 12 month persistence was higher with denosumab (breast cancer 78% vs 54 58%, prostate cancer 58% vs 50%, lung cancer 68% vs 34 60%), median time to discontinuation was longer with denosumab and switch rates were lower for denosumab (breast cancer 5% vs 14 19%, prostate cancer 2% vs 11%, lung cancer 3% vs 7 12%). Compliance at 12 months was longer for denosumab than for any bisphosphonate in breast cancer (75% vs 42 48%) and in prostate cancer (47% vs 36%). Conclusions Patients initiated on denosumab following a diagnosis of bone metastases from breast, prostate or lung cancer had greater medication persistence, longer time to discontinuation, improved compliance and lower switch rates than those initiated on a bisphosphonate.
C1 [Diel, Ingo] Praxisklin Rosengarten, Ctr Gynecol Oncol, Augustaanlage 7 11, D 68165 Mannheim, Germany.
   [Ansorge, Sonja] Vilua Healthcare GmbH, Munich, Germany.
   [Hohmann, David] Amgen GmbH, Munich, Germany.
   [Giannopoulou, Christina; Intorcia, Michele] Amgen Europe GmbH, Rotkreuz, Switzerland.
   [Niepel, Daniela] Amgen Global, Rotkreuz, Switzerland.
C3 Amgen; Amgen Research Munich GmbH; Amgen; AMGEN Europe
RP Diel, I (通讯作者)，Praxisklin Rosengarten, Ctr Gynecol Oncol, Augustaanlage 7 11, D 68165 Mannheim, Germany.
EM ingodiel@gmail.com
FU Amgen GmbH
FX This study was funded by Amgen GmbH.
CR Arellano J, 2015, VALUE HEALTH, V18, P78, DOI 10.1016/j.jval.2014.10.004
   Body JJ, 2017, CRIT REV ONCOL HEMAT, V115, P67, DOI 10.1016/j.critrevonc.2017.04.008
   Brown JE, 2012, NAT REV CLIN ONCOL, V9, P110, DOI 10.1038/nrclinonc.2011.197
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Cramer JA, 2008, VALUE HEALTH, V11, P44, DOI 10.1111/j.1524 4733.2007.00213.x
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   European Medicines Agency, 2018, BONDR IB AC SUMM PRO
   European Medicines Agency, 2018, XGEVA DEN SUMM PROD
   European Medicines Agency, 2018, ZOM ZOL AC INJ SUMM
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Gralow JR, 2013, J NATL COMPR CANC NE, V11, pS1
   Gralow JR, 2009, J NATL COMPR CANC NE, V7, pS1, DOI 10.6004/jnccn.2009.0076
   Hatoum HT, 2011, CLIN BREAST CANCER, V11, P177, DOI 10.1016/j.clbc.2011.03.015
   Hechmati G, 2015, SUPPORT CARE CANCER, V23, P21, DOI 10.1007/s00520 014 2309 x
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hernandez RK, 2014, SUPPORT CARE CANCER, V22, P2697, DOI 10.1007/s00520 014 2251 y
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Jensen AO, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 29
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Medicines.org, 2017, BON CAPS
   Medicines.org, 2017, PAM DIS 9 MG ML STER
   Mortimer JE, 2010, SEMIN ONCOL, V37, pS66, DOI 10.1053/j.seminoncol.2010.06.006
   Norgaard M, 2010, J UROLOGY, V184, P162, DOI 10.1016/j.juro.2010.03.034
   Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Pereira J, 2016, J MED ECON, V19, P611, DOI 10.3111/13696998.2016.1150852
   Qian Y, 2017, SUPPORT CARE CANCER, V25, P1845, DOI 10.1007/s00520 017 3583 1
   Roelofs AJ, 2010, CURR PHARM DESIGN, V16, P2950
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   von Moos R, 2018, J BONE ONCOL, V11, P1, DOI 10.1016/j.jbo.2017.11.004
   von Moos R, 2016, SUPPORT CARE CANCER, V24, P1327, DOI 10.1007/s00520 015 2908 1
   von Moos R, 2013, SUPPORT CARE CANCER, V21, P3497, DOI 10.1007/s00520 013 1932 2
   Wong Gary W K, 2014, Ann Am Thorac Soc, V11 Suppl 2, pS85, DOI 10.1513/AnnalsATS.201309 298RM
   Yong M, 2011, BREAST CANCER RES TR, V129, P495, DOI 10.1007/s10549 011 1475 5
   Zhang ZC, 2017, J BONE ONCOL, V9, P21, DOI 10.1016/j.jbo.2017.09.003
NR 40
TC 21
Z9 23
U1 1
U2 8
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941 4355
EI 1433 7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD NOV
PY 2020
VL 28
IS 11
BP 5223
EP 5233
DI 10.1007/s00520 020 05357 5
EA FEB 2020
PG 11
WC Oncology; Health Care Sciences & Services; Rehabilitation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA NY6VS
UT WOS:000516468600001
PM 32086567
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Covelli, V
   Buonocore, M
   Grimaldi, M
   Scrima, M
   Santoro, A
   Marino, C
   De Simone, V
   van Baarle, L
   Biscu, F
   Scala, MC
   Sala, M
   Matteoli, G
   D'Ursi, AM
   Rodriquez, M
AF Covelli, Verdiana
   Buonocore, Michela
   Grimaldi, Manuela
   Scrima, Mario
   Santoro, Angelo
   Marino, Carmen
   De Simone, Veronica
   van Baarle, Lies
   Biscu, Francesca
   Scala, Maria Carmina
   Sala, Marina
   Matteoli, Gianluca
   D'Ursi, Anna Maria
   Rodriquez, Manuela
TI Peptides as modulators of FPPS enzyme: A multifaceted evaluation from
   the design to the mechanism of action
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE FPPS; Isoprenoids; MVA pathway; Peptide ligands; Phosphopeptides;
   Pharmacomethamolomics
ID FARNESYL DIPHOSPHATE SYNTHASE; TRANSFER DIFFERENCE NMR; ACCURATE
   DOCKING; STRUCTURAL BASIS; SMALL MOLECULES; DRUG DISCOVERY; LIGAND;
   GLIDE; N6 ISOPENTENYLADENOSINE; BISPHOSPHONATES
AB Bone diseases are medical conditions caused by the loss of bone homeostasis consecutive to increased osteoclast activity and diminished osteoblast activity. The mevalonate pathway (MVA) is crucial for maintaining this balance since it drives the post translational prenylation of small guanosine triphosphatases (GTPases) proteins. Farnesyl pyrophosphate synthase (FPPS) plays a crucial role in the MVA pathway. Consequently, in the treatment of bone related diseases, FPPS is the target of FDA approved nitrogen containing bisphosphonates (N BPs), which have tropism mainly for bone tissue due to their poor penetration in soft tissues. The development of inhibitors targeting the FPPS enzyme has garnered significant interest in recent decades due to FPPS's role in the biosynthesis of cholesterol and other isoprenoids, which are implicated in cancer, bone diseases, and other conditions. In this study, we describe a multidisciplinary approach to designing novel FPPS inhibitors, combining computational modeling, biochemical assays, and biophysical techniques. A series of peptides and phosphopeptides were designed, synthesized, and evaluated for their ability to inhibit FPPS activity. Molecular docking was employed to predict the binding modes of these compounds to FPPS, while Surface Plasmon Resonance (SPR) and Nuclear Magnetic Resonance (NMR) spectroscopy experiments   based on Saturation Transfer Difference (STD) and an enzymatic NMR assay   were used to measure their binding affinities and kinetics. The biological activity of the most promising compounds was further assessed in cellular assays using murine colorectal cancer (CRC) cells. Additionally, genomics and metabolomics profiling allowed to unravel the possible mechanisms underlying the activity of the peptides, confirming their involvement in the modulation of the MVA pathway. Our findings demonstrate that the designed peptides and phosphopeptides exhibit significant inhibitory activity against FPPS and possess antiproliferative effects on CRC cells, suggesting their potential as therapeutic agents for cancer.
C1 [Covelli, Verdiana; Rodriquez, Manuela] Univ Naples Federico II, Dept Pharm, Via Domenico Montesano 49, I 80131 Naples, Italy.
   [Buonocore, Michela; Grimaldi, Manuela; Scrima, Mario; Santoro, Angelo; Marino, Carmen; Scala, Maria Carmina; Sala, Marina; D'Ursi, Anna Maria] Univ Salerno, Dept Pharm, Via Giovanni Paolo II,132, I 84084 Fisciano, SA, Italy.
   [Buonocore, Michela] Univ Naples Federico II, Dept Chem Sci, Str Comunale Cintia, I 80126 Naples, Italy.
   [Buonocore, Michela] Univ Naples Federico II, Res Ctr Bioact Peptides CIRPEB, Str Comunale Cintia, I 80126 Naples, Italy.
   [Santoro, Angelo] Univ Salerno, Scuola Specializzaz Farm Osped, Dept Pharm, Via Giovanni Paolo II,132, I 84084 Fisciano, SA, Italy.
   [De Simone, Veronica; van Baarle, Lies; Biscu, Francesca; Matteoli, Gianluca] Katholieke Univ Leuven, Translat Res Ctr Gastrointestinal Disorders TARGID, Dept Chron Dis Metab & Ageing CHROMETA, Herestr 49, B 3000 Leuven, Belgium.
C3 University of Naples Federico II; University of Salerno; University of
   Naples Federico II; University of Naples Federico II; University of
   Salerno; KU Leuven
RP Rodriquez, M (通讯作者)，Univ Naples Federico II, Dept Pharm, Via Domenico Montesano 49, I 80131 Naples, Italy.; D'Ursi, AM (通讯作者)，Univ Salerno, Dept Pharm, Via Giovanni Paolo II,132, I 84084 Fisciano, SA, Italy.
EM verdiana.covelli@unina.it; michela.buonocore@unina.it;
   magrimaldi@unisa.it; marioscrima@gmail.com; asantoro@unisa.it;
   cmarino@unisa.it; ve.desimone@gmail.com; lies.vanbaarle@kuleuven.be;
   francesca.biscu@kuleuven.be; mscala@unisa.it; msala@unisa.it;
   gianluca.matteoli@kuleuven.be; dursi@unisa.it;
   manuela.rodriquez@unina.it
RI ; D'Ursi, Anna/E 8557 2016; Grimaldi, Manuela/AAQ 2981 2020; Marino,
   Carmen/ACQ 2573 2022; Santoro, Angelo/ABB 8087 2020; Rodriquez,
   Manuela/G 2459 2011; Buonocore, Michela/IAS 0408 2023
OI Biscu, Francesca/0000 0001 8191 8865; Covelli,
   Verdiana/0000 0001 9859 086X; Santoro, Angelo/0000 0002 9690 907X;
   Matteoli, Gianluca/0000 0002 2902 4976; 
FX This research did not receive any specific grant from funding agencies
   in the public, commercial, or not for profit sectors.
CR Abate M, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14495 6
   AMIN D, 1992, J LIPID RES, V33, P1657
   Angulo J, 2011, EUR BIOPHYS J BIOPHY, V40, P1357, DOI 10.1007/s00249 011 0749 5
   [Anonymous], 2020, GraphPad Software
   Attard TJ, 2007, INT J PEPT RES THER, V13, P447, DOI 10.1007/s10989 007 9107 y
   Beger RD, 2013, METABOLITES, V3, P552, DOI 10.3390/metabo3030552
   Buonocore M, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms242115610
   Buonocore M, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2022.e11568
   Cai ML, 2019, J BIOMOL NMR, V73, P743, DOI 10.1007/s10858 019 00285 x
   Castiglioni S, 2013, ANTI CANCER AGENT ME, V13, P672, DOI 10.2174/1871520611313040016
   Chang D, 2007, J MAGN RESON, V187, P288, DOI 10.1016/j.jmr.2007.05.008
   Ciaglia E, 2017, BRIT J PHARMACOL, V174, P2287, DOI 10.1111/bph.13824
   Covelli V, 2021, MOLECULES, V26, DOI 10.3390/molecules26237146
   De Castro F, 2018, MOLECULES, V23, DOI 10.3390/molecules23092301
   De Schutter JW, 2014, J MED CHEM, V57, P5764, DOI 10.1021/jm500629e
   Diel IJ, 2004, EUR J CANCER, V40, P1704, DOI 10.1016/j.ejca.2004.03.025
   Eichler J, 2008, CURR OPIN CHEM BIOL, V12, P707, DOI 10.1016/j.cbpa.2008.09.023
   Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754
   Grimaldi M, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14030681
   Grimaldi M, 2020, BIOORG CHEM, V98, DOI 10.1016/j.bioorg.2019.103449
   Gritzalis D, 2015, BIOORG MED CHEM LETT, V25, P1117, DOI 10.1016/j.bmcl.2014.12.089
   Guerra B, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.626971
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Han S, 2019, J MED CHEM, V62, P10867, DOI 10.1021/acs.jmedchem.9b01405
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Heberle H, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859 015 0611 3
   Henninot A, 2018, J MED CHEM, V61, P1382, DOI 10.1021/acs.jmedchem.7b00318
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   Iannelli F, 2018, RECENT PAT ANTI CANC, V13, P184, DOI 10.2174/1574892812666171129141211
   Jacob D, 2017, METABOLOMICS, V13, DOI 10.1007/s11306 017 1178 y
   Jahnke W, 2010, NAT CHEM BIOL, V6, P660, DOI [10.1038/NCHEMBIO.421, 10.1038/nchembio.421]
   Johnson KA, 2011, BIOCHEMISTRY US, V50, P8264, DOI 10.1021/bi201284u
   KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003 2697(70)90146 6
   Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kloer DP, 2006, BIOCHEMISTRY US, V45, P15197, DOI 10.1021/bi061572k
   Klontzas ME, 2019, ACTA BIOMATER, V88, P224, DOI 10.1016/j.actbio.2019.02.017
   Laezza C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.279
   Laezza C, 2009, INT J CANCER, V124, P1322, DOI 10.1002/ijc.24056
   Lau JL, 2018, BIOORGAN MED CHEM, V26, P2700, DOI 10.1016/j.bmc.2017.06.052
   Leung CY, 2013, J MED CHEM, V56, P7939, DOI 10.1021/jm400946f
   Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521 3773(19990614)38:12<1784::AID ANIE1784>3.0.CO;2 Q
   Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120
   McKay RT, 2011, CONCEPT MAGN RESON A, V38A, P197, DOI 10.1002/cmr.a.20223
   MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025
   Notarnicola M, 2004, ONCOLOGY BASEL, V67, P351, DOI 10.1159/000082918
   Notarnicola M, 2012, ANTICANCER RES, V32, P2585
   Obuchowski NA, 2005, AM J ROENTGENOL, V184, P364, DOI 10.2214/ajr.184.2.01840364
   Ogata H, 1998, BIOSYSTEMS, V47, P119, DOI 10.1016/S0303 2647(98)00017 3
   Palomo JM, 2014, RSC ADV, V4, P32658, DOI 10.1039/c4ra02458c
   Pang HH, 2023, ACTA PHARM SIN B, V13, P3238, DOI 10.1016/j.apsb.2023.05.021
   Pang ZQ, 2021, NUCLEIC ACIDS RES, V49, pW388, DOI 10.1093/nar/gkab382
   Park J, 2021, FRONT CHEM, V8, DOI 10.3389/fchem.2020.612728
   Park J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14132
   Park J, 2012, BMC STRUCT BIOL, V12, DOI 10.1186/1472 6807 12 32
   Rodriguez JB, 2016, EXPERT OPIN DRUG DIS, V11, P307, DOI 10.1517/17460441.2016.1143814
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Samarasimhareddy M, 2020, ORG BIOMOL CHEM, V18, P3405, DOI 10.1039/d0ob00499e
   Santoro A, 2022, EUR J MED CHEM, V237, DOI 10.1016/j.ejmech.2022.114400
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schrodinger L., 2021, Prime
   Scognamiglio PL, 2013, CURR MED CHEM, V20, P3803
   Scrima M, 2014, J MED CHEM, V57, P7798, DOI 10.1021/jm500869x
   Sewing L, 2008, APOPTOSIS, V13, P782, DOI 10.1007/s10495 008 0211 z
   Trevor G.R., 2024, Drug Metab. Dispos.
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vanderlooy S, 2008, MACH LEARN, V72, P247, DOI 10.1007/s10994 008 5070 x
   Wang L, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 00904 4
   Wang M, 2016, NAT REV MOL CELL BIO, V17, P110, DOI 10.1038/nrm.2015.11
   Wang TT, 2016, ONCOTARGET, V7, P2532, DOI 10.18632/oncotarget.6304
   Worley B, 2013, CURR METABOL, V1, P92, DOI 10.2174/2213235X11301010092
   Xia Y, 2018, CELL, V175, P1059, DOI 10.1016/j.cell.2018.08.070
   Xu ZR, 2020, APPL MICROBIOL BIOT, V104, P575, DOI 10.1007/s00253 019 10257 8
NR 77
TC 1
Z9 1
U1 3
U2 10
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0223 5234
EI 1768 3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD DEC 5
PY 2024
VL 279
AR 116871
DI 10.1016/j.ejmech.2024.116871
EA SEP 2024
PG 17
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA G9M5G
UT WOS:001319795100001
PM 39303514
OA hybrid
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Wang, H
   Zhu, GC
   Qian, AR
   Chen, W
AF Zhang, Yan
   Wang, He
   Zhu, Guochun
   Qian, Airong
   Chen, Wei
TI F2r negatively regulates osteoclastogenesis through inhibiting the Akt
   and NFκB signaling pathways
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE F2r; osteoclasts; bone resorption; Akt signaling pathway; NF kappa B
   signaling pathway
ID C/EBP ALPHA; G PROTEIN; TGF BETA; DIFFERENTIATION; POLYMORPHISM;
   MECHANISMS
AB G protein coupled receptors (GPCRs) are pivotal drug targets for many diseases. Coagulation Factor II Thrombin Receptor (F2R) is an important member of GPCR family that is highly expressed in osteoclasts. However, the role of F2r in osteoclasts is still unclear. Here, to examine the functions of F2r on osteoclast formation, differentiation, activation, survival, and acidification, we employed loss of function and gain of function approaches to study F2r using F2r targeted short hairpin RNA (sh F2r) lentivirus and overexpression plasmid pLX304 F2r lentivirus respectively, in mouse bone marrow cells (MBMs) induced osteoclasts. We used three shRNAs targeting F2r which had the ability to efficiently and consistently knock down the expression of F2r at different levels. Notably, F2r knockdown trigged a significant increase in osteoclast activity, number, and size, as well as promoted bone resorption and F actin ring formation with increased osteoclast marker gene expression. Moreover, F2r overexpression blocked osteoclast formation, maturation, and acidification, indicating that F2r negatively regulates osteoclast formation and function. Furthermore, we investigated the mechanism(s) underlying the role of F2r in osteoclasts. We detected RANKL induced signaling pathways related protein changes F2r knockdown cells and found significantly increased pAkt levels in sh F2r infected cells, as well as significantly enhanced phosphorylation of p65 and IKB alpha in early stages of RANKL stimulation. These data demonstrated that F2r responds to RANKL stimulation to attenuate osteoclastogenesis through inhibiting the both F2r Akt and F2r NF kappa B signaling pathways, which lead a reduction in the expression of osteoclast genes. Our study suggests that targeting F2r may be a novel therapeutic approach for bone diseases, such as osteoporosis.
C1 [Zhang, Yan; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, Lab Bone Metab, Key Lab Space Biosci & Biotechnol, Xian 710072, Shaanxi, Peoples R China.
   [Zhang, Yan; Wang, He; Zhu, Guochun; Chen, Wei] Univ Alabama Birmingham, Sch Med, Dept Pathol, SHEL 815,1825 Univ Blvd, Birmingham, AL 35294 USA.
C3 Northwestern Polytechnical University; University of Alabama System;
   University of Alabama Birmingham
RP Chen, W (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Pathol, SHEL 815,1825 Univ Blvd, Birmingham, AL 35294 USA.; Qian, AR (通讯作者)，Northwestern Polytech Univ, Sch Life Sci, 127 West Youyi Rd, Xian 710072, Shaanxi, Peoples R China.
EM qianair@nwpu.edu.cn; weichen@uabmc.edu
RI ; Zhang, Yan/MTF 5312 2025
OI Zhang, Yan/0000 0001 6213 4416; 
FU National Institutes of Health [AR 070135, AG 056438]; China Scholarship
   Council [201706290105]
FX We thank Ms. Abigail McVicar for her excellent assistance with the
   manuscript. This work was supported by National Institutes of Health
   [AR 070135 and AG 056438 to W.C.]. Yan Zhang was sponsored by the China
   Scholarship Council (201706290105).
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Aronovich A, 2013, BLOOD, V122, P2562, DOI 10.1182/blood 2012 08 447458
   Austin KM, 2013, BLOOD, V121, P431, DOI 10.1182/blood 2012 09 355958
   Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cheloha RW, 2015, NAT REV ENDOCRINOL, V11, P712, DOI 10.1038/nrendo.2015.139
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen W, 2018, J BONE MINER RES, V33, P691, DOI 10.1002/jbmr.3342
   Chen W, 2018, J PATHOL, V244, P271, DOI 10.1002/path.5001
   Chen W, 2013, P NATL ACAD SCI USA, V110, P7294, DOI 10.1073/pnas.1211383110
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Diepenhorst N, 2018, PHARMACOL THERAPEUT, V184, P1, DOI 10.1016/j.pharmthera.2017.10.015
   Esguerra M, 2016, NUCLEIC ACIDS RES, V44, pW455, DOI 10.1093/nar/gkw403
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Flaumenhaft R, 2017, TRENDS PHARMACOL SCI, V38, P701, DOI 10.1016/j.tips.2017.05.001
   Friedman EA, 2016, J THROMB THROMBOLYS, V41, P656, DOI 10.1007/s11239 015 1285 4
   Gigante B, 2007, ARTERIOSCL THROM VAS, V27, P1213, DOI 10.1161/ATVBAHA.107.140541
   Gingery A, 2008, EXP CELL RES, V314, P2725, DOI 10.1016/j.yexcr.2008.06.006
   Gong HX, 2010, SCIENCE, V327, P340, DOI 10.1126/science.1174779
   Hauser AS, 2018, CELL, V172, P41, DOI 10.1016/j.cell.2017.11.033
   Helfrich MH, 2003, MICROSC RES TECHNIQ, V61, P514, DOI 10.1002/jemt.10375
   Heo JS, 2006, CELL PHYSIOL BIOCHEM, V17, P145, DOI 10.1159/000092076
   Jacobson KA, 2015, BIOCHEM PHARMACOL, V98, P541, DOI 10.1016/j.bcp.2015.08.085
   Jastrzebski S, 2019, J IMMUNOL, V203, P105, DOI 10.4049/jimmunol.1801032
   Jules J, 2018, J BIOL CHEM, V293, P1480, DOI 10.1074/jbc.M116.736009
   Jules J, 2018, BONE, V107, P104, DOI 10.1016/j.bone.2017.05.009
   Jules J, 2016, J BIOL CHEM, V291, P16390, DOI 10.1074/jbc.M115.674598
   Keinan D, 2014, FRONT BIOSCI LANDMRK, V19, P634, DOI 10.2741/4232
   Kihara Y, 2015, EXP CELL RES, V333, P171, DOI 10.1016/j.yexcr.2014.11.020
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kishikawa A, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00157
   Koch CM, 2018, AM J RESP CELL MOL, V59, P145, DOI 10.1165/rcmb.2017 0430TR
   Kong LB, 2017, CELL PHYSIOL BIOCHEM, V43, P1425, DOI 10.1159/000481874
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Luo J, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0059 6
   McAuley JR, 2019, ONCOGENE, V38, P7384, DOI 10.1038/s41388 019 0958 4
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Paoletti N, 2012, IEEE ACM T COMPUT BI, V9, P1366, DOI 10.1109/TCBB.2012.51
   Platé M, 2014, AM J PHYSIOL LUNG C, V307, pL311, DOI 10.1152/ajplung.00128.2014
   Posma JJ, 2019, ARTERIOSCL THROM VAS, V39, P13, DOI 10.1161/ATVBAHA.118.311655
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rajagopal S, 2017, CELL SIGNAL, V41, P9, DOI 10.1016/j.cellsig.2017.01.024
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sinha RK, 2018, BLOOD, V131, P1163, DOI 10.1182/blood 2017 10 810895
   Sloop KW, 2018, BRIT J PHARM S1, V175
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tiedemann K, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00054
   Worth CL, 2017, NUCL ACIDS RES
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Wu MR, 2012, INT J BIOL SCI, V8, P1398, DOI 10.7150/ijbs.5079
   Wu MR, 2010, FRONT BIOSCI LANDMRK, V15, P957, DOI 10.2741/3656
   Yang XP, 2011, NAT METHODS, V8, P659, DOI [10.1038/nmeth.1638, 10.1038/NMETH.1638]
NR 52
TC 19
Z9 19
U1 0
U2 20
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2020
VL 16
IS 9
BP 1629
EP 1639
DI 10.7150/ijbs.41867
PG 11
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA KU4NZ
UT WOS:000519687700012
PM 32226307
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Raisz, LG
AF Raisz, Lawrence G.
TI Maintaining the life long vitality and integrity of skeletal tissue
SO BONE
LA English
DT Article; Proceedings Paper
CT 34th European Symposium on Calcified Tissues
CY MAY 05 09, 2007
CL Copenhagen, DENMARK
DE bone remodelling; osteoporosis; ageing; osteocyte; Wnt signalling
ID BONE MINERAL DENSITY; RECEPTOR RELATED PROTEIN 5;
   LDL RECEPTOR RELATED PROTEIN 5 LRP5 GENE; OSTEOBLAST DIFFERENTIATION;
   OSTEOPOROTIC FRACTURE; PARATHYROID HORMONE; OSTEOCYTE DENSITY; SIGNALING
   PATHWAY; EXPRESSION; MASS
AB Although decreased bone strength and a consequent increase in fragility fractures has been regarded as an inevitable consequence of aging, there is great variability in this process. Moreover there are new findings concerning the mechanisms by which the skeleton maintains it vitality and integrity that should change this view. There are four basic mechanisms that can lead to decreased bone mass and strength and an increase in fragility fractures. 1) Genetic and lifestyle factors that impair the ability to achieve optimal peak bone mass and strength during childhood and adolescence. 2) Loss of bone mass and microarchitectural deterioration due to increased bone resorption, for which estrogen deficiency is probably the most important cause. 3) Inadequate bone formation during remodeling, which appears to be age related but for which the specific causes are not known. 4) Increased propensity to fall and decreased mobility that may be associated both with age related impairment in neuromuscular function and the use of drugs that impair balance.
   Substantial advances have been made in our understanding of the bone remodeling cycle, particularly the interaction of osteoblasts and osteoblasts that initiates resorption. Inflammatory cytokines may be involved in this process, but their specific role in human osteoporosis has not been resolved. New information on the roles of osteocytes and the Writ signaling pathway in the regulation of bone formation indicate that these may be critical in the regulation of skeleton vitality and integrity, Hence new interventions that affect regulators of bone growth and remodeling may be developed that can maintain skeletal tissue and prevent the development of osteoporosis and fragility fractures. (c) 2007 Published by Elsevier Inc.
C1 Univ Connecticut, Ctr Hlth, Musculoskeletal Inst, Farmington, CT 06030 USA.
C3 University of Connecticut
RP Raisz, LG (通讯作者)，Univ Connecticut, Ctr Hlth, Musculoskeletal Inst, Farmington, CT 06030 USA.
EM raisz@nso.uchc.edu
CR ALBRIGHT FULLER, 1940, TRANS ASSOC AMER PHYSICIANS, V55, P298
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bollerslev J, 2005, BONE, V36, P599, DOI 10.1016/j.bone.2005.01.006
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Chow JWM, 1998, J BONE MINER RES, V13, P1039, DOI 10.1359/jbmr.1998.13.6.1039
   Cooper A., 1822, A treatise of dislocation and on fractures of the joints
   Cooper C, 2005, RHEUMATOLOGY, V44, P36, DOI 10.1093/rheumatology/kei060
   Cooper C, 2006, OSTEOPOROSIS INT, V17, P337, DOI 10.1007/s00198 005 2039 5
   Falahati Nini A, 2000, J CLIN INVEST, V106, P1553, DOI 10.1172/JCI10942
   Forwood MR, 1996, J BONE MINER RES, V11, P1688
   Gardner JC, 2005, J CLIN ENDOCR METAB, V90, P6392, DOI 10.1210/jc.2005 1235
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hartikka H, 2005, J BONE MINER RES, V20, P783, DOI 10.1359/JBMR.050101
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Khosla S, 2001, J CLIN ENDOCR METAB, V86, P3555, DOI 10.1210/jc.86.8.3555
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   LIPS P, 1978, CALC TISS RES, V26, P13, DOI 10.1007/BF02013227
   Lips P, 2004, J STEROID BIOCHEM, V89 90, P611, DOI 10.1016/j.jsbmb.2004.03.040
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   Mizuguchi T, 2004, J HUM GENET, V49, P80, DOI 10.1007/s10038 003 0111 6
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Mullender MG, 1996, BONE, V18, P109, DOI 10.1016/8756 3282(95)00444 0
   Mundy GR, 2006, AM J CLIN NUTR, V83, p427S
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Power J, 2002, BONE, V30, P859, DOI 10.1016/S8756 3282(02)00731 7
   Qiu SJ, 2005, BONE, V37, P10, DOI 10.1016/j.bone.2005.01.023
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   RIGGS BL, 1982, J CLIN INVEST, V70, P716, DOI 10.1172/JCI110667
   Rosen CJ, 2004, BEST PRACT RES CL EN, V18, P423, DOI 10.1016/j.beem.2004.02.007
   SCHAPIRA D, 1992, OSTEOPOROSIS INT, V2, P164, DOI 10.1007/BF01623921
   Van Pottelbergh I, 2004, J CLIN ENDOCR METAB, V89, P4949, DOI 10.1210/jc.2003 032081
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
   Veno PA, 2006, J BONE MINER RES, V21, pS38
   Vezeridis PS, 2006, BIOCHEM BIOPH RES CO, V348, P1082, DOI 10.1016/j.bbrc.2006.07.146
   Wadhwa S, 2002, BIOCHEM BIOPH RES CO, V297, P46, DOI 10.1016/S0006 291X(02)02124 1
   Yang F, 2006, J BONE MINER RES, V21, P1676, DOI 10.1359/JBMR.060807
NR 41
TC 3
Z9 5
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2007
VL 40
IS 5
SU 1
BP S1
EP S4
DI 10.1016/j.bone.2007.02.002
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Endocrinology & Metabolism
GA 164IC
UT WOS:000246226000002
DA 2025 08 17
ER

PT J
AU Torstrick, FB
   Guldberg, RE
AF Torstrick, F. Brennan
   Guldberg, Robert E.
TI Local Strategies to Prevent and Treat Osteoporosis
SO CURRENT OSTEOPOROSIS REPORTS
LA English
DT Article
DE Osteoporosis; Local delivery; Hydroxyapatite.; Bisphosphonate; LIPUS
ID INTENSITY PULSED ULTRASOUND; OSTEOCLASTIC BONE RESORPTION;
   RECEPTOR RELATED PROTEIN 5; IN VIVO; POSTMENOPAUSAL WOMEN; ZOLEDRONIC
   ACID; GENE DELIVERY; MINERAL DENSITY; FRACTURES; BISPHOSPHONATE
AB Despite advances in systemic osteoporosis therapeutic outcomes, management of fragility fractures and implant fixation in osteoporotic bone remain difficult clinical challenges. Low initial bone density and a prolonged healing response can lead to fracture nonunion and aseptic implant loosening. Local treatment strategies could be used to prevent fracture, accelerate healing, and increase implant fixation by locally stimulating anabolic pathways or inhibiting catabolic pathways. Local strategies under investigation include direct drug release from injectable materials or implant surface coatings. Common locally delivered drugs include bisphosphonates, parathyroid hormone, and bone morphogenetic proteins, yet additional compounds targeting novel pathways in bone biology are also being actively explored. Mechanical stimulation via low intensity pulsed ultrasound, alone or in combination with drug therapy, may also prove effective to promote local bone healing and implant fixation within osteoporotic bone.
C1 [Torstrick, F. Brennan; Guldberg, Robert E.] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA.
C3 University System of Georgia; Georgia Institute of Technology
RP Guldberg, RE (通讯作者)，Georgia Inst Technol, George W Woodruff Sch Mech Engn, Parker H Petit Inst Bioengn & Biosci, 315 Ferst Dr NW, Atlanta, GA 30332 USA.
EM robert.guldberg@me.gatech.edu
CR Adami S, 2012, J BONE JOINT SURG AM, V94A, P2113, DOI 10.2106/JBJS.K.00774
   Agholme F, 2010, J BONE MINER RES, V25, P2412, DOI 10.1002/jbmr.135
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Aonuma H, 2011, J NEPAL MED ASSOC, V51, P171
   Bidwell JP, 2013, CURR OSTEOPOROS REP, V11, P117, DOI 10.1007/s11914 013 0139 2
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2010, NEW ENGL J MED, V362, P1761, DOI 10.1056/NEJMoa1001086
   Boerckel JD, 2011, BIOMATERIALS, V32, P5241, DOI 10.1016/j.biomaterials.2011.03.063
   Bolland MJ, 2010, BMJ BRIT MED J, V29, P341
   Bolon B, 2001, MOL THER, V3, P197, DOI 10.1006/mthe.2001.0245
   Bonadio J, 2000, J MOL MED, V78, P303, DOI 10.1007/s001090000118
   Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Boonen S, 2011, OSTEOPOROSIS INT, V22, P2915, DOI 10.1007/s00198 011 1639 5
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Carvalho DCL, 2004, ARTIF ORGANS, V28, P114, DOI 10.1111/j.1525 1594.2004.07091.x
   Cheung WH, 2011, ULTRASOUND MED BIOL, V37, P231, DOI 10.1016/j.ultrasmedbio.2010.11.016
   Cummings SR, 2010, NEW ENGL J MED, V362, P686, DOI 10.1056/NEJMoa0808692
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Egermann M, 2005, OSTEOPOROSIS INT, V16, pS120, DOI 10.1007/s00198 004 1817 9
   Evans CH, 2012, ADV DRUG DELIVER REV, V64, P1331, DOI 10.1016/j.addr.2012.03.013
   Fang JM, 1996, P NATL ACAD SCI USA, V93, P5753, DOI 10.1073/pnas.93.12.5753
   Gao Y, 2009, BONE, V44, P225, DOI 10.1016/j.bone.2008.10.054
   Garbuz DS, 2008, J BONE JOINT SURG AM, V90A, P1090, DOI 10.2106/JBJS.G.00415
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Giannoudis PV, 2006, J BONE JOINT SURG BR, V88B, P1272, DOI 10.1302/0301 620X.88B10.17683
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hamilton B, 2003, OSTEOPOROSIS INT, V14, P259, DOI 10.1007/s00198 002 1370 3
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   Hertel R, 2005, OSTEOPOROSIS INT, V16, pS65, DOI 10.1007/s00198 004 1714 2
   Kaneko H, 2000, BONE, V27, P479, DOI 10.1016/S8756 3282(00)00358 6
   Klazen CAH, 2010, LANCET, V376, P1085, DOI 10.1016/S0140 6736(10)60954 3
   KOKUBO T, 1990, J BIOMED MATER RES, V24, P331, DOI 10.1002/jbm.820240306
   Kwek EBK, 2008, INJURY, V39, P224, DOI 10.1016/j.injury.2007.08.036
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lim D, 2011, J ORTHOP RES, V29, P116, DOI 10.1002/jor.21191
   Liu HN, 2010, J BIOMED MATER RES A, V93A, P1180, DOI 10.1002/jbm.a.32614
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Matuszewski L, 2013, INT ORTHOP, V37, P1187, DOI 10.1007/s00264 013 1855 z
   McClellan JW, 2006, J SPINAL DISORD TECH, V19, P483, DOI 10.1097/01.bsd.0000211231.83716.4b
   McKoy BE, 2000, J BIOMED MATER RES, V53, P216, DOI 10.1002/(SICI)1097 4636(2000)53:3<216::AID JBM5>3.0.CO;2 O
   Musgrave DS, 1999, BONE, V24, P541, DOI 10.1016/S8756 3282(99)00086 1
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Panzavolta S, 2009, J INORG BIOCHEM, V103, P101, DOI 10.1016/j.jinorgbio.2008.09.012
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Peter B, 2005, BONE, V36, P52, DOI 10.1016/j.bone.2004.10.004
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Phillips Frank M, 2006, Spine J, V6, P500, DOI 10.1016/j.spinee.2006.01.014
   Roshan Ghias A, 2011, CLIN BIOMECH, V26, P1039, DOI 10.1016/j.clinbiomech.2011.06.004
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Sabokbar A, 1998, ANN RHEUM DIS, V57, P614, DOI 10.1136/ard.57.10.614
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Schousboe JT, 2013, CURR OSTEOPOROS REP, V11, P21, DOI 10.1007/s11914 013 0133 8
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sörensen TC, 2013, J PHARM PHARMACOL, V65, P201, DOI 10.1111/j.2042 7158.2012.01588.x
   Stadelmann VA, 2008, EUR CELLS MATER, V16, P10, DOI 10.22203/eCM.v016a02
   Tengvall P, 2004, BIOMATERIALS, V25, P2133, DOI 10.1016/j.biomaterials.2003.08.049
   Wang YW, 2012, BIOMATERIALS, V33, P8540, DOI 10.1016/j.biomaterials.2012.07.039
   Warden SJ, 2001, ULTRASOUND MED BIOL, V27, P989, DOI 10.1016/S0301 5629(01)00376 3
   Wardlaw D, 2009, LANCET, V373, P1016, DOI 10.1016/S0140 6736(09)60010 6
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Wong DA, 2008, SPINE J, V8, P1011, DOI 10.1016/j.spinee.2007.06.014
   Wu ZX, 2011, J ORTHOP SCI, V16, P99, DOI 10.1007/s00776 010 0019 x
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoshida A, 2013, J HARD TISSUE BIOL, V22, P301, DOI 10.2485/jhtb.22.301
   Yu NYC, 2008, J BIOMED MATER RES B, V87B, P482, DOI 10.1002/jbm.b.31130
   Yu XH, 2012, J MATER SCI MATER M, V23, P2177, DOI 10.1007/s10856 012 4682 7
   Yu XH, 2011, J BIOMED MATER RES B, V97B, P345, DOI 10.1002/jbm.b.31820
   Zara JN, 2011, TISSUE ENG PT A, V17, P1389, DOI [10.1089/ten.TEA.2010.0555, 10.1089/ten.tea.2010.0555]
   Zhao X, 2012, ULTRASOUND MED BIOL, V38, P238, DOI 10.1016/j.ultrasmedbio.2011.11.005
   Zhou H, 2012, J MATER SCI MATER M, V23, P365, DOI 10.1007/s10856 011 4524 z
   Zhou S, 2008, AGING CELL, V7, P335, DOI 10.1111/j.1474 9726.2008.00377.x
NR 77
TC 22
Z9 23
U1 0
U2 32
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
EI 1544 2241
J9 CURR OSTEOPOROS REP
JI Curr. Osteoporos. Rep.
PD MAR
PY 2014
VL 12
IS 1
BP 33
EP 40
DI 10.1007/s11914 014 0191 6
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AY0IZ
UT WOS:000347281700005
PM 24510761
DA 2025 08 17
ER

PT J
AU Yao, QM
   Li, PP
   Liang, SM
   Lu, K
   Zhu, XJ
   Liu, YX
   Zhang, F
   Yuan, T
   Wang, X
AF Yao, Qing Min
   Li, Pei Pei
   Liang, Shu Mei
   Lu, Kang
   Zhu, Xiao Juan
   Liu, Yan Xia
   Zhang, Feng
   Yuan, Ting
   Wang, Xin
TI Methylprednisolone suppresses the Wnt signaling pathway in chronic
   lymphocytic leukemia cell line MEC 1 regulated by LEF 1 expression
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Methylprednisolone; chronic lymphocytic leukemia; wnt signaling pathway;
   beta catenin; LEF 1
ID HIGH DOSE METHYLPREDNISOLONE; CYCLE PROGRESSION; HUMAN OSTEOBLASTS;
   IN VITRO; RITUXIMAB; COMBINATION; GLUCOCORTICOIDS; APOPTOSIS; THERAPY;
   DICKKOPF 1
AB High dose methylprednisolone (HDMP) has been an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia (CLL), while little is known about the exact mechanisms implicated in glucocorticoid induced cell death. To explore the mechanism of glucocorticoid induced cell death, we investigated the effect of HDMP on canonical Wnt signaling which emerged as a key pathway implicated in the pathogenesis of CLL. In this study, the human CLL cell line MEC 1 was incubated with various concentrations of methylprednisolone. Cell proliferation activity was detected by CCK8 assay, the apoptotic effect was evaluated by TUNEL assay. Western blot was used to detect active caspase 3, and the key proteins in Wnt signaling pathway (LEF 1, beta catenin). RT PCR was performed to assess the mRNA levels of beta catenin, LEF 1, c myc and cyclin D1. We observed that high concentration of methylprednisolone could suppress the proliferation activity of MEC 1 cells, promote the relative expression of active caspase 3, and induce apoptotic cell death. Furthermore, methylprednisolone could inhibit LEF 1 protein expression, consequently down regulate mRNA levels of c myc and cyclin D1, but could not affect the transcription level of beta catenin and LEF 1 mRNA. The results of this study indicate that methylprednisolone can suppress Wnt signaling pathway by down regulating LEF 1 protein expression, indicating a novel mechanism for HDMP therapy in CLL.
C1 [Yao, Qing Min; Li, Pei Pei; Lu, Kang; Zhu, Xiao Juan; Liu, Yan Xia; Zhang, Feng; Yuan, Ting; Wang, Xin] Shandong Univ, Shandong Prov Hosp, Dept Hematol, Jinan 250021, Shandong, Peoples R China.
   [Liang, Shu Mei] Shandong Univ, Shandong Prov Hosp, Dept Gynaecol, Jinan 250021, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong University; Shandong University; Shandong First
   Medical University & Shandong Academy of Medical Sciences
RP Wang, X (通讯作者)，Shandong Univ, Shandong Prov Hosp, Dept Hematol, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China.
EM xinw007@126.com
RI peipei, li/GWC 0553 2022
FU National Natural Science Foundation [81270598, 31340009]; Natural
   Science Foundations of Shandong Province [ZR2011HQ009, ZR2012HZ003];
   Technology Development Projects of Shandong Province [2010GSF 10250];
   National Public Health Grand Research Foundation [201202017]; Program of
   Shandong Medical Leading Talent and Taishan Scholar Foundation of
   Shandong Province
FX This work was partly supported by National Natural Science Foundation
   (No. 81270598, No. 31340009), Natural Science Foundations of Shandong
   Province (No. ZR2011HQ009, No. ZR2012HZ003), Technology Development
   Projects of Shandong Province (No. 2010GSF 10250), National Public
   Health Grand Research Foundation (No. 201202017), Program of Shandong
   Medical Leading Talent and Taishan Scholar Foundation of Shandong
   Province.
CR Boelens J, 2009, LEUKEMIA RES, V33, P1335, DOI 10.1016/j.leukres.2009.02.022
   Bowen DA, 2007, LEUKEMIA LYMPHOMA, V48, P2412, DOI 10.1080/10428190701724801
   Castro JE, 2008, LEUKEMIA, V22, P2048, DOI 10.1038/leu.2008.214
   Castro JE, 2009, LEUKEMIA, V23, P1779, DOI 10.1038/leu.2009.133
   Chen JZ, 2008, CANCER BIOL THER, V7, P174, DOI 10.4161/cbt.7.2.5262
   Contri A, 2005, J CLIN INVEST, V115, P369, DOI 10.1172/JC1200522094
   Dores GAM, 2007, BRIT J HAEMATOL, V139, P809, DOI 10.1111/j.1365 2141.2007.06856.x
   Dungarwalla M, 2008, HAEMATOLOGICA, V93, P475, DOI 10.3324/haematol.11903
   Filipovich A, 2010, EUR J HAEMATOL, V85, P309, DOI 10.1111/j.1600 0609.2010.01494.x
   Gabet Y, 2011, J CELL PHYSIOL, V226, P991, DOI 10.1002/jcp.22412
   Gandhirajan RK, 2010, NEOPLASIA, V12, P326, DOI 10.1593/neo.91972
   Gutierrez A, 2010, BLOOD, V116, P2975, DOI 10.1182/blood 2010 02 269878
   Johnston JB, 1997, LEUKEMIA LYMPHOMA, V26, P435, DOI 10.3109/10428199709050881
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Li PP, 2013, CHINESE MED J PEKING, V126, P4175, DOI 10.3760/cma.j.issn.0366 6999.20130414
   Lowenberg M, 2007, TRENDS MOL MED, V13, P158, DOI 10.1016/j.molmed.2007.02.001
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   Memarian A, 2009, LEUKEMIA LYMPHOMA, V50, P2061, DOI 10.3109/10428190903331082
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   Pettitt AR, 2012, J CLIN ONCOL, V30, P1647, DOI 10.1200/JCO.2011.35.9695
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Rose AL, 2002, BLOOD, V100, P1765, DOI 10.1182/blood.V100.5.1765.h81702001765_1765_1773
   Smith E, 2002, J BIOL CHEM, V277, P18191, DOI 10.1074/jbc.M109708200
   Smolej L, 2012, LEUKEMIA RES, V36, P1278, DOI 10.1016/j.leukres.2012.07.005
   Smolej L, 2012, EXPERT OPIN INV DRUG, V21, P1009, DOI 10.1517/13543784.2012.690393
   Stacchini A, 1999, LEUKEMIA RES, V23, P127, DOI 10.1016/S0145 2126(98)00154 4
   Turner JD, 2010, BIOCHEM PHARMACOL, V80, P1860, DOI 10.1016/j.bcp.2010.06.037
   Wallace K, 2010, J CELL SCI, V123, P2102, DOI 10.1242/jcs.070722
   Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004 1050
NR 31
TC 3
Z9 3
U1 0
U2 3
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936 2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 7
BP 7921
EP 7928
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA CR7OB
UT WOS:000361538900026
PM 26339357
DA 2025 08 17
ER

PT J
AU Wang, L
   Chen, K
   He, JB
   Kenny, J
   Yuan, Y
   Chen, JH
   Liu, Q
   Tan, RX
   Zhao, JM
   Xu, JK
AF Wang, Lu
   Chen, Kai
   He, Jianbo
   Kenny, Jacob
   Yuan, Yu
   Chen, Junhao
   Liu, Qian
   Tan, Renxiang
   Zhao, Jinmin
   Xu, Jiake
TI Cytochalasin Z11 inhibits RANKL induced osteoclastogenesis via
   suppressing NFATc1 activation
SO RSC ADVANCES
LA English
DT Article
ID NECROSIS FACTOR RECEPTOR; NUCLEAR FACTOR; IN VITRO; BONE;
   DIFFERENTIATION; EXPRESSION; CELLS; OSTEOPOROSIS; HEALTH
AB Excessive osteoclastogenesis and enhanced bone resorption are pathological hallmarks for bone diseases including osteolytic diseases, osteoporosis, and arthritis. Treatments targeting highly activated osteoclasts are regarded as promising therapies for osteoclast related bone disorders. Cytochalasins are known as secondary metabolites of fungi and exhibit a variety of biological activities in cell biology and medicine. Cytochalasin Z11 (CytoZ11) was previously isolated from the Endothia gyrosa through solid substrate culture and showed therapeutic potential for leukaemia. However, the effects of CytoZ11 on osteoclasts currently remain unclear. Herein, CytoZ11 was found to be able to attenuate RANKL (receptor activator of nuclear factor kappa B ligand) induced osteoclastogenesis and bone resorptive activity dose dependently. CytoZ11 could also inhibit mRNA expression of osteoclast specific genes such as Ctr, Acp5, and Ctsk. Furthermore, CytoZ11 was demonstrated to suppress NFATc1 activation, which is due to the attenuation of two signaling pathways: c Fos signaling and the NF kappa B pathway. In summary, this study revealed that CytoZ11 may become a prospective drug for osteoclast related disease by inhibiting osteoclast formation and function.
C1 [Wang, Lu] Wenzhou Med Univ, Affiliated Hosp 1, Dept Orthopaed, Wenzhou, Zhejiang, Peoples R China.
   [Chen, Kai; He, Jianbo; Kenny, Jacob; Yuan, Yu; Chen, Junhao; Liu, Qian; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
   [He, Jianbo] Guangzhou Univ Chinese Med, Guangzhou, Guangdong, Peoples R China.
   [Yuan, Yu] South China Normal Univ, Sch Phys Educ & Sports Sci, Guangzhou, Guangdong, Peoples R China.
   [Liu, Qian; Zhao, Jinmin; Xu, Jiake] Guangxi Med Univ, Res Ctr Regenerat Med, Nanning, Guangxi, Peoples R China.
   [Liu, Qian; Zhao, Jinmin] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Guangxi, Peoples R China.
   [Liu, Qian; Zhao, Jinmin] Guangxi Med Univ, Int Joint Lab Regenerat Bone & Soft Tissues, Nanning, Guangxi, Peoples R China.
   [Tan, Renxiang] Nanjing Univ, Inst Funct Biomol, State Key Lab Pharmaceut Biotechnol, Nanjing, Peoples R China.
C3 Wenzhou Medical University; University of Western Australia; Guangzhou
   University of Chinese Medicine; South China Normal University; Guangxi
   Medical University; Guangxi Medical University; Guangxi Medical
   University; Nanjing University
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.; Xu, JK (通讯作者)，Guangxi Med Univ, Res Ctr Regenerat Med, Nanning, Guangxi, Peoples R China.
EM jiake.xu@uwa.edu.au
RI Junhao, Chen/GYV 2327 2022; Yuan, Yu/HKN 3214 2023; zhao,
   jin/LBH 0351 2024; Wang, Lu/NAX 8238 2025; Chen, Kai/AAF 4663 2019
OI Kenny, Jacob/0000 0001 8169 9842; Yuan, Yu/0000 0003 1032 6330; Xu,
   Jiake/0000 0003 2021 8309
FU Australian National Health and Medical Research Council (NHMRC)
   [1107828, 1127156, 1163933]; Wenzhou Municipal Sci Tech Bureau Program
   [Y20190276]; UWA CHINA Collaborative Award (2017); Australian Government
   Research Training Program Scholarship; National Health and Medical
   Research Council of Australia [1163933] Funding Source: NHMRC
FX This study was supported by grants from the Australian National Health
   and Medical Research Council (NHMRC, No. 1107828, 1127156, 1163933), and
   Wenzhou Municipal Sci Tech Bureau Program (Y20190276). This study is
   also supported by the UWA CHINA Collaborative Award (2017). Kai Chen is
   supported by Australian Government Research Training Program
   Scholarship. We acknowledge the facilities and technical assistance of
   the Centre for Microscopy, Characterization & Analysis, The University
   of Western Australia.
CR Abu Amer Y, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2170
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cappuzzo KA, 2004, ANN PHARMACOTHER, V38, P294, DOI 10.1345/aph.1D353
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Chen K, 2019, J CELL PHYSIOL, V234, P6477, DOI 10.1002/jcp.27385
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Inoue M, 2000, ENDOCRINOLOGY, V141, P284, DOI 10.1210/en.141.1.284
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Liu R, 2008, J NAT PROD, V71, P1127, DOI 10.1021/np070539b
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Nakashima T, 2011, ANN NY ACAD SCI, V1240, pE13, DOI 10.1111/j.1749 6632.2011.06373.x
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Samsonraj RM, 2018, STEM CELL TRANSL MED, V7, P197, DOI 10.1002/sctm.17 0086
   Scherlach K, 2010, NAT PROD REP, V27, P869, DOI 10.1039/b903913a
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Trendowski M, 2015, INVEST NEW DRUG, V33, P290, DOI 10.1007/s10637 014 0203 5
   Verron E, 2014, DRUG DISCOV TODAY, V19, P312, DOI 10.1016/j.drudis.2013.08.010
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Xu S, 2009, CHEM BIODIVERS, V6, P739, DOI 10.1002/cbdv.200800034
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang HW, 2010, PLANTA MED, V76, P1616, DOI 10.1055/s 0030 1249781
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 36
TC 10
Z9 10
U1 0
U2 7
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046 2069
J9 RSC ADV
JI RSC Adv.
PD NOV 25
PY 2019
VL 9
IS 66
BP 38438
EP 38446
DI 10.1039/c9ra07240c
PG 9
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA KF7EE
UT WOS:000509401700013
PM 35540197
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hu, LC
   Xie, XD
   Xue, H
   Wang, TT
   Panayi, AC
   Lin, Z
   Xiong, Y
   Cao, FQ
   Yan, CC
   Chen, L
   Cheng, P
   Zha, KK
   Sun, Y
   Liu, GD
   Yu, CY
   Hu, YQ
   Tao, RY
   Zhou, W
   Mi, BB
   Liu, GH
AF Hu, Liangcong
   Xie, Xudong
   Xue, Hang
   Wang, Tiantian
   Panayi, Adriana C.
   Lin, Ze
   Xiong, Yuan
   Cao, Faqi
   Yan, Chengcheng
   Chen, Lang
   Cheng, Peng
   Zha, Kangkang
   Sun, Yun
   Liu, Guodong
   Yu, Chenyan
   Hu, Yiqiang
   Tao, Ranyang
   Zhou, Wu
   Mi, Bobin
   Liu, Guohui
TI MiR 1224 5p modulates osteogenesis by coordinating osteoblast/osteoclast
   differentiation via the Rap1 signaling target ADCY2
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; BONE REGENERATION; OSTEOPOROSIS; MICRORNAS
AB MicroRNAs (miRNAs) broadly regulate normal biological functions of bone and the progression of fracture healing and osteoporosis. Recently, it has been reported that miR 1224 5p in fracture plasma is a potential therapy for osteogenesis. To investigate the roles of miR 1224 5p and the Rap1 signaling pathway in fracture healing and osteoporosis development and progression, we used BMMS, BMSCs, and skull osteoblast precursor cells for in vitro osteogenesis and osteoclastogenesis studies. Osteoblastogenesis and osteoclastogenesis were detected by ALP, ARS, and TRAP staining and bone slice resorption pit assays. The miR 1224 5p target gene was assessed by siRNA mediated target gene knockdown and luciferase reporter assays. To explore the Rap1 pathway, we performed high throughput sequencing, western blotting, RT PCR, chromatin immunoprecipitation assays and immunohistochemical staining. In vivo, bone healing was judged by the cortical femoral defect, cranial bone defect and femoral fracture models. Progression of osteoporosis was evaluated by an ovariectomy model and an aged osteoporosis model. We discovered that the expression of miR 1224 5p was positively correlated with fracture healing progression. Moreover, in vitro, overexpression of miR 1224 5p slowed Rankl induced osteoclast differentiation and promoted osteoblast differentiation via the Rap1 signaling pathway by targeting ADCY2. In addition, in vivo overexpression of miR 1224 5p significantly promoted fracture healing and ameliorated the progression of osteoporosis caused by estrogen deficiency or aging. Furthermore, knockdown of miRNA 1224 5p inhibited bone regeneration in mice and accelerated the progression of osteoporosis in elderly mice. Taken together, these results identify miR 1224 5p as a key bone osteogenic regulator, which may be a potential therapeutic target for osteoporosis and fracture nonunion.
C1 [Hu, Liangcong; Xie, Xudong; Xue, Hang; Lin, Ze; Xiong, Yuan; Cao, Faqi; Yan, Chengcheng; Chen, Lang; Cheng, Peng; Zha, Kangkang; Yu, Chenyan; Hu, Yiqiang; Tao, Ranyang; Zhou, Wu; Mi, Bobin; Liu, Guohui] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan 430022, Peoples R China.
   [Hu, Liangcong; Xie, Xudong; Xue, Hang; Lin, Ze; Xiong, Yuan; Cao, Faqi; Yan, Chengcheng; Chen, Lang; Cheng, Peng; Zha, Kangkang; Sun, Yun; Yu, Chenyan; Hu, Yiqiang; Tao, Ranyang; Zhou, Wu; Mi, Bobin; Liu, Guohui] Hubei Prov Key Lab Oral & Maxillofacial Dev & Reg, Wuhan 430022, Peoples R China.
   [Wang, Tiantian] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Emergency Med, Wuhan 430022, Peoples R China.
   [Panayi, Adriana C.] Harvard Med Sch, Brigham & Womens Hosp, Div Plast Surg, Boston, MA 02115 USA.
   [Sun, Yun] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan 430022, Peoples R China.
   [Liu, Guodong] Army Med Univ, Daping Hosp, Med Ctr Trauma & War Injuries, Chongqing 400042, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Harvard University; Harvard University Medical
   Affiliates; Brigham & Women's Hospital; Harvard Medical School; Huazhong
   University of Science & Technology; Army Medical University
RP Mi, BB; Liu, GH (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan 430022, Peoples R China.; Mi, BB; Liu, GH (通讯作者)，Hubei Prov Key Lab Oral & Maxillofacial Dev & Reg, Wuhan 430022, Peoples R China.
EM mibobin@hust.edu.cn; liuguohui@hust.edu.cn
RI Liu, Guodong/C 5806 2011; Xiong, Yuan/AAQ 3642 2021; chou,
   wu/AAI 1145 2019; Panayi, Adriana/AAF 1817 2020; Tao,
   Ranyang/KEH 5298 2024; Mi, Bobin/LTD 1938 2024; 程, 鹏/GQP 7327 2022
OI Xiong, Yuan/0000 0003 1090 9288; Mi, Bobin/0000 0002 6994 4363; 
CR BONUCCI E, 1981, CLIN ORTHOP RELAT R, P252
   Dexheimer PJ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00409
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Gosch M, 2019, Z GERONTOL GERIATR, V52, P408, DOI 10.1007/s00391 019 01559 7
   Hu LC, 2021, MOL THER NUCL ACIDS, V23, P1345, DOI 10.1016/j.omtn.2021.02.008
   Kagiya T., 2013, J ORAL TISSUE ENG, V10, P142
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim J, 2012, J BIOMED MATER RES B, V100B, P1170, DOI 10.1002/jbm.b.31920
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Komatsu DE, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115758
   Li B, 2019, REJUV RES, V22, P420, DOI 10.1089/rej.2018.2126
   Lin CJ, 2019, THERANOSTICS, V9, P3780, DOI 10.7150/thno.34493
   Liu BY, 2019, CELL TISSUE BANK, V20, P173, DOI 10.1007/s10561 019 09751 0
   Liu WQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12794
   Liu WQ, 2016, IMPLANT DENT, V25, P163, DOI 10.1097/ID.0000000000000396
   Lorentzon M, 2019, J INTERN MED, V285, P381, DOI 10.1111/joim.12873
   Lyu LC, 2019, MOL DIAGN THER, V23, P53, DOI 10.1007/s40291 018 0378 0
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Mediero A, 2014, FASEB J, V28, P4901, DOI 10.1096/fj.14 255703
   Niu YN, 2011, IMMUNOLOGY, V133, P8, DOI 10.1111/j.1365 2567.2010.03374.x
   Nugent M, 2017, CALCIFIED TISSUE INT, V101, P355, DOI 10.1007/s00223 017 0296 x
   Odén A, 2013, CALCIFIED TISSUE INT, V92, P42, DOI 10.1007/s00223 012 9666 6
   Onishi M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.226
   Pan ZQ, 2019, J NEUROSCI, V39, P2125, DOI 10.1523/JNEUROSCI.1631 18.2018
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Singleton Q, 2019, CELLS BASEL, V8, DOI 10.3390/cells8010063
   Souza VR, 2019, METHODS MOL BIOL, V1916, P303, DOI 10.1007/978 1 4939 8994 2_29
   Spicer PP, 2012, NAT PROTOC, V7, P1918, DOI 10.1038/nprot.2012.113
   Sreejit P, 2012, CELL TISSUE RES, V350, P55, DOI 10.1007/s00441 012 1458 9
   Tropel P, 2004, EXP CELL RES, V295, P395, DOI 10.1016/j.yexcr.2003.12.030
   Tsou AY, 2020, JAMA J AM MED ASSOC, V324, P1543, DOI 10.1001/jama.2020.17024
   Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080
   Xiong Y, 2019, MOL THER NUCL ACIDS, V17, P223, DOI 10.1016/j.omtn.2019.06.001
   Zhu SP, 2018, BIOL REV, V93, P469, DOI 10.1111/brv.12353
   Zou W, 2013, MOL CELL BIOL, V33, P830, DOI 10.1128/MCB.00790 12
NR 36
TC 44
Z9 55
U1 5
U2 30
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD JUL
PY 2022
VL 54
IS 7
BP 961
EP 972
DI 10.1038/s12276 022 00799 9
EA JUL 2022
PG 12
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 3O2KX
UT WOS:000824311400001
PM 35831436
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU de Sousa, VC
   Sousa, FRN
   Vasconcelos, RF
   Martins, CS
   Lopes, AP
   Militao, N
   Viana, D
   Alves, K
   Leitao, R
   Brito, GAC
   Girao, V
   Goes, P
AF de Sousa, Vanessa Costa
   Sousa, Fatima Regina Nunes
   Vasconcelos, Raquel Felipe
   Martins, Conceicao S.
   Lopes, Amanda Pimentel
   Militao, Nicholas
   Viana, Delane
   Alves, Karuza
   Leitao, Renata
   Brito, Gerly A. C.
   Girao, Virginia
   Goes, Paula
TI Atorvastatin reduces zoledronic acid induced osteonecrosis of the jaws
   of rats
SO BONE
LA English
DT Article
DE Osteonecrosis; Bisphosphonates; Atorvastatin; Wnt signaling; Zoledronic
   acid
ID ACTIVATED PROTEIN KINASE; FEMORAL HEAD; BONE LOSS; SIMVASTATIN;
   MECHANISMS; STATINS; BISPHOSPHONATES; PERIODONTITIS; EXPRESSION;
   APOPTOSIS
AB The aim of this study was to evaluate the effect of Atorvastatin on Bisphosphonate induced osteonecrosis of the jaws of rats. Wistar rats were divided into 4 groups: Saline, Zoledronic Acid, Atorvastatin before or after teeth extraction. BRONJ was induced by Zoledronic Acid (0.1 mg/kg). On day 42, animals were submitted to dental extraction. Atorvastatin was administered at 27 mg/kg for 3 weeks before or after oral procedure. Animals were euthanized on day 77. Maxillae were removed for macro and microscopic analyses. Immunohistochemistry for Dickopff (DKK) 1, Wnt 10b, beta catenin and caspase 3 was performed. Gingival TNF alpha and IL 1 beta was evaluated and blood samples were collected for biochemical dosage. Atorvastatin improved mucosal healing, increased viable osteocytes (by 43 % and 47 % on pre and post Atorvastatin groups, respectively), while reduced Caspase 3 immunoexpression. ATV reduced bone sequestration and modulated inflammation, marked by reduction of gingival IL 1 and TNF. Atorvastatin improved the amount and quality of collagen, increased mineral content and reduced tissue solubility. When administrated prior to teeth extraction, Atorvastatin increased the number and activity of osteoblasts, through activation of the Wnt pathway. In summary, the anti inflammatory and bone anabolic effects of Atorvastatin, maintained bone vitality, metabolism and structure, acting as an interesting pharmacological tool to modulate the disease or to assist BRONJ therapy.
C1 [de Sousa, Vanessa Costa; Vasconcelos, Raquel Felipe; Martins, Conceicao S.] Univ Fed Ceara, Med Sch, Dept Morphol, Postgrad Program Morphol Sci, Fortaleza, CE, Brazil.
   [Sousa, Fatima Regina Nunes] Univ Fed Piaui, Med Sch, Picos, CE, Brazil.
   [Lopes, Amanda Pimentel; Militao, Nicholas; Viana, Delane; Alves, Karuza; Leitao, Renata; Brito, Gerly A. C.; Girao, Virginia] Univ Fed Ceara, Med Sch, Dept Morphol, Fortaleza, CE, Brazil.
   [Goes, Paula] Univ Fed Ceara, Med Sch, Dept Pathol & Legal Med, Fortaleza, CE, Brazil.
   [Goes, Paula] Univ Fed Ceara, Fac Med, Dept Patol & Med Legal, Rua Monsenhor Furtado,S N,Rodolfo Teofilo, BR 60441750 Fortaleza, CE, Brazil.
C3 Universidade Federal do Ceara; Universidade Federal do Piaui;
   Universidade Federal do Ceara; Universidade Federal do Ceara;
   Universidade Federal do Ceara
RP Goes, P (通讯作者)，Univ Fed Ceara, Fac Med, Dept Patol & Med Legal, Rua Monsenhor Furtado,S N,Rodolfo Teofilo, BR 60441750 Fortaleza, CE, Brazil.
EM paulagpinheiro@yahoo.com.br
RI Leitao, Renata/U 1040 2018; de Castro Brito, Gerly Anne/C 8597 2013;
   Goes, Paula/G 1504 2015; LEITÃO, RENATA/ABF 9158 2020; Girão,
   Virgínia/O 6410 2018; Brito, Gerly/C 8597 2013; costa de sousa,
   vanessa/IXD 3423 2023
OI Leitao, Renata/0000 0003 0202 771X; de Castro Brito, Gerly
   Anne/0000 0002 8214 4379; de sousa, vanessa/0000 0001 8899 043X; 
FU Finep CT INFRA; CAPES Pro Equipamentos; MCTI CNPq SisNano2.0
FX We are grateful to the Nucleus of Study in Microscopy and Image
   Processing (NEMPI) from Morphology Department of Federal University of
   Ceara (UFC) for all histology and to Central analitica UFC (open
   fa cility funded by Finep CT INFRA, CAPES Pro Equipamentos and
   MCTI CNPq SisNano2.0) for support with SEM.
CR Abou Neel EA, 2016, INT J NANOMED, V11, P4743, DOI 10.2147/IJN.S107624
   Akkus O, 2004, BONE, V34, P443, DOI 10.1016/j.bone.2003.11.003
   Arnaud C, 2005, ARTERIOSCL THROM VAS, V25, P1231, DOI 10.1161/01.ATV.0000163840.63685.0c
   Aruwajoye OO, 2015, CALCIFIED TISSUE INT, V96, P324, DOI 10.1007/s00223 015 9959 7
   Bailey AJ, 1998, MECH AGEING DEV, V106, P1, DOI 10.1016/S0047 6374(98)00119 5
   Barba Recreo P, 2014, J CRANIO MAXILL SURG, V42, P744, DOI 10.1016/j.jcms.2013.11.005
   Boyce Brendan F., 2005, Keio Journal of Medicine, V54, P127, DOI 10.2302/kjm.54.127
   Calderon RM, 2010, MAYO CLIN PROC, V85, P349, DOI 10.4065/mcp.2009.0365
   Calixto JC, 2011, J CRANIO MAXILL SURG, V39, P215, DOI 10.1016/j.jcms.2010.03.009
   Chen X, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.770899
   Creecy A, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.578477
   Cuttle L, 2005, WOUND REPAIR REGEN, V13, P198, DOI 10.1111/j.1067 1927.2005.130211.x
   Dalcico R, 2013, J PERIODONTOL, V84, P1145, DOI 10.1902/jop.2012.120114
   de Araújo AA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183506
   Ferreira VCD, 2021, CLIN ORAL INVEST, V25, P673, DOI 10.1007/s00784 020 03551 7
   Depalle B, 2016, J BONE MINER RES, V31, P380, DOI 10.1002/jbmr.2705
   Du ZB, 2013, CLIN ORAL IMPLAN RES, V24, P422, DOI 10.1111/j.1600 0501.2011.02341.x
   Dujovne CA, 2002, AM J CARDIOL, V89, P1411, DOI 10.1016/S0002 9149(02)02356 1
   Fedele S, 2010, AM J MED, V123, P1060, DOI 10.1016/j.amjmed.2010.04.033
   Fentoglu Ö, 2012, ORAL DIS, V18, P299, DOI 10.1111/j.1601 0825.2011.01880.x
   Fisslthaler B, 2009, CIRC RES, V105, P114, DOI 10.1161/CIRCRESAHA.109.201590
   Fliefel R, 2015, INT J ORAL MAX SURG, V44, P568, DOI 10.1016/j.ijom.2015.01.026
   Funayama H, 2019, BIOL PHARM BULL, V42, P929, DOI 10.1248/bpb.b18 00923
   Gao YS, 2012, MOL MED REP, V6, P611, DOI 10.3892/mmr.2012.958
   George Estee L, 2018, Bone Rep, V8, P104, DOI 10.1016/j.bonr.2018.03.003
   Goes P, 2014, J PERIODONTAL RES, V49, P45, DOI 10.1111/jre.12077
   Goes Paula, 2016, Braz. Dent. J., V27, P267, DOI 10.1590/0103 6440201600600
   Hardy R, 2009, J ENDOCRINOL, V201, P309, DOI 10.1677/JOE 08 0568
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Kapur NK, 2008, VASC HEALTH RISK MAN, V4, P341, DOI 10.2147/VHRM.S1653
   Kronmann L, 2007, CRIT CARE NURS Q, V30, P154, DOI 10.1097/01.CNQ.0000264258.82875.89
   Lima MD, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00440
   Majima T, 2007, P I MECH ENG H, V221, P537, DOI 10.1243/09544119JEIM203
   McClung MR, 2003, ENDOCRIN METAB CLIN, V32, P253, DOI 10.1016/S0889 8529(02)00079 8
   McCreadie BR, 2006, BONE, V39, P1190, DOI 10.1016/j.bone.2006.06.008
   McHugh J, 2020, NAT REV RHEUMATOL, V16, P539, DOI 10.1038/s41584 020 0498 x
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Noble BS, 2008, ARCH BIOCHEM BIOPHYS, V473, P106, DOI 10.1016/j.abb.2008.04.009
   Pabst Andreas Max, 2016, Dent J (Basel), V5, DOI 10.3390/dj5010002
   Paulo S, 2019, MATERIALS, V12, DOI 10.3390/ma12111840
   Pazianas M, 2007, CLIN THER, V29, P1548, DOI 10.1016/j.clinthera.2007.08.008
   Rauner M, 2008, AGE, V30, P273, DOI 10.1007/s11357 008 9069 9
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Shen J, 2010, OSTEOPOROSIS INT, V21, P81, DOI 10.1007/s00198 009 0949 3
   Shi C, 2018, FASEB J, V32, P440, DOI 10.1096/fj.201700485RR
   Song CL, 2008, J BONE MINER METAB, V26, P213, DOI 10.1007/s00774 007 0820 6
   Sousa LH, 2016, J PERIODONTOL, V87, P1206, DOI 10.1902/jop.2016.160075
   Takeno A, 2015, BONE, V77, P135, DOI 10.1016/j.bone.2015.04.025
   Tamaoka J, 2019, EXP THER MED, V17, P1440, DOI 10.3892/etm.2018.7076
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Tracy LE, 2016, ADV WOUND CARE, V5, P119, DOI 10.1089/wound.2014.0561
   Uda Y, 2017, CURR OSTEOPOROS REP, V15, P318, DOI 10.1007/s11914 017 0373 0
   Vieillard MH, 2008, JOINT BONE SPINE, V75, P34, DOI 10.1016/j.jbspin.2007.05.003
   Wæhre T, 2004, CIRCULATION, V109, P1966, DOI 10.1161/01.CIR.0000125700.33637.B1
   Xie YH, 2017, DRUG DELIV, V24, P1067, DOI 10.1080/10717544.2017.1347966
   Yanik S, 2016, ARCH ORAL BIOL, V65, P59, DOI 10.1016/j.archoralbio.2015.10.010
   Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618
NR 57
TC 8
Z9 8
U1 3
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2022
VL 164
AR 116523
DI 10.1016/j.bone.2022.116523
EA AUG 2022
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 5A9KK
UT WOS:000863197700001
PM 35985466
DA 2025 08 17
ER

PT J
AU Takayama, K
   Inoue, T
   Narita, S
   Maita, S
   Huang, MG
   Numakura, K
   Tsuruta, H
   Saito, M
   Maeno, A
   Satoh, S
   Tsuchiya, N
   Habuchi, T
AF Takayama, Koichiro
   Inoue, Takamitsu
   Narita, Shintaro
   Maita, Shinya
   Huang, Mingguo
   Numakura, Kazuyuki
   Tsuruta, Hiroshi
   Saito, Mitsuru
   Maeno, Atsushi
   Satoh, Shigeru
   Tsuchiya, Norihiko
   Habuchi, Tomonori
TI Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents
   castration induced acceleration of bone metastasis in
   castration insensitive prostate cancer
SO CANCER LETTERS
LA English
DT Article
DE Prostate cancer; Castration; Bone metastasis; Osteoclast;
   Osteoprotegerin; Receptor activator of nuclear factor kappa B ligand
ID ANDROGEN DEPRIVATION THERAPY; TUMOR CELLS; RECEPTOR; IDENTIFICATION;
   OSTEOBLASTS; EXPRESSION; OSTEOCYTES; DENOSUMAB; GROWTH; MEN
AB Androgen deprivation therapy (ADT) for patients with metastatic or locally advanced prostate cancer reduces bone mineral density by stimulating receptor activator of nuclear factor kappa B (RANK) signaling in osteoclasts. The involvement of the RANK/RANKL signaling in ADT induced acceleration of bone metastasis in castration insensitive prostate cancer was examined in a murine model using osteoprotegerin (OPG). Male Ball/c nude mice were divided into three groups: the non castration, castration, and castration + OPG groups. PC 3M luc C6 was injected into the left ventricle of the mice. Recombinant OPG was injected intravenously twice weekly in the castration + OPG group. In vivo imaging system (IVIS (R)) determined that the prevalence and photon counts of bone metastasis in the castration group were significantly higher than that in the non castration and castration + OPG groups. The mean number of RANKL positive osteoblasts and the mean serum RANKL level in the castration group were significantly higher than those in the non castration group. RANKL enhanced activation of osteoclasts was attenuated in the castration + OPG group. These results suggest that the mechanisms of RANK/RANKL signaling are involved in the ADT induced acceleration of bone metastasis in castration insensitive prostate cancer. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Takayama, Koichiro; Inoue, Takamitsu; Narita, Shintaro; Huang, Mingguo; Numakura, Kazuyuki; Tsuruta, Hiroshi; Saito, Mitsuru; Maeno, Atsushi; Habuchi, Tomonori] Akita Univ, Dept Urol, Grad Sch Med, Akita, Japan.
   [Inoue, Takamitsu; Narita, Shintaro; Huang, Mingguo; Habuchi, Tomonori] Japan Sci & Technol Agcy, AMED CREST, Tokyo, Japan.
   [Tsuchiya, Norihiko] Yamagata Univ, Dept Urol, Fac Med, Yamagata, Japan.
   [Maita, Shinya] Iwate Prefectural Isawa Hosp, Oshu, Iwate, Japan.
   [Satoh, Shigeru] Akita Univ Hosp, Ctr Kidney Dis & Transplantat, Akita, Japan.
C3 Akita University; Japan Science & Technology Agency (JST); Yamagata
   University; Akita University
RP Inoue, T (通讯作者)，Akita Univ, Sch Med, Dept Urol, 1 1 1 Hondo, Akita 0108543, Japan.
EM takamitu@doc.med.akita u.ac.jp
RI Narita, Shintaro/H 3017 2019; Inoue, Takamitsu/H 8165 2019; Tsuchiya,
   Norihiko/H 6538 2019
OI Inoue, Takamitsu/0000 0002 1362 4344; 
FU Japanese Society for the Promotion of Science (KAKENHI) [25293332,
   26670695, 25861409, 16H02679]; Grants in Aid for Scientific Research
   [16H02679, 25861409, 26670695] Funding Source: KAKEN
FX This work was supported by the Japanese Society for the Promotion of
   Science (KAKENHI) grant number 25293332, 26670695, 25861409, and
   16H02679.
CR ARGUELLO F, 1992, CANCER RES, V52, P2304
   Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678
   Chlenski A, 2001, PROSTATE, V47, P66
   COLVARD DS, 1989, P NATL ACAD SCI USA, V86, P854, DOI 10.1073/pnas.86.3.854
   Esposito M, 2014, PHARMACOL THERAPEUT, V141, P222, DOI 10.1016/j.pharmthera.2013.10.006
   Fiñones RR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074438
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Greenspan SL, 2005, J CLIN ENDOCR METAB, V90, P6410, DOI 10.1210/jc.2005 0183
   Heidenreich A, 2014, EUR UROL, V65, P467, DOI 10.1016/j.eururo.2013.11.002
   Huggins C, 1941, CANCER RES, V1, P293
   Inoue T, 2010, PROSTATE, V70, P1628, DOI 10.1002/pros.21198
   Jenkins DE, 2003, CLIN EXP METASTAS, V20, P745, DOI 10.1023/B:CLIN.0000006817.25962.87
   Kawano H, 2003, P NATL ACAD SCI USA, V100, P9416, DOI 10.1073/pnas.1533500100
   Li XD, 2009, BONE, V45, P669, DOI 10.1016/j.bone.2009.06.011
   Maita S, 2012, INT J CANCER, V130, P677, DOI 10.1002/ijc.26034
   Morote J, 2006, J UROLOGY, V175, P1679, DOI 10.1016/S0022 5347(05)00999 7
   Morote J, 2007, UROLOGY, V69, P500, DOI 10.1016/j.urology.2006.11.002
   Ottewell PD, 2014, ENDOCR RELAT CANCER, V21, P769, DOI 10.1530/ERC 14 0199
   Pal SK, 2015, CLIN GENITOURIN CANC, V13, P130, DOI 10.1016/j.clgc.2014.08.014
   Proell V, 2009, BONE, V45, P677, DOI 10.1016/j.bone.2009.05.024
   Rahim F, 2014, BONE MARROW RES, DOI 10.1155/2014/405920
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Russell PK, 2012, J MOL ENDOCRINOL, V49, P1, DOI 10.1530/JME 12 0014
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Sinnesael M, 2012, J BONE MINER RES, V27, P2535, DOI 10.1002/jbmr.1713
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Traish AM, 2009, J ANDROL, V30, P10, DOI 10.2164/jandrol.108.005215
   Vale CL, 2016, LANCET ONCOL, V17, P243, DOI 10.1016/S1470 2045(15)00489 1
   Wiren KM, 2004, ENDOCRINOLOGY, V145, P3507, DOI 10.1210/en.2003 1016
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 32
TC 21
Z9 23
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PD JUL 1
PY 2017
VL 397
BP 103
EP 110
DI 10.1016/j.canlet.2017.03.034
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA EU9TG
UT WOS:000401382000011
PM 28373003
DA 2025 08 17
ER

PT J
AU Mao, Y
   Xie, XR
   Jiang, T
   Chao, R
   Wan, TH
   Sun, L
   Sun, GX
   Zhou, ZH
   Xu, WF
   Chen, XZ
   Zhang, SY
AF Mao, Yi
   Xie, Xinru
   Jiang, Ting
   Chao, Rui
   Wan, Tianhao
   Sun, Lei
   Sun, Guangxin
   Zhou, Zihang
   Xu, Weifeng
   Chen, Xuzhuo
   Zhang, Shanyong
TI Xl019, a novel JAK inhibitor, suppressed osteoclasts differentiation
   induced by RANKL through MAPK signaling pathway
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Osteoclast; JAK inhibitor; XL019; Bone resorption; MAPK signaling
   pathway
AB In bone metabolism, osteoclasts are the only cells capable of resorbing bone. Hyperactivity of osteoclasts may lead to osteolytic disease like osteoporosis and arthritis. Although there are several drugs for the treatment of osteolytic diseases, they have limitations and a variety of side effects. An inhibitor of Janus kinase (JAK), XL019, has shown promising results in the treatment of myelofibrosis and other cancers. But whether it can functionally impact osteoclast activity has not been proven. In this study, the effects of XL019 on osteoclastogenesis and the mechanism pathway were investigated in vitro. It was found that XL019 could impair osteoclasts formation, interfere with bone resorption ability and downregulate the osteoclast specific genes and proteins expression. Furthermore, Western blot and molecular docking studies demonstrated that XL019 inhibited RANKL induced osteoclastogenesis by suppressing MAPK signaling. A molecular docking analysis explained how XL019 binds to MAPK pathway factors. In addition, titanium particles induced calvarial osteolysis in mice further confirming its beneficial effect on bone homeostasis in vivo. In conclusion, this study demonstrates that Osteoclast activity can be effectively inhibited by XL019 via MAPK signaling pathway, making it a promising alternative pharmacological treatment for bone metabolic disorders.
C1 [Mao, Yi; Xie, Xinru; Chao, Rui; Wan, Tianhao; Sun, Lei; Xu, Weifeng; Chen, Xuzhuo; Zhang, Shanyong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Oral Surg, Shanghai 200011, Peoples R China.
   [Mao, Yi; Xie, Xinru; Chao, Rui; Wan, Tianhao; Sun, Lei; Xu, Weifeng; Chen, Xuzhuo; Zhang, Shanyong] Shanghai Jiao Tong Univ, Coll Stomatol, Shanghai, Peoples R China.
   [Mao, Yi; Xie, Xinru; Chao, Rui; Wan, Tianhao; Sun, Lei; Xu, Weifeng; Chen, Xuzhuo; Zhang, Shanyong] Natl Ctr Stomatol, Shanghai, Peoples R China.
   [Mao, Yi; Xie, Xinru; Wan, Tianhao; Sun, Lei; Chen, Xuzhuo; Zhang, Shanyong] Natl Clin Res Ctr Oral Dis, Shanghai, Peoples R China.
   [Mao, Yi; Xie, Xinru; Wan, Tianhao; Sun, Lei; Xu, Weifeng; Chen, Xuzhuo; Zhang, Shanyong] Shanghai Key Lab Stomatol, Shanghai, Peoples R China.
   [Mao, Yi; Xie, Xinru; Wan, Tianhao; Sun, Lei; Xu, Weifeng; Chen, Xuzhuo; Zhang, Shanyong] Shanghai Res Inst Stomatol, Shanghai, Peoples R China.
   [Jiang, Ting] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Orthodont, Shanghai, Peoples R China.
   [Sun, Lei] Anhui Med Univ, Affiliated Hosp 2, Dept Stomatol, Hefei, Anhui, Peoples R China.
   [Sun, Guangxin] China Med Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Shenyang, Liaoning, Peoples R China.
   [Zhou, Zihang] Shanghai Jiao Tong Univ, Sch Med, Coll Stomatol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Anhui Medical University; China Medical
   University; Shanghai Jiao Tong University
RP Xu, WF; Chen, XZ; Zhang, SY (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Oral Surg, Shanghai 200011, Peoples R China.
EM 118037@sh9hospital.org.cn; 822015@sh9hospital.org.cn;
   ZHANGSY1787@sh9hospital.org.cn
RI Zhou, zihang/JTV 1024 2023; chao, rui/LFU 2711 2024; Chen,
   Xuzhuo/ACC 3813 2022
FU Foundation of China [82101040]; National Outstanding Youth Science Fund
   Project of National Natural Science Foundation of China [21XD1431500];
   Program of Shanghai Academic/Technology Research Leader [TMSK 2021 143];
   Open Project of Trans lational Medicine National Science and Technology
   Infrastructure [XK2020013]; Huangpu District Industry Support Fund; 
   [82071135]
FX This work was financially supported by the National Natural Science &
   nbsp;Foundation of China [Grant No. 82071135] , National Outstanding
   Youth Science Fund Project of National Natural Science Foundation of
   China [Grant No. 82101040] , the Program of Shanghai Academic/Technology
   Research Leader [21XD1431500] , Open Project of Translational Medicine
   National Science and Technology Infrastructure (TMSK 2021 143) , and
   Huangpu District Industry Support Fund (XK2020013) .r Foundation of
   China [Grant No. 82071135] , National Outstanding Youth Science Fund
   Project of National Natural Science Foundation of China [Grant No.
   82101040] , the Program of Shanghai Academic/Technology Research Leader
   [21XD1431500] , Open Project of Trans lational Medicine National Science
   and Technology Infrastructure (TMSK 2021 143) , and Huangpu District
   Industry Support Fund (XK2020013) .
CR Tang JT, 2019, NAT PLANTS, V5, P341, DOI 10.1038/s41477 019 0406 z
   Zhao ZM, 2020, CELL, V181, P151, DOI 10.1016/j.cell.2020.02.001
NR 2
TC 6
Z9 7
U1 1
U2 35
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD SEP
PY 2023
VL 215
AR 115704
DI 10.1016/j.bcp.2023.115704
EA AUG 2023
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA Q1DP4
UT WOS:001054994200001
PM 37536474
DA 2025 08 17
ER

PT J
AU Cheung, MS
   Glorieux, FH
   Rauch, F
AF Cheung, Moira S.
   Glorieux, Francis H.
   Rauch, Frank
TI Large Osteoclasts in Pediatric Osteogenesis Imperfecta Patients
   Receiving Intravenous Pamidronate
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE bisphosphonates; children; osteoclasts; osteogenesis imperfecta
ID X RAY ABSORPTIOMETRY; BONE; CHILDREN; BISPHOSPHONATES; RESORPTION;
   THERAPY
AB Intravenous pamidronate is widely used to treat children with moderate to severe osteogenesis imperfecta (01). Changes in the appearance of osteoclasts have previously been noted in children receiving pamidronate and have been interpreted as signs of toxicity. In this study, we analyzed osteoclast parameters in paired iliac bone specimens before and after 2 4 yr of cyclical intravenous pamidronate therapy in 44 pediatric OI patients (age range: 1.4 17.5 yr; 21 girls). During pamidronate treatment, average osteoclast diameter and the mean number of nuclei present per osteoclast increased by 18% (p=0.02) and 43% (p<0.001), respectively. The number of samples containing large osteoclasts (LOcs, diameter >50 mu m) increased from 6 (14%) before treatment to 23 (52%) after pamidronate therapy (p<0.001 by chi(2) test). Post treatment samples containing LOcs had a greater core width (p=0.04) and a higher cancellous bone volume per tissue volume (p<0.001), because cancellous bone volume had increased more during pamidronate treatment (p<0.001). Osteoclast number and surface were higher in samples with LOcs, but there was no difference in cancellous bone formation parameters. The presence of LOcs was independent of Of type, type of collagen type I mutation, lumbar spine BM D, and other clinical or biochemical measures. In conclusion, this study did not show any indication that LOcs during pamidronate treatment are indicative of toxicity. It seems more likely that the observed abnormalities in osteoclast morphology are part of the mechanism of action of this drug.
C1 [Rauch, Frank] Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada.
   McGill Univ, Montreal, PQ, Canada.
C3 McGill University
RP Rauch, F (通讯作者)，Shriners Hosp Children, Genet Unit, 1529 Cedar Ave, Montreal, PQ H3G 1A6, Canada.
EM frauch@shriners.mcgill.ca
RI ; Rauch, Frank/D 1554 2009
OI Cheung, Moira/0000 0003 0742 7595; Rauch, Frank/0000 0002 6261 0360
FU Fonds de la Recherche en Sante du Quebec; Shriners of North America
FX The authors thank Mark Lepik for preparation of the figure. FR is a
   Chercheur Boursier Clinicien of the Fonds de la Recherche en Sante du
   Quebec. This study was supported by the Shriners of North America.
CR Arikoski P, 2004, BONE, V34, P539, DOI 10.1016/j.bone.2003.11.019
   Åström E, 2002, ARCH DIS CHILD, V86, P356, DOI 10.1136/adc.86.5.356
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   Glorieux FH, 2000, BONE, V26, P103, DOI 10.1016/S8756 3282(99)00257 4
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Land C, 2006, J BONE MINER RES, V21, P374, DOI 10.1359/JBMR.051207
   Ogden CL, 2002, PEDIATRICS, V109, P45, DOI 10.1542/peds.109.1.45
   Partlow D. P., 1987, Journal of Materials Research, V2, P595, DOI 10.1557/JMR.1987.0595
   Rauch F, 2004, J BONE MINER RES, V19, P1191, DOI 10.1359/JBMR.040303
   Rauch F, 2004, LANCET, V363, P1377, DOI 10.1016/S0140 6736(04)16051 0
   Rauch F, 2003, J CLIN ENDOCR METAB, V88, P986, DOI 10.1210/jc.2002 021371
   Rauch F, 2002, J CLIN INVEST, V110, P1293, DOI 10.1172/JCI200215952
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   SALLE BL, 1992, ACTA PAEDIATR, V81, P953, DOI 10.1111/j.1651 2227.1992.tb12152.x
   SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
NR 17
TC 25
Z9 27
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2009
VL 24
IS 4
BP 669
EP 674
DI 10.1359/JBMR.081225
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 426RF
UT WOS:000264724700012
PM 19063679
OA Bronze
DA 2025 08 17
ER

PT J
AU Lu, X
   Zhang, XL
   Chu, K
   Zhang, GD
   Zheng, YP
AF Lu, Xing
   Zhang, Xing Lin
   Chu, Kai
   Zhang, Guo Dong
   Zheng, Yan Ping
TI Targeting Integrin β1 Impedes Cytokine Induced Osteoclast
   Differentiation: A Potential Pharmacological Intervention in
   Pathological Osteolysis
SO TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH
LA English
DT Article
DE Osteoclast differentiation; Integrin beta 1; Receptor activator of
   nuclear factor kappa B; TNF alpha; Mitogen activated protein kinase;
   Cytokines; Skeletal disease
ID BONE RESORPTION; MECHANISM
AB Purpose: To examine whether integrin beta 1 is essential for osteoclast differentiation and function and if it can be targeted for pharmacological intervention in pathological osteolysis.
   Methods: Control and Integrin beta 1 knockdown RAW 264.7 cells were treated with receptor activator of nuclear factor kappa B (RANKL) or TNF alpha and evaluated for osteoclast differentiation. Osteoclast differentiation and function were evaluated by marker protein analysis, tartrate resistant acid phosphatase (TRAP) and resorption assays. Furthermore, downstream molecular signaling analysis was probed using small molecule inhibitors and blocking antibodies, and evaluated by immunoblotting.
   Results: Integrin beta 1 knockdown cells showed reduced osteoclast differentiation following TNF alpha treatment while no change was seen after RANKL treatment (p < 0.05). Immunoblot based molecular signaling analysis showed involvement of MAPK kinase signaling in mediating TNF alpha/integrin beta 1 induced osteoclastogenesis. Finally, when MAPK kinase inhibitor (2.5 and 5 mu M; p < 0.05) and integrin beta 1 blocking antibody (2.5 and 5 mu g/mL; p < 0.05) was used to specifically attenuate TNF alpha induced osteoclastogenesis, no change was observed in RANKL induced osteoclast formation.
   Conclusion: The data obtained highlight the role of integrin beta 1 in TNF alpha induced osteoclastogenesis, but not in RANKL pathway. Given that, inflammatory cytokine secretions such as TNF alpha are progressively implicated in pathological osteolysis, targeting this pathway may attenuate osteolysis in pathological bone tissues.
C1 [Lu, Xing; Zheng, Yan Ping] Shandong Univ, Qi Lu Hosp, Dept Orthopaed Surg, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
   [Lu, Xing; Zhang, Xing Lin; Chu, Kai; Zhang, Guo Dong] Yantai Shan Hosp, Dept Orthopaed Surg, 91 Jiefang Rd, Yantai 264000, Shandong, Peoples R China.
C3 Shandong University
RP Zheng, YP (通讯作者)，Shandong Univ, Qi Lu Hosp, Dept Orthopaed Surg, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
EM zhangyanpingzyp@hotmail.com
RI Zhang, Guodong/D 9728 2011
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   DRESNERPOLLAK R, 1994, J CELL BIOCHEM, V56, P323, DOI 10.1002/jcb.240560308
   Duong L, 2000, MATRIX BIOL, V19, P97, DOI 10.1016/S0945 053X(00)00051 2
   Ikeda Kyoji, 2014, J Bone Metab, V21, P163, DOI 10.11005/jbm.2014.21.3.163
   Inoue M, 2000, ENDOCRINOLOGY, V141, P284, DOI 10.1210/en.141.1.284
   Kim JH, 2009, J IMMUNOL, V183, P1862, DOI 10.4049/jimmunol.0803007
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Lee SK, 2006, CURR OPIN RHEUMATOL, V18, P411, DOI 10.1097/01.bor.0000231911.42666.78
   Mabey T, 2015, WORLD J ORTHOP, V6, P95, DOI 10.5312/wjo.v6.i1.95
   MARKS SC, 1989, AM J MED GENET, V34, P43, DOI 10.1002/ajmg.1320340110
   McLean W, 2001, Trends Genet, V17, pS38, DOI 10.1016/S0168 9525(01)02458 1
   NESBITT S, 1993, J BIOL CHEM, V268, P16737
   Subramanian B, 2012, BIOMATERIALS, V33, P8383, DOI 10.1016/j.biomaterials.2012.08.020
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teitelbaum SL, 2000, J BONE MINER METAB, V18, P344, DOI 10.1007/s007740070007
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Townsend PA, 1999, EUR J CELL BIOL, V78, P485, DOI 10.1016/S0171 9335(99)80075 2
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
   Zou W, 2010, ANN NY ACAD SCI, V1192, P27, DOI 10.1111/j.1749 6632.2009.05245.x
NR 19
TC 3
Z9 5
U1 1
U2 7
PU PHARMACOTHERAPY GROUP
PI BENIN CITY
PA UNIV BENIN, FACULTY PHARMACY, BENIN CITY, 00000, NIGERIA
SN 1596 5996
J9 TROP J PHARM RES
JI Trop. J. Pharm. Res.
PD FEB
PY 2016
VL 15
IS 2
BP 299
EP 305
DI 10.4314/tjpr.v15i2.11
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DI3FU
UT WOS:000373384800011
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Alliston, T
AF Alliston, Tamara
TI Biological Regulation of Bone Quality
SO CURRENT OSTEOPOROSIS REPORTS
LA English
DT Article
DE Bone quality; Extracellularmatrix; Elastic modulus; Fragility;
   Nanoindentation; TGF beta Bone remodeling; Osteocyte; Perilacunar
   remodeling; Osteocyte osteolysis; Mineralization; Collagen;
   Crosslinking; Transcription factor; Signaling pathway
ID HUMAN CORTICAL BONE; OSTEOGENESIS IMPERFECTA; MECHANICAL PROPERTIES;
   TRANSCRIPTIONAL REGULATION; OSTEOPONTIN DEFICIENCY;
   ALKALINE PHOSPHATASE; MINERAL CONTENT; MOUSE MODEL; MICE; TISSUE
AB The ability of bone to resist fracture is determined by the combination of bone mass and bone quality. Like bone mass, bone quality is carefully regulated. Of the many aspects of bone quality, this review focuses on biological mechanisms that control the material quality of the bone extracellular matrix (ECM). Bone ECM quality depends upon ECM composition and organization. Proteins and signaling pathways that affect the mineral or organic constituents of bone ECM impact bone ECM material properties, such as elastic modulus and hardness. These properties are also sensitive to pathways that regulate bone remodeling by osteoblasts, osteoclasts, and osteocytes. Several extracellular proteins, signaling pathways, intracellular effectors, and transcription regulatory networks have been implicated in the control of bone ECM quality. A molecular understanding of these mechanisms will elucidate the biological control of bone quality and suggest new targets for the development of therapies to prevent bone fragility.
C1 [Alliston, Tamara] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA.
   [Alliston, Tamara] Dept Bioengn & Therapeut Sci, San Francisco, CA USA.
   [Alliston, Tamara] Dept Otolaryngol & Head & Neck Surg, San Francisco, CA USA.
   [Alliston, Tamara] Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA USA.
C3 University of California System; University of California San Francisco
RP Alliston, T (通讯作者)，Univ Calif San Francisco, Dept Orthopaed Surg, 513 Parnassus Ave,Room S 1155, San Francisco, CA 94143 USA.
EM Tamara.alliston@ucsf.edu
OI Alliston, Tamara/0000 0001 9992 2897
FU NIH [R01 DE019284]; National Institute of Dental and Craniofacial
   Research [R01DE019284] Funding Source: NIH RePORTER
FX This research was supported by NIH R01 DE019284. I would like to
   acknowledge the many colleagues, collaborators, and trainees who have
   welcomed and joined me in the gap between the biomechanics and the
   molecular biology of bone to study these important questions.
CR Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Alliston Tamara, 2008, P667
   Ammann P, 2010, BONE, V46, P1574, DOI 10.1016/j.bone.2010.02.015
   Arteaga Solis E, 2011, MATRIX BIOL, V30, P188, DOI 10.1016/j.matbio.2011.03.004
   Balooch G, 2005, P NATL ACAD SCI USA, V102, P18813, DOI 10.1073/pnas.0507417102
   BELANGER LF, 1969, CALC TISS RES, V4, P1, DOI 10.1007/BF02279101
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Boskey AL, 2002, CALCIFIED TISSUE INT, V71, P145, DOI 10.1007/s00223 001 1121 z
   Bouxsein Mary L, 2006, Curr Osteoporos Rep, V4, P49, DOI 10.1007/s11914 006 0002 9
   Brennan TC, 2009, J BONE MINER RES, V24, P800, DOI 10.1359/JBMR.081227
   Burket J, 2011, J BIOMECH, V44, P277, DOI 10.1016/j.jbiomech.2010.10.018
   Burr DB, 2011, J MUSCULOSKEL NEURON, V11, P270
   Burr D. B., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P201
   Busse B, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006286
   Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544
   Carriero A, 2014, BONE, V61, P116, DOI 10.1016/j.bone.2013.12.020
   Carriero A, 2014, J BONE MINER RES, V29, P1392, DOI 10.1002/jbmr.2172
   Chang JL, 2010, EMBO REP, V11, P765, DOI 10.1038/embor.2010.135
   Choi JS, 2012, BIOMATERIALS, V33, P4460, DOI 10.1016/j.biomaterials.2012.03.010
   CURREY JD, 1969, J BIOMECH, V2, P1, DOI 10.1016/0021 9290(69)90036 0
   Currey JD, 1999, J EXP BIOL, V202, P3285
   Dallas SL, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1145, DOI 10.1016/B978 0 12 373884 4.00067 7
   Diab T, 2006, BONE, V38, P427, DOI 10.1016/j.bone.2005.09.002
   Donnelly E, 2010, CALCIFIED TISSUE INT, V87, P450, DOI 10.1007/s00223 010 9404 x
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Duvall CL, 2007, J BONE MINER RES, V22, P286, DOI 10.1359/JBMR.061103
   Edwards JR, 2010, J BONE MINER RES, V25, P2419, DOI 10.1002/jbmr.139
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Ettinger B, 2013, BONE, V55, P495, DOI 10.1016/j.bone.2013.02.004
   Fedde KN, 1999, J BONE MINER RES, V14, P2015, DOI 10.1359/jbmr.1999.14.12.2015
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   FULLER K, 1995, J CELL SCI, V108, P2221
   Golub EE, 2011, SEMIN IMMUNOPATHOL, V33, P409, DOI 10.1007/s00281 010 0230 z
   Gourion Arsiquaud S, 2010, BONE, V46, P666, DOI 10.1016/j.bone.2009.11.011
   Gourion Arsiquaud S, 2009, J BONE MINER RES, V24, P1271, DOI [10.1359/JBMR.090201, 10.1359/jbmr.090201]
   Havill LM, 2010, BONE, V46, P835, DOI 10.1016/j.bone.2009.11.002
   Hernandez CJ, 2006, BONE, V39, P1173, DOI 10.1016/j.bone.2006.06.001
   Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399
   Ho AM, 2000, SCIENCE, V289, P265, DOI 10.1126/science.289.5477.265
   Holmbeck K, 2005, J CELL SCI, V118, P147, DOI 10.1242/jcs.01581
   Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059
   Inoue K, 2006, J BIOL CHEM, V281, P33814, DOI 10.1074/jbc.M607290200
   Jepsen KJ, 2010, J BONE MINER RES, V25, P1581, DOI 10.1002/jbmr.41
   Kacena MA, 2013, J CELL PHYSIOL, V228, P1594, DOI 10.1002/jcp.24322
   Karunaratne A, 2012, J BONE MINER RES, V27, P876, DOI 10.1002/jbmr.1495
   Kavukcuoglu NB, 2007, J BIOMED MATER RES A, V83A, P136, DOI 10.1002/jbm.a.31081
   Kawashima Y, 2009, BONE, V44, P648, DOI 10.1016/j.bone.2008.12.012
   Kerschnitzki M, 2013, J BONE MINER RES, V28, P1837, DOI 10.1002/jbmr.1927
   Kerschnitzki M, 2011, J STRUCT BIOL, V173, P303, DOI 10.1016/j.jsb.2010.11.014
   Kozloff KM, 2004, J BONE MINER RES, V19, P614, DOI 10.1359/JBMR.040111
   Kühnisch J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086115
   Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103
   Lane NE, 2003, J BONE MINER RES, V18, P2105, DOI 10.1359/jbmr.2003.18.12.2105
   LEBOY PS, 1991, J CELL PHYSIOL, V146, P370, DOI 10.1002/jcp.1041460306
   Li CY, 2006, J BONE MINER RES, V21, P865, DOI 10.1359/JBMR.060313
   Lieben L, 2012, J CLIN INVEST, V122, P1803, DOI 10.1172/JCI45890
   Makowski AJ, 2014, BONE, V62, P1, DOI 10.1016/j.bone.2014.01.021
   Marini J C, 1988, Adv Pediatr, V35, P391
   McGee Lawrence ME, 2013, BONE, V52, P296, DOI 10.1016/j.bone.2012.10.015
   Mohammad KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005275
   Mosig RA, 2007, HUM MOL GENET, V16, P1113, DOI 10.1093/hmg/ddm060
   Moutsatsou P, 2012, TRENDS MOL MED, V18, P348, DOI 10.1016/j.molmed.2012.04.005
   Mullen CA, 2013, J MECH BEHAV BIOMED, V28, P183, DOI 10.1016/j.jmbbm.2013.06.013
   Murshed M, 2010, CURR OPIN NEPHROL HY, V19, P359, DOI 10.1097/MNH.0b013e3283393a2b
   Nalla RK, 2004, BONE, V35, P1240, DOI 10.1016/j.bone.2004.07.016
   NODA M, 1988, J BIOL CHEM, V263, P13916
   NODA M, 1989, J CELL BIOL, V108, P713, DOI 10.1083/jcb.108.2.713
   Nyman JS, 2007, J ORTHOP RES, V25, P646, DOI 10.1002/jor.20337
   Nyman JS, 2011, J BONE MINER RES, V26, P1252, DOI 10.1002/jbmr.326
   Nyman JS, 2011, BONE, V48, P733, DOI 10.1016/j.bone.2010.12.016
   Poundarik AA, 2012, P NATL ACAD SCI USA, V109, P19178, DOI 10.1073/pnas.1201513109
   Qing H, 2012, J BONE MINER RES, V27, P1018, DOI 10.1002/jbmr.1567
   Qing H, 2009, INT J ORAL SCI, V1, P59, DOI 10.4248/ijos.09019
   Qiu SR, 2004, P NATL ACAD SCI USA, V101, P1811, DOI 10.1073/pnas.0307900100
   Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101
   Saito M, 2010, OSTEOPOROSIS INT, V21, P195, DOI 10.1007/s00198 009 1066 z
   Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200
   Seitz S, 2013, OSTEOPOROSIS INT, V24, P641, DOI 10.1007/s00198 012 2011 0
   Selvamurugan N, 2004, J BIOL CHEM, V279, P19327, DOI 10.1074/jbc.M314048200
   Sinder BP, 2013, J BONE MINER RES, V28, P73, DOI 10.1002/jbmr.1717
   SODEK J, 1995, ANN NY ACAD SCI, V760, P223, DOI 10.1111/j.1749 6632.1995.tb44633.x
   Sroga GE, 2012, CURR OSTEOPOROS REP, V10, P141, DOI 10.1007/s11914 012 0103 6
   Tang SY, 2009, OSTEOPOROSIS INT, V20, P887, DOI 10.1007/s00198 008 0754 4
   Tang Simon Y, 2013, Bonekey Rep, V2, P255, DOI 10.1038/bonekey.2012.255
   Tang SY, 2012, J BONE MINER RES, V27, P1936, DOI 10.1002/jbmr.1646
   Teti A, 2009, BONE, V44, P11, DOI 10.1016/j.bone.2008.09.017
   Thurner PJ, 2010, BONE, V46, P1564, DOI 10.1016/j.bone.2010.02.014
   Tjhia CK, 2012, BONE, V51, P114, DOI 10.1016/j.bone.2012.04.010
   Tommasini SM, 2007, BONE, V40, P498, DOI 10.1016/j.bone.2006.08.012
   Tseng KF, 1996, J ORTHOPAED RES, V14, P598, DOI 10.1002/jor.1100140414
   Uveges TE, 2009, J BONE MINER RES, V24, P849, DOI [10.1359/jbmr.081238, 10.1359/JBMR.081238]
   Wallace JM, 2006, BONE, V39, P106, DOI 10.1016/j.bone.2005.12.081
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Williams GA, 2011, J BONE MINER RES, V26, P1698, DOI 10.1002/jbmr.367
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156
   Zappone B, 2008, BIOPHYS J, V95, P2939, DOI 10.1529/biophysj.108.135889
   Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597
NR 98
TC 69
Z9 85
U1 0
U2 21
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1544 1873
EI 1544 2241
J9 CURR OSTEOPOROS REP
JI Curr. Osteoporos. Rep.
PD SEP
PY 2014
VL 12
IS 3
BP 366
EP 375
DI 10.1007/s11914 014 0213 4
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AY0JZ
UT WOS:000347284200014
PM 24894149
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Jiang, J
   Zhu, JX
   Lin, HJ
   Jin, SY
   He, Q
   Ji, W
AF Jiang, Jie
   Zhu, Jingxian
   Lin, Haojie
   Jin, Siyu
   He, Qing
   Ji, Wei
TI High Throughput Preosteoblastic Spheroids Elevate Fibroblast Growth
   Factor 23 via Parathyroid Hormone Signaling Pathway
SO TISSUE ENGINEERING PART C METHODS
LA English
DT Article
DE 3D culture; osteoblasts; cell spheroids; FGF23; PTH
AB Fibroblast growth factor 23 (FGF23) plays a crucial role in managing renal phosphate and the synthesis of 1,25(OH)2 vitamin D3, which is essential for bone homeostasis. Developing robust in vitro systems to study FGF23 regulating mechanisms is crucial for advancing our knowledge and identifying potential therapeutic targets. The traditional in vitro 2D culture system results in relatively low expression of FGF23, complicating further exploration of its regulatory mechanisms and potential therapeutic targets. Herein, we reported a high throughput approach to generate preosteoblastic cell spheroids with enhanced FGF23 production. For this purpose, murine preosteoblast cell line (MC3T3 E1) was cultured in our previously reported nonadherent microwells (200 mu m in diameter, 148 mu m in depth, and 100 mu m space in between) and self assembled into spheroids with a diameter of 92.3 +/  15.0 mu m after 24 h. Compared with monolayer culture, the MC3T3 E1 spheroids showed a significant upregulation of FGF23 in both gene and protein levels after 24 h of serum free induction. RNA sequencing and western blotting analysis further suggested that the enhanced FGF23 production in MC3T3 E1 spheroids was attributed to the activation of the parathyroid hormone (PTH)/PTH1R signaling pathway. Impressively, inhibition of PTH signaling through small molecular inhibitors or short hairpin RNA targeting PTH1R effectively reduced FGF23 production. In summary, the current study revealed the efficacy of the high throughput formation of preosteoblast cell spheroid in stimulating FGF23 expression for mechanistic studies. Importantly, our findings highlight the potential of the current 3D spheroid system for target identification and drug discovery.
   Impact Statement This research introduces a high throughput method for generating preosteoblastic spheroids that significantly enhance fibroblast growth factor 23 (FGF23) production via the parathyroid hormone signaling pathway. The findings offer a robust in vitro model for studying FGF23 regulation, addressing the limitations of traditional 2D cultures. This advancement not only improves our understanding of bone and mineral metabolism but also holds potential for identifying novel therapeutic targets for conditions with elevated FGF23 levels, such as chronic kidney disease and metabolic bone disorders. The scalable and efficient spheroid formation method could revolutionize the approach to drug discovery and target validation for managing FGF23 production.
C1 [Jiang, Jie; Zhu, Jingxian; Lin, Haojie; Jin, Siyu; He, Qing; Ji, Wei] Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Oral & Maxillofacial Reconstruct & R, Minist Educ,Key Lab Oral Biomed,Hubei Key Lab Stom, Luoyu Rd 237, Wuhan 430079, Peoples R China.
   [Ji, Wei] Wuhan Univ, Sch & Hosp Stomatol, Dept Implantol, Wuhan, Peoples R China.
C3 Wuhan University; Wuhan University
RP He, Q; Ji, W (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Oral & Maxillofacial Reconstruct & R, Minist Educ,Key Lab Oral Biomed,Hubei Key Lab Stom, Luoyu Rd 237, Wuhan 430079, Peoples R China.
EM qing.he@whu.edu.cn; wei.ji@whu.edu.cn
RI Jin, Siyu/AFT 2600 2022; Ji, Wei/G 8947 2011; Ji, Wei/GQY 7453 2022
OI Zhu, Jingxian/0000 0003 0095 654X; Ji, Wei/0000 0002 1473 5222; 
FU National Natural Science Foundation of China [82072483, 82170931]; Key
   Research and Development Program of Hubei Province [2022BCA052];
   Fundamental Research Funds for the Central Universities [2042024YXB018];
   ITI research grant [1721 2022]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This study was
   funded by the National Natural Science Foundation of China (No. 82072483
   to Q.H. and No. 82170931 to W.J.); the Key Research and Development
   Program of Hubei Province (2022BCA052 to Q.H.); the Fundamental Research
   Funds for the Central Universities (No. 2042024YXB018 to W.J.); and the
   ITI research grant (No.1721 2022 to W.J.).
CR Agoro R, 2023, NAT REV NEPHROL, V19, P185, DOI 10.1038/s41581 022 00665 x
   Atala A, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004890
   Belardi B, 2020, NAT REV MOL CELL BIO, V21, P750, DOI 10.1038/s41580 020 00298 7
   Bergwitz C, 2010, ANNU REV MED, V61, P91, DOI 10.1146/annurev.med.051308.111339
   Bhattacharjee T, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500655
   Chen CJ, 2023, MOL PLANT, V16, P1733, DOI 10.1016/j.molp.2023.09.010
   CHIJIWA T, 1990, J BIOL CHEM, V265, P5267
   Choudhary S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 36424 x
   Coricor G, 2016, SCI REP UK, V6, DOI 10.1038/srep38616
   Courbon G, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00154 0
   David V, 2016, KIDNEY INT, V89, P135, DOI 10.1038/ki.2015.290
   Domazetovic V, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23042103
   Donate Correa J, 2012, CYTOKINE GROWTH F R, V23, P37, DOI 10.1016/j.cytogfr.2012.01.004
   dos Santos EJL, 2023, INT J ORAL SCI, V15, DOI 10.1038/s41368 023 00259 8
   Du YX, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.778015
   Dussold C, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0051 1
   Edmonston D, 2024, NAT REV CARDIOL, V21, P11, DOI 10.1038/s41569 023 00903 0
   Edmonston D, 2020, NAT REV NEPHROL, V16, P7, DOI 10.1038/s41581 019 0189 5
   Fontoura JC, 2020, MAT SCI ENG C MATER, V107, DOI 10.1016/j.msec.2019.110264
   Fukumoto S., 2023, CURR OPIN ENDOCR MET, V29, P100445, DOI [10.1016/j.coemr.2023.100445, DOI 10.1016/J.COEMR.2023.100445]
   Fukumoto S, 2009, TRENDS ENDOCRIN MET, V20, P230, DOI 10.1016/j.tem.2009.02.001
   Guo YC, 2015, INT J ORAL SCI, V7, P8, DOI 10.1038/ijos.2015.1
   Hemmatian H, 2018, CALCIFIED TISSUE INT, V103, P675, DOI 10.1007/s00223 018 0463 8
   Kim J, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 92607 z
   Klein Nulend J, 2015, J BIOMECH, V48, P855, DOI 10.1016/j.jbiomech.2014.12.007
   Knowles HJ, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1167734
   Kobayashi K, 2022, MOL CELL, V82, P3468, DOI 10.1016/j.molcel.2022.07.003
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lee SY, 2023, SLAS DISCOV, V28, P119, DOI 10.1016/j.slasd.2023.03.006
   Leijten J, 2016, SCI REP UK, V6, DOI 10.1038/srep36011
   Michigami T, 2023, CLIN PEDIATR ENDOCRI, V32, P1, DOI [10.1297/cpe.2022 0053, 10.1297/cpe.32.2022 0053]
   Mironov N, 2022, NUTRIENTS, V14, DOI 10.3390/nu14214477
   Sawa N, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 50236 7
   Sun QL, 2018, BONE, V106, P148, DOI 10.1016/j.bone.2017.10.019
   Sun QL, 2017, BONE, V105, P245, DOI 10.1016/j.bone.2017.09.012
   Sun QL, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.26
   Sun T, 2023, CURR MED CHEM, V30, P841, DOI 10.2174/0929867329666220627122733
   Thompson WR, 2015, SCI REP UK, V5, DOI 10.1038/srep11049
   Trombetti A, 2022, NAT REV ENDOCRINOL, V18, P366, DOI 10.1038/s41574 022 00662 x
   Wheeler Jonathan A, 2019, Curr Mol Biol Rep, V5, P8, DOI 10.1007/s40610 019 0110 9
   Xiao Zhousheng, 2021, Mol Pharmacol, V101, P408, DOI 10.1124/molpharm.121.000471
   Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002 021105
   Zhang C, 2019, CURR OSTEOPOROS REP, V17, P207, DOI 10.1007/s11914 019 00521 1
   Zhu J, 2024, J DENT RES, V103, P31, DOI 10.1177/00220345231205273
NR 44
TC 1
Z9 1
U1 1
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3384
EI 1937 3392
J9 TISSUE ENG PART C ME
JI Tissue Eng. Part C Methods
PD SEP 1
PY 2024
VL 30
IS 9
BP 402
EP 413
DI 10.1089/ten.tec.2024.0195
EA AUG 2024
PG 12
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA H9T4M
UT WOS:001296364800001
PM 39109940
DA 2025 08 17
ER

PT J
AU Mendoza, S
   Noa, M
   Más, R
   Mendoza, N
AF Mendoza, S
   Noa, M
   Más, R
   Mendoza, N
TI Comparison of the effects of D 003, a mixture of high molecular weight
   aliphatic acids from sugarcane wax, and pravastatin on bones and
   osteoclast apoptosis of ovariectomized rats
SO DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH
LA English
DT Article
ID CONTAINING BISPHOSPHONATES INHIBIT; LIPID PROFILE; IN VITRO; MEVALONATE
   PATHWAY; SIMVASTATIN; MECHANISMS; RESORPTION; THERAPY; STATINS;
   HISTOMORPHOMETRY
AB The mevalonate pathway is relevant in bone cells. Statins inhibit 3 hydroxy 3 methylglutaryl coenzyme A (HMG CoA) reductase, the key enzyme of this route, stimulating osteoblast differentiation and activity, Pravastatin increases bone formation markers in postmenopausal women and bone density in diabetics. D 003 is a mixture of high molecular weight acids purified from sugarcane wax which inhibits cholesterol biosynthesis through HMG CoA reductase regulation, preventing bone loss in osteoporosis induced with ovariectomy and prednisolone in rats. We investigated the effects of D 003 (50 mg/kg) and pravastatin (20 mg/kg) orally administered for 12 weeks to ovariectomized rats. Female rats were randomized in four groups (10 rats/group): two control groups treated with the vehicle, one false operated (sham) and another ovariectomized (positive control), while two other groups received D 003 or pravastatin. Bone resorption and formation was studied through histomorphometry and apoptosis through immunohistochemistry. D 003 and pravastatin significantly (p < 0.001) prevented the changes of trabecular bone versus ovariectomized rats and (p < 0.001) the increase of the surface and number of osteoclasts versus ovariectomized controls. D 003 and pravastatin, however, did not modify osteoblast surfaces, a bone formation marker D 003 and pravastatin increased osteoclast apoptosis and reduced (p < 0.05) osteoblast and osteocyte apoptosis versus ovariectomized controls; D 003 was more effective (p < 0.05) than pravastatin. In conclusion, D 003 (50 mg/kg) orally administered for 12 weeks prevented bone loss and bone resorption in ovariectomized rats, increasing osteoclast apoptosis. The preventive effects of D 003 on bone loss and resorption in ovariectomized rats are comparable to those of pravastatin. Both drugs inhibited osteoblast apoptosis but failed to change osteoblast surface. The effects of D 003 on bone cell apoptosis were greater than those of pravastatin. Therefore, D 003 could be used to prevent or treat bone loss in postmenopausal women, but further animal studies and clinical trials are required to confirm the clinical relevance of this potential effect.
C1 Natl Ctr Sci, Ctr Nat Prod, Havana, Cuba.
RP Natl Ctr Sci, Ctr Nat Prod, Post Box 6990,Ave 25 & 158 St, Havana, Cuba.
EM clinica@enet.cu
RI Mendoza Castaño, Sarahi/IQR 9004 2023
CR Bagi CM, 1997, CALCIFIED TISSUE INT, V61, P336, DOI 10.1007/s002239900344
   Bauer DC, 2003, OSTEOPOROSIS INT, V14, P273, DOI 10.1007/s00198 002 1323 x
   Castaño G, 2003, CLIN DRUG INVEST, V23, P789, DOI 10.2165/00044011 200323120 00004
   Castaño G, 2003, CLIN DRUG INVEST, V23, P193, DOI 10.2165/00044011 200323030 00005
   Castano Gladys, 2002, Drugs R D, V3, P337, DOI 10.2165/00126839 200203050 00008
   CORO RM, 1996, REV LATINOAM PATOL, V39, P9
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Doggrell SA, 2003, DRUG TODAY, V39, P633, DOI 10.1358/dot.2003.39.8.799409
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FISHER JE, 1998, BONE, V23, pS339
   FISHER JE, 1998, BONE, V23, P339
   Gámez R, 2000, CURR THER RES CLIN E, V61, P460, DOI 10.1016/S0011 393X(00)80029 6
   Gamez Rafael, 2003, Drugs R D, V4, P219
   Garrett IR, 2001, CURR PHARM DESIGN, V7, P715, DOI 10.2174/1381612013397762
   Gohel A, 1999, ENDOCRINOLOGY, V140, P5339, DOI 10.1210/en.140.11.5339
   LOOKER AC, 1995, J BONE MINER RES, V10, P796
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Maritz FJ, 2001, ARTERIOSCL THROM VAS, V21, P1636, DOI 10.1161/hq1001.097781
   Más R, 2004, DRUG FUTURE, V29, P773, DOI 10.1358/dof.2004.029.08.828449
   Mendoza S, 2003, INT J TISSUE REACT, V25, P81
   Menéndez R, 2004, CAN J PHYSIOL PHARM, V82, P22, DOI [10.1139/y03 123, 10.1139/Y03 123]
   Menéndez R, 2002, CAN J PHYSIOL PHARM, V80, P13, DOI 10.1139/Y01 088
   Menéndez R, 2001, PHARMACOL RES, V44, P299, DOI 10.1006/phrs.2001.0851
   MOSEKILDE L, 1993, BONE, V14, P1, DOI 10.1016/8756 3282(93)90248 9
   Mostaza JM, 2001, CLIN CHIM ACTA, V308, P133, DOI 10.1016/S0009 8981(01)00476 4
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Noa M, 2004, DRUG EXP CLIN RES, V30, P35
   Noa Miriam, 2004, Drugs R D, V5, P281, DOI 10.2165/00126839 200405050 00004
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Oxlund H, 2004, BONE, V34, P609, DOI 10.1016/j.bone.2003.12.014
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Pytlik M, 2003, POL J PHARMACOL, V55, P63
   Reid IR, 2001, LANCET, V357, P509, DOI 10.1016/S0140 6736(00)04042 3
   RPITCHETT JW, 2001, CLIN ORTHOP RELAT R, V386, P173
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Sanders EJ, 1997, HISTOL HISTOPATHOL, V12, P1169
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   VONSTECHOW D, 2003, BMC MUSCULOSKEL DIS, V4, P1471
   Watts N B, 1997, J Med Assoc Ga, V86, P224
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Weinstein RS, 2000, J CLIN ENDOCR METAB, V85, P2907, DOI 10.1210/jc.85.8.2907
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   XU H, 1995, CALCIFIED TISSUE INT, V57, P293, DOI 10.1007/BF00298885
   Yaturu Subhashini, 2003, Endocr Pract, V9, P315
   Zhang Y., 1996, Bulletin of the Natural History Museum Entomology Series, V65, P1
NR 52
TC 12
Z9 18
U1 0
U2 1
PU BIOSCIENCE EDIPRINT INC
PI CAROUGE
PA RUE ALEXANDRE GAVARD 16, 1227 CAROUGE, SWITZERLAND
SN 0378 6501
J9 DRUG EXP CLIN RES
JI Drug Exp. Clin. Res
PY 2005
VL 31
IS 5 6
BP 181
EP 191
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 002ZG
UT WOS:000234650500003
PM 16425974
DA 2025 08 17
ER

PT J
AU Sun, TH
   Li, CT
   Xiong, LF
   Ning, ZY
   Leung, F
   Peng, SL
   Lu, WW
AF Sun, Tianhao
   Li, Chen Tian
   Xiong, Lifeng
   Ning, Ziyu
   Leung, Frankie
   Peng, Songlin
   Lu, William W.
TI miR 375 3p negatively regulates osteogenesis by targeting and decreasing
   the expression levels of LRP5 and β catenin
SO PLOS ONE
LA English
DT Article
ID BONE FORMATION; DIFFERENTIATION; PROLIFERATION; OSTEOPOROSIS; APOPTOSIS;
   CELLS; MASS
AB Wnt signaling pathways are essential for bone formation. Previous studies showed that Wnt signaling pathways were regulated by miR 375. Thus, we aim to explore whether miR 375 could affect osteogenesis. In the present study, we investigated the roles of miR 375 and its downstream targets. Firstly, we revealed that miR 375 3p negatively modulated osteogenesis by suppressing positive regulators of osteogenesis and promoting negative regulators of osteogenesis. In addition, the results of TUNEL cell apoptosis assay showed that miR 3753p induced MC3T3 E1 cell apoptosis. Secondly, miR 375 3p targeted low  density lipoprotein receptor  related protein 5 (LRP5), a co  receptor of the Wnt signaling pathways, and 13catenin as determined by luciferase activity assay, and it decreased the expression levels of LRP5 and p catenin. Thirdly, the decline of protein levels of p catenin was determined by immunocytochemistry and immunofluorescence. Finally, silence of LRP5 in osteoblast precursor cells resulted in diminished cell viability and cell proliferation as detected by WST 1based colorimetric assay. Additionally, all the parameters including the relative bone volume from pCT measurement suggested that LRP5 knockout in mice resulted in a looser and worse  connected trabeculae. The mRNA levels of important negative modulators relating to osteogenesis increased after the functions of LRP5 were blocked in mice. Last but not least, the expression levels of LRP5 increased during the osteogenesis of MC3T3 E1, while the levels of P catenin decreased in bone tissues from osteoporotic patients with vertebral compression fractures. In conclusion, we revealed miR 375 3p negatively regulated osteogenesis by targeting LRP5 and p catenin. In addition, loss of functions of LRP5 damaged bone formation in vivo. Clinically, miR 375 3p and its targets might be used as diagnostic biomarkers for osteoporosis and might be also as novel therapeutic agents in osteoporosis treatment. The relevant products of miR 375 3p might be developed into molecular drugs in the future. These molecules could be used in translational medicine.
C1 [Sun, Tianhao; Li, Chen Tian; Leung, Frankie; Lu, William W.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Orthopaed & Traumatol, Hong Kong, Peoples R China.
   [Sun, Tianhao; Peng, Songlin] Jinan Univ, Coll Med 2, Shenzhen Peoples Hosp, Dept Spine Surg, Shenzhen, Peoples R China.
   [Xiong, Lifeng] Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   [Ning, Ziyu] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong; Jinan University; University of Hong Kong;
   University of Hong Kong
RP Leung, F; Lu, WW (通讯作者)，Univ Hong Kong, Li Ka Shing Fac Med, Dept Orthopaed & Traumatol, Hong Kong, Peoples R China.; Peng, SL (通讯作者)，Jinan Univ, Coll Med 2, Shenzhen Peoples Hosp, Dept Spine Surg, Shenzhen, Peoples R China.
EM klleunga@hku.hk; songlin824@gmail.com; wwlu@hku.hk
RI peng, sl/ISA 1370 2023; Xiong, Lifeng/KVZ 0882 2024; Li,
   Chentian/GZN 1242 2022
OI Peng, Songlin/0000 0002 4042 7071; XIONG, LIFENG/0000 0001 5216 9236; 
FU National Natural Science Foundation of China [NSFC81371989,
   NSFC81270967]; Guangdong Science and Technology Department Project
   [2015A030313776, 2016A050503008]; Shenzhen Municipal Science and
   Technology Innovation Committee Project [CXZZ20151015151249563,
   CXZZ20150401152251209, JCYJ20140416122812013]; General Research Fund of
   Research Grant Council of Hong Kong [RGC 715213, RGC 17205714]
FX This work was supported by grants from the National Natural Science
   Foundation of China (NSFC81371989 and NSFC81270967), Guangdong Science
   and Technology Department Project (2015A030313776, 2016A050503008),
   Shenzhen Municipal Science and Technology Innovation Committee Project
   (CXZZ20151015151249563, CXZZ20150401152251209 and
   JCYJ20140416122812013), and General Research Fund of Research Grant
   Council of Hong Kong (RGC 715213 and RGC 17205714). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR [Anonymous], ONCOTARGET
   Burgers TA, 2013, BONE, V54, P244, DOI 10.1016/j.bone.2013.02.022
   Cantafio MEG, 2016, MOL THER NUCL ACIDS, V5, DOI 10.1038/mtna.2016.59
   Chen Jia Shing, 2014, BMC Res Notes, V7, P15, DOI 10.1186/1756 0500 7 15
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Delgado Calle J, 2016, BONE
   Guo Y, 2016, ONCOL REP, V36, P952, DOI 10.3892/or.2016.4852
   Jacobsen CM, 2016, BONE, V90, P127, DOI 10.1016/j.bone.2016.06.005
   Javaheri B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035726
   Jin HT, 2015, BONE, V71, P63, DOI 10.1016/j.bone.2014.07.039
   Joiner DM, 2013, TRENDS ENDOCRIN MET, V24, P31, DOI 10.1016/j.tem.2012.10.003
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Lian L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101633
   Maupin KA, 2013, BONE RES, V1, DOI 10.4248/BR201301004
   Miao CG, 2015, IMMUNOL LETT, V164, P1, DOI 10.1016/j.imlet.2015.01.003
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Riddle RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063323
   Rivadeneira F, 2016, TRENDS ENDOCRIN MET, V27, P262, DOI 10.1016/j.tem.2016.03.006
   Selth LA., 2016, Oncogene
   Sun TH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020236
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang Y, 2013, NUCLEIC ACIDS RES, V41, P3833, DOI 10.1093/nar/gks1460
   Xing LP, 2005, BIOCHEM BIOPH RES CO, V328, P709, DOI 10.1016/j.bbrc.2004.11.072
   Xu LL, 2016, ONCOTARGET, V7, P40644, DOI 10.18632/oncotarget.9811
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Yano M, 2012, ENDOCR J, V59, P653, DOI 10.1507/endocrj.EJ12 0022
   Yu X, 2016, INT J GYNECOL CANCER, V26, P851, DOI 10.1097/IGC.0000000000000711
   Zhong ZDA, 2015, DEV DYNAM, V244, P1347, DOI 10.1002/dvdy.24316
   Zhong ZDA, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.13
NR 30
TC 40
Z9 46
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD FEB 3
PY 2017
VL 12
IS 2
AR e0171281
DI 10.1371/journal.pone.0171281
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EN7DG
UT WOS:000396161700052
PM 28158288
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Ikegame, M
   Hattori, A
   Tabata, MJ
   Kitamura, K
   Tabuchi, Y
   Furusawa, Y
   Maruyama, Y
   Yamamoto, T
   Sekiguchi, T
   Matsuoka, R
   Hanmoto, T
   Ikari, T
   Endo, M
   Omori, K
   Nakano, M
   Yashima, S
   Ejiri, S
   Taya, T
   Nakashima, H
   Shimizu, N
   Nakamura, M
   Kondo, T
   Hayakawa, K
   Takasaki, I
   Kaminishi, A
   Akatsuka, R
   Sasayama, Y
   Nishiuchi, T
   Nara, M
   Iseki, H
   Chowdhury, VS
   Wada, S
   Ijiri, K
   Takeuchi, T
   Suzuki, T
   Ando, H
   Matsuda, K
   Somei, M
   Mishima, H
   Mikuni Takagaki, Y
   Funahashi, H
   Takahashi, A
   Watanabe, Y
   Maeda, M
   Uchida, H
   Hayashi, A
   Kambegawa, A
   Seki, A
   Yano, S
   Shimazu, T
   Suzuki, H
   Hirayama, J
   Suzuki, N
AF Ikegame, Mika
   Hattori, Atsuhiko
   Tabata, Makoto J.
   Kitamura, Kei ichiro
   Tabuchi, Yoshiaki
   Furusawa, Yukihiro
   Maruyama, Yusuke
   Yamamoto, Tatsuki
   Sekiguchi, Toshio
   Matsuoka, Risa
   Hanmoto, Taizo
   Ikari, Takahiro
   Endo, Masato
   Omori, Katsunori
   Nakano, Masaki
   Yashima, Sayaka
   Ejiri, Sadakazu
   Taya, Toshiki
   Nakashima, Hiroshi
   Shimizu, Nobuaki
   Nakamura, Masahisa
   Kondo, Takashi
   Hayakawa, Kazuichi
   Takasaki, Ichiro
   Kaminishi, Atsushi
   Akatsuka, Ryosuke
   Sasayama, Yuichi
   Nishiuchi, Takumi
   Nara, Masayuki
   Iseki, Hachiro
   Chowdhury, Vishwajit S.
   Wada, Shigehito
   Ijiri, Kenichi
   Takeuchi, Toshio
   Suzuki, Tohru
   Ando, Hironori
   Matsuda, Kouhei
   Somei, Masanori
   Mishima, Hiroyuki
   Mikuni Takagaki, Yuko
   Funahashi, Hisayuki
   Takahashi, Akihisa
   Watanabe, Yoshinari
   Maeda, Masahiro
   Uchida, Hideaki
   Hayashi, Akio
   Kambegawa, Akira
   Seki, Azusa
   Yano, Sachiko
   Shimazu, Toru
   Suzuki, Hiromi
   Hirayama, Jun
   Suzuki, Nobuo
TI Melatonin is a potential drug for the prevention of bone loss during
   space flight
SO JOURNAL OF PINEAL RESEARCH
LA English
DT Article
DE calcitonin; fish scales; microgravity; osteoblasts; osteoclasts; RANKL
ID EXPRESSION; DIFFERENTIATION; GOLDFISH; FISH; PROLIFERATION;
   MICROGRAVITY; OSTEOBLAST; INCREASES; SKELETAL; SCALES
AB Astronauts experience osteoporosis like loss of bone mass because of microgravity conditions during space flight. To prevent bone loss, they need a riskless and antiresorptive drug. Melatonin is reported to suppress osteoclast function. However, no studies have examined the effects of melatonin on bone metabolism under microgravity conditions. We used goldfish scales as a bone model of coexisting osteoclasts and osteoblasts and demonstrated that mRNA expression level of acetylserotonin O methyltransferase, an enzyme essential for melatonin synthesis, decreased significantly under microgravity. During space flight, microgravity stimulated osteoclastic activity and significantly increased gene expression for osteoclast differentiation and activation. Melatonin treatment significantly stimulated Calcitonin (an osteoclast inhibiting hormone) mRNA expression and decreased the mRNA expression of receptor activator of nuclear factor kappa B ligand (a promoter of osteoclastogenesis), which coincided with suppressed gene expression levels for osteoclast functions. This is the first study to report the inhibitory effect of melatonin on osteoclastic activation by microgravity. We also observed a novel action pathway of melatonin on osteoclasts via an increase in CALCITONIN secretion. Melatonin could be the source of a potential novel drug to prevent bone loss during space flight.
C1 [Ikegame, Mika] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan.
   [Hattori, Atsuhiko; Maruyama, Yusuke; Matsuoka, Risa; Nakano, Masaki; Yashima, Sayaka; Akatsuka, Ryosuke; Nara, Masayuki] Tokyo Med & Dent Univ, Coll Liberal Arts & Sci, Ichikawa, Japan.
   [Tabata, Makoto J.; Iseki, Hachiro] Tokyo Med & Dent Univ, Grad Sch, Bunkyo Ku, Tokyo, Japan.
   [Kitamura, Kei ichiro; Nakashima, Hiroshi] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Hlth Sci, Kodatsuno, Japan.
   [Tabuchi, Yoshiaki] Univ Toyama, Life Sci Res Ctr, Toyama, Japan.
   [Furusawa, Yukihiro] Toyama Prefectural Univ, Dept Liberal Arts & Sci, Toyama, Japan.
   [Yamamoto, Tatsuki; Sekiguchi, Toshio; Hanmoto, Taizo; Ikari, Takahiro; Shimizu, Nobuaki; Kaminishi, Atsushi; Sasayama, Yuichi; Somei, Masanori; Suzuki, Nobuo] Kanazawa Univ, Inst Nat & Environm Technol, Noto Marine Lab, Div Marine Environm Studies, Noto, Ishikawa 9270553, Japan.
   [Endo, Masato; Takeuchi, Toshio] Tokyo Univ Marine Sci & Technol, Dept Marine Biosci, Minato Ku, Tokyo, Japan.
   [Omori, Katsunori] Asia Univ, Fac Econ, Musashino, Tokyo, Japan.
   [Ejiri, Sadakazu] Asahi Univ, Sch Dent, Div Oral Struct Funct & Dev, Mizuho, Japan.
   [Taya, Toshiki; Uchida, Hideaki; Hayashi, Akio] Agilent Technol Japan Ltd, Hachioji, Tokyo, Japan.
   [Nakamura, Masahisa] Waseda Univ, Fac Educ & Integrated Arts & Sci, Shinjuku Ku, Tokyo, Japan.
   [Kondo, Takashi] Univ Toyama, Grad Sch Med & Pharmaceut Sci, Toyama, Japan.
   [Hayakawa, Kazuichi] Kanazawa Univ, Inst Nat & Environm Technol, Low Level Radioact Lab, Nomi, Japan.
   [Takasaki, Ichiro] Univ Toyama, Grad Sch Sci & Engn, Toyama, Japan.
   [Nishiuchi, Takumi] Kanazawa Univ, Adv Sci Res Ctr, Inst Gene Res, Kanazawa, Ishikawa, Japan.
   [Chowdhury, Vishwajit S.] Kyushu Univ, Fac Arts & Sci, Fukuoka, Japan.
   [Wada, Shigehito] Univ Toyama, Fac Med, Toyama, Japan.
   [Ijiri, Kenichi] Univ Tokyo, Radioisotope Ctr, Bunkyo Ku, Tokyo, Japan.
   [Suzuki, Tohru] Tohoku Univ, Grad Sch Agr Sci, Sendai, Miyagi, Japan.
   [Ando, Hironori] Niigata Univ, Sado Ctr Ecol Sustainabil, Marine Biol Stn, Sado, Japan.
   [Matsuda, Kouhei] Univ Toyama, Grad Sch Sci & Engn, Lab Regulatory Biol, Toyama, Japan.
   [Mishima, Hiroyuki] Tsurumi Univ, Sch Dent Med, Dept Dent Engn, Yokohama, Kanagawa, Japan.
   [Mikuni Takagaki, Yuko] Kanagawa Dent Univ, Grad Sch Dent, Yokosuka, Kanagawa, Japan.
   [Funahashi, Hisayuki] Tohto Univ, Fac Makuhari Human Care, Dept Phys Therapy, Mihama Ku, Fukaya, Saitama, Japan.
   [Takahashi, Akihisa] Gunma Univ, Heavy Ion Med Ctr, Maebashi, Gumma, Japan.
   [Watanabe, Yoshinari] Kanazawa Univ, Org Frontier Sci & Innovat, Kanazawa, Ishikawa, Japan.
   [Maeda, Masahiro] Mol Devices Japan Ltd, Chuo Ku, Tokyo, Japan.
   [Kambegawa, Akira] Kambegawa Lab, Komae, Tokyo, Japan.
   [Seki, Azusa] HAMRI Co Ltd, Koga, Japan.
   [Yano, Sachiko] Japan Aerosp Explorat Agcy, Tsukuba, Ibaraki, Japan.
   [Shimazu, Toru; Suzuki, Hiromi] Japan Space Forum, Chiyoda Ku, Tokyo, Japan.
   [Hirayama, Jun] Komatsu Univ, Fac Hlth Sci, Dept Clin Engn, Komatsu, Japan.
C3 Okayama University; Institute of Science Tokyo; Tokyo Medical & Dental
   University (TMDU); Institute of Science Tokyo; Tokyo Medical & Dental
   University (TMDU); Kanazawa University; University of Toyama; Toyama
   Prefectural University; Kanazawa University; Tokyo University of Marine
   Science & Technology; Asahi University; Agilent Technologies; Waseda
   University; University of Toyama; Kanazawa University; University of
   Toyama; Kanazawa University; Kyushu University; University of Toyama;
   University of Tokyo; Tohoku University; Niigata University; University
   of Toyama; Tsurumi University; Kanagawa Dental College; Gunma
   University; Kanazawa University; Japan Aerospace Exploration Agency
   (JAXA)
RP Suzuki, N (通讯作者)，Kanazawa Univ, Inst Nat & Environm Technol, Noto Marine Lab, Div Marine Environm Studies, Noto, Ishikawa 9270553, Japan.
EM nobuos@staff.kanazawa u.ac.jp
RI Ikegame, Mika/B 1617 2011; Tabata, Makoto/W 1239 2019; 松田,
   恒平/GWV 8192 2022; Taya, Toshiki/KII 0352 2024; Nakashima,
   Hiroshi/MIO 9975 2025; Nishiuchi, Takumi/JPA 0036 2023; shimazu,
   Toru/AAA 5311 2020; SUZUKI, Nobuo/J 8420 2015; Suzuki,
   Nobuo/J 8420 2015; , Takahiko/H 6660 2019
OI Takahashi, Akihisa/0000 0002 9960 2153; Hirayama,
   Jun/0000 0002 8485 3320; Nishiuchi, Takumi/0000 0001 9429 5396; Sur
   Chowdhury, Vishwajit/0000 0001 6709 2788; Tabuchi,
   Yoshiaki/0000 0002 6007 6176; shimazu, Toru/0000 0003 0343 8035;
   Takasaki, Ichiro/0000 0002 6083 1119; Suzuki, Nobuo/0000 0003 0283 9910;
   
FU JAXA; Kanazawa University CHOZEN project; JSPS [24620004, 18K11016];
   Institute of Nature and Environmental Technology, Kanazawa University
   [17011]; Grants in Aid for Scientific Research [24620004, 18K11016]
   Funding Source: KAKEN
FX This study was supported partly by grants to NS (JAXA, Kanazawa
   University CHOZEN project, and Grant in Aid for Scientific Research [C]
   No. 24620004 by JSPS), to MI (the cooperative research program of the
   Institute of Nature and Environmental Technology, Kanazawa University,
   No. 17011), and to AH (Grant in Aid for Scientific Research [C] No.
   18K11016 by JSPS). The authors wish to acknowledge the Japan Manned
   Space System and Chiyoda Corporation for their technical support. We
   would like to thank Mr Toshiaki Konno (NokoTech Lab.) for the sequence
   analysis, the late Professor Takeo Ohnishi for his great advice, and the
   Japanese Astronaut Mr Soichi Noguchi for performing experiments in the
   ISS.
CR Acuña Castroviejo D, 2014, CELL MOL LIFE SCI, V71, P2997, DOI 10.1007/s00018 014 1579 2
   Amstrup AK, 2015, J PINEAL RES, V59, P221, DOI 10.1111/jpi.12252
   Arfat Y, 2014, CALCIFIED TISSUE INT, V94, P569, DOI 10.1007/s00223 014 9851 x
   Arnaud SB, 2002, AM J PHYSIOL ENDOC M, V282, pE514, DOI 10.1152/ajpendo.00299.2001
   Azuma K, 2007, BIOCHEM BIOPH RES CO, V362, P594, DOI 10.1016/j.bbrc.2007.08.010
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Caillot Augusseau A, 2000, CLIN CHEM, V46, P1136
   Chatani M, 2015, SCI REP UK, V5, DOI 10.1038/srep14172
   COLE AA, 1987, J HISTOCHEM CYTOCHEM, V35, P203, DOI 10.1177/35.2.3540104
   Collet P, 1997, BONE, V20, P547, DOI 10.1016/S8756 3282(97)00052 5
   Drissi H, 1997, J BONE MINER RES, V12, P1805, DOI 10.1359/jbmr.1997.12.11.1805
   Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200
   Iimura K, 2012, J EXP ZOOL PART B, V318B, P190, DOI 10.1002/jez.b.22005
   Ishizu H, 2018, GEN COMP ENDOCR, V262, P99, DOI 10.1016/j.ygcen.2018.03.020
   JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092 8674(92)90592 Z
   Kawai M, 2014, J BIOL CHEM, V289, P1457, DOI 10.1074/jbc.M113.500850
   Kawai S, 2007, J BONE MINER RES, V22, P1362, DOI 10.1359/JBMR.070602
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215
   Kondo Y, 2001, J BONE MINER METAB, V19, P352, DOI 10.1007/s007740170004
   Korol'kov V I, 1996, Aviakosm Ekolog Med, V30, P32
   Kotlarczyk MP, 2012, J PINEAL RES, V52, P414, DOI 10.1111/j.1600 079X.2011.00956.x
   Koyama H, 2002, J BONE MINER RES, V17, P1219, DOI 10.1359/jbmr.2002.17.7.1219
   LeBlanc A, 2013, OSTEOPOROSIS INT, V24, P2105, DOI 10.1007/s00198 012 2243 z
   Lloyd SA, 2015, BONE, V81, P562, DOI 10.1016/j.bone.2015.08.021
   Man GCW, 2010, J PINEAL RES, V49, P69, DOI 10.1111/j.1600 079X.2010.00768.x
   Maria S, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12465
   Moren M, 2014, PLOS ONE, V9
   Morukov B V, 1989, Physiologist, V32, pS37
   Murata Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138799
   Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017
   Pardo SJ, 2005, AM J PHYSIOL CELL PH, V288, pC1211, DOI 10.1152/ajpcell.00222.2004
   Paulo S, 2014, ONCOL REV, V8, P44, DOI 10.4081/oncol.2014.254
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Sato M, 2017, FISHERIES SCI, V83, P543, DOI 10.1007/s12562 017 1086 0
   Sawaguchi S, 2006, ZOOL SCI, V23, P1021, DOI 10.2108/zsj.23.1021
   Sire JY, 2004, INT J DEV BIOL, V48, P233, DOI 10.1387/ijdb.15272389
   Sire JY, 2003, BIOL REV, V78, P219, DOI 10.1017/S1464793102006073
   Song C, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9156478
   St Hilaire MA, 2019, J BONE MINER METAB, V37, P60, DOI 10.1007/s00774 017 0896 6
   Suzuki N, 2000, PEPTIDES, V21, P115, DOI 10.1016/S0196 9781(99)00181 3
   Suzuki N, 2005, BONE, V36, pS302
   Suzuki N, 2004, GEN COMP ENDOCR, V138, P121, DOI 10.1016/j.ygcen.2004.05.013
   Suzuki N, 2002, J PINEAL RES, V33, P253, DOI 10.1034/j.1600 079X.2002.02953.x
   Suzuki N, 2009, SPACE UTILIZ RES, V25, P166
   Suzuki N., 2009, Biol. Sci. Space., V23, P211, DOI [10.2187/bss.23.211, DOI 10.2187/BSS.23.211]
   Suzuki N, 2008, J PINEAL RES, V45, P229, DOI 10.1111/j.1600 079X.2008.00623.x
   Suzuki N, 2011, BONE, V48, P1186, DOI 10.1016/j.bone.2011.02.004
   Swanson C, 2017, OSTEOPOROSIS INT, V28, P3205, DOI 10.1007/s00198 017 4162 5
   Takahashi JS, 2017, NAT REV GENET, V18, P164, DOI 10.1038/nrg.2016.150
   Vickaryous MK, 2009, J ANAT, V214, P441, DOI 10.1111/j.1469 7580.2008.01043.x
   Wang JS, 2012, J PINEAL RES, V53, P77, DOI 10.1111/j.1600 079X.2012.00973.x
   Witt Enderby PA, 2003, LIFE SCI, V72, P2183, DOI 10.1016/S0024 3205(03)00098 5
   Xie JF, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0089687, 10.1371/journal.pone.0102204]
   Yano S., 2012, Biol. Sci. Space, V26, P12, DOI [10.2187/ bss.26.12, DOI 10.2187/BSS.26.12]
   Yoshikubo H, 2005, LIFE SCI, V76, P2699, DOI 10.1016/j.lfs.2004.10.063
   Zayzafoon M, 2004, ENDOCRINOLOGY, V145, P2421, DOI 10.1210/en.2003 1156
NR 57
TC 68
Z9 73
U1 0
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0742 3098
EI 1600 079X
J9 J PINEAL RES
JI J. Pineal Res.
PD OCT
PY 2019
VL 67
IS 3
AR e12594
DI 10.1111/jpi.12594
EA JUL 2019
PG 13
WC Endocrinology & Metabolism; Neurosciences; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology; Physiology
GA IX8TQ
UT WOS:000478216100001
PM 31286565
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Liu, N
   Xu, N
   Wei, LH
   Chai, GL
AF Liu Ning
   Xu Ning
   Wei Li hui
   Chai Guo lin
TI Mammalian target of rapamycin inhibitor abrogates abnormal
   osteoclastogenesis in neurofibromatosis type 1
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE mammalian target of rapamycin; osteoclast; neurofibromatosis type 1;
   rapamycin
ID BONE RESORPTION; SCHWANN CELLS; NF1; GROWTH; MOUSE; CHILDREN; PATHWAY;
   PROTEIN; CANCER; BLOCK
AB Background Neurofibromatosis type 1 (NF1) is the most common genetic syndrome predisposing patients to various tumors due to dysregulation of the Ras signaling pathway. Recent research has shown NF1 patients also suffer a spectrum of bone pathologies. The pathogenesis of NF1 bone diseases is largely unknown. There is no current treatment. By Nf1 heterozygote (Nf1+/ ) mice and Nf1 conditional knockout mice, we and other groups demonstrated abnormal osteoblast and osteoclast function due to dysregulation of Ras signaling. However, the specific downstream effector pathways linked to NF1 abnormal osteoblastogenesis and osteoclastogenesis have not been defined. In this study, we investigated the Ras downstream effector related with NF1 bone disease.
   Methods We used Nf1+/+ and Nf1+/  mice as normal and NF1 models. Bone stromal cells extracted from Nf1+/+ and Nf1+/  mice were induced osteoclasts. The osteoclast cell was stained by tartrate resistant acid phosphatase staining. The osteoclast cell number was counted and the surface area of osteoclast cells was calculated under the microscope. The mRNA of mammalian target of rapamycin (mTOR) was determined by quantitative reverse transcription polymerase chain reaction. The presence of ribosomal protein S6 kinase was determined by Western blotting.
   Results Compared with Nf1+/+ mice, Nf1+/  mice had about 20% more of osteoclast cells. These osteoclast cells were larger in size with more nuclei. Hyperactive mTOR was detected in Nf1+/  osteoclast cells. Inhibition of mTOR signaling by rapamycin in Nf1+/  osteoclasts abrogated abnormalities in cellular size and number.
   Conclusion mTOR pathway inhibition may represent a viable therapy for NF1 bone diseases.
C1 [Liu Ning] Haidian Maternal & Child Hlth Hosp, Beijing 100080, Peoples R China.
   [Xu Ning] Peking Univ, Hosp 3, Dept Internal Med, Beijing 100191, Peoples R China.
   [Wei Li hui] Peking Univ, Peoples Hosp, Dept Obstet & Gynecol, Beijing 100044, Peoples R China.
   [Chai Guo lin] China Japan Friendship Hosp, Dept Hematol, Beijing 100029, Peoples R China.
C3 Peking University; Peking University; China Japan Friendship Hospital
RP Chai, GL (通讯作者)，China Japan Friendship Hosp, Dept Hematol, Beijing 100029, Peoples R China.
EM weilh19@china.com; chaiguolin@bjmu.edu.cn
FU Scientific Research Foundation for the Returned Overseas Chinese
   Scholars, State Education Ministry, China [985 2 015 24]
FX This work was supported by a grant from the Scientific Research
   Foundation for the Returned Overseas Chinese Scholars, State Education
   Ministry, China (No. 985 2 015 24).
CR Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483
   Barkan B, 2006, CLIN CANCER RES, V12, P5533, DOI 10.1158/1078 0432.CCR 06 0792
   Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362
   Blagosklonny MV, 2007, DRUG DISCOV TODAY, V12, P218, DOI 10.1016/j.drudis.2007.01.004
   Boissy P, 2002, ENDOCRINOLOGY, V143, P1913, DOI 10.1210/en.143.5.1913
   Crawford A H, 1999, J Am Acad Orthop Surg, V7, P217
   Dasgupta B, 2005, CANCER RES, V65, P2755, DOI 10.1158/0008 5472.CAN 04 4058
   Fang YQ, 2009, ANTICANCER RES, V29, P1255
   Fieber LA, 2003, NEUROBIOL DIS, V13, P136, DOI 10.1016/S0969 9961(03)00031 7
   Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542
   Friedman JM, 1999, AM J MED GENET, V89, P1
   GILBERT A, 1995, CLIN ORTHOP RELAT R, P37
   Heervä E, 2010, BONE, V47, P583, DOI 10.1016/j.bone.2010.06.001
   Hirokawa Y, 2006, CANCER BIOL THER, V5, P305, DOI 10.4161/cbt.5.3.2404
   Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79 100.2005
   Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102
   Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862
   Kim HA, 2001, J NEUROSCI, V21, P1110
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Kuorilehto T, 2004, J BONE MINER RES, V19, P983, DOI 10.1359/JBMR.040130
   Law BK, 2005, CRIT REV ONCOL HEMAT, V56, P47, DOI 10.1016/j.critrevonc.2004.09.009
   Lorget F, 2000, BIOCHEM BIOPH RES CO, V268, P899, DOI 10.1006/bbrc.2000.2229
   Ory B, 2007, CURR MED CHEM, V14, P1381, DOI 10.2174/092986707780831159
   Packer RJ, 2002, NEUROLOGY, V58, P1461, DOI 10.1212/WNL.58.10.1461
   Papapoulos SE, 1997, BAILLIERE CLIN ENDOC, V11, P117, DOI 10.1016/S0950 351X(97)80553 8
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pouysségur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871
   ROMERO DF, 1995, J BONE MINER RES, V10, P760
   Seitz S, 2010, OSTEOPOROSIS INT, V21, P119, DOI 10.1007/s00198 009 0933 y
   Stevenson DA, 2008, PEDIATR RES, V63, P697, DOI 10.1203/PDR.0b013e31816fee45
   Stevenson DA, 2007, J PEDIATR US, V150, P83, DOI 10.1016/j.jpeds.2006.10.048
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Takuwa N, 1999, MOL CELL BIOL, V19, P1346
   Tucker T, 2009, J MED GENET, V46, P259, DOI 10.1136/jmg.2008.061895
   Vitale MG, 2002, CLIN ORTHOP RELAT R, P107, DOI 10.1097/01.blo.0000022199.37246.c9
   Wullschleger S, 2006, CELL, V127, P5
   Yang FC, 2006, J CLIN INVEST, V116, P2880, DOI 10.1172/JCI29092
NR 37
TC 3
Z9 4
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0366 6999
EI 2542 5641
J9 CHINESE MED J PEKING
JI Chin. Med. J.
PD JAN 5
PY 2013
VL 126
IS 1
BP 101
EP 107
DI 10.3760/cma.j.issn.0366 6999.20121227
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 156AZ
UT WOS:000319793700019
PM 23286486
OA gold
DA 2025 08 17
ER

PT J
AU Lin, CJ
   Yang, YS
   Ma, H
   Chen, ZH
   Chen, D
   John, AA
   Xie, J
   Gao, GP
   Shim, JH
AF Lin, Chujiao
   Yang, Yeon Suk
   Ma, Hong
   Chen, Zhihao
   Chen, Dong
   John, Aijaz Ahmad
   Xie, Jun
   Gao, Guangping
   Shim, Jae Hyuck
TI Engineering a targeted and safe bone anabolic gene therapy to treat
   osteoporosis in alveolar bone loss
SO MOLECULAR THERAPY
LA English
DT Article
ID POSTMENOPAUSAL WOMEN; WNT; ALENDRONATE; PREVENTION; FRACTURES;
   MICRORNAS; PLATFORM; RISK; MICE; MASS
AB Alveolar bone loss in elderly populations is highly prevalent and increases the risk of tooth loss, gum disease susceptibility, and facial deformity. Unfortunately, there are very limited treatment options available. Here, we developed a bone targeted gene therapy that reverses alveolar bone loss in patients with osteoporosis by targeting the adaptor protein Schnurri 3 (SHN3). SHN3 is a promising therapeutic target for alveolar bone regeneration, because SHN3 expression is elevated in the mandible tissues of humans and mice with osteoporosis while deletion of SHN3 in mice greatly increases alveolar bone and tooth dentin mass. We used a bone targeted recombinant adeno associated virus (rAAV) carrying an artificial microRNA (miRNA) that silences SHN3 expression to restore alveolar bone loss in mouse models of both postmenopausal and senile osteoporosis by enhancing WNT signaling and osteoblast function. In addition, rAAV mediated silencing of SHN3 enhanced bone formation and collagen production of human skeletal organoids in xenograft mice. Finally, rAAV expression in the mandible was tightly controlled via liver  and heart specific miRNA mediated repression or via a vibration inducible mechanism. Collectively, our results demonstrate that AAV based bone anabolic gene therapy is a promising strategy to treat alveolar bone loss in osteoporosis.
C1 [Lin, Chujiao; Yang, Yeon Suk; Chen, Zhihao; John, Aijaz Ahmad; Shim, Jae Hyuck] UMass Chan Med Sch, Dept Med, Div Rheumatol, Worcester, MA 01655 USA.
   [Ma, Hong; Xie, Jun; Gao, Guangping] UMass Chan Med Sch, Dept Microbiol & Physiol Syst, Worcester, MA 01655 USA.
   [Ma, Hong; Xie, Jun; Gao, Guangping; Shim, Jae Hyuck] UMass Chan Med Sch, Horae Gene Therapy Ctr, Worcester, MA 01655 USA.
   [Ma, Hong; Xie, Jun; Gao, Guangping] UMass Chan Med Sch, Viral Vector Core, Worcester, MA 01655 USA.
   [Chen, Dong] Wuhan Univ, Sch & Hosp Stomatol, Hubei Key Lab Stomatol, State Key Lab Oral & Maxillofacial Reconstruct & R, Wuhan 430079, Peoples R China.
   [Chen, Dong] Wuhan Univ, Sch & Hosp Stomatol, Dept Implantol, Wuhan 430079, Peoples R China.
   [Gao, Guangping; Shim, Jae Hyuck] UMass Chan Med Sch, Li Weibo Inst Rare Dis Res, Worcester, MA 01655 USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; UMass Chan Medical School; University of Massachusetts
   System; University of Massachusetts Worcester; UMass Chan Medical
   School; University of Massachusetts System; UMass Chan Medical School;
   University of Massachusetts Worcester; University of Massachusetts
   System; UMass Chan Medical School; University of Massachusetts
   Worcester; Wuhan University; Wuhan University; University of
   Massachusetts System; University of Massachusetts Worcester; UMass Chan
   Medical School
RP Gao, GP (通讯作者)，UMass Chan Med Sch, Li Weibo Inst Rare Dis Res, Horae Gene Therapy Ctr, 368 Plantat St,AS6 2049, Worcester, MA 01605 USA.; Shim, JH (通讯作者)，UMass Chan Med Sch, Li Weibo Inst Rare Dis Res, Horae Gene Therapy Ctr, Dept Med,Div Rheumatol, 364 Plantat St,LRB 217, Worcester, MA 01605 USA.
EM guangping.gao@umassmed.edu; jaehyuck.shim@umassmed.edu
RI ; lin, chujiao/GXH 8413 2022; Bhat, Aijaz/HOI 0728 2023
OI Shim, Jae Hyuck/0000 0002 4947 3293; Bhat (Ph.D), Aijaz Ahmad
   John/0000 0002 8261 2742
FU NIH; NIH [R01NS076991, P01HL131471, R01AI121135, UG3HL 147367,
   R01HL097088, R01HL152723, U19AI149646, UH3H L147367]; NIAMS of the NIH
   [R01AR068983, R21AR073331]
FX We thank Dr. Steven Neier for thoughtful discussion, Drs. Laurie
   Glimcher and Melanie Trombly for reviewing the manuscript, Ms. Agustina
   Rodriguez and Ms. Emma Mayer for technical support, and many individuals
   who provided valuable reagents. Additionally, we thank Dr. Daniel Oh for
   providing hydroxyapatite (HA) based scaffold (Osteogene Tech, Inc) . We
   also thank the Electron Microscopy and the Flow Cytometry Core
   Facilities funded in part by NIH core instrument grants. G.G. holds
   support from grants under the NIH (R01NS076991, P01HL131471,
   R01AI121135, UG3HL 147367, R01HL097088, R01HL152723, U19AI149646, and
   UH3H L147367) . J. H.S. holds support from NIAMS of the NIH
   (R01AR068983, R21AR073331) .
CR Alikhani M, 2012, J DENT RES, V91, P413, DOI 10.1177/0022034512438590
   Alikhani M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211004
   Alikhani M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196540
   Avery JK., 2007, Essentials of oral histology and embryology: a clinical approach
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Becker W, 2000, J PERIODONTOL, V71, P625, DOI 10.1902/jop.2000.71.4.625
   Benjakul Sutiwa, 2019, J Oral Biol Craniofac Res, V9, P251, DOI 10.1016/j.jobcr.2019.06.003
   Benjakul S, 2018, EUR J ORTHODONT, V40, P356, DOI 10.1093/ejo/cjx062
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Borumandi F, 2015, ANTI CANCER AGENT ME, V15, P736, DOI 10.2174/1871520615666150325232857
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   Brun J, 2020, J BONE MINER RES, V35, P2458, DOI 10.1002/jbmr.4150
   Buencamino MCA, 2009, CLEV CLIN J MED, V76, P467, DOI 10.3949/ccjm.76a.08095
   Bulcha JT, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00487 6
   Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906
   Chang Jinhong, 2004, RNA Biol, V1, P106, DOI 10.4161/rna.1.2.1066
   Cho MI, 2000, PERIODONTOL 2000, V24, P9, DOI 10.1034/j.1600 0757.2000.2240102.x
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   DEVLIN H, 1991, BRIT DENT J, V170, P101, DOI 10.1038/sj.bdj.4807427
   Elsalanty ME, 2009, CRANIOMAX TRAUM REC, V2, P125, DOI 10.1055/s 0029 1215875
   Esbrit P, 2013, BIOCHEM PHARMACOL, V85, P1417, DOI 10.1016/j.bcp.2013.03.002
   Ferrer Vaquer A, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471 213X 10 121
   Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115
   Glantschnig H, 2011, J PHARMACOL EXP THER, V338, P568, DOI 10.1124/jpet.111.181404
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791
   Grisanti M, 2006, J BONE MINER RES, V21, pS25
   Hassell T M, 1993, Periodontol 2000, V3, P9, DOI 10.1111/j.1600 0757.1993.tb00230.x
   Herring SW, 2007, ARCH ORAL BIOL, V52, P296, DOI 10.1016/j.archoralbio.2006.09.010
   Iwamoto J, 2008, CLIN INTERV AGING, V3, P483, DOI 10.2147/CIA.S3177
   JAFFIN RA, 1991, J PERIODONTOL, V62, P2, DOI 10.1902/jop.1991.62.1.2
   JEFFCOAT MK, 1993, J AM DENT ASSOC, V124, P49, DOI 10.14219/jada.archive.1993.0225
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   Jones DC, 2010, P NATL ACAD SCI USA, V107, P8254, DOI 10.1073/pnas.1003727107
   Kao Solon T, 2007, Oral Maxillofac Surg Clin North Am, V19, P513, DOI 10.1016/j.coms.2007.06.002
   Karunakaran JV, 2012, J PHARM BIOALLIED SC, V4, pS125, DOI [10.4103/0975 7406.100209, 10.4103/0975 7406.113312]
   Lagos Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960 9822(02)00809 6
   Landesberg R, 2011, ANN NY ACAD SCI, V1218, P62, DOI 10.1111/j.1749 6632.2010.05835.x
   Lin CJ, 2024, HUM GENE THER, V35, P317, DOI 10.1089/hum.2024.022
   LUNDGREN D, 1994, CLIN ORAL IMPLAN RES, V5, P177, DOI 10.1034/j.1600 0501.1994.050309.x
   Martínez Maestre MA, 2010, CLIMACTERIC, V13, P523, DOI 10.3109/13697137.2010.500749
   McBride JL, 2008, P NATL ACAD SCI USA, V105, P5868, DOI 10.1073/pnas.0801775105
   Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   Oh WT, 2023, MOL THER, V31, DOI 10.1016/j.ymthe.2022.09.018
   Omi M, 2021, ORAL SCI INT, V18, P14, DOI 10.1002/osi2.1078
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rodella Luigi F, 2011, Int J Biomed Sci, V7, P81
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   SASSOUNI V, 1969, AMER J ORTHODONTICS, V55, P109, DOI 10.1016/0002 9416(69)90122 5
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Sheikh Zeeshan, 2017, Biomater Res, V21, P9
   Shim JH, 2013, J CLIN INVEST, V123, P4010, DOI 10.1172/JCI69443
   Sodek J, 2000, PERIODONTOL 2000, V24, P99, DOI 10.1034/j.1600 0757.2000.2240106.x
   van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103
   van Steenberghe D, 1990, Int J Oral Maxillofac Implants, V5, P272
   von Wowern N, 2001, Clin Oral Investig, V5, P71, DOI 10.1007/s007840100105
   Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573 019 0012 9
   Weaver CM, 2016, OSTEOPOROSIS INT, V27, P367, DOI 10.1007/s00198 015 3386 5
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Xie J, 2020, MOL THER, V28, P422, DOI 10.1016/j.ymthe.2019.11.018
   Xie J, 2018, MOL THER, V26, P436
   Xie J, 2017, MOL THER, V25, P1363, DOI 10.1016/j.ymthe.2017.03.028
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Xu R, 2017, J BONE MINER RES, V32, P1811, DOI 10.1002/jbmr.3184
   Yamaza T, 2011, J DENT RES, V90, P317, DOI 10.1177/0022034510387796
   Yamaza T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002615
   Yang YS, 2020, MOL THER METH CLIN D, V17, P922, DOI 10.1016/j.omtm.2020.04.010
   Yang YS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10809 6
   Yao Y, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 73026 y
NR 71
TC 2
Z9 2
U1 3
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525 0016
EI 1525 0024
J9 MOL THER
JI Mol. Ther.
PD SEP 4
PY 2024
VL 32
IS 9
BP 3080
EP 3100
DI 10.1016/j.ymthe.2024.06.036
EA SEP 2024
PG 21
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA F2E7X
UT WOS:001308009700001
PM 38937970
OA hybrid
DA 2025 08 17
ER

PT J
AU Jeong, HM
   Han, EH
   Jin, YH
   Hwang, YP
   Kim, HG
   Park, BH
   Kim, JY
   Chung, YC
   Lee, KY
   Jeong, HG
AF Jeong, Hyung Min
   Han, Eun Hee
   Jin, Yun Hey
   Hwang, Yong Pil
   Kim, Hyung Gyun
   Park, Bong Hwan
   Kim, Jin Young
   Chung, Young Chul
   Lee, Kwang Youl
   Jeong, Hye Gwang
TI Saponins from the roots of Platycodon grandiflorum stimulate
   osteoblast differentiation via p38 MAPK  and ERK dependent RUNX2
   activation
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Platycodon grandiflorum; Saponins; Osteoblast differentiation; RUNX2
ID PARATHYROID HORMONE REGULATION; NECROSIS FACTOR ALPHA; TRANSCRIPTION
   FACTOR; CLEIDOCRANIAL DYSPLASIA; BONE FORMATION; ENDOTHELIAL CELLS;
   CBFA1; EXPRESSION; PROTEIN; PATHWAY
AB Changkil (CK), the aqueous extract of the roots of Platycodon grandiflorum, has been used as a traditional oriental medicine for the treatment of chronic adult diseases. Although a saponin fraction derived from CK (CKS) has been suggested to have a variety of functional effects, its effect on bone is unknown. In the present study, the effects of CKS on osteoblast differentiation and function were determined by analyzing the activity of alkaline phosphatase (ALP), an osteoblast marker, and the regulation of RUNX2, a master gene of osteoblast differentiation, in a mesenchymal stem cell line. CKS upregulated ALP activity and the expression of osteogenic marker genes in C2C12 cells. In addition, CKS increased the expression and transcriptional activity of RUNX2. To determine which signaling pathways are involved in the osteogenic effects of CKS, we tested the effect of inhibitors of kinases known to regulate RUNX2. CKS induced enhancement of RUNX2 and ALP was inhibited by treatment with a p38 inhibitor (SB203580) and an ERK inhibitor (U0126). These findings suggest that CKS stimulates osteoblast differentiation by activation of RUNX2 via mechanisms related to the p38 MAPK and ERK signaling pathways. The regulation of RUNX2 activation by CKS may be an important therapeutic target for osteoporosis. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Han, Eun Hee; Hwang, Yong Pil; Kim, Hyung Gyun; Park, Bong Hwan; Kim, Jin Young; Jeong, Hye Gwang] Chungnam Natl Univ, Dept Toxicol, Coll Pharm, Taejon 305764, South Korea.
   [Jeong, Hyung Min; Jin, Yun Hey; Lee, Kwang Youl] Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea.
   [Jeong, Hyung Min; Jin, Yun Hey; Lee, Kwang Youl] Chonnam Natl Univ, Res Inst Drug Dev, Kwangju 500757, South Korea.
   [Chung, Young Chul] Korea Int Univ, Div Food Sci, Jinju, South Korea.
C3 Chungnam National University; Chonnam National University; Chonnam
   National University
RP Jeong, HG (通讯作者)，Chungnam Natl Univ, Dept Toxicol, Coll Pharm, Taejon 305764, South Korea.
EM KwangLee@chonnam.ac.kr; hgjeong@cnu.ac.kr
RI ; Han, Eun/X 8570 2019
OI Jeong, Hye Gwang/0000 0002 8020 8914; 
FU Ministry for Health, Welfare and Family Affairs, Republic of Korea
   [A090923]
FX This study was supported by grants from the Korea Healthcare Technology
   R&D Project, Ministry for Health, Welfare and Family Affairs, Republic
   of Korea (A090923).
CR Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017
   Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097 4644(19970701)66:1<1::AID JCB1>3.0.CO;2 V
   CHASE LR, 1970, J BIOL CHEM, V245, P1520
   Choi CY, 2001, INT IMMUNOPHARMACOL, V1, P1141, DOI 10.1016/S1567 5769(01)00047 9
   Choi CY, 2001, CANCER LETT, V166, P17, DOI 10.1016/S0304 3835(01)00440 2
   Choi JH, 2009, FOOD CHEM TOXICOL, V47, P1272, DOI 10.1016/j.fct.2009.02.022
   CHOI JS, 2007, KOREAN PHARM, V38, P268
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Han EH, 2009, FOOD CHEM TOXICOL, V47, P1069, DOI 10.1016/j.fct.2009.01.041
   Jiménez MJG, 1999, MOL CELL BIOL, V19, P4431
   Khanal T, 2009, FOOD CHEM TOXICOL, V47, P2749, DOI 10.1016/j.fct.2009.08.006
   Khanal T, 2009, FOOD CHEM TOXICOL, V47, P530, DOI 10.1016/j.fct.2008.12.009
   Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200
   Kim HG, 2006, TOXICOL APPL PHARM, V217, P332, DOI 10.1016/j.taap.2006.09.013
   KIM KS, 1995, J NUTR SCI VITAMINOL, V41, P485, DOI 10.3177/jnsv.41.485
   Kim YS, 2005, PLANTA MED, V71, P566, DOI 10.1055/s 2005 864161
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797 307
   LEE EB, 1973, YAKUGAKU ZASSHI, V93, P1188, DOI 10.1248/yakushi1947.93.9_1188
   Lee KJ, 2004, ARCH PHARM RES, V27, P1238, DOI 10.1007/BF02975888
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Lee KJ, 2008, CANCER LETT, V268, P233, DOI 10.1016/j.canlet.2008.03.058
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Miyazono K, 2004, ONCOGENE, V23, P4232, DOI 10.1038/sj.onc.1207131
   Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092 8674(00)80260 3
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Qiao M, 2004, J BIOL CHEM, V279, P42709, DOI 10.1074/jbc.M404480200
   QUINN CO, 1990, J BIOL CHEM, V265, P22342
   Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037
   Selvamurugan N, 2009, FEBS LETT, V583, P1141, DOI 10.1016/j.febslet.2009.02.040
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200
   van Wijnen AJ, 2004, ONCOGENE, V23, P4209, DOI 10.1038/sj.onc.1207758
   Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo reports/kvf193
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Zhou YX, 2000, HUM MOL GENET, V9, P2001, DOI 10.1093/hmg/9.13.2001
NR 40
TC 34
Z9 35
U1 1
U2 10
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278 6915
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD DEC
PY 2010
VL 48
IS 12
BP 3362
EP 3368
DI 10.1016/j.fct.2010.09.005
PG 7
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Toxicology
GA 687ZT
UT WOS:000284818000011
PM 20828597
DA 2025 08 17
ER

PT J
AU Tsuda, E
   Fukuda, C
   Okada, A
   Karibe, T
   Hiruma, Y
   Takagi, N
   Isumi, Y
   Yamamoto, T
   Hasegawa, T
   Uehara, S
   Koide, M
   Udagawa, N
   Amizuka, N
   Kumakura, S
AF Tsuda, Eisuke
   Fukuda, Chie
   Okada, Akiko
   Karibe, Tsuyoshi
   Hiruma, Yoshiharu
   Takagi, Nana
   Isumi, Yoshitaka
   Yamamoto, Tomomaya
   Hasegawa, Tomoka
   Uehara, Shunsuke
   Koide, Masanori
   Udagawa, Nobuyuki
   Amizuka, Norio
   Kumakura, Seiichiro
TI Characterization, pharmacokinetics, and pharmacodynamics of
   anti Siglec 15 antibody and its potency for treating osteoporosis and as
   follow up treatment after parathyroid hormone use
SO BONE
LA English
DT Article
DE Siglec 15; Antibody; Parathyroid hormone; Alendronate; Osteoporosis;
   Continuation therapy
ID ACID PHOSPHATASE 5B; CORTICAL BONE MASS; OSTEOCLAST DIFFERENTIATION;
   MECHANICAL PROPERTIES; SCLEROSTIN ANTIBODY; CELL FUSION; SIGLEC 15;
   ALENDRONATE; DISCONTINUATION; BISPHOSPHONATE
AB Recent studies have established the idea that Siglec 15 is involved in osteoclast differentiation and/or function, and it is anticipated that therapies suppressing Siglec 15 function can be used to treat bone diseases such as osteoporosis. We have produced rat monoclonal anti Siglec 15 antibody (32A1) and successively generated humanized monoclonal anti Siglec 15 antibody (DS 1501a) from 32A1. Studies on the biological properties of DS 1501a showed its specific binding affinity to Siglec 15 and strong activity to inhibit osteoclastogenesis. 32A1 inhibited multinucleation of osteoclasts and bone resorption (pit formation) in cultured mouse bone marrow cells. 32A1 also inhibited pit formation in cultured human osteoclast precursor cells. Maximum serum concentration and serum exposure of DS 1501a in rats were increased in a dose dependent manner after single subcutaneous or intravenous administration. Furthermore, single administration of DS 1501a significantly suppressed bone resorption markers with minimal effects on bone formation markers and suppressed the decrease in bone mineral density (BMD) of the lumbar vertebrae in ovariectomized (OVX) rats. In histological analysis, the osteoclasts distant from the chondro osseous junction of the tibia tended to be flattened, shrunken, and functionally impaired in 32A1 treated rats, while alkaline phosphatase positive osteoblasts were observed throughout the metaphyseal trabeculae. In addition, we compared the efficacy of 32A1 with that of alendronate (ALN) as follow up medicine after treatment with parathyroid hormone (PTH) using mature established osteoporosis rats. The beneficial effect of PTH on bone turnover disappeared 8 weeks after discontinuing the treatment. The administration of 32A1 once every 4 weeks for 8 weeks suppressed bone resorption and bone formation when the treatment was switched from PTH to 32A1, leading to the maintenance of BMD and bone strength. Unlike with ALN, the onset of suppression of bone resorption with 32A1 was rapid, while the suppression of bone formation was mild. The improvement of bone mass, beneficial bone turnover balance, and suppression of osteoclast differentiation/multinucleation achieved by 32A1 were supported by histomorphometry. Notably, the effects of 32A1 on bone strength, not only structural (extrinsic) but also material (intrinsic) properties, were significantly greater than those of ALN. Since the effect of 32A1 on BMD was moderate, its effect on bone strength could not be fully explained by the increase in BMD. The beneficial balance of bone turnover caused by 32A1 might, at least in part, be responsible for the improvement in bone quality. This is the first report describing the effects of anti Siglec 15 antibody in OVX rats; the findings suggest that this antibody could be an excellent candidate for treating osteoporosis, especially in continuation therapy after PTH treatment, due to its rapid action and unprecedented beneficial effects on bone quality.
C1 [Tsuda, Eisuke; Fukuda, Chie] Daiichi Sankyo Co Ltd, Specialty Med Res Labs 1, Shinagawa Ku, 1 2 58 Hiromachi, Tokyo 1408710, Japan.
   [Okada, Akiko] Daiichi Sankyo Co Ltd, Biol Res Labs, Shinagawa Ku, 1 2 58 Hiromachi, Tokyo 1408710, Japan.
   [Karibe, Tsuyoshi] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, 1 2 58 Hiromachi, Tokyo 1408710, Japan.
   [Hiruma, Yoshiharu; Takagi, Nana] Daiichi Sankyo Co Ltd, Pharmacovigilance Dept, Chuo Ku, 3 5 1 Nihonbashi Honcho, Tokyo 1038426, Japan.
   [Isumi, Yoshitaka] Daiichi Sankyo Co Ltd, Oncol Res Labs 1, Shinagawa Ku, 1 2 58 Hiromachi, Tokyo 1408710, Japan.
   [Yamamoto, Tomomaya; Hasegawa, Tomoka; Amizuka, Norio] Hokkaido Univ, Dev Biol Hard Tissue, Fac Dent Med, Kita Ku, Nishi 7 Chome,Kita 13 Jo, Sapporo, Hokkaido 0608586, Japan.
   [Uehara, Shunsuke; Udagawa, Nobuyuki] Matsumoto Dent Univ, Dept Oral Biochem, 1780 Gobara Hirooka, Nagano 3990781, Japan.
   [Koide, Masanori; Udagawa, Nobuyuki] Matsumoto Dent Univ, Inst Oral Sci, Div Hard Tissue Res, 1780 Gobara Hirooka, Nagano 3990781, Japan.
   [Kumakura, Seiichiro] Daiichi Sankyo Co Ltd, Translat Med Funct, Shinagawa Ku, 1 2 58 Hiromachi, Tokyo 1408710, Japan.
C3 Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Daiichi
   Sankyo Company Limited; Daiichi Sankyo Company Limited; Daiichi Sankyo
   Company Limited; Hokkaido University; Matsumoto Dental University;
   Matsumoto Dental University; Daiichi Sankyo Company Limited
RP Fukuda, C (通讯作者)，Daiichi Sankyo Co Ltd, R&D Div, Specialty Med Res Labs 1, Shinagawa Ku, 1 2 58 Hiromachi, Tokyo 1408710, Japan.
EM fukuda.chie.sj@daiichisankyo.co.jp
RI Amizuka, Norio/G 1397 2012; Koide, Masanori/ABE 9670 2020
OI Koide, Masanori/0000 0002 6511 9999; 
FU Grants in Aid for Scientific Research [20K21689, 21H03125, 21H03103,
   22K19638, 22K10282, 23K21488] Funding Source: KAKEN
CR Alatalo SL, 2003, J BONE MINER RES, V18, P134, DOI 10.1359/jbmr.2003.18.1.134
   Amugongo SK, 2014, OSTEOPOROSIS INT, V25, P1735, DOI 10.1007/s00198 014 2678 5
   Amugongo SK, 2014, BONE, V67, P257, DOI 10.1016/j.bone.2014.04.033
   Anastasilakis AD, 2020, EXPERT OPIN PHARMACO, V21, P477, DOI 10.1080/14656566.2020.1717468
   Azuma Y, 1998, J PHARMACOL EXP THER, V286, P128
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Camacho PM, 2016, ENDOCR PRACT, V22, P1111, DOI 10.4158/EP161435.ESGL
   Crocker PR, 2008, BIOCHEM SOC T, V36, P1467, DOI 10.1042/BST0361467
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dishy V.
   Fisher JE, 2012, BONE, V50, P1332, DOI 10.1016/j.bone.2012.03.004
   Hasegawa T, 2019, J HISTOCHEM CYTOCHEM, V67, P169, DOI 10.1369/0022155418806865
   Hasegawa T, 2011, BIOMED RES TOKYO, V32, P259, DOI 10.2220/biomedres.32.259
   Hiruma Y, 2013, BONE, V53, P87, DOI 10.1016/j.bone.2012.11.036
   Hiruma Y, 2011, BIOCHEM BIOPH RES CO, V409, P424, DOI 10.1016/j.bbrc.2011.05.015
   Ishida Kitagawa N, 2012, J BIOL CHEM, V287, P17493, DOI 10.1074/jbc.M111.324194
   Iwamoto J, 2006, EXP ANIM TOKYO, V55, P357, DOI 10.1538/expanim.55.357
   Iwasaki R, 2008, BIOCHEM BIOPH RES CO, V377, P899, DOI 10.1016/j.bbrc.2008.10.076
   Kameda Y, 2015, BONE, V71, P217, DOI 10.1016/j.bone.2014.10.027
   Kameda Y, 2013, J BONE MINER RES, V28, P2463, DOI 10.1002/jbmr.1989
   Leder BZ, 2009, J CLIN ENDOCR METAB, V94, P2915, DOI 10.1210/jc.2008 2630
   Li XD, 2011, ENDOCRINOLOGY, V152, P3312, DOI 10.1210/en.2011 0252
   MASHIBA T, 1995, BONE, V17, pS273, DOI 10.1016/8756 3282(95)00303 U
   Niimi R, 2018, JBMR PLUS, V2, P289, DOI 10.1002/jbm4.10054
   Oda K, 1999, J BIOCHEM, V126, P694, DOI 10.1093/oxfordjournals.jbchem.a022505
   Park Wyllie LY, 2011, JAMA J AM MED ASSOC, V305, P783, DOI 10.1001/jama.2011.190
   Prince R, 2005, J BONE MINER RES, V20, P1507, DOI 10.1359/JBMR.050501
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Reid IR, 2012, NAT REV RHEUMATOL, V8, P90, DOI 10.1038/nrrheum.2011.181
   Rissanen JP, 2008, CALCIFIED TISSUE INT, V82, P108, DOI 10.1007/s00223 007 9091 4
   Ryman JT, 2017, CPT PHARMACOMET SYST, V6, P576, DOI 10.1002/psp4.12224
   Saier MH, 2007, WATER AIR SOIL POLL, V181, P1, DOI 10.1007/s11270 007 9372 6
   Sakai S, 2019, CALCIFIED TISSUE INT, V104, P251, DOI 10.1007/s00223 018 0497 y
   Samnegård E, 2001, BONE, V28, P414, DOI 10.1016/S8756 3282(01)00408 2
   Sato D, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115331
   Sato D, 2018, BONE, V116, P172, DOI 10.1016/j.bone.2018.07.026
   Shimizu T, 2015, BONE, V79, P65, DOI 10.1016/j.bone.2015.05.029
   Stolina M, 2014, BONE, V67, P305, DOI 10.1016/j.bone.2014.07.031
   Stuible M, 2014, J BIOL CHEM, V289, P6498, DOI 10.1074/jbc.M113.494542
   Takamiya R, 2013, GLYCOBIOLOGY, V23, P178, DOI 10.1093/glycob/cws139
   Takeda S, 2017, CALCIFIED TISSUE INT, V101, P65, DOI 10.1007/s00223 017 0255 6
   Tsukazaki H, 2021, BONE, V152, DOI 10.1016/j.bone.2021.116095
   Wang J, 2019, NAT MED, V25, P656, DOI 10.1038/s41591 019 0374 x
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
NR 44
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2022
VL 155
AR 116241
DI 10.1016/j.bone.2021.116241
PG 17
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ZZ8ZG
UT WOS:000773552300001
PM 34715394
OA hybrid
DA 2025 08 17
ER

PT J
AU Aitken, SJ
   Landao Bassonga, E
   Ralston, SH
   Idris, AI
AF Aitken, Sarah J.
   Landao Bassonga, Euphemie
   Ralston, Stuart H.
   Idris, Aymen I.
TI β2 Adrenoreceptor ligands regulate osteoclast differentiation in
   vitro by direct and indirect mechanisms
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Bone; Osteoblast; Osteoclast; Adrenoceptors; Catecholamine;
   Isoprenaline; Noradrenaline
ID SYMPATHETIC NERVOUS SYSTEM; BONE MASS; RATS; PROPRANOLOL; RESORPTION;
   METABOLISM
AB Pharmacological modulators of beta adrenoceptors can influence bone mineral density and fracture risk in humans. Studies reported that P adrenoceptor ligands stimulate bone resorption by enhancing the expression of RANK L, whereas the mechanisms by which beta adrenoreceptors regulate bone formation are poorly understood. Here we show that beta 2 adrenoceptor is predominantly expressed by bone cells, although low levels of beta 1  and beta 3 adrenoceptors were detectable. Noradrenaline and the selective beta 2 adrenoceptor agonists isoprenaline and salmeterol Stimulated osteoclast formation and bone resorption in BM osteoblast co cultures and increased expression of RANK L by osteoblasts. All three ligands enhanced RANK L induced osteoclast formation and increased osteoclast multinuclearity. There was no significant effect of noradrenaline OF isoprenaline on osteoblast growth, differentiation or function. These findings confirm the importance of the sympathetic nervous system in the regulation of bone mass, and demonstrate that pharmacological agonists of beta 2 adrenoceptors directly and indirectly stimulate osteoclast formation, but have no direct effect on osteoblast growth, differentiation or function. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Aitken, Sarah J.; Landao Bassonga, Euphemie; Ralston, Stuart H.; Idris, Aymen I.] Univ Edinburgh, Western Gen Hosp, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
C3 University of Edinburgh
RP Idris, AI (通讯作者)，Univ Edinburgh, Western Gen Hosp, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
EM aymen.idris@ed.ac.uk
RI ; Idris, Aymen/AAX 1138 2020; Aitken, Sarah/JTU 0210 2023
OI Aitken, Sarah/0000 0002 1897 4140; Idris, Aymen/0000 0003 4327 5306;
   Landao Bassonga, Euphemie/0000 0002 5142 2946; 
CR Bonnet N, 2006, J PHARMACOL EXP THER, V318, P1118, DOI 10.1124/jpet.106.105437
   Bonnet N, 2005, BONE, V37, P622, DOI 10.1016/j.bone.2005.07.012
   Cherruau M, 1999, BONE, V25, P545, DOI 10.1016/S8756 3282(99)00211 2
   DE VF, 2007, DRUG SAFETY, V16, P612
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   MINKOWITZ B, 1991, J ORTHOPAED RES, V9, P869, DOI 10.1002/jor.1100090613
   Reid IR, 2005, J BONE MINER RES, V20, P613, DOI 10.1359/JBMR.041202
   Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756 3282(99)00215 X
   Stewart TL, 2005, CALCIFIED TISSUE INT, V77, P113, DOI 10.1007/s00223 004 0188 8
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
NR 13
TC 75
Z9 85
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0003 9861
EI 1096 0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD FEB
PY 2009
VL 482
IS 1 2
BP 96
EP 103
DI 10.1016/j.abb.2008.11.012
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 407TV
UT WOS:000263388100012
PM 19059194
DA 2025 08 17
ER

PT J
AU de Sousa, VC
   Sousa, FRN
   Vasconcelos, RF
   Barreto, GA
   Martins, CS
   Dias, NR
   Costa, S
   Bernardino, MJC
   Silva, GD
   Linhares, N
   Gondim, D
   Marques, M
   Chaves, H
   Alves, K
   Leitao, R
   Brito, GAC
   Ribeiro, MENP
   Goes, P
AF de Sousa, Vanessa Costa
   Sousa, Fatima Regina Nunes
   Vasconcelos, Raquel Felipe
   Barreto, Gisele Angelino
   Martins, Conceicao S.
   Dias, Nilson Romero
   Costa, Sislana
   Bernardino, Maria Jennifer Chaves
   Silva, George de Almeida
   Linhares, Nadine
   Gondim, Delane
   Marques, Mirna
   Chaves, Helliada
   Alves, Karuza
   Leitao, Renata
   Brito, Gerly A. C.
   Ribeiro, Maria Elenir Nobre Pinho
   Goes, Paula
TI Polysacharide of Agaricusblazei gel mitigates bone
   necrosis in model of the jaws related to bisphosphonate via Wnt
   signaling
SO SCIENTIFIC REPORTS
LA English
DT Article
DE BRONJ; Beta glucan; Osteoblast; Wnt signaling; Bone remodeling; Bone
   quality
ID MEDICATION RELATED OSTEONECROSIS; SURGEONS POSITION PAPER; ZOLEDRONIC
   ACID; AMERICAN ASSOCIATION; MINERALIZATION; EXPRESSION; COLLAGEN
AB To investigate de effect of PAb gel on the bone tissue of rats submitted to Bisphosphonate related osteonecrosis of the jaws (BRONJ). Initially, 54 animals were submitted to BRONJ model by Zoledronic Acid (ZA) (0.1 mg/kg 3x/wk for 9 wk, ip), followed by the 1st upper left molar extraction at the 8th wk. After tooth removal, the animals were divided into 3 groups, ZA that received placebo gel or PAb gel that received 1% PAb gel, inside the dental alveolus. The control Group (CONTROL) received 0.1 mg/kg of 0.9% saline and then placebo gel. Three weeks after tooth extraction, the animals were euthanized, and maxillae were colleted for macroscopic, radiographic, histological and Raman spectomery assays. Additionally, GSK3b, beta catenin, and Runx2 mRNA expressions were determined. Blood samples were collected for the analysis of Bone specific alkaline phosphatase (BALP) levels. PAb gel improved mucosal healing, increased the number of viable osteocytes, while it reduced the number of empty lacunae, as well as the amount of bone sequestration. Furthermore, PAb gel positively influenced the number and functionality of osteoblasts by stimulating Wnt signaling, thereby inducing bone remodeling. Additionally, PAb gel contributed to improved bone quality, as evidenced by an increase in bone mineral content, a decrease in bone solubility, and an enhancement in the quality of collagen, particularly type I collagen. PAb gel mitigated bone necrosis by stimulating of bone remodeling through Wnt signaling and concurrently improved bone quality. PAb gel emerges as a promising pharmacological tool for aiding in BRONJ therapy or potentially preventing the development of BRONJ.
C1 [de Sousa, Vanessa Costa; Barreto, Gisele Angelino] Univ Fed Ceara, Med Sch, Dept Morphol, Post Grad Morphol Sci, Fortaleza, CE, Brazil.
   [Sousa, Fatima Regina Nunes] Univ Fed Piaui, Med Sch, Picos, CE, Brazil.
   [Vasconcelos, Raquel Felipe] Fed Inst Ceara, Fortaleza, CE, Brazil.
   [Martins, Conceicao S.; Dias, Nilson Romero; Costa, Sislana; Bernardino, Maria Jennifer Chaves; Gondim, Delane; Alves, Karuza; Leitao, Renata; Brito, Gerly A. C.] Univ Fed Ceara, Med Sch, Dept Morphol, Fortaleza, CE, Brazil.
   [Silva, George de Almeida; Ribeiro, Maria Elenir Nobre Pinho] Univ Fed Ceara, Dept Chem, Brazi, CE, Brazil.
   [Linhares, Nadine] Univ Fed Ceara, Sch Dent, Post Grad Dent, Fortaleza, CE, Brazil.
   [Marques, Mirna] Univ Fed Ceara, Fac Med Sch, Sobral, CE, Brazil.
   [Chaves, Helliada] Univ Fed Ceara, Sch Dent, Sobral, CE, Brazil.
   [Goes, Paula] Univ Fed Ceara, Med Sch, Dept Pathol & Legal Med, Fortaleza, CE, Brazil.
   [Goes, Paula] Univ Fed Ceara, Fac Med, Dept Pathol & Legal Med, Lab Med Immunol, Rua Coronel Nunes Melo,1315 Rodolfo Teofilo, BR 60430270 Fortaleza, CE, Brazil.
C3 Universidade Federal do Ceara; Universidade Federal do Piaui; Instituto
   Federal do Ceara (IFCE); Universidade Federal do Ceara; Universidade
   Federal do Ceara; Universidade Federal do Ceara; Universidade Federal do
   Ceara; Universidade Federal do Ceara; Universidade Federal do Ceara;
   Universidade Federal do Ceara
RP Goes, P (通讯作者)，Univ Fed Ceara, Med Sch, Dept Pathol & Legal Med, Fortaleza, CE, Brazil.; Goes, P (通讯作者)，Univ Fed Ceara, Fac Med, Dept Pathol & Legal Med, Lab Med Immunol, Rua Coronel Nunes Melo,1315 Rodolfo Teofilo, BR 60430270 Fortaleza, CE, Brazil.
EM paulagpinheiro@yahoo.com.br
RI Gondim, Delane/N 9555 2017; LEITÃO, RENATA/ABF 9158 2020; BARRETO,
   GONCALO/H 6525 2019; Ribeiro, Maria Elenir/V 2384 2019; Brito,
   Gerly/C 8597 2013; costa de sousa, vanessa/IXD 3423 2023; Goes,
   Paula/G 1504 2015; Leitao, Renata/U 1040 2018
OI Gondim, Delane/0000 0002 7240 3314; de sousa,
   vanessa/0000 0001 8899 043X; Leitao, Renata/0000 0003 0202 771X
FU National Council for Scientific and Technological Development (CNPq)
   [402349/2021 0]
FX This study was funded by the National Council for Scientific and
   Technological Development (CNPq) process number 402349/2021 0.
CR Aguirre JI, 2021, BONE, V153, DOI 10.1016/j.bone.2021.116168
   Barba Recreo P, 2014, J CRANIO MAXILL SURG, V42, P744, DOI 10.1016/j.jcms.2013.11.005
   Biedron R, 2012, FUNCT FOODS HEALTH D, V2, P428, DOI 10.31989/ffhd.v2i11.72
   Campelo MD, 2023, J BIOMED MATER RES B, V111, P1035, DOI 10.1002/jbm.b.35212
   Choi M, 2022, INT J BIOL MACROMOL, V211, P556, DOI 10.1016/j.ijbiomac.2022.05.057
   Chou WY, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018530
   Colditz J, 2018, J BONE MINER RES, V33, P1698, DOI 10.1002/jbmr.3463
   Cui DP, 2020, CARBOHYD POLYM, V233, DOI 10.1016/j.carbpol.2020.115856
   Cuttle L, 2005, WOUND REPAIR REGEN, V13, P198, DOI 10.1111/j.1067 1927.2005.130211.x
   Silva PGD, 2015, ARCH ORAL BIOL, V60, P1237, DOI 10.1016/j.archoralbio.2015.05.015
   Ferreira VCD, 2021, CLIN ORAL INVEST, V25, P673, DOI 10.1007/s00784 020 03551 7
   de Sousa VC, 2022, BONE, V164, DOI 10.1016/j.bone.2022.116523
   de Vasconcelos RF, 2022, EXP GERONTOL, V167, DOI 10.1016/j.exger.2022.111921
   Diaz LAC, 2014, J TISSUE ENG, V5, DOI 10.1177/2041731414539344
   Farlay D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028736
   Ferneini EM, 2021, J ORAL MAXIL SURG, V79, P1801, DOI 10.1016/j.joms.2021.05.014
   George Estee L, 2018, Bone Rep, V8, P104, DOI 10.1016/j.bonr.2018.03.003
   Goes Paula, 2010, Braz. Dent. J., V21, P193, DOI 10.1590/S0103 64402010000300003
   Gong X, 2017, SCI REP UK, V7, DOI 10.1038/srep36129
   Hetland G, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051339
   Hsiao CM, 2016, INT WOUND J, V13, P1116, DOI 10.1111/iwj.12427
   Huang KY, 2022, CURR RES FOOD SCI, V5, P2190, DOI 10.1016/j.crfs.2022.10.029
   Jilka RL, 2013, BONE, V54, P264, DOI 10.1016/j.bone.2012.11.038
   JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772
   Kim HY, 2021, ENDOCRINOL METAB, V36, P917, DOI 10.3803/EnM.2021.1170
   Kim YS, 2012, J PERIODONTAL RES, V47, P800, DOI 10.1111/j.1600 0765.2012.01502.x
   Kün Darbois JD, 2018, CLIN ORAL INVEST, V22, P2997, DOI 10.1007/s00784 018 2385 2
   Kuroshima S, 2019, J ORAL BIOSCI, V61, P99, DOI 10.1016/j.job.2019.03.005
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luthfi M, 2020, INFECT DIS REP, V12, P40, DOI 10.4081/idr.2020.8726
   Majtan J, 2018, MOLECULES, V23, DOI 10.3390/molecules23040806
   Nakamura T., 2011, Biosci. Biotechnol. Biochem, V75, P645, DOI [10.1271/bbb.100685, DOI 10.1271/BBB.100685]
   Olczyk P, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/747584
   Park HS, 2015, BIOSCI BIOTECH BIOCH, V79, P147, DOI 10.1080/09168451.2014.963500
   Patntirapong S, 2012, J ORAL PATHOL MED, V41, P713, DOI 10.1111/j.1600 0714.2012.01154.x
   Rop O, 2009, NUTR REV, V67, P624, DOI 10.1111/j.1753 4887.2009.00230.x
   Ruggiero SL, 2022, J ORAL MAXIL SURG, V80, P920, DOI 10.1016/j.joms.2022.02.008
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Soundia A, 2018, J DENT RES, V97, P312, DOI 10.1177/0022034517732770
   Tracy LE, 2016, ADV WOUND CARE, V5, P119, DOI 10.1089/wound.2014.0561
   Unal M, 2016, J BONE MINER RES, V31, P1015, DOI 10.1002/jbmr.2768
   Wang P, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/164817
   Xia CW, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1099889
   Yanik S, 2016, ARCH ORAL BIOL, V65, P59, DOI 10.1016/j.archoralbio.2015.10.010
NR 44
TC 1
Z9 1
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD APR 8
PY 2024
VL 14
IS 1
AR 8215
DI 10.1038/s41598 024 58445 5
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NE7I6
UT WOS:001198838600092
PM 38589479
OA gold
DA 2025 08 17
ER

PT J
AU Strack, J
   Heni, H
   Gilsbach, R
   Hein, L
   Aktories, K
   Orth, JHC
AF Strack, Julia
   Heni, Hannah
   Gilsbach, Ralf
   Hein, Lutz
   Aktories, Klaus
   Orth, Joachim H. C.
TI Noncanonical G Protein Dependent Modulation of Osteoclast
   Differentiation and Bone Resorption Mediated by Pasteurella
   multocida Toxin
SO MBIO
LA English
DT Article
ID PHOSPHOLIPASE C BETA; SIGNALING PATHWAY; ACTIVATION; CELLS; EXPRESSION;
   SUBUNIT; RHOA; PYK2; RAS; SRC
AB Pasteurella multocida toxin (PMT) induces atrophic rhinitis in animals, which is characterized by a degradation of nasal turbinate bones, indicating an effect of the toxin on bone cells such as osteoblasts and osteoclasts. The underlying molecular mechanism of PMT was defined as a persistent activation of heterotrimeric G proteins by deamidation of a specific glutamine residue. Here, we show that PMT acts directly on osteoclast precursor cells such as bone marrow derived CD14(+) monocytes and RAW246.7 cells to induce osteoclastogenesis as measured by expression of osteoclast specific markers such as tartrate resistant acid phosphatase and bone resorption activity. Treatment performed solely with PMT stimulates osteoclast differentiation, showing a receptor activator of nuclear factor kappa B ligand (RANKL) independent action of the toxin. The underlying signal transduction pathway was defined as activation of the heterotrimeric G proteins G alpha(q/11) leading to the transactivation of Ras and the mitogen activated protein kinase pathway. G alpha(q/11) transactivates Ras via its effector phospholipase Ca2+ protein kinase C (PKC) involving proline rich tyrosine kinase 2 (Pyk2). PMT induced activation of the mitogen activated protein kinase pathway results in stimulation of the osteoclastogenic transcription factors AP 1, NF kappa B, and NFATc1. In addition, Ca2+ dependent calcineurin activation of NFAT is crucial for PMT induced osteoclastogenesis. The data not only elucidate a rationale for PMT dependent bone loss during atrophic rhinitis but also highlight a noncanonical, G protein dependent pathway toward bone resorption that is distinct from the RANKL RANK pathway but mimics it. We define heterotrimeric G proteins as as yet underestimated entities/players in the maturation of osteoclasts which might be of pharmacological relevance.
   IMPORTANCE Pasteurella multocida toxin (PMT) induces degradation of nasal turbinate bones, leading to the syndrome of atrophic rhinitis. Recently, the molecular mechanism and substrate specificity of PMT were identified. The toxin activates heterotrimeric G proteins by a covalent modification. However, the mechanism by which PMT induces bone degradation is poorly understood. Our report demonstrates a direct effect of PMT on osteoclast precursor cells, leading to maturation of bone degrading osteoclasts. Interestingly, PMT stimulates osteoclastogenesis independently of the cytokine RANKL, which is a key factor in induction of osteoclast differentiation. This implicates a noncanonical osteoclastogenic signaling pathway induced by PMT. The elucidated G alpha(q/11) dependent osteoclastogenic signal transduction pathway ends in osteoclastogenic NFAT signaling. The noncanonical, heterotrimeric G protein dependent osteoclast differentiation process may be of pharmacological relevance, as members of this pathway are highly druggable. In particular, modulation of G protein coupled receptor activity in osteoclast progenitors by small molecules might be of specific interest.
C1 [Strack, Julia; Heni, Hannah; Aktories, Klaus; Orth, Joachim H. C.] Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Dept 1, D 79106 Freiburg, Germany.
   [Gilsbach, Ralf; Hein, Lutz] Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Dept 2, D 79106 Freiburg, Germany.
   [Aktories, Klaus] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, D 79106 Freiburg, Germany.
C3 University of Freiburg; University of Freiburg; University of Freiburg
RP Orth, JHC (通讯作者)，Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Dept 1, Hugstetter Str 55, D 79106 Freiburg, Germany.
EM Klaus.Aktories@pharmakol.uni freiburg.de;
   Joachim.Orth@pharmakol.uni freiburg.de
RI Hein, Lutz/GRJ 8644 2022; Aktories, Klaus/CAJ 5682 2022
OI Gilsbach, Ralf/0000 0002 0895 1535; Aktories, Klaus/0000 0002 5397 0436
FU Deutsche Forschungsgemeinschaft (DFG) [OR218/1, SFB746]
FX The study was financially supported by the Deutsche
   Forschungsgemeinschaft (DFG; grants OR218/1 and SFB746).
CR Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Birnbaumer L, 2007, BBA BIOMEMBRANES, V1768, P756, DOI 10.1016/j.bbamem.2006.09.027
   Busch C, 2001, INFECT IMMUN, V69, P3628, DOI 10.1128/IAI.69.6.3628 3634.2001
   COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337
   DEJONG MF, 1990, VET REC, V126, P93
   ELLING F, 1985, VET PATHOL, V22, P469, DOI 10.1177/030098588502200506
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Girkontaite I, 2001, NAT IMMUNOL, V2, P855, DOI 10.1038/ni0901 855
   Greenfield Edward M, 2012, Curr Mol Pharmacol, V5, P127
   Guttenberg G, 2012, J BIOL CHEM, V287, P24929, DOI 10.1074/jbc.M112.347773
   Hanyu R, 2012, P NATL ACAD SCI USA, V109, P7433, DOI 10.1073/pnas.1109036109
   Henderson B, 2003, TRENDS MICROBIOL, V11, P570, DOI 10.1016/j.tim.2003.10.005
   Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428
   Hildebrand D, 2011, INFECT IMMUN, V79, P220, DOI 10.1128/IAI.00565 10
   Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527
   Horiguchi Y, 2012, CURR TOP MICROBIOL, V361, P113, DOI 10.1007/82_2012_206
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   Iwai K, 2007, J BONE MINER RES, V22, P1612, DOI 10.1359/JBMR.070612
   Jutras I, 1996, CAN J VET RES, V60, P34
   Kamitani S, 2011, FEBS J, V278, P2702, DOI 10.1111/j.1742 4658.2011.08197.x
   Knowles HJ, 2009, HISTOL HISTOPATHOL, V24, P337, DOI 10.14670/HH 24.337
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kuroda Y, 2012, WORLD J ORTHOP, V3, P167, DOI 10.5312/wjo.v3.i11.167
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905
   Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097
   MARTINEAUDOIZE B, 1993, J COMP PATHOL, V108, P81, DOI 10.1016/S0021 9975(08)80230 7
   Massey HM, 1999, BRIT J HAEMATOL, V106, P167
   Mullan PB, 1998, CALCIFIED TISSUE INT, V63, P340, DOI 10.1007/s002239900537
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Nishimura A, 2010, P NATL ACAD SCI USA, V107, P13666, DOI 10.1073/pnas.1003553107
   Orth JHC, 2005, J BIOL CHEM, V280, P36701, DOI 10.1074/jbc.M507203200
   Orth JHC, 2013, FASEB J, V27, P832, DOI 10.1096/fj.12 213900
   Orth JHC, 2009, P NATL ACAD SCI USA, V106, P7179, DOI 10.1073/pnas.0900160106
   Ray BJ, 2012, J LEUKOCYTE BIOL, V92, P1021, DOI 10.1189/jlb.0512259
   RODAN GA, 1992, BONE, V13, pS3, DOI 10.1016/S8756 3282(09)80003 3
   Roelle S, 2008, ONCOGENE, V27, P1737, DOI 10.1038/sj.onc.1210819
   Rozengurt E, 2007, J CELL PHYSIOL, V213, P589, DOI 10.1002/jcp.21246
   Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826
   Siegert P, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003385
   Souchet M, 2002, J CELL SCI, V115, P629
   STERNERKOCK A, 1995, VET PATHOL, V32, P274, DOI 10.1177/030098589503200309
   Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106
   Wilson BA, 1997, J BIOL CHEM, V272, P1268, DOI 10.1074/jbc.272.20.12961
   Wilson BA, 2013, CLIN MICROBIOL REV, V26, P631, DOI 10.1128/CMR.00024 13
   Wilson BA, 2012, CURR TOP MICROBIOL, V361, P93, DOI 10.1007/82_2012_219
   Wu MR, 2010, FRONT BIOSCI LANDMRK, V15, P957, DOI 10.2741/3656
   Yang MH, 2006, J BIOL CHEM, V281, P23598, DOI 10.1074/jbc.M602191200
NR 54
TC 16
Z9 16
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 2150 7511
J9 MBIO
JI mBio
PD NOV DEC
PY 2014
VL 5
IS 6
AR e02190 14
DI 10.1128/mBio.02190 14
PG 9
WC Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology
GA AX7CE
UT WOS:000347073600053
PM 25389180
OA Green Published
DA 2025 08 17
ER

PT J
AU Conaway, HH
   Henning, P
   Lie, A
   Tuckermann, J
   Lerner, UH
AF Conaway, H. Herschel
   Henning, Petra
   Lie, Antia
   Tuckermann, Jan
   Lerner, Ulf H.
TI Glucocorticoids employ the monomeric glucocorticoid receptor to
   potentiate vitamin D3 and parathyroid hormone induced
   osteoclastogenesis
SO FASEB JOURNAL
LA English
DT Article
DE osteoporosis; bone resorption; calcium regulating hormones; osteoclasts
ID INDUCED BONE LOSS; NF KAPPA B; INDUCED OSTEOPOROSIS; OSTEOPROTEGERIN
   LIGAND; VERTEBRAL FRACTURE; RANKL; DIFFERENTIATION; RESORPTION;
   INHIBITION; APOPTOSIS
AB Glucocorticoid (GC) therapy decreases bone mass and increases the risk of fractures. We investigated interactions between the GC dexamethasone (DEX) and the bone resorptive agents 1,25(OH)(2) vitamin D 3 (D3) and parathyroid hormone (PTH) on osteodastogenesis. We observed a synergistic potentiation of osteoclast progenitor cell differentiation and formation of osteoclasts when DEX was added to either D3  or PTH treated mouse bone marrow cell (BMC) cultures. Cotreatment of DEX with D3 or PTH increased gene encoding calcitonin receptor (Calcr), acid phosphatase 5, tartrate resistant (Acp5), cathepsin K (Ctsk), and TNF superfamily member 11 (Tnfsf11) mRNA, receptor activator of NF kappa B ligand protein (RANKL), numbers of osteoclasts on plastic, and pit formation and release of C terminal fragment of type I collagen from cells cultured on bone slices. Enhanced RANKL protein expression caused by D3 and DEX was absent in BMC from mice in which the GC receptor (GR) was deleted in stromal cells/osteoblasts. Synergistic interactions between DEX and D3 on RANKL and osteodast formation were present in BMC from mice with attenuated GR dimerization. These data demonstrate that the GR cooperates with D3 and PTH signaling, causing massive osteoclastogenesis, which may explain the rapid bone loss observed with high dosages of GC treatment.
C1 [Conaway, H. Herschel] Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA.
   [Henning, Petra; Lerner, Ulf H.] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res, Vita Straket 11, S 41345 Gothenburg, Sweden.
   [Lie, Antia] Umea Univ, Dept Mol Periodontol, Umea, Sweden.
   [Tuckermann, Jan] Univ Ulm, Inst Comparat Mol Endocrinol, Ulm, Germany.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Gothenburg; Umea University; Ulm University
RP Lerner, UH (通讯作者)，Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res, Vita Straket 11, S 41345 Gothenburg, Sweden.
EM ulf.lerner@gu.se
RI ; Henning, Petra/KIL 4650 2024
OI Lerner, Ulf/0000 0002 3579 1960; Henning, Petra/0000 0002 9330 6265
FU Swedish Research Council; Swedish government; Medical Training and
   Research Agreement (ALF) [237551]; Lundberg Foundation; Swedish
   Rheumatism Association; Royal 80 Year Fund of King Gustav V; County
   Council of Vasterbotten; Funds of the German Research Council (DFG) [CRC
   1149]; Swedish county councils
FX The authors are grateful for the skillful technical assistance by Dr.
   Christina Drevinge (Sahlgrenska Academy, University of Gothenburg),
   Inger Lundgren (Umea University), and Anna Westerlund (Sahlgrenska
   Academy, University of Gothenburg). This study was supported by the
   Swedish Research Council, the Swedish state under the agreement between
   the Swedish government and the county councils, the Medical Training and
   Research Agreement (ALF; 237551), the Lundberg Foundation, the Swedish
   Rheumatism Association, the Royal 80 Year Fund of King Gustav V, and the
   County Council of Vasterbotten. Funds of the German Research Council
   (DFG) were awarded to J.T. in the frame of the CRC 1149. The authors
   declare no conflicts of interest.
CR Angeli A, 2006, BONE, V39, P253, DOI 10.1016/j.bone.2006.02.005
   Brändström H, 2001, BIOCHEM BIOPH RES CO, V280, P831, DOI 10.1006/bbrc.2000.4223
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Carbonare LD, 2001, J BONE MINER RES, V16, P97, DOI 10.1359/jbmr.2001.16.1.97
   Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529 0131(199911)42:11<2309::AID ANR8>3.0.CO;2 K
   Conaway HH, 2016, BONE, V93, P43, DOI 10.1016/j.bone.2016.08.024
   Conaway HH, 2011, J BIOL CHEM, V286, P31425, DOI 10.1074/jbc.M111.247734
   Conaway HH, 1997, J ENDOCRINOL, V155, P513, DOI 10.1677/joe.0.1550513
   Cushing H, 1932, B JOHNS HOPKINS HOSP, V50, P137
   Frenkel B, 2015, ADV EXP MED BIOL, V872, P179, DOI 10.1007/978 1 4939 2895 8_8
   Frijters R, 2010, BMC GENOMICS, V11, DOI 10.1186/1471 2164 11 359
   Geusens PP, 2006, ARTHRITIS RHEUM US, V54, P1772, DOI 10.1002/art.21896
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hofbauer LC, 2009, ARTHRITIS RHEUM, V60, P1427, DOI 10.1002/art.24445
   Humphrey EL, 2006, BONE, V38, P652, DOI 10.1016/j.bone.2005.10.004
   Jensen PR, 2015, BONE, V73, P16, DOI 10.1016/j.bone.2014.12.004
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Kassel O, 2007, MOL CELL ENDOCRINOL, V275, P13, DOI 10.1016/j.mce.2007.07.003
   Kitazawa R, 1999, BBA GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167 4781(99)00032 9
   Kitazawa R, 2002, BIOCHEM BIOPH RES CO, V290, P650, DOI 10.1006/bbrc.2001.6251
   LAAN RFJM, 1993, CALCIFIED TISSUE INT, V52, P5, DOI 10.1007/BF00675619
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lim HW, 2015, GENOME RES, V25, P836, DOI 10.1101/gr.188581.114
   Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613
   Maresova KB, 2013, CALCIFIED TISSUE INT, V92, P354, DOI 10.1007/s00223 012 9684 4
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Moutsatsou P, 2012, TRENDS MOL MED, V18, P348, DOI 10.1016/j.molmed.2012.04.005
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Nevius E, 2015, J EXP MED, V212, P1931, DOI 10.1084/jem.20150088
   Nile CJ, 2013, J CLIN PERIODONTOL, V40, P875, DOI 10.1111/jcpe.12134
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Oakley RH, 2013, J ALLERGY CLIN IMMUN, V132, P1033, DOI 10.1016/j.jaci.2013.09.007
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Palmqvist P, 2006, J BIOL CHEM, V281, P2414, DOI 10.1074/jbc.M510160200
   PHILIBERT D, 1991, FRONT HORM RES, V19, P1
   Plotkin LI, 2011, BONE, V49, P122, DOI 10.1016/j.bone.2010.08.011
   Pluijm SMF, 2009, J BONE MINER RES, V24, P768, DOI [10.1359/jbmr.081244, 10.1359/JBMR.081244]
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092 8674(00)81183 6
   Sato AY, 2018, CLIN REV BONE MINER, V16, P33, DOI 10.1007/s12018 018 9242 3
   Sivagurunathan S, 2005, J BONE MINER RES, V20, P390, DOI 10.1359/JBMR.041233
   Soe K, 2010, J BONE MINER RES, V25, P2184, DOI 10.1002/jbmr.113
   Souza PPC, 2013, IMMUNOL INVEST, V42, P555, DOI 10.3109/08820139.2013.822766
   Swanson C, 2006, ENDOCRINOLOGY, V147, P3613, DOI 10.1210/en.2005 0717
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Vidal NOA, 1998, J ENDOCRINOL, V159, P191, DOI 10.1677/joe.0.1590191
   Wallach S, 2000, CALCIFIED TISSUE INT, V67, P277, DOI 10.1007/s002230001146
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Xiong JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05244 y
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 55
TC 15
Z9 16
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD DEC
PY 2019
VL 33
IS 12
BP 14394
EP 14409
DI 10.1096/fj.201802729RRR
PG 16
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA KC9BO
UT WOS:000507466100103
PM 31675485
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Boileau, C
   Tat, SK
   Pelletier, JP
   Cheng, S
   Martel Pelletier, J
AF Boileau, Christelle
   Tat, Steeve Kwan
   Pelletier, Jean Pierre
   Cheng, Saranette
   Martel Pelletier, Johanne
TI Diacerein inhibits the synthesis of resorptive enzymes and reduces
   osteoclastic differentiation/survival in osteoarthritic subchondral
   bone: a possible mechanism for a protective effect against subchondral
   bone remodelling
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID NF KAPPA B; EXPERIMENTAL DOG OSTEOARTHRITIS; RECEPTOR ACTIVATOR;
   CATHEPSIN K; IN VITRO; MATRIX METALLOPROTEINASES; CYTOSKELETAL
   ORGANIZATION; DIFFERENTIAL EXPRESSION; ARTICULAR CHONDROCYTES;
   RHEUMATOID ARTHRITIS
AB Introduction Subchondral bone alterations represent an essential component of osteoarthritis (OA). Modifying the abnormal subchondral bone metabolism may be indicated to treat OA. We investigated the effect of diacerein and rhein on the changes occurring in subchondral bone during OA. To this end, we determined the drugs' effects on metalloprotease 13 (MMP 13) synthesis on subchondral bone and on the osteoblast signalling pathways. In osteoclasts, we studied MMP 13 and cathepsin K production as well as cell differentiation, proliferation, and survival.
   Methods The effect of diacerein/rhein on the production of subchondral bone MMP 13 was determined by enzyme linked immunosorbent assay. Signalling pathways were evaluated on osteoblasts by Western blot. Osteoclast experiments were performed using cells from the pre osteoclastic murine cell line Raw 264.7. Osteoclast MMP 13 and cathepsin K activities were determined by specific bioassays and differentiation of these cells quantified by tartrate resistant acid phosphatase staining.
   Results Diacerein and rhein reduced, in a dose dependent manner, the interleukin 1 beta (IL 1 beta) induced MMP 13 production in OA subchondral bone. This effect occurred through the inhibition of ERK1/2 (extracellular signal regulated kinase 1/2) and p38. In osteoclasts, they significantly reduced the activity of MMP 13 and cathepsin K. Moreover, these drugs effectively blocked the IL 1 beta effect on the osteoclast differentiation process and the survival of mature osteoclasts.
   Conclusion Altogether, these data suggest that diacerein/rhein could impact the abnormal subchondral bone metabolism in OA by reducing the synthesis of resorptive factors and osteoclast formation.
C1 [Boileau, Christelle; Tat, Steeve Kwan; Pelletier, Jean Pierre; Cheng, Saranette; Martel Pelletier, Johanne] Univ Montreal, Osteoarthritis Res Unit, Ctr Hosp, Notre Dame Hosp, Montreal, PQ H2L 4M1, Canada.
C3 Universite de Montreal
RP Martel Pelletier, J (通讯作者)，Univ Montreal, Osteoarthritis Res Unit, Ctr Hosp, Notre Dame Hosp, 1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.
EM jm@martelpelletier.ca
RI Pelletier, Jean Pierre/AAG 2896 2019; Martel Pelletier,
   Johanne/AAG 2928 2019; boileau, catherine/M 4482 2017
CR ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Bettica P, 2002, ARTHRITIS RHEUM, V46, P3178, DOI 10.1002/art.10630
   CARLSON CS, 1994, J ORTHOP RES, V12, P331, DOI 10.1002/jor.1100120305
   Carlson CS, 1996, J BONE MINER RES, V11, P1209
   CASTIGLIONE S, 1993, ANTI CANCER DRUG, V4, P407, DOI 10.1097/00001813 199306000 00019
   Couchourel D, 2006, ARTHRITIS RHEUM, V54, pS572
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   DEDRICK DK, 1993, ARTHRITIS RHEUM, V36, P1460, DOI 10.1002/art.1780361019
   DELPINO A, 1992, CANCER BIOCHEM BIOPH, V12, P241
   Evans R G, 1994, Osteoarthritis Cartilage, V2, P103, DOI 10.1016/S1063 4584(05)80060 3
   FRANCHIMICHELI S, 1983, J PHARM PHARMACOL, V35, P262, DOI 10.1111/j.2042 7158.1983.tb02929.x
   Gravallese EM, 2000, ARTHRITIS RHEUM US, V43, P2143, DOI 10.1002/1529 0131(200010)43:10<2143::AID ANR1>3.3.CO;2 J
   Hilal G, 1998, ARTHRITIS RHEUM, V41, P891, DOI 10.1002/1529 0131(199805)41:5<891::AID ART17>3.0.CO;2 X
   Huang Yun hong, 2001, Yaoxue Xuebao, V36, P334
   Hummel KM, 1998, J RHEUMATOL, V25, P1887
   Hwa SY, 2001, J RHEUMATOL, V28, P825
   Ip SW, 2007, ANTICANCER RES, V27, P379
   Ji Ze quan, 2005, Zhonghua Yi Xue Za Zhi, V85, P1836
   Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320
   Jimi E, 1999, J IMMUNOL, V163, P434
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338
   Lajeunesse D, 2004, ANN RHEUM DIS, V63, P78, DOI 10.1136/ard.2002.003624
   Lee SK, 2006, BONE, V38, P678, DOI 10.1016/j.bone.2005.10.011
   Legendre F, 2007, CLIN EXP RHEUMATOL, V25, P546
   Martel Pelletier J, 1998, J RHEUMATOL, V25, P753
   Martel Pelletier J., 2007, OSTEOARTHRITIS, P15
   Martin G, 2003, INFLAMMATION, V27, P233, DOI 10.1023/A:1025040631514
   Massicotte F, 2002, OSTEOARTHR CARTILAGE, V10, P491, DOI 10.1053/joca.2002.0528
   Messent EA, 2005, OSTEOARTHR CARTILAGE, V13, P463, DOI 10.1016/j.joca.2005.01.007
   Nakamura I, 2002, J IMMUNOL, V168, P5103, DOI 10.4049/jimmunol.168.10.5103
   Okahashi N, 1998, BONE, V23, P33, DOI 10.1016/S8756 3282(98)00069 6
   Paredes Y, 2002, ARTHRITIS RHEUM, V46, P1804, DOI 10.1002/art.10357
   Pelletier JP, 1998, J RHEUMATOL, V25, P2417
   Pelletier JP, 2004, BONE, V34, P527, DOI 10.1016/j.bone.2003.11.021
   Pelletier JP, 2001, J RHEUMATOL, V28, P814
   Piva R, 2006, ANN NY ACAD SCI, V1091, P509, DOI 10.1196/annals.1378.092
   Salminen HJ, 2002, ANN RHEUM DIS, V61, P591, DOI 10.1136/ard.61.7.591
   Take I, 2005, ENDOCRINOLOGY, V146, P5204, DOI 10.1210/en.2005 0451
   Tamura T, 2002, EUR J PHARMACOL, V448, P81, DOI 10.1016/S0014 2999(02)01898 8
   Tamura T, 2001, JPN J PHARMACOL, V85, P101, DOI 10.1254/jjp.85.101
   Tat SK, 2008, CLIN EXP RHEUMATOL, V26, P295
   Uchida M, 2000, J CELL PHYSIOL, V185, P207, DOI 10.1002/1097 4652(200011)185:2<207::AID JCP5>3.0.CO;2 J
   Varghese S, 2003, J CELL BIOCHEM, V90, P1007, DOI 10.1002/jcb.10732
   Watson PJ, 1996, ARTHRITIS RHEUM, V39, P1327, DOI 10.1002/art.1780390810
   Wittrant Y, 2004, EXP CELL RES, V293, P292, DOI 10.1016/j.yexcr.2003.10.016
   Xia LH, 1999, BIOL CHEM, V380, P679, DOI 10.1515/BC.1999.084
   Yamaza T, 1998, BONE, V23, P499, DOI 10.1016/S8756 3282(98)00138 0
   Yaron M, 1999, OSTEOARTHR CARTILAGE, V7, P272, DOI 10.1053/joca.1998.0201
NR 51
TC 47
Z9 57
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2008
VL 10
IS 3
AR R71
DI 10.1186/ar2444
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 354IP
UT WOS:000259633000032
PM 18578867
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Liu, S
   Luo, ZH
   Ji, GM
   Guo, W
   Cai, JZ
   Fu, LC
   Zhou, J
   Hu, YJ
   Shen, XL
AF Liu, Shan
   Luo, Zhuo Hui
   Ji, Gui Mei
   Guo, Wei
   Cai, Jia Zhong
   Fu, Lin Chun
   Zhou, Juan
   Hu, Ying Jie
   Shen, Xiao Ling
TI Cajanolactone A from Cajanus cajan Promoted Osteoblast Differentiation
   in Human Bone Marrow Mesenchymal Stem Cells via Stimulating
   Wnt/LRP5/ Catenin Signaling
SO MOLECULES
LA English
DT Article
DE cajanolactone A; Cajanus cajan (L.) Millsp; osteoblast differentiation;
   Wnt/beta catenin signaling pathway
ID OSTEOGENIC DIFFERENTIATION; SECRETED PROTEINS; STROMAL CELLS;
   BETA CATENIN; EXTRACT; LEAVES; FAMILY; LIGAND
AB Cajanolactone A (CLA) is a stilbenoid discovered by us from Cajanus cajan (L.) Millsp. In our study, CLA was found to promote osteoblast differentiation in human bone marrow mesenchymal stem cells (hBMSCs), as judged by increased cellular alkaline phosphatase activity and extracellular calcium deposits, and elevated protein expression of Runx2, collagen 1, bone morphogenetic protein 2, and osteopontin. Mechanistic studies revealed that hBMSCs undergoing osteoblast differentiation expressed upregulated mRNA levels of Wnt3a, Wnt10b, LRP5/6, Frizzled 4,  catenin, Runx2, and Osterix from the early stage of differentiation, indicating the role of activated Wnt/ catenin signaling pathway in osteoblast differentiation. Addition of CLA to the differentiation medium further increased the mRNA level of Wnt3a, Wnt10b, Frizzled 4, LRP5, and  catenin, inferring that CLA worked by stimulating Wnt/LRP5/ catenin signaling. Wnt inhibitor dickkopf 1 antagonized CLA promoted osteoblastogenesis, indicating that CLA did not target the downstream of canonical Wnt signaling pathway. Treatment with CLA caused no changes in mRNA expression level, as well as protein secretion of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa B ligand (RANKL), indicating that CLA did not affect the OPG/RANKL axis. Our results showed that CLA, which promoted osteoblast differentiation in hBMSCs, through activating Wnt/LRP5/ catenin signaling transduction, is a promising anti osteoporotic drug candidate.
C1 [Liu, Shan; Luo, Zhuo Hui; Ji, Gui Mei; Guo, Wei; Fu, Lin Chun; Zhou, Juan; Hu, Ying Jie; Shen, Xiao Ling] Guangzhou Univ Chinese Med, Inst Trop Med, Lab Chinese Herbal Drug Discovery, Guangzhou 510405, Guangdong, Peoples R China.
   [Liu, Shan] Guangzhou Univ Chinese Med, Sch Basic Med Sci, Res Ctr Integrat Med, Guangzhou 510405, Guangdong, Peoples R China.
   [Cai, Jia Zhong] Guangzhou Univ Chinese Med, Pi Wei Inst, Guangzhou 510405, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine
RP Hu, YJ; Shen, XL (通讯作者)，Guangzhou Univ Chinese Med, Inst Trop Med, Lab Chinese Herbal Drug Discovery, Guangzhou 510405, Guangdong, Peoples R China.
EM liushan@gzucm.edu.cn; zhuohuiluo@126.com; 17620027119@163.com;
   18825099643@163.com; jiazhongcai@gzucm.edu.cn; linchunfu@gzucm.edu.cn;
   rysyxs@gzucm.edu.cn; yingjiehu@gzucm.edu.cn; xshen2@gzucm.edu.cn
RI luo, zhuohui/AAW 5436 2020; Shen, Xiao Ling/JFB 2361 2023
OI Hu, Yingjie/0000 0002 5260 4151; 
FU China National Major Projects of Science and Technology
   [2014ZX10005002]; National Natural Science Foundation of China
   [81703793]; Project of Science and Technology of Guangdong Province
   [2016A020217015]; Planned Team Project of Department of Education of
   Guangdong Province [2015KCXTD023]; Projects of Guangzhou University of
   Chinese Medicine [2016KYTD04, A1 AFD01816Z1516]
FX This work was supported by the funds of China National Major Projects of
   Science and Technology (grant number 2014ZX10005002), National Natural
   Science Foundation of China (grant number 81703793), Project of Science
   and Technology of Guangdong Province (grant number 2016A020217015),
   Planned Team Project of Department of Education of Guangdong Province
   (grant number 2015KCXTD023), Projects of Guangzhou University of Chinese
   Medicine (grant numbers 2016KYTD04 and A1 AFD01816Z1516).
CR Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Cai JZ, 2015, MOLECULES, V20, P10839, DOI 10.3390/molecules200610839
   Duker Eshun G, 2004, PHYTOTHER RES, V18, P128, DOI 10.1002/ptr.1375
   Frey JL, 2015, MOL CELL BIOL, V35, P1979, DOI 10.1128/MCB.01343 14
   Galli C, 2013, CLIN ORAL IMPLAN RES, V24, P921, DOI 10.1111/j.1600 0501.2012.02488.x
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Li JP, 2017, EUR REV MED PHARMACO, V21, P4777
   Lin FX, 2018, CELL PHYSIOL BIOCHEM, V47, P161, DOI 10.1159/000489763
   Luo M, 2010, CHEM BIOL INTERACT, V188, P151, DOI 10.1016/j.cbi.2010.07.009
   Luo QF, 2008, PHYTOMEDICINE, V15, P932, DOI 10.1016/j.phymed.2008.03.002
   Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449
   Qiu S.X., 2011, Chin. Patent, Patent No. [CN200810199012.6 [P], 2008101990126]
   Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Sreeharsha RV, 2019, PHOTOSYNTH RES, V139, P425, DOI 10.1007/s11120 018 0586 9
   Wang J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.474
   Yang RY, 2018, INT J MOL MED, V42, P2329, DOI 10.3892/ijmm.2018.3836
   Ye G.F., 2012, CHINESE PHARMACOL B, V29, P961
   Zhang JC, 2010, PHARM BIOL, V48, P89, DOI 10.3109/13880200903046179
   Zuo C, 2012, OSTEOPOROSIS INT, V23, P1653, DOI 10.1007/s00198 012 1909 x
NR 22
TC 10
Z9 13
U1 2
U2 20
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1420 3049
J9 MOLECULES
JI Molecules
PD JAN 2
PY 2019
VL 24
IS 2
AR 271
DI 10.3390/molecules24020271
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HJ4IH
UT WOS:000457137200057
PM 30642055
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Jiang, WH
   Jin, YY
   Zhang, SW
   Ding, Y
   Huo, KL
   Yang, JJ
   Zhao, L
   Nian, BN
   Zhong, TP
   Lu, WQ
   Zhang, HK
   Cao, X
   Shah, KM
   Wang, N
   Liu, MY
   Luo, J
AF Jiang, Wenhao
   Jin, Yunyun
   Zhang, Shiwei
   Ding, Yi
   Huo, Konglin
   Yang, Junjie
   Zhao, Lei
   Nian, Baoning
   Zhong, Tao P.
   Lu, Weiqiang
   Zhang, Hankun
   Cao, Xu
   Shah, Karan Mehul
   Wang, Ning
   Liu, Mingyao
   Luo, Jian
TI PGE2 activates EP4 in subchondral bone osteoclasts to regulate
   osteoarthritis
SO BONE RESEARCH
LA English
DT Article
ID NERVE GROWTH FACTOR; KNEE OSTEOARTHRITIS; PROSTAGLANDIN E 2;
   ARTICULAR CARTILAGE; RHEUMATOID ARTHRITIS; MARROW LESIONS; CROSS TALK;
   RECEPTOR; ANGIOGENESIS; PAIN
AB Prostaglandin E2 (PGE2), a major cyclooxygenase 2 (COX 2) product, is highly secreted by the osteoblast lineage in the subchondral bone tissue of osteoarthritis (OA) patients. However, NSAIDs, including COX 2 inhibitors, have severe side effects during OA treatment. Therefore, the identification of novel drug targets of PGE2 signaling in OA progression is urgently needed. Osteoclasts play a critical role in subchondral bone homeostasis and OA related pain. However, the mechanisms by which PGE2 regulates osteoclast function and subsequently subchondral bone homeostasis are largely unknown. Here, we show that PGE2 acts via EP4 receptors on osteoclasts during the progression of OA and OA related pain. Our data show that while PGE2 mediates migration and osteoclastogenesis via its EP2 and EP4 receptors, tissue specific knockout of only the EP4 receptor in osteoclasts (EP4(LysM)) reduced disease progression and osteophyte formation in a murine model of OA. Furthermore, OA related pain was alleviated in the EP4(LysM) mice, with reduced Netrin 1 secretion and CGRP positive sensory innervation of the subchondral bone. The expression of platelet derived growth factor BB (PDGF BB) was also lower in the EP4(LysM) mice, which resulted in reduced type H blood vessel formation in subchondral bone. Importantly, we identified a novel potent EP4 antagonist, HL 43, which showed in vitro and in vivo effects consistent with those observed in the EP4(LysM) mice. Finally, we showed that the G alpha s/PI3K/AKT/MAPK signaling pathway is downstream of EP4 activation via PGE2 in osteoclasts. Together, our data demonstrate that PGE2/EP4 signaling in osteoclasts mediates angiogenesis and sensory neuron innervation in subchondral bone, promoting OA progression and pain, and that inhibition of EP4 with HL 43 has therapeutic potential in OA.
C1 [Jiang, Wenhao; Luo, Jian] Tongji Univ, Yangzhi Rehabil Hosp, Sch Med, Sunshine Rehabil Ctr, Shanghai, Peoples R China.
   [Jiang, Wenhao; Jin, Yunyun; Zhang, Shiwei; Ding, Yi; Huo, Konglin; Yang, Junjie; Zhao, Lei; Nian, Baoning; Zhong, Tao P.; Lu, Weiqiang; Zhang, Hankun; Liu, Mingyao; Luo, Jian] East China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Shanghai, Peoples R China.
   [Jiang, Wenhao; Jin, Yunyun; Zhang, Shiwei; Ding, Yi; Huo, Konglin; Yang, Junjie; Zhao, Lei; Nian, Baoning; Zhong, Tao P.; Lu, Weiqiang; Zhang, Hankun; Liu, Mingyao; Luo, Jian] East China Normal Univ, Shanghai Key Lab Regulatory Biol, Sch Life Sci, Shanghai, Peoples R China.
   [Cao, Xu] Johns Hopkins Univ, Dept Orthopaed Surg, Sch Med, Baltimore, MD USA.
   [Cao, Xu] Johns Hopkins Univ, Dept Biomed Engn, Sch Med, Baltimore, MD USA.
   [Cao, Xu] Johns Hopkins Univ, Inst Cell Engn, Sch Med, Baltimore, MD USA.
   [Shah, Karan Mehul; Wang, Ning] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
C3 Tongji University; East China Normal University; East China Normal
   University; Johns Hopkins University; Johns Hopkins University; Johns
   Hopkins University; University of Sheffield
RP Luo, J (通讯作者)，Tongji Univ, Yangzhi Rehabil Hosp, Sch Med, Sunshine Rehabil Ctr, Shanghai, Peoples R China.; Luo, J (通讯作者)，East China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Shanghai, Peoples R China.; Luo, J (通讯作者)，East China Normal Univ, Shanghai Key Lab Regulatory Biol, Sch Life Sci, Shanghai, Peoples R China.
EM jluo@tongji.edu.cn
RI ; Zhang, Shiwei/JIY 4344 2023; Ding, Yi/CAG 6304 2022; Zhong,
   Tao/GOV 5060 2022; jin, yun/GQZ 6618 2022; Zhang, Hankun/NSU 3511 2025;
   Wang, Ning/HKO 8446 2023; Shah, Karan/B 2940 2012; yang,
   junjie/AAZ 2290 2020
OI WANG, NING/0000 0002 2663 7515; Jiang, Wenhao/0000 0003 2243 7732; Shah,
   Karan/0000 0001 9909 6409; 
FU National Key Research and Development Program of China [2020YFC2002800,
   2018YFC1105102]; National Natural Science Foundation of China [91949127,
   92168204]; Fundamental Research Funds for the Central Universities
   [22120210586]
FX This work is supported by grants from the National Key Research and
   Development Program of China (2020YFC2002800 to J.L. and 2018YFC1105102
   to J.L.), the National Natural Science Foundation of China (91949127,
   92168204 to J.L.), and the Fundamental Research Funds for the Central
   Universities (22120210586).
CR Aaron RK, 2018, OSTEOARTHR CARTILAGE, V26, P940, DOI 10.1016/j.joca.2018.04.003
   Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280
   Anaraki PK, 2015, J BONE MINER RES, V30, P379, DOI 10.1002/jbmr.2350
   Angeli F, 2018, EXPERT REV CLIN PHAR, V11, P1073, DOI 10.1080/17512433.2018.1540299
   Ashraf S, 2014, ANN RHEUM DIS, V73, P1710, DOI 10.1136/annrheumdis 2013 203416
   Attur M, 2008, J IMMUNOL, V181, P5082, DOI 10.4049/jimmunol.181.7.5082
   Ballal P, 2020, OSTEOARTHR CARTILAGE, V28, P1325, DOI 10.1016/j.joca.2020.07.006
   Bingham CO, 2006, ARTHRITIS RHEUM US, V54, P3494, DOI 10.1002/art.22160
   Bjarnason I, 2013, INT J CLIN PRACT, V67, P37, DOI 10.1111/ijcp.12048
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Chang SH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09491 5
   Choi WS, 2019, NATURE, V566, P254, DOI 10.1038/s41586 019 0920 1
   Cinque ME, 2018, AM J SPORT MED, V46, P2011, DOI 10.1177/0363546517730072
   Clemett D, 2000, DRUGS, V59, P957, DOI 10.2165/00003495 200059040 00017
   Cui Z, 2016, ANN RHEUM DIS, V75, P1714, DOI 10.1136/annrheumdis 2015 207923
   de Zwart AH, 2018, J REHABIL MED, V50, P140, DOI 10.2340/16501977 2284
   Dieppe PA, 2005, LANCET, V365, P965, DOI 10.1016/S0140 6736(05)71086 2
   Eriksen EF, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115352
   Farnaghi S, 2017, INT J RHEUM DIS, V20, P131, DOI 10.1111/1756 185X.13061
   Feng JJ, 2020, BIOCHEM PHARMACOL, V177, DOI 10.1016/j.bcp.2020.113960
   Gao M, 2015, P NATL ACAD SCI USA, V112, P8397, DOI 10.1073/pnas.1509565112
   Gilman KE, 2020, AM J PHYSIOL REG I, V320, pR287, DOI 10.1152/ajpregu.00185.2020
   Goldring SR, 2012, THER ADV MUSCULOSKEL, V4, P249, DOI 10.1177/1759720X12437353
   Hawkey CJ, 2001, BEST PRACT RES CL GA, V15, P801, DOI 10.1053/bega.2001.0236
   Hayami T, 2004, ARTHRITIS RHEUM US, V50, P1193, DOI 10.1002/art.20124
   Hu W., 2020, ANN RHEUM DIS
   Hunter DJ, 2006, ARTHRITIS RHEUM US, V54, P1529, DOI 10.1002/art.21789
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Jiménez G, 2018, ADV EXP MED BIOL, V1059, P63, DOI 10.1007/978 3 319 76735 2_3
   Jin J, 2017, LIFE SCI, V174, P68, DOI 10.1016/j.lfs.2017.03.001
   Johnston J E, 1992, J Miss State Med Assoc, V33, P97
   Kim BJ, 2018, J CLIN INVEST, V128, P1429, DOI 10.1172/JCI91086
   Kloppenburg M, 2020, OSTEOARTHR CARTILAGE, V28, P242, DOI 10.1016/j.joca.2020.01.002
   Kobayashi Y, 2005, J BIOL CHEM, V280, P11395, DOI 10.1074/jbc.M411189200
   Lacourt M, 2012, OSTEOARTHR CARTILAGE, V20, P572, DOI 10.1016/j.joca.2012.02.004
   Laslett LL, 2012, ANN RHEUM DIS, V71, P1322, DOI 10.1136/annrheumdis 2011 200970
   Li DZ, 2014, J BONE MINER METAB, V32, P494, DOI 10.1007/s00774 013 0530 1
   Li GY, 2015, BONE, V77, P91, DOI 10.1016/j.bone.2015.04.019
   Li GY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4405
   Li X, 2009, ARTHRITIS RHEUM US, V60, P513, DOI 10.1002/art.24258
   Lin CX, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0041 8
   Liu Q, 2018, OSTEOARTHR CARTILAGE, V26, P1636, DOI 10.1016/j.joca.2018.07.019
   Liu X., 2021, Nat. Commun, V12
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   Lu JS, 2018, J BONE MINER RES, V33, P909, DOI 10.1002/jbmr.3388
   Lu WQ, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202012798
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Madry H, 2010, KNEE SURG SPORT TR A, V18, P417, DOI 10.1007/s00167 010 1071 y
   Mano M, 2000, CALCIFIED TISSUE INT, V67, P85, DOI 10.1007/s00223001102
   Mansell JP, 2007, NAT CLIN PRACT RHEUM, V3, P306, DOI 10.1038/ncprheum0505
   Martel Pelletier J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.72
   Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006
   Mori H, 2016, METHODS MOL BIOL, V1458, P1, DOI 10.1007/978 1 4939 3801 8_1
   Nakanishi M, 2013, SEMIN IMMUNOPATHOL, V35, P123, DOI 10.1007/s00281 012 0342 8
   Nelson AE, 2018, OSTEOARTHR CARTILAGE, V26, P319, DOI 10.1016/j.joca.2017.11.014
   Ni SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13476 9
   Nishitani K, 2010, J CELL BIOCHEM, V109, P425, DOI 10.1002/jcb.22421
   Nwosu LN, 2016, ANN RHEUM DIS, V75, P1246, DOI 10.1136/annrheumdis 2014 207203
   Ono K, 2005, J BONE MINER RES, V20, P23, DOI 10.1359/JBMR.041027
   Palazzo C, 2016, ANN PHYS REHABIL MED, V59, P134, DOI 10.1016/j.rehab.2016.01.006
   Peat G, 2021, OSTEOARTHR CARTILAGE, V29, P180, DOI 10.1016/j.joca.2020.10.007
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Puljak L, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009865.pub2
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rane MA, 2020, J CARDIOVASC PHARM T, V25, P3, DOI 10.1177/1074248419871902
   Raynauld JP, 2008, ANN RHEUM DIS, V67, P683, DOI 10.1136/ard.2007.073023
   Robinson WH, 2016, NAT REV RHEUMATOL, V12, P580, DOI 10.1038/nrrheum.2016.136
   Roemer FW, 2009, ANN RHEUM DIS, V68, P1461, DOI 10.1136/ard.2008.096834
   Rossini M, 2015, RHEUMATOL INT, V35, P255, DOI 10.1007/s00296 014 3100 5
   Sato T, 2011, ANN RHEUM DIS, V70, P221, DOI 10.1136/ard.2009.118620
   Spector TD, 2005, ARTHRITIS RES THER, V7, pR625, DOI 10.1186/ar1716
   Stanaway JD, 2018, LANCET, V392, P1923, DOI 10.1016/s0140 6736(18)32225 6
   Su WP, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135446
   Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200
   Thijssen E, 2015, RHEUMATOLOGY, V54, P588, DOI 10.1093/rheumatology/keu464
   Tombran Tink J, 2004, BIOCHEM BIOPH RES CO, V316, P573, DOI 10.1016/j.bbrc.2004.02.076
   Tu ML, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0071 x
   Varenna M, 2015, RHEUMATOLOGY, V54, P1826, DOI 10.1093/rheumatology/kev123
   Vaysbrot EE, 2018, OSTEOARTHR CARTILAGE, V26, P154, DOI 10.1016/j.joca.2017.11.013
   Walker C, 2018, POSTGRAD MED, V130, P55, DOI 10.1080/00325481.2018.1412799
   Walsh DA, 2010, RHEUMATOLOGY, V49, P1852, DOI 10.1093/rheumatology/keq188
   Weinreb M, 2001, BONE, V28, P275, DOI 10.1016/S8756 3282(00)00447 6
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Yang JJ, 2020, J MED CHEM, V63, P569, DOI 10.1021/acs.jmedchem.9b01269
   Yokoyama U, 2013, PHARMACOL REV, V65, P1010, DOI 10.1124/pr.112.007195
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   Yue R, 2009, CELL, V139, P535, DOI 10.1016/j.cell.2009.08.038
   Zhang YS, 2011, BLOOD, V118, P5355, DOI 10.1182/blood 2011 04 350587
   Zhen GH, 2014, TRENDS PHARMACOL SCI, V35, P227, DOI 10.1016/j.tips.2014.03.005
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
NR 92
TC 77
Z9 88
U1 6
U2 91
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD MAR 9
PY 2022
VL 10
IS 1
AR 27
DI 10.1038/s41413 022 00201 4
PG 16
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA ZP1NA
UT WOS:000766190400002
PM 35260562
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yuan, YM
   Wu, DP
   Hou, YF
   Zhang, Y
   Tan, C
   Nie, XB
   Zhao, ZH
   Hou, JQ
AF Yuan, Yimeng
   Wu, Dapeng
   Hou, Yifan
   Zhang, Yi
   Tan, Cong
   Nie, Xiaobo
   Zhao, Zhenhua
   Hou, Junqing
TI Wnt signaling: Modulating tumor associated macrophages and related
   immunotherapeutic insights
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Wnt signaling pathways; Tumor  associated macrophages; Tumor
   microenvironment; Cancer immunotherapy; Therapeutic targets
ID RESISTANT PROSTATE CANCER; BREAST CANCER; BETA CATENIN; CELL;
   ACTIVATION; INHIBITOR; PATHWAY; METASTASIS; OSTEOSARCOMA; GLIOBLASTOMA
AB Wnt signaling pathways are highly conserved cascades that mediate multiple biological processes through canonical or noncanonical pathways, from embryonic development to tissue maintenance, but they also contribute to the pathogenesis of numerous cancers. Recent studies have revealed that Wnt signaling pathways critically control the interplay between cancer cells and tumor associated macrophages (TAMs) in the tumor microenvironment (TME) and potentially impact the efficacy of cancer immunotherapy. In this review, we summarize the evidence that Wnt signaling pathways boost the maturation and infiltration of macrophages for immune surveillance in the steady state but also polarize TAMs toward immunosuppressive M2 like phenotypes for immune escape in the TME. Both cancer cells and TAMs utilize Wnt signaling to transmit signals, and this interaction is crucial for the carcinogenesis and progression of common solid cancers, such as colorectal, gastric, hepatocellular, breast, thyroid, prostate, kidney, and lung cancers; osteosarcoma; and glioma. Specifically, compared with those in solid cancers, Wnt signaling pathways play a distinct role in the pathogenesis of leukemia. Efforts to develop Wnt based drugs for cancer treatment are still ongoing, and some indeed enhance the anticancer immune response. We believe that the combination of Wnt signaling  based therapy with conventional or immune therapies is a promising therapeutic approach and can facilitate personalized treatment for most cancers.
C1 [Yuan, Yimeng; Wu, Dapeng; Hou, Yifan; Zhang, Yi; Tan, Cong; Nie, Xiaobo; Zhao, Zhenhua] Henan Univ, Huaihe Hosp, Sch Basic Med Sci, Key Lab Receptors Mediated Gene Regulat & Drug Dis, Kaifeng, Peoples R China.
   [Yuan, Yimeng; Wu, Dapeng; Hou, Yifan; Zhang, Yi; Tan, Cong; Nie, Xiaobo; Zhao, Zhenhua] Henan Univ, Huaihe Hosp, Dept Urinary Surg, Kaifeng, Peoples R China.
   [Hou, Junqing] China RongTong Med Healthcare Grp Co Ltd, Kaifeng Hosp 155, Kaifeng, Peoples R China.
   [Nie, Xiaobo; Zhao, Zhenhua; Hou, Junqing] Henan Univ, Henan Prov Res Ctr Prevent & Diag Prostate Dis, Kaifeng, Peoples R China.
   [Nie, Xiaobo] Henan Univ, Sch Basic Med Sci, Kaifeng, Peoples R China.
C3 Henan University; Henan University; Henan University; Henan University
RP Nie, XB; Zhao, ZH (通讯作者)，Henan Univ, Huaihe Hosp, Dept Urinary Surg, Kaifeng, Peoples R China.; Hou, JQ (通讯作者)，China RongTong Med Healthcare Grp Co Ltd, Kaifeng Hosp 155, Kaifeng, Peoples R China.; Nie, XB (通讯作者)，Henan Univ, Sch Basic Med Sci, Kaifeng, Peoples R China.
EM xbnie99@henu.edu.cn; m18637831101@163.com; hjq0418@sina.com
RI Nie, Xiaobo/HGC 1041 2022; Zhao, zhenhua/AAT 7422 2021
OI Nie, Xiaobo/0000 0001 8117 4616; Hou, Junqing/0009 0004 4023 2137; 
FU Innovative & Entrepreneurial Program for College Student of Henan
   University [20231022003]; Natural Science Foundation of Henan Province
   [232300420048]; Key Program for Science & Technology of Henan Province;
   Province and Ministry Co construction Youth Program for Medical Science
   & Technology of Henan Province [SBGJ202103105]; Key Program for Science
   & Technology of Henan Province [202102310429]; Province and Ministry
   Co construction Program for Medical Science & Technology of Henan
   Province [LHGJ20190541, LHGJ20230435]
FX This work was supported by grants from the Innovative & Entrepreneurial
   Program for College Student of Henan University (20231022003) to Y.Y.;
   The Natural Science Foundation of Henan Province (232300420048), the Key
   Program for Science & Technology of Henan Province, and the Province and
   Ministry Co construction Youth Program for Medical Science & Technology
   of Henan Province (SBGJ202103105) to X.N.; The Key Program for Science &
   Technology of Henan Province (202102310429) and the Province and
   Ministry Co construction Program for Medical Science & Technology of
   Henan Province (LHGJ20190541, LHGJ20230435) to J.H.
CR Abrahamsson AE, 2009, P NATL ACAD SCI USA, V106, P3925, DOI 10.1073/pnas.0900189106
   Argentiero A, 2019, CANCERS, V11, DOI 10.3390/cancers11070942
   Avery D, 2022, BIOMATERIALS, V289, DOI 10.1016/j.biomaterials.2022.121797
   Bergenfelz C, 2012, J IMMUNOL, V188, P5448, DOI 10.4049/jimmunol.1103378
   Biazzo A, 2016, ACTA ORTHOP BELG, V82, P690
   Bin YL, 2020, CLIN CHIM ACTA, V504, P98, DOI 10.1016/j.cca.2020.01.014
   Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937
   BOTTAZZI B, 1990, J IMMUNOL, V144, P4878
   Brandon C, 2000, BLOOD, V96, P4132, DOI 10.1182/blood.V96.13.4132.h8004132_4132_4141
   Brown AL, 2012, DIFFERENTIATION, V83, P47, DOI 10.1016/j.diff.2011.08.003
   Bueno MLP, 2023, J CELL COMMUN SIGNAL, V17, P1487, DOI 10.1007/s12079 023 00773 8
   Cai Y, 2014, J CELL BIOCHEM, V115, P625, DOI 10.1002/jcb.24708
   Cancer Genome Atlas N, 2012, NATURE, V487, P330, DOI DOI 10.1038/nature11252
   Capitanio U, 2016, LANCET, V387, P894, DOI 10.1016/S0140 6736(15)00046 X
   Chaudagar K, 2023, CLIN CANCER RES, V29, P4930, DOI 10.1158/1078 0432.CCR 23 1441
   Chaudagar K, 2023, CLIN CANCER RES, V29, P1952, DOI 10.1158/1078 0432.CCR 22 3350
   Chávez Galán L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00263
   Chen J, 2018, INT J CLIN EXP PATHO, V11, P4552
   Chu HY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.658097
   Cosín Roger J, 2016, MUCOSAL IMMUNOL, V9, P986, DOI 10.1038/mi.2015.123
   Cui X, 2018, BIOMATERIALS, V161, P164, DOI 10.1016/j.biomaterials.2018.01.053
   Cui YJ, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.732860
   Cui YL, 2013, ASIAN PAC J CANCER P, V14, P1003, DOI 10.7314/APJCP.2013.14.2.1003
   Davies LC, 2011, EUR J IMMUNOL, V41, P2155, DOI 10.1002/eji.201141817
   DeVito NC, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109071
   Dholakia J, 2022, GYNECOL ONCOL, V164, P170, DOI 10.1016/j.ygyno.2021.09.026
   Diamond JR, 2020, BREAST CANCER RES TR, V184, P53, DOI 10.1007/s10549 020 05817 w
   Doo DW, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920913798
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Emons G, 2017, MOL CANCER RES, V15, P1481, DOI 10.1158/1541 7786.MCR 17 0205
   Fan YQ, 2021, CANCER MED US, V10, P8192, DOI 10.1002/cam4.4309
   Farren MR, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.130362
   Faux MC, 2022, CANCER RES COMMUN, V2, P66, DOI 10.1158/2767 9764.CRC 21 0105
   Feng Y, 2018, J AM SOC NEPHROL, V29, P182, DOI 10.1681/ASN.2017040391
   Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888
   Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510
   Gedaly R, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 23601 2
   Ginhoux F, 2014, NAT REV IMMUNOL, V14, P392, DOI 10.1038/nri3671
   Goldsberry WN, 2020, CANCERS, V12, DOI 10.3390/cancers12030766
   GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092 8674(81)90021 0
   Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109
   Han ZP, 2020, TRANSL CANCER RES, V9, P2721, DOI 10.21037/tcr.2020.02.52
   Hausman DM, 2019, PERSPECT BIOL MED, V62, P778, DOI 10.1353/pbm.2019.0046
   Hosseini F, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114758
   Huang JK, 2017, J CELL BIOCHEM, V118, P4821, DOI 10.1002/jcb.26153
   Huang Y, 2021, RADIOTHER ONCOL, V162, P34, DOI 10.1016/j.radonc.2021.06.034
   Jarman EJ, 2023, LIVER INT, V43, P208, DOI 10.1111/liv.15383
   Wang JF, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935 021 02126 0
   Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381
   Koushyar S, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12020309
   Kramer ED, 2023, JCI INSIGHT, V8, DOI 10.1172/jci.insight.160978
   Lee GT, 2018, BRIT J CANCER, V118, P670, DOI 10.1038/bjc.2017.451
   Lee JM, 2010, MOL CELL, V37, P183, DOI 10.1016/j.molcel.2009.12.022
   Li C, 2019, MOL THER, V27, P1558, DOI 10.1016/j.ymthe.2019.06.013
   Li JY, 2020, BIOMED RES INT UK, V2020, DOI 10.1155/2020/2527643
   Li ZG, 2023, J TRANSL MED, V21, DOI 10.1186/s12967 023 04120 8
   Lim S, 2013, P NATL ACAD SCI USA, V110, pE2298, DOI 10.1073/pnas.1301838110
   Lisi L, 2017, NEUROSCI LETT, V645, P106, DOI 10.1016/j.neulet.2017.02.076
   Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110
   Liu L, 2016, ONCOTARGET, V7, P47145, DOI 10.18632/oncotarget.9975
   Liu M, 2018, CELL PHYSIOL BIOCHEM, V51, P1679, DOI 10.1159/000495673
   Liu Q, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 00557 2
   Liu Q, 2020, INT J BIOL SCI, V16, P1023, DOI 10.7150/ijbs.40535
   Liu W, 2021, AGING US, V13, P19760, DOI 10.18632/aging.203388
   Liu Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046 017 0595 0
   Luo J, 2020, ONCOTARGETS THER, V13, P9257, DOI 10.2147/OTT.S245861
   Lv J, 2021, MOL CARCINOGEN, V60, P25, DOI 10.1002/mc.23268
   Lv J, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117925
   Lv SM, 2023, J PHYSIOL BIOCHEM, V79, P669, DOI 10.1007/s13105 022 00922 4
   Madan B, 2016, ONCOGENE, V35, P2197, DOI 10.1038/onc.2015.280
   Mao J, 2016, CANCER LETT, V380, P134, DOI 10.1016/j.canlet.2016.06.020
   Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802
   Matias D, 2017, BBA REV CANCER, V1868, P333, DOI 10.1016/j.bbcan.2017.05.007
   Matias D, 2019, MOL NEUROBIOL, V56, P1517, DOI 10.1007/s12035 018 1150 5
   Meyer IS, 2017, EMBO MOL MED, V9, P1279, DOI 10.15252/emmm.201707565
   Momtazi borojeni AA, 2018, J CELL PHYSIOL, V233, P2871, DOI 10.1002/jcp.26006
   Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008 5472.CAN 09 4672
   Mu GG, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.727306
   Ng M, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2584
   Nie XB, 2022, AM J PATHOL, V192, P503, DOI 10.1016/j.ajpath.2021.11.007
   Nie XB, 2021, J CELL MOL MED, V25, P6479, DOI 10.1111/jcmm.16663
   Nie XB, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01341
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092 8674(82)90409 3
   Pander J, 2011, CLIN CANCER RES, V17, P5668, DOI 10.1158/1078 0432.CCR 11 0239
   Patel KN, 2014, CURR OPIN OTOLARYNGO, V22, P121, DOI 10.1097/MOO.0000000000000037
   Patel S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02872
   Pavlovic Z, 2018, MABS AUSTIN, V10, P1157, DOI 10.1080/19420862.2018.1515565
   Pecina Slaus N, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24076733
   Perdiguero EG, 2016, NAT IMMUNOL, V17, P2, DOI 10.1038/ni.3341
   Piya S, 2019, J CLIN INVEST, V129, P1878, DOI 10.1172/JCI120654
   Pundkar C, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e16688
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Qu XD, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.994019
   RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092 8674(87)90038 9
   Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009
   Ryan K, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.016573
   Saini S, 2011, NAT REV UROL, V8, P690, DOI 10.1038/nrurol.2011.146
   Santos ALD, 2023, DRUG DELIV TRANSL RE, V13, P1420, DOI 10.1007/s13346 023 01303 0
   Sarode P, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6105
   Sekhoacha M, 2022, MOLECULES, V27, DOI 10.3390/molecules27175730
   Serafino A, 2020, EXPERT OPIN DRUG DIS, V15, P803, DOI 10.1080/17460441.2020.1746266
   Shen C, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.102227
   Sheng Y, 2016, LEUKEMIA, V30, P2106, DOI 10.1038/leu.2016.146
   Shi T, 2022, CANCER IMMUNOL RES, V10, P1506, DOI 10.1158/2326 6066.CIR 22 0218
   Siegel RL, 2023, CA CANCER J CLIN, V73, P17, DOI [10.3322/caac.21763, 10.3322/caac.21820]
   Sousa S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058 015 0621 0
   Su Y, 2019, J MOL MED, V97, P49, DOI 10.1007/s00109 018 1711 0
   Sumitomo R, 2022, ONCOL REP, V48, DOI 10.3892/or.2022.8404
   Sun GS, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc 2022 005655
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tang Y., 2021, Mol Med Rep, V24
   Tao WW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16827 z
   Tian XH, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756 9966 32 100
   Togi S, 2011, J BIOL CHEM, V286, P19170, DOI 10.1074/jbc.M110.189829
   van Amerongen R, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007914
   Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202
   van Ingen E, 2021, MOL THER NUCL ACIDS, V26, P1228, DOI 10.1016/j.omtn.2021.10.027
   Wall JA, 2021, GYNECOL ONCOL, V160, P285, DOI 10.1016/j.ygyno.2020.10.031
   Wang BJ, 2018, TRENDS PHARMACOL SCI, V39, P648, DOI 10.1016/j.tips.2018.03.008
   Wang CH, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1809947
   Wang N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00614
   Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624
   Wei C, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 0976 4
   Xiao Y, 2021, PHARMACOL THERAPEUT, V221, DOI 10.1016/j.pharmthera.2020.107753
   Xu WH, 2022, INT J BIOL SCI, V18, P4884, DOI 10.7150/ijbs.74647
   Xu XF, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01276 5
   Xue WT, 2023, DISCOV ONCOL, V14, DOI 10.1007/s12672 023 00739 7
   Yamaguchi T, 2016, GASTRIC CANCER, V19, P1052, DOI 10.1007/s10120 015 0579 8
   Yan JW, 2020, TRENDS CELL BIOL, V30, P979, DOI 10.1016/j.tcb.2020.09.006
   Yang B, 2022, MOL IMMUNOL, V146, P1, DOI 10.1016/j.molimm.2022.03.120
   Yang CG, 2021, MOL THER, V29, P2088, DOI 10.1016/j.ymthe.2021.02.006
   Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200
   Yang Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0818 0
   Ye YC, 2019, CANCER RES, V79, P4160, DOI 10.1158/0008 5472.CAN 18 1691
   Yeo EJ, 2014, CANCER RES, V74, P2962, DOI 10.1158/0008 5472.CAN 13 2421
   Zeng SW, 2022, SCI TOTAL ENVIRON, V809, DOI 10.1016/j.scitotenv.2021.152102
   Zhang JY, 2009, CELL CYCLE, V8, P2444, DOI 10.4161/cc.8.15.9170
   Zhao SJ, 2018, ONCOGENE, V37, P1049, DOI 10.1038/onc.2017.403
   Zheng X, 2017, ONCOTARGET, V8, P48436, DOI 10.18632/oncotarget.17061
   Zhou Y, 2022, CANCER LETT, V525, P84, DOI 10.1016/j.canlet.2021.10.034
   Zhuang XQ, 2017, NAT CELL BIOL, V19, P1274, DOI 10.1038/ncb3613
   Zhuo CH, 2022, BIOL DIRECT, V17, DOI 10.1186/s13062 022 00348 4
NR 142
TC 18
Z9 18
U1 2
U2 9
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAY
PY 2024
VL 223
AR 116154
DI 10.1016/j.bcp.2024.116154
EA MAR 2024
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA PU1O5
UT WOS:001216507500001
PM 38513742
OA hybrid
DA 2025 08 17
ER

PT J
AU Goldstein, SD
   Trucco, M
   Guzman, WB
   Hayashi, M
   Loeb, DM
AF Goldstein, Seth D.
   Trucco, Matteo
   Guzman, Wendy Bautista
   Hayashi, Masanori
   Loeb, David M.
TI A monoclonal antibody against the Wnt signaling inhibitor dickkopf 1
   inhibits osteosarcoma metastasis in a preclinical model
SO ONCOTARGET
LA English
DT Article
DE sarcoma; metastasis; Wnt signaling; DKK 1; mouse model
ID PROGNOSTIC FACTORS; DRUG DEVELOPMENT; SURVIVAL; EPIDEMIOLOGY;
   SURVEILLANCE; DISEASE; FAMILY; CELLS
AB The outcome of patients with metastatic osteosarcoma has not improved since the introduction of chemotherapy in the 1970s. Development of therapies targeting the metastatic cascade is a tremendous unmet medical need. The Wnt signaling pathway has been the focus of intense investigation in osteosarcoma because of its role in normal bone development. Although the role of Wnt signaling in the pathogenesis of osteosarcoma is controversial, there are several reports of dickkopf 1 (DKK 1), a Wnt signaling antagonist, possibly playing a pro tumorigenic role. In this work we investigated the effect of anti DKK 1 antibodies on the growth and metastasis of patient derived osteosarcoma xenografts. We were able to detect human DKK 1 in the blood of tumor bearing mice and found a correlation between DKK 1 level and tumor proliferation. Treatment with the anti DKK 1 antibody, BHQ880, slowed the growth of orthotopically implanted patient derived osteosarcoma xenografts and inhibited metastasis. This effect was correlated with increased nuclear beta catenin staining and increased expression of the bone differentiation marker osteopontin. These findings suggest that Wnt signaling is anti tumorigenic in osteosarcoma, and support the targeting of DKK 1 as an anti metastatic strategy for patients with osteosarcoma.
C1 [Goldstein, Seth D.; Guzman, Wendy Bautista; Hayashi, Masanori; Loeb, David M.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Pediat Oncol, Baltimore, MD USA.
   [Trucco, Matteo] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Baylor College of
   Medicine
RP Loeb, DM (通讯作者)，Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Pediat Oncol, Baltimore, MD USA.
EM loebda@jhmi.edu
RI ; Trucco, Matteo/KWU 0053 2024
OI Hayashi, Masanori/0000 0002 9508 0159; Trucco,
   Matteo/0009 0007 4259 2971; Bautista, Wendy/0000 0003 2816 4931;
   Goldstein, Seth/0000 0001 7806 4109
FU National Cancer Institute [1R01CA138212 01, 2P30CA006973]; Pablove
   Foundation; Giant Food Children's Cancer Research Fund
FX This work was supported by grants from the National Cancer Institute
   (1R01CA138212 01 to DML and 2P30CA006973 to Johns Hopkins University),
   the Pablove Foundation (to MH), and the Giant Food Children's Cancer
   Research Fund (to DML).
CR Adamson PC, 2005, CANCER J, V11, P324, DOI 10.1097/00130404 200507000 00008
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Anninga JK, 2011, EUR J CANCER, V47, P2431, DOI 10.1016/j.ejca.2011.05.030
   Cai Y, 2014, J CELL BIOCHEM, V115, P625, DOI 10.1002/jcb.24708
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Chou CT, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0107869, 10.1371/journal.pone.0105414, 10.1371/journal.pone.0104899]
   Clark JCM, 2008, J CANCER RES CLIN, V134, P281, DOI 10.1007/s00432 007 0330 x
   Duchman KR, 2015, CANCER EPIDEMIOL, V39, P593, DOI 10.1016/j.canep.2015.05.001
   Duong Linh M, 2013, J Registry Manag, V40, P59
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Goldstein SD, 2015, CLIN EXP METASTAS, V32, P703, DOI 10.1007/s10585 015 9738 x
   Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Jawad MU, 2011, J CANCER RES CLIN, V137, P597, DOI 10.1007/s00432 010 0923 7
   Johnson JI, 2001, BRIT J CANCER, V84, P1424, DOI 10.1054/bjoc.2001.1796
   Kager L, 2003, J CLIN ONCOL, V21, P2011, DOI 10.1200/JCO.2003.08.132
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kerbel RS, 2003, CANCER BIOL THER, V2, pS134
   Khanna C, 2014, CLIN CANCER RES, V20, P4200, DOI 10.1158/1078 0432.CCR 13 2574
   Krause U, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.67
   Krishnan K, 2005, CANCER J, V11, P306, DOI 10.1097/00130404 200507000 00006
   Lee N, 2007, BRIT J CANCER, V97, P1552, DOI 10.1038/sj.bjc.6604069
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   McCarthy HS, 2010, EXPERT OPIN THER TAR, V14, P221, DOI 10.1517/14728220903525720
   Mialou V, 2005, CANCER AM CANCER SOC, V104, P1100, DOI 10.1002/cncr.21263
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   Norris RE, 2012, NAT REV CANCER, V12, P776, DOI 10.1038/nrc3370
   Nusse R, 2001, NATURE, V411, P254, DOI 10.1038/35077199
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Zhao S, 2015, ONCOGENE, V34, P5069, DOI 10.1038/onc.2014.429
NR 32
TC 65
Z9 71
U1 1
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD APR 19
PY 2016
VL 7
IS 16
BP 21114
EP 21123
DI 10.18632/oncotarget.8522
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA DO3TY
UT WOS:000377705900004
PM 27049730
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Nasulewicz Goldeman, A
   Goldeman, W
   Mrówczynska, E
   Wietrzyk, J
AF Nasulewicz Goldeman, Anna
   Goldeman, Waldemar
   Mrowczynska, Ewa
   Wietrzyk, Joanna
TI Biological effects of aromatic bis[aminomethylidenebis(phosphonic)]
   acids in osteoclast precursors in vitro
SO CHEMICAL BIOLOGY & DRUG DESIGN
LA English
DT Article
DE aminomethylidenebisphosphonic acids; antiresorptive therapy;
   bisphosphonates; J774E macrophages; osteoclasts
ID NITROGEN CONTAINING BISPHOSPHONATES; CELL CYCLE ARREST; ZOLEDRONIC ACID;
   BONE RESORPTION; MEVALONATE PATHWAY; INDUCE APOPTOSIS; CANCER CELLS;
   INHIBITION; ACTIVATION; AMINOBISPHOSPHONATES
AB Nitrogen containing bisphosphonates (N BPs) inhibit bone resorption by preventing osteoclast activity. Most clinically used BPs are hydroxybisphosphonates with the exception of incadronate, which belongs to the class of aminomethylidenebisphosphonic acids. The aim of this study was to evaluate the antiproliferative activity of two previously reported aminobisphosphonates (WG8185B2 and WG9001B) in combination with doxorubicin and cisplatin toward J774E cells (a model of osteoclast precursors in vitro). WG8185B2 and WG9001B BPs enhanced the cytotoxic activity of doxorubicin and cisplatin, especially when applied 24 hr prior to cytostatics. The antiproliferative effect of studied BPs was related to the changes in cell cycle progression. WG8185B2 leads to significant accumulation of J774E cells in S phase, whereas WG9001B causes transient arrest in G(2)/M phase, followed by an increase in the percentage of cells in S phase. Moreover, WG8185B2 and WG9001B BPs showed enhanced proapoptotic activity in osteoclast precursors, which was manifested by an increase in caspase 3 activity and percentage of apoptotic cells. In addition, both compounds influenced the motility of J774E cells. The exact molecular mechanism of action of examined BPs remains to be determined; however, results show an interesting biological activity of these compounds, which may be of interest in the context of antiresorptive therapy.
C1 [Nasulewicz Goldeman, Anna; Mrowczynska, Ewa; Wietrzyk, Joanna] Hirszfeld Inst Immunol & Expt Therapy, Dept Expt Oncol, Wroclaw, Poland.
   [Goldeman, Waldemar] Wroclaw Univ Technol, Dept Organ Chem, Wroclaw, Poland.
C3 Polish Academy of Sciences; Hirszfeld Institute of Immunology &
   Experimental Therapy of the Polish Academy of Sciences; Wroclaw
   University of Science & Technology
RP Nasulewicz Goldeman, A (通讯作者)，Hirszfeld Inst Immunol & Expt Therapy, Weigla St 12, PL 53114 Wroclaw, Poland.
EM anna.nasulewicz goldeman@hirszfeld.pl
RI Wietrzyk, Joanna/O 4392 2018
OI Wietrzyk, Joanna/0000 0003 4980 6606; Mrowczynska,
   Ewa/0000 0002 1204 6108; Nasulewicz Goldeman, Anna/0000 0001 6167 5923
FU Narodowe Centrum Nauki [2014/13/B/NZ4/01105]
FX Narodowe Centrum Nauki, Grant/Award Number: 2014/13/B/NZ4/01105
CR [Anonymous], 2018, SMALL GTPASES, DOI [10.1080/21541248.2017.1299270, DOI 10.1080/21541248.2017.1299270]
   Benassi MS, 2007, CANCER LETT, V250, P194, DOI 10.1016/j.canlet.2006.10.004
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   CHOU TC, 1981, EUR J BIOCHEM, V115, P207, DOI 10.1111/j.1432 1033.1981.tb06218.x
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   Coleman RE, 2009, EUR J CANCER, V45, P1909, DOI 10.1016/j.ejca.2009.04.022
   Denoyelle C, 2003, BRIT J CANCER, V88, P1631, DOI 10.1038/sj.bjc.6600925
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fujimura T, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/325412
   Gao SY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179248
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Goffinet M, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 60
   Goldeman W, 2015, TETRAHEDRON, V71, P3282, DOI 10.1016/j.tet.2015.03.112
   Goldeman W, 2014, BIOORG MED CHEM LETT, V24, P3475, DOI 10.1016/j.bmcl.2014.05.071
   Goldeman W, 2012, TETRAHEDRON LETT, V53, P5290, DOI 10.1016/j.tetlet.2012.07.085
   Gro<ss> H., 1968, ANGEW CHEM, V80, P445, DOI 10.1002/ange.19680801112
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Iguchi K, 2010, EUR J PHARMACOL, V641, P35, DOI 10.1016/j.ejphar.2010.05.010
   Iguchi T, 2003, CELL SIGNAL, V15, P719, DOI 10.1016/S0898 6568(03)00007 X
   Karabulut B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756 9966 29 102
   Karlic H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091982
   Kimachi K, 2011, N S ARCH PHARMACOL, V383, P297, DOI 10.1007/s00210 010 0596 4
   Koto K, 2010, ONCOL REP, V24, P233, DOI 10.3892/or_00000851
   Kunzmann V, 2000, BLOOD, V96, P384
   Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Mansouri M, 2014, BIOCHIMIE, V99, P71, DOI 10.1016/j.biochi.2013.11.010
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Merrell MA, 2007, EUR J PHARMACOL, V570, P27, DOI 10.1016/j.ejphar.2007.05.075
   Michailidou M, 2010, J VASC RES, V47, P481, DOI 10.1159/000313876
   Miwa A, 2012, AM J HEMATOL, V87, P1084, DOI 10.1002/ajh.23328
   Moreau MF, 2007, BIOCHEM PHARMACOL, V73, P718, DOI 10.1016/j.bcp.2006.09.031
   O'Boyle NM, 2011, BIOORGAN MED CHEM, V19, P2306, DOI 10.1016/j.bmc.2011.02.022
   Okamoto S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.475
   Olive G, 1998, J ORG CHEM, V63, P9095, DOI 10.1021/jo980092z
   Prishchenko AA, 2009, HETEROATOM CHEM, V20, P319, DOI 10.1002/hc.20552
   Rogers MJ, 1996, J BONE MINER RES, V11, P1482
   Rogers TL, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 177
   Rossini M, 2012, CALCIFIED TISSUE INT, V91, P395, DOI 10.1007/s00223 012 9647 9
   Sharma D, 2013, VASC CELL, V5, DOI 10.1186/2045 824X 5 1
   Singh SK, 2008, BEILSTEIN J ORG CHEM, V4, DOI 10.3762/bjoc.4.42
   SKEHAN P, 1990, JNCI J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   TAKEUCHI M, 1993, CHEM PHARM BULL, V41, P688
   Tsubaki M, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 10
   Tsubaki M, 2013, BIOCHEM PHARMACOL, V85, P163, DOI 10.1016/j.bcp.2012.10.009
   Ullén A, 2005, ACTA ONCOL, V44, P644, DOI 10.1080/02841860510029617
   Wang AE, 2015, ORG LETT, V17, P732, DOI 10.1021/acs.orglett.5b00004
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   YOKOMATSU T, 1994, J ORG CHEM, V59, P7562
   Zhao M, 2012, CANCER SCI, V103, P58, DOI 10.1111/j.1349 7006.2011.02113.x
   Zhao ZC, 2018, DRUG DES DEV THER, V12, P3021, DOI 10.2147/DDDT.S168897
NR 54
TC 4
Z9 4
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1747 0277
EI 1747 0285
J9 CHEM BIOL DRUG DES
JI Chem. Biol. Drug Des.
PD OCT
PY 2019
VL 94
IS 4
BP 1835
EP 1848
DI 10.1111/cbdd.13597
EA AUG 2019
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA JH4FD
UT WOS:000484010100001
PM 31356729
DA 2025 08 17
ER

PT J
AU Cheon, YH
   Lee, CH
   Kim, S
   Do Park, G
   Kwak, SC
   Cho, HJ
   Kim, JY
   Lee, MS
AF Cheon, Yoon Hee
   Lee, Chang Hoon
   Kim, Soojin
   Do Park, Gyeong
   Kwak, Sung Chul
   Cho, Hae Joong
   Kim, Ju Young
   Lee, Myeung Su
TI Pitavastatin prevents ovariectomy induced osteoporosis by regulating
   osteoclastic resorption and osteoblastic formation
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Bone metabolism; Osteoclast; Osteoblast; Pitavastatin; Osteoporosis
ID DIFFERENTIATION; STATINS; INHIBITION; ACTIVATION; EXPRESSION; ESTROGEN
AB Excessive osteoclast activity, along with relatively weak osteoblast function, is strongly associated with bone disease. Therefore, studies to identify novel anti osteoporosis candidates with dual actions of inhibiting osteoclastogenesis and increasing osteoblastogenesis may provide an ideal approach for treating osteoporosis. Pitavastatin, an inhibitor of 3 hydroxy 3 methyl glutaryl coenzyme A reductase, has demonstrated various pharmacological activities, including anti inflammation, bone anabolic effects, vasodilation, and inhibition of revascularization; however, the precise effects and mechanisms of pitavastatin on the regulation of osteoblast and osteoclast activity need to be comprehensively elucidated. Herein, we demonstrated that pitavastatin is a potential candidate for treating osteoporosis by enhancing osteoblast differentiation and bone growth and inhibiting osteoclast differentiation and bone resorption. Pitavastatin exerted dose dependent inhibitory effects on receptor activator of nuclear factor kappa B ligand induced osteoclast formation, bone resorption, and osteoclast specific marker gene expression. These inhibitory effects were achieved by inhibiting the Akt, NF kappa B, and mitogen activated protein kinase (p38, ERK, and JNK) signaling pathways, resulting in the downregulation of major transcription factors c Fos and NFATc1. Furthermore, pitavastatin potentially stimulated osteoblast differentiation by activating alkaline phosphatase (ALP), enhancing mineralization by Alizarin Red S, and increasing the expression of osteoblastogenic marker genes such as runt related transcription factor 2, ALP, osteocalcin, and collagen type 1 alpha. Furthermore, we evaluated the therapeutic potential of pitavastatin in ovariectomy induced systematic bone loss based on micro computed tomography and histological analysis of femurs. Our findings demonstrated a new function and mechanism for pitavastatin in bone remodeling, indicating its potential as a therapeutic candidate in treating osteoporosis by inhibiting osteoclastic resorption and promoting osteoblastic formation.
C1 [Cheon, Yoon Hee; Lee, Chang Hoon; Kim, Soojin; Do Park, Gyeong; Kwak, Sung Chul; Cho, Hae Joong; Kim, Ju Young; Lee, Myeung Su] Wonkwang Univ, Sch Med, Musculoskeletal & Immune Dis Res Inst, Iksandae Ro 460, Iksan 54538, Jeonbuk, South Korea.
   [Lee, Chang Hoon; Lee, Myeung Su] Wonkwang Univ Hosp, Dept Internal Med, Div Rheumatol, Iksan 54538, Jeonbuk, South Korea.
   [Kwak, Sung Chul] Wonkwang Univ, Sch Med, Dept Anat, Iksandae Ro 460, Iksan 54538, Jeonbuk, South Korea.
   [Cho, Hae Joong] Wonkwang Univ Hosp, Dept Obstet & Gynecol, Iksan 54538, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University
RP Kim, JY (通讯作者)，Wonkwang Univ, Sch Med, Musculoskeletal & Immune Dis Res Inst, Iksandae Ro 460, Iksan 54538, Jeonbuk, South Korea.; Lee, MS (通讯作者)，Wonkwang Univ Hosp, Dept Internal Med, Div Rheumatol, 460 Iksandae Ro, Iksan 570749, Jeonbuk, South Korea.
EM kimjy1014@wku.ac.kr; ckhlms@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
FU Basic Science Research Program through National Research Foundation of
   Korea (NRF)   Ministry of Education [NRF 2018R1D1A1B07049679,
   NRF2020R1F1A1068303]; JW Pharmaceutical Co., Ltd.
FX This study was supported by a grant from the Basic Science Research
   Program through the National Research Foundation of Korea (NRF) funded
   by the Ministry of Education (NRF 2018R1D1A1B07049679)
   (NRF2020R1F1A1068303) , and by the Research Grant from JW Pharmaceutical
   Co., Ltd.
CR Bhatti H, STATPEARLS INTERNET, P2021
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Cagnacci A, 2019, MEDICINA LITHUANIA, V55, DOI 10.3390/medicina55090602
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Davies Jonathan T, 2016, Lipid Insights, V9, P13
   Davignon J, 2012, BRIT J CLIN PHARMACO, V73, P518, DOI 10.1111/j.1365 2125.2011.04139.x
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Geovanini GR, 2018, CLIN SCI, V132, P1243, DOI 10.1042/CS20180306
   Goltsov A, 2018, J BIOANAL BIOMED, V10, P154
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Jourdan JP, 2020, J PHARM PHARMACOL, V72, P1145, DOI 10.1111/jphp.13273
   Kakuda H, 2013, CLIN EXP NEPHROL, V17, P240, DOI 10.1007/s10157 012 0689 0
   Kawakami A, 2005, ARTERIOSCL THROM VAS, V25, P424, DOI 10.1161/01.ATV.0000152632.48937.2d
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kazi DS, 2017, MED CLIN N AM, V101, P689, DOI 10.1016/j.mcna.2017.03.001
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kim JH, 2011, TOXICOL SCI, V122, P1, DOI 10.1093/toxsci/kfr088
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Lv ZQ, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00191
   Majima T, 2007, INTERNAL MED, V46, P1967, DOI 10.2169/internalmedicine.46.0419
   Margaritis M, 2014, ANTIOXID REDOX SIGN, V20, P1198, DOI 10.1089/ars.2013.5430
   Momi S, 2007, EUR J PHARMACOL, V570, P115, DOI 10.1016/j.ejphar.2007.05.014
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nardone V, 2014, CLINICS, V69, P438, DOI 10.6061/clinics/2014(06)12
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Pinal Fernandez I, 2018, MED CLIN BARCELONA, V150, P398, DOI [10.1016/j.medcli.2017.11.030, 10.1016/j.medcle.2018.03.001]
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Qadir F, 2016, JCPSP J COLL PHYSICI, V26, P41, DOI 01.2016/JCPSP.4145
   Roberts SJ, 2011, STEM CELL RES, V7, P137, DOI 10.1016/j.scr.2011.04.003
   Rogers M, 2000, ARTHRITIS RES THER, V3, P66772
   Sansoy V, 2017, TURK KARDIYOL DERN A, V45, P1, DOI 10.5543/tkda.2017.88459
   Shibasaki M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138047
   Silva BC, 2011, J ENDOCRINOL INVEST, V34, P801, DOI 10.3275/7925
   Takase B, 2013, HEART ASIA, V5, P204, DOI 10.1136/heartasia 2013 010368
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Talevi A, 2020, EXPERT OPIN DRUG DIS, V15, P397, DOI 10.1080/17460441.2020.1704729
   Tang J, 2020, J BIOL CHEM, V295, P11669, DOI 10.1074/jbc.RA119.007896
   Taqueti V.R, 2017, CIRC CARDIOVASC IMAG, V10
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Zhang ZH, 2015, MOL MED REP, V12, P6932, DOI 10.3892/mmr.2015.4306
NR 46
TC 13
Z9 14
U1 0
U2 5
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JUL
PY 2021
VL 139
AR 111697
DI 10.1016/j.biopha.2021.111697
EA MAY 2021
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA SV2VK
UT WOS:000663682000009
PM 34243614
DA 2025 08 17
ER

PT J
AU Basu Roy, U
   Han, E
   Rattanakorn, K
   Gadi, A
   Verma, N
   Maurizi, G
   Gunaratne, PH
   Coarfa, C
   Kennedy, OD
   Garabedian, MJ
   Basilico, C
   Mansukhani, A
AF Basu Roy, Upal
   Han, Eugenia
   Rattanakorn, Kirk
   Gadi, Abhilash
   Verma, Narendra
   Maurizi, Giulia
   Gunaratne, Preethi H.
   Coarfa, Cristian
   Kennedy, Oran D.
   Garabedian, Michael J.
   Basilico, Claudio
   Mansukhani, Alka
TI PPARγ agonists promote differentiation of cancer stem cells by
   restraining YAP transcriptional activity
SO ONCOTARGET
LA English
DT Article
DE osteosarcoma; thiazolidinediones; cancer stem cells; osteoblast lineage;
   adipocyte
ID ORGAN SIZE CONTROL; OSTEOSARCOMA DEVELOPMENT; CANINE OSTEOSARCOMA; HIPPO
   PATHWAY; SELF RENEWAL; BONE; SOX2; GROWTH; THIAZOLIDINEDIONES;
   ROSIGLITAZONE
AB Osteosarcoma (OS) is a highly aggressive pediatric bone cancer in which most tumor cells remain immature and fail to differentiate into bone forming osteoblasts. However, OS cells readily respond to adipogenic stimuli suggesting they retain mesenchymal stem cell like properties. Here we demonstrate that nuclear receptor PPARy agonists such as the anti diabetic, thiazolidinedione (TZD) drugs induce growth arrest and cause adipogenic differentiation in human, mouse and canine OS cells as well as in tumors in mice. Gene expression analysis reveals that TZDs induce lipid metabolism pathways while suppressing targets of the Hippo YAP pathway, Wnt signaling and cancer related proliferation pathways. Significantly, TZD action appears to be restricted to the high Sox2 expressing cancer stem cell population and is dependent on PPARy expression. TZDs also affect growth and cell fate by causing the cytoplasmic sequestration of the transcription factors SOX2 and YAP that are required for tumorigenicity. Finally, we identify a TZD regulated gene signature based on Wnt/Hippo target genes and PPARy that predicts patient outcomes. Together, this work highlights a novel connection between PPARy agonist in inducing adipogenesis and mimicking the tumor suppressive hippo pathway. It also illustrates the potential of drug repurposing for TZD based differentiation therapy for osteosarcoma.
C1 [Basu Roy, Upal; Rattanakorn, Kirk; Gadi, Abhilash; Verma, Narendra; Maurizi, Giulia; Garabedian, Michael J.; Basilico, Claudio; Mansukhani, Alka] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.
   [Han, Eugenia; Garabedian, Michael J.; Basilico, Claudio; Mansukhani, Alka] Langone Med Ctr, Perlmutter Canc Ctr, New York, NY 10016 USA.
   [Gunaratne, Preethi H.] Univ Houston, Dept Biol & Biochem, Houston, TX USA.
   [Coarfa, Cristian] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   [Kennedy, Oran D.] NYU, Sch Med, Dept Orthopaed Surg, New York, NY USA.
C3 New York University; NYU Langone Medical Center; University of Houston
   System; University of Houston; Baylor College of Medicine; New York
   University
RP Mansukhani, A (通讯作者)，NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.; Mansukhani, A (通讯作者)，Langone Med Ctr, Perlmutter Canc Ctr, New York, NY 10016 USA.
EM alka.mansukhani@med.nyu.edu
OI Mansukhani, Alka/0000 0003 1020 3242; Maurizi,
   Giulia/0000 0003 0373 1370; Kennedy, Oran D./0000 0003 3343 2873
FU NCI [NIH/NC1 R21 CA186031]; NYSTEM [C029560]
FX This work was supported by NCI grant NIH/NC1 R21 CA186031 and by NYSTEM
   C029560.
CR An Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072042
   Angstadt AY, 2011, GENE CHROMOSOME CANC, V50, P859, DOI 10.1002/gcc.20908
   Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465
   Basu Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405
   Basu Roy U, 2010, CELL DEATH DIFFER, V17, P1345, DOI 10.1038/cdd.2010.57
   Basu Roy U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7411
   Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105
   Blanquicett Carmelo, 2008, Cancer Ther, V6, P25
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cariou B, 2012, TRENDS ENDOCRIN MET, V23, P205, DOI 10.1016/j.tem.2012.03.001
   Cellai I, 2010, BRIT J CANCER, V102, P685, DOI 10.1038/sj.bjc.6605506
   Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003
   Dela Cruz F, 2012, ONCOTARGET, V3, P559
   Dutchak PA, 2012, CELL, V148, P556, DOI 10.1016/j.cell.2011.11.062
   Favaro R, 2014, CANCER RES, V74, P1833, DOI 10.1158/0008 5472.CAN 13 1942
   Fenger JM, 2014, ILAR J, V55, P69, DOI 10.1093/ilar/ilu009
   Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394
   Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500
   He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078 0432.CCR 09 2499
   Heare T, 2009, CURR OPIN PEDIATR, V21, P365, DOI 10.1097/MOP.0b013e32832b1111
   Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Kelly AD, 2013, GENOME MED, V5, DOI 10.1186/gm406
   Kovac M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9940
   Lazarenko OP, 2007, ENDOCRINOLOGY, V148, P2669, DOI 10.1210/en.2006 1587
   Lewis JD, 2015, JAMA J AM MED ASSOC, V314, P265, DOI 10.1001/jama.2015.7996
   Liu Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   Martins Neves SR, 2016, CANCER LETT, V370, P286, DOI 10.1016/j.canlet.2015.11.013
   Moriarity BS, 2015, NAT GENET, V47, P615, DOI 10.1038/ng.3293
   Palacio Mancheno PE, 2014, J BONE MINER RES, V29, P142, DOI 10.1002/jbmr.2012
   Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011
   Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634
   Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007
   Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111
   Potthoff MJ, 2012, GENE DEV, V26, P312, DOI 10.1101/gad.184788.111
   Rainusso N, 2013, CURR ONCOL REP, V15, P296, DOI 10.1007/s11912 013 0321 9
   Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710
   Rong JX, 2011, PPAR RES, V2011, DOI 10.1155/2011/179454
   Seo E, 2011, MOL CELL BIOL, V31, P4593, DOI 10.1128/MCB.05798 11
   Smith MA, 2010, J CLIN ONCOL, V28, P2625, DOI 10.1200/JCO.2009.27.0421
   Soccio RE, 2014, CELL METAB, V20, P573, DOI 10.1016/j.cmet.2014.08.005
   Step SE, 2014, GENE DEV, V28, P1018, DOI 10.1101/gad.237628.114
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Tang W, 2011, CELL METAB, V14, P116, DOI 10.1016/j.cmet.2011.05.012
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Wagner ER, 2010, PPAR RES, V2010, DOI 10.1155/2010/956427
   Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808
   Wei S, 2009, CANCER LETT, V276, P119, DOI 10.1016/j.canlet.2008.08.008
   Wei W, 2012, P NATL ACAD SCI USA, V109, P3143, DOI 10.1073/pnas.1200797109
   Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044
   Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210
NR 56
TC 43
Z9 47
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 20
PY 2016
VL 7
IS 38
BP 60954
EP 60970
DI 10.18632/oncotarget.11273
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA EB2CN
UT WOS:000387164700014
PM 27528232
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Sivagurunathan, S
   Muir, MM
   Brennan, TC
   Seale, JP
   Mason, RS
AF Sivagurunathan, S
   Muir, MM
   Brennan, TC
   Seale, JP
   Mason, RS
TI Influence of glucocorticoids on human osteoclast generation and activity
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE glucocorticoids; dexamethasone; human peripheral blood mononuclear cell;
   RANKL; osteoprotegerin
ID OSTEOBLAST LIKE CELLS; RESISTANT ACID PHOSPHATASE; INTESTINAL
   CALCIUM ABSORPTION; PARATHYROID HORMONE LEVELS; COLONY STIMULATING
   FACTOR; BONE MARROW CULTURES; INDUCED OSTEOPOROSIS; OSTEOPROTEGERIN
   LIGAND; IN VITRO; MONONUCLEAR PHAGOCYTES
AB Using human peripheral blood mononuclear cells as osteoclast precursors, we showed that dexamethasone stimulated osteoclast generation at a pharmacological concentration but did not affect the life span of human osteoclasts. Dexamethasone also dose dependently increased signals for osteoclastogenesis.
   Introduction: Glucocorticoid induced osteoporosis is a common and serious disease. Glucocorticoids predominantly affect osteoblast proliferation and life span. Much of the bone loss is caused by reduced bone formation, but there is also an element of increased bone resorption.
   Materials and Methods: Human peripheral blood mononuclear cells were cultured on whale dentine and induced to differentiate to osteoclasts by RANKL and human macrophage colony stimulating factor (M CSF). Osteoclast activity was quantified by pit area. RANKL and osteoprotegerin (OPG) expression in osteoblasts were measured by real time RT PCR.
   Results: In the early phase of osteoclast generation (0 16 days), cultures from two different donors showed that dexamethasone at 10( 8) M increased pit area by 2.5 fold, whereas lower concentrations had no effect. At the highest dexamethasone concentration (10( 7) M), pit area was reduced. In 21 day cultures from three other donors, a similar increase was seen with dexamethasone at 10( 8) M. There was, however, no evidence of increased life span of osteoclasts with dexamethasone. In human primary osteoblasts, dexamethasone dose dependently reduced OPG and increased RANKL expression as measured by quantitative real time RT PCR.
   Conclusion: These data provide some explanation at a cellular and molecular level for the observed increase in bone resorption seen in patients treated with glucocorticoids and indicate that there are clear direct effects of glucocorticoids on bone resorption in human cell systems that may differ from other species.
C1 Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia.
   Univ Sydney, Inst Biomed Res, Sydney, NSW 2006, Australia.
   Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia.
C3 University of Sydney; University of Sydney; University of Sydney
RP Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia.
EM rebeccam@physiol.usyd.edu.au
RI ; Mason, Rebecca/AHB 5478 2022
OI Mason, Rebecca/0000 0003 1534 9697; Speranza, Tara/0000 0001 5472 4969
CR ADLER RA, 1994, ENDOCRIN METAB CLIN, V23, P641, DOI 10.1016/S0889 8529(18)30090 2
   ALI NN, 1984, ANAT EMBRYOL, V170, P51, DOI 10.1007/BF00319457
   ALLEN TD, 1981, SCANNING ELECTRON MI, V3, P347
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   BRESSOT C, 1979, METAB BONE DIS RELAT, V1, P303, DOI 10.1016/0221 8747(79)90024 9
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   BURGER EH, 1984, J CELL BIOL, V99, P1901, DOI 10.1083/jcb.99.6.1901
   Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023
   Carbonare LD, 2001, J BONE MINER RES, V16, P97, DOI 10.1359/jbmr.2001.16.1.97
   CHAMBERS JP, 1978, METABOLISM, V27, P801, DOI 10.1016/0026 0495(78)90215 9
   Chappard D, 1996, J BONE MINER RES, V11, P676
   Cheung J, 2003, J ENDOCRINOL, V177, P423, DOI 10.1677/joe.0.1770423
   Colquhoun D., 1971, LECT BIOSTATISTICS I
   DEMPSTER DW, 1989, J BONE MINER RES, V4, P137
   Dempster DW, 1997, J ENDOCRINOL, V154, P397, DOI 10.1677/joe.0.1540397
   EFSTRATIADIS T, 1985, ENZYME, V33, P34, DOI 10.1159/000469401
   ELFORD PR, 1987, CALCIFIED TISSUE INT, V41, P151, DOI 10.1007/BF02563795
   FUCIK RF, 1975, J CLIN ENDOCR METAB, V40, P152, DOI 10.1210/jcem 40 1 152
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   HATTERSLEY AT, 1994, CALCIFIED TISSUE INT, V54, P198, DOI 10.1007/BF00301678
   Hirayama T, 2002, J ENDOCRINOL, V175, P155, DOI 10.1677/joe.0.1750155
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   HORTON MA, 1986, J BONE MINER RES, V1, P5
   HOWARD CV, 1998, UNBIASED STEREOLOGY
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Huang L, 2001, MOL CELL ENDOCRINOL, V181, P199, DOI 10.1016/S0303 7207(01)00486 5
   Kim CH, 1999, J ENDOCRINOL, V162, P371, DOI 10.1677/joe.0.1620371
   KLEIN RG, 1977, J CLIN INVEST, V60, P253, DOI 10.1172/JCI108762
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   LUENGO M, 1991, EUR RESPIR J, V4, P441
   LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003 4819 112 5 352
   LUKERT BP, 1994, RHEUM DIS CLIN N AM, V20, P629
   LUTTRELL BM, LAB TEST GUIDE
   Manolagas SC, 2000, J BONE MINER RES, V15, P1001, DOI 10.1359/jbmr.2000.15.6.1001
   Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Namkung Matthäi H, 1998, EUR RESPIR J, V12, P1327, DOI 10.1183/09031936.98.12061327
   OSullivan BT, 1997, BIOL PSYCHIAT, V41, P574, DOI 10.1016/S0006 3223(96)00094 7
   PAZPACHECO E, 1995, J BONE MINER RES, V10, P1713
   Quinn JMW, 1997, INT J BIOCHEM CELL B, V29, P173, DOI 10.1016/S1357 2725(96)00129 X
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   RAISZ LG, 1972, ENDOCRINOLOGY, V90, P961, DOI 10.1210/endo 90 4 961
   REID IR, 1986, CALCIFIED TISSUE INT, V38, P38, DOI 10.1007/BF02556593
   REID LR, 1994, J ASTHMA, V31, P7, DOI 10.3109/02770909409056764
   Rubin MR, 2002, J CLIN ENDOCR METAB, V87, P4033, DOI 10.1210/jc.2002 012101
   Sambrook PN, 2003, ANN RHEUM DIS, V62, P1215, DOI 10.1136/ard.2003.008839
   SHUTO T, 1994, ENDOCRINOLOGY, V134, P1121, DOI 10.1210/en.134.3.1121
   SIMONET WS, 1997, J THORAC CARDIOVASC, V113, P413
   SIVAGURUNATHAN S, 2002, 8 ANN SCI M AUSTR NZ
   SLATER M, 1994, AM J PHYSIOL ENDOC M, V267, pE990, DOI 10.1152/ajpendo.1994.267.6.E990
   SLOVIK DM, 1980, CLIN ENDOCRINOL, V12, P243, DOI 10.1111/j.1365 2265.1980.tb02706.x
   Smith RD, 2003, BIOTECHNIQUES, V34, P88, DOI 10.2144/03341st05
   SNIPES RG, 1986, BLOOD, V67, P729
   STERN PH, 1969, J PHARMACOL EXP THER, V168, P211
   SUZUKI Y, 1983, METABOLISM, V32, P151, DOI 10.1016/0026 0495(83)90221 4
   TEITELBAUM SL, 1981, ENDOCRINOLOGY, V108, P795, DOI 10.1210/endo 108 3 795
   TOBIAS J, 1989, ENDOCRINOLOGY, V125, P1290, DOI 10.1210/endo 125 3 1290
   Tricarico C, 2002, ANAL BIOCHEM, V309, P293, DOI 10.1016/S0003 2697(02)00311 1
   Tsubakihara M, 2004, PROTEOMICS, V4, P261, DOI 10.1002/pmic.200300539
   UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo 125 4 1805
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Vidal NOA, 1998, J ENDOCRINOL, V159, P191, DOI 10.1677/joe.0.1590191
   Weigelt J, 1999, STRUCT FOLD DES, V7, P681, DOI 10.1016/S0969 2126(99)80089 6
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
NR 68
TC 103
Z9 112
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2005
VL 20
IS 3
BP 390
EP 398
DI 10.1359/JBMR.041233
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 898TB
UT WOS:000227098000003
PM 15746983
OA Bronze
DA 2025 08 17
ER

PT J
AU Kokabu, S
   Rosen, V
AF Kokabu, Shoichiro
   Rosen, Vicki
TI BMP3 expression by osteoblast lineage cells is regulated by canonical
   Wnt signaling
SO FEBS OPEN BIO
LA English
DT Article
DE osteoblast; osteoblastogenesis; osteocyte; osteopenia; osteoporosis;
   regenerative medicine
ID BONE MORPHOGENETIC PROTEIN 2; MARROW STROMAL CELLS; IA RECEPTOR BMPRIA;
   BETA CATENIN; DIFFERENTIATION; INHIBITION; OVEREXPRESSION; OSTEOPOROSIS;
   DISRUPTION; PREVENTS
AB Bone morphogenetic protein (BMP) and canonical Wnt (cWnt) signaling factors are both known to regulate bone mass, fracture risk, fracture repair, and osteoblastogenesis. BMP3 is the most abundant BMP and negatively regulates osteoblastogenesis and bone mass. Thus, identifying the mechanism by which BMP3 acts to depress bone formation may allow for the development of new therapeutics useful in the treatment for osteopenia and osteoporosis. Here, we report that cWnt signaling stimulates BMP3 expression in osteoblast (OB) lineage cells. The expression of BMP3 increases with OB differentiation. Treatment of cells with various cWnt proteins stimulated BMP3 expression. Mice with enhanced cWnt signaling had high expression levels of BMP3. Our data suggest that reduction in BMP3 levels may contribute beneficially to the positive effect of cWnt agonists on bone mass.
C1 [Kokabu, Shoichiro; Rosen, Vicki] Harvard Sch Dent Med, Dept Dev Biol, Boston, MA USA.
   [Kokabu, Shoichiro] Kyushu Dent Univ, Div Mol Signaling & Biochem, Dept Hlth Promot, 2 6 1 Kokurakita Ku, Kitakyushu, Fukuoka 8038580, Japan.
   [Kokabu, Shoichiro] Saitama Med Univ, Dept Oral & Maxillofacial Surg, Fac Med, Moroyama, Saitama, Japan.
C3 Harvard University; Harvard School of Dental Medicine; Kyushu Dental
   University; Saitama Medical University
RP Kokabu, S (通讯作者)，Kyushu Dent Univ, Div Mol Signaling & Biochem, Dept Hlth Promot, 2 6 1 Kokurakita Ku, Kitakyushu, Fukuoka 8038580, Japan.
EM r14kokabu@fa.kyu dent.ac.jp
RI ; Kokabu, Shoichiro/MDS 5426 2025
OI Kokabu, Shoichiro/0000 0002 6663 4327; 
FU NIAMS NIH HHS [R01 AR064227] Funding Source: Medline
CR Bahamonde ME, 2001, J BONE JOINT SURG AM, V83A, pS56
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Bajada S, 2009, BONE, V45, P726, DOI 10.1016/j.bone.2009.06.015
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Beier EE, 2014, J ORTHOP RES, V32, P1397, DOI 10.1002/jor.22677
   Blume SW, 2011, OSTEOPOROSIS INT, V22, P1835, DOI 10.1007/s00198 010 1419 7
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810
   Edwards MH, 2015, BONE, V80, P126, DOI 10.1016/j.bone.2015.04.016
   Gamer LW, 2009, DEV DYNAM, V238, P2374, DOI 10.1002/dvdy.22048
   Gamer LW, 2005, DEV BIOL, V285, P156, DOI 10.1016/j.ydbio.2005.06.012
   Gaur T, 2009, J CELL PHYSIOL, V220, P174, DOI 10.1002/jcp.21747
   Gazzerro E, 2005, ENDOCRINOLOGY, V146, P655, DOI 10.1210/en.2004 0766
   Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459
   Hill TP, 2006, DEVELOPMENT, V133, P1219, DOI 10.1242/dev.02298
   Hirata Tsuchiya S, 2014, MOL ENDOCRINOL, V28, P1460, DOI 10.1210/me.2014 1094
   Kamiya N, 2011, BIOCHEM BIOPH RES CO, V414, P326, DOI 10.1016/j.bbrc.2011.09.060
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   Kamiya N, 2008, J BONE MINER RES, V23, P2007, DOI 10.1359/JBMR.080809
   KOKABU S, 2016, STEM CELLS INT, V2016, DOI DOI 10.1155/2016/3753581
   Kokabu S, 2015, BIOCHEM BIOPH RES CO, V468, P568, DOI 10.1016/j.bbrc.2015.10.142
   Kokabu S, 2014, FEBS LETT, V588, P614, DOI 10.1016/j.febslet.2013.12.031
   Kokabu S, 2013, BIOCHEM BIOPH RES CO, V438, P205, DOI 10.1016/j.bbrc.2013.07.054
   Kokabu S, 2012, MOL ENDOCRINOL, V26, P87, DOI 10.1210/me.2011 1168
   Koncarevic A, 2010, ENDOCRINOLOGY, V151, P4289, DOI 10.1210/en.2010 0134
   Lowery JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057840
   Macsai CE, 2008, J CELL PHYSIOL, V215, P578, DOI 10.1002/jcp.21342
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   MikuniTakagaki Y, 1996, ENDOCRINOLOGY, V137, P2028, DOI 10.1210/en.137.5.2028
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Nakamura H, 2013, J BONE MINER RES, V28, P1457, DOI 10.1002/jbmr.1866
   Ovcharenko I, 2004, GENOME RES, V14, P472, DOI 10.1101/gr.2129504
   Ovcharenko I, 2004, NUCLEIC ACIDS RES, V32, pW280, DOI 10.1093/nar/gkh355
   Raisz LG, 2009, OSTEOPOROSIS INT, V20, P1805, DOI 10.1007/s00198 009 1041 8
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Rosen V, 2006, ANN NY ACAD SCI, V1068, P19, DOI 10.1196/annals.1346.005
   Salazar VS, 2016, DEVELOPMENT, V143, P4352, DOI 10.1242/dev.136879
   Sato T, 2008, BIOCHEM BIOPH RES CO, V377, P126, DOI 10.1016/j.bbrc.2008.09.114
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Turgeman G, 2002, J CELL BIOCHEM, V86, P461, DOI 10.1002/jcb.10231
   Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhang Z, 2000, J COMPUT BIOL, V7, P203, DOI 10.1089/10665270050081478
NR 46
TC 18
Z9 19
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2211 5463
J9 FEBS OPEN BIO
JI FEBS Open Bio
PD FEB
PY 2018
VL 8
IS 2
BP 168
EP 176
DI 10.1002/2211 5463.12347
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA FU8UU
UT WOS:000424132300002
PM 29435407
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cheon, YH
   Kim, JY
   Baek, JM
   Ahn, SJ
   Jun, HY
   Erkhembaatar, M
   Kim, MS
   Lee, MS
   Oh, J
AF Cheon, Yoon Hee
   Kim, Ju Young
   Baek, Jong Min
   Ahn, Sung Jun
   Jun, Hong Young
   Erkhembaatar, Munkhsoyol
   Kim, Min Seuk
   Lee, Myeung Su
   Oh, Jaemin
TI WHI 131 Promotes Osteoblast Differentiation and Prevents Osteoclast
   Formation and Resorption in Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE JANUS KINASE 3; WHI 131; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS
ID NF KAPPA B; JAK/STAT SIGNALING PATHWAY; BONE MARROW; INFLAMMATORY
   CYTOKINES; ACTIVATION; EXPRESSION; KINASE; RECEPTOR; CELLS; TYROSINE
AB The small molecule WHI 131 is a potent therapeutic agent with anti inflammatory, antiallergic, and antileukemic potential. However, the regulatory effects of WHI 131 on osteoblast and osteoclast activity are unclear. We examined the effects of WHI 131 on osteoblast and osteoclast differentiation with respect to bone remodeling. The production of receptor activator of nuclear factor kappa B ligand (RANKL) by osteoblasts in response to interleukin (IL) 1 or IL 6 stimulation decreased by 56.8% or 50.58%, respectively, in the presence of WHI 131. WHI 131 also abrogated the formation of mature osteoclasts induced by IL 1 or IL 6 stimulation. Moreover, WHI 131 treatment decreased RANKL induced osteoclast differentiation of bone marrow derived macrophages, and reduced the resorbing activity of mature osteoclasts. WHI 131 further decreased the mRNA and protein expression levels of c Fos and nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) by almost twofold, and significantly downregulated the mRNA expression of the following genes: tartrate resistant acid phosphatase (TRAP), osteoclast associated receptor (OSCAR), DC STAMP, OC STAMP, ATP6v0d2, and cathepsin K (CtsK) compared with the control group. WHI 131 further suppressed the phosphorylation of protein kinase B (Akt) and degradation of inhibitor of kappa B (IB); Ca2+ oscillation was also affected, and phosphorylation of the C terminal Src kinase (c Src) Bruton agammaglobulinemia tyrosine kinase (Btk) phospholipase C gamma 2 (PLC2) (c Src Btk PLCg2 calcium signaling pathway) was inhibited following WHI 131 treatment. The Janus kinase signal transducer and activator of transcription (JAK STAT) signaling pathway was activated by WHI 131, accompanied by phosphorylation of STAT3 Ser727 and dephosphorylation of STAT6. In osteoblasts, WHI 131 caused an approximately fourfold increase in alkaline phosphatase activity and Alizarin Red staining intensity. Treatment with WHI 131 increased the mRNA expression levels of genes related to osteoblast differentiation, and induced the phosphorylation of Akt, p38, and Smad1/5/8. Furthermore, 5 week old ICR mice treated with WHI 131 exhibited antiresorbing effects in a lipopolysaccharide induced calvaria bone loss model in vivo and increased bone forming activity in a calvarial bone formation model. Therefore, the results of this study show that WHI 131 plays a dual role by inhibiting osteoclast differentiation and promoting osteoblast differentiation. Thus, WHI 131 could be a useful pharmacological agent to treat osteoporosis by promoting bone growth and inhibiting resorption. (c) 2015 American Society for Bone and Mineral Research.
C1 [Cheon, Yoon Hee; Baek, Jong Min; Ahn, Sung Jun; Oh, Jaemin] Wonkwang Univ, Sch Med, Dept Anat, 344 2 Sinyong Dong, Iksan 570749, South Korea.
   [Kim, Ju Young; Jun, Hong Young; Lee, Myeung Su; Oh, Jaemin] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, Iksan, South Korea.
   [Erkhembaatar, Munkhsoyol; Kim, Min Seuk] Wonkwang Univ, Sch Dent, Dept Oral Physiol, Iksan, South Korea.
   [Lee, Myeung Su] Wonkwang Univ, Dept Internal Med, Div Rheumatol, Iksan, South Korea.
   [Lee, Myeung Su; Oh, Jaemin] Wonkwang Univ, Inst Skeletal Dis, Iksan, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University
RP Oh, J (通讯作者)，Wonkwang Univ, Sch Med, Dept Anat, 344 2 Sinyong Dong, Iksan 570749, South Korea.
EM jmoh@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
OI Erkhembaatar, Munkhsoyol/0009 0006 0855 9636
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF); Ministry of Education [NRF 2011 0023381]
FX This study was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF), and funded by the
   Ministry of Education (NRF 2011 0023381).
CR Abu Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417
   Abu Amer Y, 2001, J CLIN INVEST, V107, P1375, DOI 10.1172/JCI10530
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Bishop KA, 2009, MOL ENDOCRINOL, V23, P2095, DOI 10.1210/me.2009 0209
   Blume Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Dai S, 2011, J CELL BIOCHEM, V112, P2463, DOI 10.1002/jcb.23170
   Darwech I, 2010, J BIOL CHEM, V285, P25522, DOI 10.1074/jbc.M110.121533
   Demoulin JB, 1996, MOL CELL BIOL, V16, P4710
   Epple H, 2008, MOL CELL BIOL, V28, P3610, DOI 10.1128/MCB.00259 08
   Feuerer M, 2003, NAT MED, V9, P1151, DOI 10.1038/nm914
   Foster KE, 2010, P NATL ACAD SCI USA, V107, P13414, DOI 10.1073/pnas.1003747107
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Goldring SR, 2003, CALCIFIED TISSUE INT, V73, P97, DOI 10.1007/s00223 002 1049 y
   Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Johnston JA, 1996, J LEUKOCYTE BIOL, V60, P441, DOI 10.1002/jlb.60.4.441
   Jurlander J, 1997, BLOOD, V89, P4146, DOI 10.1182/blood.V89.11.4146
   Juskewitch JE, 2012, SCI REP UK, V2, DOI 10.1038/srep00918
   Kaneko S, 1997, CLIN EXP IMMUNOL, V109, P185, DOI 10.1046/j.1365 2249.1997.4191324.x
   Kim JH, 2009, J IMMUNOL, V183, P1862, DOI 10.4049/jimmunol.0803007
   LaBranche TP, 2012, ARTHRITIS RHEUM US, V64, P3531, DOI 10.1002/art.34649
   Lee JE, 2012, INT J MOL MED, V29, P864, DOI 10.3892/ijmm.2012.920
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Li CH, 2013, BIOCHEM BIOPH RES CO, V435, P533, DOI 10.1016/j.bbrc.2013.04.084
   Li Jiliang, 2013, JAKSTAT, V2, pe23930, DOI 10.4161/jkst.23930
   Lorenzo J, 2000, J CLIN INVEST, V106, P749, DOI 10.1172/JCI11089
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Migita K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3333
   Mitchell SA, 2009, BIOORG MED CHEM LETT, V19, P6991, DOI 10.1016/j.bmcl.2009.10.037
   Mori T, 2011, INT IMMUNOL, V23, P701, DOI 10.1093/intimm/dxr077
   Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Notarangelo LD, 2000, IMMUNOBIOLOGY, V202, P106, DOI 10.1016/S0171 2985(00)80058 3
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Pfeilschifter Johannes, 2003, Curr Osteoporos Rep, V1, P53, DOI 10.1007/s11914 003 0009 4
   Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963
   Siggelkow H, 2003, J BONE MINER RES, V18, P529, DOI 10.1359/jbmr.2003.18.3.529
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sudbeck EA, 1999, CLIN CANCER RES, V5, P1569
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Uckun FM, 2008, BIOORGAN MED CHEM, V16, P1287, DOI 10.1016/j.bmc.2007.10.066
   Uckun FM, 2002, BLOOD, V99, P4192, DOI 10.1182/blood.V99.11.4192
   UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461
   Xing LP, 2001, GENE DEV, V15, P241, DOI 10.1101/gad.840301
   Zhang ZY, 2005, BIOCHEM BIOPH RES CO, V328, P800, DOI 10.1016/j.bbrc.2005.01.019
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zupan J, 2013, BIOCHEM MEDICA, V23, P43, DOI 10.11613/BM.2013.007
NR 52
TC 20
Z9 24
U1 2
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2016
VL 31
IS 2
BP 403
EP 415
DI 10.1002/jbmr.2612
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DD8NE
UT WOS:000370182900018
PM 26255791
OA Bronze
DA 2025 08 17
ER

PT S
AU Leibbrandt, A
   Penninger, JM
AF Leibbrandt, Andreas
   Penninger, Josef M.
BE LopezLarrea, C
   DiazPena, R
TI RANKL/RANK as Key Factors for Osteoclast Development and Bone Loss in
   Arthropathies
SO MOLECULAR MECHANISMS OF SPONDYLOARTHROPATHIES
SE Advances in Experimental Medicine and Biology
LA English
DT Article
ID NF KAPPA B; TUMOR NECROSIS FACTOR; TNF FAMILY MEMBER; EXPANSILE SKELETAL
   HYPERPHOSPHATASIA; FACTOR RECEPTOR FAMILY; DENDRITIC CELL;
   DIFFERENTIATION FACTOR; INHIBITORY FACTOR; T CELLS; IDIOPATHIC
   HYPERPHOSPHATASIA
AB Osteoporosis or rheumatoid arthritis are bone diseases affecting hundreds of millions of people worldwide and thus pose a tremendous burden to health care. Ground breaking discoveries made in basic science over the last decade shed light on the molecular mechanisms of bone metabolism and bone turnover. Thereby, it became possible over the past years to devise new and promising strategies for treating such diseases. In particular, three molecules, the receptor activator of NF kappa B (RANK), its ligand RANKL and the decoy receptor of RANKL, osteoprotegerin (OPG), have been a major focus of scientists and pharmaceutical companies alike, since experiments using mice in which these genes have been inactivated unanimously established their pivotal role as central regulators of osteoclast function. RANK(L) signaling not only activates a variety of downstream signaling pathways required for osteoclast development, but crosstalk with other signaling pathways also fine tunes bone homeostasis both in normal physiology and disease. Consequently, novel drugs specifically targeting RANK RANKL and their signaling pathways in osteoclasts are expected to revolutionize the treatment of various bone diseases, such as cancer metastases, osteoporosis, or arthropathies.
C1 [Leibbrandt, Andreas; Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, A 1030 Vienna, Austria.
C3 Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of
   Molecular Biotechnology (IMBA)
RP Penninger, JM (通讯作者)，Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohr Gasse 3, A 1030 Vienna, Austria.
EM Josef.Penninger@imba.oeaw.ac.at
RI Penninger, Josef/I 6860 2013
OI Penninger, Josef/0000 0002 8194 3777
CR Abu Amer Y, 2001, J CLIN INVEST, V107, P1375, DOI 10.1172/JCI10530
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chan FKM, 2000, IMMUNITY, V13, P419, DOI 10.1016/S1074 7613(00)00041 8
   Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351
   Chesneau V, 2003, J BIOL CHEM, V278, P22331, DOI 10.1074/jbc.M302781200
   Chong B, 2003, J BONE MINER RES, V18, P2095, DOI 10.1359/jbmr.2003.18.12.2095
   Cohen SB, 2006, ARTHRITIS RHEUM, V54, pS831
   Cundy T, 2002, HUM MOL GENET, V11, P2119, DOI 10.1093/hmg/11.18.2119
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Dore R, 2006, ARTHRITIS RHEUM, V54, pS240
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Durán A, 2004, DEV CELL, V6, P303, DOI 10.1016/S1534 5807(03)00403 9
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Gonzalez Suarez E, 2007, MOL CELL BIOL, V27, P1442, DOI 10.1128/MCB.01298 06
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667
   Ikeda T, 2003, J BIOL CHEM, V278, P47217, DOI 10.1074/jbc.M304636200
   Ikeda T, 2001, ENDOCRINOLOGY, V142, P1419, DOI 10.1210/en.142.4.1419
   Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Ito S, 2002, J BIOL CHEM, V277, P6631, DOI 10.1074/jbc.M106525200
   Josien R, 1999, J IMMUNOL, V162, P2562
   Kalesnikoff J, 2004, REV PHYSIOL BIOCH P, V149, P87, DOI 10.1007/s10254 003 0016 y
   Kanazawa K, 2005, J BONE MINER RES, V20, P840, DOI 10.1359/JBMR.041225
   Kanazawa K, 2003, J BONE MINER RES, V18, P443, DOI 10.1359/jbmr.2003.18.3.443
   Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302 221
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kartsogiannis V, 1999, BONE, V25, P525, DOI 10.1016/S8756 3282(99)00214 8
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kobayashi T, 2003, IMMUNITY, V19, P353, DOI 10.1016/S1074 7613(03)00230 9
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Koseki T, 2002, CELL SIGNAL, V14, P31, DOI 10.1016/S0898 6568(01)00221 2
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Kwon BS, 1998, FASEB J, V12, P845, DOI 10.1096/fasebj.12.10.845
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890
   Lane NE, 2006, ARTHRITIS RHEUM, V54, pS225
   Laurin N, 2002, AM J HUM GENET, V70, P1582, DOI 10.1086/340731
   Lee ZH, 2000, MOL PHARMACOL, V58, P1536, DOI 10.1124/mol.58.6.1536
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092 8674(01)00237 9
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Loser K, 2006, NAT MED, V12, P1372, DOI 10.1038/nm1518
   Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Mócsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014 5793(95)00153 Z
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281
   Ross FP, 2005, IMMUNOL REV, V208, P88, DOI 10.1111/j.0105 2896.2005.00331.x
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Schlöndorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200
   Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sobacchi C, 2007, NAT GENET, V39, P960, DOI 10.1038/ng2076
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200
   Suzuki J, 2004, BIOCHEM BIOPH RES CO, V314, P1021, DOI 10.1016/j.bbrc.2003.12.191
   Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752
   Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378 1119(97)00509 X
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203
   Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556
   Wagner EF, 2002, ANN RHEUM DIS, V61, P40, DOI 10.1136/ard.61.suppl_2.ii40
   Whyte MP, 2002, J BONE MINER RES, V17, P26, DOI 10.1359/jbmr.2002.17.1.26
   Whyte MP, 2000, J BONE MINER RES, V15, P2330, DOI 10.1359/jbmr.2000.15.12.2330
   Williamson E, 2002, J IMMUNOL, V169, P3606, DOI 10.4049/jimmunol.169.7.3606
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Wong BR, 1999, J LEUKOCYTE BIOL, V65, P715, DOI 10.1002/jlb.65.6.715
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888
NR 104
TC 41
Z9 51
U1 0
U2 5
PU SPRINGER VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D 14197 BERLIN, GERMANY
SN 0065 2598
EI 2214 8019
BN 978 1 4419 0297 9
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2009
VL 649
BP 100
EP 113
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA BKB53
UT WOS:000267692500007
PM 19731623
DA 2025 08 17
ER

PT J
AU Pereira, RC
   Delany, AM
   Khouzam, NM
   Bowen, RE
   Freymiller, EG
   Salusky, IB
   Wesseling Perry, K
AF Pereira, Renata C.
   Delany, Anne M.
   Khouzam, Nadine M.
   Bowen, Richard E.
   Freymiller, Earl G.
   Salusky, Isidro B.
   Wesseling Perry, Katherine
TI Primary osteoblast like cells from patients with end stage kidney
   disease reflect gene expression, proliferation, and mineralization
   characteristics ex vivo
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE bone histomorphometry; CKD; osteoblasts; RNA
ID PARATHYROID HORMONE; IN VITRO; BONE; RECEPTOR;
   FIBROBLAST GROWTH FACTOR 23; IDENTIFICATION; PROGRESSION; OSTEOCYTES;
   PHOSPHATE; PROTEINS
AB Osteocytes regulate bone turnover and mineralization in chronic kidney disease. As osteocytes are derived from osteoblasts, alterations in osteoblast function may regulate osteoblast maturation, osteocytic transition, bone turnover, and skeletal mineralization. Thus, primary osteoblast like cells were cultured from bone chips obtained from 24 pediatric ESKD patients. RNA expression in cultured cells was compared with RNA expression in cells from healthy individuals, to RNA expression in the bone core itself, and to parameters of bone histomorphometry. Proliferation and mineralization rates of patient cells were compared with rates in healthy control cells. Associations were observed between bone osteoid accumulation, as assessed by bone histomorphometry, and bone core RNA expression of osterix, matrix gla protein, parathyroid hormone receptor 1, and RANKL. Gene expression of osteoblast markers was increased in cells from ESKD patients and signaling genes including Cyp24A1, Cyp27B1, VDR, and NHERF1 correlated between cells and bone cores. Cells from patients with high turnover renal osteodystrophy proliferated more rapidly and mineralized more slowly than did cells from healthy controls. Thus, primary osteoblasts obtained from patients With ESKD retain changes in gene expression ex vivo that are also observed in bone core specimens. Evaluation of these cells in vitro may provide further insights into the abnormal bone biology that persists, despite current therapies, in patients with ESKD.
C1 [Pereira, Renata C.; Khouzam, Nadine M.; Salusky, Isidro B.; Wesseling Perry, Katherine] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA.
   [Delany, Anne M.] Univ Connecticut, Ctr Hlth, Ctr Mol Med, Los Angeles, CA USA.
   [Bowen, Richard E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthoped Surg, Los Angeles, CA 90095 USA.
   [Freymiller, Earl G.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of Connecticut; University of California
   System; University of California Los Angeles; University of California
   Los Angeles Medical Center; David Geffen School of Medicine at UCLA;
   University of California System; University of California Los Angeles
RP Wesseling Perry, K (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, A2 383 MDCC,650 Charles Young Dr, Los Angeles, CA 90095 USA.
EM kwesseling@mednet.ucla.edu
RI Wesseling Perry, Katherine/IUO 0850 2023
FU USPHS [DK 67563, DK 35423, DK 080984]; CTSI [UL1 TR 000124]; UCLA
   Children's Discovery and Innovation Institute; Casey Lee Ball
   Foundation; American Society of Nephrology Norman Siegel foundation
FX This work was supported in part by USPHS Grants DK 67563, DK 35423,
   DK 080984, and CTSI Grant UL1 TR 000124, funds from the UCLA Children's
   Discovery and Innovation Institute, funds from the Casey Lee Ball
   Foundation, and funds from the American Society of Nephrology Norman
   Siegel foundation.
CR ANDRESS DL, 1991, KIDNEY INT, V39, P942, DOI 10.1038/ki.1991.118
   Bakkaloglu SA, 2010, CLIN J AM SOC NEPHRO, V5, P1860, DOI 10.2215/CJN.01330210
   BERESFORD JN, 1984, BIOCHIM BIOPHYS ACTA, V801, P58, DOI 10.1016/0304 4165(84)90212 5
   Bonewald L., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P331
   David V, 2013, ENDOCRINOLOGY, V154, P4469, DOI 10.1210/en.2013 1627
   Dillon JP, 2012, METHODS MOL BIOL, V816, P3, DOI 10.1007/978 1 61779 415 5_1
   Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122
   Fliser D, 2007, J AM SOC NEPHROL, V18, P2600, DOI 10.1681/ASN.2006080936
   GALLAGHER JA, 1984, ADV EXP MED BIOL, V171, P279
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Hollis BW, 1996, CLIN CHEM, V42, P586
   Isakova T, 2011, KIDNEY INT, V79, P1370, DOI 10.1038/ki.2011.47
   Lupp A, 2010, EUR J ENDOCRINOL, V162, P979, DOI 10.1530/EJE 09 0821
   MARIE PJ, 1989, J CLIN ENDOCR METAB, V69, P1166, DOI 10.1210/jcem 69 6 1166
   MARIE PJ, 1993, BONE, V14, P463, DOI 10.1016/8756 3282(93)90180 I
   Martin A, 2011, FASEB J, V25, P2551, DOI 10.1096/fj.10 177816
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pereira RC, 2009, BONE, V45, P1161, DOI 10.1016/j.bone.2009.08.008
   Picton ML, 2000, KIDNEY INT, V58, P1440, DOI 10.1046/j.1523 1755.2000.00306.x
   Portale AA, 2014, CLIN J AM SOC NEPHRO, V9, P344, DOI 10.2215/CJN.05840513
   Sabbagh Y, 2012, J BONE MINER RES, V27, P1757, DOI 10.1002/jbmr.1630
   Sánchez MC, 2001, AM J KIDNEY DIS, V37, P30, DOI 10.1053/ajkd.2001.20574
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   Sitara D, 2004, MATRIX BIOL, V23, P421, DOI 10.1016/j.matbio.2004.09.007
   Wesseling Perry K, 2012, CLIN J AM SOC NEPHRO, V7, P146, DOI 10.2215/CJN.05940611
   Wesseling Perry K, 2009, J CLIN ENDOCR METAB, V94, P511, DOI 10.1210/jc.2008 0326
NR 26
TC 26
Z9 26
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0085 2538
EI 1523 1755
J9 KIDNEY INT
JI Kidney Int.
PD MAR
PY 2015
VL 87
IS 3
BP 593
EP 601
DI 10.1038/ki.2014.347
PG 9
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA CC7FO
UT WOS:000350533300016
PM 25354236
OA Green Submitted, Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Li, DJ
   Tian, Y
   Yin, C
   Huai, Y
   Zhao, YP
   Su, PH
   Wang, X
   Pei, JW
   Zhang, KW
   Yang, CF
   Dang, K
   Jiang, SF
   Miao, ZP
   Li, M
   Hao, Q
   Zhang, G
   Qian, AR
AF Li, Dijie
   Tian, Ye
   Yin, Chong
   Huai, Ying
   Zhao, Yipu
   Su, Peihong
   Wang, Xue
   Pei, Jiawei
   Zhang, Kewen
   Yang, Chaofei
   Dang, Kai
   Jiang, Shanfeng
   Miao, Zhiping
   Li, Meng
   Hao, Qiang
   Zhang, Ge
   Qian, Airong
TI Silencing of lncRNA AK045490 Promotes Osteoblast Differentiation
   and Bone Formation via β Catenin/TCF1/Runx2 Signaling Axis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE AK045490; lncRNA; osteoblast differentiation; bone formation;
   osteoporosis; transcript factor
ID LONG NONCODING RNAS; MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION;
   WNT; MARROW; PATHWAY
AB Osteoporosis, a disease characterized by both loss of bone mass and structural deterioration of bone, is the most common reason for a broken bone among the elderly. It is known that the attenuated differentiation ability of osteogenic cells has been regarded as one of the greatest contributors to age related bone formation reduction. However, the effects of current therapies are still unsatisfactory. In this study we identify a novel long noncoding RNA AK045490 which is correlated with osteogenic differentiation and enriched in skeletal tissues of mice. In vitro analysis of bone derived mesenchymal stem cells (BMSCs) showed that AK045490 inhibited osteoblast differentiation. In vivo inhibition of AK045490 by its small interfering RNA rescued bone formation in ovariectomized osteoporosis mice model. Mechanistically, AK045490 inhibited the nuclear translocation of beta catenin and downregulated the expression of TCF1, LEF1, and Runx2. The results suggest that Lnc AK045490 suppresses beta catenin/TCF1/Runx2 signaling and inhibits osteoblast differentiation and bone formation, providing a novel mechanism of osteogenic differentiation and a potential drug target for osteoporosis.
C1 [Li, Dijie; Tian, Ye; Yin, Chong; Huai, Ying; Zhao, Yipu; Su, Peihong; Wang, Xue; Pei, Jiawei; Zhang, Kewen; Yang, Chaofei; Dang, Kai; Jiang, Shanfeng; Miao, Zhiping; Qian, Airong] Northwestern Polytech Univ, Lab Bone Metab, Key Lab Space Biosci & Biotechnol, Sch Life Sci, Xian 710072, Peoples R China.
   [Li, Dijie; Tian, Ye; Yin, Chong; Huai, Ying; Zhao, Yipu; Su, Peihong; Wang, Xue; Pei, Jiawei; Zhang, Kewen; Yang, Chaofei; Dang, Kai; Jiang, Shanfeng; Miao, Zhiping; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, Res Ctr Special Med & Hlth Syst Engn, Xian 710072, Peoples R China.
   [Li, Dijie; Tian, Ye; Yin, Chong; Huai, Ying; Zhao, Yipu; Su, Peihong; Wang, Xue; Pei, Jiawei; Zhang, Kewen; Yang, Chaofei; Dang, Kai; Jiang, Shanfeng; Miao, Zhiping; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, NPU UAB Joint Lab Bone Metab, Xian 710072, Peoples R China.
   [Li, Dijie; Zhang, Ge] Hong Kong Baptist Univ, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Sch Chinese Med, Hong Kong 999077, Peoples R China.
   [Li, Meng; Hao, Qiang] Fourth Mil Med Univ, Sch Pharm, Ctr Biotechnol, State Key Lab Canc Biol, Xian 710032, Peoples R China.
   [Zhang, Ge] Hong Kong Baptist Univ, Inst Integrated Bioinfomed & Translat Sci, Sch Chinese Med, Hong Kong 999077, Peoples R China.
C3 Northwestern Polytechnical University; Northwestern Polytechnical
   University; Northwestern Polytechnical University; Hong Kong Baptist
   University; Air Force Medical University; Hong Kong Baptist University
RP Qian, AR (通讯作者)，Northwestern Polytech Univ, Lab Bone Metab, Key Lab Space Biosci & Biotechnol, Sch Life Sci, Xian 710072, Peoples R China.; Qian, AR (通讯作者)，Northwestern Polytech Univ, Sch Life Sci, Res Ctr Special Med & Hlth Syst Engn, Xian 710072, Peoples R China.; Qian, AR (通讯作者)，Northwestern Polytech Univ, Sch Life Sci, NPU UAB Joint Lab Bone Metab, Xian 710072, Peoples R China.; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Sch Chinese Med, Hong Kong 999077, Peoples R China.; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Inst Integrated Bioinfomed & Translat Sci, Sch Chinese Med, Hong Kong 999077, Peoples R China.
EM lidijie@mail.nwpu.edu.cn; tianye@nwpu.edu.cn; yinchong42@nwpu.edu.cn;
   huai_@mail.nwpu.edu.cn; zhaoyipu@mail.nwpu.edu.cn;
   suph@mail.nwpu.edu.cn; wangxue1005@nwpu.edu.cn;
   peijiawei@mail.nwpu.edu.cn; zkw@mail.nwpu.edu.cn;
   yang2015@mail.nwpu.edu.cn; dangkaipower@hotmail.com;
   jiang2017@nwpu.edu.cn; miaozp@nwpu.edu.cn; limeng@fmmu.edu.cn;
   haosuq@fmmu.edu.cn; zhangge@hkbu.edu.hk; qianair@nwpu.edu.cn
RI Hao, Qiang/MIT 6089 2025; Zhang, Ge/N 4150 2013; Li,
   Dijie/KVB 3667 2024; li, fei/HJO 9520 2023; zhang, kewen/KXR 4680 2024
FU National Natural Science Foundation of China [NSFC31570940, BKJ17J004,
   2018SF 263]; Fundamental Research Funds for the Central Universities
   [3102018zy053]; Shanxi Provincial Key RD Program [2018KWZ 10]; Shanxi
   Postdoctoral Science Foundation [2017BSHEDZZ13]
FX This work is supported by National Natural Science Foundation of China
   (NSFC31570940), BKJ17J004, 2018SF 263, Fundamental Research Funds for
   the Central Universities (3102018zy053), Shanxi Provincial Key R&D
   Program (2018KWZ 10) and Shanxi Postdoctoral Science Foundation
   (2017BSHEDZZ13).
CR Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Feng L, 2018, MOL THER NUCL ACIDS, V11, P345, DOI 10.1016/j.omtn.2018.03.004
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gillespie JR, 2013, ENDOCRINOLOGY, V154, P3702, DOI 10.1210/en.2013 1155
   Hendrickx G, 2015, NAT REV RHEUMATOL, V11, P462, DOI 10.1038/nrrheum.2015.48
   Hu LF, 2018, J CELL PHYSIOL, V233, P1574, DOI 10.1002/jcp.26059
   Hu LF, 2015, BMB REP, V48, P583, DOI 10.5483/BMBRep.2015.48.10.098
   Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225
   Huynh NPT, 2017, CONNECT TISSUE RES, V58, P116, DOI 10.1080/03008207.2016.1194406
   Issa YA, 2016, EUR J HUM GENET, V24, P1430, DOI 10.1038/ejhg.2016.29
   Kour S, 2016, AGEING RES REV, V26, P1, DOI 10.1016/j.arr.2015.12.001
   Li BZ, 2019, STEM CELLS, V37, P247, DOI 10.1002/stem.2925
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Li CL, 2017, NAT CELL BIOL, V19, P106, DOI 10.1038/ncb3464
   Li DJ, 2020, ENDOCR METAB IMMUNE, V20, P50, DOI 10.2174/1871530319666190904161707
   Li ZQ, 2018, INT J MED SCI, V15, P1415, DOI 10.7150/ijms.26741
   Liao JY, 2017, ONCOTARGET, V8, P53581, DOI 10.18632/oncotarget.18655
   Liu YB, 2019, J CELL MOL MED, V23, P3855, DOI 10.1111/jcmm.14229
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu YF, 2017, FASEB J, V31, P954, DOI 10.1096/fj.201600722R
   Mulati M, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115076
   Nakamura T, 2008, J CELL MOL MED, V12, P391, DOI 10.1111/j.1582 4934.2007.00201.x
   Silva AM, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0048 9
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Xu Y, 2015, MOL MED REP, V12, P7233, DOI 10.3892/mmr.2015.4415
   Yang QL, 2018, STEM CELL REV REP, V14, P297, DOI 10.1007/s12015 018 9801 5
   Yin C, 2019, J CELL PHYSIOL, V234, P11524, DOI 10.1002/jcp.27815
   Zhang JL, 2018, INT J MOL MED, V41, P213, DOI 10.3892/ijmm.2017.3215
   Zhang WY, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0485 6
   Zhang Y, 2018, HUM GENE THER, V29, P259, DOI 10.1089/hum.2017.153
NR 32
TC 36
Z9 41
U1 0
U2 39
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2019
VL 20
IS 24
AR 6229
DI 10.3390/ijms20246229
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA KB9XE
UT WOS:000506840100123
PM 31835596
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Khedgikar, V
   Kushwaha, P
   Gautam, J
   Verma, A
   Changkija, B
   Kumar, A
   Sharma, S
   Nagar, GK
   Singh, D
   Trivedi, PK
   Sangwan, NS
   Mishra, PR
   Trivedi, R
AF Khedgikar, V.
   Kushwaha, P.
   Gautam, J.
   Verma, A.
   Changkija, B.
   Kumar, A.
   Sharma, S.
   Nagar, G. K.
   Singh, D.
   Trivedi, P. K.
   Sangwan, N. S.
   Mishra, P. R.
   Trivedi, R.
TI Withaferin A: a proteasomal inhibitor promotes healing after injury and
   exerts anabolic effect on osteoporotic bone
SO CELL DEATH & DISEASE
LA English
DT Article
DE osteoporosis; proteasome; bone formation; withaferin; drill hole; bone
   healing; micro CT
ID NF KAPPA B; NECROSIS FACTOR ALPHA; E3 UBIQUITIN LIGASE; DRILL HOLE
   INJURY; MORPHOGENETIC PROTEINS; IN VIVO; OSTEOCLAST DIFFERENTIATION;
   OVARIECTOMIZED RATS; DALBERGIA SISSOO; OSTEOBLASTS
AB Withania somnifera or Ashwagandha is a medicinal herb of Ayurveda. Though the extract and purified molecules, withanolides, from this plant have been shown to have different pharmacological activities, their effect on bone formation has not been studied. Here, we show that one of the withanolide, withaferin A (WFA) acts as a proteasomal inhibitor (PI) and binds to specific catalytic beta subunit of the 20S proteasome. It exerts positive effect on osteoblast by increasing osteoblast proliferation and differentiation. WFA increased expression of osteoblast specific transcription factor and mineralizing genes, promoted osteoblast survival and suppressed inflammatory cytokines. In osteoclast, WFA treatment decreased osteoclast number directly by decreasing expression of tartarate resistant acid phosphatase and receptor activator of nuclear factor kappa B (RANK) and indirectly by decreasing osteoprotegrin/RANK ligand ratio. Our data show that in vitro treatment of WFA to calvarial osteoblast cells decreased expression of E3 ubiquitin ligase, Smad ubiquitin regulatory factor 2 (Smurf2), preventing degradation of Runt related transcription factor 2 (RunX2) and relevant Smad proteins, which are phosphorylated by bone morphogenetic protein 2. Increased Smurf2 expression due to exogenous treatment of tumor necrosis factor alpha (TNF alpha) to primary osteoblast cells was decreased by WFA treatment. This was corroborated by using small interfering RNA against Smurf2. Further, WFA also blocked nuclear factor kappa B (NF kB) signaling as assessed by tumor necrosis factor stimulated nuclear translocation of p65 subunit of NF kB. Overall data show that in vitro proteasome inhibition by WFA simultaneously promoted osteoblastogenesis by stabilizing RunX2 and suppressed osteoclast differentiation, by inhibiting osteoclastogenesis. Oral administration of WFA to osteopenic ovariectomized mice increased osteoprogenitor cells in the bone marrow and increased expression of osteogenic genes. WFA supplementation improved trabecular micro architecture of the long bones, increased biomechanical strength parameters of the vertebra and femur, decreased bone turnover markers (osteocalcin and TNF alpha) and expression of skeletal osteoclastogenic genes. It also increased new bone formation and expression of osteogenic genes in the femur bone as compared with vehicle groups (Sham) and ovariectomy (OVx), Bortezomib (known PI), injectible parathyroid hormone and alendronate (FDA approved drugs). WFA promoted the process of cortical bone regeneration at drill holes site in the femur mid diaphysis region and cortical gap was bridged with woven bone within 11 days of both estrogen sufficient and deficient (ovariectomized, Ovx) mice. Together our data suggest that WFA stimulates bone formation by abrogating proteasomal machinery and provides knowledge base for its clinical evaluation as a bone anabolic agent.
C1 [Khedgikar, V.; Kushwaha, P.; Gautam, J.; Changkija, B.; Kumar, A.; Nagar, G. K.; Singh, D.; Trivedi, R.] Cent Drug Res Inst, CSIR, Div Endocrinol, Lucknow 226001, Uttar Pradesh, India.
   [Khedgikar, V.; Kushwaha, P.; Gautam, J.; Changkija, B.; Kumar, A.; Nagar, G. K.; Singh, D.; Trivedi, R.] Cent Drug Res Inst, CSIR, Ctr Res Anabol Skeletal Targets Hlth & Illness AS, Lucknow 226001, Uttar Pradesh, India.
   [Verma, A.; Sharma, S.; Mishra, P. R.] Cent Drug Res Inst, CSIR, Div Pharmaceut, Lucknow 226001, Uttar Pradesh, India.
   [Trivedi, P. K.] Natl Bot Res Inst, CSIR, Plant Gene Express Div, Lucknow 226001, Uttar Pradesh, India.
   [Sangwan, N. S.] Cent Inst Med & Aromat Plants, CSIR, Div Plant Biol, Lucknow 226001, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI); Council of Scientific & Industrial Research (CSIR)  
   India; CSIR   Central Drug Research Institute (CDRI); Council of
   Scientific & Industrial Research (CSIR)   India; CSIR   National
   Botanical Research Institute (NBRI); Council of Scientific & Industrial
   Research (CSIR)   India; CSIR   Central Institute of Medicinal &
   Aromatic Plants (CIMAP)
RP Trivedi, R (通讯作者)，Cent Drug Res Inst, CSIR, Div Endocrinol, Lucknow 226001, Uttar Pradesh, India.
EM ritu_trivedi@cdri.res.in
RI Verma, Ashwni Kumar/CAI 3987 2022; Verma, Ashwni/CAI 3987 2022; Sangwan,
   Neelam/AAF 4010 2021; Mishra, Prabhat/C 3814 2009
OI Verma, Ashwni Kumar/0000 0003 3717 0233; Sangwan, Prof. Dr.
   Neelam/0000 0002 7766 5428; sangwan, Neelam singh/0000 0003 2761 702X;
   Gautam, Jyoti/0000 0003 2961 9547; Kumar, Professor
   Amit/0000 0002 5913 4308; 
FU CSIR [BSC0201]; Council of Scientific and Industrial Research, New
   Delhi, Govt. of India under NMITLI scheme; BIOCERAM [ESC0103];
   University Grants Commission, New Delhi, Govt. of India; Council of
   Scientific and Industrial Research CSIR, New Delhi, Govt. of India
FX Grant from CSIR (BSC0201) is acknowledged. PKT and NSS acknowledge
   Council of Scientific and Industrial Research, New Delhi, Govt. of
   India, for providing the financial support to carry out this work under
   NMITLI scheme. PRM acknowledge funding from BIOCERAM (ESC0103). VK, JG
   acknowledge University Grants Commission, New Delhi, Govt. of India for
   fellowship, PK acknowledge Council of Scientific and Industrial Research
   CSIR, New Delhi, Govt. of India for fellowship. This is CDRI
   communication number 156/2013/RT.
CR Ahlborg HG, 2003, NEW ENGL J MED, V349, P327, DOI 10.1056/NEJMoa022464
   Ariyoshi W, 2008, J CELL BIOCHEM, V103, P1707, DOI 10.1002/jcb.21559
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Cao JJ, 2011, J ORTHOP SURG RES, V6, DOI 10.1186/1749 799X 6 30
   Cao Y, 2013, CELL MOL LIFE SCI, V70, P2305, DOI 10.1007/s00018 012 1170 7
   Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200
   Chen AL, 2004, J ORTHOP RES, V22, P1188, DOI 10.1016/j.orthres.2004.02.013
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Dixit P, 2012, BIOORG MED CHEM LETT, V22, P890, DOI 10.1016/j.bmcl.2011.12.036
   Furuya Y, 2011, J BIOL CHEM, V286, P37023, DOI 10.1074/jbc.M111.246280
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Gautam J, 2012, PHYTOMEDICINE, V19, P1134, DOI 10.1016/j.phymed.2012.07.005
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Grover A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471 2164 11 S4 S15
   Gupta GK, 2013, NANOMEDICINE UK, V8, P757, DOI [10.2217/NNM.12.171, 10.2217/nnm.12.171]
   Gupta P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062714
   He YX, 2011, BONE, V48, P1388, DOI 10.1016/j.bone.2011.03.720
   Hie M, 2010, INT J MOL MED, V26, P611, DOI 10.3892/ijmm_00000506
   Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692
   Ito Y, 2011, BIOCHEM BIOPH RES CO, V407, P225, DOI 10.1016/j.bbrc.2011.03.003
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Khedgikar V, 2012, MENOPAUSE, V19, P1336, DOI 10.1097/gme.0b013e318256b6ae
   Kitson RP, 2000, IN VIVO, V14, P265
   Kumar A, 2012, EUR J PHARM BIOPHARM, V82, P508, DOI 10.1016/j.ejpb.2012.08.001
   Kumar A, 2010, PROTEOMICS, V10, P1730, DOI 10.1002/pmic.200900666
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   LI YP, 1992, J IMMUNOL, V148, P788
   Maitra R, 2009, J INFLAMM LOND, V6, DOI 10.1186/1476 9255 6 15
   Majewski PM, 2010, J BIOL CHEM, V285, P34828, DOI 10.1074/jbc.M110.152868
   Matsuda H, 2001, BIOORGAN MED CHEM, V9, P1499, DOI 10.1016/S0968 0896(01)00024 4
   Mohamed AM, 2003, NEW ENGL J MED, V349, P1671
   Mohan Royce, 2004, Angiogenesis, V7, P115, DOI 10.1007/s10456 004 1026 3
   Motyl KJ, 2012, J CELL PHYSIOL, V227, P1326, DOI 10.1002/jcp.22844
   Murray SS, 2002, METABOLISM, V51, P1153, DOI 10.1053/meta.2002.34706
   Nagashima M, 2005, BONE, V36, P502, DOI 10.1016/j.bone.2004.11.013
   Pacifici R, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2126
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Sangwan RS, 2006, US Patent, Patent No. [2006;7:870, 20067870]
   Sashidhara KV, 2013, J MED CHEM, V56, P109, DOI 10.1021/jm301281e
   Sévère N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.217
   Shapovalov Y, 2010, INT J CANCER, V127, P67, DOI 10.1002/ijc.25024
   Sharan K, 2011, J BONE MINER RES, V26, P2096, DOI 10.1002/jbmr.434
   Siddiqui JA, 2011, OSTEOPOROSIS INT, V22, P3013, DOI 10.1007/s00198 010 1519 4
   TAKANOYAMAMOTO T, 1990, P NATL ACAD SCI USA, V87, P2172, DOI 10.1073/pnas.87.6.2172
   Tanaka K, 2010, BONE, V47, P1006, DOI 10.1016/j.bone.2010.08.016
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Trémollieres FA, 2001, OSTEOPOROSIS INT, V12, P385, DOI 10.1007/s001980170107
   Trivedi R, 2010, CURR MOL MED, V10, P14, DOI 10.2174/156652410791065372
   Trivedi R, 2010, EXPERT OPIN INV DRUG, V19, P995, DOI 10.1517/13543784.2010.501077
   Trivedi R, 2009, MOL CELL ENDOCRINOL, V302, P86, DOI 10.1016/j.mce.2009.01.011
   Tyagi AM, 2010, MOL CELL ENDOCRINOL, V325, P101, DOI 10.1016/j.mce.2010.05.016
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Wertz IE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003350
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Yang HJ, 2007, MOL PHARMACOL, V71, P426, DOI 10.1124/mol.106.030015
   Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974
NR 60
TC 113
Z9 119
U1 2
U2 30
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG
PY 2013
VL 4
AR e778
DI 10.1038/cddis.2013.294
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 214PK
UT WOS:000324146000035
PM 23969857
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Grassi, F
   Tyagi, AM
   Calvert, JW
   Gambari, L
   Walker, LD
   Yu, MC
   Robinson, J
   Li, JY
   Lisignoli, G
   Vaccaro, C
   Adams, J
   Pacifici, R
AF Grassi, Francesco
   Tyagi, Abdul Malik
   Calvert, John W.
   Gambari, Laura
   Walker, Lindsey D.
   Yu, Mingcan
   Robinson, Jerid
   Li, Jau Yi
   Lisignoli, Gina
   Vaccaro, Chiara
   Adams, Jonathan
   Pacifici, Roberto
TI Hydrogen Sulfide Is a Novel Regulator of Bone Formation Implicated in
   the Bone Loss Induced by Estrogen Deficiency
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE HYDROGEN SULFIDE; OSTEOPOROSIS; OVARIECTOMY; BONE LOSS; WNT SIGNALING
ID CYSTATHIONINE GAMMA LYASE; BETA SYNTHASE DEFICIENCY; STEM CELL FUNCTION;
   PARATHYROID HORMONE; ANABOLIC ACTIVITY; INVOLUTIONAL OSTEOPOROSIS;
   OSTEOBLAST PROGENITORS; INTERMITTENT PTH; OXIDATIVE STRESS;
   RECEPTOR ALPHA
AB Hydrogen sulfide (H2S) is a gasotransmitter known to regulate bone formation and bone mass in unperturbed mice. However, it is presently unknown whether H2S plays a role in pathologic bone loss. Here we show that ovariectomy (ovx), a model of postmenopausal bone loss, decreases serum H2S levels and the bone marrow (BM) levels of two key H2S generating enzymes, cystathione beta synthase (CBS) and cystathione gamma lyase (CSE). Treatment with the H2S donor GYY4137 (GYY) normalizes serum H2S in ovx mice, increases bone formation, and completely prevents the loss of trabecular bone induced by ovx. Mechanistic studies revealed that GYY increases murine osteoblastogenesis by activating Wnt signaling through increased production of the Wnt ligands Wnt16, Wnt2b, Wnt6, and Wnt10b in the BM. Moreover, in vitro treatment with 17 beta estradiol upregulates the expression of CBS and CSE in human BM stromal cells (hSCs), whereas an H2S releasing drug induces osteogenic differentiation of hSCs. In summary, regulation of H2S levels is a novel mechanism by which estrogen stimulates osteoblastogenesis and bone formation in mice and human cells. Blunted production of H2S contributes to ovx induced bone loss in mice by limiting the compensatory increase in bone formation elicited by ovx. Restoration of H2S levels is a potential novel therapeutic approach for postmenopausal osteoporosis. (C) 2015 American Society for Bone and Mineral Research.
C1 [Grassi, Francesco] Ist Ortoped Rizzoli, Lab Ramses, Bologna, Italy.
   [Tyagi, Abdul Malik; Walker, Lindsey D.; Yu, Mingcan; Robinson, Jerid; Li, Jau Yi; Vaccaro, Chiara; Adams, Jonathan; Pacifici, Roberto] Emory Univ, Dept Med, Div Endocrinol Metab & Lipids, 101 Woodruff Circle,Room 1309, Atlanta, GA 30322 USA.
   [Calvert, John W.] Emory Univ, Dept Surg, Div Cardiothorac Surg, Atlanta, GA 30322 USA.
   [Gambari, Laura; Lisignoli, Gina] Ist Ortoped Rizzoli, Lab Immunoreumatol & Rigeneraz Tissutale, Bologna, Italy.
   [Pacifici, Roberto] Emory Univ, Immunol & Mol Pathogenesis Program, Atlanta, GA 30322 USA.
C3 IRCCS Istituto Ortopedico Rizzoli; Emory University; Emory University;
   IRCCS Istituto Ortopedico Rizzoli; Emory University
RP Pacifici, R (通讯作者)，Emory Univ, Dept Med, Div Endocrinol Metab & Lipids, 101 Woodruff Circle,Room 1309, Atlanta, GA 30322 USA.
EM roberto.pacifici@emory.edu
RI ; Grassi, Francesco/AAE 2443 2021; Lisignoli, Gina/K 4384 2016; Malik,
   Abdul/AAX 5715 2020; Calvert, John/F 4497 2014; yang, min/H 5792 2011;
   Gambari, Laura/K 4431 2018
OI Grassi, Francesco/0000 0002 5127 9561; Lisignoli,
   Gina/0000 0003 2837 9967; Malik, Abdul/0000 0001 9012 5779; Gambari,
   Laura/0000 0001 8126 5040
FU National Institutes of Health [DK91780, DK007298, RR028009, AR061453];
   Italian Ministry of Health [RF PE 2011 02348395]; Spinner
FX This study was supported by grants from the National Institutes of
   Health (DK91780, DK007298, and RR028009) and by grant 'Ricerca
   Finalizzata' from the Italian Ministry of Health (RF PE 2011 02348395).
   JYL was supported by a grant from the National Institutes of Health
   (AR061453). LG was supported by a fellowship granted by Spinner 2013.
CR Abe K, 1996, J NEUROSCI, V16, P1066
   Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Bedi B, 2012, P NATL ACAD SCI USA, V109, pE725, DOI 10.1073/pnas.1120735109
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Bodine PVN, 2005, J CELL BIOCHEM, V96, P1212, DOI 10.1002/jcb.20599
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Calvert JW, 2009, CIRC RES, V105, P365, DOI 10.1161/CIRCRESAHA.109.199919
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Chen YH, 2005, CHEST, V128, P3205, DOI 10.1378/chest.128.5.3205
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Di Gregorio GB, 2001, J CLIN INVEST, V107, P803, DOI 10.1172/JCI11653
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   Gambari L, 2014, PHARMACOL RES, V87, P99, DOI 10.1016/j.phrs.2014.06.014
   Gao Y, 2008, CELL METAB, V8, P132, DOI 10.1016/j.cmet.2008.07.001
   Hine C, 2015, CELL, V160, P132, DOI 10.1016/j.cell.2014.11.048
   Ishigami M, 2009, ANTIOXID REDOX SIGN, V11, P205, DOI [10.1089/ars.2008.2132, 10.1089/ARS.2008.2132]
   Jackson A, 2005, BONE, V36, P585, DOI 10.1016/j.bone.2005.01.007
   Jain SK, 2010, ANTIOXID REDOX SIGN, V12, P1333, DOI 10.1089/ars.2009.2956
   Jilka RL, 1998, J CLIN INVEST, V101, P1942, DOI 10.1172/JCI1039
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04 1815fje
   Kimura Y, 2010, ANTIOXID REDOX SIGN, V12, P1, DOI 10.1089/ars.2008.2282
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261
   Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984
   Lewis JR, 2006, INJURY, V37, P698, DOI 10.1016/j.injury.2006.04.121
   Li JY, 2014, J BONE MINER RES, V29, P43, DOI 10.1002/jbmr.2044
   Li JY, 2013, BLOOD, V122, P2346, DOI 10.1182/blood 2013 03 487801
   Li JY, 2011, P NATL ACAD SCI USA, V108, P768, DOI 10.1073/pnas.1013492108
   Li L, 2008, CIRCULATION, V117, P2351, DOI 10.1161/CIRCULATIONAHA.107.753467
   Li L, 2011, ANNU REV PHARMACOL, V51, P169, DOI 10.1146/annurev pharmtox 010510 100505
   Li L, 2009, FREE RADICAL BIO MED, V47, P103, DOI 10.1016/j.freeradbiomed.2009.04.014
   Liu Y, 2014, CELL STEM CELL, V15, P66, DOI 10.1016/j.stem.2014.03.005
   Liu Z, 2013, BRIT J PHARMACOL, V169, P1795, DOI 10.1111/bph.12246
   Manferdini C, 2011, J CELL PHYSIOL, V226, P2675, DOI 10.1002/jcp.22618
   Mani S, 2013, CIRCULATION, V127, P2523, DOI 10.1161/CIRCULATIONAHA.113.002208
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Martin Millan M, 2010, MOL ENDOCRINOL, V24, P323, DOI 10.1210/me.2009 0354
   McLean RR, 2004, NEW ENGL J MED, V350, P2042, DOI 10.1056/NEJMoa032739
   Mirandola P, 2007, J CELL PHYSIOL, V213, P826, DOI 10.1002/jcp.21151
   MUDD SH, 1985, AM J HUM GENET, V37, P1
   Nagai Y, 2004, FASEB J, V18, P557, DOI 10.1096/fj.03 1052fje
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Namekata K, 2004, J BIOL CHEM, V279, P52961, DOI 10.1074/jbc.M406820200
   Nicholson CK, 2013, ARTERIOSCL THROM VAS, V33, P744, DOI 10.1161/ATVBAHA.112.300484
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   RIGGS BL, 1983, AM J MED, V75, P899, DOI 10.1016/0002 9343(83)90860 4
   RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605
   Robert K, 2005, ANAT REC PART A, V282A, P1, DOI 10.1002/ar.a.20145
   Robert K, 2004, ANAT REC PART A, V280A, P1072, DOI 10.1002/ar.a.20082
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Tawfeek H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012290
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Tobimatsu T, 2006, ENDOCRINOLOGY, V147, P2583, DOI 10.1210/en.2005 1627
   Tower RJ, 2015, BONE, V74, P171, DOI 10.1016/j.bone.2015.01.009
   van Meurs JBJ, 2004, NEW ENGL J MED, V350, P2033, DOI 10.1056/NEJMoa032546
   Vandiver MS, 2012, J MOL MED, V90, P255, DOI 10.1007/s00109 012 0873 4
   Wang KQ, 2013, CIRCULATION, V127, P2514, DOI 10.1161/CIRCULATIONAHA.113.001631
   Wang YF, 2006, BIOCHEM BIOPH RES CO, V345, P851, DOI 10.1016/j.bbrc.2006.04.162
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yang GD, 2008, SCIENCE, V322, P587, DOI 10.1126/science.1162667
   Yusuf M, 2005, BIOCHEM BIOPH RES CO, V333, P1146, DOI 10.1016/j.bbrc.2005.06.021
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zanardo RCO, 2006, FASEB J, V20, P2118, DOI 10.1096/fj.06 6270fje
   Zhao WM, 2002, AM J PHYSIOL HEART C, V283, pH474, DOI 10.1152/ajpheart.00013.2002
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
NR 70
TC 92
Z9 105
U1 2
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2016
VL 31
IS 5
BP 949
EP 963
DI 10.1002/jbmr.2757
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DN7PX
UT WOS:000377270400005
PM 26614970
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Baek, JM
   Kwak, SC
   Yoon, KH
   Kim, JY
   Lee, MS
AF Baek, Jong Min
   Kwak, Sung Chul
   Yoon, Kwon Ha
   Kim, Ju Young
   Lee, Myeung Su
TI Role of ANTXR1 in the regulation of RANKL induced osteoclast
   differentiation and function
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE ANTXR1; Bone; Osteoclast; Osteoporosis; Angiogenesis
ID NF KAPPA B; ANTHRAX TOXIN; BONE LOSS; RECEPTOR; EXPRESSION; MECHANISMS;
   DENOSUMAB; AKT
AB Anthrax toxin receptor 1 (ANTXR1) is a transmembrane protein with an extracellular domain which is deeply associated with the process of bone formation and plays an important role in angiogenesis. However, there have been no reports investigating the effects of ANTXR1 on bone metabolism mediated by the two types of bone cells, osteoclasts, and osteoblasts. The aim of this study is to reveal the role of ANTXR1 in the differentiation and function of osteoclasts and osteoblasts. We found that ANTXR1 positively regulated the receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation and bone resorption with no effects on osteoblast differentiation by performing gain  and loss of function studies. During ANTXR1 mediated regulation of osteoclastogenesis, phosphorylation of early signal transducers such as c Jun N terminal kinase (INK), Akt, inhibitor of kappa B (l kappa B), and phospholipase C gamma 2 (PLC gamma 2) was affected, which in turn altered the mRNA and protein levels of c Fos and nuclear factor of activated T cells cytoplasmic 1 (NFATc1). In addition, genetic manipulation of ANTXR1 in bone marrow macrophages (BMMs) modulated the capillary like tube formation in HUVECs via secretion of two angiogenic factors, matrix metalloproteinase 9 (MMP 9) and vascular endothelial growth factor A (VEGF A). These results elucidated the importance of ANTXR1 in osteoclast differentiation and functional activity, as well as, osteoclast mediated angiogenesis of endothelial cells. Taken together, we propose that ANTXR1 might be a promising candidate for gene therapy for bone metabolic diseases and further, might potentially serve as an important biomarker in the field of bone metastasis associated with vascularization. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Baek, Jong Min; Kwak, Sung Chul] Wonkwang Univ, Sch Med, Dept Anat, 460 Iksandae Ro, Iksan 570749, Jeonbuk, South Korea.
   [Baek, Jong Min] Hanyang Univ, HUONS Res Ctr, ERICA Campus, Ansan 15588, South Korea.
   [Yoon, Kwon Ha] Wonkwang Univ, Sch Med, Dept Radiol, 460 Iksandae Ro, Iksan 570749, Jeonbuk, South Korea.
   [Yoon, Kwon Ha; Kim, Ju Young] Wonkwang Univ Hosp, Med Convergence Res Ctr, 460 Iksandae Ro, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Myeung Su] Wonkwang Univ, Dept Internal Med, Div Rheumatol, 460 Iksandae Ro, Iksan 570749, Jeonbuk, South Korea.
C3 Wonkwang University; Hanyang University; Wonkwang University; Wonkwang
   University; Wonkwang University
RP Kim, JY (通讯作者)，Wonkwang Univ Hosp, Med Convergence Res Ctr, 460 Iksandae Ro, Iksan 570749, Jeonbuk, South Korea.; Lee, MS (通讯作者)，Wonkwang Univ, Sch Med, Dept Internal Med, Div Rheumatol, 460 Iksandae Ro, Iksan 570749, Jeonbuk, South Korea.
EM kimjy1014@gmail.com; ckhlms@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
OI Kim, Ju Young/0000 0002 4493 0264
FU Basic Science Research Program through the National Research Foundation
   of Korea   Ministry of Education [NRF 2015R1A2A2A01005899,
   NRF 2018R1D1A1B07049679]
FX This study was supported by a grant from the Basic Science Research
   Program through the National Research Foundation of Korea funded by the
   Ministry of Education (NRF 2015R1A2A2A01005899)
   (NRF 2018R1D1A1B07049679).
CR An KC, 2016, ASIAN SPINE J, V10, P787, DOI 10.4184/asj.2016.10.4.787
   Baek JM, 2018, EXP MOL MED, V50, DOI 10.1038/s12276 018 0076 3
   Bell SE, 2001, J CELL SCI, V114, P2755
   Besschetnova TY, 2015, MATRIX BIOL, V42, P56, DOI 10.1016/j.matbio.2014.12.002
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999
   Cackowski FC, 2010, BLOOD, V115, P140, DOI 10.1182/blood 2009 08 237628
   Cauley JA, 2013, J GERONTOL A BIOL, V68, P1243, DOI 10.1093/gerona/glt093
   Chaudhary A, 2012, CANCER CELL, V21, P212, DOI 10.1016/j.ccr.2012.01.004
   Chitre M, 2011, AM J HEALTH SYST PH, V68, P1409, DOI 10.2146/ajhp100493
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Hotchkiss KA, 2005, EXP CELL RES, V305, P133, DOI 10.1016/j.yexcr.2004.12.025
   Idris AI, 2010, FASEB J, V24, P4545, DOI 10.1096/fj.10 164095
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nanda A, 2004, CANCER RES, V64, P817, DOI 10.1158/0008 5472.CAN 03 2408
   Nelson ER, 2013, BONE, V53, P42, DOI 10.1016/j.bone.2012.11.011
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Raisz LG, 2001, J BONE MINER RES, V16, P1948, DOI 10.1359/jbmr.2001.16.11.1948
   Roodman GD, 2006, ANN NY ACAD SCI, V1068, P100, DOI 10.1196/annals.1346.013
   St Croix B, 2000, SCIENCE, V289, P1197
   Topini C, 2014, CLIN CASES MINER BON, V11, P129, DOI 10.11138/ccmbm/2014.11.2.129
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang QL, 2008, MATRIX BIOL, V27, P589, DOI 10.1016/j.matbio.2008.06.005
   Young JAT, 2007, ANNU REV BIOCHEM, V76, P243, DOI 10.1146/annurev.biochem.75.103004.142728
   Zaheer S, 2015, EXPERT OPIN DRUG MET, V11, P461, DOI 10.1517/17425255.2015.1000860
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
NR 28
TC 10
Z9 10
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 5
PY 2019
VL 510
IS 2
BP 296
EP 302
DI 10.1016/j.bbrc.2019.01.094
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HM1TD
UT WOS:000459235000018
PM 30686531
DA 2025 08 17
ER

PT J
AU Martínez, SB
   Cuéllar, CN
   Vila, CN
   Weiss, EP
   Romanya, RP
   de Velasco, ADF
   de Teijeiro, ME
   de Vera, JLDP
   Perez, IR
   Sánchez Pérez, A
   Zamorano León, JJ
   López Farré, A
   Alonso, MIGH
   Cuéllar, IN
AF Bacian Martinez, Sandra
   Navarro Cuellar, Carlos
   Navarro Vila, Carlos
   Palacios Weiss, Edurne
   Pujol Romanya, Roser
   Fernandez de Velasco, Alvaro del Amo
   Escrig de Teijeiro, Margarita
   del Castillo Pardo de Vera, Jose Luis
   Rodriguez Perez, Irene
   Sanchez Perez, Arturo
   Zamorano Leon, Jose J.
   Lopez Farre, Antonio
   Garcia Hidalgo Alonso, Maria Isabel
   Navarro Cuellar, Ignacio
TI Intraosseous Squamous Cell Carcinoma Associated with Denosumab Induced
   Osteonecrosis of the Jaw
SO APPLIED SCIENCES BASEL
LA English
DT Article
DE denosumab; medication related osteonecrosis of the jaw (MRNOJ); primary
   intraosseous squamous cell carcinoma
ID MEDICATION RELATED OSTEONECROSIS; ZOLEDRONIC ACID; CANCER
AB Medication related osteonecrosis of the jaw (MRONJ) has been associated with the use of different drugs administered in the treatment of malignant neoplasms or metastases and in antiresorptive therapies. Since 2010, denosumab, a monoclonal antibody whose mechanism of action is to prevent the activation of the RANK receptor on the surface of osteoclasts, has been associated with osteonecrosis of the jaw. Primary intraosseous squamous cell carcinoma (PIOSCC) is a rare neoplasm characterised by the presence of squamous cells within the maxillary or mandibular bone without an initial clinical association with the oral mucosa. We present a case of a PIOSCC in an osteonecrosis of the jaw related to a patient who received antiresorptive treatment with denosumab outlining the clinical and histopathological features of MRONJ and PIOSCC.
C1 [Bacian Martinez, Sandra; Navarro Cuellar, Carlos; Navarro Vila, Carlos; Palacios Weiss, Edurne; Pujol Romanya, Roser; Fernandez de Velasco, Alvaro del Amo; Escrig de Teijeiro, Margarita; del Castillo Pardo de Vera, Jose Luis; Navarro Cuellar, Ignacio] Hosp Univ HLA Mondoa, Maxillofacial Surg Dept, Madrid 28008, Spain.
   [Rodriguez Perez, Irene] Hosp Univ HLA Moncloa, Pathol Dept, Madrid 28008, Spain.
   [Sanchez Perez, Arturo] Murcia Univ, Fac Med, Murcia 30008, Spain.
   [Zamorano Leon, Jose J.; Lopez Farre, Antonio] Univ Complutense Madrid, Fac Med, Madrid 28040, Spain.
   [Garcia Hidalgo Alonso, Maria Isabel] Hosp Puerta de Hierro, Radiol Dept, Madrid 28222, Spain.
C3 University of Murcia; Complutense University of Madrid; Hospital Puerta
   de Hierro Majadahonda
RP Cuéllar, CN (通讯作者)，Hosp Univ HLA Mondoa, Maxillofacial Surg Dept, Madrid 28008, Spain.
EM sbacian@gmail.com; cnavarrocuellar@gmail.com; hazamachado2@gmail.com;
   edurne.palacios@gmail.com; roserpujol@gmail.com; alvaro_delamo@yahoo.es;
   margaritaescrig@gmail.com; delcastillo6@hotmail.com;
   irodriguez@analizalab.com; arturosa@um.es; josej.zamorano@gmail.com;
   ajlf@telefonica.net; mabelgha@gmail.com; nnavcu@hotmail.com
RI ; Zamorano Leon, Jose/K 2118 2013; Sánchez, Arturo/JAC 4015 2023
OI Navarro Cuellar, Carlos/0000 0001 9869 9240; ZAMORANO LEON, JOSE
   JAVIER/0000 0003 0686 4208; Sanchez Perez, Arturo/0000 0002 1045 5119; 
CR Boquete Castro A, 2016, CLIN ORAL IMPLAN RES, V27, P367, DOI 10.1111/clr.12556
   Diaz Reverand Susan A., 2018, Rev Esp Cirug Oral y Maxilofac, V40, P104, DOI 10.1016/j.maxilo.2017.06.001
   Henry D, 2014, SUPPORT CARE CANCER, V22, P679, DOI 10.1007/s00520 013 2022 1
   Li K, 2019, INT J ORAL MAX SURG, V48, P157, DOI 10.1016/j.ijom.2018.07.019
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mücke T, 2016, SEMIN MUSCULOSKEL R, V20, P305, DOI 10.1055/s 0036 1592367
   Owosho AA, 2016, J CRANIO MAXILL SURG, V44, P1047, DOI 10.1016/j.jcms.2016.05.013
   Qaisi M, 2016, CASE REP DENT, V2016, DOI 10.1155/2016/5070187
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Samieirad S, 2021, WORLD J PLAST SURG, V10, P132, DOI 10.29252/wjps.10.1.132
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tocaciu S, 2017, BRIT J ORAL MAX SURG, V55, pE53, DOI 10.1016/j.bjoms.2017.08.005
   Woolgar JA, 2013, HEAD NECK J SCI SPEC, V35, P906, DOI 10.1002/hed.22922
NR 15
TC 0
Z9 0
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2076 3417
J9 APPL SCI BASEL
JI Appl. Sci. Basel
PD AUG
PY 2021
VL 11
IS 16
AR 7646
DI 10.3390/app11167646
PG 7
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Engineering; Materials Science; Physics
GA UF6GO
UT WOS:000688670400001
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Marino, S
   Bishop, RT
   Mollat, P
   Idris, AI
AF Marino, Silvia
   Bishop, Ryan T.
   Mollat, Patrick
   Idris, Aymen I.
TI Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast
   Cancer Induced Osteolysis
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Osteolysis; IKK beta; Osteoclast; Breast cancer; Bone;
   Osteoclastogenesis
ID KAPPA B KINASE; INDUCED BONE LOSS; OSTEOCLAST DIFFERENTIATION; IN VITRO;
   DEFECTIVE INTERLEUKIN 1; MULTIPLE MYELOMA; ZOLEDRONIC ACID; CELLS;
   METASTASIS; GROWTH
AB IKK beta has previously been implicated in breast cancer bone metastasis and bone remodelling. However, the contribution of IKK beta expressed by bone cells of the tumour microenvironment to breast cancer induced osteolysis has yet to be investigated. Here, we studied the effects of the verified selective IKK beta inhibitors IKK beta(III) or IKK beta(V) on osteoclast formation and osteoblast differentiation in vitro and in vivo, human and mouse breast cancer cells' support for osteoclast formation and signalling in vitro and osteolysis ex vivo and in immunocompetent mice after supracalvarial injection of human MDA MB 231 conditioned medium or intra cardiac injection of syngeneic 4T1 breast cancer cells. Pre treatment with IKK beta(III) or IKK beta(V) prior to exposure to tumour derived factors from human and mouse breast cancer cell lines protected against breast cancer induced osteolysis in two independent immunocompetent mouse models of osteolysis and the ex vivo calvarial bone organ system. Detailed functional and mechanistic studies showed that direct inhibition of IKK beta kinase activity in osteoblasts and osteoclasts was associated with significant reduction of osteoclast formation, enhanced osteoclast apoptosis and reduced the ability of osteoblasts to support osteoclastogenesis in vitro. When combined with previous findings that suggest NF kappa B inhibition reduces breast cancer tumorigenesis and metastasis our present findings have an important clinical implication on raising the possibility that IKK beta inhibitors, as bone anabolics, osteoclast inhibitors as well as anti metastatic agents, may have advantages over anti osteoclasts agents in the treatment of both skeletal and non skeletal complications associated with metastatic breast cancer.
C1 [Marino, Silvia; Bishop, Ryan T.; Idris, Aymen I.] Univ Sheffield, Sch Med, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
   [Marino, Silvia; Idris, Aymen I.] Univ Edinburgh, MRC Inst Genet & Mol Med, Bone & Canc Grp, Edinburgh Canc Res Ctr, Edinburgh EH4 2XR, Midlothian, Scotland.
   [Mollat, Patrick] Galapagos SASU, 102 Ave Gaston Roussel, F 93230 Romainville, France.
C3 University of Sheffield; University of Edinburgh; Galapagos NV
RP Idris, AI (通讯作者)，Univ Sheffield, Sch Med, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.; Idris, AI (通讯作者)，Univ Edinburgh, MRC Inst Genet & Mol Med, Bone & Canc Grp, Edinburgh Canc Res Ctr, Edinburgh EH4 2XR, Midlothian, Scotland.
EM aymen.idris@sheffield.ac.uk
RI ; Idris, Aymen/AAX 1138 2020
OI Bishop, Ryan/0000 0002 1332 4798; Idris, Aymen/0000 0003 4327 5306
FU Moray Endowment Fund; Cancer Research UK Development Fund (Edinburgh
   Cancer Research Centre, University of Edinburgh); Medical Research
   Council [MR/P020941/1] Funding Source: researchfish; MRC [MR/P020941/1]
   Funding Source: UKRI
FX These studies were supported in part by a Moray Endowment Fund and
   Cancer Research UK Development Fund (Edinburgh Cancer Research Centre,
   University of Edinburgh).
CR Alles N, 2010, ENDOCRINOLOGY, V151, P4626, DOI 10.1210/en.2010 0399
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Body JJ, 2010, J BONE MINER RES, V25, P440, DOI 10.1359/jbmr.090810
   BOYCE BF, 1989, ENDOCRINOLOGY, V125, P1142, DOI 10.1210/endo 125 3 1142
   Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200
   Campbell Graeme M, 2014, Bonekey Rep, V3, P564, DOI 10.1038/bonekey.2014.59
   Chaisson ML, 2004, J BIOL CHEM, V279, P54841, DOI 10.1074/jbc.M406392200
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Clément JF, 2008, CELL RES, V18, P889, DOI 10.1038/cr.2008.273
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Crawford Anatasha, 2011, Current Pharmacogenomics & Personalized Medicine, V9, P184
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Gasparian AV, 2002, J CELL SCI, V115, P141
   Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378
   Idris AI, 2010, CALCIFIED TISSUE INT, V87, P525, DOI 10.1007/s00223 010 9417 5
   Idris AI, 2010, FASEB J, V24, P4545, DOI 10.1096/fj.10 164095
   Idris AI, 2009, MOL CANCER THER, V8, P2339, DOI 10.1158/1535 7163.MCT 09 0133
   Idris AI, 2009, ENDOCRINOLOGY, V150, P5, DOI 10.1210/en.2008 0998
   Jourdan M, 2007, BRIT J HAEMATOL, V138, P160, DOI 10.1111/j.1365 2141.2007.06629.x
   Kamon J, 2004, BIOCHEM BIOPH RES CO, V323, P242, DOI 10.1016/j.bbrc.2004.08.083
   Karin M, 2008, CELL RES, V18, P334, DOI 10.1038/cr.2008.30
   Kim JY, 2014, BMB REP, V47, P451, DOI 10.5483/BMBRep.2014.47.8.206
   Kishida Y, 2007, CLIN CANCER RES, V13, P59, DOI 10.1158/1078 0432.CCR 06 1559
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Lee DF, 2008, CLIN CANCER RES, V14, P5656, DOI 10.1158/1078 0432.CCR 08 0123
   Logan JG, 2013, J BONE MINER RES, V28, P1229, DOI 10.1002/jbmr.1847
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656
   Marino S, 2017, CANCER LETT, V410, P180, DOI 10.1016/j.canlet.2017.09.034
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Nakayama GR, 1997, J IMMUNOL METHODS, V204, P205, DOI 10.1016/S0022 1759(97)00043 4
   Nolan E, 2016, NAT MED, V22, P933, DOI 10.1038/nm.4118
   Oida K, 2014, SCI REP UK, V4, DOI 10.1038/srep04057
   Orriss IR, 2012, METHODS MOL BIOL, V816, P31, DOI 10.1007/978 1 61779 415 5_3
   Otero JE, 2010, J BONE MINER RES, V25, P1282, DOI 10.1002/jbmr.4
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rucci N, 2013, J BONE MINER RES, V28, P1912, DOI 10.1002/jbmr.1951
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Siclari VA, 2006, CANCER METAST REV, V25, P621, DOI 10.1007/s10555 006 9023 1
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Tanaka A, 2005, BLOOD, V105, P2324, DOI 10.1182/blood 2004 08 3247
   Taylor Sarah E B, 2014, Bonekey Rep, V3, P585, DOI 10.1038/bonekey.2014.80
   Tezil T, 2012, CELL SIGNAL, V24, P1361, DOI 10.1016/j.cellsig.2012.01.012
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   van't Hof RJ, 2000, RHEUMATOLOGY, V39, P1004, DOI 10.1093/rheumatology/39.9.1004
   van't Hof RJ, 2003, METH MOLEC MED, V80, P145
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wu LX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018447
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036
NR 54
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD AUG
PY 2018
VL 103
IS 2
BP 206
EP 216
DI 10.1007/s00223 018 0406 4
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GM7YG
UT WOS:000438413700010
PM 29455416
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Zhang, HH
   Zhou, CC
   Zhang, ZG
   Yao, S
   Bian, YS
   Fu, FD
   Luo, H
   Li, Y
   Yan, SX
   Ge, YY
   Chen, YY
   Zhan, KY
   Yue, M
   Du, WB
   Tian, K
   Jin, HT
   Li, XF
   Tong, PJ
   Ruan, HF
   Wu, CL
AF Zhang, Huihao
   Zhou, Chengcong
   Zhang, Zhiguo
   Yao, Sai
   Bian, Yishan
   Fu, Fangda
   Luo, Huan
   Li, Yan
   Yan, Shuxin
   Ge, Yuying
   Chen, Yuying
   Zhan, Kunyu
   Yue, Ming
   Du, Weibin
   Tian, Kun
   Jin, Hongting
   Li, Xiaofeng
   Tong, Peijian
   Ruan, Hongfeng
   Wu, Chengliang
TI Integration of Network Pharmacology and Experimental Validation to
   Explore the Pharmacological Mechanisms of Zhuanggu Busui Formula Against
   Osteoporosis
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE osteoporosis; Zhuanggu Busui formula; network pharmacology;
   pharmacological mechanisms; apoptosis; PI3K Akt signalling
ID OSTEOBLASTS; EXPRESSION; APOPTOSIS; PILL
AB Osteoporosis (OP) is a common skeletal disease, characterized by decreased bone formation and increased bone resorption. As a novel Chinese medicine formula, Zhuanggu Busui formula (ZGBSF) has been proved to be an effective prescription for treating OP in clinic, however, the pharmacological mechanisms underlying the beneficial effects remain obscure. In this study, we explored the pharmacological mechanisms of ZGBSF against OP via network pharmacology analysis coupled with in vivo experimental validation. The results of the network pharmacology analysis showed that a total of 86 active ingredients and 164 targets of ZGBSF associated with OP were retrieved from the corresponding databases, forming an ingredient target disease network. The protein protein interaction (PPI) network manifested that 22 core targets, including Caspase 3, BCL2L1, TP53, Akt1, etc, were hub targets. Moreover, functional enrichment analyses revealed that PI3K Akt and apoptosis signalings were significantly enriched by multiple targets and served as the targets for in vivo experimental study validation. The results of animal experiments revealed that ZGBSF not only reversed the high expression of Caspase 3, Bax, Prap, and low expression of Bcl 2 in osteoblasts of the OP mouse model but also contributed to the phosphorylation of Akt1 and expression of PI3K, thereby promoting osteogenesis and ameliorating the progression of OP. In conclusion, this study systematically and intuitively illustrated that the possible pharmacological mechanisms of ZGBSF against OP through multiple ingredients, targets, and signalings, and especially the inhibition of the apoptosis and the activation of PI3K Akt signaling.
C1 [Zhang, Huihao; Zhou, Chengcong; Zhang, Zhiguo; Yao, Sai; Bian, Yishan; Fu, Fangda; Li, Yan; Yan, Shuxin; Ge, Yuying; Du, Weibin; Jin, Hongting; Tong, Peijian; Ruan, Hongfeng; Wu, Chengliang] Zhejiang Chinese Med Univ, Inst Orthpaed & Traumatol, Affiliated Hosp 1, Hangzhou, Peoples R China.
   [Luo, Huan] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Pharm, Hangzhou, Peoples R China.
   [Chen, Yuying] Zhejiang Chinese Med Univ, Clin Med Coll 4, Hangzhou, Peoples R China.
   [Zhan, Kunyu] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Peoples R China.
   [Yue, Ming] Zhejiang Chinese Med Univ, Coll Basic Med Sci, Dept Physiol, Hangzhou, Peoples R China.
   [Du, Weibin] Zhejiang Chinese Med Univ, Res Inst Orthped, Affiliated Jiang Nan Hosp, Hangzhou, Peoples R China.
   [Tian, Kun] Zhejiang Chinese Med Univ, Dept Orthped, Affiliated Hosp 1, Hangzhou, Peoples R China.
   [Li, Xiaofeng] Shanghai Univ Tradit Chinese Med, Dept Orthoped & Traumatol, Shanghai Municipal Hosp Tradit Chinese Med, Shanghai, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang University; Zhejiang
   Chinese Medical University; Zhejiang Chinese Medical University;
   Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Zhejiang Chinese Medical University; Shanghai University of
   Traditional Chinese Medicine
RP Tong, PJ; Ruan, HF (通讯作者)，Zhejiang Chinese Med Univ, Inst Orthpaed & Traumatol, Affiliated Hosp 1, Hangzhou, Peoples R China.; Li, XF (通讯作者)，Shanghai Univ Tradit Chinese Med, Dept Orthoped & Traumatol, Shanghai Municipal Hosp Tradit Chinese Med, Shanghai, Peoples R China.
EM lixiaofeng0409@163.com; peijiantongzjtcm@163.com; rhf@zcmu.edu.cn
RI Ruan, Hongfeng/HKO 1118 2023; yue, ming/ABG 4676 2021
OI RUAN, Hongfeng/0000 0001 8868 9313; Chen, YuYing/0009 0007 2192 6485; 
FU National Natural Science Foundation of China [82174140, 82174401,
   82104164, 81973870, 81973881, 81904053, 81804121]; China Postdoctoral
   Science Foundation [2018M632154]; Natural Science Foundation of Zhejiang
   Province [LY22H270003, LBY22H270008, LY19H270006, LQ19H080001];
   Traditional Chinese Medical Administration of Zhejiang Province
   [2022ZX005, 2022ZB119, 2021ZB090]; Zhejiang medical and health science
   and technology project [2021KY222]; Research Project of Zhejiang Chinese
   Medical University Scientific [2021JKZDZC02, 2021JKZKTS036A,
   2021JKJNTZ022B, 2019ZG25, 2018ZR06]; National Undergraduate Innovation
   and Entrepreneurship Training Program [202110344005, 202110344025,
   S202110344007, 202010344004]; General Research Project of Zhejiang
   Provincial Education Department Special Project for the Reform of
   Cultivation Mode of Professional Degree Graduate Students in Higher
   Education Institutions [Y202145932]; Postgraduate Science Research Fund
   of Zhejiang Chinese Medical University [2021YKJ02, 2020YKJ07]
FX This study was financially supported by National Natural Science
   Foundation of China (No.: 82174140, 82174401, 82104164, 81973870,
   81973881, 81904053, 81804121), China Postdoctoral Science Foundation
   (No.: 2018M632154), Natural Science Foundation of Zhejiang Province
   (No.: LY22H270003, LBY22H270008, LY19H270006, and LQ19H080001),
   Traditional Chinese Medical Administration of Zhejiang Province (No.:
   2022ZX005, 2022ZB119, 2021ZB090), Zhejiang medical and health science
   and technology project (No.: 2021KY222), Research Project of Zhejiang
   Chinese Medical University Scientific (No.: 2021JKZDZC02,
   2021JKZKTS036A, 2021JKJNTZ022B, 2019ZG25, 2018ZR06), National
   Undergraduate Innovation and Entrepreneurship Training Program
   (202110344005, 202110344025, S202110344007, 202010344004), General
   Research Project of Zhejiang Provincial Education Department Special
   Project for the Reform of Cultivation Mode of Professional Degree
   Graduate Students in Higher Education Institutions (No.: Y202145932),
   Postgraduate Science Research Fund of Zhejiang Chinese Medical
   University (No.: 2021YKJ02, 2020YKJ07).
CR Amberger JS, 2015, NUCLEIC ACIDS RES, V43, pD789, DOI 10.1093/nar/gku1205
   An L, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.618262
   Barbarino JM, 2018, WIRES SYST BIOL MED, V10, DOI 10.1002/wsbm.1417
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Cai P, 2021, AGING US, V13, P17370, DOI 10.18632/aging.203227
   Che CT, 2016, MOLECULES, V21, DOI 10.3390/molecules21030239
   Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Chen M, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02239 3
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   Cui J, 2020, J CELL MOL MED, V24, P6149, DOI 10.1111/jcmm.15229
   Du A., 2021, IN VIVO APPROACH FRO, V12, DOI [10.3389/fphar.2021.763163, DOI 10.3389/FPHAR.2021.763163]
   Feng WW, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34509 1
   Fu FD, 2021, SCI REP UK, V11, DOI 10.1038/s41598 020 80756 6
   Gao L, 2021, CURR PHARM DESIGN, V27, P2925, DOI 10.2174/1381612826666201112142408
   Guo C, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.629021
   He D, 2019, DRUG DES DEV THER, V13, P3989, DOI 10.2147/DDDT.S216644
   Hussain T, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/5202908
   Jing Z, 2019, J CELL PHYSIOL, V234, P4472, DOI 10.1002/jcp.27252
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Kong Y, 2019, EXP MOL PATHOL, V110, DOI 10.1016/j.yexmp.2019.104282
   Li QL, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.648037
   Li YH, 2018, NUCLEIC ACIDS RES, V46, pD1121, DOI 10.1093/nar/gkx1076
   Liang JB, 2012, MOL MED REP, V5, P1419, DOI 10.3892/mmr.2012.854
   Lin Z, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/2098820
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Liu H, 2021, MOL CELL ENDOCRINOL, V520, DOI 10.1016/j.mce.2020.111074
   Macías I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051653
   Moriishi T, 2016, J BONE MINER RES, V31, P1366, DOI 10.1002/jbmr.2808
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Shi HS, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm 20 8165
   Sillars Hardebol AH, 2012, J PATHOL, V226, P442, DOI 10.1002/path.2983
   Song N, 2017, CHEM BIOL INTERACT, V261, P11, DOI 10.1016/j.cbi.2016.10.020
   Stelzer Gil, 2011, Human Genomics, V5, P709
   Ukon Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102557
   Vakili S, 2021, J CELL PHYSIOL, V236, P3495, DOI 10.1002/jcp.30087
   Vandenbroucke A, 2017, CLIN INTERV AGING, V12, P1065, DOI 10.2147/CIA.S131023
   Wang X, 2021, CHIN J NAT MEDICINES, V19, P1, DOI 10.1016/S1875 5364(21)60001 8
   Wang Y, 2017, BIOMED PHARMACOTHER, V96, P993, DOI 10.1016/j.biopha.2017.11.136
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wong SK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176448
   Xia CJ, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110170
   Xia HT, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.654714
   Xiao L, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6797154
   Xu R, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.711004
   Yang L, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6641838
   Ye CY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1904 7
   Yu T, 2020, AGING US, V12, P10473, DOI 10.18632/aging.103271
   Yu T, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923996
   Zhang HH, 2021, DRUG DES DEV THER, V15, P4911, DOI 10.2147/DDDT.S338439
   Zhang WJ, 2019, LIFE SCI, V235, DOI 10.1016/j.lfs.2019.116820
   Zhang Y, 2020, J CELL PHYSIOL, V235, P5511, DOI 10.1002/jcp.29261
   Zhong ZG, 2021, DRUG DES DEV THER, V15, P817, DOI 10.2147/DDDT.S293455
   Zhu B, 2018, J ETHNOPHARMACOL, V226, P143, DOI 10.1016/j.jep.2018.08.023
   Zhu Y, 2020, NANOSCALE, V12, P8720, DOI 10.1039/d0nr00867b
NR 56
TC 15
Z9 17
U1 1
U2 52
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD JAN 28
PY 2022
VL 12
AR 841668
DI 10.3389/fendo.2021.841668
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA YX0ZK
UT WOS:000753837800001
PM 35154014
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kim, J
   Yeon, A
   Parker, SJ
   Shahid, M
   Thiombane, A
   Cho, EH
   You, SY
   Emam, H
   Kim, D
   Kim, M
AF Kim, Jayoung
   Yeon, Austin
   Parker, Sarah J.
   Shahid, Muhammad
   Thiombane, Aissatou
   Cho, Eunho
   You, Sungyong
   Emam, Hany
   Kim, Do Gyoon
   Kim, Minjung
TI Alendronate induced Perturbation of the Bone Proteome and
   Microenvironmental Pathophysiology
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Osteonecrosis of the jaw; bisphosphonate; GSK signaling; clinical cone
   beam computed tomography; bone mineral density; proteomics; biomarker
ID WNT/BETA CATENIN; ZOLEDRONIC ACID; BISPHOSPHONATES; OSTEONECROSIS;
   OSTEOBLAST; APOPTOSIS; OSTEOCYTE; TARGET; GSK 3; RISK
AB Objectives: Bisphosphonates (BPs) are powerful inhibitors of osteoclastogenesis and are used to prevent osteoporotic bone loss and reduce the risk of osteoporotic fracture in patients suffering from postmenopausal osteoporosis. Patients with breast cancer or gynecological malignancies being treated with BPs or those receiving bone targeted therapy for metastatic prostate cancer are at increased risk of bisphosphonate related osteonecrosis of the jaw (BRONJ). Although BPs markedly ameliorate osteoporosis, their adverse effects largely limit the clinical application of these drugs. This study focused on providing a deeper understanding of one of the most popular BPs, the alendronate (ALN) induced perturbation of the bone proteome and microenvironmental pathophysiology. Methods: To understand the molecular mechanisms underlying ALN induced side effects, an unbiased and global proteomics approach combined with big data bioinformatics was applied. This was followed by biochemical and functional analyses to determine the clinicopathological mechanisms affected by ALN. Results: The findings from this proteomics study suggest that the RIPK3/Wnt/GSK3/beta catenin signaling pathway is significantly perturbed upon ALN treatment, resulting in abnormal angiogenesis, inflammation, anabolism, remodeling, and mineralization in bone cells in an in vitro cell culture system. Conclusion: Our investigation into potential key signaling mechanisms in response to ALN provides a rational basis for suppressing BP induced adverse effect and presents various therapeutic strategies.
C1 [Kim, Jayoung; Yeon, Austin; Shahid, Muhammad; Thiombane, Aissatou; Cho, Eunho; You, Sungyong] Cedars Sinai Med Ctr, Dept Surg & Biomed Sci, Davis 5071,8700 Beverly Blvd, Los Angeles, CA 90048 USA.
   [Kim, Jayoung] Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA.
   [Parker, Sarah J.] Cedars Sinai Med Ctr, Smidt Heart Inst, Dept Cardiol, Los Angeles, CA USA.
   [Emam, Hany] Ohio State Univ, Coll Dent, Div Orthodont, Columbus, OH 43210 USA.
   [Kim, Do Gyoon] Ohio State Univ, Coll Dent, Div Oral Surg, Columbus, OH 43210 USA.
   [Kim, Minjung] Univ S Florida, Dept Cell Biol Microbiol & Mol Biol, Tampa, FL 33620 USA.
C3 Cedars Sinai Medical Center; University of California System; University
   of California Los Angeles; Cedars Sinai Medical Center; University
   System of Ohio; Ohio State University; University System of Ohio; Ohio
   State University; State University System of Florida; University of
   South Florida
RP Kim, J (通讯作者)，Cedars Sinai Med Ctr, Dept Surg & Biomed Sci, Davis 5071,8700 Beverly Blvd, Los Angeles, CA 90048 USA.; Kim, J (通讯作者)，Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA.
EM Jayoung.kim@csmc.edu
RI You, Sungyong/AAJ 7372 2020; Kim, Dogyoon/D 5543 2012; Shahid,
   Muhammad/Y 6565 2018; Emam, Hany/H 6565 2013
OI Yeon, Austin/0000 0001 5212 234X; You, Sungyong/0000 0003 3513 1783;
   Kim, Minjung/0000 0002 5682 6640; 
FU National Institutes of Health [1U01DK103260, 1R01DK100974, U24
   DK097154]; National Institutes of Health (NIH NCATS UCLA CTSI)
   [UL1TR000124]; Department of Defense [W81XWH 15 1 0415, W81XWH1910109];
   Centers for Disease Controls and Prevention [1U01DP006079]; U.S. Egypt
   Science and Technology Development Fund by the National Academies of
   Sciences, Engineering, and Medicine; National Academies of Sciences,
   Engineering, and Medicine (NAS); United States Agency for International
   Development (USAID); U.S. Department of Defense (DOD) [W81XWH1910109]
   Funding Source: U.S. Department of Defense (DOD)
FX This research was funded by National Institutes of Health (1U01DK103260,
   1R01DK100974, U24 DK097154, NIH NCATS UCLA CTSI UL1TR000124) ,
   Department of Defense (W81XWH 15 1 0415 and W81XWH1910109) , Centers for
   Disease Controls and Prevention (1U01DP006079) , and the U.S. Egypt
   Science and Technology Development Fund by the National Academies of
   Sciences, Engineering, and Medicine (all to J.K.) . This article is
   derived from the Subject Data funded in whole or part by National
   Academies of Sciences, Engineering, and Medicine (NAS) and The United
   States Agency for International Development (USAID) . Any opinions,
   findings, conclusions, or recommendations expressed in this article are
   those of the authors alone, and do not necessarily reflect the views of
   USAID or NAS.
CR Alao JP, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 24
   Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302
   Basi DL, 2010, MOL MED REP, V3, P399, DOI 10.3892/mmr_00000271
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Bertacchini J, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6020061
   Beurel E, 2006, PROG NEUROBIOL, V79, P173, DOI 10.1016/j.pneurobio.2006.07.006
   Bozec D, 2016, ONCOTARGET, V7, P46384, DOI 10.18632/oncotarget.10135
   Chen H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0936 8
   Dai X, 2020, INT ENDOD J, V53, P1204, DOI 10.1111/iej.13323
   Dodson TB, 2015, ORAL MAXIL SURG CLIN, V27, P509, DOI 10.1016/j.coms.2015.06.003
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Fung PPL, 2017, ORAL DIS, V23, P477, DOI 10.1111/odi.12632
   George Estee L, 2018, Bone Rep, V8, P104, DOI 10.1016/j.bonr.2018.03.003
   Huh JE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054551
   Ishtiaq S, 2015, CYTOKINE, V71, P154, DOI 10.1016/j.cyto.2014.10.025
   Issack Paul S, 2008, HSS J, V4, P66, DOI 10.1007/s11420 007 9072 1
   Jackson C, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246441
   Khan A, 2016, OSTEOPOROSIS INT, V27, P853, DOI 10.1007/s00198 015 3335 3
   Kim Do Gyoon, 2014, J Bone Metab, V21, P117, DOI 10.11005/jbm.2014.21.2.117
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Lang M, 2016, BRIT J ORAL MAX SURG, V54, P889, DOI 10.1016/j.bjoms.2016.05.030
   Li H, 2010, IMMUNOLOGY, V130, P556, DOI 10.1111/j.1365 2567.2010.03256.x
   McCubrey JA, 2014, LEUKEMIA, V28, P15, DOI 10.1038/leu.2013.184
   McCubrey JA, 2014, ONCOTARGET, V5, P2881, DOI 10.18632/oncotarget.2037
   Mi HY, 2021, NUCLEIC ACIDS RES, V49, pD394, DOI 10.1093/nar/gkaa1106
   Moriwaki K, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.16
   Nye SN CE, 2018, 2018 AADR CADR ANN M
   Pabst Andreas Max, 2016, Dent J (Basel), V5, DOI 10.3390/dj5010002
   Parker SJ, 2018, AM J PHYSIOL HEART C, V315, pH1112, DOI 10.1152/ajpheart.00089.2018
   Parker SJ, 2016, PROTEOMICS, V16, P2221, DOI 10.1002/pmic.201600007
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Röst HL, 2014, NAT BIOTECHNOL, V32, P219, DOI 10.1038/nbt.2841
   Rosenberger G, 2014, SCI DATA, V1, DOI 10.1038/sdata.2014.31
   Röst HL, 2016, NAT METHODS, V13, P777, DOI [10.1038/nmeth.3954, 10.1038/NMETH.3954]
   Rouach V, 2018, J BONE ONCOL, V12, P91, DOI 10.1016/j.jbo.2018.07.011
   Schoeman MAE, 2015, J CELL BIOCHEM, V116, P2938, DOI 10.1002/jcb.25241
   Skurk C, 2005, CIRC RES, V96, P308, DOI 10.1161/01.RES.0000156273.30274.f7
   Tamari T, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 55383 5
   Taylor A, 2016, IMMUNITY, V44, P274, DOI 10.1016/j.immuni.2016.01.018
   Teleman J, 2015, BIOINFORMATICS, V31, P555, DOI 10.1093/bioinformatics/btu686
   Teo GS, 2015, J PROTEOMICS, V129, P108, DOI 10.1016/j.jprot.2015.09.013
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Wilkins Parker LR, 2021, ALENDRONATE STATPEAR
   Zhang ZC, 2016, STEM CELLS, V34, P1576, DOI 10.1002/stem.2334
   Zymperdikas VF, 2021, J DENT RES, V100, P341, DOI 10.1177/0022034520972945
NR 46
TC 9
Z9 9
U1 1
U2 8
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2021
VL 18
IS 14
BP 3261
EP 3270
DI 10.7150/ijms.61552
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA TX7YM
UT WOS:000683304200021
PM 34400895
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cheng, W
   Yao, MY
   Liu, FN
AF Cheng, Weyland
   Yao, Manye
   Liu, Fangna
TI Bitter Taste Receptor as a Therapeutic Target in Orthopaedic Disorders
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE TAS2R; calcium signaling; osteoblasts; drug target; bone inflammation
ID CALCIUM SENSING RECEPTOR; NITRIC OXIDE PRODUCTION; CHRONIC
   RHINOSINUSITIS; DELIVERY SYSTEMS; BONE; SWEET; T2R38; OSTEOBLASTS;
   SENSITIVITY; INFLAMMATION
AB Non gustatory, extraoral bitter taste receptors (T2Rs) are G protein coupled receptors that are expressed throughout the body and have various functional responses when stimulated by bitter agonists. Presently, T2Rs have been found to be expressed in osteoclasts and osteocytes where osteoclasts were capable of detecting bacterial quorum sensing molecules through the T2R38 isoform. In the innate immune system, stimulating T2Rs induces anti inflammatory and anti pathogenic effects through the phospholipase C/inositol triphosphate pathway, which leads to intracellular calcium release from the endo plasmic reticulum. The immune cells with functional responses to T2R activation also play a role in bone inflammation and orthopaedic disorders. Furthermore, increasing intracellular calcium levels in bone cells through T2R activation can potentially influence bone formation and resorption. With recent studies finding T2R expression in bone cells, we examine the potential of targeting this receptor to treat bone inflammation and to promote bone anabolism.
C1 [Cheng, Weyland; Yao, Manye; Liu, Fangna] Zhengzhou Univ, Henan Childrens Hosp, Zhengzhou Childrens Hosp, Dept Orthopaed Surg,Childrens Hosp, Zhengzhou, Henan, Peoples R China.
   [Cheng, Weyland] Zhengzhou Univ, Henan Childrens Hosp, Zhengzhou Childrens Hosp,Childrens Hosp, Henan Prov Key Lab Childrens Genet & Metab Dis, Zhengzhou, Henan, Peoples R China.
C3 Zhengzhou University; Zhengzhou University
RP Cheng, W (通讯作者)，Zhengzhou Univ, Henan Childrens Hosp, Zhengzhou Childrens Hosp, Dept Orthopaed Surg,Childrens Hosp, Zhengzhou, Henan, Peoples R China.
EM wey_c@hotmail.com
OI Yao, Manye/0000 0002 6805 7527; Cheng, Weyland/0000 0002 1846 2946
CR Abu Amer Y, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2170
   Adappa ND, 2016, INT FORUM ALLERGY RH, V6, P783, DOI 10.1002/alr.21803
   Adappa ND, 2016, INT FORUM ALLERGY RH, V6, P25, DOI 10.1002/alr.21666
   Adappa ND, 2014, INT FORUM ALLERGY RH, V4, P3, DOI 10.1002/alr.21253
   Adappa ND, 2013, INT FORUM ALLERGY RH, V3, P184, DOI 10.1002/alr.21140
   BARTOSHUK LM, 1994, PHYSIOL BEHAV, V56, P1165, DOI 10.1016/0031 9384(94)90361 1
   Bloxham CJ, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00431
   Brady RA, 2008, FEMS IMMUNOL MED MIC, V52, P13, DOI 10.1111/j.1574 695X.2007.00357.x
   Carbone EJ, 2017, NANOMED NANOTECHNOL, V13, P37, DOI 10.1016/j.nano.2016.08.015
   Carey RM, 2017, AM J RHINOL ALLERGY, V31, P211, DOI 10.2500/ajra.2017.31.4453
   Carey RM, 2016, INT FORUM ALLERGY RH, V6, P1238, DOI 10.1002/alr.21837
   Carey RM, 2015, INT FORUM ALLERGY RH, V5, P808, DOI 10.1002/alr.21568
   Chaudhari N, 2010, J CELL BIOL, V190, P285, DOI 10.1083/jcb.201003144
   Clapp TR, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471 2202 2 6
   Deloose E, 2018, NEUROGASTROENT MOTIL, V30, DOI 10.1111/nmo.13171
   Deloose E, 2017, AM J CLIN NUTR, V105, P580, DOI 10.3945/ajcn.116.138297
   Deshpande DA, 2010, NAT MED, V16, P1299, DOI 10.1038/nm.2237
   Dotson CD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003974
   Drewnowski A, 1997, CHEM SENSES, V22, P27, DOI 10.1093/chemse/22.1.27
   Ekoff M, 2014, J ALLERGY CLIN IMMUN, V134, P475, DOI 10.1016/j.jaci.2014.02.029
   Ekstedt S, 2020, ALLERGY ASTHMA CL IM, V16, DOI 10.1186/s13223 020 00438 w
   El Jawhari JJ, 2016, INJURY, V47, P2399, DOI 10.1016/j.injury.2016.10.008
   Esteban J, 2011, EXPERT OPIN PHARMACO, V12, P899, DOI 10.1517/14656566.2011.543676
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Ford CA, 2017, EXPERT REV ANTI INFE, V15, P851, DOI 10.1080/14787210.2017.1372192
   Freund JR, 2018, J BIOL CHEM, V293, P9824, DOI 10.1074/jbc.RA117.001005
   Fromigué O, 2009, J CELL MOL MED, V13, P2189, DOI 10.1111/j.1582 4934.2009.00673.x
   Gaida MM, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw004
   Goltzman D, 2015, NAT REV ENDOCRINOL, V11, P298, DOI 10.1038/nrendo.2015.30
   Gómez Barrena E, 2012, J ORTHOP RES, V30, P1634, DOI 10.1002/jor.22114
   Gopallawa I, 2021, CELL MOL LIFE SCI, V78, P271, DOI 10.1007/s00018 020 03494 y
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Jaggupilli A, 2017, MOL CELL BIOCHEM, V426, P137, DOI 10.1007/s11010 016 2902 z
   Kim UK, 2003, SCIENCE, V299, P1221, DOI 10.1126/science.1080190
   Kinnamon SC, 2012, ACTA PHYSIOL, V204, P158, DOI 10.1111/j.1748 1716.2011.02308.x
   Lee RJ, 2015, CELL MOL LIFE SCI, V72, P217, DOI 10.1007/s00018 014 1736 7
   Lee RJ, 2014, J CLIN INVEST, V124, P1393, DOI 10.1172/JCI72094
   Lee RJ, 2012, J CLIN INVEST, V122, P4145, DOI 10.1172/JCI64240
   Lindemann B, 1996, CURR BIOL, V6, P1234, DOI 10.1016/S0960 9822(96)00704 X
   Lund TC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058945
   Margolskee RF, 2002, J BIOL CHEM, V277, P1, DOI 10.1074/jbc.R100054200
   Marie PJ, 2010, BONE, V46, P571, DOI 10.1016/j.bone.2009.07.082
   Maurer S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00369
   Meyerhof W, 2010, CHEM SENSES, V35, P157, DOI 10.1093/chemse/bjp092
   Mfuna Endam L, 2014, INT FORUM ALLERGY RH, V4, P200, DOI 10.1002/alr.21275
   Orsmark Pietrast C, 2013, EUR RESPIR J, V42, P65, DOI 10.1183/09031936.00077712
   Pi M, 2000, J BIOL CHEM, V275, P3256, DOI 10.1074/jbc.275.5.3256
   Pilbeam C, 2019, HDB EXP PHARM
   Ragipoglu D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00163
   Roca H, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.75
   Roca Ferrer J, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223 018 0311 4
   Rom DI, 2017, RHINOLOGY, V55, P90, DOI [10.4193/Rhino16.181, 10.4193/Rhin16.181]
   Rüegg C, 2006, J LEUKOCYTE BIOL, V80, P682, DOI 10.1189/jlb.0606394
   Lacativa PGS, 2010, ARQ BRAS ENDOCRINOL, V54, P123, DOI 10.1590/S0004 27302010000200007
   Schempp C, 2013, US patent WO, Patent No. [2013112865A1, 2013112865]
   Schiöth HB, 2005, GEN COMP ENDOCR, V142, P94, DOI 10.1016/j.ygcen.2004.12.018
   Shah AS, 2009, SCIENCE, V325, P1131, DOI 10.1126/science.1173869
   Theman TA, 2009, CURR PHARM BIOTECHNO, V10, P289, DOI 10.2174/138920109787847538
   Thilakarathna SH, 2013, NUTRIENTS, V5, P3367, DOI 10.3390/nu5093367
   Tian XY, 2008, BONE, V42, P914, DOI 10.1016/j.bone.2007.12.228
   Tordoff MG, 2001, PHYSIOL REV, V81, P1567, DOI 10.1152/physrev.2001.81.4.1567
   Tran HTT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02949
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   Varoga D, 2009, HISTOCHEM CELL BIOL, V131, P207, DOI 10.1007/s00418 008 0522 8
   Varoga D, 2008, J ANAT, V213, P749, DOI 10.1111/j.1469 7580.2008.00992.x
   Wang Y, 2019, CHEM SENSES, V44, P339, DOI 10.1093/chemse/bjz024
   WHISSELLBUECHY D, 1989, ANN HUM BIOL, V16, P131, DOI 10.1080/03014468700006982
   WHISSELLBUECHY D, 1990, CHEM SENSES, V15, P39, DOI 10.1093/chemse/15.1.39
   Wölfle U, 2015, SKIN PHARMACOL PHYS, V28, P137, DOI 10.1159/000367631
   Yamaguchi M, 2007, MOL CELL BIOCHEM, V303, P83, DOI 10.1007/s11010 007 9458 x
   Zamora R, 2000, MOL MED, V6, P347, DOI 10.1007/BF03401781
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zhu C, 2013, INT J MOL MED, V31, P1484, DOI 10.3892/ijmm.2013.1346
NR 73
TC 9
Z9 9
U1 0
U2 18
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177 8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2021
VL 15
BP 895
EP 903
DI 10.2147/DDDT.S289614
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA QR5XJ
UT WOS:000625290300001
PM 33679130
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Joeng, KS
   Lee, YC
   Lim, J
   Chen, YQ
   Jiang, MM
   Munivez, E
   Ambrose, C
   Lee, BH
AF Joeng, Kyu Sang
   Lee, Yi Chien
   Lim, Joohyun
   Chen, Yuqing
   Jiang, Ming Ming
   Munivez, Elda
   Ambrose, Catherine
   Lee, Brendan H.
TI Osteocyte specific WNT1 regulates osteoblast function during bone
   homeostasis
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID RECESSIVE OSTEOGENESIS IMPERFECTA; SCLEROSTIN ANTIBODY TREATMENT;
   RECEPTOR RELATED PROTEIN 5; BETA CATENIN; MOUSE MODEL; SKELETAL
   CHARACTERISTICS; MUTATIONS; DIFFERENTIATION; MASS; OSTEOCLASTOGENESIS
AB Mutations in WNT1 cause osteogenesis imperfecta (OI) and early onset osteoporosis, identifying it as a key Wnt ligand in human bone homeostasis. However, how and where WNT1 acts in bone are unclear. To address this mechanism, we generated late osteoblast specific and osteocyte specific WNT1 loss and gain of function mouse models. Deletion of Wnt1 in osteocytes resulted in low bone mass with spontaneous fractures similar to that observed in OI patients. Conversely, Wnt1 overexpression from osteocytes stimulated bone formation by increasing osteoblast number and activity, which was due in part to activation of mTORC1 signaling. While antiresorptive therapy is the mainstay of OI treatment, it has limited efficacy in WNT1 related OI. In this study, anti sclerostin antibody (Scl Ab) treatment effectively improved bone mass and dramatically decreased fracture rate in swaying mice, a model of global Wnt1 loss. Collectively, our data suggest that WNT1 related OI and osteoporosis are caused in part by decreased mTORC1 dependent osteoblast function resulting from loss of WNT1 signaling in osteocytes. As such, this work identifies an anabolic function of osteocytes as a source of Wnt in bone development and homoeostasis, complementing their known function as targets of Wnt signaling in regulating osteoclastogenesis. Finally, this study suggests that Scl Ab is an effective genotype specific treatment option for WNT1 related OI and osteoporosis.
C1 [Joeng, Kyu Sang; Lee, Yi Chien; Lim, Joohyun; Chen, Yuqing; Jiang, Ming Ming; Munivez, Elda; Lee, Brendan H.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Ambrose, Catherine] Univ Texas Hlth Sci Ctr Houston, Dept Orthoped Surg, Houston, TX 77030 USA.
C3 Baylor College of Medicine; University of Texas System; University of
   Texas Health Science Center Houston
RP Lee, BH (通讯作者)，Baylor Coll Med, One Baylor Plaza, Houston, TX 77030 USA.
EM blee@bcm.edu
RI Lim, Joohyun/HIR 7445 2022; Chen, Yuqing/GWU 7343 2022
OI Lim, Joohyun/0000 0001 9670 806X; Ambrose,
   Catherine/0000 0002 3866 0683; 
FU Baylor College of Medicine (BCM) Intellectual and Developmental
   Disabilities Research Center of the Eunice Kennedy Shriver National
   Institute of Child Health and Human Development [HD024064]; BCM Advanced
   Technology Cores; NIH [AI036211, CA125123, RR024574, PO1 HD22657, PO1
   HD070394, K01 AR069002]; Rolanette and Berdon Lawrence Bone Disease
   Program of Texas; BCM Center for Skeletal Medicine and Biology; Rising
   Star Award of American Society for Bone and Mineral Research
FX The authors thank Brian Dawson and Carrie Jiang for technical
   assistance. We also appreciate Thomas Carroll, Andrew McMahon, and Jian
   Feng for providing Rosa26 Wnt1 and Dmp1 Cre mouse lines. This work was
   supported by the Baylor College of Medicine (BCM) Intellectual and
   Developmental Disabilities Research Center (HD024064) of the Eunice
   Kennedy Shriver National Institute of Child Health and Human
   Development, the BCM Advanced Technology Cores with funding from the NIH
   (AI036211, CA125123, and RR024574), the Rolanette and Berdon Lawrence
   Bone Disease Program of Texas, and the BCM Center for Skeletal Medicine
   and Biology. Research funding to authors includes NIH grants PO1 HD22657
   (to BHL), PO1 HD070394 (to BHL), K01 AR069002 (to KSJ), and the Rising
   Star Award of American Society for Bone and Mineral Research (to KSJ).
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Aldinger KA, 2016, J MED GENET, V53, P427, DOI 10.1136/jmedgenet 2015 103476
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Ballou Lisa M, 2008, J Chem Biol, V1, P27, DOI 10.1007/s12154 008 0003 5
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Carroll TJ, 2005, DEV CELL, V9, P283, DOI 10.1016/j.devcel.2005.05.016
   Chen JQ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004145
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Fahiminiya S, 2013, J MED GENET, V50, P345, DOI 10.1136/jmedgenet 2013 101567
   Faqeih E, 2013, J MED GENET, V50, P491, DOI 10.1136/jmedgenet 2013 101750
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Grafel I, 2014, NAT MED, V20, P670, DOI 10.1038/nm.3544
   Hilton MJ, 2005, DEVELOPMENT, V132, P4339, DOI 10.1242/dev.02025
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Jacobsen CM, 2014, J BONE MINER RES, V29, P2297, DOI 10.1002/jbmr.2198
   Joeng KS, 2014, HUM MOL GENET, V23, P4035, DOI 10.1093/hmg/ddu117
   Kemp JP, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004423
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Lane P.W., 1967, Mouse News Lett, V36, P40
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Liu YJ, 2016, J CHEM NY, V2016, DOI 10.1155/2016/6903524
   Lu Y, J DENT RES
   Mäkitie RE, 2016, J BONE MINER RES, V31, P1734, DOI 10.1002/jbmr.2841
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Niu TH, 2016, J BONE MINER RES, V31, P358, DOI 10.1002/jbmr.2687
   Otero K, 2012, J IMMUNOL, V188, P2612, DOI 10.4049/jimmunol.1102836
   Palomo T, 2014, BONE, V67, P63, DOI 10.1016/j.bone.2014.06.041
   Piemontese M, 2016, AM J PHYSIOL ENDOC M, V311, pE587, DOI 10.1152/ajpendo.00219.2016
   Plotkin LI, 2016, NAT REV ENDOCRINOL, V12, P593, DOI 10.1038/nrendo.2016.71
   Pyott SM, 2013, AM J HUM GENET, V92, P590, DOI 10.1016/j.ajhg.2013.02.009
   Riddle RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063323
   Roschger A, 2014, BONE, V66, P182, DOI 10.1016/j.bone.2014.06.015
   Ruiz P, 2016, SCI REP UK, V6, DOI 10.1038/srep36201
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Shang YC, 2012, AGING US, V4, P187, DOI 10.18632/aging.100440
   Sinder BP, 2014, OSTEOPOROSIS INT, V25, P2097, DOI 10.1007/s00198 014 2737 y
   Stevens JR, 2010, J BONE MINER RES, V25, P2138, DOI 10.1002/jbmr.118
   Suzuki M, 2010, HUM GENE THER, V21, P120, DOI 10.1089/hum.2009.096
   THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092 8674(91)90369 A
   Todd H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140260
   Tong JJ, 1999, IMMUNOLOGY, V97, P672
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Weivoda MM, 2016, J BONE MINER RES, V31, P65, DOI 10.1002/jbmr.2599
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 62
TC 149
Z9 166
U1 0
U2 13
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUN 30
PY 2017
VL 127
IS 7
BP 2678
EP 2688
DI 10.1172/JCI92617
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EZ2RM
UT WOS:000404557400025
PM 28628032
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Karvande, A
   Kushwaha, P
   Ahmad, N
   Adhikary, S
   Kothari, P
   Tripathi, AK
   Khedgikar, V
   Trivedi, R
AF Karvande, Anirudha
   Kushwaha, Priyanka
   Ahmad, Naseer
   Adhikary, Sulekha
   Kothari, Priyanka
   Tripathi, Ashish Kumar
   Khedgikar, Vikram
   Trivedi, Ritu
TI Glucose dependent miR 451a expression contributes to parathyroid hormone
   mediated osteoblast differentiation
SO BONE
LA English
DT Article
DE PTH; Glucose; AMPK; Osteoblast differentiation; MicroRNA
ID BONE MINERAL DENSITY; TRANSCRIPTION FACTOR; MICRORNA EXPRESSION; HUMAN
   OSTEOSARCOMA; INTERMITTENT PTH; AMPK ACTIVATION; LINING CELLS;
   LACTATION; RUNX2; RATS
AB Parathyroid hormone (PTH; amino acid 1 34, known as teriparatide) has reported promoting differentiation and glucose uptake in osteoblasts. However, how PTH regulates glucose metabolism to facilitate osteoblast differentiation is not understood. Here, we report that PTH promotes glucose dependent miR 451a expression which stimulates osteoblast differentiation. In addition to glucose uptake, PTH suppresses AMPK phosphorylation via PI3K mTOR AKT axis thereby preventing phosphorylation and inactivation of octamer binding transcription factor 1 (OCT 1) which has been reported to act on the promoter region of miR 451a. Modulation of AMPK activity controls miR 451a levels in differentiating osteoblasts. Moreover, pharmacological inhibition of PI3K mTOR AKT axis suppressed miR 451a via increased AMPK activity. We report that this glucose regulated miRNA is an anabolic target and transfection of miR 451a mimic induces osteoblast differentiation and mineralization in vitro. These actions were mediated through the suppression of Odd skipped related 1 (Osr1) and activation of Runx2 transcription. When injected in vivo, the miR 451a mimic significantly increased osteoblastogenesis, mineralization, reversed ovariectomy induced bone loss and improved bone strength. Together, these findings suggest that enhanced osteoblast differentiation associated with bone formation in case of PTH therapy is also a consequence of elevated miR 451a levels via glucose regulation. Consequently, this miRNA has the potential to be a therapeutic target for conditions of bone loss.
C1 [Karvande, Anirudha; Kushwaha, Priyanka; Ahmad, Naseer; Adhikary, Sulekha; Kothari, Priyanka; Tripathi, Ashish Kumar; Khedgikar, Vikram; Trivedi, Ritu] CSIR, Cent Drug Res Inst, Div Endocrinol, Sect 10,Jankipuram Extens,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI)
RP Trivedi, R (通讯作者)，CSIR, Cent Drug Res Inst, Div Endocrinol, Sect 10,Jankipuram Extens,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
EM ritu_trivedi@cdri.res.in
RI ; Kothari, Priyanka/AAE 3770 2021; AHMAD, NASEER/MAH 2950 2025;
   Tripathi, Ashish/JXY 6318 2024
OI Trivedi, Ritu/0000 0002 9524 2541; Tripathi, Ashish
   Kumar/0000 0002 0976 8476; 
FU Council of Scientific and Industrial Research (CSIR) India [BSC0201,
   BSC0111]; Council of Scientific and Industrial Research (CSIR);
   University Grant Commission (UGC), New Delhi, India
FX We gratefully acknowledge the Council of Scientific and Industrial
   Research (CSIR) India for the financial support from BSC0201
   (ASTHI Anabolic Skeletal Targets in Health and Illness) and BSC0111
   (INDEPTH Integrated NextGen Approaches in Disease and Environmental
   Toxicity). We are thankful to Council of Scientific and Industrial
   Research (CSIR) and University Grant Commission (UGC), New Delhi, India
   for the award of research fellowships. We thank to Dr. Dean Tantin,
   (University of Utah,) for gifting anti phospho OCT1 (S335) antibody. We
   acknowledge Dr. Kavita Singh of EM unit of CSIR CDRI for collecting
   images of confocal microscopy data reported in this paper and Dr. Kalyan
   Mitra for facilitating confocal imaging.
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Ansari KI, 2015, CELL REP, V11, P902, DOI 10.1016/j.celrep.2015.04.016
   Beier EE, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.13
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bikle DD, 2002, J BONE MINER RES, V17, P1570, DOI 10.1359/jbmr.2002.17.9.1570
   Chang SF, 2009, MOL ENDOCRINOL, V23, P1827, DOI 10.1210/me.2009 0143
   CROSS NA, 1995, J BONE MINER RES, V10, P1312
   D'Amelio P, 2015, BONE, V76, P177, DOI 10.1016/j.bone.2015.03.018
   Dai R., BLOOD, V112
   Dai RJ, 2013, BIOL SEX DIFFER, V4, DOI 10.1186/2042 6410 4 19
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Esen E, 2015, J BONE MINER RES, V30, P2137, DOI 10.1002/jbmr.2714
   Gámez B, 2013, J BIOL CHEM, V288, P14264, DOI 10.1074/jbc.M112.432104
   Godlewski J, 2010, CELL CYCLE, V9, P2742, DOI 10.4161/cc.9.14.12248
   Godlewski J, 2010, MOL CELL, V37, P620, DOI 10.1016/j.molcel.2010.02.018
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Hu CH, 2017, SCI REP UK, V7, DOI 10.1038/srep43191
   Hu R, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176099
   Iida Klein A., 2002, J BONE MINER RES, V17
   Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491
   James RG, 2006, DEVELOPMENT, V133, P2995, DOI 10.1242/dev.02442
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   KALKWARF HJ, 1995, OBSTET GYNECOL, V86, P26, DOI 10.1016/0029 7844(95)00083 4
   Karner CM, 2018, BONE, V115, P2, DOI 10.1016/j.bone.2017.08.008
   Karvande A, 2017, J PHARM PHARMACOL, V69, P1381, DOI 10.1111/jphp.12764
   Kasai T, 2009, J CELL PHYSIOL, V221, P740, DOI 10.1002/jcp.21917
   Kawai S, 2018, J BONE MINER METAB, V36, P640, DOI 10.1007/s00774 017 0885 9
   KENT GN, 1990, J BONE MINER RES, V5, P361, DOI 10.1002/jbmr.5650050409
   Khedgikar V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.294
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Kimura S, 2012, J VET MED SCI, V74, P103, DOI 10.1292/jvms.11 0328
   Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200
   Kureel J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.4
   Kushwaha P, 2016, J BIOL CHEM, V291, P3959, DOI 10.1074/jbc.M115.687152
   Li CL, 2013, INT J PEDIATR OTORHI, V77, P483, DOI 10.1016/j.ijporl.2012.12.011
   Li HF, 2015, DRUG DES DEV THER, V9, P5169, DOI 10.2147/DDDT.S81578
   Li Z., 2009, J BIOL CHEM, V284
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Lian J B, 1993, J Oral Implantol, V19, P95
   Liu W, 2017, BIOMED PHARMACOTHER, V87, P621, DOI 10.1016/j.biopha.2016.12.121
   Liu X., 2014, MOL CANC THER, V13
   Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011
   Mobasheri Ali, 2012, Front Endocrinol (Lausanne), V3, P153, DOI 10.3389/fendo.2012.00153
   Morandi F, 2013, INT IMMUNOL, V25, P279, DOI 10.1093/intimm/dxs108
   Rankin SA, 2012, DEVELOPMENT, V139, P3010, DOI 10.1242/dev.078220
   Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468
   Sardella C, 2010, J ENDOCRINOL INVEST, V33, P20, DOI 10.1007/BF03346555
   Sashidhara KV, 2014, EUR J MED CHEM, V86, P570, DOI 10.1016/j.ejmech.2014.09.015
   Stricker S, 2012, STEM CELLS DEV, V21, P623, DOI 10.1089/scd.2011.0154
   Waki T, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 0931 0
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Xi G, 2016, ENDOCRINOLOGY, V157, P268, DOI 10.1210/en.2015 1690
   Xu HD, 2014, CELL BIOCHEM BIOPHYS, V69, P163, DOI 10.1007/s12013 013 9783 5
   Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411
   Yamauchi M, 2008, GENE, V426, P81, DOI 10.1016/j.gene.2008.08.015
   Yang J., 2013, PLoS ONE, V8
   Yuan JD, 2015, MED ONCOL, V32, DOI 10.1007/s12032 014 0324 x
   Zhao Y, 2007, TRENDS BIOCHEM SCI, V32, P189, DOI 10.1016/j.tibs.2007.02.006
   Zhuo S, 2016, DIABETES, V65, P3276, DOI 10.2337/db16 0166
   Zoidis E, 2011, MOL CELL BIOCHEM, V348, P33, DOI 10.1007/s11010 010 0634 z
NR 64
TC 44
Z9 46
U1 2
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2018
VL 117
BP 98
EP 115
DI 10.1016/j.bone.2018.09.007
PG 18
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GZ2SH
UT WOS:000449237900013
PM 30218791
DA 2025 08 17
ER

EF